SE|25462139||ti|1|text|21|152|Blink reflex studies in postparalytic facial syndrome and blepharospasm: trigeminal and extratrigeminal somatosensory stimulation.
SE|25462139||ti|1|entity|C0596003|Blink Reflexes|ortf|||Blink reflex|||0|1000|21|33
SE|25462139||ti|1|entity|C0524465|Facial|spco|||facial|||0|790|59|65
SE|25462139||ti|1|entity|C0039082|Syndrome|dsyn|||syndrome|||0|790|66|74
SE|25462139||ti|1|entity|C0005747|Blepharospasm|dsyn|||blepharospasm|||0|1000|79|92

SE|25462139|PURPOSE|ab|1|text|158|341|PURPOSE: The somatosensory-evoked blink reflex (SBR) is one of the release phenomena of blink reflex, possibly resulting from increased excitability of brainstem reticular formation.
SE|25462139|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|158|165
SE|25462139|PURPOSE|ab|1|entity|C1444748|Triggered by|qlco|||evoked|||0|824|185|191
SE|25462139|PURPOSE|ab|1|entity|C0596003|Blink Reflexes|ortf|||blink reflex|||0|824|192|204
SE|25462139|PURPOSE|ab|1|entity|C0205447|One|qnco|||one|||0|1000|214|217
SE|25462139|PURPOSE|ab|1|entity|C0596003|Blink Reflexes|ortf|||blink reflex|||0|1000|246|258
SE|25462139|PURPOSE|ab|1|entity|C0332149|Possible|qlco|||possibly|||0|1000|260|268
SE|25462139|PURPOSE|ab|1|entity|C0205217|Increased|qnco|||increased|||0|888|284|293
SE|25462139|PURPOSE|ab|1|entity|C0235169|Excitability|sosy|||excitability|||0|888|294|306
SE|25462139|PURPOSE|ab|1|entity|C0006121|Brain Stem|bpoc|||brainstem|||0|901|310|319
SE|25462139|PURPOSE|ab|1|entity|C0035284|Reticular Formation|bpoc|||reticular formation|||0|901|320|339
SE|25462139|PURPOSE|ab|1|relation|0|0|C0035284|Reticular Formation|bpoc|bpoc|||reticular formation|||0|901|320|339|MOD/HEAD|PART_OF||310|339|0|0|C0006121|Brain Stem|bpoc|bpoc|||brainstem|||0|901|310|319
SE|25462139|PURPOSE|ab|1|relation|1|1|C0035284|Reticular Formation|bpoc|bpoc|||reticular formation|||0|901|320|339|PREP|LOCATION_OF||307|309|6|1|C0235169|Excitability|sosy|sosy|||excitability|||0|888|294|306

SE|25462139|METHODS|ab|2|text|341|575|METHODS: The authors investigated trigeminal blink responses and SBR in 26 patients with postparalytic facial syndrome (PFS) with synkinesia, 18 patients with essential blepharospasm, and 36 healthy volunteers (control participants).
SE|25462139|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|341|348
SE|25462139|METHODS|ab|2|entity|C0221192|Author|idcn,prog|||authors|||0|1000|354|361
SE|25462139|METHODS|ab|2|entity|C0871261|response|clna|||responses|||0|827|392|401
SE|25462139|METHODS|ab|2|entity|C1444748|Triggered by|qlco|||SBR|||0|824|406|409
SE|25462139|METHODS|ab|2|entity|C0596003|Blink Reflexes|ortf|||SBR|||0|824|406|409
SE|25462139|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|861|416|424
SE|25462139|METHODS|ab|2|entity|C0524465|Facial|spco|||facial|||0|790|444|450
SE|25462139|METHODS|ab|2|entity|C0039082|Syndrome|dsyn|||syndrome|||0|790|451|459
SE|25462139|METHODS|ab|2|entity|C0234362|Synkinesis|sosy|||synkinesia|||0|1000|471|481
SE|25462139|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|861|486|494
SE|25462139|METHODS|ab|2|entity|C0205224|Essential|qlco|||essential|||0|888|500|509
SE|25462139|METHODS|ab|2|entity|C0005747|Blepharospasm|dsyn|||blepharospasm|||0|888|510|523
SE|25462139|METHODS|ab|2|entity|C0018684|Health|idcn|||healthy|||0|754|532|539
SE|25462139|METHODS|ab|2|entity|C0042960|Voluntary Workers|prog|||volunteers|||0|754|540|550
SE|25462139|METHODS|ab|2|entity|C0243148|control|ftcn|||control|||0|872|552|559
SE|25462139|METHODS|ab|2|entity|C0679646|Participant|popg|||participants|||0|872|560|572
SE|25462139|METHODS|ab|2|relation|3|1|C0005747|Blepharospasm|dsyn|dsyn|||blepharospasm|||0|888|510|523|PREP|PROCESS_OF||495|499|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|486|494
SE|25462139|METHODS|ab|2|relation|4|1|C0596003|Blink Reflexes|ortf|ortf|||SBR|||0|824|406|409|PREP|PROCESS_OF||410|412|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|416|424
SE|25462139|METHODS|ab|2|relation|6|1|C0039082|Syndrome|dsyn|dsyn|||syndrome|||0|790|451|459|PREP|PROCESS_OF||425|429|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|416|424

SE|25462139|RESULTS|ab|3|text|575|794|RESULTS: Trigeminal blink reflex responses were elicited in all participants, whereas SBRs were elicited in 44.4% of control participants, 38.9% of patients with essential blepharospasm, and 65.4% of patients with PFS.
SE|25462139|RESULTS|ab|3|entity|C1274040|result|ftcn|||RESULTS|||0|966|575|582
SE|25462139|RESULTS|ab|3|entity|C0005757|Blinking|ortf|||blink|||0|852|595|600
SE|25462139|RESULTS|ab|3|entity|C0234675|Trigeminal reflex|ortf|||Trigeminal blink reflex|||0|852|584|607
SE|25462139|RESULTS|ab|3|entity|C0871261|response|clna|||responses|||0|852|608|617
SE|25462139|RESULTS|ab|3|entity|C0679646|Participant|popg|||participants|||0|966|639|651
SE|25462139|RESULTS|ab|3|entity|C0243148|control|ftcn|||control|||0|872|692|699
SE|25462139|RESULTS|ab|3|entity|C0679646|Participant|popg|||participants|||0|872|700|712
SE|25462139|RESULTS|ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|723|731
SE|25462139|RESULTS|ab|3|entity|C0205224|Essential|qlco|||essential|||0|888|737|746
SE|25462139|RESULTS|ab|3|entity|C0005747|Blepharospasm|dsyn|||blepharospasm|||0|888|747|760
SE|25462139|RESULTS|ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|775|783
SE|25462139|RESULTS|ab|3|entity|C0524465|Facial|spco|||PFS|||0|790|789|792
SE|25462139|RESULTS|ab|3|entity|C0039082|Syndrome|dsyn|||PFS|||0|790|789|792
SE|25462139|RESULTS|ab|3|relation|1|1|C0039082|Syndrome|dsyn|dsyn|||PFS|||0|790|789|792|PREP|PROCESS_OF||784|788|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|775|783
SE|25462139|RESULTS|ab|3|relation|3|1|C0005747|Blepharospasm|dsyn|dsyn|||blepharospasm|||0|888|747|760|PREP|PROCESS_OF||732|736|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|723|731

SE|25462139|RESULTS|ab|4|text|794|927|The mean R2 amplitude and duration and the mean amplitude and duration of SBR were highest in patients with essential blepharospasm.
SE|25462139|RESULTS|ab|4|entity|C0449238|Duration|tmco|||duration|||0|1000|820|828
SE|25462139|RESULTS|ab|4|entity|C0449238|Duration|tmco|||duration|||0|1000|856|864
SE|25462139|RESULTS|ab|4|entity|C1444748|Triggered by|qlco|||SBR|||0|824|868|871
SE|25462139|RESULTS|ab|4|entity|C0596003|Blink Reflexes|ortf|||SBR|||0|824|868|871
SE|25462139|RESULTS|ab|4|entity|C1522410|Highest|qlco|||highest|||0|1000|877|884
SE|25462139|RESULTS|ab|4|entity|C0030705|Patients|podg|||patients|||0|1000|888|896
SE|25462139|RESULTS|ab|4|entity|C0205224|Essential|qlco|||essential|||0|888|902|911
SE|25462139|RESULTS|ab|4|entity|C0005747|Blepharospasm|dsyn|||blepharospasm|||0|888|912|925
SE|25462139|RESULTS|ab|4|relation|1|1|C0005747|Blepharospasm|dsyn|dsyn|||blepharospasm|||0|888|912|925|PREP|PROCESS_OF||897|901|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|888|896
SE|25462139|RESULTS|ab|4|relation|6|2|C0596003|Blink Reflexes|ortf|ortf|||SBR|||0|824|868|871|PREP|PROCESS_OF||885|887|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|888|896

SE|25462139|RESULTS|ab|5|text|927|1050|The mean latency of SBR was shorter on the symptomatic side of patients with PFS when compared with the asymptomatic side.
SE|25462139|RESULTS|ab|5|entity|C0205275|Latent|qlco|||latency|||0|789|936|943
SE|25462139|RESULTS|ab|5|entity|C1444748|Triggered by|qlco|||SBR|||0|824|947|950
SE|25462139|RESULTS|ab|5|entity|C0596003|Blink Reflexes|ortf|||SBR|||0|824|947|950
SE|25462139|RESULTS|ab|5|entity|C0231220|Symptomatic|ftcn|||symptomatic|||0|888|970|981
SE|25462139|RESULTS|ab|5|entity|C0441987|Side|spco|||side|||0|888|982|986
SE|25462139|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|990|998
SE|25462139|RESULTS|ab|5|entity|C0524465|Facial|spco|||PFS|||0|790|1004|1007
SE|25462139|RESULTS|ab|5|entity|C0039082|Syndrome|dsyn|||PFS|||0|790|1004|1007
SE|25462139|RESULTS|ab|5|entity|C0231221|Asymptomatic|fndg|||asymptomatic|||0|888|1031|1043
SE|25462139|RESULTS|ab|5|entity|C0441987|Side|spco|||side|||0|888|1044|1048
SE|25462139|RESULTS|ab|5|relation|2|1|C0039082|Syndrome|dsyn|dsyn|||PFS|||0|790|1004|1007|PREP|PROCESS_OF||999|1003|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|990|998

SE|25462139|RESULTS|ab|6|text|1050|1162|The mean R2 duration on the symptomatic side of the patients with PFS was longer than the control participants.
SE|25462139|RESULTS|ab|6|entity|C0449238|Duration|tmco|||duration|||0|790|1062|1070
SE|25462139|RESULTS|ab|6|entity|C0231220|Symptomatic|ftcn|||symptomatic|||0|888|1078|1089
SE|25462139|RESULTS|ab|6|entity|C0441987|Side|spco|||side|||0|888|1090|1094
SE|25462139|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|1000|1102|1110
SE|25462139|RESULTS|ab|6|entity|C0524465|Facial|spco|||PFS|||0|790|1116|1119
SE|25462139|RESULTS|ab|6|entity|C0039082|Syndrome|dsyn|||PFS|||0|790|1116|1119
SE|25462139|RESULTS|ab|6|entity|C0205166|Long|qlco|||longer|||0|966|1124|1130
SE|25462139|RESULTS|ab|6|entity|C0243148|control|ftcn|||control|||0|872|1140|1147
SE|25462139|RESULTS|ab|6|entity|C0679646|Participant|popg|||participants|||0|872|1148|1160
SE|25462139|RESULTS|ab|6|relation|3|1|C0039082|Syndrome|dsyn|dsyn|||PFS|||0|790|1116|1119|PREP|PROCESS_OF||1111|1115|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1102|1110

SE|25462139|CONCLUSIONS|ab|7|text|1162|1377|CONCLUSIONS: These results showed that somatosensory stimulation could be used as an alternative method to demonstrate increased excitability in facial motor neuron in patients with PFS and essential blepharospasm.
SE|25462139|CONCLUSIONS|ab|7|entity|C1274040|result|ftcn|||results|||0|966|1181|1188
SE|25462139|CONCLUSIONS|ab|7|entity|C1523987|Alternative|cnce|||alternative|||0|888|1247|1258
SE|25462139|CONCLUSIONS|ab|7|entity|C0025663|Methods|inpr|||method|||0|888|1259|1265
SE|25462139|CONCLUSIONS|ab|7|entity|C0205217|Increased|qnco|||increased|||0|888|1281|1290
SE|25462139|CONCLUSIONS|ab|7|entity|C0235169|Excitability|sosy|||excitability|||0|888|1291|1303
SE|25462139|CONCLUSIONS|ab|7|entity|C0524465|Facial|spco|||facial|||0|901|1307|1313
SE|25462139|CONCLUSIONS|ab|7|entity|C0026609|Motor Neurons|cell|||motor neuron|||0|901|1314|1326
SE|25462139|CONCLUSIONS|ab|7|entity|C0030705|Patients|podg|||patients|||0|1000|1330|1338
SE|25462139|CONCLUSIONS|ab|7|entity|C0524465|Facial|spco|||PFS|||0|790|1344|1347
SE|25462139|CONCLUSIONS|ab|7|entity|C0039082|Syndrome|dsyn|||PFS|||0|790|1344|1347
SE|25462139|CONCLUSIONS|ab|7|entity|C0205224|Essential|qlco|||essential|||0|888|1352|1361
SE|25462139|CONCLUSIONS|ab|7|entity|C0005747|Blepharospasm|dsyn|||blepharospasm|||0|888|1362|1375
SE|25462139|CONCLUSIONS|ab|7|relation|0|0|C0524465|Facial|spco|spco|||facial|||0|901|1307|1313|MOD/HEAD|LOCATION_OF||1307|1326|0|0|C0026609|Motor Neurons|cell|cell|||motor neuron|||0|901|1314|1326
SE|25462139|CONCLUSIONS|ab|7|relation|2|1|C0005747|Blepharospasm|dsyn|dsyn|||blepharospasm|||0|888|1362|1375|PREP|PROCESS_OF||1339|1343|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1330|1338
SE|25462139|CONCLUSIONS|ab|7|relation|2|1|C0039082|Syndrome|dsyn|dsyn|||PFS|||0|790|1344|1347|PREP|PROCESS_OF||1339|1343|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1330|1338
SE|25462139|CONCLUSIONS|ab|7|relation|6|2|C0235169|Excitability|sosy|sosy|||excitability|||0|888|1291|1303|PREP|PROCESS_OF||1327|1329|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1330|1338

SE|25462139|CONCLUSIONS|ab|8|text|1377|1588|Disease states relating to different peripheral and/or suprasegmental structures could also influence blink reflex and change its basal excitability and manner in which the reflex responds to modulatory factors.
SE|25462139|CONCLUSIONS|ab|8|entity|C0012634|Disease|dsyn|||Disease|||0|872|1377|1384
SE|25462139|CONCLUSIONS|ab|8|entity|C1442792|State|ftcn|||states|||0|872|1385|1391
SE|25462139|CONCLUSIONS|ab|8|entity|C1547020|*Difference|qnco|||different|||0|853|1404|1413
SE|25462139|CONCLUSIONS|ab|8|entity|C0205100|Peripheral|spco|||peripheral|||0|853|1414|1424
SE|25462139|CONCLUSIONS|ab|8|entity|C0006104|Brain|bpoc|||suprasegmental structures|||0|1000|1432|1457
SE|25462139|CONCLUSIONS|ab|8|entity|C0596003|Blink Reflexes|ortf|||blink reflex|||0|1000|1479|1491
SE|25462139|CONCLUSIONS|ab|8|entity|C0205112|Basal|spco|||basal|||0|888|1507|1512
SE|25462139|CONCLUSIONS|ab|8|entity|C0235169|Excitability|sosy|||excitability|||0|888|1513|1525
SE|25462139|CONCLUSIONS|ab|8|entity|C1521761|Factor|ftcn|||factors|||0|827|1580|1587


SE|25462140||ti|1|text|21|169|Neuroimaging effects of 1 Hz right temporoparietal rTMS on normal auditory processing: implications for clinical hallucination treatment paradigms.
SE|25462140||ti|1|entity|C0679575|neuroimaging|diap|||Neuroimaging|||0|872|21|33
SE|25462140||ti|1|entity|C1280500|Effect|qlco|||effects|||0|872|34|41
SE|25462140||ti|1|entity|C0205090|Right|spco|||right|||0|798|50|55
SE|25462140||ti|1|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|798|72|76
SE|25462140||ti|1|entity|C0205307|Normal|qlco|||normal|||0|840|80|86
SE|25462140||ti|1|entity|C0439825|Auditory|ftcn|||auditory|||0|840|87|95
SE|25462140||ti|1|entity|C1522240|Process|phpr|||processing|||0|840|96|106
SE|25462140||ti|1|entity|C0018524|Hallucinations|mobd|||hallucination|||0|852|134|147
SE|25462140||ti|1|entity|C1516635|Clinical Treatment|topp|||clinical hallucination treatment|||0|852|125|157
SE|25462140||ti|1|entity|C0681797|paradigm|resa|||paradigms|||0|852|158|167
SE|25462140||ti|1|relation|0|0|C0681797|paradigm|resa|resa|||paradigms|||0|852|158|167|MOD/HEAD|USES||125|167|0|0|C1516635|Clinical Treatment|topp|topp|||clinical hallucination treatment|||0|852|125|157

SE|25462140|PURPOSE|ab|1|text|175|398|PURPOSE: Repetitive transcranial magnetic stimulation (rTMS) has attracted attention as a putative clinical neuromodulatory tool, including for ameliorating hallucinations, although existing clinical data are inconsistent.
SE|25462140|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|175|182
SE|25462140|PURPOSE|ab|1|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||Repetitive transcranial magnetic stimulation|||0|1000|184|228
SE|25462140|PURPOSE|ab|1|entity|C0004268|Attention|menp|||attention|||0|861|250|259
SE|25462140|PURPOSE|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|751|274|282
SE|25462140|PURPOSE|ab|1|entity|C0949370|Neuromodulators|nsba|||neuromodulatory|||0|751|283|298
SE|25462140|PURPOSE|ab|1|entity|C0336791|Tool|mnob|||tool|||0|751|299|303
SE|25462140|PURPOSE|ab|1|entity|C0018524|Hallucinations|mobd|||hallucinations|||0|861|332|346
SE|25462140|PURPOSE|ab|1|entity|C1516606|Clinical Data|inpr|||clinical data|||0|1000|366|379
SE|25462140|PURPOSE|ab|1|entity|C0442809|Inconsistent|qlco|||inconsistent|||0|1000|384|396

SE|25462140|PURPOSE|ab|2|text|398|498|There is a notable paucity of research on its physiological effects on normal neuronal functioning.
SE|25462140|PURPOSE|ab|2|entity|C0035168|research|resa|||research|||0|1000|428|436
SE|25462140|PURPOSE|ab|2|entity|C1372798|Physiological Effects|phsf|||physiological effects|||0|1000|444|465
SE|25462140|PURPOSE|ab|2|entity|C0205307|Normal|qlco|||normal|||0|840|469|475
SE|25462140|PURPOSE|ab|2|entity|C0031843|physiological aspects|phsf|||functioning|||0|840|485|496

SE|25462140|METHODS|ab|3|text|498|743|METHODS: We neuroimaged 24 healthy adult volunteers undertaking a variable loading passive auditory task, randomized into 2 matched and double-masked groups: half received a 17-minute 1 Hz right temporoparietal rTMS paradigm and half sham rTMS.
SE|25462140|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|498|505
SE|25462140|METHODS|ab|3|entity|C0686750|Well adult|fndg|||healthy adult|||0|785|525|538
SE|25462140|METHODS|ab|3|entity|C0042960|Voluntary Workers|prog|||volunteers|||0|785|539|549
SE|25462140|METHODS|ab|3|entity|C0439828|Variable|qlco|||variable|||0|762|564|572
SE|25462140|METHODS|ab|3|entity|C0439825|Auditory|ftcn|||auditory|||0|762|589|597
SE|25462140|METHODS|ab|3|entity|C0150112|psychological masking|ftcn|||masked|||0|888|641|647
SE|25462140|METHODS|ab|3|entity|C0441833|Groups|inpr|||groups|||0|888|648|654
SE|25462140|METHODS|ab|3|entity|C0702093|/minute|tmco|||minute|||0|753|675|681
SE|25462140|METHODS|ab|3|entity|C0205090|Right|spco|||right|||0|753|687|692
SE|25462140|METHODS|ab|3|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|753|709|713
SE|25462140|METHODS|ab|3|entity|C0681797|paradigm|resa|||paradigm|||0|753|714|722
SE|25462140|METHODS|ab|3|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|876|737|741
SE|25462140|METHODS|ab|3|relation|0|0|C0681797|paradigm|resa|resa|||paradigm|||0|753|714|722|MOD/HEAD|USES||709|722|0|0|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||rTMS|||0|753|709|713
SE|25462140|METHODS|ab|3|relation|0|0|C0686750|Well adult|fndg|fndg|||healthy adult|||0|785|525|538|MOD/HEAD|PROCESS_OF||525|549|0|0|C0042960|Voluntary Workers|prog,humn|humn|||volunteers|||0|785|539|549

SE|25462140|RESULTS|ab|4|text|743|896|RESULTS: One hertz rTMS led to attenuation of the underlying auditory cortex response to the stimulus and a contralateral increase in cortical activity.
SE|25462140|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|743|750
SE|25462140|RESULTS|ab|4|entity|C0205447|One|qnco|||One|||0|888|752|755
SE|25462140|RESULTS|ab|4|entity|C0439482|Hz|qnco|||hertz|||0|888|756|761
SE|25462140|RESULTS|ab|4|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|888|762|766
SE|25462140|RESULTS|ab|4|entity|C0599946|attenuation|genf|||attenuation|||0|1000|774|785
SE|25462140|RESULTS|ab|4|entity|C0004302|Auditory area|bpoc|||auditory cortex|||0|824|804|819
SE|25462140|RESULTS|ab|4|entity|C0871261|response|clna|||response|||0|824|820|828
SE|25462140|RESULTS|ab|4|entity|C0234402|Stimulus|phpr|||stimulus|||0|1000|836|844
SE|25462140|RESULTS|ab|4|entity|C0441988|Contralateral|spco|||contralateral|||0|888|851|864
SE|25462140|RESULTS|ab|4|entity|C0442805|Increase|ftcn|||increase|||0|888|865|873
SE|25462140|RESULTS|ab|4|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|861|877|885
SE|25462140|RESULTS|ab|4|relation|2|1|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||rTMS|||0|888|762|766|VERB|AFFECTS||767|770|5|1|C0599946|attenuation|genf|genf|||attenuation|||0|1000|774|785
SE|25462140|RESULTS|ab|4|relation|6|4|C0599946|attenuation|genf|genf|||attenuation|||0|1000|774|785|PREP|PROCESS_OF||874|876|1|1|C1366490|ADRBK1 gene|gngm,aapp|gngm|156|GRK2|cortical|||0|861|877|885

SE|25462140|RESULTS|ab|5|text|896|1083|Subanalysis of the auditory tasks demonstrated that rTMS effects varied with stimulus frequency and differences between the active and sham conditions were lost at the highest frequency.
SE|25462140|RESULTS|ab|5|entity|C0439825|Auditory|ftcn|||auditory|||0|872|915|923
SE|25462140|RESULTS|ab|5|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|922|948|952
SE|25462140|RESULTS|ab|5|entity|C1280500|Effect|qlco|||effects|||0|922|953|960
SE|25462140|RESULTS|ab|5|entity|C0237630|Stimulus frequency|tmco|||stimulus frequency|||0|1000|973|991
SE|25462140|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||differences|||0|966|996|1007
SE|25462140|RESULTS|ab|5|entity|C0205177|Active|ftcn|||active|||0|1000|1020|1026
SE|25462140|RESULTS|ab|5|entity|C0348080|Condition|qlco|||conditions|||0|872|1036|1046
SE|25462140|RESULTS|ab|5|entity|C0205212|High frequency|tmco|||highest frequency|||0|983|1064|1081

SE|25462140|CONCLUSIONS|ab|6|text|1083|1261|CONCLUSIONS: This work is, to the best of our knowledge, the first to neuroimage the effects of a "hallucinatory rTMS protocol" on basic auditory processing in healthy controls.
SE|25462140|CONCLUSIONS|ab|6|entity|C0043227|Work|ocac|||work|||0|1000|1101|1105
SE|25462140|CONCLUSIONS|ab|6|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|1129|1138
SE|25462140|CONCLUSIONS|ab|6|entity|C1279901|Firstly|qlco|||first|||0|660|1144|1149
SE|25462140|CONCLUSIONS|ab|6|entity|C1280500|Effect|qlco|||effects|||0|966|1168|1175
SE|25462140|CONCLUSIONS|ab|6|entity|C0018524|Hallucinations|mobd|||hallucinatory|||0|876|1182|1195
SE|25462140|CONCLUSIONS|ab|6|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|876|1196|1200
SE|25462140|CONCLUSIONS|ab|6|entity|C0442711|Protocols documentation|inpr|||protocol|||0|876|1201|1209
SE|25462140|CONCLUSIONS|ab|6|entity|C0439825|Auditory|ftcn|||auditory|||0|816|1220|1228
SE|25462140|CONCLUSIONS|ab|6|entity|C1522240|Process|phpr|||processing|||0|816|1229|1239
SE|25462140|CONCLUSIONS|ab|6|entity|C0018684|Health|idcn|||healthy|||0|836|1243|1250
SE|25462140|CONCLUSIONS|ab|6|entity|C0243148|control|ftcn|||controls|||0|836|1251|1259

SE|25462140|CONCLUSIONS|ab|7|text|1261|1413|Our data demonstrated that a so-called "inhibitory paradigm" can also produce distal neuronal activation and that effects can vary with neural loading.
SE|25462140|CONCLUSIONS|ab|7|entity|C1511726|Data|idcn|||data|||0|1000|1265|1269
SE|25462140|CONCLUSIONS|ab|7|entity|C0243077|inhibitors|chvf|||inhibitory|||0|714|1301|1311
SE|25462140|CONCLUSIONS|ab|7|entity|C0681797|paradigm|resa|||paradigm|||0|714|1312|1320
SE|25462140|CONCLUSIONS|ab|7|entity|C0205108|Distal|spco|||distal|||0|623|1339|1345
SE|25462140|CONCLUSIONS|ab|7|entity|C1280500|Effect|qlco|||effects|||0|966|1375|1382
SE|25462140|CONCLUSIONS|ab|7|entity|C0599851|relating to nervous system|ftcn|||neural|||0|694|1397|1403
SE|25462140|CONCLUSIONS|ab|7|relation|0|0|C0681797|paradigm|resa|resa|||paradigm|||0|714|1312|1320|MOD/HEAD|USES||1301|1320|0|0|C0243077|inhibitors|chvf|chvf|||inhibitory|||0|714|1301|1311

SE|25462140|CONCLUSIONS|ab|8|text|1413|1648|These results highlight the insufficient knowledge of the effects of rTMS on normal physiology, and this, combined with a lack of consensus on clinical trial parameters, may be contributing to the ambivalent data in therapeutic trials.
SE|25462140|CONCLUSIONS|ab|8|entity|C1274040|result|ftcn|||results|||0|966|1419|1426
SE|25462140|CONCLUSIONS|ab|8|entity|C0231180|Insufficient|ftcn|||insufficient|||0|888|1441|1453
SE|25462140|CONCLUSIONS|ab|8|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|1454|1463
SE|25462140|CONCLUSIONS|ab|8|entity|C1280500|Effect|qlco|||effects|||0|966|1471|1478
SE|25462140|CONCLUSIONS|ab|8|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|1000|1482|1486
SE|25462140|CONCLUSIONS|ab|8|entity|C0205307|Normal|qlco|||normal|||0|888|1490|1496
SE|25462140|CONCLUSIONS|ab|8|entity|C0031842|Physiology|bmod|||physiology|||0|888|1497|1507
SE|25462140|CONCLUSIONS|ab|8|entity|C0332268|Lacking|qlco|||lack|||0|1000|1535|1539
SE|25462140|CONCLUSIONS|ab|8|entity|C0376298|Consensus|socb|||consensus|||0|1000|1543|1552
SE|25462140|CONCLUSIONS|ab|8|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|901|1556|1570
SE|25462140|CONCLUSIONS|ab|8|entity|C0233495|Feeling mixed emotions|menp|||ambivalent|||0|853|1610|1620
SE|25462140|CONCLUSIONS|ab|8|entity|C1511726|Data|idcn|||data|||0|853|1621|1625
SE|25462140|CONCLUSIONS|ab|8|entity|C1516652|Clinical Trials, Therapy|resa|||therapeutic trials|||0|1000|1629|1647


SE|25462141||ti|1|text|21|156|Effect of repetitive transcranial magnetic stimulation on reducing spasticity in patients suffering from HTLV-1-associated myelopathy.
SE|25462141||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462141||ti|1|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|1000|31|75
SE|25462141||ti|1|entity|C0392756|Reduced|qlco|||reducing|||0|661|79|87
SE|25462141||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|102|110
SE|25462141||ti|1|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HTLV-1-associated myelopathy|||0|1000|126|154
SE|25462141||ti|1|relation|0|0|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||repetitive transcranial magnetic stimulation|||0|1000|31|75|INFER|TREATS(INFER)||99|101|0|0|C0030481|Tropical Spastic Paraparesis|dsyn|dsyn|||HTLV-1-associated myelopathy|||0|1000|126|154
SE|25462141||ti|1|relation|1|1|C0030481|Tropical Spastic Paraparesis|dsyn|dsyn|||HTLV-1-associated myelopathy|||0|1000|126|154|VERB|PROCESS_OF||111|120|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|102|110
SE|25462141||ti|1|relation|3|2|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||repetitive transcranial magnetic stimulation|||0|1000|31|75|PREP|TREATS||99|101|2|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|102|110

SE|25462141|PURPOSE|ab|1|text|162|324|PURPOSE: Human T-lymphotropic virus type 1 has been implicated in human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
SE|25462141|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|162|169
SE|25462141|PURPOSE|ab|1|entity|C1547052|*Type|qnco|||type|||0|938|198|202
SE|25462141|PURPOSE|ab|1|entity|C0020094|Human T-lymphotropic virus 1|virs|||Human T-lymphotropic virus type 1|||0|938|171|204
SE|25462141|PURPOSE|ab|1|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||human T-lymphotropic virus type 1-associated myelopathy|||0|911|228|283
SE|25462141|PURPOSE|ab|1|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||tropical spastic paraparesis|||0|911|284|312
SE|25462141|PURPOSE|ab|1|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM|||0|888|314|317
SE|25462141|PURPOSE|ab|1|entity|C0147139|Thrombospondin 1|aapp,bacs|7057|THBS1|TSP|||0|888|318|321
SE|25462141|PURPOSE|ab|1|relation|1|0|C0020094|Human T-lymphotropic virus 1|virs|virs|||Human T-lymphotropic virus type 1|||0|938|171|204|VERB|INTERACTS_WITH||214|224|2|1|C0030481|Tropical Spastic Paraparesis|dsyn|dsyn|||tropical spastic paraparesis|||0|911|284|312

SE|25462141|PURPOSE|ab|2|text|324|674|Regarding its endemicity in Iran and the role of repetitive transcranial magnetic stimulation in reducing spasticity, we decided to evaluate the efficacy of repetitive transcranial magnetic stimulation in reducing spasticity (as primary outcome) and pain, muscle power, and quality of life (as secondary outcomes) in patients suffering from HAM/TSP.
SE|25462141|PURPOSE|ab|2|entity|C0022065|Iran|geoa|||Iran|||0|1000|352|356
SE|25462141|PURPOSE|ab|2|entity|C0035820|Role|socb|||role|||0|1000|365|369
SE|25462141|PURPOSE|ab|2|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|1000|373|417
SE|25462141|PURPOSE|ab|2|entity|C0392756|Reduced|qlco|||reducing|||0|661|421|429
SE|25462141|PURPOSE|ab|2|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|1000|481|525
SE|25462141|PURPOSE|ab|2|entity|C0392756|Reduced|qlco|||reducing|||0|661|529|537
SE|25462141|PURPOSE|ab|2|entity|C1274040|result|ftcn|||outcome|||0|888|561|568
SE|25462141|PURPOSE|ab|2|entity|C0030193|Pain|sosy|||pain|||0|1000|574|578
SE|25462141|PURPOSE|ab|2|entity|C0026845|Muscle|tisu|||muscle|||0|694|580|586
SE|25462141|PURPOSE|ab|2|entity|C0332306|Quality|qlco|||quality|||0|1000|598|605
SE|25462141|PURPOSE|ab|2|entity|C0376558|Life|idcn|||life|||0|1000|609|613
SE|25462141|PURPOSE|ab|2|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|872|618|627
SE|25462141|PURPOSE|ab|2|entity|C1274040|result|ftcn|||outcomes|||0|872|628|636
SE|25462141|PURPOSE|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|641|649
SE|25462141|PURPOSE|ab|2|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM|||0|888|665|668
SE|25462141|PURPOSE|ab|2|entity|C0147139|Thrombospondin 1|aapp,bacs|7057|THBS1|TSP|||0|888|669|672
SE|25462141|PURPOSE|ab|2|relation|14|5|C0030193|Pain|sosy|sosy|||pain|||0|1000|574|578|PREP|PROCESS_OF||638|640|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|641|649

SE|25462141|METHODS|ab|3|text|674|797|METHODS: In this pretest-posttest study, nine definite patients with HAM/TSP (according to WHO guidelines) were recruited.
SE|25462141|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|674|681
SE|25462141|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|827|708|713
SE|25462141|METHODS|ab|3|entity|C0205455|Nine|qnco|||nine|||0|851|715|719
SE|25462141|METHODS|ab|3|entity|C0439544|Definite|qlco|||definite|||0|851|720|728
SE|25462141|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|851|729|737
SE|25462141|METHODS|ab|3|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM|||0|888|743|746
SE|25462141|METHODS|ab|3|entity|C0147139|Thrombospondin 1|aapp,bacs|7057|THBS1|TSP|||0|888|747|750
SE|25462141|METHODS|ab|3|entity|C0162791|Guidelines|inpr|||guidelines|||0|1000|769|779
SE|25462141|METHODS|ab|3|relation|2|1|C0147139|Thrombospondin 1|aapp,gngm,bacs|aapp|7057|THBS1|TSP|||0|888|747|750|PREP|PART_OF||738|742|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|851|729|737

SE|25462141|METHODS|ab|4|text|797|1049|All patients underwent five consecutive daily sessions of active repetitive transcranial magnetic stimulation (each session consisting of 20 trains of 10 pulses at 5 Hz and an intensity of 90% of resting motor threshold for the biceps brachii muscle).
SE|25462141|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|1000|801|809
SE|25462141|METHODS|ab|4|entity|C0205451|Five|qnco|||five|||0|597|820|824
SE|25462141|METHODS|ab|4|entity|C0332173|Daily|tmco|||daily|||0|597|837|842
SE|25462141|METHODS|ab|4|entity|C0205177|Active|ftcn|||active|||0|928|855|861
SE|25462141|METHODS|ab|4|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|928|862|906
SE|25462141|METHODS|ab|4|entity|C0034107|Pulse taking|diap|||pulses|||0|861|951|957
SE|25462141|METHODS|ab|4|entity|C0439083|>90|qnco|||90|||0|1000|986|988
SE|25462141|METHODS|ab|4|entity|C0035253|Rest|dora|||resting|||0|851|993|1000
SE|25462141|METHODS|ab|4|entity|C1513492|Motor|idcn|||motor|||0|851|1001|1006
SE|25462141|METHODS|ab|4|entity|C0449864|Threshold|ftcn|||threshold|||0|851|1007|1016
SE|25462141|METHODS|ab|4|entity|C0224235|Entire biceps brachii|bpoc|||biceps brachii|||0|901|1025|1039
SE|25462141|METHODS|ab|4|entity|C0026845|Muscle|tisu|||muscle|||0|901|1040|1046
SE|25462141|METHODS|ab|4|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|901|1040|1046|MOD/HEAD|PART_OF||1025|1046|0|0|C0224235|Entire biceps brachii|bpoc|bpoc|||biceps brachii|||0|901|1025|1039

SE|25462141|METHODS|ab|5|text|1049|1286|Main outcome measures including spasticity (by modified Ashworth scale), pain (by visual analog scale), muscle power, and quality of life (by SF 36) were measured before the study and days 5, 7, 30 after the termination of the sessions.
SE|25462141|METHODS|ab|5|entity|C0205225|Primary|qlco|||Main|||0|901|1049|1053
SE|25462141|METHODS|ab|5|entity|C0086749|Outcome Measures|qnco|||outcome measures|||0|901|1054|1070
SE|25462141|METHODS|ab|5|entity|C0205349|Altered|ftcn|||modified|||0|802|1096|1104
SE|25462141|METHODS|ab|5|entity|C0030193|Pain|sosy|||pain|||0|1000|1122|1126
SE|25462141|METHODS|ab|5|entity|C0042815|Visual Analog Scale|diap,qnco|||visual analog scale|||0|1000|1131|1150
SE|25462141|METHODS|ab|5|entity|C0026845|Muscle|tisu|||muscle|||0|694|1153|1159
SE|25462141|METHODS|ab|5|entity|C0332306|Quality|qlco|||quality|||0|1000|1171|1178
SE|25462141|METHODS|ab|5|entity|C0376558|Life|idcn|||life|||0|1000|1182|1186
SE|25462141|METHODS|ab|5|entity|C1519136|SF-36|inpr|||SF 36|||0|1000|1191|1196
SE|25462141|METHODS|ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|1223|1228
SE|25462141|METHODS|ab|5|entity|C0439228|day|tmco|||days|||0|861|1233|1237
SE|25462141|METHODS|ab|5|entity|C1549081|Termination|inpr|||termination|||0|1000|1257|1268

SE|25462141|RESULTS|ab|6|text|1286|1446|RESULTS: Seven (77.8%) females and 2 (22.2%) males were recruited with the mean age of 52 +/- 12.67 years, and the mean duration of the disease was 5 +/- 3.94.
SE|25462141|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1286|1293
SE|25462141|RESULTS|ab|6|entity|C0205453|Seven|qnco|||Seven|||0|1000|1295|1300
SE|25462141|RESULTS|ab|6|entity|C0015780|Female|orga|||females|||0|1000|1309|1316
SE|25462141|RESULTS|ab|6|entity|C0024554|Male gender|orga|||males|||0|1000|1331|1336
SE|25462141|RESULTS|ab|6|entity|C0001779|Age|orga|||age|||0|861|1366|1369
SE|25462141|RESULTS|ab|6|entity|C0439234|year|tmco|||years|||0|812|1386|1391
SE|25462141|RESULTS|ab|6|entity|C0449238|Duration|tmco|||duration|||0|861|1406|1414
SE|25462141|RESULTS|ab|6|entity|C0012634|Disease|dsyn|||disease|||0|1000|1422|1429

SE|25462141|RESULTS|ab|7|text|1446|1565|Comparison of the repeated measures showed a statistically significant decrease in pain and spasticity in lower limbs.
SE|25462141|RESULTS|ab|7|entity|C0871881|Repeated Measures|resa|||repeated measures|||0|1000|1464|1481
SE|25462141|RESULTS|ab|7|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|901|1491|1516
SE|25462141|RESULTS|ab|7|entity|C0547047|Decrease|qnco|||decrease|||0|901|1517|1525
SE|25462141|RESULTS|ab|7|entity|C0030193|Pain|sosy|||pain|||0|1000|1529|1533
SE|25462141|RESULTS|ab|7|entity|C0023216|Lower Extremity|blor|||lower limbs|||0|1000|1552|1563

SE|25462141|RESULTS|ab|8|text|1565|1715|The decrement in spasticity was persistent even 30 days after the intervention; however, the pain reduction was seen only 5 days after the procedure.
SE|25462141|RESULTS|ab|8|entity|C0205322|Persistent|tmco|||persistent|||0|791|1597|1607
SE|25462141|RESULTS|ab|8|entity|C0439228|day|tmco|||days|||0|791|1616|1620
SE|25462141|RESULTS|ab|8|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|1631|1643
SE|25462141|RESULTS|ab|8|entity|C0030193|Pain|sosy|||pain|||0|694|1658|1662
SE|25462141|RESULTS|ab|8|entity|C0439228|day|tmco|||days|||0|827|1689|1693
SE|25462141|RESULTS|ab|8|entity|C0184661|Procedures|hlca|||procedure|||0|1000|1704|1713

SE|25462141|RESULTS|ab|9|text|1715|1776|No change in quality of life, and muscle power was detected.
SE|25462141|RESULTS|ab|9|entity|C0332306|Quality|qlco|||quality|||0|1000|1728|1735
SE|25462141|RESULTS|ab|9|entity|C0376558|Life|idcn|||life|||0|1000|1739|1743
SE|25462141|RESULTS|ab|9|entity|C0026845|Muscle|tisu|||muscle|||0|694|1749|1755

SE|25462141|CONCLUSIONS|ab|10|text|1776|2158|CONCLUSIONS: It seems that repetitive transcranial magnetic stimulation could decrease spasticity and pain in patients with HAM/TSP, and this effect could persistently continue by 1 month, but it did not influence patients' muscle power and quality of life, and it could be used as an adjuvant therapy in patients suffering from human T-lymphotropic virus type 1-associated HAM/TSP.
SE|25462141|CONCLUSIONS|ab|10|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|1000|1803|1847
SE|25462141|CONCLUSIONS|ab|10|entity|C0030193|Pain|sosy|||pain|||0|1000|1878|1882
SE|25462141|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1886|1894
SE|25462141|CONCLUSIONS|ab|10|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM|||0|888|1900|1903
SE|25462141|CONCLUSIONS|ab|10|entity|C0147139|Thrombospondin 1|aapp,bacs|7057|THBS1|TSP|||0|888|1904|1907
SE|25462141|CONCLUSIONS|ab|10|entity|C1280500|Effect|qlco|||effect|||0|1000|1918|1924
SE|25462141|CONCLUSIONS|ab|10|entity|C0750508|PERSISTENTLY|idcn|||persistently|||0|1000|1931|1943
SE|25462141|CONCLUSIONS|ab|10|entity|C1442451|1 Month|tmco|||1 month|||0|1000|1956|1963
SE|25462141|CONCLUSIONS|ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1976|1979
SE|25462141|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|623|1990|1998
SE|25462141|CONCLUSIONS|ab|10|entity|C0026845|Muscle|tisu|||muscle|||0|623|2000|2006
SE|25462141|CONCLUSIONS|ab|10|entity|C0332306|Quality|qlco|||quality|||0|1000|2017|2024
SE|25462141|CONCLUSIONS|ab|10|entity|C0376558|Life|idcn|||life|||0|1000|2028|2032
SE|25462141|CONCLUSIONS|ab|10|entity|C0677850|adjuvant therapy|topp|||adjuvant therapy|||0|1000|2061|2077
SE|25462141|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|2081|2089
SE|25462141|CONCLUSIONS|ab|10|entity|C1547052|*Type|qnco|||type|||0|818|2132|2136
SE|25462141|CONCLUSIONS|ab|10|entity|C0020094|Human T-lymphotropic virus 1|virs|||human T-lymphotropic virus type 1|||0|818|2105|2138
SE|25462141|CONCLUSIONS|ab|10|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM|||0|818|2150|2153
SE|25462141|CONCLUSIONS|ab|10|entity|C0147139|Thrombospondin 1|aapp,bacs|7057|THBS1|TSP|||0|818|2154|2157
SE|25462141|CONCLUSIONS|ab|10|relation|0|0|C0147139|Thrombospondin 1|aapp,gngm,bacs|aapp|7057|THBS1|TSP|||0|888|1904|1907|INFER|ASSOCIATED_WITH(INFER)||1883|1885|0|0|C0030193|Pain|sosy|sosy|||pain|||0|1000|1878|1882
SE|25462141|CONCLUSIONS|ab|10|relation|1|1|C0147139|Thrombospondin 1|aapp,gngm,bacs|aapp|7057|THBS1|TSP|||0|818|2154|2157|VERB|AFFECTS||2090|2099|13|10|C0030193|Pain|sosy|sosy|||pain|||0|1000|1878|1882
SE|25462141|CONCLUSIONS|ab|10|relation|4|1|C0030193|Pain|sosy|sosy|||pain|||0|1000|1878|1882|PREP|PROCESS_OF||1883|1885|10|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1886|1894
SE|25462141|CONCLUSIONS|ab|10|relation|9|1|C0147139|Thrombospondin 1|aapp,gngm,bacs|aapp|7057|THBS1|TSP|||0|888|1904|1907|PREP|PART_OF||1895|1899|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1886|1894
SE|25462141|CONCLUSIONS|ab|10|relation|12|9|C0030193|Pain|sosy|sosy|||pain|||0|1000|1878|1882|PREP|PROCESS_OF||2078|2080|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|2081|2089


SE|25462142||ti|1|text|21|63|Blink reflex in type 2 diabetes mellitus.
SE|25462142||ti|1|entity|C0596003|Blink Reflexes|ortf|||Blink reflex|||0|1000|21|33
SE|25462142||ti|1|entity|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|||type 2 diabetes mellitus|||0|1000|37|61

SE|25462142|PURPOSE|ab|1|text|69|205|PURPOSE: An evaluation of the extent of damage of the central nervous system in diabetes mellitus is of high value in current research.
SE|25462142|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|69|76
SE|25462142|PURPOSE|ab|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|81|91
SE|25462142|PURPOSE|ab|1|entity|C0439792|Extent|spco|||extent|||0|1000|99|105
SE|25462142|PURPOSE|ab|1|entity|C0927232|Neuraxis|bdsy|||central nervous system|||0|1000|123|145
SE|25462142|PURPOSE|ab|1|entity|C0011849|Diabetes Mellitus|dsyn|||diabetes mellitus|||0|1000|149|166
SE|25462142|PURPOSE|ab|1|entity|C0205250|High|qlco|||high|||0|694|173|177
SE|25462142|PURPOSE|ab|1|entity|C0521116|Current|tmco|||current|||0|888|187|194
SE|25462142|PURPOSE|ab|1|entity|C0035168|research|resa|||research|||0|888|195|203

SE|25462142|PURPOSE|ab|2|text|205|312|Electrophysiological abnormalities are frequently present in asymptomatic patients with diabetes mellitus.
SE|25462142|PURPOSE|ab|2|entity|C0332183|Frequent|tmco|||frequently|||0|1000|244|254
SE|25462142|PURPOSE|ab|2|entity|C0231221|Asymptomatic|fndg|||asymptomatic|||0|888|266|278
SE|25462142|PURPOSE|ab|2|entity|C0030705|Patients|podg|||patients|||0|888|279|287
SE|25462142|PURPOSE|ab|2|entity|C0011849|Diabetes Mellitus|dsyn|||diabetes mellitus|||0|1000|293|310
SE|25462142|PURPOSE|ab|2|relation|0|0|C0231221|Asymptomatic|fndg|fndg|||asymptomatic|||0|888|266|278|MOD/HEAD|PROCESS_OF||266|287|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|888|279|287
SE|25462142|PURPOSE|ab|2|relation|1|1|C0011849|Diabetes Mellitus|dsyn|dsyn|||diabetes mellitus|||0|1000|293|310|PREP|PROCESS_OF||288|292|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|279|287

SE|25462142|PURPOSE|ab|3|text|312|384|Diabetic cranial neuropathy is one of the complications of the disease.
SE|25462142|PURPOSE|ab|3|entity|C0037303|Bone structure of cranium|bpoc|||cranial|||0|901|321|328
SE|25462142|PURPOSE|ab|3|entity|C0011882|Diabetic Neuropathies|dsyn|||Diabetic cranial neuropathy|||0|901|312|339
SE|25462142|PURPOSE|ab|3|entity|C0205447|One|qnco|||one|||0|1000|343|346
SE|25462142|PURPOSE|ab|3|entity|C0009566|Complication|patf|||complications|||0|1000|354|367
SE|25462142|PURPOSE|ab|3|entity|C0012634|Disease|dsyn|||disease|||0|1000|375|382
SE|25462142|PURPOSE|ab|3|relation|0|0|C0011882|Diabetic Neuropathies|dsyn|dsyn|||Diabetic cranial neuropathy|||0|901|312|339|SPEC|ISA||312|367|0|0|C0009566|Complication|patf|patf|||complications|||0|1000|354|367
SE|25462142|PURPOSE|ab|3|relation|0|0|C0037303|Bone structure of cranium|bpoc|bpoc|||cranial|||0|901|321|328|MOD/HEAD|LOCATION_OF||321|339|0|0|C0011882|Diabetic Neuropathies|dsyn|dsyn|||Diabetic cranial neuropathy|||0|901|312|339

SE|25462142|PURPOSE|ab|4|text|384|449|Blink reflex is used to diagnose subclinical cranial neuropathy.
SE|25462142|PURPOSE|ab|4|entity|C0596003|Blink Reflexes|ortf|||Blink reflex|||0|1000|384|396
SE|25462142|PURPOSE|ab|4|entity|C0205211|Subclinical|qlco|||subclinical|||0|901|417|428
SE|25462142|PURPOSE|ab|4|entity|C0010266|Cranial nerve diseases|dsyn|||cranial neuropathy|||0|901|429|447

SE|25462142|PURPOSE|ab|5|text|449|596|The objective is to test the utility of blink reflex in detecting subclinical cranial nerve involvement in patients with type 2 diabetes mellitus.
SE|25462142|PURPOSE|ab|5|entity|C0596003|Blink Reflexes|ortf|||blink reflex|||0|1000|489|501
SE|25462142|PURPOSE|ab|5|entity|C0205211|Subclinical|qlco|||subclinical|||0|621|515|526
SE|25462142|PURPOSE|ab|5|entity|C0010268|Cranial Nerves|bpoc|||cranial nerve|||0|621|527|540
SE|25462142|PURPOSE|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|556|564
SE|25462142|PURPOSE|ab|5|entity|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|||type 2 diabetes mellitus|||0|1000|570|594
SE|25462142|PURPOSE|ab|5|relation|2|2|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|dsyn|||type 2 diabetes mellitus|||0|1000|570|594|NOM|AFFECTS||541|552|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|556|564

SE|25462142|METHODS|ab|6|text|596|716|METHODS: Forty patients with type 2 diabetes mellitus, aged from 30 to 60 years examined clinically and neurologically.
SE|25462142|METHODS|ab|6|entity|C0025663|Methods|inpr|||METHODS|||0|1000|596|603
SE|25462142|METHODS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|611|619
SE|25462142|METHODS|ab|6|entity|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|||type 2 diabetes mellitus|||0|1000|625|649
SE|25462142|METHODS|ab|6|entity|C0439234|year|tmco|||years|||0|861|670|675
SE|25462142|METHODS|ab|6|relation|2|1|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|dsyn|||type 2 diabetes mellitus|||0|1000|625|649|PREP|PROCESS_OF||620|624|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|611|619

SE|25462142|METHODS|ab|7|text|716|849|Blink reflex and nerve conduction studies for the upper and lower limbs were performed and compared with 20 matched normal controls.
SE|25462142|METHODS|ab|7|entity|C0596003|Blink Reflexes|ortf|||Blink reflex|||0|1000|716|728
SE|25462142|METHODS|ab|7|entity|C0886413|Nerve conduction procedures|topp|||nerve conduction|||0|1000|733|749
SE|25462142|METHODS|ab|7|entity|C1282910|Upper|spco|||upper|||0|1000|766|771
SE|25462142|METHODS|ab|7|entity|C0023216|Lower Extremity|blor|||lower limbs|||0|1000|776|787
SE|25462142|METHODS|ab|7|entity|C0150103|MATCHING|resa|||matched|||0|753|824|831
SE|25462142|METHODS|ab|7|entity|C0205307|Normal|qlco|||normal|||0|753|832|838
SE|25462142|METHODS|ab|7|entity|C0243148|control|ftcn|||controls|||0|753|839|847

SE|25462142|RESULTS|ab|8|text|849|1086|RESULTS: Diabetic patients with peripheral neuropathy showed significant prolonged distal latency and reduced amplitudes of the R2C response compared with the control, patients without peripheral neuropathy showed insignificant changes.
SE|25462142|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|849|856
SE|25462142|RESULTS|ab|8|entity|C0241863|Diabetic|fndg|||Diabetic|||0|888|858|866
SE|25462142|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|888|867|875
SE|25462142|RESULTS|ab|8|entity|C0031117|Peripheral Neuropathy|dsyn|||peripheral neuropathy|||0|1000|881|902
SE|25462142|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|815|910|921
SE|25462142|RESULTS|ab|8|entity|C0439590|Prolonged|tmco|||prolonged|||0|815|922|931
SE|25462142|RESULTS|ab|8|entity|C0205108|Distal|spco|||distal|||0|815|932|938
SE|25462142|RESULTS|ab|8|entity|C0205275|Latent|qlco|||latency|||0|815|939|946
SE|25462142|RESULTS|ab|8|entity|C0392756|Reduced|qlco|||reduced|||0|694|951|958
SE|25462142|RESULTS|ab|8|entity|||gngm|913,3732,6241|CD1E,CD82,RRM2|R2C|||0|861|977|980
SE|25462142|RESULTS|ab|8|entity|C0871261|response|clna|||response|||0|861|981|989
SE|25462142|RESULTS|ab|8|entity|C0243148|control|ftcn|||control|||0|1000|1008|1015
SE|25462142|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1017|1025
SE|25462142|RESULTS|ab|8|entity|C0031117|Peripheral Neuropathy|dsyn|||peripheral neuropathy|||0|1000|1034|1055
SE|25462142|RESULTS|ab|8|relation|0|0|C0241863|Diabetic|fndg|fndg|||Diabetic|||0|888|858|866|MOD/HEAD|PROCESS_OF||858|875|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|888|867|875
SE|25462142|RESULTS|ab|8|relation|8|1|C0031117|Peripheral Neuropathy|dsyn|dsyn|||peripheral neuropathy|||0|1000|881|902|PREP|PROCESS_OF||876|880|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|867|875

SE|25462142|RESULTS|ab|9|text|1086|1174|Alteration of R2 correlated with the type of treatment and the duration of the disease.
SE|25462142|RESULTS|ab|9|entity|C1515926|Alteration|idcn|||Alteration|||0|1000|1086|1096
SE|25462142|RESULTS|ab|9|entity|C1547052|*Type|qnco|||type|||0|1000|1123|1127
SE|25462142|RESULTS|ab|9|entity|C0449238|Duration|tmco|||duration|||0|1000|1149|1157
SE|25462142|RESULTS|ab|9|entity|C0012634|Disease|dsyn|||disease|||0|1000|1165|1172

SE|25462142|RESULTS|ab|10|text|1174|1446|In patients without peripheral neuropathy, ulnar sensory distal latencies showed significant positive correlation with R2I latency, whereas its Conduction Velocity (CV) showed significant positive correlation with R2C amplitudes and negative correlation with R2C latency.
SE|25462142|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1177|1185
SE|25462142|RESULTS|ab|10|entity|C0031117|Peripheral Neuropathy|dsyn|||peripheral neuropathy|||0|1000|1194|1215
SE|25462142|RESULTS|ab|10|entity|C0442044|Ulnar|blor|||ulnar|||0|812|1217|1222
SE|25462142|RESULTS|ab|10|entity|C0445254|Sensory|qlco|||sensory|||0|812|1223|1230
SE|25462142|RESULTS|ab|10|entity|C0205108|Distal|spco|||distal|||0|812|1231|1237
SE|25462142|RESULTS|ab|10|entity|C0205275|Latent|qlco|||latencies|||0|812|1238|1247
SE|25462142|RESULTS|ab|10|entity|C0750502|Significant|idcn|||significant|||0|623|1255|1266
SE|25462142|RESULTS|ab|10|entity|C1446409|Positive|qlco|||positive|||0|623|1267|1275
SE|25462142|RESULTS|ab|10|entity|||gngm|913,3732,6241|CD1E,CD82,RRM2|R2I|||0|789|1293|1296
SE|25462142|RESULTS|ab|10|entity|C0205275|Latent|qlco|||latency|||0|789|1297|1304
SE|25462142|RESULTS|ab|10|entity|C0234084|Conduction rate of nerve cell and nerve fiber|lbtr|||Conduction Velocity|||0|1000|1318|1337
SE|25462142|RESULTS|ab|10|entity|C0750502|Significant|idcn|||significant|||0|623|1350|1361
SE|25462142|RESULTS|ab|10|entity|C1446409|Positive|qlco|||positive|||0|623|1362|1370
SE|25462142|RESULTS|ab|10|entity|||gngm|913,3732,6241|CD1E,CD82,RRM2|R2C|||0|1000|1388|1391
SE|25462142|RESULTS|ab|10|entity|C0205160|Negative|qlco|||negative|||0|694|1407|1415
SE|25462142|RESULTS|ab|10|entity|||gngm|913,3732,6241|CD1E,CD82,RRM2|R2C|||0|789|1433|1436
SE|25462142|RESULTS|ab|10|entity|C0205275|Latent|qlco|||latency|||0|789|1437|1444

SE|25462142|CONCLUSIONS|ab|11|text|1446|1591|CONCLUSIONS: R2C is the most sensitive parameter in the blink reflex, which can help in the diagnosis of subclinical diabetic cranial neuropathy.
SE|25462142|CONCLUSIONS|ab|11|entity|||gngm|913,3732,6241|CD1E,CD82,RRM2|R2C|||0|1000|1459|1462
SE|25462142|CONCLUSIONS|ab|11|entity|C0205393|Most|qnco|||most|||0|851|1470|1474
SE|25462142|CONCLUSIONS|ab|11|entity|C0332324|Sensitive|ftcn|||sensitive|||0|851|1475|1484
SE|25462142|CONCLUSIONS|ab|11|entity|C0549193|Parameter|spco|||parameter|||0|851|1485|1494
SE|25462142|CONCLUSIONS|ab|11|entity|C0596003|Blink Reflexes|ortf|||blink reflex|||0|1000|1502|1514
SE|25462142|CONCLUSIONS|ab|11|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|1538|1547
SE|25462142|CONCLUSIONS|ab|11|entity|C0205211|Subclinical|qlco|||subclinical|||0|861|1551|1562
SE|25462142|CONCLUSIONS|ab|11|entity|C0037303|Bone structure of cranium|bpoc|||cranial|||0|861|1572|1579
SE|25462142|CONCLUSIONS|ab|11|entity|C0011882|Diabetic Neuropathies|dsyn|||diabetic cranial neuropathy|||0|861|1563|1590
SE|25462142|CONCLUSIONS|ab|11|relation|0|0|C0037303|Bone structure of cranium|bpoc|bpoc|||cranial|||0|861|1572|1579|MOD/HEAD|LOCATION_OF||1572|1590|0|0|C0011882|Diabetic Neuropathies|dsyn|dsyn|||diabetic cranial neuropathy|||0|861|1563|1590


SE|25462143||ti|1|text|21|100|Intraoperative monitoring for intracranial aneurysms: the Michigan experience.
SE|25462143||ti|1|entity|C0079637|Monitoring, Intraoperative|diap|||Intraoperative monitoring|||0|1000|21|46
SE|25462143||ti|1|entity|C0007766|Intracranial Aneurysm|dsyn|||intracranial aneurysms|||0|1000|51|73
SE|25462143||ti|1|entity|C0025939|Michigan|geoa|||Michigan|||0|888|79|87
SE|25462143||ti|1|entity|C0596545|experience|menp|||experience|||0|888|88|98

SE|25462143||ab|1|text|106|263|Intraoperative neurophysiological monitoring is routinely used during the repair (endovascular or microsurgical) of intracranial aneurysms at major centers.
SE|25462143||ab|1|entity|C0430853|Intraoperative neurophysiological monitoring|diap|||Intraoperative neurophysiological monitoring|||0|1000|106|150
SE|25462143||ab|1|entity|C0043240|Wound Healing|orgf|||repair|||0|1000|180|186
SE|25462143||ab|1|entity|C0524425|Endovascular|blor|||endovascular|||0|1000|188|200
SE|25462143||ab|1|entity|C0007766|Intracranial Aneurysm|dsyn|||intracranial aneurysms|||0|1000|222|244
SE|25462143||ab|1|entity|C0205164|Major|qlco|||major|||0|872|248|253
SE|25462143||ab|1|entity|C0205099|Central|spco|||centers|||0|872|254|261

SE|25462143||ab|2|text|263|470|There is a continued need of data sets from institutions with dedicated intraoperative neurophysiological monitoring services to further define the predictive factors of postoperative neurological deficits.
SE|25462143||ab|2|entity|C0750536|CONTINUED|idcn|||continued|||0|888|274|283
SE|25462143||ab|2|entity|C0027552|Needs|qlco|||need|||0|888|284|288
SE|25462143||ab|2|entity|C0150098|data set|inpr|||data sets|||0|983|292|301
SE|25462143||ab|2|entity|C0018704|Health care facility|hcro,mnob|||institutions|||0|966|307|319
SE|25462143||ab|2|entity|C0430853|Intraoperative neurophysiological monitoring|diap|||intraoperative neurophysiological monitoring|||0|854|335|379
SE|25462143||ab|2|entity|C0557854|Services|ftcn|||services|||0|854|380|388
SE|25462143||ab|2|entity|C1517331|Further|spco|||further|||0|1000|392|399
SE|25462143||ab|2|entity|C0683956|Predictive Factor|inpr|||predictive factors|||0|983|411|429
SE|25462143||ab|2|entity|C0521654|Neurologic Deficits|fndg|||neurological deficits|||0|884|447|468

SE|25462143||ab|3|text|470|620|We retrospectively reviewed and analyzed our database of all patients who underwent repair of intracranial aneurysms (endovascular or microsurgical).
SE|25462143||ab|3|entity|C0242356|Databases|inpr|||database|||0|1000|515|523
SE|25462143||ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|531|539
SE|25462143||ab|3|entity|C0043240|Wound Healing|orgf|||repair|||0|1000|554|560
SE|25462143||ab|3|entity|C0007766|Intracranial Aneurysm|dsyn|||intracranial aneurysms|||0|1000|564|586
SE|25462143||ab|3|entity|C0524425|Endovascular|blor|||endovascular|||0|1000|588|600

SE|25462143||ab|4|text|620|670|A total of 406 patients underwent 470 procedures.
SE|25462143||ab|4|entity|C0439175|% of total|qnco|||total|||0|1000|622|627
SE|25462143||ab|4|entity|C0030705|Patients|podg|||patients|||0|861|635|643
SE|25462143||ab|4|entity|C0025664|Methodology|inpr|||procedures|||0|861|658|668

SE|25462143||ab|5|text|670|734|The changes were noted during monitoring in 3.83% of the cases.
SE|25462143||ab|5|entity|C0439086|<3|qnco|||3|||0|861|714|715
SE|25462143||ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|727|732

SE|25462143||ab|6|text|734|875|Most of the changes were first detected in somatosensory evoked potential (88.89%) followed by brainstem auditory evoked potential (16.67%).
SE|25462143||ab|6|entity|C0205393|Most|qnco|||Most|||0|1000|734|738
SE|25462143||ab|6|entity|C1279901|Firstly|qlco|||first|||0|1000|759|764
SE|25462143||ab|6|entity|C0015216|Somatosensory Evoked Potentials|ortf|||somatosensory evoked potential|||0|1000|777|807
SE|25462143||ab|6|entity|C0079319|Evoked Potentials, Auditory, Brain Stem|diap|||brainstem auditory evoked potential|||0|1000|829|864

SE|25462143||ab|7|text|875|992|Changes were completely reversible in 44.44%, only partly reversible in 22.22%, and irreversible in 33.33% of cases.
SE|25462143||ab|7|entity|C0205343|Reversible|ftcn|||reversible|||0|861|899|909
SE|25462143||ab|7|entity|C0205343|Reversible|ftcn|||reversible|||0|827|933|943
SE|25462143||ab|7|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|985|990

SE|25462143||ab|8|text|992|1160|Intraoperative neurophysiological monitoring changes demonstrated high sensitivity, specificity, and negative predictive value for postoperative neurological deficits.
SE|25462143||ab|8|entity|C0430853|Intraoperative neurophysiological monitoring|diap|||Intraoperative neurophysiological monitoring|||0|908|992|1036
SE|25462143||ab|8|entity|C1441604|HIGH SENSITIVITY|lbpr|||high sensitivity|||0|1000|1058|1074
SE|25462143||ab|8|entity|C0037791|Specificity|qnco|||specificity|||0|1000|1076|1087
SE|25462143||ab|8|entity|C0205160|Negative|qlco|||negative|||0|901|1093|1101
SE|25462143||ab|8|entity|C1514307|Predictive Value|qlco|||predictive value|||0|901|1102|1118
SE|25462143||ab|8|entity|C0521654|Neurologic Deficits|fndg|||neurological deficits|||0|884|1137|1158

SE|25462143||ab|9|text|1160|1363|The association between intraoperative neurophysiological monitoring changes and Glasgow outcome scale was significant for reversible changes compared against irreversible and partly reversible changes.
SE|25462143||ab|9|entity|C0430853|Intraoperative neurophysiological monitoring|diap|||intraoperative neurophysiological monitoring|||0|908|1184|1228
SE|25462143||ab|9|entity|C0701887|Glasgow Outcome Scale|inpr,qnco|||Glasgow outcome scale|||0|1000|1241|1262
SE|25462143||ab|9|entity|C0750502|Significant|idcn|||significant|||0|1000|1267|1278
SE|25462143||ab|9|entity|C0205343|Reversible|ftcn|||reversible|||0|872|1283|1293
SE|25462143||ab|9|entity|C0205343|Reversible|ftcn|||reversible|||0|773|1343|1353

SE|25462143||ab|10|text|1363|1546|Presence of any intraoperative neurophysiological monitoring modality change during repair of intracranial aneurysm may suggest a higher risk for postoperative neurological deficits.
SE|25462143||ab|10|entity|C0430853|Intraoperative neurophysiological monitoring|diap|||intraoperative neurophysiological monitoring|||0|875|1379|1423
SE|25462143||ab|10|entity|C0695347|Modality|idcn|||modality|||0|875|1424|1432
SE|25462143||ab|10|entity|C0043240|Wound Healing|orgf|||repair|||0|1000|1447|1453
SE|25462143||ab|10|entity|C0007766|Intracranial Aneurysm|dsyn|||intracranial aneurysm|||0|1000|1457|1478
SE|25462143||ab|10|entity|C0205250|High|qlco|||higher|||0|872|1493|1499
SE|25462143||ab|10|entity|C0035647|Risk|qlco|||risk|||0|872|1500|1504
SE|25462143||ab|10|entity|C0521654|Neurologic Deficits|fndg|||neurological deficits|||0|884|1523|1544

SE|25462143||ab|11|text|1546|1747|Reversibility of the changes is a favorable marker, whereas irreversible changes are predictive of postoperative neurological deficits with deterioration of Glasgow outcome scale on a longer follow-up.
SE|25462143||ab|11|entity|C0449261|Reversibility|tmco|||Reversibility|||0|1000|1546|1559
SE|25462143||ab|11|entity|C0005516|Biological Markers|qlco|||marker|||0|853|1590|1596
SE|25462143||ab|11|entity|C0681890|predictive|qlco|||predictive|||0|1000|1631|1641
SE|25462143||ab|11|entity|C0521654|Neurologic Deficits|fndg|||neurological deficits|||0|884|1659|1680
SE|25462143||ab|11|entity|C0868945|Deterioration|phpr|||deterioration|||0|1000|1686|1699
SE|25462143||ab|11|entity|C0701887|Glasgow Outcome Scale|inpr,qnco|||Glasgow outcome scale|||0|1000|1703|1724
SE|25462143||ab|11|entity|C0205166|Long|qlco|||longer|||0|890|1730|1736
SE|25462143||ab|11|entity|C1522577|follow-up|hlca|||follow-up|||0|890|1737|1746


SE|25462144||ti|1|text|21|119|Recovery of TES-MEPs during surgical decompression of the spine: a case series of eight patients.
SE|25462144||ti|1|entity|C0237820|Recovery|orgf|||Recovery|||0|1000|21|29
SE|25462144||ti|1|entity|C0076172|TES|orch|||TES|||0|872|33|36
SE|25462144||ti|1|entity|C0054871|Cathepsin L|aapp,enzy|||MEPs|||0|872|37|41
SE|25462144||ti|1|entity|C0376530|Decompression, Surgical|topp|||surgical decompression|||0|1000|49|71
SE|25462144||ti|1|entity|C0037949|Vertebral column|bpoc|||spine|||0|1000|79|84
SE|25462144||ti|1|entity|C0150093|Case Series|resa|||case series|||0|1000|88|99
SE|25462144||ti|1|entity|C0205454|Eight|qnco|||eight|||0|888|103|108
SE|25462144||ti|1|entity|C0030705|Patients|podg|||patients|||0|888|109|117

SE|25462144|PURPOSE|ab|1|text|125|347|PURPOSE: This study aimed to illustrate the recovery of transcranial electrical stimulation motor evoked potentials during surgical decompression of the spinal cord in patients with impaired motor function preoperatively.
SE|25462144|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|125|132
SE|25462144|PURPOSE|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|139|144
SE|25462144|PURPOSE|ab|1|entity|C0237820|Recovery|orgf|||recovery|||0|1000|169|177
SE|25462144|PURPOSE|ab|1|entity|C0455803|Transcranial electrical stimulation|topp|||transcranial electrical stimulation|||0|888|181|216
SE|25462144|PURPOSE|ab|1|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||motor evoked potentials|||0|888|217|240
SE|25462144|PURPOSE|ab|1|entity|C0376530|Decompression, Surgical|topp|||surgical decompression|||0|1000|248|270
SE|25462144|PURPOSE|ab|1|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|278|289
SE|25462144|PURPOSE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|293|301
SE|25462144|PURPOSE|ab|1|entity|C0221099|Impaired|ftcn|||impaired|||0|824|307|315
SE|25462144|PURPOSE|ab|1|entity|C0234130|Motor function|ftcn|||motor function|||0|824|316|330
SE|25462144|PURPOSE|ab|1|relation|6|3|C0282617|Evoked Potentials, Motor|diap,ortf|ortf|||motor evoked potentials|||0|888|217|240|PREP|PROCESS_OF||290|292|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|293|301

SE|25462144|PURPOSE|ab|2|text|347|470|Specific attention was paid to the duration of neurologic symptoms before surgery and the postoperative clinical recovery.
SE|25462144|PURPOSE|ab|2|entity|C0004268|Attention|menp|||attention|||0|861|356|365
SE|25462144|PURPOSE|ab|2|entity|C0449238|Duration|tmco|||duration|||0|1000|382|390
SE|25462144|PURPOSE|ab|2|entity|C0235031|Neurologic Symptoms|sosy|||neurologic symptoms|||0|1000|394|413
SE|25462144|PURPOSE|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|790|451|459
SE|25462144|PURPOSE|ab|2|entity|C0237820|Recovery|orgf|||recovery|||0|790|460|468

SE|25462144|METHODS|ab|3|text|470|583|METHODS: A case series of eight patients was selected from a cohort of 74 patients that underwent spine surgery.
SE|25462144|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|470|477
SE|25462144|METHODS|ab|3|entity|C0150093|Case Series|resa|||case series|||0|1000|481|492
SE|25462144|METHODS|ab|3|entity|C0205454|Eight|qnco|||eight|||0|888|496|501
SE|25462144|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|888|502|510
SE|25462144|METHODS|ab|3|entity|C0599755|cohort|popg|||cohort|||0|1000|531|537
SE|25462144|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|861|544|552
SE|25462144|METHODS|ab|3|entity|C0920347|Procedure on spinal cord|topp|||spine surgery|||0|1000|568|581
SE|25462144|METHODS|ab|3|relation|1|1|C0920347|Procedure on spinal cord|topp|topp|||spine surgery|||0|1000|568|581|VERB|TREATS||558|567|5|1|C0030705|Patients|podg,humn|podg|||patients|||0|861|544|552

SE|25462144|METHODS|ab|4|text|583|777|The selected patients initially had low or absent transcranial electrical stimulation motor evoked potentials followed by a significant increase after surgical decompression of the spinal cord.
SE|25462144|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|872|596|604
SE|25462144|METHODS|ab|4|entity|C0205265|Initially|tmco|||initially|||0|1000|605|614
SE|25462144|METHODS|ab|4|entity|C0205251|low|qlco|||low|||0|1000|619|622
SE|25462144|METHODS|ab|4|entity|C0332197|Absent|qnco|||absent|||0|863|626|632
SE|25462144|METHODS|ab|4|entity|C0455803|Transcranial electrical stimulation|topp|||transcranial electrical stimulation|||0|863|633|668
SE|25462144|METHODS|ab|4|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||motor evoked potentials|||0|863|669|692
SE|25462144|METHODS|ab|4|entity|C0750502|Significant|idcn|||significant|||0|888|707|718
SE|25462144|METHODS|ab|4|entity|C0442805|Increase|ftcn|||increase|||0|888|719|727
SE|25462144|METHODS|ab|4|entity|C0376530|Decompression, Surgical|topp|||surgical decompression|||0|1000|734|756
SE|25462144|METHODS|ab|4|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|764|775
SE|25462144|METHODS|ab|4|relation|2|1|C0376530|Decompression, Surgical|topp|topp|||surgical decompression|||0|1000|734|756|PREP|PRECEDES||728|733|4|2|C0282617|Evoked Potentials, Motor|diap,ortf|diap|||motor evoked potentials|||0|863|669|692

SE|25462144|RESULTS|ab|5|text|777|1062|RESULTS: A significant intraoperative increase in amplitude of motor evoked potentials was detected after decompression of the spinal cord or cauda equina in patients suffering from spinal canal stenosis (n = 2), extradural meningioma (n = 3), or a herniated nucleus polposus (n = 3).
SE|25462144|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|777|784
SE|25462144|RESULTS|ab|5|entity|C0750502|Significant|idcn|||significant|||0|851|788|799
SE|25462144|RESULTS|ab|5|entity|C0456904|Intraoperative|tmco|||intraoperative|||0|851|800|814
SE|25462144|RESULTS|ab|5|entity|C0442805|Increase|ftcn|||increase|||0|851|815|823
SE|25462144|RESULTS|ab|5|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||motor evoked potentials|||0|1000|840|863
SE|25462144|RESULTS|ab|5|entity|C0011117|Decompression, external|phpr|||decompression|||0|1000|883|896
SE|25462144|RESULTS|ab|5|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|904|915
SE|25462144|RESULTS|ab|5|entity|C0007458|Cauda Equina|bpoc|||cauda equina|||0|1000|919|931
SE|25462144|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|935|943
SE|25462144|RESULTS|ab|5|entity|C0037944|Spinal Stenosis|dsyn|||spinal canal stenosis|||0|901|959|980
SE|25462144|RESULTS|ab|5|entity|C0025286|meningioma|neop|||meningioma|||0|861|1001|1011
SE|25462144|RESULTS|ab|5|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|660|1036|1043
SE|25462144|RESULTS|ab|5|relation|6|1|C0037944|Spinal Stenosis|dsyn|dsyn|||spinal canal stenosis|||0|901|959|980|VERB|PROCESS_OF||944|953|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|935|943
SE|25462144|RESULTS|ab|5|relation|7|4|C0282617|Evoked Potentials, Motor|diap,ortf|ortf|||motor evoked potentials|||0|1000|840|863|PREP|PROCESS_OF||932|934|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|935|943

SE|25462144|RESULTS|ab|6|text|1062|1218|This was related to an enhanced neurologic outcome only if patients (n = 6) had a short onset (less than 1/2 year) of neurologic impairment before surgery.
SE|25462144|RESULTS|ab|6|entity|C0205494|Neurologic|ftcn|||neurologic|||0|750|1094|1104
SE|25462144|RESULTS|ab|6|entity|C1274040|result|ftcn|||outcome|||0|750|1105|1112
SE|25462144|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|1000|1121|1129
SE|25462144|RESULTS|ab|6|entity|C0332162|Onset|qlco|||onset|||0|888|1150|1155
SE|25462144|RESULTS|ab|6|entity|C0580272|1/2|inpr|||1/2|||0|901|1167|1170
SE|25462144|RESULTS|ab|6|entity|C0439234|year|tmco|||year|||0|901|1171|1175
SE|25462144|RESULTS|ab|6|entity|C0521654|Neurologic Deficits|fndg|||neurologic impairment|||0|950|1180|1201

SE|25462144|CONCLUSIONS|ab|7|text|1218|1500|CONCLUSIONS: In patients with a short onset of neurologic impairment because of compression of the spinal cord or caudal fibers, an intraoperative recovery of transcranial electrical stimulation motor evoked potentials can indicate an improvement of motor function postoperatively.
SE|25462144|CONCLUSIONS|ab|7|entity|C0030705|Patients|podg|||patients|||0|1000|1234|1242
SE|25462144|CONCLUSIONS|ab|7|entity|C0332162|Onset|qlco|||onset|||0|888|1256|1261
SE|25462144|CONCLUSIONS|ab|7|entity|C0521654|Neurologic Deficits|fndg|||neurologic impairment|||0|950|1265|1286
SE|25462144|CONCLUSIONS|ab|7|entity|C0332459|Compressed structure|ftcn|||compression|||0|1000|1298|1309
SE|25462144|CONCLUSIONS|ab|7|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|1317|1328
SE|25462144|CONCLUSIONS|ab|7|entity|C0205097|Caudal|blor|||caudal|||0|888|1332|1338
SE|25462144|CONCLUSIONS|ab|7|entity|C1304649|Tissue fiber|tisu|||fibers|||0|888|1339|1345
SE|25462144|CONCLUSIONS|ab|7|entity|C0456904|Intraoperative|tmco|||intraoperative|||0|888|1350|1364
SE|25462144|CONCLUSIONS|ab|7|entity|C0237820|Recovery|orgf|||recovery|||0|888|1365|1373
SE|25462144|CONCLUSIONS|ab|7|entity|C0455803|Transcranial electrical stimulation|topp|||transcranial electrical stimulation|||0|888|1377|1412
SE|25462144|CONCLUSIONS|ab|7|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||motor evoked potentials|||0|888|1413|1436
SE|25462144|CONCLUSIONS|ab|7|entity|C0234130|Motor function|ftcn|||motor function|||0|901|1468|1482

SE|25462144|CONCLUSIONS|ab|8|text|1500|1680|Therefore, transcranial electrical stimulation motor evoked potentials can be considered as a useful tool to the surgeon to monitor the quality of decompression of the spinal cord.
SE|25462144|CONCLUSIONS|ab|8|entity|C0455803|Transcranial electrical stimulation|topp|||transcranial electrical stimulation|||0|888|1511|1546
SE|25462144|CONCLUSIONS|ab|8|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||motor evoked potentials|||0|888|1547|1570
SE|25462144|CONCLUSIONS|ab|8|entity|C0336791|Tool|mnob|||tool|||0|861|1601|1605
SE|25462144|CONCLUSIONS|ab|8|entity|C0582175|Surgeon|prog|||surgeon|||0|1000|1613|1620
SE|25462144|CONCLUSIONS|ab|8|entity|C0332306|Quality|qlco|||quality|||0|1000|1636|1643
SE|25462144|CONCLUSIONS|ab|8|entity|C0011117|Decompression, external|phpr|||decompression|||0|1000|1647|1660
SE|25462144|CONCLUSIONS|ab|8|entity|C0037925|Spinal Cord|bpoc|||spinal cord|||0|1000|1668|1679


SE|25462145||ti|1|text|21|136|Train-of-four test in intraoperative neurophysiologic monitoring: differences between hand and foot train-of-four.
SE|25462145||ti|1|entity|C0205450|Four|qnco|||four|||0|888|30|34
SE|25462145||ti|1|entity|C0039593|Testing|resa|||test|||0|888|35|39
SE|25462145||ti|1|entity|C0430853|Intraoperative neurophysiological monitoring|diap|||intraoperative neurophysiologic monitoring|||0|966|43|85
SE|25462145||ti|1|entity|C1547020|*Difference|qnco|||differences|||0|966|87|98
SE|25462145||ti|1|entity|C0018563|Hand|bpoc|||hand|||0|1000|107|111
SE|25462145||ti|1|entity|C0016504|Pes|bpoc|||foot|||0|791|116|120
SE|25462145||ti|1|entity|C0205450|Four|qnco|||four|||0|791|130|134

SE|25462145|PURPOSE|ab|1|text|142|376|PURPOSE: Comparison of T1-T4 decrement between upper and lower extremity muscles can indicate differences between recovery time from neuromuscular blockade, which may have repercussions for neurophysiologic intraoperative monitoring.
SE|25462145|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|142|149
SE|25462145|PURPOSE|ab|1|entity|C1442881|SLC25A4 protein, human|aapp,bacs|291|SLC25A4|T1-T4|||0|623|165|170
SE|25462145|PURPOSE|ab|1|entity|C0040165|Thyroxine|aapp,horm,phsu|291|SLC25A4|T1-T4|||0|623|165|170
SE|25462145|PURPOSE|ab|1|entity|C1282910|Upper|spco|||upper|||0|1000|189|194
SE|25462145|PURPOSE|ab|1|entity|C0023216|Lower Extremity|blor|||lower extremity|||0|901|199|214
SE|25462145|PURPOSE|ab|1|entity|C0026845|Muscle|tisu|||muscles|||0|901|215|222
SE|25462145|PURPOSE|ab|1|entity|C1547020|*Difference|qnco|||differences|||0|966|236|247
SE|25462145|PURPOSE|ab|1|entity|C0237820|Recovery|orgf|||recovery|||0|888|256|264
SE|25462145|PURPOSE|ab|1|entity|C0040223|Time|tmco|||time|||0|888|265|269
SE|25462145|PURPOSE|ab|1|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blockade|||0|1000|275|297
SE|25462145|PURPOSE|ab|1|entity|C0079637|Monitoring, Intraoperative|diap|||intraoperative monitoring|||0|901|349|374

SE|25462145|PURPOSE|ab|2|text|376|493|We investigated decrement between T1 and T4 hand and foot muscle responses on quantitative train-of-four (TOF) test.
SE|25462145|PURPOSE|ab|2|entity|C0018563|Hand|bpoc|||hand|||0|888|420|424
SE|25462145|PURPOSE|ab|2|entity|C0016504|Pes|bpoc|||foot|||0|851|429|433
SE|25462145|PURPOSE|ab|2|entity|C0026845|Muscle|tisu|||muscle|||0|851|434|440
SE|25462145|PURPOSE|ab|2|entity|C0871261|response|clna|||responses|||0|851|441|450
SE|25462145|PURPOSE|ab|2|entity|C0392762|Quantitative|qnco|||quantitative|||0|737|454|466
SE|25462145|PURPOSE|ab|2|entity|C0205450|Four|qnco|||four|||0|737|476|480
SE|25462145|PURPOSE|ab|2|entity|C0039593|Testing|resa|||test|||0|737|487|491

SE|25462145|METHODS|ab|3|text|493|714|METHODS: Study analyzed differences between recovery of foot, abductor hallucis muscle, and hand, first dorsal interosseous muscle, by application of quantitative TOF test on 147 patients undergoing lumbar spine surgery.
SE|25462145|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|493|500
SE|25462145|METHODS|ab|3|entity|C1515960|Analyzed|qlco|||analyzed|||0|872|508|516
SE|25462145|METHODS|ab|3|entity|C1547020|*Difference|qnco|||differences|||0|872|517|528
SE|25462145|METHODS|ab|3|entity|C0237820|Recovery|orgf|||recovery|||0|1000|537|545
SE|25462145|METHODS|ab|3|entity|C0016504|Pes|bpoc|||foot|||0|1000|549|553
SE|25462145|METHODS|ab|3|entity|C0682592|Abductor muscle|tisu|||abductor hallucis muscle|||0|913|555|579
SE|25462145|METHODS|ab|3|entity|C0018563|Hand|bpoc|||hand|||0|1000|585|589
SE|25462145|METHODS|ab|3|entity|C1279901|Firstly|qlco|||first|||0|775|591|596
SE|25462145|METHODS|ab|3|entity|C0205095|Dorsal|spco|||dorsal|||0|775|597|603
SE|25462145|METHODS|ab|3|entity|C0026845|Muscle|tisu|||muscle|||0|775|617|623
SE|25462145|METHODS|ab|3|entity|C0392762|Quantitative|qnco|||quantitative|||0|737|643|655
SE|25462145|METHODS|ab|3|entity|C0205450|Four|qnco|||TOF|||0|737|656|659
SE|25462145|METHODS|ab|3|entity|C0039593|Testing|resa|||test|||0|737|660|664
SE|25462145|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|861|672|680
SE|25462145|METHODS|ab|3|entity|C0408578|Lumbar spine operations NOS|topp|||lumbar spine surgery|||0|1000|692|712
SE|25462145|METHODS|ab|3|relation|1|1|C0408578|Lumbar spine operations NOS|topp|topp|||lumbar spine surgery|||0|1000|692|712|VERB|TREATS||681|691|9|1|C0030705|Patients|podg,humn|podg|||patients|||0|861|672|680

SE|25462145|METHODS|ab|4|text|714|901|T1 to T4 decrements on hand and foot TOF were obtained and classified into different groups, depending on elapsed time after administration of neuromuscular blocking agents and its dose.
SE|25462145|METHODS|ab|4|entity|C0018563|Hand|bpoc|||hand|||0|872|737|741
SE|25462145|METHODS|ab|4|entity|C0016504|Pes|bpoc|||foot|||0|791|746|750
SE|25462145|METHODS|ab|4|entity|C0205450|Four|qnco|||TOF|||0|791|751|754
SE|25462145|METHODS|ab|4|entity|C1547020|*Difference|qnco|||different|||0|853|789|798
SE|25462145|METHODS|ab|4|entity|C0441833|Groups|inpr|||groups|||0|853|799|805
SE|25462145|METHODS|ab|4|entity|C0040223|Time|tmco|||time|||0|861|828|832
SE|25462145|METHODS|ab|4|entity|C0027866|Neuromuscular Blocking Agents|phsu|||neuromuscular blocking agents|||0|1000|857|886
SE|25462145|METHODS|ab|4|entity|C1446466|Dose|qnco|||dose|||0|1000|895|899

SE|25462145|RESULTS|ab|5|text|901|1007|RESULTS: There are significant differences between T1-T4 decrements obtained on hand and foot (P < 0.05).
SE|25462145|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|901|908
SE|25462145|RESULTS|ab|5|entity|C0750502|Significant|idcn|||significant|||0|872|920|931
SE|25462145|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||differences|||0|872|932|943
SE|25462145|RESULTS|ab|5|entity|C1442881|SLC25A4 protein, human|aapp,bacs|291|SLC25A4|T1-T4|||0|623|952|957
SE|25462145|RESULTS|ab|5|entity|C0040165|Thyroxine|aapp,horm,phsu|291|SLC25A4|T1-T4|||0|623|952|957
SE|25462145|RESULTS|ab|5|entity|C0018563|Hand|bpoc|||hand|||0|872|981|985
SE|25462145|RESULTS|ab|5|entity|C0016504|Pes|bpoc|||foot|||0|1000|990|994

SE|25462145|RESULTS|ab|6|text|1007|1157|T1-T4 decrement determined on abductor hallucis muscle was lower indicating more rapid recovery than the first dorsal interosseous muscle (P < 0.05).
SE|25462145|RESULTS|ab|6|entity|C1442881|SLC25A4 protein, human|aapp,bacs|291|SLC25A4|T1-T4|||0|623|1007|1012
SE|25462145|RESULTS|ab|6|entity|C0040165|Thyroxine|aapp,horm,phsu|291|SLC25A4|T1-T4|||0|623|1007|1012
SE|25462145|RESULTS|ab|6|entity|C0682592|Abductor muscle|tisu|||abductor hallucis muscle|||0|913|1037|1061
SE|25462145|RESULTS|ab|6|entity|C0441994|Lower|ftcn|||lower|||0|1000|1066|1071
SE|25462145|RESULTS|ab|6|entity|C0205172|More|ftcn|||more|||0|851|1083|1087
SE|25462145|RESULTS|ab|6|entity|C0439831|Rapid|qlco|||rapid|||0|851|1088|1093
SE|25462145|RESULTS|ab|6|entity|C0237820|Recovery|orgf|||recovery|||0|851|1094|1102
SE|25462145|RESULTS|ab|6|entity|C1279901|Firstly|qlco|||first|||0|775|1112|1117
SE|25462145|RESULTS|ab|6|entity|C0205095|Dorsal|spco|||dorsal|||0|775|1118|1124
SE|25462145|RESULTS|ab|6|entity|C0026845|Muscle|tisu|||muscle|||0|775|1138|1144

SE|25462145|RESULTS|ab|7|text|1157|1279|Interestingly, quite opposite, more pronounced decrement in foot TOF than hand was showed in 4% (5 out of all 147 cases).
SE|25462145|RESULTS|ab|7|entity|C1521805|Opposite|spco|||opposite|||0|861|1178|1186
SE|25462145|RESULTS|ab|7|entity|C0205172|More|ftcn|||more|||0|660|1188|1192
SE|25462145|RESULTS|ab|7|entity|C0016504|Pes|bpoc|||foot|||0|764|1217|1221
SE|25462145|RESULTS|ab|7|entity|C0205450|Four|qnco|||TOF|||0|764|1222|1225
SE|25462145|RESULTS|ab|7|entity|C0018563|Hand|bpoc|||hand|||0|1000|1231|1235
SE|25462145|RESULTS|ab|7|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|1271|1276

SE|25462145|CONCLUSIONS|ab|8|text|1279|1506|CONCLUSIONS: The observed difference between recovery of hand and foot muscles suggests that quantitative TOF test should be performed on extremities for which accurate data about the level of neuromuscular blockade is sought.
SE|25462145|CONCLUSIONS|ab|8|entity|C1547020|*Difference|qnco|||difference|||0|888|1305|1315
SE|25462145|CONCLUSIONS|ab|8|entity|C0237820|Recovery|orgf|||recovery|||0|1000|1324|1332
SE|25462145|CONCLUSIONS|ab|8|entity|C0018563|Hand|bpoc|||hand|||0|1000|1336|1340
SE|25462145|CONCLUSIONS|ab|8|entity|C0016504|Pes|bpoc|||foot|||0|888|1345|1349
SE|25462145|CONCLUSIONS|ab|8|entity|C0026845|Muscle|tisu|||muscles|||0|888|1350|1357
SE|25462145|CONCLUSIONS|ab|8|entity|C0392762|Quantitative|qnco|||quantitative|||0|737|1372|1384
SE|25462145|CONCLUSIONS|ab|8|entity|C0205450|Four|qnco|||TOF|||0|737|1385|1388
SE|25462145|CONCLUSIONS|ab|8|entity|C0039593|Testing|resa|||test|||0|737|1389|1393
SE|25462145|CONCLUSIONS|ab|8|entity|C0015385|Limb structure|bpoc|||extremities|||0|1000|1417|1428
SE|25462145|CONCLUSIONS|ab|8|entity|C0443131|Accurate|qlco|||accurate|||0|888|1439|1447
SE|25462145|CONCLUSIONS|ab|8|entity|C1511726|Data|idcn|||data|||0|888|1448|1452
SE|25462145|CONCLUSIONS|ab|8|entity|C0234119|Neuromuscular inhibition|dsyn|||neuromuscular blockade|||0|1000|1472|1494
SE|25462145|CONCLUSIONS|ab|8|relation|0|0|C0026845|Muscle|tisu|tisu|||muscles|||0|888|1350|1357|MOD/HEAD|PART_OF||1345|1357|0|0|C0016504|Pes|bpoc|bpoc|||foot|||0|888|1345|1349

SE|25462145|CONCLUSIONS|ab|9|text|1506|1599|During lumbar spine surgery monitoring, in addition to hand TOF, foot TOF should be included.
SE|25462145|CONCLUSIONS|ab|9|entity|C0408578|Lumbar spine operations NOS|topp|||lumbar spine surgery|||0|756|1513|1533
SE|25462145|CONCLUSIONS|ab|9|entity|C0018563|Hand|bpoc|||hand|||0|764|1561|1565
SE|25462145|CONCLUSIONS|ab|9|entity|C0205450|Four|qnco|||TOF|||0|764|1566|1569
SE|25462145|CONCLUSIONS|ab|9|entity|C0016504|Pes|bpoc|||foot|||0|791|1571|1575
SE|25462145|CONCLUSIONS|ab|9|entity|C0205450|Four|qnco|||TOF|||0|791|1576|1579


SE|25462146||ti|1|text|21|151|Stimulus-induced generalized epileptiform discharges: an unrecognized EEG pattern in refractory nonconvulsive status epilepticus.
SE|25462146||ti|1|entity|C0234402|Stimulus|phpr|||Stimulus|||0|1000|21|29
SE|25462146||ti|1|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|38|73
SE|25462146||ti|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|790|91|94
SE|25462146||ti|1|entity|C0449774|Patterns|spco|||pattern|||0|790|95|102
SE|25462146||ti|1|entity|C0205269|Intractable|ftcn|||refractory|||0|916|106|116
SE|25462146||ti|1|entity|C1142187|Nonconvulsive status epilepticus|dsyn|||nonconvulsive status epilepticus|||0|916|117|149
SE|25462146||ti|1|relation|3|0|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||nonconvulsive status epilepticus|||0|916|117|149|ADJ|AFFECTS|negation|106|116|3|2|C0474721|Generalized epileptiform discharges|fndg|fndg|||generalized epileptiform discharges|||0|1000|38|73

SE|25462146|PURPOSE|ab|1|text|157|509|PURPOSE: To report an unrecognized EEG pattern occurring in patients with coma with nonconvulsive status epilepticus (NCSE) treated with thiopental and characterized by a high amplitude generalized sharp wave that was induced by isolated or repetitive low frequency photic or tactile stimulation (stimulus-induced generalized epileptiform discharges).
SE|25462146|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|157|164
SE|25462146|PURPOSE|ab|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|790|192|195
SE|25462146|PURPOSE|ab|1|entity|C0449774|Patterns|spco|||pattern|||0|790|196|203
SE|25462146|PURPOSE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|217|225
SE|25462146|PURPOSE|ab|1|entity|C0009421|comatose|dsyn|||coma|||0|1000|231|235
SE|25462146|PURPOSE|ab|1|entity|C1142187|Nonconvulsive status epilepticus|dsyn|||nonconvulsive status epilepticus|||0|1000|241|273
SE|25462146|PURPOSE|ab|1|entity|C0039925|Thiopental|orch,phsu|||thiopental|||0|1000|294|304
SE|25462146|PURPOSE|ab|1|entity|C0205250|High|qlco|||high|||0|694|328|332
SE|25462146|PURPOSE|ab|1|entity|C0678544|wave|npop|||wave|||0|861|361|365
SE|25462146|PURPOSE|ab|1|entity|C0205409|Isolated|ftcn|||isolated|||0|1000|386|394
SE|25462146|PURPOSE|ab|1|entity|C0205213|Low frequency|tmco|||low frequency|||0|901|409|422
SE|25462146|PURPOSE|ab|1|entity|C0023693|Light|npop|||photic|||0|944|423|429
SE|25462146|PURPOSE|ab|1|entity|C0439815|Tactile|ftcn|||tactile|||0|888|433|440
SE|25462146|PURPOSE|ab|1|entity|C0234402|Stimulus|phpr|||stimulus|||0|1000|454|462
SE|25462146|PURPOSE|ab|1|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|471|506
SE|25462146|PURPOSE|ab|1|relation|9|1|C0039925|Thiopental|orch,phsu|phsu|||thiopental|||0|1000|294|304|VERB|TREATS||281|288|5|1|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||nonconvulsive status epilepticus|||0|1000|241|273
SE|25462146|PURPOSE|ab|1|relation|11|1|C0009421|comatose|dsyn|dsyn|||coma|||0|1000|231|235|PREP|PROCESS_OF||226|230|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|217|225

SE|25462146|METHODS|ab|2|text|509|776|METHODS: Review of clinical and EEG records of 4 patients with stimulus-induced generalized epileptiform discharges identified among patients admitted to an intensive care unit (ICU) of our institution who underwent EEG monitoring between July 2011 and January 2013.
SE|25462146|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|509|516
SE|25462146|METHODS|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|1000|528|536
SE|25462146|METHODS|ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|541|544
SE|25462146|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|861|558|566
SE|25462146|METHODS|ab|2|entity|C0234402|Stimulus|phpr|||stimulus|||0|1000|572|580
SE|25462146|METHODS|ab|2|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|589|624
SE|25462146|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|642|650
SE|25462146|METHODS|ab|2|entity|C0021708|intensive care unit|hcro,mnob|||intensive care unit|||0|1000|666|685
SE|25462146|METHODS|ab|2|entity|C0018704|Health care facility|hcro,mnob|||institution|||0|1000|699|710
SE|25462146|METHODS|ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|694|725|728
SE|25462146|METHODS|ab|2|relation|7|1|C0474721|Generalized epileptiform discharges|fndg|fndg|||generalized epileptiform discharges|||0|1000|589|624|PREP|PROCESS_OF||636|641|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|642|650

SE|25462146|RESULTS|ab|3|text|776|927|RESULTS: Four patients had refractory NCSE secondary to hepatic encephalopathy, brain tumor, immunomediated encephalopathy, or anti-NMDA encephalitis.
SE|25462146|RESULTS|ab|3|entity|C1274040|result|ftcn|||RESULTS|||0|966|776|783
SE|25462146|RESULTS|ab|3|entity|C0205450|Four|qnco|||Four|||0|888|785|789
SE|25462146|RESULTS|ab|3|entity|C0030705|Patients|podg|||patients|||0|888|790|798
SE|25462146|RESULTS|ab|3|entity|C0205269|Intractable|ftcn|||refractory|||0|916|803|813
SE|25462146|RESULTS|ab|3|entity|C1142187|Nonconvulsive status epilepticus|dsyn|||NCSE|||0|916|814|818
SE|25462146|RESULTS|ab|3|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|1000|819|828
SE|25462146|RESULTS|ab|3|entity|C0019151|Hepatic Encephalopathy|dsyn|||hepatic encephalopathy|||0|1000|832|854
SE|25462146|RESULTS|ab|3|entity|C0006118|Brain Neoplasms|neop|||brain tumor|||0|1000|856|867
SE|25462146|RESULTS|ab|3|entity|C0085584|Encephalopathies|dsyn|||encephalopathy|||0|861|884|898
SE|25462146|RESULTS|ab|3|entity|C0079883|N-Methylaspartate|aapp,phsu|||NMDA|||0|790|908|912
SE|25462146|RESULTS|ab|3|entity|C0014038|Encephalitis|dsyn|||encephalitis|||0|790|913|925
SE|25462146|RESULTS|ab|3|relation|6|1|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||NCSE|||0|916|814|818|AUX|PROCESS_OF||799|802|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|790|798

SE|25462146|RESULTS|ab|4|text|927|1117|All of them were treated with several antiepileptic drugs and anesthetics, but stimulus-induced generalized epileptiform discharges were only recorded after control of NCSE with thiopental.
SE|25462146|RESULTS|ab|4|entity|C0443302|Several|qnco|||several|||0|901|957|964
SE|25462146|RESULTS|ab|4|entity|C0003299|Antiepileptic Agents|phsu|||antiepileptic drugs|||0|901|965|984
SE|25462146|RESULTS|ab|4|entity|C0002930|Anesthesiology|bmod|||anesthetics|||0|1000|989|1000
SE|25462146|RESULTS|ab|4|entity|C0234402|Stimulus|phpr|||stimulus|||0|1000|1006|1014
SE|25462146|RESULTS|ab|4|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|1023|1058
SE|25462146|RESULTS|ab|4|entity|C0243148|control|ftcn|||control|||0|1000|1084|1091
SE|25462146|RESULTS|ab|4|entity|C1142187|Nonconvulsive status epilepticus|dsyn|||NCSE|||0|1000|1095|1099
SE|25462146|RESULTS|ab|4|entity|C0039925|Thiopental|orch,phsu|||thiopental|||0|1000|1105|1115
SE|25462146|RESULTS|ab|4|relation|2|2|C0039925|Thiopental|orch,phsu|phsu|||thiopental|||0|1000|1105|1115|NOM|TREATS||1084|1091|2|1|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||NCSE|||0|1000|1095|1099
SE|25462146|RESULTS|ab|4|relation|3|3|C0003299|Antiepileptic Agents|phsu|phsu|||antiepileptic drugs|||0|901|965|984|VERB|CAUSES||1015|1022|4|1|C0474721|Generalized epileptiform discharges|fndg|fndg|||generalized epileptiform discharges|||0|1000|1023|1058

SE|25462146|RESULTS|ab|5|text|1117|1185|The discharges occurred without associated clinical manifestations.
SE|25462146|RESULTS|ab|5|entity|C0012621|Discharge, Body Substance|bdsu|||discharges|||0|1000|1121|1131
SE|25462146|RESULTS|ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|660|1160|1168

SE|25462146|RESULTS|ab|6|text|1185|1248|Two patients died in the ICU, and two had a favorable outcome.
SE|25462146|RESULTS|ab|6|entity|C0205448|Two|qnco|||Two|||0|888|1185|1188
SE|25462146|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|888|1189|1197
SE|25462146|RESULTS|ab|6|entity|C0021708|intensive care unit|hcro,mnob|||ICU|||0|1000|1210|1213
SE|25462146|RESULTS|ab|6|entity|C0205448|Two|qnco|||two|||0|1000|1219|1222
SE|25462146|RESULTS|ab|6|entity|C1274040|result|ftcn|||outcome|||0|853|1239|1246

SE|25462146|RESULTS|ab|7|text|1248|1414|Stimulus-induced generalized epileptiform discharges were not recorded in 240 critically ill patients admitted to the ICU who had an EEG recorded during this period.
SE|25462146|RESULTS|ab|7|entity|C0234402|Stimulus|phpr|||Stimulus|||0|1000|1248|1256
SE|25462146|RESULTS|ab|7|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|1265|1300
SE|25462146|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1306|1309
SE|25462146|RESULTS|ab|7|entity|C0010340|Critical Illness|dsyn|||critically ill|||0|824|1326|1340
SE|25462146|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|824|1341|1349
SE|25462146|RESULTS|ab|7|entity|C0021708|intensive care unit|hcro,mnob|||ICU|||0|1000|1366|1369
SE|25462146|RESULTS|ab|7|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|1381|1384
SE|25462146|RESULTS|ab|7|entity|C0439531|/period|tmco|||period|||0|1000|1406|1412
SE|25462146|RESULTS|ab|7|relation|0|0|C0010340|Critical Illness|dsyn|dsyn|||critically ill|||0|824|1326|1340|MOD/HEAD|PROCESS_OF||1326|1349|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|824|1341|1349
SE|25462146|RESULTS|ab|7|relation|2|1|C0474721|Generalized epileptiform discharges|fndg|fndg|||generalized epileptiform discharges|||0|1000|1265|1300|PREP|PROCESS_OF|negation|1319|1321|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|824|1341|1349

SE|25462146|RESULTS|ab|8|text|1414|1489|Twenty-two of them were in NCSE, and only one was treated with thiopental.
SE|25462146|RESULTS|ab|8|entity|C0205448|Two|qnco|||two|||0|861|1421|1424
SE|25462146|RESULTS|ab|8|entity|C1142187|Nonconvulsive status epilepticus|dsyn|||NCSE|||0|1000|1441|1445
SE|25462146|RESULTS|ab|8|entity|C0205447|One|qnco|||one|||0|861|1456|1459
SE|25462146|RESULTS|ab|8|entity|C0039925|Thiopental|orch,phsu|||thiopental|||0|1000|1477|1487
SE|25462146|RESULTS|ab|8|relation|1|1|C0039925|Thiopental|orch,phsu|phsu|||thiopental|||0|1000|1477|1487|VERB|TREATS||1464|1471|2|2|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||NCSE|||0|1000|1441|1445

SE|25462146|CONCLUSIONS|ab|9|text|1489|1630|CONCLUSIONS: Stimulus-induced generalized epileptiform discharges is an EEG pattern occurring in patients with NCSE treated with thiopental.
SE|25462146|CONCLUSIONS|ab|9|entity|C0234402|Stimulus|phpr|||Stimulus|||0|1000|1502|1510
SE|25462146|CONCLUSIONS|ab|9|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|1519|1554
SE|25462146|CONCLUSIONS|ab|9|entity|C0013819|Electroencephalography|diap|||EEG|||0|888|1561|1564
SE|25462146|CONCLUSIONS|ab|9|entity|C0449774|Patterns|spco|||pattern|||0|888|1565|1572
SE|25462146|CONCLUSIONS|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1586|1594
SE|25462146|CONCLUSIONS|ab|9|entity|C1142187|Nonconvulsive status epilepticus|dsyn|||NCSE|||0|1000|1600|1604
SE|25462146|CONCLUSIONS|ab|9|entity|C0039925|Thiopental|orch,phsu|||thiopental|||0|1000|1618|1628
SE|25462146|CONCLUSIONS|ab|9|relation|1|1|C0039925|Thiopental|orch,phsu|phsu|||thiopental|||0|1000|1618|1628|VERB|TREATS||1605|1612|6|1|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||NCSE|||0|1000|1600|1604
SE|25462146|CONCLUSIONS|ab|9|relation|2|1|C1142187|Nonconvulsive status epilepticus|dsyn|dsyn|||NCSE|||0|1000|1600|1604|PREP|PROCESS_OF||1595|1599|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1586|1594
SE|25462146|CONCLUSIONS|ab|9|relation|4|3|C0234402|Stimulus|phpr|phpr|||Stimulus|||0|1000|1502|1510|VERB|OCCURS_IN||1573|1582|3|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1586|1594

SE|25462146|CONCLUSIONS|ab|10|text|1630|1752|The clinical relevance and pathophysiology of stimulus-induced generalized epileptiform discharges remain to be clarified.
SE|25462146|CONCLUSIONS|ab|10|entity|C0205210|Clinical|qlco|||clinical|||0|694|1634|1642
SE|25462146|CONCLUSIONS|ab|10|entity|C0031847|physiopathological|ftcn|||pathophysiology|||0|1000|1657|1672
SE|25462146|CONCLUSIONS|ab|10|entity|C0234402|Stimulus|phpr|||stimulus|||0|1000|1676|1684
SE|25462146|CONCLUSIONS|ab|10|entity|C0474721|Generalized epileptiform discharges|fndg|||generalized epileptiform discharges|||0|1000|1693|1728


SE|25462147||ti|1|text|21|155|Electroencephalographic changes in sporadic Creutzfeldt-Jakob disease and correlation with clinical stages: a retrospective analysis.
SE|25462147||ti|1|entity|C0013819|Electroencephalography|diap|||Electroencephalographic|||0|836|21|44
SE|25462147||ti|1|entity|C0205422|Sporadic|tmco|||sporadic|||0|916|56|64
SE|25462147||ti|1|entity|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|||Creutzfeldt-Jakob disease|||0|916|65|90
SE|25462147||ti|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|112|120
SE|25462147||ti|1|entity|C1306673|Stage|qlco|||stages|||0|888|121|127
SE|25462147||ti|1|entity|C1514923|Retrospective|qlco|||retrospective|||0|888|131|144
SE|25462147||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|888|145|153
SE|25462147||ti|1|relation|1|1|C0013819|Electroencephalography|diap|diap|||Electroencephalographic|||0|836|21|44|PREP|DIAGNOSES||53|55|4|1|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|dsyn|||Creutzfeldt-Jakob disease|||0|916|65|90

SE|25462147|PURPOSE|ab|1|text|161|345|PURPOSE: To analyze clinical features and EEG changes in patients with sporadic Creutzfeldt-Jakob disease and study the association between different EEG patterns and clinical stages.
SE|25462147|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|161|168
SE|25462147|PURPOSE|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|694|181|189
SE|25462147|PURPOSE|ab|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|203|206
SE|25462147|PURPOSE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|218|226
SE|25462147|PURPOSE|ab|1|entity|C0205422|Sporadic|tmco|||sporadic|||0|916|232|240
SE|25462147|PURPOSE|ab|1|entity|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|||Creutzfeldt-Jakob disease|||0|916|241|266
SE|25462147|PURPOSE|ab|1|entity|C1547020|*Difference|qnco|||different|||0|828|301|310
SE|25462147|PURPOSE|ab|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|828|311|314
SE|25462147|PURPOSE|ab|1|entity|C0449774|Patterns|spco|||patterns|||0|828|315|323
SE|25462147|PURPOSE|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|328|336
SE|25462147|PURPOSE|ab|1|entity|C1306673|Stage|qlco|||stages|||0|888|337|343
SE|25462147|PURPOSE|ab|1|relation|3|1|C0013819|Electroencephalography|diap|diap|||EEG|||0|1000|203|206|VERB|AFFECTS||207|214|5|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|218|226
SE|25462147|PURPOSE|ab|1|relation|4|1|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|dsyn|||Creutzfeldt-Jakob disease|||0|916|241|266|PREP|PROCESS_OF||227|231|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|218|226

SE|25462147|METHODS|ab|2|text|345|538|METHODS: We retrospectively analyzed the clinical features and EEG patterns of 3 patients with clinical stage II and 10 patients with stage III sporadic Creutzfeldt-Jakob disease (EEG n = 17).
SE|25462147|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|345|352
SE|25462147|METHODS|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|694|386|394
SE|25462147|METHODS|ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|888|408|411
SE|25462147|METHODS|ab|2|entity|C0449774|Patterns|spco|||patterns|||0|888|412|420
SE|25462147|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|888|426|434
SE|25462147|METHODS|ab|2|entity|C0205571|Clinical stage II|qlco|||clinical stage II|||0|1000|440|457
SE|25462147|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|861|465|473
SE|25462147|METHODS|ab|2|entity|C0441771|Stage level 3|inpr|||stage III|||0|864|479|488
SE|25462147|METHODS|ab|2|entity|C0205422|Sporadic|tmco|||sporadic|||0|864|489|497
SE|25462147|METHODS|ab|2|entity|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|||Creutzfeldt-Jakob disease|||0|864|498|523
SE|25462147|METHODS|ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|872|525|528
SE|25462147|METHODS|ab|2|relation|2|1|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|dsyn|||Creutzfeldt-Jakob disease|||0|864|498|523|PREP|PROCESS_OF||474|478|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|465|473

SE|25462147|METHODS|ab|3|text|538|629|Chi-square test was used to study the association between EEG features and disease stages.
SE|25462147|METHODS|ab|3|entity|C0008041|Chi-Square Test|qnco|||Chi-square test|||0|1000|538|553
SE|25462147|METHODS|ab|3|entity|C1285629|EEG feature|clna|||EEG features|||0|983|596|608
SE|25462147|METHODS|ab|3|entity|C0699749|disease stage|diap|||disease stages|||0|983|613|627

SE|25462147|RESULTS|ab|4|text|629|722|RESULTS: Diffuse slowing of the background was the dominant EEG pattern in stage II disease.
SE|25462147|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|629|636
SE|25462147|RESULTS|ab|4|entity|C0205219|Diffuse|qlco|||Diffuse|||0|872|638|645
SE|25462147|RESULTS|ab|4|entity|C0439834|Slow|qlco|||slowing|||0|872|646|653
SE|25462147|RESULTS|ab|4|entity|C1527180|Dominant|ftcn|||dominant|||0|851|680|688
SE|25462147|RESULTS|ab|4|entity|C0013819|Electroencephalography|diap|||EEG|||0|851|689|692
SE|25462147|RESULTS|ab|4|entity|C0449774|Patterns|spco|||pattern|||0|851|693|700
SE|25462147|RESULTS|ab|4|entity|C0441767|Stage level 2|inpr|||stage II|||0|901|704|712
SE|25462147|RESULTS|ab|4|entity|C0012634|Disease|dsyn|||disease|||0|901|713|720

SE|25462147|RESULTS|ab|5|text|722|886|All stage III patients showed additional abnormalities, such as frontal intermittent rhythmic delta activity, periodic discharges, and nonperiodic triphasic waves.
SE|25462147|RESULTS|ab|5|entity|C0441771|Stage level 3|inpr|||stage III|||0|901|726|735
SE|25462147|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|901|736|744
SE|25462147|RESULTS|ab|5|entity|C1524062|Additional|ftcn|||additional|||0|888|752|762
SE|25462147|RESULTS|ab|5|entity|C0429326|Frontal intermittent rhythmic delta activity|fndg|||frontal intermittent rhythmic delta activity|||0|1000|786|830
SE|25462147|RESULTS|ab|5|entity|C0332182|Periodic|tmco|||periodic|||0|888|832|840
SE|25462147|RESULTS|ab|5|entity|C0012621|Discharge, Body Substance|bdsu|||discharges|||0|888|841|851
SE|25462147|RESULTS|ab|5|entity|C0429303|Triphasic waves|fndg|||triphasic waves|||0|901|869|884

SE|25462147|RESULTS|ab|6|text|886|996|Periodic discharges had significant association with stage III disease, present in 64% of EEGs in this group.
SE|25462147|RESULTS|ab|6|entity|C0332182|Periodic|tmco|||Periodic|||0|888|886|894
SE|25462147|RESULTS|ab|6|entity|C0012621|Discharge, Body Substance|bdsu|||discharges|||0|888|895|905
SE|25462147|RESULTS|ab|6|entity|C0750502|Significant|idcn|||significant|||0|694|910|921
SE|25462147|RESULTS|ab|6|entity|C0441771|Stage level 3|inpr|||stage III|||0|901|939|948
SE|25462147|RESULTS|ab|6|entity|C0012634|Disease|dsyn|||disease|||0|901|949|956
SE|25462147|RESULTS|ab|6|entity|C0150312|Present|qnco|||present|||0|1000|958|965
SE|25462147|RESULTS|ab|6|entity|C0013819|Electroencephalography|diap|||EEGs|||0|966|976|980
SE|25462147|RESULTS|ab|6|entity|C0441833|Groups|inpr|||group|||0|1000|989|994

SE|25462147|RESULTS|ab|7|text|996|1116|Sixty-seven percentage of periodic discharges had a peculiar pattern labeled by us as posterior-anterior-posterior lag.
SE|25462147|RESULTS|ab|7|entity|C0205453|Seven|qnco|||seven|||0|790|1002|1007
SE|25462147|RESULTS|ab|7|entity|C0439165|Percent (qualifier value)|qnco|||percentage|||0|790|1008|1018
SE|25462147|RESULTS|ab|7|entity|C0332182|Periodic|tmco|||periodic|||0|888|1022|1030
SE|25462147|RESULTS|ab|7|entity|C0012621|Discharge, Body Substance|bdsu|||discharges|||0|888|1031|1041
SE|25462147|RESULTS|ab|7|entity|C0449774|Patterns|spco|||pattern|||0|861|1057|1064
SE|25462147|RESULTS|ab|7|entity|C0205095|Dorsal|spco|||posterior|||0|775|1082|1091
SE|25462147|RESULTS|ab|7|entity|C0205094|Anterior|spco|||anterior|||0|775|1092|1100
SE|25462147|RESULTS|ab|7|entity|C0024219|Lymphangiography|diap|||lag|||0|775|1111|1114

SE|25462147|CONCLUSIONS|ab|8|text|1116|1325|CONCLUSIONS: The EEG of stage II sporadic Creutzfeldt-Jakob disease is characterized by background slowing while the presence of periodic discharge has a significant association with stage III of the disease.
SE|25462147|CONCLUSIONS|ab|8|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|1133|1136
SE|25462147|CONCLUSIONS|ab|8|entity|C0441767|Stage level 2|inpr|||stage II|||0|864|1140|1148
SE|25462147|CONCLUSIONS|ab|8|entity|C0205422|Sporadic|tmco|||sporadic|||0|864|1149|1157
SE|25462147|CONCLUSIONS|ab|8|entity|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|||Creutzfeldt-Jakob disease|||0|864|1158|1183
SE|25462147|CONCLUSIONS|ab|8|entity|C0439834|Slow|qlco|||slowing|||0|827|1215|1222
SE|25462147|CONCLUSIONS|ab|8|entity|C0332182|Periodic|tmco|||periodic|||0|888|1245|1253
SE|25462147|CONCLUSIONS|ab|8|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|888|1254|1263
SE|25462147|CONCLUSIONS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|694|1270|1281
SE|25462147|CONCLUSIONS|ab|8|entity|C0441771|Stage level 3|inpr|||stage III|||0|1000|1299|1308
SE|25462147|CONCLUSIONS|ab|8|entity|C0012634|Disease|dsyn|||disease|||0|1000|1316|1323
SE|25462147|CONCLUSIONS|ab|8|relation|6|4|C0022336|Creutzfeldt-Jakob Syndrome|dsyn|dsyn|||Creutzfeldt-Jakob disease|||0|864|1158|1183|NOM|COEXISTS_WITH||1282|1293|2|2|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|1316|1323

SE|25462147|CONCLUSIONS|ab|9|text|1325|1405|The posterior-anterior-posterior lag of periodic discharge is a new observation.
SE|25462147|CONCLUSIONS|ab|9|entity|C0205095|Dorsal|spco|||posterior|||0|775|1329|1338
SE|25462147|CONCLUSIONS|ab|9|entity|C0205094|Anterior|spco|||anterior|||0|775|1339|1347
SE|25462147|CONCLUSIONS|ab|9|entity|C0024219|Lymphangiography|diap|||lag|||0|775|1358|1361
SE|25462147|CONCLUSIONS|ab|9|entity|C0332182|Periodic|tmco|||periodic|||0|888|1365|1373
SE|25462147|CONCLUSIONS|ab|9|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|888|1374|1383
SE|25462147|CONCLUSIONS|ab|9|entity|C0205314|New|tmco|||new|||0|694|1389|1392


SE|25462148||ti|1|text|21|143|Idiopathic normal pressure hydrocephalus, quantitative EEG findings, and the cerebrospinal fluid tap test: a pilot study.
SE|25462148||ti|1|entity|C0332240|Unknown (origin)|ftcn|||Idiopathic|||0|916|21|31
SE|25462148||ti|1|entity|C0020258|Hydrocephalus, Normal Pressure|dsyn|||normal pressure hydrocephalus|||0|916|32|61
SE|25462148||ti|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|901|63|75
SE|25462148||ti|1|entity|C0234550|EEG finding|fndg|||EEG findings|||0|901|76|88
SE|25462148||ti|1|entity|C0034115|Paracentesis|hlca|||tap|||0|916|118|121
SE|25462148||ti|1|entity|C1167875|Cerebrospinal fluid test|lbpr|||cerebrospinal fluid tap test|||0|916|98|126
SE|25462148||ti|1|entity|C0031928|Pilot Projects|resa|||pilot study|||0|1000|130|141

SE|25462148|PURPOSE|ab|1|text|149|445|PURPOSE: In this pilot study, we analyzed relationships between quantitative EEG measurements and clinical parameters in idiopathic normal pressure hydrocephalus patients, along with differences in these quantitative EEG markers between cerebrospinal fluid tap test responders and nonresponders.
SE|25462148|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|149|156
SE|25462148|PURPOSE|ab|1|entity|C0031928|Pilot Projects|resa|||pilot study|||0|1000|166|177
SE|25462148|PURPOSE|ab|1|entity|C0439849|Relationships|qlco|||relationships|||0|1000|191|204
SE|25462148|PURPOSE|ab|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|851|213|225
SE|25462148|PURPOSE|ab|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|851|226|229
SE|25462148|PURPOSE|ab|1|entity|C0242485|Measurement|ftcn|||measurements|||0|851|230|242
SE|25462148|PURPOSE|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|247|255
SE|25462148|PURPOSE|ab|1|entity|C0332240|Unknown (origin)|ftcn|||idiopathic|||0|875|270|280
SE|25462148|PURPOSE|ab|1|entity|C0020258|Hydrocephalus, Normal Pressure|dsyn|||normal pressure hydrocephalus|||0|875|281|310
SE|25462148|PURPOSE|ab|1|entity|C0030705|Patients|podg|||patients|||0|875|311|319
SE|25462148|PURPOSE|ab|1|entity|C1547020|*Difference|qnco|||differences|||0|966|332|343
SE|25462148|PURPOSE|ab|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|623|353|365
SE|25462148|PURPOSE|ab|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|623|366|369
SE|25462148|PURPOSE|ab|1|entity|C0034115|Paracentesis|hlca|||tap|||0|687|406|409
SE|25462148|PURPOSE|ab|1|entity|C1167875|Cerebrospinal fluid test|lbpr|||cerebrospinal fluid tap test|||0|687|386|414
SE|25462148|PURPOSE|ab|1|relation|0|0|C0020258|Hydrocephalus, Normal Pressure|dsyn|dsyn|||normal pressure hydrocephalus|||0|875|281|310|MOD/HEAD|PROCESS_OF||281|319|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|875|311|319

SE|25462148|METHODS|ab|2|text|445|651|METHODS: Twenty-six idiopathic normal pressure hydrocephalus patients (9 cerebrospinal fluid tap test responders and 17 cerebrospinal fluid tap test nonresponders) constituted the final group for analysis.
SE|25462148|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|445|452
SE|25462148|METHODS|ab|2|entity|C0205452|Six|qnco|||six|||0|806|461|464
SE|25462148|METHODS|ab|2|entity|C0332240|Unknown (origin)|ftcn|||idiopathic|||0|806|465|475
SE|25462148|METHODS|ab|2|entity|C0020258|Hydrocephalus, Normal Pressure|dsyn|||normal pressure hydrocephalus|||0|806|476|505
SE|25462148|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|806|506|514
SE|25462148|METHODS|ab|2|entity|C0034115|Paracentesis|hlca|||tap|||0|651|538|541
SE|25462148|METHODS|ab|2|entity|C1167875|Cerebrospinal fluid test|lbpr|||cerebrospinal fluid tap test|||0|651|518|546
SE|25462148|METHODS|ab|2|entity|C0034115|Paracentesis|hlca|||tap|||0|651|585|588
SE|25462148|METHODS|ab|2|entity|C1167875|Cerebrospinal fluid test|lbpr|||cerebrospinal fluid tap test|||0|651|565|593
SE|25462148|METHODS|ab|2|entity|C0205088|End-stage|tmco|||final|||0|888|625|630
SE|25462148|METHODS|ab|2|entity|C0441833|Groups|inpr|||group|||0|888|631|636
SE|25462148|METHODS|ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|641|649
SE|25462148|METHODS|ab|2|relation|0|0|C0020258|Hydrocephalus, Normal Pressure|dsyn|dsyn|||normal pressure hydrocephalus|||0|806|476|505|MOD/HEAD|PROCESS_OF||476|514|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|806|506|514

SE|25462148|METHODS|ab|3|text|651|741|The resting EEG was recorded and relative powers were computed for seven frequency bands.
SE|25462148|METHODS|ab|3|entity|C0035253|Rest|dora|||resting|||0|888|655|662
SE|25462148|METHODS|ab|3|entity|C0013819|Electroencephalography|diap|||EEG|||0|888|663|666
SE|25462148|METHODS|ab|3|entity|C0205345|Relative|qlco|||relative|||0|694|684|692
SE|25462148|METHODS|ab|3|entity|C0205453|Seven|qnco|||seven|||0|851|718|723
SE|25462148|METHODS|ab|3|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|851|724|733
SE|25462148|METHODS|ab|3|entity|C0175723|Bands|medd|||bands|||0|851|734|739

SE|25462148|RESULTS|ab|4|text|741|939|RESULTS: Cerebrospinal fluid tap test nonresponders, when compared with responders, showed a statistically significant increase in alpha2 band power at the right frontal and centrotemporal regions.
SE|25462148|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|741|748
SE|25462148|RESULTS|ab|4|entity|C0034115|Paracentesis|hlca|||tap|||0|687|770|773
SE|25462148|RESULTS|ab|4|entity|C1167875|Cerebrospinal fluid test|lbpr|||Cerebrospinal fluid tap test|||0|687|750|778
SE|25462148|RESULTS|ab|4|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|901|834|859
SE|25462148|RESULTS|ab|4|entity|C0442805|Increase|ftcn|||increase|||0|901|860|868
SE|25462148|RESULTS|ab|4|entity|C0175723|Bands|medd|||band|||0|660|879|883
SE|25462148|RESULTS|ab|4|entity|C0205090|Right|spco|||right|||0|888|897|902
SE|25462148|RESULTS|ab|4|entity|C0205123|Coronal|spco|||frontal|||0|888|903|910
SE|25462148|RESULTS|ab|4|entity|C0205147|Region|spco|||regions|||0|827|930|937

SE|25462148|RESULTS|ab|5|text|939|1140|Higher delta2 band powers in the frontal, central, parietal, and occipital regions and lower alpha1 band powers in the right temporal region significantly correlated with poorer cognitive performance.
SE|25462148|RESULTS|ab|5|entity|C0205250|High|qlco|||Higher|||0|580|939|945
SE|25462148|RESULTS|ab|5|entity|C0175723|Bands|medd|||band|||0|580|953|957
SE|25462148|RESULTS|ab|5|entity|C0205123|Coronal|spco|||frontal|||0|851|972|979
SE|25462148|RESULTS|ab|5|entity|C0205099|Central|spco|||central|||0|851|981|988
SE|25462148|RESULTS|ab|5|entity|C0442030|Parietal|spco|||parietal|||0|851|990|998
SE|25462148|RESULTS|ab|5|entity|C0028785|Occipital lobe|bpoc|||occipital regions|||0|983|1004|1021
SE|25462148|RESULTS|ab|5|entity|C0441994|Lower|ftcn|||lower|||0|597|1026|1031
SE|25462148|RESULTS|ab|5|entity|||gngm|146|ADRA1D|alpha1|||0|597|1032|1038
SE|25462148|RESULTS|ab|5|entity|C0175723|Bands|medd|||band|||0|597|1039|1043
SE|25462148|RESULTS|ab|5|entity|C1184320|Right temporal part of head|blor|||right temporal region|||0|1000|1058|1079
SE|25462148|RESULTS|ab|5|entity|C0032854|Poverty|grpa|||poorer|||0|840|1110|1116
SE|25462148|RESULTS|ab|5|entity|C1516691|Cognitive|ftcn|||cognitive|||0|840|1117|1126
SE|25462148|RESULTS|ab|5|entity|C0597198|Performance|inbe|||performance|||0|840|1127|1138
SE|25462148|RESULTS|ab|5|relation|2|1|C1184320|Right temporal part of head|blor|blor|||right temporal region|||0|1000|1058|1079|PREP|LOCATION_OF||1051|1053|4|2|C0028785|Occipital lobe|bpoc|bpoc|||occipital regions|||0|983|1004|1021

SE|25462148|RESULTS|ab|6|text|1140|1257|Higher theta1 band powers in the left parietal and occipital regions significantly correlated with gait dysfunction.
SE|25462148|RESULTS|ab|6|entity|C0205250|High|qlco|||Higher|||0|580|1140|1146
SE|25462148|RESULTS|ab|6|entity|C0175723|Bands|medd|||band|||0|580|1154|1158
SE|25462148|RESULTS|ab|6|entity|C0205091|Left|spco|||left|||0|888|1173|1177
SE|25462148|RESULTS|ab|6|entity|C0442030|Parietal|spco|||parietal|||0|888|1178|1186
SE|25462148|RESULTS|ab|6|entity|C0028785|Occipital lobe|bpoc|||occipital regions|||0|983|1191|1208
SE|25462148|RESULTS|ab|6|entity|C0016928|Gait|fndg|||gait|||0|888|1239|1243

SE|25462148|RESULTS|ab|7|text|1257|1367|And higher delta1 band powers in the right frontal regions significantly correlated with urinary disturbance.
SE|25462148|RESULTS|ab|7|entity|C0205250|High|qlco|||higher|||0|580|1261|1267
SE|25462148|RESULTS|ab|7|entity|||gngm|8788,28514|DLK1,DLL1|delta1|||0|580|1268|1274
SE|25462148|RESULTS|ab|7|entity|C0175723|Bands|medd|||band|||0|580|1275|1279
SE|25462148|RESULTS|ab|7|entity|C0205090|Right|spco|||right|||0|890|1294|1299
SE|25462148|RESULTS|ab|7|entity|C0016733|frontal lobe|bpoc|||frontal regions|||0|890|1300|1315
SE|25462148|RESULTS|ab|7|entity|C1524119|urinary|qlco|||urinary|||0|694|1346|1353

SE|25462148|CONCLUSIONS|ab|8|text|1367|1580|CONCLUSIONS: Our findings may encourage further research using quantitative EEG in patients with ventriculomegaly as a potential electrophysiological marker for predicting cerebrospinal fluid tap test responders.
SE|25462148|CONCLUSIONS|ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1384|1392
SE|25462148|CONCLUSIONS|ab|8|entity|C1517331|Further|spco|||further|||0|1000|1407|1414
SE|25462148|CONCLUSIONS|ab|8|entity|C0392762|Quantitative|qnco|||quantitative|||0|888|1430|1442
SE|25462148|CONCLUSIONS|ab|8|entity|C0013819|Electroencephalography|diap|||EEG|||0|888|1443|1446
SE|25462148|CONCLUSIONS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1450|1458
SE|25462148|CONCLUSIONS|ab|8|entity|C0237399|Potential|qlco|||potential|||0|890|1486|1495
SE|25462148|CONCLUSIONS|ab|8|entity|C0814247|electrophysiological markers|qlco|||electrophysiological marker|||0|890|1496|1523
SE|25462148|CONCLUSIONS|ab|8|entity|C1508497|PREDICTED|clna|||predicting|||0|648|1528|1538
SE|25462148|CONCLUSIONS|ab|8|entity|C0034115|Paracentesis|hlca|||tap|||0|648|1559|1562
SE|25462148|CONCLUSIONS|ab|8|entity|C1167875|Cerebrospinal fluid test|lbpr|||cerebrospinal fluid tap test|||0|648|1539|1567

SE|25462148|CONCLUSIONS|ab|9|text|1580|1764|This study additionally suggests that the delta, theta, and alpha bands are statistically correlated with the severity of symptoms in idiopathic normal pressure hydrocephalus patients.
SE|25462148|CONCLUSIONS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|1000|1585|1590
SE|25462148|CONCLUSIONS|ab|9|entity|C0439101|Theta|inpr|||theta|||0|1000|1629|1634
SE|25462148|CONCLUSIONS|ab|9|entity|C0439095|Alpha|inpr|||alpha|||0|888|1640|1645
SE|25462148|CONCLUSIONS|ab|9|entity|C0175723|Bands|medd|||bands|||0|888|1646|1651
SE|25462148|CONCLUSIONS|ab|9|entity|C0439793|Severities|qlco|||severity|||0|1000|1690|1698
SE|25462148|CONCLUSIONS|ab|9|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|1702|1710
SE|25462148|CONCLUSIONS|ab|9|entity|C0332240|Unknown (origin)|ftcn|||idiopathic|||0|875|1714|1724
SE|25462148|CONCLUSIONS|ab|9|entity|C0020258|Hydrocephalus, Normal Pressure|dsyn|||normal pressure hydrocephalus|||0|875|1725|1754
SE|25462148|CONCLUSIONS|ab|9|entity|C0030705|Patients|podg|||patients|||0|875|1755|1763
SE|25462148|CONCLUSIONS|ab|9|relation|0|0|C0020258|Hydrocephalus, Normal Pressure|dsyn|dsyn|||normal pressure hydrocephalus|||0|875|1725|1754|MOD/HEAD|PROCESS_OF||1725|1763|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|875|1755|1763
SE|25462148|CONCLUSIONS|ab|9|relation|6|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|1000|1702|1710|PREP|PROCESS_OF||1711|1713|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|875|1755|1763


SE|25462149||ti|1|text|21|64|Infraslow EEG changes in infantile spasms.
SE|25462149||ti|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|861|31|34
SE|25462149||ti|1|entity|C0037769|Infantile spasms|dsyn|||infantile spasms|||0|1000|46|62
SE|25462149||ti|1|relation|1|1|C0013819|Electroencephalography|diap|diap|||EEG|||0|861|31|34|VERB|AFFECTS||35|42|1|1|C0037769|Infantile spasms|dsyn|dsyn|||infantile spasms|||0|1000|46|62

SE|25462149|PURPOSE|ab|1|text|70|165|PURPOSE: Infantile spasms (IS) are a devastating epileptic encephalopathy syndrome of infancy.
SE|25462149|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|70|77
SE|25462149|PURPOSE|ab|1|entity|C0037769|Infantile spasms|dsyn|||Infantile spasms|||0|1000|79|95
SE|25462149|PURPOSE|ab|1|entity|C0543888|Encephalopathic epilepsy|dsyn|||epileptic encephalopathy|||0|824|119|143
SE|25462149|PURPOSE|ab|1|entity|C0039082|Syndrome|dsyn|||syndrome|||0|824|144|152
SE|25462149|PURPOSE|ab|1|entity|C0231330|Infancy|tmco|||infancy|||0|1000|156|163

SE|25462149|PURPOSE|ab|2|text|165|355|Analysis of infraslow EEG activity (ISA) has shown potential in the presurgical evaluation of patients with epilepsy and in differentiating between focal and generalized epilepsy syndromes.
SE|25462149|PURPOSE|ab|2|entity|C0936012|Analysis|resa|||Analysis|||0|1000|165|173
SE|25462149|PURPOSE|ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|790|187|190
SE|25462149|PURPOSE|ab|2|entity|C0237399|Potential|qlco|||potential|||0|1000|216|225
SE|25462149|PURPOSE|ab|2|entity|C0220825|Evaluation|ftcn|||evaluation|||0|861|245|255
SE|25462149|PURPOSE|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|259|267
SE|25462149|PURPOSE|ab|2|entity|C0014544|Epilepsy|dsyn|||epilepsy|||0|1000|273|281
SE|25462149|PURPOSE|ab|2|entity|C0205234|Focal|spco|||focal|||0|1000|313|318
SE|25462149|PURPOSE|ab|2|entity|C0014548|Epilepsy, Generalized|dsyn|||generalized epilepsy|||0|901|323|343
SE|25462149|PURPOSE|ab|2|entity|C0039082|Syndrome|dsyn|||syndromes|||0|901|344|353
SE|25462149|PURPOSE|ab|2|relation|3|1|C0014544|Epilepsy|dsyn|dsyn|||epilepsy|||0|1000|273|281|PREP|PROCESS_OF||268|272|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|259|267

SE|25462149|PURPOSE|ab|3|text|355|492|Infraslow EEG activity analysis may provide insights into the pathophysiology of some difficult-to-treat epilepsy syndromes, such as IS.
SE|25462149|PURPOSE|ab|3|entity|C0013819|Electroencephalography|diap|||EEG|||0|824|365|368
SE|25462149|PURPOSE|ab|3|entity|C0556570|Activity analysis|topp|||activity analysis|||0|824|369|386
SE|25462149|PURPOSE|ab|3|entity|C0233820|Insight|menp|||insights|||0|966|399|407
SE|25462149|PURPOSE|ab|3|entity|C0031847|physiopathological|ftcn|||pathophysiology|||0|1000|417|432
SE|25462149|PURPOSE|ab|3|entity|C0332218|Difficult|qlco|||difficult|||0|861|441|450
SE|25462149|PURPOSE|ab|3|entity|C0014544|Epilepsy|dsyn|||epilepsy|||0|888|460|468
SE|25462149|PURPOSE|ab|3|entity|C0039082|Syndrome|dsyn|||syndromes|||0|888|469|478
SE|25462149|PURPOSE|ab|3|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|488|490
SE|25462149|PURPOSE|ab|3|relation|3|3|C0556570|Activity analysis|topp|topp|||activity analysis|||0|824|369|386|VERB|TREATS||454|459|2|1|C0039082|Syndrome|dsyn|dsyn|||syndromes|||0|888|469|478

SE|25462149|PURPOSE|ab|4|text|492|577|To our knowledge, there are no published reports describing ISA in patients with IS.
SE|25462149|PURPOSE|ab|4|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|499|508
SE|25462149|PURPOSE|ab|4|entity|C0034037|Publishing|ocac|||published|||0|872|523|532
SE|25462149|PURPOSE|ab|4|entity|C0684224|Report (document)|inpr|||reports|||0|872|533|540
SE|25462149|PURPOSE|ab|4|entity|C0013819|Electroencephalography|diap|||ISA|||0|790|552|555
SE|25462149|PURPOSE|ab|4|entity|C0030705|Patients|podg|||patients|||0|1000|559|567
SE|25462149|PURPOSE|ab|4|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|573|575
SE|25462149|PURPOSE|ab|4|relation|1|1|C0037769|Infantile spasms|dsyn|dsyn|||IS|||0|1000|573|575|PREP|PROCESS_OF||568|572|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|559|567

SE|25462149|PURPOSE|ab|5|text|577|698|The purpose of this study was to describe ictal patterns of ISA in patients with IS and to correlate with clinical data.
SE|25462149|PURPOSE|ab|5|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|581|588
SE|25462149|PURPOSE|ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|597|602
SE|25462149|PURPOSE|ab|5|entity|C0038454|Cerebrovascular accident|dsyn|||ictal|||0|861|619|624
SE|25462149|PURPOSE|ab|5|entity|C0449774|Patterns|spco|||patterns|||0|861|625|633
SE|25462149|PURPOSE|ab|5|entity|C0013819|Electroencephalography|diap|||ISA|||0|790|637|640
SE|25462149|PURPOSE|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|644|652
SE|25462149|PURPOSE|ab|5|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|658|660
SE|25462149|PURPOSE|ab|5|entity|C1516606|Clinical Data|inpr|||clinical data|||0|1000|683|696
SE|25462149|PURPOSE|ab|5|relation|2|1|C0037769|Infantile spasms|dsyn|dsyn|||IS|||0|1000|658|660|PREP|PROCESS_OF||653|657|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|644|652

SE|25462149|METHODS|ab|6|text|698|812|METHODS: EEG recordings of all cases of IS in the past 10 years at the Alberta Children's Hospital were reviewed.
SE|25462149|METHODS|ab|6|entity|C0025663|Methods|inpr|||METHODS|||0|1000|698|705
SE|25462149|METHODS|ab|6|entity|C0013819|Electroencephalography|diap|||EEG|||0|694|707|710
SE|25462149|METHODS|ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|729|734
SE|25462149|METHODS|ab|6|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|738|740
SE|25462149|METHODS|ab|6|entity|C1444637|Past|tmco|||past|||0|802|748|752
SE|25462149|METHODS|ab|6|entity|C0439234|year|tmco|||years|||0|802|756|761
SE|25462149|METHODS|ab|6|entity|C0020017|Hospitals, Pediatric|hcro|||Children's Hospital|||0|901|777|796

SE|25462149|METHODS|ab|7|text|812|913|Inclusion criteria were a technically adequate video EEG recording that captured at least one spasm.
SE|25462149|METHODS|ab|7|entity|C1516637|Clinical Trial Eligibility Criteria|qlco|||Inclusion criteria|||0|1000|812|830
SE|25462149|METHODS|ab|7|entity|C0205411|Adequate|qlco|||adequate|||0|824|850|858
SE|25462149|METHODS|ab|7|entity|C0430801|Video EEG|diap|||video EEG|||0|824|859|868
SE|25462149|METHODS|ab|7|entity|C0205447|One|qnco|||one|||0|790|902|905
SE|25462149|METHODS|ab|7|entity|C0037763|Spasm|sosy|||spasm|||0|790|906|911

SE|25462149|METHODS|ab|8|text|913|976|For each patient, the first 10 confirmed spasms were examined.
SE|25462149|METHODS|ab|8|entity|C0030705|Patients|podg|||patient|||0|1000|922|929
SE|25462149|METHODS|ab|8|entity|C1279901|Firstly|qlco|||first|||0|775|935|940
SE|25462149|METHODS|ab|8|entity|C0750484|Confirmed|idcn|||confirmed|||0|775|944|953
SE|25462149|METHODS|ab|8|entity|C0037763|Spasm|sosy|||spasms|||0|775|954|960

SE|25462149|METHODS|ab|9|text|976|1116|Spasms were evaluated for changes in ISA, which were either generalized, lateralized, or absent ISA (g-ISA, l-ISA, or n-ISA, respectively).
SE|25462149|METHODS|ab|9|entity|C0037763|Spasm|sosy|||Spasms|||0|1000|976|982
SE|25462149|METHODS|ab|9|entity|C0013819|Electroencephalography|diap|||ISA|||0|790|1013|1016
SE|25462149|METHODS|ab|9|entity|C0332197|Absent|qnco|||absent|||0|775|1065|1071
SE|25462149|METHODS|ab|9|entity|C0013819|Electroencephalography|diap|||ISA|||0|775|1072|1075
SE|25462149|METHODS|ab|9|entity|C0013819|Electroencephalography|diap|||ISA|||0|750|1079|1082
SE|25462149|METHODS|ab|9|entity|C0013819|Electroencephalography|diap|||ISA|||0|750|1086|1089
SE|25462149|METHODS|ab|9|entity|C0013819|Electroencephalography|diap|||ISA|||0|775|1096|1099

SE|25462149|METHODS|ab|10|text|1116|1230|Results were correlated with treatments, clinical course, and information pertinent to likely etiology of the IS.
SE|25462149|METHODS|ab|10|entity|C1274040|result|ftcn|||Results|||0|966|1116|1123
SE|25462149|METHODS|ab|10|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|1000|1145|1155
SE|25462149|METHODS|ab|10|entity|C0449259|Clinical courses|tmco|||clinical course|||0|1000|1157|1172
SE|25462149|METHODS|ab|10|entity|C1533716|Information|idcn|||information|||0|1000|1178|1189
SE|25462149|METHODS|ab|10|entity|C1314792|Etiology|ftcn|||etiology|||0|888|1210|1218
SE|25462149|METHODS|ab|10|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|1226|1228
SE|25462149|METHODS|ab|10|relation|5|4|C0087111|Therapeutic procedure|topp|topp|||treatments|||0|1000|1145|1155|NOM|CAUSES||1210|1218|1|1|C0037769|Infantile spasms|dsyn|dsyn|||IS|||0|1000|1226|1228

SE|25462149|RESULTS|ab|11|text|1230|1332|RESULTS: A total of 77% of spasms were associated with ISA; 57% with g-ISA, 20% l-ISA, and 21% n-ISA.
SE|25462149|RESULTS|ab|11|entity|C1274040|result|ftcn|||RESULTS|||0|966|1230|1237
SE|25462149|RESULTS|ab|11|entity|C0439175|% of total|qnco|||total|||0|1000|1241|1246
SE|25462149|RESULTS|ab|11|entity|C0037763|Spasm|sosy|||spasms|||0|1000|1257|1263
SE|25462149|RESULTS|ab|11|entity|C0013819|Electroencephalography|diap|||ISA|||0|790|1285|1288
SE|25462149|RESULTS|ab|11|entity|C0013819|Electroencephalography|diap|||ISA|||0|750|1301|1304
SE|25462149|RESULTS|ab|11|entity|C0013819|Electroencephalography|diap|||ISA|||0|728|1312|1315
SE|25462149|RESULTS|ab|11|entity|C0013819|Electroencephalography|diap|||ISA|||0|728|1327|1330

SE|25462149|RESULTS|ab|12|text|1332|1531|All patients with exclusively g-ISA showed at least a partial response to initial therapy, while this was the case in 66.7% of those with at least some l-ISA and 50% of those with exclusively n-ISA.
SE|25462149|RESULTS|ab|12|entity|C0030705|Patients|podg|||patients|||0|1000|1336|1344
SE|25462149|RESULTS|ab|12|entity|C0013819|Electroencephalography|diap|||ISA|||0|729|1364|1367
SE|25462149|RESULTS|ab|12|entity|C1521726|partial response|fndg|||partial response|||0|1000|1386|1402
SE|25462149|RESULTS|ab|12|entity|C0205265|Initially|tmco|||initial|||0|888|1406|1413
SE|25462149|RESULTS|ab|12|entity|C0013819|Electroencephalography|diap|||ISA|||0|750|1486|1489
SE|25462149|RESULTS|ab|12|entity|C0013819|Electroencephalography|diap|||ISA|||0|708|1526|1529
SE|25462149|RESULTS|ab|12|relation|2|1|C0013819|Electroencephalography|diap|diap|||ISA|||0|729|1364|1367|VERB|DIAGNOSES||1368|1374|5|1|C1521726|partial response|fndg|fndg|||partial response|||0|1000|1386|1402

SE|25462149|RESULTS|ab|13|text|1531|1670|Other seizure types occurred in 60% of patients with exclusively g-ISA versus 83% with some l-ISA and all patients with exclusively n-ISA.
SE|25462149|RESULTS|ab|13|entity|C0009951|Convulsions|dsyn|||seizure|||0|888|1537|1544
SE|25462149|RESULTS|ab|13|entity|C0332307|Type - attribute|qlco|||types|||0|888|1545|1550
SE|25462149|RESULTS|ab|13|entity|C0030705|Patients|podg|||patients|||0|1000|1570|1578
SE|25462149|RESULTS|ab|13|entity|C0013819|Electroencephalography|diap|||ISA|||0|729|1598|1601
SE|25462149|RESULTS|ab|13|entity|C0013819|Electroencephalography|diap|||ISA|||0|750|1625|1628
SE|25462149|RESULTS|ab|13|entity|C0030705|Patients|podg|||patients|||0|1000|1637|1645
SE|25462149|RESULTS|ab|13|entity|C0013819|Electroencephalography|diap|||ISA|||0|729|1665|1668

SE|25462149|CONCLUSIONS|ab|14|text|1670|1729|CONCLUSIONS: Ictal ISA was observed in the majority of IS.
SE|25462149|CONCLUSIONS|ab|14|entity|C0038454|Cerebrovascular accident|dsyn|||Ictal|||0|756|1683|1688
SE|25462149|CONCLUSIONS|ab|14|entity|C0013819|Electroencephalography|diap|||ISA|||0|756|1689|1692
SE|25462149|CONCLUSIONS|ab|14|entity|C0680220|majority|socb|||majority|||0|1000|1713|1721
SE|25462149|CONCLUSIONS|ab|14|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|1725|1727

SE|25462149|CONCLUSIONS|ab|15|text|1729|1848|Trends were observed suggesting that the presence of exclusive g-ISA changes may be a positive prognostic factor in IS.
SE|25462149|CONCLUSIONS|ab|15|entity|C1521798|trend|tmco|||Trends|||0|1000|1729|1735
SE|25462149|CONCLUSIONS|ab|15|entity|C1548966|Exclusive|idcn|||exclusive|||0|737|1782|1791
SE|25462149|CONCLUSIONS|ab|15|entity|C0013819|Electroencephalography|diap|||ISA|||0|737|1794|1797
SE|25462149|CONCLUSIONS|ab|15|entity|C1446409|Positive|qlco|||positive|||0|901|1815|1823
SE|25462149|CONCLUSIONS|ab|15|entity|C1514474|Prognostic Factor|clna|||prognostic factor|||0|901|1824|1841
SE|25462149|CONCLUSIONS|ab|15|entity|C0037769|Infantile spasms|dsyn|||IS|||0|1000|1845|1847
SE|25462149|CONCLUSIONS|ab|15|relation|4|2|C0013819|Electroencephalography|diap|diap|||ISA|||0|737|1794|1797|PREP|DIAGNOSES||1842|1844|1|1|C0037769|Infantile spasms|dsyn|dsyn|||IS|||0|1000|1845|1847


SE|25462150||ti|1|text|21|98|Neuromuscular ultrasound findings in polyneuropathy secondary to disulfiram.
SE|25462150||ti|1|entity|C1299966|Ultrasound scan finding|lbtr|||ultrasound findings|||0|884|35|54
SE|25462150||ti|1|entity|C0152025|Polyneuropathy|dsyn|||polyneuropathy|||0|861|58|72
SE|25462150||ti|1|entity|C0175668|Secondary to|tmco|||secondary to|||0|861|73|85
SE|25462150||ti|1|entity|C0012772|Disulfiram|orch,phsu|||disulfiram|||0|861|86|96

SE|25462150||ab|1|text|104|230|Disulfiram toxicity can cause multiple neurologic problems, including a reversible distal sensorimotor axonal polyneuropathy.
SE|25462150||ab|1|entity|C0012772|Disulfiram|orch,phsu|||Disulfiram|||0|888|104|114
SE|25462150||ab|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|115|123
SE|25462150||ab|1|entity|C0439064|Numerous|qnco|||multiple|||0|890|134|142
SE|25462150||ab|1|entity|C0221571|Nervous system problem|fndg|||neurologic problems|||0|890|143|162
SE|25462150||ab|1|entity|C0205343|Reversible|ftcn|||reversible|||0|825|176|186
SE|25462150||ab|1|entity|C0205108|Distal|spco|||distal|||0|825|187|193
SE|25462150||ab|1|entity|C0004461|Axon|celc|||axonal|||0|825|207|213
SE|25462150||ab|1|entity|C0271682|Mixed sensory-motor polyneuropathy|dsyn|||sensorimotor axonal polyneuropathy|||0|825|194|228

SE|25462150||ab|2|text|230|440|Although electrodiagnosis and biopsy results have been described in the diagnosis and management of patients with disulfiram associated polyneuropathy, neuromuscular ultrasound findings have not been reported.
SE|25462150||ab|2|entity|C0013816|Electrodiagnosis|diap|||electrodiagnosis|||0|1000|239|255
SE|25462150||ab|2|entity|C0005558|Biopsy|diap|||biopsy|||0|872|260|266
SE|25462150||ab|2|entity|C1274040|result|ftcn|||results|||0|872|267|274
SE|25462150||ab|2|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|302|311
SE|25462150||ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|330|338
SE|25462150||ab|2|entity|C0012772|Disulfiram|orch,phsu|||disulfiram|||0|802|344|354
SE|25462150||ab|2|entity|C0152025|Polyneuropathy|dsyn|||polyneuropathy|||0|802|366|380
SE|25462150||ab|2|entity|C1299966|Ultrasound scan finding|lbtr|||ultrasound findings|||0|884|396|415
SE|25462150||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|421|424
SE|25462150||ab|2|relation|2|1|C0152025|Polyneuropathy|dsyn|dsyn|||polyneuropathy|||0|802|366|380|PREP|PROCESS_OF||339|343|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|330|338
SE|25462150||ab|2|relation|3|3|C0005558|Biopsy|diap|diap|||biopsy|||0|872|260|266|NOM|ADMINISTERED_TO||316|326|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|330|338
SE|25462150||ab|2|relation|3|3|C0013816|Electrodiagnosis|diap|diap|||electrodiagnosis|||0|1000|239|255|NOM|ADMINISTERED_TO||316|326|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|330|338

SE|25462150||ab|3|text|440|647|The authors present a case of electrodiagnostically confirmed axonal polyneuropathy with relative sural sparing secondary to disulfiram and describe the neuromuscular ultrasound findings in this individual.
SE|25462150||ab|3|entity|C0221192|Author|idcn,prog|||authors|||0|1000|444|451
SE|25462150||ab|3|entity|C0004461|Axon|celc|||axonal|||0|853|502|508
SE|25462150||ab|3|entity|C0152025|Polyneuropathy|dsyn|||polyneuropathy|||0|853|509|523
SE|25462150||ab|3|entity|C0205345|Relative|qlco|||relative|||0|769|529|537
SE|25462150||ab|3|entity|C0626053|sural|phsu|||sural|||0|769|538|543
SE|25462150||ab|3|entity|C0175668|Secondary to|tmco|||secondary to|||0|769|552|564
SE|25462150||ab|3|entity|C0012772|Disulfiram|orch,phsu|||disulfiram|||0|769|565|575
SE|25462150||ab|3|entity|C1299966|Ultrasound scan finding|lbtr|||ultrasound findings|||0|884|607|626
SE|25462150||ab|3|entity|C0237401|Individual|humn|||individual|||0|1000|635|645
SE|25462150||ab|3|relation|3|3|C0221192|Author|idcn,prog,humn|prog|||authors|||0|1000|444|451|VERB|DIAGNOSES||492|501|4|1|C0152025|Polyneuropathy|dsyn|dsyn|||polyneuropathy|||0|853|509|523

SE|25462150||ab|4|text|647|797|Ultrasound demonstrated distal enlargement with slight side-to-side asymmetry and normal proximal cross-sectional area in the lower extremity nerves.
SE|25462150||ab|4|entity|C0041618|Ultrasonography|diap|||Ultrasound|||0|1000|647|657
SE|25462150||ab|4|entity|C0205108|Distal|spco|||distal|||0|888|671|677
SE|25462150||ab|4|entity|C0020564|Hypertrophy|patf|||enlargement|||0|888|678|689
SE|25462150||ab|4|entity|C0547040|Minimal|qlco|||slight|||0|875|695|701
SE|25462150||ab|4|entity|C0516750|Side to side|fndg|||side-to-side|||0|875|702|714
SE|25462150||ab|4|entity|C0332514|Asymmetry|spco|||asymmetry|||0|875|715|724
SE|25462150||ab|4|entity|C0205307|Normal|qlco|||normal|||0|822|729|735
SE|25462150||ab|4|entity|C0205107|Proximal|spco|||proximal|||0|822|736|744
SE|25462150||ab|4|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|822|745|760
SE|25462150||ab|4|entity|C0205146|Area|spco|||area|||0|822|761|765
SE|25462150||ab|4|entity|C0446822|Peripheral nerve of lower limb|bpoc|||lower extremity nerves|||0|983|773|795
SE|25462150||ab|4|relation|1|1|C0041618|Ultrasonography|diap|diap|||Ultrasound|||0|1000|647|657|VERB|DIAGNOSES||658|670|4|1|C0020564|Hypertrophy|patf|patf|||enlargement|||0|888|678|689
SE|25462150||ab|4|relation|1|1|C0446822|Peripheral nerve of lower limb|bpoc|bpoc|||lower extremity nerves|||0|983|773|795|PREP|LOCATION_OF||766|768|4|3|C0020564|Hypertrophy|patf|patf|||enlargement|||0|888|678|689

SE|25462150||ab|5|text|797|953|Neuromuscular ultrasound is another diagnostic modality that may be used to assist in the diagnosis of patients with polyneuropathy secondary to disulfiram.
SE|25462150||ab|5|entity|C0041618|Ultrasonography|diap|||ultrasound|||0|861|811|821
SE|25462150||ab|5|entity|C0348026|Diagnostic|ftcn|||diagnostic|||0|888|833|843
SE|25462150||ab|5|entity|C0695347|Modality|idcn|||modality|||0|888|844|852
SE|25462150||ab|5|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|887|896
SE|25462150||ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|900|908
SE|25462150||ab|5|entity|C0152025|Polyneuropathy|dsyn|||polyneuropathy|||0|861|914|928
SE|25462150||ab|5|entity|C0175668|Secondary to|tmco|||secondary to|||0|861|929|941
SE|25462150||ab|5|entity|C0012772|Disulfiram|orch,phsu|||disulfiram|||0|861|942|952


[12]: *** ERROR *** ERROR *** ERROR ***
SE|25462152||ti|1|text|21|95|Application of next-generation sequencing technology in forensic science.
SE|25462152||ti|1|entity|C1552851|next|idcn|||next|||0|825|36|40
SE|25462152||ti|1|entity|C0079411|Generations|tmco|||generation|||0|825|41|51
SE|25462152||ti|1|entity|C1561491|Sequencing|ftcn|||sequencing|||0|825|52|62
SE|25462152||ti|1|entity|C0039421|Technology|ocdi|||technology|||0|825|63|73
SE|25462152||ti|1|entity|C1257940|Forensic Sciences|ocdi|||forensic science|||0|1000|77|93

SE|25462152||ab|1|text|101|303|Next-generation sequencing (NGS) technology, with its high-throughput capacity and low cost, has developed rapidly in recent years and become an important analytical tool for many genomics researchers.
SE|25462152||ab|1|entity|C1552851|next|idcn|||Next|||0|825|101|105
SE|25462152||ab|1|entity|C0079411|Generations|tmco|||generation|||0|825|106|116
SE|25462152||ab|1|entity|C1561491|Sequencing|ftcn|||sequencing|||0|825|117|127
SE|25462152||ab|1|entity|C0039421|Technology|ocdi|||technology|||0|825|134|144
SE|25462152||ab|1|entity|C0205250|High|qlco|||high|||0|802|155|159
SE|25462152||ab|1|entity|C1516240|Capacity|qnco|||capacity|||0|802|171|179
SE|25462152||ab|1|entity|C0205251|low|qlco|||low|||0|694|184|187
SE|25462152||ab|1|entity|C0332185|Recent|tmco|||recent|||0|888|219|225
SE|25462152||ab|1|entity|C0439234|year|tmco|||years|||0|888|226|231
SE|25462152||ab|1|entity|C0336791|Tool|mnob|||tool|||0|827|267|271
SE|25462152||ab|1|entity|C0887950|Genomics|bmod|||genomics|||0|888|281|289
SE|25462152||ab|1|entity|C0035173|Research Personnel|prog|||researchers|||0|888|290|301

SE|25462152||ab|2|text|303|587|New opportunities in the research domain of the forensic studies emerge by harnessing the power of NGS technology, which can be applied to simultaneously analyzing multiple loci of forensic interest in different genetic contexts, such as autosomes, mitochondrial and sex chromosomes.
SE|25462152||ab|2|entity|C0205314|New|tmco|||New|||0|694|303|306
SE|25462152||ab|2|entity|C0035168|research|resa|||research|||0|694|328|336
SE|25462152||ab|2|entity|C0681831|forensic study|resa|||forensic studies|||0|983|351|367
SE|25462152||ab|2|entity|C1552851|next|idcn|||NGS|||0|825|402|405
SE|25462152||ab|2|entity|C0079411|Generations|tmco|||NGS|||0|825|402|405
SE|25462152||ab|2|entity|C1561491|Sequencing|ftcn|||NGS|||0|825|402|405
SE|25462152||ab|2|entity|C0039421|Technology|ocdi|||technology|||0|825|406|416
SE|25462152||ab|2|entity|C0439064|Numerous|qnco|||multiple|||0|694|467|475
SE|25462152||ab|2|entity|C0543488|Interested|menp|||interest|||0|861|493|501
SE|25462152||ab|2|entity|C1547020|*Difference|qnco|||different|||0|816|505|514
SE|25462152||ab|2|entity|C0314603|Genetic|ftcn|||genetic|||0|816|515|522
SE|25462152||ab|2|entity|C0596142|Autosome|celc|||autosomes|||0|1000|541|550
SE|25462152||ab|2|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|1000|552|565
SE|25462152||ab|2|entity|C0036869|Sex Chromosomes|celc|||sex chromosomes|||0|1000|570|585

SE|25462152||ab|3|text|587|687|Furthermore, NGS technology can also have potential applications in many other aspects of research.
SE|25462152||ab|3|entity|C1552851|next|idcn|||NGS|||0|825|600|603
SE|25462152||ab|3|entity|C0079411|Generations|tmco|||NGS|||0|825|600|603
SE|25462152||ab|3|entity|C1561491|Sequencing|ftcn|||NGS|||0|825|600|603
SE|25462152||ab|3|entity|C0039421|Technology|ocdi|||technology|||0|825|604|614
SE|25462152||ab|3|entity|C0237399|Potential|qlco|||potential|||0|872|629|638
SE|25462152||ab|3|entity|C1547011|Aspect|qnco|||aspects|||0|966|666|673
SE|25462152||ab|3|entity|C0035168|research|resa|||research|||0|1000|677|685

SE|25462152||ab|4|text|687|885|These include DNA database construction, ancestry and phenotypic inference, monozygotic twin studies, body fluid and species identification, and forensic animal, plant and microbiological analyses.
SE|25462152||ab|4|entity|C0242575|DNA Databases|inpr|||DNA database|||0|734|701|713
SE|25462152||ab|4|entity|C0679201|inference|idcn|||inference|||0|861|752|761
SE|25462152||ab|4|entity|C0282476|Twin Studies|inpr|||twin studies|||0|901|775|787
SE|25462152||ab|4|entity|C0005889|Body Fluids|bdsu|||body fluid|||0|1000|789|799
SE|25462152||ab|4|entity|C1548151|Species|idcn|||species|||0|694|804|811
SE|25462152||ab|4|entity|C0003043|Animalia|anim|||animal|||0|861|841|847
SE|25462152||ab|4|entity|C0032098|Plants|plnt|||plant|||0|1000|849|854
SE|25462152||ab|4|entity|C0025953|Microbiological|inpr|||microbiological|||0|872|859|874
SE|25462152||ab|4|entity|C0936012|Analysis|resa|||analyses|||0|872|875|883

SE|25462152||ab|5|text|885|1047|Here we review the application of NGS technology in the field of forensic science with the aim of providing a reference for future forensics studies and practice.
SE|25462152||ab|5|entity|C1552851|next|idcn|||NGS|||0|825|919|922
SE|25462152||ab|5|entity|C0079411|Generations|tmco|||NGS|||0|825|919|922
SE|25462152||ab|5|entity|C1561491|Sequencing|ftcn|||NGS|||0|825|919|922
SE|25462152||ab|5|entity|C0039421|Technology|ocdi|||technology|||0|825|923|933
SE|25462152||ab|5|entity|C1521738|Field|cnce|||field|||0|1000|941|946
SE|25462152||ab|5|entity|C1257940|Forensic Sciences|ocdi|||forensic science|||0|1000|950|966
SE|25462152||ab|5|entity|C1514811|Reference|idcn|||reference|||0|1000|995|1004
SE|25462152||ab|5|entity|C0016884|Future|tmco|||future|||0|888|1009|1015
SE|25462152||ab|5|entity|C0016557|Forensic Medicine|bmod|||forensics|||0|888|1016|1025
SE|25462152||ab|5|entity|C0237607|experience (practice)|menp|||practice|||0|1000|1038|1046


SE|25462153||ti|1|text|21|82|Pathway-based analysis tools for complex diseases: a review.
SE|25462153||ti|1|entity|C0868995|Pathway Analysis|inpr|||Pathway-based analysis|||0|844|21|43
SE|25462153||ti|1|entity|C0336791|Tool|mnob|||tools|||0|844|44|49
SE|25462153||ti|1|entity|C0439855|Complex|qlco|||complex|||0|888|54|61
SE|25462153||ti|1|entity|C0012634|Disease|dsyn|||diseases|||0|888|62|70

SE|25462153||ab|1|text|88|153|Genetic studies are traditionally based on single-gene analysis.
SE|25462153||ab|1|entity|C0314603|Genetic|ftcn|||Genetic|||0|872|88|95
SE|25462153||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|96|103
SE|25462153||ab|1|entity|C0037179|Unmarried person|popg|||single|||0|851|131|137
SE|25462153||ab|1|entity|C0017337|Genes|gngm|||gene|||0|851|138|142
SE|25462153||ab|1|entity|C0936012|Analysis|resa|||analysis|||0|851|143|151

SE|25462153||ab|2|text|153|293|The use of these analyses can pose tremendous challenges for elucidating complicated genetic interplays involved in complex human diseases.
SE|25462153||ab|2|entity|C0936012|Analysis|resa|||analyses|||0|966|170|178
SE|25462153||ab|2|entity|C0231242|Complicated|ftcn|||complicated|||0|583|226|237
SE|25462153||ab|2|entity|C0314603|Genetic|ftcn|||genetic|||0|583|238|245
SE|25462153||ab|2|entity|C0439855|Complex|qlco|||complex|||0|851|269|276
SE|25462153||ab|2|entity|C0020114|Human|humn|||human|||0|851|277|282
SE|25462153||ab|2|entity|C0012634|Disease|dsyn|||diseases|||0|851|283|291
SE|25462153||ab|2|relation|0|0|C0012634|Disease|dsyn|dsyn|||diseases|||0|851|283|291|MOD/HEAD|PROCESS_OF||277|291|0|0|C0020114|Human|grup,humn|humn|||human|||0|851|277|282

SE|25462153||ab|3|text|293|445|Modern pathway-based analysis provides a technique, which allows a comprehensive understanding of the molecular mechanisms underlying complex diseases.
SE|25462153||ab|3|entity|C0868995|Pathway Analysis|inpr|||pathway-based analysis|||0|813|300|322
SE|25462153||ab|3|entity|C0449851|Techniques|ftcn|||technique|||0|1000|334|343
SE|25462153||ab|3|entity|C1521991|Molecular|qlco|||molecular|||0|888|395|404
SE|25462153||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|405|415
SE|25462153||ab|3|entity|C0439855|Complex|qlco|||complex|||0|888|427|434
SE|25462153||ab|3|entity|C0012634|Disease|dsyn|||diseases|||0|888|435|443

SE|25462153||ab|4|text|445|657|Extensive studies utilizing the methods and applications for pathway-based analysis have significantly advanced our capacity to explore large-scale omics data, which has rapidly accumulated in biomedical fields.
SE|25462153||ab|4|entity|C0205231|Extensive|qlco|||Extensive|||0|872|445|454
SE|25462153||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|872|455|462
SE|25462153||ab|4|entity|C0025663|Methods|inpr|||methods|||0|1000|477|484
SE|25462153||ab|4|entity|C0868995|Pathway Analysis|inpr|||pathway-based analysis|||0|890|506|528
SE|25462153||ab|4|entity|C1516240|Capacity|qnco|||capacity|||0|1000|561|569
SE|25462153||ab|4|entity|C0549177|Large|qnco|||large|||0|775|581|586
SE|25462153||ab|4|entity|C1511726|Data|idcn|||data|||0|775|599|603
SE|25462153||ab|4|entity|C1521738|Field|cnce|||fields|||0|827|649|655

SE|25462153||ab|5|text|657|832|This article is a comprehensive review of the pathway-based analysis methods-the powerful methods with the potential to uncover the biological depths of the complex diseases.
SE|25462153||ab|5|entity|C0868995|Pathway Analysis|inpr|||pathway-based analysis|||0|852|703|725
SE|25462153||ab|5|entity|C0025663|Methods|inpr|||methods|||0|852|726|733
SE|25462153||ab|5|entity|C0025663|Methods|inpr|||methods|||0|861|747|754
SE|25462153||ab|5|entity|C0237399|Potential|qlco|||potential|||0|1000|764|773
SE|25462153||ab|5|entity|C0205460|biological|ftcn|||biological|||0|872|789|799
SE|25462153||ab|5|entity|C0205125|Depth|spco|||depths|||0|872|800|806
SE|25462153||ab|5|entity|C0439855|Complex|qlco|||complex|||0|888|814|821
SE|25462153||ab|5|entity|C0012634|Disease|dsyn|||diseases|||0|888|822|830

SE|25462153||ab|6|text|832|1011|The general concepts and procedures for the pathway-based analysis methods are introduced and then, a comprehensive review of the major approaches for this analysis is presented.
SE|25462153||ab|6|entity|C0205246|Generalized|spco|||general|||0|888|836|843
SE|25462153||ab|6|entity|C0178566|concept|idcn|||concepts|||0|888|844|852
SE|25462153||ab|6|entity|C0025664|Methodology|inpr|||procedures|||0|1000|857|867
SE|25462153||ab|6|entity|C0868995|Pathway Analysis|inpr|||pathway-based analysis|||0|852|876|898
SE|25462153||ab|6|entity|C0025663|Methods|inpr|||methods|||0|852|899|906
SE|25462153||ab|6|entity|C0205164|Major|qlco|||major|||0|888|962|967
SE|25462153||ab|6|entity|C0449445|Approach|spco|||approaches|||0|888|968|978
SE|25462153||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|1000|988|996

SE|25462153||ab|7|text|1011|1103|In addition, a list of available pathway-based analysis software and databases is provided.
SE|25462153||ab|7|entity|C0745732|LIST|cnce|||list|||0|1000|1026|1030
SE|25462153||ab|7|entity|C0868995|Pathway Analysis|inpr|||pathway-based analysis|||0|623|1044|1066
SE|25462153||ab|7|entity|C0242356|Databases|inpr|||databases|||0|1000|1080|1089

SE|25462153||ab|8|text|1103|1249|Finally, future directions and challenges for the methodological development and applications of pathway-based analysis techniques are discussed.
SE|25462153||ab|8|entity|C0016884|Future|tmco|||future|||0|888|1112|1118
SE|25462153||ab|8|entity|C0439755|Directions|spco|||directions|||0|888|1119|1129
SE|25462153||ab|8|entity|C0025664|Methodology|inpr|||methodological|||0|853|1153|1167
SE|25462153||ab|8|entity|C1527148|Development|ftcn|||development|||0|853|1168|1179
SE|25462153||ab|8|entity|C0868995|Pathway Analysis|inpr|||pathway-based analysis|||0|852|1200|1222
SE|25462153||ab|8|entity|C0025664|Methodology|inpr|||techniques|||0|852|1223|1233

SE|25462153||ab|9|text|1249|1317|This review will provide a useful guide to dissect complex diseases.
SE|25462153||ab|9|entity|C0439855|Complex|qlco|||complex|||0|888|1300|1307
SE|25462153||ab|9|entity|C0012634|Disease|dsyn|||diseases|||0|888|1308|1316


SE|25462154||ti|1|text|21|142|Identification of a novel SBF2 frameshift mutation in charcot-marie-tooth disease type 4B2 using whole-exome sequencing.
SE|25462154||ti|1|entity|C0679622|novel|inpr|||novel|||0|840|41|46
SE|25462154||ti|1|entity|||gngm|81846|SBF2|SBF2|||0|840|47|51
SE|25462154||ti|1|entity|C1282684|Reading-frame-shift mutation test result|lbtr|||frameshift mutation|||0|840|52|71
SE|25462154||ti|1|entity|C0007959|Charcot-Marie-Tooth Disease|dsyn|||charcot-marie-tooth disease|||0|709|75|102
SE|25462154||ti|1|entity|C1547052|*Type|qnco|||type|||0|709|103|107
SE|25462154||ti|1|entity|C0444667|Whole|qnco|||whole|||0|802|118|123
SE|25462154||ti|1|entity|C1561491|Sequencing|ftcn|||sequencing|||0|802|130|140

SE|25462154||ab|1|text|148|304|Charcot-Marie-Tooth disease type 4B2 with early-onset glaucoma (CMT4B2, OMIM 604563) is a genetically-heterogeneous childhood-onset neuromuscular disorder.
SE|25462154||ab|1|entity|C0007959|Charcot-Marie-Tooth Disease|dsyn|||Charcot-Marie-Tooth disease|||0|709|148|175
SE|25462154||ab|1|entity|C1547052|*Type|qnco|||type|||0|709|176|180
SE|25462154||ab|1|entity|C1279919|Early|tmco|||early|||0|851|190|195
SE|25462154||ab|1|entity|C0332162|Onset|qlco|||onset|||0|851|196|201
SE|25462154||ab|1|entity|C0017601|Glaucoma|dsyn|||glaucoma|||0|851|202|210
SE|25462154||ab|1|entity|||gngm|81846|SBF2|CMT4B2|||0|1000|212|218
SE|25462154||ab|1|entity|C0950133|Online Mendelian Inheritance In Man|inpr|||OMIM|||0|861|220|224
SE|25462154||ab|1|entity|C1512425|Heterogeneous|qlco|||heterogeneous|||0|787|250|263
SE|25462154||ab|1|entity|C0231335|Childhood|tmco|||childhood|||0|787|264|273
SE|25462154||ab|1|entity|C0332162|Onset|qlco|||onset|||0|787|274|279
SE|25462154||ab|1|entity|C0027868|Neuromuscular Diseases|dsyn|||neuromuscular disorder|||0|787|280|302
SE|25462154||ab|1|relation|0|0|C0017601|Glaucoma|dsyn|dsyn|||glaucoma|||0|851|202|210|SPEC|ISA||202|302|0|0|C0027868|Neuromuscular Diseases|dsyn|dsyn|||neuromuscular disorder|||0|787|280|302

SE|25462154||ab|2|text|304|456|Here, we report the case of a 15-year-old male adolescent with lower extremity weakness, gait abnormalities, foot deformities and early-onset glaucoma.
SE|25462154||ab|2|entity|C0439234|year|tmco|||year|||0|798|337|341
SE|25462154||ab|2|entity|C0580836|Old|tmco|||old|||0|798|342|345
SE|25462154||ab|2|entity|C0001589|Adolescents, Male|aggp|||male adolescent|||0|798|346|361
SE|25462154||ab|2|entity|C0740428|Lower extremities weakness of|sosy|||lower extremity weakness|||0|1000|367|391
SE|25462154||ab|2|entity|C0575081|Gait abnormality|sosy|||gait abnormalities|||0|983|393|411
SE|25462154||ab|2|entity|C0016506|Foot Deformities|anab|||foot deformities|||0|1000|413|429
SE|25462154||ab|2|entity|C1279919|Early|tmco|||early|||0|851|434|439
SE|25462154||ab|2|entity|C0332162|Onset|qlco|||onset|||0|851|440|445
SE|25462154||ab|2|entity|C0017601|Glaucoma|dsyn|||glaucoma|||0|851|446|454
SE|25462154||ab|2|relation|4|1|C0017601|Glaucoma|dsyn|dsyn|||glaucoma|||0|851|446|454|PREP|PROCESS_OF||362|366|2|1|C0001589|Adolescents, Male|aggp,humn|humn|||male adolescent|||0|798|346|361
SE|25462154||ab|2|relation|4|1|C0575081|Gait abnormality|sosy|sosy|||gait abnormalities|||0|983|393|411|PREP|PROCESS_OF||362|366|2|1|C0001589|Adolescents, Male|aggp,humn|humn|||male adolescent|||0|798|346|361
SE|25462154||ab|2|relation|4|1|C0740428|Lower extremities weakness of|sosy|sosy|||lower extremity weakness|||0|1000|367|391|PREP|PROCESS_OF||362|366|2|1|C0001589|Adolescents, Male|aggp,humn|humn|||male adolescent|||0|798|346|361

SE|25462154||ab|3|text|456|796|Since clinical diagnosis alone was insufficient for providing pathogenetic evidence to indicate that the condition belonged to a consanguineous family, we applied whole-exome sequencing to samples from the patient, his parents and his younger brother, assuming that the patient's condition is transmitted in an autosomal recessive pattern.
SE|25462154||ab|3|entity|C0332140|Diagnosis, clinical|qlco|||clinical diagnosis|||0|1000|462|480
SE|25462154||ab|3|entity|C0231180|Insufficient|ftcn|||insufficient|||0|1000|491|503
SE|25462154||ab|3|entity|C0543483|pathogenic aspects|ftcn|||pathogenetic|||0|571|518|530
SE|25462154||ab|3|entity|C0348080|Condition|qlco|||condition|||0|1000|561|570
SE|25462154||ab|3|entity|C0009789|Consanguinity|fndg|||consanguineous|||0|853|585|599
SE|25462154||ab|3|entity|C0015576|Family|famg|||family|||0|853|600|606
SE|25462154||ab|3|entity|C0444667|Whole|qnco|||whole|||0|802|619|624
SE|25462154||ab|3|entity|C1561491|Sequencing|ftcn|||sequencing|||0|802|631|641
SE|25462154||ab|3|entity|C0030705|Patients|podg|||patient|||0|1000|662|669
SE|25462154||ab|3|entity|C0030551|parent|famg|||parents|||0|1000|675|682
SE|25462154||ab|3|entity|C0337538|Younger brother|famg|||younger brother|||0|1000|691|706
SE|25462154||ab|3|entity|C0683521|patient state|fndg|||patient's condition|||0|1000|726|745
SE|25462154||ab|3|entity|C0596142|Autosome|celc|||autosomal|||0|766|767|776
SE|25462154||ab|3|entity|C0449774|Patterns|spco|||pattern|||0|766|787|794
SE|25462154||ab|3|relation|0|0|C0009789|Consanguinity|fndg|fndg|||consanguineous|||0|853|585|599|MOD/HEAD|PROCESS_OF||585|606|0|0|C0015576|Family|famg,humn|humn|||family|||0|853|600|606

SE|25462154||ab|4|text|796|1046|A frame-shift mutation, c.4571delG (P.Gly1524Glufs*42), was revealed in the CMT4B2-related gene SBF2 (also known as MTMR13, MIM 607697), and this mutation was found to be homozygous in the proband and heterozygous in his parents and younger brother.
SE|25462154||ab|4|entity|C1282684|Reading-frame-shift mutation test result|lbtr|||frame-shift mutation|||0|1000|798|818
SE|25462154||ab|4|entity|C1522149|Related|ftcn|||related|||0|658|879|886
SE|25462154||ab|4|entity|C1413538|CMT4B2 gene|gngm|81846|SBF2|CMT4B2-related gene|||0|658|872|891
SE|25462154||ab|4|entity|||gngm|81846|SBF2|SBF2|||0|658|892|896
SE|25462154||ab|4|entity|||gngm|81846|SBF2|MTMR13|||0|1000|912|918
SE|25462154||ab|4|entity|||gngm|9788|MTSS1|MIM|||0|1000|920|923
SE|25462154||ab|4|entity|C0026882|Mutation|genf|||mutation|||0|1000|942|950
SE|25462154||ab|4|entity|C0702111|Proband|orga|||proband|||0|1000|985|992
SE|25462154||ab|4|entity|C0030551|parent|famg|||parents|||0|1000|1017|1024
SE|25462154||ab|4|entity|C0337538|Younger brother|famg|||younger brother|||0|1000|1029|1044
SE|25462154||ab|4|relation|9|4|C0026882|Mutation|genf|genf|||mutation|||0|1000|942|950|PREP|PROCESS_OF||1010|1012|2|1|C0030551|parent|famg,humn|humn|||parents|||0|1000|1017|1024
SE|25462154||ab|4|relation|9|4|C0026882|Mutation|genf|genf|||mutation|||0|1000|942|950|PREP|PROCESS_OF||1010|1012|2|1|C0337538|Younger brother|famg,humn|famg|||younger brother|||0|1000|1029|1044

SE|25462154||ab|5|text|1046|1130|Together with the results of clinical diagnosis, this case was diagnosed as CMT4B2.
SE|25462154||ab|5|entity|C1274040|result|ftcn|||results|||0|966|1064|1071
SE|25462154||ab|5|entity|C0332140|Diagnosis, clinical|qlco|||clinical diagnosis|||0|1000|1075|1093
SE|25462154||ab|5|entity|||gngm|81846|SBF2|CMT4B2|||0|1000|1122|1128

SE|25462154||ab|6|text|1130|1245|Our finding further demonstrates the use of whole-exome sequencing in the diagnosis and treatment of rare diseases.
SE|25462154||ab|6|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|1000|1134|1141
SE|25462154||ab|6|entity|C1517331|Further|spco|||further|||0|1000|1142|1149
SE|25462154||ab|6|entity|C0444667|Whole|qnco|||whole|||0|802|1174|1179
SE|25462154||ab|6|entity|C1561491|Sequencing|ftcn|||sequencing|||0|802|1186|1196
SE|25462154||ab|6|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|1204|1213
SE|25462154||ab|6|entity|C0678236|Rare Diseases|dsyn|||rare diseases|||0|1000|1231|1244


SE|25462155||ti|1|text|21|133|Computational prediction of microRNAs from Toxoplasma gondii potentially regulating the hosts' gene expression.
SE|25462155||ti|1|entity|C0681842|prediction|inpr|||prediction|||0|861|35|45
SE|25462155||ti|1|entity|C1101610|MicroRNAs|bacs,nnon|||microRNAs|||0|1000|49|58
SE|25462155||ti|1|entity|C0040557|Toxoplasma gondii|invt|||Toxoplasma gondii|||0|1000|64|81
SE|25462155||ti|1|entity|C1167395|host|celc|||hosts|||0|884|109|114
SE|25462155||ti|1|entity|C0017262|Gene Expression|genf|||gene expression|||0|884|116|131
SE|25462155||ti|1|relation|3|2|C1101610|MicroRNAs|bacs,nnon|bacs|||microRNAs|||0|1000|49|58|VERB|AFFECTS||94|104|1|1|C1167395|host|celc|celc|||hosts|||0|884|109|114

SE|25462155||ab|1|text|139|303|MicroRNAs (miRNAs) were discovered two decades ago, yet there is still a great need for further studies elucidating their genesis and targeting in different phyla.
SE|25462155||ab|1|entity|C1101610|MicroRNAs|bacs,nnon|||MicroRNAs|||0|1000|139|148
SE|25462155||ab|1|entity|C0205448|Two|qnco|||two|||0|635|174|177
SE|25462155||ab|1|entity|C1333533|FBXW7 gene|gngm|||ago|||0|635|186|189
SE|25462155||ab|1|entity|C0549177|Large|qnco|||great|||0|888|212|217
SE|25462155||ab|1|entity|C0027552|Needs|qlco|||need|||0|888|218|222
SE|25462155||ab|1|entity|C1517331|Further|spco|||further|||0|872|227|234
SE|25462155||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|235|242
SE|25462155||ab|1|entity|C1547020|*Difference|qnco|||different|||0|853|286|295
SE|25462155||ab|1|entity|C1038269|Phyla|plnt|||phyla|||0|853|296|301

SE|25462155||ab|2|text|303|480|Since experimental discovery and validation of miRNAs is difficult, computational predictions are indispensable and today most computational approaches employ machine learning.
SE|25462155||ab|2|entity|C1517004|Experimental|ftcn|||experimental|||0|694|309|321
SE|25462155||ab|2|entity|C1519941|Validation|resa|||validation|||0|1000|336|346
SE|25462155||ab|2|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|1000|350|356
SE|25462155||ab|2|entity|C0332218|Difficult|qlco|||difficult|||0|785|360|369
SE|25462155||ab|2|entity|C0681842|prediction|inpr|||predictions|||0|785|385|396
SE|25462155||ab|2|entity|C0750526|Today|tmco|||today|||0|791|419|424
SE|25462155||ab|2|entity|C0449445|Approach|spco|||approaches|||0|791|444|454
SE|25462155||ab|2|entity|C0376284|Machine Learning|mcha|||machine learning|||0|1000|462|478

SE|25462155||ab|3|text|480|619|Toxoplasma gondii, a parasite residing within the cells of its hosts like human, uses miRNAs for its post-transcriptional gene regulation.
SE|25462155||ab|3|entity|C0040557|Toxoplasma gondii|invt|||Toxoplasma gondii|||0|1000|480|497
SE|25462155||ab|3|entity|C0030498|Parasites|invt|||parasite|||0|694|501|509
SE|25462155||ab|3|entity|C0007634|Cells|cell|||cells|||0|1000|530|535
SE|25462155||ab|3|entity|C1167395|host|celc|||hosts|||0|966|543|548
SE|25462155||ab|3|entity|C0020114|Human|humn|||human|||0|1000|554|559
SE|25462155||ab|3|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|1000|566|572
SE|25462155||ab|3|entity|C0017337|Genes|gngm|||gene|||0|916|602|606
SE|25462155||ab|3|entity|C1514248|Post-Transcriptional Regulation|genf|||post-transcriptional gene regulation|||0|916|581|617
SE|25462155||ab|3|relation|2|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNAs|||0|1000|566|572|VERB|ADMINISTERED_TO||561|565|5|1|C0020114|Human|grup,humn|humn|||human|||0|1000|554|559

SE|25462155||ab|4|text|619|706|It may also regulate its hosts' gene expression, which has been shown in brain cancer.
SE|25462155||ab|4|entity|C1167395|host|celc|||hosts|||0|884|644|649
SE|25462155||ab|4|entity|C0017262|Gene Expression|genf|||gene expression|||0|884|651|666
SE|25462155||ab|4|entity|C0153633|Malignant neoplasm of brain|neop|||brain cancer|||0|1000|692|704

SE|25462155||ab|5|text|706|883|Since previous studies have shown that overexpressed miRNAs within the host are causal for disease onset, we hypothesized that T. gondii could export miRNAs into its host cell.
SE|25462155||ab|5|entity|C0205156|Previous|tmco|||previous|||0|872|712|720
SE|25462155||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|872|721|728
SE|25462155||ab|5|entity|C1514559|Protein Overexpression|genf|||overexpressed|||0|872|745|758
SE|25462155||ab|5|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|872|759|765
SE|25462155||ab|5|entity|C1167395|host|celc|||host|||0|1000|777|781
SE|25462155||ab|5|entity|C0015127|Etiology aspects|ftcn|||causal|||0|928|786|792
SE|25462155||ab|5|entity|C0277793|Onset of illness|fndg|||disease onset|||0|1000|797|810
SE|25462155||ab|5|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|1000|856|862
SE|25462155||ab|5|entity|C1167395|host|celc|||host|||0|888|872|876
SE|25462155||ab|5|entity|C0007634|Cells|cell|||cell|||0|888|877|881
SE|25462155||ab|5|relation|7|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNAs|||0|1000|856|862|PREP|ADMINISTERED_TO||863|867|1|1|C0007634|Cells|cell|cell|||cell|||0|888|877|881

SE|25462155||ab|6|text|883|1017|We computationally predicted all hairpins from the genome of T. gondii and used mouse and human models to filter possible candidates.
SE|25462155||ab|6|entity|C0017428|Genome|gngm|||genome|||0|1000|934|940
SE|25462155||ab|6|entity|C0042153|utilization qualifier|ftcn|||used|||0|853|958|962
SE|25462155||ab|6|entity|C0025914|House mice|mamm|||mouse|||0|853|963|968
SE|25462155||ab|6|entity|C0020114|Human|humn|||human|||0|1000|973|978
SE|25462155||ab|6|entity|C0332149|Possible|qlco|||possible|||0|694|996|1004

SE|25462155||ab|7|text|1017|1181|These were then further compared to known miRNAs in human and rodents and their expression was examined for T. gondii grown in mouse and human hosts, respectively.
SE|25462155||ab|7|entity|C1517331|Further|spco|||further|||0|1000|1033|1040
SE|25462155||ab|7|entity|C0205309|Known|qlco|||known|||0|888|1053|1058
SE|25462155||ab|7|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|888|1059|1065
SE|25462155||ab|7|entity|C0020114|Human|humn|||human|||0|1000|1069|1074
SE|25462155||ab|7|entity|C0035804|Rodent|mamm|||rodents|||0|1000|1079|1086
SE|25462155||ab|7|entity|C0025914|House mice|mamm|||mouse|||0|1000|1144|1149
SE|25462155||ab|7|entity|C0020114|Human|humn|||human|||0|872|1154|1159
SE|25462155||ab|7|entity|C1167395|host|celc|||hosts|||0|872|1160|1165
SE|25462155||ab|7|relation|0|0|C1167395|host|celc|celc|||hosts|||0|872|1160|1165|MOD/HEAD|PART_OF||1154|1165|0|0|C0020114|Human|grup,humn|humn|||human|||0|872|1154|1159

SE|25462155||ab|8|text|1181|1358|We found that among the millions of potential hairpins in T. gondii, only a few thousand pass filtering using a human or mouse model and that even fewer of those are expressed.
SE|25462155||ab|8|entity|C0237399|Potential|qlco|||potential|||0|694|1217|1226
SE|25462155||ab|8|entity|C0205388|Few|qnco|||few|||0|694|1257|1260
SE|25462155||ab|8|entity|C0020114|Human|humn|||human|||0|1000|1293|1298
SE|25462155||ab|8|entity|C0025914|House mice|mamm|||mouse|||0|888|1302|1307
SE|25462155||ab|8|entity|C0026336|Study models|inpr,resd|||model|||0|888|1308|1313

SE|25462155||ab|9|text|1358|1538|Since they are expressed and differentially expressed in rodents and human, we suggest that there is a chance that T. gondii may export miRNAs into its hosts for direct regulation.
SE|25462155||ab|9|entity|C0035804|Rodent|mamm|||rodents|||0|1000|1415|1422
SE|25462155||ab|9|entity|C0020114|Human|humn|||human|||0|1000|1427|1432
SE|25462155||ab|9|entity|C0237506|Chance|qlco|||chance|||0|1000|1461|1467
SE|25462155||ab|9|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|1000|1494|1500
SE|25462155||ab|9|entity|C1167395|host|celc|||hosts|||0|966|1510|1515
SE|25462155||ab|9|entity|C0851285|Regulation|gora|||regulation|||0|861|1527|1537


SE|25462156||ti|1|text|21|103|Role of intracellular prostaglandin E2 in cancer-related phenotypes in PC3 cells.
SE|25462156||ti|1|entity|C0035820|Role|socb|||Role|||0|1000|21|25
SE|25462156||ti|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|901|29|42
SE|25462156||ti|1|entity|C0012472|Dinoprostone|eico,horm,phsu|||prostaglandin E2|||0|901|43|59
SE|25462156||ti|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|851|63|69
SE|25462156||ti|1|entity|C1522149|Related|ftcn|||related|||0|851|70|77
SE|25462156||ti|1|entity|C0031437|Phenotype|orga|||phenotypes|||0|851|78|88
SE|25462156||ti|1|entity|C0135615|Proprotein Convertase 1|aapp,enzy|3853,5122,7832,10120,57332|KRT6A,PCSK1,BTG2,ACTR1B,CBX8|PC3|||0|888|92|95
SE|25462156||ti|1|entity|C0007634|Cells|cell|||cells|||0|888|96|101
SE|25462156||ti|1|relation|0|0|C0012472|Dinoprostone|eico,horm,phsu|eico|||prostaglandin E2|||0|901|43|59|MOD/HEAD|PART_OF||29|59|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|901|29|42
SE|25462156||ti|1|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|888|96|101|PREP|LOCATION_OF||89|91|3|2|C0012472|Dinoprostone|eico,horm,phsu|eico|||prostaglandin E2|||0|901|43|59

SE|25462156||ab|1|text|109|261|Prostaglandin E2 (PGE2) and hypoxia-inducible factor-1alpha (HIF-1alpha) affect many mechanisms that have been shown to play a role in prostate cancer.
SE|25462156||ab|1|entity|C0012472|Dinoprostone|eico,horm,phsu|||Prostaglandin E2|||0|1000|109|125
SE|25462156||ab|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|597|137|144
SE|25462156||ab|1|entity|C1521761|Factor|ftcn|||factor|||0|597|155|161
SE|25462156||ab|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|194|204
SE|25462156||ab|1|entity|C0035820|Role|socb|||role|||0|1000|236|240
SE|25462156||ab|1|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|1000|244|259
SE|25462156||ab|1|relation|3|3|C0012472|Dinoprostone|eico,horm,phsu|eico|||Prostaglandin E2|||0|1000|109|125|COMPLEX|AFFECTS||229|240|1|1|C0376358|Malignant neoplasm of prostate|neop|neop|||prostate cancer|||0|1000|244|259

SE|25462156||ab|2|text|261|482|In PGE2-treated LNCaP cells, up-regulation of HIF-1alpha requires the internalization of PGE2, which is in sharp contrast with the generally accepted view that PGE2 acts through EP receptors located at the cell membrane.
SE|25462156||ab|2|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|786|264|268
SE|25462156||ab|2|entity|C1292734|Treats|clas|||treated|||0|786|269|276
SE|25462156||ab|2|entity|C0007634|Cells|cell|||cells|||0|786|283|288
SE|25462156||ab|2|entity|C0162493|Transcriptional Activation|genf|||up-regulation|||0|1000|290|303
SE|25462156||ab|2|entity|C0242184|Hypoxia|patf|||HIF-1alpha|||0|597|307|317
SE|25462156||ab|2|entity|C1521761|Factor|ftcn|||HIF-1alpha|||0|597|307|317
SE|25462156||ab|2|entity|C0871786|Internalization|menp|||internalization|||0|1000|331|346
SE|25462156||ab|2|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|1000|350|354
SE|25462156||ab|2|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|1000|421|425
SE|25462156||ab|2|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|888|442|451
SE|25462156||ab|2|entity|C0007603|Cell membrane|celc|||cell membrane|||0|1000|467|480
SE|25462156||ab|2|relation|8|2|C0012472|Dinoprostone|eico,horm,phsu|eico|||PGE2|||0|1000|421|425|VERB|PART_OF||452|459|1|1|C0007603|Cell membrane|celc|celc|||cell membrane|||0|1000|467|480

SE|25462156||ab|3|text|482|627|Here we aimed to study in androgen-independent PC3 cells the role of intracellular PGE2 in several events linked to prostate cancer progression.
SE|25462156||ab|3|entity|C0002844|Androgens|horm,phsu|||androgen|||0|833|508|516
SE|25462156||ab|3|entity|C0135615|Proprotein Convertase 1|aapp,enzy|3853,5122,7832,10120,57332|KRT6A,PCSK1,BTG2,ACTR1B,CBX8|PC3|||0|833|529|532
SE|25462156||ab|3|entity|C0007634|Cells|cell|||cells|||0|833|533|538
SE|25462156||ab|3|entity|C0035820|Role|socb|||role|||0|1000|543|547
SE|25462156||ab|3|entity|C0175996|Protoplasm|celc|||intracellular|||0|901|551|564
SE|25462156||ab|3|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|901|565|569
SE|25462156||ab|3|entity|C0443302|Several|qnco|||several|||0|888|573|580
SE|25462156||ab|3|entity|C0441471|Events|evnt|||events|||0|888|581|587
SE|25462156||ab|3|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|901|598|613
SE|25462156||ab|3|entity|C0449258|Progression|ftcn|||progression|||0|901|614|625
SE|25462156||ab|3|relation|0|0|C0012472|Dinoprostone|eico,horm,phsu|eico|||PGE2|||0|901|565|569|MOD/HEAD|PART_OF||551|569|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|901|551|564
SE|25462156||ab|3|relation|4|2|C0012472|Dinoprostone|eico,horm,phsu|eico|||PGE2|||0|901|565|569|VERB|ASSOCIATED_WITH||588|594|1|1|C0376358|Malignant neoplasm of prostate|neop|neop|||prostate cancer|||0|901|598|613

SE|25462156||ab|4|text|627|819|To this end, we used bromocresol green, an inhibitor of prostaglandin uptake that blocked the immediate rise in intracellular immunoreactive PGE2 following treatment with 16,16-dimethyl-PGE2.
SE|25462156||ab|4|entity|C0006215|Bromcresol Green|irda,orch|||bromocresol green|||0|1000|648|665
SE|25462156||ab|4|entity|C0243077|inhibitors|chvf|||inhibitor|||0|966|670|679
SE|25462156||ab|4|entity|C0033554|Prostaglandins|bacs,eico,phsu|||prostaglandin|||0|888|683|696
SE|25462156||ab|4|entity|C0243144|uptake|phsf|||uptake|||0|888|697|703
SE|25462156||ab|4|entity|C0205253|Immediate|tmco|||immediate|||0|694|721|730
SE|25462156||ab|4|entity|C0175996|Protoplasm|celc|||intracellular|||0|824|739|752
SE|25462156||ab|4|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|824|768|772
SE|25462156||ab|4|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|861|813|817
SE|25462156||ab|4|relation|2|1|C0006215|Bromcresol Green|irda,orch|orch|||bromocresol green|||0|1000|648|665|NOM|DISRUPTS||670|679|5|1|C0243144|uptake|phsf|phsf|||uptake|||0|888|697|703

SE|25462156||ab|5|text|819|1214|Bromocresol green prevented the stimulatory effect of 16,16-dimethyl-PGE on cell proliferation, adhesion, migration and invasion and on HIF-1alpha expression and activity, the latter assessed as the HIF-dependent activation of (i) a hypoxia response element-luciferase plasmid construct, (ii) production of angiogenic factor vascular endothelial growth factor-A and (iii) in vitro angiogenesis.
SE|25462156||ab|5|entity|C0006215|Bromcresol Green|irda,orch|||Bromocresol green|||0|1000|819|836
SE|25462156||ab|5|entity|C0175727|Stimulator|medd|||stimulatory|||0|853|851|862
SE|25462156||ab|5|entity|C1280500|Effect|qlco|||effect|||0|853|863|869
SE|25462156||ab|5|entity|C0033559|Prostaglandins E|bacs,eico|||PGE|||0|827|888|891
SE|25462156||ab|5|entity|C0596290|Cell Proliferation|celf|||cell proliferation|||0|1000|895|913
SE|25462156||ab|5|entity|C0001511|Adhesions|acab,dsyn|||adhesion|||0|1000|915|923
SE|25462156||ab|5|entity|C0242184|Hypoxia|patf|||HIF-1alpha|||0|754|955|965
SE|25462156||ab|5|entity|C1521761|Factor|ftcn|||HIF-1alpha|||0|754|955|965
SE|25462156||ab|5|entity|C0301821|Hypothalamic inhibiting factor|horm,orch|||HIF|||0|623|1018|1021
SE|25462156||ab|5|entity|C0242184|Hypoxia|patf|||hypoxia|||0|620|1052|1059
SE|25462156||ab|5|entity|C0600508|Response Elements|bacs,nnon|||response element|||0|620|1060|1076
SE|25462156||ab|5|entity|C0024075|Luciferases|aapp,enzy,irda|||luciferase|||0|620|1077|1087
SE|25462156||ab|5|entity|C0032136|Plasmids|bacs,nnon|||plasmid|||0|620|1088|1095
SE|25462156||ab|5|entity|C0033268|production|ocac|||production|||0|1000|1112|1122
SE|25462156||ab|5|entity|C0002976|Angiogenesis Factor|bacs|||angiogenic factor|||0|901|1126|1143
SE|25462156||ab|5|entity|C1171892|VEGF protein, human|aapp,bacs|7422|VEGFA|vascular endothelial growth factor|||0|901|1144|1178
SE|25462156||ab|5|entity|C0439070|III|inpr|||iii|||0|1000|1186|1189
SE|25462156||ab|5|entity|C1533691|in vitro|qlco|||in vitro|||0|901|1191|1199
SE|25462156||ab|5|entity|C0302600|Angiogenesis|ortf|||angiogenesis|||0|901|1200|1212
SE|25462156||ab|5|relation|13|9|C0001511|Adhesions|acab,dsyn|dsyn|||adhesion|||0|1000|915|923|NOM|PRODUCES||1112|1122|3|1|C1171892|VEGF protein, human|aapp,gngm,bacs|bacs|7422|VEGFA|vascular endothelial growth factor|||0|901|1144|1178
SE|25462156||ab|5|relation|15|1|C0033559|Prostaglandins E|bacs,eico|bacs|||PGE|||0|827|888|891|NOM|AFFECTS||863|869|15|2|C0596290|Cell Proliferation|celf|celf|||cell proliferation|||0|1000|895|913

SE|25462156||ab|6|text|1214|1415|The basal phenotype of PC3 cells was also affected by bromocresol green, that substantially lowered expression of HIF-1alpha, production of vascular endothelial growth factor-A and cell proliferation.
SE|25462156||ab|6|entity|C0205112|Basal|spco|||basal|||0|888|1218|1223
SE|25462156||ab|6|entity|C0031437|Phenotype|orga|||phenotype|||0|888|1224|1233
SE|25462156||ab|6|entity|C0135615|Proprotein Convertase 1|aapp,enzy|3853,5122,7832,10120,57332|KRT6A,PCSK1,BTG2,ACTR1B,CBX8|PC3|||0|888|1237|1240
SE|25462156||ab|6|entity|C0007634|Cells|cell|||cells|||0|888|1241|1246
SE|25462156||ab|6|entity|C0006215|Bromcresol Green|irda,orch|||bromocresol green|||0|1000|1268|1285
SE|25462156||ab|6|entity|C1272755|Lowered|qnco|||lowered|||0|790|1306|1313
SE|25462156||ab|6|entity|C0242184|Hypoxia|patf|||HIF-1alpha|||0|597|1328|1338
SE|25462156||ab|6|entity|C1521761|Factor|ftcn|||HIF-1alpha|||0|597|1328|1338
SE|25462156||ab|6|entity|C0033268|production|ocac|||production|||0|1000|1340|1350
SE|25462156||ab|6|entity|C1171892|VEGF protein, human|aapp,bacs|7422|VEGFA|vascular endothelial growth factor|||0|1000|1354|1388
SE|25462156||ab|6|entity|C0596290|Cell Proliferation|celf|||cell proliferation|||0|1000|1395|1413
SE|25462156||ab|6|relation|6|1|C0006215|Bromcresol Green|irda,orch|orch|||bromocresol green|||0|1000|1268|1285|VERB|AFFECTS||1256|1264|2|1|C0007634|Cells|cell|cell|||cells|||0|888|1241|1246

SE|25462156||ab|7|text|1415|1727|These results, and the fact that we found functional intracellular EP receptors in PC3 cells, suggest that PGE2-dependent intracrine mechanisms play a role in prostate cancer Therefore, inhibition of the prostaglandin uptake transporter might be a novel therapeutic approach for the treatment of prostate cancer.
SE|25462156||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1421|1428
SE|25462156||ab|7|entity|C0205245|Functional|ftcn|||functional|||0|833|1457|1467
SE|25462156||ab|7|entity|C0175996|Protoplasm|celc|||intracellular|||0|833|1468|1481
SE|25462156||ab|7|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|833|1485|1494
SE|25462156||ab|7|entity|C0135615|Proprotein Convertase 1|aapp,enzy|3853,5122,7832,10120,57332|KRT6A,PCSK1,BTG2,ACTR1B,CBX8|PC3|||0|888|1498|1501
SE|25462156||ab|7|entity|C0007634|Cells|cell|||cells|||0|888|1502|1507
SE|25462156||ab|7|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|794|1522|1526
SE|25462156||ab|7|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|794|1548|1558
SE|25462156||ab|7|entity|C0035820|Role|socb|||role|||0|1000|1566|1570
SE|25462156||ab|7|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|901|1574|1589
SE|25462156||ab|7|entity|C0243144|uptake|phsf|||uptake|||0|901|1633|1639
SE|25462156||ab|7|entity|C0287197|prostaglandin transporter|aapp,bacs|||prostaglandin uptake transporter|||0|901|1619|1651
SE|25462156||ab|7|entity|C0679622|novel|inpr|||novel|||0|851|1663|1668
SE|25462156||ab|7|entity|C0449445|Approach|spco|||approach|||0|851|1681|1689
SE|25462156||ab|7|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|1000|1711|1726


SE|25462158||ti|1|text|21|164|Abnormal cortical lysosomal beta-hexosaminidase and beta-galactosidase activity at post-synaptic sites during Alzheimer's disease progression.
SE|25462158||ti|1|entity|C0205161|Abnormal|ftcn|||Abnormal|||0|826|21|29
SE|25462158||ti|1|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|826|30|38
SE|25462158||ti|1|entity|C0521450|Lysosomal|blor|||lysosomal|||0|826|39|48
SE|25462158||ti|1|entity|C0005270|BETA-N-ACETYLHEXOSAMINIDASE|aapp,enzy|||beta-hexosaminidase|||0|826|49|68
SE|25462158||ti|1|entity|C1150053|beta-galactosidase activity|moft|||beta-galactosidase activity|||0|1000|73|100
SE|25462158||ti|1|entity|C0039062|Synapses|bsoj|||synaptic|||0|828|109|117
SE|25462158||ti|1|entity|C0205145|Site|spco|||sites|||0|828|118|123
SE|25462158||ti|1|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|901|131|150
SE|25462158||ti|1|entity|C0449258|Progression|ftcn|||progression|||0|901|151|162
SE|25462158||ti|1|relation|0|0|C0005270|BETA-N-ACETYLHEXOSAMINIDASE|aapp,gngm,enzy|gngm|||beta-hexosaminidase|||0|826|49|68|MOD/HEAD|PART_OF||39|68|0|0|C0521450|Lysosomal|blor|blor|||lysosomal|||0|826|39|48
SE|25462158||ti|1|relation|3|2|C1150053|beta-galactosidase activity|moft|moft|||beta-galactosidase activity|||0|1000|73|100|PREP|COEXISTS_WITH||124|130|1|1|C0002395|Alzheimer's Disease|dsyn|dsyn|||Alzheimer's disease|||0|901|131|150

SE|25462158||ab|1|text|170|281|A critical role of endosomal-lysosomal system alteration in neurodegeneration is supported by several studies.
SE|25462158||ab|1|entity|C1511545|Critical|qlco|||critical|||0|888|172|180
SE|25462158||ab|1|entity|C0035820|Role|socb|||role|||0|888|181|185
SE|25462158||ab|1|entity|C0034850|Endosomes|celc|||endosomal|||0|825|189|198
SE|25462158||ab|1|entity|C0449913|System|ftcn|||system|||0|825|209|215
SE|25462158||ab|1|entity|C0544948|Lysosome alteration|comd|||lysosomal system alteration|||0|825|199|226
SE|25462158||ab|1|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|1000|230|247
SE|25462158||ab|1|entity|C0443302|Several|qnco|||several|||0|872|264|271
SE|25462158||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|272|279

SE|25462158||ab|2|text|281|371|Dysfunction of the lysosomal compartment is a common feature also in Alzheimer's disease.
SE|25462158||ab|2|entity|C0521450|Lysosomal|blor|||lysosomal|||0|888|300|309
SE|25462158||ab|2|entity|C1185625|Compartments|bsoj|||compartment|||0|888|310|321
SE|25462158||ab|2|entity|C0205214|Common|qnco|||common|||0|660|327|333
SE|25462158||ab|2|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|1000|350|369

SE|25462158||ab|3|text|371|603|Altered expression of lysosomal glycohydrolases has been demonstrated not only in the brain and peripheral tissues of Alzheimer's disease patients, but also in presymptomatic subjects before degenerative phenomenon becomes evident.
SE|25462158||ab|3|entity|C0205349|Altered|ftcn|||Altered|||0|888|371|378
SE|25462158||ab|3|entity|C0521450|Lysosomal|blor|||lysosomal|||0|888|393|402
SE|25462158||ab|3|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||glycohydrolases|||0|888|403|418
SE|25462158||ab|3|entity|C1518422|Not|ftcn|||not|||0|861|441|444
SE|25462158||ab|3|entity|C0006104|Brain|bpoc|||brain|||0|1000|457|462
SE|25462158||ab|3|entity|C0205100|Peripheral|spco|||peripheral|||0|888|467|477
SE|25462158||ab|3|entity|C0040300|Body tissue|tisu|||tissues|||0|888|478|485
SE|25462158||ab|3|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|901|489|508
SE|25462158||ab|3|entity|C0030705|Patients|podg|||patients|||0|901|509|517
SE|25462158||ab|3|entity|C1550501|subject|idcn|||subjects|||0|827|546|554
SE|25462158||ab|3|relation|0|0|C0002395|Alzheimer's Disease|dsyn|dsyn|||Alzheimer's disease|||0|901|489|508|MOD/HEAD|PROCESS_OF||489|517|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|509|517
SE|25462158||ab|3|relation|0|0|C0017976|Glycoside Hydrolases|aapp,gngm,enzy|gngm|||glycohydrolases|||0|888|403|418|MOD/HEAD|PART_OF||393|418|0|0|C0521450|Lysosomal|blor|blor|||lysosomal|||0|888|393|402
SE|25462158||ab|3|relation|4|1|C0006104|Brain|bpoc|bpoc|||brain|||0|1000|457|462|PREP|PART_OF||486|488|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|901|509|517
SE|25462158||ab|3|relation|4|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|478|485|PREP|PART_OF||486|488|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|901|509|517
SE|25462158||ab|3|relation|6|1|C0006104|Brain|bpoc|bpoc|||brain|||0|1000|457|462|PREP|LOCATION_OF||450|452|2|1|C0017976|Glycoside Hydrolases|aapp,gngm,enzy|aapp|||glycohydrolases|||0|888|403|418
SE|25462158||ab|3|relation|6|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|478|485|PREP|LOCATION_OF||450|452|2|1|C0017976|Glycoside Hydrolases|aapp,gngm,enzy|aapp|||glycohydrolases|||0|888|403|418

SE|25462158||ab|4|text|603|778|Moreover, the presence of glycohydrolases associated to the plasma membrane have been widely demonstrated and their alteration in pathological conditions has been documented.
SE|25462158||ab|4|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||glycohydrolases|||0|1000|629|644
SE|25462158||ab|4|entity|C0007603|Cell membrane|celc|||plasma membrane|||0|1000|663|678
SE|25462158||ab|4|entity|C1515926|Alteration|idcn|||alteration|||0|1000|719|729
SE|25462158||ab|4|entity|C1521733|Pathologic|ftcn|||pathological|||0|872|733|745
SE|25462158||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|872|746|756

SE|25462158||ab|5|text|778|1023|In particular, lipid microdomains-associated glycohydrolases can be functional to the maintenance of the proper glycosphingolipids pattern, especially at cell surface level, where they are crucial for the function of cell types such as neurons.
SE|25462158||ab|5|entity|C0023779|Lipids|lipd|||lipid|||0|764|793|798
SE|25462158||ab|5|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||glycohydrolases|||0|764|823|838
SE|25462158||ab|5|entity|C0205245|Functional|ftcn|||functional|||0|1000|846|856
SE|25462158||ab|5|entity|C0017978|Glycosphingolipids|lipd,phsu|||glycosphingolipids|||0|861|890|908
SE|25462158||ab|5|entity|C0699040|Cell surface|celc|||cell surface|||0|734|932|944
SE|25462158||ab|5|entity|C0031843|physiological aspects|phsf|||function|||0|1000|983|991
SE|25462158||ab|5|entity|C0007634|Cells|cell|||cell types|||0|1000|995|1005
SE|25462158||ab|5|entity|C0027882|Neurons|cell|||neurons|||0|1000|1014|1021
SE|25462158||ab|5|relation|5|1|C0699040|Cell surface|celc|celc|||cell surface|||0|734|932|944|PREP|LOCATION_OF||929|931|4|1|C0017978|Glycosphingolipids|lipd,phsu|lipd|||glycosphingolipids|||0|861|890|908

SE|25462158||ab|6|text|1023|1319|In this study we investigated the localization of beta-hexosaminidase and beta-galactosidase glycohydrolases, both involved in step by step degradation of the GM1 to GM3 gangliosides, in lipid microdomains from the cortex of both an early and advanced TgCRND8 mouse model of Alzheimer's disease.
SE|25462158||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1031|1036
SE|25462158||ab|6|entity|C0475264|localization|ftcn|||localization|||0|1000|1057|1069
SE|25462158||ab|6|entity|C0005270|BETA-N-ACETYLHEXOSAMINIDASE|aapp,enzy|||beta-hexosaminidase|||0|1000|1073|1092
SE|25462158||ab|6|entity|C0005220|beta-Galactosidase|aapp,enzy,phsu|||beta-galactosidase|||0|901|1097|1115
SE|25462158||ab|6|entity|C0017976|Glycoside Hydrolases|aapp,enzy|||glycohydrolases|||0|901|1116|1131
SE|25462158||ab|6|entity|C1261552|Step|ftcn|||step|||0|791|1150|1154
SE|25462158||ab|6|entity|C0243125|degradation|ftcn|||degradation|||0|791|1163|1174
SE|25462158||ab|6|entity|C0016897|G(M3) Ganglioside|bacs,lipd|||GM3 gangliosides|||0|983|1189|1205
SE|25462158||ab|6|entity|C0023779|Lipids|lipd|||lipid|||0|694|1210|1215
SE|25462158||ab|6|entity|C1279919|Early|tmco|||early|||0|1000|1256|1261
SE|25462158||ab|6|entity|C0025914|House mice|mamm|||mouse|||0|750|1283|1288
SE|25462158||ab|6|entity|C0026336|Study models|inpr,resd|||model|||0|750|1289|1294
SE|25462158||ab|6|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|1000|1298|1317
SE|25462158||ab|6|relation|0|0|C0005220|beta-Galactosidase|aapp,gngm,enzy,phsu|aapp|||beta-galactosidase|||0|901|1097|1115|MOD/HEAD|ISA||1097|1131|0|0|C0017976|Glycoside Hydrolases|aapp,gngm,enzy|aapp|||glycohydrolases|||0|901|1116|1131

SE|25462158||ab|7|text|1319|1634|Throughout immunoprecipitation experiments of purified cortical lipid microdomains, we demonstrated for the first time that beta-hexosaminidase and beta-galactosidase are associated with post-synaptic vesicles and that their activities are increased at both the early and the advanced stage of Alzheimer's disease.
SE|25462158||ab|7|entity|C0021069|Immunoprecipitation|lbpr|||immunoprecipitation|||0|888|1330|1349
SE|25462158||ab|7|entity|C0681814|research study|resa|||experiments|||0|888|1350|1361
SE|25462158||ab|7|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|555|1374|1382
SE|25462158||ab|7|entity|C0023779|Lipids|lipd|||lipid|||0|555|1383|1388
SE|25462158||ab|7|entity|C1279901|Firstly|qlco|||first|||0|888|1427|1432
SE|25462158||ab|7|entity|C0040223|Time|tmco|||time|||0|888|1433|1437
SE|25462158||ab|7|entity|C0005270|BETA-N-ACETYLHEXOSAMINIDASE|aapp,enzy|||beta-hexosaminidase|||0|1000|1443|1462
SE|25462158||ab|7|entity|C0005220|beta-Galactosidase|aapp,enzy,phsu|||beta-galactosidase|||0|1000|1467|1485
SE|25462158||ab|7|entity|C0039065|Synaptic Vesicles|celc|||synaptic vesicles|||0|901|1511|1528
SE|25462158||ab|7|entity|C0441655|Activities|acty|||activities|||0|1000|1544|1554
SE|25462158||ab|7|entity|C1279919|Early|tmco|||early|||0|1000|1581|1586
SE|25462158||ab|7|entity|C1306673|Stage|qlco|||stage|||0|861|1604|1609
SE|25462158||ab|7|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|1000|1613|1632

SE|25462158||ab|8|text|1634|1948|The early increase of lipid microdomain-associated beta-hexosaminidase and beta-galactosidase activities could have relevant implications for the pathophysiology of the disease since their possible pharmacological manipulation could shed light on new reliable targets and biological markers of Alzheimer's disease.
SE|25462158||ab|8|entity|C1279919|Early|tmco|||early|||0|888|1638|1643
SE|25462158||ab|8|entity|C0442805|Increase|ftcn|||increase|||0|888|1644|1652
SE|25462158||ab|8|entity|C0023779|Lipids|lipd|||lipid|||0|812|1656|1661
SE|25462158||ab|8|entity|C0005270|BETA-N-ACETYLHEXOSAMINIDASE|aapp,enzy|||beta-hexosaminidase|||0|812|1685|1704
SE|25462158||ab|8|entity|C1150053|beta-galactosidase activity|moft|||beta-galactosidase activities|||0|983|1709|1738
SE|25462158||ab|8|entity|C0031847|physiopathological|ftcn|||pathophysiology|||0|1000|1780|1795
SE|25462158||ab|8|entity|C0012634|Disease|dsyn|||disease|||0|1000|1803|1810
SE|25462158||ab|8|entity|C0332149|Possible|qlco|||possible|||0|851|1823|1831
SE|25462158||ab|8|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|851|1832|1847
SE|25462158||ab|8|entity|C0947647|Manipulation procedure|topp|||manipulation|||0|851|1848|1860
SE|25462158||ab|8|entity|C0205314|New|tmco|||new|||0|785|1881|1884
SE|25462158||ab|8|entity|C0005516|Biological Markers|qlco|||biological markers|||0|1000|1906|1924
SE|25462158||ab|8|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|1000|1928|1947


SE|25462157||ti|1|text|21|139|Characterising the association of latency with alpha(1)-antitrypsin polymerisation using a novel monoclonal antibody.
SE|25462157||ti|1|entity|C0205275|Latent|qlco|||latency|||0|928|55|62
SE|25462157||ti|1|entity|C0002191|alpha 1-Antitrypsin|aapp,bacs,phsu|||alpha(1)-antitrypsin|||0|916|68|88
SE|25462157||ti|1|entity|C0314672|Polymerization|phpr|||polymerisation|||0|916|89|103
SE|25462157||ti|1|entity|C0679622|novel|inpr|||novel|||0|901|112|117
SE|25462157||ti|1|entity|C0003250|Monoclonal Antibodies|aapp,imft|||monoclonal antibody|||0|901|118|137

SE|25462157||ab|1|text|145|282|alpha1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary tissues from proteolytic damage.
SE|25462157||ab|1|entity|||gngm|146|ADRA1D|alpha1|||0|861|145|151
SE|25462157||ab|1|entity|C0072348|Protein C Inhibitor|aapp,bacs|||Antitrypsin|||0|861|152|163
SE|25462157||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|1000|196|201
SE|25462157||ab|1|entity|C0024109|Lung|bpoc|||lung|||0|1000|221|225
SE|25462157||ab|1|entity|C0024109|Lung|bpoc|||pulmonary|||0|888|239|248
SE|25462157||ab|1|entity|C0040300|Body tissue|tisu|||tissues|||0|888|249|256
SE|25462157||ab|1|entity|C0030946|Endopeptidases|aapp,enzy,phsu|||proteolytic|||0|694|262|273
SE|25462157||ab|1|relation|0|0|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|249|256|MOD/HEAD|PART_OF||239|256|0|0|C0024109|Lung|bpoc|bpoc|||pulmonary|||0|888|239|248
SE|25462157||ab|1|relation|4|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|196|201|PREP|LOCATION_OF||189|191|1|1|C0072348|Protein C Inhibitor|aapp,gngm,bacs|aapp|||Antitrypsin|||0|861|152|163

SE|25462157||ab|2|text|282|369|The Z mutant (Glu342Lys) undergoes inactivating conformational change and polymerises.
SE|25462157||ab|2|entity|C0596988|Mutant|comd|||mutant|||0|861|288|294
SE|25462157||ab|2|entity|C0301641|Macromolecular alteration|moft|||conformational change|||0|901|330|351

SE|25462157||ab|3|text|369|539|Polymers are retained within the hepatocyte endoplasmic reticulum (ER) in homozygous (PiZZ) individuals, predisposing the individuals to hepatic cirrhosis and emphysema.
SE|25462157||ab|3|entity|C0032521|Polymers|bodm,chvs|||Polymers|||0|1000|369|377
SE|25462157||ab|3|entity|C0227525|Hepatocyte|cell|||hepatocyte|||0|901|402|412
SE|25462157||ab|3|entity|C0014239|Endoplasmic Reticulum|celc|||endoplasmic reticulum|||0|901|413|434
SE|25462157||ab|3|entity|C0237401|Individual|humn|||individuals|||0|1000|461|472
SE|25462157||ab|3|entity|C0237401|Individual|humn|||individuals|||0|1000|491|502
SE|25462157||ab|3|entity|C0023890|Liver Cirrhosis|dsyn|||hepatic cirrhosis|||0|1000|506|523
SE|25462157||ab|3|entity|C0013990|Pathological accumulation of air in tissues|patf|||emphysema|||0|1000|528|537
SE|25462157||ab|3|relation|0|0|C0014239|Endoplasmic Reticulum|celc|celc|||endoplasmic reticulum|||0|901|413|434|MOD/HEAD|PART_OF||402|434|0|0|C0227525|Hepatocyte|cell|cell|||hepatocyte|||0|901|402|412

SE|25462157||ab|4|text|539|664|Latency is an analogous process of inactivating, intra-molecular conformational change and may co-occur with polymerisation.
SE|25462157||ab|4|entity|C0205275|Latent|qlco|||Latency|||0|928|539|546
SE|25462157||ab|4|entity|C0243071|Analog|chvs|||analogous|||0|853|553|562
SE|25462157||ab|4|entity|C1522240|Process|phpr|||process|||0|853|563|570
SE|25462157||ab|4|entity|C0347985|During values|tmco|||intra|||0|861|588|593
SE|25462157||ab|4|entity|C1521991|Molecular|qlco|||molecular|||0|861|594|603
SE|25462157||ab|4|entity|C0301641|Macromolecular alteration|moft|||conformational change|||0|861|604|625
SE|25462157||ab|4|entity|C0314672|Polymerization|phpr|||polymerisation|||0|1000|648|662

SE|25462157||ab|5|text|664|781|However, the relationship between latency and polymerisation remained unexplored in the absence of a suitable probe.
SE|25462157||ab|5|entity|C0439849|Relationships|qlco|||relationship|||0|1000|677|689
SE|25462157||ab|5|entity|C0205275|Latent|qlco|||latency|||0|928|698|705
SE|25462157||ab|5|entity|C0314672|Polymerization|phpr|||polymerisation|||0|1000|710|724
SE|25462157||ab|5|entity|C0182400|Probes|medd|||probe|||0|861|774|779

SE|25462157||ab|6|text|781|1026|We have developed a novel monoclonal antibody specific for latent alpha1-antitrypsin and used it in combination with a polymer-specific antibody, to assess the association of both conformers in vitro, in disease and during augmentation therapy.
SE|25462157||ab|6|entity|C0679622|novel|inpr|||novel|||0|901|801|806
SE|25462157||ab|6|entity|C0003250|Monoclonal Antibodies|aapp,imft|||monoclonal antibody|||0|901|807|826
SE|25462157||ab|6|entity|C0205275|Latent|qlco|||latent|||0|802|840|846
SE|25462157||ab|6|entity|||gngm|146|ADRA1D|alpha1|||0|802|847|853
SE|25462157||ab|6|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|802|854|865
SE|25462157||ab|6|entity|C0205195|Combined|qlco|||combination|||0|1000|881|892
SE|25462157||ab|6|entity|C0032521|Polymers|bodm,chvs|||polymer|||0|901|900|907
SE|25462157||ab|6|entity|C0443640|Specific antibody|aapp,imft|||specific antibody|||0|901|908|925
SE|25462157||ab|6|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|972|980
SE|25462157||ab|6|entity|C0012634|Disease|dsyn|||disease|||0|1000|985|992
SE|25462157||ab|6|relation|8|4|C0443640|Specific antibody|aapp,gngm,imft|aapp|||specific antibody|||0|901|908|925|PREP|ASSOCIATED_WITH||982|984|2|1|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|985|992

SE|25462157||ab|7|text|1026|1172|In vitro kinetics analysis showed polymerisation dominated the pathway but latency could be promoted by stabilising monomeric alpha1-antitrypsin.
SE|25462157||ab|7|entity|C1533691|in vitro|qlco|||In vitro|||0|861|1026|1034
SE|25462157||ab|7|entity|C0022702|Kinetics|idcn|||kinetics|||0|861|1035|1043
SE|25462157||ab|7|entity|C0936012|Analysis|resa|||analysis|||0|861|1044|1052
SE|25462157||ab|7|entity|C0314672|Polymerization|phpr|||polymerisation|||0|1000|1060|1074
SE|25462157||ab|7|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|1000|1089|1096
SE|25462157||ab|7|entity|C0205275|Latent|qlco|||latency|||0|928|1101|1108
SE|25462157||ab|7|entity|C0184512|Stabilized|qlco|||stabilising|||0|740|1130|1141
SE|25462157||ab|7|entity|C0596973|monomer|chvs|||monomeric|||0|740|1142|1151
SE|25462157||ab|7|entity|||gngm|146|ADRA1D|alpha1|||0|740|1152|1158
SE|25462157||ab|7|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|740|1159|1170

SE|25462157||ab|8|text|1172|1357|Polymers were extensively produced in hepatocytes and a cell line expressing Z alpha1-antitrypsin but the latent protein was not detected despite manipulation of the secretory pathway.
SE|25462157||ab|8|entity|C0032521|Polymers|bodm,chvs|||Polymers|||0|1000|1172|1180
SE|25462157||ab|8|entity|C0227525|Hepatocyte|cell|||hepatocytes|||0|1000|1210|1221
SE|25462157||ab|8|entity|C0007600|Cell Line|cell|||cell line|||0|785|1228|1237
SE|25462157||ab|8|entity|||gngm|146|ADRA1D|alpha1|||0|785|1251|1257
SE|25462157||ab|8|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|785|1258|1269
SE|25462157||ab|8|entity|C0205275|Latent|qlco|||latent|||0|888|1278|1284
SE|25462157||ab|8|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|1285|1292
SE|25462157||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1297|1300
SE|25462157||ab|8|entity|C0947647|Manipulation procedure|topp|||manipulation|||0|1000|1318|1330
SE|25462157||ab|8|entity|C1159342|secretory pathway|celf|||secretory pathway|||0|1000|1338|1355
SE|25462157||ab|8|relation|2|1|C0227525|Hepatocyte|cell|cell|||hepatocytes|||0|1000|1210|1221|ADJ|INTERACTS_WITH||1238|1248|2|0|C0072348|Protein C Inhibitor|aapp,gngm,bacs|gngm|||antitrypsin|||0|785|1258|1269

SE|25462157||ab|9|text|1357|1583|However, alpha1-antitrypsin augmentation therapy contains latent alpha1-antitrypsin, as did the plasma of 63/274 PiZZ individuals treated with augmentation therapy but 0/264 who were not receiving this medication (p<10(-14)).
SE|25462157||ab|9|entity|||gngm|146|ADRA1D|alpha1|||0|775|1366|1372
SE|25462157||ab|9|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|775|1373|1384
SE|25462157||ab|9|entity|C0205275|Latent|qlco|||latent|||0|802|1415|1421
SE|25462157||ab|9|entity|||gngm|146|ADRA1D|alpha1|||0|802|1422|1428
SE|25462157||ab|9|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|802|1429|1440
SE|25462157||ab|9|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|1453|1459
SE|25462157||ab|9|entity|C0237401|Individual|humn|||individuals|||0|812|1475|1486
SE|25462157||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1540|1543
SE|25462157||ab|9|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|1559|1569
SE|25462157||ab|9|entity|C0083903|P 10|bodm|||p<10|||0|1000|1571|1575
SE|25462157||ab|9|relation|3|1|C0032105|Plasma|bdsu|bdsu|||plasma|||0|1000|1453|1459|PREP|PART_OF||1460|1462|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|812|1475|1486
SE|25462157||ab|9|relation|5|5|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication|||0|1000|1559|1569|NOM|STIMULATES||1385|1397|0|0|C0072348|Protein C Inhibitor|aapp,gngm,bacs|gngm|||antitrypsin|||0|775|1373|1384

SE|25462157||ab|10|text|1583|1855|We conclude that latent alpha1-antitrypsin is a by-product of the polymerisation pathway, that the intracellular folding environment is resistant to formation of the latent conformer but that augmentation therapy introduces latent alpha1-antitrypsin into the circulation.
SE|25462157||ab|10|entity|C0205275|Latent|qlco|||latent|||0|802|1600|1606
SE|25462157||ab|10|entity|||gngm|146|ADRA1D|alpha1|||0|802|1607|1613
SE|25462157||ab|10|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|802|1614|1625
SE|25462157||ab|10|entity|C1514468|product|qnco|||product|||0|861|1634|1641
SE|25462157||ab|10|entity|C0314672|Polymerization|phpr|||polymerisation|||0|888|1649|1663
SE|25462157||ab|10|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|1664|1671
SE|25462157||ab|10|entity|C0175996|Protoplasm|celc|||intracellular|||0|851|1682|1695
SE|25462157||ab|10|entity|C0185026|Plication|topp|||folding|||0|851|1696|1703
SE|25462157||ab|10|entity|C0014406|Environment|spco|||environment|||0|851|1704|1715
SE|25462157||ab|10|entity|C0332325|Resistant|ftcn|||resistant|||0|1000|1719|1728
SE|25462157||ab|10|entity|C1522492|Formation|ftcn|||formation|||0|1000|1732|1741
SE|25462157||ab|10|entity|C0205275|Latent|qlco|||latent|||0|694|1749|1755
SE|25462157||ab|10|entity|C0205275|Latent|qlco|||latent|||0|802|1807|1813
SE|25462157||ab|10|entity|||gngm|146|ADRA1D|alpha1|||0|802|1814|1820
SE|25462157||ab|10|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|802|1821|1832

SE|25462157||ab|11|text|1855|2057|A suite of monoclonal antibodies and methodologies developed in this study can characterise alpha1-antitrypsin folding and conformational transitions, and screen methods to improve augmentation therapy.
SE|25462157||ab|11|entity|C0003250|Monoclonal Antibodies|aapp,imft|||monoclonal antibodies|||0|1000|1866|1887
SE|25462157||ab|11|entity|C0025664|Methodology|inpr|||methodologies|||0|966|1892|1905
SE|25462157||ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|1924|1929
SE|25462157||ab|11|entity|||gngm|146|ADRA1D|alpha1|||0|790|1947|1953
SE|25462157||ab|11|entity|C0072348|Protein C Inhibitor|aapp,bacs|||antitrypsin|||0|790|1954|1965
SE|25462157||ab|11|entity|C0185026|Plication|topp|||folding|||0|790|1966|1973
SE|25462157||ab|11|entity|C0430054|Toxicology screen, general|lbpr|||screen|||0|888|2010|2016
SE|25462157||ab|11|entity|C0025663|Methods|inpr|||methods|||0|888|2017|2024


SE|25462159||ti|1|text|21|90|Oncogenic Human Papillomavirus 16E7 modulates SUMOylation of FoxM1b.
SE|25462159||ti|1|entity|C0007090|Carcinogens|hops|||Oncogenic|||0|622|21|30
SE|25462159||ti|1|entity|C0021344|Human Papillomavirus|virs|||Human Papillomavirus|||0|622|31|51
SE|25462159||ti|1|entity|C0179400|box|mnob|||FoxM1b|||0|660|82|88

SE|25462159||ab|1|text|96|235|The oncogenic transcription factor Forkhead box M1b (FoxM1b), a key regulator of cell cycle, is often overexpressed in many human cancers.
SE|25462159||ab|1|entity|C0007090|Carcinogens|hops|||oncogenic|||0|571|100|109
SE|25462159||ab|1|entity|C0040648|TRANSCRIPTION FACTOR|aapp,bacs|||transcription factor|||0|571|110|130
SE|25462159||ab|1|entity|C0179400|box|mnob|||box|||0|571|140|143
SE|25462159||ab|1|entity|C1554080|Key|idcn|||key|||0|872|160|163
SE|25462159||ab|1|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|1000|177|187
SE|25462159||ab|1|entity|C0332183|Frequent|tmco|||often|||0|1000|192|197
SE|25462159||ab|1|entity|C0020114|Human|humn|||human|||0|888|220|225
SE|25462159||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancers|||0|888|226|233
SE|25462159||ab|1|relation|0|0|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|888|226|233|MOD/HEAD|PROCESS_OF||220|233|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|220|225
SE|25462159||ab|1|relation|3|1|C0007586|Cell Cycle|celf|celf|||cell cycle|||0|1000|177|187|PREP|PROCESS_OF||212|214|1|1|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|888|226|233

SE|25462159||ab|2|text|235|364|Interestingly, posttranslational modifications are known to play important role in regulating the levels and activity of FoxM1b.
SE|25462159||ab|2|entity|C0033666|Protein Processing, Post-Translational|moft|||posttranslational modifications|||0|1000|250|281
SE|25462159||ab|2|entity|C0035820|Role|socb|||role|||0|861|310|314
SE|25462159||ab|2|entity|C0441889|Levels|inpr|||levels|||0|1000|333|339
SE|25462159||ab|2|entity|C0179400|box|mnob|||FoxM1b|||0|660|356|362

SE|25462159||ab|3|text|364|514|The purpose of the present study was to characterize the SUMOylation of FoxM1b and identify the functional consequences including viral pathogenesis.
SE|25462159||ab|3|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|368|375
SE|25462159||ab|3|entity|C0150312|Present|qnco|||present|||0|888|383|390
SE|25462159||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|391|396
SE|25462159||ab|3|entity|C0179400|box|mnob|||FoxM1b|||0|660|436|442
SE|25462159||ab|3|entity|C0205245|Functional|ftcn|||functional|||0|694|460|470
SE|25462159||ab|3|entity|C1520005|Viral Pathogenesis|patf|||viral pathogenesis|||0|1000|494|512

SE|25462159||ab|4|text|514|633|Here, we report that FoxM1b interacts with SUMOylating enzymes Ubc9 and PIAS1 and acts as a substrate for SUMOylation.
SE|25462159||ab|4|entity|C0179400|box|mnob|||FoxM1b|||0|660|535|541
SE|25462159||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|660|569|576
SE|25462159||ab|4|entity|||gngm|7329|UBE2I|Ubc9|||0|660|577|581
SE|25462159||ab|4|entity|||gngm|8554|PIAS1|PIAS1|||0|1000|586|591

SE|25462159||ab|5|text|633|739|We also show that SUMOylation facilitates FoxM1b protein destabilization and nucleocytoplasmic shuttling.
SE|25462159||ab|5|entity|C0118111|Forkhead Transcription Factors|aapp,bacs|||FoxM1b protein|||0|711|675|689
SE|25462159||ab|5|entity|C0872070|nucleocytoplasmic transport|celf|||nucleocytoplasmic shuttling|||0|1000|710|737

SE|25462159||ab|6|text|739|889|More importantly, we provide the first evidence for a role of E7 oncoprotein in high risk human papillomavirus (HPV) mediated upregulation of FoxM1b.
SE|25462159||ab|6|entity|C0205172|More|ftcn|||More|||0|861|739|743
SE|25462159||ab|6|entity|C1279901|Firstly|qlco|||first|||0|694|772|777
SE|25462159||ab|6|entity|C0035820|Role|socb|||role|||0|1000|793|797
SE|25462159||ab|6|entity|C0029005|Oncogene Proteins|aapp,bacs|||oncoprotein|||0|861|804|815
SE|25462159||ab|6|entity|C0205250|High|qlco|||high|||0|861|819|823
SE|25462159||ab|6|entity|C0035647|Risk|qlco|||risk|||0|861|824|828
SE|25462159||ab|6|entity|C0021344|Human Papillomavirus|virs|||human papillomavirus|||0|861|829|849
SE|25462159||ab|6|entity|C0041904|Up-Regulation (Physiology)|celf,moft|||upregulation|||0|1000|865|877
SE|25462159||ab|6|entity|C0179400|box|mnob|||FoxM1b|||0|660|881|887
SE|25462159||ab|6|relation|4|2|C0029005|Oncogene Proteins|aapp,gngm,bacs|aapp|||oncoprotein|||0|861|804|815|VERB|AFFECTS||856|864|2|1|C0041904|Up-Regulation (Physiology)|celf,moft|celf|||upregulation|||0|1000|865|877

SE|25462159||ab|7|text|889|1045|The elevated expression of FoxM1 was determined to be posttranscriptional and was attributed to decreased SUMOylation of FoxM1b in the E7-expressing cells.
SE|25462159||ab|7|entity|C0205250|High|qlco|||elevated|||0|888|893|901
SE|25462159||ab|7|entity|||gngm|2305|FOXM1|FoxM1|||0|1000|916|921
SE|25462159||ab|7|entity|C0205216|Decreased|qnco|||decreased|||0|694|985|994
SE|25462159||ab|7|entity|C0179400|box|mnob|||FoxM1b|||0|660|1010|1016
SE|25462159||ab|7|entity|C0007634|Cells|cell|||cells|||0|827|1038|1043
SE|25462159||ab|7|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|827|1038|1043|PREP|LOCATION_OF||1017|1019|5|4|||gngm,aapp|aapp|2305|FOXM1|FoxM1|||0|1000|916|921

SE|25462159||ab|8|text|1045|1258|Moreover, we demonstrate the involvement of SUMOylation in regulation of FoxM1 and present biochemical evidence that HPV16 E7 oncoprotein can modulate SUMOylation of FoxM1b by impairing its interaction with Ubc9.
SE|25462159||ab|8|entity|C0851285|Regulation|gora|||regulation|||0|1000|1104|1114
SE|25462159||ab|8|entity|||gngm|2305|FOXM1|FoxM1|||0|1000|1118|1123
SE|25462159||ab|8|entity|C0150312|Present|qnco|||present|||0|623|1128|1135
SE|25462159||ab|8|entity|C0205474|Biochemical|ftcn|||biochemical|||0|623|1136|1147
SE|25462159||ab|8|entity|C0069508|Human Papillomavirus Type 16, E7 Protein|aapp,imft,phsu|||HPV16 E7|||0|901|1162|1170
SE|25462159||ab|8|entity|C0029005|Oncogene Proteins|aapp,bacs|||oncoprotein|||0|901|1171|1182
SE|25462159||ab|8|entity|C0179400|box|mnob|||FoxM1b|||0|660|1211|1217
SE|25462159||ab|8|entity|C0221099|Impaired|ftcn|||impairing|||0|966|1221|1230
SE|25462159||ab|8|entity|||gngm|7329|UBE2I|Ubc9|||0|1000|1252|1256
SE|25462159||ab|8|relation|0|0|C0029005|Oncogene Proteins|aapp,gngm,bacs|bacs|||oncoprotein|||0|901|1171|1182|MOD/HEAD|PART_OF||1162|1182|0|0|C0069508|Human Papillomavirus Type 16, E7 Protein|aapp,gngm,imft,phsu|aapp|||HPV16 E7|||0|901|1162|1170
SE|25462159||ab|8|relation|0|0|C0069508|Human Papillomavirus Type 16, E7 Protein|aapp,gngm,imft,phsu|aapp|||HPV16 E7|||0|901|1162|1170|MOD/HEAD|ISA||1162|1182|0|0|C0029005|Oncogene Proteins|aapp,gngm,bacs|aapp|||oncoprotein|||0|901|1171|1182

SE|25462159||ab|9|text|1258|1363|Together, these results provide a novel connection between SUMOylation of FoxM1b and HPV carcinogenesis.
SE|25462159||ab|9|entity|C1274040|result|ftcn|||results|||0|966|1274|1281
SE|25462159||ab|9|entity|C0679622|novel|inpr|||novel|||0|888|1292|1297
SE|25462159||ab|9|entity|C0449379|Connection|inpr|||connection|||0|888|1298|1308
SE|25462159||ab|9|entity|C0179400|box|mnob|||FoxM1b|||0|660|1332|1338
SE|25462159||ab|9|entity|C0021344|Human Papillomavirus|virs|||HPV|||0|901|1343|1346
SE|25462159||ab|9|entity|C0596263|Carcinogenesis|neop|||carcinogenesis|||0|901|1347|1361
SE|25462159||ab|9|relation|0|0|C0596263|Carcinogenesis|neop|neop|||carcinogenesis|||0|901|1347|1361|MOD/HEAD|PART_OF||1343|1361|0|0|C0021344|Human Papillomavirus|virs|virs|||HPV|||0|901|1343|1346

SE|25462159||ab|10|text|1363|1460|The findings may have important implications in the discovery of future anti-cancer therapeutics.
SE|25462159||ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1367|1375
SE|25462159||ab|10|entity|C0016884|Future|tmco|||future|||0|775|1428|1434
SE|25462159||ab|10|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|775|1440|1446


SE|25462160||ti|1|text|21|105|Crosstalk of mesenchymal stem cells and macrophages promotes cardiac muscle repair.
SE|25462160||ti|1|entity|C1504598|Crosstalk|inpo|||Crosstalk|||0|1000|21|30
SE|25462160||ti|1|entity|C1257975|Mesenchymal Stem Cells|cell|||mesenchymal stem cells|||0|1000|34|56
SE|25462160||ti|1|entity|C0024432|macrophage|cell|||macrophages|||0|1000|61|72
SE|25462160||ti|1|entity|C0027061|Myocardium|tisu|||cardiac muscle|||0|901|82|96
SE|25462160||ti|1|entity|C0043240|Wound Healing|orgf|||repair|||0|901|97|103
SE|25462160||ti|1|relation|0|0|C0027061|Myocardium|tisu|tisu|||cardiac muscle|||0|901|82|96|MOD/HEAD|LOCATION_OF||82|103|0|0|C0043240|Wound Healing|orgf|orgf|||repair|||0|901|97|103

SE|25462160||ab|1|text|111|240|Transplantation of bone-marrow derived mesenchymal stem cells (MSCs) has potential therapeutic effects on cardiac muscle repair.
SE|25462160||ab|1|entity|C0040732|Transplantation|topp|||Transplantation|||0|1000|111|126
SE|25462160||ab|1|entity|C0005953|Bone Marrow|bpoc|||bone-marrow|||0|1000|130|141
SE|25462160||ab|1|entity|C1257975|Mesenchymal Stem Cells|cell|||mesenchymal stem cells|||0|1000|150|172
SE|25462160||ab|1|entity|C0237399|Potential|qlco|||potential|||0|890|184|193
SE|25462160||ab|1|entity|C1527144|Therapeutic Effect|hlca|||therapeutic effects|||0|890|194|213
SE|25462160||ab|1|entity|C0027061|Myocardium|tisu|||cardiac muscle|||0|901|217|231
SE|25462160||ab|1|entity|C0043240|Wound Healing|orgf|||repair|||0|901|232|238
SE|25462160||ab|1|relation|0|0|C0027061|Myocardium|tisu|tisu|||cardiac muscle|||0|901|217|231|MOD/HEAD|LOCATION_OF||217|238|0|0|C0043240|Wound Healing|orgf|orgf|||repair|||0|901|232|238

SE|25462160||ab|2|text|240|308|However, the underlying mechanism remains not completely clarified.
SE|25462160||ab|2|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|264|273
SE|25462160||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|282|285

SE|25462160||ab|3|text|308|444|Here we show that transplantation of MSCs significantly increased local recruitment of macrophages to facilitate cardiac muscle repair.
SE|25462160||ab|3|entity|C0040732|Transplantation|topp|||transplantation|||0|1000|326|341
SE|25462160||ab|3|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|345|349
SE|25462160||ab|3|entity|C0205276|Local|spco|||local|||0|888|374|379
SE|25462160||ab|3|entity|C0024432|macrophage|cell|||macrophages|||0|1000|395|406
SE|25462160||ab|3|entity|C0027061|Myocardium|tisu|||cardiac muscle|||0|901|421|435
SE|25462160||ab|3|entity|C0043240|Wound Healing|orgf|||repair|||0|901|436|442
SE|25462160||ab|3|relation|0|0|C0027061|Myocardium|tisu|tisu|||cardiac muscle|||0|901|421|435|MOD/HEAD|LOCATION_OF||421|442|0|0|C0043240|Wound Healing|orgf|orgf|||repair|||0|901|436|442
SE|25462160||ab|3|relation|2|1|C1257975|Mesenchymal Stem Cells|cell|cell|||MSCs|||0|1000|345|349|NOM|INTERACTS_WITH||380|391|2|1|C0024432|macrophage|cell|cell|||macrophages|||0|1000|395|406
SE|25462160||ab|3|relation|4|4|C0040732|Transplantation|topp|topp|||transplantation|||0|1000|326|341|VERB|STIMULATES||410|420|1|1|C0043240|Wound Healing|orgf|orgf|||repair|||0|901|436|442

SE|25462160||ab|4|text|444|641|MSCs-induced recovery of cardiac function and attenuation of fibrosis after injury were all abolished by either impaired macrophage infiltration, or by MSCs depletion after macrophage recruitment.
SE|25462160||ab|4|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|875|444|448
SE|25462160||ab|4|entity|C0205263|Induced|ftcn|||induced|||0|875|449|456
SE|25462160||ab|4|entity|C0237820|Recovery|orgf|||recovery|||0|875|457|465
SE|25462160||ab|4|entity|C0232164|Cardiac function|ortf|||cardiac function|||0|1000|469|485
SE|25462160||ab|4|entity|C0599946|attenuation|genf|||attenuation|||0|1000|490|501
SE|25462160||ab|4|entity|C0016059|Fibrosis|patf|||fibrosis|||0|1000|505|513
SE|25462160||ab|4|entity|C0175677|Injury|inpo|||injury|||0|1000|520|526
SE|25462160||ab|4|entity|C0221099|Impaired|ftcn|||impaired|||0|775|556|564
SE|25462160||ab|4|entity|C0024432|macrophage|cell|||macrophage|||0|775|565|575
SE|25462160||ab|4|entity|C0332448|Infiltration|patf|||infiltration|||0|775|576|588
SE|25462160||ab|4|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|916|596|600
SE|25462160||ab|4|entity|C0333668|Depletion|ftcn|||depletion|||0|916|601|610
SE|25462160||ab|4|entity|C0024432|macrophage|cell|||macrophage|||0|888|617|627

SE|25462160||ab|5|text|641|940|However, angiogenesis seemed to be only affected by depletion of macrophages, but not by depletion of MSCs, suggesting that macrophages are responsible for the augmented angiogenesis after MSCs transplantation, while MSCs do not directly contribute to angiogenesis in the functional cardiac repair.
SE|25462160||ab|5|entity|C0302600|Angiogenesis|ortf|||angiogenesis|||0|1000|650|662
SE|25462160||ab|5|entity|C0333668|Depletion|ftcn|||depletion|||0|1000|693|702
SE|25462160||ab|5|entity|C0024432|macrophage|cell|||macrophages|||0|1000|706|717
SE|25462160||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|723|726
SE|25462160||ab|5|entity|C0333668|Depletion|ftcn|||depletion|||0|1000|730|739
SE|25462160||ab|5|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|743|747
SE|25462160||ab|5|entity|C0024432|macrophage|cell|||macrophages|||0|1000|765|776
SE|25462160||ab|5|entity|C0205217|Increased|qnco|||augmented|||0|888|801|810
SE|25462160||ab|5|entity|C0302600|Angiogenesis|ortf|||angiogenesis|||0|888|811|823
SE|25462160||ab|5|entity|C1257990|Mesenchymal Stem Cell Transplantation|topp|||MSCs transplantation|||0|991|830|850
SE|25462160||ab|5|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|858|862
SE|25462160||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|866|869
SE|25462160||ab|5|entity|C0302600|Angiogenesis|ortf|||angiogenesis|||0|1000|893|905
SE|25462160||ab|5|entity|C0205245|Functional|ftcn|||functional|||0|851|913|923
SE|25462160||ab|5|entity|C0018787|Heart|bpoc|||cardiac|||0|851|924|931
SE|25462160||ab|5|entity|C0043240|Wound Healing|orgf|||repair|||0|851|932|938
SE|25462160||ab|5|relation|10|2|C1257990|Mesenchymal Stem Cell Transplantation|topp|topp|||MSCs transplantation|||0|991|830|850|VERB|AFFECTS|negation|879|889|2|1|C0302600|Angiogenesis|ortf|ortf|||angiogenesis|||0|1000|893|905
SE|25462160||ab|5|relation|11|1|C0302600|Angiogenesis|ortf|ortf|||angiogenesis|||0|1000|893|905|PREP|COEXISTS_WITH||906|908|1|1|C0043240|Wound Healing|orgf|orgf|||repair|||0|851|932|938

SE|25462160||ab|6|text|940|1275|Moreover, high level of transforming growth factor beta 1 (TGFbeta1) was detected in macrophages and high level of BMP7 was detected in MSCs, suggesting that MSCs not only may recruit macrophages to enhance angiogenesis to promote regeneration, but also may secrete BMP7 to contradict the fibrogenic effect of TGFbeta1 by macrophages.
SE|25462160||ab|6|entity|C0205250|High|qlco|||high|||0|861|950|954
SE|25462160||ab|6|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|transforming growth factor beta 1|||0|1000|964|997
SE|25462160||ab|6|entity|C0024432|macrophage|cell|||macrophages|||0|1000|1025|1036
SE|25462160||ab|6|entity|C0205250|High|qlco|||high|||0|861|1041|1045
SE|25462160||ab|6|entity|C0083867|bone morphogenetic protein 7|aapp,bacs|655|BMP7|BMP7|||0|1000|1055|1059
SE|25462160||ab|6|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|1076|1080
SE|25462160||ab|6|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|1098|1102
SE|25462160||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1103|1106
SE|25462160||ab|6|entity|C0024432|macrophage|cell|||macrophages|||0|1000|1124|1135
SE|25462160||ab|6|entity|C0302600|Angiogenesis|ortf|||angiogenesis|||0|1000|1147|1159
SE|25462160||ab|6|entity|C0083867|bone morphogenetic protein 7|aapp,bacs|655|BMP7|BMP7|||0|1000|1206|1210
SE|25462160||ab|6|entity|C1280500|Effect|qlco|||effect|||0|861|1240|1246
SE|25462160||ab|6|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|TGFbeta1|||0|1000|1250|1258
SE|25462160||ab|6|entity|C0024432|macrophage|cell|||macrophages|||0|1000|1262|1273
SE|25462160||ab|6|relation|1|1|C0024432|macrophage|cell|cell|||macrophages|||0|1000|1262|1273|NOM|INTERACTS_WITH||1240|1246|1|1|C0080222|TGFB1 protein, human|aapp,gngm,bacs|gngm|7040|TGFB1|TGFbeta1|||0|1000|1250|1258
SE|25462160||ab|6|relation|6|1|C1257975|Mesenchymal Stem Cells|cell|cell|||MSCs|||0|1000|1098|1102|VERB|INTERACTS_WITH|negation|1116|1123|6|1|C0024432|macrophage|cell|cell|||macrophages|||0|1000|1124|1135
SE|25462160||ab|6|relation|8|1|C1257975|Mesenchymal Stem Cells|cell|cell|||MSCs|||0|1000|1076|1080|PREP|LOCATION_OF||1073|1075|4|1|C0083867|bone morphogenetic protein 7|aapp,gngm,bacs|aapp|655|BMP7|BMP7|||0|1000|1055|1059
SE|25462160||ab|6|relation|9|2|C0302600|Angiogenesis|ortf|ortf|||angiogenesis|||0|1000|1147|1159|VERB|PRODUCES||1198|1205|3|1|C0083867|bone morphogenetic protein 7|aapp,gngm,bacs|bacs|655|BMP7|BMP7|||0|1000|1206|1210
SE|25462160||ab|6|relation|11|1|C0024432|macrophage|cell|cell|||macrophages|||0|1000|1025|1036|PREP|LOCATION_OF||1022|1024|1|0|C0080222|TGFB1 protein, human|aapp,gngm,bacs|aapp|7040|TGFB1|transforming growth factor beta 1|||0|1000|964|997

SE|25462160||ab|7|text|1275|1416|Our study thus sheds new insight on the interaction of MSCs and macrophages in a functional cardiac repair triggered by MSCs transplantation.
SE|25462160||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1279|1284
SE|25462160||ab|7|entity|C0205314|New|tmco|||new|||0|888|1296|1299
SE|25462160||ab|7|entity|C0233820|Insight|menp|||insight|||0|888|1300|1307
SE|25462160||ab|7|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|1330|1334
SE|25462160||ab|7|entity|C0024432|macrophage|cell|||macrophages|||0|1000|1339|1350
SE|25462160||ab|7|entity|C0205245|Functional|ftcn|||functional|||0|851|1356|1366
SE|25462160||ab|7|entity|C0018787|Heart|bpoc|||cardiac|||0|851|1367|1374
SE|25462160||ab|7|entity|C0043240|Wound Healing|orgf|||repair|||0|851|1375|1381
SE|25462160||ab|7|entity|C1257990|Mesenchymal Stem Cell Transplantation|topp|||MSCs transplantation|||0|991|1395|1415


SE|25462161||ti|1|text|21|71|The role of lipotoxicity in smoke cardiomyopathy.
SE|25462161||ti|1|entity|C0035820|Role|socb|||role|||0|1000|25|29
SE|25462161||ti|1|entity|C0037366|Smoke|eehu,hops|||smoke|||0|888|49|54
SE|25462161||ti|1|entity|C0878544|Cardiomyopathies|dsyn|||cardiomyopathy|||0|888|55|69

SE|25462161|BACKGROUND/AIMS|ab|1|text|77|240|BACKGROUND/AIMS: Experimental and clinical studies have shown the direct toxic effects of cigarette smoke (CS) on the myocardium, independent of vascular effects.
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C1517004|Experimental|ftcn|||Experimental|||0|1000|94|106
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C0008972|Clinical Research|resa|||clinical studies|||0|1000|111|127
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C0600688|Toxic effect|inpo|||toxic effects|||0|884|150|163
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C0239059|Cigarette smoke|hops|||cigarette smoke|||0|1000|167|182
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C0027061|Myocardium|tisu|||myocardium|||0|1000|195|205
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|872|222|230
SE|25462161|BACKGROUND/AIMS|ab|1|entity|C1280500|Effect|qlco|||effects|||0|872|231|238
SE|25462161|BACKGROUND/AIMS|ab|1|relation|2|1|C0027061|Myocardium|tisu|tisu|||myocardium|||0|1000|195|205|PREP|LOCATION_OF||188|190|5|1|C0239059|Cigarette smoke|hops|hops|||cigarette smoke|||0|1000|167|182
SE|25462161|BACKGROUND/AIMS|ab|1|relation|6|2|C0239059|Cigarette smoke|hops|hops|||cigarette smoke|||0|1000|167|182|NOM|AFFECTS||231|238|6|0|C0005847|Blood Vessels|bpoc|bpoc|||vascular|||0|872|222|230

SE|25462161|BACKGROUND/AIMS|ab|2|text|240|295|However, the underlying mechanisms are not well known.
SE|25462161|BACKGROUND/AIMS|ab|2|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|861|264|274
SE|25462161|BACKGROUND/AIMS|ab|2|entity|C1518422|Not|ftcn|||not|||0|851|279|282
SE|25462161|BACKGROUND/AIMS|ab|2|entity|C0205170|Good|qlco|||well|||0|851|283|287
SE|25462161|BACKGROUND/AIMS|ab|2|entity|C0205309|Known|qlco|||known|||0|851|288|293

SE|25462161|METHODS|ab|3|text|295|379|METHODS: Wistar rats were allocated to control (C) and cigarette smoke (CS) groups.
SE|25462161|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|295|302
SE|25462161|METHODS|ab|3|entity|C0034716|Rats, Wistar|mamm|||Wistar rats|||0|1000|304|315
SE|25462161|METHODS|ab|3|entity|C0239059|Cigarette smoke|hops|||cigarette smoke|||0|1000|350|365
SE|25462161|METHODS|ab|3|entity|C0239059|Cigarette smoke|hops|||CS|||0|1000|367|369
SE|25462161|METHODS|ab|3|entity|C0441833|Groups|inpr|||groups|||0|1000|371|377

SE|25462161|METHODS|ab|4|text|379|433|CS rats were exposed to cigarette smoke for 2 months.
SE|25462161|METHODS|ab|4|entity|C0239059|Cigarette smoke|hops|||CS|||0|901|379|381
SE|25462161|METHODS|ab|4|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|901|382|386
SE|25462161|METHODS|ab|4|entity|C0239059|Cigarette smoke|hops|||cigarette smoke|||0|1000|403|418
SE|25462161|METHODS|ab|4|entity|C1442456|2 Months|tmco|||2 months|||0|1000|423|431

SE|25462161|RESULTS|ab|5|text|433|520|RESULTS: After that morphometric, functional and biochemical parameters were measured.
SE|25462161|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|433|440
SE|25462161|RESULTS|ab|5|entity|C0200760|Morphometric analysis|lbpr|||morphometric|||0|853|453|465
SE|25462161|RESULTS|ab|5|entity|C0205245|Functional|ftcn|||functional|||0|853|467|477
SE|25462161|RESULTS|ab|5|entity|C0205474|Biochemical|ftcn|||biochemical|||0|888|482|493

SE|25462161|RESULTS|ab|6|text|520|666|The echocardiographic study showed enlargement of the left atria, increase in the left ventricular systolic volume and reduced systolic function.
SE|25462161|RESULTS|ab|6|entity|C0013516|Echocardiography|diap|||echocardiographic|||0|853|524|541
SE|25462161|RESULTS|ab|6|entity|C0008972|Clinical Research|resa|||study|||0|853|542|547
SE|25462161|RESULTS|ab|6|entity|C0020564|Hypertrophy|patf|||enlargement|||0|1000|555|566
SE|25462161|RESULTS|ab|6|entity|C0225860|Left atrial structure|bpoc|||left atria|||0|983|574|584
SE|25462161|RESULTS|ab|6|entity|C0442805|Increase|ftcn|||increase|||0|1000|586|594
SE|25462161|RESULTS|ab|6|entity|C0225897|Left ventricular structure|bpoc|||left ventricular|||0|843|602|618
SE|25462161|RESULTS|ab|6|entity|C0039155|Systole|tmco|||systolic|||0|843|619|627
SE|25462161|RESULTS|ab|6|entity|C0449468|Volume|qnco|||volume|||0|843|628|634
SE|25462161|RESULTS|ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|851|639|646
SE|25462161|RESULTS|ab|6|entity|C0039155|Systole|tmco|||systolic|||0|851|647|655
SE|25462161|RESULTS|ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|851|656|664
SE|25462161|RESULTS|ab|6|relation|4|1|C0225860|Left atrial structure|bpoc|bpoc|||left atria|||0|983|574|584|PREP|LOCATION_OF||567|569|2|1|C0020564|Hypertrophy|patf|patf|||enlargement|||0|1000|555|566

SE|25462161|RESULTS|ab|7|text|666|826|Within the cardiac metabolism, exposure to CS decreased beta hydroxy acyl coenzyme A dehydrogenases and citrate synthases and increased lactate dehydrogenases.
SE|25462161|RESULTS|ab|7|entity|C0018787|Heart|bpoc|||cardiac|||0|888|677|684
SE|25462161|RESULTS|ab|7|entity|C0025519|Metabolism|orgf|||metabolism|||0|888|685|695
SE|25462161|RESULTS|ab|7|entity|C0239059|Cigarette smoke|hops|||CS|||0|789|709|711
SE|25462161|RESULTS|ab|7|entity|C0205216|Decreased|qnco|||decreased|||0|789|712|721
SE|25462161|RESULTS|ab|7|entity|C0050688|acyl-CoA dehydrogenase|aapp,enzy|||acyl coenzyme A dehydrogenases|||0|789|735|765
SE|25462161|RESULTS|ab|7|entity|C0008855|Citrate (si)-Synthase|aapp,enzy|||citrate synthases|||0|983|770|787
SE|25462161|RESULTS|ab|7|entity|C0205217|Increased|qnco|||increased|||0|901|792|801
SE|25462161|RESULTS|ab|7|entity|C0022917|Lactate Dehydrogenase|aapp,enzy|||lactate dehydrogenases|||0|901|802|824

SE|25462161|RESULTS|ab|8|text|826|1014|Peroxisome proliferator-activated receptor alpha (PPARalpha) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1alpha) were expressed similarly in both groups.
SE|25462161|RESULTS|ab|8|entity|C0166415|PPAR alpha|aapp,rcpt|||Peroxisome proliferator-activated receptor alpha|||0|1000|826|874
SE|25462161|RESULTS|ab|8|entity|C0672767|PGC-1 protein|aapp,bacs|||peroxisome proliferator-activated receptor gamma coactivator 1|||0|951|891|953
SE|25462161|RESULTS|ab|8|entity|C0439095|Alpha|inpr|||alpha|||0|951|954|959
SE|25462161|RESULTS|ab|8|entity|||gngm|5225|PGC|PGC|||0|1000|961|964
SE|25462161|RESULTS|ab|8|entity|C0441833|Groups|inpr|||groups|||0|1000|1006|1012

SE|25462161|RESULTS|ab|9|text|1014|1079|CS increased serum lipids and myocardial triacylglycerols (TGs).
SE|25462161|RESULTS|ab|9|entity|C0239059|Cigarette smoke|hops|||CS|||0|857|1014|1016
SE|25462161|RESULTS|ab|9|entity|C0205217|Increased|qnco|||increased|||0|857|1017|1026
SE|25462161|RESULTS|ab|9|entity|C0428462|Measurement of serum lipid level|lbpr|||serum lipids|||0|857|1027|1039
SE|25462161|RESULTS|ab|9|entity|C0027061|Myocardium|tisu|||myocardial|||0|888|1044|1054
SE|25462161|RESULTS|ab|9|entity|C0041004|Triglycerides|bacs,lipd|||triacylglycerols|||0|888|1055|1071
SE|25462161|RESULTS|ab|9|relation|0|0|C0041004|Triglycerides|bacs,lipd|bacs|||triacylglycerols|||0|888|1055|1071|MOD/HEAD|PART_OF||1044|1071|0|0|C0027061|Myocardium|tisu|tisu|||myocardial|||0|888|1044|1054

SE|25462161|RESULTS|ab|10|text|1079|1204|These data suggest that impairment in fatty acid oxidation and the accumulation of cardiac lipids characterize lipotoxicity.
SE|25462161|RESULTS|ab|10|entity|C1511726|Data|idcn|||data|||0|1000|1085|1089
SE|25462161|RESULTS|ab|10|entity|C1158366|fatty acid oxidation|moft|||fatty acid oxidation|||0|1000|1117|1137
SE|25462161|RESULTS|ab|10|entity|C0018787|Heart|bpoc|||cardiac|||0|888|1162|1169
SE|25462161|RESULTS|ab|10|entity|C0023779|Lipids|lipd|||lipids|||0|888|1170|1176
SE|25462161|RESULTS|ab|10|relation|0|0|C0023779|Lipids|lipd|lipd|||lipids|||0|888|1170|1176|MOD/HEAD|PART_OF||1162|1176|0|0|C0018787|Heart|bpoc|bpoc|||cardiac|||0|888|1162|1169

SE|25462161|RESULTS|ab|11|text|1204|1285|CS group exhibited increased oxidative stress and decreased antioxidant defense.
SE|25462161|RESULTS|ab|11|entity|C0239059|Cigarette smoke|hops|||CS|||0|901|1204|1206
SE|25462161|RESULTS|ab|11|entity|C0441833|Groups|inpr|||group|||0|901|1207|1212
SE|25462161|RESULTS|ab|11|entity|C0311404|Oxidative|ftcn|||oxidative|||0|901|1233|1242
SE|25462161|RESULTS|ab|11|entity|C0231298|Increased stress|ftcn|||increased oxidative stress|||0|901|1223|1249
SE|25462161|RESULTS|ab|11|entity|C0205216|Decreased|qnco|||decreased|||0|818|1254|1263
SE|25462161|RESULTS|ab|11|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|818|1264|1275
SE|25462161|RESULTS|ab|11|entity|C0679190|defensiveness|inbe|||defense|||0|818|1276|1283

SE|25462161|RESULTS|ab|12|text|1285|1380|Finally, the myocyte cross-sectional area and active Caspase 3 were increased in the CS group.
SE|25462161|RESULTS|ab|12|entity|C0596981|Muscle Cells|cell|||myocyte|||0|837|1298|1305
SE|25462161|RESULTS|ab|12|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|837|1306|1321
SE|25462161|RESULTS|ab|12|entity|C0205146|Area|spco|||area|||0|837|1322|1326
SE|25462161|RESULTS|ab|12|entity|C0205177|Active|ftcn|||active|||0|901|1331|1337
SE|25462161|RESULTS|ab|12|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|Caspase 3|||0|901|1338|1347
SE|25462161|RESULTS|ab|12|entity|C0239059|Cigarette smoke|hops|||CS|||0|901|1370|1372
SE|25462161|RESULTS|ab|12|entity|C0441833|Groups|inpr|||group|||0|901|1373|1378

SE|25462161|CONCLUSION|ab|13|text|1380|1558|CONCLUSION: The cardiac remodeling that was observed in the CS exposure model may be explained by abnormalities in energy metabolism, including lipotoxicity and oxidative stress.
SE|25462161|CONCLUSION|ab|13|entity|C0018787|Heart|bpoc|||cardiac|||0|694|1396|1403
SE|25462161|CONCLUSION|ab|13|entity|C0239059|Cigarette smoke|hops|||CS|||0|824|1440|1442
SE|25462161|CONCLUSION|ab|13|entity|C0026336|Study models|inpr,resd|||model|||0|824|1452|1457
SE|25462161|CONCLUSION|ab|13|entity|C0014272|Energy Metabolism|phsf|||energy metabolism|||0|1000|1495|1512
SE|25462161|CONCLUSION|ab|13|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|1000|1541|1557


SE|25462162||ti|1|text|21|195|Antibiotic exposure in a low-income country: screening urine samples for presence of antibiotics and antibiotic resistance in coagulase negative staphylococcal contaminants.
SE|25462162||ti|1|entity|C0003232|Antibiotics|antb|||Antibiotic|||0|694|21|31
SE|25462162||ti|1|entity|C1331016|Low income|qlco|||low-income|||0|901|46|56
SE|25462162||ti|1|entity|C0454664|Country|geoa|||country|||0|901|57|64
SE|25462162||ti|1|entity|C0444180|Urine specimen|bdsu|||urine samples|||0|983|76|89
SE|25462162||ti|1|entity|C0003232|Antibiotics|antb|||antibiotics|||0|1000|106|117
SE|25462162||ti|1|entity|C0085818|Antibiotic Resistance|orga|||antibiotic resistance|||0|1000|122|143
SE|25462162||ti|1|entity|C0445625|Staphylococcus, coagulase negative|bact|||coagulase negative staphylococcal|||0|733|147|180

SE|25462162||ab|1|text|201|305|Development of antimicrobial resistance has been assigned to excess and misuse of antimicrobial agents.
SE|25462162||ab|1|entity|C1527148|Development|ftcn|||Development|||0|1000|201|212
SE|25462162||ab|1|entity|C1456627|Antimicrobial Resistance|clna|||antimicrobial resistance|||0|1000|216|240
SE|25462162||ab|1|entity|C0442802|Excessive|qlco|||excess|||0|928|262|268
SE|25462162||ab|1|entity|C0549649|MISUSE|fndg|||misuse|||0|1000|273|279
SE|25462162||ab|1|entity|C1136254|Microbicides|phsu|||antimicrobial agents|||0|1000|283|303

SE|25462162||ab|2|text|305|447|Staphylococci are part of the normal flora but are also potential pathogens that have become essentially resistant to many known antibiotics.
SE|25462162||ab|2|entity|C0449719|Part|spco|||part|||0|1000|323|327
SE|25462162||ab|2|entity|C0314761|Normal flora|bact|||normal flora|||0|1000|335|347
SE|25462162||ab|2|entity|C0237399|Potential|qlco|||potential|||0|737|361|370
SE|25462162||ab|2|entity|C0332325|Resistant|ftcn|||resistant|||0|861|410|419
SE|25462162||ab|2|entity|C0205309|Known|qlco|||known|||0|888|428|433
SE|25462162||ab|2|entity|C0003232|Antibiotics|antb|||antibiotics|||0|888|434|445

SE|25462162||ab|3|text|447|593|Resistances in coagulase negative staphylococci (CoNS) are suggested to evolve due to positive selective pressure following antibiotic treatment.
SE|25462162||ab|3|entity|C0445625|Staphylococcus, coagulase negative|bact|||coagulase negative staphylococci|||0|988|462|494
SE|25462162||ab|3|entity|C1446409|Positive|qlco|||positive|||0|802|533|541
SE|25462162||ab|3|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|802|552|560
SE|25462162||ab|3|entity|C0003232|Antibiotics|antb|||antibiotic|||0|888|571|581

SE|25462162||ab|4|text|593|772|This study investigated the presence of the nine most commonly used antimicrobial agents in human urine from outpatients in two hospitals in Ghana in relation to CoNS resistance.
SE|25462162||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|598|603
SE|25462162||ab|4|entity|C0205455|Nine|qnco|||nine|||0|861|637|641
SE|25462162||ab|4|entity|C1136254|Microbicides|phsu|||antimicrobial agents|||0|1000|661|681
SE|25462162||ab|4|entity|C0020114|Human|humn|||human|||0|888|685|690
SE|25462162||ab|4|entity|C0042036|Urine|bdsu|||urine|||0|888|691|696
SE|25462162||ab|4|entity|C0029921|Outpatients|podg|||outpatients|||0|1000|702|713
SE|25462162||ab|4|entity|C0205448|Two|qnco|||two|||0|888|717|720
SE|25462162||ab|4|entity|C0019994|Hospitals|hcro,mnob|||hospitals|||0|888|721|730
SE|25462162||ab|4|entity|C0017516|Ghana|geoa|||Ghana|||0|1000|734|739
SE|25462162||ab|4|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|745|755|759
SE|25462162||ab|4|relation|0|0|C0042036|Urine|bdsu|bdsu|||urine|||0|888|691|696|MOD/HEAD|PART_OF||685|696|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|685|690
SE|25462162||ab|4|relation|3|1|C0019994|Hospitals|hcro,mnob|hcro|||hospitals|||0|888|721|730|PREP|LOCATION_OF||714|716|5|5|C0008972|Clinical Research|resa|resa|||study|||0|1000|598|603
SE|25462162||ab|4|relation|4|1|C0029921|Outpatients|podg,humn|humn|||outpatients|||0|1000|702|713|PREP|LOCATION_OF||697|701|4|1|C0042036|Urine|bdsu|bdsu|||urine|||0|888|691|696

SE|25462162||ab|5|text|772|875|Urine and CoNS were sampled (n = 246 and n = 96 respectively) from patients in two hospitals in Ghana.
SE|25462162||ab|5|entity|C0042036|Urine|bdsu|||Urine|||0|1000|772|777
SE|25462162||ab|5|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|988|782|786
SE|25462162||ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|839|847
SE|25462162||ab|5|entity|C0205448|Two|qnco|||two|||0|888|851|854
SE|25462162||ab|5|entity|C0019994|Hospitals|hcro,mnob|||hospitals|||0|888|855|864
SE|25462162||ab|5|entity|C0017516|Ghana|geoa|||Ghana|||0|1000|868|873

SE|25462162||ab|6|text|875|1057|CoNS were identified using Gram staining, coagulase test, and MALDI-TOF/MS, and the antimicrobial susceptibility to 12 commonly used antimicrobials was determined by disk diffusion.
SE|25462162||ab|6|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|988|875|879
SE|25462162||ab|6|entity|C0200966|Bacterial stain, routine|lbpr|||Gram|||0|694|902|906
SE|25462162||ab|6|entity|C0201122|Coagulase test|lbpr|||coagulase test|||0|1000|917|931
SE|25462162||ab|6|entity|||gngm|2626,55079|GATA4,FEZF2|TOF|||0|913|943|946
SE|25462162||ab|6|entity|C0282597|Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization|lbpr|||MALDI-TOF/MS|||0|913|937|949
SE|25462162||ab|6|entity|C0427965|Antimicrobial susceptibility|fndg|||antimicrobial susceptibility|||0|1000|959|987
SE|25462162||ab|6|entity|C0042153|utilization qualifier|ftcn|||used|||0|714|1003|1007
SE|25462162||ab|6|entity|C1136254|Microbicides|phsu|||antimicrobials|||0|714|1008|1022
SE|25462162||ab|6|entity|C0441665|Disk diffusion|lbpr|||disk diffusion|||0|1000|1041|1055
SE|25462162||ab|6|relation|1|1|C0441665|Disk diffusion|lbpr|lbpr|||disk diffusion|||0|1000|1041|1055|VERB|MEASURES||1027|1037|6|1|C1136254|Microbicides|phsu|phsu|||antimicrobials|||0|714|1008|1022

SE|25462162||ab|7|text|1057|1280|Moreover an analytical method was developed for the determination of the nine most commonly used antimicrobial agents in Ghana by using solid-phase extraction in combination with HPLC-MS/MS using electron spray ionization.
SE|25462162||ab|7|entity|C0178476|analytical method|inpr|||analytical method|||0|1000|1069|1086
SE|25462162||ab|7|entity|C0680730|Adjudication|gora|||determination|||0|1000|1109|1122
SE|25462162||ab|7|entity|C0205455|Nine|qnco|||nine|||0|861|1130|1134
SE|25462162||ab|7|entity|C1136254|Microbicides|phsu|||antimicrobial agents|||0|1000|1154|1174
SE|25462162||ab|7|entity|C0017516|Ghana|geoa|||Ghana|||0|1000|1178|1183
SE|25462162||ab|7|entity|C0205208|Solid|qlco|||solid|||0|851|1193|1198
SE|25462162||ab|7|entity|C0205390|Phase|tmco|||phase|||0|851|1199|1204
SE|25462162||ab|7|entity|C0185115|Extraction|topp|||extraction|||0|851|1205|1215
SE|25462162||ab|7|entity|C0205195|Combined|qlco|||combination|||0|1000|1219|1230
SE|25462162||ab|7|entity|C0008562|High pressure liquid chromatography procedure|lbpr|||HPLC|||0|660|1236|1240
SE|25462162||ab|7|entity|C0013852|Electrons|qnco|||electron|||0|851|1253|1261
SE|25462162||ab|7|entity|C1154182|Spray|sbst|||spray|||0|851|1262|1267
SE|25462162||ab|7|entity|C0596801|ionization|phpr|||ionization|||0|851|1268|1278

SE|25462162||ab|8|text|1280|1405|The highest frequency of resistance to CoNS was observed for penicillin V (98%), trimethoprim (67%), and tetracycline (63%).
SE|25462162||ab|8|entity|C0205212|High frequency|tmco|||highest frequency|||0|983|1284|1301
SE|25462162||ab|8|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|988|1319|1323
SE|25462162||ab|8|entity|C0030840|Penicillin V|antb,orch|||penicillin V|||0|1000|1341|1353
SE|25462162||ab|8|entity|C0041041|Trimethoprim|orch,phsu|||trimethoprim|||0|1000|1361|1373
SE|25462162||ab|8|entity|C0039644|Tetracycline|antb,orch|||tetracycline|||0|1000|1385|1397

SE|25462162||ab|9|text|1405|1510|S. haemolyticus was the most common isolate (75%), followed by S. epidermidis (13%) and S. hominis (6%).
SE|25462162||ab|9|entity|C0205393|Most|qnco|||most|||0|623|1429|1433
SE|25462162||ab|9|entity|C0205214|Common|qnco|||common|||0|623|1434|1440
SE|25462162||ab|9|entity|C0038174|Staphylococcus epidermidis|bact|||S. epidermidis|||0|1000|1468|1482

SE|25462162||ab|10|text|1510|1599|S. haemolyticus was also the species displaying the highest resistance prevalence (82%).
SE|25462162||ab|10|entity|C1548151|Species|idcn|||species|||0|1000|1539|1546
SE|25462162||ab|10|entity|C1512456|High Prevalence|qnco|||highest resistance prevalence|||0|896|1562|1591

SE|25462162||ab|11|text|1599|1719|69% of the isolated CoNS were multiple drug resistant (? 4 antibiotics) and 45% of the CoNS were methicillin resistant.
SE|25462162||ab|11|entity|C0205409|Isolated|ftcn|||isolated|||0|908|1610|1618
SE|25462162||ab|11|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|908|1619|1623
SE|25462162||ab|11|entity|C0242640|Multi-Drug Resistance|orga|||multiple drug resistant|||0|964|1629|1652
SE|25462162||ab|11|entity|C0003232|Antibiotics|antb|||antibiotics|||0|861|1658|1669
SE|25462162||ab|11|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|988|1686|1690
SE|25462162||ab|11|entity|C0025643|Methicillin|antb,orch|||methicillin|||0|1000|1696|1707
SE|25462162||ab|11|entity|C0332325|Resistant|ftcn|||resistant|||0|1000|1708|1717

SE|25462162||ab|12|text|1719|1922|Antimicrobial agents were detected in 64% of the analysed urine samples (n = 121) where the most frequently detected antimicrobials were ciprofloxacin (30%), trimethoprim (27%), and metronidazole (17%).
SE|25462162||ab|12|entity|C1136254|Microbicides|phsu|||Antimicrobial agents|||0|1000|1719|1739
SE|25462162||ab|12|entity|C1515960|Analyzed|qlco|||analysed|||0|890|1768|1776
SE|25462162||ab|12|entity|C0444180|Urine specimen|bdsu|||urine samples|||0|890|1777|1790
SE|25462162||ab|12|entity|C0205393|Most|qnco|||most|||0|833|1811|1815
SE|25462162||ab|12|entity|C0332183|Frequent|tmco|||frequently|||0|833|1816|1826
SE|25462162||ab|12|entity|C1136254|Microbicides|phsu|||antimicrobials|||0|833|1836|1850
SE|25462162||ab|12|entity|C0008809|Ciprofloxacin|orch,phsu|||ciprofloxacin|||0|1000|1856|1869
SE|25462162||ab|12|entity|C0041041|Trimethoprim|orch,phsu|||trimethoprim|||0|1000|1877|1889
SE|25462162||ab|12|entity|C0025872|Metronidazole|orch,phsu|||metronidazole|||0|1000|1901|1914

SE|25462162||ab|13|text|1922|2224|The major findings of this study was that the prevalence of detected antimicrobials in urine was more frequent than the use reported by the patients and the prevalence of resistant S. haemolyticus was more frequent than other resistant CoNS species when antimicrobial agents were detected in the urine.
SE|25462162||ab|13|entity|C0205164|Major|qlco|||major|||0|888|1926|1931
SE|25462162||ab|13|entity|C0243095|Finding|ftcn|||findings|||0|888|1932|1940
SE|25462162||ab|13|entity|C0008972|Clinical Research|resa|||study|||0|1000|1949|1954
SE|25462162||ab|13|entity|C1136254|Microbicides|phsu|||antimicrobials|||0|888|1991|2005
SE|25462162||ab|13|entity|C0042036|Urine|bdsu|||urine|||0|1000|2009|2014
SE|25462162||ab|13|entity|C0205172|More|ftcn|||more|||0|888|2019|2023
SE|25462162||ab|13|entity|C0332183|Frequent|tmco|||frequent|||0|888|2024|2032
SE|25462162||ab|13|entity|C0030705|Patients|podg|||patients|||0|1000|2062|2070
SE|25462162||ab|13|entity|C0332325|Resistant|ftcn|||resistant|||0|606|2093|2102
SE|25462162||ab|13|entity|C0205172|More|ftcn|||more|||0|888|2123|2127
SE|25462162||ab|13|entity|C0332183|Frequent|tmco|||frequent|||0|888|2128|2136
SE|25462162||ab|13|entity|C0332325|Resistant|ftcn|||resistant|||0|868|2148|2157
SE|25462162||ab|13|entity|C0445625|Staphylococcus, coagulase negative|bact|||CoNS|||0|868|2158|2162
SE|25462162||ab|13|entity|C1548151|Species|idcn|||species|||0|868|2163|2170
SE|25462162||ab|13|entity|C1136254|Microbicides|phsu|||antimicrobial agents|||0|1000|2176|2196
SE|25462162||ab|13|entity|C0042036|Urine|bdsu|||urine|||0|1000|2218|2223


SE|25462165||ti|1|text|21|91|Modelling the spatial behaviour of a tropical tuna purse seine fleet.
SE|25462165||ti|1|entity|C0037774|Spatial Behavior|inbe|||spatial behaviour|||0|1000|35|52
SE|25462165||ti|1|entity|C0591516|Fleet|inpr|||fleet|||0|804|84|89

SE|25462165||ab|1|text|97|314|Industrial tuna fisheries operate in the Indian, Atlantic and Pacific Oceans, but concerns over sustainability and environmental impacts of these fisheries have resulted in increased scrutiny of how they are managed.
SE|25462165||ab|1|entity|C0021267|Industry|ocac|||Industrial|||0|766|97|107
SE|25462165||ab|1|entity|C0016162|Fisheries|orgt|||fisheries|||0|766|113|122
SE|25462165||ab|1|entity|C0422792|Indian ethnic group|popg|||Indian|||0|1000|138|144
SE|25462165||ab|1|entity|C0030171|Pacific Ocean|geoa|||Pacific Oceans|||0|983|159|173
SE|25462165||ab|1|entity|C0205136|Over|spco|||over|||0|694|188|192
SE|25462165||ab|1|entity|C0282165|Impacts, Environmental|phpr|||environmental impacts|||0|1000|212|233
SE|25462165||ab|1|entity|C0016162|Fisheries|orgt|||fisheries|||0|1000|243|252
SE|25462165||ab|1|entity|C0205217|Increased|qnco|||increased|||0|694|270|279

SE|25462165||ab|2|text|314|458|An important but often overlooked factor in the success or failure of tuna fisheries management is the behaviour of fishers and fishing fleets.
SE|25462165||ab|2|entity|C0332183|Frequent|tmco|||often|||0|802|331|336
SE|25462165||ab|2|entity|C1521761|Factor|ftcn|||factor|||0|802|348|354
SE|25462165||ab|2|entity|C0597535|Success|socb|||success|||0|1000|362|369
SE|25462165||ab|2|entity|C0016162|Fisheries|orgt|||fisheries|||0|790|389|398
SE|25462165||ab|2|entity|C0004927|Behavior|inbe|||behaviour|||0|1000|417|426
SE|25462165||ab|2|entity|C0325045|Martes pennanti|mamm|||fishers|||0|966|430|437
SE|25462165||ab|2|entity|C0016163|Fishes|fish|||fishing|||0|855|442|449
SE|25462165||ab|2|entity|C0591516|Fleet|inpr|||fleets|||0|855|450|456
SE|25462165||ab|2|relation|0|0|C0597535|Success|socb|socb|||success|||0|1000|362|369|SPEC|ISA||362|426|0|0|C0004927|Behavior|inbe|inbe|||behaviour|||0|1000|417|426

SE|25462165||ab|3|text|458|718|Uncertainty in how a fishing fleet will respond to management or other influences can be reduced by anticipating fleet behaviour, although to date there has been little research directed at understanding and anticipating the human dimension of tuna fisheries.
SE|25462165||ab|3|entity|C0087130|Uncertainty|idcn|||Uncertainty|||0|1000|458|469
SE|25462165||ab|3|entity|C0016163|Fishes|fish|||fishing|||0|872|479|486
SE|25462165||ab|3|entity|C0591516|Fleet|inpr|||fleet|||0|872|487|492
SE|25462165||ab|3|entity|C0591516|Fleet|inpr|||fleet|||0|790|571|576
SE|25462165||ab|3|entity|C0004927|Behavior|inbe|||behaviour|||0|790|577|586
SE|25462165||ab|3|entity|C0023882|Little's Disease|dsyn|||little|||0|888|620|626
SE|25462165||ab|3|entity|C0035168|research|resa|||research|||0|888|627|635
SE|25462165||ab|3|entity|C0020114|Human|humn|||human|||0|888|683|688
SE|25462165||ab|3|entity|C0439534|Dimensions|qnco|||dimension|||0|888|689|698
SE|25462165||ab|3|entity|C0016162|Fisheries|orgt|||fisheries|||0|861|707|716

SE|25462165||ab|4|text|718|880|The aim of this study was to address gaps in knowledge of the behaviour of tuna fleets, using the Indian Ocean tropical tuna purse seine fishery as a case study.
SE|25462165||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|734|739
SE|25462165||ab|4|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||gaps|||0|966|755|759
SE|25462165||ab|4|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|763|772
SE|25462165||ab|4|entity|C0004927|Behavior|inbe|||behaviour|||0|1000|780|789
SE|25462165||ab|4|entity|C0591516|Fleet|inpr|||fleets|||0|827|798|804
SE|25462165||ab|4|entity|C0376441|Indian Ocean|geoa|||Indian Ocean|||0|801|816|828
SE|25462165||ab|4|entity|C0016162|Fisheries|orgt|||fishery|||0|801|855|862
SE|25462165||ab|4|entity|C0085973|Case Study|inpr|||case study|||0|1000|868|878

SE|25462165||ab|5|text|880|1026|We use statistical modelling to examine the factors that influence the spatial behaviour of the purse seine fleet at broad spatiotemporal scales.
SE|25462165||ab|5|entity|C0026348|Models, Statistical|inpr,qnco|||statistical modelling|||0|1000|887|908
SE|25462165||ab|5|entity|C1521761|Factor|ftcn|||factors|||0|966|924|931
SE|25462165||ab|5|entity|C0037774|Spatial Behavior|inbe|||spatial behaviour|||0|1000|951|968
SE|25462165||ab|5|entity|C0591516|Fleet|inpr|||fleet|||0|827|988|993
SE|25462165||ab|5|entity|C0332464|Widening|spco|||broad|||0|802|997|1002

SE|25462165||ab|6|text|1026|1239|This analysis reveals very high consistency between years in the use of seasonal fishing grounds by the fleet, as well as a forcing influence of biophysical ocean conditions on the distribution of fishing effort.
SE|25462165||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|1000|1031|1039
SE|25462165||ab|6|entity|C0442804|Very high|fndg|||very high|||0|901|1048|1057
SE|25462165||ab|6|entity|C0332529|Consistency|qlco|||consistency|||0|901|1058|1069
SE|25462165||ab|6|entity|C0439234|year|tmco|||years|||0|1000|1078|1083
SE|25462165||ab|6|entity|C0439601|Seasonal|tmco|||seasonal|||0|606|1098|1106
SE|25462165||ab|6|entity|C0016163|Fishes|fish|||fishing|||0|606|1107|1114
SE|25462165||ab|6|entity|C0591516|Fleet|inpr|||fleet|||0|1000|1130|1135
SE|25462165||ab|6|entity|C0441722|Force|phpr|||forcing|||0|661|1150|1157
SE|25462165||ab|6|entity|C0005553|Biophysics|bmod|||biophysical|||0|836|1171|1182
SE|25462165||ab|6|entity|C0028814|Oceans|geoa|||ocean|||0|836|1183|1188
SE|25462165||ab|6|entity|C0520511|Distributing|idcn|||distribution|||0|1000|1207|1219
SE|25462165||ab|6|entity|C0016163|Fishes|fish|||fishing|||0|872|1223|1230

SE|25462165||ab|7|text|1239|1456|These findings suggest strong inertia in the spatial behaviour of the fleet, which has important implications for predicting the response of the fleet to natural events or management measures (e.g., spatial closures).
SE|25462165||ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|1245|1253
SE|25462165||ab|7|entity|C0442821|Strong|qlco|||strong|||0|694|1262|1268
SE|25462165||ab|7|entity|C0037774|Spatial Behavior|inbe|||spatial behaviour|||0|1000|1284|1301
SE|25462165||ab|7|entity|C0591516|Fleet|inpr|||fleet|||0|1000|1309|1314
SE|25462165||ab|7|entity|C1508497|PREDICTED|clna|||predicting|||0|966|1353|1363
SE|25462165||ab|7|entity|C0871261|response|clna|||response|||0|1000|1368|1376
SE|25462165||ab|7|entity|C0591516|Fleet|inpr|||fleet|||0|1000|1384|1389
SE|25462165||ab|7|entity|C0205296|Natural|ftcn|||natural|||0|888|1393|1400
SE|25462165||ab|7|entity|C0441471|Events|evnt|||events|||0|888|1401|1407
SE|25462165||ab|7|entity|C0079809|Measures|qnco|||measures|||0|888|1422|1430
SE|25462165||ab|7|entity|C0185003|Reparative closure|topp|||closures|||0|861|1446|1454


SE|25462164||ti|1|text|21|105|Vasoprotective effects of urocortin 1 against atherosclerosis in vitro and in vivo.
SE|25462164||ti|1|entity|C1280500|Effect|qlco|||effects|||0|827|36|43
SE|25462164||ti|1|entity|C0383757|urocortin|aapp,nsba|7349|UCN|urocortin|||0|861|47|56
SE|25462164||ti|1|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|1000|67|82
SE|25462164||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|83|91
SE|25462164||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|1000|96|103

SE|25462164|AIM|ab|1|text|111|330|AIM: Atherosclerosis is the complex lesion that consists of endothelial inflammation, macrophage foam cell formation, vascular smooth muscle cell (VSMC) migration and proliferation, and extracellular matrix production.
SE|25462164|AIM|ab|1|entity|C0004153|Atherosclerosis|dsyn|||Atherosclerosis|||0|1000|116|131
SE|25462164|AIM|ab|1|entity|C0439855|Complex|qlco|||complex|||0|888|139|146
SE|25462164|AIM|ab|1|entity|C0221198|Lesion|fndg|||lesion|||0|888|147|153
SE|25462164|AIM|ab|1|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|endothelial|||0|888|171|182
SE|25462164|AIM|ab|1|entity|C0021368|Inflammation|patf|||inflammation|||0|888|183|195
SE|25462164|AIM|ab|1|entity|C0024432|macrophage|cell|||macrophage|||0|861|197|207
SE|25462164|AIM|ab|1|entity|C0016390|Foam Cells|cell|||foam cell|||0|861|208|217
SE|25462164|AIM|ab|1|entity|C1522492|Formation|ftcn|||formation|||0|861|218|227
SE|25462164|AIM|ab|1|entity|C0026844|Muscle, Smooth, Vascular|tisu|||vascular smooth muscle|||0|893|229|251
SE|25462164|AIM|ab|1|entity|C0007608|cell motility|celf|||cell (VSMC) migration|||0|893|252|273
SE|25462164|AIM|ab|1|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|278|291
SE|25462164|AIM|ab|1|entity|C0015350|Extracellular Matrix|tisu|||extracellular matrix|||0|901|297|317
SE|25462164|AIM|ab|1|entity|C0033268|production|ocac|||production|||0|901|318|328
SE|25462164|AIM|ab|1|relation|7|6|C0004153|Atherosclerosis|dsyn|dsyn|||Atherosclerosis|||0|1000|116|131|NOM|PRODUCES||318|328|7|0|C0015350|Extracellular Matrix|tisu|tisu|||extracellular matrix|||0|901|297|317

SE|25462164|AIM|ab|2|text|330|492|Human urocortin 1 (Ucn1), a 40-amino acid peptide member of the corticotrophin-releasing factor/urotensin I family, has potent cardiovascular protective effects.
SE|25462164|AIM|ab|2|entity|C0020114|Human|humn|||Human|||0|790|330|335
SE|25462164|AIM|ab|2|entity|C0383757|urocortin|aapp,nsba|7349|UCN|urocortin|||0|790|336|345
SE|25462164|AIM|ab|2|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|833|361|371
SE|25462164|AIM|ab|2|entity|C0030956|Peptides|aapp|||peptide|||0|833|372|379
SE|25462164|AIM|ab|2|entity|C0680022|member|popg|||member|||0|833|380|386
SE|25462164|AIM|ab|2|entity|C0010132|Corticotropin-Releasing Hormone|aapp,horm,nsba|||corticotrophin-releasing factor|||0|864|394|425
SE|25462164|AIM|ab|2|entity|C0077931|urotensin I|aapp,bacs|||urotensin I|||0|864|426|437
SE|25462164|AIM|ab|2|entity|C0015576|Family|famg|||family|||0|864|438|444
SE|25462164|AIM|ab|2|entity|C0237399|Potential|qlco|||potent|||0|712|450|456
SE|25462164|AIM|ab|2|entity|C1280500|Effect|qlco|||effects|||0|712|483|490
SE|25462164|AIM|ab|2|relation|1|1|C0002520|Amino Acids|aapp,gngm,bacs,phsu|bacs|||amino acid|||0|833|361|371|PREP|PART_OF||387|389|2|1|C0077931|urotensin I|aapp,gngm,bacs|aapp|||urotensin I|||0|864|426|437

SE|25462164|AIM|ab|3|text|492|576|This peptide induces potent and long-lasting hypotension and coronary vasodilation.
SE|25462164|AIM|ab|3|entity|C0030956|Peptides|aapp|||peptide|||0|1000|497|504
SE|25462164|AIM|ab|3|entity|C0237399|Potential|qlco|||potent|||0|900|513|519
SE|25462164|AIM|ab|3|entity|C0205166|Long|qlco|||long|||0|802|524|528
SE|25462164|AIM|ab|3|entity|C0020649|Hypotension|fndg|||hypotension|||0|802|537|548
SE|25462164|AIM|ab|3|entity|C0596385|Coronary vasodilator|phsu|||coronary vasodilation|||0|950|553|574

SE|25462164|AIM|ab|4|text|576|648|However, the relationship of Ucn1 with atherosclerosis remains unclear.
SE|25462164|AIM|ab|4|entity|C0439849|Relationships|qlco|||relationship|||0|1000|589|601
SE|25462164|AIM|ab|4|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|605|609
SE|25462164|AIM|ab|4|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|1000|615|630

SE|25462164|AIM|ab|5|text|648|731|The present study was performed to clarify the effects of Ucn1 on atherosclerosis.
SE|25462164|AIM|ab|5|entity|C0150312|Present|qnco|||present|||0|888|652|659
SE|25462164|AIM|ab|5|entity|C0008972|Clinical Research|resa|||study|||0|888|660|665
SE|25462164|AIM|ab|5|entity|C1280500|Effect|qlco|||effects|||0|966|695|702
SE|25462164|AIM|ab|5|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|706|710
SE|25462164|AIM|ab|5|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|1000|714|729

SE|25462164|METHODS|ab|6|text|731|1062|METHODS: We assessed the effects of Ucn1 on the inflammatory response and proliferation of human endothelial cells (ECs), human macrophage foam cell formation, migration and proliferation of human VSMCs, extracellular matrix expression in VSMCs, and the development of atherosclerosis in apolipoprotein E-deficient (Apoe-/-) mice.
SE|25462164|METHODS|ab|6|entity|C0025663|Methods|inpr|||METHODS|||0|1000|731|738
SE|25462164|METHODS|ab|6|entity|C1280500|Effect|qlco|||effects|||0|966|756|763
SE|25462164|METHODS|ab|6|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|767|771
SE|25462164|METHODS|ab|6|entity|C1155266|Inflammatory Response|patf|||inflammatory response|||0|1000|779|800
SE|25462164|METHODS|ab|6|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|805|818
SE|25462164|METHODS|ab|6|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|endothelial|||0|901|828|839
SE|25462164|METHODS|ab|6|entity|C0427861|Human cells|lbtr|||human endothelial cells|||0|901|822|845
SE|25462164|METHODS|ab|6|entity|C0020114|Human|humn|||human|||0|840|853|858
SE|25462164|METHODS|ab|6|entity|C0024432|macrophage|cell|||macrophage|||0|840|859|869
SE|25462164|METHODS|ab|6|entity|C0016390|Foam Cells|cell|||foam cell|||0|840|870|879
SE|25462164|METHODS|ab|6|entity|C1522492|Formation|ftcn|||formation|||0|840|880|889
SE|25462164|METHODS|ab|6|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|905|918
SE|25462164|METHODS|ab|6|entity|C0020114|Human|humn|||human|||0|694|922|927
SE|25462164|METHODS|ab|6|entity|C0015350|Extracellular Matrix|tisu|||extracellular matrix|||0|901|935|955
SE|25462164|METHODS|ab|6|entity|C1527148|Development|ftcn|||development|||0|1000|985|996
SE|25462164|METHODS|ab|6|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|1000|1000|1015
SE|25462164|METHODS|ab|6|entity|C0003595|Apolipoprotein E|aapp,bacs|||apolipoprotein E|||0|901|1019|1035
SE|25462164|METHODS|ab|6|entity|C0011155|Deficiency|ftcn|||deficient|||0|901|1036|1045
SE|25462164|METHODS|ab|6|entity|C0003595|Apolipoprotein E|aapp,bacs|348|APOE|Apoe|||0|1000|1047|1051
SE|25462164|METHODS|ab|6|entity|C0026809|Mus|mamm|||mice|||0|1000|1056|1060
SE|25462164|METHODS|ab|6|relation|14|8|C0015350|Extracellular Matrix|tisu|tisu|||extracellular matrix|||0|901|935|955|NOM|AFFECTS||756|763|14|1|C1155266|Inflammatory Response|patf|patf|||inflammatory response|||0|1000|779|800

SE|25462164|RESULTS|ab|7|text|1062|1283|RESULTS: Ucn1 significantly suppressed cell proliferation without inducing apoptosis, and lipopolysaccharide-induced up-regulation of monocyte chemoattractant protein-1 and intercellular adhesion molecule-1 in human ECs.
SE|25462164|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1062|1069
SE|25462164|RESULTS|ab|7|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|780|1071|1075
SE|25462164|RESULTS|ab|7|entity|C1260953|Suppressed|ftcn|||suppressed|||0|780|1090|1100
SE|25462164|RESULTS|ab|7|entity|C0596290|Cell Proliferation|celf|||cell proliferation|||0|780|1101|1119
SE|25462164|RESULTS|ab|7|entity|C0205263|Induced|ftcn|||inducing|||0|872|1128|1136
SE|25462164|RESULTS|ab|7|entity|C0162638|Apoptosis|celf|||apoptosis|||0|872|1137|1146
SE|25462164|RESULTS|ab|7|entity|C0023810|Lipopolysaccharides|lipd|||lipopolysaccharide|||0|1000|1152|1170
SE|25462164|RESULTS|ab|7|entity|C0162493|Transcriptional Activation|genf|||up-regulation|||0|1000|1179|1192
SE|25462164|RESULTS|ab|7|entity|C0128897|Monocyte Chemoattractant Protein-1|aapp,imft|||monocyte chemoattractant protein-1|||0|1000|1196|1230
SE|25462164|RESULTS|ab|7|entity|C0063695|Intercellular adhesion molecule 1|aapp,imft|||intercellular adhesion molecule-1|||0|1000|1235|1268
SE|25462164|RESULTS|ab|7|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|ECs|||0|901|1278|1281
SE|25462164|RESULTS|ab|7|entity|C0427861|Human cells|lbtr|||human ECs|||0|901|1272|1281
SE|25462164|RESULTS|ab|7|relation|2|1|C0063695|Intercellular adhesion molecule 1|aapp,gngm,imft|aapp|||intercellular adhesion molecule-1|||0|1000|1235|1268|PREP|LOCATION_OF||1193|1195|5|1|C0162493|Transcriptional Activation|genf|genf|||up-regulation|||0|1000|1179|1192
SE|25462164|RESULTS|ab|7|relation|2|1|C0128897|Monocyte Chemoattractant Protein-1|aapp,gngm,imft|gngm|||monocyte chemoattractant protein-1|||0|1000|1196|1230|PREP|LOCATION_OF||1193|1195|5|1|C0162493|Transcriptional Activation|genf|genf|||up-regulation|||0|1000|1179|1192
SE|25462164|RESULTS|ab|7|relation|4|1|C0023810|Lipopolysaccharides|lipd|lipd|||lipopolysaccharide|||0|1000|1152|1170|VERB|AUGMENTS||1171|1178|2|1|C0162493|Transcriptional Activation|genf|genf|||up-regulation|||0|1000|1179|1192

SE|25462164|RESULTS|ab|8|text|1283|1496|Ucn1 significantly reduced oxidized low-density lipoprotein-induced foam cell formation with a significant down-regulation of CD36 and acyl-CoA:cholesterol acyltransferase 1 in human monocyte-derived macrophages.
SE|25462164|RESULTS|ab|8|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|1283|1287
SE|25462164|RESULTS|ab|8|entity|C0348035|oxidized low density lipoprotein|aapp,bacs|||oxidized low-density lipoprotein|||0|854|1310|1342
SE|25462164|RESULTS|ab|8|entity|C0205263|Induced|ftcn|||induced|||0|854|1343|1350
SE|25462164|RESULTS|ab|8|entity|C0016390|Foam Cells|cell|||foam cell|||0|854|1351|1360
SE|25462164|RESULTS|ab|8|entity|C1522492|Formation|ftcn|||formation|||0|854|1361|1370
SE|25462164|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|888|1378|1389
SE|25462164|RESULTS|ab|8|entity|C0013081|Down-Regulation|celf|||down-regulation|||0|888|1390|1405
SE|25462164|RESULTS|ab|8|entity|C1366645|CD36 gene|gngm|948|CD36|CD36|||0|1000|1409|1413
SE|25462164|RESULTS|ab|8|entity|C0001374|Acyl Coenzyme A|bacs,lipd,nnon|||acyl-CoA|||0|1000|1418|1426
SE|25462164|RESULTS|ab|8|entity|C0008380|Sterol O-Acyltransferase|aapp,enzy|||cholesterol acyltransferase|||0|901|1427|1454
SE|25462164|RESULTS|ab|8|entity|C0020114|Human|humn|||human|||0|916|1460|1465
SE|25462164|RESULTS|ab|8|entity|C0024432|macrophage|cell|||monocyte-derived macrophages|||0|916|1466|1494
SE|25462164|RESULTS|ab|8|relation|0|0|C0024432|macrophage|cell|cell|||monocyte-derived macrophages|||0|916|1466|1494|MOD/HEAD|PART_OF||1460|1494|0|0|C0020114|Human|grup,humn|humn|||human|||0|916|1460|1465
SE|25462164|RESULTS|ab|8|relation|0|0|C0348035|oxidized low density lipoprotein|aapp,gngm,bacs|aapp|||oxidized low-density lipoprotein|||0|854|1310|1342|ADJ|STIMULATES||1343|1350|0|0|C0016390|Foam Cells|cell|cell|||foam cell|||0|854|1351|1360
SE|25462164|RESULTS|ab|8|relation|1|1|C0024432|macrophage|cell|cell|||monocyte-derived macrophages|||0|916|1466|1494|PREP|LOCATION_OF||1457|1459|4|1|C0001374|Acyl Coenzyme A|bacs,lipd,nnon|lipd|||acyl-CoA|||0|1000|1418|1426
SE|25462164|RESULTS|ab|8|relation|1|1|C0024432|macrophage|cell|cell|||monocyte-derived macrophages|||0|916|1466|1494|PREP|LOCATION_OF||1457|1459|4|1|C1366645|CD36 gene|gngm,aapp|aapp|948|CD36|CD36|||0|1000|1409|1413

SE|25462164|RESULTS|ab|9|text|1496|1664|Ucn1 significantly suppressed the migration and proliferation of human VSMCs and increased the activities of matrix metalloproteinase-2 (MMP2) and MMP9 in human VSMCs.
SE|25462164|RESULTS|ab|9|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|1496|1500
SE|25462164|RESULTS|ab|9|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|1544|1557
SE|25462164|RESULTS|ab|9|entity|C0020114|Human|humn|||human|||0|694|1561|1566
SE|25462164|RESULTS|ab|9|entity|C0441655|Activities|acty|||activities|||0|1000|1591|1601
SE|25462164|RESULTS|ab|9|entity|C0172537|Gelatinase A|aapp,enzy|||matrix metalloproteinase-2|||0|1000|1605|1631
SE|25462164|RESULTS|ab|9|entity|C0165519|Gelatinase B|aapp,enzy|4318|MMP9|MMP9|||0|1000|1643|1647
SE|25462164|RESULTS|ab|9|entity|C0020114|Human|humn|||human|||0|694|1651|1656

SE|25462164|RESULTS|ab|10|text|1664|1802|Intraperitoneal injection of Ucn1 into Apoe-/- mice for 4 weeks significantly retarded the development of aortic atherosclerotic lesions.
SE|25462164|RESULTS|ab|10|entity|C0021493|Injections, Intraperitoneal|topp|||Intraperitoneal injection|||0|1000|1664|1689
SE|25462164|RESULTS|ab|10|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|1693|1697
SE|25462164|RESULTS|ab|10|entity|C0003595|Apolipoprotein E|aapp,bacs|348|APOE|Apoe|||0|888|1703|1707
SE|25462164|RESULTS|ab|10|entity|C0026809|Mus|mamm|||mice|||0|888|1711|1715
SE|25462164|RESULTS|ab|10|entity|C1442465|4 Weeks|tmco|||4 weeks|||0|1000|1720|1727
SE|25462164|RESULTS|ab|10|entity|C1527148|Development|ftcn|||development|||0|1000|1755|1766
SE|25462164|RESULTS|ab|10|entity|C0003483|Aorta|bpoc|||aortic|||0|851|1770|1776
SE|25462164|RESULTS|ab|10|entity|C0333482|Atherosclerotic|ftcn|||atherosclerotic|||0|851|1777|1792
SE|25462164|RESULTS|ab|10|entity|C0221198|Lesion|fndg|||lesions|||0|851|1793|1800
SE|25462164|RESULTS|ab|10|relation|1|1|C0021493|Injections, Intraperitoneal|topp|topp|||Intraperitoneal injection|||0|1000|1664|1689|PREP|ADMINISTERED_TO||1698|1702|4|1|C0026809|Mus|mamm|mamm|||mice|||0|888|1711|1715

SE|25462164|CONCLUSIONS|ab|11|text|1802|2037|CONCLUSIONS: This study provided the first evidence that Ucn1 prevents the development of atherosclerosis by suppressing EC inflammatory response and proliferation, macrophage foam cell formation, and VSMC migration and proliferation.
SE|25462164|CONCLUSIONS|ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|1820|1825
SE|25462164|CONCLUSIONS|ab|11|entity|C1279901|Firstly|qlco|||first|||0|694|1839|1844
SE|25462164|CONCLUSIONS|ab|11|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|1859|1863
SE|25462164|CONCLUSIONS|ab|11|entity|C1527148|Development|ftcn|||development|||0|1000|1877|1888
SE|25462164|CONCLUSIONS|ab|11|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|1000|1892|1907
SE|25462164|CONCLUSIONS|ab|11|entity|C1260953|Suppressed|ftcn|||suppressing|||0|852|1911|1922
SE|25462164|CONCLUSIONS|ab|11|entity|C1155266|Inflammatory Response|patf|||inflammatory response|||0|852|1926|1947
SE|25462164|CONCLUSIONS|ab|11|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|1952|1965
SE|25462164|CONCLUSIONS|ab|11|entity|C0024432|macrophage|cell|||macrophage|||0|861|1967|1977
SE|25462164|CONCLUSIONS|ab|11|entity|C0016390|Foam Cells|cell|||foam cell|||0|861|1978|1987
SE|25462164|CONCLUSIONS|ab|11|entity|C1522492|Formation|ftcn|||formation|||0|861|1988|1997
SE|25462164|CONCLUSIONS|ab|11|entity|C0026844|Muscle, Smooth, Vascular|tisu|||VSMC|||0|893|2003|2007
SE|25462164|CONCLUSIONS|ab|11|entity|C0007608|cell motility|celf|||VSMC migration|||0|893|2003|2017
SE|25462164|CONCLUSIONS|ab|11|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|2022|2035

SE|25462164|CONCLUSIONS|ab|12|text|2037|2134|Thus, Ucn1 could serve as a novel therapeutic target for atherosclerotic cardiovascular diseases.
SE|25462164|CONCLUSIONS|ab|12|entity|C0383757|urocortin|aapp,nsba|7349|UCN|Ucn1|||0|861|2043|2047
SE|25462164|CONCLUSIONS|ab|12|entity|C0679622|novel|inpr|||novel|||0|851|2065|2070
SE|25462164|CONCLUSIONS|ab|12|entity|C0003972|Cardiovascular arteriosclerosis unspecified|dsyn|||atherosclerotic cardiovascular diseases|||0|988|2094|2133


SE|25462166||ti|1|text|21|137|Molecular mechanism of regulation of villus cell Na-K-ATPase in the chronically inflamed mammalian small intestine.
SE|25462166||ti|1|entity|C1521991|Molecular|qlco|||Molecular|||0|888|21|30
SE|25462166||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|31|40
SE|25462166||ti|1|entity|C0851285|Regulation|gora|||regulation|||0|1000|44|54
SE|25462166||ti|1|entity|C1519988|Villus|bpoc|||villus|||0|875|58|64
SE|25462166||ti|1|entity|C0007634|Cells|cell|||cell|||0|875|65|69
SE|25462166||ti|1|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|875|70|81
SE|25462166||ti|1|entity|C0021852|Intestines, Small|bpoc|||small intestine|||0|901|120|135

SE|25462166||ab|1|text|143|367|Na-K-ATPase located on the basolateral membrane (BLM) of intestinal epithelial cells provides a favorable intracellular Na+ gradient to promote all Na dependent co-transport processes across the brush border membrane (BBM).
SE|25462166||ab|1|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|1000|143|154
SE|25462166||ab|1|entity|C0596156|basolateral membrane|celc|||basolateral membrane|||0|1000|170|190
SE|25462166||ab|1|entity|C0021853|Intestines|bpoc|||intestinal|||0|901|200|210
SE|25462166||ab|1|entity|C0014597|Epithelial Cells|cell|||epithelial cells|||0|901|211|227
SE|25462166||ab|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|815|249|262
SE|25462166||ab|1|entity|C0439182|% gradient|qnco|||gradient|||0|815|267|275
SE|25462166||ab|1|entity|C1519628|Transport Process|moft|||transport processes|||0|826|307|326
SE|25462166||ab|1|entity|C0178523|brush border membrane|celc|||brush border membrane|||0|1000|338|359
SE|25462166||ab|1|relation|0|0|C0014597|Epithelial Cells|cell|cell|||epithelial cells|||0|901|211|227|MOD/HEAD|PART_OF||200|227|0|0|C0021853|Intestines|bpoc|bpoc|||intestinal|||0|901|200|210
SE|25462166||ab|1|relation|1|1|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,gngm,enzy|aapp|||Na-K-ATPase|||0|1000|143|154|VERB|PART_OF||155|162|5|1|C0596156|basolateral membrane|celc|celc|||basolateral membrane|||0|1000|170|190
SE|25462166||ab|1|relation|1|1|C0178523|brush border membrane|celc|celc|||brush border membrane|||0|1000|338|359|PREP|LOCATION_OF||327|333|5|1|C1519628|Transport Process|moft|moft|||transport processes|||0|826|307|326
SE|25462166||ab|1|relation|2|1|C0596156|basolateral membrane|celc|celc|||basolateral membrane|||0|1000|170|190|PREP|PART_OF||197|199|4|1|C0014597|Epithelial Cells|cell|cell|||epithelial cells|||0|901|211|227

SE|25462166||ab|2|text|367|524|Down-regulation of Na-K-ATPase activity has been postulated to alter the absorption via Na-solute co-transporters in human inflammatory bowel disease (IBD).
SE|25462166||ab|2|entity|C0013081|Down-Regulation|celf|||Down-regulation|||0|1000|367|382
SE|25462166||ab|2|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|916|386|397
SE|25462166||ab|2|entity|C0597488|solute|chvs|||solute|||0|762|458|464
SE|25462166||ab|2|entity|C0598849|symporter|aapp,bacs|||co-transporters|||0|762|465|480
SE|25462166||ab|2|entity|C0020114|Human|humn|||human|||0|916|484|489
SE|25462166||ab|2|entity|C0021390|Inflammatory Bowel Diseases|dsyn|||inflammatory bowel disease|||0|916|490|516
SE|25462166||ab|2|relation|0|0|C0021390|Inflammatory Bowel Diseases|dsyn|dsyn|||inflammatory bowel disease|||0|916|490|516|MOD/HEAD|PROCESS_OF||484|516|0|0|C0020114|Human|grup,humn|humn|||human|||0|916|484|489
SE|25462166||ab|2|relation|2|1|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,gngm,enzy|aapp|||Na-K-ATPase|||0|916|386|397|VERB|INTERACTS_WITH||430|435|2|1|C0598849|symporter|aapp,gngm,bacs|aapp|||co-transporters|||0|762|465|480
SE|25462166||ab|2|relation|3|1|C0598849|symporter|aapp,gngm,bacs|aapp|||co-transporters|||0|762|465|480|PREP|ASSOCIATED_WITH||481|483|1|1|C0021390|Inflammatory Bowel Diseases|dsyn|dsyn|||inflammatory bowel disease|||0|916|490|516

SE|25462166||ab|3|text|524|676|Further, the altered activity of a variety of Na-solute co-transporters in intact villus cells has been reported in animal models of chronic enteritis.
SE|25462166||ab|3|entity|C1517331|Further|spco|||Further|||0|1000|524|531
SE|25462166||ab|3|entity|C0205349|Altered|ftcn|||altered|||0|888|537|544
SE|25462166||ab|3|entity|C0597488|solute|chvs|||solute|||0|861|573|579
SE|25462166||ab|3|entity|C0598849|symporter|aapp,bacs|||co-transporters|||0|861|580|595
SE|25462166||ab|3|entity|C1519988|Villus|bpoc|||villus|||0|890|606|612
SE|25462166||ab|3|entity|C0682538|intact cell|cell|||intact villus cells|||0|890|599|618
SE|25462166||ab|3|entity|C0599779|Animal Model|anim|||animal models|||0|1000|640|653
SE|25462166||ab|3|entity|C0205191|chronic|tmco|||chronic|||0|888|657|664
SE|25462166||ab|3|entity|C0014335|enteritis|dsyn|||enteritis|||0|888|665|674
SE|25462166||ab|3|relation|0|0|C0682538|intact cell|cell|cell|||intact villus cells|||0|890|599|618|MOD/HEAD|PART_OF||606|618|0|0|C1519988|Villus|bpoc|bpoc|||villus|||0|890|606|612
SE|25462166||ab|3|relation|2|1|C0599779|Animal Model|anim|anim|||animal models|||0|1000|640|653|PREP|LOCATION_OF||637|639|4|2|C0598849|symporter|aapp,gngm,bacs|aapp|||co-transporters|||0|861|580|595
SE|25462166||ab|3|relation|3|1|C0682538|intact cell|cell|cell|||intact villus cells|||0|890|599|618|PREP|LOCATION_OF||596|598|3|1|C0598849|symporter|aapp,gngm,bacs|aapp|||co-transporters|||0|861|580|595

SE|25462166||ab|4|text|676|752|But the molecular mechanism of down-regulation of Na-K-ATPase is not known.
SE|25462166||ab|4|entity|C1521991|Molecular|qlco|||molecular|||0|888|684|693
SE|25462166||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|694|703
SE|25462166||ab|4|entity|C0013081|Down-Regulation|celf|||down-regulation|||0|1000|707|722
SE|25462166||ab|4|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|1000|726|737
SE|25462166||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|741|744

SE|25462166||ab|5|text|752|909|In the present study, using a rabbit model of chronic intestinal inflammation, which resembles human IBD, Na-K-ATPase in villus cells was shown to decrease.
SE|25462166||ab|5|entity|C0150312|Present|qnco|||present|||0|888|759|766
SE|25462166||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|888|767|772
SE|25462166||ab|5|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbit|||0|888|782|788
SE|25462166||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|888|789|794
SE|25462166||ab|5|entity|C0021853|Intestines|bpoc|||intestinal|||0|901|806|816
SE|25462166||ab|5|entity|C0021376|Chronic inflammation|patf|||chronic intestinal inflammation|||0|901|798|829
SE|25462166||ab|5|entity|C0020114|Human|humn|||human|||0|916|847|852
SE|25462166||ab|5|entity|C0021390|Inflammatory Bowel Diseases|dsyn|||IBD|||0|916|853|856
SE|25462166||ab|5|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|1000|858|869
SE|25462166||ab|5|entity|C1519988|Villus|bpoc|||villus|||0|888|873|879
SE|25462166||ab|5|entity|C0007634|Cells|cell|||cells|||0|888|880|885
SE|25462166||ab|5|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|888|880|885|MOD/HEAD|PART_OF||873|885|0|0|C1519988|Villus|bpoc|bpoc|||villus|||0|888|873|879
SE|25462166||ab|5|relation|0|0|C0021390|Inflammatory Bowel Diseases|dsyn|dsyn|||IBD|||0|916|853|856|MOD/HEAD|PROCESS_OF||847|856|0|0|C0020114|Human|grup,humn|humn|||human|||0|916|847|852
SE|25462166||ab|5|relation|0|0|C0021853|Intestines|bpoc|bpoc|||intestinal|||0|901|806|816|MOD/HEAD|LOCATION_OF||806|829|0|0|C0021376|Chronic inflammation|patf|patf|||chronic intestinal inflammation|||0|901|798|829
SE|25462166||ab|5|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|888|880|885|PREP|LOCATION_OF||870|872|5|1|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,gngm,enzy|aapp|||Na-K-ATPase|||0|1000|858|869
SE|25462166||ab|5|relation|1|1|C0008972|Clinical Research|resa|resa|||study|||0|888|767|772|VERB|USES||774|779|5|1|C0026336|Study models|inpr,resd|resd|||model|||0|888|789|794

SE|25462166||ab|6|text|909|1040|The relative mRNA abundance of alpha-1 and beta-1 subunits was not altered in villus cells during chronic intestinal inflammation.
SE|25462166||ab|6|entity|C0205345|Relative|qlco|||relative|||0|623|913|921
SE|25462166||ab|6|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA|||0|623|922|926
SE|25462166||ab|6|entity|C0439095|Alpha|inpr|||alpha|||0|861|940|945
SE|25462166||ab|6|entity|C1264631|Beta subunit|qlco|||beta-1 subunits|||0|896|952|967
SE|25462166||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|972|975
SE|25462166||ab|6|entity|C1519988|Villus|bpoc|||villus|||0|888|987|993
SE|25462166||ab|6|entity|C0007634|Cells|cell|||cells|||0|888|994|999
SE|25462166||ab|6|entity|C0021853|Intestines|bpoc|||intestinal|||0|901|1015|1025
SE|25462166||ab|6|entity|C0021376|Chronic inflammation|patf|||chronic intestinal inflammation|||0|901|1007|1038
SE|25462166||ab|6|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|888|994|999|MOD/HEAD|PART_OF||987|999|0|0|C1519988|Villus|bpoc|bpoc|||villus|||0|888|987|993
SE|25462166||ab|6|relation|0|0|C0021853|Intestines|bpoc|bpoc|||intestinal|||0|901|1015|1025|MOD/HEAD|LOCATION_OF||1015|1038|0|0|C0021376|Chronic inflammation|patf|patf|||chronic intestinal inflammation|||0|901|1007|1038

SE|25462166||ab|7|text|1040|1152|Similarly, the protein levels of these subunits were also not altered in villus cells during chronic enteritis.
SE|25462166||ab|7|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|1055|1062
SE|25462166||ab|7|entity|C0441889|Levels|inpr|||levels|||0|888|1063|1069
SE|25462166||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1098|1101
SE|25462166||ab|7|entity|C1519988|Villus|bpoc|||villus|||0|888|1113|1119
SE|25462166||ab|7|entity|C0007634|Cells|cell|||cells|||0|888|1120|1125
SE|25462166||ab|7|entity|C0205191|chronic|tmco|||chronic|||0|888|1133|1140
SE|25462166||ab|7|entity|C0014335|enteritis|dsyn|||enteritis|||0|888|1141|1150
SE|25462166||ab|7|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|888|1120|1125|MOD/HEAD|PART_OF||1113|1125|0|0|C1519988|Villus|bpoc|bpoc|||villus|||0|888|1113|1119

SE|25462166||ab|8|text|1152|1282|However, the BLM concentration of alpha-1 and beta-1 subunits was diminished in the chronically inflamed intestinal villus cells.
SE|25462166||ab|8|entity|C0596156|basolateral membrane|celc|||BLM|||0|734|1165|1168
SE|25462166||ab|8|entity|C0439095|Alpha|inpr|||alpha|||0|861|1186|1191
SE|25462166||ab|8|entity|C1264631|Beta subunit|qlco|||beta-1 subunits|||0|896|1198|1213
SE|25462166||ab|8|entity|C0227266|Intestinal villus|bpoc|||intestinal villus|||0|901|1257|1274
SE|25462166||ab|8|entity|C0007634|Cells|cell|||cells|||0|901|1275|1280
SE|25462166||ab|8|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|901|1275|1280|MOD/HEAD|PART_OF||1257|1280|0|0|C0227266|Intestinal villus|bpoc|bpoc|||intestinal villus|||0|901|1257|1274

SE|25462166||ab|9|text|1282|1390|An ankyrin-spectrin skeleton is necessary for the proper trafficking of Na-K-ATPase to the BLM of the cell.
SE|25462166||ab|9|entity|C0051926|Ankyrins|aapp,bacs|||ankyrin|||0|851|1285|1292
SE|25462166||ab|9|entity|C0037799|Spectrin|aapp,bacs|||spectrin|||0|851|1293|1301
SE|25462166||ab|9|entity|C0037253|Skeletal system|bdsy|||skeleton|||0|851|1302|1310
SE|25462166||ab|9|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|1000|1354|1365
SE|25462166||ab|9|entity|C0596156|basolateral membrane|celc|||BLM|||0|1000|1373|1376
SE|25462166||ab|9|entity|C0007634|Cells|cell|||cell|||0|1000|1384|1388
SE|25462166||ab|9|relation|5|1|C0596156|basolateral membrane|celc|celc|||BLM|||0|1000|1373|1376|PREP|PART_OF||1377|1379|1|1|C0007634|Cells|cell|cell|||cell|||0|1000|1384|1388

SE|25462166||ab|10|text|1390|1561|In the present study, ankyrin expression was markedly diminished in villus cells from the chronically inflamed intestine resulting in depolarization of ankyrin-G protein.
SE|25462166||ab|10|entity|C0150312|Present|qnco|||present|||0|888|1397|1404
SE|25462166||ab|10|entity|C0008972|Clinical Research|resa|||study|||0|888|1405|1410
SE|25462166||ab|10|entity|C0051926|Ankyrins|aapp,bacs|||ankyrin|||0|888|1412|1419
SE|25462166||ab|10|entity|C0522501|Massive|qlco|||markedly|||0|1000|1435|1443
SE|25462166||ab|10|entity|C1519988|Villus|bpoc|||villus|||0|888|1458|1464
SE|25462166||ab|10|entity|C0007634|Cells|cell|||cells|||0|888|1465|1470
SE|25462166||ab|10|entity|C0333348|Inflammatory|ftcn|||inflamed|||0|790|1492|1500
SE|25462166||ab|10|entity|C0021853|Intestines|bpoc|||intestine|||0|790|1501|1510
SE|25462166||ab|10|entity|C1395184|depolarization|patf|||depolarization|||0|1000|1524|1538
SE|25462166||ab|10|entity|C0051926|Ankyrins|aapp,bacs|||ankyrin|||0|901|1542|1549
SE|25462166||ab|10|entity|C0086376|GTP-Binding Proteins|aapp,enzy|||G protein|||0|901|1550|1559
SE|25462166||ab|10|relation|0|0|C0007634|Cells|cell|cell|||cells|||0|888|1465|1470|MOD/HEAD|PART_OF||1458|1470|0|0|C1519988|Villus|bpoc|bpoc|||villus|||0|888|1458|1464
SE|25462166||ab|10|relation|2|1|C0051926|Ankyrins|aapp,gngm,bacs|aapp|||ankyrin|||0|888|1412|1419|VERB|DISRUPTS||1444|1454|4|1|C0007634|Cells|cell|cell|||cells|||0|888|1465|1470

SE|25462166||ab|11|text|1561|1661|The decrease of Na-K-ATPase activity was comparable to that seen in ankyrin knockdown IEC-18 cells.
SE|25462166||ab|11|entity|C0547047|Decrease|qnco|||decrease|||0|1000|1565|1573
SE|25462166||ab|11|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|916|1577|1588
SE|25462166||ab|11|entity|C0051926|Ankyrins|aapp,bacs|||ankyrin|||0|786|1629|1636
SE|25462166||ab|11|entity|C0007634|Cells|cell|||cells|||0|786|1654|1659
SE|25462166||ab|11|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|786|1654|1659|PREP|LOCATION_OF||1626|1628|3|2|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,gngm,enzy|aapp|||Na-K-ATPase|||0|916|1577|1588

SE|25462166||ab|12|text|1661|1860|Therefore, altered localization of Na-K-ATPase as a result of transcriptional down-regulation of ankyrin-G mediates the down-regulation of Na-K-ATPase activity during chronic intestinal inflammation.
SE|25462166||ab|12|entity|C0205349|Altered|ftcn|||altered|||0|888|1672|1679
SE|25462166||ab|12|entity|C0475264|localization|ftcn|||localization|||0|888|1680|1692
SE|25462166||ab|12|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|1000|1696|1707
SE|25462166||ab|12|entity|C0023032|Lanugo|bpoc|||down|||0|882|1739|1743
SE|25462166||ab|12|entity|C1158770|Transcriptional Regulation|celf|||transcriptional down-regulation|||0|882|1723|1754
SE|25462166||ab|12|entity|C0051926|Ankyrins|aapp,bacs|||ankyrin|||0|872|1758|1765
SE|25462166||ab|12|entity|C0013081|Down-Regulation|celf|||down-regulation|||0|1000|1781|1796
SE|25462166||ab|12|entity|C0001479|Na(+)-K(+)-Exchanging ATPase|aapp,enzy|||Na-K-ATPase|||0|916|1800|1811
SE|25462166||ab|12|entity|C0021853|Intestines|bpoc|||intestinal|||0|901|1836|1846
SE|25462166||ab|12|entity|C0021376|Chronic inflammation|patf|||chronic intestinal inflammation|||0|901|1828|1859
SE|25462166||ab|12|relation|0|0|C0021853|Intestines|bpoc|bpoc|||intestinal|||0|901|1836|1846|MOD/HEAD|LOCATION_OF||1836|1859|0|0|C0021376|Chronic inflammation|patf|patf|||chronic intestinal inflammation|||0|901|1828|1859
SE|25462166||ab|12|relation|5|2|C1158770|Transcriptional Regulation|celf|celf|||transcriptional down-regulation|||0|882|1723|1754|VERB|AFFECTS||1768|1776|3|1|C0013081|Down-Regulation|celf|celf|||down-regulation|||0|1000|1781|1796


SE|25462167||ti|1|text|21|120|Scolopendin 2, a cationic antimicrobial peptide from centipede, and its membrane-active mechanism.
SE|25462167||ti|1|entity|C0007447|Cations|chvs|||cationic|||0|816|38|46
SE|25462167||ti|1|entity|C1136254|Microbicides|phsu|||antimicrobial|||0|816|47|60
SE|25462167||ti|1|entity|C0030956|Peptides|aapp|||peptide|||0|816|61|68
SE|25462167||ti|1|entity|C0323819|Chilopoda|invt|||centipede|||0|1000|74|83
SE|25462167||ti|1|entity|C0596901|Membrane|celc|||membrane|||0|851|93|101
SE|25462167||ti|1|entity|C0205177|Active|ftcn|||active|||0|851|102|108
SE|25462167||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|851|109|118

SE|25462167||ab|1|text|126|240|Scolopendin 2 is a 16-mer peptide (AGLQFPVGRIGRLLRK) derived from the centipede Scolopendra subspinipes mutilans.
SE|25462167||ab|1|entity|C1364081|MERTK gene|gngm|10461|MERTK|mer|||0|790|148|151
SE|25462167||ab|1|entity|C0030956|Peptides|aapp|||peptide|||0|790|152|159
SE|25462167||ab|1|entity|C0323819|Chilopoda|invt|||centipede|||0|658|196|205
SE|25462167||ab|1|entity|C1018441|Scolopendra subspinipes|invt|||Scolopendra subspinipes|||0|658|206|229

SE|25462167||ab|2|text|240|444|We observed that this peptide exhibited antimicrobial activity in a salt-dependent manner against various fungal and bacterial pathogens and showed no hemolytic effect in the range of 1.6 MUM to 100 MUM.
SE|25462167||ab|2|entity|C0030956|Peptides|aapp|||peptide|||0|1000|262|269
SE|25462167||ab|2|entity|C1271650|Antimicrobial activity|lbtr|||antimicrobial activity|||0|1000|280|302
SE|25462167||ab|2|entity|C0036140|Salts|chvs|||salt|||0|623|308|312
SE|25462167||ab|2|entity|C0016832|fungus|fngs|||fungal|||0|861|346|352
SE|25462167||ab|2|entity|C0521009|Bacterial|ftcn|||bacterial|||0|835|357|366
SE|25462167||ab|2|entity|C0312853|Hemolytic|ftcn|||hemolytic|||0|888|391|400
SE|25462167||ab|2|entity|C1280500|Effect|qlco|||effect|||0|888|401|407
SE|25462167||ab|2|entity|C1514721|Range|qnco|||range|||0|1000|415|420
SE|25462167||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|428|431
SE|25462167||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|439|442

SE|25462167||ab|3|text|444|529|Circular dichroism analysis showed that the peptide has an alpha-helical properties.
SE|25462167||ab|3|entity|C0008813|Circular Dichroism|lbpr,npop|||Circular dichroism|||0|901|444|462
SE|25462167||ab|3|entity|C0936012|Analysis|resa|||analysis|||0|901|463|471
SE|25462167||ab|3|entity|C0030956|Peptides|aapp|||peptide|||0|1000|488|495
SE|25462167||ab|3|entity|C0599214|Alpha Helix|spco|||alpha-helical|||0|866|503|516
SE|25462167||ab|3|entity|C0871161|Property|qlco|||properties|||0|866|517|527

SE|25462167||ab|4|text|529|665|Furthermore, we determined the mechanism(s) of action using flow cytometry and by investigating the release of intracellular potassium.
SE|25462167||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|560|569
SE|25462167||ab|4|entity|C0016263|Flow Cytometry|lbpr|||flow cytometry|||0|1000|589|603
SE|25462167||ab|4|entity|C1292732|Investigates|ftcn|||investigating|||0|966|611|624
SE|25462167||ab|4|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|640|653
SE|25462167||ab|4|entity|C0032821|Potassium|bacs,elii|||potassium|||0|888|654|663
SE|25462167||ab|4|relation|0|0|C0032821|Potassium|bacs,elii|bacs|||potassium|||0|888|654|663|MOD/HEAD|PART_OF||640|663|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|888|640|653

SE|25462167||ab|5|text|665|827|The results showed that the peptide permeabilized the membranes of Escherichia coli O157 and Candida albicans, resulting in loss of intracellular potassium ions.
SE|25462167||ab|5|entity|C1274040|result|ftcn|||results|||0|966|669|676
SE|25462167||ab|5|entity|C0030956|Peptides|aapp|||peptide|||0|1000|693|700
SE|25462167||ab|5|entity|C0025255|Tissue membrane|tisu|||membranes|||0|1000|719|728
SE|25462167||ab|5|entity|C0376625|Escherichia coli O157|bact|||Escherichia coli O157|||0|1000|732|753
SE|25462167||ab|5|entity|C0006837|Candida albicans|fngs|||Candida albicans|||0|1000|758|774
SE|25462167||ab|5|entity|C1517945|Loss|qnco|||loss|||0|1000|789|793
SE|25462167||ab|5|entity|C0175996|Protoplasm|celc|||intracellular|||0|901|797|810
SE|25462167||ab|5|entity|C0597277|Potassium Ions|bacs,elii|||potassium ions|||0|901|811|825
SE|25462167||ab|5|relation|0|0|C0597277|Potassium Ions|bacs,elii|bacs|||potassium ions|||0|901|811|825|MOD/HEAD|PART_OF||797|825|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|901|797|810
SE|25462167||ab|5|relation|3|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|1000|719|728|PREP|PART_OF||729|731|4|1|C0006837|Candida albicans|fngs|fngs|||Candida albicans|||0|1000|758|774
SE|25462167||ab|5|relation|3|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|1000|719|728|PREP|PART_OF||729|731|4|1|C0376625|Escherichia coli O157|bact|bact|||Escherichia coli O157|||0|1000|732|753

SE|25462167||ab|6|text|827|996|Additionally, bis-(1,3-dibutylbarbituric acid) trimethine oxonol and 3,3'-dipropylthiacarbocyanine iodide assays showed that the peptide caused membrane depolarization.
SE|25462167||ab|6|entity|||gngm|9531|BAG3|bis|||0|1000|841|844
SE|25462167||ab|6|entity|C0001128|Acids|chem|||acid|||0|802|868|872
SE|25462167||ab|6|entity|C0021966|Iodides|inch|||iodide|||0|764|926|932
SE|25462167||ab|6|entity|C1510438|Assay|lbpr|||assays|||0|764|933|939
SE|25462167||ab|6|entity|C0030956|Peptides|aapp|||peptide|||0|1000|956|963
SE|25462167||ab|6|entity|C0596901|Membrane|celc|||membrane|||0|888|971|979
SE|25462167||ab|6|entity|C1395184|depolarization|patf|||depolarization|||0|888|980|994
SE|25462167||ab|6|relation|5|1|C0030956|Peptides|aapp,gngm|aapp|||peptide|||0|1000|956|963|VERB|CAUSES||964|970|1|1|C1395184|depolarization|patf|patf|||depolarization|||0|888|980|994

SE|25462167||ab|7|text|996|1321|Using giant unilamellar vesicles encapsulating calcein and large unilamellar vesicles containing fluorescein isothiocyanate-dextran, which were similar in composition to typical E. coli O157 and C. albicans membranes, we demonstrated that scolopendin 2 disrupts membranes, resulting in a pore size between 4.8 nm and 5.0 nm.
SE|25462167||ab|7|entity|C0017547|Gigantism|dsyn|||giant|||0|802|1002|1007
SE|25462167||ab|7|entity|C0333262|Vesicle|acab|||vesicles|||0|802|1020|1028
SE|25462167||ab|7|entity|C0060549|Fluorexon stain|irda,orch|||calcein|||0|1000|1043|1050
SE|25462167||ab|7|entity|C0549177|Large|qnco|||large|||0|802|1055|1060
SE|25462167||ab|7|entity|C0333262|Vesicle|acab|||vesicles|||0|802|1073|1081
SE|25462167||ab|7|entity|C0060527|fluorescein isothiocyanate dextran|carb,irda|||fluorescein isothiocyanate-dextran|||0|1000|1093|1127
SE|25462167||ab|7|entity|C0486616|Composition|clna|||composition|||0|1000|1151|1162
SE|25462167||ab|7|entity|C0445148|O157|inpr|||O157|||0|747|1182|1186
SE|25462167||ab|7|entity|C0025255|Tissue membrane|tisu|||membranes|||0|827|1203|1212
SE|25462167||ab|7|entity|C0025255|Tissue membrane|tisu|||membranes|||0|1000|1258|1267
SE|25462167||ab|7|entity|C0456389|size|spco|||size|||0|861|1289|1293
SE|25462167||ab|7|relation|8|5|C0060527|fluorescein isothiocyanate dextran|carb,irda|carb|||fluorescein isothiocyanate-dextran|||0|1000|1093|1127|VERB|DISRUPTS||1249|1257|4|1|C0025255|Tissue membrane|tisu|tisu|||membranes|||0|1000|1258|1267

SE|25462167||ab|8|text|1321|1488|Thus, we have demonstrated that a cationic antimicrobial peptide, scolopendin 2, exerts its broad-spectrum antimicrobial effects by forming pores in the cell membrane.
SE|25462167||ab|8|entity|C0007447|Cations|chvs|||cationic|||0|816|1355|1363
SE|25462167||ab|8|entity|C1136254|Microbicides|phsu|||antimicrobial|||0|816|1364|1377
SE|25462167||ab|8|entity|C0030956|Peptides|aapp|||peptide|||0|816|1378|1385
SE|25462167||ab|8|entity|C0332464|Widening|spco|||broad|||0|813|1413|1418
SE|25462167||ab|8|entity|C1516022|Antimicrobial Effect|celf|||antimicrobial effects|||0|813|1428|1449
SE|25462167||ab|8|entity|C0205431|Formed|ftcn|||forming|||0|694|1453|1460
SE|25462167||ab|8|entity|C0007603|Cell membrane|celc|||cell membrane|||0|1000|1474|1487


SE|25462168||ti|1|text|21|127|Transport across the outer membrane porin of mycolic acid containing actinomycetales: Nocardia farcinica.
SE|25462168||ti|1|entity|C1167331|outer membrane|celc|||outer membrane|||0|901|42|56
SE|25462168||ti|1|entity|C0071728|porin|aapp,imft|7416|VDAC1|porin|||0|901|57|62
SE|25462168||ti|1|entity|C0026930|Mycolic Acid|bacs,lipd|||mycolic acid|||0|861|66|78
SE|25462168||ti|1|entity|C0332256|Containing|ftcn|||containing|||0|861|79|89
SE|25462168||ti|1|entity|C0001254|Actinomycetales|bact|||actinomycetales|||0|861|90|105
SE|25462168||ti|1|entity|C0317900|Nocardia farcinica|bact|||Nocardia farcinica|||0|1000|107|125
SE|25462168||ti|1|relation|0|0|C0071728|porin|aapp,gngm,imft|aapp|7416|VDAC1|porin|||0|901|57|62|MOD/HEAD|PART_OF||42|62|0|0|C1167331|outer membrane|celc|celc|||outer membrane|||0|901|42|56
SE|25462168||ti|1|relation|2|1|C0071728|porin|aapp,gngm,imft|aapp|7416|VDAC1|porin|||0|901|57|62|PREP|PART_OF||63|65|2|1|C0001254|Actinomycetales|bact|bact|||actinomycetales|||0|861|90|105

SE|25462168||ab|1|text|133|321|The role of the outer-membrane channel from a mycolic acid containing Gram-positive bacteria Nocardia farcinica, which forms a hydrophilic pathway across the cell wall, was characterized.
SE|25462168||ab|1|entity|C0035820|Role|socb|||role|||0|1000|137|141
SE|25462168||ab|1|entity|C1167331|outer membrane|celc|||outer-membrane|||0|901|149|163
SE|25462168||ab|1|entity|C0439799|Channel|spco|||channel|||0|901|164|171
SE|25462168||ab|1|entity|C0026930|Mycolic Acid|bacs,lipd|||mycolic acid|||0|840|179|191
SE|25462168||ab|1|entity|C0332256|Containing|ftcn|||containing|||0|840|192|202
SE|25462168||ab|1|entity|C0018154|Gram-Positive Bacteria|bact|||Gram-positive bacteria|||0|840|203|225
SE|25462168||ab|1|entity|C0317900|Nocardia farcinica|bact|||Nocardia farcinica|||0|840|226|244
SE|25462168||ab|1|entity|C0475370|Hydrophilic|ftcn|||hydrophilic|||0|888|260|271
SE|25462168||ab|1|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|272|279
SE|25462168||ab|1|entity|C0007623|Cell Wall|celc|||cell wall|||0|1000|291|300
SE|25462168||ab|1|relation|0|0|C0317900|Nocardia farcinica|bact|bact|||Nocardia farcinica|||0|840|226|244|MOD/HEAD|ISA||203|244|0|0|C0018154|Gram-Positive Bacteria|bact|bact|||Gram-positive bacteria|||0|840|203|225
SE|25462168||ab|1|relation|1|1|C0007623|Cell Wall|celc|celc|||cell wall|||0|1000|291|300|PREP|LOCATION_OF||280|286|4|2|C0317900|Nocardia farcinica|bact|bact|||Nocardia farcinica|||0|840|226|244

SE|25462168||ab|2|text|321|490|Single channel electrophysiology measurements and liposome swelling assays revealed the permeation of hydrophilic solutes including sugars, amino acids and antibiotics.
SE|25462168||ab|2|entity|C0037179|Unmarried person|popg|||Single|||0|775|321|327
SE|25462168||ab|2|entity|C0439799|Channel|spco|||channel|||0|775|328|335
SE|25462168||ab|2|entity|C0242485|Measurement|ftcn|||measurements|||0|775|354|366
SE|25462168||ab|2|entity|C0023828|Liposomes|celc,lipd|||liposome|||0|840|371|379
SE|25462168||ab|2|entity|C0013604|Edema|patf|||swelling|||0|840|380|388
SE|25462168||ab|2|entity|C1510438|Assay|lbpr|||assays|||0|840|389|395
SE|25462168||ab|2|entity|C0475370|Hydrophilic|ftcn|||hydrophilic|||0|872|423|434
SE|25462168||ab|2|entity|C0597488|solute|chvs|||solutes|||0|872|435|442
SE|25462168||ab|2|entity|C0242209|Sugars|carb,phsu|||sugars|||0|1000|453|459
SE|25462168||ab|2|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|461|472
SE|25462168||ab|2|entity|C0003232|Antibiotics|antb|||antibiotics|||0|1000|477|488

SE|25462168||ab|3|text|490|687|The cation selective N. farcinica channel exhibited strong interaction with the positively charged antibiotics; amikacin and kanamycin, and surprisingly also with the negatively charged ertapenem.
SE|25462168||ab|3|entity|C0007447|Cations|chvs|||cation|||0|742|494|500
SE|25462168||ab|3|entity|C0439799|Channel|spco|||channel|||0|742|524|531
SE|25462168||ab|3|entity|C0442821|Strong|qlco|||strong|||0|888|542|548
SE|25462168||ab|3|entity|C0007961|charge amounts|qnco|||charged|||0|773|581|588
SE|25462168||ab|3|entity|C0003232|Antibiotics|antb|||antibiotics|||0|773|589|600
SE|25462168||ab|3|entity|C0002499|Amikacin|antb,carb|||amikacin|||0|1000|602|610
SE|25462168||ab|3|entity|C0022487|Kanamycin|antb,carb|||kanamycin|||0|1000|615|624
SE|25462168||ab|3|entity|C0007961|charge amounts|qnco|||charged|||0|773|668|675
SE|25462168||ab|3|entity|C1120106|ertapenem|antb,orch|||ertapenem|||0|773|676|685

SE|25462168||ab|4|text|687|809|Voltage dependent kinetics of amikacin and kanamycin interactions were studied to distinguish binding from translocation.
SE|25462168||ab|4|entity|C0598352|voltage|qnco|||Voltage|||0|851|687|694
SE|25462168||ab|4|entity|C0022702|Kinetics|idcn|||kinetics|||0|851|705|713
SE|25462168||ab|4|entity|C0002499|Amikacin|antb,carb|||amikacin|||0|1000|717|725
SE|25462168||ab|4|entity|C0022487|Kanamycin|antb,carb|||kanamycin|||0|694|730|739

SE|25462168||ab|5|text|809|978|Moreover, the importance of charged residues inside the channel was investigated using mutational studies that revealed rate limiting interactions during the permeation.
SE|25462168||ab|5|entity|C0007961|charge amounts|qnco|||charged|||0|830|837|844
SE|25462168||ab|5|entity|C0439799|Channel|spco|||channel|||0|1000|865|872
SE|25462168||ab|5|entity|C0026882|Mutation|genf|||mutational|||0|928|896|906
SE|25462168||ab|5|entity|C0443289|Revealed|qlco|||revealed|||0|597|920|928
SE|25462168||ab|5|entity|C1521828|Rate|qnco|||rate|||0|597|929|933
SE|25462168||ab|5|entity|C0439801|Limited|ftcn|||limiting|||0|597|934|942


SE|25462169||ti|1|text|21|125|Folding and stability of the aquaglyceroporin GlpF: Implications for human aqua(glycero)porin diseases.
SE|25462169||ti|1|entity|C0185026|Plication|topp|||Folding|||0|1000|21|28
SE|25462169||ti|1|entity|C1317741|STABILITY|qlco|||stability|||0|1000|33|42
SE|25462169||ti|1|entity|C0020114|Human|humn|||human|||0|694|90|95
SE|25462169||ti|1|entity|C0071728|porin|aapp,imft|7416|VDAC1|porin|||0|888|109|114
SE|25462169||ti|1|entity|C0012634|Disease|dsyn|||diseases|||0|888|115|123

SE|25462169||ab|1|text|131|305|Aquaporins are highly selective polytopic transmembrane channel proteins that facilitate the permeation of water across cellular membranes in a large diversity of organisms.
SE|25462169||ab|1|entity|C0599635|water channel|aapp,bacs|||Aquaporins|||0|1000|131|141
SE|25462169||ab|1|entity|C0439799|Channel|spco|||channel|||0|751|187|194
SE|25462169||ab|1|entity|C0021699|Integral Membrane Proteins|aapp,rcpt|||transmembrane channel proteins|||0|751|173|203
SE|25462169||ab|1|entity|C0020311|Hydrotherapy|topp|||water|||0|1000|238|243
SE|25462169||ab|1|entity|C1516370|Cellular Membrane|celc|||cellular membranes|||0|983|251|269
SE|25462169||ab|1|entity|C0549177|Large|qnco|||large|||0|694|275|280
SE|25462169||ab|1|entity|C0029235|Organism|orgm|||organisms|||0|1000|294|303
SE|25462169||ab|1|relation|3|1|C1516370|Cellular Membrane|celc|celc|||cellular membranes|||0|983|251|269|PREP|LOCATION_OF||244|250|4|4|C0599635|water channel|aapp,gngm,bacs|aapp|||Aquaporins|||0|1000|131|141

SE|25462169||ab|2|text|305|461|Defects in aquaporin function are associated with common diseases, such as nephrogenic diabetes insipidus, congenital cataract and certain types of cancer.
SE|25462169||ab|2|entity|C0599635|water channel|aapp,bacs|||aquaporin|||0|888|316|325
SE|25462169||ab|2|entity|C0031843|physiological aspects|phsf|||function|||0|888|326|334
SE|25462169||ab|2|entity|C0205214|Common|qnco|||common|||0|888|355|361
SE|25462169||ab|2|entity|C0012634|Disease|dsyn|||diseases|||0|888|362|370
SE|25462169||ab|2|entity|C0162283|Diabetes Insipidus, Nephrogenic|dsyn|||nephrogenic diabetes insipidus|||0|1000|380|410
SE|25462169||ab|2|entity|C0009691|Congenital cataract|cgab|||congenital cataract|||0|1000|412|431
SE|25462169||ab|2|entity|C0332307|Type - attribute|qlco|||types|||0|888|444|449
SE|25462169||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|453|459
SE|25462169||ab|2|relation|0|0|C0162283|Diabetes Insipidus, Nephrogenic|dsyn|dsyn|||nephrogenic diabetes insipidus|||0|1000|380|410|SPEC|ISA||362|410|0|0|C0012634|Disease|dsyn|dsyn|||diseases|||0|888|362|370
SE|25462169||ab|2|relation|0|0|C0599635|water channel|aapp,gngm,bacs|aapp|||aquaporin|||0|888|316|325|INFER|ASSOCIATED_WITH(SPEC)||362|410|0|0|C0162283|Diabetes Insipidus, Nephrogenic|dsyn|dsyn|||nephrogenic diabetes insipidus|||0|1000|380|410
SE|25462169||ab|2|relation|2|1|C0599635|water channel|aapp,gngm,bacs|aapp|||aquaporin|||0|888|316|325|VERB|ASSOCIATED_WITH||339|349|5|1|C0012634|Disease|dsyn|dsyn|||diseases|||0|888|362|370

SE|25462169||ab|3|text|461|547|In general, aquaporins have a highly conserved structure; from prokaryotes to humans.
SE|25462169||ab|3|entity|C0205246|Generalized|spco|||general|||0|888|464|471
SE|25462169||ab|3|entity|C0599635|water channel|aapp,bacs|||aquaporins|||0|888|473|483
SE|25462169||ab|3|entity|C0678594|Structure|spco|||structure|||0|827|508|517
SE|25462169||ab|3|entity|C0033368|Prokaryotic Cells|cell|||prokaryotes|||0|1000|524|535
SE|25462169||ab|3|entity|C0020114|Human|humn|||humans|||0|1000|539|545

SE|25462169||ab|4|text|547|675|The conserved structure, together with structural dynamics and the structural framework for substrate selectivity is discussed.
SE|25462169||ab|4|entity|C0678594|Structure|spco|||structure|||0|861|561|570

SE|25462169||ab|5|text|675|762|The folding pathway of aquaporins has been a topic of several studies in recent years.
SE|25462169||ab|5|entity|C0185026|Plication|topp|||folding|||0|888|679|686
SE|25462169||ab|5|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|687|694
SE|25462169||ab|5|entity|C0599635|water channel|aapp,bacs|||aquaporins|||0|1000|698|708
SE|25462169||ab|5|entity|C1555712|topic|idcn|||topic|||0|1000|720|725
SE|25462169||ab|5|entity|C0443302|Several|qnco|||several|||0|872|729|736
SE|25462169||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|872|737|744
SE|25462169||ab|5|entity|C0332185|Recent|tmco|||recent|||0|888|748|754
SE|25462169||ab|5|entity|C0439234|year|tmco|||years|||0|888|755|760

SE|25462169||ab|6|text|762|876|These studies revealed that a conserved protein structure can be reached by following different folding pathways.
SE|25462169||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|768|775
SE|25462169||ab|6|entity|C1510464|Protein Structure|aapp|||protein structure|||0|901|802|819
SE|25462169||ab|6|entity|C1547020|*Difference|qnco|||different|||0|587|848|857
SE|25462169||ab|6|entity|C0185026|Plication|topp|||folding|||0|587|858|865

SE|25462169||ab|7|text|876|1067|Based on the available data, we suggest a complex folding pathway for aquaporins, starting from the insertion of individual helices up to the formation of the tetrameric aquaporin structure.
SE|25462169||ab|7|entity|C1511726|Data|idcn|||data|||0|888|899|903
SE|25462169||ab|7|entity|C0439855|Complex|qlco|||complex|||0|851|918|925
SE|25462169||ab|7|entity|C0185026|Plication|topp|||folding|||0|851|926|933
SE|25462169||ab|7|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|851|934|941
SE|25462169||ab|7|entity|C0599635|water channel|aapp,bacs|||aquaporins|||0|1000|946|956
SE|25462169||ab|7|entity|C0021107|Implantation procedure|topp|||insertion|||0|1000|976|985
SE|25462169||ab|7|entity|C0237401|Individual|humn|||individual|||0|694|989|999
SE|25462169||ab|7|entity|C1522492|Formation|ftcn|||formation|||0|1000|1018|1027
SE|25462169||ab|7|entity|C0039686|Tetrameres|invt|||tetrameric|||0|828|1035|1045
SE|25462169||ab|7|entity|C0599635|water channel|aapp,bacs|||aquaporin|||0|828|1046|1055
SE|25462169||ab|7|entity|C0678594|Structure|spco|||structure|||0|828|1056|1065

SE|25462169||ab|8|text|1067|1229|The consequences of some known mutations in human aquaporin-encoding genes, which most likely affect the folding and stability of human aquaporins, are discussed.
SE|25462169||ab|8|entity|C0205309|Known|qlco|||known|||0|888|1092|1097
SE|25462169||ab|8|entity|C0026882|Mutation|genf|||mutations|||0|888|1098|1107
SE|25462169||ab|8|entity|C0599635|water channel|aapp,bacs|||aquaporin|||0|813|1117|1126
SE|25462169||ab|8|entity|C0314604|Human gene|gngm|||human aquaporin-encoding genes|||0|813|1111|1141
SE|25462169||ab|8|entity|C0205393|Most|qnco|||most|||0|1000|1149|1153
SE|25462169||ab|8|entity|C0185026|Plication|topp|||folding|||0|1000|1172|1179
SE|25462169||ab|8|entity|C1317741|STABILITY|qlco|||stability|||0|1000|1184|1193
SE|25462169||ab|8|entity|C0020114|Human|humn|||human|||0|888|1197|1202
SE|25462169||ab|8|entity|C0599635|water channel|aapp,bacs|||aquaporins|||0|888|1203|1213
SE|25462169||ab|8|relation|0|0|C0599635|water channel|aapp,gngm,bacs|aapp|||aquaporins|||0|888|1203|1213|MOD/HEAD|PART_OF||1197|1213|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|1197|1202


SE|25462170||ti|1|text|21|75|VCA1008: An Anion-Selective Porin of Vibrio Cholerae.
SE|25462170||ti|1|entity|C0003075|Anions|elii|||Anion|||0|802|33|38
SE|25462170||ti|1|entity|C0071728|porin|aapp,imft|7416|VDAC1|Porin|||0|802|49|54
SE|25462170||ti|1|entity|C0042629|Vibrio cholerae|bact|||Vibrio Cholerae|||0|1000|58|73
SE|25462170||ti|1|relation|2|1|C0071728|porin|aapp,gngm,imft|aapp|7416|VDAC1|Porin|||0|802|49|54|PREP|PART_OF||55|57|1|1|C0042629|Vibrio cholerae|bact|bact|||Vibrio Cholerae|||0|1000|58|73

SE|25462170||ab|1|text|81|156|A putative porin function has been assigned to VCA1008 of Vibrio cholerae.
SE|25462170||ab|1|entity|C0071728|porin|aapp,imft|7416|VDAC1|porin|||0|790|92|97
SE|25462170||ab|1|entity|C0031843|physiological aspects|phsf|||function|||0|790|98|106
SE|25462170||ab|1|entity|C0042629|Vibrio cholerae|bact|||Vibrio cholerae|||0|1000|139|154

SE|25462170||ab|2|text|156|305|Its coding gene, vca1008, is expressed upon colonization of the small intestine in infant mice and human volunteers, and is essential for infection.
SE|25462170||ab|2|entity|C0009219|Coding|ocac|||coding|||0|888|160|166
SE|25462170||ab|2|entity|C0017337|Genes|gngm|||gene|||0|888|167|171
SE|25462170||ab|2|entity|C0021852|Intestines, Small|bpoc|||small intestine|||0|1000|220|235
SE|25462170||ab|2|entity|C0021270|Infant|aggp|||infant|||0|888|239|245
SE|25462170||ab|2|entity|C0026809|Mus|mamm|||mice|||0|888|246|250
SE|25462170||ab|2|entity|C0020155|Human Volunteers|popg|||human volunteers|||0|1000|255|271
SE|25462170||ab|2|entity|C0205224|Essential|qlco|||essential|||0|1000|280|289

SE|25462170||ab|3|text|305|459|In vitro, vca1008 is expressed under inorganic phosphate limitation and, in this condition, VCA1008 is the major outer membrane protein of the bacterium.
SE|25462170||ab|3|entity|C1533691|in vitro|qlco|||In vitro|||0|734|305|313
SE|25462170||ab|3|entity|C0031603|inorganic phosphate|inch|||inorganic phosphate|||0|901|342|361
SE|25462170||ab|3|entity|C0449295|Limitation|ftcn|||limitation|||0|901|362|372
SE|25462170||ab|3|entity|C0348080|Condition|qlco|||condition|||0|1000|386|395
SE|25462170||ab|3|entity|C0205164|Major|qlco|||major|||0|861|412|417
SE|25462170||ab|3|entity|C1167331|outer membrane|celc|||outer membrane|||0|861|418|432
SE|25462170||ab|3|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|433|440
SE|25462170||ab|3|entity|C0004611|Bacteria|bact|||bacterium|||0|1000|448|457
SE|25462170||ab|3|relation|5|1|C1167331|outer membrane|celc|celc|||outer membrane|||0|861|418|432|PREP|PART_OF||441|443|1|1|C0004611|Bacteria|bact|bact|||bacterium|||0|1000|448|457

SE|25462170||ab|4|text|459|567|Here, we provide the first functional characterization of VCA1008 reconstituted into planar lipid bilayers.
SE|25462170||ab|4|entity|C1279901|Firstly|qlco|||first|||0|623|480|485
SE|25462170||ab|4|entity|C0205245|Functional|ftcn|||functional|||0|623|486|496
SE|25462170||ab|4|entity|C0023768|Lipid Bilayers|celc|||lipid bilayers|||0|901|551|565

SE|25462170||ab|5|text|567|1264|Our main findings were: 1) VCA1008 forms an ion channel that, at high voltage (~+/-100 mV), presents a voltage-dependent activity and displays closures typical of trimeric porins, with a conductance of 4.28+/-0.04 nS (n=164) in 1M KCl; 2) It has a preferred selectivity for anions over cations; 3) Its conductance saturates with increasing inorganic phosphate concentration, suggesting VCA1008 contains binding site(s) for this anion; 4) Its ion selectivity is controlled by both fixed charged residues within the channel and diffusion along the pore; 5) Partitioning of poly (ethylene glycol)s (PEGs) of different molecular mass suggests that VCA1008 channel has a pore exclusion limit of 0.9 nm.
SE|25462170||ab|5|entity|C0205225|Primary|qlco|||main|||0|888|571|575
SE|25462170||ab|5|entity|C0243095|Finding|ftcn|||findings|||0|888|576|584
SE|25462170||ab|5|entity|C0022023|Ions|elii|||ion|||0|1000|611|614
SE|25462170||ab|5|entity|C0205250|High|qlco|||high|||0|888|632|636
SE|25462170||ab|5|entity|C0598352|voltage|qnco|||voltage|||0|888|637|644
SE|25462170||ab|5|entity|C0598352|voltage|qnco|||voltage|||0|851|670|677
SE|25462170||ab|5|entity|C0185003|Reparative closure|topp|||closures|||0|1000|710|718
SE|25462170||ab|5|entity|C0071728|porin|aapp,imft|7416|VDAC1|porins|||0|861|739|745
SE|25462170||ab|5|entity|C1548789|Preferred|qlco|||preferred|||0|694|815|824
SE|25462170||ab|5|entity|C0003075|Anions|elii|||anions|||0|802|841|847
SE|25462170||ab|5|entity|C0007447|Cations|chvs|||cations|||0|802|853|860
SE|25462170||ab|5|entity|C0442808|Increasing|ftcn|||increasing|||0|658|896|906
SE|25462170||ab|5|entity|C0031603|inorganic phosphate|inch|||inorganic phosphate|||0|658|907|926
SE|25462170||ab|5|entity|C0005456|Binding Sites|rcpt|||binding site|||0|1000|970|982
SE|25462170||ab|5|entity|C0003075|Anions|elii|||anion|||0|1000|995|1000
SE|25462170||ab|5|entity|C0022023|Ions|elii|||ion|||0|694|1009|1012
SE|25462170||ab|5|entity|C0007961|charge amounts|qnco|||charged|||0|830|1053|1060
SE|25462170||ab|5|entity|C0439799|Channel|spco|||channel|||0|1000|1081|1088
SE|25462170||ab|5|entity|C0012222|Diffusion|npop|||diffusion|||0|1000|1093|1102
SE|25462170||ab|5|entity|C0747726|POLY|cnce|||poly|||0|1000|1138|1142
SE|25462170||ab|5|entity|C0015083|ethylene glycol|hops,orch|||ethylene glycol|||0|1000|1144|1159
SE|25462170||ab|5|entity|C1547020|*Difference|qnco|||different|||0|877|1172|1181
SE|25462170||ab|5|entity|C0598892|Molecular Mass|qnco|||molecular mass|||0|877|1182|1196
SE|25462170||ab|5|entity|C0439799|Channel|spco|||channel|||0|861|1219|1226
SE|25462170||ab|5|entity|C0680251|Exclusion|ftcn|||exclusion|||0|790|1238|1247
SE|25462170||ab|5|entity|C1549649|Limit|idcn|||limit|||0|790|1248|1253


SE|25462171||ti|1|text|21|111|Effect of extracellular polymeric substances on the mechanical properties of Rhodococcus.
SE|25462171||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462171||ti|1|entity|C0521119|Extracellular|celc|||extracellular|||0|828|31|44
SE|25462171||ti|1|entity|C0032521|Polymers|bodm,chvs|||polymeric|||0|828|45|54
SE|25462171||ti|1|entity|C0439861|Substance|sbst|||substances|||0|828|55|65
SE|25462171||ti|1|entity|C0871161|Property|qlco|||properties|||0|827|84|94
SE|25462171||ti|1|entity|C0035496|Rhodococcus|bact|||Rhodococcus|||0|1000|98|109

SE|25462171||ab|1|text|117|241|The mechanical properties of Rhodococcus RC291 were measured using force spectroscopy equipped with a bacterial cell probe.
SE|25462171||ab|1|entity|C0871161|Property|qlco|||properties|||0|827|132|142
SE|25462171||ab|1|entity|C0035496|Rhodococcus|bact|||Rhodococcus|||0|694|146|157
SE|25462171||ab|1|entity|C0441722|Force|phpr|||force|||0|888|184|189
SE|25462171||ab|1|entity|C0037812|Spectrum Analysis|lbpr|||spectroscopy|||0|888|190|202
SE|25462171||ab|1|entity|C0563199|Bacterial cell|bact|||bacterial cell|||0|901|219|233
SE|25462171||ab|1|entity|C0182400|Probes|medd|||probe|||0|901|234|239

SE|25462171||ab|2|text|241|400|Rhodococcal cells in the late growth stage of development were found to have greater adhesion to a silicon oxide surface than those in the early growth stage.
SE|25462171||ab|2|entity|C0007634|Cells|cell|||cells|||0|861|253|258
SE|25462171||ab|2|entity|C0205087|Late|tmco|||late|||0|851|266|270
SE|25462171||ab|2|entity|C0018270|Growth|orgf|||growth|||0|851|271|277
SE|25462171||ab|2|entity|C1306673|Stage|qlco|||stage|||0|851|278|283
SE|25462171||ab|2|entity|C1527148|Development|ftcn|||development|||0|1000|287|298
SE|25462171||ab|2|entity|C0443228|Largest|qnco|||greater|||0|888|318|325
SE|25462171||ab|2|entity|C0001511|Adhesions|acab,dsyn|||adhesion|||0|888|326|334
SE|25462171||ab|2|entity|C0037107|Silicon|bacs,elii|||silicon|||0|851|340|347
SE|25462171||ab|2|entity|C0030015|Oxides|inch|||oxide|||0|851|348|353
SE|25462171||ab|2|entity|C0205148|Surface|spco|||surface|||0|851|354|361
SE|25462171||ab|2|entity|C1279919|Early|tmco|||early|||0|851|380|385
SE|25462171||ab|2|entity|C0018270|Growth|orgf|||growth|||0|851|386|392
SE|25462171||ab|2|entity|C1306673|Stage|qlco|||stage|||0|851|393|398

SE|25462171||ab|3|text|400|556|This is because there are more extracellular polymeric substances (EPS) that contain nonspecific binding sites available on the cells of late growth stage.
SE|25462171||ab|3|entity|C0205172|More|ftcn|||more|||0|815|426|430
SE|25462171||ab|3|entity|C0521119|Extracellular|celc|||extracellular|||0|815|431|444
SE|25462171||ab|3|entity|C0032521|Polymers|bodm,chvs|||polymeric|||0|815|445|454
SE|25462171||ab|3|entity|C0439861|Substance|sbst|||substances|||0|815|455|465
SE|25462171||ab|3|entity|C0750540|NONSPECIFIC|idcn|||nonspecific|||0|901|485|496
SE|25462171||ab|3|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|497|510
SE|25462171||ab|3|entity|C0007634|Cells|cell|||cells|||0|1000|528|533
SE|25462171||ab|3|entity|C0205087|Late|tmco|||late|||0|851|537|541
SE|25462171||ab|3|entity|C0018270|Growth|orgf|||growth|||0|851|542|548
SE|25462171||ab|3|entity|C1306673|Stage|qlco|||stage|||0|851|549|554

SE|25462171||ab|4|text|556|784|It is found that EPS in the late exponential phase are less densely bound but consist of chains able to extend further into their local environment, while the denser EPS at the late stationary phase act more to sheath the cell.
SE|25462171||ab|4|entity|C0521119|Extracellular|celc|||EPS|||0|828|573|576
SE|25462171||ab|4|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|828|573|576
SE|25462171||ab|4|entity|C0439861|Substance|sbst|||EPS|||0|828|573|576
SE|25462171||ab|4|entity|C0205087|Late|tmco|||late|||0|851|584|588
SE|25462171||ab|4|entity|C1552645|exponential|qlco|||exponential|||0|851|589|600
SE|25462171||ab|4|entity|C0205390|Phase|tmco|||phase|||0|851|601|606
SE|25462171||ab|4|entity|C1517331|Further|spco|||further|||0|1000|667|674
SE|25462171||ab|4|entity|C0205276|Local|spco|||local|||0|888|686|691
SE|25462171||ab|4|entity|C0014406|Environment|spco|||environment|||0|888|692|703
SE|25462171||ab|4|entity|C0439794|Dense|qlco|||denser|||0|807|715|721
SE|25462171||ab|4|entity|C0521119|Extracellular|celc|||EPS|||0|807|722|725
SE|25462171||ab|4|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|807|722|725
SE|25462171||ab|4|entity|C0439861|Substance|sbst|||EPS|||0|807|722|725
SE|25462171||ab|4|entity|C0205087|Late|tmco|||late|||0|851|733|737
SE|25462171||ab|4|entity|C0439835|Stationary|qlco|||stationary|||0|851|738|748
SE|25462171||ab|4|entity|C0205390|Phase|tmco|||phase|||0|851|749|754
SE|25462171||ab|4|entity|C0205172|More|ftcn|||more|||0|1000|759|763
SE|25462171||ab|4|entity|C0009653|Condoms, Male|medd|||sheath|||0|1000|767|773
SE|25462171||ab|4|entity|C0007634|Cells|cell|||cell|||0|1000|778|782

SE|25462171||ab|5|text|784|972|Contraction and extension of the EPS could change the density of the binding sites, and therefore affect the magnitude of the adhesion force between the EPS and the silicon oxide surface.
SE|25462171||ab|5|entity|C1140999|Contraction|patf|||Contraction|||0|1000|784|795
SE|25462171||ab|5|entity|C0231448|Extension|ftcn|||extension|||0|1000|800|809
SE|25462171||ab|5|entity|C0521119|Extracellular|celc|||EPS|||0|828|817|820
SE|25462171||ab|5|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|828|817|820
SE|25462171||ab|5|entity|C0439861|Substance|sbst|||EPS|||0|828|817|820
SE|25462171||ab|5|entity|C0178587|density|npop|||density|||0|1000|838|845
SE|25462171||ab|5|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|853|866
SE|25462171||ab|5|entity|C0449286|Degree or extent|qnco|||magnitude|||0|966|893|902
SE|25462171||ab|5|entity|C0001511|Adhesions|acab,dsyn|||adhesion|||0|888|910|918
SE|25462171||ab|5|entity|C0441722|Force|phpr|||force|||0|888|919|924
SE|25462171||ab|5|entity|C0521119|Extracellular|celc|||EPS|||0|828|937|940
SE|25462171||ab|5|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|828|937|940
SE|25462171||ab|5|entity|C0439861|Substance|sbst|||EPS|||0|828|937|940
SE|25462171||ab|5|entity|C0037107|Silicon|bacs,elii|||silicon|||0|851|949|956
SE|25462171||ab|5|entity|C0030015|Oxides|inch|||oxide|||0|851|957|962
SE|25462171||ab|5|entity|C0205148|Surface|spco|||surface|||0|851|963|970
SE|25462171||ab|5|relation|3|3|C1140999|Contraction|patf|patf|||Contraction|||0|1000|784|795|VERB|AFFECTS||827|833|6|1|C0178587|density|npop|npop|||density|||0|1000|838|845

SE|25462171||ab|6|text|972|1235|By treating rhodococcal EPS as a surface-grafted polyelectrolyte layer and using scaling theory, the interaction between EPS and a solid substrate was modelled for the cell approaching the surface which revealed that EPS possess a large capacity to store charge.
SE|25462171||ab|6|entity|C1522326|Treating|qlco|||treating|||0|748|975|983
SE|25462171||ab|6|entity|C0521119|Extracellular|celc|||EPS|||0|748|996|999
SE|25462171||ab|6|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|748|996|999
SE|25462171||ab|6|entity|C0439861|Substance|sbst|||EPS|||0|748|996|999
SE|25462171||ab|6|entity|C0205148|Surface|spco|||surface|||0|583|1005|1012
SE|25462171||ab|6|entity|C0700106|Transplanted|ftcn|||grafted|||0|583|1013|1020
SE|25462171||ab|6|entity|C0237849|Scaling|fndg|||scaling|||0|872|1053|1060
SE|25462171||ab|6|entity|C0871935|Theories|idcn|||theory|||0|872|1061|1067
SE|25462171||ab|6|entity|C0521119|Extracellular|celc|||EPS|||0|828|1093|1096
SE|25462171||ab|6|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|828|1093|1096
SE|25462171||ab|6|entity|C0439861|Substance|sbst|||EPS|||0|828|1093|1096
SE|25462171||ab|6|entity|C0205208|Solid|qlco|||solid|||0|694|1103|1108
SE|25462171||ab|6|entity|C0007634|Cells|cell|||cell|||0|1000|1140|1144
SE|25462171||ab|6|entity|C0205148|Surface|spco|||surface|||0|1000|1161|1168
SE|25462171||ab|6|entity|C0521119|Extracellular|celc|||EPS|||0|828|1189|1192
SE|25462171||ab|6|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|828|1189|1192
SE|25462171||ab|6|entity|C0439861|Substance|sbst|||EPS|||0|828|1189|1192
SE|25462171||ab|6|entity|C0549177|Large|qnco|||large|||0|888|1203|1208
SE|25462171||ab|6|entity|C1516240|Capacity|qnco|||capacity|||0|888|1209|1217

SE|25462171||ab|7|text|1235|1323|Changing the pH of the surrounding medium acts to change the conformation of EPS chains.
SE|25462171||ab|7|entity|C1282914|Surrounding|spco|||surrounding|||0|888|1258|1269
SE|25462171||ab|7|entity|C0439536|Medium|qlco|||medium|||0|888|1270|1276
SE|25462171||ab|7|entity|C0521119|Extracellular|celc|||EPS|||0|828|1312|1315
SE|25462171||ab|7|entity|C0032521|Polymers|bodm,chvs|||EPS|||0|828|1312|1315
SE|25462171||ab|7|entity|C0439861|Substance|sbst|||EPS|||0|828|1312|1315


SE|25462172||ti|1|text|21|178|Very long chain ceramides interfere with C16-ceramide-induced channel formation: A plausible mechanism for regulating the initiation of intrinsic apoptosis.
SE|25462172||ti|1|entity|C0442824|Very|qlco|||Very|||0|775|21|25
SE|25462172||ti|1|entity|C0205166|Long|qlco|||long|||0|775|26|30
SE|25462172||ti|1|entity|C0007745|Ceramides|bacs,lipd|||ceramides|||0|775|37|46
SE|25462172||ti|1|entity|C0386062|N-palmitoylsphingosine|orch|||C16-ceramide|||0|840|62|74
SE|25462172||ti|1|entity|C0205263|Induced|ftcn|||induced|||0|840|75|82
SE|25462172||ti|1|entity|C0439799|Channel|spco|||channel|||0|840|83|90
SE|25462172||ti|1|entity|C1522492|Formation|ftcn|||formation|||0|840|91|100
SE|25462172||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|114|123
SE|25462172||ti|1|entity|C0205102|Intrinsic|spco|||intrinsic|||0|888|157|166
SE|25462172||ti|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|167|176
SE|25462172||ti|1|relation|1|1|C0007745|Ceramides|bacs,lipd|lipd|||ceramides|||0|775|37|46|ADJ|AUGMENTS||75|82|3|3|C0162638|Apoptosis|celf|celf|||apoptosis|||0|888|167|176

SE|25462172||ab|1|text|184|235|Mitochondria mediate both cell survival and death.
SE|25462172||ab|1|entity|C0026237|Mitochondria|celc|||Mitochondria|||0|1000|184|196
SE|25462172||ab|1|entity|C0007620|Cell Survival|celf|||cell survival|||0|1000|210|223
SE|25462172||ab|1|entity|C0011065|Cessation of life|orgf|||death|||0|1000|228|233
SE|25462172||ab|1|relation|1|1|C0026237|Mitochondria|celc|celc|||Mitochondria|||0|1000|184|196|VERB|AFFECTS||197|204|2|1|C0007620|Cell Survival|celf|celf|||cell survival|||0|1000|210|223
SE|25462172||ab|1|relation|1|1|C0026237|Mitochondria|celc|celc|||Mitochondria|||0|1000|184|196|VERB|AFFECTS||197|204|2|1|C0011065|Cessation of life|orgf|orgf|||death|||0|1000|228|233

SE|25462172||ab|2|text|235|394|The intrinsic apoptotic pathway is initiated by the permeabilization of the mitochondrial outer membrane to pro-apoptotic inter-membrane space (IMS) proteins.
SE|25462172||ab|2|entity|C0205102|Intrinsic|spco|||intrinsic|||0|877|239|248
SE|25462172||ab|2|entity|C0162638|Apoptosis|celf|||apoptotic pathway|||0|877|249|266
SE|25462172||ab|2|entity|C0230839|Mitochondrial Membrane, Outer|celc|||mitochondrial outer membrane|||0|1000|311|339
SE|25462172||ab|2|entity|C0205103|Intermediate|spco|||inter|||0|816|357|362
SE|25462172||ab|2|entity|C0596901|Membrane|celc|||membrane|||0|816|363|371
SE|25462172||ab|2|entity|C1565115|Apoptosis Inducing Proteins|aapp,bacs|||pro-apoptotic inter-membrane space (IMS) proteins|||0|816|343|392

SE|25462172||ab|3|text|394|442|Many pathways cause the egress of IMS proteins.
SE|25462172||ab|3|entity|C0205103|Intermediate|spco|||IMS|||0|824|428|431
SE|25462172||ab|3|entity|C0025252|Membrane Proteins|aapp,bacs|||IMS proteins|||0|824|428|440

SE|25462172||ab|4|text|442|545|Of particular interest is the ability of ceramide to self-assemble into dynamic water-filled channels.
SE|25462172||ab|4|entity|C0543488|Interested|menp|||interest|||0|861|456|464
SE|25462172||ab|4|entity|C0085732|Ability|orga|||ability|||0|1000|472|479
SE|25462172||ab|4|entity|C0007745|Ceramides|bacs,lipd|||ceramide|||0|1000|483|491
SE|25462172||ab|4|entity|C0036588|Self|idcn|||self|||0|1000|495|499
SE|25462172||ab|4|entity|C0729333|Dynamic|ftcn|||dynamic|||0|813|514|521
SE|25462172||ab|4|entity|C0599635|water channel|aapp,bacs|||water-filled channels|||0|813|522|543

SE|25462172||ab|5|text|545|651|The formation of ceramide channels is regulated extensively by Bcl-2 family proteins and dihydroceramide.
SE|25462172||ab|5|entity|C1522492|Formation|ftcn|||formation|||0|1000|549|558
SE|25462172||ab|5|entity|C0007745|Ceramides|bacs,lipd|||ceramide|||0|872|562|570
SE|25462172||ab|5|entity|C0439799|Channel|spco|||channels|||0|872|571|579
SE|25462172||ab|5|entity|C0015576|Family|famg|||family|||0|908|614|620
SE|25462172||ab|5|entity|C0597712|BCL-2 Protein|aapp,bacs|||Bcl-2 family proteins|||0|908|608|629
SE|25462172||ab|5|entity|C0668446|dihydroceramide|lipd|||dihydroceramide|||0|1000|634|649
SE|25462172||ab|5|relation|0|0|C0597712|BCL-2 Protein|aapp,gngm,bacs|aapp|||Bcl-2 family proteins|||0|908|608|629|MOD/HEAD|PART_OF||614|629|0|0|C0015576|Family|famg,humn|humn|||family|||0|908|614|620
SE|25462172||ab|5|relation|2|1|C0597712|BCL-2 Protein|aapp,gngm,bacs|aapp|||Bcl-2 family proteins|||0|908|608|629|VERB|INTERACTS_WITH||583|592|2|1|C0007745|Ceramides|bacs,lipd|bacs|||ceramide|||0|872|562|570
SE|25462172||ab|5|relation|2|1|C0668446|dihydroceramide|lipd|lipd|||dihydroceramide|||0|1000|634|649|VERB|INTERACTS_WITH||583|592|2|1|C0007745|Ceramides|bacs,lipd|bacs|||ceramide|||0|872|562|570

SE|25462172||ab|6|text|651|762|Here, we show that the chain length of biologically active ceramides serves as an important regulatory factor.
SE|25462172||ab|6|entity|C1444754|Length|qnco|||length|||0|861|680|686
SE|25462172||ab|6|entity|C0205177|Active|ftcn|||active|||0|790|703|709
SE|25462172||ab|6|entity|C0007745|Ceramides|bacs,lipd|||ceramides|||0|790|710|719
SE|25462172||ab|6|entity|C0220905|regulatory|rnlw|||regulatory|||0|790|743|753
SE|25462172||ab|6|entity|C1521761|Factor|ftcn|||factor|||0|790|754|760

SE|25462172||ab|7|text|762|934|Ceramides are synthesized by a family of six mammalian ceramide synthases (CerS) each of which produces a subset of ceramides that differ in their fatty acyl chain length.
SE|25462172||ab|7|entity|C0007745|Ceramides|bacs,lipd|||Ceramides|||0|1000|762|771
SE|25462172||ab|7|entity|C0015576|Family|famg|||family|||0|1000|793|799
SE|25462172||ab|7|entity|C0205452|Six|qnco|||six|||0|813|803|806
SE|25462172||ab|7|entity|C0665744|dihydroceramide desaturase|aapp,enzy|||ceramide synthases|||0|813|817|835
SE|25462172||ab|7|entity|C0007745|Ceramides|bacs,lipd|||ceramides|||0|1000|878|887
SE|25462172||ab|7|entity|C1444754|Length|qnco|||length|||0|812|926|932
SE|25462172||ab|7|relation|3|1|C0665744|dihydroceramide desaturase|aapp,gngm,enzy|gngm|||ceramide synthases|||0|813|817|835|VERB|PRODUCES||857|865|3|2|C0007745|Ceramides|bacs,lipd|bacs|||ceramides|||0|1000|878|887

SE|25462172||ab|8|text|934|994|Various ceramides permeabilize mitochondria differentially.
SE|25462172||ab|8|entity|C0007745|Ceramides|bacs,lipd|||ceramides|||0|861|942|951
SE|25462172||ab|8|entity|C0026237|Mitochondria|celc|||mitochondria|||0|861|965|977

SE|25462172||ab|9|text|994|1312|Interestingly, the presence of very long chain ceramides reduces the potency of C16-mediated mitochondrial permeabilization indicating that the intercalation of the lipids in the dynamic channel has a destabilizing effect, reminiscent of dihydroceramide inhibition of ceramide channel formation (Stiban et al., 2006).
SE|25462172||ab|9|entity|C0442824|Very|qlco|||very|||0|775|1025|1029
SE|25462172||ab|9|entity|C0205166|Long|qlco|||long|||0|775|1030|1034
SE|25462172||ab|9|entity|C0007745|Ceramides|bacs,lipd|||ceramides|||0|775|1041|1050
SE|25462172||ab|9|entity|C0237399|Potential|qlco|||potency|||0|884|1063|1070
SE|25462172||ab|9|entity|C0086597|Mediating|socb|||mediated|||0|566|1078|1086
SE|25462172||ab|9|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|566|1087|1100
SE|25462172||ab|9|entity|C0023779|Lipids|lipd|||lipids|||0|1000|1159|1165
SE|25462172||ab|9|entity|C0729333|Dynamic|ftcn|||dynamic|||0|888|1173|1180
SE|25462172||ab|9|entity|C0439799|Channel|spco|||channel|||0|888|1181|1188
SE|25462172||ab|9|entity|C1280500|Effect|qlco|||effect|||0|861|1209|1215
SE|25462172||ab|9|entity|C0871247|Reminiscence|menp|||reminiscent|||0|928|1217|1228
SE|25462172||ab|9|entity|C0668446|dihydroceramide|lipd|||dihydroceramide|||0|888|1232|1247
SE|25462172||ab|9|entity|C0007745|Ceramides|bacs,lipd|||ceramide|||0|851|1262|1270
SE|25462172||ab|9|entity|C0439799|Channel|spco|||channel|||0|851|1271|1278
SE|25462172||ab|9|entity|C1522492|Formation|ftcn|||formation|||0|851|1279|1288
SE|25462172||ab|9|relation|9|4|C0023779|Lipids|lipd|lipd|||lipids|||0|1000|1159|1165|NOM|INHIBITS||1248|1258|9|0|C0668446|dihydroceramide|lipd|lipd|||dihydroceramide|||0|888|1232|1247

SE|25462172||ab|10|text|1312|1588|Moreover, mitochondria isolated from cells overexpressing the ceramide synthase responsible for the production of C16-ceramide (CerS5) are permeabilized faster upon the exogenous addition of C16-ceramide whereas they are resistant to permeabilization with added C24-ceramide.
SE|25462172||ab|10|entity|C0026237|Mitochondria|celc|||mitochondria|||0|1000|1322|1334
SE|25462172||ab|10|entity|C0007634|Cells|cell|||cells|||0|1000|1349|1354
SE|25462172||ab|10|entity|C0665744|dihydroceramide desaturase|aapp,enzy|||ceramide synthase|||0|1000|1374|1391
SE|25462172||ab|10|entity|C0033268|production|ocac|||production|||0|1000|1412|1422
SE|25462172||ab|10|entity|C0386062|N-palmitoylsphingosine|orch|||C16-ceramide|||0|1000|1426|1438
SE|25462172||ab|10|entity|C0456962|Fast|qlco|||faster|||0|966|1465|1471
SE|25462172||ab|10|entity|C0205228|Exogenous|ftcn|||exogenous|||0|853|1481|1490
SE|25462172||ab|10|entity|C0442796|Additive|qlco|||addition|||0|853|1491|1499
SE|25462172||ab|10|entity|C0386062|N-palmitoylsphingosine|orch|||C16-ceramide|||0|1000|1503|1515
SE|25462172||ab|10|entity|C0332325|Resistant|ftcn|||resistant|||0|1000|1533|1542
SE|25462172||ab|10|entity|C1524062|Additional|ftcn|||added|||0|785|1568|1573
SE|25462172||ab|10|entity|C0007745|Ceramides|bacs,lipd|||ceramide|||0|785|1578|1586
SE|25462172||ab|10|relation|2|1|C0007634|Cells|cell|cell|||cells|||0|1000|1349|1354|VERB|PRODUCES||1355|1369|10|1|C0665744|dihydroceramide desaturase|aapp,gngm,enzy|aapp|||ceramide synthase|||0|1000|1374|1391
SE|25462172||ab|10|relation|4|4|C0026237|Mitochondria|celc|celc|||mitochondria|||0|1000|1322|1334|NOM|PRODUCES||1412|1422|7|1|C0386062|N-palmitoylsphingosine|orch|orch|||C16-ceramide|||0|1000|1426|1438

SE|25462172||ab|11|text|1588|1779|On the other hand mitochondria isolated from CerS2-overexpressing cells show the opposite pattern, indicating that the product of CerS2 inhibits C16-channel formation ex vivo and vice versa.
SE|25462172||ab|11|entity|C0026237|Mitochondria|celc|||mitochondria|||0|888|1606|1618
SE|25462172||ab|11|entity|C1514559|Protein Overexpression|genf|||overexpressing|||0|773|1639|1653
SE|25462172||ab|11|entity|C0007634|Cells|cell|||cells|||0|773|1654|1659
SE|25462172||ab|11|entity|C1521805|Opposite|spco|||opposite|||0|888|1669|1677
SE|25462172||ab|11|entity|C0449774|Patterns|spco|||pattern|||0|888|1678|1685
SE|25462172||ab|11|entity|C1514468|product|qnco|||product|||0|1000|1707|1714
SE|25462172||ab|11|entity|C0439799|Channel|spco|||channel|||0|790|1737|1744
SE|25462172||ab|11|entity|C1522492|Formation|ftcn|||formation|||0|790|1745|1754
SE|25462172||ab|11|entity|C0814670|vice|idcn|||vice|||0|861|1767|1771

SE|25462172||ab|12|text|1779|2019|This interplay between different ceramide metabolic enzymes and their products adds a new dimension to the complexity of mitochondrial-mediated apoptosis, and emphasizes its role as a key regulatory step that commits cells to life or death.
SE|25462172||ab|12|entity|C1547020|*Difference|qnco|||different|||0|815|1802|1811
SE|25462172||ab|12|entity|C0007745|Ceramides|bacs,lipd|||ceramide|||0|815|1812|1820
SE|25462172||ab|12|entity|C0311400|Metabolic|ftcn|||metabolic|||0|815|1821|1830
SE|25462172||ab|12|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|815|1831|1838
SE|25462172||ab|12|entity|C1514468|product|qnco|||products|||0|966|1849|1857
SE|25462172||ab|12|entity|C0205314|New|tmco|||new|||0|888|1865|1868
SE|25462172||ab|12|entity|C0439534|Dimensions|qnco|||dimension|||0|888|1869|1878
SE|25462172||ab|12|entity|C0439855|Complex|qlco|||complexity|||0|928|1886|1896
SE|25462172||ab|12|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|840|1900|1913
SE|25462172||ab|12|entity|C0086597|Mediating|socb|||mediated|||0|840|1914|1922
SE|25462172||ab|12|entity|C0162638|Apoptosis|celf|||apoptosis|||0|840|1923|1932
SE|25462172||ab|12|entity|C0035820|Role|socb|||role|||0|1000|1953|1957
SE|25462172||ab|12|entity|C1554080|Key|idcn|||key|||0|1000|1963|1966
SE|25462172||ab|12|entity|C0220905|regulatory|rnlw|||regulatory|||0|1000|1967|1977
SE|25462172||ab|12|entity|C0007634|Cells|cell|||cells|||0|1000|1996|2001
SE|25462172||ab|12|entity|C0376558|Life|idcn|||life|||0|840|2005|2009
SE|25462172||ab|12|entity|C0011065|Cessation of life|orgf|||death|||0|840|2013|2018


SE|25462174||ti|1|text|21|150|Neutral diiron(III) complexes with Fe2(MU-E)2 (E = O, S, Se) core structures: reactivity of an iron(I) dimer towards chalcogens.
SE|25462174||ti|1|entity|C0439070|III|inpr|||III|||0|1000|36|39
SE|25462174||ti|1|entity|C0439855|Complex|qlco|||complexes|||0|1000|41|50
SE|25462174||ti|1|entity|C0444669|Core|spco|||core|||0|872|82|86
SE|25462174||ti|1|entity|C0678594|Structure|spco|||structures|||0|872|87|97
SE|25462174||ti|1|entity|C0205332|Reactive|qlco|||reactivity|||0|928|99|109
SE|25462174||ti|1|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|116|120
SE|25462174||ti|1|entity|C0596448|dimer|chvs|||dimer|||0|1000|124|129
SE|25462174||ti|1|entity|C0206763|Chalcogens|elii|||chalcogens|||0|1000|138|148

SE|25462174||ab|1|text|156|429|Three neutral bis(MU-chalcogenido)diiron(III) complexes, [{(N,N'-Pipiso)Fe(MU-E)}2] (Pipiso(-) = [(DipN)2C(cis-2,6-Me2NC5H8)](-), (Dip = C6H3Pr(I)2-2,6; E = O, S or Se) have been prepared by reactions of the iron(I) dimer [{(MU-N,N'-Pipiso)Fe}2] with O2, S8 or Seinfinity.
SE|25462174||ab|1|entity|C0205449|Three|qnco|||Three|||0|660|156|161
SE|25462174||ab|1|entity|||gngm|9531|BAG3|bis|||0|660|170|173
SE|25462174||ab|1|entity|C0439070|III|inpr|||III|||0|1000|197|200
SE|25462174||ab|1|entity|C0439855|Complex|qlco|||complexes|||0|1000|202|211
SE|25462174||ab|1|entity|C0302583|Iron|bacs,elii,phsu|||Fe|||0|812|228|230
SE|25462174||ab|1|entity|C0067503|N-(3-N-(benzyloxycarbonyl)amino-1-carboxypropyl)leucyl-O-methyltyrosine N-methylamide|aapp,phsu|1154|CISH|cis-2|||0|983|263|268
SE|25462174||ab|1|entity|C0378785|3,5-diisopropylsalicylic acid|orch|||Dip|||0|966|287|290
SE|25462174||ab|1|entity|C0443286|Reaction|ftcn|||reactions|||0|966|347|356
SE|25462174||ab|1|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|1000|364|368
SE|25462174||ab|1|entity|C0596448|dimer|chvs|||dimer|||0|1000|372|377
SE|25462174||ab|1|entity|C0302583|Iron|bacs,elii,phsu|||Fe|||0|861|396|398

SE|25462174||ab|2|text|429|569|Treating the MU-selenido compound [{(N,N'-Pipiso)Fe(MU-Se)}2] with O2 cleanly generated its MU-oxo counterpart, [{(N,N'-Pipiso)Fe(MU-O)}2].
SE|25462174||ab|2|entity|C0205198|Compound|qlco|||compound|||0|827|454|462
SE|25462174||ab|2|entity|C0302583|Iron|bacs,elii,phsu|||Fe|||0|824|478|480
SE|25462174||ab|2|entity|C0309531|MU-SE|orch,phsu,vita|||MU-Se|||0|824|481|486
SE|25462174||ab|2|entity|C0302583|Iron|bacs,elii,phsu|||Fe|||0|824|556|558
SE|25462174||ab|2|entity|C0030054|Oxygen|elii,phsu|||O)}2|||0|824|562|566

SE|25462174||ab|3|text|569|764|X-ray crystallographic analyses of the compounds showed them to possess Fe2(MU-E)2 core structures with distorted square planar (E = O) or tetrahedral (E = S or Se) iron coordination geometries.
SE|25462174||ab|3|entity|C0206755|Crystallography, X-Ray|lbpr|||X-ray crystallographic|||0|866|569|591
SE|25462174||ab|3|entity|C0936012|Analysis|resa|||analyses|||0|866|592|600
SE|25462174||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|608|617
SE|25462174||ab|3|entity|C0444669|Core|spco|||core|||0|861|652|656
SE|25462174||ab|3|entity|C0700135|Distorted|ftcn|||distorted|||0|660|673|682
SE|25462174||ab|3|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|785|734|738
SE|25462174||ab|3|entity|C0449829|Geometry|spco|||geometries|||0|785|752|762

SE|25462174||ab|4|text|764|946|Magnetic, (57)Fe Mossbauer spectroscopic and computational studies indicate medium to strong antiferromagnetic coupling between the two high-spin Fe(III) ions in all three compounds.
SE|25462174||ab|4|entity|C0024488|Study of magnetics|ocdi|||Magnetic|||0|1000|764|772
SE|25462174||ab|4|entity|C0037812|Spectrum Analysis|lbpr|||spectroscopic|||0|928|791|804
SE|25462174||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|827|823|830
SE|25462174||ab|4|entity|C0439536|Medium|qlco|||medium|||0|1000|840|846
SE|25462174||ab|4|entity|C0442821|Strong|qlco|||strong|||0|660|850|856
SE|25462174||ab|4|entity|C0205448|Two|qnco|||two|||0|757|896|899
SE|25462174||ab|4|entity|C0205250|High|qlco|||high|||0|757|900|904
SE|25462174||ab|4|entity|C0302583|Iron|bacs,elii,phsu|||Fe|||0|757|910|912
SE|25462174||ab|4|entity|C0439070|III|inpr|||III|||0|757|913|916
SE|25462174||ab|4|entity|C0022023|Ions|elii|||ions|||0|1000|918|922
SE|25462174||ab|4|entity|C0205449|Three|qnco|||three|||0|872|930|935
SE|25462174||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|872|936|945


SE|25462173||ti|1|text|21|103|Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
SE|25462173||ti|1|entity|C0205191|chronic|tmco|||Chronic|||0|623|21|28
SE|25462173||ti|1|entity|C0018787|Heart|bpoc|||heart|||0|623|29|34
SE|25462173||ti|1|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|888|52|63
SE|25462173||ti|1|entity|C0024027|Lovastatin|orch,phsu|||lovastatin|||0|1000|91|101

SE|25462173||ab|1|text|109|263|The anticancer efficacy of anthracyclines is limited by cumulative dose-dependent early and delayed cardiotoxicity resulting in congestive heart failure.
SE|25462173||ab|1|entity|C0003234|Anthracycline Antibiotics|antb,orch|||anthracyclines|||0|1000|136|150
SE|25462173||ab|1|entity|C1511559|Cumulative|qlco|||cumulative|||0|861|165|175
SE|25462173||ab|1|entity|C1512045|Dose-dependent|qnco|||dose-dependent|||0|861|176|190
SE|25462173||ab|1|entity|C1279919|Early|tmco|||early|||0|861|191|196
SE|25462173||ab|1|entity|C0205421|Deferred|tmco|||delayed|||0|888|201|208
SE|25462173||ab|1|entity|C0876994|Cardiotoxicity|inpo|||cardiotoxicity|||0|888|209|223
SE|25462173||ab|1|entity|C0018802|Congestive heart failure|dsyn|||congestive heart failure|||0|1000|237|261
SE|25462173||ab|1|relation|4|1|C0876994|Cardiotoxicity|inpo|inpo|||cardiotoxicity|||0|888|209|223|VERB|CAUSES||224|233|1|1|C0018802|Congestive heart failure|dsyn|dsyn|||congestive heart failure|||0|1000|237|261

SE|25462173||ab|2|text|263|405|Mechanisms responsible for anthracycline-induced heart damage are controversially discussed and effective preventive measures are preferable.
SE|25462173||ab|2|entity|C0441712|Mechanisms|ftcn|||Mechanisms|||0|1000|263|273
SE|25462173||ab|2|entity|C0205263|Induced|ftcn|||induced|||0|583|304|311
SE|25462173||ab|2|entity|C0018787|Heart|bpoc|||heart|||0|583|312|317
SE|25462173||ab|2|entity|C0033107|prevention & control|inpr|||preventive measures|||0|901|369|388

SE|25462173||ab|3|text|405|620|Here, we analyzed the influence of the lipid lowering drug lovastatin on anthracycline-induced late cardiotoxicity three month after treatment of C57BL/6 mice with five low doses of doxorubicin (5*3mg/kg BW; i.p.).
SE|25462173||ab|3|entity|C0003367|Antilipemic Agents|phsu|||lipid lowering drug|||0|916|444|463
SE|25462173||ab|3|entity|C0024027|Lovastatin|orch,phsu|||lovastatin|||0|916|464|474
SE|25462173||ab|3|entity|C0205263|Induced|ftcn|||induced|||0|769|492|499
SE|25462173||ab|3|entity|C0205087|Late|tmco|||late|||0|769|500|504
SE|25462173||ab|3|entity|C0876994|Cardiotoxicity|inpo|||cardiotoxicity|||0|769|505|519
SE|25462173||ab|3|entity|C0205449|Three|qnco|||three|||0|769|520|525
SE|25462173||ab|3|entity|C0439231|month|tmco|||month|||0|769|526|531
SE|25462173||ab|3|entity|C0025921|Mice, Inbred C57BL|mamm|||C57BL/6 mice|||0|913|551|563
SE|25462173||ab|3|entity|C0205451|Five|qnco|||five|||0|890|569|573
SE|25462173||ab|3|entity|C0445550|Low dose|qnco|||low doses|||0|890|574|583
SE|25462173||ab|3|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|1000|587|598
SE|25462173||ab|3|relation|0|0|C0024027|Lovastatin|orch,phsu|orch|||lovastatin|||0|916|464|474|MOD/HEAD|ISA||444|474|0|0|C0003367|Antilipemic Agents|phsu|phsu|||lipid lowering drug|||0|916|444|463
SE|25462173||ab|3|relation|3|2|C0024027|Lovastatin|orch,phsu|phsu|||lovastatin|||0|916|464|474|NOM|TREATS||538|547|5|1|C0025921|Mice, Inbred C57BL|mamm|mamm|||C57BL/6 mice|||0|913|551|563

SE|25462173||ab|4|text|620|737|Doxorubicin increased the cardiac mRNA levels of BNP, IL-6 and CTGF, while the expression of ANP remained unchanged.
SE|25462173||ab|4|entity|C0013089|Doxorubicin|antb,orch|||Doxorubicin|||0|1000|620|631
SE|25462173||ab|4|entity|C0018787|Heart|bpoc|||cardiac|||0|851|646|653
SE|25462173||ab|4|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA|||0|851|654|658
SE|25462173||ab|4|entity|C0441889|Levels|inpr|||levels|||0|851|659|665
SE|25462173||ab|4|entity|||gngm|4879|NPPB|BNP|||0|1000|669|672
SE|25462173||ab|4|entity|C0021760|Interleukin-6|aapp,imft|||IL-6|||0|1000|674|678
SE|25462173||ab|4|entity|C0110610|connective tissue growth factor|aapp,bacs|1490|CTGF|CTGF|||0|1000|683|687
SE|25462173||ab|4|entity|C0027481|Atrial Natriuretic Factor|aapp,bacs|4878|NPPA|ANP|||0|1000|713|716
SE|25462173||ab|4|relation|1|1|C0013089|Doxorubicin|antb,orch|antb|||Doxorubicin|||0|1000|620|631|VERB|STIMULATES||632|641|7|2|||gngm,aapp|gngm|4879|NPPB|BNP|||0|1000|669|672
SE|25462173||ab|4|relation|1|1|C0013089|Doxorubicin|antb,orch|antb|||Doxorubicin|||0|1000|620|631|VERB|STIMULATES||632|641|7|2|C0021760|Interleukin-6|aapp,gngm,imft|gngm|||IL-6|||0|1000|674|678
SE|25462173||ab|4|relation|1|1|C0013089|Doxorubicin|antb,orch|antb|||Doxorubicin|||0|1000|620|631|VERB|STIMULATES||632|641|7|2|C0110610|connective tissue growth factor|aapp,gngm,bacs|gngm|1490|CTGF|CTGF|||0|1000|683|687

SE|25462173||ab|5|text|737|832|Lovastatin counteracted these persisting cardiac stress responses evoked by the anthracycline.
SE|25462173||ab|5|entity|C0024027|Lovastatin|orch,phsu|||Lovastatin|||0|1000|737|747
SE|25462173||ab|5|entity|C0018787|Heart|bpoc|||cardiac|||0|813|778|785
SE|25462173||ab|5|entity|C0149784|biological adaptation to stress|phsf|||stress responses|||0|813|786|802
SE|25462173||ab|5|relation|0|0|C0149784|biological adaptation to stress|phsf|phsf|||stress responses|||0|813|786|802|MOD/HEAD|PROCESS_OF||778|802|0|0|C0018787|Heart|bpoc|bpoc|||cardiac|||0|813|778|785
SE|25462173||ab|5|relation|1|1|C0024027|Lovastatin|orch,phsu|orch|||Lovastatin|||0|1000|737|747|VERB|DISRUPTS||748|760|2|1|C0149784|biological adaptation to stress|phsf|phsf|||stress responses|||0|813|786|802

SE|25462173||ab|6|text|832|1001|Doxorubicin-induced fibrotic alterations were neither detected by histochemical collagen staining of heart sections nor by analysis of the mRNA expression of collagens.
SE|25462173||ab|6|entity|C0013089|Doxorubicin|antb,orch|||Doxorubicin|||0|825|832|843
SE|25462173||ab|6|entity|C0205263|Induced|ftcn|||induced|||0|825|844|851
SE|25462173||ab|6|entity|C0334129|Fibrotic|ftcn|||fibrotic|||0|825|852|860
SE|25462173||ab|6|entity|C1515926|Alteration|idcn|||alterations|||0|825|861|872
SE|25462173||ab|6|entity|C0019635|Histocytochemistry|lbpr|||histochemical|||0|587|898|911
SE|25462173||ab|6|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|587|912|920
SE|25462173||ab|6|entity|C0018787|Heart|bpoc|||heart|||0|872|933|938
SE|25462173||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|1000|955|963
SE|25462173||ab|6|entity|C1515670|mRNA Expression|genf|||mRNA expression|||0|1000|971|986
SE|25462173||ab|6|entity|C0009325|Collagen|aapp,bacs,bodm|||collagens|||0|1000|990|999
SE|25462173||ab|6|relation|1|1|C0009325|Collagen|aapp,gngm,bacs,bodm|gngm|||collagens|||0|1000|990|999|PREP|LOCATION_OF||987|989|5|1|C1515670|mRNA Expression|genf|genf|||mRNA expression|||0|1000|971|986

SE|25462173||ab|7|text|1001|1190|Extensive qRT-PCR-array based analyses revealed a large increase in the mRNA level of heat shock protein Hspa1b in doxorubicin-treated mice, which was mitigated by lovastatin co-treatment.
SE|25462173||ab|7|entity|C0205231|Extensive|qlco|||Extensive|||0|768|1001|1010
SE|25462173||ab|7|entity|C1510941|Array|spco|||array|||0|768|1019|1024
SE|25462173||ab|7|entity|C0200931|Polymerase chain reaction analysis|lbpr|||PCR-array based analyses|||0|768|1015|1039
SE|25462173||ab|7|entity|C0549177|Large|qnco|||large|||0|888|1051|1056
SE|25462173||ab|7|entity|C0442805|Increase|ftcn|||increase|||0|888|1057|1065
SE|25462173||ab|7|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA|||0|694|1073|1077
SE|25462173||ab|7|entity|C0018850|Heat shock proteins|aapp,bacs|||heat shock protein|||0|756|1087|1105
SE|25462173||ab|7|entity|||gngm|3304|HSPA1B|Hspa1b|||0|756|1106|1112
SE|25462173||ab|7|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|840|1116|1127
SE|25462173||ab|7|entity|C1292734|Treats|clas|||treated|||0|840|1128|1135
SE|25462173||ab|7|entity|C0026809|Mus|mamm|||mice|||0|840|1136|1140
SE|25462173||ab|7|entity|C0024027|Lovastatin|orch,phsu|||lovastatin|||0|901|1165|1175
SE|25462173||ab|7|entity|C0814472|co-treatment|hlca|||co-treatment|||0|901|1176|1188
SE|25462173||ab|7|relation|0|0|C0814472|co-treatment|hlca|hlca|||co-treatment|||0|901|1176|1188|MOD/HEAD|USES||1165|1188|0|0|C0024027|Lovastatin|orch,phsu|phsu|||lovastatin|||0|901|1165|1175
SE|25462173||ab|7|relation|2|1|C0026809|Mus|mamm|mamm|||mice|||0|840|1136|1140|PREP|LOCATION_OF||1113|1115|4|1|||gngm,aapp|aapp|3304|HSPA1B|Hspa1b|||0|756|1106|1112

SE|25462173||ab|8|text|1190|1368|Electron microscopy together with qPCR-based analysis of mitochondrial DNA content indicate that lovastatin attenuates doxorubicin-stimulated hyperproliferation of mitochondria.
SE|25462173||ab|8|entity|C0026019|Electron Microscopy|lbpr|||Electron microscopy|||0|1000|1190|1209
SE|25462173||ab|8|entity|C0936012|Analysis|resa|||analysis|||0|773|1235|1243
SE|25462173||ab|8|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|901|1247|1260
SE|25462173||ab|8|entity|C0032246|Ploidies|qnco|||DNA content|||0|901|1261|1272
SE|25462173||ab|8|entity|C0024027|Lovastatin|orch,phsu|||lovastatin|||0|1000|1287|1297
SE|25462173||ab|8|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|660|1309|1320
SE|25462173||ab|8|entity|C0026237|Mitochondria|celc|||mitochondria|||0|1000|1354|1366

SE|25462173||ab|9|text|1368|1488|This was not paralleled by increased expression of oxidative stress responsive genes or senescence-associated proteins.
SE|25462173||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1377|1380
SE|25462173||ab|9|entity|C0205217|Increased|qnco|||increased|||0|888|1395|1404
SE|25462173||ab|9|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|861|1419|1435
SE|25462173||ab|9|entity|C0205342|Responsive|ftcn|||responsive|||0|861|1436|1446
SE|25462173||ab|9|entity|C0017337|Genes|gngm|||genes|||0|861|1447|1452
SE|25462173||ab|9|entity|C0001792|Elderly|aggp|||senescence|||0|802|1456|1466
SE|25462173||ab|9|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|802|1478|1486

SE|25462173||ab|10|text|1488|1776|Echocardiographic analyses disclosed that lovastatin protects from the doxorubicin-induced decrease in the left ventricular posterior wall diameter (LVPWD), while constrictions in fractional shortening (FS) and ejection fraction (EF) evoked by doxorubicin were not amended by the statin.
SE|25462173||ab|10|entity|C0013516|Echocardiography|diap|||Echocardiographic|||0|836|1488|1505
SE|25462173||ab|10|entity|C0936012|Analysis|resa|||analyses|||0|836|1506|1514
SE|25462173||ab|10|entity|C0024027|Lovastatin|orch,phsu|||lovastatin|||0|1000|1530|1540
SE|25462173||ab|10|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|851|1559|1570
SE|25462173||ab|10|entity|C0205263|Induced|ftcn|||induced|||0|851|1571|1578
SE|25462173||ab|10|entity|C0547047|Decrease|qnco|||decrease|||0|851|1579|1587
SE|25462173||ab|10|entity|C0205091|Left|spco|||left|||0|840|1595|1599
SE|25462173||ab|10|entity|C0205095|Dorsal|spco|||posterior|||0|840|1612|1621
SE|25462173||ab|10|entity|C0507618|Wall of ventricle|bpoc|||ventricular posterior wall|||0|840|1600|1626
SE|25462173||ab|10|entity|C1301886|Caliber|qnco|||diameter|||0|840|1627|1635
SE|25462173||ab|10|entity|C0009813|Constriction procedure|topp|||constrictions|||0|1000|1651|1664
SE|25462173||ab|10|entity|C1264633|Fraction of|qnco|||fractional|||0|623|1668|1678
SE|25462173||ab|10|entity|C0489482|Ejection fraction|fndg|||ejection fraction|||0|1000|1699|1716
SE|25462173||ab|10|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|1000|1732|1743
SE|25462173||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1749|1752
SE|25462173||ab|10|entity|C1420485|STN gene|gngm|1917|EEF1A2|statin|||0|1000|1768|1774
SE|25462173||ab|10|relation|2|1|C0013089|Doxorubicin|antb,orch|antb|||doxorubicin|||0|1000|1732|1743|VERB|CAUSES||1722|1728|7|1|C0489482|Ejection fraction|fndg|fndg|||ejection fraction|||0|1000|1699|1716

SE|25462173||ab|11|text|1776|1894|Taken together, the data suggest beneficial effects of lovastatin against doxorubicin-induced delayed cardiotoxicity.
SE|25462173||ab|11|entity|C1511726|Data|idcn|||data|||0|1000|1796|1800
SE|25462173||ab|11|entity|C1280500|Effect|qlco|||effects|||0|827|1820|1827
SE|25462173||ab|11|entity|C0024027|Lovastatin|orch,phsu|||lovastatin|||0|1000|1831|1841
SE|25462173||ab|11|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|1000|1850|1861
SE|25462173||ab|11|entity|C0205421|Deferred|tmco|||delayed|||0|888|1870|1877
SE|25462173||ab|11|entity|C0876994|Cardiotoxicity|inpo|||cardiotoxicity|||0|888|1878|1892
SE|25462173||ab|11|relation|4|1|C0013089|Doxorubicin|antb,orch|antb|||doxorubicin|||0|1000|1850|1861|VERB|CAUSES||1862|1869|1|1|C0876994|Cardiotoxicity|inpo|inpo|||cardiotoxicity|||0|888|1878|1892

SE|25462173||ab|12|text|1894|2030|Clinical studies are preferable to scrutinize the usefulness of statins for the prevention of anthracycline-induced late cardiotoxicity.
SE|25462173||ab|12|entity|C0008972|Clinical Research|resa|||Clinical studies|||0|1000|1894|1910
SE|25462173||ab|12|entity|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|||statins|||0|1000|1958|1965
SE|25462173||ab|12|entity|C0199176|Prophylactic treatment|topp|||prevention|||0|1000|1974|1984
SE|25462173||ab|12|entity|C0205263|Induced|ftcn|||induced|||0|775|2002|2009
SE|25462173||ab|12|entity|C0205087|Late|tmco|||late|||0|775|2010|2014
SE|25462173||ab|12|entity|C0876994|Cardiotoxicity|inpo|||cardiotoxicity|||0|775|2015|2029
SE|25462173||ab|12|relation|4|1|C0360714|Hydroxymethylglutaryl-CoA Reductase Inhibitors|orch,phsu|orch|||statins|||0|1000|1958|1965|NOM|PREVENTS||1974|1984|1|1|C0876994|Cardiotoxicity|inpo|inpo|||cardiotoxicity|||0|775|2015|2029


SE|25462175||ti|1|text|21|155|Interferon gamma is involved in apoptosis of trophoblast cells at the maternal-fetal interface following Toxoplasma gondii infection.
SE|25462175||ti|1|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|Interferon gamma|||0|1000|21|37
SE|25462175||ti|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|53|62
SE|25462175||ti|1|entity|C1519658|Trophoblastic Cell|cell|||trophoblast cells|||0|947|66|83
SE|25462175||ti|1|entity|C0026591|Mothers|famg|||maternal|||0|623|91|99
SE|25462175||ti|1|entity|C0521457|Foeto-|ftcn|||fetal|||0|623|100|105
SE|25462175||ti|1|entity|C0040558|Toxoplasmosis|dsyn|||Toxoplasma gondii infection|||0|1000|126|153
SE|25462175||ti|1|relation|1|1|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|aapp|3458|IFNG|Interferon gamma|||0|1000|21|37|VERB|AFFECTS||41|49|4|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|1000|53|62
SE|25462175||ti|1|relation|3|1|C1519658|Trophoblastic Cell|cell|cell|||trophoblast cells|||0|947|66|83|PREP|LOCATION_OF||63|65|2|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|1000|53|62

SE|25462175|OBJECTIVE|ab|1|text|161|403|OBJECTIVE: To assess whether interferon gamma (IFN-gamma) secreted by decidual natural killer (dNK) cells at the maternal-fetal interface is involved in the apoptosis of trophoblast cells (trophoblasts) following Toxoplasma gondii infection.
SE|25462175|OBJECTIVE|ab|1|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|interferon gamma|||0|1000|190|206
SE|25462175|OBJECTIVE|ab|1|entity|C0521453|Decidual|blor|||decidual|||0|916|231|239
SE|25462175|OBJECTIVE|ab|1|entity|C0022688|Natural Killer Cells|cell|||natural killer (dNK) cells|||0|916|240|266
SE|25462175|OBJECTIVE|ab|1|entity|C0026591|Mothers|famg|||maternal|||0|623|274|282
SE|25462175|OBJECTIVE|ab|1|entity|C0521457|Foeto-|ftcn|||fetal|||0|623|283|288
SE|25462175|OBJECTIVE|ab|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|318|327
SE|25462175|OBJECTIVE|ab|1|entity|C1519658|Trophoblastic Cell|cell|||trophoblast cells|||0|947|331|348
SE|25462175|OBJECTIVE|ab|1|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|350|362
SE|25462175|OBJECTIVE|ab|1|entity|C0040558|Toxoplasmosis|dsyn|||Toxoplasma gondii infection|||0|1000|374|401
SE|25462175|OBJECTIVE|ab|1|relation|3|1|C1519658|Trophoblastic Cell|cell|cell|||trophoblast cells|||0|947|331|348|PREP|LOCATION_OF||328|330|5|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|1000|318|327
SE|25462175|OBJECTIVE|ab|1|relation|6|1|C0022688|Natural Killer Cells|cell|cell|||natural killer (dNK) cells|||0|916|240|266|VERB|PRODUCES||219|227|2|1|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|aapp|3458|IFNG|interferon gamma|||0|1000|190|206

SE|25462175|METHODS|ab|2|text|403|497|METHODS: Human dNK cells were infected with T. gondii and then co-cultured with trophoblasts.
SE|25462175|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|403|410
SE|25462175|METHODS|ab|2|entity|C0020114|Human|humn|||Human|||0|875|412|417
SE|25462175|METHODS|ab|2|entity|C0521453|Decidual|blor|||dNK|||0|875|418|421
SE|25462175|METHODS|ab|2|entity|C0022688|Natural Killer Cells|cell|||dNK cells|||0|875|418|427
SE|25462175|METHODS|ab|2|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|483|495

SE|25462175|METHODS|ab|3|text|497|592|The infected co-cultured cells were treated with or without IFN-gamma neutralizing antibodies.
SE|25462175|METHODS|ab|3|entity|C0439663|Infected|ftcn|||infected|||0|1000|501|509
SE|25462175|METHODS|ab|3|entity|C0007634|Cells|cell|||cells|||0|1000|522|527
SE|25462175|METHODS|ab|3|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|888|557|566
SE|25462175|METHODS|ab|3|entity|C1142254|Neutralising antibodies|diap|||neutralizing antibodies|||0|888|567|590
SE|25462175|METHODS|ab|3|relation|0|0|C1142254|Neutralising antibodies|diap|diap|||neutralizing antibodies|||0|888|567|590|MOD/HEAD|USES||557|590|0|0|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|phsu|3458|IFNG|IFN-gamma|||0|888|557|566

SE|25462175|METHODS|ab|4|text|592|644|Uninfected co-cultured cells were used as controls.
SE|25462175|METHODS|ab|4|entity|C0007634|Cells|cell|||cells|||0|1000|615|620
SE|25462175|METHODS|ab|4|entity|C0243148|control|ftcn|||controls|||0|966|634|642

SE|25462175|METHODS|ab|5|text|644|788|The level of IFN-gamma in the supernatant of co-culture was measured by ELISA and the apoptosis of trophoblasts was analyzed by flow cytometry.
SE|25462175|METHODS|ab|5|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|1000|657|666
SE|25462175|METHODS|ab|5|entity|C1550101|Supernatant|bdsu|||supernatant|||0|1000|674|685
SE|25462175|METHODS|ab|5|entity|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|||ELISA|||0|1000|716|721
SE|25462175|METHODS|ab|5|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|730|739
SE|25462175|METHODS|ab|5|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|743|755
SE|25462175|METHODS|ab|5|entity|C0016263|Flow Cytometry|lbpr|||flow cytometry|||0|1000|772|786
SE|25462175|METHODS|ab|5|relation|4|1|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|lbpr|||ELISA|||0|1000|716|721|VERB|MEASURES||704|712|3|2|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|aapp|3458|IFNG|IFN-gamma|||0|1000|657|666
SE|25462175|METHODS|ab|5|relation|5|1|C1550101|Supernatant|bdsu|bdsu|||supernatant|||0|1000|674|685|PREP|LOCATION_OF||667|669|2|1|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|aapp|3458|IFNG|IFN-gamma|||0|1000|657|666

SE|25462175|METHODS|ab|6|text|788|909|The expression of caspase 3 and caspase 8 of trophoblasts cells was determined by Western blotting and real-time RT-PCR.
SE|25462175|METHODS|ab|6|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|caspase 3|||0|1000|806|815
SE|25462175|METHODS|ab|6|entity|C0667830|caspase-8|aapp,enzy|841|CASP8|caspase 8|||0|1000|820|829
SE|25462175|METHODS|ab|6|entity|C1519658|Trophoblastic Cell|cell|||trophoblasts cells|||0|941|833|851
SE|25462175|METHODS|ab|6|entity|C0005863|Blotting, Western|lbpr,mbrt|||Western blotting|||0|1000|870|886
SE|25462175|METHODS|ab|6|entity|C1550177|Real Time|idcn|||real-time|||0|901|891|900
SE|25462175|METHODS|ab|6|entity|C0599161|Reverse Transcriptase Polymerase Chain Reaction|mbrt|||RT-PCR|||0|901|901|907
SE|25462175|METHODS|ab|6|relation|1|0|C0291573|caspase-3|aapp,gngm,enzy|aapp|836|CASP3|caspase 3|||0|1000|806|815|PREP|PART_OF||830|832|3|1|C1519658|Trophoblastic Cell|cell|cell|||trophoblasts cells|||0|941|833|851
SE|25462175|METHODS|ab|6|relation|1|0|C0667830|caspase-8|aapp,gngm,enzy|aapp|841|CASP8|caspase 8|||0|1000|820|829|PREP|PART_OF||830|832|3|1|C1519658|Trophoblastic Cell|cell|cell|||trophoblasts cells|||0|941|833|851
SE|25462175|METHODS|ab|6|relation|2|1|C0005863|Blotting, Western|lbpr,mbrt|lbpr|||Western blotting|||0|1000|870|886|VERB|MEASURES||856|866|2|1|C0291573|caspase-3|aapp,gngm,enzy|aapp|836|CASP3|caspase 3|||0|1000|806|815
SE|25462175|METHODS|ab|6|relation|2|1|C0005863|Blotting, Western|lbpr,mbrt|lbpr|||Western blotting|||0|1000|870|886|VERB|MEASURES||856|866|2|1|C0667830|caspase-8|aapp,gngm,enzy|aapp|841|CASP8|caspase 8|||0|1000|820|829
SE|25462175|METHODS|ab|6|relation|2|1|C0599161|Reverse Transcriptase Polymerase Chain Reaction|mbrt|mbrt|||RT-PCR|||0|901|901|907|VERB|MEASURES||856|866|2|1|C0667830|caspase-8|aapp,gngm,enzy|aapp|841|CASP8|caspase 8|||0|1000|820|829
SE|25462175|METHODS|ab|6|relation|2|2|C0599161|Reverse Transcriptase Polymerase Chain Reaction|mbrt|mbrt|||RT-PCR|||0|901|901|907|VERB|MEASURES||856|866|2|1|C0291573|caspase-3|aapp,gngm,enzy|aapp|836|CASP3|caspase 3|||0|1000|806|815

SE|25462175|RESULTS|ab|7|text|909|1027|RESULTS: The levels of IFN-gamma were increased at <24h following T. gondii infection and were maintained thereafter.
SE|25462175|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|909|916
SE|25462175|RESULTS|ab|7|entity|C0441889|Levels|inpr|||levels|||0|1000|922|928
SE|25462175|RESULTS|ab|7|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|1000|932|941
SE|25462175|RESULTS|ab|7|entity|C0456696|/24h|tmco|||24h|||0|1000|961|964

SE|25462175|RESULTS|ab|8|text|1027|1152|Caspase 3, caspase 8, and the apoptosis of trophoblasts co-cultured with dNK cells were increased compared with the control.
SE|25462175|RESULTS|ab|8|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|Caspase 3|||0|1000|1027|1036
SE|25462175|RESULTS|ab|8|entity|C0667830|caspase-8|aapp,enzy|841|CASP8|caspase 8|||0|1000|1038|1047
SE|25462175|RESULTS|ab|8|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1057|1066
SE|25462175|RESULTS|ab|8|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|1070|1082
SE|25462175|RESULTS|ab|8|entity|C0521453|Decidual|blor|||dNK|||0|916|1100|1103
SE|25462175|RESULTS|ab|8|entity|C0022688|Natural Killer Cells|cell|||dNK cells|||0|916|1100|1109
SE|25462175|RESULTS|ab|8|entity|C0243148|control|ftcn|||control|||0|1000|1143|1150

SE|25462175|RESULTS|ab|9|text|1152|1292|Meanwhile, IFN-gamma, caspase 3, caspase 8, and trophoblast apoptosis were up-regulated upon increased ratios of dNK cells to trophoblasts.
SE|25462175|RESULTS|ab|9|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|1000|1163|1172
SE|25462175|RESULTS|ab|9|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|caspase 3|||0|1000|1174|1183
SE|25462175|RESULTS|ab|9|entity|C0667830|caspase-8|aapp,enzy|841|CASP8|caspase 8|||0|1000|1185|1194
SE|25462175|RESULTS|ab|9|entity|C0041178|trophoblast|emst|||trophoblast|||0|888|1200|1211
SE|25462175|RESULTS|ab|9|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|1212|1221
SE|25462175|RESULTS|ab|9|entity|C0205217|Increased|qnco|||increased|||0|888|1245|1254
SE|25462175|RESULTS|ab|9|entity|C0456603|Ratio|inpr|||ratios|||0|888|1255|1261
SE|25462175|RESULTS|ab|9|entity|C0521453|Decidual|blor|||dNK|||0|916|1265|1268
SE|25462175|RESULTS|ab|9|entity|C0022688|Natural Killer Cells|cell|||dNK cells|||0|916|1265|1274
SE|25462175|RESULTS|ab|9|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|1278|1290

SE|25462175|RESULTS|ab|10|text|1292|1483|Compared to the infected group, the levels of IFN-gamma, caspase 3, caspase 8, and trophoblast apoptosis were significantly decreased upon treatment with the IFN-gamma neutralizing antibody.
SE|25462175|RESULTS|ab|10|entity|C0439663|Infected|ftcn|||infected|||0|888|1308|1316
SE|25462175|RESULTS|ab|10|entity|C0441833|Groups|inpr|||group|||0|888|1317|1322
SE|25462175|RESULTS|ab|10|entity|C0441889|Levels|inpr|||levels|||0|1000|1328|1334
SE|25462175|RESULTS|ab|10|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|1000|1338|1347
SE|25462175|RESULTS|ab|10|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|caspase 3|||0|1000|1349|1358
SE|25462175|RESULTS|ab|10|entity|C0667830|caspase-8|aapp,enzy|841|CASP8|caspase 8|||0|1000|1360|1369
SE|25462175|RESULTS|ab|10|entity|C0041178|trophoblast|emst|||trophoblast|||0|888|1375|1386
SE|25462175|RESULTS|ab|10|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|1387|1396
SE|25462175|RESULTS|ab|10|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|888|1450|1459
SE|25462175|RESULTS|ab|10|entity|C0475463|Neutralizing antibody|aapp,imft|||neutralizing antibody|||0|888|1460|1481
SE|25462175|RESULTS|ab|10|relation|6|3|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|aapp|3458|IFNG|IFN-gamma|||0|1000|1338|1347|VERB|compared_with||1292|1300|6|6|C0475463|Neutralizing antibody|aapp,gngm,imft|aapp|||neutralizing antibody|||0|888|1460|1481

SE|25462175|RESULTS|ab|11|text|1483|1584|IFN-gamma levels were correlated positively with the apoptosis of trophoblasts (r=0.7163, p < 0.01).
SE|25462175|RESULTS|ab|11|entity|C1168022|Interferon gamma level|lbpr|||IFN-gamma levels|||0|983|1483|1499
SE|25462175|RESULTS|ab|11|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1536|1545
SE|25462175|RESULTS|ab|11|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|1549|1561

SE|25462175|CONCLUSIONS|ab|12|text|1584|1760|CONCLUSIONS: The levels of IFN-gamma secreted by dNK cells at the maternal-fetal interface were closely correlated with the apoptosis of trophoblasts upon T. gondii infection.
SE|25462175|CONCLUSIONS|ab|12|entity|C0441889|Levels|inpr|||levels|||0|1000|1601|1607
SE|25462175|CONCLUSIONS|ab|12|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|1000|1611|1620
SE|25462175|CONCLUSIONS|ab|12|entity|C0521453|Decidual|blor|||dNK|||0|916|1633|1636
SE|25462175|CONCLUSIONS|ab|12|entity|C0022688|Natural Killer Cells|cell|||dNK cells|||0|916|1633|1642
SE|25462175|CONCLUSIONS|ab|12|entity|C0026591|Mothers|famg|||maternal|||0|623|1650|1658
SE|25462175|CONCLUSIONS|ab|12|entity|C0521457|Foeto-|ftcn|||fetal|||0|623|1659|1664
SE|25462175|CONCLUSIONS|ab|12|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1708|1717
SE|25462175|CONCLUSIONS|ab|12|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|1721|1733
SE|25462175|CONCLUSIONS|ab|12|relation|5|1|C0022688|Natural Killer Cells|cell|cell|||dNK cells|||0|916|1633|1642|VERB|PRODUCES||1621|1629|3|1|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|aapp|3458|IFNG|IFN-gamma|||0|1000|1611|1620

SE|25462175|CONCLUSIONS|ab|13|text|1760|1952|The apoptosis of trophoblasts induced by the increase in IFN-gamma depended on the caspase pathway, which may contribute to the abnormal pregnancy outcomes that occur with T. gondii infection.
SE|25462175|CONCLUSIONS|ab|13|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1764|1773
SE|25462175|CONCLUSIONS|ab|13|entity|C0041178|trophoblast|emst|||trophoblasts|||0|1000|1777|1789
SE|25462175|CONCLUSIONS|ab|13|entity|C0442805|Increase|ftcn|||increase|||0|1000|1805|1813
SE|25462175|CONCLUSIONS|ab|13|entity|C0021740|Recombinant Interferon-gamma|aapp,imft,phsu|3458|IFNG|IFN-gamma|||0|1000|1817|1826
SE|25462175|CONCLUSIONS|ab|13|entity|C0010656|caspase|aapp,enzy|||caspase|||0|888|1843|1850
SE|25462175|CONCLUSIONS|ab|13|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|1851|1858
SE|25462175|CONCLUSIONS|ab|13|entity|C0205161|Abnormal|ftcn|||abnormal|||0|901|1888|1896
SE|25462175|CONCLUSIONS|ab|13|entity|C0032972|Pregnancy Outcome|qlco|||pregnancy outcomes|||0|901|1897|1915
SE|25462175|CONCLUSIONS|ab|13|relation|3|1|C0010656|caspase|aapp,gngm,enzy|aapp|||caspase|||0|888|1843|1850|VERB|STIMULATES||1827|1835|4|1|C0021740|Recombinant Interferon-gamma|aapp,gngm,imft,phsu|gngm|3458|IFNG|IFN-gamma|||0|1000|1817|1826


SE|25462176||ti|1|text|21|125|First case of osteomyelitis due to Erysipelothrix rhusiopathiae: pubic osteomyelitis in a gored farmer.
SE|25462176||ti|1|entity|C1279901|Firstly|qlco|||First|||0|694|21|26
SE|25462176||ti|1|entity|C0029443|Osteomyelitis|dsyn|||osteomyelitis|||0|1000|35|48
SE|25462176||ti|1|entity|C0014738|Erysipelothrix rhusiopathiae|bact|||Erysipelothrix rhusiopathiae|||0|1000|56|84
SE|25462176||ti|1|entity|C0034014|Bone structure of pubis|bpoc|||pubic|||0|888|86|91
SE|25462176||ti|1|entity|C0029443|Osteomyelitis|dsyn|||osteomyelitis|||0|888|92|105
SE|25462176||ti|1|entity|C0221460|Farmer, unspecified|prog|||farmer|||0|861|117|123
SE|25462176||ti|1|relation|0|0|C0034014|Bone structure of pubis|bpoc|bpoc|||pubic|||0|888|86|91|MOD/HEAD|LOCATION_OF||86|105|0|0|C0029443|Osteomyelitis|dsyn|dsyn|||osteomyelitis|||0|888|92|105
SE|25462176||ti|1|relation|3|1|C0014738|Erysipelothrix rhusiopathiae|bact|bact|||Erysipelothrix rhusiopathiae|||0|1000|56|84|PREP|CAUSES||49|55|2|1|C0029443|Osteomyelitis|dsyn|dsyn|||osteomyelitis|||0|1000|35|48
SE|25462176||ti|1|relation|4|1|C0029443|Osteomyelitis|dsyn|dsyn|||osteomyelitis|||0|888|92|105|PREP|PROCESS_OF||106|108|1|1|C0221460|Farmer, unspecified|prog,humn|humn|||farmer|||0|861|117|123

SE|25462176||ab|1|text|131|217|We report the first proven case of osteomyelitis due to Erysipelothrix rhusiopathiae.
SE|25462176||ab|1|entity|C1279901|Firstly|qlco|||first|||0|660|145|150
SE|25462176||ab|1|entity|C0029443|Osteomyelitis|dsyn|||osteomyelitis|||0|1000|166|179
SE|25462176||ab|1|entity|C0014738|Erysipelothrix rhusiopathiae|bact|||Erysipelothrix rhusiopathiae|||0|1000|187|215
SE|25462176||ab|1|relation|1|1|C0014738|Erysipelothrix rhusiopathiae|bact|bact|||Erysipelothrix rhusiopathiae|||0|1000|187|215|PREP|CAUSES||180|186|2|1|C0029443|Osteomyelitis|dsyn|dsyn|||osteomyelitis|||0|1000|166|179

SE|25462176||ab|2|text|217|350|This infection occurred almost 20 years after traumatic inoculation of the bacterium, when the patient was gored by one of his cows.
SE|25462176||ab|2|entity|C0439234|year|tmco|||years|||0|827|251|256
SE|25462176||ab|2|entity|C0332663|Traumatic|ftcn|||traumatic|||0|888|263|272
SE|25462176||ab|2|entity|C0042196|Vaccination|topp|||inoculation|||0|888|273|284
SE|25462176||ab|2|entity|C0004611|Bacteria|bact|||bacterium|||0|1000|292|301
SE|25462176||ab|2|entity|C0030705|Patients|podg|||patient|||0|1000|312|319
SE|25462176||ab|2|entity|C0205447|One|qnco|||one|||0|1000|333|336
SE|25462176||ab|2|entity|C0007452|Cattle|mamm|||cows|||0|1000|344|348

SE|25462176||ab|3|text|350|451|Diagnosis was made by bone biopsies, and treatment included rifampicin and levofloxacin for 3 months.
SE|25462176||ab|3|entity|C0011900|Diagnosis|hlca|||Diagnosis|||0|1000|350|359
SE|25462176||ab|3|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|888|372|376
SE|25462176||ab|3|entity|C0005558|Biopsy|diap|||biopsies|||0|888|377|385
SE|25462176||ab|3|entity|C0035608|Rifampin|antb,orch|||rifampicin|||0|1000|410|420
SE|25462176||ab|3|entity|C0282386|Levofloxacin|orch,phsu|||levofloxacin|||0|1000|425|437
SE|25462176||ab|3|entity|C1442461|3 Months|tmco|||3 months|||0|1000|442|450


SE|25462177||ti|1|text|21|185|Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.
SE|25462177||ti|1|entity|C0032529|Polymorphism, Genetic|genf|||Polymorphism|||0|1000|21|33
SE|25462177||ti|1|entity|C1425475|IL28B gene|gngm|282617|IFNL3|IL28B gene|||0|1000|41|51
SE|25462177||ti|1|entity|C0205466|virologic|ftcn|||virological|||0|888|80|91
SE|25462177||ti|1|entity|C0871261|response|clna|||response|||0|888|92|100
SE|25462177||ti|1|entity|C1148363|Hepatitis C virus genotype|fndg|||hepatitis C virus genotype|||0|840|114|140
SE|25462177||ti|1|entity|C0030705|Patients|podg|||patients|||0|840|143|151
SE|25462177||ti|1|entity|C0279030|interferon therapy|topp|||interferon therapy|||0|901|165|183
SE|25462177||ti|1|relation|6|1|C1425475|IL28B gene|gngm,aapp|gngm|282617|IFNL3|IL28B gene|||0|1000|41|51|PREP|LOCATION_OF||34|36|1|1|C0032529|Polymorphism, Genetic|genf|genf|||Polymorphism|||0|1000|21|33

SE|25462177|BACKGROUND|ab|1|text|191|342|BACKGROUND: The gold standard treatment for chronic hepatitis C virus (HCV) infection is pegylated interferon (PEG-IFN) in combination with ribavirin.
SE|25462177|BACKGROUND|ab|1|entity|C0150110|GOLD STANDARD|qlco|||gold standard|||0|901|207|220
SE|25462177|BACKGROUND|ab|1|entity|C0220847|Hepatitis C virus|virs|||hepatitis C virus|||0|893|243|260
SE|25462177|BACKGROUND|ab|1|entity|C0151317|Chronic infectious disease|dsyn|||chronic hepatitis C virus (HCV) infection|||0|893|235|276
SE|25462177|BACKGROUND|ab|1|entity|C0021747|Interferons|aapp,imft,phsu|||interferon|||0|861|290|300
SE|25462177|BACKGROUND|ab|1|entity|C0205195|Combined|qlco|||combination|||0|1000|314|325
SE|25462177|BACKGROUND|ab|1|entity|C0035525|Ribavirin|nnon,phsu|||ribavirin|||0|1000|331|340
SE|25462177|BACKGROUND|ab|1|relation|4|2|C0021747|Interferons|aapp,gngm,imft,phsu|phsu|||interferon|||0|861|290|300|NOM|TREATS||221|230|4|1|C0151317|Chronic infectious disease|dsyn|dsyn|||chronic hepatitis C virus (HCV) infection|||0|893|235|276
SE|25462177|BACKGROUND|ab|1|relation|4|2|C0035525|Ribavirin|nnon,phsu|phsu|||ribavirin|||0|1000|331|340|NOM|TREATS||221|230|4|1|C0151317|Chronic infectious disease|dsyn|dsyn|||chronic hepatitis C virus (HCV) infection|||0|893|235|276

SE|25462177|BACKGROUND|ab|2|text|342|425|Most patients treated with PEG-IFN achieve a sustained virological response (SVR).
SE|25462177|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|347|355
SE|25462177|BACKGROUND|ab|2|entity|C0021747|Interferons|aapp,imft,phsu|||PEG-IFN|||0|861|369|376
SE|25462177|BACKGROUND|ab|2|entity|C0443318|Sustained|ftcn|||sustained|||0|851|387|396
SE|25462177|BACKGROUND|ab|2|entity|C0205466|virologic|ftcn|||virological|||0|851|397|408
SE|25462177|BACKGROUND|ab|2|entity|C0871261|response|clna|||response|||0|851|409|417
SE|25462177|BACKGROUND|ab|2|relation|2|1|C0021747|Interferons|aapp,gngm,imft,phsu|phsu|||PEG-IFN|||0|861|369|376|VERB|TREATS||356|363|1|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|347|355

SE|25462177|BACKGROUND|ab|3|text|425|570|However host genetic factors play a vital role in the spontaneous and treatment-induced clearance of HCV infection from these infected patients.
SE|25462177|BACKGROUND|ab|3|entity|C0314603|Genetic|ftcn|||genetic|||0|872|438|445
SE|25462177|BACKGROUND|ab|3|entity|C1521761|Factor|ftcn|||factors|||0|872|446|453
SE|25462177|BACKGROUND|ab|3|entity|C0442732|Vital|qlco|||vital|||0|888|461|466
SE|25462177|BACKGROUND|ab|3|entity|C0035820|Role|socb|||role|||0|888|467|471
SE|25462177|BACKGROUND|ab|3|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|1000|479|490
SE|25462177|BACKGROUND|ab|3|entity|C0205263|Induced|ftcn|||induced|||0|851|505|512
SE|25462177|BACKGROUND|ab|3|entity|C0449297|Clearance|qlco|||clearance|||0|851|513|522
SE|25462177|BACKGROUND|ab|3|entity|C0220847|Hepatitis C virus|virs|||HCV|||0|916|526|529
SE|25462177|BACKGROUND|ab|3|entity|C0439663|Infected|ftcn|||infected|||0|888|551|559
SE|25462177|BACKGROUND|ab|3|entity|C0030705|Patients|podg|||patients|||0|888|560|568

SE|25462177|BACKGROUND|ab|4|text|570|751|In the current study, polymorphisms of IL28B (rs8099917 and rs12979860) were analyzed and their association with the virological response to PEG-IFN alpha treatment was determined.
SE|25462177|BACKGROUND|ab|4|entity|C0521116|Current|tmco|||current|||0|888|577|584
SE|25462177|BACKGROUND|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|888|585|590
SE|25462177|BACKGROUND|ab|4|entity|C0032529|Polymorphism, Genetic|genf|||polymorphisms|||0|966|592|605
SE|25462177|BACKGROUND|ab|4|entity|||gngm|282617|IFNL3|IL28B|||0|1000|609|614
SE|25462177|BACKGROUND|ab|4|entity|C0205466|virologic|ftcn|||virological|||0|888|687|698
SE|25462177|BACKGROUND|ab|4|entity|C0871261|response|clna|||response|||0|888|699|707
SE|25462177|BACKGROUND|ab|4|entity|C0907160|pegylated interferon alfa|imft,orch,phsu|||PEG-IFN alpha|||0|916|711|724
SE|25462177|BACKGROUND|ab|4|relation|6|1|||gngm,aapp|gngm|282617|IFNL3|IL28B|||0|1000|609|614|PREP|LOCATION_OF||606|608|2|1|C0032529|Polymorphism, Genetic|genf|genf|||polymorphisms|||0|966|592|605

SE|25462177|METHODS|ab|5|text|751|914|METHODS: One hundred and fifty HCV genotype 3 patients were assessed to study the correlation of IL28B with a therapeutic regimen of PEG-IFN alpha plus ribavirin.
SE|25462177|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|751|758
SE|25462177|METHODS|ab|5|entity|C0205447|One|qnco|||One|||0|1000|760|763
SE|25462177|METHODS|ab|5|entity|C1148363|Hepatitis C virus genotype|fndg|||HCV genotype|||0|840|782|794
SE|25462177|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|840|797|805
SE|25462177|METHODS|ab|5|entity|||gngm|282617|IFNL3|IL28B|||0|1000|848|853
SE|25462177|METHODS|ab|5|entity|C1276413|Therapeutic regimen|topp|||therapeutic regimen|||0|1000|861|880
SE|25462177|METHODS|ab|5|entity|C0907160|pegylated interferon alfa|imft,orch,phsu|||PEG-IFN alpha|||0|875|884|897
SE|25462177|METHODS|ab|5|entity|C0332287|In addition to|ftcn|||plus|||0|875|898|902
SE|25462177|METHODS|ab|5|entity|C0035525|Ribavirin|nnon,phsu|||ribavirin|||0|875|903|912

SE|25462177|METHODS|ab|6|text|914|1044|Twenty patients were excluded due to a refusal to participate in the study and 25 patients failed to meet the inclusion criteria.
SE|25462177|METHODS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|921|929
SE|25462177|METHODS|ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|983|988
SE|25462177|METHODS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|996|1004
SE|25462177|METHODS|ab|6|entity|C1516637|Clinical Trial Eligibility Criteria|qlco|||inclusion criteria|||0|1000|1024|1042

SE|25462177|METHODS|ab|7|text|1044|1124|Of the 105 patients recruited, 49 (46.7%) were male and 56 (53.3%) were female.
SE|25462177|METHODS|ab|7|entity|C0030705|Patients|podg|||patients|||0|861|1055|1063
SE|25462177|METHODS|ab|7|entity|C0015780|Female|orga|||female|||0|1000|1116|1122

SE|25462177|METHODS|ab|8|text|1124|1361|In order to determine single nucleotide polymorphisms of rs8099917 and rs12979860, the sample was amplified by PCR and then IL28B typing was carried out by restriction fragment length polymorphism (RFLP) followed by standard sequencing.
SE|25462177|METHODS|ab|8|entity|C0752046|Single Nucleotide Polymorphism|nusq|||single nucleotide polymorphisms|||0|1000|1146|1177
SE|25462177|METHODS|ab|8|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|1000|1235|1238
SE|25462177|METHODS|ab|8|entity|||gngm|282617|IFNL3|IL28B|||0|1000|1248|1253
SE|25462177|METHODS|ab|8|entity|C0439787|Out|spco|||out|||0|1000|1273|1276
SE|25462177|METHODS|ab|8|entity|C0035268|Restriction fragment length polymorphism|clna|||restriction fragment length polymorphism|||0|1000|1280|1320
SE|25462177|METHODS|ab|8|entity|C1442989|STANDARD|ftcn|||standard|||0|888|1340|1348
SE|25462177|METHODS|ab|8|entity|C1561491|Sequencing|ftcn|||sequencing|||0|888|1349|1359

SE|25462177|RESULTS|ab|9|text|1361|1518|RESULTS: We found three types of genotype in rs8099917 of IL28B: wild-type TT in 60.0% of patients, heterozygous GT minor genotype in 36.2%, and GG in 3.8%.
SE|25462177|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1361|1368
SE|25462177|RESULTS|ab|9|entity|C0205449|Three|qnco|||three|||0|888|1379|1384
SE|25462177|RESULTS|ab|9|entity|C0332307|Type - attribute|qlco|||types|||0|888|1385|1390
SE|25462177|RESULTS|ab|9|entity|C0017431|Genotype|orga|||genotype|||0|1000|1394|1402
SE|25462177|RESULTS|ab|9|entity|||gngm|282617|IFNL3|IL28B|||0|1000|1419|1424
SE|25462177|RESULTS|ab|9|entity|C0445392|Wild|inpr|||wild|||0|623|1426|1430
SE|25462177|RESULTS|ab|9|entity|C1547052|*Type|qnco|||type|||0|623|1431|1435
SE|25462177|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1451|1459
SE|25462177|RESULTS|ab|9|entity|C0017431|Genotype|orga|||genotype|||0|750|1483|1491
SE|25462177|RESULTS|ab|9|entity|C0439086|<3|qnco|||3|||0|861|1512|1513

SE|25462177|RESULTS|ab|10|text|1518|1607|The frequency of the CC genotype of rs12979860 was 54.3%, CT was 37.1%, and TT was 8.6%.
SE|25462177|RESULTS|ab|10|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|1522|1531
SE|25462177|RESULTS|ab|10|entity|C0017431|Genotype|orga|||genotype|||0|888|1542|1550

SE|25462177|RESULTS|ab|11|text|1607|1655|Overall, SVR was achieved in 68.6% of patients.
SE|25462177|RESULTS|ab|11|entity|C1561607|Overall|qlco|||Overall|||0|1000|1607|1614
SE|25462177|RESULTS|ab|11|entity|C0205466|virologic|ftcn|||SVR|||0|851|1616|1619
SE|25462177|RESULTS|ab|11|entity|C0871261|response|clna|||SVR|||0|851|1616|1619
SE|25462177|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1645|1653

SE|25462177|RESULTS|ab|12|text|1655|1837|A higher SVR was achieved for patients with the favorable genotype CC of rs12979860, with 84.2% as compared to 56.4% and 22.2% for minor genotype CT and TT, respectively (p=0.0001).
SE|25462177|RESULTS|ab|12|entity|C0205250|High|qlco|||higher|||0|825|1657|1663
SE|25462177|RESULTS|ab|12|entity|C0443318|Sustained|ftcn|||SVR|||0|825|1664|1667
SE|25462177|RESULTS|ab|12|entity|C0205466|virologic|ftcn|||SVR|||0|825|1664|1667
SE|25462177|RESULTS|ab|12|entity|C0871261|response|clna|||SVR|||0|825|1664|1667
SE|25462177|RESULTS|ab|12|entity|C0030705|Patients|podg|||patients|||0|1000|1685|1693
SE|25462177|RESULTS|ab|12|entity|C0017431|Genotype|orga|||genotype|||0|828|1713|1721
SE|25462177|RESULTS|ab|12|entity|C0017431|Genotype|orga|||genotype|||0|623|1792|1800

SE|25462177|RESULTS|ab|13|text|1837|1968|We did not find a significant association for SVR to antiviral treatment in patients with genotype TT (rs8099917) (71.9%, p=0.36).
SE|25462177|RESULTS|ab|13|entity|C1518422|Not|ftcn|||not|||0|1000|1844|1847
SE|25462177|RESULTS|ab|13|entity|C0750502|Significant|idcn|||significant|||0|694|1855|1866
SE|25462177|RESULTS|ab|13|entity|C0443318|Sustained|ftcn|||SVR|||0|851|1883|1886
SE|25462177|RESULTS|ab|13|entity|C0205466|virologic|ftcn|||SVR|||0|851|1883|1886
SE|25462177|RESULTS|ab|13|entity|C0871261|response|clna|||SVR|||0|851|1883|1886
SE|25462177|RESULTS|ab|13|entity|C0030705|Patients|podg|||patients|||0|1000|1913|1921
SE|25462177|RESULTS|ab|13|entity|C0017431|Genotype|orga|||genotype|||0|694|1927|1935

SE|25462177|RESULTS|ab|14|text|1968|2087|The rapid virological response (RVR) rate was significantly higher in patients with major genotype TT (88.9%, p=0.04).
SE|25462177|RESULTS|ab|14|entity|C0439831|Rapid|qlco|||rapid|||0|851|1972|1977
SE|25462177|RESULTS|ab|14|entity|C0205466|virologic|ftcn|||virological|||0|851|1978|1989
SE|25462177|RESULTS|ab|14|entity|C0871261|response|clna|||response|||0|851|1990|1998
SE|25462177|RESULTS|ab|14|entity|||gngm|9975|NR1D2|RVR|||0|1000|2000|2003
SE|25462177|RESULTS|ab|14|entity|C1521828|Rate|qnco|||rate|||0|1000|2005|2009
SE|25462177|RESULTS|ab|14|entity|C0205250|High|qlco|||higher|||0|827|2028|2034
SE|25462177|RESULTS|ab|14|entity|C0030705|Patients|podg|||patients|||0|1000|2038|2046
SE|25462177|RESULTS|ab|14|entity|C0205164|Major|qlco|||major|||0|623|2052|2057
SE|25462177|RESULTS|ab|14|entity|C0017431|Genotype|orga|||genotype|||0|623|2058|2066

SE|25462177|RESULTS|ab|15|text|2087|2229|These results show that IL28B polymorphism is highly associated with SVR to therapy in the Pakistani population infected with HCV genotype 3.
SE|25462177|RESULTS|ab|15|entity|C1274040|result|ftcn|||results|||0|966|2093|2100
SE|25462177|RESULTS|ab|15|entity|||gngm|282617|IFNL3|IL28B|||0|861|2111|2116
SE|25462177|RESULTS|ab|15|entity|C0032529|Polymorphism, Genetic|genf|||polymorphism|||0|861|2117|2129
SE|25462177|RESULTS|ab|15|entity|C0443318|Sustained|ftcn|||SVR|||0|851|2156|2159
SE|25462177|RESULTS|ab|15|entity|C0205466|virologic|ftcn|||SVR|||0|851|2156|2159
SE|25462177|RESULTS|ab|15|entity|C0871261|response|clna|||SVR|||0|851|2156|2159
SE|25462177|RESULTS|ab|15|entity|C1257890|Population Group|popg|||population|||0|861|2188|2198
SE|25462177|RESULTS|ab|15|entity|C1148363|Hepatitis C virus genotype|fndg|||HCV genotype|||0|937|2213|2225
SE|25462177|RESULTS|ab|15|relation|1|1|C1257890|Population Group|popg,humn|humn|||population|||0|861|2188|2198|PREP|LOCATION_OF||2171|2173|4|3|||gngm,aapp|aapp|282617|IFNL3|IL28B|||0|861|2111|2116

SE|25462177|CONCLUSIONS|ab|16|text|2229|2317|CONCLUSIONS: HCV-infected patients carrying homozygous C/C have a higher chance of SVR.
SE|25462177|CONCLUSIONS|ab|16|entity|C0220847|Hepatitis C virus|virs|||HCV|||0|875|2242|2245
SE|25462177|CONCLUSIONS|ab|16|entity|C0439663|Infected|ftcn|||infected|||0|875|2246|2254
SE|25462177|CONCLUSIONS|ab|16|entity|C0030705|Patients|podg|||patients|||0|875|2255|2263
SE|25462177|CONCLUSIONS|ab|16|entity|C0205250|High|qlco|||higher|||0|872|2295|2301
SE|25462177|CONCLUSIONS|ab|16|entity|C0237506|Chance|qlco|||chance|||0|872|2302|2308
SE|25462177|CONCLUSIONS|ab|16|entity|C0443318|Sustained|ftcn|||SVR|||0|851|2312|2315
SE|25462177|CONCLUSIONS|ab|16|entity|C0205466|virologic|ftcn|||SVR|||0|851|2312|2315
SE|25462177|CONCLUSIONS|ab|16|entity|C0871261|response|clna|||SVR|||0|851|2312|2315

SE|25462177|CONCLUSIONS|ab|17|text|2317|2393|In addition, patients who carry T/T (rs8099917) have a higher chance of RVR.
SE|25462177|CONCLUSIONS|ab|17|entity|C0030705|Patients|podg|||patients|||0|1000|2330|2338
SE|25462177|CONCLUSIONS|ab|17|entity|C0205250|High|qlco|||higher|||0|872|2372|2378
SE|25462177|CONCLUSIONS|ab|17|entity|C0237506|Chance|qlco|||chance|||0|872|2379|2385
SE|25462177|CONCLUSIONS|ab|17|entity|||gngm|9975|NR1D2|RVR|||0|1000|2389|2392


SE|25462178||ti|1|text|21|176|An albumin, collagen IV, and longitudinal diameter of spleen scoring system superior to APRI for assessing liver fibrosis in chronic hepatitis B patients.
SE|25462178||ti|1|entity|C0001924|Albumins|aapp,bacs|||albumin|||0|1000|24|31
SE|25462178||ti|1|entity|C0009333|Collagen Type IV|aapp,bacs|||collagen IV|||0|1000|33|44
SE|25462178||ti|1|entity|C0205127|Longitudinal|spco|||longitudinal|||0|888|50|62
SE|25462178||ti|1|entity|C1301886|Caliber|qnco|||diameter|||0|888|63|71
SE|25462178||ti|1|entity|C0037993|Spleen|bpoc|||spleen|||0|851|75|81
SE|25462178||ti|1|entity|C1552081|scoring|idcn|||scoring|||0|851|82|89
SE|25462178||ti|1|entity|C0449913|System|ftcn|||system|||0|851|90|96
SE|25462178||ti|1|entity|C1282910|Upper|spco|||superior|||0|1000|97|105
SE|25462178||ti|1|entity|C0004002|Aspartate Transaminase|aapp,enzy|||APRI|||0|742|109|113
SE|25462178||ti|1|entity|C0005821|Blood Platelets|cell|||APRI|||0|742|109|113
SE|25462178||ti|1|entity|C0456603|Ratio|inpr|||APRI|||0|742|109|113
SE|25462178||ti|1|entity|C0918012|Index|inpr|||APRI|||0|742|109|113
SE|25462178||ti|1|entity|C0220825|Evaluation|ftcn|||assessing|||0|890|118|127
SE|25462178||ti|1|entity|C0239946|Fibrosis, Liver|dsyn|||liver fibrosis|||0|890|128|142
SE|25462178||ti|1|entity|C0524909|Hepatitis B, Chronic|dsyn|||chronic hepatitis B|||0|916|146|165
SE|25462178||ti|1|entity|C0030705|Patients|podg|||patients|||0|916|166|174
SE|25462178||ti|1|relation|0|0|C0524909|Hepatitis B, Chronic|dsyn|dsyn|||chronic hepatitis B|||0|916|146|165|MOD/HEAD|PROCESS_OF||146|174|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|916|166|174
SE|25462178||ti|1|relation|6|1|C0239946|Fibrosis, Liver|dsyn|dsyn|||liver fibrosis|||0|890|128|142|PREP|PROCESS_OF||143|145|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|916|166|174

SE|25462178|OBJECTIVES|ab|1|text|182|378|OBJECTIVES: The aim of this study was to screen the non-invasive indexes correlated with liver fibrosis and establish a scoring system for the diagnosis of liver fibrosis in hepatitis B patients.
SE|25462178|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|182|192
SE|25462178|OBJECTIVES|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|210|215
SE|25462178|OBJECTIVES|ab|1|entity|C0205303|Non-invasive|ftcn|||non-invasive|||0|901|234|246
SE|25462178|OBJECTIVES|ab|1|entity|C0918012|Index|inpr|||indexes|||0|901|247|254
SE|25462178|OBJECTIVES|ab|1|entity|C0239946|Fibrosis, Liver|dsyn|||liver fibrosis|||0|1000|271|285
SE|25462178|OBJECTIVES|ab|1|entity|C1552081|scoring|idcn|||scoring|||0|888|302|309
SE|25462178|OBJECTIVES|ab|1|entity|C0449913|System|ftcn|||system|||0|888|310|316
SE|25462178|OBJECTIVES|ab|1|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|325|334
SE|25462178|OBJECTIVES|ab|1|entity|C0239946|Fibrosis, Liver|dsyn|||liver fibrosis|||0|1000|338|352
SE|25462178|OBJECTIVES|ab|1|entity|C0019163|Hepatitis B|dsyn|||hepatitis B|||0|901|356|367
SE|25462178|OBJECTIVES|ab|1|entity|C0030705|Patients|podg|||patients|||0|901|368|376
SE|25462178|OBJECTIVES|ab|1|relation|0|0|C0019163|Hepatitis B|dsyn|dsyn|||hepatitis B|||0|901|356|367|MOD/HEAD|PROCESS_OF||356|376|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|368|376
SE|25462178|OBJECTIVES|ab|1|relation|8|1|C0239946|Fibrosis, Liver|dsyn|dsyn|||liver fibrosis|||0|1000|338|352|PREP|PROCESS_OF||353|355|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|901|368|376

SE|25462178|METHODS|ab|2|text|378|464|METHODS: Data of 34 non-invasive indexes were collected for 208 hepatitis B patients.
SE|25462178|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|378|385
SE|25462178|METHODS|ab|2|entity|C1511726|Data|idcn|||Data|||0|1000|387|391
SE|25462178|METHODS|ab|2|entity|C0205303|Non-invasive|ftcn|||non-invasive|||0|824|398|410
SE|25462178|METHODS|ab|2|entity|C0918012|Index|inpr|||indexes|||0|824|411|418
SE|25462178|METHODS|ab|2|entity|C0019163|Hepatitis B|dsyn|||hepatitis B|||0|824|442|453
SE|25462178|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|824|454|462
SE|25462178|METHODS|ab|2|relation|0|0|C0019163|Hepatitis B|dsyn|dsyn|||hepatitis B|||0|824|442|453|MOD/HEAD|PROCESS_OF||442|462|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|824|454|462

SE|25462178|METHODS|ab|3|text|464|595|Correlation analysis and stepwise discriminant analysis was used to screen out indexes useful for the diagnosis of liver fibrosis.
SE|25462178|METHODS|ab|3|entity|C0010101|Correlation Study|inpr,resa|||Correlation analysis|||0|1000|464|484
SE|25462178|METHODS|ab|3|entity|C0012630|Discriminant Analysis|qnco,resa|||discriminant analysis|||0|901|498|519
SE|25462178|METHODS|ab|3|entity|C0439787|Out|spco|||out|||0|1000|539|542
SE|25462178|METHODS|ab|3|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|566|575
SE|25462178|METHODS|ab|3|entity|C0239946|Fibrosis, Liver|dsyn|||liver fibrosis|||0|1000|579|593

SE|25462178|METHODS|ab|4|text|595|742|Finally, a scoring system composed of indexes screened out by stepwise discriminant analysis was established for the assessment of liver fibrosis.
SE|25462178|METHODS|ab|4|entity|C1552081|scoring|idcn|||scoring|||0|888|606|613
SE|25462178|METHODS|ab|4|entity|C0449913|System|ftcn|||system|||0|888|614|620
SE|25462178|METHODS|ab|4|entity|C0918012|Index|inpr|||indexes|||0|1000|633|640
SE|25462178|METHODS|ab|4|entity|C0439787|Out|spco|||out|||0|1000|650|653
SE|25462178|METHODS|ab|4|entity|C0012630|Discriminant Analysis|qnco,resa|||discriminant analysis|||0|901|666|687
SE|25462178|METHODS|ab|4|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|712|722
SE|25462178|METHODS|ab|4|entity|C0239946|Fibrosis, Liver|dsyn|||liver fibrosis|||0|1000|726|740

SE|25462178|RESULTS|ab|5|text|742|893|RESULTS: Twenty-one indexes correlating with liver fibrosis were screened out by correlation analysis; hyaluronic acid had the highest r-value, 0.456.
SE|25462178|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|742|749
SE|25462178|RESULTS|ab|5|entity|C0205447|One|qnco|||one|||0|790|758|761
SE|25462178|RESULTS|ab|5|entity|C0918012|Index|inpr|||indexes|||0|790|762|769
SE|25462178|RESULTS|ab|5|entity|C0239946|Fibrosis, Liver|dsyn|||liver fibrosis|||0|1000|787|801
SE|25462178|RESULTS|ab|5|entity|C0439787|Out|spco|||out|||0|1000|816|819
SE|25462178|RESULTS|ab|5|entity|C0010101|Correlation Study|inpr,resa|||correlation analysis|||0|1000|823|843
SE|25462178|RESULTS|ab|5|entity|C0020196|Hyaluronic Acid|bacs,carb,phsu|||hyaluronic acid|||0|1000|845|860
SE|25462178|RESULTS|ab|5|entity|C1522410|Highest|qlco|||highest|||0|606|869|876

SE|25462178|RESULTS|ab|6|text|893|1003|A scoring system including albumin, collagen IV, and the longitudinal diameter of the spleen was established.
SE|25462178|RESULTS|ab|6|entity|C1552081|scoring|idcn|||scoring|||0|888|895|902
SE|25462178|RESULTS|ab|6|entity|C0449913|System|ftcn|||system|||0|888|903|909
SE|25462178|RESULTS|ab|6|entity|C0001924|Albumins|aapp,bacs|||albumin|||0|1000|920|927
SE|25462178|RESULTS|ab|6|entity|C0009333|Collagen Type IV|aapp,bacs|||collagen IV|||0|1000|929|940
SE|25462178|RESULTS|ab|6|entity|C0205127|Longitudinal|spco|||longitudinal|||0|888|950|962
SE|25462178|RESULTS|ab|6|entity|C1301886|Caliber|qnco|||diameter|||0|888|963|971
SE|25462178|RESULTS|ab|6|entity|C0037993|Spleen|bpoc|||spleen|||0|1000|979|985

SE|25462178|RESULTS|ab|7|text|1003|1288|The areas under the receiver operating characteristic curves (AUC) for this scoring system and the aspartate aminotransferase to platelet ratio index (APRI) in differentiating S3-4 from S0-2 were 0.79 (95% confidence interval (CI) 0.72-0.85) and 0.27 (95% CI 0.18-0.35), respectively.
SE|25462178|RESULTS|ab|7|entity|C0034772|Receiver Operating Characteristic|qnco|||receiver operating characteristic|||0|875|1023|1056
SE|25462178|RESULTS|ab|7|entity|C0205134|Curved|spco|||curves|||0|875|1057|1063
SE|25462178|RESULTS|ab|7|entity|C0376690|Area Under Curve|qnco|||AUC|||0|1000|1065|1068
SE|25462178|RESULTS|ab|7|entity|C1552081|scoring|idcn|||scoring|||0|888|1079|1086
SE|25462178|RESULTS|ab|7|entity|C0449913|System|ftcn|||system|||0|888|1087|1093
SE|25462178|RESULTS|ab|7|entity|C0004002|Aspartate Transaminase|aapp,enzy|||aspartate aminotransferase|||0|742|1102|1128
SE|25462178|RESULTS|ab|7|entity|C0005821|Blood Platelets|cell|||platelet|||0|742|1132|1140
SE|25462178|RESULTS|ab|7|entity|C0456603|Ratio|inpr|||ratio|||0|742|1141|1146
SE|25462178|RESULTS|ab|7|entity|C0918012|Index|inpr|||index|||0|742|1147|1152
SE|25462178|RESULTS|ab|7|entity|C1179706|S3|blor|||S3-4|||0|827|1179|1183
SE|25462178|RESULTS|ab|7|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|818|1209|1228
SE|25462178|RESULTS|ab|7|entity|C0009667|Confidence Intervals|qnco|||CI|||0|818|1259|1261

SE|25462178|RESULTS|ab|8|text|1288|1469|With a cut-off value of <3, the presence of significant fibrosis (S3-4) could be excluded by this scoring system with a negative predictive value of 86.1% and sensitivity of 86.8%.
SE|25462178|RESULTS|ab|8|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|734|1295|1302
SE|25462178|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|888|1332|1343
SE|25462178|RESULTS|ab|8|entity|C0016059|Fibrosis|patf|||fibrosis|||0|888|1344|1352
SE|25462178|RESULTS|ab|8|entity|C1179706|S3|blor|||S3-4|||0|861|1354|1358
SE|25462178|RESULTS|ab|8|entity|C1552081|scoring|idcn|||scoring|||0|888|1386|1393
SE|25462178|RESULTS|ab|8|entity|C0449913|System|ftcn|||system|||0|888|1394|1400
SE|25462178|RESULTS|ab|8|entity|C0205160|Negative|qlco|||negative|||0|901|1408|1416
SE|25462178|RESULTS|ab|8|entity|C1514307|Predictive Value|qlco|||predictive value|||0|901|1417|1433

SE|25462178|RESULTS|ab|9|text|1469|1619|With a cut-off of >6, the presence of S3-4 fibrosis could be correctly identified with a positive predictive value of 73.6% and specificity of 87.6%.
SE|25462178|RESULTS|ab|9|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|1000|1476|1483
SE|25462178|RESULTS|ab|9|entity|C1179706|S3|blor|||S3-4|||0|802|1507|1511
SE|25462178|RESULTS|ab|9|entity|C0016059|Fibrosis|patf|||fibrosis|||0|802|1512|1520
SE|25462178|RESULTS|ab|9|entity|C1446409|Positive|qlco|||positive|||0|901|1558|1566
SE|25462178|RESULTS|ab|9|entity|C1514307|Predictive Value|qlco|||predictive value|||0|901|1567|1583
SE|25462178|RESULTS|ab|9|entity|C0037791|Specificity|qnco|||specificity|||0|1000|1597|1608

SE|25462178|RESULTS|ab|10|text|1619|1718|Using this scoring system, 53.4% of patients could be classified correctly and avoid liver biopsy.
SE|25462178|RESULTS|ab|10|entity|C1552081|scoring|idcn|||scoring|||0|888|1630|1637
SE|25462178|RESULTS|ab|10|entity|C0449913|System|ftcn|||system|||0|888|1638|1644
SE|25462178|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1655|1663
SE|25462178|RESULTS|ab|10|entity|C0023884|Liver|bpoc|||liver|||0|888|1704|1709
SE|25462178|RESULTS|ab|10|entity|C0005558|Biopsy|diap|||biopsy|||0|888|1710|1716
SE|25462178|RESULTS|ab|10|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|1704|1709|MOD/HEAD|LOCATION_OF||1704|1716|0|0|C0005558|Biopsy|diap|diap|||biopsy|||0|888|1710|1716

SE|25462178|CONCLUSIONS|ab|11|text|1718|1848|CONCLUSIONS: The scoring system provides a simpler method to identify significant fibrosis (S3-4) in chronic hepatitis B patients.
SE|25462178|CONCLUSIONS|ab|11|entity|C1552081|scoring|idcn|||scoring|||0|888|1735|1742
SE|25462178|CONCLUSIONS|ab|11|entity|C0449913|System|ftcn|||system|||0|888|1743|1749
SE|25462178|CONCLUSIONS|ab|11|entity|C0205352|Simple|qlco|||simpler|||0|872|1761|1768
SE|25462178|CONCLUSIONS|ab|11|entity|C0025663|Methods|inpr|||method|||0|872|1769|1775
SE|25462178|CONCLUSIONS|ab|11|entity|C0750502|Significant|idcn|||significant|||0|888|1788|1799
SE|25462178|CONCLUSIONS|ab|11|entity|C0016059|Fibrosis|patf|||fibrosis|||0|888|1800|1808
SE|25462178|CONCLUSIONS|ab|11|entity|C1179706|S3|blor|||S3-4|||0|861|1810|1814
SE|25462178|CONCLUSIONS|ab|11|entity|C0524909|Hepatitis B, Chronic|dsyn|||chronic hepatitis B|||0|916|1819|1838
SE|25462178|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|916|1839|1847
SE|25462178|CONCLUSIONS|ab|11|relation|0|0|C0524909|Hepatitis B, Chronic|dsyn|dsyn|||chronic hepatitis B|||0|916|1819|1838|MOD/HEAD|PROCESS_OF||1819|1847|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|916|1839|1847
SE|25462178|CONCLUSIONS|ab|11|relation|4|1|C0016059|Fibrosis|patf|patf|||fibrosis|||0|888|1800|1808|PREP|PROCESS_OF||1816|1818|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|916|1839|1847


SE|25462179||ti|1|text|21|122|The impact of temperature and humidity measures on influenza A (H7N9) outbreaks-evidence from China.
SE|25462179||ti|1|entity|C0039476|Temperature|qnco|||temperature|||0|1000|35|46
SE|25462179||ti|1|entity|C0020167|Humidity|npop|||humidity|||0|1000|51|59
SE|25462179||ti|1|entity|C0021400|Influenza|dsyn|||influenza|||0|861|72|81
SE|25462179||ti|1|entity|C0220888|increasing incidence|ftcn|||outbreaks|||0|694|91|100
SE|25462179||ti|1|entity|C0008115|China|geoa|||China|||0|1000|115|120

SE|25462179|OBJECTIVES|ab|1|text|128|376|OBJECTIVES: To examine the non-linear effects of meteorological factors on the incidence of influenza A H7N9 and to determine what meteorological measure, and on which day preceding symptom onset, has the most significant effect on H7N9 infection.
SE|25462179|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|128|138
SE|25462179|OBJECTIVES|ab|1|entity|C0205132|Linear|spco|||linear|||0|773|159|165
SE|25462179|OBJECTIVES|ab|1|entity|C1280500|Effect|qlco|||effects|||0|773|166|173
SE|25462179|OBJECTIVES|ab|1|entity|C0025594|Meteorological Factors|npop|||meteorological factors|||0|1000|177|199
SE|25462179|OBJECTIVES|ab|1|entity|C0021149|Incidence|qnco|||incidence|||0|1000|207|216
SE|25462179|OBJECTIVES|ab|1|entity|C0021400|Influenza|dsyn|||influenza|||0|660|220|229
SE|25462179|OBJECTIVES|ab|1|entity|C0025595|Meteorology|ocdi|||meteorological|||0|853|259|273
SE|25462179|OBJECTIVES|ab|1|entity|C0079809|Measures|qnco|||measure|||0|853|274|281
SE|25462179|OBJECTIVES|ab|1|entity|C0439228|day|tmco|||day|||0|833|296|299
SE|25462179|OBJECTIVES|ab|1|entity|C0332152|Status pre-|tmco|||preceding|||0|833|300|309
SE|25462179|OBJECTIVES|ab|1|entity|C1457887|Symptoms|sosy|||symptom|||0|833|310|317
SE|25462179|OBJECTIVES|ab|1|entity|C0332162|Onset|qlco|||onset|||0|833|318|323
SE|25462179|OBJECTIVES|ab|1|entity|C1299394|Most significant|qlco|||most significant|||0|901|333|349
SE|25462179|OBJECTIVES|ab|1|entity|C1280500|Effect|qlco|||effect|||0|901|350|356

SE|25462179|METHODS|ab|2|text|376|724|METHODS: We applied a zero truncated Poisson regression model incorporating smoothed spline functions to assess the non-linear effect of temperature (maximum, minimum, and daily difference) and relative humidity on H7N9 human case numbers occurring in China from February 19, 2013 to February 18, 2014, adjusting for the effects of age and gender.
SE|25462179|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|376|383
SE|25462179|METHODS|ab|2|entity|C0026336|Study models|inpr,resd|||model|||0|528|432|437
SE|25462179|METHODS|ab|2|entity|C0205357|Smooth|qlco|||smoothed|||0|528|452|460
SE|25462179|METHODS|ab|2|entity|C0205132|Linear|spco|||linear|||0|790|496|502
SE|25462179|METHODS|ab|2|entity|C1280500|Effect|qlco|||effect|||0|790|503|509
SE|25462179|METHODS|ab|2|entity|C0039476|Temperature|qnco|||temperature|||0|1000|513|524
SE|25462179|METHODS|ab|2|entity|C0806909|Maximum|fndg|||maximum|||0|1000|526|533
SE|25462179|METHODS|ab|2|entity|C1524031|Minimum|qlco|||minimum|||0|1000|535|542
SE|25462179|METHODS|ab|2|entity|C0332173|Daily|tmco|||daily|||0|888|548|553
SE|25462179|METHODS|ab|2|entity|C1547020|*Difference|qnco|||difference|||0|888|554|564
SE|25462179|METHODS|ab|2|entity|C0428696|Relative humidity|fndg|||relative humidity|||0|1000|570|587
SE|25462179|METHODS|ab|2|entity|C0020114|Human|humn|||human|||0|763|596|601
SE|25462179|METHODS|ab|2|entity|C0237753|Numbers|qnco|||numbers|||0|763|607|614
SE|25462179|METHODS|ab|2|entity|C0008115|China|geoa|||China|||0|1000|628|633
SE|25462179|METHODS|ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|697|704
SE|25462179|METHODS|ab|2|entity|C0001779|Age|orga|||age|||0|1000|708|711
SE|25462179|METHODS|ab|2|entity|C0079399|Gender|orga|||gender|||0|1000|716|722

SE|25462179|RESULTS|ab|3|text|724|860|RESULTS: Both daily minimum and daily maximum temperature contributed significantly to human infection with the influenza A H7N9 virus.
SE|25462179|RESULTS|ab|3|entity|C1274040|result|ftcn|||RESULTS|||0|966|724|731
SE|25462179|RESULTS|ab|3|entity|C0332173|Daily|tmco|||daily|||0|888|738|743
SE|25462179|RESULTS|ab|3|entity|C1524031|Minimum|qlco|||minimum|||0|888|744|751
SE|25462179|RESULTS|ab|3|entity|C0332173|Daily|tmco|||daily|||0|851|756|761
SE|25462179|RESULTS|ab|3|entity|C0806909|Maximum|fndg|||maximum|||0|851|762|769
SE|25462179|RESULTS|ab|3|entity|C0039476|Temperature|qnco|||temperature|||0|851|770|781
SE|25462179|RESULTS|ab|3|entity|C0020114|Human|humn|||human|||0|888|811|816
SE|25462179|RESULTS|ab|3|entity|C0029347|Influenza A virus|virs|||influenza A H7N9 virus|||0|923|836|858

SE|25462179|RESULTS|ab|4|text|860|1018|Models incorporating the non-linear effect of minimum or maximum temperature on day 13 prior to disease onset were found to have the best predictive ability.
SE|25462179|RESULTS|ab|4|entity|C0205132|Linear|spco|||linear|||0|790|889|895
SE|25462179|RESULTS|ab|4|entity|C1280500|Effect|qlco|||effect|||0|790|896|902
SE|25462179|RESULTS|ab|4|entity|C1524031|Minimum|qlco|||minimum|||0|1000|906|913
SE|25462179|RESULTS|ab|4|entity|C0806909|Maximum|fndg|||maximum|||0|888|917|924
SE|25462179|RESULTS|ab|4|entity|C0039476|Temperature|qnco|||temperature|||0|888|925|936
SE|25462179|RESULTS|ab|4|entity|C0439228|day|tmco|||day|||0|861|940|943
SE|25462179|RESULTS|ab|4|entity|C0277793|Onset of illness|fndg|||disease onset|||0|1000|956|969
SE|25462179|RESULTS|ab|4|entity|C0681890|predictive|qlco|||predictive|||0|851|998|1008
SE|25462179|RESULTS|ab|4|entity|C0085732|Ability|orga|||ability|||0|851|1009|1016

SE|25462179|RESULTS|ab|5|text|1018|1204|For minimum temperature, high risk was found to range from approximately 5 to 9 degrees C and moderate risk from -10 to 0 degrees C; temperatures of >9 degrees C represented a low risk.
SE|25462179|RESULTS|ab|5|entity|C1524031|Minimum|qlco|||minimum|||0|888|1022|1029
SE|25462179|RESULTS|ab|5|entity|C0039476|Temperature|qnco|||temperature|||0|888|1030|1041
SE|25462179|RESULTS|ab|5|entity|C0205250|High|qlco|||high|||0|888|1043|1047
SE|25462179|RESULTS|ab|5|entity|C0035647|Risk|qlco|||risk|||0|888|1048|1052
SE|25462179|RESULTS|ab|5|entity|C1514721|Range|qnco|||range|||0|1000|1066|1071
SE|25462179|RESULTS|ab|5|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|1077|1090
SE|25462179|RESULTS|ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1098|1107
SE|25462179|RESULTS|ab|5|entity|C0035647|Risk|qlco|||risk|||0|861|1121|1125
SE|25462179|RESULTS|ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1140|1149
SE|25462179|RESULTS|ab|5|entity|C0039476|Temperature|qnco|||temperatures|||0|1000|1151|1163
SE|25462179|RESULTS|ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1170|1179
SE|25462179|RESULTS|ab|5|entity|C0205251|low|qlco|||low|||0|888|1194|1197
SE|25462179|RESULTS|ab|5|entity|C0035647|Risk|qlco|||risk|||0|888|1198|1202

SE|25462179|RESULTS|ab|6|text|1204|1391|For maximum temperature, high risk was found to range from approximately 13 to 18 degrees C and moderate risk from 0 to 4 degrees C; temperatures of >18 degrees C represented a low risk.
SE|25462179|RESULTS|ab|6|entity|C0806909|Maximum|fndg|||maximum|||0|888|1208|1215
SE|25462179|RESULTS|ab|6|entity|C0039476|Temperature|qnco|||temperature|||0|888|1216|1227
SE|25462179|RESULTS|ab|6|entity|C0205250|High|qlco|||high|||0|888|1229|1233
SE|25462179|RESULTS|ab|6|entity|C0035647|Risk|qlco|||risk|||0|888|1234|1238
SE|25462179|RESULTS|ab|6|entity|C1514721|Range|qnco|||range|||0|1000|1252|1257
SE|25462179|RESULTS|ab|6|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|1263|1276
SE|25462179|RESULTS|ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1286|1295
SE|25462179|RESULTS|ab|6|entity|C0035647|Risk|qlco|||risk|||0|861|1309|1313
SE|25462179|RESULTS|ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1326|1335
SE|25462179|RESULTS|ab|6|entity|C0039476|Temperature|qnco|||temperatures|||0|1000|1337|1349
SE|25462179|RESULTS|ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1357|1366
SE|25462179|RESULTS|ab|6|entity|C0205251|low|qlco|||low|||0|888|1381|1384
SE|25462179|RESULTS|ab|6|entity|C0035647|Risk|qlco|||risk|||0|888|1385|1389

SE|25462179|RESULTS|ab|7|text|1391|1475|Relative humidity was not significantly associated with the incidence of infection.
SE|25462179|RESULTS|ab|7|entity|C0428696|Relative humidity|fndg|||Relative humidity|||0|1000|1391|1408
SE|25462179|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1413|1416
SE|25462179|RESULTS|ab|7|entity|C0021149|Incidence|qnco|||incidence|||0|1000|1451|1460

SE|25462179|RESULTS|ab|8|text|1475|1591|The incidence of H7N9 was higher for males compared to females (p<0.01) and it peaked at around 60-70 years of age.
SE|25462179|RESULTS|ab|8|entity|C0021149|Incidence|qnco|||incidence|||0|1000|1479|1488
SE|25462179|RESULTS|ab|8|entity|C0205250|High|qlco|||higher|||0|966|1501|1507
SE|25462179|RESULTS|ab|8|entity|C0024554|Male gender|orga|||males|||0|1000|1512|1517
SE|25462179|RESULTS|ab|8|entity|C0015780|Female|orga|||females|||0|1000|1530|1537
SE|25462179|RESULTS|ab|8|entity|C0439234|year|tmco|||years|||0|827|1577|1582
SE|25462179|RESULTS|ab|8|entity|C0001779|Age|orga|||age|||0|1000|1586|1589

SE|25462179|CONCLUSIONS|ab|9|text|1591|1811|CONCLUSIONS: We provide direct evidence to support the role of climate conditions in the spread of H7N9 and thereby address a critical question fundamental to our understanding of the epidemiology and evolution of H7N9.
SE|25462179|CONCLUSIONS|ab|9|entity|C0035820|Role|socb|||role|||0|1000|1646|1650
SE|25462179|CONCLUSIONS|ab|9|entity|C0008946|Climate|npop|||climate|||0|1000|1654|1661
SE|25462179|CONCLUSIONS|ab|9|entity|C1511545|Critical|qlco|||critical|||0|694|1717|1725
SE|25462179|CONCLUSIONS|ab|9|entity|C0014507|Epidemiology|bmod|||epidemiology|||0|1000|1775|1787
SE|25462179|CONCLUSIONS|ab|9|entity|C0015219|Evolution|genf|||evolution|||0|1000|1792|1801

SE|25462179|CONCLUSIONS|ab|10|text|1811|1936|These findings could be used to inform targeted surveillance and control efforts aimed at reducing the future spread of H7N9.
SE|25462179|CONCLUSIONS|ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1817|1825
SE|25462179|CONCLUSIONS|ab|10|entity|C0599894|targeting|celf|||targeted|||0|661|1850|1858
SE|25462179|CONCLUSIONS|ab|10|entity|C0243148|control|ftcn|||control|||0|888|1876|1883
SE|25462179|CONCLUSIONS|ab|10|entity|C0392756|Reduced|qlco|||reducing|||0|966|1901|1909
SE|25462179|CONCLUSIONS|ab|10|entity|C0016884|Future|tmco|||future|||0|1000|1914|1920


SE|25462180||ti|1|text|21|168|Estimating influenza vaccine effectiveness using routine surveillance data among children aged 6-59 months for five consecutive influenza seasons.
SE|25462180||ti|1|entity|C0750572|Estimated|qnco|||Estimating|||0|850|21|31
SE|25462180||ti|1|entity|C0021403|Influenza virus vaccine|imft,orch,phsu|||influenza vaccine|||0|850|32|49
SE|25462180||ti|1|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|850|50|63
SE|25462180||ti|1|entity|C0205547|Routine|qlco|||routine|||0|802|70|77
SE|25462180||ti|1|entity|C1511726|Data|idcn|||data|||0|802|91|95
SE|25462180||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|102|110
SE|25462180||ti|1|entity|C0439231|month|tmco|||months|||0|827|121|127
SE|25462180||ti|1|entity|C0205451|Five|qnco|||five|||0|775|132|136
SE|25462180||ti|1|entity|C0021400|Influenza|dsyn|||influenza|||0|775|149|158
SE|25462180||ti|1|entity|C0036497|Seasons|tmco|||seasons|||0|775|159|166

SE|25462180|OBJECTIVES|ab|1|text|174|334|OBJECTIVES: We aimed to estimate the pooled vaccine effectiveness (VE) in children over five winters through data linkage of two existing surveillance systems.
SE|25462180|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|174|184
SE|25462180|OBJECTIVES|ab|1|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|790|218|225
SE|25462180|OBJECTIVES|ab|1|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|790|226|239
SE|25462180|OBJECTIVES|ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|764|248|256
SE|25462180|OBJECTIVES|ab|1|entity|C0205451|Five|qnco|||five|||0|764|262|266
SE|25462180|OBJECTIVES|ab|1|entity|C0241737|winter|tmco|||winters|||0|764|267|274
SE|25462180|OBJECTIVES|ab|1|entity|C0242239|Data Linkage|resa|||data linkage|||0|1000|283|295
SE|25462180|OBJECTIVES|ab|1|entity|C0205448|Two|qnco|||two|||0|791|299|302
SE|25462180|OBJECTIVES|ab|1|entity|C0449913|System|ftcn|||systems|||0|791|325|332

SE|25462180|METHODS|ab|2|text|334|467|METHODS: Five test-negative case-control studies were conducted from November to February during the 2004/2005 to 2008/2009 seasons.
SE|25462180|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|334|341
SE|25462180|METHODS|ab|2|entity|C0205451|Five|qnco|||Five|||0|851|343|347
SE|25462180|METHODS|ab|2|entity|C0039593|Testing|resa|||test|||0|851|348|352
SE|25462180|METHODS|ab|2|entity|C0205160|Negative|qlco|||negative|||0|851|353|361
SE|25462180|METHODS|ab|2|entity|C0007328|Case-Control Studies|resa|||case-control studies|||0|851|362|382
SE|25462180|METHODS|ab|2|entity|C0036497|Seasons|tmco|||seasons|||0|827|458|465

SE|25462180|METHODS|ab|3|text|467|611|Sentinel physicians from the Viral Surveillance Network enrolled children aged 6-59 months with influenza-like illness to collect throat swabs.
SE|25462180|METHODS|ab|3|entity|C0950580|Sentinel|hops,orch|||Sentinel|||0|888|467|475
SE|25462180|METHODS|ab|3|entity|C0031831|Physicians|prog|||physicians|||0|888|476|486
SE|25462180|METHODS|ab|3|entity|C0521026|Viral|ftcn|||Viral|||0|754|496|501
SE|25462180|METHODS|ab|3|entity|C0679670|network|popg|||Network|||0|754|515|522
SE|25462180|METHODS|ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|754|532|540
SE|25462180|METHODS|ab|3|entity|C0439231|month|tmco|||months|||0|827|551|557
SE|25462180|METHODS|ab|3|entity|C0021400|Influenza|dsyn|||influenza|||0|1000|563|572
SE|25462180|METHODS|ab|3|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|578|585
SE|25462180|METHODS|ab|3|entity|C0031354|Pharyngeal structure|bpoc|||throat|||0|888|597|603
SE|25462180|METHODS|ab|3|entity|C1261188|Swab|medd|||swabs|||0|888|604|609
SE|25462180|METHODS|ab|3|relation|0|0|C0031354|Pharyngeal structure|bpoc|bpoc|||throat|||0|888|597|603|MOD/HEAD|LOCATION_OF||597|609|0|0|C1261188|Swab|medd|medd|||swabs|||0|888|604|609

SE|25462180|METHODS|ab|4|text|611|773|Through linking with a nationwide vaccination registry, we measured the VE with a logistic regression model adjusting for age, gender, and week of symptom onset.
SE|25462180|METHODS|ab|4|entity|C0042196|Vaccination|topp|||vaccination|||0|790|645|656
SE|25462180|METHODS|ab|4|entity|C0034975|Registries|inpr,qnco|||registry|||0|790|657|665
SE|25462180|METHODS|ab|4|entity|C0042210|Vaccines|imft,phsu|||VE|||0|888|683|685
SE|25462180|METHODS|ab|4|entity|C1280519|Effectiveness|qlco|||VE|||0|888|683|685
SE|25462180|METHODS|ab|4|entity|C0206031|Logistic Regression|resa|||logistic regression|||0|850|693|712
SE|25462180|METHODS|ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|850|713|718
SE|25462180|METHODS|ab|4|entity|C1439356|ADJUSTED|qlco|||adjusting|||0|850|719|728
SE|25462180|METHODS|ab|4|entity|C0001779|Age|orga|||age|||0|1000|733|736
SE|25462180|METHODS|ab|4|entity|C0079399|Gender|orga|||gender|||0|1000|738|744
SE|25462180|METHODS|ab|4|entity|C0439230|week|tmco|||week|||0|1000|750|754
SE|25462180|METHODS|ab|4|entity|C1457887|Symptoms|sosy|||symptom|||0|888|758|765
SE|25462180|METHODS|ab|4|entity|C0332162|Onset|qlco|||onset|||0|888|766|771

SE|25462180|METHODS|ab|5|text|773|850|Both fixed-effects and random-effects models were used in the meta-analysis.
SE|25462180|METHODS|ab|5|entity|C1280500|Effect|qlco|||effects|||0|966|784|791
SE|25462180|METHODS|ab|5|entity|C0439605|Random|qlco|||random|||0|872|796|802
SE|25462180|METHODS|ab|5|entity|C1280500|Effect|qlco|||effects|||0|872|803|810
SE|25462180|METHODS|ab|5|entity|C0920317|Meta-Analysis|inpr|||meta-analysis|||0|1000|835|848

SE|25462180|RESULTS|ab|6|text|850|926|RESULTS: Four thousand four hundred and ninety-four subjects were included.
SE|25462180|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|850|857
SE|25462180|RESULTS|ab|6|entity|C0205450|Four|qnco|||Four|||0|764|859|863
SE|25462180|RESULTS|ab|6|entity|C1550501|subject|idcn|||subjects|||0|764|902|910

SE|25462180|RESULTS|ab|7|text|926|1105|The proportion of influenza test-positive subjects across the five seasons was 11.5% (132/1151), 7.2% (41/572), 23.9% (189/791), 6.6% (75/1135), and 11.2% (95/845), respectively.
SE|25462180|RESULTS|ab|7|entity|C0205351|Proportional|qlco|||proportion|||0|928|930|940
SE|25462180|RESULTS|ab|7|entity|C0021400|Influenza|dsyn|||influenza|||0|825|944|953
SE|25462180|RESULTS|ab|7|entity|C0039593|Testing|resa|||test|||0|825|954|958
SE|25462180|RESULTS|ab|7|entity|C1446409|Positive|qlco|||positive|||0|825|959|967
SE|25462180|RESULTS|ab|7|entity|C1550501|subject|idcn|||subjects|||0|825|968|976
SE|25462180|RESULTS|ab|7|entity|C0205451|Five|qnco|||five|||0|888|988|992
SE|25462180|RESULTS|ab|7|entity|C0036497|Seasons|tmco|||seasons|||0|888|993|1000
SE|25462180|RESULTS|ab|7|entity|C0442750|6/6|fndg|||6.6|||0|1000|1055|1058

SE|25462180|RESULTS|ab|8|text|1105|1195|The pooled VE was 62% (95% confidence interval (CI) 48-83%) in both meta-analysis models.
SE|25462180|RESULTS|ab|8|entity|C0042210|Vaccines|imft,phsu|||VE|||0|790|1116|1118
SE|25462180|RESULTS|ab|8|entity|C1280519|Effectiveness|qlco|||VE|||0|790|1116|1118
SE|25462180|RESULTS|ab|8|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|840|1132|1151
SE|25462180|RESULTS|ab|8|entity|C0920317|Meta-Analysis|inpr|||meta-analysis|||0|734|1173|1186

SE|25462180|RESULTS|ab|9|text|1195|1319|By age category, VE was 51% (95% CI 23-68%) for those aged 6-23 months and 75% (95% CI 60-84%) for those aged 24-59 months.
SE|25462180|RESULTS|ab|9|entity|C0027362|Human Age Group|aggp|||age category|||0|983|1198|1210
SE|25462180|RESULTS|ab|9|entity|C0042210|Vaccines|imft,phsu|||VE|||0|888|1212|1214
SE|25462180|RESULTS|ab|9|entity|C1280519|Effectiveness|qlco|||VE|||0|888|1212|1214
SE|25462180|RESULTS|ab|9|entity|C0009667|Confidence Intervals|qnco|||CI|||0|840|1228|1230
SE|25462180|RESULTS|ab|9|entity|C1510828|Age-Months|orga|||aged 6-23 months|||0|867|1249|1265
SE|25462180|RESULTS|ab|9|entity|C0009667|Confidence Intervals|qnco|||CI|||0|840|1279|1281
SE|25462180|RESULTS|ab|9|entity|C1510828|Age-Months|orga|||aged 24-59 months|||0|867|1300|1317

SE|25462180|CONCLUSIONS|ab|10|text|1319|1558|CONCLUSIONS: Influenza vaccination provided measurable protection against laboratory-confirmed influenza among children aged 6-59 months despite variations in the vaccine match during the 2004/2005 to 2008/2009 influenza seasons in Taiwan.
SE|25462180|CONCLUSIONS|ab|10|entity|C0042200|Influenza vaccination|topp|||Influenza vaccination|||0|1000|1332|1353
SE|25462180|CONCLUSIONS|ab|10|entity|C1513040|Measurable|ftcn|||measurable|||0|888|1363|1373
SE|25462180|CONCLUSIONS|ab|10|entity|C0022877|Laboratory|mnob,orgt|||laboratory|||0|851|1393|1403
SE|25462180|CONCLUSIONS|ab|10|entity|C0750484|Confirmed|idcn|||confirmed|||0|851|1404|1413
SE|25462180|CONCLUSIONS|ab|10|entity|C0021400|Influenza|dsyn|||influenza|||0|851|1414|1423
SE|25462180|CONCLUSIONS|ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1430|1438
SE|25462180|CONCLUSIONS|ab|10|entity|C0439231|month|tmco|||months|||0|827|1449|1455
SE|25462180|CONCLUSIONS|ab|10|entity|C0205419|Variant|qlco|||variations|||0|966|1464|1474
SE|25462180|CONCLUSIONS|ab|10|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|872|1482|1489
SE|25462180|CONCLUSIONS|ab|10|entity|C0336766|Matches|mnob|||match|||0|872|1490|1495
SE|25462180|CONCLUSIONS|ab|10|entity|C0021400|Influenza|dsyn|||influenza|||0|750|1530|1539
SE|25462180|CONCLUSIONS|ab|10|entity|C0036497|Seasons|tmco|||seasons|||0|750|1540|1547
SE|25462180|CONCLUSIONS|ab|10|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|1551|1557
SE|25462180|CONCLUSIONS|ab|10|relation|4|1|C0021400|Influenza|dsyn|dsyn|||influenza|||0|851|1414|1423|PREP|PROCESS_OF||1424|1429|6|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1430|1438


[41]: *** ERROR *** ERROR *** ERROR ***
[42]: *** ERROR *** ERROR *** ERROR ***
SE|25462183||ti|1|text|21|99|OXA-48-producing Enterobacteriaceae causing bacteremia, United Arab Emirates.
SE|25462183||ti|1|entity|C0376938|oxytocin, Asp(5)-|aapp|||OXA-48|||0|753|21|27
SE|25462183||ti|1|entity|C0014346|Enterobacteriaceae|bact|||Enterobacteriaceae|||0|753|38|56
SE|25462183||ti|1|entity|C0004610|Bacteremia|dsyn|||bacteremia|||0|753|65|75
SE|25462183||ti|1|entity|C0041698|United Arab Emirates|geoa|||United Arab Emirates|||0|1000|77|97
SE|25462183||ti|1|relation|0|0|C0014346|Enterobacteriaceae|bact|bact|||Enterobacteriaceae|||0|753|38|56|ADJ|PRODUCES||28|37|0|0|C0376938|oxytocin, Asp(5)-|aapp,gngm|aapp|||OXA-48|||0|753|21|27

SE|25462183||ab|1|text|105|316|OXA-48-producing isolates were identified in approximately 4% and less than 1% of ESBL-producing and non-ESBL-producing E. coli and K. pneumoniae causing bacteremia at the largest tertiary hospital in Abu Dhabi.
SE|25462183||ab|1|entity|C0376938|oxytocin, Asp(5)-|aapp|||OXA-48|||0|645|105|111
SE|25462183||ab|1|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|861|150|163
SE|25462183||ab|1|entity|C1444096|ESBL|bact|||ESBL|||0|694|187|191
SE|25462183||ab|1|entity|C1444096|ESBL|bact|||ESBL|||0|558|210|214
SE|25462183||ab|1|entity|C0032285|Pneumonia|dsyn|||pneumoniae|||0|833|240|250
SE|25462183||ab|1|entity|C0004610|Bacteremia|dsyn|||bacteremia|||0|833|259|269
SE|25462183||ab|1|entity|C0443228|Largest|qnco|||largest|||0|851|277|284
SE|25462183||ab|1|entity|C0205372|Tertiary|qnco|||tertiary|||0|851|285|293
SE|25462183||ab|1|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|851|294|302
SE|25462183||ab|1|entity|C0000863|Abu Dhabi|geoa|||Abu Dhabi|||0|1000|306|315


SE|25462184||ti|1|text|21|163|Gender-related differences in outcomes and attrition on antiretroviral treatment among an HIV-infected patient cohort in Zimbabwe: 2007-2010.
SE|25462184||ti|1|entity|C1522149|Related|ftcn|||related|||0|901|28|35
SE|25462184||ti|1|entity|C0036866|Sex Characteristics|orga|||Gender-related differences|||0|901|21|47
SE|25462184||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|966|51|59
SE|25462184||ti|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|833|111|114
SE|25462184||ti|1|entity|C0439663|Infected|ftcn|||infected|||0|833|115|123
SE|25462184||ti|1|entity|C0030705|Patients|podg|||patient|||0|833|124|131
SE|25462184||ti|1|entity|C0599755|cohort|popg|||cohort|||0|833|132|138
SE|25462184||ti|1|entity|C0043476|Zimbabwe|geoa|||Zimbabwe|||0|1000|142|150

SE|25462184|OBJECTIVES|ab|1|text|169|334|OBJECTIVES: To determine (1) gender-related differences in antiretroviral therapy (ART) outcomes, and (2) gender-specific characteristics associated with attrition.
SE|25462184|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|169|179
SE|25462184|OBJECTIVES|ab|1|entity|C1522149|Related|ftcn|||related|||0|901|205|212
SE|25462184|OBJECTIVES|ab|1|entity|C0036866|Sex Characteristics|orga|||gender-related differences|||0|901|198|224
SE|25462184|OBJECTIVES|ab|1|entity|C1274040|result|ftcn|||outcomes|||0|773|257|265
SE|25462184|OBJECTIVES|ab|1|entity|C0079399|Gender|orga|||gender|||0|802|275|281
SE|25462184|OBJECTIVES|ab|1|entity|C1521970|Characteristics|grpa|||characteristics|||0|802|291|306

SE|25462184|METHODS|ab|2|text|334|528|METHODS: This was a retrospective patient record review of 3919 HIV-infected patients aged >=15 years who initiated ART between 2007 and 2009 in 40 randomly selected ART facilities countrywide.
SE|25462184|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|334|341
SE|25462184|METHODS|ab|2|entity|C1514923|Retrospective|qlco|||retrospective|||0|608|354|367
SE|25462184|METHODS|ab|2|entity|C0030705|Patients|podg|||patient|||0|608|368|375
SE|25462184|METHODS|ab|2|entity|C0034869|Records|inpr|||record|||0|608|376|382
SE|25462184|METHODS|ab|2|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|775|398|401
SE|25462184|METHODS|ab|2|entity|C0439663|Infected|ftcn|||infected|||0|775|402|410
SE|25462184|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|775|411|419
SE|25462184|METHODS|ab|2|entity|C0439234|year|tmco|||years|||0|861|430|435
SE|25462184|METHODS|ab|2|entity|C1547538|Facility|idcn|||facilities|||0|773|504|514

SE|25462184|RESULTS|ab|3|text|528|721|RESULTS: Compared to females, males had more documented active tuberculosis (12% vs. 9%; p<0.02) and a lower median CD4 cell count (117 cells/MUl vs. 143 cells/MUl; p<0.001) at ART initiation.
SE|25462184|RESULTS|ab|3|entity|C1274040|result|ftcn|||RESULTS|||0|966|528|535
SE|25462184|RESULTS|ab|3|entity|C0015780|Female|orga|||females|||0|1000|549|556
SE|25462184|RESULTS|ab|3|entity|C0024554|Male gender|orga|||males|||0|1000|558|563
SE|25462184|RESULTS|ab|3|entity|C0205172|More|ftcn|||more|||0|1000|568|572
SE|25462184|RESULTS|ab|3|entity|C0151332|Tuberculosis, active|dsyn|||active tuberculosis|||0|1000|584|603
SE|25462184|RESULTS|ab|3|entity|C0441994|Lower|ftcn|||lower|||0|850|631|636
SE|25462184|RESULTS|ab|3|entity|C0243009|CD4 Count determination procedure|lbpr|||CD4 cell count|||0|850|644|658
SE|25462184|RESULTS|ab|3|entity|C0007634|Cells|cell|||cells|||0|660|664|669
SE|25462184|RESULTS|ab|3|entity|||gngm|4591|TRIM37|MUl|||0|660|670|673
SE|25462184|RESULTS|ab|3|entity|C0007634|Cells|cell|||cells|||0|660|682|687
SE|25462184|RESULTS|ab|3|entity|||gngm|4591|TRIM37|MUl|||0|660|688|691

SE|25462184|RESULTS|ab|4|text|721|877|Males had a higher risk of attrition (adjusted hazard ratio (AHR) 1.28, 95% confidence interval (CI) 1.10-1.49) and mortality (AHR 1.56, 95% CI 1.10-2.20).
SE|25462184|RESULTS|ab|4|entity|C0024554|Male gender|orga|||Males|||0|1000|721|726
SE|25462184|RESULTS|ab|4|entity|C0205250|High|qlco|||higher|||0|872|733|739
SE|25462184|RESULTS|ab|4|entity|C0035647|Risk|qlco|||risk|||0|872|740|744
SE|25462184|RESULTS|ab|4|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|736|759|767
SE|25462184|RESULTS|ab|4|entity|C0598697|hazard|qlco|||hazard|||0|736|768|774
SE|25462184|RESULTS|ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|736|775|780
SE|25462184|RESULTS|ab|4|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|818|797|816
SE|25462184|RESULTS|ab|4|entity|C1439356|ADJUSTED|qlco|||AHR|||0|736|848|851
SE|25462184|RESULTS|ab|4|entity|C0598697|hazard|qlco|||AHR|||0|736|848|851
SE|25462184|RESULTS|ab|4|entity|C0456603|Ratio|inpr|||AHR|||0|736|848|851
SE|25462184|RESULTS|ab|4|entity|C0009667|Confidence Intervals|qnco|||CI|||0|818|862|864

SE|25462184|RESULTS|ab|5|text|877|1124|Factors associated with attrition for both sexes were lower baseline weight (<45kg and 45-60kg vs. >60kg), initiating ART at an urban health facility, and care at central/provincial or district/mission hospitals vs. primary healthcare facilities.
SE|25462184|RESULTS|ab|5|entity|C1521761|Factor|ftcn|||Factors|||0|966|877|884
SE|25462184|RESULTS|ab|5|entity|C0441994|Lower|ftcn|||lower|||0|901|931|936
SE|25462184|RESULTS|ab|5|entity|C1303013|Baseline weight|orga|||baseline weight|||0|901|937|952
SE|25462184|RESULTS|ab|5|entity|C0041933|Urban Health|idcn|||urban health|||0|901|1005|1017
SE|25462184|RESULTS|ab|5|entity|C1547538|Facility|idcn|||facility|||0|901|1018|1026
SE|25462184|RESULTS|ab|5|entity|C0205099|Central|spco|||central|||0|694|1040|1047
SE|25462184|RESULTS|ab|5|entity|C0026219|Missions|orgt|||mission|||0|901|1071|1078
SE|25462184|RESULTS|ab|5|entity|C0020006|Hospitals, District|hcro|||district/mission hospitals|||0|901|1062|1088
SE|25462184|RESULTS|ab|5|entity|C0033137|Primary Health Care|hlca|||primary healthcare|||0|890|1093|1111
SE|25462184|RESULTS|ab|5|entity|C1547538|Facility|idcn|||facilities|||0|890|1112|1122

SE|25462184|CONCLUSIONS|ab|6|text|1124|1221|CONCLUSIONS: Our findings show that males presented late for ART initiation compared to females.
SE|25462184|CONCLUSIONS|ab|6|entity|C0243095|Finding|ftcn|||findings|||0|1000|1141|1149
SE|25462184|CONCLUSIONS|ab|6|entity|C0024554|Male gender|orga|||males|||0|1000|1160|1165
SE|25462184|CONCLUSIONS|ab|6|entity|C0205087|Late|tmco|||late|||0|1000|1176|1180
SE|25462184|CONCLUSIONS|ab|6|entity|C0015780|Female|orga|||females|||0|1000|1212|1219

SE|25462184|CONCLUSIONS|ab|7|text|1221|1400|Similar to other studies, males had higher patient attrition and mortality compared to females and this may be attributed in part to late presentation for HIV treatment and care.
SE|25462184|CONCLUSIONS|ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|966|1238|1245
SE|25462184|CONCLUSIONS|ab|7|entity|C0024554|Male gender|orga|||males|||0|1000|1247|1252
SE|25462184|CONCLUSIONS|ab|7|entity|C0205250|High|qlco|||higher|||0|606|1257|1263
SE|25462184|CONCLUSIONS|ab|7|entity|C0030705|Patients|podg|||patient|||0|606|1264|1271
SE|25462184|CONCLUSIONS|ab|7|entity|C0015780|Female|orga|||females|||0|1000|1308|1315
SE|25462184|CONCLUSIONS|ab|7|entity|C0449719|Part|spco|||part|||0|1000|1346|1350
SE|25462184|CONCLUSIONS|ab|7|entity|C0205087|Late|tmco|||late|||0|888|1354|1358
SE|25462184|CONCLUSIONS|ab|7|entity|C0449450|Presentation|idcn|||presentation|||0|888|1359|1371
SE|25462184|CONCLUSIONS|ab|7|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|888|1376|1379

SE|25462184|CONCLUSIONS|ab|8|text|1400|1578|These observations highlight the need to encourage early HIV testing and enrolment into HIV treatment and care, and eventually patient retention on ART, particularly amongst men.
SE|25462184|CONCLUSIONS|ab|8|entity|C0027552|Needs|qlco|||need|||0|1000|1433|1437
SE|25462184|CONCLUSIONS|ab|8|entity|C1279919|Early|tmco|||early|||0|901|1451|1456
SE|25462184|CONCLUSIONS|ab|8|entity|C1321876|Human immunodeficiency virus test|lbpr|||HIV testing|||0|901|1457|1468
SE|25462184|CONCLUSIONS|ab|8|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|888|1488|1491
SE|25462184|CONCLUSIONS|ab|8|entity|C0679857|patient retention|inbe|||patient retention|||0|901|1527|1544
SE|25462184|CONCLUSIONS|ab|8|entity|C0025266|Male population group|popg|||men|||0|1000|1574|1577
SE|25462184|CONCLUSIONS|ab|8|relation|8|2|C0679857|patient retention|inbe|inbe|||patient retention|||0|901|1527|1544|PREP|PROCESS_OF||1566|1573|1|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1574|1577


SE|25462185||ti|1|text|21|164|Dominance of two genotypes of Bordetella pertussis during a period of increased pertussis activity in Alberta, Canada: January to August 2012.
SE|25462185||ti|1|entity|C0870441|Dominance|idcn|||Dominance|||0|1000|21|30
SE|25462185||ti|1|entity|C0205448|Two|qnco|||two|||0|888|34|37
SE|25462185||ti|1|entity|C0017431|Genotype|orga|||genotypes|||0|888|38|47
SE|25462185||ti|1|entity|C0043167|Pertussis|dsyn|||pertussis|||0|861|62|71
SE|25462185||ti|1|entity|C0439531|/period|tmco|||period|||0|1000|81|87
SE|25462185||ti|1|entity|C0205217|Increased|qnco|||increased|||0|851|91|100
SE|25462185||ti|1|entity|C0043167|Pertussis|dsyn|||pertussis|||0|851|101|110
SE|25462185||ti|1|entity|C0006823|Canada|geoa|||Canada|||0|1000|132|138

SE|25462185|OBJECTIVES|ab|1|text|170|368|OBJECTIVES: The purpose of this study was to undertake an epidemiological analysis of an increase in Bordetella pertussis activity during the period January 1 to August 31, 2012 in Alberta, Canada.
SE|25462185|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|170|180
SE|25462185|OBJECTIVES|ab|1|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|186|193
SE|25462185|OBJECTIVES|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|202|207
SE|25462185|OBJECTIVES|ab|1|entity|C0014507|Epidemiology|bmod|||epidemiological|||0|853|228|243
SE|25462185|OBJECTIVES|ab|1|entity|C0936012|Analysis|resa|||analysis|||0|853|244|252
SE|25462185|OBJECTIVES|ab|1|entity|C0442805|Increase|ftcn|||increase|||0|1000|259|267
SE|25462185|OBJECTIVES|ab|1|entity|C0043167|Pertussis|dsyn|||pertussis|||0|790|282|291
SE|25462185|OBJECTIVES|ab|1|entity|C0439531|/period|tmco|||period|||0|827|312|318
SE|25462185|OBJECTIVES|ab|1|entity|C0006823|Canada|geoa|||Canada|||0|1000|360|366

SE|25462185|OBJECTIVES|ab|2|text|368|521|B. pertussis testing was done using an IS481 real-time PCR assay with PCR-positive and indeterminate specimens cultured and stored for further analysis.
SE|25462185|OBJECTIVES|ab|2|entity|C0006017|Bordetella pertussis Bacterium|bact|||B. pertussis|||0|901|368|380
SE|25462185|OBJECTIVES|ab|2|entity|C0039593|Testing|resa|||testing|||0|901|381|388
SE|25462185|OBJECTIVES|ab|2|entity|C1550177|Real Time|idcn|||real-time|||0|798|413|422
SE|25462185|OBJECTIVES|ab|2|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|798|423|426
SE|25462185|OBJECTIVES|ab|2|entity|C1510438|Assay|lbpr|||assay|||0|798|427|432
SE|25462185|OBJECTIVES|ab|2|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|888|438|441
SE|25462185|OBJECTIVES|ab|2|entity|C1446409|Positive|qlco|||positive|||0|888|442|450
SE|25462185|OBJECTIVES|ab|2|entity|C0205258|Indeterminate|idcn|||indeterminate|||0|872|455|468
SE|25462185|OBJECTIVES|ab|2|entity|C0370003|Specimen|sbst|||specimens|||0|872|469|478
SE|25462185|OBJECTIVES|ab|2|entity|C1517331|Further|spco|||further|||0|888|503|510
SE|25462185|OBJECTIVES|ab|2|entity|C0936012|Analysis|resa|||analysis|||0|888|511|519
SE|25462185|OBJECTIVES|ab|2|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|798|427|432|MOD/HEAD|USES||423|432|0|0|C0032520|Polymerase Chain Reaction|lbpr,mbrt|lbpr|||PCR|||0|798|423|426

SE|25462185|METHODS|ab|3|text|521|731|METHODS: Laboratory data were linked to Alberta Health (AH) cases that were reported in the Communicable Disease Reporting System (CDRS) to identify case isolates; exclusion criteria were used to avoid biases.
SE|25462185|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|521|528
SE|25462185|METHODS|ab|3|entity|C0022877|Laboratory|mnob,orgt|||Laboratory|||0|888|530|540
SE|25462185|METHODS|ab|3|entity|C1511726|Data|idcn|||data|||0|888|541|545
SE|25462185|METHODS|ab|3|entity|C0018684|Health|idcn|||Health|||0|790|569|575
SE|25462185|METHODS|ab|3|entity|C0868928|Case (situation)|ftcn|||cases|||0|790|581|586
SE|25462185|METHODS|ab|3|entity|C1442536|Communicable disease report|hlca|||Communicable Disease Reporting|||0|905|613|643
SE|25462185|METHODS|ab|3|entity|C0449913|System|ftcn|||System|||0|905|644|650
SE|25462185|METHODS|ab|3|entity|C1516989|Exclusion Criteria|qlco|||exclusion criteria|||0|1000|685|703
SE|25462185|METHODS|ab|3|entity|C0242568|Biases|idcn|||biases|||0|1000|723|729

SE|25462185|METHODS|ab|4|text|731|887|Case isolates were analyzed at the National Microbiology Laboratory (NML) by pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST).
SE|25462185|METHODS|ab|4|entity|C0025953|Microbiological|inpr|||Microbiology|||0|890|775|787
SE|25462185|METHODS|ab|4|entity|C0332081|National Laboratories|hcro|||National Microbiology Laboratory|||0|890|766|798
SE|25462185|METHODS|ab|4|entity|C0085117|Electrophoresis, Gel, Pulsed-Field|lbpr|||pulsed-field gel electrophoresis|||0|1000|808|840
SE|25462185|METHODS|ab|4|entity|C1519249|Sequence|ftcn|||sequence|||0|660|863|871

SE|25462185|METHODS|ab|5|text|887|1027|Pertussis immunization data were extracted from the Alberta Provincial Immunization Repository (Imm/ARI) and linked to the pertussis cases.
SE|25462185|METHODS|ab|5|entity|C0042203|Pertussis vaccination|topp|||Pertussis immunization|||0|901|887|909
SE|25462185|METHODS|ab|5|entity|C1511726|Data|idcn|||data|||0|901|910|914
SE|25462185|METHODS|ab|5|entity|C0020971|Immunization|topp|||Immunization|||0|750|958|970
SE|25462185|METHODS|ab|5|entity|C0872261|repository|hcro|||Repository|||0|750|971|981
SE|25462185|METHODS|ab|5|entity|C0043167|Pertussis|dsyn|||pertussis|||0|888|1010|1019
SE|25462185|METHODS|ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|1020|1025

SE|25462185|RESULTS|ab|6|text|1027|1258|RESULTS: Using PFGE and MLST, 52 case isolates could be divided into two main sequence type groups: 41 cases belonged to the ST-1 group (ST-1 and the novel ST-19) and 11 cases belonged to the ST-2 group (ST-2 and the novel ST-20).
SE|25462185|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1027|1034
SE|25462185|RESULTS|ab|6|entity|C0085117|Electrophoresis, Gel, Pulsed-Field|lbpr|||PFGE|||0|1000|1042|1046
SE|25462185|RESULTS|ab|6|entity|C1519249|Sequence|ftcn|||MLST|||0|660|1051|1055
SE|25462185|RESULTS|ab|6|entity|C0205448|Two|qnco|||two|||0|822|1096|1099
SE|25462185|RESULTS|ab|6|entity|C0205225|Primary|qlco|||main|||0|822|1100|1104
SE|25462185|RESULTS|ab|6|entity|C1519249|Sequence|ftcn|||sequence|||0|822|1105|1113
SE|25462185|RESULTS|ab|6|entity|C1547052|*Type|qnco|||type|||0|822|1114|1118
SE|25462185|RESULTS|ab|6|entity|C0441833|Groups|inpr|||groups|||0|822|1119|1125
SE|25462185|RESULTS|ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|1130|1135
SE|25462185|RESULTS|ab|6|entity|C0441833|Groups|inpr|||group|||0|802|1157|1162
SE|25462185|RESULTS|ab|6|entity|C0679622|novel|inpr|||novel|||0|790|1177|1182
SE|25462185|RESULTS|ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|1197|1202
SE|25462185|RESULTS|ab|6|entity|C0441833|Groups|inpr|||group|||0|802|1224|1229
SE|25462185|RESULTS|ab|6|entity|C0679622|novel|inpr|||novel|||0|790|1244|1249

SE|25462185|RESULTS|ab|7|text|1258|1421|Of the total cases genotyped (N=52), 18 (34.6%) had a history of immunization, 28 (53.8%) were not immunized, and six (11.6%) had an unknown immunization history.
SE|25462185|RESULTS|ab|7|entity|C0439175|% of total|qnco|||total|||0|888|1265|1270
SE|25462185|RESULTS|ab|7|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|1271|1276
SE|25462185|RESULTS|ab|7|entity|C0019664|Recording of previous events|ocdi|||history|||0|1000|1312|1319
SE|25462185|RESULTS|ab|7|entity|C0020971|Immunization|topp|||immunization|||0|1000|1323|1335
SE|25462185|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1353|1356
SE|25462185|RESULTS|ab|7|entity|C0205452|Six|qnco|||six|||0|1000|1372|1375
SE|25462185|RESULTS|ab|7|entity|C0439673|Unknown|idcn|||unknown|||0|851|1391|1398
SE|25462185|RESULTS|ab|7|entity|C0020971|Immunization|topp|||immunization|||0|851|1399|1411
SE|25462185|RESULTS|ab|7|entity|C0019664|Recording of previous events|ocdi|||history|||0|851|1412|1419

SE|25462185|RESULTS|ab|8|text|1421|1497|Of the total non-immunized cases, 25/28 (89.2%) belonged to the ST-1 group.
SE|25462185|RESULTS|ab|8|entity|C0439175|% of total|qnco|||total|||0|791|1428|1433
SE|25462185|RESULTS|ab|8|entity|C0868928|Case (situation)|ftcn|||cases|||0|791|1448|1453
SE|25462185|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|802|1490|1495

SE|25462185|RESULTS|ab|9|text|1497|1640|Furthermore, of the 41 ST-1 group cases, 25 were not immunized compared to only three of the ST-2 group cases (p=0.0004, Fisher's exact test).
SE|25462185|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|740|1525|1530
SE|25462185|RESULTS|ab|9|entity|C0868928|Case (situation)|ftcn|||cases|||0|740|1531|1536
SE|25462185|RESULTS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1546|1549
SE|25462185|RESULTS|ab|9|entity|C0205449|Three|qnco|||three|||0|827|1577|1582
SE|25462185|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|775|1595|1600
SE|25462185|RESULTS|ab|9|entity|C0868928|Case (situation)|ftcn|||cases|||0|775|1601|1606
SE|25462185|RESULTS|ab|9|entity|C0325045|Martes pennanti|mamm|||Fisher's|||0|802|1618|1626
SE|25462185|RESULTS|ab|9|entity|C0039593|Testing|resa|||test|||0|802|1633|1637

SE|25462185|CONCLUSIONS|ab|10|text|1640|1823|CONCLUSIONS: This study shows the dominance of two genotypes of B. pertussis in our jurisdiction and indicates less pertussis immunization in individuals infected with the ST-1 group.
SE|25462185|CONCLUSIONS|ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1658|1663
SE|25462185|CONCLUSIONS|ab|10|entity|C0870441|Dominance|idcn|||dominance|||0|1000|1674|1683
SE|25462185|CONCLUSIONS|ab|10|entity|C0205448|Two|qnco|||two|||0|888|1687|1690
SE|25462185|CONCLUSIONS|ab|10|entity|C0017431|Genotype|orga|||genotypes|||0|888|1691|1700
SE|25462185|CONCLUSIONS|ab|10|entity|C0006017|Bordetella pertussis Bacterium|bact|||B. pertussis|||0|1000|1704|1716
SE|25462185|CONCLUSIONS|ab|10|entity|C0680647|jurisdiction|idcn|||jurisdiction|||0|1000|1724|1736
SE|25462185|CONCLUSIONS|ab|10|entity|C0042203|Pertussis vaccination|topp|||pertussis immunization|||0|901|1756|1778
SE|25462185|CONCLUSIONS|ab|10|entity|C0237401|Individual|humn|||individuals|||0|1000|1782|1793
SE|25462185|CONCLUSIONS|ab|10|entity|C0441833|Groups|inpr|||group|||0|802|1817|1822
SE|25462185|CONCLUSIONS|ab|10|relation|7|1|C0042203|Pertussis vaccination|topp|topp|||pertussis immunization|||0|901|1756|1778|PREP|TREATS||1779|1781|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1782|1793


SE|25462186||ti|1|text|21|227|Comparative performance of the GeneXpert C. difficile PCR assay and C. diff Quik Chek Complete kit assay for detection of Clostridium difficile antigen and toxins in symptomatic community-onset infections.
SE|25462186||ti|1|entity|C0597198|Performance|inbe|||performance|||0|861|33|44
SE|25462186||ti|1|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|728|75|78
SE|25462186||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|728|79|84
SE|25462186||ti|1|entity|C0082282|Diff Quik|orch|||diff Quik|||0|769|92|101
SE|25462186||ti|1|entity|C0205197|Complete|qlco|||Complete|||0|769|107|115
SE|25462186||ti|1|entity|C0920288|C-KIT Gene|gngm|||C. diff Quik Chek Complete kit|||0|769|89|119
SE|25462186||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|769|120|125
SE|25462186||ti|1|entity|C1511790|Detection|topp|||detection|||0|1000|130|139
SE|25462186||ti|1|entity|C0079134|Clostridium difficile|bact|||Clostridium difficile|||0|901|143|164
SE|25462186||ti|1|entity|C0003320|Antigens|bacs,imft|||antigen|||0|901|165|172
SE|25462186||ti|1|entity|C0040549|Toxin|bacs,hops|||toxins|||0|1000|177|183
SE|25462186||ti|1|entity|C0231220|Symptomatic|ftcn|||symptomatic|||0|833|187|198
SE|25462186||ti|1|entity|C0009462|Community|geoa|||community|||0|833|199|208
SE|25462186||ti|1|entity|C0332162|Onset|qlco|||onset|||0|833|209|214
SE|25462186||ti|1|entity|C0021311|Infection|dsyn|||infections|||0|833|215|225
SE|25462186||ti|1|relation|0|0|C0003320|Antigens|bacs,imft|bacs|||antigen|||0|901|165|172|MOD/HEAD|PART_OF||143|172|0|0|C0079134|Clostridium difficile|bact|bact|||Clostridium difficile|||0|901|143|164
SE|25462186||ti|1|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|728|79|84|MOD/HEAD|USES||75|84|0|0|C0032520|Polymerase Chain Reaction|lbpr,mbrt|lbpr|||PCR|||0|728|75|78
SE|25462186||ti|1|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|769|120|125|MOD/HEAD|USES||89|125|0|0|C0920288|C-KIT Gene|gngm,aapp|aapp|||C. diff Quik Chek Complete kit|||0|769|89|119
SE|25462186||ti|1|relation|3|1|C1510438|Assay|lbpr|lbpr|||assay|||0|728|79|84|PREP|METHOD_OF||126|129|4|1|C1511790|Detection|topp|topp|||detection|||0|1000|130|139
SE|25462186||ti|1|relation|3|1|C1510438|Assay|lbpr|lbpr|||assay|||0|769|120|125|PREP|METHOD_OF||126|129|4|1|C1511790|Detection|topp|topp|||detection|||0|1000|130|139
SE|25462186||ti|1|relation|6|4|C1510438|Assay|lbpr|lbpr|||assay|||0|728|79|84|PREP|DIAGNOSES||184|186|1|1|C0021311|Infection|dsyn|dsyn|||infections|||0|833|215|225
SE|25462186||ti|1|relation|6|4|C1510438|Assay|lbpr|lbpr|||assay|||0|769|120|125|PREP|DIAGNOSES||184|186|1|1|C0021311|Infection|dsyn|dsyn|||infections|||0|833|215|225

SE|25462186|OBJECTIVES|ab|1|text|233|560|OBJECTIVES: To evaluate the performance of the GeneXpert C. difficile assay and C. diff Quik Chek Complete (QCC) kit for the detection of toxins from fecal specimens and cooked meat broth (CMB) culture using toxigenic stool culture as reference method, for the diagnosis of C. difficile infection (CDI) in a community setting.
SE|25462186|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|233|243
SE|25462186|OBJECTIVES|ab|1|entity|C0597198|Performance|inbe|||performance|||0|1000|261|272
SE|25462186|OBJECTIVES|ab|1|entity|C1510438|Assay|lbpr|||assay|||0|812|303|308
SE|25462186|OBJECTIVES|ab|1|entity|C0082282|Diff Quik|orch|||diff Quik|||0|786|316|325
SE|25462186|OBJECTIVES|ab|1|entity|C0205197|Complete|qlco|||Complete|||0|786|331|339
SE|25462186|OBJECTIVES|ab|1|entity|C0920288|C-KIT Gene|gngm|||C. diff Quik Chek Complete (QCC) kit|||0|786|313|349
SE|25462186|OBJECTIVES|ab|1|entity|C1511790|Detection|topp|||detection|||0|1000|358|367
SE|25462186|OBJECTIVES|ab|1|entity|C0040549|Toxin|bacs,hops|||toxins|||0|1000|371|377
SE|25462186|OBJECTIVES|ab|1|entity|C0475360|Stool specimen|bdsu|||fecal specimens|||0|947|383|398
SE|25462186|OBJECTIVES|ab|1|entity|C0335326|Cooking|dora|||cooked|||0|775|403|409
SE|25462186|OBJECTIVES|ab|1|entity|C0025017|Meat|food|||meat|||0|775|410|414
SE|25462186|OBJECTIVES|ab|1|entity|C0220814|Cultural|ftcn|||culture|||0|775|427|434
SE|25462186|OBJECTIVES|ab|1|entity|C0445332|Toxigenic|inpr|||toxigenic|||0|901|441|450
SE|25462186|OBJECTIVES|ab|1|entity|C0430414|Stool culture|lbpr|||stool culture|||0|901|451|464
SE|25462186|OBJECTIVES|ab|1|entity|C1514811|Reference|idcn|||reference|||0|888|468|477
SE|25462186|OBJECTIVES|ab|1|entity|C0025663|Methods|inpr|||method|||0|888|478|484
SE|25462186|OBJECTIVES|ab|1|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|494|503
SE|25462186|OBJECTIVES|ab|1|entity|C0009462|Community|geoa|||community|||0|888|541|550
SE|25462186|OBJECTIVES|ab|1|entity|C0542559|contextual factors|ftcn|||setting|||0|888|551|558
SE|25462186|OBJECTIVES|ab|1|relation|7|1|C0475360|Stool specimen|bdsu|bdsu|||fecal specimens|||0|947|383|398|PREP|LOCATION_OF||378|382|6|1|C0040549|Toxin|bacs,hops|bacs|||toxins|||0|1000|371|377
SE|25462186|OBJECTIVES|ab|1|relation|8|6|C1510438|Assay|lbpr|lbpr|||assay|||0|812|303|308|VERB|USES||435|440|5|1|C0430414|Stool culture|lbpr|lbpr|||stool culture|||0|901|451|464
SE|25462186|OBJECTIVES|ab|1|relation|9|1|C1511790|Detection|topp|topp|||detection|||0|1000|358|367|PREP|USES||350|353|4|1|C0920288|C-KIT Gene|gngm,aapp|aapp|||C. diff Quik Chek Complete (QCC) kit|||0|786|313|349

SE|25462186|METHODS|ab|2|text|560|643|METHODS: Non-repeat stool samples were tested simultaneously by GeneXpert and QCC.
SE|25462186|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|560|567
SE|25462186|METHODS|ab|2|entity|C0205341|Repeat|ftcn|||repeat|||0|813|573|579
SE|25462186|METHODS|ab|2|entity|C0475360|Stool specimen|bdsu|||stool samples|||0|813|580|593
SE|25462186|METHODS|ab|2|entity|C0205197|Complete|qlco|||QCC|||0|827|638|641

SE|25462186|METHODS|ab|3|text|643|730|Toxin detection was done on neat stool samples, inoculated CMB, and isolated colonies.
SE|25462186|METHODS|ab|3|entity|C0430417|Toxin detection|lbpr|||Toxin detection|||0|1000|643|658
SE|25462186|METHODS|ab|3|entity|C0475360|Stool specimen|bdsu|||stool samples|||0|884|676|689
SE|25462186|METHODS|ab|3|entity|C0335326|Cooking|dora|||CMB|||0|623|702|705
SE|25462186|METHODS|ab|3|entity|C0025017|Meat|food|||CMB|||0|623|702|705
SE|25462186|METHODS|ab|3|entity|C0205409|Isolated|ftcn|||isolated|||0|888|711|719
SE|25462186|METHODS|ab|3|entity|C0439158|colonies|qnco|||colonies|||0|888|720|728

SE|25462186|RESULTS|ab|4|text|730|909|RESULTS: Nineteen (4.6%) of 409 samples were positive for glutamate dehydrogenase (GDH) in stool and CMB by the QCC assay; seven (1.7%) were positive for both GDH and toxins A/B.
SE|25462186|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|730|737
SE|25462186|RESULTS|ab|4|entity|C0470354|4+6|qnco|||4.6|||0|1000|749|752
SE|25462186|RESULTS|ab|4|entity|C1446409|Positive|qlco|||positive|||0|1000|775|783
SE|25462186|RESULTS|ab|4|entity|C0017786|Glutamate Dehydrogenase|aapp,enzy|||glutamate dehydrogenase|||0|1000|788|811
SE|25462186|RESULTS|ab|4|entity|C0015733|Feces|bdsu|||stool|||0|1000|821|826
SE|25462186|RESULTS|ab|4|entity|C0335326|Cooking|dora|||CMB|||0|623|831|834
SE|25462186|RESULTS|ab|4|entity|C0025017|Meat|food|||CMB|||0|623|831|834
SE|25462186|RESULTS|ab|4|entity|C0205197|Complete|qlco|||QCC|||0|750|842|845
SE|25462186|RESULTS|ab|4|entity|C1510438|Assay|lbpr|||assay|||0|750|846|851
SE|25462186|RESULTS|ab|4|entity|C0205453|Seven|qnco|||seven|||0|1000|853|858
SE|25462186|RESULTS|ab|4|entity|C1446409|Positive|qlco|||positive|||0|1000|871|879
SE|25462186|RESULTS|ab|4|entity|C0017786|Glutamate Dehydrogenase|aapp,enzy|||GDH|||0|1000|889|892
SE|25462186|RESULTS|ab|4|entity|C0040549|Toxin|bacs,hops|||toxins|||0|1000|897|903
SE|25462186|RESULTS|ab|4|relation|8|1|C0015733|Feces|bdsu|bdsu|||stool|||0|1000|821|826|PREP|LOCATION_OF||818|820|5|1|C0017786|Glutamate Dehydrogenase|aapp,gngm,enzy|aapp|||glutamate dehydrogenase|||0|1000|788|811

SE|25462186|RESULTS|ab|5|text|909|1087|The sensitivities of QCC to detect C. difficile toxin directly in stool specimens and CMB were 68.4% and 100%, respectively, while specificities were 100% and 83%, respectively.
SE|25462186|RESULTS|ab|5|entity|C0040549|Toxin|bacs,hops|||toxin|||0|812|957|962
SE|25462186|RESULTS|ab|5|entity|C0475360|Stool specimen|bdsu|||stool specimens|||0|983|975|990
SE|25462186|RESULTS|ab|5|entity|C0335326|Cooking|dora|||CMB|||0|623|995|998
SE|25462186|RESULTS|ab|5|entity|C0025017|Meat|food|||CMB|||0|623|995|998
SE|25462186|RESULTS|ab|5|entity|C0037791|Specificity|qnco|||specificities|||0|966|1040|1053
SE|25462186|RESULTS|ab|5|relation|3|1|C0475360|Stool specimen|bdsu|bdsu|||stool specimens|||0|983|975|990|PREP|LOCATION_OF||972|974|2|1|C0040549|Toxin|bacs,hops|bacs|||toxin|||0|812|957|962

SE|25462186|RESULTS|ab|6|text|1087|1161|C. difficile toxin was detected in 10 (2.5%) specimens and 13 (3.2%) CMB.
SE|25462186|RESULTS|ab|6|entity|C0040549|Toxin|bacs,hops|||toxin|||0|827|1100|1105
SE|25462186|RESULTS|ab|6|entity|C0450346|2/5|qnco|||2.5|||0|1000|1126|1129
SE|25462186|RESULTS|ab|6|entity|C0370003|Specimen|sbst|||specimens|||0|966|1132|1141
SE|25462186|RESULTS|ab|6|entity|C0439086|<3|qnco|||3|||0|861|1150|1151
SE|25462186|RESULTS|ab|6|entity|C0335326|Cooking|dora|||CMB|||0|623|1156|1159
SE|25462186|RESULTS|ab|6|entity|C0025017|Meat|food|||CMB|||0|623|1156|1159

SE|25462186|RESULTS|ab|7|text|1161|1302|Thirteen (68.4%) of 19 isolates were positive for C. difficile toxin by GeneXpert and QCC and were taken as the reference toxigenic culture.
SE|25462186|RESULTS|ab|7|entity|C1446409|Positive|qlco|||positive|||0|1000|1198|1206
SE|25462186|RESULTS|ab|7|entity|C0040549|Toxin|bacs,hops|||toxin|||0|827|1224|1229
SE|25462186|RESULTS|ab|7|entity|C0205197|Complete|qlco|||QCC|||0|827|1247|1250
SE|25462186|RESULTS|ab|7|entity|C1514811|Reference|idcn|||reference|||0|851|1273|1282
SE|25462186|RESULTS|ab|7|entity|C0445332|Toxigenic|inpr|||toxigenic|||0|851|1283|1292
SE|25462186|RESULTS|ab|7|entity|C0220814|Cultural|ftcn|||culture|||0|851|1293|1300

SE|25462186|RESULTS|ab|8|text|1302|1336|The disease burden was thus 3.2%.
SE|25462186|RESULTS|ab|8|entity|C0012634|Disease|dsyn|||disease|||0|694|1306|1313

SE|25462186|RESULTS|ab|9|text|1336|1473|The sensitivities of GeneXpert in stool and CMB were 81.3% and 100%, respectively, while specificities were 100% and 100%, respectively.
SE|25462186|RESULTS|ab|9|entity|C0015733|Feces|bdsu|||stool|||0|1000|1370|1375
SE|25462186|RESULTS|ab|9|entity|C0335326|Cooking|dora|||CMB|||0|623|1380|1383
SE|25462186|RESULTS|ab|9|entity|C0025017|Meat|food|||CMB|||0|623|1380|1383
SE|25462186|RESULTS|ab|9|entity|C0037791|Specificity|qnco|||specificities|||0|966|1425|1438

SE|25462186|CONCLUSION|ab|10|text|1473|1620|CONCLUSION: The GeneXpert assay was more sensitive than QCC for the detection of C. difficile toxin in stool, but both assays were highly specific.
SE|25462186|CONCLUSION|ab|10|entity|C1510438|Assay|lbpr|||assay|||0|861|1499|1504
SE|25462186|CONCLUSION|ab|10|entity|C0205172|More|ftcn|||more|||0|888|1509|1513
SE|25462186|CONCLUSION|ab|10|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|1514|1523
SE|25462186|CONCLUSION|ab|10|entity|C1511790|Detection|topp|||detection|||0|1000|1541|1550
SE|25462186|CONCLUSION|ab|10|entity|C0040549|Toxin|bacs,hops|||toxin|||0|827|1567|1572
SE|25462186|CONCLUSION|ab|10|entity|C0015733|Feces|bdsu|||stool|||0|1000|1576|1581
SE|25462186|CONCLUSION|ab|10|entity|C1510438|Assay|lbpr|||assays|||0|966|1592|1598
SE|25462186|CONCLUSION|ab|10|relation|3|1|C0015733|Feces|bdsu|bdsu|||stool|||0|1000|1576|1581|PREP|LOCATION_OF||1573|1575|5|1|C0040549|Toxin|bacs,hops|bacs|||toxin|||0|827|1567|1572


SE|25462187||ti|1|text|21|176|Viral genome and antiviral drug sensitivity analysis of two patients from a family cluster caused by the influenza A(H7N9) virus in Zhejiang, China, 2013.
SE|25462187||ti|1|entity|C0042720|Viral Genome|gngm|||Viral genome|||0|1000|21|33
SE|25462187||ti|1|entity|C0003451|Antiviral Agents|phsu|||antiviral drug|||0|861|38|52
SE|25462187||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|861|65|73
SE|25462187||ti|1|entity|C0205448|Two|qnco|||two|||0|888|77|80
SE|25462187||ti|1|entity|C0030705|Patients|podg|||patients|||0|888|81|89
SE|25462187||ti|1|entity|C0015576|Family|famg|||family|||0|694|97|103
SE|25462187||ti|1|entity|C0021400|Influenza|dsyn|||influenza|||0|861|126|135
SE|25462187||ti|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|144|149
SE|25462187||ti|1|entity|C0008115|China|geoa|||China|||0|1000|163|168

SE|25462187|OBJECTIVES|ab|1|text|182|320|OBJECTIVES: In the winter of 2013, people were facing the risk of human-to-human transmission of the re-emerging influenza A(H7N9) virus.
SE|25462187|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|182|192
SE|25462187|OBJECTIVES|ab|1|entity|C0241737|winter|tmco|||winter|||0|1000|201|207
SE|25462187|OBJECTIVES|ab|1|entity|C0027361|Persons|popg|||people|||0|1000|217|223
SE|25462187|OBJECTIVES|ab|1|entity|C0035647|Risk|qlco|||risk|||0|1000|240|244
SE|25462187|OBJECTIVES|ab|1|entity|C1444005|Human to human transmission|clas|||human-to-human transmission|||0|1000|248|275
SE|25462187|OBJECTIVES|ab|1|entity|C0021400|Influenza|dsyn|||influenza|||0|861|295|304
SE|25462187|OBJECTIVES|ab|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|313|318

SE|25462187|OBJECTIVES|ab|2|text|320|516|We report herein information on the clinical features of two patients from the same family infected with this virus, the genomic sequences of the viruses harbored, and antiviral drug sensitivity.
SE|25462187|OBJECTIVES|ab|2|entity|C1533716|Information|idcn|||information|||0|861|337|348
SE|25462187|OBJECTIVES|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|694|356|364
SE|25462187|OBJECTIVES|ab|2|entity|C0205448|Two|qnco|||two|||0|888|377|380
SE|25462187|OBJECTIVES|ab|2|entity|C0030705|Patients|podg|||patients|||0|888|381|389
SE|25462187|OBJECTIVES|ab|2|entity|C0445247|Same|qlco|||same|||0|888|399|403
SE|25462187|OBJECTIVES|ab|2|entity|C0015576|Family|famg|||family|||0|888|404|410
SE|25462187|OBJECTIVES|ab|2|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|430|435
SE|25462187|OBJECTIVES|ab|2|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|861|449|458
SE|25462187|OBJECTIVES|ab|2|entity|C0042776|Virus|virs|||viruses|||0|1000|466|473
SE|25462187|OBJECTIVES|ab|2|entity|C0237865|Drugs Sensitivity|orga|||drug sensitivity|||0|901|498|514
SE|25462187|OBJECTIVES|ab|2|relation|6|1|C0162326|DNA Sequence|nnon,nusq|nusq|||sequences|||0|861|449|458|PREP|PART_OF||459|461|2|1|C0042776|Virus|virs|virs|||viruses|||0|1000|466|473

SE|25462187|METHODS|ab|3|text|516|625|METHODS: Clinical and epidemiological data of two patients from the same family were collected and analyzed.
SE|25462187|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|516|523
SE|25462187|METHODS|ab|3|entity|C0205210|Clinical|qlco|||Clinical|||0|1000|525|533
SE|25462187|METHODS|ab|3|entity|C0014507|Epidemiology|bmod|||epidemiological|||0|853|538|553
SE|25462187|METHODS|ab|3|entity|C1511726|Data|idcn|||data|||0|853|554|558
SE|25462187|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|888|562|565
SE|25462187|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|888|566|574
SE|25462187|METHODS|ab|3|entity|C0445247|Same|qlco|||same|||0|888|584|588
SE|25462187|METHODS|ab|3|entity|C0015576|Family|famg|||family|||0|888|589|595

SE|25462187|METHODS|ab|4|text|625|829|Sequencing was done for the viruses isolated from these two patients and one epidemiologically related chicken, and the sequences of the eight gene segments of the viruses were analyzed phylogenetically.
SE|25462187|METHODS|ab|4|entity|C1561491|Sequencing|ftcn|||Sequencing|||0|1000|625|635
SE|25462187|METHODS|ab|4|entity|C0042776|Virus|virs|||viruses|||0|1000|653|660
SE|25462187|METHODS|ab|4|entity|C0205448|Two|qnco|||two|||0|888|681|684
SE|25462187|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|888|685|693
SE|25462187|METHODS|ab|4|entity|C0205447|One|qnco|||one|||0|775|698|701
SE|25462187|METHODS|ab|4|entity|C1522149|Related|ftcn|||related|||0|775|720|727
SE|25462187|METHODS|ab|4|entity|C0008051|Chickens|bird|||chicken|||0|775|728|735
SE|25462187|METHODS|ab|4|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|1000|745|754
SE|25462187|METHODS|ab|4|entity|C0205454|Eight|qnco|||eight|||0|888|762|767
SE|25462187|METHODS|ab|4|entity|C0017337|Genes|gngm|||gene|||0|888|768|772
SE|25462187|METHODS|ab|4|entity|C0042776|Virus|virs|||viruses|||0|1000|789|796

SE|25462187|METHODS|ab|5|text|829|951|The sensitivity of the viruses to antiviral drug treatment was determined by neuraminidase inhibitor susceptibility test.
SE|25462187|METHODS|ab|5|entity|C0042776|Virus|virs|||viruses|||0|1000|852|859
SE|25462187|METHODS|ab|5|entity|C0003451|Antiviral Agents|phsu|||antiviral drug|||0|901|863|877
SE|25462187|METHODS|ab|5|entity|C1443650|Neuraminidase inhibitor|phsu|||neuraminidase inhibitor|||0|861|906|929
SE|25462187|METHODS|ab|5|entity|C0220898|Predisposition|orga|||susceptibility|||0|861|930|944
SE|25462187|METHODS|ab|5|entity|C0039593|Testing|resa|||test|||0|861|945|949
SE|25462187|METHODS|ab|5|relation|2|0|C0003451|Antiviral Agents|phsu|phsu|||antiviral drug|||0|901|863|877|NOM|TREATS||878|887|2|1|C0042776|Virus|virs|virs|||viruses|||0|1000|852|859

SE|25462187|RESULTS|ab|6|text|951|1093|RESULTS: The two patients from one family cluster shared the same symptoms but had different outcomes, and had a strong epidemiological link.
SE|25462187|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|951|958
SE|25462187|RESULTS|ab|6|entity|C0205448|Two|qnco|||two|||0|888|964|967
SE|25462187|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|888|968|976
SE|25462187|RESULTS|ab|6|entity|C0205447|One|qnco|||one|||0|623|982|985
SE|25462187|RESULTS|ab|6|entity|C0015576|Family|famg|||family|||0|623|986|992
SE|25462187|RESULTS|ab|6|entity|C0445247|Same|qlco|||same|||0|888|1012|1016
SE|25462187|RESULTS|ab|6|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|1017|1025
SE|25462187|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||different|||0|836|1034|1043
SE|25462187|RESULTS|ab|6|entity|C1274040|result|ftcn|||outcomes|||0|836|1044|1052
SE|25462187|RESULTS|ab|6|entity|C0442821|Strong|qlco|||strong|||0|587|1064|1070
SE|25462187|RESULTS|ab|6|entity|C0014507|Epidemiology|bmod|||epidemiological|||0|587|1071|1086

SE|25462187|RESULTS|ab|7|text|1093|1177|Three strains, two from these two patients and one from the chicken, were isolated.
SE|25462187|RESULTS|ab|7|entity|C0205449|Three|qnco|||Three|||0|888|1093|1098
SE|25462187|RESULTS|ab|7|entity|C0205448|Two|qnco|||two|||0|1000|1108|1111
SE|25462187|RESULTS|ab|7|entity|C0205448|Two|qnco|||two|||0|888|1123|1126
SE|25462187|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|888|1127|1135
SE|25462187|RESULTS|ab|7|entity|C0205447|One|qnco|||one|||0|1000|1140|1143
SE|25462187|RESULTS|ab|7|entity|C0008051|Chickens|bird|||chicken|||0|1000|1153|1160

SE|25462187|RESULTS|ab|8|text|1177|1287|Genome sequencing and analyses of phylogenetic trees demonstrated that the two viruses were almost identical.
SE|25462187|RESULTS|ab|8|entity|C1328887|genome sequencing|mbrt|||Genome sequencing|||0|1000|1177|1194
SE|25462187|RESULTS|ab|8|entity|C0936012|Analysis|resa|||analyses|||0|966|1199|1207
SE|25462187|RESULTS|ab|8|entity|C0871077|Phylogenesis|idcn|||phylogenetic|||0|853|1211|1223
SE|25462187|RESULTS|ab|8|entity|C0040811|Trees|plnt|||trees|||0|853|1224|1229
SE|25462187|RESULTS|ab|8|entity|C0205448|Two|qnco|||two|||0|888|1252|1255
SE|25462187|RESULTS|ab|8|entity|C0042776|Virus|virs|||viruses|||0|888|1256|1263
SE|25462187|RESULTS|ab|8|entity|C0205280|Identical|qlco|||identical|||0|861|1276|1285

SE|25462187|RESULTS|ab|9|text|1287|1473|We noted the presence of the PB2 E627K amino acid substitution that was not present in isolates from the first wave, as well as two new mutations in the NA gene and six in the PB2 gene.
SE|25462187|RESULTS|ab|9|entity|C0525038|Amino Acid Substitution|genf,mbrt|||amino acid substitution|||0|884|1326|1349
SE|25462187|RESULTS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1359|1362
SE|25462187|RESULTS|ab|9|entity|C1279901|Firstly|qlco|||first|||0|888|1392|1397
SE|25462187|RESULTS|ab|9|entity|C0678544|wave|npop|||wave|||0|888|1398|1402
SE|25462187|RESULTS|ab|9|entity|C0205448|Two|qnco|||two|||0|851|1415|1418
SE|25462187|RESULTS|ab|9|entity|C0205314|New|tmco|||new|||0|851|1419|1422
SE|25462187|RESULTS|ab|9|entity|C0026882|Mutation|genf|||mutations|||0|851|1423|1432
SE|25462187|RESULTS|ab|9|entity|C1417587|NA gene|gngm|7504|XK|NA gene|||0|1000|1440|1447
SE|25462187|RESULTS|ab|9|entity|C0205452|Six|qnco|||six|||0|1000|1452|1455
SE|25462187|RESULTS|ab|9|entity|C0017337|Genes|gngm|||gene|||0|861|1467|1471
SE|25462187|RESULTS|ab|9|relation|5|4|C0525038|Amino Acid Substitution|genf,mbrt|genf|||amino acid substitution|||0|884|1326|1349|PREP|PROCESS_OF||1433|1435|2|1|C1417587|NA gene|gngm,aapp|gngm|7504|XK|NA gene|||0|1000|1440|1447

SE|25462187|RESULTS|ab|10|text|1473|1585|Drug sensitivity testing showed that the new isolates were resistant to oseltamivir but sensitive to peramivir.
SE|25462187|RESULTS|ab|10|entity|C0038577|Substance Abuse Detection|lbpr|||Drug sensitivity testing|||0|901|1473|1497
SE|25462187|RESULTS|ab|10|entity|C0205314|New|tmco|||new|||0|694|1514|1517
SE|25462187|RESULTS|ab|10|entity|C0332325|Resistant|ftcn|||resistant to|||0|901|1532|1544
SE|25462187|RESULTS|ab|10|entity|C0874161|Oseltamivir|orch,phsu|||oseltamivir|||0|901|1545|1556
SE|25462187|RESULTS|ab|10|entity|C0332324|Sensitive|ftcn|||sensitive to|||0|734|1561|1573

SE|25462187|CONCLUSIONS|ab|11|text|1585|1688|CONCLUSIONS: The two patients from one family cluster were probable human-to-human transmission cases.
SE|25462187|CONCLUSIONS|ab|11|entity|C0205448|Two|qnco|||two|||0|888|1602|1605
SE|25462187|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|888|1606|1614
SE|25462187|CONCLUSIONS|ab|11|entity|C0205447|One|qnco|||one|||0|623|1620|1623
SE|25462187|CONCLUSIONS|ab|11|entity|C0015576|Family|famg|||family|||0|623|1624|1630
SE|25462187|CONCLUSIONS|ab|11|entity|C1444005|Human to human transmission|clas|||human-to-human transmission|||0|876|1653|1680
SE|25462187|CONCLUSIONS|ab|11|entity|C0868928|Case (situation)|ftcn|||cases|||0|876|1681|1686

SE|25462187|CONCLUSIONS|ab|12|text|1688|1779|The new isolates were sensitive to peramivir but showed reduced sensitivity to oseltamivir.
SE|25462187|CONCLUSIONS|ab|12|entity|C0205314|New|tmco|||new|||0|694|1692|1695
SE|25462187|CONCLUSIONS|ab|12|entity|C0332324|Sensitive|ftcn|||sensitive to|||0|734|1710|1722
SE|25462187|CONCLUSIONS|ab|12|entity|C0392756|Reduced|qlco|||reduced|||0|888|1744|1751
SE|25462187|CONCLUSIONS|ab|12|entity|C0874161|Oseltamivir|orch,phsu|||oseltamivir|||0|1000|1767|1778


SE|25462188||ti|1|text|21|131|Stenotrophomonas maltophilia with histopathological features mimicking cutaneous gamma/delta T-cell lymphoma.
SE|25462188||ti|1|entity|C0318290|Stenotrophomonas maltophilia|bact|||Stenotrophomonas maltophilia|||0|1000|21|49
SE|25462188||ti|1|entity|C0243140|Histopathological aspects|ftcn|||histopathological|||0|623|55|72
SE|25462188||ti|1|entity|C0079773|Lymphoma, T-Cell, Cutaneous|neop|||cutaneous gamma/delta T-cell lymphoma|||0|919|92|129

SE|25462188||ab|1|text|137|325|We report a case of cutaneous Stenotrophomonas maltophilia infection which presented with clinical and histopathological findings that mimicked a gamma/delta (gammadelta) T-cell lymphoma.
SE|25462188||ab|1|entity|C0221912|Cutaneous|spco|||cutaneous|||0|916|157|166
SE|25462188||ab|1|entity|C0948224|Stenotrophomonas infection|dsyn|||Stenotrophomonas maltophilia infection|||0|916|167|205
SE|25462188||ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|1000|227|235
SE|25462188||ab|1|entity|C0428093|Histopathology finding|lbtr|||histopathological findings|||0|947|240|266
SE|25462188||ab|1|entity|C0079772|T-Cell Lymphoma|neop|||T-cell lymphoma|||0|1000|308|323

SE|25462188||ab|2|text|325|512|In this case, tissue culture of the biopsy specimen was key to determining the diagnosis and allowing appropriate treatment with oral trimethoprim-sulfamethoxazole and topical silvadene.
SE|25462188||ab|2|entity|C0040284|Tissue culture|lbpr|||tissue culture|||0|1000|339|353
SE|25462188||ab|2|entity|C0677862|Biopsy sample|tisu|||biopsy specimen|||0|1000|361|376
SE|25462188||ab|2|entity|C1554080|Key|idcn|||key|||0|1000|381|384
SE|25462188||ab|2|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|404|413
SE|25462188||ab|2|entity|C0683607|allowing|socb|||allowing|||0|851|418|426
SE|25462188||ab|2|entity|C1548787|Appropriate|qlco|||appropriate|||0|851|427|438
SE|25462188||ab|2|entity|C0442027|Oral|spco|||oral|||0|901|454|458
SE|25462188||ab|2|entity|C0041044|Trimethoprim-Sulfamethoxazole Combination|orch,phsu|||trimethoprim-sulfamethoxazole|||0|901|459|488
SE|25462188||ab|2|entity|C0728768|Silvadene|orch,phsu|||silvadene|||0|861|501|510
SE|25462188||ab|2|relation|0|0|C0040284|Tissue culture|lbpr|lbpr|||tissue culture|||0|1000|339|353|SPEC|ISA||339|413|0|0|C0011900|Diagnosis|hlca|hlca|||diagnosis|||0|1000|404|413
SE|25462188||ab|2|relation|7|1|C0677862|Biopsy sample|tisu|tisu|||biopsy specimen|||0|1000|361|376|PREP|LOCATION_OF||354|356|2|1|C0040284|Tissue culture|lbpr|lbpr|||tissue culture|||0|1000|339|353

SE|25462188||ab|3|text|512|707|A prompt complete resolution of lesions was observed following antibiotic treatment, with no recurrence of disease over the last 5 years, supporting an infectious rather than malignant etiology.
SE|25462188||ab|3|entity|C0205197|Complete|qlco|||complete|||0|851|521|529
SE|25462188||ab|3|entity|C1514893|Resolution|ftcn|||resolution|||0|851|530|540
SE|25462188||ab|3|entity|C0221198|Lesion|fndg|||lesions|||0|1000|544|551
SE|25462188||ab|3|entity|C0003232|Antibiotics|antb|||antibiotic|||0|888|575|585
SE|25462188||ab|3|entity|C0034897|Recurrence|phpr|||recurrence|||0|1000|605|615
SE|25462188||ab|3|entity|C0012634|Disease|dsyn|||disease|||0|1000|619|626
SE|25462188||ab|3|entity|C0205136|Over|spco|||over|||0|1000|627|631
SE|25462188||ab|3|entity|C1517741|Last|qlco|||last|||0|802|636|640
SE|25462188||ab|3|entity|C0439234|year|tmco|||years|||0|802|643|648
SE|25462188||ab|3|entity|C1550587|infectious|idcn|||infectious|||0|1000|664|674
SE|25462188||ab|3|entity|C1314792|Etiology|ftcn|||etiology|||0|861|697|705
SE|25462188||ab|3|relation|2|0|C0003232|Antibiotics|antb|antb|||antibiotic|||0|888|575|585|NOM|TREATS||586|595|6|2|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|619|626

SE|25462188||ab|4|text|707|873|In our patient, radiation therapy was indicated based on the misdiagnosis of gammadelta T-cell lymphoma, which was supported both clinically and histopathologically.
SE|25462188||ab|4|entity|C0030705|Patients|podg|||patient|||0|1000|714|721
SE|25462188||ab|4|entity|C0034618|Radiation therapy|topp|||radiation therapy|||0|1000|723|740
SE|25462188||ab|4|entity|C0679838|misdiagnosis|fndg|||misdiagnosis|||0|1000|768|780
SE|25462188||ab|4|entity|C0079772|T-Cell Lymphoma|neop|||T-cell lymphoma|||0|923|795|810

SE|25462188||ab|5|text|873|1058|However, tissue culture in this case avoided unnecessary radiation exposure and highlights the role of tissue culture in the evaluation of the biopsy of an undiagnosed cutaneous lesion.
SE|25462188||ab|5|entity|C0040284|Tissue culture|lbpr|||tissue culture|||0|1000|882|896
SE|25462188||ab|5|entity|C0034519|Electromagnetic Energy|npop|||radiation|||0|660|930|939
SE|25462188||ab|5|entity|C0035820|Role|socb|||role|||0|1000|968|972
SE|25462188||ab|5|entity|C0040284|Tissue culture|lbpr|||tissue culture|||0|1000|976|990
SE|25462188||ab|5|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|998|1008
SE|25462188||ab|5|entity|C0005558|Biopsy|diap|||biopsy|||0|1000|1016|1022
SE|25462188||ab|5|entity|C1408353|undiagnosed|fndg|||undiagnosed|||0|882|1029|1040
SE|25462188||ab|5|entity|C0037284|Skin lesion|acab|||cutaneous lesion|||0|882|1041|1057


SE|25462189||ti|1|text|21|78|Models of charge pair generation in organic solar cells.
SE|25462189||ti|1|entity|C0079411|Generations|tmco|||generation|||0|793|43|53
SE|25462189||ti|1|entity|C0747055|ORGANIC|qlco|||organic|||0|833|57|64
SE|25462189||ti|1|entity|C0038817|Sunlight|npop|||solar|||0|833|65|70
SE|25462189||ti|1|entity|C0007634|Cells|cell|||cells|||0|833|71|76

SE|25462189||ab|1|text|84|277|Efficient charge pair generation is observed in many organic photovoltaic (OPV) heterojunctions, despite nominal electron-hole binding energies which greatly exceed the average thermal energy.
SE|25462189||ab|1|entity|C0442799|Efficient|qlco|||Efficient|||0|775|84|93
SE|25462189||ab|1|entity|C0079411|Generations|tmco|||generation|||0|775|106|116
SE|25462189||ab|1|entity|C0747055|ORGANIC|qlco|||organic|||0|660|137|144
SE|25462189||ab|1|entity|C0013852|Electrons|qnco|||electron|||0|729|197|205
SE|25462189||ab|1|entity|C0544726|Hole|fndg|||hole|||0|729|206|210
SE|25462189||ab|1|entity|C0424589|Vitality|fndg|||energies|||0|729|219|227
SE|25462189||ab|1|entity|C1510992|Average|qnco|||average|||0|901|253|260
SE|25462189||ab|1|entity|C0018837|Heat (physical force)|npop|||thermal energy|||0|901|261|275

SE|25462189||ab|2|text|277|480|Empirically, the efficiency of this process appears to be related to the choice of donor and acceptor materials, the resulting sequence of excited state energy levels and the structure of the interface.
SE|25462189||ab|2|entity|C0013682|Efficiency|qnco|||efficiency|||0|1000|294|304
SE|25462189||ab|2|entity|C1522240|Process|phpr|||process|||0|1000|313|320
SE|25462189||ab|2|entity|C0000901|Acceptors|popg|||acceptor|||0|872|370|378
SE|25462189||ab|2|entity|C0520510|Materials|sbst|||materials|||0|872|379|388
SE|25462189||ab|2|entity|C1274040|result|ftcn|||resulting|||0|872|394|403
SE|25462189||ab|2|entity|C1519249|Sequence|ftcn|||sequence|||0|872|404|412
SE|25462189||ab|2|entity|C0424589|Vitality|fndg|||energy|||0|813|430|436
SE|25462189||ab|2|entity|C0683927|state wide area|spco|||state energy levels|||0|813|424|443
SE|25462189||ab|2|entity|C0678594|Structure|spco|||structure|||0|1000|452|461

SE|25462189||ab|3|text|480|749|In order to establish a suitable physical model for the process, a range of different theoretical studies have addressed the nature and energies of the interfacial states, the energetic profile close to the heterojunction and the dynamics of excited state transitions.
SE|25462189||ab|3|entity|C0599491|physical model|resd|||physical model|||0|901|513|527
SE|25462189||ab|3|entity|C1522240|Process|phpr|||process|||0|1000|536|543
SE|25462189||ab|3|entity|C1514721|Range|qnco|||range|||0|1000|547|552
SE|25462189||ab|3|entity|C1547020|*Difference|qnco|||different|||0|877|556|565
SE|25462189||ab|3|entity|C0039778|Theoretical Study|inpr,resa|||theoretical studies|||0|877|566|585
SE|25462189||ab|3|entity|C0349590|Nature|idcn|||nature|||0|1000|605|611
SE|25462189||ab|3|entity|C0424589|Vitality|fndg|||energies|||0|966|616|624
SE|25462189||ab|3|entity|C1442792|State|ftcn|||states|||0|827|644|650
SE|25462189||ab|3|entity|C1554158|State transition|idcn|||state transitions|||0|884|730|747

SE|25462189||ab|4|text|749|970|In this paper, we review recent developments underpinning the theory of charge pair generation and phenomena, focussing on electronic structure calculations, electrostatic models and approaches to excited state dynamics.
SE|25462189||ab|4|entity|C0030351|Paper|mnob|||paper|||0|1000|757|762
SE|25462189||ab|4|entity|C0332185|Recent|tmco|||recent|||0|872|774|780
SE|25462189||ab|4|entity|C1527148|Development|ftcn|||developments|||0|872|781|793
SE|25462189||ab|4|entity|C0871935|Theories|idcn|||theory|||0|966|811|817
SE|25462189||ab|4|entity|C0079411|Generations|tmco|||generation|||0|793|833|843
SE|25462189||ab|4|entity|C0013850|Electronic|mnob|||electronic|||0|840|872|882
SE|25462189||ab|4|entity|C0678594|Structure|spco|||structure|||0|840|883|892
SE|25462189||ab|4|entity|C1441506|CALCULATION|lbpr|||calculations|||0|840|893|905
SE|25462189||ab|4|entity|C1442792|State|ftcn|||state|||0|660|954|959

SE|25462189||ab|5|text|970|1073|We discuss the remaining challenges in achieving a predictive approach to charge generation efficiency.
SE|25462189||ab|5|entity|C1527428|Remaining|qlco|||remaining|||0|872|985|994
SE|25462189||ab|5|entity|C0681890|predictive|qlco|||predictive|||0|888|1021|1031
SE|25462189||ab|5|entity|C0449445|Approach|spco|||approach|||0|888|1032|1040
SE|25462189||ab|5|entity|C0079411|Generations|tmco|||generation|||0|872|1051|1061
SE|25462189||ab|5|entity|C0013682|Efficiency|qnco|||efficiency|||0|872|1062|1072


SE|25462190||ti|1|text|21|199|Epidemiology, risk factors and genotypes of HBV in HIV-infected patients in the northeast region of Colombia: high prevalence of occult hepatitis B and F3 subgenotype dominance.
SE|25462190||ti|1|entity|C0014507|Epidemiology|bmod|||Epidemiology|||0|1000|21|33
SE|25462190||ti|1|entity|C0035648|risk factors|qnco|||risk factors|||0|1000|35|47
SE|25462190||ti|1|entity|C0017431|Genotype|orga|||genotypes|||0|1000|52|61
SE|25462190||ti|1|entity|C0019169|Hepatitis B Virus|virs|||HBV|||0|1000|65|68
SE|25462190||ti|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|875|72|75
SE|25462190||ti|1|entity|C0439663|Infected|ftcn|||infected|||0|875|76|84
SE|25462190||ti|1|entity|C0030705|Patients|podg|||patients|||0|875|85|93
SE|25462190||ti|1|entity|C0205147|Region|spco|||region|||0|861|111|117
SE|25462190||ti|1|entity|C0009367|Colombia|geoa|||Colombia|||0|1000|121|129
SE|25462190||ti|1|entity|C1512456|High Prevalence|qnco|||high prevalence|||0|1000|131|146
SE|25462190||ti|1|entity|C0028794|Occultism|idcn|||occult|||0|901|150|156
SE|25462190||ti|1|entity|C0019163|Hepatitis B|dsyn|||hepatitis B|||0|901|157|168
SE|25462190||ti|1|entity|C0870441|Dominance|idcn|||dominance|||0|802|188|197
SE|25462190||ti|1|relation|4|1|C0019169|Hepatitis B Virus|virs|virs|||HBV|||0|1000|65|68|PREP|PROCESS_OF||69|71|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|875|85|93

SE|25462190|INTRODUCTION|ab|1|text|205|371|INTRODUCTION: Chronic hepatitis B virus (HBV) infection is an increasing cause of morbidity and mortality in human immunodeficiency virus (HIV)-infected individuals.
SE|25462190|INTRODUCTION|ab|1|entity|C1293116|Introduction procedure|hlca|||INTRODUCTION|||0|1000|205|217
SE|25462190|INTRODUCTION|ab|1|entity|C0019169|Hepatitis B Virus|virs|||hepatitis B virus|||0|893|227|244
SE|25462190|INTRODUCTION|ab|1|entity|C0151317|Chronic infectious disease|dsyn|||Chronic hepatitis B virus (HBV) infection|||0|893|219|260
SE|25462190|INTRODUCTION|ab|1|entity|C0442808|Increasing|ftcn|||increasing|||0|872|267|277
SE|25462190|INTRODUCTION|ab|1|entity|C0015127|Etiology aspects|ftcn|||cause|||0|872|278|283
SE|25462190|INTRODUCTION|ab|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||human immunodeficiency virus|||0|875|314|342
SE|25462190|INTRODUCTION|ab|1|entity|C0439663|Infected|ftcn|||infected|||0|875|349|357
SE|25462190|INTRODUCTION|ab|1|entity|C0237401|Individual|humn|||individuals|||0|875|358|369
SE|25462190|INTRODUCTION|ab|1|relation|5|4|C0151317|Chronic infectious disease|dsyn|dsyn|||Chronic hepatitis B virus (HBV) infection|||0|893|219|260|PREP|PROCESS_OF||311|313|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|875|358|369

SE|25462190|INTRODUCTION|ab|2|text|371|465|HIV-positive patients are commonly co-infected with HBV due to shared routes of transmission.
SE|25462190|INTRODUCTION|ab|2|entity|C0019699|HIV Seropositivity|fndg|||HIV-positive|||0|928|371|383
SE|25462190|INTRODUCTION|ab|2|entity|C0030705|Patients|podg|||patients|||0|928|384|392
SE|25462190|INTRODUCTION|ab|2|entity|C0439663|Infected|ftcn|||infected|||0|773|409|417
SE|25462190|INTRODUCTION|ab|2|entity|C0019169|Hepatitis B Virus|virs|||HBV|||0|1000|423|426
SE|25462190|INTRODUCTION|ab|2|entity|C0449444|Route|spco|||routes|||0|827|441|447
SE|25462190|INTRODUCTION|ab|2|relation|0|0|C0019699|HIV Seropositivity|fndg|fndg|||HIV-positive|||0|928|371|383|MOD/HEAD|PROCESS_OF||371|392|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|928|384|392

SE|25462190|OBJECTIVES|ab|3|text|465|693|OBJECTIVES: Our aim was to determine the risk factors, prevalence, genotypes, and mutations of the Surface S gene of HBV, and occult hepatitis B infection (OBI) among patients infected with HIV in a northeastern Colombian city.
SE|25462190|OBJECTIVES|ab|3|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|465|475
SE|25462190|OBJECTIVES|ab|3|entity|C0035648|risk factors|qnco|||risk factors|||0|1000|506|518
SE|25462190|OBJECTIVES|ab|3|entity|C0017431|Genotype|orga|||genotypes|||0|1000|532|541
SE|25462190|OBJECTIVES|ab|3|entity|C0026882|Mutation|genf|||mutations|||0|1000|547|556
SE|25462190|OBJECTIVES|ab|3|entity|C0205148|Surface|spco|||Surface|||0|840|564|571
SE|25462190|OBJECTIVES|ab|3|entity|C0017337|Genes|gngm|||gene|||0|840|574|578
SE|25462190|OBJECTIVES|ab|3|entity|C0019169|Hepatitis B Virus|virs|||HBV|||0|1000|582|585
SE|25462190|OBJECTIVES|ab|3|entity|C0028794|Occultism|idcn|||occult|||0|916|591|597
SE|25462190|OBJECTIVES|ab|3|entity|C0019163|Hepatitis B|dsyn|||hepatitis B infection|||0|916|598|619
SE|25462190|OBJECTIVES|ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|632|640
SE|25462190|OBJECTIVES|ab|3|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|1000|655|658
SE|25462190|OBJECTIVES|ab|3|entity|C1553372|Colombian|popg|||Colombian|||0|790|677|686
SE|25462190|OBJECTIVES|ab|3|entity|C0008848|Cities|geoa|||city|||0|790|687|691
SE|25462190|OBJECTIVES|ab|3|relation|10|2|C0019163|Hepatitis B|dsyn|dsyn|||hepatitis B infection|||0|916|598|619|PREP|PROCESS_OF||626|631|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|632|640
SE|25462190|OBJECTIVES|ab|3|relation|11|4|C0019169|Hepatitis B Virus|virs|virs|||HBV|||0|1000|582|585|VERB|INTERACTS_WITH||641|649|2|1|C0001175|Acquired Immunodeficiency Syndrome|dsyn|dsyn|||HIV|||0|1000|655|658

SE|25462190|METHODS|ab|4|text|693|845|METHODS: A cross-sectional study was conducted with 275 HIV-positive patients attending an outpatient clinic in Bucaramanga, Colombia during 2009-2010.
SE|25462190|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|693|700
SE|25462190|METHODS|ab|4|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional study|||0|1000|704|725
SE|25462190|METHODS|ab|4|entity|C0019699|HIV Seropositivity|fndg|||HIV-positive|||0|876|749|761
SE|25462190|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|876|762|770
SE|25462190|METHODS|ab|4|entity|C0002424|Ambulatory Care Facilities|hcro,mnob|||outpatient clinic|||0|1000|784|801
SE|25462190|METHODS|ab|4|entity|C0009367|Colombia|geoa|||Colombia|||0|1000|818|826
SE|25462190|METHODS|ab|4|relation|0|0|C0019699|HIV Seropositivity|fndg|fndg|||HIV-positive|||0|876|749|761|MOD/HEAD|PROCESS_OF||749|770|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|876|762|770

SE|25462190|METHODS|ab|5|text|845|970|Blood samples were collected and screened for serological markers of HBV (anti-HBs, anti-HBc and HBsAg) through ELISA assay.
SE|25462190|METHODS|ab|5|entity|C0178913|Blood specimen|bdsu|||Blood samples|||0|983|845|858
SE|25462190|METHODS|ab|5|entity|C0205473|Serologic|ftcn|||serological|||0|694|891|902
SE|25462190|METHODS|ab|5|entity|C0019169|Hepatitis B Virus|virs|||HBV|||0|1000|914|917
SE|25462190|METHODS|ab|5|entity|C0369334|Hepatitis B Virus Surface Antibody|aapp,imft|||anti-HBs|||0|1000|919|927
SE|25462190|METHODS|ab|5|entity|C0312631|Antibody to hepatitis B core antigen|aapp,imft|85348|KRT88P|anti-HBc|||0|1000|929|937
SE|25462190|METHODS|ab|5|entity|C0014441|Enzyme-Linked Immunosorbent Assay|lbpr|||ELISA assay|||0|1000|957|968

SE|25462190|METHODS|ab|6|text|970|1129|Regardless of their serological profile, all samples were tested for the HBV S gene by nested-PCR and HBV genotypes were determined by phylogenetic inference.
SE|25462190|METHODS|ab|6|entity|C0205473|Serologic|ftcn|||serological|||0|694|990|1001
SE|25462190|METHODS|ab|6|entity|C0019169|Hepatitis B Virus|virs|||HBV|||0|864|1043|1046
SE|25462190|METHODS|ab|6|entity|C0017337|Genes|gngm|||gene|||0|864|1049|1053
SE|25462190|METHODS|ab|6|entity|C0242574|Nested Polymerase Chain Reaction|mbrt|||nested-PCR|||0|1000|1057|1067
SE|25462190|METHODS|ab|6|entity|C1148362|HEPATITIS B VIRUS GENOTYPE|orga|||HBV genotypes|||0|983|1072|1085
SE|25462190|METHODS|ab|6|entity|C0871077|Phylogenesis|idcn|||phylogenetic|||0|853|1105|1117
SE|25462190|METHODS|ab|6|entity|C0679201|inference|idcn|||inference|||0|853|1118|1127

SE|25462190|METHODS|ab|7|text|1129|1278|Clinical records were used to examine demographic, clinical, virological, immunological and antiretroviral therapy (ART) variables of HIV infection.
SE|25462190|METHODS|ab|7|entity|C0205210|Clinical|qlco|||Clinical|||0|888|1129|1137
SE|25462190|METHODS|ab|7|entity|C0034869|Records|inpr|||records|||0|888|1138|1145
SE|25462190|METHODS|ab|7|entity|C0011298|Demography|ocdi|||demographic|||0|825|1167|1178
SE|25462190|METHODS|ab|7|entity|C0205466|virologic|ftcn|||virological|||0|825|1190|1201
SE|25462190|METHODS|ab|7|entity|C1319413|Clinical immunology|bmod|||clinical, virological, immunological|||0|825|1180|1216
SE|25462190|METHODS|ab|7|entity|C0439828|Variable|qlco|||variables|||0|773|1250|1259
SE|25462190|METHODS|ab|7|entity|C0019693|HIV Infections|dsyn|||HIV infection|||0|1000|1263|1276

SE|25462190|RESULTS|ab|8|text|1278|1350|RESULTS: Participants were on average 37+/-11 years old and 65.1% male.
SE|25462190|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|1278|1285
SE|25462190|RESULTS|ab|8|entity|C0679646|Participant|popg|||Participants|||0|966|1287|1299
SE|25462190|RESULTS|ab|8|entity|C1510992|Average|qnco|||average|||0|791|1308|1315
SE|25462190|RESULTS|ab|8|entity|C0439234|year|tmco|||years|||0|791|1324|1329
SE|25462190|RESULTS|ab|8|entity|C0580836|Old|tmco|||old|||0|1000|1330|1333

SE|25462190|RESULTS|ab|9|text|1350|1466|The prevalence of HIV-HBV coinfection was 12% (95%CI 8.4-16.4) of which 3.3% had active HBV infection and 8.7% OBI.
SE|25462190|RESULTS|ab|9|entity|C0682458|immunodeficiency virus|virs|||HIV|||0|689|1368|1371
SE|25462190|RESULTS|ab|9|entity|C0019169|Hepatitis B Virus|virs|||HIV-HBV|||0|689|1368|1375
SE|25462190|RESULTS|ab|9|entity|C0387382|CI 4|aapp,phsu|||CI 8.4|||0|839|1400|1406
SE|25462190|RESULTS|ab|9|entity|C0439086|<3|qnco|||3|||0|861|1422|1423
SE|25462190|RESULTS|ab|9|entity|C0205177|Active|ftcn|||active|||0|875|1431|1437
SE|25462190|RESULTS|ab|9|entity|C0042769|Virus Diseases|dsyn|||HBV|||0|875|1438|1441
SE|25462190|RESULTS|ab|9|entity|C0019163|Hepatitis B|dsyn|||HBV infection|||0|875|1438|1451
SE|25462190|RESULTS|ab|9|relation|0|0|C0019163|Hepatitis B|dsyn|dsyn|||HBV infection|||0|875|1438|1451|MOD/HEAD|ISA||1438|1451|0|0|C0042769|Virus Diseases|dsyn|dsyn|||HBV|||0|875|1438|1441

SE|25462190|RESULTS|ab|10|text|1466|1554|The prevalence of HIV-HBV coinfection was associated with AIDS stage and ART treatment.
SE|25462190|RESULTS|ab|10|entity|C0682458|immunodeficiency virus|virs|||HIV|||0|689|1484|1487
SE|25462190|RESULTS|ab|10|entity|C0019169|Hepatitis B Virus|virs|||HIV-HBV|||0|689|1484|1491
SE|25462190|RESULTS|ab|10|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||AIDS|||0|888|1524|1528
SE|25462190|RESULTS|ab|10|entity|C1306673|Stage|qlco|||stage|||0|888|1529|1534

SE|25462190|RESULTS|ab|11|text|1554|1667|Sequence analysis identified genotype F, subgenotype F3 in 93.8% of patients and genotype A in 6.2% of patients.
SE|25462190|RESULTS|ab|11|entity|C0162801|Sequence Analysis|lbpr,mbrt|||Sequence analysis|||0|1000|1554|1571
SE|25462190|RESULTS|ab|11|entity|C0017431|Genotype|orga|||genotype|||0|872|1583|1591
SE|25462190|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1622|1630
SE|25462190|RESULTS|ab|11|entity|C0017431|Genotype|orga|||genotype|||0|1000|1635|1643
SE|25462190|RESULTS|ab|11|entity|C0595228|6+2|qnco|||6.2|||0|1000|1649|1652
SE|25462190|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1657|1665

SE|25462190|RESULTS|ab|12|text|1667|1777|A C149R mutation, which may have resulted from failure in HBsAg detection, was found in one patient with OBI.
SE|25462190|RESULTS|ab|12|entity|C0026882|Mutation|genf|||mutation|||0|861|1675|1683
SE|25462190|RESULTS|ab|12|entity|C1511790|Detection|topp|||detection|||0|861|1731|1740
SE|25462190|RESULTS|ab|12|entity|C0205447|One|qnco|||one|||0|888|1755|1758
SE|25462190|RESULTS|ab|12|entity|C0030705|Patients|podg|||patient|||0|888|1759|1766
SE|25462190|RESULTS|ab|12|relation|3|1|C1511790|Detection|topp|topp|||detection|||0|861|1731|1740|PREP|TREATS||1752|1754|2|1|C0030705|Patients|podg,humn|podg|||patient|||0|888|1759|1766

SE|25462190|CONCLUSIONS|ab|13|text|1777|1930|CONCLUSIONS: The present study found a high prevalence of HIV-HBV coinfection with an incidence of OBI 2.6-fold higher compared to active HBV infection.
SE|25462190|CONCLUSIONS|ab|13|entity|C0150312|Present|qnco|||present|||0|888|1794|1801
SE|25462190|CONCLUSIONS|ab|13|entity|C0008972|Clinical Research|resa|||study|||0|888|1802|1807
SE|25462190|CONCLUSIONS|ab|13|entity|C1512456|High Prevalence|qnco|||high prevalence|||0|1000|1816|1831
SE|25462190|CONCLUSIONS|ab|13|entity|C0682458|immunodeficiency virus|virs|||HIV|||0|689|1835|1838
SE|25462190|CONCLUSIONS|ab|13|entity|C0019169|Hepatitis B Virus|virs|||HIV-HBV|||0|689|1835|1842
SE|25462190|CONCLUSIONS|ab|13|entity|C0021149|Incidence|qnco|||incidence|||0|1000|1863|1872
SE|25462190|CONCLUSIONS|ab|13|entity|C0332462|Fold|spco|||fold|||0|812|1884|1888
SE|25462190|CONCLUSIONS|ab|13|entity|C0205250|High|qlco|||higher|||0|966|1889|1895
SE|25462190|CONCLUSIONS|ab|13|entity|C0205177|Active|ftcn|||active|||0|875|1908|1914
SE|25462190|CONCLUSIONS|ab|13|entity|C0042769|Virus Diseases|dsyn|||HBV|||0|875|1915|1918
SE|25462190|CONCLUSIONS|ab|13|entity|C0019163|Hepatitis B|dsyn|||HBV infection|||0|875|1915|1928
SE|25462190|CONCLUSIONS|ab|13|relation|0|0|C0019163|Hepatitis B|dsyn|dsyn|||HBV infection|||0|875|1915|1928|MOD/HEAD|ISA||1915|1928|0|0|C0042769|Virus Diseases|dsyn|dsyn|||HBV|||0|875|1915|1918

SE|25462190|CONCLUSIONS|ab|14|text|1930|2062|These findings suggest including HBV DNA testing to detect OBI in addition to screening for HBV serological markers in HIV patients.
SE|25462190|CONCLUSIONS|ab|14|entity|C0243095|Finding|ftcn|||findings|||0|1000|1936|1944
SE|25462190|CONCLUSIONS|ab|14|entity|C0369332|Hepatitis B virus DNA|bacs,nnon|||HBV DNA|||0|928|1963|1970
SE|25462190|CONCLUSIONS|ab|14|entity|C0039593|Testing|resa|||testing|||0|928|1971|1978
SE|25462190|CONCLUSIONS|ab|14|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|2008|2017
SE|25462190|CONCLUSIONS|ab|14|entity|C0019169|Hepatitis B Virus|virs|||HBV|||0|687|2022|2025
SE|25462190|CONCLUSIONS|ab|14|entity|C0205473|Serologic|ftcn|||serological|||0|687|2026|2037
SE|25462190|CONCLUSIONS|ab|14|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|916|2049|2052
SE|25462190|CONCLUSIONS|ab|14|entity|C0030705|Patients|podg|||patients|||0|916|2053|2061
SE|25462190|CONCLUSIONS|ab|14|relation|0|0|C0001175|Acquired Immunodeficiency Syndrome|dsyn|dsyn|||HIV|||0|916|2049|2052|MOD/HEAD|PROCESS_OF||2049|2061|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|916|2053|2061
SE|25462190|CONCLUSIONS|ab|14|relation|0|0|C0220908|Screening procedure|hlca|hlca|||screening|||0|1000|2008|2017|INFER|TREATS(INFER)||2046|2048|0|0|C0001175|Acquired Immunodeficiency Syndrome|dsyn|dsyn|||HIV|||0|916|2049|2052
SE|25462190|CONCLUSIONS|ab|14|relation|6|2|C0220908|Screening procedure|hlca|hlca|||screening|||0|1000|2008|2017|PREP|TREATS||2046|2048|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|916|2053|2061


SE|25462191||ti|1|text|21|130|Exploring human 40S ribosomal proteins binding to the 18S rRNA fragment containing major 3'-terminal domain.
SE|25462191||ti|1|entity|C0020114|Human|humn|||human|||0|787|31|36
SE|25462191||ti|1|entity|C0439509|/40|tmco|||40S|||0|787|37|40
SE|25462191||ti|1|entity|C0035552|Ribosomal Proteins|aapp,bacs|||ribosomal proteins|||0|787|41|59
SE|25462191||ti|1|entity|C1552132|Supernumerary mandibular left second molar|bpoc|||18S|||0|840|75|78
SE|25462191||ti|1|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|840|79|83
SE|25462191||ti|1|entity|C0486805|FRAGMENTS|bdsu|||fragment|||0|840|84|92
SE|25462191||ti|1|entity|C0205164|Major|qlco|||major|||0|597|104|109

SE|25462191||ab|1|text|136|280|Association of ribosomal proteins with rRNA during assembly of ribosomal subunits is an intricate process, which is strictly regulated in vivo.
SE|25462191||ab|1|entity|C0035552|Ribosomal Proteins|aapp,bacs|||ribosomal proteins|||0|1000|151|169
SE|25462191||ab|1|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|1000|175|179
SE|25462191||ab|1|entity|C1441152|RIBOSOMAL|celc|||ribosomal|||0|694|199|208
SE|25462191||ab|1|entity|C1522240|Process|phpr|||process|||0|861|234|241
SE|25462191||ab|1|entity|C1515655|in vivo|spco|||in vivo|||0|1000|271|278
SE|25462191||ab|1|relation|6|2|C0035701|Ribosomal RNA|bacs,nnon|bacs|||rRNA|||0|1000|175|179|NOM|COEXISTS_WITH||136|147|6|1|C0035552|Ribosomal Proteins|aapp,gngm,bacs|aapp|||ribosomal proteins|||0|1000|151|169

SE|25462191||ab|2|text|280|364|As for the assembly in vitro, it was reported so far only for prokaryotic subunits.
SE|25462191||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|300|308

SE|25462191||ab|3|text|364|488|Bacterial ribosomal proteins are capable of selective binding to 16S rRNA as well as to its separate morphological domains.
SE|25462191||ab|3|entity|C1441152|RIBOSOMAL|celc|||ribosomal|||0|901|374|383
SE|25462191||ab|3|entity|C0004627|Bacterial Proteins|aapp,bacs|||Bacterial ribosomal proteins|||0|901|364|392
SE|25462191||ab|3|entity|C1552130|16s|bpoc|||16S|||0|888|429|432
SE|25462191||ab|3|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|888|433|437
SE|25462191||ab|3|entity|C0443299|Separate|spco|||separate|||0|623|456|464
SE|25462191||ab|3|entity|C0543482|morphological|spco|||morphological|||0|623|465|478
SE|25462191||ab|3|relation|0|0|C0004627|Bacterial Proteins|aapp,gngm,bacs|aapp|||Bacterial ribosomal proteins|||0|901|364|392|MOD/HEAD|PART_OF||374|392|0|0|C1441152|RIBOSOMAL|celc|celc|||ribosomal|||0|901|374|383
SE|25462191||ab|3|relation|0|0|C0035701|Ribosomal RNA|bacs,nnon|bacs|||rRNA|||0|888|433|437|MOD/HEAD|PART_OF||429|437|0|0|C1552130|16s|bpoc|bpoc|||16S|||0|888|429|432
SE|25462191||ab|3|relation|2|2|C0004627|Bacterial Proteins|aapp,gngm,bacs|aapp|||Bacterial ribosomal proteins|||0|901|364|392|NOM|INTERACTS_WITH||418|425|2|1|C0035701|Ribosomal RNA|bacs,nnon|bacs|||rRNA|||0|888|433|437

SE|25462191||ab|4|text|488|642|In this work, we explored binding of total protein of human 40S ribosomal subunit to the RNA transcript corresponding to the major 3'-domain of 18S rRNA.
SE|25462191||ab|4|entity|C0043227|Work|ocac|||work|||0|1000|496|500
SE|25462191||ab|4|entity|C0439175|% of total|qnco|||total|||0|888|525|530
SE|25462191||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|531|538
SE|25462191||ab|4|entity|C0020114|Human|humn|||human|||0|916|542|547
SE|25462191||ab|4|entity|C1166820|cytosolic small ribosomal subunit (sensu Eukarya)|celc|||40S ribosomal subunit|||0|916|548|569
SE|25462191||ab|4|entity|C0035668|RNA|bacs,nnon|||RNA|||0|888|577|580
SE|25462191||ab|4|entity|C1519595|Transcript|nnon|||transcript|||0|888|581|591
SE|25462191||ab|4|entity|C0205164|Major|qlco|||major|||0|660|613|618
SE|25462191||ab|4|entity|C1552132|Supernumerary mandibular left second molar|bpoc|||18S|||0|888|632|635
SE|25462191||ab|4|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|888|636|640
SE|25462191||ab|4|relation|0|0|C0035701|Ribosomal RNA|bacs,nnon|bacs|||rRNA|||0|888|636|640|MOD/HEAD|PART_OF||632|640|0|0|C1552132|Supernumerary mandibular left second molar|bpoc|bpoc|||18S|||0|888|632|635
SE|25462191||ab|4|relation|0|0|C1166820|cytosolic small ribosomal subunit (sensu Eukarya)|celc|celc|||40S ribosomal subunit|||0|916|548|569|MOD/HEAD|PART_OF||542|569|0|0|C0020114|Human|grup,humn|humn|||human|||0|916|542|547

SE|25462191||ab|5|text|642|876|We showed that the resulting ribonucleoprotein particles contained almost all of the expected ribosomal proteins, whose binding sites are located in this 18S rRNA domain in the 40S subunit, together with several nonspecific proteins.
SE|25462191||ab|5|entity|C1274040|result|ftcn|||resulting|||0|879|661|670
SE|25462191||ab|5|entity|C0684076|ribonucleoprotein particle|celc|||ribonucleoprotein particles|||0|879|671|698
SE|25462191||ab|5|entity|C1517001|Expected|idcn|||expected|||0|901|727|735
SE|25462191||ab|5|entity|C0035552|Ribosomal Proteins|aapp,bacs|||ribosomal proteins|||0|901|736|754
SE|25462191||ab|5|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|762|775
SE|25462191||ab|5|entity|C1552132|Supernumerary mandibular left second molar|bpoc|||18S|||0|623|796|799
SE|25462191||ab|5|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|623|800|804
SE|25462191||ab|5|entity|C0443302|Several|qnco|||several|||0|851|846|853
SE|25462191||ab|5|entity|C0750540|NONSPECIFIC|idcn|||nonspecific|||0|851|854|865
SE|25462191||ab|5|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|851|866|874

SE|25462191||ab|6|text|876|963|The binding in solution was accompanied with aggregation of the RNA-protein complexes.
SE|25462191||ab|6|entity|C0037633|Solutions|sbst|||solution|||0|1000|891|899
SE|25462191||ab|6|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|921|932
SE|25462191||ab|6|entity|C0035668|RNA|bacs,nnon|||RNA|||0|890|940|943
SE|25462191||ab|6|entity|C1180347|Protein complex|aapp,bacs|||protein complexes|||0|890|944|961

SE|25462191||ab|7|text|963|1240|Ribosomal proteins bound to the RNA transcript protected from chemical modification mostly those 18S rRNA nucleotides that are known to be involved in binding with the proteins in the 40S subunit and thereby demonstrated their ability to selectively bind to the rRNA in vitro.
SE|25462191||ab|7|entity|C0035552|Ribosomal Proteins|aapp,bacs|||Ribosomal proteins|||0|1000|963|981
SE|25462191||ab|7|entity|C0035668|RNA|bacs,nnon|||RNA|||0|888|995|998
SE|25462191||ab|7|entity|C1519595|Transcript|nnon|||transcript|||0|888|999|1009
SE|25462191||ab|7|entity|C0220806|Chemicals|chem|||chemical|||0|851|1025|1033
SE|25462191||ab|7|entity|C1522413|Modification|ftcn|||modification|||0|851|1034|1046
SE|25462191||ab|7|entity|C0750554|MOSTLY|idcn|||mostly|||0|851|1047|1053
SE|25462191||ab|7|entity|C1552132|Supernumerary mandibular left second molar|bpoc|||18S|||0|851|1060|1063
SE|25462191||ab|7|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|851|1064|1068
SE|25462191||ab|7|entity|C0028630|Nucleotides|nnon|||nucleotides|||0|851|1069|1080
SE|25462191||ab|7|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|1131|1139
SE|25462191||ab|7|entity|C0085732|Ability|orga|||ability|||0|1000|1190|1197
SE|25462191||ab|7|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|1000|1225|1229
SE|25462191||ab|7|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|1230|1238
SE|25462191||ab|7|relation|0|0|C0035701|Ribosomal RNA|bacs,nnon|bacs|||rRNA|||0|851|1064|1068|MOD/HEAD|ISA||1064|1080|0|0|C0028630|Nucleotides|nnon|nnon|||nucleotides|||0|851|1069|1080
SE|25462191||ab|7|relation|1|1|C0035552|Ribosomal Proteins|aapp,gngm,bacs|aapp|||Ribosomal proteins|||0|1000|963|981|VERB|INTERACTS_WITH||982|987|9|1|C1519595|Transcript|nnon|nnon|||transcript|||0|888|999|1009
SE|25462191||ab|7|relation|8|3|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|1131|1139|VERB|INTERACTS_WITH||1213|1217|2|1|C0035701|Ribosomal RNA|bacs,nnon|bacs|||rRNA|||0|1000|1225|1229

SE|25462191||ab|8|text|1240|1434|The possible implication of unstructured extensions of eukaryotic ribosomal proteins in their nonspecific binding with rRNA and in subsequent aggregation of the resulting complexes is discussed.
SE|25462191||ab|8|entity|C0332149|Possible|qlco|||possible|||0|694|1244|1252
SE|25462191||ab|8|entity|C0231448|Extension|ftcn|||extensions|||0|827|1281|1291
SE|25462191||ab|8|entity|C0684063|Eukaryota|orgm|||eukaryotic|||0|865|1295|1305
SE|25462191||ab|8|entity|C0035552|Ribosomal Proteins|aapp,bacs|||ribosomal proteins|||0|865|1306|1324
SE|25462191||ab|8|entity|C0750540|NONSPECIFIC|idcn|||nonspecific|||0|694|1334|1345
SE|25462191||ab|8|entity|C0035701|Ribosomal RNA|bacs,nnon|||rRNA|||0|1000|1359|1363
SE|25462191||ab|8|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|888|1371|1381
SE|25462191||ab|8|entity|C0332621|Aggregation|ftcn|||aggregation|||0|888|1382|1393
SE|25462191||ab|8|entity|C1274040|result|ftcn|||resulting|||0|872|1401|1410
SE|25462191||ab|8|entity|C0439855|Complex|qlco|||complexes|||0|872|1411|1420
SE|25462191||ab|8|relation|0|0|C0035552|Ribosomal Proteins|aapp,gngm,bacs|aapp|||ribosomal proteins|||0|865|1306|1324|MOD/HEAD|PART_OF||1295|1324|0|0|C0684063|Eukaryota|orgm|orgm|||eukaryotic|||0|865|1295|1305


SE|25462192||ti|1|text|21|50|DAMPs and neurodegeneration.
SE|25462192||ti|1|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|1000|31|48

SE|25462192||ab|1|text|56|259|The concept of neuroinflammation has come a full circle; from being initially regarded as a controversial viewpoint to its present day acceptance as an integral component of neurodegenerative processes.
SE|25462192||ab|1|entity|C0178566|concept|idcn|||concept|||0|1000|60|67
SE|25462192||ab|1|entity|C0443225|Full|qlco|||full|||0|694|100|104
SE|25462192||ab|1|entity|C0205265|Initially|tmco|||initially|||0|1000|124|133
SE|25462192||ab|1|entity|C0680243|controversy|socb|||controversial|||0|853|148|161
SE|25462192||ab|1|entity|C0282411|Published Comment|inpr|||viewpoint|||0|853|162|171
SE|25462192||ab|1|entity|C0150312|Present|qnco|||present|||0|623|179|186
SE|25462192||ab|1|entity|C0439228|day|tmco|||day|||0|623|187|190
SE|25462192||ab|1|entity|C0443238|Integral|qnco|||integral|||0|888|208|216
SE|25462192||ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|888|217|226
SE|25462192||ab|1|entity|C1522240|Process|phpr|||processes|||0|827|248|257

SE|25462192||ab|2|text|259|537|A closer look at the etiopathogenesis of many neurodegenerative conditions will reveal a patho-symbiotic relationship between neuroinflammation and neurodegeneration, where the two liaise with each other to form a self-sustaining vicious cycle that facilitates neuronal demise.
SE|25462192||ab|2|entity|C1522666|Closest|spco|||closer|||0|966|261|267
SE|25462192||ab|2|entity|C1510540|Etiopathogenesis|ftcn|||etiopathogenesis|||0|1000|280|296
SE|25462192||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|827|323|333
SE|25462192||ab|2|entity|C0231202|Symbiotic|ftcn|||symbiotic|||0|790|354|363
SE|25462192||ab|2|entity|C0439849|Relationships|qlco|||relationship|||0|790|364|376
SE|25462192||ab|2|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|1000|407|424
SE|25462192||ab|2|entity|C0205448|Two|qnco|||two|||0|1000|436|439
SE|25462192||ab|2|entity|C0036588|Self|idcn|||self|||0|764|473|477
SE|25462192||ab|2|entity|C0443318|Sustained|ftcn|||sustaining|||0|764|478|488
SE|25462192||ab|2|entity|C0750729|Course|tmco|||cycle|||0|764|497|502

SE|25462192||ab|3|text|537|710|Here, we focus on damage associated molecular patterns or DAMPs as a potentially important nexus in the context of this lethal neuroinflammation-neurodegeneration alliance.
SE|25462192||ab|3|entity|C0205234|Focal|spco|||focus|||0|1000|546|551
SE|25462192||ab|3|entity|C1521991|Molecular|qlco|||molecular|||0|888|573|582
SE|25462192||ab|3|entity|C0449774|Patterns|spco|||patterns|||0|888|583|591
SE|25462192||ab|3|entity|C0206117|Gap Junctions|bsoj|||nexus|||0|827|628|633
SE|25462192||ab|3|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|750|682|699
SE|25462192||ab|3|entity|C0680207|alliance|socb|||alliance|||0|750|700|708

SE|25462192||ab|4|text|710|882|Since their nomenclature as "DAMPs" about a decade ago, these endogenous moieties have consistently been reported as novel players in sterile (non-infective) inflammation.
SE|25462192||ab|4|entity|C0600281|Nomenclature|inpr|||nomenclature|||0|1000|722|734
SE|25462192||ab|4|entity|C1333533|FBXW7 gene|gngm|||ago|||0|694|761|764
SE|25462192||ab|4|entity|C0205227|Endogenous|ftcn|||endogenous|||0|694|772|782
SE|25462192||ab|4|entity|C0679622|novel|inpr|||novel|||0|694|827|832
SE|25462192||ab|4|entity|C0678108|Sterility|patf|||sterile|||0|1000|844|851
SE|25462192||ab|4|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|868|880

SE|25462192||ab|5|text|882|1057|However, their roles in inflammatory responses in the central nervous system (CNS), especially during chronic neurodegenerative disorders are still being actively researched.
SE|25462192||ab|5|entity|C0035820|Role|socb|||roles|||0|1000|897|902
SE|25462192||ab|5|entity|C1155266|Inflammatory Response|patf|||inflammatory responses|||0|983|906|928
SE|25462192||ab|5|entity|C0927232|Neuraxis|bdsy|||central nervous system|||0|1000|936|958
SE|25462192||ab|5|entity|C0205191|chronic|tmco|||chronic|||0|901|984|991
SE|25462192||ab|5|entity|C0524851|Neurodegenerative Disorders|dsyn|||neurodegenerative disorders|||0|901|992|1019
SE|25462192||ab|5|relation|3|2|C1155266|Inflammatory Response|patf|patf|||inflammatory responses|||0|983|906|928|PREP|COEXISTS_WITH||977|983|1|1|C0524851|Neurodegenerative Disorders|dsyn|dsyn|||neurodegenerative disorders|||0|901|992|1019

SE|25462192||ab|6|text|1057|1227|The aim of this review is to first provide a general overview of the neuroimmune response in the CNS within the purview of DAMPs, its receptors and downstream signaling.
SE|25462192||ab|6|entity|C1279901|Firstly|qlco|||first|||0|1000|1086|1091
SE|25462192||ab|6|entity|C0205246|Generalized|spco|||general|||0|888|1102|1109
SE|25462192||ab|6|entity|C0814812|overview|inpr|||overview|||0|888|1110|1118
SE|25462192||ab|6|entity|C0871261|response|clna|||response|||0|861|1138|1146
SE|25462192||ab|6|entity|C0927232|Neuraxis|bdsy|||CNS|||0|1000|1154|1157
SE|25462192||ab|6|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|1000|1191|1200
SE|25462192||ab|6|entity|C0522506|Downstream|spco|||downstream|||0|888|1205|1215
SE|25462192||ab|6|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|1216|1225

SE|25462192||ab|7|text|1227|1369|This is then followed by discussions on some of the DAMP-mediated neuroinflammatory responses involved in chronic neurodegenerative diseases.
SE|25462192||ab|7|entity|C0205381|Moist|qlco|||DAMP|||0|824|1279|1283
SE|25462192||ab|7|entity|C0870868|Mediated Responses|menp|||mediated neuroinflammatory responses|||0|824|1284|1320
SE|25462192||ab|7|entity|C0008679|Chronic Disease|dsyn|||chronic neurodegenerative diseases|||0|913|1333|1367

SE|25462192||ab|8|text|1369|1641|Along the way, we also highlighted some important gaps in our existing knowledge regarding the role of DAMPs in neurodegeneration, the clarification of which we believe would aid in the prospects of developing treatment or screening strategies directed at these molecules.
SE|25462192||ab|8|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||gaps|||0|827|1419|1423
SE|25462192||ab|8|entity|C0376554|Knowledge|inpr|||knowledge|||0|861|1440|1449
SE|25462192||ab|8|entity|C0035820|Role|socb|||role|||0|1000|1464|1468
SE|25462192||ab|8|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|1000|1481|1498
SE|25462192||ab|8|entity|C0023981|Longitudinal Studies|qnco,resa|||prospects|||0|916|1555|1564
SE|25462192||ab|8|entity|C0220908|Screening procedure|hlca|||screening|||0|888|1592|1601
SE|25462192||ab|8|entity|C0567416|Molecule|sbst|||molecules|||0|966|1631|1640
SE|25462192||ab|8|relation|4|3|C0061928|GTPase-Activating Proteins|aapp,gngm,bacs|aapp|||gaps|||0|827|1419|1423|PREP|ASSOCIATED_WITH||1478|1480|6|1|C0027746|Nerve Degeneration|comd|comd|||neurodegeneration|||0|1000|1481|1498


SE|25462193||ti|1|text|21|60|ShcC proteins: brain aging and beyond.
SE|25462193||ti|1|entity|C1312067|SHC3 protein, human|aapp,bacs|53358|SHC3|ShcC|||0|888|21|25
SE|25462193||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|26|34
SE|25462193||ti|1|entity|C0006104|Brain|bpoc|||brain|||0|888|36|41
SE|25462193||ti|1|entity|C0001811|Aging|orgf|||aging|||0|888|42|47

SE|25462193||ab|1|text|66|255|To date, most studies of Shc family of signaling adaptor proteins have been focused on the near-ubiquitously expressed ShcA, indicating its relevance to age-related diseases and longevity.
SE|25462193||ab|1|entity|C0205393|Most|qnco|||most|||0|1000|75|79
SE|25462193||ab|1|entity|C1312062|SHC1 protein, human|aapp,bacs|6464|SHC1|Shc|||0|888|91|94
SE|25462193||ab|1|entity|C0015576|Family|famg|||family|||0|888|95|101
SE|25462193||ab|1|entity|C1335962|Signaling Protein|aapp,bacs|||signaling adaptor proteins|||0|896|105|131
SE|25462193||ab|1|entity|C0475806|1/3 meter|fndg|||near|||0|791|157|161
SE|25462193||ab|1|entity|C1312062|SHC1 protein, human|aapp,bacs|6464|SHC1|ShcA|||0|791|185|189
SE|25462193||ab|1|entity|C0001779|Age|orga|||age|||0|851|219|222
SE|25462193||ab|1|entity|C1522149|Related|ftcn|||related|||0|851|223|230
SE|25462193||ab|1|entity|C0012634|Disease|dsyn|||diseases|||0|851|231|239
SE|25462193||ab|1|entity|C0023980|Longevity|tmco|||longevity|||0|1000|244|253
SE|25462193||ab|1|relation|2|1|C1312062|SHC1 protein, human|aapp,gngm,bacs|bacs|6464|SHC1|Shc|||0|888|91|94|PREP|PART_OF||102|104|5|1|C1335962|Signaling Protein|aapp,gngm,bacs|aapp|||signaling adaptor proteins|||0|896|105|131

SE|25462193||ab|2|text|255|475|Although the role of the neuronal ShcC protein is much less investigated, accumulated evidence suggests its importance for neuroprotection against such aging-associated conditions as brain ischemia and oxidative stress.
SE|25462193||ab|2|entity|C0035820|Role|socb|||role|||0|1000|268|272
SE|25462193||ab|2|entity|C1312067|SHC3 protein, human|aapp,bacs|53358|SHC3|ShcC|||0|851|289|293
SE|25462193||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|851|294|301
SE|25462193||ab|2|entity|C0598958|Neuroprotection|moft|||neuroprotection|||0|1000|378|393
SE|25462193||ab|2|entity|C0001811|Aging|orgf|||aging|||0|901|407|412
SE|25462193||ab|2|entity|C0243082|associated conditions|patf|||associated conditions|||0|901|413|434
SE|25462193||ab|2|entity|C0007786|Brain Ischemia|dsyn|||brain ischemia|||0|1000|438|452
SE|25462193||ab|2|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|1000|457|473

SE|25462193||ab|3|text|475|787|Here, we summarize more than decade of studies on the ShcC expression and function in normal brain, age-related brain pathologies and immune disorders with a focus on the interactions of ShcC with signaling proteins/pathways, and the possible implications of these interactions for changes associated with aging.
SE|25462193||ab|3|entity|C0205172|More|ftcn|||more|||0|1000|494|498
SE|25462193||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|966|514|521
SE|25462193||ab|3|entity|C1312067|SHC3 protein, human|aapp,bacs|53358|SHC3|ShcC|||0|888|529|533
SE|25462193||ab|3|entity|C0031843|physiological aspects|phsf|||function|||0|1000|549|557
SE|25462193||ab|3|entity|C0205307|Normal|qlco|||normal|||0|888|561|567
SE|25462193||ab|3|entity|C0006104|Brain|bpoc|||brain|||0|888|568|573
SE|25462193||ab|3|entity|C0001779|Age|orga|||age|||0|852|575|578
SE|25462193||ab|3|entity|C1522149|Related|ftcn|||related|||0|852|579|586
SE|25462193||ab|3|entity|C0006119|Pathology, Brain|patf|||brain pathologies|||0|852|587|604
SE|25462193||ab|3|entity|C0021053|Immune System Diseases|dsyn|||immune disorders|||0|1000|609|625
SE|25462193||ab|3|entity|C0205234|Focal|spco|||focus|||0|1000|633|638
SE|25462193||ab|3|entity|C1312067|SHC3 protein, human|aapp,bacs|53358|SHC3|ShcC|||0|1000|662|666
SE|25462193||ab|3|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|890|682|690
SE|25462193||ab|3|entity|C0037080|Signal Pathways|celf,moft|||signaling proteins/pathways|||0|890|672|699
SE|25462193||ab|3|entity|C0332149|Possible|qlco|||possible|||0|694|709|717
SE|25462193||ab|3|entity|C0001811|Aging|orgf|||aging|||0|1000|781|786
SE|25462193||ab|3|relation|1|1|C0001811|Aging|orgf|orgf|||aging|||0|1000|781|786|VERB|ASSOCIATED_WITH||765|775|14|8|C0021053|Immune System Diseases|dsyn|dsyn|||immune disorders|||0|1000|609|625
SE|25462193||ab|3|relation|4|1|C0031843|physiological aspects|phsf|phsf|||function|||0|1000|549|557|PREP|PROCESS_OF||558|560|11|1|C0006104|Brain|bpoc|bpoc|||brain|||0|888|568|573


SE|25462195||ti|1|text|21|118|Consistent age-dependent declines in human semen quality: a systematic review and meta-analysis.
SE|25462195||ti|1|entity|C0001779|Age|orga|||age|||0|790|32|35
SE|25462195||ti|1|entity|C0020114|Human|humn|||human|||0|851|58|63
SE|25462195||ti|1|entity|C0036614|Seminal fluid|bdsu|||semen|||0|851|64|69
SE|25462195||ti|1|entity|C0332306|Quality|qlco|||quality|||0|851|70|77
SE|25462195||ti|1|entity|C0220922|systematic|ftcn|||systematic|||0|694|81|91
SE|25462195||ti|1|entity|C0920317|Meta-Analysis|inpr|||meta-analysis|||0|1000|103|116

SE|25462195||ab|1|text|124|303|Reduced fertility typically occurs among women in their late 30s, but increasing evidence indicates that advanced paternal age is associated with changes in reproduction as well.
SE|25462195||ab|1|entity|C0392756|Reduced|qlco|||Reduced|||0|888|124|131
SE|25462195||ab|1|entity|C0015895|Fertility|orgf|||fertility|||0|888|132|141
SE|25462195||ab|1|entity|C0043210|Woman|popg|||women|||0|1000|165|170
SE|25462195||ab|1|entity|C0205087|Late|tmco|||late|||0|888|180|184
SE|25462195||ab|1|entity|C1552144|30s|bpoc|||30s|||0|888|185|188
SE|25462195||ab|1|entity|C0442808|Increasing|ftcn|||increasing|||0|694|194|204
SE|25462195||ab|1|entity|C0337493|Paternal|qlco|||paternal|||0|901|238|246
SE|25462195||ab|1|entity|C0001792|Elderly|aggp|||advanced paternal age|||0|901|229|250
SE|25462195||ab|1|entity|C0035150|Reproduction|orgf|||reproduction|||0|1000|281|293
SE|25462195||ab|1|entity|C0205170|Good|qlco|||well|||0|1000|297|301
SE|25462195||ab|1|relation|1|1|C0015895|Fertility|orgf|orgf|||fertility|||0|888|132|141|VERB|OCCURS_IN||152|158|7|1|C0043210|Woman|popg,humn|popg|||women|||0|1000|165|170

SE|25462195||ab|2|text|303|453|Numerous studies have investigated age-based declines in semen traits, but the impact of paternal age on semen parameter values remains inconclusive.
SE|25462195||ab|2|entity|C0439064|Numerous|qnco|||Numerous|||0|872|303|311
SE|25462195||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|872|312|319
SE|25462195||ab|2|entity|C1292732|Investigates|ftcn|||investigated|||0|872|325|337
SE|25462195||ab|2|entity|C0001779|Age|orga|||age|||0|872|338|341
SE|25462195||ab|2|entity|C0036614|Seminal fluid|bdsu|||semen|||0|872|360|365
SE|25462195||ab|2|entity|C0599883|trait|orga|||traits|||0|872|366|372
SE|25462195||ab|2|entity|C0030652|Paternal Age|tmco|||paternal age|||0|1000|392|404
SE|25462195||ab|2|entity|C0036614|Seminal fluid|bdsu|||semen|||0|851|408|413
SE|25462195||ab|2|entity|C0549193|Parameter|spco|||parameter|||0|851|414|423
SE|25462195||ab|2|entity|C0042295|Values|qlco|||values|||0|851|424|430

SE|25462195||ab|3|text|453|739|Using data from 90 studies (93,839 subjects), we conducted a systematic review and meta-analysis to quantify the effect of male age on seven ejaculate traits (semen volume, sperm concentration, total sperm count, morphology, total motility, progressive motility and DNA fragmentation).
SE|25462195||ab|3|entity|C1511726|Data|idcn|||data|||0|1000|459|463
SE|25462195||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|872|472|479
SE|25462195||ab|3|entity|C1550501|subject|idcn|||subjects|||0|793|488|496
SE|25462195||ab|3|entity|C0220922|systematic|ftcn|||systematic|||0|694|514|524
SE|25462195||ab|3|entity|C0920317|Meta-Analysis|inpr|||meta-analysis|||0|1000|536|549
SE|25462195||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|566|572
SE|25462195||ab|3|entity|C0001779|Age|orga|||age|||0|861|581|584
SE|25462195||ab|3|entity|C0205453|Seven|qnco|||seven|||0|1000|588|593
SE|25462195||ab|3|entity|C0599883|trait|orga|||traits|||0|966|604|610
SE|25462195||ab|3|entity|C0036614|Seminal fluid|bdsu|||semen|||0|888|612|617
SE|25462195||ab|3|entity|C0449468|Volume|qnco|||volume|||0|888|618|624
SE|25462195||ab|3|entity|C1261167|Sperm density result|lbtr|||sperm concentration|||0|1000|626|645
SE|25462195||ab|3|entity|C0439175|% of total|qnco|||total|||0|802|647|652
SE|25462195||ab|3|entity|C0750480|Count|idcn|||count|||0|802|659|664
SE|25462195||ab|3|entity|C0332437|Morphology|qlco|||morphology|||0|1000|666|676
SE|25462195||ab|3|entity|C0439175|% of total|qnco|||total|||0|888|678|683
SE|25462195||ab|3|entity|C1510470|Motility|orgf|||motility|||0|888|684|692
SE|25462195||ab|3|entity|C0205329|Progressive|ftcn|||progressive|||0|888|694|705
SE|25462195||ab|3|entity|C1510470|Motility|orgf|||motility|||0|888|706|714
SE|25462195||ab|3|entity|C0376669|DNA Fragmentation|moft|||DNA fragmentation|||0|1000|719|736

SE|25462195||ab|4|text|739|966|Age-associated declines in semen volume, percentage motility, progressive motility, normal morphology and unfragmented cells were statistically significant and results generally seemed to be robust against confounding factors.
SE|25462195||ab|4|entity|C0001779|Age|orga|||Age|||0|1000|739|742
SE|25462195||ab|4|entity|C0036614|Seminal fluid|bdsu|||semen|||0|888|766|771
SE|25462195||ab|4|entity|C0449468|Volume|qnco|||volume|||0|888|772|778
SE|25462195||ab|4|entity|C0439165|Percent (qualifier value)|qnco|||percentage|||0|888|780|790
SE|25462195||ab|4|entity|C1510470|Motility|orgf|||motility|||0|888|791|799
SE|25462195||ab|4|entity|C0205329|Progressive|ftcn|||progressive|||0|888|801|812
SE|25462195||ab|4|entity|C1510470|Motility|orgf|||motility|||0|888|813|821
SE|25462195||ab|4|entity|C0541590|Normal Morphologies|spco|||normal morphology|||0|983|823|840
SE|25462195||ab|4|entity|C0007634|Cells|cell|||cells|||0|861|858|863
SE|25462195||ab|4|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|1000|869|894
SE|25462195||ab|4|entity|C1521761|Factor|ftcn|||factors|||0|827|957|964

SE|25462195||ab|5|text|966|1108|Unexpectedly, sperm concentration did not decline with increasing male age, even though we found that sperm concentration declined over time.
SE|25462195||ab|5|entity|C1261167|Sperm density result|lbtr|||sperm concentration|||0|1000|980|999
SE|25462195||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1004|1007
SE|25462195||ab|5|entity|C0442808|Increasing|ftcn|||increasing|||0|802|1021|1031
SE|25462195||ab|5|entity|C0001779|Age|orga|||age|||0|802|1037|1040
SE|25462195||ab|5|entity|C1261167|Sperm density result|lbtr|||sperm concentration|||0|1000|1068|1087
SE|25462195||ab|5|entity|C0205136|Over|spco|||over|||0|888|1097|1101
SE|25462195||ab|5|entity|C0040223|Time|tmco|||time|||0|888|1102|1106

SE|25462195||ab|6|text|1108|1302|Our findings indicate that male age needs more recognition as a potential contributor to the negative pregnancy outcomes and reduced offspring health associated with delayed first reproduction.
SE|25462195||ab|6|entity|C0243095|Finding|ftcn|||findings|||0|1000|1112|1120
SE|25462195||ab|6|entity|C0001779|Age|orga|||age|||0|861|1140|1143
SE|25462195||ab|6|entity|C0205172|More|ftcn|||more|||0|694|1150|1154
SE|25462195||ab|6|entity|C0237399|Potential|qlco|||potential|||0|694|1172|1181
SE|25462195||ab|6|entity|C0205160|Negative|qlco|||negative|||0|901|1201|1209
SE|25462195||ab|6|entity|C0032972|Pregnancy Outcome|qlco|||pregnancy outcomes|||0|901|1210|1228
SE|25462195||ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|851|1233|1240
SE|25462195||ab|6|entity|C0680063|Offspring|famg|||offspring|||0|851|1241|1250
SE|25462195||ab|6|entity|C0018684|Health|idcn|||health|||0|851|1251|1257
SE|25462195||ab|6|entity|C0205421|Deferred|tmco|||delayed|||0|873|1274|1281
SE|25462195||ab|6|entity|C0016145|First Birth|tmco|||first reproduction|||0|873|1282|1300

SE|25462195||ab|7|text|1302|1495|We suggest that greater focus on collection of DNA fragmentation and progressive motility in a clinical setting may lead to better patient outcomes during fertility treatments of aging couples.
SE|25462195||ab|7|entity|C0443228|Largest|qnco|||greater|||0|888|1318|1325
SE|25462195||ab|7|entity|C0205234|Focal|spco|||focus|||0|888|1326|1331
SE|25462195||ab|7|entity|C1516698|Collection|ftcn|||collection|||0|1000|1335|1345
SE|25462195||ab|7|entity|C0376669|DNA Fragmentation|moft|||DNA fragmentation|||0|1000|1349|1366
SE|25462195||ab|7|entity|C0205329|Progressive|ftcn|||progressive|||0|888|1371|1382
SE|25462195||ab|7|entity|C1510470|Motility|orgf|||motility|||0|888|1383|1391
SE|25462195||ab|7|entity|C0205210|Clinical|qlco|||clinical|||0|888|1397|1405
SE|25462195||ab|7|entity|C0542559|contextual factors|ftcn|||setting|||0|888|1406|1413
SE|25462195||ab|7|entity|C0332272|Better|qlco|||better|||0|764|1426|1432
SE|25462195||ab|7|entity|C0030705|Patients|podg|||patient|||0|764|1433|1440
SE|25462195||ab|7|entity|C1274040|result|ftcn|||outcomes|||0|764|1441|1449
SE|25462195||ab|7|entity|C0015895|Fertility|orgf|||fertility|||0|888|1457|1466
SE|25462195||ab|7|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|888|1467|1477
SE|25462195||ab|7|entity|C0001811|Aging|orgf|||aging|||0|888|1481|1486
SE|25462195||ab|7|entity|C0010222|Couples|famg|||couples|||0|888|1487|1494
SE|25462195||ab|7|relation|0|0|C0001811|Aging|orgf|orgf|||aging|||0|888|1481|1486|MOD/HEAD|PROCESS_OF||1481|1494|0|0|C0010222|Couples|famg,humn|humn|||couples|||0|888|1487|1494


SE|25462196||ti|1|text|21|155|Weight dependent modulation of motor resonance induced by weight estimation during observation of partially occluded lifting actions.
SE|25462196||ti|1|entity|C0043100|Weight|qnco|||Weight|||0|623|21|27
SE|25462196||ti|1|entity|C1513492|Motor|idcn|||motor|||0|888|52|57
SE|25462196||ti|1|entity|C0459800|Vibration - physical agent|npop|||resonance|||0|888|58|67
SE|25462196||ti|1|entity|C0043100|Weight|qnco|||weight|||0|888|79|85
SE|25462196||ti|1|entity|C0680844|estimation|menp|||estimation|||0|888|86|96
SE|25462196||ti|1|entity|C0206244|Lifting|acty|||lifting|||0|694|138|145

SE|25462196||ab|1|text|161|272|Seeing others performing an action induces the observers' motor cortex to "resonate" with the observed action.
SE|25462196||ab|1|entity|C0042789|Vision|orgf|||Seeing|||0|694|161|167
SE|25462196||ab|1|entity|C0870992|Observers|prog|||observers|||0|901|208|217
SE|25462196||ab|1|entity|C0026607|Motor Cortex|bpoc|||motor cortex|||0|901|219|231

SE|25462196||ab|2|text|272|463|Transcranial magnetic stimulation (TMS) studies suggest that such motor resonance reflects the encoding of various motor features of the observed action, including the apparent motor effort.
SE|25462196||ab|2|entity|C0436548|Transcranial magnetic stimulation|topp|||Transcranial magnetic stimulation|||0|908|272|305
SE|25462196||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|908|312|319
SE|25462196||ab|2|entity|C1513492|Motor|idcn|||motor|||0|888|338|343
SE|25462196||ab|2|entity|C0459800|Vibration - physical agent|npop|||resonance|||0|888|344|353
SE|25462196||ab|2|entity|C1513492|Motor|idcn|||motor|||0|861|387|392
SE|25462196||ab|2|entity|C0750489|APPARENT|idcn|||apparent|||0|851|440|448
SE|25462196||ab|2|entity|C1513492|Motor|idcn|||motor|||0|851|449|454
SE|25462196||ab|2|relation|0|0|C0008972|Clinical Research|resa|resa|||studies|||0|908|312|319|MOD/HEAD|USES||272|319|0|0|C0436548|Transcranial magnetic stimulation|topp|topp|||Transcranial magnetic stimulation|||0|908|272|305

SE|25462196||ab|3|text|463|631|However, it is unclear whether such encoding requires direct observation or whether force requirements can be inferred when the moving body part is partially occluded.
SE|25462196||ab|3|entity|C0441722|Force|phpr|||force|||0|872|547|552
SE|25462196||ab|3|entity|C1514873|Requirement|idcn|||requirements|||0|872|553|565
SE|25462196||ab|3|entity|C0560560|Moving|orgf|||moving|||0|901|591|597
SE|25462196||ab|3|entity|C0229962|Body part|bpoc|||body part|||0|901|598|607

SE|25462196||ab|4|text|631|788|To address this issue, we presented participants with videos of a right hand lifting a box of three different weights and asked them to estimate its weight.
SE|25462196||ab|4|entity|C0679646|Participant|popg|||participants|||0|966|667|679
SE|25462196||ab|4|entity|C0441069|Video|mnob|||videos|||0|966|685|691
SE|25462196||ab|4|entity|C1288948|Entire right hand|bpoc|||right hand|||0|1000|697|707
SE|25462196||ab|4|entity|C0179400|box|mnob|||box|||0|1000|718|721
SE|25462196||ab|4|entity|C0205449|Three|qnco|||three|||0|828|725|730
SE|25462196||ab|4|entity|C1547020|*Difference|qnco|||different|||0|828|731|740
SE|25462196||ab|4|entity|C0043100|Weight|qnco|||weights|||0|828|741|748
SE|25462196||ab|4|entity|C0043100|Weight|qnco|||weight|||0|1000|780|786

SE|25462196||ab|5|text|788|1093|During each trial we delivered one transcranial magnetic stimulation (TMS) pulse over the left primary motor cortex of the observer and recorded the motor evoked potentials (MEPs) from three muscles of the right hand (first dorsal interosseous, FDI, abductor digiti minimi, ADM, and brachioradialis, BR).
SE|25462196||ab|5|entity|C0008976|Clinical Trials|resa|||trial|||0|1000|800|805
SE|25462196||ab|5|entity|C0205447|One|qnco|||one|||0|916|819|822
SE|25462196||ab|5|entity|C0436548|Transcranial magnetic stimulation|topp|||transcranial magnetic stimulation|||0|916|823|856
SE|25462196||ab|5|entity|C0436548|Transcranial magnetic stimulation|topp|||TMS|||0|1000|858|861
SE|25462196||ab|5|entity|C0205136|Over|spco|||over|||0|1000|869|873
SE|25462196||ab|5|entity|C0205091|Left|spco|||left|||0|861|878|882
SE|25462196||ab|5|entity|C0026607|Motor Cortex|bpoc|||motor cortex|||0|861|891|903
SE|25462196||ab|5|entity|C0870992|Observers|prog|||observer|||0|966|911|919
SE|25462196||ab|5|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||motor evoked potentials|||0|1000|937|960
SE|25462196||ab|5|entity|C0205449|Three|qnco|||three|||0|888|973|978
SE|25462196||ab|5|entity|C0026845|Muscle|tisu|||muscles|||0|888|979|986
SE|25462196||ab|5|entity|C1288948|Entire right hand|bpoc|||right hand|||0|1000|994|1004
SE|25462196||ab|5|entity|C1279901|Firstly|qlco|||first|||0|583|1006|1011
SE|25462196||ab|5|entity|C0205095|Dorsal|spco|||dorsal|||0|583|1012|1018
SE|25462196||ab|5|entity|C0000741|Abducens nerve structure|bpoc|||abductor digiti minimi|||0|1000|1038|1060
SE|25462196||ab|5|entity|||gngm|133|ADM|ADM|||0|1000|1062|1065
SE|25462196||ab|5|relation|6|1|C0026607|Motor Cortex|bpoc|bpoc|||motor cortex|||0|861|891|903|PREP|PART_OF||904|906|8|1|C0870992|Observers|prog,humn|humn|||observer|||0|966|911|919
SE|25462196||ab|5|relation|6|1|C0026845|Muscle|tisu|tisu|||muscles|||0|888|979|986|PREP|LOCATION_OF||968|972|8|1|C0282617|Evoked Potentials, Motor|diap,ortf|diap|||motor evoked potentials|||0|1000|937|960
SE|25462196||ab|5|relation|9|1|C0026845|Muscle|tisu|tisu|||muscles|||0|888|979|986|PREP|PART_OF||987|989|5|1|C1288948|Entire right hand|bpoc|bpoc|||right hand|||0|1000|994|1004

SE|25462196||ab|6|text|1093|1384|Importantly, because the hand shown in the videos was hidden behind a screen, only the contractions in the actor's BR muscle under the bare skin were observable during the entire videos, while the contractions in the actor's FDI and ADM muscles were hidden during the grasp and actual lift.
SE|25462196||ab|6|entity|C0018563|Hand|bpoc|||hand|||0|1000|1118|1122
SE|25462196||ab|6|entity|C0441069|Video|mnob|||videos|||0|966|1136|1142
SE|25462196||ab|6|entity|C0205095|Dorsal|spco|||behind|||0|1000|1154|1160
SE|25462196||ab|6|entity|C0430054|Toxicology screen, general|lbpr|||screen|||0|1000|1163|1169
SE|25462196||ab|6|entity|C1140999|Contraction|patf|||contractions|||0|966|1180|1192
SE|25462196||ab|6|entity|C0335083|Actor|prog|||actor's|||0|851|1200|1207
SE|25462196||ab|6|entity|C0026845|Muscle|tisu|||muscle|||0|851|1211|1217
SE|25462196||ab|6|entity|C0037267|Integumentary system|bdsy|||skin|||0|861|1233|1237
SE|25462196||ab|6|entity|C0439751|Entire|qnco|||entire|||0|872|1265|1271
SE|25462196||ab|6|entity|C0441069|Video|mnob|||videos|||0|872|1272|1278
SE|25462196||ab|6|entity|C1140999|Contraction|patf|||contractions|||0|966|1290|1302
SE|25462196||ab|6|entity|C0335083|Actor|prog|||actor's|||0|694|1310|1317
SE|25462196||ab|6|entity|||gngm|133|ADM|ADM|||0|861|1326|1329
SE|25462196||ab|6|entity|C0026845|Muscle|tisu|||muscles|||0|861|1330|1337
SE|25462196||ab|6|entity|C0220843|grasp|orgf|||grasp|||0|1000|1361|1366
SE|25462196||ab|6|entity|C0237400|Actual|qlco|||actual|||0|888|1371|1377
SE|25462196||ab|6|entity|C0181620|Hoist device|medd|||lift|||0|888|1378|1382
SE|25462196||ab|6|relation|9|1|C0026845|Muscle|tisu|tisu|||muscle|||0|851|1211|1217|PREP|LOCATION_OF||1193|1195|4|2|C0430054|Toxicology screen, general|lbpr|lbpr|||screen|||0|1000|1163|1169

SE|25462196||ab|7|text|1384|1507|The amplitudes of the MEPs recorded from the BR (observable) and FDI (hidden) muscle increased with the weight of the box.
SE|25462196||ab|7|entity|C0282617|Evoked Potentials, Motor|diap,ortf|||MEPs|||0|1000|1406|1410
SE|25462196||ab|7|entity|C0205262|Occult|qlco|||hidden|||0|1000|1454|1460
SE|25462196||ab|7|entity|C0026845|Muscle|tisu|||muscle|||0|1000|1462|1468
SE|25462196||ab|7|entity|C0043100|Weight|qnco|||weight|||0|1000|1488|1494
SE|25462196||ab|7|entity|C0179400|box|mnob|||box|||0|1000|1502|1505

SE|25462196||ab|8|text|1507|1699|These findings indicate that the modulation of motor excitability induced by action observation extends to the cortical representation of muscles with contractions that could not be observed.
SE|25462196||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1513|1521
SE|25462196||ab|8|entity|C1513492|Motor|idcn|||motor|||0|888|1554|1559
SE|25462196||ab|8|entity|C0235169|Excitability|sosy|||excitability|||0|888|1560|1572
SE|25462196||ab|8|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|638|1618|1626
SE|25462196||ab|8|entity|C0026845|Muscle|tisu|||muscles|||0|1000|1645|1652
SE|25462196||ab|8|entity|C1140999|Contraction|patf|||contractions|||0|966|1658|1670
SE|25462196||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1682|1685

SE|25462196||ab|9|text|1699|1840|Thus, motor resonance appears to reflect force requirements of observed lifting actions even when the moving body part is occluded from view.
SE|25462196||ab|9|entity|C1513492|Motor|idcn|||motor|||0|888|1705|1710
SE|25462196||ab|9|entity|C0459800|Vibration - physical agent|npop|||resonance|||0|888|1711|1720
SE|25462196||ab|9|entity|C0441722|Force|phpr|||force|||0|872|1740|1745
SE|25462196||ab|9|entity|C1514873|Requirement|idcn|||requirements|||0|872|1746|1758
SE|25462196||ab|9|entity|C0206244|Lifting|acty|||lifting|||0|583|1771|1778
SE|25462196||ab|9|entity|C0560560|Moving|orgf|||moving|||0|901|1801|1807
SE|25462196||ab|9|entity|C0229962|Body part|bpoc|||body part|||0|901|1808|1817
SE|25462196||ab|9|entity|C0449911|View|orga|||view|||0|1000|1835|1839


SE|25462197||ti|1|text|21|90|Semantic variability predicts neural variability of object concepts.
SE|25462197||ti|1|entity|C0036612|Semantics|ocdi|||Semantic|||0|853|21|29
SE|25462197||ti|1|entity|C0439828|Variable|qlco|||variability|||0|853|30|41
SE|25462197||ti|1|entity|C0599851|relating to nervous system|ftcn|||neural|||0|853|51|57
SE|25462197||ti|1|entity|C0439828|Variable|qlco|||variability|||0|853|58|69
SE|25462197||ti|1|entity|C0178566|concept|idcn|||concepts|||0|861|80|88

SE|25462197||ab|1|text|96|344|The prevailing approach to the neuroscientific study of concepts is to characterize the neural pattern evoked by a given concept, averaging over any variation that might occur upon multiple retrieval attempts (e.g., across time, tasks, or people).
SE|25462197||ab|1|entity|C0449445|Approach|spco|||approach|||0|861|111|119
SE|25462197||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|861|143|148
SE|25462197||ab|1|entity|C0178566|concept|idcn|||concepts|||0|1000|152|160
SE|25462197||ab|1|entity|C0599851|relating to nervous system|ftcn|||neural|||0|888|184|190
SE|25462197||ab|1|entity|C0449774|Patterns|spco|||pattern|||0|888|191|198
SE|25462197||ab|1|entity|C1442162|GIVEN|cnce|||given|||0|888|211|216
SE|25462197||ab|1|entity|C0178566|concept|idcn|||concept|||0|888|217|224
SE|25462197||ab|1|entity|C0205136|Over|spco|||over|||0|1000|236|240
SE|25462197||ab|1|entity|C0205419|Variant|qlco|||variation|||0|1000|245|254
SE|25462197||ab|1|entity|C0439064|Numerous|qnco|||multiple|||0|840|277|285
SE|25462197||ab|1|entity|C1514918|Retrieval|hlca|||retrieval|||0|840|286|295
SE|25462197||ab|1|entity|C1516084|Attempt|evnt|||attempts|||0|840|296|304
SE|25462197||ab|1|entity|C0040223|Time|tmco|||time|||0|1000|319|323
SE|25462197||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|335|341

SE|25462197||ab|2|text|344|487|This approach-which diverges substantially from approaches to studying conceptual processing with other methods-treats all variation as noise.
SE|25462197||ab|2|entity|C0449445|Approach|spco|||approach|||0|1000|349|357
SE|25462197||ab|2|entity|C0449445|Approach|spco|||approaches|||0|1000|392|402
SE|25462197||ab|2|entity|C0008972|Clinical Research|resa|||studying|||0|805|406|414
SE|25462197||ab|2|entity|C0178566|concept|idcn|||conceptual|||0|805|415|425
SE|25462197||ab|2|entity|C1522240|Process|phpr|||processing|||0|805|426|436
SE|25462197||ab|2|entity|C0025663|Methods|inpr|||methods|||0|1000|448|455
SE|25462197||ab|2|entity|C0205419|Variant|qlco|||variation|||0|1000|467|476
SE|25462197||ab|2|entity|C0028263|Noise|phpr|||noise|||0|1000|480|485

SE|25462197||ab|3|text|487|708|Here, our goal is to determine whether variation in neural patterns evoked by semantic retrieval of a given concept is more than just measurement error, and instead reflects variation arising from contextual variability.
SE|25462197||ab|3|entity|C0018017|objective (goal)|inpr|||goal|||0|1000|497|501
SE|25462197||ab|3|entity|C0205419|Variant|qlco|||variation|||0|1000|526|535
SE|25462197||ab|3|entity|C0599851|relating to nervous system|ftcn|||neural|||0|888|539|545
SE|25462197||ab|3|entity|C0449774|Patterns|spco|||patterns|||0|888|546|554
SE|25462197||ab|3|entity|C0036612|Semantics|ocdi|||semantic|||0|888|565|573
SE|25462197||ab|3|entity|C1514918|Retrieval|hlca|||retrieval|||0|888|574|583
SE|25462197||ab|3|entity|C1442162|GIVEN|cnce|||given|||0|888|589|594
SE|25462197||ab|3|entity|C0178566|concept|idcn|||concept|||0|888|595|602
SE|25462197||ab|3|entity|C0205172|More|ftcn|||more|||0|1000|606|610
SE|25462197||ab|3|entity|C0681899|accuracy of variables and methods|qnco|||measurement error|||0|901|621|638
SE|25462197||ab|3|entity|C0205419|Variant|qlco|||variation|||0|694|661|670
SE|25462197||ab|3|entity|C0439828|Variable|qlco|||variability|||0|789|695|706

SE|25462197||ab|4|text|708|857|We measured each concept's diversity of semantic contexts ("SV") by analyzing its word frequency and co-occurrence statistics in large text corpora.
SE|25462197||ab|4|entity|C0178566|concept|idcn|||concept's|||0|694|725|734
SE|25462197||ab|4|entity|C0036612|Semantics|ocdi|||semantic|||0|872|748|756
SE|25462197||ab|4|entity|C0560132|sievert|qnco|||SV|||0|1000|768|770
SE|25462197||ab|4|entity|C1515960|Analyzed|qlco|||analyzing|||0|966|776|785
SE|25462197||ab|4|entity|C0871614|Word Frequency|qnco|||word frequency|||0|1000|790|804
SE|25462197||ab|4|entity|C0243132|occurrence|qnco|||occurrence|||0|660|812|822
SE|25462197||ab|4|entity|C0549177|Large|qnco|||large|||0|623|837|842
SE|25462197||ab|4|entity|C1527021|Text|inpr|||text|||0|623|843|847

SE|25462197||ab|5|text|857|1029|To measure neural variability, we conducted an fMRI study and sampled neural activity associated with each concept when it appeared in three separate, randomized contexts.
SE|25462197||ab|5|entity|C0599851|relating to nervous system|ftcn|||neural|||0|853|868|874
SE|25462197||ab|5|entity|C0439828|Variable|qlco|||variability|||0|853|875|886
SE|25462197||ab|5|entity|C0376335|fMRI|diap|||fMRI|||0|888|904|908
SE|25462197||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|888|909|914
SE|25462197||ab|5|entity|C0870078|Sampling|idcn|||sampled|||0|840|919|926
SE|25462197||ab|5|entity|C0599851|relating to nervous system|ftcn|||neural|||0|840|927|933
SE|25462197||ab|5|entity|C0178566|concept|idcn|||concept|||0|1000|964|971
SE|25462197||ab|5|entity|C0205449|Three|qnco|||three|||0|825|992|997
SE|25462197||ab|5|entity|C0443299|Separate|spco|||separate|||0|825|998|1006
SE|25462197||ab|5|entity|C1514720|Randomized|ftcn|||randomized|||0|825|1008|1018

SE|25462197||ab|6|text|1029|1225|We predicted that concepts with low SV would exhibit uniform activation patterns across stimulus presentations, whereas concepts with high SV would exhibit more dynamic representations over time.
SE|25462197||ab|6|entity|C0178566|concept|idcn|||concepts|||0|1000|1047|1055
SE|25462197||ab|6|entity|C0205251|low|qlco|||low|||0|888|1061|1064
SE|25462197||ab|6|entity|C0449774|Patterns|spco|||patterns|||0|827|1101|1109
SE|25462197||ab|6|entity|C0234402|Stimulus|phpr|||stimulus|||0|872|1117|1125
SE|25462197||ab|6|entity|C0449450|Presentation|idcn|||presentations|||0|872|1126|1139
SE|25462197||ab|6|entity|C0178566|concept|idcn|||concepts|||0|1000|1149|1157
SE|25462197||ab|6|entity|C0205250|High|qlco|||high|||0|888|1163|1167
SE|25462197||ab|6|entity|C0205172|More|ftcn|||more|||0|762|1185|1189
SE|25462197||ab|6|entity|C0729333|Dynamic|ftcn|||dynamic|||0|762|1190|1197
SE|25462197||ab|6|entity|C0040223|Time|tmco|||time|||0|762|1219|1223

SE|25462197||ab|7|text|1225|1311|We observed that a concept's SV score predicted its corresponding neural variability.
SE|25462197||ab|7|entity|C0178566|concept|idcn|||concept's|||0|851|1244|1253
SE|25462197||ab|7|entity|C0449820|Score|qnco|||score|||0|851|1257|1262
SE|25462197||ab|7|entity|C0599851|relating to nervous system|ftcn|||neural|||0|754|1291|1297
SE|25462197||ab|7|entity|C0439828|Variable|qlco|||variability|||0|754|1298|1309

SE|25462197||ab|8|text|1311|1488|This finding supports a flexible, distributed organization of semantic memory, where a concept's meaning and its neural activity patterns both continuously vary across contexts.
SE|25462197||ab|8|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|1000|1316|1323
SE|25462197||ab|8|entity|C0443220|Flexible|qlco|||flexible|||0|840|1335|1343
SE|25462197||ab|8|entity|C0520511|Distributing|idcn|||distributed|||0|840|1345|1356
SE|25462197||ab|8|entity|C0220885|organizational|qlco|||organization|||0|840|1357|1369
SE|25462197||ab|8|entity|C0542312|Semantic memory|menp|||semantic memory|||0|1000|1373|1388
SE|25462197||ab|8|entity|C0178566|concept|idcn|||concept's|||0|888|1398|1407
SE|25462197||ab|8|entity|C0876919|Meaning|idcn|||meaning|||0|888|1408|1415
SE|25462197||ab|8|entity|C0599851|relating to nervous system|ftcn|||neural|||0|851|1424|1430
SE|25462197||ab|8|entity|C0449774|Patterns|spco|||patterns|||0|851|1440|1448


SE|25462194||ti|1|text|21|78|Sleep disorders, obesity, and aging: the role of orexin.
SE|25462194||ti|1|entity|C0851578|Sleep Disorders|dsyn|||Sleep disorders|||0|1000|21|36
SE|25462194||ti|1|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|38|45
SE|25462194||ti|1|entity|C0001811|Aging|orgf|||aging|||0|1000|51|56
SE|25462194||ti|1|entity|C0035820|Role|socb|||role|||0|1000|62|66
SE|25462194||ti|1|entity|C1113688|orexin|aapp,nsba|||orexin|||0|1000|70|76

SE|25462194||ab|1|text|84|265|The hypothalamic neuropeptides orexin A and B (hypocretin 1 and 2) are important homeostatic mediators of central control of energy metabolism and maintenance of sleep/wake states.
SE|25462194||ab|1|entity|C0027895|Neuropeptides|aapp,nsba|594857|NPS|neuropeptides|||0|790|101|114
SE|25462194||ab|1|entity|C1113688|orexin|aapp,nsba|||orexin|||0|790|115|121
SE|25462194||ab|1|entity|C1113696|hypocretin|aapp,nsba|||hypocretin|||0|827|131|141
SE|25462194||ab|1|entity|C0019868|Homeostasis|orgf|||homeostatic|||0|589|165|176
SE|25462194||ab|1|entity|C0205099|Central|spco|||central|||0|888|190|197
SE|25462194||ab|1|entity|C0243148|control|ftcn|||control|||0|888|198|205
SE|25462194||ab|1|entity|C0014272|Energy Metabolism|phsf|||energy metabolism|||0|1000|209|226
SE|25462194||ab|1|entity|C0037313|Sleep|orgf|||sleep|||0|785|246|251
SE|25462194||ab|1|entity|C1442792|State|ftcn|||states|||0|785|257|263
SE|25462194||ab|1|relation|0|0|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|790|115|121|MOD/HEAD|ISA||101|121|0|0|C0027895|Neuropeptides|aapp,gngm,nsba|aapp|594857|NPS|neuropeptides|||0|790|101|114

SE|25462194||ab|2|text|265|374|Dysregulation or loss of orexin signaling has been linked to narcolepsy, obesity, and age-related disorders.
SE|25462194||ab|2|entity|C1517945|Loss|qnco|||loss|||0|1000|282|286
SE|25462194||ab|2|entity|C1113688|orexin|aapp,nsba|||orexin|||0|888|290|296
SE|25462194||ab|2|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|297|306
SE|25462194||ab|2|entity|C0027404|Narcolepsy|dsyn|||narcolepsy|||0|1000|326|336
SE|25462194||ab|2|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|338|345
SE|25462194||ab|2|entity|C0001779|Age|orga|||age|||0|851|351|354
SE|25462194||ab|2|entity|C1522149|Related|ftcn|||related|||0|851|355|362
SE|25462194||ab|2|entity|C0012634|Disease|dsyn|||disorders|||0|851|363|372
SE|25462194||ab|2|relation|3|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|888|290|296|VERB|ASSOCIATED_WITH||316|322|3|1|C0012634|Disease|dsyn|dsyn|||disorders|||0|851|363|372
SE|25462194||ab|2|relation|3|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|888|290|296|VERB|ASSOCIATED_WITH||316|322|3|1|C0027404|Narcolepsy|dsyn|dsyn|||narcolepsy|||0|1000|326|336
SE|25462194||ab|2|relation|3|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|888|290|296|VERB|ASSOCIATED_WITH||316|322|3|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|338|345

SE|25462194||ab|3|text|374|546|In this review, we present an overview of our current understanding of orexin function, focusing on sleep disorders, energy balance, and aging, in both rodents and humans.
SE|25462194||ab|3|entity|C0814812|overview|inpr|||overview|||0|1000|404|412
SE|25462194||ab|3|entity|C0521116|Current|tmco|||current|||0|888|420|427
SE|25462194||ab|3|entity|C1113688|orexin|aapp,nsba|||orexin|||0|888|445|451
SE|25462194||ab|3|entity|C0031843|physiological aspects|phsf|||function|||0|888|452|460
SE|25462194||ab|3|entity|C0851578|Sleep Disorders|dsyn|||sleep disorders|||0|1000|474|489
SE|25462194||ab|3|entity|C0597987|Energy Balance|orgf|||energy balance|||0|1000|491|505
SE|25462194||ab|3|entity|C0001811|Aging|orgf|||aging|||0|1000|511|516
SE|25462194||ab|3|entity|C0035804|Rodent|mamm|||rodents|||0|1000|526|533
SE|25462194||ab|3|entity|C0020114|Human|humn|||humans|||0|1000|538|544
SE|25462194||ab|3|relation|7|1|C0001811|Aging|orgf|orgf|||aging|||0|1000|511|516|PREP|PROCESS_OF||518|520|2|1|C0020114|Human|grup,humn|humn|||humans|||0|1000|538|544
SE|25462194||ab|3|relation|7|1|C0001811|Aging|orgf|orgf|||aging|||0|1000|511|516|PREP|PROCESS_OF||518|520|2|1|C0035804|Rodent|mamm|mamm|||rodents|||0|1000|526|533
SE|25462194||ab|3|relation|7|1|C0597987|Energy Balance|orgf|orgf|||energy balance|||0|1000|491|505|PREP|PROCESS_OF||518|520|2|1|C0035804|Rodent|mamm|mamm|||rodents|||0|1000|526|533
SE|25462194||ab|3|relation|7|2|C0597987|Energy Balance|orgf|orgf|||energy balance|||0|1000|491|505|PREP|PROCESS_OF||518|520|2|2|C0020114|Human|grup,humn|humn|||humans|||0|1000|538|544

SE|25462194||ab|4|text|546|850|We first discuss animal models used in studies of obesity and sleep, including loss of function using transgenic or viral-mediated approaches, gain of function models using exogenous delivery of orexin receptor agonist, and naturally-occurring models in which orexin responsiveness varies by individual.
SE|25462194||ab|4|entity|C1279901|Firstly|qlco|||first|||0|1000|549|554
SE|25462194||ab|4|entity|C0599779|Animal Model|anim|||animal models|||0|1000|563|576
SE|25462194||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|966|585|592
SE|25462194||ab|4|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|596|603
SE|25462194||ab|4|entity|C0037313|Sleep|orgf|||sleep|||0|1000|608|613
SE|25462194||ab|4|entity|C1517945|Loss|qnco|||loss|||0|1000|625|629
SE|25462194||ab|4|entity|C0031843|physiological aspects|phsf|||function|||0|1000|633|641
SE|25462194||ab|4|entity|C0521026|Viral|ftcn|||viral|||0|840|662|667
SE|25462194||ab|4|entity|C0086597|Mediating|socb|||mediated|||0|840|668|676
SE|25462194||ab|4|entity|C0449445|Approach|spco|||approaches|||0|840|677|687
SE|25462194||ab|4|entity|C1517378|Gain|qnco|||gain|||0|1000|689|693
SE|25462194||ab|4|entity|C0031843|physiological aspects|phsf|||function|||0|694|697|705
SE|25462194||ab|4|entity|C0205228|Exogenous|ftcn|||exogenous|||0|694|719|728
SE|25462194||ab|4|entity|C1113688|orexin|aapp,nsba|||orexin|||0|851|741|747
SE|25462194||ab|4|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|851|748|756
SE|25462194||ab|4|entity|C0243192|agonists|phsu|||agonist|||0|851|757|764
SE|25462194||ab|4|entity|C1113688|orexin|aapp,nsba|||orexin|||0|853|806|812
SE|25462194||ab|4|entity|C0205342|Responsive|ftcn|||responsiveness|||0|853|813|827
SE|25462194||ab|4|entity|C0237401|Individual|humn|||individual|||0|1000|838|848

SE|25462194||ab|5|text|850|1001|We next explore rodent models of orexin in aging, presenting evidence that orexin loss contributes to age-related changes in sleep and energy balance.
SE|25462194||ab|5|entity|C1552851|next|idcn|||next|||0|1000|853|857
SE|25462194||ab|5|entity|C0035804|Rodent|mamm|||rodent|||0|1000|866|872
SE|25462194||ab|5|entity|C1113688|orexin|aapp,nsba|||orexin|||0|1000|883|889
SE|25462194||ab|5|entity|C0001811|Aging|orgf|||aging|||0|1000|893|898
SE|25462194||ab|5|entity|C1113688|orexin|aapp,nsba|||orexin|||0|888|925|931
SE|25462194||ab|5|entity|C1517945|Loss|qnco|||loss|||0|888|932|936
SE|25462194||ab|5|entity|C0001779|Age|orga|||age|||0|840|952|955
SE|25462194||ab|5|entity|C1522149|Related|ftcn|||related|||0|840|956|963
SE|25462194||ab|5|entity|C0037313|Sleep|orgf|||sleep|||0|1000|975|980
SE|25462194||ab|5|entity|C0597987|Energy Balance|orgf|||energy balance|||0|1000|985|999
SE|25462194||ab|5|relation|6|4|C0001811|Aging|orgf|orgf|||aging|||0|1000|893|898|PREP|COEXISTS_WITH||972|974|2|1|C0037313|Sleep|orgf|orgf|||sleep|||0|1000|975|980
SE|25462194||ab|5|relation|6|4|C0001811|Aging|orgf|orgf|||aging|||0|1000|893|898|PREP|COEXISTS_WITH||972|974|2|1|C0597987|Energy Balance|orgf|orgf|||energy balance|||0|1000|985|999

SE|25462194||ab|6|text|1001|1100|In the next section, we focus on clinical importance of orexin in human obesity, sleep, and aging.
SE|25462194||ab|6|entity|C1552851|next|idcn|||next|||0|888|1008|1012
SE|25462194||ab|6|entity|C0205234|Focal|spco|||focus|||0|1000|1025|1030
SE|25462194||ab|6|entity|C0205210|Clinical|qlco|||clinical|||0|694|1034|1042
SE|25462194||ab|6|entity|C1113688|orexin|aapp,nsba|||orexin|||0|1000|1057|1063
SE|25462194||ab|6|entity|C0020114|Human|humn|||human|||0|888|1067|1072
SE|25462194||ab|6|entity|C0028754|Obesity|dsyn|||obesity|||0|888|1073|1080
SE|25462194||ab|6|entity|C0037313|Sleep|orgf|||sleep|||0|1000|1082|1087
SE|25462194||ab|6|entity|C0001811|Aging|orgf|||aging|||0|1000|1093|1098
SE|25462194||ab|6|relation|0|0|C0028754|Obesity|dsyn|dsyn|||obesity|||0|888|1073|1080|MOD/HEAD|PROCESS_OF||1067|1080|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|1067|1072
SE|25462194||ab|6|relation|4|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|1000|1057|1063|PREP|ASSOCIATED_WITH||1064|1066|3|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|888|1073|1080

SE|25462194||ab|7|text|1100|1354|We include discussion of orexin loss in narcolepsy and potential importance of orexin in insomnia, correlations between animal and human studies of age-related decline, and evidence for orexin involvement in age-related changes in cognitive performance.
SE|25462194||ab|7|entity|C1113688|orexin|aapp,nsba|||orexin|||0|888|1125|1131
SE|25462194||ab|7|entity|C1517945|Loss|qnco|||loss|||0|888|1132|1136
SE|25462194||ab|7|entity|C0027404|Narcolepsy|dsyn|||narcolepsy|||0|1000|1140|1150
SE|25462194||ab|7|entity|C0237399|Potential|qlco|||potential|||0|694|1155|1164
SE|25462194||ab|7|entity|C1113688|orexin|aapp,nsba|||orexin|||0|1000|1179|1185
SE|25462194||ab|7|entity|C0917801|Sleeplessness|sosy|||insomnia|||0|1000|1189|1197
SE|25462194||ab|7|entity|C0003043|Animalia|anim|||animal|||0|1000|1220|1226
SE|25462194||ab|7|entity|C0020114|Human|humn|||human|||0|1000|1231|1236
SE|25462194||ab|7|entity|C0001779|Age|orga|||age|||0|623|1248|1251
SE|25462194||ab|7|entity|C1522149|Related|ftcn|||related|||0|623|1252|1259
SE|25462194||ab|7|entity|C1113688|orexin|aapp,nsba|||orexin|||0|694|1286|1292
SE|25462194||ab|7|entity|C0001779|Age|orga|||age|||0|840|1308|1311
SE|25462194||ab|7|entity|C1522149|Related|ftcn|||related|||0|840|1312|1319
SE|25462194||ab|7|entity|C1516691|Cognitive|ftcn|||cognitive|||0|888|1331|1340
SE|25462194||ab|7|entity|C0597198|Performance|inbe|||performance|||0|888|1341|1352
SE|25462194||ab|7|relation|2|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|888|1125|1131|PREP|ASSOCIATED_WITH||1137|1139|12|1|C0027404|Narcolepsy|dsyn|dsyn|||narcolepsy|||0|1000|1140|1150
SE|25462194||ab|7|relation|5|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|1000|1179|1185|PREP|ASSOCIATED_WITH||1186|1188|9|1|C0917801|Sleeplessness|sosy|sosy|||insomnia|||0|1000|1189|1197

SE|25462194||ab|8|text|1354|1442|Finally, we present a summary of recent studies of orexin in neurodegenerative disease.
SE|25462194||ab|8|entity|C1552616|summary|tmco|||summary|||0|1000|1376|1383
SE|25462194||ab|8|entity|C0332185|Recent|tmco|||recent|||0|872|1387|1393
SE|25462194||ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|872|1394|1401
SE|25462194||ab|8|entity|C1113688|orexin|aapp,nsba|||orexin|||0|1000|1405|1411
SE|25462194||ab|8|entity|C0524851|Neurodegenerative Disorders|dsyn|||neurodegenerative disease|||0|1000|1415|1440
SE|25462194||ab|8|relation|3|1|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|1000|1405|1411|PREP|ASSOCIATED_WITH||1412|1414|1|1|C0524851|Neurodegenerative Disorders|dsyn|dsyn|||neurodegenerative disease|||0|1000|1415|1440

SE|25462194||ab|9|text|1442|1685|We conclude that orexin acts as an integrative homeostatic signal influencing numerous brain regions, and that this pivotal role results in potential dysregulation of multiple physiological processes when orexin signaling is disrupted or lost.
SE|25462194||ab|9|entity|C1113688|orexin|aapp,nsba|||orexin|||0|872|1459|1465
SE|25462194||ab|9|entity|C0427611|Activated clotting time measurement|lbpr|||acts|||0|872|1466|1470
SE|25462194||ab|9|entity|C0019868|Homeostasis|orgf|||homeostatic|||0|589|1489|1500
SE|25462194||ab|9|entity|C0439064|Numerous|qnco|||numerous|||0|890|1520|1528
SE|25462194||ab|9|entity|C1273723|Brain region|blor|||brain regions|||0|890|1529|1542
SE|25462194||ab|9|entity|C0035820|Role|socb|||role|||0|861|1566|1570
SE|25462194||ab|9|entity|C0237399|Potential|qlco|||potential|||0|694|1582|1591
SE|25462194||ab|9|entity|C0439064|Numerous|qnco|||multiple|||0|901|1609|1617
SE|25462194||ab|9|entity|C0031845|Physiological Processes|phsf|||physiological processes|||0|901|1618|1641
SE|25462194||ab|9|entity|C1113688|orexin|aapp,nsba|||orexin|||0|888|1647|1653
SE|25462194||ab|9|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|1654|1663
SE|25462194||ab|9|relation|0|0|C0427611|Activated clotting time measurement|lbpr|lbpr|||acts|||0|872|1466|1470|MOD/HEAD|USES||1459|1470|0|0|C1113688|orexin|aapp,gngm,nsba|aapp|||orexin|||0|872|1459|1465


SE|25462198||ti|1|text|21|110|Dissociating effect of upper limb non-use and overuse on space and body representations.
SE|25462198||ti|1|entity|C1280500|Effect|qlco|||effect|||0|861|34|40
SE|25462198||ti|1|entity|C1140618|Upper Extremity|bpoc|||upper limb|||0|824|44|54

SE|25462198||ab|1|text|116|327|Accurate and updated representations of the space where the body acts, i.e. the peripersonal space (PPS), and the location and dimension of body parts (body representation, BR) are essential to perform actions.
SE|25462198||ab|1|entity|C0443131|Accurate|qlco|||Accurate|||0|1000|116|124
SE|25462198||ab|1|entity|C1519814|Update|tmco|||updated|||0|661|129|136
SE|25462198||ab|1|entity|C0427611|Activated clotting time measurement|lbpr|||acts|||0|827|181|185
SE|25462198||ab|1|entity|C0450429|Location|spco|||location|||0|1000|230|238
SE|25462198||ab|1|entity|C0439534|Dimensions|qnco|||dimension|||0|1000|243|252
SE|25462198||ab|1|entity|C0229962|Body part|bpoc|||body parts|||0|1000|256|266
SE|25462198||ab|1|entity|C0205224|Essential|qlco|||essential|||0|1000|297|306

SE|25462198||ab|2|text|327|579|Because both PPS and BR are involved in motor execution and display the same plastic proprieties after the use of a tool to reach far objects, it has been suggested that they overlap in a unique representation of the body in a space devoted to action.
SE|25462198||ab|2|entity|C1513492|Motor|idcn|||motor|||0|694|367|372
SE|25462198||ab|2|entity|C0445247|Same|qlco|||same|||0|623|399|403
SE|25462198||ab|2|entity|C0032167|Plastics|sbst|||plastic|||0|623|404|411
SE|25462198||ab|2|entity|C0336791|Tool|mnob|||tool|||0|1000|443|447
SE|25462198||ab|2|entity|C1517331|Further|spco|||far|||0|872|457|460
SE|25462198||ab|2|entity|C0347997|Physical object|mnob|||objects|||0|872|461|468

SE|25462198||ab|3|text|579|762|Here we determined whether manipulating actions in space, without modifying body metrics, i.e. through immobilization, induces a dissociation of the plastic properties of PPS and BR.
SE|25462198||ab|3|entity|C0205349|Altered|ftcn|||modifying|||0|769|645|654
SE|25462198||ab|3|entity|C0699680|Metric|orch,phsu|||metrics|||0|769|660|667
SE|25462198||ab|3|entity|C0020944|Immobilization|topp|||immobilization|||0|1000|682|696
SE|25462198||ab|3|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|708|720
SE|25462198||ab|3|entity|C0700108|plastic property|npop|||plastic properties|||0|983|728|746
SE|25462198||ab|3|relation|5|3|C0699680|Metric|orch,phsu|orch|||metrics|||0|769|660|667|VERB|CAUSES||698|705|4|1|C0086168|Dissociation|mobd|mobd|||dissociation|||0|1000|708|720

SE|25462198||ab|4|text|762|915|In 39 healthy subjects we evaluated PPS and BR for the non-used right limb and the overused left limb before and after 10 h of right arm immobilization.
SE|25462198||ab|4|entity|C0018684|Health|idcn|||healthy|||0|737|768|775
SE|25462198||ab|4|entity|C1550501|subject|idcn|||subjects|||0|737|776|784
SE|25462198||ab|4|entity|C0042153|utilization qualifier|ftcn|||used|||0|751|821|825
SE|25462198||ab|4|entity|C0205090|Right|spco|||right|||0|751|826|831
SE|25462198||ab|4|entity|C1280090|Entire limb|bpoc|||limb|||0|751|832|836
SE|25462198||ab|4|entity|C0205091|Left|spco|||left|||0|790|854|858
SE|25462198||ab|4|entity|C1280090|Entire limb|bpoc|||limb|||0|790|859|863
SE|25462198||ab|4|entity|C0205090|Right|spco|||right|||0|851|889|894
SE|25462198||ab|4|entity|C1140618|Upper Extremity|bpoc|||arm|||0|851|895|898
SE|25462198||ab|4|entity|C0020944|Immobilization|topp|||immobilization|||0|851|899|913

SE|25462198||ab|5|text|915|1077|We observed that non-use reduces PPS representation around the immobilized arm, without affecting the metric representation (i.e. perceived length) of that limb.
SE|25462198||ab|5|entity|C1140618|Upper Extremity|bpoc|||arm|||0|861|990|993
SE|25462198||ab|5|entity|C0699680|Metric|orch,phsu|||metric|||0|694|1017|1023
SE|25462198||ab|5|entity|C1444754|Length|qnco|||length|||0|812|1055|1061
SE|25462198||ab|5|entity|C1280090|Entire limb|bpoc|||limb|||0|1000|1071|1075

SE|25462198||ab|6|text|1077|1191|In contrast, overuse modulates the metric representation of the free arm, leaving PPS unchanged around that limb.
SE|25462198||ab|6|entity|C0699680|Metric|orch,phsu|||metric|||0|694|1112|1118
SE|25462198||ab|6|entity|C1140618|Upper Extremity|bpoc|||arm|||0|861|1146|1149
SE|25462198||ab|6|entity|C1280090|Entire limb|bpoc|||limb|||0|1000|1185|1189

SE|25462198||ab|7|text|1191|1495|These results suggest that the plasticity in PPS and BR depends on different mechanisms; while PPS representation is shaped as a function of the dimension of the acting space, metric characteristics of BR are forged on a complex interplay between visual and sensorimotor information related to the body.
SE|25462198||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1197|1204
SE|25462198||ab|7|entity|C1547020|*Difference|qnco|||different|||0|853|1258|1267
SE|25462198||ab|7|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|853|1268|1278
SE|25462198||ab|7|entity|C0031843|physiological aspects|phsf|||function|||0|1000|1320|1328
SE|25462198||ab|7|entity|C0439534|Dimensions|qnco|||dimension|||0|1000|1336|1345
SE|25462198||ab|7|entity|C0699680|Metric|orch,phsu|||metric|||0|888|1367|1373
SE|25462198||ab|7|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|1374|1389
SE|25462198||ab|7|entity|C0439855|Complex|qlco|||complex|||0|694|1412|1419
SE|25462198||ab|7|entity|C0234621|Visual|ftcn|||visual|||0|1000|1438|1444
SE|25462198||ab|7|entity|C1533716|Information|idcn|||information|||0|861|1462|1473

SE|25462198||ab|8|text|1495|1631|This behavioral dissociation between PPS and BR defines a new scenario for the role of action in shaping space and body representations.
SE|25462198||ab|8|entity|C0086168|Dissociation|mobd|||dissociation|||0|861|1511|1523
SE|25462198||ab|8|entity|C0205314|New|tmco|||new|||0|888|1553|1556
SE|25462198||ab|8|entity|C0683579|scenario|ftcn|||scenario|||0|888|1557|1565
SE|25462198||ab|8|entity|C0035820|Role|socb|||role|||0|1000|1574|1578
SE|25462198||ab|8|entity|C0332479|Shapes|spco|||shaping|||0|661|1592|1599


SE|25462199||ti|1|text|21|156|Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis.
SE|25462199||ti|1|entity|C0038952|Continuance of life|acty|||survival|||0|872|47|55
SE|25462199||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|872|56|64
SE|25462199||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|68|76
SE|25462199||ti|1|entity|C0280631|Uterine leiomyosarcoma|neop|||uterine leiomyosarcoma|||0|901|93|115
SE|25462199||ti|1|entity|C0220922|systematic|ftcn|||systematic|||0|694|119|129
SE|25462199||ti|1|entity|C0920317|Meta-Analysis|inpr|||meta-analysis|||0|1000|141|154
SE|25462199||ti|1|relation|3|1|C0280631|Uterine leiomyosarcoma|neop|neop|||uterine leiomyosarcoma|||0|901|93|115|PREP|PROCESS_OF||77|81|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|68|76

SE|25462199|OBJECTIVE|ab|1|text|162|395|OBJECTIVE: To review the current evidence on the effects of intra-abdominal morcellation on survival outcomes of patients affected by unexpected uterine leiomyosarcoma (ULMS) and to estimate the risk of recurrence in those patients.
SE|25462199|OBJECTIVE|ab|1|entity|C0521116|Current|tmco|||current|||0|694|187|194
SE|25462199|OBJECTIVE|ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|211|218
SE|25462199|OBJECTIVE|ab|1|entity|C1512910|Intra-abdominal|spco|||intra-abdominal|||0|734|222|237
SE|25462199|OBJECTIVE|ab|1|entity|C0038952|Continuance of life|acty|||survival|||0|872|254|262
SE|25462199|OBJECTIVE|ab|1|entity|C1274040|result|ftcn|||outcomes|||0|872|263|271
SE|25462199|OBJECTIVE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|275|283
SE|25462199|OBJECTIVE|ab|1|entity|C0280631|Uterine leiomyosarcoma|neop|||uterine leiomyosarcoma|||0|901|307|329
SE|25462199|OBJECTIVE|ab|1|entity|C0035647|Risk|qlco|||risk|||0|1000|357|361
SE|25462199|OBJECTIVE|ab|1|entity|C0034897|Recurrence|phpr|||recurrence|||0|1000|365|375
SE|25462199|OBJECTIVE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|385|393
SE|25462199|OBJECTIVE|ab|1|relation|4|1|C0280631|Uterine leiomyosarcoma|neop|neop|||uterine leiomyosarcoma|||0|901|307|329|VERB|AFFECTS||284|292|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|275|283

SE|25462199|METHODS|ab|2|text|395|628|METHODS: PubMed (MEDLINE), Scopus, Embase, Web of Science databases as well as ClinicalTrials.gov, were searched for data evaluating the effects of intra-abdominal morcellation on survival outcomes of patients with undiagnosed ULMS.
SE|25462199|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|395|402
SE|25462199|METHODS|ab|2|entity|C1138432|PubMed|inpr|||PubMed|||0|1000|404|410
SE|25462199|METHODS|ab|2|entity|C0025141|MEDLINE|inpr|||MEDLINE|||0|1000|412|419
SE|25462199|METHODS|ab|2|entity|C1004593|Scopus|bird|||Scopus|||0|1000|422|428
SE|25462199|METHODS|ab|2|entity|C0332875|Congenital webbing|cgab|||Web|||0|1000|438|441
SE|25462199|METHODS|ab|2|entity|C0036397|Science|ocdi|||Science|||0|888|445|452
SE|25462199|METHODS|ab|2|entity|C0242356|Databases|inpr|||databases|||0|888|453|462
SE|25462199|METHODS|ab|2|entity|C1511726|Data|idcn|||data|||0|1000|512|516
SE|25462199|METHODS|ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|532|539
SE|25462199|METHODS|ab|2|entity|C1512910|Intra-abdominal|spco|||intra-abdominal|||0|734|543|558
SE|25462199|METHODS|ab|2|entity|C0038952|Continuance of life|acty|||survival|||0|872|575|583
SE|25462199|METHODS|ab|2|entity|C1274040|result|ftcn|||outcomes|||0|872|584|592
SE|25462199|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|596|604
SE|25462199|METHODS|ab|2|entity|C1408353|undiagnosed|fndg|||undiagnosed|||0|824|610|621
SE|25462199|METHODS|ab|2|entity|C0280631|Uterine leiomyosarcoma|neop|||ULMS|||0|824|622|626
SE|25462199|METHODS|ab|2|relation|1|1|C0280631|Uterine leiomyosarcoma|neop|neop|||ULMS|||0|824|622|626|PREP|PROCESS_OF||605|609|13|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|596|604

SE|25462199|METHODS|ab|3|text|628|814|Studies were evaluated per the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) and the American College of Obstetricians and Gynecologists (ACOG) guidelines.
SE|25462199|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||Studies|||0|966|628|635
SE|25462199|METHODS|ab|3|entity|C0034866|Recommendation|idcn|||Recommendations|||0|701|670|685
SE|25462199|METHODS|ab|3|entity|C0220825|Evaluation|ftcn|||Assessment|||0|701|687|697
SE|25462199|METHODS|ab|3|entity|C1527148|Development|ftcn|||Development|||0|701|699|710
SE|25462199|METHODS|ab|3|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|701|716|726
SE|25462199|METHODS|ab|3|entity|C1515938|American College of Obstetricians and Gynecologists|pros|||American College of Obstetricians and Gynecologists|||0|1000|743|794
SE|25462199|METHODS|ab|3|entity|C0162791|Guidelines|inpr|||guidelines|||0|1000|802|812

SE|25462199|RESULTS|ab|4|text|814|908|RESULTS: Sixty manuscripts were screened, 11 (18%) were selected and four (7%) were included.
SE|25462199|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|814|821
SE|25462199|RESULTS|ab|4|entity|C0600659|Manuscripts|inpr,mnob|||manuscripts|||0|861|829|840
SE|25462199|RESULTS|ab|4|entity|C0205450|Four|qnco|||four|||0|1000|883|887

SE|25462199|RESULTS|ab|5|text|908|1023|Overall, 202 patients were included: 75 (37%) patients had morcellation of ULMS, while 127 (63%) patients had not.
SE|25462199|RESULTS|ab|5|entity|C1561607|Overall|qlco|||Overall|||0|1000|908|915
SE|25462199|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|861|921|929
SE|25462199|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|954|962
SE|25462199|RESULTS|ab|5|entity|C0280631|Uterine leiomyosarcoma|neop|||ULMS|||0|901|983|987
SE|25462199|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|1005|1013
SE|25462199|RESULTS|ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1018|1021

SE|25462199|RESULTS|ab|6|text|1023|1112|A meta-analysis of these studies showed that morcellation increased the overall (62% vs.
SE|25462199|RESULTS|ab|6|entity|C0920317|Meta-Analysis|inpr|||meta-analysis|||0|1000|1025|1038
SE|25462199|RESULTS|ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|1048|1055
SE|25462199|RESULTS|ab|6|entity|C1561607|Overall|qlco|||overall|||0|1000|1095|1102

SE|25462199|RESULTS|ab|7|text|1112|1177|39%; OR: 3.16 (95% CI: 1.38, 7.26)) and intra-abdominal (39% vs.
SE|25462199|RESULTS|ab|7|entity|C1512910|Intra-abdominal|spco|||intra-abdominal|||0|1000|1152|1167

SE|25462199|RESULTS|ab|8|text|1177|1260|9%; OR: 4.11 (95% CI: 1.92, 8.81)) recurrence rates as well as death rate (48% vs.
SE|25462199|RESULTS|ab|8|entity|C0034897|Recurrence|phpr|||recurrence|||0|872|1212|1222
SE|25462199|RESULTS|ab|8|entity|C1521828|Rate|qnco|||rates|||0|872|1223|1228
SE|25462199|RESULTS|ab|8|entity|C0205848|Death Rate|qnco|||death rate|||0|1000|1240|1250

SE|25462199|RESULTS|ab|9|text|1260|1297|29%; OR: 2.42 (95% CI: 1.19, 4.92)).

SE|25462199|RESULTS|ab|10|text|1297|1417|No between-group difference in cumulative extra-abdominal recurrence (OR: 0.34 (95% CI: 0.07, 1.59)) rate was observed.
SE|25462199|RESULTS|ab|10|entity|C0441833|Groups|inpr|||group|||0|790|1308|1313
SE|25462199|RESULTS|ab|10|entity|C1547020|*Difference|qnco|||difference|||0|790|1314|1324
SE|25462199|RESULTS|ab|10|entity|C1511559|Cumulative|qlco|||cumulative|||0|775|1328|1338
SE|25462199|RESULTS|ab|10|entity|C0000726|Abdomen|blor|||abdominal|||0|775|1345|1354
SE|25462199|RESULTS|ab|10|entity|C0034897|Recurrence|phpr|||recurrence|||0|775|1355|1365
SE|25462199|RESULTS|ab|10|entity|C1521828|Rate|qnco|||rate|||0|1000|1398|1402

SE|25462199|CONCLUSIONS|ab|11|text|1417|1595|CONCLUSIONS: Our data support a significant correlation between uterine morcellation and an increased risk of intra-abdominal recurrence in patients affected by unexpected ULMS.
SE|25462199|CONCLUSIONS|ab|11|entity|C1511726|Data|idcn|||data|||0|1000|1434|1438
SE|25462199|CONCLUSIONS|ab|11|entity|C0750502|Significant|idcn|||significant|||0|694|1449|1460
SE|25462199|CONCLUSIONS|ab|11|entity|C0042149|Uterus|bpoc|||uterine|||0|694|1481|1488
SE|25462199|CONCLUSIONS|ab|11|entity|C0205217|Increased|qnco|||increased|||0|888|1509|1518
SE|25462199|CONCLUSIONS|ab|11|entity|C0035647|Risk|qlco|||risk|||0|888|1519|1523
SE|25462199|CONCLUSIONS|ab|11|entity|C1512910|Intra-abdominal|spco|||intra-abdominal|||0|901|1527|1542
SE|25462199|CONCLUSIONS|ab|11|entity|C0034897|Recurrence|phpr|||recurrence|||0|901|1543|1553
SE|25462199|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1557|1565
SE|25462199|CONCLUSIONS|ab|11|entity|C0280631|Uterine leiomyosarcoma|neop|||ULMS|||0|861|1589|1593
SE|25462199|CONCLUSIONS|ab|11|relation|1|1|C0280631|Uterine leiomyosarcoma|neop|neop|||ULMS|||0|861|1589|1593|VERB|AFFECTS||1566|1574|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1557|1565

SE|25462199|CONCLUSIONS|ab|12|text|1595|1831|However, the limited data on this issue and the absence of high level of evidence suggest the need of further studies designed to estimate the risk to benefit ratio of morcellation in patients with uterine fibroids and undiagnosed ULMS.
SE|25462199|CONCLUSIONS|ab|12|entity|C0439801|Limited|ftcn|||limited|||0|888|1608|1615
SE|25462199|CONCLUSIONS|ab|12|entity|C1511726|Data|idcn|||data|||0|888|1616|1620
SE|25462199|CONCLUSIONS|ab|12|entity|C0205250|High|qlco|||high|||0|861|1654|1658
SE|25462199|CONCLUSIONS|ab|12|entity|C0027552|Needs|qlco|||need|||0|1000|1689|1693
SE|25462199|CONCLUSIONS|ab|12|entity|C1517331|Further|spco|||further|||0|872|1697|1704
SE|25462199|CONCLUSIONS|ab|12|entity|C0008972|Clinical Research|resa|||studies|||0|872|1705|1712
SE|25462199|CONCLUSIONS|ab|12|entity|C0035647|Risk|qlco|||risk|||0|1000|1738|1742
SE|25462199|CONCLUSIONS|ab|12|entity|C0456603|Ratio|inpr|||ratio|||0|1000|1754|1759
SE|25462199|CONCLUSIONS|ab|12|entity|C0030705|Patients|podg|||patients|||0|1000|1779|1787
SE|25462199|CONCLUSIONS|ab|12|entity|C0042133|Uterine Fibroids|neop|||uterine fibroids|||0|1000|1793|1809
SE|25462199|CONCLUSIONS|ab|12|entity|C1408353|undiagnosed|fndg|||undiagnosed|||0|824|1814|1825
SE|25462199|CONCLUSIONS|ab|12|entity|C0280631|Uterine leiomyosarcoma|neop|||ULMS|||0|824|1826|1830
SE|25462199|CONCLUSIONS|ab|12|relation|2|1|C0042133|Uterine Fibroids|neop|neop|||uterine fibroids|||0|1000|1793|1809|PREP|PROCESS_OF||1788|1792|11|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1779|1787
SE|25462199|CONCLUSIONS|ab|12|relation|2|1|C0280631|Uterine leiomyosarcoma|neop|neop|||ULMS|||0|824|1826|1830|PREP|PROCESS_OF||1788|1792|11|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1779|1787


SE|25462200||ti|1|text|21|119|A systematic review of the supportive care needs of women living with and beyond cervical cancer.
SE|25462200||ti|1|entity|C0220922|systematic|ftcn|||systematic|||0|694|23|33
SE|25462200||ti|1|entity|C0344211|Supportive care|topp|||supportive care|||0|1000|48|63
SE|25462200||ti|1|entity|C0043210|Woman|popg|||women|||0|1000|73|78
SE|25462200||ti|1|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|102|117

SE|25462200|BACKGROUND|ab|1|text|125|249|BACKGROUND: Women with cervical cancer constitute a patient population in need for ongoing, person-centred supportive care.
SE|25462200|BACKGROUND|ab|1|entity|C0043210|Woman|popg|||Women|||0|1000|137|142
SE|25462200|BACKGROUND|ab|1|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|148|163
SE|25462200|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patient|||0|888|177|184
SE|25462200|BACKGROUND|ab|1|entity|C1257890|Population Group|popg|||population|||0|888|185|195
SE|25462200|BACKGROUND|ab|1|entity|C0027552|Needs|qlco|||need|||0|1000|199|203
SE|25462200|BACKGROUND|ab|1|entity|C0027361|Persons|popg|||person|||0|775|217|223
SE|25462200|BACKGROUND|ab|1|entity|C0205099|Central|spco|||centred|||0|775|224|231
SE|25462200|BACKGROUND|ab|1|entity|C0344211|Supportive care|topp|||supportive care|||0|775|232|247
SE|25462200|BACKGROUND|ab|1|relation|0|0|C0030705|Patients|podg,humn|podg|||patient|||0|888|177|184|MOD/HEAD|ISA||177|195|0|0|C1257890|Population Group|popg,humn|popg|||population|||0|888|185|195
SE|25462200|BACKGROUND|ab|1|relation|4|1|C0007847|Malignant neoplasm of cervix uteri|neop|neop|||cervical cancer|||0|1000|148|163|PREP|PROCESS_OF||143|147|2|1|C0043210|Woman|popg,humn|humn|||Women|||0|1000|137|142

SE|25462200|BACKGROUND|ab|2|text|249|392|Our aim was to synthesise current available evidence with regard to the supportive care needs of women living with and beyond cervical cancer.
SE|25462200|BACKGROUND|ab|2|entity|C0521116|Current|tmco|||current|||0|623|275|282
SE|25462200|BACKGROUND|ab|2|entity|C0344211|Supportive care|topp|||supportive care|||0|1000|321|336
SE|25462200|BACKGROUND|ab|2|entity|C0043210|Woman|popg|||women|||0|1000|346|351
SE|25462200|BACKGROUND|ab|2|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|375|390

SE|25462200|METHODS|ab|3|text|392|481|METHODS: A systematic review was conducted according to the PRISMA Statement guidelines.
SE|25462200|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|392|399
SE|25462200|METHODS|ab|3|entity|C0220922|systematic|ftcn|||systematic|||0|694|403|413
SE|25462200|METHODS|ab|3|entity|C0138404|prisma|orch,phsu|||PRISMA|||0|802|452|458
SE|25462200|METHODS|ab|3|entity|C0162791|Guidelines|inpr|||guidelines|||0|802|469|479

SE|25462200|METHODS|ab|4|text|481|654|Seven electronic databases (DARE, Cochrane, MEDLINE, CINAHL, BNI, PsychINFO and EMBASE) were searched to identify studies employing qualitative and/or quantitative methods.
SE|25462200|METHODS|ab|4|entity|C0205453|Seven|qnco|||Seven|||0|890|481|486
SE|25462200|METHODS|ab|4|entity|C0242356|Databases|inpr|||electronic databases|||0|890|487|507
SE|25462200|METHODS|ab|4|entity|C0025141|MEDLINE|inpr|||MEDLINE|||0|1000|525|532
SE|25462200|METHODS|ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|966|595|602
SE|25462200|METHODS|ab|4|entity|C0205556|Qualitative|qlco|||qualitative|||0|1000|613|624
SE|25462200|METHODS|ab|4|entity|C1510568|Quantitative Methods|resa|||quantitative methods|||0|1000|632|652

SE|25462200|METHODS|ab|5|text|654|748|Pre-specified selection criteria were applied to all records published between 1990 and 2013.
SE|25462200|METHODS|ab|5|entity|C0242801|Selection Criteria|qlco|||selection criteria|||0|1000|668|686
SE|25462200|METHODS|ab|5|entity|C0034869|Records|inpr|||records|||0|1000|707|714

SE|25462200|METHODS|ab|6|text|748|845|Methodological quality evaluation was conducted using the standardised QualSyst evaluation tool.
SE|25462200|METHODS|ab|6|entity|C0815254|methodological quality|resa|||Methodological quality|||0|901|748|770
SE|25462200|METHODS|ab|6|entity|C0220825|Evaluation|ftcn|||evaluation|||0|901|771|781
SE|25462200|METHODS|ab|6|entity|C0220825|Evaluation|ftcn|||evaluation|||0|750|828|838
SE|25462200|METHODS|ab|6|entity|C0336791|Tool|mnob|||tool|||0|750|839|843

SE|25462200|METHODS|ab|7|text|845|896|Findings were integrated in a narrative synthesis.
SE|25462200|METHODS|ab|7|entity|C0243095|Finding|ftcn|||Findings|||0|1000|845|853
SE|25462200|METHODS|ab|7|entity|C0870937|Narratives|socb|||narrative|||0|872|875|884
SE|25462200|METHODS|ab|7|entity|C0869032|Synthesis|phpr|||synthesis|||0|872|885|894

SE|25462200|FINDINGS|ab|8|text|896|1004|FINDINGS: Of 4936 references initially retrieved, 15 articles (13 unique studies) met eligibility criteria.
SE|25462200|FINDINGS|ab|8|entity|C0243095|Finding|ftcn|||FINDINGS|||0|1000|896|904
SE|25462200|FINDINGS|ab|8|entity|C1514811|Reference|idcn|||references|||0|827|914|924
SE|25462200|FINDINGS|ab|8|entity|C0205265|Initially|tmco|||initially|||0|1000|925|934
SE|25462200|FINDINGS|ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|793|969|976
SE|25462200|FINDINGS|ab|8|entity|C0243161|criteria|inpr|||criteria|||0|802|994|1002

SE|25462200|FINDINGS|ab|9|text|1004|1099|One study fell below a pre-specified 55% threshold of methodological quality and was excluded.
SE|25462200|FINDINGS|ab|9|entity|C0205447|One|qnco|||One|||0|888|1004|1007
SE|25462200|FINDINGS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|888|1008|1013
SE|25462200|FINDINGS|ab|9|entity|C0542339|Inferior|spco|||below|||0|1000|1019|1024
SE|25462200|FINDINGS|ab|9|entity|C0449864|Threshold|ftcn|||threshold|||0|861|1045|1054
SE|25462200|FINDINGS|ab|9|entity|C0815254|methodological quality|resa|||methodological quality|||0|1000|1058|1080

SE|25462200|FINDINGS|ab|10|text|1099|1158|Individual needs were classified into ten domains of need.
SE|25462200|FINDINGS|ab|10|entity|C0237401|Individual|humn|||Individual|||0|888|1099|1109
SE|25462200|FINDINGS|ab|10|entity|C0027552|Needs|qlco|||needs|||0|888|1110|1115
SE|25462200|FINDINGS|ab|10|entity|C0205456|Ten|qnco|||ten|||0|694|1137|1140
SE|25462200|FINDINGS|ab|10|entity|C0027552|Needs|qlco|||need|||0|1000|1152|1156

SE|25462200|FINDINGS|ab|11|text|1158|1332|Interpersonal/intimacy (10; 83.3%), health system/information (8; 66.7%), psychological/emotional (7; 58.3%) and physical needs (6; 50%) were those most frequently explored.
SE|25462200|FINDINGS|ab|11|entity|C0679995|intimacy|inbe|||intimacy|||0|861|1172|1180
SE|25462200|FINDINGS|ab|11|entity|C0449913|System|ftcn|||system|||0|901|1201|1207
SE|25462200|FINDINGS|ab|11|entity|C0850397|Information, health|hlca|||health system/information|||0|901|1194|1219
SE|25462200|FINDINGS|ab|11|entity|C0205486|Psychologic|ftcn|||psychological|||0|888|1232|1245
SE|25462200|FINDINGS|ab|11|entity|C0849912|Emotional|fndg|||emotional|||0|888|1246|1255
SE|25462200|FINDINGS|ab|11|entity|C0205485|Physical|ftcn|||physical|||0|888|1271|1279
SE|25462200|FINDINGS|ab|11|entity|C0027552|Needs|qlco|||needs|||0|888|1280|1285
SE|25462200|FINDINGS|ab|11|entity|C0205393|Most|qnco|||most|||0|1000|1306|1310
SE|25462200|FINDINGS|ab|11|entity|C0332183|Frequent|tmco|||frequently|||0|1000|1311|1321

SE|25462200|FINDINGS|ab|12|text|1332|1475|Spiritual/existential (1; 8.3%), family-related (2; 16.7%), practical (2; 16.7%), and daily living needs (2; 16.7%) were only rarely explored.
SE|25462200|FINDINGS|ab|12|entity|C0015576|Family|famg|||family|||0|888|1365|1371
SE|25462200|FINDINGS|ab|12|entity|C1522149|Related|ftcn|||related|||0|888|1372|1379
SE|25462200|FINDINGS|ab|12|entity|C0237607|experience (practice)|menp|||practical|||0|928|1392|1401
SE|25462200|FINDINGS|ab|12|entity|C0332173|Daily|tmco|||daily|||0|802|1418|1423
SE|25462200|FINDINGS|ab|12|entity|C0027552|Needs|qlco|||needs|||0|802|1431|1436
SE|25462200|FINDINGS|ab|12|entity|C0522498|Rare|qlco|||rarely|||0|1000|1458|1464

SE|25462200|FINDINGS|ab|13|text|1475|1567|Patient-clinician communication needs and social needs were addressed in 4 studies (33.3%).
SE|25462200|FINDINGS|ab|13|entity|C0030705|Patients|podg|||Patient|||0|833|1475|1482
SE|25462200|FINDINGS|ab|13|entity|C1550470|clinician|idcn|||clinician|||0|833|1483|1492
SE|25462200|FINDINGS|ab|13|entity|C0009452|Communication|socb|||communication|||0|833|1493|1506
SE|25462200|FINDINGS|ab|13|entity|C0027552|Needs|qlco|||needs|||0|833|1507|1512
SE|25462200|FINDINGS|ab|13|entity|C0728831|SOCIAL|ftcn|||social|||0|888|1517|1523
SE|25462200|FINDINGS|ab|13|entity|C0027552|Needs|qlco|||needs|||0|888|1524|1529
SE|25462200|FINDINGS|ab|13|entity|C0008972|Clinical Research|resa|||studies|||0|827|1550|1557

SE|25462200|FINDINGS|ab|14|text|1567|1855|Dealing with fear of cancer recurrence, concerns about appearance/body image, lack of sexual desire, requiring more sexuality-related information, dealing with pain, and dealing with difficulties in relationship with partner were the most frequently cited individual needs (>=4 studies).
SE|25462200|FINDINGS|ab|14|entity|C0015726|Fright|menp|||fear|||0|1000|1580|1584
SE|25462200|FINDINGS|ab|14|entity|C0920420|cancer recurrence|neop|||cancer recurrence|||0|1000|1588|1605
SE|25462200|FINDINGS|ab|14|entity|C0700364|Appearance|qlco|||appearance|||0|901|1622|1632
SE|25462200|FINDINGS|ab|14|entity|C0005891|Body Image|qlco|||body image|||0|901|1633|1643
SE|25462200|FINDINGS|ab|14|entity|C0332268|Lacking|qlco|||lack|||0|1000|1645|1649
SE|25462200|FINDINGS|ab|14|entity|C0424400|Erotic interest|fndg|||sexual desire|||0|1000|1653|1666
SE|25462200|FINDINGS|ab|14|entity|C0205172|More|ftcn|||more|||0|833|1678|1682
SE|25462200|FINDINGS|ab|14|entity|C0036864|Sex Behavior|inbe|||sexuality|||0|833|1683|1692
SE|25462200|FINDINGS|ab|14|entity|C1522149|Related|ftcn|||related|||0|833|1693|1700
SE|25462200|FINDINGS|ab|14|entity|C1533716|Information|idcn|||information|||0|833|1701|1712
SE|25462200|FINDINGS|ab|14|entity|C0030193|Pain|sosy|||pain|||0|1000|1727|1731
SE|25462200|FINDINGS|ab|14|entity|C0439849|Relationships|qlco|||relationship|||0|1000|1766|1778
SE|25462200|FINDINGS|ab|14|entity|C0205393|Most|qnco|||most|||0|1000|1801|1805
SE|25462200|FINDINGS|ab|14|entity|C0332183|Frequent|tmco|||frequently|||0|1000|1806|1816
SE|25462200|FINDINGS|ab|14|entity|C0237401|Individual|humn|||individual|||0|888|1823|1833
SE|25462200|FINDINGS|ab|14|entity|C0027552|Needs|qlco|||needs|||0|888|1834|1839
SE|25462200|FINDINGS|ab|14|entity|C0008972|Clinical Research|resa|||studies|||0|827|1845|1852

SE|25462200|CONCLUSIONS|ab|15|text|1855|2029|CONCLUSIONS: Despite a host of additional needs experienced by women with cervical cancer, a predominant focus on sexuality/intimacy and information seeking issues is noted.
SE|25462200|CONCLUSIONS|ab|15|entity|C1524062|Additional|ftcn|||additional|||0|888|1886|1896
SE|25462200|CONCLUSIONS|ab|15|entity|C0027552|Needs|qlco|||needs|||0|888|1897|1902
SE|25462200|CONCLUSIONS|ab|15|entity|C0043210|Woman|popg|||women|||0|1000|1918|1923
SE|25462200|CONCLUSIONS|ab|15|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|1929|1944
SE|25462200|CONCLUSIONS|ab|15|entity|C0205234|Focal|spco|||focus|||0|861|1960|1965
SE|25462200|CONCLUSIONS|ab|15|entity|C0036864|Sex Behavior|inbe|||sexuality|||0|888|1969|1978
SE|25462200|CONCLUSIONS|ab|15|entity|C0679995|intimacy|inbe|||intimacy|||0|888|1979|1987
SE|25462200|CONCLUSIONS|ab|15|entity|C0392349|Seeks information|fndg|||information seeking|||0|734|1992|2011
SE|25462200|CONCLUSIONS|ab|15|relation|4|1|C0007847|Malignant neoplasm of cervix uteri|neop|neop|||cervical cancer|||0|1000|1929|1944|PREP|PROCESS_OF||1924|1928|4|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1918|1923

SE|25462200|CONCLUSIONS|ab|16|text|2029|2177|Study limitations preclude drawing conclusions as to how these needs evolve over time from diagnosis to treatment and subsequently to survivorship.
SE|25462200|CONCLUSIONS|ab|16|entity|C0008972|Clinical Research|resa|||Study|||0|872|2029|2034
SE|25462200|CONCLUSIONS|ab|16|entity|C0449295|Limitation|ftcn|||limitations|||0|872|2035|2046
SE|25462200|CONCLUSIONS|ab|16|entity|C0013113|drawing|inpr|||drawing|||0|694|2056|2063
SE|25462200|CONCLUSIONS|ab|16|entity|C0027552|Needs|qlco|||needs|||0|1000|2092|2097
SE|25462200|CONCLUSIONS|ab|16|entity|C0205136|Over|spco|||over|||0|888|2105|2109
SE|25462200|CONCLUSIONS|ab|16|entity|C0040223|Time|tmco|||time|||0|888|2110|2114
SE|25462200|CONCLUSIONS|ab|16|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|2120|2129
SE|25462200|CONCLUSIONS|ab|16|entity|C0038952|Continuance of life|acty|||survivorship|||0|1000|2163|2175

SE|25462200|CONCLUSIONS|ab|17|text|2177|2354|Whether demographic or clinical variables such as age, race/ethnicity, disease stage or treatment modality play a moderating role, only remains to be answered in future studies.
SE|25462200|CONCLUSIONS|ab|17|entity|C0011298|Demography|ocdi|||demographic|||0|928|2185|2196
SE|25462200|CONCLUSIONS|ab|17|entity|C0205210|Clinical|qlco|||clinical|||0|872|2200|2208
SE|25462200|CONCLUSIONS|ab|17|entity|C0439828|Variable|qlco|||variables|||0|872|2209|2218
SE|25462200|CONCLUSIONS|ab|17|entity|C0001779|Age|orga|||age|||0|1000|2227|2230
SE|25462200|CONCLUSIONS|ab|17|entity|C0034510|Racial group|popg|||race|||0|888|2232|2236
SE|25462200|CONCLUSIONS|ab|17|entity|C0015031|Ethnic group|popg|||ethnicity|||0|888|2237|2246
SE|25462200|CONCLUSIONS|ab|17|entity|C0699749|disease stage|diap|||disease stage|||0|1000|2248|2261
SE|25462200|CONCLUSIONS|ab|17|entity|C0695347|Modality|idcn|||modality|||0|888|2275|2283
SE|25462200|CONCLUSIONS|ab|17|entity|C0035820|Role|socb|||role|||0|861|2302|2306
SE|25462200|CONCLUSIONS|ab|17|entity|C0016884|Future|tmco|||future|||0|872|2339|2345
SE|25462200|CONCLUSIONS|ab|17|entity|C0008972|Clinical Research|resa|||studies|||0|872|2346|2353


SE|25462201||ti|1|text|21|128|Transversus abdominis plane block in robotic gynecologic oncology: a randomized, placebo-controlled trial.
SE|25462201||ti|1|entity|C0028778|Obstruction|patf|||block|||0|812|49|54
SE|25462201||ti|1|entity|C0336537|Robot|mnob|||robotic|||0|877|58|65
SE|25462201||ti|1|entity|C1321164|Gynecologic Oncology|bmod|||gynecologic oncology|||0|877|66|86
SE|25462201||ti|1|entity|C1514720|Randomized|ftcn|||randomized|||0|833|90|100
SE|25462201||ti|1|entity|C0032042|Placebos|medd,topp|||placebo|||0|833|102|109
SE|25462201||ti|1|entity|C0702113|Controlled|ftcn|||controlled|||0|833|110|120
SE|25462201||ti|1|entity|C0008976|Clinical Trials|resa|||trial|||0|833|121|126

SE|25462201|OBJECTIVE|ab|1|text|134|294|OBJECTIVE: Although robotic surgery decreases pain compared to laparotomy, postoperative pain can be a concern near the site of a larger assistant trocar site.
SE|25462201|OBJECTIVE|ab|1|entity|C0336537|Robot|mnob|||robotic|||0|853|154|161
SE|25462201|OBJECTIVE|ab|1|entity|C0030193|Pain|sosy|||pain|||0|1000|180|184
SE|25462201|OBJECTIVE|ab|1|entity|C0023038|Laparotomy|topp|||laparotomy|||0|1000|197|207
SE|25462201|OBJECTIVE|ab|1|entity|C0030201|Pain, Postoperative|sosy|||postoperative pain|||0|1000|209|227
SE|25462201|OBJECTIVE|ab|1|entity|C0205145|Site|spco|||site|||0|1000|254|258
SE|25462201|OBJECTIVE|ab|1|entity|C0443228|Largest|qnco|||larger|||0|775|264|270
SE|25462201|OBJECTIVE|ab|1|entity|C0041158|Trocar|medd|||trocar|||0|775|281|287
SE|25462201|OBJECTIVE|ab|1|entity|C0205145|Site|spco|||site|||0|775|288|292

SE|25462201|OBJECTIVE|ab|2|text|294|471|The aim of this study was to determine the efficacy of transversus abdominis plane (TAP) block on 24-hour postoperative opiate use after robotic surgery for gynecologic cancer.
SE|25462201|OBJECTIVE|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|310|315
SE|25462201|OBJECTIVE|ab|2|entity|C0028778|Obstruction|patf|||block|||0|812|383|388
SE|25462201|OBJECTIVE|ab|2|entity|C0439584|24 hour time frame|tmco|||24-hour|||0|777|392|399
SE|25462201|OBJECTIVE|ab|2|entity|C0376196|Opiates|hops,phsu|||opiate|||0|777|414|420
SE|25462201|OBJECTIVE|ab|2|entity|C0336537|Robot|mnob|||robotic|||0|853|431|438
SE|25462201|OBJECTIVE|ab|2|entity|C0699889|Female reproductive neoplasm malignant NOS|neop|||gynecologic cancer|||0|1000|451|469
SE|25462201|OBJECTIVE|ab|2|relation|2|1|C0008972|Clinical Research|resa|resa|||study|||0|1000|310|315|VERB|MEASURES||323|332|5|2|C0028778|Obstruction|patf|patf|||block|||0|812|383|388

SE|25462201|METHODS|ab|3|text|471|606|METHODS: Sixty-four subjects with gynecologic malignancies who were scheduled to undergo robotic surgery were enrolled into the study.
SE|25462201|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|471|478
SE|25462201|METHODS|ab|3|entity|C0205450|Four|qnco|||four|||0|861|486|490
SE|25462201|METHODS|ab|3|entity|C0205480|Gynecologic|spco|||gynecologic|||0|888|505|516
SE|25462201|METHODS|ab|3|entity|C0006826|Malignant Neoplasms|neop|||malignancies|||0|888|517|529
SE|25462201|METHODS|ab|3|entity|C0336537|Robot|mnob|||robotic|||0|853|560|567
SE|25462201|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|599|604

SE|25462201|METHODS|ab|4|text|606|720|They were randomized to receive a unilateral TAP block to the side of the assistant port via ultrasound guidance.
SE|25462201|METHODS|ab|4|entity|C0205092|Unilateral|spco|||unilateral|||0|786|640|650
SE|25462201|METHODS|ab|4|entity|C0028778|Obstruction|patf|||block|||0|786|655|660
SE|25462201|METHODS|ab|4|entity|C0441987|Side|spco|||side|||0|1000|668|672
SE|25462201|METHODS|ab|4|entity|C0475311|Harbor|mnob|||port|||0|790|690|694
SE|25462201|METHODS|ab|4|entity|C0442973|Ultrasonic guidance procedure|diap|||ultrasound guidance|||0|790|699|718

SE|25462201|METHODS|ab|5|text|720|811|The block was comprised of 30 cc of 0.25% bupivacaine with 3 mcg/mL epinephrine or saline.
SE|25462201|METHODS|ab|5|entity|C0028778|Obstruction|patf|||block|||0|1000|724|729
SE|25462201|METHODS|ab|5|entity|C0006400|Bupivacaine|orch,phsu|||bupivacaine|||0|827|762|773
SE|25462201|METHODS|ab|5|entity|C0439211|microgram|qnco|||mcg|||0|833|781|784
SE|25462201|METHODS|ab|5|entity|C0014563|Epinephrine|horm,nsba,orch,phsu|||epinephrine|||0|833|788|799
SE|25462201|METHODS|ab|5|entity|C0036082|Saline|clnd|||saline|||0|1000|803|809

SE|25462201|METHODS|ab|6|text|811|879|Opiate use was measured and converted into IV morphine equivalents.
SE|25462201|METHODS|ab|6|entity|C0376196|Opiates|hops,phsu|||Opiate|||0|888|811|817
SE|25462201|METHODS|ab|6|entity|C0026549|Morphine|orch,phsu|||morphine|||0|851|857|865
SE|25462201|METHODS|ab|6|entity|C0439185|Eq|qnco|||equivalents|||0|851|866|877

SE|25462201|METHODS|ab|7|text|879|982|Patient-reported pain was measured using the Brief Pain Inventory (BPI) and Visual Analog Scale (VAS).
SE|25462201|METHODS|ab|7|entity|C0030705|Patients|podg|||Patient|||0|901|879|886
SE|25462201|METHODS|ab|7|entity|C0518088|Reported pain|fndg|||reported pain|||0|901|887|900
SE|25462201|METHODS|ab|7|entity|C1511326|Brief Pain Inventory|inpr|||Brief Pain Inventory|||0|1000|924|944
SE|25462201|METHODS|ab|7|entity|C0042815|Visual Analog Scale|diap,qnco|||Visual Analog Scale|||0|1000|955|974

SE|25462201|RESULTS|ab|8|text|982|1119|RESULTS: The treatment group used a mean of 64.9 mg morphine in the first 24h compared to 69.3mg for controls (primary outcome, p=0.52).
SE|25462201|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|982|989
SE|25462201|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|888|1005|1010
SE|25462201|RESULTS|ab|8|entity|C0651569|9-(1'-hydroxy-2'-(hydroxymethyl)ethoxy)methylguanine|nnon|||9 mg|||0|824|1029|1033
SE|25462201|RESULTS|ab|8|entity|C0026549|Morphine|orch,phsu|||morphine|||0|824|1034|1042
SE|25462201|RESULTS|ab|8|entity|C1279901|Firstly|qlco|||first|||0|888|1050|1055
SE|25462201|RESULTS|ab|8|entity|C0456696|/24h|tmco|||24h|||0|888|1056|1059
SE|25462201|RESULTS|ab|8|entity|C0243148|control|ftcn|||controls|||0|966|1083|1091
SE|25462201|RESULTS|ab|8|entity|C1274040|result|ftcn|||outcome|||0|888|1101|1108

SE|25462201|RESULTS|ab|9|text|1119|1221|After age-adjustment, the treatment group used a mean of 11.1mg morphine less than controls (p=0.09).
SE|25462201|RESULTS|ab|9|entity|C0001779|Age|orga|||age|||0|694|1125|1128
SE|25462201|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|888|1155|1160
SE|25462201|RESULTS|ab|9|entity|C0026549|Morphine|orch,phsu|||morphine|||0|812|1183|1191
SE|25462201|RESULTS|ab|9|entity|C0243148|control|ftcn|||controls|||0|966|1202|1210

SE|25462201|RESULTS|ab|10|text|1221|1344|Postoperative pain scores assessed by the BPI (6.44 vs. 6.97, p=0.37) and the VAS (3.12 vs. 3.61, p=0.30) were equivalent.
SE|25462201|RESULTS|ab|10|entity|C0030201|Pain, Postoperative|sosy|||Postoperative pain|||0|901|1221|1239
SE|25462201|RESULTS|ab|10|entity|C0449820|Score|qnco|||scores|||0|901|1240|1246
SE|25462201|RESULTS|ab|10|entity|C1511326|Brief Pain Inventory|inpr|||BPI|||0|1000|1263|1266
SE|25462201|RESULTS|ab|10|entity|C0042815|Visual Analog Scale|diap,qnco|||VAS|||0|1000|1299|1302
SE|25462201|RESULTS|ab|10|entity|C0442761|3/12|fndg|||3.12|||0|1000|1304|1308
SE|25462201|RESULTS|ab|10|entity|C0069919|ranpirnase|aapp,enzy,phsu|||p=0.30|||0|913|1319|1325
SE|25462201|RESULTS|ab|10|entity|C0439185|Eq|qnco|||equivalent|||0|1000|1332|1342

SE|25462201|RESULTS|ab|11|text|1344|1434|Block placement was uncomplicated in 98.4% of participants with mean BMI of 35.3 kg/m(2).
SE|25462201|RESULTS|ab|11|entity|C0028778|Obstruction|patf|||Block|||0|888|1344|1349
SE|25462201|RESULTS|ab|11|entity|C0443334|Uncomplicated|qlco|||uncomplicated|||0|1000|1364|1377
SE|25462201|RESULTS|ab|11|entity|C0679646|Participant|popg|||participants|||0|966|1390|1402
SE|25462201|RESULTS|ab|11|entity|C1305855|Body mass index|clna|||BMI|||0|861|1413|1416
SE|25462201|RESULTS|ab|11|entity|C1532718|kg-m|qnco|||kg/m|||0|861|1425|1429

SE|25462201|RESULTS|ab|12|text|1434|1562|Linear regression revealed an approximate 8.1mg decrease in morphine equivalents used per additional decade of life (p=0.0008).
SE|25462201|RESULTS|ab|12|entity|C0023733|Linear Regression|qnco|||Linear regression|||0|1000|1434|1451
SE|25462201|RESULTS|ab|12|entity|C0332232|Approximate|ftcn,qlco|||approximate|||0|791|1464|1475
SE|25462201|RESULTS|ab|12|entity|C0547047|Decrease|qnco|||decrease|||0|791|1482|1490
SE|25462201|RESULTS|ab|12|entity|C0026549|Morphine|orch,phsu|||morphine|||0|888|1494|1502
SE|25462201|RESULTS|ab|12|entity|C0439185|Eq|qnco|||equivalents|||0|888|1503|1514
SE|25462201|RESULTS|ab|12|entity|C1524062|Additional|ftcn|||additional|||0|694|1524|1534
SE|25462201|RESULTS|ab|12|entity|C0376558|Life|idcn|||life|||0|1000|1545|1549

SE|25462201|RESULTS|ab|13|text|1562|1714|There was a positive correlation between the amount of opiates and BMI with an additional 8.8 mg of morphine per 10 kg/m(2) increase in BMI (p=0.0012).
SE|25462201|RESULTS|ab|13|entity|C1446409|Positive|qlco|||positive|||0|694|1574|1582
SE|25462201|RESULTS|ab|13|entity|C1265611|Quantity|qnco|||amount|||0|1000|1607|1613
SE|25462201|RESULTS|ab|13|entity|C0029095|Opioid abuse|mobd|||opiates|||0|1000|1617|1624
SE|25462201|RESULTS|ab|13|entity|C1305855|Body mass index|clna|||BMI|||0|1000|1629|1632
SE|25462201|RESULTS|ab|13|entity|C1524062|Additional|ftcn|||additional|||0|791|1641|1651
SE|25462201|RESULTS|ab|13|entity|C0026549|Morphine|orch,phsu|||morphine|||0|1000|1662|1670
SE|25462201|RESULTS|ab|13|entity|C1532718|kg-m|qnco|||kg/m|||0|901|1678|1682
SE|25462201|RESULTS|ab|13|entity|C1305855|Body mass index|clna|||BMI|||0|1000|1698|1701

SE|25462201|CONCLUSIONS|ab|14|text|1714|1828|CONCLUSIONS: TAP block is safe and feasible in this patient population with a large proportion of morbid obesity.
SE|25462201|CONCLUSIONS|ab|14|entity|C0028778|Obstruction|patf|||block|||0|812|1731|1736
SE|25462201|CONCLUSIONS|ab|14|entity|C0030705|Patients|podg|||patient|||0|888|1766|1773
SE|25462201|CONCLUSIONS|ab|14|entity|C1257890|Population Group|popg|||population|||0|888|1774|1784
SE|25462201|CONCLUSIONS|ab|14|entity|C0549177|Large|qnco|||large|||0|853|1792|1797
SE|25462201|CONCLUSIONS|ab|14|entity|C0205351|Proportional|qlco|||proportion|||0|853|1798|1808
SE|25462201|CONCLUSIONS|ab|14|entity|C0028756|Obesity, Morbid|dsyn|||morbid obesity|||0|1000|1812|1826
SE|25462201|CONCLUSIONS|ab|14|relation|0|0|C0028778|Obstruction|patf|patf|||block|||0|812|1731|1736|INFER|PROCESS_OF(SPEC)||1766|1784|0|0|C0030705|Patients|podg,humn|podg|||patient|||0|888|1766|1773
SE|25462201|CONCLUSIONS|ab|14|relation|0|0|C0030705|Patients|podg,humn|podg|||patient|||0|888|1766|1773|MOD/HEAD|ISA||1766|1784|0|0|C1257890|Population Group|popg,humn|popg|||population|||0|888|1774|1784
SE|25462201|CONCLUSIONS|ab|14|relation|4|3|C0028778|Obstruction|patf|patf|||block|||0|812|1731|1736|PREP|PROCESS_OF||1758|1760|3|1|C1257890|Population Group|popg,humn|humn|||population|||0|888|1774|1784

SE|25462201|CONCLUSIONS|ab|15|text|1828|1895|Preoperative TAP block does not significantly decrease opiate use.
SE|25462201|CONCLUSIONS|ab|15|entity|C0445204|Preoperative|tmco|||Preoperative|||0|786|1828|1840
SE|25462201|CONCLUSIONS|ab|15|entity|C0028778|Obstruction|patf|||block|||0|786|1845|1850
SE|25462201|CONCLUSIONS|ab|15|entity|C1518422|Not|ftcn|||not|||0|1000|1856|1859
SE|25462201|CONCLUSIONS|ab|15|entity|C0376196|Opiates|hops,phsu|||opiate|||0|888|1883|1889

SE|25462201|CONCLUSIONS|ab|16|text|1895|2054|However; based on these data, a clinically useful nomogram has been created to aid clinicians in postoperative opiate-dosing for patients based on age and BMI.
SE|25462201|CONCLUSIONS|ab|16|entity|C1511726|Data|idcn|||data|||0|1000|1919|1923
SE|25462201|CONCLUSIONS|ab|16|entity|C1450294|Nomograms|inpr|||nomogram|||0|827|1945|1953
SE|25462201|CONCLUSIONS|ab|16|entity|C0871685|Clinicians|prog|||clinicians|||0|1000|1978|1988
SE|25462201|CONCLUSIONS|ab|16|entity|C0376196|Opiates|hops,phsu|||opiate|||0|861|2006|2012
SE|25462201|CONCLUSIONS|ab|16|entity|C0030705|Patients|podg|||patients|||0|1000|2024|2032
SE|25462201|CONCLUSIONS|ab|16|entity|C0001779|Age|orga|||age|||0|1000|2042|2045
SE|25462201|CONCLUSIONS|ab|16|entity|C1305855|Body mass index|clna|||BMI|||0|1000|2050|2053


SE|25462202||ti|1|text|21|271|Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery - a mono-institutional prospective study.
SE|25462202||ti|1|entity|C0018684|Health|idcn|||Health|||0|1000|21|27
SE|25462202||ti|1|entity|C0332306|Quality|qlco|||quality|||0|1000|36|43
SE|25462202||ti|1|entity|C0376558|Life|idcn|||life|||0|1000|47|51
SE|25462202||ti|1|entity|C1317600|PATIENT SYMPTOMS|fndg|||patient reported symptoms|||0|901|56|81
SE|25462202||ti|1|entity|C0443196|Definitive|tmco|||definitive|||0|888|100|110
SE|25462202||ti|1|entity|C1304639|Radio|mnob|||radio|||0|888|111|116
SE|25462202||ti|1|entity|C0392920|Chemotherapy-Oncologic Procedure|topp|||chemo|||0|888|117|122
SE|25462202||ti|1|entity|C0025086|Medical Imaging|diap|||image|||0|825|137|142
SE|25462202||ti|1|entity|C0181090|Professional guide|prog|||guided|||0|825|143|149
SE|25462202||ti|1|entity|C0231193|Adaptive|ftcn|||adaptive|||0|825|150|158
SE|25462202||ti|1|entity|C0006098|Brachytherapy|topp|||brachytherapy|||0|825|159|172
SE|25462202||ti|1|entity|C1517927|Locally|spco|||locally|||0|1000|177|184
SE|25462202||ti|1|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|194|209
SE|25462202||ti|1|entity|C1279919|Early|tmco|||early|||0|888|214|219
SE|25462202||ti|1|entity|C0237820|Recovery|orgf|||recovery|||0|888|220|228
SE|25462202||ti|1|entity|C0018704|Health care facility|hcro,mnob|||institutional|||0|789|238|251
SE|25462202||ti|1|entity|C0033522|Prospective Studies|qnco,resa|||prospective study|||0|789|252|269

SE|25462202|OBJECTIVE|ab|1|text|277|556|OBJECTIVE: To evaluate health-related quality of life (HR-QoL) and patient reported symptoms (PRS) before, during and early after treatment with external-beam radiotherapy (EBRT), chemotherapy and image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer.
SE|25462202|OBJECTIVE|ab|1|entity|C0018684|Health|idcn|||health|||0|875|300|306
SE|25462202|OBJECTIVE|ab|1|entity|C1522149|Related|ftcn|||related|||0|875|307|314
SE|25462202|OBJECTIVE|ab|1|entity|C0034380|Quality of life|qlco|||quality of life|||0|875|315|330
SE|25462202|OBJECTIVE|ab|1|entity|C1317600|PATIENT SYMPTOMS|fndg|||patient reported symptoms|||0|824|344|369
SE|25462202|OBJECTIVE|ab|1|entity|C1279919|Early|tmco|||early|||0|1000|395|400
SE|25462202|OBJECTIVE|ab|1|entity|C0419095|Teleradiotherapy procedure|topp|||external-beam radiotherapy|||0|1000|422|448
SE|25462202|OBJECTIVE|ab|1|entity|C0013216|Pharmacotherapy|topp|||chemotherapy|||0|1000|457|469
SE|25462202|OBJECTIVE|ab|1|entity|C0025086|Medical Imaging|diap|||image|||0|825|474|479
SE|25462202|OBJECTIVE|ab|1|entity|C0181090|Professional guide|prog|||guided|||0|825|480|486
SE|25462202|OBJECTIVE|ab|1|entity|C0231193|Adaptive|ftcn|||adaptive|||0|825|487|495
SE|25462202|OBJECTIVE|ab|1|entity|C0006098|Brachytherapy|topp|||brachytherapy|||0|825|496|509
SE|25462202|OBJECTIVE|ab|1|entity|C1517927|Locally|spco|||locally|||0|1000|522|529
SE|25462202|OBJECTIVE|ab|1|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|539|554
SE|25462202|OBJECTIVE|ab|1|relation|4|1|C0006098|Brachytherapy|topp|topp|||brachytherapy|||0|825|496|509|NOM|TREATS||407|416|2|1|C1317600|PATIENT SYMPTOMS|fndg|fndg|||patient reported symptoms|||0|824|344|369
SE|25462202|OBJECTIVE|ab|1|relation|4|1|C0013216|Pharmacotherapy|topp|topp|||chemotherapy|||0|1000|457|469|NOM|TREATS||407|416|2|1|C1317600|PATIENT SYMPTOMS|fndg|fndg|||patient reported symptoms|||0|824|344|369
SE|25462202|OBJECTIVE|ab|1|relation|4|1|C0419095|Teleradiotherapy procedure|topp|topp|||external-beam radiotherapy|||0|1000|422|448|NOM|TREATS||407|416|2|1|C1317600|PATIENT SYMPTOMS|fndg|fndg|||patient reported symptoms|||0|824|344|369

SE|25462202|METHODS|ab|2|text|556|762|METHODS: In fifty consecutive patients, HR-QoL and PRS were prospectively assessed with the EORTC-QLQ-C30+CX24 questionnaire prior to and during treatment, one week after IGABT and three months thereafter.
SE|25462202|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|556|563
SE|25462202|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|827|586|594
SE|25462202|METHODS|ab|2|entity|C0018684|Health|idcn|||HR-QoL|||0|875|596|602
SE|25462202|METHODS|ab|2|entity|C1522149|Related|ftcn|||HR-QoL|||0|875|596|602
SE|25462202|METHODS|ab|2|entity|C0034380|Quality of life|qlco|||HR-QoL|||0|875|596|602
SE|25462202|METHODS|ab|2|entity|C1317600|PATIENT SYMPTOMS|fndg|||PRS|||0|901|607|610
SE|25462202|METHODS|ab|2|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|804|667|680
SE|25462202|METHODS|ab|2|entity|C0205447|One|qnco|||one|||0|809|712|715
SE|25462202|METHODS|ab|2|entity|C0439230|week|tmco|||week|||0|809|716|720
SE|25462202|METHODS|ab|2|entity|C0001762|Afterimage|menp,ortf|||after IGABT|||0|809|721|732
SE|25462202|METHODS|ab|2|entity|C0181090|Professional guide|prog|||IGABT|||0|809|727|732
SE|25462202|METHODS|ab|2|entity|C0231193|Adaptive|ftcn|||IGABT|||0|809|727|732
SE|25462202|METHODS|ab|2|entity|C0006098|Brachytherapy|topp|||IGABT|||0|809|727|732
SE|25462202|METHODS|ab|2|entity|C0205449|Three|qnco|||three|||0|790|737|742
SE|25462202|METHODS|ab|2|entity|C0439231|month|tmco|||months|||0|790|743|749

SE|25462202|METHODS|ab|3|text|762|840|HR-QoL was compared to an age-matched, female normative reference population.
SE|25462202|METHODS|ab|3|entity|C0018684|Health|idcn|||HR-QoL|||0|875|762|768
SE|25462202|METHODS|ab|3|entity|C1522149|Related|ftcn|||HR-QoL|||0|875|762|768
SE|25462202|METHODS|ab|3|entity|C0034380|Quality of life|qlco|||HR-QoL|||0|875|762|768
SE|25462202|METHODS|ab|3|entity|C0001779|Age|orga|||age|||0|744|788|791
SE|25462202|METHODS|ab|3|entity|C0150103|MATCHING|resa|||matched|||0|744|792|799
SE|25462202|METHODS|ab|3|entity|C0015780|Female|orga|||female|||0|744|801|807
SE|25462202|METHODS|ab|3|entity|C1514811|Reference|idcn|||reference|||0|744|818|827
SE|25462202|METHODS|ab|3|entity|C1257890|Population Group|popg|||population|||0|744|828|838

SE|25462202|METHODS|ab|4|text|840|964|Prevalence rates of individual PRS are presented and defined as "substantial", if reported as "quite a bit" or "very much".
SE|25462202|METHODS|ab|4|entity|C1521828|Rate|qnco|||rates|||0|827|851|856
SE|25462202|METHODS|ab|4|entity|C0237401|Individual|humn|||individual|||0|861|860|870
SE|25462202|METHODS|ab|4|entity|C1317600|PATIENT SYMPTOMS|fndg|||PRS|||0|861|871|874
SE|25462202|METHODS|ab|4|entity|C0045724|2-(4-ethoxybenzyl)-1-diethylaminoethyl-5-isothiocyanatobenzimidazole|orch,phsu|||bit|||0|1000|943|946
SE|25462202|METHODS|ab|4|entity|C0442824|Very|qlco|||very|||0|1000|952|956

SE|25462202|RESULTS|ab|5|text|964|1173|RESULTS: Global health status and physical and role functioning show a highly significant decline during treatment (p<=0.001), before returning to near the baseline levels three months after end of treatment.
SE|25462202|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|964|971
SE|25462202|RESULTS|ab|5|entity|C1456573|Global Health|grpa|||Global health|||0|901|973|986
SE|25462202|RESULTS|ab|5|entity|C0449438|Status|qlco|||status|||0|901|987|993
SE|25462202|RESULTS|ab|5|entity|C0205485|Physical|ftcn|||physical|||0|1000|998|1006
SE|25462202|RESULTS|ab|5|entity|C0035820|Role|socb|||role|||0|872|1011|1015
SE|25462202|RESULTS|ab|5|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|1016|1027
SE|25462202|RESULTS|ab|5|entity|C1299395|Highly significant|qlco|||highly significant|||0|734|1035|1053
SE|25462202|RESULTS|ab|5|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|827|1080|1081
SE|25462202|RESULTS|ab|5|entity|C0205107|Proximal|spco|||near|||0|827|1111|1115
SE|25462202|RESULTS|ab|5|entity|C1442488|BASELINE|qnco|||baseline|||0|833|1120|1128
SE|25462202|RESULTS|ab|5|entity|C0441889|Levels|inpr|||levels|||0|833|1129|1135
SE|25462202|RESULTS|ab|5|entity|C0205449|Three|qnco|||three|||0|833|1136|1141
SE|25462202|RESULTS|ab|5|entity|C0439231|month|tmco|||months|||0|833|1142|1148
SE|25462202|RESULTS|ab|5|entity|C0444930|End|spco|||end|||0|1000|1155|1158

SE|25462202|RESULTS|ab|6|text|1173|1288|Compared to the reference population, the global health status and emotional and role functioning remain impaired.
SE|25462202|RESULTS|ab|6|entity|C1514811|Reference|idcn|||reference|||0|888|1189|1198
SE|25462202|RESULTS|ab|6|entity|C1257890|Population Group|popg|||population|||0|888|1199|1209
SE|25462202|RESULTS|ab|6|entity|C1456573|Global Health|grpa|||global health|||0|901|1215|1228
SE|25462202|RESULTS|ab|6|entity|C0449438|Status|qlco|||status|||0|901|1229|1235
SE|25462202|RESULTS|ab|6|entity|C0849912|Emotional|fndg|||emotional|||0|1000|1240|1249
SE|25462202|RESULTS|ab|6|entity|C0035820|Role|socb|||role|||0|872|1254|1258
SE|25462202|RESULTS|ab|6|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|1259|1270

SE|25462202|RESULTS|ab|7|text|1288|1501|The most frequently reported substantial PRS during active treatment are: fatigue (78%), diarrhea (68%), urinary frequency (60%) and nausea (54%); these recover to some degree three months after end of treatment.
SE|25462202|RESULTS|ab|7|entity|C0205393|Most|qnco|||most|||0|1000|1292|1296
SE|25462202|RESULTS|ab|7|entity|C0332183|Frequent|tmco|||frequently|||0|1000|1297|1307
SE|25462202|RESULTS|ab|7|entity|C1317600|PATIENT SYMPTOMS|fndg|||PRS|||0|824|1329|1332
SE|25462202|RESULTS|ab|7|entity|C0205177|Active|ftcn|||active|||0|888|1340|1346
SE|25462202|RESULTS|ab|7|entity|C0015672|Fatigue|sosy|||fatigue|||0|1000|1362|1369
SE|25462202|RESULTS|ab|7|entity|C0011991|Diarrhea|sosy|||diarrhea|||0|1000|1377|1385
SE|25462202|RESULTS|ab|7|entity|C0677481|Frequency of micturition|sosy|||urinary frequency|||0|1000|1393|1410
SE|25462202|RESULTS|ab|7|entity|C0027497|Nausea|sosy|||nausea|||0|1000|1421|1427
SE|25462202|RESULTS|ab|7|entity|C0205449|Three|qnco|||three|||0|790|1464|1469
SE|25462202|RESULTS|ab|7|entity|C0439231|month|tmco|||months|||0|790|1470|1476
SE|25462202|RESULTS|ab|7|entity|C0444930|End|spco|||end|||0|1000|1483|1486

SE|25462202|RESULTS|ab|8|text|1501|1632|However, fatigue remains increased (50%) and an onset of hot flashes (44%), sexual worries (38%) and limb edema (22%) is observed.
SE|25462202|RESULTS|ab|8|entity|C0015672|Fatigue|sosy|||fatigue|||0|694|1510|1517
SE|25462202|RESULTS|ab|8|entity|C0332162|Onset|qlco|||onset|||0|1000|1549|1554
SE|25462202|RESULTS|ab|8|entity|C0020040|Menopausal hot flushes|sosy|||hot flashes|||0|1000|1558|1569
SE|25462202|RESULTS|ab|8|entity|C0233481|Worried|fndg|||worries|||0|861|1584|1591
SE|25462202|RESULTS|ab|8|entity|C1280090|Entire limb|bpoc|||limb|||0|888|1602|1606
SE|25462202|RESULTS|ab|8|entity|C0013604|Edema|patf|||edema|||0|888|1607|1612
SE|25462202|RESULTS|ab|8|relation|0|0|C1280090|Entire limb|bpoc|bpoc|||limb|||0|888|1602|1606|MOD/HEAD|LOCATION_OF||1602|1612|0|0|C0013604|Edema|patf|patf|||edema|||0|888|1607|1612

SE|25462202|CONCLUSIONS|ab|9|text|1632|1897|CONCLUSIONS: Several impairments in HR-QoL and PRS were found during definitive radio(chemo)therapy with IGABT, with different patterns of progress over time and signs of recovery three months thereafter, although some aspects of functional HR-QoL remain impaired.
SE|25462202|CONCLUSIONS|ab|9|entity|C0443302|Several|qnco|||Several|||0|872|1645|1652
SE|25462202|CONCLUSIONS|ab|9|entity|C0018684|Health|idcn|||HR-QoL|||0|823|1668|1674
SE|25462202|CONCLUSIONS|ab|9|entity|C1522149|Related|ftcn|||HR-QoL|||0|823|1668|1674
SE|25462202|CONCLUSIONS|ab|9|entity|C0034380|Quality of life|qlco|||HR-QoL|||0|823|1668|1674
SE|25462202|CONCLUSIONS|ab|9|entity|C1317600|PATIENT SYMPTOMS|fndg|||PRS|||0|901|1679|1682
SE|25462202|CONCLUSIONS|ab|9|entity|C0443196|Definitive|tmco|||definitive|||0|888|1701|1711
SE|25462202|CONCLUSIONS|ab|9|entity|C1304639|Radio|mnob|||radio|||0|888|1712|1717
SE|25462202|CONCLUSIONS|ab|9|entity|C0392920|Chemotherapy-Oncologic Procedure|topp|||chemo|||0|888|1718|1723
SE|25462202|CONCLUSIONS|ab|9|entity|C0025086|Medical Imaging|diap|||IGABT|||0|825|1737|1742
SE|25462202|CONCLUSIONS|ab|9|entity|C0181090|Professional guide|prog|||IGABT|||0|825|1737|1742
SE|25462202|CONCLUSIONS|ab|9|entity|C0231193|Adaptive|ftcn|||IGABT|||0|825|1737|1742
SE|25462202|CONCLUSIONS|ab|9|entity|C0006098|Brachytherapy|topp|||IGABT|||0|825|1737|1742
SE|25462202|CONCLUSIONS|ab|9|entity|C1547020|*Difference|qnco|||different|||0|853|1749|1758
SE|25462202|CONCLUSIONS|ab|9|entity|C0449774|Patterns|spco|||patterns|||0|853|1759|1767
SE|25462202|CONCLUSIONS|ab|9|entity|C1280477|Progressing to|ftcn|||progress|||0|802|1771|1779
SE|25462202|CONCLUSIONS|ab|9|entity|C0040223|Time|tmco|||time|||0|802|1785|1789
SE|25462202|CONCLUSIONS|ab|9|entity|C0220913|Manufactured sign|mnob|||signs|||0|1000|1794|1799
SE|25462202|CONCLUSIONS|ab|9|entity|C0237820|Recovery|orgf|||recovery|||0|775|1803|1811
SE|25462202|CONCLUSIONS|ab|9|entity|C0205449|Three|qnco|||three|||0|775|1812|1817
SE|25462202|CONCLUSIONS|ab|9|entity|C0439231|month|tmco|||months|||0|775|1818|1824
SE|25462202|CONCLUSIONS|ab|9|entity|C1547011|Aspect|qnco|||aspects|||0|966|1851|1858
SE|25462202|CONCLUSIONS|ab|9|entity|C0518882|Functional Health|inpr|||functional HR-QoL|||0|751|1862|1879
SE|25462202|CONCLUSIONS|ab|9|entity|C1522149|Related|ftcn|||HR-QoL|||0|751|1873|1879
SE|25462202|CONCLUSIONS|ab|9|entity|C0332306|Quality|qlco|||HR-QoL|||0|751|1873|1879
SE|25462202|CONCLUSIONS|ab|9|entity|C0376558|Life|idcn|||HR-QoL|||0|751|1873|1879

SE|25462202|CONCLUSIONS|ab|10|text|1897|2079|These findings support a comprehensive patients' counseling on what to expect and how to organize professional, social and family life and plan additional support during this period.
SE|25462202|CONCLUSIONS|ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1903|1911
SE|25462202|CONCLUSIONS|ab|10|entity|C0600047|Patient counseled|hlca|||patients' counseling|||0|884|1936|1956
SE|25462202|CONCLUSIONS|ab|10|entity|C0728831|SOCIAL|ftcn|||social|||0|861|2009|2015
SE|25462202|CONCLUSIONS|ab|10|entity|C0015608|Family Relationship|socb|||family life|||0|1000|2020|2031
SE|25462202|CONCLUSIONS|ab|10|entity|C1524062|Additional|ftcn|||additional|||0|888|2041|2051
SE|25462202|CONCLUSIONS|ab|10|entity|C0439531|/period|tmco|||period|||0|1000|2072|2078


SE|25462203||ti|1|text|21|144|A cost-effectiveness analysis of a chemoresponse assay for treatment of patients with recurrent epithelial ovarian cancer.
SE|25462203||ti|1|entity|C1511536|Cost Effectiveness Analysis|ocac|||cost-effectiveness analysis|||0|1000|23|50
SE|25462203||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|861|70|75
SE|25462203||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|93|101
SE|25462203||ti|1|entity|C0034897|Recurrence|phpr|||recurrent|||0|916|107|116
SE|25462203||ti|1|entity|C0677886|Epithelial ovarian cancer|neop|||epithelial ovarian cancer|||0|916|117|142
SE|25462203||ti|1|relation|1|1|C0677886|Epithelial ovarian cancer|neop|neop|||epithelial ovarian cancer|||0|916|117|142|PREP|PROCESS_OF||102|106|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|93|101

SE|25462203|OBJECTIVE|ab|1|text|150|396|OBJECTIVE: Clinical validation of a chemoresponse assay was recently published, demonstrating a significant increase in overall survival in recurrent ovarian cancer patients treated with therapies to which their tumor was sensitive in the assay.
SE|25462203|OBJECTIVE|ab|1|entity|C0205210|Clinical|qlco|||Clinical|||0|888|161|169
SE|25462203|OBJECTIVE|ab|1|entity|C1519941|Validation|resa|||validation|||0|888|170|180
SE|25462203|OBJECTIVE|ab|1|entity|C1510438|Assay|lbpr|||assay|||0|861|200|205
SE|25462203|OBJECTIVE|ab|1|entity|C0332185|Recent|tmco|||recently|||0|1000|210|218
SE|25462203|OBJECTIVE|ab|1|entity|C0750502|Significant|idcn|||significant|||0|888|246|257
SE|25462203|OBJECTIVE|ab|1|entity|C0442805|Increase|ftcn|||increase|||0|888|258|266
SE|25462203|OBJECTIVE|ab|1|entity|C1561607|Overall|qlco|||overall|||0|888|270|277
SE|25462203|OBJECTIVE|ab|1|entity|C0038952|Continuance of life|acty|||survival|||0|888|278|286
SE|25462203|OBJECTIVE|ab|1|entity|C0205065|Ovaro-|bpoc|||ovarian|||0|861|300|307
SE|25462203|OBJECTIVE|ab|1|entity|C0549379|Recurrent Carcinoma|neop|||recurrent ovarian cancer|||0|861|290|314
SE|25462203|OBJECTIVE|ab|1|entity|C0030705|Patients|podg|||patients|||0|861|315|323
SE|25462203|OBJECTIVE|ab|1|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|1000|337|346
SE|25462203|OBJECTIVE|ab|1|entity|C0027651|Neoplasm|neop|||tumor|||0|1000|362|367
SE|25462203|OBJECTIVE|ab|1|entity|C0332324|Sensitive|ftcn|||sensitive|||0|1000|372|381
SE|25462203|OBJECTIVE|ab|1|entity|C1510438|Assay|lbpr|||assay|||0|1000|389|394
SE|25462203|OBJECTIVE|ab|1|relation|0|0|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|1000|337|346|INFER|TREATS(INFER)||324|331|0|0|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|861|290|314
SE|25462203|OBJECTIVE|ab|1|relation|0|0|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|861|290|314|MOD/HEAD|PROCESS_OF||290|323|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|861|315|323
SE|25462203|OBJECTIVE|ab|1|relation|4|1|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|1000|337|346|VERB|TREATS||324|331|6|1|C0030705|Patients|podg,humn|podg|||patients|||0|861|315|323

SE|25462203|OBJECTIVE|ab|2|text|396|540|The current study investigates the cost effectiveness of using the assay at the time of ovarian cancer recurrence from the payer's perspective.
SE|25462203|OBJECTIVE|ab|2|entity|C0521116|Current|tmco|||current|||0|888|400|407
SE|25462203|OBJECTIVE|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|408|413
SE|25462203|OBJECTIVE|ab|2|entity|C0010181|Cost Effectiveness|qnco|||cost effectiveness|||0|1000|431|449
SE|25462203|OBJECTIVE|ab|2|entity|C1510438|Assay|lbpr|||assay|||0|1000|463|468
SE|25462203|OBJECTIVE|ab|2|entity|C0040223|Time|tmco|||time|||0|1000|476|480
SE|25462203|OBJECTIVE|ab|2|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|901|484|498
SE|25462203|OBJECTIVE|ab|2|entity|C0034897|Recurrence|phpr|||recurrence|||0|901|499|509

SE|25462203|METHODS|ab|3|text|540|825|METHODS: Using a Markov state transition model, patient characteristics and survival data from the recent clinical study, the cumulative costs over the study horizon (71 months) for both the baseline (no assay) and intervention (assay consistent, hypothetical) cohorts were evaluated.
SE|25462203|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|540|547
SE|25462203|METHODS|ab|3|entity|C1554158|State transition|idcn|||state transition|||0|824|564|580
SE|25462203|METHODS|ab|3|entity|C0026336|Study models|inpr,resd|||model|||0|824|581|586
SE|25462203|METHODS|ab|3|entity|C0815172|patient characteristics|clna|||patient characteristics|||0|1000|588|611
SE|25462203|METHODS|ab|3|entity|C0038952|Continuance of life|acty|||survival|||0|888|616|624
SE|25462203|METHODS|ab|3|entity|C1511726|Data|idcn|||data|||0|888|625|629
SE|25462203|METHODS|ab|3|entity|C0332185|Recent|tmco|||recent|||0|901|639|645
SE|25462203|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||clinical study|||0|901|646|660
SE|25462203|METHODS|ab|3|entity|C1511559|Cumulative|qlco|||cumulative|||0|1000|666|676
SE|25462203|METHODS|ab|3|entity|C0205136|Over|spco|||over|||0|1000|683|687
SE|25462203|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|694|692|697
SE|25462203|METHODS|ab|3|entity|C0439231|month|tmco|||months|||0|861|710|716
SE|25462203|METHODS|ab|3|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|731|739
SE|25462203|METHODS|ab|3|entity|C1510438|Assay|lbpr|||assay|||0|1000|744|749
SE|25462203|METHODS|ab|3|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|755|767
SE|25462203|METHODS|ab|3|entity|C1510438|Assay|lbpr|||assay|||0|660|769|774
SE|25462203|METHODS|ab|3|entity|C0599755|cohort|popg|||cohorts|||0|966|801|808

SE|25462203|RESULTS|ab|4|text|825|985|RESULTS: The assay consistent cohort had an incremental cost effectiveness ratio (ICER) of $6206 per life year saved (LYS), as compared to the baseline cohort.
SE|25462203|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|825|832
SE|25462203|RESULTS|ab|4|entity|C1510438|Assay|lbpr|||assay|||0|802|838|843
SE|25462203|RESULTS|ab|4|entity|C0599755|cohort|popg|||cohort|||0|802|855|861
SE|25462203|RESULTS|ab|4|entity|C0010181|Cost Effectiveness|qnco|||cost effectiveness|||0|824|881|899
SE|25462203|RESULTS|ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|824|900|905
SE|25462203|RESULTS|ab|4|entity|C0376558|Life|idcn|||life|||0|750|926|930
SE|25462203|RESULTS|ab|4|entity|C0439234|year|tmco|||year|||0|750|931|935
SE|25462203|RESULTS|ab|4|entity|C1442488|BASELINE|qnco|||baseline|||0|888|968|976
SE|25462203|RESULTS|ab|4|entity|C0599755|cohort|popg|||cohort|||0|888|977|983

SE|25462203|RESULTS|ab|5|text|985|1187|Cost-effectiveness was further demonstrated in platinum-sensitive and platinum-resistant populations treated with assay-sensitive therapies, with ICERs of $2773 per LYS and $2736 per LYS, respectively.
SE|25462203|RESULTS|ab|5|entity|C0010181|Cost Effectiveness|qnco|||Cost-effectiveness|||0|1000|985|1003
SE|25462203|RESULTS|ab|5|entity|C1517331|Further|spco|||further|||0|1000|1008|1015
SE|25462203|RESULTS|ab|5|entity|C0032207|Platinum|elii|||platinum|||0|888|1032|1040
SE|25462203|RESULTS|ab|5|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|1041|1050
SE|25462203|RESULTS|ab|5|entity|C0032207|Platinum|elii|||platinum|||0|851|1055|1063
SE|25462203|RESULTS|ab|5|entity|C0332325|Resistant|ftcn|||resistant|||0|851|1064|1073
SE|25462203|RESULTS|ab|5|entity|C0032659|geographic population|qnco|||populations|||0|851|1074|1085
SE|25462203|RESULTS|ab|5|entity|C1510438|Assay|lbpr|||assay|||0|851|1099|1104
SE|25462203|RESULTS|ab|5|entity|C0332324|Sensitive|ftcn|||sensitive|||0|851|1105|1114
SE|25462203|RESULTS|ab|5|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|851|1115|1124
SE|25462203|RESULTS|ab|5|entity|C0376558|Life|idcn|||LYS|||0|750|1150|1153
SE|25462203|RESULTS|ab|5|entity|C0439234|year|tmco|||LYS|||0|750|1150|1153
SE|25462203|RESULTS|ab|5|entity|C0376558|Life|idcn|||LYS|||0|750|1168|1171
SE|25462203|RESULTS|ab|5|entity|C0439234|year|tmco|||LYS|||0|750|1168|1171

SE|25462203|CONCLUSIONS|ab|6|text|1187|1398|CONCLUSIONS: The use of a chemoresponse assay to inform treatment decisions in recurrent ovarian cancer patients has the potential to be cost-effective in both platinum-sensitive and platinum-resistant patients.
SE|25462203|CONCLUSIONS|ab|6|entity|C0679006|decision|inpr|||decisions|||0|872|1253|1262
SE|25462203|CONCLUSIONS|ab|6|entity|C0205065|Ovaro-|bpoc|||ovarian|||0|861|1276|1283
SE|25462203|CONCLUSIONS|ab|6|entity|C0549379|Recurrent Carcinoma|neop|||recurrent ovarian cancer|||0|861|1266|1290
SE|25462203|CONCLUSIONS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|1291|1299
SE|25462203|CONCLUSIONS|ab|6|entity|C0237399|Potential|qlco|||potential|||0|1000|1308|1317
SE|25462203|CONCLUSIONS|ab|6|entity|C0010181|Cost Effectiveness|qnco|||cost-effective|||0|928|1324|1338
SE|25462203|CONCLUSIONS|ab|6|entity|C0032207|Platinum|elii|||platinum|||0|888|1347|1355
SE|25462203|CONCLUSIONS|ab|6|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|1356|1365
SE|25462203|CONCLUSIONS|ab|6|entity|C0032207|Platinum|elii|||platinum|||0|851|1370|1378
SE|25462203|CONCLUSIONS|ab|6|entity|C0332325|Resistant|ftcn|||resistant|||0|851|1379|1388
SE|25462203|CONCLUSIONS|ab|6|entity|C0030705|Patients|podg|||patients|||0|851|1389|1397
SE|25462203|CONCLUSIONS|ab|6|relation|0|0|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|861|1266|1290|MOD/HEAD|PROCESS_OF||1266|1299|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|861|1291|1299


SE|25462204||ti|1|text|21|132|Brown algae phlorotannins enhance the tumoricidal effect of cisplatin and ameliorate cisplatin nephrotoxicity.
SE|25462204||ti|1|entity|C0002031|Algae, Brown|alga|||Brown algae|||0|734|21|32
SE|25462204||ti|1|entity|C1280500|Effect|qlco|||effect|||0|861|71|77
SE|25462204||ti|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|1000|81|90
SE|25462204||ti|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|888|106|115
SE|25462204||ti|1|entity|C0599918|NEPHROTOXICITY|inpo|||nephrotoxicity|||0|888|116|130
SE|25462204||ti|1|relation|3|1|C0008838|Cisplatin|inch,phsu|phsu|||cisplatin|||0|1000|81|90|VERB|TREATS||95|105|1|1|C0599918|NEPHROTOXICITY|inpo|inpo|||nephrotoxicity|||0|888|116|130

SE|25462204|OBJECTIVE|ab|1|text|138|243|OBJECTIVE: The clinical application of cisplatin is limited due to its drug resistance and side effects.
SE|25462204|OBJECTIVE|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|153|161
SE|25462204|OBJECTIVE|ab|1|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|1000|177|186
SE|25462204|OBJECTIVE|ab|1|entity|C0013203|Drug resistance|biof|||drug resistance|||0|1000|209|224
SE|25462204|OBJECTIVE|ab|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|1000|229|241

SE|25462204|OBJECTIVE|ab|2|text|243|432|We investigated the effect of a phlorotannin-rich extract from the edible brown alga Ecklonia cava (PREC) and its major phlorotannin (dieckol) on cisplatin responsiveness and side effects.
SE|25462204|OBJECTIVE|ab|2|entity|C1280500|Effect|qlco|||effect|||0|1000|263|269
SE|25462204|OBJECTIVE|ab|2|entity|C0699759|Wealthy|qlco|||rich|||0|790|288|292
SE|25462204|OBJECTIVE|ab|2|entity|C1555707|extract|idcn|||extract|||0|790|293|300
SE|25462204|OBJECTIVE|ab|2|entity|C0002031|Algae, Brown|alga|||brown alga|||0|818|317|327
SE|25462204|OBJECTIVE|ab|2|entity|C1048932|Ecklonia cava|plnt|||Ecklonia cava|||0|818|328|341
SE|25462204|OBJECTIVE|ab|2|entity|C0205164|Major|qlco|||major|||0|694|357|362
SE|25462204|OBJECTIVE|ab|2|entity|C1620047|dieckol|bacs,orch,phsu|||dieckol|||0|1000|377|384
SE|25462204|OBJECTIVE|ab|2|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|853|389|398
SE|25462204|OBJECTIVE|ab|2|entity|C0205342|Responsive|ftcn|||responsiveness|||0|853|399|413
SE|25462204|OBJECTIVE|ab|2|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|1000|418|430
SE|25462204|OBJECTIVE|ab|2|relation|0|0|C1048932|Ecklonia cava|plnt|plnt|||Ecklonia cava|||0|818|328|341|MOD/HEAD|ISA||317|341|0|0|C0002031|Algae, Brown|alga|alga|||brown alga|||0|818|317|327

SE|25462204|METHODS|ab|3|text|432|532|METHODS: The A2780 and SKOV3 ovarian cancer cell lines and the SKOV3-bearing mouse model were used.
SE|25462204|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|432|439
SE|25462204|METHODS|ab|3|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|826|461|475
SE|25462204|METHODS|ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|826|476|486
SE|25462204|METHODS|ab|3|entity|C0025914|House mice|mamm|||mouse|||0|750|509|514
SE|25462204|METHODS|ab|3|entity|C0026336|Study models|inpr,resd|||model|||0|750|515|520

SE|25462204|METHODS|ab|4|text|532|645|The MTT assay was applied to assess cell viability, and the annexin V assay was employed for apoptosis analysis.
SE|25462204|METHODS|ab|4|entity|C0647210|monooxyethylene trimethylolpropane tristearate|lipd|||MTT|||0|872|536|539
SE|25462204|METHODS|ab|4|entity|C1510438|Assay|lbpr|||assay|||0|872|540|545
SE|25462204|METHODS|ab|4|entity|C0007620|Cell Survival|celf|||cell viability|||0|1000|568|582
SE|25462204|METHODS|ab|4|entity|C0059249|annexin A5|aapp,bacs|||annexin V|||0|901|592|601
SE|25462204|METHODS|ab|4|entity|C1510438|Assay|lbpr|||assay|||0|901|602|607
SE|25462204|METHODS|ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|625|634
SE|25462204|METHODS|ab|4|entity|C0936012|Analysis|resa|||analysis|||0|888|635|643
SE|25462204|METHODS|ab|4|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|901|602|607|MOD/HEAD|USES||592|607|0|0|C0059249|annexin A5|aapp,gngm,bacs|aapp|||annexin V|||0|901|592|601

SE|25462204|METHODS|ab|5|text|645|779|Reactive oxygen species (ROS) production and protein expression were assessed by H2DCFDA staining and Western blotting, respectively.
SE|25462204|METHODS|ab|5|entity|C0162772|Reactive Oxygen Species|bacs,elii|||Reactive oxygen species|||0|916|645|668
SE|25462204|METHODS|ab|5|entity|C0033268|production|ocac|||production|||0|916|675|685
SE|25462204|METHODS|ab|5|entity|C1171362|Protein Expression|genf|||protein expression|||0|1000|690|708
SE|25462204|METHODS|ab|5|entity|C0670829|2',7'-dichlorodihydrofluorescein diacetate|irda,orch|||H2DCFDA|||0|694|726|733
SE|25462204|METHODS|ab|5|entity|C0005863|Blotting, Western|lbpr,mbrt|||Western blotting|||0|1000|747|763

SE|25462204|RESULTS|ab|6|text|779|951|RESULTS: We found that PREC enhanced the tumor growth-inhibitory effect of cisplatin and diminished cisplatin-induced nephrotoxicity and weight loss in SKOV3-bearing mice.
SE|25462204|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|779|786
SE|25462204|RESULTS|ab|6|entity|C0027651|Neoplasm|neop|||tumor|||0|843|820|825
SE|25462204|RESULTS|ab|6|entity|C0018282|Growth Inhibitors|bacs,phsu|||growth-inhibitory|||0|843|826|843
SE|25462204|RESULTS|ab|6|entity|C1280500|Effect|qlco|||effect|||0|843|844|850
SE|25462204|RESULTS|ab|6|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|1000|854|863
SE|25462204|RESULTS|ab|6|entity|C0205216|Decreased|qnco|||diminished|||0|833|868|878
SE|25462204|RESULTS|ab|6|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|833|879|888
SE|25462204|RESULTS|ab|6|entity|C0205263|Induced|ftcn|||induced|||0|833|889|896
SE|25462204|RESULTS|ab|6|entity|C0599918|NEPHROTOXICITY|inpo|||nephrotoxicity|||0|833|897|911
SE|25462204|RESULTS|ab|6|entity|C0043096|Body Weight decreased|fndg|||weight loss|||0|1000|916|927
SE|25462204|RESULTS|ab|6|entity|C0026809|Mus|mamm|||mice|||0|827|945|949
SE|25462204|RESULTS|ab|6|relation|2|0|C0018282|Growth Inhibitors|bacs,phsu|bacs|||growth-inhibitory|||0|843|826|843|NOM|INTERACTS_WITH||844|850|4|1|C0008838|Cisplatin|inch,phsu|inch|||cisplatin|||0|1000|854|863
SE|25462204|RESULTS|ab|6|relation|4|0|C0008838|Cisplatin|inch,phsu|inch|||cisplatin|||0|833|879|888|ADJ|CAUSES||889|896|4|0|C0043096|Body Weight decreased|fndg|fndg|||weight loss|||0|1000|916|927
SE|25462204|RESULTS|ab|6|relation|4|0|C0008838|Cisplatin|inch,phsu|inch|||cisplatin|||0|833|879|888|ADJ|CAUSES||889|896|4|0|C0599918|NEPHROTOXICITY|inpo|inpo|||nephrotoxicity|||0|833|897|911

SE|25462204|RESULTS|ab|7|text|951|1058|PREC augmented cisplatin-induced apoptosis by activating caspases in SKOV3 and A2780 ovarian cancer cells.
SE|25462204|RESULTS|ab|7|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|851|966|975
SE|25462204|RESULTS|ab|7|entity|C0205263|Induced|ftcn|||induced|||0|851|976|983
SE|25462204|RESULTS|ab|7|entity|C0162638|Apoptosis|celf|||apoptosis|||0|851|984|993
SE|25462204|RESULTS|ab|7|entity|C1515877|Activate|ftcn|||activating|||0|872|997|1007
SE|25462204|RESULTS|ab|7|entity|C0010656|caspase|aapp,enzy|||caspases|||0|872|1008|1016
SE|25462204|RESULTS|ab|7|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|824|1036|1050
SE|25462204|RESULTS|ab|7|entity|C0007634|Cells|cell|||cells|||0|824|1051|1056
SE|25462204|RESULTS|ab|7|relation|1|0|C0008838|Cisplatin|inch,phsu|phsu|||cisplatin|||0|851|966|975|ADJ|CAUSES||976|983|1|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|851|984|993

SE|25462204|RESULTS|ab|8|text|1058|1194|In addition, a combination of PREC and cisplatin-induced ovarian cancer cell apoptosis by downregulating the Akt and NFkappaB pathways.
SE|25462204|RESULTS|ab|8|entity|C0205195|Combined|qlco|||combination|||0|1000|1073|1084
SE|25462204|RESULTS|ab|8|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|827|1097|1106
SE|25462204|RESULTS|ab|8|entity|C0205263|Induced|ftcn|||induced|||0|827|1107|1114
SE|25462204|RESULTS|ab|8|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|827|1115|1129
SE|25462204|RESULTS|ab|8|entity|C0007634|Cells|cell|||cell|||0|827|1130|1134
SE|25462204|RESULTS|ab|8|entity|C0162638|Apoptosis|celf|||apoptosis|||0|827|1135|1144
SE|25462204|RESULTS|ab|8|entity|C0164786|Proto-Oncogene Proteins c-akt|aapp,enzy|207|AKT1|Akt|||0|1000|1167|1170
SE|25462204|RESULTS|ab|8|entity|||gngm|4790|NFKB1|NFkappaB|||0|1000|1175|1183
SE|25462204|RESULTS|ab|8|relation|3|0|C0008838|Cisplatin|inch,phsu|phsu|||cisplatin|||0|827|1097|1106|ADJ|CAUSES||1107|1114|3|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|827|1135|1144

SE|25462204|RESULTS|ab|9|text|1194|1366|We further demonstrated that PREC increased intracellular ROS and that antioxidants significantly attenuated Akt-NFkappaB activation and apoptosis in ovarian cancer cells.
SE|25462204|RESULTS|ab|9|entity|C1517331|Further|spco|||further|||0|1000|1197|1204
SE|25462204|RESULTS|ab|9|entity|C0175996|Protoplasm|celc|||intracellular|||0|916|1238|1251
SE|25462204|RESULTS|ab|9|entity|C0162772|Reactive Oxygen Species|bacs,elii|||ROS|||0|916|1252|1255
SE|25462204|RESULTS|ab|9|entity|C0003402|Antioxidants|phsu|||antioxidants|||0|580|1265|1277
SE|25462204|RESULTS|ab|9|entity|C0164786|Proto-Oncogene Proteins c-akt|aapp,enzy|207|AKT1|Akt|||0|580|1303|1306
SE|25462204|RESULTS|ab|9|entity|||gngm|4790|NFKB1|NFkappaB|||0|580|1307|1315
SE|25462204|RESULTS|ab|9|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1331|1340
SE|25462204|RESULTS|ab|9|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|901|1344|1358
SE|25462204|RESULTS|ab|9|entity|C0007634|Cells|cell|||cells|||0|901|1359|1364
SE|25462204|RESULTS|ab|9|relation|0|0|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||ROS|||0|916|1252|1255|MOD/HEAD|PART_OF||1238|1255|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|916|1238|1251
SE|25462204|RESULTS|ab|9|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|901|1359|1364|PREP|LOCATION_OF||1341|1343|4|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|1000|1331|1340

SE|25462204|RESULTS|ab|10|text|1366|1473|In contrast, PREC inhibited cisplatin-induced ROS production and cell death in normal HEK293 kidney cells.
SE|25462204|RESULTS|ab|10|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|851|1394|1403
SE|25462204|RESULTS|ab|10|entity|C0205263|Induced|ftcn|||induced|||0|851|1404|1411
SE|25462204|RESULTS|ab|10|entity|C0162772|Reactive Oxygen Species|bacs,elii|||ROS|||0|851|1412|1415
SE|25462204|RESULTS|ab|10|entity|C0033268|production|ocac|||production|||0|851|1416|1426
SE|25462204|RESULTS|ab|10|entity|C0007587|Cell Death|celf|||cell death|||0|1000|1431|1441
SE|25462204|RESULTS|ab|10|entity|C0022646|Kidney|bpoc|||kidney|||0|813|1459|1465
SE|25462204|RESULTS|ab|10|entity|C1268443|Normal cell|cell|||normal HEK293 kidney cells|||0|813|1445|1471
SE|25462204|RESULTS|ab|10|relation|0|0|C1268443|Normal cell|cell|cell|||normal HEK293 kidney cells|||0|813|1445|1471|MOD/HEAD|PART_OF||1459|1471|0|0|C0022646|Kidney|bpoc|bpoc|||kidney|||0|813|1459|1465
SE|25462204|RESULTS|ab|10|relation|1|1|C1268443|Normal cell|cell|cell|||normal HEK293 kidney cells|||0|813|1445|1471|PREP|LOCATION_OF||1442|1444|4|1|C0007587|Cell Death|celf|celf|||cell death|||0|1000|1431|1441
SE|25462204|RESULTS|ab|10|relation|2|0|C0008838|Cisplatin|inch,phsu|inch|||cisplatin|||0|851|1394|1403|ADJ|STIMULATES||1404|1411|2|0|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||ROS|||0|851|1412|1415

SE|25462204|RESULTS|ab|11|text|1473|1633|Dieckol, a major compound in PREC, significantly enhanced the inhibition of tumor growth by cisplatin with less weight loss and kidney damage in a mouse model.
SE|25462204|RESULTS|ab|11|entity|C1620047|dieckol|bacs,orch,phsu|||Dieckol|||0|1000|1473|1480
SE|25462204|RESULTS|ab|11|entity|C0205164|Major|qlco|||major|||0|888|1484|1489
SE|25462204|RESULTS|ab|11|entity|C0205198|Compound|qlco|||compound|||0|888|1490|1498
SE|25462204|RESULTS|ab|11|entity|C0598934|tumor growth|neop|||tumor growth|||0|1000|1549|1561
SE|25462204|RESULTS|ab|11|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|1000|1565|1574
SE|25462204|RESULTS|ab|11|entity|C0043096|Body Weight decreased|fndg|||weight loss|||0|901|1585|1596
SE|25462204|RESULTS|ab|11|entity|C0022646|Kidney|bpoc|||kidney|||0|694|1601|1607
SE|25462204|RESULTS|ab|11|entity|C0025914|House mice|mamm|||mouse|||0|888|1620|1625
SE|25462204|RESULTS|ab|11|entity|C0026336|Study models|inpr,resd|||model|||0|888|1626|1631
SE|25462204|RESULTS|ab|11|relation|5|2|C0008838|Cisplatin|inch,phsu|inch|||cisplatin|||0|1000|1565|1574|NOM|DISRUPTS||1535|1545|5|1|C0598934|tumor growth|neop|neop|||tumor growth|||0|1000|1549|1561

SE|25462204|CONCLUSION|ab|12|text|1633|1899|CONCLUSION: These data suggest that brown algae phlorotannins may improve the efficacy of platinum drugs for ovarian cancer by enhancing cancer cell apoptosis via the ROS/Akt/NFkappaB pathway and reduce nephrotoxicity by protecting against normal kidney cell damage.
SE|25462204|CONCLUSION|ab|12|entity|C1511726|Data|idcn|||data|||0|1000|1651|1655
SE|25462204|CONCLUSION|ab|12|entity|C0002031|Algae, Brown|alga|||brown algae|||0|734|1669|1680
SE|25462204|CONCLUSION|ab|12|entity|C0032207|Platinum|elii|||platinum|||0|888|1723|1731
SE|25462204|CONCLUSION|ab|12|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|1732|1737
SE|25462204|CONCLUSION|ab|12|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|1000|1742|1756
SE|25462204|CONCLUSION|ab|12|entity|C0334227|Tumor cells, malignant|cell|||cancer cell|||0|619|1770|1781
SE|25462204|CONCLUSION|ab|12|entity|C0162638|Apoptosis|celf|||apoptosis|||0|619|1782|1791
SE|25462204|CONCLUSION|ab|12|entity|C0162772|Reactive Oxygen Species|bacs,elii|||ROS|||0|816|1800|1803
SE|25462204|CONCLUSION|ab|12|entity|C0164786|Proto-Oncogene Proteins c-akt|aapp,enzy|207|AKT1|Akt|||0|816|1804|1807
SE|25462204|CONCLUSION|ab|12|entity|||gngm|4790|NFKB1|NFkappaB|||0|816|1808|1816
SE|25462204|CONCLUSION|ab|12|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|816|1817|1824
SE|25462204|CONCLUSION|ab|12|entity|C0599918|NEPHROTOXICITY|inpo|||nephrotoxicity|||0|1000|1836|1850
SE|25462204|CONCLUSION|ab|12|entity|C0205307|Normal|qlco|||normal|||0|861|1873|1879
SE|25462204|CONCLUSION|ab|12|entity|C0022646|Kidney|bpoc|||kidney|||0|861|1880|1886
SE|25462204|CONCLUSION|ab|12|entity|C0599732|cell injury|comd|||cell damage|||0|861|1887|1898
SE|25462204|CONCLUSION|ab|12|relation|5|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|888|1732|1737|PREP|TREATS||1738|1741|6|1|C0029925|Ovarian Carcinoma|neop|neop|||ovarian cancer|||0|1000|1742|1756
SE|25462204|CONCLUSION|ab|12|relation|8|1|||gngm,aapp|aapp|4790|NFKB1|NFkappaB|||0|816|1808|1816|VERB|PREVENTS||1829|1835|3|1|C0599918|NEPHROTOXICITY|inpo|inpo|||nephrotoxicity|||0|1000|1836|1850
SE|25462204|CONCLUSION|ab|12|relation|9|5|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|888|1732|1737|NOM|PREVENTS||1854|1864|1|1|C0599732|cell injury|comd|comd|||cell damage|||0|861|1887|1898


SE|25462205||ti|1|text|21|260|Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
SE|25462205||ti|1|entity|C0282460|Clinical Trials, Phase II|resa|||Phase II study|||0|1000|21|35
SE|25462205||ti|1|entity|C0045093|gemcitabine|nnon,phsu|||gemcitabine|||0|1000|39|50
SE|25462205||ti|1|entity|C0078257|vinorelbine|orch,phsu|||vinorelbine|||0|1000|55|66
SE|25462205||ti|1|entity|C0457385|seconds|tmco|||second|||0|1000|70|76
SE|25462205||ti|1|entity|C0205437|Third|qnco|||third|||0|851|81|86
SE|25462205||ti|1|entity|C0205132|Linear|spco|||line|||0|851|87|91
SE|25462205||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|103|111
SE|25462205||ti|1|entity|C0205269|Intractable|ftcn|||refractory|||0|888|125|135
SE|25462205||ti|1|entity|C0032207|Platinum|elii|||platinum|||0|833|139|147
SE|25462205||ti|1|entity|C0332325|Resistant|ftcn|||resistant|||0|833|148|157
SE|25462205||ti|1|entity|C0034897|Recurrence|phpr|||recurrent|||0|833|158|167
SE|25462205||ti|1|entity|C0205065|Ovaro-|bpoc|||ovarian|||0|833|168|175
SE|25462205||ti|1|entity|C0153467|[X]Malignant neoplasm of peritoneum, unspecified|neop|||peritoneal cancer|||0|901|188|205
SE|25462205||ti|1|entity|C0337903|Koreans (ethnic group)|popg|||Korean|||0|673|213|219
SE|25462205||ti|1|entity|C0006826|Malignant Neoplasms|neop|||Cancer|||0|673|220|226
SE|25462205||ti|1|entity|C0008972|Clinical Research|resa|||Study|||0|673|227|232
SE|25462205||ti|1|entity|C0441833|Groups|inpr|||Group|||0|673|233|238
SE|25462205||ti|1|relation|5|3|C0045093|gemcitabine|nnon,phsu|phsu|||gemcitabine|||0|1000|39|50|PREP|TREATS||100|102|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|103|111
SE|25462205||ti|1|relation|5|3|C0078257|vinorelbine|orch,phsu|phsu|||vinorelbine|||0|1000|55|66|PREP|TREATS||100|102|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|103|111

SE|25462205|OBJECTIVE|ab|1|text|266|529|OBJECTIVE: The main aim of this study was to evaluate the antitumor activity and safety of vinorelbine and gemcitabine combination chemotherapy in patients with primary refractory or recurrent platinum-resistant epithelial ovarian and primary peritoneal cancers.
SE|25462205|OBJECTIVE|ab|1|entity|C0205225|Primary|qlco|||main|||0|694|281|285
SE|25462205|OBJECTIVE|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|298|303
SE|25462205|OBJECTIVE|ab|1|entity|C0036043|Safety|hcpp|||safety|||0|1000|347|353
SE|25462205|OBJECTIVE|ab|1|entity|C0078257|vinorelbine|orch,phsu|||vinorelbine|||0|1000|357|368
SE|25462205|OBJECTIVE|ab|1|entity|C0045093|gemcitabine|nnon,phsu|||gemcitabine|||0|901|373|384
SE|25462205|OBJECTIVE|ab|1|entity|C0013218|Combination Drug Therapy|topp|||combination chemotherapy|||0|901|385|409
SE|25462205|OBJECTIVE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|413|421
SE|25462205|OBJECTIVE|ab|1|entity|C0205269|Intractable|ftcn|||refractory|||0|888|435|445
SE|25462205|OBJECTIVE|ab|1|entity|C0034897|Recurrence|phpr|||recurrent|||0|822|449|458
SE|25462205|OBJECTIVE|ab|1|entity|C0032207|Platinum|elii|||platinum|||0|822|459|467
SE|25462205|OBJECTIVE|ab|1|entity|C0332325|Resistant|ftcn|||resistant|||0|822|468|477
SE|25462205|OBJECTIVE|ab|1|entity|C0221908|Epithelial|ftcn|||epithelial|||0|822|478|488
SE|25462205|OBJECTIVE|ab|1|entity|C0205065|Ovaro-|bpoc|||ovarian|||0|822|489|496
SE|25462205|OBJECTIVE|ab|1|entity|C0153467|[X]Malignant neoplasm of peritoneum, unspecified|neop|||peritoneal cancers|||0|890|509|527
SE|25462205|OBJECTIVE|ab|1|relation|0|0|C0013218|Combination Drug Therapy|topp|topp|||combination chemotherapy|||0|901|385|409|MOD/HEAD|USES||373|409|0|0|C0045093|gemcitabine|nnon,phsu|phsu|||gemcitabine|||0|901|373|384
SE|25462205|OBJECTIVE|ab|1|relation|7|1|C0013218|Combination Drug Therapy|topp|topp|||combination chemotherapy|||0|901|385|409|PREP|TREATS||410|412|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|413|421
SE|25462205|OBJECTIVE|ab|1|relation|7|1|C0078257|vinorelbine|orch,phsu|phsu|||vinorelbine|||0|1000|357|368|PREP|TREATS||410|412|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|413|421

SE|25462205|METHODS|ab|2|text|529|616|METHODS: Patients with platinum-resistant or primary refractory disease were eligible.
SE|25462205|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|529|536
SE|25462205|METHODS|ab|2|entity|C0030705|Patients|podg|||Patients|||0|1000|538|546
SE|25462205|METHODS|ab|2|entity|C0032207|Platinum|elii|||platinum|||0|888|552|560
SE|25462205|METHODS|ab|2|entity|C0332325|Resistant|ftcn|||resistant|||0|888|561|570
SE|25462205|METHODS|ab|2|entity|C0205269|Intractable|ftcn|||refractory|||0|901|582|592
SE|25462205|METHODS|ab|2|entity|C0277554|Primary disease|dsyn|||primary refractory disease|||0|901|574|600
SE|25462205|METHODS|ab|2|entity|C1548635|Eligible|idcn|||eligible|||0|1000|606|614

SE|25462205|METHODS|ab|3|text|616|724|Patients were allowed one prior chemotherapy for the treatment of platinum-resistant or refractory disease.
SE|25462205|METHODS|ab|3|entity|C0030705|Patients|podg|||Patients|||0|1000|616|624
SE|25462205|METHODS|ab|3|entity|C0205447|One|qnco|||one|||0|901|638|641
SE|25462205|METHODS|ab|3|entity|C1514457|Prior Chemotherapy|clna|||prior chemotherapy|||0|901|642|660
SE|25462205|METHODS|ab|3|entity|C0032207|Platinum|elii|||platinum|||0|888|682|690
SE|25462205|METHODS|ab|3|entity|C0332325|Resistant|ftcn|||resistant|||0|888|691|700
SE|25462205|METHODS|ab|3|entity|C1514815|Refractory Disease|fndg|||refractory disease|||0|1000|704|722

SE|25462205|METHODS|ab|4|text|724|845|Vinorelbine 25mg/m(2), followed by gemcitabine 1000mg/m(2), was administered intravenously on days 1 and 8 every 3weeks.
SE|25462205|METHODS|ab|4|entity|C0078257|vinorelbine|orch,phsu|||Vinorelbine|||0|802|724|735
SE|25462205|METHODS|ab|4|entity|C0045093|gemcitabine|nnon,phsu|||gemcitabine|||0|802|759|770
SE|25462205|METHODS|ab|4|entity|C0439228|day|tmco|||days|||0|861|818|822

SE|25462205|METHODS|ab|5|text|845|985|Response Evaluation Criteria in Solid Tumors (RECIST) 1.0 and cancer antigen 125 test (CA-125 criteria) were adopted to classify responses.
SE|25462205|METHODS|ab|5|entity|C0871261|response|clna|||Response|||0|734|845|853
SE|25462205|METHODS|ab|5|entity|C0935549|Evaluation Criteria|inpr|||Evaluation Criteria|||0|734|854|873
SE|25462205|METHODS|ab|5|entity|C0280100|Solid tumor|neop|||Solid Tumors|||0|734|877|889
SE|25462205|METHODS|ab|5|entity|C0851097|Test, cancer antigen 125|lbpr|||cancer antigen 125 test|||0|1000|907|930
SE|25462205|METHODS|ab|5|entity|C0201925|Calcium measurement|lbpr|||CA-125|||0|802|932|938
SE|25462205|METHODS|ab|5|entity|C0243161|criteria|inpr|||criteria|||0|802|939|947
SE|25462205|METHODS|ab|5|entity|C0871261|response|clna|||responses|||0|1000|974|983

SE|25462205|RESULTS|ab|6|text|985|1107|RESULTS: 44 patients received the median of 4 (range, 1-24) treatments with fifteen (34.1%) receiving six or more cycles.
SE|25462205|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|985|992
SE|25462205|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|997|1005
SE|25462205|RESULTS|ab|6|entity|C1514721|Range|qnco|||range|||0|1000|1032|1037
SE|25462205|RESULTS|ab|6|entity|C0442766|1/24|fndg|||1-24|||0|1000|1039|1043
SE|25462205|RESULTS|ab|6|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|1000|1045|1055
SE|25462205|RESULTS|ab|6|entity|C1514756|Received|qlco|||receiving|||0|872|1077|1086
SE|25462205|RESULTS|ab|6|entity|C0205452|Six|qnco|||six|||0|872|1087|1090
SE|25462205|RESULTS|ab|6|entity|C0205172|More|ftcn|||more|||0|872|1094|1098
SE|25462205|RESULTS|ab|6|entity|C0750729|Course|tmco|||cycles|||0|872|1099|1105

SE|25462205|RESULTS|ab|7|text|1107|1154|The overall objective response rate was 22.7%.
SE|25462205|RESULTS|ab|7|entity|C1561607|Overall|qlco|||overall|||0|824|1111|1118
SE|25462205|RESULTS|ab|7|entity|C0237629|Frequency of Responses|tmco|||response rate|||0|824|1129|1142

SE|25462205|RESULTS|ab|8|text|1154|1280|One patient (2.3%) had complete while 9 patients (20.4%) had partial responses with median duration of response of 5.9months.
SE|25462205|RESULTS|ab|8|entity|C0205447|One|qnco|||One|||0|888|1154|1157
SE|25462205|RESULTS|ab|8|entity|C0030705|Patients|podg|||patient|||0|888|1158|1165
SE|25462205|RESULTS|ab|8|entity|C0205197|Complete|qlco|||complete|||0|1000|1177|1185
SE|25462205|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|861|1194|1202
SE|25462205|RESULTS|ab|8|entity|C1521726|partial response|fndg|||partial responses|||0|983|1215|1232
SE|25462205|RESULTS|ab|8|entity|C0449238|Duration|tmco|||duration|||0|861|1245|1253
SE|25462205|RESULTS|ab|8|entity|C0871261|response|clna|||response|||0|1000|1257|1265
SE|25462205|RESULTS|ab|8|relation|4|1|C1521726|partial response|fndg|fndg|||partial responses|||0|983|1215|1232|AUX|PROCESS_OF||1211|1214|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|1194|1202

SE|25462205|RESULTS|ab|9|text|1280|1346|17 patients (38.6%) had stable disease for a median of 3.3months.
SE|25462205|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|861|1283|1291
SE|25462205|RESULTS|ab|9|entity|C0677946|Stable Disease|fndg|||stable disease|||0|1000|1304|1318
SE|25462205|RESULTS|ab|9|relation|3|1|C0677946|Stable Disease|fndg|fndg|||stable disease|||0|1000|1304|1318|AUX|PROCESS_OF||1300|1303|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|1283|1291

SE|25462205|RESULTS|ab|10|text|1346|1441|Median progression-free survival (PFS) was 3.4months and overall survival (OS) was 14.5months.
SE|25462205|RESULTS|ab|10|entity|C0242792|Progression-Free Survival|qnco|||progression-free survival|||0|923|1353|1378
SE|25462205|RESULTS|ab|10|entity|C1561607|Overall|qlco|||overall|||0|888|1403|1410
SE|25462205|RESULTS|ab|10|entity|C0038952|Continuance of life|acty|||survival|||0|888|1411|1419

SE|25462205|RESULTS|ab|11|text|1441|1483|Four (9.1%) patients were not assessable.
SE|25462205|RESULTS|ab|11|entity|C0205450|Four|qnco|||Four|||0|1000|1441|1445
SE|25462205|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1453|1461
SE|25462205|RESULTS|ab|11|entity|C1518422|Not|ftcn|||not|||0|694|1467|1470

SE|25462205|RESULTS|ab|12|text|1483|1592|Neutropenia was the most frequently encountered toxicity, with grade 3 or 4 observed in 22 patients (50.0%).
SE|25462205|RESULTS|ab|12|entity|C0027947|Neutropenia|dsyn|||Neutropenia|||0|1000|1483|1494
SE|25462205|RESULTS|ab|12|entity|C0205393|Most|qnco|||most|||0|825|1503|1507
SE|25462205|RESULTS|ab|12|entity|C0332183|Frequent|tmco|||frequently|||0|825|1508|1518
SE|25462205|RESULTS|ab|12|entity|C0545082|Visit|ftcn|||encountered|||0|825|1519|1530
SE|25462205|RESULTS|ab|12|entity|C0600688|Toxic effect|inpo|||toxicity|||0|825|1531|1539
SE|25462205|RESULTS|ab|12|entity|C0450094|Grade three rank|qlco|||grade 3|||0|1000|1546|1553
SE|25462205|RESULTS|ab|12|entity|C0030705|Patients|podg|||patients|||0|861|1574|1582
SE|25462205|RESULTS|ab|12|relation|2|1|C0600688|Toxic effect|inpo|inpo|||toxicity|||0|825|1531|1539|PREP|PROCESS_OF||1568|1570|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|1574|1582

SE|25462205|RESULTS|ab|13|text|1592|1650|Fifteen patients (34.1%) needed immediate dose reduction.
SE|25462205|RESULTS|ab|13|entity|C0030705|Patients|podg|||patients|||0|861|1600|1608
SE|25462205|RESULTS|ab|13|entity|C0205253|Immediate|tmco|||immediate|||0|623|1624|1633
SE|25462205|RESULTS|ab|13|entity|C1446466|Dose|qnco|||dose|||0|623|1634|1638

SE|25462205|RESULTS|ab|14|text|1650|1691|No treatment related death was reported.
SE|25462205|RESULTS|ab|14|entity|C1522149|Related|ftcn|||related|||0|851|1663|1670
SE|25462205|RESULTS|ab|14|entity|C0011065|Cessation of life|orgf|||death|||0|851|1671|1676

SE|25462205|CONCLUSIONS|ab|15|text|1691|1881|CONCLUSIONS: The combination chemotherapy with gemcitabine and vinorelbine achieved the primary end point of our clinical trial in management of platinum resistant recurrent ovarian cancer.
SE|25462205|CONCLUSIONS|ab|15|entity|C0013218|Combination Drug Therapy|topp|||combination chemotherapy|||0|1000|1708|1732
SE|25462205|CONCLUSIONS|ab|15|entity|C0045093|gemcitabine|nnon,phsu|||gemcitabine|||0|1000|1738|1749
SE|25462205|CONCLUSIONS|ab|15|entity|C0078257|vinorelbine|orch,phsu|||vinorelbine|||0|1000|1754|1765
SE|25462205|CONCLUSIONS|ab|15|entity|C0150100|End Point|resa|||end point|||0|901|1787|1796
SE|25462205|CONCLUSIONS|ab|15|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|1000|1804|1818
SE|25462205|CONCLUSIONS|ab|15|entity|C0032207|Platinum|elii|||platinum|||0|840|1836|1844
SE|25462205|CONCLUSIONS|ab|15|entity|C0332325|Resistant|ftcn|||resistant|||0|840|1845|1854
SE|25462205|CONCLUSIONS|ab|15|entity|C0205065|Ovaro-|bpoc|||ovarian|||0|840|1865|1872
SE|25462205|CONCLUSIONS|ab|15|entity|C0549379|Recurrent Carcinoma|neop|||recurrent ovarian cancer|||0|840|1855|1879
SE|25462205|CONCLUSIONS|ab|15|relation|0|0|C0205065|Ovaro-|bpoc|bpoc|||ovarian|||0|840|1865|1872|MOD/HEAD|LOCATION_OF||1865|1879|0|0|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|840|1855|1879
SE|25462205|CONCLUSIONS|ab|15|relation|6|3|C0013218|Combination Drug Therapy|topp|topp|||combination chemotherapy|||0|1000|1708|1732|NOM|TREATS||1822|1832|1|1|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|840|1855|1879
SE|25462205|CONCLUSIONS|ab|15|relation|6|3|C0045093|gemcitabine|nnon,phsu|phsu|||gemcitabine|||0|1000|1738|1749|NOM|TREATS||1822|1832|1|1|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|840|1855|1879
SE|25462205|CONCLUSIONS|ab|15|relation|6|3|C0078257|vinorelbine|orch,phsu|orch|||vinorelbine|||0|1000|1754|1765|NOM|TREATS||1822|1832|1|1|C0549379|Recurrent Carcinoma|neop|neop|||recurrent ovarian cancer|||0|840|1855|1879

SE|25462205|CONCLUSIONS|ab|16|text|1881|2027|However, further sophisticated dosing and scheduling of combination chemotherapy are needed because of a significant proportion of dose reduction.
SE|25462205|CONCLUSIONS|ab|16|entity|C1517331|Further|spco|||further|||0|660|1890|1897
SE|25462205|CONCLUSIONS|ab|16|entity|C0013218|Combination Drug Therapy|topp|||combination chemotherapy|||0|1000|1937|1961
SE|25462205|CONCLUSIONS|ab|16|entity|C0750502|Significant|idcn|||significant|||0|853|1986|1997
SE|25462205|CONCLUSIONS|ab|16|entity|C0205351|Proportional|qlco|||proportion|||0|853|1998|2008
SE|25462205|CONCLUSIONS|ab|16|entity|C1446466|Dose|qnco|||dose|||0|694|2012|2016


SE|25462206||ti|1|text|21|142|The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes.
SE|25462206||ti|1|entity|C1521798|trend|tmco|||trend|||0|1000|25|30
SE|25462206||ti|1|entity|C0205281|Invasive|qlco|||invasive|||0|790|49|57
SE|25462206||ti|1|entity|C0007103|Malignant neoplasm of endometrium|neop|||endometrial cancer|||0|1000|76|94
SE|25462206||ti|1|entity|C0444454|Access|spco|||ACS-NSQIP|||0|802|99|108
SE|25462206||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|802|109|119
SE|25462206||ti|1|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|872|123|131
SE|25462206||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|872|132|140

SE|25462206|OBJECTIVE|ab|1|text|148|317|OBJECTIVE: Our objective was to evaluate the surgical trend towards increased MIS in the management of endometrial cancer in regard to improvements in patient outcomes.
SE|25462206|OBJECTIVE|ab|1|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|888|193|201
SE|25462206|OBJECTIVE|ab|1|entity|C1521798|trend|tmco|||trend|||0|888|202|207
SE|25462206|OBJECTIVE|ab|1|entity|C0205217|Increased|qnco|||increased|||0|775|216|225
SE|25462206|OBJECTIVE|ab|1|entity|C0205281|Invasive|qlco|||MIS|||0|775|226|229
SE|25462206|OBJECTIVE|ab|1|entity|C0007103|Malignant neoplasm of endometrium|neop|||endometrial cancer|||0|1000|251|269
SE|25462206|OBJECTIVE|ab|1|entity|C0030705|Patients|podg|||patient|||0|872|299|306
SE|25462206|OBJECTIVE|ab|1|entity|C1274040|result|ftcn|||outcomes|||0|872|307|315

SE|25462206|METHODS|ab|2|text|317|572|METHODS: Using the American College of Surgeons-National Surgical Quality Improvement Project's database, patients who underwent hysterectomy for endometrial cancer from 2006-2010 were identified and categorized into exploratory laparotomy (XLAP) or MIS.
SE|25462206|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|317|324
SE|25462206|METHODS|ab|2|entity|C0596070|American|popg|||American|||0|888|336|344
SE|25462206|METHODS|ab|2|entity|C0557806|College|eehu|||College|||0|888|345|352
SE|25462206|METHODS|ab|2|entity|C0582175|Surgeon|prog|||Surgeons|||0|749|356|364
SE|25462206|METHODS|ab|2|entity|C0543467|Operative Surgical Procedures|topp|||Surgical|||0|749|374|382
SE|25462206|METHODS|ab|2|entity|C0332306|Quality|qlco|||Quality|||0|749|383|390
SE|25462206|METHODS|ab|2|entity|C0242356|Databases|inpr|||database|||0|749|413|421
SE|25462206|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|423|431
SE|25462206|METHODS|ab|2|entity|C0020699|Hysterectomy|topp|||hysterectomy|||0|1000|446|458
SE|25462206|METHODS|ab|2|entity|C0007103|Malignant neoplasm of endometrium|neop|||endometrial cancer|||0|1000|463|481
SE|25462206|METHODS|ab|2|entity|C0085704|Exploratory laparotomy|diap|||exploratory laparotomy|||0|1000|534|556
SE|25462206|METHODS|ab|2|entity|C0205281|Invasive|qlco|||MIS|||0|790|567|570
SE|25462206|METHODS|ab|2|relation|5|1|C0020699|Hysterectomy|topp|topp|||hysterectomy|||0|1000|446|458|PREP|TREATS||459|462|4|1|C0007103|Malignant neoplasm of endometrium|neop|neop|||endometrial cancer|||0|1000|463|481
SE|25462206|METHODS|ab|2|relation|5|1|C0020699|Hysterectomy|topp|topp|||hysterectomy|||0|1000|446|458|VERB|TREATS||436|445|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|423|431

SE|25462206|METHODS|ab|3|text|572|718|Comparative analyses were performed and stratified by year of surgery to evaluate demographics, surgical outcomes, and 30-day surgical morbidity.
SE|25462206|METHODS|ab|3|entity|C0683941|comparative analysis|resa|||Comparative analyses|||0|983|572|592
SE|25462206|METHODS|ab|3|entity|C0439234|year|tmco|||year|||0|1000|626|630
SE|25462206|METHODS|ab|3|entity|C0011298|Demography|ocdi|||demographics|||0|1000|654|666
SE|25462206|METHODS|ab|3|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|872|668|676
SE|25462206|METHODS|ab|3|entity|C1274040|result|ftcn|||outcomes|||0|872|677|685
SE|25462206|METHODS|ab|3|entity|C0439228|day|tmco|||day|||0|583|694|697
SE|25462206|METHODS|ab|3|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|583|698|706

SE|25462206|RESULTS|ab|4|text|718|845|RESULTS: A total of 2076 patients (1269 XLAP and 807 MIS) underwent hysterectomy for endometrial cancer between 2006 and 2010.
SE|25462206|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|718|725
SE|25462206|RESULTS|ab|4|entity|C0439175|% of total|qnco|||total|||0|1000|729|734
SE|25462206|RESULTS|ab|4|entity|C0030705|Patients|podg|||patients|||0|861|743|751
SE|25462206|RESULTS|ab|4|entity|C0205281|Invasive|qlco|||MIS|||0|750|771|774
SE|25462206|RESULTS|ab|4|entity|C0020699|Hysterectomy|topp|||hysterectomy|||0|1000|786|798
SE|25462206|RESULTS|ab|4|entity|C0007103|Malignant neoplasm of endometrium|neop|||endometrial cancer|||0|1000|803|821
SE|25462206|RESULTS|ab|4|relation|2|1|C0020699|Hysterectomy|topp|topp|||hysterectomy|||0|1000|786|798|VERB|TREATS||776|785|5|3|C0030705|Patients|podg,humn|podg|||patients|||0|861|743|751
SE|25462206|RESULTS|ab|4|relation|6|1|C0020699|Hysterectomy|topp|topp|||hysterectomy|||0|1000|786|798|PREP|TREATS||799|802|1|1|C0007103|Malignant neoplasm of endometrium|neop|neop|||endometrial cancer|||0|1000|803|821

SE|25462206|RESULTS|ab|5|text|845|1053|Longer operative times were seen in MIS compared to XLAP (192 vs. 148 min; p<0.001) as well as significant increase in mean hospital stay in the XLAP group of 3.8 days compared to 1.6 days in MIS (p<0.0001).
SE|25462206|RESULTS|ab|5|entity|C0205166|Long|qlco|||Longer|||0|769|845|851
SE|25462206|RESULTS|ab|5|entity|C0040223|Time|tmco|||times|||0|769|862|867
SE|25462206|RESULTS|ab|5|entity|C0205281|Invasive|qlco|||MIS|||0|790|881|884
SE|25462206|RESULTS|ab|5|entity|C0439232|Minute of time|tmco|||min|||0|861|915|918
SE|25462206|RESULTS|ab|5|entity|C0750502|Significant|idcn|||significant|||0|888|940|951
SE|25462206|RESULTS|ab|5|entity|C0442805|Increase|ftcn|||increase|||0|888|952|960
SE|25462206|RESULTS|ab|5|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|660|969|977
SE|25462206|RESULTS|ab|5|entity|C0441833|Groups|inpr|||group|||0|861|995|1000
SE|25462206|RESULTS|ab|5|entity|C1442459|3 Days|tmco|||3.8 days|||0|913|1004|1012
SE|25462206|RESULTS|ab|5|entity|C1442449|1 Day|tmco|||1.6 days|||0|896|1025|1033
SE|25462206|RESULTS|ab|5|entity|C0205281|Invasive|qlco|||MIS|||0|790|1037|1040

SE|25462206|RESULTS|ab|6|text|1053|1229|When controlling for preoperative comorbidities, significant increases in postoperative complications were observed in XLAP compared to MIS group (total 396 vs. 91; p<0.0001).
SE|25462206|RESULTS|ab|6|entity|C0445204|Preoperative|tmco|||preoperative|||0|888|1074|1086
SE|25462206|RESULTS|ab|6|entity|C0009488|Comorbidity|idcn|||comorbidities|||0|888|1087|1100
SE|25462206|RESULTS|ab|6|entity|C0750502|Significant|idcn|||significant|||0|872|1102|1113
SE|25462206|RESULTS|ab|6|entity|C0442805|Increase|ftcn|||increases|||0|872|1114|1123
SE|25462206|RESULTS|ab|6|entity|C0032787|Postoperative Complications|patf|||postoperative complications|||0|1000|1127|1154
SE|25462206|RESULTS|ab|6|entity|C0205281|Invasive|qlco|||MIS|||0|736|1189|1192
SE|25462206|RESULTS|ab|6|entity|C0441833|Groups|inpr|||group|||0|736|1193|1198
SE|25462206|RESULTS|ab|6|entity|C0439175|% of total|qnco|||total|||0|861|1200|1205

SE|25462206|RESULTS|ab|7|text|1229|1343|MIS increased from 16% in 2006 to 48% in 2010, which correlated to decreases in complications and hospital stays.
SE|25462206|RESULTS|ab|7|entity|C0205281|Invasive|qlco|||MIS|||0|790|1229|1232
SE|25462206|RESULTS|ab|7|entity|C0547047|Decrease|qnco|||decreases|||0|966|1296|1305
SE|25462206|RESULTS|ab|7|entity|C0009566|Complication|patf|||complications|||0|1000|1309|1322
SE|25462206|RESULTS|ab|7|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|694|1327|1335

SE|25462206|RESULTS|ab|8|text|1343|1428|Each 10% increase in MIS would save $2.8 million and 41 postoperative complications.
SE|25462206|RESULTS|ab|8|entity|C0442805|Increase|ftcn|||increase|||0|861|1352|1360
SE|25462206|RESULTS|ab|8|entity|C0205281|Invasive|qlco|||MIS|||0|790|1364|1367
SE|25462206|RESULTS|ab|8|entity|C0032787|Postoperative Complications|patf|||postoperative complications|||0|901|1399|1426

SE|25462206|RESULTS|ab|9|text|1428|1506|If used exclusively, MIS would save 6434 hospital days and 416 complications.
SE|25462206|RESULTS|ab|9|entity|C0205281|Invasive|qlco|||MIS|||0|790|1449|1452
SE|25462206|RESULTS|ab|9|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|750|1469|1477
SE|25462206|RESULTS|ab|9|entity|C0439228|day|tmco|||days|||0|750|1478|1482
SE|25462206|RESULTS|ab|9|entity|C0009566|Complication|patf|||complications|||0|861|1491|1504

SE|25462206|CONCLUSIONS|ab|10|text|1506|1670|CONCLUSIONS: Despite increases in operative times, MIS for the treatment of endometrial cancer significantly reduces perioperative complications and hospital stay.
SE|25462206|CONCLUSIONS|ab|10|entity|C0442805|Increase|ftcn|||increases|||0|966|1527|1536
SE|25462206|CONCLUSIONS|ab|10|entity|C0040223|Time|tmco|||times|||0|827|1550|1555
SE|25462206|CONCLUSIONS|ab|10|entity|C0205281|Invasive|qlco|||MIS|||0|790|1557|1560
SE|25462206|CONCLUSIONS|ab|10|entity|C0007103|Malignant neoplasm of endometrium|neop|||endometrial cancer|||0|1000|1582|1600
SE|25462206|CONCLUSIONS|ab|10|entity|C1518988|perioperative|tmco|||perioperative|||0|888|1623|1636
SE|25462206|CONCLUSIONS|ab|10|entity|C0009566|Complication|patf|||complications|||0|888|1637|1650
SE|25462206|CONCLUSIONS|ab|10|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|694|1655|1663

SE|25462206|CONCLUSIONS|ab|11|text|1670|1863|Considering the improvements in patient outcomes and the potential savings to the health care system, MIS should be the preferred route for the surgical treatment of this disease when feasible.
SE|25462206|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patient|||0|872|1702|1709
SE|25462206|CONCLUSIONS|ab|11|entity|C1274040|result|ftcn|||outcomes|||0|872|1710|1718
SE|25462206|CONCLUSIONS|ab|11|entity|C0237399|Potential|qlco|||potential|||0|888|1727|1736
SE|25462206|CONCLUSIONS|ab|11|entity|C0036245|Savings|qnco|||savings|||0|888|1737|1744
SE|25462206|CONCLUSIONS|ab|11|entity|C0018696|Health Care Systems|hcro|||health care system|||0|1000|1752|1770
SE|25462206|CONCLUSIONS|ab|11|entity|C0205281|Invasive|qlco|||MIS|||0|790|1772|1775
SE|25462206|CONCLUSIONS|ab|11|entity|C1548789|Preferred|qlco|||preferred|||0|888|1790|1799
SE|25462206|CONCLUSIONS|ab|11|entity|C0449444|Route|spco|||route|||0|888|1800|1805
SE|25462206|CONCLUSIONS|ab|11|entity|C0543467|Operative Surgical Procedures|topp|||surgical treatment|||0|1000|1814|1832
SE|25462206|CONCLUSIONS|ab|11|entity|C0012634|Disease|dsyn|||disease|||0|1000|1841|1848


SE|25462207||ti|1|text|21|109|Application of therapeutic harp sounds for quality of life among hospitalized patients.
SE|25462207||ti|1|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|888|48|52
SE|25462207||ti|1|entity|C0034380|Quality of life|qlco|||quality of life|||0|923|64|79
SE|25462207||ti|1|entity|C0870668|Hospitalized Patients|podg|||hospitalized patients|||0|1000|86|107

SE|25462207|CONTEXT|ab|1|text|115|327|CONTEXT: Hospitalized patients experience symptoms including pain and anxiety that may negatively affect their well-being and overall quality of life (QOL), even when medical interventions are deemed successful.
SE|25462207|CONTEXT|ab|1|entity|C0870668|Hospitalized Patients|podg|||Hospitalized patients|||0|1000|124|145
SE|25462207|CONTEXT|ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|157|165
SE|25462207|CONTEXT|ab|1|entity|C0030193|Pain|sosy|||pain|||0|1000|176|180
SE|25462207|CONTEXT|ab|1|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|185|192
SE|25462207|CONTEXT|ab|1|entity|C0031206|Personal Satisfaction|fndg|||well-being|||0|1000|226|236
SE|25462207|CONTEXT|ab|1|entity|C1561607|Overall|qlco|||overall|||0|916|241|248
SE|25462207|CONTEXT|ab|1|entity|C0034380|Quality of life|qlco|||quality of life|||0|916|249|264
SE|25462207|CONTEXT|ab|1|entity|C0205476|Medical|ftcn|||medical|||0|888|282|289
SE|25462207|CONTEXT|ab|1|entity|C1273869|Intervention regimes|hlca|||interventions|||0|888|290|303
SE|25462207|CONTEXT|ab|1|entity|C1272703|Successful|qlco|||successful|||0|1000|315|325
SE|25462207|CONTEXT|ab|1|relation|6|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|1000|157|165|VERB|PROCESS_OF||146|156|2|1|C0870668|Hospitalized Patients|podg,humn|humn|||Hospitalized patients|||0|1000|124|145

SE|25462207|OBJECTIVES|ab|2|text|327|467|OBJECTIVES: The objective of the study was to assess the efficacy of prescriptive live therapeutic harp sounds on patient symptoms and QOL.
SE|25462207|OBJECTIVES|ab|2|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|327|337
SE|25462207|OBJECTIVES|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|360|365
SE|25462207|OBJECTIVES|ab|2|entity|C1548795|Live|qlco|||live|||0|775|409|413
SE|25462207|OBJECTIVES|ab|2|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|775|426|430
SE|25462207|OBJECTIVES|ab|2|entity|C1317600|PATIENT SYMPTOMS|fndg|||patient symptoms|||0|1000|441|457
SE|25462207|OBJECTIVES|ab|2|entity|C0034380|Quality of life|qlco|||QOL|||0|1000|462|465

SE|25462207|METHODS|ab|3|text|467|560|METHODS: The study was a two-period, two-treatment arm crossover, randomized clinical trial.
SE|25462207|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|467|474
SE|25462207|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|480|485
SE|25462207|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|888|492|495
SE|25462207|METHODS|ab|3|entity|C0439531|/period|tmco|||period|||0|888|496|502
SE|25462207|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|608|504|507
SE|25462207|METHODS|ab|3|entity|C1140618|Upper Extremity|bpoc|||arm|||0|608|518|521
SE|25462207|METHODS|ab|3|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|1000|544|558

SE|25462207|METHODS|ab|4|text|560|724|Individuals were randomized to harp music and standard care for the first 24 hours of the hospital stay, followed by 24 hours of only standard care, or vice versa.
SE|25462207|METHODS|ab|4|entity|C0237401|Individual|humn|||Individuals|||0|1000|560|571
SE|25462207|METHODS|ab|4|entity|C0026867|Music|inpr|||music|||0|1000|596|601
SE|25462207|METHODS|ab|4|entity|C1442989|STANDARD|ftcn|||standard|||0|694|606|614
SE|25462207|METHODS|ab|4|entity|C1279901|Firstly|qlco|||first|||0|901|628|633
SE|25462207|METHODS|ab|4|entity|C0439584|24 hour time frame|tmco|||24 hours|||0|901|634|642
SE|25462207|METHODS|ab|4|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|694|650|658
SE|25462207|METHODS|ab|4|entity|C0439584|24 hour time frame|tmco|||24 hours|||0|1000|677|685
SE|25462207|METHODS|ab|4|entity|C1442989|STANDARD|ftcn|||standard|||0|660|694|702
SE|25462207|METHODS|ab|4|entity|C0814670|vice|idcn|||vice|||0|861|712|716

SE|25462207|METHODS|ab|5|text|724|861|The harp intervention was 30-40 minutes of prescriptive live therapeutic harp sounds in the form of solo harp pieces and improvisations.
SE|25462207|METHODS|ab|5|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|888|728|732
SE|25462207|METHODS|ab|5|entity|C1273869|Intervention regimes|hlca|||intervention|||0|888|733|745
SE|25462207|METHODS|ab|5|entity|C0456693|/30 min|tmco|||30-40 minutes|||0|901|750|763
SE|25462207|METHODS|ab|5|entity|C1548795|Live|qlco|||live|||0|775|780|784
SE|25462207|METHODS|ab|5|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|775|797|801
SE|25462207|METHODS|ab|5|entity|C1522492|Formation|ftcn|||form|||0|1000|816|820
SE|25462207|METHODS|ab|5|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|660|829|833
SE|25462207|METHODS|ab|5|entity|C1510549|Improvisation|acty|||improvisations|||0|966|845|859

SE|25462207|METHODS|ab|6|text|861|936|Patients recorded well-being and symptom scores on linear analogue scales.
SE|25462207|METHODS|ab|6|entity|C0030705|Patients|podg|||Patients|||0|1000|861|869
SE|25462207|METHODS|ab|6|entity|C0031206|Personal Satisfaction|fndg|||well-being|||0|1000|879|889
SE|25462207|METHODS|ab|6|entity|C1457887|Symptoms|sosy|||symptom|||0|1000|894|901
SE|25462207|METHODS|ab|6|entity|C0205132|Linear|spco|||linear|||0|851|912|918
SE|25462207|METHODS|ab|6|entity|C0243071|Analog|chvs|||analogue|||0|851|919|927

SE|25462207|METHODS|ab|7|text|936|1071|Entry criteria included at least 18 years and a score of 3 or below on a 1-5 linear analogue scale indicating compromised overall QOL.
SE|25462207|METHODS|ab|7|entity|C0243161|criteria|inpr|||criteria|||0|861|942|950
SE|25462207|METHODS|ab|7|entity|C0439234|year|tmco|||years|||0|827|972|977
SE|25462207|METHODS|ab|7|entity|C0449820|Score|qnco|||score|||0|1000|984|989
SE|25462207|METHODS|ab|7|entity|C0542339|Inferior|spco|||below|||0|1000|998|1003
SE|25462207|METHODS|ab|7|entity|C0205132|Linear|spco|||linear|||0|787|1013|1019
SE|25462207|METHODS|ab|7|entity|C0243071|Analog|chvs|||analogue|||0|787|1020|1028
SE|25462207|METHODS|ab|7|entity|C0518613|Compromise|fndg|||compromised|||0|861|1046|1057
SE|25462207|METHODS|ab|7|entity|C1561607|Overall|qlco|||overall|||0|861|1058|1065
SE|25462207|METHODS|ab|7|entity|C0034380|Quality of life|qlco|||QOL|||0|861|1066|1069

SE|25462207|RESULTS|ab|8|text|1071|1145|RESULTS: Ninety-two eligible patients participated in the clinical trial.
SE|25462207|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|1071|1078
SE|25462207|RESULTS|ab|8|entity|C0205448|Two|qnco|||two|||0|775|1087|1090
SE|25462207|RESULTS|ab|8|entity|C1548635|Eligible|idcn|||eligible|||0|775|1091|1099
SE|25462207|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|775|1100|1108
SE|25462207|RESULTS|ab|8|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|1000|1129|1143

SE|25462207|RESULTS|ab|9|text|1145|1287|All the QOL variables had significantly higher percentages of patients with improvements during the harp treatment than during standard care.
SE|25462207|RESULTS|ab|9|entity|C0034380|Quality of life|qlco|||QOL|||0|846|1153|1156
SE|25462207|RESULTS|ab|9|entity|C0439828|Variable|qlco|||variables|||0|846|1157|1166
SE|25462207|RESULTS|ab|9|entity|C0205250|High|qlco|||higher|||0|756|1185|1191
SE|25462207|RESULTS|ab|9|entity|C0439165|Percent (qualifier value)|qnco|||percentages|||0|756|1192|1203
SE|25462207|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1207|1215
SE|25462207|RESULTS|ab|9|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|888|1245|1249
SE|25462207|RESULTS|ab|9|entity|C1442989|STANDARD|ftcn|||standard|||0|694|1272|1280

SE|25462207|RESULTS|ab|10|text|1287|1417|Five symptoms--fatigue, anxiety, sadness, relaxation, and pain--were significantly improved following therapeutic harp treatment.
SE|25462207|RESULTS|ab|10|entity|C0205451|Five|qnco|||Five|||0|888|1287|1291
SE|25462207|RESULTS|ab|10|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|1292|1300
SE|25462207|RESULTS|ab|10|entity|C0015672|Fatigue|sosy|||fatigue|||0|1000|1302|1309
SE|25462207|RESULTS|ab|10|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|1311|1318
SE|25462207|RESULTS|ab|10|entity|C0344315|Depressed mood|fndg|||sadness|||0|1000|1320|1327
SE|25462207|RESULTS|ab|10|entity|C0035028|Relaxation|dora,topp|||relaxation|||0|1000|1329|1339
SE|25462207|RESULTS|ab|10|entity|C0030193|Pain|sosy|||pain|||0|1000|1345|1349
SE|25462207|RESULTS|ab|10|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|851|1401|1405

SE|25462207|RESULTS|ab|11|text|1417|1526|Approximately 30% to 50% of patients showed a significant increase in the QOL measures after harp treatment.
SE|25462207|RESULTS|ab|11|entity|C0332232|Approximate|ftcn,qlco|||Approximately|||0|861|1417|1430
SE|25462207|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1445|1453
SE|25462207|RESULTS|ab|11|entity|C0750502|Significant|idcn|||significant|||0|888|1463|1474
SE|25462207|RESULTS|ab|11|entity|C0442805|Increase|ftcn|||increase|||0|888|1475|1483
SE|25462207|RESULTS|ab|11|entity|C0034380|Quality of life|qlco|||QOL|||0|884|1491|1494
SE|25462207|RESULTS|ab|11|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|888|1510|1514

SE|25462207|CONCLUSION|ab|12|text|1526|1690|CONCLUSION: There is evidence of strong positive effects on the QOL of hospitalized patients who received therapeutic harp sound treatment along with standard care.
SE|25462207|CONCLUSION|ab|12|entity|C0442821|Strong|qlco|||strong|||0|840|1559|1565
SE|25462207|CONCLUSION|ab|12|entity|C1446409|Positive|qlco|||positive|||0|840|1566|1574
SE|25462207|CONCLUSION|ab|12|entity|C1280500|Effect|qlco|||effects|||0|840|1575|1582
SE|25462207|CONCLUSION|ab|12|entity|C0034380|Quality of life|qlco|||QOL|||0|884|1590|1593
SE|25462207|CONCLUSION|ab|12|entity|C0870668|Hospitalized Patients|podg|||hospitalized patients|||0|1000|1597|1618
SE|25462207|CONCLUSION|ab|12|entity|C0084084|pleiotrophin|aapp,bacs|||harp|||0|833|1644|1648
SE|25462207|CONCLUSION|ab|12|entity|C1442989|STANDARD|ftcn|||standard|||0|694|1676|1684


SE|25462209||ti|1|text|21|150|Perceptions of complementary medicine integration in supportive cancer care of Arabs and Jews in Israel: a cross-cultural study.
SE|25462209||ti|1|entity|C0030971|Perception|menp|||Perceptions|||0|1000|21|32
SE|25462209||ti|1|entity|C1148474|Complementary Medicine|bmod|||complementary medicine|||0|734|36|58
SE|25462209||ti|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|901|85|91
SE|25462209||ti|1|entity|C0344211|Supportive care|topp|||supportive cancer care|||0|901|74|96
SE|25462209||ti|1|entity|C0282540|arab ethnic group|popg|||Arabs|||0|1000|100|105
SE|25462209||ti|1|entity|C0022389|Jews|popg|||Jews|||0|1000|110|114
SE|25462209||ti|1|entity|C0022271|Israel|geoa|||Israel|||0|1000|118|124
SE|25462209||ti|1|entity|C0087107|Transcultural Studies|resa|||cross-cultural study|||0|1000|128|148

SE|25462209|CONTEXT|ab|1|text|156|332|CONTEXT: There is a dearth of studies on how cultural background influences patients' attitudes and choices regarding complementary and traditional medicine (CTM) integration.
SE|25462209|CONTEXT|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|186|193
SE|25462209|CONTEXT|ab|1|entity|C0010447|Cultural Background|idcn|||cultural background|||0|901|201|220
SE|25462209|CONTEXT|ab|1|entity|C0870289|Client Attitudes|menp|||patients' attitudes|||0|983|232|251
SE|25462209|CONTEXT|ab|1|entity|C1148474|Complementary Medicine|bmod|||complementary and traditional medicine|||0|875|274|312

SE|25462209|OBJECTIVES|ab|2|text|332|474|OBJECTIVES: To explore Arab and Jewish patients' perspectives regarding CTM use and its possible integration within conventional cancer care.
SE|25462209|OBJECTIVES|ab|2|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|332|342
SE|25462209|OBJECTIVES|ab|2|entity|C0282540|arab ethnic group|popg|||Arab|||0|1000|355|359
SE|25462209|OBJECTIVES|ab|2|entity|C0022422|Judaism|idcn|||Jewish|||0|623|364|370
SE|25462209|OBJECTIVES|ab|2|entity|C0030705|Patients|podg|||patients|||0|623|371|379
SE|25462209|OBJECTIVES|ab|2|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|812|404|407
SE|25462209|OBJECTIVES|ab|2|entity|C0332149|Possible|qlco|||possible|||0|694|420|428
SE|25462209|OBJECTIVES|ab|2|entity|C0439858|Conventional|qlco|||conventional|||0|901|448|460
SE|25462209|OBJECTIVES|ab|2|entity|C0920687|cancer care|topp|||cancer care|||0|901|461|472

SE|25462209|METHODS|ab|3|text|474|516|METHODS: This was a cross-cultural study.
SE|25462209|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|474|481
SE|25462209|METHODS|ab|3|entity|C0087107|Transcultural Studies|resa|||cross-cultural study|||0|1000|494|514

SE|25462209|METHODS|ab|4|text|516|643|We developed a 27-item questionnaire that evaluates patients' perceptions regarding CTM integration in supportive cancer care.
SE|25462209|METHODS|ab|4|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|827|539|552
SE|25462209|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|888|568|576
SE|25462209|METHODS|ab|4|entity|C0030971|Perception|menp|||perceptions|||0|888|578|589
SE|25462209|METHODS|ab|4|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|875|600|603
SE|25462209|METHODS|ab|4|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|901|630|636
SE|25462209|METHODS|ab|4|entity|C0344211|Supportive care|topp|||supportive cancer care|||0|901|619|641

SE|25462209|METHODS|ab|5|text|643|780|The questionnaire was administered to a convenience sample of patients receiving cancer care in community and hospital oncology centers.
SE|25462209|METHODS|ab|5|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|1000|647|660
SE|25462209|METHODS|ab|5|entity|C0150095|convenience sample|resa|||convenience sample|||0|1000|683|701
SE|25462209|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|705|713
SE|25462209|METHODS|ab|5|entity|C0920687|cancer care|topp|||cancer care|||0|1000|724|735
SE|25462209|METHODS|ab|5|entity|C0009462|Community|geoa|||community|||0|1000|739|748
SE|25462209|METHODS|ab|5|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|785|753|761
SE|25462209|METHODS|ab|5|entity|C0205099|Central|spco|||centers|||0|785|771|778
SE|25462209|METHODS|ab|5|relation|3|1|C0920687|cancer care|topp|topp|||cancer care|||0|1000|724|735|VERB|ADMINISTERED_TO||714|723|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|705|713

SE|25462209|RESULTS|ab|6|text|780|942|RESULTS: Of the 770 respondents (response rate 88%), 324 defined their religion as Muslim, Christian, or Druze (henceforth, regarded as Arabs) and 446 were Jews.
SE|25462209|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|780|787
SE|25462209|RESULTS|ab|6|entity|C0282122|Respondents|popg|||respondents|||0|861|800|811
SE|25462209|RESULTS|ab|6|entity|C0237629|Frequency of Responses|tmco|||response rate|||0|901|813|826
SE|25462209|RESULTS|ab|6|entity|C0035039|Religion|idcn|||religion|||0|1000|851|859
SE|25462209|RESULTS|ab|6|entity|C0026870|Muslim population group|popg|||Muslim|||0|1000|863|869
SE|25462209|RESULTS|ab|6|entity|C0008532|Christianity|idcn|||Christian|||0|1000|871|880
SE|25462209|RESULTS|ab|6|entity|C0815324|Druze|popg|||Druze|||0|1000|885|890
SE|25462209|RESULTS|ab|6|entity|C0282540|arab ethnic group|popg|||Arabs|||0|1000|916|921
SE|25462209|RESULTS|ab|6|entity|C0022389|Jews|popg|||Jews|||0|1000|936|940

SE|25462209|RESULTS|ab|7|text|942|1138|Respondents in the two groups differed significantly in terms of age, gender, marital status, number of children, education, religiosity, and prevalence of cancer types (excluding breast cancer).
SE|25462209|RESULTS|ab|7|entity|C0282122|Respondents|popg|||Respondents|||0|1000|942|953
SE|25462209|RESULTS|ab|7|entity|C0205448|Two|qnco|||two|||0|888|961|964
SE|25462209|RESULTS|ab|7|entity|C0441833|Groups|inpr|||groups|||0|888|965|971
SE|25462209|RESULTS|ab|7|entity|C0001779|Age|orga|||age|||0|1000|1007|1010
SE|25462209|RESULTS|ab|7|entity|C0079399|Gender|orga|||gender|||0|1000|1012|1018
SE|25462209|RESULTS|ab|7|entity|C0024819|Marital Status|grpa|||marital status|||0|1000|1020|1034
SE|25462209|RESULTS|ab|7|entity|C0237753|Numbers|qnco|||number|||0|1000|1036|1042
SE|25462209|RESULTS|ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1046|1054
SE|25462209|RESULTS|ab|7|entity|C0013621|Knowledge acquisition|edac|||education|||0|1000|1056|1065
SE|25462209|RESULTS|ab|7|entity|C0681189|Religiosity|idcn|||religiosity|||0|1000|1067|1078
SE|25462209|RESULTS|ab|7|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|888|1098|1104
SE|25462209|RESULTS|ab|7|entity|C0332307|Type - attribute|qlco|||types|||0|888|1105|1110
SE|25462209|RESULTS|ab|7|entity|C0332196|Exclude|ftcn|||excluding|||0|884|1112|1121
SE|25462209|RESULTS|ab|7|entity|C0006142|Malignant neoplasm of breast|neop|||breast cancer|||0|884|1122|1135

SE|25462209|RESULTS|ab|8|text|1138|1392|Although Arab respondents reported less use of CTM for cancer-related outcomes (39.6% vs. 52.1%; P = 0.001), they expressed greater support than Jewish respondents for optional CTM consultation if provided within conventional oncology care (P < 0.0001).
SE|25462209|RESULTS|ab|8|entity|C0282540|arab ethnic group|popg|||Arab|||0|888|1147|1151
SE|25462209|RESULTS|ab|8|entity|C0282122|Respondents|popg|||respondents|||0|888|1152|1163
SE|25462209|RESULTS|ab|8|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|875|1185|1188
SE|25462209|RESULTS|ab|8|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|840|1193|1199
SE|25462209|RESULTS|ab|8|entity|C1522149|Related|ftcn|||related|||0|840|1200|1207
SE|25462209|RESULTS|ab|8|entity|C1274040|result|ftcn|||outcomes|||0|840|1208|1216
SE|25462209|RESULTS|ab|8|entity|C0443228|Largest|qnco|||greater|||0|888|1262|1269
SE|25462209|RESULTS|ab|8|entity|C0022422|Judaism|idcn|||Jewish|||0|888|1283|1289
SE|25462209|RESULTS|ab|8|entity|C0282122|Respondents|popg|||respondents|||0|888|1290|1301
SE|25462209|RESULTS|ab|8|entity|C1518600|Optional|qlco|||optional|||0|752|1306|1314
SE|25462209|RESULTS|ab|8|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|752|1315|1318
SE|25462209|RESULTS|ab|8|entity|C0009818|Consultation|hlca|||consultation|||0|752|1319|1331
SE|25462209|RESULTS|ab|8|entity|C0439858|Conventional|qlco|||conventional|||0|660|1351|1363

SE|25462209|RESULTS|ab|9|text|1392|1594|Respondents in both groups stated that their primary expectation from the oncologist concerning CTM was to participate in formulating a CTM treatment plan to be provided within the oncology department.
SE|25462209|RESULTS|ab|9|entity|C0282122|Respondents|popg|||Respondents|||0|1000|1392|1403
SE|25462209|RESULTS|ab|9|entity|C0441833|Groups|inpr|||groups|||0|1000|1412|1418
SE|25462209|RESULTS|ab|9|entity|C0679138|Expectation|menp|||expectation|||0|888|1445|1456
SE|25462209|RESULTS|ab|9|entity|C0259990|Oncologist|prog|||oncologist|||0|1000|1466|1476
SE|25462209|RESULTS|ab|9|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|902|1488|1491
SE|25462209|RESULTS|ab|9|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|787|1528|1531

SE|25462209|RESULTS|ab|10|text|1594|1779|Compared with Arab respondents, Jews expected CTM consultations to focus on improving daily functioning and coping, reducing chemotherapy side effects, and providing spiritual support.
SE|25462209|RESULTS|ab|10|entity|C0282540|arab ethnic group|popg|||Arab|||0|888|1608|1612
SE|25462209|RESULTS|ab|10|entity|C0282122|Respondents|popg|||respondents|||0|888|1613|1624
SE|25462209|RESULTS|ab|10|entity|C0022389|Jews|popg|||Jews|||0|1000|1626|1630
SE|25462209|RESULTS|ab|10|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|812|1640|1643
SE|25462209|RESULTS|ab|10|entity|C0009818|Consultation|hlca|||consultations|||0|812|1644|1657
SE|25462209|RESULTS|ab|10|entity|C0205234|Focal|spco|||focus|||0|1000|1661|1666
SE|25462209|RESULTS|ab|10|entity|C1272745|Improving|inpr|||improving|||0|840|1670|1679
SE|25462209|RESULTS|ab|10|entity|C0332173|Daily|tmco|||daily|||0|840|1680|1685
SE|25462209|RESULTS|ab|10|entity|C0031843|physiological aspects|phsf|||functioning|||0|840|1686|1697
SE|25462209|RESULTS|ab|10|entity|C0013216|Pharmacotherapy|topp|||chemotherapy|||0|901|1719|1731
SE|25462209|RESULTS|ab|10|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|901|1732|1744
SE|25462209|RESULTS|ab|10|entity|C0150355|Spiritual support|hlca|||spiritual support|||0|890|1760|1777

SE|25462209|CONCLUSION|ab|11|text|1779|2035|CONCLUSION: Although quality of life-related expectations are more pronounced among Jewish respondents, both groups share the expectation from their health care providers to be actively involved in construction of a tailored integrative CTM treatment plan.
SE|25462209|CONCLUSION|ab|11|entity|C0332306|Quality|qlco|||quality|||0|1000|1800|1807
SE|25462209|CONCLUSION|ab|11|entity|C0376558|Life|idcn|||life|||0|851|1811|1815
SE|25462209|CONCLUSION|ab|11|entity|C1522149|Related|ftcn|||related|||0|851|1816|1823
SE|25462209|CONCLUSION|ab|11|entity|C0679138|Expectation|menp|||expectations|||0|851|1824|1836
SE|25462209|CONCLUSION|ab|11|entity|C0205172|More|ftcn|||more|||0|1000|1841|1845
SE|25462209|CONCLUSION|ab|11|entity|C0022422|Judaism|idcn|||Jewish|||0|888|1863|1869
SE|25462209|CONCLUSION|ab|11|entity|C0282122|Respondents|popg|||respondents|||0|888|1870|1881
SE|25462209|CONCLUSION|ab|11|entity|C0441833|Groups|inpr|||groups|||0|1000|1888|1894
SE|25462209|CONCLUSION|ab|11|entity|C0679138|Expectation|menp|||expectation|||0|1000|1905|1916
SE|25462209|CONCLUSION|ab|11|entity|C0018724|Health Personnel|prog|||health care providers|||0|1000|1928|1949
SE|25462209|CONCLUSION|ab|11|entity|C1148474|Complementary Medicine|bmod|||CTM|||0|730|2016|2019
SE|25462209|CONCLUSION|ab|11|entity|C0599880|TREATMENT PLAN|inpr|||treatment plan|||0|730|2020|2034
SE|25462209|CONCLUSION|ab|11|relation|3|1|C0679138|Expectation|menp|menp|||expectations|||0|851|1824|1836|PREP|PROCESS_OF||1857|1862|5|1|C0282122|Respondents|popg,humn|humn|||respondents|||0|888|1870|1881


SE|25462210||ti|1|text|21|118|Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
SE|25462210||ti|1|entity|C0032042|Placebos|medd,topp|||placebo|||0|814|35|42
SE|25462210||ti|1|entity|C0702113|Controlled|ftcn|||controlled|||0|814|43|53
SE|25462210||ti|1|entity|C1514720|Randomized|ftcn|||randomized|||0|814|55|65
SE|25462210||ti|1|entity|C0008976|Clinical Trials|resa|||trial|||0|814|66|71
SE|25462210||ti|1|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|1000|75|85
SE|25462210||ti|1|entity|C0021843|Intestinal Obstruction|acab,dsyn|||bowel obstruction|||0|901|99|116
SE|25462210||ti|1|relation|2|1|C0028833|Octreotide|aapp,gngm,horm,phsu|aapp|||octreotide|||0|1000|75|85|PREP|ASSOCIATED_WITH||86|88|1|1|C0021843|Intestinal Obstruction|acab,dsyn|dsyn|||bowel obstruction|||0|901|99|116

SE|25462210|CONTEXT|ab|1|text|124|205|CONTEXT: Does octreotide reduce vomiting in cancer-associated bowel obstruction?
SE|25462210|CONTEXT|ab|1|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|1000|138|148
SE|25462210|CONTEXT|ab|1|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|156|164
SE|25462210|CONTEXT|ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|824|168|174
SE|25462210|CONTEXT|ab|1|entity|C0021843|Intestinal Obstruction|acab,dsyn|||bowel obstruction|||0|824|186|203
SE|25462210|CONTEXT|ab|1|relation|2|1|C0028833|Octreotide|aapp,gngm,horm,phsu|phsu|||octreotide|||0|1000|138|148|VERB|PREVENTS||149|155|2|1|C0042963|Vomiting|sosy|sosy|||vomiting|||0|1000|156|164
SE|25462210|CONTEXT|ab|1|relation|3|1|C0042963|Vomiting|sosy|sosy|||vomiting|||0|1000|156|164|PREP|DIAGNOSES||165|167|1|1|C0021843|Intestinal Obstruction|acab,dsyn|acab|||bowel obstruction|||0|824|186|203

SE|25462210|OBJECTIVES|ab|2|text|205|453|OBJECTIVES: To evaluate the net effect of adding octreotide or placebo to standardized therapies on the number of days free of vomiting for populations presenting with vomiting and inoperable bowel obstruction secondary to cancer or its treatment.
SE|25462210|OBJECTIVES|ab|2|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|205|215
SE|25462210|OBJECTIVES|ab|2|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|888|233|236
SE|25462210|OBJECTIVES|ab|2|entity|C1280500|Effect|qlco|||effect|||0|888|237|243
SE|25462210|OBJECTIVES|ab|2|entity|C1524062|Additional|ftcn|||adding|||0|872|247|253
SE|25462210|OBJECTIVES|ab|2|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|872|254|264
SE|25462210|OBJECTIVES|ab|2|entity|C0032042|Placebos|medd,topp|||placebo|||0|1000|268|275
SE|25462210|OBJECTIVES|ab|2|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|861|292|301
SE|25462210|OBJECTIVES|ab|2|entity|C0237753|Numbers|qnco|||number|||0|1000|309|315
SE|25462210|OBJECTIVES|ab|2|entity|C0439228|day|tmco|||days|||0|1000|319|323
SE|25462210|OBJECTIVES|ab|2|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|332|340
SE|25462210|OBJECTIVES|ab|2|entity|C0032659|geographic population|qnco|||populations|||0|1000|345|356
SE|25462210|OBJECTIVES|ab|2|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|373|381
SE|25462210|OBJECTIVES|ab|2|entity|C0205187|Inoperable|qlco|||inoperable|||0|901|386|396
SE|25462210|OBJECTIVES|ab|2|entity|C0021843|Intestinal Obstruction|acab,dsyn|||bowel obstruction|||0|901|397|414
SE|25462210|OBJECTIVES|ab|2|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|1000|415|424
SE|25462210|OBJECTIVES|ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|428|434
SE|25462210|OBJECTIVES|ab|2|relation|1|0|C0812375|ELK3 gene|gngm,aapp|gngm|2004,131096|ELK3,KCNH8|net|||0|888|233|236|NOM|INTERACTS_WITH||237|243|13|1|C0028833|Octreotide|aapp,gngm,horm,phsu|aapp|||octreotide|||0|872|254|264
SE|25462210|OBJECTIVES|ab|2|relation|2|1|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|1000|428|434|ADJ|CAUSES||415|424|12|1|C0021843|Intestinal Obstruction|acab,dsyn|dsyn|||bowel obstruction|||0|901|397|414

SE|25462210|METHODS|ab|3|text|453|642|METHODS: Twelve services enrolled people with advanced cancer presenting with vomiting secondary to bowel obstruction where surgery or anti-cancer therapies were not indicated immediately.
SE|25462210|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|453|460
SE|25462210|METHODS|ab|3|entity|C0205458|Twelve|qnco|||Twelve|||0|888|462|468
SE|25462210|METHODS|ab|3|entity|C0557854|Services|ftcn|||services|||0|888|469|477
SE|25462210|METHODS|ab|3|entity|C0027361|Persons|popg|||people|||0|1000|487|493
SE|25462210|METHODS|ab|3|entity|C0877373|Advanced cancer|neop|||advanced cancer|||0|890|499|514
SE|25462210|METHODS|ab|3|entity|C0150312|Present|qnco|||presenting|||0|890|515|525
SE|25462210|METHODS|ab|3|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|531|539
SE|25462210|METHODS|ab|3|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|1000|540|549
SE|25462210|METHODS|ab|3|entity|C0028778|Obstruction|patf|||obstruction|||0|824|559|570
SE|25462210|METHODS|ab|3|entity|C0192573|Operation on intestine|topp|||bowel obstruction where surgery|||0|824|553|584
SE|25462210|METHODS|ab|3|entity|C0920425|Cancer Treatment|topp|||cancer therapies|||0|884|593|609
SE|25462210|METHODS|ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|615|618
SE|25462210|METHODS|ab|3|entity|C0205548|Stat (do immediately)|tmco|||immediately|||0|1000|629|640

SE|25462210|METHODS|ab|4|text|642|753|In a double-blind study, participants were randomized to placebo or octreotide (600 MUg/24 hours by infusion).
SE|25462210|METHODS|ab|4|entity|C0013072|Double-Blind Method|resa|||double-blind study|||0|1000|647|665
SE|25462210|METHODS|ab|4|entity|C0679646|Participant|popg|||participants|||0|966|667|679
SE|25462210|METHODS|ab|4|entity|C0032042|Placebos|medd,topp|||placebo|||0|1000|699|706
SE|25462210|METHODS|ab|4|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|1000|710|720
SE|25462210|METHODS|ab|4|entity|C0439584|24 hour time frame|tmco|||24 hours|||0|861|730|738
SE|25462210|METHODS|ab|4|entity|C0574032|Infusion procedures|topp|||infusion|||0|1000|742|750

SE|25462210|METHODS|ab|5|text|753|928|Both arms received standardized supportive therapy (infusion of ranitidine [200 mg/24 hours], dexamethasone [8 mg/24 hours], and parenteral hydration [10-20 mL/kg/24 hours]).
SE|25462210|METHODS|ab|5|entity|C0446516|Upper arm|blor|||arms|||0|1000|758|762
SE|25462210|METHODS|ab|5|entity|C0344211|Supportive care|topp|||supportive therapy|||0|901|785|803
SE|25462210|METHODS|ab|5|entity|C0574032|Infusion procedures|topp|||infusion|||0|1000|805|813
SE|25462210|METHODS|ab|5|entity|C0034665|Ranitidine|orch,phsu|||ranitidine|||0|1000|817|827
SE|25462210|METHODS|ab|5|entity|C0439584|24 hour time frame|tmco|||24 hours|||0|824|836|844
SE|25462210|METHODS|ab|5|entity|C0011777|Dexamethasone|phsu,strd|||dexamethasone|||0|1000|847|860
SE|25462210|METHODS|ab|5|entity|C1292429|8 Hours|tmco|||8 mg/24 hours|||0|824|862|875
SE|25462210|METHODS|ab|5|entity|C1442445|10 Hours|tmco|||10-20 mL/kg/24 hours|||0|768|904|924

SE|25462210|METHODS|ab|6|text|928|1004|The primary outcome was patient-reported days free of vomiting at 72 hours.
SE|25462210|METHODS|ab|6|entity|C1274040|result|ftcn|||outcome|||0|888|940|947
SE|25462210|METHODS|ab|6|entity|C0747307|PATIENT REPORT|inpr|||patient-reported|||0|890|952|968
SE|25462210|METHODS|ab|6|entity|C0439228|day|tmco|||days|||0|890|969|973
SE|25462210|METHODS|ab|6|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|982|990
SE|25462210|METHODS|ab|6|entity|C1292423|72 Hours|tmco|||72 hours|||0|1000|994|1002

SE|25462210|RESULTS|ab|7|text|1004|1155|RESULTS: In a study that recruited to the numbers identified in its power calculation, 87 participants provided data at 72 hours (45, octreotide arm).
SE|25462210|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1004|1011
SE|25462210|RESULTS|ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1018|1023
SE|25462210|RESULTS|ab|7|entity|C0237753|Numbers|qnco|||numbers|||0|1000|1046|1053
SE|25462210|RESULTS|ab|7|entity|C1441506|CALCULATION|lbpr|||calculation|||0|861|1078|1089
SE|25462210|RESULTS|ab|7|entity|C0679646|Participant|popg|||participants|||0|827|1094|1106
SE|25462210|RESULTS|ab|7|entity|C1511726|Data|idcn|||data|||0|1000|1116|1120
SE|25462210|RESULTS|ab|7|entity|C1292423|72 Hours|tmco|||72 hours|||0|1000|1124|1132
SE|25462210|RESULTS|ab|7|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|888|1138|1148
SE|25462210|RESULTS|ab|7|entity|C1140618|Upper Extremity|bpoc|||arm|||0|888|1149|1152

SE|25462210|RESULTS|ab|8|text|1155|1249|Seventeen people (octreotide) and 14 (placebo) were free of vomiting for 72 hours (P = 0.67).
SE|25462210|RESULTS|ab|8|entity|C0027361|Persons|popg|||people|||0|861|1165|1171
SE|25462210|RESULTS|ab|8|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|1000|1173|1183
SE|25462210|RESULTS|ab|8|entity|C0032042|Placebos|medd,topp|||placebo|||0|1000|1193|1200
SE|25462210|RESULTS|ab|8|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|1215|1223
SE|25462210|RESULTS|ab|8|entity|C1292423|72 Hours|tmco|||72 hours|||0|1000|1228|1236

SE|25462210|RESULTS|ab|9|text|1249|1347|Mean days free of vomiting were 1.87 (SD 1.10; octreotide) and 1.69 (SD 1.15; placebo; P = 0.47).
SE|25462210|RESULTS|ab|9|entity|C0439228|day|tmco|||days|||0|861|1254|1258
SE|25462210|RESULTS|ab|9|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|1267|1275
SE|25462210|RESULTS|ab|9|entity|C0221124|Serologically defined locus-1|gngm|57306|CUP2Q35|SD 1|||0|901|1287|1291
SE|25462210|RESULTS|ab|9|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|1000|1296|1306
SE|25462210|RESULTS|ab|9|entity|C0221124|Serologically defined locus-1|gngm|57306|CUP2Q35|SD 1|||0|901|1318|1322
SE|25462210|RESULTS|ab|9|entity|C0032042|Placebos|medd,topp|||placebo|||0|1000|1327|1334

SE|25462210|RESULTS|ab|10|text|1347|1727|An adjusted multivariate regression of the incidence of vomiting over the study showed a reduced number of episodes of vomiting in the octreotide group (incidence rate ratio = 0.40; 95% CI: 0.19-0.86; P = 0.019); however, people in the octreotide arm were 2.02 times more likely to be administered hyoscine butylbromide (P = 0.004), potentially reflecting increased colicky pain.
SE|25462210|RESULTS|ab|10|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|660|1350|1358
SE|25462210|RESULTS|ab|10|entity|C0021149|Incidence|qnco|||incidence|||0|1000|1390|1399
SE|25462210|RESULTS|ab|10|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|1403|1411
SE|25462210|RESULTS|ab|10|entity|C0205136|Over|spco|||over|||0|1000|1412|1416
SE|25462210|RESULTS|ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1421|1426
SE|25462210|RESULTS|ab|10|entity|C0392756|Reduced|qlco|||reduced|||0|888|1436|1443
SE|25462210|RESULTS|ab|10|entity|C0237753|Numbers|qnco|||number|||0|888|1444|1450
SE|25462210|RESULTS|ab|10|entity|C0332189|Episode of|tmco|||episodes|||0|1000|1454|1462
SE|25462210|RESULTS|ab|10|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|1466|1474
SE|25462210|RESULTS|ab|10|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|888|1482|1492
SE|25462210|RESULTS|ab|10|entity|C0441833|Groups|inpr|||group|||0|888|1493|1498
SE|25462210|RESULTS|ab|10|entity|C0021149|Incidence|qnco|||incidence|||0|851|1500|1509
SE|25462210|RESULTS|ab|10|entity|C1521828|Rate|qnco|||rate|||0|851|1510|1514
SE|25462210|RESULTS|ab|10|entity|C0456603|Ratio|inpr|||ratio|||0|851|1515|1520
SE|25462210|RESULTS|ab|10|entity|C0027361|Persons|popg|||people|||0|1000|1569|1575
SE|25462210|RESULTS|ab|10|entity|C0028833|Octreotide|aapp,horm,phsu|||octreotide|||0|888|1583|1593
SE|25462210|RESULTS|ab|10|entity|C1140618|Upper Extremity|bpoc|||arm|||0|888|1594|1597
SE|25462210|RESULTS|ab|10|entity|C0040223|Time|tmco|||times|||0|725|1608|1613
SE|25462210|RESULTS|ab|10|entity|C0006519|Butylscopolammonium Bromide|orch,phsu|||hyoscine butylbromide|||0|1000|1645|1666
SE|25462210|RESULTS|ab|10|entity|C0205217|Increased|qnco|||increased|||0|901|1703|1712
SE|25462210|RESULTS|ab|10|entity|C0232488|Abdominal colic|sosy|||colicky pain|||0|901|1713|1725
SE|25462210|RESULTS|ab|10|relation|3|1|C1140618|Upper Extremity|bpoc|bpoc|||arm|||0|888|1594|1597|PREP|LOCATION_OF||1576|1578|12|5|C0042963|Vomiting|sosy|sosy|||vomiting|||0|1000|1466|1474
SE|25462210|RESULTS|ab|10|relation|14|7|C0042963|Vomiting|sosy|sosy|||vomiting|||0|1000|1466|1474|VERB|COEXISTS_WITH||1692|1702|1|1|C0232488|Abdominal colic|sosy|sosy|||colicky pain|||0|901|1713|1725

SE|25462210|CONCLUSION|ab|11|text|1727|1920|CONCLUSION: Although there was no reduction in the number of days free of vomiting, the multivariate analysis suggests that further study of somatostatin analogues in this setting is warranted.
SE|25462210|CONCLUSION|ab|11|entity|C0237753|Numbers|qnco|||number|||0|1000|1778|1784
SE|25462210|CONCLUSION|ab|11|entity|C0439228|day|tmco|||days|||0|1000|1788|1792
SE|25462210|CONCLUSION|ab|11|entity|C0042963|Vomiting|sosy|||vomiting|||0|1000|1801|1809
SE|25462210|CONCLUSION|ab|11|entity|C0026777|Multivariate Analysis|qnco|||multivariate analysis|||0|1000|1815|1836
SE|25462210|CONCLUSION|ab|11|entity|C1517331|Further|spco|||further|||0|888|1851|1858
SE|25462210|CONCLUSION|ab|11|entity|C0008972|Clinical Research|resa|||study|||0|888|1859|1864
SE|25462210|CONCLUSION|ab|11|entity|C0732165|Somatostatin analog|aapp,horm,phsu|6750|SST|somatostatin analogues|||0|983|1868|1890
SE|25462210|CONCLUSION|ab|11|entity|C0542559|contextual factors|ftcn|||setting|||0|1000|1899|1906


SE|25462211||ti|1|text|21|113|Is resveratrol a potential substitute for leuprolide acetate in experimental endometriosis?
SE|25462211||ti|1|entity|C0073096|resveratrol|orch,phsu|||resveratrol|||0|1000|24|35
SE|25462211||ti|1|entity|C0237399|Potential|qlco|||potential|||0|694|38|47
SE|25462211||ti|1|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||leuprolide acetate|||0|1000|63|81
SE|25462211||ti|1|entity|C1517004|Experimental|ftcn|||experimental|||0|888|85|97
SE|25462211||ti|1|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriosis|||0|888|98|111
SE|25462211||ti|1|relation|3|1|C0700596|Leuprolide Acetate|aapp,gngm,horm,phsu|aapp|||leuprolide acetate|||0|1000|63|81|PREP|ASSOCIATED_WITH||82|84|1|1|C0014175|Endometriosis, site unspecified|dsyn|dsyn|||endometriosis|||0|888|98|111

SE|25462211|OBJECTIVE|ab|1|text|119|233|OBJECTIVE: Resveratrol, a phytoalexin polyphenol, has anti-angiogenic, antioxidant, anti-inflammatory properties.
SE|25462211|OBJECTIVE|ab|1|entity|C0073096|resveratrol|orch,phsu|||Resveratrol|||0|1000|130|141
SE|25462211|OBJECTIVE|ab|1|entity|C1130460|phytoalexin|bacs|||phytoalexin|||0|888|145|156
SE|25462211|OBJECTIVE|ab|1|entity|C0071649|polyphenols|orch|||polyphenol|||0|888|157|167
SE|25462211|OBJECTIVE|ab|1|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|827|190|201
SE|25462211|OBJECTIVE|ab|1|entity|C1515999|Anti-inflammatory|qlco|||anti-inflammatory|||0|884|203|220
SE|25462211|OBJECTIVE|ab|1|entity|C0871161|Property|qlco|||properties|||0|884|221|231

SE|25462211|OBJECTIVE|ab|2|text|233|386|We aimed to compare the anti-inflammatory and anti-angiogenic effects of resveratrol and leuprolide acetate (LA) in an experimental endometriosis model.
SE|25462211|OBJECTIVE|ab|2|entity|C1515999|Anti-inflammatory|qlco|||anti-inflammatory|||0|1000|257|274
SE|25462211|OBJECTIVE|ab|2|entity|C1280500|Effect|qlco|||effects|||0|793|295|302
SE|25462211|OBJECTIVE|ab|2|entity|C0073096|resveratrol|orch,phsu|||resveratrol|||0|1000|306|317
SE|25462211|OBJECTIVE|ab|2|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||leuprolide acetate|||0|1000|322|340
SE|25462211|OBJECTIVE|ab|2|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriosis|||0|901|365|378
SE|25462211|OBJECTIVE|ab|2|entity|C0086272|Experimental Model|inpr|||experimental endometriosis model|||0|901|352|384
SE|25462211|OBJECTIVE|ab|2|relation|5|3|C0073096|resveratrol|orch,phsu|orch|||resveratrol|||0|1000|306|317|VERB|compared_with||245|252|5|4|C0700596|Leuprolide Acetate|aapp,gngm,horm,phsu|aapp|||leuprolide acetate|||0|1000|322|340

SE|25462211|STUDY DESIGN|ab|3|text|386|489|STUDY DESIGN: A prospective experimental study was conducted in a University Surgical Research Center.
SE|25462211|STUDY DESIGN|ab|3|entity|C0035171|Research Design|resa|||STUDY DESIGN|||0|1000|386|398
SE|25462211|STUDY DESIGN|ab|3|entity|C1517004|Experimental|ftcn|||experimental|||0|901|414|426
SE|25462211|STUDY DESIGN|ab|3|entity|C0033522|Prospective Studies|qnco,resa|||prospective experimental study|||0|901|402|432
SE|25462211|STUDY DESIGN|ab|3|entity|C0041740|Universities|mnob,orgt|||University|||0|861|452|462
SE|25462211|STUDY DESIGN|ab|3|entity|C0543467|Operative Surgical Procedures|topp|||Surgical|||0|861|463|471
SE|25462211|STUDY DESIGN|ab|3|entity|C0683939|research organization|mnob,orgt|||Research Center|||0|861|472|487
SE|25462211|STUDY DESIGN|ab|3|relation|1|1|C0683939|research organization|mnob,orgt|orgt|||Research Center|||0|861|472|487|PREP|LOCATION_OF||447|449|2|1|C0033522|Prospective Studies|qnco,resa|resa|||prospective experimental study|||0|901|402|432

SE|25462211|STUDY DESIGN|ab|4|text|489|652|Thirty-three non-pregnant female Sprague-Dawley rats, in which experimental model of endometriosis were surgically induced were randomly divided into four groups.
SE|25462211|STUDY DESIGN|ab|4|entity|C0205449|Three|qnco|||three|||0|784|496|501
SE|25462211|STUDY DESIGN|ab|4|entity|C0033011|Pregnant Women|popg|||pregnant female|||0|784|506|521
SE|25462211|STUDY DESIGN|ab|4|entity|C0034715|Rats, Sprague-Dawley|mamm|||Sprague-Dawley rats|||0|784|522|541
SE|25462211|STUDY DESIGN|ab|4|entity|C0086272|Experimental Model|inpr|||experimental model|||0|1000|552|570
SE|25462211|STUDY DESIGN|ab|4|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriosis|||0|1000|574|587
SE|25462211|STUDY DESIGN|ab|4|entity|C0205450|Four|qnco|||four|||0|888|639|643
SE|25462211|STUDY DESIGN|ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|644|650

SE|25462211|STUDY DESIGN|ab|5|text|652|843|Group 1 was administered 30 mg/kg resveratrol i.m. for 14 days, group 2 was given 1mg/kg s.c. single dose LA, group 3 was administered both resveratrol and LA, and group 4 had no medication.
SE|25462211|STUDY DESIGN|ab|5|entity|C0441861|Group 1|inpr|||Group 1|||0|1000|652|659
SE|25462211|STUDY DESIGN|ab|5|entity|C0073096|resveratrol|orch,phsu|||resveratrol|||0|762|686|697
SE|25462211|STUDY DESIGN|ab|5|entity|C1532718|kg-m|qnco|||kg resveratrol i.m|||0|762|683|701
SE|25462211|STUDY DESIGN|ab|5|entity|C0439228|day|tmco|||days|||0|861|710|714
SE|25462211|STUDY DESIGN|ab|5|entity|C0441865|Group 2|inpr|||group 2|||0|1000|716|723
SE|25462211|STUDY DESIGN|ab|5|entity|C0037179|Unmarried person|popg|||single|||0|744|746|752
SE|25462211|STUDY DESIGN|ab|5|entity|C1446466|Dose|qnco|||dose|||0|744|753|757
SE|25462211|STUDY DESIGN|ab|5|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||LA|||0|744|758|760
SE|25462211|STUDY DESIGN|ab|5|entity|C0441869|Group 3|inpr|||group 3|||0|1000|762|769
SE|25462211|STUDY DESIGN|ab|5|entity|C0073096|resveratrol|orch,phsu|||resveratrol|||0|1000|792|803
SE|25462211|STUDY DESIGN|ab|5|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||LA|||0|1000|808|810
SE|25462211|STUDY DESIGN|ab|5|entity|C0441876|Group 4|inpr|||group 4|||0|1000|816|823
SE|25462211|STUDY DESIGN|ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|831|841

SE|25462211|STUDY DESIGN|ab|6|text|843|1066|After two weeks medication rats were sacrificed and size, histopathology and immunreactivity to matrix metalloproteinase (mmp)2, mmp9, vascular endothelial growth factor (VEGF) of the endometriotic implants were evaluated.
SE|25462211|STUDY DESIGN|ab|6|entity|C0205448|Two|qnco|||two|||0|833|849|852
SE|25462211|STUDY DESIGN|ab|6|entity|C0439230|week|tmco|||weeks|||0|833|853|858
SE|25462211|STUDY DESIGN|ab|6|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|833|859|869
SE|25462211|STUDY DESIGN|ab|6|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|833|870|874
SE|25462211|STUDY DESIGN|ab|6|entity|C0456389|size|spco|||size|||0|1000|895|899
SE|25462211|STUDY DESIGN|ab|6|entity|C0243140|Histopathological aspects|ftcn|||histopathology|||0|1000|901|915
SE|25462211|STUDY DESIGN|ab|6|entity|C0172537|Gelatinase A|aapp,enzy|||matrix metalloproteinase (mmp)2|||0|1000|939|970
SE|25462211|STUDY DESIGN|ab|6|entity|C0165519|Gelatinase B|aapp,enzy|4318|MMP9|mmp9|||0|1000|972|976
SE|25462211|STUDY DESIGN|ab|6|entity|C1171892|VEGF protein, human|aapp,bacs|7422|VEGFA|vascular endothelial growth factor|||0|1000|978|1012
SE|25462211|STUDY DESIGN|ab|6|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriotic|||0|853|1027|1040
SE|25462211|STUDY DESIGN|ab|6|entity|C0021102|Implants|medd|||implants|||0|853|1041|1049

SE|25462211|STUDY DESIGN|ab|7|text|1066|1189|Plasma and peritoneal fluid levels of interleukin (IL)-6, IL-8, and tumor necrosis factor-alpha (TNF-alpha) were analyzed.
SE|25462211|STUDY DESIGN|ab|7|entity|C0032105|Plasma|bdsu|||Plasma|||0|1000|1066|1072
SE|25462211|STUDY DESIGN|ab|7|entity|C0003964|Peritoneal Fluid|bdsu,bpoc|||peritoneal fluid|||0|901|1077|1093
SE|25462211|STUDY DESIGN|ab|7|entity|C0441889|Levels|inpr|||levels|||0|901|1094|1100
SE|25462211|STUDY DESIGN|ab|7|entity|C0021760|Interleukin-6|aapp,imft|||interleukin (IL)-6|||0|1000|1104|1122
SE|25462211|STUDY DESIGN|ab|7|entity|C0079633|Interleukin-8|aapp,imft|||IL-8|||0|1000|1124|1128
SE|25462211|STUDY DESIGN|ab|7|entity|C1448177|TNF protein, human|aapp,bacs|7124|TNF|tumor necrosis factor-alpha|||0|1000|1134|1161

SE|25462211|RESULTS|ab|8|text|1189|1507|RESULTS: The endometriotic implant volumes, histopathological grade and immunreactivity to mmp2, mmp9 and VEGF were significantly reduced (p<0.001), and plasma and peritoneal fluid levels of IL-6, IL-8 and TNF-alpha were significantly decreased in group 1 and group 2 in comparison to group 3 and group 4 (p < 0.001).
SE|25462211|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|1189|1196
SE|25462211|RESULTS|ab|8|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriotic|||0|816|1202|1215
SE|25462211|RESULTS|ab|8|entity|C0021102|Implants|medd|||implant|||0|816|1216|1223
SE|25462211|RESULTS|ab|8|entity|C0449468|Volume|qnco|||volumes|||0|816|1224|1231
SE|25462211|RESULTS|ab|8|entity|C0919553|Histopathologic Grade|clas|||histopathological grade|||0|950|1233|1256
SE|25462211|RESULTS|ab|8|entity|C0172537|Gelatinase A|aapp,enzy|4313|MMP2|mmp2|||0|1000|1280|1284
SE|25462211|RESULTS|ab|8|entity|C0165519|Gelatinase B|aapp,enzy|4318|MMP9|mmp9|||0|1000|1286|1290
SE|25462211|RESULTS|ab|8|entity|C1171892|VEGF protein, human|aapp,bacs|7422|VEGFA|VEGF|||0|1000|1295|1299
SE|25462211|RESULTS|ab|8|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|1342|1348
SE|25462211|RESULTS|ab|8|entity|C0003964|Peritoneal Fluid|bdsu,bpoc|||peritoneal fluid|||0|901|1353|1369
SE|25462211|RESULTS|ab|8|entity|C0441889|Levels|inpr|||levels|||0|901|1370|1376
SE|25462211|RESULTS|ab|8|entity|C0021760|Interleukin-6|aapp,imft|||IL-6|||0|1000|1380|1384
SE|25462211|RESULTS|ab|8|entity|C0079633|Interleukin-8|aapp,imft|||IL-8|||0|1000|1386|1390
SE|25462211|RESULTS|ab|8|entity|C1448177|TNF protein, human|aapp,bacs|7124|TNF|TNF-alpha|||0|1000|1395|1404
SE|25462211|RESULTS|ab|8|entity|C0441861|Group 1|inpr|||group 1|||0|1000|1437|1444
SE|25462211|RESULTS|ab|8|entity|C0441865|Group 2|inpr|||group 2|||0|1000|1449|1456
SE|25462211|RESULTS|ab|8|entity|C0441869|Group 3|inpr|||group 3|||0|1000|1474|1481
SE|25462211|RESULTS|ab|8|entity|C0441876|Group 4|inpr|||group 4|||0|1000|1486|1493

SE|25462211|CONCLUSION|ab|9|text|1507|1626|CONCLUSION: Resveratrol alone is a potential agent for the treatment of endometriosis and may be an alternative to LA.
SE|25462211|CONCLUSION|ab|9|entity|C0073096|resveratrol|orch,phsu|||Resveratrol|||0|1000|1519|1530
SE|25462211|CONCLUSION|ab|9|entity|C0237399|Potential|qlco|||potential|||0|888|1542|1551
SE|25462211|CONCLUSION|ab|9|entity|C0450442|Agent|chvf|||agent|||0|888|1552|1557
SE|25462211|CONCLUSION|ab|9|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriosis|||0|1000|1579|1592
SE|25462211|CONCLUSION|ab|9|entity|C1523987|Alternative|cnce|||alternative|||0|824|1607|1618
SE|25462211|CONCLUSION|ab|9|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||LA|||0|824|1622|1624
SE|25462211|CONCLUSION|ab|9|relation|2|2|C0700596|Leuprolide Acetate|aapp,gngm,horm,phsu|horm|||LA|||0|824|1622|1624|NOM|TREATS||1566|1575|2|1|C0014175|Endometriosis, site unspecified|dsyn|dsyn|||endometriosis|||0|1000|1579|1592

SE|25462211|CONCLUSION|ab|10|text|1626|1752|In contrast, the combination of LA and resveratrol decreased the anti-inflammatory and anti-angiogenic effects of each agent.
SE|25462211|CONCLUSION|ab|10|entity|C0205195|Combined|qlco|||combination|||0|1000|1643|1654
SE|25462211|CONCLUSION|ab|10|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||LA|||0|1000|1658|1660
SE|25462211|CONCLUSION|ab|10|entity|C0073096|resveratrol|orch,phsu|||resveratrol|||0|1000|1665|1676
SE|25462211|CONCLUSION|ab|10|entity|C1515999|Anti-inflammatory|qlco|||anti-inflammatory|||0|1000|1691|1708
SE|25462211|CONCLUSION|ab|10|entity|C1280500|Effect|qlco|||effects|||0|793|1729|1736
SE|25462211|CONCLUSION|ab|10|entity|C0450442|Agent|chvf|||agent|||0|1000|1745|1750

SE|25462211|CONCLUSION|ab|11|text|1752|1882|Since resveratrol is widely used as an alternative therapy for a variety of conditions, it can undermine the effectiveness of LA.
SE|25462211|CONCLUSION|ab|11|entity|C0073096|resveratrol|orch,phsu|||resveratrol|||0|1000|1758|1769
SE|25462211|CONCLUSION|ab|11|entity|C0949216|Alternative Therapies|topp|||alternative therapy|||0|1000|1791|1810
SE|25462211|CONCLUSION|ab|11|entity|C0348080|Condition|qlco|||conditions|||0|966|1828|1838
SE|25462211|CONCLUSION|ab|11|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|1861|1874
SE|25462211|CONCLUSION|ab|11|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||LA|||0|1000|1878|1880

SE|25462211|CONCLUSION|ab|12|text|1882|1964|Therefore, caution should be exercised when used in combination with other agents.
SE|25462211|CONCLUSION|ab|12|entity|C0205195|Combined|qlco|||combination|||0|1000|1934|1945
SE|25462211|CONCLUSION|ab|12|entity|C0450442|Agent|chvf|||agents|||0|966|1957|1963


SE|25462212||ti|1|text|21|142|Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats?
SE|25462212||ti|1|entity|C0298130|montelukast|orch,phsu|||montelukast|||0|1000|24|35
SE|25462212||ti|1|entity|C0227843|Endometrio-|spco|||endometrial|||0|888|63|74
SE|25462212||ti|1|entity|C0021102|Implants|medd|||implants|||0|888|75|83
SE|25462212||ti|1|entity|C0205263|Induced|ftcn|||induced|||0|775|105|112
SE|25462212||ti|1|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriosis|||0|775|113|126
SE|25462212||ti|1|entity|C0026336|Study models|inpr,resd|||model|||0|775|127|132
SE|25462212||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|136|140
SE|25462212||ti|1|relation|4|1|C0021102|Implants|medd|medd|||implants|||0|888|75|83|ADJ|CAUSES||105|112|4|0|C0014175|Endometriosis, site unspecified|dsyn|dsyn|||endometriosis|||0|775|113|126
SE|25462212||ti|1|relation|5|2|C0021102|Implants|medd|medd|||implants|||0|888|75|83|PREP|TREATS||133|135|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|136|140

SE|25462212|OBJECTIVE|ab|1|text|148|322|OBJECTIVE: Montelukast, a selective antagonist of Type 1 cysteinyl leukotriene receptors (CysLT1Rs), antagonizes the proinflammatory and proasthmatic activities of CysLT1Rs.
SE|25462212|OBJECTIVE|ab|1|entity|C0298130|montelukast|orch,phsu|||Montelukast|||0|1000|159|170
SE|25462212|OBJECTIVE|ab|1|entity|C0441729|Type 1|clas|||Type 1|||0|885|198|204
SE|25462212|OBJECTIVE|ab|1|entity|C0753791|cysteinyl leukotriene receptor|aapp,rcpt|||cysteinyl leukotriene receptors|||0|885|205|236
SE|25462212|OBJECTIVE|ab|1|entity|C0441655|Activities|acty|||activities|||0|861|298|308
SE|25462212|OBJECTIVE|ab|1|entity|C0753791|cysteinyl leukotriene receptor|aapp,rcpt|||CysLT1Rs|||0|983|312|320
SE|25462212|OBJECTIVE|ab|1|relation|2|1|C0298130|montelukast|orch,phsu|orch|||Montelukast|||0|1000|159|170|NOM|INHIBITS||184|194|4|1|C0753791|cysteinyl leukotriene receptor|aapp,gngm,rcpt|gngm|||cysteinyl leukotriene receptors|||0|885|205|236

SE|25462212|OBJECTIVE|ab|2|text|322|413|We investigated the effect of montelukast on a surgically induced endometriosis rat model.
SE|25462212|OBJECTIVE|ab|2|entity|C1280500|Effect|qlco|||effect|||0|1000|342|348
SE|25462212|OBJECTIVE|ab|2|entity|C0298130|montelukast|orch,phsu|||montelukast|||0|1000|352|363
SE|25462212|OBJECTIVE|ab|2|entity|C0205263|Induced|ftcn|||induced|||0|771|380|387
SE|25462212|OBJECTIVE|ab|2|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriosis|||0|771|388|401
SE|25462212|OBJECTIVE|ab|2|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|771|402|405
SE|25462212|OBJECTIVE|ab|2|entity|C0026336|Study models|inpr,resd|||model|||0|771|406|411
SE|25462212|OBJECTIVE|ab|2|relation|2|1|C0298130|montelukast|orch,phsu|orch|||montelukast|||0|1000|352|363|ADJ|CAUSES||380|387|2|0|C0014175|Endometriosis, site unspecified|dsyn|dsyn|||endometriosis|||0|771|388|401

SE|25462212|STUDY DESIGN|ab|3|text|413|589|STUDY DESIGN: Thirty-two sexually mature, cycling, female Wistar-Albino rats, in which endometriotic implants were surgically induced, were randomly divided into three groups.
SE|25462212|STUDY DESIGN|ab|3|entity|C0035171|Research Design|resa|||STUDY DESIGN|||0|1000|413|425
SE|25462212|STUDY DESIGN|ab|3|entity|C0205448|Two|qnco|||two|||0|763|434|437
SE|25462212|STUDY DESIGN|ab|3|entity|C0205286|Mature|tmco|||mature|||0|763|447|453
SE|25462212|STUDY DESIGN|ab|3|entity|C0015780|Female|orga|||female|||0|861|464|470
SE|25462212|STUDY DESIGN|ab|3|entity|C0001916|Albinism|cgab|||Albino|||0|861|478|484
SE|25462212|STUDY DESIGN|ab|3|entity|C0034716|Rats, Wistar|mamm|||Wistar-Albino rats|||0|861|471|489
SE|25462212|STUDY DESIGN|ab|3|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriotic|||0|853|500|513
SE|25462212|STUDY DESIGN|ab|3|entity|C0021102|Implants|medd|||implants|||0|853|514|522
SE|25462212|STUDY DESIGN|ab|3|entity|C0205449|Three|qnco|||three|||0|888|575|580
SE|25462212|STUDY DESIGN|ab|3|entity|C0441833|Groups|inpr|||groups|||0|888|581|587

SE|25462212|STUDY DESIGN|ab|4|text|589|677|Group I [Montelukast (M), 10 rats)] was given 1.6 mg/kg/day of oral montelukast sodium.
SE|25462212|STUDY DESIGN|ab|4|entity|C0441833|Groups|inpr|||Group|||0|1000|589|594
SE|25462212|STUDY DESIGN|ab|4|entity|C0298130|montelukast|orch,phsu|||Montelukast|||0|1000|598|609
SE|25462212|STUDY DESIGN|ab|4|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|861|618|622
SE|25462212|STUDY DESIGN|ab|4|entity|C1442449|1 Day|tmco|||1.6 mg/kg/day|||0|794|635|648
SE|25462212|STUDY DESIGN|ab|4|entity|C0298130|montelukast|orch,phsu|||montelukast|||0|901|657|668
SE|25462212|STUDY DESIGN|ab|4|entity|C0357155|Oral form sodium|clnd|||oral montelukast sodium|||0|901|652|675

SE|25462212|STUDY DESIGN|ab|5|text|677|777|Group II [Leuprolide acetate (L), 11 rats] was given 1 mg/kg single dose of s.c.leuprolide acetate.
SE|25462212|STUDY DESIGN|ab|5|entity|C0441833|Groups|inpr|||Group|||0|694|677|682
SE|25462212|STUDY DESIGN|ab|5|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||Leuprolide acetate|||0|1000|687|705
SE|25462212|STUDY DESIGN|ab|5|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|861|714|718
SE|25462212|STUDY DESIGN|ab|5|entity|C0037179|Unmarried person|popg|||single|||0|888|738|744
SE|25462212|STUDY DESIGN|ab|5|entity|C1446466|Dose|qnco|||dose|||0|888|745|749
SE|25462212|STUDY DESIGN|ab|5|entity|C0565930|per second|qnco|||s.c|||0|824|753|756
SE|25462212|STUDY DESIGN|ab|5|entity|C0700596|Leuprolide Acetate|aapp,horm,phsu|||leuprolide acetate|||0|824|757|775

SE|25462212|STUDY DESIGN|ab|6|text|777|886|Group III [Control (C), 11 rats] received saline solution through an orogastric tube and served as controls.
SE|25462212|STUDY DESIGN|ab|6|entity|C0441833|Groups|inpr|||Group|||0|888|777|782
SE|25462212|STUDY DESIGN|ab|6|entity|C0439070|III|inpr|||III|||0|888|783|786
SE|25462212|STUDY DESIGN|ab|6|entity|C0243148|control|ftcn|||Control|||0|1000|788|795
SE|25462212|STUDY DESIGN|ab|6|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|861|804|808
SE|25462212|STUDY DESIGN|ab|6|entity|C0036082|Saline|clnd|||saline solution|||0|1000|819|834
SE|25462212|STUDY DESIGN|ab|6|entity|C0450104|Orogastric|spco|||orogastric|||0|888|846|856
SE|25462212|STUDY DESIGN|ab|6|entity|C1561954|tube|cnce|||tube|||0|888|857|861
SE|25462212|STUDY DESIGN|ab|6|entity|C0243148|control|ftcn|||controls|||0|966|876|884

SE|25462212|STUDY DESIGN|ab|7|text|886|1088|After a 3-weeks medication, the rats were sacrificed to investigate the endometriotic implants for size and morphological and histological characteristics, including immunoreactivity of MMP-2 and VEGF.
SE|25462212|STUDY DESIGN|ab|7|entity|C1442462|3 Weeks|tmco|||3-weeks|||0|901|894|901
SE|25462212|STUDY DESIGN|ab|7|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|901|902|912
SE|25462212|STUDY DESIGN|ab|7|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|918|922
SE|25462212|STUDY DESIGN|ab|7|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriotic|||0|853|958|971
SE|25462212|STUDY DESIGN|ab|7|entity|C0021102|Implants|medd|||implants|||0|853|972|980
SE|25462212|STUDY DESIGN|ab|7|entity|C0456389|size|spco|||size|||0|1000|985|989
SE|25462212|STUDY DESIGN|ab|7|entity|C0543482|morphological|spco|||morphological|||0|1000|994|1007
SE|25462212|STUDY DESIGN|ab|7|entity|C0205462|Histologic|ftcn|||histological|||0|888|1012|1024
SE|25462212|STUDY DESIGN|ab|7|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|1025|1040
SE|25462212|STUDY DESIGN|ab|7|entity|C0597879|Immunoreactivity|moft|||immunoreactivity|||0|1000|1052|1068
SE|25462212|STUDY DESIGN|ab|7|entity|C0172537|Gelatinase A|aapp,enzy|||MMP-2|||0|1000|1072|1077
SE|25462212|STUDY DESIGN|ab|7|entity|||gngm|7422|VEGFA|VEGF|||0|1000|1082|1086

SE|25462212|RESULTS|ab|8|text|1088|1271|RESULTS: The mean area of implants decreased from 48.2 +/- 24.7 to 29.3 +/- 15.8mm(2) in Group I (M) (P = 0.008) and from 62 +/- 32.1 to 39.9 +/- 18.1mm(2) in Group II (L) (P=0.003).
SE|25462212|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|1088|1095
SE|25462212|RESULTS|ab|8|entity|C0205146|Area|spco|||area|||0|861|1106|1110
SE|25462212|RESULTS|ab|8|entity|C0021102|Implants|medd|||implants|||0|1000|1114|1122
SE|25462212|RESULTS|ab|8|entity|C0441847|Group M|inpr|||Group I (M|||0|913|1177|1187
SE|25462212|RESULTS|ab|8|entity|C0441833|Groups|inpr|||Group|||0|694|1247|1252

SE|25462212|RESULTS|ab|9|text|1271|1367|In Group III (C), the mean area increased from 41.1 +/- 31.1 to 60.4 +/- 37.1mm(2) (P = 0.025).
SE|25462212|RESULTS|ab|9|entity|C0441833|Groups|inpr|||Group|||0|888|1274|1279
SE|25462212|RESULTS|ab|9|entity|C0439070|III|inpr|||III|||0|888|1280|1283
SE|25462212|RESULTS|ab|9|entity|C0205146|Area|spco|||area|||0|861|1298|1302

SE|25462212|RESULTS|ab|10|text|1367|1510|Histopathological analysis showed statistically significant lower scores in rats treated with montelukast compared to leuprolide and controls.
SE|25462212|RESULTS|ab|10|entity|C0243140|Histopathological aspects|ftcn|||Histopathological|||0|853|1367|1384
SE|25462212|RESULTS|ab|10|entity|C0936012|Analysis|resa|||analysis|||0|853|1385|1393
SE|25462212|RESULTS|ab|10|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|861|1401|1426
SE|25462212|RESULTS|ab|10|entity|C0441994|Lower|ftcn|||lower|||0|861|1427|1432
SE|25462212|RESULTS|ab|10|entity|C0449820|Score|qnco|||scores|||0|861|1433|1439
SE|25462212|RESULTS|ab|10|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|1443|1447
SE|25462212|RESULTS|ab|10|entity|C0298130|montelukast|orch,phsu|||montelukast|||0|1000|1461|1472
SE|25462212|RESULTS|ab|10|entity|C0085272|Leuprolide|aapp,horm,nsba,phsu|||leuprolide|||0|861|1485|1495
SE|25462212|RESULTS|ab|10|entity|C0243148|control|ftcn|||controls|||0|966|1500|1508
SE|25462212|RESULTS|ab|10|relation|3|1|C0298130|montelukast|orch,phsu|phsu|||montelukast|||0|1000|1461|1472|VERB|TREATS||1448|1455|3|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|1443|1447

SE|25462212|RESULTS|ab|11|text|1510|1614|MMP H scores were not different between the groups in both epithelial and stromal MMP-2 immunostaining.
SE|25462212|RESULTS|ab|11|entity|C0919336|MMP|gngm|||MMP|||0|851|1510|1513
SE|25462212|RESULTS|ab|11|entity|C0449820|Score|qnco|||scores|||0|851|1516|1522
SE|25462212|RESULTS|ab|11|entity|C1518422|Not|ftcn|||not|||0|853|1528|1531
SE|25462212|RESULTS|ab|11|entity|C1547020|*Difference|qnco|||different|||0|853|1532|1541
SE|25462212|RESULTS|ab|11|entity|C0441833|Groups|inpr|||groups|||0|1000|1554|1560
SE|25462212|RESULTS|ab|11|entity|C0221908|Epithelial|ftcn|||epithelial|||0|1000|1569|1579
SE|25462212|RESULTS|ab|11|entity|C0927195|Stroma|bpoc|||stromal|||0|634|1584|1591
SE|25462212|RESULTS|ab|11|entity|C0172537|Gelatinase A|aapp,enzy|||MMP-2|||0|634|1592|1597

SE|25462212|RESULTS|ab|12|text|1614|1761|VEGF H scores were statistically lower in Group 1 (M) in epithelial VEGF immunostaining when compared to Group II (L) and Group III (C) (P=0.006).
SE|25462212|RESULTS|ab|12|entity|||gngm|7422|VEGFA|VEGF|||0|790|1614|1618
SE|25462212|RESULTS|ab|12|entity|C0449820|Score|qnco|||scores|||0|790|1621|1627
SE|25462212|RESULTS|ab|12|entity|C0441994|Lower|ftcn|||lower|||0|861|1647|1652
SE|25462212|RESULTS|ab|12|entity|C0441861|Group 1|inpr|||Group 1|||0|1000|1656|1663
SE|25462212|RESULTS|ab|12|entity|C0221908|Epithelial|ftcn|||epithelial|||0|660|1671|1681
SE|25462212|RESULTS|ab|12|entity|||gngm|7422|VEGFA|VEGF|||0|660|1682|1686
SE|25462212|RESULTS|ab|12|entity|C0441833|Groups|inpr|||Group|||0|694|1719|1724
SE|25462212|RESULTS|ab|12|entity|C0441833|Groups|inpr|||Group|||0|888|1736|1741
SE|25462212|RESULTS|ab|12|entity|C0439070|III|inpr|||III|||0|888|1742|1745

SE|25462212|CONCLUSION(S)|ab|13|text|1761|1871|CONCLUSION(S): Montelukast may effectively cause a significant decrease in the area of endometriotic implants.
SE|25462212|CONCLUSION(S)|ab|13|entity|C0298130|montelukast|orch,phsu|||Montelukast|||0|1000|1776|1787
SE|25462212|CONCLUSION(S)|ab|13|entity|C0750502|Significant|idcn|||significant|||0|888|1812|1823
SE|25462212|CONCLUSION(S)|ab|13|entity|C0547047|Decrease|qnco|||decrease|||0|888|1824|1832
SE|25462212|CONCLUSION(S)|ab|13|entity|C0205146|Area|spco|||area|||0|1000|1840|1844
SE|25462212|CONCLUSION(S)|ab|13|entity|C0014175|Endometriosis, site unspecified|dsyn|||endometriotic|||0|853|1848|1861
SE|25462212|CONCLUSION(S)|ab|13|entity|C0021102|Implants|medd|||implants|||0|853|1862|1870


SE|25462214||ti|1|text|21|127|The impact of gynecologic oncology training in the management of cancer patients: is it really necessary?
SE|25462214||ti|1|entity|C1321164|Gynecologic Oncology|bmod|||gynecologic oncology|||0|901|35|55
SE|25462214||ti|1|entity|C0220931|Training|edac|||training|||0|901|56|64
SE|25462214||ti|1|entity|C1516213|Cancer Patient|podg|||cancer patients|||0|983|86|101

SE|25462214||ti|2|text|127|155|A prospective cohort study.
SE|25462214||ti|2|entity|C0599755|cohort|popg|||cohort|||0|901|141|147
SE|25462214||ti|2|entity|C0033522|Prospective Studies|qnco,resa|||prospective cohort study|||0|901|129|153

SE|25462214|OBJECTIVES|ab|1|text|161|379|OBJECTIVES: To assess patients' perceptions of physician, nurse, and care organization quality of care and services received during hospitalization with or without a sub-specialized setting in gynaecological oncology.
SE|25462214|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|161|171
SE|25462214|OBJECTIVES|ab|1|entity|C0030705|Patients|podg|||patients|||0|888|183|191
SE|25462214|OBJECTIVES|ab|1|entity|C0030971|Perception|menp|||perceptions|||0|888|193|204
SE|25462214|OBJECTIVES|ab|1|entity|C0031831|Physicians|prog|||physician|||0|1000|208|217
SE|25462214|OBJECTIVES|ab|1|entity|C0028661|Nurses|prog|||nurse|||0|1000|219|224
SE|25462214|OBJECTIVES|ab|1|entity|C0220885|organizational|qlco|||organization|||0|790|235|247
SE|25462214|OBJECTIVES|ab|1|entity|C0332306|Quality|qlco|||quality|||0|790|248|255
SE|25462214|OBJECTIVES|ab|1|entity|C0557854|Services|ftcn|||services|||0|1000|268|276
SE|25462214|OBJECTIVES|ab|1|entity|C0019993|Hospitalization|hlca|||hospitalization|||0|1000|293|308
SE|25462214|OBJECTIVES|ab|1|entity|C0542339|Inferior|spco|||sub|||0|851|327|330
SE|25462214|OBJECTIVES|ab|1|entity|C0205555|Special (qualifier)|qlco|||specialized|||0|851|331|342
SE|25462214|OBJECTIVES|ab|1|entity|C0542559|contextual factors|ftcn|||setting|||0|851|343|350
SE|25462214|OBJECTIVES|ab|1|entity|C1321164|Gynecologic Oncology|bmod|||gynaecological oncology|||0|1000|354|377
SE|25462214|OBJECTIVES|ab|1|relation|3|1|C0019993|Hospitalization|hlca|hlca|||hospitalization|||0|1000|293|308|VERB|ADMINISTERED_TO||277|285|7|4|C0028661|Nurses|prog,humn|humn|||nurse|||0|1000|219|224

SE|25462214|STUDY DESIGN|ab|2|text|379|649|STUDY DESIGN: Consecutive patients affected by gynaecologic cancer, referred to the Division of Gynaecology of University Campus Bio-Medico of Rome to underwent to surgery (surgical ward) or to chemotherapy (medical ward) from January 2010 to April 2014, were enrolled.
SE|25462214|STUDY DESIGN|ab|2|entity|C0035171|Research Design|resa|||STUDY DESIGN|||0|1000|379|391
SE|25462214|STUDY DESIGN|ab|2|entity|C0030705|Patients|podg|||patients|||0|861|405|413
SE|25462214|STUDY DESIGN|ab|2|entity|C0699889|Female reproductive neoplasm malignant NOS|neop|||gynaecologic cancer|||0|1000|426|445
SE|25462214|STUDY DESIGN|ab|2|entity|C0018417|Gynecology|bmod|||Gynaecology|||0|1000|475|486
SE|25462214|STUDY DESIGN|ab|2|entity|C0041740|Universities|mnob,orgt|||University|||0|597|490|500
SE|25462214|STUDY DESIGN|ab|2|entity|C0870243|Campuses|mnob|||Campus|||0|597|501|507
SE|25462214|STUDY DESIGN|ab|2|entity|C0205460|biological|ftcn|||Bio|||0|597|508|511
SE|25462214|STUDY DESIGN|ab|2|entity|C0035831|Rome|geoa|||Rome|||0|1000|522|526
SE|25462214|STUDY DESIGN|ab|2|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|694|552|560
SE|25462214|STUDY DESIGN|ab|2|entity|C0013216|Pharmacotherapy|topp|||chemotherapy|||0|1000|573|585
SE|25462214|STUDY DESIGN|ab|2|entity|C0205476|Medical|ftcn|||medical|||0|694|587|594
SE|25462214|STUDY DESIGN|ab|2|entity|C0681761|2010s|tmco|||2010|||0|827|614|618
SE|25462214|STUDY DESIGN|ab|2|entity|C1332090|ANP32B gene|gngm|10541|ANP32B|April|||0|861|622|627
SE|25462214|STUDY DESIGN|ab|2|relation|9|1|C0699889|Female reproductive neoplasm malignant NOS|neop|neop|||gynaecologic cancer|||0|1000|426|445|VERB|AFFECTS||414|422|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|405|413

SE|25462214|STUDY DESIGN|ab|3|text|649|899|Eligible subjects were divided into two groups: Group A: standard unit care, consisting of doctors and nurses without a specific training and Group B: Expert unit care, consisting of doctors and nurses with specific training in gynecologic oncology.
SE|25462214|STUDY DESIGN|ab|3|entity|C1548635|Eligible|idcn|||Eligible|||0|872|649|657
SE|25462214|STUDY DESIGN|ab|3|entity|C1550501|subject|idcn|||subjects|||0|872|658|666
SE|25462214|STUDY DESIGN|ab|3|entity|C0205448|Two|qnco|||two|||0|888|685|688
SE|25462214|STUDY DESIGN|ab|3|entity|C0441833|Groups|inpr|||groups|||0|888|689|695
SE|25462214|STUDY DESIGN|ab|3|entity|C0441833|Groups|inpr|||Group A|||0|802|697|704
SE|25462214|STUDY DESIGN|ab|3|entity|C0030705|Patients|podg|||Group A|||0|802|697|704
SE|25462214|STUDY DESIGN|ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|623|706|714
SE|25462214|STUDY DESIGN|ab|3|entity|C0439148|Unit|qnco|||unit|||0|623|715|719
SE|25462214|STUDY DESIGN|ab|3|entity|C0031831|Physicians|prog|||doctors|||0|1000|740|747
SE|25462214|STUDY DESIGN|ab|3|entity|C0220931|Training|edac|||training|||0|861|778|786
SE|25462214|STUDY DESIGN|ab|3|entity|C0441833|Groups|inpr|||Group|||0|872|791|796
SE|25462214|STUDY DESIGN|ab|3|entity|C0439148|Unit|qnco|||unit|||0|660|807|811
SE|25462214|STUDY DESIGN|ab|3|entity|C0031831|Physicians|prog|||doctors|||0|1000|832|839
SE|25462214|STUDY DESIGN|ab|3|entity|C0220931|Training|edac|||training|||0|861|865|873
SE|25462214|STUDY DESIGN|ab|3|entity|C1321164|Gynecologic Oncology|bmod|||gynecologic oncology|||0|1000|877|897

SE|25462214|STUDY DESIGN|ab|4|text|899|1106|Patients were asked to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cancer Module (QLQ-C30) and the Patient Satisfaction Questionnaire (IN-PATSAT32).
SE|25462214|STUDY DESIGN|ab|4|entity|C0030705|Patients|podg|||Patients|||0|1000|899|907
SE|25462214|STUDY DESIGN|ab|4|entity|C1516985|European Organization for Research and Treatment of Cancer|hcro|||European Organization for Research and Treatment of Cancer|||0|956|935|993
SE|25462214|STUDY DESIGN|ab|4|entity|C0332306|Quality|qlco|||Quality|||0|956|994|1001
SE|25462214|STUDY DESIGN|ab|4|entity|C0376558|Life|idcn|||Life|||0|808|1005|1009
SE|25462214|STUDY DESIGN|ab|4|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|808|1010|1023
SE|25462214|STUDY DESIGN|ab|4|entity|C0006826|Malignant Neoplasms|neop|||Cancer|||0|808|1024|1030
SE|25462214|STUDY DESIGN|ab|4|entity|C1031041|Modulus|invt|||Module|||0|808|1031|1037
SE|25462214|STUDY DESIGN|ab|4|entity|C0030702|Client satisfaction|qlco|||Patient Satisfaction|||0|901|1056|1076
SE|25462214|STUDY DESIGN|ab|4|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|901|1077|1090

SE|25462214|RESULTS|ab|5|text|1106|1215|RESULTS: The sample (n = 150) is organized into two groups: 78 patients (Group A) and 72 patients (Group B).
SE|25462214|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1106|1113
SE|25462214|RESULTS|ab|5|entity|C0205448|Two|qnco|||two|||0|740|1154|1157
SE|25462214|RESULTS|ab|5|entity|C0441833|Groups|inpr|||groups|||0|740|1158|1164
SE|25462214|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|740|1169|1177
SE|25462214|RESULTS|ab|5|entity|C0030705|Patients|podg|||patients|||0|861|1195|1203
SE|25462214|RESULTS|ab|5|entity|C0441833|Groups|inpr|||Group|||0|872|1205|1210

SE|25462214|RESULTS|ab|6|text|1215|1563|Analysing the results of IN-PATSAT32, comparing Group A versus Group B, we find statistically significant difference considering doctors' information provision (items 7-9) (p = 0.0470), nurses' technical skills (items 12-14) (p = 0.0369) and nurses' information provision (items 18-20) (p = 0.0089) and general satisfaction (item 32) (p = 0.0214).
SE|25462214|RESULTS|ab|6|entity|C1274040|result|ftcn|||results|||0|966|1229|1236
SE|25462214|RESULTS|ab|6|entity|C0441833|Groups|inpr|||Group A|||0|802|1263|1270
SE|25462214|RESULTS|ab|6|entity|C0030705|Patients|podg|||Group A|||0|802|1263|1270
SE|25462214|RESULTS|ab|6|entity|C0441833|Groups|inpr|||Group|||0|872|1278|1283
SE|25462214|RESULTS|ab|6|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|822|1295|1320
SE|25462214|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||difference|||0|822|1321|1331
SE|25462214|RESULTS|ab|6|entity|C0750591|CONSIDER|idcn|||considering|||0|822|1332|1343
SE|25462214|RESULTS|ab|6|entity|C0031831|Physicians|prog|||doctors|||0|822|1344|1351
SE|25462214|RESULTS|ab|6|entity|C0681319|information provision|inpr|||information provision|||0|822|1353|1374
SE|25462214|RESULTS|ab|6|entity|C0025664|Methodology|inpr|||technical|||0|853|1409|1418
SE|25462214|RESULTS|ab|6|entity|C0678856|skills|inbe|||skills|||0|853|1419|1425
SE|25462214|RESULTS|ab|6|entity|C0681319|information provision|inpr|||information provision|||0|1000|1465|1486
SE|25462214|RESULTS|ab|6|entity|C0205246|Generalized|spco|||general|||0|888|1518|1525
SE|25462214|RESULTS|ab|6|entity|C0242428|Satisfaction|menp|||satisfaction|||0|888|1526|1538

SE|25462214|CONCLUSIONS|ab|7|text|1563|1717|CONCLUSIONS: This study highlights the potential benefits specialty training for doctors and nurses that work in an oncologic ward (surgical or medical).
SE|25462214|CONCLUSIONS|ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1581|1586
SE|25462214|CONCLUSIONS|ab|7|entity|C0237399|Potential|qlco|||potential|||0|1000|1602|1611
SE|25462214|CONCLUSIONS|ab|7|entity|C0037778|Medical Specialities|bmod|||specialty|||0|888|1621|1630
SE|25462214|CONCLUSIONS|ab|7|entity|C0220931|Training|edac|||training|||0|888|1631|1639
SE|25462214|CONCLUSIONS|ab|7|entity|C0031831|Physicians|prog|||doctors|||0|1000|1644|1651
SE|25462214|CONCLUSIONS|ab|7|entity|C0043227|Work|ocac|||work|||0|1000|1668|1672
SE|25462214|CONCLUSIONS|ab|7|entity|C0205478|Oncologic|bmod|||oncologic|||0|694|1679|1688
SE|25462214|CONCLUSIONS|ab|7|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|1000|1695|1703
SE|25462214|CONCLUSIONS|ab|7|entity|C0205476|Medical|ftcn|||medical|||0|1000|1707|1714

SE|25462214|CONCLUSIONS|ab|8|text|1717|1908|In fact, the necessity for a separate sub-specialty in gynaecological oncology and a distinct training programme may be the key to achieve the higher satisfaction in this setting of patients.
SE|25462214|CONCLUSIONS|ab|8|entity|C0443299|Separate|spco|||separate|||0|851|1746|1754
SE|25462214|CONCLUSIONS|ab|8|entity|C0542339|Inferior|spco|||sub|||0|851|1755|1758
SE|25462214|CONCLUSIONS|ab|8|entity|C0037778|Medical Specialities|bmod|||specialty|||0|851|1759|1768
SE|25462214|CONCLUSIONS|ab|8|entity|C1321164|Gynecologic Oncology|bmod|||gynaecological oncology|||0|1000|1772|1795
SE|25462214|CONCLUSIONS|ab|8|entity|C0040607|Training Programs|edac|||training programme|||0|901|1811|1829
SE|25462214|CONCLUSIONS|ab|8|entity|C1554080|Key|idcn|||key|||0|1000|1841|1844
SE|25462214|CONCLUSIONS|ab|8|entity|C0205250|High|qlco|||higher|||0|872|1860|1866
SE|25462214|CONCLUSIONS|ab|8|entity|C0242428|Satisfaction|menp|||satisfaction|||0|872|1867|1879
SE|25462214|CONCLUSIONS|ab|8|entity|C0542559|contextual factors|ftcn|||setting|||0|1000|1888|1895
SE|25462214|CONCLUSIONS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1899|1907


SE|25462213||ti|1|text|21|98|Medical management of unwanted pregnancy in France: modalities and outcomes.
SE|25462213||ti|1|entity|C0205476|Medical|ftcn|||Medical|||0|888|21|28
SE|25462213||ti|1|entity|C0032995|Unwanted pregnancy|hcpp|||unwanted pregnancy|||0|1000|43|61
SE|25462213||ti|1|entity|C0016674|France|geoa|||France|||0|1000|65|71
SE|25462213||ti|1|entity|C0695347|Modality|idcn|||modalities|||0|966|73|83
SE|25462213||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|966|88|96

SE|25462213||ti|2|text|98|115|The aMaYa study.
SE|25462213||ti|2|entity|C0008972|Clinical Research|resa|||study|||0|861|108|113

SE|25462213|OBJECTIVES|ab|1|text|121|299|OBJECTIVES: Medical termination of pregnancy (MToP) has become more frequently used, and specific recommendations have been issued by the French Authorities regarding protocols.
SE|25462213|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|121|131
SE|25462213|OBJECTIVES|ab|1|entity|C0000820|Therapeutic Abortion|topp|||Medical termination of pregnancy|||0|1000|133|165
SE|25462213|OBJECTIVES|ab|1|entity|C0205172|More|ftcn|||more|||0|1000|184|188
SE|25462213|OBJECTIVES|ab|1|entity|C0332183|Frequent|tmco|||frequently|||0|1000|189|199
SE|25462213|OBJECTIVES|ab|1|entity|C0034866|Recommendation|idcn|||recommendations|||0|861|219|234
SE|25462213|OBJECTIVES|ab|1|entity|C0599437|Authority|socb|||Authorities|||0|827|266|277

SE|25462213|OBJECTIVES|ab|2|text|299|499|The aim of this prospective, multicenter, longitudinal observational study was to record actual practices and to describe efficacy and safety of drugs used for MToP in real-life conditions in France.
SE|25462213|OBJECTIVES|ab|2|entity|C0033522|Prospective Studies|qnco,resa|||prospective, multicenter, longitudinal observational study|||0|902|315|373
SE|25462213|OBJECTIVES|ab|2|entity|C0237400|Actual|qlco|||actual|||0|1000|388|394
SE|25462213|OBJECTIVES|ab|2|entity|C0036043|Safety|hcpp|||safety|||0|1000|434|440
SE|25462213|OBJECTIVES|ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|444|449
SE|25462213|OBJECTIVES|ab|2|entity|C0000820|Therapeutic Abortion|topp|||MToP|||0|937|459|463
SE|25462213|OBJECTIVES|ab|2|entity|C0871222|Reality|idcn|||real|||0|853|467|471
SE|25462213|OBJECTIVES|ab|2|entity|C0376558|Life|idcn|||life|||0|853|472|476
SE|25462213|OBJECTIVES|ab|2|entity|C0016674|France|geoa|||France|||0|1000|491|497
SE|25462213|OBJECTIVES|ab|2|relation|6|5|C0033522|Prospective Studies|qnco,resa|resa|||prospective, multicenter, longitudinal observational study|||0|902|315|373|VERB|USES||450|454|2|1|C0000820|Therapeutic Abortion|topp|topp|||MToP|||0|937|459|463

SE|25462213|STUDY DESIGN|ab|3|text|499|624|STUDY DESIGN: The study was performed between 2011 and 2012 in a representative sample of 47 centers dealing with abortions.
SE|25462213|STUDY DESIGN|ab|3|entity|C0035171|Research Design|resa|||STUDY DESIGN|||0|1000|499|511
SE|25462213|STUDY DESIGN|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|517|522
SE|25462213|STUDY DESIGN|ab|3|entity|C0205099|Central|spco|||centers|||0|827|592|599
SE|25462213|STUDY DESIGN|ab|3|entity|C0156543|Unspecified Abortion|fndg|||abortions|||0|1000|613|622

SE|25462213|STUDY DESIGN|ab|4|text|624|861|Pregnant women with less than 14 weeks of amenorrhea, requesting MToP, for whom a drug regimen including mifepristone was decided, were recruited and information was recorded from the center and through the patient's auto questionnaire.
SE|25462213|STUDY DESIGN|ab|4|entity|C0033011|Pregnant Women|popg|||Pregnant women|||0|1000|624|638
SE|25462213|STUDY DESIGN|ab|4|entity|C0439230|week|tmco|||weeks|||0|861|657|662
SE|25462213|STUDY DESIGN|ab|4|entity|C0002453|Amenorrhea|dsyn|||amenorrhea|||0|1000|666|676
SE|25462213|STUDY DESIGN|ab|4|entity|C0000820|Therapeutic Abortion|topp|||MToP|||0|1000|689|693
SE|25462213|STUDY DESIGN|ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|888|706|710
SE|25462213|STUDY DESIGN|ab|4|entity|C0040808|Treatment Protocols|resa,topp|||regimen|||0|888|711|718
SE|25462213|STUDY DESIGN|ab|4|entity|C0026088|Mifepristone|phsu,strd|||mifepristone|||0|1000|729|741
SE|25462213|STUDY DESIGN|ab|4|entity|C1533716|Information|idcn|||information|||0|1000|774|785
SE|25462213|STUDY DESIGN|ab|4|entity|C0205099|Central|spco|||center|||0|1000|808|814
SE|25462213|STUDY DESIGN|ab|4|entity|C0030705|Patients|podg|||patient's|||0|851|831|840
SE|25462213|STUDY DESIGN|ab|4|entity|C1441488|AUTO|lbpr|||auto|||0|851|841|845
SE|25462213|STUDY DESIGN|ab|4|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|851|846|859
SE|25462213|STUDY DESIGN|ab|4|relation|0|0|C0040808|Treatment Protocols|resa,topp|topp|||regimen|||0|888|711|718|MOD/HEAD|USES||706|718|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|888|706|710

SE|25462213|STUDY DESIGN|ab|5|text|861|939|The main efficacy parameter was complete abortion without surgical procedure.
SE|25462213|STUDY DESIGN|ab|5|entity|C0205225|Primary|qlco|||main|||0|802|865|869
SE|25462213|STUDY DESIGN|ab|5|entity|C0549193|Parameter|spco|||parameter|||0|802|879|888
SE|25462213|STUDY DESIGN|ab|5|entity|C0205197|Complete|qlco|||complete|||0|888|893|901
SE|25462213|STUDY DESIGN|ab|5|entity|C0000811|Termination of pregnancy|topp|||abortion|||0|888|902|910
SE|25462213|STUDY DESIGN|ab|5|entity|C0543467|Operative Surgical Procedures|topp|||surgical procedure|||0|1000|919|937

SE|25462213|RESULTS|ab|6|text|939|1030|RESULTS: A total of 1585 women (mean age: 27.6 +/- 6.8 years) were included by 47 centers.
SE|25462213|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|939|946
SE|25462213|RESULTS|ab|6|entity|C0439175|% of total|qnco|||total|||0|1000|950|955
SE|25462213|RESULTS|ab|6|entity|C0043210|Woman|popg|||women|||0|861|964|969
SE|25462213|RESULTS|ab|6|entity|C0001779|Age|orga|||age|||0|861|976|979
SE|25462213|RESULTS|ab|6|entity|C0439234|year|tmco|||years|||0|804|994|999
SE|25462213|RESULTS|ab|6|entity|C0205099|Central|spco|||centers|||0|827|1021|1028

SE|25462213|RESULTS|ab|7|text|1030|1218|At inclusion time, when women were given mifepristone, the mean term of pregnancy was 46.5 +/- 7.8 days of amenorrhea (DA), the term was >49 DA for 28.3% of patients, and >63 DA for 1.6%.
SE|25462213|RESULTS|ab|7|entity|C1512693|Inclusion|qlco|||inclusion|||0|888|1033|1042
SE|25462213|RESULTS|ab|7|entity|C0040223|Time|tmco|||time|||0|888|1043|1047
SE|25462213|RESULTS|ab|7|entity|C0043210|Woman|popg|||women|||0|1000|1054|1059
SE|25462213|RESULTS|ab|7|entity|C0026088|Mifepristone|phsu,strd|||mifepristone|||0|1000|1071|1083
SE|25462213|RESULTS|ab|7|entity|C1515273|Term|tmco|||term|||0|861|1094|1098
SE|25462213|RESULTS|ab|7|entity|C0032961|Pregnancy|orgf|||pregnancy|||0|1000|1102|1111
SE|25462213|RESULTS|ab|7|entity|C1547085|7 days|tmco|||7.8 days|||0|765|1125|1133
SE|25462213|RESULTS|ab|7|entity|C0002453|Amenorrhea|dsyn|||amenorrhea|||0|765|1137|1147
SE|25462213|RESULTS|ab|7|entity|C1515273|Term|tmco|||term|||0|1000|1158|1162
SE|25462213|RESULTS|ab|7|entity|C0439228|day|tmco|||DA|||0|763|1171|1173
SE|25462213|RESULTS|ab|7|entity|C0002453|Amenorrhea|dsyn|||DA|||0|763|1171|1173
SE|25462213|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|1000|1187|1195
SE|25462213|RESULTS|ab|7|entity|C0439228|day|tmco|||DA|||0|763|1205|1207
SE|25462213|RESULTS|ab|7|entity|C0002453|Amenorrhea|dsyn|||DA|||0|763|1205|1207
SE|25462213|RESULTS|ab|7|relation|5|1|C0026088|Mifepristone|phsu,strd|phsu|||mifepristone|||0|1000|1071|1083|VERB|ADMINISTERED_TO||1065|1070|2|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1054|1059

SE|25462213|RESULTS|ab|8|text|1218|1524|The most frequently used protocol was the one recommended by the French authorities (mifepristone 600 mg-misoprostol 400 MUg oral), used in 35.4% of patients, but other protocols were used (mifepristone 600 mg or 200mg in association with misoprostol 2 * 400 MUg per os, for respectively 23.4% and 13.5%).
SE|25462213|RESULTS|ab|8|entity|C0205393|Most|qnco|||most|||0|815|1222|1226
SE|25462213|RESULTS|ab|8|entity|C0332183|Frequent|tmco|||frequently|||0|815|1227|1237
SE|25462213|RESULTS|ab|8|entity|C0042153|utilization qualifier|ftcn|||used|||0|815|1238|1242
SE|25462213|RESULTS|ab|8|entity|C0442711|Protocols documentation|inpr|||protocol|||0|815|1243|1251
SE|25462213|RESULTS|ab|8|entity|C0205447|One|qnco|||one|||0|1000|1260|1263
SE|25462213|RESULTS|ab|8|entity|C0599437|Authority|socb|||authorities|||0|827|1290|1301
SE|25462213|RESULTS|ab|8|entity|C0026088|Mifepristone|phsu,strd|||mifepristone|||0|552|1303|1315
SE|25462213|RESULTS|ab|8|entity|C0085174|Misoprostol|eico,phsu|||misoprostol|||0|552|1323|1334
SE|25462213|RESULTS|ab|8|entity|C0442027|Oral|spco|||oral|||0|1000|1343|1347
SE|25462213|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1367|1375
SE|25462213|RESULTS|ab|8|entity|C0026088|Mifepristone|phsu,strd|||mifepristone|||0|802|1408|1420
SE|25462213|RESULTS|ab|8|entity|C0085174|Misoprostol|eico,phsu|||misoprostol|||0|861|1457|1468
SE|25462213|RESULTS|ab|8|entity|C0205531|Oral route|ftcn|||per os|||0|694|1481|1487

SE|25462213|RESULTS|ab|9|text|1524|1583|Gemeprost prostaglandin was used by 1.4% of patients only.
SE|25462213|RESULTS|ab|9|entity|C0044923|gemeprost|eico,phsu|||Gemeprost|||0|888|1524|1533
SE|25462213|RESULTS|ab|9|entity|C0033554|Prostaglandins|bacs,eico,phsu|||prostaglandin|||0|888|1534|1547
SE|25462213|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|861|1568|1576
SE|25462213|RESULTS|ab|9|relation|0|0|C0044923|gemeprost|eico,phsu|eico|||Gemeprost|||0|888|1524|1533|MOD/HEAD|ISA||1524|1547|0|0|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandin|||0|888|1534|1547

SE|25462213|RESULTS|ab|10|text|1583|1677|Of the patients, 10.3% did not return to the center and were considered as lost to follow up.
SE|25462213|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1590|1598
SE|25462213|RESULTS|ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1610|1613
SE|25462213|RESULTS|ab|10|entity|C0205099|Central|spco|||center|||0|1000|1628|1634
SE|25462213|RESULTS|ab|10|entity|C1522577|follow-up|hlca|||follow up|||0|901|1666|1675

SE|25462213|RESULTS|ab|11|text|1677|1775|For the 1421 patients for whom information was available, the successful abortion rate was 94.4%.
SE|25462213|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|861|1690|1698
SE|25462213|RESULTS|ab|11|entity|C1533716|Information|idcn|||information|||0|1000|1708|1719
SE|25462213|RESULTS|ab|11|entity|C1272703|Successful|qlco|||successful|||0|901|1739|1749
SE|25462213|RESULTS|ab|11|entity|C0000794|Abortion Rate|qnco|||abortion rate|||0|901|1750|1763

SE|25462213|RESULTS|ab|12|text|1775|1893|In the remaining 5.6% there were no ongoing pregnancies, but their condition required a secondary surgical procedure.
SE|25462213|RESULTS|ab|12|entity|C1527428|Remaining|qlco|||remaining|||0|827|1782|1791
SE|25462213|RESULTS|ab|12|entity|C0032961|Pregnancy|orgf|||pregnancies|||0|861|1819|1830
SE|25462213|RESULTS|ab|12|entity|C0348080|Condition|qlco|||condition|||0|1000|1842|1851
SE|25462213|RESULTS|ab|12|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|901|1873|1881
SE|25462213|RESULTS|ab|12|entity|C0445275|Secondary procedure|topp|||secondary surgical procedure|||0|901|1863|1891

SE|25462213|RESULTS|ab|13|text|1893|1973|Over 90% of the 1421 patients with follow-up were satisfied with the procedure.
SE|25462213|RESULTS|ab|13|entity|C0205136|Over|spco|||Over|||0|888|1893|1897
SE|25462213|RESULTS|ab|13|entity|C0439083|>90|qnco|||90|||0|888|1898|1900
SE|25462213|RESULTS|ab|13|entity|C0030705|Patients|podg|||patients|||0|861|1914|1922
SE|25462213|RESULTS|ab|13|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1928|1937
SE|25462213|RESULTS|ab|13|entity|C0184661|Procedures|hlca|||procedure|||0|1000|1962|1971

SE|25462213|RESULTS|ab|14|text|1973|2099|Safety was good, with only 16 cases of major bleeding(1%), and one of endometritis (0.1%) reported as serious adverse events.
SE|25462213|RESULTS|ab|14|entity|C0036043|Safety|hcpp|||Safety|||0|1000|1973|1979
SE|25462213|RESULTS|ab|14|entity|C0205170|Good|qlco|||good|||0|1000|1984|1988
SE|25462213|RESULTS|ab|14|entity|C0868928|Case (situation)|ftcn|||cases|||0|827|2003|2008
SE|25462213|RESULTS|ab|14|entity|C0205164|Major|qlco|||major|||0|888|2012|2017
SE|25462213|RESULTS|ab|14|entity|C0019080|Hemorrhage|fndg|||bleeding|||0|888|2018|2026
SE|25462213|RESULTS|ab|14|entity|C0205447|One|qnco|||one|||0|1000|2036|2039
SE|25462213|RESULTS|ab|14|entity|C0014179|Endometritis|dsyn|||endometritis|||0|1000|2043|2055
SE|25462213|RESULTS|ab|14|entity|C1519255|Serious Adverse Event|fndg|||serious adverse events|||0|988|2075|2097

SE|25462213|CONCLUSION|ab|15|text|2099|2185|CONCLUSION: Our study showed, in real-life settings, a high rate of success for MToP.
SE|25462213|CONCLUSION|ab|15|entity|C0008972|Clinical Research|resa|||study|||0|1000|2115|2120
SE|25462213|CONCLUSION|ab|15|entity|C0871222|Reality|idcn|||real|||0|816|2132|2136
SE|25462213|CONCLUSION|ab|15|entity|C0376558|Life|idcn|||life|||0|816|2137|2141
SE|25462213|CONCLUSION|ab|15|entity|C0542559|contextual factors|ftcn|||settings|||0|816|2142|2150
SE|25462213|CONCLUSION|ab|15|entity|C0205250|High|qlco|||high|||0|888|2154|2158
SE|25462213|CONCLUSION|ab|15|entity|C1521828|Rate|qnco|||rate|||0|888|2159|2163
SE|25462213|CONCLUSION|ab|15|entity|C0597535|Success|socb|||success|||0|1000|2167|2174
SE|25462213|CONCLUSION|ab|15|entity|C0000820|Therapeutic Abortion|topp|||MToP|||0|937|2179|2183

SE|25462213|CONCLUSION|ab|16|text|2185|2303|Whatever the protocol used, this approach is effective, well tolerated, and satisfactory for the majority of patients.
SE|25462213|CONCLUSION|ab|16|entity|C0442711|Protocols documentation|inpr|||protocol|||0|1000|2198|2206
SE|25462213|CONCLUSION|ab|16|entity|C0449445|Approach|spco|||approach|||0|1000|2218|2226
SE|25462213|CONCLUSION|ab|16|entity|C0205170|Good|qlco|||well|||0|1000|2241|2245
SE|25462213|CONCLUSION|ab|16|entity|C1547307|Satisfactory|inpr|||satisfactory|||0|1000|2261|2273
SE|25462213|CONCLUSION|ab|16|entity|C0680220|majority|socb|||majority|||0|1000|2282|2290
SE|25462213|CONCLUSION|ab|16|entity|C0030705|Patients|podg|||patients|||0|1000|2294|2302


SE|25462215||ti|1|text|21|104|Cost-effectiveness analysis in the treatment of heavy menstrual bleeding in Spain.
SE|25462215||ti|1|entity|C1511536|Cost Effectiveness Analysis|ocac|||Cost-effectiveness analysis|||0|1000|21|48
SE|25462215||ti|1|entity|C0025344|Menstruation|orgf|||menstrual|||0|790|75|84
SE|25462215||ti|1|entity|C0019080|Hemorrhage|fndg|||bleeding|||0|790|85|93
SE|25462215||ti|1|entity|C0037747|Spain|geoa|||Spain|||0|1000|97|102

SE|25462215|OBJECTIVE|ab|1|text|110|259|OBJECTIVE: To compare the effectiveness and costs associated with first-line medical treatments for chronic heavy menstrual bleeding (HMB) in Spain.
SE|25462215|OBJECTIVE|ab|1|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|136|149
SE|25462215|OBJECTIVE|ab|1|entity|C1279901|Firstly|qlco|||first|||0|833|176|181
SE|25462215|OBJECTIVE|ab|1|entity|C0205132|Linear|spco|||line|||0|833|182|186
SE|25462215|OBJECTIVE|ab|1|entity|C0205476|Medical|ftcn|||medical|||0|833|187|194
SE|25462215|OBJECTIVE|ab|1|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|833|195|205
SE|25462215|OBJECTIVE|ab|1|entity|C0025344|Menstruation|orgf|||menstrual|||0|824|224|233
SE|25462215|OBJECTIVE|ab|1|entity|C0333278|Chronic hemorrhage|patf|||chronic heavy menstrual bleeding|||0|824|210|242
SE|25462215|OBJECTIVE|ab|1|entity|C0037747|Spain|geoa|||Spain|||0|1000|252|257
SE|25462215|OBJECTIVE|ab|1|relation|3|1|C0087111|Therapeutic procedure|topp|topp|||treatments|||0|833|195|205|PREP|TREATS||206|209|2|1|C0333278|Chronic hemorrhage|patf|patf|||chronic heavy menstrual bleeding|||0|824|210|242

SE|25462215|STUDY DESIGN|ab|2|text|259|523|STUDY DESIGN: A cost-effectiveness analysis was conducted comparing the levonorgestrel-releasing intrauterine system (LNG-IUS) with the estradiol valerate/dienogest multiphase oral contraceptive (E2V/DNG), combined oral contraceptives (COC) and progestins (PROG).
SE|25462215|STUDY DESIGN|ab|2|entity|C0035171|Research Design|resa|||STUDY DESIGN|||0|1000|259|271
SE|25462215|STUDY DESIGN|ab|2|entity|C1511536|Cost Effectiveness Analysis|ocac|||cost-effectiveness analysis|||0|1000|275|302
SE|25462215|STUDY DESIGN|ab|2|entity|C0023566|Levonorgestrel|phsu,strd|||levonorgestrel|||0|762|331|345
SE|25462215|STUDY DESIGN|ab|2|entity|C0694756|Intrauterine|bsoj|||intrauterine|||0|762|356|368
SE|25462215|STUDY DESIGN|ab|2|entity|C0449913|System|ftcn|||system|||0|762|369|375
SE|25462215|STUDY DESIGN|ab|2|entity|C0059623|estradiol valerate|horm,phsu,strd|||estradiol valerate|||0|786|395|413
SE|25462215|STUDY DESIGN|ab|2|entity|C0057916|dienogest|horm,phsu,strd|||dienogest|||0|786|414|423
SE|25462215|STUDY DESIGN|ab|2|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptive|||0|786|435|453
SE|25462215|STUDY DESIGN|ab|2|entity|C0009905|Contraceptives, Oral|phsu|||oral contraceptives|||0|1000|474|493
SE|25462215|STUDY DESIGN|ab|2|entity|C0033306|Progestins|horm,phsu,strd|||progestins|||0|1000|504|514
SE|25462215|STUDY DESIGN|ab|2|relation|4|3|C0009905|Contraceptives, Oral|phsu|phsu|||oral contraceptives|||0|1000|474|493|VERB|compared_with||317|326|4|4|C0033306|Progestins|horm,phsu,strd|horm|||progestins|||0|1000|504|514

SE|25462215|STUDY DESIGN|ab|3|text|523|616|Study patients were fertile women diagnosed with HMB who initially wished to remain fertile.
SE|25462215|STUDY DESIGN|ab|3|entity|C0008972|Clinical Research|resa|||Study|||0|888|523|528
SE|25462215|STUDY DESIGN|ab|3|entity|C0030705|Patients|podg|||patients|||0|888|529|537
SE|25462215|STUDY DESIGN|ab|3|entity|C0015895|Fertility|orgf|||fertile|||0|888|543|550
SE|25462215|STUDY DESIGN|ab|3|entity|C0043210|Woman|popg|||women|||0|888|551|556
SE|25462215|STUDY DESIGN|ab|3|entity|C0025344|Menstruation|orgf|||HMB|||0|790|572|575
SE|25462215|STUDY DESIGN|ab|3|entity|C0019080|Hemorrhage|fndg|||HMB|||0|790|572|575
SE|25462215|STUDY DESIGN|ab|3|entity|C0205265|Initially|tmco|||initially|||0|1000|580|589
SE|25462215|STUDY DESIGN|ab|3|entity|C0015895|Fertility|orgf|||fertile|||0|1000|607|614
SE|25462215|STUDY DESIGN|ab|3|relation|0|0|C0015895|Fertility|orgf|orgf|||fertile|||0|888|543|550|MOD/HEAD|PROCESS_OF||543|556|0|0|C0043210|Woman|popg,humn|humn|||women|||0|888|551|556
SE|25462215|STUDY DESIGN|ab|3|relation|2|1|C0019080|Hemorrhage|fndg|fndg|||HMB|||0|790|572|575|VERB|PROCESS_OF||557|566|2|1|C0043210|Woman|popg,humn|humn|||women|||0|888|551|556

SE|25462215|STUDY DESIGN|ab|4|text|616|711|A Markov model based on reported clinical data and the opinion of a panel of experts was used.
SE|25462215|STUDY DESIGN|ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|861|625|630
SE|25462215|STUDY DESIGN|ab|4|entity|C1516606|Clinical Data|inpr|||clinical data|||0|901|649|662
SE|25462215|STUDY DESIGN|ab|4|entity|C0871010|Opinions|menp|||opinion|||0|966|671|678

SE|25462215|STUDY DESIGN|ab|5|text|711|757|The time horizon of the analysis was 5 years.
SE|25462215|STUDY DESIGN|ab|5|entity|C0040223|Time|tmco|||time|||0|694|715|719
SE|25462215|STUDY DESIGN|ab|5|entity|C0936012|Analysis|resa|||analysis|||0|1000|735|743
SE|25462215|STUDY DESIGN|ab|5|entity|C0439234|year|tmco|||years|||0|888|750|755

SE|25462215|STUDY DESIGN|ab|6|text|757|926|The analysis was conducted from the perspective of the Spanish National Health System (NHS), discounting both costs (? 2013) and future effects at an annual rate of 3%.
SE|25462215|STUDY DESIGN|ab|6|entity|C0936012|Analysis|resa|||analysis|||0|1000|761|769
SE|25462215|STUDY DESIGN|ab|6|entity|C0086409|Hispanics|popg|||Spanish|||0|861|812|819
SE|25462215|STUDY DESIGN|ab|6|entity|C1456613|Health System|hcro|||Health System|||0|861|829|842
SE|25462215|STUDY DESIGN|ab|6|entity|C0016884|Future|tmco|||future|||0|872|886|892
SE|25462215|STUDY DESIGN|ab|6|entity|C1280500|Effect|qlco|||effects|||0|872|893|900
SE|25462215|STUDY DESIGN|ab|6|entity|C0332181|Annual|tmco|||annual|||0|888|907|913
SE|25462215|STUDY DESIGN|ab|6|entity|C1521828|Rate|qnco|||rate|||0|888|914|918

SE|25462215|STUDY DESIGN|ab|7|text|926|1048|One-way sensitivity analyses and probabilistic sensitivity analysis were performed to test the robustness of the results.
SE|25462215|STUDY DESIGN|ab|7|entity|C0205447|One|qnco|||One|||0|764|926|929
SE|25462215|STUDY DESIGN|ab|7|entity|C0936012|Analysis|resa|||analyses|||0|764|946|954
SE|25462215|STUDY DESIGN|ab|7|entity|C0936012|Analysis|resa|||analysis|||0|790|985|993
SE|25462215|STUDY DESIGN|ab|7|entity|C1274040|result|ftcn|||results|||0|966|1039|1046

SE|25462215|RESULTS|ab|8|text|1048|1226|RESULTS: In the analysis at 5 years, the LNG-IUS was associated with a gain of 0.67, 2.22, and 3.53 symptoms free months (SFM) compared with E2V/DNG, COC and PROG, respectively.
SE|25462215|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|1048|1055
SE|25462215|RESULTS|ab|8|entity|C0936012|Analysis|resa|||analysis|||0|1000|1064|1072
SE|25462215|RESULTS|ab|8|entity|C0439234|year|tmco|||years|||0|888|1078|1083
SE|25462215|RESULTS|ab|8|entity|C0023566|Levonorgestrel|phsu,strd|||LNG-IUS|||0|762|1089|1096
SE|25462215|RESULTS|ab|8|entity|C0694756|Intrauterine|bsoj|||LNG-IUS|||0|762|1089|1096
SE|25462215|RESULTS|ab|8|entity|C0449913|System|ftcn|||LNG-IUS|||0|762|1089|1096
SE|25462215|RESULTS|ab|8|entity|C1517378|Gain|qnco|||gain|||0|1000|1119|1123
SE|25462215|RESULTS|ab|8|entity|C1457887|Symptoms|sosy|||symptoms|||0|803|1148|1156
SE|25462215|RESULTS|ab|8|entity|C1442461|3 Months|tmco|||3.53 symptoms free months|||0|803|1143|1168
SE|25462215|RESULTS|ab|8|entity|C0009871|Contraceptive Agents|phsu|||COC|||0|1000|1198|1201
SE|25462215|RESULTS|ab|8|entity|C0033306|Progestins|horm,phsu,strd|||PROG|||0|1000|1206|1210
SE|25462215|RESULTS|ab|8|relation|3|2|C0009871|Contraceptive Agents|phsu|phsu|||COC|||0|1000|1198|1201|VERB|compared_with||1175|1183|3|3|C0033306|Progestins|horm,phsu,strd|horm|||PROG|||0|1000|1206|1210

SE|25462215|RESULTS|ab|9|text|1226|1376|LNG-IUS contributed more quality-adjusted life months (QALM) than the other treatment alternatives (+1.74 vs. E2V/DNG, +3.33 vs. COC +3.53 vs. PROG).
SE|25462215|RESULTS|ab|9|entity|C0023566|Levonorgestrel|phsu,strd|||LNG-IUS|||0|825|1226|1233
SE|25462215|RESULTS|ab|9|entity|C0694756|Intrauterine|bsoj|||LNG-IUS|||0|825|1226|1233
SE|25462215|RESULTS|ab|9|entity|C0449913|System|ftcn|||LNG-IUS|||0|825|1226|1233
SE|25462215|RESULTS|ab|9|entity|C0205172|More|ftcn|||more|||0|822|1246|1250
SE|25462215|RESULTS|ab|9|entity|C0332306|Quality|qlco|||quality|||0|822|1251|1258
SE|25462215|RESULTS|ab|9|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|822|1259|1267
SE|25462215|RESULTS|ab|9|entity|C0376558|Life|idcn|||life|||0|822|1268|1272
SE|25462215|RESULTS|ab|9|entity|C0439231|month|tmco|||months|||0|822|1273|1279
SE|25462215|RESULTS|ab|9|entity|C1523987|Alternative|cnce|||alternatives|||0|872|1312|1324
SE|25462215|RESULTS|ab|9|entity|C0009871|Contraceptive Agents|phsu|||COC|||0|827|1355|1358
SE|25462215|RESULTS|ab|9|entity|C0033306|Progestins|horm,phsu,strd|||PROG|||0|1000|1369|1373

SE|25462215|RESULTS|ab|10|text|1376|1430|First-line LNG-IUS treatment resulted in savings of ?
SE|25462215|RESULTS|ab|10|entity|C1279901|Firstly|qlco|||First|||0|804|1376|1381
SE|25462215|RESULTS|ab|10|entity|C0205132|Linear|spco|||line|||0|804|1382|1386
SE|25462215|RESULTS|ab|10|entity|C0023566|Levonorgestrel|phsu,strd|||LNG-IUS|||0|804|1387|1394
SE|25462215|RESULTS|ab|10|entity|C0694756|Intrauterine|bsoj|||LNG-IUS|||0|804|1387|1394
SE|25462215|RESULTS|ab|10|entity|C0449913|System|ftcn|||LNG-IUS|||0|804|1387|1394
SE|25462215|RESULTS|ab|10|entity|C0036245|Savings|qnco|||savings|||0|1000|1417|1424

SE|25462215|RESULTS|ab|11|text|1430|1437|583, ?

SE|25462215|RESULTS|ab|12|text|1437|1448|988, and ?

SE|25462215|RESULTS|ab|13|text|1448|1457|1891 vs.

SE|25462215|RESULTS|ab|14|text|1457|1494|E2V/DNG, COC and PROG, respectively.
SE|25462215|RESULTS|ab|14|entity|C0009871|Contraceptive Agents|phsu|||COC|||0|1000|1466|1469
SE|25462215|RESULTS|ab|14|entity|C0033306|Progestins|horm,phsu,strd|||PROG|||0|1000|1474|1478

SE|25462215|RESULTS|ab|15|text|1494|1659|These cost benefits, coupled with the greater clinical benefits in terms of SFM and QALM, show that LNG-IUS is the dominant option (less costly and more effective).
SE|25462215|RESULTS|ab|15|entity|C0010187|Cost Benefit|qnco|||cost benefits|||0|983|1500|1513
SE|25462215|RESULTS|ab|15|entity|C0443228|Largest|qnco|||greater|||0|851|1532|1539
SE|25462215|RESULTS|ab|15|entity|C0205210|Clinical|qlco|||clinical|||0|851|1540|1548
SE|25462215|RESULTS|ab|15|entity|C0814225|Benefits|qnco|||benefits|||0|851|1549|1557
SE|25462215|RESULTS|ab|15|entity|C1457887|Symptoms|sosy|||SFM|||0|802|1570|1573
SE|25462215|RESULTS|ab|15|entity|C0439231|month|tmco|||SFM|||0|802|1570|1573
SE|25462215|RESULTS|ab|15|entity|C0332306|Quality|qlco|||QALM|||0|833|1578|1582
SE|25462215|RESULTS|ab|15|entity|C1439356|ADJUSTED|qlco|||QALM|||0|833|1578|1582
SE|25462215|RESULTS|ab|15|entity|C0376558|Life|idcn|||QALM|||0|833|1578|1582
SE|25462215|RESULTS|ab|15|entity|C0439231|month|tmco|||QALM|||0|833|1578|1582
SE|25462215|RESULTS|ab|15|entity|C0023566|Levonorgestrel|phsu,strd|||LNG-IUS|||0|762|1594|1601
SE|25462215|RESULTS|ab|15|entity|C0694756|Intrauterine|bsoj|||LNG-IUS|||0|762|1594|1601
SE|25462215|RESULTS|ab|15|entity|C0449913|System|ftcn|||LNG-IUS|||0|762|1594|1601
SE|25462215|RESULTS|ab|15|entity|C1527180|Dominant|ftcn|||dominant|||0|888|1609|1617
SE|25462215|RESULTS|ab|15|entity|C1550456|option|idcn|||option|||0|888|1618|1624
SE|25462215|RESULTS|ab|15|entity|C0205172|More|ftcn|||more|||0|888|1642|1646

SE|25462215|CONCLUSION|ab|16|text|1659|1769|CONCLUSION: LNG-IUS is the medical treatment of choice and cost-saving option for the control of HMB in Spain.
SE|25462215|CONCLUSION|ab|16|entity|C0023566|Levonorgestrel|phsu,strd|||LNG-IUS|||0|825|1671|1678
SE|25462215|CONCLUSION|ab|16|entity|C0694756|Intrauterine|bsoj|||LNG-IUS|||0|825|1671|1678
SE|25462215|CONCLUSION|ab|16|entity|C0449913|System|ftcn|||LNG-IUS|||0|825|1671|1678
SE|25462215|CONCLUSION|ab|16|entity|C0205476|Medical|ftcn|||medical|||0|888|1686|1693
SE|25462215|CONCLUSION|ab|16|entity|C1550456|option|idcn|||option|||0|1000|1730|1736
SE|25462215|CONCLUSION|ab|16|entity|C0243148|control|ftcn|||control|||0|1000|1745|1752
SE|25462215|CONCLUSION|ab|16|entity|C0025344|Menstruation|orgf|||HMB|||0|790|1756|1759
SE|25462215|CONCLUSION|ab|16|entity|C0019080|Hemorrhage|fndg|||HMB|||0|790|1756|1759
SE|25462215|CONCLUSION|ab|16|entity|C0037747|Spain|geoa|||Spain|||0|1000|1763|1768


SE|25462216||ti|1|text|21|140|Chaos in balance: non-linear measures of postural control predict individual variations in visual illusions of motion.
SE|25462216||ti|1|entity|C1194380|Chaos|invt|||Chaos|||0|1000|21|26
SE|25462216||ti|1|entity|C0014653|Equilibrium|orgf|||balance|||0|1000|30|37
SE|25462216||ti|1|entity|C0205132|Linear|spco|||linear|||0|790|43|49
SE|25462216||ti|1|entity|C0079809|Measures|qnco|||measures|||0|790|50|58
SE|25462216||ti|1|entity|C0205278|Postural|ftcn|||postural|||0|888|62|70
SE|25462216||ti|1|entity|C0243148|control|ftcn|||control|||0|888|71|78
SE|25462216||ti|1|entity|C0237401|Individual|humn|||individual|||0|872|87|97
SE|25462216||ti|1|entity|C0205419|Variant|qlco|||variations|||0|872|98|108
SE|25462216||ti|1|entity|C0751246|Illusions, Visual|mobd|||visual illusions|||0|1000|112|128
SE|25462216||ti|1|entity|C0026597|Motion|npop|||motion|||0|1000|132|138

SE|25462216||ab|1|text|146|298|Visually-induced illusions of self-motion (vection) can be compelling for some people, but they are subject to large individual variations in strength.
SE|25462216||ab|1|entity|C0205263|Induced|ftcn|||induced|||0|790|155|162
SE|25462216||ab|1|entity|C0020903|Illusions|mobd|||illusions|||0|790|163|172
SE|25462216||ab|1|entity|C0036588|Self|idcn|||self|||0|888|176|180
SE|25462216||ab|1|entity|C0026597|Motion|npop|||motion|||0|888|181|187
SE|25462216||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|225|231
SE|25462216||ab|1|entity|C0549177|Large|qnco|||large|||0|840|257|262
SE|25462216||ab|1|entity|C0237401|Individual|humn|||individual|||0|840|263|273
SE|25462216||ab|1|entity|C0205419|Variant|qlco|||variations|||0|840|274|284
SE|25462216||ab|1|entity|C0808080|STRENGTH|idcn|||strength|||0|1000|288|296
SE|25462216||ab|1|relation|0|0|C0237401|Individual|grup,humn|grup|||individual|||0|840|263|273|SPEC|ISA||225|273|0|0|C0027361|Persons|popg,humn|popg|||people|||0|1000|225|231

SE|25462216||ab|2|text|298|427|Do these variations depend, at least in part, on the extent to which people rely on vision to maintain their postural stability?
SE|25462216||ab|2|entity|C0205419|Variant|qlco|||variations|||0|966|307|317
SE|25462216||ab|2|entity|C0449719|Part|spco|||part|||0|1000|338|342
SE|25462216||ab|2|entity|C0439792|Extent|spco|||extent|||0|1000|351|357
SE|25462216||ab|2|entity|C0027361|Persons|popg|||people|||0|1000|367|373
SE|25462216||ab|2|entity|C0042789|Vision|orgf|||vision|||0|1000|382|388
SE|25462216||ab|2|entity|C0205278|Postural|ftcn|||postural|||0|888|407|415
SE|25462216||ab|2|entity|C1317741|STABILITY|qlco|||stability|||0|888|416|425

SE|25462216||ab|3|text|427|513|We investigated by comparing physical posture measures to subjective vection ratings.
SE|25462216||ab|3|entity|C0205485|Physical|ftcn|||physical|||0|790|456|464
SE|25462216||ab|3|entity|C0032818|Posture|orga|||posture|||0|790|465|472
SE|25462216||ab|3|entity|C0439655|Subjective|qlco|||subjective|||0|785|485|495
SE|25462216||ab|3|entity|C0871208|Rating|resa|||ratings|||0|785|504|511

SE|25462216||ab|4|text|513|724|Using a Bertec balance plate in a brightly-lit room, we measured 13 participants' excursions of the centre of foot pressure (CoP) over a 60-second period with eyes open and with eyes closed during quiet stance.
SE|25462216||ab|4|entity|C0014653|Equilibrium|orgf|||balance|||0|790|528|535
SE|25462216||ab|4|entity|C0005971|Bone plates|medd|||plate|||0|790|536|541
SE|25462216||ab|4|entity|C0023693|Light|npop|||lit|||0|790|556|559
SE|25462216||ab|4|entity|C1547703|Room|spco|||room|||0|790|560|564
SE|25462216||ab|4|entity|C0679646|Participant|popg|||participants|||0|627|581|593
SE|25462216||ab|4|entity|C0205099|Central|spco|||centre|||0|719|613|619
SE|25462216||ab|4|entity|C0016504|Pes|bpoc|||foot|||0|719|623|627
SE|25462216||ab|4|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|719|628|636
SE|25462216||ab|4|entity|C0205136|Over|spco|||over|||0|1000|643|647
SE|25462216||ab|4|entity|C0457385|seconds|tmco|||second|||0|790|653|659
SE|25462216||ab|4|entity|C0439531|/period|tmco|||period|||0|790|660|666
SE|25462216||ab|4|entity|C0015392|Eye|bpoc|||eyes|||0|1000|672|676
SE|25462216||ab|4|entity|C0015392|Eye|bpoc|||eyes|||0|1000|691|695
SE|25462216||ab|4|entity|C0439654|Quiet|qlco|||quiet|||0|694|710|715

SE|25462216||ab|5|text|724|876|Subsequently, we collected vection strength ratings for large optic flow displays while seated, using both verbal ratings and online throttle measures.
SE|25462216||ab|5|entity|C0808080|STRENGTH|idcn|||strength|||0|773|759|767
SE|25462216||ab|5|entity|C0871208|Rating|resa|||ratings|||0|773|768|775
SE|25462216||ab|5|entity|C0549177|Large|qnco|||large|||0|833|780|785
SE|25462216||ab|5|entity|C0029144|Optics|ocdi|||optic|||0|833|786|791
SE|25462216||ab|5|entity|C0806140|Flow|orga|||flow|||0|833|792|796
SE|25462216||ab|5|entity|C0870432|Display - arrangement|ftcn|||displays|||0|833|797|805
SE|25462216||ab|5|entity|C0439824|Verbal|orgf|||verbal|||0|872|831|837
SE|25462216||ab|5|entity|C0871208|Rating|resa|||ratings|||0|872|838|845
SE|25462216||ab|5|entity|C0079809|Measures|qnco|||measures|||0|827|866|874

SE|25462216||ab|6|text|876|1031|We also collected measures of postural sway (changes in anterior-posterior CoP) in response to the same visual motion stimuli while standing on the plate.
SE|25462216||ab|6|entity|C1516695|Collected|idcn|||collected|||0|790|884|893
SE|25462216||ab|6|entity|C0079809|Measures|qnco|||measures|||0|790|894|902
SE|25462216||ab|6|entity|C0205278|Postural|ftcn|||postural|||0|694|906|914
SE|25462216||ab|6|entity|C0886365|Anterior-Posterior|spco|||anterior-posterior|||0|742|932|950
SE|25462216||ab|6|entity|C0205099|Central|spco|||CoP|||0|742|951|954
SE|25462216||ab|6|entity|C0016504|Pes|bpoc|||CoP|||0|742|951|954
SE|25462216||ab|6|entity|C0033095|Pressure- physical agent|phpr|||CoP|||0|742|951|954
SE|25462216||ab|6|entity|C0445247|Same|qlco|||same|||0|852|975|979
SE|25462216||ab|6|entity|C0026597|Motion|npop|||motion|||0|852|987|993
SE|25462216||ab|6|entity|C0597664|visual stimulus|ortf|||visual motion stimuli|||0|852|980|1001
SE|25462216||ab|6|entity|C0005971|Bone plates|medd|||plate|||0|1000|1024|1029

SE|25462216||ab|7|text|1031|1212|The magnitude of standing sway in response to expanding optic flow (in comparison to blank fixation periods) was predictive of both verbal and throttle measures for seated vection.
SE|25462216||ab|7|entity|C0449286|Degree or extent|qnco|||magnitude|||0|966|1035|1044
SE|25462216||ab|7|entity|C0231472|Orthostatic body position|spco|||standing|||0|694|1048|1056
SE|25462216||ab|7|entity|C0205229|Expanding|spco|||expanding|||0|851|1077|1086
SE|25462216||ab|7|entity|C0029144|Optics|ocdi|||optic|||0|851|1087|1092
SE|25462216||ab|7|entity|C0806140|Flow|orga|||flow|||0|851|1093|1097
SE|25462216||ab|7|entity|C0439531|/period|tmco|||periods|||0|827|1131|1138
SE|25462216||ab|7|entity|C0681890|predictive|qlco|||predictive|||0|1000|1144|1154
SE|25462216||ab|7|entity|C0439824|Verbal|orgf|||verbal|||0|1000|1163|1169
SE|25462216||ab|7|entity|C0079809|Measures|qnco|||measures|||0|861|1183|1191
SE|25462216||ab|7|entity|C1283233|Seating|mnob|||seated|||0|661|1196|1202

SE|25462216||ab|8|text|1212|1396|In addition, the ratio between eyes-open and eyes-closed CoP excursions during quiet stance (using the area of postural sway) significantly predicted seated vection for both measures.
SE|25462216||ab|8|entity|C0456603|Ratio|inpr|||ratio|||0|1000|1229|1234
SE|25462216||ab|8|entity|C0015392|Eye|bpoc|||eyes|||0|888|1243|1247
SE|25462216||ab|8|entity|C0175566|Open|spco|||open|||0|888|1248|1252
SE|25462216||ab|8|entity|C0015392|Eye|bpoc|||eyes|||0|724|1257|1261
SE|25462216||ab|8|entity|C0587267|Closed|ftcn|||closed|||0|724|1262|1268
SE|25462216||ab|8|entity|C0205099|Central|spco|||CoP|||0|724|1269|1272
SE|25462216||ab|8|entity|C0016504|Pes|bpoc|||CoP|||0|724|1269|1272
SE|25462216||ab|8|entity|C0033095|Pressure- physical agent|phpr|||CoP|||0|724|1269|1272
SE|25462216||ab|8|entity|C0439654|Quiet|qlco|||quiet|||0|694|1291|1296
SE|25462216||ab|8|entity|C0205146|Area|spco|||area|||0|1000|1315|1319
SE|25462216||ab|8|entity|C0205278|Postural|ftcn|||postural|||0|694|1323|1331
SE|25462216||ab|8|entity|C1283233|Seating|mnob|||seated|||0|661|1362|1368
SE|25462216||ab|8|entity|C0079809|Measures|qnco|||measures|||0|1000|1386|1394

SE|25462216||ab|9|text|1396|1539|Interestingly, these relationships were weaker for contracting optic flow displays, though these produced both stronger vection and more sway.
SE|25462216||ab|9|entity|C0439849|Relationships|qlco|||relationships|||0|1000|1417|1430
SE|25462216||ab|9|entity|C0004093|Asthenia|sosy|||weaker|||0|966|1436|1442
SE|25462216||ab|9|entity|C0332522|Contract agreement|inpr|||contracting|||0|833|1447|1458
SE|25462216||ab|9|entity|C0029144|Optics|ocdi|||optic|||0|833|1459|1464
SE|25462216||ab|9|entity|C0806140|Flow|orga|||flow|||0|833|1465|1469
SE|25462216||ab|9|entity|C0870432|Display - arrangement|ftcn|||displays|||0|833|1470|1478
SE|25462216||ab|9|entity|C0442821|Strong|qlco|||stronger|||0|661|1507|1515
SE|25462216||ab|9|entity|C0205172|More|ftcn|||more|||0|1000|1528|1532

SE|25462216||ab|10|text|1539|1823|Next we used a non-linear analysis (recurrence quantification analysis, RQA) of the fluctuations in anterior-posterior position during quiet stance (both with eyes closed and eyes open); this was a much stronger predictor of seated vection for both expanding and contracting stimuli.
SE|25462216||ab|10|entity|C1552851|next|idcn|||Next|||0|1000|1539|1543
SE|25462216||ab|10|entity|C0205132|Linear|spco|||linear|||0|790|1558|1564
SE|25462216||ab|10|entity|C0936012|Analysis|resa|||analysis|||0|790|1565|1573
SE|25462216||ab|10|entity|C0034897|Recurrence|phpr|||recurrence|||0|802|1575|1585
SE|25462216||ab|10|entity|C0936012|Analysis|resa|||analysis|||0|802|1601|1609
SE|25462216||ab|10|entity|C0231239|Fluctuation|sosy|||fluctuations|||0|966|1623|1635
SE|25462216||ab|10|entity|C0886365|Anterior-Posterior|spco|||anterior-posterior|||0|901|1639|1657
SE|25462216||ab|10|entity|C0733755|Positioning Attribute|spco|||position|||0|901|1658|1666
SE|25462216||ab|10|entity|C0439654|Quiet|qlco|||quiet|||0|694|1674|1679
SE|25462216||ab|10|entity|C0015392|Eye|bpoc|||eyes|||0|1000|1698|1702
SE|25462216||ab|10|entity|C0015392|Eye|bpoc|||eyes|||0|1000|1714|1718
SE|25462216||ab|10|entity|C0442821|Strong|qlco|||stronger|||0|661|1742|1750
SE|25462216||ab|10|entity|C1283233|Seating|mnob|||seated|||0|661|1764|1770
SE|25462216||ab|10|entity|C0205229|Expanding|spco|||expanding|||0|1000|1788|1797
SE|25462216||ab|10|entity|C0332522|Contract agreement|inpr|||contracting|||0|888|1802|1813
SE|25462216||ab|10|entity|C0234402|Stimulus|phpr|||stimuli|||0|888|1814|1821

SE|25462216||ab|11|text|1823|2083|Given the complex multisensory integration involved in postural control, our study adds to the growing evidence that non-linear measures drawn from complexity theory may provide a more informative measure of postural sway than the conventional linear measures.
SE|25462216||ab|11|entity|C0439855|Complex|qlco|||complex|||0|660|1833|1840
SE|25462216||ab|11|entity|C0205278|Postural|ftcn|||postural|||0|888|1878|1886
SE|25462216||ab|11|entity|C0243148|control|ftcn|||control|||0|888|1887|1894
SE|25462216||ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|1900|1905
SE|25462216||ab|11|entity|C0205132|Linear|spco|||linear|||0|790|1944|1950
SE|25462216||ab|11|entity|C0079809|Measures|qnco|||measures|||0|790|1951|1959
SE|25462216||ab|11|entity|C0439855|Complex|qlco|||complexity|||0|836|1971|1981
SE|25462216||ab|11|entity|C0871935|Theories|idcn|||theory|||0|836|1982|1988
SE|25462216||ab|11|entity|C0205172|More|ftcn|||more|||0|802|2003|2007
SE|25462216||ab|11|entity|C0079809|Measures|qnco|||measure|||0|802|2020|2027
SE|25462216||ab|11|entity|C0205278|Postural|ftcn|||postural|||0|694|2031|2039
SE|25462216||ab|11|entity|C0439858|Conventional|qlco|||conventional|||0|851|2054|2066
SE|25462216||ab|11|entity|C0205132|Linear|spco|||linear|||0|851|2067|2073
SE|25462216||ab|11|entity|C0079809|Measures|qnco|||measures|||0|851|2074|2082


SE|25462217||ti|1|text|21|111|Blunted cardiovascular reactivity in dysphoria during reward and punishment anticipation.
SE|25462217||ti|1|entity|C0870246|Cardiovascular Reactivity|qlco|||cardiovascular reactivity|||0|901|29|54
SE|25462217||ti|1|entity|C0233477|Dysphoric mood|mobd|||dysphoria|||0|1000|58|67
SE|25462217||ti|1|entity|C0035397|Rewards|menp|||reward|||0|1000|75|81
SE|25462217||ti|1|entity|C0034119|Punishment|idcn|||punishment|||0|888|86|96
SE|25462217||ti|1|entity|C0679106|anticipation|menp|||anticipation|||0|888|97|109

SE|25462217||ab|1|text|117|226|Hyposensitivity to reward in depression and dysphoria has been found in behavioral and neuroimaging studies.
SE|25462217||ab|1|entity|C0233490|Hyposensitivity|sosy|||Hyposensitivity|||0|1000|117|132
SE|25462217||ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|146|156
SE|25462217||ab|1|entity|C0233477|Dysphoric mood|mobd|||dysphoria|||0|1000|161|170
SE|25462217||ab|1|entity|C0679575|neuroimaging|diap|||neuroimaging|||0|872|204|216
SE|25462217||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|217|224

SE|25462217||ab|2|text|226|358|For punishment responsiveness, some studies showed hyposensitivity to punishment while other studies demonstrated hypersensitivity.
SE|25462217||ab|2|entity|C0034119|Punishment|idcn|||punishment|||0|853|230|240
SE|25462217||ab|2|entity|C0205342|Responsive|ftcn|||responsiveness|||0|853|241|255
SE|25462217||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|966|262|269
SE|25462217||ab|2|entity|C0233490|Hyposensitivity|sosy|||hyposensitivity|||0|1000|277|292
SE|25462217||ab|2|entity|C0034119|Punishment|idcn|||punishment|||0|1000|296|306
SE|25462217||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|966|319|326
SE|25462217||ab|2|entity|C0020517|Hypersensitivity|patf|||hypersensitivity|||0|1000|340|356

SE|25462217||ab|3|text|358|530|Only few studies have addressed the motivational question as to whether depressed individuals mobilize less effort in anticipation of a positive or a negative consequence.
SE|25462217||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|793|367|374
SE|25462217||ab|3|entity|C0026605|Motivation|menp|||motivational|||0|623|394|406
SE|25462217||ab|3|entity|C0237401|Individual|humn|||individuals|||0|861|440|451
SE|25462217||ab|3|entity|C0679106|anticipation|menp|||anticipation|||0|1000|476|488
SE|25462217||ab|3|entity|C1446409|Positive|qlco|||positive|||0|1000|494|502
SE|25462217||ab|3|entity|C0205160|Negative|qlco|||negative|||0|694|508|516

SE|25462217||ab|4|text|530|675|The present study aimed at investigating reward and punishment responsiveness in subclinical depression from an effort mobilization perspective.
SE|25462217||ab|4|entity|C0150312|Present|qnco|||present|||0|888|534|541
SE|25462217||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|888|542|547
SE|25462217||ab|4|entity|C1292732|Investigates|ftcn|||investigating|||0|872|557|570
SE|25462217||ab|4|entity|C0035397|Rewards|menp|||reward|||0|872|571|577
SE|25462217||ab|4|entity|C0034119|Punishment|idcn|||punishment|||0|853|582|592
SE|25462217||ab|4|entity|C0205342|Responsive|ftcn|||responsiveness|||0|853|593|607
SE|25462217||ab|4|entity|C0205211|Subclinical|qlco|||subclinical|||0|888|611|622
SE|25462217||ab|4|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|623|633
SE|25462217||ab|4|entity|C0300926|mobilization|ftcn|||mobilization|||0|623|649|661

SE|25462217||ab|5|text|675|872|Working on a recognition memory task, one third of the participants could earn small amounts of money, one third could lose small amounts of money, and one third could neither earn nor lose money.
SE|25462217||ab|5|entity|C0043227|Work|ocac|||Working|||0|1000|675|682
SE|25462217||ab|5|entity|C0025260|Memory|menp|||memory|||0|790|700|706
SE|25462217||ab|5|entity|C0205447|One|qnco|||one|||0|888|713|716
SE|25462217||ab|5|entity|C0205437|Third|qnco|||third|||0|888|717|722
SE|25462217||ab|5|entity|C0679646|Participant|popg|||participants|||0|966|730|742
SE|25462217||ab|5|entity|C0700321|Small|qnco|||small|||0|872|754|759
SE|25462217||ab|5|entity|C1265611|Quantity|qnco|||amounts|||0|872|760|767
SE|25462217||ab|5|entity|C0870909|Money|mnob|||money|||0|1000|771|776
SE|25462217||ab|5|entity|C0205447|One|qnco|||one|||0|1000|778|781
SE|25462217||ab|5|entity|C0205437|Third|qnco|||third|||0|1000|782|787
SE|25462217||ab|5|entity|C0700321|Small|qnco|||small|||0|872|799|804
SE|25462217||ab|5|entity|C1265611|Quantity|qnco|||amounts|||0|872|805|812
SE|25462217||ab|5|entity|C0870909|Money|mnob|||money|||0|1000|816|821
SE|25462217||ab|5|entity|C0205447|One|qnco|||one|||0|1000|827|830
SE|25462217||ab|5|entity|C0205437|Third|qnco|||third|||0|1000|831|836
SE|25462217||ab|5|entity|C0870909|Money|mnob|||money|||0|1000|865|870

SE|25462217||ab|6|text|872|980|Effort mobilization was operationalized as participants' cardiovascular reactivity during task performance.
SE|25462217||ab|6|entity|C0300926|mobilization|ftcn|||mobilization|||0|888|879|891
SE|25462217||ab|6|entity|C0679646|Participant|popg|||participants|||0|890|915|927
SE|25462217||ab|6|entity|C0870246|Cardiovascular Reactivity|qlco|||cardiovascular reactivity|||0|890|929|954
SE|25462217||ab|6|entity|C0039333|Task Performance|topp|||task performance|||0|1000|962|978

SE|25462217||ab|7|text|980|1198|As expected, reactivity of cardiac pre-ejection period and heart rate was higher in both incentive conditions compared to the neutral condition for nondysphorics, while it was blunted across conditions for dysphorics.
SE|25462217||ab|7|entity|C0205332|Reactive|qlco|||reactivity|||0|928|993|1003
SE|25462217||ab|7|entity|C0018787|Heart|bpoc|||cardiac|||0|916|1007|1014
SE|25462217||ab|7|entity|C0807477|PRE EJECTION PERIOD|orga|||pre-ejection period|||0|916|1015|1034
SE|25462217||ab|7|entity|C0018810|heart rate|orga|||heart rate|||0|1000|1039|1049
SE|25462217||ab|7|entity|C0205250|High|qlco|||higher|||0|966|1054|1060
SE|25462217||ab|7|entity|C0021147|Incentives|qlco|||incentive|||0|872|1069|1078
SE|25462217||ab|7|entity|C0348080|Condition|qlco|||conditions|||0|872|1079|1089
SE|25462217||ab|7|entity|C0348080|Condition|qlco|||condition|||0|861|1114|1123
SE|25462217||ab|7|entity|C0348080|Condition|qlco|||conditions|||0|966|1171|1181

SE|25462217||ab|8|text|1198|1299|Moreover, the present study found that dysphorics show an altered behavioral response to punishment.
SE|25462217||ab|8|entity|C0150312|Present|qnco|||present|||0|888|1212|1219
SE|25462217||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|888|1220|1225
SE|25462217||ab|8|entity|C0205349|Altered|ftcn|||altered|||0|802|1256|1263
SE|25462217||ab|8|entity|C0871261|response|clna|||response|||0|802|1275|1283
SE|25462217||ab|8|entity|C0034119|Punishment|idcn|||punishment|||0|1000|1287|1297

SE|25462217||ab|9|text|1299|1467|These findings thus show that dysphorics present a reduced motivation to obtain a reward or to avoid a punishment in terms of reduced effort-related cardiac reactivity.
SE|25462217||ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1305|1313
SE|25462217||ab|9|entity|C0392756|Reduced|qlco|||reduced|||0|888|1350|1357
SE|25462217||ab|9|entity|C0026605|Motivation|menp|||motivation|||0|888|1358|1368
SE|25462217||ab|9|entity|C0035397|Rewards|menp|||reward|||0|1000|1381|1387
SE|25462217||ab|9|entity|C0034119|Punishment|idcn|||punishment|||0|1000|1402|1412
SE|25462217||ab|9|entity|C0392756|Reduced|qlco|||reduced|||0|807|1425|1432
SE|25462217||ab|9|entity|C1522149|Related|ftcn|||related|||0|807|1440|1447
SE|25462217||ab|9|entity|C0018787|Heart|bpoc|||cardiac|||0|807|1448|1455
SE|25462217||ab|9|entity|C0205332|Reactive|qlco|||reactivity|||0|807|1456|1466


SE|25462218||ti|1|text|21|135|Topographic distribution of EEG alpha attractor correlation dimension values in wake and drowsy states in humans.
SE|25462218||ti|1|entity|C0412670|Digital slit-beam radiograph|diap|||Topographic|||0|853|21|32
SE|25462218||ti|1|entity|C0520511|Distributing|idcn|||distribution|||0|853|33|45
SE|25462218||ti|1|entity|C0013819|Electroencephalography|diap|||EEG|||0|746|49|52
SE|25462218||ti|1|entity|C0439095|Alpha|inpr|||alpha|||0|746|53|58
SE|25462218||ti|1|entity|C0439534|Dimensions|qnco|||dimension|||0|746|81|90
SE|25462218||ti|1|entity|C0042295|Values|qlco|||values|||0|746|91|97
SE|25462218||ti|1|entity|C0013144|Drowsiness|sosy|||drowsy|||0|1000|110|116
SE|25462218||ti|1|entity|C0020114|Human|humn|||humans|||0|1000|127|133
SE|25462218||ti|1|relation|4|1|C0013144|Drowsiness|sosy|sosy|||drowsy|||0|1000|110|116|PREP|PROCESS_OF||124|126|1|1|C0020114|Human|grup,humn|humn|||humans|||0|1000|127|133

SE|25462218||ab|1|text|141|326|Organization of resting state cortical networks is of fundamental importance for the phenomenon of awareness, which is altered in the first part of hypnagogic period (Hori stages 1-4).
SE|25462218||ab|1|entity|C0220885|organizational|qlco|||Organization|||0|1000|141|153
SE|25462218||ab|1|entity|C0679218|Resting state|fndg|||resting state|||0|831|157|170
SE|25462218||ab|1|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|831|171|179
SE|25462218||ab|1|entity|C0679670|network|popg|||networks|||0|831|180|188
SE|25462218||ab|1|entity|C0004448|Awareness|menp|||awareness|||0|1000|240|249
SE|25462218||ab|1|entity|C1279901|Firstly|qlco|||first|||0|888|275|280
SE|25462218||ab|1|entity|C0449719|Part|spco|||part|||0|888|281|285
SE|25462218||ab|1|entity|C0439531|/period|tmco|||period|||0|861|300|306

SE|25462218||ab|2|text|326|494|Our aim was to investigate the change in brain topography pattern of EEG alpha attractor correlation dimension (CD) in the period of transition from Hori stage 1 to 4.
SE|25462218||ab|2|entity|C0006104|Brain|bpoc|||brain|||0|851|367|372
SE|25462218||ab|2|entity|C0870781|Landscapes|spco|||topography|||0|851|373|383
SE|25462218||ab|2|entity|C0449774|Patterns|spco|||pattern|||0|851|384|391
SE|25462218||ab|2|entity|C0013819|Electroencephalography|diap|||EEG|||0|762|395|398
SE|25462218||ab|2|entity|C0439095|Alpha|inpr|||alpha|||0|762|399|404
SE|25462218||ab|2|entity|C0439534|Dimensions|qnco|||dimension|||0|762|427|436
SE|25462218||ab|2|entity|C0439531|/period|tmco|||period|||0|1000|449|455
SE|25462218||ab|2|entity|C0441766|Stage level 1|inpr|||stage 1|||0|901|480|487

SE|25462218||ab|3|text|494|714|EEG of ten healthy adult individuals was recorded in the wake and drowsy states, using a 14 channel average reference montage, from which 91 bipolar channels were derived and filtered in the wider alpha (6-14 Hz) range.
SE|25462218||ab|3|entity|C0013819|Electroencephalography|diap|||EEG|||0|1000|494|497
SE|25462218||ab|3|entity|C0205456|Ten|qnco|||ten|||0|861|501|504
SE|25462218||ab|3|entity|C0686750|Well adult|fndg|||healthy adult|||0|861|505|518
SE|25462218||ab|3|entity|C0237401|Individual|humn|||individuals|||0|861|519|530
SE|25462218||ab|3|entity|C0013144|Drowsiness|sosy|||drowsy|||0|872|560|566
SE|25462218||ab|3|entity|C1442792|State|ftcn|||states|||0|872|567|573
SE|25462218||ab|3|entity|C1510992|Average|qnco|||average|||0|623|594|601
SE|25462218||ab|3|entity|C1514811|Reference|idcn|||reference|||0|623|602|611
SE|25462218||ab|3|entity|C0443156|Bipolar|spco|||bipolar|||0|773|635|642
SE|25462218||ab|3|entity|C0439799|Channel|spco|||channels|||0|773|643|651
SE|25462218||ab|3|entity|C0332464|Widening|spco|||wider|||0|872|685|690
SE|25462218||ab|3|entity|C0439095|Alpha|inpr|||alpha|||0|872|691|696
SE|25462218||ab|3|entity|C1514721|Range|qnco|||range|||0|1000|707|712
SE|25462218||ab|3|relation|0|0|C0686750|Well adult|fndg|fndg|||healthy adult|||0|861|505|518|MOD/HEAD|PROCESS_OF||505|530|0|0|C0237401|Individual|grup,humn|humn|||individuals|||0|861|519|530

SE|25462218||ab|4|text|714|844|Sixty 1s long epochs of each state and individual were subjected to CD calculation according to the Grassberger-Procaccia method.
SE|25462218||ab|4|entity|C0205166|Long|qlco|||long|||0|583|723|727
SE|25462218||ab|4|entity|C1442792|State|ftcn|||state|||0|1000|743|748
SE|25462218||ab|4|entity|C0237401|Individual|humn|||individual|||0|1000|753|763
SE|25462218||ab|4|entity|C0439534|Dimensions|qnco|||CD|||0|790|782|784
SE|25462218||ab|4|entity|C1441506|CALCULATION|lbpr|||calculation|||0|790|785|796
SE|25462218||ab|4|entity|C0025663|Methods|inpr|||method|||0|827|836|842

SE|25462218||ab|5|text|844|966|For such a collection of signals, two embedding dimensions, d={5, 10}, and 22 time delays tau=2-23 samples were explored.
SE|25462218||ab|5|entity|C1516698|Collection|ftcn|||collection|||0|1000|855|865
SE|25462218||ab|5|entity|C0205448|Two|qnco|||two|||0|802|878|881
SE|25462218||ab|5|entity|C0439534|Dimensions|qnco|||dimensions|||0|802|892|902
SE|25462218||ab|5|entity|C0040223|Time|tmco|||time|||0|861|922|926

SE|25462218||ab|6|text|966|1092|Optimal values were d=10 and tau=18, where both saturation and second zero crossing of the autocorrelation function occurred.
SE|25462218||ab|6|entity|C0042295|Values|qlco|||values|||0|861|974|980
SE|25462218||ab|6|entity|C0678572|saturation|npop|||saturation|||0|1000|1014|1024
SE|25462218||ab|6|entity|C0457385|seconds|tmco|||second|||0|660|1029|1035
SE|25462218||ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|861|1073|1081

SE|25462218||ab|7|text|1092|1266|Bipolar channel CD underwent a significant decrease during the transition and showed a positive linear correlation with electrode distance, stronger in the wake individuals.
SE|25462218||ab|7|entity|C0443156|Bipolar|spco|||Bipolar|||0|775|1092|1099
SE|25462218||ab|7|entity|C0439799|Channel|spco|||channel|||0|775|1100|1107
SE|25462218||ab|7|entity|C0439534|Dimensions|qnco|||CD|||0|775|1108|1110
SE|25462218||ab|7|entity|C0750502|Significant|idcn|||significant|||0|888|1123|1134
SE|25462218||ab|7|entity|C0547047|Decrease|qnco|||decrease|||0|888|1135|1143
SE|25462218||ab|7|entity|C1446409|Positive|qlco|||positive|||0|623|1179|1187
SE|25462218||ab|7|entity|C0205132|Linear|spco|||linear|||0|623|1188|1194
SE|25462218||ab|7|entity|C0013812|electrode|mnob|||electrode|||0|888|1212|1221
SE|25462218||ab|7|entity|C0012751|Distance|qnco|||distance|||0|888|1222|1230
SE|25462218||ab|7|entity|C0442821|Strong|qlco|||stronger|||0|966|1232|1240
SE|25462218||ab|7|entity|C0237401|Individual|humn|||individuals|||0|861|1253|1264

SE|25462218||ab|8|text|1266|1474|Topographic distribution of bipolar channels with above median CD changed from longitudinal anterior-posterior pattern (awake) to a more diagonal pattern, with localization in posterior regions (drowsiness).
SE|25462218||ab|8|entity|C0412670|Digital slit-beam radiograph|diap|||Topographic|||0|853|1266|1277
SE|25462218||ab|8|entity|C0520511|Distributing|idcn|||distribution|||0|853|1278|1290
SE|25462218||ab|8|entity|C0443156|Bipolar|spco|||bipolar|||0|872|1294|1301
SE|25462218||ab|8|entity|C0439799|Channel|spco|||channels|||0|872|1302|1310
SE|25462218||ab|8|entity|C1282910|Upper|spco|||above|||0|791|1316|1321
SE|25462218||ab|8|entity|C0439534|Dimensions|qnco|||CD|||0|791|1329|1331
SE|25462218||ab|8|entity|C0205127|Longitudinal|spco|||longitudinal|||0|861|1345|1357
SE|25462218||ab|8|entity|C0886365|Anterior-Posterior|spco|||anterior-posterior|||0|861|1358|1376
SE|25462218||ab|8|entity|C0449774|Patterns|spco|||pattern|||0|861|1377|1384
SE|25462218||ab|8|entity|C0234422|Awake|fndg,ftcn|||awake|||0|1000|1386|1391
SE|25462218||ab|8|entity|C0205172|More|ftcn|||more|||0|851|1398|1402
SE|25462218||ab|8|entity|C0443198|Diagonal|spco|||diagonal|||0|851|1403|1411
SE|25462218||ab|8|entity|C0449774|Patterns|spco|||pattern|||0|851|1412|1419
SE|25462218||ab|8|entity|C0475264|localization|ftcn|||localization|||0|1000|1426|1438
SE|25462218||ab|8|entity|C0205095|Dorsal|spco|||posterior|||0|872|1442|1451
SE|25462218||ab|8|entity|C0205147|Region|spco|||regions|||0|872|1452|1459
SE|25462218||ab|8|entity|C0013144|Drowsiness|sosy|||drowsiness|||0|1000|1461|1471

SE|25462218||ab|9|text|1474|1629|Our data are in line with the literature reporting functional segregation of neuronal assemblies in anterior and posterior regions during this transition.
SE|25462218||ab|9|entity|C1511726|Data|idcn|||data|||0|1000|1478|1482
SE|25462218||ab|9|entity|C0205132|Linear|spco|||line|||0|1000|1490|1494
SE|25462218||ab|9|entity|C0023866|Literature|inpr|||literature|||0|1000|1504|1514
SE|25462218||ab|9|entity|C0205245|Functional|ftcn|||functional|||0|888|1525|1535
SE|25462218||ab|9|entity|C0080141|Segregation|inbe,socb|||segregation|||0|888|1536|1547
SE|25462218||ab|9|entity|C0205094|Anterior|spco|||anterior|||0|1000|1574|1582
SE|25462218||ab|9|entity|C0205095|Dorsal|spco|||posterior|||0|872|1587|1596
SE|25462218||ab|9|entity|C0205147|Region|spco|||regions|||0|872|1597|1604

SE|25462218||ab|10|text|1629|1777|Our results should contribute to understanding of complex reorganization of the cortical part of alpha generators during the wake/drowsy transition.
SE|25462218||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1633|1640
SE|25462218||ab|10|entity|C0439855|Complex|qlco|||complex|||0|888|1679|1686
SE|25462218||ab|10|entity|C0680829|reorganization|idcn|||reorganization|||0|888|1687|1701
SE|25462218||ab|10|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|861|1709|1717
SE|25462218||ab|10|entity|C0449719|Part|spco|||part|||0|861|1718|1722
SE|25462218||ab|10|entity|C0439095|Alpha|inpr|||alpha|||0|888|1726|1731
SE|25462218||ab|10|entity|C0237638|Generators|mnob|||generators|||0|888|1732|1742
SE|25462218||ab|10|entity|C0013144|Drowsiness|sosy|||drowsy|||0|660|1759|1765


SE|25462220||ti|1|text|21|228|Antimycobacterial activity of natural products and synthetic agents: pyrrolodiquinolines and vermelhotin as anti-tubercular leads against clinical multidrug resistant isolates of Mycobacterium tuberculosis.
SE|25462220||ti|1|entity|C1566558|Natural Products|bacs|||natural products|||0|1000|51|67
SE|25462220||ti|1|entity|C0450442|Agent|chvf|||agents|||0|827|82|88
SE|25462220||ti|1|entity|C0332250|Tubercular|ftcn|||tubercular|||0|861|134|144
SE|25462220||ti|1|entity|C0205210|Clinical|qlco|||clinical|||0|634|159|167
SE|25462220||ti|1|entity|C0242640|Multi-Drug Resistance|orga|||multidrug resistant|||0|634|168|187
SE|25462220||ti|1|entity|C0026926|Mycobacterium tuberculosis|bact|||Mycobacterium tuberculosis|||0|1000|200|226

SE|25462220||ab|1|text|234|405|Various classes of natural products and synthetic compounds were tested against reference strains and clinical multidrug resistant isolates of Mycobacterium tuberculosis.
SE|25462220||ab|1|entity|C0456387|Class|inpr|||classes|||0|861|242|249
SE|25462220||ab|1|entity|C1566558|Natural Products|bacs|||natural products|||0|1000|253|269
SE|25462220||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|827|284|293
SE|25462220||ab|1|entity|C1514811|Reference|idcn|||reference|||0|888|314|323
SE|25462220||ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|634|336|344
SE|25462220||ab|1|entity|C0242640|Multi-Drug Resistance|orga|||multidrug resistant|||0|634|345|364
SE|25462220||ab|1|entity|C0026926|Mycobacterium tuberculosis|bact|||Mycobacterium tuberculosis|||0|1000|377|403

SE|25462220||ab|2|text|405|534|Vermelhotin (19), a natural tetramic acid from fungi, was the most active toward clinical MDR TB isolates (MIC 1.5-12.5 MUg/mL).
SE|25462220||ab|2|entity|C0205296|Natural|ftcn|||natural|||0|901|425|432
SE|25462220||ab|2|entity|C0076314|tetramic acid|orch|||tetramic acid|||0|901|433|446
SE|25462220||ab|2|entity|C0016832|fungus|fngs|||fungi|||0|1000|452|457
SE|25462220||ab|2|entity|C0205393|Most|qnco|||most|||0|888|467|471
SE|25462220||ab|2|entity|C0205177|Active|ftcn|||active|||0|888|472|478
SE|25462220||ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|645|486|494
SE|25462220||ab|2|entity|C1335222|GDF15 gene|gngm|9518|GDF15|MIC 1|||0|801|512|517
SE|25462220||ab|2|relation|4|1|C0016832|fungus|fngs|fngs|||fungi|||0|1000|452|457|PREP|LOCATION_OF||447|451|2|1|C0076314|tetramic acid|orch|orch|||tetramic acid|||0|901|433|446

SE|25462220||ab|3|text|534|679|Synthetic compounds (i.e. benzoxazocines, coumarins, chromenes, and pyrrolodiquinoline derivatives) were prepared by green chemistry approaches.
SE|25462220||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|827|544|553
SE|25462220||ab|3|entity|C0010207|Coumarins|orch,phsu|||coumarins|||0|1000|576|585
SE|25462220||ab|3|entity|C0005078|Benzopyrans|orch|||chromenes|||0|1000|587|596
SE|25462220||ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|861|621|632
SE|25462220||ab|3|entity|C0079107|chemical aspects|clas|||chemistry|||0|790|657|666
SE|25462220||ab|3|entity|C0449445|Approach|spco|||approaches|||0|790|667|677
SE|25462220||ab|3|relation|0|0|C0010207|Coumarins|orch,phsu|orch|||coumarins|||0|1000|576|585|SPEC|ISA||576|596|0|0|C0005078|Benzopyrans|orch|orch|||chromenes|||0|1000|587|596

SE|25462220||ab|4|text|679|881|Under microwave irradiation, a one-pot synthesis of pyrrolodiquinoline 85 was achieved by homocoupling of 1-methylquinolinium iodide; the structure of 85 was confirmed by single-crystal X-ray analysis.
SE|25462220||ab|4|entity|C0034618|Radiation therapy|topp|||irradiation|||0|861|695|706
SE|25462220||ab|4|entity|C0205447|One|qnco|||one|||0|802|710|713
SE|25462220||ab|4|entity|C0869032|Synthesis|phpr|||synthesis|||0|802|718|727
SE|25462220||ab|4|entity|C0954072|1-methylquinolinium iodide|orch|||1-methylquinolinium iodide|||0|1000|785|811
SE|25462220||ab|4|entity|C0678594|Structure|spco|||structure|||0|1000|817|826
SE|25462220||ab|4|entity|C0037179|Unmarried person|popg|||single|||0|794|850|856
SE|25462220||ab|4|entity|C0034571|roentgenographic|ftcn|||X-ray|||0|794|865|870
SE|25462220||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|794|871|879

SE|25462220||ab|5|text|881|1074|Compound 85 and its derivative 86 exhibited potent anti-tubercular activity (MIC 0.3-6.2 MUg/mL) against clinical MDR TB isolates, and they displayed weak cytotoxicity toward normal cell line.
SE|25462220||ab|5|entity|C0205198|Compound|qlco|||Compound|||0|861|881|889
SE|25462220||ab|5|entity|C1527240|Derivative|ftcn|||derivative|||0|704|901|911
SE|25462220||ab|5|entity|C0015272|Exhibits|mnob|||exhibited|||0|704|915|924
SE|25462220||ab|5|entity|C0237399|Potential|qlco|||potent|||0|704|925|931
SE|25462220||ab|5|entity|C0332250|Tubercular|ftcn|||tubercular|||0|704|937|947
SE|25462220||ab|5|entity|C0427978|Minimum Inhibitory Concentration measurement|lbpr|||MIC|||0|782|958|961
SE|25462220||ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|645|986|994
SE|25462220||ab|5|entity|C0004093|Asthenia|sosy|||weak|||0|888|1031|1035
SE|25462220||ab|5|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|1036|1048
SE|25462220||ab|5|entity|C1268443|Normal cell|cell|||normal cell|||0|901|1056|1067
SE|25462220||ab|5|entity|C0205132|Linear|spco|||line|||0|901|1068|1072

SE|25462220||ab|6|text|1074|1144|The scaffold of 85 and 86 is potential for antimycobacterial activity.
SE|25462220||ab|6|entity|C0337143|Scaffold|mnob|||scaffold|||0|1000|1078|1086
SE|25462220||ab|6|entity|C0237399|Potential|qlco|||potential|||0|1000|1103|1112


SE|25462219||ti|1|text|21|98|Learning models of PTSD: Theoretical accounts and psychobiological evidence.
SE|25462219||ti|1|entity|C0023185|Learning|menp|||Learning|||0|694|21|29
SE|25462219||ti|1|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|40|44
SE|25462219||ti|1|entity|C1551359|account|idcn|||accounts|||0|827|58|66
SE|25462219||ti|1|entity|C0871172|Psychobiology|ocdi|||psychobiological|||0|623|71|87

SE|25462219||ab|1|text|104|197|Learning abnormalities have long been centrally implicated in posttraumatic psychopathology.
SE|25462219||ab|1|entity|C0023185|Learning|menp|||Learning|||0|888|104|112
SE|25462219||ab|1|entity|C0205166|Long|qlco|||long|||0|1000|132|136
SE|25462219||ab|1|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|861|180|195

SE|25462219||ab|2|text|197|308|Indeed, of all anxiety disorders, PTSD may be most clearly attributable to discrete, aversive learning events.
SE|25462219||ab|2|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|212|229
SE|25462219||ab|2|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|231|235
SE|25462219||ab|2|entity|C0205393|Most|qnco|||most|||0|660|243|247
SE|25462219||ab|2|entity|C0023185|Learning|menp|||learning|||0|750|291|299
SE|25462219||ab|2|entity|C0441471|Events|evnt|||events|||0|750|300|306

SE|25462219||ab|3|text|308|550|In PTSD, such learning is acquired during the traumatic encounter and is expressed as both conditioned fear to stimuli associated with the event and more general over-reactivity-or failure to adapt-to intense, novel, or fear-related stimuli.
SE|25462219||ab|3|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|311|315
SE|25462219||ab|3|entity|C0023185|Learning|menp|||learning|||0|1000|322|330
SE|25462219||ab|3|entity|C0332663|Traumatic|ftcn|||traumatic|||0|888|354|363
SE|25462219||ab|3|entity|C0545082|Visit|ftcn|||encounter|||0|888|364|373
SE|25462219||ab|3|entity|C1510535|Conditioned Fear|menp|||conditioned fear|||0|1000|399|415
SE|25462219||ab|3|entity|C0234402|Stimulus|phpr|||stimuli|||0|1000|419|426
SE|25462219||ab|3|entity|C0441471|Events|evnt|||event|||0|1000|447|452
SE|25462219||ab|3|entity|C0205172|More|ftcn|||more|||0|751|457|461
SE|25462219||ab|3|entity|C0205246|Generalized|spco|||general|||0|751|462|469
SE|25462219||ab|3|entity|C0205332|Reactive|qlco|||reactivity|||0|751|475|485
SE|25462219||ab|3|entity|C0679622|novel|inpr|||novel|||0|861|518|523
SE|25462219||ab|3|entity|C0015726|Fright|menp|||fear|||0|851|528|532
SE|25462219||ab|3|entity|C1522149|Related|ftcn|||related|||0|851|533|540
SE|25462219||ab|3|entity|C0234402|Stimulus|phpr|||stimuli|||0|851|541|548

SE|25462219||ab|4|text|550|890|The relatively straightforward link between PTSD and these basic, evolutionarily old, learning processes of conditioning, sensitization, and habituation affords models of PTSD comprised of fundamental, experimentally tractable mechanisms of learning that have been well characterized across a variety of mammalian species including humans.
SE|25462219||ab|4|entity|C1272701|Straightforward|qlco|||straightforward|||0|660|565|580
SE|25462219||ab|4|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|594|598
SE|25462219||ab|4|entity|C0580836|Old|tmco|||old|||0|766|631|634
SE|25462219||ab|4|entity|C1522240|Process|phpr|||processes|||0|966|645|654
SE|25462219||ab|4|entity|C1325847|Sensitization|menp|||sensitization|||0|1000|672|685
SE|25462219||ab|4|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|721|725
SE|25462219||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|812|777|787
SE|25462219||ab|4|entity|C0023185|Learning|menp|||learning|||0|1000|791|799
SE|25462219||ab|4|entity|C0205170|Good|qlco|||well|||0|861|815|819
SE|25462219||ab|4|entity|C1548151|Species|idcn|||species|||0|861|864|871
SE|25462219||ab|4|entity|C0020114|Human|humn|||humans|||0|1000|882|888

SE|25462219||ab|5|text|890|1122|Though such learning mechanisms have featured prominently in explanatory models of psychological maladjustment to trauma for at least 90years, much of the empirical testing of these models has occurred only in the past two decades.
SE|25462219||ab|5|entity|C0023185|Learning|menp|||learning|||0|888|902|910
SE|25462219||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|911|921
SE|25462219||ab|5|entity|C0681841|explanation|resa|||explanatory|||0|694|951|962
SE|25462219||ab|5|entity|C0205486|Psychologic|ftcn|||psychological|||0|888|973|986
SE|25462219||ab|5|entity|C0281902|Maladjustment|mobd|||maladjustment|||0|888|987|1000
SE|25462219||ab|5|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|1000|1004|1010
SE|25462219||ab|5|entity|C0039593|Testing|resa|||testing|||0|861|1055|1062
SE|25462219||ab|5|entity|C1444637|Past|tmco|||past|||0|623|1104|1108
SE|25462219||ab|5|entity|C0205448|Two|qnco|||two|||0|623|1109|1112

SE|25462219||ab|6|text|1122|1452|The current review delineates the variety of theories forming this longstanding tradition of learning-based models of PTSD, details empirical evidence for such models, attempts an integrative account of results from this literature, and specifies limitations of, and future directions for, studies testing learning models of PTSD.
SE|25462219||ab|6|entity|C0521116|Current|tmco|||current|||0|694|1126|1133
SE|25462219||ab|6|entity|C0871935|Theories|idcn|||theories|||0|1000|1167|1175
SE|25462219||ab|6|entity|C0683624|traditions|socb|||tradition|||0|827|1202|1211
SE|25462219||ab|6|entity|C0023185|Learning|menp|||learning|||0|606|1215|1223
SE|25462219||ab|6|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|1240|1244
SE|25462219||ab|6|entity|C1551359|account|idcn|||account|||0|861|1314|1321
SE|25462219||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1325|1332
SE|25462219||ab|6|entity|C0023866|Literature|inpr|||literature|||0|1000|1343|1353
SE|25462219||ab|6|entity|C0449295|Limitation|ftcn|||limitations|||0|966|1369|1380
SE|25462219||ab|6|entity|C0016884|Future|tmco|||future|||0|888|1389|1395
SE|25462219||ab|6|entity|C0439755|Directions|spco|||directions|||0|888|1396|1406
SE|25462219||ab|6|entity|C0023185|Learning|menp|||learning|||0|694|1428|1436
SE|25462219||ab|6|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|1447|1451


SE|25462221||ti|1|text|21|142|Synthesis and evaluation of in vitro antimycobacterial activity of novel 1H-benzo[d]imidazole derivatives and analogues.
SE|25462221||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462221||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|35|45
SE|25462221||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|824|49|57
SE|25462221||ti|1|entity|C0679622|novel|inpr|||novel|||0|623|88|93
SE|25462221||ti|1|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|888|105|114
SE|25462221||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|888|115|126
SE|25462221||ti|1|entity|C0243071|Analog|chvs|||analogues|||0|966|131|140

SE|25462221||ab|1|text|148|286|A series of novel 1H-benzo[d]imidazole derivatives and analogues (1-25) have been synthesized and evaluated for tuberculostatic activity.
SE|25462221||ab|1|entity|C0679622|novel|inpr|||novel|||0|623|160|165
SE|25462221||ab|1|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|888|177|186
SE|25462221||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|888|187|198
SE|25462221||ab|1|entity|C0243071|Analog|chvs|||analogues|||0|966|203|212

SE|25462221||ab|2|text|286|438|Benzimidazoles substituted at the C-2 position with cyclohexylethyl, cyclohexylpropyl and phenylpropyl moiety or 4-phenylpyridine system were obtained.
SE|25462221||ab|2|entity|C0005050|Benzimidazoles|orch|||Benzimidazoles|||0|1000|286|300
SE|25462221||ab|2|entity|||gngm|717|C2|C-2|||0|827|320|323
SE|25462221||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|827|324|332
SE|25462221||ab|2|entity|C0048683|4-phenylpyridine|orch,phsu|||4-phenylpyridine|||0|901|399|415
SE|25462221||ab|2|entity|C0449913|System|ftcn|||system|||0|901|416|422

SE|25462221||ab|3|text|438|742|Compounds 3, 4, 6 and 7 bearing halogen atoms or methyl groups at the benzimidazole system and cyclohexylethyl substituent at the C-2 position showed an excellent tuberculostatic activity against Mycobacterium tuberculosis and Mycobacterium bovis strains with MIC values ranging from 0.75 to 1.5 MUg/mL.
SE|25462221||ab|3|entity|C0205198|Compound|qlco|||Compounds|||0|827|438|447
SE|25462221||ab|3|entity|C0018544|Halogens|elii|||halogen|||0|750|470|477
SE|25462221||ab|3|entity|C0567415|Atom|elii|||atoms|||0|750|478|483
SE|25462221||ab|3|entity|C0596922|methyl group|orch|||methyl groups|||0|983|487|500
SE|25462221||ab|3|entity|C0005050|Benzimidazoles|orch|||benzimidazole|||0|888|508|521
SE|25462221||ab|3|entity|C0449913|System|ftcn|||system|||0|888|522|528
SE|25462221||ab|3|entity|||gngm|717|C2|C-2|||0|827|568|571
SE|25462221||ab|3|entity|C0733755|Positioning Attribute|spco|||position|||0|827|572|580
SE|25462221||ab|3|entity|C0026926|Mycobacterium tuberculosis|bact|||Mycobacterium tuberculosis|||0|1000|634|660
SE|25462221||ab|3|entity|C0026917|Mycobacterium bovis|bact|||Mycobacterium bovis|||0|1000|665|684
SE|25462221||ab|3|entity|C0427978|Minimum Inhibitory Concentration measurement|lbpr|||MIC|||0|888|698|701
SE|25462221||ab|3|entity|C0042295|Values|qlco|||values|||0|888|702|708
SE|25462221||ab|3|entity|C0450316|1/5|qnco|||1.5|||0|824|730|733

SE|25462221||ab|4|text|742|1034|More importantly, derivatives 4 (5-Bromo-2-(2-cyclohexylethyl)-1H-benzo[d]imidazole) and 6 (2-(2-cyclohexylethyl)-5,6-dimethyl-1H-benzo[d]imidazole) appeared selective for M. tuberculosis and M. bovis as compared with non-malignant eukaryotic cells (LLC-PK1 pig kidney epithelial cell line).
SE|25462221||ab|4|entity|C0205172|More|ftcn|||More|||0|861|742|746
SE|25462221||ab|4|entity|C0243072|derivatives|chvs|||derivatives|||0|861|760|771
SE|25462221||ab|4|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|1000|816|825
SE|25462221||ab|4|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|1000|880|889
SE|25462221||ab|4|entity|C0026926|Mycobacterium tuberculosis|bact|||M. tuberculosis|||0|1000|914|929
SE|25462221||ab|4|entity|C1518371|Non-Malignant|qlco|||non-malignant|||0|888|960|973
SE|25462221||ab|4|entity|C0015161|Eukaryotic Cell|cell|||eukaryotic cells|||0|888|974|990
SE|25462221||ab|4|entity|C0039005|Family suidae|mamm|||pig|||0|836|1000|1003
SE|25462221||ab|4|entity|C0022646|Kidney|bpoc|||kidney|||0|836|1004|1010
SE|25462221||ab|4|entity|C0221908|Epithelial|ftcn|||epithelial|||0|836|1011|1021
SE|25462221||ab|4|entity|C0242598|LLC-PK1 Cells|cell|||LLC-PK1 pig kidney epithelial cell|||0|836|992|1026
SE|25462221||ab|4|entity|C0205132|Linear|spco|||line|||0|836|1027|1031

SE|25462221||ab|5|text|1034|1120|These compounds may thus represent a novel, selective class of anti-tubercular agents.
SE|25462221||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|1040|1049
SE|25462221||ab|5|entity|C0679622|novel|inpr|||novel|||0|802|1071|1076
SE|25462221||ab|5|entity|C0008902|Classification|clas|||class|||0|802|1088|1093
SE|25462221||ab|5|entity|C0332250|Tubercular|ftcn|||tubercular|||0|901|1102|1112
SE|25462221||ab|5|entity|C0040616|Anti-Anxiety Agents|phsu|||anti-tubercular agents|||0|901|1097|1119


SE|25462222||ti|1|text|21|182|Design, synthesis and structure--activity relationship (SAR) studies of imidazo[4,5-b]pyridine derived purine isosteres and their potential as cytotoxic agents.
SE|25462222||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|850|29|38
SE|25462222||ti|1|entity|C0038477|Structure-Activity Relationship|qlco|||structure--activity relationship|||0|850|43|75
SE|25462222||ti|1|entity|C0914738|B-pyridine|orch,phsu|||b]pyridine|||0|901|105|115
SE|25462222||ti|1|entity|C0034140|Purines|orch|||purine|||0|694|124|130
SE|25462222||ti|1|entity|C0237399|Potential|qlco|||potential|||0|1000|151|160
SE|25462222||ti|1|entity|C0304497|Cytotoxic agent|phsu|||cytotoxic agents|||0|983|164|180

SE|25462222||ab|1|text|188|325|Drug resistance to chemotherapeutic agents paved the way to develop novel synthetic molecules which are active on MDR cancer cell lines.
SE|25462222||ab|1|entity|C0013203|Drug resistance|biof|||Drug resistance|||0|1000|188|203
SE|25462222||ab|1|entity|C0003392|Antineoplastic Agents|phsu|||chemotherapeutic agents|||0|983|207|230
SE|25462222||ab|1|entity|C0679622|novel|inpr|||novel|||0|785|256|261
SE|25462222||ab|1|entity|C0567416|Molecule|sbst|||molecules|||0|785|272|281
SE|25462222||ab|1|entity|C0205177|Active|ftcn|||active|||0|1000|292|298
SE|25462222||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|824|306|312
SE|25462222||ab|1|entity|C0007600|Cell Line|cell|||cell lines|||0|824|313|323

SE|25462222||ab|2|text|325|471|Regio-isomeric imidazo[4,5-b]pyridine analogues were synthesized and evaluated for their cytotoxic activity against a range of cancer cell lines.
SE|25462222||ab|2|entity|C0022203|Isomerism|npop|||isomeric|||0|589|331|339
SE|25462222||ab|2|entity|C0914738|B-pyridine|orch,phsu|||b]pyridine|||0|852|352|362
SE|25462222||ab|2|entity|C0243071|Analog|chvs|||analogues|||0|852|363|372
SE|25462222||ab|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|414|423
SE|25462222||ab|2|entity|C1514721|Range|qnco|||range|||0|1000|443|448
SE|25462222||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|901|452|458
SE|25462222||ab|2|entity|C0007600|Cell Line|cell|||cell lines|||0|901|459|469

SE|25462222||ab|3|text|471|574|The structure-activity relationship (SAR) studies of the imidazopyridine analogues are also described.
SE|25462222||ab|3|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationship|||0|1000|475|506
SE|25462222||ab|3|entity|C0869032|Synthesis|phpr|||SAR|||0|850|508|511
SE|25462222||ab|3|entity|C0038477|Structure-Activity Relationship|qlco|||SAR|||0|850|508|511
SE|25462222||ab|3|entity|C0243071|Analog|chvs|||analogues|||0|827|544|553

SE|25462222||ab|4|text|574|646|Analogue 6b displayed strong cytotoxicity and good microsomal stability.
SE|25462222||ab|4|entity|C0243071|Analog|chvs|||Analogue|||0|694|574|582
SE|25462222||ab|4|entity|C0442821|Strong|qlco|||strong|||0|888|596|602
SE|25462222||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|603|615
SE|25462222||ab|4|entity|C0205170|Good|qlco|||good|||0|828|620|624
SE|25462222||ab|4|entity|C0026029|Microsomes|celc|||microsomal|||0|828|625|635
SE|25462222||ab|4|entity|C1317741|STABILITY|qlco|||stability|||0|828|636|645


SE|25462223||ti|1|text|21|160|Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.
SE|25462223||ti|1|entity|C1517331|Further|spco|||Further|||0|872|21|28
SE|25462223||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|29|36
SE|25462223||ti|1|entity|C0205447|One|qnco|||ones|||0|966|90|94
SE|25462223||ti|1|entity|C0237399|Potential|qlco|||potent|||0|900|98|104
SE|25462223||ti|1|entity|C0020114|Human|humn|||human|||0|816|119|124
SE|25462223||ti|1|entity|C0815050|adenosine receptor antagonist|nnon,phsu|||adenosine receptor antagonists|||0|816|128|158

SE|25462223||ab|1|text|166|339|A new series of pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones was synthesized and tested in radioligand binding assays on human A1, A2A and A3 adenosine receptors.
SE|25462223||ab|1|entity|C0205314|New|tmco|||new|||0|888|168|171
SE|25462223||ab|1|entity|C0205549|Series|qnco|||series|||0|888|172|178
SE|25462223||ab|1|entity|C0205447|One|qnco|||ones|||0|966|232|236
SE|25462223||ab|1|entity|C0034596|Radioligand Assay|lbpr|||radioligand binding assays|||0|913|267|293
SE|25462223||ab|1|entity|C0020114|Human|humn|||human|||0|888|297|302
SE|25462223||ab|1|entity|C1181031|Apical ramus of trunk of posterior segmental artery|bpoc|||A2A|||0|1000|307|310
SE|25462223||ab|1|entity|C0001471|Receptors, Purinergic P1|aapp,rcpt|||adenosine receptors|||0|901|318|337

SE|25462223||ab|2|text|339|476|Most of the compounds showed high selectivity of action towards A1 receptor and high affinity with Ki values in the low nanomolar range.
SE|25462223||ab|2|entity|C0205393|Most|qnco|||Most|||0|1000|339|343
SE|25462223||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|351|360
SE|25462223||ab|2|entity|C0205250|High|qlco|||high|||0|694|368|372
SE|25462223||ab|2|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|888|406|414
SE|25462223||ab|2|entity|C0205250|High|qlco|||high|||0|888|419|423
SE|25462223||ab|2|entity|C0042295|Values|qlco|||values|||0|861|441|447
SE|25462223||ab|2|entity|C0205251|low|qlco|||low|||0|851|455|458
SE|25462223||ab|2|entity|C0439282|Nanomole/liter|qnco|||nanomolar|||0|851|459|468
SE|25462223||ab|2|entity|C1514721|Range|qnco|||range|||0|851|469|474

SE|25462223||ab|3|text|476|604|The pharmacological profile of the most active molecules towards A1 adenosine receptors was evaluated in cAMP functional assay.
SE|25462223||ab|3|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|694|480|495
SE|25462223||ab|3|entity|C0205393|Most|qnco|||most|||0|840|511|515
SE|25462223||ab|3|entity|C0205177|Active|ftcn|||active|||0|840|516|522
SE|25462223||ab|3|entity|C0567416|Molecule|sbst|||molecules|||0|840|523|532
SE|25462223||ab|3|entity|C0001471|Receptors, Purinergic P1|aapp,rcpt|||adenosine receptors|||0|901|544|563
SE|25462223||ab|3|entity|||gngm|820|CAMP|cAMP|||0|790|581|585
SE|25462223||ab|3|entity|C0205245|Functional|ftcn|||functional|||0|790|586|596
SE|25462223||ab|3|entity|C1510438|Assay|lbpr|||assay|||0|790|597|602

SE|25462223||ab|4|text|604|743|Compounds demonstrated their ability to completely counteract the effect of the agonist NECA, thus demonstrating their antagonist profile.
SE|25462223||ab|4|entity|C0205198|Compound|qlco|||Compounds|||0|966|604|613
SE|25462223||ab|4|entity|C0085732|Ability|orga|||ability|||0|1000|633|640
SE|25462223||ab|4|entity|C1280500|Effect|qlco|||effect|||0|1000|670|676
SE|25462223||ab|4|entity|C0243192|agonists|phsu|||agonist|||0|888|684|691
SE|25462223||ab|4|entity|C0050789|Adenosine-5'-(N-ethylcarboxamide)|nnon,phsu|||NECA|||0|888|692|696

SE|25462223||ab|5|text|743|887|Moreover, the most interesting compound, tested in the mouse passive avoidance, exhibited an antiamnesic effect at the doses of 10 and 30 mg/kg.
SE|25462223||ab|5|entity|C0205393|Most|qnco|||most|||0|802|757|761
SE|25462223||ab|5|entity|C0205198|Compound|qlco|||compound|||0|802|774|782
SE|25462223||ab|5|entity|C0025914|House mice|mamm|||mouse|||0|901|798|803
SE|25462223||ab|5|entity|C0871047|Passive Avoidance|menp|||passive avoidance|||0|901|804|821
SE|25462223||ab|5|entity|C1280500|Effect|qlco|||effect|||0|861|848|854
SE|25462223||ab|5|entity|C1446466|Dose|qnco|||doses|||0|1000|862|867
SE|25462223||ab|5|relation|0|0|C0871047|Passive Avoidance|menp|menp|||passive avoidance|||0|901|804|821|MOD/HEAD|PROCESS_OF||798|821|0|0|C0025914|House mice|mamm|mamm|||mouse|||0|901|798|803


SE|25462225||ti|1|text|21|107|Hairpin oligonucleotides forming G-quadruplexes: new aptamers with anti-HIV activity.
SE|25462225||ti|1|entity|C0028953|Oligonucleotides|nnon|||oligonucleotides|||0|861|29|45
SE|25462225||ti|1|entity|C1517336|G-Quartets|nusq|||G-quadruplexes|||0|1000|54|68
SE|25462225||ti|1|entity|C0205314|New|tmco|||new|||0|872|70|73
SE|25462225||ti|1|entity|C0599013|Aptamer|nnon|||aptamers|||0|872|74|82
SE|25462225||ti|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|790|93|96

SE|25462225||ab|1|text|113|382|We describe the facile syntheses of new modified oligonucleotides based on d(TG3AG) that form bimolecular G-quadruplexes and possess a HEG loop as an inversion of polarity site 3'-3' or 5'-5' and aromatic residues conjugated to the 5'-end through phosphodiester bonds.
SE|25462225||ab|1|entity|C1547538|Facility|idcn|||facile|||0|836|129|135
SE|25462225||ab|1|entity|C0869032|Synthesis|phpr|||syntheses|||0|836|136|145
SE|25462225||ab|1|entity|C0205314|New|tmco|||new|||0|851|149|152
SE|25462225||ab|1|entity|C0205349|Altered|ftcn|||modified|||0|851|153|161
SE|25462225||ab|1|entity|C0028953|Oligonucleotides|nnon|||oligonucleotides|||0|851|162|178
SE|25462225||ab|1|entity|C1517336|G-Quartets|nusq|||G-quadruplexes|||0|901|219|233
SE|25462225||ab|1|entity|||gngm|57493|HEG1|HEG|||0|861|248|251
SE|25462225||ab|1|entity|C0445022|Loop|spco|||loop|||0|861|252|256
SE|25462225||ab|1|entity|C0596963|polarity|qnco|||polarity|||0|750|276|284
SE|25462225||ab|1|entity|C0205145|Site|spco|||site|||0|750|285|289
SE|25462225||ab|1|entity|C0772162|AROMATICS|orch,phsu|||aromatic|||0|847|309|317
SE|25462225||ab|1|entity|C0444930|End|spco|||end|||0|888|348|351
SE|25462225||ab|1|entity|C0599124|phosphodiester|opco|||phosphodiester|||0|694|360|374

SE|25462225||ab|2|text|382|575|The conjugated hairpin G-quadruplexes exhibited parallel orientation, high thermal stability, elevated resistance in human serum and high or moderate anti-HIV-1 activity with low cytotoxicity.
SE|25462225||ab|2|entity|C0522529|Conjugated|spco|||conjugated|||0|824|386|396
SE|25462225||ab|2|entity|C1517336|G-Quartets|nusq|||G-quadruplexes|||0|824|405|419
SE|25462225||ab|2|entity|C0205250|High|qlco|||high|||0|802|452|456
SE|25462225||ab|2|entity|C1317741|STABILITY|qlco|||stability|||0|802|465|474
SE|25462225||ab|2|entity|C0205250|High|qlco|||elevated|||0|694|476|484
SE|25462225||ab|2|entity|C0020114|Human|humn|||human|||0|888|499|504
SE|25462225||ab|2|entity|C0229671|Serum|bdsu|||serum|||0|888|505|510
SE|25462225||ab|2|entity|C0205250|High|qlco|||high|||0|1000|515|519
SE|25462225||ab|2|entity|C0019704|HIV-1|virs|||HIV-1|||0|822|537|542
SE|25462225||ab|2|entity|C1513375|Moderate Exercise|dora|||moderate anti-HIV-1 activity|||0|822|523|551
SE|25462225||ab|2|entity|C0205251|low|qlco|||low|||0|888|557|560
SE|25462225||ab|2|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|561|573
SE|25462225||ab|2|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|505|510|MOD/HEAD|PART_OF||499|510|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|499|504

SE|25462225||ab|3|text|575|705|Further, these molecules showed significant binding to HIV envelope glycoproteins gp120, gp41 and HSA, as revealed by SPR assays.
SE|25462225||ab|3|entity|C1517331|Further|spco|||Further|||0|1000|575|582
SE|25462225||ab|3|entity|C0567416|Molecule|sbst|||molecules|||0|966|590|599
SE|25462225||ab|3|entity|C0750502|Significant|idcn|||significant|||0|694|607|618
SE|25462225||ab|3|entity|C0019691|HIV Envelope Protein gp120|aapp,bacs|||HIV envelope glycoproteins gp120|||0|991|630|662
SE|25462225||ab|3|entity|||gngm|213|ALB|HSA|||0|1000|673|676
SE|25462225||ab|3|entity|C0164209|Substance P Receptor|aapp,rcpt|6697|SPR|SPR|||0|872|693|696
SE|25462225||ab|3|entity|C1510438|Assay|lbpr|||assays|||0|872|697|703
SE|25462225||ab|3|relation|0|0|C1510438|Assay|lbpr|lbpr|||assays|||0|872|697|703|MOD/HEAD|USES||693|703|0|0|C0164209|Substance P Receptor|aapp,gngm,rcpt|aapp|6697|SPR|SPR|||0|872|693|696

SE|25462225||ab|4|text|705|840|As a result, these conjugated hairpins represent the first active anti-HIV-1 bimolecular G-quadruplexes based on the d(TG3AG) sequence.
SE|25462225||ab|4|entity|C0522529|Conjugated|spco|||conjugated|||0|694|724|734
SE|25462225||ab|4|entity|C1279901|Firstly|qlco|||first|||0|749|758|763
SE|25462225||ab|4|entity|C0205177|Active|ftcn|||active|||0|749|764|770
SE|25462225||ab|4|entity|C0019704|HIV-1|virs|||HIV-1|||0|749|776|781
SE|25462225||ab|4|entity|C1517336|G-Quartets|nusq|||G-quadruplexes|||0|749|794|808
SE|25462225||ab|4|entity|C1519249|Sequence|ftcn|||sequence|||0|1000|831|839


SE|25462224||ti|1|text|21|137|Synthesis, crystal structure and antitumor effect of a novel copper(II) complex bearing zoledronic acid derivative.
SE|25462224||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462224||ti|1|entity|C0444626|Crystal Structure|chvs|||crystal structure|||0|1000|32|49
SE|25462224||ti|1|entity|C1280500|Effect|qlco|||effect|||0|861|64|70
SE|25462224||ti|1|entity|C0679622|novel|inpr|||novel|||0|888|76|81
SE|25462224||ti|1|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|888|82|88
SE|25462224||ti|1|entity|C0439855|Complex|qlco|||complex|||0|794|93|100
SE|25462224||ti|1|entity|C0257685|zoledronic acid|opco,phsu|||zoledronic acid|||0|794|109|124
SE|25462224||ti|1|entity|C1527240|Derivative|ftcn|||derivative|||0|794|125|135

SE|25462224||ab|1|text|143|297|A great majority of Cu(II) complexes currently studied in the anticancer research field exert their antiproliferative activities through ligand exchange.
SE|25462224||ab|1|entity|C0549177|Large|qnco|||great|||0|888|145|150
SE|25462224||ab|1|entity|C0680220|majority|socb|||majority|||0|888|151|159
SE|25462224||ab|1|entity|C0439855|Complex|qlco|||complexes|||0|1000|170|179
SE|25462224||ab|1|entity|C0521116|Current|tmco|||currently|||0|1000|180|189
SE|25462224||ab|1|entity|C0035168|research|resa|||research|||0|790|216|224
SE|25462224||ab|1|entity|C1521738|Field|cnce|||field|||0|790|225|230
SE|25462224||ab|1|entity|C0441655|Activities|acty|||activities|||0|861|261|271
SE|25462224||ab|1|entity|C0023688|Ligands|chem|||ligand|||0|888|280|286
SE|25462224||ab|1|entity|C0678640|exchange|socb|||exchange|||0|888|287|295

SE|25462224||ab|2|text|297|599|In this work, we present the synthesis and structural characterization of two novel Cu(II) complexes, {[Cu3(ZL)2(H2O)6].6H2O}n (1) (ZL = 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid) and [Cu(IPrDP)2].3H2O (2) (IPrDP = 1-hydroxy-3-(1H-imidazol-1-yl)propane-1,1-diyldiphosphonic acid).
SE|25462224||ab|2|entity|C0043227|Work|ocac|||work|||0|1000|305|309
SE|25462224||ab|2|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|326|335
SE|25462224||ab|2|entity|C0205448|Two|qnco|||two|||0|851|371|374
SE|25462224||ab|2|entity|C0679622|novel|inpr|||novel|||0|851|375|380
SE|25462224||ab|2|entity|C0439855|Complex|qlco|||complexes|||0|1000|388|397
SE|25462224||ab|2|entity|C0020923|Imidazole|orch,phsu|||imidazol|||0|583|450|458
SE|25462224||ab|2|entity|C0014969|Ethane|hops,orch|||ethane|||0|861|464|470
SE|25462224||ab|2|entity|C0001128|Acids|chem|||acid|||0|827|492|496
SE|25462224||ab|2|entity|C0020923|Imidazole|orch,phsu|||imidazol|||0|583|549|557
SE|25462224||ab|2|entity|C0033434|Propane|orch|||propane|||0|861|563|570
SE|25462224||ab|2|entity|C0001128|Acids|chem|||acid|||0|827|592|596

SE|25462224||ab|3|text|599|719|Due to the insolubility of polymer 1 in common solvents, only the biological activities of complex 2 were investigated.
SE|25462224||ab|3|entity|C0032521|Polymers|bodm,chvs|||polymer|||0|861|626|633
SE|25462224||ab|3|entity|C0205214|Common|qnco|||common|||0|888|639|645
SE|25462224||ab|3|entity|C0037638|Solvents|irda|||solvents|||0|888|646|654
SE|25462224||ab|3|entity|C0205460|biological|ftcn|||biological|||0|888|665|675
SE|25462224||ab|3|entity|C0441655|Activities|acty|||activities|||0|888|676|686
SE|25462224||ab|3|entity|C0439855|Complex|qlco|||complex|||0|861|690|697

SE|25462224||ab|4|text|719|865|The antitumor activity of complex 2 was evaluated against a panel of human cancer cell lines, including U2OS, A549, HCT116, MDA-MB-231 and HepG2.
SE|25462224||ab|4|entity|C0439855|Complex|qlco|||complex|||0|861|745|752
SE|25462224||ab|4|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|908|794|800
SE|25462224||ab|4|entity|C0682523|Human Cell Line|cell|||human cancer cell lines|||0|908|788|811
SE|25462224||ab|4|entity|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|||MDA-MB|||0|790|843|849
SE|25462224||ab|4|entity|C1533164|Megabase|qnco|||MDA-MB|||0|790|843|849

SE|25462224||ab|5|text|865|1081|Complex 2 exhibited comparable cytotoxic effect to cisplatin (CDDP) against the human colon carcinoma cells HCT116, and superior selectivity for inhibiting human hepatocarcinoma cells rather than normal liver cells.
SE|25462224||ab|5|entity|C0439855|Complex|qlco|||Complex|||0|732|865|872
SE|25462224||ab|5|entity|C0015272|Exhibits|mnob|||exhibited|||0|732|875|884
SE|25462224||ab|5|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|732|896|905
SE|25462224||ab|5|entity|C1280500|Effect|qlco|||effect|||0|732|906|912
SE|25462224||ab|5|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|1000|916|925
SE|25462224||ab|5|entity|C0699790|Colon Carcinoma|neop|||colon carcinoma|||0|660|951|966
SE|25462224||ab|5|entity|C0427861|Human cells|lbtr|||human colon carcinoma cells|||0|660|945|972
SE|25462224||ab|5|entity|C1282910|Upper|spco|||superior|||0|694|985|993
SE|25462224||ab|5|entity|C0311403|Inhibited|qlco|||inhibiting|||0|852|1010|1020
SE|25462224||ab|5|entity|C0019204|Primary carcinoma of the liver cells|neop|||hepatocarcinoma|||0|852|1027|1042
SE|25462224||ab|5|entity|C0427861|Human cells|lbtr|||human hepatocarcinoma cells|||0|852|1021|1048
SE|25462224||ab|5|entity|C0205307|Normal|qlco|||normal|||0|901|1061|1067
SE|25462224||ab|5|entity|C0227525|Hepatocyte|cell|||liver cells|||0|901|1068|1079

SE|25462224||ab|6|text|1081|1282|The cell cycle distribution analysis indicates that complex 2 inhibits human carcinoma cells by inducing the cell cycle arrest at the G2/M phase, showing a similar mechanism of action to that of CDDP.
SE|25462224||ab|6|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|861|1085|1095
SE|25462224||ab|6|entity|C0520511|Distributing|idcn|||distribution|||0|861|1096|1108
SE|25462224||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|861|1109|1117
SE|25462224||ab|6|entity|C0439855|Complex|qlco|||complex|||0|861|1133|1140
SE|25462224||ab|6|entity|C0007097|Carcinoma|neop|||carcinoma|||0|901|1158|1167
SE|25462224||ab|6|entity|C0427861|Human cells|lbtr|||human carcinoma cells|||0|901|1152|1173
SE|25462224||ab|6|entity|C0205263|Induced|ftcn|||inducing|||0|966|1177|1185
SE|25462224||ab|6|entity|C1155873|Cell Cycle Arrest|celf|||cell cycle arrest|||0|1000|1190|1207
SE|25462224||ab|6|entity|C0079396|G2 Phase|celf|||G2/M phase|||0|901|1215|1225
SE|25462224||ab|6|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|853|1245|1254

SE|25462224||ab|7|text|1282|1503|The binding interaction of complex 2 with calf thymus DNA (CT-DNA) has been explored by UV-vis absorption and circular dichroism (CD), demonstrating complex 2 has a moderate binding affinity for DNA through intercalation.
SE|25462224||ab|7|entity|C0439855|Complex|qlco|||complex|||0|861|1309|1316
SE|25462224||ab|7|entity|C0966503|calf thymus DNA|nnon,phsu|||calf thymus DNA|||0|1000|1324|1339
SE|25462224||ab|7|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|1000|1392|1410
SE|25462224||ab|7|entity|C0439855|Complex|qlco|||complex|||0|861|1431|1438
SE|25462224||ab|7|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|1477|1480
SE|25462224||ab|7|relation|4|3|C0966503|calf thymus DNA|nnon,phsu|nnon|||calf thymus DNA|||0|1000|1324|1339|NOM|INTERACTS_WITH||1464|1472|2|1|C0012854|DNA|bacs,nnon|bacs|||DNA|||0|1000|1477|1480


SE|25462226||ti|1|text|21|179|Synthesis, structure, spectral characterization, electrochemistry and evaluation of antibacterial potentiality of a novel oxime-based palladium(II) compound.
SE|25462226||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462226||ti|1|entity|C0678594|Structure|spco|||structure|||0|1000|32|41
SE|25462226||ti|1|entity|C0013803|Electrochemistry|ocdi|||electrochemistry|||0|1000|70|86
SE|25462226||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|91|101
SE|25462226||ti|1|entity|C0279516|Anti-Bacterial Agents|antb|||antibacterial|||0|853|105|118
SE|25462226||ti|1|entity|C0237399|Potential|qlco|||potentiality|||0|853|119|131
SE|25462226||ti|1|entity|C0679622|novel|inpr|||novel|||0|825|137|142
SE|25462226||ti|1|entity|C0030020|Oximes|orch|||oxime|||0|825|143|148
SE|25462226||ti|1|entity|C0030230|Palladium|elii|||palladium|||0|825|155|164
SE|25462226||ti|1|entity|C0205198|Compound|qlco|||compound|||0|1000|169|177

SE|25462226||ab|1|text|185|427|The title monomeric Pd(II) compound, [Pd(L)(Cl)], was synthesized in moderate yield out of the reaction of equimolar proportion of Na2[PdCl4] and 3-[(5-bromo-2-hydroxy-benzylidene)-hydrazono]-butan-2-one oxime (LH) in tetrahydrofuran milieu.
SE|25462226||ab|1|entity|C1519530|Title|idcn|||title|||0|828|189|194
SE|25462226||ab|1|entity|C0596973|monomer|chvs|||monomeric|||0|828|195|204
SE|25462226||ab|1|entity|C0205198|Compound|qlco|||compound|||0|1000|212|220
SE|25462226||ab|1|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|280|288
SE|25462226||ab|1|entity|C0205351|Proportional|qlco|||proportion|||0|789|302|312
SE|25462226||ab|1|entity|C0205447|One|qnco|||one|||0|750|385|388
SE|25462226||ab|1|entity|C0030020|Oximes|orch|||oxime|||0|750|389|394
SE|25462226||ab|1|entity|C0076271|tetrahydrofuran|orch|||tetrahydrofuran|||0|694|403|418

SE|25462226||ab|2|text|427|531|LH is a 1:1 Schiff-base condensate of 2,3-butanedionemonoxime monohydrazone and 5-bromosalicylaldehyde.
SE|25462226||ab|2|entity|C0036311|Schiff Bases|orch|||Schiff-base|||0|694|439|450

SE|25462226||ab|3|text|531|708|[Pd(L)(Cl)] has been characterized by C, H and N microanalyses, (1)H and (13)C NMR, FAB-MS, FT-IR, Raman spectra, UV-Vis spectra and molar electrical conductivity measurements.
SE|25462226||ab|3|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|538|540
SE|25462226||ab|3|entity|C0024485|Magnetic Resonance Imaging|diap|||NMR|||0|861|610|613
SE|25462226||ab|3|entity|C0596482|electrical measurement|lbpr|||electrical conductivity measurements|||0|858|670|706

SE|25462226||ab|4|text|708|736|[Pd(L)(Cl)] is diamagnetic.
SE|25462226||ab|4|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|715|717

SE|25462226||ab|5|text|736|855|Structural elucidation reveals that the palladium center in [Pd(L)(Cl)] is nested in 'N2OCl' coordination environment.
SE|25462226||ab|5|entity|C0030230|Palladium|elii|||palladium|||0|888|776|785
SE|25462226||ab|5|entity|C0205099|Central|spco|||center|||0|888|786|792
SE|25462226||ab|5|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|803|805
SE|25462226||ab|5|entity|C0332285|Within|spco|||in|||0|791|818|820
SE|25462226||ab|5|entity|C0014406|Environment|spco|||environment|||0|791|842|853

SE|25462226||ab|6|text|855|921|The geometry around Pd in [Pd(L)(Cl)] is distorted square-planar.
SE|25462226||ab|6|entity|C0449829|Geometry|spco|||geometry|||0|1000|859|867
SE|25462226||ab|6|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|888|890

SE|25462226||ab|7|text|921|1029|The redox behavior of [Pd(L)(Cl)] in DMF shows a reduction couple, Pd(II)/Pd(I) at -0.836 V versus Ag/AgCl.
SE|25462226||ab|7|entity|C0030012|Oxidation-Reduction|npop|||redox|||0|888|925|930
SE|25462226||ab|7|entity|C0004927|Behavior|inbe|||behavior|||0|888|931|939
SE|25462226||ab|7|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|950|952
SE|25462226||ab|7|entity|C0060056|doxorubicin/fluorouracil/mitomycin protocol|topp|||DMF|||0|1000|958|961
SE|25462226||ab|7|entity|C0010222|Couples|famg|||couple|||0|827|980|986

SE|25462226||ab|8|text|1029|1165|The in vitro antimicrobial activity of [Pd(L)(Cl)] was screened against both Gram-positive and Gram-negative human pathogenic bacteria.
SE|25462226||ab|8|entity|C1533691|in vitro|qlco|||in vitro|||0|888|1033|1041
SE|25462226||ab|8|entity|C1271650|Antimicrobial activity|lbtr|||antimicrobial activity|||0|888|1042|1064
SE|25462226||ab|8|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|1075|1077
SE|25462226||ab|8|entity|C0200966|Bacterial stain, routine|lbpr|||Gram|||0|888|1106|1110
SE|25462226||ab|8|entity|C1446409|Positive|qlco|||positive|||0|888|1111|1119
SE|25462226||ab|8|entity|C0020114|Human|humn|||human|||0|857|1138|1143
SE|25462226||ab|8|entity|C1136169|Pathogenicity|orga,qlco|||pathogenic|||0|857|1144|1154
SE|25462226||ab|8|entity|C0018150|Gram-Negative Bacteria|bact|||Gram-negative human pathogenic bacteria|||0|857|1124|1163

SE|25462226||ab|9|text|1165|1216|This bioactivity was substantiated with SEM study.
SE|25462226||ab|9|entity|C0262878|Microscopes, Electron, Scanning|medd|||SEM|||0|872|1205|1208
SE|25462226||ab|9|entity|C0008972|Clinical Research|resa|||study|||0|872|1209|1214
SE|25462226||ab|9|relation|0|0|C0008972|Clinical Research|resa|resa|||study|||0|872|1209|1214|MOD/HEAD|USES||1205|1214|0|0|C0262878|Microscopes, Electron, Scanning|medd|medd|||SEM|||0|872|1205|1208

SE|25462226||ab|10|text|1216|1298|[Pd(L)(Cl)] exhibits satisfactory bactericidal as well as bacteriostatic activity.
SE|25462226||ab|10|entity|C0201952|Chloride measurement|lbpr|||Cl|||0|1000|1223|1225
SE|25462226||ab|10|entity|C1547307|Satisfactory|inpr|||satisfactory|||0|853|1237|1249
SE|25462226||ab|10|entity|C0004611|Bacteria|bact|||bactericidal|||0|853|1250|1262


SE|25462227||ti|1|text|21|151|Synthesis, characterization and biological activity of new mixed ligand complexes of Zn(II) naproxen with nitrogen based ligands.
SE|25462227||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462227||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|53|63
SE|25462227||ti|1|entity|C0205314|New|tmco|||new|||0|833|76|79
SE|25462227||ti|1|entity|C0205430|Mixed|ftcn|||mixed|||0|833|80|85
SE|25462227||ti|1|entity|C0023688|Ligands|chem|||ligand|||0|833|86|92
SE|25462227||ti|1|entity|C0439855|Complex|qlco|||complexes|||0|833|93|102
SE|25462227||ti|1|entity|C0027396|Naproxen|orch,phsu|||naproxen|||0|1000|113|121
SE|25462227||ti|1|entity|C0028158|Nitrogen|elii|||nitrogen|||0|840|127|135
SE|25462227||ti|1|entity|C0023688|Ligands|chem|||ligands|||0|840|142|149

SE|25462227||ab|1|text|157|606|A series of novel Zn(II) complexes [Zn2(nap)4] (1), [Zn(nap)21,10-phen](2), [Zn(nap)22,9-dmphen] (3), [Zn(nap)2(2-ampy)2] (4), [Zn(nap)2(imid)2] (5), [Zn(nap)2(1,2-dmimid)2] (6) (nap = naproxen, 1,10-phen = 1,10-phenanthroline, 2,9-dmphen = 2,9-dimethyl-1,10-phenanthroline, 2-ampy = 2-aminopyridine, imid = imidazole, 1,2-dmimid = 1,2-dimethyl imidazole) were synthesized and characterized using IR, UV-Vis, (1)H NMR, (13)C{(1)H} NMR spectroscopy.
SE|25462227||ab|1|entity|C0679622|novel|inpr|||novel|||0|888|169|174
SE|25462227||ab|1|entity|C0439855|Complex|qlco|||complexes|||0|1000|182|191
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|197|200
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|213|216
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|237|240
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|263|266
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|288|291
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|311|314
SE|25462227||ab|1|entity|C0067518|N-(4-aminophenethyl)spiroperidol|orch|||nap|||0|966|336|339
SE|25462227||ab|1|entity|C0027396|Naproxen|orch,phsu|||naproxen|||0|1000|342|350
SE|25462227||ab|1|entity|C0031370|Phenanthrolines|orch|||phenanthroline|||0|861|369|383
SE|25462227||ab|1|entity|C0031370|Phenanthrolines|orch|||phenanthroline|||0|861|416|430
SE|25462227||ab|1|entity|C0051326|alpha-aminopyridine|orch,phsu|||2-aminopyridine|||0|1000|441|456
SE|25462227||ab|1|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|1000|465|474
SE|25462227||ab|1|entity|C0020923|Imidazole|orch,phsu|||imidazole|||0|827|502|511
SE|25462227||ab|1|entity|C0024485|Magnetic Resonance Imaging|diap|||NMR|||0|888|571|574
SE|25462227||ab|1|entity|C0877853|Spectroscopy, Nuclear Magnetic Resonance|diap|||NMR spectroscopy|||0|901|588|604

SE|25462227||ab|2|text|606|696|The crystal structure of complex 3 was determined using single-crystal X-ray diffraction.
SE|25462227||ab|2|entity|C0444626|Crystal Structure|chvs|||crystal structure|||0|1000|610|627
SE|25462227||ab|2|entity|C0439855|Complex|qlco|||complex|||0|861|631|638
SE|25462227||ab|2|entity|C0034571|roentgenographic|ftcn|||X-ray|||0|893|677|682
SE|25462227||ab|2|entity|C0206755|Crystallography, X-Ray|lbpr|||single-crystal X-ray diffraction|||0|893|662|694
SE|25462227||ab|2|relation|1|1|C0206755|Crystallography, X-Ray|lbpr|lbpr|||single-crystal X-ray diffraction|||0|893|662|694|VERB|MEASURES||645|655|1|1|C0444626|Crystal Structure|chvs|chvs|||crystal structure|||0|1000|610|627

SE|25462227||ab|3|text|696|1036|In order to assess the effect of the metal ions on the anti-bacterial activity, complexes 1-6 have been screened in vitro, against (G(+)) bacteria (Staphylococcus aureus and Micrococcus luteus) and (G(-)) bacteria (Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis and Escherichia coli) using the agar well diffusion method.
SE|25462227||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|719|725
SE|25462227||ab|3|entity|C0025552|Metals|inch|||metal|||0|888|733|738
SE|25462227||ab|3|entity|C0022023|Ions|elii|||ions|||0|888|739|743
SE|25462227||ab|3|entity|C0544570|Bactericidal activity|phsf|||bacterial activity|||0|851|756|774
SE|25462227||ab|3|entity|C0439855|Complex|qlco|||complexes|||0|827|776|785
SE|25462227||ab|3|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|809|817
SE|25462227||ab|3|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|834|842
SE|25462227||ab|3|entity|C0038172|Staphylococcus aureus|bact|||Staphylococcus aureus|||0|1000|844|865
SE|25462227||ab|3|entity|C0085493|Micrococcus luteus|bact|||Micrococcus luteus|||0|1000|870|888
SE|25462227||ab|3|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|901|909
SE|25462227||ab|3|entity|C0001699|Klebsiella pneumonia bacterium|bact|||Klebsiella pneumoniae|||0|1000|911|932
SE|25462227||ab|3|entity|C0033809|Pseudomonas aeruginosa|bact|||Pseudomonas aeruginosa|||0|1000|934|956
SE|25462227||ab|3|entity|C0033701|Proteus mirabilis|bact|||Proteus mirabilis|||0|1000|958|975
SE|25462227||ab|3|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|1000|980|996
SE|25462227||ab|3|entity|C0205170|Good|qlco|||well|||0|861|1013|1017
SE|25462227||ab|3|entity|C1441457|AGAR DIFFUSION|lbpr|||agar well diffusion|||0|861|1008|1027
SE|25462227||ab|3|entity|C0025663|Methods|inpr|||method|||0|861|1028|1034
SE|25462227||ab|3|relation|14|1|C0022023|Ions|elii|elii|||ions|||0|888|739|743|NOM|AFFECTS||719|725|14|2|C0544570|Bactericidal activity|phsf|phsf|||bacterial activity|||0|851|756|774

SE|25462227||ab|4|text|1036|1225|Complex 2 was the only complex that showed antibacterial activity against P. aeruginosa, where the complexation of the parent ligand 1,10-phenathroline enhanced significantly the activity.
SE|25462227||ab|4|entity|C0439855|Complex|qlco|||Complex|||0|861|1036|1043
SE|25462227||ab|4|entity|C0439855|Complex|qlco|||complex|||0|861|1059|1066
SE|25462227||ab|4|entity|C0279516|Anti-Bacterial Agents|antb|||antibacterial|||0|888|1079|1092
SE|25462227||ab|4|entity|C0033809|Pseudomonas aeruginosa|bact|||P. aeruginosa|||0|1000|1110|1123
SE|25462227||ab|4|entity|C0030551|parent|famg|||parent|||0|790|1155|1161
SE|25462227||ab|4|entity|C0023688|Ligands|chem|||ligand|||0|790|1162|1168

SE|25462227||ab|5|text|1225|1356|All the complexes showed different activity against the different bacteria, and were compared with activity of the parent ligands.
SE|25462227||ab|5|entity|C0439855|Complex|qlco|||complexes|||0|1000|1233|1242
SE|25462227||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|1250|1259
SE|25462227||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|1281|1290
SE|25462227||ab|5|entity|C0004611|Bacteria|bact|||bacteria|||0|853|1291|1299
SE|25462227||ab|5|entity|C0030551|parent|famg|||parent|||0|888|1340|1346
SE|25462227||ab|5|entity|C0023688|Ligands|chem|||ligands|||0|888|1347|1354

SE|25462227||ab|6|text|1356|1533|The complexes were tested also for their anti-malarial activity using two methods: a semi-quantitative micro-assay and a previously self-developed quantitative in-vitro method.
SE|25462227||ab|6|entity|C0439855|Complex|qlco|||complexes|||0|1000|1360|1369
SE|25462227||ab|6|entity|C0024530|Malaria|dsyn|||malarial|||0|754|1402|1410
SE|25462227||ab|6|entity|C0205448|Two|qnco|||two|||0|888|1426|1429
SE|25462227||ab|6|entity|C0025663|Methods|inpr|||methods|||0|888|1430|1437
SE|25462227||ab|6|entity|C0522525|Semi-quantitative|qnco|||semi-quantitative|||0|824|1441|1458
SE|25462227||ab|6|entity|C1510438|Assay|lbpr|||assay|||0|824|1465|1470
SE|25462227||ab|6|entity|C0036588|Self|idcn|||self|||0|761|1488|1492
SE|25462227||ab|6|entity|C1533691|in vitro|qlco|||in-vitro|||0|761|1516|1524
SE|25462227||ab|6|entity|C1510568|Quantitative Methods|resa|||quantitative in-vitro method|||0|761|1503|1531

SE|25462227||ab|7|text|1533|1643|Both were used to study the efficiency of these complexes in inhibiting the formation of the Malaria pigment.
SE|25462227||ab|7|entity|C0013682|Efficiency|qnco|||efficiency|||0|1000|1561|1571
SE|25462227||ab|7|entity|C0439855|Complex|qlco|||complexes|||0|1000|1581|1590
SE|25462227||ab|7|entity|C0311403|Inhibited|qlco|||inhibiting|||0|966|1594|1604
SE|25462227||ab|7|entity|C1522492|Formation|ftcn|||formation|||0|1000|1609|1618
SE|25462227||ab|7|entity|C0062496|hemozoin|bacs,orch|||Malaria pigment|||0|1000|1626|1641

SE|25462227||ab|8|text|1643|1752|This is considered an important target of many known anti-malarial drugs such as Chloroquine and Amodaquine.
SE|25462227||ab|8|entity|C0205309|Known|qlco|||known|||0|751|1690|1695
SE|25462227||ab|8|entity|C0024530|Malaria|dsyn|||malarial|||0|751|1701|1709
SE|25462227||ab|8|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|751|1710|1715
SE|25462227||ab|8|entity|C0008269|Chloroquine|orch,phsu|||Chloroquine|||0|1000|1724|1735
SE|25462227||ab|8|relation|0|0|C0008269|Chloroquine|orch,phsu|orch|||Chloroquine|||0|1000|1724|1735|SPEC|ISA||1710|1735|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|751|1710|1715

SE|25462227||ab|9|text|1752|1853|Results showed that the efficiency of complex 3 in preventing the formation of beta-hematin was 75%.
SE|25462227||ab|9|entity|C1274040|result|ftcn|||Results|||0|966|1752|1759
SE|25462227||ab|9|entity|C0013682|Efficiency|qnco|||efficiency|||0|1000|1776|1786
SE|25462227||ab|9|entity|C0439855|Complex|qlco|||complex|||0|861|1790|1797
SE|25462227||ab|9|entity|C1522492|Formation|ftcn|||formation|||0|1000|1818|1827
SE|25462227||ab|9|entity|C0062496|hemozoin|bacs,orch|||beta-hematin|||0|1000|1831|1843

SE|25462227||ab|10|text|1853|1928|The efficiency of Amodiaquine as a standard drug was reported to give 92.5.
SE|25462227||ab|10|entity|C0013682|Efficiency|qnco|||efficiency|||0|1000|1857|1867
SE|25462227||ab|10|entity|C0002641|Amodiaquine|orch,phsu|||Amodiaquine|||0|1000|1871|1882
SE|25462227||ab|10|entity|C1442989|STANDARD|ftcn|||standard|||0|888|1888|1896
SE|25462227||ab|10|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|888|1897|1901


SE|25462228||ti|1|text|21|157|Synthesis of a platinum(II) complex with 2-(4-methoxy-phenyl) imidazo [4,5-f]-[1,10] phenanthrolin and study of its antitumor activity.
SE|25462228||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462228||ti|1|entity|C0032207|Platinum|elii|||platinum|||0|1000|36|44
SE|25462228||ti|1|entity|C0439855|Complex|qlco|||complex|||0|1000|49|56
SE|25462228||ti|1|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|827|75|81
SE|25462228||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|124|129

SE|25462228||ab|1|text|163|349|A new platinum(II) complex of [Pt(II)(L) (pn)]Cl.2H2O (1) (pn = 1,3-propanediamine) with 2-(4-methoxy-phenyl)imidazo [4,5-f]-[1,10]phenanthrolin (H-L) was synthesized and characterized.
SE|25462228||ab|1|entity|C0205314|New|tmco|||new|||0|888|165|168
SE|25462228||ab|1|entity|C0032207|Platinum|elii|||platinum|||0|888|169|177
SE|25462228||ab|1|entity|C0439855|Complex|qlco|||complex|||0|1000|182|189
SE|25462228||ab|1|entity|C0030193|Pain|sosy|||pn|||0|1000|205|207
SE|25462228||ab|1|entity|C0259833|Propanediamine|orch|||propanediamine|||0|888|231|245
SE|25462228||ab|1|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|827|265|271
SE|25462228||ab|1|entity|C0033727|Protons|elii|||H-L|||0|694|309|312

SE|25462228||ab|2|text|349|426|In complex 1, the platinum adopts a four-coordinated square planar geometry.
SE|25462228||ab|2|entity|C0439855|Complex|qlco|||complex|||0|861|352|359
SE|25462228||ab|2|entity|C0032207|Platinum|elii|||platinum|||0|1000|367|375
SE|25462228||ab|2|entity|C0205450|Four|qnco|||four|||0|762|385|389
SE|25462228||ab|2|entity|C0427184|No incoordination|fndg|||coordinated|||0|762|390|401
SE|25462228||ab|2|entity|C0449829|Geometry|spco|||geometry|||0|762|416|424

SE|25462228||ab|3|text|426|657|Complex 1 exhibited selective cytotoxicity against NCI-H460, BEL-7402, SK-OV-3, SK-OV-3/DDP and HeLa cell lines with IC50 values in the micromolar range (9.7-35.8 MUM), but low cytotoxicity toward normal human liver HL-7702 cells.
SE|25462228||ab|3|entity|C0439855|Complex|qlco|||Complex|||0|742|426|433
SE|25462228||ab|3|entity|C0015272|Exhibits|mnob|||exhibited|||0|742|436|445
SE|25462228||ab|3|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|742|456|468
SE|25462228||ab|3|entity|C0008838|Cisplatin|inch,phsu|||DDP|||0|812|514|517
SE|25462228||ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|901|527|537
SE|25462228||ab|3|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|543|547
SE|25462228||ab|3|entity|C0042295|Values|qlco|||values|||0|888|548|554
SE|25462228||ab|3|entity|C0439300|Micromole/liter|qnco|||micromolar|||0|888|562|572
SE|25462228||ab|3|entity|C1514721|Range|qnco|||range|||0|888|573|578
SE|25462228||ab|3|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|804|589|592
SE|25462228||ab|3|entity|C0205251|low|qlco|||low|||0|888|599|602
SE|25462228||ab|3|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|603|615
SE|25462228||ab|3|entity|C0205307|Normal|qlco|||normal|||0|780|623|629
SE|25462228||ab|3|entity|C0023884|Liver|bpoc|||liver|||0|780|636|641
SE|25462228||ab|3|entity|C0427861|Human cells|lbtr|||human liver HL-7702 cells|||0|780|630|655

SE|25462228||ab|4|text|657|772|Complex 1 caused HeLa cell cycle arrest at S phase and it induced HeLa apoptosis by the activation of caspase-3/9.
SE|25462228||ab|4|entity|C0439855|Complex|qlco|||Complex|||0|744|657|664
SE|25462228||ab|4|entity|C0015127|Etiology aspects|ftcn|||caused|||0|744|667|673
SE|25462228||ab|4|entity|C1155873|Cell Cycle Arrest|celf|||cell cycle arrest|||0|744|679|696
SE|25462228||ab|4|entity|C0080129|S Phase|genf|||S phase|||0|744|700|707
SE|25462228||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|861|728|737
SE|25462228||ab|4|entity|C0910167|caspase-9|aapp,enzy|||caspase-3/9|||0|913|759|770

SE|25462228||ab|5|text|772|860|Various experiments showed that complex 1 preferred to bind with G-quadruplex in c-myc.
SE|25462228||ab|5|entity|C0681814|research study|resa|||experiments|||0|861|780|791
SE|25462228||ab|5|entity|C0439855|Complex|qlco|||complex|||0|861|804|811
SE|25462228||ab|5|entity|C1517336|G-Quartets|nusq|||G-quadruplex|||0|1000|837|849
SE|25462228||ab|5|entity|C0079068|c-myc Genes|gngm|4609|MYC|c-myc|||0|1000|853|858
SE|25462228||ab|5|relation|2|1|C1517336|G-Quartets|nusq|nusq|||G-quadruplex|||0|1000|837|849|PREP|COEXISTS_WITH||850|852|1|1|C0079068|c-myc Genes|gngm,aapp|gngm|4609|MYC|c-myc|||0|1000|853|858

SE|25462228||ab|6|text|860|1031|Taken together, we found that complex 1 exerted its antitumor activity mainly via inhibiting telomerase by interaction with c-myc quadruplex and activation of caspase-3/9.
SE|25462228||ab|6|entity|C0439855|Complex|qlco|||complex|||0|861|890|897
SE|25462228||ab|6|entity|C0311403|Inhibited|qlco|||inhibiting|||0|726|942|952
SE|25462228||ab|6|entity|C0087071|Telomerase|aapp,enzy|||telomerase|||0|726|953|963
SE|25462228||ab|6|entity|C0079068|c-myc Genes|gngm|4609|MYC|c-myc|||0|734|984|989
SE|25462228||ab|6|entity|C0910167|caspase-9|aapp,enzy|||caspase-3/9|||0|913|1019|1030


SE|25462229||ti|1|text|21|152|Novel chalcone derivatives as hypoxia-inducible factor (HIF)-1 inhibitor: synthesis, anti-invasive and anti-angiogenic properties.
SE|25462229||ti|1|entity|C0679622|novel|inpr|||Novel|||0|851|21|26
SE|25462229||ti|1|entity|C0007935|Chalcone|orch|||chalcone|||0|851|27|35
SE|25462229||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|851|36|47
SE|25462229||ti|1|entity|C0215848|Hypoxia-Inducible Factor 1|aapp,bacs|||hypoxia-inducible factor (HIF)-1|||0|922|51|83
SE|25462229||ti|1|entity|C0243077|inhibitors|chvf|||inhibitor|||0|922|84|93
SE|25462229||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|95|104
SE|25462229||ti|1|entity|C0205281|Invasive|qlco|||invasive|||0|861|111|119
SE|25462229||ti|1|entity|C0871161|Property|qlco|||properties|||0|793|140|150
SE|25462229||ti|1|relation|1|1|C0007935|Chalcone|orch|orch|||chalcone|||0|851|27|35|NOM|INHIBITS||84|93|1|0|C0215848|Hypoxia-Inducible Factor 1|aapp,gngm,bacs|gngm|||hypoxia-inducible factor (HIF)-1|||0|922|51|83

SE|25462229||ab|1|text|158|276|A novel series of chalcone derivatives were synthesized and their biological activities against HIF-1 were evaluated.
SE|25462229||ab|1|entity|C0679622|novel|inpr|||novel|||0|888|160|165
SE|25462229||ab|1|entity|C0205549|Series|qnco|||series|||0|888|166|172
SE|25462229||ab|1|entity|C0007935|Chalcone|orch|||chalcone|||0|888|176|184
SE|25462229||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|888|185|196
SE|25462229||ab|1|entity|C0205460|biological|ftcn|||biological|||0|888|224|234
SE|25462229||ab|1|entity|C0441655|Activities|acty|||activities|||0|888|235|245
SE|25462229||ab|1|entity|C0215848|Hypoxia-Inducible Factor 1|aapp,bacs|||HIF-1|||0|1000|254|259

SE|25462229||ab|2|text|276|421|Among these compounds, 5d exhibited clearly inhibitory effects on HIF-1 by downregulating the expression of HIF-1alpha under hypoxic conditions.
SE|25462229||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|288|297
SE|25462229||ab|2|entity|C0243077|inhibitors|chvf|||inhibitory|||0|737|320|330
SE|25462229||ab|2|entity|C1280500|Effect|qlco|||effects|||0|737|331|338
SE|25462229||ab|2|entity|C0215848|Hypoxia-Inducible Factor 1|aapp,bacs|||HIF-1|||0|1000|342|347
SE|25462229||ab|2|entity|C0242184|Hypoxia|patf|||HIF|||0|597|384|387
SE|25462229||ab|2|entity|C1521761|Factor|ftcn|||HIF|||0|597|384|387
SE|25462229||ab|2|entity|C0242184|Hypoxia|patf|||hypoxic|||0|872|401|408
SE|25462229||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|872|409|419

SE|25462229||ab|3|text|421|554|Meanwhile, it also significantly suppressed VEGF-induced migration and invasion of Hep3B and HUVEC cells in nontoxic concentrations.
SE|25462229||ab|3|entity|C1260953|Suppressed|ftcn|||suppressed|||0|561|454|464
SE|25462229||ab|3|entity|||gngm|7422|VEGFA|VEGF|||0|561|465|469
SE|25462229||ab|3|entity|C0205263|Induced|ftcn|||induced|||0|561|470|477
SE|25462229||ab|3|entity|C0007634|Cells|cell|||cells|||0|861|520|525
SE|25462229||ab|3|entity|C1518413|Nontoxic|qlco|||nontoxic|||0|888|529|537

SE|25462229||ab|4|text|554|634|Additionally, tube formation assay demonstrated its anti-angiogenesis activity.
SE|25462229||ab|4|entity|C0332208|Tubular formation|spco|||tube formation|||0|877|568|582
SE|25462229||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|877|583|588
SE|25462229||ab|4|entity|C0281318|antiangiogenesis therapy|topp|||anti-angiogenesis|||0|901|606|623

SE|25462229||ab|5|text|634|797|Moreover, the in vivo study indicated that compound 5d could retard tumor growth of Hep3B xenograft models and reduced CD31 and MMP-2 expression in tumor tissues.
SE|25462229||ab|5|entity|C1515655|in vivo|spco|||in vivo|||0|901|648|655
SE|25462229||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|901|656|661
SE|25462229||ab|5|entity|C0205198|Compound|qlco|||compound|||0|888|677|685
SE|25462229||ab|5|entity|C0598934|tumor growth|neop|||tumor growth|||0|1000|702|714
SE|25462229||ab|5|entity|C1520166|Xenograft Model|emod|||xenograft models|||0|884|724|740
SE|25462229||ab|5|entity|C0392756|Reduced|qlco|||reduced|||0|888|745|752
SE|25462229||ab|5|entity|C1335205|PECAM1 gene|gngm|5175|PECAM1|CD31|||0|888|753|757
SE|25462229||ab|5|entity|C0172537|Gelatinase A|aapp,enzy|||MMP-2|||0|901|762|767
SE|25462229||ab|5|entity|C0475358|Tumor tissue sample|bpoc|||tumor tissues|||0|983|782|795
SE|25462229||ab|5|relation|1|1|C0475358|Tumor tissue sample|bpoc|bpoc|||tumor tissues|||0|983|782|795|PREP|LOCATION_OF||779|781|6|2|C1335205|PECAM1 gene|gngm,aapp|aapp|5175|PECAM1|CD31|||0|888|753|757

SE|25462229||ab|6|text|797|920|Finally, in acute intravenous toxicity, 5d was well tolerated and was found to be non-toxic up to 200 mg/kg in Swiss mice.
SE|25462229||ab|6|entity|C0205178|acute|tmco|||acute|||0|851|809|814
SE|25462229||ab|6|entity|C0348016|Intravenous|spco|||intravenous|||0|851|815|826
SE|25462229||ab|6|entity|C0600688|Toxic effect|inpo|||toxicity|||0|851|827|835
SE|25462229||ab|6|entity|C0205170|Good|qlco|||well|||0|1000|844|848
SE|25462229||ab|6|entity|C1407029|Toxic|qlco|||toxic|||0|861|883|888
SE|25462229||ab|6|entity|C0162416|Mouse, Swiss|mamm|||Swiss mice|||0|1000|908|918

SE|25462229||ab|7|text|920|1066|These findings support the further investigation on the anti-invasive and anti-angiogenic potential of this class of compounds as HIF-1 inhibitor.
SE|25462229||ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|926|934
SE|25462229||ab|7|entity|C1517331|Further|spco|||further|||0|888|947|954
SE|25462229||ab|7|entity|C0205281|Invasive|qlco|||invasive|||0|861|981|989
SE|25462229||ab|7|entity|C0237399|Potential|qlco|||potential|||0|827|1010|1019
SE|25462229||ab|7|entity|C0008902|Classification|clas|||class|||0|1000|1028|1033
SE|25462229||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|966|1037|1046
SE|25462229||ab|7|entity|C0215848|Hypoxia-Inducible Factor 1|aapp,bacs|||HIF-1|||0|922|1050|1055
SE|25462229||ab|7|entity|C0243077|inhibitors|chvf|||inhibitor|||0|922|1056|1065


SE|25462230||ti|1|text|21|118|In silico design of novel 2H-chromen-2-one derivatives as potent and selective MAO-B inhibitors.
SE|25462230||ti|1|entity|C0679622|novel|inpr|||novel|||0|746|41|46
SE|25462230||ti|1|entity|C0205447|One|qnco|||one|||0|746|60|63
SE|25462230||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|746|64|75
SE|25462230||ti|1|entity|C0237399|Potential|qlco|||potent|||0|900|79|85
SE|25462230||ti|1|entity|C0026456|Monoamine Oxidase B|aapp,enzy|||MAO-B|||0|824|100|105
SE|25462230||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|824|106|116

SE|25462230||ab|1|text|124|492|Inhibition data on rat monoamine oxidase B isoform of a large number of 7-metahalobenzyloxy-2H-chromen-2-one derivatives (67 compounds) carrying at position 4 a variety of substituents differing in steric, electrostatic, lipophilic and H-bonding properties, were modeled by Gaussian field-based 3D-QSAR and docking simulations carried out on rat MAO-B homology model.
SE|25462230||ab|1|entity|C1511726|Data|idcn|||data|||0|888|135|139
SE|25462230||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|687|143|146
SE|25462230||ab|1|entity|C0026456|Monoamine Oxidase B|aapp,enzy|4129|MAOB|monoamine oxidase B|||0|687|147|166
SE|25462230||ab|1|entity|C0549177|Large|qnco|||large|||0|888|180|185
SE|25462230||ab|1|entity|C0237753|Numbers|qnco|||number|||0|888|186|192
SE|25462230||ab|1|entity|C0205447|One|qnco|||one|||0|720|229|232
SE|25462230||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|720|233|244
SE|25462230||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|827|249|258
SE|25462230||ab|1|entity|C0206243|Carrying|acty|||carrying|||0|1000|260|268
SE|25462230||ab|1|entity|C0733755|Positioning Attribute|spco|||position|||0|861|272|280
SE|25462230||ab|1|entity|C0677040|Stereochemistry|moft|||steric|||0|731|322|328
SE|25462230||ab|1|entity|C0598631|Lipophilicity|qnco|||lipophilic|||0|731|345|355
SE|25462230||ab|1|entity|C0028758|Object Attachment|menp|||bonding|||0|840|362|369
SE|25462230||ab|1|entity|C0871161|Property|qlco|||properties|||0|840|370|380
SE|25462230||ab|1|entity|C1521738|Field|cnce|||field|||0|790|407|412
SE|25462230||ab|1|entity|C0887820|3D-QSAR|qnco|||3D-QSAR|||0|790|419|426
SE|25462230||ab|1|entity|C1522290|Docking|moft|||docking|||0|872|431|438
SE|25462230||ab|1|entity|C0679083|simulation|resa|||simulations|||0|872|439|450
SE|25462230||ab|1|entity|C0439787|Out|spco|||out|||0|1000|459|462
SE|25462230||ab|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|815|466|469
SE|25462230||ab|1|entity|C0026456|Monoamine Oxidase B|aapp,enzy|||MAO-B|||0|815|470|475
SE|25462230||ab|1|entity|C1334043|Homologous Gene|gngm|||homology|||0|815|476|484
SE|25462230||ab|1|entity|C0026336|Study models|inpr,resd|||model|||0|815|485|490
SE|25462230||ab|1|relation|0|0|C0026456|Monoamine Oxidase B|aapp,gngm,enzy|aapp|4129|MAOB|monoamine oxidase B|||0|687|147|166|MOD/HEAD|PART_OF||143|166|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|687|143|146

SE|25462230||ab|2|text|492|733|The computational study combining two different approaches provided easily interpretable binding modes, highlighting the dominant role of the steric effects at position 4, and guided the design of new, potent and selective MAO-B inhibitors.
SE|25462230||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|861|510|515
SE|25462230||ab|2|entity|C0205448|Two|qnco|||two|||0|828|526|529
SE|25462230||ab|2|entity|C1547020|*Difference|qnco|||different|||0|828|530|539
SE|25462230||ab|2|entity|C0449445|Approach|spco|||approaches|||0|828|540|550
SE|25462230||ab|2|entity|C0332219|Easy|qlco|||easily|||0|775|560|566
SE|25462230||ab|2|entity|C1513371|Mode|ftcn|||modes|||0|775|589|594
SE|25462230||ab|2|entity|C1527180|Dominant|ftcn|||dominant|||0|888|613|621
SE|25462230||ab|2|entity|C0035820|Role|socb|||role|||0|888|622|626
SE|25462230||ab|2|entity|C0677040|Stereochemistry|moft|||steric|||0|836|634|640
SE|25462230||ab|2|entity|C1280500|Effect|qlco|||effects|||0|836|641|648
SE|25462230||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|861|652|660
SE|25462230||ab|2|entity|C0205314|New|tmco|||new|||0|838|689|692
SE|25462230||ab|2|entity|C0237399|Potential|qlco|||potent|||0|838|694|700
SE|25462230||ab|2|entity|C0026456|Monoamine Oxidase B|aapp,enzy|||MAO-B|||0|824|715|720
SE|25462230||ab|2|entity|C0243077|inhibitors|chvf|||inhibitors|||0|824|721|731

SE|25462230||ab|3|text|733|1037|The 4-hydroxyethyl-, 4-chloroethyl-, 4-carboxamidoethyl-coumarin derivatives 70, 71, and 76, respectively, were endowed with high MAO-B inhibitory potency (pIC50 = 8.13, 7.89 and 7.82, respectively) and good selectivity over MAO-A (pIC50 = 5.33, 3% inhibition at 10 MUM, and pIC50 = 5.37, respectively).
SE|25462230||ab|3|entity|C0010206|coumarin|orch,phsu|||coumarin|||0|728|789|797
SE|25462230||ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|728|798|809
SE|25462230||ab|3|entity|C0205250|High|qlco|||high|||0|828|858|862
SE|25462230||ab|3|entity|C0026456|Monoamine Oxidase B|aapp,enzy|||MAO-B|||0|828|863|868
SE|25462230||ab|3|entity|C0234122|Inhibitory potential|ortf|||inhibitory potency|||0|828|869|887
SE|25462230||ab|3|entity|C0205170|Good|qlco|||good|||0|812|936|940
SE|25462230||ab|3|entity|C0026455|Monoamine Oxidase A|aapp,enzy|||MAO-A|||0|812|958|963
SE|25462230||ab|3|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|999|1002

SE|25462230||ab|4|text|1037|1200|New compounds with moderate to low MAO-B inhibitory activity were also designed and prepared to challenge the predictive power of our docking-based 3D-QSAR model.
SE|25462230||ab|4|entity|C0205314|New|tmco|||New|||0|872|1037|1040
SE|25462230||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|872|1041|1050
SE|25462230||ab|4|entity|C0205251|low|qlco|||low|||0|822|1068|1071
SE|25462230||ab|4|entity|C0026456|Monoamine Oxidase B|aapp,enzy|||MAO-B|||0|822|1072|1077
SE|25462230||ab|4|entity|C0243077|inhibitors|chvf|||inhibitory|||0|822|1078|1088
SE|25462230||ab|4|entity|C0681890|predictive|qlco|||predictive|||0|694|1147|1157
SE|25462230||ab|4|entity|C1522290|Docking|moft|||docking|||0|833|1171|1178
SE|25462230||ab|4|entity|C0887820|3D-QSAR|qnco|||3D-QSAR|||0|833|1185|1192
SE|25462230||ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|833|1193|1198

SE|25462230||ab|5|text|1200|1473|The good match between predicted and experimental pIC50 values for all the newly designed compounds confirmed the robustness of our model (r(2) = 0.856, RMSE = 0.421) and its transparent rationale in unveiling the main molecular determinants for high potency towards MAO-B.
SE|25462230||ab|5|entity|C0205170|Good|qlco|||good|||0|872|1204|1208
SE|25462230||ab|5|entity|C0336766|Matches|mnob|||match|||0|872|1209|1214
SE|25462230||ab|5|entity|C1508497|PREDICTED|clna|||predicted|||0|1000|1223|1232
SE|25462230||ab|5|entity|C1517004|Experimental|ftcn|||experimental|||0|802|1237|1249
SE|25462230||ab|5|entity|C0042295|Values|qlco|||values|||0|802|1256|1262
SE|25462230||ab|5|entity|C0750546|NEWLY|idcn|||newly|||0|785|1275|1280
SE|25462230||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|785|1290|1299
SE|25462230||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|1000|1332|1337
SE|25462230||ab|5|entity|C0522503|Translucent|qlco|||transparent|||0|694|1375|1386
SE|25462230||ab|5|entity|C0205225|Primary|qlco|||main|||0|623|1414|1418
SE|25462230||ab|5|entity|C1521991|Molecular|qlco|||molecular|||0|623|1419|1428
SE|25462230||ab|5|entity|C0205250|High|qlco|||high|||0|831|1446|1450
SE|25462230||ab|5|entity|C0237399|Potential|qlco|||potency|||0|831|1451|1458
SE|25462230||ab|5|entity|C0026456|Monoamine Oxidase B|aapp,enzy|||MAO-B|||0|1000|1467|1472


SE|25462231||ti|1|text|21|208|Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11beta-hydroxylase.
SE|25462231||ti|1|entity|C0205314|New|tmco|||new|||0|861|34|37
SE|25462231||ti|1|entity|C0010207|Coumarins|orch,phsu|||coumarins|||0|827|71|80
SE|25462231||ti|1|entity|C0001006|Acetophenones|orch|||acetophenones|||0|827|113|126
SE|25462231||ti|1|entity|C0243071|Analog|chvs|||analogues|||0|966|132|141
SE|25462231||ti|1|entity|C0237399|Potential|qlco|||potent|||0|900|145|151
SE|25462231||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|861|166|176
SE|25462231||ti|1|entity|C0038296|Steroid 11-beta-Monooxygenase|aapp,enzy|||steroid-11beta-hydroxylase|||0|1000|180|206

SE|25462231||ab|1|text|214|504|Diseases triggered by an abnormally high level of cortisol (hypercortisolism), such as the Cushing's and metabolic syndromes, could be successfully tackled by inhibitors of CYP11B1, a steroidal cytochrome P450 enzyme that catalyzes the last hydroxylation step of the cortisol biosynthesis.
SE|25462231||ab|1|entity|C0012634|Disease|dsyn|||Diseases|||0|1000|214|222
SE|25462231||ab|1|entity|C1299351|Abnormally high|qlco|||abnormally high|||0|901|239|254
SE|25462231||ab|1|entity|C0020268|Hydrocortisone|horm,phsu,strd|||cortisol|||0|1000|264|272
SE|25462231||ab|1|entity|C0001622|Adrenal Gland Hyperfunction|dsyn|||hypercortisolism|||0|1000|274|290
SE|25462231||ab|1|entity|C0742927|CUSHING|dsyn|||Cushing's|||0|1000|305|314
SE|25462231||ab|1|entity|C0948265|Metabolic syndrome|dsyn|||metabolic syndromes|||0|983|319|338
SE|25462231||ab|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|373|383
SE|25462231||ab|1|entity|C0038296|Steroid 11-beta-Monooxygenase|aapp,enzy|1584|CYP11B1|CYP11B1|||0|1000|387|394
SE|25462231||ab|1|entity|C0038317|Steroids|strd|||steroidal|||0|837|398|407
SE|25462231||ab|1|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P450|||0|837|408|423
SE|25462231||ab|1|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|837|424|430
SE|25462231||ab|1|entity|C1517741|Last|qlco|||last|||0|851|450|454
SE|25462231||ab|1|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|851|455|468
SE|25462231||ab|1|entity|C1261552|Step|ftcn|||step|||0|851|469|473
SE|25462231||ab|1|entity|C0020268|Hydrocortisone|horm,phsu,strd|||cortisol|||0|888|481|489
SE|25462231||ab|1|entity|C0005572|bioformation|ftcn|||biosynthesis|||0|888|490|502
SE|25462231||ab|1|relation|6|4|C0020268|Hydrocortisone|horm,phsu,strd|horm|||cortisol|||0|1000|264|272|NOM|INHIBITS||373|383|4|1|C0038296|Steroid 11-beta-Monooxygenase|aapp,gngm,enzy|gngm|1584|CYP11B1|CYP11B1|||0|1000|387|394
SE|25462231||ab|1|relation|9|1|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||cytochrome P450|||0|837|408|423|VERB|INTERACTS_WITH||436|445|2|2|C0020268|Hydrocortisone|horm,phsu,strd|horm|||cortisol|||0|888|481|489

SE|25462231||ab|2|text|504|1007|Structural optimization of 7-(benzyloxy)-4-(1H-imidazol-1-ylmethyl)-2H-chromen-2-one 2, a selective aromatase inhibitor, afforded the 4-(1H-imidazol-1-ylmethyl)-7-{[3-(trifluoromethoxy)benzyl]oxy}-2H-chromen-2-one 7, with improved inhibitory potency at human CYP11B1 (IC50 = 5 nM) and an enhanced selectivity over human CYP11B2 (SIB = 25) compared to lead compound 2 (IC50 = 72 nM, SIB = 4.0) and metyrapone (IC50 = 15 nM, SIB = 4.8), a non-selective drug used in the therapy of the Cushing's syndrome.
SE|25462231||ab|2|entity|C0020923|Imidazole|orch,phsu|||imidazol|||0|583|551|559
SE|25462231||ab|2|entity|C0205447|One|qnco|||one|||0|764|585|588
SE|25462231||ab|2|entity|C0593802|Aromatase Inhibitors|phsu|||aromatase inhibitor|||0|901|604|623
SE|25462231||ab|2|entity|C0020923|Imidazole|orch,phsu|||imidazol|||0|583|644|652
SE|25462231||ab|2|entity|C0205447|One|qnco|||one|||0|746|714|717
SE|25462231||ab|2|entity|C0184511|Improved|qlco|||improved|||0|862|726|734
SE|25462231||ab|2|entity|C0234122|Inhibitory potential|ortf|||inhibitory potency|||0|862|735|753
SE|25462231||ab|2|entity|C0020114|Human|humn|||human|||0|888|757|762
SE|25462231||ab|2|entity|C0038296|Steroid 11-beta-Monooxygenase|aapp,enzy|1584|CYP11B1|CYP11B1|||0|888|763|770
SE|25462231||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|772|776
SE|25462231||ab|2|entity|C0020114|Human|humn|||human|||0|728|818|823
SE|25462231||ab|2|entity|C0075233|Aldosterone Synthase|aapp,enzy|1585|CYP11B2|CYP11B2|||0|728|824|831
SE|25462231||ab|2|entity|C0037047|sibling|famg|||SIB|||0|966|833|836
SE|25462231||ab|2|entity|C0205198|Compound|qlco|||compound|||0|861|860|868
SE|25462231||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|872|876
SE|25462231||ab|2|entity|C0037047|sibling|famg|||SIB|||0|966|886|889
SE|25462231||ab|2|entity|C0025876|Metyrapone|irda,orch,phsu|||metyrapone|||0|1000|901|911
SE|25462231||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|913|917
SE|25462231||ab|2|entity|C0037047|sibling|famg|||SIB|||0|966|927|930
SE|25462231||ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|827|955|959
SE|25462231||ab|2|entity|C0010481|Cushing Syndrome|dsyn|||Cushing's syndrome|||0|1000|987|1005
SE|25462231||ab|2|relation|0|0|C0038296|Steroid 11-beta-Monooxygenase|aapp,gngm,enzy|aapp|1584|CYP11B1|CYP11B1|||0|888|763|770|MOD/HEAD|PART_OF||757|770|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|757|762
SE|25462231||ab|2|relation|0|0|C0075233|Aldosterone Synthase|aapp,gngm,enzy|aapp|1585|CYP11B2|CYP11B2|||0|728|824|831|MOD/HEAD|PART_OF||818|831|0|0|C0020114|Human|grup,humn|humn|||human|||0|728|818|823
SE|25462231||ab|2|relation|13|2|C0075233|Aldosterone Synthase|aapp,gngm,enzy|aapp|1585|CYP11B2|CYP11B2|||0|728|824|831|VERB|compared_with||843|851|10|4|C0025876|Metyrapone|irda,orch,phsu|irda|||metyrapone|||0|1000|901|911
SE|25462231||ab|2|relation|21|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|827|955|959|NOM|TREATS||972|979|1|1|C0010481|Cushing Syndrome|dsyn|dsyn|||Cushing's syndrome|||0|1000|987|1005

SE|25462231||ab|3|text|1007|1208|Structure-activity relationship studies allowed the design and optimization of a novel series of potent and selective compounds, that can be regarded as open analogues of 2H-chromen-2-one derivatives.
SE|25462231||ab|3|entity|C0038477|Structure-Activity Relationship|qlco|||Structure-activity relationship|||0|908|1007|1038
SE|25462231||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|908|1039|1046
SE|25462231||ab|3|entity|C0679622|novel|inpr|||novel|||0|888|1088|1093
SE|25462231||ab|3|entity|C0205549|Series|qnco|||series|||0|888|1094|1100
SE|25462231||ab|3|entity|C0237399|Potential|qlco|||potent|||0|900|1104|1110
SE|25462231||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|827|1125|1134
SE|25462231||ab|3|entity|C0175566|Open|spco|||open|||0|872|1160|1164
SE|25462231||ab|3|entity|C0243071|Analog|chvs|||analogues|||0|872|1165|1174
SE|25462231||ab|3|entity|C0205447|One|qnco|||one|||0|762|1191|1194
SE|25462231||ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|762|1195|1206

SE|25462231||ab|4|text|1208|1517|Compound 23, 2-(1H-imidazol-1-yl)-1-(4-{[3(trifluoromethoxy)benzyl]oxy}phenyl) ethanone, was the most interesting inhibitor of the series displaying a high potency at CYP11B1 (IC50 = 15 nM), increased selectivities over CYP11B2 (SIB = 33), CYP19 (SIB = 390) and CYP17 (5% inhibition at 2.5 MUM concentration).
SE|25462231||ab|4|entity|C0205198|Compound|qlco|||Compound|||0|861|1208|1216
SE|25462231||ab|4|entity|C0020923|Imidazole|orch,phsu|||imidazol|||0|583|1227|1235
SE|25462231||ab|4|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|861|1279|1285
SE|25462231||ab|4|entity|C0205393|Most|qnco|||most|||0|785|1305|1309
SE|25462231||ab|4|entity|C0243077|inhibitors|chvf|||inhibitor|||0|785|1322|1331
SE|25462231||ab|4|entity|C0205549|Series|qnco|||series|||0|1000|1339|1345
SE|25462231||ab|4|entity|C0205250|High|qlco|||high|||0|831|1359|1363
SE|25462231||ab|4|entity|C0237399|Potential|qlco|||potency|||0|831|1364|1371
SE|25462231||ab|4|entity|C0038296|Steroid 11-beta-Monooxygenase|aapp,enzy|1584|CYP11B1|CYP11B1|||0|1000|1375|1382
SE|25462231||ab|4|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|1384|1388
SE|25462231||ab|4|entity|C0205217|Increased|qnco|||increased|||0|791|1399|1408
SE|25462231||ab|4|entity|C0075233|Aldosterone Synthase|aapp,enzy|1585|CYP11B2|CYP11B2|||0|791|1428|1435
SE|25462231||ab|4|entity|C0037047|sibling|famg|||SIB|||0|966|1437|1440
SE|25462231||ab|4|entity|C0003805|Aromatase|aapp,enzy|1588|CYP19A1|CYP19|||0|1000|1448|1453
SE|25462231||ab|4|entity|C0037047|sibling|famg|||SIB|||0|966|1455|1458
SE|25462231||ab|4|entity|C0038302|Steroid 17-alpha-monooxygenase|aapp,enzy|1586|CYP17A1|CYP17|||0|1000|1470|1475
SE|25462231||ab|4|entity|C0450346|2/5|qnco|||2.5|||0|658|1494|1497
SE|25462231||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|658|1498|1501


SE|25462232||ti|1|text|21|45|Studies on indolizines.
SE|25462232||ti|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|21|28
SE|25462232||ti|1|entity|C0021243|Indolizines|orch|||indolizines|||0|1000|32|43

SE|25462232||ti|2|text|45|158|Evaluation of their biological properties as microtubule-interacting agents and as melanoma targeting compounds.
SE|25462232||ti|2|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|45|55
SE|25462232||ti|2|entity|C0205460|biological|ftcn|||biological|||0|872|65|75
SE|25462232||ti|2|entity|C0871161|Property|qlco|||properties|||0|872|76|86
SE|25462232||ti|2|entity|C0026046|Microtubules|celc|||microtubule|||0|785|90|101
SE|25462232||ti|2|entity|C0450442|Agent|chvf|||agents|||0|785|114|120
SE|25462232||ti|2|entity|C0025202|melanoma|neop|||melanoma|||0|840|128|136
SE|25462232||ti|2|entity|C0205198|Compound|qlco|||compounds|||0|840|147|156

SE|25462232||ab|1|text|164|477|With the aim of investigating new analogues of phenstatin with an indolizin-3-yl unit, in particular as the B-ring, three new series of compounds (6-8, 9-34 and 54) were synthesized and tested for interactions with tubulin polymerization and evaluated for cytotoxicity on an NCI-60 human cancer cell lines panel.
SE|25462232||ab|1|entity|C1292732|Investigates|ftcn|||investigating|||0|829|180|193
SE|25462232||ab|1|entity|C0205314|New|tmco|||new|||0|829|194|197
SE|25462232||ab|1|entity|C0243071|Analog|chvs|||analogues|||0|829|198|207
SE|25462232||ab|1|entity|C0439148|Unit|qnco|||unit|||0|812|245|249
SE|25462232||ab|1|entity|C0205449|Three|qnco|||three|||0|851|280|285
SE|25462232||ab|1|entity|C0205314|New|tmco|||new|||0|851|286|289
SE|25462232||ab|1|entity|C0205549|Series|qnco|||series|||0|851|290|296
SE|25462232||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|966|300|309
SE|25462232||ab|1|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|888|379|386
SE|25462232||ab|1|entity|C0314672|Polymerization|phpr|||polymerization|||0|888|387|401
SE|25462232||ab|1|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|420|432
SE|25462232||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|619|452|458
SE|25462232||ab|1|entity|C0682523|Human Cell Line|cell|||human cancer cell lines|||0|619|446|469

SE|25462232||ab|2|text|477|652|The replacement of the 3'-hydroxy-4'-methoxyphenyl B-ring of phenstatin with substituted indolizine unit results in the conservation of both antitubulin and cytotoxic effect.
SE|25462232||ab|2|entity|C0035139|Surgical Replantation|topp|||replacement|||0|1000|481|492
SE|25462232||ab|2|entity|C0021243|Indolizines|orch|||indolizine|||0|790|566|576
SE|25462232||ab|2|entity|C0439148|Unit|qnco|||unit|||0|790|577|581
SE|25462232||ab|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|634|643
SE|25462232||ab|2|entity|C1280500|Effect|qlco|||effect|||0|888|644|650

SE|25462232||ab|3|text|652|901|Indolizines 9 and 17 were the most effective in the present study and showed the highest antiproliferative effect on melanoma cell lines MDA-MB-435 (GI50 = 30 nM) and could serve as new lead compounds for the development of anti-cancer therapeutics.
SE|25462232||ab|3|entity|C0021243|Indolizines|orch|||Indolizines|||0|861|652|663
SE|25462232||ab|3|entity|C0205393|Most|qnco|||most|||0|888|682|686
SE|25462232||ab|3|entity|C0150312|Present|qnco|||present|||0|888|704|711
SE|25462232||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|712|717
SE|25462232||ab|3|entity|C1522410|Highest|qlco|||highest|||0|802|733|740
SE|25462232||ab|3|entity|C1280500|Effect|qlco|||effect|||0|802|759|765
SE|25462232||ab|3|entity|C0025202|melanoma|neop|||melanoma|||0|787|769|777
SE|25462232||ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|787|778|788
SE|25462232||ab|3|entity|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|||MDA-MB|||0|787|789|795
SE|25462232||ab|3|entity|C1533164|Megabase|qnco|||MDA-MB|||0|787|789|795
SE|25462232||ab|3|entity|C0205314|New|tmco|||new|||0|890|834|837
SE|25462232||ab|3|entity|C0303231|Lead compound|chvs|||lead compounds|||0|890|838|852
SE|25462232||ab|3|entity|C1527148|Development|ftcn|||development|||0|1000|861|872
SE|25462232||ab|3|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|790|881|887


SE|25462233||ti|1|text|21|158|Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
SE|25462233||ti|1|entity|C0032334|podophyllotoxin|orch,phsu|||podophyllotoxin|||0|888|38|53
SE|25462233||ti|1|entity|C0014898|Esters|orch|||esters|||0|888|54|60
SE|25462233||ti|1|entity|C0237399|Potential|qlco|||potential|||0|785|64|73
SE|25462233||ti|1|entity|C0450442|Agent|chvf|||agents|||0|785|85|91
SE|25462233||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|93|102
SE|25462233||ti|1|entity|C0205460|biological|ftcn|||biological|||0|872|104|114
SE|25462233||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|115|122
SE|25462233||ti|1|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|840|127|134
SE|25462233||ti|1|entity|C0871161|Property|qlco|||properties|||0|840|146|156
SE|25462233||ti|1|relation|5|4|C0014898|Esters|orch|orch|||esters|||0|888|54|60|NOM|INHIBITS||135|145|5|0|C0041348|Tubulin|aapp,gngm,bacs|gngm|||tubulin|||0|840|127|134

SE|25462233||ab|1|text|164|427|A series of fifteen podophyllotoxin derived esters have been synthesized and their anti-cancer properties have been evaluated against A549 (lung cancer), DU-145 (prostate cancer), HepG2 (liver cancer), HeLa (cervical cancer) and MCF-7 (breast cancer) cell lines.
SE|25462233||ab|1|entity|C0032334|podophyllotoxin|orch,phsu|||podophyllotoxin|||0|775|184|199
SE|25462233||ab|1|entity|C0014898|Esters|orch|||esters|||0|775|208|214
SE|25462233||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|773|252|258
SE|25462233||ab|1|entity|C0871161|Property|qlco|||properties|||0|773|259|269
SE|25462233||ab|1|entity|C0242379|Malignant neoplasm of lung|neop|||lung cancer|||0|1000|304|315
SE|25462233||ab|1|entity|C0013295|Duodenal Ulcer|dsyn|||DU-145|||0|861|318|324
SE|25462233||ab|1|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|1000|326|341
SE|25462233||ab|1|entity|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|||liver cancer|||0|1000|351|363
SE|25462233||ab|1|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|372|387
SE|25462233||ab|1|entity|C0008015|Macrophage Chemotactic Factors|imft|||MCF-7|||0|861|393|398
SE|25462233||ab|1|entity|C0006142|Malignant neoplasm of breast|neop|||breast cancer|||0|1000|400|413
SE|25462233||ab|1|entity|C0007600|Cell Line|cell|||cell lines|||0|1000|415|425

SE|25462233||ab|2|text|427|527|Five compounds of the series 8a, 8g-h, 8m and 8o showed IC50 values in the range of 0.71-10.94 MUM.
SE|25462233||ab|2|entity|C0205451|Five|qnco|||Five|||0|872|427|431
SE|25462233||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|872|432|441
SE|25462233||ab|2|entity|C0205549|Series|qnco|||series|||0|888|449|455
SE|25462233||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|483|487
SE|25462233||ab|2|entity|C0042295|Values|qlco|||values|||0|888|488|494
SE|25462233||ab|2|entity|C1514721|Range|qnco|||range|||0|1000|502|507
SE|25462233||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|804|522|525

SE|25462233||ab|3|text|527|627|Among compounds, 8g and 8h showed significant cytotoxicity towards all the types of cancer studied.
SE|25462233||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|533|542
SE|25462233||ab|3|entity|C0750502|Significant|idcn|||significant|||0|888|561|572
SE|25462233||ab|3|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|573|585
SE|25462233||ab|3|entity|C0332307|Type - attribute|qlco|||types|||0|1000|602|607
SE|25462233||ab|3|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|611|617

SE|25462233||ab|4|text|627|733|Cell cycle analysis revealed that the compounds 8a, 8m and 8o inhibit proliferation by cell cycle arrest.
SE|25462233||ab|4|entity|C0007586|Cell Cycle|celf|||Cell cycle|||0|901|627|637
SE|25462233||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|901|638|646
SE|25462233||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|872|665|674
SE|25462233||ab|4|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|697|710
SE|25462233||ab|4|entity|C1155873|Cell Cycle Arrest|celf|||cell cycle arrest|||0|1000|714|731

SE|25462233||ab|5|text|733|833|Also Hoechst-positive nucleus indicating apoptosis of these cells was observed in presence of 8g-h.
SE|25462233||ab|5|entity|C1446409|Positive|qlco|||positive|||0|750|746|754
SE|25462233||ab|5|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|750|755|762
SE|25462233||ab|5|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|774|783
SE|25462233||ab|5|entity|C0007634|Cells|cell|||cells|||0|1000|793|798
SE|25462233||ab|5|relation|3|1|C0007634|Cells|cell|cell|||cells|||0|1000|793|798|PREP|LOCATION_OF||784|786|2|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|1000|774|783

SE|25462233||ab|6|text|833|1029|Further studies revealed that these compounds inhibit tubulin polymerization and leads to the inactivation of AKT/PKB that are known to play an important role in the proliferation of cancer cells.
SE|25462233||ab|6|entity|C1517331|Further|spco|||Further|||0|872|833|840
SE|25462233||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|872|841|848
SE|25462233||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|869|878
SE|25462233||ab|6|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|888|887|894
SE|25462233||ab|6|entity|C0314672|Polymerization|phpr|||polymerization|||0|888|895|909
SE|25462233||ab|6|entity|C0544461|Inactivation|comd|||inactivation|||0|1000|927|939
SE|25462233||ab|6|entity|C0164786|Proto-Oncogene Proteins c-akt|aapp,enzy|207|AKT1|AKT|||0|888|943|946
SE|25462233||ab|6|entity|C0285558|RAC-Alpha Serine/Threonine Kinase|aapp,enzy|207,2185|AKT1,PTK2B|PKB|||0|888|947|950
SE|25462233||ab|6|entity|C0035820|Role|socb|||role|||0|861|987|991
SE|25462233||ab|6|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|999|1012
SE|25462233||ab|6|entity|C0334227|Tumor cells, malignant|cell|||cancer cells|||0|983|1016|1028


SE|25462234||ti|1|text|21|132|Rational design, synthesis and anti-proliferative evaluation of novel 1,4-benzoxazine-[1,2,3]triazole hybrids.
SE|25462234||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|38|47
SE|25462234||ti|1|entity|C0334094|Proliferation|ftcn|||proliferative|||0|790|57|70
SE|25462234||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|790|71|81
SE|25462234||ti|1|entity|C0679622|novel|inpr|||novel|||0|861|85|90
SE|25462234||ti|1|entity|C0598594|Benzoxazines|orch|||benzoxazine|||0|861|95|106
SE|25462234||ti|1|entity|C0040880|Triazoles|orch|||triazole|||0|888|114|122
SE|25462234||ti|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|888|123|130

SE|25462234||ab|1|text|138|435|A series of novel 1,2,3-triazole-1,4-benzoxazine hybrids 5a-n were efficiently synthesized employing click chemistry approach and evaluated for anti-proliferative activity against four cancer cell lines such as HeLa (cervical), MIAPACA (pancreatic), MDA-MB-231 (breast) and IMR32 (neuroblastoma).
SE|25462234||ab|1|entity|C0679622|novel|inpr|||novel|||0|861|150|155
SE|25462234||ab|1|entity|C0040880|Triazoles|orch|||triazole|||0|790|162|170
SE|25462234||ab|1|entity|C0598594|Benzoxazines|orch|||benzoxazine|||0|762|175|186
SE|25462234||ab|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|762|187|194
SE|25462234||ab|1|entity|C0079107|chemical aspects|clas|||chemistry|||0|790|245|254
SE|25462234||ab|1|entity|C0449445|Approach|spco|||approach|||0|790|255|263
SE|25462234||ab|1|entity|C0334094|Proliferation|ftcn|||proliferative|||0|790|287|300
SE|25462234||ab|1|entity|C0205450|Four|qnco|||four|||0|861|318|322
SE|25462234||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|861|323|329
SE|25462234||ab|1|entity|C0007600|Cell Line|cell|||cell lines|||0|861|330|340
SE|25462234||ab|1|entity|C0205064|Cervical|spco|||cervical|||0|1000|355|363
SE|25462234||ab|1|entity|C0030274|Pancreas|bpoc|||pancreatic|||0|1000|375|385
SE|25462234||ab|1|entity|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|||MDA-MB|||0|790|388|394
SE|25462234||ab|1|entity|C1533164|Megabase|qnco|||MDA-MB|||0|790|388|394
SE|25462234||ab|1|entity|C0006141|Breast|bpoc|||breast|||0|1000|400|406
SE|25462234||ab|1|entity|C0027819|Neuroblastoma|neop|||neuroblastoma|||0|1000|419|432

SE|25462234||ab|2|text|435|765|Compounds 5n and 5g exhibited promising anti-proliferative activity with GI50 values ranging from 1.2 to 2.5 MUM and 0.1-1.1 MUM respectively against all cell lines, like HeLa, MDA-MB-231, MIAPACA and IMR32, while compound 5l showed significant activity against MDA-MB-231 and IMR32 with GI50 values ranging from 1.1 and 1.4 MUM.
SE|25462234||ab|2|entity|C0205198|Compound|qlco|||Compounds|||0|661|435|444
SE|25462234||ab|2|entity|C0334094|Proliferation|ftcn|||proliferative|||0|790|480|493
SE|25462234||ab|2|entity|C0042295|Values|qlco|||values|||0|861|513|519
SE|25462234||ab|2|entity|C0580272|1/2|inpr|||1.2|||0|1000|533|536
SE|25462234||ab|2|entity|C0450346|2/5|qnco|||2.5|||0|901|540|543
SE|25462234||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|901|544|547
SE|25462234||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|799|560|563
SE|25462234||ab|2|entity|C0007600|Cell Line|cell|||cell lines|||0|1000|589|599
SE|25462234||ab|2|entity|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|||MDA-MB|||0|790|612|618
SE|25462234||ab|2|entity|C1533164|Megabase|qnco|||MDA-MB|||0|790|612|618
SE|25462234||ab|2|entity|C0205198|Compound|qlco|||compound|||0|888|649|657
SE|25462234||ab|2|entity|C0750502|Significant|idcn|||significant|||0|888|668|679
SE|25462234||ab|2|entity|C0000379|3,4-Methylenedioxyamphetamine|orch,phsu|||MDA-MB|||0|790|697|703
SE|25462234||ab|2|entity|C1533164|Megabase|qnco|||MDA-MB|||0|790|697|703
SE|25462234||ab|2|entity|C0042295|Values|qlco|||values|||0|861|728|734
SE|25462234||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|760|763

SE|25462234||ab|3|text|765|892|This is the first report on the synthesis and in vitro anti-proliferative evaluation of 1,2,3-triazole-1,4-benzoxazine hybrids.
SE|25462234||ab|3|entity|C1279901|Firstly|qlco|||first|||0|888|777|782
SE|25462234||ab|3|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|797|806
SE|25462234||ab|3|entity|C1533691|in vitro|qlco|||in vitro|||0|785|811|819
SE|25462234||ab|3|entity|C0334094|Proliferation|ftcn|||proliferative|||0|785|825|838
SE|25462234||ab|3|entity|C0220825|Evaluation|ftcn|||evaluation|||0|785|839|849
SE|25462234||ab|3|entity|C0040880|Triazoles|orch|||triazole|||0|790|859|867
SE|25462234||ab|3|entity|C0598594|Benzoxazines|orch|||benzoxazine|||0|790|872|883
SE|25462234||ab|3|entity|C0020205|Hybrids|orgm|||hybrids|||0|790|884|891


SE|25462235||ti|1|text|21|115|Comparative (Q)SAR analysis of benzodiazepine derivatives with different biological activity.
SE|25462235||ti|1|entity|C0038477|Structure-Activity Relationship|qlco|||SAR|||0|810|36|39
SE|25462235||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|810|40|48
SE|25462235||ti|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine|||0|888|52|66
SE|25462235||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|888|67|78
SE|25462235||ti|1|entity|C1547020|*Difference|qnco|||different|||0|828|84|93
SE|25462235||ti|1|entity|C0205460|biological|ftcn|||biological|||0|828|94|104

SE|25462235||ab|1|text|121|490|211 compounds containing a benzodiazepine moiety (BZD) and belonging to 4 groups of different biological activity (H - inhibitors of reverse transcriptase of HIV-I virus, A - antiarrhythmic agents, G - ligands of benzodiazepine receptor in GABAergic system and C - cholecystokinin receptor antagonists) were subjected to structure-activity relationship (SAR) analysis.
SE|25462235||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|827|125|134
SE|25462235||ab|1|entity|C0005064|Benzodiazepines|orch,phsu|||benzodiazepine|||0|694|148|162
SE|25462235||ab|1|entity|C0441833|Groups|inpr|||groups|||0|861|195|201
SE|25462235||ab|1|entity|C1547020|*Difference|qnco|||different|||0|828|205|214
SE|25462235||ab|1|entity|C0205460|biological|ftcn|||biological|||0|828|215|225
SE|25462235||ab|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|240|250
SE|25462235||ab|1|entity|C0035379|RNA-Directed DNA Polymerase|aapp,enzy|||reverse transcriptase|||0|1000|254|275
SE|25462235||ab|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|1000|279|282
SE|25462235||ab|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|285|290
SE|25462235||ab|1|entity|C0003195|Anti-Arrhythmia Agents|phsu|||antiarrhythmic agents|||0|983|296|317
SE|25462235||ab|1|entity|C0023688|Ligands|chem|||ligands|||0|861|323|330
SE|25462235||ab|1|entity|C0205923|Benzodiazepine Receptor|aapp,rcpt|||benzodiazepine receptor|||0|1000|334|357
SE|25462235||ab|1|entity|C0449913|System|ftcn|||system|||0|861|371|377
SE|25462235||ab|1|entity|C0034791|Cholecystokinin Receptor|aapp,nsba,rcpt|||cholecystokinin receptor|||0|824|386|410
SE|25462235||ab|1|entity|C0243076|antagonists|chvf|||antagonists|||0|824|411|422
SE|25462235||ab|1|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationship|||0|810|442|473
SE|25462235||ab|1|entity|C0936012|Analysis|resa|||analysis|||0|810|480|488
SE|25462235||ab|1|relation|13|7|C0035379|RNA-Directed DNA Polymerase|aapp,gngm,enzy|aapp|||reverse transcriptase|||0|1000|254|275|NOM|INHIBITS||411|422|13|0|C0034791|Cholecystokinin Receptor|aapp,gngm,nsba,rcpt|aapp|||cholecystokinin receptor|||0|824|386|410

SE|25462235||ab|2|text|490|675|SAR investigations of all 211 BZD were based on Discriminant Function Analysis (DFA) of physicochemical data connected with BBB (blood-brain barrier) permeability of studied compounds.
SE|25462235||ab|2|entity|C0038477|Structure-Activity Relationship|qlco|||SAR|||0|810|490|493
SE|25462235||ab|2|entity|C0005064|Benzodiazepines|orch,phsu|||BZD|||0|660|520|523
SE|25462235||ab|2|entity|C0012630|Discriminant Analysis|qnco,resa|||Discriminant Function Analysis|||0|1000|538|568
SE|25462235||ab|2|entity|C1511726|Data|idcn|||data|||0|861|594|598
SE|25462235||ab|2|entity|C0005854|Blood - brain barrier anatomy|bpoc|||BBB|||0|1000|614|617
SE|25462235||ab|2|entity|C0005854|Blood - brain barrier anatomy|bpoc|||blood-brain barrier|||0|1000|619|638
SE|25462235||ab|2|entity|C0031164|Permeability|npop|||permeability|||0|1000|640|652
SE|25462235||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|827|664|673

SE|25462235||ab|3|text|675|842|DFA was performed with STATISTICA 10.0 software by the stepwise method and resulted in 3 discriminant functions whose quality was assessed by Wilk's lambda parameter.
SE|25462235||ab|3|entity|C0012630|Discriminant Analysis|qnco,resa|||DFA|||0|1000|675|678
SE|25462235||ab|3|entity|C0025663|Methods|inpr|||method|||0|861|739|745
SE|25462235||ab|3|entity|C0542341|Function|ftcn|||functions|||0|802|777|786
SE|25462235||ab|3|entity|C0332306|Quality|qlco|||quality|||0|1000|793|800
SE|25462235||ab|3|entity|C0926407|Lambda|blor|||lambda|||0|790|824|830
SE|25462235||ab|3|entity|C0549193|Parameter|spco|||parameter|||0|790|831|840

SE|25462235||ab|4|text|842|1027|Calculated discriminant functions (roots) were applied to draw the scatter diagram of canonical values that showed all 211 cases divided into 4 groups of different biological activity.
SE|25462235||ab|4|entity|C0542341|Function|ftcn|||functions|||0|827|866|875
SE|25462235||ab|4|entity|C0681494|diagram|inpr|||diagram|||0|861|917|924
SE|25462235||ab|4|entity|C0042295|Values|qlco|||values|||0|861|938|944
SE|25462235||ab|4|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|965|970
SE|25462235||ab|4|entity|C0441833|Groups|inpr|||groups|||0|861|986|992
SE|25462235||ab|4|entity|C1547020|*Difference|qnco|||different|||0|828|996|1005
SE|25462235||ab|4|entity|C0205460|biological|ftcn|||biological|||0|828|1006|1016

SE|25462235||ab|5|text|1027|1142|The method was successfully validated with a set of 38 BZD derivatives expected to belong to groups H, A, G and C.
SE|25462235||ab|5|entity|C0025663|Methods|inpr|||method|||0|1000|1031|1037
SE|25462235||ab|5|entity|C0005064|Benzodiazepines|orch,phsu|||BZD|||0|763|1082|1085
SE|25462235||ab|5|entity|C0243072|derivatives|chvs|||derivatives|||0|763|1086|1097
SE|25462235||ab|5|entity|C0441842|Group H|inpr|||groups H|||0|983|1120|1128

SE|25462235||ab|6|text|1142|1224|The reliability of the obtained model was confirmed with a cross-validation test.
SE|25462235||ab|6|entity|C1301820|Obtained|ftcn|||obtained|||0|888|1165|1173
SE|25462235||ab|6|entity|C0026336|Study models|inpr,resd|||model|||0|888|1174|1179
SE|25462235||ab|6|entity|C0681935|cross-validation|resa|||cross-validation|||0|901|1201|1217
SE|25462235||ab|6|entity|C0039593|Testing|resa|||test|||0|901|1218|1222

SE|25462235||ab|7|text|1224|1343|Classification functions presented in this study may be used as a practical tool for predicting new BZD drugs activity.
SE|25462235||ab|7|entity|C0008902|Classification|clas|||Classification|||0|888|1224|1238
SE|25462235||ab|7|entity|C0542341|Function|ftcn|||functions|||0|888|1239|1248
SE|25462235||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1267|1272
SE|25462235||ab|7|entity|C0237607|experience (practice)|menp|||practical|||0|853|1290|1299
SE|25462235||ab|7|entity|C0336791|Tool|mnob|||tool|||0|853|1300|1304
SE|25462235||ab|7|entity|C1508497|PREDICTED|clna|||predicting|||0|744|1309|1319
SE|25462235||ab|7|entity|C0205314|New|tmco|||new|||0|744|1320|1323
SE|25462235||ab|7|entity|C0005064|Benzodiazepines|orch,phsu|||BZD|||0|744|1324|1327
SE|25462235||ab|7|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|744|1328|1333


SE|25462237||ti|1|text|21|82|Thiazolidone derivatives as inhibitors of chikungunya virus.
SE|25462237||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|861|34|45
SE|25462237||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|49|59
SE|25462237||ti|1|entity|C0008056|Chikungunya virus|virs|||chikungunya virus|||0|1000|63|80

SE|25462237||ab|1|text|88|301|A series of arylalkylidene derivatives of 1,3-thiazolidin-4-one (1-20) were synthesized and tested for their antiviral activity against chikungunya virus (LR2006_OPY1) in Vero cell culture by CPE reduction assay.
SE|25462237||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|861|115|126
SE|25462237||ab|1|entity|C0205447|One|qnco|||one|||0|824|148|151
SE|25462237||ab|1|entity|C0008056|Chikungunya virus|virs|||chikungunya virus|||0|1000|224|241
SE|25462237||ab|1|entity|C0042542|Vero Cells|cell|||Vero cell|||0|901|259|268
SE|25462237||ab|1|entity|C0220814|Cultural|ftcn|||culture|||0|901|269|276
SE|25462237||ab|1|entity|||gngm|1363|CPE|CPE|||0|827|280|283
SE|25462237||ab|1|entity|C1510438|Assay|lbpr|||assay|||0|827|294|299

SE|25462237||ab|2|text|301|413|Five compounds (7-9, 16 and 19) were identified to have anti-ChikV activity at lower micro molar concentration.
SE|25462237||ab|2|entity|C0205451|Five|qnco|||Five|||0|872|301|305
SE|25462237||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|872|306|315
SE|25462237||ab|2|entity|C0441994|Lower|ftcn|||lower|||0|645|380|385

SE|25462237||ab|3|text|413|531|The compounds 7, 8, 9, 16 and 19 inhibited the virus at 0.42, 4.2, 3.6, 40.1 and 6.8 MUM concentrations respectively.
SE|25462237||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|827|417|426
SE|25462237||ab|3|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|460|465
SE|25462237||ab|3|entity|C0442759|3/6|fndg|||3.6|||0|1000|480|483
SE|25462237||ab|3|entity|C0439509|/40|tmco|||40|||0|861|485|487
SE|25462237||ab|3|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|728|498|501

SE|25462237||ab|4|text|531|709|Molecular docking simulation has been carried out using the available X-ray crystal structure of the ChikV nsp2 protease, in order to elucidate the possible mechanism of action.
SE|25462237||ab|4|entity|C1521991|Molecular|qlco|||Molecular|||0|851|531|540
SE|25462237||ab|4|entity|C1522290|Docking|moft|||docking|||0|851|541|548
SE|25462237||ab|4|entity|C0679083|simulation|resa|||simulation|||0|851|549|559
SE|25462237||ab|4|entity|C0439787|Out|spco|||out|||0|1000|577|580
SE|25462237||ab|4|entity|C0034571|roentgenographic|ftcn|||X-ray|||0|857|601|606
SE|25462237||ab|4|entity|C0444626|Crystal Structure|chvs|||crystal structure|||0|857|607|624
SE|25462237||ab|4|entity|C1332386|BCAR3 gene|gngm|8412|BCAR3|nsp2|||0|790|638|642
SE|25462237||ab|4|entity|C0030946|Endopeptidases|aapp,enzy,phsu|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|protease|||0|790|643|651
SE|25462237||ab|4|entity|C0332149|Possible|qlco|||possible|||0|888|679|687
SE|25462237||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|688|697

SE|25462237||ab|5|text|709|865|Interaction of ligands with ChikV nsp2 protease (PDB Code: 3TRK) suggested the possible mechanism of protease inhibition to act as potent anti-ChikV agents.
SE|25462237||ab|5|entity|C0023688|Ligands|chem|||ligands|||0|1000|724|731
SE|25462237||ab|5|entity|C1332386|BCAR3 gene|gngm|8412|BCAR3|nsp2|||0|790|743|747
SE|25462237||ab|5|entity|C0030946|Endopeptidases|aapp,enzy,phsu|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|protease|||0|790|748|756
SE|25462237||ab|5|entity|||gngm|5131|PDB1|PDB|||0|861|758|761
SE|25462237||ab|5|entity|C0805701|Code|inpr|||Code|||0|861|762|766
SE|25462237||ab|5|entity|C0332149|Possible|qlco|||possible|||0|888|788|796
SE|25462237||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|797|806
SE|25462237||ab|5|entity|C0030946|Endopeptidases|aapp,enzy,phsu|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|protease|||0|888|810|818
SE|25462237||ab|5|entity|C0237399|Potential|qlco|||potent|||0|791|840|846
SE|25462237||ab|5|entity|C0040616|Anti-Anxiety Agents|phsu|||anti-ChikV agents|||0|791|847|864
SE|25462237||ab|5|relation|7|2|C0030946|Endopeptidases|aapp,gngm,enzy,phsu|aapp|449619,619465,100616101,100616102,100616103,100775105,100862683,100862684,100862685|ERVK-7,ERVK-8,ERVK-10,ERVK-9,ERVK-21,ERVK-18,ERVK-25,ERVK-24,ERVK-19|protease|||0|790|748|756|NOM|INTERACTS_WITH||709|720|7|1|C0023688|Ligands|chem|chem|||ligands|||0|1000|724|731


SE|25462236||ti|1|text|21|136|Synthesis and structure--activity relationship of new cytotoxic agents targeting human glutathione-S-transferases.
SE|25462236||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462236||ti|1|entity|C0678594|Structure|spco|||structure|||0|1000|35|44
SE|25462236||ti|1|entity|C0439849|Relationships|qlco|||relationship|||0|888|55|67
SE|25462236||ti|1|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|901|75|84
SE|25462236||ti|1|entity|C1518316|New Agents|clas|||new cytotoxic agents|||0|901|71|91
SE|25462236||ti|1|entity|C0020114|Human|humn|||human|||0|916|102|107
SE|25462236||ti|1|entity|C0017837|Glutathione S-Transferase|aapp,enzy|||glutathione|||0|916|108|119

SE|25462236||ab|1|text|142|461|The 6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexan-1-ol (NBDHEX, 1), a "suicide inhibitor" of the glutathione-S-transferase GSTP1-1, showed pro-apoptotic properties in tumor cells, but in vivo studies were limited by poor bioavailability and high affinity towards GSTM2-2, expressed in many non-cancerous tissues.
SE|25462236||ab|1|entity|||gngm|30|ACAA1|thio|||0|1000|187|191
SE|25462236||ab|1|entity|C0044399|1-hexanol|orch,phsu|||hexan-1-ol|||0|1000|192|202
SE|25462236||ab|1|entity|C0038661|Suicide|inpo|||suicide|||0|872|219|226
SE|25462236||ab|1|entity|C0243077|inhibitors|chvf|||inhibitor|||0|872|227|236
SE|25462236||ab|1|entity|C0017837|Glutathione S-Transferase|aapp,enzy|||glutathione|||0|854|245|256
SE|25462236||ab|1|entity|C0537086|glutathione S-transferase pi|aapp,enzy|2950|GSTP1|GSTP1-1|||0|854|271|278
SE|25462236||ab|1|entity|C0033382|Proline|aapp,bacs|||pro|||0|840|287|290
SE|25462236||ab|1|entity|C1516044|Apoptotic|qlco|||apoptotic|||0|840|291|300
SE|25462236||ab|1|entity|C0871161|Property|qlco|||properties|||0|840|301|311
SE|25462236||ab|1|entity|C0431085|[M]Unspecified tumor cell NOS|cell|||tumor cells|||0|1000|315|326
SE|25462236||ab|1|entity|C1515655|in vivo|spco|||in vivo|||0|884|332|339
SE|25462236||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|884|340|347
SE|25462236||ab|1|entity|C0032854|Poverty|grpa|||poor|||0|888|364|368
SE|25462236||ab|1|entity|C0005508|Biological Availability|qnco|||bioavailability|||0|888|369|384
SE|25462236||ab|1|entity|C0205250|High|qlco|||high|||0|888|389|393
SE|25462236||ab|1|entity|||gngm|2946|GSTM2|GSTM2-2|||0|1000|411|418
SE|25462236||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancerous|||0|754|442|451
SE|25462236||ab|1|entity|C0040300|Body tissue|tisu|||tissues|||0|754|452|459
SE|25462236||ab|1|relation|0|0|C0040300|Body tissue|tisu|tisu|||tissues|||0|754|452|459|MOD/HEAD|PART_OF|negation|442|459|0|0|C0006826|Malignant Neoplasms|neop|neop|||cancerous|||0|754|442|451
SE|25462236||ab|1|relation|1|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|754|452|459|PREP|LOCATION_OF||430|432|12|0|||gngm,aapp|aapp|2946|GSTM2|GSTM2-2|||0|1000|411|418
SE|25462236||ab|1|relation|6|2|C0044399|1-hexanol|orch,phsu|orch|||hexan-1-ol|||0|1000|192|202|NOM|INHIBITS||227|236|6|1|C0537086|glutathione S-transferase pi|aapp,gngm,enzy|gngm|2950|GSTP1|GSTP1-1|||0|854|271|278

SE|25462236||ab|2|text|461|692|Here we describe the synthesis and biological characterization of new 1 analogs (2-40), in which the hydroxyhexyl portion at the C4-sulfur atom has been replaced with phenyl-containing moieties as well as substituted alkyl chains.
SE|25462236||ab|2|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|482|491
SE|25462236||ab|2|entity|C0205460|biological|ftcn|||biological|||0|694|496|506
SE|25462236||ab|2|entity|C0205314|New|tmco|||new|||0|785|527|530
SE|25462236||ab|2|entity|C0243071|Analog|chvs|||analogs|||0|785|533|540
SE|25462236||ab|2|entity|C0439509|/40|tmco|||2-40|||0|861|542|546
SE|25462236||ab|2|entity|C0038774|Sulfur|elii,phsu|||sulfur|||0|790|593|599
SE|25462236||ab|2|entity|C0567415|Atom|elii|||atom|||0|790|600|604
SE|25462236||ab|2|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|623|628|634
SE|25462236||ab|2|entity|C0332256|Containing|ftcn|||containing|||0|623|635|645
SE|25462236||ab|2|entity|C1177206|ALKYL|phsu|||alkyl|||0|660|678|683

SE|25462236||ab|3|text|692|880|Some of the new compounds displayed 10-100 times increased water-solubility (8, 11, 17, 26-28, 34, 35), and most of them showed higher GSTP1-1 selectivity (2-20, 23-26, 31-33, 35) than 1.
SE|25462236||ab|3|entity|C0205314|New|tmco|||new|||0|872|704|707
SE|25462236||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|872|708|717
SE|25462236||ab|3|entity|C0040223|Time|tmco|||times|||0|793|735|740
SE|25462236||ab|3|entity|C0597682|water solubility|qnco|||water-solubility|||0|1000|751|767
SE|25462236||ab|3|entity|C0205393|Most|qnco|||most|||0|1000|800|804
SE|25462236||ab|3|entity|C0205250|High|qlco|||higher|||0|566|820|826
SE|25462236||ab|3|entity|C0537086|glutathione S-transferase pi|aapp,enzy|2950|GSTP1|GSTP1-1|||0|566|827|834

SE|25462236||ab|4|text|880|1039|The presence of a phenyl ring with polar substituents is in general associated, with some exceptions (23, 24) to low cytotoxicity in osteosarcoma U-2OS cells.
SE|25462236||ab|4|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|694|898|904
SE|25462236||ab|4|entity|C0813983|polar|qnco|||polar|||0|694|915|920
SE|25462236||ab|4|entity|C0205246|Generalized|spco|||general|||0|694|940|947
SE|25462236||ab|4|entity|C1554961|exception|idcn|||exceptions|||0|966|970|980
SE|25462236||ab|4|entity|C0205251|low|qlco|||low|||0|888|993|996
SE|25462236||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|997|1009
SE|25462236||ab|4|entity|C0029463|osteosarcoma|neop|||osteosarcoma|||0|813|1013|1025
SE|25462236||ab|4|entity|C0301863|"U" lymphocyte|cell|||U-2OS cells|||0|813|1026|1037

SE|25462236||ab|5|text|1039|1147|Differently, some alkyl derivatives possess cytotoxicity comparable (26, 34, 35) or higher (30, 32) than 1.
SE|25462236||ab|5|entity|C1177206|ALKYL|phsu|||alkyl|||0|888|1057|1062
SE|25462236||ab|5|entity|C0243072|derivatives|chvs|||derivatives|||0|888|1063|1074
SE|25462236||ab|5|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|1083|1095
SE|25462236||ab|5|entity|C0205250|High|qlco|||higher|||0|966|1123|1129

SE|25462236||ab|6|text|1147|1270|Among the novel compounds, selected ones (26, 27, 34, and 35) deserve further investigation for their anticancer potential.
SE|25462236||ab|6|entity|C0679622|novel|inpr|||novel|||0|872|1157|1162
SE|25462236||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|872|1163|1172
SE|25462236||ab|6|entity|C0205447|One|qnco|||ones|||0|855|1183|1187
SE|25462236||ab|6|entity|C1517331|Further|spco|||further|||0|888|1217|1224
SE|25462236||ab|6|entity|C0237399|Potential|qlco|||potential|||0|861|1260|1269


SE|25462238||ti|1|text|21|158|Identification and nanoentrapment of polyphenolic phytocomplex from Fraxinus angustifolia: in vitro and in vivo wound healing potential.
SE|25462238||ti|1|entity|C1079105|Fraxinus angustifolia|plnt|||Fraxinus angustifolia|||0|1000|89|110
SE|25462238||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|112|120
SE|25462238||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|857|125|132
SE|25462238||ti|1|entity|C0043240|Wound Healing|orgf|||wound healing|||0|857|133|146
SE|25462238||ti|1|entity|C0237399|Potential|qlco|||potential|||0|857|147|156

SE|25462238||ab|1|text|164|337|The aim of the present study was to elucidate the polyphenolic composition of Fraxinus angustifolia leaf and bark extracts, and to evaluate their efficacy in wound healing.
SE|25462238||ab|1|entity|C0150312|Present|qnco|||present|||0|888|179|186
SE|25462238||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|187|192
SE|25462238||ab|1|entity|C0486616|Composition|clna|||composition|||0|861|227|238
SE|25462238||ab|1|entity|C1079105|Fraxinus angustifolia|plnt|||Fraxinus angustifolia|||0|901|242|263
SE|25462238||ab|1|entity|C0242724|Plant Leaves|plnt|||leaf|||0|901|264|268
SE|25462238||ab|1|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|bark|||0|872|273|277
SE|25462238||ab|1|entity|C1555707|extract|idcn|||extracts|||0|872|278|286
SE|25462238||ab|1|entity|C0043240|Wound Healing|orgf|||wound healing|||0|1000|322|335

SE|25462238||ab|2|text|337|436|Quercetin, catechin, rutin and tannic acid were identified as the main components of the extracts.
SE|25462238||ab|2|entity|C0034392|Quercetin|orch,phsu,vita|||Quercetin|||0|1000|337|346
SE|25462238||ab|2|entity|C0007404|Catechin|orch,phsu|||catechin|||0|1000|348|356
SE|25462238||ab|2|entity|C0035976|Rutin|orch,phsu|||rutin|||0|1000|358|363
SE|25462238||ab|2|entity|C0039294|Tannic Acid|orch,phsu|||tannic acid|||0|1000|368|379
SE|25462238||ab|2|entity|C0205225|Primary|qlco|||main|||0|872|403|407
SE|25462238||ab|2|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|872|408|418
SE|25462238||ab|2|entity|C1555707|extract|idcn|||extracts|||0|966|426|434

SE|25462238||ab|3|text|436|664|In order to improve their skin bioavailability, the polyphenolic phytocomplexes were incorporated in different nanovesicles, namely ethosomes and phospholipid vesicles containing Transcutol((r)) P (Trc) or ethylene glycol (EG).
SE|25462238||ab|3|entity|C0037267|Integumentary system|bdsy|||skin|||0|888|462|466
SE|25462238||ab|3|entity|C0005508|Biological Availability|qnco|||bioavailability|||0|888|467|482
SE|25462238||ab|3|entity|C1547020|*Difference|qnco|||different|||0|623|537|546
SE|25462238||ab|3|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|888|582|594
SE|25462238||ab|3|entity|C0333262|Vesicle|acab|||vesicles|||0|888|595|603
SE|25462238||ab|3|entity|C0146512|Transcutol|orch|||Transcutol|||0|1000|615|625
SE|25462238||ab|3|entity|||gngm|7183|TRC-GCA24-1|Trc|||0|660|634|637
SE|25462238||ab|3|entity|C0015083|ethylene glycol|hops,orch|||ethylene glycol|||0|1000|642|657

SE|25462238||ab|4|text|664|827|The latter had never been used before as a component of phospholipid vesicles, and it was found to play a key role in improving extract efficacy in wound healing.
SE|25462238||ab|4|entity|C1549495|Never|idcn|||never|||0|1000|679|684
SE|25462238||ab|4|entity|C0332152|Status pre-|tmco|||before|||0|1000|695|701
SE|25462238||ab|4|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|1000|707|716
SE|25462238||ab|4|entity|C0031676|Phospholipids|bacs,lipd|||phospholipid|||0|888|720|732
SE|25462238||ab|4|entity|C0333262|Vesicle|acab|||vesicles|||0|888|733|741
SE|25462238||ab|4|entity|C1554080|Key|idcn|||key|||0|888|770|773
SE|25462238||ab|4|entity|C0035820|Role|socb|||role|||0|888|774|778
SE|25462238||ab|4|entity|C1272745|Improving|inpr|||improving|||0|623|782|791
SE|25462238||ab|4|entity|C1555707|extract|idcn|||extract|||0|623|792|799
SE|25462238||ab|4|entity|C0043240|Wound Healing|orgf|||wound healing|||0|1000|812|825

SE|25462238||ab|5|text|827|1162|Results of cryogenic transmission electron microscopy (cryo-TEM), Photon Correlation Spectroscopy (PCS) and Small-Angle X-ray Scattering (SAXS) showed that ethosomes and EG-PEVs were small, monodispersed, unilamellar vesicles, while Trc-PEVs were larger, less homogeneously dispersed and multilamellar, with a large bilayer thickness.
SE|25462238||ab|5|entity|C1274040|result|ftcn|||Results|||0|966|827|834
SE|25462238||ab|5|entity|C0678118|Transmission Electron Microscopy|lbpr|||transmission electron microscopy|||0|923|848|880
SE|25462238||ab|5|entity|C0086805|Photons|sbst|||Photon|||0|802|893|899
SE|25462238||ab|5|entity|C0037812|Spectrum Analysis|lbpr|||Spectroscopy|||0|802|912|924
SE|25462238||ab|5|entity|C1537058|small angle X ray scattering|lbpr|||Small-Angle X-ray Scattering|||0|1000|935|963
SE|25462238||ab|5|entity|C0015083|ethylene glycol|hops,orch|||EG|||0|884|997|999
SE|25462238||ab|5|entity|C1321916|cisplatin/etoposide/vindesine protocol|topp|||PEVs|||0|884|1000|1004
SE|25462238||ab|5|entity|C0700321|Small|qnco|||small|||0|791|1010|1015
SE|25462238||ab|5|entity|C0333262|Vesicle|acab|||vesicles|||0|791|1044|1052
SE|25462238||ab|5|entity|||gngm|7183|TRC-GCA24-1|Trc|||0|827|1060|1063
SE|25462238||ab|5|entity|C1321916|cisplatin/etoposide/vindesine protocol|topp|||PEVs|||0|827|1064|1068
SE|25462238||ab|5|entity|C0443228|Largest|qnco|||larger|||0|861|1074|1080
SE|25462238||ab|5|entity|C0549177|Large|qnco|||large|||0|802|1137|1142
SE|25462238||ab|5|entity|C1280412|Thick|qlco|||thickness|||0|802|1151|1160

SE|25462238||ab|6|text|1162|1404|Free extracts did not show relevant ability to protect in vitro human keratinocytes from H2O2 damages, while when entrapped in nanovesicles, they significantly inhibited H2O2 stress damages, probably related to a higher level of cell uptake.
SE|25462238||ab|6|entity|C1555707|extract|idcn|||extracts|||0|827|1167|1175
SE|25462238||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1180|1183
SE|25462238||ab|6|entity|C0085732|Ability|orga|||ability|||0|861|1198|1205
SE|25462238||ab|6|entity|C1533691|in vitro|qlco|||in vitro|||0|861|1217|1225
SE|25462238||ab|6|entity|C0020114|Human|humn|||human|||0|861|1226|1231
SE|25462238||ab|6|entity|C0022567|keratinocyte|cell|||keratinocytes|||0|861|1232|1245
SE|25462238||ab|6|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|694|1251|1255
SE|25462238||ab|6|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|623|1332|1336
SE|25462238||ab|6|entity|C0038435|Stress|fndg|||stress|||0|623|1337|1343
SE|25462238||ab|6|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|1353|1361
SE|25462238||ab|6|entity|C0205250|High|qlco|||higher|||0|661|1375|1381
SE|25462238||ab|6|entity|C0007634|Cells|cell|||cell|||0|888|1391|1395
SE|25462238||ab|6|entity|C0243144|uptake|phsf|||uptake|||0|888|1396|1402
SE|25462238||ab|6|relation|0|0|C0022567|keratinocyte|cell|cell|||keratinocytes|||0|861|1232|1245|MOD/HEAD|PART_OF||1226|1245|0|0|C0020114|Human|grup,humn|humn|||human|||0|861|1226|1231

SE|25462238||ab|7|text|1404|1583|On the other hand, in vivo results showed that the highest antioxidant and anti-inflammatory effects were provided by the phytocomplexes in EG-PEVs, which favoured wound healing.
SE|25462238||ab|7|entity|C1515655|in vivo|spco|||in vivo|||0|884|1423|1430
SE|25462238||ab|7|entity|C1274040|result|ftcn|||results|||0|884|1431|1438
SE|25462238||ab|7|entity|C1522410|Highest|qlco|||highest|||0|888|1455|1462
SE|25462238||ab|7|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|1463|1474
SE|25462238||ab|7|entity|C1516019|Antiinflammatory Effect|phsf|||anti-inflammatory effects|||0|983|1479|1504
SE|25462238||ab|7|entity|C0015083|ethylene glycol|hops,orch|||EG|||0|884|1544|1546
SE|25462238||ab|7|entity|C1321916|cisplatin/etoposide/vindesine protocol|topp|||PEVs|||0|884|1547|1551
SE|25462238||ab|7|entity|C0043240|Wound Healing|orgf|||wound healing|||0|1000|1568|1581

SE|25462238||ab|8|text|1583|1717|Moreover, non-entrapped F. angustifolia extracts showed a marginal effect, comparable to that of free quercetin dispersion (control).
SE|25462238||ab|8|entity|C1555707|extract|idcn|||extracts|||0|708|1623|1631
SE|25462238||ab|8|entity|C0205284|Marginal|spco|||marginal|||0|888|1641|1649
SE|25462238||ab|8|entity|C1280500|Effect|qlco|||effect|||0|888|1650|1656
SE|25462238||ab|8|entity|C0034392|Quercetin|orch,phsu,vita|||quercetin|||0|790|1685|1694
SE|25462238||ab|8|entity|C0332624|Dispersion|ftcn,spco|||dispersion|||0|790|1695|1705
SE|25462238||ab|8|entity|C0243148|control|ftcn|||control|||0|1000|1707|1714

SE|25462238||ab|9|text|1717|1818|In conclusion, our results depict that these extracts may find potential applications in biomedicine.
SE|25462238||ab|9|entity|C1274040|result|ftcn|||results|||0|966|1736|1743
SE|25462238||ab|9|entity|C1555707|extract|idcn|||extracts|||0|966|1762|1770
SE|25462238||ab|9|entity|C0237399|Potential|qlco|||potential|||0|872|1780|1789


SE|25462240||ti|1|text|21|108|Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands.
SE|25462240||ti|1|entity|C0007007|Carbolines|orch|||Carboline|||0|1000|21|30
SE|25462240||ti|1|entity|C0031434|phenothiazine|orch,phsu|||phenothiazine|||0|660|36|49
SE|25462240||ti|1|entity|C0237399|Potential|qlco|||potent|||0|729|76|82
SE|25462240||ti|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|729|91|98
SE|25462240||ti|1|entity|C0023688|Ligands|chem|||ligands|||0|729|99|106

SE|25462240||ab|1|text|114|197|Sigma 1 receptors are associated with neurodegenerative and psychiatric disorders.
SE|25462240||ab|1|entity|C0539266|sigma-1 receptor|aapp,rcpt|||Sigma 1 receptors|||0|1000|114|131
SE|25462240||ab|1|entity|C0004936|Mental disorders|mobd|||psychiatric disorders|||0|1000|174|195

SE|25462240||ab|2|text|197|409|These receptors, via their chaperoning functions that counteract endoplasmic reticulum stress and block neurodegeneration, may serve as a target for a new generation of antidepressants or neuroprotective agents.
SE|25462240||ab|2|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|1000|203|212
SE|25462240||ab|2|entity|C1550513|via|idcn|||via|||0|1000|214|217
SE|25462240||ab|2|entity|C0243041|Molecular Chaperones|aapp,bacs|||chaperoning|||0|966|224|235
SE|25462240||ab|2|entity|C0014239|Endoplasmic Reticulum|celc|||endoplasmic reticulum|||0|901|262|283
SE|25462240||ab|2|entity|C0038435|Stress|fndg|||stress|||0|901|284|290
SE|25462240||ab|2|entity|C0028778|Obstruction|patf|||block|||0|888|295|300
SE|25462240||ab|2|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|888|301|318
SE|25462240||ab|2|entity|C0205314|New|tmco|||new|||0|872|348|351
SE|25462240||ab|2|entity|C0079411|Generations|tmco|||generation|||0|872|352|362
SE|25462240||ab|2|entity|C0003289|Antidepressive Agents|phsu|||antidepressants|||0|1000|366|381
SE|25462240||ab|2|entity|C0242912|Neuroprotective Agents|phsu|||neuroprotective agents|||0|1000|385|407
SE|25462240||ab|2|relation|3|1|C0243041|Molecular Chaperones|aapp,gngm,bacs|aapp|||chaperoning|||0|966|224|235|VERB|DISRUPTS||251|261|6|1|C0027746|Nerve Degeneration|comd|comd|||neurodegeneration|||0|888|301|318
SE|25462240||ab|2|relation|3|1|C0243041|Molecular Chaperones|aapp,gngm,bacs|aapp|||chaperoning|||0|966|224|235|VERB|DISRUPTS||251|261|6|1|C0038435|Stress|fndg|fndg|||stress|||0|901|284|290

SE|25462240||ab|3|text|409|499|The involvement of these receptors has also been observed in neuropathic pain and cancer.
SE|25462240||ab|3|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|1000|434|443
SE|25462240||ab|3|entity|C0423716|Neuropathic pain|sosy|||neuropathic pain|||0|1000|470|486
SE|25462240||ab|3|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|491|497
SE|25462240||ab|3|relation|2|1|C0597357|receptor|aapp,gngm,rcpt|aapp|||receptors|||0|1000|434|443|PREP|ASSOCIATED_WITH||467|469|2|1|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|1000|491|497
SE|25462240||ab|3|relation|2|1|C0597357|receptor|aapp,gngm,rcpt|aapp|||receptors|||0|1000|434|443|PREP|ASSOCIATED_WITH||467|469|2|1|C0423716|Neuropathic pain|sosy|sosy|||neuropathic pain|||0|1000|470|486

SE|25462240||ab|4|text|499|592|Only a few ligands, such as Igmesine and Anavex 2-73, have been involved in clinical trials.
SE|25462240||ab|4|entity|C0205388|Few|qnco|||few|||0|888|506|509
SE|25462240||ab|4|entity|C0023688|Ligands|chem|||ligands|||0|888|510|517
SE|25462240||ab|4|entity|C0246221|igmesine|orch,phsu|||Igmesine|||0|1000|527|535
SE|25462240||ab|4|entity|C0008976|Clinical Trials|resa|||clinical trials|||0|1000|575|590

SE|25462240||ab|5|text|592|677|Thus the development of sigma 1 ligands is of interest to a new generation of drugs.
SE|25462240||ab|5|entity|C1527148|Development|ftcn|||development|||0|1000|601|612
SE|25462240||ab|5|entity|C0023688|Ligands|chem|||ligands|||0|827|624|631
SE|25462240||ab|5|entity|C0543488|Interested|menp|||interest|||0|1000|638|646
SE|25462240||ab|5|entity|C0205314|New|tmco|||new|||0|872|652|655
SE|25462240||ab|5|entity|C0079411|Generations|tmco|||generation|||0|872|656|666
SE|25462240||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|670|675

SE|25462240||ab|6|text|677|785|Previous work in our lab underlined the potency of benzannulated bicyclic compounds as interesting ligands.
SE|25462240||ab|6|entity|C0205156|Previous|tmco|||Previous|||0|888|677|685
SE|25462240||ab|6|entity|C0043227|Work|ocac|||work|||0|888|686|690
SE|25462240||ab|6|entity|C0022877|Laboratory|mnob,orgt|||lab|||0|1000|698|701
SE|25462240||ab|6|entity|C0237399|Potential|qlco|||potency|||0|884|717|724
SE|25462240||ab|6|entity|C0005378|Bicyclo Compounds|orch|||bicyclic compounds|||0|884|742|760
SE|25462240||ab|6|entity|C0023688|Ligands|chem|||ligands|||0|861|776|783

SE|25462240||ab|7|text|785|856|Herein the work was extended to a series of novel tricyclic compounds.
SE|25462240||ab|7|entity|C0043227|Work|ocac|||work|||0|1000|796|800
SE|25462240||ab|7|entity|C0679622|novel|inpr|||novel|||0|829|829|834
SE|25462240||ab|7|entity|C0003290|Antidepressive Agents, Tricyclic|orch,phsu|||tricyclic|||0|829|835|844
SE|25462240||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|829|845|854

SE|25462240||ab|8|text|856|936|Carboline- and phenothiazine-derivated compounds were designed and synthesized.
SE|25462240||ab|8|entity|C0007007|Carbolines|orch|||Carboline|||0|1000|856|865
SE|25462240||ab|8|entity|C0031434|phenothiazine|orch,phsu|||phenothiazine|||0|785|871|884
SE|25462240||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|785|895|904

SE|25462240||ab|9|text|936|1164|In vitro competition binding assays for sigma 1 and 2 receptors showed that most of them have high affinity for sigma 1 receptor (Ki = 2.5-18 nM), and selectivity toward sigma 2 receptor, without cytotoxic effects on SY5Y cells.
SE|25462240||ab|9|entity|C1533691|in vitro|qlco|||In vitro|||0|831|936|944
SE|25462240||ab|9|entity|C0005458|Binding, Competitive|moft|||competition binding|||0|831|945|964
SE|25462240||ab|9|entity|C1510438|Assay|lbpr|||assays|||0|831|965|971
SE|25462240||ab|9|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|861|990|999
SE|25462240||ab|9|entity|C0205393|Most|qnco|||most|||0|1000|1012|1016
SE|25462240||ab|9|entity|C0205250|High|qlco|||high|||0|888|1030|1034
SE|25462240||ab|9|entity|C0539266|sigma-1 receptor|aapp,rcpt|||sigma 1 receptor|||0|1000|1048|1064
SE|25462240||ab|9|entity|C0450346|2/5|qnco|||2.5|||0|694|1071|1074
SE|25462240||ab|9|entity|C0539267|sigma-2 receptor|aapp,rcpt|||sigma 2 receptor|||0|1000|1106|1122
SE|25462240||ab|9|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|872|1132|1141
SE|25462240||ab|9|entity|C1280500|Effect|qlco|||effects|||0|872|1142|1149
SE|25462240||ab|9|entity|C0007634|Cells|cell|||cells|||0|861|1158|1163
SE|25462240||ab|9|relation|8|1|C0539267|sigma-2 receptor|aapp,gngm,rcpt|gngm|||sigma 2 receptor|||0|1000|1106|1122|NOM|INTERACTS_WITH|negation|1142|1149|1|1|C0007634|Cells|cell|cell|||cells|||0|861|1158|1163


SE|25462239||ti|1|text|21|143|Malonate-based inhibitors of mammalian serine racemase: kinetic characterization and structure-based computational study.
SE|25462239||ti|1|entity|C0220875|Malonate|bacs,orch|||Malonate|||0|840|21|29
SE|25462239||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|840|36|46
SE|25462239||ti|1|entity|C0768762|serine racemase|aapp,enzy|63826|SRR|serine racemase|||0|901|60|75
SE|25462239||ti|1|entity|C0022702|Kinetics|idcn|||kinetic|||0|694|77|84
SE|25462239||ti|1|entity|C0678594|Structure|spco|||structure|||0|764|106|115
SE|25462239||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|764|136|141
SE|25462239||ti|1|relation|1|1|C0220875|Malonate|bacs,orch|bacs|||Malonate|||0|840|21|29|PREP|PART_OF||47|49|3|1|C0768762|serine racemase|aapp,gngm,enzy|aapp|63826|SRR|serine racemase|||0|901|60|75

SE|25462239||ab|1|text|149|312|Overactivation of NMDA receptors has been implicated in various neuropathological conditions, including brain ischaemia, neurodegenerative disorders and epilepsy.
SE|25462239||ab|1|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDA receptors|||0|1000|167|181
SE|25462239||ab|1|entity|C0876934|Neuropathology|bmod|||neuropathological|||0|737|213|230
SE|25462239||ab|1|entity|C0348080|Condition|qlco|||conditions|||0|737|231|241
SE|25462239||ab|1|entity|C0007786|Brain Ischemia|dsyn|||brain ischaemia|||0|1000|253|268
SE|25462239||ab|1|entity|C0524851|Neurodegenerative Disorders|dsyn|||neurodegenerative disorders|||0|1000|270|297
SE|25462239||ab|1|entity|C0014544|Epilepsy|dsyn|||epilepsy|||0|1000|302|310

SE|25462239||ab|2|text|312|470|Production of d-serine, an NMDA receptor co-agonist, from l-serine is catalyzed in vivo by the pyridoxal-5'-phosphate (PLP)-dependent enzyme serine racemase.
SE|25462239||ab|2|entity|C0033268|production|ocac|||Production|||0|1000|312|322
SE|25462239||ab|2|entity|C0036720|Serine|aapp,bacs,phsu|||serine|||0|1000|328|334
SE|25462239||ab|2|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDA receptor|||0|852|339|352
SE|25462239||ab|2|entity|C0243192|agonists|phsu|||agonist|||0|852|356|363
SE|25462239||ab|2|entity|C0036720|Serine|aapp,bacs,phsu|||l-serine|||0|1000|370|378
SE|25462239||ab|2|entity|C1515655|in vivo|spco|||in vivo|||0|1000|392|399
SE|25462239||ab|2|entity|C0034266|Pyridoxal Phosphate|orch,phsu,vita|||pyridoxal-5'-phosphate|||0|1000|407|429
SE|25462239||ab|2|entity|||gngm|5354,5744,25824,57026|PLP1,PTHLH,PRDX5,PDXP|PLP)|||0|798|431|435
SE|25462239||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|798|446|452
SE|25462239||ab|2|entity|C0768762|serine racemase|aapp,enzy|63826|SRR|serine racemase|||0|798|453|468
SE|25462239||ab|2|relation|6|0|||gngm,aapp|gngm|5354,5744,25824,57026|PLP1,PTHLH,PRDX5,PDXP|PLP)|||0|798|431|435|ADJ|STIMULATES||436|445|6|0|C0768762|serine racemase|aapp,gngm,enzy|gngm|63826|SRR|serine racemase|||0|798|453|468

SE|25462239||ab|3|text|470|625|Specific inhibition of this enzyme has been proposed as a promising strategy for treatment of neurological conditions caused by NMDA receptor dysfunction.
SE|25462239||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|498|504
SE|25462239||ab|3|entity|C1555307|promise|idcn|||promising|||0|872|528|537
SE|25462239||ab|3|entity|C0205494|Neurologic|ftcn|||neurological|||0|872|564|576
SE|25462239||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|872|577|587
SE|25462239||ab|3|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDA receptor|||0|901|598|611

SE|25462239||ab|4|text|625|750|Here we present the synthesis and activity analysis of a series of malonate-based inhibitors of mouse serine racemase (mSR).
SE|25462239||ab|4|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|645|654
SE|25462239||ab|4|entity|C0556570|Activity analysis|topp|||activity analysis|||0|1000|659|676
SE|25462239||ab|4|entity|C0220875|Malonate|bacs,orch|||malonate|||0|840|692|700
SE|25462239||ab|4|entity|C0243077|inhibitors|chvf|||inhibitors|||0|840|707|717
SE|25462239||ab|4|entity|C0025914|House mice|mamm|||mouse|||0|901|721|726
SE|25462239||ab|4|entity|C0768762|serine racemase|aapp,enzy|63826|SRR|serine racemase|||0|901|727|742
SE|25462239||ab|4|relation|0|0|C0768762|serine racemase|aapp,gngm,enzy|aapp|63826|SRR|serine racemase|||0|901|727|742|MOD/HEAD|PART_OF||721|742|0|0|C0025914|House mice|mamm|mamm|||mouse|||0|901|721|726
SE|25462239||ab|4|relation|4|1|C0220875|Malonate|bacs,orch|bacs|||malonate|||0|840|692|700|PREP|PART_OF||718|720|1|1|C0768762|serine racemase|aapp,gngm,enzy|aapp|63826|SRR|serine racemase|||0|901|727|742

SE|25462239||ab|5|text|750|954|The compounds possessed IC50 values ranging from 40 +/- 11 mM for 2,2-bis(hydroxymethyl)malonate down to 57 +/- 1 MUM for 2,2-dichloromalonate, the most effective competitive mSR inhibitor known to date.
SE|25462239||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|754|763
SE|25462239||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|774|778
SE|25462239||ab|5|entity|C0042295|Values|qlco|||values|||0|888|779|785
SE|25462239||ab|5|entity|||gngm|9531|BAG3|bis|||0|1000|820|823
SE|25462239||ab|5|entity|C0220875|Malonate|bacs,orch|||malonate|||0|1000|838|846
SE|25462239||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|864|867
SE|25462239||ab|5|entity|C0205393|Most|qnco|||most|||0|813|898|902
SE|25462239||ab|5|entity|C0679932|competition|socb|||competitive|||0|813|913|924
SE|25462239||ab|5|entity|C0025914|House mice|mamm|||mSR|||0|813|925|928
SE|25462239||ab|5|entity|C0768762|serine racemase|aapp,enzy|63826|SRR|mSR|||0|813|925|928
SE|25462239||ab|5|entity|C0243077|inhibitors|chvf|||inhibitor|||0|813|929|938
SE|25462239||ab|5|relation|8|3|C0220875|Malonate|bacs,orch|bacs|||malonate|||0|1000|838|846|NOM|INHIBITS||929|938|8|0|C0768762|serine racemase|aapp,gngm,enzy|gngm|63826|SRR|mSR|||0|813|925|928

SE|25462239||ab|6|text|954|1202|The structure-activity relationship of the whole series in the human orthologue (hSR) was interpreted using Glide docking, WaterMap analysis of hydration and quantum mechanical calculations based on the X-ray structure of the hSR/malonate complex.
SE|25462239||ab|6|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationship|||0|1000|958|989
SE|25462239||ab|6|entity|C0444667|Whole|qnco|||whole|||0|888|997|1002
SE|25462239||ab|6|entity|C0205549|Series|qnco|||series|||0|888|1003|1009
SE|25462239||ab|6|entity|C0020114|Human|humn|||human|||0|888|1017|1022
SE|25462239||ab|6|entity|C1335144|Orthologous Gene|gngm|||orthologue|||0|888|1023|1033
SE|25462239||ab|6|entity|C0018757|Health Services Research|hlca,resa|||hSR|||0|1000|1035|1038
SE|25462239||ab|6|entity|C1522290|Docking|moft|||docking|||0|861|1068|1075
SE|25462239||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|861|1086|1094
SE|25462239||ab|6|entity|C1514629|Quantum Mechanics|ocdi|||quantum mechanical|||0|866|1112|1130
SE|25462239||ab|6|entity|C1441506|CALCULATION|lbpr|||calculations|||0|866|1131|1143
SE|25462239||ab|6|entity|C0034571|roentgenographic|ftcn|||X-ray|||0|901|1157|1162
SE|25462239||ab|6|entity|C0678594|Structure|spco|||structure|||0|901|1163|1172
SE|25462239||ab|6|entity|C0018757|Health Services Research|hlca,resa|||hSR|||0|851|1180|1183
SE|25462239||ab|6|entity|C0220875|Malonate|bacs,orch|||malonate|||0|851|1184|1192
SE|25462239||ab|6|entity|C0439855|Complex|qlco|||complex|||0|851|1193|1200
SE|25462239||ab|6|relation|0|0|C1335144|Orthologous Gene|gngm,aapp|gngm|||orthologue|||0|888|1023|1033|MOD/HEAD|PART_OF||1017|1033|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|1017|1022

SE|25462239||ab|7|text|1202|1359|Docking into the hSR active site with three thermodynamically favourable water molecules was able to discern qualitatively between good and weak inhibitors.
SE|25462239||ab|7|entity|C1522290|Docking|moft|||Docking|||0|1000|1202|1209
SE|25462239||ab|7|entity|C0018757|Health Services Research|hlca,resa|||hSR|||0|901|1219|1222
SE|25462239||ab|7|entity|C0205681|Active Site|ftcn,spco|||active site|||0|901|1223|1234
SE|25462239||ab|7|entity|C0205449|Three|qnco|||three|||0|740|1240|1245
SE|25462239||ab|7|entity|C0020311|Hydrotherapy|topp|||water|||0|740|1275|1280
SE|25462239||ab|7|entity|C0567416|Molecule|sbst|||molecules|||0|740|1281|1290
SE|25462239||ab|7|entity|C0205170|Good|qlco|||good|||0|1000|1333|1337
SE|25462239||ab|7|entity|C0004093|Asthenia|sosy|||weak|||0|888|1342|1346
SE|25462239||ab|7|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|1347|1357

SE|25462239||ab|8|text|1359|1556|Further improvement in ranking was obtained using advanced PM6-D3H4X/COSMO semiempirical quantum mechanics-based scoring which distinguished between the compounds with IC50 better/worse than 2 mM.
SE|25462239||ab|8|entity|C1517331|Further|spco|||Further|||0|694|1359|1366
SE|25462239||ab|8|entity|C1514629|Quantum Mechanics|ocdi|||quantum mechanics|||0|701|1448|1465
SE|25462239||ab|8|entity|C1552081|scoring|idcn|||scoring|||0|701|1472|1479
SE|25462239||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|966|1512|1521
SE|25462239||ab|8|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|851|1527|1531
SE|25462239||ab|8|entity|C0332272|Better|qlco|||better|||0|851|1532|1538
SE|25462239||ab|8|entity|C1279889|Deterioration of status|qlco|||worse|||0|851|1539|1544

SE|25462239||ab|9|text|1556|1760|We have thus not only found a new potent hSR inhibitor but also worked out a computer-assisted protocol to rationalize the binding affinity which will thus aid in search for more effective SR inhibitors.
SE|25462239||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1569|1572
SE|25462239||ab|9|entity|C0205314|New|tmco|||new|||0|799|1586|1589
SE|25462239||ab|9|entity|C0237399|Potential|qlco|||potent|||0|799|1590|1596
SE|25462239||ab|9|entity|C0018757|Health Services Research|hlca,resa|||hSR|||0|799|1597|1600
SE|25462239||ab|9|entity|C0243077|inhibitors|chvf|||inhibitor|||0|799|1601|1610
SE|25462239||ab|9|entity|C0439787|Out|spco|||out|||0|1000|1627|1630
SE|25462239||ab|9|entity|C0009622|Computers|mnob|||computer|||0|851|1633|1641
SE|25462239||ab|9|entity|C1269765|Assisted|fndg|||assisted|||0|851|1642|1650
SE|25462239||ab|9|entity|C0442711|Protocols documentation|inpr|||protocol|||0|851|1651|1659
SE|25462239||ab|9|entity|C1552603|search|idcn|||search|||0|1000|1719|1725
SE|25462239||ab|9|entity|C0205172|More|ftcn|||more|||0|833|1730|1734
SE|25462239||ab|9|entity|C0243077|inhibitors|chvf|||inhibitors|||0|833|1748|1758

SE|25462239||ab|10|text|1760|1928|Novel, potent hSR inhibitors may represent interesting research tools as well as drug candidates for treatment of diseases associated with NMDA receptor overactivation.
SE|25462239||ab|10|entity|C0679622|novel|inpr|||Novel|||0|808|1760|1765
SE|25462239||ab|10|entity|C0237399|Potential|qlco|||potent|||0|808|1767|1773
SE|25462239||ab|10|entity|C0018757|Health Services Research|hlca,resa|||hSR|||0|808|1774|1777
SE|25462239||ab|10|entity|C0243077|inhibitors|chvf|||inhibitors|||0|808|1778|1788
SE|25462239||ab|10|entity|C0035168|research|resa|||research|||0|872|1815|1823
SE|25462239||ab|10|entity|C0336791|Tool|mnob|||tools|||0|872|1824|1829
SE|25462239||ab|10|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|694|1841|1845
SE|25462239||ab|10|entity|C0012634|Disease|dsyn|||diseases|||0|1000|1874|1882
SE|25462239||ab|10|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDA receptor|||0|734|1899|1912
SE|25462239||ab|10|relation|3|3|C0243077|inhibitors|chvf|chvf|||inhibitors|||0|808|1778|1788|NOM|TREATS||1861|1870|2|1|C0012634|Disease|dsyn|dsyn|||diseases|||0|1000|1874|1882


SE|25462241||ti|1|text|21|125|A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry.
SE|25462241||ti|1|entity|C0521116|Current|tmco|||current|||0|872|47|54
SE|25462241||ti|1|entity|C1527148|Development|ftcn|||developments|||0|872|55|67
SE|25462241||ti|1|entity|C0053246|benzothiazole|orch|||benzothiazole|||0|829|71|84
SE|25462241||ti|1|entity|C0567416|Molecule|sbst|||molecules|||0|829|91|100
SE|25462241||ti|1|entity|C0008003|Chemistry, Pharmaceutical|bmod|||medicinal chemistry|||0|1000|104|123

SE|25462241||ab|1|text|131|316|Benzothiazole (BTA) and its derivatives are the most important heterocyclic compounds, which are common and integral feature of a variety of natural products and pharmaceutical agents.
SE|25462241||ab|1|entity|C0053246|benzothiazole|orch|||Benzothiazole|||0|1000|131|144
SE|25462241||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|1000|159|170
SE|25462241||ab|1|entity|C0205393|Most|qnco|||most|||0|824|179|183
SE|25462241||ab|1|entity|C0019398|Heterocyclic Compounds|orch|||heterocyclic compounds|||0|824|194|216
SE|25462241||ab|1|entity|C0205214|Common|qnco|||common|||0|1000|228|234
SE|25462241||ab|1|entity|C0443238|Integral|qnco|||integral|||0|694|239|247
SE|25462241||ab|1|entity|C1566558|Natural Products|bacs|||natural products|||0|1000|272|288
SE|25462241||ab|1|entity|C1254351|Pharmacologic Substance|phsu|||pharmaceutical agents|||0|983|293|314
SE|25462241||ab|1|relation|0|0|C0053246|benzothiazole|orch|orch|||Benzothiazole|||0|1000|131|144|SPEC|ISA||131|216|0|0|C0019398|Heterocyclic Compounds|orch|orch|||heterocyclic compounds|||0|824|194|216

SE|25462241||ab|2|text|316|492|BTA shows a variety of pharmacological properties, and its analogs offer a high degree of structural diversity that has proven useful for the search of new therapeutic agents.
SE|25462241||ab|2|entity|C0053246|benzothiazole|orch|||BTA|||0|1000|316|319
SE|25462241||ab|2|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|872|339|354
SE|25462241||ab|2|entity|C0871161|Property|qlco|||properties|||0|872|355|365
SE|25462241||ab|2|entity|C0243071|Analog|chvs|||analogs|||0|966|375|382
SE|25462241||ab|2|entity|C0205250|High|qlco|||high|||0|694|391|395
SE|25462241||ab|2|entity|C1552603|search|idcn|||search|||0|1000|458|464
SE|25462241||ab|2|entity|C1518316|New Agents|clas|||new therapeutic agents|||0|901|468|490

SE|25462241||ab|3|text|492|638|The broad spectrum of pharmacological activity in individual BTA derivative indicates that, this series of compounds is of an undoubted interest.
SE|25462241||ab|3|entity|C0332464|Widening|spco|||broad|||0|861|496|501
SE|25462241||ab|3|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|888|514|529
SE|25462241||ab|3|entity|C0237401|Individual|humn|||individual|||0|851|542|552
SE|25462241||ab|3|entity|C0053246|benzothiazole|orch|||BTA|||0|851|553|556
SE|25462241||ab|3|entity|C1527240|Derivative|ftcn|||derivative|||0|851|557|567
SE|25462241||ab|3|entity|C0205549|Series|qnco|||series|||0|1000|589|595
SE|25462241||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|599|608
SE|25462241||ab|3|entity|C0543488|Interested|menp|||interest|||0|861|628|636

SE|25462241||ab|4|text|638|773|The related research and developments in BTA-based medicinal chemistry have become a rapidly developing and increasingly active topic.
SE|25462241||ab|4|entity|C1522149|Related|ftcn|||related|||0|888|642|649
SE|25462241||ab|4|entity|C0035168|research|resa|||research|||0|888|650|658
SE|25462241||ab|4|entity|C1527148|Development|ftcn|||developments|||0|966|663|675
SE|25462241||ab|4|entity|C0053246|benzothiazole|orch|||BTA|||0|852|679|682
SE|25462241||ab|4|entity|C0008003|Chemistry, Pharmaceutical|bmod|||medicinal chemistry|||0|852|689|708
SE|25462241||ab|4|entity|C0205177|Active|ftcn|||active|||0|790|759|765
SE|25462241||ab|4|entity|C1555712|topic|idcn|||topic|||0|790|766|771

SE|25462241||ab|5|text|773|939|Particularly, numerous BTA-based compounds as clinical drugs have been extensively used in practice to treat various types of diseases with high therapeutic potency.
SE|25462241||ab|5|entity|C0439064|Numerous|qnco|||numerous|||0|816|787|795
SE|25462241||ab|5|entity|C0053246|benzothiazole|orch|||BTA|||0|816|796|799
SE|25462241||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|816|806|815
SE|25462241||ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|888|819|827
SE|25462241||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|828|833
SE|25462241||ab|5|entity|C0237607|experience (practice)|menp|||practice|||0|1000|864|872
SE|25462241||ab|5|entity|C0332307|Type - attribute|qlco|||types|||0|861|890|895
SE|25462241||ab|5|entity|C0012634|Disease|dsyn|||diseases|||0|1000|899|907
SE|25462241||ab|5|entity|C0205250|High|qlco|||high|||0|813|913|917
SE|25462241||ab|5|entity|C0237399|Potential|qlco|||potency|||0|813|930|937

SE|25462241||ab|6|text|939|1296|This work systematically gives a comprehensive review in current developments of BTA-based compounds in the whole range of medicinal chemistry as anticancer, antibacterial, antifungal, antiinflammatory, analgesic, anti-HIV, antioxidant, anticonvulsant, antitubercular, antidiabetic, antileishmanial, antihistaminic, antimalarial and other medicinal agents.
SE|25462241||ab|6|entity|C0043227|Work|ocac|||work|||0|1000|944|948
SE|25462241||ab|6|entity|C0521116|Current|tmco|||current|||0|872|996|1003
SE|25462241||ab|6|entity|C1527148|Development|ftcn|||developments|||0|872|1004|1016
SE|25462241||ab|6|entity|C0053246|benzothiazole|orch|||BTA|||0|829|1020|1023
SE|25462241||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|829|1030|1039
SE|25462241||ab|6|entity|C0444667|Whole|qnco|||whole|||0|888|1047|1052
SE|25462241||ab|6|entity|C1514721|Range|qnco|||range|||0|888|1053|1058
SE|25462241||ab|6|entity|C0008003|Chemistry, Pharmaceutical|bmod|||medicinal chemistry|||0|1000|1062|1081
SE|25462241||ab|6|entity|C0279516|Anti-Bacterial Agents|antb|||antibacterial|||0|729|1097|1110
SE|25462241||ab|6|entity|C0002771|Analgesics|phsu|||analgesic|||0|729|1142|1151
SE|25462241||ab|6|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|861|1158|1161
SE|25462241||ab|6|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|1000|1163|1174
SE|25462241||ab|6|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant|||0|1000|1176|1190
SE|25462241||ab|6|entity|C0003448|Antitubercular Agents|phsu|||antitubercular|||0|966|1192|1206
SE|25462241||ab|6|entity|C0935929|Antidiabetics|phsu|||antidiabetic|||0|1000|1208|1220
SE|25462241||ab|6|entity|C0003360|Antihistamines|phsu|||antihistaminic|||0|966|1239|1253
SE|25462241||ab|6|entity|C0003374|Antimalarials|phsu|||antimalarial|||0|1000|1255|1267
SE|25462241||ab|6|entity|C0450442|Agent|chvf|||agents|||0|827|1288|1294

SE|25462241||ab|7|text|1296|1512|It is believed that, this review article is helpful for new thoughts in the quest for rational designs of more active and less toxic BTA-based drugs, as well as more effective diagnostic agents and pathologic probes.
SE|25462241||ab|7|entity|C1552861|help|idcn|||helpful|||0|928|1340|1347
SE|25462241||ab|7|entity|C0205314|New|tmco|||new|||0|694|1352|1355
SE|25462241||ab|7|entity|C0750565|QUEST|idcn|||quest|||0|1000|1372|1377
SE|25462241||ab|7|entity|C0205172|More|ftcn|||more|||0|888|1402|1406
SE|25462241||ab|7|entity|C0205177|Active|ftcn|||active|||0|888|1407|1413
SE|25462241||ab|7|entity|C1407029|Toxic|qlco|||toxic|||0|762|1423|1428
SE|25462241||ab|7|entity|C0053246|benzothiazole|orch|||BTA|||0|762|1429|1432
SE|25462241||ab|7|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|762|1439|1444
SE|25462241||ab|7|entity|C0205172|More|ftcn|||more|||0|861|1457|1461
SE|25462241||ab|7|entity|C0358514|Diagnostic agents|irda|||diagnostic agents|||0|861|1472|1489
SE|25462241||ab|7|entity|C1521733|Pathologic|ftcn|||pathologic|||0|888|1494|1504
SE|25462241||ab|7|entity|C0182400|Probes|medd|||probes|||0|888|1505|1511


SE|25462242||ti|1|text|21|88|Benzodioxane-benzamides as new bacterial cell division inhibitors.
SE|25462242||ti|1|entity|C0005029|Benzamides|orch|||benzamides|||0|861|34|44
SE|25462242||ti|1|entity|C0205314|New|tmco|||new|||0|840|48|51
SE|25462242||ti|1|entity|C0521009|Bacterial|ftcn|||bacterial|||0|840|52|61
SE|25462242||ti|1|entity|C0007590|Cell division|celf|||cell division|||0|840|62|75
SE|25462242||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|840|76|86
SE|25462242||ti|1|relation|1|1|C0005029|Benzamides|orch|orch|||benzamides|||0|861|34|44|NOM|DISRUPTS||76|86|1|0|C0007590|Cell division|celf|celf|||cell division|||0|840|62|75

SE|25462242||ab|1|text|94|369|A SAR study was performed on 3-substituted 2,6-difluorobenzamides, known inhibitors of the essential bacterial cell division protein FtsZ, through a series of modifications first of 2,6-difluoro-3-nonyloxybenzamide and then of its 3-pyridothiazolylmethoxy analogue PC190723.
SE|25462242||ab|1|entity|C1175175|Severe Acute Respiratory Syndrome|dsyn|||SAR|||0|872|96|99
SE|25462242||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|872|100|105
SE|25462242||ab|1|entity|C0205309|Known|qlco|||known|||0|888|161|166
SE|25462242||ab|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|888|167|177
SE|25462242||ab|1|entity|C0205224|Essential|qlco|||essential|||0|638|185|194
SE|25462242||ab|1|entity|C0007590|Cell division|celf|||cell division|||0|638|205|218
SE|25462242||ab|1|entity|C0004627|Bacterial Proteins|aapp,bacs|||bacterial cell division protein|||0|638|195|226
SE|25462242||ab|1|entity|C1522413|Modification|ftcn|||modifications|||0|872|253|266
SE|25462242||ab|1|entity|C1279901|Firstly|qlco|||first|||0|872|267|272
SE|25462242||ab|1|entity|C0243071|Analog|chvs|||analogue|||0|597|350|358

SE|25462242||ab|2|text|369|537|The study led to the identification of chiral 2,6-difluorobenzamides bearing 1,4-benzodioxane-2-methyl residue at the 3-position as potent antistaphylococcal compounds.
SE|25462242||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|373|378
SE|25462242||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|888|489|497
SE|25462242||ab|2|entity|C0237399|Potential|qlco|||potent|||0|735|501|507
SE|25462242||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|735|527|536


SE|25462243||ti|1|text|21|181|Synthesis, molecular structure, biological properties and molecular docking studies on Mn(II), Co(II) and Zn(II) complexes containing bipyridine-azide ligands.
SE|25462243||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462243||ti|1|entity|C0026383|Molecular Structure|mosq|||molecular structure|||0|1000|32|51
SE|25462243||ti|1|entity|C0205460|biological|ftcn|||biological|||0|872|53|63
SE|25462243||ti|1|entity|C0871161|Property|qlco|||properties|||0|872|64|74
SE|25462243||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|840|79|88
SE|25462243||ti|1|entity|C1522290|Docking|moft|||docking|||0|840|89|96
SE|25462243||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|840|97|104
SE|25462243||ti|1|entity|C0439855|Complex|qlco|||complexes|||0|1000|134|143
SE|25462243||ti|1|entity|C0175774|Bipyridine|irda,orch|||bipyridine|||0|851|155|165
SE|25462243||ti|1|entity|C0004492|Azides|chvs|||azide|||0|851|166|171
SE|25462243||ti|1|entity|C0023688|Ligands|chem|||ligands|||0|851|172|179

SE|25462243||ab|1|text|187|409|Metal complexes of the type Mn(bpy)2(N3)2 (1), Co(bpy)2(N3)2.3H2O (2) and Zn2(bpy)2(N3)4 (3) (Where bpy = 2,2-bipyridine) have been synthesized and characterized by elemental analysis and spectral (FT-IR, UV-vis) studies.
SE|25462243||ab|1|entity|C0596913|metal complex|chvs|||Metal complexes|||0|983|187|202
SE|25462243||ab|1|entity|C1547052|*Type|qnco|||type|||0|888|210|214
SE|25462243||ab|1|entity|C0175774|Bipyridine|irda,orch|||bipyridine|||0|861|297|307
SE|25462243||ab|1|entity|C0013879|Elements|elii|||elemental|||0|853|352|361
SE|25462243||ab|1|entity|C0936012|Analysis|resa|||analysis|||0|853|362|370
SE|25462243||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|400|407

SE|25462243||ab|2|text|409|711|The structure of complexes (1-3) have been determined by single crystal X-ray diffraction studies and the configuration of ligand-coordinated metal(II) ion was well described as distorted octahedral coordination geometry for Mn(II), Co(II) and distorted square pyramidal geometry for Zn(II) complexes.
SE|25462243||ab|2|entity|C0678594|Structure|spco|||structure|||0|1000|413|422
SE|25462243||ab|2|entity|C0439855|Complex|qlco|||complexes|||0|1000|426|435
SE|25462243||ab|2|entity|C0034571|roentgenographic|ftcn|||X-ray|||0|857|481|486
SE|25462243||ab|2|entity|C0206755|Crystallography, X-Ray|lbpr|||single crystal X-ray diffraction|||0|857|466|498
SE|25462243||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|857|499|506
SE|25462243||ab|2|entity|C0023688|Ligands|chem|||ligand|||0|851|532|538
SE|25462243||ab|2|entity|C0427184|No incoordination|fndg|||coordinated|||0|851|539|550
SE|25462243||ab|2|entity|C0025552|Metals|inch|||metal|||0|851|551|556
SE|25462243||ab|2|entity|C0022023|Ions|elii|||ion|||0|1000|561|564
SE|25462243||ab|2|entity|C0205170|Good|qlco|||well|||0|888|569|573
SE|25462243||ab|2|entity|C1552738|described|idcn|||described|||0|888|574|583
SE|25462243||ab|2|entity|C0700135|Distorted|ftcn|||distorted|||0|791|587|596
SE|25462243||ab|2|entity|C0449829|Geometry|spco|||geometry|||0|791|621|629
SE|25462243||ab|2|entity|C0700135|Distorted|ftcn|||distorted|||0|791|653|662
SE|25462243||ab|2|entity|C0449829|Geometry|spco|||geometry|||0|791|680|688
SE|25462243||ab|2|entity|C0439855|Complex|qlco|||complexes|||0|1000|700|709

SE|25462243||ab|3|text|711|872|DNA binding interaction of these complexes (1-3) were investigated by UV-vis absorption, fluorescence circular dichroism spectral and molecular docking studies.
SE|25462243||ab|3|entity|C1148673|DNA Binding|genf|||DNA binding interaction|||0|1000|711|734
SE|25462243||ab|3|entity|C0439855|Complex|qlco|||complexes|||0|1000|744|753
SE|25462243||ab|3|entity|C0016315|Fluorescence|npop|||fluorescence|||0|901|800|812
SE|25462243||ab|3|entity|C0008813|Circular Dichroism|lbpr,npop|||circular dichroism|||0|901|813|831
SE|25462243||ab|3|entity|C1521991|Molecular|qlco|||molecular|||0|840|845|854
SE|25462243||ab|3|entity|C1522290|Docking|moft|||docking|||0|840|855|862
SE|25462243||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|840|863|870

SE|25462243||ab|4|text|872|1052|The intrinsic binding constants Kb of complexes 1, 2 and 3 with CT-DNA obtained from UV-vis absorption studies were 8.37 * 10(4), 2.23 * 10(5) and 5.52 * 10(4) M(-1) respectively.
SE|25462243||ab|4|entity|C0205102|Intrinsic|spco|||intrinsic|||0|580|876|885
SE|25462243||ab|4|entity|C1547014|*Constant|qnco|||constants|||0|580|894|903
SE|25462243||ab|4|entity|C0439855|Complex|qlco|||complexes|||0|861|910|919
SE|25462243||ab|4|entity|C0012854|DNA|bacs,nnon|||CT-DNA|||0|861|936|942
SE|25462243||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|775|975|982

SE|25462243||ab|5|text|1052|1180|The results indicated that the three complexes are able to bind to DNA with different binding affinity, in the order 2 > 1 > 3.
SE|25462243||ab|5|entity|C1274040|result|ftcn|||results|||0|966|1056|1063
SE|25462243||ab|5|entity|C0205449|Three|qnco|||three|||0|888|1083|1088
SE|25462243||ab|5|entity|C0439855|Complex|qlco|||complexes|||0|888|1089|1098
SE|25462243||ab|5|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|1119|1122
SE|25462243||ab|5|entity|C1547020|*Difference|qnco|||different|||0|766|1128|1137

SE|25462243||ab|6|text|1180|1317|Complexes (1-3) exhibit a good binding propensity to bovine serum albumin (BSA) proteins having relatively high binding constant values.
SE|25462243||ab|6|entity|C0439855|Complex|qlco|||Complexes|||0|1000|1180|1189
SE|25462243||ab|6|entity|C0205170|Good|qlco|||good|||0|660|1206|1210
SE|25462243||ab|6|entity|C0036774|Serum Albumin, Bovine|aapp,bacs|||bovine serum albumin|||0|916|1233|1253
SE|25462243||ab|6|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|916|1260|1268
SE|25462243||ab|6|entity|C0205250|High|qlco|||high|||0|740|1287|1291
SE|25462243||ab|6|entity|C1547014|*Constant|qnco|||constant|||0|740|1300|1308
SE|25462243||ab|6|entity|C0042295|Values|qlco|||values|||0|740|1309|1315

SE|25462243||ab|7|text|1317|1696|Gel electrophoresis assay demonstrated the ability of the complexes 1-3 promote the cleavage ability of the pBR322 plasmid DNA in the presence of the reducing agent 3-mercaptopropionic acid (MPA) but with different cleavage mechanisms: the complex 3 cleaves DNA via hydrolytic pathway (T4 DNA ligase assay), while the DNA cleavage by complexes 1 and 2 follows oxidative pathway.
SE|25462243||ab|7|entity|C0596607|Gel Electrophoresis|lbpr|||Gel electrophoresis|||0|901|1317|1336
SE|25462243||ab|7|entity|C1510438|Assay|lbpr|||assay|||0|901|1337|1342
SE|25462243||ab|7|entity|C0085732|Ability|orga|||ability|||0|1000|1360|1367
SE|25462243||ab|7|entity|C0439855|Complex|qlco|||complexes|||0|827|1375|1384
SE|25462243||ab|7|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|888|1401|1409
SE|25462243||ab|7|entity|C0085732|Ability|orga|||ability|||0|888|1410|1417
SE|25462243||ab|7|entity|C0032136|Plasmids|bacs,nnon|||plasmid|||0|790|1432|1439
SE|25462243||ab|7|entity|C0012854|DNA|bacs,nnon|||DNA|||0|790|1440|1443
SE|25462243||ab|7|entity|C0376446|Reducing Agents|irda|||reducing agent|||0|812|1467|1481
SE|25462243||ab|7|entity|C0001128|Acids|chem|||acid|||0|812|1502|1506
SE|25462243||ab|7|entity|C1547020|*Difference|qnco|||different|||0|828|1522|1531
SE|25462243||ab|7|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|828|1532|1540
SE|25462243||ab|7|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|828|1541|1551
SE|25462243||ab|7|entity|C0439855|Complex|qlco|||complex|||0|861|1557|1564
SE|25462243||ab|7|entity|C0012854|DNA|bacs,nnon|||DNA|||0|751|1575|1578
SE|25462243||ab|7|entity|C0020291|Hydrolysis|npop|||hydrolytic|||0|751|1583|1593
SE|25462243||ab|7|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|751|1594|1601
SE|25462243||ab|7|entity|C0039213|T4 DNA Ligase|aapp,enzy|||T4 DNA ligase|||0|916|1603|1616
SE|25462243||ab|7|entity|C1510438|Assay|lbpr|||assay|||0|916|1617|1622
SE|25462243||ab|7|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|1635|1638
SE|25462243||ab|7|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|888|1639|1647
SE|25462243||ab|7|entity|C0439855|Complex|qlco|||complexes|||0|861|1651|1660
SE|25462243||ab|7|entity|C0311404|Oxidative|ftcn|||oxidative|||0|888|1677|1686
SE|25462243||ab|7|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|888|1687|1694
SE|25462243||ab|7|relation|0|0|C0032136|Plasmids|bacs,nnon|bacs|||plasmid|||0|790|1432|1439|MOD/HEAD|ISA||1432|1443|0|0|C0012854|DNA|bacs,nnon|bacs|||DNA|||0|790|1440|1443
SE|25462243||ab|7|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|901|1337|1342|MOD/HEAD|USES||1317|1342|0|0|C0596607|Gel Electrophoresis|lbpr|lbpr|||Gel electrophoresis|||0|901|1317|1336
SE|25462243||ab|7|relation|0|0|C1510438|Assay|lbpr|lbpr|||assay|||0|916|1617|1622|MOD/HEAD|USES||1603|1622|0|0|C0039213|T4 DNA Ligase|aapp,gngm,enzy|aapp|||T4 DNA ligase|||0|916|1603|1616
SE|25462243||ab|7|relation|6|4|C0085732|Ability|orga|orga|||ability|||0|888|1410|1417|NOM|MANIFESTATION_OF||1541|1551|6|0|C1330957|Cytokinesis of the fertilized ovum|celf|celf|||cleavage|||0|828|1532|1540

SE|25462243||ab|8|text|1696|1757|The chemical nuclease activity follows the order: 2 > 1 > 3.
SE|25462243||ab|8|entity|C0220806|Chemicals|chem|||chemical|||0|901|1700|1708
SE|25462243||ab|8|entity|C1148806|nuclease activity|genf|||nuclease activity|||0|901|1709|1726

SE|25462243||ab|9|text|1757|1892|The effects of various activators were also investigated and the nuclease activity efficacy followed the order MPA > GSH > H2O2 > Asc.
SE|25462243||ab|9|entity|C1280500|Effect|qlco|||effects|||0|966|1761|1768
SE|25462243||ab|9|entity|C1148806|nuclease activity|genf|||nuclease activity|||0|734|1822|1839
SE|25462243||ab|9|entity|C0001128|Acids|chem|||MPA|||0|827|1868|1871
SE|25462243||ab|9|entity|C0020281|Hydrogen Peroxide|inch,irda,phsu|||H2O2|||0|1000|1880|1884
SE|25462243||ab|9|entity|||gngm|412,29108|STS,PYCARD|Asc|||0|1000|1887|1890

SE|25462243||ab|10|text|1892|2018|The cytotoxicity studies of complexes 1-3 were tested in vitro on breast cancer cell line (MCF-7) and they found to be active.
SE|25462243||ab|10|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|1896|1908
SE|25462243||ab|10|entity|C0439855|Complex|qlco|||complexes|||0|827|1920|1929
SE|25462243||ab|10|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|1946|1954
SE|25462243||ab|10|entity|C1512505|Breast Cancer Cell|cell|||breast cancer cell|||0|916|1958|1976
SE|25462243||ab|10|entity|C0205132|Linear|spco|||line|||0|916|1977|1981
SE|25462243||ab|10|entity|C0008015|Macrophage Chemotactic Factors|imft|||MCF-7|||0|861|1983|1988
SE|25462243||ab|10|entity|C0205177|Active|ftcn|||active|||0|1000|2011|2017


SE|25462244||ti|1|text|21|167|Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation.
SE|25462244||ti|1|entity|C0679622|novel|inpr|||Novel|||0|872|21|26
SE|25462244||ti|1|entity|C0243071|Analog|chvs|||analogs|||0|872|27|34
SE|25462244||ti|1|entity|C1328831|antitumor agent|phsu|||antitumor agent|||0|824|38|53
SE|25462244||ti|1|entity|C0108171|Calixarenes|orch,phsu|||calixarene|||0|824|54|64
SE|25462244||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|71|80
SE|25462244||ti|1|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|82|94
SE|25462244||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|901|147|154
SE|25462244||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|901|155|165

SE|25462244||ab|1|text|173|349|Calixarene 0118 is a potent anti-angiogenic agent that effectively inhibited tumor growth in preclinical studies, and is currently being evaluated in a phase I clinical trial.
SE|25462244||ab|1|entity|C0108171|Calixarenes|orch,phsu|||Calixarene|||0|861|173|183
SE|25462244||ab|1|entity|C0237399|Potential|qlco|||potent|||0|883|194|200
SE|25462244||ab|1|entity|C0596087|Angiogenesis Inhibitors|bacs,phsu|||anti-angiogenic agent|||0|883|201|222
SE|25462244||ab|1|entity|C0598934|tumor growth|neop|||tumor growth|||0|1000|250|262
SE|25462244||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|827|278|285
SE|25462244||ab|1|entity|C0521116|Current|tmco|||currently|||0|1000|294|303
SE|25462244||ab|1|entity|C0205390|Phase|tmco|||phase|||0|1000|325|330
SE|25462244||ab|1|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|1000|333|347
SE|25462244||ab|1|relation|1|1|C0596087|Angiogenesis Inhibitors|bacs,phsu|bacs|||anti-angiogenic agent|||0|883|201|222|VERB|DISRUPTS||240|249|4|1|C0598934|tumor growth|neop|neop|||tumor growth|||0|1000|250|262

SE|25462244||ab|2|text|349|576|We have designed two close mimetics of calixarene 0118 containing a terminal alkynyl-functional group, and developed an optimized semi-automated procedure for radiolabeling with 2-[(18)F]fluoroethylazide using click chemistry.
SE|25462244||ab|2|entity|C0205448|Two|qnco|||two|||0|802|366|369
SE|25462244||ab|2|entity|C0920591|mimetics|bmod|||mimetics|||0|802|376|384
SE|25462244||ab|2|entity|C0108171|Calixarenes|orch,phsu|||calixarene|||0|861|388|398
SE|25462244||ab|2|entity|C0598132|functional group|chvf|||functional group|||0|824|434|450
SE|25462244||ab|2|entity|C0205554|Automated|ftcn|||automated|||0|750|484|493
SE|25462244||ab|2|entity|C0184661|Procedures|hlca|||procedure|||0|750|494|503
SE|25462244||ab|2|entity|C0597354|radiotracer|irda|||radiolabeling|||0|966|508|521
SE|25462244||ab|2|entity|C0079107|chemical aspects|clas|||chemistry|||0|861|565|574

SE|25462244||ab|3|text|576|923|Following semi-preparative HPLC purification and formulation, the lower-rim modified analog [(18)F]6 and the equatorially labeled [(18)F]13 were obtained in >97% radiochemical purity and overall decay-corrected isolated radiochemical yields of 18.7 +/- 2.7% (n = 4) and 10.2 +/- 5.0% (n = 4), respectively, in a total synthesis time of about 2 h.
SE|25462244||ab|3|entity|C0008562|High pressure liquid chromatography procedure|lbpr|||HPLC|||0|750|603|607
SE|25462244||ab|3|entity|C0243114|purification|lbpr,resa|||purification|||0|750|608|620
SE|25462244||ab|3|entity|C0441994|Lower|ftcn|||lower|||0|694|642|647
SE|25462244||ab|3|entity|C0243071|Analog|chvs|||analog|||0|1000|661|667
SE|25462244||ab|3|entity|C0439082|>97|qnco|||97|||0|623|734|736
SE|25462244||ab|3|entity|C0599914|radiochemical|chvf|||radiochemical|||0|623|738|751
SE|25462244||ab|3|entity|C1561607|Overall|qlco|||overall|||0|888|763|770
SE|25462244||ab|3|entity|C1265875|Disintegration|acab|||decay|||0|888|771|776
SE|25462244||ab|3|entity|C0205409|Isolated|ftcn|||isolated|||0|623|787|795
SE|25462244||ab|3|entity|C0599914|radiochemical|chvf|||radiochemical|||0|623|796|809
SE|25462244||ab|3|entity|C0439175|% of total|qnco|||total|||0|851|888|893
SE|25462244||ab|3|entity|C0869032|Synthesis|phpr|||synthesis|||0|851|894|903
SE|25462244||ab|3|entity|C0040223|Time|tmco|||time|||0|851|904|908

SE|25462244||ab|4|text|923|1139|Preliminary in vivo studies in nude mice bearing human tumor xenografts revealed highest accumulation of both tracers in the liver, followed by spleen, kidney, lung and bone, with no substantial uptake in the tumor.
SE|25462244||ab|4|entity|C0439611|Preliminary|tmco|||Preliminary|||0|850|923|934
SE|25462244||ab|4|entity|C1515655|in vivo|spco|||in vivo|||0|850|935|942
SE|25462244||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|850|943|950
SE|25462244||ab|4|entity|C0025932|Mice, Nude|mamm|||nude mice|||0|1000|954|963
SE|25462244||ab|4|entity|C0020114|Human|humn|||human|||0|851|972|977
SE|25462244||ab|4|entity|C0027651|Neoplasm|neop|||tumor|||0|851|978|983
SE|25462244||ab|4|entity|C0520484|Xenograft procedure|topp|||xenografts|||0|851|984|994
SE|25462244||ab|4|entity|C1522410|Highest|qlco|||highest|||0|694|1004|1011
SE|25462244||ab|4|entity|C1522485|Tracer|irda|||tracers|||0|966|1033|1040
SE|25462244||ab|4|entity|C0023884|Liver|bpoc|||liver|||0|1000|1048|1053
SE|25462244||ab|4|entity|C0037993|Spleen|bpoc|||spleen|||0|1000|1067|1073
SE|25462244||ab|4|entity|C0022646|Kidney|bpoc|||kidney|||0|1000|1075|1081
SE|25462244||ab|4|entity|C0024109|Lung|bpoc|||lung|||0|1000|1083|1087
SE|25462244||ab|4|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|1000|1092|1096
SE|25462244||ab|4|entity|C0243144|uptake|phsf|||uptake|||0|861|1118|1124
SE|25462244||ab|4|entity|C0027651|Neoplasm|neop|||tumor|||0|1000|1132|1137
SE|25462244||ab|4|relation|11|9|C0520484|Xenograft procedure|topp|topp|||xenografts|||0|851|984|994|PREP|TREATS|negation|1125|1127|1|1|C0027651|Neoplasm|neop|neop|||tumor|||0|1000|1132|1137

SE|25462244||ab|5|text|1139|1406|Still, these first-in-class radiotracers are a valuable tool for pharmacokinetic profiling and improvement of calixarene-based anti-angiogenic therapeutics in the future, as similar radiolabeling strategies may be applied to other compounds in the calixarene series.
SE|25462244||ab|5|entity|C1279901|Firstly|qlco|||first|||0|764|1152|1157
SE|25462244||ab|5|entity|C0008902|Classification|clas|||class|||0|764|1161|1166
SE|25462244||ab|5|entity|C0597354|radiotracer|irda|||radiotracers|||0|764|1167|1179
SE|25462244||ab|5|entity|C0336791|Tool|mnob|||tool|||0|861|1195|1199
SE|25462244||ab|5|entity|C0031328|Pharmacokinetic|ftcn|||pharmacokinetic|||0|694|1204|1219
SE|25462244||ab|5|entity|C0108171|Calixarenes|orch,phsu|||calixarene|||0|751|1249|1259
SE|25462244||ab|5|entity|C0016884|Future|tmco|||future|||0|1000|1302|1308
SE|25462244||ab|5|entity|C0597354|radiotracer|irda|||radiolabeling|||0|816|1321|1334
SE|25462244||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|1370|1379
SE|25462244||ab|5|entity|C0108171|Calixarenes|orch,phsu|||calixarene|||0|888|1387|1397
SE|25462244||ab|5|entity|C0205549|Series|qnco|||series|||0|888|1398|1404

SE|25462244||ab|6|text|1406|1747|The cold reference compounds of the radiotracers were characterized in terms of cytotoxicity and anti-proliferative effects on HUVEC cells and on MA148 human ovarian carcinoma cells, along with the respective precursors, a small series of 0118 analogs modified with short-chain linear alkyl substituents, and a PEG3-spaced calixarene dimer.
SE|25462244||ab|6|entity|C1514811|Reference|idcn|||reference|||0|773|1415|1424
SE|25462244||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|773|1425|1434
SE|25462244||ab|6|entity|C0597354|radiotracer|irda|||radiotracers|||0|966|1442|1454
SE|25462244||ab|6|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|1486|1498
SE|25462244||ab|6|entity|C0334094|Proliferation|ftcn|||proliferative|||0|773|1508|1521
SE|25462244||ab|6|entity|C1280500|Effect|qlco|||effects|||0|773|1522|1529
SE|25462244||ab|6|entity|C0007634|Cells|cell|||cells|||0|861|1539|1544
SE|25462244||ab|6|entity|C0029925|Ovarian Carcinoma|neop|||ovarian carcinoma|||0|826|1564|1581
SE|25462244||ab|6|entity|C0427861|Human cells|lbtr|||human ovarian carcinoma cells|||0|826|1558|1587
SE|25462244||ab|6|entity|C0700321|Small|qnco|||small|||0|888|1629|1634
SE|25462244||ab|6|entity|C0205549|Series|qnco|||series|||0|888|1635|1641
SE|25462244||ab|6|entity|C0243071|Analog|chvs|||analogs|||0|827|1650|1657
SE|25462244||ab|6|entity|C0205132|Linear|spco|||linear|||0|623|1684|1690
SE|25462244||ab|6|entity|C1177206|ALKYL|phsu|||alkyl|||0|623|1691|1696
SE|25462244||ab|6|entity|||gngm|5178|PEG3|PEG3|||0|750|1717|1721
SE|25462244||ab|6|entity|C0108171|Calixarenes|orch,phsu|||calixarene|||0|750|1729|1739
SE|25462244||ab|6|entity|C0596448|dimer|chvs|||dimer|||0|750|1740|1745
SE|25462244||ab|6|relation|8|8|C0108171|Calixarenes|orch,phsu|orch|||calixarene|||0|750|1729|1739|NOM|AFFECTS||1522|1529|8|1|C0007634|Cells|cell|cell|||cells|||0|861|1539|1544

SE|25462244||ab|7|text|1747|2012|While all of the new analogs proved at least equipotent to parent 0118, some of them inhibited HUVEC and MA148 cell growth almost 4- and 10-fold more effectively, rendering these analogs promising candidates for further evaluation in anti-angiogenic cancer therapy.
SE|25462244||ab|7|entity|C0205314|New|tmco|||new|||0|872|1764|1767
SE|25462244||ab|7|entity|C0243071|Analog|chvs|||analogs|||0|872|1768|1775
SE|25462244||ab|7|entity|C0030551|parent|famg|||parent|||0|804|1806|1812
SE|25462244||ab|7|entity|C0007595|Cell Growth|celf|||cell growth|||0|840|1858|1869
SE|25462244||ab|7|entity|C0332462|Fold|spco|||fold|||0|812|1887|1891
SE|25462244||ab|7|entity|C0243071|Analog|chvs|||analogs|||0|966|1926|1933
SE|25462244||ab|7|entity|C1517331|Further|spco|||further|||0|888|1959|1966
SE|25462244||ab|7|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|1967|1977
SE|25462244||ab|7|entity|C0920425|Cancer Treatment|topp|||cancer therapy|||0|861|1997|2011


SE|25462245||ti|1|text|21|160|New tetracyclic tacrine analogs containing pyrano[2,3-c]pyrazole: efficient synthesis, biological assessment and docking simulation study.
SE|25462245||ti|1|entity|C0205314|New|tmco|||New|||0|764|21|24
SE|25462245||ti|1|entity|C0039245|Tacrine|orch,phsu|||tacrine|||0|764|37|44
SE|25462245||ti|1|entity|C0243071|Analog|chvs|||analogs|||0|764|45|52
SE|25462245||ti|1|entity|C0072662|pyrazole|orch|||pyrazole|||0|1000|77|85
SE|25462245||ti|1|entity|C0442799|Efficient|qlco|||efficient|||0|888|87|96
SE|25462245||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|888|97|106
SE|25462245||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|108|118
SE|25462245||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|119|129
SE|25462245||ti|1|entity|C1522290|Docking|moft|||docking|||0|851|134|141
SE|25462245||ti|1|entity|C0679083|simulation|resa|||simulation|||0|851|142|152
SE|25462245||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|851|153|158

SE|25462245||ab|1|text|166|335|A new series of tacrine-based acetylcholinesterase (AChE) inhibitors 7a-l were designed by replacing the benzene ring of tacrine with aryl-dihydropyrano[2,3-c]pyrazole.
SE|25462245||ab|1|entity|C0205314|New|tmco|||new|||0|888|168|171
SE|25462245||ab|1|entity|C0205549|Series|qnco|||series|||0|888|172|178
SE|25462245||ab|1|entity|C0039245|Tacrine|orch,phsu|||tacrine|||0|816|182|189
SE|25462245||ab|1|entity|C0001046|Acetylcholinesterase Inhibitors|phsu|||acetylcholinesterase (AChE) inhibitors|||0|816|196|234
SE|25462245||ab|1|entity|C1554078|Replace|idcn|||replacing|||0|966|257|266
SE|25462245||ab|1|entity|C1440128|BENZENE RING|imft|||benzene ring|||0|1000|271|283
SE|25462245||ab|1|entity|C0039245|Tacrine|orch,phsu|||tacrine|||0|1000|287|294
SE|25462245||ab|1|entity|C0072662|pyrazole|orch|||pyrazole|||0|1000|325|333

SE|25462245||ab|2|text|335|542|The poly-functionalized hybrid molecules 7a-l were efficiently synthesized through multi-component reaction and subsequent Friedlander reaction between the obtained pyrano[2,3-c]pyrazoles and cyclohexanone.
SE|25462245||ab|2|entity|C0747726|POLY|cnce|||poly|||0|750|339|343
SE|25462245||ab|2|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|750|359|365
SE|25462245||ab|2|entity|C0567416|Molecule|sbst|||molecules|||0|750|366|375
SE|25462245||ab|2|entity|C1442112|MULTI|qnco|||multi|||0|851|418|423
SE|25462245||ab|2|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|424|433
SE|25462245||ab|2|entity|C0443286|Reaction|ftcn|||reaction|||0|851|434|442
SE|25462245||ab|2|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|802|447|457
SE|25462245||ab|2|entity|C0443286|Reaction|ftcn|||reaction|||0|802|470|478
SE|25462245||ab|2|entity|C1301820|Obtained|ftcn|||obtained|||0|694|491|499
SE|25462245||ab|2|entity|C0034242|Pyrazoles|orch|||pyrazoles|||0|1000|513|522
SE|25462245||ab|2|entity|C0056760|cyclohexanone|orch|||cyclohexanone|||0|1000|527|540

SE|25462245||ab|3|text|542|639|Most of target compounds showed potent and selective anti-AChE activity at sub-micromolar range.
SE|25462245||ab|3|entity|C0205393|Most|qnco|||Most|||0|1000|542|546
SE|25462245||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|872|557|566
SE|25462245||ab|3|entity|C0237399|Potential|qlco|||potent|||0|900|574|580
SE|25462245||ab|3|entity|C1149827|acetylcholinesterase activity|moft|||AChE activity|||0|861|600|613
SE|25462245||ab|3|entity|C0542339|Inferior|spco|||sub|||0|851|617|620
SE|25462245||ab|3|entity|C0439300|Micromole/liter|qnco|||micromolar|||0|851|621|631
SE|25462245||ab|3|entity|C1514721|Range|qnco|||range|||0|851|632|637

SE|25462245||ab|4|text|639|748|The most potent compound 7h bearing a 3,4-dimethoxyphenyl group was more active than reference drug tacrine.
SE|25462245||ab|4|entity|C0205393|Most|qnco|||most|||0|808|643|647
SE|25462245||ab|4|entity|C0237399|Potential|qlco|||potent|||0|808|648|654
SE|25462245||ab|4|entity|C0205198|Compound|qlco|||compound|||0|808|655|663
SE|25462245||ab|4|entity|C0441833|Groups|inpr|||group|||0|827|697|702
SE|25462245||ab|4|entity|C0205172|More|ftcn|||more|||0|888|707|711
SE|25462245||ab|4|entity|C0205177|Active|ftcn|||active|||0|888|712|718
SE|25462245||ab|4|entity|C1514811|Reference|idcn|||reference|||0|851|724|733
SE|25462245||ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|851|734|738
SE|25462245||ab|4|entity|C0039245|Tacrine|orch,phsu|||tacrine|||0|851|739|746
SE|25462245||ab|4|relation|0|0|C0039245|Tacrine|orch,phsu|orch|||tacrine|||0|851|739|746|MOD/HEAD|ISA||734|746|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|851|734|738

SE|25462245||ab|5|text|748|886|The representative compound 7h could significantly protect neurons against oxidative stress as potent as quercetin at low concentrations.
SE|25462245||ab|5|entity|C0205198|Compound|qlco|||compound|||0|790|767|775
SE|25462245||ab|5|entity|C0027882|Neurons|cell|||neurons|||0|1000|807|814
SE|25462245||ab|5|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|1000|823|839
SE|25462245||ab|5|entity|C0237399|Potential|qlco|||potent|||0|900|843|849
SE|25462245||ab|5|entity|C0034392|Quercetin|orch,phsu,vita|||quercetin|||0|1000|853|862
SE|25462245||ab|5|entity|C0205251|low|qlco|||low|||0|888|866|869

SE|25462245||ab|6|text|886|1043|The docking study of compound 7h with AChE enzyme revealed that the (R)-enantiomer binds preferably to CAS while the (S)-enantiomer prone to be a PAS binder.
SE|25462245||ab|6|entity|C1522290|Docking|moft|||docking|||0|888|890|897
SE|25462245||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|888|898|903
SE|25462245||ab|6|entity|C0205198|Compound|qlco|||compound|||0|888|907|915
SE|25462245||ab|6|entity|C0001044|Acetylcholinesterase|aapp,enzy|||AChE|||0|888|924|928
SE|25462245||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|929|935
SE|25462245||ab|6|entity|C0599473|enantiomer|chvs|||enantiomer|||0|861|958|968
SE|25462245||ab|6|entity|C1366459|BCAR1 gene|gngm|9564|BCAR1|CAS|||0|1000|989|992
SE|25462245||ab|6|entity|C0599473|enantiomer|chvs|||enantiomer|||0|1000|1007|1017
SE|25462245||ab|6|entity|C0030125|p-Aminosalicylic Acid|orch,phsu|||PAS|||0|888|1032|1035
SE|25462245||ab|6|entity|C0179302|Binder|medd|||binder|||0|888|1036|1042
SE|25462245||ab|6|relation|0|0|C0179302|Binder|medd|medd|||binder|||0|888|1036|1042|MOD/HEAD|USES||1032|1042|0|0|C0030125|p-Aminosalicylic Acid|orch,phsu|phsu|||PAS|||0|888|1032|1035


SE|25462246||ti|1|text|21|114|Synthesis and evaluation of new indole-based chalcones as potential antiinflammatory agents.
SE|25462246||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462246||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|35|45
SE|25462246||ti|1|entity|C0205314|New|tmco|||new|||0|825|49|52
SE|25462246||ti|1|entity|C0021236|indole|orch|||indole|||0|825|53|59
SE|25462246||ti|1|entity|C1456331|Chalcones|orch|||chalcones|||0|825|66|75
SE|25462246||ti|1|entity|C0237399|Potential|qlco|||potential|||0|901|79|88
SE|25462246||ti|1|entity|C0003209|Anti-Inflammatory Agents|phsu|||antiinflammatory agents|||0|901|89|112

SE|25462246||ab|1|text|120|319|In the present work, new indole-based chalcone derivatives were obtained via the reaction of 5-substituted-1H-indole-3-carboxaldehydes/1-methylindole-3-carboxaldehyde with appropriate acetophenones.
SE|25462246||ab|1|entity|C0150312|Present|qnco|||present|||0|888|127|134
SE|25462246||ab|1|entity|C0043227|Work|ocac|||work|||0|888|135|139
SE|25462246||ab|1|entity|C0205314|New|tmco|||new|||0|815|141|144
SE|25462246||ab|1|entity|C0021236|indole|orch|||indole|||0|815|145|151
SE|25462246||ab|1|entity|C0007935|Chalcone|orch|||chalcone|||0|815|158|166
SE|25462246||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|815|167|178
SE|25462246||ab|1|entity|C1550513|via|idcn|||via|||0|1000|193|196
SE|25462246||ab|1|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|201|209
SE|25462246||ab|1|entity|C0063490|indole-3-carbaldehyde|orch|||1H-indole-3-carboxaldehydes|||0|686|227|254
SE|25462246||ab|1|entity|C1548787|Appropriate|qlco|||appropriate|||0|888|292|303
SE|25462246||ab|1|entity|C0001006|Acetophenones|orch|||acetophenones|||0|888|304|317

SE|25462246||ab|2|text|319|419|The synthesized compounds were investigated for their in vitro COX-1 and COX-2 inhibitory activity.
SE|25462246||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|827|335|344
SE|25462246||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|888|373|381
SE|25462246||ab|2|entity|C0389003|cyclooxygenase 1|aapp,enzy|||COX-1|||0|888|382|387
SE|25462246||ab|2|entity|C1257954|Cyclooxygenase 2 Inhibitors|orch,phsu|||COX-2 inhibitory|||0|892|392|408

SE|25462246||ab|3|text|419|564|The most effective COX inhibitors were also evaluated for their in vivo antiinflammatory and antioxidant activities in LPS induced sepsis model.
SE|25462246||ab|3|entity|C0205393|Most|qnco|||most|||0|833|423|427
SE|25462246||ab|3|entity|C0033551|Prostaglandin-Endoperoxide Synthase|aapp,enzy|1351,9377|COX8A,COX5A|COX|||0|833|438|441
SE|25462246||ab|3|entity|C0243077|inhibitors|chvf|||inhibitors|||0|833|442|452
SE|25462246||ab|3|entity|C1515655|in vivo|spco|||in vivo|||0|884|483|490
SE|25462246||ab|3|entity|C1148564|antioxidant activity|moft|||antioxidant activities|||0|983|512|534
SE|25462246||ab|3|entity|C0023810|Lipopolysaccharides|lipd|||LPS|||0|1000|538|541
SE|25462246||ab|3|entity|C0036690|Septicemia|dsyn|||sepsis|||0|888|550|556
SE|25462246||ab|3|entity|C0026336|Study models|inpr,resd|||model|||0|888|557|562

SE|25462246||ab|4|text|564|707|Furthermore, the CCK-8 assay was carried out to determine cytotoxic effects of all compounds against NIH/3T3 mouse embryonic fibroblast cells.
SE|25462246||ab|4|entity|C0037167|Sincalide|aapp,bacs,horm,phsu|885|CCK|CCK-8|||0|901|581|586
SE|25462246||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|901|587|592
SE|25462246||ab|4|entity|C0439787|Out|spco|||out|||0|1000|605|608
SE|25462246||ab|4|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|872|622|631
SE|25462246||ab|4|entity|C1280500|Effect|qlco|||effects|||0|872|632|639
SE|25462246||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|647|656
SE|25462246||ab|4|entity|C1516828|Embryonic Tissue - MEF (MMHCC)|tisu|||mouse embryonic fibroblast|||0|888|673|699
SE|25462246||ab|4|entity|C1257739|NIH 3T3 Cells|cell|||NIH/3T3 mouse embryonic fibroblast cells|||0|888|665|705
SE|25462246||ab|4|relation|0|0|C1257739|NIH 3T3 Cells|cell|cell|||NIH/3T3 mouse embryonic fibroblast cells|||0|888|665|705|MOD/HEAD|PART_OF||673|705|0|0|C1516828|Embryonic Tissue - MEF (MMHCC)|tisu|tisu|||mouse embryonic fibroblast|||0|888|673|699

SE|25462246||ab|5|text|707|1023|3-(5-Bromo-1H-indol-3-yl)-1-(4-cyanophenyl)prop-2-en-1-one (6) can be considered as a non-selective COX inhibitor (COX-1 IC50 = 8.1 +/- 0.2 MUg/mL, COX-2 IC50 = 9.5 +/- 0.8 MUg/mL), whereas 3-(5-methoxy-1H-indol-3-yl)-1-(4-(methylsulfonyl)phenyl)prop-2-en-1-one (1) inhibited only COX-1 (IC50 = 8.6 +/- 0.1 MUg/mL).
SE|25462246||ab|5|entity|C0205447|One|qnco|||one|||0|804|762|765
SE|25462246||ab|5|entity|C0033551|Prostaglandin-Endoperoxide Synthase|aapp,enzy|1351,9377|COX8A,COX5A|COX|||0|733|807|810
SE|25462246||ab|5|entity|C0243077|inhibitors|chvf|||inhibitor|||0|733|811|820
SE|25462246||ab|5|entity|C0389003|cyclooxygenase 1|aapp,enzy|||COX-1|||0|901|822|827
SE|25462246||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|901|828|832
SE|25462246||ab|5|entity|C1367485|PTGS2 gene|gngm|5743|PTGS2|COX-2|||0|888|855|860
SE|25462246||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|861|865
SE|25462246||ab|5|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|1000|946|952
SE|25462246||ab|5|entity|C0205447|One|qnco|||one|||0|804|965|968
SE|25462246||ab|5|entity|C0389003|cyclooxygenase 1|aapp,enzy|||COX-1|||0|901|988|993
SE|25462246||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|995|999

SE|25462246||ab|6|text|1023|1128|According to in vivo studies, these compounds also displayed antiinflammatory and antioxidant activities.
SE|25462246||ab|6|entity|C1515655|in vivo|spco|||in vivo|||0|884|1036|1043
SE|25462246||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|884|1044|1051
SE|25462246||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|1059|1068
SE|25462246||ab|6|entity|C1148564|antioxidant activity|moft|||antioxidant activities|||0|983|1105|1127


SE|25462247||ti|1|text|21|155|In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.
SE|25462247||ti|1|entity|C1533691|in vitro|qlco|||In vitro|||0|1000|21|29
SE|25462247||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|734|34|41
SE|25462247||ti|1|entity|C0005068|Benzofurans|orch|||benzofuran|||0|888|64|74
SE|25462247||ti|1|entity|C1527240|Derivative|ftcn|||derivative|||0|888|75|85
SE|25462247||ti|1|entity|C0237399|Potential|qlco|||potential|||0|802|89|98
SE|25462247||ti|1|entity|C0450442|Agent|chvf|||agent|||0|802|110|115
SE|25462247||ti|1|entity|C0679622|novel|inpr|||novel|||0|868|122|127
SE|25462247||ti|1|entity|C1439287|aurora kinase B|aapp,enzy|||Aurora B kinase|||0|868|128|143
SE|25462247||ti|1|entity|C0243077|inhibitors|chvf|||inhibitor|||0|868|144|153
SE|25462247||ti|1|relation|4|2|C0005068|Benzofurans|orch|orch|||benzofuran|||0|888|64|74|NOM|INHIBITS||144|153|4|0|C1439287|aurora kinase B|aapp,gngm,enzy|gngm|||Aurora B kinase|||0|868|128|143

SE|25462247||ab|1|text|161|268|Aurora B is a serine/threonine kinase that has a key role in mitosis and is overexpressed in cancer cells.
SE|25462247||ab|1|entity|C0072402|Protein-Serine-Threonine Kinases|aapp,enzy|||serine/threonine kinase|||0|1000|175|198
SE|25462247||ab|1|entity|C1554080|Key|idcn|||key|||0|888|210|213
SE|25462247||ab|1|entity|C0035820|Role|socb|||role|||0|888|214|218
SE|25462247||ab|1|entity|C0026255|Mitosis|celf|||mitosis|||0|1000|222|229
SE|25462247||ab|1|entity|C0334227|Tumor cells, malignant|cell|||cancer cells|||0|983|254|266
SE|25462247||ab|1|relation|2|1|C0072402|Protein-Serine-Threonine Kinases|aapp,gngm,enzy|aapp|||serine/threonine kinase|||0|1000|175|198|NOM|AFFECTS||214|218|2|1|C0026255|Mitosis|celf|celf|||mitosis|||0|1000|222|229

SE|25462247||ab|2|text|268|436|Aberrations in Aurora B are highly correlated with tumorigenesis and cancer development, so many studies have focused on the development of Aurora B kinase inhibitors.
SE|25462247||ab|2|entity|C0443127|Aberrant|qlco|||Aberrations|||0|916|268|279
SE|25462247||ab|2|entity|C1326912|Tumorigenesis|neop|||tumorigenesis|||0|1000|319|332
SE|25462247||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|888|337|343
SE|25462247||ab|2|entity|C1527148|Development|ftcn|||development|||0|888|344|355
SE|25462247||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|966|365|372
SE|25462247||ab|2|entity|C1527148|Development|ftcn|||development|||0|1000|393|404
SE|25462247||ab|2|entity|C1439287|aurora kinase B|aapp,enzy|||Aurora B kinase|||0|916|408|423
SE|25462247||ab|2|entity|C0243077|inhibitors|chvf|||inhibitors|||0|916|424|434

SE|25462247||ab|3|text|436|634|Based on one of our previous high-throughput screening studies, we identified lead compound S6, a small-molecule benzofuran derivative that binds Aurora B and inhibits its kinase activity in vitro.
SE|25462247||ab|3|entity|C0205447|One|qnco|||one|||0|1000|445|448
SE|25462247||ab|3|entity|C0205156|Previous|tmco|||previous|||0|868|456|464
SE|25462247||ab|3|entity|C0872187|High Throughput Screening|diap|||high-throughput screening|||0|868|465|490
SE|25462247||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|868|491|498
SE|25462247||ab|3|entity|C0303231|Lead compound|chvs|||lead compound|||0|734|514|527
SE|25462247||ab|3|entity|C1328819|small molecule|orch|||small-molecule|||0|861|534|548
SE|25462247||ab|3|entity|C0005068|Benzofurans|orch|||benzofuran|||0|861|549|559
SE|25462247||ab|3|entity|C1527240|Derivative|ftcn|||derivative|||0|861|560|570
SE|25462247||ab|3|entity|C1150423|kinase activity|moft|||kinase activity|||0|1000|608|623
SE|25462247||ab|3|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|624|632
SE|25462247||ab|3|relation|5|2|C0005068|Benzofurans|orch|orch|||benzofuran|||0|861|549|559|VERB|DISRUPTS||595|603|2|1|C1150423|kinase activity|moft|moft|||kinase activity|||0|1000|608|623

SE|25462247||ab|4|text|634|694|S6 also displayed high selectivity for Aurora B inhibition.
SE|25462247||ab|4|entity|C0205250|High|qlco|||high|||0|694|652|656

SE|25462247||ab|5|text|694|771|The cytotoxicity of S6 was assessed against a panel of 21 cancer cell lines.
SE|25462247||ab|5|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|698|710
SE|25462247||ab|5|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|824|752|758
SE|25462247||ab|5|entity|C0007600|Cell Line|cell|||cell lines|||0|824|759|769

SE|25462247||ab|6|text|771|910|The cervical cancer cell line HeLa, liver cancer cell line HepG2 and colon cancer cell line SW620 were the most sensitive to S6 treatment.
SE|25462247||ab|6|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|660|775|790
SE|25462247||ab|6|entity|C0007600|Cell Line|cell|||cell line|||0|660|791|800
SE|25462247||ab|6|entity|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|||liver cancer|||0|660|807|819
SE|25462247||ab|6|entity|C0007600|Cell Line|cell|||cell line|||0|660|820|829
SE|25462247||ab|6|entity|C0007102|Malignant tumor of colon|neop|||colon cancer|||0|660|840|852
SE|25462247||ab|6|entity|C0007600|Cell Line|cell|||cell line|||0|660|853|862
SE|25462247||ab|6|entity|C0205393|Most|qnco|||most|||0|888|878|882
SE|25462247||ab|6|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|883|892

SE|25462247||ab|7|text|910|1079|We found that S6 decreased the proliferation and colony formation of these three cell lines and elevated their percentages of cells in the G2/M phase of the cell cycle.
SE|25462247||ab|7|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|941|954
SE|25462247||ab|7|entity|C0439158|colonies|qnco|||colony|||0|872|959|965
SE|25462247||ab|7|entity|C1522492|Formation|ftcn|||formation|||0|872|966|975
SE|25462247||ab|7|entity|C0205449|Three|qnco|||three|||0|901|985|990
SE|25462247||ab|7|entity|C0007600|Cell Line|cell|||cell lines|||0|901|991|1001
SE|25462247||ab|7|entity|C0439165|Percent (qualifier value)|qnco|||percentages|||0|966|1021|1032
SE|25462247||ab|7|entity|C0007634|Cells|cell|||cells|||0|1000|1036|1041
SE|25462247||ab|7|entity|C0079396|G2 Phase|celf|||G2/M phase|||0|901|1049|1059
SE|25462247||ab|7|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|1000|1067|1077

SE|25462247||ab|8|text|1079|1180|S6 also inhibited phospho-histone H3 on Ser 10, a natural biomarker of endogenous Aurora B activity.
SE|25462247||ab|8|entity|C0019647|Histone H3|aapp,bacs|||histone H3|||0|901|1105|1115
SE|25462247||ab|8|entity|C0205549|Series|qnco|||Ser|||0|861|1119|1122
SE|25462247||ab|8|entity|C0205296|Natural|ftcn|||natural|||0|888|1129|1136
SE|25462247||ab|8|entity|C0005516|Biological Markers|qlco|||biomarker|||0|888|1137|1146
SE|25462247||ab|8|entity|C0205227|Endogenous|ftcn|||endogenous|||0|764|1150|1160

SE|25462247||ab|9|text|1180|1386|The growth suppression of liver cancer QGY-7401 xenograft tumors was observed in nude mice after S6 administration, and this effect was accompanied by the in vivo inhibition of phospho-histone H3 (Ser 10).
SE|25462247||ab|9|entity|C0151686|Growth retardation|patf|||growth suppression|||0|1000|1184|1202
SE|25462247||ab|9|entity|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|||liver cancer|||0|774|1206|1218
SE|25462247||ab|9|entity|C0520484|Xenograft procedure|topp|||xenograft|||0|774|1228|1237
SE|25462247||ab|9|entity|C0027651|Neoplasm|neop|||tumors|||0|774|1238|1244
SE|25462247||ab|9|entity|C0025932|Mice, Nude|mamm|||nude mice|||0|1000|1261|1270
SE|25462247||ab|9|entity|C1280500|Effect|qlco|||effect|||0|1000|1305|1311
SE|25462247||ab|9|entity|C1515655|in vivo|spco|||in vivo|||0|901|1335|1342
SE|25462247||ab|9|entity|C0019647|Histone H3|aapp,bacs|||histone H3|||0|901|1365|1375
SE|25462247||ab|9|entity|C0205549|Series|qnco|||Ser|||0|861|1377|1380
SE|25462247||ab|9|relation|2|1|C0027651|Neoplasm|neop|neop|||tumors|||0|774|1238|1244|PREP|PROCESS_OF||1258|1260|5|1|C0025932|Mice, Nude|mamm|mamm|||nude mice|||0|1000|1261|1270

SE|25462247||ab|10|text|1386|1538|Taken together, we conclude that targeting Aurora B with compound S6 may be a novel strategy for cancer treatment, and additional studies are warranted.
SE|25462247||ab|10|entity|C0205198|Compound|qlco|||compound|||0|694|1443|1451
SE|25462247||ab|10|entity|C0679622|novel|inpr|||novel|||0|888|1464|1469
SE|25462247||ab|10|entity|C0920425|Cancer Treatment|topp|||cancer treatment|||0|1000|1483|1499
SE|25462247||ab|10|entity|C1524062|Additional|ftcn|||additional|||0|872|1505|1515
SE|25462247||ab|10|entity|C0008972|Clinical Research|resa|||studies|||0|872|1516|1523


SE|25462248||ti|1|text|21|170|1-Arylsulfonyl-5-(N-hydroxyacrylamide)tetrahydroquinolines as potent histone deacetylase inhibitors suppressing the growth of prostate cancer cells.
SE|25462248||ti|1|entity|C0237399|Potential|qlco|||potent|||0|872|83|89
SE|25462248||ti|1|entity|C1512474|Histone Deacetylase Inhibitor|chvf|||histone deacetylase inhibitors|||0|872|90|120
SE|25462248||ti|1|entity|C0018270|Growth|orgf|||growth|||0|1000|137|143
SE|25462248||ti|1|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|901|147|162
SE|25462248||ti|1|entity|C0007634|Cells|cell|||cells|||0|901|163|168

SE|25462248||ab|1|text|176|368|This study describes the development of a series of 1-arylsulfonyl-6-(N-hydroxyacrylamide)tetrahydroquinolines, potent histone deacetylase (HDAC) inhibitors which are cytotoxic to PC-3 cells.
SE|25462248||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|181|186
SE|25462248||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|201|212
SE|25462248||ab|1|entity|C0237399|Potential|qlco|||potent|||0|872|288|294
SE|25462248||ab|1|entity|C1512474|Histone Deacetylase Inhibitor|chvf|||histone deacetylase (HDAC) inhibitors|||0|872|295|332
SE|25462248||ab|1|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|1000|343|352
SE|25462248||ab|1|entity|C0007634|Cells|cell|||cells|||0|802|361|366

SE|25462248||ab|2|text|368|616|(E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide (11) exhibits marked anti-HDAC and antiproliferative activity, and is slightly more effective than N(1)-hydroxy-N(8)-phenyloctanediamide (SAHA, Vorinostat, 1).
SE|25462248||ab|2|entity|C0050587|Acrylamide|hops,orch|||acrylamide|||0|1000|445|455
SE|25462248||ab|2|entity|C0522501|Massive|qlco|||marked|||0|824|470|476
SE|25462248||ab|2|entity|C0019643|Histone Deacetylase|aapp,enzy|||HDAC|||0|824|482|486
SE|25462248||ab|2|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|802|526|534

SE|25462248||ab|3|text|616|792|In a xenograft tumor model, 11, at doses of 100 or 200 mg/kg orally, suppresses the growth of PC-3 cells and leads to tumor growth inhibition of 38.8% and 57.9%, respectively.
SE|25462248||ab|3|entity|C0027651|Neoplasm|neop|||tumor|||0|901|631|636
SE|25462248||ab|3|entity|C1520166|Xenograft Model|emod|||xenograft tumor model|||0|901|621|642
SE|25462248||ab|3|entity|C1446466|Dose|qnco|||doses|||0|1000|651|656
SE|25462248||ab|3|entity|C0018270|Growth|orgf|||growth|||0|1000|700|706
SE|25462248||ab|3|entity|C0007634|Cells|cell|||cells|||0|802|715|720
SE|25462248||ab|3|entity|C0598934|tumor growth|neop|||tumor growth|||0|901|734|746
SE|25462248||ab|3|relation|0|0|C0027651|Neoplasm|neop|neop|||tumor|||0|901|631|636|MOD/HEAD|PROCESS_OF||631|642|0|0|C1520166|Xenograft Model|emod|emod|||xenograft tumor model|||0|901|621|642

SE|25462248||ab|4|text|792|887|Compound 11 is a lead compound for further development of potential prostate cancer inhibitors.
SE|25462248||ab|4|entity|C0205198|Compound|qlco|||Compound|||0|861|792|800
SE|25462248||ab|4|entity|C0303231|Lead compound|chvs|||lead compound|||0|1000|809|822
SE|25462248||ab|4|entity|C1517331|Further|spco|||further|||0|888|827|834
SE|25462248||ab|4|entity|C1527148|Development|ftcn|||development|||0|888|835|846
SE|25462248||ab|4|entity|C0237399|Potential|qlco|||potential|||0|861|850|859
SE|25462248||ab|4|entity|C0376358|Malignant neoplasm of prostate|neop|||prostate cancer|||0|861|860|875
SE|25462248||ab|4|entity|C0243077|inhibitors|chvf|||inhibitors|||0|861|876|886


SE|25462249||ti|1|text|21|149|(99m)Tc-labeled-2-arylbenzoxazole derivatives as potential Abeta imaging probes for single-photon emission computed tomography.
SE|25462249||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|827|55|66
SE|25462249||ti|1|entity|C0237399|Potential|qlco|||potential|||0|775|70|79
SE|25462249||ti|1|entity|C1364818|APP gene|gngm|||Abeta|||0|775|80|85
SE|25462249||ti|1|entity|C0182400|Probes|medd|||probes|||0|775|94|100
SE|25462249||ti|1|entity|C0040399|Tomography, Emission-Computed, Single-Photon|diap|||single-photon emission computed tomography|||0|1000|105|147
SE|25462249||ti|1|relation|1|1|C0040399|Tomography, Emission-Computed, Single-Photon|diap|diap|||single-photon emission computed tomography|||0|1000|105|147|PREP|USES||101|104|4|1|C0182400|Probes|medd|medd|||probes|||0|775|94|100

SE|25462249||ab|1|text|155|336|Four neutral (99m)Tc/Re-labeled 2-arylbenzoxazole derivatives conjugated to bis (aminoethanethiol) (BAT) chelating ligand via a short propoxy spacer were synthesized and evaluated.
SE|25462249||ab|1|entity|C0205450|Four|qnco|||Four|||0|694|155|159
SE|25462249||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|827|205|216
SE|25462249||ab|1|entity|||gngm|9531|BAG3|bis|||0|1000|231|234
SE|25462249||ab|1|entity|C0008139|Chiroptera|mamm|||BAT|||0|1000|255|258
SE|25462249||ab|1|entity|C0023688|Ligands|chem|||ligand|||0|660|270|276

SE|25462249||ab|2|text|336|453|In vitro binding assay showed that they displayed binding affinities to Abeta1-42 aggregates (Ki = 15.86-393.18 nM).
SE|25462249||ab|2|entity|C1533691|in vitro|qlco|||In vitro|||0|824|336|344
SE|25462249||ab|2|entity|C1510438|Assay|lbpr|||assay|||0|824|353|358
SE|25462249||ab|2|entity|C0205418|Aggregate|qlco|||aggregates|||0|793|418|428

SE|25462249||ab|3|text|453|611|In vitro autoradiography studies further confirmed the high and specific binding of [(99m)Tc]20 to beta-amyloid plaques on brain sections of transgenic mice.
SE|25462249||ab|3|entity|C1533691|in vitro|qlco|||In vitro|||0|901|453|461
SE|25462249||ab|3|entity|C0004400|Autoradiography|lbpr|||autoradiography|||0|901|462|477
SE|25462249||ab|3|entity|C1517331|Further|spco|||further|||0|1000|486|493
SE|25462249||ab|3|entity|C0205250|High|qlco|||high|||0|1000|508|512
SE|25462249||ab|3|entity|C0333463|Senile Plaques|acab|||amyloid plaques|||0|901|557|572
SE|25462249||ab|3|entity|C0006104|Brain|bpoc|||brain|||0|872|576|581
SE|25462249||ab|3|entity|C0025936|Mice, Transgenic|mamm|||transgenic mice|||0|1000|594|609
SE|25462249||ab|3|relation|6|0|C0006104|Brain|bpoc|bpoc|||brain|||0|872|576|581|NOM|PART_OF||582|590|1|1|C0025936|Mice, Transgenic|mamm|mamm|||transgenic mice|||0|1000|594|609

SE|25462249||ab|4|text|611|866|Biodistribution study of [(99m)Tc]17-20 in normal mice displayed moderate initial brain uptake (0.96-1.55%ID/g at 2 min), and fast washed out from the brain (0.14-0.40%ID/g at 60 min), especially for [(99m)Tc]20 with a brain2min/brain60min ratio of 8.86.
SE|25462249||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|861|627|632
SE|25462249||ab|4|entity|C0205307|Normal|qlco|||normal|||0|888|654|660
SE|25462249||ab|4|entity|C0026809|Mus|mamm|||mice|||0|888|661|665
SE|25462249||ab|4|entity|C0205265|Initially|tmco|||initial|||0|775|685|692
SE|25462249||ab|4|entity|C0006104|Brain|bpoc|||brain|||0|775|693|698
SE|25462249||ab|4|entity|C0243144|uptake|phsf|||uptake|||0|775|699|705
SE|25462249||ab|4|entity|C0439232|Minute of time|tmco|||min|||0|861|727|730
SE|25462249||ab|4|entity|C0456962|Fast|qlco|||fast|||0|901|737|741
SE|25462249||ab|4|entity|C0392674|Exhaustion|sosy|||washed out|||0|901|742|752
SE|25462249||ab|4|entity|C0006104|Brain|bpoc|||brain|||0|1000|762|767
SE|25462249||ab|4|entity|C0439232|Minute of time|tmco|||min|||0|861|790|793
SE|25462249||ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|827|851|856
SE|25462249||ab|4|relation|0|0|C0243144|uptake|phsf|phsf|||uptake|||0|775|699|705|MOD/HEAD|PROCESS_OF||693|705|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|775|693|698
SE|25462249||ab|4|relation|6|1|C0006104|Brain|bpoc|bpoc|||brain|||0|1000|762|767|PREP|LOCATION_OF||753|757|8|1|C0392674|Exhaustion|sosy|sosy|||washed out|||0|901|742|752

SE|25462249||ab|5|text|866|1008|Taken together, these preliminary data suggested that [(99m)Tc]20 may be a potential imaging probe for detecting amyloid plaques in the brain.
SE|25462249||ab|5|entity|C0439611|Preliminary|tmco|||preliminary|||0|888|888|899
SE|25462249||ab|5|entity|C1511726|Data|idcn|||data|||0|888|900|904
SE|25462249||ab|5|entity|C0237399|Potential|qlco|||potential|||0|802|941|950
SE|25462249||ab|5|entity|C0182400|Probes|medd|||probe|||0|802|959|964
SE|25462249||ab|5|entity|C0333463|Senile Plaques|acab|||amyloid plaques|||0|890|979|994
SE|25462249||ab|5|entity|C0006104|Brain|bpoc|||brain|||0|1000|1002|1007
SE|25462249||ab|5|relation|1|1|C0006104|Brain|bpoc|bpoc|||brain|||0|1000|1002|1007|PREP|LOCATION_OF||995|997|5|1|C0333463|Senile Plaques|acab|acab|||amyloid plaques|||0|890|979|994


SE|25462250||ti|1|text|21|100|Inhibition of pseudolysin and thermolysin by hydroxamate-based MMP inhibitors.
SE|25462250||ti|1|entity|C0208103|pseudolysin, Pseudomonas aeruginosa|aapp,enzy|||pseudolysin|||0|1000|35|46
SE|25462250||ti|1|entity|C0039815|Thermolysin|aapp,enzy|||thermolysin|||0|1000|51|62
SE|25462250||ti|1|entity|C0178696|hydroxamate|orch|||hydroxamate|||0|858|66|77
SE|25462250||ti|1|entity|C1513016|Matrix Metalloproteinase Inhibitor|phsu|||MMP inhibitors|||0|858|84|98

SE|25462250||ab|1|text|106|352|In the present study, we have investigated the inhibition of thermolysin and pseudolysin by a series of compounds previously identified as matrix metalloproteinase (MMP) inhibitors using experimental binding studies and theoretical calculations.
SE|25462250||ab|1|entity|C0150312|Present|qnco|||present|||0|888|113|120
SE|25462250||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|121|126
SE|25462250||ab|1|entity|C0039815|Thermolysin|aapp,enzy|||thermolysin|||0|1000|167|178
SE|25462250||ab|1|entity|C0208103|pseudolysin, Pseudomonas aeruginosa|aapp,enzy|||pseudolysin|||0|1000|183|194
SE|25462250||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|966|210|219
SE|25462250||ab|1|entity|C1513016|Matrix Metalloproteinase Inhibitor|phsu|||matrix metalloproteinase (MMP) inhibitors|||0|983|245|286
SE|25462250||ab|1|entity|C0681814|research study|resa|||experimental binding studies|||0|896|293|321
SE|25462250||ab|1|entity|C1441506|CALCULATION|lbpr|||calculations|||0|827|338|350

SE|25462250||ab|2|text|352|482|The experimental studies showed that some of the compounds were able to inhibit thermolysin and pseudolysin in the low MUM range.
SE|25462250||ab|2|entity|C0681814|research study|resa|||experimental studies|||0|983|356|376
SE|25462250||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|401|410
SE|25462250||ab|2|entity|C0039815|Thermolysin|aapp,enzy|||thermolysin|||0|1000|432|443
SE|25462250||ab|2|entity|C0208103|pseudolysin, Pseudomonas aeruginosa|aapp,enzy|||pseudolysin|||0|1000|448|459
SE|25462250||ab|2|entity|C0205251|low|qlco|||low|||0|851|467|470
SE|25462250||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|851|471|474
SE|25462250||ab|2|entity|C1514721|Range|qnco|||range|||0|851|475|480

SE|25462250||ab|3|text|482|663|The studies revealed that, in general, the compounds bound in the order MMPs > pseudolysin > thermolysin, and the strongest pseudolysin and thermolysin binders were compounds 8-12.
SE|25462250||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|966|486|493
SE|25462250||ab|3|entity|C0205246|Generalized|spco|||general|||0|1000|512|519
SE|25462250||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|525|534
SE|25462250||ab|3|entity|C0623362|Matrix Metalloproteinases|aapp,enzy|||MMPs|||0|861|554|558
SE|25462250||ab|3|entity|C0208103|pseudolysin, Pseudomonas aeruginosa|aapp,enzy|||pseudolysin|||0|1000|561|572
SE|25462250||ab|3|entity|C0039815|Thermolysin|aapp,enzy|||thermolysin|||0|1000|575|586
SE|25462250||ab|3|entity|C0442821|Strong|qlco|||strongest|||0|872|596|605
SE|25462250||ab|3|entity|C0208103|pseudolysin, Pseudomonas aeruginosa|aapp,enzy|||pseudolysin|||0|872|606|617
SE|25462250||ab|3|entity|C0039815|Thermolysin|aapp,enzy|||thermolysin|||0|888|622|633
SE|25462250||ab|3|entity|C0179302|Binder|medd|||binders|||0|888|634|641
SE|25462250||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|890|647|656
SE|25462250||ab|3|entity|C0470359|8+12|qnco|||8-12|||0|890|657|661

SE|25462250||ab|4|text|663|786|Furthermore, compounds 8 and 9 were unique in that they bound much stronger to the two bacterial enzymes than to the MMPs.
SE|25462250||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|827|676|685
SE|25462250||ab|4|entity|C0442821|Strong|qlco|||stronger|||0|966|730|738
SE|25462250||ab|4|entity|C0205448|Two|qnco|||two|||0|851|746|749
SE|25462250||ab|4|entity|C0521009|Bacterial|ftcn|||bacterial|||0|851|750|759
SE|25462250||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|851|760|767
SE|25462250||ab|4|entity|C0623362|Matrix Metalloproteinases|aapp,enzy|||MMPs|||0|1000|780|784

SE|25462250||ab|5|text|786|1004|The docking calculations suggested that the phenyl group of the strongest binders (compounds 8 and 9) occupy the S2(')-subpocket, while a second ring system occupy the S1-subpocket in both thermolysin and pseudolysin.
SE|25462250||ab|5|entity|C1522290|Docking|moft|||docking|||0|872|790|797
SE|25462250||ab|5|entity|C1441506|CALCULATION|lbpr|||calculations|||0|872|798|810
SE|25462250||ab|5|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|888|830|836
SE|25462250||ab|5|entity|C0441833|Groups|inpr|||group|||0|888|837|842
SE|25462250||ab|5|entity|C0442821|Strong|qlco|||strongest|||0|872|850|859
SE|25462250||ab|5|entity|C0179302|Binder|medd|||binders|||0|872|860|867
SE|25462250||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|827|869|878
SE|25462250||ab|5|entity|C0457385|seconds|tmco|||second|||0|802|924|930
SE|25462250||ab|5|entity|C0449913|System|ftcn|||system|||0|802|936|942
SE|25462250||ab|5|entity|C0039815|Thermolysin|aapp,enzy|||thermolysin|||0|1000|975|986
SE|25462250||ab|5|entity|C0208103|pseudolysin, Pseudomonas aeruginosa|aapp,enzy|||pseudolysin|||0|1000|991|1002

SE|25462250||ab|6|text|1004|1129|When the compounds possess two ring systems, the largest and most electron rich ring system seems to occupy the S1-subpocket.
SE|25462250||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|1013|1022
SE|25462250||ab|6|entity|C0205448|Two|qnco|||two|||0|802|1031|1034
SE|25462250||ab|6|entity|C0449913|System|ftcn|||systems|||0|802|1040|1047
SE|25462250||ab|6|entity|C0443228|Largest|qnco|||largest|||0|1000|1053|1060
SE|25462250||ab|6|entity|C0013852|Electrons|qnco|||electron|||0|775|1070|1078
SE|25462250||ab|6|entity|C0699759|Wealthy|qlco|||rich|||0|775|1079|1083
SE|25462250||ab|6|entity|C0449913|System|ftcn|||system|||0|775|1089|1095


SE|25462251||ti|1|text|21|172|Design, synthesis, and biological evaluation of 2-arylethenylquinoline derivatives as multifunctional agents for the treatment of Alzheimer's disease.
SE|25462251||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462251||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|44|54
SE|25462251||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|55|65
SE|25462251||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|827|92|103
SE|25462251||ti|1|entity|C0450442|Agent|chvf|||agents|||0|827|123|129
SE|25462251||ti|1|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|1000|151|170
SE|25462251||ti|1|relation|5|1|C0450442|Agent|chvf|chvf|||agents|||0|827|123|129|NOM|TREATS||138|147|1|1|C0002395|Alzheimer's Disease|dsyn|dsyn|||Alzheimer's disease|||0|1000|151|170

SE|25462251||ab|1|text|178|404|A series of new 2-arylethenylquinoline derivatives (4a1-4a12, 4b1-4b8, 4c1-4c4, 4d1-4d3 and 4e1-4e9) were designed, synthesized, and evaluated as potential multifunctional agents for the treatment of Alzheimer's disease (AD).
SE|25462251||ab|1|entity|C0205314|New|tmco|||new|||0|791|190|193
SE|25462251||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|791|217|228
SE|25462251||ab|1|entity|C0237399|Potential|qlco|||potential|||0|785|324|333
SE|25462251||ab|1|entity|C0450442|Agent|chvf|||agents|||0|785|350|356
SE|25462251||ab|1|entity|C0002395|Alzheimer's Disease|dsyn|||Alzheimer's disease|||0|1000|378|397
SE|25462251||ab|1|relation|8|1|C0450442|Agent|chvf|chvf|||agents|||0|785|350|356|NOM|TREATS||365|374|1|1|C0002395|Alzheimer's Disease|dsyn|dsyn|||Alzheimer's disease|||0|1000|378|397

SE|25462251||ab|2|text|404|635|In vitro studies showed that these synthetic compounds inhibited self-induced Abeta1-42 aggregation effectively ranged from 23.6% to 83.9% at the concentration of 20 MUM, and acted as potential antioxidants and biometal chelators.
SE|25462251||ab|2|entity|C1533691|in vitro|qlco|||In vitro|||0|884|404|412
SE|25462251||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|884|413|420
SE|25462251||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|827|449|458
SE|25462251||ab|2|entity|C0036588|Self|idcn|||self|||0|762|469|473
SE|25462251||ab|2|entity|C0205263|Induced|ftcn|||induced|||0|762|474|481
SE|25462251||ab|2|entity|C0332621|Aggregation|ftcn|||aggregation|||0|762|492|503
SE|25462251||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|570|573
SE|25462251||ab|2|entity|C0237399|Potential|qlco|||potential|||0|888|588|597
SE|25462251||ab|2|entity|C0003402|Antioxidants|phsu|||antioxidants|||0|888|598|610
SE|25462251||ab|2|entity|C0040577|Trace Elements|bacs,elii|||biometal|||0|872|615|623
SE|25462251||ab|2|entity|C0007974|Chelating Agents|irda,phsu|||chelators|||0|872|624|633

SE|25462251||ab|3|text|635|703|Their structure-activity relationships were obtained and discussed.
SE|25462251||ab|3|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationships|||0|1000|641|673

SE|25462251||ab|4|text|703|1101|In particular, compound 4b1, the most active compound, displayed strong inhibitory activity with an IC50 value of 9.7 MUM for self-induced Abeta1-42 aggregation, good antioxidative activity with a value of 3.9-fold of Trolox, potent inhibitory activity for cholinesterase with IC50 values of 0.2 MUM and 64.1 MUM against butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE), respectively.
SE|25462251||ab|4|entity|C0205198|Compound|qlco|||compound|||0|660|718|726
SE|25462251||ab|4|entity|C0205393|Most|qnco|||most|||0|851|736|740
SE|25462251||ab|4|entity|C0205177|Active|ftcn|||active|||0|851|741|747
SE|25462251||ab|4|entity|C0205198|Compound|qlco|||compound|||0|851|748|756
SE|25462251||ab|4|entity|C0442821|Strong|qlco|||strong|||0|828|768|774
SE|25462251||ab|4|entity|C0243077|inhibitors|chvf|||inhibitory|||0|828|775|785
SE|25462251||ab|4|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|694|803|807
SE|25462251||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|821|824
SE|25462251||ab|4|entity|C0036588|Self|idcn|||self|||0|762|829|833
SE|25462251||ab|4|entity|C0205263|Induced|ftcn|||induced|||0|762|834|841
SE|25462251||ab|4|entity|C0332621|Aggregation|ftcn|||aggregation|||0|762|852|863
SE|25462251||ab|4|entity|C0205170|Good|qlco|||good|||0|802|865|869
SE|25462251||ab|4|entity|C0442760|3/9|fndg|||3.9|||0|901|909|912
SE|25462251||ab|4|entity|C0332462|Fold|spco|||fold|||0|901|913|917
SE|25462251||ab|4|entity|C0237399|Potential|qlco|||potent|||0|794|929|935
SE|25462251||ab|4|entity|C0243077|inhibitors|chvf|||inhibitory|||0|794|936|946
SE|25462251||ab|4|entity|C0008429|Cholinesterases|aapp,enzy|||cholinesterase|||0|1000|960|974
SE|25462251||ab|4|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|980|984
SE|25462251||ab|4|entity|C0042295|Values|qlco|||values|||0|888|985|991
SE|25462251||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|999|1002
SE|25462251||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|1012|1015
SE|25462251||ab|4|entity|C0728810|Butyrylcholinesterase|aapp,enzy|||butyrylcholinesterase|||0|1000|1024|1045
SE|25462251||ab|4|entity|C0001044|Acetylcholinesterase|aapp,enzy|||acetylcholinesterase|||0|1000|1058|1078

SE|25462251||ab|5|text|1101|1283|Besides, 4b1 was also capable of disassembling the self-induced Abeta1-42 aggregation fibrils with a ratio of 59.8% at 20 MUM concentration, and had a good metal chelating activity.
SE|25462251||ab|5|entity|C0036588|Self|idcn|||self|||0|738|1152|1156
SE|25462251||ab|5|entity|C0205263|Induced|ftcn|||induced|||0|738|1157|1164
SE|25462251||ab|5|entity|C0332621|Aggregation|ftcn|||aggregation|||0|738|1175|1186
SE|25462251||ab|5|entity|C0225328|Fibril|celc|||fibrils|||0|738|1187|1194
SE|25462251||ab|5|entity|C0456603|Ratio|inpr|||ratio|||0|1000|1202|1207
SE|25462251||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|660|1223|1226
SE|25462251||ab|5|entity|C0205170|Good|qlco|||good|||0|916|1252|1256
SE|25462251||ab|5|entity|C1154714|metal chelating activity|moft|||metal chelating activity|||0|916|1257|1281

SE|25462251||ab|6|text|1283|1391|Taken together, these results suggest that compound 4b1 might be a promising lead compound for AD treatment.
SE|25462251||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1305|1312
SE|25462251||ab|6|entity|C0205198|Compound|qlco|||compound|||0|694|1326|1334
SE|25462251||ab|6|entity|C1555307|promise|idcn|||promising|||0|890|1350|1359
SE|25462251||ab|6|entity|C0303231|Lead compound|chvs|||lead compound|||0|890|1360|1373
SE|25462251||ab|6|entity|C0002395|Alzheimer's Disease|dsyn|||AD|||0|901|1378|1380
SE|25462251||ab|6|relation|3|1|C0303231|Lead compound|chvs|chvs|||lead compound|||0|890|1360|1373|NOM|TREATS||1381|1390|3|0|C0002395|Alzheimer's Disease|dsyn|dsyn|||AD|||0|901|1378|1380


SE|25462252||ti|1|text|21|117|Design, synthesis and anti-leishmanial activity of novel symmetrical bispyridinium cyclophanes.
SE|25462252||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462252||ti|1|entity|C0023270|Genus: Leishmania|invt|||leishmanial|||0|790|48|59
SE|25462252||ti|1|entity|C0679622|novel|inpr|||novel|||0|583|72|77
SE|25462252||ti|1|entity|C0332516|Symmetry|spco|||symmetrical|||0|583|78|89

SE|25462252||ab|1|text|123|195|Nine novel symmetrical bispyridinium cyclophanes have been synthesized.
SE|25462252||ab|1|entity|C0205455|Nine|qnco|||Nine|||0|569|123|127
SE|25462252||ab|1|entity|C0679622|novel|inpr|||novel|||0|569|128|133
SE|25462252||ab|1|entity|C0332516|Symmetry|spco|||symmetrical|||0|569|134|145

SE|25462252||ab|2|text|195|357|They are rigid derivatives with an upper spacer which joins the two exocyclic amino groups, and a lower spacer joining the two positively charged nitrogen atoms.
SE|25462252||ab|2|entity|C0026837|Muscle Rigidity|sosy|||rigid|||0|888|204|209
SE|25462252||ab|2|entity|C0243072|derivatives|chvs|||derivatives|||0|888|210|221
SE|25462252||ab|2|entity|C1282910|Upper|spco|||upper|||0|694|230|235
SE|25462252||ab|2|entity|C0205448|Two|qnco|||two|||0|813|259|262
SE|25462252||ab|2|entity|C0596072|amino group|inch|||amino groups|||0|813|273|285
SE|25462252||ab|2|entity|C0441994|Lower|ftcn|||lower|||0|660|293|298
SE|25462252||ab|2|entity|C0205448|Two|qnco|||two|||0|758|318|321
SE|25462252||ab|2|entity|C0007961|charge amounts|qnco|||charged|||0|758|333|340
SE|25462252||ab|2|entity|C0028158|Nitrogen|elii|||nitrogen|||0|758|341|349
SE|25462252||ab|2|entity|C0567415|Atom|elii|||atoms|||0|758|350|355

SE|25462252||ab|3|text|357|454|At least one of the two spacers is an aliphatic linker, such as an alkane or oxyalkane fragment.
SE|25462252||ab|3|entity|C0205447|One|qnco|||one|||0|861|366|369
SE|25462252||ab|3|entity|C0205448|Two|qnco|||two|||0|888|377|380
SE|25462252||ab|3|entity|C0221874|spacer device|medd|||spacers|||0|888|381|388
SE|25462252||ab|3|entity|C0002065|Alkanes|orch|||alkane|||0|1000|424|430
SE|25462252||ab|3|entity|C0486805|FRAGMENTS|bdsu|||fragment|||0|827|444|452

SE|25462252||ab|4|text|454|602|The activity of these compounds has been evaluated against promastigotes and intracellular amastigotes of Leishmania donovani and Leishmania major.
SE|25462252||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|476|485
SE|25462252||ab|4|entity|C0175996|Protoplasm|celc|||intracellular|||0|694|531|544
SE|25462252||ab|4|entity|C0023273|Leishmania donovani|invt|||Leishmania donovani|||0|1000|560|579
SE|25462252||ab|4|entity|C0023276|Leishmania major|invt|||Leishmania major|||0|1000|584|600

SE|25462252||ab|5|text|602|913|All the cyclophanes are more active against L. major, with EC50 in intracellular amastigotes of between 1 and 17 MUM, they exhibit very low toxicity against mammalian cells THP-1 and in some cases they present a higher selectivity index than the reference anti-leishmanial drugs amphotericin B and miltefosine.
SE|25462252||ab|5|entity|C0205172|More|ftcn|||more|||0|888|626|630
SE|25462252||ab|5|entity|C0205177|Active|ftcn|||active|||0|888|631|637
SE|25462252||ab|5|entity|C0205164|Major|qlco|||major|||0|861|649|654
SE|25462252||ab|5|entity|C0175996|Protoplasm|celc|||intracellular|||0|694|669|682
SE|25462252||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|715|718
SE|25462252||ab|5|entity|C0600688|Toxic effect|inpo|||toxicity|||0|901|742|750
SE|25462252||ab|5|entity|C1512977|Mammalian Cell|cell|||mammalian cells|||0|844|759|774
SE|25462252||ab|5|entity|||gngm|2736|GLI2|THP-1|||0|844|775|780
SE|25462252||ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|793|798
SE|25462252||ab|5|entity|C0205250|High|qlco|||higher|||0|785|814|820
SE|25462252||ab|5|entity|C0918012|Index|inpr|||index|||0|785|833|838
SE|25462252||ab|5|entity|C1514811|Reference|idcn|||reference|||0|827|848|857
SE|25462252||ab|5|entity|C0023270|Genus: Leishmania|invt|||leishmanial|||0|827|863|874
SE|25462252||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|827|875|880
SE|25462252||ab|5|entity|C0085795|Amphotericin|antb,carb|||amphotericin|||0|827|881|893
SE|25462252||ab|5|entity|C0432618|Blood group antibody B|aapp,imft|||anti-leishmanial drugs amphotericin B|||0|827|858|895
SE|25462252||ab|5|entity|C0068006|miltefosine|opco,phsu|||miltefosine|||0|1000|900|911

SE|25462252||ab|6|text|913|1225|Compound 9 [2,8-Diaza-1,9(4,1)-dipyridinacyclotetradecaphan-1(1),9(1)-bis(ilium) dibromide] is the most active one among cyclophane derivatives against intracellular amastigotes of L. donovani (EC50 7.6 +/- 0.2 MUM) while L. major amastigotes are 6-fold more susceptible to the compound (EC50 1.26 +/- 0.3 MUM).
SE|25462252||ab|6|entity|C0205198|Compound|qlco|||Compound|||0|861|913|921
SE|25462252||ab|6|entity|||gngm|9531|BAG3|bis|||0|1000|983|986
SE|25462252||ab|6|entity|C1279102|Entire ilium|bpoc|||ilium|||0|1000|987|992
SE|25462252||ab|6|entity|C0205393|Most|qnco|||most|||0|851|1012|1016
SE|25462252||ab|6|entity|C0205177|Active|ftcn|||active|||0|851|1017|1023
SE|25462252||ab|6|entity|C0205447|One|qnco|||one|||0|851|1024|1027
SE|25462252||ab|6|entity|C0243072|derivatives|chvs|||derivatives|||0|861|1045|1056
SE|25462252||ab|6|entity|C0175996|Protoplasm|celc|||intracellular|||0|694|1065|1078
SE|25462252||ab|6|entity|C0857306|L.donovani|dsyn|||L. donovani|||0|1000|1094|1105
SE|25462252||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|799|1124|1127
SE|25462252||ab|6|entity|C0205164|Major|qlco|||major|||0|660|1138|1143
SE|25462252||ab|6|entity|C0332462|Fold|spco|||fold|||0|861|1162|1166
SE|25462252||ab|6|entity|C0205172|More|ftcn|||more|||0|888|1167|1171
SE|25462252||ab|6|entity|C0231204|Susceptible|ftcn|||susceptible|||0|888|1172|1183
SE|25462252||ab|6|entity|C0205198|Compound|qlco|||compound|||0|1000|1191|1199
SE|25462252||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|799|1219|1222

SE|25462252||ab|7|text|1225|1361|Compound 9 produces depolarization of the mitochondrial membrane and a decrease in the ATP levels that leads to death of the parasites.
SE|25462252||ab|7|entity|C0205198|Compound|qlco|||Compound|||0|861|1225|1233
SE|25462252||ab|7|entity|C1395184|depolarization|patf|||depolarization|||0|1000|1245|1259
SE|25462252||ab|7|entity|C0596952|Mitochondrial Membranes|celc|||mitochondrial membrane|||0|1000|1267|1289
SE|25462252||ab|7|entity|C0547047|Decrease|qnco|||decrease|||0|1000|1296|1304
SE|25462252||ab|7|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|888|1312|1315
SE|25462252||ab|7|entity|C0441889|Levels|inpr|||levels|||0|888|1316|1322
SE|25462252||ab|7|entity|C0011065|Cessation of life|orgf|||death|||0|1000|1337|1342
SE|25462252||ab|7|entity|C0030498|Parasites|invt|||parasites|||0|1000|1350|1359
SE|25462252||ab|7|relation|3|3|C1395184|depolarization|patf|patf|||depolarization|||0|1000|1245|1259|PREP|ASSOCIATED_WITH||1305|1307|3|1|C1366628|ATP8A2 gene|gngm,aapp|gngm|51761|ATP8A2|ATP|||0|888|1312|1315
SE|25462252||ab|7|relation|4|1|C1366628|ATP8A2 gene|gngm,aapp|gngm|51761|ATP8A2|ATP|||0|888|1312|1315|VERB|CAUSES||1328|1333|2|1|C0011065|Cessation of life|orgf|orgf|||death|||0|1000|1337|1342

SE|25462252||ab|8|text|1361|1510|The anti-leishmanial activity of this macrocyclic salts is independent of the Leishmania enzymes ethanolamine kinase and choline/ethanolamine kinase.
SE|25462252||ab|8|entity|C0023270|Genus: Leishmania|invt|||leishmanial|||0|790|1370|1381
SE|25462252||ab|8|entity|C0036140|Salts|chvs|||salts|||0|861|1411|1416
SE|25462252||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|824|1450|1457
SE|25462252||ab|8|entity|C0059697|Ethanolamine kinase|aapp,enzy|||ethanolamine kinase|||0|824|1458|1477
SE|25462252||ab|8|entity|C0014983|Ethanolamines|orch|||ethanolamine|||0|901|1490|1502
SE|25462252||ab|8|entity|C0008415|Choline Kinase|aapp,enzy|||choline/ethanolamine kinase|||0|901|1482|1509


SE|25462253||ti|1|text|21|166|Design, synthesis and in vitro evaluation of novel dehydroabietic acid derivatives containing a dipeptide moiety as potential anticancer agents.
SE|25462253||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462253||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|901|43|51
SE|25462253||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|901|52|62
SE|25462253||ti|1|entity|C0679622|novel|inpr|||novel|||0|861|66|71
SE|25462253||ti|1|entity|C0057268|dehydroabietic acid|orch|||dehydroabietic acid|||0|861|72|91
SE|25462253||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|861|92|103
SE|25462253||ti|1|entity|C0012512|Dipeptides|aapp|||dipeptide|||0|694|117|126
SE|25462253||ti|1|entity|C0237399|Potential|qlco|||potential|||0|785|137|146
SE|25462253||ti|1|entity|C0450442|Agent|chvf|||agents|||0|785|158|164

SE|25462253||ab|1|text|172|303|A series of novel dehydroabietic acid (DHA) chiral dipeptide derivatives were designed and synthesized as potent antitumor agents.
SE|25462253||ab|1|entity|C0679622|novel|inpr|||novel|||0|769|184|189
SE|25462253||ab|1|entity|C0057268|dehydroabietic acid|orch|||dehydroabietic acid|||0|769|190|209
SE|25462253||ab|1|entity|C0012512|Dipeptides|aapp|||dipeptide|||0|769|223|232
SE|25462253||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|769|233|244
SE|25462253||ab|1|entity|C0237399|Potential|qlco|||potent|||0|856|278|284
SE|25462253||ab|1|entity|C1328831|antitumor agent|phsu|||antitumor agents|||0|856|285|301
SE|25462253||ab|1|relation|2|1|C0012512|Dipeptides|aapp,gngm|aapp|||dipeptide|||0|769|223|232|VERB|INTERACTS_WITH||263|274|1|1|C1328831|antitumor agent|phsu|phsu|||antitumor agents|||0|856|285|301

SE|25462253||ab|2|text|303|484|The inhibitory activities of these compounds against NCI-H460 (lung), HeLa (epithelial cervical) and MGC-803 (gastric) human cancer cell lines were estimated by MTT assay in vitro.
SE|25462253||ab|2|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|307|317
SE|25462253||ab|2|entity|C0441655|Activities|acty|||activities|||0|853|318|328
SE|25462253||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|338|347
SE|25462253||ab|2|entity|C0024109|Lung|bpoc|||lung|||0|1000|366|370
SE|25462253||ab|2|entity|C0221908|Epithelial|ftcn|||epithelial|||0|888|379|389
SE|25462253||ab|2|entity|C0205064|Cervical|spco|||cervical|||0|888|390|398
SE|25462253||ab|2|entity|C0038351|Stomach|bpoc|||gastric|||0|1000|413|420
SE|25462253||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|908|428|434
SE|25462253||ab|2|entity|C0682523|Human Cell Line|cell|||human cancer cell lines|||0|908|422|445
SE|25462253||ab|2|entity|C0647210|monooxyethylene trimethylolpropane tristearate|lipd|||MTT|||0|966|464|467
SE|25462253||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|474|482

SE|25462253||ab|3|text|484|778|The antitumor activities screening indicated that many compounds showed moderate to high levels of antitumor activities against these three cancer cell lines and most of these compounds displayed more potent inhibitory activities compared with commercial anticancer drug 5-fluorouracil (5-FU).
SE|25462253||ab|3|entity|C0441655|Activities|acty|||activities|||0|861|498|508
SE|25462253||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|539|548
SE|25462253||ab|3|entity|C0205250|High|qlco|||high|||0|888|568|572
SE|25462253||ab|3|entity|C0441889|Levels|inpr|||levels|||0|888|573|579
SE|25462253||ab|3|entity|C0441655|Activities|acty|||activities|||0|861|593|603
SE|25462253||ab|3|entity|C0205449|Three|qnco|||three|||0|861|618|623
SE|25462253||ab|3|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|861|624|630
SE|25462253||ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|861|631|641
SE|25462253||ab|3|entity|C0205393|Most|qnco|||most|||0|1000|646|650
SE|25462253||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|660|669
SE|25462253||ab|3|entity|C0205172|More|ftcn|||more|||0|790|680|684
SE|25462253||ab|3|entity|C0237399|Potential|qlco|||potent|||0|790|685|691
SE|25462253||ab|3|entity|C0243077|inhibitors|chvf|||inhibitory|||0|790|692|702
SE|25462253||ab|3|entity|C0441655|Activities|acty|||activities|||0|790|703|713
SE|25462253||ab|3|entity|C0680536|commercial|inpr|||commercial|||0|754|728|738
SE|25462253||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|754|750|754
SE|25462253||ab|3|entity|C0016360|Fluorouracil|nnon,phsu|||fluorouracil|||0|754|757|769
SE|25462253||ab|3|entity|C0016360|Fluorouracil|nnon,phsu|||5-FU|||0|1000|771|775
SE|25462253||ab|3|relation|8|1|C0243077|inhibitors|chvf|chvf|||inhibitory|||0|790|692|702|VERB|compared_with||714|722|2|1|C0016360|Fluorouracil|nnon,phsu|nnon|||fluorouracil|||0|754|757|769

SE|25462253||ab|4|text|778|1166|The induction of apoptosis and affects on the cell cycle distribution with compound 8k were investigated by acridine orange/ethidium bromide staining, Hoechst 33258 staining, JC-1 mitochondrial membrane potential staining, TUNEL assay, flow cytometry and the activities of caspase-3 and -9 assay in Hela cells, which exhibited that the compound could induce cell apoptosis in Hela cells.
SE|25462253||ab|4|entity|C0857127|Induction|topp|||induction|||0|1000|782|791
SE|25462253||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|795|804
SE|25462253||ab|4|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|901|824|834
SE|25462253||ab|4|entity|C0520511|Distributing|idcn|||distribution|||0|901|835|847
SE|25462253||ab|4|entity|C0205198|Compound|qlco|||compound|||0|694|853|861
SE|25462253||ab|4|entity|C0001185|Acridine Orange|irda,orch|||acridine orange|||0|660|886|901
SE|25462253||ab|4|entity|C0019873|Ethidium Bromide|orch,phsu|||ethidium bromide|||0|660|902|918
SE|25462253||ab|4|entity|C0878435|Hoechst 33258|irda,orch,phsu|||Hoechst 33258|||0|734|929|942
SE|25462253||ab|4|entity|C0097797|5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine|orch,phsu|||JC-1|||0|638|953|957
SE|25462253||ab|4|entity|C0596952|Mitochondrial Membranes|celc|||mitochondrial membrane|||0|638|958|980
SE|25462253||ab|4|entity|C0237399|Potential|qlco|||potential|||0|638|981|990
SE|25462253||ab|4|entity|C1515232|TdT-Mediated dUTP Nick End Labeling Assay|mbrt|||TUNEL assay|||0|1000|1001|1012
SE|25462253||ab|4|entity|C0016263|Flow Cytometry|lbpr|||flow cytometry|||0|1000|1014|1028
SE|25462253||ab|4|entity|C0441655|Activities|acty|||activities|||0|1000|1037|1047
SE|25462253||ab|4|entity|C0291573|caspase-3|aapp,enzy|||caspase-3|||0|1000|1051|1060
SE|25462253||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|861|1068|1073
SE|25462253||ab|4|entity|C0018873|Hela Cells|cell|||Hela cells|||0|1000|1077|1087
SE|25462253||ab|4|entity|C0205198|Compound|qlco|||compound|||0|1000|1114|1122
SE|25462253||ab|4|entity|C0007634|Cells|cell|||cell|||0|888|1136|1140
SE|25462253||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|1141|1150
SE|25462253||ab|4|entity|C0018873|Hela Cells|cell|||Hela cells|||0|1000|1154|1164
SE|25462253||ab|4|relation|0|0|C0007634|Cells|cell|cell|||cell|||0|888|1136|1140|MOD/HEAD|LOCATION_OF||1136|1150|0|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|888|1141|1150
SE|25462253||ab|4|relation|1|1|C0018873|Hela Cells|cell|cell|||Hela cells|||0|1000|1154|1164|PREP|LOCATION_OF||1151|1153|14|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|888|1141|1150
SE|25462253||ab|4|relation|4|1|C0018873|Hela Cells|cell|cell|||Hela cells|||0|1000|1077|1087|PREP|LOCATION_OF||1074|1076|11|1|C0291573|caspase-3|aapp,gngm,enzy|aapp|||caspase-3|||0|1000|1051|1060

SE|25462253||ab|5|text|1166|1464|In addition, further investigation showed that apoptosis were associated with loss of mitochondrial membrane potential, enhancement of mitochondrial cytochrome c release and intracellular ROS production, elevation of Bax expression, down-regulation of Bcl-2, and the activation of caspase-9 and -3.
SE|25462253||ab|5|entity|C1517331|Further|spco|||further|||0|888|1179|1186
SE|25462253||ab|5|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1213|1222
SE|25462253||ab|5|entity|C1517945|Loss|qnco|||loss|||0|1000|1244|1248
SE|25462253||ab|5|entity|C0596952|Mitochondrial Membranes|celc|||mitochondrial membrane|||0|901|1252|1274
SE|25462253||ab|5|entity|C0237399|Potential|qlco|||potential|||0|901|1275|1284
SE|25462253||ab|5|entity|C0521451|Mitochondrial|ftcn|||mitochondrial|||0|861|1301|1314
SE|25462253||ab|5|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome c|||0|861|1315|1327
SE|25462253||ab|5|entity|C0175996|Protoplasm|celc|||intracellular|||0|802|1340|1353
SE|25462253||ab|5|entity|||gngm|6098|ROS1|ROS|||0|802|1354|1357
SE|25462253||ab|5|entity|C0033268|production|ocac|||production|||0|802|1358|1368
SE|25462253||ab|5|entity|C0439775|Elevation procedure|topp|||elevation|||0|1000|1370|1379
SE|25462253||ab|5|entity|C0812198|BAX gene|gngm|581|BAX|Bax|||0|888|1383|1386
SE|25462253||ab|5|entity|C0013081|Down-Regulation|celf|||down-regulation|||0|1000|1399|1414
SE|25462253||ab|5|entity|C1153488|apoptogenic cytochrome c release channel activity|moft|||Bcl-2|||0|1000|1418|1423
SE|25462253||ab|5|entity|C0910167|caspase-9|aapp,enzy|||caspase-9|||0|1000|1447|1456
SE|25462253||ab|5|relation|0|0|||gngm,aapp|gngm|6098|ROS1|ROS|||0|802|1354|1357|MOD/HEAD|PART_OF||1340|1357|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|802|1340|1353
SE|25462253||ab|5|relation|10|1|C0812198|BAX gene|gngm,aapp|gngm|581|BAX|Bax|||0|888|1383|1386|NOM|DISRUPTS||1399|1414|1|1|C1153488|apoptogenic cytochrome c release channel activity|moft|moft|||Bcl-2|||0|1000|1418|1423
SE|25462253||ab|5|relation|11|4|||gngm,aapp|gngm|6098|ROS1|ROS|||0|802|1354|1357|NOM|STIMULATES||1433|1443|0|1|C0910167|caspase-9|aapp,gngm,enzy|gngm|||caspase-9|||0|1000|1447|1456


SE|25462254||ti|1|text|21|173|A small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activity.
SE|25462254||ti|1|entity|C1328819|small molecule|orch|||small-molecule|||0|833|23|37
SE|25462254||ti|1|entity|C0007634|Cells|cell|||cell|||0|833|38|42
SE|25462254||ti|1|entity|C0430054|Toxicology screen, general|lbpr|||screen|||0|833|49|55
SE|25462254||ti|1|entity|C0237399|Potential|qlco|||potent|||0|761|119|125
SE|25462254||ti|1|entity|C0332464|Widening|spco|||broad|||0|786|130|135

SE|25462254||ab|1|text|179|331|An in vitro screening of the anti-apicomplexan activity of 51 compounds, stemming from our chemical library and from chemical synthesis, was performed.
SE|25462254||ab|1|entity|C1533691|in vitro|qlco|||in vitro|||0|901|182|190
SE|25462254||ab|1|entity|C0220908|Screening procedure|hlca|||screening|||0|901|191|200
SE|25462254||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|827|241|250
SE|25462254||ab|1|entity|C0598139|chemical library|inpr|||chemical library|||0|1000|270|286
SE|25462254||ab|1|entity|C0007987|chemical synthesis|npop|||chemical synthesis|||0|1000|296|314

SE|25462254||ab|2|text|331|501|As a study model, we used Toxoplasma gondii (T. gondii), expressing beta-galactosidase for the colorimetric assessment of drug activity on parasites cultivated in vitro.
SE|25462254||ab|2|entity|C0026336|Study models|inpr,resd|||study model|||0|983|336|347
SE|25462254||ab|2|entity|C0040557|Toxoplasma gondii|invt|||Toxoplasma gondii|||0|1000|357|374
SE|25462254||ab|2|entity|C0005220|beta-Galactosidase|aapp,enzy,phsu|||beta-galactosidase|||0|1000|399|417
SE|25462254||ab|2|entity|C0009407|Colorimetry|lbpr|||colorimetric|||0|853|426|438
SE|25462254||ab|2|entity|C0220825|Evaluation|ftcn|||assessment|||0|853|439|449
SE|25462254||ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|888|453|457
SE|25462254||ab|2|entity|C0030498|Parasites|invt|||parasites|||0|1000|470|479
SE|25462254||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|491|499

SE|25462254||ab|3|text|501|648|This approach allowed the validation of a new series of molecules with a biphenylimidazoazine scaffold as inhibitors of T. gondii growth in vitro.
SE|25462254||ab|3|entity|C0449445|Approach|spco|||approach|||0|1000|506|514
SE|25462254||ab|3|entity|C1519941|Validation|resa|||validation|||0|1000|527|537
SE|25462254||ab|3|entity|C0205314|New|tmco|||new|||0|888|543|546
SE|25462254||ab|3|entity|C0205549|Series|qnco|||series|||0|888|547|553
SE|25462254||ab|3|entity|C0567416|Molecule|sbst|||molecules|||0|966|557|566
SE|25462254||ab|3|entity|C0337143|Scaffold|mnob|||scaffold|||0|861|595|603
SE|25462254||ab|3|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|607|617
SE|25462254||ab|3|entity|C0040557|Toxoplasma gondii|invt|||T. gondii|||0|901|621|630
SE|25462254||ab|3|entity|C0018270|Growth|orgf|||growth|||0|901|631|637
SE|25462254||ab|3|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|638|646

SE|25462254||ab|4|text|648|828|Hence, 8 molecules significantly inhibited intracellular replication of T. gondii in vitro, with EC50 < 1 MUM, while being non-toxic for human fibroblasts at these concentrations.
SE|25462254||ab|4|entity|C0567416|Molecule|sbst|||molecules|||0|827|657|666
SE|25462254||ab|4|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|691|704
SE|25462254||ab|4|entity|C0040557|Toxoplasma gondii|invt|||T. gondii|||0|1000|720|729
SE|25462254||ab|4|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|730|738
SE|25462254||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|754|757
SE|25462254||ab|4|entity|C1407029|Toxic|qlco|||toxic|||0|861|775|780
SE|25462254||ab|4|entity|C0020114|Human|humn|||human|||0|888|785|790
SE|25462254||ab|4|entity|C0016030|Fibroblasts|cell|||fibroblasts|||0|888|791|802
SE|25462254||ab|4|relation|0|0|C0016030|Fibroblasts|cell|cell|||fibroblasts|||0|888|791|802|MOD/HEAD|PART_OF||785|802|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|785|790

SE|25462254||ab|5|text|828|1027|Most attractive candidates were then selected for further biological investigations on other apicomplexan parasites (Neospora caninum, Besnoitia besnoiti, Eimeria tenella and Plasmodium falciparum).
SE|25462254||ab|5|entity|C0205393|Most|qnco|||Most|||0|660|828|832
SE|25462254||ab|5|entity|C1517331|Further|spco|||further|||0|851|878|885
SE|25462254||ab|5|entity|C0205460|biological|ftcn|||biological|||0|851|886|896
SE|25462254||ab|5|entity|C0030498|Parasites|invt|||parasites|||0|861|934|943
SE|25462254||ab|5|entity|C0242906|Neospora caninum|invt|||Neospora caninum|||0|1000|945|961
SE|25462254||ab|5|entity|C0320701|Besnoitia besnoiti|invt|||Besnoitia besnoiti|||0|1000|963|981
SE|25462254||ab|5|entity|C0085320|Eimeria tenella|invt|||Eimeria tenella|||0|1000|983|998
SE|25462254||ab|5|entity|C0032150|Plasmodium falciparum|invt|||Plasmodium falciparum|||0|1000|1003|1024

SE|25462254||ab|6|text|1027|1180|Finally, two compounds were able to inhibit growth of four different apicomplexans with EC50 in the submicromolar to nanomolar range, for each parasite.
SE|25462254||ab|6|entity|C0205448|Two|qnco|||two|||0|872|1036|1039
SE|25462254||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|872|1040|1049
SE|25462254||ab|6|entity|C0018270|Growth|orgf|||growth|||0|1000|1071|1077
SE|25462254||ab|6|entity|C0205450|Four|qnco|||four|||0|587|1081|1085
SE|25462254||ab|6|entity|C1547020|*Difference|qnco|||different|||0|587|1086|1095
SE|25462254||ab|6|entity|C0439282|Nanomole/liter|qnco|||nanomolar|||0|888|1144|1153
SE|25462254||ab|6|entity|C1514721|Range|qnco|||range|||0|888|1154|1159
SE|25462254||ab|6|entity|C0030498|Parasites|invt|||parasite|||0|1000|1170|1178

SE|25462254||ab|7|text|1180|1373|These data, including the broad anti-parasite spectrum of these inhibitors, define a new generation of potential anti-parasite compounds of wide interest, including for veterinary application.
SE|25462254||ab|7|entity|C1511726|Data|idcn|||data|||0|1000|1186|1190
SE|25462254||ab|7|entity|C0332464|Widening|spco|||broad|||0|597|1206|1211
SE|25462254||ab|7|entity|C0030498|Parasites|invt|||parasite|||0|597|1217|1225
SE|25462254||ab|7|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|1244|1254
SE|25462254||ab|7|entity|C0205314|New|tmco|||new|||0|872|1265|1268
SE|25462254||ab|7|entity|C0079411|Generations|tmco|||generation|||0|872|1269|1279
SE|25462254||ab|7|entity|C0237399|Potential|qlco|||potential|||0|764|1283|1292
SE|25462254||ab|7|entity|C0030498|Parasites|invt|||parasite|||0|764|1298|1306
SE|25462254||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|764|1307|1316
SE|25462254||ab|7|entity|C0332464|Widening|spco|||wide|||0|888|1320|1324
SE|25462254||ab|7|entity|C0543488|Interested|menp|||interest|||0|888|1325|1333

SE|25462254||ab|8|text|1373|1497|Studies realized on E. tenella suggest that these molecules act during the intracellular development steps of the parasite.
SE|25462254||ab|8|entity|C0008972|Clinical Research|resa|||Studies|||0|966|1373|1380
SE|25462254||ab|8|entity|C0567416|Molecule|sbst|||molecules|||0|966|1423|1432
SE|25462254||ab|8|entity|C0175996|Protoplasm|celc|||intracellular|||0|840|1448|1461
SE|25462254||ab|8|entity|C1527148|Development|ftcn|||development|||0|840|1462|1473
SE|25462254||ab|8|entity|C1261552|Step|ftcn|||steps|||0|840|1474|1479
SE|25462254||ab|8|entity|C0030498|Parasites|invt|||parasite|||0|1000|1487|1495

SE|25462254||ab|9|text|1497|1587|Further experiments should be done to identify the molecular target(s) of these compounds.
SE|25462254||ab|9|entity|C1517331|Further|spco|||Further|||0|888|1497|1504
SE|25462254||ab|9|entity|C0681814|research study|resa|||experiments|||0|888|1505|1516
SE|25462254||ab|9|entity|C1513403|Molecular Target|chvf,chvs|||molecular target|||0|1000|1548|1564
SE|25462254||ab|9|entity|C0205198|Compound|qlco|||compounds|||0|966|1577|1586


SE|25462255||ti|1|text|21|134|Anthraquinone-chalcone hybrids: synthesis, preliminary antiproliferative evaluation and DNA-interaction studies.
SE|25462255||ti|1|entity|C0003174|Anthraquinones|orch|||Anthraquinone|||0|851|21|34
SE|25462255||ti|1|entity|C0007935|Chalcone|orch|||chalcone|||0|851|35|43
SE|25462255||ti|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|851|44|51
SE|25462255||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|53|62
SE|25462255||ti|1|entity|C0439611|Preliminary|tmco|||preliminary|||0|802|64|75
SE|25462255||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|802|94|104
SE|25462255||ti|1|entity|C0012854|DNA|bacs,nnon|||DNA|||0|840|109|112
SE|25462255||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|840|125|132

SE|25462255||ab|1|text|140|352|Novel anthraquinone based chalcone compounds were synthesized starting from 1-acetylanthraquinone in a Claisen-Schmidt reaction and evaluated for their anticancer potential against three human cancer cell lines.
SE|25462255||ab|1|entity|C0679622|novel|inpr|||Novel|||0|888|140|145
SE|25462255||ab|1|entity|C0003174|Anthraquinones|orch|||anthraquinone|||0|888|146|159
SE|25462255||ab|1|entity|C0007935|Chalcone|orch|||chalcone|||0|872|166|174
SE|25462255||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|872|175|184
SE|25462255||ab|1|entity|C0085860|Autoimmune Syndrome Type II, Polyglandular|dsyn|||Schmidt|||0|790|251|258
SE|25462255||ab|1|entity|C0443286|Reaction|ftcn|||reaction|||0|790|259|267
SE|25462255||ab|1|entity|C0237399|Potential|qlco|||potential|||0|861|303|312
SE|25462255||ab|1|entity|C0205449|Three|qnco|||three|||0|868|321|326
SE|25462255||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|868|333|339
SE|25462255||ab|1|entity|C0682523|Human Cell Line|cell|||human cancer cell lines|||0|868|327|350

SE|25462255||ab|2|text|352|532|Compounds 4a, 4b and 4j showed promising activity in inhibition of HeLa cells with IC50 values ranging from 2.36 to 2.73 MUM and low cytotoxicity against healthy MRC-5 cell lines.
SE|25462255||ab|2|entity|C0205198|Compound|qlco|||Compounds|||0|872|352|361
SE|25462255||ab|2|entity|C1555307|promise|idcn|||promising|||0|872|383|392
SE|25462255||ab|2|entity|C0018873|Hela Cells|cell|||HeLa cells|||0|1000|419|429
SE|25462255||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|435|439
SE|25462255||ab|2|entity|C0042295|Values|qlco|||values|||0|888|440|446
SE|25462255||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|473|476
SE|25462255||ab|2|entity|C0205251|low|qlco|||low|||0|888|481|484
SE|25462255||ab|2|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|485|497
SE|25462255||ab|2|entity|C0018684|Health|idcn|||healthy|||0|776|506|513
SE|25462255||ab|2|entity|C0007600|Cell Line|cell|||cell lines|||0|776|520|530

SE|25462255||ab|3|text|532|623|The effects that compounds produces on the cell cycle were investigated by flow cytometry.
SE|25462255||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|536|543
SE|25462255||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|549|558
SE|25462255||ab|3|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|1000|575|585
SE|25462255||ab|3|entity|C0016263|Flow Cytometry|lbpr|||flow cytometry|||0|1000|607|621

SE|25462255||ab|4|text|623|779|It was found that 4a, 4b and 4j cause the accumulation of cells in the S and G2/M phases in a dose-dependent manner and induce caspase-dependent apoptosis.
SE|25462255||ab|4|entity|C0007634|Cells|cell|||cells|||0|1000|681|686
SE|25462255||ab|4|entity|C0079396|G2 Phase|celf|||G2/M phases|||0|901|700|711
SE|25462255||ab|4|entity|C1512045|Dose-dependent|qnco|||dose-dependent|||0|734|717|731
SE|25462255||ab|4|entity|C0010656|caspase|aapp,enzy|||caspase|||0|851|750|757
SE|25462255||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|851|768|777
SE|25462255||ab|4|relation|8|0|C0010656|caspase|aapp,gngm,enzy|aapp|||caspase|||0|851|750|757|ADJ|AUGMENTS||758|767|8|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|851|768|777
SE|25462255||ab|4|relation|8|2|C0079396|G2 Phase|celf|celf|||G2/M phases|||0|901|700|711|VERB|CAUSES||743|749|1|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|851|768|777

SE|25462255||ab|5|text|779|844|All of three compounds exhibit calf thymus DNA-binding activity.
SE|25462255||ab|5|entity|C0205449|Three|qnco|||three|||0|872|786|791
SE|25462255||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|872|792|801
SE|25462255||ab|5|entity|C0966503|calf thymus DNA|nnon,phsu|||calf thymus DNA|||0|850|810|825

SE|25462255||ab|6|text|844|1166|The determined binding constants by absorption titrations (2.65 * 10(3) M(-1), 1.36 * 10(3) M(-1)and 2.51 * 10(3) M(-1) of 4a/CT-DNA, 4b/CT-DNA and 4j/CT-DNA, respectively) together with fluorescence displacement analysis designate 4a, 4b and 4j as strong minor groove binders, but no cleavage of plasmid DNA was observed.
SE|25462255||ab|6|entity|C0680730|Adjudication|gora|||determined|||0|750|848|858
SE|25462255||ab|6|entity|C1547014|*Constant|qnco|||constants|||0|750|867|876
SE|25462255||ab|6|entity|C0162621|Titration|lbpr|||titrations|||0|861|891|901
SE|25462255||ab|6|entity|C0442767|1/36|fndg|||1.36|||0|1000|923|927
SE|25462255||ab|6|entity|C0012854|DNA|bacs,nnon|||CT-DNA|||0|802|970|976
SE|25462255||ab|6|entity|C0012854|DNA|bacs,nnon|||CT-DNA|||0|802|981|987
SE|25462255||ab|6|entity|C0012854|DNA|bacs,nnon|||CT-DNA|||0|827|995|1001
SE|25462255||ab|6|entity|C0016315|Fluorescence|npop|||fluorescence|||0|754|1031|1043
SE|25462255||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|754|1057|1065
SE|25462255||ab|6|entity|C0442821|Strong|qlco|||strong|||0|861|1093|1099
SE|25462255||ab|6|entity|C1513315|Minor Groove|bacs,nnon|||minor groove|||0|861|1100|1112
SE|25462255||ab|6|entity|C0179302|Binder|medd|||binders|||0|861|1113|1120
SE|25462255||ab|6|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|1000|1129|1137
SE|25462255||ab|6|entity|C0032136|Plasmids|bacs,nnon|||plasmid|||0|888|1141|1148
SE|25462255||ab|6|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|1149|1152
SE|25462255||ab|6|relation|0|0|C0032136|Plasmids|bacs,nnon|bacs|||plasmid|||0|888|1141|1148|MOD/HEAD|ISA||1141|1152|0|0|C0012854|DNA|bacs,nnon|bacs|||DNA|||0|888|1149|1152


SE|25462256||ti|1|text|21|134|6-Substituted 9-fluoroquino[3,2-b]benzo[1,4]thiazines display strong antiproliferative and antitumor properties.
SE|25462256||ti|1|entity|C0039858|Thiazines|orch|||thiazines|||0|1000|65|74
SE|25462256||ti|1|entity|C0442821|Strong|qlco|||strong|||0|694|83|89
SE|25462256||ti|1|entity|C0871161|Property|qlco|||properties|||0|827|122|132

SE|25462256||ab|1|text|140|454|6-Substituted 9-fluoroquino[3,2-b]benzo[1,4]thiazines - a new type of tetracyclic azaphenothiazines-were obtained from of 6H-9-fluoroquinobenzothiazine by the introduction of appropriate substituents to the thiazine nitrogen atom (alkyl, aminoalkyl, amidoalkyl, sulfonamidoalkyl and nitrogen half-mustard groups).
SE|25462256||ab|1|entity|C0039858|Thiazines|orch|||thiazines|||0|1000|184|193
SE|25462256||ab|1|entity|C1554124|New type|idcn|||new type|||0|1000|198|206
SE|25462256||ab|1|entity|C1292428|6 Hours|tmco|||6H-9|||0|660|262|266
SE|25462256||ab|1|entity|C1293116|Introduction procedure|hlca|||introduction|||0|1000|299|311
SE|25462256||ab|1|entity|C1548787|Appropriate|qlco|||appropriate|||0|694|315|326
SE|25462256||ab|1|entity|C0039858|Thiazines|orch|||thiazine|||0|851|347|355
SE|25462256||ab|1|entity|C0028158|Nitrogen|elii|||nitrogen|||0|851|356|364
SE|25462256||ab|1|entity|C0567415|Atom|elii|||atom|||0|851|365|369
SE|25462256||ab|1|entity|C1177206|ALKYL|phsu|||alkyl|||0|1000|371|376
SE|25462256||ab|1|entity|C0025033|Mechlorethamine|hops,orch,phsu|||nitrogen half-mustard|||0|824|423|444
SE|25462256||ab|1|entity|C0441833|Groups|inpr|||groups|||0|824|445|451

SE|25462256||ab|2|text|454|638|The compounds displayed differential cytotoxic as well as antiproliferative actions against human peripheral blood mononuclear cells (PBMC) stimulated with phytohemagglutinin A (PHA).
SE|25462256||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|458|467
SE|25462256||ab|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|861|491|500
SE|25462256||ab|2|entity|C0020114|Human|humn|||human|||0|920|546|551
SE|25462256||ab|2|entity|C1321301|Peripheral blood mononuclear cell|cell|||peripheral blood mononuclear cells|||0|920|552|586
SE|25462256||ab|2|entity|C0031858|Phytohemagglutinins|aapp,imft,irda|||phytohemagglutinin|||0|827|610|628
SE|25462256||ab|2|relation|0|0|C1321301|Peripheral blood mononuclear cell|cell|cell|||peripheral blood mononuclear cells|||0|920|552|586|MOD/HEAD|PART_OF||546|586|0|0|C0020114|Human|grup,humn|humn|||human|||0|920|546|551

SE|25462256||ab|3|text|638|787|In addition, they suppressed lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF-alpha) production by whole blood human cell cultures.
SE|25462256||ab|3|entity|C0023810|Lipopolysaccharides|lipd|||lipopolysaccharide|||0|863|667|685
SE|25462256||ab|3|entity|C0205263|Induced|ftcn|||induced|||0|863|692|699
SE|25462256||ab|3|entity|C1448177|TNF protein, human|aapp,bacs|7124|TNF|tumor necrosis factor alpha|||0|863|700|727
SE|25462256||ab|3|entity|C0033268|production|ocac|||production|||0|863|740|750
SE|25462256||ab|3|entity|C0370231|whole blood|bdsu|||whole blood|||0|857|754|765
SE|25462256||ab|3|entity|C0020114|Human|humn|||human|||0|857|766|771
SE|25462256||ab|3|entity|C0007585|Cell Culture Techniques|lbpr|||cell cultures|||0|857|772|785
SE|25462256||ab|3|relation|1|0|C0023810|Lipopolysaccharides|lipd|lipd|||lipopolysaccharide|||0|863|667|685|ADJ|STIMULATES||692|699|1|0|C1448177|TNF protein, human|aapp,gngm,bacs|gngm|7124|TNF|tumor necrosis factor alpha|||0|863|700|727

SE|25462256||ab|4|text|787|976|Two compounds (4 and 15, with the propargyl and methanesulfonamidopropyl groups) were selected for further experiments because of lack of cytotoxicity and strong antiproliferative actions.
SE|25462256||ab|4|entity|C0205448|Two|qnco|||Two|||0|872|787|790
SE|25462256||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|872|791|800
SE|25462256||ab|4|entity|C0441833|Groups|inpr|||groups|||0|861|860|866
SE|25462256||ab|4|entity|C1517331|Further|spco|||further|||0|888|886|893
SE|25462256||ab|4|entity|C0681814|research study|resa|||experiments|||0|888|894|905
SE|25462256||ab|4|entity|C0332268|Lacking|qlco|||lack|||0|1000|917|921
SE|25462256||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|925|937
SE|25462256||ab|4|entity|C0442821|Strong|qlco|||strong|||0|660|942|948

SE|25462256||ab|5|text|976|1199|Compound 4 showed strong suppressive actions on growth of L1210, SW948, A-431 and CX-1 tumor cell lines which were close to those of cisplatin, the reference drug (e.g. GI50 of 2.28 MUg/mL vs. 1.86 MUg/mL for L1210 cells).
SE|25462256||ab|5|entity|C0205198|Compound|qlco|||Compound|||0|861|976|984
SE|25462256||ab|5|entity|C0442821|Strong|qlco|||strong|||0|623|994|1000
SE|25462256||ab|5|entity|C0205367|Suppressive|ftcn|||suppressive|||0|623|1001|1012
SE|25462256||ab|5|entity|C0018270|Growth|orgf|||growth|||0|1000|1024|1030
SE|25462256||ab|5|entity|C0731029|CX 1|clnd|||CX-1|||0|893|1058|1062
SE|25462256||ab|5|entity|C0085983|Cell Line, Tumor|cell|||tumor cell lines|||0|893|1063|1079
SE|25462256||ab|5|entity|C0008838|Cisplatin|inch,phsu|||cisplatin|||0|1000|1109|1118
SE|25462256||ab|5|entity|C1514811|Reference|idcn|||reference|||0|888|1124|1133
SE|25462256||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|888|1134|1138
SE|25462256||ab|5|entity|C0007634|Cells|cell|||cells|||0|861|1191|1196

SE|25462256||ab|6|text|1199|1346|Further, the compound appeared to be equally effective as cyclosporine A (CsA) in the inhibition of human two-way mixed lymphocyte reaction (MLR).
SE|25462256||ab|6|entity|C1517331|Further|spco|||Further|||0|1000|1199|1206
SE|25462256||ab|6|entity|C0205198|Compound|qlco|||compound|||0|1000|1212|1220
SE|25462256||ab|6|entity|C0010592|Cyclosporine|aapp,phsu|||cyclosporine A|||0|1000|1257|1271
SE|25462256||ab|6|entity|||gngm|1161,1442,3313|ERCC8,CSH1,HSPA9|CsA|||0|1000|1273|1276
SE|25462256||ab|6|entity|C0020114|Human|humn|||human|||0|804|1299|1304
SE|25462256||ab|6|entity|C0205448|Two|qnco|||two|||0|804|1305|1308
SE|25462256||ab|6|entity|C0023509|Lymphocyte Culture Test, Mixed|lbpr|||mixed lymphocyte reaction|||0|804|1313|1338

SE|25462256||ab|7|text|1346|1446|The compound did not significantly inhibit interleukin 2 (IL-2)-induced growth of CTLL-2 cell line.
SE|25462256||ab|7|entity|C0205198|Compound|qlco|||compound|||0|1000|1350|1358
SE|25462256||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1363|1366
SE|25462256||ab|7|entity|C0021756|Interleukin-2|aapp,imft|3558|IL2|interleukin 2|||0|861|1389|1402
SE|25462256||ab|7|entity|C0205263|Induced|ftcn|||induced|||0|861|1410|1417
SE|25462256||ab|7|entity|C0018270|Growth|orgf|||growth|||0|861|1418|1424
SE|25462256||ab|7|entity|C0007600|Cell Line|cell|||cell line|||0|861|1435|1444
SE|25462256||ab|7|relation|1|0|C0021756|Interleukin-2|aapp,gngm,imft|gngm|3558|IL2|interleukin 2|||0|861|1389|1402|ADJ|CAUSES||1410|1417|1|0|C0018270|Growth|orgf|orgf|||growth|||0|861|1418|1424

SE|25462256||ab|8|text|1446|1639|In addition, inhibition of prostaglandin (PG) synthesis by indomethacin or block of PG receptors did not interfere with the inhibitory effect of the compound on PHA-induced cell proliferation.
SE|25462256||ab|8|entity|C0033554|Prostaglandins|bacs,eico,phsu|||prostaglandin|||0|888|1473|1486
SE|25462256||ab|8|entity|C0869032|Synthesis|phpr|||synthesis|||0|888|1492|1501
SE|25462256||ab|8|entity|C0021246|Indomethacin|orch,phsu|||indomethacin|||0|1000|1505|1517
SE|25462256||ab|8|entity|C0028778|Obstruction|patf|||block|||0|1000|1521|1526
SE|25462256||ab|8|entity|C0034835|Prostaglandin Receptor|aapp,rcpt|||PG receptors|||0|1000|1530|1542
SE|25462256||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1547|1550
SE|25462256||ab|8|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|1570|1580
SE|25462256||ab|8|entity|C1280500|Effect|qlco|||effect|||0|853|1581|1587
SE|25462256||ab|8|entity|C0205198|Compound|qlco|||compound|||0|1000|1595|1603
SE|25462256||ab|8|entity|C0031858|Phytohemagglutinins|aapp,imft,irda|||PHA|||0|762|1607|1610
SE|25462256||ab|8|entity|C0205263|Induced|ftcn|||induced|||0|762|1611|1618
SE|25462256||ab|8|entity|C0596290|Cell Proliferation|celf|||cell proliferation|||0|762|1619|1637
SE|25462256||ab|8|relation|6|1|C0034835|Prostaglandin Receptor|aapp,gngm,rcpt|aapp|||PG receptors|||0|1000|1530|1542|COMPLEX|DISRUPTS|negation|1570|1587|1|2|C0596290|Cell Proliferation|celf|celf|||cell proliferation|||0|762|1619|1637
SE|25462256||ab|8|relation|6|2|C0021246|Indomethacin|orch,phsu|orch|||indomethacin|||0|1000|1505|1517|NOM|INHIBITS||1459|1469|6|1|C0033554|Prostaglandins|bacs,eico,phsu|bacs|||prostaglandin|||0|888|1473|1486

SE|25462256||ab|9|text|1639|1749|Therefore, it is likely that the compound acts by inhibiting cell cycle as proposed for other phenothiazines.
SE|25462256||ab|9|entity|C0205198|Compound|qlco|||compound|||0|872|1672|1680
SE|25462256||ab|9|entity|C0427611|Activated clotting time measurement|lbpr|||acts|||0|872|1681|1685
SE|25462256||ab|9|entity|C0311403|Inhibited|qlco|||inhibiting|||0|884|1689|1699
SE|25462256||ab|9|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|884|1700|1710
SE|25462256||ab|9|entity|C0031436|Phenothiazines|orch,phsu|||phenothiazines|||0|1000|1733|1747

SE|25462256||ab|10|text|1749|1900|Further studies are required for the elucidation of the mechanism of action and therapeutic utility of these compounds in more advanced in vivo models.
SE|25462256||ab|10|entity|C1517331|Further|spco|||Further|||0|872|1749|1756
SE|25462256||ab|10|entity|C0008972|Clinical Research|resa|||studies|||0|872|1757|1764
SE|25462256||ab|10|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|1805|1814
SE|25462256||ab|10|entity|C0205198|Compound|qlco|||compounds|||0|966|1858|1867
SE|25462256||ab|10|entity|C0205172|More|ftcn|||more|||0|1000|1871|1875
SE|25462256||ab|10|entity|C1515657|in vivo Model|resa|||in vivo models|||0|983|1885|1899


SE|25462257||ti|1|text|21|92|A review on recent developments of indole-containing antiviral agents.
SE|25462257||ti|1|entity|C0332185|Recent|tmco|||recent|||0|872|33|39
SE|25462257||ti|1|entity|C1527148|Development|ftcn|||developments|||0|872|40|52
SE|25462257||ti|1|entity|C0021236|indole|orch|||indole|||0|1000|56|62
SE|25462257||ti|1|entity|C0003451|Antiviral Agents|phsu|||antiviral agents|||0|1000|74|90

SE|25462257||ab|1|text|98|182|Indole represents one of the most important privileged scaffolds in drug discovery.
SE|25462257||ab|1|entity|C0021236|indole|orch|||Indole|||0|1000|98|104
SE|25462257||ab|1|entity|C0205447|One|qnco|||one|||0|1000|116|119
SE|25462257||ab|1|entity|C0205393|Most|qnco|||most|||0|775|127|131
SE|25462257||ab|1|entity|C0337143|Scaffold|mnob|||scaffolds|||0|775|153|162
SE|25462257||ab|1|entity|C0920472|Drug Discovery|resa|||drug discovery|||0|1000|166|180

SE|25462257||ab|2|text|182|395|Indole derivatives have the unique property of mimicking the structure of peptides and to bind reversibly to enzymes, which provide tremendous opportunities to discover novel drugs with different modes of action.
SE|25462257||ab|2|entity|C0021236|indole|orch|||Indole|||0|888|182|188
SE|25462257||ab|2|entity|C0243072|derivatives|chvs|||derivatives|||0|888|189|200
SE|25462257||ab|2|entity|C0871161|Property|qlco|||property|||0|861|217|225
SE|25462257||ab|2|entity|C0678594|Structure|spco|||structure|||0|1000|243|252
SE|25462257||ab|2|entity|C0030956|Peptides|aapp|||peptides|||0|1000|256|264
SE|25462257||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|1000|291|298
SE|25462257||ab|2|entity|C0679622|novel|inpr|||novel|||0|888|351|356
SE|25462257||ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|357|362
SE|25462257||ab|2|entity|C1547020|*Difference|qnco|||different|||0|836|368|377
SE|25462257||ab|2|entity|C1513371|Mode|ftcn|||modes|||0|836|378|383
SE|25462257||ab|2|relation|5|1|C0030956|Peptides|aapp,gngm|aapp|||peptides|||0|1000|256|264|VERB|INTERACTS_WITH||272|276|5|1|C0014442|Enzymes|enzy,orch|enzy|||enzymes|||0|1000|291|298

SE|25462257||ab|3|text|395|508|There are seven indole-containing commercial drugs in the Top-200 Best Selling Drugs by US Retail Sales in 2012.
SE|25462257||ab|3|entity|C0205453|Seven|qnco|||seven|||0|888|405|410
SE|25462257||ab|3|entity|C0021236|indole|orch|||indole|||0|888|411|417
SE|25462257||ab|3|entity|C0680536|commercial|inpr|||commercial|||0|888|429|439
SE|25462257||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|440|445
SE|25462257||ab|3|entity|C0687750|Selling drugs|ocac|||Selling Drugs|||0|794|466|479
SE|25462257||ab|3|entity|C0036070|Sales|ocac|||Sales|||0|1000|493|498

SE|25462257||ab|4|text|508|688|There are also an amazing number of approved indole-containing drugs in the market as well as compounds currently going through different clinical phases or registration statuses.
SE|25462257||ab|4|entity|C0237753|Numbers|qnco|||number|||0|861|534|540
SE|25462257||ab|4|entity|C0205540|Approved|qlco|||approved|||0|833|544|552
SE|25462257||ab|4|entity|C0021236|indole|orch|||indole|||0|833|553|559
SE|25462257||ab|4|entity|C0332256|Containing|ftcn|||containing|||0|833|560|570
SE|25462257||ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|833|571|576
SE|25462257||ab|4|entity|C1318228|Market|geoa|||market|||0|1000|584|590
SE|25462257||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|602|611
SE|25462257||ab|4|entity|C0521116|Current|tmco|||currently|||0|1000|612|621
SE|25462257||ab|4|entity|C1547020|*Difference|qnco|||different|||0|828|636|645
SE|25462257||ab|4|entity|C0205210|Clinical|qlco|||clinical|||0|828|646|654
SE|25462257||ab|4|entity|C0205390|Phase|tmco|||phases|||0|828|655|661
SE|25462257||ab|4|entity|C0585727|Registration status|ftcn|||registration statuses|||0|983|665|686

SE|25462257||ab|5|text|688|1252|This review focused on the recent development of indole derivatives as antiviral agents with the following objectives: 1) To present one of the most comprehensive listings of indole antiviral agents, drugs on market or compounds in clinical trials; 2) To focus on recent developments of indole compounds (including natural products) and their antiviral activities, summarize the structure property, hoping to inspire new and even more creative approaches; 3) To offer perspectives on how indole scaffolds as a privileged structure might be exploited in the future.
SE|25462257||ab|5|entity|C0332185|Recent|tmco|||recent|||0|888|715|721
SE|25462257||ab|5|entity|C1527148|Development|ftcn|||development|||0|888|722|733
SE|25462257||ab|5|entity|C0021236|indole|orch|||indole|||0|888|737|743
SE|25462257||ab|5|entity|C0243072|derivatives|chvs|||derivatives|||0|888|744|755
SE|25462257||ab|5|entity|C0003451|Antiviral Agents|phsu|||antiviral agents|||0|1000|759|775
SE|25462257||ab|5|entity|C0332282|Following|tmco|||following|||0|888|785|794
SE|25462257||ab|5|entity|C0018017|objective (goal)|inpr|||objectives|||0|888|795|805
SE|25462257||ab|5|entity|C0205447|One|qnco|||one|||0|1000|821|824
SE|25462257||ab|5|entity|C0205393|Most|qnco|||most|||0|660|832|836
SE|25462257||ab|5|entity|C0021236|indole|orch|||indole|||0|901|863|869
SE|25462257||ab|5|entity|C0003451|Antiviral Agents|phsu|||antiviral agents|||0|901|870|886
SE|25462257||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|888|893
SE|25462257||ab|5|entity|C1318228|Market|geoa|||market|||0|1000|897|903
SE|25462257||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|907|916
SE|25462257||ab|5|entity|C0008976|Clinical Trials|resa|||clinical trials|||0|1000|920|935
SE|25462257||ab|5|entity|C0205234|Focal|spco|||focus|||0|1000|943|948
SE|25462257||ab|5|entity|C0332185|Recent|tmco|||recent|||0|872|952|958
SE|25462257||ab|5|entity|C1527148|Development|ftcn|||developments|||0|872|959|971
SE|25462257||ab|5|entity|C0021236|indole|orch|||indole|||0|872|975|981
SE|25462257||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|872|982|991
SE|25462257||ab|5|entity|C1566558|Natural Products|bacs|||natural products|||0|1000|1003|1019
SE|25462257||ab|5|entity|C0441655|Activities|acty|||activities|||0|861|1041|1051
SE|25462257||ab|5|entity|C0678594|Structure|spco|||structure|||0|888|1067|1076
SE|25462257||ab|5|entity|C0871161|Property|qlco|||property|||0|888|1077|1085
SE|25462257||ab|5|entity|C0392347|hope|menp|||hoping|||0|966|1087|1093
SE|25462257||ab|5|entity|C0205314|New|tmco|||new|||0|1000|1105|1108
SE|25462257||ab|5|entity|C0010297|Creativeness|menp|||creative|||0|714|1123|1131
SE|25462257||ab|5|entity|C0449445|Approach|spco|||approaches|||0|714|1132|1142
SE|25462257||ab|5|entity|C0021236|indole|orch|||indole|||0|773|1176|1182
SE|25462257||ab|5|entity|C0337143|Scaffold|mnob|||scaffolds|||0|773|1183|1192
SE|25462257||ab|5|entity|C0678594|Structure|spco|||structure|||0|861|1209|1218
SE|25462257||ab|5|entity|C0016884|Future|tmco|||future|||0|1000|1245|1251


SE|25462258||ti|1|text|21|126|Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors.
SE|25462258||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462258||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|43|53
SE|25462258||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|54|64
SE|25462258||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|861|82|93
SE|25462258||ti|1|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|Hsp90|||0|825|97|102
SE|25462258||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|825|114|124

SE|25462258||ab|1|text|132|276|Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatment of cancer and neurodegenerative diseases.
SE|25462258||ab|1|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|Hsp90|||0|825|146|151
SE|25462258||ab|1|entity|C0031843|physiological aspects|phsf|||function|||0|825|163|171
SE|25462258||ab|1|entity|C1555307|promise|idcn|||promising|||0|840|185|194
SE|25462258||ab|1|entity|C0449445|Approach|spco|||approach|||0|840|207|215
SE|25462258||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|237|243
SE|25462258||ab|1|entity|C0524851|Neurodegenerative Disorders|dsyn|||neurodegenerative diseases|||0|1000|248|274

SE|25462258||ab|2|text|276|423|Current drug discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor.
SE|25462258||ab|2|entity|C0521116|Current|tmco|||Current|||0|861|276|283
SE|25462258||ab|2|entity|C0920472|Drug Discovery|resa|||drug discovery|||0|861|284|298
SE|25462258||ab|2|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|Hsp90|||0|815|314|319
SE|25462258||ab|2|entity|C0205234|Focal|spco|||focus|||0|815|342|347
SE|25462258||ab|2|entity|C0028458|Novobiocin|antb,carb|||novobiocin|||0|1000|351|361
SE|25462258||ab|2|entity|C0003232|Antibiotics|antb|||antibiotic|||0|1000|366|376
SE|25462258||ab|2|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|Hsp90|||0|872|406|411
SE|25462258||ab|2|entity|C0243077|inhibitors|chvf|||inhibitor|||0|872|412|421
SE|25462258||ab|2|relation|3|2|C0003232|Antibiotics|antb|antb|||antibiotic|||0|1000|366|376|NOM|INHIBITS||331|341|3|1|C0028458|Novobiocin|antb,carb|antb|||novobiocin|||0|1000|351|361

SE|25462258||ab|3|text|423|686|Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors.
SE|25462258||ab|3|entity|C1533716|Information|idcn|||information|||0|861|443|454
SE|25462258||ab|3|entity|C1527148|Development|ftcn|||development|||0|1000|475|486
SE|25462258||ab|3|entity|C0028458|Novobiocin|antb,carb|||novobiocin|||0|888|490|500
SE|25462258||ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|888|501|512
SE|25462258||ab|3|entity|C1521991|Molecular|qlco|||molecular|||0|840|517|526
SE|25462258||ab|3|entity|C1522290|Docking|moft|||docking|||0|840|527|534
SE|25462258||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|840|535|542
SE|25462258||ab|3|entity|C0337143|Scaffold|mnob|||scaffolds|||0|966|544|553
SE|25462258||ab|3|entity|C0058372|diphenyl|hops,orch|||biphenyl|||0|694|567|575
SE|25462258||ab|3|entity|C0010206|coumarin|orch,phsu|||coumarin|||0|802|598|606
SE|25462258||ab|3|entity|C0150312|Present|qnco|||present|||0|802|612|619
SE|25462258||ab|3|entity|C0028458|Novobiocin|antb,carb|||novobiocin|||0|1000|623|633
SE|25462258||ab|3|entity|C0205314|New|tmco|||new|||0|815|653|656
SE|25462258||ab|3|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|Hsp90|||0|815|657|662
SE|25462258||ab|3|entity|C0243077|inhibitors|chvf|||inhibitors|||0|815|674|684

SE|25462258||ab|4|text|686|889|Structure-activity relationship studies produced new derivatives that inhibit the proliferation of breast cancer cell lines at nanomolar concentrations, which corresponded directly with Hsp90 inhibition.
SE|25462258||ab|4|entity|C0038477|Structure-Activity Relationship|qlco|||Structure-activity relationship|||0|1000|686|717
SE|25462258||ab|4|entity|C0205314|New|tmco|||new|||0|790|735|738
SE|25462258||ab|4|entity|C0243072|derivatives|chvs|||derivatives|||0|790|739|750
SE|25462258||ab|4|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|768|781
SE|25462258||ab|4|entity|C1512505|Breast Cancer Cell|cell|||breast cancer cell|||0|923|785|803
SE|25462258||ab|4|entity|C0439282|Nanomole/liter|qnco|||nanomolar|||0|888|813|822
SE|25462258||ab|4|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|Hsp90|||0|888|872|877


SE|25462259||ti|1|text|21|188|Neuroprotective effects of a brain permeant 6-aminoquinoxaline derivative in cell culture conditions that model the loss of dopaminergic neurons in Parkinson disease.
SE|25462259||ti|1|entity|C0815279|neuroprotective effects|ftcn|||Neuroprotective effects|||0|1000|21|44
SE|25462259||ti|1|entity|C0006104|Brain|bpoc|||brain|||0|786|50|55
SE|25462259||ti|1|entity|C1527240|Derivative|ftcn|||derivative|||0|786|84|94
SE|25462259||ti|1|entity|C0007634|Cells|cell|||cell|||0|888|98|102
SE|25462259||ti|1|entity|C0220814|Cultural|ftcn|||culture|||0|888|103|110
SE|25462259||ti|1|entity|C0026336|Study models|inpr,resd|||model|||0|1000|127|132
SE|25462259||ti|1|entity|C1517945|Loss|qnco|||loss|||0|1000|137|141
SE|25462259||ti|1|entity|C0815003|dopaminergic neuron|cell|||dopaminergic neurons|||0|983|145|165
SE|25462259||ti|1|entity|C0030567|Parkinson Disease|dsyn|||Parkinson disease|||0|1000|169|186

SE|25462259||ab|1|text|194|399|Parkinson disease is a neurodegenerative disorder of aging, characterized by disabling motor symptoms resulting from the loss of midbrain dopaminergic neurons and the decrease of dopamine in the striatum.
SE|25462259||ab|1|entity|C0030567|Parkinson Disease|dsyn|||Parkinson disease|||0|1000|194|211
SE|25462259||ab|1|entity|C0524851|Neurodegenerative Disorders|dsyn|||neurodegenerative disorder|||0|1000|217|243
SE|25462259||ab|1|entity|C0001811|Aging|orgf|||aging|||0|1000|247|252
SE|25462259||ab|1|entity|C0426980|Motor symptoms|sosy|||motor symptoms|||0|901|281|295
SE|25462259||ab|1|entity|C1517945|Loss|qnco|||loss|||0|1000|315|319
SE|25462259||ab|1|entity|C1280997|Entire midbrain|bpoc|||midbrain|||0|890|323|331
SE|25462259||ab|1|entity|C0815003|dopaminergic neuron|cell|||dopaminergic neurons|||0|890|332|352
SE|25462259||ab|1|entity|C0547047|Decrease|qnco|||decrease|||0|1000|361|369
SE|25462259||ab|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine|||0|1000|373|381
SE|25462259||ab|1|entity|C0162512|Neostriatum|bpoc|||striatum|||0|1000|389|397
SE|25462259||ab|1|relation|0|0|C0030567|Parkinson Disease|dsyn|dsyn|||Parkinson disease|||0|1000|194|211|SPEC|ISA||194|243|0|0|C0524851|Neurodegenerative Disorders|dsyn|dsyn|||neurodegenerative disorder|||0|1000|217|243
SE|25462259||ab|1|relation|0|0|C0426980|Motor symptoms|sosy|sosy|||motor symptoms|||0|901|281|295|INFER|ASSOCIATED_WITH(SPEC)||194|243|0|0|C0030567|Parkinson Disease|dsyn|dsyn|||Parkinson disease|||0|1000|194|211
SE|25462259||ab|1|relation|0|0|C0815003|dopaminergic neuron|cell|cell|||dopaminergic neurons|||0|890|332|352|MOD/HEAD|PART_OF||323|352|0|0|C1280997|Entire midbrain|bpoc|bpoc|||midbrain|||0|890|323|331
SE|25462259||ab|1|relation|1|1|C0162512|Neostriatum|bpoc|bpoc|||striatum|||0|1000|389|397|PREP|LOCATION_OF||382|384|8|1|C0013030|Dopamine|nsba,orch,phsu|orch|||dopamine|||0|1000|373|381
SE|25462259||ab|1|relation|6|1|C0426980|Motor symptoms|sosy|sosy|||motor symptoms|||0|901|281|295|VERB|ASSOCIATED_WITH||254|267|3|2|C0524851|Neurodegenerative Disorders|dsyn|dsyn|||neurodegenerative disorder|||0|1000|217|243

SE|25462259||ab|2|text|399|503|Current therapies are directed at treating the symptoms but there is presently no cure for the disease.
SE|25462259||ab|2|entity|C0521116|Current|tmco|||Current|||0|888|399|406
SE|25462259||ab|2|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|888|407|416
SE|25462259||ab|2|entity|C1522326|Treating|qlco|||treating|||0|1000|433|441
SE|25462259||ab|2|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|446|454
SE|25462259||ab|2|entity|C0750528|PRESENTLY|idcn|||presently|||0|1000|468|477
SE|25462259||ab|2|entity|C0012634|Disease|dsyn|||disease|||0|1000|494|501

SE|25462259||ab|3|text|503|719|In order to discover neuroprotective compounds with a therapeutical potential, our research team has established original and highly regioselective methods for the synthesis of 2,3-disubstituted 6-aminoquinoxalines.
SE|25462259||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|827|540|549
SE|25462259||ab|3|entity|C0237399|Potential|qlco|||potential|||0|861|571|580
SE|25462259||ab|3|entity|C0035168|research|resa|||research|||0|872|586|594
SE|25462259||ab|3|entity|C0871489|Teams|grup|||team|||0|872|595|599
SE|25462259||ab|3|entity|C0443211|Established|qlco|||established|||0|888|604|615
SE|25462259||ab|3|entity|C0205313|Original|idcn|||original|||0|888|616|624
SE|25462259||ab|3|entity|C0025663|Methods|inpr|||methods|||0|827|651|658
SE|25462259||ab|3|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|667|676

SE|25462259||ab|4|text|719|879|To evaluate the neuroprotective activity of these molecules, we used midbrain cultures and various experimental conditions that promote dopaminergic cell loss.
SE|25462259||ab|4|entity|C0567416|Molecule|sbst|||molecules|||0|966|769|778
SE|25462259||ab|4|entity|C1280997|Entire midbrain|bpoc|||midbrain|||0|888|788|796
SE|25462259||ab|4|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|888|797|805
SE|25462259||ab|4|entity|C1517004|Experimental|ftcn|||experimental|||0|773|818|830
SE|25462259||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|773|831|841
SE|25462259||ab|4|entity|C1512035|Dopaminergic Cell|cell|||dopaminergic cell|||0|901|855|872
SE|25462259||ab|4|entity|C1517945|Loss|qnco|||loss|||0|901|873|877

SE|25462259||ab|5|text|879|1094|Among a series of 11 molecules, only compound MPAQ (2-methyl-3-phenyl-6-aminoquinoxaline) afforded substantial protection in a paradigm where dopaminergic neurons die spontaneously and progressively as they mature.
SE|25462259||ab|5|entity|C0567416|Molecule|sbst|||molecules|||0|827|900|909
SE|25462259||ab|5|entity|C0205198|Compound|qlco|||compound|||0|660|916|924
SE|25462259||ab|5|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|799|942|948
SE|25462259||ab|5|entity|C0911810|2-aminoquinoxaline|orch|||2-methyl-3-phenyl-6-aminoquinoxaline|||0|799|931|967
SE|25462259||ab|5|entity|C0681797|paradigm|resa|||paradigm|||0|813|1006|1014
SE|25462259||ab|5|entity|C0815003|dopaminergic neuron|cell|||dopaminergic neurons|||0|813|1021|1041
SE|25462259||ab|5|entity|C0205286|Mature|tmco|||mature|||0|1000|1086|1092

SE|25462259||ab|6|text|1094|1288|Prediction of blood-brain barrier permeation by Quantitative Structure-Activity Relationship studies (QSARs) suggested that MPAQ was able to reach the brain parenchyma with sufficient efficacy.
SE|25462259||ab|6|entity|C0681842|prediction|inpr|||Prediction|||0|1000|1094|1104
SE|25462259||ab|6|entity|C0005854|Blood - brain barrier anatomy|bpoc|||blood-brain barrier|||0|756|1108|1127
SE|25462259||ab|6|entity|C0887819|Quantitative Structure-Activity Relationship|qnco|||Quantitative Structure-Activity Relationship|||0|922|1142|1186
SE|25462259||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|922|1187|1194
SE|25462259||ab|6|entity|C0006104|Brain|bpoc|||brain|||0|888|1245|1250
SE|25462259||ab|6|entity|C0933845|Parenchyma|bpoc|||parenchyma|||0|888|1251|1261
SE|25462259||ab|6|entity|C0205410|Sufficient|qlco|||sufficient|||0|694|1267|1277
SE|25462259||ab|6|relation|0|0|C0933845|Parenchyma|bpoc|bpoc|||parenchyma|||0|888|1251|1261|MOD/HEAD|PART_OF||1245|1261|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|888|1245|1250

SE|25462259||ab|7|text|1288|1616|HPLC-MS/MS quantification in brain homogenates and MALDI-TOF mass spectrometry imaging on brain tissue sections performed in MPAQ-treated mice allowed us to confirm this prediction and to demonstrate, by MALDI-TOF mass spectrometry imaging, that MPAQ was localized in areas containing vulnerable neurons and/or their terminals.
SE|25462259||ab|7|entity|C0008562|High pressure liquid chromatography procedure|lbpr|||HPLC|||0|645|1288|1292
SE|25462259||ab|7|entity|C0006104|Brain|bpoc|||brain|||0|694|1317|1322
SE|25462259||ab|7|entity|C1518101|MALDI-TOF Mass Spectrometry|resa|||MALDI-TOF mass spectrometry|||0|1000|1339|1366
SE|25462259||ab|7|entity|C0459385|Brain tissue|bpoc|||brain tissue|||0|890|1378|1390
SE|25462259||ab|7|entity|C1292734|Treats|clas|||treated|||0|773|1418|1425
SE|25462259||ab|7|entity|C0026809|Mus|mamm|||mice|||0|773|1426|1430
SE|25462259||ab|7|entity|C0681842|prediction|inpr|||prediction|||0|1000|1458|1468
SE|25462259||ab|7|entity|C1518101|MALDI-TOF Mass Spectrometry|resa|||MALDI-TOF mass spectrometry|||0|1000|1492|1519
SE|25462259||ab|7|entity|C0027882|Neurons|cell|||neurons|||0|861|1584|1591
SE|25462259||ab|7|relation|8|7|C0027882|Neurons|cell|cell|||neurons|||0|861|1584|1591|NOM|PART_OF||1391|1399|3|0|C0459385|Brain tissue|bpoc|bpoc|||brain tissue|||0|890|1378|1390

SE|25462259||ab|8|text|1616|1837|Of interest, MPAQ also rescued dopaminergic neurons, which (i) acquired dependency on the trophic peptide GDNF for their survival or (ii) underwent oxidative stress-mediated insults mediated by catalytically active iron.
SE|25462259||ab|8|entity|C0543488|Interested|menp|||interest|||0|1000|1619|1627
SE|25462259||ab|8|entity|C0815003|dopaminergic neuron|cell|||dopaminergic neurons|||0|823|1647|1667
SE|25462259||ab|8|entity|C0439661|Acquired|tmco|||acquired|||0|694|1679|1687
SE|25462259||ab|8|entity|C0600072|Feeding and dietary regimes|topp|||trophic|||0|833|1706|1713
SE|25462259||ab|8|entity|C0030956|Peptides|aapp|||peptide|||0|833|1714|1721
SE|25462259||ab|8|entity|C0207072|glial cell-line derived neurotrophic factor|aapp,bacs|2668|GDNF|GDNF|||0|833|1722|1726
SE|25462259||ab|8|entity|C0038952|Continuance of life|acty|||survival|||0|1000|1737|1745
SE|25462259||ab|8|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|647|1764|1780
SE|25462259||ab|8|entity|C0086597|Mediating|socb|||mediated|||0|647|1781|1789
SE|25462259||ab|8|entity|C0205177|Active|ftcn|||active|||0|790|1824|1830
SE|25462259||ab|8|entity|C0302583|Iron|bacs,elii,phsu|||iron|||0|790|1831|1835
SE|25462259||ab|8|relation|1|1|C0302583|Iron|bacs,elii,phsu|bacs|||iron|||0|790|1831|1835|VERB|AFFECTS||1798|1806|7|6|C0815003|dopaminergic neuron|cell|cell|||dopaminergic neurons|||0|823|1647|1667

SE|25462259||ab|9|text|1837|2038|In summary, MPAQ possesses an interesting pharmacological profile as it penetrates the brain parenchyma and counteracts mechanisms possibly contributive to dopaminergic cell death in Parkinson disease.
SE|25462259||ab|9|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|660|1879|1894
SE|25462259||ab|9|entity|C0006104|Brain|bpoc|||brain|||0|888|1924|1929
SE|25462259||ab|9|entity|C0933845|Parenchyma|bpoc|||parenchyma|||0|888|1930|1940
SE|25462259||ab|9|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|1957|1967
SE|25462259||ab|9|entity|C0332149|Possible|qlco|||possibly|||0|694|1968|1976
SE|25462259||ab|9|entity|C0007587|Cell Death|celf|||cell death|||0|901|2006|2016
SE|25462259||ab|9|entity|C0030567|Parkinson Disease|dsyn|||Parkinson disease|||0|1000|2020|2037
SE|25462259||ab|9|relation|0|0|C0933845|Parenchyma|bpoc|bpoc|||parenchyma|||0|888|1930|1940|MOD/HEAD|PART_OF||1924|1940|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|888|1924|1929


SE|25462260||ti|1|text|21|110|Synthesis of oleanolic acid dimers linked at C-28 and evaluation of anti-tumor activity.
SE|25462260||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462260||ti|1|entity|C0028925|Oleanolic Acid|bacs,orch|||oleanolic acid|||0|884|34|48
SE|25462260||ti|1|entity|C0596448|dimer|chvs|||dimers|||0|884|49|55
SE|25462260||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|75|85
SE|25462260||ti|1|entity|C0027651|Neoplasm|neop|||tumor|||0|790|94|99

SE|25462260||ab|1|text|116|440|Five dimeric oleanolic acids linked at C-28 by 1,6-hexanediamine, or built around the carbon chains of varying lengths between two carboxyl groups were synthesized, to investigate the effect of internal spacer length and species upon the stereochemical features and anti-tumor activity of the resultant bis-oleanolic acids.
SE|25462260||ab|1|entity|C0205451|Five|qnco|||Five|||0|834|116|120
SE|25462260||ab|1|entity|C0596448|dimer|chvs|||dimeric|||0|834|121|128
SE|25462260||ab|1|entity|C0028925|Oleanolic Acid|bacs,orch|||oleanolic acids|||0|834|129|144
SE|25462260||ab|1|entity|C0007009|Carbon|elii|||carbon|||0|1000|202|208
SE|25462260||ab|1|entity|C1548673|Varies|inpr|||varying|||0|872|219|226
SE|25462260||ab|1|entity|C1444754|Length|qnco|||lengths|||0|872|227|234
SE|25462260||ab|1|entity|C0205448|Two|qnco|||two|||0|890|243|246
SE|25462260||ab|1|entity|C0596260|carboxyl group|inch|||carboxyl groups|||0|890|247|262
SE|25462260||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|300|306
SE|25462260||ab|1|entity|C0205102|Intrinsic|spco|||internal|||0|802|310|318
SE|25462260||ab|1|entity|C1444754|Length|qnco|||length|||0|802|326|332
SE|25462260||ab|1|entity|C1548151|Species|idcn|||species|||0|1000|337|344
SE|25462260||ab|1|entity|C0677040|Stereochemistry|moft|||stereochemical|||0|623|354|368
SE|25462260||ab|1|entity|C0027651|Neoplasm|neop|||tumor|||0|790|387|392
SE|25462260||ab|1|entity|||gngm|9531|BAG3|bis|||0|844|419|422
SE|25462260||ab|1|entity|C0028925|Oleanolic Acid|bacs,orch|||oleanolic acids|||0|844|423|438

SE|25462260||ab|2|text|440|612|The IC50 values of these dimeric compounds for cytotoxicity evaluation in vitro against Hep-G2, A549, BGC-823, MCF-7 and PC-3 tumor cell lines, were mainly under 10.0 MUM.
SE|25462260||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|444|448
SE|25462260||ab|2|entity|C0042295|Values|qlco|||values|||0|888|449|455
SE|25462260||ab|2|entity|C0596448|dimer|chvs|||dimeric|||0|836|465|472
SE|25462260||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|836|473|482
SE|25462260||ab|2|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|487|499
SE|25462260||ab|2|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|500|510
SE|25462260||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|511|519
SE|25462260||ab|2|entity|C0205054|Hepatic|blor|||Hep|||0|888|528|531
SE|25462260||ab|2|entity|C0008015|Macrophage Chemotactic Factors|imft|||MCF-7|||0|861|551|556
SE|25462260||ab|2|entity|C0085983|Cell Line, Tumor|cell|||tumor cell lines|||0|850|566|582
SE|25462260||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|607|610

SE|25462260||ab|3|text|612|790|This result was much better than the inhibition of proliferation against tested tumor cell lines of the monomer oleanolic acid and the commercial anticancer drug 5-fluorouracil.
SE|25462260||ab|3|entity|C1274040|result|ftcn|||result|||0|1000|617|623
SE|25462260||ab|3|entity|C0332272|Better|qlco|||better|||0|1000|633|639
SE|25462260||ab|3|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|663|676
SE|25462260||ab|3|entity|C0039593|Testing|resa|||tested|||0|905|685|691
SE|25462260||ab|3|entity|C0085983|Cell Line, Tumor|cell|||tumor cell lines|||0|905|692|708
SE|25462260||ab|3|entity|C0596973|monomer|chvs|||monomer|||0|901|716|723
SE|25462260||ab|3|entity|C0028925|Oleanolic Acid|bacs,orch|||oleanolic acid|||0|901|724|738
SE|25462260||ab|3|entity|C0680536|commercial|inpr|||commercial|||0|754|747|757
SE|25462260||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|754|769|773
SE|25462260||ab|3|entity|C0016360|Fluorouracil|nnon,phsu|||fluorouracil|||0|754|776|788

SE|25462260||ab|4|text|790|921|The cytotoxicity selectivity detection revealed that dimer 11c exhibited low cytotoxicity towards normal human liver cell HL-7702.
SE|25462260||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|802|794|806
SE|25462260||ab|4|entity|C1511790|Detection|topp|||detection|||0|802|819|828
SE|25462260||ab|4|entity|C0596448|dimer|chvs|||dimer|||0|694|843|848
SE|25462260||ab|4|entity|C0205251|low|qlco|||low|||0|888|863|866
SE|25462260||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|867|879
SE|25462260||ab|4|entity|C0020114|Human|humn|||human|||0|762|895|900
SE|25462260||ab|4|entity|C0023884|Liver|bpoc|||liver|||0|762|901|906
SE|25462260||ab|4|entity|C1268443|Normal cell|cell|||normal human liver cell|||0|762|888|911

SE|25462260||ab|5|text|921|1056|A combination of fluorescence staining observation and flow cytometric analysis indicated that 11c could induce Hep-G2 cell apoptosis.
SE|25462260||ab|5|entity|C0205195|Combined|qlco|||combination|||0|1000|923|934
SE|25462260||ab|5|entity|C0303920|Fluorescent stain|irda,orch|||fluorescence staining|||0|682|938|959
SE|25462260||ab|5|entity|C0016263|Flow Cytometry|lbpr|||flow cytometric|||0|877|976|991
SE|25462260||ab|5|entity|C0936012|Analysis|resa|||analysis|||0|877|992|1000
SE|25462260||ab|5|entity|C0205054|Hepatic|blor|||Hep|||0|833|1033|1036
SE|25462260||ab|5|entity|C0007634|Cells|cell|||cell|||0|833|1040|1044
SE|25462260||ab|5|entity|C0162638|Apoptosis|celf|||apoptosis|||0|833|1045|1054

SE|25462260||ab|6|text|1056|1292|Molecular mechanism studies suggested that 11c induced apoptosis is mediated through the intrinsic apoptotic pathway with changes in mitochondrial membrane potential by finally activating effector caspase-3/9 to trigger cell apoptosis.
SE|25462260||ab|6|entity|C1521991|Molecular|qlco|||Molecular|||0|840|1056|1065
SE|25462260||ab|6|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|840|1066|1075
SE|25462260||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|840|1076|1083
SE|25462260||ab|6|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1111|1120
SE|25462260||ab|6|entity|C0205102|Intrinsic|spco|||intrinsic|||0|877|1145|1154
SE|25462260||ab|6|entity|C0162638|Apoptosis|celf|||apoptotic pathway|||0|877|1155|1172
SE|25462260||ab|6|entity|C0596952|Mitochondrial Membranes|celc|||mitochondrial membrane|||0|901|1189|1211
SE|25462260||ab|6|entity|C0237399|Potential|qlco|||potential|||0|901|1212|1221
SE|25462260||ab|6|entity|C0910167|caspase-9|aapp,enzy|||caspase-3/9|||0|875|1253|1264
SE|25462260||ab|6|entity|C0007634|Cells|cell|||cell|||0|888|1276|1280
SE|25462260||ab|6|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|1281|1290
SE|25462260||ab|6|relation|0|0|C0007634|Cells|cell|cell|||cell|||0|888|1276|1280|MOD/HEAD|LOCATION_OF||1276|1290|0|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|888|1281|1290

SE|25462260||ab|7|text|1292|1380|Further studies revealed that 11c caused cell cycle arrest at G1 phase in Hep-G2 cells.
SE|25462260||ab|7|entity|C1517331|Further|spco|||Further|||0|872|1292|1299
SE|25462260||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|872|1300|1307
SE|25462260||ab|7|entity|C1155873|Cell Cycle Arrest|celf|||cell cycle arrest|||0|1000|1333|1350
SE|25462260||ab|7|entity|C0079395|G1 Phase|tmco|||G1 phase|||0|1000|1354|1362
SE|25462260||ab|7|entity|C0205054|Hepatic|blor|||Hep|||0|851|1366|1369
SE|25462260||ab|7|entity|C0007634|Cells|cell|||cells|||0|851|1373|1378
SE|25462260||ab|7|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|851|1373|1378|PREP|LOCATION_OF||1363|1365|4|2|C1155873|Cell Cycle Arrest|celf|celf|||cell cycle arrest|||0|1000|1333|1350

SE|25462260||ab|8|text|1380|1484|Taken together, these results suggest that 11c may be a potential candidate for further cancer research.
SE|25462260||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1402|1409
SE|25462260||ab|8|entity|C0237399|Potential|qlco|||potential|||0|694|1436|1445
SE|25462260||ab|8|entity|C1517331|Further|spco|||further|||0|851|1460|1467
SE|25462260||ab|8|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|851|1468|1474
SE|25462260||ab|8|entity|C0035168|research|resa|||research|||0|851|1475|1483


SE|25462261||ti|1|text|21|126|4-Aminoquinoline-pyrimidine hybrids: synthesis, antimalarial activity, heme binding and docking studies.
SE|25462261||ti|1|entity|C0048060|4-aminoquinoline|orch,phsu|||4-Aminoquinoline|||0|861|21|37
SE|25462261||ti|1|entity|C0034284|Pyrimidine|orch|||pyrimidine|||0|861|38|48
SE|25462261||ti|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|861|49|56
SE|25462261||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|58|67
SE|25462261||ti|1|entity|C0003374|Antimalarials|phsu|||antimalarial|||0|888|69|81
SE|25462261||ti|1|entity|C1148616|heme binding|moft|||heme binding|||0|1000|92|104
SE|25462261||ti|1|entity|C1522290|Docking|moft|||docking|||0|872|109|116
SE|25462261||ti|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|117|124

SE|25462261||ab|1|text|132|254|A series of novel 4-aminoquinoline-pyrimidine hybrids has been synthesized and evaluated for their antimalarial activity.
SE|25462261||ab|1|entity|C0679622|novel|inpr|||novel|||0|758|144|149
SE|25462261||ab|1|entity|C0002588|Aminoquinolines|orch|||aminoquinoline|||0|758|152|166
SE|25462261||ab|1|entity|C0034284|Pyrimidine|orch|||pyrimidine|||0|758|167|177
SE|25462261||ab|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|758|178|185
SE|25462261||ab|1|entity|C0003374|Antimalarials|phsu|||antimalarial|||0|888|231|243

SE|25462261||ab|2|text|254|400|Several compounds showed promising in vitro antimalarial activity against both CQ-sensitive and CQ-resistant strains with high selectivity index.
SE|25462261||ab|2|entity|C0443302|Several|qnco|||Several|||0|872|254|261
SE|25462261||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|872|262|271
SE|25462261||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|861|289|297
SE|25462261||ab|2|entity|C0003374|Antimalarials|phsu|||antimalarial|||0|861|298|310
SE|25462261||ab|2|entity|C0332324|Sensitive|ftcn|||sensitive|||0|861|336|345
SE|25462261||ab|2|entity|C0332325|Resistant|ftcn|||resistant|||0|790|353|362
SE|25462261||ab|2|entity|C0205250|High|qlco|||high|||0|802|376|380
SE|25462261||ab|2|entity|C0918012|Index|inpr|||index|||0|802|393|398

SE|25462261||ab|3|text|400|474|All the compounds were found to be non-toxic to the mammalian cell lines.
SE|25462261||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|408|417
SE|25462261||ab|3|entity|C1407029|Toxic|qlco|||toxic|||0|861|439|444
SE|25462261||ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|901|462|472

SE|25462261||ab|4|text|474|566|Selected compound 7g exhibited significant suppression of parasitemia in the in vivo assay.
SE|25462261||ab|4|entity|C0205198|Compound|qlco|||compound|||0|840|483|491
SE|25462261||ab|4|entity|C0750502|Significant|idcn|||significant|||0|888|505|516
SE|25462261||ab|4|entity|C0242723|Parasitemia|dsyn|||parasitemia|||0|1000|532|543
SE|25462261||ab|4|entity|C1515655|in vivo|spco|||in vivo|||0|901|551|558
SE|25462261||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|901|559|564

SE|25462261||ab|5|text|566|665|The heme binding studies were conducted to determine the mode of action of these hybrid molecules.
SE|25462261||ab|5|entity|C1148616|heme binding|moft|||heme binding|||0|890|570|582
SE|25462261||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|890|583|590
SE|25462261||ab|5|entity|C1513371|Mode|ftcn|||mode|||0|1000|623|627
SE|25462261||ab|5|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|872|647|653
SE|25462261||ab|5|entity|C0567416|Molecule|sbst|||molecules|||0|872|654|663

SE|25462261||ab|6|text|665|794|These compounds form a stable 1:1 complex with hematin suggesting that heme may be one of the possible targets of these hybrids.
SE|25462261||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|671|680
SE|25462261||ab|6|entity|C0439855|Complex|qlco|||complex|||0|861|699|706
SE|25462261||ab|6|entity|C0018927|Hematin|bacs,orch|||hematin|||0|1000|712|719
SE|25462261||ab|6|entity|C0018966|Heme|bacs,orch|||heme|||0|1000|736|740
SE|25462261||ab|6|entity|C0205447|One|qnco|||one|||0|1000|748|751
SE|25462261||ab|6|entity|C0332149|Possible|qlco|||possible|||0|872|759|767
SE|25462261||ab|6|entity|C0020205|Hybrids|orgm|||hybrids|||0|1000|785|792

SE|25462261||ab|7|text|794|923|The interaction of these conjugate hybrids was also investigated by the molecular docking studies in the binding site of PfDHFR.
SE|25462261||ab|7|entity|C0020205|Hybrids|orgm|||hybrids|||0|861|829|836
SE|25462261||ab|7|entity|C1521991|Molecular|qlco|||molecular|||0|840|866|875
SE|25462261||ab|7|entity|C1522290|Docking|moft|||docking|||0|840|876|883
SE|25462261||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|840|884|891
SE|25462261||ab|7|entity|C0005456|Binding Sites|rcpt|||binding site|||0|1000|899|911

SE|25462261||ab|8|text|923|1026|The pharmacokinetic property analysis of best active compounds was also studied using ADMET prediction.
SE|25462261||ab|8|entity|C0031328|Pharmacokinetic|ftcn|||pharmacokinetic|||0|851|927|942
SE|25462261||ab|8|entity|C0871161|Property|qlco|||property|||0|851|943|951
SE|25462261||ab|8|entity|C0936012|Analysis|resa|||analysis|||0|851|952|960
SE|25462261||ab|8|entity|C0205177|Active|ftcn|||active|||0|840|969|975
SE|25462261||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|840|976|985
SE|25462261||ab|8|entity|C0681842|prediction|inpr|||prediction|||0|861|1015|1025


SE|25462262||ti|1|text|21|151|Development and evaluation of ST-1829 based on 5-benzylidene-2-phenylthiazolones as promising agent for anti-leukotriene therapy.
SE|25462262||ti|1|entity|C1527148|Development|ftcn|||Development|||0|1000|21|32
SE|25462262||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|37|47
SE|25462262||ti|1|entity|C1555307|promise|idcn|||promising|||0|872|105|114
SE|25462262||ti|1|entity|C0450442|Agent|chvf|||agent|||0|872|115|120
SE|25462262||ti|1|entity|C0023545|Leukotrienes|bacs,eico|||leukotriene|||0|790|130|141

SE|25462262||ab|1|text|157|331|Different inflammatory diseases and allergic reactions are mediated by leukotrienes, which arise from the oxygenation of arachidonic acid catalyzed by 5-lipoxygenase (5-LO).
SE|25462262||ab|1|entity|C1547020|*Difference|qnco|||Different|||0|866|157|166
SE|25462262||ab|1|entity|C1290884|Inflammatory disorder|dsyn|||inflammatory diseases|||0|866|167|188
SE|25462262||ab|1|entity|C1527304|Allergic Reaction|patf|||allergic reactions|||0|1000|193|211
SE|25462262||ab|1|entity|C0023545|Leukotrienes|bacs,eico|||leukotrienes|||0|1000|228|240
SE|25462262||ab|1|entity|C0231940|Alveolar ventilation function|ortf|||oxygenation|||0|1000|263|274
SE|25462262||ab|1|entity|C0003695|Arachidonic Acid|eico|||arachidonic acid|||0|1000|278|294
SE|25462262||ab|1|entity|C0023837|Lipoxygenase|aapp,enzy|||lipoxygenase|||0|888|310|322
SE|25462262||ab|1|entity|C0439084|>5|qnco|||5-LO|||0|694|324|328
SE|25462262||ab|1|relation|2|1|C0023837|Lipoxygenase|aapp,gngm,enzy|aapp|||lipoxygenase|||0|888|310|322|VERB|INTERACTS_WITH||295|304|5|1|C0003695|Arachidonic Acid|eico|eico|||arachidonic acid|||0|1000|278|294
SE|25462262||ab|1|relation|5|1|C0023545|Leukotrienes|bacs,eico|bacs|||leukotrienes|||0|1000|228|240|VERB|ASSOCIATED_WITH||216|224|2|1|C1290884|Inflammatory disorder|dsyn|dsyn|||inflammatory diseases|||0|866|167|188
SE|25462262||ab|1|relation|5|1|C0023545|Leukotrienes|bacs,eico|bacs|||leukotrienes|||0|1000|228|240|VERB|ASSOCIATED_WITH||216|224|2|1|C1527304|Allergic Reaction|patf|patf|||allergic reactions|||0|1000|193|211

SE|25462262||ab|2|text|331|434|One promising approach for an effective anti-leukotriene therapy is the inhibition of this key enzyme.
SE|25462262||ab|2|entity|C0205447|One|qnco|||One|||0|840|331|334
SE|25462262||ab|2|entity|C1555307|promise|idcn|||promising|||0|840|335|344
SE|25462262||ab|2|entity|C0449445|Approach|spco|||approach|||0|840|345|353
SE|25462262||ab|2|entity|C0023545|Leukotrienes|bacs,eico|||leukotriene|||0|775|376|387
SE|25462262||ab|2|entity|C1554080|Key|idcn|||key|||0|888|422|425
SE|25462262||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|426|432

SE|25462262||ab|3|text|434|677|This study presents the synthesis and development of a potent and direct 5-LO inhibitor based on the well characterized 5-benzylidene-2-phenylthiazolone C06, whose further pharmacological investigation was precluded due to its low solubility.
SE|25462262||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|439|444
SE|25462262||ab|3|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|458|467
SE|25462262||ab|3|entity|C1527148|Development|ftcn|||development|||0|1000|472|483
SE|25462262||ab|3|entity|C0237399|Potential|qlco|||potent|||0|900|489|495
SE|25462262||ab|3|entity|C0439084|>5|qnco|||5-LO|||0|785|507|511
SE|25462262||ab|3|entity|C0243077|inhibitors|chvf|||inhibitor|||0|785|512|521
SE|25462262||ab|3|entity|C0205170|Good|qlco|||well|||0|629|535|539
SE|25462262||ab|3|entity|C1517331|Further|spco|||further|||0|851|598|605
SE|25462262||ab|3|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|851|606|621
SE|25462262||ab|3|entity|C0205251|low|qlco|||low|||0|888|661|664
SE|25462262||ab|3|entity|C0037628|Solubility|qnco|||solubility|||0|888|665|675

SE|25462262||ab|4|text|677|970|Through optimization of C06, evaluation of structure-activity relationships including profound assessment of the thiazolone core and consideration of the solubility, the 5-benzyl-2-phenyl-4-hydroxythiazoles represented by 46 (ST-1829, 5-(4-chlorobenzyl)-2-p-tolylthiazol-4-ol) were developed.
SE|25462262||ab|4|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|706|716
SE|25462262||ab|4|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationships|||0|1000|720|752
SE|25462262||ab|4|entity|C0439808|Profound|qlco|||profound|||0|888|763|771
SE|25462262||ab|4|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|772|782
SE|25462262||ab|4|entity|C0444669|Core|spco|||core|||0|861|801|805
SE|25462262||ab|4|entity|C0037628|Solubility|qnco|||solubility|||0|1000|831|841
SE|25462262||ab|4|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|580|858|864

SE|25462262||ab|5|text|970|1151|Compound 46 showed an improved 5-LO inhibitory activity in cell-based (IC50 values 0.14 MUM) and cell-free assays (IC50 values 0.03 MUM) as well as a prominent enhanced solubility.
SE|25462262||ab|5|entity|C0205198|Compound|qlco|||Compound|||0|861|970|978
SE|25462262||ab|5|entity|C0184511|Improved|qlco|||improved|||0|739|992|1000
SE|25462262||ab|5|entity|||gngm|240|ALOX5|5-LO|||0|739|1001|1005
SE|25462262||ab|5|entity|C0243077|inhibitors|chvf|||inhibitory|||0|739|1006|1016
SE|25462262||ab|5|entity|C0007634|Cells|cell|||cell|||0|872|1029|1033
SE|25462262||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|762|1041|1045
SE|25462262||ab|5|entity|C0042295|Values|qlco|||values|||0|762|1046|1052
SE|25462262||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|762|1058|1061
SE|25462262||ab|5|entity|C1516365|Cellular Assay|resa|||cell-free assays|||0|861|1067|1083
SE|25462262||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|762|1085|1089
SE|25462262||ab|5|entity|C0042295|Values|qlco|||values|||0|762|1090|1096
SE|25462262||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|762|1102|1105
SE|25462262||ab|5|entity|C0205402|Prominent|qlco|||prominent|||0|802|1120|1129
SE|25462262||ab|5|entity|C0037628|Solubility|qnco|||solubility|||0|802|1139|1149
SE|25462262||ab|5|relation|4|2|C1516365|Cellular Assay|resa|resa|||cell-free assays|||0|861|1067|1083|ADJ|USES||1034|1039|1|1|C0243077|inhibitors|chvf|chvf|||inhibitory|||0|739|1006|1016

SE|25462262||ab|6|text|1151|1284|Furthermore, it kept its promising inhibitory potency in the presence of blood serum, excluding excessive binding to serum proteins.
SE|25462262||ab|6|entity|C1555307|promise|idcn|||promising|||0|851|1176|1185
SE|25462262||ab|6|entity|C0234122|Inhibitory potential|ortf|||inhibitory potency|||0|851|1186|1204
SE|25462262||ab|6|entity|C0229671|Serum|bdsu|||blood serum|||0|1000|1224|1235
SE|25462262||ab|6|entity|C0442802|Excessive|qlco|||excessive|||0|694|1247|1256
SE|25462262||ab|6|entity|C0036825|Serum Proteins|aapp,bacs|||serum proteins|||0|1000|1268|1282

SE|25462262||ab|7|text|1284|1401|These facts combined with the non-cytotoxic profile mark a major step towards an effective anti-inflammatory therapy.
SE|25462262||ab|7|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|660|1318|1327
SE|25462262||ab|7|entity|C0205164|Major|qlco|||major|||0|888|1343|1348
SE|25462262||ab|7|entity|C1261552|Step|ftcn|||step|||0|888|1349|1353
SE|25462262||ab|7|entity|C1096024|Antiinflammatory therapy|topp|||anti-inflammatory therapy|||0|901|1375|1400


SE|25462263||ti|1|text|21|149|Phenyl acetate derivatives, fluorine-substituted on the phenyl group, as rapid recovery hypnotic agents with reflex depression.
SE|25462263||ti|1|entity|C0220893|phenylacetate|orch,phsu|||Phenyl acetate|||0|901|21|35
SE|25462263||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|901|36|47
SE|25462263||ti|1|entity|C0016330|Fluorine|bacs,elii,hops|||fluorine|||0|1000|49|57
SE|25462263||ti|1|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|888|77|83
SE|25462263||ti|1|entity|C0441833|Groups|inpr|||group|||0|888|84|89
SE|25462263||ti|1|entity|C0439831|Rapid|qlco|||rapid|||0|852|94|99
SE|25462263||ti|1|entity|C0237820|Recovery|orgf|||recovery|||0|852|100|108
SE|25462263||ti|1|entity|C0020591|Hypnotics|phsu|||hypnotic agents|||0|852|109|124
SE|25462263||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|861|137|147

SE|25462263||ab|1|text|155|259|We report the synthesis of novel, potentially hypnotic fluorine-substituted phenyl acetate derivatives.
SE|25462263||ab|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|169|178
SE|25462263||ab|1|entity|C0679622|novel|inpr|||novel|||0|740|182|187
SE|25462263||ab|1|entity|C0020591|Hypnotics|phsu|||hypnotic|||0|740|201|209
SE|25462263||ab|1|entity|C0016330|Fluorine|bacs,elii,hops|||fluorine|||0|740|210|218
SE|25462263||ab|1|entity|C0220893|phenylacetate|orch,phsu|||phenyl acetate|||0|740|231|245
SE|25462263||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|740|246|257

SE|25462263||ab|2|text|259|429|We describe the structure-activity relationship that led us to the promising derivative: ethyl 2-(4-(2-(diethylamino)-2-oxoethoxy)-5-ethoxy-2-fluorophenyl) acetate (55).
SE|25462263||ab|2|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationship|||0|1000|275|306
SE|25462263||ab|2|entity|C0023175|Lead|elii|||led|||0|966|312|315
SE|25462263||ab|2|entity|C1555307|promise|idcn|||promising|||0|872|326|335
SE|25462263||ab|2|entity|C1527240|Derivative|ftcn|||derivative|||0|872|336|346
SE|25462263||ab|2|entity|C0000975|Acetate|orch,phsu|||acetate|||0|1000|415|422

SE|25462263||ab|3|text|429|629|The unique pharmacological features of compound 55 are its relatively high affinity for the GABAA receptor, together with a unique affinity for the NMDA receptor, different to propanidid and AZD3043.
SE|25462263||ab|3|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|660|440|455
SE|25462263||ab|3|entity|C0205198|Compound|qlco|||compound|||0|861|468|476
SE|25462263||ab|3|entity|C0205250|High|qlco|||high|||0|790|499|503
SE|25462263||ab|3|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|861|527|535
SE|25462263||ab|3|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDA receptor|||0|1000|577|590
SE|25462263||ab|3|entity|C1547020|*Difference|qnco|||different|||0|928|592|601
SE|25462263||ab|3|entity|C0033439|Propanidid|orch,phsu|||propanidid|||0|1000|605|615
SE|25462263||ab|3|entity||<<same>>||||different|||||592|601
SE|25462263||ab|3|relation|6|2|C0080093|N-Methyl-D-Aspartate Receptors|aapp,gngm,rcpt|aapp|||NMDA receptor|||0|1000|577|590|PREP|compared_with||602|604|2|1|C0033439|Propanidid|orch,phsu|orch|||propanidid|||0|1000|605|615
SE|25462263||ab|3|relation|6|2|C0080093|N-Methyl-D-Aspartate Receptors|aapp,gngm,rcpt|aapp|||NMDA receptor|||0|1000|577|590|PREP|same_as|negation|602|604|2|1|C0033439|Propanidid|orch,phsu|orch|||propanidid|||0|1000|605|615

SE|25462263||ab|4|text|629|827|In animal models, compound 55 showed stronger hypnotic potency and longer duration of LORR than propanidid and AZD3043, but also maintained a rapid recovery time to walking and behavioral recovery.
SE|25462263||ab|4|entity|C0599779|Animal Model|anim|||animal models|||0|1000|632|645
SE|25462263||ab|4|entity|C0205198|Compound|qlco|||compound|||0|861|647|655
SE|25462263||ab|4|entity|C0442821|Strong|qlco|||stronger|||0|802|666|674
SE|25462263||ab|4|entity|C0020591|Hypnotics|phsu|||hypnotic|||0|802|675|683
SE|25462263||ab|4|entity|C0237399|Potential|qlco|||potency|||0|802|684|691
SE|25462263||ab|4|entity|C0439591|Long duration|qlco|||longer duration|||0|983|696|711
SE|25462263||ab|4|entity|C0033439|Propanidid|orch,phsu|||propanidid|||0|1000|725|735
SE|25462263||ab|4|entity|C0439831|Rapid|qlco|||rapid|||0|851|771|776
SE|25462263||ab|4|entity|C0237820|Recovery|orgf|||recovery|||0|851|777|785
SE|25462263||ab|4|entity|C0040223|Time|tmco|||time|||0|851|786|790
SE|25462263||ab|4|entity|C0080331|Walking|dora|||walking|||0|1000|794|801
SE|25462263||ab|4|entity|C0237820|Recovery|orgf|||recovery|||0|861|817|825

SE|25462263||ab|5|text|827|898|In particular, compound 55 displayed reflex depression during infusion.
SE|25462263||ab|5|entity|C0205198|Compound|qlco|||compound|||0|720|842|850
SE|25462263||ab|5|entity|C0870432|Display - arrangement|ftcn|||displayed|||0|720|854|863
SE|25462263||ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|720|871|881
SE|25462263||ab|5|entity|C0574032|Infusion procedures|topp|||infusion|||0|1000|889|897


SE|25462264||ti|1|text|21|142|Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities.
SE|25462264||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462264||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|43|53
SE|25462264||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|54|64
SE|25462264||ti|1|entity|C0679622|novel|inpr|||novel|||0|888|68|73
SE|25462264||ti|1|entity|C0030956|Peptides|aapp|||peptides|||0|888|74|82
SE|25462264||ti|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|861|93|99
SE|25462264||ti|1|entity|C0013203|Drug resistance|biof|||drug resistance|||0|850|104|119
SE|25462264||ti|1|entity|C1555029|reverses|idcn|||reversing|||0|850|120|129
SE|25462264||ti|1|entity|C0441655|Activities|acty|||activities|||0|850|130|140

SE|25462264||ab|1|text|148|296|Chemotherapy is an important approach used to treat cancer, but severe side effects and emerging drug resistance restrict its clinical application.
SE|25462264||ab|1|entity|C0013216|Pharmacotherapy|topp|||Chemotherapy|||0|1000|148|160
SE|25462264||ab|1|entity|C0449445|Approach|spco|||approach|||0|861|177|185
SE|25462264||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|200|206
SE|25462264||ab|1|entity|C0205082|Severe|qlco|||severe|||0|901|212|218
SE|25462264||ab|1|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|901|219|231
SE|25462264||ab|1|entity|C0013203|Drug resistance|biof|||drug resistance|||0|901|245|260
SE|25462264||ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|274|282
SE|25462264||ab|1|relation|2|2|C0013216|Pharmacotherapy|topp|topp|||Chemotherapy|||0|1000|148|160|VERB|TREATS||194|199|4|1|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|1000|200|206

SE|25462264||ab|2|text|296|389|In this present study, we found that peptide B1 showed specific cytotoxicity to tumor cells.
SE|25462264||ab|2|entity|C0150312|Present|qnco|||present|||0|888|304|311
SE|25462264||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|312|317
SE|25462264||ab|2|entity|C0030956|Peptides|aapp|||peptide|||0|888|333|340
SE|25462264||ab|2|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|861|360|372
SE|25462264||ab|2|entity|C0431085|[M]Unspecified tumor cell NOS|cell|||tumor cells|||0|1000|376|387

SE|25462264||ab|3|text|389|535|Moreover, a helix-wheel plot predicted that the Ser14 in this peptide is located at the interface of the hydrophobic and hydrophilic faces of B1.
SE|25462264||ab|3|entity|C0030956|Peptides|aapp|||peptide|||0|1000|451|458
SE|25462264||ab|3|entity|C0475370|Hydrophilic|ftcn|||hydrophilic|||0|888|510|521
SE|25462264||ab|3|entity|C0015450|Face|blor|||faces|||0|888|522|527

SE|25462264||ab|4|text|535|750|Subsequently, we wondered whether replacing Ser14 would alter the activity of B1, and so a series of B1 analogs were synthesized where the Ser14 was replaced by amino acids with distinct physicochemical properties.
SE|25462264||ab|4|entity|C1554078|Replace|idcn|||replacing|||0|661|569|578
SE|25462264||ab|4|entity|C0243071|Analog|chvs|||analogs|||0|872|639|646
SE|25462264||ab|4|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|696|707
SE|25462264||ab|4|entity|C0871161|Property|qlco|||properties|||0|793|738|748

SE|25462264||ab|5|text|750|871|Amongst them, peptides where Ser14 was substituted by a nonpolar and basic amino acid had improved anti-cancer activity.
SE|25462264||ab|5|entity|C0030956|Peptides|aapp|||peptides|||0|660|764|772
SE|25462264||ab|5|entity|C0813984|nonpolar|qnco|||nonpolar|||0|1000|806|814
SE|25462264||ab|5|entity|C0301714|Amino Acids, Basic|aapp|||basic amino acid|||0|1000|819|835
SE|25462264||ab|5|entity|C0184511|Improved|qlco|||improved|||0|775|840|848
SE|25462264||ab|5|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|775|854|860

SE|25462264||ab|6|text|871|1065|Further investigations revealed that B1 and its analogs were capable of penetrating into cytoplasm and triggering cytochrome C release from mitochondria, which ultimately resulted in apoptosis.
SE|25462264||ab|6|entity|C1517331|Further|spco|||Further|||0|888|871|878
SE|25462264||ab|6|entity|C0243071|Analog|chvs|||analogs|||0|966|919|926
SE|25462264||ab|6|entity|C0205321|Penetration|ftcn|||penetrating|||0|1000|943|954
SE|25462264||ab|6|entity|C0010834|Cytoplasm|celc|||cytoplasm|||0|1000|960|969
SE|25462264||ab|6|entity|C1444748|Triggered by|qlco|||triggering|||0|850|974|984
SE|25462264||ab|6|entity|C0010749|CYTOCHROME C|aapp,enzy|||cytochrome C|||0|850|985|997
SE|25462264||ab|6|entity|C0026237|Mitochondria|celc|||mitochondria|||0|1000|1011|1023
SE|25462264||ab|6|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1054|1063

SE|25462264||ab|7|text|1065|1136|Meanwhile, B1 and its analogs inhibited the migration of cancer cells.
SE|25462264||ab|7|entity|C0243071|Analog|chvs|||analogs|||0|966|1087|1094
SE|25462264||ab|7|entity|C0334227|Tumor cells, malignant|cell|||cancer cells|||0|983|1122|1134

SE|25462264||ab|8|text|1136|1232|The peptides also acted against drug-resistant cells and had drug resistance-reversing effects.
SE|25462264||ab|8|entity|C0030956|Peptides|aapp|||peptides|||0|1000|1140|1148
SE|25462264||ab|8|entity|C0013203|Drug resistance|biof|||drug-resistant|||0|865|1168|1182
SE|25462264||ab|8|entity|C0007634|Cells|cell|||cells|||0|865|1183|1188
SE|25462264||ab|8|entity|C0013203|Drug resistance|biof|||drug resistance|||0|838|1197|1212
SE|25462264||ab|8|entity|C1555029|reverses|idcn|||reversing|||0|838|1213|1222
SE|25462264||ab|8|entity|C1280500|Effect|qlco|||effects|||0|838|1223|1230

SE|25462264||ab|9|text|1232|1308|In conclusion, these peptides might be promising candidates for oncotherapy.
SE|25462264||ab|9|entity|C0030956|Peptides|aapp|||peptides|||0|1000|1253|1261
SE|25462264||ab|9|entity|C1555307|promise|idcn|||promising|||0|661|1271|1280


SE|25462265||ti|1|text|21|128|Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones.
SE|25462265||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462265||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|824|43|51
SE|25462265||ti|1|entity|C0679622|novel|inpr|||novel|||0|872|74|79
SE|25462265||ti|1|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|747|96|102
SE|25462265||ti|1|entity|C0205447|One|qnco|||ones|||0|747|122|126

SE|25462265||ab|1|text|134|373|A novel series of N-substituted-4-phenylphthalazin-1-ones 14a-g bearing different anilines at the N-2 of phthalazin-1-one scaffold via acetyl-flexible linker was designed and synthesized for the development of potential anticancer agents.
SE|25462265||ab|1|entity|C0679622|novel|inpr|||novel|||0|888|136|141
SE|25462265||ab|1|entity|C0205549|Series|qnco|||series|||0|888|142|148
SE|25462265||ab|1|entity|C0205447|One|qnco|||ones|||0|690|187|191
SE|25462265||ab|1|entity|C1553646|Maxillary left first molar abutment|medd|||14a|||0|690|192|195
SE|25462265||ab|1|entity|C1547020|*Difference|qnco|||different|||0|836|206|215
SE|25462265||ab|1|entity|C0003036|Aniline|hops,orch|||anilines|||0|836|216|224
SE|25462265||ab|1|entity|C0441922|N+|inpr|||N-2|||0|861|232|235
SE|25462265||ab|1|entity|C0205447|One|qnco|||one|||0|541|252|255
SE|25462265||ab|1|entity|C0337143|Scaffold|mnob|||scaffold|||0|541|256|264
SE|25462265||ab|1|entity|C0443220|Flexible|qlco|||flexible|||0|541|276|284
SE|25462265||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|329|340
SE|25462265||ab|1|entity|C0237399|Potential|qlco|||potential|||0|785|344|353
SE|25462265||ab|1|entity|C0450442|Agent|chvf|||agents|||0|785|365|371

SE|25462265||ab|2|text|373|516|Compounds 19a-g were synthesized by insertion of methylene (CH2) bridge at C4-position of 14a-g to provide a flexibility for the phenyl group.
SE|25462265||ab|2|entity|C0205198|Compound|qlco|||Compounds|||0|829|373|382
SE|25462265||ab|2|entity|C1553655|Mandibular left first molar abutment|medd|||19a|||0|829|383|386
SE|25462265||ab|2|entity|C0021107|Implantation procedure|topp|||insertion|||0|1000|409|418
SE|25462265||ab|2|entity|C0054666|carbene|orch,phsu|||methylene|||0|1000|422|431
SE|25462265||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|861|451|459
SE|25462265||ab|2|entity|C1553646|Maxillary left first molar abutment|medd|||14a|||0|694|463|466
SE|25462265||ab|2|entity|C0242808|Pliability|qlco|||flexibility|||0|1000|482|493
SE|25462265||ab|2|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|888|502|508
SE|25462265||ab|2|entity|C0441833|Groups|inpr|||group|||0|888|509|514

SE|25462265||ab|3|text|516|730|The newly synthesized compounds 14a-g and 19a-g were evaluated for their anti-proliferative activity against three human tumor cell lines HepG2 hepatocellular carcinoma, HT-29 colon cancer and MCF-7 breast cancer.
SE|25462265||ab|3|entity|C0750546|NEWLY|idcn|||newly|||0|750|520|525
SE|25462265||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|750|538|547
SE|25462265||ab|3|entity|C1553646|Maxillary left first molar abutment|medd|||14a|||0|750|548|551
SE|25462265||ab|3|entity|C1553655|Mandibular left first molar abutment|medd|||19a|||0|694|558|561
SE|25462265||ab|3|entity|C0334094|Proliferation|ftcn|||proliferative|||0|790|594|607
SE|25462265||ab|3|entity|C0205449|Three|qnco|||three|||0|785|625|630
SE|25462265||ab|3|entity|C0020114|Human|humn|||human|||0|785|631|636
SE|25462265||ab|3|entity|C0085983|Cell Line, Tumor|cell|||tumor cell lines|||0|785|637|653
SE|25462265||ab|3|entity|C0019204|Primary carcinoma of the liver cells|neop|||hepatocellular carcinoma|||0|785|660|684
SE|25462265||ab|3|entity|C0282639|HT29 Cells|cell|||HT-29|||0|888|686|691
SE|25462265||ab|3|entity|C0007102|Malignant tumor of colon|neop|||colon cancer|||0|888|692|704
SE|25462265||ab|3|entity|C0008015|Macrophage Chemotactic Factors|imft|||MCF-7|||0|824|709|714
SE|25462265||ab|3|entity|C0006142|Malignant neoplasm of breast|neop|||breast cancer|||0|824|715|728
SE|25462265||ab|3|relation|0|0|C0282639|HT29 Cells|cell|cell|||HT-29|||0|888|686|691|MOD/HEAD|LOCATION_OF||686|704|0|0|C0007102|Malignant tumor of colon|neop|neop|||colon cancer|||0|888|692|704

SE|25462265||ab|4|text|730|833|In particular, HepG2 and HT-29 cancer cell lines were more susceptible to the synthesized derivatives.
SE|25462265||ab|4|entity|C0282639|HT29 Cells|cell|||HT-29|||0|857|755|760
SE|25462265||ab|4|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|857|761|767
SE|25462265||ab|4|entity|C0007600|Cell Line|cell|||cell lines|||0|857|768|778
SE|25462265||ab|4|entity|C0205172|More|ftcn|||more|||0|888|784|788
SE|25462265||ab|4|entity|C0231204|Susceptible|ftcn|||susceptible|||0|888|789|800
SE|25462265||ab|4|entity|C0243072|derivatives|chvs|||derivatives|||0|861|820|831

SE|25462265||ab|5|text|833|1042|Compound 19d (IC50 = 1.2 +/- 0.09 MUM) was found to be the most potent derivative against HepG2 as it was 2.9 times more active than doxorubicin (IC50 = 3.45 +/- 0.54) and sorafenib (IC50 = 3.5 +/- 1.04 MUM).
SE|25462265||ab|5|entity|C0205198|Compound|qlco|||Compound|||0|888|833|841
SE|25462265||ab|5|entity|C1552108|Mandibular left first molar distal hemisection|bpoc|||19d|||0|888|842|845
SE|25462265||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|847|851
SE|25462265||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|804|867|870
SE|25462265||ab|5|entity|C0205393|Most|qnco|||most|||0|818|892|896
SE|25462265||ab|5|entity|C0237399|Potential|qlco|||potent|||0|818|897|903
SE|25462265||ab|5|entity|C1527240|Derivative|ftcn|||derivative|||0|818|904|914
SE|25462265||ab|5|entity|C0040223|Time|tmco|||times|||0|793|943|948
SE|25462265||ab|5|entity|C0205172|More|ftcn|||more|||0|888|949|953
SE|25462265||ab|5|entity|C0205177|Active|ftcn|||active|||0|888|954|960
SE|25462265||ab|5|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|1000|966|977
SE|25462265||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|979|983
SE|25462265||ab|5|entity|C1516119|sorafenib|orch,phsu|||sorafenib|||0|1000|1005|1014
SE|25462265||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|1016|1020
SE|25462265||ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|804|1036|1039

SE|25462265||ab|6|text|1042|1239|Compounds 14e, 14g, 19d and 19g with IC50 = (3.29 +/- 0.45), (3.50 +/- 0.846), (1.20 +/- 0.09) and (3.52 +/- 0.70) MUM, respectively, were found to be active candidates against HepG2 cancer cells.
SE|25462265||ab|6|entity|C0205198|Compound|qlco|||Compounds|||0|661|1042|1051
SE|25462265||ab|6|entity|C0470537|14 grams|qnco|||14g|||0|1000|1057|1060
SE|25462265||ab|6|entity|C1552108|Mandibular left first molar distal hemisection|bpoc|||19d|||0|1000|1062|1065
SE|25462265||ab|6|entity|C0470539|19g|qnco|||19g|||0|1000|1070|1073
SE|25462265||ab|6|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|1079|1083
SE|25462265||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|1000|1157|1160
SE|25462265||ab|6|entity|C0205177|Active|ftcn|||active|||0|694|1193|1199
SE|25462265||ab|6|entity|C0334227|Tumor cells, malignant|cell|||cancer cells|||0|884|1225|1237

SE|25462265||ab|7|text|1239|1583|Compounds 14e, 14g, 19d and 19g were able to induce apoptosis in HepG2, this was assured by; the significant increase in the percentage of annexin V-FITC-positive apoptotic cells (UR + LR), the down-regulation of the anti-apoptotic protein Bcl-2 and the up-regulation of the pro-apoptotic protein Bax, in addition to boosting caspase-3 levels.
SE|25462265||ab|7|entity|C0205198|Compound|qlco|||Compounds|||0|661|1239|1248
SE|25462265||ab|7|entity|C0470537|14 grams|qnco|||14g|||0|1000|1254|1257
SE|25462265||ab|7|entity|C1552108|Mandibular left first molar distal hemisection|bpoc|||19d|||0|1000|1259|1262
SE|25462265||ab|7|entity|C0470539|19g|qnco|||19g|||0|1000|1267|1270
SE|25462265||ab|7|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1291|1300
SE|25462265||ab|7|entity|C0750502|Significant|idcn|||significant|||0|888|1336|1347
SE|25462265||ab|7|entity|C0442805|Increase|ftcn|||increase|||0|888|1348|1356
SE|25462265||ab|7|entity|C0439165|Percent (qualifier value)|qnco|||percentage|||0|1000|1364|1374
SE|25462265||ab|7|entity|C0059249|annexin A5|aapp,bacs|||annexin V|||0|839|1378|1387
SE|25462265||ab|7|entity|C0085216|Fluorescein-5-isothiocyanate|irda,orch|||FITC|||0|839|1388|1392
SE|25462265||ab|7|entity|C1516044|Apoptotic|qlco|||apoptotic|||0|839|1402|1411
SE|25462265||ab|7|entity|C0439178|% positive cells|qnco|||positive apoptotic cells|||0|839|1393|1417
SE|25462265||ab|7|entity|C0013081|Down-Regulation|celf|||down-regulation|||0|1000|1433|1448
SE|25462265||ab|7|entity|C1565114|Apoptosis Inhibiting Proteins|aapp,bacs|||anti-apoptotic protein|||0|886|1456|1478
SE|25462265||ab|7|entity|C1153488|apoptogenic cytochrome c release channel activity|moft|||Bcl-2|||0|886|1479|1484
SE|25462265||ab|7|entity|C0162493|Transcriptional Activation|genf|||up-regulation|||0|1000|1493|1506
SE|25462265||ab|7|entity|C1565115|Apoptosis Inducing Proteins|aapp,bacs|||pro-apoptotic protein|||0|908|1514|1535
SE|25462265||ab|7|entity|C0812198|BAX gene|gngm|581|BAX|Bax|||0|908|1536|1539
SE|25462265||ab|7|entity|C1511253|Boost|ftcn|||boosting|||0|852|1556|1564
SE|25462265||ab|7|entity|C0291573|caspase-3|aapp,enzy|||caspase-3|||0|852|1565|1574
SE|25462265||ab|7|entity|C0441889|Levels|inpr|||levels|||0|852|1575|1581
SE|25462265||ab|7|relation|3|1|C0812198|BAX gene|gngm,aapp|gngm|581|BAX|Bax|||0|908|1536|1539|PREP|LOCATION_OF||1507|1509|13|1|C0162493|Transcriptional Activation|genf|genf|||up-regulation|||0|1000|1493|1506

SE|25462265||ab|8|text|1583|1857|Moreover, cytotoxicity evaluation of the newly synthesized compounds in HT-29 revealed that compounds 14e, 14f, 19e and 19f (IC50 = 3.05 +/- 0.78, 4.02 +/- 1.18, 3.68 +/- 0.79 and 2.98 +/- 0.47 MUM, respectively) were more potent than doxorubicin (IC50 = 7.70 +/- 1.78 MUM).
SE|25462265||ab|8|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|1593|1605
SE|25462265||ab|8|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|1606|1616
SE|25462265||ab|8|entity|C0750546|NEWLY|idcn|||newly|||0|785|1624|1629
SE|25462265||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|785|1642|1651
SE|25462265||ab|8|entity|C0282639|HT29 Cells|cell|||HT-29|||0|1000|1655|1660
SE|25462265||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|661|1675|1684
SE|25462265||ab|8|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|1708|1712
SE|25462265||ab|8|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|804|1777|1780
SE|25462265||ab|8|entity|C0205172|More|ftcn|||more|||0|838|1801|1805
SE|25462265||ab|8|entity|C0237399|Potential|qlco|||potent|||0|838|1806|1812
SE|25462265||ab|8|entity|C0013089|Doxorubicin|antb,orch|||doxorubicin|||0|1000|1818|1829
SE|25462265||ab|8|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|1831|1835
SE|25462265||ab|8|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|804|1852|1855


SE|25462266||ti|1|text|21|108|Purinergic P2X receptors: structural models and analysis of ligand-target interaction.
SE|25462266||ti|1|entity|C1152841|ATP-gated cation channel activity|moft|||P2X|||0|901|32|35
SE|25462266||ti|1|entity|C0034836|Purinoceptor|aapp,rcpt|||Purinergic P2X receptors|||0|901|21|45
SE|25462266||ti|1|entity|C0026349|Models, Structural|mnob|||structural models|||0|1000|47|64
SE|25462266||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|1000|69|77
SE|25462266||ti|1|entity|C0023688|Ligands|chem|||ligand|||0|851|81|87

SE|25462266||ab|1|text|114|216|The purinergic P2X receptors are ligand-gated cation channels activated by the endogenous ligand ATP.
SE|25462266||ab|1|entity|C1152841|ATP-gated cation channel activity|moft|||P2X|||0|901|129|132
SE|25462266||ab|1|entity|C0034836|Purinoceptor|aapp,rcpt|||purinergic P2X receptors|||0|901|118|142
SE|25462266||ab|1|entity|C0007447|Cations|chvs|||cation|||0|905|160|166
SE|25462266||ab|1|entity|C0599831|ligand gated channel|aapp,bacs|||ligand-gated cation channels|||0|905|147|175
SE|25462266||ab|1|entity|C0205227|Endogenous|ftcn|||endogenous|||0|851|193|203
SE|25462266||ab|1|entity|C0023688|Ligands|chem|||ligand|||0|851|204|210
SE|25462266||ab|1|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|851|211|214
SE|25462266||ab|1|relation|2|1|C0599831|ligand gated channel|aapp,gngm,bacs|aapp|||ligand-gated cation channels|||0|905|147|175|VERB|STIMULATES||176|185|1|1|C1366628|ATP8A2 gene|gngm,aapp|gngm|51761|ATP8A2|ATP|||0|851|211|214

SE|25462266||ab|2|text|216|449|They assemble as homo- or heterotrimers from seven cloned subtypes (P2X1-7) and all trimer subunits present a common topology consisting in intracellular N- and C- termini, two transmembrane domains and a large extracellular domain.
SE|25462266||ab|2|entity|C1300203|Homo|mamm|||homo|||0|1000|233|237
SE|25462266||ab|2|entity|C0205453|Seven|qnco|||seven|||0|829|261|266
SE|25462266||ab|2|entity|C0009013|Clone Cells|cell|||cloned|||0|829|267|273
SE|25462266||ab|2|entity|C0449560|Subtype|clas|||subtypes|||0|829|274|282
SE|25462266||ab|2|entity|C0205214|Common|qnco|||common|||0|694|326|332
SE|25462266||ab|2|entity|C0175996|Protoplasm|celc|||intracellular|||0|872|356|369
SE|25462266||ab|2|entity|C0205448|Two|qnco|||two|||0|890|389|392
SE|25462266||ab|2|entity|C1519623|Transmembrane Domain|amas|||transmembrane domains|||0|890|393|414
SE|25462266||ab|2|entity|C0549177|Large|qnco|||large|||0|901|421|426
SE|25462266||ab|2|entity|C1517050|Extracellular Domain|spco|||extracellular domain|||0|901|427|447

SE|25462266||ab|3|text|449|602|These membrane proteins are present in virtually all mammalian tissues and regulate a large variety of responses in physio- and pathological conditions.
SE|25462266||ab|3|entity|C0025252|Membrane Proteins|aapp,bacs|||membrane proteins|||0|1000|455|472
SE|25462266||ab|3|entity|C0150312|Present|qnco|||present|||0|1000|477|484
SE|25462266||ab|3|entity|C0040300|Body tissue|tisu|||tissues|||0|861|512|519
SE|25462266||ab|3|entity|C0549177|Large|qnco|||large|||0|694|535|540
SE|25462266||ab|3|entity|C0871261|response|clna|||responses|||0|1000|552|561
SE|25462266||ab|3|entity|C1521733|Pathologic|ftcn|||pathological|||0|872|577|589
SE|25462266||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|872|590|600

SE|25462266||ab|4|text|602|878|The development of ligands that selectively activate or block specific P2X receptor subtypes hence represents a promising strategy to obtain novel pharmacological tools for the treatment of pain, cancer, inflammation, and neurological, cardiovascular, and endocrine diseases.
SE|25462266||ab|4|entity|C1527148|Development|ftcn|||development|||0|1000|606|617
SE|25462266||ab|4|entity|C0023688|Ligands|chem|||ligands|||0|1000|621|628
SE|25462266||ab|4|entity|C0968185|P2X-receptor|aapp,rcpt|||P2X receptor|||0|813|673|685
SE|25462266||ab|4|entity|C0449560|Subtype|clas|||subtypes|||0|813|686|694
SE|25462266||ab|4|entity|C1555307|promise|idcn|||promising|||0|872|714|723
SE|25462266||ab|4|entity|C0679622|novel|inpr|||novel|||0|840|743|748
SE|25462266||ab|4|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|840|749|764
SE|25462266||ab|4|entity|C0336791|Tool|mnob|||tools|||0|840|765|770
SE|25462266||ab|4|entity|C0030193|Pain|sosy|||pain|||0|1000|792|796
SE|25462266||ab|4|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|798|804
SE|25462266||ab|4|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|806|818
SE|25462266||ab|4|entity|C0205494|Neurologic|ftcn|||neurological|||0|694|824|836
SE|25462266||ab|4|entity|C0014130|Endocrine System Diseases|dsyn|||endocrine diseases|||0|1000|858|876

SE|25462266||ab|5|text|878|1166|The publication of the crystal structures of zebrafish P2X4 receptor in inactive and ATP-bound active forms provided structural data for the analysis of the receptor structure, the interpretation of mutagenesis data, and the depiction of ligand binding and receptor activation mechanism.
SE|25462266||ab|5|entity|C0034036|Publications|inpr,mnob|||publication|||0|1000|882|893
SE|25462266||ab|5|entity|C0043457|Zebrafish|fish|||zebrafish|||0|802|923|932
SE|25462266||ab|5|entity|||gngm|5025|P2RX4|P2X4|||0|802|933|937
SE|25462266||ab|5|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|802|938|946
SE|25462266||ab|5|entity|C0205254|Sedentary|fndg|||inactive|||0|1000|950|958
SE|25462266||ab|5|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|775|963|966
SE|25462266||ab|5|entity|C0205177|Active|ftcn|||active|||0|775|973|979
SE|25462266||ab|5|entity|C1511726|Data|idcn|||data|||0|861|1006|1010
SE|25462266||ab|5|entity|C0936012|Analysis|resa|||analysis|||0|1000|1019|1027
SE|25462266||ab|5|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|888|1035|1043
SE|25462266||ab|5|entity|C0678594|Structure|spco|||structure|||0|888|1044|1053
SE|25462266||ab|5|entity|C0459471|Interpretation|inpr|||interpretation|||0|1000|1059|1073
SE|25462266||ab|5|entity|C0079866|Mutagenesis|moft|||mutagenesis|||0|888|1077|1088
SE|25462266||ab|5|entity|C1511726|Data|idcn|||data|||0|888|1089|1093
SE|25462266||ab|5|entity|C1517880|Ligand Binding|moft|||ligand binding|||0|1000|1116|1130
SE|25462266||ab|5|entity|C1514758|Receptor Activation|celf|||receptor activation|||0|901|1135|1154
SE|25462266||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|901|1155|1164
SE|25462266||ab|5|relation|0|0|||gngm,aapp|gngm|5025|P2RX4|P2X4|||0|802|933|937|MOD/HEAD|PART_OF||923|937|0|0|C0043457|Zebrafish|fish|fish|||zebrafish|||0|802|923|932

SE|25462266||ab|6|text|1166|1417|In addition, the availability of ATP-competitive ligands presenting selectivity for P2X receptor subtypes supports the design of new potent and selective ligands with possibly improved pharmacokinetic profiles, with the final aim to obtain new drugs.
SE|25462266||ab|6|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|851|1199|1202
SE|25462266||ab|6|entity|C0679932|competition|socb|||competitive|||0|851|1203|1214
SE|25462266||ab|6|entity|C0023688|Ligands|chem|||ligands|||0|851|1215|1222
SE|25462266||ab|6|entity|C0968185|P2X-receptor|aapp,rcpt|||P2X receptor|||0|890|1250|1262
SE|25462266||ab|6|entity|C0449560|Subtype|clas|||subtypes|||0|890|1263|1271
SE|25462266||ab|6|entity|C0205314|New|tmco|||new|||0|838|1295|1298
SE|25462266||ab|6|entity|C0237399|Potential|qlco|||potent|||0|838|1299|1305
SE|25462266||ab|6|entity|C0023688|Ligands|chem|||ligands|||0|861|1320|1327
SE|25462266||ab|6|entity|C0332149|Possible|qlco|||possibly|||0|1000|1333|1341
SE|25462266||ab|6|entity|C0031328|Pharmacokinetic|ftcn|||pharmacokinetic|||0|694|1351|1366
SE|25462266||ab|6|entity|C0205088|End-stage|tmco|||final|||0|694|1386|1391
SE|25462266||ab|6|entity|C0205314|New|tmco|||new|||0|888|1406|1409
SE|25462266||ab|6|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|1410|1415

SE|25462266||ab|7|text|1417|1571|This study describes molecular modelling studies performed to develop structural models of the human and rat P2X receptors in inactive and active states.
SE|25462266||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1422|1427
SE|25462266||ab|7|entity|C0600115|Molecular Modeling|inpr,resa|||molecular modelling|||0|890|1438|1457
SE|25462266||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|890|1458|1465
SE|25462266||ab|7|entity|C0026349|Models, Structural|mnob|||structural models|||0|1000|1487|1504
SE|25462266||ab|7|entity|C0020114|Human|humn|||human|||0|1000|1512|1517
SE|25462266||ab|7|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|890|1522|1525
SE|25462266||ab|7|entity|C0968185|P2X-receptor|aapp,rcpt|||P2X receptors|||0|890|1526|1539
SE|25462266||ab|7|entity|C0205254|Sedentary|fndg|||inactive|||0|1000|1543|1551
SE|25462266||ab|7|entity|C0679217|active state|fndg|||active states|||0|983|1556|1569
SE|25462266||ab|7|relation|0|0|C0968185|P2X-receptor|aapp,gngm,rcpt|aapp|||P2X receptors|||0|890|1526|1539|MOD/HEAD|PART_OF||1522|1539|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|890|1522|1525

SE|25462266||ab|8|text|1571|1770|These models allowed to analyse the role of some non-conserved residues at ATP binding site and to study the receptor interaction with some non-specific or subtype selective agonists and antagonists.
SE|25462266||ab|8|entity|C0035820|Role|socb|||role|||0|1000|1607|1611
SE|25462266||ab|8|entity|C1148923|ATP binding|moft|||ATP binding|||0|901|1646|1657
SE|25462266||ab|8|entity|C0205145|Site|spco|||site|||0|901|1658|1662
SE|25462266||ab|8|entity|C1372999|Receptor Interactions|moft|||receptor interaction|||0|983|1680|1700
SE|25462266||ab|8|entity|C0205370|Unspecified|qlco|||non-specific|||0|1000|1711|1723
SE|25462266||ab|8|entity|C0449560|Subtype|clas|||subtype|||0|802|1727|1734
SE|25462266||ab|8|entity|C0243192|agonists|phsu|||agonists|||0|802|1745|1753
SE|25462266||ab|8|entity|C0243076|antagonists|chvf|||antagonists|||0|1000|1758|1769


SE|25462267||ti|1|text|21|174|Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
SE|25462267||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462267||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|43|53
SE|25462267||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|54|64
SE|25462267||ti|1|entity|||gngm|9531|BAG3|bis|||0|793|68|71
SE|25462267||ti|1|entity|C0041942|Urea|bacs,orch,phsu|||ureas|||0|793|77|82
SE|25462267||ti|1|entity|C0002482|Amides|orch|||amides|||0|1000|87|93
SE|25462267||ti|1|entity|C0337143|Scaffold|mnob|||scaffold|||0|804|129|137
SE|25462267||ti|1|entity|C0439787|Out|spco|||out|||0|816|145|148
SE|25462267||ti|1|entity|C0104940|Proto-Oncogene Proteins B-raf|aapp,enzy|22882|ZHX2|B-Raf kinase|||0|816|149|161
SE|25462267||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|816|162|172
SE|25462267||ti|1|relation|6|2|C0002482|Amides|orch|orch|||amides|||0|1000|87|93|NOM|INHIBITS||162|172|6|0|C0104940|Proto-Oncogene Proteins B-raf|aapp,gngm,enzy|gngm|22882|ZHX2|B-Raf kinase|||0|816|149|161
SE|25462267||ti|1|relation|6|2|C0041942|Urea|bacs,orch,phsu|orch|||ureas|||0|793|77|82|NOM|INHIBITS||162|172|6|0|C0104940|Proto-Oncogene Proteins B-raf|aapp,gngm,enzy|gngm|22882|ZHX2|B-Raf kinase|||0|816|149|161

SE|25462267||ab|1|text|180|384|By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-Raf(V600E) inhibitors.
SE|25462267||ab|1|entity|C0205195|Combined|qlco|||combining|||0|966|183|192
SE|25462267||ab|1|entity|C0337143|Scaffold|mnob|||scaffolds|||0|966|197|206
SE|25462267||ab|1|entity|C1516119|sorafenib|orch,phsu|||Sorafenib|||0|1000|221|230
SE|25462267||ab|1|entity|||gngm|9531|BAG3|bis|||0|793|244|247
SE|25462267||ab|1|entity|C0041942|Urea|bacs,orch,phsu|||ureas|||0|793|253|258
SE|25462267||ab|1|entity|C0002482|Amides|orch|||amides|||0|1000|263|269
SE|25462267||ab|1|entity|C0679622|novel|inpr|||novel|||0|562|345|350
SE|25462267||ab|1|entity|C0439787|Out|spco|||out|||0|562|355|358
SE|25462267||ab|1|entity|||gngm|22882|ZHX2|Raf|||0|562|361|364
SE|25462267||ab|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|372|382
SE|25462267||ab|1|relation|7|2|C0002482|Amides|orch|orch|||amides|||0|1000|263|269|VERB|INTERACTS_WITH||330|341|3|1|||gngm,aapp|gngm|22882|ZHX2|Raf|||0|562|361|364
SE|25462267||ab|1|relation|7|2|C0041942|Urea|bacs,orch,phsu|orch|||ureas|||0|793|253|258|VERB|INTERACTS_WITH||330|341|3|1|||gngm,aapp|gngm|22882|ZHX2|Raf|||0|562|361|364

SE|25462267||ab|2|text|384|657|Among them, 20c-e, 20g and 21h displayed potent antiproliferative activities against melanoma A375 (B-Raf(V600E)) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 MUM and 1.839 MUM, respectively, comparable with the positive control Vemurafenib (IC50 = 3.32 MUM).
SE|25462267||ab|2|entity|C0237399|Potential|qlco|||potent|||0|752|425|431
SE|25462267||ab|2|entity|C0441655|Activities|acty|||activities|||0|752|450|460
SE|25462267||ab|2|entity|C0025202|melanoma|neop|||melanoma|||0|694|469|477
SE|25462267||ab|2|entity|||gngm|22882|ZHX2|Raf|||0|1000|486|489
SE|25462267||ab|2|entity|C0007600|Cell Line|cell|||cell lines|||0|1000|498|508
SE|25462267||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|514|518
SE|25462267||ab|2|entity|C0042295|Values|qlco|||values|||0|888|519|525
SE|25462267||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|556|559
SE|25462267||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|570|573
SE|25462267||ab|2|entity|C1446409|Positive|qlco|||positive|||0|623|609|617
SE|25462267||ab|2|entity|C0243148|control|ftcn|||control|||0|623|618|625
SE|25462267||ab|2|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|639|643
SE|25462267||ab|2|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|802|651|654

SE|25462267||ab|3|text|657|802|Selected compounds were tested for the ERK inhibition in human melanoma A375 (B-Raf(V600E)) and SK-MEL-2 (B-Raf(WT)) cell lines by Western blot.
SE|25462267||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|855|666|675
SE|25462267||ab|3|entity|||gngm|2048,5594|EPHB2,MAPK1|ERK|||0|861|696|699
SE|25462267||ab|3|entity|C0020114|Human|humn|||human|||0|623|714|719
SE|25462267||ab|3|entity|C0025202|melanoma|neop|||melanoma|||0|623|720|728
SE|25462267||ab|3|entity|||gngm|22882|ZHX2|Raf|||0|1000|737|740
SE|25462267||ab|3|entity|C0218530|Rab8 protein|aapp,enzy|||SK-MEL|||0|827|753|759
SE|25462267||ab|3|entity|||gngm|22882|ZHX2|Raf|||0|1000|765|768
SE|25462267||ab|3|entity|C0043100|Weight|qnco|||WT|||0|1000|769|771
SE|25462267||ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|1000|774|784
SE|25462267||ab|3|entity|C0949466|Western Blot|lbpr|||Western blot|||0|1000|788|800

SE|25462267||ab|4|text|802|1007|The results revealed that our compounds inhibited the proliferation of melanoma A375 cells (B-Raf(V600E)) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-Raf(WT)).
SE|25462267||ab|4|entity|C1274040|result|ftcn|||results|||0|966|806|813
SE|25462267||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|832|841
SE|25462267||ab|4|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|856|869
SE|25462267||ab|4|entity|C1513095|Melanoma Cell|cell|||melanoma A375 cells|||0|896|873|892
SE|25462267||ab|4|entity|||gngm|22882|ZHX2|Raf|||0|1000|896|899
SE|25462267||ab|4|entity|||gngm|2048,5594|EPHB2,MAPK1|ERK|||0|861|916|919
SE|25462267||ab|4|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|861|920|927
SE|25462267||ab|4|entity|C0205310|Paradoxical|qlco|||paradoxical|||0|694|937|948
SE|25462267||ab|4|entity|||gngm|2048,5594|EPHB2,MAPK1|ERK|||0|1000|963|966
SE|25462267||ab|4|entity|C0218530|Rab8 protein|aapp,enzy|||SK-MEL|||0|792|979|985
SE|25462267||ab|4|entity|C1513095|Melanoma Cell|cell|||melanoma SK-MEL-2 cells|||0|792|970|993
SE|25462267||ab|4|entity|||gngm|22882|ZHX2|Raf|||0|1000|997|1000
SE|25462267||ab|4|relation|3|1|C1513095|Melanoma Cell|cell|cell|||melanoma SK-MEL-2 cells|||0|792|970|993|PREP|LOCATION_OF||967|969|9|1|||gngm,aapp|aapp|2048,5594|EPHB2,MAPK1|ERK|||0|1000|963|966

SE|25462267||ab|5|text|1007|1131|Eventually, 20g and 21h were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice.
SE|25462267||ab|5|entity|C0243077|inhibitors|chvf|||inhibitory|||0|836|1062|1072
SE|25462267||ab|5|entity|C1280500|Effect|qlco|||effects|||0|836|1073|1080
SE|25462267||ab|5|entity|C0598934|tumor growth|neop|||tumor growth|||0|1000|1084|1096
SE|25462267||ab|5|entity|C0520484|Xenograft procedure|topp|||xenograft|||0|861|1105|1114
SE|25462267||ab|5|entity|C0026809|Mus|mamm|||mice|||0|1000|1125|1129
SE|25462267||ab|5|relation|2|0|C0243077|inhibitors|chvf|chvf|||inhibitory|||0|836|1062|1072|NOM|AFFECTS||1073|1080|3|1|C0598934|tumor growth|neop|neop|||tumor growth|||0|1000|1084|1096
SE|25462267||ab|5|relation|5|2|C0598934|tumor growth|neop|neop|||tumor growth|||0|1000|1084|1096|PREP|PROCESS_OF||1122|1124|1|1|C0026809|Mus|mamm|mamm|||mice|||0|1000|1125|1129

SE|25462267||ab|6|text|1131|1348|Compound 20g exhibited equivalent antitumor efficacy in vivo (T/C = 44.37%), compared to Sorafenib (T/C = 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body weight loss.
SE|25462267||ab|6|entity|C0205198|Compound|qlco|||Compound|||0|694|1131|1139
SE|25462267||ab|6|entity|C0439185|Eq|qnco|||equivalent|||0|660|1154|1164
SE|25462267||ab|6|entity|C1515655|in vivo|spco|||in vivo|||0|1000|1184|1191
SE|25462267||ab|6|entity|C1516119|sorafenib|orch,phsu|||Sorafenib|||0|1000|1220|1229
SE|25462267||ab|6|entity|C0439228|day|tmco|||day|||0|763|1252|1255
SE|25462267||ab|6|entity|C0037179|Unmarried person|popg|||single|||0|888|1287|1293
SE|25462267||ab|6|entity|C1446466|Dose|qnco|||dose|||0|888|1294|1298
SE|25462267||ab|6|entity|C0750502|Significant|idcn|||significant|||0|861|1319|1330
SE|25462267||ab|6|entity|C0005910|Body Weight|orga|||body weight|||0|861|1331|1342
SE|25462267||ab|6|entity|C1517945|Loss|qnco|||loss|||0|861|1343|1347


SE|25462268||ti|1|text|21|141|1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.
SE|25462268||ti|1|entity|C0205314|New|tmco|||new|||0|888|74|77
SE|25462268||ti|1|entity|C0008902|Classification|clas|||class|||0|888|78|83
SE|25462268||ti|1|entity|C0237399|Potential|qlco|||potent|||0|900|87|93
SE|25462268||ti|1|entity|C0002007|Aldosterone Antagonists|phsu|||aldosterone synthase inhibitors|||0|858|108|139

SE|25462268||ab|1|text|147|453|1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols and related compounds were synthesized and evaluated for inhibition of aldosterone synthase (CYP11B2), a potential target for cardiovascular diseases associated with elevated plasma aldosterone levels like congestive heart failure and myocardial fibrosis.
SE|25462268||ab|1|entity|C0600686|related compounds|chvs|||related compounds|||0|1000|201|218
SE|25462268||ab|1|entity|C0075233|Aldosterone Synthase|aapp,enzy|||aldosterone synthase|||0|1000|268|288
SE|25462268||ab|1|entity|C0075233|Aldosterone Synthase|aapp,enzy|1585|CYP11B2|CYP11B2|||0|1000|290|297
SE|25462268||ab|1|entity|C0237399|Potential|qlco|||potential|||0|888|302|311
SE|25462268||ab|1|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular diseases|||0|1000|323|346
SE|25462268||ab|1|entity|C0205250|High|qlco|||elevated|||0|905|363|371
SE|25462268||ab|1|entity|C1272143|Plasma aldosterone level|lbpr|||plasma aldosterone levels|||0|905|372|397
SE|25462268||ab|1|entity|C0018802|Congestive heart failure|dsyn|||congestive heart failure|||0|1000|403|427
SE|25462268||ab|1|entity|C0151654|Myocardial fibrosis|patf|||myocardial fibrosis|||0|1000|432|451

SE|25462268||ab|2|text|453|590|Introduction of substituents at the phenylsulfinyl moiety and changes of the substitution pattern at the naphthalene core were examined.
SE|25462268||ab|2|entity|C1293116|Introduction procedure|hlca|||Introduction|||0|1000|453|465
SE|25462268||ab|2|entity|C1555721|Substitution|idcn|||substitution|||0|888|530|542
SE|25462268||ab|2|entity|C0449774|Patterns|spco|||pattern|||0|888|543|550
SE|25462268||ab|2|entity|C0027375|Naphthalene|orch|||naphthalene|||0|888|558|569
SE|25462268||ab|2|entity|C0444669|Core|spco|||core|||0|888|570|574

SE|25462268||ab|3|text|590|769|Potent compounds were further examined for selectivity versus other important steroidogenic CYP enzymes, i.e. the highly homologous 11beta-hydroxylase (CYP11B1), CYP17 and CYP19.
SE|25462268||ab|3|entity|C0237399|Potential|qlco|||Potent|||0|822|590|596
SE|25462268||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|822|597|606
SE|25462268||ab|3|entity|C1517331|Further|spco|||further|||0|1000|612|619
SE|25462268||ab|3|entity|C0010798|Cytochromes|aapp,bacs|9360|PPIG|CYP|||0|750|682|685
SE|25462268||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|750|686|693
SE|25462268||ab|3|entity|C1334043|Homologous Gene|gngm|||homologous|||0|728|711|721
SE|25462268||ab|3|entity|C0020364|Mixed Function Oxygenases|aapp,enzy|||hydroxylase|||0|728|729|740
SE|25462268||ab|3|entity|C0038296|Steroid 11-beta-Monooxygenase|aapp,enzy|1584|CYP11B1|CYP11B1|||0|1000|742|749
SE|25462268||ab|3|entity|C0038302|Steroid 17-alpha-monooxygenase|aapp,enzy|1586|CYP17A1|CYP17|||0|1000|752|757
SE|25462268||ab|3|entity|C0003805|Aromatase|aapp,enzy|1588|CYP19A1|CYP19|||0|1000|762|767
SE|25462268||ab|3|relation|0|0|C0038296|Steroid 11-beta-Monooxygenase|aapp,gngm,enzy|aapp|1584|CYP11B1|CYP11B1|||0|1000|742|749|SPEC|ISA||729|749|0|0|C0020364|Mixed Function Oxygenases|aapp,gngm,enzy|aapp|||hydroxylase|||0|728|729|740

SE|25462268||ab|4|text|769|979|The most potent compound (IC50 = 14 nM) discovered was the meta-trifluoromethoxy derivative 11, which also exhibited excellent selectivity toward CYP11B1 (SF = 415), and showed no inhibition of CYP17 and CYP19.
SE|25462268||ab|4|entity|C0205393|Most|qnco|||most|||0|818|773|777
SE|25462268||ab|4|entity|C0237399|Potential|qlco|||potent|||0|818|778|784
SE|25462268||ab|4|entity|C0205198|Compound|qlco|||compound|||0|818|785|793
SE|25462268||ab|4|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|795|799
SE|25462268||ab|4|entity|C1042496|Meta|invt|||meta|||0|763|828|832
SE|25462268||ab|4|entity|C1527240|Derivative|ftcn|||derivative|||0|763|850|860
SE|25462268||ab|4|entity|C0038296|Steroid 11-beta-Monooxygenase|aapp,enzy|1584|CYP11B1|CYP11B1|||0|1000|915|922
SE|25462268||ab|4|entity|C0038302|Steroid 17-alpha-monooxygenase|aapp,enzy|1586|CYP17A1|CYP17|||0|1000|963|968
SE|25462268||ab|4|entity|C0003805|Aromatase|aapp,enzy|1588|CYP19A1|CYP19|||0|1000|973|978
SE|25462268||ab|4|relation|6|2|C0038296|Steroid 11-beta-Monooxygenase|aapp,gngm,enzy|aapp|1584|CYP11B1|CYP11B1|||0|1000|915|922|NOM|INHIBITS|negation|949|959|2|1|C0003805|Aromatase|aapp,gngm,enzy|aapp|1588|CYP19A1|CYP19|||0|1000|973|978
SE|25462268||ab|4|relation|6|2|C0038296|Steroid 11-beta-Monooxygenase|aapp,gngm,enzy|aapp|1584|CYP11B1|CYP11B1|||0|1000|915|922|NOM|INHIBITS|negation|949|959|2|1|C0038302|Steroid 17-alpha-monooxygenase|aapp,gngm,enzy|aapp|1586|CYP17A1|CYP17|||0|1000|963|968


SE|25462269||ti|1|text|21|203|From mixed sigma-2 receptor/P-glycoprotein targeting agents to selective P-glycoprotein modulators: small structural changes address the mechanism of interaction at the efflux pump.
SE|25462269||ti|1|entity|C0205430|Mixed|ftcn|||mixed|||0|829|26|31
SE|25462269||ti|1|entity|C0539267|sigma-2 receptor|aapp,rcpt|||sigma-2 receptor|||0|829|32|48
SE|25462269||ti|1|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-glycoprotein|||0|829|49|63
SE|25462269||ti|1|entity|C0450442|Agent|chvf|||agents|||0|829|74|80
SE|25462269||ti|1|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-glycoprotein|||0|694|94|108
SE|25462269||ti|1|entity|C0700321|Small|qnco|||small|||0|785|121|126
SE|25462269||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|158|167

SE|25462269||ab|1|text|209|426|Generations of modulators of the efflux pump P-glycoprotein (P-gp) have been produced as tools to counteract the Multidrug Resistance (MDR) phenomenon in tumor therapy, but clinical trials were not successful so far.
SE|25462269||ab|1|entity|C0079411|Generations|tmco|||Generations|||0|1000|209|220
SE|25462269||ab|1|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-glycoprotein|||0|861|254|268
SE|25462269||ab|1|entity|C0336791|Tool|mnob|||tools|||0|966|298|303
SE|25462269||ab|1|entity|C0242640|Multi-Drug Resistance|orga|||Multidrug Resistance|||0|734|322|342
SE|25462269||ab|1|entity|C0027651|Neoplasm|neop|||tumor|||0|888|363|368
SE|25462269||ab|1|entity|C0008976|Clinical Trials|resa|||clinical trials|||0|1000|382|397
SE|25462269||ab|1|entity|C1518422|Not|ftcn|||not|||0|888|403|406
SE|25462269||ab|1|entity|C1272703|Successful|qlco|||successful|||0|888|407|417

SE|25462269||ab|2|text|426|628|With the aim of contributing to the development of novel P-gp modulators, we started from recently studied high-affinity sigma-2 (sigma2) receptor ligands that showed also potent interaction with P-gp.
SE|25462269||ab|2|entity|C1527148|Development|ftcn|||development|||0|1000|462|473
SE|25462269||ab|2|entity|C0679622|novel|inpr|||novel|||0|623|477|482
SE|25462269||ab|2|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|623|483|487
SE|25462269||ab|2|entity|C0332185|Recent|tmco|||recently|||0|1000|516|524
SE|25462269||ab|2|entity|C0205250|High|qlco|||high|||0|750|533|537
SE|25462269||ab|2|entity|C0597358|Receptor Binding|moft|||receptor ligands|||0|983|564|580
SE|25462269||ab|2|entity|C0237399|Potential|qlco|||potent|||0|740|598|604
SE|25462269||ab|2|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|901|622|626

SE|25462269||ab|3|text|628|712|For sigma2 receptors high-affinity binding, a basic N-atom is a strict requirement.
SE|25462269||ab|3|entity|C0205250|High|qlco|||high|||0|790|649|653
SE|25462269||ab|3|entity|C0597358|Receptor Binding|moft|||receptors high-affinity binding|||0|790|639|670
SE|25462269||ab|3|entity|C0567415|Atom|elii|||atom|||0|816|682|686
SE|25462269||ab|3|entity|C1514873|Requirement|idcn|||requirement|||0|861|699|710

SE|25462269||ab|4|text|712|877|Therefore, we reduced the basic character of the N-atom present in these ligands, and we obtained potent P-gp modulators with poor or null sigma2 receptor affinity.
SE|25462269||ab|4|entity|C0567415|Atom|elii|||atom|||0|851|763|767
SE|25462269||ab|4|entity|C0150312|Present|qnco|||present|||0|851|768|775
SE|25462269||ab|4|entity|C0023688|Ligands|chem|||ligands|||0|1000|785|792
SE|25462269||ab|4|entity|C0237399|Potential|qlco|||potent|||0|590|810|816
SE|25462269||ab|4|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|590|817|821
SE|25462269||ab|4|entity|C0032854|Poverty|grpa|||poor|||0|1000|838|842
SE|25462269||ab|4|entity|C0456148|Null|qnco|||null|||0|775|846|850
SE|25462269||ab|4|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|775|858|866
SE|25462269||ab|4|relation|3|1|C0023688|Ligands|chem|chem|||ligands|||0|1000|785|792|NOM|INTERACTS_WITH||822|832|3|0|C0242643|P-Glycoprotein|aapp,gngm,bacs|aapp|||P-gp|||0|590|817|821

SE|25462269||ab|5|text|877|1045|We also evaluated whether modulation of P-gp by these novel compounds involved consumption of ATP (as P-gp substrates do), as a source of energy to support the efflux.
SE|25462269||ab|5|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|901|917|921
SE|25462269||ab|5|entity|C0679622|novel|inpr|||novel|||0|872|931|936
SE|25462269||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|872|937|946
SE|25462269||ab|5|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|1000|971|974
SE|25462269||ab|5|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|694|979|983
SE|25462269||ab|5|entity|C0424589|Vitality|fndg|||energy|||0|1000|1015|1021

SE|25462269||ab|6|text|1045|1179|Surprisingly, even small structural changes resulted in opposite behavior, with amide 13 depleting ATP, in contrast to its isomer 18.
SE|25462269||ab|6|entity|C0700321|Small|qnco|||small|||0|747|1064|1069
SE|25462269||ab|6|entity|C1521805|Opposite|spco|||opposite|||0|888|1101|1109
SE|25462269||ab|6|entity|C0004927|Behavior|inbe|||behavior|||0|888|1110|1118
SE|25462269||ab|6|entity|C0002482|Amides|orch|||amide|||0|764|1125|1130
SE|25462269||ab|6|entity|C0333668|Depletion|ftcn|||depleting|||0|764|1134|1143
SE|25462269||ab|6|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|ATP|||0|764|1144|1147
SE|25462269||ab|6|entity|C0022203|Isomerism|npop|||isomer|||0|861|1168|1174

SE|25462269||ab|7|text|1179|1312|Two compounds, 15 and 25, emerged for their potent activity at P-gp, and deserve further investigations as tools for P-gp modulation.
SE|25462269||ab|7|entity|C0205448|Two|qnco|||Two|||0|872|1179|1182
SE|25462269||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|872|1183|1192
SE|25462269||ab|7|entity|C0237399|Potential|qlco|||potent|||0|838|1223|1229
SE|25462269||ab|7|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|901|1242|1246
SE|25462269||ab|7|entity|C1517331|Further|spco|||further|||0|888|1260|1267
SE|25462269||ab|7|entity|C0336791|Tool|mnob|||tools|||0|966|1286|1291
SE|25462269||ab|7|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|694|1296|1300


SE|25462270||ti|1|text|21|141|Synthesis, molecular docking and anti-mycobacterial evaluation of new imidazo[1,2-a]pyridine-2-carboxamide derivatives.
SE|25462270||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462270||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|888|32|41
SE|25462270||ti|1|entity|C1522290|Docking|moft|||docking|||0|888|42|49
SE|25462270||ti|1|entity|C0521015|Mycobacterial|ftcn|||mycobacterial|||0|790|59|72
SE|25462270||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|790|73|83
SE|25462270||ti|1|entity|C0205314|New|tmco|||new|||0|694|87|90
SE|25462270||ti|1|entity|C0034251|pyridine|irda,orch|||pyridine|||0|791|105|113
SE|25462270||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|791|128|139

SE|25462270||ab|1|text|147|267|New anti-tubercular agents, imidazo[1,2-a]pyridine-2-carboxamide derivatives (5a-q) have been designed and synthesized.
SE|25462270||ab|1|entity|C0205314|New|tmco|||New|||0|861|147|150
SE|25462270||ab|1|entity|C0332250|Tubercular|ftcn|||tubercular|||0|861|156|166
SE|25462270||ab|1|entity|C0040616|Anti-Anxiety Agents|phsu|||anti-tubercular agents|||0|861|151|173
SE|25462270||ab|1|entity|C0034251|pyridine|irda,orch|||pyridine|||0|791|189|197
SE|25462270||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|791|212|223

SE|25462270||ab|2|text|267|430|The structural considerations of the designed molecules were further supported by the docking study with a long-chain enoyl-acyl carrier protein reductase (InhA).
SE|25462270||ab|2|entity|C0567416|Molecule|sbst|||molecules|||0|827|313|322
SE|25462270||ab|2|entity|C1517331|Further|spco|||further|||0|1000|328|335
SE|25462270||ab|2|entity|C1522290|Docking|moft|||docking|||0|888|353|360
SE|25462270||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|361|366
SE|25462270||ab|2|entity|C0205166|Long|qlco|||long|||0|802|374|378
SE|25462270||ab|2|entity|C0001369|Acyl Carrier Protein|aapp,bacs|||acyl carrier protein|||0|802|391|411
SE|25462270||ab|2|entity|C0030016|Oxidoreductase|aapp,enzy|||reductase|||0|802|412|421
SE|25462270||ab|2|entity|C1334130|INHA gene|gngm|3623|INHA|InhA|||0|1000|423|427

SE|25462270||ab|3|text|430|551|The chemical structures of the new compounds were characterized by IR, (1)H NMR, (13)C NMR, HRMS and elemental analysis.
SE|25462270||ab|3|entity|C0220807|Chemical Structure|inpr|||chemical structures|||0|983|434|453
SE|25462270||ab|3|entity|C0205314|New|tmco|||new|||0|872|461|464
SE|25462270||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|872|465|474
SE|25462270||ab|3|entity|C0024485|Magnetic Resonance Imaging|diap|||NMR|||0|888|506|509
SE|25462270||ab|3|entity|C0024485|Magnetic Resonance Imaging|diap|||NMR|||0|861|517|520
SE|25462270||ab|3|entity|C0013879|Elements|elii|||elemental|||0|853|531|540
SE|25462270||ab|3|entity|C0936012|Analysis|resa|||analysis|||0|853|541|549

SE|25462270||ab|4|text|551|637|In addition, single crystal X-ray diffraction has also been recorded for compound 5f.
SE|25462270||ab|4|entity|C0034571|roentgenographic|ftcn|||X-ray|||0|893|579|584
SE|25462270||ab|4|entity|C0206755|Crystallography, X-Ray|lbpr|||single crystal X-ray diffraction|||0|893|564|596
SE|25462270||ab|4|entity|C0205198|Compound|qlco|||compound|||0|694|624|632

SE|25462270||ab|5|text|637|758|Compounds were evaluated in vitro against Mycobacterium tuberculosis H37Rv, and cytotoxicity against HEK-293T cell line.
SE|25462270||ab|5|entity|C0205198|Compound|qlco|||Compounds|||0|966|637|646
SE|25462270||ab|5|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|662|670
SE|25462270||ab|5|entity|C1449831|Mycobacterium tuberculosis H37Rv|bact|||Mycobacterium tuberculosis H37Rv|||0|1000|679|711
SE|25462270||ab|5|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|717|729
SE|25462270||ab|5|entity|C0121258|EphA3 Receptor|aapp,enzy,rcpt|||HEK-293T|||0|824|738|746
SE|25462270||ab|5|entity|C0007600|Cell Line|cell|||cell line|||0|824|747|756

SE|25462270||ab|6|text|758|868|Amongst the tested compounds 5j, 5l and 5q were emerged as good anti-tubercular agents with low cytotoxicity.
SE|25462270||ab|6|entity|C0039593|Testing|resa|||tested|||0|590|770|776
SE|25462270||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|590|777|786
SE|25462270||ab|6|entity|C0205170|Good|qlco|||good|||0|861|817|821
SE|25462270||ab|6|entity|C0332250|Tubercular|ftcn|||tubercular|||0|861|827|837
SE|25462270||ab|6|entity|C0040616|Anti-Anxiety Agents|phsu|||anti-tubercular agents|||0|861|822|844
SE|25462270||ab|6|entity|C0205251|low|qlco|||low|||0|888|850|853
SE|25462270||ab|6|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|888|854|866

SE|25462270||ab|7|text|868|968|The structure-anti TB activity relationship of these derivatives was explained by molecular docking.
SE|25462270||ab|7|entity|C0038477|Structure-Activity Relationship|qlco|||structure-anti TB activity relationship|||0|911|872|911
SE|25462270||ab|7|entity|C0243072|derivatives|chvs|||derivatives|||0|1000|921|932
SE|25462270||ab|7|entity|C1521991|Molecular|qlco|||molecular|||0|888|950|959
SE|25462270||ab|7|entity|C1522290|Docking|moft|||docking|||0|888|960|967


SE|25462271||ti|1|text|21|133|Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.
SE|25462271||ti|1|entity|C1527148|Development|ftcn|||Development|||0|1000|21|32
SE|25462271||ti|1|entity|||gngm|9734|HDAC9|HDAC|||0|742|63|67
SE|25462271||ti|1|entity|C0243077|inhibitors|chvf|||inhibitors|||0|742|68|78
SE|25462271||ti|1|entity|C0237399|Potential|qlco|||potent|||0|851|84|90
SE|25462271||ti|1|entity|C1533691|in vitro|qlco|||in vitro|||0|851|91|99
SE|25462271||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|785|104|111
SE|25462271||ti|1|entity|C0027651|Neoplasm|neop|||tumor|||0|785|117|122

SE|25462271||ab|1|text|139|322|Inhibition of histone deacetylases (HDACs) has diverse effects on cell function, such as causing differentiation, growth arrest and apoptosis in nearly all types of tumor cell lines.
SE|25462271||ab|1|entity|C0019643|Histone Deacetylase|aapp,enzy|||histone deacetylases|||0|1000|153|173
SE|25462271||ab|1|entity|C1280500|Effect|qlco|||effects|||0|827|194|201
SE|25462271||ab|1|entity|C0007613|Cell physiology|celf|||cell function|||0|1000|205|218
SE|25462271||ab|1|entity|C0333951|Growth arrest|patf|||growth arrest|||0|1000|253|266
SE|25462271||ab|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|271|280
SE|25462271||ab|1|entity|C0332307|Type - attribute|qlco|||types|||0|1000|295|300
SE|25462271||ab|1|entity|C0085983|Cell Line, Tumor|cell|||tumor cell lines|||0|1000|304|320
SE|25462271||ab|1|relation|6|3|C0333951|Growth arrest|patf|patf|||growth arrest|||0|1000|253|266|NOM|AFFECTS||194|201|6|1|C0007613|Cell physiology|celf|celf|||cell function|||0|1000|205|218

SE|25462271||ab|2|text|322|577|In our previous work, we have designed and synthesized a novel series of 4-hydroxycinnamamide-based and 3-hydroxycinnamamide-based HDAC inhibitors (HDACIs), among which, 3-hydroxycinnamamide-based HDACIs 1a-1c exhibited moderate inhibition against HDACs.
SE|25462271||ab|2|entity|C0205156|Previous|tmco|||previous|||0|888|329|337
SE|25462271||ab|2|entity|C0043227|Work|ocac|||work|||0|888|338|342
SE|25462271||ab|2|entity|C0679622|novel|inpr|||novel|||0|888|379|384
SE|25462271||ab|2|entity|C0205549|Series|qnco|||series|||0|888|385|391
SE|25462271||ab|2|entity|||gngm|9734|HDAC9|HDAC|||0|742|453|457
SE|25462271||ab|2|entity|C0243077|inhibitors|chvf|||inhibitors|||0|742|458|468
SE|25462271||ab|2|entity|||gngm|9734|HDAC9|HDACIs|||0|544|519|525
SE|25462271||ab|2|entity|C0243077|inhibitors|chvf|||HDACIs|||0|544|519|525
SE|25462271||ab|2|entity|C0019643|Histone Deacetylase|aapp,enzy|||HDACs|||0|1000|570|575

SE|25462271||ab|3|text|577|772|In this article, we report the development of a more potent class of 3-hydroxycinnamamide-based HDACIs, compound 7o exhibited much higher pan-HDAC inhibitory activity than positive control SAHA.
SE|25462271||ab|3|entity|C1527148|Development|ftcn|||development|||0|1000|608|619
SE|25462271||ab|3|entity|C0205172|More|ftcn|||more|||0|818|625|629
SE|25462271||ab|3|entity|C0237399|Potential|qlco|||potent|||0|818|630|636
SE|25462271||ab|3|entity|C0008902|Classification|clas|||class|||0|818|637|642
SE|25462271||ab|3|entity|||gngm|9734|HDAC9|HDACIs|||0|742|673|679
SE|25462271||ab|3|entity|C0243077|inhibitors|chvf|||HDACIs|||0|742|673|679
SE|25462271||ab|3|entity|C0205198|Compound|qlco|||compound|||0|694|681|689
SE|25462271||ab|3|entity|C0205250|High|qlco|||higher|||0|728|708|714
SE|25462271||ab|3|entity|||gngm|9734|HDAC9|HDAC|||0|728|719|723
SE|25462271||ab|3|entity|C0243077|inhibitors|chvf|||inhibitory|||0|728|724|734
SE|25462271||ab|3|entity|C1446409|Positive|qlco|||positive|||0|623|749|757
SE|25462271||ab|3|entity|C0243148|control|ftcn|||control|||0|623|758|765

SE|25462271||ab|4|text|772|945|In addition, compound 7h showed excellent in vitro growth inhibitory activity against more than ten cell lines and induced U937 cells apoptosis in micromolar concentration.
SE|25462271||ab|4|entity|C0205198|Compound|qlco|||compound|||0|888|785|793
SE|25462271||ab|4|entity|C1533691|in vitro|qlco|||in vitro|||0|787|814|822
SE|25462271||ab|4|entity|C0018282|Growth Inhibitors|bacs,phsu|||growth inhibitory|||0|787|823|840
SE|25462271||ab|4|entity|C0205172|More|ftcn|||more|||0|1000|858|862
SE|25462271||ab|4|entity|C0205456|Ten|qnco|||ten|||0|901|868|871
SE|25462271||ab|4|entity|C0007600|Cell Line|cell|||cell lines|||0|901|872|882
SE|25462271||ab|4|entity|C0205263|Induced|ftcn|||induced|||0|861|887|894
SE|25462271||ab|4|entity|C0600531|U937 Cells|cell|||U937 cells|||0|861|895|905
SE|25462271||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|861|906|915
SE|25462271||ab|4|entity|C0439300|Micromole/liter|qnco|||micromolar|||0|694|919|929
SE|25462271||ab|4|relation|0|0|C0600531|U937 Cells|cell|cell|||U937 cells|||0|861|895|905|MOD/HEAD|LOCATION_OF||895|915|0|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|861|906|915
SE|25462271||ab|4|relation|4|2|C0018282|Growth Inhibitors|bacs,phsu|phsu|||growth inhibitory|||0|787|823|840|ADJ|CAUSES||887|894|4|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|861|906|915

SE|25462271||ab|5|text|945|1039|In vivo assay in U937 xenograft model identified compound 7h as a potent, orally active HDACI.
SE|25462271||ab|5|entity|C1515655|in vivo|spco|||In vivo|||0|1000|945|952
SE|25462271||ab|5|entity|C1520166|Xenograft Model|emod|||xenograft model|||0|901|967|982
SE|25462271||ab|5|entity|C0205198|Compound|qlco|||compound|||0|888|994|1002
SE|25462271||ab|5|entity|C0237399|Potential|qlco|||potent|||0|547|1011|1017
SE|25462271||ab|5|entity|C0205177|Active|ftcn|||active|||0|547|1026|1032


SE|25462272||ti|1|text|21|97|Identification of quinoline-chalcone hybrids as potential antiulcer agents.
SE|25462272||ti|1|entity|C0034423|quinoline|irda,orch|||quinoline|||0|851|39|48
SE|25462272||ti|1|entity|C0007935|Chalcone|orch|||chalcone|||0|851|49|57
SE|25462272||ti|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|851|58|65
SE|25462272||ti|1|entity|C0237399|Potential|qlco|||potential|||0|901|69|78
SE|25462272||ti|1|entity|C0003216|Anti-Ulcer Agents|phsu|||antiulcer agents|||0|901|79|95

SE|25462272||ab|1|text|103|184|Antiulcer activity of novel quinoline-chalcone hybrids (13-37) was investigated.
SE|25462272||ab|1|entity|C0679622|novel|inpr|||novel|||0|833|125|130
SE|25462272||ab|1|entity|C0034423|quinoline|irda,orch|||quinoline|||0|833|131|140
SE|25462272||ab|1|entity|C0007935|Chalcone|orch|||chalcone|||0|833|141|149
SE|25462272||ab|1|entity|C0020205|Hybrids|orgm|||hybrids|||0|833|150|157

SE|25462272||ab|2|text|184|325|Among them, eight compounds (14, 16, 17, 23, 29, 31, 32 and 35) were found to be active in various ulcer models in Sprague-Dawley (SD) rats.
SE|25462272||ab|2|entity|C0205454|Eight|qnco|||eight|||0|872|196|201
SE|25462272||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|872|202|211
SE|25462272||ab|2|entity|C0205177|Active|ftcn|||active|||0|1000|265|271
SE|25462272||ab|2|entity|C0041582|Ulcer|patf|||ulcer|||0|861|283|288
SE|25462272||ab|2|entity|C0034715|Rats, Sprague-Dawley|mamm|||Sprague-Dawley (SD) rats|||0|1000|299|323
SE|25462272||ab|2|relation|3|1|C0041582|Ulcer|patf|patf|||ulcer|||0|861|283|288|PREP|PROCESS_OF||296|298|1|1|C0034715|Rats, Sprague-Dawley|mamm|mamm|||Sprague-Dawley (SD) rats|||0|1000|299|323

SE|25462272||ab|3|text|325|471|To understand the mechanism of action of these hybrids, the effects of the compounds on antisecretory and cytoprotective activities were studied.
SE|25462272||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|343|352
SE|25462272||ab|3|entity|C0020205|Hybrids|orgm|||hybrids|||0|1000|372|379
SE|25462272||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|385|392
SE|25462272||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|966|400|409
SE|25462272||ab|3|entity|C0441655|Activities|acty|||activities|||0|861|446|456

SE|25462272||ab|4|text|471|621|All these active hybrids improved the depleted levels of mucin and consequently inhibited the formation of erosions in a pyloric ligated ulcer model.
SE|25462272||ab|4|entity|C0205177|Active|ftcn|||active|||0|888|481|487
SE|25462272||ab|4|entity|C0020205|Hybrids|orgm|||hybrids|||0|888|488|495
SE|25462272||ab|4|entity|C0333668|Depletion|ftcn|||depleted|||0|888|509|517
SE|25462272||ab|4|entity|C0441889|Levels|inpr|||levels|||0|888|518|524
SE|25462272||ab|4|entity|C0026682|Mucins|aapp,bacs|||mucin|||0|1000|528|533
SE|25462272||ab|4|entity|C1522492|Formation|ftcn|||formation|||0|1000|565|574
SE|25462272||ab|4|entity|C0333307|Superficial ulcer|acab|||erosions|||0|966|578|586
SE|25462272||ab|4|entity|C0240848|Pyloric ulcer|dsyn|||pyloric ligated ulcer|||0|824|592|613
SE|25462272||ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|824|614|619
SE|25462272||ab|4|relation|3|1|C0026682|Mucins|aapp,gngm,bacs|aapp|||mucin|||0|1000|528|533|VERB|DISRUPTS||551|560|3|2|C0333307|Superficial ulcer|acab|acab|||erosions|||0|966|578|586

SE|25462272||ab|5|text|621|728|In addition, they also significantly increased the gastric PGE2 content in an aspirin induced ulcer model.
SE|25462272||ab|5|entity|C0012472|Dinoprostone|eico,horm,phsu|||PGE2|||0|890|680|684
SE|25462272||ab|5|entity|C0038352|Stomach Contents|bdsu|||gastric PGE2 content|||0|890|672|692
SE|25462272||ab|5|entity|C0004057|Aspirin|orch,phsu|||aspirin|||0|1000|699|706
SE|25462272||ab|5|entity|C0041582|Ulcer|patf|||ulcer|||0|888|715|720
SE|25462272||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|888|721|726

SE|25462272||ab|6|text|728|985|The additional experiments including the in vitro metabolic stability and in vivo pharmacokinetics led to the identification of compound 17 as an orally active and safe candidate that is worthy of further investigation to be developed as an antiulcer agent.
SE|25462272||ab|6|entity|C1524062|Additional|ftcn|||additional|||0|888|732|742
SE|25462272||ab|6|entity|C0681814|research study|resa|||experiments|||0|888|743|754
SE|25462272||ab|6|entity|C1533691|in vitro|qlco|||in vitro|||0|861|769|777
SE|25462272||ab|6|entity|C0311400|Metabolic|ftcn|||metabolic|||0|861|778|787
SE|25462272||ab|6|entity|C1317741|STABILITY|qlco|||stability|||0|861|788|797
SE|25462272||ab|6|entity|C1515655|in vivo|spco|||in vivo|||0|901|802|809
SE|25462272||ab|6|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics|||0|901|810|826
SE|25462272||ab|6|entity|C0605315|compound 17|orch,phsu|||compound 17|||0|1000|856|867
SE|25462272||ab|6|entity|C0205177|Active|ftcn|||active|||0|861|881|887
SE|25462272||ab|6|entity|C1517331|Further|spco|||further|||0|888|925|932
SE|25462272||ab|6|entity|C0003216|Anti-Ulcer Agents|phsu|||antiulcer agent|||0|983|969|984


SE|25462273||ti|1|text|21|134|Synthesis of 2,3-di- and 2,2,3-trisubstituted-3-methoxycarbonyl-gamma-butyrolactones as potent antitumor agents.
SE|25462273||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462273||ti|1|entity|C0000481|4-Butyrolactone|bacs,irda,orch,phsu|||gamma-butyrolactones|||0|794|85|105
SE|25462273||ti|1|entity|C0237399|Potential|qlco|||potent|||0|856|109|115
SE|25462273||ti|1|entity|C1328831|antitumor agent|phsu|||antitumor agents|||0|856|116|132

SE|25462273||ab|1|text|140|296|Various 2,3-substituted gamma-butyrolactones have been synthesized by three-component reaction of aryl bromides, dimethyl itaconate and carbonyl compounds.
SE|25462273||ab|1|entity|C0000481|4-Butyrolactone|bacs,irda,orch,phsu|||gamma-butyrolactones|||0|813|164|184
SE|25462273||ab|1|entity|C0205449|Three|qnco|||three|||0|851|210|215
SE|25462273||ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|216|225
SE|25462273||ab|1|entity|C0443286|Reaction|ftcn|||reaction|||0|851|226|234
SE|25462273||ab|1|entity|C0006222|Bromides|inch|||bromides|||0|861|243|251
SE|25462273||ab|1|entity|C0124235|itaconate|orch|||itaconate|||0|861|262|271
SE|25462273||ab|1|entity|C0596258|carbonyl compound|orch|||carbonyl compounds|||0|983|276|294
SE|25462273||ab|1|relation|1|1|C0000481|4-Butyrolactone|bacs,irda,orch,phsu|bacs|||gamma-butyrolactones|||0|813|164|184|VERB|INTERACTS_WITH||195|206|4|2|C0006222|Bromides|inch|inch|||bromides|||0|861|243|251
SE|25462273||ab|1|relation|1|1|C0000481|4-Butyrolactone|bacs,irda,orch,phsu|bacs|||gamma-butyrolactones|||0|813|164|184|VERB|INTERACTS_WITH||195|206|4|2|C0124235|itaconate|orch|orch|||itaconate|||0|861|262|271
SE|25462273||ab|1|relation|1|1|C0000481|4-Butyrolactone|bacs,irda,orch,phsu|bacs|||gamma-butyrolactones|||0|813|164|184|VERB|INTERACTS_WITH||195|206|4|2|C0596258|carbonyl compound|orch|orch|||carbonyl compounds|||0|983|276|294

SE|25462273||ab|2|text|296|468|The in vitro cytotoxic activity of these products was evaluated against a representative panel of cancer cell lines (KB, HCT116, MCF7, MCF7R, PC3, SK-OV3, HL60 and HL60R).
SE|25462273||ab|2|entity|C1533691|in vitro|qlco|||in vitro|||0|861|300|308
SE|25462273||ab|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|861|309|318
SE|25462273||ab|2|entity|C1514468|product|qnco|||products|||0|966|337|345
SE|25462273||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|901|394|400
SE|25462273||ab|2|entity|C0007600|Cell Line|cell|||cell lines|||0|901|401|411
SE|25462273||ab|2|entity|C0596890|MCF7|cell|||MCF7|||0|1000|425|429
SE|25462273||ab|2|entity|C0135615|Proprotein Convertase 1|aapp,enzy|3853,5122,7832,10120,57332|KRT6A,PCSK1,BTG2,ACTR1B,CBX8|PC3|||0|1000|438|441
SE|25462273||ab|2|entity|C1512310|HL60|cell|||HL60|||0|1000|451|455

SE|25462273||ab|3|text|468|569|One compound (4x) displays a good anti-proliferative activity with IC50 in the sub-micromolar range.
SE|25462273||ab|3|entity|C0205447|One|qnco|||One|||0|888|468|471
SE|25462273||ab|3|entity|C0205198|Compound|qlco|||compound|||0|888|472|480
SE|25462273||ab|3|entity|C0205170|Good|qlco|||good|||0|775|497|501
SE|25462273||ab|3|entity|C0334094|Proliferation|ftcn|||proliferative|||0|775|507|520
SE|25462273||ab|3|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|535|539
SE|25462273||ab|3|entity|C0542339|Inferior|spco|||sub|||0|851|547|550
SE|25462273||ab|3|entity|C0439300|Micromole/liter|qnco|||micromolar|||0|851|551|561
SE|25462273||ab|3|entity|C1514721|Range|qnco|||range|||0|851|562|567

SE|25462273||ab|4|text|569|636|The mechanism of action has been investigated using flow cytometry.
SE|25462273||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|573|582
SE|25462273||ab|4|entity|C0016263|Flow Cytometry|lbpr|||flow cytometry|||0|1000|621|635


SE|25462274||ti|1|text|21|119|Benzimidazole--ibuprofen/mesalamine conjugates: potential candidates for multifactorial diseases.
SE|25462274||ti|1|entity|C0005050|Benzimidazoles|orch|||Benzimidazole|||0|1000|21|34
SE|25462274||ti|1|entity|C0020740|Ibuprofen|orch,phsu|||ibuprofen|||0|623|36|45
SE|25462274||ti|1|entity|C0127615|mesalamine|aapp,phsu|||mesalamine|||0|623|46|56
SE|25462274||ti|1|entity|C0237399|Potential|qlco|||potential|||0|694|69|78
SE|25462274||ti|1|entity|C0012634|Disease|dsyn|||diseases|||0|861|109|117

SE|25462274||ab|1|text|125|305|Ibuprofen (IB) and mesalamine (MES) are commonly used NSAIDs whereas benzimidazole (BZ) and 2-aminobenzimidazole (ABZ) are important pharmacophore for immunomodulatory activities.
SE|25462274||ab|1|entity|C0020740|Ibuprofen|orch,phsu|||Ibuprofen|||0|1000|125|134
SE|25462274||ab|1|entity|C0127615|mesalamine|aapp,phsu|||mesalamine|||0|1000|144|154
SE|25462274||ab|1|entity|C0042153|utilization qualifier|ftcn|||used|||0|754|174|178
SE|25462274||ab|1|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAIDs|||0|754|179|185
SE|25462274||ab|1|entity|C0005050|Benzimidazoles|orch|||benzimidazole|||0|1000|194|207
SE|25462274||ab|1|entity|C0092556|2-aminobenzimidazole|orch,phsu|||2-aminobenzimidazole|||0|1000|217|237
SE|25462274||ab|1|entity|C0599740|pharmacophore|rcpt|||pharmacophore|||0|861|258|271
SE|25462274||ab|1|entity|C0005525|Biological Response Modifiers|phsu|||immunomodulatory|||0|853|276|292
SE|25462274||ab|1|entity|C0441655|Activities|acty|||activities|||0|853|293|303
SE|25462274||ab|1|relation|0|0|C0020740|Ibuprofen|orch,phsu|orch|||Ibuprofen|||0|1000|125|134|SPEC|ISA||125|185|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs|||0|754|179|185
SE|25462274||ab|1|relation|0|0|C0127615|mesalamine|aapp,gngm,phsu|aapp|||mesalamine|||0|1000|144|154|SPEC|ISA||125|185|0|0|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|phsu|||NSAIDs|||0|754|179|185
SE|25462274||ab|1|relation|5|1|C0005050|Benzimidazoles|orch|orch|||benzimidazole|||0|1000|194|207|ADJ|INTERACTS_WITH||248|257|1|1|C0005525|Biological Response Modifiers|phsu|phsu|||immunomodulatory|||0|853|276|292
SE|25462274||ab|1|relation|5|1|C0092556|2-aminobenzimidazole|orch,phsu|orch|||2-aminobenzimidazole|||0|1000|217|237|ADJ|INTERACTS_WITH||248|257|1|1|C0005525|Biological Response Modifiers|phsu|phsu|||immunomodulatory|||0|853|276|292

SE|25462274||ab|2|text|305|588|In the present study, IB and MES were coupled with variedly substituted BZ or ABZ nucleus to synthesize IB-BZ (2a-2e), IB-ABZ (3a-3e), MES-BZ (4a-4e) and MES-ABZ (5a-5e) chimeric conjugates as novel compounds that could elicit both anti-inflammatory and immunomodulatory activities.
SE|25462274||ab|2|entity|C0150312|Present|qnco|||present|||0|888|312|319
SE|25462274||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|320|325
SE|25462274||ab|2|entity|C0020740|Ibuprofen|orch,phsu|||IB|||0|1000|327|329
SE|25462274||ab|2|entity|C0127615|mesalamine|aapp,phsu|||MES|||0|1000|334|337
SE|25462274||ab|2|entity|C0005050|Benzimidazoles|orch|||BZ|||0|827|377|379
SE|25462274||ab|2|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|861|387|394
SE|25462274||ab|2|entity|C0020740|Ibuprofen|orch,phsu|||IB|||0|888|409|411
SE|25462274||ab|2|entity|C0005050|Benzimidazoles|orch|||BZ|||0|888|412|414
SE|25462274||ab|2|entity|C0020740|Ibuprofen|orch,phsu|||IB|||0|694|424|426
SE|25462274||ab|2|entity|C0127615|mesalamine|aapp,phsu|||MES|||0|888|440|443
SE|25462274||ab|2|entity|C0005050|Benzimidazoles|orch|||BZ|||0|888|444|446
SE|25462274||ab|2|entity|C0127615|mesalamine|aapp,phsu|||MES|||0|694|459|462
SE|25462274||ab|2|entity|C0333678|Chimerism|orga|||chimeric|||0|623|475|483
SE|25462274||ab|2|entity|C0679622|novel|inpr|||novel|||0|872|498|503
SE|25462274||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|872|504|513
SE|25462274||ab|2|entity|C1515999|Anti-inflammatory|qlco|||anti-inflammatory|||0|1000|537|554
SE|25462274||ab|2|entity|C0005525|Biological Response Modifiers|phsu|||immunomodulatory|||0|853|559|575
SE|25462274||ab|2|entity|C0441655|Activities|acty|||activities|||0|853|576|586
SE|25462274||ab|2|relation|3|1|C0020740|Ibuprofen|orch,phsu|phsu|||IB|||0|1000|327|329|VERB|COEXISTS_WITH||343|350|14|1|C0005050|Benzimidazoles|orch|orch|||BZ|||0|827|377|379
SE|25462274||ab|2|relation|3|1|C0127615|mesalamine|aapp,gngm,phsu|aapp|||MES|||0|1000|334|337|VERB|COEXISTS_WITH||343|350|14|1|C0005050|Benzimidazoles|orch|orch|||BZ|||0|827|377|379
SE|25462274||ab|2|relation|5|1|C0007610|Cell Nucleus|celc|celc|||nucleus|||0|861|387|394|VERB|PRODUCES||398|408|12|1|C0005050|Benzimidazoles|orch|orch|||BZ|||0|888|412|414

SE|25462274||ab|3|text|588|663|Each compound retained the anti-inflammatory activity of the parent NSAID.
SE|25462274||ab|3|entity|C0205198|Compound|qlco|||compound|||0|1000|593|601
SE|25462274||ab|3|entity|C1515999|Anti-inflammatory|qlco|||anti-inflammatory|||0|901|615|632
SE|25462274||ab|3|entity|C0030551|parent|famg|||parent|||0|888|649|655
SE|25462274||ab|3|entity|C0003211|Anti-Inflammatory Agents, Non-Steroidal|phsu|||NSAID|||0|888|656|661

SE|25462274||ab|4|text|663|781|The BZ conjugates (2 and 4) were found immunostimulatory whereas the ABZ conjugates (3 and 5) were immunosuppressive.
SE|25462274||ab|4|entity|C0005050|Benzimidazoles|orch|||BZ|||0|694|667|669

SE|25462274||ab|5|text|781|897|Each compound also exhibited good antioxidant activity, which is attributed to the electron rich BZ and ABZ nuclei.
SE|25462274||ab|5|entity|C0205198|Compound|qlco|||compound|||0|1000|786|794
SE|25462274||ab|5|entity|C0205170|Good|qlco|||good|||0|901|810|814
SE|25462274||ab|5|entity|C1148564|antioxidant activity|moft|||antioxidant activity|||0|901|815|835
SE|25462274||ab|5|entity|C0013852|Electrons|qnco|||electron|||0|851|864|872
SE|25462274||ab|5|entity|C0699759|Wealthy|qlco|||rich|||0|851|873|877
SE|25462274||ab|5|entity|C0005050|Benzimidazoles|orch|||BZ|||0|851|878|880
SE|25462274||ab|5|entity|C0007610|Cell Nucleus|celc|||nuclei|||0|827|889|895

SE|25462274||ab|6|text|897|1010|Compound 2a, 2e, 3a, 3e and 5b exhibited the most significant anti-inflammatory and immunomodulatory activities.
SE|25462274||ab|6|entity|C0205198|Compound|qlco|||Compound|||0|888|897|905
SE|25462274||ab|6|entity|C1299394|Most significant|qlco|||most significant|||0|888|942|958
SE|25462274||ab|6|entity|C1515999|Anti-inflammatory|qlco|||anti-inflammatory|||0|888|959|976
SE|25462274||ab|6|entity|C0005525|Biological Response Modifiers|phsu|||immunomodulatory|||0|853|981|997
SE|25462274||ab|6|entity|C0441655|Activities|acty|||activities|||0|853|998|1008

SE|25462274||ab|7|text|1010|1080|Hence, these were evaluated for in vivo acute gastric ulcerogenicity.
SE|25462274||ab|7|entity|C1515655|in vivo|spco|||in vivo|||0|832|1042|1049
SE|25462274||ab|7|entity|C0205178|acute|tmco|||acute|||0|832|1050|1055
SE|25462274||ab|7|entity|C0038358|Gastric ulcer|anab,dsyn|||gastric ulcerogenicity|||0|832|1056|1078

SE|25462274||ab|8|text|1080|1219|The compounds were safe to gastric mucosa, probably due to masking of the free -COOH group of IB and MES, and/or to the BZ nucleus itself.
SE|25462274||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|966|1084|1093
SE|25462274||ab|8|entity|C0017136|Gastric mucosa|tisu|||gastric mucosa|||0|1000|1107|1121
SE|25462274||ab|8|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|1123|1131
SE|25462274||ab|8|entity|C0441833|Groups|inpr|||group|||0|827|1165|1170
SE|25462274||ab|8|entity|C0020740|Ibuprofen|orch,phsu|||IB|||0|1000|1174|1176
SE|25462274||ab|8|entity|C0127615|mesalamine|aapp,phsu|||MES|||0|1000|1181|1184
SE|25462274||ab|8|entity|C0005050|Benzimidazoles|orch|||BZ|||0|888|1200|1202
SE|25462274||ab|8|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|888|1203|1210

SE|25462274||ab|9|text|1219|1308|A benzoyl group at 5-position of BZ and ABZ incurred maximum immunostimulatory activity.
SE|25462274||ab|9|entity|C0441833|Groups|inpr|||group|||0|861|1229|1234
SE|25462274||ab|9|entity|C0733755|Positioning Attribute|spco|||position|||0|888|1240|1248
SE|25462274||ab|9|entity|C0005050|Benzimidazoles|orch|||BZ|||0|1000|1252|1254
SE|25462274||ab|9|entity|C0806909|Maximum|fndg|||maximum|||0|802|1272|1279

SE|25462274||ab|10|text|1308|1381|In contrast, a -NO2 group incurred the maximum immunosuppressive action.
SE|25462274||ab|10|entity|C0441833|Groups|inpr|||group|||0|861|1328|1333
SE|25462274||ab|10|entity|C0806909|Maximum|fndg|||maximum|||0|660|1347|1354

SE|25462274||ab|11|text|1381|1509|Docking analysis revealed the compounds to be more selective towards COX-2 enzyme, which support the gastroprotective activity.
SE|25462274||ab|11|entity|C1522290|Docking|moft|||Docking|||0|888|1381|1388
SE|25462274||ab|11|entity|C0936012|Analysis|resa|||analysis|||0|888|1389|1397
SE|25462274||ab|11|entity|C0205198|Compound|qlco|||compounds|||0|966|1411|1420
SE|25462274||ab|11|entity|C0205172|More|ftcn|||more|||0|694|1427|1431
SE|25462274||ab|11|entity|C1367485|PTGS2 gene|gngm|5743|PTGS2|COX-2|||0|888|1450|1455
SE|25462274||ab|11|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|1456|1462

SE|25462274||ab|12|text|1509|1700|These results suggest that the compounds can be taken as lead for development of new drugs for the treatment of immune related inflammatory disorders, such as cancer and rheumatoid arthritis.
SE|25462274||ab|12|entity|C1274040|result|ftcn|||results|||0|966|1515|1522
SE|25462274||ab|12|entity|C0205198|Compound|qlco|||compounds|||0|966|1540|1549
SE|25462274||ab|12|entity|C1527148|Development|ftcn|||development|||0|1000|1575|1586
SE|25462274||ab|12|entity|C0205314|New|tmco|||new|||0|888|1590|1593
SE|25462274||ab|12|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|1594|1599
SE|25462274||ab|12|entity|C1522149|Related|ftcn|||related|||0|861|1628|1635
SE|25462274||ab|12|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|861|1636|1648
SE|25462274||ab|12|entity|C0021053|Immune System Diseases|dsyn|||immune related inflammatory disorders|||0|861|1621|1658
SE|25462274||ab|12|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|1668|1674
SE|25462274||ab|12|entity|C0003873|Rheumatoid Arthritis|dsyn|||rheumatoid arthritis|||0|1000|1679|1699


SE|25462275||ti|1|text|21|165|Prospects of an alternative treatment against Trypanosoma cruzi based on abietic acid derivatives show promising results in Balb/c mouse model.
SE|25462275||ti|1|entity|C0023981|Longitudinal Studies|qnco,resa|||Prospects|||0|916|21|30
SE|25462275||ti|1|entity|C1523987|Alternative|cnce|||alternative|||0|888|37|48
SE|25462275||ti|1|entity|C0041221|Trypanosoma cruzi|invt|||Trypanosoma cruzi|||0|1000|67|84
SE|25462275||ti|1|entity|C0050365|abietic acid|orch,phsu|||abietic acid|||0|901|94|106
SE|25462275||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|901|107|118
SE|25462275||ti|1|entity|C1555307|promise|idcn|||promising|||0|855|124|133
SE|25462275||ti|1|entity|C1274040|result|ftcn|||results|||0|855|134|141
SE|25462275||ti|1|entity|C0025919|Mice, Inbred BALB C|mamm|||Balb/c mouse|||0|916|145|157
SE|25462275||ti|1|entity|C0026336|Study models|inpr,resd|||model|||0|916|158|163

SE|25462275||ab|1|text|171|303|Chagas disease, caused by the protozoa parasite Trypanosoma cruzi, is an example of extended parasitaemia with unmet medical needs.
SE|25462275||ab|1|entity|C0041234|Chagas Disease|dsyn|||Chagas disease|||0|1000|171|185
SE|25462275||ab|1|entity|C0033739|Protozoa|invt|||protozoa|||0|861|201|209
SE|25462275||ab|1|entity|C0030498|Parasites|invt|||parasite|||0|861|210|218
SE|25462275||ab|1|entity|C0041221|Trypanosoma cruzi|invt|||Trypanosoma cruzi|||0|861|219|236
SE|25462275||ab|1|entity|C0231449|Extended|spco|||extended|||0|888|255|263
SE|25462275||ab|1|entity|C0242723|Parasitemia|dsyn|||parasitaemia|||0|888|264|276
SE|25462275||ab|1|entity|C0205476|Medical|ftcn|||medical|||0|790|288|295
SE|25462275||ab|1|entity|C0027552|Needs|qlco|||needs|||0|790|296|301
SE|25462275||ab|1|relation|0|0|C0041221|Trypanosoma cruzi|invt|invt|||Trypanosoma cruzi|||0|861|219|236|MOD/HEAD|ISA||210|236|0|0|C0030498|Parasites|invt|invt|||parasite|||0|861|210|218
SE|25462275||ab|1|relation|4|1|C0041221|Trypanosoma cruzi|invt|invt|||Trypanosoma cruzi|||0|861|219|236|VERB|CAUSES||187|193|1|1|C0041234|Chagas Disease|dsyn|dsyn|||Chagas disease|||0|1000|171|185

SE|25462275||ab|2|text|303|487|Current treatments based on old-featured benznidazole (Bz) and nifurtimox are expensive and do not fulfil the criteria of effectiveness, and a lack of toxicity devoid to modern drugs.
SE|25462275||ab|2|entity|C0521116|Current|tmco|||Current|||0|888|303|310
SE|25462275||ab|2|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|888|311|321
SE|25462275||ab|2|entity|C0580836|Old|tmco|||old|||0|802|331|334
SE|25462275||ab|2|entity|C0053230|benzonidazole|orch,phsu|||benznidazole|||0|802|344|356
SE|25462275||ab|2|entity|C0028073|Nifurtimox|orch,phsu|||nifurtimox|||0|1000|366|376
SE|25462275||ab|2|entity|C0680864|expense|qnco|||expensive|||0|928|381|390
SE|25462275||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|398|401
SE|25462275||ab|2|entity|C0243161|criteria|inpr|||criteria|||0|1000|413|421
SE|25462275||ab|2|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|425|438
SE|25462275||ab|2|entity|C0332268|Lacking|qlco|||lack|||0|1000|446|450
SE|25462275||ab|2|entity|C0600688|Toxic effect|inpo|||toxicity|||0|1000|454|462
SE|25462275||ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|861|480|485

SE|25462275||ab|3|text|487|654|In this work, a group of abietic acid derivatives that are chemically stable and well characterised were introduced as candidates for the treatment of Chagas disease.
SE|25462275||ab|3|entity|C0043227|Work|ocac|||work|||0|1000|495|499
SE|25462275||ab|3|entity|C0441833|Groups|inpr|||group|||0|1000|503|508
SE|25462275||ab|3|entity|C0050365|abietic acid|orch,phsu|||abietic acid|||0|901|512|524
SE|25462275||ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|901|525|536
SE|25462275||ab|3|entity|C0205170|Good|qlco|||well|||0|1000|568|572
SE|25462275||ab|3|entity|C0041234|Chagas Disease|dsyn|||Chagas disease|||0|1000|638|652
SE|25462275||ab|3|relation|5|3|C0050365|abietic acid|orch,phsu|phsu|||abietic acid|||0|901|512|524|NOM|TREATS||625|634|1|1|C0041234|Chagas Disease|dsyn|dsyn|||Chagas disease|||0|1000|638|652

SE|25462275||ab|4|text|654|752|In vitro and in vivo assays were performed in order to test the effectiveness of these compounds.
SE|25462275||ab|4|entity|C1533691|in vitro|qlco|||In vitro|||0|1000|654|662
SE|25462275||ab|4|entity|C1515655|in vivo|spco|||in vivo|||0|884|667|674
SE|25462275||ab|4|entity|C1510438|Assay|lbpr|||assays|||0|884|675|681
SE|25462275||ab|4|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|718|731
SE|25462275||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|741|750

SE|25462275||ab|5|text|752|883|Finally, those which showed the best activity underwent additional studies in order to elucidate the possible mechanism of action.
SE|25462275||ab|5|entity|C1524062|Additional|ftcn|||additional|||0|872|808|818
SE|25462275||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|872|819|826
SE|25462275||ab|5|entity|C0332149|Possible|qlco|||possible|||0|888|853|861
SE|25462275||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|862|871

SE|25462275||ab|6|text|883|1058|In vitro results indicated that some compounds have low toxicity (i.e. >150 MUM, against Vero cell) combined with high efficacy (i.e. <20 MUM) against some forms of T. cruzi.
SE|25462275||ab|6|entity|C1533691|in vitro|qlco|||In vitro|||0|884|883|891
SE|25462275||ab|6|entity|C1274040|result|ftcn|||results|||0|884|892|899
SE|25462275||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|920|929
SE|25462275||ab|6|entity|C0205251|low|qlco|||low|||0|888|935|938
SE|25462275||ab|6|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|939|947
SE|25462275||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|959|962
SE|25462275||ab|6|entity|C0042542|Vero Cells|cell|||Vero cell|||0|1000|972|981
SE|25462275||ab|6|entity|C0205250|High|qlco|||high|||0|694|997|1001
SE|25462275||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|1021|1024
SE|25462275||ab|6|entity|C0041234|Chagas Disease|dsyn|||T. cruzi|||0|1000|1048|1056

SE|25462275||ab|7|text|1058|1158|Further in vivo studies on mice models confirmed the expectations of improvements in infected mice.
SE|25462275||ab|7|entity|C1517331|Further|spco|||Further|||0|850|1058|1065
SE|25462275||ab|7|entity|C1515655|in vivo|spco|||in vivo|||0|850|1066|1073
SE|25462275||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|850|1074|1081
SE|25462275||ab|7|entity|C0026809|Mus|mamm|||mice|||0|1000|1085|1089
SE|25462275||ab|7|entity|C0679138|Expectation|menp|||expectations|||0|1000|1111|1123
SE|25462275||ab|7|entity|C0439663|Infected|ftcn|||infected|||0|888|1143|1151
SE|25462275||ab|7|entity|C0026809|Mus|mamm|||mice|||0|888|1152|1156
SE|25462275||ab|7|relation|4|2|C0679138|Expectation|menp|menp|||expectations|||0|1000|1111|1123|PREP|PROCESS_OF||1140|1142|1|1|C0026809|Mus|mamm|mamm|||mice|||0|888|1152|1156

SE|25462275||ab|8|text|1158|1411|In vivo tests on the acute phase gave parasitaemia inhibition values higher those of Bz, and a remarkable decrease in the reactivation of parasitaemia was found in the chronic phase after immunosuppression of the mice treated with one of the compounds.
SE|25462275||ab|8|entity|C1515655|in vivo|spco|||In vivo|||0|901|1158|1165
SE|25462275||ab|8|entity|C0392366|Tests|inpr|||tests|||0|901|1166|1171
SE|25462275||ab|8|entity|C0439557|Acute phase|tmco|||acute phase|||0|1000|1179|1190
SE|25462275||ab|8|entity|C0242723|Parasitemia|dsyn|||parasitaemia|||0|851|1196|1208
SE|25462275||ab|8|entity|C0042295|Values|qlco|||values|||0|851|1220|1226
SE|25462275||ab|8|entity|C0205250|High|qlco|||higher|||0|966|1227|1233
SE|25462275||ab|8|entity|C0053230|benzonidazole|orch,phsu|||Bz|||0|1000|1243|1245
SE|25462275||ab|8|entity|C1550002|Remark|idcn|||remarkable|||0|853|1253|1263
SE|25462275||ab|8|entity|C0547047|Decrease|qnco|||decrease|||0|853|1264|1272
SE|25462275||ab|8|entity|C0242723|Parasitemia|dsyn|||parasitaemia|||0|1000|1296|1308
SE|25462275||ab|8|entity|C0457343|Chronic phase|tmco|||chronic phase|||0|1000|1326|1339
SE|25462275||ab|8|entity|C0026809|Mus|mamm|||mice|||0|1000|1371|1375
SE|25462275||ab|8|entity|C0205447|One|qnco|||one|||0|1000|1389|1392
SE|25462275||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|966|1400|1409

SE|25462275||ab|9|text|1411|1585|The morphological alterations found in treated parasites with our derivatives confirmed extensive damage; energetic metabolism disturbances were also registered by (1)H NMR.
SE|25462275||ab|9|entity|C1260954|Morphologically altered structure|anab|||morphological alterations|||0|933|1415|1440
SE|25462275||ab|9|entity|C1292734|Treats|clas|||treated|||0|872|1450|1457
SE|25462275||ab|9|entity|C0030498|Parasites|invt|||parasites|||0|872|1458|1467
SE|25462275||ab|9|entity|C0243072|derivatives|chvs|||derivatives|||0|1000|1477|1488
SE|25462275||ab|9|entity|C0205231|Extensive|qlco|||extensive|||0|694|1499|1508
SE|25462275||ab|9|entity|C0746556|METABOLIC DISTURBANCE|dsyn|||metabolism disturbances|||0|848|1527|1550
SE|25462275||ab|9|entity|C0024485|Magnetic Resonance Imaging|diap|||NMR|||0|888|1580|1583
SE|25462275||ab|9|relation|4|1|C0243072|derivatives|chvs|chvs|||derivatives|||0|1000|1477|1488|ADJ|TREATS||1450|1457|1|1|C1260954|Morphologically altered structure|anab|anab|||morphological alterations|||0|933|1415|1440

SE|25462275||ab|10|text|1585|1838|The demonstrated in vivo activity and low toxicity, together with the use of affordable starting products and the lack of synthetic complexity, put these abietic acid derivatives in a remarkable position toward the development of an anti-Chagasic agent.
SE|25462275||ab|10|entity|C1515655|in vivo|spco|||in vivo|||0|824|1602|1609
SE|25462275||ab|10|entity|C0205251|low|qlco|||low|||0|888|1623|1626
SE|25462275||ab|10|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|1627|1635
SE|25462275||ab|10|entity|C0814630|economic availability or accessibility|qnco|||affordable|||0|805|1662|1672
SE|25462275||ab|10|entity|C1272689|Started|qlco|||starting|||0|805|1673|1681
SE|25462275||ab|10|entity|C1514468|product|qnco|||products|||0|805|1682|1690
SE|25462275||ab|10|entity|C0332268|Lacking|qlco|||lack|||0|1000|1699|1703
SE|25462275||ab|10|entity|C0439855|Complex|qlco|||complexity|||0|789|1717|1727
SE|25462275||ab|10|entity|C0050365|abietic acid|orch,phsu|||abietic acid|||0|901|1739|1751
SE|25462275||ab|10|entity|C0243072|derivatives|chvs|||derivatives|||0|901|1752|1763
SE|25462275||ab|10|entity|C1550002|Remark|idcn|||remarkable|||0|853|1769|1779
SE|25462275||ab|10|entity|C0733755|Positioning Attribute|spco|||position|||0|853|1780|1788
SE|25462275||ab|10|entity|C1527148|Development|ftcn|||development|||0|1000|1800|1811
SE|25462275||ab|10|entity|C0040616|Anti-Anxiety Agents|phsu|||anti-Chagasic agent|||0|896|1818|1837


SE|25462276||ti|1|text|21|202|Deconstruction of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety to separate P-glycoprotein (P-gp) activity from sigma2 receptor affinity in mixed P-gp/sigma2 receptor agents.
SE|25462276||ti|1|entity|C0259969|Tetrahydroisoquinolines|orch,phsu|||tetrahydroisoquinoline|||0|660|61|83
SE|25462276||ti|1|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-glycoprotein|||0|901|103|117
SE|25462276||ti|1|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|790|146|154
SE|25462276||ti|1|entity|C0205430|Mixed|ftcn|||mixed|||0|762|167|172
SE|25462276||ti|1|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|762|173|177
SE|25462276||ti|1|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|762|185|193
SE|25462276||ti|1|entity|C0450442|Agent|chvf|||agents|||0|762|194|200

SE|25462276||ab|1|text|208|356|6,7-Dimethoxytetrahydroisoquinoline is widely used as basic moiety in sigma2 receptor ligands, in order to provide sigma2versus sigma1 selectivity.
SE|25462276||ab|1|entity|C0597358|Receptor Binding|moft|||receptor ligands|||0|884|285|301

SE|25462276||ab|2|text|356|503|This same moiety is also widely exploited in modulators of P-glycoprotein (P-gp) efflux pump, so that mixed sigma2/P-gp agents are often obtained.
SE|25462276||ab|2|entity|C0445247|Same|qlco|||same|||0|694|361|365
SE|25462276||ab|2|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-glycoprotein|||0|1000|415|429
SE|25462276||ab|2|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|1000|431|435
SE|25462276||ab|2|entity|C0205430|Mixed|ftcn|||mixed|||0|786|458|463
SE|25462276||ab|2|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|786|471|475
SE|25462276||ab|2|entity|C0450442|Agent|chvf|||agents|||0|786|476|482
SE|25462276||ab|2|entity|C0332183|Frequent|tmco|||often|||0|1000|487|492

SE|25462276||ab|3|text|503|773|Deconstruction of 6,7-dimethoxytetrahydroisoquinoline moiety present in the potent mixed sigma2/P-gp agent 6,7-dimethoxy-2-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]-1,2,3,4-tetrahydroisoquinoline (1) could lead to the separation of sigma2 affinity from P-gp activity.
SE|25462276||ab|3|entity|C0150312|Present|qnco|||present|||0|812|564|571
SE|25462276||ab|3|entity|C0237399|Potential|qlco|||potent|||0|739|579|585
SE|25462276||ab|3|entity|C0205430|Mixed|ftcn|||mixed|||0|739|586|591
SE|25462276||ab|3|entity|C0017968|Glycoproteins|aapp,carb|||P-gp|||0|739|599|603
SE|25462276||ab|3|entity|C0450442|Agent|chvf|||agent|||0|739|604|609
SE|25462276||ab|3|entity|C0072521|PS-6|orch,phsu|||P-gp agent 6|||0|739|599|611
SE|25462276||ab|3|entity|C0259969|Tetrahydroisoquinolines|orch,phsu|||tetrahydroisoquinoline|||0|861|678|700
SE|25462276||ab|3|entity|C0036679|Diastasis|patf|||separation|||0|1000|723|733
SE|25462276||ab|3|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|901|758|762
SE|25462276||ab|3|relation|6|1|C0259969|Tetrahydroisoquinolines|orch,phsu|orch|||tetrahydroisoquinoline|||0|861|678|700|VERB|CAUSES||711|715|3|1|C0036679|Diastasis|patf|patf|||separation|||0|1000|723|733

SE|25462276||ab|4|text|773|851|Therefore, phenethylamino-, benzylamino- and indanamine series were obtained.
SE|25462276||ab|4|entity|C0205549|Series|qnco|||series|||0|861|829|835

SE|25462276||ab|5|text|851|1010|The NH group was also methylated in the N-phenethylamino series, and ethylated in the benzylamino series, to better match 6,7-dimethoxytetrahydroisoquinoline.
SE|25462276||ab|5|entity|C0441833|Groups|inpr|||group|||0|888|858|863
SE|25462276||ab|5|entity|C0205549|Series|qnco|||series|||0|802|908|914
SE|25462276||ab|5|entity|C0205549|Series|qnco|||series|||0|861|949|955
SE|25462276||ab|5|entity|C0332272|Better|qlco|||better|||0|1000|960|966

SE|25462276||ab|6|text|1010|1180|The sigma2 affinity drastically decreased with the increase of conformational freedom, whereas alkylation of the NH-group was beneficial for sigma2 receptor interaction.
SE|25462276||ab|6|entity|C0442805|Increase|ftcn|||increase|||0|1000|1061|1069
SE|25462276||ab|6|entity|C0016694|Freedom|idcn|||freedom|||0|861|1088|1095
SE|25462276||ab|6|entity|C0002074|Alkylation|npop|||alkylation|||0|1000|1105|1115
SE|25462276||ab|6|entity|C0441833|Groups|inpr|||group|||0|888|1126|1131
SE|25462276||ab|6|entity|C1372999|Receptor Interactions|moft|||receptor interaction|||0|884|1158|1178

SE|25462276||ab|7|text|1180|1354|By contrast, deconstruction of 6,7-dimethoxytetrahydroisoquinoline slightly reduced P-gp activity, with dimethoxy-substituted derivatives displaying potent P-gp interaction.
SE|25462276||ab|7|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|753|1247|1255
SE|25462276||ab|7|entity|C0392756|Reduced|qlco|||reduced|||0|753|1256|1263
SE|25462276||ab|7|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|753|1264|1268
SE|25462276||ab|7|entity|C0243072|derivatives|chvs|||derivatives|||0|827|1306|1317
SE|25462276||ab|7|entity|C0237399|Potential|qlco|||potent|||0|883|1329|1335
SE|25462276||ab|7|entity|C1373084|P-Glycoprotein Interactions|moft|||P-gp interaction|||0|883|1336|1352

SE|25462276||ab|8|text|1354|1525|Therefore, 'ring-opened' 6,7-dimethoxytetrahydroisoquinoline derivatives represent a promising strategy to obtain P-gp selective agents devoid of sigma2 receptor affinity.
SE|25462276||ab|8|entity|C0175566|Open|spco|||opened|||0|793|1371|1377
SE|25462276||ab|8|entity|C0243072|derivatives|chvs|||derivatives|||0|827|1415|1426
SE|25462276||ab|8|entity|C1555307|promise|idcn|||promising|||0|872|1439|1448
SE|25462276||ab|8|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-gp|||0|813|1468|1472
SE|25462276||ab|8|entity|C0450442|Agent|chvf|||agents|||0|813|1483|1489
SE|25462276||ab|8|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|790|1507|1515


SE|25462277||ti|1|text|21|119|Synthesis of novel substituted purine derivatives and identification of the cell death mechanism.
SE|25462277||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462277||ti|1|entity|C0679622|novel|inpr|||novel|||0|775|34|39
SE|25462277||ti|1|entity|C0034140|Purines|orch|||purine|||0|775|52|58
SE|25462277||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|775|59|70
SE|25462277||ti|1|entity|C0007587|Cell Death|celf|||cell death|||0|901|97|107
SE|25462277||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|901|108|117

SE|25462277||ab|1|text|125|485|Novel 9-(substituted amino/piperazinoethyl)adenines (4-12), 6-(substituted piperazino/amino)purines (15-27), 9-(p-toluenesulfonyl/cyclopentyl/ethoxycarbonylmethyl)-6-(substituted amino/piperazino)purines (28-34, 36, 37, 38-41) were synthesized and evaluated initially for their cytotoxic activities on liver Huh7, breast T47D and colon HCT116 carcinoma cells.
SE|25462277||ab|1|entity|C0679622|novel|inpr|||Novel|||0|861|125|130
SE|25462277||ab|1|entity|C0001407|Adenine|bacs,nnon|||adenines|||0|966|168|176
SE|25462277||ab|1|entity|C0034140|Purines|orch|||purines|||0|1000|217|224
SE|25462277||ab|1|entity|C0034140|Purines|orch|||purines|||0|1000|321|328
SE|25462277||ab|1|entity|C0205265|Initially|tmco|||initially|||0|1000|383|392
SE|25462277||ab|1|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|403|412
SE|25462277||ab|1|entity|C0441655|Activities|acty|||activities|||0|888|413|423
SE|25462277||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|694|427|432
SE|25462277||ab|1|entity|||gngm|284424|MIR7-3HG|Huh7|||0|694|433|437
SE|25462277||ab|1|entity|C0006141|Breast|bpoc|||breast|||0|694|439|445
SE|25462277||ab|1|entity|C0009368|Colon|bpoc|||colon|||0|861|455|460
SE|25462277||ab|1|entity|C0007097|Carcinoma|neop|||carcinoma|||0|861|468|477
SE|25462277||ab|1|entity|C1258005|HCT116 Cells|cell|||HCT116 carcinoma cells|||0|861|461|483
SE|25462277||ab|1|relation|0|0|||gngm,aapp|gngm|284424|MIR7-3HG|Huh7|||0|694|433|437|MOD/HEAD|PART_OF||427|437|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|694|427|432

SE|25462277||ab|2|text|485|642|N(6)-(4-Trifluoromethylphenyl)piperazine derivative (17) and its 9-(p-toluene-sulfonyl)/9-cyclopentyl analogues (28, 36) had promising cytotoxic activities.
SE|25462277||ab|2|entity|C0304303|Piperazine derivative|orch,phsu|||piperazine derivative|||0|1000|515|536
SE|25462277||ab|2|entity|C0040383|Toluene|orch|||toluene|||0|623|555|562
SE|25462277||ab|2|entity|C0243071|Analog|chvs|||analogues|||0|793|587|596
SE|25462277||ab|2|entity|C1555307|promise|idcn|||promising|||0|840|610|619
SE|25462277||ab|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|840|620|629
SE|25462277||ab|2|entity|C0441655|Activities|acty|||activities|||0|840|630|640

SE|25462277||ab|3|text|642|752|Compounds 17, 28 and 36 were further analysed for their cytotoxicity in a panel of a liver cancer cell lines.
SE|25462277||ab|3|entity|C0605315|compound 17|orch,phsu|||Compounds 17|||0|983|642|654
SE|25462277||ab|3|entity|C1517331|Further|spco|||further|||0|1000|671|678
SE|25462277||ab|3|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|698|710
SE|25462277||ab|3|entity|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|||liver cancer|||0|888|727|739
SE|25462277||ab|3|entity|C0007600|Cell Line|cell|||cell lines|||0|888|740|750

SE|25462277||ab|4|text|752|914|The compound 36 had better cytotoxic activities (IC50 <= 1 MUM) than the nucleobase 5-FU and nucleosides fludarabine, cladribine, and pentostatine on Huh7 cells.
SE|25462277||ab|4|entity|C0205198|Compound|qlco|||compound|||0|861|756|764
SE|25462277||ab|4|entity|C0332272|Better|qlco|||better|||0|851|772|778
SE|25462277||ab|4|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|851|779|788
SE|25462277||ab|4|entity|C0441655|Activities|acty|||activities|||0|851|789|799
SE|25462277||ab|4|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|1000|801|805
SE|25462277||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|811|814
SE|25462277||ab|4|entity|C0597101|nucleobase|nnon|||nucleobase|||0|802|825|835
SE|25462277||ab|4|entity|C0016360|Fluorouracil|nnon,phsu|||5-FU|||0|802|836|840
SE|25462277||ab|4|entity|C0028621|Nucleosides|nnon|||nucleosides|||0|888|845|856
SE|25462277||ab|4|entity|C0059985|fludarabine|nnon,phsu|||fludarabine|||0|888|857|868
SE|25462277||ab|4|entity|C0092801|Cladribine|nnon,phsu|||cladribine|||0|1000|870|880
SE|25462277||ab|4|entity|C0030896|Pentostatin|nnon,phsu|||pentostatine|||0|1000|886|898
SE|25462277||ab|4|entity|||gngm|284424|MIR7-3HG|Huh7|||0|861|902|906
SE|25462277||ab|4|entity|C0007634|Cells|cell|||cells|||0|861|907|912
SE|25462277||ab|4|relation|0|0|C0016360|Fluorouracil|nnon,phsu|nnon|||5-FU|||0|802|836|840|MOD/HEAD|ISA||825|840|0|0|C0597101|nucleobase|nnon|nnon|||nucleobase|||0|802|825|835
SE|25462277||ab|4|relation|0|0|C0059985|fludarabine|nnon,phsu|nnon|||fludarabine|||0|888|857|868|MOD/HEAD|ISA||845|868|0|0|C0028621|Nucleosides|nnon|nnon|||nucleosides|||0|888|845|856

SE|25462277||ab|5|text|914|1019|Cytotoxicity induced by 36 was later identified as senescence associated cell death by SA-beta-Gal assay.
SE|25462277||ab|5|entity|C0596402|cytotoxicity|comd|||Cytotoxicity|||0|1000|914|926
SE|25462277||ab|5|entity|C0001792|Elderly|aggp|||senescence|||0|1000|965|975
SE|25462277||ab|5|entity|C0007587|Cell Death|celf|||cell death|||0|1000|987|997
SE|25462277||ab|5|entity|C0560013|gal|qnco|||Gal|||0|775|1009|1012
SE|25462277||ab|5|entity|C1510438|Assay|lbpr|||assay|||0|775|1013|1018


SE|25462278||ti|1|text|21|153|Design, synthesis, and structure--activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists.
SE|25462278||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462278||ti|1|entity|C0678594|Structure|spco|||structure|||0|1000|44|53
SE|25462278||ti|1|entity|C0439849|Relationships|qlco|||relationship|||0|888|64|76
SE|25462278||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|861|107|118
SE|25462278||ti|1|entity|C0237399|Potential|qlco|||potent|||0|818|122|128
SE|25462278||ti|1|entity|C1311076|SMO protein, human|aapp,rcpt|6608|SMO|smoothened|||0|818|129|139
SE|25462278||ti|1|entity|C0243076|antagonists|chvf|||antagonists|||0|818|140|151

SE|25462278||ab|1|text|159|313|The Smoothened (Smo) receptor is an important component of the hedgehog (Hh) signaling pathway, which plays a critical role during embryonic development.
SE|25462278||ab|1|entity|C1311076|SMO protein, human|aapp,rcpt|6608|SMO|Smoothened|||0|888|163|173
SE|25462278||ab|1|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|888|180|188
SE|25462278||ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|861|205|214
SE|25462278||ab|1|entity|C1155468|smoothened signaling pathway|moft|||hedgehog (Hh) signaling pathway|||0|1000|222|253
SE|25462278||ab|1|entity|C1511545|Critical|qlco|||critical|||0|888|269|277
SE|25462278||ab|1|entity|C0035820|Role|socb|||role|||0|888|278|282
SE|25462278||ab|1|entity|C0013936|Embryonic Development|ortf|||embryonic development|||0|1000|290|311

SE|25462278||ab|2|text|313|425|In adults, Hh signaling is curtailed and has limited functions such as stem cell maintenance and tissue repair.
SE|25462278||ab|2|entity|C0001675|Adult|aggp|||adults|||0|1000|316|322
SE|25462278||ab|2|entity|C0018866|Erinaceidae|mamm|||Hh|||0|888|324|326
SE|25462278||ab|2|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|327|336
SE|25462278||ab|2|entity|C0439801|Limited|ftcn|||limited|||0|888|358|365
SE|25462278||ab|2|entity|C0542341|Function|ftcn|||functions|||0|888|366|375
SE|25462278||ab|2|entity|C1160576|stem cell maintenance|orgf|||stem cell maintenance|||0|1000|384|405
SE|25462278||ab|2|entity|C0043240|Wound Healing|orgf|||tissue repair|||0|1000|410|423

SE|25462278||ab|3|text|425|525|However, aberrant activity of the Hh signaling in adults has been linked to numerous human cancers.
SE|25462278||ab|3|entity|C0443127|Aberrant|qlco|||aberrant|||0|888|434|442
SE|25462278||ab|3|entity|C0018866|Erinaceidae|mamm|||Hh|||0|888|459|461
SE|25462278||ab|3|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|462|471
SE|25462278||ab|3|entity|C0001675|Adult|aggp|||adults|||0|1000|475|481
SE|25462278||ab|3|entity|C0439064|Numerous|qnco|||numerous|||0|851|501|509
SE|25462278||ab|3|entity|C0020114|Human|humn|||human|||0|851|510|515
SE|25462278||ab|3|entity|C0006826|Malignant Neoplasms|neop|||cancers|||0|851|516|523
SE|25462278||ab|3|relation|0|0|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|851|516|523|MOD/HEAD|PROCESS_OF||510|523|0|0|C0020114|Human|grup,humn|humn|||human|||0|851|510|515

SE|25462278||ab|4|text|525|661|Inhibition of Smo leads to the blockade of Hh signaling, and therefore represents a promising approach toward novel anticancer therapy.
SE|25462278||ab|4|entity|C1311076|SMO protein, human|aapp,rcpt|6608|SMO|Smo|||0|1000|539|542
SE|25462278||ab|4|entity|C0018866|Erinaceidae|mamm|||Hh|||0|888|568|570
SE|25462278||ab|4|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|571|580
SE|25462278||ab|4|entity|C1555307|promise|idcn|||promising|||0|872|609|618
SE|25462278||ab|4|entity|C0449445|Approach|spco|||approach|||0|872|619|627
SE|25462278||ab|4|entity|C0679622|novel|inpr|||novel|||0|802|635|640

SE|25462278||ab|5|text|661|792|Through scaffold morphing of a few known Smo antagonists, a series of novel tetrahydrothiazolopyridine derivatives were developed.
SE|25462278||ab|5|entity|C0337143|Scaffold|mnob|||scaffold|||0|872|669|677
SE|25462278||ab|5|entity|C0700329|Physical shape|fndg|||morphing|||0|872|678|686
SE|25462278||ab|5|entity|C0205388|Few|qnco|||few|||0|833|692|695
SE|25462278||ab|5|entity|C0205309|Known|qlco|||known|||0|833|696|701
SE|25462278||ab|5|entity|C1311076|SMO protein, human|aapp,rcpt|6608|SMO|Smo|||0|833|702|705
SE|25462278||ab|5|entity|C0243076|antagonists|chvf|||antagonists|||0|833|706|717
SE|25462278||ab|5|entity|C0679622|novel|inpr|||novel|||0|802|731|736
SE|25462278||ab|5|entity|C0243072|derivatives|chvs|||derivatives|||0|802|764|775
SE|25462278||ab|5|relation|1|0|C1311076|SMO protein, human|aapp,gngm,rcpt|aapp|6608|SMO|Smo|||0|833|702|705|NOM|DISRUPTS||706|717|1|1|C0700329|Physical shape|fndg|fndg|||morphing|||0|872|678|686

SE|25462278||ab|6|text|792|931|Compounds from this new scaffold demonstrated excellent Hh signaling inhibition which was comparable to or better than that of Vismodegib.
SE|25462278||ab|6|entity|C0205198|Compound|qlco|||Compounds|||0|966|792|801
SE|25462278||ab|6|entity|C0205314|New|tmco|||new|||0|888|812|815
SE|25462278||ab|6|entity|C0337143|Scaffold|mnob|||scaffold|||0|888|816|824
SE|25462278||ab|6|entity|C0018866|Erinaceidae|mamm|||Hh|||0|775|848|850
SE|25462278||ab|6|entity|C0037083|Signal Transduction|celf|||signaling|||0|775|851|860
SE|25462278||ab|6|entity|C0332272|Better|qlco|||better|||0|1000|899|905

SE|25462278||ab|7|text|931|1173|Further, compound 30 exhibited a lower melting point and a moderately improved solubility compared with those of Vismodegib; compounds 11 and 30 showed good pharmacokinetic profiles with 34% and 77% oral bioavailability in rat, respectively.
SE|25462278||ab|7|entity|C1517331|Further|spco|||Further|||0|1000|931|938
SE|25462278||ab|7|entity|C0604129|compound 30|orch|||compound 30|||0|1000|940|951
SE|25462278||ab|7|entity|C0441994|Lower|ftcn|||lower|||0|790|964|969
SE|25462278||ab|7|entity|C0599882|melting|npop|||melting|||0|790|970|977
SE|25462278||ab|7|entity|C0184511|Improved|qlco|||improved|||0|790|1001|1009
SE|25462278||ab|7|entity|C0037628|Solubility|qnco|||solubility|||0|790|1010|1020
SE|25462278||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|827|1056|1065
SE|25462278||ab|7|entity|C0205170|Good|qlco|||good|||0|623|1083|1087
SE|25462278||ab|7|entity|C0031328|Pharmacokinetic|ftcn|||pharmacokinetic|||0|623|1088|1103
SE|25462278||ab|7|entity|C0442027|Oral|spco|||oral|||0|790|1130|1134
SE|25462278||ab|7|entity|C0005508|Biological Availability|qnco|||bioavailability|||0|790|1135|1150
SE|25462278||ab|7|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|1154|1157
SE|25462278||ab|7|relation|1|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1154|1157|PREP|LOCATION_OF||1151|1153|5|5|C0604129|compound 30|orch|orch|||compound 30|||0|1000|940|951

SE|25462278||ab|8|text|1173|1296|Collectively, these results strongly support further optimization of this novel scaffold to develop better Smo antagonists.
SE|25462278||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1193|1200
SE|25462278||ab|8|entity|C1517331|Further|spco|||further|||0|694|1218|1225
SE|25462278||ab|8|entity|C0679622|novel|inpr|||novel|||0|888|1247|1252
SE|25462278||ab|8|entity|C0337143|Scaffold|mnob|||scaffold|||0|888|1253|1261
SE|25462278||ab|8|entity|C0332272|Better|qlco|||better|||0|851|1273|1279
SE|25462278||ab|8|entity|C1311076|SMO protein, human|aapp,rcpt|6608|SMO|Smo|||0|851|1280|1283
SE|25462278||ab|8|entity|C0243076|antagonists|chvf|||antagonists|||0|851|1284|1295


SE|25462279||ti|1|text|21|114|Structural factors affecting affinity of cytotoxic oxathiole-fused chalcones toward tubulin.
SE|25462279||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|827|32|39
SE|25462279||ti|1|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|775|62|71
SE|25462279||ti|1|entity|C0699952|Fused|ftcn|||fused|||0|775|82|87
SE|25462279||ti|1|entity|C1456331|Chalcones|orch|||chalcones|||0|775|88|97
SE|25462279||ti|1|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|105|112

SE|25462279||ab|1|text|120|290|Synthesis, in vitro cytotoxic activity, and interaction with tubulin of (E)-1-(6-alkoxybenzo[d][1,3]oxathiol-5-yl)-3-phenylprop-2-en-1-one derivatives (2) are described.
SE|25462279||ab|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|120|129
SE|25462279||ab|1|entity|C1533691|in vitro|qlco|||in vitro|||0|861|131|139
SE|25462279||ab|1|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|861|140|149
SE|25462279||ab|1|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|181|188
SE|25462279||ab|1|entity|C0069742|oxathiol|irda,orch|||oxathiol|||0|660|220|228
SE|25462279||ab|1|entity|C0205447|One|qnco|||one|||0|752|255|258
SE|25462279||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|752|259|270

SE|25462279||ab|2|text|290|471|Some of the compounds demonstrated cytotoxic activity at submicromolar concentrations, and the activity could be related to interaction with tubulin at the colchicine binding site.
SE|25462279||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|302|311
SE|25462279||ab|2|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|325|334
SE|25462279||ab|2|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|431|438
SE|25462279||ab|2|entity|C0009262|Colchicine|orch,phsu|||colchicine|||0|901|446|456
SE|25462279||ab|2|entity|C0005456|Binding Sites|rcpt|||binding site|||0|901|457|469
SE|25462279||ab|2|relation|2|1|C0041348|Tubulin|aapp,gngm,bacs|aapp|||tubulin|||0|1000|431|438|NOM|INTERACTS_WITH||414|425|2|2|C0005456|Binding Sites|rcpt|rcpt|||binding site|||0|901|457|469

SE|25462279||ab|3|text|471|620|Interaction of selected derivatives with tubulin was evaluated using molecular modeling, and two different modes of the interaction were identified.
SE|25462279||ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|872|495|506
SE|25462279||ab|3|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|512|519
SE|25462279||ab|3|entity|C0600115|Molecular Modeling|inpr,resa|||molecular modeling|||0|1000|540|558
SE|25462279||ab|3|entity|C0205448|Two|qnco|||two|||0|816|564|567
SE|25462279||ab|3|entity|C1547020|*Difference|qnco|||different|||0|816|568|577
SE|25462279||ab|3|entity|C1513371|Mode|ftcn|||modes|||0|816|578|583

SE|25462279||ab|4|text|620|794|The proposed models demonstrate how particular structural fragments participate in binding to the tubulin and explain the importance of the fragments for cytotoxic activity.
SE|25462279||ab|4|entity|C1441414|PROPOSED|idcn|||proposed|||0|694|624|632
SE|25462279||ab|4|entity|C0486805|FRAGMENTS|bdsu|||fragments|||0|812|678|687
SE|25462279||ab|4|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|718|725
SE|25462279||ab|4|entity|C0486805|FRAGMENTS|bdsu|||fragments|||0|1000|760|769
SE|25462279||ab|4|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|774|783

SE|25462279||ab|5|text|794|1003|It was demonstrated that concerning binding to tubulin, the 6-alkoxybenzoxathiole ring can be considered as structural equivalent of trimethoxyphenyl motif of colchicine, podophyllotoxin or combretastatin A4.
SE|25462279||ab|5|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|1000|841|848
SE|25462279||ab|5|entity|C0439185|Eq|qnco|||equivalent|||0|861|913|923
SE|25462279||ab|5|entity|C0009262|Colchicine|orch,phsu|||colchicine|||0|1000|953|963
SE|25462279||ab|5|entity|C0032334|podophyllotoxin|orch,phsu|||podophyllotoxin|||0|1000|965|980
SE|25462279||ab|5|entity|C0056154|combretastatin A-4|orch,phsu|||combretastatin A4|||0|1000|984|1001
SE|25462279||ab|5|relation|7|6|C0009262|Colchicine|orch,phsu|orch|||colchicine|||0|1000|953|963|NOM|INTERACTS_WITH||830|837|7|1|C0041348|Tubulin|aapp,gngm,bacs|aapp|||tubulin|||0|1000|841|848
SE|25462279||ab|5|relation|7|6|C0032334|podophyllotoxin|orch,phsu|orch|||podophyllotoxin|||0|1000|965|980|NOM|INTERACTS_WITH||830|837|7|1|C0041348|Tubulin|aapp,gngm,bacs|aapp|||tubulin|||0|1000|841|848
SE|25462279||ab|5|relation|7|6|C0056154|combretastatin A-4|orch,phsu|orch|||combretastatin A4|||0|1000|984|1001|NOM|INTERACTS_WITH||830|837|7|1|C0041348|Tubulin|aapp,gngm,bacs|aapp|||tubulin|||0|1000|841|848

SE|25462279||ab|6|text|1003|1098|The observation opened new ways of rational modifications of several groups of tubulin binders.
SE|25462279||ab|6|entity|C0205314|New|tmco|||new|||0|694|1026|1029
SE|25462279||ab|6|entity|C1522413|Modification|ftcn|||modifications|||0|827|1047|1060
SE|25462279||ab|6|entity|C0443302|Several|qnco|||several|||0|888|1064|1071
SE|25462279||ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|1072|1078
SE|25462279||ab|6|entity|C0041348|Tubulin|aapp,bacs|||tubulin|||0|888|1082|1089
SE|25462279||ab|6|entity|C0179302|Binder|medd|||binders|||0|888|1090|1097


SE|25462280||ti|1|text|21|75|Mannich bases in medicinal chemistry and drug design.
SE|25462280||ti|1|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|1000|21|34
SE|25462280||ti|1|entity|C0008003|Chemistry, Pharmaceutical|bmod|||medicinal chemistry|||0|1000|38|57
SE|25462280||ti|1|entity|C0013171|Drug Design|ocdi|||drug design|||0|1000|62|73

SE|25462280||ab|1|text|81|399|The biological activity of Mannich bases, a structurally heterogeneous class of chemical compounds that are generated from various substrates through the introduction of an aminomethyl function by means of the Mannich reaction, is surveyed, with emphasis on the relationship between structure and biological activity.
SE|25462280||ab|1|entity|C0205460|biological|ftcn|||biological|||0|888|85|95
SE|25462280||ab|1|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|1000|108|121
SE|25462280||ab|1|entity|C1512425|Heterogeneous|qlco|||heterogeneous|||0|790|138|151
SE|25462280||ab|1|entity|C0008902|Classification|clas|||class|||0|790|152|157
SE|25462280||ab|1|entity|C0220806|Chemicals|chem|||chemical compounds|||0|1000|161|179
SE|25462280||ab|1|entity|C1293116|Introduction procedure|hlca|||introduction|||0|1000|235|247
SE|25462280||ab|1|entity|C0031843|physiological aspects|phsf|||function|||0|861|266|274
SE|25462280||ab|1|entity|C0443286|Reaction|ftcn|||reaction|||0|861|299|307
SE|25462280||ab|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|343|355
SE|25462280||ab|1|entity|C0678594|Structure|spco|||structure|||0|1000|364|373
SE|25462280||ab|1|entity|C0205460|biological|ftcn|||biological|||0|888|378|388

SE|25462280||ab|2|text|399|608|The review covers extensively the literature reports that have disclosed Mannich bases as anticancer and cytotoxic agents, or compounds with potential antibacterial and antifungal activity in the last decade.
SE|25462280||ab|2|entity|C0023866|Literature|inpr|||literature|||0|1000|433|443
SE|25462280||ab|2|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|901|472|485
SE|25462280||ab|2|entity|C0304497|Cytotoxic agent|phsu|||cytotoxic agents|||0|983|504|520
SE|25462280||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|525|534
SE|25462280||ab|2|entity|C0237399|Potential|qlco|||potential|||0|888|540|549
SE|25462280||ab|2|entity|C0279516|Anti-Bacterial Agents|antb|||antibacterial|||0|888|550|563
SE|25462280||ab|2|entity|C1517741|Last|qlco|||last|||0|694|595|599

SE|25462280||ab|3|text|608|763|The most relevant studies on the activity of Mannich bases as antimycobacterial agents, antimalarials, or antiviral candidates have been included as well.
SE|25462280||ab|3|entity|C0205393|Most|qnco|||most|||0|785|612|616
SE|25462280||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|785|626|633
SE|25462280||ab|3|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|1000|653|666
SE|25462280||ab|3|entity|C0360390|Anti-Mycobacterial Agents|phsu|||antimycobacterial agents|||0|1000|670|694
SE|25462280||ab|3|entity|C0003374|Antimalarials|phsu|||antimalarials|||0|1000|696|709
SE|25462280||ab|3|entity|C0205170|Good|qlco|||well|||0|1000|757|761

SE|25462280||ab|4|text|763|901|The review contains also a thorough coverage of anticonvulsant, anti-inflammatory, analgesic and antioxidant activities of Mannich bases.
SE|25462280||ab|4|entity|C1551362|coverage|idcn|||coverage|||0|861|799|807
SE|25462280||ab|4|entity|C0003286|Anticonvulsants|phsu|||anticonvulsant|||0|916|811|825
SE|25462280||ab|4|entity|C0002773|Analgesics, Anti-Inflammatory|phsu|||anti-inflammatory, analgesic|||0|916|827|855
SE|25462280||ab|4|entity|C1148564|antioxidant activity|moft|||antioxidant activities|||0|983|860|882
SE|25462280||ab|4|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|1000|886|899

SE|25462280||ab|5|text|901|1184|In addition, several minor biological activities of Mannich bases, such as their ability to regulate blood pressure or inhibit platelet aggregation, their antiparasitic and anti-ulcer effects, as well as their use as agents for the treatment of mental disorders have been presented.
SE|25462280||ab|5|entity|C0443302|Several|qnco|||several|||0|833|914|921
SE|25462280||ab|5|entity|C0205460|biological|ftcn|||biological|||0|833|928|938
SE|25462280||ab|5|entity|C0441655|Activities|acty|||activities|||0|833|939|949
SE|25462280||ab|5|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|1000|953|966
SE|25462280||ab|5|entity|C0085732|Ability|orga|||ability|||0|1000|982|989
SE|25462280||ab|5|entity|C0005823|Blood Pressure|orgf|||blood pressure|||0|1000|1002|1016
SE|25462280||ab|5|entity|C0032176|Platelet aggregation|celf|||platelet aggregation|||0|1000|1028|1048
SE|25462280||ab|5|entity|C0041582|Ulcer|patf|||ulcer|||0|773|1079|1084
SE|25462280||ab|5|entity|C1280500|Effect|qlco|||effects|||0|773|1085|1092
SE|25462280||ab|5|entity|C0450442|Agent|chvf|||agents|||0|966|1118|1124
SE|25462280||ab|5|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|1146|1162
SE|25462280||ab|5|relation|4|2|C0024728|Mannich Bases|irda,orch|irda|||Mannich bases|||0|1000|953|966|VERB|AFFECTS||993|1001|8|1|C0005823|Blood Pressure|orgf|orgf|||blood pressure|||0|1000|1002|1016
SE|25462280||ab|5|relation|5|3|C0024728|Mannich Bases|irda,orch|orch|||Mannich bases|||0|1000|953|966|VERB|DISRUPTS||1020|1027|7|1|C0032176|Platelet aggregation|celf|celf|||platelet aggregation|||0|1000|1028|1048
SE|25462280||ab|5|relation|7|5|C0024728|Mannich Bases|irda,orch|irda|||Mannich bases|||0|1000|953|966|NOM|AFFECTS||1085|1092|7|0|C0041582|Ulcer|patf|patf|||ulcer|||0|773|1079|1084
SE|25462280||ab|5|relation|10|1|C0450442|Agent|chvf|chvf|||agents|||0|966|1118|1124|NOM|TREATS||1133|1142|1|1|C0004936|Mental disorders|mobd|mobd|||mental disorders|||0|1000|1146|1162

SE|25462280||ab|6|text|1184|1329|The review gives in the end a brief overview of the potential of Mannich bases as inhibitors of various enzymes or ligands for several receptors.
SE|25462280||ab|6|entity|C1282927|Shortened|tmco|||brief|||0|888|1214|1219
SE|25462280||ab|6|entity|C0814812|overview|inpr|||overview|||0|888|1220|1228
SE|25462280||ab|6|entity|C0237399|Potential|qlco|||potential|||0|1000|1236|1245
SE|25462280||ab|6|entity|C0024728|Mannich Bases|irda,orch|||Mannich bases|||0|1000|1249|1262
SE|25462280||ab|6|entity|C0243077|inhibitors|chvf|||inhibitors|||0|1000|1266|1276
SE|25462280||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|861|1288|1295
SE|25462280||ab|6|entity|C0023688|Ligands|chem|||ligands|||0|1000|1299|1306
SE|25462280||ab|6|entity|C0443302|Several|qnco|||several|||0|888|1311|1318
SE|25462280||ab|6|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|888|1319|1328


SE|25462281||ti|1|text|21|97|Structural development studies of PPARs ligands based on tyrosine scaffold.
SE|25462281||ti|1|entity|C1527148|Development|ftcn|||development|||0|861|32|43
SE|25462281||ti|1|entity|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,rcpt|5465|PPARA|PPARs|||0|872|55|60
SE|25462281||ti|1|entity|C0023688|Ligands|chem|||ligands|||0|872|61|68
SE|25462281||ti|1|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|888|78|86
SE|25462281||ti|1|entity|C0337143|Scaffold|mnob|||scaffold|||0|888|87|95

SE|25462281||ab|1|text|103|199|PPARs are nuclear receptors with a critical physiological role in lipid and glucose metabolism.
SE|25462281||ab|1|entity|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,rcpt|5465|PPARA|PPARs|||0|966|103|108
SE|25462281||ab|1|entity|C0206588|Receptors, Nuclear|aapp,rcpt|||nuclear receptors|||0|1000|113|130
SE|25462281||ab|1|entity|C1511545|Critical|qlco|||critical|||0|851|138|146
SE|25462281||ab|1|entity|C0205463|Physiological|ftcn|||physiological|||0|851|147|160
SE|25462281||ab|1|entity|C0035820|Role|socb|||role|||0|851|161|165
SE|25462281||ab|1|entity|C0023779|Lipids|lipd|||lipid|||0|1000|169|174
SE|25462281||ab|1|entity|C0596620|glucose metabolism|moft|||glucose metabolism|||0|1000|179|197
SE|25462281||ab|1|relation|0|0|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,gngm,rcpt|aapp|5465|PPARA|PPARs|||0|966|103|108|INFER|INTERACTS_WITH(SPEC)||103|130|0|0|C0023779|Lipids|lipd|lipd|||lipid|||0|1000|169|174
SE|25462281||ab|1|relation|0|0|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,gngm,rcpt|aapp|5465|PPARA|PPARs|||0|966|103|108|SPEC|ISA||103|130|0|0|C0206588|Receptors, Nuclear|aapp,gngm,rcpt|aapp|||nuclear receptors|||0|1000|113|130
SE|25462281||ab|1|relation|2|1|C0206588|Receptors, Nuclear|aapp,gngm,rcpt|aapp|||nuclear receptors|||0|1000|113|130|NOM|INTERACTS_WITH||161|165|2|1|C0023779|Lipids|lipd|lipd|||lipid|||0|1000|169|174

SE|25462281||ab|2|text|199|404|As part of our effort to develop new and selective PPAR agonists containing stilbene and its bioisoster phenyldiazene, novel analogs were synthesized starting from tyrosine and evaluated as PPAR agonists.
SE|25462281||ab|2|entity|C0449719|Part|spco|||part|||0|1000|202|206
SE|25462281||ab|2|entity|C0205314|New|tmco|||new|||0|1000|232|235
SE|25462281||ab|2|entity|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,rcpt|5465|PPARA|PPAR|||0|790|250|254
SE|25462281||ab|2|entity|C0243192|agonists|phsu|||agonists|||0|790|255|263
SE|25462281||ab|2|entity|C0038333|Stilbenes|orch|||stilbene|||0|1000|275|283
SE|25462281||ab|2|entity|C0070671|phenyldiazene|orch|||phenyldiazene|||0|861|303|316
SE|25462281||ab|2|entity|C0679622|novel|inpr|||novel|||0|872|318|323
SE|25462281||ab|2|entity|C0243071|Analog|chvs|||analogs|||0|872|324|331
SE|25462281||ab|2|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|1000|363|371
SE|25462281||ab|2|entity|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,rcpt|5465|PPARA|PPAR|||0|888|389|393
SE|25462281||ab|2|entity|C0243192|agonists|phsu|||agonists|||0|888|394|402
SE|25462281||ab|2|relation|8|1|C0041485|Tyrosine|aapp,gngm,bacs,phsu|aapp|||tyrosine|||0|1000|363|371|NOM|STIMULATES||394|402|8|0|C0166418|Peroxisome Proliferator-Activated Receptors|aapp,gngm,rcpt|gngm|5465|PPARA|PPAR|||0|888|389|393

SE|25462281||ab|3|text|404|597|We tested the effects of phenyloxazole replacement of GW409544, a well-known PPARalpha/gamma dual agonist, with stilbene or phenyldiazene moiety, spaced by an ether bridge to tyrosine portion.
SE|25462281||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|418|425
SE|25462281||ab|3|entity|C0035139|Surgical Replantation|topp|||replacement|||0|861|443|454
SE|25462281||ab|3|entity|C1100276|GW 409544|aapp|||GW409544|||0|1000|458|466
SE|25462281||ab|3|entity|C0205170|Good|qlco|||well|||0|753|470|474
SE|25462281||ab|3|entity|C0205309|Known|qlco|||known|||0|753|475|480
SE|25462281||ab|3|entity|C0166415|PPAR alpha|aapp,rcpt|5465|PPARA|PPARalpha|||0|753|481|490
SE|25462281||ab|3|entity|C0243192|agonists|phsu|||agonist|||0|753|502|509
SE|25462281||ab|3|entity|C0038333|Stilbenes|orch|||stilbene|||0|1000|516|524
SE|25462281||ab|3|entity|C0070671|phenyldiazene|orch|||phenyldiazene|||0|694|528|541
SE|25462281||ab|3|entity|C0014994|Ether, Ethyl|orch,phsu|||ether|||0|694|563|568
SE|25462281||ab|3|entity|C0041485|Tyrosine|aapp,bacs,phsu|||tyrosine|||0|694|579|587

SE|25462281||ab|4|text|597|678|These structural modifications provided potent and selective PPARgamma agonists.
SE|25462281||ab|4|entity|C0581602|Structural modification|topp|||structural modifications|||0|983|603|627
SE|25462281||ab|4|entity|C0237399|Potential|qlco|||potent|||0|900|637|643
SE|25462281||ab|4|entity|C0166417|PPAR gamma|aapp,rcpt|5465|PPARA|PPARgamma|||0|790|658|667
SE|25462281||ab|4|entity|C0243192|agonists|phsu|||agonists|||0|790|668|676

SE|25462281||ab|5|text|678|851|Molecular docking studies performed on these new compounds complemented the experimental results and allowed to gain some insights into the nature of binding of the ligands.
SE|25462281||ab|5|entity|C1521991|Molecular|qlco|||Molecular|||0|840|678|687
SE|25462281||ab|5|entity|C1522290|Docking|moft|||docking|||0|840|688|695
SE|25462281||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|840|696|703
SE|25462281||ab|5|entity|C0205314|New|tmco|||new|||0|872|723|726
SE|25462281||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|872|727|736
SE|25462281||ab|5|entity|C1517004|Experimental|ftcn|||experimental|||0|872|754|766
SE|25462281||ab|5|entity|C1274040|result|ftcn|||results|||0|872|767|774
SE|25462281||ab|5|entity|C0233820|Insight|menp|||insights|||0|966|800|808
SE|25462281||ab|5|entity|C0349590|Nature|idcn|||nature|||0|1000|818|824
SE|25462281||ab|5|entity|C0023688|Ligands|chem|||ligands|||0|1000|843|850


SE|25462282||ti|1|text|21|211|Design, synthesis and biological evaluation of 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazolines as efficient EGFR inhibitors exerting cytotoxic effects both under normoxia and hypoxia.
SE|25462282||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462282||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|43|53
SE|25462282||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|54|64
SE|25462282||ti|1|entity|C0028179|Nitroimidazoles|orch,phsu|||nitroimidazole|||0|623|71|85
SE|25462282||ti|1|entity|C0442799|Efficient|qlco|||efficient|||0|890|125|134
SE|25462282||ti|1|entity|C1443775|Epidermal growth factor receptor inhibitor|phsu|||EGFR inhibitors|||0|890|135|150
SE|25462282||ti|1|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|872|160|169
SE|25462282||ti|1|entity|C1280500|Effect|qlco|||effects|||0|872|170|177
SE|25462282||ti|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|202|209

SE|25462282||ab|1|text|217|494|A series of novel 6-(nitroimidazole-1H-alkyloxyl)-4-anilinoquinazoline derivatives (15a-15r) were designed, synthesized and evaluated as efficient EGFR inhibitors through introduction of hypoxia activated nitroimidazole moiety into the quinazoline scaffold of EGFR inhibitors.
SE|25462282||ab|1|entity|C0679622|novel|inpr|||novel|||0|861|229|234
SE|25462282||ab|1|entity|C0028179|Nitroimidazoles|orch,phsu|||nitroimidazole|||0|623|238|252
SE|25462282||ab|1|entity|C0243072|derivatives|chvs|||derivatives|||0|827|288|299
SE|25462282||ab|1|entity|C1553647|Maxillary left second molar abutment|medd|||15a|||0|694|301|304
SE|25462282||ab|1|entity|C0442799|Efficient|qlco|||efficient|||0|890|354|363
SE|25462282||ab|1|entity|C1443775|Epidermal growth factor receptor inhibitor|phsu|||EGFR inhibitors|||0|890|364|379
SE|25462282||ab|1|entity|C1293116|Introduction procedure|hlca|||introduction|||0|1000|388|400
SE|25462282||ab|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|404|411
SE|25462282||ab|1|entity|C0028179|Nitroimidazoles|orch,phsu|||nitroimidazole|||0|694|422|436
SE|25462282||ab|1|entity|C0034407|Quinazolines|orch|||quinazoline|||0|888|453|464
SE|25462282||ab|1|entity|C0337143|Scaffold|mnob|||scaffold|||0|888|465|473
SE|25462282||ab|1|entity|C1443775|Epidermal growth factor receptor inhibitor|phsu|||EGFR inhibitors|||0|983|477|492

SE|25462282||ab|2|text|494|709|The majority of these newly synthesized compounds exhibited comparable EGFR inhibitory activities to gefitinib and moderate to excellent anti-proliferative activities against HT-29 cells under normoxia and hypoxia.
SE|25462282||ab|2|entity|C0680220|majority|socb|||majority|||0|1000|498|506
SE|25462282||ab|2|entity|C0750546|NEWLY|idcn|||newly|||0|785|516|521
SE|25462282||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|785|534|543
SE|25462282||ab|2|entity|C1443775|Epidermal growth factor receptor inhibitor|phsu|||EGFR inhibitory|||0|801|565|580
SE|25462282||ab|2|entity|C0441655|Activities|acty|||activities|||0|801|581|591
SE|25462282||ab|2|entity|C1122962|gefitinib|orch,phsu|||gefitinib|||0|1000|595|604
SE|25462282||ab|2|entity|C0334094|Proliferation|ftcn|||proliferative|||0|750|636|649
SE|25462282||ab|2|entity|C0441655|Activities|acty|||activities|||0|750|650|660
SE|25462282||ab|2|entity|C0282639|HT29 Cells|cell|||HT-29 cells|||0|1000|669|680
SE|25462282||ab|2|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|700|707

SE|25462282||ab|3|text|709|936|The most promising compound 15c displayed the IC50 value of 0.47 nM against EGFR kinase and excellent cytotoxic effect against HT-29 cells under normoxia and hypoxia with the IC50 values of 2.21 MUM and 1.62 MUM, respectively.
SE|25462282||ab|3|entity|C0205393|Most|qnco|||most|||0|597|713|717
SE|25462282||ab|3|entity|C1555307|promise|idcn|||promising|||0|597|718|727
SE|25462282||ab|3|entity|C0205198|Compound|qlco|||compound|||0|597|728|736
SE|25462282||ab|3|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|694|755|759
SE|25462282||ab|3|entity|C1150617|epidermal growth factor receptor activity|moft|||EGFR|||0|888|785|789
SE|25462282||ab|3|entity|C0031727|Phosphotransferases|aapp,enzy|||kinase|||0|888|790|796
SE|25462282||ab|3|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|790|811|820
SE|25462282||ab|3|entity|C1280500|Effect|qlco|||effect|||0|790|821|827
SE|25462282||ab|3|entity|C0282639|HT29 Cells|cell|||HT-29 cells|||0|1000|836|847
SE|25462282||ab|3|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|867|874
SE|25462282||ab|3|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|884|888
SE|25462282||ab|3|entity|C0042295|Values|qlco|||values|||0|888|889|895
SE|25462282||ab|3|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|904|907
SE|25462282||ab|3|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|827|917|920

SE|25462282||ab|4|text|936|1206|The mimic reductive activation study revealed that compound 15c exerted reductive activation properties under hypoxia, which were consistent with the in vitro metabolic study, wherein 15c was easily reductive activated under hypoxia and much more stable under normoxia.
SE|25462282||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|827|967|972
SE|25462282||ab|4|entity|C0205198|Compound|qlco|||compound|||0|694|987|995
SE|25462282||ab|4|entity|C0871161|Property|qlco|||properties|||0|793|1029|1039
SE|25462282||ab|4|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|1046|1053
SE|25462282||ab|4|entity|C1533691|in vitro|qlco|||in vitro|||0|877|1086|1094
SE|25462282||ab|4|entity|C0280606|metabolic abnormality assessment|diap|||metabolic study|||0|877|1095|1110
SE|25462282||ab|4|entity|C0332219|Easy|qlco|||easily|||0|694|1128|1134
SE|25462282||ab|4|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|1161|1168
SE|25462282||ab|4|entity|C0205172|More|ftcn|||more|||0|694|1178|1182
SE|25462282||ab|4|relation|8|3|C0280606|metabolic abnormality assessment|diap|diap|||metabolic study|||0|877|1095|1110|VERB|AFFECTS||1145|1154|3|1|C0242184|Hypoxia|patf|patf|||hypoxia|||0|1000|1161|1168

SE|25462282||ab|5|text|1206|1353|All these results suggested that 15c was a potential cancer therapeutic agent both under normoxia and hypoxia and was worth of further development.
SE|25462282||ab|5|entity|C1274040|result|ftcn|||results|||0|966|1216|1223
SE|25462282||ab|5|entity|C0237399|Potential|qlco|||potential|||0|861|1249|1258
SE|25462282||ab|5|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|861|1259|1265
SE|25462282||ab|5|entity|C0304231|Therapeutic agent|idcn|||therapeutic agent|||0|861|1266|1283
SE|25462282||ab|5|entity|C0242184|Hypoxia|patf|||hypoxia|||0|1000|1308|1315
SE|25462282||ab|5|entity|C1517331|Further|spco|||further|||0|888|1333|1340
SE|25462282||ab|5|entity|C1527148|Development|ftcn|||development|||0|888|1341|1352


SE|25462283||ti|1|text|21|125|Synthesis, bioassay, and QSAR study of bronchodilatory active 4H-pyrano[3,2-c]pyridine-3-carbonitriles.
SE|25462283||ti|1|entity|C0869032|Synthesis|phpr|||Synthesis|||0|1000|21|30
SE|25462283||ti|1|entity|C0005507|Biological Assay|lbpr|||bioassay|||0|1000|32|40
SE|25462283||ti|1|entity|C0887819|Quantitative Structure-Activity Relationship|qnco|||QSAR|||0|888|46|50
SE|25462283||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|888|51|56
SE|25462283||ti|1|entity|C0205177|Active|ftcn|||active|||0|583|76|82
SE|25462283||ti|1|entity|C0034251|pyridine|irda,orch|||pyridine|||0|660|99|107

SE|25462283||ab|1|text|131|382|A statistically significant QSAR model describing the bioactivity of bronchodilatory active 4H-pyrano[3,2-c]pyridine-3-carbonitriles (N = 41, n = 8, R(2) = 0.824, R(2)cv = 0.724, F = 18.749, s(2) = 0.0018) was obtained employing CODESSA-Pro software.
SE|25462283||ab|1|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|861|133|158
SE|25462283||ab|1|entity|C0887819|Quantitative Structure-Activity Relationship|qnco|||QSAR|||0|861|159|163
SE|25462283||ab|1|entity|C0026336|Study models|inpr,resd|||model|||0|861|164|169
SE|25462283||ab|1|entity|C0205177|Active|ftcn|||active|||0|583|216|222
SE|25462283||ab|1|entity|C0034251|pyridine|irda,orch|||pyridine|||0|660|239|247

SE|25462283||ab|2|text|382|612|The bronchodilatory active 4H-pyrano[3,2-c]pyridine-3-carbonitriles 17-57 were synthesized through a facile approach via reaction of 1-alkyl-4-piperidones 1-4 with ylidenemalononitriles 5-16 in methanol in the presence of sodium.
SE|25462283||ab|2|entity|C0205177|Active|ftcn|||active|||0|583|402|408
SE|25462283||ab|2|entity|C0034251|pyridine|irda,orch|||pyridine|||0|804|425|433
SE|25462283||ab|2|entity|C1547538|Facility|idcn|||facile|||0|751|483|489
SE|25462283||ab|2|entity|C0449445|Approach|spco|||approach|||0|751|490|498
SE|25462283||ab|2|entity|C0443286|Reaction|ftcn|||reaction|||0|751|503|511
SE|25462283||ab|2|entity|C1177206|ALKYL|phsu|||alkyl|||0|728|517|522
SE|25462283||ab|2|entity|C0031961|Piperidones|orch|||piperidones|||0|728|525|536
SE|25462283||ab|2|entity|C0001963|Methanol|hops,orch|||methanol|||0|1000|576|584
SE|25462283||ab|2|entity|C0037473|Sodium|bacs,elii|||sodium|||0|1000|604|610
SE|25462283||ab|2|relation|4|1|C0001963|Methanol|hops,orch|hops|||methanol|||0|1000|576|584|NOM|COEXISTS_WITH||592|600|1|1|C0037473|Sodium|bacs,elii|bacs|||sodium|||0|1000|604|610

SE|25462283||ab|3|text|612|821|The bronchodilation properties of 17-57 were investigated in vitro using isolated guinea pig tracheal rings pre-contracted with histamine (standard method) and compared with theophylline (standard reference).
SE|25462283||ab|3|entity|C1371299|Bronchodilation|ortf|||bronchodilation|||0|872|616|631
SE|25462283||ab|3|entity|C0871161|Property|qlco|||properties|||0|872|632|642
SE|25462283||ab|3|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|670|678
SE|25462283||ab|3|entity|C0205409|Isolated|ftcn|||isolated|||0|849|685|693
SE|25462283||ab|3|entity|C0085979|Cavia|mamm|||guinea pig|||0|849|694|704
SE|25462283||ab|3|entity|C1446783|TRACHEAL RING|anab|||tracheal rings|||0|849|705|719
SE|25462283||ab|3|entity|C0740175|Before values|tmco|||pre|||0|888|720|723
SE|25462283||ab|3|entity|C1140999|Contraction|patf|||contracted|||0|888|724|734
SE|25462283||ab|3|entity|C0019588|Histamine|nsba,orch|||histamine|||0|1000|740|749
SE|25462283||ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|888|751|759
SE|25462283||ab|3|entity|C0025663|Methods|inpr|||method|||0|888|760|766
SE|25462283||ab|3|entity|C0039771|Theophylline|bacs,orch,phsu|||theophylline|||0|1000|786|798
SE|25462283||ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|888|800|808
SE|25462283||ab|3|entity|C1514811|Reference|idcn|||reference|||0|888|809|818
SE|25462283||ab|3|relation|0|0|C1446783|TRACHEAL RING|anab|anab|||tracheal rings|||0|849|705|719|MOD/HEAD|PART_OF||694|719|0|0|C0085979|Cavia|mamm|mamm|||guinea pig|||0|849|694|704
SE|25462283||ab|3|relation|6|2|C0019588|Histamine|nsba,orch|nsba|||histamine|||0|1000|740|749|VERB|compared_with||772|780|2|1|C0039771|Theophylline|bacs,orch,phsu|bacs|||theophylline|||0|1000|786|798

SE|25462283||ab|4|text|821|932|Most of the compounds synthesized exhibit promising bronchodilation properties especially, compounds 25 and 28.
SE|25462283||ab|4|entity|C0205393|Most|qnco|||Most|||0|1000|821|825
SE|25462283||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|833|842
SE|25462283||ab|4|entity|C0015272|Exhibits|mnob|||exhibit|||0|754|855|862
SE|25462283||ab|4|entity|C1555307|promise|idcn|||promising|||0|754|863|872
SE|25462283||ab|4|entity|C1371299|Bronchodilation|ortf|||bronchodilation|||0|754|873|888
SE|25462283||ab|4|entity|C0871161|Property|qlco|||properties|||0|754|889|899
SE|25462283||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|827|912|921


SE|25462284||ti|1|text|21|175|Exploring binding affinity of oxaliplatin and carboplatin, to nucleoprotein structure of chromatin: spectroscopic study and histone proteins as a target.
SE|25462284||ti|1|entity|C0069717|oxaliplatin|orch,phsu|||oxaliplatin|||0|1000|51|62
SE|25462284||ti|1|entity|C0079083|Carboplatin|orch,phsu|||carboplatin|||0|1000|67|78
SE|25462284||ti|1|entity|C0028612|Nucleoproteins|aapp,bacs|||nucleoprotein|||0|888|83|96
SE|25462284||ti|1|entity|C0678594|Structure|spco|||structure|||0|888|97|106
SE|25462284||ti|1|entity|C0008546|Chromatin|aapp|||chromatin|||0|1000|110|119
SE|25462284||ti|1|entity|C0037812|Spectrum Analysis|lbpr|||spectroscopic|||0|853|121|134
SE|25462284||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|853|135|140
SE|25462284||ti|1|entity|C0019652|Histones|aapp,bacs|||histone|||0|888|145|152
SE|25462284||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|153|161
SE|25462284||ti|1|relation|7|6|C0019652|Histones|aapp,gngm,bacs|aapp|||histone|||0|888|145|152|NOM|INTERACTS_WITH||39|47|7|1|C0069717|oxaliplatin|orch,phsu|orch|||oxaliplatin|||0|1000|51|62
SE|25462284||ti|1|relation|7|6|C0019652|Histones|aapp,gngm,bacs|aapp|||histone|||0|888|145|152|NOM|INTERACTS_WITH||39|47|7|1|C0079083|Carboplatin|orch,phsu|orch|||carboplatin|||0|1000|67|78

SE|25462284||ab|1|text|181|262|Platinum drugs are potent chemotherapeutic agents widely used in cancer therapy.
SE|25462284||ab|1|entity|C0032207|Platinum|elii|||Platinum|||0|888|181|189
SE|25462284||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|190|195
SE|25462284||ab|1|entity|C0237399|Potential|qlco|||potent|||0|856|200|206
SE|25462284||ab|1|entity|C0003392|Antineoplastic Agents|phsu|||chemotherapeutic agents|||0|856|207|230
SE|25462284||ab|1|entity|C0920425|Cancer Treatment|topp|||cancer therapy|||0|1000|246|260
SE|25462284||ab|1|relation|0|0|C0003392|Antineoplastic Agents|phsu|phsu|||chemotherapeutic agents|||0|856|207|230|SPEC|ISA||190|230|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|888|190|195

SE|25462284||ab|2|text|262|461|They exert their biological activity by binding to DNA, producing DNA adducts; however, in the cell nucleus, DNA is complexed with histone proteins into a nucleoprotein structure known as chromatin.
SE|25462284||ab|2|entity|C0205460|biological|ftcn|||biological|||0|888|279|289
SE|25462284||ab|2|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|313|316
SE|25462284||ab|2|entity|C0242958|DNA Adducts|bacs,nnon|||DNA adducts|||0|1000|328|339
SE|25462284||ab|2|entity|C0007610|Cell Nucleus|celc|||cell nucleus|||0|1000|357|369
SE|25462284||ab|2|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|371|374
SE|25462284||ab|2|entity|C0019652|Histones|aapp,bacs|||histone|||0|888|393|400
SE|25462284||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|401|409
SE|25462284||ab|2|entity|C0028612|Nucleoproteins|aapp,bacs|||nucleoprotein|||0|888|417|430
SE|25462284||ab|2|entity|C0678594|Structure|spco|||structure|||0|888|431|440
SE|25462284||ab|2|entity|C0008546|Chromatin|aapp|||chromatin|||0|1000|450|459

SE|25462284||ab|3|text|461|652|The aim of this study was to explore the binding affinity of oxaliplatin and carboplatin to chromatin using spectroscopic as well as thermal denaturation and equilibrium dialysis techniques.
SE|25462284||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|477|482
SE|25462284||ab|3|entity|C0069717|oxaliplatin|orch,phsu|||oxaliplatin|||0|1000|522|533
SE|25462284||ab|3|entity|C0079083|Carboplatin|orch,phsu|||carboplatin|||0|1000|538|549
SE|25462284||ab|3|entity|C0008546|Chromatin|aapp|||chromatin|||0|1000|553|562
SE|25462284||ab|3|entity|C0037812|Spectrum Analysis|lbpr|||spectroscopic|||0|928|569|582
SE|25462284||ab|3|entity|C0301642|Denaturation|moft|||denaturation|||0|861|602|614
SE|25462284||ab|3|entity|C1553177|Equilibrium dialysis|lbpr|||equilibrium dialysis|||0|901|619|639
SE|25462284||ab|3|entity|C0025664|Methodology|inpr|||techniques|||0|901|640|650

SE|25462284||ab|4|text|652|823|The results showed that the drugs quenched with chromophores of chromatin and the quenching effect for oxaliplatin (Ksv = 3.156) was higher than carboplatin (Ksv = 0.28).
SE|25462284||ab|4|entity|C1274040|result|ftcn|||results|||0|966|656|663
SE|25462284||ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|680|685
SE|25462284||ab|4|entity|C0596335|chromophore|chvf|||chromophores|||0|966|700|712
SE|25462284||ab|4|entity|C0008546|Chromatin|aapp|||chromatin|||0|1000|716|725
SE|25462284||ab|4|entity|C1280500|Effect|qlco|||effect|||0|861|744|750
SE|25462284||ab|4|entity|C0069717|oxaliplatin|orch,phsu|||oxaliplatin|||0|1000|755|766
SE|25462284||ab|4|entity|C0205250|High|qlco|||higher|||0|966|785|791
SE|25462284||ab|4|entity|C0079083|Carboplatin|orch,phsu|||carboplatin|||0|1000|797|808
SE|25462284||ab|4|entity||<<height/highness>>||||higher|||||785|791
SE|25462284||ab|4|relation|8|3|C0069717|oxaliplatin|orch,phsu|orch|||oxaliplatin|||0|1000|755|766|PREP|compared_with||792|796|2|1|C0079083|Carboplatin|orch,phsu|orch|||carboplatin|||0|1000|797|808
SE|25462284||ab|4|relation|8|3|C0069717|oxaliplatin|orch,phsu|orch|||oxaliplatin|||0|1000|755|766|PREP|higher_than||792|796|2|1|C0079083|Carboplatin|orch,phsu|orch|||carboplatin|||0|1000|797|808

SE|25462284||ab|5|text|823|940|The binding of the drugs exhibited hypochromicity both in thermal denaturation profiles and UV absorbance at 210 nm.
SE|25462284||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|842|847
SE|25462284||ab|5|entity|C0333912|Hypochromatism|comd|||hypochromicity|||0|900|858|872
SE|25462284||ab|5|entity|C0301642|Denaturation|moft|||denaturation|||0|660|889|901
SE|25462284||ab|5|entity|C1268822|Optical density function|clna|||absorbance|||0|888|918|928

SE|25462284||ab|6|text|940|1194|The binding was positive cooperation with spontaneous reaction and oxaliplatin (Ka = 5.3 * 10(3) M(-1), n = 1.7) exhibited higher binding constant and number of binding sites than carboplatin (Ka = 0.33 * 10(3) M(-1), n = 1.0) upon binding to chromatin.
SE|25462284||ab|6|entity|C1446409|Positive|qlco|||positive|||0|888|956|964
SE|25462284||ab|6|entity|C0392337|cooperation|socb|||cooperation|||0|888|965|976
SE|25462284||ab|6|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|888|982|993
SE|25462284||ab|6|entity|C0443286|Reaction|ftcn|||reaction|||0|888|994|1002
SE|25462284||ab|6|entity|C0069717|oxaliplatin|orch,phsu|||oxaliplatin|||0|1000|1007|1018
SE|25462284||ab|6|entity|C0205250|High|qlco|||higher|||0|785|1063|1069
SE|25462284||ab|6|entity|C1547014|*Constant|qnco|||constant|||0|785|1078|1086
SE|25462284||ab|6|entity|C0237753|Numbers|qnco|||number|||0|1000|1091|1097
SE|25462284||ab|6|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|1101|1114
SE|25462284||ab|6|entity|C0079083|Carboplatin|orch,phsu|||carboplatin|||0|1000|1120|1131
SE|25462284||ab|6|entity|C0008546|Chromatin|aapp|||chromatin|||0|1000|1183|1192
SE|25462284||ab|6|relation|7|4|C0069717|oxaliplatin|orch,phsu|orch|||oxaliplatin|||0|1000|1007|1018|NOM|INTERACTS_WITH||1070|1077|8|8|C0008546|Chromatin|aapp,gngm|aapp|||chromatin|||0|1000|1183|1192

SE|25462284||ab|7|text|1194|1273|Also secondary structure of chromatin proteins was altered upon drugs binding.
SE|25462284||ab|7|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|790|1199|1208
SE|25462284||ab|7|entity|C0678594|Structure|spco|||structure|||0|790|1209|1218
SE|25462284||ab|7|entity|C0598996|chromatin protein|aapp,bacs|||chromatin proteins|||0|983|1222|1240
SE|25462284||ab|7|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|1258|1263
SE|25462284||ab|7|relation|2|1|C0598996|chromatin protein|aapp,gngm,bacs|aapp|||chromatin proteins|||0|983|1222|1240|VERB|INTERACTS_WITH||1245|1252|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|1000|1258|1263

SE|25462284||ab|8|text|1273|1379|It is concluded that oxaliplatin represents higher binding affinity to chromatin compared to carboplatin.
SE|25462284||ab|8|entity|C0069717|oxaliplatin|orch,phsu|||oxaliplatin|||0|1000|1294|1305
SE|25462284||ab|8|entity|C0205250|High|qlco|||higher|||0|785|1317|1323
SE|25462284||ab|8|entity|C0008546|Chromatin|aapp|||chromatin|||0|1000|1344|1353
SE|25462284||ab|8|entity|C0079083|Carboplatin|orch,phsu|||carboplatin|||0|1000|1366|1377
SE|25462284||ab|8|relation|3|1|C0008546|Chromatin|aapp,gngm|aapp|||chromatin|||0|1000|1344|1353|VERB|compared_with||1354|1362|1|1|C0079083|Carboplatin|orch,phsu|orch|||carboplatin|||0|1000|1366|1377

SE|25462284||ab|9|text|1379|1578|In chromatin where DNA is compacted into nucleosomes structure with histones, the affinity of the platinated drugs is reduced and histone proteins may play a fundamental role in this binding process.
SE|25462284||ab|9|entity|C0008546|Chromatin|aapp|||chromatin|||0|802|1382|1391
SE|25462284||ab|9|entity|C0012854|DNA|bacs,nnon|||DNA|||0|802|1398|1401
SE|25462284||ab|9|entity|C0028623|Nucleosomes|aapp,bacs|||nucleosomes|||0|1000|1420|1431
SE|25462284||ab|9|entity|C0019652|Histones|aapp,bacs|||histones|||0|1000|1447|1455
SE|25462284||ab|9|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|861|1488|1493
SE|25462284||ab|9|entity|C0019652|Histones|aapp,bacs|||histone|||0|888|1509|1516
SE|25462284||ab|9|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|1517|1525
SE|25462284||ab|9|entity|C0035820|Role|socb|||role|||0|861|1549|1553
SE|25462284||ab|9|entity|C1522240|Process|phpr|||process|||0|861|1570|1577
SE|25462284||ab|9|relation|4|2|C0019652|Histones|aapp,gngm,bacs|aapp|||histone|||0|888|1509|1516|NOM|INTERACTS_WITH||1461|1469|4|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|861|1488|1493


SE|25462285||ti|1|text|21|116|Design, synthesis and biological evaluation of novel pyrenyl derivatives as anticancer agents.
SE|25462285||ti|1|entity|C0869032|Synthesis|phpr|||synthesis|||0|1000|29|38
SE|25462285||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|43|53
SE|25462285||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|54|64
SE|25462285||ti|1|entity|C0679622|novel|inpr|||novel|||0|802|68|73
SE|25462285||ti|1|entity|C0243072|derivatives|chvs|||derivatives|||0|802|82|93
SE|25462285||ti|1|entity|C0450442|Agent|chvf|||agents|||0|827|108|114

SE|25462285||ab|1|text|122|237|Polycyclic aromatic hydrocarbons are widespread in nature with a toxicity range from non-toxic to extremely toxic.
SE|25462285||ab|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||Polycyclic aromatic hydrocarbons|||0|1000|122|154
SE|25462285||ab|1|entity|C0205391|Widespread|spco|||widespread|||0|1000|159|169
SE|25462285||ab|1|entity|C0349590|Nature|idcn|||nature|||0|1000|173|179
SE|25462285||ab|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|187|195
SE|25462285||ab|1|entity|C1514721|Range|qnco|||range|||0|888|196|201
SE|25462285||ab|1|entity|C1407029|Toxic|qlco|||toxic|||0|637|211|216

SE|25462285||ab|2|text|237|416|A series of pyrenyl derivatives has been synthesized following a four-step strategy where the pyrene nucleus is attached with a basic heterocyclic moiety through a carbon linker.
SE|25462285||ab|2|entity|C0243072|derivatives|chvs|||derivatives|||0|861|257|268
SE|25462285||ab|2|entity|C0205450|Four|qnco|||four|||0|775|302|306
SE|25462285||ab|2|entity|C1261552|Step|ftcn|||step|||0|775|307|311
SE|25462285||ab|2|entity|C0034243|Pyrenes|hops,orch|||pyrene|||0|888|331|337
SE|25462285||ab|2|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|888|338|345
SE|25462285||ab|2|entity|C0007009|Carbon|elii|||carbon|||0|694|401|407

SE|25462285||ab|3|text|416|507|Virtual screening of the physicochemical properties and druggability has been carried out.
SE|25462285||ab|3|entity|C0220908|Screening procedure|hlca|||screening|||0|861|424|433
SE|25462285||ab|3|entity|C0871161|Property|qlco|||properties|||0|827|457|467
SE|25462285||ab|3|entity|C0439787|Out|spco|||out|||0|1000|502|505

SE|25462285||ab|4|text|507|786|The cytotoxicity of the compounds (1-8) have been evaluated in vitro against a small panel of human cancer cell lines which includes two liver cancer (HepG2 and Hepa 1-6), two colon cancer (HT-29 and Caco-2) and one each for cervical (HeLa) and breast (MCF-7) cancer cell lines.
SE|25462285||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|511|523
SE|25462285||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|531|540
SE|25462285||ab|4|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|567|575
SE|25462285||ab|4|entity|C0700321|Small|qnco|||small|||0|694|586|591
SE|25462285||ab|4|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|908|607|613
SE|25462285||ab|4|entity|C0682523|Human Cell Line|cell|||human cancer cell lines|||0|908|601|624
SE|25462285||ab|4|entity|C0205448|Two|qnco|||two|||0|901|640|643
SE|25462285||ab|4|entity|C0279000|Liver and Intrahepatic Biliary Tract Carcinoma|neop|||liver cancer|||0|901|644|656
SE|25462285||ab|4|entity|C0205448|Two|qnco|||two|||0|901|679|682
SE|25462285||ab|4|entity|C0007102|Malignant tumor of colon|neop|||colon cancer|||0|901|683|695
SE|25462285||ab|4|entity|C0282639|HT29 Cells|cell|||HT-29|||0|1000|697|702
SE|25462285||ab|4|entity|C0205447|One|qnco|||one|||0|1000|719|722
SE|25462285||ab|4|entity|C0205064|Cervical|spco|||cervical|||0|1000|732|740
SE|25462285||ab|4|entity|C0006141|Breast|bpoc|||breast|||0|1000|752|758
SE|25462285||ab|4|entity|C0008015|Macrophage Chemotactic Factors|imft|||MCF-7|||0|861|760|765
SE|25462285||ab|4|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|901|767|773
SE|25462285||ab|4|entity|C0007600|Cell Line|cell|||cell lines|||0|901|774|784

SE|25462285||ab|5|text|786|1099|The IC50 data indicate that compound 6 and 8 are the most effective cytotoxic agents in the present set of pyrenyl derivatives, suggesting that having a 4-carbon linker is more effective than a 5-carbon linker and the presence of amide carbonyl groups in the linker severely reduces the efficacy of the compound.
SE|25462285||ab|5|entity|C0600495|Inhibitory Concentration 50|qnco|||IC50|||0|888|790|794
SE|25462285||ab|5|entity|C1511726|Data|idcn|||data|||0|888|795|799
SE|25462285||ab|5|entity|C0205198|Compound|qlco|||compound|||0|861|814|822
SE|25462285||ab|5|entity|C0205393|Most|qnco|||most|||0|852|839|843
SE|25462285||ab|5|entity|C0304497|Cytotoxic agent|phsu|||cytotoxic agents|||0|852|854|870
SE|25462285||ab|5|entity|C0150312|Present|qnco|||present|||0|694|878|885
SE|25462285||ab|5|entity|C0243072|derivatives|chvs|||derivatives|||0|861|901|912
SE|25462285||ab|5|entity|C0007009|Carbon|elii|||carbon|||0|660|941|947
SE|25462285||ab|5|entity|C0205172|More|ftcn|||more|||0|888|958|962
SE|25462285||ab|5|entity|C0007009|Carbon|elii|||carbon|||0|623|982|988
SE|25462285||ab|5|entity|C0002482|Amides|orch|||amide|||0|694|1016|1021
SE|25462285||ab|5|entity|C0205082|Severe|qlco|||severely|||0|1000|1052|1060
SE|25462285||ab|5|entity|C0205198|Compound|qlco|||compound|||0|1000|1089|1097

SE|25462285||ab|6|text|1099|1219|The compounds showed selectivity toward cancer cells at lower doses (<5 MUM) when compared with the normal hepatocytes.
SE|25462285||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|1103|1112
SE|25462285||ab|6|entity|C0334227|Tumor cells, malignant|cell|||cancer cells|||0|983|1139|1151
SE|25462285||ab|6|entity|C0441994|Lower|ftcn|||lower|||0|888|1155|1160
SE|25462285||ab|6|entity|C1446466|Dose|qnco|||doses|||0|888|1161|1166
SE|25462285||ab|6|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|888|1171|1174
SE|25462285||ab|6|entity|C0205307|Normal|qlco|||normal|||0|888|1199|1205
SE|25462285||ab|6|entity|C0227525|Hepatocyte|cell|||hepatocytes|||0|888|1206|1217

SE|25462285||ab|7|text|1219|1445|The mechanism of action supports the cell death through apoptosis in a caspase-independent manner without cleavage of poly (ADP-ribose) polymerase (PARP), even though the compounds cause plasma membrane morphological changes.
SE|25462285||ab|7|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|1223|1232
SE|25462285||ab|7|entity|C0007587|Cell Death|celf|||cell death|||0|1000|1256|1266
SE|25462285||ab|7|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1275|1284
SE|25462285||ab|7|entity|C0010656|caspase|aapp,enzy|||caspase|||0|623|1290|1297
SE|25462285||ab|7|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|1000|1325|1333
SE|25462285||ab|7|entity|C0747726|POLY|cnce|||poly|||0|1000|1337|1341
SE|25462285||ab|7|entity|C0001461|Adenosine Diphosphate Ribose|bacs,carb,nnon|||ADP-ribose|||0|1000|1343|1353
SE|25462285||ab|7|entity|C1335439|Polymerase|aapp,enzy|||polymerase|||0|1000|1355|1365
SE|25462285||ab|7|entity|||gngm|142,1302|PARP1,COL11A2|PARP|||0|1000|1367|1371
SE|25462285||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|966|1390|1399
SE|25462285||ab|7|entity|C0007603|Cell membrane|celc|||plasma membrane|||0|850|1406|1421
SE|25462285||ab|7|entity|C0543482|morphological|spco|||morphological|||0|850|1422|1435

SE|25462285||ab|8|text|1445|1541|The compounds, whether highly cytotoxic or mildly cytotoxic, localize to the membrane of cells.
SE|25462285||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|966|1449|1458
SE|25462285||ab|8|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|861|1475|1484
SE|25462285||ab|8|entity|C0750532|MILDLY|idcn|||mildly|||0|888|1488|1494
SE|25462285||ab|8|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|1495|1504
SE|25462285||ab|8|entity|C0596901|Membrane|celc|||membrane|||0|1000|1522|1530
SE|25462285||ab|8|entity|C0007634|Cells|cell|||cells|||0|1000|1534|1539
SE|25462285||ab|8|relation|4|1|C0596901|Membrane|celc|celc|||membrane|||0|1000|1522|1530|PREP|PART_OF||1531|1533|1|1|C0007634|Cells|cell|cell|||cells|||0|1000|1534|1539

SE|25462285||ab|9|text|1541|1763|The compounds with either a piperidine ring (6) or an N-methyl piperazine (8) in the side chain were both capable of circumventing the drug resistance in SKOV3-MDR1-M6/6 ovarian cancer cells overexpressing P-glycoprotein.
SE|25462285||ab|9|entity|C0205198|Compound|qlco|||compounds|||0|966|1545|1554
SE|25462285||ab|9|entity|C0031959|piperidine|orch|||piperidine|||0|694|1569|1579
SE|25462285||ab|9|entity|C0031957|piperazine|orch,phsu|||piperazine|||0|802|1604|1614
SE|25462285||ab|9|entity|C0441987|Side|spco|||side|||0|861|1626|1630
SE|25462285||ab|9|entity|C0013203|Drug resistance|biof|||drug resistance|||0|1000|1676|1691
SE|25462285||ab|9|entity|C0376622|ABCB1 gene|gngm|5243|ABCB1|SKOV3-MDR1|||0|756|1695|1705
SE|25462285||ab|9|entity|C0029925|Ovarian Carcinoma|neop|||ovarian cancer|||0|756|1711|1725
SE|25462285||ab|9|entity|C0007634|Cells|cell|||cells|||0|756|1726|1731
SE|25462285||ab|9|entity|C0242643|P-Glycoprotein|aapp,bacs|||P-glycoprotein|||0|1000|1747|1761
SE|25462285||ab|9|relation|2|1|C0007634|Cells|cell|cell|||cells|||0|756|1726|1731|PREP|LOCATION_OF||1692|1694|7|5|C0031957|piperazine|orch,phsu|orch|||piperazine|||0|802|1604|1614
SE|25462285||ab|9|relation|8|1|C0007634|Cells|cell|cell|||cells|||0|756|1726|1731|VERB|PRODUCES||1732|1746|1|1|C0242643|P-Glycoprotein|aapp,gngm,bacs|aapp|||P-glycoprotein|||0|1000|1747|1761

SE|25462285||ab|10|text|1763|1829|Qualitative structure-activity relationship has also been studied.
SE|25462285||ab|10|entity|C0205556|Qualitative|qlco|||Qualitative|||0|916|1763|1774
SE|25462285||ab|10|entity|C0038477|Structure-Activity Relationship|qlco|||structure-activity relationship|||0|916|1775|1806


SE|25462286||ti|1|text|21|117|Structures of mGluRs shed light on the challenges of drug development of allosteric modulators.
SE|25462286||ti|1|entity|C0678594|Structure|spco|||Structures|||0|966|21|31
SE|25462286||ti|1|entity|C0872152|Drug Development|bmod|||drug development|||0|1000|74|90

SE|25462286||ab|1|text|123|314|The metabotropic glutamate receptor family includes many potential therapeutic targets for a wide range of neurological disorders however to date no approved drugs have progressed to market.
SE|25462286||ab|1|entity|C0206529|Receptors, Metabotropic Glutamate|aapp,rcpt|||metabotropic glutamate receptor|||0|916|127|158
SE|25462286||ab|1|entity|C0015576|Family|famg|||family|||0|916|159|165
SE|25462286||ab|1|entity|C0237399|Potential|qlco|||potential|||0|840|180|189
SE|25462286||ab|1|entity|C0332464|Widening|spco|||wide|||0|888|216|220
SE|25462286||ab|1|entity|C1514721|Range|qnco|||range|||0|888|221|226
SE|25462286||ab|1|entity|C0027765|nervous system disorder|dsyn|||neurological disorders|||0|901|230|252
SE|25462286||ab|1|entity|C0205540|Approved|qlco|||approved|||0|888|272|280
SE|25462286||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|281|286

SE|25462286||ab|2|text|314|426|For some receptor subtypes it has been difficult to separate therapeutic benefit from undesirable side effects.
SE|25462286||ab|2|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|872|323|331
SE|25462286||ab|2|entity|C0449560|Subtype|clas|||subtypes|||0|872|332|340
SE|25462286||ab|2|entity|C0332218|Difficult|qlco|||difficult|||0|1000|353|362
SE|25462286||ab|2|entity|C0814225|Benefits|qnco|||benefit|||0|872|387|394
SE|25462286||ab|2|entity|C0441987|Side|spco|||side|||0|901|412|416
SE|25462286||ab|2|entity|C0001688|aspects of adverse effects|ftcn|||undesirable side effects|||0|901|400|424

SE|25462286||ab|3|text|426|496|For others finding suitable drug like molecules has been challenging.
SE|25462286||ab|3|entity|C0205394|Other|qlco|||others|||0|966|430|436
SE|25462286||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|861|454|458
SE|25462286||ab|3|entity|C0567416|Molecule|sbst|||molecules|||0|966|464|473
SE|25462286||ab|3|entity|C0805586|CHALLENGE|idcn|||challenging|||0|966|483|494

SE|25462286||ab|4|text|496|607|Chemotypes identified from screening have been limited and difficult to optimise away from undesirable groups.
SE|25462286||ab|4|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|523|532
SE|25462286||ab|4|entity|C0332218|Difficult|qlco|||difficult|||0|1000|555|564
SE|25462286||ab|4|entity|C0441833|Groups|inpr|||groups|||0|861|599|605

SE|25462286||ab|5|text|607|694|Frequently within related series, compounds have switched from agonist to antagonists.
SE|25462286||ab|5|entity|C0332183|Frequent|tmco|||Frequently|||0|1000|607|617
SE|25462286||ab|5|entity|C1522149|Related|ftcn|||related|||0|888|625|632
SE|25462286||ab|5|entity|C0205549|Series|qnco|||series|||0|888|633|639
SE|25462286||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|641|650
SE|25462286||ab|5|entity|C0243192|agonists|phsu|||agonist|||0|1000|670|677
SE|25462286||ab|5|entity|C0243076|antagonists|chvf|||antagonists|||0|1000|681|692

SE|25462286||ab|6|text|694|966|Recently the structures of the transmembrane domain of mGlu1 and mGlu5 have been solved revealing the binding site of allosteric modulators which provides an understanding of the difficulties to date and an opportunity for future structure based approaches to drug design.
SE|25462286||ab|6|entity|C0332185|Recent|tmco|||Recently|||0|1000|694|702
SE|25462286||ab|6|entity|C0678594|Structure|spco|||structures|||0|966|707|717
SE|25462286||ab|6|entity|C1519623|Transmembrane Domain|amas|||transmembrane domain|||0|1000|725|745
SE|25462286||ab|6|entity|C1333711|GRM1 gene|gngm|2911|GRM1|mGlu1|||0|1000|749|754
SE|25462286||ab|6|entity|C1333712|GRM5 gene|gngm|2915|GRM5|mGlu5|||0|1000|759|764
SE|25462286||ab|6|entity|C0005456|Binding Sites|rcpt|||binding site|||0|1000|796|808
SE|25462286||ab|6|entity|C0016884|Future|tmco|||future|||0|825|917|923
SE|25462286||ab|6|entity|C0678594|Structure|spco|||structure|||0|825|924|933
SE|25462286||ab|6|entity|C0449445|Approach|spco|||approaches|||0|825|940|950
SE|25462286||ab|6|entity|C0013171|Drug Design|ocdi|||drug design|||0|1000|954|965


SE|25462287||ti|1|text|21|93|Allosteric modulators of NMDA receptors: multiple sites and mechanisms.
SE|25462287||ti|1|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDA receptors|||0|1000|46|60
SE|25462287||ti|1|entity|C0439064|Numerous|qnco|||multiple|||0|888|62|70
SE|25462287||ti|1|entity|C0205145|Site|spco|||sites|||0|888|71|76
SE|25462287||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|81|91

SE|25462287||ab|1|text|99|258|N-methyl-D-aspartate receptors (NMDARs) are glutamate-gated ion channels that are essential mediators of excitatory neurotransmission and synaptic plasticity.
SE|25462287||ab|1|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||N-methyl-D-aspartate receptors|||0|1000|99|129
SE|25462287||ab|1|entity|C0017789|Glutamates|aapp|||glutamate|||0|802|143|152
SE|25462287||ab|1|entity|C0022023|Ions|elii|||ion|||0|802|159|162
SE|25462287||ab|1|entity|C0205224|Essential|qlco|||essential|||0|694|181|190
SE|25462287||ab|1|entity|C0678903|Neuronal Transmission|celf|||neurotransmission|||0|861|215|232
SE|25462287||ab|1|entity|C0039062|Synapses|bsoj|||synaptic|||0|853|237|245

SE|25462287||ab|2|text|258|396|NMDARs are also implicated in a plethora of neuropathological conditions thus receiving strong interest as potential therapeutic targets.
SE|25462287||ab|2|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDARs|||0|1000|258|264
SE|25462287||ab|2|entity|C0232370|Plethora|fndg|||plethora|||0|1000|290|298
SE|25462287||ab|2|entity|C0876934|Neuropathology|bmod|||neuropathological|||0|836|302|319
SE|25462287||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|836|320|330
SE|25462287||ab|2|entity|C0442821|Strong|qlco|||strong|||0|888|346|352
SE|25462287||ab|2|entity|C0543488|Interested|menp|||interest|||0|888|353|361
SE|25462287||ab|2|entity|C0237399|Potential|qlco|||potential|||0|840|365|374
SE|25462287||ab|2|relation|0|0|C0080093|N-Methyl-D-Aspartate Receptors|aapp,gngm,rcpt|aapp|||NMDARs|||0|1000|258|264|VERB|AFFECTS||274|284|4|1|C0232370|Plethora|fndg|fndg|||plethora|||0|1000|290|298

SE|25462287||ab|3|text|396|697|Recent years have witnessed major progress in our understanding of the structure and pharmacology of NMDARs with the decoding of the first full-length receptor crystal structures and the discovery of allosteric modulators acting at novel binding sites and with unique patterns of subunit selectivity.
SE|25462287||ab|3|entity|C0332185|Recent|tmco|||Recent|||0|888|396|402
SE|25462287||ab|3|entity|C0439234|year|tmco|||years|||0|888|403|408
SE|25462287||ab|3|entity|C0205164|Major|qlco|||major|||0|888|424|429
SE|25462287||ab|3|entity|C1280477|Progressing to|ftcn|||progress|||0|888|430|438
SE|25462287||ab|3|entity|C0678594|Structure|spco|||structure|||0|1000|467|476
SE|25462287||ab|3|entity|C0031330|Pharmacology|bmod|||pharmacology|||0|1000|481|493
SE|25462287||ab|3|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDARs|||0|947|497|503
SE|25462287||ab|3|entity|C0870395|Decoding|menp|||decoding|||0|1000|513|521
SE|25462287||ab|3|entity|C1279901|Firstly|qlco|||first|||0|821|529|534
SE|25462287||ab|3|entity|C0443225|Full|qlco|||full|||0|821|535|539
SE|25462287||ab|3|entity|C1444754|Length|qnco|||length|||0|821|540|546
SE|25462287||ab|3|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|821|547|555
SE|25462287||ab|3|entity|C0444626|Crystal Structure|chvs|||crystal structures|||0|821|556|574
SE|25462287||ab|3|entity|C0679622|novel|inpr|||novel|||0|901|628|633
SE|25462287||ab|3|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|634|647
SE|25462287||ab|3|entity|C0449774|Patterns|spco|||patterns|||0|861|664|672

SE|25462287||ab|4|text|697|850|Here we review the properties and structural mechanisms of various allosteric modulators that target NMDARs, emphasizing the newly identified compounds.
SE|25462287||ab|4|entity|C0871161|Property|qlco|||properties|||0|966|716|726
SE|25462287||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|861|742|752
SE|25462287||ab|4|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDARs|||0|1000|798|804
SE|25462287||ab|4|entity|C0750546|NEWLY|idcn|||newly|||0|840|822|827
SE|25462287||ab|4|entity|C0205396|Identified|qlco|||identified|||0|840|828|838
SE|25462287||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|840|839|848

SE|25462287||ab|5|text|850|1000|The expanding pharmacology of NMDARs should help delineate the roles of various NMDAR subtypes in brain function, with potential for drug development.
SE|25462287||ab|5|entity|C0205229|Expanding|spco|||expanding|||0|888|854|863
SE|25462287||ab|5|entity|C0031330|Pharmacology|bmod|||pharmacology|||0|888|864|876
SE|25462287||ab|5|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||NMDARs|||0|947|880|886
SE|25462287||ab|5|entity|C0035820|Role|socb|||roles|||0|1000|913|918
SE|25462287||ab|5|entity|C0449560|Subtype|clas|||subtypes|||0|793|936|944
SE|25462287||ab|5|entity|C0678908|brain function|ortf|||brain function|||0|1000|948|962
SE|25462287||ab|5|entity|C0237399|Potential|qlco|||potential|||0|1000|969|978
SE|25462287||ab|5|entity|C0872152|Drug Development|bmod|||drug development|||0|1000|983|999


SE|25462288||ti|1|text|21|78|Targeting glutamatergic synapses in Parkinson's disease.
SE|25462288||ti|1|entity|C0039062|Synapses|bsoj|||synapses|||0|861|45|53
SE|25462288||ti|1|entity|C0030567|Parkinson Disease|dsyn|||Parkinson's disease|||0|1000|57|76

SE|25462288||ab|1|text|84|248|Parkinson's disease (PD) is characterized by progressive degeneration of dopaminergic neurons of the substantia nigra and dramatic motor and cognitive impairments.
SE|25462288||ab|1|entity|C0030567|Parkinson Disease|dsyn|||Parkinson's disease|||0|1000|84|103
SE|25462288||ab|1|entity|C0205329|Progressive|ftcn|||progressive|||0|888|129|140
SE|25462288||ab|1|entity|C0011164|Degenerative abnormality|patf|||degeneration|||0|888|141|153
SE|25462288||ab|1|entity|C0815003|dopaminergic neuron|cell|||dopaminergic neurons|||0|983|157|177
SE|25462288||ab|1|entity|C1269578|Entire substantia nigra|bpoc|||substantia nigra|||0|1000|185|201
SE|25462288||ab|1|entity|C0013109|Drama|inpr|||dramatic|||0|853|206|214
SE|25462288||ab|1|entity|C1513492|Motor|idcn|||motor|||0|853|215|220
SE|25462288||ab|1|entity|C0338656|Impaired cognition|fndg|||cognitive impairments|||0|983|225|246
SE|25462288||ab|1|relation|3|1|C0815003|dopaminergic neuron|cell|cell|||dopaminergic neurons|||0|983|157|177|PREP|PART_OF||178|180|3|1|C1269578|Entire substantia nigra|bpoc|bpoc|||substantia nigra|||0|1000|185|201
SE|25462288||ab|1|relation|5|1|C0011164|Degenerative abnormality|patf|patf|||degeneration|||0|888|141|153|VERB|COEXISTS_WITH||112|125|1|1|C0030567|Parkinson Disease|dsyn|dsyn|||Parkinson's disease|||0|1000|84|103

SE|25462288||ab|2|text|248|407|The current knowledge indicates that the strength of glutamatergic signals from the cortex to the striatum is regulated during the progression of the disease.
SE|25462288||ab|2|entity|C0521116|Current|tmco|||current|||0|888|252|259
SE|25462288||ab|2|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|260|269
SE|25462288||ab|2|entity|C0808080|STRENGTH|idcn|||strength|||0|1000|289|297
SE|25462288||ab|2|entity|C0162512|Neostriatum|bpoc|||striatum|||0|1000|346|354
SE|25462288||ab|2|entity|C0449258|Progression|ftcn|||progression|||0|1000|379|390
SE|25462288||ab|2|entity|C0012634|Disease|dsyn|||disease|||0|1000|398|405

SE|25462288||ab|3|text|407|639|The efficacy of ionotropic glutamate receptors to modulate synaptic transmission in the striatum indicates that modulation of the activity of these receptors may represent a key target to rescue the altered neurotransmission in PD.
SE|25462288||ab|3|entity|C0061465|Glutamate Receptor|aapp,rcpt|||glutamate receptors|||0|901|434|453
SE|25462288||ab|3|entity|C0027793|Synaptic Transmission|ortf|||synaptic transmission|||0|1000|466|487
SE|25462288||ab|3|entity|C0162512|Neostriatum|bpoc|||striatum|||0|1000|495|503
SE|25462288||ab|3|entity|C0597357|receptor|aapp,rcpt|||receptors|||0|1000|555|564
SE|25462288||ab|3|entity|C1554080|Key|idcn|||key|||0|888|581|584
SE|25462288||ab|3|entity|C0205349|Altered|ftcn|||altered|||0|888|606|613
SE|25462288||ab|3|entity|C0678903|Neuronal Transmission|celf|||neurotransmission|||0|888|614|631
SE|25462288||ab|3|entity|C0030567|Parkinson Disease|dsyn|||PD|||0|1000|635|637
SE|25462288||ab|3|relation|2|1|C0061465|Glutamate Receptor|aapp,gngm,rcpt|aapp|||glutamate receptors|||0|901|434|453|VERB|AFFECTS||457|465|8|1|C0027793|Synaptic Transmission|ortf|ortf|||synaptic transmission|||0|1000|466|487
SE|25462288||ab|3|relation|9|3|C0597357|receptor|aapp,gngm,rcpt|aapp|||receptors|||0|1000|555|564|PREP|ASSOCIATED_WITH||632|634|1|1|C0030567|Parkinson Disease|dsyn|dsyn|||PD|||0|1000|635|637

SE|25462288||ab|4|text|639|851|Preclinical and clinical studies suggest that agents targeting ionotropic glutamate receptors may ameliorate the motor symptoms of PD as well as to reduce the onset of levodopa-induced dyskinetic motor behaviour.
SE|25462288||ab|4|entity|C0008972|Clinical Research|resa|||clinical studies|||0|1000|655|671
SE|25462288||ab|4|entity|C0450442|Agent|chvf|||agents|||0|966|685|691
SE|25462288||ab|4|entity|C0061465|Glutamate Receptor|aapp,rcpt|||glutamate receptors|||0|901|713|732
SE|25462288||ab|4|entity|C0426980|Motor symptoms|sosy|||motor symptoms|||0|1000|752|766
SE|25462288||ab|4|entity|C0030567|Parkinson Disease|dsyn|||PD|||0|1000|770|772
SE|25462288||ab|4|entity|C0332162|Onset|qlco|||onset|||0|1000|798|803
SE|25462288||ab|4|entity|C0023570|Levodopa|aapp,nsba,phsu|||levodopa|||0|840|807|815
SE|25462288||ab|4|entity|C0205263|Induced|ftcn|||induced|||0|840|816|823
SE|25462288||ab|4|entity|C0439842|Dyskinetic|ftcn|||dyskinetic|||0|840|824|834
SE|25462288||ab|4|entity|C0026606|Physical activity|dora|||motor behaviour|||0|840|835|850
SE|25462288||ab|4|relation|4|2|C0450442|Agent|chvf|chvf|||agents|||0|966|685|691|VERB|TREATS||737|747|4|1|C0426980|Motor symptoms|sosy|sosy|||motor symptoms|||0|1000|752|766


SE|25462289||ti|1|text|21|97|Targeting metabotropic glutamate receptors (mGluRs) in Parkinson's disease.
SE|25462289||ti|1|entity|C0206529|Receptors, Metabotropic Glutamate|aapp,rcpt|||metabotropic glutamate receptors|||0|1000|31|63
SE|25462289||ti|1|entity|C0030567|Parkinson Disease|dsyn|||Parkinson's disease|||0|1000|76|95
SE|25462289||ti|1|relation|1|1|C0206529|Receptors, Metabotropic Glutamate|aapp,gngm,rcpt|aapp|||metabotropic glutamate receptors|||0|1000|31|63|PREP|ASSOCIATED_WITH||73|75|1|1|C0030567|Parkinson Disease|dsyn|dsyn|||Parkinson's disease|||0|1000|76|95

SE|25462289||ab|1|text|103|228|The interplay between dopamine and glutamate in the basal ganglia regulate critical aspects of motor and cognitive behavior.
SE|25462289||ab|1|entity|C0013030|Dopamine|nsba,orch,phsu|||dopamine|||0|1000|125|133
SE|25462289||ab|1|entity|C0017789|Glutamates|aapp|||glutamate|||0|1000|138|147
SE|25462289||ab|1|entity|C0004781|Basal Ganglia|bpoc|||basal ganglia|||0|1000|155|168
SE|25462289||ab|1|entity|C1511545|Critical|qlco|||critical|||0|872|178|186
SE|25462289||ab|1|entity|C1547011|Aspect|qnco|||aspects|||0|872|187|194
SE|25462289||ab|1|entity|C1513492|Motor|idcn|||motor|||0|1000|198|203
SE|25462289||ab|1|entity|C0945984|Cognition:behavior|inbe|||cognitive behavior|||0|964|208|226
SE|25462289||ab|1|relation|4|1|C0004781|Basal Ganglia|bpoc|bpoc|||basal ganglia|||0|1000|155|168|PREP|LOCATION_OF||148|150|3|1|C0013030|Dopamine|nsba,orch,phsu|orch|||dopamine|||0|1000|125|133
SE|25462289||ab|1|relation|4|1|C0004781|Basal Ganglia|bpoc|bpoc|||basal ganglia|||0|1000|155|168|PREP|LOCATION_OF||148|150|3|1|C0017789|Glutamates|aapp,gngm|aapp|||glutamate|||0|1000|138|147
SE|25462289||ab|1|relation|6|2|C0017789|Glutamates|aapp,gngm|aapp|||glutamate|||0|1000|138|147|NOM|INTERACTS_WITH||107|116|6|1|C0013030|Dopamine|nsba,orch,phsu|nsba|||dopamine|||0|1000|125|133

SE|25462289||ab|2|text|228|345|Metabotropic glutamate (mGlu) receptors are key modulators of glutamatergic dysfunction in Parkinson's disease (PD).
SE|25462289||ab|2|entity|C0206529|Receptors, Metabotropic Glutamate|aapp,rcpt|||Metabotropic glutamate (mGlu) receptors|||0|1000|228|267
SE|25462289||ab|2|entity|C1554080|Key|idcn|||key|||0|694|272|275
SE|25462289||ab|2|entity|C0030567|Parkinson Disease|dsyn|||Parkinson's disease|||0|1000|319|338
SE|25462289||ab|2|relation|3|3|C0206529|Receptors, Metabotropic Glutamate|aapp,gngm,rcpt|aapp|||Metabotropic glutamate (mGlu) receptors|||0|1000|228|267|PREP|ASSOCIATED_WITH||316|318|1|1|C0030567|Parkinson Disease|dsyn|dsyn|||Parkinson's disease|||0|1000|319|338

SE|25462289||ab|3|text|345|612|Preclinical evidence demonstrate that group I mGlu receptor antagonism and groups II and III mGlu receptor activation improve motor symptomatology of PD and decrease l-DOPA-induced dyskinesia by regulating excitatory and inhibitory transmission in the basal ganglia.
SE|25462289||ab|3|entity|C0441833|Groups|inpr|||group|||0|1000|383|388
SE|25462289||ab|3|entity|C0206529|Receptors, Metabotropic Glutamate|aapp,rcpt|||mGlu receptor|||0|916|391|404
SE|25462289||ab|3|entity|C0680242|antagonism|socb|||antagonism|||0|916|405|415
SE|25462289||ab|3|entity|C0439070|III|inpr|||III|||0|794|434|437
SE|25462289||ab|3|entity|C0017789|Glutamates|aapp|||mGlu|||0|794|438|442
SE|25462289||ab|3|entity|C1514758|Receptor Activation|celf|||receptor activation|||0|794|443|462
SE|25462289||ab|3|entity|C1513492|Motor|idcn|||motor|||0|694|471|476
SE|25462289||ab|3|entity|C0030567|Parkinson Disease|dsyn|||PD|||0|1000|495|497
SE|25462289||ab|3|entity|C0547047|Decrease|qnco|||decrease|||0|840|502|510
SE|25462289||ab|3|entity|C0023570|Levodopa|aapp,nsba,phsu|||l-DOPA|||0|840|511|517
SE|25462289||ab|3|entity|C0205263|Induced|ftcn|||induced|||0|840|518|525
SE|25462289||ab|3|entity|C0013384|Dyskinetic syndrome|dsyn|||dyskinesia|||0|840|526|536
SE|25462289||ab|3|entity|C0243077|inhibitors|chvf|||inhibitory|||0|623|566|576
SE|25462289||ab|3|entity|C0004781|Basal Ganglia|bpoc|||basal ganglia|||0|1000|597|610
SE|25462289||ab|3|relation|7|0|C0023570|Levodopa|aapp,gngm,nsba,phsu|aapp|||l-DOPA|||0|840|511|517|ADJ|CAUSES||518|525|7|0|C0013384|Dyskinetic syndrome|dsyn|dsyn|||dyskinesia|||0|840|526|536
SE|25462289||ab|3|relation|7|0|C0023570|Levodopa|aapp,gngm,nsba,phsu|aapp|||l-DOPA|||0|840|511|517|ADJ|CAUSES||518|525|7|0|C0030567|Parkinson Disease|dsyn|dsyn|||PD|||0|1000|495|497

SE|25462289||ab|4|text|612|670|Emotional and cognitive deficits are also observed in PD.
SE|25462289||ab|4|entity|C0849912|Emotional|fndg|||Emotional|||0|1000|612|621
SE|25462289||ab|4|entity|C0679466|COGNITIVE DEFICIT|mobd|||cognitive deficits|||0|1000|626|644
SE|25462289||ab|4|entity|C0030567|Parkinson Disease|dsyn|||PD|||0|1000|666|668
SE|25462289||ab|4|relation|2|1|C0679466|COGNITIVE DEFICIT|mobd|mobd|||cognitive deficits|||0|1000|626|644|PREP|COEXISTS_WITH||663|665|1|1|C0030567|Parkinson Disease|dsyn|dsyn|||PD|||0|1000|666|668
SE|25462289||ab|4|relation|2|1|C0849912|Emotional|fndg|fndg|||Emotional|||0|1000|612|621|PREP|COEXISTS_WITH||663|665|1|1|C0030567|Parkinson Disease|dsyn|dsyn|||PD|||0|1000|666|668

SE|25462289||ab|5|text|670|804|Treatment of these symptoms is challenging and underscore the need for novel effective and well tolerated pharmacological treatments.
SE|25462289||ab|5|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|689|697
SE|25462289||ab|5|entity|C0027552|Needs|qlco|||need|||0|1000|732|736
SE|25462289||ab|5|entity|C0679622|novel|inpr|||novel|||0|888|741|746
SE|25462289||ab|5|entity|C0205170|Good|qlco|||well|||0|1000|761|765
SE|25462289||ab|5|entity|C1519033|Pharmacological Treatment|topp|||pharmacological treatments|||0|1000|776|802
SE|25462289||ab|5|relation|4|4|C1519033|Pharmacological Treatment|topp|topp|||pharmacological treatments|||0|1000|776|802|NOM|TREATS||670|679|4|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|1000|689|697

SE|25462289||ab|6|text|804|977|This article will thus review the currently available knowledge regarding the therapeutic potential of targeting mGlu receptors to restore motor and nonmotor symptoms of PD.
SE|25462289||ab|6|entity|C0521116|Current|tmco|||currently|||0|851|838|847
SE|25462289||ab|6|entity|C0376554|Knowledge|inpr|||knowledge|||0|851|858|867
SE|25462289||ab|6|entity|C0237399|Potential|qlco|||potential|||0|888|894|903
SE|25462289||ab|6|entity|C0206529|Receptors, Metabotropic Glutamate|aapp,rcpt|||mGlu receptors|||0|916|917|931
SE|25462289||ab|6|entity|C1513492|Motor|idcn|||motor|||0|1000|943|948
SE|25462289||ab|6|entity|C1457887|Symptoms|sosy|||symptoms|||0|861|962|970
SE|25462289||ab|6|entity|C0030567|Parkinson Disease|dsyn|||PD|||0|1000|974|976


SE|25462290||ti|1|text|21|79|How does ketamine elicit a rapid antidepressant response?
SE|25462290||ti|1|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|30|38
SE|25462290||ti|1|entity|C0439831|Rapid|qlco|||rapid|||0|851|48|53
SE|25462290||ti|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant|||0|851|54|68
SE|25462290||ti|1|entity|C0871261|response|clna|||response|||0|851|69|77

SE|25462290||ab|1|text|85|310|A single sub-psychotomimetic dose of ketamine, an ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor antagonist, produces a fast-acting antidepressant response in patients suffering from major depressive disorder.
SE|25462290||ab|1|entity|C0037179|Unmarried person|popg|||single|||0|825|87|93
SE|25462290||ab|1|entity|C0542339|Inferior|spco|||sub|||0|825|94|97
SE|25462290||ab|1|entity|C0684170|psychotomimetics|hops|||psychotomimetic|||0|825|98|113
SE|25462290||ab|1|entity|C1446466|Dose|qnco|||dose|||0|825|114|118
SE|25462290||ab|1|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|122|130
SE|25462290||ab|1|entity|C0949756|D-Aspartate|aapp,bacs|||D-aspartate|||0|730|169|180
SE|25462290||ab|1|entity|C1179928|Ionotropic receptor|aapp,rcpt|||ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor|||0|730|135|196
SE|25462290||ab|1|entity|C0456962|Fast|qlco|||fast|||0|775|220|224
SE|25462290||ab|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant|||0|775|232|246
SE|25462290||ab|1|entity|C0871261|response|clna|||response|||0|775|247|255
SE|25462290||ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|259|267
SE|25462290||ab|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|1000|283|308
SE|25462290||ab|1|relation|1|1|C1269683|Major Depressive Disorder|mobd|mobd|||major depressive disorder|||0|1000|283|308|VERB|PROCESS_OF||268|277|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|259|267
SE|25462290||ab|1|relation|2|1|C0022614|Ketamine|orch,phsu|orch|||ketamine|||0|1000|122|130|NOM|INHIBITS||197|207|2|0|C1179928|Ionotropic receptor|aapp,gngm,rcpt|gngm|||ionotropic glutamatergic n-methyl-D-aspartate (NMDA) receptor|||0|730|135|196
SE|25462290||ab|1|relation|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|259|267|PREP|LOCATION_OF||256|258|3|3|C0684170|psychotomimetics|hops|hops|||psychotomimetic|||0|825|98|113

SE|25462290||ab|2|text|310|466|Depressed patients report alleviation of core symptoms within 2 h of a single low-dose intravenous infusion of ketamine with effects lasting up to 2 weeks.
SE|25462290||ab|2|entity|C0030705|Patients|podg|||patients|||0|861|320|328
SE|25462290||ab|2|entity|C0444669|Core|spco|||core|||0|888|351|355
SE|25462290||ab|2|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|356|364
SE|25462290||ab|2|entity|C0037179|Unmarried person|popg|||single|||0|857|381|387
SE|25462290||ab|2|entity|C0445550|Low dose|qnco|||low-dose|||0|857|388|396
SE|25462290||ab|2|entity|C0013125|intravenous administration|spco|||intravenous infusion|||0|857|397|417
SE|25462290||ab|2|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|421|429
SE|25462290||ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|435|442
SE|25462290||ab|2|entity|C1442457|2 Weeks|tmco|||2 weeks|||0|1000|457|464

SE|25462290||ab|3|text|466|621|The rapidity of ketamine action implies that major symptoms of depression can be alleviated without substantial structural plasticity or circuit rewiring.
SE|25462290||ab|3|entity|C0439831|Rapid|qlco|||rapidity|||0|928|470|478
SE|25462290||ab|3|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|694|482|490
SE|25462290||ab|3|entity|C0205164|Major|qlco|||major|||0|888|511|516
SE|25462290||ab|3|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|517|525
SE|25462290||ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|529|539

SE|25462290||ab|4|text|621|823|Therefore, the ability of ketamine to exert a rapid effect provides a unique opportunity to elucidate the types of acute synaptic plasticity changes that can be recruited to counter depression symptoms.
SE|25462290||ab|4|entity|C0085732|Ability|orga|||ability|||0|1000|636|643
SE|25462290||ab|4|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|647|655
SE|25462290||ab|4|entity|C0439831|Rapid|qlco|||rapid|||0|888|667|672
SE|25462290||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|673|679
SE|25462290||ab|4|entity|C0332307|Type - attribute|qlco|||types|||0|1000|727|732
SE|25462290||ab|4|entity|C0205178|acute|tmco|||acute|||0|828|736|741
SE|25462290||ab|4|entity|C0039062|Synapses|bsoj|||synaptic|||0|828|742|750
SE|25462290||ab|4|entity|C0086132|Depressive Symptoms|sosy|||depression symptoms|||0|865|803|822


SE|25462291||ti|1|text|21|131|Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics.
SE|25462291||ti|1|entity|C0441833|Groups|inpr|||Group|||0|1000|21|26
SE|25462291||ti|1|entity|C0441833|Groups|inpr|||group|||0|629|33|38
SE|25462291||ti|1|entity|C0206529|Receptors, Metabotropic Glutamate|aapp,rcpt|||metabotropic glutamate receptor|||0|629|42|73
SE|25462291||ti|1|entity|C0679622|novel|inpr|||novel|||0|851|99|104
SE|25462291||ti|1|entity|C0237399|Potential|qlco|||potential|||0|851|105|114
SE|25462291||ti|1|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotics|||0|851|115|129

SE|25462291||ab|1|text|137|240|Recently, there has been a shift in the schizophrenia field focusing on restoring glutamate signaling.
SE|25462291||ab|1|entity|C0332185|Recent|tmco|||Recently|||0|1000|137|145
SE|25462291||ab|1|entity|C0036341|Schizophrenia|mobd|||schizophrenia|||0|851|177|190
SE|25462291||ab|1|entity|C1521738|Field|cnce|||field|||0|851|191|196
SE|25462291||ab|1|entity|C0000936|Visual Accommodation|clna|||focusing|||0|851|197|205
SE|25462291||ab|1|entity|C0017789|Glutamates|aapp|||glutamate|||0|790|219|228
SE|25462291||ab|1|entity|C0037083|Signal Transduction|celf|||signaling|||0|790|229|238

SE|25462291||ab|2|text|240|392|Extensive preclinical data suggests that mGlu5 PAMs could have efficacy in all three symptom domains but there is concern of potential adverse effects.
SE|25462291||ab|2|entity|C0205231|Extensive|qlco|||Extensive|||0|802|240|249
SE|25462291||ab|2|entity|C1511726|Data|idcn|||data|||0|802|262|266
SE|25462291||ab|2|entity|C1333712|GRM5 gene|gngm|2915|GRM5|mGlu5|||0|872|281|286
SE|25462291||ab|2|entity|C0027961|Nevus of Ota|neop|||PAMs|||0|872|287|291
SE|25462291||ab|2|entity|C0205449|Three|qnco|||three|||0|623|319|324
SE|25462291||ab|2|entity|C1457887|Symptoms|sosy|||symptom|||0|623|325|332
SE|25462291||ab|2|entity|C0237399|Potential|qlco|||potential|||0|901|365|374
SE|25462291||ab|2|entity|C0879626|Adverse effects|patf|||adverse effects|||0|901|375|390

SE|25462291||ab|3|text|392|499|New insights into mechanisms underlying this toxicity may provide a path for discovery of safe mGlu5 PAMs.
SE|25462291||ab|3|entity|C0205314|New|tmco|||New|||0|872|392|395
SE|25462291||ab|3|entity|C0233820|Insight|menp|||insights|||0|872|396|404
SE|25462291||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|410|420
SE|25462291||ab|3|entity|C0600688|Toxic effect|inpo|||toxicity|||0|1000|437|445
SE|25462291||ab|3|entity|C0030664|Pathology|bmod|||path|||0|1000|460|464
SE|25462291||ab|3|entity|C1333712|GRM5 gene|gngm|2915|GRM5|mGlu5|||0|773|487|492
SE|25462291||ab|3|entity|C0027961|Nevus of Ota|neop|||PAMs|||0|773|493|497

SE|25462291||ab|4|text|499|624|Genetic mutations in mGlu1 have been described in schizophrenics creating interest in this receptor as a therapeutic target.
SE|25462291||ab|4|entity|C0026882|Mutation|genf|||Genetic mutations|||0|983|499|516
SE|25462291||ab|4|entity|C1333711|GRM1 gene|gngm|2911|GRM1|mGlu1|||0|1000|520|525
SE|25462291||ab|4|entity|C0543488|Interested|menp|||interest|||0|1000|573|581
SE|25462291||ab|4|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|1000|590|598
SE|25462291||ab|4|relation|1|1|C0026882|Mutation|genf|genf|||Genetic mutations|||0|983|499|516|PREP|PROCESS_OF||517|519|5|1|C1333711|GRM1 gene|gngm,aapp|gngm|2911|GRM1|mGlu1|||0|1000|520|525
SE|25462291||ab|4|relation|4|4|C0026882|Mutation|genf|genf|||Genetic mutations|||0|983|499|516|PREP|PROCESS_OF||582|584|2|1|C0597357|receptor|aapp,gngm,rcpt|gngm|||receptor|||0|1000|590|598

SE|25462291||ab|5|text|624|743|Preclinical data demonstrated the antipsychotic potential of mGlu2/3 agonists but clinical trials were not successful.
SE|25462291||ab|5|entity|C1511726|Data|idcn|||data|||0|861|636|640
SE|25462291||ab|5|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotic|||0|872|658|671
SE|25462291||ab|5|entity|C0237399|Potential|qlco|||potential|||0|872|672|681
SE|25462291||ab|5|entity|||gngm|2912|GRM2|mGlu2|||0|827|685|690
SE|25462291||ab|5|entity|C0243192|agonists|phsu|||agonists|||0|827|693|701
SE|25462291||ab|5|entity|C0008976|Clinical Trials|resa|||clinical trials|||0|1000|706|721
SE|25462291||ab|5|entity|C1518422|Not|ftcn|||not|||0|888|727|730
SE|25462291||ab|5|entity|C1272703|Successful|qlco|||successful|||0|888|731|741

SE|25462291||ab|6|text|743|891|However, studies have suggested that mGlu2 is the subtype mediating antipsychotic effects and selective mGlu2 PAMs are now in clinical development.
SE|25462291||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|752|759
SE|25462291||ab|6|entity|||gngm|2912|GRM2|mGlu2|||0|1000|780|785
SE|25462291||ab|6|entity|C0449560|Subtype|clas|||subtype|||0|1000|793|800
SE|25462291||ab|6|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotic|||0|855|811|824
SE|25462291||ab|6|entity|C1280500|Effect|qlco|||effects|||0|855|825|832
SE|25462291||ab|6|entity|||gngm|2912|GRM2|mGlu2|||0|793|847|852
SE|25462291||ab|6|entity|C0027961|Nevus of Ota|neop|||PAMs|||0|793|853|857
SE|25462291||ab|6|entity|C0205210|Clinical|qlco|||clinical|||0|888|869|877
SE|25462291||ab|6|entity|C1527148|Development|ftcn|||development|||0|888|878|889
SE|25462291||ab|6|relation|3|2|||gngm,aapp|gngm|2912|GRM2|mGlu2|||0|1000|780|785|NOM|INTERACTS_WITH||825|832|3|0|C0040615|Antipsychotic Agents|phsu|phsu|||antipsychotic|||0|855|811|824

SE|25462291||ab|7|text|891|969|Finally, recent genetic studies suggest mGlu3 modulators may be pro-cognitive.
SE|25462291||ab|7|entity|C0332185|Recent|tmco|||recent|||0|840|900|906
SE|25462291||ab|7|entity|C0314603|Genetic|ftcn|||genetic|||0|840|907|914
SE|25462291||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|840|915|922
SE|25462291||ab|7|entity|||gngm|2913|GRM3|mGlu3|||0|1000|931|936
SE|25462291||ab|7|entity|C1516691|Cognitive|ftcn|||cognitive|||0|888|959|968


SE|25462292||ti|1|text|21|92|AMPA receptor potentiators: from drug design to cognitive enhancement.
SE|25462292||ti|1|entity|C0072899|Receptors, AMPA|aapp,rcpt|||AMPA receptor|||0|734|21|34
SE|25462292||ti|1|entity|C0013171|Drug Design|ocdi|||drug design|||0|1000|54|65
SE|25462292||ti|1|entity|C1516691|Cognitive|ftcn|||cognitive|||0|694|69|78

SE|25462292||ab|1|text|98|306|Positive allosteric modulators of ionotropic glutamate receptors have emerged as a target for treating cognitive impairment and neurodegeneration, but also mental illnesses such as major depressive disorder.
SE|25462292||ab|1|entity|C1446409|Positive|qlco|||Positive|||0|660|98|106
SE|25462292||ab|1|entity|C0061465|Glutamate Receptor|aapp,rcpt|||glutamate receptors|||0|901|143|162
SE|25462292||ab|1|entity|C1522326|Treating|qlco|||treating|||0|901|192|200
SE|25462292||ab|1|entity|C0338656|Impaired cognition|fndg|||cognitive impairment|||0|901|201|221
SE|25462292||ab|1|entity|C0027746|Nerve Degeneration|comd|||neurodegeneration|||0|1000|226|243
SE|25462292||ab|1|entity|C0004936|Mental disorders|mobd|||mental illnesses|||0|884|254|270
SE|25462292||ab|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|1000|279|304
SE|25462292||ab|1|relation|0|0|C1269683|Major Depressive Disorder|mobd|mobd|||major depressive disorder|||0|1000|279|304|SPEC|ISA||254|304|0|0|C0004936|Mental disorders|mobd|mobd|||mental illnesses|||0|884|254|270

SE|25462292||ab|2|text|306|540|The possibility of creating a new class of pharmaceutical agent to treat refractive mental health issues has compelled researchers to redouble their efforts to develop a safe, effective treatment for memory and cognition impairments.
SE|25462292||ab|2|entity|C0205314|New|tmco|||new|||0|888|336|339
SE|25462292||ab|2|entity|C0008902|Classification|clas|||class|||0|888|340|345
SE|25462292||ab|2|entity|C1254351|Pharmacologic Substance|phsu|||pharmaceutical agent|||0|1000|349|369
SE|25462292||ab|2|entity|C0025353|mental health|idcn|||mental health|||0|694|390|403
SE|25462292||ab|2|entity|C0035173|Research Personnel|prog|||researchers|||0|861|425|436
SE|25462292||ab|2|entity|C0025260|Memory|menp|||memory|||0|1000|506|512
SE|25462292||ab|2|entity|C0338656|Impaired cognition|fndg|||cognition impairments|||0|947|517|538

SE|25462292||ab|3|text|540|841|Coupled with the more robust research methodologies that have emerged, including more sophisticated high-throughput-screens, higher resolution structural biology techniques, and more focused assessment on pharmacokinetics, the development of positive modulators of AMPA receptors holds great promise.
SE|25462292||ab|3|entity|C0205172|More|ftcn|||more|||0|813|557|561
SE|25462292||ab|3|entity|C0086912|Research Methodology|resa|||research methodologies|||0|813|569|591
SE|25462292||ab|3|entity|C0205172|More|ftcn|||more|||0|1000|621|625
SE|25462292||ab|3|entity|C0205250|High|qlco|||high|||0|802|640|644
SE|25462292||ab|3|entity|C0183185|Screens|medd|||screens|||0|802|656|663
SE|25462292||ab|3|entity|C0205250|High|qlco|||higher|||0|833|665|671
SE|25462292||ab|3|entity|C1514893|Resolution|ftcn|||resolution|||0|833|672|682
SE|25462292||ab|3|entity|C0597531|Structural Biology|ocdi|||structural biology|||0|833|683|701
SE|25462292||ab|3|entity|C0025664|Methodology|inpr|||techniques|||0|833|702|712
SE|25462292||ab|3|entity|C0205172|More|ftcn|||more|||0|840|718|722
SE|25462292||ab|3|entity|C0000936|Visual Accommodation|clna|||focused|||0|840|723|730
SE|25462292||ab|3|entity|C0220825|Evaluation|ftcn|||assessment|||0|840|731|741
SE|25462292||ab|3|entity|C0031327|Drug Kinetics|phsf|||pharmacokinetics|||0|1000|745|761
SE|25462292||ab|3|entity|C1527148|Development|ftcn|||development|||0|1000|767|778
SE|25462292||ab|3|entity|C1446409|Positive|qlco|||positive|||0|694|782|790
SE|25462292||ab|3|entity|C0072899|Receptors, AMPA|aapp,rcpt|||AMPA receptors|||0|1000|805|819
SE|25462292||ab|3|entity|C0549177|Large|qnco|||great|||0|888|826|831
SE|25462292||ab|3|entity|C1555307|promise|idcn|||promise|||0|888|832|839

SE|25462292||ab|4|text|841|1011|We describe recent approaches that improve our understanding of the basic physiology underlying memory and cognition, and their application toward promoting human health.
SE|25462292||ab|4|entity|C0332185|Recent|tmco|||recent|||0|888|853|859
SE|25462292||ab|4|entity|C0449445|Approach|spco|||approaches|||0|888|860|870
SE|25462292||ab|4|entity|C0031842|Physiology|bmod|||physiology|||0|751|915|925
SE|25462292||ab|4|entity|C0025260|Memory|menp|||memory|||0|751|937|943
SE|25462292||ab|4|entity|C0009240|Cognition|menp|||cognition|||0|1000|948|957
SE|25462292||ab|4|entity|C0020114|Human|humn|||human|||0|790|998|1003
SE|25462292||ab|4|entity|C0018684|Health|idcn|||health|||0|790|1004|1010


SE|25462294||ti|1|text|21|117|Reproductive responses of the earthworm (Eisenia fetida) to antiparasitic albendazole exposure.
SE|25462294||ti|1|entity|C0748342|REPRODUCTIVE|clas|||Reproductive|||0|888|21|33
SE|25462294||ti|1|entity|C0871261|response|clna|||responses|||0|888|34|43
SE|25462294||ti|1|entity|C0086194|Pheretima sieboldi|invt|||earthworm|||0|1000|51|60
SE|25462294||ti|1|entity|C0524676|Eisenia foetida|invt|||Eisenia fetida|||0|1000|62|76
SE|25462294||ti|1|entity|C0001911|Albendazole|orch,phsu|||albendazole|||0|660|95|106

SE|25462294||ab|1|text|123|204|Albendazole (ABZ) is a veterinary drug with a high efficiency against helminths.
SE|25462294||ab|1|entity|C0001911|Albendazole|orch,phsu|||Albendazole|||0|1000|123|134
SE|25462294||ab|1|entity|C0376438|Veterinary Drugs|phsu|||veterinary drug|||0|1000|146|161
SE|25462294||ab|1|entity|C0205250|High|qlco|||high|||0|888|169|173
SE|25462294||ab|1|entity|C0013682|Efficiency|qnco|||efficiency|||0|888|174|184
SE|25462294||ab|1|entity|C0018893|Helminths|invt|||helminths|||0|1000|193|202

SE|25462294||ab|2|text|204|544|Here reproductive responses of earthworms Eisenia fetida to ABZ exposure (0, 1, 3, 6, 9 and 12 mg kg(-1) soil dry weight) were investigated for 56 d in chronic reproduction test, and deformed sperm were counted and morphological alterations in the seminal vesicles were qualitatively assessed by light and transmission electron microscopy.
SE|25462294||ab|2|entity|C0748342|REPRODUCTIVE|clas|||reproductive|||0|790|209|221
SE|25462294||ab|2|entity|C0871261|response|clna|||responses|||0|790|222|231
SE|25462294||ab|2|entity|C0086194|Pheretima sieboldi|invt|||earthworms|||0|901|235|245
SE|25462294||ab|2|entity|C0524676|Eisenia foetida|invt|||Eisenia fetida|||0|901|246|260
SE|25462294||ab|2|entity|C0001911|Albendazole|orch,phsu|||ABZ|||0|694|264|267
SE|25462294||ab|2|entity|C0439209|Kilogram|qnco|||kg|||0|750|302|304
SE|25462294||ab|2|entity|C0037592|Soil|sbst|||soil|||0|901|309|313
SE|25462294||ab|2|entity|C1439839|DRY WEIGHT|qnco|||dry weight|||0|901|314|324
SE|25462294||ab|2|entity|C0205191|chronic|tmco|||chronic|||0|882|356|363
SE|25462294||ab|2|entity|C0679560|Genetic screening method|lbpr|||reproduction test|||0|882|364|381
SE|25462294||ab|2|entity|C0333067|Deformed|ftcn|||deformed|||0|694|387|395
SE|25462294||ab|2|entity|C1260954|Morphologically altered structure|anab|||morphological alterations|||0|933|419|444
SE|25462294||ab|2|entity|C0036628|Seminal Vesicles|bpoc|||seminal vesicles|||0|1000|452|468
SE|25462294||ab|2|entity|C0678118|Transmission Electron Microscopy|lbpr|||transmission electron microscopy|||0|1000|510|542
SE|25462294||ab|2|relation|3|1|C0036628|Seminal Vesicles|bpoc|bpoc|||seminal vesicles|||0|1000|452|468|PREP|LOCATION_OF||445|447|8|1|C1260954|Morphologically altered structure|anab|anab|||morphological alterations|||0|933|419|444

SE|25462294||ab|3|text|544|787|Results have showed that cocoon number of earthworms was more sensitive to low concentrations of ABZ than cocoon hatching success and hatching survival, showing a significant dose-related decrease in cocoon number at 3, 6, 9 and 12 mg kg(-1).
SE|25462294||ab|3|entity|C1274040|result|ftcn|||Results|||0|966|544|551
SE|25462294||ab|3|entity|C0237753|Numbers|qnco|||number|||0|861|576|582
SE|25462294||ab|3|entity|C0086194|Pheretima sieboldi|invt|||earthworms|||0|1000|586|596
SE|25462294||ab|3|entity|C0205172|More|ftcn|||more|||0|888|601|605
SE|25462294||ab|3|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|606|615
SE|25462294||ab|3|entity|C0205251|low|qlco|||low|||0|888|619|622
SE|25462294||ab|3|entity|C0001911|Albendazole|orch,phsu|||ABZ|||0|1000|641|644
SE|25462294||ab|3|entity|C0598016|hatching|orgf|||hatching|||0|790|657|665
SE|25462294||ab|3|entity|C0597535|Success|socb|||success|||0|790|666|673
SE|25462294||ab|3|entity|C0598016|hatching|orgf|||hatching|||0|888|678|686
SE|25462294||ab|3|entity|C0038952|Continuance of life|acty|||survival|||0|888|687|695
SE|25462294||ab|3|entity|C0750502|Significant|idcn|||significant|||0|833|707|718
SE|25462294||ab|3|entity|C1446466|Dose|qnco|||dose|||0|833|719|723
SE|25462294||ab|3|entity|C1522149|Related|ftcn|||related|||0|833|724|731
SE|25462294||ab|3|entity|C0547047|Decrease|qnco|||decrease|||0|833|732|740
SE|25462294||ab|3|entity|C0237753|Numbers|qnco|||number|||0|861|751|757
SE|25462294||ab|3|entity|C0439209|Kilogram|qnco|||kg|||0|750|779|781

SE|25462294||ab|4|text|787|1234|In short-time exposure of 14 d, the sperm deformity (%) of earthworms increased at 6, 9 and 12 mg kg(-1), and the microstructural alteration in seminal vesicles was also observed at these concentrations, whereas ultrastructural alteration of germ cells, particularly morphology of mitochondria, was observed at 3 mg kg(-1) and above, suggesting the high sensitivity of germ cell ultrastructure to low concentrations of ABZ in short-time exposure.
SE|25462294||ab|4|entity|C0040223|Time|tmco|||time|||0|623|796|800
SE|25462294||ab|4|entity|C0000768|Congenital Abnormality|cgab|||deformity|||0|861|829|838
SE|25462294||ab|4|entity|C0086194|Pheretima sieboldi|invt|||earthworms|||0|1000|846|856
SE|25462294||ab|4|entity|C0439209|Kilogram|qnco|||kg|||0|750|885|887
SE|25462294||ab|4|entity|C1515926|Alteration|idcn|||alteration|||0|861|917|927
SE|25462294||ab|4|entity|C0036628|Seminal Vesicles|bpoc|||seminal vesicles|||0|1000|931|947
SE|25462294||ab|4|entity|C0041623|Ultrastructure|idcn|||ultrastructural|||0|853|999|1014
SE|25462294||ab|4|entity|C1515926|Alteration|idcn|||alteration|||0|853|1015|1025
SE|25462294||ab|4|entity|C0017471|Germ Cells|cell|||germ cells|||0|1000|1029|1039
SE|25462294||ab|4|entity|C0332437|Morphology|qlco|||morphology|||0|861|1054|1064
SE|25462294||ab|4|entity|C0026237|Mitochondria|celc|||mitochondria|||0|1000|1068|1080
SE|25462294||ab|4|entity|C0439209|Kilogram|qnco|||kg|||0|775|1103|1105
SE|25462294||ab|4|entity|C1282910|Upper|spco|||above|||0|1000|1114|1119
SE|25462294||ab|4|entity|C1441604|HIGH SENSITIVITY|lbpr|||high sensitivity|||0|1000|1136|1152
SE|25462294||ab|4|entity|C0017471|Germ Cells|cell|||germ cell|||0|901|1156|1165
SE|25462294||ab|4|entity|C0041623|Ultrastructure|idcn|||ultrastructure|||0|901|1166|1180
SE|25462294||ab|4|entity|C0205251|low|qlco|||low|||0|888|1184|1187
SE|25462294||ab|4|entity|C0001911|Albendazole|orch,phsu|||ABZ|||0|1000|1206|1209
SE|25462294||ab|4|entity|C0040223|Time|tmco|||time|||0|623|1219|1223

SE|25462294||ab|5|text|1234|1337|The results can provide important information for prediction of ecologically significant toxic effects.
SE|25462294||ab|5|entity|C1274040|result|ftcn|||results|||0|966|1238|1245
SE|25462294||ab|5|entity|C1533716|Information|idcn|||information|||0|861|1268|1279
SE|25462294||ab|5|entity|C0681842|prediction|inpr|||prediction|||0|1000|1284|1294
SE|25462294||ab|5|entity|C0750502|Significant|idcn|||significant|||0|813|1311|1322
SE|25462294||ab|5|entity|C0600688|Toxic effect|inpo|||toxic effects|||0|813|1323|1336


SE|25462295||ti|1|text|21|103|Impact of repeated single-metal and multi-metal pollution events on soil quality.
SE|25462295||ti|1|entity|C0205341|Repeat|ftcn|||repeated|||0|851|31|39
SE|25462295||ti|1|entity|C0037179|Unmarried person|popg|||single|||0|851|40|46
SE|25462295||ti|1|entity|C0025552|Metals|inch|||metal|||0|851|47|52
SE|25462295||ti|1|entity|C1442112|MULTI|qnco|||multi|||0|833|57|62
SE|25462295||ti|1|entity|C0025552|Metals|inch|||metal|||0|833|63|68
SE|25462295||ti|1|entity|C0392355|Pollution|eehu|||pollution|||0|833|69|78
SE|25462295||ti|1|entity|C0441471|Events|evnt|||events|||0|833|79|85
SE|25462295||ti|1|entity|C0037592|Soil|sbst|||soil|||0|888|89|93
SE|25462295||ti|1|entity|C0332306|Quality|qlco|||quality|||0|888|94|101

SE|25462295||ab|1|text|109|302|Most frequently, soil metal pollution results from the occurrence of repeated single-metal and, above all, multi-metal pollution events, with concomitant adverse consequences for soil quality.
SE|25462295||ab|1|entity|C0205393|Most|qnco|||Most|||0|888|109|113
SE|25462295||ab|1|entity|C0332183|Frequent|tmco|||frequently|||0|888|114|124
SE|25462295||ab|1|entity|C0025552|Metals|inch|||metal|||0|901|131|136
SE|25462295||ab|1|entity|C0522737|Soil pollution|eehu|||soil metal pollution|||0|901|126|146
SE|25462295||ab|1|entity|C0243132|occurrence|qnco|||occurrence|||0|1000|164|174
SE|25462295||ab|1|entity|C0205341|Repeat|ftcn|||repeated|||0|851|178|186
SE|25462295||ab|1|entity|C0037179|Unmarried person|popg|||single|||0|851|187|193
SE|25462295||ab|1|entity|C0025552|Metals|inch|||metal|||0|851|194|199
SE|25462295||ab|1|entity|C1442112|MULTI|qnco|||multi|||0|833|216|221
SE|25462295||ab|1|entity|C0025552|Metals|inch|||metal|||0|833|222|227
SE|25462295||ab|1|entity|C0392355|Pollution|eehu|||pollution|||0|833|228|237
SE|25462295||ab|1|entity|C0441471|Events|evnt|||events|||0|833|238|244
SE|25462295||ab|1|entity|C1516780|Concomitant|qlco|||concomitant|||0|660|251|262
SE|25462295||ab|1|entity|C0037592|Soil|sbst|||soil|||0|888|288|292
SE|25462295||ab|1|entity|C0332306|Quality|qlco|||quality|||0|888|293|300

SE|25462295||ab|2|text|302|566|Therefore, in this study, we evaluated the impact of repeated single-metal and multi-metal (Cd, Pb, Cu, Zn) pollution events on soil quality, as reflected by the values of a variety of soil microbial parameters with potential as bioindicators of soil functioning.
SE|25462295||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|321|326
SE|25462295||ab|2|entity|C0205341|Repeat|ftcn|||repeated|||0|851|355|363
SE|25462295||ab|2|entity|C0037179|Unmarried person|popg|||single|||0|851|364|370
SE|25462295||ab|2|entity|C0025552|Metals|inch|||metal|||0|851|371|376
SE|25462295||ab|2|entity|C1442112|MULTI|qnco|||multi|||0|888|381|386
SE|25462295||ab|2|entity|C0025552|Metals|inch|||metal|||0|888|387|392
SE|25462295||ab|2|entity|C0392355|Pollution|eehu|||pollution|||0|888|410|419
SE|25462295||ab|2|entity|C0441471|Events|evnt|||events|||0|888|420|426
SE|25462295||ab|2|entity|C0037592|Soil|sbst|||soil|||0|888|430|434
SE|25462295||ab|2|entity|C0332306|Quality|qlco|||quality|||0|888|435|442
SE|25462295||ab|2|entity|C0042295|Values|qlco|||values|||0|1000|464|470
SE|25462295||ab|2|entity|C0037592|Soil|sbst|||soil|||0|851|487|491
SE|25462295||ab|2|entity|C0599840|microbial|orgm|||microbial|||0|851|492|501
SE|25462295||ab|2|entity|C0237399|Potential|qlco|||potential|||0|1000|518|527
SE|25462295||ab|2|entity|C0037592|Soil|sbst|||soil|||0|872|548|552
SE|25462295||ab|2|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|553|564

SE|25462295||ab|3|text|566|873|Specifically, parameters of microbial activity (potentially mineralizable nitrogen, beta-glucosidase and acid phosphatase activity) and biomass (fungal and bacterial gene abundance by RT-qPCR) were determined, in the artificially metal-polluted soil samples, at regular intervals over a period of 26 weeks.
SE|25462295||ab|3|entity|C0599840|microbial|orgm|||microbial|||0|888|594|603
SE|25462295||ab|3|entity|C0028158|Nitrogen|elii|||nitrogen|||0|827|640|648
SE|25462295||ab|3|entity|C0005223|beta-Glucosidase|aapp,enzy|||beta-glucosidase|||0|1000|650|666
SE|25462295||ab|3|entity|C1149886|acid phosphatase activity|moft|||acid phosphatase activity|||0|1000|671|696
SE|25462295||ab|3|entity|C0005535|Biomass|qnco|||biomass|||0|1000|702|709
SE|25462295||ab|3|entity|C0016832|fungus|fngs|||fungal|||0|1000|711|717
SE|25462295||ab|3|entity|C0017339|Genes, Bacterial|gngm|||bacterial gene|||0|734|722|736
SE|25462295||ab|3|entity|C0025552|Metals|inch|||metal|||0|619|796|801
SE|25462295||ab|3|entity|C0522737|Soil pollution|eehu|||polluted soil|||0|619|802|815
SE|25462295||ab|3|entity|C0205272|Regular|qlco|||regular|||0|872|828|835
SE|25462295||ab|3|entity|C1272706|Interval|tmco|||intervals|||0|872|836|845
SE|25462295||ab|3|entity|C0205136|Over|spco|||over|||0|1000|846|850
SE|25462295||ab|3|entity|C0439531|/period|tmco|||period|||0|1000|853|859
SE|25462295||ab|3|entity|C0439230|week|tmco|||weeks|||0|861|866|871

SE|25462295||ab|4|text|873|1009|Similarly, we studied the evolution over time of CaCl2-extractable metal fractions, in order to estimate metal bioavailability in soil.
SE|25462295||ab|4|entity|C0015219|Evolution|genf|||evolution|||0|802|899|908
SE|25462295||ab|4|entity|C0040223|Time|tmco|||time|||0|802|914|918
SE|25462295||ab|4|entity|C0025552|Metals|inch|||metal|||0|750|940|945
SE|25462295||ab|4|entity|C1264633|Fraction of|qnco|||fractions|||0|750|946|955
SE|25462295||ab|4|entity|C0025552|Metals|inch|||metal|||0|888|978|983
SE|25462295||ab|4|entity|C0005508|Biological Availability|qnco|||bioavailability|||0|888|984|999
SE|25462295||ab|4|entity|C0037592|Soil|sbst|||soil|||0|1000|1003|1007

SE|25462295||ab|5|text|1009|1224|Different metals showed different values of bioavailability and relative bioavailability ([metal]bio/[metal]tot) in soil throughout the experiment, under both repeated single-metal and multi-metal pollution events.
SE|25462295||ab|5|entity|C1547020|*Difference|qnco|||Different|||0|853|1009|1018
SE|25462295||ab|5|entity|C0025552|Metals|inch|||metals|||0|853|1019|1025
SE|25462295||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|1033|1042
SE|25462295||ab|5|entity|C0042295|Values|qlco|||values|||0|853|1043|1049
SE|25462295||ab|5|entity|C0005508|Biological Availability|qnco|||bioavailability|||0|1000|1053|1068
SE|25462295||ab|5|entity|C0205345|Relative|qlco|||relative|||0|888|1073|1081
SE|25462295||ab|5|entity|C0005508|Biological Availability|qnco|||bioavailability|||0|888|1082|1097
SE|25462295||ab|5|entity|C0025552|Metals|inch|||metal|||0|1000|1100|1105
SE|25462295||ab|5|entity|C0205460|biological|ftcn|||bio|||0|1000|1106|1109
SE|25462295||ab|5|entity|C0025552|Metals|inch|||metal|||0|1000|1111|1116
SE|25462295||ab|5|entity|C0037592|Soil|sbst|||soil|||0|1000|1125|1129
SE|25462295||ab|5|entity|C0681814|research study|resa|||experiment|||0|1000|1145|1155
SE|25462295||ab|5|entity|C0205341|Repeat|ftcn|||repeated|||0|851|1168|1176
SE|25462295||ab|5|entity|C0037179|Unmarried person|popg|||single|||0|851|1177|1183
SE|25462295||ab|5|entity|C0025552|Metals|inch|||metal|||0|851|1184|1189
SE|25462295||ab|5|entity|C1442112|MULTI|qnco|||multi|||0|833|1194|1199
SE|25462295||ab|5|entity|C0025552|Metals|inch|||metal|||0|833|1200|1205
SE|25462295||ab|5|entity|C0392355|Pollution|eehu|||pollution|||0|833|1206|1215
SE|25462295||ab|5|entity|C0441471|Events|evnt|||events|||0|833|1216|1222

SE|25462295||ab|6|text|1224|1521|Both repeated Zn-pollution and multi-metal pollution events led to a significant reduction in the values of acid phosphatase activity, and bacterial and fungal gene abundance, reflecting the negative impact of these repeated events on soil microbial activity and biomass, and, hence, soil quality.
SE|25462295||ab|6|entity|C0205341|Repeat|ftcn|||repeated|||0|851|1229|1237
SE|25462295||ab|6|entity|C0392355|Pollution|eehu|||pollution|||0|851|1241|1250
SE|25462295||ab|6|entity|C1442112|MULTI|qnco|||multi|||0|833|1255|1260
SE|25462295||ab|6|entity|C0025552|Metals|inch|||metal|||0|833|1261|1266
SE|25462295||ab|6|entity|C0392355|Pollution|eehu|||pollution|||0|833|1267|1276
SE|25462295||ab|6|entity|C0441471|Events|evnt|||events|||0|833|1277|1283
SE|25462295||ab|6|entity|C0750502|Significant|idcn|||significant|||0|694|1293|1304
SE|25462295||ab|6|entity|C0042295|Values|qlco|||values|||0|1000|1322|1328
SE|25462295||ab|6|entity|C1149886|acid phosphatase activity|moft|||acid phosphatase activity|||0|1000|1332|1357
SE|25462295||ab|6|entity|C0521009|Bacterial|ftcn|||bacterial|||0|1000|1363|1372
SE|25462295||ab|6|entity|C0017345|Genes, Fungal|gngm|||fungal gene|||0|734|1377|1388
SE|25462295||ab|6|entity|C0205160|Negative|qlco|||negative|||0|888|1415|1423
SE|25462295||ab|6|entity|C0205341|Repeat|ftcn|||repeated|||0|888|1440|1448
SE|25462295||ab|6|entity|C0441471|Events|evnt|||events|||0|888|1449|1455
SE|25462295||ab|6|entity|C0037592|Soil|sbst|||soil|||0|851|1459|1463
SE|25462295||ab|6|entity|C0599840|microbial|orgm|||microbial|||0|851|1464|1473
SE|25462295||ab|6|entity|C0005535|Biomass|qnco|||biomass|||0|1000|1487|1494
SE|25462295||ab|6|entity|C0037592|Soil|sbst|||soil|||0|888|1508|1512
SE|25462295||ab|6|entity|C0332306|Quality|qlco|||quality|||0|888|1513|1520


SE|25462293||ti|1|text|21|88|Recent insights into the mode of action of memantine and ketamine.
SE|25462293||ti|1|entity|C0332185|Recent|tmco|||Recent|||0|872|21|27
SE|25462293||ti|1|entity|C0233820|Insight|menp|||insights|||0|872|28|36
SE|25462293||ti|1|entity|C1513371|Mode|ftcn|||mode|||0|1000|46|50
SE|25462293||ti|1|entity|C0025242|Memantine|orch,phsu|||memantine|||0|1000|64|73
SE|25462293||ti|1|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|78|86

SE|25462293||ab|1|text|94|294|The clinical benefits of the glutamate receptor antagonists memantine and ketamine have helped sustain optimism that glutamate receptors represent viable targets for development of therapeutic drugs.
SE|25462293||ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|98|106
SE|25462293||ab|1|entity|C0814225|Benefits|qnco|||benefits|||0|888|107|115
SE|25462293||ab|1|entity|C0242910|Excitatory Amino Acid Antagonists|phsu|||glutamate receptor antagonists|||0|916|123|153
SE|25462293||ab|1|entity|C0025242|Memantine|orch,phsu|||memantine|||0|916|154|163
SE|25462293||ab|1|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|168|176
SE|25462293||ab|1|entity|C0237428|Positive attitude|menp|||optimism|||0|1000|197|205
SE|25462293||ab|1|entity|C0061465|Glutamate Receptor|aapp,rcpt|||glutamate receptors|||0|1000|211|230
SE|25462293||ab|1|entity|C0443348|Viable|qlco|||viable|||0|872|241|247
SE|25462293||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|260|271
SE|25462293||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|888|287|292
SE|25462293||ab|1|relation|0|0|C0025242|Memantine|orch,phsu|orch|||memantine|||0|916|154|163|MOD/HEAD|ISA||123|163|0|0|C0242910|Excitatory Amino Acid Antagonists|phsu|phsu|||glutamate receptor antagonists|||0|916|123|153

SE|25462293||ab|2|text|294|455|Both memantine and ketamine antagonize N-methyl-D-aspartate receptors (NMDARs), a glutamate receptor subfamily, by blocking the receptor-associated ion channel.
SE|25462293||ab|2|entity|C0025242|Memantine|orch,phsu|||memantine|||0|1000|299|308
SE|25462293||ab|2|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|313|321
SE|25462293||ab|2|entity|C0080093|N-Methyl-D-Aspartate Receptors|aapp,rcpt|||N-methyl-D-aspartate receptors|||0|1000|333|363
SE|25462293||ab|2|entity|C0061465|Glutamate Receptor|aapp,rcpt|||glutamate receptor|||0|734|376|394
SE|25462293||ab|2|entity|C0332206|Blocking|ftcn|||blocking|||0|1000|409|417
SE|25462293||ab|2|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|824|422|430
SE|25462293||ab|2|entity|C0022009|Ion Channel|aapp,bacs|||ion channel|||0|824|442|453
SE|25462293||ab|2|relation|2|1|C0022614|Ketamine|orch,phsu|orch|||ketamine|||0|1000|313|321|VERB|INHIBITS||322|332|3|1|C0080093|N-Methyl-D-Aspartate Receptors|aapp,gngm,rcpt|gngm|||N-methyl-D-aspartate receptors|||0|1000|333|363
SE|25462293||ab|2|relation|2|1|C0025242|Memantine|orch,phsu|orch|||memantine|||0|1000|299|308|VERB|INHIBITS||322|332|3|1|C0080093|N-Methyl-D-Aspartate Receptors|aapp,gngm,rcpt|gngm|||N-methyl-D-aspartate receptors|||0|1000|333|363

SE|25462293||ab|3|text|455|642|Although many of the basic characteristics of NMDAR inhibition by memantine and ketamine appear similar, their effects on humans and to a lesser extent on rodents are strongly divergent.
SE|25462293||ab|3|entity|C1521970|Characteristics|grpa|||characteristics|||0|853|482|497
SE|25462293||ab|3|entity|C0025242|Memantine|orch,phsu|||memantine|||0|1000|521|530
SE|25462293||ab|3|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|535|543
SE|25462293||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|566|573
SE|25462293||ab|3|entity|C0020114|Human|humn|||humans|||0|1000|577|583
SE|25462293||ab|3|entity|C0547044|Smaller|qlco|||lesser|||0|888|593|599
SE|25462293||ab|3|entity|C0439792|Extent|spco|||extent|||0|888|600|606
SE|25462293||ab|3|entity|C0035804|Rodent|mamm|||rodents|||0|1000|610|617
SE|25462293||ab|3|entity|C0443204|Divergence|spco|||divergent|||0|789|631|640
SE|25462293||ab|3|relation|2|1|C0035804|Rodent|mamm|mamm|||rodents|||0|1000|610|617|PREP|LOCATION_OF||607|609|8|5|C0022614|Ketamine|orch,phsu|orch|||ketamine|||0|1000|535|543
SE|25462293||ab|3|relation|2|1|C0035804|Rodent|mamm|mamm|||rodents|||0|1000|610|617|PREP|LOCATION_OF||607|609|8|5|C0025242|Memantine|orch,phsu|orch|||memantine|||0|1000|521|530

SE|25462293||ab|4|text|642|820|Some recent research suggests that preferential inhibition by memantine and ketamine of distinct NMDAR subpopulations may contribute to the drugs' differential clinical effects.
SE|25462293||ab|4|entity|C0332185|Recent|tmco|||recent|||0|888|647|653
SE|25462293||ab|4|entity|C0035168|research|resa|||research|||0|888|654|662
SE|25462293||ab|4|entity|C0558295|preference|clna|||preferential|||0|853|677|689
SE|25462293||ab|4|entity|C0025242|Memantine|orch,phsu|||memantine|||0|1000|704|713
SE|25462293||ab|4|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|718|726
SE|25462293||ab|4|entity|C0205210|Clinical|qlco|||clinical|||0|813|802|810
SE|25462293||ab|4|entity|C0728866|Drug effect|ftcn|||drugs' differential clinical effects|||0|813|782|818

SE|25462293||ab|5|text|820|946|Here we review studies that shed light on possible explanations for differences between the effects of memantine and ketamine.
SE|25462293||ab|5|entity|C0332149|Possible|qlco|||possible|||0|872|862|870
SE|25462293||ab|5|entity|C0681841|explanation|resa|||explanations|||0|872|871|883
SE|25462293||ab|5|entity|C1547020|*Difference|qnco|||differences|||0|966|888|899
SE|25462293||ab|5|entity|C1280500|Effect|qlco|||effects|||0|966|912|919
SE|25462293||ab|5|entity|C0025242|Memantine|orch,phsu|||memantine|||0|1000|923|932
SE|25462293||ab|5|entity|C0022614|Ketamine|orch,phsu|||ketamine|||0|1000|937|945


SE|25462296||ti|1|text|21|102|Evaluation of toxicity data to green algae and relationship with hydrophobicity.
SE|25462296||ti|1|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|21|31
SE|25462296||ti|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|35|43
SE|25462296||ti|1|entity|C1511726|Data|idcn|||data|||0|888|44|48
SE|25462296||ti|1|entity|C0002032|Algae, Green|alga|||green algae|||0|1000|52|63
SE|25462296||ti|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|68|80
SE|25462296||ti|1|entity|C0598629|Hydrophobicity|qlco|||hydrophobicity|||0|1000|86|100

SE|25462296||ab|1|text|108|264|The quality of the biological activity data is of great importance for the development of algal quantitative structure-activity relationship (QSAR) models.
SE|25462296||ab|1|entity|C0332306|Quality|qlco|||quality|||0|1000|112|119
SE|25462296||ab|1|entity|C0205460|biological|ftcn|||biological|||0|851|127|137
SE|25462296||ab|1|entity|C1511726|Data|idcn|||data|||0|851|147|151
SE|25462296||ab|1|entity|C0549177|Large|qnco|||great|||0|694|158|163
SE|25462296||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|183|194
SE|25462296||ab|1|entity|C0002028|Algae|alga|||algal|||0|803|198|203
SE|25462296||ab|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|803|204|216
SE|25462296||ab|1|entity|C0439849|Relationships|qlco|||relationship|||0|803|236|248
SE|25462296||ab|1|entity|C0026349|Models, Structural|mnob|||-activity relationship (QSAR) models|||0|803|226|262

SE|25462296||ab|2|text|264|445|However, a number of algal QSAR models in the literature were developed based on toxicity data without considering the response endpoints, exposure periods and species sensitivity.
SE|25462296||ab|2|entity|C0002028|Algae|alga|||algal|||0|914|285|290
SE|25462296||ab|2|entity|C0887819|Quantitative Structure-Activity Relationship|qnco|||QSAR|||0|914|291|295
SE|25462296||ab|2|entity|C0023866|Literature|inpr|||literature|||0|1000|310|320
SE|25462296||ab|2|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|345|353
SE|25462296||ab|2|entity|C1511726|Data|idcn|||data|||0|888|354|358
SE|25462296||ab|2|entity|C0750591|CONSIDER|idcn|||considering|||0|966|367|378
SE|25462296||ab|2|entity|C0871261|response|clna|||response|||0|888|383|391
SE|25462296||ab|2|entity|C0150100|End Point|resa|||endpoints|||0|888|392|401
SE|25462296||ab|2|entity|C0439531|/period|tmco|||periods|||0|827|412|419
SE|25462296||ab|2|entity|C1548151|Species|idcn|||species|||0|888|424|431

SE|25462296||ab|3|text|445|730|In this paper, 2323 algal toxicity data (log 1/EC50) in different toxicity response endpoints for 1081 compounds to 26 algal species within different exposure periods (14 and 15 min; 24, 48, 72, 96, 168 and 192 h) were used to evaluate the quality of the toxicity data to green algae.
SE|25462296||ab|3|entity|C0030351|Paper|mnob|||paper|||0|1000|453|458
SE|25462296||ab|3|entity|C0304056|Algal toxin|hops,orch|||algal toxicity|||0|791|465|479
SE|25462296||ab|3|entity|C1511726|Data|idcn|||data|||0|791|480|484
SE|25462296||ab|3|entity|C1547020|*Difference|qnco|||different|||0|815|501|510
SE|25462296||ab|3|entity|C0600688|Toxic effect|inpo|||toxicity|||0|815|511|519
SE|25462296||ab|3|entity|C0871261|response|clna|||response|||0|815|520|528
SE|25462296||ab|3|entity|C0150100|End Point|resa|||endpoints|||0|815|529|538
SE|25462296||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|827|548|557
SE|25462296||ab|3|entity|C0002028|Algae|alga|||algal|||0|754|564|569
SE|25462296||ab|3|entity|C1548151|Species|idcn|||species|||0|754|570|577
SE|25462296||ab|3|entity|C1547020|*Difference|qnco|||different|||0|750|585|594
SE|25462296||ab|3|entity|C0439531|/period|tmco|||periods|||0|750|604|611
SE|25462296||ab|3|entity|C0439232|Minute of time|tmco|||min|||0|861|623|626
SE|25462296||ab|3|entity|C0332306|Quality|qlco|||quality|||0|1000|685|692
SE|25462296||ab|3|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|700|708
SE|25462296||ab|3|entity|C1511726|Data|idcn|||data|||0|888|709|713
SE|25462296||ab|3|entity|C0002032|Algae, Green|alga|||green algae|||0|1000|717|728

SE|25462296||ab|4|text|730|930|Analysis of 72 h toxicity to algae showed that the closed test had the same sensitivity as the open test for most of the test compounds, but a significant difference was observed for a few compounds.
SE|25462296||ab|4|entity|C0936012|Analysis|resa|||Analysis|||0|1000|730|738
SE|25462296||ab|4|entity|C0600688|Toxic effect|inpo|||toxicity|||0|790|747|755
SE|25462296||ab|4|entity|C0002028|Algae|alga|||algae|||0|1000|759|764
SE|25462296||ab|4|entity|C0587267|Closed|ftcn|||closed|||0|888|781|787
SE|25462296||ab|4|entity|C0039593|Testing|resa|||test|||0|888|788|792
SE|25462296||ab|4|entity|C0445247|Same|qlco|||same|||0|888|801|805
SE|25462296||ab|4|entity|C0175566|Open|spco|||open|||0|888|825|829
SE|25462296||ab|4|entity|C0039593|Testing|resa|||test|||0|888|830|834
SE|25462296||ab|4|entity|C0205393|Most|qnco|||most|||0|1000|839|843
SE|25462296||ab|4|entity|C0039593|Testing|resa|||test|||0|872|851|855
SE|25462296||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|872|856|865
SE|25462296||ab|4|entity|C0750502|Significant|idcn|||significant|||0|888|873|884
SE|25462296||ab|4|entity|C1547020|*Difference|qnco|||difference|||0|888|885|895
SE|25462296||ab|4|entity|C0205388|Few|qnco|||few|||0|872|915|918
SE|25462296||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|872|919|928

SE|25462296||ab|5|text|930|1062|The overall average difference for all compounds ranges from 0.15 to 0.43 log units between toxicity endpoints (yield-growth rate).
SE|25462296||ab|5|entity|C1561607|Overall|qlco|||overall|||0|851|934|941
SE|25462296||ab|5|entity|C1510992|Average|qnco|||average|||0|851|942|949
SE|25462296||ab|5|entity|C1547020|*Difference|qnco|||difference|||0|851|950|960
SE|25462296||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|969|978
SE|25462296||ab|5|entity|C0439148|Unit|qnco|||units|||0|812|1008|1013
SE|25462296||ab|5|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|1022|1030
SE|25462296||ab|5|entity|C0150100|End Point|resa|||endpoints|||0|888|1031|1040
SE|25462296||ab|5|entity|C0449249|Growth rate|tmco|||growth rate|||0|901|1048|1059

SE|25462296||ab|6|text|1062|1315|The relationships between exposure periods of 24, 48, 72 and 96 h indicated that 48 h exposure period is the most sensitive for algal growth inhibition test, and its sensitivity is 0.25 log units greater than 72 and 96 h exposure periods, respectively.
SE|25462296||ab|6|entity|C0439849|Relationships|qlco|||relationships|||0|1000|1066|1079
SE|25462296||ab|6|entity|C0439531|/period|tmco|||periods|||0|827|1097|1104
SE|25462296||ab|6|entity|C0439531|/period|tmco|||period|||0|763|1157|1163
SE|25462296||ab|6|entity|C0205393|Most|qnco|||most|||0|888|1171|1175
SE|25462296||ab|6|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|1176|1185
SE|25462296||ab|6|entity|C0002028|Algae|alga|||algal|||0|837|1190|1195
SE|25462296||ab|6|entity|C0018270|Growth|orgf|||growth|||0|837|1196|1202
SE|25462296||ab|6|entity|C0201783|Inhibition test|lbpr|||inhibition test|||0|837|1203|1218
SE|25462296||ab|6|entity|C0439148|Unit|qnco|||units|||0|812|1252|1257
SE|25462296||ab|6|entity|C0443228|Largest|qnco|||greater|||0|1000|1258|1265
SE|25462296||ab|6|entity|C0439531|/period|tmco|||periods|||0|747|1292|1299

SE|25462296||ab|7|text|1315|1629|Interspecies relationships showed that some algal species have very close sensitivity (e.g. Pseudokirchneriella subcapitata and Chlorella pyrenoidosa or Chlorella vulgaris and Scenedesmus obliquus, respectively), whereas some species have significantly different sensitivity (e.g. P. subcapitata and S. obliquus).
SE|25462296||ab|7|entity|C0439849|Relationships|qlco|||relationships|||0|861|1328|1341
SE|25462296||ab|7|entity|C0002028|Algae|alga|||algal|||0|853|1359|1364
SE|25462296||ab|7|entity|C1548151|Species|idcn|||species|||0|853|1365|1372
SE|25462296||ab|7|entity|C0442824|Very|qlco|||very|||0|1000|1378|1382
SE|25462296||ab|7|entity|C1089415|Selenastrum capricornutum|alga|||Pseudokirchneriella subcapitata|||0|1000|1407|1438
SE|25462296||ab|7|entity|C0996439|Chlorella pyrenoidosa|plnt|||Chlorella pyrenoidosa|||0|1000|1443|1464
SE|25462296||ab|7|entity|C0996438|Chlorella vulgaris|alga|||Chlorella vulgaris|||0|1000|1468|1486
SE|25462296||ab|7|entity|C0996446|Scenedesmus obliquus|plnt|||Scenedesmus obliquus|||0|1000|1491|1511
SE|25462296||ab|7|entity|C1548151|Species|idcn|||species|||0|1000|1541|1548
SE|25462296||ab|7|entity|C1547020|*Difference|qnco|||different|||0|754|1568|1577

SE|25462296||ab|8|text|1629|1852|Relationships between toxicity and hydrophobicity demonstrated that no difference was observed for non-polar narcotics within different exposure periods (24, 48, 72, and 96 h) or response variables (yield and growth rate).
SE|25462296||ab|8|entity|C0439849|Relationships|qlco|||Relationships|||0|1000|1629|1642
SE|25462296||ab|8|entity|C0600688|Toxic effect|inpo|||toxicity|||0|1000|1651|1659
SE|25462296||ab|8|entity|C0598629|Hydrophobicity|qlco|||hydrophobicity|||0|1000|1664|1678
SE|25462296||ab|8|entity|C1547020|*Difference|qnco|||difference|||0|1000|1700|1710
SE|25462296||ab|8|entity|C0813983|polar|qnco|||polar|||0|790|1732|1737
SE|25462296||ab|8|entity|C0027415|Narcotics|hops,phsu|||narcotics|||0|790|1738|1747
SE|25462296||ab|8|entity|C1547020|*Difference|qnco|||different|||0|750|1755|1764
SE|25462296||ab|8|entity|C0439531|/period|tmco|||periods|||0|750|1774|1781
SE|25462296||ab|8|entity|C0871261|response|clna|||response|||0|872|1808|1816
SE|25462296||ab|8|entity|C0439828|Variable|qlco|||variables|||0|872|1817|1826
SE|25462296||ab|8|entity|C0449249|Growth rate|tmco|||growth rate|||0|1000|1838|1849

SE|25462296||ab|9|text|1852|1993|For polar narcotics, in contrast, algal toxicity is dependent on algal species and is related to the response variables and exposure period.
SE|25462296||ab|9|entity|C0813983|polar|qnco|||polar|||0|888|1856|1861
SE|25462296||ab|9|entity|C0027415|Narcotics|hops,phsu|||narcotics|||0|888|1862|1871
SE|25462296||ab|9|entity|C0304056|Algal toxin|hops,orch|||algal toxicity|||0|950|1886|1900
SE|25462296||ab|9|entity|C0002028|Algae|alga|||algal|||0|853|1917|1922
SE|25462296||ab|9|entity|C1548151|Species|idcn|||species|||0|853|1923|1930
SE|25462296||ab|9|entity|C0871261|response|clna|||response|||0|872|1953|1961
SE|25462296||ab|9|entity|C0439828|Variable|qlco|||variables|||0|872|1962|1971
SE|25462296||ab|9|entity|C0439531|/period|tmco|||period|||0|861|1985|1991

SE|25462296||ab|10|text|1993|2154|We cannot expect significant QSAR models between algal toxicity and descriptors without considering species sensitivity, exposure periods and response endpoints.
SE|25462296||ab|10|entity|C0750502|Significant|idcn|||significant|||0|928|2010|2021
SE|25462296||ab|10|entity|C0887819|Quantitative Structure-Activity Relationship|qnco|||QSAR|||0|928|2022|2026
SE|25462296||ab|10|entity|C0304056|Algal toxin|hops,orch|||algal toxicity|||0|950|2042|2056
SE|25462296||ab|10|entity|C0282354|Descriptors|inpr|||descriptors|||0|1000|2061|2072
SE|25462296||ab|10|entity|C0750591|CONSIDER|idcn|||considering|||0|840|2081|2092
SE|25462296||ab|10|entity|C1548151|Species|idcn|||species|||0|840|2093|2100
SE|25462296||ab|10|entity|C0439531|/period|tmco|||periods|||0|827|2123|2130
SE|25462296||ab|10|entity|C0871261|response|clna|||response|||0|888|2135|2143
SE|25462296||ab|10|entity|C0150100|End Point|resa|||endpoints|||0|888|2144|2153


SE|25462297||ti|1|text|21|135|PFOA and PFOS are associated with reduced expression of the parathyroid hormone 2 receptor (PTH2R) gene in women.
SE|25462297||ti|1|entity|C0054616|caprylic acid|lipd,phsu|||PFOA|||0|901|21|25
SE|25462297||ti|1|entity|C0905462|perfluorooctane sulfonate|orch,phsu|||PFOS|||0|1000|30|34
SE|25462297||ti|1|entity|C0392756|Reduced|qlco|||reduced|||0|888|55|62
SE|25462297||ti|1|entity|C0070094|Parathyroid Hormone Receptor|aapp,rcpt|||parathyroid hormone 2 receptor|||0|841|81|111
SE|25462297||ti|1|entity|C0017337|Genes|gngm|||gene|||0|841|120|124
SE|25462297||ti|1|entity|C0043210|Woman|popg|||women|||0|1000|128|133
SE|25462297||ti|1|relation|1|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|128|133|PREP|LOCATION_OF||125|127|4|1|C0070094|Parathyroid Hormone Receptor|aapp,gngm,rcpt|aapp|||parathyroid hormone 2 receptor|||0|841|81|111
SE|25462297||ti|1|relation|2|1|C0054616|caprylic acid|lipd,phsu|phsu|||PFOA|||0|901|21|25|ADJ|INHIBITS||55|62|2|1|C0070094|Parathyroid Hormone Receptor|aapp,gngm,rcpt|gngm|||parathyroid hormone 2 receptor|||0|841|81|111
SE|25462297||ti|1|relation|2|1|C0905462|perfluorooctane sulfonate|orch,phsu|orch|||PFOS|||0|1000|30|34|ADJ|INHIBITS||55|62|2|1|C0070094|Parathyroid Hormone Receptor|aapp,gngm,rcpt|gngm|||parathyroid hormone 2 receptor|||0|841|81|111

SE|25462297||ab|1|text|141|248|Little is known about interactions between environmental and genetic risk factors for osteoarthritis (OA).
SE|25462297||ab|1|entity|C0023882|Little's Disease|dsyn|||Little|||0|1000|141|147
SE|25462297||ab|1|entity|C0814299|genetic risk factors|qlco|||genetic risk factors|||0|1000|202|222
SE|25462297||ab|1|entity|C0029408|Degenerative polyarthritis|dsyn|||osteoarthritis|||0|1000|227|241

SE|25462297||ab|2|text|248|347|Genetic factors include variation or mutation in genes involved in parathyroid hormone signalling.
SE|25462297||ab|2|entity|C0314603|Genetic|ftcn|||Genetic|||0|872|248|255
SE|25462297||ab|2|entity|C1521761|Factor|ftcn|||factors|||0|872|256|263
SE|25462297||ab|2|entity|C0205419|Variant|qlco|||variation|||0|1000|272|281
SE|25462297||ab|2|entity|C0026882|Mutation|genf|||mutation|||0|1000|285|293
SE|25462297||ab|2|entity|C0017337|Genes|gngm|||genes|||0|1000|297|302
SE|25462297||ab|2|entity|C0020063|PTH protein, human|aapp,horm|5741|PTH|parathyroid hormone|||0|901|315|334
SE|25462297||ab|2|entity|C0037083|Signal Transduction|celf|||signalling|||0|901|335|345
SE|25462297||ab|2|relation|3|1|C0026882|Mutation|genf|genf|||mutation|||0|1000|285|293|PREP|PROCESS_OF||294|296|2|1|C0017337|Genes|gngm,aapp|gngm|||genes|||0|1000|297|302
SE|25462297||ab|2|relation|4|1|C0017337|Genes|gngm,aapp|gngm|||genes|||0|1000|297|302|VERB|AFFECTS||303|311|1|1|C0037083|Signal Transduction|celf|celf|||signalling|||0|901|335|345

SE|25462297||ab|3|text|347|584|Exposure to the endocrine disrupting chemicals perfluoro-octanoic acid (PFOA) or perfluorooctane sulfonate (PFOS) have been suggested as potential environmental contributors, although evidence to support this association is conflicting.
SE|25462297||ab|3|entity|C1568245|Endocrine Disruptors|hops|||endocrine disrupting chemicals|||0|836|363|393
SE|25462297||ab|3|entity|C0001128|Acids|chem|||acid|||0|836|413|417
SE|25462297||ab|3|entity|C0905462|perfluorooctane sulfonate|orch,phsu|||perfluorooctane sulfonate|||0|1000|428|453
SE|25462297||ab|3|entity|C0237399|Potential|qlco|||potential|||0|660|484|493

SE|25462297||ab|4|text|584|781|Here we test the hypothesis that PFOA and PFOS may alter the mRNA expression of genes in the parathyroid signalling cascade to provide evidence on possible pathways between these chemicals and OA.
SE|25462297||ab|4|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|601|611
SE|25462297||ab|4|entity|C0054616|caprylic acid|lipd,phsu|||PFOA|||0|901|617|621
SE|25462297||ab|4|entity|C0905462|perfluorooctane sulfonate|orch,phsu|||PFOS|||0|1000|626|630
SE|25462297||ab|4|entity|C1515670|mRNA Expression|genf|||mRNA expression|||0|1000|645|660
SE|25462297||ab|4|entity|C0017337|Genes|gngm|||genes|||0|1000|664|669
SE|25462297||ab|4|entity|C0037083|Signal Transduction|celf|||signalling|||0|861|689|699
SE|25462297||ab|4|entity|C0332149|Possible|qlco|||possible|||0|694|731|739
SE|25462297||ab|4|entity|C0220806|Chemicals|chem|||chemicals|||0|1000|763|772
SE|25462297||ab|4|entity|C0029408|Degenerative polyarthritis|dsyn|||OA|||0|1000|777|779
SE|25462297||ab|4|relation|3|1|C0054616|caprylic acid|lipd,phsu|phsu|||PFOA|||0|901|617|621|VERB|INTERACTS_WITH||635|640|7|2|C0017337|Genes|gngm,aapp|gngm|||genes|||0|1000|664|669
SE|25462297||ab|4|relation|3|1|C0905462|perfluorooctane sulfonate|orch,phsu|orch|||PFOS|||0|1000|626|630|VERB|INTERACTS_WITH||635|640|7|2|C0017337|Genes|gngm,aapp|gngm|||genes|||0|1000|664|669

SE|25462297||ab|5|text|781|1157|We measured the relationship between PFOA or PFOS serum levels and the in vivo expression of the Parathyroid hormone 1 and 2 genes (PTH, PTH2), Parathyroid hormone 1 and 2 receptor genes (PTH1R, PTH2R) and the parathyroid hormone-like (PTHLH) gene in peripheral blood from a cross-sectional population study designed to assess the potential health effects of these chemicals.
SE|25462297||ab|5|entity|C0439849|Relationships|qlco|||relationship|||0|1000|797|809
SE|25462297||ab|5|entity|C0054616|caprylic acid|lipd,phsu|||PFOA|||0|901|818|822
SE|25462297||ab|5|entity|C0905462|perfluorooctane sulfonate|orch,phsu|||PFOS|||0|861|826|830
SE|25462297||ab|5|entity|C0229671|Serum|bdsu|||serum|||0|861|831|836
SE|25462297||ab|5|entity|C0441889|Levels|inpr|||levels|||0|861|837|843
SE|25462297||ab|5|entity|C1515655|in vivo|spco|||in vivo|||0|901|852|859
SE|25462297||ab|5|entity|C0020063|PTH protein, human|aapp,horm|5741|PTH|Parathyroid hormone|||0|901|878|897
SE|25462297||ab|5|entity|C0017337|Genes|gngm|||genes|||0|861|906|911
SE|25462297||ab|5|entity|C1419072|PTH gene|gngm|5741|PTH|PTH|||0|1000|913|916
SE|25462297||ab|5|entity|||gngm|5741|PTH|PTH2|||0|1000|918|922
SE|25462297||ab|5|entity|C0020063|PTH protein, human|aapp,horm|5741|PTH|Parathyroid hormone|||0|901|925|944
SE|25462297||ab|5|entity|C1335671|Receptor Gene|gngm|||receptor genes|||0|884|953|967
SE|25462297||ab|5|entity|||gngm|5741|PTH|PTH1R|||0|1000|969|974
SE|25462297||ab|5|entity|C0070094|Parathyroid Hormone Receptor|aapp,rcpt|||PTH2R|||0|923|976|981
SE|25462297||ab|5|entity|C0020063|PTH protein, human|aapp,horm|5741|PTH|parathyroid hormone|||0|1000|991|1010
SE|25462297||ab|5|entity|C1335272|PTHLH gene|gngm|5744|PTHLH|PTHLH|||0|1000|1017|1022
SE|25462297||ab|5|entity|C0017337|Genes|gngm|||gene|||0|1000|1024|1028
SE|25462297||ab|5|entity|C0229664|peripheral blood|bdsu|||peripheral blood|||0|1000|1032|1048
SE|25462297||ab|5|entity|C1257890|Population Group|popg|||population|||0|916|1072|1082
SE|25462297||ab|5|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional population study|||0|916|1056|1088
SE|25462297||ab|5|entity|C0237399|Potential|qlco|||potential|||0|840|1112|1121
SE|25462297||ab|5|entity|C0018684|Health|idcn|||health|||0|840|1122|1128
SE|25462297||ab|5|entity|C1280500|Effect|qlco|||effects|||0|840|1129|1136
SE|25462297||ab|5|entity|C0220806|Chemicals|chem|||chemicals|||0|1000|1146|1155
SE|25462297||ab|5|relation|0|0|C1419072|PTH gene|gngm,aapp|gngm|5741|PTH|PTH|||0|1000|913|916|SPEC|ISA||906|916|0|0|C0017337|Genes|gngm,aapp|gngm|||genes|||0|861|906|911
SE|25462297||ab|5|relation|4|1|C0229664|peripheral blood|bdsu|bdsu|||peripheral blood|||0|1000|1032|1048|PREP|LOCATION_OF||1029|1031|13|1|C0017337|Genes|gngm,aapp|aapp|||gene|||0|1000|1024|1028

SE|25462297||ab|6|text|1157|1418|We used multivariate linear regression models and found that PFOA or PFOS was inversely correlated with parathyroid hormone 2 receptor (PTH2R) expression (coefficients=-0.43 and -0.32, p=p=0.017 and 0.006 for PFOA and PFOS respectively) in 189 female subjects.
SE|25462297||ab|6|entity|C0023732|Linear Models|qnco|||linear regression models|||0|875|1178|1202
SE|25462297||ab|6|entity|C0054616|caprylic acid|lipd,phsu|||PFOA|||0|901|1218|1222
SE|25462297||ab|6|entity|C0905462|perfluorooctane sulfonate|orch,phsu|||PFOS|||0|1000|1226|1230
SE|25462297||ab|6|entity|C0070094|Parathyroid Hormone Receptor|aapp,rcpt|||parathyroid hormone 2 receptor|||0|923|1261|1291
SE|25462297||ab|6|entity|C0070094|Parathyroid Hormone Receptor|aapp,rcpt|||PTH2R|||0|923|1293|1298
SE|25462297||ab|6|entity|C1547015|*Coefficient|qnco|||coefficients|||0|966|1312|1324
SE|25462297||ab|6|entity|C0054616|caprylic acid|lipd,phsu|||PFOA|||0|901|1366|1370
SE|25462297||ab|6|entity|C0905462|perfluorooctane sulfonate|orch,phsu|||PFOS|||0|901|1375|1379
SE|25462297||ab|6|entity|C0015780|Female|orga|||female|||0|773|1401|1407
SE|25462297||ab|6|entity|C1550501|subject|idcn|||subjects|||0|773|1408|1416
SE|25462297||ab|6|relation|3|1|C0054616|caprylic acid|lipd,phsu|phsu|||PFOA|||0|901|1218|1222|VERB|COEXISTS_WITH||1245|1255|7|1|C0070094|Parathyroid Hormone Receptor|aapp,gngm,rcpt|aapp|||parathyroid hormone 2 receptor|||0|923|1261|1291
SE|25462297||ab|6|relation|3|1|C0905462|perfluorooctane sulfonate|orch,phsu|orch|||PFOS|||0|1000|1226|1230|VERB|COEXISTS_WITH||1245|1255|7|1|C0070094|Parathyroid Hormone Receptor|aapp,gngm,rcpt|aapp|||parathyroid hormone 2 receptor|||0|923|1261|1291

SE|25462297||ab|7|text|1418|1585|The levels of PTH2 transcripts encoding the ligand of PTH2r, were also found to be lower in women with OA (median 2.08) compared with controls (median 3.41, p=0.046).
SE|25462297||ab|7|entity|C0441889|Levels|inpr|||levels|||0|1000|1422|1428
SE|25462297||ab|7|entity|||gngm|5741|PTH|PTH2|||0|861|1432|1436
SE|25462297||ab|7|entity|C1519595|Transcript|nnon|||transcripts|||0|861|1437|1448
SE|25462297||ab|7|entity|C0023688|Ligands|chem|||ligand|||0|1000|1462|1468
SE|25462297||ab|7|entity|||gngm|5741|PTH|PTH2r|||0|1000|1472|1477
SE|25462297||ab|7|entity|C0441994|Lower|ftcn|||lower|||0|1000|1501|1506
SE|25462297||ab|7|entity|C0043210|Woman|popg|||women|||0|1000|1510|1515
SE|25462297||ab|7|entity|C0029408|Degenerative polyarthritis|dsyn|||OA|||0|1000|1521|1523
SE|25462297||ab|7|entity|C0243148|control|ftcn|||controls|||0|966|1552|1560
SE|25462297||ab|7|relation|2|1|C0029408|Degenerative polyarthritis|dsyn|dsyn|||OA|||0|1000|1521|1523|PREP|PROCESS_OF||1516|1520|6|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1510|1515
SE|25462297||ab|7|relation|3|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1510|1515|PREP|LOCATION_OF||1507|1509|5|2|||gngm,aapp|aapp|5741|PTH|PTH2r|||0|1000|1472|1477

SE|25462297||ab|8|text|1585|1801|As the parathyroid signalling cascade is a known candidate for osteoarthritis risk and our findings raise the possibility that exposure to these chemicals may contribute to the pathogenesis of OA in some individuals.
SE|25462297||ab|8|entity|C0037083|Signal Transduction|celf|||signalling|||0|660|1604|1614
SE|25462297||ab|8|entity|C0205309|Known|qlco|||known|||0|694|1628|1633
SE|25462297||ab|8|entity|C0029408|Degenerative polyarthritis|dsyn|||osteoarthritis|||0|888|1648|1662
SE|25462297||ab|8|entity|C0035647|Risk|qlco|||risk|||0|888|1663|1667
SE|25462297||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1676|1684
SE|25462297||ab|8|entity|C0220806|Chemicals|chem|||chemicals|||0|1000|1730|1739
SE|25462297||ab|8|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|1000|1762|1774
SE|25462297||ab|8|entity|C0029408|Degenerative polyarthritis|dsyn|||OA|||0|1000|1778|1780
SE|25462297||ab|8|entity|C0237401|Individual|humn|||individuals|||0|1000|1789|1800
SE|25462297||ab|8|relation|7|1|C0220806|Chemicals|chem|chem|||chemicals|||0|1000|1730|1739|NOM|CAUSES||1762|1774|2|1|C0029408|Degenerative polyarthritis|dsyn|dsyn|||OA|||0|1000|1778|1780
SE|25462297||ab|8|relation|9|1|C0029408|Degenerative polyarthritis|dsyn|dsyn|||OA|||0|1000|1778|1780|PREP|PROCESS_OF||1781|1783|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1789|1800


SE|25462299||ti|1|text|21|133|A short-term sublethal toxicity assay with zebra fish based on preying rate and its integration with mortality.
SE|25462299||ti|1|entity|C0443303|Short-term|tmco|||short-term|||0|785|23|33
SE|25462299||ti|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|785|44|52
SE|25462299||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|785|53|58
SE|25462299||ti|1|entity|C0043457|Zebrafish|fish|||zebra fish|||0|1000|64|74
SE|25462299||ti|1|entity|C1521828|Rate|qnco|||rate|||0|861|92|96

SE|25462299||ab|1|text|139|389|Contaminant-induced feeding inhibition has direct and immediate consequences at higher levels of biological organization, by depressing the population consumption and thus hampering ecosystem functioning (e.g. grazing, organic matter decomposition).
SE|25462299||ab|1|entity|C0205263|Induced|ftcn|||induced|||0|763|151|158
SE|25462299||ab|1|entity|C0205253|Immediate|tmco|||immediate|||0|694|193|202
SE|25462299||ab|1|entity|C0205250|High|qlco|||higher|||0|872|219|225
SE|25462299||ab|1|entity|C0441889|Levels|inpr|||levels|||0|872|226|232
SE|25462299||ab|1|entity|C0205460|biological|ftcn|||biological|||0|888|236|246
SE|25462299||ab|1|entity|C0220885|organizational|qlco|||organization|||0|888|247|259
SE|25462299||ab|1|entity|C1257890|Population Group|popg|||population|||0|888|279|289
SE|25462299||ab|1|entity|C0162358|Ecosystem|npop|||ecosystem|||0|872|321|330
SE|25462299||ab|1|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|331|342
SE|25462299||ab|1|entity|C0043242|Superficial abrasion|inpo|||grazing|||0|566|349|356
SE|25462299||ab|1|entity|C0747055|ORGANIC|qlco|||organic|||0|566|358|365

SE|25462299||ab|2|text|389|556|Thus, similarly to lethality and avoidance, feeding is mechanistically linked to ecosystem processes and is therefore an unequivocal ecologically meaningful response.
SE|25462299||ab|2|entity|C1031740|Lethe|invt|||lethality|||0|900|408|417
SE|25462299||ab|2|entity|C0870186|Avoidance|menp|||avoidance|||0|1000|422|431
SE|25462299||ab|2|entity|C0162358|Ecosystem|npop|||ecosystem|||0|872|470|479
SE|25462299||ab|2|entity|C1522240|Process|phpr|||processes|||0|872|480|489
SE|25462299||ab|2|entity|C0870867|Meaningfulness|qlco|||meaningful|||0|714|535|545
SE|25462299||ab|2|entity|C0871261|response|clna|||response|||0|714|546|554

SE|25462299||ab|3|text|556|687|The objective of the present study was to develop a short-term assay with the small freshwater fish Danio rerio, based on feeding.
SE|25462299||ab|3|entity|C0150312|Present|qnco|||present|||0|888|577|584
SE|25462299||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|585|590
SE|25462299||ab|3|entity|C0443303|Short-term|tmco|||short-term|||0|901|608|618
SE|25462299||ab|3|entity|C1510438|Assay|lbpr|||assay|||0|901|619|624
SE|25462299||ab|3|entity|C0700321|Small|qnco|||small|||0|840|634|639
SE|25462299||ab|3|entity|C0016710|Fresh Water|sbst|||freshwater|||0|840|640|650
SE|25462299||ab|3|entity|C0016163|Fishes|fish|||fish|||0|840|651|655
SE|25462299||ab|3|entity|C0043457|Zebrafish|fish|||Danio rerio|||0|840|656|667
SE|25462299||ab|3|relation|0|0|C0043457|Zebrafish|fish|fish|||Danio rerio|||0|840|656|667|MOD/HEAD|ISA||651|667|0|0|C0016163|Fishes|fish|fish|||fish|||0|840|651|655

SE|25462299||ab|4|text|687|900|For this, a methodology to easily and precisely quantify feeding was first optimized: each fish was allowed to prey on ten live Daphnia magna juveniles, for 1h, just before the end of a 48-h exposure test period.
SE|25462299||ab|4|entity|C0025664|Methodology|inpr|||methodology|||0|1000|699|710
SE|25462299||ab|4|entity|C0332219|Easy|qlco|||easily|||0|1000|714|720
SE|25462299||ab|4|entity|C1279901|Firstly|qlco|||first|||0|1000|756|761
SE|25462299||ab|4|entity|C0016163|Fishes|fish|||fish|||0|1000|778|782
SE|25462299||ab|4|entity|C0205456|Ten|qnco|||ten|||0|831|806|809
SE|25462299||ab|4|entity|C1548795|Live|qlco|||live|||0|831|810|814
SE|25462299||ab|4|entity|C1081963|Daphnia magna|invt|||Daphnia magna|||0|831|815|828
SE|25462299||ab|4|entity|C0205653|Adolescent|aggp|||juveniles|||0|831|829|838
SE|25462299||ab|4|entity|C0444930|End|spco|||end|||0|1000|864|867
SE|25462299||ab|4|entity|C0039593|Testing|resa|||test|||0|740|887|891
SE|25462299||ab|4|entity|C0439531|/period|tmco|||period|||0|740|892|898

SE|25462299||ab|5|text|900|989|Secondly, copper sensitivity of feeding relatively to survival and growth was evaluated.
SE|25462299||ab|5|entity|C0205436|second (number)|qnco|||Secondly|||0|1000|900|908
SE|25462299||ab|5|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|888|910|916
SE|25462299||ab|5|entity|C0038952|Continuance of life|acty|||survival|||0|1000|954|962
SE|25462299||ab|5|entity|C0018270|Growth|orgf|||growth|||0|1000|967|973

SE|25462299||ab|6|text|989|1127|At the growth EC20 (40 MUg L(-1)), feeding was inhibited by 53%, and at the feeding EC50 (36 MUg L(-1)), mortality was negligible (1.3%).
SE|25462299||ab|6|entity|C0018270|Growth|orgf|||growth|||0|694|996|1002
SE|25462299||ab|6|entity|C0332269|Negligible|ftcn,qlco|||negligible|||0|1000|1108|1118

SE|25462299||ab|7|text|1127|1244|Integrating feeding and survival revealed a 97% depression in the population consumption at the LC50 (61 MUg L(-1)).
SE|25462299||ab|7|entity|C0038952|Continuance of life|acty|||survival|||0|1000|1151|1159
SE|25462299||ab|7|entity|C0439082|>97|qnco|||97|||0|888|1171|1173
SE|25462299||ab|7|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1175|1185
SE|25462299||ab|7|entity|C1257890|Population Group|popg|||population|||0|888|1193|1203

SE|25462299||ab|8|text|1244|1459|Thirdly, the influence of pH, conductivity and hardness on the feeding background variability was assessed by assaying waters collected at eight reference sites and was found to be negligible, within tested ranges.
SE|25462299||ab|8|entity|C0205437|Third|qnco|||Thirdly|||0|1000|1244|1251
SE|25462299||ab|8|entity|C0018599|Hardness|qlco|||hardness|||0|1000|1291|1299
SE|25462299||ab|8|entity|C0439828|Variable|qlco|||variability|||0|755|1326|1337
SE|25462299||ab|8|entity|C1510438|Assay|lbpr|||assaying|||0|872|1354|1362
SE|25462299||ab|8|entity|C0043047|Water|inch,phsu|||waters|||0|872|1363|1369
SE|25462299||ab|8|entity|C0205454|Eight|qnco|||eight|||0|851|1383|1388
SE|25462299||ab|8|entity|C1514811|Reference|idcn|||reference|||0|851|1389|1398
SE|25462299||ab|8|entity|C0205145|Site|spco|||sites|||0|851|1399|1404
SE|25462299||ab|8|entity|C0332269|Negligible|ftcn,qlco|||negligible|||0|1000|1425|1435
SE|25462299||ab|8|entity|C0039593|Testing|resa|||tested|||0|872|1444|1450
SE|25462299||ab|8|entity|C1514721|Range|qnco|||ranges|||0|872|1451|1457

SE|25462299||ab|9|text|1459|1686|Fourthly, feeding assays with natural waters contaminated with acid mine drainage confirmed the integration of lethality and feeding to be pertinent at estimating contaminant effects at higher levels of biological organization.
SE|25462299||ab|9|entity|C0205438|Fourth|qnco|||Fourthly|||0|1000|1459|1467
SE|25462299||ab|9|entity|C1510438|Assay|lbpr|||assays|||0|966|1477|1483
SE|25462299||ab|9|entity|C0205296|Natural|ftcn|||natural|||0|888|1489|1496
SE|25462299||ab|9|entity|C0043047|Water|inch,phsu|||waters|||0|888|1497|1503
SE|25462299||ab|9|entity|C0001128|Acids|chem|||acid|||0|1000|1522|1526
SE|25462299||ab|9|entity|C0012621|Discharge, Body Substance|bdsu|||drainage|||0|1000|1532|1540
SE|25462299||ab|9|entity|C1031740|Lethe|invt|||lethality|||0|900|1570|1579
SE|25462299||ab|9|entity|C0750572|Estimated|qnco|||estimating|||0|769|1611|1621
SE|25462299||ab|9|entity|C1280500|Effect|qlco|||effects|||0|769|1634|1641
SE|25462299||ab|9|entity|C0205250|High|qlco|||higher|||0|872|1645|1651
SE|25462299||ab|9|entity|C0441889|Levels|inpr|||levels|||0|872|1652|1658
SE|25462299||ab|9|entity|C0205460|biological|ftcn|||biological|||0|888|1662|1672
SE|25462299||ab|9|entity|C0220885|organizational|qlco|||organization|||0|888|1673|1685
SE|25462299||ab|9|relation|1|1|C1510438|Assay|lbpr|lbpr|||assays|||0|966|1477|1483|PREP|USES||1484|1488|10|1|C0043047|Water|inch,phsu|phsu|||waters|||0|888|1497|1503


SE|25462298||ti|1|text|21|87|High resistance of Acropora coral gametes facing copper exposure.
SE|25462298||ti|1|entity|C0205250|High|qlco|||High|||0|861|21|25
SE|25462298||ti|1|entity|C0997909|Acropora|invt|||Acropora|||0|851|40|48
SE|25462298||ti|1|entity|C0324034|Coral|invt|||coral|||0|851|49|54
SE|25462298||ti|1|entity|C0017471|Germ Cells|cell|||gametes|||0|851|55|62
SE|25462298||ti|1|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|694|70|76

SE|25462298||ab|1|text|93|285|Pollution by heavy metals remains today an important threat to the health of humans and ecosystems, but there is still a paucity of data on the response of early life stages of key organisms.
SE|25462298||ab|1|entity|C0392355|Pollution|eehu|||Pollution|||0|1000|93|102
SE|25462298||ab|1|entity|C0347988|Metals, Heavy|elii|||heavy metals|||0|1000|106|118
SE|25462298||ab|1|entity|C0750526|Today|tmco|||today|||0|1000|127|132
SE|25462298||ab|1|entity|C0018684|Health|idcn|||health|||0|1000|160|166
SE|25462298||ab|1|entity|C0020114|Human|humn|||humans|||0|1000|170|176
SE|25462298||ab|1|entity|C0162358|Ecosystem|npop|||ecosystems|||0|1000|181|191
SE|25462298||ab|1|entity|C1511726|Data|idcn|||data|||0|1000|225|229
SE|25462298||ab|1|entity|C0871261|response|clna|||response|||0|1000|237|245
SE|25462298||ab|1|entity|C1279919|Early|tmco|||early|||0|888|249|254
SE|25462298||ab|1|entity|C0376558|Life|idcn|||life|||0|888|255|259
SE|25462298||ab|1|entity|C1554080|Key|idcn|||key|||0|888|270|273
SE|25462298||ab|1|entity|C0029235|Organism|orgm|||organisms|||0|888|274|283

SE|25462298||ab|2|text|285|505|In this context, the present work assessed the fertilization success rate of two Acropora species (A. cytherea and A. pulchra) from the French Polynesia reefs exposed to six increasing copper concentrations in seawater.
SE|25462298||ab|2|entity|C0150312|Present|qnco|||present|||0|888|306|313
SE|25462298||ab|2|entity|C0043227|Work|ocac|||work|||0|888|314|318
SE|25462298||ab|2|entity|C0015914|Fertilization|orgf|||fertilization|||0|851|332|345
SE|25462298||ab|2|entity|C0597535|Success|socb|||success|||0|851|346|353
SE|25462298||ab|2|entity|C1521828|Rate|qnco|||rate|||0|851|354|358
SE|25462298||ab|2|entity|C0205448|Two|qnco|||two|||0|851|362|365
SE|25462298||ab|2|entity|C0997909|Acropora|invt|||Acropora|||0|851|366|374
SE|25462298||ab|2|entity|C1548151|Species|idcn|||species|||0|851|375|382
SE|25462298||ab|2|entity|C0016704|French Polynesia|geoa|||French Polynesia|||0|734|421|437
SE|25462298||ab|2|entity|C0205452|Six|qnco|||six|||0|833|455|458
SE|25462298||ab|2|entity|C0442808|Increasing|ftcn|||increasing|||0|833|459|469
SE|25462298||ab|2|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|833|470|476
SE|25462298||ab|2|entity|C0036499|Seawater|sbst|||seawater|||0|1000|495|503

SE|25462298||ab|3|text|505|678|The two species showed a relatively high tolerance to copper (4h30-EC50 was 69.4 +/- 4.8 MUg L(-1) and 75.4 +/- 6.4 MUg L(-1) for A. cytherea and A. pulchra, respectively).
SE|25462298||ab|3|entity|C0205448|Two|qnco|||two|||0|888|509|512
SE|25462298||ab|3|entity|C1548151|Species|idcn|||species|||0|888|513|520
SE|25462298||ab|3|entity|C0205250|High|qlco|||high|||0|660|541|545
SE|25462298||ab|3|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|1000|559|565
SE|25462298||ab|3|entity|C0593273|75+6|qnco|||75.4 +/- 6|||0|829|608|618

SE|25462298||ab|4|text|678|852|As Cu concentration increases, an increasing proportion of deformed embryos was recorded (67.6% and 58.5% for A. cytherea and A. pulchra, respectively, at 220 MUg Cu L(-1)).
SE|25462298||ab|4|entity|C0442805|Increase|ftcn|||increases|||0|785|698|707
SE|25462298||ab|4|entity|C0442808|Increasing|ftcn|||increasing|||0|853|712|722
SE|25462298||ab|4|entity|C0205351|Proportional|qlco|||proportion|||0|853|723|733
SE|25462298||ab|4|entity|C0333067|Deformed|ftcn|||deformed|||0|888|737|745
SE|25462298||ab|4|entity|C0013935|Embryo|emst|||embryos|||0|888|746|753

SE|25462298||ab|5|text|852|1040|These results demonstrated thus, that high levels of copper could negatively impair the normal fertilization process of coral gametes and therefore alter the renewal of coral populations.
SE|25462298||ab|5|entity|C1274040|result|ftcn|||results|||0|966|858|865
SE|25462298||ab|5|entity|C0205250|High|qlco|||high|||0|888|890|894
SE|25462298||ab|5|entity|C0441889|Levels|inpr|||levels|||0|888|895|901
SE|25462298||ab|5|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|1000|905|911
SE|25462298||ab|5|entity|C0205307|Normal|qlco|||normal|||0|851|940|946
SE|25462298||ab|5|entity|C0015914|Fertilization|orgf|||fertilization|||0|851|947|960
SE|25462298||ab|5|entity|C1522240|Process|phpr|||process|||0|851|961|968
SE|25462298||ab|5|entity|C0324034|Coral|invt|||coral|||0|888|972|977
SE|25462298||ab|5|entity|C0017471|Germ Cells|cell|||gametes|||0|888|978|985
SE|25462298||ab|5|entity|C0324034|Coral|invt|||coral|||0|888|1021|1026
SE|25462298||ab|5|entity|C0032659|geographic population|qnco|||populations|||0|888|1027|1038

SE|25462298||ab|6|text|1040|1334|Since the two Acropora species investigated in this study displayed a high resistance to copper, these results should be considered in the context of multiple stressors associated with climate change, where rising temperature or ocean acidification may significantly exacerbate copper toxicity.
SE|25462298||ab|6|entity|C0205448|Two|qnco|||two|||0|851|1050|1053
SE|25462298||ab|6|entity|C0997909|Acropora|invt|||Acropora|||0|851|1054|1062
SE|25462298||ab|6|entity|C1548151|Species|idcn|||species|||0|851|1063|1070
SE|25462298||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1092|1097
SE|25462298||ab|6|entity|C0205250|High|qlco|||high|||0|861|1110|1114
SE|25462298||ab|6|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|1000|1129|1135
SE|25462298||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1143|1150
SE|25462298||ab|6|entity|C0439064|Numerous|qnco|||multiple|||0|872|1190|1198
SE|25462298||ab|6|entity|C0597530|stressor|fndg|||stressors|||0|872|1199|1208
SE|25462298||ab|6|entity|C0008946|Climate|npop|||climate|||0|888|1225|1232
SE|25462298||ab|6|entity|C0039476|Temperature|qnco|||temperature|||0|827|1254|1265
SE|25462298||ab|6|entity|C0028814|Oceans|geoa|||ocean|||0|872|1269|1274
SE|25462298||ab|6|entity|C1522821|acidification|celf|||acidification|||0|872|1275|1288
SE|25462298||ab|6|entity|C0009968|Copper|bacs,elii,phsu|||copper|||0|888|1318|1324
SE|25462298||ab|6|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|1325|1333
SE|25462298||ab|6|relation|10|7|C0009968|Copper|bacs,elii,phsu|bacs|||copper|||0|1000|1129|1135|VERB|AFFECTS||1307|1317|1|1|C0600688|Toxic effect|inpo|inpo|||toxicity|||0|888|1325|1333


SE|25462300||ti|1|text|21|181|Distribution and composition pattern of polycyclic aromatic hydrocarbons in different tissues of sturgeons collected from Iranian coastline of the Caspian Sea.
SE|25462300||ti|1|entity|C0520511|Distributing|idcn|||Distribution|||0|1000|21|33
SE|25462300||ti|1|entity|C0486616|Composition|clna|||composition|||0|888|38|49
SE|25462300||ti|1|entity|C0449774|Patterns|spco|||pattern|||0|888|50|57
SE|25462300||ti|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||polycyclic aromatic hydrocarbons|||0|1000|61|93
SE|25462300||ti|1|entity|C1547020|*Difference|qnco|||different|||0|853|97|106
SE|25462300||ti|1|entity|C0040300|Body tissue|tisu|||tissues|||0|853|107|114
SE|25462300||ti|1|entity|C0327752|Acipenser|fish|||sturgeons|||0|966|118|127
SE|25462300||ti|1|entity|C0036493|Sea|geoa|||Sea|||0|861|176|179
SE|25462300||ti|1|relation|4|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|853|107|114|PREP|LOCATION_OF||94|96|3|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||polycyclic aromatic hydrocarbons|||0|1000|61|93
SE|25462300||ti|1|relation|4|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|853|107|114|PREP|PART_OF||115|117|3|1|C0327752|Acipenser|fish|fish|||sturgeons|||0|966|118|127

SE|25462300||ab|1|text|187|486|The levels of 16 polycyclic aromatic hydrocarbons (PAHs) were determined in the liver, kidney, gills and muscle tissues of Persian sturgeon (Acipenser persicus; n=16), and Stellate sturgeon (Acipenser stellatus; n=7) collected from coastal waters of the South Caspian Sea from March and April 2011.
SE|25462300||ab|1|entity|C0441889|Levels|inpr|||levels|||0|1000|191|197
SE|25462300||ab|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||polycyclic aromatic hydrocarbons|||0|923|204|236
SE|25462300||ab|1|entity|C0023884|Liver|bpoc|||liver|||0|1000|267|272
SE|25462300||ab|1|entity|C0022646|Kidney|bpoc|||kidney|||0|1000|274|280
SE|25462300||ab|1|entity|C0017558|Gill structure|bpoc|||gills|||0|1000|282|287
SE|25462300||ab|1|entity|C0026845|Muscle|tisu|||muscle tissues|||0|983|292|306
SE|25462300||ab|1|entity|C0699776|Persian population group|popg|||Persian|||0|888|310|317
SE|25462300||ab|1|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|318|326
SE|25462300||ab|1|entity|C1023154|Acipenser persicus|fish|||Acipenser persicus|||0|1000|328|346
SE|25462300||ab|1|entity|C0205141|Stellate|spco|||Stellate|||0|888|359|367
SE|25462300||ab|1|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|368|376
SE|25462300||ab|1|entity|C0998825|Acipenser stellatus|fish|||Acipenser stellatus|||0|1000|378|397
SE|25462300||ab|1|entity|C0442542|Coastal water|geoa|||coastal waters|||0|983|419|433
SE|25462300||ab|1|entity|C0036493|Sea|geoa|||Sea|||0|827|455|458
SE|25462300||ab|1|entity|C1332090|ANP32B gene|gngm|10541|ANP32B|April|||0|861|474|479
SE|25462300||ab|1|relation|0|0|C0017558|Gill structure|bpoc|bpoc|||gills|||0|1000|282|287|INFER|PART_OF(SPEC)||318|346|0|0|C1023154|Acipenser persicus|fish|fish|||Acipenser persicus|||0|1000|328|346
SE|25462300||ab|1|relation|0|0|C0022646|Kidney|bpoc|bpoc|||kidney|||0|1000|274|280|INFER|PART_OF(SPEC)||318|346|0|0|C1023154|Acipenser persicus|fish|fish|||Acipenser persicus|||0|1000|328|346
SE|25462300||ab|1|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|267|272|INFER|PART_OF(SPEC)||318|346|0|0|C1023154|Acipenser persicus|fish|fish|||Acipenser persicus|||0|1000|328|346
SE|25462300||ab|1|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle tissues|||0|983|292|306|INFER|PART_OF(SPEC)||318|346|0|0|C1023154|Acipenser persicus|fish|fish|||Acipenser persicus|||0|1000|328|346
SE|25462300||ab|1|relation|0|0|C0998825|Acipenser stellatus|fish|fish|||Acipenser stellatus|||0|1000|378|397|SPEC|ISA||368|397|0|0|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|368|376
SE|25462300||ab|1|relation|0|0|C1023154|Acipenser persicus|fish|fish|||Acipenser persicus|||0|1000|328|346|SPEC|ISA||318|346|0|0|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|318|326
SE|25462300||ab|1|relation|6|1|C0017558|Gill structure|bpoc|bpoc|||gills|||0|1000|282|287|PREP|PART_OF||307|309|9|1|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|318|326
SE|25462300||ab|1|relation|6|1|C0022646|Kidney|bpoc|bpoc|||kidney|||0|1000|274|280|PREP|PART_OF||307|309|9|1|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|318|326
SE|25462300||ab|1|relation|6|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|267|272|PREP|PART_OF||307|309|9|1|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|318|326
SE|25462300||ab|1|relation|6|1|C0026845|Muscle|tisu|tisu|||muscle tissues|||0|983|292|306|PREP|PART_OF||307|309|9|1|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|318|326
SE|25462300||ab|1|relation|13|1|C0017558|Gill structure|bpoc|bpoc|||gills|||0|1000|282|287|PREP|LOCATION_OF||260|262|2|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||polycyclic aromatic hydrocarbons|||0|923|204|236
SE|25462300||ab|1|relation|13|1|C0022646|Kidney|bpoc|bpoc|||kidney|||0|1000|274|280|PREP|LOCATION_OF||260|262|2|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||polycyclic aromatic hydrocarbons|||0|923|204|236
SE|25462300||ab|1|relation|13|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|267|272|PREP|LOCATION_OF||260|262|2|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||polycyclic aromatic hydrocarbons|||0|923|204|236
SE|25462300||ab|1|relation|13|1|C0026845|Muscle|tisu|tisu|||muscle tissues|||0|983|292|306|PREP|LOCATION_OF||260|262|2|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||polycyclic aromatic hydrocarbons|||0|923|204|236

SE|25462300||ab|2|text|486|718|The distribution and composition pattern of PAHs in the different tissues of sturgeons, and the effects of lipid content in sturgeon tissues and the octanol-water partition coefficient (Kow) of PAHs congeners on them were analyzed.
SE|25462300||ab|2|entity|C0520511|Distributing|idcn|||distribution|||0|1000|490|502
SE|25462300||ab|2|entity|C0486616|Composition|clna|||composition|||0|888|507|518
SE|25462300||ab|2|entity|C0449774|Patterns|spco|||pattern|||0|888|519|526
SE|25462300||ab|2|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|1000|530|534
SE|25462300||ab|2|entity|C1547020|*Difference|qnco|||different|||0|853|542|551
SE|25462300||ab|2|entity|C0040300|Body tissue|tisu|||tissues|||0|853|552|559
SE|25462300||ab|2|entity|C0327752|Acipenser|fish|||sturgeons|||0|966|563|572
SE|25462300||ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|582|589
SE|25462300||ab|2|entity|C0023779|Lipids|lipd|||lipid|||0|694|593|598
SE|25462300||ab|2|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|610|618
SE|25462300||ab|2|entity|C0040300|Body tissue|tisu|||tissues|||0|888|619|626
SE|25462300||ab|2|entity|C0001979|Octanols|lipd|||octanol|||0|861|635|642
SE|25462300||ab|2|entity|C0020311|Hydrotherapy|topp|||water|||0|861|643|648
SE|25462300||ab|2|entity|C1518903|Partition Coefficient|qnco|||partition coefficient|||0|861|649|670
SE|25462300||ab|2|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|900|680|684
SE|25462300||ab|2|entity|C0678518|congener|chvs|||congeners|||0|900|685|694
SE|25462300||ab|2|relation|0|0|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|619|626|MOD/HEAD|PART_OF||610|626|0|0|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|610|618
SE|25462300||ab|2|relation|4|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|853|552|559|PREP|PART_OF||560|562|7|1|C0327752|Acipenser|fish|fish|||sturgeons|||0|966|563|572
SE|25462300||ab|2|relation|4|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|888|619|626|PREP|LOCATION_OF||607|609|7|1|C0023779|Lipids|lipd|lipd|||lipid|||0|694|593|598
SE|25462300||ab|2|relation|5|3|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||PAHs|||0|1000|530|534|NOM|INTERACTS_WITH||582|589|5|1|C0023779|Lipids|lipd|lipd|||lipid|||0|694|593|598
SE|25462300||ab|2|relation|8|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|853|552|559|PREP|LOCATION_OF||535|537|3|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||PAHs|||0|1000|530|534

SE|25462300||ab|3|text|718|881|The levels of total PAHs in the various tissues of Persian sturgeon and Stellate sturgeon ranged from 2.095 to 6.587 and 1.942 to 6.206 MUg g(-1)dw, respectively.
SE|25462300||ab|3|entity|C0441889|Levels|inpr|||levels|||0|1000|722|728
SE|25462300||ab|3|entity|C0439175|% of total|qnco|||total|||0|916|732|737
SE|25462300||ab|3|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|916|738|742
SE|25462300||ab|3|entity|C0040300|Body tissue|tisu|||tissues|||0|861|758|765
SE|25462300||ab|3|entity|C0699776|Persian population group|popg|||Persian|||0|888|769|776
SE|25462300||ab|3|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|777|785
SE|25462300||ab|3|entity|C0205141|Stellate|spco|||Stellate|||0|888|790|798
SE|25462300||ab|3|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|799|807
SE|25462300||ab|3|entity|C0720544|G-1|orch,phsu|||g(-1|||0|840|858|862
SE|25462300||ab|3|relation|3|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|861|758|765|PREP|PART_OF||766|768|3|1|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|777|785
SE|25462300||ab|3|relation|3|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|861|758|765|PREP|PART_OF||766|768|3|1|C0327752|Acipenser|fish|fish|||sturgeon|||0|888|799|807
SE|25462300||ab|3|relation|4|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|861|758|765|PREP|LOCATION_OF||743|745|2|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||PAHs|||0|916|738|742

SE|25462300||ab|4|text|881|983|Stellate sturgeon showed significantly higher levels of heavy PAHs (? 4-rings) than Persian sturgeon.
SE|25462300||ab|4|entity|C0205141|Stellate|spco|||Stellate|||0|888|881|889
SE|25462300||ab|4|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|890|898
SE|25462300||ab|4|entity|C0205250|High|qlco|||higher|||0|773|920|926
SE|25462300||ab|4|entity|C0441889|Levels|inpr|||levels|||0|773|927|933
SE|25462300||ab|4|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|923|943|947
SE|25462300||ab|4|entity|C1260969|Ring device|medd|||rings|||0|861|953|958
SE|25462300||ab|4|entity|C0699776|Persian population group|popg|||Persian|||0|888|965|972
SE|25462300||ab|4|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|973|981

SE|25462300||ab|5|text|983|1108|The analysis has revealed a high degree of differential accumulation of the studied PAHs in the tissues of the both species.
SE|25462300||ab|5|entity|C0936012|Analysis|resa|||analysis|||0|1000|987|995
SE|25462300||ab|5|entity|C0205250|High|qlco|||high|||0|694|1011|1015
SE|25462300||ab|5|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|923|1067|1071
SE|25462300||ab|5|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|1079|1086
SE|25462300||ab|5|entity|C1548151|Species|idcn|||species|||0|1000|1099|1106
SE|25462300||ab|5|relation|2|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|1000|1079|1086|PREP|LOCATION_OF||1072|1074|4|1|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||PAHs|||0|923|1067|1071

SE|25462300||ab|6|text|1108|1206|Low molecular weight PAHs predominated in the sturgeons, accounting for 81.89% of the total PAHs.
SE|25462300||ab|6|entity|C1521991|Molecular|qlco|||molecular|||0|864|1112|1121
SE|25462300||ab|6|entity|C0041667|Underweight|fndg|||Low molecular weight|||0|864|1108|1128
SE|25462300||ab|6|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|864|1129|1133
SE|25462300||ab|6|entity|C0327752|Acipenser|fish|||sturgeons|||0|966|1154|1163
SE|25462300||ab|6|entity|C0439175|% of total|qnco|||total|||0|916|1194|1199
SE|25462300||ab|6|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|916|1200|1204

SE|25462300||ab|7|text|1206|1320|Among the sixteen tested PAHs, naphthalene was the most dominant congener, followed by phenanthrene and fluorene.
SE|25462300||ab|7|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|1000|1231|1235
SE|25462300||ab|7|entity|C0027375|Naphthalene|orch|||naphthalene|||0|1000|1237|1248
SE|25462300||ab|7|entity|C0205393|Most|qnco|||most|||0|851|1257|1261
SE|25462300||ab|7|entity|C1527180|Dominant|ftcn|||dominant|||0|851|1262|1270
SE|25462300||ab|7|entity|C0678518|congener|chvs|||congener|||0|851|1271|1279
SE|25462300||ab|7|entity|C0031367|phenanthrene|orch|||phenanthrene|||0|1000|1293|1305
SE|25462300||ab|7|entity|C0016311|Fluorenes|hops,orch|||fluorene|||0|1000|1310|1318
SE|25462300||ab|7|relation|0|0|C0031367|phenanthrene|orch|orch|||phenanthrene|||0|1000|1293|1305|SPEC|ISA||1231|1305|0|0|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||PAHs|||0|1000|1231|1235

SE|25462300||ab|8|text|1320|1468|The PAHs levels and distribution in the tissues of sturgeons are dependent on both the Kow of PAH congeners and the lipid content in these tissues.
SE|25462300||ab|8|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|916|1324|1328
SE|25462300||ab|8|entity|C0441889|Levels|inpr|||levels|||0|916|1329|1335
SE|25462300||ab|8|entity|C0520511|Distributing|idcn|||distribution|||0|1000|1340|1352
SE|25462300||ab|8|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|1360|1367
SE|25462300||ab|8|entity|C0327752|Acipenser|fish|||sturgeons|||0|966|1371|1380
SE|25462300||ab|8|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAH|||0|872|1414|1417
SE|25462300||ab|8|entity|C0678518|congener|chvs|||congeners|||0|872|1418|1427
SE|25462300||ab|8|entity|C0023779|Lipids|lipd|||lipid|||0|694|1436|1441
SE|25462300||ab|8|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|1459|1466
SE|25462300||ab|8|relation|1|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|1000|1459|1466|PREP|LOCATION_OF||1450|1452|8|1|C0023779|Lipids|lipd|lipd|||lipid|||0|694|1436|1441
SE|25462300||ab|8|relation|3|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|1000|1360|1367|PREP|PART_OF||1368|1370|6|1|C0327752|Acipenser|fish|fish|||sturgeons|||0|966|1371|1380
SE|25462300||ab|8|relation|7|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|1000|1360|1367|PREP|LOCATION_OF||1353|1355|2|2|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|orch|||PAHs|||0|916|1324|1328

SE|25462300||ab|9|text|1468|1572|There was a significant positive relationship (r=0.868, p<0.005) between lipid content and PAHs levels.
SE|25462300||ab|9|entity|C0750502|Significant|idcn|||significant|||0|851|1480|1491
SE|25462300||ab|9|entity|C1446409|Positive|qlco|||positive|||0|851|1492|1500
SE|25462300||ab|9|entity|C0439849|Relationships|qlco|||relationship|||0|851|1501|1513
SE|25462300||ab|9|entity|C0023779|Lipids|lipd|||lipid|||0|694|1541|1546
SE|25462300||ab|9|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|916|1559|1563
SE|25462300||ab|9|entity|C0441889|Levels|inpr|||levels|||0|916|1564|1570

SE|25462300||ab|10|text|1572|1737|The statistically significant negative relationships (p<0.01) were found between log Kow and log-transformed PAHs levels for muscle tissues of both sturgeon species.
SE|25462300||ab|10|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|861|1576|1601
SE|25462300||ab|10|entity|C0205160|Negative|qlco|||negative|||0|861|1602|1610
SE|25462300||ab|10|entity|C0439849|Relationships|qlco|||relationships|||0|861|1611|1624
SE|25462300||ab|10|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|817|1681|1685
SE|25462300||ab|10|entity|C0441889|Levels|inpr|||levels|||0|817|1686|1692
SE|25462300||ab|10|entity|C0026845|Muscle|tisu|||muscle tissues|||0|983|1697|1711
SE|25462300||ab|10|entity|C0327752|Acipenser|fish|||sturgeon|||0|888|1720|1728
SE|25462300||ab|10|entity|C1548151|Species|idcn|||species|||0|888|1729|1736


SE|25462301||ti|1|text|21|227|Serum cotinine and urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol levels among non-Hispanic Asian American smokers and nonsmokers as compared to other race/ethnicities: data from NHANES 2011-2012.
SE|25462301||ti|1|entity|C0229671|Serum|bdsu|||Serum|||0|888|21|26
SE|25462301||ti|1|entity|C0010194|Cotinine|orch,phsu|||cotinine|||0|888|27|35
SE|25462301||ti|1|entity|C1524119|urinary|qlco|||urinary|||0|861|40|47
SE|25462301||ti|1|entity|C0441889|Levels|inpr|||levels|||0|827|96|102
SE|25462301||ti|1|entity|C0078988|Asians|popg|||Asian|||0|851|122|127
SE|25462301||ti|1|entity|C0019576|Hispanic Americans|popg|||Hispanic Asian American|||0|851|113|136
SE|25462301||ti|1|entity|C0337672|Non-smoker|fndg|||non-Hispanic Asian American smokers|||0|851|109|144
SE|25462301||ti|1|entity|C0337672|Non-smoker|fndg|||nonsmokers|||0|966|149|159
SE|25462301||ti|1|entity|C0034510|Racial group|popg|||race|||0|872|181|185
SE|25462301||ti|1|entity|C0015031|Ethnic group|popg|||ethnicities|||0|872|186|197
SE|25462301||ti|1|entity|C1511726|Data|idcn|||data|||0|1000|199|203
SE|25462301||ti|1|entity|C0376344|National Health and Nutrition Examination Survey|resa|||NHANES|||0|827|209|215
SE|25462301||ti|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||Serum|||0|888|21|26|MOD/HEAD|LOCATION_OF||21|35|0|0|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|888|27|35
SE|25462301||ti|1|relation|0|0|C0337672|Non-smoker|fndg|fndg|||non-Hispanic Asian American smokers|||0|851|109|144|MOD/HEAD|PROCESS_OF||113|144|0|0|C0019576|Hispanic Americans|popg,humn|humn|||Hispanic Asian American|||0|851|113|136

SE|25462301||ab|1|text|233|489|The objective of this study was to evaluate serum cotinine and total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanonol (NNAL) levels from a nationally representative sample of non-Hispanic Asian Americans as compared with other racial/ethnic groups.
SE|25462301||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|255|260
SE|25462301||ab|1|entity|C0229671|Serum|bdsu|||serum|||0|888|277|282
SE|25462301||ab|1|entity|C0010194|Cotinine|orch,phsu|||cotinine|||0|888|283|291
SE|25462301||ab|1|entity|C0439175|% of total|qnco|||total|||0|790|296|301
SE|25462301||ab|1|entity|C1524119|urinary|qlco|||urinary|||0|790|302|309
SE|25462301||ab|1|entity|C0441889|Levels|inpr|||levels|||0|1000|365|371
SE|25462301||ab|1|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|888|415|427
SE|25462301||ab|1|entity|C0003988|Asian Americans|popg|||Asian Americans|||0|888|428|443
SE|25462301||ab|1|entity|C0680174|ethnic|fndg|||ethnic|||0|890|474|480
SE|25462301||ab|1|entity|C0034510|Racial group|popg|||racial/ethnic groups|||0|890|467|487
SE|25462301||ab|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|277|282|MOD/HEAD|LOCATION_OF||277|291|0|0|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|888|283|291

SE|25462301||ab|2|text|489|611|Data from the latest National Health and Nutrition Examination Survey for the years 2011-2012 were used for this purpose.
SE|25462301||ab|2|entity|C1511726|Data|idcn|||Data|||0|1000|489|493
SE|25462301||ab|2|entity|C0205087|Late|tmco|||latest|||0|840|503|509
SE|25462301||ab|2|entity|C0018684|Health|idcn|||Health|||0|840|519|525
SE|25462301||ab|2|entity|C0028713|Nutrition Surveys|resa|||Nutrition Examination Survey|||0|913|530|558
SE|25462301||ab|2|entity|C0439234|year|tmco|||years|||0|827|567|572
SE|25462301||ab|2|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|602|609

SE|25462301||ab|3|text|611|648|The total sample size used was 4580.
SE|25462301||ab|3|entity|C0439175|% of total|qnco|||total|||0|901|615|620
SE|25462301||ab|3|entity|C0242618|Sample Size|qnco|||sample size|||0|901|621|632

SE|25462301||ab|4|text|648|833|Regression models were fitted to estimate serum cotinine and urinary NNAL levels for smokers and nonsmokers aged 20 years and older adjusted for other factors that affect these levels.
SE|25462301||ab|4|entity|C0229671|Serum|bdsu|||serum|||0|888|690|695
SE|25462301||ab|4|entity|C0010194|Cotinine|orch,phsu|||cotinine|||0|888|696|704
SE|25462301||ab|4|entity|C0243173|urinary levels|ftcn|||urinary NNAL levels|||0|913|709|728
SE|25462301||ab|4|entity|C0337664|Smoker|fndg|||smokers|||0|966|733|740
SE|25462301||ab|4|entity|C0337672|Non-smoker|fndg|||nonsmokers|||0|966|745|755
SE|25462301||ab|4|entity|C0439234|year|tmco|||years|||0|861|764|769
SE|25462301||ab|4|entity|C0580836|Old|tmco|||older|||0|966|774|779
SE|25462301||ab|4|entity|C1521761|Factor|ftcn|||factors|||0|966|799|806
SE|25462301||ab|4|entity|C0441889|Levels|inpr|||levels|||0|1000|825|831
SE|25462301||ab|4|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|690|695|MOD/HEAD|LOCATION_OF||690|704|0|0|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|888|696|704

SE|25462301||ab|5|text|833|1043|For nonsmokers, exposure to second hand smoke at home was associated with about 30 times higher serum cotinine levels when compared to those without such exposure (0.717 ng mL(-1) vs. 0.024 ng mL(-1), p<0.01).
SE|25462301||ab|5|entity|C0337672|Non-smoker|fndg|||nonsmokers|||0|966|837|847
SE|25462301||ab|5|entity|C0813971|Environmental Tobacco Smoke|hops|||second hand smoke|||0|1000|861|878
SE|25462301||ab|5|entity|C0040223|Time|tmco|||times|||0|722|916|921
SE|25462301||ab|5|entity|C0205250|High|qlco|||higher|||0|722|922|928
SE|25462301||ab|5|entity|C0229671|Serum|bdsu|||serum|||0|722|929|934
SE|25462301||ab|5|entity|C0010194|Cotinine|orch,phsu|||cotinine|||0|722|935|943
SE|25462301||ab|5|entity|C0441889|Levels|inpr|||levels|||0|722|944|950
SE|25462301||ab|5|entity|C0439242|milliliter|qnco|||mL|||0|785|1006|1008
SE|25462301||ab|5|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1003|1011
SE|25462301||ab|5|entity|C0439242|milliliter|qnco|||mL|||0|785|1026|1028
SE|25462301||ab|5|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1023|1031
SE|25462301||ab|5|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|722|929|934|MOD/HEAD|LOCATION_OF||929|943|0|0|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|722|935|943
SE|25462301||ab|5|relation|2|1|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|722|935|943|VERB|COEXISTS_WITH||891|901|4|2|C0813971|Environmental Tobacco Smoke|hops|hops|||second hand smoke|||0|1000|861|878

SE|25462301||ab|6|text|1043|1223|NNAL levels among nonsmokers with second hand smoke exposure at home were about twenty times what they were in those without such exposure (9 pg mL(-1) vs. 109 pg mL(-1), p<0.01).
SE|25462301||ab|6|entity|C0441889|Levels|inpr|||levels|||0|861|1048|1054
SE|25462301||ab|6|entity|C0337672|Non-smoker|fndg|||nonsmokers|||0|966|1061|1071
SE|25462301||ab|6|entity|C1545750|SECOND HAND SMOKE EXPOSURE|fndg|||second hand smoke exposure|||0|1000|1077|1103
SE|25462301||ab|6|entity|C0040223|Time|tmco|||times|||0|793|1130|1135
SE|25462301||ab|6|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|mL(-1|||0|861|1188|1193
SE|25462301||ab|6|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|mL(-1|||0|861|1206|1211

SE|25462301||ab|7|text|1223|1491|As compared to other racial/ethnic groups, the lowest adjusted serum cotinine levels occurred in non-Hispanic Asian smokers (92.6 ng mL(-1)) and Hispanics (84.5 ng mL(-1)) as compared to non-Hispanic whites (143.8 ng mL(-1)) and non-Hispanic blacks (158.4 ng mL(-1)).
SE|25462301||ab|7|entity|C0680174|ethnic|fndg|||ethnic|||0|890|1251|1257
SE|25462301||ab|7|entity|C0034510|Racial group|popg|||racial/ethnic groups|||0|890|1244|1264
SE|25462301||ab|7|entity|C0205251|low|qlco|||lowest|||0|815|1270|1276
SE|25462301||ab|7|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|815|1277|1285
SE|25462301||ab|7|entity|C0229671|Serum|bdsu|||serum|||0|815|1286|1291
SE|25462301||ab|7|entity|C0010194|Cotinine|orch,phsu|||cotinine|||0|815|1292|1300
SE|25462301||ab|7|entity|C0441889|Levels|inpr|||levels|||0|815|1301|1307
SE|25462301||ab|7|entity|C0086409|Hispanics|popg|||Hispanic|||0|852|1324|1332
SE|25462301||ab|7|entity|C0078988|Asians|popg|||Asian|||0|852|1333|1338
SE|25462301||ab|7|entity|C0337672|Non-smoker|fndg|||non-Hispanic Asian smokers|||0|852|1320|1346
SE|25462301||ab|7|entity|C0439242|milliliter|qnco|||mL|||0|785|1356|1358
SE|25462301||ab|7|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1353|1361
SE|25462301||ab|7|entity|C0086409|Hispanics|popg|||Hispanics|||0|1000|1368|1377
SE|25462301||ab|7|entity|C0439242|milliliter|qnco|||mL|||0|785|1387|1389
SE|25462301||ab|7|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1384|1392
SE|25462301||ab|7|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1410|1422
SE|25462301||ab|7|entity|C0007457|Caucasoid Race|popg|||whites|||0|901|1423|1429
SE|25462301||ab|7|entity|C0439242|milliliter|qnco|||mL|||0|785|1440|1442
SE|25462301||ab|7|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1437|1445
SE|25462301||ab|7|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1452|1464
SE|25462301||ab|7|entity|C0005680|Black race|popg|||blacks|||0|901|1465|1471
SE|25462301||ab|7|entity|C0439242|milliliter|qnco|||mL|||0|785|1482|1484
SE|25462301||ab|7|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1479|1487
SE|25462301||ab|7|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|815|1286|1291|MOD/HEAD|LOCATION_OF||1286|1300|0|0|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|815|1292|1300
SE|25462301||ab|7|relation|0|0|C0337672|Non-smoker|fndg|fndg|||non-Hispanic Asian smokers|||0|852|1320|1346|MOD/HEAD|PROCESS_OF||1333|1346|0|0|C0078988|Asians|popg,humn|humn|||Asian|||0|852|1333|1338
SE|25462301||ab|7|relation|2|1|C0010194|Cotinine|orch,phsu|phsu|||cotinine|||0|815|1292|1300|PREP|TREATS||1317|1319|4|1|C0337672|Non-smoker|fndg|fndg|||non-Hispanic Asian smokers|||0|852|1320|1346

SE|25462301||ab|8|text|1491|1684|Urinary NNAL levels for smokers were in the order: non-Hispanic Asian (0.121 ng mL(-1))<non-Hispanic blacks (0.139 ng mL(-1))<Hispanics (0.201 ng mL(-1))<non-Hispanic whites (0.234 ng mL(-1)).
SE|25462301||ab|8|entity|C0243173|urinary levels|ftcn|||Urinary NNAL levels|||0|913|1491|1510
SE|25462301||ab|8|entity|C0337664|Smoker|fndg|||smokers|||0|966|1515|1522
SE|25462301||ab|8|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1542|1554
SE|25462301||ab|8|entity|C0078988|Asians|popg|||Asian|||0|901|1555|1560
SE|25462301||ab|8|entity|C0439242|milliliter|qnco|||mL|||0|785|1571|1573
SE|25462301||ab|8|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1568|1576
SE|25462301||ab|8|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1579|1591
SE|25462301||ab|8|entity|C0005680|Black race|popg|||blacks|||0|901|1592|1598
SE|25462301||ab|8|entity|C0439242|milliliter|qnco|||mL|||0|785|1609|1611
SE|25462301||ab|8|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1606|1614
SE|25462301||ab|8|entity|C0086409|Hispanics|popg|||Hispanics|||0|1000|1617|1626
SE|25462301||ab|8|entity|C0439242|milliliter|qnco|||mL|||0|785|1637|1639
SE|25462301||ab|8|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1634|1642
SE|25462301||ab|8|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1645|1657
SE|25462301||ab|8|entity|C0007457|Caucasoid Race|popg|||whites|||0|901|1658|1664
SE|25462301||ab|8|entity|C0439242|milliliter|qnco|||mL|||0|785|1675|1677
SE|25462301||ab|8|entity|C0964553|interleukin-19|aapp,imft|||ng mL(-1|||0|785|1672|1680

SE|25462301||ab|9|text|1684|1953|Compared to non-Hispanic whites, non-Hispanic blacks had substantially higher levels of serum cotinine but substantially lower levels of urinary NNAL irrespective of smoking status thus pointing towards differences in elimination kinetics of nicotine/cotinine and NNAL.
SE|25462301||ab|9|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1696|1708
SE|25462301||ab|9|entity|C0007457|Caucasoid Race|popg|||whites|||0|901|1709|1715
SE|25462301||ab|9|entity|C1518424|Not Hispanic or Latino|popg|||non-Hispanic|||0|901|1717|1729
SE|25462301||ab|9|entity|C0005680|Black race|popg|||blacks|||0|901|1730|1736
SE|25462301||ab|9|entity|C0205250|High|qlco|||higher|||0|773|1755|1761
SE|25462301||ab|9|entity|C0441889|Levels|inpr|||levels|||0|773|1762|1768
SE|25462301||ab|9|entity|C0229671|Serum|bdsu|||serum|||0|888|1772|1777
SE|25462301||ab|9|entity|C0010194|Cotinine|orch,phsu|||cotinine|||0|888|1778|1786
SE|25462301||ab|9|entity|C0441994|Lower|ftcn|||lower|||0|790|1805|1810
SE|25462301||ab|9|entity|C0441889|Levels|inpr|||levels|||0|790|1811|1817
SE|25462301||ab|9|entity|C1524119|urinary|qlco|||urinary|||0|694|1821|1828
SE|25462301||ab|9|entity|C1519386|Smoking Status|clna|||smoking status|||0|1000|1850|1864
SE|25462301||ab|9|entity|C1547020|*Difference|qnco|||differences|||0|966|1887|1898
SE|25462301||ab|9|entity|C0022702|Kinetics|idcn|||kinetics|||0|888|1914|1922
SE|25462301||ab|9|entity|C0946251|NICOTINE AND COTININE|orch,phsu|||nicotine/cotinine|||0|1000|1926|1943
SE|25462301||ab|9|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|1772|1777|MOD/HEAD|LOCATION_OF||1772|1786|0|0|C0010194|Cotinine|orch,phsu|orch|||cotinine|||0|888|1778|1786


SE|25462302||ti|1|text|21|125|Biological uptake and depuration of sulfadiazine and sulfamethoxazole in common carp (Cyprinus carpio).
SE|25462302||ti|1|entity|C0205460|biological|ftcn|||Biological|||0|888|21|31
SE|25462302||ti|1|entity|C0243144|uptake|phsf|||uptake|||0|888|32|38
SE|25462302||ti|1|entity|C0038675|Sulfadiazine|orch,phsu|||sulfadiazine|||0|1000|57|69
SE|25462302||ti|1|entity|C0038689|Sulfamethoxazole|orch,phsu|||sulfamethoxazole|||0|1000|74|90
SE|25462302||ti|1|entity|C0328038|Cyprinus carpio|fish|||common carp|||0|1000|94|105
SE|25462302||ti|1|entity|C0328038|Cyprinus carpio|fish|||Cyprinus carpio|||0|1000|107|122
SE|25462302||ti|1|relation|4|4|C0243144|uptake|phsf|phsf|||uptake|||0|888|32|38|PREP|PROCESS_OF||91|93|2|1|C0328038|Cyprinus carpio|fish|fish|||common carp|||0|1000|94|105

SE|25462302||ab|1|text|131|301|Sulfonamides, a class of the most commonly used antibiotics, are being increasingly released into the aquatic environment and have recently caused considerable concerns.
SE|25462302||ab|1|entity|C0038760|Sulfonamides|orch,phsu|||Sulfonamides|||0|1000|131|143
SE|25462302||ab|1|entity|C0008902|Classification|clas|||class|||0|1000|147|152
SE|25462302||ab|1|entity|C0205393|Most|qnco|||most|||0|751|160|164
SE|25462302||ab|1|entity|C0042153|utilization qualifier|ftcn|||used|||0|751|174|178
SE|25462302||ab|1|entity|C0003232|Antibiotics|antb|||antibiotics|||0|751|179|190
SE|25462302||ab|1|entity|C0563034|Aquatic environment|phpr|||aquatic environment|||0|1000|233|252
SE|25462302||ab|1|entity|C0332185|Recent|tmco|||recently|||0|1000|262|270

SE|25462302||ab|2|text|301|409|However, knowledge on their fate and ecotoxicological effects upon aquatic organisms is not understood yet.
SE|25462302||ab|2|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|310|319
SE|25462302||ab|2|entity|C1302234|Fatal|qlco|||fate|||0|928|329|333
SE|25462302||ab|2|entity|C1280500|Effect|qlco|||effects|||0|827|355|362
SE|25462302||ab|2|entity|C0596121|aquatic organism|orgm|||aquatic organisms|||0|983|368|385
SE|25462302||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|389|392

SE|25462302||ab|3|text|409|650|This work investigated mainly the bioconcentration kinetics (uptake/depuration) of sulfadiazine (SDZ) and sulfamethoxazole (SMZ) in common carp (Cyprinus carpio) by exposure in different concentrations under semi-static conditions for 48 d.
SE|25462302||ab|3|entity|C0043227|Work|ocac|||work|||0|1000|414|418
SE|25462302||ab|3|entity|C0022702|Kinetics|idcn|||kinetics|||0|861|460|468
SE|25462302||ab|3|entity|C0243144|uptake|phsf|||uptake|||0|694|470|476
SE|25462302||ab|3|entity|C0038675|Sulfadiazine|orch,phsu|||sulfadiazine|||0|1000|492|504
SE|25462302||ab|3|entity|C0038689|Sulfamethoxazole|orch,phsu|||sulfamethoxazole|||0|1000|515|531
SE|25462302||ab|3|entity|C0328038|Cyprinus carpio|fish|||common carp|||0|1000|541|552
SE|25462302||ab|3|entity|C0328038|Cyprinus carpio|fish|||Cyprinus carpio|||0|1000|554|569
SE|25462302||ab|3|entity|C1547020|*Difference|qnco|||different|||0|853|586|595
SE|25462302||ab|3|entity|C0441463|Static|qlco|||static|||0|773|622|628
SE|25462302||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|773|629|639

SE|25462302||ab|4|text|650|887|The uptake rate (k1), growth-corrected depuration rate (k 2g), and biological half-lives (t1/2) of two sulfonamides in liver and muscle were determined and they were 0.135-9.84 L kg(-1)d(-1), 0.0361-0.838 d(-1), 8.3-19.2d, respectively.
SE|25462302||ab|4|entity|C0243144|uptake|phsf|||uptake|||0|888|654|660
SE|25462302||ab|4|entity|C1521828|Rate|qnco|||rate|||0|888|661|665
SE|25462302||ab|4|entity|C0205202|Corrected|qlco|||corrected|||0|824|679|688
SE|25462302||ab|4|entity|C0449249|Growth rate|tmco|||growth-corrected depuration rate|||0|824|672|704
SE|25462302||ab|4|entity|C0205460|biological|ftcn|||biological|||0|873|717|727
SE|25462302||ab|4|entity|C0018517|Half-Life|tmco|||half-lives|||0|873|728|738
SE|25462302||ab|4|entity|C0205448|Two|qnco|||two|||0|888|749|752
SE|25462302||ab|4|entity|C0038760|Sulfonamides|orch,phsu|||sulfonamides|||0|888|753|765
SE|25462302||ab|4|entity|C0023884|Liver|bpoc|||liver|||0|1000|769|774
SE|25462302||ab|4|entity|C0026845|Muscle|tisu|||muscle|||0|1000|779|785
SE|25462302||ab|4|entity|C0439209|Kilogram|qnco|||kg|||0|795|829|831
SE|25462302||ab|4|relation|6|6|C0243144|uptake|phsf|phsf|||uptake|||0|888|654|660|PREP|PROCESS_OF||766|768|3|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|769|774

SE|25462302||ab|5|text|887|1069|With exposure concentrations increasing, the uptake rates in liver and muscle decreased obviously but the depuration rates were not closely related with the exposure concentrations.
SE|25462302||ab|5|entity|C0243144|uptake|phsf|||uptake|||0|872|932|938
SE|25462302||ab|5|entity|C1521828|Rate|qnco|||rates|||0|872|939|944
SE|25462302||ab|5|entity|C0023884|Liver|bpoc|||liver|||0|1000|948|953
SE|25462302||ab|5|entity|C0026845|Muscle|tisu|||muscle|||0|1000|958|964
SE|25462302||ab|5|entity|C1521828|Rate|qnco|||rates|||0|827|1004|1009
SE|25462302||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1015|1018
SE|25462302||ab|5|relation|2|1|C0243144|uptake|phsf|phsf|||uptake|||0|872|932|938|PREP|PROCESS_OF||945|947|4|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|948|953

SE|25462302||ab|6|text|1069|1222|SDZ exhibited higher uptake but lower excretion rates in almost all the liver and muscle than SMZ, resulting in both higher BCFs and half-lives for SDZ.
SE|25462302||ab|6|entity|C0038675|Sulfadiazine|orch,phsu|||SDZ|||0|1000|1069|1072
SE|25462302||ab|6|entity|C0205250|High|qlco|||higher|||0|872|1083|1089
SE|25462302||ab|6|entity|C0243144|uptake|phsf|||uptake|||0|872|1090|1096
SE|25462302||ab|6|entity|C0441994|Lower|ftcn|||lower|||0|840|1101|1106
SE|25462302||ab|6|entity|C0221102|Excretory function|phsf|||excretion|||0|840|1107|1116
SE|25462302||ab|6|entity|C1521828|Rate|qnco|||rates|||0|840|1117|1122
SE|25462302||ab|6|entity|C0023884|Liver|bpoc|||liver|||0|1000|1141|1146
SE|25462302||ab|6|entity|C0026845|Muscle|tisu|||muscle|||0|1000|1151|1157
SE|25462302||ab|6|entity|C0038689|Sulfamethoxazole|orch,phsu|||SMZ|||0|1000|1163|1166
SE|25462302||ab|6|entity|C0205250|High|qlco|||higher|||0|661|1186|1192
SE|25462302||ab|6|entity|C0018517|Half-Life|tmco|||half-lives|||0|958|1202|1212
SE|25462302||ab|6|entity|C0038675|Sulfadiazine|orch,phsu|||SDZ|||0|1000|1217|1220

SE|25462302||ab|7|text|1222|1430|The growth-corrected bioconcentration factors (BCF kg) were measured to be 1.65-165.73 L kg(-1)ww and their averages were in good consistency with the values predicted by previous models within one log unit.
SE|25462302||ab|7|entity|C0205202|Corrected|qlco|||corrected|||0|824|1233|1242
SE|25462302||ab|7|entity|C0018284|Growth Factor|bacs|||growth-corrected bioconcentration factors|||0|824|1226|1267
SE|25462302||ab|7|entity|C0439209|Kilogram|qnco|||kg|||0|795|1311|1313
SE|25462302||ab|7|entity|C1510992|Average|qnco|||averages|||0|966|1330|1338
SE|25462302||ab|7|entity|C0205170|Good|qlco|||good|||0|888|1347|1351
SE|25462302||ab|7|entity|C0332529|Consistency|qlco|||consistency|||0|888|1352|1363
SE|25462302||ab|7|entity|C0042295|Values|qlco|||values|||0|1000|1373|1379
SE|25462302||ab|7|entity|C0205156|Previous|tmco|||previous|||0|694|1393|1401
SE|25462302||ab|7|entity|C0205447|One|qnco|||one|||0|802|1416|1419
SE|25462302||ab|7|entity|C0439148|Unit|qnco|||unit|||0|802|1424|1428

SE|25462302||ab|8|text|1430|1547|The work presented here was the first to model bioconcentration of SMZ and SDZ from water by laboratory-exposed fish.
SE|25462302||ab|8|entity|C0043227|Work|ocac|||work|||0|1000|1434|1438
SE|25462302||ab|8|entity|C1279901|Firstly|qlco|||first|||0|1000|1462|1467
SE|25462302||ab|8|entity|C0026336|Study models|inpr,resd|||model|||0|694|1471|1476
SE|25462302||ab|8|entity|C0038689|Sulfamethoxazole|orch,phsu|||SMZ|||0|1000|1497|1500
SE|25462302||ab|8|entity|C0038675|Sulfadiazine|orch,phsu|||SDZ|||0|1000|1505|1508
SE|25462302||ab|8|entity|C0020311|Hydrotherapy|topp|||water|||0|1000|1514|1519
SE|25462302||ab|8|entity|C0022877|Laboratory|mnob,orgt|||laboratory|||0|851|1523|1533
SE|25462302||ab|8|entity|C0332157|Exposure to|clna|||exposed|||0|851|1534|1541
SE|25462302||ab|8|entity|C0016163|Fishes|fish|||fish|||0|851|1542|1546


SE|25462303||ti|1|text|21|144|Modulation of excitatory synaptic transmission in rat hippocampal CA3 neurons by triphenyltin, an environmental pollutant.
SE|25462303||ti|1|entity|C0234107|Excitatory synaptic transmission|ortf|||excitatory synaptic transmission|||0|1000|35|67
SE|25462303||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|791|71|74
SE|25462303||ti|1|entity|||gngm|761|CA3|CA3|||0|791|87|90
SE|25462303||ti|1|entity|C0027882|Neurons|cell|||neurons|||0|791|91|98
SE|25462303||ti|1|entity|C0077259|triphenyltin|orch|||triphenyltin|||0|1000|102|114
SE|25462303||ti|1|entity|C0014417|Environmental Pollutants|hops|||environmental pollutant|||0|983|119|142
SE|25462303||ti|1|relation|4|3|C0077259|triphenyltin|orch|orch|||triphenyltin|||0|1000|102|114|NOM|AFFECTS||21|31|4|1|C0234107|Excitatory synaptic transmission|ortf|ortf|||excitatory synaptic transmission|||0|1000|35|67

SE|25462303||ab|1|text|150|286|Triphenyltin (TPT) is an organometallic compound that poses a known environmental hazard to some fish and mollusks, as well as mammals.
SE|25462303||ab|1|entity|C0077259|triphenyltin|orch|||Triphenyltin|||0|1000|150|162
SE|25462303||ab|1|entity|C0029252|Organometallic Compounds|orch|||organometallic compound|||0|1000|175|198
SE|25462303||ab|1|entity|C0205309|Known|qlco|||known|||0|901|212|217
SE|25462303||ab|1|entity|C0079291|Hazards, Environmental|hops|||environmental hazard|||0|901|218|238
SE|25462303||ab|1|entity|C0016163|Fishes|fish|||fish|||0|1000|247|251
SE|25462303||ab|1|entity|C0026391|Mollusca|invt|||mollusks|||0|1000|256|264
SE|25462303||ab|1|entity|C0024660|Mammals|mamm|||mammals|||0|1000|277|284
SE|25462303||ab|1|relation|0|0|C0077259|triphenyltin|orch|orch|||Triphenyltin|||0|1000|150|162|SPEC|ISA||150|198|0|0|C0029252|Organometallic Compounds|orch|orch|||organometallic compound|||0|1000|175|198

SE|25462303||ab|2|text|286|363|However, its neurotoxic mechanisms in the mammalian brain are still unclear.
SE|25462303||ab|2|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|861|310|320
SE|25462303||ab|2|entity|C0006104|Brain|bpoc|||brain|||0|861|338|343

SE|25462303||ab|3|text|363|643|Thus, we have investigated mechanisms through which TPT modulates glutamatergic synaptic transmission, including spontaneous, miniature, and evoked excitatory postsynaptic currents (sEPSCs, mEPSCs, and eEPSCs respectively), in a rat hippocampal CA3 'synaptic-bouton' preparation.
SE|25462303||ab|3|entity|C1292732|Investigates|ftcn|||investigated|||0|872|377|389
SE|25462303||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|872|390|400
SE|25462303||ab|3|entity|C0077259|triphenyltin|orch|||TPT|||0|1000|415|418
SE|25462303||ab|3|entity|C1523698|synaptic transmission, glutamatergic|celf|||glutamatergic synaptic transmission|||0|1000|429|464
SE|25462303||ab|3|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|694|476|487
SE|25462303||ab|3|entity|C1444748|Triggered by|qlco|||evoked|||0|775|504|510
SE|25462303||ab|3|entity|C0521116|Current|tmco|||currents|||0|775|535|543
SE|25462303||ab|3|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|780|592|595
SE|25462303||ab|3|entity|||gngm|761|CA3|CA3|||0|780|608|611
SE|25462303||ab|3|entity|C0206181|Presynaptic Terminals|celc|||synaptic-bouton|||0|780|613|628
SE|25462303||ab|3|entity|C1521827|Preparation|ftcn|||preparation|||0|780|630|641
SE|25462303||ab|3|relation|2|1|C0077259|triphenyltin|orch|orch|||TPT|||0|1000|415|418|VERB|AFFECTS||419|428|7|1|C1523698|synaptic transmission, glutamatergic|celf|celf|||glutamatergic synaptic transmission|||0|1000|429|464

SE|25462303||ab|4|text|643|849|TPT, at environmentally relevant concentrations (30 nM to 1 MUM), significantly increased the frequency of sEPSCs and mEPSCs in a concentration-dependent manner, without affecting the currents' amplitudes.
SE|25462303||ab|4|entity|C0077259|triphenyltin|orch|||TPT|||0|1000|643|646
SE|25462303||ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|703|706
SE|25462303||ab|4|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|737|746
SE|25462303||ab|4|entity|C0521116|Current|tmco|||currents|||0|661|827|835

SE|25462303||ab|5|text|849|975|The facilitatory effects of TPT on mEPSC frequency were seen even in a Ca(2+)-free external solution containing tetrodotoxin.
SE|25462303||ab|5|entity|C1280500|Effect|qlco|||effects|||0|827|866|873
SE|25462303||ab|5|entity|C0077259|triphenyltin|orch|||TPT|||0|1000|877|880
SE|25462303||ab|5|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|861|890|899
SE|25462303||ab|5|entity|C0205101|Extrinsic|spco|||external|||0|771|932|940
SE|25462303||ab|5|entity|C0037633|Solutions|sbst|||solution|||0|771|941|949
SE|25462303||ab|5|entity|C0332256|Containing|ftcn|||containing|||0|771|950|960
SE|25462303||ab|5|entity|C0039705|Tetrodotoxin|bacs,hops,orch|||tetrodotoxin|||0|771|961|973
SE|25462303||ab|5|relation|4|4|C0039705|Tetrodotoxin|bacs,hops,orch|bacs|||tetrodotoxin|||0|771|961|973|NOM|INTERACTS_WITH||866|873|4|1|C0077259|triphenyltin|orch|orch|||TPT|||0|1000|877|880

SE|25462303||ab|6|text|975|1095|These effects were further prolonged by adding caffeine, which releases Ca(2+) from intracellular Ca(2+) storage sites.
SE|25462303||ab|6|entity|C1280500|Effect|qlco|||effects|||0|966|981|988
SE|25462303||ab|6|entity|C1517331|Further|spco|||further|||0|1000|994|1001
SE|25462303||ab|6|entity|C1524062|Additional|ftcn|||adding|||0|872|1015|1021
SE|25462303||ab|6|entity|C0006644|Caffeine|orch,phsu|||caffeine|||0|872|1022|1030
SE|25462303||ab|6|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|1059|1072
SE|25462303||ab|6|entity|C0205145|Site|spco|||sites|||0|888|1088|1093

SE|25462303||ab|7|text|1095|1314|In glutamatergic eEPSCs evoked by paired-pulse stimuli, TPT at concentrations greater than or equal to 100 nM markedly increased the current amplitude by the first pulse and decreased failure rate and pair-pulse ratio.
SE|25462303||ab|7|entity|C0597163|paired stimuli|ortf|||paired-pulse stimuli|||0|913|1129|1149
SE|25462303||ab|7|entity|C0077259|triphenyltin|orch|||TPT|||0|1000|1151|1154
SE|25462303||ab|7|entity|C0443228|Largest|qnco|||greater|||0|1000|1173|1180
SE|25462303||ab|7|entity|C0205163|Equal|qlco|||equal|||0|1000|1189|1194
SE|25462303||ab|7|entity|C0522501|Massive|qlco|||markedly|||0|1000|1205|1213
SE|25462303||ab|7|entity|C0521116|Current|tmco|||current|||0|694|1228|1235
SE|25462303||ab|7|entity|C1279901|Firstly|qlco|||first|||0|694|1253|1258
SE|25462303||ab|7|entity|C0205216|Decreased|qnco|||decreased|||0|802|1269|1278
SE|25462303||ab|7|entity|C1521828|Rate|qnco|||rate|||0|802|1287|1291
SE|25462303||ab|7|entity|C0456603|Ratio|inpr|||ratio|||0|827|1307|1312

SE|25462303||ab|8|text|1314|1438|On the other hand, both voltage-dependent Na(+) and Ca(2+) channels were unaffected by submicromolar concentrations of TPT.
SE|25462303||ab|8|entity|C0598352|voltage|qnco|||voltage|||0|851|1338|1345
SE|25462303||ab|8|entity|C0337443|Sodium measurement|lbpr|||Na|||0|851|1356|1358
SE|25462303||ab|8|entity|C0439799|Channel|spco|||channels|||0|966|1373|1381
SE|25462303||ab|8|entity|C0077259|triphenyltin|orch|||TPT|||0|1000|1433|1436

SE|25462303||ab|9|text|1438|1612|Overall, these results suggest that TPT, at environmentally relevant concentrations, affects presynaptic transmitter release machinery by directly modulating Ca(2+) storage.
SE|25462303||ab|9|entity|C1561607|Overall|qlco|||Overall|||0|1000|1438|1445
SE|25462303||ab|9|entity|C1274040|result|ftcn|||results|||0|966|1453|1460
SE|25462303||ab|9|entity|C0077259|triphenyltin|orch|||TPT|||0|1000|1474|1477
SE|25462303||ab|9|entity|C0337076|Industrial machine|mnob|||machinery|||0|750|1563|1572

SE|25462303||ab|10|text|1612|1719|Further, findings of this study imply that excitotoxic mechanisms may underlie TPT-induced neuronal damage.
SE|25462303||ab|10|entity|C1517331|Further|spco|||Further|||0|1000|1612|1619
SE|25462303||ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1621|1629
SE|25462303||ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1638|1643
SE|25462303||ab|10|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|861|1667|1677
SE|25462303||ab|10|entity|C0077259|triphenyltin|orch|||TPT|||0|608|1691|1694
SE|25462303||ab|10|entity|C0205263|Induced|ftcn|||induced|||0|608|1695|1702


SE|25462304||ti|1|text|21|172|Toxic potencies of metabolite(s) of non-cylindrospermopsin producing Cylindrospermopsis raciborskii isolated from temperate zone in human white cells.
SE|25462304||ti|1|entity|C0243169|toxic potential|qnco|||Toxic potencies|||0|940|21|36
SE|25462304||ti|1|entity|C0870883|Metabolites|bacs|||metabolite|||0|966|40|50
SE|25462304||ti|1|entity|C0259656|cylindrospermopsin|nnon|||cylindrospermopsin|||0|790|61|79
SE|25462304||ti|1|entity|C1032308|Cylindrospermopsis raciborskii|bact|||Cylindrospermopsis raciborskii|||0|790|90|120
SE|25462304||ti|1|entity|C0039475|Temperance|inbe|||temperate|||0|817|135|144
SE|25462304||ti|1|entity|C0007457|Caucasoid Race|popg|||white|||0|901|159|164
SE|25462304||ti|1|entity|C0427861|Human cells|lbtr|||human white cells|||0|901|153|170
SE|25462304||ti|1|relation|3|0|C1032308|Cylindrospermopsis raciborskii|bact|bact|||Cylindrospermopsis raciborskii|||0|790|90|120|ADJ|PRODUCES||80|89|3|2|C0870883|Metabolites|bacs|bacs|||metabolite|||0|966|40|50

SE|25462304||ab|1|text|178|342|Cylindrospermopsis raciborskii (Nostocales, Cyanobacteria) has worldwide distribution and is well known for producing the toxic alkaloid, cylindrospermopsin (CYN).
SE|25462304||ab|1|entity|C1032308|Cylindrospermopsis raciborskii|bact|||Cylindrospermopsis raciborskii|||0|1000|178|208
SE|25462304||ab|1|entity|C0562696|Nostocales|bact|||Nostocales|||0|1000|210|220
SE|25462304||ab|1|entity|C1047211|Cyanobacterium|bact|||Cyanobacteria|||0|1000|222|235
SE|25462304||ab|1|entity|C0520511|Distributing|idcn|||distribution|||0|861|251|263
SE|25462304||ab|1|entity|C0205170|Good|qlco|||well|||0|888|271|275
SE|25462304||ab|1|entity|C0205309|Known|qlco|||known|||0|888|276|281
SE|25462304||ab|1|entity|C1407029|Toxic|qlco|||toxic|||0|888|300|305
SE|25462304||ab|1|entity|C0002062|Alkaloids|orch|||alkaloid|||0|888|306|314
SE|25462304||ab|1|entity|C0259656|cylindrospermopsin|nnon|||cylindrospermopsin|||0|1000|316|334
SE|25462304||ab|1|relation|0|0|C1032308|Cylindrospermopsis raciborskii|bact|bact|||Cylindrospermopsis raciborskii|||0|1000|178|208|SPEC|ISA||178|220|0|0|C0562696|Nostocales|bact|bact|||Nostocales|||0|1000|210|220

SE|25462304||ab|2|text|342|443|Strains unable to synthesize this compound but potentially toxic were recently identified in Europe.
SE|25462304||ab|2|entity|C0205198|Compound|qlco|||compound|||0|1000|376|384
SE|25462304||ab|2|entity|C1407029|Toxic|qlco|||toxic|||0|861|401|406
SE|25462304||ab|2|entity|C0332185|Recent|tmco|||recently|||0|1000|412|420
SE|25462304||ab|2|entity|C0015176|Europe|geoa|||Europe|||0|1000|435|441

SE|25462304||ab|3|text|443|636|Here, for the first time the effect of cell-free extracts of a non-CYN-producing strain of C. raciborskii was studied in human cells (neutrophils and lymphocytes) isolated from healthy donors.
SE|25462304||ab|3|entity|C1279901|Firstly|qlco|||first|||0|888|457|462
SE|25462304||ab|3|entity|C0040223|Time|tmco|||time|||0|888|463|467
SE|25462304||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|472|478
SE|25462304||ab|3|entity|C0007634|Cells|cell|||cell|||0|785|482|486
SE|25462304||ab|3|entity|C1555707|extract|idcn|||extracts|||0|785|492|500
SE|25462304||ab|3|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|763|510|513
SE|25462304||ab|3|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|763|524|530
SE|25462304||ab|3|entity|C0427861|Human cells|lbtr|||human cells|||0|1000|564|575
SE|25462304||ab|3|entity|C0027950|neutrophil|cell|||neutrophils|||0|1000|577|588
SE|25462304||ab|3|entity|C0024264|Lymphocyte|cell|||lymphocytes|||0|1000|593|604
SE|25462304||ab|3|entity|C0018684|Health|idcn|||healthy|||0|853|620|627
SE|25462304||ab|3|entity|C0013018|Donor person|humn|||donors|||0|853|628|634

SE|25462304||ab|4|text|636|718|The observed effects were compared to those induced by CYN (1.0-0.01 MUg mL(-1)).
SE|25462304||ab|4|entity|C1280500|Effect|qlco|||effects|||0|872|649|656
SE|25462304||ab|4|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|1000|691|694
SE|25462304||ab|4|entity|C0439242|milliliter|qnco|||mL|||0|795|709|711

SE|25462304||ab|5|text|718|895|Short-term (1h) extract treatments resulted in altered viability of cells demonstrated by increased necrosis and apoptosis in neutrophils and elevated apoptosis in lymphocytes.
SE|25462304||ab|5|entity|C0443303|Short-term|tmco|||Short-term|||0|1000|718|728
SE|25462304||ab|5|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|1000|742|752
SE|25462304||ab|5|entity|C0205349|Altered|ftcn|||altered|||0|853|765|772
SE|25462304||ab|5|entity|C0443348|Viable|qlco|||viability|||0|853|773|782
SE|25462304||ab|5|entity|C0007634|Cells|cell|||cells|||0|1000|786|791
SE|25462304||ab|5|entity|C0205217|Increased|qnco|||increased|||0|888|808|817
SE|25462304||ab|5|entity|C0027540|Necrosis|patf|||necrosis|||0|888|818|826
SE|25462304||ab|5|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|831|840
SE|25462304||ab|5|entity|C0027950|neutrophil|cell|||neutrophils|||0|1000|844|855
SE|25462304||ab|5|entity|C0205250|High|qlco|||elevated|||0|888|860|868
SE|25462304||ab|5|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|869|878
SE|25462304||ab|5|entity|C0024264|Lymphocyte|cell|||lymphocytes|||0|1000|882|893
SE|25462304||ab|5|relation|1|1|C0024264|Lymphocyte|cell|cell|||lymphocytes|||0|1000|882|893|PREP|LOCATION_OF||879|881|9|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|888|869|878
SE|25462304||ab|5|relation|3|1|C0027950|neutrophil|cell|cell|||neutrophils|||0|1000|844|855|PREP|LOCATION_OF||841|843|7|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|1000|831|840

SE|25462304||ab|6|text|895|970|CYN did not induce similar effects, regardless of the toxin concentration.
SE|25462304||ab|6|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|1000|895|898
SE|25462304||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|903|906
SE|25462304||ab|6|entity|C1280500|Effect|qlco|||effects|||0|836|922|929
SE|25462304||ab|6|entity|C0040549|Toxin|bacs,hops|||toxin|||0|694|949|954

SE|25462304||ab|7|text|970|1141|Exposure of T-lymphocytes to 100% C. raciborskii extract in isolated and whole-blood 72 h cultures resulted in decrease of proliferation by 20.6% and 32.5%, respectively.
SE|25462304||ab|7|entity|C0039194|T-Lymphocyte|cell|||T-lymphocytes|||0|1000|982|995
SE|25462304||ab|7|entity|C0205409|Isolated|ftcn|||isolated|||0|1000|1030|1038
SE|25462304||ab|7|entity|C0370231|whole blood|bdsu|||whole-blood|||0|785|1043|1054
SE|25462304||ab|7|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|785|1060|1068
SE|25462304||ab|7|entity|C0547047|Decrease|qnco|||decrease|||0|1000|1081|1089
SE|25462304||ab|7|entity|C0334094|Proliferation|ftcn|||proliferation|||0|1000|1093|1106

SE|25462304||ab|8|text|1141|1301|In comparison, exposure to 1.0 MUg mL(-1) of CYN caused lymphocytes proliferation to be inhibited by 91.0% in isolated cultures and 56.5% in whole-blood assay.
SE|25462304||ab|8|entity|C0439242|milliliter|qnco|||mL|||0|804|1176|1178
SE|25462304||ab|8|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|844|1186|1189
SE|25462304||ab|8|entity|C0015127|Etiology aspects|ftcn|||caused|||0|844|1190|1196
SE|25462304||ab|8|entity|C0596873|lymphocyte proliferation|celf|||lymphocytes proliferation|||0|844|1197|1222
SE|25462304||ab|8|entity|C0205409|Isolated|ftcn|||isolated|||0|888|1251|1259
SE|25462304||ab|8|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|888|1260|1268
SE|25462304||ab|8|entity|C0370231|whole blood|bdsu|||whole-blood|||0|901|1282|1293
SE|25462304||ab|8|entity|C1510438|Assay|lbpr|||assay|||0|901|1294|1299

SE|25462304||ab|9|text|1301|1408|Significant antiproliferative properties were also found for 0.1 MUg mL(-1) of CYN in whole-blood culture.
SE|25462304||ab|9|entity|C0750502|Significant|idcn|||Significant|||0|785|1301|1312
SE|25462304||ab|9|entity|C0871161|Property|qlco|||properties|||0|785|1331|1341
SE|25462304||ab|9|entity|C0439242|milliliter|qnco|||mL|||0|804|1370|1372
SE|25462304||ab|9|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|1000|1380|1383
SE|25462304||ab|9|entity|C0370231|whole blood|bdsu|||whole-blood|||0|901|1387|1398
SE|25462304||ab|9|entity|C0220814|Cultural|ftcn|||culture|||0|901|1399|1406

SE|25462304||ab|10|text|1408|1622|From the results we conclude that strains occurring in temperate zones may pose a threat to human health through the production of hitherto unknown metabolites that reveal a toxic pattern different to that of CYN.
SE|25462304||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1417|1424
SE|25462304||ab|10|entity|C0039475|Temperance|inbe|||temperate|||0|811|1463|1472
SE|25462304||ab|10|entity|C0020114|Human|humn|||human|||0|888|1500|1505
SE|25462304||ab|10|entity|C0018684|Health|idcn|||health|||0|888|1506|1512
SE|25462304||ab|10|entity|C0033268|production|ocac|||production|||0|1000|1525|1535
SE|25462304||ab|10|entity|C0439673|Unknown|idcn|||unknown|||0|790|1548|1555
SE|25462304||ab|10|entity|C0870883|Metabolites|bacs|||metabolites|||0|790|1556|1567
SE|25462304||ab|10|entity|C1407029|Toxic|qlco|||toxic|||0|888|1582|1587
SE|25462304||ab|10|entity|C0449774|Patterns|spco|||pattern|||0|888|1588|1595
SE|25462304||ab|10|entity|C1547020|*Difference|qnco|||different|||0|928|1596|1605
SE|25462304||ab|10|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|1000|1617|1620

SE|25462304||ab|11|text|1622|1731|At the same time our study demonstrates that CYN is a powerful but slowly-acting toxin in human immune cells.
SE|25462304||ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|1643|1648
SE|25462304||ab|11|entity|C0259656|cylindrospermopsin|nnon|||CYN|||0|1000|1667|1670
SE|25462304||ab|11|entity|C0040549|Toxin|bacs,hops|||toxin|||0|827|1703|1708
SE|25462304||ab|11|entity|C0439662|Immune|ftcn|||immune|||0|901|1718|1724
SE|25462304||ab|11|entity|C0427861|Human cells|lbtr|||human immune cells|||0|901|1712|1730


SE|25462305||ti|1|text|21|114|Adsorption kinetics of pesticide in soil assessed by optofluidics-based biosensing platform.
SE|25462305||ti|1|entity|C0001674|Adsorption|lbpr|||Adsorption|||0|888|21|31
SE|25462305||ti|1|entity|C0022702|Kinetics|idcn|||kinetics|||0|888|32|40
SE|25462305||ti|1|entity|C0031253|Pesticides|hops|||pesticide|||0|1000|44|53
SE|25462305||ti|1|entity|C0037592|Soil|sbst|||soil|||0|1000|57|61

SE|25462305||ab|1|text|120|262|The adsorption of pesticides in soil is a key process that affects transport, degradation, mobility, and bioaccumulation of these substances.
SE|25462305||ab|1|entity|C0001674|Adsorption|lbpr|||adsorption|||0|1000|124|134
SE|25462305||ab|1|entity|C0031253|Pesticides|hops|||pesticides|||0|1000|138|148
SE|25462305||ab|1|entity|C0037592|Soil|sbst|||soil|||0|1000|152|156
SE|25462305||ab|1|entity|C1554080|Key|idcn|||key|||0|888|162|165
SE|25462305||ab|1|entity|C1522240|Process|phpr|||process|||0|888|166|173
SE|25462305||ab|1|entity|C0243125|degradation|ftcn|||degradation|||0|1000|198|209
SE|25462305||ab|1|entity|C0311432|Bioaccumulation|ortf|||bioaccumulation|||0|1000|225|240
SE|25462305||ab|1|entity|C0439861|Substance|sbst|||substances|||0|1000|250|260

SE|25462305||ab|2|text|262|494|To obtain extensive knowledge regarding the adsorption processes of pesticides in the environment, the new green assay technologies for the rapid, sensitive, field-deployable, and accurate quantification of pesticides are required.
SE|25462305||ab|2|entity|C0205231|Extensive|qlco|||extensive|||0|888|272|281
SE|25462305||ab|2|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|282|291
SE|25462305||ab|2|entity|C0001674|Adsorption|lbpr|||adsorption|||0|872|306|316
SE|25462305||ab|2|entity|C1522240|Process|phpr|||processes|||0|872|317|326
SE|25462305||ab|2|entity|C0031253|Pesticides|hops|||pesticides|||0|1000|330|340
SE|25462305||ab|2|entity|C0014406|Environment|spco|||environment|||0|1000|348|359
SE|25462305||ab|2|entity|C1510438|Assay|lbpr|||assay|||0|813|375|380
SE|25462305||ab|2|entity|C0683887|new technology|inpr|||new green assay technologies|||0|813|365|393
SE|25462305||ab|2|entity|C0439831|Rapid|qlco|||rapid|||0|608|402|407
SE|25462305||ab|2|entity|C0332324|Sensitive|ftcn|||sensitive|||0|608|409|418
SE|25462305||ab|2|entity|C1521738|Field|cnce|||field|||0|608|420|425
SE|25462305||ab|2|entity|C0443131|Accurate|qlco|||accurate|||0|694|442|450
SE|25462305||ab|2|entity|C0031253|Pesticides|hops|||pesticides|||0|1000|469|479

SE|25462305||ab|3|text|494|741|In the present study, an evanescent wave-based optofluidics biosensing platform (EWOB) was developed by combining advanced photonics and microfluidics technology for the rapid sensitive immunodetection and adsorption kinetics assay of pesticides.
SE|25462305||ab|3|entity|C0150312|Present|qnco|||present|||0|888|501|508
SE|25462305||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|509|514
SE|25462305||ab|3|entity|C0678544|wave|npop|||wave|||0|532|530|534
SE|25462305||ab|3|entity|C0205195|Combined|qlco|||combining|||0|785|598|607
SE|25462305||ab|3|entity|C1328817|photonics|clas|||photonics|||0|785|617|626
SE|25462305||ab|3|entity|C1257867|Microfluidics|ocdi|||microfluidics|||0|888|631|644
SE|25462305||ab|3|entity|C0039421|Technology|ocdi|||technology|||0|888|645|655
SE|25462305||ab|3|entity|C0439831|Rapid|qlco|||rapid|||0|623|664|669
SE|25462305||ab|3|entity|C0332324|Sensitive|ftcn|||sensitive|||0|623|670|679
SE|25462305||ab|3|entity|C0001674|Adsorption|lbpr|||adsorption|||0|888|700|710
SE|25462305||ab|3|entity|C0022702|Kinetics|idcn|||kinetics|||0|888|711|719
SE|25462305||ab|3|entity|C0031253|Pesticides|hops|||pesticides|||0|1000|729|739
SE|25462305||ab|3|relation|0|0|C1257867|Microfluidics|ocdi|ocdi|||microfluidics|||0|888|631|644|MOD/HEAD|ISA||631|655|0|0|C0039421|Technology|ocdi|ocdi|||technology|||0|888|645|655

SE|25462305||ab|4|text|741|866|The robustness, reusability, and accuracy of the EWOB allow an enhanced prediction of pesticide adsorption kinetics in soil.
SE|25462305||ab|4|entity|C0443131|Accurate|qlco|||accuracy|||0|928|774|782
SE|25462305||ab|4|entity|C0678544|wave|npop|||EWOB|||0|532|790|794
SE|25462305||ab|4|entity|C0681842|prediction|inpr|||prediction|||0|861|813|823
SE|25462305||ab|4|entity|C0031253|Pesticides|hops|||pesticide|||0|851|827|836
SE|25462305||ab|4|entity|C0001674|Adsorption|lbpr|||adsorption|||0|851|837|847
SE|25462305||ab|4|entity|C0022702|Kinetics|idcn|||kinetics|||0|851|848|856
SE|25462305||ab|4|entity|C0037592|Soil|sbst|||soil|||0|1000|860|864

SE|25462305||ab|5|text|866|1000|Using atrazine (ATZ) as the target model, we found that the adsorption kinetics in soil followed a pseudo-second-order kinetic model.
SE|25462305||ab|5|entity|C0004237|Atrazine|hops,orch|||atrazine|||0|1000|872|880
SE|25462305||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|888|901|906
SE|25462305||ab|5|entity|C0001674|Adsorption|lbpr|||adsorption|||0|888|926|936
SE|25462305||ab|5|entity|C0022702|Kinetics|idcn|||kinetics|||0|888|937|945
SE|25462305||ab|5|entity|C0037592|Soil|sbst|||soil|||0|1000|949|953
SE|25462305||ab|5|entity|C0205237|False|qlco|||pseudo|||0|757|965|971
SE|25462305||ab|5|entity|C0457385|seconds|tmco|||second|||0|757|972|978
SE|25462305||ab|5|entity|C0022702|Kinetics|idcn|||kinetic|||0|757|985|992
SE|25462305||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|757|993|998

SE|25462305||ab|6|text|1000|1157|EWOB was compared with liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method and yielded a good correlation coefficient (r(2)=0.9968).
SE|25462305||ab|6|entity|C0678544|wave|npop|||EWOB|||0|532|1000|1004
SE|25462305||ab|6|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||liquid chromatography-mass spectrometry|||0|856|1023|1062
SE|25462305||ab|6|entity|C0025663|Methods|inpr|||method|||0|856|1092|1098
SE|25462305||ab|6|entity|C0205170|Good|qlco|||good|||0|802|1113|1117
SE|25462305||ab|6|entity|C1547015|*Coefficient|qnco|||coefficient|||0|802|1130|1141

SE|25462305||ab|7|text|1157|1300|The underestimated results of LC-MS/MS resulted in a higher adsorption constant of ATZ in soil derived from LC-MS/MS than that of a biosensor.
SE|25462305||ab|7|entity|C1274040|result|ftcn|||results|||0|827|1176|1183
SE|25462305||ab|7|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC-MS/MS|||0|734|1187|1195
SE|25462305||ab|7|entity|C0205250|High|qlco|||higher|||0|840|1210|1216
SE|25462305||ab|7|entity|C0001674|Adsorption|lbpr|||adsorption|||0|840|1217|1227
SE|25462305||ab|7|entity|C1547014|*Constant|qnco|||constant|||0|840|1228|1236
SE|25462305||ab|7|entity|C0004237|Atrazine|hops,orch|||ATZ|||0|1000|1240|1243
SE|25462305||ab|7|entity|C0037592|Soil|sbst|||soil|||0|1000|1247|1251
SE|25462305||ab|7|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC-MS/MS|||0|734|1265|1273
SE|25462305||ab|7|entity|C0600364|Biosensors|medd,resd|||biosensor|||0|1000|1289|1298

SE|25462305||ab|8|text|1300|1439|The proposed EWOB system provides a simple, green, and powerful tool to investigate the transport mechanism and fate of pesticide residues.
SE|25462305||ab|8|entity|C1441414|PROPOSED|idcn|||proposed|||0|724|1304|1312
SE|25462305||ab|8|entity|C0678544|wave|npop|||EWOB|||0|724|1313|1317
SE|25462305||ab|8|entity|C0449913|System|ftcn|||system|||0|724|1318|1324
SE|25462305||ab|8|entity|C0205352|Simple|qlco|||simple|||0|694|1336|1342
SE|25462305||ab|8|entity|C0336794|Power tool|mnob|||powerful tool|||0|964|1355|1368
SE|25462305||ab|8|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|1398|1407
SE|25462305||ab|8|entity|C1302234|Fatal|qlco|||fate|||0|928|1412|1416
SE|25462305||ab|8|entity|C0031251|Pesticide Residues|hops|||pesticide residues|||0|1000|1420|1438


SE|25462306||ti|1|text|21|153|In vitro immune toxicity of polybrominated diphenyl ethers on murine peritoneal macrophages: apoptosis and immune cell dysfunction.
SE|25462306||ti|1|entity|C1533691|in vitro|qlco|||In vitro|||0|861|21|29
SE|25462306||ti|1|entity|C0439662|Immune|ftcn|||immune|||0|861|30|36
SE|25462306||ti|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|861|37|45
SE|25462306||ti|1|entity|C0070605|phenyl ether|orch|||diphenyl ethers|||0|884|64|79
SE|25462306||ti|1|entity|C0026809|Mus|mamm|||murine|||0|901|83|89
SE|25462306||ti|1|entity|C0206190|Macrophages, Peritoneal|cell|||peritoneal macrophages|||0|901|90|112
SE|25462306||ti|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|114|123
SE|25462306||ti|1|entity|C0007634|Cells|cell|||cell|||0|901|135|139
SE|25462306||ti|1|entity|C0021053|Immune System Diseases|dsyn|||immune cell dysfunction|||0|901|128|151
SE|25462306||ti|1|relation|0|0|C0206190|Macrophages, Peritoneal|cell|cell|||peritoneal macrophages|||0|901|90|112|MOD/HEAD|PART_OF||83|112|0|0|C0026809|Mus|mamm|mamm|||murine|||0|901|83|89
SE|25462306||ti|1|relation|3|1|C0206190|Macrophages, Peritoneal|cell|cell|||peritoneal macrophages|||0|901|90|112|PREP|LOCATION_OF||80|82|2|1|C0070605|phenyl ether|orch|orch|||diphenyl ethers|||0|884|64|79

SE|25462306||ab|1|text|159|359|Polybrominated diphenyl ethers (PBDEs) are widely used as flame retardants and are often detected in the environment, wildlife, and humans, presenting potential threats to ecosystem and human health.
SE|25462306||ab|1|entity|C0070605|phenyl ether|orch|||diphenyl ethers|||0|884|174|189
SE|25462306||ab|1|entity|C0016198|Flame Retardants|chvf|||flame retardants|||0|1000|217|233
SE|25462306||ab|1|entity|C0332183|Frequent|tmco|||often|||0|1000|242|247
SE|25462306||ab|1|entity|C0014406|Environment|spco|||environment|||0|1000|264|275
SE|25462306||ab|1|entity|C0020114|Human|humn|||humans|||0|1000|291|297
SE|25462306||ab|1|entity|C0237399|Potential|qlco|||potential|||0|872|310|319
SE|25462306||ab|1|entity|C0162358|Ecosystem|npop|||ecosystem|||0|1000|331|340
SE|25462306||ab|1|entity|C0020114|Human|humn|||human|||0|888|345|350
SE|25462306||ab|1|entity|C0018684|Health|idcn|||health|||0|888|351|357

SE|25462306||ab|2|text|359|432|PBDEs can cause neurotoxicity, hepatotoxicity, and endocrine disruption.
SE|25462306||ab|2|entity|C0070605|phenyl ether|orch|||PBDEs|||0|884|359|364
SE|25462306||ab|2|entity|C0235378|Hepatotoxicity|inpo|||hepatotoxicity|||0|1000|390|404
SE|25462306||ab|2|entity|C0521425|Endocrine|ftcn|||endocrine|||0|888|410|419
SE|25462306||ab|2|entity|C0332453|Disruption|ftcn|||disruption|||0|888|420|430

SE|25462306||ab|3|text|432|534|However, data on PBDE immunotoxicity are limited, and the toxicity mechanisms remain largely unknown.
SE|25462306||ab|3|entity|C1511726|Data|idcn|||data|||0|1000|441|445
SE|25462306||ab|3|entity|C0253007|pentabromodiphenyl ether|orch|||PBDE|||0|888|449|453
SE|25462306||ab|3|entity|C0596763|immunotoxicity|dsyn|||immunotoxicity|||0|888|454|468
SE|25462306||ab|3|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|490|498
SE|25462306||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|499|509
SE|25462306||ab|3|entity|C0439673|Unknown|idcn|||unknown|||0|861|525|532
SE|25462306||ab|3|relation|2|1|C0596763|immunotoxicity|dsyn|dsyn|||immunotoxicity|||0|888|454|468|NOM|MANIFESTATION_OF||499|509|2|0|C0600688|Toxic effect|inpo|inpo|||toxicity|||0|888|490|498

SE|25462306||ab|4|text|534|622|Both immune cell death and dysfunction can modulate the responses of the immune system.
SE|25462306||ab|4|entity|C0439662|Immune|ftcn|||immune|||0|901|539|545
SE|25462306||ab|4|entity|C0007587|Cell Death|celf|||cell death|||0|901|546|556
SE|25462306||ab|4|entity|C0871261|response|clna|||responses|||0|1000|590|599
SE|25462306||ab|4|entity|C0020962|Immune system|bdsy|||immune system|||0|1000|607|620

SE|25462306||ab|5|text|622|812|This study examined the toxic effects of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and decabromodiphenyl ether (BDE-209) on the immune system by using peritoneal macrophages as the model.
SE|25462306||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|627|632
SE|25462306||ab|5|entity|C0600688|Toxic effect|inpo|||toxic effects|||0|983|646|659
SE|25462306||ab|5|entity|C0014994|Ether, Ethyl|orch,phsu|||ether|||0|827|692|697
SE|25462306||ab|5|entity|C0014994|Ether, Ethyl|orch,phsu|||ether|||0|861|729|734
SE|25462306||ab|5|entity|C1454121|BDE-209|orch|||BDE-209|||0|1000|736|743
SE|25462306||ab|5|entity|C0020962|Immune system|bdsy|||immune system|||0|1000|752|765
SE|25462306||ab|5|entity|C0206190|Macrophages, Peritoneal|cell|||peritoneal macrophages|||0|1000|775|797
SE|25462306||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|1000|805|810

SE|25462306||ab|6|text|812|929|The macrophages were exposed to PBDEs, and cell death was determined through flow cytometry and immunochemical blot.
SE|25462306||ab|6|entity|C0024432|macrophage|cell|||macrophages|||0|1000|816|827
SE|25462306||ab|6|entity|C0070605|phenyl ether|orch|||PBDEs|||0|884|844|849
SE|25462306||ab|6|entity|C0007587|Cell Death|celf|||cell death|||0|1000|855|865
SE|25462306||ab|6|entity|C0016263|Flow Cytometry|lbpr|||flow cytometry|||0|1000|889|903

SE|25462306||ab|7|text|929|1128|The results showed that after 24h of exposure, BDE-47 (>5 MUM) and BDE-209 (>20 MUM) induced cell apoptosis, increased intracellular reactive oxygen species (ROS) formation and depleted glutathione.
SE|25462306||ab|7|entity|C1274040|result|ftcn|||results|||0|966|933|940
SE|25462306||ab|7|entity|C0456696|/24h|tmco|||24h|||0|1000|959|962
SE|25462306||ab|7|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|888|987|990
SE|25462306||ab|7|entity|C1454121|BDE-209|orch|||BDE-209|||0|1000|996|1003
SE|25462306||ab|7|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|1009|1012
SE|25462306||ab|7|entity|C0205263|Induced|ftcn|||induced|||0|851|1014|1021
SE|25462306||ab|7|entity|C0007634|Cells|cell|||cell|||0|851|1022|1026
SE|25462306||ab|7|entity|C0162638|Apoptosis|celf|||apoptosis|||0|851|1027|1036
SE|25462306||ab|7|entity|C0175996|Protoplasm|celc|||intracellular|||0|875|1048|1061
SE|25462306||ab|7|entity|C0162772|Reactive Oxygen Species|bacs,elii|||reactive oxygen species|||0|875|1062|1085
SE|25462306||ab|7|entity|C1522492|Formation|ftcn|||formation|||0|875|1092|1101
SE|25462306||ab|7|entity|C0333668|Depletion|ftcn|||depleted|||0|888|1106|1114
SE|25462306||ab|7|entity|C0017817|Glutathione|aapp,bacs|||glutathione|||0|888|1115|1126
SE|25462306||ab|7|relation|0|0|C0007634|Cells|cell|cell|||cell|||0|851|1022|1026|MOD/HEAD|LOCATION_OF||1022|1036|0|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|851|1027|1036
SE|25462306||ab|7|relation|0|0|C0162772|Reactive Oxygen Species|bacs,elii|bacs|||reactive oxygen species|||0|875|1062|1085|MOD/HEAD|PART_OF||1048|1085|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|875|1048|1061
SE|25462306||ab|7|relation|5|1|C1454121|BDE-209|orch|orch|||BDE-209|||0|1000|996|1003|ADJ|CAUSES||1014|1021|5|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|851|1027|1036

SE|25462306||ab|8|text|1128|1295|BDE-47 was more potent than BDE-209; the cytotoxic concentrations for BDE-47 and BDE-209 were determined to be 5 MUM and 20 MUM, respectively, during 24h of exposure.
SE|25462306||ab|8|entity|C0205172|More|ftcn|||more|||0|838|1139|1143
SE|25462306||ab|8|entity|C0237399|Potential|qlco|||potent|||0|838|1144|1150
SE|25462306||ab|8|entity|C1454121|BDE-209|orch|||BDE-209|||0|1000|1156|1163
SE|25462306||ab|8|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|888|1169|1178
SE|25462306||ab|8|entity|C1454121|BDE-209|orch|||BDE-209|||0|1000|1209|1216
SE|25462306||ab|8|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|888|1241|1244
SE|25462306||ab|8|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|1252|1255
SE|25462306||ab|8|entity|C0456696|/24h|tmco|||24h|||0|1000|1278|1281

SE|25462306||ab|9|text|1295|1400|However, pretreatment with n-acetyl-l-cysteine (ROS scavenger) partially reversed the cytotoxic effects.
SE|25462306||ab|9|entity|C0001047|Acetylcysteine|aapp,phsu|||n-acetyl-l-cysteine|||0|1000|1322|1341
SE|25462306||ab|9|entity|C0162772|Reactive Oxygen Species|bacs,elii|||ROS|||0|900|1343|1346
SE|25462306||ab|9|entity|C1003377|Lethrinidae|fish|||scavenger|||0|900|1347|1356
SE|25462306||ab|9|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|872|1381|1390
SE|25462306||ab|9|entity|C1280500|Effect|qlco|||effects|||0|872|1391|1398

SE|25462306||ab|10|text|1400|1546|Further gene expression analyses on Caspase-3,-8,-9, TNFR1, and Bax revealed that both intrinsic and extrinsic apoptotic pathways were activated.
SE|25462306||ab|10|entity|C1517331|Further|spco|||Further|||0|850|1400|1407
SE|25462306||ab|10|entity|C0017262|Gene Expression|genf|||gene expression|||0|850|1408|1423
SE|25462306||ab|10|entity|C0936012|Analysis|resa|||analyses|||0|850|1424|1432
SE|25462306||ab|10|entity|C0291573|caspase-3|aapp,enzy|||Caspase-3|||0|1000|1436|1445
SE|25462306||ab|10|entity|C0255808|tumor necrosis factor receptor 1A|aapp,rcpt|7132|TNFRSF1A|TNFR1|||0|1000|1453|1458
SE|25462306||ab|10|entity|C0812198|BAX gene|gngm|581|BAX|Bax|||0|1000|1464|1467
SE|25462306||ab|10|entity|C0205102|Intrinsic|spco|||intrinsic|||0|1000|1487|1496
SE|25462306||ab|10|entity|C0205101|Extrinsic|spco|||extrinsic|||0|866|1501|1510
SE|25462306||ab|10|entity|C0162638|Apoptosis|celf|||apoptotic pathways|||0|866|1511|1529

SE|25462306||ab|11|text|1546|1770|More importantly, non-cytotoxic concentrations BDE-47 (<2 MUM) and BDE-209 (<10 MUM) could impair macrophage accessory cell function in a concentration-dependent manner, but no effects were observed on phagocytic responses.
SE|25462306||ab|11|entity|C0205172|More|ftcn|||More|||0|861|1546|1550
SE|25462306||ab|11|entity|C1511636|cytotoxic|ftcn|||cytotoxic|||0|725|1568|1577
SE|25462306||ab|11|entity|C0067295|N,N'-bis(dodecyldimethyl)-1,2-ethanediammonium|orch|||BDE-47|||0|725|1593|1599
SE|25462306||ab|11|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|1604|1607
SE|25462306||ab|11|entity|C1454121|BDE-209|orch|||BDE-209|||0|1000|1613|1620
SE|25462306||ab|11|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUM|||0|861|1626|1629
SE|25462306||ab|11|entity|C0024432|macrophage|cell|||macrophage|||0|861|1644|1654
SE|25462306||ab|11|entity|C0003315|Antigen-Presenting Cells|cell|||accessory cell|||0|861|1655|1669
SE|25462306||ab|11|entity|C0031843|physiological aspects|phsf|||function|||0|861|1670|1678
SE|25462306||ab|11|entity|C1280500|Effect|qlco|||effects|||0|966|1723|1730
SE|25462306||ab|11|entity|C0871261|response|clna|||responses|||0|861|1759|1768
SE|25462306||ab|11|relation|2|1|C1454121|BDE-209|orch|orch|||BDE-209|||0|1000|1613|1620|VERB|DISRUPTS||1637|1643|4|1|C0003315|Antigen-Presenting Cells|cell|cell|||accessory cell|||0|861|1655|1669
SE|25462306||ab|11|relation|3|3|C0067295|N,N'-bis(dodecyldimethyl)-1,2-ethanediammonium|orch|orch|||BDE-47|||0|725|1593|1599|ADJ|AFFECTS||1698|1707|2|2|C0871261|response|clna|clna|||responses|||0|861|1759|1768

SE|25462306||ab|12|text|1770|1981|These revealed effects of PBDEs on macrophages may shed light on the toxicity mechanisms of PBDEs and suggest the necessity of evaluating cellular functionality during the risk assessment of PBDE immunotoxicity.
SE|25462306||ab|12|entity|C0443289|Revealed|qlco|||revealed|||0|872|1776|1784
SE|25462306||ab|12|entity|C1280500|Effect|qlco|||effects|||0|872|1785|1792
SE|25462306||ab|12|entity|C0070605|phenyl ether|orch|||PBDEs|||0|884|1796|1801
SE|25462306||ab|12|entity|C0024432|macrophage|cell|||macrophages|||0|1000|1805|1816
SE|25462306||ab|12|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|1839|1847
SE|25462306||ab|12|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|1848|1858
SE|25462306||ab|12|entity|C0070605|phenyl ether|orch|||PBDEs|||0|884|1862|1867
SE|25462306||ab|12|entity|C0007613|Cell physiology|celf|||cellular functionality|||0|851|1908|1930
SE|25462306||ab|12|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|1000|1942|1957
SE|25462306||ab|12|entity|C0253007|pentabromodiphenyl ether|orch|||PBDE|||0|888|1961|1965
SE|25462306||ab|12|entity|C0596763|immunotoxicity|dsyn|||immunotoxicity|||0|888|1966|1980
SE|25462306||ab|12|relation|9|1|C0070605|phenyl ether|orch|orch|||PBDEs|||0|884|1796|1801|NOM|AFFECTS||1785|1792|9|2|C0024432|macrophage|cell|cell|||macrophages|||0|1000|1805|1816


SE|25462307||ti|1|text|21|156|Transformation pathways of MeO-PBDEs catalyzed by active center of P450 enzymes: a DFT investigation employing 6-MeO-BDE-47 as a case.
SE|25462307||ti|1|entity|C0070605|phenyl ether|orch|||MeO-PBDEs|||0|844|48|57
SE|25462307||ti|1|entity|C0205177|Active|ftcn|||active|||0|888|71|77
SE|25462307||ti|1|entity|C0205099|Central|spco|||center|||0|888|78|84
SE|25462307||ti|1|entity|||gngm|1555|CYP2B6|P450|||0|888|88|92
SE|25462307||ti|1|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|93|100
SE|25462307||ti|1|entity|C1566070|2-(2',4'-dibromophenoxy)-3,5-dibromoanisole|orch|||MeO-BDE-47|||0|923|134|144

SE|25462307||ab|1|text|162|376|Recent in vivo and in vitro experiments indicated that methoxylated polybrominated diphenyl ethers (MeO-PBDEs) can be biotransformed into hydroxylated PBDEs (HO-PBDEs) that are more toxic than PBDEs and MeO-PBDEs.
SE|25462307||ab|1|entity|C0332185|Recent|tmco|||Recent|||0|901|162|168
SE|25462307||ab|1|entity|C1515655|in vivo|spco|||in vivo|||0|901|169|176
SE|25462307||ab|1|entity|C1533691|in vitro|qlco|||in vitro|||0|901|181|189
SE|25462307||ab|1|entity|C0681814|research study|resa|||experiments|||0|901|190|201
SE|25462307||ab|1|entity|C0070605|phenyl ether|orch|||diphenyl ethers|||0|844|245|260
SE|25462307||ab|1|entity|C0205172|More|ftcn|||more|||0|888|339|343
SE|25462307||ab|1|entity|C1407029|Toxic|qlco|||toxic|||0|888|344|349
SE|25462307||ab|1|entity|C0070605|phenyl ether|orch|||MeO-PBDEs|||0|844|365|374

SE|25462307||ab|2|text|376|443|Nevertheless, the enzymatic transformation mechanism is not clear.
SE|25462307||ab|2|entity|C0596524|enzyme mechanism|moft|||enzymatic transformation mechanism|||0|877|394|428
SE|25462307||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|432|435

SE|25462307||ab|3|text|443|614|We hypothesized that cytochrome P450 enzymes (CYPs) play a key role in the transformation and employed the density functional theory calculations to unveil the mechanism.
SE|25462307||ab|3|entity|C0010762|Cytochrome P450|aapp,enzy|||cytochrome P450|||0|901|464|479
SE|25462307||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|901|480|487
SE|25462307||ab|3|entity|C1554080|Key|idcn|||key|||0|888|502|505
SE|25462307||ab|3|entity|C0035820|Role|socb|||role|||0|888|506|510
SE|25462307||ab|3|entity|C0178587|density|npop|||density|||0|816|550|557
SE|25462307||ab|3|entity|C0205245|Functional|ftcn|||functional|||0|816|558|568
SE|25462307||ab|3|entity|C0871935|Theories|idcn|||theory|||0|816|569|575
SE|25462307||ab|3|entity|C1441506|CALCULATION|lbpr|||calculations|||0|816|576|588
SE|25462307||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|603|612

SE|25462307||ab|4|text|614|735|The transformation of a model compound, 6-MeO-BDE-47, catalyzed by the active center of CYPs (Compound I), was computed.
SE|25462307||ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|888|638|643
SE|25462307||ab|4|entity|C0205198|Compound|qlco|||compound|||0|888|644|652
SE|25462307||ab|4|entity|C1566070|2-(2',4'-dibromophenoxy)-3,5-dibromoanisole|orch|||MeO-BDE-47|||0|923|656|666
SE|25462307||ab|4|entity|C0205177|Active|ftcn|||active|||0|888|685|691
SE|25462307||ab|4|entity|C0205099|Central|spco|||center|||0|888|692|698
SE|25462307||ab|4|entity|C0010762|Cytochrome P450|aapp,enzy|||CYPs|||0|901|702|706
SE|25462307||ab|4|entity|C0014442|Enzymes|enzy,orch|||CYPs|||0|901|702|706
SE|25462307||ab|4|entity|C0205198|Compound|qlco|||Compound|||0|1000|708|716

SE|25462307||ab|5|text|735|1001|For the first time, our results show that the energy barriers for the addition of Compound I to the C atoms on the phenyl of 6-MeO-BDE-47 are much higher than that for hydroxylation of the methoxyl, indicating that O-demethylation is a dominating metabolic pathway.
SE|25462307||ab|5|entity|C1279901|Firstly|qlco|||first|||0|888|743|748
SE|25462307||ab|5|entity|C0040223|Time|tmco|||time|||0|888|749|753
SE|25462307||ab|5|entity|C1274040|result|ftcn|||results|||0|966|759|766
SE|25462307||ab|5|entity|C0424589|Vitality|fndg|||energy|||0|694|781|787
SE|25462307||ab|5|entity|C0442796|Additive|qlco|||addition|||0|928|805|813
SE|25462307||ab|5|entity|C0205198|Compound|qlco|||Compound|||0|1000|817|825
SE|25462307||ab|5|entity|C0567415|Atom|elii|||atoms|||0|861|837|842
SE|25462307||ab|5|entity|C1177221|PHENYL|orch,phsu|||phenyl|||0|1000|850|856
SE|25462307||ab|5|entity|C1566070|2-(2',4'-dibromophenoxy)-3,5-dibromoanisole|orch|||MeO-BDE-47|||0|923|862|872
SE|25462307||ab|5|entity|C0205250|High|qlco|||higher|||0|966|882|888
SE|25462307||ab|5|entity|C0020365|Hydroxylation|npop|||hydroxylation|||0|1000|903|916
SE|25462307||ab|5|entity|C0598864|demethylation|npop|||demethylation|||0|888|952|965
SE|25462307||ab|5|entity|C1291081|Metabolic Pathway|ftcn|||metabolic pathway|||0|901|982|999

SE|25462307||ab|6|text|1001|1069|This is in line with experimental observations performed by others.
SE|25462307||ab|6|entity|C0205132|Linear|spco|||line|||0|1000|1012|1016
SE|25462307||ab|6|entity|C1517004|Experimental|ftcn|||experimental|||0|694|1022|1034
SE|25462307||ab|6|entity|C0205394|Other|qlco|||others|||0|966|1061|1067

SE|25462307||ab|7|text|1069|1161|The pathways for the transformation of 6-MeO-BDE-47 catalyzed by Compound I were clarified.
SE|25462307||ab|7|entity|C1566070|2-(2',4'-dibromophenoxy)-3,5-dibromoanisole|orch|||MeO-BDE-47|||0|923|1110|1120
SE|25462307||ab|7|entity|C0205198|Compound|qlco|||Compound|||0|1000|1134|1142

SE|25462307||ab|8|text|1161|1365|A C-H bond of the methoxyl is activated by Compound I, followed by radical rebound to form carbinol intermediates, then the carbinols decompose to form 6-HO-BDE-47 with the assistance of water molecules.
SE|25462307||ab|8|entity|C0205198|Compound|qlco|||Compound|||0|1000|1204|1212
SE|25462307||ab|8|entity|C0302912|Radicals (chemistry)|chvs|||radical|||0|1000|1228|1235
SE|25462307||ab|8|entity|C0001963|Methanol|hops,orch|||carbinol|||0|872|1252|1260
SE|25462307||ab|8|entity|C0205103|Intermediate|spco|||intermediates|||0|872|1261|1274
SE|25462307||ab|8|entity|C0001963|Methanol|hops,orch|||carbinols|||0|966|1285|1294
SE|25462307||ab|8|entity|C0262512|History of present illness|orga|||6-HO|||0|812|1313|1317
SE|25462307||ab|8|entity|||gngm|3239|HOXD13|BDE|||0|812|1318|1321
SE|25462307||ab|8|entity|C0018896|Helping Behavior|socb|||assistance|||0|1000|1334|1344
SE|25462307||ab|8|entity|C0020311|Hydrotherapy|topp|||water|||0|872|1348|1353
SE|25462307||ab|8|entity|C0567416|Molecule|sbst|||molecules|||0|872|1354|1363

SE|25462307||ab|9|text|1365|1500|The computational method can be potentially employed to develop models that predict biotransformation of xenobiotics catalyzed by CYPs.
SE|25462307||ab|9|entity|C0025663|Methods|inpr|||method|||0|861|1383|1389
SE|25462307||ab|9|entity|C0220798|biotransformational|ftcn|||biotransformation|||0|1000|1449|1466
SE|25462307||ab|9|entity|C0043335|Xenobiotics|bacs,hops|||xenobiotics|||0|1000|1470|1481
SE|25462307||ab|9|entity|C0010762|Cytochrome P450|aapp,enzy|||CYPs|||0|901|1495|1499
SE|25462307||ab|9|entity|C0014442|Enzymes|enzy,orch|||CYPs|||0|901|1495|1499
SE|25462307||ab|9|relation|1|1|C0010762|Cytochrome P450|aapp,gngm,enzy|aapp|||CYPs|||0|901|1495|1499|VERB|INTERACTS_WITH||1482|1491|3|1|C0043335|Xenobiotics|bacs,hops|bacs|||xenobiotics|||0|1000|1470|1481


SE|25462308||ti|1|text|21|86|Effect of malachite green toxicity on non target soil organisms.
SE|25462308||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462308||ti|1|entity|C0065555|Malachite green|hops,irda,orch|||malachite green|||0|901|31|46
SE|25462308||ti|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|901|47|55
SE|25462308||ti|1|entity|C1518389|Non-Target|qlco|||non target|||0|861|59|69
SE|25462308||ti|1|entity|C0037592|Soil|sbst|||soil|||0|861|70|74
SE|25462308||ti|1|entity|C0029235|Organism|orgm|||organisms|||0|861|75|84

SE|25462308||ab|1|text|92|319|Although malachite green (MG), is banned in Europe and US for its carcinogenic and teratogenic effect, the dye being cheap, is persistently used in various countries for fish farming, silk, dye, leather and textile industries.
SE|25462308||ab|1|entity|C0065555|Malachite green|hops,irda,orch|||malachite green|||0|1000|101|116
SE|25462308||ab|1|entity|C0015176|Europe|geoa|||Europe|||0|1000|136|142
SE|25462308||ab|1|entity|C0007090|Carcinogens|hops|||carcinogenic|||0|928|158|170
SE|25462308||ab|1|entity|C0232910|Teratogenesis|patf|||teratogenic effect|||0|1000|175|193
SE|25462308||ab|1|entity|C0013343|Dyes|irda|||dye|||0|1000|199|202
SE|25462308||ab|1|entity|C0750508|PERSISTENTLY|idcn|||persistently|||0|1000|219|231
SE|25462308||ab|1|entity|C0454664|Country|geoa|||countries|||0|861|248|257
SE|25462308||ab|1|entity|C0016163|Fishes|fish|||fish|||0|872|262|266
SE|25462308||ab|1|entity|C0557759|Farming environment|geoa|||farming|||0|872|267|274
SE|25462308||ab|1|entity|C0074529|Silk|aapp,bacs,phsu|||silk|||0|1000|276|280
SE|25462308||ab|1|entity|C0013343|Dyes|irda|||dye|||0|1000|282|285
SE|25462308||ab|1|entity|C0336889|Leather|mnob|||leather|||0|1000|287|294
SE|25462308||ab|1|entity|C0039716|Textile Industry|orgt|||textile industries|||0|1000|299|317

SE|25462308||ab|2|text|319|431|Current research, however, fails to elucidate adequate knowledge concerning the effects of MG in our ecosystem.
SE|25462308||ab|2|entity|C0521116|Current|tmco|||Current|||0|888|319|326
SE|25462308||ab|2|entity|C0035168|research|resa|||research|||0|888|327|335
SE|25462308||ab|2|entity|C0205411|Adequate|qlco|||adequate|||0|888|365|373
SE|25462308||ab|2|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|374|383
SE|25462308||ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|399|406
SE|25462308||ab|2|entity|C0065555|Malachite green|hops,irda,orch|||MG|||0|1000|410|412
SE|25462308||ab|2|entity|C0162358|Ecosystem|npop|||ecosystem|||0|1000|420|429
SE|25462308||ab|2|relation|2|1|C0065555|Malachite green|hops,irda,orch|hops|||MG|||0|1000|410|412|NOM|AFFECTS||399|406|2|2|C0162358|Ecosystem|npop|npop|||ecosystem|||0|1000|420|429

SE|25462308||ab|3|text|431|721|In the present investigation, for the first time, an attempt has been made to study the effects of MG on soil biota by testing Bacillus subtilis, Azotobacter chroococcum, Saccharomyces cerevisiae, Penicillium roqueforti, Eisenia fetida and seeds of three crop plants of different families.
SE|25462308||ab|3|entity|C0150312|Present|qnco|||present|||0|888|438|445
SE|25462308||ab|3|entity|C1279901|Firstly|qlco|||first|||0|888|469|474
SE|25462308||ab|3|entity|C0040223|Time|tmco|||time|||0|888|475|479
SE|25462308||ab|3|entity|C1516084|Attempt|evnt|||attempt|||0|1000|484|491
SE|25462308||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|519|526
SE|25462308||ab|3|entity|C0065555|Malachite green|hops,irda,orch|||MG|||0|1000|530|532
SE|25462308||ab|3|entity|C0037592|Soil|sbst|||soil|||0|888|536|540
SE|25462308||ab|3|entity|C1253910|Biota|qlco|||biota|||0|888|541|546
SE|25462308||ab|3|entity|C0039593|Testing|resa|||testing|||0|901|550|557
SE|25462308||ab|3|entity|C0004595|Bacillus subtilis|bact|||Bacillus subtilis|||0|901|558|575
SE|25462308||ab|3|entity|C0995322|Azotobacter chroococcum|bact|||Azotobacter chroococcum|||0|1000|577|600
SE|25462308||ab|3|entity|C0036025|Saccharomyces cerevisiae|fngs|||Saccharomyces cerevisiae|||0|1000|602|626
SE|25462308||ab|3|entity|C0522427|Penicillium roqueforti|fngs|||Penicillium roqueforti|||0|1000|628|650
SE|25462308||ab|3|entity|C0524676|Eisenia foetida|invt|||Eisenia fetida|||0|1000|652|666
SE|25462308||ab|3|entity|C0036563|Seeds|plnt|||seeds|||0|1000|671|676
SE|25462308||ab|3|entity|C0205449|Three|qnco|||three|||0|802|680|685
SE|25462308||ab|3|entity|C0032098|Plants|plnt|||plants|||0|802|691|697
SE|25462308||ab|3|entity|C1547020|*Difference|qnco|||different|||0|853|701|710
SE|25462308||ab|3|entity|C0015576|Family|famg|||families|||0|853|711|719

SE|25462308||ab|4|text|721|848|Various tests were conducted for determining cytotoxicity, genotoxicity, acute toxicity, morphological and germination effect.
SE|25462308||ab|4|entity|C0392366|Tests|inpr|||tests|||0|861|729|734
SE|25462308||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|861|766|778
SE|25462308||ab|4|entity|C0598309|genotoxicity|comd|||genotoxicity|||0|1000|780|792
SE|25462308||ab|4|entity|C0205178|acute|tmco|||acute|||0|888|794|799
SE|25462308||ab|4|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|800|808
SE|25462308||ab|4|entity|C0543482|morphological|spco|||morphological|||0|1000|810|823
SE|25462308||ab|4|entity|C0242735|Germination|biof|||germination|||0|888|828|839
SE|25462308||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|840|846
SE|25462308||ab|4|relation|5|3|C0598309|genotoxicity|comd|comd|||genotoxicity|||0|1000|780|792|NOM|AFFECTS||840|846|5|0|C0242735|Germination|biof|biof|||germination|||0|888|828|839

SE|25462308||ab|5|text|848|976|Our data confirmed MG toxicity on fungi and bacteria (gram positive and gram negative organisms) showing elevated level of ROS.
SE|25462308||ab|5|entity|C1511726|Data|idcn|||data|||0|1000|852|856
SE|25462308||ab|5|entity|C0065555|Malachite green|hops,irda,orch|||MG|||0|901|867|869
SE|25462308||ab|5|entity|C0600688|Toxic effect|inpo|||toxicity|||0|901|870|878
SE|25462308||ab|5|entity|C0016832|fungus|fngs|||fungi|||0|1000|882|887
SE|25462308||ab|5|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|892|900
SE|25462308||ab|5|entity|C0200966|Bacterial stain, routine|lbpr|||gram|||0|888|902|906
SE|25462308||ab|5|entity|C1446409|Positive|qlco|||positive|||0|888|907|915
SE|25462308||ab|5|entity|C0200966|Bacterial stain, routine|lbpr|||gram|||0|851|920|924
SE|25462308||ab|5|entity|C0205160|Negative|qlco|||negative|||0|851|925|933
SE|25462308||ab|5|entity|C0029235|Organism|orgm|||organisms|||0|851|934|943
SE|25462308||ab|5|entity|C0205250|High|qlco|||elevated|||0|694|953|961
SE|25462308||ab|5|entity|||gngm|6098|ROS1|ROS|||0|1000|971|974

SE|25462308||ab|6|text|976|1070|Genotoxicity caused in the microorganisms was detected by DNA polymorphism and fragmentation.
SE|25462308||ab|6|entity|C0598309|genotoxicity|comd|||Genotoxicity|||0|1000|976|988
SE|25462308||ab|6|entity|C0445623|Microorganism|idcn,orgm|||microorganisms|||0|1000|1003|1017
SE|25462308||ab|6|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|1034|1037
SE|25462308||ab|6|entity|C0032529|Polymorphism, Genetic|genf|||polymorphism|||0|888|1038|1050
SE|25462308||ab|6|entity|C0185061|fragmentation procedure|topp|||fragmentation|||0|1000|1055|1068

SE|25462308||ab|7|text|1070|1270|Also, scanning electron microscopy data suggests that the inhibitory effect of MG to these beneficial microbes in the ecosystem might be due to pore formation in the cell and its eventual disruption.
SE|25462308||ab|7|entity|C0026020|Microscopy, Electron, Scanning|lbpr|||scanning electron microscopy|||0|916|1076|1104
SE|25462308||ab|7|entity|C1511726|Data|idcn|||data|||0|916|1105|1109
SE|25462308||ab|7|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|1128|1138
SE|25462308||ab|7|entity|C1280500|Effect|qlco|||effect|||0|853|1139|1145
SE|25462308||ab|7|entity|C0065555|Malachite green|hops,irda,orch|||MG|||0|1000|1149|1151
SE|25462308||ab|7|entity|C0599840|microbial|orgm|||microbes|||0|777|1172|1180
SE|25462308||ab|7|entity|C0162358|Ecosystem|npop|||ecosystem|||0|1000|1188|1197
SE|25462308||ab|7|entity|C1326292|pore complex location biogenesis|celf|||pore formation|||0|1000|1214|1228
SE|25462308||ab|7|entity|C0007634|Cells|cell|||cell|||0|1000|1236|1240
SE|25462308||ab|7|entity|C0332453|Disruption|ftcn|||disruption|||0|861|1258|1268
SE|25462308||ab|7|relation|2|1|C0007634|Cells|cell|cell|||cell|||0|1000|1236|1240|PREP|LOCATION_OF||1229|1231|6|1|C1326292|pore complex location biogenesis|celf|celf|||pore formation|||0|1000|1214|1228

SE|25462308||ab|8|text|1270|1436|Filter paper and artificial soil test conducted on earthworms demonstrated a LC 50 of 2.6 mg cm(-2) and 1.45 mg kg(-1) respectively with severe morphological damage.
SE|25462308||ab|8|entity|C0180859|Filter Papers|medd|||Filter paper|||0|966|1270|1282
SE|25462308||ab|8|entity|C0205237|False|qlco|||artificial|||0|851|1287|1297
SE|25462308||ab|8|entity|C0037592|Soil|sbst|||soil|||0|851|1298|1302
SE|25462308||ab|8|entity|C0039593|Testing|resa|||test|||0|851|1303|1307
SE|25462308||ab|8|entity|C0086194|Pheretima sieboldi|invt|||earthworms|||0|1000|1321|1331
SE|25462308||ab|8|entity|C0439209|Kilogram|qnco|||kg|||0|728|1382|1384
SE|25462308||ab|8|entity|C0205082|Severe|qlco|||severe|||0|623|1407|1413
SE|25462308||ab|8|entity|C0543482|morphological|spco|||morphological|||0|623|1414|1427

SE|25462308||ab|9|text|1436|1571|However, seed germination of Mung bean, Wheat and Mustard was found to be unaffected in presence of MG up to 100 mL(-1) concentration.
SE|25462308||ab|9|entity|C1160189|seed germination|orgf|||seed germination|||0|1000|1445|1461
SE|25462308||ab|9|entity|C0453223|Mung beans|food|||Mung bean|||0|1000|1465|1474
SE|25462308||ab|9|entity|C0043137|Wheat|food|||Wheat|||0|1000|1476|1481
SE|25462308||ab|9|entity|C0025033|Mechlorethamine|hops,orch,phsu|||Mustard|||0|1000|1486|1493
SE|25462308||ab|9|entity|C0065555|Malachite green|hops,irda,orch|||MG|||0|1000|1536|1538
SE|25462308||ab|9|entity|C1366628|ATP8A2 gene|gngm|51761|ATP8A2|mL(-1|||0|901|1549|1554
SE|25462308||ab|9|relation|5|2|C0025033|Mechlorethamine|hops,orch,phsu|hops|||Mustard|||0|1000|1486|1493|NOM|COEXISTS_WITH||1524|1532|2|1|C0065555|Malachite green|hops,irda,orch|hops|||MG|||0|1000|1536|1538

SE|25462308||ab|10|text|1571|1743|Thus, understanding MG toxicity in non target soil organisms and emphasis on its toxicological effects would potentially explicate its role as an environmental contaminant.
SE|25462308||ab|10|entity|C0065555|Malachite green|hops,irda,orch|||MG|||0|901|1591|1593
SE|25462308||ab|10|entity|C0600688|Toxic effect|inpo|||toxicity|||0|901|1594|1602
SE|25462308||ab|10|entity|C1518389|Non-Target|qlco|||non target|||0|861|1606|1616
SE|25462308||ab|10|entity|C0037592|Soil|sbst|||soil|||0|861|1617|1621
SE|25462308||ab|10|entity|C0029235|Organism|orgm|||organisms|||0|861|1622|1631
SE|25462308||ab|10|entity|C0205472|Toxicologic|ftcn|||toxicological|||0|872|1652|1665
SE|25462308||ab|10|entity|C1280500|Effect|qlco|||effects|||0|872|1666|1673
SE|25462308||ab|10|entity|C0035820|Role|socb|||role|||0|1000|1706|1710


SE|25462309||ti|1|text|21|138|Speciation and environmental risk assessment of heavy metal in bio-oil from liquefaction/pyrolysis of sewage sludge.
SE|25462309||ti|1|entity|C0035647|Risk|qlco|||risk|||0|901|50|54
SE|25462309||ti|1|entity|C0558004|Environmental assessment|hlca|||environmental risk assessment|||0|901|36|65
SE|25462309||ti|1|entity|C0347988|Metals, Heavy|elii|||heavy metal|||0|1000|69|80
SE|25462309||ti|1|entity|C0205460|biological|ftcn|||bio|||0|888|84|87
SE|25462309||ti|1|entity|C0028908|Oils|lipd|||oil|||0|888|88|91
SE|25462309||ti|1|entity|C0487112|LIQUEFACTION|lbtr|||liquefaction|||0|694|97|109
SE|25462309||ti|1|entity|C0036861|Sewage|eehu|||sewage|||0|694|123|129
SE|25462309||ti|1|relation|3|1|C0347988|Metals, Heavy|elii|elii|||heavy metal|||0|1000|69|80|PREP|COEXISTS_WITH||81|83|3|1|C0028908|Oils|lipd|lipd|||oil|||0|888|88|91

SE|25462309||ab|1|text|144|418|Liquefaction bio-oil (LBO) produced with ethanol (or acetone) as the solvent and pyrolysis bio-oil (PBO) produced at 550 degrees C (or 850 degrees C) from sewage sludge (SS) were produced, and were characterized and evaluated in terms of their heavy metal (HM) composition.
SE|25462309||ab|1|entity|C0487112|LIQUEFACTION|lbtr|||Liquefaction|||0|851|144|156
SE|25462309||ab|1|entity|C0205460|biological|ftcn|||bio|||0|851|157|160
SE|25462309||ab|1|entity|C0028908|Oils|lipd|||oil|||0|851|161|164
SE|25462309||ab|1|entity|C0001962|Ethanol|orch,phsu|||ethanol|||0|1000|185|192
SE|25462309||ab|1|entity|C0001002|Acetone|orch,phsu|||acetone|||0|1000|197|204
SE|25462309||ab|1|entity|C0037638|Solvents|irda|||solvent|||0|1000|213|220
SE|25462309||ab|1|entity|C0205460|biological|ftcn|||bio|||0|790|235|238
SE|25462309||ab|1|entity|C0028908|Oils|lipd|||oil|||0|790|239|242
SE|25462309||ab|1|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|265|274
SE|25462309||ab|1|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|283|292
SE|25462309||ab|1|entity|C0036861|Sewage|eehu|||sewage|||0|694|299|305
SE|25462309||ab|1|entity|C0347988|Metals, Heavy|elii|||heavy metal|||0|901|388|399
SE|25462309||ab|1|entity|C0486616|Composition|clna|||composition|||0|901|405|416

SE|25462309||ab|2|text|418|557|The total concentration, speciation and leaching characteristic of HMs (Cu, Cr, Pb, Zn, Cd, and Ni) in both LBO and PBO were investigated.
SE|25462309||ab|2|entity|C0439175|% of total|qnco|||total|||0|694|422|427
SE|25462309||ab|2|entity|C1521970|Characteristics|grpa|||characteristic|||0|966|467|481
SE|25462309||ab|2|entity|C0720803|HMS|horm,phsu,strd|||HMs|||0|1000|485|488
SE|25462309||ab|2|entity|C0487112|LIQUEFACTION|lbtr|||LBO|||0|851|526|529
SE|25462309||ab|2|entity|C0205460|biological|ftcn|||LBO|||0|851|526|529
SE|25462309||ab|2|entity|C0028908|Oils|lipd|||LBO|||0|851|526|529
SE|25462309||ab|2|entity|C0205460|biological|ftcn|||PBO|||0|790|534|537
SE|25462309||ab|2|entity|C0028908|Oils|lipd|||PBO|||0|790|534|537
SE|25462309||ab|2|relation|11|7|C0720803|HMS|horm,phsu,strd|horm|||HMs|||0|1000|485|488|PREP|COEXISTS_WITH||518|520|2|1|C0028908|Oils|lipd|lipd|||LBO|||0|851|526|529
SE|25462309||ab|2|relation|11|7|C0720803|HMS|horm,phsu,strd|horm|||HMs|||0|1000|485|488|PREP|COEXISTS_WITH||518|520|2|1|C0028908|Oils|lipd|lipd|||PBO|||0|790|534|537

SE|25462309||ab|3|text|557|666|The total concentration and exchangeable fraction of Zn and Ni in bio-oils were at surprisingly high levels.
SE|25462309||ab|3|entity|C0439175|% of total|qnco|||total|||0|694|561|566
SE|25462309||ab|3|entity|C0678640|exchange|socb|||exchangeable|||0|623|585|597
SE|25462309||ab|3|entity|C0205460|biological|ftcn|||bio|||0|1000|623|626
SE|25462309||ab|3|entity|C0205250|High|qlco|||high|||0|790|653|657
SE|25462309||ab|3|entity|C0441889|Levels|inpr|||levels|||0|790|658|664

SE|25462309||ab|4|text|666|845|Quantitative risk assessment of HM in bio-oils was performed by the method of risk assessment code (RAC), potential ecological risk index (PERI) and geo-accumulation index (GAI).
SE|25462309||ab|4|entity|C0392762|Quantitative|qnco|||Quantitative|||0|901|666|678
SE|25462309||ab|4|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|901|679|694
SE|25462309||ab|4|entity|C0347988|Metals, Heavy|elii|||HM|||0|1000|698|700
SE|25462309||ab|4|entity|C0205460|biological|ftcn|||bio|||0|1000|704|707
SE|25462309||ab|4|entity|C0025663|Methods|inpr|||method|||0|1000|734|740
SE|25462309||ab|4|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|901|744|759
SE|25462309||ab|4|entity|C0805701|Code|inpr|||code|||0|901|760|764
SE|25462309||ab|4|entity|C0237399|Potential|qlco|||potential|||0|815|772|781
SE|25462309||ab|4|entity|C0013546|Ecology|ocdi|||ecological|||0|815|782|792
SE|25462309||ab|4|entity|C0035647|Risk|qlco|||risk|||0|815|793|797
SE|25462309||ab|4|entity|C0918012|Index|inpr|||index|||0|815|798|803
SE|25462309||ab|4|entity|C1517526|Geographic|spco|||geo|||0|802|815|818
SE|25462309||ab|4|entity|C0918012|Index|inpr|||index|||0|802|832|837

SE|25462309||ab|5|text|845|1071|Ni in bio-oil produced by pyrolysis at 850 degrees C (PBO850) and Zn in bio-oil by liquefaction at 360 degrees C with ethanol as solvent (LBO-360E) were evaluated to possess very high risk to the environment according to RAC.
SE|25462309||ab|5|entity|C0205460|biological|ftcn|||bio|||0|888|851|854
SE|25462309||ab|5|entity|C0028908|Oils|lipd|||oil|||0|888|855|858
SE|25462309||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|888|897
SE|25462309||ab|5|entity|C0205460|biological|ftcn|||bio|||0|888|917|920
SE|25462309||ab|5|entity|C0028908|Oils|lipd|||oil|||0|888|921|924
SE|25462309||ab|5|entity|C0487112|LIQUEFACTION|lbtr|||liquefaction|||0|1000|928|940
SE|25462309||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|948|957
SE|25462309||ab|5|entity|C0001962|Ethanol|orch,phsu|||ethanol|||0|1000|963|970
SE|25462309||ab|5|entity|C0037638|Solvents|irda|||solvent|||0|1000|974|981
SE|25462309||ab|5|entity|C0487112|LIQUEFACTION|lbtr|||LBO|||0|608|983|986
SE|25462309||ab|5|entity|C0205460|biological|ftcn|||LBO|||0|608|983|986
SE|25462309||ab|5|entity|C0028908|Oils|lipd|||LBO|||0|608|983|986
SE|25462309||ab|5|entity|C0442804|Very high|fndg|||very high|||0|901|1019|1028
SE|25462309||ab|5|entity|C0035647|Risk|qlco|||risk|||0|901|1029|1033
SE|25462309||ab|5|entity|C0014406|Environment|spco|||environment|||0|1000|1041|1052
SE|25462309||ab|5|entity|C0086930|Risk Assessment|hlca|||RAC|||0|901|1066|1069
SE|25462309||ab|5|entity|C0805701|Code|inpr|||RAC|||0|901|1066|1069

SE|25462309||ab|6|text|1071|1265|Additionally, Cd in PBO850 and LBO-360E were evaluated by PERI to have very high risk and high risk, respectively, while Cd in all bio-oils was assessed moderately contaminated according to GAI.
SE|25462309||ab|6|entity|C0487112|LIQUEFACTION|lbtr|||LBO|||0|608|1102|1105
SE|25462309||ab|6|entity|C0205460|biological|ftcn|||LBO|||0|608|1102|1105
SE|25462309||ab|6|entity|C0028908|Oils|lipd|||LBO|||0|608|1102|1105
SE|25462309||ab|6|entity|C0237399|Potential|qlco|||PERI|||0|815|1129|1133
SE|25462309||ab|6|entity|C0013546|Ecology|ocdi|||PERI|||0|815|1129|1133
SE|25462309||ab|6|entity|C0035647|Risk|qlco|||PERI|||0|815|1129|1133
SE|25462309||ab|6|entity|C0918012|Index|inpr|||PERI|||0|815|1129|1133
SE|25462309||ab|6|entity|C0442804|Very high|fndg|||very high|||0|901|1142|1151
SE|25462309||ab|6|entity|C0035647|Risk|qlco|||risk|||0|901|1152|1156
SE|25462309||ab|6|entity|C0205250|High|qlco|||high|||0|790|1161|1165
SE|25462309||ab|6|entity|C0035647|Risk|qlco|||risk|||0|790|1166|1170
SE|25462309||ab|6|entity|C0205460|biological|ftcn|||bio|||0|1000|1202|1205
SE|25462309||ab|6|entity|C1517526|Geographic|spco|||GAI|||0|802|1261|1264
SE|25462309||ab|6|entity|C0918012|Index|inpr|||GAI|||0|802|1261|1264


SE|25462310||ti|1|text|21|133|The phosphorus speciations in the sediments up- and down-stream of cascade dams along the middle Lancang River.
SE|25462310||ti|1|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|694|25|35
SE|25462310||ti|1|entity|C0023032|Lanugo|bpoc|||down|||0|722|73|77
SE|25462310||ti|1|entity|C0442540|Streams|npop|||stream|||0|722|78|84
SE|25462310||ti|1|entity|C0444598|Middle|spco|||middle|||0|802|111|117
SE|25462310||ti|1|entity|C0337050|Rivers|npop|||River|||0|802|126|131

SE|25462310||ab|1|text|139|370|We detected the longitudinal variability of phosphorus speciations and its relation to metals and grain size distribution of sediments in three cascade canyon reservoirs (Xiaowan, Manwan and Dachaoshan) along Lancang River, China.
SE|25462310||ab|1|entity|C0205127|Longitudinal|spco|||longitudinal|||0|853|155|167
SE|25462310||ab|1|entity|C0439828|Variable|qlco|||variability|||0|853|168|179
SE|25462310||ab|1|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|694|183|193
SE|25462310||ab|1|entity|C0869014|Relations|socb|||relation|||0|966|214|222
SE|25462310||ab|1|entity|C0025552|Metals|inch|||metals|||0|1000|226|232
SE|25462310||ab|1|entity|C0007757|Cereals|food|||grain|||0|851|237|242
SE|25462310||ab|1|entity|C0456389|size|spco|||size|||0|851|243|247
SE|25462310||ab|1|entity|C0520511|Distributing|idcn|||distribution|||0|851|248|260
SE|25462310||ab|1|entity|C0205449|Three|qnco|||three|||0|791|277|282
SE|25462310||ab|1|entity|C0182967|Reservoirs|medd|||reservoirs|||0|791|298|308
SE|25462310||ab|1|entity|C0337050|Rivers|npop|||River|||0|861|356|361
SE|25462310||ab|1|entity|C0008115|China|geoa|||China|||0|1000|363|368

SE|25462310||ab|2|text|370|559|Five phosphorus speciations including loosely bound P (ex-P), reductant soluble P (BD-P), metal oxide-bound P (NaOH-P) calcium-bound P (HCl-P) and residual-P were extracted and quantified.
SE|25462310||ab|2|entity|C0205451|Five|qnco|||Five|||0|623|370|374
SE|25462310||ab|2|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|623|375|385
SE|25462310||ab|2|entity|C0376446|Reducing Agents|irda|||reductant|||0|562|432|441
SE|25462310||ab|2|entity|C0421451|Date of birth|fndg|||BD-P|||0|562|453|457
SE|25462310||ab|2|entity|C0596917|metal oxide|inch|||metal oxide|||0|548|460|471
SE|25462310||ab|2|entity|C0006675|Calcium|bacs,elii|||calcium|||0|548|489|496
SE|25462310||ab|2|entity|C1609982|Residual|qlco|||residual|||0|888|517|525

SE|25462310||ab|3|text|559|827|Results showed that in Manwan Reservoir HCl-P accounted for the largest part of total phosphorus (TP) (49.69%), while in Xiaowan and Dachaoshan reservoirs, NaOH-P was the most abundant speciation which accounted for 57.21% and 55.19% of total phosphorus respectively.
SE|25462310||ab|3|entity|C1274040|result|ftcn|||Results|||0|966|559|566
SE|25462310||ab|3|entity|C0442537|Reservoir|geoa|||Reservoir|||0|763|589|598
SE|25462310||ab|3|entity|C0443228|Largest|qnco|||largest|||0|888|623|630
SE|25462310||ab|3|entity|C0449719|Part|spco|||part|||0|888|631|635
SE|25462310||ab|3|entity|C0439175|% of total|qnco|||total|||0|888|639|644
SE|25462310||ab|3|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|888|645|655
SE|25462310||ab|3|entity|C0182967|Reservoirs|medd|||reservoirs|||0|861|703|713
SE|25462310||ab|3|entity|C0205393|Most|qnco|||most|||0|660|730|734
SE|25462310||ab|3|entity|C0439175|% of total|qnco|||total|||0|790|796|801
SE|25462310||ab|3|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|790|802|812

SE|25462310||ab|4|text|827|961|Higher contents of bio-available phosphorus in Xiaowan and Dachaoshan reservoirs suggested a high rate of P releasing from sediments.
SE|25462310||ab|4|entity|C0205250|High|qlco|||Higher|||0|872|827|833
SE|25462310||ab|4|entity|C0456205|Contents|sbst|||contents|||0|872|834|842
SE|25462310||ab|4|entity|C0205460|biological|ftcn|||bio|||0|851|846|849
SE|25462310||ab|4|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|851|860|870
SE|25462310||ab|4|entity|C0182967|Reservoirs|medd|||reservoirs|||0|861|897|907
SE|25462310||ab|4|entity|C0205250|High|qlco|||high|||0|888|920|924
SE|25462310||ab|4|entity|C1521828|Rate|qnco|||rate|||0|888|925|929
SE|25462310||ab|4|entity|C0205346|Released|ftcn|||releasing|||0|872|935|944

SE|25462310||ab|5|text|961|1030|Results also showed ex-P and HCl-P had positive correlation with Ca.
SE|25462310||ab|5|entity|C1446409|Positive|qlco|||positive|||0|694|1000|1008

SE|25462310||ab|6|text|1030|1082|Total phosphorus was positively correlated with Fe.
SE|25462310||ab|6|entity|C0439175|% of total|qnco|||Total|||0|888|1030|1035
SE|25462310||ab|6|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|888|1036|1046

SE|25462310||ab|7|text|1082|1226|The silt/clay contents of the sediments had close relationship with ex-P (r=0.413, p<0.05), NaOH-P (r=0.428, p<0.05) and BAP (r=0.458, p<0.05).
SE|25462310||ab|7|entity|C0055863|clay|inch|||clay|||0|790|1091|1095
SE|25462310||ab|7|entity|C0456205|Contents|sbst|||contents|||0|790|1096|1104
SE|25462310||ab|7|entity|C0439849|Relationships|qlco|||relationship|||0|861|1132|1144
SE|25462310||ab|7|entity|||gngm|11331,64374|PHB2,SIL1|BAP|||0|1000|1203|1206

SE|25462310||ab|8|text|1226|1387|The concentration of Ca, Mn and silt/clay speciation in the sediments explained 40%, 10% and 4% of the spatial variation of phosphorus speciations, respectively.
SE|25462310||ab|8|entity|C0055863|clay|inch|||clay|||0|660|1263|1267
SE|25462310||ab|8|entity|C0439509|/40|tmco|||40|||0|1000|1306|1308
SE|25462310||ab|8|entity|C0205419|Variant|qlco|||variation|||0|861|1337|1346
SE|25462310||ab|8|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|694|1350|1360


SE|25462311||ti|1|text|21|173|Discrimination of excess toxicity from narcotic effect: influence of species sensitivity and bioconcentration on the classification of modes of action.
SE|25462311||ti|1|entity|C0442802|Excessive|qlco|||excess|||0|853|39|45
SE|25462311||ti|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|853|46|54
SE|25462311||ti|1|entity|C0027415|Narcotics|hops,phsu|||narcotic|||0|888|60|68
SE|25462311||ti|1|entity|C1280500|Effect|qlco|||effect|||0|888|69|75
SE|25462311||ti|1|entity|C1548151|Species|idcn|||species|||0|888|90|97
SE|25462311||ti|1|entity|C0008902|Classification|clas|||classification|||0|1000|138|152
SE|25462311||ti|1|entity|C1513371|Mode|ftcn|||modes|||0|779|156|161

SE|25462311||ab|1|text|179|380|The toxicity data of 2624 chemicals to fish, Daphniamagna, Tetrahymenapyriformis and Vibriofischeri were used to investigate the effects of species sensitivity and bioconcentration on excess toxicity.
SE|25462311||ab|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|183|191
SE|25462311||ab|1|entity|C1511726|Data|idcn|||data|||0|888|192|196
SE|25462311||ab|1|entity|C0220806|Chemicals|chem|||chemicals|||0|861|205|214
SE|25462311||ab|1|entity|C0016163|Fishes|fish|||fish|||0|1000|218|222
SE|25462311||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|308|315
SE|25462311||ab|1|entity|C1548151|Species|idcn|||species|||0|888|319|326
SE|25462311||ab|1|entity|C0442802|Excessive|qlco|||excess|||0|853|363|369
SE|25462311||ab|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|853|370|378

SE|25462311||ab|2|text|380|579|The results showed that 47 chemical classes were identified as having the same modes of action (MOAs) to all four species, but more than half of the classes were identified as having different MOAs.
SE|25462311||ab|2|entity|C1274040|result|ftcn|||results|||0|966|384|391
SE|25462311||ab|2|entity|C0220806|Chemicals|chem|||chemical|||0|790|407|415
SE|25462311||ab|2|entity|C0456387|Class|inpr|||classes|||0|790|416|423
SE|25462311||ab|2|entity|C0445247|Same|qlco|||same|||0|846|454|458
SE|25462311||ab|2|entity|C1524059|mechanism of action qualifier|ftcn|||modes of action|||0|846|459|474
SE|25462311||ab|2|entity|C0205450|Four|qnco|||four|||0|888|489|493
SE|25462311||ab|2|entity|C1548151|Species|idcn|||species|||0|888|494|501
SE|25462311||ab|2|entity|C0205172|More|ftcn|||more|||0|1000|507|511
SE|25462311||ab|2|entity|C0456387|Class|inpr|||classes|||0|1000|529|536
SE|25462311||ab|2|entity|C1547020|*Difference|qnco|||different|||0|890|563|572
SE|25462311||ab|2|entity|C1524059|mechanism of action qualifier|ftcn|||MOAs|||0|890|573|577

SE|25462311||ab|3|text|579|696|Difference in chemical MOAs is one of the reasons resulting in the difference in toxic effect to these four species.
SE|25462311||ab|3|entity|C1547020|*Difference|qnco|||Difference|||0|1000|579|589
SE|25462311||ab|3|entity|C0220806|Chemicals|chem|||chemical|||0|846|593|601
SE|25462311||ab|3|entity|C1524059|mechanism of action qualifier|ftcn|||MOAs|||0|846|602|606
SE|25462311||ab|3|entity|C0205447|One|qnco|||one|||0|1000|610|613
SE|25462311||ab|3|entity|C0392360|Reason for|idcn|||reasons|||0|1000|621|628
SE|25462311||ab|3|entity|C1547020|*Difference|qnco|||difference|||0|1000|646|656
SE|25462311||ab|3|entity|C0600688|Toxic effect|inpo|||toxic effect|||0|1000|660|672
SE|25462311||ab|3|entity|C0205450|Four|qnco|||four|||0|888|682|686
SE|25462311||ab|3|entity|C1548151|Species|idcn|||species|||0|888|687|694

SE|25462311||ab|4|text|696|787|Other important reasons are the difference in sensitivity and bioconcentration of species.
SE|25462311||ab|4|entity|C0392360|Reason for|idcn|||reasons|||0|861|712|719
SE|25462311||ab|4|entity|C1547020|*Difference|qnco|||difference|||0|1000|728|738
SE|25462311||ab|4|entity|C1548151|Species|idcn|||species|||0|1000|778|785

SE|25462311||ab|5|text|787|874|Among the four species, V. fischeri has the most compounds identified as reactive MOA.
SE|25462311||ab|5|entity|C0205450|Four|qnco|||four|||0|888|797|801
SE|25462311||ab|5|entity|C1548151|Species|idcn|||species|||0|888|802|809
SE|25462311||ab|5|entity|C0205393|Most|qnco|||most|||0|872|831|835
SE|25462311||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|872|836|845
SE|25462311||ab|5|entity|C0205332|Reactive|qlco|||reactive|||0|694|860|868

SE|25462311||ab|6|text|874|1082|This may be due to some compounds can be easily absorbed into the bacteria, react with the DNA or proteins, disrupt the normal function of the cell and exhibit significantly greater toxicity to the bacteria.
SE|25462311||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|966|898|907
SE|25462311||ab|6|entity|C0332219|Easy|qlco|||easily|||0|1000|915|921
SE|25462311||ab|6|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|940|948
SE|25462311||ab|6|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|965|968
SE|25462311||ab|6|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|972|980
SE|25462311||ab|6|entity|C0205307|Normal|qlco|||normal|||0|888|994|1000
SE|25462311||ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|888|1001|1009
SE|25462311||ab|6|entity|C0007634|Cells|cell|||cell|||0|1000|1017|1021
SE|25462311||ab|6|entity|C0443228|Largest|qnco|||greater|||0|790|1048|1055
SE|25462311||ab|6|entity|C0600688|Toxic effect|inpo|||toxicity|||0|790|1056|1064
SE|25462311||ab|6|entity|C0004611|Bacteria|bact|||bacteria|||0|1000|1072|1080
SE|25462311||ab|6|relation|4|1|C0012854|DNA|bacs,nnon|bacs|||DNA|||0|1000|965|968|VERB|DISRUPTS||982|989|4|2|C0007634|Cells|cell|cell|||cell|||0|1000|1017|1021
SE|25462311||ab|6|relation|4|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|972|980|VERB|DISRUPTS||982|989|4|2|C0007634|Cells|cell|cell|||cell|||0|1000|1017|1021

SE|25462311||ab|7|text|1082|1262|On the other hand, the skin and lipid content of aqueous organisms can strongly inhibit the bio-uptake for some reactive compounds, resulting in a less toxic effect than expected.
SE|25462311||ab|7|entity|C0037267|Integumentary system|bdsy|||skin|||0|1000|1105|1109
SE|25462311||ab|7|entity|C0023779|Lipids|lipd|||lipid|||0|694|1114|1119
SE|25462311||ab|7|entity|C0599956|Aqueous|qlco|||aqueous|||0|888|1131|1138
SE|25462311||ab|7|entity|C0029235|Organism|orgm|||organisms|||0|888|1139|1148
SE|25462311||ab|7|entity|C0205460|biological|ftcn|||bio|||0|888|1174|1177
SE|25462311||ab|7|entity|C0243144|uptake|phsf|||uptake|||0|888|1178|1184
SE|25462311||ab|7|entity|C0205332|Reactive|qlco|||reactive|||0|872|1194|1202
SE|25462311||ab|7|entity|C0205198|Compound|qlco|||compounds|||0|872|1203|1212
SE|25462311||ab|7|entity|C0600688|Toxic effect|inpo|||toxic effect|||0|901|1234|1246
SE|25462311||ab|7|relation|3|1|C0023779|Lipids|lipd|lipd|||lipid|||0|694|1114|1119|PREP|PART_OF||1128|1130|4|1|C0029235|Organism|orgm|orgm|||organisms|||0|888|1139|1148
SE|25462311||ab|7|relation|4|2|C0023779|Lipids|lipd|lipd|||lipid|||0|694|1114|1119|VERB|DISRUPTS||1162|1169|3|1|C0243144|uptake|phsf|phsf|||uptake|||0|888|1178|1184
SE|25462311||ab|7|relation|6|4|C0023779|Lipids|lipd|lipd|||lipid|||0|694|1114|1119|VERB|CAUSES||1214|1223|1|1|C0600688|Toxic effect|inpo|inpo|||toxic effect|||0|901|1234|1246

SE|25462311||ab|8|text|1262|1371|D. magna is the most sensitive species and T. pyriformis is the least sensitive species of the four species.
SE|25462311||ab|8|entity|C0205393|Most|qnco|||most|||0|851|1278|1282
SE|25462311||ab|8|entity|C0332324|Sensitive|ftcn|||sensitive|||0|851|1283|1292
SE|25462311||ab|8|entity|C1548151|Species|idcn|||species|||0|851|1293|1300
SE|25462311||ab|8|entity|C0332324|Sensitive|ftcn|||sensitive|||0|790|1332|1341
SE|25462311||ab|8|entity|C1548151|Species|idcn|||species|||0|790|1342|1349
SE|25462311||ab|8|entity|C0205450|Four|qnco|||four|||0|888|1357|1361
SE|25462311||ab|8|entity|C1548151|Species|idcn|||species|||0|888|1362|1369

SE|25462311||ab|9|text|1371|1478|For a comparison of interspecies toxicity, we need to use the same reference threshold of excess toxicity.
SE|25462311||ab|9|entity|C0600688|Toxic effect|inpo|||toxicity|||0|861|1404|1412
SE|25462311||ab|9|entity|C0445247|Same|qlco|||same|||0|851|1433|1437
SE|25462311||ab|9|entity|C1514811|Reference|idcn|||reference|||0|851|1438|1447
SE|25462311||ab|9|entity|C0449864|Threshold|ftcn|||threshold|||0|851|1448|1457
SE|25462311||ab|9|entity|C0442802|Excessive|qlco|||excess|||0|853|1461|1467
SE|25462311||ab|9|entity|C0600688|Toxic effect|inpo|||toxicity|||0|853|1468|1476

SE|25462311||ab|10|text|1478|1649|However, some reactive compounds may be identified as baseline or less inert compounds for low sensitive species from the threshold developed from high sensitive species.
SE|25462311||ab|10|entity|C0205332|Reactive|qlco|||reactive|||0|872|1492|1500
SE|25462311||ab|10|entity|C0205198|Compound|qlco|||compounds|||0|872|1501|1510
SE|25462311||ab|10|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1532|1540
SE|25462311||ab|10|entity|C0205198|Compound|qlco|||compounds|||0|793|1555|1564
SE|25462311||ab|10|entity|C0205251|low|qlco|||low|||0|851|1569|1572
SE|25462311||ab|10|entity|C0332324|Sensitive|ftcn|||sensitive|||0|851|1573|1582
SE|25462311||ab|10|entity|C1548151|Species|idcn|||species|||0|851|1583|1590
SE|25462311||ab|10|entity|C0449864|Threshold|ftcn|||threshold|||0|1000|1600|1609
SE|25462311||ab|10|entity|C1441604|HIGH SENSITIVITY|lbpr|||high sensitive|||0|877|1625|1639
SE|25462311||ab|10|entity|C1548151|Species|idcn|||species|||0|877|1640|1647

SE|25462311||ab|11|text|1649|1859|The difference in the discrimination of excess toxicity to different species is not only because of the difference in MOAs for some compounds, but also due to the difference in sensitivity and bioconcentration.
SE|25462311||ab|11|entity|C1547020|*Difference|qnco|||difference|||0|1000|1653|1663
SE|25462311||ab|11|entity|C0442802|Excessive|qlco|||excess|||0|853|1689|1695
SE|25462311||ab|11|entity|C0600688|Toxic effect|inpo|||toxicity|||0|853|1696|1704
SE|25462311||ab|11|entity|C1547020|*Difference|qnco|||different|||0|853|1708|1717
SE|25462311||ab|11|entity|C1548151|Species|idcn|||species|||0|853|1718|1725
SE|25462311||ab|11|entity|C1518422|Not|ftcn|||not|||0|861|1729|1732
SE|25462311||ab|11|entity|C1547020|*Difference|qnco|||difference|||0|1000|1753|1763
SE|25462311||ab|11|entity|C1524059|mechanism of action qualifier|ftcn|||MOAs|||0|912|1767|1771
SE|25462311||ab|11|entity|C0205198|Compound|qlco|||compounds|||0|966|1781|1790
SE|25462311||ab|11|entity|C1547020|*Difference|qnco|||difference|||0|1000|1812|1822


SE|25462312||ti|1|text|21|211|Cerium chloride heptahydrate (CeCl3 . 7H2O) induces muscle paralysis in the generalist herbivore, Melanoplus sanguinipes (Fabricius) (Orthoptera: Acrididae), fed contaminated plant tissues.
SE|25462312||ti|1|entity|C0007828|Cerium|elii|||Cerium|||0|623|21|27
SE|25462312||ti|1|entity|C0008203|Chlorides|inch|||chloride|||0|623|28|36
SE|25462312||ti|1|entity|C0055122|cerous chloride|inch|||CeCl3|||0|694|51|56
SE|25462312||ti|1|entity|C0235062|Induction of neuromuscular blockade|topp|||muscle paralysis|||0|1000|73|89
SE|25462312||ti|1|entity|C0017319|General Practitioners|prog|||generalist|||0|888|97|107
SE|25462312||ti|1|entity|C0562691|Herbivore|anim|||herbivore|||0|888|108|117
SE|25462312||ti|1|entity|C1025548|Melanoplus sanguinipes|invt|||Melanoplus sanguinipes|||0|1000|119|141
SE|25462312||ti|1|entity|C0029361|Orthoptera|invt|||Orthoptera|||0|1000|155|165
SE|25462312||ti|1|entity|C0600226|Acrididae|invt|||Acrididae|||0|1000|167|176
SE|25462312||ti|1|entity|C0205279|Contaminated|ftcn|||contaminated|||0|851|183|195
SE|25462312||ti|1|entity|C0032098|Plants|plnt|||plant|||0|851|196|201
SE|25462312||ti|1|entity|C0040300|Body tissue|tisu|||tissues|||0|851|202|209
SE|25462312||ti|1|relation|0|0|C0040300|Body tissue|tisu|tisu|||tissues|||0|851|202|209|MOD/HEAD|PART_OF||196|209|0|0|C0032098|Plants|plnt|plnt|||plant|||0|851|196|201

SE|25462312||ab|1|text|217|287|Of increasing economic importance are the rare earth elements (REEs).
SE|25462312||ab|1|entity|C0442808|Increasing|ftcn|||increasing|||0|623|220|230
SE|25462312||ab|1|entity|C0013557|Economic|ftcn|||economic|||0|623|231|239
SE|25462312||ab|1|entity|C0025556|Metals, Rare Earth|elii|||rare earth elements|||0|1000|259|278

SE|25462312||ab|2|text|287|377|Pollution from mining and processing activity is expected to rise with industrial demand.
SE|25462312||ab|2|entity|C0392355|Pollution|eehu|||Pollution|||0|1000|287|296
SE|25462312||ab|2|entity|C0026175|Mining|ocac|||mining|||0|1000|302|308
SE|25462312||ab|2|entity|C1522240|Process|phpr|||processing|||0|872|313|323
SE|25462312||ab|2|entity|C0021267|Industry|ocac|||industrial|||0|623|358|368

SE|25462312||ab|3|text|377|466|Plants are known to accumulate REEs, although levels vary with species and soil content.
SE|25462312||ab|3|entity|C0032098|Plants|plnt|||Plants|||0|1000|377|383
SE|25462312||ab|3|entity|C0025556|Metals, Rare Earth|elii|||REEs|||0|1000|408|412
SE|25462312||ab|3|entity|C0441889|Levels|inpr|||levels|||0|1000|423|429
SE|25462312||ab|3|entity|C1548151|Species|idcn|||species|||0|1000|440|447
SE|25462312||ab|3|entity|C0037592|Soil|sbst|||soil|||0|694|452|456
SE|25462312||ab|3|relation|1|1|C0032098|Plants|plnt|plnt|||Plants|||0|1000|377|383|VERB|LOCATION_OF||397|407|4|1|C0025556|Metals, Rare Earth|elii|elii|||REEs|||0|1000|408|412

SE|25462312||ab|4|text|466|563|However, the effect on wildlife of ingesting REE contaminated vegetation is not well understood.
SE|25462312||ab|4|entity|C1280500|Effect|qlco|||effect|||0|1000|479|485
SE|25462312||ab|4|entity|C0232478|Ingestion|biof|||ingesting|||0|661|501|510
SE|25462312||ab|4|entity|C1285498|Vegetation|anab|||vegetation|||0|1000|528|538
SE|25462312||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|542|545
SE|25462312||ab|4|entity|C0205170|Good|qlco|||well|||0|1000|546|550

SE|25462312||ab|5|text|563|713|Here we examined the effect of consuming vegetation with elevated levels of cerium on the generalist grasshopper, Melanoplus sanguinipes (Fabricius).
SE|25462312||ab|5|entity|C1280500|Effect|qlco|||effect|||0|1000|584|590
SE|25462312||ab|5|entity|C1285498|Vegetation|anab|||vegetation|||0|861|604|614
SE|25462312||ab|5|entity|C0205250|High|qlco|||elevated|||0|888|620|628
SE|25462312||ab|5|entity|C0441889|Levels|inpr|||levels|||0|888|629|635
SE|25462312||ab|5|entity|C0007828|Cerium|elii|||cerium|||0|1000|639|645
SE|25462312||ab|5|entity|C0017319|General Practitioners|prog|||generalist|||0|888|653|663
SE|25462312||ab|5|entity|C0018211|Grasshoppers|invt|||grasshopper|||0|888|664|675
SE|25462312||ab|5|entity|C1025548|Melanoplus sanguinipes|invt|||Melanoplus sanguinipes|||0|1000|677|699
SE|25462312||ab|5|relation|6|5|C1025548|Melanoplus sanguinipes|invt|invt|||Melanoplus sanguinipes|||0|1000|677|699|NOM|INTERACTS_WITH||584|590|6|4|C0018211|Grasshoppers|invt|invt|||grasshopper|||0|888|664|675

SE|25462312||ab|6|text|713|778|Adults excreted a substantial portion of ingested contamination.
SE|25462312||ab|6|entity|C0001675|Adult|aggp|||Adults|||0|1000|713|719
SE|25462312||ab|6|entity|C0232478|Ingestion|biof|||ingested|||0|888|754|762
SE|25462312||ab|6|entity|C0259846|adulteration|hcpp|||contamination|||0|888|763|776

SE|25462312||ab|7|text|778|926|However, after only four-days of feeding, accumulation in the body occurred at all doses and paralysis of appendages resulted at the highest doses.
SE|25462312||ab|7|entity|C0205450|Four|qnco|||four|||0|790|798|802
SE|25462312||ab|7|entity|C0439228|day|tmco|||days|||0|790|803|807
SE|25462312||ab|7|entity|C1446466|Dose|qnco|||doses|||0|1000|861|866
SE|25462312||ab|7|entity|C0522224|Paralysed|fndg|||paralysis|||0|1000|871|880
SE|25462312||ab|7|entity|C0598782|appendage|bpoc|||appendages|||0|966|884|894
SE|25462312||ab|7|entity|C0444956|High dose|qnco|||highest doses|||0|966|911|924
SE|25462312||ab|7|relation|2|1|C0598782|appendage|bpoc|bpoc|||appendages|||0|966|884|894|PREP|LOCATION_OF||881|883|6|1|C0522224|Paralysed|fndg|fndg|||paralysis|||0|1000|871|880

SE|25462312||ab|8|text|926|1015|Short-term toxicity studies may underestimate the impact of ingesting REE contamination.
SE|25462312||ab|8|entity|C0443303|Short-term|tmco|||Short-term|||0|850|926|936
SE|25462312||ab|8|entity|C0600688|Toxic effect|inpo|||toxicity|||0|850|937|945
SE|25462312||ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|850|946|953
SE|25462312||ab|8|entity|C0232478|Ingestion|biof|||ingesting|||0|785|986|995
SE|25462312||ab|8|entity|C0259846|adulteration|hcpp|||contamination|||0|785|1000|1013

SE|25462312||ab|9|text|1015|1173|Metals tend to be low in toxicity; however, their persistence in the environment may be better represented by exposure over longer portions of the life cycle.
SE|25462312||ab|9|entity|C0025552|Metals|inch|||Metals|||0|1000|1015|1021
SE|25462312||ab|9|entity|C0205251|low|qlco|||low|||0|1000|1033|1036
SE|25462312||ab|9|entity|C0600688|Toxic effect|inpo|||toxicity|||0|1000|1040|1048
SE|25462312||ab|9|entity|C0546816|Persistence|menp|||persistence|||0|1000|1065|1076
SE|25462312||ab|9|entity|C0014406|Environment|spco|||environment|||0|1000|1084|1095
SE|25462312||ab|9|entity|C0332272|Better|qlco|||better|||0|1000|1103|1109
SE|25462312||ab|9|entity|C0205166|Long|qlco|||longer|||0|612|1139|1145
SE|25462312||ab|9|entity|C0376558|Life|idcn|||life|||0|888|1162|1166
SE|25462312||ab|9|entity|C0750729|Course|tmco|||cycle|||0|888|1167|1172
SE|25462312||ab|9|relation|2|2|C0025552|Metals|inch|inch|||Metals|||0|1000|1015|1021|PREP|ASSOCIATED_WITH||1037|1039|6|1|C0600688|Toxic effect|inpo|inpo|||toxicity|||0|1000|1040|1048


SE|25462313||ti|1|text|21|152|QSTR modeling for predicting aquatic toxicity of pharmacological active compounds in multiple test species for regulatory purpose.
SE|25462313||ti|1|entity|C0870071|Modeling|inpr,resa|||modeling|||0|861|26|34
SE|25462313||ti|1|entity|C1508497|PREDICTED|clna|||predicting|||0|856|39|49
SE|25462313||ti|1|entity|C1282240|Aquatic toxin|bacs,hops|||aquatic toxicity|||0|856|50|66
SE|25462313||ti|1|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|840|70|85
SE|25462313||ti|1|entity|C0205177|Active|ftcn|||active|||0|840|86|92
SE|25462313||ti|1|entity|C0205198|Compound|qlco|||compounds|||0|840|93|102
SE|25462313||ti|1|entity|C0439064|Numerous|qnco|||multiple|||0|851|106|114
SE|25462313||ti|1|entity|C0039593|Testing|resa|||test|||0|851|115|119
SE|25462313||ti|1|entity|C1548151|Species|idcn|||species|||0|851|120|127
SE|25462313||ti|1|entity|C0220905|regulatory|rnlw|||regulatory|||0|888|132|142
SE|25462313||ti|1|entity|C1285529|Purpose|ftcn|||purpose|||0|888|143|150

SE|25462313||ab|1|text|158|485|High concentrations of pharmacological active compounds (PACs) detected in global drinking water resources and their toxicological implications in aquatic life has become a matter of concern compelling for the development of reliable QSTRs (qualitative/quantitative structure-toxicity relationships) for their risk assessment.
SE|25462313||ab|1|entity|C0205250|High|qlco|||High|||0|888|158|162
SE|25462313||ab|1|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|840|181|196
SE|25462313||ab|1|entity|C0205177|Active|ftcn|||active|||0|840|197|203
SE|25462313||ab|1|entity|C0205198|Compound|qlco|||compounds|||0|840|204|213
SE|25462313||ab|1|entity|C0205246|Generalized|spco|||global|||0|861|233|239
SE|25462313||ab|1|entity|C0599638|Drinking Water|sbst|||drinking water|||0|861|240|254
SE|25462313||ab|1|entity|C0035201|Resources|idcn|||resources|||0|861|255|264
SE|25462313||ab|1|entity|C0205472|Toxicologic|ftcn|||toxicological|||0|694|275|288
SE|25462313||ab|1|entity|C0376558|Life|idcn|||life|||0|861|313|317
SE|25462313||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|368|379
SE|25462313||ab|1|entity|C0205556|Qualitative|qlco|||qualitative|||0|822|399|410
SE|25462313||ab|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|822|411|423
SE|25462313||ab|1|entity|C0678594|Structure|spco|||structure|||0|822|424|433
SE|25462313||ab|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|822|434|442
SE|25462313||ab|1|entity|C0439849|Relationships|qlco|||relationships|||0|822|443|456
SE|25462313||ab|1|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|1000|468|483

SE|25462313||ab|2|text|485|826|Robust QSTRs, such as decision treeboost (DTB) and decision tree forest (DTF) models implementing stochastic gradient boosting and bagging algorithms were established by experimental toxicity data of structurally diverse PACs in daphnia using molecular descriptors for predicting toxicity of new untested compounds in multiple test species.
SE|25462313||ab|2|entity|C0679006|decision|inpr|||decision|||0|694|507|515
SE|25462313||ab|2|entity|C0011115|Decision Trees|inpr|||decision tree|||0|658|536|549
SE|25462313||ab|2|entity|C0086312|Forests|geoa|||forest|||0|658|550|556
SE|25462313||ab|2|entity|C0439182|% gradient|qnco|||gradient|||0|773|594|602
SE|25462313||ab|2|entity|C1511253|Boost|ftcn|||boosting|||0|773|603|611
SE|25462313||ab|2|entity|C0179196|Bag device|mnob|||bagging|||0|872|616|623
SE|25462313||ab|2|entity|C0002045|algorithm|inpr|||algorithms|||0|872|624|634
SE|25462313||ab|2|entity|C1517004|Experimental|ftcn|||experimental|||0|851|655|667
SE|25462313||ab|2|entity|C0600688|Toxic effect|inpo|||toxicity|||0|851|668|676
SE|25462313||ab|2|entity|C1511726|Data|idcn|||data|||0|851|677|681
SE|25462313||ab|2|entity|C0205464|pharmacological|ftcn|||PACs|||0|725|706|710
SE|25462313||ab|2|entity|C0205177|Active|ftcn|||PACs|||0|725|706|710
SE|25462313||ab|2|entity|C0205198|Compound|qlco|||PACs|||0|725|706|710
SE|25462313||ab|2|entity|C0010979|Daphnia|invt|||daphnia|||0|1000|714|721
SE|25462313||ab|2|entity|C1521991|Molecular|qlco|||molecular|||0|888|728|737
SE|25462313||ab|2|entity|C0282354|Descriptors|inpr|||descriptors|||0|888|738|749
SE|25462313||ab|2|entity|C1508497|PREDICTED|clna|||predicting|||0|872|754|764
SE|25462313||ab|2|entity|C0600688|Toxic effect|inpo|||toxicity|||0|872|765|773
SE|25462313||ab|2|entity|C0205314|New|tmco|||new|||0|785|777|780
SE|25462313||ab|2|entity|C0205198|Compound|qlco|||compounds|||0|785|790|799
SE|25462313||ab|2|entity|C0439064|Numerous|qnco|||multiple|||0|851|803|811
SE|25462313||ab|2|entity|C0039593|Testing|resa|||test|||0|851|812|816
SE|25462313||ab|2|entity|C1548151|Species|idcn|||species|||0|851|817|824

SE|25462313||ab|3|text|826|1041|Developed models were rigorously validated using OECD recommended internal and external validation procedures and predictive power tested with external data of different trophic level test species (algae and fish).
SE|25462313||ab|3|entity|C0205102|Intrinsic|spco|||internal|||0|1000|892|900
SE|25462313||ab|3|entity|C0205101|Extrinsic|spco|||external|||0|851|905|913
SE|25462313||ab|3|entity|C1519941|Validation|resa|||validation|||0|851|914|924
SE|25462313||ab|3|entity|C0025664|Methodology|inpr|||procedures|||0|851|925|935
SE|25462313||ab|3|entity|C0681890|predictive|qlco|||predictive|||0|694|940|950
SE|25462313||ab|3|entity|C0205101|Extrinsic|spco|||external|||0|888|969|977
SE|25462313||ab|3|entity|C1511726|Data|idcn|||data|||0|888|978|982
SE|25462313||ab|3|entity|C1547020|*Difference|qnco|||different|||0|726|986|995
SE|25462313||ab|3|entity|C0600072|Feeding and dietary regimes|topp|||trophic|||0|726|996|1003
SE|25462313||ab|3|entity|C0039593|Testing|resa|||test|||0|726|1010|1014
SE|25462313||ab|3|entity|C1548151|Species|idcn|||species|||0|726|1015|1022
SE|25462313||ab|3|entity|C0002028|Algae|alga|||algae|||0|1000|1024|1029
SE|25462313||ab|3|entity|C0016163|Fishes|fish|||fish|||0|1000|1034|1038

SE|25462313||ab|4|text|1041|1191|Classification QSTRs (DTB, DTF) rendered accuracy of 98.73% and 97.47%, respectively in daphnia and 84.38%, 85.94% (algae), 78.46% and 79.23% (fish).
SE|25462313||ab|4|entity|C0008902|Classification|clas|||Classification|||0|694|1041|1055
SE|25462313||ab|4|entity|C0679006|decision|inpr|||DTB|||0|694|1063|1066
SE|25462313||ab|4|entity|C0011115|Decision Trees|inpr|||DTF|||0|901|1068|1071
SE|25462313||ab|4|entity|C0086312|Forests|geoa|||DTF|||0|901|1068|1071
SE|25462313||ab|4|entity|C0443131|Accurate|qlco|||accuracy|||0|789|1082|1090
SE|25462313||ab|4|entity|C0439082|>97|qnco|||97|||0|861|1105|1107
SE|25462313||ab|4|entity|C0010979|Daphnia|invt|||daphnia|||0|1000|1129|1136
SE|25462313||ab|4|entity|C0002028|Algae|alga|||algae|||0|1000|1157|1162
SE|25462313||ab|4|entity|C0016163|Fishes|fish|||fish|||0|1000|1184|1188

SE|25462313||ab|5|text|1191|1362|On the other hand, the regression QSTRs (DTB, DTF) yielded squared correlation coefficient values of 0.831, 0.852 (daphnia), 0.534, 0.556 (algae) and 0.620, 0.637 (fish).
SE|25462313||ab|5|entity|C0679006|decision|inpr|||DTB|||0|694|1232|1235
SE|25462313||ab|5|entity|C0011115|Decision Trees|inpr|||DTF|||0|901|1237|1240
SE|25462313||ab|5|entity|C0086312|Forests|geoa|||DTF|||0|901|1237|1240
SE|25462313||ab|5|entity|C1547015|*Coefficient|qnco|||coefficient|||0|750|1270|1281
SE|25462313||ab|5|entity|C0042295|Values|qlco|||values|||0|750|1282|1288
SE|25462313||ab|5|entity|C0010979|Daphnia|invt|||daphnia|||0|1000|1306|1313
SE|25462313||ab|5|entity|C0002028|Algae|alga|||algae|||0|1000|1330|1335
SE|25462313||ab|5|entity|C0016163|Fishes|fish|||fish|||0|1000|1355|1359

SE|25462313||ab|6|text|1362|1584|QSTRs developed in this study passed the OECD validation criteria and performed better than reported earlier for predicting toxicity of PACs, and can be used for screening the new untested compounds for regulatory purpose.
SE|25462313||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1386|1391
SE|25462313||ab|6|entity|C1519941|Validation|resa|||validation|||0|790|1408|1418
SE|25462313||ab|6|entity|C0243161|criteria|inpr|||criteria|||0|790|1419|1427
SE|25462313||ab|6|entity|C0332272|Better|qlco|||better|||0|1000|1442|1448
SE|25462313||ab|6|entity|C1279919|Early|tmco|||earlier|||0|966|1463|1470
SE|25462313||ab|6|entity|C1508497|PREDICTED|clna|||predicting|||0|872|1475|1485
SE|25462313||ab|6|entity|C0600688|Toxic effect|inpo|||toxicity|||0|872|1486|1494
SE|25462313||ab|6|entity|C0205464|pharmacological|ftcn|||PACs|||0|840|1498|1502
SE|25462313||ab|6|entity|C0205177|Active|ftcn|||PACs|||0|840|1498|1502
SE|25462313||ab|6|entity|C0205198|Compound|qlco|||PACs|||0|840|1498|1502
SE|25462313||ab|6|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|1524|1533
SE|25462313||ab|6|entity|C0205314|New|tmco|||new|||0|785|1538|1541
SE|25462313||ab|6|entity|C0205198|Compound|qlco|||compounds|||0|785|1551|1560
SE|25462313||ab|6|entity|C0220905|regulatory|rnlw|||regulatory|||0|888|1565|1575
SE|25462313||ab|6|entity|C1285529|Purpose|ftcn|||purpose|||0|888|1576|1583


SE|25462314||ti|1|text|21|130|Survey of the mutagenicity of surface water, sediments, and drinking water from the Penobscot Indian Nation.
SE|25462314||ti|1|entity|C0038951|Surveys|resa|||Survey|||0|1000|21|27
SE|25462314||ti|1|entity|C0026879|Mutagens|hops|||mutagenicity|||0|900|35|47
SE|25462314||ti|1|entity|C0205148|Surface|spco|||surface|||0|888|51|58
SE|25462314||ti|1|entity|C0020311|Hydrotherapy|topp|||water|||0|888|59|64
SE|25462314||ti|1|entity|C0599638|Drinking Water|sbst|||drinking water|||0|1000|81|95
SE|25462314||ti|1|entity|C0422792|Indian ethnic group|popg|||Indian|||0|790|115|121
SE|25462314||ti|1|entity|C1555720|Nation|orgt|||Nation|||0|790|122|128

SE|25462314||ab|1|text|136|141|U.S.
SE|25462314||ab|1|entity|C0041703|United States|geoa|||U.|||0|1000|136|138

SE|25462314||ab|2|text|141|350|Environmental Protection Agency (US EPA) Regional Applied Research Effort (RARE) projects address the effects of environmental pollutants in a particular region on the health of the population in that region.
SE|25462314||ab|2|entity|C0242228|Protection, Environmental|gora,socb|||Environmental Protection|||0|890|141|165
SE|25462314||ab|2|entity|C0237463|Agencies|orgt|||Agency|||0|890|166|172
SE|25462314||ab|2|entity|C0041712|United States Environmental Protection Agency|orgt|||EPA|||0|1000|177|180
SE|25462314||ab|2|entity|C0205147|Region|spco|||Regional|||0|794|182|190
SE|25462314||ab|2|entity|C0260206|Research Project Grants|resa|||Research Effort (RARE) projects|||0|794|199|230
SE|25462314||ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|243|250
SE|25462314||ab|2|entity|C0014417|Environmental Pollutants|hops|||environmental pollutants|||0|1000|254|278
SE|25462314||ab|2|entity|C0205147|Region|spco|||region|||0|861|295|301
SE|25462314||ab|2|entity|C0018684|Health|idcn|||health|||0|1000|309|315
SE|25462314||ab|2|entity|C1257890|Population Group|popg|||population|||0|1000|323|333
SE|25462314||ab|2|entity|C0205147|Region|spco|||region|||0|1000|342|348

SE|25462314||ab|3|text|350|574|This report is part of a RARE project that addresses this for the Penobscot Indian Nation (PIN), Penobscot Island, Maine, U.S., where the Penobscot River has had fish advisories for many years due to high levels of mercury.
SE|25462314||ab|3|entity|C0449719|Part|spco|||part|||0|1000|365|369
SE|25462314||ab|3|entity|C0035168|research|resa|||RARE|||0|888|375|379
SE|25462314||ab|3|entity|C0422792|Indian ethnic group|popg|||Indian|||0|790|426|432
SE|25462314||ab|3|entity|C1555720|Nation|orgt|||Nation|||0|790|433|439
SE|25462314||ab|3|entity|C0022130|Islands|geoa|||Island|||0|861|457|463
SE|25462314||ab|3|entity|C0024497|Maine|geoa|||Maine|||0|1000|465|470
SE|25462314||ab|3|entity|C0041703|United States|geoa|||U.|||0|1000|472|474
SE|25462314||ab|3|entity|C0337050|Rivers|npop|||River|||0|861|498|503
SE|25462314||ab|3|entity|C0016163|Fishes|fish|||fish|||0|694|512|516
SE|25462314||ab|3|entity|C0439234|year|tmco|||years|||0|1000|537|542
SE|25462314||ab|3|entity|C0205250|High|qlco|||high|||0|888|550|554
SE|25462314||ab|3|entity|C0441889|Levels|inpr|||levels|||0|888|555|561
SE|25462314||ab|3|entity|C0025424|Mercury|elii,hops|||mercury|||0|1000|565|572

SE|25462314||ab|4|text|574|889|We used the Salmonella mutagenicity assay with strains TA100, TA98, YG1041, and YG1042 with and without metabolic activation to assess the mutagenic potencies of organic extracts of the Penobscot River water and sediment, as well as drinking-water samples, all collected by the PIN Department of Natural Resources.
SE|25462314||ab|4|entity|C0036111|Salmonella|bact|||Salmonella|||0|818|586|596
SE|25462314||ab|4|entity|C0026879|Mutagens|hops|||mutagenicity|||0|818|597|609
SE|25462314||ab|4|entity|C1510438|Assay|lbpr|||assay|||0|818|610|615
SE|25462314||ab|4|entity|C0025513|Activation, Metabolic|orgf|||metabolic activation|||0|1000|678|698
SE|25462314||ab|4|entity|C0026879|Mutagens|hops|||mutagenic|||0|793|713|722
SE|25462314||ab|4|entity|C0237399|Potential|qlco|||potencies|||0|793|723|732
SE|25462314||ab|4|entity|C0747055|ORGANIC|qlco|||organic|||0|872|736|743
SE|25462314||ab|4|entity|C1555707|extract|idcn|||extracts|||0|872|744|752
SE|25462314||ab|4|entity|C0337050|Rivers|npop|||River|||0|790|770|775
SE|25462314||ab|4|entity|C0020311|Hydrotherapy|topp|||water|||0|790|776|781
SE|25462314||ab|4|entity|C1550099|Sediment|bdsu|||sediment|||0|1000|786|794
SE|25462314||ab|4|entity|C0001948|Alcohol consumption|inbe|||drinking|||0|890|807|815
SE|25462314||ab|4|entity|C1550678|Water Specimen|inch|||water samples|||0|890|816|829
SE|25462314||ab|4|entity|C0422792|Indian ethnic group|popg|||PIN|||0|583|852|855
SE|25462314||ab|4|entity|C1555720|Nation|orgt|||PIN|||0|583|852|855
SE|25462314||ab|4|entity|C0027492|Natural Resources|idcn|||Natural Resources|||0|1000|870|887

SE|25462314||ab|5|text|889|1001|The source water for the PIN drinking water is gravel-packed groundwater wells adjacent to the Penobscot River.
SE|25462314||ab|5|entity|C0020311|Hydrotherapy|topp|||water|||0|888|900|905
SE|25462314||ab|5|entity|C0422792|Indian ethnic group|popg|||PIN|||0|798|914|917
SE|25462314||ab|5|entity|C1555720|Nation|orgt|||PIN|||0|798|914|917
SE|25462314||ab|5|entity|C0599638|Drinking Water|sbst|||drinking water|||0|798|918|932
SE|25462314||ab|5|entity|C0184967|Insertion of pack|topp|||packed|||0|861|943|949
SE|25462314||ab|5|entity|C0596631|ground water|spco|||groundwater|||0|861|950|961
SE|25462314||ab|5|entity|C0205117|Adjacent|spco|||adjacent|||0|1000|968|976
SE|25462314||ab|5|entity|C0337050|Rivers|npop|||River|||0|861|994|999

SE|25462314||ab|6|text|1001|1100|Most samples of all extracts were either not mutagenic or had low to moderate mutagenic potencies.
SE|25462314||ab|6|entity|C1555707|extract|idcn|||extracts|||0|966|1021|1029
SE|25462314||ab|6|entity|C1518422|Not|ftcn|||not|||0|853|1042|1045
SE|25462314||ab|6|entity|C0026879|Mutagens|hops|||mutagenic|||0|853|1046|1055
SE|25462314||ab|6|entity|C0205251|low|qlco|||low|||0|1000|1063|1066
SE|25462314||ab|6|entity|C0026879|Mutagens|hops|||mutagenic|||0|793|1079|1088
SE|25462314||ab|6|entity|C0237399|Potential|qlco|||potencies|||0|793|1089|1098

SE|25462314||ab|7|text|1100|1337|The average mutagenic potencies (revertants/L-equivalent) were 337 for the drinking-water extracts and 177 for the river-water extracts; the average mutagenic potency for the river-sediment extracts was 244 revertants(g-equivalent)(-1).
SE|25462314||ab|7|entity|C1510992|Average|qnco|||average|||0|788|1104|1111
SE|25462314||ab|7|entity|C0026879|Mutagens|hops|||mutagenic|||0|788|1112|1121
SE|25462314||ab|7|entity|C0237399|Potential|qlco|||potencies|||0|788|1122|1131
SE|25462314||ab|7|entity|C0439185|Eq|qnco|||equivalent|||0|773|1146|1156
SE|25462314||ab|7|entity|C0599638|Drinking Water|sbst|||drinking-water|||0|884|1175|1189
SE|25462314||ab|7|entity|C1555707|extract|idcn|||extracts|||0|884|1190|1198
SE|25462314||ab|7|entity|C0337050|Rivers|npop|||river|||0|840|1215|1220
SE|25462314||ab|7|entity|C0020311|Hydrotherapy|topp|||water|||0|840|1221|1226
SE|25462314||ab|7|entity|C1555707|extract|idcn|||extracts|||0|840|1227|1235
SE|25462314||ab|7|entity|C1510992|Average|qnco|||average|||0|789|1241|1248
SE|25462314||ab|7|entity|C0026879|Mutagens|hops|||mutagenic|||0|789|1249|1258
SE|25462314||ab|7|entity|C0237399|Potential|qlco|||potency|||0|789|1259|1266
SE|25462314||ab|7|entity|C0337050|Rivers|npop|||river|||0|840|1275|1280
SE|25462314||ab|7|entity|C1550099|Sediment|bdsu|||sediment|||0|840|1281|1289
SE|25462314||ab|7|entity|C1555707|extract|idcn|||extracts|||0|840|1290|1298
SE|25462314||ab|7|entity|C0439185|Eq|qnco|||equivalent|||0|861|1320|1330

SE|25462314||ab|8|text|1337|1687|This part of the RARE project showed that extracts of the Penobscot River water and sediments and Penobscot drinking water have little to no mutagenic activity that might be due to the classes of compounds that the Salmonella mutagenicity assay detects, such as polycyclic aromatic hydrocarbons (PAHs), nitro-PAHs (nitroarenes), and aromatic amines.
SE|25462314||ab|8|entity|C0449719|Part|spco|||part|||0|1000|1342|1346
SE|25462314||ab|8|entity|C0700032|research project|resa|||RARE project|||0|901|1354|1366
SE|25462314||ab|8|entity|C1555707|extract|idcn|||extracts|||0|966|1379|1387
SE|25462314||ab|8|entity|C0337050|Rivers|npop|||River|||0|790|1405|1410
SE|25462314||ab|8|entity|C0020311|Hydrotherapy|topp|||water|||0|790|1411|1416
SE|25462314||ab|8|entity|C0599638|Drinking Water|sbst|||drinking water|||0|901|1445|1459
SE|25462314||ab|8|entity|C0023882|Little's Disease|dsyn|||little|||0|1000|1465|1471
SE|25462314||ab|8|entity|C0026879|Mutagens|hops|||mutagenic|||0|853|1478|1487
SE|25462314||ab|8|entity|C0456387|Class|inpr|||classes|||0|1000|1522|1529
SE|25462314||ab|8|entity|C0205198|Compound|qlco|||compounds|||0|966|1533|1542
SE|25462314||ab|8|entity|C0036111|Salmonella|bact|||Salmonella|||0|818|1552|1562
SE|25462314||ab|8|entity|C0026879|Mutagens|hops|||mutagenicity|||0|818|1563|1575
SE|25462314||ab|8|entity|C1510438|Assay|lbpr|||assay|||0|818|1576|1581
SE|25462314||ab|8|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||polycyclic aromatic hydrocarbons|||0|1000|1599|1631
SE|25462314||ab|8|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||PAHs|||0|923|1646|1650
SE|25462314||ab|8|entity|C0682958|Aromatic Amines|orch|||aromatic amines|||0|1000|1670|1685

SE|25462314||ab|9|text|1687|1796|This study is the first to examine the mutagenicity of environmental samples from a tribal nation in the U.S.
SE|25462314||ab|9|entity|C0008972|Clinical Research|resa|||study|||0|1000|1692|1697
SE|25462314||ab|9|entity|C1279901|Firstly|qlco|||first|||0|1000|1705|1710
SE|25462314||ab|9|entity|C0026879|Mutagens|hops|||mutagenicity|||0|900|1726|1738
SE|25462314||ab|9|entity|C1555720|Nation|orgt|||nation|||0|861|1778|1784
SE|25462314||ab|9|entity|C0041703|United States|geoa|||U.|||0|1000|1792|1794


SE|25462315||ti|1|text|21|108|Cumulative risk assessment lessons learned: a review of case studies and issue papers.
SE|25462315||ti|1|entity|C1511559|Cumulative|qlco|||Cumulative|||0|658|21|31
SE|25462315||ti|1|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|658|32|47
SE|25462315||ti|1|entity|C0085973|Case Study|inpr|||case studies|||0|1000|77|89
SE|25462315||ti|1|entity|C0030351|Paper|mnob|||papers|||0|861|100|106

SE|25462315||ab|1|text|114|252|Cumulative risk assessments (CRAs) examine potential risks posed by exposure to multiple and sometimes disparate environmental stressors.
SE|25462315||ab|1|entity|C1511559|Cumulative|qlco|||Cumulative|||0|901|114|124
SE|25462315||ab|1|entity|C0086930|Risk Assessment|hlca|||risk assessments|||0|901|125|141
SE|25462315||ab|1|entity|C0237399|Potential|qlco|||potential|||0|1000|157|166
SE|25462315||ab|1|entity|C0439064|Numerous|qnco|||multiple|||0|1000|194|202
SE|25462315||ab|1|entity|C0596519|environmental stressor|fndg|||environmental stressors|||0|844|227|250

SE|25462315||ab|2|text|252|378|CRAs are more resource intensive than single chemical assessments, and pose additional challenges and sources of uncertainty.
SE|25462315||ab|2|entity|C1511559|Cumulative|qlco|||CRAs|||0|901|252|256
SE|25462315||ab|2|entity|C0086930|Risk Assessment|hlca|||CRAs|||0|901|252|256
SE|25462315||ab|2|entity|C0205172|More|ftcn|||more|||0|888|261|265
SE|25462315||ab|2|entity|C0035201|Resources|idcn|||resource|||0|888|266|274
SE|25462315||ab|2|entity|C0037179|Unmarried person|popg|||single|||0|840|290|296
SE|25462315||ab|2|entity|C0220806|Chemicals|chem|||chemical|||0|840|297|305
SE|25462315||ab|2|entity|C0220825|Evaluation|ftcn|||assessments|||0|840|306|317
SE|25462315||ab|2|entity|C1524062|Additional|ftcn|||additional|||0|872|328|338
SE|25462315||ab|2|entity|C0087130|Uncertainty|idcn|||uncertainty|||0|1000|365|376

SE|25462315||ab|3|text|378|565|CRAs may examine the impact of several factors on risk, including exposure magnitude and timing, chemical mixture composition, as well as physical, biological, or psychosocial stressors.
SE|25462315||ab|3|entity|C1511559|Cumulative|qlco|||CRAs|||0|901|378|382
SE|25462315||ab|3|entity|C0086930|Risk Assessment|hlca|||CRAs|||0|901|378|382
SE|25462315||ab|3|entity|C0443302|Several|qnco|||several|||0|872|409|416
SE|25462315||ab|3|entity|C1521761|Factor|ftcn|||factors|||0|872|417|424
SE|25462315||ab|3|entity|C0035647|Risk|qlco|||risk|||0|1000|428|432
SE|25462315||ab|3|entity|C0449286|Degree or extent|qnco|||magnitude|||0|827|453|462
SE|25462315||ab|3|entity|C0449243|Timing|tmco|||timing|||0|1000|467|473
SE|25462315||ab|3|entity|C0439962|Mixture|sbst|||mixture|||0|901|484|491
SE|25462315||ab|3|entity|C0243176|chemical composition|npop|||chemical mixture composition|||0|901|475|503
SE|25462315||ab|3|entity|C0205485|Physical|ftcn|||physical|||0|888|516|524
SE|25462315||ab|3|entity|C0205460|biological|ftcn|||biological|||0|888|526|536
SE|25462315||ab|3|entity|C0748073|PSYCHOSOCIAL STRESSOR|mobd|||psychosocial stressors|||0|983|541|563

SE|25462315||ab|4|text|565|772|CRAs are meant to increase the relevance of risk assessments, providing decision makers with information based on real world exposure scenarios that improve the characterization of actual risks and hazards.
SE|25462315||ab|4|entity|C1511559|Cumulative|qlco|||CRAs|||0|901|565|569
SE|25462315||ab|4|entity|C0086930|Risk Assessment|hlca|||CRAs|||0|901|565|569
SE|25462315||ab|4|entity|C0086930|Risk Assessment|hlca|||risk assessments|||0|1000|609|625
SE|25462315||ab|4|entity|C0679006|decision|inpr|||decision|||0|872|637|645
SE|25462315||ab|4|entity|C0554244|Maker NOS|prog|||makers|||0|872|646|652
SE|25462315||ab|4|entity|C1533716|Information|idcn|||information|||0|1000|658|669
SE|25462315||ab|4|entity|C0871222|Reality|idcn|||real|||0|739|679|683
SE|25462315||ab|4|entity|C0683579|scenario|ftcn|||scenarios|||0|739|699|708
SE|25462315||ab|4|entity|C0237400|Actual|qlco|||actual|||0|1000|746|752
SE|25462315||ab|4|entity|C0598697|hazard|qlco|||hazards|||0|1000|763|770

SE|25462315||ab|5|text|772|781|The U.S.
SE|25462315||ab|5|entity|C0041703|United States|geoa|||U.|||0|1000|776|778

SE|25462315||ab|6|text|781|955|Environmental Protection Agency has evaluated a number of CRAs, performed by or commissioned for the Agency, to seek insight into CRA concepts, methods, and lessons learned.
SE|25462315||ab|6|entity|C0242228|Protection, Environmental|gora,socb|||Environmental Protection|||0|890|781|805
SE|25462315||ab|6|entity|C0237463|Agencies|orgt|||Agency|||0|890|806|812
SE|25462315||ab|6|entity|C1511559|Cumulative|qlco|||CRAs|||0|901|839|843
SE|25462315||ab|6|entity|C0086930|Risk Assessment|hlca|||CRAs|||0|901|839|843
SE|25462315||ab|6|entity|C0237463|Agencies|orgt|||Agency|||0|966|882|888
SE|25462315||ab|6|entity|C0233820|Insight|menp|||insight|||0|1000|898|905
SE|25462315||ab|6|entity|C1516627|Clinical Research Associate|prog|||CRA|||0|888|911|914
SE|25462315||ab|6|entity|C0178566|concept|idcn|||concepts|||0|888|915|923
SE|25462315||ab|6|entity|C0025663|Methods|inpr|||methods|||0|1000|925|932

SE|25462315||ab|7|text|955|1110|In this article, ten case studies and five issue papers on key CRA topics are examined and a set of lessons learned are identified for CRA implementation.
SE|25462315||ab|7|entity|C0205456|Ten|qnco|||ten|||0|901|972|975
SE|25462315||ab|7|entity|C0085973|Case Study|inpr|||case studies|||0|901|976|988
SE|25462315||ab|7|entity|C0205451|Five|qnco|||five|||0|802|993|997
SE|25462315||ab|7|entity|C0030351|Paper|mnob|||papers|||0|802|1004|1010
SE|25462315||ab|7|entity|C1554080|Key|idcn|||key|||0|840|1014|1017
SE|25462315||ab|7|entity|C1516627|Clinical Research Associate|prog|||CRA|||0|840|1018|1021
SE|25462315||ab|7|entity|C1555712|topic|idcn|||topics|||0|840|1022|1028
SE|25462315||ab|7|entity|C1516627|Clinical Research Associate|prog|||CRA|||0|694|1090|1093

SE|25462315||ab|8|text|1110|1388|The lessons address the iterative nature of CRAs, importance of considering vulnerability, need for stakeholder engagement, value of a tiered approach, new methods to assess multiroute exposures to chemical mixtures, and the impact of geographical scale on approach and purpose.
SE|25462315||ab|8|entity|C0349590|Nature|idcn|||nature|||0|861|1144|1150
SE|25462315||ab|8|entity|C1511559|Cumulative|qlco|||CRAs|||0|901|1154|1158
SE|25462315||ab|8|entity|C0086930|Risk Assessment|hlca|||CRAs|||0|901|1154|1158
SE|25462315||ab|8|entity|C0750591|CONSIDER|idcn|||considering|||0|661|1174|1185
SE|25462315||ab|8|entity|C0027552|Needs|qlco|||need|||0|1000|1201|1205
SE|25462315||ab|8|entity|C0425152|Engaged to be married|socb|||engagement|||0|861|1222|1232
SE|25462315||ab|8|entity|C0449445|Approach|spco|||approach|||0|861|1252|1260
SE|25462315||ab|8|entity|C0205314|New|tmco|||new|||0|888|1262|1265
SE|25462315||ab|8|entity|C0025663|Methods|inpr|||methods|||0|888|1266|1273
SE|25462315||ab|8|entity|C0274281|Injury due to exposure to external cause|inpo|||exposures|||0|861|1295|1304
SE|25462315||ab|8|entity|C0220806|Chemicals|chem|||chemical|||0|872|1308|1316
SE|25462315||ab|8|entity|C0439962|Mixture|sbst|||mixtures|||0|872|1317|1325
SE|25462315||ab|8|entity|C0017447|Geography|ocdi|||geographical|||0|853|1345|1357
SE|25462315||ab|8|entity|C0449445|Approach|spco|||approach|||0|1000|1367|1375
SE|25462315||ab|8|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|1380|1387


SE|25462316||ti|1|text|21|100|Assessing the transfer of risk due to transportation of agricultural products.
SE|25462316||ti|1|entity|C0348011|Transfer procedure|ftcn|||transfer|||0|1000|35|43
SE|25462316||ti|1|entity|C0035647|Risk|qlco|||risk|||0|1000|47|51
SE|25462316||ti|1|entity|C0001829|Agriculture|ocdi|||agricultural|||0|836|77|89
SE|25462316||ti|1|entity|C1514468|product|qnco|||products|||0|836|90|98

SE|25462316||ab|1|text|106|201|Health risk assessment (HRA) is the process used to estimate adverse health effects on humans.
SE|25462316||ab|1|entity|C0679809|health risk assessment|topp|||Health risk assessment|||0|1000|106|128
SE|25462316||ab|1|entity|C1522240|Process|phpr|||process|||0|1000|142|149
SE|25462316||ab|1|entity|C0018684|Health|idcn|||health|||0|901|175|181
SE|25462316||ab|1|entity|C0879626|Adverse effects|patf|||adverse health effects|||0|901|167|189
SE|25462316||ab|1|entity|C0020114|Human|humn|||humans|||0|1000|193|199

SE|25462316||ab|2|text|201|347|The importance and sensitivity of food chains to HRA have been observed, but the impact of the transportation of food has generally been ignored.
SE|25462316||ab|2|entity|C0596583|Food Chain|npop|||food chains|||0|1000|235|246
SE|25462316||ab|2|entity|C0679809|health risk assessment|topp|||HRA|||0|1000|250|253
SE|25462316||ab|2|entity|C0016452|Food|food|||food|||0|1000|314|318

SE|25462316||ab|3|text|347|478|This study developed an exposure assessment to demonstrate the significance of the transportation of agricultural products in HRA.
SE|25462316||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|352|357
SE|25462316||ab|3|entity|C0220825|Evaluation|ftcn|||assessment|||0|861|380|390
SE|25462316||ab|3|entity|C0750502|Significant|idcn|||significance|||0|928|410|422
SE|25462316||ab|3|entity|C0001829|Agriculture|ocdi|||agricultural|||0|836|448|460
SE|25462316||ab|3|entity|C1514468|product|qnco|||products|||0|836|461|469
SE|25462316||ab|3|entity|C0679809|health risk assessment|topp|||HRA|||0|1000|473|476

SE|25462316||ab|4|text|478|592|The associated case study estimated the health risks derived from various sources of arsenic emissions in Taiwan.
SE|25462316||ab|4|entity|C0085973|Case Study|inpr|||case study|||0|901|493|503
SE|25462316||ab|4|entity|C0018684|Health|idcn|||health|||0|1000|518|524
SE|25462316||ab|4|entity|C0003818|Arsenic|elii,hops|||arsenic|||0|872|563|570
SE|25462316||ab|4|entity|C0233929|Emission|orgf|||emissions|||0|872|571|580
SE|25462316||ab|4|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|584|590

SE|25462316||ab|5|text|592|780|Two assessment scenarios, self-sufficiency and transportation of agricultural products, were compared to calculate risk transfer ratios that show the impact of agriculture transportation.
SE|25462316||ab|5|entity|C0205448|Two|qnco|||Two|||0|840|592|595
SE|25462316||ab|5|entity|C0220825|Evaluation|ftcn|||assessment|||0|840|596|606
SE|25462316||ab|5|entity|C0683579|scenario|ftcn|||scenarios|||0|840|607|616
SE|25462316||ab|5|entity|C0680212|self-sufficiency|inbe|||self-sufficiency|||0|1000|618|634
SE|25462316||ab|5|entity|C0001829|Agriculture|ocdi|||agricultural|||0|836|657|669
SE|25462316||ab|5|entity|C1514468|product|qnco|||products|||0|836|670|678
SE|25462316||ab|5|entity|C0348011|Transfer procedure|ftcn|||transfer|||0|901|712|720
SE|25462316||ab|5|entity|C0028873|Odds Ratio|qnco|||risk transfer ratios|||0|901|707|727
SE|25462316||ab|5|entity|C0001829|Agriculture|ocdi|||agriculture|||0|694|752|763

SE|25462316||ab|6|text|780|946|The risk transfer ratios found by the study range from 0.22 to 42.10, indicating that the quantity of transportation of agricultural products is the critical factor.
SE|25462316||ab|6|entity|C0348011|Transfer procedure|ftcn|||transfer|||0|901|789|797
SE|25462316||ab|6|entity|C0028873|Odds Ratio|qnco|||risk transfer ratios|||0|901|784|804
SE|25462316||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|888|818|823
SE|25462316||ab|6|entity|C1514721|Range|qnco|||range|||0|888|824|829
SE|25462316||ab|6|entity|C1265611|Quantity|qnco|||quantity|||0|1000|870|878
SE|25462316||ab|6|entity|C0001829|Agriculture|ocdi|||agricultural|||0|836|900|912
SE|25462316||ab|6|entity|C1514468|product|qnco|||products|||0|836|913|921
SE|25462316||ab|6|entity|C1511545|Critical|qlco|||critical|||0|888|929|937
SE|25462316||ab|6|entity|C1521761|Factor|ftcn|||factor|||0|888|938|944

SE|25462316||ab|7|text|946|1098|High air deposition and high agricultural production are the two main contributors to the effect of the transportation of agricultural products on HRA.
SE|25462316||ab|7|entity|C0205250|High|qlco|||High|||0|851|946|950
SE|25462316||ab|7|entity|C0001861|Air|sbst|||air|||0|851|951|954
SE|25462316||ab|7|entity|C0333562|Deposition|ftcn|||deposition|||0|851|955|965
SE|25462316||ab|7|entity|C0205250|High|qlco|||high|||0|828|970|974
SE|25462316||ab|7|entity|C0001829|Agriculture|ocdi|||agricultural|||0|828|975|987
SE|25462316||ab|7|entity|C0033268|production|ocac|||production|||0|828|988|998
SE|25462316||ab|7|entity|C0205448|Two|qnco|||two|||0|623|1007|1010
SE|25462316||ab|7|entity|C0205225|Primary|qlco|||main|||0|623|1011|1015
SE|25462316||ab|7|entity|C1280500|Effect|qlco|||effect|||0|1000|1036|1042
SE|25462316||ab|7|entity|C0001829|Agriculture|ocdi|||agricultural|||0|836|1068|1080
SE|25462316||ab|7|entity|C1514468|product|qnco|||products|||0|836|1081|1089
SE|25462316||ab|7|entity|C0679809|health risk assessment|topp|||HRA|||0|1000|1093|1096

SE|25462316||ab|8|text|1098|1259|Risk reduction measures could be applied to high-pollution areas as well as to areas with high agricultural productivity to reduce ingestion risks to residents.
SE|25462316||ab|8|entity|C1137094|Risk Reduction|topp|||Risk reduction|||0|901|1098|1112
SE|25462316||ab|8|entity|C0079809|Measures|qnco|||measures|||0|901|1113|1121
SE|25462316||ab|8|entity|C0205250|High|qlco|||high|||0|851|1142|1146
SE|25462316||ab|8|entity|C0392355|Pollution|eehu|||pollution|||0|851|1147|1156
SE|25462316||ab|8|entity|C0205250|High|qlco|||high|||0|828|1188|1192
SE|25462316||ab|8|entity|C0001829|Agriculture|ocdi|||agricultural|||0|828|1193|1205
SE|25462316||ab|8|entity|C0033269|Productivity|qnco|||productivity|||0|828|1206|1218
SE|25462316||ab|8|entity|C0232478|Ingestion|biof|||ingestion|||0|1000|1229|1238
SE|25462316||ab|8|entity|C1549439|Resident|inpr|||residents|||0|966|1248|1257

SE|25462316||ab|9|text|1259|1420|Certain areas that are sensitive to the transportation of agricultural products may incur more risks if emissions increase in agriculturally productive counties.
SE|25462316||ab|9|entity|C0332324|Sensitive|ftcn|||sensitive|||0|1000|1282|1291
SE|25462316||ab|9|entity|C0001829|Agriculture|ocdi|||agricultural|||0|836|1317|1329
SE|25462316||ab|9|entity|C1514468|product|qnco|||products|||0|836|1330|1338
SE|25462316||ab|9|entity|C0205172|More|ftcn|||more|||0|1000|1349|1353
SE|25462316||ab|9|entity|C0233929|Emission|orgf|||emissions|||0|966|1363|1372
SE|25462316||ab|9|entity|C0033269|Productivity|qnco|||productive|||0|754|1400|1410
SE|25462316||ab|9|entity|C0079170|Counties|geoa|||counties|||0|754|1411|1419


SE|25462317||ti|1|text|21|154|Acute toxicity and risk assessment of permethrin, naled, and dichlorvos to larval butterflies via ingestion of contaminated foliage.
SE|25462317||ti|1|entity|C0205178|acute|tmco|||Acute|||0|888|21|26
SE|25462317||ti|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|27|35
SE|25462317||ti|1|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|1000|40|55
SE|25462317||ti|1|entity|C0070455|Permethrin|hops,orch,phsu|||permethrin|||0|1000|59|69
SE|25462317||ti|1|entity|C0027350|Naled|hops,opco|||naled|||0|1000|71|76
SE|25462317||ti|1|entity|C0012087|Dichlorvos|hops,opco|||dichlorvos|||0|1000|82|92
SE|25462317||ti|1|entity|C0023047|Larva|invt|||larval|||0|751|96|102
SE|25462317||ti|1|entity|C0006496|Butterflies|invt|||butterflies|||0|751|103|114
SE|25462317||ti|1|entity|C0232478|Ingestion|biof|||ingestion|||0|751|119|128
SE|25462317||ti|1|entity|C0205279|Contaminated|ftcn|||contaminated|||0|694|132|144

SE|25462317||ab|1|text|160|501|Three Florida native larval butterflies (Junonia coenia, Anartia jatrophae, Eumaeus atala) were used in the present study to determine the acute toxicity, hazard, and risk of a 24h ingestion of leaves contaminated with the adult mosquito control insecticides permethrin, naled, and dichlorvos to late 4th and early 5th in-star caterpillars.
SE|25462317||ab|1|entity|C0205449|Three|qnco|||Three|||0|807|160|165
SE|25462317||ab|1|entity|C0016253|Florida|geoa|||Florida|||0|807|166|173
SE|25462317||ab|1|entity|C0302891|Native|ftcn|||native|||0|807|174|180
SE|25462317||ab|1|entity|C0023047|Larva|invt|||larval|||0|807|181|187
SE|25462317||ab|1|entity|C0006496|Butterflies|invt|||butterflies|||0|807|188|199
SE|25462317||ab|1|entity|C1095811|Junonia coenia|invt|||Junonia coenia|||0|1000|201|215
SE|25462317||ab|1|entity|C1078790|Anartia jatrophae|invt|||Anartia jatrophae|||0|1000|217|234
SE|25462317||ab|1|entity|C0150312|Present|qnco|||present|||0|888|268|275
SE|25462317||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|276|281
SE|25462317||ab|1|entity|C0205178|acute|tmco|||acute|||0|888|299|304
SE|25462317||ab|1|entity|C0600688|Toxic effect|inpo|||toxicity|||0|888|305|313
SE|25462317||ab|1|entity|C0598697|hazard|qlco|||hazard|||0|1000|315|321
SE|25462317||ab|1|entity|C0035647|Risk|qlco|||risk|||0|1000|327|331
SE|25462317||ab|1|entity|C0456696|/24h|tmco|||24h|||0|888|337|340
SE|25462317||ab|1|entity|C0232478|Ingestion|biof|||ingestion|||0|888|341|350
SE|25462317||ab|1|entity|C0001675|Adult|aggp|||adult|||0|840|383|388
SE|25462317||ab|1|entity|C0026581|Mosquito Control|ocac|||mosquito control|||0|840|389|405
SE|25462317||ab|1|entity|C0021576|Insecticides|hops|||insecticides|||0|840|406|418
SE|25462317||ab|1|entity|C0070455|Permethrin|hops,orch,phsu|||permethrin|||0|840|419|429
SE|25462317||ab|1|entity|C0027350|Naled|hops,opco|||naled|||0|1000|431|436
SE|25462317||ab|1|entity|C0012087|Dichlorvos|hops,opco|||dichlorvos|||0|1000|442|452
SE|25462317||ab|1|entity|C0205087|Late|tmco|||late|||0|888|456|460
SE|25462317||ab|1|entity|C0205438|Fourth|qnco|||4th|||0|888|461|464
SE|25462317||ab|1|entity|C1279919|Early|tmco|||early|||0|888|469|474
SE|25462317||ab|1|entity|C0205439|Fifth|qnco|||5th|||0|888|475|478
SE|25462317||ab|1|entity|C0995242|Stella|bact|||star|||0|844|482|486
SE|25462317||ab|1|entity|C0322496|Caterpillar|invt|||caterpillars|||0|844|487|499
SE|25462317||ab|1|relation|0|0|C0070455|Permethrin|hops,orch,phsu|hops|||permethrin|||0|840|419|429|MOD/HEAD|ISA||406|429|0|0|C0021576|Insecticides|hops|hops|||insecticides|||0|840|406|418
SE|25462317||ab|1|relation|0|0|C1095811|Junonia coenia|invt|invt|||Junonia coenia|||0|1000|201|215|SPEC|ISA||188|215|0|0|C0006496|Butterflies|invt|invt|||butterflies|||0|807|188|199

SE|25462317||ab|2|text|501|613|Based on 24-h LD50s for ingestion, naled was more acutely toxic than permethrin and dichlorvos to caterpillars.
SE|25462317||ab|2|entity|C0456696|/24h|tmco|||24-h|||0|734|510|514
SE|25462317||ab|2|entity|C0232478|Ingestion|biof|||ingestion|||0|1000|525|534
SE|25462317||ab|2|entity|C0027350|Naled|hops,opco|||naled|||0|1000|536|541
SE|25462317||ab|2|entity|C0205172|More|ftcn|||more|||0|802|546|550
SE|25462317||ab|2|entity|C1407029|Toxic|qlco|||toxic|||0|802|559|564
SE|25462317||ab|2|entity|C0070455|Permethrin|hops,orch,phsu|||permethrin|||0|1000|570|580
SE|25462317||ab|2|entity|C0012087|Dichlorvos|hops,opco|||dichlorvos|||0|1000|585|595
SE|25462317||ab|2|entity|C0322496|Caterpillar|invt|||caterpillars|||0|966|599|611
SE|25462317||ab|2|entity||<<toxicity>>||||toxic|||||559|564
SE|25462317||ab|2|relation|4|2|C0027350|Naled|hops,opco|hops|||naled|||0|1000|536|541|PREP|compared_with||565|569|3|1|C0070455|Permethrin|hops,orch,phsu|hops|||permethrin|||0|1000|570|580
SE|25462317||ab|2|relation|4|2|C0027350|Naled|hops,opco|hops|||naled|||0|1000|536|541|PREP|higher_than||565|569|3|1|C0070455|Permethrin|hops,orch,phsu|hops|||permethrin|||0|1000|570|580

SE|25462317||ab|3|text|613|939|Hazard quotients using the ratio of the highest doses and the 90th percentile doses from field measurements in host plant foliage following actual mosquito control applications to the toxicological benchmarks from laboratory toxicity tests indicate potential high acute hazard for naled compared to permethrin and dichlorvos.
SE|25462317||ab|3|entity|C0598697|hazard|qlco|||Hazard|||0|694|613|619
SE|25462317||ab|3|entity|C0456603|Ratio|inpr|||ratio|||0|1000|640|645
SE|25462317||ab|3|entity|C0444956|High dose|qnco|||highest doses|||0|966|653|666
SE|25462317||ab|3|entity|C1264641|Percentile|qnco|||percentile|||0|790|680|690
SE|25462317||ab|3|entity|C1446466|Dose|qnco|||doses|||0|790|691|696
SE|25462317||ab|3|entity|C1521738|Field|cnce|||field|||0|888|702|707
SE|25462317||ab|3|entity|C0242485|Measurement|ftcn|||measurements|||0|888|708|720
SE|25462317||ab|3|entity|C0868970|Host plants|plnt|||host plant|||0|717|724|734
SE|25462317||ab|3|entity|C0237400|Actual|qlco|||actual|||0|852|753|759
SE|25462317||ab|3|entity|C0026581|Mosquito Control|ocac|||mosquito control|||0|852|760|776
SE|25462317||ab|3|entity|C0205472|Toxicologic|ftcn|||toxicological|||0|694|797|810
SE|25462317||ab|3|entity|C0600688|Toxic effect|inpo|||toxicity|||0|901|838|846
SE|25462317||ab|3|entity|C0022885|Laboratory Procedures|lbpr|||laboratory toxicity tests|||0|901|827|852
SE|25462317||ab|3|entity|C0237399|Potential|qlco|||potential|||0|833|862|871
SE|25462317||ab|3|entity|C0205250|High|qlco|||high|||0|833|872|876
SE|25462317||ab|3|entity|C0205178|acute|tmco|||acute|||0|833|877|882
SE|25462317||ab|3|entity|C0598697|hazard|qlco|||hazard|||0|833|883|889
SE|25462317||ab|3|entity|C0027350|Naled|hops,opco|||naled|||0|1000|894|899
SE|25462317||ab|3|entity|C0070455|Permethrin|hops,orch,phsu|||permethrin|||0|1000|912|922
SE|25462317||ab|3|entity|C0012087|Dichlorvos|hops,opco|||dichlorvos|||0|1000|927|937
SE|25462317||ab|3|relation|11|1|C0027350|Naled|hops,opco|hops|||naled|||0|1000|894|899|VERB|compared_with||900|908|2|1|C0070455|Permethrin|hops,orch,phsu|hops|||permethrin|||0|1000|912|922

SE|25462317||ab|4|text|939|1110|Based on probabilistic ecological risk methods, naled exposure doses in the environment also presented a higher acute risk to caterpillars than permethrin and dichlorvos.
SE|25462317||ab|4|entity|C0013546|Ecology|ocdi|||ecological|||0|751|962|972
SE|25462317||ab|4|entity|C0035647|Risk|qlco|||risk|||0|751|973|977
SE|25462317||ab|4|entity|C0025663|Methods|inpr|||methods|||0|751|978|985
SE|25462317||ab|4|entity|C0027350|Naled|hops,opco|||naled|||0|802|987|992
SE|25462317||ab|4|entity|C1446466|Dose|qnco|||doses|||0|802|1002|1007
SE|25462317||ab|4|entity|C0014406|Environment|spco|||environment|||0|1000|1015|1026
SE|25462317||ab|4|entity|C0205250|High|qlco|||higher|||0|840|1044|1050
SE|25462317||ab|4|entity|C0205178|acute|tmco|||acute|||0|840|1051|1056
SE|25462317||ab|4|entity|C0035647|Risk|qlco|||risk|||0|840|1057|1061
SE|25462317||ab|4|entity|C0322496|Caterpillar|invt|||caterpillars|||0|966|1065|1077
SE|25462317||ab|4|entity|C0070455|Permethrin|hops,orch,phsu|||permethrin|||0|1000|1083|1093
SE|25462317||ab|4|entity|C0012087|Dichlorvos|hops,opco|||dichlorvos|||0|1000|1098|1108

SE|25462317||ab|5|text|1110|1242|The acute toxicity laboratory results and ecological risk assessment are based only on dietary ingestion and single chemical doses.
SE|25462317||ab|5|entity|C0205178|acute|tmco|||acute|||0|825|1114|1119
SE|25462317||ab|5|entity|C0600688|Toxic effect|inpo|||toxicity|||0|825|1120|1128
SE|25462317||ab|5|entity|C0022877|Laboratory|mnob,orgt|||laboratory|||0|825|1129|1139
SE|25462317||ab|5|entity|C1274040|result|ftcn|||results|||0|825|1140|1147
SE|25462317||ab|5|entity|C0013546|Ecology|ocdi|||ecological|||0|877|1152|1162
SE|25462317||ab|5|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|877|1163|1178
SE|25462317||ab|5|entity|C0232478|Ingestion|biof|||ingestion|||0|861|1205|1214
SE|25462317||ab|5|entity|C0037179|Unmarried person|popg|||single|||0|851|1219|1225
SE|25462317||ab|5|entity|C0220806|Chemicals|chem|||chemical|||0|851|1226|1234
SE|25462317||ab|5|entity|C1446466|Dose|qnco|||doses|||0|851|1235|1240

SE|25462317||ab|6|text|1242|1330|It does not include other typical exposure scenarios that may occur in the environment.
SE|25462317||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1250|1253
SE|25462317||ab|6|entity|C0683579|scenario|ftcn|||scenarios|||0|793|1285|1294
SE|25462317||ab|6|entity|C0014406|Environment|spco|||environment|||0|1000|1317|1328

SE|25462317||ab|7|text|1330|1476|It is thus plausible to state that the ecological risk assessment presented here underestimates the potential risks in the field to caterpillars.
SE|25462317||ab|7|entity|C0013546|Ecology|ocdi|||ecological|||0|877|1369|1379
SE|25462317||ab|7|entity|C0086930|Risk Assessment|hlca|||risk assessment|||0|877|1380|1395
SE|25462317||ab|7|entity|C0237399|Potential|qlco|||potential|||0|1000|1430|1439
SE|25462317||ab|7|entity|C1521738|Field|cnce|||field|||0|1000|1453|1458
SE|25462317||ab|7|entity|C0322496|Caterpillar|invt|||caterpillars|||0|966|1462|1474

SE|25462317||ab|8|text|1476|1827|However, one assumption that is scientifically feasible and certainly real from the results - if the environmental exposure doses of mosquito control operations are similar or higher to those presented here in leaves from the field, after applications, there will likely be significant mortalities and other adverse effects on caterpillar populations.
SE|25462317||ab|8|entity|C0205447|One|qnco|||one|||0|694|1485|1488
SE|25462317||ab|8|entity|C0871222|Reality|idcn|||real|||0|789|1546|1550
SE|25462317||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1560|1567
SE|25462317||ab|8|entity|C0014412|Environmental Exposure|inpo|||environmental exposure|||0|901|1577|1599
SE|25462317||ab|8|entity|C1446466|Dose|qnco|||doses|||0|901|1600|1605
SE|25462317||ab|8|entity|C0026581|Mosquito Control|ocac|||mosquito control|||0|901|1609|1625
SE|25462317||ab|8|entity|C0038895|Surgical aspects|ftcn|||operations|||0|901|1626|1636
SE|25462317||ab|8|entity|C0205250|High|qlco|||higher|||0|966|1652|1658
SE|25462317||ab|8|entity|C0150312|Present|qnco|||presented|||0|827|1668|1677
SE|25462317||ab|8|entity|C1521738|Field|cnce|||field|||0|1000|1702|1707
SE|25462317||ab|8|entity|C0750502|Significant|idcn|||significant|||0|888|1750|1761
SE|25462317||ab|8|entity|C0026565|Mortality Vital Statistics|qnco|||mortalities|||0|888|1762|1773
SE|25462317||ab|8|entity|C0879626|Adverse effects|patf|||adverse effects|||0|1000|1784|1799
SE|25462317||ab|8|entity|C0322496|Caterpillar|invt|||caterpillar|||0|888|1803|1814
SE|25462317||ab|8|entity|C0032659|geographic population|qnco|||populations|||0|888|1815|1826


SE|25462318||ti|1|text|21|160|Acute nitrogen dioxide (NO2) exposure enhances airway inflammation via modulating Th1/Th2 differentiation and activating JAK-STAT pathway.
SE|25462318||ti|1|entity|C0205178|acute|tmco|||Acute|||0|901|21|26
SE|25462318||ti|1|entity|C0028160|Nitrogen Dioxide|hops,inch|||nitrogen dioxide|||0|901|27|43
SE|25462318||ti|1|entity|C0021368|Inflammation|patf|||inflammation|||0|535|75|87
SE|25462318||ti|1|entity|C0443264|Modulated|spco|||modulating|||0|535|92|102
SE|25462318||ti|1|entity|||gngm|51497|NELFCD|Th1|||0|535|103|106
SE|25462318||ti|1|entity|C1515877|Activate|ftcn|||activating|||0|775|131|141
SE|25462318||ti|1|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|775|151|158

SE|25462318||ab|1|text|166|326|Nitrogen dioxide (NO2) is an air pollutant associated with poor respiratory health, asthma exacerbation, and an increased likelihood of inhalational allergies.
SE|25462318||ab|1|entity|C0028160|Nitrogen Dioxide|hops,inch|||Nitrogen dioxide|||0|1000|166|182
SE|25462318||ab|1|entity|C0001869|Air Pollutants|hops|||air pollutant|||0|983|195|208
SE|25462318||ab|1|entity|C0521346|respiratory|ftcn|||respiratory|||0|901|230|241
SE|25462318||ab|1|entity|C0683321|poor health|fndg|||poor respiratory health|||0|901|225|248
SE|25462318||ab|1|entity|C0004096|Asthma|dsyn|||asthma|||0|694|250|256
SE|25462318||ab|1|entity|C0205217|Increased|qnco|||increased|||0|853|278|287
SE|25462318||ab|1|entity|C0004048|Inspiration function|ortf|||inhalational|||0|853|302|314
SE|25462318||ab|1|entity|C0020517|Hypersensitivity|patf|||allergies|||0|853|315|324
SE|25462318||ab|1|relation|0|0|C0028160|Nitrogen Dioxide|hops,inch|hops|||Nitrogen dioxide|||0|1000|166|182|INFER|AFFECTS(SPEC)||166|208|0|0|C0004096|Asthma|dsyn|dsyn|||asthma|||0|694|250|256
SE|25462318||ab|1|relation|0|0|C0028160|Nitrogen Dioxide|hops,inch|hops|||Nitrogen dioxide|||0|1000|166|182|SPEC|ISA||166|208|0|0|C0001869|Air Pollutants|hops|hops|||air pollutant|||0|983|195|208
SE|25462318||ab|1|relation|4|2|C0001869|Air Pollutants|hops|hops|||air pollutant|||0|983|195|208|NOM|AFFECTS||257|269|4|0|C0004096|Asthma|dsyn|dsyn|||asthma|||0|694|250|256

SE|25462318||ab|2|text|326|376|However, the underlying mechanisms are not clear.
SE|25462318||ab|2|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|861|350|360
SE|25462318||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|365|368

SE|25462318||ab|3|text|376|498|In the present study, the airway inflammatory response was first assessed in rats exposed to 5mg/m(3) NO2 for seven days.
SE|25462318||ab|3|entity|C0150312|Present|qnco|||present|||0|888|383|390
SE|25462318||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|391|396
SE|25462318||ab|3|entity|C1155266|Inflammatory Response|patf|||inflammatory response|||0|901|409|430
SE|25462318||ab|3|entity|C1279901|Firstly|qlco|||first|||0|1000|435|440
SE|25462318||ab|3|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|453|457
SE|25462318||ab|3|entity|C0205453|Seven|qnco|||seven|||0|888|486|491
SE|25462318||ab|3|entity|C0439228|day|tmco|||days|||0|888|492|496
SE|25462318||ab|3|relation|2|1|C1155266|Inflammatory Response|patf|patf|||inflammatory response|||0|901|409|430|PREP|PROCESS_OF||450|452|4|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|453|457

SE|25462318||ab|4|text|498|629|The results showed that NO2 exposure caused the pulmonary pathological alteration, and significantly stimulated MUC5AC expression.
SE|25462318||ab|4|entity|C1274040|result|ftcn|||results|||0|966|502|509
SE|25462318||ab|4|entity|C0748168|Pulmonary Pathology|dsyn|||pulmonary pathological|||0|877|546|568
SE|25462318||ab|4|entity|C1515926|Alteration|idcn|||alteration|||0|877|569|579
SE|25462318||ab|4|entity|||gngm|4586|MUC5AC|MUC5AC|||0|812|610|616

SE|25462318||ab|5|text|629|750|Following this, obviously up-regulated changes of pro-inflammatory cytokines (IL-1beta, IL-6, and ICAM-1) were observed.
SE|25462318||ab|5|entity|C0033382|Proline|aapp,bacs|||pro|||0|851|679|682
SE|25462318||ab|5|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|851|683|695
SE|25462318||ab|5|entity|C0079189|cytokine|aapp,imft|||cytokines|||0|851|696|705
SE|25462318||ab|5|entity|C0021753|Interleukin-1 beta|aapp,imft|||IL-1beta|||0|1000|707|715
SE|25462318||ab|5|entity|C0021760|Interleukin-6|aapp,imft|||IL-6|||0|1000|717|721
SE|25462318||ab|5|entity|C0063695|Intercellular adhesion molecule 1|aapp,imft|||ICAM-1|||0|1000|727|733

SE|25462318||ab|6|text|750|942|Also, NO2 inhalation induced the imbalance in the ratio of Th1/Th2 differentiation (IL-4, IFN-gamma, GATA-3 and T-bet) and the activation of following JAK-STAT pathway (JAK1, JAK3 and STAT6).
SE|25462318||ab|6|entity|C0004048|Inspiration function|ortf|||inhalation|||0|861|760|770
SE|25462318||ab|6|entity|C1397014|imbalance|sosy|||imbalance|||0|1000|783|792
SE|25462318||ab|6|entity|C0456603|Ratio|inpr|||ratio|||0|1000|800|805
SE|25462318||ab|6|entity|||gngm|51497|NELFCD|Th1|||0|1000|809|812
SE|25462318||ab|6|entity|C0021758|Interleukin-4|aapp,imft|||IL-4|||0|1000|834|838
SE|25462318||ab|6|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|IFN|||0|694|840|843
SE|25462318||ab|6|entity|||gngm|2625|GATA3|GATA-3|||0|1000|851|857
SE|25462318||ab|6|entity|C0332282|Following|tmco|||following|||0|791|891|900
SE|25462318||ab|6|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|791|910|917
SE|25462318||ab|6|entity|C0169658|Janus kinase 1|aapp,enzy|3716|JAK1|JAK1|||0|1000|919|923
SE|25462318||ab|6|entity|C0253457|Janus kinase 3|aapp,enzy|3718|JAK3|JAK3|||0|1000|925|929
SE|25462318||ab|6|entity|C1335877|STAT6 gene|gngm|6778|STAT6|STAT6|||0|1000|934|939

SE|25462318||ab|7|text|942|1091|The findings clarify an important mechanism for NO2 inhalation being injurious to the lung and augmenting the degree of allergic airway inflammation.
SE|25462318||ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|946|954
SE|25462318||ab|7|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|976|985
SE|25462318||ab|7|entity|C0004048|Inspiration function|ortf|||inhalation|||0|861|994|1004
SE|25462318||ab|7|entity|C0175677|Injury|inpo|||injurious|||0|928|1011|1020
SE|25462318||ab|7|entity|C0024109|Lung|bpoc|||lung|||0|1000|1028|1032
SE|25462318||ab|7|entity|C0205217|Increased|qnco|||augmenting|||0|966|1037|1047
SE|25462318||ab|7|entity|C0021375|Inflammation, allergic|patf|||allergic airway inflammation|||0|913|1062|1090


SE|25462319||ti|1|text|21|148|Hepatic positive and negative antioxidant responses in zebrafish after intraperitoneal administration of toxic microcystin-LR.
SE|25462319||ti|1|entity|C0205054|Hepatic|blor|||Hepatic|||0|888|21|28
SE|25462319||ti|1|entity|C1446409|Positive|qlco|||positive|||0|888|29|37
SE|25462319||ti|1|entity|C0205160|Negative|qlco|||negative|||0|851|42|50
SE|25462319||ti|1|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|851|51|62
SE|25462319||ti|1|entity|C0871261|response|clna|||responses|||0|851|63|72
SE|25462319||ti|1|entity|C0043457|Zebrafish|fish|||zebrafish|||0|1000|76|85
SE|25462319||ti|1|entity|C0021493|Injections, Intraperitoneal|topp|||intraperitoneal administration|||0|1000|92|122
SE|25462319||ti|1|entity|C1407029|Toxic|qlco|||toxic|||0|901|126|131
SE|25462319||ti|1|entity|C0056661|cyanoginosin LR|aapp,phsu|||microcystin-LR|||0|901|132|146

SE|25462319||ab|1|text|154|226|Microcystin-LR (MC-LR) is the most toxic and common among microcystins.
SE|25462319||ab|1|entity|C0056661|cyanoginosin LR|aapp,phsu|||Microcystin-LR|||0|1000|154|168
SE|25462319||ab|1|entity|C0205393|Most|qnco|||most|||0|888|184|188
SE|25462319||ab|1|entity|C1407029|Toxic|qlco|||toxic|||0|888|189|194
SE|25462319||ab|1|entity|C0205214|Common|qnco|||common|||0|1000|199|205
SE|25462319||ab|1|entity|C0211296|microcystin|aapp,phsu|||microcystins|||0|966|212|224

SE|25462319||ab|2|text|226|733|In order to understand the possible molecular mechanisms of hepatic antioxidation and detoxification, the activities and transcriptional levels of antioxidant enzymes including catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx) and glutathione S-transferases (GST), and glutathione (GSH) contents as well as histopathological changes were studied in the liver of female zebrafish injected intraperitoneally (i.p.) at doses of 50 and 200 MUg MC-LR kg(-1) body weight (BW) respectively.
SE|25462319||ab|2|entity|C0332149|Possible|qlco|||possible|||0|851|253|261
SE|25462319||ab|2|entity|C1521991|Molecular|qlco|||molecular|||0|851|262|271
SE|25462319||ab|2|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|851|272|282
SE|25462319||ab|2|entity|C0205054|Hepatic|blor|||hepatic|||0|853|286|293
SE|25462319||ab|2|entity|C0003402|Antioxidants|phsu|||antioxidation|||0|853|294|307
SE|25462319||ab|2|entity|C0025516|Metabolic Detoxication, Drug|orgf|||detoxification|||0|1000|312|326
SE|25462319||ab|2|entity|C0441655|Activities|acty|||activities|||0|1000|332|342
SE|25462319||ab|2|entity|C0040649|Transcription, Genetic|genf|||transcriptional|||0|853|347|362
SE|25462319||ab|2|entity|C0441889|Levels|inpr|||levels|||0|853|363|369
SE|25462319||ab|2|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|373|384
SE|25462319||ab|2|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|385|392
SE|25462319||ab|2|entity|C0007367|CATALASE|aapp,enzy|||catalase|||0|1000|403|411
SE|25462319||ab|2|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|1000|419|439
SE|25462319||ab|2|entity|C0017822|GLUTATHIONE PEROXIDASE|aapp,enzy|||glutathione peroxidase|||0|1000|447|469
SE|25462319||ab|2|entity|C0017837|Glutathione S-Transferase|aapp,enzy|||glutathione S-transferases|||0|1000|480|506
SE|25462319||ab|2|entity|C0017817|Glutathione|aapp,bacs|||glutathione|||0|1000|518|529
SE|25462319||ab|2|entity|C0456205|Contents|sbst|||contents|||0|1000|536|544
SE|25462319||ab|2|entity|C0243140|Histopathological aspects|ftcn|||histopathological|||0|836|556|573
SE|25462319||ab|2|entity|C0023884|Liver|bpoc|||liver|||0|1000|602|607
SE|25462319||ab|2|entity|C0015780|Female|orga|||female|||0|888|611|617
SE|25462319||ab|2|entity|C0043457|Zebrafish|fish|||zebrafish|||0|888|618|627
SE|25462319||ab|2|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|1000|658|659
SE|25462319||ab|2|entity|C1446466|Dose|qnco|||doses|||0|1000|665|670
SE|25462319||ab|2|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|762|689|694
SE|25462319||ab|2|entity|C0439209|Kilogram|qnco|||kg|||0|762|695|697
SE|25462319||ab|2|entity|C0005910|Body Weight|orga|||body weight|||0|901|702|713
SE|25462319||ab|2|relation|5|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|602|607|PREP|LOCATION_OF||595|597|15|4|C0007367|CATALASE|aapp,gngm,enzy|aapp|||catalase|||0|1000|403|411
SE|25462319||ab|2|relation|5|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|602|607|PREP|LOCATION_OF||595|597|15|4|C0017817|Glutathione|aapp,gngm,bacs|aapp|||glutathione|||0|1000|518|529
SE|25462319||ab|2|relation|5|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|602|607|PREP|LOCATION_OF||595|597|15|4|C0017822|GLUTATHIONE PEROXIDASE|aapp,gngm,enzy|aapp|||glutathione peroxidase|||0|1000|447|469
SE|25462319||ab|2|relation|5|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|602|607|PREP|LOCATION_OF||595|597|15|4|C0017837|Glutathione S-Transferase|aapp,gngm,enzy|aapp|||glutathione S-transferases|||0|1000|480|506
SE|25462319||ab|2|relation|5|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|602|607|PREP|LOCATION_OF||595|597|15|4|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||superoxide dismutase|||0|1000|419|439
SE|25462319||ab|2|relation|16|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|602|607|PREP|PART_OF||608|610|4|1|C0043457|Zebrafish|fish|fish|||zebrafish|||0|888|618|627

SE|25462319||ab|3|text|733|987|In the low dose group (50 MUg MC-LR kg(-1)), zebrafish displayed a little unease at the initial 1h post-injection (hpi), slight hepatic injury and quick recovery, and enhanced enzymatic activities and up-regulated gene expression of antioxidant enzymes.
SE|25462319||ab|3|entity|C0445550|Low dose|qnco|||low dose|||0|901|740|748
SE|25462319||ab|3|entity|C0441833|Groups|inpr|||group|||0|901|749|754
SE|25462319||ab|3|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|762|763|768
SE|25462319||ab|3|entity|C0439209|Kilogram|qnco|||kg|||0|762|769|771
SE|25462319||ab|3|entity|C0043457|Zebrafish|fish|||zebrafish|||0|1000|778|787
SE|25462319||ab|3|entity|C0023882|Little's Disease|dsyn|||little|||0|853|800|806
SE|25462319||ab|3|entity|C0424142|Ill-at-ease|fndg|||unease|||0|853|807|813
SE|25462319||ab|3|entity|C0205265|Initially|tmco|||initial|||0|888|821|828
SE|25462319||ab|3|entity|C1533685|Injection procedure|topp|||injection|||0|888|837|846
SE|25462319||ab|3|entity|C0262512|History of present illness|orga|||hpi|||0|1000|848|851
SE|25462319||ab|3|entity|C0547040|Minimal|qlco|||slight|||0|901|854|860
SE|25462319||ab|3|entity|C0160390|Injury to liver, NOS|inpo|||hepatic injury|||0|901|861|875
SE|25462319||ab|3|entity|C0439831|Rapid|qlco|||quick|||0|888|880|885
SE|25462319||ab|3|entity|C0237820|Recovery|orgf|||recovery|||0|888|886|894
SE|25462319||ab|3|entity|C0243102|enzyme activity|moft|||enzymatic activities|||0|848|909|929
SE|25462319||ab|3|entity|C0017262|Gene Expression|genf|||gene expression|||0|1000|947|962
SE|25462319||ab|3|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|966|977
SE|25462319||ab|3|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|978|985

SE|25462319||ab|4|text|987|1205|In contrast, high dose of MC-LR (200 MUg MC-LR kg(-1)) resulted in uneasiness and frantic swimming, severe hepatic injury, and suppressed enzymatic activities and down-regulated gene expression of antioxidant enzymes.
SE|25462319||ab|4|entity|C0444956|High dose|qnco|||high dose|||0|1000|1000|1009
SE|25462319||ab|4|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|1000|1013|1018
SE|25462319||ab|4|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|762|1028|1033
SE|25462319||ab|4|entity|C0439209|Kilogram|qnco|||kg|||0|762|1034|1036
SE|25462319||ab|4|entity|C0039003|Swimming|dora|||swimming|||0|861|1077|1085
SE|25462319||ab|4|entity|C0205082|Severe|qlco|||severe|||0|901|1087|1093
SE|25462319||ab|4|entity|C0160390|Injury to liver, NOS|inpo|||hepatic injury|||0|901|1094|1108
SE|25462319||ab|4|entity|C1260953|Suppressed|ftcn|||suppressed|||0|866|1114|1124
SE|25462319||ab|4|entity|C0243102|enzyme activity|moft|||enzymatic activities|||0|866|1125|1145
SE|25462319||ab|4|entity|C0017262|Gene Expression|genf|||gene expression|||0|1000|1165|1180
SE|25462319||ab|4|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|1184|1195
SE|25462319||ab|4|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|1196|1203
SE|25462319||ab|4|relation|7|2|C0160390|Injury to liver, NOS|inpo|inpo|||hepatic injury|||0|901|1094|1108|COMPLEX|DISRUPTS||1150|1164|2|1|C0017262|Gene Expression|genf|genf|||gene expression|||0|1000|1165|1180

SE|25462319||ab|5|text|1205|1428|GSH depletion in both dose groups may be explained by enhanced antioxidant reactions and higher rates of MC conjugation, suggesting the crucial roles of GSH in both cellular antioxidant protection and MC-LR detoxification.
SE|25462319||ab|5|entity|C0333668|Depletion|ftcn|||depletion|||0|861|1209|1218
SE|25462319||ab|5|entity|C1446466|Dose|qnco|||dose|||0|888|1227|1231
SE|25462319||ab|5|entity|C0441833|Groups|inpr|||groups|||0|888|1232|1238
SE|25462319||ab|5|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|773|1268|1279
SE|25462319||ab|5|entity|C0443286|Reaction|ftcn|||reactions|||0|773|1280|1289
SE|25462319||ab|5|entity|C0205250|High|qlco|||higher|||0|855|1294|1300
SE|25462319||ab|5|entity|C1521828|Rate|qnco|||rates|||0|855|1301|1306
SE|25462319||ab|5|entity|C1160466|conjugation|celf|||conjugation|||0|888|1313|1324
SE|25462319||ab|5|entity|C0035820|Role|socb|||roles|||0|861|1349|1354
SE|25462319||ab|5|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|877|1379|1390
SE|25462319||ab|5|entity|C0524828|Cytoprotection|phsf|||cellular antioxidant protection|||0|877|1370|1401
SE|25462319||ab|5|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|901|1406|1411
SE|25462319||ab|5|entity|C0025516|Metabolic Detoxication, Drug|orgf|||detoxification|||0|901|1412|1426
SE|25462319||ab|5|relation|5|1|C1160466|conjugation|celf|celf|||conjugation|||0|888|1313|1324|NOM|AFFECTS||1349|1354|3|2|C0025516|Metabolic Detoxication, Drug|orgf|orgf|||detoxification|||0|901|1412|1426
SE|25462319||ab|5|relation|5|1|C1160466|conjugation|celf|celf|||conjugation|||0|888|1313|1324|NOM|AFFECTS||1349|1354|3|2|C0524828|Cytoprotection|phsf|phsf|||cellular antioxidant protection|||0|877|1370|1401

SE|25462319||ab|6|text|1428|1578|This study demonstrated that administration of MC-LR caused a positive response in the low dose group but a negative response in the high dose group.
SE|25462319||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1433|1438
SE|25462319||ab|6|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|1000|1475|1480
SE|25462319||ab|6|entity|C1446409|Positive|qlco|||positive|||0|888|1490|1498
SE|25462319||ab|6|entity|C0871261|response|clna|||response|||0|888|1499|1507
SE|25462319||ab|6|entity|C0445550|Low dose|qnco|||low dose|||0|901|1515|1523
SE|25462319||ab|6|entity|C0441833|Groups|inpr|||group|||0|901|1524|1529
SE|25462319||ab|6|entity|C0205160|Negative|qlco|||negative|||0|888|1536|1544
SE|25462319||ab|6|entity|C0871261|response|clna|||response|||0|888|1545|1553
SE|25462319||ab|6|entity|C0444956|High dose|qnco|||high dose|||0|901|1561|1570
SE|25462319||ab|6|entity|C0441833|Groups|inpr|||group|||0|901|1571|1576

SE|25462319||ab|7|text|1578|1753|Hepatic positive/negative responses in the low/high dose group might result from an increased/decreased synthesis of antioxidant enzymes at the molecular level, respectively.
SE|25462319||ab|7|entity|C0205054|Hepatic|blor|||Hepatic|||0|833|1578|1585
SE|25462319||ab|7|entity|C1446409|Positive|qlco|||positive|||0|833|1586|1594
SE|25462319||ab|7|entity|C0205160|Negative|qlco|||negative|||0|833|1595|1603
SE|25462319||ab|7|entity|C0871261|response|clna|||responses|||0|833|1604|1613
SE|25462319||ab|7|entity|C0205250|High|qlco|||high|||0|861|1625|1629
SE|25462319||ab|7|entity|C0445550|Low dose|qnco|||low/high dose|||0|861|1621|1634
SE|25462319||ab|7|entity|C0441833|Groups|inpr|||group|||0|861|1635|1640
SE|25462319||ab|7|entity|C0205217|Increased|qnco|||increased|||0|851|1662|1671
SE|25462319||ab|7|entity|C0205216|Decreased|qnco|||decreased|||0|851|1672|1681
SE|25462319||ab|7|entity|C0869032|Synthesis|phpr|||synthesis|||0|851|1682|1691
SE|25462319||ab|7|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|1695|1706
SE|25462319||ab|7|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|888|1707|1714
SE|25462319||ab|7|entity|C1521991|Molecular|qlco|||molecular|||0|694|1722|1731

SE|25462319||ab|8|text|1753|1959|These results illustrated that antioxidant status played an important role in zebrafish protection against MC-LR-caused oxidative stress through regulating antioxidant enzyme gene expression and activities.
SE|25462319||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1759|1766
SE|25462319||ab|8|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|1784|1795
SE|25462319||ab|8|entity|C0449438|Status|qlco|||status|||0|888|1796|1802
SE|25462319||ab|8|entity|C0035820|Role|socb|||role|||0|861|1823|1827
SE|25462319||ab|8|entity|C0043457|Zebrafish|fish|||zebrafish|||0|888|1831|1840
SE|25462319||ab|8|entity|C0056661|cyanoginosin LR|aapp,phsu|||MC-LR|||0|851|1860|1865
SE|25462319||ab|8|entity|C0015127|Etiology aspects|ftcn|||caused|||0|851|1866|1872
SE|25462319||ab|8|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|851|1873|1889
SE|25462319||ab|8|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|861|1909|1920
SE|25462319||ab|8|entity|C1333402|Enzyme Gene|gngm|||enzyme gene|||0|861|1921|1932
SE|25462319||ab|8|entity|C0441655|Activities|acty|||activities|||0|1000|1948|1958
SE|25462319||ab|8|relation|3|2|C0003402|Antioxidants|phsu|phsu|||antioxidant|||0|888|1784|1795|NOM|PREVENTS||1841|1851|3|1|C0242606|Oxidative Stress|comd|comd|||oxidative stress|||0|851|1873|1889


SE|25462320||ti|1|text|21|191|[Unexpectedly high proportion of preschool children immune to hepatitis A virus. Contact tracing investigation shows the need for vaccination prior to traveling abroad].
SE|25462320||ti|1|entity|C0205250|High|qlco|||high|||0|754|35|39
SE|25462320||ti|1|entity|C0205351|Proportional|qlco|||proportion|||0|754|40|50
SE|25462320||ti|1|entity|C0008100|Child, Preschool|aggp|||preschool children|||0|1000|54|72
SE|25462320||ti|1|entity|C0439662|Immune|ftcn|||immune|||0|1000|73|79
SE|25462320||ti|1|entity|C0376325|Hepatitis A Virus|virs|||hepatitis A virus|||0|1000|83|100
SE|25462320||ti|1|entity|C0027552|Needs|qlco|||need|||0|1000|142|146
SE|25462320||ti|1|entity|C0042196|Vaccination|topp|||vaccination|||0|1000|151|162
SE|25462320||ti|1|entity|C0040802|travel|dora|||traveling|||0|861|172|181

SE|25462320||ab|1|text|197|391|Hepatitis A (HAV) is a low incidence infectious disease in Sweden, and a majority of cases in this country are acquired abroad, although domestic cases are not uncommon in the day care setting.
SE|25462320||ab|1|entity|C0019159|Hepatitis A|dsyn|||Hepatitis A|||0|1000|197|208
SE|25462320||ab|1|entity|C0201472|Hepatitis A virus measurement|lbpr|||HAV|||0|1000|210|213
SE|25462320||ab|1|entity|C0205251|low|qlco|||low|||0|861|220|223
SE|25462320||ab|1|entity|C0021149|Incidence|qnco|||incidence|||0|861|224|233
SE|25462320||ab|1|entity|C0009450|Communicable Diseases|dsyn|||infectious disease|||0|861|234|252
SE|25462320||ab|1|entity|C0038995|Sweden|geoa|||Sweden|||0|1000|256|262
SE|25462320||ab|1|entity|C0680220|majority|socb|||majority|||0|1000|270|278
SE|25462320||ab|1|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|282|287
SE|25462320||ab|1|entity|C0454664|Country|geoa|||country|||0|1000|296|303
SE|25462320||ab|1|entity|C0442519|Home environment|mnob|||domestic|||0|888|334|342
SE|25462320||ab|1|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|343|348
SE|25462320||ab|1|entity|C1518422|Not|ftcn|||not|||0|888|353|356
SE|25462320||ab|1|entity|C0522498|Rare|qlco|||uncommon|||0|888|357|365
SE|25462320||ab|1|entity|C0011017|Day Care|hlca|||day care|||0|901|373|381
SE|25462320||ab|1|entity|C0542559|contextual factors|ftcn|||setting|||0|901|382|389

SE|25462320||ab|2|text|391|561|We investigated an outbreak of hepatitis A in two day care centres and found that a large proportion (23%) of the 113 unvaccinated preschool children were immune to HAV.
SE|25462320||ab|2|entity|C0012652|Disease Outbreaks|phpr|||outbreak|||0|1000|410|418
SE|25462320||ab|2|entity|C0019159|Hepatitis A|dsyn|||hepatitis A|||0|1000|422|433
SE|25462320||ab|2|entity|C0205448|Two|qnco|||two|||0|916|437|440
SE|25462320||ab|2|entity|C0175952|Day care center (for any age)|mnob,orgt|||day care centres|||0|916|441|457
SE|25462320||ab|2|entity|C0549177|Large|qnco|||large|||0|853|475|480
SE|25462320||ab|2|entity|C0205351|Proportional|qlco|||proportion|||0|853|481|491
SE|25462320||ab|2|entity|C0008100|Child, Preschool|aggp|||preschool children|||0|861|522|540
SE|25462320||ab|2|entity|C0439662|Immune|ftcn|||immune|||0|1000|546|552
SE|25462320||ab|2|entity|C0201472|Hepatitis A virus measurement|lbpr|||HAV|||0|1000|556|559

SE|25462320||ab|3|text|561|659|This observation indicates that there may have been sub-clinical cases of HAV at the two centres.
SE|25462320||ab|3|entity|C0542339|Inferior|spco|||sub|||0|851|613|616
SE|25462320||ab|3|entity|C0205210|Clinical|qlco|||clinical|||0|851|617|625
SE|25462320||ab|3|entity|C0868928|Case (situation)|ftcn|||cases|||0|851|626|631
SE|25462320||ab|3|entity|C0201472|Hepatitis A virus measurement|lbpr|||HAV|||0|1000|635|638
SE|25462320||ab|3|entity|C0205448|Two|qnco|||two|||0|872|646|649
SE|25462320||ab|3|entity|C0205099|Central|spco|||centres|||0|872|650|657

SE|25462320||ab|4|text|659|806|The results of our study underscore the importance of HAV vaccination in preschool children prior to travel to areas where this disease is common.
SE|25462320||ab|4|entity|C1274040|result|ftcn|||results|||0|966|663|670
SE|25462320||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|678|683
SE|25462320||ab|4|entity|C0201472|Hepatitis A virus measurement|lbpr|||HAV|||0|888|713|716
SE|25462320||ab|4|entity|C0042196|Vaccination|topp|||vaccination|||0|888|717|728
SE|25462320||ab|4|entity|C0008100|Child, Preschool|aggp|||preschool children|||0|1000|732|750
SE|25462320||ab|4|entity|C0040802|travel|dora|||travel|||0|1000|760|766
SE|25462320||ab|4|entity|C0012634|Disease|dsyn|||disease|||0|1000|787|794
SE|25462320||ab|4|entity|C0205214|Common|qnco|||common|||0|1000|798|804
SE|25462320||ab|4|relation|4|1|C0042196|Vaccination|topp|topp|||vaccination|||0|888|717|728|PREP|TREATS||729|731|5|1|C0008100|Child, Preschool|aggp,humn|aggp|||preschool children|||0|1000|732|750

SE|25462320||ab|5|text|806|943|The findings also highlight the need for up-to-date national seroepidemiological data on HAV immunity in different age groups in Sweden.
SE|25462320||ab|5|entity|C0243095|Finding|ftcn|||findings|||0|1000|810|818
SE|25462320||ab|5|entity|C0027552|Needs|qlco|||need|||0|1000|838|842
SE|25462320||ab|5|entity|C1511726|Data|idcn|||data|||0|728|887|891
SE|25462320||ab|5|entity|C0201472|Hepatitis A virus measurement|lbpr|||HAV|||0|888|895|898
SE|25462320||ab|5|entity|C0020964|Immunity|phsf|||immunity|||0|888|899|907
SE|25462320||ab|5|entity|C1547020|*Difference|qnco|||different|||0|877|911|920
SE|25462320||ab|5|entity|C0027362|Human Age Group|aggp|||age groups|||0|877|921|931
SE|25462320||ab|5|entity|C0038995|Sweden|geoa|||Sweden|||0|1000|935|941
SE|25462320||ab|5|relation|4|1|C0020964|Immunity|phsf|phsf|||immunity|||0|888|899|907|PREP|PROCESS_OF||908|910|2|1|C0027362|Human Age Group|aggp,humn|humn|||age groups|||0|877|921|931

SE|25462320||ab|6|text|943|1114|Studies aimed at obtaining such information could also provide a basis for deciding whether targeted vaccination strategies against HAV are needed in the day care setting.
SE|25462320||ab|6|entity|C0008972|Clinical Research|resa|||Studies|||0|966|943|950
SE|25462320||ab|6|entity|C1301820|Obtained|ftcn|||obtaining|||0|966|960|969
SE|25462320||ab|6|entity|C1533716|Information|idcn|||information|||0|1000|975|986
SE|25462320||ab|6|entity|C1527178|Basis|ftcn|||basis|||0|1000|1008|1013
SE|25462320||ab|6|entity|C0599894|targeting|celf|||targeted|||0|840|1035|1043
SE|25462320||ab|6|entity|C0042196|Vaccination|topp|||vaccination|||0|840|1044|1055
SE|25462320||ab|6|entity|C0201472|Hepatitis A virus measurement|lbpr|||HAV|||0|1000|1075|1078
SE|25462320||ab|6|entity|C0011017|Day Care|hlca|||day care|||0|901|1097|1105
SE|25462320||ab|6|entity|C0542559|contextual factors|ftcn|||setting|||0|901|1106|1113


[180]: *** ERROR *** ERROR *** ERROR ***
SE|25462324||ti|1|text|21|131|[Sexual counseling is important in cardiovascular disease. Returning to sexual activity is a common concern].
SE|25462324||ti|1|entity|C0036870|Sex Counseling|hlca|||Sexual counseling|||0|1000|22|39
SE|25462324||ti|1|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular disease|||0|1000|56|78
SE|25462324||ti|1|entity|C0036864|Sex Behavior|inbe|||sexual activity|||0|1000|93|108
SE|25462324||ti|1|entity|C0205214|Common|qnco|||common|||0|694|114|120
SE|25462324||ti|1|relation|2|2|C0036870|Sex Counseling|hlca|hlca|||Sexual counseling|||0|1000|22|39|PREP|TREATS||53|55|3|1|C0007222|Cardiovascular Diseases|dsyn|dsyn|||cardiovascular disease|||0|1000|56|78

SE|25462324||ab|1|text|137|210|Decreased sexual activity among cardiac patients is frequently reported.
SE|25462324||ab|1|entity|C0086439|Hypokinesia|sosy|||Decreased sexual activity|||0|913|137|162
SE|25462324||ab|1|entity|C0741926|CARDIAC PATIENT|podg|||cardiac patients|||0|983|169|185
SE|25462324||ab|1|entity|C0332183|Frequent|tmco|||frequently|||0|1000|189|199
SE|25462324||ab|1|relation|1|1|C0086439|Hypokinesia|sosy|sosy|||Decreased sexual activity|||0|913|137|162|PREP|PROCESS_OF||163|168|1|1|C0741926|CARDIAC PATIENT|podg,humn|humn|||cardiac patients|||0|983|169|185

SE|25462324||ab|2|text|210|399|Rates of erectile dysfunction among men with cardiovascular disease (CVD) are twice as high as those in the general population with similar rates of sexual dysfunction in females with CVD.
SE|25462324||ab|2|entity|C1521828|Rate|qnco|||Rates|||0|966|210|215
SE|25462324||ab|2|entity|C0242350|Erectile dysfunction|dsyn|||erectile dysfunction|||0|1000|219|239
SE|25462324||ab|2|entity|C0025266|Male population group|popg|||men|||0|1000|246|249
SE|25462324||ab|2|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular disease|||0|1000|255|277
SE|25462324||ab|2|entity|C0205250|High|qlco|||high|||0|1000|297|301
SE|25462324||ab|2|entity|C0683971|General Population|popg|||general population|||0|901|318|336
SE|25462324||ab|2|entity|C1521828|Rate|qnco|||rates|||0|836|350|355
SE|25462324||ab|2|entity|C0033953|Psychosexual Disorders|mobd|||sexual dysfunction|||0|1000|359|377
SE|25462324||ab|2|entity|C0015780|Female|orga|||females|||0|1000|381|388
SE|25462324||ab|2|entity|C0007222|Cardiovascular Diseases|dsyn|||CVD|||0|1000|394|397
SE|25462324||ab|2|relation|2|1|C0242350|Erectile dysfunction|dsyn|dsyn|||erectile dysfunction|||0|1000|219|239|PREP|PROCESS_OF||240|245|8|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|246|249
SE|25462324||ab|2|relation|7|1|C0007222|Cardiovascular Diseases|dsyn|dsyn|||cardiovascular disease|||0|1000|255|277|PREP|PROCESS_OF||250|254|3|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|246|249

SE|25462324||ab|3|text|399|527|Returning to sexual activity is a common concern, and patients frequently request information on how to resume sexual activity.
SE|25462324||ab|3|entity|C0036864|Sex Behavior|inbe|||sexual activity|||0|1000|412|427
SE|25462324||ab|3|entity|C0205214|Common|qnco|||common|||0|694|433|439
SE|25462324||ab|3|entity|C0332183|Frequent|tmco|||frequently|||0|852|462|472
SE|25462324||ab|3|entity|C1546490|Patient request|idcn|||patients frequently request|||0|852|453|480
SE|25462324||ab|3|entity|C1533716|Information|idcn|||information|||0|852|481|492
SE|25462324||ab|3|entity|C0036864|Sex Behavior|inbe|||sexual activity|||0|1000|510|525

SE|25462324||ab|4|text|527|679|Partners also have considerable concerns, often more so than patients; why sexual counseling is important for both cardiac patients and their partners.
SE|25462324||ab|4|entity|C0332183|Frequent|tmco|||often|||0|827|569|574
SE|25462324||ab|4|entity|C0030705|Patients|podg|||patients|||0|1000|588|596
SE|25462324||ab|4|entity|C0036870|Sex Counseling|hlca|||sexual counseling|||0|901|602|619
SE|25462324||ab|4|entity|C0741926|CARDIAC PATIENT|podg|||cardiac patients|||0|983|642|658

SE|25462324||ab|5|text|679|937|In general, healthcare professionals, in caring for patients recognize the importance of discussing sexual function and activity and also express their responsibility to do so, although many healthcare professionals do not know what specific advice to give.
SE|25462324||ab|5|entity|C0205246|Generalized|spco|||general|||0|890|682|689
SE|25462324||ab|5|entity|C0018724|Health Personnel|prog|||healthcare professionals|||0|890|691|715
SE|25462324||ab|5|entity|C0150499|Caring|inbe,socb|||caring|||0|1000|720|726
SE|25462324||ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|731|739
SE|25462324||ab|5|entity|C0278092|Sexual function|fndg,orgf|||sexual function|||0|901|779|794
SE|25462324||ab|5|entity|C0678341|responsibility|inbe|||responsibility|||0|1000|831|845
SE|25462324||ab|5|entity|C0018724|Health Personnel|prog|||healthcare professionals|||0|983|870|894
SE|25462324||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|898|901
SE|25462324||ab|5|entity|C0150600|Advice|hlca|||advice|||0|861|921|927

SE|25462324||ab|6|text|937|1246|Therefore, the intent of a consensus statement made by the American and European heart associations is to summarize current evidence related to sexual counseling in cardiovascular disease, and to provide direction to physicians, nurses, and other healthcare professionals in the practice of sexual counseling.
SE|25462324||ab|6|entity|C1283828|intent|menp|||intent|||0|1000|952|958
SE|25462324||ab|6|entity|C0376298|Consensus|socb|||consensus|||0|694|964|973
SE|25462324||ab|6|entity|C0596070|American|popg|||American|||0|1000|996|1004
SE|25462324||ab|6|entity|C0018787|Heart|bpoc|||heart|||0|790|1018|1023
SE|25462324||ab|6|entity|C0521116|Current|tmco|||current|||0|694|1053|1060
SE|25462324||ab|6|entity|C0036870|Sex Counseling|hlca|||sexual counseling|||0|1000|1081|1098
SE|25462324||ab|6|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular disease|||0|1000|1102|1124
SE|25462324||ab|6|entity|C0449738|Direction|spco|||direction|||0|1000|1141|1150
SE|25462324||ab|6|entity|C0031831|Physicians|prog|||physicians|||0|1000|1154|1164
SE|25462324||ab|6|entity|C0028661|Nurses|prog|||nurses|||0|1000|1166|1172
SE|25462324||ab|6|entity|C0018724|Health Personnel|prog|||healthcare professionals|||0|983|1184|1208
SE|25462324||ab|6|entity|C0237607|experience (practice)|menp|||practice|||0|1000|1216|1224
SE|25462324||ab|6|entity|C0036870|Sex Counseling|hlca|||sexual counseling|||0|1000|1228|1245
SE|25462324||ab|6|relation|0|0|C0028661|Nurses|prog,humn|prog|||nurses|||0|1000|1166|1172|SPEC|ISA||1166|1208|0|0|C0018724|Health Personnel|prog,humn|prog|||healthcare professionals|||0|983|1184|1208
SE|25462324||ab|6|relation|0|0|C0031831|Physicians|prog,humn|prog|||physicians|||0|1000|1154|1164|SPEC|ISA||1166|1208|0|0|C0018724|Health Personnel|prog,humn|prog|||healthcare professionals|||0|983|1184|1208
SE|25462324||ab|6|relation|6|1|C0036870|Sex Counseling|hlca|hlca|||sexual counseling|||0|1000|1081|1098|PREP|TREATS||1099|1101|7|1|C0007222|Cardiovascular Diseases|dsyn|dsyn|||cardiovascular disease|||0|1000|1102|1124


SE|25462323||ti|1|text|21|179|[Prolonged disorder of consciousness after severe acquired brain injury in adults. New recommendations provide a basis for investigation and rehabilitation].
SE|25462323||ti|1|entity|C0439590|Prolonged|tmco|||Prolonged|||0|888|22|31
SE|25462323||ti|1|entity|C0012634|Disease|dsyn|||disorder|||0|888|32|40
SE|25462323||ti|1|entity|C0234421|Conscious|menp|||consciousness|||0|1000|44|57
SE|25462323||ti|1|entity|C0205082|Severe|qlco|||severe|||0|861|64|70
SE|25462323||ti|1|entity|C0439661|Acquired|tmco|||acquired|||0|861|71|79
SE|25462323||ti|1|entity|C0270611|Brain Injuries|inpo|||brain injury|||0|861|80|92
SE|25462323||ti|1|entity|C0001675|Adult|aggp|||adults|||0|851|96|102
SE|25462323||ti|1|entity|C0205314|New|tmco|||New|||0|851|104|107
SE|25462323||ti|1|entity|C0034866|Recommendation|idcn|||recommendations|||0|851|108|123
SE|25462323||ti|1|entity|C1527178|Basis|ftcn|||basis|||0|1000|134|139

SE|25462323||ab|1|text|185|393|After severe acquired brain injury some patients develop a prolonged disorder of consciousness (vegetative state or minimally conscious state), and as such cannot actively participate in neurorehabilitation.
SE|25462323||ab|1|entity|C0205082|Severe|qlco|||severe|||0|861|191|197
SE|25462323||ab|1|entity|C0439661|Acquired|tmco|||acquired|||0|861|198|206
SE|25462323||ab|1|entity|C0270611|Brain Injuries|inpo|||brain injury|||0|861|207|219
SE|25462323||ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|225|233
SE|25462323||ab|1|entity|C0439590|Prolonged|tmco|||prolonged|||0|888|244|253
SE|25462323||ab|1|entity|C0012634|Disease|dsyn|||disorder|||0|888|254|262
SE|25462323||ab|1|entity|C0234421|Conscious|menp|||consciousness|||0|1000|266|279
SE|25462323||ab|1|entity|C0917808|Vegetative State|dsyn|||vegetative state|||0|1000|281|297
SE|25462323||ab|1|entity|C0751699|Minimally Conscious State|dsyn|||minimally conscious state|||0|1000|301|326
SE|25462323||ab|1|relation|5|1|C0012634|Disease|dsyn|dsyn|||disorder|||0|888|254|262|VERB|PROCESS_OF||234|241|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|225|233

SE|25462323||ab|2|text|393|556|However, international opinion and recent research developments emphasize the need for involvement of rehabilitation medicine units in the care of these patients.
SE|25462323||ab|2|entity|C1512888|International|idcn|||international|||0|872|402|415
SE|25462323||ab|2|entity|C0871010|Opinions|menp|||opinion|||0|872|416|423
SE|25462323||ab|2|entity|C0332185|Recent|tmco|||recent|||0|840|428|434
SE|25462323||ab|2|entity|C0035168|research|resa|||research|||0|840|435|443
SE|25462323||ab|2|entity|C1527148|Development|ftcn|||developments|||0|840|444|456
SE|25462323||ab|2|entity|C0027552|Needs|qlco|||need|||0|1000|471|475
SE|25462323||ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||medicine|||0|790|510|518
SE|25462323||ab|2|entity|C0439148|Unit|qnco|||units|||0|790|519|524
SE|25462323||ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|546|554

SE|25462323||ab|3|text|556|806|The article presents recommendations for the care of adult patients with prolonged disorders of consciousness, which have been developed by a multidisciplinary working party, in order to promote good care, and identify areas for further improvements.
SE|25462323||ab|3|entity|C0034866|Recommendation|idcn|||recommendations|||0|1000|577|592
SE|25462323||ab|3|entity|C0001675|Adult|aggp|||adult|||0|888|609|614
SE|25462323||ab|3|entity|C0030705|Patients|podg|||patients|||0|888|615|623
SE|25462323||ab|3|entity|C0439590|Prolonged|tmco|||prolonged|||0|888|629|638
SE|25462323||ab|3|entity|C0012634|Disease|dsyn|||disorders|||0|888|639|648
SE|25462323||ab|3|entity|C0234421|Conscious|menp|||consciousness|||0|1000|652|665
SE|25462323||ab|3|entity|C0242479|Interdisciplinary Studies|ocac|||multidisciplinary|||0|623|698|715
SE|25462323||ab|3|entity|C0043227|Work|ocac|||working|||0|623|716|723
SE|25462323||ab|3|entity|C0205170|Good|qlco|||good|||0|694|751|755
SE|25462323||ab|3|entity|C1517331|Further|spco|||further|||0|694|785|792
SE|25462323||ab|3|relation|7|1|C0012634|Disease|dsyn|dsyn|||disorders|||0|888|639|648|PREP|PROCESS_OF||624|628|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|615|623


SE|25462325||ti|1|text|21|176|Identification of gene knockout strategies using a hybrid of an ant colony optimization algorithm and flux balance analysis to optimize microbial strains.
SE|25462325||ti|1|entity|C0599772|Gene Knockout|mbrt|||gene knockout|||0|901|39|52
SE|25462325||ti|1|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|1000|72|78
SE|25462325||ti|1|entity|C0003455|Ants|invt|||ant|||0|764|85|88
SE|25462325||ti|1|entity|C0439158|colonies|qnco|||colony|||0|764|89|95
SE|25462325||ti|1|entity|C0002045|algorithm|inpr|||algorithm|||0|764|109|118
SE|25462325||ti|1|entity|C0014653|Equilibrium|orgf|||balance|||0|790|128|135
SE|25462325||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|790|136|144
SE|25462325||ti|1|entity|C0599840|microbial|orgm|||microbial|||0|888|157|166
SE|25462325||ti|1|relation|2|1|C0599772|Gene Knockout|mbrt|mbrt|||gene knockout|||0|901|39|52|VERB|USES||64|69|4|1|C0007597|Cell hybridization|lbpr|lbpr|||hybrid|||0|1000|72|78

SE|25462325||ab|1|text|182|295|Reconstructions of genome-scale metabolic networks from different organisms have become popular in recent years.
SE|25462325||ab|1|entity|C0524865|Reconstructive Surgical Procedures|topp|||Reconstructions|||0|966|182|197
SE|25462325||ab|1|entity|C0017428|Genome|gngm|||genome|||0|861|201|207
SE|25462325||ab|1|entity|C0243123|biochemical pathways|ftcn|||metabolic networks|||0|861|214|232
SE|25462325||ab|1|entity|C1547020|*Difference|qnco|||different|||0|853|238|247
SE|25462325||ab|1|entity|C0029235|Organism|orgm|||organisms|||0|853|248|257
SE|25462325||ab|1|entity|C0679970|popularity|socb|||popular|||0|928|270|277
SE|25462325||ab|1|entity|C0332185|Recent|tmco|||recent|||0|888|281|287
SE|25462325||ab|1|entity|C0439234|year|tmco|||years|||0|888|288|293

SE|25462325||ab|2|text|295|389|Metabolic engineering can simulate the reconstruction process to obtain desirable phenotypes.
SE|25462325||ab|2|entity|C0311400|Metabolic|ftcn|||Metabolic|||0|888|295|304
SE|25462325||ab|2|entity|C0014279|Engineering|ocdi|||engineering|||0|888|305|316
SE|25462325||ab|2|entity|C0524865|Reconstructive Surgical Procedures|topp|||reconstruction|||0|888|334|348
SE|25462325||ab|2|entity|C1522240|Process|phpr|||process|||0|888|349|356
SE|25462325||ab|2|entity|C0031437|Phenotype|orga|||phenotypes|||0|861|377|387

SE|25462325||ab|3|text|389|545|In previous studies, optimization algorithms have been implemented to identify the near-optimal sets of knockout genes for improving metabolite production.
SE|25462325||ab|3|entity|C0205156|Previous|tmco|||previous|||0|872|392|400
SE|25462325||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|872|401|408
SE|25462325||ab|3|entity|C0002045|algorithm|inpr|||algorithms|||0|861|423|433
SE|25462325||ab|3|entity|C0475806|1/3 meter|fndg|||near|||0|660|472|476
SE|25462325||ab|3|entity|C0599772|Gene Knockout|mbrt|||knockout genes|||0|983|493|507
SE|25462325||ab|3|entity|C1272745|Improving|inpr|||improving|||0|840|512|521
SE|25462325||ab|3|entity|C0870883|Metabolites|bacs|||metabolite|||0|840|522|532
SE|25462325||ab|3|entity|C0033268|production|ocac|||production|||0|840|533|543

SE|25462325||ab|4|text|545|653|However, previous works contained premature convergence and the stop criteria were not clear for each case.
SE|25462325||ab|4|entity|C0205156|Previous|tmco|||previous|||0|872|554|562
SE|25462325||ab|4|entity|C0043227|Work|ocac|||works|||0|872|563|568
SE|25462325||ab|4|entity|C0205252|Immature|tmco|||premature|||0|888|579|588
SE|25462325||ab|4|entity|C0443193|Convergence|spco|||convergence|||0|888|589|600
SE|25462325||ab|4|entity|C0243161|criteria|inpr|||criteria|||0|861|614|622
SE|25462325||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|628|631

SE|25462325||ab|5|text|653|918|Therefore, this study proposes an algorithm that is a hybrid of the ant colony optimization algorithm and flux balance analysis (ACOFBA) to predict near optimal sets of gene knockouts in an effort to maximize growth rates and the production of certain metabolites.
SE|25462325||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|669|674
SE|25462325||ab|5|entity|C0002045|algorithm|inpr|||algorithm|||0|1000|687|696
SE|25462325||ab|5|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|1000|707|713
SE|25462325||ab|5|entity|C0003455|Ants|invt|||ant|||0|764|721|724
SE|25462325||ab|5|entity|C0439158|colonies|qnco|||colony|||0|764|725|731
SE|25462325||ab|5|entity|C0002045|algorithm|inpr|||algorithm|||0|764|745|754
SE|25462325||ab|5|entity|C0014653|Equilibrium|orgf|||balance|||0|790|764|771
SE|25462325||ab|5|entity|C0936012|Analysis|resa|||analysis|||0|790|772|780
SE|25462325||ab|5|entity|C0475806|1/3 meter|fndg|||near|||0|660|801|805
SE|25462325||ab|5|entity|C0599772|Gene Knockout|mbrt|||gene knockouts|||0|983|822|836
SE|25462325||ab|5|entity|C0449249|Growth rate|tmco|||growth rates|||0|983|862|874
SE|25462325||ab|5|entity|C0033268|production|ocac|||production|||0|1000|883|893
SE|25462325||ab|5|entity|C0870883|Metabolites|bacs|||metabolites|||0|888|905|916

SE|25462325||ab|6|text|918|1096|Here, we present a case study that uses Baker's yeast, also known as Saccharomyces cerevisiae, as the model organism and target the rate of vanillin production for optimization.
SE|25462325||ab|6|entity|C0085973|Case Study|inpr|||case study|||0|1000|937|947
SE|25462325||ab|6|entity|C0036025|Saccharomyces cerevisiae|fngs|||Baker's yeast|||0|1000|958|971
SE|25462325||ab|6|entity|C0036025|Saccharomyces cerevisiae|fngs|||Saccharomyces cerevisiae|||0|1000|987|1011
SE|25462325||ab|6|entity|C0026336|Study models|inpr,resd|||model|||0|888|1020|1025
SE|25462325||ab|6|entity|C0029235|Organism|orgm|||organism|||0|888|1026|1034
SE|25462325||ab|6|entity|C1521828|Rate|qnco|||rate|||0|1000|1050|1054
SE|25462325||ab|6|entity|C0078032|vanillin|orch,phsu|||vanillin|||0|888|1058|1066
SE|25462325||ab|6|entity|C0033268|production|ocac|||production|||0|888|1067|1077

SE|25462325||ab|7|text|1096|1214|The results of this study are the growth rate of the model organism after gene deletion and a list of knockout genes.
SE|25462325||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1100|1107
SE|25462325||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1116|1121
SE|25462325||ab|7|entity|C0449249|Growth rate|tmco|||growth rate|||0|1000|1130|1141
SE|25462325||ab|7|entity|C0026336|Study models|inpr,resd|||model|||0|888|1149|1154
SE|25462325||ab|7|entity|C0029235|Organism|orgm|||organism|||0|888|1155|1163
SE|25462325||ab|7|entity|C0017260|Gene Deletion|genf|||gene deletion|||0|1000|1170|1183
SE|25462325||ab|7|entity|C0745732|LIST|cnce|||list|||0|1000|1190|1194
SE|25462325||ab|7|entity|C0599772|Gene Knockout|mbrt|||knockout genes|||0|983|1198|1212

SE|25462325||ab|8|text|1214|1355|The ACOFBA algorithm was found to improve the yield of vanillin in terms of growth rate and production compared with the previous algorithms.
SE|25462325||ab|8|entity|C0002045|algorithm|inpr|||algorithm|||0|861|1225|1234
SE|25462325||ab|8|entity|C0078032|vanillin|orch,phsu|||vanillin|||0|1000|1269|1277
SE|25462325||ab|8|entity|C0449249|Growth rate|tmco|||growth rate|||0|1000|1290|1301
SE|25462325||ab|8|entity|C0033268|production|ocac|||production|||0|1000|1306|1316
SE|25462325||ab|8|entity|C0205156|Previous|tmco|||previous|||0|888|1335|1343
SE|25462325||ab|8|entity|C0002045|algorithm|inpr|||algorithms|||0|888|1344|1354


SE|25462326||ti|1|text|21|172|Molecular simulation investigation on the interaction between barrier-to-autointegration factor dimer or its Gly25Glu mutant and LEM domain of emerin.
SE|25462326||ti|1|entity|C1521991|Molecular|qlco|||Molecular|||0|851|21|30
SE|25462326||ti|1|entity|C0679083|simulation|resa|||simulation|||0|851|31|41
SE|25462326||ti|1|entity|C0671829|barrier-to-autointegration factor|aapp,bacs|||barrier-to-autointegration factor|||0|928|83|116
SE|25462326||ti|1|entity|C0596448|dimer|chvs|||dimer|||0|928|117|122
SE|25462326||ti|1|entity|C0596988|Mutant|comd|||mutant|||0|861|139|145
SE|25462326||ti|1|entity|C0064834|leukocyte endogenous mediator|bacs|||LEM|||0|694|150|153
SE|25462326||ti|1|entity|C0295734|emerin|aapp|||emerin|||0|1000|164|170

SE|25462326||ab|1|text|178|327|The interaction between barrier-to-autointegration factor dimer (BAF2) and LEM domain of emerin (EmLEM) was studied by molecular simulation methods.
SE|25462326||ab|1|entity|C0671829|barrier-to-autointegration factor|aapp,bacs|||barrier-to-autointegration factor|||0|928|202|235
SE|25462326||ab|1|entity|C0596448|dimer|chvs|||dimer|||0|928|236|241
SE|25462326||ab|1|entity|||gngm|140836|BANF2|BAF2|||0|1000|243|247
SE|25462326||ab|1|entity|C0064834|leukocyte endogenous mediator|bacs|||LEM|||0|694|253|256
SE|25462326||ab|1|entity|C0295734|emerin|aapp|||emerin|||0|1000|267|273
SE|25462326||ab|1|entity|C1521991|Molecular|qlco|||molecular|||0|901|297|306
SE|25462326||ab|1|entity|C0869023|Simulation methods|inpr|||simulation methods|||0|901|307|325

SE|25462326||ab|2|text|327|431|Nonspecific fragment of double-strand DNA molecule was docked with each chain of BAF2 by ZDOCK program.
SE|25462326||ab|2|entity|C0750540|NONSPECIFIC|idcn|||Nonspecific|||0|872|327|338
SE|25462326||ab|2|entity|C0486805|FRAGMENTS|bdsu|||fragment|||0|872|339|347
SE|25462326||ab|2|entity|C0311474|DNA, Double-Stranded|bacs,nnon|||double-strand DNA|||0|898|351|368
SE|25462326||ab|2|entity|C0567416|Molecule|sbst|||molecule|||0|898|369|377
SE|25462326||ab|2|entity|||gngm|140836|BANF2|BAF2|||0|1000|408|412

SE|25462326||ab|3|text|431|482|The model of DNA2:BAF2:EmLEM was thus constructed.
SE|25462326||ab|3|entity|C0026336|Study models|inpr,resd|||model|||0|1000|435|440
SE|25462326||ab|3|entity|||gngm|1763|DNA2|DNA2|||0|1000|444|448
SE|25462326||ab|3|entity|||gngm|140836|BANF2|BAF2|||0|1000|449|453

SE|25462326||ab|4|text|482|616|The mutant Gly25Glu of BAF2 was manually constructed to explore the detailed effect of the mutation on the binding of BAF2 and EmLEM.
SE|25462326||ab|4|entity|C0596988|Mutant|comd|||mutant|||0|694|486|492
SE|25462326||ab|4|entity|||gngm|140836|BANF2|BAF2|||0|1000|505|509
SE|25462326||ab|4|entity|C1522508|Details|qlco|||detailed|||0|872|550|558
SE|25462326||ab|4|entity|C1280500|Effect|qlco|||effect|||0|872|559|565
SE|25462326||ab|4|entity|C0026882|Mutation|genf|||mutation|||0|1000|573|581
SE|25462326||ab|4|entity|||gngm|140836|BANF2|BAF2|||0|1000|600|604
SE|25462326||ab|4|relation|2|1|||gngm,aapp|gngm|140836|BANF2|BAF2|||0|1000|505|509|NOM|AFFECTS||559|565|4|1|C0026882|Mutation|genf|genf|||mutation|||0|1000|573|581

SE|25462326||ab|5|text|616|730|It has been experimentally suggested that point mutation Gly25Glu can disturb the binding between BAF2 and EmLEM.
SE|25462326||ab|5|entity|C0162735|Point Mutation|genf|||point mutation|||0|734|658|672
SE|25462326||ab|5|entity|||gngm|140836|BANF2|BAF2|||0|1000|714|718

SE|25462326||ab|6|text|730|845|Then, molecular dynamics (MD) simulations were performed on DNA2:BAF2(WT):EmLEM and DNA2:BAF2(MT):EmLEM complexes.
SE|25462326||ab|6|entity|C0596957|Molecular Dynamics|moft|||molecular dynamics|||0|890|736|754
SE|25462326||ab|6|entity|C0679083|simulation|resa|||simulations|||0|890|760|771
SE|25462326||ab|6|entity|||gngm|1763|DNA2|DNA2|||0|1000|790|794
SE|25462326||ab|6|entity|||gngm|140836|BANF2|BAF2|||0|1000|795|799
SE|25462326||ab|6|entity|C0043100|Weight|qnco|||WT|||0|1000|800|802
SE|25462326||ab|6|entity|||gngm|1763|DNA2|DNA2|||0|1000|814|818
SE|25462326||ab|6|entity|||gngm|140836|BANF2|BAF2|||0|1000|819|823
SE|25462326||ab|6|entity|C0036525|Metastatic to|ftcn|||MT|||0|1000|824|826
SE|25462326||ab|6|entity|C0439855|Complex|qlco|||complexes|||0|861|834|843

SE|25462326||ab|7|text|845|965|30ns trajectories revealed that the trajectory fluctuations of MT complex are more violent than that of the WT complex.
SE|25462326||ab|7|entity|C0231239|Fluctuation|sosy|||fluctuations|||0|827|892|904
SE|25462326||ab|7|entity|C0439855|Complex|qlco|||complex|||0|888|911|918
SE|25462326||ab|7|entity|C0205172|More|ftcn|||more|||0|888|923|927
SE|25462326||ab|7|entity|C0242151|Violent|mobd|||violent|||0|888|928|935
SE|25462326||ab|7|entity|C0439855|Complex|qlco|||complex|||0|888|956|963

SE|25462326||ab|8|text|965|1154|Further, the binding free energy analysis showed that the electronegative residues Asp57, Glu61 and Asp65 from chain A, glu36 from chain B of BAF2 mainly contribute to interact with EmLEM.
SE|25462326||ab|8|entity|C1517331|Further|spco|||Further|||0|1000|965|972
SE|25462326||ab|8|entity|C0678591|Free Energy|npop|||free energy|||0|824|986|997
SE|25462326||ab|8|entity|C0936012|Analysis|resa|||analysis|||0|824|998|1006
SE|25462326||ab|8|entity|C0678604|electronegativity|npop|||electronegative|||0|546|1023|1038
SE|25462326||ab|8|entity|||gngm|140836|BANF2|BAF2|||0|1000|1107|1111

SE|25462326||ab|9|text|1154|1265|Besides, a stable pi-pi stack between trp62 and phe39 from BAF2(WT) chain B is destroyed by Glu25 in BAF2(MT).
SE|25462326||ab|9|entity|||gngm|140836|BANF2|BAF2|||0|1000|1213|1217
SE|25462326||ab|9|entity|||gngm|9531|BAG3|B is|||0|1000|1228|1232
SE|25462326||ab|9|entity|||gngm|140836|BANF2|BAF2|||0|1000|1255|1259
SE|25462326||ab|9|relation|7|2|||gngm,aapp|gngm|9531|BAG3|B is|||0|1000|1228|1232|PREP|COEXISTS_WITH||1252|1254|2|1|||gngm,aapp|gngm|140836|BANF2|BAF2|||0|1000|1255|1259

SE|25462326||ab|10|text|1265|1369|As a result, trp62 forms an interaction with glu25, and phe39 converts to strengthen affinity to EmLEM.

SE|25462326||ab|11|text|1369|1454|On the other hand, Trp62 from chain A also forms a strong interaction with MT Glu25.
SE|25462326||ab|11|entity|C0442821|Strong|qlco|||strong|||0|888|1420|1426

SE|25462326||ab|12|text|1454|1539|Thus, with the docking of DNA, BAF2(MT) has higher affinity with EmLEM than BAF2(WT).
SE|25462326||ab|12|entity|C1522290|Docking|moft|||docking|||0|1000|1469|1476
SE|25462326||ab|12|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|1480|1483
SE|25462326||ab|12|entity|||gngm|140836|BANF2|BAF2|||0|1000|1485|1489
SE|25462326||ab|12|entity|C0205250|High|qlco|||higher|||0|872|1498|1504
SE|25462326||ab|12|entity|||gngm|140836|BANF2|BAF2|||0|1000|1530|1534


SE|25462327||ti|1|text|21|112|Hierarchical closeness efficiently predicts disease genes in a directed signaling network.
SE|25462327||ti|1|entity|C0699032|Hierarchy|ftcn|||Hierarchical|||0|817|21|33
SE|25462327||ti|1|entity|C1522666|Closest|spco|||closeness|||0|817|34|43
SE|25462327||ti|1|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|955|65|78
SE|25462327||ti|1|entity|C0037083|Signal Transduction|celf|||signaling|||0|790|93|102
SE|25462327||ti|1|entity|C0679670|network|popg|||network|||0|790|103|110
SE|25462327||ti|1|relation|1|1|C0679670|network|popg,humn|humn|||network|||0|790|103|110|PREP|LOCATION_OF||79|81|2|1|C1416989|MAL gene|gngm,aapp|aapp|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|955|65|78

SE|25462327|BACKGROUND|ab|1|text|118|238|BACKGROUND: Many structural centrality measures were proposed to predict putative disease genes on biological networks.
SE|25462327|BACKGROUND|ab|1|entity|C0205099|Central|spco|||centrality|||0|754|146|156
SE|25462327|BACKGROUND|ab|1|entity|C0079809|Measures|qnco|||measures|||0|754|157|165
SE|25462327|BACKGROUND|ab|1|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|856|200|213
SE|25462327|BACKGROUND|ab|1|entity|C0205460|biological|ftcn|||biological|||0|872|217|227
SE|25462327|BACKGROUND|ab|1|entity|C0679670|network|popg|||networks|||0|872|228|236
SE|25462327|BACKGROUND|ab|1|relation|1|1|C0679670|network|popg,humn|humn|||networks|||0|872|228|236|PREP|LOCATION_OF||214|216|3|1|C1416989|MAL gene|gngm,aapp|aapp|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|856|200|213

SE|25462327|BACKGROUND|ab|2|text|238|419|Closeness is one of the best-known structural centrality measures, and its effectiveness for disease gene prediction on undirected biological networks has been frequently reported.
SE|25462327|BACKGROUND|ab|2|entity|C1522666|Closest|spco|||Closeness|||0|928|238|247
SE|25462327|BACKGROUND|ab|2|entity|C0205447|One|qnco|||one|||0|1000|251|254
SE|25462327|BACKGROUND|ab|2|entity|C0339510|Vitelliform dystrophy|dsyn|||best|||0|739|262|266
SE|25462327|BACKGROUND|ab|2|entity|C0205309|Known|qlco|||known|||0|739|267|272
SE|25462327|BACKGROUND|ab|2|entity|C0205099|Central|spco|||centrality|||0|739|284|294
SE|25462327|BACKGROUND|ab|2|entity|C0079809|Measures|qnco|||measures|||0|739|295|303
SE|25462327|BACKGROUND|ab|2|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|313|326
SE|25462327|BACKGROUND|ab|2|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease gene|||0|882|331|343
SE|25462327|BACKGROUND|ab|2|entity|C0681842|prediction|inpr|||prediction|||0|882|344|354
SE|25462327|BACKGROUND|ab|2|entity|C0205460|biological|ftcn|||biological|||0|773|369|379
SE|25462327|BACKGROUND|ab|2|entity|C0679670|network|popg|||networks|||0|773|380|388
SE|25462327|BACKGROUND|ab|2|entity|C0332183|Frequent|tmco|||frequently|||0|1000|398|408

SE|25462327|BACKGROUND|ab|3|text|419|563|However, it is not clear whether closeness is effective for disease gene prediction on directed biological networks such as signaling networks.
SE|25462327|BACKGROUND|ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|434|437
SE|25462327|BACKGROUND|ab|3|entity|C1522666|Closest|spco|||closeness|||0|928|452|461
SE|25462327|BACKGROUND|ab|3|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease gene|||0|882|479|491
SE|25462327|BACKGROUND|ab|3|entity|C0681842|prediction|inpr|||prediction|||0|882|492|502
SE|25462327|BACKGROUND|ab|3|entity|C0205460|biological|ftcn|||biological|||0|773|515|525
SE|25462327|BACKGROUND|ab|3|entity|C0679670|network|popg|||networks|||0|773|526|534
SE|25462327|BACKGROUND|ab|3|entity|C0037083|Signal Transduction|celf|||signaling|||0|872|543|552
SE|25462327|BACKGROUND|ab|3|entity|C0679670|network|popg|||networks|||0|872|553|561

SE|25462327|RESULTS|ab|4|text|563|787|RESULTS: In this paper, we first show that closeness does not significantly outperform other well-known centrality measures such as Degree, Betweenness, and PageRank for disease gene prediction on a human signaling network.
SE|25462327|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|563|570
SE|25462327|RESULTS|ab|4|entity|C0030351|Paper|mnob|||paper|||0|1000|580|585
SE|25462327|RESULTS|ab|4|entity|C1279901|Firstly|qlco|||first|||0|1000|590|595
SE|25462327|RESULTS|ab|4|entity|C1522666|Closest|spco|||closeness|||0|928|606|615
SE|25462327|RESULTS|ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|621|624
SE|25462327|RESULTS|ab|4|entity|C0205170|Good|qlco|||well|||0|828|656|660
SE|25462327|RESULTS|ab|4|entity|C0205309|Known|qlco|||known|||0|828|661|666
SE|25462327|RESULTS|ab|4|entity|C0205099|Central|spco|||centrality|||0|828|667|677
SE|25462327|RESULTS|ab|4|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease gene|||0|882|733|745
SE|25462327|RESULTS|ab|4|entity|C0681842|prediction|inpr|||prediction|||0|882|746|756
SE|25462327|RESULTS|ab|4|entity|C0020114|Human|humn|||human|||0|851|762|767
SE|25462327|RESULTS|ab|4|entity|C0037083|Signal Transduction|celf|||signaling|||0|851|768|777
SE|25462327|RESULTS|ab|4|entity|C0679670|network|popg|||network|||0|851|778|785

SE|25462327|RESULTS|ab|5|text|787|1018|In addition, we observed that prediction accuracy by the closeness measure was worse than that by a reachability measure, but closeness could efficiently predict disease genes among a set of genes with the same reachability value.
SE|25462327|RESULTS|ab|5|entity|C0681842|prediction|inpr|||prediction|||0|853|817|827
SE|25462327|RESULTS|ab|5|entity|C0443131|Accurate|qlco|||accuracy|||0|853|828|836
SE|25462327|RESULTS|ab|5|entity|C1522666|Closest|spco|||closeness|||0|853|844|853
SE|25462327|RESULTS|ab|5|entity|C0079809|Measures|qnco|||measure|||0|853|854|861
SE|25462327|RESULTS|ab|5|entity|C1279889|Deterioration of status|qlco|||worse|||0|1000|866|871
SE|25462327|RESULTS|ab|5|entity|C0596012|Does reach|fndg,ftcn|||reachability|||0|838|887|899
SE|25462327|RESULTS|ab|5|entity|C0079809|Measures|qnco|||measure|||0|838|900|907
SE|25462327|RESULTS|ab|5|entity|C1522666|Closest|spco|||closeness|||0|928|913|922
SE|25462327|RESULTS|ab|5|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|955|949|962
SE|25462327|RESULTS|ab|5|entity|C0017337|Genes|gngm|||genes|||0|1000|978|983
SE|25462327|RESULTS|ab|5|entity|C0445247|Same|qlco|||same|||0|573|993|997
SE|25462327|RESULTS|ab|5|entity|C0596012|Does reach|fndg,ftcn|||reachability|||0|573|998|1010

SE|25462327|RESULTS|ab|6|text|1018|1272|Based on this observation, we devised a novel structural measure, hierarchical closeness, by combining reachability and closeness such that all genes are first ranked by the degree of reachability and then the tied genes are further ranked by closeness.
SE|25462327|RESULTS|ab|6|entity|C0679622|novel|inpr|||novel|||0|802|1058|1063
SE|25462327|RESULTS|ab|6|entity|C0079809|Measures|qnco|||measure|||0|802|1075|1082
SE|25462327|RESULTS|ab|6|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|817|1084|1096
SE|25462327|RESULTS|ab|6|entity|C1522666|Closest|spco|||closeness|||0|817|1097|1106
SE|25462327|RESULTS|ab|6|entity|C0205195|Combined|qlco|||combining|||0|822|1111|1120
SE|25462327|RESULTS|ab|6|entity|C0596012|Does reach|fndg,ftcn|||reachability|||0|822|1121|1133
SE|25462327|RESULTS|ab|6|entity|C1522666|Closest|spco|||closeness|||0|928|1138|1147
SE|25462327|RESULTS|ab|6|entity|C0017337|Genes|gngm|||genes|||0|1000|1162|1167
SE|25462327|RESULTS|ab|6|entity|C1279901|Firstly|qlco|||first|||0|1000|1172|1177
SE|25462327|RESULTS|ab|6|entity|C0596012|Does reach|fndg,ftcn|||reachability|||0|900|1202|1214
SE|25462327|RESULTS|ab|6|entity|C1366528|TIE gene|gngm|||tied genes|||0|966|1228|1238
SE|25462327|RESULTS|ab|6|entity|C1517331|Further|spco|||further|||0|1000|1243|1250
SE|25462327|RESULTS|ab|6|entity|C1522666|Closest|spco|||closeness|||0|928|1261|1270

SE|25462327|RESULTS|ab|7|text|1272|1391|We discovered that hierarchical closeness outperforms other structural centrality measures in disease gene prediction.
SE|25462327|RESULTS|ab|7|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|817|1291|1303
SE|25462327|RESULTS|ab|7|entity|C1522666|Closest|spco|||closeness|||0|817|1304|1313
SE|25462327|RESULTS|ab|7|entity|C0205099|Central|spco|||centrality|||0|789|1343|1353
SE|25462327|RESULTS|ab|7|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease gene|||0|882|1366|1378
SE|25462327|RESULTS|ab|7|entity|C0681842|prediction|inpr|||prediction|||0|882|1379|1389

SE|25462327|RESULTS|ab|8|text|1391|1544|We also found that the set of highly ranked genes in terms of hierarchical closeness is clearly different from that of hub genes with high connectivity.
SE|25462327|RESULTS|ab|8|entity|C0699794|Rank|inpr|||ranked|||0|773|1428|1434
SE|25462327|RESULTS|ab|8|entity|C0017337|Genes|gngm|||genes|||0|773|1435|1440
SE|25462327|RESULTS|ab|8|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|817|1453|1465
SE|25462327|RESULTS|ab|8|entity|C1522666|Closest|spco|||closeness|||0|817|1466|1475
SE|25462327|RESULTS|ab|8|entity|C1547020|*Difference|qnco|||different|||0|789|1487|1496
SE|25462327|RESULTS|ab|8|entity|C0017337|Genes|gngm|||genes|||0|861|1514|1519
SE|25462327|RESULTS|ab|8|entity|C0205250|High|qlco|||high|||0|694|1525|1529

SE|25462327|RESULTS|ab|9|text|1544|1643|More interestingly, these findings were consistently reproduced in a random Boolean network model.
SE|25462327|RESULTS|ab|9|entity|C0205172|More|ftcn|||More|||0|861|1544|1548
SE|25462327|RESULTS|ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1570|1578
SE|25462327|RESULTS|ab|9|entity|C0439605|Random|qlco|||random|||0|833|1613|1619
SE|25462327|RESULTS|ab|9|entity|C1552663|Boolean|idcn|||Boolean|||0|833|1620|1627
SE|25462327|RESULTS|ab|9|entity|C0679670|network|popg|||network|||0|833|1628|1635
SE|25462327|RESULTS|ab|9|entity|C0026336|Study models|inpr,resd|||model|||0|833|1636|1641

SE|25462327|RESULTS|ab|10|text|1643|1932|Finally, we found that genes with relatively high hierarchical closeness are significantly likely to encode proteins in the extracellular matrix and receptor proteins in a human signaling network, supporting the fact that half of all modern medicinal drugs target receptor-encoding genes.
SE|25462327|RESULTS|ab|10|entity|C0017337|Genes|gngm|||genes|||0|1000|1666|1671
SE|25462327|RESULTS|ab|10|entity|C0205250|High|qlco|||high|||0|727|1688|1692
SE|25462327|RESULTS|ab|10|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|727|1693|1705
SE|25462327|RESULTS|ab|10|entity|C1522666|Closest|spco|||closeness|||0|727|1706|1715
SE|25462327|RESULTS|ab|10|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|1751|1759
SE|25462327|RESULTS|ab|10|entity|C0015350|Extracellular Matrix|tisu|||extracellular matrix|||0|1000|1767|1787
SE|25462327|RESULTS|ab|10|entity|C0597357|receptor|aapp,rcpt|||receptor proteins|||0|1000|1792|1809
SE|25462327|RESULTS|ab|10|entity|C0020114|Human|humn|||human|||0|851|1815|1820
SE|25462327|RESULTS|ab|10|entity|C0037083|Signal Transduction|celf|||signaling|||0|851|1821|1830
SE|25462327|RESULTS|ab|10|entity|C0679670|network|popg|||network|||0|851|1831|1838
SE|25462327|RESULTS|ab|10|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|827|1894|1899
SE|25462327|RESULTS|ab|10|entity|C1335671|Receptor Gene|gngm|||receptor-encoding genes|||0|896|1907|1930
SE|25462327|RESULTS|ab|10|relation|5|1|C0020114|Human|grup,humn|humn|||human|||0|851|1815|1820|PREP|LOCATION_OF||1810|1812|5|1|C0597357|receptor|aapp,gngm,rcpt|aapp|||receptor proteins|||0|1000|1792|1809
SE|25462327|RESULTS|ab|10|relation|7|1|C0015350|Extracellular Matrix|tisu|tisu|||extracellular matrix|||0|1000|1767|1787|PREP|LOCATION_OF||1760|1762|3|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|1751|1759
SE|25462327|RESULTS|ab|10|relation|9|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|827|1894|1899|VERB|INTERACTS_WITH||1900|1906|1|1|C1335671|Receptor Gene|gngm,aapp|gngm|||receptor-encoding genes|||0|896|1907|1930

SE|25462327|CONCLUSION|ab|11|text|1932|2114|CONCLUSION: Taken together, hierarchical closeness proposed in this study is a novel structural measure to efficiently predict putative disease genes in a directed signaling network.
SE|25462327|CONCLUSION|ab|11|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|817|1960|1972
SE|25462327|CONCLUSION|ab|11|entity|C1522666|Closest|spco|||closeness|||0|817|1973|1982
SE|25462327|CONCLUSION|ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|2000|2005
SE|25462327|CONCLUSION|ab|11|entity|C0679622|novel|inpr|||novel|||0|763|2011|2016
SE|25462327|CONCLUSION|ab|11|entity|C0079809|Measures|qnco|||measure|||0|763|2028|2035
SE|25462327|CONCLUSION|ab|11|entity|C1416989|MAL gene|gngm|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|856|2068|2081
SE|25462327|CONCLUSION|ab|11|entity|C0037083|Signal Transduction|celf|||signaling|||0|790|2096|2105
SE|25462327|CONCLUSION|ab|11|entity|C0679670|network|popg|||network|||0|790|2106|2113
SE|25462327|CONCLUSION|ab|11|relation|1|1|C0679670|network|popg,humn|humn|||network|||0|790|2106|2113|PREP|LOCATION_OF||2082|2084|5|1|C1416989|MAL gene|gngm,aapp|aapp|925,4118,57591,114609|CD8A,MAL,MKL1,TIRAP|disease genes|||0|856|2068|2081


SE|25462328||ti|1|text|21|170|Inferring biological basis about psychrophilicity by interpreting the rules generated from the correctly classified input instances by a classifier.
SE|25462328||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|31|41
SE|25462328||ti|1|entity|C1527178|Basis|ftcn|||basis|||0|888|42|47
SE|25462328||ti|1|entity|C1285553|Interprets|ftcn|||interpreting|||0|966|74|86
SE|25462328||ti|1|entity|C0870077|Rules|inpr|||rules|||0|1000|91|96
SE|25462328||ti|1|entity|C0008902|Classification|clas|||classified|||0|747|126|136
SE|25462328||ti|1|entity|C1550608|instance|idcn|||instances|||0|747|143|152

SE|25462328||ab|1|text|176|391|Organisms thriving at extreme cold surroundings are called as psychrophiles and they present a wealth of knowledge about sequence adjustments in proteins that had occurred during the adaptation to low temperatures.
SE|25462328||ab|1|entity|C0029235|Organism|orgm|||Organisms|||0|1000|176|185
SE|25462328||ab|1|entity|C0205403|Extreme|qlco|||extreme|||0|660|198|205
SE|25462328||ab|1|entity|C0699759|Wealthy|qlco|||wealth|||0|928|271|277
SE|25462328||ab|1|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|281|290
SE|25462328||ab|1|entity|C1519249|Sequence|ftcn|||sequence|||0|888|297|305
SE|25462328||ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|321|329
SE|25462328||ab|1|entity|C0000934|Acclimatization|orgf|||adaptation|||0|1000|359|369
SE|25462328||ab|1|entity|C0009264|cold temperature|npop|||low temperatures|||0|983|373|389

SE|25462328||ab|2|text|391|486|In this paper, we propose a new cascading model to investigate the basis for psychrophilicity.
SE|25462328||ab|2|entity|C0030351|Paper|mnob|||paper|||0|1000|399|404
SE|25462328||ab|2|entity|C0205314|New|tmco|||new|||0|802|419|422
SE|25462328||ab|2|entity|C0026336|Study models|inpr,resd|||model|||0|802|433|438
SE|25462328||ab|2|entity|C1527178|Basis|ftcn|||basis|||0|1000|458|463

SE|25462328||ab|3|text|486|764|In this model, a superior classifier was used to discriminate psychrophilic from mesophilic protein sequences, and then the PART rule generating algorithm was applied on the input instances that are correctly classified by the classifier, to generate human interpretable rules.
SE|25462328||ab|3|entity|C0026336|Study models|inpr,resd|||model|||0|1000|494|499
SE|25462328||ab|3|entity|C1282910|Upper|spco|||superior|||0|694|503|511
SE|25462328||ab|3|entity|C0002518|Amino Acid Sequence|amas|||protein sequences|||0|884|578|595
SE|25462328||ab|3|entity|C0449719|Part|spco|||PART|||0|764|610|614
SE|25462328||ab|3|entity|C0870077|Rules|inpr|||rule|||0|764|615|619
SE|25462328||ab|3|entity|C0002045|algorithm|inpr|||algorithm|||0|764|631|640
SE|25462328||ab|3|entity|C1550608|instance|idcn|||instances|||0|827|666|675
SE|25462328||ab|3|entity|C0020114|Human|humn|||human|||0|802|737|742
SE|25462328||ab|3|entity|C0870077|Rules|inpr|||rules|||0|802|757|762

SE|25462328||ab|4|text|764|924|These derived rules were further validated on a structural dataset and finally analyzed to discover the underlying biological basis about the psychrophilicity.
SE|25462328||ab|4|entity|C0870077|Rules|inpr|||rules|||0|888|778|783
SE|25462328||ab|4|entity|C1517331|Further|spco|||further|||0|1000|789|796
SE|25462328||ab|4|entity|C0205460|biological|ftcn|||biological|||0|790|879|889
SE|25462328||ab|4|entity|C1527178|Basis|ftcn|||basis|||0|790|890|895

SE|25462328||ab|5|text|924|1151|In this study, we have used one of the key features of psychrophilic proteins accountable for remaining functional in extreme cold temperature surroundings i.e., global patterns of amino acid composition as the input features.
SE|25462328||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|932|937
SE|25462328||ab|5|entity|C0205447|One|qnco|||one|||0|1000|952|955
SE|25462328||ab|5|entity|C1554080|Key|idcn|||key|||0|694|963|966
SE|25462328||ab|5|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|861|993|1001
SE|25462328||ab|5|entity|C0078889|Accountability|idcn|||accountable|||0|928|1002|1013
SE|25462328||ab|5|entity|C1527428|Remaining|qlco|||remaining|||0|1000|1018|1027
SE|25462328||ab|5|entity|C0205245|Functional|ftcn|||functional|||0|1000|1028|1038
SE|25462328||ab|5|entity|C0205403|Extreme|qlco|||extreme|||0|741|1042|1049
SE|25462328||ab|5|entity|C0009264|cold temperature|npop|||cold temperature|||0|741|1050|1066
SE|25462328||ab|5|entity|C0205246|Generalized|spco|||global|||0|741|1086|1092
SE|25462328||ab|5|entity|C0449774|Patterns|spco|||patterns|||0|741|1093|1101
SE|25462328||ab|5|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|888|1105|1115
SE|25462328||ab|5|entity|C0486616|Composition|clna|||composition|||0|888|1116|1127

SE|25462328||ab|6|text|1151|1277|The rotation forest classifier outperformed all the other classifiers with maximum accuracy of 70.5% and maximum AUC of 0.78.
SE|25462328||ab|6|entity|C0035868|Rotation|ftcn|||rotation|||0|623|1155|1163
SE|25462328||ab|6|entity|C0086312|Forests|geoa|||forest|||0|623|1164|1170
SE|25462328||ab|6|entity|C0806909|Maximum|fndg|||maximum|||0|853|1226|1233
SE|25462328||ab|6|entity|C0443131|Accurate|qlco|||accuracy|||0|853|1234|1242
SE|25462328||ab|6|entity|C0806909|Maximum|fndg|||maximum|||0|888|1256|1263
SE|25462328||ab|6|entity|C0376690|Area Under Curve|qnco|||AUC|||0|888|1264|1267

SE|25462328||ab|7|text|1277|1361|The effect of sequence length on the classification accuracy was also investigated.
SE|25462328||ab|7|entity|C1280500|Effect|qlco|||effect|||0|1000|1281|1287
SE|25462328||ab|7|entity|C1519249|Sequence|ftcn|||sequence|||0|888|1291|1299
SE|25462328||ab|7|entity|C1444754|Length|qnco|||length|||0|888|1300|1306
SE|25462328||ab|7|entity|C0008902|Classification|clas|||classification|||0|853|1314|1328
SE|25462328||ab|7|entity|C0443131|Accurate|qlco|||accuracy|||0|853|1329|1337

SE|25462328||ab|8|text|1361|1596|The analysis of the derived rules and interpretation of the analyzed results had revealed some interesting phenomena such as the amino acids A, D, G, F, and S are over-represented, and T is under-represented in psychrophilic proteins.
SE|25462328||ab|8|entity|C0936012|Analysis|resa|||analysis|||0|1000|1365|1373
SE|25462328||ab|8|entity|C0870077|Rules|inpr|||rules|||0|888|1389|1394
SE|25462328||ab|8|entity|C0459471|Interpretation|inpr|||interpretation|||0|1000|1399|1413
SE|25462328||ab|8|entity|C1515960|Analyzed|qlco|||analyzed|||0|872|1421|1429
SE|25462328||ab|8|entity|C1274040|result|ftcn|||results|||0|872|1430|1437
SE|25462328||ab|8|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|1000|1490|1501
SE|25462328||ab|8|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|861|1586|1594

SE|25462328||ab|9|text|1596|1685|These findings augment the existing domain knowledge for psychrophilic sequence features.
SE|25462328||ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1602|1610
SE|25462328||ab|9|entity|C0376554|Knowledge|inpr|||knowledge|||0|827|1639|1648
SE|25462328||ab|9|entity|C1519249|Sequence|ftcn|||sequence|||0|660|1667|1675


SE|25462329||ti|1|text|21|126|Identification of miR159s and their target genes and expression analysis under drought stress in potato.
SE|25462329||ti|1|entity|C0017337|Genes|gngm|||genes|||0|888|64|69
SE|25462329||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|888|85|93
SE|25462329||ti|1|entity|C0013140|Drought|npop|||drought|||0|888|100|107
SE|25462329||ti|1|entity|C0038435|Stress|fndg|||stress|||0|888|108|114
SE|25462329||ti|1|entity|C0032846|Potato|food|||potato|||0|1000|118|124

SE|25462329||ab|1|text|132|383|The MYB proteins comprise one of the largest families of plant transcription factors (TFs) and many of MYB families, which play essential roles in plant growth, development and respond to environmental stresses, and have yet been identified in plant.
SE|25462329||ab|1|entity|C0026900|v-myb Genes|gngm|4602|MYB|MYB|||0|888|136|139
SE|25462329||ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|140|148
SE|25462329||ab|1|entity|C0205447|One|qnco|||one|||0|1000|158|161
SE|25462329||ab|1|entity|C0443228|Largest|qnco|||largest|||0|888|169|176
SE|25462329||ab|1|entity|C0015576|Family|famg|||families|||0|888|177|185
SE|25462329||ab|1|entity|C0032098|Plants|plnt|||plant|||0|901|189|194
SE|25462329||ab|1|entity|C0040648|TRANSCRIPTION FACTOR|aapp,bacs|||transcription factors|||0|901|195|216
SE|25462329||ab|1|entity|C0040679|Transferrin|aapp,bacs|||TFs|||0|966|218|221
SE|25462329||ab|1|entity|C0026900|v-myb Genes|gngm|4602|MYB|MYB|||0|888|235|238
SE|25462329||ab|1|entity|C0015576|Family|famg|||families|||0|888|239|247
SE|25462329||ab|1|entity|C0205224|Essential|qlco|||essential|||0|888|260|269
SE|25462329||ab|1|entity|C0035820|Role|socb|||roles|||0|888|270|275
SE|25462329||ab|1|entity|C0597252|plant growth/development|orgf|||plant growth|||0|1000|279|291
SE|25462329||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|293|304
SE|25462329||ab|1|entity|C0871732|Environmental Stress|phpr|||environmental stresses|||0|983|320|342
SE|25462329||ab|1|entity|C0032098|Plants|plnt|||plant|||0|1000|376|381
SE|25462329||ab|1|relation|0|0|C0032098|Plants|plnt|plnt|||plant|||0|901|189|194|MOD/HEAD|LOCATION_OF||189|216|0|0|C0040648|TRANSCRIPTION FACTOR|aapp,gngm,bacs|aapp|||transcription factors|||0|901|195|216
SE|25462329||ab|1|relation|1|1|C0032098|Plants|plnt|plnt|||plant|||0|1000|376|381|PREP|LOCATION_OF||373|375|10|7|C0040648|TRANSCRIPTION FACTOR|aapp,gngm,bacs|aapp|||transcription factors|||0|901|195|216
SE|25462329||ab|1|relation|6|1|C0026900|v-myb Genes|gngm,aapp|gngm|4602|MYB|MYB|||0|888|235|238|COMPLEX|AFFECTS||255|275|4|1|C0597252|plant growth/development|orgf|orgf|||plant growth|||0|1000|279|291

SE|25462329||ab|2|text|383|505|Previous research has shown that miR159 family members repressed the conserved plant R2R3 MYB domain TFs in model plants.
SE|25462329||ab|2|entity|C0205156|Previous|tmco|||Previous|||0|888|383|391
SE|25462329||ab|2|entity|C0035168|research|resa|||research|||0|888|392|400
SE|25462329||ab|2|entity|C0086282|Family member|famg|||family members|||0|901|423|437
SE|25462329||ab|2|entity|C0032098|Plants|plnt|||plant|||0|720|462|467
SE|25462329||ab|2|entity|C0026900|v-myb Genes|gngm|4602|MYB|MYB|||0|720|473|476
SE|25462329||ab|2|entity|C0040679|Transferrin|aapp,bacs|||TFs|||0|720|484|487
SE|25462329||ab|2|entity|C0026336|Study models|inpr,resd|||model|||0|888|491|496
SE|25462329||ab|2|entity|C0032098|Plants|plnt|||plants|||0|888|497|503
SE|25462329||ab|2|relation|1|1|C0032098|Plants|plnt|plnt|||plants|||0|888|497|503|PREP|LOCATION_OF||488|490|3|1|C0040679|Transferrin|aapp,gngm,bacs|aapp|||TFs|||0|720|484|487

SE|25462329||ab|3|text|505|669|In the present research, we identified three potato novel miR159 family members named as stu-miR159a, stu-miR159b and stu-miR159c based on bioinformatics analysis.
SE|25462329||ab|3|entity|C0150312|Present|qnco|||present|||0|888|512|519
SE|25462329||ab|3|entity|C0035168|research|resa|||research|||0|888|520|528
SE|25462329||ab|3|entity|C0205449|Three|qnco|||three|||0|769|544|549
SE|25462329||ab|3|entity|C0032846|Potato|food|||potato|||0|769|550|556
SE|25462329||ab|3|entity|C0679622|novel|inpr|||novel|||0|769|557|562
SE|25462329||ab|3|entity|C0086282|Family member|famg|||family members|||0|769|570|584
SE|25462329||ab|3|entity|C1140694|Bio-Informatics|bmod|||bioinformatics|||0|888|644|658
SE|25462329||ab|3|entity|C0936012|Analysis|resa|||analysis|||0|888|659|667

SE|25462329||ab|4|text|669|814|Target prediction showed that they have a bite sit on the three GAMyb-like genes (StGAMyb-like1, StGAMyb-like2.1 and StGAMyb-like2.2) of potato.
SE|25462329||ab|4|entity|C0681842|prediction|inpr|||prediction|||0|888|676|686
SE|25462329||ab|4|entity|C0205449|Three|qnco|||three|||0|694|727|732
SE|25462329||ab|4|entity|C0017337|Genes|gngm|||genes|||0|1000|744|749
SE|25462329||ab|4|entity|C0032846|Potato|food|||potato|||0|1000|806|812

SE|25462329||ab|5|text|814|922|Those GAMyb-like genes also have been selected and cloned from potato, which belong to R2R3 MYB domain TFs.
SE|25462329||ab|5|entity|C0017337|Genes|gngm|||genes|||0|1000|831|836
SE|25462329||ab|5|entity|C0032846|Potato|food|||potato|||0|1000|877|883
SE|25462329||ab|5|entity|C0026900|v-myb Genes|gngm|4602|MYB|MYB|||0|747|906|909
SE|25462329||ab|5|entity|C0040679|Transferrin|aapp,bacs|||TFs|||0|747|917|920

SE|25462329||ab|6|text|922|1105|We further measured expressional levels of stu-miR159s and potato GAMyb-like genes during the different periods of drought treated samples using quantitative real-time PCR (qRT-PCR).
SE|25462329||ab|6|entity|C1517331|Further|spco|||further|||0|1000|925|932
SE|25462329||ab|6|entity|C0185117|Expression procedure|topp|||expressional|||0|853|942|954
SE|25462329||ab|6|entity|C0441889|Levels|inpr|||levels|||0|853|955|961
SE|25462329||ab|6|entity|C0032846|Potato|food|||potato|||0|694|981|987
SE|25462329||ab|6|entity|C0017337|Genes|gngm|||genes|||0|1000|999|1004
SE|25462329||ab|6|entity|C1547020|*Difference|qnco|||different|||0|836|1016|1025
SE|25462329||ab|6|entity|C0439531|/period|tmco|||periods|||0|836|1026|1033
SE|25462329||ab|6|entity|C0013140|Drought|npop|||drought|||0|606|1037|1044
SE|25462329||ab|6|entity|C1292734|Treats|clas|||treated|||0|606|1045|1052
SE|25462329||ab|6|entity|C0392762|Quantitative|qnco|||quantitative|||0|861|1067|1079
SE|25462329||ab|6|entity|C1550177|Real Time|idcn|||real-time|||0|861|1080|1089
SE|25462329||ab|6|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|861|1090|1093

SE|25462329||ab|7|text|1105|1407|The results showed that they had a opposite expression pattern, briefly, three stu-miR159 members showed similar expressional trends which were significantly decreased expression after experiencing 25 days of drought stress treatment, while the potato GAMyb-like family members were greatly increased.
SE|25462329||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1109|1116
SE|25462329||ab|7|entity|C1521805|Opposite|spco|||opposite|||0|851|1140|1148
SE|25462329||ab|7|entity|C0449774|Patterns|spco|||pattern|||0|851|1160|1167
SE|25462329||ab|7|entity|C0205449|Three|qnco|||three|||0|775|1178|1183
SE|25462329||ab|7|entity|C0680022|member|popg|||members|||0|775|1195|1202
SE|25462329||ab|7|entity|C0185117|Expression procedure|topp|||expressional|||0|804|1218|1230
SE|25462329||ab|7|entity|C1521798|trend|tmco|||trends|||0|804|1231|1237
SE|25462329||ab|7|entity|C0205216|Decreased|qnco|||decreased|||0|790|1263|1272
SE|25462329||ab|7|entity|C0439228|day|tmco|||days|||0|861|1306|1310
SE|25462329||ab|7|entity|C0013140|Drought|npop|||drought|||0|851|1314|1321
SE|25462329||ab|7|entity|C0038435|Stress|fndg|||stress|||0|851|1322|1328
SE|25462329||ab|7|entity|C0032846|Potato|food|||potato|||0|694|1350|1356
SE|25462329||ab|7|entity|C0086282|Family member|famg|||family members|||0|1000|1368|1382

SE|25462329||ab|8|text|1407|1549|Therefore, we suggested that stu-miR159s negatively regulated the expression of potato GAMyb-like genes which responsible for drought stress.
SE|25462329||ab|8|entity|C0032846|Potato|food|||potato|||0|694|1487|1493
SE|25462329||ab|8|entity|C0017337|Genes|gngm|||genes|||0|1000|1505|1510
SE|25462329||ab|8|entity|C0013140|Drought|npop|||drought|||0|888|1533|1540
SE|25462329||ab|8|entity|C0038435|Stress|fndg|||stress|||0|888|1541|1547
SE|25462329||ab|8|relation|4|1|C0017337|Genes|gngm,aapp|gngm|||genes|||0|1000|1505|1510|ADJ|CAUSES||1517|1528|1|1|C0038435|Stress|fndg|fndg|||stress|||0|888|1541|1547

SE|25462329||ab|9|text|1549|1702|The findings can facilitate functional studies of miRNAs in plants and provide molecular evidence for involvement process of drought tolerance in potato.
SE|25462329||ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1553|1561
SE|25462329||ab|9|entity|C0205245|Functional|ftcn|||functional|||0|872|1577|1587
SE|25462329||ab|9|entity|C0008972|Clinical Research|resa|||studies|||0|872|1588|1595
SE|25462329||ab|9|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|1000|1599|1605
SE|25462329||ab|9|entity|C0032098|Plants|plnt|||plants|||0|1000|1609|1615
SE|25462329||ab|9|entity|C1521991|Molecular|qlco|||molecular|||0|694|1628|1637
SE|25462329||ab|9|entity|C1522240|Process|phpr|||process|||0|861|1663|1670
SE|25462329||ab|9|entity|C0013140|Drought|npop|||drought|||0|694|1674|1681
SE|25462329||ab|9|entity|C0032846|Potato|food|||potato|||0|1000|1695|1701


SE|25462330||ti|1|text|21|122|Disruption of murine Tcte3-3 induces tissue specific apoptosis via co-expression of Anxa5 and Pebp1.
SE|25462330||ti|1|entity|C0332453|Disruption|ftcn|||Disruption|||0|1000|21|31
SE|25462330||ti|1|entity|C0026809|Mus|mamm|||murine|||0|827|35|41
SE|25462330||ti|1|entity|||gngm|6991|TCTE3|Tcte3|||0|827|42|47
SE|25462330||ti|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|708|74|83
SE|25462330||ti|1|entity|C0059249|annexin A5|aapp,bacs|308|ANXA5|Anxa5|||0|1000|105|110
SE|25462330||ti|1|entity|||gngm|5037|PEBP1|Pebp1|||0|1000|115|120

SE|25462330||ab|1|text|128|232|Programmed cell death or apoptosis plays a vital physiological role in the development and homeostasis.
SE|25462330||ab|1|entity|C0162638|Apoptosis|celf|||Programmed cell death|||0|1000|128|149
SE|25462330||ab|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|153|162
SE|25462330||ab|1|entity|C0442732|Vital|qlco|||vital|||0|851|171|176
SE|25462330||ab|1|entity|C0205463|Physiological|ftcn|||physiological|||0|851|177|190
SE|25462330||ab|1|entity|C0035820|Role|socb|||role|||0|851|191|195
SE|25462330||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|203|214
SE|25462330||ab|1|entity|C0019868|Homeostasis|orgf|||homeostasis|||0|1000|219|230

SE|25462330||ab|2|text|232|380|Any discrepancy in apoptosis may trigger testicular and neurodegenerative diseases, ischemic damage, autoimmune disorders and many types of cancer.
SE|25462330||ab|2|entity|C1290905|Discrepancy|fndg|||discrepancy|||0|1000|236|247
SE|25462330||ab|2|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|251|260
SE|25462330||ab|2|entity|C0205070|Testiculo-|spco|||testicular|||0|1000|273|283
SE|25462330||ab|2|entity|C0524851|Neurodegenerative Disorders|dsyn|||neurodegenerative diseases|||0|1000|288|314
SE|25462330||ab|2|entity|C0475224|Ischemic|ftcn|||ischemic|||0|694|316|324
SE|25462330||ab|2|entity|C0004364|Autoimmune Diseases|dsyn|||autoimmune disorders|||0|1000|333|353
SE|25462330||ab|2|entity|C0332307|Type - attribute|qlco|||types|||0|1000|363|368
SE|25462330||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|372|378

SE|25462330||ab|3|text|380|547|Tcte3 (T-complex testis expressed 3) is an accessory component of axonemal and cytoplasmic dynein which expresses predominantly in meiotic and postmeiotic germ cells.
SE|25462330||ab|3|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|380|385
SE|25462330||ab|3|entity|C0439855|Complex|qlco|||complex|||0|790|389|396
SE|25462330||ab|3|entity|C0039597|Testis|bpoc|||testis|||0|790|397|403
SE|25462330||ab|3|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|861|433|442
SE|25462330||ab|3|entity|C0230750|Axial filament complex, of cilium or flagellum, not bacterial|celc|||axonemal|||0|928|446|454
SE|25462330||ab|3|entity|C1180334|Cytoplasmic dynein|aapp,bacs|||cytoplasmic dynein|||0|1000|459|477
SE|25462330||ab|3|entity|C0026207|Miotics|phsu|||meiotic|||0|1000|511|518
SE|25462330||ab|3|entity|C0017471|Germ Cells|cell|||germ cells|||0|901|535|545
SE|25462330||ab|3|relation|2|2|||gngm,aapp|gngm|6991|TCTE3|Tcte3|||0|1000|380|385|NOM|PART_OF||433|442|4|1|C0230750|Axial filament complex, of cilium or flagellum, not bacterial|celc|celc|||axonemal|||0|928|446|454
SE|25462330||ab|3|relation|5|1|C1180334|Cytoplasmic dynein|aapp,gngm,bacs|aapp|||cytoplasmic dynein|||0|1000|459|477|VERB|INTERACTS_WITH||484|493|2|1|C0026207|Miotics|phsu|phsu|||meiotic|||0|1000|511|518

SE|25462330||ab|4|text|547|713|It plays an essential role during spermatogenesis; however, to explore its diverse and complex functioning in male germ cell apoptosis, requires further prosecution.
SE|25462330||ab|4|entity|C0205224|Essential|qlco|||essential|||0|888|559|568
SE|25462330||ab|4|entity|C0035820|Role|socb|||role|||0|888|569|573
SE|25462330||ab|4|entity|C0037864|Spermatogenesis|celf|||spermatogenesis|||0|1000|581|596
SE|25462330||ab|4|entity|C0439855|Complex|qlco|||complex|||0|872|634|641
SE|25462330||ab|4|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|642|653
SE|25462330||ab|4|entity|C0017471|Germ Cells|cell|||germ cell|||0|824|662|671
SE|25462330||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|824|672|681
SE|25462330||ab|4|entity|C1517331|Further|spco|||further|||0|888|692|699
SE|25462330||ab|4|entity|C0205255|Imprisonment|gora|||prosecution|||0|888|700|711
SE|25462330||ab|4|relation|0|0|C0017471|Germ Cells|cell|cell|||germ cell|||0|824|662|671|MOD/HEAD|LOCATION_OF||662|681|0|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|824|672|681
SE|25462330||ab|4|relation|4|1|C0031843|physiological aspects|phsf|phsf|||functioning|||0|872|642|653|PREP|COEXISTS_WITH||654|656|2|1|C0162638|Apoptosis|celf|celf|||apoptosis|||0|824|672|681

SE|25462330||ab|5|text|713|895|Here, 2D-gel electrophoresis, mass spectrometry and qRT-PCR analyses were performed to elucidate the differential expression of genes, in both wild-type and homozygous Tcte3-3 mice.
SE|25462330||ab|5|entity|C0013860|Electrophoresis, Gel, Two-Dimensional|lbpr|||2D-gel electrophoresis|||0|1000|719|741
SE|25462330||ab|5|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|1000|743|760
SE|25462330||ab|5|entity|C0200931|Polymerase chain reaction analysis|lbpr|||PCR analyses|||0|884|769|781
SE|25462330||ab|5|entity|C0017337|Genes|gngm|||genes|||0|1000|841|846
SE|25462330||ab|5|entity|C0445392|Wild|inpr|||wild|||0|888|856|860
SE|25462330||ab|5|entity|C1547052|*Type|qnco|||type|||0|888|861|865
SE|25462330||ab|5|entity|||gngm|6991|TCTE3|Tcte3|||0|812|881|886
SE|25462330||ab|5|entity|C0026809|Mus|mamm|||mice|||0|812|889|893

SE|25462330||ab|6|text|895|988|We observed an increased expression of Tcte3 in homozygotes as compared to wild-type testes.
SE|25462330||ab|6|entity|C0205217|Increased|qnco|||increased|||0|888|910|919
SE|25462330||ab|6|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|934|939
SE|25462330||ab|6|entity|C0019904|Homozygote|orgm|||homozygotes|||0|1000|943|954
SE|25462330||ab|6|entity|C0445392|Wild|inpr|||wild|||0|851|970|974
SE|25462330||ab|6|entity|C1547052|*Type|qnco|||type|||0|851|975|979
SE|25462330||ab|6|entity|C0021358|Inferior Colliculus|bpoc|||testes|||0|851|980|986
SE|25462330||ab|6|relation|2|1|C0019904|Homozygote|orgm|orgm|||homozygotes|||0|1000|943|954|PREP|LOCATION_OF||940|942|2|1|||gngm,aapp|aapp|6991|TCTE3|Tcte3|||0|1000|934|939

SE|25462330||ab|7|text|988|1112|Perpetually, an increased expression of Anxa5 and Pebp1, while a lower expression of Rsph1 was detected in Tcte3-3-/- mice.
SE|25462330||ab|7|entity|C0205217|Increased|qnco|||increased|||0|888|1004|1013
SE|25462330||ab|7|entity|C0059249|annexin A5|aapp,bacs|308|ANXA5|Anxa5|||0|1000|1028|1033
SE|25462330||ab|7|entity|||gngm|5037|PEBP1|Pebp1|||0|1000|1038|1043
SE|25462330||ab|7|entity|C0441994|Lower|ftcn|||lower|||0|888|1053|1058
SE|25462330||ab|7|entity|||gngm|89765|RSPH1|Rsph1|||0|1000|1073|1078
SE|25462330||ab|7|entity|||gngm|6991|TCTE3|Tcte3|||0|827|1095|1100
SE|25462330||ab|7|entity|C0026809|Mus|mamm|||mice|||0|827|1106|1110
SE|25462330||ab|7|relation|1|1|C0026809|Mus|mamm|mamm|||mice|||0|827|1106|1110|PREP|LOCATION_OF||1092|1094|5|1|||gngm,aapp|aapp|89765|RSPH1|Rsph1|||0|1000|1073|1078

SE|25462330||ab|8|text|1112|1221|We propose that over-expression of Pebp1 and Anxa5 in Tcte3-3-/- testes might be due to increased apoptosis.
SE|25462330||ab|8|entity|C0205136|Over|spco|||over|||0|888|1128|1132
SE|25462330||ab|8|entity|||gngm|5037|PEBP1|Pebp1|||0|1000|1147|1152
SE|25462330||ab|8|entity|C0059249|annexin A5|aapp,bacs|308|ANXA5|Anxa5|||0|1000|1157|1162
SE|25462330||ab|8|entity|||gngm|6991|TCTE3|Tcte3|||0|827|1166|1171
SE|25462330||ab|8|entity|C0021358|Inferior Colliculus|bpoc|||testes|||0|827|1177|1183
SE|25462330||ab|8|entity|C0205217|Increased|qnco|||increased|||0|888|1200|1209
SE|25462330||ab|8|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|1210|1219
SE|25462330||ab|8|relation|2|1|C0021358|Inferior Colliculus|bpoc|bpoc|||testes|||0|827|1177|1183|PREP|LOCATION_OF||1163|1165|3|1|||gngm,aapp|aapp|5037|PEBP1|Pebp1|||0|1000|1147|1152
SE|25462330||ab|8|relation|2|1|C0021358|Inferior Colliculus|bpoc|bpoc|||testes|||0|827|1177|1183|PREP|LOCATION_OF||1163|1165|3|1|C0059249|annexin A5|aapp,gngm,bacs|aapp|308|ANXA5|Anxa5|||0|1000|1157|1162

SE|25462330||ab|9|text|1221|1401|To evaluate this possibility, testes specific microarray data set extracted from NCBI gene ontology omnibus (GEO) was used to cluster the possible co-expression partners of Tcte3.
SE|25462330||ab|9|entity|C0021358|Inferior Colliculus|bpoc|||testes|||0|812|1251|1257
SE|25462330||ab|9|entity|C0150098|data set|inpr|||data set|||0|812|1278|1286
SE|25462330||ab|9|entity|C1138831|Gene_Ontology|inpr|||gene ontology|||0|694|1307|1320
SE|25462330||ab|9|entity|C1517526|Geographic|spco|||GEO|||0|1000|1330|1333
SE|25462330||ab|9|entity|C0332149|Possible|qlco|||possible|||0|840|1359|1367
SE|25462330||ab|9|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|1394|1399

SE|25462330||ab|10|text|1401|1554|Further functional coherence of compiled candidate genes was monitored computationally by studying the common TFBS overlapped at the regulatory regions.
SE|25462330||ab|10|entity|C1517331|Further|spco|||Further|||0|623|1401|1408
SE|25462330||ab|10|entity|C0205245|Functional|ftcn|||functional|||0|623|1409|1419
SE|25462330||ab|10|entity|C1332838|Candidate Disease Gene|gngm|||candidate genes|||0|901|1442|1457
SE|25462330||ab|10|entity|C0008972|Clinical Research|resa|||studying|||0|966|1491|1499
SE|25462330||ab|10|entity|C0205214|Common|qnco|||common|||0|694|1504|1510
SE|25462330||ab|10|entity|C0034987|Regulatory Sequences, Nucleic Acid|bacs,nnon|||regulatory regions|||0|1000|1534|1552

SE|25462330||ab|11|text|1554|1744|Differential expression of Tcte3-3 and its involvement in apoptosis may provide a basis for the investigation of transcriptional specificities of other Tcte3 paralogs (Tcte3-1 and Tcte3-2).
SE|25462330||ab|11|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|1581|1586
SE|25462330||ab|11|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1612|1621
SE|25462330||ab|11|entity|C1527178|Basis|ftcn|||basis|||0|1000|1636|1641
SE|25462330||ab|11|entity|C0040649|Transcription, Genetic|genf|||transcriptional|||0|836|1667|1682
SE|25462330||ab|11|entity|C0037791|Specificity|qnco|||specificities|||0|836|1683|1696
SE|25462330||ab|11|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|1706|1711
SE|25462330||ab|11|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|1722|1727
SE|25462330||ab|11|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|1734|1739

SE|25462330||ab|12|text|1744|1927|A complete understanding of controlling factors which have implications in regulating tissue-specific Tcte3 expression would provide additional insights into the gene control events.
SE|25462330||ab|12|entity|C0205197|Complete|qlco|||complete|||0|888|1746|1754
SE|25462330||ab|12|entity|C1521761|Factor|ftcn|||factors|||0|827|1784|1791
SE|25462330||ab|12|entity|||gngm|6991|TCTE3|Tcte3|||0|812|1846|1851
SE|25462330||ab|12|entity|C1524062|Additional|ftcn|||additional|||0|872|1877|1887
SE|25462330||ab|12|entity|C0233820|Insight|menp|||insights|||0|872|1888|1896
SE|25462330||ab|12|entity|C0017337|Genes|gngm|||gene|||0|851|1906|1910
SE|25462330||ab|12|entity|C0243148|control|ftcn|||control|||0|851|1911|1918
SE|25462330||ab|12|entity|C0441471|Events|evnt|||events|||0|851|1919|1925

SE|25462330||ab|13|text|1927|2107|The collective knowledge may prove useful for the development of novel therapeutic regimen and would open new avenues in defining selective roles of Tcte3 in germ cell development.
SE|25462330||ab|13|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|1942|1951
SE|25462330||ab|13|entity|C1527148|Development|ftcn|||development|||0|1000|1977|1988
SE|25462330||ab|13|entity|C0679622|novel|inpr|||novel|||0|901|1992|1997
SE|25462330||ab|13|entity|C1276413|Therapeutic regimen|topp|||therapeutic regimen|||0|901|1998|2017
SE|25462330||ab|13|entity|C0205314|New|tmco|||new|||0|694|2033|2036
SE|25462330||ab|13|entity|C0035820|Role|socb|||roles|||0|827|2067|2072
SE|25462330||ab|13|entity|||gngm|6991|TCTE3|Tcte3|||0|1000|2076|2081
SE|25462330||ab|13|entity|C1160501|germ cell development|celf|||germ cell development|||0|1000|2085|2106
SE|25462330||ab|13|relation|2|1|||gngm,aapp|gngm|6991|TCTE3|Tcte3|||0|1000|2076|2081|NOM|AFFECTS||2067|2072|2|2|C1160501|germ cell development|celf|celf|||germ cell development|||0|1000|2085|2106


SE|25462331||ti|1|text|21|152|How do the protonation states of E296 and D312 in OmpF and D299 and D315 in homologous OmpC affect protein structure and dynamics?
SE|25462331||ti|1|entity|C0178812|protonation|phpr|||protonation|||0|1000|32|43
SE|25462331||ti|1|entity|C1334043|Homologous Gene|gngm|||homologous|||0|623|97|107
SE|25462331||ti|1|entity|C1510464|Protein Structure|aapp|||protein structure|||0|1000|120|137

SE|25462331||ti|2|text|152|172|Simulation studies.
SE|25462331||ti|2|entity|C0679083|simulation|resa|||Simulation|||0|872|152|162
SE|25462331||ti|2|entity|C0008972|Clinical Research|resa|||studies|||0|872|163|170

SE|25462331||ab|1|text|178|347|In this study, the structural and dynamic properties of two major porins (OmpF and OmpC) in Escherichia coli are investigated using molecular dynamics (MD) simulations.
SE|25462331||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|186|191
SE|25462331||ab|1|entity|C0729333|Dynamic|ftcn|||dynamic|||0|872|212|219
SE|25462331||ab|1|entity|C0871161|Property|qlco|||properties|||0|872|220|230
SE|25462331||ab|1|entity|C0205448|Two|qnco|||two|||0|851|234|237
SE|25462331||ab|1|entity|C0205164|Major|qlco|||major|||0|851|238|243
SE|25462331||ab|1|entity|C0071728|porin|aapp,imft|||porins|||0|851|244|250
SE|25462331||ab|1|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|1000|270|286
SE|25462331||ab|1|entity|C0596957|Molecular Dynamics|moft|||molecular dynamics|||0|890|310|328
SE|25462331||ab|1|entity|C0679083|simulation|resa|||simulations|||0|890|334|345
SE|25462331||ab|1|relation|2|1|C0014834|Escherichia coli|bact|bact|||Escherichia coli|||0|1000|270|286|PREP|LOCATION_OF||267|269|6|3|C0071728|porin|aapp,gngm,imft|aapp|||porins|||0|851|244|250

SE|25462331||ab|2|text|347|451|Both porins have the extracellular loop L3 folded halfway through the pore to form a constriction area.
SE|25462331||ab|2|entity|C0071728|porin|aapp,imft|||porins|||0|1000|352|358
SE|25462331||ab|2|entity|C0521119|Extracellular|celc|||extracellular|||0|623|368|381
SE|25462331||ab|2|entity|C0445022|Loop|spco|||loop|||0|623|382|386
SE|25462331||ab|2|entity|C0009813|Constriction procedure|topp|||constriction|||0|888|432|444
SE|25462331||ab|2|entity|C0205146|Area|spco|||area|||0|888|445|449

SE|25462331||ab|3|text|451|515|The solute influx and efflux are controlled by the L3 movement.
SE|25462331||ab|3|entity|C0597488|solute|chvs|||solute|||0|694|455|461
SE|25462331||ab|3|entity|C0026649|Movement|orgf|||movement|||0|861|505|513

SE|25462331||ab|4|text|515|653|E296 and D312 in OmpF and homologous D299 and D315 in OmpC located on the barrel wall are found to play a key role in L3 gating activity.
SE|25462331||ab|4|entity|C1334043|Homologous Gene|gngm|||homologous|||0|623|541|551
SE|25462331||ab|4|entity|C1552933|barrel|qnco|||barrel|||0|694|589|595
SE|25462331||ab|4|entity|C1554080|Key|idcn|||key|||0|888|621|624
SE|25462331||ab|4|entity|C0035820|Role|socb|||role|||0|888|625|629

SE|25462331||ab|5|text|653|808|All possible charged states of both E296(D299) and D312(315) are applied in this study to observe changes in overall structure and especially L3 movement.
SE|25462331||ab|5|entity|C0332149|Possible|qlco|||possible|||0|829|657|665
SE|25462331||ab|5|entity|C0007961|charge amounts|qnco|||charged|||0|829|666|673
SE|25462331||ab|5|entity|C1442792|State|ftcn|||states|||0|829|674|680
SE|25462331||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|734|739
SE|25462331||ab|5|entity|C1561607|Overall|qlco|||overall|||0|888|762|769
SE|25462331||ab|5|entity|C0678594|Structure|spco|||structure|||0|888|770|779
SE|25462331||ab|5|entity|C0026649|Movement|orgf|||movement|||0|827|798|806

SE|25462331||ab|6|text|808|958|The results show that different protonation states of both residues cause the large-scale deviations in structure and pore cavity especially in OmpF.
SE|25462331||ab|6|entity|C1274040|result|ftcn|||results|||0|966|812|819
SE|25462331||ab|6|entity|C1547020|*Difference|qnco|||different|||0|853|830|839
SE|25462331||ab|6|entity|C0178812|protonation|phpr|||protonation|||0|853|840|851
SE|25462331||ab|6|entity|C0549177|Large|qnco|||large|||0|840|886|891
SE|25462331||ab|6|entity|C0012727|Spatial Displacement|spco|||deviations|||0|840|898|908
SE|25462331||ab|6|entity|C0678594|Structure|spco|||structure|||0|1000|912|921

SE|25462331||ab|7|text|958|1045|Fully charged E296(D299) and D312(315) increase the protein flexibility significantly.
SE|25462331||ab|7|entity|C0007961|charge amounts|qnco|||charged|||0|627|964|971
SE|25462331||ab|7|entity|C0033684|Proteins|aapp,bacs|||protein|||0|790|1010|1017
SE|25462331||ab|7|entity|C0242808|Pliability|qlco|||flexibility|||0|790|1018|1029

SE|25462331||ab|8|text|1045|1162|Deprotonating at least one of E296(D299) and D312(315) helps to fasten L3 to the barrel wall and maintain pore size.
SE|25462331||ab|8|entity|C0205447|One|qnco|||one|||0|861|1068|1071
SE|25462331||ab|8|entity|C1552933|barrel|qnco|||barrel|||0|694|1126|1132
SE|25462331||ab|8|entity|C0456389|size|spco|||size|||0|861|1156|1160

SE|25462331||ab|9|text|1162|1239|Lacking of interactions with D312(315) can lead to the pore closure in OmpF.
SE|25462331||ab|9|entity|C0332268|Lacking|qlco|||Lacking|||0|1000|1162|1169

SE|25462331||ab|10|text|1239|1374|Comparing with OmpC, not only is OmpF less stable, but it is also more sensitive to the charge states of both E296(D299) and D312(315).
SE|25462331||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1260|1263
SE|25462331||ab|10|entity|C0332324|Sensitive|ftcn|||sensitive|||0|827|1310|1319


SE|25462332||ti|1|text|21|124|Computational analysis of 3'UTR region of CASP3 with respect to miRSNPs and SNPs in targetting miRNAs.
SE|25462332||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|861|35|43
SE|25462332||ti|1|entity|C0600600|3' Untranslated Regions|bacs,nnon|||3'UTR|||0|901|47|52
SE|25462332||ti|1|entity|C0205147|Region|spco|||region|||0|901|53|59
SE|25462332||ti|1|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|CASP3|||0|1000|63|68
SE|25462332||ti|1|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|1000|97|101
SE|25462332||ti|1|entity|C0599894|targeting|celf|||targetting|||0|888|105|115
SE|25462332||ti|1|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|888|116|122

SE|25462332||ab|1|text|130|223|Apoptosis is a strictly organized course which keeps the healthy survival/death equilibrium.
SE|25462332||ab|1|entity|C0162638|Apoptosis|celf|||Apoptosis|||0|1000|130|139
SE|25462332||ab|1|entity|C1300196|Organized|qlco|||organized|||0|790|154|163
SE|25462332||ab|1|entity|C0750729|Course|tmco|||course|||0|790|164|170
SE|25462332||ab|1|entity|C0018684|Health|idcn|||healthy|||0|815|187|194
SE|25462332||ab|1|entity|C0038952|Continuance of life|acty|||survival|||0|815|195|203
SE|25462332||ab|1|entity|C0011065|Cessation of life|orgf|||death|||0|815|204|209
SE|25462332||ab|1|entity|C0014653|Equilibrium|orgf|||equilibrium|||0|815|210|221

SE|25462332||ab|2|text|223|339|Disregulation in apoptosis may lead autoimmunity or cancer, but increased apoptosis can lead degenerative diseases.
SE|25462332||ab|2|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|240|249
SE|25462332||ab|2|entity|C0004368|Autoimmunity|patf|||autoimmunity|||0|1000|259|271
SE|25462332||ab|2|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|275|281
SE|25462332||ab|2|entity|C0205217|Increased|qnco|||increased|||0|888|287|296
SE|25462332||ab|2|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|297|306
SE|25462332||ab|2|entity|C1285162|Degenerative disorder|dsyn|||degenerative diseases|||0|983|316|337

SE|25462332||ab|3|text|339|527|Studies during the last several years have identified numerous affected miRNAs in association with apoptosis, their target genes and biological functions, and possible drug interventions.
SE|25462332||ab|3|entity|C0008972|Clinical Research|resa|||Studies|||0|966|339|346
SE|25462332||ab|3|entity|C1517741|Last|qlco|||last|||0|802|358|362
SE|25462332||ab|3|entity|C0439234|year|tmco|||years|||0|802|371|376
SE|25462332||ab|3|entity|C0205396|Identified|qlco|||identified|||0|833|382|392
SE|25462332||ab|3|entity|C0439064|Numerous|qnco|||numerous|||0|833|393|401
SE|25462332||ab|3|entity|C0392760|Affecting|ftcn|||affected|||0|833|402|410
SE|25462332||ab|3|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|833|411|417
SE|25462332||ab|3|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|438|447
SE|25462332||ab|3|entity|C0017337|Genes|gngm|||genes|||0|888|462|467
SE|25462332||ab|3|entity|C0277784|Biological function, NOS|biof|||biological functions|||0|983|472|492
SE|25462332||ab|3|entity|C0332149|Possible|qlco|||possible|||0|851|498|506
SE|25462332||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|851|507|511
SE|25462332||ab|3|entity|C1273869|Intervention regimes|hlca|||interventions|||0|851|512|525
SE|25462332||ab|3|relation|0|0|C1273869|Intervention regimes|hlca|hlca|||interventions|||0|851|512|525|MOD/HEAD|USES||507|525|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|851|507|511

SE|25462332||ab|4|text|527|613|Polymorphisms in miRNA genes or miRNA target sites (miRSNPs) can modify miRNA action.
SE|25462332||ab|4|entity|C0032529|Polymorphism, Genetic|genf|||Polymorphisms|||0|966|527|540
SE|25462332||ab|4|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|888|544|549
SE|25462332||ab|4|entity|C0017337|Genes|gngm|||genes|||0|888|550|555
SE|25462332||ab|4|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|851|559|564
SE|25462332||ab|4|entity|C0205145|Site|spco|||sites|||0|851|572|577
SE|25462332||ab|4|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|694|599|604

SE|25462332||ab|5|text|613|732|While polymorphisms in miRNA genes are relatively rare, SNPs in miRNA-binding sites in target genes are more frequent.
SE|25462332||ab|5|entity|C0032529|Polymorphism, Genetic|genf|||polymorphisms|||0|966|619|632
SE|25462332||ab|5|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|888|636|641
SE|25462332||ab|5|entity|C0017337|Genes|gngm|||genes|||0|888|642|647
SE|25462332||ab|5|entity|C0522498|Rare|qlco|||rare|||0|790|663|667
SE|25462332||ab|5|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|790|669|673
SE|25462332||ab|5|entity|C1523647|miRNA binding|genf|||miRNA-binding|||0|901|677|690
SE|25462332||ab|5|entity|C0205145|Site|spco|||sites|||0|901|691|696
SE|25462332||ab|5|entity|C0017337|Genes|gngm|||genes|||0|888|707|712
SE|25462332||ab|5|entity|C0205172|More|ftcn|||more|||0|888|717|721
SE|25462332||ab|5|entity|C0332183|Frequent|tmco|||frequent|||0|888|722|730

SE|25462332||ab|6|text|732|918|Several studies have shown that SNPs in miRNA target sites enhance or weaken the interaction between miRNA and its target transcripts and are associated with cancers and other diseases.
SE|25462332||ab|6|entity|C0443302|Several|qnco|||Several|||0|872|732|739
SE|25462332||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|872|740|747
SE|25462332||ab|6|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|1000|764|768
SE|25462332||ab|6|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|851|772|777
SE|25462332||ab|6|entity|C0205145|Site|spco|||sites|||0|851|785|790
SE|25462332||ab|6|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|1000|833|838
SE|25462332||ab|6|entity|C1519595|Transcript|nnon|||transcripts|||0|888|854|865
SE|25462332||ab|6|entity|C0006826|Malignant Neoplasms|neop|||cancers|||0|1000|890|897
SE|25462332||ab|6|entity|C0012634|Disease|dsyn|||diseases|||0|1000|908|916
SE|25462332||ab|6|relation|0|0|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|1000|890|897|SPEC|ISA||890|916|0|0|C0012634|Disease|dsyn|dsyn|||diseases|||0|1000|908|916
SE|25462332||ab|6|relation|0|0|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNPs|||0|1000|764|768|INFER|ASSOCIATED_WITH(SPEC)||890|916|0|0|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|1000|890|897
SE|25462332||ab|6|relation|4|2|C1519595|Transcript|nnon|nnon|||transcripts|||0|888|854|865|NOM|INTERACTS_WITH||813|824|4|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNA|||0|1000|833|838
SE|25462332||ab|6|relation|6|5|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNPs|||0|1000|764|768|VERB|ASSOCIATED_WITH||874|884|2|1|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|1000|890|897
SE|25462332||ab|6|relation|6|5|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNPs|||0|1000|764|768|VERB|ASSOCIATED_WITH||874|884|2|1|C0012634|Disease|dsyn|dsyn|||diseases|||0|1000|908|916

SE|25462332||ab|7|text|918|1161|We aimed to identify miRSNPs on executioner caspase, CASP3 gene (caspase-3) and SNPs in miRNA genes targeting 3'UTR of CASP3 and assessing the impact of these miRSNPs and SNPs of miRNA genes targeting 3'UTR of CASP3 with respect to apoptosis.
SE|25462332||ab|7|entity|C0010656|caspase|aapp,enzy|||caspase|||0|861|962|969
SE|25462332||ab|7|entity|C1413132|CASP3 gene|gngm|836|CASP3|CASP3 gene|||0|1000|971|981
SE|25462332||ab|7|entity|C0291573|caspase-3|aapp,enzy|||caspase-3|||0|1000|983|992
SE|25462332||ab|7|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|1000|998|1002
SE|25462332||ab|7|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|888|1006|1011
SE|25462332||ab|7|entity|C0017337|Genes|gngm|||genes|||0|888|1012|1017
SE|25462332||ab|7|entity|C0600600|3' Untranslated Regions|bacs,nnon|||3'UTR|||0|1000|1028|1033
SE|25462332||ab|7|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|CASP3|||0|1000|1037|1042
SE|25462332||ab|7|entity|C0220825|Evaluation|ftcn|||assessing|||0|966|1047|1056
SE|25462332||ab|7|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|1000|1089|1093
SE|25462332||ab|7|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|888|1097|1102
SE|25462332||ab|7|entity|C0017337|Genes|gngm|||genes|||0|888|1103|1108
SE|25462332||ab|7|entity|C0600600|3' Untranslated Regions|bacs,nnon|||3'UTR|||0|1000|1119|1124
SE|25462332||ab|7|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|CASP3|||0|1000|1128|1133
SE|25462332||ab|7|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1150|1159
SE|25462332||ab|7|relation|4|1|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNPs|||0|1000|998|1002|PREP|COEXISTS_WITH||1003|1005|12|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNA|||0|888|1006|1011
SE|25462332||ab|7|relation|5|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNA|||0|888|1006|1011|VERB|INTERACTS_WITH||1018|1027|11|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1028|1033
SE|25462332||ab|7|relation|6|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1028|1033|PREP|PART_OF||1034|1036|10|1|C0291573|caspase-3|aapp,gngm,enzy|aapp|836|CASP3|CASP3|||0|1000|1037|1042
SE|25462332||ab|7|relation|12|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNA|||0|888|1097|1102|VERB|INTERACTS_WITH||1109|1118|4|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1119|1124
SE|25462332||ab|7|relation|13|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1119|1124|PREP|PART_OF||1125|1127|3|1|C0291573|caspase-3|aapp,gngm,enzy|aapp|836|CASP3|CASP3|||0|1000|1128|1133

SE|25462332||ab|8|text|1161|1314|We identified 89 different miRNA binding sites (for 43 different miRNAs) and 16 different SNPs in binding sites of miRNA in the 3'UTR of the CASP3 gene.
SE|25462332||ab|8|entity|C1547020|*Difference|qnco|||different|||0|781|1178|1187
SE|25462332||ab|8|entity|C1523647|miRNA binding|genf|||miRNA binding|||0|781|1188|1201
SE|25462332||ab|8|entity|C0205145|Site|spco|||sites|||0|781|1202|1207
SE|25462332||ab|8|entity|C1547020|*Difference|qnco|||different|||0|754|1216|1225
SE|25462332||ab|8|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|754|1226|1232
SE|25462332||ab|8|entity|C1547020|*Difference|qnco|||different|||0|754|1241|1250
SE|25462332||ab|8|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|754|1251|1255
SE|25462332||ab|8|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|1000|1259|1272
SE|25462332||ab|8|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|1000|1276|1281
SE|25462332||ab|8|entity|C0600600|3' Untranslated Regions|bacs,nnon|||3'UTR|||0|1000|1289|1294
SE|25462332||ab|8|entity|C1413132|CASP3 gene|gngm|836|CASP3|CASP3 gene|||0|1000|1302|1312
SE|25462332||ab|8|relation|3|1|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNPs|||0|754|1251|1255|PREP|COEXISTS_WITH||1256|1258|4|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites|||0|1000|1259|1272
SE|25462332||ab|8|relation|5|1|C1101610|MicroRNAs|bacs,nnon|bacs|||miRNA|||0|1000|1276|1281|PREP|COEXISTS_WITH||1282|1284|2|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1289|1294
SE|25462332||ab|8|relation|6|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1289|1294|PREP|PART_OF||1295|1297|1|1|C1413132|CASP3 gene|gngm,aapp|aapp|836|CASP3|CASP3 gene|||0|1000|1302|1312

SE|25462332||ab|9|text|1314|1401|Also, 2 SNPs (rs372435266 and rs190144655) were found on this miRNA' genomic sequence.
SE|25462332||ab|9|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|861|1322|1326
SE|25462332||ab|9|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|802|1376|1381
SE|25462332||ab|9|entity|C1519249|Sequence|ftcn|||sequence|||0|802|1391|1399

SE|25462332||ab|10|text|1401|1483|One of them crossmatched with a SNP in the 3'UTR of CASP3 that we found formerly.
SE|25462332||ab|10|entity|C0205447|One|qnco|||One|||0|1000|1401|1404
SE|25462332||ab|10|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNP|||0|1000|1433|1436
SE|25462332||ab|10|entity|C0600600|3' Untranslated Regions|bacs,nnon|||3'UTR|||0|1000|1444|1449
SE|25462332||ab|10|entity|C0291573|caspase-3|aapp,enzy|836|CASP3|CASP3|||0|1000|1453|1458
SE|25462332||ab|10|relation|2|1|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNP|||0|1000|1433|1436|PREP|COEXISTS_WITH||1437|1439|2|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1444|1449
SE|25462332||ab|10|relation|3|1|C0600600|3' Untranslated Regions|bacs,nnon|bacs|||3'UTR|||0|1000|1444|1449|PREP|PART_OF||1450|1452|1|1|C0291573|caspase-3|aapp,gngm,enzy|aapp|836|CASP3|CASP3|||0|1000|1453|1458

SE|25462332||ab|11|text|1483|1511|This miRNA was miR-4802-3p.
SE|25462332||ab|11|entity|C1101610|MicroRNAs|bacs,nnon|||miRNA|||0|1000|1488|1493
SE|25462332||ab|11|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|802|1498|1501

SE|25462332||ab|12|text|1511|1598|Besides, miR-4802-3p targets three other apoptosis related genes, XIAP, IL1A and SOX2.
SE|25462332||ab|12|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|802|1520|1523
SE|25462332||ab|12|entity|C0205449|Three|qnco|||three|||0|1000|1540|1545
SE|25462332||ab|12|entity|C0162638|Apoptosis|celf|||apoptosis|||0|851|1552|1561
SE|25462332||ab|12|entity|C1522149|Related|ftcn|||related|||0|851|1562|1569
SE|25462332||ab|12|entity|C0017337|Genes|gngm|||genes|||0|851|1570|1575
SE|25462332||ab|12|entity|C1337109|BIRC4 gene|gngm|331|XIAP|XIAP|||0|1000|1577|1581
SE|25462332||ab|12|entity|C0600251|Interleukin-1 alpha|aapp,imft|3552|IL1A|IL1A|||0|1000|1583|1587
SE|25462332||ab|12|entity|||gngm|6657|SOX2|SOX2|||0|1000|1592|1596

SE|25462332||ab|13|text|1598|1716|This means that miR-4802-3p may also have a critical effect on apoptosis via different pathways other than caspase-3.
SE|25462332||ab|13|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|802|1614|1617
SE|25462332||ab|13|entity|C1511545|Critical|qlco|||critical|||0|888|1642|1650
SE|25462332||ab|13|entity|C1280500|Effect|qlco|||effect|||0|888|1651|1657
SE|25462332||ab|13|entity|C1547020|*Difference|qnco|||different|||0|789|1675|1684
SE|25462332||ab|13|entity|C0162638|Apoptosis|celf|||apoptosis via different pathways|||0|789|1661|1693
SE|25462332||ab|13|entity|C0291573|caspase-3|aapp,enzy|||caspase-3|||0|1000|1705|1714

SE|25462332||ab|14|text|1716|1873|We can therefore conclude that this is the first study proving a strong association between miR-4802-3p and apoptosis upon computational targetting analysis.
SE|25462332||ab|14|entity|C1279901|Firstly|qlco|||first|||0|888|1759|1764
SE|25462332||ab|14|entity|C0008972|Clinical Research|resa|||study|||0|888|1765|1770
SE|25462332||ab|14|entity|C0442821|Strong|qlco|||strong|||0|694|1781|1787
SE|25462332||ab|14|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|802|1808|1811
SE|25462332||ab|14|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1824|1833
SE|25462332||ab|14|entity|C0599894|targeting|celf|||targetting|||0|790|1853|1863
SE|25462332||ab|14|entity|C0936012|Analysis|resa|||analysis|||0|790|1864|1872


SE|25462334||ti|1|text|21|107|Three-dimensional protein structure prediction: Methods and computational strategies.
SE|25462334||ti|1|entity|C0450363|Three-dimensional|spco|||Three-dimensional|||0|857|21|38
SE|25462334||ti|1|entity|C1510464|Protein Structure|aapp|||protein structure|||0|857|39|56
SE|25462334||ti|1|entity|C0681842|prediction|inpr|||prediction|||0|857|57|67
SE|25462334||ti|1|entity|C0025663|Methods|inpr|||Methods|||0|1000|69|76

SE|25462334||ab|1|text|113|287|A long standing problem in structural bioinformatics is to determine the three-dimensional (3-D) structure of a protein when only a sequence of amino acid residues is given.
SE|25462334||ab|1|entity|C0205166|Long|qlco|||long|||0|851|115|119
SE|25462334||ab|1|entity|C0231472|Orthostatic body position|spco|||standing|||0|851|120|128
SE|25462334||ab|1|entity|C1140694|Bio-Informatics|bmod|||bioinformatics|||0|861|151|165
SE|25462334||ab|1|entity|C0450363|Three-dimensional|spco|||three-dimensional|||0|1000|186|203
SE|25462334||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|225|232
SE|25462334||ab|1|entity|C1519249|Sequence|ftcn|||sequence|||0|1000|245|253
SE|25462334||ab|1|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|847|257|267

SE|25462334||ab|2|text|287|427|Many computational methodologies and algorithms have been proposed as a solution to the 3-D Protein Structure Prediction (3-D-PSP) problem.
SE|25462334||ab|2|entity|C0025664|Methodology|inpr|||methodologies|||0|827|306|319
SE|25462334||ab|2|entity|C0002045|algorithm|inpr|||algorithms|||0|1000|324|334
SE|25462334||ab|2|entity|C0037633|Solutions|sbst|||solution|||0|1000|359|367
SE|25462334||ab|2|entity|C1510464|Protein Structure|aapp|||Protein Structure|||0|857|379|396
SE|25462334||ab|2|entity|C0681842|prediction|inpr|||Prediction|||0|857|397|407
SE|25462334||ab|2|entity|C1367466|MSMB gene|gngm|4477|MSMB|PSP|||0|1000|413|416

SE|25462334||ab|3|text|427|707|These methods can be divided in four main classes: (a) first principle methods without database information; (b) first principle methods with database information; (c) fold recognition and threading methods; and (d) comparative modeling methods and sequence alignment strategies.
SE|25462334||ab|3|entity|C0025663|Methods|inpr|||methods|||0|1000|433|440
SE|25462334||ab|3|entity|C0205450|Four|qnco|||four|||0|851|459|463
SE|25462334||ab|3|entity|C0205225|Primary|qlco|||main|||0|851|464|468
SE|25462334||ab|3|entity|C0456387|Class|inpr|||classes|||0|851|469|476
SE|25462334||ab|3|entity|C1279901|Firstly|qlco|||first|||0|802|482|487
SE|25462334||ab|3|entity|C0025663|Methods|inpr|||methods|||0|802|498|505
SE|25462334||ab|3|entity|C0242356|Databases|inpr|||database|||0|888|514|522
SE|25462334||ab|3|entity|C1533716|Information|idcn|||information|||0|888|523|534
SE|25462334||ab|3|entity|C1279901|Firstly|qlco|||first|||0|763|540|545
SE|25462334||ab|3|entity|C0025663|Methods|inpr|||methods|||0|763|556|563
SE|25462334||ab|3|entity|C0242356|Databases|inpr|||database|||0|888|569|577
SE|25462334||ab|3|entity|C1533716|Information|idcn|||information|||0|888|578|589
SE|25462334||ab|3|entity|C0332462|Fold|spco|||fold|||0|694|595|599
SE|25462334||ab|3|entity|C0025663|Methods|inpr|||methods|||0|861|626|633
SE|25462334||ab|3|entity|C0870071|Modeling|inpr,resa|||modeling|||0|790|655|663
SE|25462334||ab|3|entity|C0025663|Methods|inpr|||methods|||0|790|664|671
SE|25462334||ab|3|entity|C0080143|Sequence Alignment|mbrt|||sequence alignment|||0|901|676|694

SE|25462334||ab|4|text|707|903|Deterministic computational techniques, optimization techniques, data mining and machine learning approaches are typically used in the construction of computational solutions for the PSP problem.
SE|25462334||ab|4|entity|C0870407|Determinism|idcn|||Deterministic|||0|866|707|720
SE|25462334||ab|4|entity|C1516769|Computational Technique|resa|||computational techniques|||0|866|721|745
SE|25462334||ab|4|entity|C0025664|Methodology|inpr|||techniques|||0|861|760|770
SE|25462334||ab|4|entity|C1328866|data mining|mcha,ocac|||data mining|||0|1000|772|783
SE|25462334||ab|4|entity|C0376284|Machine Learning|mcha|||machine learning|||0|901|788|804
SE|25462334||ab|4|entity|C0449445|Approach|spco|||approaches|||0|901|805|815
SE|25462334||ab|4|entity|C0037633|Solutions|sbst|||solutions|||0|861|872|881
SE|25462334||ab|4|entity|C1367466|MSMB gene|gngm|4477|MSMB|PSP|||0|888|890|893

SE|25462334||ab|5|text|903|1036|Our main goal with this work is to review the methods and computational strategies that are currently used in 3-D protein prediction.
SE|25462334||ab|5|entity|C0205225|Primary|qlco|||main|||0|888|907|911
SE|25462334||ab|5|entity|C0018017|objective (goal)|inpr|||goal|||0|888|912|916
SE|25462334||ab|5|entity|C0043227|Work|ocac|||work|||0|1000|927|931
SE|25462334||ab|5|entity|C0025663|Methods|inpr|||methods|||0|1000|949|956
SE|25462334||ab|5|entity|C0521116|Current|tmco|||currently|||0|1000|995|1004
SE|25462334||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|1017|1024
SE|25462334||ab|5|entity|C0681842|prediction|inpr|||prediction|||0|861|1025|1035


SE|25462333||ti|1|text|21|155|Metabolic network motifs can provide novel insights into evolution: The evolutionary origin of Eukaryotic organelles as a case study.
SE|25462333||ti|1|entity|C0243123|biochemical pathways|ftcn|||Metabolic network|||0|717|21|38
SE|25462333||ti|1|entity|C0679622|novel|inpr|||novel|||0|872|58|63
SE|25462333||ti|1|entity|C0233820|Insight|menp|||insights|||0|872|64|72
SE|25462333||ti|1|entity|C0015219|Evolution|genf|||evolution|||0|1000|78|87
SE|25462333||ti|1|entity|C0015219|Evolution|genf|||evolutionary|||0|853|93|105
SE|25462333||ti|1|entity|C0439659|Beginning|tmco|||origin|||0|853|106|112
SE|25462333||ti|1|entity|C0684063|Eukaryota|orgm|||Eukaryotic|||0|853|116|126
SE|25462333||ti|1|entity|C0029219|Organelles|celc|||organelles|||0|853|127|137
SE|25462333||ti|1|entity|C0085973|Case Study|inpr|||case study|||0|1000|143|153
SE|25462333||ti|1|relation|0|0|C0029219|Organelles|celc|celc|||organelles|||0|853|127|137|MOD/HEAD|PART_OF||116|137|0|0|C0684063|Eukaryota|orgm|orgm|||Eukaryotic|||0|853|116|126

SE|25462333||ab|1|text|161|327|Phylogenetic trees are typically constructed using genetic and genomic data, and provide robust evolutionary relationships of species from the genomic point of view.
SE|25462333||ab|1|entity|C0871077|Phylogenesis|idcn|||Phylogenetic|||0|853|161|173
SE|25462333||ab|1|entity|C0040811|Trees|plnt|||trees|||0|853|174|179
SE|25462333||ab|1|entity|C0314603|Genetic|ftcn|||genetic|||0|1000|212|219
SE|25462333||ab|1|entity|C1511726|Data|idcn|||data|||0|861|232|236
SE|25462333||ab|1|entity|C0015219|Evolution|genf|||evolutionary|||0|754|257|269
SE|25462333||ab|1|entity|C0439849|Relationships|qlco|||relationships|||0|754|270|283
SE|25462333||ab|1|entity|C1548151|Species|idcn|||species|||0|1000|287|294
SE|25462333||ab|1|entity|C0449911|View|orga|||view|||0|1000|321|325

SE|25462333||ab|2|text|327|516|We present an application of network motif mining and analysis of metabolic pathways that when used in combination with phylogenetic trees can provide a more complete picture of evolution.
SE|25462333||ab|2|entity|C0679670|network|popg|||network|||0|802|356|363
SE|25462333||ab|2|entity|C0026175|Mining|ocac|||mining|||0|802|370|376
SE|25462333||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|381|389
SE|25462333||ab|2|entity|C1291081|Metabolic Pathway|ftcn|||metabolic pathways|||0|1000|393|411
SE|25462333||ab|2|entity|C0205195|Combined|qlco|||combination|||0|1000|430|441
SE|25462333||ab|2|entity|C0871077|Phylogenesis|idcn|||phylogenetic|||0|853|447|459
SE|25462333||ab|2|entity|C0040811|Trees|plnt|||trees|||0|853|460|465
SE|25462333||ab|2|entity|C0205172|More|ftcn|||more|||0|1000|480|484
SE|25462333||ab|2|entity|C0441469|Picture|mnob|||picture|||0|1000|494|501
SE|25462333||ab|2|entity|C0015219|Evolution|genf|||evolution|||0|1000|505|514

SE|25462333||ab|3|text|516|768|By using distributions of three-node motifs as a proxy for metabolic similarity, we analyze the ancestral origin of Eukaryotic organelles from the metabolic point of view to illustrate the application of our motif mining and analysis network approach.
SE|25462333||ab|3|entity|C0037775|Spatial Distribution|spco|||distributions|||0|1000|525|538
SE|25462333||ab|3|entity|C0205449|Three|qnco|||three|||0|623|542|547
SE|25462333||ab|3|entity|C0746922|NODE|bpoc|||node|||0|623|548|552
SE|25462333||ab|3|entity|C0600420|Proxy|grup|||proxy|||0|1000|565|570
SE|25462333||ab|3|entity|C0311400|Metabolic|ftcn|||metabolic|||0|838|575|584
SE|25462333||ab|3|entity|C0871364|Simile|inpr|||similarity|||0|838|585|595
SE|25462333||ab|3|entity|C0439659|Beginning|tmco|||origin|||0|861|622|628
SE|25462333||ab|3|entity|C0684063|Eukaryota|orgm|||Eukaryotic|||0|853|632|642
SE|25462333||ab|3|entity|C0029219|Organelles|celc|||organelles|||0|853|643|653
SE|25462333||ab|3|entity|C0311400|Metabolic|ftcn|||metabolic|||0|694|663|672
SE|25462333||ab|3|entity|C0449911|View|orga|||view|||0|1000|682|686
SE|25462333||ab|3|entity|C0026175|Mining|ocac|||mining|||0|861|730|736
SE|25462333||ab|3|entity|C0936012|Analysis|resa|||analysis|||0|851|741|749
SE|25462333||ab|3|entity|C0679670|network|popg|||network|||0|851|750|757
SE|25462333||ab|3|entity|C0449445|Approach|spco|||approach|||0|851|758|766
SE|25462333||ab|3|relation|0|0|C0029219|Organelles|celc|celc|||organelles|||0|853|643|653|MOD/HEAD|PART_OF||632|653|0|0|C0684063|Eukaryota|orgm|orgm|||Eukaryotic|||0|853|632|642

SE|25462333||ab|4|text|768|854|Our analysis suggests that the hypothesis of an early proto-Eukaryote could be valid.
SE|25462333||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|1000|772|780
SE|25462333||ab|4|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|799|809
SE|25462333||ab|4|entity|C1279919|Early|tmco|||early|||0|802|816|821
SE|25462333||ab|4|entity|C0015161|Eukaryotic Cell|cell|||Eukaryote|||0|802|828|837

SE|25462333||ab|5|text|854|990|It also suggests that a delta- or epsilon-Proteobacteria may have been the endosymbiotic partner that gave rise to modern mitochondria.
SE|25462333||ab|5|entity|C0751990|Epsilonproteobacteria|bact|||epsilon-Proteobacteria|||0|1000|888|910
SE|25462333||ab|5|entity|C0026237|Mitochondria|celc|||mitochondria|||0|861|976|988

SE|25462333||ab|6|text|990|1204|Our evolutionary analysis needs to be extended by building metabolic network reconstructions of species from the phylum Crenarchaeota, which is considered to be a possible archaeal ancestor of the eukaryotic cell.
SE|25462333||ab|6|entity|C0015219|Evolution|genf|||evolutionary|||0|853|994|1006
SE|25462333||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|853|1007|1015
SE|25462333||ab|6|entity|C0243123|biochemical pathways|ftcn|||metabolic network|||0|802|1049|1066
SE|25462333||ab|6|entity|C0524865|Reconstructive Surgical Procedures|topp|||reconstructions|||0|802|1067|1082
SE|25462333||ab|6|entity|C1548151|Species|idcn|||species|||0|1000|1086|1093
SE|25462333||ab|6|entity|C1038269|Phyla|plnt|||phylum|||0|872|1103|1109
SE|25462333||ab|6|entity|C0524831|Crenarchaeota|arch|||Crenarchaeota|||0|872|1110|1123
SE|25462333||ab|6|entity|C0332149|Possible|qlco|||possible|||0|816|1153|1161
SE|25462333||ab|6|entity|C0003732|Archaea|arch|||archaeal|||0|816|1162|1170
SE|25462333||ab|6|entity|C0870134|Ancestors|famg|||ancestor|||0|816|1171|1179
SE|25462333||ab|6|entity|C0015161|Eukaryotic Cell|cell|||eukaryotic cell|||0|1000|1187|1202

SE|25462333||ab|7|text|1204|1411|In this paper, we also propose a methodology for constructing phylogenetic trees that incorporates metabolic network signatures to identify regions of genomically-estimated phylogenies that may be spurious.
SE|25462333||ab|7|entity|C0030351|Paper|mnob|||paper|||0|1000|1212|1217
SE|25462333||ab|7|entity|C0025664|Methodology|inpr|||methodology|||0|1000|1237|1248
SE|25462333||ab|7|entity|C0871077|Phylogenesis|idcn|||phylogenetic|||0|754|1266|1278
SE|25462333||ab|7|entity|C0040811|Trees|plnt|||trees|||0|754|1279|1284
SE|25462333||ab|7|entity|C0243123|biochemical pathways|ftcn|||metabolic network|||0|879|1303|1320
SE|25462333||ab|7|entity|C1519316|Signature|inpr|||signatures|||0|879|1321|1331
SE|25462333||ab|7|entity|C0205147|Region|spco|||regions|||0|966|1344|1351
SE|25462333||ab|7|entity|C0750572|Estimated|qnco|||estimated|||0|790|1367|1376
SE|25462333||ab|7|entity|C0031797|Phylogeny|idcn|||phylogenies|||0|790|1377|1388
SE|25462333||ab|7|entity|C0205237|False|qlco|||spurious|||0|1000|1401|1409

SE|25462333||ab|8|text|1411|1560|We find that results generated from our approach are consistent with a parallel phylogenetic analysis using the method of feature frequency profiles.
SE|25462333||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1424|1431
SE|25462333||ab|8|entity|C0449445|Approach|spco|||approach|||0|1000|1451|1459
SE|25462333||ab|8|entity|C1519068|Phylogenetic Analysis|resa|||phylogenetic analysis|||0|901|1491|1512
SE|25462333||ab|8|entity|C0025663|Methods|inpr|||method|||0|1000|1523|1529
SE|25462333||ab|8|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|660|1541|1550


SE|25462335||ti|1|text|21|121|On the modelling and analysis of the regulatory network of dengue virus pathogenesis and clearance.
SE|25462335||ti|1|entity|C0870071|Modeling|inpr,resa|||modelling|||0|1000|28|37
SE|25462335||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|1000|42|50
SE|25462335||ti|1|entity|C0220905|regulatory|rnlw|||regulatory|||0|888|58|68
SE|25462335||ti|1|entity|C0679670|network|popg|||network|||0|888|69|76
SE|25462335||ti|1|entity|C0920672|virus pathogenesis|comd|||virus pathogenesis|||0|901|87|105
SE|25462335||ti|1|entity|C0449297|Clearance|qlco|||clearance|||0|1000|110|119
SE|25462335||ti|1|relation|0|0|C0679670|network|popg,humn|popg|||network|||0|888|69|76|MOD/HEAD|USES||58|76|0|0|C0220905|regulatory|rnlw|rnlw|||regulatory|||0|888|58|68

SE|25462335||ab|1|text|127|202|Dengue virus can ignite both protective and pathogenic responses in human.
SE|25462335||ab|1|entity|C0011315|Dengue Virus|virs|||Dengue virus|||0|1000|127|139
SE|25462335||ab|1|entity|C1136169|Pathogenicity|orga,qlco|||pathogenic|||0|853|171|181
SE|25462335||ab|1|entity|C0871261|response|clna|||responses|||0|853|182|191
SE|25462335||ab|1|entity|C0020114|Human|humn|||human|||0|1000|195|200
SE|25462335||ab|1|relation|3|3|C0011315|Dengue Virus|virs|virs|||Dengue virus|||0|1000|127|139|PREP|PROCESS_OF||192|194|1|1|C0020114|Human|grup,humn|humn|||human|||0|1000|195|200

SE|25462335||ab|2|text|202|295|The pathogenesis is related with modified functioning of our immune system during infection.
SE|25462335||ab|2|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|1000|206|218
SE|25462335||ab|2|entity|C0205349|Altered|ftcn|||modified|||0|872|235|243
SE|25462335||ab|2|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|244|255
SE|25462335||ab|2|entity|C0020962|Immune system|bdsy|||immune system|||0|1000|263|276

SE|25462335||ab|3|text|295|426|Pattern recognition receptors like Toll like receptor 3 is vital for the induction of innate immunity in case of Dengue infection.
SE|25462335||ab|3|entity|C1564907|Receptors, Pattern Recognition|aapp,imft,rcpt|||Pattern recognition receptors|||0|1000|295|324
SE|25462335||ab|3|entity|C1321919|TLR4 protein, human|aapp,rcpt|7099|TLR4|Toll|||0|1000|330|334
SE|25462335||ab|3|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|861|340|348
SE|25462335||ab|3|entity|C0442732|Vital|qlco|||vital|||0|1000|354|359
SE|25462335||ab|3|entity|C0857127|Induction|topp|||induction|||0|1000|368|377
SE|25462335||ab|3|entity|C0020969|Immunity, Natural|orga|||innate immunity|||0|1000|381|396

SE|25462335||ab|4|text|426|551|Toll like receptor 3 induces TRIF mediated activation of Type 1 interferons and Fc receptor mediated induction of cytokines.
SE|25462335||ab|4|entity|C1321919|TLR4 protein, human|aapp,rcpt|7099|TLR4|Toll|||0|1000|426|430
SE|25462335||ab|4|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|861|436|444
SE|25462335||ab|4|entity|||gngm|140691,148022|TRIM69,TICAM1|TRIF|||0|1000|455|459
SE|25462335||ab|4|entity|C0441729|Type 1|clas|||Type 1|||0|901|483|489
SE|25462335||ab|4|entity|C0021747|Interferons|aapp,imft,phsu|||interferons|||0|901|490|501
SE|25462335||ab|4|entity|C0034805|Fc Receptor|aapp,imft,rcpt|||Fc receptor|||0|1000|506|517
SE|25462335||ab|4|entity|C0857127|Induction|topp|||induction|||0|1000|527|536
SE|25462335||ab|4|entity|C0079189|cytokine|aapp,imft|||cytokines|||0|1000|540|549
SE|25462335||ab|4|relation|1|1|C1321919|TLR4 protein, human|aapp,gngm,rcpt|aapp|7099|TLR4|Toll|||0|1000|426|430|VERB|STIMULATES||447|454|6|1|||gngm,aapp|gngm|140691,148022|TRIM69,TICAM1|TRIF|||0|1000|455|459

SE|25462335||ab|5|text|551|686|Interferons have been related with clearance of Dengue virus but it has adopted modified regulatory mechanisms to counter this effect.
SE|25462335||ab|5|entity|C0021747|Interferons|aapp,imft,phsu|||Interferons|||0|1000|551|562
SE|25462335||ab|5|entity|C0449297|Clearance|qlco|||clearance|||0|1000|586|595
SE|25462335||ab|5|entity|C0011315|Dengue Virus|virs|||Dengue virus|||0|1000|599|611
SE|25462335||ab|5|entity|C0220905|regulatory|rnlw|||regulatory|||0|888|640|650
SE|25462335||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|651|661
SE|25462335||ab|5|entity|C1280500|Effect|qlco|||effect|||0|1000|678|684

SE|25462335||ab|6|text|686|864|SOCS protein is also induced due to the interferon and cytokine mediated signalling which can subsequently play its part in the regulation of interferon and cytokine production.
SE|25462335||ab|6|entity|C1564682|Suppressor of Cytokine Signaling Proteins|aapp,bacs|1154|CISH|SOCS protein|||0|983|686|698
SE|25462335||ab|6|entity|C0021747|Interferons|aapp,imft,phsu|||interferon|||0|1000|726|736
SE|25462335||ab|6|entity|C0079189|cytokine|aapp,imft|||cytokine|||0|1000|741|749
SE|25462335||ab|6|entity|C0037083|Signal Transduction|celf|||signalling|||0|1000|759|769
SE|25462335||ab|6|entity|C0449719|Part|spco|||part|||0|1000|802|806
SE|25462335||ab|6|entity|C0851285|Regulation|gora|||regulation|||0|1000|814|824
SE|25462335||ab|6|entity|C0021747|Interferons|aapp,imft,phsu|||interferon|||0|1000|828|838
SE|25462335||ab|6|entity|C1155099|cytokine biosynthesis|moft|||cytokine production|||0|1000|843|862
SE|25462335||ab|6|relation|1|1|C1564682|Suppressor of Cytokine Signaling Proteins|aapp,gngm,bacs|aapp|1154|CISH|SOCS protein|||0|983|686|698|VERB|STIMULATES||707|714|7|1|C0021747|Interferons|aapp,gngm,imft,phsu|gngm|||interferon|||0|1000|726|736
SE|25462335||ab|6|relation|1|1|C1564682|Suppressor of Cytokine Signaling Proteins|aapp,gngm,bacs|aapp|1154|CISH|SOCS protein|||0|983|686|698|VERB|STIMULATES||707|714|7|1|C0079189|cytokine|aapp,gngm,imft|aapp|||cytokine|||0|1000|741|749
SE|25462335||ab|6|relation|3|1|C0021747|Interferons|aapp,gngm,imft,phsu|aapp|||interferon|||0|1000|726|736|VERB|AFFECTS||750|758|5|1|C0037083|Signal Transduction|celf|celf|||signalling|||0|1000|759|769
SE|25462335||ab|6|relation|3|1|C0079189|cytokine|aapp,gngm,imft|aapp|||cytokine|||0|1000|741|749|VERB|AFFECTS||750|758|5|1|C0037083|Signal Transduction|celf|celf|||signalling|||0|1000|759|769

SE|25462335||ab|7|text|864|992|Our hypothesis in this study relates the pathogenesis of Dengue virus with the SOCS mediated inhibition of our innate immunity.
SE|25462335||ab|7|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|868|878
SE|25462335||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|887|892
SE|25462335||ab|7|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|1000|905|917
SE|25462335||ab|7|entity|C0011315|Dengue Virus|virs|||Dengue virus|||0|1000|921|933
SE|25462335||ab|7|entity|C0299250|Cytokine Inducible SH2-Containing Protein|aapp,bacs|1154|CISH|SOCS|||0|1000|943|947
SE|25462335||ab|7|entity|C0020969|Immunity, Natural|orga|||innate immunity|||0|1000|975|990
SE|25462335||ab|7|relation|3|1|C0299250|Cytokine Inducible SH2-Containing Protein|aapp,gngm,bacs|aapp|1154|CISH|SOCS|||0|1000|943|947|PREP|PART_OF||934|938|4|1|C0011315|Dengue Virus|virs|virs|||Dengue virus|||0|1000|921|933

SE|25462335||ab|8|text|992|1183|We used the qualitative formalism of Rene Thomas to model the biological regulatory network of Toll like receptor 3 mediated signalling pathway in an association with pathogenesis of dengue.
SE|25462335||ab|8|entity|C0205556|Qualitative|qlco|||qualitative|||0|694|1004|1015
SE|25462335||ab|8|entity|C0026336|Study models|inpr,resd|||model|||0|1000|1044|1049
SE|25462335||ab|8|entity|C0205460|biological|ftcn|||biological|||0|851|1054|1064
SE|25462335||ab|8|entity|C0220905|regulatory|rnlw|||regulatory|||0|851|1065|1075
SE|25462335||ab|8|entity|C0679670|network|popg|||network|||0|851|1076|1083
SE|25462335||ab|8|entity|C1321919|TLR4 protein, human|aapp,rcpt|7099|TLR4|Toll|||0|1000|1087|1091
SE|25462335||ab|8|entity|C0086597|Mediating|socb|||mediated|||0|786|1108|1116
SE|25462335||ab|8|entity|C1514762|Receptor Signaling|moft|||receptor 3 mediated signalling|||0|786|1097|1127
SE|25462335||ab|8|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|786|1128|1135
SE|25462335||ab|8|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|1000|1159|1171
SE|25462335||ab|8|relation|0|0|C0679670|network|popg,humn|popg|||network|||0|851|1076|1083|MOD/HEAD|USES||1065|1083|0|0|C0220905|regulatory|rnlw|rnlw|||regulatory|||0|851|1065|1075

SE|25462335||ab|9|text|1183|1303|Logical parameters for the qualitative modelling were inferred using a model checking approach implemented in SMBioNet.
SE|25462335||ab|9|entity|C0023963|Logic|idcn|||Logical|||0|853|1183|1190
SE|25462335||ab|9|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|1210|1221
SE|25462335||ab|9|entity|C0870071|Modeling|inpr,resa|||modelling|||0|888|1222|1231
SE|25462335||ab|9|entity|C0026336|Study models|inpr,resd|||model|||0|802|1254|1259
SE|25462335||ab|9|entity|C0449445|Approach|spco|||approach|||0|802|1269|1277

SE|25462335||ab|10|text|1303|1461|A linear hybrid model, parametric linear hybrid automaton, was constructed to incorporate the activation and inhibition time delays in the qualitative model.
SE|25462335||ab|10|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|901|1312|1318
SE|25462335||ab|10|entity|C0023732|Linear Models|qnco|||linear hybrid model|||0|901|1305|1324
SE|25462335||ab|10|entity|C0449381|Observation parameter|fndg|||parametric|||0|815|1326|1336
SE|25462335||ab|10|entity|C0205132|Linear|spco|||linear|||0|815|1337|1343
SE|25462335||ab|10|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|815|1344|1350
SE|25462335||ab|10|entity|C0336537|Robot|mnob|||automaton|||0|815|1351|1360
SE|25462335||ab|10|entity|C0040223|Time|tmco|||time|||0|888|1423|1427
SE|25462335||ab|10|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|1442|1453
SE|25462335||ab|10|entity|C0026336|Study models|inpr,resd|||model|||0|888|1454|1459

SE|25462335||ab|11|text|1461|1685|The qualitative model captured all the possible expression dynamics of the proteins in the form of paths, some of which were observed as abstract cycles (representing homoeostasis) and diverging paths towards stable states.
SE|25462335||ab|11|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|1465|1476
SE|25462335||ab|11|entity|C0026336|Study models|inpr,resd|||model|||0|888|1477|1482
SE|25462335||ab|11|entity|C0332149|Possible|qlco|||possible|||0|623|1500|1508
SE|25462335||ab|11|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|1536|1544
SE|25462335||ab|11|entity|C1522492|Formation|ftcn|||form|||0|1000|1552|1556
SE|25462335||ab|11|entity|C0030664|Pathology|bmod|||paths|||0|966|1560|1565
SE|25462335||ab|11|entity|C1552863|Abstract|idcn|||abstract|||0|872|1598|1606
SE|25462335||ab|11|entity|C0750729|Course|tmco|||cycles|||0|872|1607|1613
SE|25462335||ab|11|entity|C0019868|Homeostasis|orgf|||homoeostasis|||0|861|1628|1640
SE|25462335||ab|11|entity|C0030664|Pathology|bmod|||paths|||0|827|1656|1661
SE|25462335||ab|11|entity|C1442792|State|ftcn|||states|||0|827|1677|1683

SE|25462335||ab|12|text|1685|1849|The analysis of the qualitative model highlighted the importance of SOCS protein in elevating propagation of dengue virus through inhibition of type 1 interferons.
SE|25462335||ab|12|entity|C0936012|Analysis|resa|||analysis|||0|1000|1689|1697
SE|25462335||ab|12|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|1705|1716
SE|25462335||ab|12|entity|C0026336|Study models|inpr,resd|||model|||0|888|1717|1722
SE|25462335||ab|12|entity|C1564682|Suppressor of Cytokine Signaling Proteins|aapp,bacs|1154|CISH|SOCS protein|||0|983|1753|1765
SE|25462335||ab|12|entity|C0205250|High|qlco|||elevating|||0|844|1769|1778
SE|25462335||ab|12|entity|C0011315|Dengue Virus|virs|||dengue virus|||0|1000|1794|1806
SE|25462335||ab|12|entity|C0441729|Type 1|clas|||type 1|||0|901|1829|1835
SE|25462335||ab|12|entity|C0021747|Interferons|aapp,imft,phsu|||interferons|||0|901|1836|1847
SE|25462335||ab|12|relation|6|3|C1564682|Suppressor of Cytokine Signaling Proteins|aapp,gngm,bacs|aapp|1154|CISH|SOCS protein|||0|983|1753|1765|NOM|INHIBITS||1815|1825|1|1|C0021747|Interferons|aapp,gngm,imft,phsu|aapp|||interferons|||0|901|1836|1847

SE|25462335||ab|13|text|1849|2092|Detailed qualitative analysis of regulatory network endorses our hypothesis that elevated levels of cytokine subsequently induce SOCS expression which in turn results into the continuous down-regulation of Toll like receptor 3 and interferon.
SE|25462335||ab|13|entity|C1522508|Details|qlco|||Detailed|||0|840|1849|1857
SE|25462335||ab|13|entity|C0205556|Qualitative|qlco|||qualitative|||0|840|1858|1869
SE|25462335||ab|13|entity|C0936012|Analysis|resa|||analysis|||0|840|1870|1878
SE|25462335||ab|13|entity|C0220905|regulatory|rnlw|||regulatory|||0|888|1882|1892
SE|25462335||ab|13|entity|C0679670|network|popg|||network|||0|888|1893|1900
SE|25462335||ab|13|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|1914|1924
SE|25462335||ab|13|entity|C0205250|High|qlco|||elevated|||0|888|1930|1938
SE|25462335||ab|13|entity|C0441889|Levels|inpr|||levels|||0|888|1939|1945
SE|25462335||ab|13|entity|C0079189|cytokine|aapp,imft|||cytokine|||0|1000|1949|1957
SE|25462335||ab|13|entity|C0299250|Cytokine Inducible SH2-Containing Protein|aapp,bacs|1154|CISH|SOCS|||0|888|1978|1982
SE|25462335||ab|13|entity|C0549178|Continuous|tmco|||continuous|||0|888|2025|2035
SE|25462335||ab|13|entity|C0013081|Down-Regulation|celf|||down-regulation|||0|888|2036|2051
SE|25462335||ab|13|entity|C1321919|TLR4 protein, human|aapp,rcpt|7099|TLR4|Toll|||0|1000|2055|2059
SE|25462335||ab|13|entity|C0597357|receptor|aapp,rcpt|||receptor|||0|861|2065|2073
SE|25462335||ab|13|entity|C0021747|Interferons|aapp,imft,phsu|||interferon|||0|1000|2080|2090
SE|25462335||ab|13|relation|0|0|C0679670|network|popg,humn|popg|||network|||0|888|1893|1900|MOD/HEAD|USES||1882|1900|0|0|C0220905|regulatory|rnlw|rnlw|||regulatory|||0|888|1882|1892
SE|25462335||ab|13|relation|5|1|C0079189|cytokine|aapp,gngm,imft|aapp|||cytokine|||0|1000|1949|1957|VERB|STIMULATES||1971|1977|5|1|C0299250|Cytokine Inducible SH2-Containing Protein|aapp,gngm,bacs|gngm|1154|CISH|SOCS|||0|888|1978|1982

SE|25462335||ab|14|text|2092|2176|This may result into the Dengue pathogenesis during the stage of immunosuppression.
SE|25462335||ab|14|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|861|2124|2136
SE|25462335||ab|14|entity|C1306673|Stage|qlco|||stage|||0|1000|2148|2153

SE|25462335||ab|15|text|2176|2423|Further analysis with HyTech (HYbrid TECHnology) tool provided us with the real-time constraints (delay constraints) of the proteins involved in the cyclic paths of the regulatory network backing the evidence provided by the qualitative analysis.
SE|25462335||ab|15|entity|C1517331|Further|spco|||Further|||0|888|2176|2183
SE|25462335||ab|15|entity|C0936012|Analysis|resa|||analysis|||0|888|2184|2192
SE|25462335||ab|15|entity|C0007597|Cell hybridization|lbpr|||HYbrid|||0|888|2206|2212
SE|25462335||ab|15|entity|C0039421|Technology|ocdi|||TECHnology|||0|888|2213|2223
SE|25462335||ab|15|entity|C0336791|Tool|mnob|||tool|||0|1000|2225|2229
SE|25462335||ab|15|entity|C1550177|Real Time|idcn|||real-time|||0|734|2251|2260
SE|25462335||ab|15|entity|C0205421|Deferred|tmco|||delay|||0|694|2274|2279
SE|25462335||ab|15|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|2300|2308
SE|25462335||ab|15|entity|C0439596|Cyclical|tmco|||cyclic|||0|872|2325|2331
SE|25462335||ab|15|entity|C0030664|Pathology|bmod|||paths|||0|872|2332|2337
SE|25462335||ab|15|entity|C0220905|regulatory|rnlw|||regulatory|||0|888|2345|2355
SE|25462335||ab|15|entity|C0679670|network|popg|||network|||0|888|2356|2363
SE|25462335||ab|15|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|2401|2412
SE|25462335||ab|15|entity|C0936012|Analysis|resa|||analysis|||0|888|2413|2421
SE|25462335||ab|15|relation|0|0|C0679670|network|popg,humn|popg|||network|||0|888|2356|2363|MOD/HEAD|USES||2345|2363|0|0|C0220905|regulatory|rnlw|rnlw|||regulatory|||0|888|2345|2355
SE|25462335||ab|15|relation|1|1|C0936012|Analysis|resa|resa|||analysis|||0|888|2413|2421|PREP|METHOD_OF||2394|2396|10|3|C0030664|Pathology|bmod|bmod|||paths|||0|872|2332|2337

SE|25462335||ab|16|text|2423|2502|The HyTech results also suggest that the role of SOCS is vital in homoeostasis.
SE|25462335||ab|16|entity|C0035820|Role|socb|||role|||0|1000|2464|2468
SE|25462335||ab|16|entity|C0299250|Cytokine Inducible SH2-Containing Protein|aapp,bacs|1154|CISH|SOCS|||0|1000|2472|2476
SE|25462335||ab|16|entity|C0442732|Vital|qlco|||vital|||0|1000|2480|2485
SE|25462335||ab|16|entity|C0019868|Homeostasis|orgf|||homoeostasis|||0|1000|2489|2501


SE|25462336||ti|1|text|21|108|Seeding-inspired chemotaxis genetic algorithm for the inference of biological systems.
SE|25462336||ti|1|entity|C0004048|Inspiration function|ortf|||inspired|||0|798|29|37
SE|25462336||ti|1|entity|C0008018|Chemotaxis|celf|||chemotaxis|||0|798|38|48
SE|25462336||ti|1|entity|C1517503|Genetic Programming|inpr|||genetic algorithm|||0|798|49|66
SE|25462336||ti|1|entity|C0679201|inference|idcn|||inference|||0|1000|75|84
SE|25462336||ti|1|entity|C0205460|biological|ftcn|||biological|||0|888|88|98
SE|25462336||ti|1|entity|C0449913|System|ftcn|||systems|||0|888|99|106

SE|25462336||ab|1|text|114|272|A large challenge in the post-genomic era is to obtain the quantitatively dynamic interactive information of the important constitutes of underlying systems.
SE|25462336||ab|1|entity|C0549177|Large|qnco|||large|||0|888|116|121
SE|25462336||ab|1|entity|C0681698|historical period|tmco|||era|||0|802|152|155
SE|25462336||ab|1|entity|C0729333|Dynamic|ftcn|||dynamic|||0|763|188|195
SE|25462336||ab|1|entity|C1533716|Information|idcn|||information|||0|763|208|219
SE|25462336||ab|1|entity|C0449913|System|ftcn|||systems|||0|861|263|270

SE|25462336||ab|2|text|272|406|The S-system is a dynamic and structurally rich model that determines the net strength of interactions between genes and/or proteins.
SE|25462336||ab|2|entity|C0449913|System|ftcn|||system|||0|888|278|284
SE|25462336||ab|2|entity|C0729333|Dynamic|ftcn|||dynamic|||0|1000|290|297
SE|25462336||ab|2|entity|C0699759|Wealthy|qlco|||rich|||0|790|315|319
SE|25462336||ab|2|entity|C0026336|Study models|inpr,resd|||model|||0|790|320|325
SE|25462336||ab|2|entity|C0812375|ELK3 gene|gngm|2004,131096|ELK3,KCNH8|net|||0|888|346|349
SE|25462336||ab|2|entity|C0808080|STRENGTH|idcn|||strength|||0|888|350|358
SE|25462336||ab|2|entity|C0017337|Genes|gngm|||genes|||0|1000|383|388
SE|25462336||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|396|404

SE|25462336||ab|3|text|406|554|Good generation characteristics without the need for prior information have allowed S-systems to become one of the most promising canonical models.
SE|25462336||ab|3|entity|C0205170|Good|qlco|||Good|||0|840|406|410
SE|25462336||ab|3|entity|C0079411|Generations|tmco|||generation|||0|840|411|421
SE|25462336||ab|3|entity|C1521970|Characteristics|grpa|||characteristics|||0|840|422|437
SE|25462336||ab|3|entity|C0027552|Needs|qlco|||need|||0|1000|450|454
SE|25462336||ab|3|entity|C0332152|Status pre-|tmco|||prior|||0|888|459|464
SE|25462336||ab|3|entity|C1533716|Information|idcn|||information|||0|888|465|476
SE|25462336||ab|3|entity|C0683607|allowing|socb|||allowed|||0|829|482|489
SE|25462336||ab|3|entity|C0449913|System|ftcn|||systems|||0|829|492|499
SE|25462336||ab|3|entity|C0205447|One|qnco|||one|||0|1000|510|513
SE|25462336||ab|3|entity|C0205393|Most|qnco|||most|||0|566|521|525
SE|25462336||ab|3|entity|C1555307|promise|idcn|||promising|||0|566|526|535

SE|25462336||ab|4|text|554|706|Various evolutionary computation technologies have recently been developed for the identification of system parameters and skeletal-network structures.
SE|25462336||ab|4|entity|C0015219|Evolution|genf|||evolutionary|||0|711|562|574
SE|25462336||ab|4|entity|C0039421|Technology|ocdi|||technologies|||0|711|587|599
SE|25462336||ab|4|entity|C0332185|Recent|tmco|||recently|||0|1000|605|613
SE|25462336||ab|4|entity|C0449913|System|ftcn|||system|||0|888|655|661
SE|25462336||ab|4|entity|C0521324|Skeletal|spco|||skeletal|||0|840|677|685
SE|25462336||ab|4|entity|C0679670|network|popg|||network|||0|840|686|693
SE|25462336||ab|4|entity|C0678594|Structure|spco|||structures|||0|840|694|704

SE|25462336||ab|5|text|706|784|However, the gaps between the truncated and preserved terms remain too small.
SE|25462336||ab|5|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||gaps|||0|966|719|723
SE|25462336||ab|5|entity|C0456735|preserved|ocac|||preserved|||0|872|750|759
SE|25462336||ab|5|entity|C1515273|Term|tmco|||terms|||0|872|760|765
SE|25462336||ab|5|entity|C0700321|Small|qnco|||small|||0|861|777|782

SE|25462336||ab|6|text|784|923|Additionally, current research methods fail to identify the structures of high dimensional systems (e.g., 30 genes with 1800 connections).
SE|25462336||ab|6|entity|C0521116|Current|tmco|||current|||0|901|798|805
SE|25462336||ab|6|entity|C0086912|Research Methodology|resa|||research methods|||0|901|806|822
SE|25462336||ab|6|entity|C0678594|Structure|spco|||structures|||0|966|844|854
SE|25462336||ab|6|entity|C0205250|High|qlco|||high|||0|828|858|862
SE|25462336||ab|6|entity|C0439534|Dimensions|qnco|||dimensional|||0|828|863|874
SE|25462336||ab|6|entity|C0449913|System|ftcn|||systems|||0|828|875|882
SE|25462336||ab|6|entity|C0017337|Genes|gngm|||genes|||0|861|893|898
SE|25462336||ab|6|entity|C0449379|Connection|inpr|||connections|||0|827|909|920

SE|25462336||ab|7|text|923|1024|Optimization technologies should converge fast and have the ability to adaptively adjust the search.
SE|25462336||ab|7|entity|C0039421|Technology|ocdi|||technologies|||0|827|936|948
SE|25462336||ab|7|entity|C0456962|Fast|qlco|||fast|||0|1000|965|969
SE|25462336||ab|7|entity|C0085732|Ability|orga|||ability|||0|1000|983|990
SE|25462336||ab|7|entity|C1552603|search|idcn|||search|||0|1000|1016|1022

SE|25462336||ab|8|text|1024|1198|In this study, we propose a seeding-inspired chemotaxis genetic algorithm (SCGA) that can force evolution to adjust the population movement to identify a favorable location.
SE|25462336||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1032|1037
SE|25462336||ab|8|entity|C0004048|Inspiration function|ortf|||inspired|||0|798|1060|1068
SE|25462336||ab|8|entity|C0008018|Chemotaxis|celf|||chemotaxis|||0|798|1069|1079
SE|25462336||ab|8|entity|C1517503|Genetic Programming|inpr|||genetic algorithm|||0|798|1080|1097
SE|25462336||ab|8|entity|C0015219|Evolution|genf|||evolution|||0|1000|1120|1129
SE|25462336||ab|8|entity|C1257890|Population Group|popg|||population|||0|888|1144|1154
SE|25462336||ab|8|entity|C0026649|Movement|orgf|||movement|||0|888|1155|1163
SE|25462336||ab|8|entity|C0450429|Location|spco|||location|||0|853|1188|1196
SE|25462336||ab|8|relation|0|0|C0026649|Movement|orgf|orgf|||movement|||0|888|1155|1163|MOD/HEAD|PROCESS_OF||1144|1163|0|0|C1257890|Population Group|popg,humn|humn|||population|||0|888|1144|1154

SE|25462336||ab|9|text|1198|1300|The seeding-inspired training strategy is a method to achieve optimal results with limited resources.
SE|25462336||ab|9|entity|C0004048|Inspiration function|ortf|||inspired|||0|775|1210|1218
SE|25462336||ab|9|entity|C0220931|Training|edac|||training|||0|775|1219|1227
SE|25462336||ab|9|entity|C0025663|Methods|inpr|||method|||0|1000|1242|1248
SE|25462336||ab|9|entity|C1274040|result|ftcn|||results|||0|827|1268|1275
SE|25462336||ab|9|entity|C0439801|Limited|ftcn|||limited|||0|888|1281|1288
SE|25462336||ab|9|entity|C0035201|Resources|idcn|||resources|||0|888|1289|1298

SE|25462336||ab|10|text|1300|1588|SCGA introduces seeding-inspired genetic operations to allow a population to possess competitive power (exploitation and exploration) and a winner-chemotaxis-induced population migration to force a population to repeatedly tumble away from an attractor and swim toward another attractor.
SE|25462336||ab|10|entity|C0004048|Inspiration function|ortf|||SCGA|||0|798|1300|1304
SE|25462336||ab|10|entity|C0008018|Chemotaxis|celf|||SCGA|||0|798|1300|1304
SE|25462336||ab|10|entity|C1517503|Genetic Programming|inpr|||SCGA|||0|798|1300|1304
SE|25462336||ab|10|entity|C0004048|Inspiration function|ortf|||inspired|||0|775|1324|1332
SE|25462336||ab|10|entity|C0314603|Genetic|ftcn|||genetic|||0|775|1333|1340
SE|25462336||ab|10|entity|C0038895|Surgical aspects|ftcn|||operations|||0|775|1341|1351
SE|25462336||ab|10|entity|C1257890|Population Group|popg|||population|||0|1000|1363|1373
SE|25462336||ab|10|entity|C0679932|competition|socb|||competitive|||0|694|1385|1396
SE|25462336||ab|10|entity|C1280903|Exploration procedure|topp|||exploration|||0|1000|1421|1432
SE|25462336||ab|10|entity|C0008018|Chemotaxis|celf|||chemotaxis|||0|798|1447|1457
SE|25462336||ab|10|entity|C0205263|Induced|ftcn|||induced|||0|798|1458|1465
SE|25462336||ab|10|entity|C0600210|population migration|acty|||population migration|||0|798|1466|1486
SE|25462336||ab|10|entity|C1257890|Population Group|popg|||population|||0|1000|1498|1508

SE|25462336||ab|11|text|1588|1645|SCGA was tested on several canonical biological systems.
SE|25462336||ab|11|entity|C0004048|Inspiration function|ortf|||SCGA|||0|798|1588|1592
SE|25462336||ab|11|entity|C0008018|Chemotaxis|celf|||SCGA|||0|798|1588|1592
SE|25462336||ab|11|entity|C1517503|Genetic Programming|inpr|||SCGA|||0|798|1588|1592
SE|25462336||ab|11|entity|C0443302|Several|qnco|||several|||0|775|1607|1614
SE|25462336||ab|11|entity|C0205460|biological|ftcn|||biological|||0|775|1625|1635
SE|25462336||ab|11|entity|C0449913|System|ftcn|||systems|||0|775|1636|1643

SE|25462336||ab|12|text|1645|1761|SCGA not only learned the correct structure within only one to three pruning steps but also ensures pruning safety.
SE|25462336||ab|12|entity|C0004048|Inspiration function|ortf|||SCGA|||0|798|1645|1649
SE|25462336||ab|12|entity|C0008018|Chemotaxis|celf|||SCGA|||0|798|1645|1649
SE|25462336||ab|12|entity|C1517503|Genetic Programming|inpr|||SCGA|||0|798|1645|1649
SE|25462336||ab|12|entity|C1518422|Not|ftcn|||not|||0|1000|1650|1653
SE|25462336||ab|12|entity|C0678594|Structure|spco|||structure|||0|861|1679|1688
SE|25462336||ab|12|entity|C0205447|One|qnco|||one|||0|861|1701|1704
SE|25462336||ab|12|entity|C0205449|Three|qnco|||three|||0|829|1708|1713
SE|25462336||ab|12|entity|C0453309|Prunes|food|||pruning|||0|829|1714|1721
SE|25462336||ab|12|entity|C1261552|Step|ftcn|||steps|||0|829|1722|1727
SE|25462336||ab|12|entity|C0036043|Safety|hcpp|||safety|||0|1000|1753|1759

SE|25462336||ab|13|text|1761|1854|The values of the truncated terms were all smaller than 10-14, even for a thirty-gene system.
SE|25462336||ab|13|entity|C0042295|Values|qlco|||values|||0|1000|1765|1771
SE|25462336||ab|13|entity|C1515273|Term|tmco|||terms|||0|827|1789|1794
SE|25462336||ab|13|entity|C0547044|Smaller|qlco|||smaller|||0|1000|1804|1811
SE|25462336||ab|13|entity|C0017337|Genes|gngm|||gene|||0|790|1842|1846
SE|25462336||ab|13|entity|C0449913|System|ftcn|||system|||0|790|1847|1853


SE|25462337||ti|1|text|21|78|Docking assay of small molecule antivirals to p7 of HCV.
SE|25462337||ti|1|entity|C1510438|Assay|lbpr|||assay|||0|1000|29|34
SE|25462337||ti|1|entity|C1328819|small molecule|orch|||small molecule|||0|901|38|52
SE|25462337||ti|1|entity|C0003451|Antiviral Agents|phsu|||antivirals|||0|901|53|63
SE|25462337||ti|1|entity|C0220847|Hepatitis C virus|virs|||HCV|||0|1000|73|76

SE|25462337||ab|1|text|84|204|Protein p7 of HCV is a 63 amino acid channel forming membrane protein essential for the progression of viral infection.
SE|25462337||ab|1|entity|C0033684|Proteins|aapp,bacs|||Protein|||0|694|84|91
SE|25462337||ab|1|entity|C0220847|Hepatitis C virus|virs|||HCV|||0|1000|98|101
SE|25462337||ab|1|entity|C0949771|Amino Acid Transporter|aapp,bacs|||amino acid channel|||0|818|110|128
SE|25462337||ab|1|entity|C0205431|Formed|ftcn|||forming|||0|818|129|136
SE|25462337||ab|1|entity|C0025252|Membrane Proteins|aapp,bacs|||membrane protein|||0|818|137|153
SE|25462337||ab|1|entity|C0205224|Essential|qlco|||essential|||0|1000|154|163
SE|25462337||ab|1|entity|C0449258|Progression|ftcn|||progression|||0|1000|172|183
SE|25462337||ab|1|entity|C0042769|Virus Diseases|dsyn|||viral infection|||0|1000|187|202

SE|25462337||ab|2|text|204|286|With this momentousness, p7 emerges as an important target for antiviral therapy.
SE|25462337||ab|2|entity|C0280274|Antiviral Therapy|topp|||antiviral therapy|||0|1000|267|284

SE|25462337||ab|3|text|286|455|A series of small molecule drugs, such as amantadine, rimantadine, amiloride, hexamethylene amiloride, NN-DNJ and BIT225 have been found to affect the channel activity.
SE|25462337||ab|3|entity|C1328819|small molecule|orch|||small molecule|||0|901|298|312
SE|25462337||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|901|313|318
SE|25462337||ab|3|entity|C0002403|Amantadine|orch,phsu|||amantadine|||0|1000|328|338
SE|25462337||ab|3|entity|C0035629|Rimantadine|orch,phsu|||rimantadine|||0|1000|340|351
SE|25462337||ab|3|entity|C0002502|Amiloride|orch,phsu|||amiloride|||0|1000|353|362
SE|25462337||ab|3|entity|C0049019|5-(N,N-hexamethylene)amiloride|orch,phsu|||hexamethylene amiloride|||0|1000|364|387
SE|25462337||ab|3|entity|C0674666|N-nonyl-1-deoxynojirimycin|orch,phsu|||NN-DNJ|||0|1000|389|395
SE|25462337||ab|3|entity|C0439799|Channel|spco|||channel|||0|888|437|444
SE|25462337||ab|3|relation|0|0|C0002403|Amantadine|orch,phsu|orch|||amantadine|||0|1000|328|338|SPEC|ISA||313|338|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|901|313|318
SE|25462337||ab|3|relation|0|0|C0049019|5-(N,N-hexamethylene)amiloride|orch,phsu|orch|||hexamethylene amiloride|||0|1000|364|387|SPEC|ISA||353|387|0|0|C0002502|Amiloride|orch,phsu|orch|||amiloride|||0|1000|353|362

SE|25462337||ab|4|text|455|649|These compounds are docked against monomeric and hexameric structures of p7 taken at various time steps from a molecular dynamics simulation of the protein embedded in a hydrated lipid bilayer.
SE|25462337||ab|4|entity|C0205198|Compound|qlco|||compounds|||0|966|461|470
SE|25462337||ab|4|entity|C0596973|monomer|chvs|||monomeric|||0|928|490|499
SE|25462337||ab|4|entity|C0678594|Structure|spco|||structures|||0|827|514|524
SE|25462337||ab|4|entity|C0040223|Time|tmco|||time|||0|773|548|552
SE|25462337||ab|4|entity|C1261552|Step|ftcn|||steps|||0|773|553|558
SE|25462337||ab|4|entity|C0596957|Molecular Dynamics|moft|||molecular dynamics|||0|901|566|584
SE|25462337||ab|4|entity|C0679083|simulation|resa|||simulation|||0|901|585|595
SE|25462337||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|603|610
SE|25462337||ab|4|entity|C0720930|Hydrate|orch,phsu|||hydrated|||0|890|625|633
SE|25462337||ab|4|entity|C0023768|Lipid Bilayers|celc|||lipid bilayer|||0|890|634|647
SE|25462337||ab|4|relation|1|1|C0023768|Lipid Bilayers|celc|celc|||lipid bilayer|||0|890|634|647|PREP|LOCATION_OF||620|622|7|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein|||0|1000|603|610

SE|25462337||ab|5|text|649|742|The energetics of binding identifies the guanidine based ligands as the most potent ligands.
SE|25462337||ab|5|entity|C0018320|Guanidines|orch|||guanidine|||0|840|690|699
SE|25462337||ab|5|entity|C0023688|Ligands|chem|||ligands|||0|840|706|713
SE|25462337||ab|5|entity|C0205393|Most|qnco|||most|||0|818|721|725
SE|25462337||ab|5|entity|C0237399|Potential|qlco|||potent|||0|818|726|732
SE|25462337||ab|5|entity|C0023688|Ligands|chem|||ligands|||0|818|733|740

SE|25462337||ab|6|text|742|799|The adamantanes and NN-DNJ show weaker binding energies.
SE|25462337||ab|6|entity|C0674666|N-nonyl-1-deoxynojirimycin|orch,phsu|||NN-DNJ|||0|1000|762|768
SE|25462337||ab|6|entity|C0004093|Asthenia|sosy|||weaker|||0|769|774|780
SE|25462337||ab|6|entity|C0424589|Vitality|fndg|||energies|||0|769|789|797

SE|25462337||ab|7|text|799|893|The lowest energy poses are those at the site of the loop region for the monomer and hexamer.
SE|25462337||ab|7|entity|C0205251|low|qlco|||lowest|||0|606|803|809
SE|25462337||ab|7|entity|C0424589|Vitality|fndg|||energy|||0|606|810|816
SE|25462337||ab|7|entity|C0205145|Site|spco|||site|||0|1000|840|844
SE|25462337||ab|7|entity|C0445022|Loop|spco|||loop|||0|888|852|856
SE|25462337||ab|7|entity|C0205147|Region|spco|||region|||0|888|857|863
SE|25462337||ab|7|entity|C0596973|monomer|chvs|||monomer|||0|1000|872|879

SE|25462337||ab|8|text|893|980|For the latter, the poses show a tendency of the ligand to face the lumen of the pore.
SE|25462337||ab|8|entity|C0023688|Ligands|chem|||ligand|||0|1000|942|948

SE|25462337||ab|9|text|980|1117|The mode of binding is that of a balance between hydrophobic interactions and hydrogen bond formation with backbone atoms of the protein.
SE|25462337||ab|9|entity|C1513371|Mode|ftcn|||mode|||0|1000|984|988
SE|25462337||ab|9|entity|C0014653|Equilibrium|orgf|||balance|||0|1000|1013|1020
SE|25462337||ab|9|entity|C0678607|Hydrophobic Interactions|moft|||hydrophobic interactions|||0|1000|1029|1053
SE|25462337||ab|9|entity|C0020276|Hydrogen Bonding|npop|||hydrogen bond|||0|901|1058|1071
SE|25462337||ab|9|entity|C1522492|Formation|ftcn|||formation|||0|901|1072|1081
SE|25462337||ab|9|entity|C0037949|Vertebral column|bpoc|||backbone|||0|888|1087|1095
SE|25462337||ab|9|entity|C0567415|Atom|elii|||atoms|||0|888|1096|1101
SE|25462337||ab|9|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1109|1116
SE|25462337||ab|9|relation|0|0|C0567415|Atom|elii|elii|||atoms|||0|888|1096|1101|MOD/HEAD|PART_OF||1087|1101|0|0|C0037949|Vertebral column|bpoc|bpoc|||backbone|||0|888|1087|1095


SE|25462338||ti|1|text|21|139|Involvement of non-polyalanine (polyA) residues in aggregation of polyA proteins: Clue for inhibition of aggregation.
SE|25462338||ti|1|entity|C0071505|polyalanine|aapp|||polyalanine|||0|748|40|51
SE|25462338||ti|1|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|72|83
SE|25462338||ti|1|entity|C0071505|polyalanine|aapp|||polyA|||0|888|87|92
SE|25462338||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|93|101
SE|25462338||ti|1|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|126|137

SE|25462338||ab|1|text|145|313|Presence of polyalanine (polyA) stretches in some proteins is found to be associated with their aggregation, which causes disorders in various developmental processes.
SE|25462338||ab|1|entity|C0071505|polyalanine|aapp|||polyalanine|||0|1000|157|168
SE|25462338||ab|1|entity|C0071505|polyalanine|aapp|||polyA|||0|1000|170|175
SE|25462338||ab|1|entity|C0270814|Spastic syndrome|dsyn|||stretches|||0|1000|177|186
SE|25462338||ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|195|203
SE|25462338||ab|1|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|241|252
SE|25462338||ab|1|entity|C0012634|Disease|dsyn|||disorders|||0|1000|267|276
SE|25462338||ab|1|entity|C1511806|Developmental Process|ortf|||developmental processes|||0|884|288|311
SE|25462338||ab|1|relation|4|3|C0071505|polyalanine|aapp,gngm|aapp|||polyalanine|||0|1000|157|168|PREP|COEXISTS_WITH||187|189|4|1|C0033684|Proteins|aapp,gngm,bacs|gngm|||proteins|||0|1000|195|203
SE|25462338||ab|1|relation|6|2|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|195|203|VERB|CAUSES||260|266|2|1|C0012634|Disease|dsyn|dsyn|||disorders|||0|1000|267|276

SE|25462338||ab|2|text|313|586|In this work, inherent propensities towards aggregation of some residues, which are not part of the polyA stretches, have been identified by using the primary sequences of seven polyA proteins with the help of Betascan, PASTA and Tango programs and explored unambiguously.
SE|25462338||ab|2|entity|C0043227|Work|ocac|||work|||0|1000|321|325
SE|25462338||ab|2|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|357|368
SE|25462338||ab|2|entity|C1518422|Not|ftcn|||not|||0|888|397|400
SE|25462338||ab|2|entity|C0449719|Part|spco|||part|||0|888|401|405
SE|25462338||ab|2|entity|C0071505|polyalanine|aapp|||polyA|||0|888|413|418
SE|25462338||ab|2|entity|C0270814|Spastic syndrome|dsyn|||stretches|||0|888|419|428
SE|25462338||ab|2|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|888|472|481
SE|25462338||ab|2|entity|C0205453|Seven|qnco|||seven|||0|851|485|490
SE|25462338||ab|2|entity|C0071505|polyalanine|aapp|||polyA|||0|851|491|496
SE|25462338||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|851|497|505
SE|25462338||ab|2|entity|C0452694|Pasta|food|||PASTA|||0|1000|533|538

SE|25462338||ab|3|text|586|671|This provides a basis for proposing molecular mechanism of this type of aggregation.
SE|25462338||ab|3|entity|C1527178|Basis|ftcn|||basis|||0|1000|602|607
SE|25462338||ab|3|entity|C1441414|PROPOSED|idcn|||proposing|||0|840|612|621
SE|25462338||ab|3|entity|C1521991|Molecular|qlco|||molecular|||0|840|622|631
SE|25462338||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|840|632|641
SE|25462338||ab|3|entity|C1547052|*Type|qnco|||type|||0|1000|650|654
SE|25462338||ab|3|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|658|669

SE|25462338||ab|4|text|671|804|Reported suppression of aggregation of polyA proteins by chaperones like HSP40 and HSP70 is substantiated through molecular docking.
SE|25462338||ab|4|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|695|706
SE|25462338||ab|4|entity|C0071505|polyalanine|aapp|||polyA|||0|888|710|715
SE|25462338||ab|4|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|716|724
SE|25462338||ab|4|entity|C0243041|Molecular Chaperones|aapp,bacs|||chaperones|||0|966|728|738
SE|25462338||ab|4|entity|||gngm|3337,171221|DNAJB1,DNAJB1P1|HSP40|||0|1000|744|749
SE|25462338||ab|4|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|1000|754|759
SE|25462338||ab|4|entity|C1521991|Molecular|qlco|||molecular|||0|888|785|794
SE|25462338||ab|4|entity|C1522290|Docking|moft|||docking|||0|888|795|802

SE|25462338||ab|5|text|804|930|The hydrophobic residues of identified aggregating region are found to be interacting with hydrophobic surface of chaperones.
SE|25462338||ab|5|entity|C0205396|Identified|qlco|||identified|||0|840|832|842
SE|25462338||ab|5|entity|C0205418|Aggregate|qlco|||aggregating|||0|840|843|854
SE|25462338||ab|5|entity|C0205147|Region|spco|||region|||0|840|855|861
SE|25462338||ab|5|entity|C0949783|Hydrophobic Surfaces|phob|||hydrophobic surface|||0|983|895|914
SE|25462338||ab|5|entity|C0243041|Molecular Chaperones|aapp,bacs|||chaperones|||0|966|918|928

SE|25462338||ab|6|text|930|1020|This suggests a crucial clue for possible way to inhibit the aggregation of such proteins.
SE|25462338||ab|6|entity|C0332149|Possible|qlco|||possible|||0|694|963|971
SE|25462338||ab|6|entity|C0332621|Aggregation|ftcn|||aggregation|||0|1000|991|1002
SE|25462338||ab|6|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|1011|1019


SE|25462339||ti|1|text|21|129|Predicting protein-RNA interaction amino acids using random forest based on submodularity subset selection.
SE|25462339||ti|1|entity|C1508497|PREDICTED|clna|||Predicting|||0|820|21|31
SE|25462339||ti|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|820|32|39
SE|25462339||ti|1|entity|C0035668|RNA|bacs,nnon|||RNA|||0|820|40|43
SE|25462339||ti|1|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|820|56|67
SE|25462339||ti|1|entity|C0439605|Random|qlco|||random|||0|888|74|80
SE|25462339||ti|1|entity|C0086312|Forests|geoa|||forest|||0|888|81|87

SE|25462339||ab|1|text|135|327|Protein-RNA interaction plays a very crucial role in many biological processes, such as protein synthesis, transcription and post-transcription of gene expression and pathogenesis of disease.
SE|25462339||ab|1|entity|C0033684|Proteins|aapp,bacs|||Protein|||0|851|135|142
SE|25462339||ab|1|entity|C0035668|RNA|bacs,nnon|||RNA|||0|851|143|146
SE|25462339||ab|1|entity|C0442824|Very|qlco|||very|||0|802|167|171
SE|25462339||ab|1|entity|C0035820|Role|socb|||role|||0|802|180|184
SE|25462339||ab|1|entity|C0277784|Biological function, NOS|biof|||biological processes|||0|983|193|213
SE|25462339||ab|1|entity|C0597295|Protein Biosynthesis|moft|||protein synthesis|||0|1000|223|240
SE|25462339||ab|1|entity|C0040649|Transcription, Genetic|genf|||transcription|||0|1000|242|255
SE|25462339||ab|1|entity|C0205095|Dorsal|spco|||post|||0|888|260|264
SE|25462339||ab|1|entity|C0040649|Transcription, Genetic|genf|||transcription|||0|888|265|278
SE|25462339||ab|1|entity|C0017262|Gene Expression|genf|||gene expression|||0|1000|282|297
SE|25462339||ab|1|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|1000|302|314
SE|25462339||ab|1|entity|C0012634|Disease|dsyn|||disease|||0|1000|318|325
SE|25462339||ab|1|relation|7|3|C0040649|Transcription, Genetic|genf|genf|||transcription|||0|1000|242|255|COMPLEX|AFFECTS||159|184|7|1|C0277784|Biological function, NOS|biof|biof|||biological processes|||0|983|193|213

SE|25462339||ab|2|text|327|388|Especially RNAs always function through binding to proteins.
SE|25462339||ab|2|entity|C0035668|RNA|bacs,nnon|||RNAs|||0|827|338|342
SE|25462339||ab|2|entity|C1549493|Always|idcn|||always|||0|1000|343|349
SE|25462339||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|378|386
SE|25462339||ab|2|relation|1|1|C0035668|RNA|bacs,nnon|bacs|||RNAs|||0|827|338|342|NOM|INTERACTS_WITH||367|374|1|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|378|386

SE|25462339||ab|3|text|388|500|Identification of binding interface region is especially useful for cellular pathways analysis and drug design.
SE|25462339||ab|3|entity|C0205147|Region|spco|||region|||0|827|424|430
SE|25462339||ab|3|entity|C0178539|Cellular|ftcn|||cellular|||0|890|456|464
SE|25462339||ab|3|entity|C0868995|Pathway Analysis|inpr|||pathways analysis|||0|890|465|482
SE|25462339||ab|3|entity|C0013171|Drug Design|ocdi|||drug design|||0|1000|487|498

SE|25462339||ab|4|text|500|792|In this study, we proposed a novel approach for binding sites identification in proteins, which not only integrates local features and global features from protein sequence directly, but also constructed a balanced training dataset using sub-sampling based on submodularity subset selection.
SE|25462339||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|508|513
SE|25462339||ab|4|entity|C0679622|novel|inpr|||novel|||0|888|529|534
SE|25462339||ab|4|entity|C0449445|Approach|spco|||approach|||0|888|535|543
SE|25462339||ab|4|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|734|548|561
SE|25462339||ab|4|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|580|588
SE|25462339||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|596|599
SE|25462339||ab|4|entity|C0205276|Local|spco|||local|||0|694|616|621
SE|25462339||ab|4|entity|C0205246|Generalized|spco|||global|||0|694|635|641
SE|25462339||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|656|663
SE|25462339||ab|4|entity|C0220931|Training|edac|||training|||0|660|715|723
SE|25462339||ab|4|entity|C0542339|Inferior|spco|||sub|||0|1000|738|741
SE|25462339||ab|4|relation|3|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites|||0|734|548|561|PREP|COEXISTS_WITH||577|579|7|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|580|588

SE|25462339||ab|5|text|792|922|Firstly we extracted local features and global features from protein sequence, such as evolution information and molecule weight.
SE|25462339||ab|5|entity|C1279901|Firstly|qlco|||Firstly|||0|1000|792|799
SE|25462339||ab|5|entity|C0205276|Local|spco|||local|||0|694|813|818
SE|25462339||ab|5|entity|C0205246|Generalized|spco|||global|||0|694|832|838
SE|25462339||ab|5|entity|C0002518|Amino Acid Sequence|amas|||protein sequence|||0|1000|853|869
SE|25462339||ab|5|entity|C0015219|Evolution|genf|||evolution|||0|888|879|888
SE|25462339||ab|5|entity|C1533716|Information|idcn|||information|||0|888|889|900
SE|25462339||ab|5|entity|C0026385|Molecular Weight|qnco|||molecule weight|||0|964|905|920

SE|25462339||ab|6|text|922|1130|Secondly, the number of non-interaction sites is much more than interaction sites, which leads to a sample imbalance problem, and hence biased machine learning model with preference to non-interaction sites.
SE|25462339||ab|6|entity|C0205436|second (number)|qnco|||Secondly|||0|1000|922|930
SE|25462339||ab|6|entity|C0237753|Numbers|qnco|||number|||0|1000|936|942
SE|25462339||ab|6|entity|C0205145|Site|spco|||sites|||0|790|962|967
SE|25462339||ab|6|entity|C0205172|More|ftcn|||more|||0|1000|976|980
SE|25462339||ab|6|entity|C0205145|Site|spco|||sites|||0|888|998|1003
SE|25462339||ab|6|entity|C0575090|Equilibration disorder|sosy|||imbalance problem|||0|901|1029|1046
SE|25462339||ab|6|entity|C0242568|Biases|idcn|||biased|||0|790|1058|1064
SE|25462339||ab|6|entity|C0376284|Machine Learning|mcha|||machine learning|||0|790|1065|1081
SE|25462339||ab|6|entity|C0026336|Study models|inpr,resd|||model|||0|790|1082|1087
SE|25462339||ab|6|entity|C0558295|preference|clna|||preference|||0|1000|1093|1103
SE|25462339||ab|6|entity|C0205145|Site|spco|||sites|||0|790|1123|1128

SE|25462339||ab|7|text|1130|1374|To better resolve this problem, instead of previous randomly sub-sampling over-represented non-interaction sites, a novel sampling approach based on submodularity subset selection was employed, which can select more representative data subset.
SE|25462339||ab|7|entity|C0332272|Better|qlco|||better|||0|1000|1133|1139
SE|25462339||ab|7|entity|C0205156|Previous|tmco|||previous|||0|1000|1173|1181
SE|25462339||ab|7|entity|C0205145|Site|spco|||sites|||0|790|1237|1242
SE|25462339||ab|7|entity|C0679622|novel|inpr|||novel|||0|851|1246|1251
SE|25462339||ab|7|entity|C0870078|Sampling|idcn|||sampling|||0|851|1252|1260
SE|25462339||ab|7|entity|C0449445|Approach|spco|||approach|||0|851|1261|1269
SE|25462339||ab|7|entity|C0205172|More|ftcn|||more|||0|597|1341|1345
SE|25462339||ab|7|entity|C1511726|Data|idcn|||data|||0|597|1361|1365

SE|25462339||ab|8|text|1374|1478|Finally random forest were trained on optimally selected training subsets to predict interaction sites.
SE|25462339||ab|8|entity|C0439605|Random|qlco|||random|||0|790|1382|1388
SE|25462339||ab|8|entity|C0086312|Forests|geoa|||forest|||0|790|1389|1395
SE|25462339||ab|8|entity|C0220931|Training|edac|||training|||0|694|1431|1439
SE|25462339||ab|8|entity|C0205145|Site|spco|||sites|||0|888|1471|1476

SE|25462339||ab|9|text|1478|1675|Our result showed that our proposed method is very promising for predicting protein-RNA interaction residues, it achieved an accuracy of 0.863, which is better than other state-of-the-art methods.
SE|25462339||ab|9|entity|C1274040|result|ftcn|||result|||0|1000|1482|1488
SE|25462339||ab|9|entity|C1441414|PROPOSED|idcn|||proposed|||0|888|1505|1513
SE|25462339||ab|9|entity|C0025663|Methods|inpr|||method|||0|888|1514|1520
SE|25462339||ab|9|entity|C0442824|Very|qlco|||very|||0|1000|1524|1528
SE|25462339||ab|9|entity|C1508497|PREDICTED|clna|||predicting|||0|798|1543|1553
SE|25462339||ab|9|entity|C0033684|Proteins|aapp,bacs|||protein|||0|798|1554|1561
SE|25462339||ab|9|entity|C0035668|RNA|bacs,nnon|||RNA|||0|798|1562|1565
SE|25462339||ab|9|entity|C0443131|Accurate|qlco|||accuracy|||0|928|1603|1611
SE|25462339||ab|9|entity|C0332272|Better|qlco|||better|||0|1000|1631|1637
SE|25462339||ab|9|entity|C0025663|Methods|inpr|||methods|||0|762|1666|1673

SE|25462339||ab|10|text|1675|1858|Furthermore, it also indicated the extracted global features have very strong discriminate ability for identifying interaction residues from random forest feature importance analysis.
SE|25462339||ab|10|entity|C1555707|extract|idcn|||extracted|||0|606|1710|1719
SE|25462339||ab|10|entity|C0205246|Generalized|spco|||global|||0|606|1720|1726
SE|25462339||ab|10|entity|C0442824|Very|qlco|||very|||0|888|1741|1745
SE|25462339||ab|10|entity|C0442821|Strong|qlco|||strong|||0|888|1746|1752
SE|25462339||ab|10|entity|C0085732|Ability|orga|||ability|||0|1000|1766|1773
SE|25462339||ab|10|entity|C0205396|Identified|qlco|||identifying|||0|812|1778|1789
SE|25462339||ab|10|entity|C0439605|Random|qlco|||random|||0|762|1816|1822
SE|25462339||ab|10|entity|C0086312|Forests|geoa|||forest|||0|762|1823|1829
SE|25462339||ab|10|entity|C0936012|Analysis|resa|||analysis|||0|762|1849|1857


SE|25462340||ti|1|text|21|78|A novel k-word relative measure for sequence comparison.
SE|25462340||ti|1|entity|C0679622|novel|inpr|||novel|||0|811|23|28
SE|25462340||ti|1|entity|C0439824|Verbal|orgf|||word|||0|811|31|35
SE|25462340||ti|1|entity|C0205345|Relative|qlco|||relative|||0|811|36|44
SE|25462340||ti|1|entity|C0079809|Measures|qnco|||measure|||0|811|45|52
SE|25462340||ti|1|entity|C1519249|Sequence|ftcn|||sequence|||0|694|57|65

SE|25462340||ab|1|text|84|228|In order to extract phylogenetic information from DNA sequences, the new normalized k-word average relative distance is proposed in this paper.
SE|25462340||ab|1|entity|C0871077|Phylogenesis|idcn|||phylogenetic|||0|853|104|116
SE|25462340||ab|1|entity|C1533716|Information|idcn|||information|||0|853|117|128
SE|25462340||ab|1|entity|C0162326|DNA Sequence|nnon,nusq|||DNA sequences|||0|983|134|147
SE|25462340||ab|1|entity|C0205314|New|tmco|||new|||0|753|153|156
SE|25462340||ab|1|entity|C0439824|Verbal|orgf|||word|||0|753|170|174
SE|25462340||ab|1|entity|C1510992|Average|qnco|||average|||0|753|175|182
SE|25462340||ab|1|entity|C0205345|Relative|qlco|||relative|||0|753|183|191
SE|25462340||ab|1|entity|C0012751|Distance|qnco|||distance|||0|753|192|200
SE|25462340||ab|1|entity|C0030351|Paper|mnob|||paper|||0|1000|221|226

SE|25462340||ab|2|text|228|312|The proposed measure was tested by discriminate analysis and phylogenetic analysis.
SE|25462340||ab|2|entity|C1441414|PROPOSED|idcn|||proposed|||0|888|232|240
SE|25462340||ab|2|entity|C0079809|Measures|qnco|||measure|||0|888|241|248
SE|25462340||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|276|284
SE|25462340||ab|2|entity|C1519068|Phylogenetic Analysis|resa|||phylogenetic analysis|||0|1000|289|310

SE|25462340||ab|3|text|312|422|The phylogenetic trees based on the Manhattan distance measure are reconstructed with k ranging from 1 to 12.
SE|25462340||ab|3|entity|C0871077|Phylogenesis|idcn|||phylogenetic|||0|853|316|328
SE|25462340||ab|3|entity|C0040811|Trees|plnt|||trees|||0|853|329|334
SE|25462340||ab|3|entity|C0012751|Distance|qnco|||distance|||0|790|358|366
SE|25462340||ab|3|entity|C0079809|Measures|qnco|||measure|||0|790|367|374
SE|25462340||ab|3|entity|C1514721|Range|qnco|||ranging|||0|872|400|407

SE|25462340||ab|4|text|422|563|At the same time, a new method is suggested to reduce the matrix dimension, can greatly lessen the amount of calculation and operation time.
SE|25462340||ab|4|entity|C0205314|New|tmco|||new|||0|888|442|445
SE|25462340||ab|4|entity|C0025663|Methods|inpr|||method|||0|888|446|452
SE|25462340||ab|4|entity|C0331858|Matrix|hcro|||matrix|||0|888|480|486
SE|25462340||ab|4|entity|C0439534|Dimensions|qnco|||dimension|||0|888|487|496
SE|25462340||ab|4|entity|C1265611|Quantity|qnco|||amount|||0|1000|521|527
SE|25462340||ab|4|entity|C1441506|CALCULATION|lbpr|||calculation|||0|1000|531|542
SE|25462340||ab|4|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|888|547|556
SE|25462340||ab|4|entity|C0040223|Time|tmco|||time|||0|888|557|561

SE|25462340||ab|5|text|563|636|The experimental assessment demonstrated that our measure was efficient.
SE|25462340||ab|5|entity|C1517004|Experimental|ftcn|||experimental|||0|888|567|579
SE|25462340||ab|5|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|580|590
SE|25462340||ab|5|entity|C0079809|Measures|qnco|||measure|||0|1000|613|620
SE|25462340||ab|5|entity|C0442799|Efficient|qlco|||efficient|||0|1000|625|634

SE|25462340||ab|6|text|636|760|What's more, comparing with other methods' results shows that our method is feasible and powerful for phylogenetic analysis.
SE|25462340||ab|6|entity|C0205172|More|ftcn|||more|||0|1000|643|647
SE|25462340||ab|6|entity|C0025663|Methods|inpr|||methods|||0|872|670|677
SE|25462340||ab|6|entity|C1274040|result|ftcn|||results|||0|872|679|686
SE|25462340||ab|6|entity|C0025663|Methods|inpr|||method|||0|1000|702|708
SE|25462340||ab|6|entity|C1519068|Phylogenetic Analysis|resa|||phylogenetic analysis|||0|1000|738|759


SE|25462341||ti|1|text|21|153|Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
SE|25462341||ti|1|entity|C0599946|attenuation|genf|||Attenuation|||0|1000|21|32
SE|25462341||ti|1|entity|C0206548|Vesiculovirus|virs|||vesicular stomatitis virus|||0|916|36|62
SE|25462341||ti|1|entity|C0006104|Brain|bpoc|||brain|||0|1000|76|81
SE|25462341||ti|1|entity|C0003451|Antiviral Agents|phsu|||antiviral drugs|||0|1000|88|103
SE|25462341||ti|1|entity|C1564874|Adeno-Associated Virus|virs|||adeno-associated virus|||0|875|111|133
SE|25462341||ti|1|entity|C0021747|Interferons|aapp,imft,phsu|||interferon|||0|875|134|144
SE|25462341||ti|1|entity|C0442335|Vectors|spco|||vector|||0|875|145|151

SE|25462341||ab|1|text|159|247|Vesicular stomatitis virus (VSV) shows promise as a vaccine-vector and oncolytic virus.
SE|25462341||ab|1|entity|C0206548|Vesiculovirus|virs|||Vesicular stomatitis virus|||0|1000|159|185
SE|25462341||ab|1|entity|C1555307|promise|idcn|||promise|||0|1000|198|205
SE|25462341||ab|1|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|888|211|218
SE|25462341||ab|1|entity|C0442335|Vectors|spco|||vector|||0|888|219|225
SE|25462341||ab|1|entity|C0029020|Oncolytic Viruses|virs|||oncolytic virus|||0|1000|230|245

SE|25462341||ab|2|text|247|306|However, reports of neurotoxicity of VSV remain a concern.

SE|25462341||ab|3|text|306|455|We compared 12 antiviral compounds to control infection of VSV-CT9-M51 and VSV-rp30 using murine and human brain cultures, and in vivo mouse models.
SE|25462341||ab|3|entity|C0205198|Compound|qlco|||compounds|||0|793|331|340
SE|25462341||ab|3|entity|||gngm|25794|FSCN2|rp30|||0|1000|385|389
SE|25462341||ab|3|entity|C0026809|Mus|mamm|||murine|||0|1000|396|402
SE|25462341||ab|3|entity|C0020114|Human|humn|||human|||0|851|407|412
SE|25462341||ab|3|entity|C0006104|Brain|bpoc|||brain|||0|851|413|418
SE|25462341||ab|3|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|851|419|427
SE|25462341||ab|3|entity|C0025914|House mice|mamm|||mouse|||0|905|441|446
SE|25462341||ab|3|entity|C1515657|in vivo Model|resa|||in vivo mouse models|||0|905|433|453

SE|25462341||ab|4|text|455|650|Inhibition of replication, cytotoxicity and infectivity was strongest with ribavirin and IFN-alpha and to some extent with mycophenolic acid, chloroquine, and adenine 9-beta-d-arabinofuranoside.
SE|25462341||ab|4|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|1000|482|494
SE|25462341||ab|4|entity|C0030657|Pathogenicity Aspects|qlco|||infectivity|||0|1000|499|510
SE|25462341||ab|4|entity|C0442821|Strong|qlco|||strongest|||0|966|515|524
SE|25462341||ab|4|entity|C0035525|Ribavirin|nnon,phsu|||ribavirin|||0|1000|530|539
SE|25462341||ab|4|entity|C1610033|Interferon Alpha, Human|aapp,imft|3439|IFNA1|IFN-alpha|||0|1000|544|553
SE|25462341||ab|4|entity|C0439792|Extent|spco|||extent|||0|1000|566|572
SE|25462341||ab|4|entity|C0026933|Mycophenolic Acid|antb,lipd|||mycophenolic acid|||0|1000|578|595
SE|25462341||ab|4|entity|C0008269|Chloroquine|orch,phsu|||chloroquine|||0|1000|597|608
SE|25462341||ab|4|entity|C0001407|Adenine|bacs,nnon|||adenine|||0|660|614|621

SE|25462341||ab|5|text|650|859|To generate continuous IFN exposure, we made an adeno-associated virus vector expressing murine IFN; AAV-mIFN-beta protected mouse brain cells from VSV, as did a combination of IFN, ribavirin and chloroquine.
SE|25462341||ab|5|entity|C0549178|Continuous|tmco|||continuous|||0|623|662|672
SE|25462341||ab|5|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|IFN|||0|623|673|676
SE|25462341||ab|5|entity|C1564874|Adeno-Associated Virus|virs|||adeno-associated virus|||0|916|698|720
SE|25462341||ab|5|entity|C0442335|Vectors|spco|||vector|||0|916|721|727
SE|25462341||ab|5|entity|C0026809|Mus|mamm|||murine|||0|888|739|745
SE|25462341||ab|5|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|IFN|||0|888|746|749
SE|25462341||ab|5|entity|||gngm|17|AAVS1|AAV|||0|1000|751|754
SE|25462341||ab|5|entity|C0025914|House mice|mamm|||mouse|||0|890|775|780
SE|25462341||ab|5|entity|C0596208|brain cell|cell|||brain cells|||0|890|781|792
SE|25462341||ab|5|entity|C0205195|Combined|qlco|||combination|||0|1000|812|823
SE|25462341||ab|5|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|IFN|||0|1000|827|830
SE|25462341||ab|5|entity|C0035525|Ribavirin|nnon,phsu|||ribavirin|||0|1000|832|841
SE|25462341||ab|5|entity|C0008269|Chloroquine|orch,phsu|||chloroquine|||0|1000|846|857
SE|25462341||ab|5|relation|0|0|C0596208|brain cell|cell|cell|||brain cells|||0|890|781|792|MOD/HEAD|PART_OF||775|792|0|0|C0025914|House mice|mamm|mamm|||mouse|||0|890|775|780
SE|25462341||ab|5|relation|0|0|C0733470|human leukocyte interferon|aapp,gngm,imft,phsu|aapp|3439|IFNA1|IFN|||0|888|746|749|MOD/HEAD|PART_OF||739|749|0|0|C0026809|Mus|mamm|mamm|||murine|||0|888|739|745

SE|25462341||ab|6|text|859|927|Intracranial AAV-mIFN-beta protected the brain against VSV-CT9-M51.
SE|25462341||ab|6|entity|C0524466|Intracranial|blor|||Intracranial|||0|645|859|871
SE|25462341||ab|6|entity|||gngm|17|AAVS1|AAV|||0|645|872|875
SE|25462341||ab|6|entity|C0006104|Brain|bpoc|||brain|||0|1000|900|905

SE|25462341||ab|7|text|927|1012|In SCID mice bearing human glioblastoma, AAV-mIFN-beta moderately enhanced survival.
SE|25462341||ab|7|entity|C0085112|SCID Mice|mamm|||SCID mice|||0|1000|930|939
SE|25462341||ab|7|entity|C0020114|Human|humn|||human|||0|888|948|953
SE|25462341||ab|7|entity|C0017636|Glioblastoma|neop|||glioblastoma|||0|888|954|966
SE|25462341||ab|7|entity|||gngm|17|AAVS1|AAV|||0|799|968|971
SE|25462341||ab|7|entity|C0038952|Continuance of life|acty|||survival|||0|799|1002|1010
SE|25462341||ab|7|relation|0|0|C0017636|Glioblastoma|neop|neop|||glioblastoma|||0|888|954|966|MOD/HEAD|PROCESS_OF||948|966|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|948|953

SE|25462341||ab|8|text|1012|1142|VSV-CT9-M51 doubled median survival when administered after AAV-mIFN-beta; some surviving mice showed complete tumor destruction.
SE|25462341||ab|8|entity|C0038952|Continuance of life|acty|||survival|||0|861|1039|1047
SE|25462341||ab|8|entity|||gngm|17|AAVS1|AAV|||0|1000|1072|1075
SE|25462341||ab|8|entity|C0026809|Mus|mamm|||mice|||0|872|1102|1106
SE|25462341||ab|8|entity|C0205197|Complete|qlco|||complete|||0|901|1114|1122
SE|25462341||ab|8|entity|C1446301|Tumor destruction|topp|||tumor destruction|||0|901|1123|1140

SE|25462341||ab|9|text|1142|1289|Together, these data suggest that AAV-IFN or IFN with ribavirin and chloroquine provide an optimal anti-virus combination against VSV in the brain.
SE|25462341||ab|9|entity|C1511726|Data|idcn|||data|||0|1000|1158|1162
SE|25462341||ab|9|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|AAV-IFN|||0|861|1176|1183
SE|25462341||ab|9|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|IFN|||0|1000|1187|1190
SE|25462341||ab|9|entity|C0035525|Ribavirin|nnon,phsu|||ribavirin|||0|1000|1196|1205
SE|25462341||ab|9|entity|C0008269|Chloroquine|orch,phsu|||chloroquine|||0|1000|1210|1221
SE|25462341||ab|9|entity|C0042769|Virus Diseases|dsyn|||virus|||0|750|1246|1251
SE|25462341||ab|9|entity|C0205195|Combined|qlco|||combination|||0|750|1252|1263
SE|25462341||ab|9|entity|C0006104|Brain|bpoc|||brain|||0|1000|1283|1288
SE|25462341||ab|9|relation|1|1|C0006104|Brain|bpoc|bpoc|||brain|||0|1000|1283|1288|PREP|LOCATION_OF||1276|1278|7|2|C0042769|Virus Diseases|dsyn|dsyn|||virus|||0|750|1246|1251


SE|25462342||ti|1|text|21|157|SHAPE analysis of the RNA secondary structure of the Mouse Hepatitis Virus 5' untranslated region and N-terminal nsp1 coding sequences.
SE|25462342||ti|1|entity|C0332479|Shapes|spco|||SHAPE|||0|888|21|26
SE|25462342||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|888|27|35
SE|25462342||ti|1|entity|C0035668|RNA|bacs,nnon|||RNA|||0|851|43|46
SE|25462342||ti|1|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|851|47|56
SE|25462342||ti|1|entity|C0678594|Structure|spco|||structure|||0|851|57|66
SE|25462342||ti|1|entity|C0019185|Murine hepatitis virus|virs|||Mouse Hepatitis Virus|||0|836|74|95
SE|25462342||ti|1|entity|C0205147|Region|spco|||region|||0|836|112|118
SE|25462342||ti|1|entity|C1309025|SH2D3A protein, human|aapp,bacs|10045|SH2D3A|nsp1|||0|815|134|138
SE|25462342||ti|1|entity|C0009219|Coding|ocac|||coding|||0|815|139|145
SE|25462342||ti|1|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|815|146|155

SE|25462342||ab|1|text|163|367|SHAPE technology was used to analyze RNA secondary structure of the 5' most 474 nts of the MHV-A59 genome encompassing the minimal 5' cis-acting region required for defective interfering RNA replication.
SE|25462342||ab|1|entity|C0332479|Shapes|spco|||SHAPE|||0|888|163|168
SE|25462342||ab|1|entity|C0039421|Technology|ocdi|||technology|||0|888|169|179
SE|25462342||ab|1|entity|C0035668|RNA|bacs,nnon|||RNA|||0|851|200|203
SE|25462342||ab|1|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|851|204|213
SE|25462342||ab|1|entity|C0678594|Structure|spco|||structure|||0|851|214|223
SE|25462342||ab|1|entity|C0175518|Nucleus solitarius|bpoc|||nts|||0|861|243|246
SE|25462342||ab|1|entity|C0017428|Genome|gngm|||genome|||0|827|262|268
SE|25462342||ab|1|entity|C0547040|Minimal|qlco|||minimal|||0|751|286|293
SE|25462342||ab|1|entity|||gngm|1154|CISH|cis-|||0|751|297|301
SE|25462342||ab|1|entity|C0427611|Activated clotting time measurement|lbpr|||acting|||0|751|301|307
SE|25462342||ab|1|entity|C0205147|Region|spco|||region|||0|751|308|314
SE|25462342||ab|1|entity|C0332452|Defective|ftcn|||defective|||0|824|328|337
SE|25462342||ab|1|entity|C1328949|RNA replication|moft|||RNA replication|||0|824|350|365

SE|25462342||ab|2|text|367|531|The structures generated were in agreement with previous characterizations of SL1 through SL4 and two recently predicted secondary structure elements, S5 and SL5A.
SE|25462342||ab|2|entity|C0678594|Structure|spco|||structures|||0|966|371|381
SE|25462342||ab|2|entity|C0680240|Agreement|socb|||agreement|||0|1000|400|409
SE|25462342||ab|2|entity|C0205156|Previous|tmco|||previous|||0|694|415|423
SE|25462342||ab|2|entity|||gngm|4314,9013,9014,9015|MMP3,TAF1C,TAF1B,TAF1A|SL1|||0|1000|445|448
SE|25462342||ab|2|entity|C0205448|Two|qnco|||two|||0|1000|465|468
SE|25462342||ab|2|entity|C0332185|Recent|tmco|||recently|||0|1000|469|477
SE|25462342||ab|2|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|851|488|497
SE|25462342||ab|2|entity|C0678594|Structure|spco|||structure|||0|851|498|507
SE|25462342||ab|2|entity|C0013879|Elements|elii|||elements|||0|851|508|516

SE|25462342||ab|3|text|531|646|SHAPE provided biochemical support for four additional stem-loops not previously functionally investigated in MHV.
SE|25462342||ab|3|entity|C0205474|Biochemical|ftcn|||biochemical|||0|840|546|557
SE|25462342||ab|3|entity|C0205450|Four|qnco|||four|||0|775|570|574
SE|25462342||ab|3|entity|C1524062|Additional|ftcn|||additional|||0|775|575|585
SE|25462342||ab|3|entity|C0181687|Loops|medd|||loops|||0|775|591|596
SE|25462342||ab|3|entity|C1518422|Not|ftcn|||not|||0|861|597|600

SE|25462342||ab|4|text|646|770|Secondary structure predictions for 5' regions of MHV-A59, BCoV and SARS-CoV were similar despite high sequence divergence.
SE|25462342||ab|4|entity|C1522484|metastatic qualifier|qnco|||Secondary|||0|840|646|655
SE|25462342||ab|4|entity|C0678594|Structure|spco|||structure|||0|840|656|665
SE|25462342||ab|4|entity|C0681842|prediction|inpr|||predictions|||0|840|666|677
SE|25462342||ab|4|entity|C0205147|Region|spco|||regions|||0|872|685|692
SE|25462342||ab|4|entity|C1175175|Severe Acute Respiratory Syndrome|dsyn|||SARS|||0|694|714|718
SE|25462342||ab|4|entity|C0205250|High|qlco|||high|||0|851|744|748
SE|25462342||ab|4|entity|C1519249|Sequence|ftcn|||sequence|||0|851|749|757
SE|25462342||ab|4|entity|C0443204|Divergence|spco|||divergence|||0|851|758|768

SE|25462342||ab|5|text|770|1035|The pattern of SHAPE reactivity of in virio genomic RNA, ex virio genomic RNA, and in vitro synthesized RNA was similar, suggesting that binding of N protein or other proteins to virion RNA fails to protect the RNA from reaction with lipid permeable SHAPE reagent.
SE|25462342||ab|5|entity|C0449774|Patterns|spco|||pattern|||0|1000|774|781
SE|25462342||ab|5|entity|C0332479|Shapes|spco|||SHAPE|||0|853|785|790
SE|25462342||ab|5|entity|C0205332|Reactive|qlco|||reactivity|||0|853|791|801
SE|25462342||ab|5|entity|C0035668|RNA|bacs,nnon|||RNA|||0|827|822|825
SE|25462342||ab|5|entity|C0035668|RNA|bacs,nnon|||RNA|||0|791|844|847
SE|25462342||ab|5|entity|C1533691|in vitro|qlco|||in vitro|||0|824|853|861
SE|25462342||ab|5|entity|C0035668|RNA|bacs,nnon|||RNA|||0|824|874|877
SE|25462342||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|920|927
SE|25462342||ab|5|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|937|945
SE|25462342||ab|5|entity|C0042760|Virion|celc|||virion|||0|888|949|955
SE|25462342||ab|5|entity|C0035668|RNA|bacs,nnon|||RNA|||0|888|956|959
SE|25462342||ab|5|entity|C0035668|RNA|bacs,nnon|||RNA|||0|1000|981|984
SE|25462342||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|990|998
SE|25462342||ab|5|entity|C0023779|Lipids|lipd|||lipid|||0|833|1004|1009
SE|25462342||ab|5|entity|C0205326|Permeable|ftcn|||permeable|||0|833|1010|1019
SE|25462342||ab|5|entity|C0332479|Shapes|spco|||SHAPE|||0|833|1020|1025
SE|25462342||ab|5|entity|C0034760|Reagents|irda|||reagent|||0|833|1026|1033
SE|25462342||ab|5|relation|0|0|C0035668|RNA|bacs,nnon|bacs|||RNA|||0|888|956|959|MOD/HEAD|PART_OF||949|959|0|0|C0042760|Virion|celc|celc|||virion|||0|888|949|955

SE|25462342||ab|6|text|1035|1162|Reverse genetic experiments suggested that SL5C and SL6 within the nsp1 coding sequence are not required for viral replication.
SE|25462342||ab|6|entity|C0314603|Genetic|ftcn|||genetic|||0|888|1043|1050
SE|25462342||ab|6|entity|C0681814|research study|resa|||experiments|||0|888|1051|1062
SE|25462342||ab|6|entity|C1309025|SH2D3A protein, human|aapp,bacs|10045|SH2D3A|nsp1|||0|851|1102|1106
SE|25462342||ab|6|entity|C0009219|Coding|ocac|||coding|||0|851|1107|1113
SE|25462342||ab|6|entity|C1519249|Sequence|ftcn|||sequence|||0|851|1114|1122
SE|25462342||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1127|1130
SE|25462342||ab|6|entity|C0521026|Viral|ftcn|||viral|||0|888|1144|1149


SE|25462343||ti|1|text|21|135|Sequence variation of koala retrovirus transmembrane protein p15E among koalas from different geographic regions.
SE|25462343||ti|1|entity|C1519249|Sequence|ftcn|||Sequence|||0|888|21|29
SE|25462343||ti|1|entity|C0205419|Variant|qlco|||variation|||0|888|30|39
SE|25462343||ti|1|entity|C0324717|Phascolarctos cinereus|mamm|||koala|||0|632|43|48
SE|25462343||ti|1|entity|C0035366|Retroviridae|virs|||retrovirus|||0|632|49|59
SE|25462343||ti|1|entity|C0021699|Integral Membrane Proteins|aapp,rcpt|||transmembrane protein|||0|632|60|81
SE|25462343||ti|1|entity|C0324717|Phascolarctos cinereus|mamm|||koalas|||0|1000|93|99
SE|25462343||ti|1|entity|C1547020|*Difference|qnco|||different|||0|877|105|114
SE|25462343||ti|1|entity|C0017446|Geographic Locations|geoa|||geographic regions|||0|877|115|133

SE|25462343||ab|1|text|141|285|The koala retrovirus (KoRV), which is transitioning from an exogenous to an endogenous form, has been associated with high mortality in koalas.
SE|25462343||ab|1|entity|C0324717|Phascolarctos cinereus|mamm|||koala|||0|888|145|150
SE|25462343||ab|1|entity|C0035366|Retroviridae|virs|||retrovirus|||0|888|151|161
SE|25462343||ab|1|entity|C0205228|Exogenous|ftcn|||exogenous|||0|1000|201|210
SE|25462343||ab|1|entity|C0205227|Endogenous|ftcn|||endogenous|||0|888|217|227
SE|25462343||ab|1|entity|C1522492|Formation|ftcn|||form|||0|888|228|232
SE|25462343||ab|1|entity|C0205250|High|qlco|||high|||0|694|259|263
SE|25462343||ab|1|entity|C0324717|Phascolarctos cinereus|mamm|||koalas|||0|1000|277|283
SE|25462343||ab|1|relation|0|0|C0035366|Retroviridae|virs|virs|||retrovirus|||0|888|151|161|MOD/HEAD|PROCESS_OF||145|161|0|0|C0324717|Phascolarctos cinereus|mamm|mamm|||koala|||0|888|145|150
SE|25462343||ab|1|relation|5|5|C0035366|Retroviridae|virs|virs|||retrovirus|||0|888|151|161|PREP|PROCESS_OF||274|276|1|1|C0324717|Phascolarctos cinereus|mamm|mamm|||koalas|||0|1000|277|283

SE|25462343||ab|2|text|285|392|For other retroviruses, the envelope protein p15E has been considered a candidate for vaccine development.
SE|25462343||ab|2|entity|C0035366|Retroviridae|virs|||retroviruses|||0|1000|295|307
SE|25462343||ab|2|entity|C0017278|Gene Products, env|aapp,bacs|||envelope protein|||0|734|313|329
SE|25462343||ab|2|entity|C0597634|Vaccine Development|resa|||vaccine development|||0|1000|371|390

SE|25462343||ab|3|text|392|522|We therefore examined proviral sequence variation of KoRV p15E in a captive Queensland and three wild southern Australian koalas.
SE|25462343||ab|3|entity|C1519249|Sequence|ftcn|||sequence|||0|790|423|431
SE|25462343||ab|3|entity|C0205419|Variant|qlco|||variation|||0|790|432|441
SE|25462343||ab|3|entity|C0324717|Phascolarctos cinereus|mamm|||KoRV|||0|623|445|449
SE|25462343||ab|3|entity|C0035366|Retroviridae|virs|||KoRV|||0|623|445|449
SE|25462343||ab|3|entity|C0034391|Queensland|geoa|||Queensland|||0|861|468|478
SE|25462343||ab|3|entity|C0205449|Three|qnco|||three|||0|757|483|488
SE|25462343||ab|3|entity|C0445392|Wild|inpr|||wild|||0|757|489|493
SE|25462343||ab|3|entity|C0238711|AUSTRALIAN|fndg|||Australian|||0|757|503|513
SE|25462343||ab|3|entity|C0324717|Phascolarctos cinereus|mamm|||koalas|||0|757|514|520

SE|25462343||ab|4|text|522|625|We generated 163 sequences with intact open reading frames, which grouped into 39 distinct haplotypes.
SE|25462343||ab|4|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|861|539|548
SE|25462343||ab|4|entity|C0205266|Intact|qlco|||intact|||0|916|554|560
SE|25462343||ab|4|entity|C0079941|Open Reading Frames|gngm|||open reading frames|||0|916|561|580
SE|25462343||ab|4|entity|C0018591|Haplotypes|orga|||haplotypes|||0|827|613|623
SE|25462343||ab|4|relation|2|1|C0079941|Open Reading Frames|gngm,aapp|gngm|||open reading frames|||0|916|561|580|PREP|PART_OF||549|553|1|1|C0162326|DNA Sequence|nnon,nusq|nusq|||sequences|||0|861|539|548

SE|25462343||ab|5|text|625|723|Sixteen distinct haplotypes comprising 139 of the sequences (85%) coded for the same polypeptide.
SE|25462343||ab|5|entity|C0018591|Haplotypes|orga|||haplotypes|||0|827|642|652
SE|25462343||ab|5|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|1000|675|684
SE|25462343||ab|5|entity|C0445247|Same|qlco|||same|||0|888|705|709
SE|25462343||ab|5|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|888|710|721

SE|25462343||ab|6|text|723|881|Among the remaining 23 haplotypes, 22 were detected only once among the sequences, and each had 1 or 2 non-synonymous differences from the majority sequence.
SE|25462343||ab|6|entity|C1527428|Remaining|qlco|||remaining|||0|802|733|742
SE|25462343||ab|6|entity|C0018591|Haplotypes|orga|||haplotypes|||0|802|746|756
SE|25462343||ab|6|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|1000|795|804
SE|25462343||ab|6|entity|C0871468|Synonyms|inpr|||synonymous|||0|697|830|840
SE|25462343||ab|6|entity|C1547020|*Difference|qnco|||differences|||0|697|841|852
SE|25462343||ab|6|entity|C0680220|majority|socb|||majority|||0|888|862|870
SE|25462343||ab|6|entity|C1519249|Sequence|ftcn|||sequence|||0|888|871|879

SE|25462343||ab|7|text|881|949|Several analyses suggested that p15E was under purifying selection.
SE|25462343||ab|7|entity|C0443302|Several|qnco|||Several|||0|872|881|888
SE|25462343||ab|7|entity|C0936012|Analysis|resa|||analyses|||0|872|889|897

SE|25462343||ab|8|text|949|1072|Important epitopes and domains were highly conserved across the p15E sequences and in previously reported exogenous KoRVs.
SE|25462343||ab|8|entity|C0003316|Epitopes|imft|||epitopes|||0|861|959|967
SE|25462343||ab|8|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|861|1018|1027
SE|25462343||ab|8|entity|C0205228|Exogenous|ftcn|||exogenous|||0|694|1055|1064

SE|25462343||ab|9|text|1072|1158|Overall, these results support the potential use of p15E for KoRV vaccine development.
SE|25462343||ab|9|entity|C1561607|Overall|qlco|||Overall|||0|1000|1072|1079
SE|25462343||ab|9|entity|C1274040|result|ftcn|||results|||0|966|1087|1094
SE|25462343||ab|9|entity|C0237399|Potential|qlco|||potential|||0|888|1107|1116
SE|25462343||ab|9|entity|C0324717|Phascolarctos cinereus|mamm|||KoRV|||0|861|1133|1137
SE|25462343||ab|9|entity|C0035366|Retroviridae|virs|||KoRV|||0|861|1133|1137
SE|25462343||ab|9|entity|C0597634|Vaccine Development|resa|||vaccine development|||0|861|1138|1157


SE|25462345||ti|1|text|21|120|Structural characterization of the HSP70 interaction domain of the hepatitis C viral protein NS5A.
SE|25462345||ti|1|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|623|56|61
SE|25462345||ti|1|entity|C0019196|Hepatitis C|dsyn|||hepatitis C|||0|660|88|99
SE|25462345||ti|1|entity|C0042736|Viral Proteins|aapp,bacs|||viral protein|||0|660|100|113

SE|25462345||ab|1|text|126|353|We previously identified the NS5A/HSP70 binding site to be a hairpin moiety at C-terminus of NS5A domain I and showed a corresponding cyclized polyarginine-tagged synthetic peptide (HCV4) significantly blocks virus production.
SE|25462345||ab|1|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|824|160|165
SE|25462345||ab|1|entity|C0005456|Binding Sites|rcpt|||binding site|||0|824|166|178
SE|25462345||ab|1|entity|C0071514|polyarginine|aapp|||polyarginine|||0|757|269|281
SE|25462345||ab|1|entity|C0244435|tyrosyl-alanyl-glycine|aapp,bacs|||tagged synthetic peptide|||0|757|282|306
SE|25462345||ab|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|888|335|340
SE|25462345||ab|1|entity|C0033268|production|ocac|||production|||0|888|341|351
SE|25462345||ab|1|relation|6|2|C0244435|tyrosyl-alanyl-glycine|aapp,gngm,bacs|aapp|||tagged synthetic peptide|||0|757|282|306|VERB|AFFECTS||328|334|1|1|C0042769|Virus Diseases|dsyn|dsyn|||virus|||0|888|335|340

SE|25462345||ab|2|text|353|420|Here, sequence comparison confirmed five residues to be conserved.
SE|25462345||ab|2|entity|C1519249|Sequence|ftcn|||sequence|||0|694|359|367
SE|25462345||ab|2|entity|C0205451|Five|qnco|||five|||0|847|389|393

SE|25462345||ab|3|text|420|535|Based on NS5A domain I crystal structure, Phe171, Val173, and Tyr178 were predicted to form the binding interface.
SE|25462345||ab|3|entity|C0444626|Crystal Structure|chvs|||crystal structure|||0|1000|443|460

SE|25462345||ab|4|text|535|727|Substitution of Phe171 and Val173 with more hydrophobic unusual amino acids improved peptide antiviral activity and HSP70 binding, while similar substitutions at Tyr178 had a negative effect.
SE|25462345||ab|4|entity|C1555721|Substitution|idcn|||Substitution|||0|1000|535|547
SE|25462345||ab|4|entity|C0205172|More|ftcn|||more|||0|812|574|578
SE|25462345||ab|4|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|812|599|610
SE|25462345||ab|4|entity|C0030956|Peptides|aapp|||peptide|||0|802|620|627
SE|25462345||ab|4|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|694|651|656
SE|25462345||ab|4|entity|C1555721|Substitution|idcn|||substitutions|||0|836|680|693
SE|25462345||ab|4|entity|C0205160|Negative|qlco|||negative|||0|888|710|718
SE|25462345||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|719|725
SE|25462345||ab|4|relation|5|2|C0002520|Amino Acids|aapp,gngm,bacs,phsu|aapp|||amino acids|||0|812|599|610|NOM|INTERACTS_WITH||657|664|5|0|C0243043|Heat-Shock Proteins 70|aapp,gngm,bacs|aapp|3308|HSPA4|HSP70|||0|694|651|656

SE|25462345||ab|5|text|727|885|Substitution of non-conserved residues with arginines maintained antiviral activity and HSP70 binding and dispensed with polyarginine tag for cellular entry.
SE|25462345||ab|5|entity|C1555721|Substitution|idcn|||Substitution|||0|1000|727|739
SE|25462345||ab|5|entity|C0003765|Arginine|aapp,bacs,phsu|||arginines|||0|966|771|780
SE|25462345||ab|5|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|694|815|820
SE|25462345||ab|5|entity|C0071514|polyarginine|aapp|||polyarginine|||0|888|848|860
SE|25462345||ab|5|entity|C1522485|Tracer|irda|||tag|||0|888|861|864
SE|25462345||ab|5|entity|C0178539|Cellular|ftcn|||cellular|||0|694|869|877

SE|25462345||ab|6|text|885|952|Peptide cyclization improved antiviral activity and HSP70 binding.
SE|25462345||ab|6|entity|C0030956|Peptides|aapp|||Peptide|||0|888|885|892
SE|25462345||ab|6|entity|C0010546|Cyclization|npop|||cyclization|||0|888|893|904
SE|25462345||ab|6|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|694|937|942

SE|25462345||ab|7|text|952|1025|The cyclic retro-inverso analog displayed the best antiviral properties.
SE|25462345||ab|7|entity|C0439596|Cyclical|tmco|||cyclic|||0|916|956|962
SE|25462345||ab|7|entity|C1514919|Retro-Inverso Peptide|aapp,phsu|||retro-inverso analog|||0|916|963|983
SE|25462345||ab|7|entity|C0871161|Property|qlco|||properties|||0|785|1013|1023

SE|25462345||ab|8|text|1025|1162|FTIR spectroscopy confirmed a secondary structure consisting of an N-terminal beta-sheet followed by a turn and a C-terminal beta-sheet.
SE|25462345||ab|8|entity|C0206055|Spectroscopy, Fourier Transform Infrared|resa|||FTIR spectroscopy|||0|1000|1025|1042
SE|25462345||ab|8|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|888|1055|1064
SE|25462345||ab|8|entity|C0678594|Structure|spco|||structure|||0|888|1065|1074
SE|25462345||ab|8|entity|C0599215|Beta Sheet|celc|||beta-sheet|||0|850|1103|1113
SE|25462345||ab|8|entity|C0541749|Does turn|fndg|||turn|||0|966|1128|1132
SE|25462345||ab|8|entity|C0599215|Beta Sheet|celc|||beta-sheet|||0|787|1150|1160

SE|25462345||ab|9|text|1162|1222|These peptides constitute a new class of anti-HCV compounds.
SE|25462345||ab|9|entity|C0030956|Peptides|aapp|||peptides|||0|1000|1168|1176
SE|25462345||ab|9|entity|C0205314|New|tmco|||new|||0|888|1190|1193
SE|25462345||ab|9|entity|C0008902|Classification|clas|||class|||0|888|1194|1199
SE|25462345||ab|9|entity|C0166049|Hepatitis C Antibodies|imft|||anti-HCV|||0|890|1203|1211
SE|25462345||ab|9|entity|C0205198|Compound|qlco|||compounds|||0|890|1212|1221


SE|25462346||ti|1|text|21|198|Woodchuck hepatitis virus core antigen-based DNA and protein vaccines induce qualitatively different immune responses that affect T cell recall responses and antiviral effects.
SE|25462346||ti|1|entity|C0043219|Woodchucks|mamm|||Woodchuck|||0|818|21|30
SE|25462346||ti|1|entity|C0598995|virus core|aapp,nnon|||virus core|||0|818|41|51
SE|25462346||ti|1|entity|C0282571|Hepatitis Antigens|imft|||hepatitis virus core antigen|||0|818|31|59
SE|25462346||ti|1|entity|C0012854|DNA|bacs,nnon|||DNA|||0|818|66|69
SE|25462346||ti|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|74|81
SE|25462346||ti|1|entity|C0042210|Vaccines|imft,phsu|||vaccines|||0|888|82|90
SE|25462346||ti|1|entity|C1547020|*Difference|qnco|||different|||0|789|112|121
SE|25462346||ti|1|entity|C0301872|Immune response|orgf|||immune responses|||0|789|122|138
SE|25462346||ti|1|entity|C0039194|T-Lymphocyte|cell|||T cell|||0|824|151|157
SE|25462346||ti|1|entity|C0871261|response|clna|||responses|||0|824|165|174
SE|25462346||ti|1|entity|C1280500|Effect|qlco|||effects|||0|827|189|196

SE|25462346||ab|1|text|204|320|T helper type 1 (Th1) immunity was considered to play a dominant role in viral clearance of hepadnaviral infection.
SE|25462346||ab|1|entity|C0441729|Type 1|clas|||type 1|||0|861|213|219
SE|25462346||ab|1|entity|||gngm|51497|NELFCD|Th1|||0|1000|221|224
SE|25462346||ab|1|entity|C0020964|Immunity|phsf|||immunity|||0|1000|226|234
SE|25462346||ab|1|entity|C1527180|Dominant|ftcn|||dominant|||0|888|260|268
SE|25462346||ab|1|entity|C0035820|Role|socb|||role|||0|888|269|273
SE|25462346||ab|1|entity|C0521026|Viral|ftcn|||viral|||0|888|277|282
SE|25462346||ab|1|entity|C0449297|Clearance|qlco|||clearance|||0|888|283|292

SE|25462346||ab|2|text|320|433|However, pre-primed Th2 type responses were able to efficiently control hepadnaviral infection in animal models.
SE|25462346||ab|2|entity|C0871133|Priming|ftcn|||primed|||0|749|333|339
SE|25462346||ab|2|entity|C1547052|*Type|qnco|||type|||0|749|344|348
SE|25462346||ab|2|entity|C0871261|response|clna|||responses|||0|749|349|358
SE|25462346||ab|2|entity|C0599779|Animal Model|anim|||animal models|||0|1000|418|431

SE|25462346||ab|3|text|433|555|We investigated how pre-primed Th1/2 responses control hepadnaviral replication using the newly established mouse models.
SE|25462346||ab|3|entity|C0871133|Priming|ftcn|||primed|||0|726|457|463
SE|25462346||ab|3|entity|||gngm|51497|NELFCD|Th1|||0|726|464|467
SE|25462346||ab|3|entity|C0871261|response|clna|||responses|||0|726|470|479
SE|25462346||ab|3|entity|C0750546|NEWLY|idcn|||newly|||0|608|523|528
SE|25462346||ab|3|entity|C0443211|Established|qlco|||established|||0|608|529|540
SE|25462346||ab|3|entity|C0025914|House mice|mamm|||mouse|||0|608|541|546

SE|25462346||ab|4|text|555|734|DNA (pWHcIm, pCTLA-4-C) and protein vaccines based on the nucleocapsid protein (WHcAg) of woodchuck hepatitis virus (WHV) primed specific immune responses with distinct features.
SE|25462346||ab|4|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|555|558
SE|25462346||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|583|590
SE|25462346||ab|4|entity|C0042210|Vaccines|imft,phsu|||vaccines|||0|888|591|599
SE|25462346||ab|4|entity|C0524816|Nucleocapsid Proteins|aapp,bacs|||nucleocapsid protein|||0|1000|613|633
SE|25462346||ab|4|entity|C0043219|Woodchucks|mamm|||woodchuck|||0|901|645|654
SE|25462346||ab|4|entity|C0019186|Hepatitis Viruses|virs|||hepatitis virus|||0|901|655|670
SE|25462346||ab|4|entity|C0683201|specific immunity|ortf|||specific immune responses|||0|988|684|709
SE|25462346||ab|4|relation|0|0|C0019186|Hepatitis Viruses|virs|virs|||hepatitis virus|||0|901|655|670|MOD/HEAD|PROCESS_OF||645|670|0|0|C0043219|Woodchucks|mamm|mamm|||woodchuck|||0|901|645|654

SE|25462346||ab|5|text|734|867|The pre-primed responses determined the characteristics of recall responses if challenged with a WHcAg-expressing adenoviral vector.
SE|25462346||ab|5|entity|C0871133|Priming|ftcn|||primed|||0|840|742|748
SE|25462346||ab|5|entity|C0871261|response|clna|||responses|||0|840|749|758
SE|25462346||ab|5|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|774|789
SE|25462346||ab|5|entity|C0871261|response|clna|||responses|||0|861|800|809
SE|25462346||ab|5|entity|C1510800|Adenovirus Vector|nnon|||adenoviral vector|||0|1000|848|865

SE|25462346||ab|6|text|867|1113|Vaccination with pWHcIm and pCTLA4-C facilitated viral control in the hydrodynamic injection model and reduced WHV loads by about 3 and 2 logs in WHV-transgenic mice, respectively, despite of different kinetics of specific CD8+ T cell responses.
SE|25462346||ab|6|entity|C0042196|Vaccination|topp|||Vaccination|||0|1000|867|878
SE|25462346||ab|6|entity|C0521026|Viral|ftcn|||viral|||0|888|916|921
SE|25462346||ab|6|entity|C0243148|control|ftcn|||control|||0|888|922|929
SE|25462346||ab|6|entity|C1533685|Injection procedure|topp|||injection|||0|790|950|959
SE|25462346||ab|6|entity|C0026336|Study models|inpr,resd|||model|||0|790|960|965
SE|25462346||ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|861|970|977
SE|25462346||ab|6|entity|C0043219|Woodchucks|mamm|||WHV|||0|861|978|981
SE|25462346||ab|6|entity|C0019186|Hepatitis Viruses|virs|||WHV|||0|861|978|981
SE|25462346||ab|6|entity|C0043219|Woodchucks|mamm|||WHV|||0|857|1013|1016
SE|25462346||ab|6|entity|C0019186|Hepatitis Viruses|virs|||WHV|||0|857|1013|1016
SE|25462346||ab|6|entity|C0025936|Mice, Transgenic|mamm|||transgenic mice|||0|857|1017|1032
SE|25462346||ab|6|entity|C1547020|*Difference|qnco|||different|||0|853|1059|1068
SE|25462346||ab|6|entity|C0022702|Kinetics|idcn|||kinetics|||0|853|1069|1077
SE|25462346||ab|6|entity|C0242629|CD8-Positive T-Lymphocytes|cell|||CD8+ T cell|||0|798|1090|1101
SE|25462346||ab|6|entity|C0871261|response|clna|||responses|||0|798|1102|1111
SE|25462346||ab|6|relation|0|0|C0019186|Hepatitis Viruses|virs|virs|||WHV|||0|861|978|981|MOD/HEAD|PROCESS_OF||978|981|0|0|C0043219|Woodchucks|mamm|mamm|||WHV|||0|861|978|981

SE|25462346||ab|7|text|1113|1280|Thus, pre-primed Th2-biased responses facilitate the development of CD8+ T cell responses in mice compared with naive controls and thereby confer better viral control.
SE|25462346||ab|7|entity|C0871133|Priming|ftcn|||primed|||0|741|1123|1129
SE|25462346||ab|7|entity|C0242568|Biases|idcn|||biased|||0|741|1134|1140
SE|25462346||ab|7|entity|C0871261|response|clna|||responses|||0|741|1141|1150
SE|25462346||ab|7|entity|C1527148|Development|ftcn|||development|||0|1000|1166|1177
SE|25462346||ab|7|entity|C0242629|CD8-Positive T-Lymphocytes|cell|||CD8+ T cell|||0|861|1181|1192
SE|25462346||ab|7|entity|C0871261|response|clna|||responses|||0|861|1193|1202
SE|25462346||ab|7|entity|C0026809|Mus|mamm|||mice|||0|1000|1206|1210
SE|25462346||ab|7|entity|C0243148|control|ftcn|||controls|||0|827|1231|1239
SE|25462346||ab|7|entity|C0332272|Better|qlco|||better|||0|851|1259|1265
SE|25462346||ab|7|entity|C0521026|Viral|ftcn|||viral|||0|851|1266|1271
SE|25462346||ab|7|entity|C0243148|control|ftcn|||control|||0|851|1272|1279


SE|25462344||ti|1|text|21|133|Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes.
SE|25462344||ti|1|entity|C0026447|Monkeys|mamm|||monkeys|||0|1000|34|41
SE|25462344||ti|1|entity|C0522424|Simian-Human immunodeficiency virus|virs|||simian-human immunodeficiency viruses|||0|991|45|82
SE|25462344||ti|1|entity|C0263541|Equine laminitis|dsyn|||founder|||0|565|100|107
SE|25462344||ti|1|entity|C0019704|HIV-1|virs|||C HIV-1|||0|565|114|121

SE|25462344||ab|1|text|139|322|Simian-human immunodeficiency viruses (SHIVs) that mirror natural transmitted/founder (T/F) viruses in man are needed for evaluation of HIV-1 vaccine candidates in nonhuman primates.
SE|25462344||ab|1|entity|C0522424|Simian-Human immunodeficiency virus|virs|||Simian-human immunodeficiency viruses|||0|991|139|176
SE|25462344||ab|1|entity|C0205296|Natural|ftcn|||natural|||0|775|197|204
SE|25462344||ab|1|entity|C0263541|Equine laminitis|dsyn|||founder|||0|775|217|224
SE|25462344||ab|1|entity|C0042776|Virus|virs|||viruses|||0|775|231|238
SE|25462344||ab|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|261|271
SE|25462344||ab|1|entity|C0086413|HIV Vaccine|imft,phsu|||HIV-1 vaccine|||0|708|275|288
SE|25462344||ab|1|entity|C0237798|Nonhuman Primates|mamm|||nonhuman primates|||0|1000|303|320
SE|25462344||ab|1|relation|5|4|C0042776|Virus|virs|virs|||viruses|||0|775|231|238|PREP|PROCESS_OF||300|302|1|1|C0237798|Nonhuman Primates|mamm|mamm|||nonhuman primates|||0|1000|303|320

SE|25462344||ab|2|text|322|521|Currently available SHIVs contain HIV-1 env genes from chronically-infected individuals and do not reflect the characteristics of biologically relevant HIV-1 strains that mediate human transmission.
SE|25462344||ab|2|entity|C0521116|Current|tmco|||Currently|||0|883|322|331
SE|25462344||ab|2|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|883|342|347
SE|25462344||ab|2|entity|C0019704|HIV-1|virs|||HIV-1|||0|888|356|361
SE|25462344||ab|2|entity|C0017343|Genes, env|gngm|30816,100616444,100775105,110006328|ERVW-1,ERVK-20,ERVK-18,ERVK-32|env genes|||0|888|362|371
SE|25462344||ab|2|entity|C0439663|Infected|ftcn|||infected|||0|790|389|397
SE|25462344||ab|2|entity|C0237401|Individual|humn|||individuals|||0|790|398|409
SE|25462344||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|417|420
SE|25462344||ab|2|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|433|448
SE|25462344||ab|2|entity|C0019704|HIV-1|virs|||HIV-1|||0|785|474|479
SE|25462344||ab|2|entity|C0020114|Human|humn|||human|||0|694|501|506
SE|25462344||ab|2|relation|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|790|398|409|PREP|LOCATION_OF||372|376|2|1|C0017343|Genes, env|gngm,aapp|aapp|30816,100616444,100775105,110006328|ERVW-1,ERVK-20,ERVK-18,ERVK-32|env genes|||0|888|362|371

SE|25462344||ab|3|text|521|621|We chose to develop clade C SHIVs, as clade C is the major infecting subtype of HIV-1 in the world.
SE|25462344||ab|3|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|863|549|554
SE|25462344||ab|3|entity|C0205164|Major|qlco|||major|||0|840|574|579
SE|25462344||ab|3|entity|C0439663|Infected|ftcn|||infecting|||0|840|580|589
SE|25462344||ab|3|entity|C0449560|Subtype|clas|||subtype|||0|840|590|597
SE|25462344||ab|3|entity|C0019704|HIV-1|virs|||HIV-1|||0|1000|601|606

SE|25462344||ab|4|text|621|695|We constructed 10 clade C SHIVs expressing Env proteins from T/F viruses.
SE|25462344||ab|4|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|829|647|652
SE|25462344||ab|4|entity|C0017278|Gene Products, env|aapp,bacs|30816,100616444,100775105,110006328|ERVW-1,ERVK-20,ERVK-18,ERVK-32|Env proteins|||0|983|664|676
SE|25462344||ab|4|entity|C0263541|Equine laminitis|dsyn|||T/F|||0|790|682|685
SE|25462344||ab|4|entity|C0042776|Virus|virs|||viruses|||0|790|686|693
SE|25462344||ab|4|relation|1|1|C0042776|Virus|virs|virs|||viruses|||0|790|686|693|PREP|LOCATION_OF||677|681|2|1|C0017278|Gene Products, env|aapp,gngm,bacs|aapp|30816,100616444,100775105,110006328|ERVW-1,ERVK-20,ERVK-18,ERVK-32|Env proteins|||0|983|664|676

SE|25462344||ab|5|text|695|807|Three of these ten clade C SHIVs (SHIV KB9 C3, SHIV KB9 C4 and SHIV KB9 C5) replicated in naive rhesus monkeys.
SE|25462344||ab|5|entity|C0205449|Three|qnco|||Three|||0|1000|695|700
SE|25462344||ab|5|entity|C0205456|Ten|qnco|||ten|||0|825|710|713
SE|25462344||ab|5|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|825|722|727
SE|25462344||ab|5|entity|C0024400|Macaca mulatta|mamm|||rhesus monkeys|||0|901|791|805
SE|25462344||ab|5|relation|4|4|C0522424|Simian-Human immunodeficiency virus|virs|virs|||SHIVs|||0|825|722|727|PREP|PROCESS_OF||782|784|1|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus monkeys|||0|901|791|805

SE|25462344||ab|6|text|807|932|These three SHIVs are mucosally transmissible and are neutralized by sCD4 and several HIV-1 broadly neutralizing antibodies.
SE|25462344||ab|6|entity|C0205449|Three|qnco|||three|||0|922|813|818
SE|25462344||ab|6|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|922|819|824
SE|25462344||ab|6|entity|||gngm|79966|SCD5|sCD4|||0|1000|876|880
SE|25462344||ab|6|entity|C0443302|Several|qnco|||several|||0|828|885|892
SE|25462344||ab|6|entity|C0369497|Human immunodeficiency virus type 1 antibody|aapp,imft|||HIV-1 broadly neutralizing antibodies|||0|828|893|930

SE|25462344||ab|7|text|932|1040|However, like natural T/F viruses, they exhibit low Env reactivity and a Tier 2 neutralization sensitivity.
SE|25462344||ab|7|entity|C0205296|Natural|ftcn|||natural|||0|775|946|953
SE|25462344||ab|7|entity|C0263541|Equine laminitis|dsyn|||T/F|||0|775|954|957
SE|25462344||ab|7|entity|C0042776|Virus|virs|||viruses|||0|775|958|965
SE|25462344||ab|7|entity|C0205251|low|qlco|||low|||0|766|980|983
SE|25462344||ab|7|entity|||gngm|30816,100616444,100775105,110006328|ERVW-1,ERVK-20,ERVK-18,ERVK-32|Env|||0|766|984|987
SE|25462344||ab|7|entity|C0205332|Reactive|qlco|||reactivity|||0|766|988|998
SE|25462344||ab|7|entity|C1446680|Neutralization|lbpr|||neutralization|||0|750|1012|1026

SE|25462344||ab|8|text|1040|1243|Of note, none of the clade C T/F SHIVs elicited detectable autologous neutralizing antibodies in the infected monkeys, even though antibodies that neutralized a heterologous Tier 1 HIV-1 were generated.
SE|25462344||ab|8|entity|C1317574|NOTE|inpr|||note|||0|1000|1043|1047
SE|25462344||ab|8|entity|C0263541|Equine laminitis|dsyn|||T/F|||0|869|1069|1072
SE|25462344||ab|8|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|869|1073|1078
SE|25462344||ab|8|entity|C0439859|Autologous|qlco|||autologous|||0|824|1099|1109
SE|25462344||ab|8|entity|C1142254|Neutralising antibodies|diap|||neutralizing antibodies|||0|824|1110|1133
SE|25462344||ab|8|entity|C0439663|Infected|ftcn|||infected|||0|888|1141|1149
SE|25462344||ab|8|entity|C0026447|Monkeys|mamm|||monkeys|||0|888|1150|1157
SE|25462344||ab|8|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|1000|1171|1181
SE|25462344||ab|8|entity|C0439860|Heterologous|qlco|||heterologous|||0|764|1201|1213
SE|25462344||ab|8|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV-1|||0|764|1221|1226
SE|25462344||ab|8|relation|3|1|C0522424|Simian-Human immunodeficiency virus|virs|virs|||SHIVs|||0|869|1073|1078|PREP|PROCESS_OF||1134|1136|2|1|C0026447|Monkeys|mamm|mamm|||monkeys|||0|888|1150|1157

SE|25462344||ab|9|text|1243|1371|Challenge with these three new clade C SHIVs will provide biologically relevant tests for vaccine protection in rhesus macaques.
SE|25462344||ab|9|entity|C0205449|Three|qnco|||three|||0|793|1264|1269
SE|25462344||ab|9|entity|C0205314|New|tmco|||new|||0|793|1270|1273
SE|25462344||ab|9|entity|C0522424|Simian-Human immunodeficiency virus|virs|||SHIVs|||0|793|1282|1287
SE|25462344||ab|9|entity|C0392366|Tests|inpr|||tests|||0|827|1323|1328
SE|25462344||ab|9|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|888|1333|1340
SE|25462344||ab|9|entity|C0024400|Macaca mulatta|mamm|||rhesus macaques|||0|1000|1355|1370
SE|25462344||ab|9|relation|4|3|C0522424|Simian-Human immunodeficiency virus|virs|virs|||SHIVs|||0|793|1282|1287|PREP|PROCESS_OF||1352|1354|1|1|C0024400|Macaca mulatta|mamm|mamm|||rhesus macaques|||0|1000|1355|1370


SE|25462347||ti|1|text|21|130|RAB1A promotes Vaccinia virus replication by facilitating the production of intracellular enveloped virions.
SE|25462347||ti|1|entity|||gngm|5861|RAB1A|RAB1A|||0|1000|21|26
SE|25462347||ti|1|entity|C0042216|Vaccinia virus|virs|||Vaccinia virus|||0|901|36|50
SE|25462347||ti|1|entity|C0033268|production|ocac|||production|||0|1000|83|93
SE|25462347||ti|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|802|97|110
SE|25462347||ti|1|entity|C0042760|Virion|celc|||virions|||0|802|121|128

SE|25462347||ab|1|text|136|282|Vaccinia virus (VACV) is a large double-stranded DNA virus with a complex cytoplasmic replication cycle that exploits numerous cellular proteins.
SE|25462347||ab|1|entity|C0042216|Vaccinia virus|virs|||Vaccinia virus|||0|1000|136|150
SE|25462347||ab|1|entity|C0549177|Large|qnco|||large|||0|928|163|168
SE|25462347||ab|1|entity|C1512048|Double Stranded DNA Virus|virs|||double-stranded DNA virus|||0|928|169|194
SE|25462347||ab|1|entity|C0439855|Complex|qlco|||complex|||0|833|202|209
SE|25462347||ab|1|entity|C0521449|Cytoplasmic|blor|||cytoplasmic|||0|833|210|221
SE|25462347||ab|1|entity|C0750729|Course|tmco|||cycle|||0|833|234|239
SE|25462347||ab|1|entity|C0439064|Numerous|qnco|||numerous|||0|851|254|262
SE|25462347||ab|1|entity|C0178539|Cellular|ftcn|||cellular|||0|851|263|271
SE|25462347||ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|851|272|280
SE|25462347||ab|1|relation|0|0|C0042216|Vaccinia virus|virs|virs|||Vaccinia virus|||0|1000|136|150|SPEC|ISA||136|194|0|0|C1512048|Double Stranded DNA Virus|virs|virs|||double-stranded DNA virus|||0|928|169|194

SE|25462347||ab|2|text|282|392|This work characterises the role of a proviral cellular protein, the small GTPase RAB1A, in VACV replication.
SE|25462347||ab|2|entity|C0043227|Work|ocac|||work|||0|1000|287|291
SE|25462347||ab|2|entity|C0035820|Role|socb|||role|||0|1000|310|314
SE|25462347||ab|2|entity|C0178539|Cellular|ftcn|||cellular|||0|790|329|337
SE|25462347||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|790|338|345
SE|25462347||ab|2|entity|C0751984|Monomeric GTP-Binding Proteins|aapp,enzy|||small GTPase|||0|717|351|363
SE|25462347||ab|2|entity|||gngm|5861|RAB1A|RAB1A|||0|717|364|369
SE|25462347||ab|2|entity|C0042216|Vaccinia virus|virs|||VACV|||0|901|374|378

SE|25462347||ab|3|text|392|544|Using siRNA, we identified RAB1A as required for the production of extracellular enveloped virions (EEVs), but not intracellular mature virions (IMVs).
SE|25462347||ab|3|entity|C1099354|RNA, Small Interfering|bacs,nnon|||siRNA|||0|1000|398|403
SE|25462347||ab|3|entity|||gngm|5861|RAB1A|RAB1A|||0|1000|419|424
SE|25462347||ab|3|entity|C0033268|production|ocac|||production|||0|1000|445|455
SE|25462347||ab|3|entity|C0521119|Extracellular|celc|||extracellular|||0|802|459|472
SE|25462347||ab|3|entity|C0042760|Virion|celc|||virions|||0|802|483|490
SE|25462347||ab|3|entity|C1518422|Not|ftcn|||not|||0|833|503|506
SE|25462347||ab|3|entity|C0175996|Protoplasm|celc|||intracellular|||0|833|507|520
SE|25462347||ab|3|entity|C0205286|Mature|tmco|||mature|||0|833|521|527
SE|25462347||ab|3|entity|C0042760|Virion|celc|||virions|||0|833|528|535

SE|25462347||ab|4|text|544|708|Immunofluorescence and electron microscopy further refined the role of RAB1A as facilitating the wrapping of IMVs to become intracellular enveloped virions (IEVs).
SE|25462347||ab|4|entity|C0079603|Immunofluorescence|lbpr|||Immunofluorescence|||0|1000|544|562
SE|25462347||ab|4|entity|C0026019|Electron Microscopy|lbpr|||electron microscopy|||0|1000|567|586
SE|25462347||ab|4|entity|C1517331|Further|spco|||further|||0|1000|587|594
SE|25462347||ab|4|entity|C0035820|Role|socb|||role|||0|1000|607|611
SE|25462347||ab|4|entity|||gngm|5861|RAB1A|RAB1A|||0|1000|615|620
SE|25462347||ab|4|entity|C0445414|Wrapping|hlca|||wrapping|||0|1000|641|649
SE|25462347||ab|4|entity|C0175996|Protoplasm|celc|||IMVs|||0|851|653|657
SE|25462347||ab|4|entity|C0205286|Mature|tmco|||IMVs|||0|851|653|657
SE|25462347||ab|4|entity|C0042760|Virion|celc|||IMVs|||0|851|653|657
SE|25462347||ab|4|entity|C0175996|Protoplasm|celc|||intracellular|||0|802|668|681
SE|25462347||ab|4|entity|C0042760|Virion|celc|||virions|||0|802|692|699

SE|25462347||ab|5|text|708|801|This is consistent with the known function of RAB1A in maintenance of ER to Golgi transport.
SE|25462347||ab|5|entity|C0205309|Known|qlco|||known|||0|888|736|741
SE|25462347||ab|5|entity|C0031843|physiological aspects|phsf|||function|||0|888|742|750
SE|25462347||ab|5|entity|||gngm|5861|RAB1A|RAB1A|||0|1000|754|759

SE|25462347||ab|6|text|801|965|VACV can therefore be added to the growing list of viruses which require RAB1A for optimal replication, highlighting this protein as a broadly proviral host factor.
SE|25462347||ab|6|entity|C0042216|Vaccinia virus|virs|||VACV|||0|1000|801|805
SE|25462347||ab|6|entity|C0745732|LIST|cnce|||list|||0|861|844|848
SE|25462347||ab|6|entity|C0042776|Virus|virs|||viruses|||0|1000|852|859
SE|25462347||ab|6|entity|||gngm|5861|RAB1A|RAB1A|||0|1000|874|879
SE|25462347||ab|6|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|923|930
SE|25462347||ab|6|entity|C0284965|Integration Host Factors|aapp,bacs|||host factor|||0|861|953|964


SE|25462348||ti|1|text|21|99|Ectromelia virus encodes an anti-apoptotic protein that regulates cell death.
SE|25462348||ti|1|entity|C0013590|Mouse Pox Virus|virs|||Ectromelia virus|||0|1000|21|37
SE|25462348||ti|1|entity|C1565114|Apoptosis Inhibiting Proteins|aapp,bacs|||anti-apoptotic protein|||0|988|49|71
SE|25462348||ti|1|entity|C0007587|Cell Death|celf|||cell death|||0|1000|87|97
SE|25462348||ti|1|relation|2|1|C1565114|Apoptosis Inhibiting Proteins|aapp,gngm,bacs|aapp|||anti-apoptotic protein|||0|988|49|71|VERB|AFFECTS||77|86|1|1|C0007587|Cell Death|celf|celf|||cell death|||0|1000|87|97

SE|25462348||ab|1|text|105|188|Apoptosis serves as a powerful defense against damaged or pathogen-infected cells.
SE|25462348||ab|1|entity|C0162638|Apoptosis|celf|||Apoptosis|||0|1000|105|114
SE|25462348||ab|1|entity|C0679190|defensiveness|inbe|||defense|||0|761|136|143
SE|25462348||ab|1|entity|C0439663|Infected|ftcn|||infected|||0|818|172|180
SE|25462348||ab|1|entity|C0007634|Cells|cell|||cells|||0|818|181|186

SE|25462348||ab|2|text|188|335|Since apoptosis is an effective defense against viral infection, many viruses including poxviruses, encode proteins to prevent or delay apoptosis.
SE|25462348||ab|2|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|194|203
SE|25462348||ab|2|entity|C0679190|defensiveness|inbe|||defense|||0|838|220|227
SE|25462348||ab|2|entity|C0042769|Virus Diseases|dsyn|||viral infection|||0|1000|236|251
SE|25462348||ab|2|entity|C0042776|Virus|virs|||viruses|||0|1000|258|265
SE|25462348||ab|2|entity|C0032868|Poxviridae|virs|||poxviruses|||0|1000|276|286
SE|25462348||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|295|303
SE|25462348||ab|2|entity|C0205421|Deferred|tmco|||delay|||0|888|318|323
SE|25462348||ab|2|entity|C0162638|Apoptosis|celf|||apoptosis|||0|888|324|333

SE|25462348||ab|3|text|335|445|Here we show that ectromelia virus, the causative agent of mousepox encodes an anti-apoptotic protein EVM025.
SE|25462348||ab|3|entity|C0013590|Mouse Pox Virus|virs|||ectromelia virus|||0|1000|353|369
SE|25462348||ab|3|entity|C0449411|Causative_agents|fndg|||causative agent|||0|1000|375|390
SE|25462348||ab|3|entity|C0013590|Mouse Pox Virus|virs|||mousepox|||0|1000|394|402
SE|25462348||ab|3|entity|C1565114|Apoptosis Inhibiting Proteins|aapp,bacs|||anti-apoptotic protein|||0|745|414|436

SE|25462348||ab|4|text|445|582|Here we demonstrate that expression of functional EVM025 is crucial to prevent apoptosis triggered by virus infection and staurosporine.
SE|25462348||ab|4|entity|C0205245|Functional|ftcn|||functional|||0|694|484|494
SE|25462348||ab|4|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|524|533
SE|25462348||ab|4|entity|C0042769|Virus Diseases|dsyn|||virus infection|||0|1000|547|562
SE|25462348||ab|4|entity|C0075193|Staurosporine|orch,phsu|||staurosporine|||0|1000|567|580

SE|25462348||ab|5|text|582|796|We demonstrate that the expression of EVM025 prevents the conformational activation of the pro-apoptotic proteins Bak and Bax, allowing the maintenance of mitochondrial membrane integrity upon infection with ECTV.
SE|25462348||ab|5|entity|C1565115|Apoptosis Inducing Proteins|aapp,bacs|||pro-apoptotic proteins|||0|916|673|695
SE|25462348||ab|5|entity|C1332379|BAK1 gene|gngm|578|BAK1|Bak|||0|916|696|699
SE|25462348||ab|5|entity|C0812198|BAX gene|gngm|581|BAX|Bax|||0|1000|704|707
SE|25462348||ab|5|entity|C0596952|Mitochondrial Membranes|celc|||mitochondrial membrane|||0|901|737|759
SE|25462348||ab|5|entity|C0205266|Intact|qlco|||integrity|||0|901|760|769

SE|25462348||ab|6|text|796|852|Additionally, EVM025 interacted with intracellular Bak.
SE|25462348||ab|6|entity|C0175996|Protoplasm|celc|||intracellular|||0|888|833|846
SE|25462348||ab|6|entity|C1332379|BAK1 gene|gngm|578|BAK1|Bak|||0|888|847|850
SE|25462348||ab|6|relation|0|0|C1332379|BAK1 gene|gngm,aapp|gngm|578|BAK1|Bak|||0|888|847|850|MOD/HEAD|PART_OF||833|850|0|0|C0175996|Protoplasm|celc|celc|||intracellular|||0|888|833|846

SE|25462348||ab|7|text|852|1016|We were able to demonstrate that EVM025 ability to inhibit Bax activation is a function of its ability to inhibit the activity of an upstream BH3 only protein Bim.
SE|25462348||ab|7|entity|C0085732|Ability|orga|||ability|||0|861|892|899
SE|25462348||ab|7|entity|C0812198|BAX gene|gngm|581|BAX|Bax|||0|694|911|914
SE|25462348||ab|7|entity|C0031843|physiological aspects|phsf|||function|||0|1000|931|939
SE|25462348||ab|7|entity|C0085732|Ability|orga|||ability|||0|1000|947|954
SE|25462348||ab|7|entity|C0522505|Upstream|spco|||upstream|||0|762|985|993
SE|25462348||ab|7|entity|C0033684|Proteins|aapp,bacs|||protein|||0|762|1003|1010
SE|25462348||ab|7|entity|C1332396|BCL2-Related Protein 11|aapp,bacs|10018|BCL2L11|Bim|||0|762|1011|1014

SE|25462348||ab|8|text|1016|1143|Collectively, our data indicates that EVM025 inhibits apoptosis by sequestering Bak and inhibiting the activity of Bak and Bax.
SE|25462348||ab|8|entity|C1511726|Data|idcn|||data|||0|1000|1034|1038
SE|25462348||ab|8|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|1070|1079
SE|25462348||ab|8|entity|C0869026|maintenance of localization|celf|||sequestering|||0|888|1083|1095
SE|25462348||ab|8|entity|C1332379|BAK1 gene|gngm|578|BAK1|Bak|||0|888|1096|1099
SE|25462348||ab|8|entity|C0311403|Inhibited|qlco|||inhibiting|||0|966|1104|1114
SE|25462348||ab|8|entity|C1332379|BAK1 gene|gngm|578|BAK1|Bak|||0|1000|1131|1134
SE|25462348||ab|8|entity|C0812198|BAX gene|gngm|581|BAX|Bax|||0|1000|1139|1142


SE|25462350||ti|1|text|21|107|Tetherin restricts HSV-2 release and is counteracted by multiple viral glycoproteins.
SE|25462350||ti|1|entity|||gngm|684|BST2|Tetherin|||0|1000|21|29
SE|25462350||ti|1|entity|C0019351|Herpesvirus 2, Human|virs|||HSV-2|||0|901|40|45
SE|25462350||ti|1|entity|C0439064|Numerous|qnco|||multiple|||0|851|77|85
SE|25462350||ti|1|entity|C0521026|Viral|ftcn|||viral|||0|851|86|91
SE|25462350||ti|1|entity|C0017968|Glycoproteins|aapp,carb|||glycoproteins|||0|851|92|105
SE|25462350||ti|1|relation|1|1|C0017968|Glycoproteins|aapp,gngm,carb|aapp|||glycoproteins|||0|851|92|105|VERB|INHIBITS||61|73|2|2|||gngm,aapp|gngm|684|BST2|Tetherin|||0|1000|21|29

SE|25462350||ab|1|text|113|209|Tetherin has been defined as a restriction factor of HIV-1 and several other enveloped viruses.
SE|25462350||ab|1|entity|||gngm|684|BST2|Tetherin|||0|1000|113|121
SE|25462350||ab|1|entity|C1521761|Factor|ftcn|||factor|||0|861|156|162
SE|25462350||ab|1|entity|C0019704|HIV-1|virs|||HIV-1|||0|1000|166|171
SE|25462350||ab|1|entity|C0443302|Several|qnco|||several|||0|1000|176|183
SE|25462350||ab|1|entity|C0042776|Virus|virs|||viruses|||0|861|200|207

SE|25462350||ab|2|text|209|299|However, the significance of tetherin in viral infection remains to be further addressed.
SE|25462350||ab|2|entity|C0750502|Significant|idcn|||significance|||0|928|222|234
SE|25462350||ab|2|entity|||gngm|684|BST2|tetherin|||0|1000|238|246
SE|25462350||ab|2|entity|C0042769|Virus Diseases|dsyn|||viral infection|||0|1000|250|265
SE|25462350||ab|2|entity|C1517331|Further|spco|||further|||0|1000|280|287
SE|25462350||ab|2|relation|2|1|||gngm,aapp|gngm|684|BST2|tetherin|||0|1000|238|246|PREP|ASSOCIATED_WITH||247|249|1|1|C0042769|Virus Diseases|dsyn|dsyn|||viral infection|||0|1000|250|265

SE|25462350||ab|3|text|299|371|Here, we investigated whether tetherin plays a role in HSV-2 infection.
SE|25462350||ab|3|entity|||gngm|684|BST2|tetherin|||0|1000|329|337
SE|25462350||ab|3|entity|C0035820|Role|socb|||role|||0|1000|346|350
SE|25462350||ab|3|entity|C1504513|HSV infection|dsyn|||HSV-2 infection|||0|913|354|369
SE|25462350||ab|3|relation|1|1|||gngm,aapp|gngm|684|BST2|tetherin|||0|1000|329|337|COMPLEX|AFFECTS||338|350|1|1|C1504513|HSV infection|dsyn|dsyn|||HSV-2 infection|||0|913|354|369

SE|25462350||ab|4|text|371|544|Our study revealed that overexpression of tetherin restricted the release of HSV-2 into the extracellular medium, while knockdown of tetherin by siRNA enhanced its release.
SE|25462350||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|375|380
SE|25462350||ab|4|entity|||gngm|684|BST2|tetherin|||0|1000|413|421
SE|25462350||ab|4|entity|C0019351|Herpesvirus 2, Human|virs|||HSV-2|||0|1000|448|453
SE|25462350||ab|4|entity|C0521119|Extracellular|celc|||extracellular|||0|888|463|476
SE|25462350||ab|4|entity|C0439536|Medium|qlco|||medium|||0|888|477|483
SE|25462350||ab|4|entity|||gngm|684|BST2|tetherin|||0|1000|504|512
SE|25462350||ab|4|entity|C1099354|RNA, Small Interfering|bacs,nnon|||siRNA|||0|1000|516|521

SE|25462350||ab|5|text|544|709|We further demonstrated that HSV-2 infection and viral glycoproteins gB, gD, gH and gL but not gM significantly downregulated the endogenous expression of tetherin.
SE|25462350||ab|5|entity|C1517331|Further|spco|||further|||0|1000|547|554
SE|25462350||ab|5|entity|C1504513|HSV infection|dsyn|||HSV-2 infection|||0|913|573|588
SE|25462350||ab|5|entity|C0521026|Viral|ftcn|||viral|||0|623|593|598
SE|25462350||ab|5|entity|C0017968|Glycoproteins|aapp,carb|||glycoproteins|||0|623|599|612
SE|25462350||ab|5|entity|C1518422|Not|ftcn|||not|||0|694|635|638
SE|25462350||ab|5|entity|C0205227|Endogenous|ftcn|||endogenous|||0|888|674|684
SE|25462350||ab|5|entity|||gngm|684|BST2|tetherin|||0|1000|699|707

SE|25462350||ab|6|text|709|803|Additional study indicated that tetherin likely physically interacted with gB, gD, gH and gL.
SE|25462350||ab|6|entity|C1524062|Additional|ftcn|||Additional|||0|888|709|719
SE|25462350||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|888|720|725
SE|25462350||ab|6|entity|||gngm|684|BST2|tetherin|||0|694|741|749

SE|25462350||ab|7|text|803|915|This is the first time that tetherin has been shown to be counteracted by multiple viral components of a virus.
SE|25462350||ab|7|entity|C1279901|Firstly|qlco|||first|||0|888|815|820
SE|25462350||ab|7|entity|C0040223|Time|tmco|||time|||0|888|821|825
SE|25462350||ab|7|entity|||gngm|684|BST2|tetherin|||0|1000|831|839
SE|25462350||ab|7|entity|C0439064|Numerous|qnco|||multiple|||0|890|877|885
SE|25462350||ab|7|entity|C1268456|Viral component|celc|||viral components|||0|890|886|902
SE|25462350||ab|7|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|908|913

SE|25462350||ab|8|text|915|1115|Our findings inform the complexity of HSV-2-host interactions, providing basis for understanding the role of tetherin as a viral restriction factor and the mechanisms underlying viral countermeasures.
SE|25462350||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|919|927
SE|25462350||ab|8|entity|C0439855|Complex|qlco|||complexity|||0|928|939|949
SE|25462350||ab|8|entity|C0019351|Herpesvirus 2, Human|virs|||HSV-2|||0|658|953|958
SE|25462350||ab|8|entity|C1167395|host|celc|||host|||0|658|959|963
SE|25462350||ab|8|entity|C1527178|Basis|ftcn|||basis|||0|1000|988|993
SE|25462350||ab|8|entity|C0035820|Role|socb|||role|||0|1000|1016|1020
SE|25462350||ab|8|entity|||gngm|684|BST2|tetherin|||0|1000|1024|1032
SE|25462350||ab|8|entity|C0521026|Viral|ftcn|||viral|||0|802|1038|1043
SE|25462350||ab|8|entity|C1521761|Factor|ftcn|||factor|||0|802|1056|1062
SE|25462350||ab|8|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|1071|1081
SE|25462350||ab|8|entity|C0521026|Viral|ftcn|||viral|||0|694|1093|1098


SE|25462349||ti|1|text|21|82|An MHC class I immune evasion gene of Marek's disease virus.
SE|25462349||ti|1|entity|||gngm|3107|HLA-C|MHC|||0|861|24|27
SE|25462349||ti|1|entity|C0008902|Classification|clas|||class|||0|861|28|33
SE|25462349||ti|1|entity|C0439662|Immune|ftcn|||immune|||0|802|36|42
SE|25462349||ti|1|entity|C0017337|Genes|gngm|||gene|||0|802|51|55
SE|25462349||ti|1|entity|C0024794|Herpesvirus 2, Gallid|virs|||Marek's disease virus|||0|1000|59|80

SE|25462349||ab|1|text|88|189|Marek's disease virus (MDV) is a widespread alpha-herpesvirus of chickens that causes T cell tumors.
SE|25462349||ab|1|entity|C0024794|Herpesvirus 2, Gallid|virs|||Marek's disease virus|||0|1000|88|109
SE|25462349||ab|1|entity|C0205391|Widespread|spco|||widespread|||0|888|121|131
SE|25462349||ab|1|entity|C0682451|alphaherpesvirus|virs|||alpha-herpesvirus|||0|888|132|149
SE|25462349||ab|1|entity|C0008051|Chickens|bird|||chickens|||0|1000|153|161
SE|25462349||ab|1|entity|C0039194|T-Lymphocyte|cell|||T cell|||0|901|174|180
SE|25462349||ab|1|entity|C0027651|Neoplasm|neop|||tumors|||0|901|181|187
SE|25462349||ab|1|relation|0|0|C0039194|T-Lymphocyte|cell|cell|||T cell|||0|901|174|180|MOD/HEAD|LOCATION_OF||174|187|0|0|C0027651|Neoplasm|neop|neop|||tumors|||0|901|181|187
SE|25462349||ab|1|relation|3|2|C0682451|alphaherpesvirus|virs|virs|||alpha-herpesvirus|||0|888|132|149|VERB|CAUSES||167|173|1|1|C0027651|Neoplasm|neop|neop|||tumors|||0|901|181|187

SE|25462349||ab|2|text|189|388|Acute, but not latent, MDV infection has previously been shown to lead to downregulation of cell-surface MHC class I (Virology 282:198-205 (2001)), but the gene(s) involved have not been identified.
SE|25462349||ab|2|entity|C0205178|acute|tmco|||Acute|||0|1000|189|194
SE|25462349||ab|2|entity|C1518422|Not|ftcn|||not|||0|864|200|203
SE|25462349||ab|2|entity|C0024794|Herpesvirus 2, Gallid|virs|||MDV|||0|864|212|215
SE|25462349||ab|2|entity|C0872054|Latent Infection|dsyn|||latent, MDV infection|||0|864|204|225
SE|25462349||ab|2|entity|C0013081|Down-Regulation|celf|||downregulation|||0|1000|263|277
SE|25462349||ab|2|entity|C0699040|Cell surface|celc|||cell-surface|||0|824|281|293
SE|25462349||ab|2|entity|||gngm|3107|HLA-C|MHC|||0|824|294|297
SE|25462349||ab|2|entity|C0008902|Classification|clas|||class|||0|824|298|303
SE|25462349||ab|2|entity|C0205466|virologic|ftcn|||Virology|||0|861|307|315
SE|25462349||ab|2|entity|C0017337|Genes|gngm|||gene|||0|1000|345|349
SE|25462349||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|367|370
SE|25462349||ab|2|relation|2|1|C0872054|Latent Infection|dsyn|dsyn|||latent, MDV infection|||0|864|204|225|VERB|AFFECTS|negation|255|259|4|1|C0013081|Down-Regulation|celf|celf|||downregulation|||0|1000|263|277

SE|25462349||ab|3|text|388|509|Here we demonstrate that an MDV gene, MDV012, is capable of reducing surface expression of MHC class I on chicken cells.
SE|25462349||ab|3|entity|C0024794|Herpesvirus 2, Gallid|virs|||MDV|||0|916|416|419
SE|25462349||ab|3|entity|C0017337|Genes|gngm|||gene|||0|916|420|424
SE|25462349||ab|3|entity|C0392756|Reduced|qlco|||reducing|||0|840|448|456
SE|25462349||ab|3|entity|C0205148|Surface|spco|||surface|||0|840|457|464
SE|25462349||ab|3|entity|||gngm|3107|HLA-C|MHC|||0|861|479|482
SE|25462349||ab|3|entity|C0008902|Classification|clas|||class|||0|861|483|488
SE|25462349||ab|3|entity|C1516469|Chicken Cells|cell|||chicken cells|||0|1000|494|507
SE|25462349||ab|3|relation|1|1|C1516469|Chicken Cells|cell|cell|||chicken cells|||0|1000|494|507|PREP|LOCATION_OF||491|493|5|5|C0024794|Herpesvirus 2, Gallid|virs|virs|||MDV|||0|916|416|419

SE|25462349||ab|4|text|509|800|Co-expression of an MHC class I-binding peptide targeted to the endoplasmic reticulum (bypassing the requirement for the TAP peptide transporter) partially rescued MHC class I expression in the presence of MDV012, suggesting that MDV012 is a TAP-blocking MHC class I immune evasion protein.
SE|25462349||ab|4|entity|||gngm|3107|HLA-C|MHC|||0|861|529|532
SE|25462349||ab|4|entity|C0008902|Classification|clas|||class|||0|861|533|538
SE|25462349||ab|4|entity|C0030956|Peptides|aapp|||peptide|||0|861|549|556
SE|25462349||ab|4|entity|C0014239|Endoplasmic Reticulum|celc|||endoplasmic reticulum|||0|1000|573|594
SE|25462349||ab|4|entity|C1514873|Requirement|idcn|||requirement|||0|1000|610|621
SE|25462349||ab|4|entity|C0214697|trypsinogen activation peptide|aapp|||TAP peptide|||0|901|630|641
SE|25462349||ab|4|entity|C0596902|Membrane Transport Proteins|aapp,bacs|||transporter|||0|901|642|653
SE|25462349||ab|4|entity|||gngm|3107|HLA-C|MHC|||0|812|673|676
SE|25462349||ab|4|entity|C0008902|Classification|clas|||class|||0|812|677|682
SE|25462349||ab|4|entity|C0034115|Paracentesis|hlca|||TAP|||0|775|751|754
SE|25462349||ab|4|entity|C0332206|Blocking|ftcn|||blocking|||0|775|755|763
SE|25462349||ab|4|entity|||gngm|3107|HLA-C|MHC|||0|775|764|767
SE|25462349||ab|4|entity|C0008902|Classification|clas|||class|||0|775|768|773
SE|25462349||ab|4|entity|C0439662|Immune|ftcn|||immune|||0|802|776|782
SE|25462349||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|802|791|798
SE|25462349||ab|4|relation|0|0|C0596902|Membrane Transport Proteins|aapp,gngm,bacs|bacs|||transporter|||0|901|642|653|MOD/HEAD|PART_OF||630|653|0|0|C0214697|trypsinogen activation peptide|aapp,gngm|aapp|||TAP peptide|||0|901|630|641

SE|25462349||ab|5|text|800|981|This is the first unique non-mammalian MHC class I immune evasion gene identified, and suggests that alpha-herpesviruses have conserved this function for at least 100 million years.
SE|25462349||ab|5|entity|C1279901|Firstly|qlco|||first|||0|783|812|817
SE|25462349||ab|5|entity|||gngm|3107|HLA-C|MHC|||0|783|839|842
SE|25462349||ab|5|entity|C0008902|Classification|clas|||class|||0|783|843|848
SE|25462349||ab|5|entity|C0439662|Immune|ftcn|||immune|||0|802|851|857
SE|25462349||ab|5|entity|C0017337|Genes|gngm|||gene|||0|802|866|870
SE|25462349||ab|5|entity|C0682451|alphaherpesvirus|virs|||alpha-herpesviruses|||0|966|901|920
SE|25462349||ab|5|entity|C0031843|physiological aspects|phsf|||function|||0|1000|941|949
SE|25462349||ab|5|entity|C0439234|year|tmco|||years|||0|812|975|980


SE|25462351||ti|1|text|21|174|Mutations altering the gammaretrovirus endoproteolytic motif affect glycosylation of the envelope glycoprotein and early events of the virus life cycle.
SE|25462351||ti|1|entity|C0026882|Mutation|genf|||Mutations|||0|1000|21|30
SE|25462351||ti|1|entity|C0206464|Gammaretrovirus|virs|||gammaretrovirus|||0|660|44|59
SE|25462351||ti|1|entity|C0017982|glycosylation|npop|||glycosylation|||0|1000|89|102
SE|25462351||ti|1|entity|C0017968|Glycoproteins|aapp,carb|||glycoprotein|||0|861|119|131
SE|25462351||ti|1|entity|C1279919|Early|tmco|||early|||0|888|136|141
SE|25462351||ti|1|entity|C0441471|Events|evnt|||events|||0|888|142|148
SE|25462351||ti|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|851|156|161
SE|25462351||ti|1|entity|C0376558|Life|idcn|||life|||0|851|162|166
SE|25462351||ti|1|entity|C0750729|Course|tmco|||cycle|||0|851|167|172
SE|25462351||ti|1|relation|2|2|C0026882|Mutation|genf|genf|||Mutations|||0|1000|21|30|VERB|AFFECTS||82|88|4|1|C0017982|glycosylation|npop|npop|||glycosylation|||0|1000|89|102

SE|25462351||ab|1|text|180|352|Previously, we found that mutation of glutamine to proline in the endoproteolytic cleavage signal of the PERV-C envelope (RQKK to RPKK) resulted in non-infectious vectors.
SE|25462351||ab|1|entity|C0026882|Mutation|genf|||mutation|||0|1000|206|214
SE|25462351||ab|1|entity|C0017797|Glutamine|aapp,bacs|||glutamine|||0|1000|218|227
SE|25462351||ab|1|entity|C0033382|Proline|aapp,bacs|||proline|||0|1000|231|238
SE|25462351||ab|1|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|660|262|270
SE|25462351||ab|1|entity|C1550587|infectious|idcn|||infectious|||0|790|332|342
SE|25462351||ab|1|entity|C0442335|Vectors|spco|||vectors|||0|790|343|350
SE|25462351||ab|1|relation|7|1|C0017797|Glutamine|aapp,gngm,bacs|gngm|||glutamine|||0|1000|218|227|PREP|LOCATION_OF||215|217|1|1|C0026882|Mutation|genf|genf|||mutation|||0|1000|206|214

SE|25462351||ab|2|text|352|512|Here, we show that RPKK results in a non-infectious vector when placed in not only a PERV envelope, but also the envelope of a related gammaretrovirus, FeLV-B.
SE|25462351||ab|2|entity|C1550587|infectious|idcn|||infectious|||0|790|393|403
SE|25462351||ab|2|entity|C0442335|Vectors|spco|||vector|||0|790|404|410
SE|25462351||ab|2|entity|C1518422|Not|ftcn|||not|||0|861|426|429
SE|25462351||ab|2|entity|C1522149|Related|ftcn|||related|||0|888|479|486
SE|25462351||ab|2|entity|C0206464|Gammaretrovirus|virs|||gammaretrovirus|||0|888|487|502
SE|25462351||ab|2|entity|C0015767|Leukemia Virus, Feline|virs|||FeLV|||0|872|504|508

SE|25462351||ab|3|text|512|638|The amino acid substitutions do not prevent envelope precursor cleavage, viral core and genome assembly, or receptor binding.
SE|25462351||ab|3|entity|C0525038|Amino Acid Substitution|genf,mbrt|||amino acid substitutions|||0|1000|516|540
SE|25462351||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|544|547
SE|25462351||ab|3|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|827|575|583
SE|25462351||ab|3|entity|C1268457|Viral core|celc|||viral core|||0|1000|585|595
SE|25462351||ab|3|entity|C0017428|Genome|gngm|||genome|||0|694|600|606
SE|25462351||ab|3|entity|C0597358|Receptor Binding|moft|||receptor binding|||0|1000|620|636

SE|25462351||ab|4|text|638|878|Rather, the mutations result in the formation of hyperglycosylated glycoprotein and a reduction in the reverse transcribed minus strand synthesis and undetectable 2-LTR circular DNA in cells exposed to vectors with these mutated envelopes.
SE|25462351||ab|4|entity|C0026882|Mutation|genf|||mutations|||0|1000|650|659
SE|25462351||ab|4|entity|C1522492|Formation|ftcn|||formation|||0|1000|674|683
SE|25462351||ab|4|entity|C0017968|Glycoproteins|aapp,carb|||glycoprotein|||0|861|705|717
SE|25462351||ab|4|entity|C1555029|reverses|idcn|||reverse|||0|770|741|748
SE|25462351||ab|4|entity|C0869032|Synthesis|phpr|||synthesis|||0|770|774|783
SE|25462351||ab|4|entity|C0023978|Long Terminal Repeat|nnon|||2-LTR|||0|785|801|806
SE|25462351||ab|4|entity|C0012925|DNA, Circular|bacs,nnon|||circular DNA|||0|785|807|819
SE|25462351||ab|4|entity|C0007634|Cells|cell|||cells|||0|1000|823|828
SE|25462351||ab|4|entity|C0442335|Vectors|spco|||vectors|||0|1000|840|847
SE|25462351||ab|4|entity|C1513776|Mutate|genf|||mutated|||0|661|859|866
SE|25462351||ab|4|relation|3|1|C0007634|Cells|cell|cell|||cells|||0|1000|823|828|PREP|LOCATION_OF||820|822|6|4|C0017968|Glycoproteins|aapp,gngm,carb|aapp|||glycoprotein|||0|861|705|717

SE|25462351||ab|5|text|878|1037|Our findings suggest novel functions associated with the cleavage signal sequence that may affect trafficking through the glycosylation machinery of the cell.
SE|25462351||ab|5|entity|C0243095|Finding|ftcn|||findings|||0|1000|882|890
SE|25462351||ab|5|entity|C0679622|novel|inpr|||novel|||0|888|899|904
SE|25462351||ab|5|entity|C0542341|Function|ftcn|||functions|||0|888|905|914
SE|25462351||ab|5|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|694|935|943
SE|25462351||ab|5|entity|C0017982|glycosylation|npop|||glycosylation|||0|888|1000|1013
SE|25462351||ab|5|entity|C0337076|Industrial machine|mnob|||machinery|||0|888|1014|1023
SE|25462351||ab|5|entity|C0007634|Cells|cell|||cell|||0|1000|1031|1035

SE|25462351||ab|6|text|1037|1216|Further, the glycosylation status of the envelope appears to impact post-binding events of the viral life cycle, either membrane fusion, internalization, or reverse transcription.
SE|25462351||ab|6|entity|C1517331|Further|spco|||Further|||0|1000|1037|1044
SE|25462351||ab|6|entity|C0017982|glycosylation|npop|||glycosylation|||0|888|1050|1063
SE|25462351||ab|6|entity|C0449438|Status|qlco|||status|||0|888|1064|1070
SE|25462351||ab|6|entity|C1546087|POST {EVENT}|clna|||post-binding events|||0|813|1105|1124
SE|25462351||ab|6|entity|C1160638|Viral life cycle|biof|||viral life cycle|||0|1000|1132|1148
SE|25462351||ab|6|entity|C0025246|Membrane Fusion|moft|||membrane fusion|||0|901|1157|1172
SE|25462351||ab|6|entity|C0871786|Internalization|menp|||internalization|||0|1000|1174|1189
SE|25462351||ab|6|entity|C0035380|Reverse Transcription|genf|||reverse transcription|||0|1000|1194|1215
SE|25462351||ab|6|relation|4|4|C0035380|Reverse Transcription|genf|genf|||reverse transcription|||0|1000|1194|1215|NOM|AFFECTS||1098|1104|4|1|C1160638|Viral life cycle|biof|biof|||viral life cycle|||0|1000|1132|1148


SE|25462352||ti|1|text|21|168|Poor growth of human adenovirus-12 compared to adenovirus-2 correlates with a failure to impair PKR activation during the late phase of infection.
SE|25462352||ti|1|entity|C0032854|Poverty|grpa|||Poor|||0|888|21|25
SE|25462352||ti|1|entity|C0018270|Growth|orgf|||growth|||0|888|26|32
SE|25462352||ti|1|entity|C0319175|Human adenovirus 12|virs|||human adenovirus-12|||0|1000|36|55
SE|25462352||ti|1|entity|C0001483|Adenoviruses|virs|||adenovirus|||0|660|68|78
SE|25462352||ti|1|entity|C0031727|Phosphotransferases|aapp,enzy|||PKR|||0|852|117|120
SE|25462352||ti|1|entity|C0599177|protein activation|genf|||PKR activation|||0|852|117|131
SE|25462352||ti|1|entity|C0205087|Late|tmco|||late|||0|888|143|147
SE|25462352||ti|1|entity|C0205390|Phase|tmco|||phase|||0|888|148|153

SE|25462352||ab|1|text|174|357|Human adenovirus type 12 (HAdV-12) displays a relatively low virulence and slow replication in cultured human cells, which is manifested by premature death of HAdV-12-infected cells.
SE|25462352||ab|1|entity|C1547052|*Type|qnco|||type|||0|916|191|195
SE|25462352||ab|1|entity|C0319175|Human adenovirus 12|virs|||Human adenovirus type 12|||0|916|174|198
SE|25462352||ab|1|entity|C0205251|low|qlco|||low|||0|790|231|234
SE|25462352||ab|1|entity|C0042765|Virulence|biof|||virulence|||0|790|235|244
SE|25462352||ab|1|entity|C0439834|Slow|qlco|||slow|||0|888|249|253
SE|25462352||ab|1|entity|C0020114|Human|humn|||human|||0|901|278|283
SE|25462352||ab|1|entity|C0007585|Cell Culture Techniques|lbpr|||cultured human cells|||0|901|269|289
SE|25462352||ab|1|entity|C0205252|Immature|tmco|||premature|||0|888|314|323
SE|25462352||ab|1|entity|C0011065|Cessation of life|orgf|||death|||0|888|324|329
SE|25462352||ab|1|entity|C1547052|*Type|qnco|||HAdV-12|||0|851|333|340
SE|25462352||ab|1|entity|C0319175|Human adenovirus 12|virs|||HAdV-12|||0|851|333|340
SE|25462352||ab|1|entity|C0439663|Infected|ftcn|||infected|||0|851|341|349
SE|25462352||ab|1|entity|C0007634|Cells|cell|||cells|||0|851|350|355

SE|25462352||ab|2|text|357|588|Whereas HAdV-2 induction of IFN-beta expression was transient, HAdV-12-infected cells maintained high levels of IFN-beta expression, protein kinase R (PKR) activation and eIF-2alpha phosphorylation throughout the infectious cycle.
SE|25462352||ab|2|entity|C0857127|Induction|topp|||induction|||0|827|372|381
SE|25462352||ab|2|entity|C0015980|Interferon-beta|aapp,imft,phsu|3439|IFNA1|IFN-beta|||0|901|385|393
SE|25462352||ab|2|entity|C0040704|Transient Population Group|popg|||transient|||0|836|409|418
SE|25462352||ab|2|entity|C1547052|*Type|qnco|||HAdV-12|||0|836|420|427
SE|25462352||ab|2|entity|C0319175|Human adenovirus 12|virs|||HAdV-12|||0|836|420|427
SE|25462352||ab|2|entity|C0439663|Infected|ftcn|||infected|||0|836|428|436
SE|25462352||ab|2|entity|C0007634|Cells|cell|||cells|||0|836|437|442
SE|25462352||ab|2|entity|C0205250|High|qlco|||high|||0|888|454|458
SE|25462352||ab|2|entity|C0441889|Levels|inpr|||levels|||0|888|459|465
SE|25462352||ab|2|entity|C0015980|Interferon-beta|aapp,imft,phsu|3439|IFNA1|IFN-beta|||0|901|469|477
SE|25462352||ab|2|entity|C0031727|Phosphotransferases|aapp,enzy|||kinase|||0|852|498|504
SE|25462352||ab|2|entity|C0599177|protein activation|genf|||protein kinase R (PKR) activation|||0|852|490|523
SE|25462352||ab|2|entity|C0013733|Eukaryotic Initiation Factor-2, alpha Subunit|aapp,bacs|||eIF-2alpha|||0|901|528|538
SE|25462352||ab|2|entity|C0031715|Phosphorylation|moft|||phosphorylation|||0|901|539|554
SE|25462352||ab|2|entity|C1550587|infectious|idcn|||infectious|||0|888|570|580
SE|25462352||ab|2|entity|C0750729|Course|tmco|||cycle|||0|888|581|586
SE|25462352||ab|2|relation|6|4|C0007634|Cells|cell|cell|||cells|||0|836|437|442|NOM|INTERACTS_WITH||539|554|6|0|C0013733|Eukaryotic Initiation Factor-2, alpha Subunit|aapp,gngm,bacs|gngm|||eIF-2alpha|||0|901|528|538

SE|25462352||ab|3|text|588|750|The importance of the IFN-inducible PKR kinase in restriction of HAdV-12 was supported by the enhanced growth of the virus following PKR knockdown in HeLa cells.
SE|25462352||ab|3|entity|C0733470|human leukocyte interferon|aapp,imft,phsu|3439|IFNA1|IFN|||0|651|610|613
SE|25462352||ab|3|entity|C0872251|protein kinase R|aapp,enzy|||PKR|||0|651|624|627
SE|25462352||ab|3|entity|C1547052|*Type|qnco|||HAdV-12|||0|916|653|660
SE|25462352||ab|3|entity|C0319175|Human adenovirus 12|virs|||HAdV-12|||0|916|653|660
SE|25462352||ab|3|entity|C0018270|Growth|orgf|||growth|||0|861|691|697
SE|25462352||ab|3|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|705|710
SE|25462352||ab|3|entity|C0872251|protein kinase R|aapp,enzy|||PKR|||0|756|721|724
SE|25462352||ab|3|entity|C0018873|Hela Cells|cell|||HeLa cells|||0|1000|738|748
SE|25462352||ab|3|relation|1|1|C0018873|Hela Cells|cell|cell|||HeLa cells|||0|1000|738|748|PREP|LOCATION_OF||735|737|6|3|C0319175|Human adenovirus 12|virs|virs|||HAdV-12|||0|916|653|660

SE|25462352||ab|4|text|750|927|Ectopic expression of HAdV-2 VA RNAI increased HAdV-12 hexon protein expression, suggesting that insufficient VA RNA expression contributes to the restricted growth of HAdV-12.
SE|25462352||ab|4|entity|C1512167|Ectopic Expression|genf|||Ectopic expression|||0|1000|750|768
SE|25462352||ab|4|entity|C1136031|RNA Interference|genf|||RNAI|||0|750|782|786
SE|25462352||ab|4|entity|C1547052|*Type|qnco|||HAdV-12|||0|798|797|804
SE|25462352||ab|4|entity|C0319175|Human adenovirus 12|virs|||HAdV-12|||0|798|797|804
SE|25462352||ab|4|entity|C1171362|Protein Expression|genf|||protein expression|||0|798|811|829
SE|25462352||ab|4|entity|C0231180|Insufficient|ftcn|||insufficient|||0|861|847|859
SE|25462352||ab|4|entity|C0050800|adenovirus associated RNA|nnon|||VA RNA|||0|861|860|866
SE|25462352||ab|4|entity|C0443288|Restricted|ftcn|||restricted|||0|888|897|907
SE|25462352||ab|4|entity|C0018270|Growth|orgf|||growth|||0|888|908|914
SE|25462352||ab|4|entity|C1547052|*Type|qnco|||HAdV-12|||0|916|918|925
SE|25462352||ab|4|entity|C0319175|Human adenovirus 12|virs|||HAdV-12|||0|916|918|925
SE|25462352||ab|4|relation|4|1|C0050800|adenovirus associated RNA|nnon|nnon|||VA RNA|||0|861|860|866|VERB|AFFECTS||878|889|1|1|C0018270|Growth|orgf|orgf|||growth|||0|888|908|914

SE|25462352||ab|5|text|927|1042|Although some adenovirus species are known to persist in human lymphoid tissues, HAdV12 has so far not been found.
SE|25462352||ab|5|entity|C0001483|Adenoviruses|virs|||adenovirus|||0|888|941|951
SE|25462352||ab|5|entity|C1548151|Species|idcn|||species|||0|888|952|959
SE|25462352||ab|5|entity|C0020114|Human|humn|||human|||0|901|984|989
SE|25462352||ab|5|entity|C0024296|Lymphoid Tissue|tisu|||lymphoid tissues|||0|901|990|1006
SE|25462352||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1026|1029
SE|25462352||ab|5|relation|0|0|C0024296|Lymphoid Tissue|tisu|tisu|||lymphoid tissues|||0|901|990|1006|MOD/HEAD|PART_OF||984|1006|0|0|C0020114|Human|grup,humn|humn|||human|||0|901|984|989

SE|25462352||ab|6|text|1042|1205|Thus, it is possible that the inability of HAdV12 to evade the INF response may have implications for the virus to establish long-lasting or persistent infections.
SE|25462352||ab|6|entity|C0332149|Possible|qlco|||possible|||0|1000|1054|1062
SE|25462352||ab|6|entity|||gngm|2694|GIF|INF|||0|861|1105|1108
SE|25462352||ab|6|entity|C0871261|response|clna|||response|||0|861|1109|1117
SE|25462352||ab|6|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|1148|1153
SE|25462352||ab|6|entity|C0205166|Long|qlco|||long|||0|861|1167|1171
SE|25462352||ab|6|entity|C1264606|Persistent infection|dsyn|||persistent infections|||0|983|1183|1204


SE|25462353||ti|1|text|21|84|Attenuation of monkeypox virus by deletion of genomic regions.
SE|25462353||ti|1|entity|C0599946|attenuation|genf|||Attenuation|||0|1000|21|32
SE|25462353||ti|1|entity|C0026432|Monkeypox virus|virs|||monkeypox virus|||0|1000|36|51
SE|25462353||ti|1|entity|C1442161|DELETION|comd|||deletion|||0|1000|55|63
SE|25462353||ti|1|entity|C0205147|Region|spco|||regions|||0|827|75|82

SE|25462353||ab|1|text|90|190|Monkeypox virus (MPXV) is an emerging pathogen from Africa that causes disease similar to smallpox.
SE|25462353||ab|1|entity|C0026432|Monkeypox virus|virs|||Monkeypox virus|||0|1000|90|105
SE|25462353||ab|1|entity|C0001737|Africa|geoa|||Africa|||0|1000|142|148
SE|25462353||ab|1|entity|C0012634|Disease|dsyn|||disease|||0|1000|161|168
SE|25462353||ab|1|entity|C0037354|Smallpox|dsyn|||smallpox|||0|1000|180|188
SE|25462353||ab|1|relation|3|3|C0026432|Monkeypox virus|virs|virs|||Monkeypox virus|||0|1000|90|105|VERB|CAUSES||154|160|3|1|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|161|168

SE|25462353||ab|2|text|190|276|Two clades with different geographic distributions and virulence have been described.
SE|25462353||ab|2|entity|C0205448|Two|qnco|||Two|||0|694|190|193
SE|25462353||ab|2|entity|C1547020|*Difference|qnco|||different|||0|866|206|215
SE|25462353||ab|2|entity|C0681686|Geographic Distribution|tmco|||geographic distributions|||0|866|216|240
SE|25462353||ab|2|entity|C0042765|Virulence|biof|||virulence|||0|1000|245|254

SE|25462353||ab|3|text|276|498|Here, we utilized bioinformatic tools to identify genomic regions in MPXV containing multiple virulence genes and explored their roles in pathogenicity; two selected regions were then deleted singularly or in combination.
SE|25462353||ab|3|entity|C0336791|Tool|mnob|||tools|||0|827|308|313
SE|25462353||ab|3|entity|C0205147|Region|spco|||regions|||0|827|334|341
SE|25462353||ab|3|entity|C0026432|Monkeypox virus|virs|||MPXV|||0|1000|345|349
SE|25462353||ab|3|entity|C0439064|Numerous|qnco|||multiple|||0|851|361|369
SE|25462353||ab|3|entity|C0042765|Virulence|biof|||virulence|||0|851|370|379
SE|25462353||ab|3|entity|C0017337|Genes|gngm|||genes|||0|851|380|385
SE|25462353||ab|3|entity|C0035820|Role|socb|||roles|||0|1000|405|410
SE|25462353||ab|3|entity|C1136169|Pathogenicity|orga,qlco|||pathogenicity|||0|1000|414|427
SE|25462353||ab|3|entity|C0205448|Two|qnco|||two|||0|829|429|432
SE|25462353||ab|3|entity|C0205147|Region|spco|||regions|||0|829|442|449
SE|25462353||ab|3|entity|C0205195|Combined|qlco|||combination|||0|1000|485|496

SE|25462353||ab|4|text|498|639|In vitro and in vivo studies indicated that these regions play a significant role in MPXV replication, tissue spread, and mortality in mice.
SE|25462353||ab|4|entity|C1533691|in vitro|qlco|||In vitro|||0|1000|498|506
SE|25462353||ab|4|entity|C1515655|in vivo|spco|||in vivo|||0|884|511|518
SE|25462353||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|884|519|526
SE|25462353||ab|4|entity|C0205147|Region|spco|||regions|||0|966|548|555
SE|25462353||ab|4|entity|C0750502|Significant|idcn|||significant|||0|888|563|574
SE|25462353||ab|4|entity|C0035820|Role|socb|||role|||0|888|575|579
SE|25462353||ab|4|entity|C0276180|Monkeypox|dsyn|||MPXV|||0|901|583|587
SE|25462353||ab|4|entity|C0042774|Virus Replication|orgf|||MPXV replication|||0|901|583|599
SE|25462353||ab|4|entity|C0026809|Mus|mamm|||mice|||0|1000|633|637
SE|25462353||ab|4|relation|7|3|C0042774|Virus Replication|orgf|orgf|||MPXV replication|||0|901|583|599|PREP|PROCESS_OF||630|632|1|1|C0026809|Mus|mamm|mamm|||mice|||0|1000|633|637

SE|25462353||ab|5|text|639|772|Interestingly, while deletion of either region led to decreased virulence in mice, one region had no effect on in vitro replication.
SE|25462353||ab|5|entity|C1442161|DELETION|comd|||deletion|||0|1000|660|668
SE|25462353||ab|5|entity|C0205147|Region|spco|||region|||0|861|679|685
SE|25462353||ab|5|entity|C0205216|Decreased|qnco|||decreased|||0|888|693|702
SE|25462353||ab|5|entity|C0042765|Virulence|biof|||virulence|||0|888|703|712
SE|25462353||ab|5|entity|C0026809|Mus|mamm|||mice|||0|1000|716|720
SE|25462353||ab|5|entity|C0205447|One|qnco|||one|||0|888|722|725
SE|25462353||ab|5|entity|C0205147|Region|spco|||region|||0|888|726|732
SE|25462353||ab|5|entity|C1280500|Effect|qlco|||effect|||0|1000|740|746
SE|25462353||ab|5|entity|C1533691|in vitro|qlco|||in vitro|||0|901|750|758
SE|25462353||ab|5|relation|2|2|C1442161|DELETION|comd|comd|||deletion|||0|1000|660|668|VERB|AFFECTS||686|689|5|1|C0042765|Virulence|biof|biof|||virulence|||0|888|703|712
SE|25462353||ab|5|relation|3|1|C0042765|Virulence|biof|biof|||virulence|||0|888|703|712|PREP|PROCESS_OF||713|715|4|1|C0026809|Mus|mamm|mamm|||mice|||0|1000|716|720

SE|25462353||ab|6|text|772|931|Deletion of both regions simultaneously also reduced cell culture replication and significantly increased the attenuation in vivo over either single deletion.
SE|25462353||ab|6|entity|C1442161|DELETION|comd|||Deletion|||0|1000|772|780
SE|25462353||ab|6|entity|C0205147|Region|spco|||regions|||0|760|789|796
SE|25462353||ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|760|817|824
SE|25462353||ab|6|entity|C0220814|Cultural|ftcn|||culture|||0|760|830|837
SE|25462353||ab|6|entity|C0007590|Cell division|celf|||cell culture replication|||0|760|825|849
SE|25462353||ab|6|entity|C0599946|attenuation|genf|||attenuation|||0|758|882|893
SE|25462353||ab|6|entity|C1515655|in vivo|spco|||in vivo|||0|758|894|901
SE|25462353||ab|6|entity|C0037179|Unmarried person|popg|||single|||0|758|914|920
SE|25462353||ab|6|entity|C1442161|DELETION|comd|||deletion|||0|758|921|929

SE|25462353||ab|7|text|931|1110|Attenuated MPXV with genomic deletions present a safe and efficacious tool in the study of MPX pathogenesis and in the identification of genetic factors associated with virulence.
SE|25462353||ab|7|entity|C0026432|Monkeypox virus|virs|||MPXV|||0|901|942|946
SE|25462353||ab|7|entity|C1442161|DELETION|comd|||deletions|||0|827|960|969
SE|25462353||ab|7|entity|C0336791|Tool|mnob|||tool|||0|861|1001|1005
SE|25462353||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|1000|1013|1018
SE|25462353||ab|7|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|861|1026|1038
SE|25462353||ab|7|entity|C0314603|Genetic|ftcn|||genetic|||0|872|1068|1075
SE|25462353||ab|7|entity|C1521761|Factor|ftcn|||factors|||0|872|1076|1083
SE|25462353||ab|7|entity|C0042765|Virulence|biof|||virulence|||0|1000|1100|1109
SE|25462353||ab|7|relation|1|1|C0042765|Virulence|biof|biof|||virulence|||0|1000|1100|1109|VERB|AFFECTS||1084|1094|8|8|C0026432|Monkeypox virus|virs|virs|||MPXV|||0|901|942|946


SE|25462354||ti|1|text|21|118|The interaction between the hepatitis C proteins NS4B and NS5A is involved in viral replication.
SE|25462354||ti|1|entity|C0019196|Hepatitis C|dsyn|||hepatitis C|||0|658|49|60
SE|25462354||ti|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|658|61|69
SE|25462354||ti|1|entity|C0521026|Viral|ftcn|||viral|||0|888|99|104

SE|25462354||ab|1|text|124|227|Hepatitis C virus (HCV) replicates in membrane associated, highly ordered replication complexes (RCs).
SE|25462354||ab|1|entity|C0220847|Hepatitis C virus|virs|||Hepatitis C virus|||0|1000|124|141
SE|25462354||ab|1|entity|C0596901|Membrane|celc|||membrane|||0|756|162|170
SE|25462354||ab|1|entity|C0439855|Complex|qlco|||complexes|||0|756|210|219

SE|25462354||ab|2|text|227|319|These complexes include viral and host proteins necessary for viral RNA genome replication.
SE|25462354||ab|2|entity|C0439855|Complex|qlco|||complexes|||0|1000|233|242
SE|25462354||ab|2|entity|C0521026|Viral|ftcn|||viral|||0|1000|251|256
SE|25462354||ab|2|entity|C1167395|host|celc|||host|||0|888|261|265
SE|25462354||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|266|274
SE|25462354||ab|2|entity|C0035668|RNA|bacs,nnon|||RNA|||0|916|295|298
SE|25462354||ab|2|entity|C1160701|viral genome replication|celf|||viral RNA genome replication|||0|916|289|317

SE|25462354||ab|3|text|319|450|The interaction network among viral and host proteins underlying the formation of these RCs is yet to be thoroughly characterized.
SE|25462354||ab|3|entity|C0679670|network|popg|||network|||0|888|335|342
SE|25462354||ab|3|entity|C0521026|Viral|ftcn|||viral|||0|1000|349|354
SE|25462354||ab|3|entity|C1167395|host|celc|||host|||0|888|359|363
SE|25462354||ab|3|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|364|372
SE|25462354||ab|3|entity|C1522492|Formation|ftcn|||formation|||0|1000|388|397
SE|25462354||ab|3|entity|C0439855|Complex|qlco|||RCs|||0|888|407|410

SE|25462354||ab|4|text|450|539|Here, we investigated the association between NS4B and NS5A, two critical RC components.
SE|25462354||ab|4|entity|C0205448|Two|qnco|||two|||0|764|511|514
SE|25462354||ab|4|entity|C1511545|Critical|qlco|||critical|||0|764|515|523
SE|25462354||ab|4|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|764|527|537

SE|25462354||ab|5|text|539|675|We characterized the interaction between these proteins using fluorescence resonance energy transfer and a mammalian two-hybrid system.
SE|25462354||ab|5|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|586|594
SE|25462354||ab|5|entity|C0597717|Fluorescence Resonance Energy Transfer|lbpr|||fluorescence resonance energy transfer|||0|1000|601|639
SE|25462354||ab|5|entity|C0599647|Yeast One/Two-Hybrid System|mbrt|||two-hybrid|||0|824|656|666
SE|25462354||ab|5|entity|C0449913|System|ftcn|||system|||0|824|667|673

SE|25462354||ab|6|text|675|787|Specific tryptophan residues within the C-terminal domain (CTD) of NS4B were shown to mediate this interaction.
SE|25462354||ab|6|entity|C0041249|Tryptophan|aapp,bacs,phsu|||tryptophan|||0|748|684|694
SE|25462354||ab|6|entity|C1335071|Nuclear LIM Interactor-Interacting Factor 2|aapp,enzy|1283|CTD|CTD|||0|1000|734|737

SE|25462354||ab|7|text|787|858|Domain I of NS5A, was sufficient to mediate its interaction with NS4B.
SE|25462354||ab|7|entity|C0205410|Sufficient|qlco|||sufficient|||0|1000|809|819

SE|25462354||ab|8|text|858|933|Mutations in the NS4B CTD tryptophan residues abolished viral replication.
SE|25462354||ab|8|entity|C0026882|Mutation|genf|||Mutations|||0|1000|858|867
SE|25462354||ab|8|entity|C1335071|Nuclear LIM Interactor-Interacting Factor 2|aapp,enzy|1283|CTD|CTD|||0|747|880|883
SE|25462354||ab|8|entity|C0041249|Tryptophan|aapp,bacs,phsu|||tryptophan|||0|747|884|894
SE|25462354||ab|8|entity|C0521026|Viral|ftcn|||viral|||0|888|914|919

SE|25462354||ab|9|text|933|1007|Moreover, one of these mutations also affected NS5A hyperphosphorylation.
SE|25462354||ab|9|entity|C0205447|One|qnco|||one|||0|1000|943|946
SE|25462354||ab|9|entity|C0026882|Mutation|genf|||mutations|||0|754|956|965
SE|25462354||ab|9|entity|C0392760|Affecting|ftcn|||affected|||0|754|971|979
SE|25462354||ab|9|entity|C1327332|hyperphosphorylation|moft|||hyperphosphorylation|||0|754|985|1005

SE|25462354||ab|10|text|1007|1191|These findings provide new insights into the importance of the NS4B-NS5A interaction and serve as a starting point for studying the complex interactions between the replicase subunits.
SE|25462354||ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1013|1021
SE|25462354||ab|10|entity|C0205314|New|tmco|||new|||0|872|1030|1033
SE|25462354||ab|10|entity|C0233820|Insight|menp|||insights|||0|872|1034|1042
SE|25462354||ab|10|entity|C1272689|Started|qlco|||starting|||0|661|1107|1115
SE|25462354||ab|10|entity|C0008972|Clinical Research|resa|||studying|||0|966|1126|1134
SE|25462354||ab|10|entity|C0439855|Complex|qlco|||complex|||0|694|1139|1146
SE|25462354||ab|10|entity|C0178827|replicase|aapp,enzy|||replicase|||0|694|1172|1181


SE|25462355||ti|1|text|21|202|Comparative live bioluminescence imaging of monkeypox virus dissemination in a wild-derived inbred mouse (Mus musculus castaneus) and outbred African dormouse (Graphiurus kelleni).
SE|25462355||ti|1|entity|C1548795|Live|qlco|||live|||0|790|33|37
SE|25462355||ti|1|entity|C0162404|Bioluminescence|biof|||bioluminescence|||0|790|38|53
SE|25462355||ti|1|entity|C0026432|Monkeypox virus|virs|||monkeypox virus|||0|734|65|80
SE|25462355||ti|1|entity|C0445392|Wild|inpr|||wild|||0|1000|100|104
SE|25462355||ti|1|entity|C1512690|Inbred Mouse|mamm|||inbred mouse|||0|1000|113|125
SE|25462355||ti|1|entity|C0025914|House mice|mamm|||Mus musculus|||0|901|127|139
SE|25462355||ti|1|entity|C0027132|Myoxidae|mamm|||dormouse|||0|827|171|179
SE|25462355||ti|1|entity|C1015936|Graphiurus|mamm|||Graphiurus|||0|694|181|191

SE|25462355||ab|1|text|208|427|Monkeypox virus belongs to the orthopoxvirus genus, infects rodents and monkeys in Africa, produces a smallpox-like zoonotic disease in humans, and has the potential for global spread and exploitation for bioterrorism.
SE|25462355||ab|1|entity|C0026432|Monkeypox virus|virs|||Monkeypox virus|||0|1000|208|223
SE|25462355||ab|1|entity|C0206580|Orthopoxvirus|virs|||orthopoxvirus|||0|694|239|252
SE|25462355||ab|1|entity|C0035804|Rodent|mamm|||rodents|||0|1000|268|275
SE|25462355||ab|1|entity|C0026447|Monkeys|mamm|||monkeys|||0|1000|280|287
SE|25462355||ab|1|entity|C0001737|Africa|geoa|||Africa|||0|1000|291|297
SE|25462355||ab|1|entity|C0037354|Smallpox|dsyn|||smallpox|||0|1000|310|318
SE|25462355||ab|1|entity|C0043528|Zoonoses|dsyn|||zoonotic|||0|853|324|332
SE|25462355||ab|1|entity|C0012634|Disease|dsyn|||disease|||0|853|333|340
SE|25462355||ab|1|entity|C0020114|Human|humn|||humans|||0|1000|344|350
SE|25462355||ab|1|entity|C0237399|Potential|qlco|||potential|||0|1000|364|373
SE|25462355||ab|1|entity|C0205246|Generalized|spco|||global|||0|888|378|384
SE|25462355||ab|1|entity|C0332261|Spreading|qlco|||spread|||0|888|385|391
SE|25462355||ab|1|entity|C0872021|Bioterrorism|acty|||bioterrorism|||0|1000|413|425
SE|25462355||ab|1|relation|0|0|C0043528|Zoonoses|dsyn|dsyn|||zoonotic|||0|853|324|332|INFER|PROCESS_OF(SPEC)||324|340|0|0|C0020114|Human|grup,humn|humn|||humans|||0|1000|344|350
SE|25462355||ab|1|relation|0|0|C0043528|Zoonoses|dsyn|dsyn|||zoonotic|||0|853|324|332|MOD/HEAD|ISA||324|340|0|0|C0012634|Disease|dsyn|dsyn|||disease|||0|853|333|340
SE|25462355||ab|1|relation|5|5|C0026432|Monkeypox virus|virs|virs|||Monkeypox virus|||0|1000|208|223|VERB|CAUSES||299|307|7|1|C0037354|Smallpox|dsyn|dsyn|||smallpox|||0|1000|310|318
SE|25462355||ab|1|relation|7|1|C0012634|Disease|dsyn|dsyn|||disease|||0|853|333|340|PREP|PROCESS_OF||341|343|5|1|C0020114|Human|grup,humn|humn|||humans|||0|1000|344|350

SE|25462355||ab|2|text|427|521|Several small animal models for studying monkeypox virus pathogenesis have been investigated.
SE|25462355||ab|2|entity|C0443302|Several|qnco|||Several|||0|861|427|434
SE|25462355||ab|2|entity|C0700321|Small|qnco|||small|||0|861|435|440
SE|25462355||ab|2|entity|C0599779|Animal Model|anim|||animal models|||0|861|441|454
SE|25462355||ab|2|entity|C0008972|Clinical Research|resa|||studying|||0|852|459|467
SE|25462355||ab|2|entity|C0276180|Monkeypox|dsyn|||monkeypox|||0|852|468|477
SE|25462355||ab|2|entity|C0920672|virus pathogenesis|comd|||virus pathogenesis|||0|852|478|496

SE|25462355||ab|3|text|521|622|The African dormouse is a candidate natural host but is outbred and no immunological reagents exist.
SE|25462355||ab|3|entity|C0027132|Myoxidae|mamm|||dormouse|||0|861|533|541
SE|25462355||ab|3|entity|C0205296|Natural|ftcn|||natural|||0|790|557|564
SE|25462355||ab|3|entity|C1167395|host|celc|||host|||0|790|565|569
SE|25462355||ab|3|entity|C1140588|Immunology Reagents|irda|||immunological reagents|||0|964|592|614

SE|25462355||ab|4|text|622|733|Although not a natural host, the CAST/EiJ mouse is inbred and animals and reagents are commercially available.
SE|25462355||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|631|634
SE|25462355||ab|4|entity|C0205296|Natural|ftcn|||natural|||0|888|637|644
SE|25462355||ab|4|entity|C1167395|host|celc|||host|||0|888|645|649
SE|25462355||ab|4|entity|C0025914|House mice|mamm|||mouse|||0|861|664|669
SE|25462355||ab|4|entity|C0003062|Animals|anim|||animals|||0|1000|684|691
SE|25462355||ab|4|entity|C0034760|Reagents|irda|||reagents|||0|1000|696|704
SE|25462355||ab|4|relation|0|0|C0025914|House mice|mamm|mamm|||mouse|||0|861|664|669|SPEC|ISA||664|691|0|0|C0003062|Animals|anim|anim|||animals|||0|1000|684|691

SE|25462355||ab|5|text|733|839|We compared the dissemination of monkeypox virus by bioluminescence imaging in CAST/EiJ mice and dormice.
SE|25462355||ab|5|entity|C0026432|Monkeypox virus|virs|||monkeypox virus|||0|1000|766|781
SE|25462355||ab|5|entity|C0162404|Bioluminescence|biof|||bioluminescence|||0|1000|785|800
SE|25462355||ab|5|entity|C0026809|Mus|mamm|||mice|||0|861|821|825
SE|25462355||ab|5|entity|C0027132|Myoxidae|mamm|||dormice|||0|1000|830|837

SE|25462355||ab|6|text|839|1012|In CAST/EiJ mice, intense replication occurred at the intranasal site of inoculation and virus spread rapidly to lungs and abdominal organs, which had a lower virus burden.
SE|25462355||ab|6|entity|C0026809|Mus|mamm|||mice|||0|861|851|855
SE|25462355||ab|6|entity|C0205145|Site|spco|||site|||0|861|904|908
SE|25462355||ab|6|entity|C0042196|Vaccination|topp|||inoculation|||0|1000|912|923
SE|25462355||ab|6|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|928|933
SE|25462355||ab|6|entity|C0024109|Lung|bpoc|||lungs|||0|1000|952|957
SE|25462355||ab|6|entity|C0446633|Abdominal organ|bpoc|||abdominal organs|||0|983|962|978
SE|25462355||ab|6|entity|C0441994|Lower|ftcn|||lower|||0|623|992|997
SE|25462355||ab|6|entity|C0042769|Virus Diseases|dsyn|||virus|||0|623|998|1003

SE|25462355||ab|7|text|1012|1212|Compared to CAST/EiJ mice, dormice exhibited a greater variation of virus spread, a slower time course, less replication in the head and chest, and more replication in abdominal organs prior to death.
SE|25462355||ab|7|entity|C0026809|Mus|mamm|||mice|||0|861|1033|1037
SE|25462355||ab|7|entity|C0027132|Myoxidae|mamm|||dormice|||0|1000|1039|1046
SE|25462355||ab|7|entity|C0443228|Largest|qnco|||greater|||0|888|1059|1066
SE|25462355||ab|7|entity|C0205419|Variant|qlco|||variation|||0|888|1067|1076
SE|25462355||ab|7|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|1080|1085
SE|25462355||ab|7|entity|C0439834|Slow|qlco|||slower|||0|884|1096|1102
SE|25462355||ab|7|entity|C0449247|Time course|tmco|||time course|||0|884|1103|1114
SE|25462355||ab|7|entity|C0018670|Head|blor|||head|||0|1000|1140|1144
SE|25462355||ab|7|entity|C0817096|Chest|blor|||chest|||0|1000|1149|1154
SE|25462355||ab|7|entity|C0205172|More|ftcn|||more|||0|888|1160|1164
SE|25462355||ab|7|entity|C0446633|Abdominal organ|bpoc|||abdominal organs|||0|983|1180|1196
SE|25462355||ab|7|entity|C0011065|Cessation of life|orgf|||death|||0|1000|1206|1211
SE|25462355||ab|7|relation|5|1|C0018670|Head|blor|blor|||head|||0|1000|1140|1144|PREP|LOCATION_OF||1133|1135|6|3|C0042769|Virus Diseases|dsyn|dsyn|||virus|||0|1000|1080|1085
SE|25462355||ab|7|relation|5|1|C0817096|Chest|blor|blor|||chest|||0|1000|1149|1154|PREP|LOCATION_OF||1133|1135|6|3|C0042769|Virus Diseases|dsyn|dsyn|||virus|||0|1000|1080|1085


SE|25462356||ti|1|text|21|134|Identification and characterization of an emerging small ruminant lentivirus circulating recombinant form (CRF).
SE|25462356||ti|1|entity|C1474518|Small ruminant lentivirus|virs|||small ruminant lentivirus|||0|923|72|97
SE|25462356||ti|1|entity|C1522492|Formation|ftcn|||form|||0|840|122|126

SE|25462356||ab|1|text|140|327|The molecular epidemiology of small ruminant lentiviruses (SRLVs) is constantly changing due to animal movements, cross species transmission and because of their rapid evolutionary rate.
SE|25462356||ab|1|entity|C0206173|Epidemiology, Molecular|bmod|||molecular epidemiology|||0|1000|144|166
SE|25462356||ab|1|entity|C1474518|Small ruminant lentivirus|virs|||small ruminant lentiviruses|||0|988|170|197
SE|25462356||ab|1|entity|C0003043|Animalia|anim|||animal|||0|888|236|242
SE|25462356||ab|1|entity|C0026649|Movement|orgf|||movements|||0|888|243|252
SE|25462356||ab|1|entity|C1548151|Species|idcn|||species|||0|660|260|267
SE|25462356||ab|1|entity|C0439831|Rapid|qlco|||rapid|||0|828|302|307
SE|25462356||ab|1|entity|C0015219|Evolution|genf|||evolutionary|||0|828|308|320
SE|25462356||ab|1|entity|C1521828|Rate|qnco|||rate|||0|828|321|325
SE|25462356||ab|1|relation|0|0|C0026649|Movement|orgf|orgf|||movements|||0|888|243|252|MOD/HEAD|PROCESS_OF||236|252|0|0|C0003043|Animalia|anim|anim|||animal|||0|888|236|242

SE|25462356||ab|2|text|327|509|This study reports a comprehensive genetic and phylogenetic analysis based on consensus gag and pol sequences covering 3kb of the SRLV genome from small ruminants in Quebec, Canada.
SE|25462356||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|332|337
SE|25462356||ab|2|entity|C0314603|Genetic|ftcn|||genetic|||0|861|362|369
SE|25462356||ab|2|entity|C1519068|Phylogenetic Analysis|resa|||phylogenetic analysis|||0|1000|374|395
SE|25462356||ab|2|entity|C0376298|Consensus|socb|||consensus|||0|888|405|414
SE|25462356||ab|2|entity|C0017346|GAG Gene|gngm|||gag|||0|888|415|418
SE|25462356||ab|2|entity|C0017360|pol genes|gngm|100616496|ERVW-4|pol|||0|888|423|426
SE|25462356||ab|2|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|888|427|436
SE|25462356||ab|2|entity|C0017428|Genome|gngm|||genome|||0|861|462|468
SE|25462356||ab|2|entity|C0700321|Small|qnco|||small|||0|888|474|479
SE|25462356||ab|2|entity|C0035950|Ruminants|mamm|||ruminants|||0|888|480|489
SE|25462356||ab|2|entity|C0034390|Quebec|geoa|||Quebec|||0|1000|493|499
SE|25462356||ab|2|entity|C0006823|Canada|geoa|||Canada|||0|1000|501|507

SE|25462356||ab|3|text|509|655|A group of strains obtained from goats originating from different flocks, segregated in a unique clade distinct from currently known SRLV groups.
SE|25462356||ab|3|entity|C0441833|Groups|inpr|||group|||0|1000|511|516
SE|25462356||ab|3|entity|C0018019|Capra hircus|mamm|||goats|||0|1000|542|547
SE|25462356||ab|3|entity|C1547020|*Difference|qnco|||different|||0|623|565|574
SE|25462356||ab|3|entity|C0521116|Current|tmco|||currently|||0|775|626|635
SE|25462356||ab|3|entity|C0205309|Known|qlco|||known|||0|775|636|641
SE|25462356||ab|3|entity|C0441833|Groups|inpr|||groups|||0|775|647|653

SE|25462356||ab|4|text|655|856|Genetic dissection of the gag gene from these strains revealed that it originated as a result of a recombination event between parental strains currently circulating in small ruminants of the country.
SE|25462356||ab|4|entity|C0314603|Genetic|ftcn|||Genetic|||0|888|655|662
SE|25462356||ab|4|entity|C0012737|Dissection|topp|||dissection|||0|888|663|673
SE|25462356||ab|4|entity|C0017346|GAG Gene|gngm|||gag gene|||0|1000|681|689
SE|25462356||ab|4|entity|C0034865|Recombination, Genetic|genf|||recombination|||0|888|754|767
SE|25462356||ab|4|entity|C0441471|Events|evnt|||event|||0|888|768|773
SE|25462356||ab|4|entity|C0521116|Current|tmco|||currently|||0|1000|799|808
SE|25462356||ab|4|entity|C0700321|Small|qnco|||small|||0|888|824|829
SE|25462356||ab|4|entity|C0035950|Ruminants|mamm|||ruminants|||0|888|830|839
SE|25462356||ab|4|entity|C0454664|Country|geoa|||country|||0|1000|847|854
SE|25462356||ab|4|relation|6|6|C0012737|Dissection|topp|topp|||dissection|||0|888|663|673|PREP|TREATS||821|823|2|1|C0035950|Ruminants|mamm|mamm|||ruminants|||0|888|830|839

SE|25462356||ab|5|text|856|981|Following HIV nomenclature, we propose to call this group of strains, circulating recombinant form 1 SRLV, or CRF01_AB SRLV.
SE|25462356||ab|5|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|888|866|869
SE|25462356||ab|5|entity|C0600281|Nomenclature|inpr|||nomenclature|||0|888|870|882
SE|25462356||ab|5|entity|C0441833|Groups|inpr|||group|||0|1000|908|913
SE|25462356||ab|5|entity|C1522492|Formation|ftcn|||form|||0|725|950|954

SE|25462356||ab|6|text|981|1146|In addition, the study confirms the existence of genetically distinct and homogeneous populations of SRLVs infecting sheep and goats housed in single species flocks.
SE|25462356||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|998|1003
SE|25462356||ab|6|entity|C0032659|geographic population|qnco|||populations|||0|861|1067|1078
SE|25462356||ab|6|entity|C1474518|Small ruminant lentivirus|virs|||SRLVs|||0|988|1082|1087
SE|25462356||ab|6|entity|C0036945|Sheep|mamm|||sheep|||0|1000|1098|1103
SE|25462356||ab|6|entity|C0018019|Capra hircus|mamm|||goats|||0|1000|1108|1113
SE|25462356||ab|6|entity|C0037179|Unmarried person|popg|||single|||0|623|1124|1130
SE|25462356||ab|6|entity|C1548151|Species|idcn|||species|||0|623|1131|1138


SE|25462357||ti|1|text|21|200|On the isobaric space of 25-hydroxyvitamin D in human serum: potential for interferences in liquid chromatography/tandem mass spectrometry, systematic errors and accuracy issues.
SE|25462357||ti|1|entity|C0535968|25-hydroxyvitamin D|strd,vita|||25-hydroxyvitamin D|||0|1000|46|65
SE|25462357||ti|1|entity|C0020114|Human|humn|||human|||0|888|69|74
SE|25462357||ti|1|entity|C0229671|Serum|bdsu|||serum|||0|888|75|80
SE|25462357||ti|1|entity|C0237399|Potential|qlco|||potential|||0|1000|82|91
SE|25462357||ti|1|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||liquid chromatography/tandem mass spectrometry|||0|928|113|159
SE|25462357||ti|1|entity|C0220922|systematic|ftcn|||systematic|||0|888|161|171
SE|25462357||ti|1|entity|C0743559|error|qlco|||errors|||0|888|172|178
SE|25462357||ti|1|entity|C0443131|Accurate|qlco|||accuracy|||0|623|183|191
SE|25462357||ti|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|75|80|MOD/HEAD|PART_OF||69|80|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|69|74

SE|25462357|RATIONALE|ab|1|text|206|507|RATIONALE: Isobaric interferences in human serum can potentially influence the measured concentration levels of 25-hydroxyvitamin D [25(OH)D], when low resolving power liquid chromatography/tandem mass spectrometry (LC/MS/MS) instruments and non-specific MS/MS product ions are employed for analysis.
SE|25462357|RATIONALE|ab|1|entity|C0020114|Human|humn|||human|||0|888|243|248
SE|25462357|RATIONALE|ab|1|entity|C0229671|Serum|bdsu|||serum|||0|888|249|254
SE|25462357|RATIONALE|ab|1|entity|C0444706|Measured|qlco|||measured|||0|802|285|293
SE|25462357|RATIONALE|ab|1|entity|C0441889|Levels|inpr|||levels|||0|802|308|314
SE|25462357|RATIONALE|ab|1|entity|C0535968|25-hydroxyvitamin D|strd,vita|||25-hydroxyvitamin D|||0|1000|318|337
SE|25462357|RATIONALE|ab|1|entity|C0750521|RESOLVING|idcn|||resolving|||0|826|358|367
SE|25462357|RATIONALE|ab|1|entity|C0231406|Powerlessness, low|fndg|||low resolving power|||0|826|354|373
SE|25462357|RATIONALE|ab|1|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||liquid chromatography/tandem mass spectrometry|||0|826|374|420
SE|25462357|RATIONALE|ab|1|entity|C0243113|instruments|mnob|||instruments|||0|826|432|443
SE|25462357|RATIONALE|ab|1|entity|C0205370|Unspecified|qlco|||non-specific|||0|774|448|460
SE|25462357|RATIONALE|ab|1|entity|C1514468|product|qnco|||product|||0|774|467|474
SE|25462357|RATIONALE|ab|1|entity|C0022023|Ions|elii|||ions|||0|774|475|479
SE|25462357|RATIONALE|ab|1|entity|C0936012|Analysis|resa|||analysis|||0|1000|497|505
SE|25462357|RATIONALE|ab|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|249|254|MOD/HEAD|PART_OF||243|254|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|243|248

SE|25462357|RATIONALE|ab|2|text|507|653|In this study, we provide a detailed characterization of these interferences and a technical solution to reduce the associated systematic errors.
SE|25462357|RATIONALE|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|515|520
SE|25462357|RATIONALE|ab|2|entity|C1522508|Details|qlco|||detailed|||0|661|535|543
SE|25462357|RATIONALE|ab|2|entity|C0025664|Methodology|inpr|||technical|||0|853|590|599
SE|25462357|RATIONALE|ab|2|entity|C0037633|Solutions|sbst|||solution|||0|853|600|608
SE|25462357|RATIONALE|ab|2|entity|C0220922|systematic|ftcn|||systematic|||0|790|634|644
SE|25462357|RATIONALE|ab|2|entity|C0743559|error|qlco|||errors|||0|790|645|651

SE|25462357|METHODS|ab|3|text|653|886|METHODS: Detailed electrospray ionization Fourier transform ion cyclotron resonance (FTICR) high-resolution mass spectrometry (HRMS) experiments were used to characterize co-extracted isobaric components of 25(OH)D from human serum.
SE|25462357|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|653|660
SE|25462357|METHODS|ab|3|entity|C1522508|Details|qlco|||Detailed|||0|813|662|670
SE|25462357|METHODS|ab|3|entity|C1516801|Electrospray Ionization|lbpr|||electrospray ionization|||0|813|671|694
SE|25462357|METHODS|ab|3|entity|C0282183|Fourier Transform|qnco|||Fourier transform|||0|813|695|712
SE|25462357|METHODS|ab|3|entity|C0205250|High|qlco|||high|||0|813|745|749
SE|25462357|METHODS|ab|3|entity|C1514893|Resolution|ftcn|||resolution|||0|813|750|760
SE|25462357|METHODS|ab|3|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|813|761|765
SE|25462357|METHODS|ab|3|entity|C0596799|ion cyclotron resonance spectrometry|lbpr|||ion cyclotron resonance (FTICR) high-resolution mass spectrometry|||0|813|713|778
SE|25462357|METHODS|ab|3|entity|C0681814|research study|resa|||experiments|||0|813|786|797
SE|25462357|METHODS|ab|3|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|827|846|856
SE|25462357|METHODS|ab|3|entity|C0020114|Human|humn|||human|||0|888|873|878
SE|25462357|METHODS|ab|3|entity|C0229671|Serum|bdsu|||serum|||0|888|879|884
SE|25462357|METHODS|ab|3|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|879|884|MOD/HEAD|PART_OF||873|884|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|873|878

SE|25462357|METHODS|ab|4|text|886|1047|Differential ion mobility spectrometry (DMS), as a gas-phase ion filter, was implemented on a triple quadrupole mass spectrometer for separation of the isobars.
SE|25462357|METHODS|ab|4|entity|C0022023|Ions|elii|||ion|||0|763|899|902
SE|25462357|METHODS|ab|4|entity|C0436196|Spectrometry|lbpr|||spectrometry|||0|763|912|924
SE|25462357|METHODS|ab|4|entity|C0017110|Gases|chvs|||gas|||0|833|937|940
SE|25462357|METHODS|ab|4|entity|C0205390|Phase|tmco|||phase|||0|833|941|946
SE|25462357|METHODS|ab|4|entity|C0022023|Ions|elii|||ion|||0|833|947|950
SE|25462357|METHODS|ab|4|entity|C0180860|Filters|medd|||filter|||0|833|951|957
SE|25462357|METHODS|ab|4|entity|C0205174|Triplicate|qnco|||triple|||0|808|980|986
SE|25462357|METHODS|ab|4|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|808|998|1015
SE|25462357|METHODS|ab|4|entity|C0036679|Diastasis|patf|||separation|||0|1000|1020|1030
SE|25462357|METHODS|ab|4|relation|3|1|C0183396|Spectrometers, Mass|medd|medd|||mass spectrometer|||0|808|998|1015|PREP|TREATS||1016|1019|2|1|C0036679|Diastasis|patf|patf|||separation|||0|1000|1020|1030

SE|25462357|RESULTS|ab|5|text|1047|1183|RESULTS: HRMS revealed the presence of multiple isobaric compounds in extracts of human serum for different sample preparation methods.
SE|25462357|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1047|1054
SE|25462357|RESULTS|ab|5|entity|C0205250|High|qlco|||HRMS|||0|861|1056|1060
SE|25462357|RESULTS|ab|5|entity|C1514893|Resolution|ftcn|||HRMS|||0|861|1056|1060
SE|25462357|RESULTS|ab|5|entity|C0037813|Spectrum Analysis, Mass|lbpr|||HRMS|||0|861|1056|1060
SE|25462357|RESULTS|ab|5|entity|C0439064|Numerous|qnco|||multiple|||0|785|1086|1094
SE|25462357|RESULTS|ab|5|entity|C0205198|Compound|qlco|||compounds|||0|785|1104|1113
SE|25462357|RESULTS|ab|5|entity|C1555707|extract|idcn|||extracts|||0|966|1117|1125
SE|25462357|RESULTS|ab|5|entity|C0020114|Human|humn|||human|||0|888|1129|1134
SE|25462357|RESULTS|ab|5|entity|C0229671|Serum|bdsu|||serum|||0|888|1135|1140
SE|25462357|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||different|||0|751|1145|1154
SE|25462357|RESULTS|ab|5|entity|C1521827|Preparation|ftcn|||preparation|||0|751|1162|1173
SE|25462357|RESULTS|ab|5|entity|C0025663|Methods|inpr|||methods|||0|751|1174|1181
SE|25462357|RESULTS|ab|5|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|1135|1140|MOD/HEAD|PART_OF||1129|1140|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|1129|1134

SE|25462357|RESULTS|ab|6|text|1183|1308|Several of these isobars had the potential to increase the peak areas measured for 25(OH)D on low-resolution MS instruments.
SE|25462357|RESULTS|ab|6|entity|C0443302|Several|qnco|||Several|||0|1000|1183|1190
SE|25462357|RESULTS|ab|6|entity|C0237399|Potential|qlco|||potential|||0|1000|1216|1225
SE|25462357|RESULTS|ab|6|entity|C0205251|low|qlco|||low|||0|775|1277|1280
SE|25462357|RESULTS|ab|6|entity|C1514893|Resolution|ftcn|||resolution|||0|775|1281|1291
SE|25462357|RESULTS|ab|6|entity|C0243113|instruments|mnob|||instruments|||0|775|1295|1306

SE|25462357|RESULTS|ab|7|text|1308|1468|A major isobaric component was identified as pentaerythritol oleate, a technical lubricant, which was probably an artifact from the analytical instrumentation.
SE|25462357|RESULTS|ab|7|entity|C0205164|Major|qlco|||major|||0|802|1310|1315
SE|25462357|RESULTS|ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|802|1325|1334
SE|25462357|RESULTS|ab|7|entity|C0070276|pentaerythritol|orch,phsu|||pentaerythritol|||0|888|1353|1368
SE|25462357|RESULTS|ab|7|entity|C0133788|Oleates|lipd|||oleate|||0|888|1369|1375
SE|25462357|RESULTS|ab|7|entity|C0025664|Methodology|inpr|||technical|||0|853|1379|1388
SE|25462357|RESULTS|ab|7|entity|C0282222|Lubricants|sbst|||lubricant|||0|853|1389|1398
SE|25462357|RESULTS|ab|7|entity|C0332148|Probable diagnosis|qlco|||probably|||0|1000|1410|1418
SE|25462357|RESULTS|ab|7|entity|C0085089|Morphologic artifacts|hcpp|||artifact|||0|1000|1422|1430
SE|25462357|RESULTS|ab|7|entity|C0021632|instrumentation|qnco|||instrumentation|||0|861|1451|1466

SE|25462357|RESULTS|ab|8|text|1468|1608|DMS was able to remove several of these isobars prior to MS/MS, when implemented on the low-resolution triple quadrupole mass spectrometer.
SE|25462357|RESULTS|ab|8|entity|C0022023|Ions|elii|||DMS|||0|763|1468|1471
SE|25462357|RESULTS|ab|8|entity|C0436196|Spectrometry|lbpr|||DMS|||0|763|1468|1471
SE|25462357|RESULTS|ab|8|entity|C0443302|Several|qnco|||several|||0|1000|1491|1498
SE|25462357|RESULTS|ab|8|entity|C0205251|low|qlco|||low|||0|760|1556|1559
SE|25462357|RESULTS|ab|8|entity|C1514893|Resolution|ftcn|||resolution|||0|760|1560|1570
SE|25462357|RESULTS|ab|8|entity|C0205174|Triplicate|qnco|||triple|||0|760|1571|1577
SE|25462357|RESULTS|ab|8|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|760|1589|1606

SE|25462357|CONCLUSIONS|ab|9|text|1608|1807|CONCLUSIONS: It was shown in this proof-of-concept study that DMS-MS has the potential to significantly decrease systematic errors, and thus improve accuracy of vitamin D measurements using LC/MS/MS.
SE|25462357|CONCLUSIONS|ab|9|entity|C0556981|% proof|qnco|||proof|||0|1000|1642|1647
SE|25462357|CONCLUSIONS|ab|9|entity|C0178566|concept|idcn|||concept|||0|1000|1651|1658
SE|25462357|CONCLUSIONS|ab|9|entity|C0022023|Ions|elii|||DMS|||0|575|1670|1673
SE|25462357|CONCLUSIONS|ab|9|entity|C0436196|Spectrometry|lbpr|||DMS|||0|575|1670|1673
SE|25462357|CONCLUSIONS|ab|9|entity|C0237399|Potential|qlco|||potential|||0|861|1685|1694
SE|25462357|CONCLUSIONS|ab|9|entity|C0220922|systematic|ftcn|||systematic|||0|888|1721|1731
SE|25462357|CONCLUSIONS|ab|9|entity|C0743559|error|qlco|||errors|||0|888|1732|1738
SE|25462357|CONCLUSIONS|ab|9|entity|C0443131|Accurate|qlco|||accuracy|||0|928|1757|1765
SE|25462357|CONCLUSIONS|ab|9|entity|C0919758|Vitamin D measurement|lbpr|||vitamin D measurements|||0|983|1769|1791
SE|25462357|CONCLUSIONS|ab|9|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS/MS|||0|928|1798|1806
SE|25462357|CONCLUSIONS|ab|9|relation|7|1|C0919758|Vitamin D measurement|lbpr|lbpr|||vitamin D measurements|||0|983|1769|1791|VERB|USES||1792|1797|1|1|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|lbpr|||LC/MS/MS|||0|928|1798|1806


SE|25462358||ti|1|text|21|97|Knudsen cell mass spectrometry using restricted molecular beam collimation.
SE|25462358||ti|1|entity|C0007634|Cells|cell|||cell|||0|824|29|33
SE|25462358||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|824|34|51
SE|25462358||ti|1|entity|C0443288|Restricted|ftcn|||restricted|||0|775|58|68
SE|25462358||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|775|69|78
SE|25462358||ti|1|entity|C0454169|Collimator|medd|||collimation|||0|775|84|95
SE|25462358||ti|1|relation|1|1|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||mass spectrometry|||0|824|34|51|VERB|USES||52|57|1|1|C0454169|Collimator|medd|medd|||collimation|||0|775|84|95

SE|25462358||ti|2|text|97|100|I.

SE|25462358||ti|3|text|100|154|Optimization of the beam from the vaporizing surface.
SE|25462358||ti|3|entity|C0205148|Surface|spco|||surface|||0|861|145|152

SE|25462358|RATIONALE|ab|1|text|160|313|RATIONALE: This study analyzes molecular beam sampling by mass spectrometry by the Knudsen method using the so-called " restricted collimation device" .
SE|25462358|RATIONALE|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|176|181
SE|25462358|RATIONALE|ab|1|entity|C1521991|Molecular|qlco|||molecular|||0|802|191|200
SE|25462358|RATIONALE|ab|1|entity|C0870078|Sampling|idcn|||sampling|||0|802|206|214
SE|25462358|RATIONALE|ab|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|1000|218|235
SE|25462358|RATIONALE|ab|1|entity|C0025663|Methods|inpr|||method|||0|861|251|257
SE|25462358|RATIONALE|ab|1|entity|C0443288|Restricted|ftcn|||restricted|||0|736|280|290
SE|25462358|RATIONALE|ab|1|entity|C0454169|Collimator|medd|||collimation|||0|736|291|302
SE|25462358|RATIONALE|ab|1|entity|C0699733|Devices|mnob|||device|||0|736|303|309

SE|25462358|RATIONALE|ab|2|text|313|598|This device, defined by the field and source apertures, was proposed in order to eliminate any additional contribution to the genuine molecular beam of surface vaporizations coming from the vicinity of the effusion orifice as usually detected by the ion source of a mass spectrometer.
SE|25462358|RATIONALE|ab|2|entity|C0699733|Devices|mnob|||device|||0|1000|318|324
SE|25462358|RATIONALE|ab|2|entity|C1521738|Field|cnce|||field|||0|1000|341|346
SE|25462358|RATIONALE|ab|2|entity|C1524062|Additional|ftcn|||additional|||0|694|408|418
SE|25462358|RATIONALE|ab|2|entity|C0392344|Genuineness|inbe|||genuine|||0|587|439|446
SE|25462358|RATIONALE|ab|2|entity|C1521991|Molecular|qlco|||molecular|||0|587|447|456
SE|25462358|RATIONALE|ab|2|entity|C0205148|Surface|spco|||surface|||0|888|465|472
SE|25462358|RATIONALE|ab|2|entity|C0581699|Physical process of vaporization|npop|||vaporizations|||0|888|473|486
SE|25462358|RATIONALE|ab|2|entity|C0013687|effusion|patf|||effusion|||0|888|519|527
SE|25462358|RATIONALE|ab|2|entity|C0444567|Ostium|bsoj|||orifice|||0|888|528|535
SE|25462358|RATIONALE|ab|2|entity|C0022023|Ions|elii|||ion|||0|888|563|566
SE|25462358|RATIONALE|ab|2|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|966|579|596

SE|25462358|METHODS|ab|3|text|598|959|METHODS: The molecular transmission of the " restricted collimation device" was calculated using a vaporization law under vacuum taking into account the real surface where the molecules are emitted, i.e., the sample evaporation surface in the Knudsen cell or the effusion orifice section, towards the ion source inlet by integration of elementary solid angles.
SE|25462358|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|598|605
SE|25462358|METHODS|ab|3|entity|C1521991|Molecular|qlco|||molecular|||0|694|611|620
SE|25462358|METHODS|ab|3|entity|C0443288|Restricted|ftcn|||restricted|||0|851|643|653
SE|25462358|METHODS|ab|3|entity|C0454169|Collimator|medd|||collimation|||0|851|654|665
SE|25462358|METHODS|ab|3|entity|C0699733|Devices|mnob|||device|||0|851|666|672
SE|25462358|METHODS|ab|3|entity|C0023150|Rules of conduct|rnlw|||law|||0|861|710|713
SE|25462358|METHODS|ab|3|entity|C0042221|Vacuum|npop|||vacuum|||0|694|720|726
SE|25462358|METHODS|ab|3|entity|C0871222|Reality|idcn|||real|||0|754|751|755
SE|25462358|METHODS|ab|3|entity|C0205148|Surface|spco|||surface|||0|754|756|763
SE|25462358|METHODS|ab|3|entity|C0567416|Molecule|sbst|||molecules|||0|966|774|783
SE|25462358|METHODS|ab|3|entity|C0596539|evaporation|npop|||evaporation|||0|790|814|825
SE|25462358|METHODS|ab|3|entity|C0205148|Surface|spco|||surface|||0|790|826|833
SE|25462358|METHODS|ab|3|entity|C0007634|Cells|cell|||cell|||0|861|849|853
SE|25462358|METHODS|ab|3|entity|C0013687|effusion|patf|||effusion|||0|851|861|869
SE|25462358|METHODS|ab|3|entity|C0444567|Ostium|bsoj|||orifice|||0|851|870|877
SE|25462358|METHODS|ab|3|entity|C0022023|Ions|elii|||ion|||0|623|899|902
SE|25462358|METHODS|ab|3|entity|C0013879|Elements|elii|||elementary|||0|816|934|944
SE|25462358|METHODS|ab|3|entity|C0205208|Solid|qlco|||solid|||0|816|945|950
SE|25462358|METHODS|ab|3|entity|C0205143|Angular|spco|||angles|||0|816|951|957

SE|25462358|RESULTS|ab|4|text|959|1120|RESULTS: An optimum is observed depending on the pair of selected apertures that define the restricted collimation device, i.e., the field and source apertures.
SE|25462358|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|959|966
SE|25462358|RESULTS|ab|4|entity|C0443288|Restricted|ftcn|||restricted|||0|851|1051|1061
SE|25462358|RESULTS|ab|4|entity|C0454169|Collimator|medd|||collimation|||0|851|1062|1073
SE|25462358|RESULTS|ab|4|entity|C0699733|Devices|mnob|||device|||0|851|1074|1080
SE|25462358|RESULTS|ab|4|entity|C1521738|Field|cnce|||field|||0|1000|1092|1097

SE|25462358|RESULTS|ab|5|text|1120|1274|This optimum is different from that previously calculated when taking into account only the solid angle, as defined by the restricted collimation device.
SE|25462358|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||different|||0|928|1136|1145
SE|25462358|RESULTS|ab|5|entity|C1551359|account|idcn|||account|||0|861|1195|1202
SE|25462358|RESULTS|ab|5|entity|C0205208|Solid|qlco|||solid|||0|888|1212|1217
SE|25462358|RESULTS|ab|5|entity|C0205143|Angular|spco|||angle|||0|888|1218|1223
SE|25462358|RESULTS|ab|5|entity|C0443288|Restricted|ftcn|||restricted|||0|851|1243|1253
SE|25462358|RESULTS|ab|5|entity|C0454169|Collimator|medd|||collimation|||0|851|1254|1265
SE|25462358|RESULTS|ab|5|entity|C0699733|Devices|mnob|||device|||0|851|1266|1272

SE|25462358|CONCLUSIONS|ab|6|text|1274|1516|CONCLUSIONS: This difference is attributed to the previously approximate assumption that optimizing the restricted collimation solid angle automatically optimizes the sampling of the effused beam included in the restricted collimation angle.
SE|25462358|CONCLUSIONS|ab|6|entity|C1547020|*Difference|qnco|||difference|||0|1000|1292|1302
SE|25462358|CONCLUSIONS|ab|6|entity|C0332232|Approximate|ftcn,qlco|||approximate|||0|660|1335|1346
SE|25462358|CONCLUSIONS|ab|6|entity|C0443288|Restricted|ftcn|||restricted|||0|833|1378|1388
SE|25462358|CONCLUSIONS|ab|6|entity|C0454169|Collimator|medd|||collimation|||0|833|1389|1400
SE|25462358|CONCLUSIONS|ab|6|entity|C0205208|Solid|qlco|||solid|||0|833|1401|1406
SE|25462358|CONCLUSIONS|ab|6|entity|C0205143|Angular|spco|||angle|||0|833|1407|1412
SE|25462358|CONCLUSIONS|ab|6|entity|C0870078|Sampling|idcn|||sampling|||0|1000|1441|1449
SE|25462358|CONCLUSIONS|ab|6|entity|C0333259|Effused|ftcn|||effused|||0|694|1457|1464
SE|25462358|CONCLUSIONS|ab|6|entity|C0443288|Restricted|ftcn|||restricted|||0|851|1486|1496
SE|25462358|CONCLUSIONS|ab|6|entity|C0454169|Collimator|medd|||collimation|||0|851|1497|1508
SE|25462358|CONCLUSIONS|ab|6|entity|C0205143|Angular|spco|||angle|||0|851|1509|1514

SE|25462358|CONCLUSIONS|ab|7|text|1516|1919|Moreover, the location of the evaporating surface for molecules traveling through the collimation device towards the ionization chamber remains an important factor: the distance between the sample evaporation surface and the field aperture is of paramount importance as it changes the molecular transmission to the mass spectrometer or to any target collection device in the conventional Knudsen method.
SE|25462358|CONCLUSIONS|ab|7|entity|C0450429|Location|spco|||location|||0|1000|1530|1538
SE|25462358|CONCLUSIONS|ab|7|entity|C0205148|Surface|spco|||surface|||0|861|1558|1565
SE|25462358|CONCLUSIONS|ab|7|entity|C0567416|Molecule|sbst|||molecules|||0|872|1570|1579
SE|25462358|CONCLUSIONS|ab|7|entity|C0040802|travel|dora|||traveling|||0|872|1580|1589
SE|25462358|CONCLUSIONS|ab|7|entity|C0454169|Collimator|medd|||collimation|||0|888|1602|1613
SE|25462358|CONCLUSIONS|ab|7|entity|C0699733|Devices|mnob|||device|||0|888|1614|1620
SE|25462358|CONCLUSIONS|ab|7|entity|C0596801|ionization|phpr|||ionization|||0|888|1633|1643
SE|25462358|CONCLUSIONS|ab|7|entity|C0935616|Chamber|bpoc|||chamber|||0|888|1644|1651
SE|25462358|CONCLUSIONS|ab|7|entity|C1521761|Factor|ftcn|||factor|||0|861|1673|1679
SE|25462358|CONCLUSIONS|ab|7|entity|C0012751|Distance|qnco|||distance|||0|1000|1685|1693
SE|25462358|CONCLUSIONS|ab|7|entity|C0596539|evaporation|npop|||evaporation|||0|790|1713|1724
SE|25462358|CONCLUSIONS|ab|7|entity|C0205148|Surface|spco|||surface|||0|790|1725|1732
SE|25462358|CONCLUSIONS|ab|7|entity|C1521738|Field|cnce|||field|||0|694|1741|1746
SE|25462358|CONCLUSIONS|ab|7|entity|C1521991|Molecular|qlco|||molecular|||0|694|1801|1810
SE|25462358|CONCLUSIONS|ab|7|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|966|1831|1848
SE|25462358|CONCLUSIONS|ab|7|entity|C1516698|Collection|ftcn|||collection|||0|851|1866|1876
SE|25462358|CONCLUSIONS|ab|7|entity|C0699733|Devices|mnob|||device|||0|851|1877|1883
SE|25462358|CONCLUSIONS|ab|7|entity|C0439858|Conventional|qlco|||conventional|||0|802|1891|1903
SE|25462358|CONCLUSIONS|ab|7|entity|C0025663|Methods|inpr|||method|||0|802|1912|1918


SE|25462359||ti|1|text|21|195|Rapid detection and isotopic measurement of discrete inorganic samples using acoustically actuated droplet ejection and extractive electrospray ionization mass spectrometry.
SE|25462359||ti|1|entity|C0439831|Rapid|qlco|||Rapid|||0|888|21|26
SE|25462359||ti|1|entity|C1511790|Detection|topp|||detection|||0|888|27|36
SE|25462359||ti|1|entity|C0022262|Isotopes|elii|||isotopic|||0|853|41|49
SE|25462359||ti|1|entity|C0242485|Measurement|ftcn|||measurement|||0|853|50|61
SE|25462359||ti|1|entity|C0596495|Spectrometry, Mass, Electrospray Ionization|lbpr|||electrospray ionization mass spectrometry|||0|937|152|193

SE|25462359|RATIONALE|ab|1|text|201|438|RATIONALE: The rapid detection, screening, and isotopic signature analysis of inorganics provide invaluable information for a variety of applications including explosive device detection, nuclear forensics, and environmental monitoring.
SE|25462359|RATIONALE|ab|1|entity|C0439831|Rapid|qlco|||rapid|||0|888|216|221
SE|25462359|RATIONALE|ab|1|entity|C1511790|Detection|topp|||detection|||0|888|222|231
SE|25462359|RATIONALE|ab|1|entity|C0022262|Isotopes|elii|||isotopic|||0|828|248|256
SE|25462359|RATIONALE|ab|1|entity|C1519316|Signature|inpr|||signature|||0|828|257|266
SE|25462359|RATIONALE|ab|1|entity|C0936012|Analysis|resa|||analysis|||0|828|267|275
SE|25462359|RATIONALE|ab|1|entity|C1533716|Information|idcn|||information|||0|861|309|320
SE|25462359|RATIONALE|ab|1|entity|C0015330|Explosive device|mnob|||explosive device|||0|901|361|377
SE|25462359|RATIONALE|ab|1|entity|C1511790|Detection|topp|||detection|||0|901|378|387
SE|25462359|RATIONALE|ab|1|entity|C0521447|Nuclear|spco|||nuclear|||0|888|389|396
SE|25462359|RATIONALE|ab|1|entity|C0016557|Forensic Medicine|bmod|||forensics|||0|888|397|406
SE|25462359|RATIONALE|ab|1|entity|C0014416|Environmental Monitoring|ocac|||environmental monitoring|||0|1000|412|436

SE|25462359|RATIONALE|ab|2|text|438|639|The coupling of ultrasonic nebulization and extractive electrospray ionization (EESI) enabled the mass spectrometric (MS) detection and analysis of inorganics from microliter sample solution aliquots.
SE|25462359|RATIONALE|ab|2|entity|C0220934|Ultrasonic|ftcn|||ultrasonic|||0|694|454|464
SE|25462359|RATIONALE|ab|2|entity|C1516801|Electrospray Ionization|lbpr|||electrospray ionization|||0|901|493|516
SE|25462359|RATIONALE|ab|2|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometric|||0|877|536|554
SE|25462359|RATIONALE|ab|2|entity|C1511790|Detection|topp|||detection|||0|877|560|569
SE|25462359|RATIONALE|ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|574|582
SE|25462359|RATIONALE|ab|2|entity|C0439243|uL|qnco|||microliter|||0|764|602|612
SE|25462359|RATIONALE|ab|2|entity|C0037633|Solutions|sbst|||solution|||0|764|620|628
SE|25462359|RATIONALE|ab|2|entity|C1510844|Aliquot|qnco|||aliquots|||0|764|629|637

SE|25462359|METHODS|ab|3|text|639|884|METHODS: Ultrasonic nebulization and acoustic pressure wave focusing within an array of exponential horn structures were utilized for the efficient atomization of discrete liquid samples ranging in volume from 3 MUL to 10 MUL pipetted aliquots.
SE|25462359|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|639|646
SE|25462359|METHODS|ab|3|entity|C0220934|Ultrasonic|ftcn|||Ultrasonic|||0|694|648|658
SE|25462359|METHODS|ab|3|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|847|685|693
SE|25462359|METHODS|ab|3|entity|C0037709|Sound - physical agent|npop|||acoustic pressure wave|||0|847|676|698
SE|25462359|METHODS|ab|3|entity|C0000936|Visual Accommodation|clna|||focusing|||0|847|699|707
SE|25462359|METHODS|ab|3|entity|C1510941|Array|spco|||array|||0|1000|718|723
SE|25462359|METHODS|ab|3|entity|C1552645|exponential|qlco|||exponential|||0|840|727|738
SE|25462359|METHODS|ab|3|entity|C0019939|Horns|bpoc|||horn|||0|840|739|743
SE|25462359|METHODS|ab|3|entity|C0678594|Structure|spco|||structures|||0|840|744|754
SE|25462359|METHODS|ab|3|entity|C0442799|Efficient|qlco|||efficient|||0|694|777|786
SE|25462359|METHODS|ab|3|entity|C0449468|Volume|qnco|||volume|||0|1000|837|843
SE|25462359|METHODS|ab|3|entity|||gngm|4591|TRIM37|MUL|||0|694|851|854
SE|25462359|METHODS|ab|3|entity|||gngm|4591|TRIM37|MUL|||0|716|861|864
SE|25462359|METHODS|ab|3|entity|C0181836|Pipettes|medd|||pipetted|||0|716|865|873
SE|25462359|METHODS|ab|3|entity|C1510844|Aliquot|qnco|||aliquots|||0|716|874|882

SE|25462359|METHODS|ab|4|text|884|1163|In conjunction with an electro-flow focusing source for extractive electrospray ionization (EESI), in-source collision-induced dissociation (CID) was utilized to enhance inorganic detection through fragmentation of adducts and reduction in chemical noise from organic compounds.
SE|25462359|METHODS|ab|4|entity|C0806140|Flow|orga|||flow|||0|775|915|919
SE|25462359|METHODS|ab|4|entity|C0000936|Visual Accommodation|clna|||focusing|||0|775|920|928
SE|25462359|METHODS|ab|4|entity|C1516801|Electrospray Ionization|lbpr|||electrospray ionization|||0|901|951|974
SE|25462359|METHODS|ab|4|entity|C1516801|Electrospray Ionization|lbpr|||EESI|||0|901|976|980
SE|25462359|METHODS|ab|4|entity|C0337196|Collision|phpr|||collision|||0|833|993|1002
SE|25462359|METHODS|ab|4|entity|C0205263|Induced|ftcn|||induced|||0|833|1003|1010
SE|25462359|METHODS|ab|4|entity|C0086168|Dissociation|mobd|||dissociation|||0|833|1011|1023
SE|25462359|METHODS|ab|4|entity|C1511790|Detection|topp|||detection|||0|861|1064|1073
SE|25462359|METHODS|ab|4|entity|C0185061|fragmentation procedure|topp|||fragmentation|||0|1000|1082|1095
SE|25462359|METHODS|ab|4|entity|C0596040|adduct|chvs|||adducts|||0|966|1099|1106
SE|25462359|METHODS|ab|4|entity|C0220806|Chemicals|chem|||chemical|||0|888|1124|1132
SE|25462359|METHODS|ab|4|entity|C0028263|Noise|phpr|||noise|||0|888|1133|1138
SE|25462359|METHODS|ab|4|entity|C0029224|Organic Chemicals|orch|||organic compounds|||0|1000|1144|1161
SE|25462359|METHODS|ab|4|relation|3|2|C1516801|Electrospray Ionization|lbpr|lbpr|||electrospray ionization|||0|901|951|974|PREP|DIAGNOSES||983|985|7|1|C0086168|Dissociation|mobd|mobd|||dissociation|||0|833|1011|1023
SE|25462359|METHODS|ab|4|relation|5|1|C1511790|Detection|topp|topp|||detection|||0|861|1064|1073|PREP|METHOD_OF||1074|1081|5|1|C0185061|fragmentation procedure|topp|topp|||fragmentation|||0|1000|1082|1095

SE|25462359|RESULTS|ab|5|text|1163|1351|RESULTS: The investigated system enhanced detection of the singly charged elemental cation species and provided accurate measurements of isotopic distributions for a number of metal ions.
SE|25462359|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1163|1170
SE|25462359|RESULTS|ab|5|entity|C1292732|Investigates|ftcn|||investigated|||0|872|1176|1188
SE|25462359|RESULTS|ab|5|entity|C0449913|System|ftcn|||system|||0|872|1189|1195
SE|25462359|RESULTS|ab|5|entity|C1511790|Detection|topp|||detection|||0|1000|1205|1214
SE|25462359|RESULTS|ab|5|entity|C0013879|Elements|elii|||elemental|||0|828|1237|1246
SE|25462359|RESULTS|ab|5|entity|C0007447|Cations|chvs|||cation|||0|828|1247|1253
SE|25462359|RESULTS|ab|5|entity|C1548151|Species|idcn|||species|||0|828|1254|1261
SE|25462359|RESULTS|ab|5|entity|C0443131|Accurate|qlco|||accurate|||0|840|1275|1283
SE|25462359|RESULTS|ab|5|entity|C0242485|Measurement|ftcn|||measurements|||0|840|1284|1296
SE|25462359|RESULTS|ab|5|entity|C0022262|Isotopes|elii|||isotopic|||0|853|1300|1308
SE|25462359|RESULTS|ab|5|entity|C0037775|Spatial Distribution|spco|||distributions|||0|853|1309|1322
SE|25462359|RESULTS|ab|5|entity|C0025552|Metals|inch|||metal|||0|888|1339|1344
SE|25462359|RESULTS|ab|5|entity|C0022023|Ions|elii|||ions|||0|888|1345|1349

SE|25462359|RESULTS|ab|6|text|1351|1570|The extent of CID demonstrated the competition between ligand loss from hydrate clusters and charge reduction from the doubly charged to singly charged cations for the alkaline earth metal ions of strontium and barium.
SE|25462359|RESULTS|ab|6|entity|C0439792|Extent|spco|||extent|||0|1000|1355|1361
SE|25462359|RESULTS|ab|6|entity|C0337196|Collision|phpr|||CID|||0|851|1365|1368
SE|25462359|RESULTS|ab|6|entity|C0205263|Induced|ftcn|||CID|||0|851|1365|1368
SE|25462359|RESULTS|ab|6|entity|C0086168|Dissociation|mobd|||CID|||0|851|1365|1368
SE|25462359|RESULTS|ab|6|entity|C0679932|competition|socb|||competition|||0|1000|1386|1397
SE|25462359|RESULTS|ab|6|entity|C0023688|Ligands|chem|||ligand|||0|888|1406|1412
SE|25462359|RESULTS|ab|6|entity|C1517945|Loss|qnco|||loss|||0|888|1413|1417
SE|25462359|RESULTS|ab|6|entity|C0720930|Hydrate|orch,phsu|||hydrate|||0|694|1423|1430
SE|25462359|RESULTS|ab|6|entity|C0007961|charge amounts|qnco|||charged|||0|733|1495|1502
SE|25462359|RESULTS|ab|6|entity|C0007447|Cations|chvs|||cations|||0|733|1503|1510
SE|25462359|RESULTS|ab|6|entity|C0025555|Metals, Alkaline Earth|elii|||alkaline earth metal|||0|916|1519|1539
SE|25462359|RESULTS|ab|6|entity|C0022023|Ions|elii|||ions|||0|916|1540|1544
SE|25462359|RESULTS|ab|6|entity|C0038467|Strontium|bacs,elii|||strontium|||0|1000|1548|1557
SE|25462359|RESULTS|ab|6|entity|C0004749|Barium|elii|||barium|||0|1000|1562|1568

SE|25462359|RESULTS|ab|7|text|1570|1717|Inorganics were also detected from complex matrices, including synthetic fingerprint material and sediment, without detriment to device operation.
SE|25462359|RESULTS|ab|7|entity|C0439855|Complex|qlco|||complex|||0|872|1605|1612
SE|25462359|RESULTS|ab|7|entity|C0331858|Matrix|hcro|||matrices|||0|872|1613|1621
SE|25462359|RESULTS|ab|7|entity|C0016126|Fingerprints|mnob|||fingerprint|||0|901|1643|1654
SE|25462359|RESULTS|ab|7|entity|C0440251|Synthetic material|mnob|||synthetic fingerprint material|||0|901|1633|1663
SE|25462359|RESULTS|ab|7|entity|C1550099|Sediment|bdsu|||sediment|||0|1000|1668|1676
SE|25462359|RESULTS|ab|7|entity|C0699733|Devices|mnob|||device|||0|888|1699|1705
SE|25462359|RESULTS|ab|7|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|888|1706|1715

SE|25462359|CONCLUSIONS|ab|8|text|1717|1926|CONCLUSIONS: The described system provides a versatile tool for the rapid detection, speciation, and isotopic identification of inorganic compounds at nanogram to sub-nanogram levels from microliter aliquots.
SE|25462359|CONCLUSIONS|ab|8|entity|C1552738|described|idcn|||described|||0|888|1734|1743
SE|25462359|CONCLUSIONS|ab|8|entity|C0449913|System|ftcn|||system|||0|888|1744|1750
SE|25462359|CONCLUSIONS|ab|8|entity|C0336791|Tool|mnob|||tool|||0|861|1772|1776
SE|25462359|CONCLUSIONS|ab|8|entity|C0439831|Rapid|qlco|||rapid|||0|888|1785|1790
SE|25462359|CONCLUSIONS|ab|8|entity|C1511790|Detection|topp|||detection|||0|888|1791|1800
SE|25462359|CONCLUSIONS|ab|8|entity|C0022262|Isotopes|elii|||isotopic|||0|623|1818|1826
SE|25462359|CONCLUSIONS|ab|8|entity|C0021521|Inorganic Chemicals|inch|||inorganic compounds|||0|1000|1845|1864
SE|25462359|CONCLUSIONS|ab|8|entity|C0439212|nanogram|qnco|||nanogram|||0|1000|1868|1876
SE|25462359|CONCLUSIONS|ab|8|entity|C0542339|Inferior|spco|||sub|||0|851|1880|1883
SE|25462359|CONCLUSIONS|ab|8|entity|C0439212|nanogram|qnco|||nanogram|||0|851|1884|1892
SE|25462359|CONCLUSIONS|ab|8|entity|C0441889|Levels|inpr|||levels|||0|851|1893|1899
SE|25462359|CONCLUSIONS|ab|8|entity|C0439243|uL|qnco|||microliter|||0|872|1905|1915
SE|25462359|CONCLUSIONS|ab|8|entity|C1510844|Aliquot|qnco|||aliquots|||0|872|1916|1924

SE|25462359|CONCLUSIONS|ab|9|text|1926|1945|Published in 2014.

SE|25462359|CONCLUSIONS|ab|10|text|1945|1968|This article is a U.S.

SE|25462359|CONCLUSIONS|ab|11|text|1968|2023|Government work and is in the public domain in the USA.
SE|25462359|CONCLUSIONS|ab|11|entity|C0018104|Government|orgt|||Government|||0|888|1968|1978
SE|25462359|CONCLUSIONS|ab|11|entity|C0043227|Work|ocac|||work|||0|888|1979|1983
SE|25462359|CONCLUSIONS|ab|11|entity|C0162592|Public Domain|popg|||public domain|||0|1000|1998|2011


SE|25462360||ti|1|text|21|177|New insights into dissociation of deprotonated 2,4-dinitrotoluene by combined high-resolution mass spectrometry and density functional theory calculations.
SE|25462360||ti|1|entity|C0205314|New|tmco|||New|||0|872|21|24
SE|25462360||ti|1|entity|C0233820|Insight|menp|||insights|||0|872|25|33
SE|25462360||ti|1|entity|C0086168|Dissociation|mobd|||dissociation|||0|1000|39|51
SE|25462360||ti|1|entity|C0301070|Dinitrotoluene|orch|||dinitrotoluene|||0|861|72|86
SE|25462360||ti|1|entity|C0205195|Combined|qlco|||combined|||0|840|90|98
SE|25462360||ti|1|entity|C0205250|High|qlco|||high|||0|840|99|103
SE|25462360||ti|1|entity|C1514893|Resolution|ftcn|||resolution|||0|840|104|114
SE|25462360||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|840|115|132
SE|25462360||ti|1|entity|C0178587|density|npop|||density|||0|816|137|144
SE|25462360||ti|1|entity|C0205245|Functional|ftcn|||functional|||0|816|145|155
SE|25462360||ti|1|entity|C0871935|Theories|idcn|||theory|||0|816|156|162
SE|25462360||ti|1|entity|C1441506|CALCULATION|lbpr|||calculations|||0|816|163|175

SE|25462360|RATIONALE|ab|1|text|183|361|RATIONALE: 2,4-Dinitrotoluene (2,4-DNT) is a nitroaromatic explosive which is commonly found in environmental samples close to training points, firing places, and manufacturers.
SE|25462360|RATIONALE|ab|1|entity|C0301070|Dinitrotoluene|orch|||Dinitrotoluene|||0|861|198|212
SE|25462360|RATIONALE|ab|1|entity|C0045622|2,6-dinitrotoluene|hops,orch|||4-DNT|||0|861|216|221
SE|25462360|RATIONALE|ab|1|entity|C0220931|Training|edac|||training|||0|694|310|318
SE|25462360|RATIONALE|ab|1|entity|C0442504|Place|spco|||places|||0|1000|334|340

SE|25462360|RATIONALE|ab|2|text|361|485|Mass spectrometry analysis of this compound shows one main product ion that distinguishes it from the other isomers of DNT.
SE|25462360|RATIONALE|ab|2|entity|C0037813|Spectrum Analysis, Mass|lbpr|||Mass spectrometry|||0|901|361|378
SE|25462360|RATIONALE|ab|2|entity|C0936012|Analysis|resa|||analysis|||0|901|379|387
SE|25462360|RATIONALE|ab|2|entity|C0205198|Compound|qlco|||compound|||0|1000|396|404
SE|25462360|RATIONALE|ab|2|entity|C0205447|One|qnco|||one|||0|833|411|414
SE|25462360|RATIONALE|ab|2|entity|C0205225|Primary|qlco|||main|||0|833|415|419
SE|25462360|RATIONALE|ab|2|entity|C1514468|product|qnco|||product|||0|833|420|427
SE|25462360|RATIONALE|ab|2|entity|C0022023|Ions|elii|||ion|||0|833|428|431
SE|25462360|RATIONALE|ab|2|entity|C0022203|Isomerism|npop|||isomers|||0|966|469|476
SE|25462360|RATIONALE|ab|2|entity|C0045622|2,6-dinitrotoluene|hops,orch|||DNT|||0|1000|480|483

SE|25462360|RATIONALE|ab|3|text|485|560|We present here a detailed mechanistic study on the formation of this ion.
SE|25462360|RATIONALE|ab|3|entity|C1522508|Details|qlco|||detailed|||0|816|503|511
SE|25462360|RATIONALE|ab|3|entity|C0441712|Mechanisms|ftcn|||mechanistic|||0|816|512|523
SE|25462360|RATIONALE|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|816|524|529
SE|25462360|RATIONALE|ab|3|entity|C1522492|Formation|ftcn|||formation|||0|1000|537|546
SE|25462360|RATIONALE|ab|3|entity|C0022023|Ions|elii|||ion|||0|1000|555|558

SE|25462360|METHODS|ab|4|text|560|744|METHODS: 2,4-DNT was analyzed using negative electrospray ionization high-resolution mass spectrometry (ESI-HRMS) using a linear ion trap quadrupole LTQ-Orbitrap XL mass spectrometer.
SE|25462360|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|560|567
SE|25462360|METHODS|ab|4|entity|C0045622|2,6-dinitrotoluene|hops,orch|||4-DNT|||0|861|571|576
SE|25462360|METHODS|ab|4|entity|C0205160|Negative|qlco|||negative|||0|863|596|604
SE|25462360|METHODS|ab|4|entity|C0205250|High|qlco|||high|||0|863|629|633
SE|25462360|METHODS|ab|4|entity|C1514893|Resolution|ftcn|||resolution|||0|863|634|644
SE|25462360|METHODS|ab|4|entity|C0596495|Spectrometry, Mass, Electrospray Ionization|lbpr|||electrospray ionization high-resolution mass spectrometry|||0|863|605|662
SE|25462360|METHODS|ab|4|entity|C0205132|Linear|spco|||linear|||0|738|682|688
SE|25462360|METHODS|ab|4|entity|C0022023|Ions|elii|||ion|||0|738|689|692
SE|25462360|METHODS|ab|4|entity|C0167627|CD40 Ligand|aapp,imft|100187907|TRAP|trap|||0|738|693|697
SE|25462360|METHODS|ab|4|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|738|725|742
SE|25462360|METHODS|ab|4|relation|3|1|C0596495|Spectrometry, Mass, Electrospray Ionization|lbpr|lbpr|||electrospray ionization high-resolution mass spectrometry|||0|863|605|662|VERB|USES||674|679|1|1|C0183396|Spectrometers, Mass|medd|medd|||mass spectrometer|||0|738|725|742

SE|25462360|METHODS|ab|5|text|744|838|Collision-induced dissociation (CID) experiments were performed on the [M-H](-) ion obtained.
SE|25462360|METHODS|ab|5|entity|C0337196|Collision|phpr|||Collision|||0|833|744|753
SE|25462360|METHODS|ab|5|entity|C0205263|Induced|ftcn|||induced|||0|833|754|761
SE|25462360|METHODS|ab|5|entity|C0086168|Dissociation|mobd|||dissociation|||0|833|762|774
SE|25462360|METHODS|ab|5|entity|C0681814|research study|resa|||experiments|||0|833|781|792
SE|25462360|METHODS|ab|5|entity|C0033727|Protons|elii|||H|||0|888|818|819
SE|25462360|METHODS|ab|5|entity|C0022023|Ions|elii|||ion|||0|1000|824|827

SE|25462360|METHODS|ab|6|text|838|931|Density functional theory (DFT) calculations were used to support experimental observations.
SE|25462360|METHODS|ab|6|entity|C0178587|density|npop|||Density|||0|816|838|845
SE|25462360|METHODS|ab|6|entity|C0205245|Functional|ftcn|||functional|||0|816|846|856
SE|25462360|METHODS|ab|6|entity|C0871935|Theories|idcn|||theory|||0|816|857|863
SE|25462360|METHODS|ab|6|entity|C1441506|CALCULATION|lbpr|||calculations|||0|816|870|882
SE|25462360|METHODS|ab|6|entity|C1517004|Experimental|ftcn|||experimental|||0|694|904|916

SE|25462360|RESULTS|ab|7|text|931|1035|RESULTS: Fragmentation of deprotonated 2,4-DNT [M-H](-) (m/z 181) yields a main product ion at m/z 116.
SE|25462360|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|931|938
SE|25462360|RESULTS|ab|7|entity|C0185061|fragmentation procedure|topp|||Fragmentation|||0|1000|940|953
SE|25462360|RESULTS|ab|7|entity|C0045622|2,6-dinitrotoluene|hops,orch|||4-DNT|||0|861|972|977
SE|25462360|RESULTS|ab|7|entity|C0033727|Protons|elii|||H|||0|888|981|982
SE|25462360|RESULTS|ab|7|entity|C0205225|Primary|qlco|||main|||0|851|1006|1010
SE|25462360|RESULTS|ab|7|entity|C1514468|product|qnco|||product|||0|851|1011|1018
SE|25462360|RESULTS|ab|7|entity|C0022023|Ions|elii|||ion|||0|851|1019|1022

SE|25462360|RESULTS|ab|8|text|1035|1144|The mechanism of formation of this diagnostic product ion is not obvious and it has never been rationalized.
SE|25462360|RESULTS|ab|8|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|1039|1048
SE|25462360|RESULTS|ab|8|entity|C1522492|Formation|ftcn|||formation|||0|1000|1052|1061
SE|25462360|RESULTS|ab|8|entity|C0348026|Diagnostic|ftcn|||diagnostic|||0|851|1070|1080
SE|25462360|RESULTS|ab|8|entity|C1514468|product|qnco|||product|||0|851|1081|1088
SE|25462360|RESULTS|ab|8|entity|C0022023|Ions|elii|||ion|||0|851|1089|1092
SE|25462360|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|694|1096|1099
SE|25462360|RESULTS|ab|8|entity|C1549495|Never|idcn|||never|||0|1000|1119|1124

SE|25462360|RESULTS|ab|9|text|1144|1247|Calculations were performed to probe different mechanistic variants, which are discussed in this work.
SE|25462360|RESULTS|ab|9|entity|C1441506|CALCULATION|lbpr|||Calculations|||0|966|1144|1156
SE|25462360|RESULTS|ab|9|entity|C1547020|*Difference|qnco|||different|||0|793|1181|1190
SE|25462360|RESULTS|ab|9|entity|C0441712|Mechanisms|ftcn|||mechanistic|||0|793|1191|1202
SE|25462360|RESULTS|ab|9|entity|C0205419|Variant|qlco|||variants|||0|793|1203|1211
SE|25462360|RESULTS|ab|9|entity|C0043227|Work|ocac|||work|||0|1000|1241|1245

SE|25462360|CONCLUSIONS|ab|10|text|1247|1458|CONCLUSIONS: Analysis of possible pathways to form the m/z 116 ion from the m/z 181 precursor shows that its formation is likely to proceed first via NO(*) loss, followed by eliminations of H2 O and then HO(*) .
SE|25462360|CONCLUSIONS|ab|10|entity|C0936012|Analysis|resa|||Analysis|||0|1000|1260|1268
SE|25462360|CONCLUSIONS|ab|10|entity|C0332149|Possible|qlco|||possible|||0|694|1272|1280
SE|25462360|CONCLUSIONS|ab|10|entity|C0022023|Ions|elii|||ion|||0|791|1310|1313
SE|25462360|CONCLUSIONS|ab|10|entity|C1522492|Formation|ftcn|||formation|||0|1000|1356|1365
SE|25462360|CONCLUSIONS|ab|10|entity|C1279901|Firstly|qlco|||first|||0|694|1387|1392
SE|25462360|CONCLUSIONS|ab|10|entity|C1517945|Loss|qnco|||loss|||0|1000|1403|1407


SE|25462361||ti|1|text|21|185|The benefits and limitations of reaction cell and sector field inductively coupled plasma mass spectrometry in the detection and quantification of phosphopeptides.
SE|25462361||ti|1|entity|C0814225|Benefits|qnco|||benefits|||0|1000|25|33
SE|25462361||ti|1|entity|C0449295|Limitation|ftcn|||limitations|||0|966|38|49
SE|25462361||ti|1|entity|C0443286|Reaction|ftcn|||reaction|||0|888|53|61
SE|25462361||ti|1|entity|C0007634|Cells|cell|||cell|||0|888|62|66
SE|25462361||ti|1|entity|C0439741|Sectoral|spco|||sector|||0|740|71|77
SE|25462361||ti|1|entity|C1521738|Field|cnce|||field|||0|740|78|83
SE|25462361||ti|1|entity|C0032105|Plasma|bdsu|||plasma|||0|740|104|110
SE|25462361||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|740|111|128
SE|25462361||ti|1|entity|C1511790|Detection|topp|||detection|||0|1000|136|145
SE|25462361||ti|1|entity|C0031684|Phosphopeptides|aapp|||phosphopeptides|||0|1000|168|183

SE|25462361|RATIONALE|ab|1|text|191|307|RATIONALE: The phosphorylation of proteins is one of the most important post-translational modifications in nature.
SE|25462361|RATIONALE|ab|1|entity|C0031715|Phosphorylation|moft|||phosphorylation|||0|1000|206|221
SE|25462361|RATIONALE|ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|225|233
SE|25462361|RATIONALE|ab|1|entity|C0205447|One|qnco|||one|||0|1000|237|240
SE|25462361|RATIONALE|ab|1|entity|C0205393|Most|qnco|||most|||0|850|248|252
SE|25462361|RATIONALE|ab|1|entity|C0033666|Protein Processing, Post-Translational|moft|||post-translational modifications|||0|850|263|295
SE|25462361|RATIONALE|ab|1|entity|C0349590|Nature|idcn|||nature|||0|1000|299|305
SE|25462361|RATIONALE|ab|1|relation|0|0|C0031715|Phosphorylation|moft|moft|||phosphorylation|||0|1000|206|221|SPEC|ISA||206|295|0|0|C0033666|Protein Processing, Post-Translational|moft|moft|||post-translational modifications|||0|850|263|295

SE|25462361|RATIONALE|ab|2|text|307|416|Knowledge of the quantity or degree of protein phosphorylation in biological samples is extremely important.
SE|25462361|RATIONALE|ab|2|entity|C0376554|Knowledge|inpr|||Knowledge|||0|1000|307|316
SE|25462361|RATIONALE|ab|2|entity|C1265611|Quantity|qnco|||quantity|||0|1000|324|332
SE|25462361|RATIONALE|ab|2|entity|C0031715|Phosphorylation|moft|||protein phosphorylation|||0|1000|346|369
SE|25462361|RATIONALE|ab|2|entity|C0205460|biological|ftcn|||biological|||0|694|373|383

SE|25462361|RATIONALE|ab|3|text|416|592|A combination of liquid chromatography (LC) and inductively coupled plasma mass spectrometry (ICP-MS) allows the absolute and relative quantification of the phosphorus signal.
SE|25462361|RATIONALE|ab|3|entity|C0205195|Combined|qlco|||combination|||0|1000|418|429
SE|25462361|RATIONALE|ab|3|entity|C0008565|Liquid Chromatography|lbpr|||liquid chromatography|||0|1000|433|454
SE|25462361|RATIONALE|ab|3|entity|C0032105|Plasma|bdsu|||plasma|||0|787|484|490
SE|25462361|RATIONALE|ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|787|491|508
SE|25462361|RATIONALE|ab|3|entity|C0205344|Absolute|qlco|||absolute|||0|1000|529|537
SE|25462361|RATIONALE|ab|3|entity|C0205345|Relative|qlco|||relative|||0|694|542|550
SE|25462361|RATIONALE|ab|3|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|694|573|583

SE|25462361|METHODS|ab|4|text|592|878|METHODS: A comparison between dynamic reaction cell quadrupole ICP-MS (DRC-Q-ICP-MS) and high-resolution sector field ICP-MS (SF-ICP-MS) in detecting signals of phosphorus-containing species using identical capillary LC (reversed-phase technology) and nebulizer settings was performed.
SE|25462361|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|592|599
SE|25462361|METHODS|ab|4|entity|C0729333|Dynamic|ftcn|||dynamic|||0|736|622|629
SE|25462361|METHODS|ab|4|entity|C0443286|Reaction|ftcn|||reaction|||0|736|630|638
SE|25462361|METHODS|ab|4|entity|C0007634|Cells|cell|||cell|||0|736|639|643
SE|25462361|METHODS|ab|4|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|736|655|661
SE|25462361|METHODS|ab|4|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|736|655|661
SE|25462361|METHODS|ab|4|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|727|669|675
SE|25462361|METHODS|ab|4|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|727|669|675
SE|25462361|METHODS|ab|4|entity|C0205250|High|qlco|||high|||0|730|681|685
SE|25462361|METHODS|ab|4|entity|C1514893|Resolution|ftcn|||resolution|||0|730|686|696
SE|25462361|METHODS|ab|4|entity|C0439741|Sectoral|spco|||sector|||0|730|697|703
SE|25462361|METHODS|ab|4|entity|C1521738|Field|cnce|||field|||0|730|704|709
SE|25462361|METHODS|ab|4|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|730|710|716
SE|25462361|METHODS|ab|4|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|730|710|716
SE|25462361|METHODS|ab|4|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|773|721|727
SE|25462361|METHODS|ab|4|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|773|721|727
SE|25462361|METHODS|ab|4|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|851|753|763
SE|25462361|METHODS|ab|4|entity|C0332256|Containing|ftcn|||containing|||0|851|764|774
SE|25462361|METHODS|ab|4|entity|C1548151|Species|idcn|||species|||0|851|775|782
SE|25462361|METHODS|ab|4|entity|C0205280|Identical|qlco|||identical|||0|861|789|798
SE|25462361|METHODS|ab|4|entity|C0006901|Blood capillaries|bpoc|||capillary|||0|861|799|808
SE|25462361|METHODS|ab|4|entity|C0008565|Liquid Chromatography|lbpr|||LC|||0|861|809|811
SE|25462361|METHODS|ab|4|entity|C1555029|reverses|idcn|||reversed|||0|840|813|821
SE|25462361|METHODS|ab|4|entity|C0205390|Phase|tmco|||phase|||0|840|822|827
SE|25462361|METHODS|ab|4|entity|C0039421|Technology|ocdi|||technology|||0|840|828|838
SE|25462361|METHODS|ab|4|entity|C0027524|Nebulizers|medd|||nebulizer|||0|872|844|853
SE|25462361|METHODS|ab|4|entity|C0542559|contextual factors|ftcn|||settings|||0|872|854|862
SE|25462361|METHODS|ab|4|relation|8|4|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||ICP-MS|||0|730|710|716|VERB|USES||783|788|3|1|C0008565|Liquid Chromatography|lbpr|lbpr|||LC|||0|861|809|811

SE|25462361|RESULTS|ab|5|text|878|1030|RESULTS: A method to diminish the reversed-phase gradient-related signal instability in phosphorus detection with LC/ICP-MS applications was developed.
SE|25462361|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|878|885
SE|25462361|RESULTS|ab|5|entity|C0025663|Methods|inpr|||method|||0|1000|889|895
SE|25462361|RESULTS|ab|5|entity|C1555029|reverses|idcn|||reversed|||0|756|912|920
SE|25462361|RESULTS|ab|5|entity|C0205390|Phase|tmco|||phase|||0|756|921|926
SE|25462361|RESULTS|ab|5|entity|C0439182|% gradient|qnco|||gradient|||0|756|927|935
SE|25462361|RESULTS|ab|5|entity|C1522149|Related|ftcn|||related|||0|756|936|943
SE|25462361|RESULTS|ab|5|entity|C1444783|Instability|fndg|||instability|||0|756|951|962
SE|25462361|RESULTS|ab|5|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|888|966|976
SE|25462361|RESULTS|ab|5|entity|C1511790|Detection|topp|||detection|||0|888|977|986
SE|25462361|RESULTS|ab|5|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|789|995|1001
SE|25462361|RESULTS|ab|5|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/ICP-MS|||0|789|992|1001
SE|25462361|RESULTS|ab|5|relation|0|0|C1511790|Detection|topp|topp|||detection|||0|888|977|986|MOD/HEAD|USES||966|986|0|0|C0031705|Phosphorus|elii,phsu|phsu|||phosphorus|||0|888|966|976

SE|25462361|RESULTS|ab|6|text|1030|1190|Bis(4-nitrophenyl)phosphate (BNPP) was used as a standard to compare signal-to-noise ratios and limits of detection (LODs) between the two instrumental setups.
SE|25462361|RESULTS|ab|6|entity|||gngm|9531|BAG3|Bis|||0|1000|1030|1033
SE|25462361|RESULTS|ab|6|entity|C0048584|4-nitrophenyl|orch,phsu|||4-nitrophenyl|||0|1000|1034|1047
SE|25462361|RESULTS|ab|6|entity|C1442989|STANDARD|ftcn|||standard|||0|1000|1079|1087
SE|25462361|RESULTS|ab|6|entity|C0037083|Signal Transduction|celf|||signal|||0|764|1099|1105
SE|25462361|RESULTS|ab|6|entity|C0028263|Noise|phpr|||noise|||0|764|1109|1114
SE|25462361|RESULTS|ab|6|entity|C0456603|Ratio|inpr|||ratios|||0|764|1115|1121
SE|25462361|RESULTS|ab|6|entity|C1511790|Detection|topp|||detection|||0|785|1136|1145
SE|25462361|RESULTS|ab|6|entity|C0205448|Two|qnco|||two|||0|816|1165|1168
SE|25462361|RESULTS|ab|6|entity|C0243113|instruments|mnob|||instrumental|||0|816|1169|1181
SE|25462361|RESULTS|ab|6|entity|C1550029|Setup|idcn|||setups|||0|816|1182|1188

SE|25462361|RESULTS|ab|7|text|1190|1339|The LOD reaches a value of 0.8 ug L(-1) when applying the DRC technology in Q-ICP-MS and an LOD of 0.09 ug L(-1) was found with the SF-ICP-MS setup.
SE|25462361|RESULTS|ab|7|entity|C0039421|Technology|ocdi|||technology|||0|861|1252|1262
SE|25462361|RESULTS|ab|7|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|751|1268|1274
SE|25462361|RESULTS|ab|7|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|751|1268|1274
SE|25462361|RESULTS|ab|7|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|768|1325|1331
SE|25462361|RESULTS|ab|7|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|768|1325|1331
SE|25462361|RESULTS|ab|7|entity|C1550029|Setup|idcn|||setup|||0|768|1332|1337

SE|25462361|RESULTS|ab|8|text|1339|1468|This BNPP standard was further used to compare the absolute quantification possibilities of phosphopeptides in these two setups.
SE|25462361|RESULTS|ab|8|entity|C1442989|STANDARD|ftcn|||standard|||0|861|1349|1357
SE|25462361|RESULTS|ab|8|entity|C1517331|Further|spco|||further|||0|1000|1362|1369
SE|25462361|RESULTS|ab|8|entity|C0205344|Absolute|qlco|||absolute|||0|660|1390|1398
SE|25462361|RESULTS|ab|8|entity|C0031684|Phosphopeptides|aapp|||phosphopeptides|||0|1000|1431|1446
SE|25462361|RESULTS|ab|8|entity|C0205448|Two|qnco|||two|||0|872|1456|1459
SE|25462361|RESULTS|ab|8|entity|C1550029|Setup|idcn|||setups|||0|872|1460|1466

SE|25462361|CONCLUSIONS|ab|9|text|1468|1654|CONCLUSIONS: This one-to-one comparison of two interference-reducing ICP-MS instruments demonstrates that absolute quantification of individual LC-separated phosphopeptides is possible.
SE|25462361|CONCLUSIONS|ab|9|entity|C0205447|One|qnco|||one|||0|645|1486|1489
SE|25462361|CONCLUSIONS|ab|9|entity|C0205448|Two|qnco|||two|||0|694|1511|1514
SE|25462361|CONCLUSIONS|ab|9|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|779|1537|1543
SE|25462361|CONCLUSIONS|ab|9|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|779|1537|1543
SE|25462361|CONCLUSIONS|ab|9|entity|C0243113|instruments|mnob|||instruments|||0|779|1544|1555
SE|25462361|CONCLUSIONS|ab|9|entity|C0205344|Absolute|qlco|||absolute|||0|694|1574|1582
SE|25462361|CONCLUSIONS|ab|9|entity|C0237401|Individual|humn|||individual|||0|840|1601|1611
SE|25462361|CONCLUSIONS|ab|9|entity|C0008565|Liquid Chromatography|lbpr|||LC|||0|840|1612|1614
SE|25462361|CONCLUSIONS|ab|9|entity|C0687118|Detached|ftcn|||separated|||0|840|1615|1624
SE|25462361|CONCLUSIONS|ab|9|entity|C0031684|Phosphopeptides|aapp|||phosphopeptides|||0|840|1625|1640
SE|25462361|CONCLUSIONS|ab|9|entity|C0332149|Possible|qlco|||possible|||0|1000|1644|1652

SE|25462361|CONCLUSIONS|ab|10|text|1654|1804|However, based on the LOD values, SF-ICP-MS has a higher sensitivity in detecting phosphorus signals and thus is preferred in phosphopeptide analysis.
SE|25462361|CONCLUSIONS|ab|10|entity|C0042295|Values|qlco|||values|||0|861|1680|1686
SE|25462361|CONCLUSIONS|ab|10|entity|C0032105|Plasma|bdsu|||ICP-MS|||0|773|1691|1697
SE|25462361|CONCLUSIONS|ab|10|entity|C0037813|Spectrum Analysis, Mass|lbpr|||ICP-MS|||0|773|1691|1697
SE|25462361|CONCLUSIONS|ab|10|entity|C1441604|HIGH SENSITIVITY|lbpr|||higher sensitivity|||0|983|1704|1722
SE|25462361|CONCLUSIONS|ab|10|entity|C0031705|Phosphorus|elii,phsu|||phosphorus|||0|606|1736|1746
SE|25462361|CONCLUSIONS|ab|10|entity|C0031684|Phosphopeptides|aapp|||phosphopeptide|||0|888|1780|1794
SE|25462361|CONCLUSIONS|ab|10|entity|C0936012|Analysis|resa|||analysis|||0|888|1795|1803


SE|25462362||ti|1|text|21|141|Efficient coupling of nanosecond laser pulses with the cluster medium: Generation of hydrogen-like [C](5+) atomic ions.
SE|25462362||ti|1|entity|C0442799|Efficient|qlco|||Efficient|||0|694|21|30
SE|25462362||ti|1|entity|C0439225|nanosecond|qnco|||nanosecond|||0|888|43|53
SE|25462362||ti|1|entity|C0023089|Lasers|mnob|||laser|||0|888|54|59
SE|25462362||ti|1|entity|C0439536|Medium|qlco|||medium|||0|861|84|90
SE|25462362||ti|1|entity|C0079411|Generations|tmco|||Generation|||0|966|92|102
SE|25462362||ti|1|entity|C0020275|Hydrogen|elii|||hydrogen|||0|1000|106|114
SE|25462362||ti|1|entity|C0567415|Atom|elii|||atomic|||0|853|128|134
SE|25462362||ti|1|entity|C0022023|Ions|elii|||ions|||0|853|135|139

SE|25462362|RATIONALE|ab|1|text|147|288|RATIONALE: Clusters exhibit diverse photochemical behavior as a function of laser parameters, i.e. wavelength, pulse duration and intensity.
SE|25462362|RATIONALE|ab|1|entity|C0004927|Behavior|inbe|||behavior|||0|827|197|205
SE|25462362|RATIONALE|ab|1|entity|C0031843|physiological aspects|phsf|||function|||0|1000|211|219
SE|25462362|RATIONALE|ab|1|entity|C0023089|Lasers|mnob|||laser|||0|888|223|228
SE|25462362|RATIONALE|ab|1|entity|C0449819|Wavelength|qnco|||wavelength|||0|827|246|256
SE|25462362|RATIONALE|ab|1|entity|C0449238|Duration|tmco|||duration|||0|861|264|272

SE|25462362|RATIONALE|ab|2|text|288|457|One such aspect of cluster photochemistry is the generation of energetic multiply charged atomic ions, upon efficient interaction of clusters with intense laser pulses.
SE|25462362|RATIONALE|ab|2|entity|C0205447|One|qnco|||One|||0|1000|288|291
SE|25462362|RATIONALE|ab|2|entity|C1547011|Aspect|qnco|||aspect|||0|1000|297|303
SE|25462362|RATIONALE|ab|2|entity|C0031739|Photochemistry|ocdi|||photochemistry|||0|861|315|329
SE|25462362|RATIONALE|ab|2|entity|C0079411|Generations|tmco|||generation|||0|966|337|347
SE|25462362|RATIONALE|ab|2|entity|C0567415|Atom|elii|||atomic|||0|853|378|384
SE|25462362|RATIONALE|ab|2|entity|C0022023|Ions|elii|||ions|||0|853|385|389
SE|25462362|RATIONALE|ab|2|entity|C0442799|Efficient|qlco|||efficient|||0|888|396|405
SE|25462362|RATIONALE|ab|2|entity|C0023089|Lasers|mnob|||laser|||0|790|443|448
SE|25462362|RATIONALE|ab|2|entity|C0034107|Pulse taking|diap|||pulses|||0|790|449|455

SE|25462362|RATIONALE|ab|3|text|457|800|In the present work, mass spectrometric investigations have been carried out on clusters of tetrahydrofuran (THF, C4 H8 O) - a saturated cyclic ether - subjected to nanosecond laser pulse (spanning from UV to IR wavelength range) with the aim of shedding light on the complex mechanism of laser-cluster interactions, which is still ambiguous.
SE|25462362|RATIONALE|ab|3|entity|C0150312|Present|qnco|||present|||0|888|464|471
SE|25462362|RATIONALE|ab|3|entity|C0043227|Work|ocac|||work|||0|888|472|476
SE|25462362|RATIONALE|ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometric|||0|877|478|496
SE|25462362|RATIONALE|ab|3|entity|C0439787|Out|spco|||out|||0|1000|530|533
SE|25462362|RATIONALE|ab|3|entity|C0076271|tetrahydrofuran|orch|||tetrahydrofuran|||0|1000|549|564
SE|25462362|RATIONALE|ab|3|entity|C0029408|Degenerative polyarthritis|dsyn|||O) - a|||0|764|577|583
SE|25462362|RATIONALE|ab|3|entity|C0522534|Saturated|qnco|||saturated|||0|764|584|593
SE|25462362|RATIONALE|ab|3|entity|C0014997|Ethers, Cyclic|orch|||cyclic ether|||0|764|594|606
SE|25462362|RATIONALE|ab|3|entity|C0439225|nanosecond|qnco|||nanosecond|||0|623|622|632
SE|25462362|RATIONALE|ab|3|entity|C0023089|Lasers|mnob|||laser|||0|623|633|638
SE|25462362|RATIONALE|ab|3|entity|C0449819|Wavelength|qnco|||wavelength|||0|790|669|679
SE|25462362|RATIONALE|ab|3|entity|C1514721|Range|qnco|||range|||0|790|680|685
SE|25462362|RATIONALE|ab|3|entity|C0439855|Complex|qlco|||complex|||0|888|725|732
SE|25462362|RATIONALE|ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|733|742
SE|25462362|RATIONALE|ab|3|entity|C0023089|Lasers|mnob|||laser|||0|660|746|751

SE|25462362|METHODS|ab|4|text|800|1021|METHODS: THF clusters, generated via supersonic expansion of room-temperature THF vapours seeded in argon, were subjected to gigawatt intensity laser pulses (355, 532 and 1064 nm) obtained from a nanosecond Nd:YAG laser.
SE|25462362|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|800|807
SE|25462362|METHODS|ab|4|entity|C1550513|via|idcn|||via|||0|660|833|836
SE|25462362|METHODS|ab|4|entity|C1548796|Room temperature|qlco|||room-temperature|||0|808|861|877
SE|25462362|METHODS|ab|4|entity|C0597635|vapor|chvs|||vapours|||0|808|882|889
SE|25462362|METHODS|ab|4|entity|C0003781|Argon|elii|||argon|||0|1000|900|905
SE|25462362|METHODS|ab|4|entity|C0023089|Lasers|mnob|||laser|||0|728|944|949
SE|25462362|METHODS|ab|4|entity|C0034107|Pulse taking|diap|||pulses|||0|728|950|956
SE|25462362|METHODS|ab|4|entity|C0439225|nanosecond|qnco|||nanosecond|||0|916|996|1006
SE|25462362|METHODS|ab|4|entity|C0392276|Neodymium-YAG laser|medd|||Nd:YAG laser|||0|916|1007|1019

SE|25462362|METHODS|ab|5|text|1021|1132|The ions generated upon laser-cluster interaction were characterized using a time-of-flight mass spectrometer.
SE|25462362|METHODS|ab|5|entity|C0022023|Ions|elii|||ions|||0|1000|1025|1029
SE|25462362|METHODS|ab|5|entity|C0023089|Lasers|mnob|||laser|||0|802|1045|1050
SE|25462362|METHODS|ab|5|entity|C0040223|Time|tmco|||time|||0|1000|1098|1102
SE|25462362|METHODS|ab|5|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|867|1113|1130

SE|25462362|RESULTS|ab|6|text|1132|1396|RESULTS: At 355 nm, THF clusters exhibit the usual multiphoton dissociation/ionization behavior while, at 532 nm, observation of multiply charged atomic ions of carbon (up to [C](4+) ) and oxygen (up to [O](3+) ) was ascribed to Coulomb explosion of THF clusters.
SE|25462362|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1132|1139
SE|25462362|RESULTS|ab|6|entity|C0086168|Dissociation|mobd|||dissociation|||0|736|1195|1207
SE|25462362|RESULTS|ab|6|entity|C0596801|ionization|phpr|||ionization|||0|736|1208|1218
SE|25462362|RESULTS|ab|6|entity|C0004927|Behavior|inbe|||behavior|||0|736|1219|1227
SE|25462362|RESULTS|ab|6|entity|C0567415|Atom|elii|||atomic|||0|853|1278|1284
SE|25462362|RESULTS|ab|6|entity|C0022023|Ions|elii|||ions|||0|853|1285|1289
SE|25462362|RESULTS|ab|6|entity|C0007009|Carbon|elii|||carbon|||0|1000|1293|1299
SE|25462362|RESULTS|ab|6|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|1000|1321|1327
SE|25462362|RESULTS|ab|6|entity|C0562424|coulomb|qnco|||Coulomb|||0|888|1361|1368
SE|25462362|RESULTS|ab|6|entity|C0015329|Explosion|phpr|||explosion|||0|888|1369|1378

SE|25462362|RESULTS|ab|7|text|1396|1580|For studies carried out at 1064 nm, multiply charged atomic ions of carbon up to [C](5+) having an ionization energy of ~392 eV were observed, at a laser intensity of 10(10) W/cm(2) .
SE|25462362|RESULTS|ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|966|1400|1407
SE|25462362|RESULTS|ab|7|entity|C0439787|Out|spco|||out|||0|1000|1416|1419
SE|25462362|RESULTS|ab|7|entity|C0567415|Atom|elii|||atomic|||0|853|1449|1455
SE|25462362|RESULTS|ab|7|entity|C0022023|Ions|elii|||ions|||0|853|1456|1460
SE|25462362|RESULTS|ab|7|entity|C0007009|Carbon|elii|||carbon|||0|1000|1464|1470
SE|25462362|RESULTS|ab|7|entity|C0678602|ionization energy|npop|||ionization energy|||0|1000|1495|1512
SE|25462362|RESULTS|ab|7|entity|C0023089|Lasers|mnob|||laser|||0|694|1544|1549

SE|25462362|CONCLUSIONS|ab|8|text|1580|1738|CONCLUSIONS: The observation of [C](5+) atomic ions signifies efficient coupling of the laser energy with the cluster medium, using a nanosecond laser pulse.
SE|25462362|CONCLUSIONS|ab|8|entity|C0567415|Atom|elii|||atomic|||0|853|1620|1626
SE|25462362|CONCLUSIONS|ab|8|entity|C0022023|Ions|elii|||ions|||0|853|1627|1631
SE|25462362|CONCLUSIONS|ab|8|entity|C0442799|Efficient|qlco|||efficient|||0|694|1642|1651
SE|25462362|CONCLUSIONS|ab|8|entity|C0023089|Lasers|mnob|||laser|||0|888|1668|1673
SE|25462362|CONCLUSIONS|ab|8|entity|C0424589|Vitality|fndg|||energy|||0|888|1674|1680
SE|25462362|CONCLUSIONS|ab|8|entity|C0439536|Medium|qlco|||medium|||0|861|1698|1704
SE|25462362|CONCLUSIONS|ab|8|entity|C0439225|nanosecond|qnco|||nanosecond|||0|623|1714|1724
SE|25462362|CONCLUSIONS|ab|8|entity|C0023089|Lasers|mnob|||laser|||0|623|1725|1730

SE|25462362|CONCLUSIONS|ab|9|text|1738|2036|The results have been rationalized on the basis of a three-stage cluster ionization mechanism, suggesting the crucial role of the threshold laser intensity for initiating ionization within the cluster and generation of optimum charge centers for efficient extraction of energy from the laser pulse.
SE|25462362|CONCLUSIONS|ab|9|entity|C1274040|result|ftcn|||results|||0|966|1742|1749
SE|25462362|CONCLUSIONS|ab|9|entity|C1527178|Basis|ftcn|||basis|||0|1000|1780|1785
SE|25462362|CONCLUSIONS|ab|9|entity|C0205449|Three|qnco|||three|||0|757|1791|1796
SE|25462362|CONCLUSIONS|ab|9|entity|C1306673|Stage|qlco|||stage|||0|757|1797|1802
SE|25462362|CONCLUSIONS|ab|9|entity|C0596801|ionization|phpr|||ionization|||0|757|1811|1821
SE|25462362|CONCLUSIONS|ab|9|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|757|1822|1831
SE|25462362|CONCLUSIONS|ab|9|entity|C0035820|Role|socb|||role|||0|861|1856|1860
SE|25462362|CONCLUSIONS|ab|9|entity|C0449864|Threshold|ftcn|||threshold|||0|623|1868|1877
SE|25462362|CONCLUSIONS|ab|9|entity|C0023089|Lasers|mnob|||laser|||0|623|1878|1883
SE|25462362|CONCLUSIONS|ab|9|entity|C1548602|Initiate|idcn|||initiating|||0|872|1898|1908
SE|25462362|CONCLUSIONS|ab|9|entity|C0596801|ionization|phpr|||ionization|||0|872|1909|1919
SE|25462362|CONCLUSIONS|ab|9|entity|C0079411|Generations|tmco|||generation|||0|966|1943|1953
SE|25462362|CONCLUSIONS|ab|9|entity|C0205099|Central|spco|||centers|||0|793|1972|1979
SE|25462362|CONCLUSIONS|ab|9|entity|C0442799|Efficient|qlco|||efficient|||0|888|1984|1993
SE|25462362|CONCLUSIONS|ab|9|entity|C0185115|Extraction|topp|||extraction|||0|888|1994|2004
SE|25462362|CONCLUSIONS|ab|9|entity|C0424589|Vitality|fndg|||energy|||0|1000|2008|2014
SE|25462362|CONCLUSIONS|ab|9|entity|C0023089|Lasers|mnob|||laser|||0|694|2024|2029


SE|25462363||ti|1|text|21|274|Development of methodology for the determination of carbon isotope ratios using gas chromatography/combustion/isotope ratio mass spectrometry and applications in the biodegradation of phenolic brominated flame retardants and their degradation products.
SE|25462363||ti|1|entity|C1527148|Development|ftcn|||Development|||0|1000|21|32
SE|25462363||ti|1|entity|C0025664|Methodology|inpr|||methodology|||0|1000|36|47
SE|25462363||ti|1|entity|C0680730|Adjudication|gora|||determination|||0|1000|56|69
SE|25462363||ti|1|entity|C0007017|Carbon Isotopes|elii|||carbon isotope|||0|901|73|87
SE|25462363||ti|1|entity|C0456603|Ratio|inpr|||ratios|||0|901|88|94
SE|25462363||ti|1|entity|C0022262|Isotopes|elii|||isotope|||0|823|131|138
SE|25462363||ti|1|entity|C0456603|Ratio|inpr|||ratio|||0|823|139|144
SE|25462363||ti|1|entity|C0024868|Mass Fragmentography|lbpr|||gas chromatography/combustion/isotope ratio mass spectrometry|||0|823|101|162
SE|25462363||ti|1|entity|C0005482|Biodegradation|npop|||biodegradation|||0|1000|187|201
SE|25462363||ti|1|entity|C0359916|Phenolics|orch,phsu|||phenolic|||0|813|205|213
SE|25462363||ti|1|entity|C0016198|Flame Retardants|chvf|||flame retardants|||0|813|225|241
SE|25462363||ti|1|entity|C0243125|degradation|ftcn|||degradation|||0|872|252|263
SE|25462363||ti|1|entity|C1514468|product|qnco|||products|||0|872|264|272

SE|25462363|RATIONALE|ab|1|text|280|504|RATIONALE: Compound-specific stable carbon isotope analysis of phenolic brominated flame retardants (BFRs) and bisphenol A (BPA) has proven informative to discriminate their source and fate apportionment in the environment.
SE|25462363|RATIONALE|ab|1|entity|C0205198|Compound|qlco|||Compound|||0|781|291|299
SE|25462363|RATIONALE|ab|1|entity|C0007009|Carbon|elii|||carbon|||0|781|316|322
SE|25462363|RATIONALE|ab|1|entity|C0302918|Stable isotope|elii|||stable carbon isotope|||0|781|309|330
SE|25462363|RATIONALE|ab|1|entity|C0936012|Analysis|resa|||analysis|||0|781|331|339
SE|25462363|RATIONALE|ab|1|entity|C0359916|Phenolics|orch,phsu|||phenolic|||0|813|343|351
SE|25462363|RATIONALE|ab|1|entity|C0016198|Flame Retardants|chvf|||flame retardants|||0|813|363|379
SE|25462363|RATIONALE|ab|1|entity|C0053800|bisphenol A|hops,orch|||bisphenol A|||0|1000|391|402
SE|25462363|RATIONALE|ab|1|entity|C1302234|Fatal|qlco|||fate|||0|623|465|469
SE|25462363|RATIONALE|ab|1|entity|C0014406|Environment|spco|||environment|||0|1000|491|502

SE|25462363|RATIONALE|ab|2|text|504|783|However, because these compounds contain highly polar functional groups and exist as complex mixtures in environment matrices, derivatization is a necessary step, which adds additional non-analyte carbon atoms for analyses and may alter the original stable carbon isotope ratio.
SE|25462363|RATIONALE|ab|2|entity|C0205198|Compound|qlco|||compounds|||0|966|527|536
SE|25462363|RATIONALE|ab|2|entity|C0813983|polar|qnco|||polar|||0|813|552|557
SE|25462363|RATIONALE|ab|2|entity|C0598132|functional group|chvf|||functional groups|||0|813|558|575
SE|25462363|RATIONALE|ab|2|entity|C1258022|Complex Mixtures|chem|||complex mixtures|||0|1000|589|605
SE|25462363|RATIONALE|ab|2|entity|C0014406|Environment|spco|||environment|||0|872|609|620
SE|25462363|RATIONALE|ab|2|entity|C0331858|Matrix|hcro|||matrices|||0|872|621|629
SE|25462363|RATIONALE|ab|2|entity|C1261552|Step|ftcn|||step|||0|861|661|665
SE|25462363|RATIONALE|ab|2|entity|C1524062|Additional|ftcn|||additional|||0|766|678|688
SE|25462363|RATIONALE|ab|2|entity|C0443354|Analyte|chvf|||analyte|||0|766|693|700
SE|25462363|RATIONALE|ab|2|entity|C0007009|Carbon|elii|||carbon|||0|766|701|707
SE|25462363|RATIONALE|ab|2|entity|C0567415|Atom|elii|||atoms|||0|766|708|713
SE|25462363|RATIONALE|ab|2|entity|C0936012|Analysis|resa|||analyses|||0|966|718|726
SE|25462363|RATIONALE|ab|2|entity|C0205313|Original|idcn|||original|||0|840|745|753
SE|25462363|RATIONALE|ab|2|entity|C0007009|Carbon|elii|||carbon|||0|840|761|767
SE|25462363|RATIONALE|ab|2|entity|C0302918|Stable isotope|elii|||stable carbon isotope|||0|840|754|775
SE|25462363|RATIONALE|ab|2|entity|C0456603|Ratio|inpr|||ratio|||0|840|776|781

SE|25462363|RATIONALE|ab|3|text|783|957|It is, therefore, imperative to gain an insight into the relationship between the delta(13) C values of the BFRs and BPA derivatives and those of underivatized BFRs and BPA.
SE|25462363|RATIONALE|ab|3|entity|C0233820|Insight|menp|||insight|||0|1000|823|830
SE|25462363|RATIONALE|ab|3|entity|C0439849|Relationships|qlco|||relationship|||0|1000|840|852
SE|25462363|RATIONALE|ab|3|entity|C0042295|Values|qlco|||values|||0|861|877|883
SE|25462363|RATIONALE|ab|3|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|901|891|895
SE|25462363|RATIONALE|ab|3|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|901|900|903
SE|25462363|RATIONALE|ab|3|entity|C0243072|derivatives|chvs|||derivatives|||0|901|904|915
SE|25462363|RATIONALE|ab|3|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|861|943|947
SE|25462363|RATIONALE|ab|3|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|1000|952|955

SE|25462363|METHODS|ab|4|text|957|1159|METHODS: The delta(13) C values of BFRs and BPA N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) derivatives were measured by gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS).
SE|25462363|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|957|964
SE|25462363|METHODS|ab|4|entity|C0042295|Values|qlco|||values|||0|861|982|988
SE|25462363|METHODS|ab|4|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|901|992|996
SE|25462363|METHODS|ab|4|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|890|1001|1004
SE|25462363|METHODS|ab|4|entity|||gngm|9531|BAG3|bis|||0|694|1009|1012
SE|25462363|METHODS|ab|4|entity|C0077116|trifluoroacetamide|orch|||trifluoroacetamide|||0|1000|1028|1046
SE|25462363|METHODS|ab|4|entity|C0067333|N,N-bis(trimethylsilyl)-2,2,2-trifluoroacetamide|orch,phsu|||BSTFA|||0|1000|1048|1053
SE|25462363|METHODS|ab|4|entity|C0243072|derivatives|chvs|||derivatives|||0|1000|1055|1066
SE|25462363|METHODS|ab|4|entity|C0022262|Isotopes|elii|||isotope|||0|823|1114|1121
SE|25462363|METHODS|ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|823|1122|1127
SE|25462363|METHODS|ab|4|entity|C0024868|Mass Fragmentography|lbpr|||gas chromatography/combustion/isotope ratio mass spectrometry|||0|823|1084|1145
SE|25462363|METHODS|ab|4|relation|1|1|C0024868|Mass Fragmentography|lbpr|lbpr|||gas chromatography/combustion/isotope ratio mass spectrometry|||0|823|1084|1145|VERB|MEASURES||1072|1080|9|1|C0243072|derivatives|chvs|chvs|||derivatives|||0|1000|1055|1066

SE|25462363|METHODS|ab|5|text|1159|1331|The delta(13) C values of the BSTFA reagent and the standard underivatized BFRs and BPA were determined using elemental analyzer/isotope ratio mass spectrometry (EA/IRMS).
SE|25462363|METHODS|ab|5|entity|C0042295|Values|qlco|||values|||0|861|1175|1181
SE|25462363|METHODS|ab|5|entity|C0067333|N,N-bis(trimethylsilyl)-2,2,2-trifluoroacetamide|orch,phsu|||BSTFA|||0|888|1189|1194
SE|25462363|METHODS|ab|5|entity|C0034760|Reagents|irda|||reagent|||0|888|1195|1202
SE|25462363|METHODS|ab|5|entity|C1442989|STANDARD|ftcn|||standard|||0|812|1211|1219
SE|25462363|METHODS|ab|5|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|812|1234|1238
SE|25462363|METHODS|ab|5|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|1000|1243|1246
SE|25462363|METHODS|ab|5|entity|C0013879|Elements|elii|||elemental|||0|812|1269|1278
SE|25462363|METHODS|ab|5|entity|C0179038|Analyzer|medd|||analyzer|||0|812|1279|1287
SE|25462363|METHODS|ab|5|entity|C0022262|Isotopes|elii|||isotope|||0|812|1288|1295
SE|25462363|METHODS|ab|5|entity|C0456603|Ratio|inpr|||ratio|||0|812|1296|1301
SE|25462363|METHODS|ab|5|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|812|1302|1319
SE|25462363|METHODS|ab|5|relation|2|1|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||mass spectrometry|||0|812|1302|1319|VERB|MEASURES||1252|1262|4|2|C0034760|Reagents|irda|irda|||reagent|||0|888|1195|1202

SE|25462363|METHODS|ab|6|text|1331|1468|The experimentally obtained delta(13) C values for BFRs and BPA derivatives were then compared with the theoretically calculated values.
SE|25462363|METHODS|ab|6|entity|C1301820|Obtained|ftcn|||obtained|||0|660|1350|1358
SE|25462363|METHODS|ab|6|entity|C0042295|Values|qlco|||values|||0|861|1371|1377
SE|25462363|METHODS|ab|6|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|901|1382|1386
SE|25462363|METHODS|ab|6|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|901|1391|1394
SE|25462363|METHODS|ab|6|entity|C0243072|derivatives|chvs|||derivatives|||0|901|1395|1406
SE|25462363|METHODS|ab|6|entity|C0042295|Values|qlco|||values|||0|827|1460|1466

SE|25462363|RESULTS|ab|7|text|1468|1749|RESULTS: The derivatization process introduces no isotopic fractionation for BFRs and BPA (the average difference between the theoretically calculated and experimentally obtained delta(13) C values was 0.06 +/- 0.150/00, within the precision limits of the GC/C/IRMS measurements).
SE|25462363|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1468|1475
SE|25462363|RESULTS|ab|7|entity|C1522240|Process|phpr|||process|||0|861|1496|1503
SE|25462363|RESULTS|ab|7|entity|C0022262|Isotopes|elii|||isotopic|||0|853|1518|1526
SE|25462363|RESULTS|ab|7|entity|C0016640|Fractionation|lbpr|||fractionation|||0|853|1527|1540
SE|25462363|RESULTS|ab|7|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|901|1545|1549
SE|25462363|RESULTS|ab|7|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|1000|1554|1557
SE|25462363|RESULTS|ab|7|entity|C1510992|Average|qnco|||average|||0|888|1563|1570
SE|25462363|RESULTS|ab|7|entity|C1547020|*Difference|qnco|||difference|||0|888|1571|1581
SE|25462363|RESULTS|ab|7|entity|C1301820|Obtained|ftcn|||obtained|||0|660|1638|1646
SE|25462363|RESULTS|ab|7|entity|C0042295|Values|qlco|||values|||0|861|1659|1665
SE|25462363|RESULTS|ab|7|entity|C0022262|Isotopes|elii|||GC/C/IRMS|||0|803|1724|1733
SE|25462363|RESULTS|ab|7|entity|C0456603|Ratio|inpr|||GC/C/IRMS|||0|803|1724|1733
SE|25462363|RESULTS|ab|7|entity|C0024868|Mass Fragmentography|lbpr|||GC/C/IRMS|||0|803|1724|1733
SE|25462363|RESULTS|ab|7|entity|C0242485|Measurement|ftcn|||measurements|||0|803|1734|1746
SE|25462363|RESULTS|ab|7|relation|0|0|C0016640|Fractionation|lbpr|lbpr|||fractionation|||0|853|1527|1540|MOD/HEAD|USES||1518|1540|0|0|C0022262|Isotopes|elii|elii|||isotopic|||0|853|1518|1526

SE|25462363|RESULTS|ab|8|text|1749|1874|Therefore, the delta(13) C values for the original underivatized BFRs and BPA were computed through a mass balance equation.
SE|25462363|RESULTS|ab|8|entity|C0042295|Values|qlco|||values|||0|861|1776|1782
SE|25462363|RESULTS|ab|8|entity|C0205313|Original|idcn|||original|||0|812|1791|1799
SE|25462363|RESULTS|ab|8|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|812|1814|1818
SE|25462363|RESULTS|ab|8|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|1000|1823|1826
SE|25462363|RESULTS|ab|8|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|851|1851|1855
SE|25462363|RESULTS|ab|8|entity|C0014653|Equilibrium|orgf|||balance|||0|851|1856|1863
SE|25462363|RESULTS|ab|8|entity|C0552449|Equation|cnce|||equation|||0|851|1864|1872

SE|25462363|CONCLUSIONS|ab|9|text|1874|2127|CONCLUSIONS: This work offers a novel tool to research the biotic or abiotic transformation processes of BFRs and BPA in the environment and will offer a perspective for the identification of the environmental source and fate of these organic compounds.
SE|25462363|CONCLUSIONS|ab|9|entity|C0043227|Work|ocac|||work|||0|1000|1892|1896
SE|25462363|CONCLUSIONS|ab|9|entity|C0679622|novel|inpr|||novel|||0|888|1906|1911
SE|25462363|CONCLUSIONS|ab|9|entity|C0336791|Tool|mnob|||tool|||0|888|1912|1916
SE|25462363|CONCLUSIONS|ab|9|entity|C1522240|Process|phpr|||processes|||0|793|1966|1975
SE|25462363|CONCLUSIONS|ab|9|entity|C0016198|Flame Retardants|chvf|||BFRs|||0|901|1979|1983
SE|25462363|CONCLUSIONS|ab|9|entity|C0053800|bisphenol A|hops,orch|||BPA|||0|1000|1988|1991
SE|25462363|CONCLUSIONS|ab|9|entity|C0014406|Environment|spco|||environment|||0|1000|1999|2010
SE|25462363|CONCLUSIONS|ab|9|entity|C1302234|Fatal|qlco|||fate|||0|928|2095|2099
SE|25462363|CONCLUSIONS|ab|9|entity|C0029224|Organic Chemicals|orch|||organic compounds|||0|1000|2109|2126


SE|25462364||ti|1|text|21|82|Urine analysis concerning xenon for doping control purposes.
SE|25462364||ti|1|entity|C0042014|Urinalysis|lbpr|||Urine analysis|||0|824|21|35
SE|25462364||ti|1|entity|C0043339|Xenon|elii,phsu|||xenon|||0|824|47|52
SE|25462364||ti|1|entity|C0243148|control|ftcn|||control|||0|773|64|71
SE|25462364||ti|1|entity|C1285529|Purpose|ftcn|||purposes|||0|773|72|80

SE|25462364|RATIONALE|ab|1|text|88|317|RATIONALE: On September 1(st) 2014, a modified Prohibited List as established by the World Anti-Doping Agency (WADA) became effective featuring xenon as a banned substance categorized as hypoxia-inducible factor (HIF) activator.
SE|25462364|RATIONALE|ab|1|entity|C1300072|Tumor stage|clna|||st|||0|861|114|116
SE|25462364|RATIONALE|ab|1|entity|C0205349|Altered|ftcn|||modified|||0|840|126|134
SE|25462364|RATIONALE|ab|1|entity|C0138547|Prohibit|carb,imft,phsu|||Prohibited|||0|840|135|145
SE|25462364|RATIONALE|ab|1|entity|C0745732|LIST|cnce|||List|||0|840|146|150
SE|25462364|RATIONALE|ab|1|entity|C0237463|Agencies|orgt|||Agency|||0|779|191|197
SE|25462364|RATIONALE|ab|1|entity|C0043339|Xenon|elii,phsu|||xenon|||0|802|232|237
SE|25462364|RATIONALE|ab|1|entity|C0105185|BANS|orch,phsu|||banned|||0|872|243|249
SE|25462364|RATIONALE|ab|1|entity|C0439861|Substance|sbst|||substance|||0|872|250|259
SE|25462364|RATIONALE|ab|1|entity|C0242184|Hypoxia|patf|||hypoxia|||0|597|275|282
SE|25462364|RATIONALE|ab|1|entity|C1521761|Factor|ftcn|||factor|||0|597|293|299

SE|25462364|RATIONALE|ab|2|text|317|555|Consequently, the analysis of xenon from commonly provided doping control specimens such as blood and urine is desirable, and first data on the determination of xenon from urine in the context of human sports drug testing, are presented.
SE|25462364|RATIONALE|ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|335|343
SE|25462364|RATIONALE|ab|2|entity|C0043339|Xenon|elii,phsu|||xenon|||0|1000|347|352
SE|25462364|RATIONALE|ab|2|entity|C1550040|Control specimen|idcn|||control specimens|||0|767|383|400
SE|25462364|RATIONALE|ab|2|entity|C0005767|Blood|tisu|||blood|||0|1000|409|414
SE|25462364|RATIONALE|ab|2|entity|C0042036|Urine|bdsu|||urine|||0|1000|419|424
SE|25462364|RATIONALE|ab|2|entity|C1279901|Firstly|qlco|||first|||0|888|443|448
SE|25462364|RATIONALE|ab|2|entity|C1511726|Data|idcn|||data|||0|888|449|453
SE|25462364|RATIONALE|ab|2|entity|C0680730|Adjudication|gora|||determination|||0|1000|461|474
SE|25462364|RATIONALE|ab|2|entity|C0043339|Xenon|elii,phsu|||xenon|||0|1000|478|483
SE|25462364|RATIONALE|ab|2|entity|C0042036|Urine|bdsu|||urine|||0|1000|489|494
SE|25462364|RATIONALE|ab|2|entity|C0020114|Human|humn|||human|||0|861|513|518
SE|25462364|RATIONALE|ab|2|entity|C0038039|Sports|dora|||sports|||0|861|519|525
SE|25462364|RATIONALE|ab|2|entity|C0038577|Substance Abuse Detection|lbpr|||drug testing|||0|861|526|538

SE|25462364|METHODS|ab|3|text|555|904|METHODS: In accordance to earlier studies utilizing plasma as doping control matrix, urine was enriched to saturation with xenon, sequentially diluted, and the target analyte was detected as supported by the internal standard d6 -cyclohexanone by means of gas chromatography/triple quadrupole mass spectrometry (GC/MS/MS) using headspace injection.
SE|25462364|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|555|562
SE|25462364|METHODS|ab|3|entity|C1279919|Early|tmco|||earlier|||0|716|581|588
SE|25462364|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|716|589|596
SE|25462364|METHODS|ab|3|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|607|613
SE|25462364|METHODS|ab|3|entity|C0243148|control|ftcn|||control|||0|790|624|631
SE|25462364|METHODS|ab|3|entity|C0331858|Matrix|hcro|||matrix|||0|790|632|638
SE|25462364|METHODS|ab|3|entity|C0042036|Urine|bdsu|||urine|||0|1000|640|645
SE|25462364|METHODS|ab|3|entity|C0678572|saturation|npop|||saturation|||0|1000|662|672
SE|25462364|METHODS|ab|3|entity|C0043339|Xenon|elii,phsu|||xenon|||0|1000|678|683
SE|25462364|METHODS|ab|3|entity|C0443354|Analyte|chvf|||analyte|||0|888|722|729
SE|25462364|METHODS|ab|3|entity|C0205102|Intrinsic|spco|||internal|||0|833|763|771
SE|25462364|METHODS|ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|833|772|780
SE|25462364|METHODS|ab|3|entity|C0056760|cyclohexanone|orch|||cyclohexanone|||0|833|785|798
SE|25462364|METHODS|ab|3|entity|C0205174|Triplicate|qnco|||triple|||0|857|830|836
SE|25462364|METHODS|ab|3|entity|C0024868|Mass Fragmentography|lbpr|||gas chromatography/triple quadrupole mass spectrometry|||0|857|811|865
SE|25462364|METHODS|ab|3|entity|C0024868|Mass Fragmentography|lbpr|||GC/MS|||0|734|867|872
SE|25462364|METHODS|ab|3|entity|C1533685|Injection procedure|topp|||injection|||0|861|893|902

SE|25462364|METHODS|ab|4|text|904|1090|Three major xenon isotopes at m/z 128.9, 130.9 and 131.9 were targeted in (pseudo) selected reaction monitoring mode enabling the unambiguous identification of the prohibited substance.
SE|25462364|METHODS|ab|4|entity|C0205449|Three|qnco|||Three|||0|861|904|909
SE|25462364|METHODS|ab|4|entity|C0205164|Major|qlco|||major|||0|861|910|915
SE|25462364|METHODS|ab|4|entity|C0043340|Xenon Isotopes|elii|||xenon isotopes|||0|861|916|930
SE|25462364|METHODS|ab|4|entity|C0205237|False|qlco|||pseudo|||0|1000|979|985
SE|25462364|METHODS|ab|4|entity|C0443286|Reaction|ftcn|||reaction|||0|764|996|1004
SE|25462364|METHODS|ab|4|entity|C1513371|Mode|ftcn|||mode|||0|764|1016|1020
SE|25462364|METHODS|ab|4|entity|C0138547|Prohibit|carb,imft,phsu|||prohibited|||0|872|1068|1078
SE|25462364|METHODS|ab|4|entity|C0439861|Substance|sbst|||substance|||0|872|1079|1088

SE|25462364|METHODS|ab|5|text|1090|1273|Assay characteristics including limit of detection (LOD), intraday/interday precision, and specificity as well as analyte recovery under different storage conditions were determined.
SE|25462364|METHODS|ab|5|entity|C1510438|Assay|lbpr|||Assay|||0|888|1090|1095
SE|25462364|METHODS|ab|5|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|1096|1111
SE|25462364|METHODS|ab|5|entity|C1549649|Limit|idcn|||limit|||0|802|1122|1127
SE|25462364|METHODS|ab|5|entity|C1511790|Detection|topp|||detection|||0|802|1131|1140
SE|25462364|METHODS|ab|5|entity|C0037791|Specificity|qnco|||specificity|||0|1000|1181|1192
SE|25462364|METHODS|ab|5|entity|C0443354|Analyte|chvf|||analyte|||0|888|1204|1211
SE|25462364|METHODS|ab|5|entity|C0237820|Recovery|orgf|||recovery|||0|888|1212|1220
SE|25462364|METHODS|ab|5|entity|C1547020|*Difference|qnco|||different|||0|816|1227|1236
SE|25462364|METHODS|ab|5|entity|C0348080|Condition|qlco|||conditions|||0|816|1245|1255

SE|25462364|METHODS|ab|6|text|1273|1461|Proof-of-concept data were generated by applying the established method to urine samples collected from five patients before, during and after (up to 48 h) xenon-based general anesthesia.
SE|25462364|METHODS|ab|6|entity|C0556981|% proof|qnco|||Proof|||0|1000|1273|1278
SE|25462364|METHODS|ab|6|entity|C0178566|concept|idcn|||concept|||0|888|1282|1289
SE|25462364|METHODS|ab|6|entity|C1511726|Data|idcn|||data|||0|888|1290|1294
SE|25462364|METHODS|ab|6|entity|C0443211|Established|qlco|||established|||0|888|1326|1337
SE|25462364|METHODS|ab|6|entity|C0025663|Methods|inpr|||method|||0|888|1338|1344
SE|25462364|METHODS|ab|6|entity|C0444180|Urine specimen|bdsu|||urine samples|||0|983|1348|1361
SE|25462364|METHODS|ab|6|entity|C0205451|Five|qnco|||five|||0|790|1377|1381
SE|25462364|METHODS|ab|6|entity|C0030705|Patients|podg|||patients|||0|790|1382|1390
SE|25462364|METHODS|ab|6|entity|C0043339|Xenon|elii,phsu|||xenon|||0|852|1429|1434
SE|25462364|METHODS|ab|6|entity|C0002915|General Anesthesia|topp|||general anesthesia|||0|852|1441|1459
SE|25462364|METHODS|ab|6|relation|7|0|C0002915|General Anesthesia|topp|topp|||general anesthesia|||0|852|1441|1459|ADJ|USES||1435|1440|7|0|C0043339|Xenon|elii,phsu|phsu|||xenon|||0|852|1429|1434

SE|25462364|RESULTS|ab|7|text|1461|1580|RESULTS: Xenon was traceable in enriched human urine samples down to the detection limit of approximately 0.5 nmol/mL.
SE|25462364|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1461|1468
SE|25462364|RESULTS|ab|7|entity|C0043339|Xenon|elii,phsu|||Xenon|||0|1000|1470|1475
SE|25462364|RESULTS|ab|7|entity|C0359583|Enrich|food|||enriched|||0|844|1493|1501
SE|25462364|RESULTS|ab|7|entity|C0020114|Human|humn|||human|||0|844|1502|1507
SE|25462364|RESULTS|ab|7|entity|C0444180|Urine specimen|bdsu|||urine samples|||0|844|1508|1521
SE|25462364|RESULTS|ab|7|entity|C1511790|Detection|topp|||detection|||0|888|1534|1543
SE|25462364|RESULTS|ab|7|entity|C1549649|Limit|idcn|||limit|||0|888|1544|1549
SE|25462364|RESULTS|ab|7|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|857|1553|1566
SE|25462364|RESULTS|ab|7|entity|C0444499|0/5|qnco|||0.5|||0|857|1567|1570
SE|25462364|RESULTS|ab|7|entity|C1532049|nmol/mL|qnco|||nmol/mL|||0|857|1571|1578
SE|25462364|RESULTS|ab|7|relation|0|0|C0444180|Urine specimen|bdsu|bdsu|||urine samples|||0|844|1508|1521|MOD/HEAD|PART_OF||1502|1521|0|0|C0020114|Human|grup,humn|humn|||human|||0|844|1502|1507

SE|25462364|RESULTS|ab|8|text|1580|1891|The intraday and interday imprecision values of the method were found below 25%, and specificity was demonstrated by analyzing 20 different blank urine samples that corroborated the fitness-for-purpose of the analytical approach to unequivocally detect xenon at non-physiological concentrations in human urine.
SE|25462364|RESULTS|ab|8|entity|C0042295|Values|qlco|||values|||0|827|1618|1624
SE|25462364|RESULTS|ab|8|entity|C0025663|Methods|inpr|||method|||0|1000|1632|1638
SE|25462364|RESULTS|ab|8|entity|C0542339|Inferior|spco|||below|||0|861|1650|1655
SE|25462364|RESULTS|ab|8|entity|C0037791|Specificity|qnco|||specificity|||0|1000|1665|1676
SE|25462364|RESULTS|ab|8|entity|C1515960|Analyzed|qlco|||analyzing|||0|753|1697|1706
SE|25462364|RESULTS|ab|8|entity|C1547020|*Difference|qnco|||different|||0|753|1710|1719
SE|25462364|RESULTS|ab|8|entity|C0750479|blank|fndg|||blank|||0|753|1720|1725
SE|25462364|RESULTS|ab|8|entity|C0444180|Urine specimen|bdsu|||urine samples|||0|753|1726|1739
SE|25462364|RESULTS|ab|8|entity|C1456706|Fitness|dora|||fitness|||0|1000|1762|1769
SE|25462364|RESULTS|ab|8|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|1774|1781
SE|25462364|RESULTS|ab|8|entity|C0449445|Approach|spco|||approach|||0|827|1800|1808
SE|25462364|RESULTS|ab|8|entity|C0043339|Xenon|elii,phsu|||xenon|||0|1000|1833|1838
SE|25462364|RESULTS|ab|8|entity|C0205463|Physiological|ftcn|||physiological|||0|790|1846|1859
SE|25462364|RESULTS|ab|8|entity|C0020114|Human|humn|||human|||0|888|1878|1883
SE|25462364|RESULTS|ab|8|entity|C0042036|Urine|bdsu|||urine|||0|888|1884|1889
SE|25462364|RESULTS|ab|8|relation|0|0|C0042036|Urine|bdsu|bdsu|||urine|||0|888|1884|1889|MOD/HEAD|PART_OF||1878|1889|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|1878|1883

SE|25462364|RESULTS|ab|9|text|1891|2059|The patients' urine specimens returned 'xenon-positive' test results up to 40 h post-anesthesia, indicating the limits of the expected doping control detection window.
SE|25462364|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|890|1895|1903
SE|25462364|RESULTS|ab|9|entity|C0444180|Urine specimen|bdsu|||urine specimens|||0|890|1905|1920
SE|25462364|RESULTS|ab|9|entity|C0043339|Xenon|elii,phsu|||xenon|||0|908|1931|1936
SE|25462364|RESULTS|ab|9|entity|C1335447|Positive Test Result|fndg|||positive' test results|||0|908|1937|1959
SE|25462364|RESULTS|ab|9|entity|C0002903|Anesthesia procedures|topp|||anesthesia|||0|888|1976|1986
SE|25462364|RESULTS|ab|9|entity|C1549649|Limit|idcn|||limits|||0|966|2003|2009
SE|25462364|RESULTS|ab|9|entity|C1517001|Expected|idcn|||expected|||0|766|2017|2025
SE|25462364|RESULTS|ab|9|entity|C0243148|control|ftcn|||control|||0|766|2033|2040
SE|25462364|RESULTS|ab|9|entity|C1511790|Detection|topp|||detection|||0|766|2041|2050
SE|25462364|RESULTS|ab|9|entity|C0557702|Window|mnob|||window|||0|766|2051|2057

SE|25462364|CONCLUSIONS|ab|10|text|2059|2256|CONCLUSIONS: Since xenon has been considered a prohibited substance according to WADA regulations in September 2014, its analysis from common specimens of routine sports drug testing is desirable.
SE|25462364|CONCLUSIONS|ab|10|entity|C0043339|Xenon|elii,phsu|||xenon|||0|1000|2078|2083
SE|25462364|CONCLUSIONS|ab|10|entity|C0138547|Prohibit|carb,imft,phsu|||prohibited|||0|872|2106|2116
SE|25462364|CONCLUSIONS|ab|10|entity|C0439861|Substance|sbst|||substance|||0|872|2117|2126
SE|25462364|CONCLUSIONS|ab|10|entity|C0237463|Agencies|orgt|||WADA|||0|712|2140|2144
SE|25462364|CONCLUSIONS|ab|10|entity|C0220905|regulatory|rnlw|||regulations|||0|712|2145|2156
SE|25462364|CONCLUSIONS|ab|10|entity|C0936012|Analysis|resa|||analysis|||0|1000|2180|2188
SE|25462364|CONCLUSIONS|ab|10|entity|C0205214|Common|qnco|||common|||0|872|2194|2200
SE|25462364|CONCLUSIONS|ab|10|entity|C0370003|Specimen|sbst|||specimens|||0|872|2201|2210
SE|25462364|CONCLUSIONS|ab|10|entity|C0205547|Routine|qlco|||routine|||0|861|2214|2221
SE|25462364|CONCLUSIONS|ab|10|entity|C0038039|Sports|dora|||sports|||0|861|2222|2228
SE|25462364|CONCLUSIONS|ab|10|entity|C0038577|Substance Abuse Detection|lbpr|||drug testing|||0|861|2229|2241

SE|25462364|CONCLUSIONS|ab|11|text|2256|2454|In previous studies, its traceability in whole blood and plasma was shown, and herein a complementary approach utilizing doping control urine samples for the GC/MS/MS analysis of xenon was reported.
SE|25462364|CONCLUSIONS|ab|11|entity|C0205156|Previous|tmco|||previous|||0|872|2259|2267
SE|25462364|CONCLUSIONS|ab|11|entity|C0008972|Clinical Research|resa|||studies|||0|872|2268|2275
SE|25462364|CONCLUSIONS|ab|11|entity|C0370231|whole blood|bdsu|||whole blood|||0|1000|2297|2308
SE|25462364|CONCLUSIONS|ab|11|entity|C0032105|Plasma|bdsu|||plasma|||0|1000|2313|2319
SE|25462364|CONCLUSIONS|ab|11|entity|C0449445|Approach|spco|||approach|||0|737|2358|2366
SE|25462364|CONCLUSIONS|ab|11|entity|C0243148|control|ftcn|||control|||0|737|2384|2391
SE|25462364|CONCLUSIONS|ab|11|entity|C0444180|Urine specimen|bdsu|||urine samples|||0|737|2392|2405
SE|25462364|CONCLUSIONS|ab|11|entity|C0024868|Mass Fragmentography|lbpr|||GC/MS|||0|824|2414|2419
SE|25462364|CONCLUSIONS|ab|11|entity|C0936012|Analysis|resa|||analysis|||0|824|2423|2431
SE|25462364|CONCLUSIONS|ab|11|entity|C0043339|Xenon|elii,phsu|||xenon|||0|1000|2435|2440


SE|25462365||ti|1|text|21|135|Remote laser ablation electrospray ionization mass spectrometry for non-proximate analysis of biological tissues.
SE|25462365||ti|1|entity|C0205157|Remote|spco|||Remote|||0|873|21|27
SE|25462365||ti|1|entity|C0348007|Laser ablation|ftcn|||laser ablation|||0|873|28|42
SE|25462365||ti|1|entity|C0596495|Spectrometry, Mass, Electrospray Ionization|lbpr|||electrospray ionization mass spectrometry|||0|873|43|84
SE|25462365||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|827|103|111
SE|25462365||ti|1|entity|C0457457|Biological tissue|tisu|||biological tissues|||0|983|115|133

SE|25462365|RATIONALE|ab|1|text|141|271|RATIONALE: We introduce remote laser ablation electrospray ionization (LAESI), a novel, non-proximate ambient sampling technique.
SE|25462365|RATIONALE|ab|1|entity|C0205157|Remote|spco|||remote|||0|857|165|171
SE|25462365|RATIONALE|ab|1|entity|C0348007|Laser ablation|ftcn|||laser ablation|||0|857|172|186
SE|25462365|RATIONALE|ab|1|entity|C1516801|Electrospray Ionization|lbpr|||electrospray ionization|||0|857|187|210
SE|25462365|RATIONALE|ab|1|entity|C0679622|novel|inpr|||novel|||0|756|222|227
SE|25462365|RATIONALE|ab|1|entity|C0870078|Sampling|idcn|||sampling|||0|756|251|259
SE|25462365|RATIONALE|ab|1|entity|C0449851|Techniques|ftcn|||technique|||0|756|260|269

SE|25462365|RATIONALE|ab|2|text|271|372|Remote LAESI allows additional analytical instrumentation to be incorporated during sample analysis.
SE|25462365|RATIONALE|ab|2|entity|C0205157|Remote|spco|||Remote|||0|857|271|277
SE|25462365|RATIONALE|ab|2|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|857|278|283
SE|25462365|RATIONALE|ab|2|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|857|278|283
SE|25462365|RATIONALE|ab|2|entity|C1524062|Additional|ftcn|||additional|||0|802|291|301
SE|25462365|RATIONALE|ab|2|entity|C0021632|instrumentation|qnco|||instrumentation|||0|802|313|328
SE|25462365|RATIONALE|ab|2|entity|C1303103|Sample analysis|lbpr|||sample analysis|||0|1000|355|370

SE|25462365|RATIONALE|ab|3|text|372|532|This work demonstrates the utility of remote LAESI and, when combined with optical microscopy, allows for the microscopy-guided sampling of biological tissues.
SE|25462365|RATIONALE|ab|3|entity|C0043227|Work|ocac|||work|||0|1000|377|381
SE|25462365|RATIONALE|ab|3|entity|C0205157|Remote|spco|||remote|||0|857|410|416
SE|25462365|RATIONALE|ab|3|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|857|417|422
SE|25462365|RATIONALE|ab|3|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|857|417|422
SE|25462365|RATIONALE|ab|3|entity|C0042789|Vision|orgf|||optical|||0|861|447|454
SE|25462365|RATIONALE|ab|3|entity|C0026018|Microscopy|lbpr|||microscopy|||0|861|455|465
SE|25462365|RATIONALE|ab|3|entity|C0026018|Microscopy|lbpr|||microscopy|||0|840|482|492
SE|25462365|RATIONALE|ab|3|entity|C0181090|Professional guide|prog|||guided|||0|840|493|499
SE|25462365|RATIONALE|ab|3|entity|C0870078|Sampling|idcn|||sampling|||0|840|500|508
SE|25462365|RATIONALE|ab|3|entity|C0457457|Biological tissue|tisu|||biological tissues|||0|983|512|530

SE|25462365|METHODS|ab|4|text|532|638|METHODS: Rapid prototyping using a 3D printer was applied to produce various ablation chamber geometries.
SE|25462365|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|532|539
SE|25462365|METHODS|ab|4|entity|C0439831|Rapid|qlco|||Rapid|||0|694|541|546
SE|25462365|METHODS|ab|4|entity|C0547070|Ablation|topp|||ablation|||0|764|609|617
SE|25462365|METHODS|ab|4|entity|C0935616|Chamber|bpoc|||chamber|||0|764|618|625
SE|25462365|METHODS|ab|4|entity|C0449829|Geometry|spco|||geometries|||0|764|626|636

SE|25462365|METHODS|ab|5|text|638|766|A focused 5 ns, 2.94 um laser pulse kept at 10 Hz ablated the sample within the chamber, remote to the mass spectrometer inlet.
SE|25462365|METHODS|ab|5|entity|C0000936|Visual Accommodation|clna|||focused|||0|785|640|647
SE|25462365|METHODS|ab|5|entity|C0023089|Lasers|mnob|||laser|||0|637|662|667
SE|25462365|METHODS|ab|5|entity|C0935616|Chamber|bpoc|||chamber|||0|1000|718|725
SE|25462365|METHODS|ab|5|entity|C0205157|Remote|spco|||remote|||0|1000|727|733
SE|25462365|METHODS|ab|5|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|701|741|758

SE|25462365|METHODS|ab|6|text|766|884|Ablated particulates were carried through a transfer tube by N2 gas, delivered to the electrospray plume and ionized.
SE|25462365|METHODS|ab|6|entity|C0849355|Removes|topp|||Ablated|||0|853|766|773
SE|25462365|METHODS|ab|6|entity|C0457784|Particulate|qlco|||particulates|||0|853|774|786
SE|25462365|METHODS|ab|6|entity|C0184161|Tubes, Transfer|medd|||transfer tube|||0|983|810|823
SE|25462365|METHODS|ab|6|entity|C0017110|Gases|chvs|||gas|||0|861|830|833

SE|25462365|METHODS|ab|7|text|884|984|A long-distance microscope was used to capture images of tissues before, during and after ablation.
SE|25462365|METHODS|ab|7|entity|C0205166|Long|qlco|||long|||0|851|886|890
SE|25462365|METHODS|ab|7|entity|C0012751|Distance|qnco|||distance|||0|851|891|899
SE|25462365|METHODS|ab|7|entity|C0181839|Microscope|medd|||microscope|||0|851|900|910
SE|25462365|METHODS|ab|7|entity|C0025086|Medical Imaging|diap|||images|||0|966|931|937
SE|25462365|METHODS|ab|7|entity|C0040300|Body tissue|tisu|||tissues|||0|861|941|948
SE|25462365|METHODS|ab|7|entity|C0547070|Ablation|topp|||ablation|||0|1000|974|982
SE|25462365|METHODS|ab|7|relation|1|1|C0547070|Ablation|topp|topp|||ablation|||0|1000|974|982|PREP|PRECEDES||968|973|3|2|C0025086|Medical Imaging|diap|diap|||images|||0|966|931|937
SE|25462365|METHODS|ab|7|relation|2|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|861|941|948|PREP|LOCATION_OF||938|940|2|1|C0025086|Medical Imaging|diap|diap|||images|||0|966|931|937

SE|25462365|RESULTS|ab|8|text|984|1129|RESULTS: Optimized remote LAESI was found to have a 27% transport efficiency compared with conventional LAESI, sufficient for many applications.
SE|25462365|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|984|991
SE|25462365|RESULTS|ab|8|entity|C0205157|Remote|spco|||remote|||0|805|1003|1009
SE|25462365|RESULTS|ab|8|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|805|1010|1015
SE|25462365|RESULTS|ab|8|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|805|1010|1015
SE|25462365|RESULTS|ab|8|entity|C0013682|Efficiency|qnco|||efficiency|||0|827|1050|1060
SE|25462365|RESULTS|ab|8|entity|C0439858|Conventional|qlco|||conventional|||0|857|1075|1087
SE|25462365|RESULTS|ab|8|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|857|1088|1093
SE|25462365|RESULTS|ab|8|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|857|1088|1093
SE|25462365|RESULTS|ab|8|entity|C0205410|Sufficient|qlco|||sufficient|||0|1000|1095|1105

SE|25462365|RESULTS|ab|9|text|1129|1226|A comparable molecular coverage was obtained with remote LAESI for the analysis of plant tissue.
SE|25462365|RESULTS|ab|9|entity|C1521991|Molecular|qlco|||molecular|||0|790|1142|1151
SE|25462365|RESULTS|ab|9|entity|C1551362|coverage|idcn|||coverage|||0|790|1152|1160
SE|25462365|RESULTS|ab|9|entity|C0205157|Remote|spco|||remote|||0|857|1179|1185
SE|25462365|RESULTS|ab|9|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|857|1186|1191
SE|25462365|RESULTS|ab|9|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|857|1186|1191
SE|25462365|RESULTS|ab|9|entity|C0936012|Analysis|resa|||analysis|||0|1000|1200|1208
SE|25462365|RESULTS|ab|9|entity|C0032098|Plants|plnt|||plant|||0|694|1212|1217

SE|25462365|RESULTS|ab|10|text|1226|1492|Proof-of-principle experiments using a pansy flower and a maple leaf indicated the functionality of this approach for selecting domains of interest for analysis by optical microscopy and obtaining chemical information from those selected regions by remote LAESI-MS.
SE|25462365|RESULTS|ab|10|entity|C0556981|% proof|qnco|||Proof|||0|1000|1226|1231
SE|25462365|RESULTS|ab|10|entity|C0681814|research study|resa|||experiments|||0|861|1245|1256
SE|25462365|RESULTS|ab|10|entity|C0330463|Viola|plnt|||pansy|||0|888|1265|1270
SE|25462365|RESULTS|ab|10|entity|C0330090|Flowers|plnt|||flower|||0|888|1271|1277
SE|25462365|RESULTS|ab|10|entity|C0330996|Acer|plnt|||maple|||0|888|1284|1289
SE|25462365|RESULTS|ab|10|entity|C0242724|Plant Leaves|plnt|||leaf|||0|888|1290|1294
SE|25462365|RESULTS|ab|10|entity|C0205245|Functional|ftcn|||functionality|||0|928|1309|1322
SE|25462365|RESULTS|ab|10|entity|C0449445|Approach|spco|||approach|||0|1000|1331|1339
SE|25462365|RESULTS|ab|10|entity|C1519229|Selenium and Vitamin E Efficacy Trial|resa|||selecting|||0|661|1344|1353
SE|25462365|RESULTS|ab|10|entity|C0543488|Interested|menp|||interest|||0|1000|1365|1373
SE|25462365|RESULTS|ab|10|entity|C0936012|Analysis|resa|||analysis|||0|1000|1378|1386
SE|25462365|RESULTS|ab|10|entity|C0042789|Vision|orgf|||optical|||0|861|1390|1397
SE|25462365|RESULTS|ab|10|entity|C0026018|Microscopy|lbpr|||microscopy|||0|861|1398|1408
SE|25462365|RESULTS|ab|10|entity|C1301820|Obtained|ftcn|||obtaining|||0|840|1413|1422
SE|25462365|RESULTS|ab|10|entity|C0220806|Chemicals|chem|||chemical|||0|840|1423|1431
SE|25462365|RESULTS|ab|10|entity|C1533716|Information|idcn|||information|||0|840|1432|1443
SE|25462365|RESULTS|ab|10|entity|C0205147|Region|spco|||regions|||0|855|1464|1471
SE|25462365|RESULTS|ab|10|entity|C0205157|Remote|spco|||remote|||0|638|1475|1481
SE|25462365|RESULTS|ab|10|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|638|1482|1487
SE|25462365|RESULTS|ab|10|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|638|1482|1487

SE|25462365|CONCLUSIONS|ab|11|text|1492|1618|CONCLUSIONS: Remote LAESI is an ambient non-proximate sampling technique, proven to detect metabolites in biological tissues.
SE|25462365|CONCLUSIONS|ab|11|entity|C0205157|Remote|spco|||Remote|||0|857|1505|1511
SE|25462365|CONCLUSIONS|ab|11|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|857|1512|1517
SE|25462365|CONCLUSIONS|ab|11|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|857|1512|1517
SE|25462365|CONCLUSIONS|ab|11|entity|C0870078|Sampling|idcn|||sampling|||0|728|1546|1554
SE|25462365|CONCLUSIONS|ab|11|entity|C0449851|Techniques|ftcn|||technique|||0|728|1555|1564
SE|25462365|CONCLUSIONS|ab|11|entity|C0870883|Metabolites|bacs|||metabolites|||0|1000|1583|1594
SE|25462365|CONCLUSIONS|ab|11|entity|C0457457|Biological tissue|tisu|||biological tissues|||0|983|1598|1616
SE|25462365|CONCLUSIONS|ab|11|relation|1|1|C0457457|Biological tissue|tisu|tisu|||biological tissues|||0|983|1598|1616|PREP|LOCATION_OF||1595|1597|4|3|C1516801|Electrospray Ionization|lbpr|lbpr|||LAESI|||0|857|1512|1517

SE|25462365|CONCLUSIONS|ab|12|text|1618|1753|When combined with optical microscopy, remote LAESI allows for the simultaneous acquisition of morphological and chemical information.
SE|25462365|CONCLUSIONS|ab|12|entity|C0042789|Vision|orgf|||optical|||0|861|1637|1644
SE|25462365|CONCLUSIONS|ab|12|entity|C0026018|Microscopy|lbpr|||microscopy|||0|861|1645|1655
SE|25462365|CONCLUSIONS|ab|12|entity|C0205157|Remote|spco|||remote|||0|857|1657|1663
SE|25462365|CONCLUSIONS|ab|12|entity|C0348007|Laser ablation|ftcn|||LAESI|||0|857|1664|1669
SE|25462365|CONCLUSIONS|ab|12|entity|C1516801|Electrospray Ionization|lbpr|||LAESI|||0|857|1664|1669
SE|25462365|CONCLUSIONS|ab|12|entity|C0521115|Simultaneous|tmco|||simultaneous|||0|694|1685|1697
SE|25462365|CONCLUSIONS|ab|12|entity|C0543482|morphological|spco|||morphological|||0|1000|1713|1726
SE|25462365|CONCLUSIONS|ab|12|entity|C0220806|Chemicals|chem|||chemical|||0|888|1731|1739
SE|25462365|CONCLUSIONS|ab|12|entity|C1533716|Information|idcn|||information|||0|888|1740|1751

SE|25462365|CONCLUSIONS|ab|13|text|1753|1888|This technique has important implications for histology, where chemical information for specific locations within a tissue is critical.
SE|25462365|CONCLUSIONS|ab|13|entity|C0449851|Techniques|ftcn|||technique|||0|1000|1758|1767
SE|25462365|CONCLUSIONS|ab|13|entity|C0019638|Histology|bmod|||histology|||0|1000|1799|1808
SE|25462365|CONCLUSIONS|ab|13|entity|C0220806|Chemicals|chem|||chemical|||0|790|1816|1824
SE|25462365|CONCLUSIONS|ab|13|entity|C1533716|Information|idcn|||information|||0|790|1825|1836
SE|25462365|CONCLUSIONS|ab|13|entity|C0450429|Location|spco|||locations|||0|861|1850|1859
SE|25462365|CONCLUSIONS|ab|13|entity|C1511545|Critical|qlco|||critical|||0|1000|1879|1887


SE|25462366||ti|1|text|21|158|Gas-phase reactions of alcohols with hexamethylene triperoxide diamine (HMTD) under atmospheric pressure chemical ionization conditions.
SE|25462366||ti|1|entity|C0017110|Gases|chvs|||Gas|||0|840|21|24
SE|25462366||ti|1|entity|C0205390|Phase|tmco|||phase|||0|840|25|30
SE|25462366||ti|1|entity|C0443286|Reaction|ftcn|||reactions|||0|840|31|40
SE|25462366||ti|1|entity|C0001975|Alcohols|orch,phsu|||alcohols|||0|1000|44|52
SE|25462366||ti|1|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||hexamethylene triperoxide diamine|||0|1000|58|91
SE|25462366||ti|1|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|840|117|125
SE|25462366||ti|1|entity|C0220806|Chemicals|chem|||chemical|||0|840|126|134
SE|25462366||ti|1|entity|C0596801|ionization|phpr|||ionization|||0|840|135|145
SE|25462366||ti|1|entity|C0681779|atmospheric condition|npop|||atmospheric pressure chemical ionization conditions|||0|840|105|156

SE|25462366|RATIONALE|ab|1|text|164|277|RATIONALE: Hexamethylene triperoxide diamine (HMTD) is a sensitive peroxide explosive first synthesized in 1885.
SE|25462366|RATIONALE|ab|1|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||Hexamethylene triperoxide diamine|||0|1000|175|208
SE|25462366|RATIONALE|ab|1|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||HMTD|||0|1000|210|214
SE|25462366|RATIONALE|ab|1|entity|C0332324|Sensitive|ftcn|||sensitive|||0|775|221|230
SE|25462366|RATIONALE|ab|1|entity|C0031180|Peroxides|inch|||peroxide|||0|775|231|239
SE|25462366|RATIONALE|ab|1|entity|C1279901|Firstly|qlco|||first|||0|775|250|255
SE|25462366|RATIONALE|ab|1|relation|3|2|C0635764|hexamethylenetriperoxidediamine|orch,phsu|orch|||Hexamethylene triperoxide diamine|||0|1000|175|208|ADJ|INTERACTS_WITH||221|230|3|0|C0031180|Peroxides|inch|inch|||peroxide|||0|775|231|239

SE|25462366|RATIONALE|ab|2|text|277|412|HMTD exhibits an unusual gas-phase phenomenon in the presence of alcohols that has been previously observed, but incorrectly resolved.
SE|25462366|RATIONALE|ab|2|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||HMTD|||0|1000|277|281
SE|25462366|RATIONALE|ab|2|entity|C0017110|Gases|chvs|||gas|||0|583|302|305
SE|25462366|RATIONALE|ab|2|entity|C0205390|Phase|tmco|||phase|||0|583|306|311
SE|25462366|RATIONALE|ab|2|entity|C0001975|Alcohols|orch,phsu|||alcohols|||0|1000|342|350
SE|25462366|RATIONALE|ab|2|relation|2|2|C0635764|hexamethylenetriperoxidediamine|orch,phsu|orch|||HMTD|||0|1000|277|281|NOM|COEXISTS_WITH||330|338|1|1|C0001975|Alcohols|orch,phsu|orch|||alcohols|||0|1000|342|350

SE|25462366|RATIONALE|ab|3|text|412|468|We are attempting to determine this specific mechanism.
SE|25462366|RATIONALE|ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|457|466

SE|25462366|METHODS|ab|4|text|468|594|METHODS: We used positive ion mode atmospheric pressure chemical ionization (APCI) as the interface to the mass spectrometer.
SE|25462366|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|468|475
SE|25462366|METHODS|ab|4|entity|C1446409|Positive|qlco|||positive|||0|818|485|493
SE|25462366|METHODS|ab|4|entity|C0022023|Ions|elii|||ion|||0|818|494|497
SE|25462366|METHODS|ab|4|entity|C1513371|Mode|ftcn|||mode|||0|818|498|502
SE|25462366|METHODS|ab|4|entity|C0004180|Atmospheric Pressure|npop|||atmospheric pressure|||0|818|503|523
SE|25462366|METHODS|ab|4|entity|C0220806|Chemicals|chem|||chemical|||0|818|524|532
SE|25462366|METHODS|ab|4|entity|C0596801|ionization|phpr|||ionization|||0|818|533|543
SE|25462366|METHODS|ab|4|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|966|575|592

SE|25462366|METHODS|ab|5|text|594|731|HMTD was infused with various solvents including (18) O- and (2) H-labeled methanol in order to determine gas-phase reaction mechanisms.
SE|25462366|METHODS|ab|5|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||HMTD|||0|1000|594|598
SE|25462366|METHODS|ab|5|entity|C0037638|Solvents|irda|||solvents|||0|861|624|632
SE|25462366|METHODS|ab|5|entity|C0181496|Labels|mnob|||labeled|||0|840|661|668
SE|25462366|METHODS|ab|5|entity|C0001963|Methanol|hops,orch|||methanol|||0|840|669|677
SE|25462366|METHODS|ab|5|entity|C0017110|Gases|chvs|||gas|||0|833|700|703
SE|25462366|METHODS|ab|5|entity|C0205390|Phase|tmco|||phase|||0|833|704|709
SE|25462366|METHODS|ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|833|710|718
SE|25462366|METHODS|ab|5|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|833|719|729

SE|25462366|RESULTS|ab|6|text|731|898|RESULTS: Based on these labeled experiments, it was determined that, under APCI conditions, the alcohol oxygen attacks a methylene carbon of HMTD and releases H2 O2 .
SE|25462366|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|731|738
SE|25462366|RESULTS|ab|6|entity|C0181496|Labels|mnob|||labeled|||0|872|755|762
SE|25462366|RESULTS|ab|6|entity|C0681814|research study|resa|||experiments|||0|872|763|774
SE|25462366|RESULTS|ab|6|entity|C0033095|Pressure- physical agent|phpr|||APCI|||0|840|806|810
SE|25462366|RESULTS|ab|6|entity|C0220806|Chemicals|chem|||APCI|||0|840|806|810
SE|25462366|RESULTS|ab|6|entity|C0596801|ionization|phpr|||APCI|||0|840|806|810
SE|25462366|RESULTS|ab|6|entity|C0681779|atmospheric condition|npop|||APCI conditions|||0|840|806|821
SE|25462366|RESULTS|ab|6|entity|C0001962|Ethanol|orch,phsu|||alcohol|||0|888|827|834
SE|25462366|RESULTS|ab|6|entity|C0030054|Oxygen|elii,phsu|||oxygen|||0|888|835|841
SE|25462366|RESULTS|ab|6|entity|C0054666|carbene|orch,phsu|||methylene|||0|888|852|861
SE|25462366|RESULTS|ab|6|entity|C0007009|Carbon|elii|||carbon|||0|888|862|868
SE|25462366|RESULTS|ab|6|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||HMTD|||0|1000|872|876
SE|25462366|RESULTS|ab|6|relation|4|1|C0030054|Oxygen|elii,phsu|elii|||oxygen|||0|888|835|841|VERB|INTERACTS_WITH||842|849|3|1|C0007009|Carbon|elii|elii|||carbon|||0|888|862|868

SE|25462366|RESULTS|ab|7|text|898|1044|This was attempted with nine different alcohols and, in each case, the alcohol is fully incorporated into the molecule with the peroxide release.
SE|25462366|RESULTS|ab|7|entity|C0205455|Nine|qnco|||nine|||0|828|922|926
SE|25462366|RESULTS|ab|7|entity|C1547020|*Difference|qnco|||different|||0|828|927|936
SE|25462366|RESULTS|ab|7|entity|C0001975|Alcohols|orch,phsu|||alcohols|||0|828|937|945
SE|25462366|RESULTS|ab|7|entity|C0001962|Ethanol|orch,phsu|||alcohol|||0|1000|969|976
SE|25462366|RESULTS|ab|7|entity|C0567416|Molecule|sbst|||molecule|||0|1000|1008|1016
SE|25462366|RESULTS|ab|7|entity|C0031180|Peroxides|inch|||peroxide|||0|888|1026|1034

SE|25462366|RESULTS|ab|8|text|1044|1093|A mechanism for this reaction has been proposed.
SE|25462366|RESULTS|ab|8|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|1000|1046|1055
SE|25462366|RESULTS|ab|8|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|1065|1073

SE|25462366|CONCLUSIONS|ab|9|text|1093|1198|CONCLUSIONS: This work appears to have confirmed the gas-phase reaction mechanism of HMTD with alcohols.
SE|25462366|CONCLUSIONS|ab|9|entity|C0043227|Work|ocac|||work|||0|1000|1111|1115
SE|25462366|CONCLUSIONS|ab|9|entity|C0017110|Gases|chvs|||gas|||0|833|1146|1149
SE|25462366|CONCLUSIONS|ab|9|entity|C0205390|Phase|tmco|||phase|||0|833|1150|1155
SE|25462366|CONCLUSIONS|ab|9|entity|C0443286|Reaction|ftcn|||reaction|||0|833|1156|1164
SE|25462366|CONCLUSIONS|ab|9|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|833|1165|1174
SE|25462366|CONCLUSIONS|ab|9|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||HMTD|||0|1000|1178|1182
SE|25462366|CONCLUSIONS|ab|9|entity|C0001975|Alcohols|orch,phsu|||alcohols|||0|1000|1188|1196

SE|25462366|CONCLUSIONS|ab|10|text|1198|1348|As we continue efforts to characterize this unusual molecule, the information may prove useful in determining formation and degradation mechanism(s).
SE|25462366|CONCLUSIONS|ab|10|entity|C0567416|Molecule|sbst|||molecule|||0|861|1250|1258
SE|25462366|CONCLUSIONS|ab|10|entity|C1533716|Information|idcn|||information|||0|1000|1264|1275
SE|25462366|CONCLUSIONS|ab|10|entity|C1522492|Formation|ftcn|||formation|||0|861|1308|1317
SE|25462366|CONCLUSIONS|ab|10|entity|C0243125|degradation|ftcn|||degradation|||0|888|1322|1333
SE|25462366|CONCLUSIONS|ab|10|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|888|1334|1343

SE|25462366|CONCLUSIONS|ab|11|text|1348|1423|In addition, this property of HMTD may find use in other fields of science.
SE|25462366|CONCLUSIONS|ab|11|entity|C0871161|Property|qlco|||property|||0|1000|1366|1374
SE|25462366|CONCLUSIONS|ab|11|entity|C0635764|hexamethylenetriperoxidediamine|orch,phsu|||HMTD|||0|1000|1378|1382
SE|25462366|CONCLUSIONS|ab|11|entity|C1521738|Field|cnce|||fields|||0|966|1405|1411
SE|25462366|CONCLUSIONS|ab|11|entity|C0036397|Science|ocdi|||science|||0|1000|1415|1422


SE|25462367||ti|1|text|21|194|Headspace quantification of pure and aqueous solutions of binary mixtures of key volatile organic compounds in Swiss cheeses using selected ion flow tube mass spectrometry.
SE|25462367||ti|1|entity|C0599956|Aqueous|qlco|||aqueous|||0|888|58|65
SE|25462367||ti|1|entity|C0037633|Solutions|sbst|||solutions|||0|888|66|75
SE|25462367||ti|1|entity|C0439962|Mixture|sbst|||mixtures|||0|827|86|94
SE|25462367||ti|1|entity|C1554080|Key|idcn|||key|||0|861|98|101
SE|25462367||ti|1|entity|C0373746|Assay of volatiles|lbpr|||volatile|||0|861|102|110
SE|25462367||ti|1|entity|C0029224|Organic Chemicals|orch|||organic compounds|||0|861|111|128
SE|25462367||ti|1|entity|C0241315|Swiss|popg|||Swiss|||0|888|132|137
SE|25462367||ti|1|entity|C0007968|Cheese|food|||cheeses|||0|888|138|145
SE|25462367||ti|1|entity|C0022023|Ions|elii|||ion|||0|820|161|164
SE|25462367||ti|1|entity|C0806140|Flow|orga|||flow|||0|820|165|169
SE|25462367||ti|1|entity|C1561954|tube|cnce|||tube|||0|820|170|174
SE|25462367||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|820|175|192

SE|25462367|RATIONALE|ab|1|text|200|335|RATIONALE: Twelve volatile organic compounds (VOCs) have recently been identified as key compounds in Swiss cheese with split defects.
SE|25462367|RATIONALE|ab|1|entity|C0205458|Twelve|qnco|||Twelve|||0|861|211|217
SE|25462367|RATIONALE|ab|1|entity|C0373746|Assay of volatiles|lbpr|||volatile|||0|861|218|226
SE|25462367|RATIONALE|ab|1|entity|C0029224|Organic Chemicals|orch|||organic compounds|||0|861|227|244
SE|25462367|RATIONALE|ab|1|entity|C0332185|Recent|tmco|||recently|||0|1000|257|265
SE|25462367|RATIONALE|ab|1|entity|C1554080|Key|idcn|||key|||0|872|285|288
SE|25462367|RATIONALE|ab|1|entity|C0205198|Compound|qlco|||compounds|||0|872|289|298
SE|25462367|RATIONALE|ab|1|entity|C0241315|Swiss|popg|||Swiss|||0|888|302|307
SE|25462367|RATIONALE|ab|1|entity|C0007968|Cheese|food|||cheese|||0|888|308|314

SE|25462367|RATIONALE|ab|2|text|335|471|It is important to know how these VOCs interact in binary mixtures and if their behavior changes with concentration in binary mixtures.
SE|25462367|RATIONALE|ab|2|entity|C0205309|Known|qlco|||know|||0|779|354|358
SE|25462367|RATIONALE|ab|2|entity|C0373746|Assay of volatiles|lbpr|||VOCs|||0|901|369|373
SE|25462367|RATIONALE|ab|2|entity|C0029224|Organic Chemicals|orch|||VOCs|||0|901|369|373
SE|25462367|RATIONALE|ab|2|entity|C0439962|Mixture|sbst|||mixtures|||0|827|393|401
SE|25462367|RATIONALE|ab|2|entity|C0004927|Behavior|inbe|||behavior|||0|1000|415|423
SE|25462367|RATIONALE|ab|2|entity|C0439962|Mixture|sbst|||mixtures|||0|827|461|469

SE|25462367|METHODS|ab|3|text|471|608|METHODS: Selected ion flow tube mass spectrometry (SIFT-MS) was used for the headspace analysis of VOCs commonly found in Swiss cheeses.
SE|25462367|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|471|478
SE|25462367|METHODS|ab|3|entity|C0022023|Ions|elii|||ion|||0|820|489|492
SE|25462367|METHODS|ab|3|entity|C0806140|Flow|orga|||flow|||0|820|493|497
SE|25462367|METHODS|ab|3|entity|C1561954|tube|cnce|||tube|||0|820|498|502
SE|25462367|METHODS|ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|820|503|520
SE|25462367|METHODS|ab|3|entity|C0936012|Analysis|resa|||analysis|||0|861|558|566
SE|25462367|METHODS|ab|3|entity|C0373746|Assay of volatiles|lbpr|||VOCs|||0|901|570|574
SE|25462367|METHODS|ab|3|entity|C0029224|Organic Chemicals|orch|||VOCs|||0|901|570|574
SE|25462367|METHODS|ab|3|entity|C0241315|Swiss|popg|||Swiss|||0|888|593|598
SE|25462367|METHODS|ab|3|entity|C0007968|Cheese|food|||cheeses|||0|888|599|606

SE|25462367|METHODS|ab|4|text|608|775|Headspace (H/S) sampling and quantification checks using SIFT-MS and further linear regression analyses were carried out on twelve selected aqueous solutions of VOCs.
SE|25462367|METHODS|ab|4|entity|C0870078|Sampling|idcn|||sampling|||0|861|624|632
SE|25462367|METHODS|ab|4|entity|C1517331|Further|spco|||further|||0|861|677|684
SE|25462367|METHODS|ab|4|entity|C0205132|Linear|spco|||linear|||0|861|685|691
SE|25462367|METHODS|ab|4|entity|C0034980|Regression Analysis|qnco|||regression analyses|||0|861|692|711
SE|25462367|METHODS|ab|4|entity|C0439787|Out|spco|||out|||0|1000|725|728
SE|25462367|METHODS|ab|4|entity|C0205458|Twelve|qnco|||twelve|||0|1000|732|738
SE|25462367|METHODS|ab|4|entity|C0599956|Aqueous|qlco|||aqueous|||0|888|748|755
SE|25462367|METHODS|ab|4|entity|C0037633|Solutions|sbst|||solutions|||0|888|756|765
SE|25462367|METHODS|ab|4|entity|C0373746|Assay of volatiles|lbpr|||VOCs|||0|901|769|773
SE|25462367|METHODS|ab|4|entity|C0029224|Organic Chemicals|orch|||VOCs|||0|901|769|773

SE|25462367|METHODS|ab|5|text|775|895|Five binary mixtures of standard solutions of VOCs were also prepared and the H/S profile of each mixture was analyzed.
SE|25462367|METHODS|ab|5|entity|C0205451|Five|qnco|||Five|||0|785|775|779
SE|25462367|METHODS|ab|5|entity|C0439962|Mixture|sbst|||mixtures|||0|785|787|795
SE|25462367|METHODS|ab|5|entity|C1442989|STANDARD|ftcn|||standard|||0|888|799|807
SE|25462367|METHODS|ab|5|entity|C0037633|Solutions|sbst|||solutions|||0|888|808|817
SE|25462367|METHODS|ab|5|entity|C0373746|Assay of volatiles|lbpr|||VOCs|||0|901|821|825
SE|25462367|METHODS|ab|5|entity|C0029224|Organic Chemicals|orch|||VOCs|||0|901|821|825
SE|25462367|METHODS|ab|5|entity|C0439962|Mixture|sbst|||mixture|||0|1000|873|880

SE|25462367|RESULTS|ab|6|text|895|1081|RESULTS: A very good fit of linearity for the twelve VOCs (95% confidence level) confirms direct proportionality between the H/S and the aqueous concentration of the standard solutions.
SE|25462367|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|895|902
SE|25462367|RESULTS|ab|6|entity|C0442824|Very|qlco|||very|||0|851|906|910
SE|25462367|RESULTS|ab|6|entity|C0205170|Good|qlco|||good|||0|851|911|915
SE|25462367|RESULTS|ab|6|entity|C0036572|Seizures|sosy|||fit|||0|851|916|919
SE|25462367|RESULTS|ab|6|entity|C0205132|Linear|spco|||linearity|||0|928|923|932
SE|25462367|RESULTS|ab|6|entity|C0205458|Twelve|qnco|||twelve|||0|861|941|947
SE|25462367|RESULTS|ab|6|entity|C0373746|Assay of volatiles|lbpr|||VOCs|||0|861|948|952
SE|25462367|RESULTS|ab|6|entity|C0029224|Organic Chemicals|orch|||VOCs|||0|861|948|952
SE|25462367|RESULTS|ab|6|entity|C0518578|Confidence level|fndg|||confidence level|||0|901|958|974
SE|25462367|RESULTS|ab|6|entity|C0205351|Proportional|qlco|||proportionality|||0|789|992|1007
SE|25462367|RESULTS|ab|6|entity|C0599956|Aqueous|qlco|||aqueous|||0|694|1032|1039
SE|25462367|RESULTS|ab|6|entity|C1442989|STANDARD|ftcn|||standard|||0|888|1061|1069
SE|25462367|RESULTS|ab|6|entity|C0037633|Solutions|sbst|||solutions|||0|888|1070|1079

SE|25462367|RESULTS|ab|7|text|1081|1156|Henry's Law coefficients were calculated with a high degree of confidence.
SE|25462367|RESULTS|ab|7|entity|C0582517|henry|qnco|||Henry's|||0|840|1081|1088
SE|25462367|RESULTS|ab|7|entity|C0023150|Rules of conduct|rnlw|||Law|||0|840|1089|1092
SE|25462367|RESULTS|ab|7|entity|C1547015|*Coefficient|qnco|||coefficients|||0|840|1093|1105
SE|25462367|RESULTS|ab|7|entity|C0205250|High|qlco|||high|||0|694|1129|1133
SE|25462367|RESULTS|ab|7|entity|C0237529|Self-confidence|menp|||confidence|||0|1000|1144|1154

SE|25462367|RESULTS|ab|8|text|1156|1397|SIFT-MS analysis of five binary mixtures showed that the more polar compounds reduced the H/S concentration of the less polar compounds, while the addition of a less polar compound increased the H/S concentration of the more polar compound.
SE|25462367|RESULTS|ab|8|entity|C0936012|Analysis|resa|||analysis|||0|861|1164|1172
SE|25462367|RESULTS|ab|8|entity|C0205451|Five|qnco|||five|||0|785|1176|1180
SE|25462367|RESULTS|ab|8|entity|C0439962|Mixture|sbst|||mixtures|||0|785|1188|1196
SE|25462367|RESULTS|ab|8|entity|C0205172|More|ftcn|||more|||0|840|1213|1217
SE|25462367|RESULTS|ab|8|entity|C0813983|polar|qnco|||polar|||0|840|1218|1223
SE|25462367|RESULTS|ab|8|entity|C0205198|Compound|qlco|||compounds|||0|840|1224|1233
SE|25462367|RESULTS|ab|8|entity|C0813983|polar|qnco|||polar|||0|773|1276|1281
SE|25462367|RESULTS|ab|8|entity|C0205198|Compound|qlco|||compounds|||0|773|1282|1291
SE|25462367|RESULTS|ab|8|entity|C0442796|Additive|qlco|||addition|||0|928|1303|1311
SE|25462367|RESULTS|ab|8|entity|C0813983|polar|qnco|||polar|||0|790|1322|1327
SE|25462367|RESULTS|ab|8|entity|C0205198|Compound|qlco|||compound|||0|790|1328|1336
SE|25462367|RESULTS|ab|8|entity|C0205172|More|ftcn|||more|||0|851|1376|1380
SE|25462367|RESULTS|ab|8|entity|C0813983|polar|qnco|||polar|||0|851|1381|1386
SE|25462367|RESULTS|ab|8|entity|C0205198|Compound|qlco|||compound|||0|851|1387|1395

SE|25462367|CONCLUSIONS|ab|9|text|1397|1565|CONCLUSIONS: In the binary experiment, it was shown that the behavior of a compound in the headspace can be significantly affected by the presence of another compound.
SE|25462367|CONCLUSIONS|ab|9|entity|C0681814|research study|resa|||experiment|||0|861|1424|1434
SE|25462367|CONCLUSIONS|ab|9|entity|C0004927|Behavior|inbe|||behavior|||0|1000|1458|1466
SE|25462367|CONCLUSIONS|ab|9|entity|C0205198|Compound|qlco|||compound|||0|1000|1472|1480
SE|25462367|CONCLUSIONS|ab|9|entity|C0205198|Compound|qlco|||compound|||0|1000|1555|1563

SE|25462367|CONCLUSIONS|ab|10|text|1565|1663|Thus, the matrix effect plays a significant role in the behavior of molecules in a mixed solution.
SE|25462367|CONCLUSIONS|ab|10|entity|C0331858|Matrix|hcro|||matrix|||0|888|1575|1581
SE|25462367|CONCLUSIONS|ab|10|entity|C1280500|Effect|qlco|||effect|||0|888|1582|1588
SE|25462367|CONCLUSIONS|ab|10|entity|C0750502|Significant|idcn|||significant|||0|888|1597|1608
SE|25462367|CONCLUSIONS|ab|10|entity|C0035820|Role|socb|||role|||0|888|1609|1613
SE|25462367|CONCLUSIONS|ab|10|entity|C0004927|Behavior|inbe|||behavior|||0|1000|1621|1629
SE|25462367|CONCLUSIONS|ab|10|entity|C0567416|Molecule|sbst|||molecules|||0|966|1633|1642
SE|25462367|CONCLUSIONS|ab|10|entity|C0205430|Mixed|ftcn|||mixed|||0|888|1648|1653
SE|25462367|CONCLUSIONS|ab|10|entity|C0037633|Solutions|sbst|||solution|||0|888|1654|1662


SE|25462368||ti|1|text|21|98|Gas chromatography with parallel hard and soft ionization mass spectrometry.
SE|25462368||ti|1|entity|C0008555|Gas Chromatography|lbpr|||Gas chromatography|||0|1000|21|39
SE|25462368||ti|1|entity|C0018599|Hardness|qlco|||hard|||0|861|54|58
SE|25462368||ti|1|entity|C0596801|ionization|phpr|||ionization|||0|861|68|78
SE|25462368||ti|1|entity|C0746416|Soft mass|fndg|||soft ionization mass|||0|861|63|83
SE|25462368||ti|1|entity|C0436196|Spectrometry|lbpr|||spectrometry|||0|861|84|96

SE|25462368|RATIONALE|ab|1|text|104|391|RATIONALE: Mass spectrometric identification of compounds in chromatography can be obtained from molecular masses from soft ionization mass spectrometry techniques such as field ionization (FI) and fragmentation patterns from hard ionization techniques such as electron ionization (EI).
SE|25462368|RATIONALE|ab|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||Mass spectrometric|||0|698|115|133
SE|25462368|RATIONALE|ab|1|entity|C0205198|Compound|qlco|||compounds|||0|966|152|161
SE|25462368|RATIONALE|ab|1|entity|C0008550|Chromatography|lbpr|||chromatography|||0|1000|165|179
SE|25462368|RATIONALE|ab|1|entity|C0598892|Molecular Mass|qnco|||molecular masses|||0|983|201|217
SE|25462368|RATIONALE|ab|1|entity|C0596801|ionization|phpr|||ionization|||0|840|228|238
SE|25462368|RATIONALE|ab|1|entity|C0746416|Soft mass|fndg|||soft ionization mass|||0|840|223|243
SE|25462368|RATIONALE|ab|1|entity|C0436196|Spectrometry|lbpr|||spectrometry|||0|840|244|256
SE|25462368|RATIONALE|ab|1|entity|C0025664|Methodology|inpr|||techniques|||0|840|257|267
SE|25462368|RATIONALE|ab|1|entity|C1521738|Field|cnce|||field|||0|888|276|281
SE|25462368|RATIONALE|ab|1|entity|C0596801|ionization|phpr|||ionization|||0|888|282|292
SE|25462368|RATIONALE|ab|1|entity|C0185061|fragmentation procedure|topp|||fragmentation|||0|888|302|315
SE|25462368|RATIONALE|ab|1|entity|C0449774|Patterns|spco|||patterns|||0|888|316|324
SE|25462368|RATIONALE|ab|1|entity|C0018599|Hardness|qlco|||hard|||0|851|330|334
SE|25462368|RATIONALE|ab|1|entity|C0596801|ionization|phpr|||ionization|||0|851|335|345
SE|25462368|RATIONALE|ab|1|entity|C0025664|Methodology|inpr|||techniques|||0|851|346|356
SE|25462368|RATIONALE|ab|1|entity|C0013852|Electrons|qnco|||electron|||0|888|365|373
SE|25462368|RATIONALE|ab|1|entity|C0596801|ionization|phpr|||ionization|||0|888|374|384

SE|25462368|RATIONALE|ab|2|text|391|509|Simultaneous detection by EI and FI mass spectrometry allows alignment of the different information from each method.
SE|25462368|RATIONALE|ab|2|entity|C0521115|Simultaneous|tmco|||Simultaneous|||0|888|391|403
SE|25462368|RATIONALE|ab|2|entity|C1511790|Detection|topp|||detection|||0|888|404|413
SE|25462368|RATIONALE|ab|2|entity|C0013852|Electrons|qnco|||EI|||0|888|417|419
SE|25462368|RATIONALE|ab|2|entity|C0596801|ionization|phpr|||EI|||0|888|417|419
SE|25462368|RATIONALE|ab|2|entity|C0260257|Field ionization mass spectrometry|lbpr|||FI mass spectrometry|||0|1000|424|444
SE|25462368|RATIONALE|ab|2|entity|C1547020|*Difference|qnco|||different|||0|853|469|478
SE|25462368|RATIONALE|ab|2|entity|C1533716|Information|idcn|||information|||0|853|479|490
SE|25462368|RATIONALE|ab|2|entity|C0025663|Methods|inpr|||method|||0|1000|501|507

SE|25462368|METHODS|ab|3|text|509|690|METHODS: We report the construction and characteristics of a combined instrument consisting of a gas chromatograph and two parallel mass spectrometry ionization sources, EI and FI.
SE|25462368|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|509|516
SE|25462368|METHODS|ab|3|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|549|564
SE|25462368|METHODS|ab|3|entity|C0205195|Combined|qlco|||combined|||0|888|570|578
SE|25462368|METHODS|ab|3|entity|C0348000|Instrument|mnob|||instrument|||0|888|579|589
SE|25462368|METHODS|ab|3|entity|C0008555|Gas Chromatography|lbpr|||gas chromatograph|||0|950|606|623
SE|25462368|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|773|628|631
SE|25462368|METHODS|ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|773|641|658
SE|25462368|METHODS|ab|3|entity|C0596801|ionization|phpr|||ionization|||0|773|659|669
SE|25462368|METHODS|ab|3|entity|C0013852|Electrons|qnco|||EI|||0|888|679|681
SE|25462368|METHODS|ab|3|entity|C0596801|ionization|phpr|||EI|||0|888|679|681
SE|25462368|METHODS|ab|3|entity|C1521738|Field|cnce|||FI|||0|888|686|688
SE|25462368|METHODS|ab|3|entity|C0596801|ionization|phpr|||FI|||0|888|686|688

SE|25462368|METHODS|ab|4|text|690|904|When considering both ion yield and signal-to-noise it was postulated that good-quality EI and FI mass spectra could be obtained simultaneously using a post-column splitter with a split fraction of 1:10 for EI/FI.
SE|25462368|METHODS|ab|4|entity|C0750591|CONSIDER|idcn|||considering|||0|966|695|706
SE|25462368|METHODS|ab|4|entity|C0022023|Ions|elii|||ion|||0|694|712|715
SE|25462368|METHODS|ab|4|entity|C0028263|Noise|phpr|||noise|||0|827|736|741
SE|25462368|METHODS|ab|4|entity|C0205170|Good|qlco|||good|||0|833|765|769
SE|25462368|METHODS|ab|4|entity|C0332306|Quality|qlco|||quality|||0|833|770|777
SE|25462368|METHODS|ab|4|entity|C0013852|Electrons|qnco|||EI|||0|833|778|780
SE|25462368|METHODS|ab|4|entity|C0596801|ionization|phpr|||EI|||0|833|778|780
SE|25462368|METHODS|ab|4|entity|C1521738|Field|cnce|||FI|||0|608|785|787
SE|25462368|METHODS|ab|4|entity|C0596801|ionization|phpr|||FI|||0|608|785|787
SE|25462368|METHODS|ab|4|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|608|788|792
SE|25462368|METHODS|ab|4|entity|C0205095|Dorsal|spco|||post|||0|623|842|846
SE|25462368|METHODS|ab|4|entity|C1185738|Column|bpoc|||column|||0|623|847|853
SE|25462368|METHODS|ab|4|entity|C0013852|Electrons|qnco|||EI|||0|608|897|899
SE|25462368|METHODS|ab|4|entity|C0596801|ionization|phpr|||EI|||0|608|897|899
SE|25462368|METHODS|ab|4|entity|C1521738|Field|cnce|||FI|||0|608|900|902

SE|25462368|METHODS|ab|5|text|904|1003|This has been realised and we report its application for the analysis of several complex mixtures.
SE|25462368|METHODS|ab|5|entity|C0936012|Analysis|resa|||analysis|||0|1000|965|973
SE|25462368|METHODS|ab|5|entity|C0443302|Several|qnco|||several|||0|901|977|984
SE|25462368|METHODS|ab|5|entity|C1258022|Complex Mixtures|chem|||complex mixtures|||0|901|985|1001

SE|25462368|RESULTS|ab|6|text|1003|1247|RESULTS: The differences between the full width at half maximum (FWHM) of the EI and FI chromatograms were statistically insignificant, and the retention times of the chromatograms were highly correlated (r(2) =0.9999) with no detectable bias.
SE|25462368|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1003|1010
SE|25462368|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||differences|||0|966|1016|1027
SE|25462368|RESULTS|ab|6|entity|C0443225|Full|qlco|||full|||0|720|1040|1044
SE|25462368|RESULTS|ab|6|entity|C0487742|Width|qnco|||width|||0|720|1045|1050
SE|25462368|RESULTS|ab|6|entity|C0806909|Maximum|fndg|||maximum|||0|720|1059|1066
SE|25462368|RESULTS|ab|6|entity|C0013852|Electrons|qnco|||EI|||0|888|1081|1083
SE|25462368|RESULTS|ab|6|entity|C0596801|ionization|phpr|||EI|||0|888|1081|1083
SE|25462368|RESULTS|ab|6|entity|C1521738|Field|cnce|||FI|||0|816|1088|1090
SE|25462368|RESULTS|ab|6|entity|C0596801|ionization|phpr|||FI|||0|816|1088|1090
SE|25462368|RESULTS|ab|6|entity|C0008550|Chromatography|lbpr|||chromatograms|||0|816|1091|1104
SE|25462368|RESULTS|ab|6|entity|C0040223|Time|tmco|||times|||0|872|1157|1162
SE|25462368|RESULTS|ab|6|entity|C0008550|Chromatography|lbpr|||chromatograms|||0|893|1170|1183
SE|25462368|RESULTS|ab|6|entity|C0242568|Biases|idcn|||bias|||0|861|1241|1245

SE|25462368|RESULTS|ab|7|text|1247|1524|The applicability and significance of this combined instrument and the attendant methodology are illustrated by the analysis of standard samples of 13 compounds with diverse structures, and the analysis of mixtures of fatty acids, fish oil, hydrocarbons and yeast metabolites.
SE|25462368|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significance|||0|928|1269|1281
SE|25462368|RESULTS|ab|7|entity|C0205195|Combined|qlco|||combined|||0|888|1290|1298
SE|25462368|RESULTS|ab|7|entity|C0348000|Instrument|mnob|||instrument|||0|888|1299|1309
SE|25462368|RESULTS|ab|7|entity|C0025664|Methodology|inpr|||methodology|||0|872|1328|1339
SE|25462368|RESULTS|ab|7|entity|C0936012|Analysis|resa|||analysis|||0|1000|1363|1371
SE|25462368|RESULTS|ab|7|entity|C1442989|STANDARD|ftcn|||standard|||0|694|1375|1383
SE|25462368|RESULTS|ab|7|entity|C0205198|Compound|qlco|||compounds|||0|827|1398|1407
SE|25462368|RESULTS|ab|7|entity|C0678594|Structure|spco|||structures|||0|827|1421|1431
SE|25462368|RESULTS|ab|7|entity|C0936012|Analysis|resa|||analysis|||0|1000|1441|1449
SE|25462368|RESULTS|ab|7|entity|C0439962|Mixture|sbst|||mixtures|||0|966|1453|1461
SE|25462368|RESULTS|ab|7|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acids|||0|1000|1465|1476
SE|25462368|RESULTS|ab|7|entity|C0016157|Fish Oils|bacs,lipd,phsu|||fish oil|||0|1000|1478|1486
SE|25462368|RESULTS|ab|7|entity|C0020242|Hydrocarbons|orch|||hydrocarbons|||0|1000|1488|1500
SE|25462368|RESULTS|ab|7|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|888|1505|1510
SE|25462368|RESULTS|ab|7|entity|C0870883|Metabolites|bacs|||metabolites|||0|888|1511|1522

SE|25462368|CONCLUSIONS|ab|8|text|1524|1744|CONCLUSIONS: This combined dual-source instrument saves time and resources, and more importantly generates equivalent chromatograms aligned in time, in EI and FI (i.e. peaks with similar shapes and identical positions).
SE|25462368|CONCLUSIONS|ab|8|entity|C0205195|Combined|qlco|||combined|||0|775|1542|1550
SE|25462368|CONCLUSIONS|ab|8|entity|C0348000|Instrument|mnob|||instrument|||0|775|1563|1573
SE|25462368|CONCLUSIONS|ab|8|entity|C0040223|Time|tmco|||time|||0|1000|1580|1584
SE|25462368|CONCLUSIONS|ab|8|entity|C0035201|Resources|idcn|||resources|||0|1000|1589|1598
SE|25462368|CONCLUSIONS|ab|8|entity|C0205172|More|ftcn|||more|||0|1000|1604|1608
SE|25462368|CONCLUSIONS|ab|8|entity|C0439185|Eq|qnco|||equivalent|||0|835|1631|1641
SE|25462368|CONCLUSIONS|ab|8|entity|C0008550|Chromatography|lbpr|||chromatograms|||0|835|1642|1655
SE|25462368|CONCLUSIONS|ab|8|entity|C0040223|Time|tmco|||time|||0|1000|1667|1671
SE|25462368|CONCLUSIONS|ab|8|entity|C0013852|Electrons|qnco|||EI|||0|888|1676|1678
SE|25462368|CONCLUSIONS|ab|8|entity|C0596801|ionization|phpr|||EI|||0|888|1676|1678
SE|25462368|CONCLUSIONS|ab|8|entity|C1521738|Field|cnce|||FI|||0|888|1683|1685
SE|25462368|CONCLUSIONS|ab|8|entity|C0596801|ionization|phpr|||FI|||0|888|1683|1685
SE|25462368|CONCLUSIONS|ab|8|entity|C0332479|Shapes|spco|||shapes|||0|853|1711|1717
SE|25462368|CONCLUSIONS|ab|8|entity|C0205280|Identical|qlco|||identical|||0|872|1722|1731
SE|25462368|CONCLUSIONS|ab|8|entity|C0733755|Positioning Attribute|spco|||positions|||0|872|1732|1741

SE|25462368|CONCLUSIONS|ab|9|text|1744|1943|The identical FWHMs and retention times of the EI and FI chromatograms in this combined instrument enable the accurate assignment of fragment ions from EI to their corresponding molecular ions in FI.
SE|25462368|CONCLUSIONS|ab|9|entity|C0205280|Identical|qlco|||identical|||0|694|1748|1757
SE|25462368|CONCLUSIONS|ab|9|entity|C0040223|Time|tmco|||times|||0|872|1778|1783
SE|25462368|CONCLUSIONS|ab|9|entity|C0013852|Electrons|qnco|||EI|||0|888|1791|1793
SE|25462368|CONCLUSIONS|ab|9|entity|C0596801|ionization|phpr|||EI|||0|888|1791|1793
SE|25462368|CONCLUSIONS|ab|9|entity|C1521738|Field|cnce|||FI|||0|816|1798|1800
SE|25462368|CONCLUSIONS|ab|9|entity|C0596801|ionization|phpr|||FI|||0|816|1798|1800
SE|25462368|CONCLUSIONS|ab|9|entity|C0008550|Chromatography|lbpr|||chromatograms|||0|816|1801|1814
SE|25462368|CONCLUSIONS|ab|9|entity|C0205195|Combined|qlco|||combined|||0|888|1823|1831
SE|25462368|CONCLUSIONS|ab|9|entity|C0348000|Instrument|mnob|||instrument|||0|888|1832|1842
SE|25462368|CONCLUSIONS|ab|9|entity|C0443131|Accurate|qlco|||accurate|||0|888|1854|1862
SE|25462368|CONCLUSIONS|ab|9|entity|C1516050|Assignment|ftcn|||assignment|||0|888|1863|1873
SE|25462368|CONCLUSIONS|ab|9|entity|C0486805|FRAGMENTS|bdsu|||fragment|||0|872|1877|1885
SE|25462368|CONCLUSIONS|ab|9|entity|C0022023|Ions|elii|||ions|||0|872|1886|1890
SE|25462368|CONCLUSIONS|ab|9|entity|C0013852|Electrons|qnco|||EI|||0|888|1896|1898
SE|25462368|CONCLUSIONS|ab|9|entity|C0596801|ionization|phpr|||EI|||0|888|1896|1898
SE|25462368|CONCLUSIONS|ab|9|entity|C1521991|Molecular|qlco|||molecular|||0|790|1922|1931
SE|25462368|CONCLUSIONS|ab|9|entity|C0022023|Ions|elii|||ions|||0|790|1932|1936
SE|25462368|CONCLUSIONS|ab|9|entity|C1521738|Field|cnce|||FI|||0|888|1940|1942
SE|25462368|CONCLUSIONS|ab|9|entity|C0596801|ionization|phpr|||FI|||0|888|1940|1942


SE|25462369||ti|1|text|21|100|Reactive paper spray mass spectrometry for in situ identification of quinones.
SE|25462369||ti|1|entity|C0205332|Reactive|qlco|||Reactive|||0|840|21|29
SE|25462369||ti|1|entity|C0030351|Paper|mnob|||paper|||0|840|30|35
SE|25462369||ti|1|entity|C1154182|Spray|sbst|||spray|||0|840|36|41
SE|25462369||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|840|42|59
SE|25462369||ti|1|entity|C0444498|In situ|spco|||in situ|||0|734|64|71
SE|25462369||ti|1|entity|C0034435|Quinones|orch|||quinones|||0|1000|90|98

SE|25462369|RATIONALE|ab|1|text|106|314|RATIONALE: The polycyclic aromatic hydrocarbons quinones are reported to be harmful and could cause mutations and cancer via the generation of reactive oxygen species through their redox cycle in human body.
SE|25462369|RATIONALE|ab|1|entity|C0032458|Polycyclic Hydrocarbons, Aromatic|orch|||polycyclic aromatic hydrocarbons|||0|916|121|153
SE|25462369|RATIONALE|ab|1|entity|C0034435|Quinones|orch|||quinones|||0|916|154|162
SE|25462369|RATIONALE|ab|1|entity|C0026882|Mutation|genf|||mutations|||0|1000|206|215
SE|25462369|RATIONALE|ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|694|220|226
SE|25462369|RATIONALE|ab|1|entity|C0079411|Generations|tmco|||generation|||0|966|235|245
SE|25462369|RATIONALE|ab|1|entity|C0162772|Reactive Oxygen Species|bacs,elii|||reactive oxygen species|||0|1000|249|272
SE|25462369|RATIONALE|ab|1|entity|C0030012|Oxidation-Reduction|npop|||redox|||0|888|287|292
SE|25462369|RATIONALE|ab|1|entity|C0750729|Course|tmco|||cycle|||0|888|293|298
SE|25462369|RATIONALE|ab|1|entity|C0242821|Human body|humn|||human body|||0|1000|302|312
SE|25462369|RATIONALE|ab|1|relation|8|5|C0026882|Mutation|genf|genf|||mutations|||0|1000|206|215|PREP|PROCESS_OF||299|301|1|1|C0242821|Human body|grup,humn|humn|||human body|||0|1000|302|312

SE|25462369|RATIONALE|ab|2|text|314|656|For detection by gas chromatography and high-performance liquid chromatography mass spectrometry (MS), sample pretreatments and chromatographic separation prior to MS are generally required, which makes the whole analytical process laborious and time-consuming, resulting in difficulties for fast screening targets from complicated matrices.
SE|25462369|RATIONALE|ab|2|entity|C1511790|Detection|topp|||detection|||0|1000|318|327
SE|25462369|RATIONALE|ab|2|entity|C0008555|Gas Chromatography|lbpr|||gas chromatography|||0|1000|331|349
SE|25462369|RATIONALE|ab|2|entity|C0008562|High pressure liquid chromatography procedure|lbpr|||high-performance liquid chromatography|||0|901|354|392
SE|25462369|RATIONALE|ab|2|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|901|393|410
SE|25462369|RATIONALE|ab|2|entity|C0008550|Chromatography|lbpr|||chromatographic|||0|853|442|457
SE|25462369|RATIONALE|ab|2|entity|C0036679|Diastasis|patf|||separation|||0|853|458|468
SE|25462369|RATIONALE|ab|2|entity|C0037813|Spectrum Analysis, Mass|lbpr|||MS|||0|1000|478|480
SE|25462369|RATIONALE|ab|2|entity|C0444667|Whole|qnco|||whole|||0|802|521|526
SE|25462369|RATIONALE|ab|2|entity|C1522240|Process|phpr|||process|||0|802|538|545
SE|25462369|RATIONALE|ab|2|entity|C0022864|Labor (Childbirth)|orgf|||laborious|||0|928|546|555
SE|25462369|RATIONALE|ab|2|entity|C0040223|Time|tmco|||time|||0|861|560|564
SE|25462369|RATIONALE|ab|2|entity|C0456962|Fast|qlco|||fast|||0|840|606|610
SE|25462369|RATIONALE|ab|2|entity|C0220908|Screening procedure|hlca|||screening|||0|840|611|620
SE|25462369|RATIONALE|ab|2|entity|C0231242|Complicated|ftcn|||complicated|||0|872|634|645
SE|25462369|RATIONALE|ab|2|entity|C0331858|Matrix|hcro|||matrices|||0|872|646|654
SE|25462369|RATIONALE|ab|2|relation|0|0|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||mass spectrometry|||0|901|393|410|MOD/HEAD|USES||354|410|0|0|C0008562|High pressure liquid chromatography procedure|lbpr|lbpr|||high-performance liquid chromatography|||0|901|354|392
SE|25462369|RATIONALE|ab|2|relation|11|1|C0008555|Gas Chromatography|lbpr|lbpr|||gas chromatography|||0|1000|331|349|PREP|METHOD_OF||328|330|1|1|C1511790|Detection|topp|topp|||detection|||0|1000|318|327
SE|25462369|RATIONALE|ab|2|relation|11|1|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||mass spectrometry|||0|901|393|410|PREP|METHOD_OF||328|330|1|1|C1511790|Detection|topp|topp|||detection|||0|1000|318|327

SE|25462369|RATIONALE|ab|3|text|656|770|Thus facile, rapid and reliable MS methods for detection of quinones in complicated matrices are in great demand.
SE|25462369|RATIONALE|ab|3|entity|C1547538|Facility|idcn|||facile|||0|754|661|667
SE|25462369|RATIONALE|ab|3|entity|C0439831|Rapid|qlco|||rapid|||0|754|669|674
SE|25462369|RATIONALE|ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||MS|||0|824|688|690
SE|25462369|RATIONALE|ab|3|entity|C0025663|Methods|inpr|||methods|||0|824|691|698
SE|25462369|RATIONALE|ab|3|entity|C1511790|Detection|topp|||detection|||0|1000|703|712
SE|25462369|RATIONALE|ab|3|entity|C0034435|Quinones|orch|||quinones|||0|1000|716|724
SE|25462369|RATIONALE|ab|3|entity|C0231242|Complicated|ftcn|||complicated|||0|872|728|739
SE|25462369|RATIONALE|ab|3|entity|C0331858|Matrix|hcro|||matrices|||0|872|740|748
SE|25462369|RATIONALE|ab|3|entity|C0549177|Large|qnco|||great|||0|694|756|761
SE|25462369|RATIONALE|ab|3|relation|1|0|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||MS|||0|824|688|690|NOM|METHOD_OF||691|698|4|1|C1511790|Detection|topp|topp|||detection|||0|1000|703|712

SE|25462369|METHODS|ab|4|text|770|911|METHODS: Reactive paper spray mass spectrometry is reported for rapid identification and quantification of quinones in complicated matrices.
SE|25462369|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|770|777
SE|25462369|METHODS|ab|4|entity|C0205332|Reactive|qlco|||Reactive|||0|840|779|787
SE|25462369|METHODS|ab|4|entity|C0030351|Paper|mnob|||paper|||0|840|788|793
SE|25462369|METHODS|ab|4|entity|C1154182|Spray|sbst|||spray|||0|840|794|799
SE|25462369|METHODS|ab|4|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|840|800|817
SE|25462369|METHODS|ab|4|entity|C0439831|Rapid|qlco|||rapid|||0|694|834|839
SE|25462369|METHODS|ab|4|entity|C0034435|Quinones|orch|||quinones|||0|1000|877|885
SE|25462369|METHODS|ab|4|entity|C0231242|Complicated|ftcn|||complicated|||0|872|889|900
SE|25462369|METHODS|ab|4|entity|C0331858|Matrix|hcro|||matrices|||0|872|901|909
SE|25462369|METHODS|ab|4|relation|1|1|C0331858|Matrix|hcro|hcro|||matrices|||0|872|901|909|PREP|LOCATION_OF||886|888|5|4|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||mass spectrometry|||0|840|800|817

SE|25462369|METHODS|ab|5|text|911|1055|The method is based on an in situ derivatization reaction between cysteamine and quinones prior to analysis with paper spray mass spectrometry.
SE|25462369|METHODS|ab|5|entity|C0025663|Methods|inpr|||method|||0|1000|915|921
SE|25462369|METHODS|ab|5|entity|C0444498|In situ|spco|||in situ|||0|824|937|944
SE|25462369|METHODS|ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|824|960|968
SE|25462369|METHODS|ab|5|entity|C0010648|Cysteamine|orch,phsu|||cysteamine|||0|1000|977|987
SE|25462369|METHODS|ab|5|entity|C0034435|Quinones|orch|||quinones|||0|1000|992|1000
SE|25462369|METHODS|ab|5|entity|C0936012|Analysis|resa|||analysis|||0|1000|1010|1018
SE|25462369|METHODS|ab|5|entity|C0030351|Paper|mnob|||paper|||0|861|1024|1029
SE|25462369|METHODS|ab|5|entity|C1154182|Spray|sbst|||spray|||0|861|1030|1035
SE|25462369|METHODS|ab|5|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|861|1036|1053

SE|25462369|METHODS|ab|6|text|1055|1167|With the addition of an easily charged chemical tag, the ionization efficiency of analysts is greatly improved.
SE|25462369|METHODS|ab|6|entity|C0442796|Additive|qlco|||addition|||0|928|1064|1072
SE|25462369|METHODS|ab|6|entity|C0332219|Easy|qlco|||easily|||0|1000|1079|1085
SE|25462369|METHODS|ab|6|entity|C0220806|Chemicals|chem|||chemical|||0|888|1094|1102
SE|25462369|METHODS|ab|6|entity|C1522485|Tracer|irda|||tag|||0|888|1103|1106
SE|25462369|METHODS|ab|6|entity|C0596801|ionization|phpr|||ionization|||0|888|1112|1122
SE|25462369|METHODS|ab|6|entity|C0013682|Efficiency|qnco|||efficiency|||0|888|1123|1133
SE|25462369|METHODS|ab|6|entity|C0870132|Analysts|prog|||analysts|||0|1000|1137|1145

SE|25462369|METHODS|ab|7|text|1167|1309|Due to the high ionization efficiency of the drivatives, quinones in complicated matrices could be detected rapidly without any pretreatment.
SE|25462369|METHODS|ab|7|entity|C0205250|High|qlco|||high|||0|851|1178|1182
SE|25462369|METHODS|ab|7|entity|C0596801|ionization|phpr|||ionization|||0|851|1183|1193
SE|25462369|METHODS|ab|7|entity|C0013682|Efficiency|qnco|||efficiency|||0|851|1194|1204
SE|25462369|METHODS|ab|7|entity|C0034435|Quinones|orch|||quinones|||0|1000|1224|1232
SE|25462369|METHODS|ab|7|entity|C0231242|Complicated|ftcn|||complicated|||0|872|1236|1247
SE|25462369|METHODS|ab|7|entity|C0331858|Matrix|hcro|||matrices|||0|872|1248|1256

SE|25462369|RESULTS|ab|8|text|1309|1497|RESULTS: Under the optimized experimental conditions, the linear dynamic ranges for both 1,4-benzoquinone and 1,4-naphthoquinone are 0.4-40 ng and that for 1,4-anthraquinone is 0.4-20 ng.
SE|25462369|RESULTS|ab|8|entity|C1274040|result|ftcn|||RESULTS|||0|966|1309|1316
SE|25462369|RESULTS|ab|8|entity|C1517004|Experimental|ftcn|||experimental|||0|773|1338|1350
SE|25462369|RESULTS|ab|8|entity|C0348080|Condition|qlco|||conditions|||0|773|1351|1361
SE|25462369|RESULTS|ab|8|entity|C0205132|Linear|spco|||linear|||0|851|1367|1373
SE|25462369|RESULTS|ab|8|entity|C0729333|Dynamic|ftcn|||dynamic|||0|851|1374|1381
SE|25462369|RESULTS|ab|8|entity|C1514721|Range|qnco|||ranges|||0|851|1382|1388
SE|25462369|RESULTS|ab|8|entity|C0053241|benzoquinone|orch|||benzoquinone|||0|861|1402|1414
SE|25462369|RESULTS|ab|8|entity|C0027388|Naphthoquinones|orch|||naphthoquinone|||0|861|1423|1437
SE|25462369|RESULTS|ab|8|entity|C0439509|/40|tmco|||4-40|||0|750|1444|1448
SE|25462369|RESULTS|ab|8|entity|C0003174|Anthraquinones|orch|||anthraquinone|||0|861|1469|1482

SE|25462369|RESULTS|ab|9|text|1497|1631|Limits of detection for these three analytes were measured to be 160, 40 and 200 pg using methyl-p-benzoquinone as internal standard.
SE|25462369|RESULTS|ab|9|entity|C1549649|Limit|idcn|||Limits|||0|966|1497|1503
SE|25462369|RESULTS|ab|9|entity|C1511790|Detection|topp|||detection|||0|1000|1507|1516
SE|25462369|RESULTS|ab|9|entity|C0205449|Three|qnco|||three|||0|872|1527|1532
SE|25462369|RESULTS|ab|9|entity|C0443354|Analyte|chvf|||analytes|||0|872|1533|1541
SE|25462369|RESULTS|ab|9|entity|C0244646|2-methyl-1,4-benzoquinone|orch|||methyl-p-benzoquinone|||0|1000|1587|1608
SE|25462369|RESULTS|ab|9|entity|C0205102|Intrinsic|spco|||internal|||0|888|1612|1620
SE|25462369|RESULTS|ab|9|entity|C1442989|STANDARD|ftcn|||standard|||0|888|1621|1629

SE|25462369|RESULTS|ab|10|text|1631|1818|The capability to conduct MS analysis under ambient pressure is illustrated by identification of 1,4-naphthoquinone and 1,4-anthraquinone in raw urine, raw serum and cell culture medium.
SE|25462369|RESULTS|ab|10|entity|C0037813|Spectrum Analysis, Mass|lbpr|||MS|||0|901|1657|1659
SE|25462369|RESULTS|ab|10|entity|C0936012|Analysis|resa|||analysis|||0|901|1660|1668
SE|25462369|RESULTS|ab|10|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|861|1683|1691
SE|25462369|RESULTS|ab|10|entity|C0027388|Naphthoquinones|orch|||naphthoquinone|||0|861|1732|1746
SE|25462369|RESULTS|ab|10|entity|C0003174|Anthraquinones|orch|||anthraquinone|||0|861|1755|1768
SE|25462369|RESULTS|ab|10|entity|C0042036|Urine|bdsu|||urine|||0|861|1776|1781
SE|25462369|RESULTS|ab|10|entity|C0229671|Serum|bdsu|||serum|||0|861|1787|1792
SE|25462369|RESULTS|ab|10|entity|C1139023|Culture Media, Cell|medd|||cell culture medium|||0|983|1797|1816
SE|25462369|RESULTS|ab|10|relation|3|1|C0042036|Urine|bdsu|bdsu|||urine|||0|861|1776|1781|PREP|LOCATION_OF||1769|1771|6|1|C0003174|Anthraquinones|orch|orch|||anthraquinone|||0|861|1755|1768

SE|25462369|CONCLUSIONS|ab|11|text|1818|1926|CONCLUSIONS: Reactive paper spray could be applied to fast screening of quinones from complicated matrices.
SE|25462369|CONCLUSIONS|ab|11|entity|C0205332|Reactive|qlco|||Reactive|||0|851|1831|1839
SE|25462369|CONCLUSIONS|ab|11|entity|C0030351|Paper|mnob|||paper|||0|851|1840|1845
SE|25462369|CONCLUSIONS|ab|11|entity|C1154182|Spray|sbst|||spray|||0|851|1846|1851
SE|25462369|CONCLUSIONS|ab|11|entity|C0456962|Fast|qlco|||fast|||0|888|1872|1876
SE|25462369|CONCLUSIONS|ab|11|entity|C0220908|Screening procedure|hlca|||screening|||0|888|1877|1886
SE|25462369|CONCLUSIONS|ab|11|entity|C0034435|Quinones|orch|||quinones|||0|1000|1890|1898
SE|25462369|CONCLUSIONS|ab|11|entity|C0231242|Complicated|ftcn|||complicated|||0|872|1904|1915
SE|25462369|CONCLUSIONS|ab|11|entity|C0331858|Matrix|hcro|||matrices|||0|872|1916|1924

SE|25462369|CONCLUSIONS|ab|12|text|1926|2094|Therefore, we believe that reactive paper spray mass spectrometry might be potentially useful in the fields of environmental sciences, metabolomics and clinic analysis.
SE|25462369|CONCLUSIONS|ab|12|entity|C0205332|Reactive|qlco|||reactive|||0|840|1953|1961
SE|25462369|CONCLUSIONS|ab|12|entity|C0030351|Paper|mnob|||paper|||0|840|1962|1967
SE|25462369|CONCLUSIONS|ab|12|entity|C1154182|Spray|sbst|||spray|||0|840|1968|1973
SE|25462369|CONCLUSIONS|ab|12|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|840|1974|1991
SE|25462369|CONCLUSIONS|ab|12|entity|C1521738|Field|cnce|||fields|||0|966|2027|2033
SE|25462369|CONCLUSIONS|ab|12|entity|C0013546|Ecology|ocdi|||environmental sciences|||0|1000|2037|2059
SE|25462369|CONCLUSIONS|ab|12|entity|C1328813|metabolomics|orgf|||metabolomics|||0|1000|2061|2073
SE|25462369|CONCLUSIONS|ab|12|entity|C0002424|Ambulatory Care Facilities|hcro,mnob|||clinic|||0|888|2078|2084
SE|25462369|CONCLUSIONS|ab|12|entity|C0936012|Analysis|resa|||analysis|||0|888|2085|2093
SE|25462369|CONCLUSIONS|ab|12|relation|0|0|C0002424|Ambulatory Care Facilities|hcro,mnob|hcro|||clinic|||0|888|2078|2084|MOD/HEAD|LOCATION_OF||2078|2093|0|0|C0936012|Analysis|resa|resa|||analysis|||0|888|2085|2093


SE|25462370||ti|1|text|21|132|Calcined bone provides a reliable substrate for strontium isotope ratios as shown by an enrichment experiment.
SE|25462370||ti|1|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|861|30|34
SE|25462370||ti|1|entity|C0038468|Strontium Isotopes|elii|||strontium isotope|||0|901|69|86
SE|25462370||ti|1|entity|C0456603|Ratio|inpr|||ratios|||0|901|87|93
SE|25462370||ti|1|entity|C0681814|research study|resa|||experiment|||0|861|120|130

SE|25462370|RATIONALE|ab|1|text|138|323|RATIONALE: Strontium isotopes ((87) Sr/(86) Sr) are used in archaeological and forensic science as markers of residence or mobility because they reflect the local geological substrate.
SE|25462370|RATIONALE|ab|1|entity|C0038468|Strontium Isotopes|elii|||Strontium isotopes|||0|1000|149|167
SE|25462370|RATIONALE|ab|1|entity|C1335806|SCTR gene|gngm|6344|SCTR|Sr|||0|1000|174|176
SE|25462370|RATIONALE|ab|1|entity|C0003733|Archaeology|ocdi|||archaeological|||0|928|198|212
SE|25462370|RATIONALE|ab|1|entity|C1257940|Forensic Sciences|ocdi|||forensic science|||0|1000|217|233
SE|25462370|RATIONALE|ab|1|entity|C0237096|residence|spco|||residence|||0|1000|248|257
SE|25462370|RATIONALE|ab|1|entity|C0205276|Local|spco|||local|||0|587|295|300
SE|25462370|RATIONALE|ab|1|entity|C0017448|Geology|ocdi|||geological|||0|587|301|311

SE|25462370|RATIONALE|ab|2|text|323|484|Currently, tooth enamel is considered to be the most reliable tissue, but it rarely survives heating so that in cremations only calcined bone fragments survive.
SE|25462370|RATIONALE|ab|2|entity|C0521116|Current|tmco|||Currently|||0|1000|323|332
SE|25462370|RATIONALE|ab|2|entity|C0011350|Dental Enamel|bdsu|||tooth enamel|||0|1000|334|346
SE|25462370|RATIONALE|ab|2|entity|C0205393|Most|qnco|||most|||0|660|371|375
SE|25462370|RATIONALE|ab|2|entity|C0522498|Rare|qlco|||rarely|||0|1000|400|406
SE|25462370|RATIONALE|ab|2|entity|C0018851|Heating|eehu|||heating|||0|1000|416|423
SE|25462370|RATIONALE|ab|2|entity|C0010302|Cremation|acty|||cremations|||0|1000|435|445
SE|25462370|RATIONALE|ab|2|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|888|460|464
SE|25462370|RATIONALE|ab|2|entity|C0486805|FRAGMENTS|bdsu|||fragments|||0|888|465|474

SE|25462370|RATIONALE|ab|3|text|484|845|We set out to test the proposition that calcined bone might prove resistant to diagenesis, given its relatively high crystallinity, as the ability to measure in vivo (87) Sr/(86) Sr from calcined bone would greatly extend application to places and periods in which cremation was the dominant mortuary practice, or where unburned bone and enamel do not survive.
SE|25462370|RATIONALE|ab|3|entity|C0439787|Out|spco|||out|||0|1000|491|494
SE|25462370|RATIONALE|ab|3|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|861|533|537
SE|25462370|RATIONALE|ab|3|entity|C0332325|Resistant|ftcn|||resistant|||0|1000|550|559
SE|25462370|RATIONALE|ab|3|entity|C0205250|High|qlco|||high|||0|740|596|600
SE|25462370|RATIONALE|ab|3|entity|C0427896|Crystal - human material|bdsu|||crystallinity|||0|740|601|614
SE|25462370|RATIONALE|ab|3|entity|C0085732|Ability|orga|||ability|||0|1000|623|630
SE|25462370|RATIONALE|ab|3|entity|C1515655|in vivo|spco|||in vivo|||0|1000|642|649
SE|25462370|RATIONALE|ab|3|entity|C1335806|SCTR gene|gngm|6344|SCTR|Sr|||0|1000|655|657
SE|25462370|RATIONALE|ab|3|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|861|680|684
SE|25462370|RATIONALE|ab|3|entity|C0442504|Place|spco|||places|||0|1000|721|727
SE|25462370|RATIONALE|ab|3|entity|C0439531|/period|tmco|||periods|||0|966|732|739
SE|25462370|RATIONALE|ab|3|entity|C0010302|Cremation|acty|||cremation|||0|1000|749|758
SE|25462370|RATIONALE|ab|3|entity|C1527180|Dominant|ftcn|||dominant|||0|901|767|775
SE|25462370|RATIONALE|ab|3|entity|C0026572|Mortuary Practice|ocdi|||mortuary practice|||0|901|776|793
SE|25462370|RATIONALE|ab|3|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|827|813|817
SE|25462370|RATIONALE|ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|832|835

SE|25462370|METHODS|ab|4|text|845|953|METHODS: Tooth enamel and calcined bone samples were exposed to a (87) Sr-spiked solution for up to 1 year.
SE|25462370|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|845|852
SE|25462370|METHODS|ab|4|entity|C0011350|Dental Enamel|bdsu|||Tooth enamel|||0|1000|854|866
SE|25462370|METHODS|ab|4|entity|C0444227|Bone specimen|bpoc|||bone samples|||0|884|880|892
SE|25462370|METHODS|ab|4|entity|C0037633|Solutions|sbst|||solution|||0|802|926|934
SE|25462370|METHODS|ab|4|entity|C0439234|year|tmco|||year|||0|861|947|951

SE|25462370|METHODS|ab|5|text|953|1096|Samples were removed after various intervals, and attempts were made to remove the contamination using acetic acid washes and ultrasonication.
SE|25462370|METHODS|ab|5|entity|C1272706|Interval|tmco|||intervals|||0|827|988|997
SE|25462370|METHODS|ab|5|entity|C1516084|Attempt|evnt|||attempts|||0|966|1003|1011
SE|25462370|METHODS|ab|5|entity|C0259846|adulteration|hcpp|||contamination|||0|1000|1036|1049
SE|25462370|METHODS|ab|5|entity|C0000983|Acetic Acid|irda,orch,phsu|||acetic acid|||0|734|1056|1067

SE|25462370|METHODS|ab|6|text|1096|1256|(87) Sr/(86) Sr was measured before and after pre-treatment on a Nu Plasma multi-collector induced coupled plasma mass spectrometer using NBS987 as a standard.
SE|25462370|METHODS|ab|6|entity|C1335806|SCTR gene|gngm|6344|SCTR|Sr|||0|1000|1101|1103
SE|25462370|METHODS|ab|6|entity|C0740175|Before values|tmco|||pre|||0|888|1142|1145
SE|25462370|METHODS|ab|6|entity|C0032105|Plasma|bdsu|||Plasma|||0|825|1164|1170
SE|25462370|METHODS|ab|6|entity|C1442112|MULTI|qnco|||multi|||0|825|1171|1176
SE|25462370|METHODS|ab|6|entity|C0180011|Collectors|medd|||collector|||0|825|1177|1186
SE|25462370|METHODS|ab|6|entity|C0032105|Plasma|bdsu|||plasma|||0|838|1203|1209
SE|25462370|METHODS|ab|6|entity|C0183396|Spectrometers, Mass|medd|||mass spectrometer|||0|838|1210|1227
SE|25462370|METHODS|ab|6|entity|C1442989|STANDARD|ftcn|||standard|||0|1000|1246|1254

SE|25462370|RESULTS|ab|7|text|1256|1446|RESULTS: The strontium isotopic ratios of all samples immersed in the spiked solution were strongly modified showing that significant amounts of strontium had been adsorbed or incorporated.
SE|25462370|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1256|1263
SE|25462370|RESULTS|ab|7|entity|C0038468|Strontium Isotopes|elii|||strontium isotopic|||0|877|1269|1287
SE|25462370|RESULTS|ab|7|entity|C0456603|Ratio|inpr|||ratios|||0|877|1288|1294
SE|25462370|RESULTS|ab|7|entity|C0037633|Solutions|sbst|||solution|||0|861|1333|1341
SE|25462370|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significant|||0|872|1378|1389
SE|25462370|RESULTS|ab|7|entity|C1265611|Quantity|qnco|||amounts|||0|872|1390|1397
SE|25462370|RESULTS|ab|7|entity|C0038467|Strontium|bacs,elii|||strontium|||0|1000|1401|1410

SE|25462370|RESULTS|ab|8|text|1446|1598|After pre-treatment the enamel samples still contained significant amounts of (87) Sr-enriched contamination while the calcined bone fragments did not.
SE|25462370|RESULTS|ab|8|entity|C0740175|Before values|tmco|||pre|||0|888|1452|1455
SE|25462370|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|872|1501|1512
SE|25462370|RESULTS|ab|8|entity|C1265611|Quantity|qnco|||amounts|||0|872|1513|1520
SE|25462370|RESULTS|ab|8|entity|C0359583|Enrich|food|||enriched|||0|840|1532|1540
SE|25462370|RESULTS|ab|8|entity|C0259846|adulteration|hcpp|||contamination|||0|840|1541|1554
SE|25462370|RESULTS|ab|8|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|790|1574|1578
SE|25462370|RESULTS|ab|8|entity|C0486805|FRAGMENTS|bdsu|||fragments|||0|790|1579|1588
SE|25462370|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1593|1596

SE|25462370|CONCLUSIONS|ab|9|text|1598|1828|CONCLUSIONS: The results of the artificial enrichment experiment demonstrate that calcined bone is more resistant to post-mortem exchange than tooth enamel, and that in vivo strontium isotopic ratios are retained in calcined bone.
SE|25462370|CONCLUSIONS|ab|9|entity|C1274040|result|ftcn|||results|||0|966|1615|1622
SE|25462370|CONCLUSIONS|ab|9|entity|C0205237|False|qlco|||artificial|||0|802|1630|1640
SE|25462370|CONCLUSIONS|ab|9|entity|C0681814|research study|resa|||experiment|||0|802|1652|1662
SE|25462370|CONCLUSIONS|ab|9|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|861|1689|1693
SE|25462370|CONCLUSIONS|ab|9|entity|C0205172|More|ftcn|||more|||0|840|1697|1701
SE|25462370|CONCLUSIONS|ab|9|entity|C0332325|Resistant|ftcn|||resistant to|||0|840|1702|1714
SE|25462370|CONCLUSIONS|ab|9|entity|C0004398|Autopsy|diap|||post-mortem|||0|840|1715|1726
SE|25462370|CONCLUSIONS|ab|9|entity|C0678640|exchange|socb|||exchange|||0|840|1727|1735
SE|25462370|CONCLUSIONS|ab|9|entity|C0011350|Dental Enamel|bdsu|||tooth enamel|||0|1000|1741|1753
SE|25462370|CONCLUSIONS|ab|9|entity|C1515655|in vivo|spco|||in vivo|||0|839|1764|1771
SE|25462370|CONCLUSIONS|ab|9|entity|C0038468|Strontium Isotopes|elii|||strontium isotopic|||0|839|1772|1790
SE|25462370|CONCLUSIONS|ab|9|entity|C0456603|Ratio|inpr|||ratios|||0|839|1791|1797
SE|25462370|CONCLUSIONS|ab|9|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|861|1823|1827


SE|25462371||ti|1|text|21|77|Detection of (135) Cs by accelerator mass spectrometry.
SE|25462371||ti|1|entity|C1511790|Detection|topp|||Detection|||0|1000|21|30
SE|25462371||ti|1|entity|C0681602|accelerator|mnob|||accelerator|||0|901|46|57
SE|25462371||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|901|58|75
SE|25462371||ti|1|relation|1|1|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||mass spectrometry|||0|901|58|75|PREP|METHOD_OF||43|45|2|2|C1511790|Detection|topp|topp|||Detection|||0|1000|21|30

SE|25462371|RATIONALE|ab|1|text|83|233|RATIONALE: The ability to measure both (135) Cs and (137) Cs can provide an estimate of the age and source of Cs isotopes in an environmental sample.
SE|25462371|RATIONALE|ab|1|entity|C0085732|Ability|orga|||ability|||0|1000|98|105
SE|25462371|RATIONALE|ab|1|entity|C0001779|Age|orga|||age|||0|1000|175|178
SE|25462371|RATIONALE|ab|1|entity|C0022262|Isotopes|elii|||isotopes|||0|888|196|204

SE|25462371|RATIONALE|ab|2|text|233|424|Accelerator mass spectrometry (AMS) consistently reports lower abundance sensitivities than other techniques and, with the addition of an on-line reaction cell, simpler isobaric suppression.
SE|25462371|RATIONALE|ab|2|entity|C0681602|accelerator|mnob|||Accelerator|||0|901|233|244
SE|25462371|RATIONALE|ab|2|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|901|245|262
SE|25462371|RATIONALE|ab|2|entity|C0441994|Lower|ftcn|||lower|||0|802|290|295
SE|25462371|RATIONALE|ab|2|entity|C0025664|Methodology|inpr|||techniques|||0|1000|331|341
SE|25462371|RATIONALE|ab|2|entity|C0442796|Additive|qlco|||addition|||0|928|356|364
SE|25462371|RATIONALE|ab|2|entity|C0205132|Linear|spco|||line|||0|775|374|378
SE|25462371|RATIONALE|ab|2|entity|C0443286|Reaction|ftcn|||reaction|||0|775|379|387
SE|25462371|RATIONALE|ab|2|entity|C0007634|Cells|cell|||cell|||0|775|388|392
SE|25462371|RATIONALE|ab|2|entity|C0205352|Simple|qlco|||simpler|||0|785|394|401

SE|25462371|RATIONALE|ab|3|text|424|525|Therefore, an AMS methodology was developed to measure Cs isotopes using CsF2- as the initial anion.
SE|25462371|RATIONALE|ab|3|entity|C0681602|accelerator|mnob|||AMS|||0|861|438|441
SE|25462371|RATIONALE|ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||AMS|||0|861|438|441
SE|25462371|RATIONALE|ab|3|entity|C0025664|Methodology|inpr|||methodology|||0|861|442|453
SE|25462371|RATIONALE|ab|3|entity|C0022262|Isotopes|elii|||isotopes|||0|888|482|490
SE|25462371|RATIONALE|ab|3|entity|C0079460|Granulocyte-Macrophage Colony-Stimulating Factor|aapp,imft|1437|CSF2|CsF2|||0|1000|497|501
SE|25462371|RATIONALE|ab|3|entity|C0205265|Initially|tmco|||initial|||0|888|510|517
SE|25462371|RATIONALE|ab|3|entity|C0003075|Anions|elii|||anion|||0|888|518|523

SE|25462371|METHODS|ab|4|text|525|714|METHODS: The ion beam is passed through the Isobar Separator for Anions (ISA) where it is captured by radiofrequency quadrupoles in a gas cell before injection into the tandem accelerator.
SE|25462371|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|525|532
SE|25462371|METHODS|ab|4|entity|C0022023|Ions|elii|||ion|||0|694|538|541
SE|25462371|METHODS|ab|4|entity|C0183212|Separators|medd|||Separator|||0|702|576|585
SE|25462371|METHODS|ab|4|entity|C0003075|Anions|elii|||Anions|||0|702|590|596
SE|25462371|METHODS|ab|4|entity|C0920725|radiofrequency|npop|||radiofrequency|||0|694|627|641
SE|25462371|METHODS|ab|4|entity|C0017110|Gases|chvs|||gas|||0|888|659|662
SE|25462371|METHODS|ab|4|entity|C0007634|Cells|cell|||cell|||0|888|663|667
SE|25462371|METHODS|ab|4|entity|C1533685|Injection procedure|topp|||injection|||0|1000|675|684
SE|25462371|METHODS|ab|4|entity|C0681602|accelerator|mnob|||accelerator|||0|888|701|712
SE|25462371|METHODS|ab|4|relation|3|1|C0007634|Cells|cell|cell|||cell|||0|888|663|667|PREP|LOCATION_OF||654|656|3|1|C0003075|Anions|elii|elii|||Anions|||0|702|590|596

SE|25462371|METHODS|ab|5|text|714|883|In the ISA, the beam reacts with O2 gas, selectively removing the BaF2- and leaving the Cs analyte to be reaccelerated and sent through the remainder of the AMS system.
SE|25462371|METHODS|ab|5|entity|C0183212|Separators|medd|||ISA|||0|711|721|724
SE|25462371|METHODS|ab|5|entity|C0003075|Anions|elii|||ISA|||0|711|721|724
SE|25462371|METHODS|ab|5|entity|C0017110|Gases|chvs|||gas|||0|888|750|753
SE|25462371|METHODS|ab|5|entity|||gngm|140836|BANF2|BaF2|||0|1000|780|784
SE|25462371|METHODS|ab|5|entity|C0443354|Analyte|chvf|||analyte|||0|888|805|812
SE|25462371|METHODS|ab|5|entity|C0681602|accelerator|mnob|||AMS|||0|861|871|874
SE|25462371|METHODS|ab|5|entity|C0037813|Spectrum Analysis, Mass|lbpr|||AMS|||0|861|871|874
SE|25462371|METHODS|ab|5|entity|C0449913|System|ftcn|||system|||0|861|875|881

SE|25462371|RESULTS|ab|6|text|883|1034|RESULTS: The BaF2- signal was attenuated by a factor of 10(5) in the ISA while 25% of the original CsF2- current was transmitted into the accelerator.
SE|25462371|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|883|890
SE|25462371|RESULTS|ab|6|entity|||gngm|140836|BANF2|BaF2|||0|1000|896|900
SE|25462371|RESULTS|ab|6|entity|C1521761|Factor|ftcn|||factor|||0|1000|929|935
SE|25462371|RESULTS|ab|6|entity|C0183212|Separators|medd|||ISA|||0|711|952|955
SE|25462371|RESULTS|ab|6|entity|C0003075|Anions|elii|||ISA|||0|711|952|955
SE|25462371|RESULTS|ab|6|entity|C0205313|Original|idcn|||original|||0|851|973|981
SE|25462371|RESULTS|ab|6|entity|C0079460|Granulocyte-Macrophage Colony-Stimulating Factor|aapp,imft|1437|CSF2|CsF2|||0|851|982|986
SE|25462371|RESULTS|ab|6|entity|C0521116|Current|tmco|||current|||0|851|988|995
SE|25462371|RESULTS|ab|6|entity|C0681602|accelerator|mnob|||accelerator|||0|1000|1021|1032

SE|25462371|RESULTS|ab|7|text|1034|1142|(135) Cs was measured without any interference from (133) Cs to an abundance sensitivity of 1.3 * 10(-10) .

SE|25462371|RESULTS|ab|8|text|1142|1297|The abundances of four stable Ba isotopes (masses 133, 134, 135 and 137) were measured and no isotope-dependent bias was detected using the ISA in vacuum.
SE|25462371|RESULTS|ab|8|entity|C0205450|Four|qnco|||four|||0|852|1160|1164
SE|25462371|RESULTS|ab|8|entity|C0302918|Stable isotope|elii|||stable Ba isotopes|||0|852|1165|1183
SE|25462371|RESULTS|ab|8|entity|C1306372|Mass, a measure of quantity of matter|qnco|||masses|||0|827|1185|1191
SE|25462371|RESULTS|ab|8|entity|C0022262|Isotopes|elii|||isotope|||0|851|1236|1243
SE|25462371|RESULTS|ab|8|entity|C0242568|Biases|idcn|||bias|||0|851|1254|1258
SE|25462371|RESULTS|ab|8|entity|C0183212|Separators|medd|||ISA|||0|725|1282|1285
SE|25462371|RESULTS|ab|8|entity|C0003075|Anions|elii|||ISA|||0|725|1282|1285
SE|25462371|RESULTS|ab|8|entity|C0042221|Vacuum|npop|||vacuum|||0|1000|1289|1295

SE|25462371|CONCLUSIONS|ab|9|text|1297|1515|CONCLUSIONS: The results demonstrate the feasibility of measuring long-lived Cs isotopes without Ba interference by AMS with on-line isobar separation and the ability to use shorter lived Cs isotopes for yield tracing.
SE|25462371|CONCLUSIONS|ab|9|entity|C1274040|result|ftcn|||results|||0|966|1314|1321
SE|25462371|CONCLUSIONS|ab|9|entity|C0079809|Measures|qnco|||measuring|||0|808|1353|1362
SE|25462371|CONCLUSIONS|ab|9|entity|C0205166|Long|qlco|||long|||0|808|1363|1367
SE|25462371|CONCLUSIONS|ab|9|entity|C1548795|Live|qlco|||lived|||0|808|1368|1373
SE|25462371|CONCLUSIONS|ab|9|entity|C0022262|Isotopes|elii|||isotopes|||0|808|1377|1385
SE|25462371|CONCLUSIONS|ab|9|entity|C0681602|accelerator|mnob|||AMS|||0|901|1413|1416
SE|25462371|CONCLUSIONS|ab|9|entity|C0037813|Spectrum Analysis, Mass|lbpr|||AMS|||0|901|1413|1416
SE|25462371|CONCLUSIONS|ab|9|entity|C0205132|Linear|spco|||line|||0|763|1425|1429
SE|25462371|CONCLUSIONS|ab|9|entity|C0036679|Diastasis|patf|||separation|||0|763|1437|1447
SE|25462371|CONCLUSIONS|ab|9|entity|C0085732|Ability|orga|||ability|||0|1000|1456|1463
SE|25462371|CONCLUSIONS|ab|9|entity|C1548795|Live|qlco|||lived|||0|816|1479|1484
SE|25462371|CONCLUSIONS|ab|9|entity|C0022262|Isotopes|elii|||isotopes|||0|816|1488|1496
SE|25462371|CONCLUSIONS|ab|9|relation|8|3|C0037813|Spectrum Analysis, Mass|lbpr|lbpr|||AMS|||0|901|1413|1416|VERB|USES||1467|1470|2|1|C0022262|Isotopes|elii|elii|||isotopes|||0|816|1488|1496


SE|25462372||ti|1|text|21|157|Comparison of peak-picking workflows for untargeted liquid chromatography/high-resolution mass spectrometry metabolomics data analysis.
SE|25462372||ti|1|entity|C0205250|High|qlco|||high|||0|808|95|99
SE|25462372||ti|1|entity|C1514893|Resolution|ftcn|||resolution|||0|808|100|110
SE|25462372||ti|1|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||liquid chromatography/high-resolution mass spectrometry|||0|808|73|128
SE|25462372||ti|1|entity|C1328813|metabolomics|orgf|||metabolomics|||0|808|129|141
SE|25462372||ti|1|entity|C0010992|Data Analysis|ocac|||data analysis|||0|808|142|155

SE|25462372|RATIONALE|ab|1|text|163|368|RATIONALE: Data analysis is a key step in mass spectrometry based untargeted metabolomics, starting with the generation of generic peak lists from raw liquid chromatography/mass spectrometry (LC/MS) data.
SE|25462372|RATIONALE|ab|1|entity|C0010992|Data Analysis|ocac|||Data analysis|||0|1000|174|187
SE|25462372|RATIONALE|ab|1|entity|C1554080|Key|idcn|||key|||0|888|193|196
SE|25462372|RATIONALE|ab|1|entity|C1261552|Step|ftcn|||step|||0|888|197|201
SE|25462372|RATIONALE|ab|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|1000|205|222
SE|25462372|RATIONALE|ab|1|entity|C1328813|metabolomics|orgf|||metabolomics|||0|861|240|252
SE|25462372|RATIONALE|ab|1|entity|C0079411|Generations|tmco|||generation|||0|966|272|282
SE|25462372|RATIONALE|ab|1|entity|C0745732|LIST|cnce|||lists|||0|793|299|304
SE|25462372|RATIONALE|ab|1|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||liquid chromatography/mass spectrometry|||0|876|314|353
SE|25462372|RATIONALE|ab|1|entity|C1511726|Data|idcn|||data|||0|876|362|366

SE|25462372|RATIONALE|ab|2|text|368|499|Due to the use of various algorithms by different workflows, the results of different peak-picking strategies often differ widely.
SE|25462372|RATIONALE|ab|2|entity|C0002045|algorithm|inpr|||algorithms|||0|861|394|404
SE|25462372|RATIONALE|ab|2|entity|C1547020|*Difference|qnco|||different|||0|623|408|417
SE|25462372|RATIONALE|ab|2|entity|C1274040|result|ftcn|||results|||0|966|433|440
SE|25462372|RATIONALE|ab|2|entity|C1547020|*Difference|qnco|||different|||0|755|444|453
SE|25462372|RATIONALE|ab|2|entity|C0332183|Frequent|tmco|||often|||0|1000|478|483

SE|25462372|METHODS|ab|3|text|499|740|METHODS: Raw LC/HRMS data from two types of biological samples (bile and urine), as well as a standard mixture of 84 metabolites, were processed with four peak-picking softwares: Peakview(r), MarkerviewTM, MetabolitePilotTM and XCMS Online.
SE|25462372|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|499|506
SE|25462372|METHODS|ab|3|entity|C1511726|Data|idcn|||data|||0|812|520|524
SE|25462372|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|888|530|533
SE|25462372|METHODS|ab|3|entity|C0332307|Type - attribute|qlco|||types|||0|888|534|539
SE|25462372|METHODS|ab|3|entity|C0205460|biological|ftcn|||biological|||0|694|543|553
SE|25462372|METHODS|ab|3|entity|C0042036|Urine|bdsu|||urine|||0|1000|572|577
SE|25462372|METHODS|ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|888|593|601
SE|25462372|METHODS|ab|3|entity|C0439962|Mixture|sbst|||mixture|||0|888|602|609
SE|25462372|METHODS|ab|3|entity|C0870883|Metabolites|bacs|||metabolites|||0|861|616|627
SE|25462372|METHODS|ab|3|entity|C0205450|Four|qnco|||four|||0|645|649|653

SE|25462372|METHODS|ab|4|text|740|828|The overlaps between the results of each peak-generating method were then investigated.
SE|25462372|METHODS|ab|4|entity|C1274040|result|ftcn|||results|||0|966|765|772
SE|25462372|METHODS|ab|4|entity|C0025663|Methods|inpr|||method|||0|827|797|803

SE|25462372|METHODS|ab|5|text|828|1073|To gauge the relevance of peak lists, a database search using the METLIN online database was performed to determine which features had accurate masses matching known metabolites as well as a secondary filtering based on MS/MS spectral matching.
SE|25462372|METHODS|ab|5|entity|C0745732|LIST|cnce|||lists|||0|827|859|864
SE|25462372|METHODS|ab|5|entity|C0242356|Databases|inpr|||database|||0|888|868|876
SE|25462372|METHODS|ab|5|entity|C1552603|search|idcn|||search|||0|888|877|883
SE|25462372|METHODS|ab|5|entity|C0871840|Online Databases|inpr|||online database|||0|884|901|916
SE|25462372|METHODS|ab|5|entity|C0443131|Accurate|qlco|||accurate|||0|872|963|971
SE|25462372|METHODS|ab|5|entity|C1306372|Mass, a measure of quantity of matter|qnco|||masses|||0|872|972|978
SE|25462372|METHODS|ab|5|entity|C0205309|Known|qlco|||known|||0|888|988|993
SE|25462372|METHODS|ab|5|entity|C0870883|Metabolites|bacs|||metabolites|||0|888|994|1005
SE|25462372|METHODS|ab|5|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|872|1019|1028
SE|25462372|METHODS|ab|5|entity|C0150103|MATCHING|resa|||matching|||0|812|1063|1071

SE|25462372|RESULTS|ab|6|text|1073|1193|RESULTS: In this study, only a small proportion of all peaks (less than 10%) were common to all four software programs.
SE|25462372|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1073|1080
SE|25462372|RESULTS|ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1090|1095
SE|25462372|RESULTS|ab|6|entity|C0700321|Small|qnco|||small|||0|853|1104|1109
SE|25462372|RESULTS|ab|6|entity|C0205351|Proportional|qlco|||proportion|||0|853|1110|1120
SE|25462372|RESULTS|ab|6|entity|C0205214|Common|qnco|||common|||0|1000|1155|1161
SE|25462372|RESULTS|ab|6|entity|C0205450|Four|qnco|||four|||0|660|1169|1173

SE|25462372|RESULTS|ab|7|text|1193|1397|Comparison of database searching results showed peaks found uniquely by one workflow have less chance of being found in the METLIN metabolomics database and are even less likely to be confirmed by MS/MS.
SE|25462372|RESULTS|ab|7|entity|C0242356|Databases|inpr|||database|||0|829|1207|1215
SE|25462372|RESULTS|ab|7|entity|C1552603|search|idcn|||searching|||0|829|1216|1225
SE|25462372|RESULTS|ab|7|entity|C1274040|result|ftcn|||results|||0|829|1226|1233
SE|25462372|RESULTS|ab|7|entity|C0205447|One|qnco|||one|||0|694|1265|1268
SE|25462372|RESULTS|ab|7|entity|C0237506|Chance|qlco|||chance|||0|861|1288|1294
SE|25462372|RESULTS|ab|7|entity|C1328813|metabolomics|orgf|||metabolomics|||0|790|1324|1336
SE|25462372|RESULTS|ab|7|entity|C0242356|Databases|inpr|||database|||0|790|1337|1345

SE|25462372|CONCLUSIONS|ab|8|text|1397|1529|CONCLUSIONS: It was shown that the performance of peak-generating workflows has a direct impact on untargeted metabolomics results.
SE|25462372|CONCLUSIONS|ab|8|entity|C0597198|Performance|inbe|||performance|||0|1000|1432|1443
SE|25462372|CONCLUSIONS|ab|8|entity|C1328813|metabolomics|orgf|||metabolomics|||0|773|1507|1519
SE|25462372|CONCLUSIONS|ab|8|entity|C1274040|result|ftcn|||results|||0|773|1520|1527

SE|25462372|CONCLUSIONS|ab|9|text|1529|1878|As it was demonstrated that the peaks found in more than one peak detection workflow have higher potential to be identified by accurate mass as well as MS/MS spectrum matching, it is suggested to use the overlap of different peak-picking workflows as preliminary peak lists for more rugged statistical analysis in global metabolomics investigations.
SE|25462372|CONCLUSIONS|ab|9|entity|C0205172|More|ftcn|||more|||0|1000|1576|1580
SE|25462372|CONCLUSIONS|ab|9|entity|C0205447|One|qnco|||one|||0|597|1586|1589
SE|25462372|CONCLUSIONS|ab|9|entity|C1511790|Detection|topp|||detection|||0|597|1595|1604
SE|25462372|CONCLUSIONS|ab|9|entity|C0205250|High|qlco|||higher|||0|872|1619|1625
SE|25462372|CONCLUSIONS|ab|9|entity|C0237399|Potential|qlco|||potential|||0|872|1626|1635
SE|25462372|CONCLUSIONS|ab|9|entity|C0443131|Accurate|qlco|||accurate|||0|888|1656|1664
SE|25462372|CONCLUSIONS|ab|9|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|888|1665|1669
SE|25462372|CONCLUSIONS|ab|9|entity|C0150103|MATCHING|resa|||matching|||0|812|1696|1704
SE|25462372|CONCLUSIONS|ab|9|entity|C1547020|*Difference|qnco|||different|||0|574|1744|1753
SE|25462372|CONCLUSIONS|ab|9|entity|C0439611|Preliminary|tmco|||preliminary|||0|785|1780|1791
SE|25462372|CONCLUSIONS|ab|9|entity|C0745732|LIST|cnce|||lists|||0|785|1797|1802
SE|25462372|CONCLUSIONS|ab|9|entity|C0205172|More|ftcn|||more|||0|824|1807|1811
SE|25462372|CONCLUSIONS|ab|9|entity|C0871424|Statistical Analysis|resa|||statistical analysis|||0|824|1819|1839
SE|25462372|CONCLUSIONS|ab|9|entity|C0205246|Generalized|spco|||global|||0|851|1843|1849
SE|25462372|CONCLUSIONS|ab|9|entity|C1328813|metabolomics|orgf|||metabolomics|||0|851|1850|1862


SE|25462373||ti|1|text|21|125|Impact of data-dependent exclusion list based mass spectrometry on label-free proteomic quantification.
SE|25462373||ti|1|entity|C0680251|Exclusion|ftcn|||exclusion|||0|822|46|55
SE|25462373||ti|1|entity|C0745732|LIST|cnce|||list|||0|822|56|60
SE|25462373||ti|1|entity|C0242356|Databases|inpr|||data-dependent exclusion list based|||0|822|31|66
SE|25462373||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|822|67|84
SE|25462373||ti|1|entity|C0181496|Labels|mnob|||label|||0|645|88|93

SE|25462373|RATIONALE|ab|1|text|131|272|RATIONALE: Spectral count analysis via data-dependent acquisition (DDA) mode mass spectrometry is used as label-free protein quantification.
SE|25462373|RATIONALE|ab|1|entity|C0750480|Count|idcn|||count|||0|715|151|156
SE|25462373|RATIONALE|ab|1|entity|C0936012|Analysis|resa|||analysis|||0|715|157|165
SE|25462373|RATIONALE|ab|1|entity|C1511726|Data|idcn|||data|||0|715|170|174
SE|25462373|RATIONALE|ab|1|entity|C1513371|Mode|ftcn|||mode|||0|715|203|207
SE|25462373|RATIONALE|ab|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|715|208|225
SE|25462373|RATIONALE|ab|1|entity|C0181496|Labels|mnob|||label|||0|597|237|242
SE|25462373|RATIONALE|ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|597|248|255

SE|25462373|RATIONALE|ab|2|text|272|397|However, combination of the DDA mode with exclusion list based DDA (DDA-EL) for the similar purpose has not yet been tested.
SE|25462373|RATIONALE|ab|2|entity|C0205195|Combined|qlco|||combination|||0|1000|281|292
SE|25462373|RATIONALE|ab|2|entity|C1511726|Data|idcn|||DDA|||0|775|300|303
SE|25462373|RATIONALE|ab|2|entity|C1513371|Mode|ftcn|||mode|||0|775|304|308
SE|25462373|RATIONALE|ab|2|entity|C0680251|Exclusion|ftcn|||exclusion|||0|596|314|323
SE|25462373|RATIONALE|ab|2|entity|C0745732|LIST|cnce|||list|||0|596|324|328
SE|25462373|RATIONALE|ab|2|entity|C1511726|Data|idcn|||DDA|||0|596|335|338
SE|25462373|RATIONALE|ab|2|entity|C1511726|Data|idcn|||DDA|||0|583|340|343
SE|25462373|RATIONALE|ab|2|entity|C1285529|Purpose|ftcn|||purpose|||0|853|364|371
SE|25462373|RATIONALE|ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|376|379

SE|25462373|RATIONALE|ab|3|text|397|513|Therefore, we have taken the initiative to check the protein abundance using DDA-EL and measured their suitability.
SE|25462373|RATIONALE|ab|3|entity|C0424093|Initiative|menp|||initiative|||0|1000|426|436
SE|25462373|RATIONALE|ab|3|entity|C0033684|Proteins|aapp,bacs|||protein|||0|694|450|457
SE|25462373|RATIONALE|ab|3|entity|C1511726|Data|idcn|||DDA|||0|583|474|477

SE|25462373|METHODS|ab|4|text|513|693|METHODS: To check the protein abundance correlation between different samples, multiple replicates of mass spectrometric analysis of peptides were conducted primarily in DDA mode.
SE|25462373|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|513|520
SE|25462373|METHODS|ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|660|535|542
SE|25462373|METHODS|ab|4|entity|C1547020|*Difference|qnco|||different|||0|623|573|582
SE|25462373|METHODS|ab|4|entity|C0439064|Numerous|qnco|||multiple|||0|1000|592|600
SE|25462373|METHODS|ab|4|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometric|||0|877|615|633
SE|25462373|METHODS|ab|4|entity|C0936012|Analysis|resa|||analysis|||0|877|634|642
SE|25462373|METHODS|ab|4|entity|C0030956|Peptides|aapp|||peptides|||0|1000|646|654
SE|25462373|METHODS|ab|4|entity|C1511726|Data|idcn|||DDA|||0|775|683|686
SE|25462373|METHODS|ab|4|entity|C1513371|Mode|ftcn|||mode|||0|775|687|691

SE|25462373|METHODS|ab|5|text|693|837|Subsequently, peptides were analyzed in multiple replicates in DDA-EL mode with an exclusion mass list prepared from the previous DDA analyses.
SE|25462373|METHODS|ab|5|entity|C0030956|Peptides|aapp|||peptides|||0|1000|707|715
SE|25462373|METHODS|ab|5|entity|C0439064|Numerous|qnco|||multiple|||0|1000|733|741
SE|25462373|METHODS|ab|5|entity|C1511726|Data|idcn|||DDA|||0|762|756|759
SE|25462373|METHODS|ab|5|entity|C1513371|Mode|ftcn|||mode|||0|762|763|767
SE|25462373|METHODS|ab|5|entity|C0680251|Exclusion|ftcn|||exclusion|||0|851|776|785
SE|25462373|METHODS|ab|5|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|851|786|790
SE|25462373|METHODS|ab|5|entity|C0745732|LIST|cnce|||list|||0|851|791|795
SE|25462373|METHODS|ab|5|entity|C0205156|Previous|tmco|||previous|||0|794|814|822
SE|25462373|METHODS|ab|5|entity|C0010992|Data Analysis|ocac|||DDA analyses|||0|794|823|835

SE|25462373|METHODS|ab|6|text|837|1056|The normalized spectral abundance factor (NSAF) for each identified protein was compared among replicated datasets of single DDA, DDA-EL, merged two DDAs, and merged DDA + DDA-EL or between different types of datasets.
SE|25462373|METHODS|ab|6|entity|C1521761|Factor|ftcn|||factor|||0|812|871|877
SE|25462373|METHODS|ab|6|entity|C0205396|Identified|qlco|||identified|||0|888|894|904
SE|25462373|METHODS|ab|6|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|905|912
SE|25462373|METHODS|ab|6|entity|C0205173|Duplicate|ftcn|||replicated|||0|661|932|942
SE|25462373|METHODS|ab|6|entity|C0037179|Unmarried person|popg|||single|||0|608|955|961
SE|25462373|METHODS|ab|6|entity|C1511726|Data|idcn|||DDA|||0|608|962|965
SE|25462373|METHODS|ab|6|entity|C1511726|Data|idcn|||DDA|||0|583|967|970
SE|25462373|METHODS|ab|6|entity|C0205448|Two|qnco|||two|||0|660|982|985
SE|25462373|METHODS|ab|6|entity|C1511726|Data|idcn|||DDA|||0|534|1003|1006
SE|25462373|METHODS|ab|6|entity|C1547020|*Difference|qnco|||different|||0|853|1027|1036
SE|25462373|METHODS|ab|6|entity|C0332307|Type - attribute|qlco|||types|||0|853|1037|1042

SE|25462373|RESULTS|ab|7|text|1056|1213|RESULTS: A strong and linear NSAF correlation with an average correlation coefficient of 0.939 was observed in the comparison between each pair of DDA data.
SE|25462373|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1056|1063
SE|25462373|RESULTS|ab|7|entity|C0442821|Strong|qlco|||strong|||0|1000|1067|1073
SE|25462373|RESULTS|ab|7|entity|C0205132|Linear|spco|||linear|||0|598|1078|1084
SE|25462373|RESULTS|ab|7|entity|C1521761|Factor|ftcn|||NSAF|||0|598|1085|1089
SE|25462373|RESULTS|ab|7|entity|C1510992|Average|qnco|||average|||0|802|1110|1117
SE|25462373|RESULTS|ab|7|entity|C1547015|*Coefficient|qnco|||coefficient|||0|802|1130|1141
SE|25462373|RESULTS|ab|7|entity|C1511726|Data|idcn|||DDA|||0|583|1203|1206

SE|25462373|RESULTS|ab|8|text|1213|1460|Similar connotation was also monitored in the comparison among DDA-EL data (r =0.928) or among merged DDA + DDA-EL data (r =0.960) while a reduced correlation coefficient (r =0.892) with increased deviation was marked between DDA and DDA-EL data.
SE|25462373|RESULTS|ab|8|entity|C0870339|Connotations|menp|||connotation|||0|836|1221|1232
SE|25462373|RESULTS|ab|8|entity|C1511726|Data|idcn|||DDA|||0|562|1276|1279
SE|25462373|RESULTS|ab|8|entity|C1511726|Data|idcn|||DDA|||0|530|1315|1318
SE|25462373|RESULTS|ab|8|entity|C0392756|Reduced|qlco|||reduced|||0|802|1352|1359
SE|25462373|RESULTS|ab|8|entity|C1547015|*Coefficient|qnco|||coefficient|||0|802|1372|1383
SE|25462373|RESULTS|ab|8|entity|C0205217|Increased|qnco|||increased|||0|888|1400|1409
SE|25462373|RESULTS|ab|8|entity|C0012727|Spatial Displacement|spco|||deviation|||0|888|1410|1419
SE|25462373|RESULTS|ab|8|entity|C1511726|Data|idcn|||DDA|||0|623|1439|1442
SE|25462373|RESULTS|ab|8|entity|C1511726|Data|idcn|||DDA|||0|562|1447|1450

SE|25462373|CONCLUSIONS|ab|9|text|1460|1620|CONCLUSIONS: Evaluation of protein abundance patterns from different cellular states can successfully be conducted by DDA-EL-based mass spectrometric analysis.
SE|25462373|CONCLUSIONS|ab|9|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|1473|1483
SE|25462373|CONCLUSIONS|ab|9|entity|C1317658|PROTEIN PATTERN|clna|||protein abundance patterns|||0|896|1487|1513
SE|25462373|CONCLUSIONS|ab|9|entity|C1547020|*Difference|qnco|||different|||0|816|1519|1528
SE|25462373|CONCLUSIONS|ab|9|entity|C0178539|Cellular|ftcn|||cellular|||0|816|1529|1537
SE|25462373|CONCLUSIONS|ab|9|entity|C1442792|State|ftcn|||states|||0|816|1538|1544
SE|25462373|CONCLUSIONS|ab|9|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometric|||0|745|1591|1609
SE|25462373|CONCLUSIONS|ab|9|entity|C0010992|Data Analysis|ocac|||DDA-EL-based mass spectrometric analysis|||0|745|1578|1618

SE|25462373|CONCLUSIONS|ab|10|text|1620|1755|Therefore, the new workflow, DDA-EL merged to DDA mode, is a potential alternative to protein identification and quantification method.
SE|25462373|CONCLUSIONS|ab|10|entity|C0205314|New|tmco|||new|||0|694|1635|1638
SE|25462373|CONCLUSIONS|ab|10|entity|C1511726|Data|idcn|||DDA|||0|583|1649|1652
SE|25462373|CONCLUSIONS|ab|10|entity|C1511726|Data|idcn|||DDA|||0|775|1666|1669
SE|25462373|CONCLUSIONS|ab|10|entity|C1513371|Mode|ftcn|||mode|||0|775|1670|1674
SE|25462373|CONCLUSIONS|ab|10|entity|C0237399|Potential|qlco|||potential|||0|888|1681|1690
SE|25462373|CONCLUSIONS|ab|10|entity|C1523987|Alternative|cnce|||alternative|||0|888|1691|1702
SE|25462373|CONCLUSIONS|ab|10|entity|C0033684|Proteins|aapp,bacs|||protein|||0|694|1706|1713
SE|25462373|CONCLUSIONS|ab|10|entity|C0025663|Methods|inpr|||method|||0|861|1748|1754


SE|25462374||ti|1|text|21|193|Automated annotation and quantitation of glycans by liquid chromatography/electrospray ionization mass spectrometric analysis using the MultiGlycan-ESI computational tool.
SE|25462374||ti|1|entity|C0205554|Automated|ftcn|||Automated|||0|694|21|30
SE|25462374||ti|1|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|1000|62|69
SE|25462374||ti|1|entity|C1516801|Electrospray Ionization|lbpr|||electrospray ionization|||0|861|95|118
SE|25462374||ti|1|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||liquid chromatography/electrospray ionization mass spectrometric|||0|861|73|137
SE|25462374||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|861|138|146
SE|25462374||ti|1|entity|C1516801|Electrospray Ionization|lbpr|||ESI|||0|763|169|172
SE|25462374||ti|1|entity|C0336791|Tool|mnob|||tool|||0|763|187|191

SE|25462374|RATIONALE|ab|1|text|199|409|RATIONALE: Liquid chromatography/mass spectrometry (LC/MS) is currently considered to be a conventional glycomics analysis strategy due to the high sensitivity and ability to handle complex biological samples.
SE|25462374|RATIONALE|ab|1|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||Liquid chromatography/mass spectrometry|||0|1000|210|249
SE|25462374|RATIONALE|ab|1|entity|C0521116|Current|tmco|||currently|||0|1000|261|270
SE|25462374|RATIONALE|ab|1|entity|C0439858|Conventional|qlco|||conventional|||0|775|290|302
SE|25462374|RATIONALE|ab|1|entity|C0936012|Analysis|resa|||analysis|||0|775|313|321
SE|25462374|RATIONALE|ab|1|entity|C1441604|HIGH SENSITIVITY|lbpr|||high sensitivity|||0|1000|342|358
SE|25462374|RATIONALE|ab|1|entity|C0085732|Ability|orga|||ability|||0|1000|363|370
SE|25462374|RATIONALE|ab|1|entity|C0439855|Complex|qlco|||complex|||0|583|381|388
SE|25462374|RATIONALE|ab|1|entity|C0205460|biological|ftcn|||biological|||0|583|389|399

SE|25462374|RATIONALE|ab|2|text|409|511|Interpretation of LC/MS data is a major bottleneck in high-throughput glycomics LC/MS-based analysis.
SE|25462374|RATIONALE|ab|2|entity|C0459471|Interpretation|inpr|||Interpretation|||0|1000|409|423
SE|25462374|RATIONALE|ab|2|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|928|427|432
SE|25462374|RATIONALE|ab|2|entity|C1511726|Data|idcn|||data|||0|928|433|437
SE|25462374|RATIONALE|ab|2|entity|C0205164|Major|qlco|||major|||0|694|443|448
SE|25462374|RATIONALE|ab|2|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|806|489|494
SE|25462374|RATIONALE|ab|2|entity|C0872186|high throughput analysis|diap|||high-throughput glycomics LC/MS-based analysis|||0|806|463|509

SE|25462374|RATIONALE|ab|3|text|511|692|The complexity of LC/MS data associated with biological samples prompts the needs to develop computational tools capable of facilitating automated data annotation and quantitation.
SE|25462374|RATIONALE|ab|3|entity|C0439855|Complex|qlco|||complexity|||0|928|515|525
SE|25462374|RATIONALE|ab|3|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|928|529|534
SE|25462374|RATIONALE|ab|3|entity|C1511726|Data|idcn|||data|||0|928|535|539
SE|25462374|RATIONALE|ab|3|entity|C0205460|biological|ftcn|||biological|||0|694|556|566
SE|25462374|RATIONALE|ab|3|entity|C0027552|Needs|qlco|||needs|||0|1000|587|592
SE|25462374|RATIONALE|ab|3|entity|C0336791|Tool|mnob|||tools|||0|827|618|623
SE|25462374|RATIONALE|ab|3|entity|C0205554|Automated|ftcn|||automated|||0|583|648|657
SE|25462374|RATIONALE|ab|3|entity|C1511726|Data|idcn|||data|||0|583|658|662

SE|25462374|METHODS|ab|4|text|692|838|METHODS: An LC/MS-based automated data annotation and quantitation software, MultiGlycan-ESI, was developed and utilized for glycan quantitation.
SE|25462374|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|692|699
SE|25462374|METHODS|ab|4|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|1000|704|709
SE|25462374|METHODS|ab|4|entity|C0205554|Automated|ftcn|||automated|||0|623|716|725
SE|25462374|METHODS|ab|4|entity|C1511726|Data|idcn|||data|||0|623|726|730
SE|25462374|METHODS|ab|4|entity|C1516801|Electrospray Ionization|lbpr|||ESI|||0|861|781|784
SE|25462374|METHODS|ab|4|entity|C0032594|Polysaccharides|carb,phsu|||glycan|||0|694|817|823

SE|25462374|METHODS|ab|5|text|838|1026|Data generated by the software from LC/MS analysis of permethylated N-glycans derived from fetuin were initially validated by manual integration to assess the performance of the software.
SE|25462374|METHODS|ab|5|entity|C1511726|Data|idcn|||Data|||0|1000|838|842
SE|25462374|METHODS|ab|5|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|928|874|879
SE|25462374|METHODS|ab|5|entity|C0936012|Analysis|resa|||analysis|||0|928|880|888
SE|25462374|METHODS|ab|5|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|827|908|915
SE|25462374|METHODS|ab|5|entity|C0002210|alpha-Fetoproteins|aapp,bacs|||fetuin|||0|1000|929|935
SE|25462374|METHODS|ab|5|entity|C0205265|Initially|tmco|||initially|||0|1000|941|950
SE|25462374|METHODS|ab|5|entity|C0024763|Manuals|inpr,mnob|||manual|||0|694|964|970
SE|25462374|METHODS|ab|5|entity|C0597198|Performance|inbe|||performance|||0|1000|997|1008
SE|25462374|METHODS|ab|5|relation|4|1|C0002210|alpha-Fetoproteins|aapp,gngm,bacs|aapp|||fetuin|||0|1000|929|935|VERB|CONVERTS_TO||916|923|4|1|C0032594|Polysaccharides|carb,phsu|carb|||glycans|||0|827|908|915

SE|25462374|METHODS|ab|6|text|1026|1242|The performance of MultiGlycan-ESI was then assessed for the quantitation of permethylated fetuin N-glycans analyzed at different concentrations or spiked with permethylated N-glycans derived from human blood serum.
SE|25462374|METHODS|ab|6|entity|C0597198|Performance|inbe|||performance|||0|1000|1030|1041
SE|25462374|METHODS|ab|6|entity|C1516801|Electrospray Ionization|lbpr|||ESI|||0|861|1057|1060
SE|25462374|METHODS|ab|6|entity|C0002210|alpha-Fetoproteins|aapp,bacs|||fetuin|||0|764|1117|1123
SE|25462374|METHODS|ab|6|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|764|1126|1133
SE|25462374|METHODS|ab|6|entity|C1547020|*Difference|qnco|||different|||0|853|1146|1155
SE|25462374|METHODS|ab|6|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|827|1202|1209
SE|25462374|METHODS|ab|6|entity|C0020114|Human|humn|||human|||0|901|1223|1228
SE|25462374|METHODS|ab|6|entity|C0229671|Serum|bdsu|||blood serum|||0|901|1229|1240
SE|25462374|METHODS|ab|6|relation|0|0|C0229671|Serum|bdsu|bdsu|||blood serum|||0|901|1229|1240|MOD/HEAD|PART_OF||1223|1240|0|0|C0020114|Human|grup,humn|humn|||human|||0|901|1223|1228

SE|25462374|RESULTS|ab|7|text|1242|1492|RESULTS: The relative abundance differences between data generated by the software and those generated by manual integration were less than 5%, indicating the reliability of MultiGlycan-ESI in quantitation of permethylated glycans analyzed by LC/MS.
SE|25462374|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1242|1249
SE|25462374|RESULTS|ab|7|entity|C0205345|Relative|qlco|||relative|||0|785|1255|1263
SE|25462374|RESULTS|ab|7|entity|C1547020|*Difference|qnco|||differences|||0|785|1274|1285
SE|25462374|RESULTS|ab|7|entity|C1511726|Data|idcn|||data|||0|1000|1294|1298
SE|25462374|RESULTS|ab|7|entity|C0024763|Manuals|inpr,mnob|||manual|||0|694|1348|1354
SE|25462374|RESULTS|ab|7|entity|C1516801|Electrospray Ionization|lbpr|||ESI|||0|861|1428|1431
SE|25462374|RESULTS|ab|7|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|861|1465|1472
SE|25462374|RESULTS|ab|7|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|1000|1485|1490
SE|25462374|RESULTS|ab|7|relation|1|1|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|lbpr|||LC/MS|||0|1000|1485|1490|PREP|METHOD_OF||1482|1484|9|3|C1516801|Electrospray Ionization|lbpr|lbpr|||ESI|||0|861|1428|1431

SE|25462374|RESULTS|ab|8|text|1492|1664|Automated quantitation resulted in a linear relationship for all six N-glycans derived from 50 ng to 400 ng fetuin with correlation coefficients (R(2) ) greater than 0.93.
SE|25462374|RESULTS|ab|8|entity|C0205554|Automated|ftcn|||Automated|||0|694|1492|1501
SE|25462374|RESULTS|ab|8|entity|C0205132|Linear|spco|||linear|||0|888|1529|1535
SE|25462374|RESULTS|ab|8|entity|C0439849|Relationships|qlco|||relationship|||0|888|1536|1548
SE|25462374|RESULTS|ab|8|entity|C0205452|Six|qnco|||six|||0|802|1557|1560
SE|25462374|RESULTS|ab|8|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|802|1563|1570
SE|25462374|RESULTS|ab|8|entity|C0002210|alpha-Fetoproteins|aapp,bacs|||fetuin|||0|790|1600|1606
SE|25462374|RESULTS|ab|8|entity|C1547015|*Coefficient|qnco|||coefficients|||0|827|1624|1636
SE|25462374|RESULTS|ab|8|entity|C0443228|Largest|qnco|||greater|||0|1000|1645|1652

SE|25462374|RESULTS|ab|9|text|1664|1866|Spiking of permethylated fetuin N-glycans at different concentrations in permethylated N-glycan samples derived from a 0.02 MUL of HBS also exhibited linear agreement with R(2) values greater than 0.9.
SE|25462374|RESULTS|ab|9|entity|C0002210|alpha-Fetoproteins|aapp,bacs|||fetuin|||0|764|1689|1695
SE|25462374|RESULTS|ab|9|entity|C0032594|Polysaccharides|carb,phsu|||glycans|||0|764|1698|1705
SE|25462374|RESULTS|ab|9|entity|C1547020|*Difference|qnco|||different|||0|853|1709|1718
SE|25462374|RESULTS|ab|9|entity|C0032594|Polysaccharides|carb,phsu|||glycan|||0|645|1753|1759
SE|25462374|RESULTS|ab|9|entity|||gngm|4591|TRIM37|MUL|||0|1000|1788|1791
SE|25462374|RESULTS|ab|9|entity|C0019043|Sickle Hemoglobin|aapp,bacs|||HBS|||0|1000|1795|1798
SE|25462374|RESULTS|ab|9|entity|C0205132|Linear|spco|||linear|||0|888|1814|1820
SE|25462374|RESULTS|ab|9|entity|C0680240|Agreement|socb|||agreement|||0|888|1821|1830
SE|25462374|RESULTS|ab|9|entity|C0042295|Values|qlco|||values|||0|1000|1841|1847
SE|25462374|RESULTS|ab|9|entity|C0443228|Largest|qnco|||greater|||0|1000|1848|1855
SE|25462374|RESULTS|ab|9|relation|5|1|||gngm,aapp|gngm|4591|TRIM37|MUL|||0|1000|1788|1791|VERB|CONVERTS_TO||1768|1775|4|1|C0032594|Polysaccharides|carb,phsu|carb|||glycan|||0|645|1753|1759

SE|25462374|CONCLUSIONS|ab|10|text|1866|2060|CONCLUSIONS: With a variety of options, including mass accuracy, merged adducts, and filtering criteria, MultiGlycan-ESI allows automated annotation and quantitation of LC/ESI-MS N-glycan data.
SE|25462374|CONCLUSIONS|ab|10|entity|C1518601|Options|ftcn|||options|||0|1000|1897|1904
SE|25462374|CONCLUSIONS|ab|10|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|853|1916|1920
SE|25462374|CONCLUSIONS|ab|10|entity|C0443131|Accurate|qlco|||accuracy|||0|853|1921|1929
SE|25462374|CONCLUSIONS|ab|10|entity|C0596040|adduct|chvs|||adducts|||0|827|1938|1945
SE|25462374|CONCLUSIONS|ab|10|entity|C0243161|criteria|inpr|||criteria|||0|872|1961|1969
SE|25462374|CONCLUSIONS|ab|10|entity|C1516801|Electrospray Ionization|lbpr|||ESI|||0|861|1983|1986
SE|25462374|CONCLUSIONS|ab|10|entity|C0205554|Automated|ftcn|||automated|||0|694|1994|2003
SE|25462374|CONCLUSIONS|ab|10|entity|C1516801|Electrospray Ionization|lbpr|||ESI-MS|||0|769|2038|2044
SE|25462374|CONCLUSIONS|ab|10|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||ESI-MS|||0|769|2038|2044
SE|25462374|CONCLUSIONS|ab|10|entity|C0032594|Polysaccharides|carb,phsu|||glycan|||0|769|2047|2053
SE|25462374|CONCLUSIONS|ab|10|entity|C1511726|Data|idcn|||data|||0|769|2054|2058

SE|25462374|CONCLUSIONS|ab|11|text|2060|2128|The software allows the reliable quantitation of glycan LC/MS data.
SE|25462374|CONCLUSIONS|ab|11|entity|C0032594|Polysaccharides|carb,phsu|||glycan|||0|888|2109|2115
SE|25462374|CONCLUSIONS|ab|11|entity|C0872318|Liquid Chromatography Mass Spectrometry|lbpr|||LC/MS|||0|888|2116|2121
SE|25462374|CONCLUSIONS|ab|11|entity|C1511726|Data|idcn|||data|||0|888|2122|2126

SE|25462374|CONCLUSIONS|ab|12|text|2128|2259|The software is reliable for automated glycan quantitation, thus facilitating rapid and reliable high-throughput glycomics studies.
SE|25462374|CONCLUSIONS|ab|12|entity|C0205554|Automated|ftcn|||automated|||0|623|2157|2166
SE|25462374|CONCLUSIONS|ab|12|entity|C0032594|Polysaccharides|carb,phsu|||glycan|||0|623|2167|2173
SE|25462374|CONCLUSIONS|ab|12|entity|C0439831|Rapid|qlco|||rapid|||0|1000|2206|2211
SE|25462374|CONCLUSIONS|ab|12|entity|C0205250|High|qlco|||high|||0|747|2225|2229
SE|25462374|CONCLUSIONS|ab|12|entity|C0008972|Clinical Research|resa|||studies|||0|747|2251|2258


SE|25462376||ti|1|text|21|172|Visible spectroscopy on carcass fat combined with chemometrics to distinguish pasture-fed, concentrate-fed and concentrate-finished pasture-fed lambs.
SE|25462376||ti|1|entity|C0205379|Visible|qlco|||Visible|||0|888|21|28
SE|25462376||ti|1|entity|C0037812|Spectrum Analysis|lbpr|||spectroscopy|||0|888|29|41
SE|25462376||ti|1|entity|C0229961|Carcass|ffas|||carcass|||0|888|45|52
SE|25462376||ti|1|entity|C0204695|Feeding patient|hlca|||fed|||0|612|107|110
SE|25462376||ti|1|entity|C0204695|Feeding patient|hlca|||fed|||0|712|161|164
SE|25462376||ti|1|entity|C1123019|Domestic Sheep|mamm|||lambs|||0|712|165|170

SE|25462376||ab|1|text|178|343|We used visible spectroscopy of fat to discriminate lambs that were pasture-fed (n=76), concentrate-fed (n=79) or concentrate-finished after pasture-feeding (n=69).
SE|25462376||ab|1|entity|C0205379|Visible|qlco|||visible|||0|888|186|193
SE|25462376||ab|1|entity|C0037812|Spectrum Analysis|lbpr|||spectroscopy|||0|888|194|206
SE|25462376||ab|1|entity|C1123019|Domestic Sheep|mamm|||lambs|||0|1000|230|235
SE|25462376||ab|1|entity|C0204695|Feeding patient|hlca|||fed|||0|827|254|257
SE|25462376||ab|1|entity|C0204695|Feeding patient|hlca|||fed|||0|827|278|281

SE|25462376||ab|2|text|343|456|The reflectance spectrum of perirenal and subcutaneous caudal fat was measured at slaughter and 24h post mortem.
SE|25462376||ab|2|entity|C0205097|Caudal|blor|||caudal|||0|901|398|404
SE|25462376||ab|2|entity|C0222331|Subcutaneous Fat|tisu|||subcutaneous caudal fat|||0|901|385|408
SE|25462376||ab|2|entity|C0456696|/24h|tmco|||24h|||0|1000|439|442
SE|25462376||ab|2|entity|C0004398|Autopsy|diap|||post mortem|||0|1000|443|454

SE|25462376||ab|3|text|456|615|In Method 1 (W450-510), the optical data were used at wavelengths in the range of 450-510nm to calculate an index quantifying light absorption by carotenoids.
SE|25462376||ab|3|entity|C0025663|Methods|inpr|||Method|||0|861|459|465
SE|25462376||ab|3|entity|C0042789|Vision|orgf|||optical|||0|861|484|491
SE|25462376||ab|3|entity|C1511726|Data|idcn|||data|||0|861|492|496
SE|25462376||ab|3|entity|C0449819|Wavelength|qnco|||wavelengths|||0|966|510|521
SE|25462376||ab|3|entity|C1514721|Range|qnco|||range|||0|1000|529|534
SE|25462376||ab|3|entity|C0918012|Index|inpr|||index|||0|1000|564|569
SE|25462376||ab|3|entity|C0234682|Light absorption|moft|||light absorption|||0|1000|582|598
SE|25462376||ab|3|entity|C0007271|Carotenoids|bacs,orch|||carotenoids|||0|1000|602|613

SE|25462376||ab|4|text|615|778|In Method 2 (W400-700), the full set of data at wavelengths in the range of 400-700nm was used to differentiate carcasses using PLS-DA as a classification method.
SE|25462376||ab|4|entity|C0025663|Methods|inpr|||Method|||0|861|618|624
SE|25462376||ab|4|entity|C0443225|Full|qlco|||full|||0|694|643|647
SE|25462376||ab|4|entity|C1511726|Data|idcn|||data|||0|1000|655|659
SE|25462376||ab|4|entity|C0449819|Wavelength|qnco|||wavelengths|||0|966|663|674
SE|25462376||ab|4|entity|C1514721|Range|qnco|||range|||0|1000|682|687
SE|25462376||ab|4|entity|C0229961|Carcass|ffas|||carcasses|||0|1000|727|736
SE|25462376||ab|4|entity|C1366503|HOXA10 gene|gngm|3206|HOXA10|PLS-DA|||0|855|743|749
SE|25462376||ab|4|entity|C0051767|amsonic acid|orch,phsu|||PLS-DA|||0|855|743|749
SE|25462376||ab|4|entity|C0008902|Classification|clas|||classification|||0|888|755|769
SE|25462376||ab|4|entity|C0025663|Methods|inpr|||method|||0|888|770|776

SE|25462376||ab|5|text|778|834|W400-700 proved more reliable than W450-510 (P<0.0001).
SE|25462376||ab|5|entity|C0205172|More|ftcn|||more|||0|694|794|798

SE|25462376||ab|6|text|834|987|The proportion of correctly classified lambs using W400-700 was 95.6% and 95.9% for measurements made on perirenal fat at slaughter and 24h post mortem.
SE|25462376||ab|6|entity|C0205351|Proportional|qlco|||proportion|||0|928|838|848
SE|25462376||ab|6|entity|C0008902|Classification|clas|||classified|||0|790|862|872
SE|25462376||ab|6|entity|C1123019|Domestic Sheep|mamm|||lambs|||0|790|873|878
SE|25462376||ab|6|entity|C0242485|Measurement|ftcn|||measurements|||0|1000|918|930
SE|25462376||ab|6|entity|C1280415|Entire perirenal fat|bpoc|||perirenal fat|||0|1000|939|952
SE|25462376||ab|6|entity|C0456696|/24h|tmco|||24h|||0|1000|970|973
SE|25462376||ab|6|entity|C0004398|Autopsy|diap|||post mortem|||0|1000|974|985

SE|25462376||ab|7|text|987|1110|The intensity of light absorption by carotenoids decreased exponentially with live weight gain during the finishing period.
SE|25462376||ab|7|entity|C0234682|Light absorption|moft|||light absorption|||0|1000|1004|1020
SE|25462376||ab|7|entity|C0007271|Carotenoids|bacs,orch|||carotenoids|||0|1000|1024|1035
SE|25462376||ab|7|entity|C1548795|Live|qlco|||live|||0|901|1065|1069
SE|25462376||ab|7|entity|C0043094|Weight Gain|fndg|||weight gain|||0|901|1070|1081
SE|25462376||ab|7|entity|C0439531|/period|tmco|||period|||0|861|1103|1109


SE|25462375||ti|1|text|21|138|The MC4R c.893G>A mutation: a marker for growth and leanness associated with boar taint odour in Belgian pig breeds.
SE|25462375||ti|1|entity|C0668289|Melanocortin 4 Receptor|aapp,rcpt|4160|MC4R|MC4R|||0|679|25|29
SE|25462375||ti|1|entity|C0026882|Mutation|genf|||mutation|||0|1000|39|47
SE|25462375||ti|1|entity|C0005516|Biological Markers|qlco|||marker|||0|1000|51|57
SE|25462375||ti|1|entity|C0018270|Growth|orgf|||growth|||0|1000|62|68
SE|25462375||ti|1|entity|C0039870|Thinness|fndg|||leanness|||0|1000|73|81
SE|25462375||ti|1|entity|C0039005|Family suidae|mamm|||boar|||0|785|98|102
SE|25462375||ti|1|entity|C0028884|Odors|npop|||odour|||0|785|109|114
SE|25462375||ti|1|entity|C0337797|Belgians|popg|||Belgian|||0|829|118|125
SE|25462375||ti|1|entity|C0039005|Family suidae|mamm|||pig|||0|829|126|129
SE|25462375||ti|1|entity|C1548147|Breed|idcn|||breeds|||0|829|130|136
SE|25462375||ti|1|relation|2|1|C0028884|Odors|npop|npop|||odour|||0|785|109|114|VERB|AFFECTS||82|92|5|2|C0018270|Growth|orgf|orgf|||growth|||0|1000|62|68

SE|25462375||ab|1|text|144|311|Since surgical castration of male piglets without anaesthesia is under heavy societal pressure, finding a sustainable solution to reduce boar taint has become urgent.
SE|25462375||ab|1|entity|C0007344|Castration|topp|||surgical castration|||0|1000|150|169
SE|25462375||ab|1|entity|C0002903|Anesthesia procedures|topp|||anaesthesia|||0|1000|194|205
SE|25462375||ab|1|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|827|230|238
SE|25462375||ab|1|entity|C0037633|Solutions|sbst|||solution|||0|861|262|270
SE|25462375||ab|1|entity|C0039005|Family suidae|mamm|||boar|||0|661|281|285
SE|25462375||ab|1|entity|C0439609|Urgent|tmco|||urgent|||0|1000|303|309

SE|25462375||ab|2|text|311|473|One way to circumvent this animal welfare violation is raising entire male pigs whilst selecting against the tainted phenotype through marker-assisted selection.
SE|25462375||ab|2|entity|C0205447|One|qnco|||One|||0|861|311|314
SE|25462375||ab|2|entity|C0003061|Animal Welfare|acty|||animal welfare|||0|734|338|352
SE|25462375||ab|2|entity|C1284842|Entire male|orga|||entire male|||0|901|374|385
SE|25462375||ab|2|entity|C0039005|Family suidae|mamm|||pigs|||0|901|386|390
SE|25462375||ab|2|entity|C0031437|Phenotype|orga|||phenotype|||0|861|428|437
SE|25462375||ab|2|entity|C0005516|Biological Markers|qlco|||marker|||0|623|446|452
SE|25462375||ab|2|entity|C1269765|Assisted|fndg|||assisted|||0|623|453|461

SE|25462375||ab|3|text|473|622|Since slaughtering at a lower weight is often suggested to reduce boar taint, selection using a marker for that trait could be a promising strategy.
SE|25462375||ab|3|entity|C0441994|Lower|ftcn|||lower|||0|888|497|502
SE|25462375||ab|3|entity|C0043100|Weight|qnco|||weight|||0|888|503|509
SE|25462375||ab|3|entity|C0332183|Frequent|tmco|||often|||0|1000|513|518
SE|25462375||ab|3|entity|C0039005|Family suidae|mamm|||boar|||0|661|539|543
SE|25462375||ab|3|entity|C0005516|Biological Markers|qlco|||marker|||0|1000|569|575
SE|25462375||ab|3|entity|C0599883|trait|orga|||trait|||0|1000|585|590
SE|25462375||ab|3|entity|C1555307|promise|idcn|||promising|||0|872|602|611

SE|25462375||ab|4|text|622|871|Therefore, in this study a melanocortin 4 receptor (MC4R) mutation, frequently described in different pig breeds as marker for fat content, weight gain and feed intake, was examined in relation to boar taint in pig breeds used in Belgian pig farms.
SE|25462375||ab|4|entity|C0668289|Melanocortin 4 Receptor|aapp,rcpt|4160|MC4R|melanocortin 4 receptor|||0|916|649|672
SE|25462375||ab|4|entity|C0026882|Mutation|genf|||mutation|||0|916|680|688
SE|25462375||ab|4|entity|C0332183|Frequent|tmco|||frequently|||0|1000|690|700
SE|25462375||ab|4|entity|C1547020|*Difference|qnco|||different|||0|853|714|723
SE|25462375||ab|4|entity|C0039005|Family suidae|mamm|||pig|||0|853|724|727
SE|25462375||ab|4|entity|C0005516|Biological Markers|qlco|||marker|||0|1000|738|744
SE|25462375||ab|4|entity|C0043094|Weight Gain|fndg|||weight gain|||0|1000|762|773
SE|25462375||ab|4|entity|C0204695|Feeding patient|hlca|||feed|||0|888|778|782
SE|25462375||ab|4|entity|C1512806|Intake|ftcn|||intake|||0|888|783|789
SE|25462375||ab|4|entity|C0039005|Family suidae|mamm|||boar|||0|661|819|823
SE|25462375||ab|4|entity|C0039005|Family suidae|mamm|||pig|||0|872|833|836
SE|25462375||ab|4|entity|C1548147|Breed|idcn|||breeds|||0|872|837|843
SE|25462375||ab|4|entity|C0337797|Belgians|popg|||Belgian|||0|829|852|859
SE|25462375||ab|4|entity|C0039005|Family suidae|mamm|||pig|||0|829|860|863
SE|25462375||ab|4|entity|C0557759|Farming environment|geoa|||farms|||0|829|864|869
SE|25462375||ab|4|relation|8|1|C0039005|Family suidae|mamm|mamm|||pig|||0|853|724|727|PREP|LOCATION_OF||711|713|1|1|C0668289|Melanocortin 4 Receptor|aapp,gngm,rcpt|aapp|4160|MC4R|melanocortin 4 receptor|||0|916|649|672

SE|25462375||ab|5|text|871|1133|Although results suggest an association between this mutation and a boar taint odour score assigned by experts, no association was found between the mutation and the concentration of the individual chemical boar taint components androstenone, skatole and indole.
SE|25462375||ab|5|entity|C1274040|result|ftcn|||results|||0|966|880|887
SE|25462375||ab|5|entity|C0026882|Mutation|genf|||mutation|||0|1000|924|932
SE|25462375||ab|5|entity|C0039005|Family suidae|mamm|||boar|||0|764|939|943
SE|25462375||ab|5|entity|C0028884|Odors|npop|||odour|||0|764|950|955
SE|25462375||ab|5|entity|C0449820|Score|qnco|||score|||0|764|956|961
SE|25462375||ab|5|entity|C0026882|Mutation|genf|||mutation|||0|1000|1020|1028
SE|25462375||ab|5|entity|C0237401|Individual|humn|||individual|||0|551|1058|1068
SE|25462375||ab|5|entity|C0220806|Chemicals|chem|||chemical|||0|551|1069|1077
SE|25462375||ab|5|entity|C0039005|Family suidae|mamm|||boar|||0|551|1078|1082
SE|25462375||ab|5|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|551|1089|1099
SE|25462375||ab|5|entity|C0037248|Skatole|bacs,orch|||skatole|||0|1000|1114|1121
SE|25462375||ab|5|entity|C0021236|indole|orch|||indole|||0|1000|1126|1132


SE|25462377||ti|1|text|21|127|Resting of MAP (modified atmosphere packed) beef steaks prior to cooking and effects on consumer quality.
SE|25462377||ti|1|entity|C0024779|Maps|inpr,mnob|||MAP|||0|1000|32|35
SE|25462377||ti|1|entity|C0205349|Altered|ftcn|||modified|||0|888|37|45
SE|25462377||ti|1|entity|C0004178|Atmosphere, planetary|npop|||atmosphere|||0|888|46|56
SE|25462377||ti|1|entity|C0452850|Beef steak|food|||beef steaks|||0|983|65|76
SE|25462377||ti|1|entity|C0335326|Cooking|dora|||cooking|||0|1000|86|93
SE|25462377||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|98|105
SE|25462377||ti|1|entity|C0332306|Quality|qlco|||quality|||0|861|118|125

SE|25462377||ab|1|text|133|429|This study investigated the meat preparation effects prior to cooking on the sensory consumer quality of modified atmosphere (MA) packed (100ml CO2/100ml pack gas, 50ml O2:20ml CO2:30ml N2/100ml pack gas, 70ml O2:30ml CO2/100ml pack gas and 80ml O2:20ml CO2/100ml pack gas) striploin beef steak.
SE|25462377||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|138|143
SE|25462377||ab|1|entity|C0025017|Meat|food|||meat|||0|840|161|165
SE|25462377||ab|1|entity|C1521827|Preparation|ftcn|||preparation|||0|840|166|177
SE|25462377||ab|1|entity|C1280500|Effect|qlco|||effects|||0|840|178|185
SE|25462377||ab|1|entity|C0335326|Cooking|dora|||cooking|||0|1000|195|202
SE|25462377||ab|1|entity|C1455667|Sensation quality|qlco|||sensory consumer quality|||0|877|210|234
SE|25462377||ab|1|entity|C0205349|Altered|ftcn|||modified|||0|888|238|246
SE|25462377||ab|1|entity|C0004178|Atmosphere, planetary|npop|||atmosphere|||0|888|247|257
SE|25462377||ab|1|entity|C0470436|100mL|qnco|||100ml|||0|757|271|276
SE|25462377||ab|1|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|757|277|280
SE|25462377||ab|1|entity|C0441122|Pack|medd|||pack|||0|757|287|291
SE|25462377||ab|1|entity|C0017110|Gases|chvs|||gas|||0|757|292|295
SE|25462377||ab|1|entity|C0470420|50mL|qnco|||50ml|||0|888|297|301
SE|25462377||ab|1|entity|C0470407|20mL|qnco|||20ml|||0|888|305|309
SE|25462377||ab|1|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|888|310|313
SE|25462377||ab|1|entity|C0470414|30mL|qnco|||30ml|||0|766|314|318
SE|25462377||ab|1|entity|C0470436|100mL|qnco|||100ml|||0|766|322|327
SE|25462377||ab|1|entity|C0441122|Pack|medd|||pack|||0|766|328|332
SE|25462377||ab|1|entity|C0017110|Gases|chvs|||gas|||0|766|333|336
SE|25462377||ab|1|entity|C0470431|70mL|qnco|||70ml|||0|888|338|342
SE|25462377||ab|1|entity|C0470414|30mL|qnco|||30ml|||0|822|346|350
SE|25462377||ab|1|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|822|351|354
SE|25462377||ab|1|entity|C0470436|100mL|qnco|||100ml|||0|822|355|360
SE|25462377||ab|1|entity|C0441122|Pack|medd|||pack|||0|822|361|365
SE|25462377||ab|1|entity|C0017110|Gases|chvs|||gas|||0|822|366|369
SE|25462377||ab|1|entity|C0470433|80mL|qnco|||80ml|||0|888|374|378
SE|25462377||ab|1|entity|C0470407|20mL|qnco|||20ml|||0|822|382|386
SE|25462377||ab|1|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|822|387|390
SE|25462377||ab|1|entity|C0470436|100mL|qnco|||100ml|||0|822|391|396
SE|25462377||ab|1|entity|C0441122|Pack|medd|||pack|||0|822|397|401
SE|25462377||ab|1|entity|C0017110|Gases|chvs|||gas|||0|822|402|405
SE|25462377||ab|1|entity|C0452850|Beef steak|food|||beef steak|||0|901|417|427

SE|25462377||ab|2|text|429|711|Beef steaks were stored at 4 degrees C for 7days (616lx) to simulate retail display conditions and tested by consumers (n=40) for appearance, liking of flavour, overall acceptability, juiciness, tenderness, oxidation flavour, off-flavour, and sourness of the resulting cooked meat.
SE|25462377||ab|2|entity|C0452850|Beef steak|food|||Beef steaks|||0|983|429|440
SE|25462377||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|458|467
SE|25462377||ab|2|entity|C0348080|Condition|qlco|||conditions|||0|793|513|523
SE|25462377||ab|2|entity|C0700364|Appearance|qlco|||appearance|||0|1000|559|569
SE|25462377||ab|2|entity|C0475332|Flavoring|chvf,sbst|||flavour|||0|1000|581|588
SE|25462377||ab|2|entity|C1561607|Overall|qlco|||overall|||0|888|590|597
SE|25462377||ab|2|entity|C0814633|acceptability|qlco|||acceptability|||0|888|598|611
SE|25462377||ab|2|entity|C0234233|Sore to touch|sosy|||tenderness|||0|1000|624|634
SE|25462377||ab|2|entity|C0030011|Oxidation|phpr|||oxidation|||0|888|636|645
SE|25462377||ab|2|entity|C0475332|Flavoring|chvf,sbst|||flavour|||0|888|646|653
SE|25462377||ab|2|entity|C0475332|Flavoring|chvf,sbst|||flavour|||0|1000|659|666
SE|25462377||ab|2|entity|C0678583|sourness|qlco|||sourness|||0|1000|672|680
SE|25462377||ab|2|entity|C1274040|result|ftcn|||resulting|||0|840|688|697
SE|25462377||ab|2|entity|C0335326|Cooking|dora|||cooked|||0|840|698|704
SE|25462377||ab|2|entity|C0025017|Meat|food|||meat|||0|840|705|709

SE|25462377||ab|3|text|711|785|Additionally, TVC, pH, colour, drip loss, and cooking loss were measured.
SE|25462377||ab|3|entity|C0009393|Color|npop|||colour|||0|1000|734|740
SE|25462377||ab|3|entity|C1517945|Loss|qnco|||loss|||0|861|747|751
SE|25462377||ab|3|entity|C0335326|Cooking|dora|||cooking|||0|888|757|764
SE|25462377||ab|3|entity|C1517945|Loss|qnco|||loss|||0|888|765|769

SE|25462377||ab|4|text|785|936|One steak from each of the experimental treatments was taken immediately from the respective MA packs and cooked before serving straight to consumers.
SE|25462377||ab|4|entity|C0205447|One|qnco|||One|||0|694|785|788
SE|25462377||ab|4|entity|C1517004|Experimental|ftcn|||experimental|||0|888|812|824
SE|25462377||ab|4|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|888|825|835
SE|25462377||ab|4|entity|C0205548|Stat (do immediately)|tmco|||immediately|||0|1000|846|857
SE|25462377||ab|4|entity|C0205349|Altered|ftcn|||MA|||0|775|878|880
SE|25462377||ab|4|entity|C0004178|Atmosphere, planetary|npop|||MA|||0|775|878|880
SE|25462377||ab|4|entity|C0441122|Pack|medd|||packs|||0|775|881|886
SE|25462377||ab|4|entity|C1519269|Serving|qnco|||serving|||0|1000|905|912
SE|25462377||ab|4|entity|C0445291|Straight|spco|||straight|||0|1000|913|921

SE|25462377||ab|5|text|936|1053|A second steak from each pack was treated similarly, but left in ambient air for 30min prior to cooking and serving.
SE|25462377||ab|5|entity|C0457385|seconds|tmco|||second|||0|694|938|944
SE|25462377||ab|5|entity|C0441122|Pack|medd|||pack|||0|1000|961|965
SE|25462377||ab|5|entity|C0001861|Air|sbst|||air|||0|861|1009|1012
SE|25462377||ab|5|entity|C0335326|Cooking|dora|||cooking|||0|1000|1032|1039
SE|25462377||ab|5|entity|C1519269|Serving|qnco|||serving|||0|1000|1044|1051

SE|25462377||ab|6|text|1053|1205|Consumers perceived cooked steak from samples left for 30min prior to cooking as significantly (P<0.05) less sour tasting than those cooked immediately.
SE|25462377||ab|6|entity|C0335326|Cooking|dora|||cooked|||0|694|1073|1079
SE|25462377||ab|6|entity|C0335326|Cooking|dora|||cooking|||0|1000|1123|1130
SE|25462377||ab|6|entity|C1537059|sour|qlco|||sour|||0|790|1162|1166
SE|25462377||ab|6|entity|C0039336|Taste Perception|ortf|||tasting|||0|790|1167|1174
SE|25462377||ab|6|entity|C0205548|Stat (do immediately)|tmco|||immediately|||0|1000|1193|1204


SE|25462378||ti|1|text|21|138|Nutritional properties and consumer evaluation of donkey bresaola and salami: comparison with conventional products.
SE|25462378||ti|1|entity|C1521739|Nutritional|qlco|||Nutritional|||0|872|21|32
SE|25462378||ti|1|entity|C0871161|Property|qlco|||properties|||0|872|33|43
SE|25462378||ti|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|861|57|67
SE|25462378||ti|1|entity|C0324145|Equus asinus|mamm|||donkey|||0|694|71|77
SE|25462378||ti|1|entity|C0452943|Salami|food|||salami|||0|1000|91|97
SE|25462378||ti|1|entity|C0439858|Conventional|qlco|||conventional|||0|872|115|127
SE|25462378||ti|1|entity|C1514468|product|qnco|||products|||0|872|128|136

SE|25462378||ab|1|text|144|294|Nutritional properties and consumer evaluation were performed in bresaola and salami from donkey meat compared with respective conventional products.
SE|25462378||ab|1|entity|C1521739|Nutritional|qlco|||Nutritional|||0|872|144|155
SE|25462378||ab|1|entity|C0871161|Property|qlco|||properties|||0|872|156|166
SE|25462378||ab|1|entity|C0220825|Evaluation|ftcn|||evaluation|||0|861|180|190
SE|25462378||ab|1|entity|C0452943|Salami|food|||salami|||0|1000|222|228
SE|25462378||ab|1|entity|C0324145|Equus asinus|mamm|||donkey|||0|888|234|240
SE|25462378||ab|1|entity|C0025017|Meat|food|||meat|||0|888|241|245
SE|25462378||ab|1|entity|C0439858|Conventional|qlco|||conventional|||0|773|271|283
SE|25462378||ab|1|entity|C1514468|product|qnco|||products|||0|773|284|292

SE|25462378||ab|2|text|294|415|Donkey bresaola and salami showed higher content of protein and lower content of fat than beef bresaola and pork salami.
SE|25462378||ab|2|entity|C0324145|Equus asinus|mamm|||Donkey|||0|694|294|300
SE|25462378||ab|2|entity|C0452943|Salami|food|||salami|||0|1000|314|320
SE|25462378||ab|2|entity|C0205250|High|qlco|||higher|||0|661|328|334
SE|25462378||ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|346|353
SE|25462378||ab|2|entity|C0441994|Lower|ftcn|||lower|||0|694|358|363
SE|25462378||ab|2|entity|C0452849|Beef|food|||beef|||0|694|384|388
SE|25462378||ab|2|entity|C0452867|Pork|food|||pork|||0|888|402|406
SE|25462378||ab|2|entity|C0452943|Salami|food|||salami|||0|888|407|413

SE|25462378||ab|3|text|415|492|Significant differences in the unsaturation level of fatty acids were found.
SE|25462378||ab|3|entity|C0750502|Significant|idcn|||Significant|||0|872|415|426
SE|25462378||ab|3|entity|C1547020|*Difference|qnco|||differences|||0|872|427|438
SE|25462378||ab|3|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acids|||0|1000|468|479

SE|25462378||ab|4|text|492|683|Particularly, donkey meat products showed lower saturated fatty acids, higher polyunsatured fatty acid content and better nutritional indices than conventional beef bresaola and pork salami.
SE|25462378||ab|4|entity|C0324145|Equus asinus|mamm|||donkey|||0|901|506|512
SE|25462378||ab|4|entity|C0025018|Meat Products|food|||meat products|||0|901|513|526
SE|25462378||ab|4|entity|C0441994|Lower|ftcn|||lower|||0|916|534|539
SE|25462378||ab|4|entity|C0522102|Fatty Acids, Saturated|bacs,lipd|||saturated fatty acids|||0|916|540|561
SE|25462378||ab|4|entity|C0205250|High|qlco|||higher|||0|606|563|569
SE|25462378||ab|4|entity|C0015684|Fatty Acids|bacs,lipd|||fatty acid|||0|606|584|594
SE|25462378||ab|4|entity|C0332272|Better|qlco|||better|||0|851|607|613
SE|25462378||ab|4|entity|C1521739|Nutritional|qlco|||nutritional|||0|851|614|625
SE|25462378||ab|4|entity|C0918012|Index|inpr|||indices|||0|851|626|633
SE|25462378||ab|4|entity|C0439858|Conventional|qlco|||conventional|||0|623|639|651
SE|25462378||ab|4|entity|C0452849|Beef|food|||beef|||0|623|652|656
SE|25462378||ab|4|entity|C0452867|Pork|food|||pork|||0|888|670|674
SE|25462378||ab|4|entity|C0452943|Salami|food|||salami|||0|888|675|681

SE|25462378||ab|5|text|683|792|Furthermore, donkey meat products, especially bresaola, showed the highest content of essential amino acids.
SE|25462378||ab|5|entity|C0324145|Equus asinus|mamm|||donkey|||0|901|696|702
SE|25462378||ab|5|entity|C0025018|Meat Products|food|||meat products|||0|901|703|716
SE|25462378||ab|5|entity|C1522410|Highest|qlco|||highest|||0|694|750|757
SE|25462378||ab|5|entity|C0002525|Amino Acids, Essential|aapp,bacs,phsu|||essential amino acids|||0|1000|769|790

SE|25462378||ab|6|text|792|944|Both donkey meat products resulted to be more tender than conventional products, in addition donkey bresaola showed also higher consumer acceptability.
SE|25462378||ab|6|entity|C0324145|Equus asinus|mamm|||donkey|||0|901|797|803
SE|25462378||ab|6|entity|C0025018|Meat Products|food|||meat products|||0|901|804|817
SE|25462378||ab|6|entity|C0205172|More|ftcn|||more|||0|888|833|837
SE|25462378||ab|6|entity|C0234234|Tender|qlco|||tender|||0|888|838|844
SE|25462378||ab|6|entity|C0439858|Conventional|qlco|||conventional|||0|872|850|862
SE|25462378||ab|6|entity|C1514468|product|qnco|||products|||0|872|863|871
SE|25462378||ab|6|entity|C0324145|Equus asinus|mamm|||donkey|||0|587|885|891
SE|25462378||ab|6|entity|C0205250|High|qlco|||higher|||0|747|913|919
SE|25462378||ab|6|entity|C0814633|acceptability|qlco|||acceptability|||0|747|929|942

SE|25462378||ab|7|text|944|1092|Our investigation demonstrates the possibility of processing donkey meat into products comparable to traditional ones with a high nutritional value.
SE|25462378||ab|7|entity|C0324145|Equus asinus|mamm|||donkey|||0|890|1005|1011
SE|25462378||ab|7|entity|C0452956|Processed meat|food|||processing donkey meat|||0|890|994|1016
SE|25462378||ab|7|entity|C1514468|product|qnco|||products|||0|966|1022|1030
SE|25462378||ab|7|entity|C0205447|One|qnco|||ones|||0|827|1057|1061
SE|25462378||ab|7|entity|C0205250|High|qlco|||high|||0|901|1069|1073
SE|25462378||ab|7|entity|C0028722|Nutritive Value|qlco,qnco|||nutritional value|||0|901|1074|1091


SE|25462379||ti|1|text|21|196|Effect of frozen storage, different thawing methods and cooking processes on the survival of Salmonella spp. and Escherichia coli O157:H7 in commercially shaped beef patties.
SE|25462379||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462379||ti|1|entity|C1548793|Specimen Condition -frozen|qlco|||frozen|||0|888|31|37
SE|25462379||ti|1|entity|C1547020|*Difference|qnco|||different|||0|766|47|56
SE|25462379||ti|1|entity|C0025663|Methods|inpr|||methods|||0|766|65|72
SE|25462379||ti|1|entity|C0335326|Cooking|dora|||cooking|||0|872|77|84
SE|25462379||ti|1|entity|C1522240|Process|phpr|||processes|||0|872|85|94
SE|25462379||ti|1|entity|C0038952|Continuance of life|acty|||survival|||0|1000|102|110
SE|25462379||ti|1|entity|C0036111|Salmonella|bact|||Salmonella|||0|888|114|124
SE|25462379||ti|1|entity|C1150110|signal peptide peptidase activity|moft|||spp|||0|888|125|128
SE|25462379||ti|1|entity|C0376625|Escherichia coli O157|bact|||Escherichia coli O157|||0|1000|134|155
SE|25462379||ti|1|entity|C0332479|Shapes|spco|||shaped|||0|566|175|181
SE|25462379||ti|1|entity|C0452849|Beef|food|||beef|||0|566|182|186

SE|25462379||ab|1|text|202|376|The effect of common handling practices (i.e., freezing, thawing and cooking) of beef patties on the survival of Salmonella spp. and Escherichia coli O157:H7, was evaluated.
SE|25462379||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|206|212
SE|25462379||ab|1|entity|C0205214|Common|qnco|||common|||0|694|216|222
SE|25462379||ab|1|entity|C0335326|Cooking|dora|||cooking|||0|1000|271|278
SE|25462379||ab|1|entity|C0452849|Beef|food|||beef|||0|694|283|287
SE|25462379||ab|1|entity|C0038952|Continuance of life|acty|||survival|||0|1000|303|311
SE|25462379||ab|1|entity|C0036111|Salmonella|bact|||Salmonella|||0|888|315|325
SE|25462379||ab|1|entity|C1150110|signal peptide peptidase activity|moft|||spp|||0|888|326|329
SE|25462379||ab|1|entity|C0376625|Escherichia coli O157|bact|||Escherichia coli O157|||0|1000|335|356

SE|25462379||ab|2|text|376|447|Inoculated ground beef was stored at -22  degrees C for 5 and 75 days.
SE|25462379||ab|2|entity|C0452849|Beef|food|||beef|||0|861|394|398
SE|25462379||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|418|427
SE|25462379||ab|2|entity|C0439228|day|tmco|||days|||0|861|441|445

SE|25462379||ab|3|text|447|688|After thawing at 4  degrees C/16 h, 20  degrees C/12 h, in microwave/22-24 min, or without prior thawing, beef patties (90 g) were shaped and cooked in oven-broiler or in pan-grill to internal temperatures of 60  degrees C or 71  degrees C.
SE|25462379||ab|3|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|790|467|476
SE|25462379||ab|3|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|826|487|496
SE|25462379||ab|3|entity|C0456695|/12h|tmco|||12 h|||0|826|497|501
SE|25462379||ab|3|entity|C0439232|Minute of time|tmco|||min|||0|812|522|525
SE|25462379||ab|3|entity|C0332152|Status pre-|tmco|||prior|||0|694|538|543
SE|25462379||ab|3|entity|C0452849|Beef|food|||beef|||0|694|553|557
SE|25462379||ab|3|entity|C0336755|Oven|mnob|||oven|||0|694|599|603
SE|25462379||ab|3|entity|C0205102|Intrinsic|spco|||internal|||0|888|631|639
SE|25462379||ab|3|entity|C0039476|Temperature|qnco|||temperatures|||0|888|640|652
SE|25462379||ab|3|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|660|669
SE|25462379||ab|3|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|677|686

SE|25462379||ab|4|text|688|795|Cooking in oven-broiler was more effective compared to pan-grill, especially when cooked to 71  degrees C.
SE|25462379||ab|4|entity|C0335326|Cooking|dora|||Cooking|||0|1000|688|695
SE|25462379||ab|4|entity|C0336755|Oven|mnob|||oven|||0|694|699|703
SE|25462379||ab|4|entity|C0205172|More|ftcn|||more|||0|888|716|720
SE|25462379||ab|4|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|784|793

SE|25462379||ab|5|text|795|912|Defrosting methods did not affect significantly (P >= 0.05) the survival of the pathogens during subsequent cooking.
SE|25462379||ab|5|entity|C0025663|Methods|inpr|||methods|||0|861|806|813
SE|25462379||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|818|821
SE|25462379||ab|5|entity|C0202178|Phosphorus measurement|lbpr|||P|||0|827|844|845
SE|25462379||ab|5|entity|C0038952|Continuance of life|acty|||survival|||0|1000|859|867
SE|25462379||ab|5|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|888|892|902
SE|25462379||ab|5|entity|C0335326|Cooking|dora|||cooking|||0|888|903|910

SE|25462379||ab|6|text|912|1065|Frozen storage for 75 days enhanced the survival of E. coli O157:H7, as the pathogen survived 3.1 logCFU/g when cooked in oven-broiler at 71  degrees C.
SE|25462379||ab|6|entity|C1548793|Specimen Condition -frozen|qlco|||Frozen|||0|888|912|918
SE|25462379||ab|6|entity|C0439228|day|tmco|||days|||0|861|934|938
SE|25462379||ab|6|entity|C0038952|Continuance of life|acty|||survival|||0|1000|952|960
SE|25462379||ab|6|entity|C0376625|Escherichia coli O157|bact|||E. coli O157|||0|1000|964|976
SE|25462379||ab|6|entity|C0336755|Oven|mnob|||oven|||0|694|1034|1038
SE|25462379||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1054|1063

SE|25462379||ab|7|text|1065|1235|Results may supplement the existing guidelines for the appropriate practices, associated with freezing, thawing and cooking of patties in households or catering services.
SE|25462379||ab|7|entity|C1274040|result|ftcn|||Results|||0|966|1065|1072
SE|25462379||ab|7|entity|C0162791|Guidelines|inpr|||guidelines|||0|861|1101|1111
SE|25462379||ab|7|entity|C1548787|Appropriate|qlco|||appropriate|||0|1000|1120|1131
SE|25462379||ab|7|entity|C0016701|Freezing|npop|||freezing|||0|1000|1159|1167
SE|25462379||ab|7|entity|C0335326|Cooking|dora|||cooking|||0|1000|1181|1188
SE|25462379||ab|7|entity|C0020052|Households|famg|||households|||0|1000|1203|1213
SE|25462379||ab|7|entity|C0557854|Services|ftcn|||services|||0|861|1226|1234
SE|25462379||ab|7|relation|6|2|C0335326|Cooking|dora|dora|||cooking|||0|1000|1181|1188|PREP|TREATS||1200|1202|2|1|C0020052|Households|famg,humn|humn|||households|||0|1000|1203|1213


SE|25462380||ti|1|text|21|171|Effect of packaging technology on microbiological and sensory quality of a cooked blood sausage, Morcela de Arroz, from Monchique region of Portugal.
SE|25462380||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462380||ti|1|entity|C0030176|Packaging|hcpp|||packaging|||0|888|31|40
SE|25462380||ti|1|entity|C0039421|Technology|ocdi|||technology|||0|888|41|51
SE|25462380||ti|1|entity|C0025953|Microbiological|inpr|||microbiological|||0|1000|55|70
SE|25462380||ti|1|entity|C1455667|Sensation quality|qlco|||sensory quality|||0|964|75|90
SE|25462380||ti|1|entity|C0335326|Cooking|dora|||cooked|||0|851|96|102
SE|25462380||ti|1|entity|C0005767|Blood|tisu|||blood|||0|851|103|108
SE|25462380||ti|1|entity|C0452945|Sausage|food|||sausage|||0|851|109|116
SE|25462380||ti|1|entity|C0205147|Region|spco|||region|||0|861|151|157
SE|25462380||ti|1|entity|C0032729|Portugal|geoa|||Portugal|||0|1000|161|169

SE|25462380||ab|1|text|177|342|Morcela de Arroz (MA), a popular Portuguese blood sausage, with high pH and water activity (aw), is traditionally commercialized without preservatives and unpacked.
SE|25462380||ab|1|entity|C0679970|popularity|socb|||popular|||0|751|202|209
SE|25462380||ab|1|entity|C0005767|Blood|tisu|||blood|||0|751|221|226
SE|25462380||ab|1|entity|C0452945|Sausage|food|||sausage|||0|751|227|234
SE|25462380||ab|1|entity|C0205250|High|qlco|||high|||0|888|241|245
SE|25462380||ab|1|entity|C0020311|Hydrotherapy|topp|||water|||0|888|253|258
SE|25462380||ab|1|entity|C1321974|PRESERVATIVE|bodm,orch|||preservatives|||0|966|314|327

SE|25462380||ab|2|text|342|548|This study evaluated the best packaging solution to extend MA shelf life stored at 4+/-1 degrees C for 44days: without packaging (WP), vacuum (VP) and modified atmosphere packaging (MAP) (80% CO2; 20% N2).
SE|25462380||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|347|352
SE|25462380||ab|2|entity|C0030176|Packaging|hcpp|||packaging|||0|851|372|381
SE|25462380||ab|2|entity|C0037633|Solutions|sbst|||solution|||0|851|382|390
SE|25462380||ab|2|entity|C0376558|Life|idcn|||life|||0|804|410|414
SE|25462380||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|861|431|440
SE|25462380||ab|2|entity|C0030176|Packaging|hcpp|||packaging|||0|1000|461|470
SE|25462380||ab|2|entity|C0042221|Vacuum|npop|||vacuum|||0|1000|477|483
SE|25462380||ab|2|entity|C0205349|Altered|ftcn|||modified|||0|851|493|501
SE|25462380||ab|2|entity|C0004178|Atmosphere, planetary|npop|||atmosphere|||0|851|502|512
SE|25462380||ab|2|entity|C0030176|Packaging|hcpp|||packaging|||0|851|513|522
SE|25462380||ab|2|entity|C0007012|Carbon Dioxide|bacs,inch|||CO2|||0|861|534|537

SE|25462380||ab|3|text|548|807|Mesophilic (MTVC), psychrotrophic (PTVC), lactic acid bacteria (LAB), pseudomonads, molds and yeasts, Enterobacteriaceae, Listeria monocytogenes, Salmonella spp., Bacillus cereus, Clostridium perfringens, sensory properties, pH, moisture and aw were studied.
SE|25462380||ab|3|entity|C0678170|lactic acid bacteria|bact|||lactic acid bacteria|||0|1000|590|610
SE|25462380||ab|3|entity|C0369241|Fungi, Filamentous|fngs|||molds|||0|1000|632|637
SE|25462380||ab|3|entity|C0043393|Yeasts|fngs|||yeasts|||0|1000|642|648
SE|25462380||ab|3|entity|C0014346|Enterobacteriaceae|bact|||Enterobacteriaceae|||0|1000|650|668
SE|25462380||ab|3|entity|C0023861|Listeria monocytogenes|bact|||Listeria monocytogenes|||0|1000|670|692
SE|25462380||ab|3|entity|C0036111|Salmonella|bact|||Salmonella|||0|888|694|704
SE|25462380||ab|3|entity|C1150110|signal peptide peptidase activity|moft|||spp|||0|888|705|708
SE|25462380||ab|3|entity|C0004590|Bacillus cereus|bact|||Bacillus cereus|||0|1000|711|726
SE|25462380||ab|3|entity|C0009063|Clostridium perfringens|bact|||Clostridium perfringens|||0|1000|728|751
SE|25462380||ab|3|entity|C0445254|Sensory|qlco|||sensory|||0|872|753|760
SE|25462380||ab|3|entity|C0871161|Property|qlco|||properties|||0|872|761|771
SE|25462380||ab|3|entity|C0868994|MOISTURE|sbst|||moisture|||0|1000|777|785

SE|25462380||ab|4|text|807|849|Moisture and aw decreased (p<0.05) in WP.
SE|25462380||ab|4|entity|C0868994|MOISTURE|sbst|||Moisture|||0|1000|807|815

SE|25462380||ab|5|text|849|892|pH decreased in WP and MAP during storage.
SE|25462380||ab|5|entity|C0205349|Altered|ftcn|||MAP|||0|851|872|875
SE|25462380||ab|5|entity|C0004178|Atmosphere, planetary|npop|||MAP|||0|851|872|875
SE|25462380||ab|5|entity|C0030176|Packaging|hcpp|||MAP|||0|851|872|875

SE|25462380||ab|6|text|892|972|MTVC and PTVC counts increased to values around 7logCFU/g at 44days of storage.
SE|25462380||ab|6|entity|C0439157|counts|qnco|||counts|||0|861|906|912
SE|25462380||ab|6|entity|C0042295|Values|qlco|||values|||0|1000|926|932

SE|25462380||ab|7|text|972|1034|LAB and Enterobacteriaceae counts were higher (p<0.05) in VP.
SE|25462380||ab|7|entity|C0678170|lactic acid bacteria|bact|||LAB|||0|1000|972|975
SE|25462380||ab|7|entity|C0014346|Enterobacteriaceae|bact|||Enterobacteriaceae|||0|888|980|998
SE|25462380||ab|7|entity|C0439157|counts|qnco|||counts|||0|888|999|1005
SE|25462380||ab|7|entity|C0205250|High|qlco|||higher|||0|966|1011|1017

SE|25462380||ab|8|text|1034|1102|Pseudomonads were inhibited (p<0.05) by MAP after 8days of storage.
SE|25462380||ab|8|entity|C0205349|Altered|ftcn|||MAP|||0|851|1074|1077
SE|25462380||ab|8|entity|C0004178|Atmosphere, planetary|npop|||MAP|||0|851|1074|1077
SE|25462380||ab|8|entity|C0030176|Packaging|hcpp|||MAP|||0|851|1074|1077

SE|25462380||ab|9|text|1102|1175|Sensory parameters were affected (p<0.05) by packaging and storage time.
SE|25462380||ab|9|entity|C0445254|Sensory|qlco|||Sensory|||0|888|1102|1109
SE|25462380||ab|9|entity|C0030176|Packaging|hcpp|||packaging|||0|1000|1147|1156
SE|25462380||ab|9|entity|C0040223|Time|tmco|||time|||0|888|1169|1173

SE|25462380||ab|10|text|1175|1206|Globally, MAP performed better.
SE|25462380||ab|10|entity|C0205349|Altered|ftcn|||MAP|||0|851|1185|1188
SE|25462380||ab|10|entity|C0004178|Atmosphere, planetary|npop|||MAP|||0|851|1185|1188
SE|25462380||ab|10|entity|C0030176|Packaging|hcpp|||MAP|||0|851|1185|1188
SE|25462380||ab|10|entity|C0332272|Better|qlco|||better|||0|1000|1199|1205


SE|25462381||ti|1|text|21|132|Effects of vacuum packaging conditions on the quality, biochemical changes and the durability of ostrich meat.
SE|25462381||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|21|28
SE|25462381||ti|1|entity|C0042221|Vacuum|npop|||vacuum|||0|840|32|38
SE|25462381||ti|1|entity|C0030176|Packaging|hcpp|||packaging|||0|840|39|48
SE|25462381||ti|1|entity|C0348080|Condition|qlco|||conditions|||0|840|49|59
SE|25462381||ti|1|entity|C0332306|Quality|qlco|||quality|||0|1000|67|74
SE|25462381||ti|1|entity|C0205474|Biochemical|ftcn|||biochemical|||0|872|76|87
SE|25462381||ti|1|entity|C0325336|Struthio camelus|bird|||ostrich|||0|888|118|125
SE|25462381||ti|1|entity|C0025017|Meat|food|||meat|||0|888|126|130

SE|25462381||ab|1|text|138|342|In this study, the effects of vacuum packaging conditions on the concentrations of lactic acid, malondialdehyde, pH, microbial and sensory analysis were determined during chilled storage of ostrich meat.
SE|25462381||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|146|151
SE|25462381||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|157|164
SE|25462381||ab|1|entity|C0042221|Vacuum|npop|||vacuum|||0|840|168|174
SE|25462381||ab|1|entity|C0030176|Packaging|hcpp|||packaging|||0|840|175|184
SE|25462381||ab|1|entity|C0348080|Condition|qlco|||conditions|||0|840|185|195
SE|25462381||ab|1|entity|C0064582|Lactic acid|bacs,orch,phsu|||lactic acid|||0|1000|221|232
SE|25462381||ab|1|entity|C0024643|Malondialdehyde|orch|||malondialdehyde|||0|1000|234|249
SE|25462381||ab|1|entity|C0599840|microbial|orgm|||microbial|||0|1000|255|264
SE|25462381||ab|1|entity|C0445254|Sensory|qlco|||sensory|||0|888|269|276
SE|25462381||ab|1|entity|C0936012|Analysis|resa|||analysis|||0|888|277|285
SE|25462381||ab|1|entity|C0085593|Chills|sosy|||chilled|||0|872|309|316
SE|25462381||ab|1|entity|C0325336|Struthio camelus|bird|||ostrich|||0|888|328|335
SE|25462381||ab|1|entity|C0025017|Meat|food|||meat|||0|888|336|340

SE|25462381||ab|2|text|342|468|Meat was packed as follows: vacuum packed from 1st day (VP-1), vacuum packed from 3rd day (VP-3) and non-vacuum packed (NVP).
SE|25462381||ab|2|entity|C0025017|Meat|food|||Meat|||0|1000|342|346
SE|25462381||ab|2|entity|C0042221|Vacuum|npop|||vacuum|||0|1000|370|376
SE|25462381||ab|2|entity|C0205435|First (number)|qnco|||1st|||0|888|389|392
SE|25462381||ab|2|entity|C0439228|day|tmco|||day|||0|888|393|396
SE|25462381||ab|2|entity|C0042221|Vacuum|npop|||vacuum|||0|1000|405|411
SE|25462381||ab|2|entity|C0205437|Third|qnco|||3rd|||0|888|424|427
SE|25462381||ab|2|entity|C0439228|day|tmco|||day|||0|888|428|431
SE|25462381||ab|2|entity|C0042221|Vacuum|npop|||vacuum|||0|790|447|453

SE|25462381||ab|3|text|468|537|Analysis were performed at 1st, 7th, 14th, 21st day after slaughter.
SE|25462381||ab|3|entity|C0936012|Analysis|resa|||Analysis|||0|1000|468|476
SE|25462381||ab|3|entity|C0205435|First (number)|qnco|||1st|||0|1000|495|498
SE|25462381||ab|3|entity|C0439228|day|tmco|||day|||0|861|516|519

SE|25462381||ab|4|text|537|598|Meat consisted of 74.69% water, 2.29% fats, 20.95% proteins.
SE|25462381||ab|4|entity|C0025017|Meat|food|||Meat|||0|1000|537|541
SE|25462381||ab|4|entity|C0020311|Hydrotherapy|topp|||water|||0|827|562|567
SE|25462381||ab|4|entity|C0015677|Fatty acid glycerol esters|lipd,phsu|||fats|||0|827|575|579
SE|25462381||ab|4|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|827|588|596

SE|25462381||ab|5|text|598|953|Package conditions had significant effect on the pH (NVP: 6.54 on the 14th day, VP-1: 6.05 and VP-3: 6.07 on the 21th day p<0.001), amount of malondialdehyde (NVP: 8.62mg/kg on the 14th day; VP-1: 1.95 and VP-3: 2.55 on the 21th day; p<0.001) and total microbial count (NVP: 7.4 log CFU/g on the 14th day; VP-1: 6.7 and VP-3: 6.8 on the 21th day p<0.01).
SE|25462381||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|827|606|616
SE|25462381||ab|5|entity|C0750502|Significant|idcn|||significant|||0|888|621|632
SE|25462381||ab|5|entity|C1280500|Effect|qlco|||effect|||0|888|633|639
SE|25462381||ab|5|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|719|647|649
SE|25462381||ab|5|entity|C0042221|Vacuum|npop|||NVP|||0|719|651|654
SE|25462381||ab|5|entity|C0439228|day|tmco|||day|||0|861|673|676
SE|25462381||ab|5|entity|C0439228|day|tmco|||day|||0|728|716|719
SE|25462381||ab|5|entity|C1265611|Quantity|qnco|||amount|||0|1000|730|736
SE|25462381||ab|5|entity|C0024643|Malondialdehyde|orch|||malondialdehyde|||0|1000|740|755
SE|25462381||ab|5|entity|C0042221|Vacuum|npop|||NVP|||0|790|757|760
SE|25462381||ab|5|entity|C0439228|day|tmco|||day|||0|861|784|787
SE|25462381||ab|5|entity|C0439228|day|tmco|||day|||0|861|827|830
SE|25462381||ab|5|entity|C0439175|% of total|qnco|||total|||0|851|845|850
SE|25462381||ab|5|entity|C0599840|microbial|orgm|||microbial|||0|851|851|860
SE|25462381||ab|5|entity|C0750480|Count|idcn|||count|||0|851|861|866
SE|25462381||ab|5|entity|C0042221|Vacuum|npop|||NVP|||0|790|868|871
SE|25462381||ab|5|entity|C0314587|Colony-forming unit, granulocyte|cell|||CFU/g|||0|840|881|886
SE|25462381||ab|5|entity|C0439228|day|tmco|||day|||0|861|899|902
SE|25462381||ab|5|entity|C0439228|day|tmco|||day|||0|728|940|943

SE|25462381||ab|6|text|953|1075|Based on these results we can assess that vacuum packed from 1st day is necessary for the 21 days storage of ostrich meat.
SE|25462381||ab|6|entity|C1274040|result|ftcn|||results|||0|966|968|975
SE|25462381||ab|6|entity|C0042221|Vacuum|npop|||vacuum|||0|1000|995|1001
SE|25462381||ab|6|entity|C0205435|First (number)|qnco|||1st|||0|888|1014|1017
SE|25462381||ab|6|entity|C0439228|day|tmco|||day|||0|888|1018|1021
SE|25462381||ab|6|entity|C0439228|day|tmco|||days|||0|790|1046|1050
SE|25462381||ab|6|entity|C0325336|Struthio camelus|bird|||ostrich|||0|888|1062|1069
SE|25462381||ab|6|entity|C0025017|Meat|food|||meat|||0|888|1070|1074


SE|25462382||ti|1|text|21|183|Comparison of whole carcass condemnation and partial carcass condemnation data for integration in a national syndromic surveillance system: the Swiss experience.
SE|25462382||ti|1|entity|C0444667|Whole|qnco|||whole|||0|623|35|40
SE|25462382||ti|1|entity|C0229961|Carcass|ffas|||carcass|||0|623|41|48
SE|25462382||ti|1|entity|C0728938|Partial|qnco|||partial|||0|775|66|73
SE|25462382||ti|1|entity|C0229961|Carcass|ffas|||carcass|||0|775|74|81
SE|25462382||ti|1|entity|C1511726|Data|idcn|||data|||0|775|95|99
SE|25462382||ti|1|entity|C0449913|System|ftcn|||system|||0|791|153|159
SE|25462382||ti|1|entity|C0241315|Swiss|popg|||Swiss|||0|888|165|170
SE|25462382||ti|1|entity|C0596545|experience|menp|||experience|||0|888|171|181
SE|25462382||ti|1|relation|0|0|C0596545|experience|menp|menp|||experience|||0|888|171|181|MOD/HEAD|PROCESS_OF||165|181|0|0|C0241315|Swiss|popg,humn|humn|||Swiss|||0|888|165|170

SE|25462382||ab|1|text|189|293|We obtained partial carcass condemnation (PCC) data for cattle (2009-2010) from a Swiss slaughterhouse.
SE|25462382||ab|1|entity|C0728938|Partial|qnco|||partial|||0|775|201|208
SE|25462382||ab|1|entity|C0229961|Carcass|ffas|||carcass|||0|775|209|216
SE|25462382||ab|1|entity|C1511726|Data|idcn|||data|||0|775|236|240
SE|25462382||ab|1|entity|C0007452|Cattle|mamm|||cattle|||0|1000|245|251
SE|25462382||ab|1|entity|C0241315|Swiss|popg|||Swiss|||0|888|271|276
SE|25462382||ab|1|entity|C0000715|Abattoirs|mnob|||slaughterhouse|||0|888|277|291

SE|25462382||ab|2|text|293|454|Data on whole carcass condemnations (WCC) carried out at the same slaughterhouse over those years were extracted from the national database for meat inspection.
SE|25462382||ab|2|entity|C1511726|Data|idcn|||Data|||0|1000|293|297
SE|25462382||ab|2|entity|C0444667|Whole|qnco|||whole|||0|623|301|306
SE|25462382||ab|2|entity|C0229961|Carcass|ffas|||carcass|||0|623|307|314
SE|25462382||ab|2|entity|C0439787|Out|spco|||out|||0|1000|343|346
SE|25462382||ab|2|entity|C0445247|Same|qlco|||same|||0|888|354|358
SE|25462382||ab|2|entity|C0000715|Abattoirs|mnob|||slaughterhouse|||0|888|359|373
SE|25462382||ab|2|entity|C0205136|Over|spco|||over|||0|1000|374|378
SE|25462382||ab|2|entity|C0439234|year|tmco|||years|||0|1000|385|390
SE|25462382||ab|2|entity|C0242356|Databases|inpr|||database|||0|888|424|432
SE|25462382||ab|2|entity|C0025017|Meat|food|||meat|||0|694|437|441

SE|25462382||ab|3|text|454|667|We found that given the differences observed in the WCC and PCC time series, it is likely that both indicators respond to different health events in the population and that one cannot be substituted by the other.
SE|25462382||ab|3|entity|C1442162|GIVEN|cnce|||given|||0|1000|468|473
SE|25462382||ab|3|entity|C1547020|*Difference|qnco|||differences|||0|966|478|489
SE|25462382||ab|3|entity|C0444667|Whole|qnco|||WCC|||0|623|506|509
SE|25462382||ab|3|entity|C0229961|Carcass|ffas|||WCC|||0|623|506|509
SE|25462382||ab|3|entity|C0728938|Partial|qnco|||PCC|||0|785|514|517
SE|25462382||ab|3|entity|C0229961|Carcass|ffas|||PCC|||0|785|514|517
SE|25462382||ab|3|entity|C0871939|Time Series|tmco|||time series|||0|785|518|529
SE|25462382||ab|3|entity|C0021212|Indicators|irda|||indicators|||0|1000|554|564
SE|25462382||ab|3|entity|C1547020|*Difference|qnco|||different|||0|828|576|585
SE|25462382||ab|3|entity|C0018684|Health|idcn|||health|||0|828|586|592
SE|25462382||ab|3|entity|C0441471|Events|evnt|||events|||0|828|593|599
SE|25462382||ab|3|entity|C1257890|Population Group|popg|||population|||0|1000|607|617
SE|25462382||ab|3|entity|C0205447|One|qnco|||one|||0|1000|627|630

SE|25462382||ab|4|text|667|826|Because PCC recordings are promising for syndromic surveillance, the meat inspection database should be capable to record both WCC and PCC data in the future.
SE|25462382||ab|4|entity|C0728938|Partial|qnco|||PCC|||0|583|675|678
SE|25462382||ab|4|entity|C0229961|Carcass|ffas|||PCC|||0|583|675|678
SE|25462382||ab|4|entity|C0025017|Meat|food|||meat|||0|802|736|740
SE|25462382||ab|4|entity|C0242356|Databases|inpr|||database|||0|802|752|760
SE|25462382||ab|4|entity|C0444667|Whole|qnco|||WCC|||0|623|794|797
SE|25462382||ab|4|entity|C0229961|Carcass|ffas|||WCC|||0|623|794|797
SE|25462382||ab|4|entity|C0728938|Partial|qnco|||PCC|||0|775|802|805
SE|25462382||ab|4|entity|C0229961|Carcass|ffas|||PCC|||0|775|802|805
SE|25462382||ab|4|entity|C1511726|Data|idcn|||data|||0|775|806|810
SE|25462382||ab|4|entity|C0016884|Future|tmco|||future|||0|1000|818|824

SE|25462382||ab|5|text|826|937|However, a standardised list of reasons for PCC needs to be defined and used nationwide in all slaughterhouses.
SE|25462382||ab|5|entity|C0745732|LIST|cnce|||list|||0|861|850|854
SE|25462382||ab|5|entity|C0392360|Reason for|idcn|||reasons|||0|1000|858|865
SE|25462382||ab|5|entity|C0728938|Partial|qnco|||PCC|||0|623|870|873
SE|25462382||ab|5|entity|C0229961|Carcass|ffas|||PCC|||0|623|870|873
SE|25462382||ab|5|entity|C0042153|utilization qualifier|ftcn|||used|||0|623|898|902
SE|25462382||ab|5|entity|C0000715|Abattoirs|mnob|||slaughterhouses|||0|1000|921|936


SE|25462383||ti|1|text|21|68|The effects of blast chilling on pork quality.
SE|25462383||ti|1|entity|C1280500|Effect|qlco|||effects|||0|966|25|32
SE|25462383||ti|1|entity|C0337026|Blast|npop|||blast|||0|888|36|41
SE|25462383||ti|1|entity|C0085593|Chills|sosy|||chilling|||0|888|42|50
SE|25462383||ti|1|entity|C0452867|Pork|food|||pork|||0|888|54|58
SE|25462383||ti|1|entity|C0332306|Quality|qlco|||quality|||0|888|59|66

SE|25462383||ab|1|text|74|241|The aim of this study was to determine the effects of blast chilling of pig carcasses on the physiochemical and sensory properties of the longissimus lumborum muscle.
SE|25462383||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|90|95
SE|25462383||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|117|124
SE|25462383||ab|1|entity|C0337026|Blast|npop|||blast|||0|888|128|133
SE|25462383||ab|1|entity|C0085593|Chills|sosy|||chilling|||0|888|134|142
SE|25462383||ab|1|entity|C0039005|Family suidae|mamm|||pig|||0|888|146|149
SE|25462383||ab|1|entity|C0229961|Carcass|ffas|||carcasses|||0|888|150|159
SE|25462383||ab|1|entity|C0445254|Sensory|qlco|||sensory|||0|872|186|193
SE|25462383||ab|1|entity|C0871161|Property|qlco|||properties|||0|872|194|204
SE|25462383||ab|1|entity|C0224306|Longissimus|bpoc|||longissimus lumborum muscle|||0|913|212|239
SE|25462383||ab|1|relation|0|0|C0229961|Carcass|ffas|ffas|||carcasses|||0|888|150|159|MOD/HEAD|PART_OF||146|159|0|0|C0039005|Family suidae|mamm|mamm|||pig|||0|888|146|149

SE|25462383||ab|2|text|241|442|To this end, right half-carcasses were blast-chilled for 70min at -24 degrees C and then for 22h and 50min at 1 degrees C, while left half-carcasses were chilled conventionally at 1 degrees C for 24h.
SE|25462383||ab|2|entity|C0205090|Right|spco|||right|||0|802|254|259
SE|25462383||ab|2|entity|C0229961|Carcass|ffas|||carcasses|||0|802|265|274
SE|25462383||ab|2|entity|C0337026|Blast|npop|||blast|||0|1000|280|285
SE|25462383||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|311|320
SE|25462383||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|353|362
SE|25462383||ab|2|entity|C0205091|Left|spco|||left|||0|802|370|374
SE|25462383||ab|2|entity|C0229961|Carcass|ffas|||carcasses|||0|802|380|389
SE|25462383||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|423|432
SE|25462383||ab|2|entity|C0456696|/24h|tmco|||24h|||0|1000|437|440

SE|25462383||ab|3|text|442|610|At 2h and 6h post mortem, blast chilling had significantly reduced the temperature of the carcasses, as well as the rate of pH decrease and the rate of increase in EC.
SE|25462383||ab|3|entity|C0004398|Autopsy|diap|||post mortem|||0|833|455|466
SE|25462383||ab|3|entity|C0337026|Blast|npop|||blast|||0|833|468|473
SE|25462383||ab|3|entity|C0085593|Chills|sosy|||chilling|||0|833|474|482
SE|25462383||ab|3|entity|C0039476|Temperature|qnco|||temperature|||0|1000|513|524
SE|25462383||ab|3|entity|C0229961|Carcass|ffas|||carcasses|||0|1000|532|541
SE|25462383||ab|3|entity|C1521828|Rate|qnco|||rate|||0|1000|558|562
SE|25462383||ab|3|entity|C0728725|Hydrogen ion increase|fndg|||pH decrease|||0|1000|566|577
SE|25462383||ab|3|entity|C1521828|Rate|qnco|||rate|||0|1000|586|590
SE|25462383||ab|3|entity|C0442805|Increase|ftcn|||increase|||0|1000|594|602

SE|25462383||ab|4|text|610|805|It had no significant effect on the ultimate pH or its range, or on EC at 24h post mortem, but it significantly lowered L*, b*, C* and drip loss compared to the conventionally chilled carcasses.
SE|25462383||ab|4|entity|C0750502|Significant|idcn|||significant|||0|888|620|631
SE|25462383||ab|4|entity|C1280500|Effect|qlco|||effect|||0|888|632|638
SE|25462383||ab|4|entity|C1514721|Range|qnco|||range|||0|1000|665|670
SE|25462383||ab|4|entity|C0456696|/24h|tmco|||24h|||0|1000|684|687
SE|25462383||ab|4|entity|C0004398|Autopsy|diap|||post mortem|||0|1000|688|699
SE|25462383||ab|4|entity|C1272755|Lowered|qnco|||lowered|||0|773|722|729
SE|25462383||ab|4|entity|C1517945|Loss|qnco|||loss|||0|861|750|754
SE|25462383||ab|4|entity|C0085593|Chills|sosy|||chilled|||0|773|786|793
SE|25462383||ab|4|entity|C0229961|Carcass|ffas|||carcasses|||0|773|794|803

SE|25462383||ab|5|text|805|894|Blast chilling adversely affected sensory characteristics such as tenderness and flavor.
SE|25462383||ab|5|entity|C0337026|Blast|npop|||Blast|||0|888|805|810
SE|25462383||ab|5|entity|C0085593|Chills|sosy|||chilling|||0|888|811|819
SE|25462383||ab|5|entity|C0445254|Sensory|qlco|||sensory|||0|888|839|846
SE|25462383||ab|5|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|847|862
SE|25462383||ab|5|entity|C0234233|Sore to touch|sosy|||tenderness|||0|1000|871|881
SE|25462383||ab|5|entity|C0475332|Flavoring|chvf,sbst|||flavor|||0|1000|886|892

SE|25462383||ab|6|text|894|1040|There were no significant differences between the effects of blast and conventional chilling systems on meat quality between conformation classes.
SE|25462383||ab|6|entity|C0750502|Significant|idcn|||significant|||0|872|908|919
SE|25462383||ab|6|entity|C1547020|*Difference|qnco|||differences|||0|872|920|931
SE|25462383||ab|6|entity|C1280500|Effect|qlco|||effects|||0|966|944|951
SE|25462383||ab|6|entity|C0337026|Blast|npop|||blast|||0|1000|955|960
SE|25462383||ab|6|entity|C0439858|Conventional|qlco|||conventional|||0|851|965|977
SE|25462383||ab|6|entity|C0085593|Chills|sosy|||chilling|||0|851|978|986
SE|25462383||ab|6|entity|C0449913|System|ftcn|||systems|||0|851|987|994
SE|25462383||ab|6|entity|C0025017|Meat|food|||meat|||0|888|998|1002
SE|25462383||ab|6|entity|C0332306|Quality|qlco|||quality|||0|888|1003|1010
SE|25462383||ab|6|entity|C0456387|Class|inpr|||classes|||0|861|1032|1039


SE|25462384||ti|1|text|21|259|Glycolytic potential and activity of adenosine monophosphate kinase (AMPK), glycogen phosphorylase (GP) and glycogen debranching enzyme (GDE) in steer carcasses with normal (<5.8) or high (>5.9) 24h pH determined in M. longissimus dorsi.
SE|25462384||ti|1|entity|C0017952|Glycolysis|moft|||Glycolytic|||0|853|21|31
SE|25462384||ti|1|entity|C0237399|Potential|qlco|||potential|||0|853|32|41
SE|25462384||ti|1|entity|C0001464|Adenosine Kinase|aapp,enzy|||adenosine monophosphate kinase|||0|803|58|88
SE|25462384||ti|1|entity|C0917785|Glycogen Phosphorylase|aapp,enzy|||glycogen phosphorylase|||0|1000|97|119
SE|25462384||ti|1|entity|C0086358|Glycogen Debranching Enzyme|aapp,enzy|||glycogen debranching enzyme|||0|1000|129|156
SE|25462384||ti|1|entity|C0229961|Carcass|ffas|||carcasses|||0|861|172|181
SE|25462384||ti|1|entity|C0205307|Normal|qlco|||normal|||0|1000|187|193
SE|25462384||ti|1|entity|C0205250|High|qlco|||high|||0|1000|204|208
SE|25462384||ti|1|entity|C0456696|/24h|tmco|||24h|||0|888|216|219
SE|25462384||ti|1|entity|C0224306|Longissimus|bpoc|||longissimus|||0|790|240|251
SE|25462384||ti|1|relation|5|1|C0229961|Carcass|ffas|ffas|||carcasses|||0|861|172|181|PREP|LOCATION_OF||163|165|4|1|C0086358|Glycogen Debranching Enzyme|aapp,gngm,enzy|aapp|||glycogen debranching enzyme|||0|1000|129|156
SE|25462384||ti|1|relation|5|1|C0229961|Carcass|ffas|ffas|||carcasses|||0|861|172|181|PREP|LOCATION_OF||163|165|4|1|C0917785|Glycogen Phosphorylase|aapp,gngm,enzy|aapp|||glycogen phosphorylase|||0|1000|97|119

SE|25462384||ab|1|text|265|614|Muscle glycogen concentration (MGC) and lactate (LA), activity of glycogen debranching enzyme (GDE), glycogen phosphorylase (GP) and adenosine monophosphate kinase (AMPK) were determined at 0.5h (T0) and 24h (T24) post-mortem in Longissimus dorsi samples from 38 steers that produced high pH (>5.9) and normal pH (<5.8) carcasses at 24h postmortem.
SE|25462384||ab|1|entity|C0026845|Muscle|tisu|||Muscle|||0|623|265|271
SE|25462384||ab|1|entity|C0017911|Glycogen|bacs,carb|||glycogen|||0|623|272|280
SE|25462384||ab|1|entity|C0022924|Lactates|orch|||lactate|||0|1000|305|312
SE|25462384||ab|1|entity|C0086358|Glycogen Debranching Enzyme|aapp,enzy|||glycogen debranching enzyme|||0|1000|331|358
SE|25462384||ab|1|entity|C0086358|Glycogen Debranching Enzyme|aapp,enzy|||GDE|||0|1000|360|363
SE|25462384||ab|1|entity|C0917785|Glycogen Phosphorylase|aapp,enzy|||glycogen phosphorylase|||0|1000|366|388
SE|25462384||ab|1|entity|C0917785|Glycogen Phosphorylase|aapp,enzy|||GP|||0|1000|390|392
SE|25462384||ab|1|entity|C0001464|Adenosine Kinase|aapp,enzy|||adenosine monophosphate kinase|||0|913|398|428
SE|25462384||ab|1|entity|C0001464|Adenosine Kinase|aapp,enzy|||AMPK|||0|803|430|434
SE|25462384||ab|1|entity|C0456696|/24h|tmco|||24h|||0|1000|469|472
SE|25462384||ab|1|entity|C0004398|Autopsy|diap|||post-mortem|||0|1000|479|490
SE|25462384||ab|1|entity|C0224306|Longissimus|bpoc|||Longissimus|||0|660|494|505
SE|25462384||ab|1|entity|C0205250|High|qlco|||high|||0|728|549|553
SE|25462384||ab|1|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|728|554|556
SE|25462384||ab|1|entity|C0205307|Normal|qlco|||normal|||0|750|568|574
SE|25462384||ab|1|entity|C0020283|Hydrogen-Ion Concentration|qnco|||pH|||0|750|575|577
SE|25462384||ab|1|entity|C0229961|Carcass|ffas|||carcasses|||0|1000|585|594
SE|25462384||ab|1|entity|C0456696|/24h|tmco|||24h|||0|888|598|601
SE|25462384||ab|1|entity|C0004398|Autopsy|diap|||postmortem|||0|888|602|612
SE|25462384||ab|1|relation|0|0|C0017911|Glycogen|bacs,carb|bacs|||glycogen|||0|623|272|280|MOD/HEAD|PART_OF||265|280|0|0|C0026845|Muscle|tisu|tisu|||Muscle|||0|623|265|271

SE|25462384||ab|2|text|614|692|MGC, LA and glycolytic potential were higher (P<0.05) in normal pH carcasses.
SE|25462384||ab|2|entity|C0026845|Muscle|tisu|||MGC|||0|623|614|617
SE|25462384||ab|2|entity|C0017911|Glycogen|bacs,carb|||MGC|||0|623|614|617
SE|25462384||ab|2|entity|C0022924|Lactates|orch|||LA|||0|1000|619|621
SE|25462384||ab|2|entity|C0017952|Glycolysis|moft|||glycolytic|||0|853|626|636
SE|25462384||ab|2|entity|C0237399|Potential|qlco|||potential|||0|853|637|646
SE|25462384||ab|2|entity|C0205250|High|qlco|||higher|||0|966|652|658
SE|25462384||ab|2|entity|C0205307|Normal|qlco|||normal|||0|851|671|677
SE|25462384||ab|2|entity|C0229961|Carcass|ffas|||carcasses|||0|851|681|690
SE|25462384||ab|2|relation|0|0|C0017911|Glycogen|bacs,carb|bacs|||MGC|||0|623|614|617|MOD/HEAD|PART_OF||614|617|0|0|C0026845|Muscle|tisu|tisu|||MGC|||0|623|614|617
SE|25462384||ab|2|relation|1|1|C0229961|Carcass|ffas|ffas|||carcasses|||0|851|681|690|PREP|LOCATION_OF||668|670|4|3|C0022924|Lactates|orch|orch|||LA|||0|1000|619|621

SE|25462384||ab|3|text|692|749|GDE activity was similar (P>0.05) in both pH categories.
SE|25462384||ab|3|entity|C1149623|glycogen debranching enzyme activity|moft|||GDE activity|||0|1000|692|704
SE|25462384||ab|3|entity|C0683312|Categories|inpr|||categories|||0|888|737|747

SE|25462384||ab|4|text|749|819|GP activity increased between T0 and T24 only in normal pH carcasses.
SE|25462384||ab|4|entity|C1152162|glycogen phosphorylase activity|moft|||GP activity|||0|1000|749|760
SE|25462384||ab|4|entity|C0205307|Normal|qlco|||normal|||0|851|798|804
SE|25462384||ab|4|entity|C0229961|Carcass|ffas|||carcasses|||0|851|808|817

SE|25462384||ab|5|text|819|932|AMPK activity was four times higher in normal pH v/s high pH carcasses, without changing its activity over time.
SE|25462384||ab|5|entity|C0001464|Adenosine Kinase|aapp,enzy|||AMPK|||0|614|819|823
SE|25462384||ab|5|entity|C0205450|Four|qnco|||four|||0|872|837|841
SE|25462384||ab|5|entity|C0040223|Time|tmco|||times|||0|872|842|847
SE|25462384||ab|5|entity|C0205250|High|qlco|||higher|||0|966|848|854
SE|25462384||ab|5|entity|C0205307|Normal|qlco|||normal|||0|742|858|864
SE|25462384||ab|5|entity|C0860761|pH high|fndg|||pH v/s high|||0|742|865|876
SE|25462384||ab|5|entity|C0229961|Carcass|ffas|||carcasses|||0|742|880|889
SE|25462384||ab|5|entity|C0392747|Changing|ftcn|||changing|||0|1000|899|907
SE|25462384||ab|5|entity|C0040223|Time|tmco|||time|||0|802|926|930

SE|25462384||ab|6|text|932|1260|Results reinforce the idea that differences in postmortem glycogenolytic/glycolytic flow in L. dorsi of steers showing normal v/s high muscle pH at 24h, could be explained not only by the higher initial MGC in normal pH carcasses, but also by a high and sustained activity of AMPK and an increased GP activity at 24h postmortem.
SE|25462384||ab|6|entity|C1274040|result|ftcn|||Results|||0|966|932|939
SE|25462384||ab|6|entity|C1547020|*Difference|qnco|||differences|||0|966|964|975
SE|25462384||ab|6|entity|C0004398|Autopsy|diap|||postmortem|||0|797|979|989
SE|25462384||ab|6|entity|C0596624|Glycogenolysis|moft|||glycogenolytic|||0|797|990|1004
SE|25462384||ab|6|entity|C0017952|Glycolysis|moft|||glycolytic|||0|797|1005|1015
SE|25462384||ab|6|entity|C0806140|Flow|orga|||flow|||0|797|1016|1020
SE|25462384||ab|6|entity|C0205307|Normal|qlco|||normal|||0|756|1051|1057
SE|25462384||ab|6|entity|C0205250|High|qlco|||high|||0|756|1062|1066
SE|25462384||ab|6|entity|C0026845|Muscle|tisu|||muscle|||0|756|1067|1073
SE|25462384||ab|6|entity|C0456696|/24h|tmco|||24h|||0|1000|1080|1083
SE|25462384||ab|6|entity|C1518422|Not|ftcn|||not|||0|861|1104|1107
SE|25462384||ab|6|entity|C0205250|High|qlco|||higher|||0|596|1120|1126
SE|25462384||ab|6|entity|C0205265|Initially|tmco|||initial|||0|596|1127|1134
SE|25462384||ab|6|entity|C0026845|Muscle|tisu|||MGC|||0|596|1135|1138
SE|25462384||ab|6|entity|C0017911|Glycogen|bacs,carb|||MGC|||0|596|1135|1138
SE|25462384||ab|6|entity|C0205307|Normal|qlco|||normal|||0|851|1142|1148
SE|25462384||ab|6|entity|C0229961|Carcass|ffas|||carcasses|||0|851|1152|1161
SE|25462384||ab|6|entity|C0205250|High|qlco|||high|||0|1000|1177|1181
SE|25462384||ab|6|entity|C0443318|Sustained|ftcn|||sustained|||0|888|1186|1195
SE|25462384||ab|6|entity|C0001464|Adenosine Kinase|aapp,enzy|||AMPK|||0|780|1208|1212
SE|25462384||ab|6|entity|C0205217|Increased|qnco|||increased|||0|916|1220|1229
SE|25462384||ab|6|entity|C1152162|glycogen phosphorylase activity|moft|||GP activity|||0|916|1230|1241
SE|25462384||ab|6|entity|C0456696|/24h|tmco|||24h|||0|888|1245|1248
SE|25462384||ab|6|entity|C0004398|Autopsy|diap|||postmortem|||0|888|1249|1259
SE|25462384||ab|6|relation|0|0|C0017911|Glycogen|bacs,carb|bacs|||MGC|||0|596|1135|1138|MOD/HEAD|PART_OF||1135|1138|0|0|C0026845|Muscle|tisu|tisu|||MGC|||0|596|1135|1138
SE|25462384||ab|6|relation|5|1|C0229961|Carcass|ffas|ffas|||carcasses|||0|851|1152|1161|PREP|LOCATION_OF||1139|1141|8|1|C0017911|Glycogen|bacs,carb|carb|||MGC|||0|596|1135|1138


SE|25462385||ti|1|text|21|162|Development of a sensitive and specific multiplex PCR method for the simultaneous detection of chicken, duck and goose DNA in meat products.
SE|25462385||ti|1|entity|C1527148|Development|ftcn|||Development|||0|1000|21|32
SE|25462385||ti|1|entity|C0332324|Sensitive|ftcn|||sensitive|||0|1000|38|47
SE|25462385||ti|1|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|750|71|74
SE|25462385||ti|1|entity|C0025663|Methods|inpr|||method|||0|750|75|81
SE|25462385||ti|1|entity|C0521115|Simultaneous|tmco|||simultaneous|||0|888|90|102
SE|25462385||ti|1|entity|C1511790|Detection|topp|||detection|||0|888|103|112
SE|25462385||ti|1|entity|C0008051|Chickens|bird|||chicken|||0|1000|116|123
SE|25462385||ti|1|entity|C0013268|Ducks|bird|||duck|||0|1000|125|129
SE|25462385||ti|1|entity|C0999182|Anser species|bird|||goose|||0|888|134|139
SE|25462385||ti|1|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|140|143
SE|25462385||ti|1|entity|C0025018|Meat Products|food|||meat products|||0|1000|147|160
SE|25462385||ti|1|relation|2|0|C0032520|Polymerase Chain Reaction|lbpr,mbrt|lbpr|||PCR|||0|750|71|74|NOM|METHOD_OF||75|81|5|1|C1511790|Detection|topp|topp|||detection|||0|888|103|112

SE|25462385||ab|1|text|168|303|Identifying the origin of animal species in manufactured meat products is of considerable economic, religious and sanitary importance.
SE|25462385||ab|1|entity|C0439659|Beginning|tmco|||origin|||0|1000|184|190
SE|25462385||ab|1|entity|C0003043|Animalia|anim|||animal|||0|888|194|200
SE|25462385||ab|1|entity|C1548151|Species|idcn|||species|||0|888|201|208
SE|25462385||ab|1|entity|C0025017|Meat|food|||meat|||0|890|225|229
SE|25462385||ab|1|entity|C1554201|manufactured product|idcn|||manufactured meat products|||0|890|212|238
SE|25462385||ab|1|entity|C0013557|Economic|ftcn|||economic|||0|660|258|266

SE|25462385||ab|2|text|303|466|In this study, we developed a multiplex PCR method to simultaneously detect chicken, duck and goose DNA in meat products derived from beef, pork, mutton or quail.
SE|25462385||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|311|316
SE|25462385||ab|2|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|790|343|346
SE|25462385||ab|2|entity|C0025663|Methods|inpr|||method|||0|790|347|353
SE|25462385||ab|2|entity|C0008051|Chickens|bird|||chicken|||0|1000|379|386
SE|25462385||ab|2|entity|C0013268|Ducks|bird|||duck|||0|1000|388|392
SE|25462385||ab|2|entity|C0999182|Anser species|bird|||goose|||0|888|397|402
SE|25462385||ab|2|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|403|406
SE|25462385||ab|2|entity|C0025018|Meat Products|food|||meat products|||0|1000|410|423
SE|25462385||ab|2|entity|C0452849|Beef|food|||beef|||0|1000|437|441
SE|25462385||ab|2|entity|C0452867|Pork|food|||pork|||0|1000|443|447
SE|25462385||ab|2|entity|C1440988|MUTTON|imft|||mutton|||0|1000|449|455
SE|25462385||ab|2|entity|C0034374|Quail|bird|||quail|||0|1000|459|464

SE|25462385||ab|3|text|466|654|The PCR primers were designed based on the sequence of mitochondrial genes of each avian species, and the amplicon sizes were 131, 283 and 387bp for chicken, duck and goose, respectively.
SE|25462385||ab|3|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|694|470|473
SE|25462385||ab|3|entity|C1519249|Sequence|ftcn|||sequence|||0|1000|509|517
SE|25462385||ab|3|entity|C1563761|Genes, Mitochondrial|gngm|||mitochondrial genes|||0|1000|521|540
SE|25462385||ab|3|entity|C0005595|Aves|bird|||avian|||0|888|549|554
SE|25462385||ab|3|entity|C1548151|Species|idcn|||species|||0|888|555|562
SE|25462385||ab|3|entity|C0456389|size|spco|||sizes|||0|861|581|586
SE|25462385||ab|3|entity|C0008051|Chickens|bird|||chicken|||0|1000|615|622
SE|25462385||ab|3|entity|C0013268|Ducks|bird|||duck|||0|1000|624|628
SE|25462385||ab|3|entity|C0999182|Anser species|bird|||goose|||0|1000|633|638

SE|25462385||ab|4|text|654|857|The method had no cross-reaction with DNA isolated from beef, mutton, pork or quail, and generated products at a target DNA content as low as 0.05ng, or a target meat content of 1% of total meat weight.
SE|25462385||ab|4|entity|C0025663|Methods|inpr|||method|||0|1000|658|664
SE|25462385||ab|4|entity|C0010357|Cross Reactions|moft|||cross-reaction|||0|1000|672|686
SE|25462385||ab|4|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|692|695
SE|25462385||ab|4|entity|C0452849|Beef|food|||beef|||0|1000|710|714
SE|25462385||ab|4|entity|C1440988|MUTTON|imft|||mutton|||0|1000|716|722
SE|25462385||ab|4|entity|C0452867|Pork|food|||pork|||0|1000|724|728
SE|25462385||ab|4|entity|C0034374|Quail|bird|||quail|||0|1000|732|737
SE|25462385||ab|4|entity|C1514468|product|qnco|||products|||0|827|753|761
SE|25462385||ab|4|entity|C0032246|Ploidies|qnco|||DNA content|||0|901|774|785
SE|25462385||ab|4|entity|C0205251|low|qlco|||low|||0|1000|789|792
SE|25462385||ab|4|entity|C0025017|Meat|food|||meat|||0|623|816|820
SE|25462385||ab|4|entity|C0439175|% of total|qnco|||total|||0|851|838|843
SE|25462385||ab|4|entity|C0025017|Meat|food|||meat|||0|851|844|848
SE|25462385||ab|4|entity|C0043100|Weight|qnco|||weight|||0|851|849|855

SE|25462385||ab|5|text|857|1147|Moreover, screening of 24 commercial meat samples using this method indicated that six, two and one samples were contaminated with chicken, duck, or both, respectively, suggesting its usefulness for the simultaneous identification of chicken, duck and goose DNA in commercial meat products.
SE|25462385||ab|5|entity|C0680536|commercial|inpr|||commercial|||0|583|883|893
SE|25462385||ab|5|entity|C0025017|Meat|food|||meat|||0|583|894|898
SE|25462385||ab|5|entity|C0025663|Methods|inpr|||method|||0|1000|918|924
SE|25462385||ab|5|entity|C0205452|Six|qnco|||six|||0|1000|940|943
SE|25462385||ab|5|entity|C0205448|Two|qnco|||two|||0|1000|945|948
SE|25462385||ab|5|entity|C0205447|One|qnco|||one|||0|694|953|956
SE|25462385||ab|5|entity|C0008051|Chickens|bird|||chicken|||0|1000|988|995
SE|25462385||ab|5|entity|C0013268|Ducks|bird|||duck|||0|1000|997|1001
SE|25462385||ab|5|entity|C0521115|Simultaneous|tmco|||simultaneous|||0|694|1060|1072
SE|25462385||ab|5|entity|C0008051|Chickens|bird|||chicken|||0|1000|1091|1098
SE|25462385||ab|5|entity|C0013268|Ducks|bird|||duck|||0|1000|1100|1104
SE|25462385||ab|5|entity|C0999182|Anser species|bird|||goose|||0|888|1109|1114
SE|25462385||ab|5|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|1115|1118
SE|25462385||ab|5|entity|C0680536|commercial|inpr|||commercial|||0|901|1122|1132
SE|25462385||ab|5|entity|C0025018|Meat Products|food|||meat products|||0|901|1133|1146


SE|25462387||ti|1|text|21|179|Visuospatial learning and memory in the Cebus apella and microglial morphology in the molecular layer of the dentate gyrus and CA1 lacunosum molecular layer.
SE|25462387||ti|1|entity|C0023185|Learning|menp|||learning|||0|861|34|42
SE|25462387||ti|1|entity|C0025260|Memory|menp|||memory|||0|1000|47|53
SE|25462387||ti|1|entity|C0999514|Cebus apella|mamm|||Cebus apella|||0|1000|61|73
SE|25462387||ti|1|entity|C0521398|Microglial|blor|||microglial|||0|888|78|88
SE|25462387||ti|1|entity|C0332437|Morphology|qlco|||morphology|||0|888|89|99
SE|25462387||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|861|107|116
SE|25462387||ti|1|entity|C1281026|Entire dentate gyrus|bpoc|||dentate gyrus|||0|1000|130|143
SE|25462387||ti|1|entity|||gngm|759,6281|CA1,S100A10|CA1|||0|812|148|151
SE|25462387||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|812|162|171
SE|25462387||ti|1|relation|2|1|C0023185|Learning|menp|menp|||learning|||0|861|34|42|PREP|PROCESS_OF||54|56|5|1|C0999514|Cebus apella|mamm|mamm|||Cebus apella|||0|1000|61|73
SE|25462387||ti|1|relation|2|1|C0025260|Memory|menp|menp|||memory|||0|1000|47|53|PREP|PROCESS_OF||54|56|5|1|C0999514|Cebus apella|mamm|mamm|||Cebus apella|||0|1000|61|73

SE|25462387||ab|1|text|185|431|We investigated whether the morphology of microglia in the molecular layer of the dentate gyrus (DG-Mol) or in the lacunosum molecular layer of CA1 (CA1-LMol) was correlated with spatial learning and memory in the capuchin monkey (Cebus apella).
SE|25462387||ab|1|entity|C0332437|Morphology|qlco|||morphology|||0|1000|213|223
SE|25462387||ab|1|entity|C0206116|Microglia|cell|||microglia|||0|1000|227|236
SE|25462387||ab|1|entity|C1521991|Molecular|qlco|||molecular|||0|861|244|253
SE|25462387||ab|1|entity|C1281026|Entire dentate gyrus|bpoc|||dentate gyrus|||0|1000|267|280
SE|25462387||ab|1|entity|C0027960|Nevus|neop|||Mol|||0|888|285|288
SE|25462387||ab|1|entity|C1521991|Molecular|qlco|||molecular|||0|827|310|319
SE|25462387||ab|1|entity|||gngm|759,6281|CA1,S100A10|CA1|||0|1000|329|332
SE|25462387||ab|1|entity|||gngm|759,6281|CA1,S100A10|CA1|||0|1000|334|337
SE|25462387||ab|1|entity|C0582587|Visual learning|inbe,menp|||spatial learning|||0|1000|364|380
SE|25462387||ab|1|entity|C0025260|Memory|menp|||memory|||0|1000|385|391
SE|25462387||ab|1|entity|C0007526|Capuchin Monkey|mamm|||capuchin monkey|||0|1000|399|414
SE|25462387||ab|1|entity|C0999514|Cebus apella|mamm|||Cebus apella|||0|1000|416|428
SE|25462387||ab|1|relation|0|0|C0025260|Memory|menp|menp|||memory|||0|1000|385|391|INFER|PROCESS_OF(SPEC)||399|428|0|0|C0999514|Cebus apella|mamm|mamm|||Cebus apella|||0|1000|416|428
SE|25462387||ab|1|relation|0|0|C0582587|Visual learning|inbe,menp|menp|||spatial learning|||0|1000|364|380|INFER|PROCESS_OF(SPEC)||399|428|0|0|C0999514|Cebus apella|mamm|mamm|||Cebus apella|||0|1000|416|428
SE|25462387||ab|1|relation|0|0|C0999514|Cebus apella|mamm|mamm|||Cebus apella|||0|1000|416|428|SPEC|ISA||399|428|0|0|C0007526|Capuchin Monkey|mamm|mamm|||capuchin monkey|||0|1000|399|414
SE|25462387||ab|1|relation|2|1|C0206116|Microglia|cell|cell|||microglia|||0|1000|227|236|NOM|PART_OF||254|259|9|1|C1281026|Entire dentate gyrus|bpoc|bpoc|||dentate gyrus|||0|1000|267|280
SE|25462387||ab|1|relation|10|1|C0025260|Memory|menp|menp|||memory|||0|1000|385|391|PREP|PROCESS_OF||392|394|2|1|C0007526|Capuchin Monkey|mamm|mamm|||capuchin monkey|||0|1000|399|414
SE|25462387||ab|1|relation|10|1|C0582587|Visual learning|inbe,menp|menp|||spatial learning|||0|1000|364|380|PREP|PROCESS_OF||392|394|2|1|C0007526|Capuchin Monkey|mamm|mamm|||capuchin monkey|||0|1000|399|414

SE|25462387||ab|2|text|431|590|Learning and memory was tested in 4 monkeys with visuo-spatial, paired associated learning (PAL) tasks from the Cambridge battery of neuropsychological tests.
SE|25462387||ab|2|entity|C0023185|Learning|menp|||Learning|||0|1000|431|439
SE|25462387||ab|2|entity|C0025260|Memory|menp|||memory|||0|1000|444|450
SE|25462387||ab|2|entity|C0026447|Monkeys|mamm|||monkeys|||0|861|467|474
SE|25462387||ab|2|entity|C0030210|Paired-Associate Learning|menp|||paired associated learning|||0|900|495|521
SE|25462387||ab|2|entity|C0027902|Neuropsychological Tests|diap|||neuropsychological tests|||0|1000|564|588
SE|25462387||ab|2|relation|2|1|C0023185|Learning|menp|menp|||Learning|||0|1000|431|439|PREP|PROCESS_OF||462|464|4|1|C0026447|Monkeys|mamm|mamm|||monkeys|||0|861|467|474
SE|25462387||ab|2|relation|2|1|C0025260|Memory|menp|menp|||memory|||0|1000|444|450|PREP|PROCESS_OF||462|464|4|1|C0026447|Monkeys|mamm|mamm|||monkeys|||0|861|467|474

SE|25462387||ab|3|text|590|661|After testing, monkeys were sacrificed, and hippocampi were sectioned.
SE|25462387||ab|3|entity|C0039593|Testing|resa|||testing|||0|1000|596|603
SE|25462387||ab|3|entity|C0026447|Monkeys|mamm|||monkeys|||0|1000|605|612
SE|25462387||ab|3|entity|C1284077|Entire hippocampus|bpoc|||hippocampi|||0|966|634|644

SE|25462387||ab|4|text|661|772|We specifically immunolabeled microglia with an antibody against the adapter binding, ionized calcium protein.
SE|25462387||ab|4|entity|C0206116|Microglia|cell|||microglia|||0|827|691|700
SE|25462387||ab|4|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|1000|709|717
SE|25462387||ab|4|entity|C0178959|Adapters|medd|||adapter|||0|661|730|737
SE|25462387||ab|4|entity|C0373561|Ionized calcium|bacs,elii|||ionized calcium|||0|901|747|762
SE|25462387||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|901|763|770
SE|25462387||ab|4|relation|3|1|C0003241|Antibodies|aapp,gngm,imft|aapp|||antibody|||0|1000|709|717|PREP|PART_OF||701|705|1|1|C0206116|Microglia|cell|cell|||microglia|||0|827|691|700

SE|25462387||ab|5|text|772|967|Microglia were selected from the middle and outer thirds of the DG-Mol (n=268) and the CA1-LMol (n=185) for three-dimensional reconstructions created with Neurolucida and Neuroexplorer software.
SE|25462387||ab|5|entity|C0206116|Microglia|cell|||Microglia|||0|1000|772|781
SE|25462387||ab|5|entity|C0444598|Middle|spco|||middle|||0|1000|805|811
SE|25462387||ab|5|entity|C0205101|Extrinsic|spco|||outer|||0|694|816|821
SE|25462387||ab|5|entity|C0027960|Nevus|neop|||Mol|||0|888|839|842
SE|25462387||ab|5|entity|||gngm|759,6281|CA1,S100A10|CA1|||0|1000|859|862
SE|25462387||ab|5|entity|C0729707|Computerized tomography, 3 dimensional reconstruction|diap|||three-dimensional reconstructions|||0|983|880|913

SE|25462387||ab|6|text|967|1178|Cluster and discriminant analyses, based on microglial morphometric parameters, identified two major morphological microglia phenotypes (types I and II) found in both the CA1-LMol and DG-Mol of all individuals.
SE|25462387||ab|6|entity|C0012630|Discriminant Analysis|qnco,resa|||discriminant analyses|||0|1000|979|1000
SE|25462387||ab|6|entity|C0521398|Microglial|blor|||microglial|||0|828|1011|1021
SE|25462387||ab|6|entity|C0200760|Morphometric analysis|lbpr|||morphometric|||0|828|1022|1034
SE|25462387||ab|6|entity|C0205448|Two|qnco|||two|||0|822|1058|1061
SE|25462387||ab|6|entity|C0205164|Major|qlco|||major|||0|822|1062|1067
SE|25462387||ab|6|entity|C0543482|morphological|spco|||morphological|||0|822|1068|1081
SE|25462387||ab|6|entity|C0206116|Microglia|cell|||microglia|||0|822|1082|1091
SE|25462387||ab|6|entity|C0031437|Phenotype|orga|||phenotypes|||0|822|1092|1102
SE|25462387||ab|6|entity|C0332307|Type - attribute|qlco|||types|||0|1000|1104|1109
SE|25462387||ab|6|entity|||gngm|759,6281|CA1,S100A10|CA1|||0|1000|1138|1141
SE|25462387||ab|6|entity|C0027960|Nevus|neop|||Mol|||0|888|1154|1157
SE|25462387||ab|6|entity|C0237401|Individual|humn|||individuals|||0|1000|1165|1176
SE|25462387||ab|6|relation|0|0|C0543482|morphological|spco|spco|||morphological|||0|822|1068|1081|MOD/HEAD|LOCATION_OF||1068|1091|0|0|C0206116|Microglia|cell|cell|||microglia|||0|822|1082|1091
SE|25462387||ab|6|relation|8|1|C0027960|Nevus|neop|neop|||Mol|||0|888|1154|1157|PREP|PART_OF||1158|1160|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1165|1176

SE|25462387||ab|7|text|1178|1326|Compared to type II, type I microglia were significantly smaller, thinner, more tortuous and ramified, and less complex (lower fractal dimensions).
SE|25462387||ab|7|entity|C0441730|Type 2|clas|||type II|||0|1000|1190|1197
SE|25462387||ab|7|entity|C1547052|*Type|qnco|||type|||0|1000|1199|1203
SE|25462387||ab|7|entity|C0206116|Microglia|cell|||microglia|||0|1000|1206|1215
SE|25462387||ab|7|entity|C0547044|Smaller|qlco|||smaller|||0|773|1235|1242
SE|25462387||ab|7|entity|C0556614|Thinners|hops|||thinner|||0|773|1244|1251
SE|25462387||ab|7|entity|C0205172|More|ftcn|||more|||0|853|1253|1257
SE|25462387||ab|7|entity|C0333076|Tortuosity|spco|||tortuous|||0|853|1258|1266
SE|25462387||ab|7|entity|C0439855|Complex|qlco|||complex|||0|861|1290|1297
SE|25462387||ab|7|entity|C0206163|Fractals|cnce|||fractal|||0|888|1305|1312
SE|25462387||ab|7|entity|C0439534|Dimensions|qnco|||dimensions|||0|888|1313|1323

SE|25462387||ab|8|text|1326|1512|PAL performance was both linearly and non-linearly correlated with type I microglial morphological features from the rostral and caudal DG-Mol, but not with microglia from the CA1-LMol.
SE|25462387||ab|8|entity|C0030210|Paired-Associate Learning|menp|||PAL|||0|908|1326|1329
SE|25462387||ab|8|entity|C0597198|Performance|inbe|||performance|||0|908|1330|1341
SE|25462387||ab|8|entity|C1547052|*Type|qnco|||type|||0|1000|1393|1397
SE|25462387||ab|8|entity|C0521398|Microglial|blor|||microglial|||0|623|1400|1410
SE|25462387||ab|8|entity|C0543482|morphological|spco|||morphological|||0|623|1411|1424
SE|25462387||ab|8|entity|C0205096|Cephalic|spco|||rostral|||0|1000|1443|1450
SE|25462387||ab|8|entity|C0205097|Caudal|blor|||caudal|||0|851|1455|1461
SE|25462387||ab|8|entity|C0027960|Nevus|neop|||Mol|||0|851|1465|1468
SE|25462387||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1474|1477
SE|25462387||ab|8|entity|C0206116|Microglia|cell|||microglia|||0|1000|1483|1492
SE|25462387||ab|8|entity|||gngm|759,6281|CA1,S100A10|CA1|||0|1000|1502|1505

SE|25462387||ab|9|text|1512|1704|These differences in microglial morphology and correlations with PAL performance were consistent with previous proposals of hippocampal regional contributions for spatial learning and memory.
SE|25462387||ab|9|entity|C1547020|*Difference|qnco|||differences|||0|966|1518|1529
SE|25462387||ab|9|entity|C0521398|Microglial|blor|||microglial|||0|888|1533|1543
SE|25462387||ab|9|entity|C0332437|Morphology|qlco|||morphology|||0|888|1544|1554
SE|25462387||ab|9|entity|C0030210|Paired-Associate Learning|menp|||PAL|||0|908|1577|1580
SE|25462387||ab|9|entity|C0597198|Performance|inbe|||performance|||0|908|1581|1592
SE|25462387||ab|9|entity|C0205156|Previous|tmco|||previous|||0|872|1614|1622
SE|25462387||ab|9|entity|C1555306|proposal|idcn|||proposals|||0|872|1623|1632
SE|25462387||ab|9|entity|C0205147|Region|spco|||regional|||0|660|1648|1656
SE|25462387||ab|9|entity|C0582587|Visual learning|inbe,menp|||spatial learning|||0|1000|1675|1691
SE|25462387||ab|9|entity|C0025260|Memory|menp|||memory|||0|1000|1696|1702

SE|25462387||ab|10|text|1704|1903|Our results suggested that at least two morphological microglial phenotypes provided distinct physiological roles to learning-associated activity in the rostral and caudal DG-Mol of the monkey brain.
SE|25462387||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1708|1715
SE|25462387||ab|10|entity|C0205448|Two|qnco|||two|||0|771|1740|1743
SE|25462387||ab|10|entity|C0543482|morphological|spco|||morphological|||0|771|1744|1757
SE|25462387||ab|10|entity|C0521398|Microglial|blor|||microglial|||0|771|1758|1768
SE|25462387||ab|10|entity|C0031437|Phenotype|orga|||phenotypes|||0|771|1769|1779
SE|25462387||ab|10|entity|C0205463|Physiological|ftcn|||physiological|||0|790|1798|1811
SE|25462387||ab|10|entity|C0035820|Role|socb|||roles|||0|790|1812|1817
SE|25462387||ab|10|entity|C0023185|Learning|menp|||learning|||0|802|1821|1829
SE|25462387||ab|10|entity|C0205096|Cephalic|spco|||rostral|||0|1000|1857|1864
SE|25462387||ab|10|entity|C0205097|Caudal|blor|||caudal|||0|851|1869|1875
SE|25462387||ab|10|entity|C0027960|Nevus|neop|||Mol|||0|851|1879|1882
SE|25462387||ab|10|entity|C0026447|Monkeys|mamm|||monkey|||0|888|1890|1896
SE|25462387||ab|10|entity|C0006104|Brain|bpoc|||brain|||0|888|1897|1902
SE|25462387||ab|10|relation|0|0|C0006104|Brain|bpoc|bpoc|||brain|||0|888|1897|1902|MOD/HEAD|PART_OF||1890|1902|0|0|C0026447|Monkeys|mamm|mamm|||monkey|||0|888|1890|1896
SE|25462387||ab|10|relation|1|1|C0006104|Brain|bpoc|bpoc|||brain|||0|888|1897|1902|PREP|LOCATION_OF||1883|1885|6|1|C0027960|Nevus|neop|neop|||Mol|||0|851|1879|1882


SE|25462386||ti|1|text|21|145|Acid-sensing ion channel 1 and nitric oxide synthase are in adjacent layers in the wall of rat and human cerebral arteries.
SE|25462386||ti|1|entity|C0001128|Acids|chem|||Acid|||0|790|21|25
SE|25462386||ti|1|entity|C0022009|Ion Channel|aapp,bacs|||ion channel|||0|790|34|45
SE|25462386||ti|1|entity|C0132555|Nitric Oxide Synthase|aapp,enzy|||nitric oxide synthase|||0|1000|52|73
SE|25462386||ti|1|entity|C0205117|Adjacent|spco|||adjacent|||0|694|81|89
SE|25462386||ti|1|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|112|115
SE|25462386||ti|1|entity|C0020114|Human|humn|||human|||0|901|120|125
SE|25462386||ti|1|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|901|126|143
SE|25462386||ti|1|relation|0|0|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|901|126|143|MOD/HEAD|PART_OF||120|143|0|0|C0020114|Human|grup,humn|humn|||human|||0|901|120|125

SE|25462386||ab|1|text|151|254|Extracellular acidification activates a family of proteins known as acid-sensing ion channels (ASICs).
SE|25462386||ab|1|entity|C0521119|Extracellular|celc|||Extracellular|||0|888|151|164
SE|25462386||ab|1|entity|C1522821|acidification|celf|||acidification|||0|888|165|178
SE|25462386||ab|1|entity|C0015576|Family|famg|||family|||0|1000|191|197
SE|25462386||ab|1|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|201|209
SE|25462386||ab|1|entity|C0001128|Acids|chem|||acid|||0|813|219|223
SE|25462386||ab|1|entity|C0022009|Ion Channel|aapp,bacs|||ion channels|||0|813|232|244
SE|25462386||ab|1|relation|1|1|C1522821|acidification|celf|celf|||acidification|||0|888|165|178|VERB|AFFECTS||179|188|3|1|C0015576|Family|famg,humn|humn|||family|||0|1000|191|197

SE|25462386||ab|2|text|254|397|One ASIC subtype, ASIC type 1 (ASIC1), may play an important role in synaptic plasticity, memory, fear conditioning and ischemic brain injury.
SE|25462386||ab|2|entity|C0205447|One|qnco|||One|||0|802|254|257
SE|25462386||ab|2|entity|||gngm|41|ASIC1|ASIC|||0|802|258|262
SE|25462386||ab|2|entity|C0449560|Subtype|clas|||subtype|||0|802|263|270
SE|25462386||ab|2|entity|||gngm|41|ASIC1|ASIC|||0|901|272|276
SE|25462386||ab|2|entity|C0441729|Type 1|clas|||type 1|||0|901|277|283
SE|25462386||ab|2|entity|||gngm|41|ASIC1|ASIC1|||0|1000|285|290
SE|25462386||ab|2|entity|C0035820|Role|socb|||role|||0|861|315|319
SE|25462386||ab|2|entity|C0039062|Synapses|bsoj|||synaptic|||0|853|323|331
SE|25462386||ab|2|entity|C0025260|Memory|menp|||memory|||0|1000|344|350
SE|25462386||ab|2|entity|C0015726|Fright|menp|||fear|||0|694|352|356
SE|25462386||ab|2|entity|C0751015|Brain Injury, Ischemic|patf|||ischemic brain injury|||0|1000|374|395

SE|25462386||ab|3|text|397|512|ASIC1 is found primarily in neurons, but one report showed its expression in isolated mouse cerebrovascular cells.
SE|25462386||ab|3|entity|||gngm|41|ASIC1|ASIC1|||0|1000|397|402
SE|25462386||ab|3|entity|C0027882|Neurons|cell|||neurons|||0|1000|425|432
SE|25462386||ab|3|entity|C0205447|One|qnco|||one|||0|888|438|441
SE|25462386||ab|3|entity|C0205409|Isolated|ftcn|||isolated|||0|775|474|482
SE|25462386||ab|3|entity|C0025914|House mice|mamm|||mouse|||0|775|483|488
SE|25462386||ab|3|entity|C0007634|Cells|cell|||cells|||0|775|505|510
SE|25462386||ab|3|relation|4|1|C0027882|Neurons|cell|cell|||neurons|||0|1000|425|432|VERB|LOCATION_OF||406|411|1|1|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|397|402

SE|25462386||ab|4|text|512|619|In this study, we sought to determine if ASIC1 is present in intact rat and human major cerebral arteries.
SE|25462386||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|520|525
SE|25462386||ab|4|entity|||gngm|41|ASIC1|ASIC1|||0|1000|553|558
SE|25462386||ab|4|entity|C0150312|Present|qnco|||present|||0|1000|562|569
SE|25462386||ab|4|entity|C0205266|Intact|qlco|||intact|||0|888|573|579
SE|25462386||ab|4|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|580|583
SE|25462386||ab|4|entity|C0020114|Human|humn|||human|||0|861|588|593
SE|25462386||ab|4|entity|C0205164|Major|qlco|||major|||0|861|594|599
SE|25462386||ab|4|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|861|600|617
SE|25462386||ab|4|relation|2|1|C0020114|Human|grup,humn|humn|||human|||0|861|588|593|ADJ|LOCATION_OF||562|569|2|1|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|553|558
SE|25462386||ab|4|relation|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|580|583|ADJ|LOCATION_OF||562|569|2|1|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|553|558

SE|25462386||ab|5|text|619|842|A potential physiological significance of such a finding is suggested by studies showing that nitric oxide (NO), which acts as a powerful vasodilator, may modulate proton-gated currents in cultured cells expressing ASIC1s.
SE|25462386||ab|5|entity|C0237399|Potential|qlco|||potential|||0|828|621|630
SE|25462386||ab|5|entity|C0205463|Physiological|ftcn|||physiological|||0|828|631|644
SE|25462386||ab|5|entity|C0750502|Significant|idcn|||significance|||0|828|645|657
SE|25462386||ab|5|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|1000|668|675
SE|25462386||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|966|692|699
SE|25462386||ab|5|entity|C0028128|Nitric Oxide|bacs,inch|||nitric oxide|||0|1000|713|725
SE|25462386||ab|5|entity|C0033727|Protons|elii|||proton|||0|785|783|789
SE|25462386||ab|5|entity|C0521116|Current|tmco|||currents|||0|785|796|804
SE|25462386||ab|5|entity|C0007585|Cell Culture Techniques|lbpr|||cultured cells|||0|1000|808|822
SE|25462386||ab|5|entity|||gngm|41|ASIC1|ASIC1s|||0|1000|834|840
SE|25462386||ab|5|relation|7|4|C0028128|Nitric Oxide|bacs,inch|bacs|||nitric oxide|||0|1000|713|725|VERB|INTERACTS_WITH||823|833|1|1|||gngm,aapp|gngm|41|ASIC1|ASIC1s|||0|1000|834|840

SE|25462386||ab|6|text|842|1110|Because both constitutive NO synthesizing enzymes, neuronal nitric oxide synthase (nNOS) and endothelial NOS (eNOS), are expressed in cerebral arteries we also studied the anatomical relationship between ASIC1 and nNOS or eNOS in both rat and human cerebral arteries.
SE|25462386||ab|6|entity|C0028128|Nitric Oxide|bacs,inch|||NO|||0|794|868|870
SE|25462386||ab|6|entity|C0014442|Enzymes|enzy,orch|||enzymes|||0|794|884|891
SE|25462386||ab|6|entity|C0669368|Nitric Oxide Synthase Type I|aapp,enzy|||neuronal nitric oxide synthase|||0|1000|893|923
SE|25462386||ab|6|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|endothelial|||0|888|935|946
SE|25462386||ab|6|entity|C0669372|NOS2A protein, human|aapp,enzy|4843|NOS2|NOS|||0|888|947|950
SE|25462386||ab|6|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|1000|976|993
SE|25462386||ab|6|entity|C0933844|Anatomical relationship|cnce|||anatomical relationship|||0|1000|1014|1037
SE|25462386||ab|6|entity|||gngm|41|ASIC1|ASIC1|||0|1000|1046|1051
SE|25462386||ab|6|entity|C0669368|Nitric Oxide Synthase Type I|aapp,enzy|||nNOS|||0|1000|1056|1060
SE|25462386||ab|6|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|eNOS|||0|888|1064|1068
SE|25462386||ab|6|entity|C0669372|NOS2A protein, human|aapp,enzy|4843|NOS2|eNOS|||0|888|1064|1068
SE|25462386||ab|6|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|1077|1080
SE|25462386||ab|6|entity|C0020114|Human|humn|||human|||0|901|1085|1090
SE|25462386||ab|6|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|901|1091|1108
SE|25462386||ab|6|relation|0|0|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|901|1091|1108|MOD/HEAD|PART_OF||1085|1108|0|0|C0020114|Human|grup,humn|humn|||human|||0|901|1085|1090
SE|25462386||ab|6|relation|2|1|C0020114|Human|grup,humn|humn|||human|||0|901|1085|1090|PREP|LOCATION_OF||1069|1071|8|1|C0669372|NOS2A protein, human|aapp,gngm,enzy|aapp|4843|NOS2|eNOS|||0|888|1064|1068
SE|25462386||ab|6|relation|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1077|1080|PREP|LOCATION_OF||1069|1071|8|1|C0669368|Nitric Oxide Synthase Type I|aapp,gngm,enzy|aapp|||nNOS|||0|1000|1056|1060
SE|25462386||ab|6|relation|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1077|1080|PREP|LOCATION_OF||1069|1071|8|1|C0669372|NOS2A protein, human|aapp,gngm,enzy|aapp|4843|NOS2|eNOS|||0|888|1064|1068
SE|25462386||ab|6|relation|2|2|C0020114|Human|grup,humn|humn|||human|||0|901|1085|1090|PREP|LOCATION_OF||1069|1071|8|2|C0669368|Nitric Oxide Synthase Type I|aapp,gngm,enzy|aapp|||nNOS|||0|1000|1056|1060
SE|25462386||ab|6|relation|7|1|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|1000|976|993|PREP|LOCATION_OF||973|975|3|1|C0669368|Nitric Oxide Synthase Type I|aapp,gngm,enzy|aapp|||neuronal nitric oxide synthase|||0|1000|893|923
SE|25462386||ab|6|relation|7|1|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|1000|976|993|PREP|LOCATION_OF||973|975|3|1|C0669372|NOS2A protein, human|aapp,gngm,enzy|aapp|4843|NOS2|NOS|||0|888|947|950

SE|25462386||ab|7|text|1110|1191|Western blot analysis demonstrated ASIC1 in cerebral arteries from both species.
SE|25462386||ab|7|entity|C0949466|Western Blot|lbpr|||Western blot analysis|||0|1000|1110|1131
SE|25462386||ab|7|entity|||gngm|41|ASIC1|ASIC1|||0|1000|1145|1150
SE|25462386||ab|7|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|1000|1154|1171
SE|25462386||ab|7|entity|C1548151|Species|idcn|||species|||0|1000|1182|1189
SE|25462386||ab|7|relation|2|1|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|1000|1154|1171|PREP|LOCATION_OF||1151|1153|2|1|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|1145|1150

SE|25462386||ab|8|text|1191|1524|Immunofluorescent histochemistry and confocal microscopy also showed that ASIC1-immunoreactivity (IR), colocalized with the smooth muscle marker alpha-smooth muscle actin (SMA), was present in the anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA) and basilar artery (BA) of rat and human.
SE|25462386||ab|8|entity|C0019635|Histocytochemistry|lbpr|||histochemistry|||0|861|1209|1223
SE|25462386||ab|8|entity|C0242842|Microscopy, Confocal|lbpr|||confocal microscopy|||0|1000|1228|1247
SE|25462386||ab|8|entity|||gngm|41|ASIC1|ASIC1|||0|861|1265|1270
SE|25462386||ab|8|entity|C0597879|Immunoreactivity|moft|||immunoreactivity|||0|861|1271|1287
SE|25462386||ab|8|entity|C1267092|Smooth muscle (tissue)|tisu|||smooth muscle|||0|785|1315|1328
SE|25462386||ab|8|entity|C0005516|Biological Markers|qlco|||marker|||0|785|1329|1335
SE|25462386||ab|8|entity|C0002240|alpha-Actin|aapp,bacs|||alpha-smooth muscle actin|||0|785|1336|1361
SE|25462386||ab|8|entity|C0150312|Present|qnco|||present|||0|1000|1373|1380
SE|25462386||ab|8|entity|C1269011|Entire anterior cerebral artery|bpoc|||anterior cerebral artery|||0|1000|1388|1412
SE|25462386||ab|8|entity|C0149561|Structure of anterior cerebral artery|bpoc|||ACA|||0|1000|1414|1417
SE|25462386||ab|8|entity|C1269012|Entire middle cerebral artery|bpoc|||middle cerebral artery|||0|1000|1420|1442
SE|25462386||ab|8|entity|C1269013|Entire posterior cerebral artery|bpoc|||posterior cerebral artery|||0|1000|1450|1475
SE|25462386||ab|8|entity|C1269881|Entire basilar artery|bpoc|||basilar artery|||0|1000|1486|1500
SE|25462386||ab|8|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|1509|1512
SE|25462386||ab|8|entity|C0020114|Human|humn|||human|||0|1000|1517|1522
SE|25462386||ab|8|relation|7|1|C1269011|Entire anterior cerebral artery|bpoc|bpoc|||anterior cerebral artery|||0|1000|1388|1412|ADJ|LOCATION_OF||1373|1380|4|1|C0002240|alpha-Actin|aapp,gngm,bacs|aapp|||alpha-smooth muscle actin|||0|785|1336|1361
SE|25462386||ab|8|relation|10|1|C1269012|Entire middle cerebral artery|bpoc|bpoc|||middle cerebral artery|||0|1000|1420|1442|PREP|PART_OF||1506|1508|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1509|1512
SE|25462386||ab|8|relation|10|1|C1269881|Entire basilar artery|bpoc|bpoc|||basilar artery|||0|1000|1486|1500|PREP|PART_OF||1506|1508|2|1|C0020114|Human|grup,humn|humn|||human|||0|1000|1517|1522
SE|25462386||ab|8|relation|10|1|C1269881|Entire basilar artery|bpoc|bpoc|||basilar artery|||0|1000|1486|1500|PREP|PART_OF||1506|1508|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1509|1512
SE|25462386||ab|8|relation|10|2|C1269013|Entire posterior cerebral artery|bpoc|bpoc|||posterior cerebral artery|||0|1000|1450|1475|PREP|PART_OF||1506|1508|2|1|C0020114|Human|grup,humn|humn|||human|||0|1000|1517|1522
SE|25462386||ab|8|relation|10|2|C1269013|Entire posterior cerebral artery|bpoc|bpoc|||posterior cerebral artery|||0|1000|1450|1475|PREP|PART_OF||1506|1508|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1509|1512
SE|25462386||ab|8|relation|10|3|C1269012|Entire middle cerebral artery|bpoc|bpoc|||middle cerebral artery|||0|1000|1420|1442|PREP|PART_OF||1506|1508|2|2|C0020114|Human|grup,humn|humn|||human|||0|1000|1517|1522

SE|25462386||ab|9|text|1524|1659|Expression of ASIC1 in cerebral arteries is consistent with a role for ASIC1 in modulating cerebrovascular tone both in rat and human.
SE|25462386||ab|9|entity|||gngm|41|ASIC1|ASIC1|||0|1000|1538|1543
SE|25462386||ab|9|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|1000|1547|1564
SE|25462386||ab|9|entity|C0035820|Role|socb|||role|||0|1000|1586|1590
SE|25462386||ab|9|entity|||gngm|41|ASIC1|ASIC1|||0|1000|1595|1600
SE|25462386||ab|9|entity|C0443264|Modulated|spco|||modulating|||0|735|1604|1614
SE|25462386||ab|9|entity|C0439216|ton|qnco|||tone|||0|735|1631|1635
SE|25462386||ab|9|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|1000|1644|1647
SE|25462386||ab|9|entity|C0020114|Human|humn|||human|||0|1000|1652|1657
SE|25462386||ab|9|relation|2|1|C0020114|Human|grup,humn|humn|||human|||0|1000|1652|1657|PREP|LOCATION_OF||1641|1643|7|2|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|1595|1600
SE|25462386||ab|9|relation|2|1|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|1000|1644|1647|PREP|LOCATION_OF||1641|1643|7|2|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|1595|1600
SE|25462386||ab|9|relation|7|1|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|1000|1547|1564|PREP|LOCATION_OF||1544|1546|2|1|||gngm,aapp|aapp|41|ASIC1|ASIC1|||0|1000|1538|1543

SE|25462386||ab|10|text|1659|1905|Potential interactions between smooth muscle ASIC1 and nNOS or eNOS were supported by the presence of nNOS-IR in the neighboring adventitial layer and the presence of nNOS-IR and eNOS-IR in the adjacent endothelial layer of the cerebral arteries.
SE|25462386||ab|10|entity|C0237399|Potential|qlco|||Potential|||0|694|1659|1668
SE|25462386||ab|10|entity|C1267092|Smooth muscle (tissue)|tisu|||smooth muscle|||0|734|1690|1703
SE|25462386||ab|10|entity|||gngm|41|ASIC1|ASIC1|||0|734|1704|1709
SE|25462386||ab|10|entity|C0669368|Nitric Oxide Synthase Type I|aapp,enzy|||nNOS|||0|1000|1714|1718
SE|25462386||ab|10|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|eNOS|||0|888|1722|1726
SE|25462386||ab|10|entity|C0669372|NOS2A protein, human|aapp,enzy|4843|NOS2|eNOS|||0|888|1722|1726
SE|25462386||ab|10|entity|C0669368|Nitric Oxide Synthase Type I|aapp,enzy|||nNOS|||0|928|1761|1765
SE|25462386||ab|10|entity|C0597879|Immunoreactivity|moft|||IR|||0|928|1766|1768
SE|25462386||ab|10|entity|C1553702|neighbor|popg|||neighboring|||0|571|1776|1787
SE|25462386||ab|10|entity|C0225342|Adventitia|tisu|||adventitial|||0|571|1788|1799
SE|25462386||ab|10|entity|C0669368|Nitric Oxide Synthase Type I|aapp,enzy|||nNOS|||0|928|1826|1830
SE|25462386||ab|10|entity|C0597879|Immunoreactivity|moft|||IR|||0|928|1831|1833
SE|25462386||ab|10|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|eNOS|||0|851|1838|1842
SE|25462386||ab|10|entity|C0669372|NOS2A protein, human|aapp,enzy|4843|NOS2|eNOS|||0|851|1838|1842
SE|25462386||ab|10|entity|C0597879|Immunoreactivity|moft|||IR|||0|851|1843|1845
SE|25462386||ab|10|entity|C0205117|Adjacent|spco|||adjacent|||0|623|1853|1861
SE|25462386||ab|10|entity|C0669365|NOS3 protein, human|aapp,enzy|4846|NOS3|endothelial|||0|623|1862|1873
SE|25462386||ab|10|entity|C0007770|Structure of cerebral artery|bpoc|||cerebral arteries|||0|1000|1887|1904
SE|25462386||ab|10|relation|0|0|||gngm,aapp|gngm|41|ASIC1|ASIC1|||0|734|1704|1709|MOD/HEAD|PART_OF||1690|1709|0|0|C1267092|Smooth muscle (tissue)|tisu|tisu|||smooth muscle|||0|734|1690|1703
SE|25462386||ab|10|relation|6|3|C0669368|Nitric Oxide Synthase Type I|aapp,gngm,enzy|aapp|||nNOS|||0|1000|1714|1718|NOM|PART_OF||1800|1805|6|0|C0225342|Adventitia|tisu|tisu|||adventitial|||0|571|1788|1799
SE|25462386||ab|10|relation|6|3|C0669372|NOS2A protein, human|aapp,gngm,enzy|aapp|4843|NOS2|eNOS|||0|888|1722|1726|NOM|PART_OF||1800|1805|6|0|C0225342|Adventitia|tisu|tisu|||adventitial|||0|571|1788|1799
SE|25462386||ab|10|relation|10|0|C0669365|NOS3 protein, human|aapp,gngm,enzy|aapp|4846|NOS3|endothelial|||0|623|1862|1873|NOM|PART_OF||1874|1879|1|1|C0007770|Structure of cerebral artery|bpoc|bpoc|||cerebral arteries|||0|1000|1887|1904
SE|25462386||ab|10|relation|11|2|C0669368|Nitric Oxide Synthase Type I|aapp,gngm,enzy|aapp|||nNOS|||0|1000|1714|1718|NOM|INTERACTS_WITH||1669|1681|11|1|||gngm,aapp|gngm|41|ASIC1|ASIC1|||0|734|1704|1709


SE|25462388||ti|1|text|21|125|Depression as a risk factor for overall and hormone-related cancer: the Korean cancer prevention study.
SE|25462388||ti|1|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|21|31
SE|25462388||ti|1|entity|C0035648|risk factors|qnco|||risk factor|||0|1000|37|48
SE|25462388||ti|1|entity|C1561607|Overall|qlco|||overall|||0|1000|53|60
SE|25462388||ti|1|entity|C0019932|Hormones|horm|||hormone|||0|851|65|72
SE|25462388||ti|1|entity|C1522149|Related|ftcn|||related|||0|851|73|80
SE|25462388||ti|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|851|81|87
SE|25462388||ti|1|entity|C0337903|Koreans (ethnic group)|popg|||Korean|||0|861|93|99
SE|25462388||ti|1|entity|C0281206|cancer prevention|topp|||cancer prevention|||0|861|100|117
SE|25462388||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|861|118|123
SE|25462388||ti|1|relation|0|0|C0008972|Clinical Research|resa|resa|||study|||0|861|118|123|MOD/HEAD|USES||100|123|0|0|C0281206|cancer prevention|topp|topp|||cancer prevention|||0|861|100|117

SE|25462388||ab|1|text|131|231|Depression has been hypothesized to be a risk factor of cancer, especially hormone-related cancers.
SE|25462388||ab|1|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|131|141
SE|25462388||ab|1|entity|C0035648|risk factors|qnco|||risk factor|||0|1000|172|183
SE|25462388||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|187|193
SE|25462388||ab|1|entity|C0019932|Hormones|horm|||hormone|||0|775|206|213
SE|25462388||ab|1|entity|C1522149|Related|ftcn|||related|||0|775|214|221
SE|25462388||ab|1|entity|C0006826|Malignant Neoplasms|neop|||cancers|||0|775|222|229

SE|25462388||ab|2|text|231|377|However, few studies have been conducted with large enough sample size and sufficient follow-up period to rigorously estimate these associations.
SE|25462388||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|966|244|251
SE|25462388||ab|2|entity|C0549177|Large|qnco|||large|||0|1000|277|282
SE|25462388||ab|2|entity|C0456389|size|spco|||size|||0|1000|297|301
SE|25462388||ab|2|entity|C0205410|Sufficient|qlco|||sufficient|||0|861|306|316
SE|25462388||ab|2|entity|C1522577|follow-up|hlca|||follow-up|||0|861|317|326
SE|25462388||ab|2|entity|C0439531|/period|tmco|||period|||0|861|327|333

SE|25462388||ab|3|text|377|500|We aim to examine the relationship between depression and risk of registry-documented overall and hormone-related cancers.
SE|25462388||ab|3|entity|C0439849|Relationships|qlco|||relationship|||0|1000|399|411
SE|25462388||ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|420|430
SE|25462388||ab|3|entity|C0035647|Risk|qlco|||risk|||0|1000|435|439
SE|25462388||ab|3|entity|C0034975|Registries|inpr,qnco|||registry|||0|851|443|451
SE|25462388||ab|3|entity|C1561607|Overall|qlco|||overall|||0|851|463|470
SE|25462388||ab|3|entity|C0019932|Hormones|horm|||hormone|||0|851|475|482
SE|25462388||ab|3|entity|C1522149|Related|ftcn|||related|||0|851|483|490
SE|25462388||ab|3|entity|C0006826|Malignant Neoplasms|neop|||cancers|||0|851|491|498

SE|25462388||ab|4|text|500|696|In this 19 year prospective cohort study of general population, 601,775 Koreans aged 30-64 years had a biennial medical evaluation by the National Health Insurance Service in either 1992 or 1994.
SE|25462388||ab|4|entity|C0439234|year|tmco|||year|||0|798|511|515
SE|25462388||ab|4|entity|C0599755|cohort|popg|||cohort|||0|798|528|534
SE|25462388||ab|4|entity|C0033522|Prospective Studies|qnco,resa|||prospective cohort study|||0|798|516|540
SE|25462388||ab|4|entity|C0683971|General Population|popg|||general population|||0|1000|544|562
SE|25462388||ab|4|entity|C0439234|year|tmco|||years|||0|827|591|596
SE|25462388||ab|4|entity|C0205476|Medical|ftcn|||medical|||0|790|612|619
SE|25462388||ab|4|entity|C0220825|Evaluation|ftcn|||evaluation|||0|790|620|630
SE|25462388||ab|4|entity|C0021672|Insurance|idcn|||Insurance|||0|916|654|663
SE|25462388||ab|4|entity|C0027462|Health Services, National|hlca|||National Health Insurance Service|||0|916|638|671

SE|25462388||ab|5|text|696|777|Major and minor depression was ascertained by a 9-item depression questionnaire.
SE|25462388||ab|5|entity|C0205164|Major|qlco|||Major|||0|1000|696|701
SE|25462388||ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|712|722
SE|25462388||ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|750|751|761
SE|25462388||ab|5|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|750|762|775

SE|25462388||ab|6|text|777|912|At baseline, major depression was identified in 7.4% and 10.2% and minor depression in 19.3% and 21.4% in men and women, respectively.
SE|25462388||ab|6|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|780|788
SE|25462388||ab|6|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|790|806
SE|25462388||ab|6|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|850|860
SE|25462388||ab|6|entity|C0025266|Male population group|popg|||men|||0|1000|883|886
SE|25462388||ab|6|entity|C0043210|Woman|popg|||women|||0|1000|891|896
SE|25462388||ab|6|relation|3|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|850|860|PREP|PROCESS_OF||880|882|2|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|883|886
SE|25462388||ab|6|relation|3|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|850|860|PREP|PROCESS_OF||880|882|2|1|C0043210|Woman|popg,humn|popg|||women|||0|1000|891|896

SE|25462388||ab|7|text|912|991|During the follow-up, 49,744 cancers were identified in men and 7860 in women.
SE|25462388||ab|7|entity|C1522577|follow-up|hlca|||follow-up|||0|812|923|932
SE|25462388||ab|7|entity|C0006826|Malignant Neoplasms|neop|||cancers|||0|812|941|948
SE|25462388||ab|7|entity|C0025266|Male population group|popg|||men|||0|1000|968|971
SE|25462388||ab|7|entity|C0043210|Woman|popg|||women|||0|1000|984|989
SE|25462388||ab|7|relation|1|1|C0006826|Malignant Neoplasms|neop|neop|||cancers|||0|812|941|948|PREP|PROCESS_OF||965|967|2|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|968|971

SE|25462388||ab|8|text|991|1230|Prostate cancer in men was positively related to minor depression (HR 1.13, 95% CI 1.05, 1.23), and cervical cancer in women was inversely related to major depression (HR 0.90, 95% CI 0.83, 0.98) after adjusting for potential confounders.
SE|25462388||ab|8|entity|C0376358|Malignant neoplasm of prostate|neop|||Prostate cancer|||0|1000|991|1006
SE|25462388||ab|8|entity|C0025266|Male population group|popg|||men|||0|1000|1010|1013
SE|25462388||ab|8|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1046|1056
SE|25462388||ab|8|entity|C0007847|Malignant neoplasm of cervix uteri|neop|||cervical cancer|||0|1000|1091|1106
SE|25462388||ab|8|entity|C0043210|Woman|popg|||women|||0|1000|1110|1115
SE|25462388||ab|8|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|1141|1157
SE|25462388||ab|8|entity|C1439356|ADJUSTED|qlco|||adjusting|||0|966|1193|1202
SE|25462388||ab|8|entity|C0237399|Potential|qlco|||potential|||0|694|1207|1216
SE|25462388||ab|8|relation|1|1|C0376358|Malignant neoplasm of prostate|neop|neop|||Prostate cancer|||0|1000|991|1006|PREP|PROCESS_OF||1007|1009|7|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1010|1013
SE|25462388||ab|8|relation|2|2|C0376358|Malignant neoplasm of prostate|neop|neop|||Prostate cancer|||0|1000|991|1006|VERB|COEXISTS_WITH||1029|1036|6|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|1046|1056
SE|25462388||ab|8|relation|4|1|C0007847|Malignant neoplasm of cervix uteri|neop|neop|||cervical cancer|||0|1000|1091|1106|PREP|PROCESS_OF||1107|1109|4|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1110|1115
SE|25462388||ab|8|relation|5|2|C0007847|Malignant neoplasm of cervix uteri|neop|neop|||cervical cancer|||0|1000|1091|1106|VERB|COEXISTS_WITH||1130|1137|3|1|C1269683|Major Depressive Disorder|mobd|mobd|||major depression|||0|1000|1141|1157

SE|25462388||ab|9|text|1230|1411|Regarding overall cancer, major depression was positively related to overall cancer in men (HR 1.04, 95% CI 1.00, 1.08) and inversely related in women (HR 0.90, 95% CI 0.83, 0.98).
SE|25462388||ab|9|entity|C1561607|Overall|qlco|||overall|||0|888|1240|1247
SE|25462388||ab|9|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|888|1248|1254
SE|25462388||ab|9|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|1256|1272
SE|25462388||ab|9|entity|C1561607|Overall|qlco|||overall|||0|888|1299|1306
SE|25462388||ab|9|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|888|1307|1313
SE|25462388||ab|9|entity|C0025266|Male population group|popg|||men|||0|1000|1317|1320
SE|25462388||ab|9|entity|C0043210|Woman|popg|||women|||0|1000|1375|1380
SE|25462388||ab|9|relation|2|1|C1269683|Major Depressive Disorder|mobd|mobd|||major depression|||0|1000|1256|1272|VERB|COEXISTS_WITH||1288|1295|3|1|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|888|1307|1313
SE|25462388||ab|9|relation|3|1|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|888|1307|1313|PREP|PROCESS_OF||1314|1316|2|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1317|1320
SE|25462388||ab|9|relation|4|4|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|888|1248|1254|PREP|PROCESS_OF||1372|1374|1|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1375|1380

SE|25462388||ab|10|text|1411|1474|There was no association between breast cancer and depression.
SE|25462388||ab|10|entity|C0006142|Malignant neoplasm of breast|neop|||breast cancer|||0|1000|1444|1457
SE|25462388||ab|10|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1462|1472

SE|25462388||ab|11|text|1474|1673|Different direction and magnitude of association among gender and cancer subtypes suggest different psycho-behavioral and biological pathways in which depression may affect later cancer development.
SE|25462388||ab|11|entity|C1547020|*Difference|qnco|||Different|||0|853|1474|1483
SE|25462388||ab|11|entity|C0449738|Direction|spco|||direction|||0|853|1484|1493
SE|25462388||ab|11|entity|C0449286|Degree or extent|qnco|||magnitude|||0|966|1498|1507
SE|25462388||ab|11|entity|C0079399|Gender|orga|||gender|||0|1000|1529|1535
SE|25462388||ab|11|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|872|1540|1546
SE|25462388||ab|11|entity|C0449560|Subtype|clas|||subtypes|||0|872|1547|1555
SE|25462388||ab|11|entity|C1547020|*Difference|qnco|||different|||0|589|1564|1573
SE|25462388||ab|11|entity|C0205460|biological|ftcn|||biological|||0|694|1596|1606
SE|25462388||ab|11|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1625|1635
SE|25462388||ab|11|entity|C0205087|Late|tmco|||later|||0|840|1647|1652
SE|25462388||ab|11|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|840|1653|1659
SE|25462388||ab|11|entity|C1527148|Development|ftcn|||development|||0|840|1660|1671
SE|25462388||ab|11|relation|8|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|1625|1635|VERB|AFFECTS||1640|1646|1|1|C0006826|Malignant Neoplasms|neop|neop|||cancer|||0|840|1653|1659

SE|25462388||ab|12|text|1673|1811|Further studies on the association of depression and cancer and the underlying mechanisms should be conducted on specific cancer subtypes.
SE|25462388||ab|12|entity|C1517331|Further|spco|||Further|||0|872|1673|1680
SE|25462388||ab|12|entity|C0008972|Clinical Research|resa|||studies|||0|872|1681|1688
SE|25462388||ab|12|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1711|1721
SE|25462388||ab|12|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|1726|1732
SE|25462388||ab|12|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|861|1752|1762
SE|25462388||ab|12|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|773|1795|1801
SE|25462388||ab|12|entity|C0449560|Subtype|clas|||subtypes|||0|773|1802|1810


SE|25462389||ti|1|text|21|179|Association of inflammatory biomarkers with depressive symptoms and cognitive decline in a community-dwelling healthy older sample: a 3-year follow-up study.
SE|25462389||ti|1|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|888|36|48
SE|25462389||ti|1|entity|C0005516|Biological Markers|qlco|||biomarkers|||0|888|49|59
SE|25462389||ti|1|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|65|84
SE|25462389||ti|1|entity|C0338656|Impaired cognition|fndg|||cognitive decline|||0|1000|89|106
SE|25462389||ti|1|entity|C0009462|Community|geoa|||community|||0|578|112|121
SE|25462389||ti|1|entity|C0442519|Home environment|mnob|||dwelling|||0|578|122|130
SE|25462389||ti|1|entity|C0018684|Health|idcn|||healthy|||0|578|131|138
SE|25462389||ti|1|entity|C0580836|Old|tmco|||older|||0|578|139|144
SE|25462389||ti|1|entity|C0439234|year|tmco|||year|||0|875|157|161
SE|25462389||ti|1|entity|C0016441|Follow-Up Studies|resa|||follow-up study|||0|875|162|177

SE|25462389|BACKGROUND|ab|1|text|185|291|BACKGROUND: The relationship between the pathophysiology of dementia and neuroinflammation is well-known.
SE|25462389|BACKGROUND|ab|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|201|213
SE|25462389|BACKGROUND|ab|1|entity|C0031847|physiopathological|ftcn|||pathophysiology|||0|1000|226|241
SE|25462389|BACKGROUND|ab|1|entity|C0497327|Dementia|mobd|||dementia|||0|1000|245|253
SE|25462389|BACKGROUND|ab|1|entity|C0205170|Good|qlco|||well|||0|888|279|283
SE|25462389|BACKGROUND|ab|1|entity|C0205309|Known|qlco|||known|||0|888|284|289

SE|25462389|BACKGROUND|ab|2|text|291|397|The number of reports stating that depression is a risk factor for dementia has recently been increasing.
SE|25462389|BACKGROUND|ab|2|entity|C0237753|Numbers|qnco|||number|||0|1000|295|301
SE|25462389|BACKGROUND|ab|2|entity|C0684224|Report (document)|inpr|||reports|||0|1000|305|312
SE|25462389|BACKGROUND|ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|326|336
SE|25462389|BACKGROUND|ab|2|entity|C0035648|risk factors|qnco|||risk factor|||0|1000|342|353
SE|25462389|BACKGROUND|ab|2|entity|C0497327|Dementia|mobd|||dementia|||0|1000|358|366
SE|25462389|BACKGROUND|ab|2|entity|C0332185|Recent|tmco|||recently|||0|1000|371|379

SE|25462389|BACKGROUND|ab|3|text|397|551|These epidemiological findings suggest the possibility that both depression and dementia have common pathophysiological backgrounds of neuroinflammation.
SE|25462389|BACKGROUND|ab|3|entity|C0014507|Epidemiology|bmod|||epidemiological|||0|853|403|418
SE|25462389|BACKGROUND|ab|3|entity|C0243095|Finding|ftcn|||findings|||0|853|419|427
SE|25462389|BACKGROUND|ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|462|472
SE|25462389|BACKGROUND|ab|3|entity|C0497327|Dementia|mobd|||dementia|||0|1000|477|485
SE|25462389|BACKGROUND|ab|3|entity|C0205214|Common|qnco|||common|||0|587|491|497
SE|25462389|BACKGROUND|ab|3|entity|C0031847|physiopathological|ftcn|||pathophysiological|||0|587|498|516

SE|25462389|METHODS|ab|4|text|551|660|METHODS: The sample consists of 64 non-demented community-dwelling older participants aged 65 years or over.
SE|25462389|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|551|558
SE|25462389|METHODS|ab|4|entity|C0860630|Demented|mobd|||demented|||0|722|590|598
SE|25462389|METHODS|ab|4|entity|C0009462|Community|geoa|||community|||0|722|599|608
SE|25462389|METHODS|ab|4|entity|C0442519|Home environment|mnob|||dwelling|||0|722|609|617
SE|25462389|METHODS|ab|4|entity|C0580836|Old|tmco|||older|||0|722|618|623
SE|25462389|METHODS|ab|4|entity|C0679646|Participant|popg|||participants|||0|722|624|636
SE|25462389|METHODS|ab|4|entity|C0439234|year|tmco|||years|||0|861|645|650
SE|25462389|METHODS|ab|4|entity|C0205136|Over|spco|||over|||0|1000|654|658

SE|25462389|METHODS|ab|5|text|660|742|Participants were assessed at baseline (2004-2006) and 3 years later (2007-2009).
SE|25462389|METHODS|ab|5|entity|C0679646|Participant|popg|||Participants|||0|966|660|672
SE|25462389|METHODS|ab|5|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|690|698
SE|25462389|METHODS|ab|5|entity|C0439234|year|tmco|||years|||0|888|717|722
SE|25462389|METHODS|ab|5|entity|C0205087|Late|tmco|||later|||0|966|723|728

SE|25462389|METHODS|ab|6|text|742|1020|Plasma concentration of markers of inflammation (interleukins (IL)-1beta, IL-2, IL-6, soluble interleukin-2 receptor (sIL-2R), soluble interleukin-6 receptor (sIL-6R), high sensitivity C-reactive protein (hsCRP) and tumor necrosis factor (TNF)-alpha) were measured at baseline.
SE|25462389|METHODS|ab|6|entity|C0683150|plasma drug concentration|qnco|||Plasma concentration|||0|1000|742|762
SE|25462389|METHODS|ab|6|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|777|789
SE|25462389|METHODS|ab|6|entity|C0021753|Interleukin-1 beta|aapp,imft|||interleukins (IL)-1beta|||0|983|791|814
SE|25462389|METHODS|ab|6|entity|C0021756|Interleukin-2|aapp,imft|||IL-2|||0|983|816|820
SE|25462389|METHODS|ab|6|entity|C0021760|Interleukin-6|aapp,imft|||IL-6|||0|983|822|826
SE|25462389|METHODS|ab|6|entity|C0487019|Interleukin 2 receptor, soluble|aapp,imft,rcpt|||soluble interleukin-2 receptor|||0|1000|828|858
SE|25462389|METHODS|ab|6|entity|C0063717|Interleukin 6 Receptor|aapp,imft,rcpt|||interleukin-6 receptor|||0|923|877|899
SE|25462389|METHODS|ab|6|entity|C0257766|SILV protein, human|aapp,bacs|6490|PMEL|sIL|||0|694|901|904
SE|25462389|METHODS|ab|6|entity|C1441604|HIGH SENSITIVITY|lbpr|||high sensitivity|||0|893|910|926
SE|25462389|METHODS|ab|6|entity|C0006560|C-reactive protein|aapp,imft|||C-reactive protein|||0|893|927|945
SE|25462389|METHODS|ab|6|entity|C1448177|TNF protein, human|aapp,bacs|7124|TNF|tumor necrosis factor (TNF)-alpha|||0|1000|958|991
SE|25462389|METHODS|ab|6|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1010|1018

SE|25462389|METHODS|ab|7|text|1020|1266|Depression symptoms were assessed with the Beck Depression Inventory (BDI) and cognitive decline was assessed with the Mini-Mental State Examination (MMSE), Frontal Assessment Battery (FAB) and Clock Drawing Test (CDT) at baseline and follow-up.
SE|25462389|METHODS|ab|7|entity|C0086132|Depressive Symptoms|sosy|||Depression symptoms|||0|964|1020|1039
SE|25462389|METHODS|ab|7|entity|C0451022|Beck depression inventory|diap|||Beck Depression Inventory|||0|1000|1063|1088
SE|25462389|METHODS|ab|7|entity|C0338656|Impaired cognition|fndg|||cognitive decline|||0|1000|1099|1116
SE|25462389|METHODS|ab|7|entity|C0451306|Mini-mental state examination|diap,inpr|||Mini-Mental State Examination|||0|1000|1139|1168
SE|25462389|METHODS|ab|7|entity|C0205123|Coronal|spco|||Frontal|||0|623|1177|1184
SE|25462389|METHODS|ab|7|entity|C0220825|Evaluation|ftcn|||Assessment|||0|623|1185|1195
SE|25462389|METHODS|ab|7|entity|C0013113|drawing|inpr|||Drawing|||0|790|1220|1227
SE|25462389|METHODS|ab|7|entity|C0039593|Testing|resa|||Test|||0|790|1228|1232
SE|25462389|METHODS|ab|7|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1242|1250
SE|25462389|METHODS|ab|7|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1255|1264

SE|25462389|METHODS|ab|8|text|1266|1333|All analyses were adjusted for age, gender and years of education.
SE|25462389|METHODS|ab|8|entity|C0936012|Analysis|resa|||analyses|||0|966|1270|1278
SE|25462389|METHODS|ab|8|entity|C0001779|Age|orga|||age|||0|1000|1297|1300
SE|25462389|METHODS|ab|8|entity|C0079399|Gender|orga|||gender|||0|1000|1302|1308
SE|25462389|METHODS|ab|8|entity|C0439234|year|tmco|||years|||0|1000|1313|1318
SE|25462389|METHODS|ab|8|entity|C0013621|Knowledge acquisition|edac|||education|||0|1000|1322|1331

SE|25462389|RESULTS|ab|9|text|1333|1492|RESULTS: In the cross-sectional analysis, the present study found soluble IL-2 receptor (sIL-2R) to be associated only with the MMSE score at baseline in men.
SE|25462389|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1333|1340
SE|25462389|RESULTS|ab|9|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional analysis|||0|1000|1349|1373
SE|25462389|RESULTS|ab|9|entity|C0150312|Present|qnco|||present|||0|888|1379|1386
SE|25462389|RESULTS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|888|1387|1392
SE|25462389|RESULTS|ab|9|entity|C0487019|Interleukin 2 receptor, soluble|aapp,imft,rcpt|||soluble IL-2 receptor|||0|991|1399|1420
SE|25462389|RESULTS|ab|9|entity|C0487019|Interleukin 2 receptor, soluble|aapp,imft,rcpt|||sIL-2R|||0|1000|1422|1428
SE|25462389|RESULTS|ab|9|entity|C1532985|Mini mental state score|inpr|||MMSE score|||0|933|1461|1471
SE|25462389|RESULTS|ab|9|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1475|1483
SE|25462389|RESULTS|ab|9|entity|C0025266|Male population group|popg|||men|||0|1000|1487|1490
SE|25462389|RESULTS|ab|9|relation|1|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1487|1490|PREP|LOCATION_OF||1484|1486|7|4|C0487019|Interleukin 2 receptor, soluble|aapp,gngm,imft,rcpt|aapp|||soluble IL-2 receptor|||0|991|1399|1420

SE|25462389|RESULTS|ab|10|text|1492|1628|In the longitudinal analysis, none of our inflammatory biomarkers were associated with either depressive symptoms or cognitive decline.
SE|25462389|RESULTS|ab|10|entity|C0205127|Longitudinal|spco|||longitudinal|||0|888|1499|1511
SE|25462389|RESULTS|ab|10|entity|C0936012|Analysis|resa|||analysis|||0|888|1512|1520
SE|25462389|RESULTS|ab|10|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|888|1534|1546
SE|25462389|RESULTS|ab|10|entity|C0005516|Biological Markers|qlco|||biomarkers|||0|888|1547|1557
SE|25462389|RESULTS|ab|10|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|901|1586|1605
SE|25462389|RESULTS|ab|10|entity|C0338656|Impaired cognition|fndg|||cognitive decline|||0|1000|1609|1626

SE|25462389|LIMITATIONS|ab|11|text|1628|1752|LIMITATIONS: The present study consists of small number of participants and body mass index (BMI) scores were not obtained.
SE|25462389|LIMITATIONS|ab|11|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1628|1639
SE|25462389|LIMITATIONS|ab|11|entity|C0150312|Present|qnco|||present|||0|888|1645|1652
SE|25462389|LIMITATIONS|ab|11|entity|C0008972|Clinical Research|resa|||study|||0|888|1653|1658
SE|25462389|LIMITATIONS|ab|11|entity|C0700321|Small|qnco|||small|||0|888|1671|1676
SE|25462389|LIMITATIONS|ab|11|entity|C0237753|Numbers|qnco|||number|||0|888|1677|1683
SE|25462389|LIMITATIONS|ab|11|entity|C0679646|Participant|popg|||participants|||0|966|1687|1699
SE|25462389|LIMITATIONS|ab|11|entity|C0005893|Body mass index procedure|diap|||body mass index|||0|916|1704|1719
SE|25462389|LIMITATIONS|ab|11|entity|C0449820|Score|qnco|||scores|||0|916|1726|1732
SE|25462389|LIMITATIONS|ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|1738|1741

SE|25462389|CONCLUSIONS|ab|12|text|1752|1852|CONCLUSIONS: Our findings suggest that sIL-2R is associated with current cognitive function in men.
SE|25462389|CONCLUSIONS|ab|12|entity|C0243095|Finding|ftcn|||findings|||0|1000|1769|1777
SE|25462389|CONCLUSIONS|ab|12|entity|C0487019|Interleukin 2 receptor, soluble|aapp,imft,rcpt|||sIL-2R|||0|1000|1791|1797
SE|25462389|CONCLUSIONS|ab|12|entity|C0521116|Current|tmco|||current|||0|901|1817|1824
SE|25462389|CONCLUSIONS|ab|12|entity|C0392335|Cognitive functions|menp|||cognitive function|||0|901|1825|1843
SE|25462389|CONCLUSIONS|ab|12|entity|C0025266|Male population group|popg|||men|||0|1000|1847|1850
SE|25462389|CONCLUSIONS|ab|12|relation|1|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1847|1850|PREP|LOCATION_OF||1844|1846|4|2|C0487019|Interleukin 2 receptor, soluble|aapp,gngm,imft,rcpt|aapp|||sIL-2R|||0|1000|1791|1797

SE|25462389|CONCLUSIONS|ab|13|text|1852|1987|None of our inflammatory markers predicted future depressive state or cognitive decline in our community-dwelling healthy older sample.
SE|25462389|CONCLUSIONS|ab|13|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|694|1864|1876
SE|25462389|CONCLUSIONS|ab|13|entity|C0016884|Future|tmco|||future|||0|901|1895|1901
SE|25462389|CONCLUSIONS|ab|13|entity|C0011570|Mental Depression|mobd|||depressive state|||0|901|1902|1918
SE|25462389|CONCLUSIONS|ab|13|entity|C0338656|Impaired cognition|fndg|||cognitive decline|||0|1000|1922|1939
SE|25462389|CONCLUSIONS|ab|13|entity|C0009462|Community|geoa|||community|||0|578|1947|1956
SE|25462389|CONCLUSIONS|ab|13|entity|C0442519|Home environment|mnob|||dwelling|||0|578|1957|1965
SE|25462389|CONCLUSIONS|ab|13|entity|C0018684|Health|idcn|||healthy|||0|578|1966|1973
SE|25462389|CONCLUSIONS|ab|13|entity|C0580836|Old|tmco|||older|||0|578|1974|1979


SE|25462391||ti|1|text|21|148|Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase.
SE|25462391||ti|1|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||Thiobarbituric acid reactive substances|||0|1000|21|60
SE|25462391||ti|1|entity|C1442792|State|ftcn|||state|||0|888|74|79
SE|25462391||ti|1|entity|C0005516|Biological Markers|qlco|||biomarker|||0|888|80|89
SE|25462391||ti|1|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|1000|93|109
SE|25462391||ti|1|entity|C0443156|Bipolar|spco|||bipolar|||0|888|113|120
SE|25462391||ti|1|entity|C0030705|Patients|podg|||patients|||0|888|121|129
SE|25462391||ti|1|entity|C0338831|Manic|mobd|||manic|||0|888|135|140
SE|25462391||ti|1|entity|C0205390|Phase|tmco|||phase|||0|888|141|146
SE|25462391||ti|1|relation|1|1|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|orch|||Thiobarbituric acid reactive substances|||0|1000|21|60|NOM|PREDISPOSES||80|89|3|1|C0242606|Oxidative Stress|comd|comd|||oxidative stress|||0|1000|93|109
SE|25462391||ti|1|relation|3|1|C0242606|Oxidative Stress|comd|comd|||oxidative stress|||0|1000|93|109|PREP|PROCESS_OF||110|112|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|121|129

SE|25462391|OBJECTIVES|ab|1|text|154|242|OBJECTIVES: Oxidative stress may contribute to the pathophysiology of bipolar disorder.
SE|25462391|OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|154|164
SE|25462391|OBJECTIVES|ab|1|entity|C0242606|Oxidative Stress|comd|||Oxidative stress|||0|1000|166|182
SE|25462391|OBJECTIVES|ab|1|entity|C0031847|physiopathological|ftcn|||pathophysiology|||0|1000|205|220
SE|25462391|OBJECTIVES|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|224|240

SE|25462391|OBJECTIVES|ab|2|text|242|620|The aim of this study was to investigate the serum levels or activities of oxidative stress markers in bipolar patients in a manic phase, and evaluate the changes in superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCC) and 8-hydroxy 2'-deoxyguanosine after treatment (8-OHdG).
SE|25462391|OBJECTIVES|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|258|263
SE|25462391|OBJECTIVES|ab|2|entity|C0229671|Serum|bdsu|||serum|||0|888|287|292
SE|25462391|OBJECTIVES|ab|2|entity|C0441889|Levels|inpr|||levels|||0|888|293|299
SE|25462391|OBJECTIVES|ab|2|entity|C0441655|Activities|acty|||activities|||0|1000|303|313
SE|25462391|OBJECTIVES|ab|2|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|734|317|333
SE|25462391|OBJECTIVES|ab|2|entity|C0443156|Bipolar|spco|||bipolar|||0|888|345|352
SE|25462391|OBJECTIVES|ab|2|entity|C0030705|Patients|podg|||patients|||0|888|353|361
SE|25462391|OBJECTIVES|ab|2|entity|C0338831|Manic|mobd|||manic|||0|888|367|372
SE|25462391|OBJECTIVES|ab|2|entity|C0205390|Phase|tmco|||phase|||0|888|373|378
SE|25462391|OBJECTIVES|ab|2|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||superoxide dismutase|||0|1000|408|428
SE|25462391|OBJECTIVES|ab|2|entity|C0007367|CATALASE|aapp,enzy|||catalase|||0|1000|436|444
SE|25462391|OBJECTIVES|ab|2|entity|C0017822|GLUTATHIONE PEROXIDASE|aapp,enzy|||glutathione peroxidase|||0|1000|452|474
SE|25462391|OBJECTIVES|ab|2|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||thiobarbituric acid reactive substances|||0|1000|482|521
SE|25462391|OBJECTIVES|ab|2|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||TBARS|||0|1000|523|528
SE|25462391|OBJECTIVES|ab|2|entity|C0033684|Proteins|aapp,bacs|||protein|||0|660|531|538
SE|25462391|OBJECTIVES|ab|2|entity|C0050078|8-hydroxy-2'-deoxyguanosine|nnon|||8-hydroxy 2'-deoxyguanosine|||0|1000|566|593
SE|25462391|OBJECTIVES|ab|2|relation|12|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|353|361|PREP|LOCATION_OF||342|344|5|3|C0229671|Serum|bdsu|bdsu|||serum|||0|888|287|292

SE|25462391|METHODS|ab|3|text|620|719|METHODS: We consecutively enrolled 23 bipolar inpatients in a manic phase and 40 healthy subjects.
SE|25462391|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|620|627
SE|25462391|METHODS|ab|3|entity|C0443156|Bipolar|spco|||bipolar|||0|790|658|665
SE|25462391|METHODS|ab|3|entity|C0021562|inpatient|podg|||inpatients|||0|790|666|676
SE|25462391|METHODS|ab|3|entity|C0338831|Manic|mobd|||manic|||0|888|682|687
SE|25462391|METHODS|ab|3|entity|C0205390|Phase|tmco|||phase|||0|888|688|693
SE|25462391|METHODS|ab|3|entity|C0018684|Health|idcn|||healthy|||0|816|701|708
SE|25462391|METHODS|ab|3|entity|C1550501|subject|idcn|||subjects|||0|816|709|717

SE|25462391|METHODS|ab|4|text|719|781|Serum oxidative stress markers were measured with assay kits.
SE|25462391|METHODS|ab|4|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|888|725|741
SE|25462391|METHODS|ab|4|entity|C0162491|Serum Markers|qlco|||Serum oxidative stress markers|||0|888|719|749
SE|25462391|METHODS|ab|4|entity|C1510438|Assay|lbpr|||assay|||0|694|769|774

SE|25462391|METHODS|ab|5|text|781|915|All patients were evaluated by examining the correlation between oxidative stress markers and Young Mania Rating Scale (YMRS) scores.
SE|25462391|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|1000|785|793
SE|25462391|METHODS|ab|5|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|734|846|862
SE|25462391|METHODS|ab|5|entity|C0332239|Young|tmco|||Young|||0|840|875|880
SE|25462391|METHODS|ab|5|entity|C0338831|Manic|mobd|||Mania|||0|840|881|886
SE|25462391|METHODS|ab|5|entity|C0681889|rating scale|inpr,qnco|||Rating Scale|||0|840|887|899
SE|25462391|METHODS|ab|5|entity|C0449820|Score|qnco|||scores|||0|840|907|913

SE|25462391|RESULTS|ab|6|text|915|1137|RESULTS: The serum TBARS levels in bipolar patients in a manic phase were significantly higher than those of healthy subjects (p=0.006), and serum GPx activity was significant lower than that of healthy subjects (p<0.05).
SE|25462391|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|915|922
SE|25462391|RESULTS|ab|6|entity|C0229671|Serum|bdsu|||serum|||0|888|928|933
SE|25462391|RESULTS|ab|6|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||TBARS|||0|888|934|939
SE|25462391|RESULTS|ab|6|entity|C0441889|Levels|inpr|||levels|||0|888|940|946
SE|25462391|RESULTS|ab|6|entity|C0443156|Bipolar|spco|||bipolar|||0|888|950|957
SE|25462391|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|888|958|966
SE|25462391|RESULTS|ab|6|entity|C0338831|Manic|mobd|||manic|||0|888|972|977
SE|25462391|RESULTS|ab|6|entity|C0205390|Phase|tmco|||phase|||0|888|978|983
SE|25462391|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|827|1003|1009
SE|25462391|RESULTS|ab|6|entity|C0018684|Health|idcn|||healthy|||0|836|1024|1031
SE|25462391|RESULTS|ab|6|entity|C1550501|subject|idcn|||subjects|||0|836|1032|1040
SE|25462391|RESULTS|ab|6|entity|C0229671|Serum|bdsu|||serum|||0|916|1056|1061
SE|25462391|RESULTS|ab|6|entity|C1151528|glutathione peroxidase activity|moft|||GPx activity|||0|916|1062|1074
SE|25462391|RESULTS|ab|6|entity|C0750502|Significant|idcn|||significant|||0|888|1079|1090
SE|25462391|RESULTS|ab|6|entity|C0441994|Lower|ftcn|||lower|||0|888|1091|1096
SE|25462391|RESULTS|ab|6|entity|C0018684|Health|idcn|||healthy|||0|836|1110|1117
SE|25462391|RESULTS|ab|6|entity|C1550501|subject|idcn|||subjects|||0|836|1118|1126
SE|25462391|RESULTS|ab|6|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|928|933|MOD/HEAD|LOCATION_OF||928|939|0|0|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|orch|||TBARS|||0|888|934|939

SE|25462391|RESULTS|ab|7|text|1137|1291|The YMRS scores had a significantly positive association with CAT activity and PCC levels (p<0.05) and a negative association with GPx activity (p<0.05).
SE|25462391|RESULTS|ab|7|entity|C0332239|Young|tmco|||YMRS|||0|840|1141|1145
SE|25462391|RESULTS|ab|7|entity|C0338831|Manic|mobd|||YMRS|||0|840|1141|1145
SE|25462391|RESULTS|ab|7|entity|C0681889|rating scale|inpr,qnco|||YMRS|||0|840|1141|1145
SE|25462391|RESULTS|ab|7|entity|C0449820|Score|qnco|||scores|||0|840|1146|1152
SE|25462391|RESULTS|ab|7|entity|C1446409|Positive|qlco|||positive|||0|660|1173|1181
SE|25462391|RESULTS|ab|7|entity|C1151515|catalase activity|moft|||CAT activity|||0|1000|1199|1211
SE|25462391|RESULTS|ab|7|entity|C0033684|Proteins|aapp,bacs|||PCC|||0|791|1216|1219
SE|25462391|RESULTS|ab|7|entity|C0441889|Levels|inpr|||levels|||0|791|1220|1226
SE|25462391|RESULTS|ab|7|entity|C0205160|Negative|qlco|||negative|||0|694|1242|1250
SE|25462391|RESULTS|ab|7|entity|C1151528|glutathione peroxidase activity|moft|||GPx activity|||0|1000|1268|1280

SE|25462391|RESULTS|ab|8|text|1291|1407|Twenty bipolar patients were followed up, and their oxidative stress markers were measured at the end of treatment.
SE|25462391|RESULTS|ab|8|entity|C0443156|Bipolar|spco|||bipolar|||0|790|1298|1305
SE|25462391|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|790|1306|1314
SE|25462391|RESULTS|ab|8|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|734|1343|1359
SE|25462391|RESULTS|ab|8|entity|C0444930|End|spco|||end|||0|1000|1389|1392

SE|25462391|RESULTS|ab|9|text|1407|1522|We found significantly decreased changes in TBARS levels only in bipolar manic patients after treatment (p=0.019).
SE|25462391|RESULTS|ab|9|entity|C0205216|Decreased|qnco|||decreased|||0|773|1430|1439
SE|25462391|RESULTS|ab|9|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||TBARS|||0|876|1451|1456
SE|25462391|RESULTS|ab|9|entity|C0441889|Levels|inpr|||levels|||0|876|1457|1463
SE|25462391|RESULTS|ab|9|entity|C0443156|Bipolar|spco|||bipolar|||0|851|1472|1479
SE|25462391|RESULTS|ab|9|entity|C0338831|Manic|mobd|||manic|||0|851|1480|1485
SE|25462391|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|851|1486|1494
SE|25462391|RESULTS|ab|9|relation|0|0|C0338831|Manic|mobd|mobd|||manic|||0|851|1480|1485|MOD/HEAD|PROCESS_OF||1480|1494|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|851|1486|1494

SE|25462391|LIMITATION|ab|10|text|1522|1563|LIMITATION: Our sample size was limited.
SE|25462391|LIMITATION|ab|10|entity|C0449295|Limitation|ftcn|||LIMITATION|||0|1000|1522|1532
SE|25462391|LIMITATION|ab|10|entity|C0242618|Sample Size|qnco|||sample size|||0|1000|1538|1549

SE|25462391|CONCLUSION|ab|11|text|1563|1724|CONCLUSION: Our results suggest that serum TBARS levels might be a state biomarker of oxidative stress in bipolar patients in a manic phase and after treatment.
SE|25462391|CONCLUSION|ab|11|entity|C1274040|result|ftcn|||results|||0|966|1579|1586
SE|25462391|CONCLUSION|ab|11|entity|C0229671|Serum|bdsu|||serum|||0|888|1600|1605
SE|25462391|CONCLUSION|ab|11|entity|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|||TBARS|||0|888|1606|1611
SE|25462391|CONCLUSION|ab|11|entity|C0441889|Levels|inpr|||levels|||0|888|1612|1618
SE|25462391|CONCLUSION|ab|11|entity|C1442792|State|ftcn|||state|||0|888|1630|1635
SE|25462391|CONCLUSION|ab|11|entity|C0005516|Biological Markers|qlco|||biomarker|||0|888|1636|1645
SE|25462391|CONCLUSION|ab|11|entity|C0242606|Oxidative Stress|comd|||oxidative stress|||0|1000|1649|1665
SE|25462391|CONCLUSION|ab|11|entity|C0443156|Bipolar|spco|||bipolar|||0|888|1669|1676
SE|25462391|CONCLUSION|ab|11|entity|C0030705|Patients|podg|||patients|||0|888|1677|1685
SE|25462391|CONCLUSION|ab|11|entity|C0338831|Manic|mobd|||manic|||0|888|1691|1696
SE|25462391|CONCLUSION|ab|11|entity|C0205390|Phase|tmco|||phase|||0|888|1697|1702
SE|25462391|CONCLUSION|ab|11|relation|0|0|C0229671|Serum|bdsu|bdsu|||serum|||0|888|1600|1605|MOD/HEAD|LOCATION_OF||1600|1611|0|0|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|orch|||TBARS|||0|888|1606|1611
SE|25462391|CONCLUSION|ab|11|relation|3|1|C0162781|Thiobarbituric Acid Reactive Substances|irda,orch|orch|||TBARS|||0|888|1606|1611|NOM|PREDISPOSES||1636|1645|4|1|C0242606|Oxidative Stress|comd|comd|||oxidative stress|||0|1000|1649|1665
SE|25462391|CONCLUSION|ab|11|relation|5|1|C0242606|Oxidative Stress|comd|comd|||oxidative stress|||0|1000|1649|1665|PREP|PROCESS_OF||1666|1668|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|1677|1685

SE|25462391|CONCLUSION|ab|12|text|1724|1797|In addition, GPx deficit might be a trait biomarker of severity of mania.
SE|25462391|CONCLUSION|ab|12|entity|C0017822|GLUTATHIONE PEROXIDASE|aapp,enzy|||GPx|||0|901|1737|1740
SE|25462391|CONCLUSION|ab|12|entity|C0011155|Deficiency|ftcn|||deficit|||0|901|1741|1748
SE|25462391|CONCLUSION|ab|12|entity|C0599883|trait|orga|||trait|||0|888|1760|1765
SE|25462391|CONCLUSION|ab|12|entity|C0005516|Biological Markers|qlco|||biomarker|||0|888|1766|1775
SE|25462391|CONCLUSION|ab|12|entity|C0439793|Severities|qlco|||severity|||0|1000|1779|1787
SE|25462391|CONCLUSION|ab|12|entity|C0338831|Manic|mobd|||mania|||0|1000|1791|1796


SE|25462390||ti|1|text|21|117|Cognitive and family correlates of current suicidal ideation in children with bipolar disorder.
SE|25462390||ti|1|entity|C1516691|Cognitive|ftcn|||Cognitive|||0|1000|21|30
SE|25462390||ti|1|entity|C0015576|Family|famg|||family|||0|1000|35|41
SE|25462390||ti|1|entity|C0521116|Current|tmco|||current|||0|901|56|63
SE|25462390||ti|1|entity|C0424000|Feeling suicidal|fndg|||suicidal ideation|||0|901|64|81
SE|25462390||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|85|93
SE|25462390||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|99|115
SE|25462390||ti|1|relation|1|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|99|115|PREP|PROCESS_OF||94|98|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|85|93

SE|25462390|BACKGROUND|ab|1|text|123|244|BACKGROUND: Suicidality among youth with bipolar disorder is an extreme, but largely unaddressed, public health problem.
SE|25462390|BACKGROUND|ab|1|entity|C0438696|Suicidal|fndg|||Suicidality|||0|928|135|146
SE|25462390|BACKGROUND|ab|1|entity|C0087178|Youth|aggp|||youth|||0|1000|153|158
SE|25462390|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|164|180
SE|25462390|BACKGROUND|ab|1|entity|C0205403|Extreme|qlco|||extreme|||0|1000|187|194
SE|25462390|BACKGROUND|ab|1|entity|C0018684|Health|idcn|||health|||0|728|228|234
SE|25462390|BACKGROUND|ab|1|relation|2|1|C0438696|Suicidal|fndg|fndg|||Suicidality|||0|928|135|146|PREP|PROCESS_OF||147|152|4|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|153|158
SE|25462390|BACKGROUND|ab|1|relation|3|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|164|180|PREP|PROCESS_OF||159|163|3|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|153|158

SE|25462390|BACKGROUND|ab|2|text|244|434|The current study examined the psychosocial characteristics differentiating youth with varying severities of suicidal ideation that may dictate targets for suicide prevention interventions.
SE|25462390|BACKGROUND|ab|2|entity|C0521116|Current|tmco|||current|||0|888|248|255
SE|25462390|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|256|261
SE|25462390|BACKGROUND|ab|2|entity|C0542298|Psychosocial|ftcn|||psychosocial|||0|888|275|287
SE|25462390|BACKGROUND|ab|2|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|288|303
SE|25462390|BACKGROUND|ab|2|entity|C0087178|Youth|aggp|||youth|||0|1000|320|325
SE|25462390|BACKGROUND|ab|2|entity|C1548673|Varies|inpr|||varying|||0|872|331|338
SE|25462390|BACKGROUND|ab|2|entity|C0439793|Severities|qlco|||severities|||0|872|339|349
SE|25462390|BACKGROUND|ab|2|entity|C0424000|Feeling suicidal|fndg|||suicidal ideation|||0|1000|353|370
SE|25462390|BACKGROUND|ab|2|entity|C0204732|Suicide prevention|topp|||suicide prevention|||0|901|400|418
SE|25462390|BACKGROUND|ab|2|entity|C1273869|Intervention regimes|hlca|||interventions|||0|901|419|432

SE|25462390|METHODS|ab|3|text|434|563|METHODS: Participants included 72 youth aged 7-13 (M=9.19, SD=1.61) with DSM-IV-TR bipolar I, II, or NOS and a parent/caregiver.
SE|25462390|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|434|441
SE|25462390|METHODS|ab|3|entity|C0679646|Participant|popg|||Participants|||0|966|443|455
SE|25462390|METHODS|ab|3|entity|C0087178|Youth|aggp|||youth|||0|861|468|473
SE|25462390|METHODS|ab|3|entity|C0220952|DSM-IV|inpr|||DSM-IV-TR|||0|734|507|516
SE|25462390|METHODS|ab|3|entity|C0443156|Bipolar|spco|||bipolar|||0|1000|517|524
SE|25462390|METHODS|ab|3|entity|C0669372|NOS2A protein, human|aapp,enzy|4843|NOS2|NOS|||0|1000|535|538
SE|25462390|METHODS|ab|3|entity|C0030551|parent|famg|||parent|||0|888|545|551
SE|25462390|METHODS|ab|3|entity|C0085537|Caregiver|prog|||caregiver|||0|888|552|561

SE|25462390|METHODS|ab|4|text|563|859|Current suicidal ideation and correlates were assessed at intake, including: demographics and clinical factors (diagnosis, symptom severity, psychiatric comorbidity); child factors (cognitive risk and quality of life); and family factors (parenting stress, family cohesion, and family rigidity).
SE|25462390|METHODS|ab|4|entity|C0521116|Current|tmco|||Current|||0|901|563|570
SE|25462390|METHODS|ab|4|entity|C0424000|Feeling suicidal|fndg|||suicidal ideation|||0|901|571|588
SE|25462390|METHODS|ab|4|entity|C1512806|Intake|ftcn|||intake|||0|1000|621|627
SE|25462390|METHODS|ab|4|entity|C0011298|Demography|ocdi|||demographics|||0|1000|640|652
SE|25462390|METHODS|ab|4|entity|C0205210|Clinical|qlco|||clinical|||0|872|657|665
SE|25462390|METHODS|ab|4|entity|C1521761|Factor|ftcn|||factors|||0|872|666|673
SE|25462390|METHODS|ab|4|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|675|684
SE|25462390|METHODS|ab|4|entity|C1457887|Symptoms|sosy|||symptom|||0|888|686|693
SE|25462390|METHODS|ab|4|entity|C0439793|Severities|qlco|||severity|||0|888|694|702
SE|25462390|METHODS|ab|4|entity|C0205487|Psychiatric|ftcn|||psychiatric|||0|888|704|715
SE|25462390|METHODS|ab|4|entity|C0009488|Comorbidity|idcn|||comorbidity|||0|888|716|727
SE|25462390|METHODS|ab|4|entity|C0008059|Child|aggp,inpr|||child|||0|872|730|735
SE|25462390|METHODS|ab|4|entity|C1521761|Factor|ftcn|||factors|||0|872|736|743
SE|25462390|METHODS|ab|4|entity|C1516691|Cognitive|ftcn|||cognitive|||0|888|745|754
SE|25462390|METHODS|ab|4|entity|C0035647|Risk|qlco|||risk|||0|888|755|759
SE|25462390|METHODS|ab|4|entity|C0332306|Quality|qlco|||quality|||0|1000|764|771
SE|25462390|METHODS|ab|4|entity|C0376558|Life|idcn|||life|||0|1000|775|779
SE|25462390|METHODS|ab|4|entity|C0015576|Family|famg|||family|||0|872|786|792
SE|25462390|METHODS|ab|4|entity|C1521761|Factor|ftcn|||factors|||0|872|793|800
SE|25462390|METHODS|ab|4|entity|C0038435|Stress|fndg|||stress|||0|861|812|818
SE|25462390|METHODS|ab|4|entity|C0680064|family cohesion|socb|||family cohesion|||0|1000|820|835
SE|25462390|METHODS|ab|4|entity|C0015576|Family|famg|||family|||0|694|841|847

SE|25462390|RESULTS|ab|5|text|859|979|RESULTS: Current ideation was prevalent in this young sample: 41% endorsed any ideation, and 31% endorsed active forms.
SE|25462390|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|859|866
SE|25462390|RESULTS|ab|5|entity|C0521116|Current|tmco|||Current|||0|888|868|875
SE|25462390|RESULTS|ab|5|entity|C0392348|Ideation|menp|||ideation|||0|888|876|884
SE|25462390|RESULTS|ab|5|entity|C0033105|Statistical Prevalence|qnco|||prevalent|||0|928|889|898
SE|25462390|RESULTS|ab|5|entity|C0332239|Young|tmco|||young|||0|694|907|912
SE|25462390|RESULTS|ab|5|entity|C0392348|Ideation|menp|||ideation|||0|1000|938|946
SE|25462390|RESULTS|ab|5|entity|C0205177|Active|ftcn|||active|||0|750|965|971

SE|25462390|RESULTS|ab|6|text|979|1120|Depression symptoms, quality of life, hopelessness, self-esteem, and family rigidity differentiated youth with increasing ideation severity.
SE|25462390|RESULTS|ab|6|entity|C0086132|Depressive Symptoms|sosy|||Depression symptoms|||0|964|979|998
SE|25462390|RESULTS|ab|6|entity|C0332306|Quality|qlco|||quality|||0|1000|1000|1007
SE|25462390|RESULTS|ab|6|entity|C0376558|Life|idcn|||life|||0|1000|1011|1015
SE|25462390|RESULTS|ab|6|entity|C0150041|Feeling hopeless|sosy|||hopelessness|||0|1000|1017|1029
SE|25462390|RESULTS|ab|6|entity|C0036597|Self Esteem|inbe,menp|||self-esteem|||0|1000|1031|1042
SE|25462390|RESULTS|ab|6|entity|C0015576|Family|famg|||family|||0|694|1048|1054
SE|25462390|RESULTS|ab|6|entity|C0087178|Youth|aggp|||youth|||0|1000|1079|1084
SE|25462390|RESULTS|ab|6|entity|C0442808|Increasing|ftcn|||increasing|||0|851|1090|1100
SE|25462390|RESULTS|ab|6|entity|C0392348|Ideation|menp|||ideation|||0|851|1101|1109
SE|25462390|RESULTS|ab|6|entity|C0439793|Severities|qlco|||severity|||0|851|1110|1118

SE|25462390|RESULTS|ab|7|text|1120|1260|Separate logistic regressions examined all significant child- and family-level factors, controlling for demographic and clinical variables.
SE|25462390|RESULTS|ab|7|entity|C0206031|Logistic Regression|resa|||logistic regressions|||0|1000|1129|1149
SE|25462390|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significant|||0|888|1163|1174
SE|25462390|RESULTS|ab|7|entity|C0008059|Child|aggp,inpr|||child|||0|888|1175|1180
SE|25462390|RESULTS|ab|7|entity|C0015576|Family|famg|||family|||0|785|1186|1192
SE|25462390|RESULTS|ab|7|entity|C1521761|Factor|ftcn|||factors|||0|785|1199|1206
SE|25462390|RESULTS|ab|7|entity|C0011298|Demography|ocdi|||demographic|||0|928|1224|1235
SE|25462390|RESULTS|ab|7|entity|C0205210|Clinical|qlco|||clinical|||0|872|1240|1248
SE|25462390|RESULTS|ab|7|entity|C0439828|Variable|qlco|||variables|||0|872|1249|1258

SE|25462390|RESULTS|ab|8|text|1260|1367|Greater family rigidity and lower self-esteem remained significant predictors of current planful ideation.
SE|25462390|RESULTS|ab|8|entity|C0443228|Largest|qnco|||Greater|||0|623|1260|1267
SE|25462390|RESULTS|ab|8|entity|C0015576|Family|famg|||family|||0|623|1268|1274
SE|25462390|RESULTS|ab|8|entity|C0036597|Self Esteem|inbe,menp|||self-esteem|||0|1000|1294|1305
SE|25462390|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|694|1315|1326
SE|25462390|RESULTS|ab|8|entity|C0521116|Current|tmco|||current|||0|802|1341|1348
SE|25462390|RESULTS|ab|8|entity|C0392348|Ideation|menp|||ideation|||0|802|1357|1365

SE|25462390|RESULTS|ab|9|text|1367|1494|Diagnosis, index episode, comorbidity, and mania severity did not differentiate non-ideators from those with current ideation.
SE|25462390|RESULTS|ab|9|entity|C0011900|Diagnosis|hlca|||Diagnosis|||0|1000|1367|1376
SE|25462390|RESULTS|ab|9|entity|C0918012|Index|inpr|||index|||0|694|1378|1383
SE|25462390|RESULTS|ab|9|entity|C0009488|Comorbidity|idcn|||comorbidity|||0|1000|1393|1404
SE|25462390|RESULTS|ab|9|entity|C0338831|Manic|mobd|||mania|||0|888|1410|1415
SE|25462390|RESULTS|ab|9|entity|C0439793|Severities|qlco|||severity|||0|888|1416|1424
SE|25462390|RESULTS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1429|1432
SE|25462390|RESULTS|ab|9|entity|C0521116|Current|tmco|||current|||0|790|1476|1483
SE|25462390|RESULTS|ab|9|entity|C0392348|Ideation|menp|||ideation|||0|790|1484|1492

SE|25462390|LIMITATIONS|ab|10|text|1494|1683|LIMITATIONS: Limitations include the small sample to examine low base-rate severe ideation, cross-sectional analyses and generalizability of findings beyond the outpatient clinical sample.
SE|25462390|LIMITATIONS|ab|10|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1494|1505
SE|25462390|LIMITATIONS|ab|10|entity|C0449295|Limitation|ftcn|||Limitations|||0|966|1507|1518
SE|25462390|LIMITATIONS|ab|10|entity|C0700321|Small|qnco|||small|||0|694|1531|1536
SE|25462390|LIMITATIONS|ab|10|entity|C0205251|low|qlco|||low|||0|822|1555|1558
SE|25462390|LIMITATIONS|ab|10|entity|C1521828|Rate|qnco|||rate|||0|822|1564|1568
SE|25462390|LIMITATIONS|ab|10|entity|C0205082|Severe|qlco|||severe|||0|822|1569|1575
SE|25462390|LIMITATIONS|ab|10|entity|C0392348|Ideation|menp|||ideation|||0|822|1576|1584
SE|25462390|LIMITATIONS|ab|10|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional analyses|||0|1000|1586|1610
SE|25462390|LIMITATIONS|ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1635|1643
SE|25462390|LIMITATIONS|ab|10|entity|C0002424|Ambulatory Care Facilities|hcro,mnob|||outpatient clinical|||0|698|1655|1674

SE|25462390|CONCLUSIONS|ab|11|text|1683|1874|CONCLUSIONS: Findings underscore the importance of assessing and addressing suicidality in preadolescent youth with bipolar disorder, before youth progress to more severe suicidal behaviors.
SE|25462390|CONCLUSIONS|ab|11|entity|C0243095|Finding|ftcn|||Findings|||0|1000|1696|1704
SE|25462390|CONCLUSIONS|ab|11|entity|C0220825|Evaluation|ftcn|||assessing|||0|966|1734|1743
SE|25462390|CONCLUSIONS|ab|11|entity|C1442065|Address|spco|||addressing|||0|836|1748|1758
SE|25462390|CONCLUSIONS|ab|11|entity|C0438696|Suicidal|fndg|||suicidality|||0|836|1759|1770
SE|25462390|CONCLUSIONS|ab|11|entity|C0683972|preadolescent|aggp|||preadolescent|||0|888|1774|1787
SE|25462390|CONCLUSIONS|ab|11|entity|C0087178|Youth|aggp|||youth|||0|888|1788|1793
SE|25462390|CONCLUSIONS|ab|11|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|1799|1815
SE|25462390|CONCLUSIONS|ab|11|entity|C0087178|Youth|aggp|||youth|||0|1000|1824|1829
SE|25462390|CONCLUSIONS|ab|11|entity|C0205082|Severe|qlco|||severe|||0|774|1847|1853
SE|25462390|CONCLUSIONS|ab|11|entity|C0563664|At risk for suicide|mobd|||suicidal behaviors|||0|774|1854|1872
SE|25462390|CONCLUSIONS|ab|11|relation|3|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|1799|1815|PREP|PROCESS_OF||1794|1798|6|1|C0087178|Youth|aggp,humn|humn|||youth|||0|888|1788|1793
SE|25462390|CONCLUSIONS|ab|11|relation|5|1|C0438696|Suicidal|fndg|fndg|||suicidality|||0|836|1759|1770|PREP|PROCESS_OF||1771|1773|4|1|C0087178|Youth|aggp,humn|humn|||youth|||0|888|1788|1793

SE|25462390|CONCLUSIONS|ab|12|text|1874|2013|Results also highlight child self-esteem and family rigidity as key treatment targets to reduce suicide risk in pediatric bipolar disorder.
SE|25462390|CONCLUSIONS|ab|12|entity|C0008059|Child|aggp,inpr|||child|||0|901|1897|1902
SE|25462390|CONCLUSIONS|ab|12|entity|C0036597|Self Esteem|inbe,menp|||self-esteem|||0|901|1903|1914
SE|25462390|CONCLUSIONS|ab|12|entity|C0015576|Family|famg|||family|||0|694|1919|1925
SE|25462390|CONCLUSIONS|ab|12|entity|C1554080|Key|idcn|||key|||0|888|1938|1941
SE|25462390|CONCLUSIONS|ab|12|entity|C0038661|Suicide|inpo|||suicide|||0|888|1970|1977
SE|25462390|CONCLUSIONS|ab|12|entity|C0035647|Risk|qlco|||risk|||0|888|1978|1982
SE|25462390|CONCLUSIONS|ab|12|entity|C0443156|Bipolar|spco|||bipolar|||0|901|1996|2003
SE|25462390|CONCLUSIONS|ab|12|entity|C0679381|pediatric disorder|dsyn|||pediatric bipolar disorder|||0|901|1986|2012
SE|25462390|CONCLUSIONS|ab|12|relation|0|0|C0036597|Self Esteem|inbe,menp|inbe|||self-esteem|||0|901|1903|1914|MOD/HEAD|PROCESS_OF||1897|1914|0|0|C0008059|Child|aggp,humn,inpr|humn|||child|||0|901|1897|1902
SE|25462390|CONCLUSIONS|ab|12|relation|4|1|C0038661|Suicide|inpo|inpo|||suicide|||0|888|1970|1977|PREP|COEXISTS_WITH||1983|1985|1|1|C0679381|pediatric disorder|dsyn|dsyn|||pediatric bipolar disorder|||0|901|1986|2012


SE|25462392||ti|1|text|21|62|Affective temperaments in tango dancers.
SE|25462392||ti|1|entity|C0039474|Temperament|menp|||temperaments|||0|861|31|43
SE|25462392||ti|1|entity|C0335081|Dancer|prog|||dancers|||0|827|53|60
SE|25462392||ti|1|relation|1|1|C0039474|Temperament|menp|menp|||temperaments|||0|861|31|43|PREP|PROCESS_OF||44|46|1|1|C0335081|Dancer|prog,humn|humn|||dancers|||0|827|53|60

SE|25462392|BACKGROUND|ab|1|text|68|182|BACKGROUND: Links between affective temperaments and folk culture have been infrequently explored systematically.
SE|25462392|BACKGROUND|ab|1|entity|C0039474|Temperament|menp|||temperaments|||0|861|104|116
SE|25462392|BACKGROUND|ab|1|entity|C0220814|Cultural|ftcn|||culture|||0|861|126|133
SE|25462392|BACKGROUND|ab|1|entity|C0521114|Infrequent|tmco|||infrequently|||0|1000|144|156

SE|25462392|BACKGROUND|ab|2|text|182|282|Creativity and personality and temperament studies, conversely, have reported several associations.
SE|25462392|BACKGROUND|ab|2|entity|C0010297|Creativeness|menp|||Creativity|||0|1000|182|192
SE|25462392|BACKGROUND|ab|2|entity|C0031208|Personality|menp|||personality|||0|1000|197|208
SE|25462392|BACKGROUND|ab|2|entity|C0039474|Temperament|menp|||temperament|||0|872|213|224
SE|25462392|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|872|225|232
SE|25462392|BACKGROUND|ab|2|entity|C0443302|Several|qnco|||several|||0|888|260|267

SE|25462392|BACKGROUND|ab|3|text|282|359|Tango is one of the most typical Argentinean folk dance-musical repertoires.
SE|25462392|BACKGROUND|ab|3|entity|C0205447|One|qnco|||one|||0|1000|291|294
SE|25462392|BACKGROUND|ab|3|entity|C0205393|Most|qnco|||most|||0|553|302|306
SE|25462392|BACKGROUND|ab|3|entity|C0238689|Argentinean|popg|||Argentinean|||0|553|315|326
SE|25462392|BACKGROUND|ab|3|entity|C0010963|Dancing|dora|||dance|||0|553|332|337
SE|25462392|BACKGROUND|ab|3|entity|C0681246|musical|inpr|||musical|||0|553|338|345

SE|25462392|BACKGROUND|ab|4|text|359|502|The main purpose of this study is to compare affective temperaments between Argentinean professional tango dancers and the general population.
SE|25462392|BACKGROUND|ab|4|entity|C0205225|Primary|qlco|||main|||0|888|363|367
SE|25462392|BACKGROUND|ab|4|entity|C1285529|Purpose|ftcn|||purpose|||0|888|368|375
SE|25462392|BACKGROUND|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|384|389
SE|25462392|BACKGROUND|ab|4|entity|C0039474|Temperament|menp|||temperaments|||0|861|414|426
SE|25462392|BACKGROUND|ab|4|entity|C0238689|Argentinean|popg|||Argentinean|||0|775|435|446
SE|25462392|BACKGROUND|ab|4|entity|C0335081|Dancer|prog|||dancers|||0|775|466|473
SE|25462392|BACKGROUND|ab|4|entity|C0683971|General Population|popg|||general population|||0|1000|482|500

SE|25462392|METHODS|ab|5|text|502|664|METHODS: TEMPS-A was administered to a sample of 63 professional tango dancers and 63 comparison subjects from the general population who did not practice tango.
SE|25462392|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|502|509
SE|25462392|METHODS|ab|5|entity|C0039476|Temperature|qnco|||TEMPS|||0|966|511|516
SE|25462392|METHODS|ab|5|entity|C0335081|Dancer|prog|||dancers|||0|779|573|580
SE|25462392|METHODS|ab|5|entity|C0683971|General Population|popg|||general population|||0|1000|617|635
SE|25462392|METHODS|ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|644|647

SE|25462392|METHODS|ab|6|text|664|757|Subscale median scores and total median scores with non-parametric statistics were analyzed.
SE|25462392|METHODS|ab|6|entity|C0459443|Subscale score|qnco|||Subscale median scores|||0|896|664|686
SE|25462392|METHODS|ab|6|entity|C0439175|% of total|qnco|||total|||0|802|691|696
SE|25462392|METHODS|ab|6|entity|C0449820|Score|qnco|||scores|||0|802|704|710
SE|25462392|METHODS|ab|6|entity|C0242932|Statistics, Nonparametric|qnco|||non-parametric statistics|||0|1000|716|741

SE|25462392|RESULTS|ab|7|text|757|950|RESULTS: Median scores on hyperthymic subscale (p <= 0.001), irritable subscale (p=0.05) and total median score were significantly higher among tango dancers compared to controls (p <= 0.001).
SE|25462392|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|757|764
SE|25462392|RESULTS|ab|7|entity|C0449820|Score|qnco|||scores|||0|861|773|779
SE|25462392|RESULTS|ab|7|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|827|805|806
SE|25462392|RESULTS|ab|7|entity|C0439175|% of total|qnco|||total|||0|802|850|855
SE|25462392|RESULTS|ab|7|entity|C0449820|Score|qnco|||score|||0|802|863|868
SE|25462392|RESULTS|ab|7|entity|C0205250|High|qlco|||higher|||0|827|888|894
SE|25462392|RESULTS|ab|7|entity|C0335081|Dancer|prog|||dancers|||0|827|907|914
SE|25462392|RESULTS|ab|7|entity|C0243148|control|ftcn|||controls|||0|966|927|935
SE|25462392|RESULTS|ab|7|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|827|937|938

SE|25462392|LIMITATIONS|ab|8|text|950|995|LIMITATIONS: Self-report measures were used.
SE|25462392|LIMITATIONS|ab|8|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|950|961
SE|25462392|LIMITATIONS|ab|8|entity|C0036588|Self|idcn|||Self|||0|851|963|967
SE|25462392|LIMITATIONS|ab|8|entity|C0079809|Measures|qnco|||measures|||0|851|975|983

SE|25462392|LIMITATIONS|ab|9|text|995|1081|A larger sample size would have provided greater statistical power for data analysis.
SE|25462392|LIMITATIONS|ab|9|entity|C0443228|Largest|qnco|||larger|||0|901|997|1003
SE|25462392|LIMITATIONS|ab|9|entity|C0242618|Sample Size|qnco|||sample size|||0|901|1004|1015
SE|25462392|LIMITATIONS|ab|9|entity|C0443228|Largest|qnco|||greater|||0|901|1036|1043
SE|25462392|LIMITATIONS|ab|9|entity|C0814897|statistical power|resa|||statistical power|||0|901|1044|1061
SE|25462392|LIMITATIONS|ab|9|entity|C0010992|Data Analysis|ocac|||data analysis|||0|1000|1066|1079

SE|25462392|LIMITATIONS|ab|10|text|1081|1241|Besides, the naturalistic study design did not allow controlling for other clinical variables and limited the generalization of results to broader populations.
SE|25462392|LIMITATIONS|ab|10|entity|C0035171|Research Design|resa|||study design|||0|901|1107|1119
SE|25462392|LIMITATIONS|ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1124|1127
SE|25462392|LIMITATIONS|ab|10|entity|C0205210|Clinical|qlco|||clinical|||0|872|1156|1164
SE|25462392|LIMITATIONS|ab|10|entity|C0439828|Variable|qlco|||variables|||0|872|1165|1174
SE|25462392|LIMITATIONS|ab|10|entity|C1274040|result|ftcn|||results|||0|966|1209|1216
SE|25462392|LIMITATIONS|ab|10|entity|C0332464|Widening|spco|||broader|||0|872|1220|1227
SE|25462392|LIMITATIONS|ab|10|entity|C0032659|geographic population|qnco|||populations|||0|872|1228|1239

SE|25462392|CONCLUSIONS|ab|11|text|1241|1359|CONCLUSIONS: Our data adds new evidence for the hypothesis that artistic performance is related to one's temperament.
SE|25462392|CONCLUSIONS|ab|11|entity|C1511726|Data|idcn|||data|||0|1000|1258|1262
SE|25462392|CONCLUSIONS|ab|11|entity|C0205314|New|tmco|||new|||0|694|1268|1271
SE|25462392|CONCLUSIONS|ab|11|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|1289|1299
SE|25462392|CONCLUSIONS|ab|11|entity|C0402043|Artist|prog|||artistic|||0|853|1305|1313
SE|25462392|CONCLUSIONS|ab|11|entity|C0597198|Performance|inbe|||performance|||0|853|1314|1325
SE|25462392|CONCLUSIONS|ab|11|entity|C0205447|One|qnco|||one's|||0|790|1340|1345
SE|25462392|CONCLUSIONS|ab|11|entity|C0039474|Temperament|menp|||temperament|||0|790|1346|1357
SE|25462392|CONCLUSIONS|ab|11|relation|0|0|C0597198|Performance|inbe|inbe|||performance|||0|853|1314|1325|MOD/HEAD|PROCESS_OF||1305|1325|0|0|C0402043|Artist|prog,humn|humn|||artistic|||0|853|1305|1313

SE|25462392|CONCLUSIONS|ab|12|text|1359|1527|Tango passionata, which has both melancholic and vigorous (including "upbeat") features, seems to impart tango dancers' hyperthymic and irritable temperament features.
SE|25462392|CONCLUSIONS|ab|12|entity|C0344315|Depressed mood|fndg|||melancholic|||0|1000|1392|1403
SE|25462392|CONCLUSIONS|ab|12|entity|C0335081|Dancer|prog|||dancers|||0|627|1470|1477
SE|25462392|CONCLUSIONS|ab|12|entity|C0039474|Temperament|menp|||temperament|||0|660|1505|1516

SE|25462392|CONCLUSIONS|ab|13|text|1527|1694|Our study supports the increasing literature on the validity of utilizing temperament as a sub-affective traits in relation to artistic creativity and performing arts.
SE|25462392|CONCLUSIONS|ab|13|entity|C0008972|Clinical Research|resa|||study|||0|1000|1531|1536
SE|25462392|CONCLUSIONS|ab|13|entity|C0442808|Increasing|ftcn|||increasing|||0|888|1550|1560
SE|25462392|CONCLUSIONS|ab|13|entity|C0023866|Literature|inpr|||literature|||0|888|1561|1571
SE|25462392|CONCLUSIONS|ab|13|entity|C0039474|Temperament|menp|||temperament|||0|861|1601|1612
SE|25462392|CONCLUSIONS|ab|13|entity|C0542339|Inferior|spco|||sub|||0|785|1618|1621
SE|25462392|CONCLUSIONS|ab|13|entity|C0599883|trait|orga|||traits|||0|785|1632|1638
SE|25462392|CONCLUSIONS|ab|13|entity|C0681226|artistic creativity|idcn|||artistic creativity|||0|1000|1654|1673
SE|25462392|CONCLUSIONS|ab|13|entity|C0682001|performing arts|ocdi|||performing arts|||0|1000|1678|1693


SE|25462393||ti|1|text|21|131|The effectiveness of short- and long-term psychotherapy on personality functioning during a 5-year follow-up.
SE|25462393||ti|1|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|25|38
SE|25462393||ti|1|entity|C0443252|Long-term|tmco|||long-term|||0|901|53|62
SE|25462393||ti|1|entity|C0033968|Psychotherapy|topp|||psychotherapy|||0|901|63|76
SE|25462393||ti|1|entity|C0031208|Personality|menp|||personality|||0|872|80|91
SE|25462393||ti|1|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|92|103
SE|25462393||ti|1|entity|C0439234|year|tmco|||year|||0|888|115|119
SE|25462393||ti|1|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|120|129

SE|25462393|BACKGROUND|ab|1|text|137|286|BACKGROUND: Only few randomized trials comparing sustained effects of short- and long-term psychotherapies in personality functioning are available.
SE|25462393|BACKGROUND|ab|1|entity|C1514720|Randomized|ftcn|||randomized|||0|733|158|168
SE|25462393|BACKGROUND|ab|1|entity|C0008976|Clinical Trials|resa|||trials|||0|733|169|175
SE|25462393|BACKGROUND|ab|1|entity|C0443318|Sustained|ftcn|||sustained|||0|872|186|195
SE|25462393|BACKGROUND|ab|1|entity|C1280500|Effect|qlco|||effects|||0|872|196|203
SE|25462393|BACKGROUND|ab|1|entity|C0443252|Long-term|tmco|||long-term|||0|901|218|227
SE|25462393|BACKGROUND|ab|1|entity|C0033968|Psychotherapy|topp|||psychotherapies|||0|901|228|243
SE|25462393|BACKGROUND|ab|1|entity|C0031208|Personality|menp|||personality|||0|872|247|258
SE|25462393|BACKGROUND|ab|1|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|259|270

SE|25462393|BACKGROUND|ab|2|text|286|458|In this study we compared the effects of two short-term therapies and long-term psychodynamic psychotherapy on patients' personality functioning during a 5-year follow-up.
SE|25462393|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|294|299
SE|25462393|BACKGROUND|ab|2|entity|C1280500|Effect|qlco|||effects|||0|966|316|323
SE|25462393|BACKGROUND|ab|2|entity|C0205448|Two|qnco|||two|||0|861|327|330
SE|25462393|BACKGROUND|ab|2|entity|C0443303|Short-term|tmco|||short-term|||0|861|331|341
SE|25462393|BACKGROUND|ab|2|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|861|342|351
SE|25462393|BACKGROUND|ab|2|entity|C0579055|Long-term psychodynamic psychotherapy|topp|||long-term psychodynamic psychotherapy|||0|1000|356|393
SE|25462393|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|840|397|405
SE|25462393|BACKGROUND|ab|2|entity|C0031208|Personality|menp|||personality|||0|840|407|418
SE|25462393|BACKGROUND|ab|2|entity|C0031843|physiological aspects|phsf|||functioning|||0|840|419|430
SE|25462393|BACKGROUND|ab|2|entity|C0439234|year|tmco|||year|||0|888|442|446
SE|25462393|BACKGROUND|ab|2|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|447|456
SE|25462393|BACKGROUND|ab|2|relation|6|2|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|861|342|351|VERB|compared_with||303|311|6|3|C0579055|Long-term psychodynamic psychotherapy|topp|topp|||long-term psychodynamic psychotherapy|||0|1000|356|393

SE|25462393|METHODS|ab|3|text|458|822|METHODS: Altogether 326 patients of the Helsinki Psychotherapy Study, with anxiety or mood disorder, were randomly assigned to either short-term psychotherapy of about six months (solution-focused therapy (SFT, n=97) or short-term psychodynamic psychotherapy (SPP, n=101)), or to long-term psychodynamic psychotherapy (LPP, n=128), lasting on average three years.
SE|25462393|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|458|465
SE|25462393|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|827|482|490
SE|25462393|METHODS|ab|3|entity|C0033968|Psychotherapy|topp|||Psychotherapy|||0|790|507|520
SE|25462393|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||Study|||0|790|521|526
SE|25462393|METHODS|ab|3|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|533|540
SE|25462393|METHODS|ab|3|entity|C0525045|Mood Disorders|mobd|||mood disorder|||0|1000|544|557
SE|25462393|METHODS|ab|3|entity|C0033970|Psychotherapy, Brief|topp|||short-term psychotherapy|||0|923|592|616
SE|25462393|METHODS|ab|3|entity|C0205452|Six|qnco|||six|||0|790|626|629
SE|25462393|METHODS|ab|3|entity|C0439231|month|tmco|||months|||0|790|630|636
SE|25462393|METHODS|ab|3|entity|C0037633|Solutions|sbst|||solution|||0|840|638|646
SE|25462393|METHODS|ab|3|entity|C0000936|Visual Accommodation|clna|||focused|||0|840|647|654
SE|25462393|METHODS|ab|3|entity|||gngm|7321|UBE2D1|SFT|||0|1000|664|667
SE|25462393|METHODS|ab|3|entity|C0033970|Psychotherapy, Brief|topp|||short-term psychodynamic psychotherapy|||0|923|678|716
SE|25462393|METHODS|ab|3|entity|C1150110|signal peptide peptidase activity|moft|||SPP|||0|1000|718|721
SE|25462393|METHODS|ab|3|entity|C0579055|Long-term psychodynamic psychotherapy|topp|||long-term psychodynamic psychotherapy|||0|1000|738|775
SE|25462393|METHODS|ab|3|entity|||gngm|4026|LPP|LPP|||0|1000|777|780
SE|25462393|METHODS|ab|3|entity|C1510992|Average|qnco|||average|||0|851|801|808
SE|25462393|METHODS|ab|3|entity|C0205449|Three|qnco|||three|||0|851|809|814
SE|25462393|METHODS|ab|3|entity|C0439234|year|tmco|||years|||0|851|815|820
SE|25462393|METHODS|ab|3|relation|0|0|C0008972|Clinical Research|resa|resa|||Study|||0|790|521|526|MOD/HEAD|USES||507|526|0|0|C0033968|Psychotherapy|topp|topp|||Psychotherapy|||0|790|507|520

SE|25462393|METHODS|ab|4|text|822|1112|Outcomes in personality functioning (i.e., self-concept, defense style, interpersonal problems, and level of personality organization) were assessed five to seven times using, respectively, questionnaires (SASB, DSQ, IIP) and interview (LPO) during the 5-year follow-up from randomization.
SE|25462393|METHODS|ab|4|entity|C1274040|result|ftcn|||Outcomes|||0|966|822|830
SE|25462393|METHODS|ab|4|entity|C0031208|Personality|menp|||personality|||0|872|834|845
SE|25462393|METHODS|ab|4|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|846|857
SE|25462393|METHODS|ab|4|entity|C0036594|Self Concept|menp|||self-concept|||0|861|865|877
SE|25462393|METHODS|ab|4|entity|C0679190|defensiveness|inbe|||defense|||0|838|879|886
SE|25462393|METHODS|ab|4|entity|C0814588|interpersonal problems|socb|||interpersonal problems|||0|1000|894|916
SE|25462393|METHODS|ab|4|entity|C0031208|Personality|menp|||personality|||0|888|931|942
SE|25462393|METHODS|ab|4|entity|C0220885|organizational|qlco|||organization|||0|888|943|955
SE|25462393|METHODS|ab|4|entity|C0205451|Five|qnco|||five|||0|764|971|975
SE|25462393|METHODS|ab|4|entity|C0205453|Seven|qnco|||seven|||0|764|979|984
SE|25462393|METHODS|ab|4|entity|C0040223|Time|tmco|||times|||0|764|985|990
SE|25462393|METHODS|ab|4|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|1000|1012|1026
SE|25462393|METHODS|ab|4|entity|C0021822|Interview|inpr,resa|||interview|||0|1000|1048|1057
SE|25462393|METHODS|ab|4|entity|||gngm|4025|LPO|LPO|||0|1000|1059|1062
SE|25462393|METHODS|ab|4|entity|C0439234|year|tmco|||year|||0|888|1077|1081
SE|25462393|METHODS|ab|4|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1082|1091
SE|25462393|METHODS|ab|4|entity|C0034656|Random Allocation|resa|||randomization|||0|1000|1097|1110

SE|25462393|RESULTS|ab|5|text|1112|1177|RESULTS: Personality functioning improved in all therapy groups.
SE|25462393|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1112|1119
SE|25462393|RESULTS|ab|5|entity|C0031208|Personality|menp|||Personality|||0|872|1121|1132
SE|25462393|RESULTS|ab|5|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|1133|1144
SE|25462393|RESULTS|ab|5|entity|C0033971|Group Psychotherapy|topp|||therapy groups|||0|983|1161|1175

SE|25462393|RESULTS|ab|6|text|1177|1339|Both short-term therapies fared better than LPP during the first year of follow-up, by faster improvement in self-concept and decrease in immature defense style.
SE|25462393|RESULTS|ab|6|entity|C0443303|Short-term|tmco|||short-term|||0|901|1182|1192
SE|25462393|RESULTS|ab|6|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|901|1193|1202
SE|25462393|RESULTS|ab|6|entity|C0332272|Better|qlco|||better|||0|1000|1209|1215
SE|25462393|RESULTS|ab|6|entity|||gngm|4026|LPP|LPP|||0|1000|1221|1224
SE|25462393|RESULTS|ab|6|entity|C1279901|Firstly|qlco|||first|||0|888|1236|1241
SE|25462393|RESULTS|ab|6|entity|C0439234|year|tmco|||year|||0|888|1242|1246
SE|25462393|RESULTS|ab|6|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1250|1259
SE|25462393|RESULTS|ab|6|entity|C0456962|Fast|qlco|||faster|||0|661|1264|1270
SE|25462393|RESULTS|ab|6|entity|C0036594|Self Concept|menp|||self-concept|||0|1000|1286|1298
SE|25462393|RESULTS|ab|6|entity|C0547047|Decrease|qnco|||decrease|||0|1000|1303|1311
SE|25462393|RESULTS|ab|6|entity|C0205252|Immature|tmco|||immature|||0|818|1315|1323
SE|25462393|RESULTS|ab|6|entity|C0679190|defensiveness|inbe|||defense|||0|818|1324|1331
SE|25462393|RESULTS|ab|6|entity||<<goodness>>||||better|||||1209|1215
SE|25462393|RESULTS|ab|6|relation|2|2|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|901|1193|1202|PREP|compared_with||1216|1220|7|1|||gngm,aapp|gngm|4026|LPP|LPP|||0|1000|1221|1224
SE|25462393|RESULTS|ab|6|relation|2|2|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|901|1193|1202|PREP|higher_than||1216|1220|7|1|||gngm,aapp|gngm|4026|LPP|LPP|||0|1000|1221|1224

SE|25462393|RESULTS|ab|7|text|1339|1403|SFT also showed more early reduction of interpersonal problems.
SE|25462393|RESULTS|ab|7|entity|||gngm|7321|UBE2D1|SFT|||0|1000|1339|1342
SE|25462393|RESULTS|ab|7|entity|C0205172|More|ftcn|||more|||0|623|1355|1359
SE|25462393|RESULTS|ab|7|entity|C1279919|Early|tmco|||early|||0|623|1360|1365
SE|25462393|RESULTS|ab|7|entity|C0814588|interpersonal problems|socb|||interpersonal problems|||0|1000|1379|1401

SE|25462393|RESULTS|ab|8|text|1403|1528|However, LPP thereafter showed larger and more sustained benefits than SFT and SPP, through greater changes in self-concept.
SE|25462393|RESULTS|ab|8|entity|||gngm|4026|LPP|LPP|||0|1000|1412|1415
SE|25462393|RESULTS|ab|8|entity|C0443228|Largest|qnco|||larger|||0|1000|1434|1440
SE|25462393|RESULTS|ab|8|entity|C0205172|More|ftcn|||more|||0|851|1445|1449
SE|25462393|RESULTS|ab|8|entity|C0443318|Sustained|ftcn|||sustained|||0|851|1450|1459
SE|25462393|RESULTS|ab|8|entity|C0814225|Benefits|qnco|||benefits|||0|851|1460|1468
SE|25462393|RESULTS|ab|8|entity|||gngm|7321|UBE2D1|SFT|||0|1000|1474|1477
SE|25462393|RESULTS|ab|8|entity|C1150110|signal peptide peptidase activity|moft|||SPP|||0|1000|1482|1485
SE|25462393|RESULTS|ab|8|entity|C0443228|Largest|qnco|||greater|||0|872|1495|1502
SE|25462393|RESULTS|ab|8|entity|C0036594|Self Concept|menp|||self-concept|||0|1000|1514|1526

SE|25462393|RESULTS|ab|9|text|1528|1649|Additionally, LPP outperformed SFT at the end of the follow-up in IIP and LPO, after adjustment for auxiliary treatment.
SE|25462393|RESULTS|ab|9|entity|||gngm|4026|LPP|LPP|||0|1000|1542|1545
SE|25462393|RESULTS|ab|9|entity|||gngm|7321|UBE2D1|SFT|||0|1000|1559|1562
SE|25462393|RESULTS|ab|9|entity|C0444930|End|spco|||end|||0|1000|1570|1573
SE|25462393|RESULTS|ab|9|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1581|1590
SE|25462393|RESULTS|ab|9|entity|||gngm|4025|LPO|LPO|||0|1000|1602|1605

SE|25462393|RESULTS|ab|10|text|1649|1734|No differences were noted between the short-term therapies at any measurement point.
SE|25462393|RESULTS|ab|10|entity|C1547020|*Difference|qnco|||differences|||0|966|1652|1663
SE|25462393|RESULTS|ab|10|entity|C0443303|Short-term|tmco|||short-term|||0|901|1687|1697
SE|25462393|RESULTS|ab|10|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|901|1698|1707
SE|25462393|RESULTS|ab|10|entity|C0242485|Measurement|ftcn|||measurement|||0|694|1715|1726

SE|25462393|LIMITATIONS|ab|11|text|1734|1871|LIMITATIONS: Auxiliary treatment was used relatively widely which limits generalization to exclusive use of short- or long-term therapy.
SE|25462393|LIMITATIONS|ab|11|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1734|1745
SE|25462393|LIMITATIONS|ab|11|entity|C1548966|Exclusive|idcn|||exclusive|||0|888|1825|1834
SE|25462393|LIMITATIONS|ab|11|entity|C0443252|Long-term|tmco|||long-term|||0|901|1852|1861

SE|25462393|CONCLUSIONS|ab|12|text|1871|2010|CONCLUSIONS: LPP seems to be somewhat more effective than short-term therapies in facilitating longterm changes in personality functioning.
SE|25462393|CONCLUSIONS|ab|12|entity|||gngm|4026|LPP|LPP|||0|1000|1884|1887
SE|25462393|CONCLUSIONS|ab|12|entity|C0443303|Short-term|tmco|||short-term|||0|901|1929|1939
SE|25462393|CONCLUSIONS|ab|12|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|901|1940|1949
SE|25462393|CONCLUSIONS|ab|12|entity|C0031208|Personality|menp|||personality|||0|872|1986|1997
SE|25462393|CONCLUSIONS|ab|12|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|1998|2009
SE|25462393|CONCLUSIONS|ab|12|entity||<<effectiveness>>||||effective|||||1914|1923
SE|25462393|CONCLUSIONS|ab|12|relation|3|2|||gngm,aapp|gngm|4026|LPP|LPP|||0|1000|1884|1887|PREP|compared_with||1924|1928|3|1|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|901|1940|1949
SE|25462393|CONCLUSIONS|ab|12|relation|3|2|||gngm,aapp|gngm|4026|LPP|LPP|||0|1000|1884|1887|PREP|higher_than||1924|1928|3|1|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|901|1940|1949
SE|25462393|CONCLUSIONS|ab|12|relation|5|2|||gngm,aapp|gngm|4026|LPP|LPP|||0|1000|1884|1887|VERB|AFFECTS||1975|1982|1|1|C0031843|physiological aspects|phsf|phsf|||functioning|||0|872|1998|2009
SE|25462393|CONCLUSIONS|ab|12|relation|5|2|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|901|1940|1949|VERB|AFFECTS||1975|1982|1|1|C0031843|physiological aspects|phsf|phsf|||functioning|||0|872|1998|2009


SE|25462394||ti|1|text|21|125|Temperament and prodromal symptoms prior to first manic/hypomanic episodes: results from a pilot study.
SE|25462394||ti|1|entity|C0039474|Temperament|menp|||Temperament|||0|1000|21|32
SE|25462394||ti|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|861|47|55
SE|25462394||ti|1|entity|C0338831|Manic|mobd|||manic|||0|834|71|76
SE|25462394||ti|1|entity|C0241934|Hypomania|mobd|||hypomanic|||0|834|77|86
SE|25462394||ti|1|entity|C0439615|First episode|tmco|||first manic/hypomanic episodes|||0|834|65|95
SE|25462394||ti|1|entity|C1274040|result|ftcn|||results|||0|966|97|104
SE|25462394||ti|1|entity|C0031928|Pilot Projects|resa|||pilot study|||0|1000|112|123

SE|25462394|BACKGROUND|ab|1|text|131|221|BACKGROUND: Prodromal symptoms prior to first episode mania/hypomania have been reported.
SE|25462394|BACKGROUND|ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|861|153|161
SE|25462394|BACKGROUND|ab|1|entity|C0439615|First episode|tmco|||first episode|||0|861|171|184
SE|25462394|BACKGROUND|ab|1|entity|C0338831|Manic|mobd|||mania|||0|861|185|190
SE|25462394|BACKGROUND|ab|1|entity|C0241934|Hypomania|mobd|||hypomania|||0|861|191|200

SE|25462394|BACKGROUND|ab|2|text|221|333|However, the relationship between temperament and manic/hypomanic prodromal symptoms has not been investigated.
SE|25462394|BACKGROUND|ab|2|entity|C0439849|Relationships|qlco|||relationship|||0|1000|234|246
SE|25462394|BACKGROUND|ab|2|entity|C0039474|Temperament|menp|||temperament|||0|1000|255|266
SE|25462394|BACKGROUND|ab|2|entity|C0241934|Hypomania|mobd|||hypomanic|||0|789|277|286
SE|25462394|BACKGROUND|ab|2|entity|C0746402|MANIC SYMPTOM|mobd|||manic/hypomanic prodromal symptoms|||0|789|271|305
SE|25462394|BACKGROUND|ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|310|313

SE|25462394|BACKGROUND|ab|3|text|333|472|We hypothesized that subjects scoring higher on cyclothymic and irritable temperament scales show more manic/hypomanic prodromal symptoms.
SE|25462394|BACKGROUND|ab|3|entity|C1550501|subject|idcn|||subjects|||0|966|354|362
SE|25462394|BACKGROUND|ab|3|entity|C0205250|High|qlco|||higher|||0|966|371|377
SE|25462394|BACKGROUND|ab|3|entity|C0039474|Temperament|menp|||temperament|||0|790|407|418
SE|25462394|BACKGROUND|ab|3|entity|C0205172|More|ftcn|||more|||0|768|431|435
SE|25462394|BACKGROUND|ab|3|entity|C0241934|Hypomania|mobd|||hypomanic|||0|768|442|451
SE|25462394|BACKGROUND|ab|3|entity|C0746402|MANIC SYMPTOM|mobd|||manic/hypomanic prodromal symptoms|||0|768|436|470

SE|25462394|METHOD|ab|4|text|472|751|METHOD: Euthymic patients diagnosed with bipolar-I or -II disorder within 8 years underwent retrospective assessments with the Temperament Evaluation of Memphis, Pisa, Paris and San Diego-autoquestionnaire (TEMPS-A) and the Bipolar Prodrome Symptom Scale-Retrospective (BPSS-R).
SE|25462394|METHOD|ab|4|entity|C0025663|Methods|inpr|||METHOD|||0|1000|472|478
SE|25462394|METHOD|ab|4|entity|C0948853|Euthymia|mobd|||Euthymic|||0|853|480|488
SE|25462394|METHOD|ab|4|entity|C0030705|Patients|podg|||patients|||0|853|489|497
SE|25462394|METHOD|ab|4|entity|C0443156|Bipolar|spco|||bipolar|||0|1000|513|520
SE|25462394|METHOD|ab|4|entity|C0012634|Disease|dsyn|||disorder|||0|861|530|538
SE|25462394|METHOD|ab|4|entity|C0439234|year|tmco|||years|||0|861|548|553
SE|25462394|METHOD|ab|4|entity|C1514923|Retrospective|qlco|||retrospective|||0|872|564|577
SE|25462394|METHOD|ab|4|entity|C0220825|Evaluation|ftcn|||assessments|||0|872|578|589
SE|25462394|METHOD|ab|4|entity|C0039474|Temperament|menp|||Temperament|||0|671|599|610
SE|25462394|METHOD|ab|4|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|671|611|621
SE|25462394|METHOD|ab|4|entity|C1061320|Memphis|invt|||Memphis|||0|671|625|632
SE|25462394|METHOD|ab|4|entity|C0030561|Paris, France|geoa|||Paris|||0|671|640|645
SE|25462394|METHOD|ab|4|entity|C0443156|Bipolar|spco|||Bipolar|||0|822|696|703
SE|25462394|METHOD|ab|4|entity|C0240805|Prodrome|sosy|||Prodrome|||0|822|704|712
SE|25462394|METHOD|ab|4|entity|C1457887|Symptoms|sosy|||Symptom|||0|822|713|720
SE|25462394|METHOD|ab|4|entity|C1514923|Retrospective|qlco|||Retrospective|||0|822|727|740
SE|25462394|METHOD|ab|4|relation|0|0|C0948853|Euthymia|mobd|mobd|||Euthymic|||0|853|480|488|MOD/HEAD|PROCESS_OF||480|497|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|853|489|497

SE|25462394|RESULTS|ab|5|text|751|1125|RESULTS: Among 39 subjects (36.1 +/- 9.9 years, females = 59%, bipolar-I = 62%) 100% and 92.3% reported subthreshold mania (mean = 7.4 +/- 2.9) or subthreshold depressive symptoms (mean = 2.4 +/- 1.5), and 87.2% and 43.6% reported general psychopathology (mean = 3.2 +/- 2.0) or subthreshold psychotic symptoms (mean = 0.7 +/- 1.0) prior to their first hypo-/manic episode.
SE|25462394|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|751|758
SE|25462394|RESULTS|ab|5|entity|C1550501|subject|idcn|||subjects|||0|827|769|777
SE|25462394|RESULTS|ab|5|entity|C0439234|year|tmco|||years|||0|804|792|797
SE|25462394|RESULTS|ab|5|entity|C0015780|Female|orga|||females|||0|1000|799|806
SE|25462394|RESULTS|ab|5|entity|C0443156|Bipolar|spco|||bipolar|||0|1000|814|821
SE|25462394|RESULTS|ab|5|entity|C0338831|Manic|mobd|||mania|||0|742|868|873
SE|25462394|RESULTS|ab|5|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|901|911|930
SE|25462394|RESULTS|ab|5|entity|C0205246|Generalized|spco|||general|||0|736|982|989
SE|25462394|RESULTS|ab|5|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|736|990|1005
SE|25462394|RESULTS|ab|5|entity|C0871189|Psychotic symptom|sosy|||psychotic symptoms|||0|901|1043|1061
SE|25462394|RESULTS|ab|5|entity|C0858246|Hypos|dsyn|||hypo|||0|852|1104|1108
SE|25462394|RESULTS|ab|5|entity|C0338831|Manic|mobd|||manic|||0|852|1110|1115
SE|25462394|RESULTS|ab|5|entity|C0439615|First episode|tmco|||first hypo-/manic episode|||0|852|1098|1123

SE|25462394|RESULTS|ab|6|text|1125|1609|Subjects with higher cyclothymic and irritable temperament scores showed more subthreshold symptoms prior to the first manic/hypomanic episode, mainly subthreshold hypo-/manic symptoms (cyclothymic temperament r = 0.430; p = 0.006; irritable temperament r = 0.330; p = 0.040), general psychopathology symptoms (cyclothymic temperament r = 0.316; p = 0.05; irritable temperament r = 0.349; p = 0.029) and subthreshold psychotic symptoms (cyclothymic temperament r = 0.413; p = 0.009).
SE|25462394|RESULTS|ab|6|entity|C1550501|subject|idcn|||Subjects|||0|966|1125|1133
SE|25462394|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|661|1139|1145
SE|25462394|RESULTS|ab|6|entity|C0039474|Temperament|menp|||temperament|||0|790|1172|1183
SE|25462394|RESULTS|ab|6|entity|C0449820|Score|qnco|||scores|||0|790|1184|1190
SE|25462394|RESULTS|ab|6|entity|C0205172|More|ftcn|||more|||0|802|1198|1202
SE|25462394|RESULTS|ab|6|entity|C1457887|Symptoms|sosy|||symptoms|||0|802|1216|1224
SE|25462394|RESULTS|ab|6|entity|C0338831|Manic|mobd|||manic|||0|843|1244|1249
SE|25462394|RESULTS|ab|6|entity|C0241934|Hypomania|mobd|||hypomanic|||0|843|1250|1259
SE|25462394|RESULTS|ab|6|entity|C0439615|First episode|tmco|||first manic/hypomanic episode|||0|843|1238|1267
SE|25462394|RESULTS|ab|6|entity|C0858246|Hypos|dsyn|||hypo|||0|763|1289|1293
SE|25462394|RESULTS|ab|6|entity|C0746402|MANIC SYMPTOM|mobd|||manic symptoms|||0|763|1295|1309
SE|25462394|RESULTS|ab|6|entity|C0039474|Temperament|menp|||temperament|||0|712|1323|1334
SE|25462394|RESULTS|ab|6|entity|C0039474|Temperament|menp|||temperament|||0|712|1367|1378
SE|25462394|RESULTS|ab|6|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|901|1410|1425
SE|25462394|RESULTS|ab|6|entity|C0159028|[D]General symptoms|sosy|||general psychopathology symptoms|||0|901|1402|1434
SE|25462394|RESULTS|ab|6|entity|C0039474|Temperament|menp|||temperament|||0|712|1448|1459
SE|25462394|RESULTS|ab|6|entity|C0039474|Temperament|menp|||temperament|||0|712|1491|1502
SE|25462394|RESULTS|ab|6|entity|C0871189|Psychotic symptom|sosy|||psychotic symptoms|||0|901|1542|1560
SE|25462394|RESULTS|ab|6|entity|C0039474|Temperament|menp|||temperament|||0|712|1574|1585

SE|25462394|RESULTS|ab|7|text|1609|1773|In regression analyses, cyclothymic temperament explained 16.1% and 12.5% of the variance of the BPSS-R total score (p = 0.045) and psychosis subscore (p = 0.029).
SE|25462394|RESULTS|ab|7|entity|C0034980|Regression Analysis|qnco|||regression analyses|||0|1000|1612|1631
SE|25462394|RESULTS|ab|7|entity|C0039474|Temperament|menp|||temperament|||0|861|1645|1656
SE|25462394|RESULTS|ab|7|entity|C0205419|Variant|qlco|||variance|||0|928|1690|1698
SE|25462394|RESULTS|ab|7|entity|C0443156|Bipolar|spco|||BPSS-R|||0|809|1706|1712
SE|25462394|RESULTS|ab|7|entity|C0240805|Prodrome|sosy|||BPSS-R|||0|809|1706|1712
SE|25462394|RESULTS|ab|7|entity|C1457887|Symptoms|sosy|||BPSS-R|||0|809|1706|1712
SE|25462394|RESULTS|ab|7|entity|C1514923|Retrospective|qlco|||BPSS-R|||0|809|1706|1712
SE|25462394|RESULTS|ab|7|entity|C0439175|% of total|qnco|||total|||0|809|1713|1718
SE|25462394|RESULTS|ab|7|entity|C0449820|Score|qnco|||score|||0|809|1719|1724
SE|25462394|RESULTS|ab|7|entity|C0033975|Psychotic Disorders|mobd|||psychosis|||0|694|1741|1750

SE|25462394|LIMITATIONS|ab|8|text|1773|1844|LIMITATIONS: Retrospective study, no control group, small sample size.
SE|25462394|LIMITATIONS|ab|8|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1773|1784
SE|25462394|LIMITATIONS|ab|8|entity|C0035363|Retrospective Studies|qnco|||Retrospective study|||0|1000|1786|1805
SE|25462394|LIMITATIONS|ab|8|entity|C0009932|Control Groups|grup|||control group|||0|1000|1810|1823

SE|25462394|CONCLUSION|ab|9|text|1844|2016|CONCLUSION: We present data, which indicate a relationship between cyclothymic and irritable temperament and prodromal symptoms prior to the first manic/hypomanic episode.
SE|25462394|CONCLUSION|ab|9|entity|C1511726|Data|idcn|||data|||0|1000|1867|1871
SE|25462394|CONCLUSION|ab|9|entity|C0439849|Relationships|qlco|||relationship|||0|1000|1890|1902
SE|25462394|CONCLUSION|ab|9|entity|C0039474|Temperament|menp|||temperament|||0|861|1937|1948
SE|25462394|CONCLUSION|ab|9|entity|C1457887|Symptoms|sosy|||symptoms|||0|861|1963|1971
SE|25462394|CONCLUSION|ab|9|entity|C0338831|Manic|mobd|||manic|||0|843|1991|1996
SE|25462394|CONCLUSION|ab|9|entity|C0241934|Hypomania|mobd|||hypomanic|||0|843|1997|2006
SE|25462394|CONCLUSION|ab|9|entity|C0439615|First episode|tmco|||first manic/hypomanic episode|||0|843|1985|2014

SE|25462394|CONCLUSION|ab|10|text|2016|2230|These findings support the notion that assessing cyclothymic temperament to identify people at-risk of developing bipolar-I and -II disorder may help to increase the predictive validity of applied at-risk criteria.
SE|25462394|CONCLUSION|ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|2022|2030
SE|25462394|CONCLUSION|ab|10|entity|C0220825|Evaluation|ftcn|||assessing|||0|785|2055|2064
SE|25462394|CONCLUSION|ab|10|entity|C0039474|Temperament|menp|||temperament|||0|785|2077|2088
SE|25462394|CONCLUSION|ab|10|entity|C0027361|Persons|popg|||people|||0|1000|2101|2107
SE|25462394|CONCLUSION|ab|10|entity|C1444641|At risk|qlco|||at-risk|||0|1000|2108|2115
SE|25462394|CONCLUSION|ab|10|entity|C0443156|Bipolar|spco|||bipolar|||0|861|2130|2137
SE|25462394|CONCLUSION|ab|10|entity|C0012634|Disease|dsyn|||disorder|||0|861|2148|2156
SE|25462394|CONCLUSION|ab|10|entity|C0681898|predictive validity|qlco,resa|||predictive validity|||0|1000|2182|2201
SE|25462394|CONCLUSION|ab|10|entity|C1444641|At risk|qlco|||at-risk|||0|901|2213|2220
SE|25462394|CONCLUSION|ab|10|entity|C0243161|criteria|inpr|||criteria|||0|901|2221|2229


SE|25462395||ti|1|text|21|122|Cortico-limbic network abnormalities in individuals with current and past major depressive disorder.
SE|25462395||ti|1|entity|C0679670|network|popg|||network|||0|750|36|43
SE|25462395||ti|1|entity|C0237401|Individual|humn|||individuals|||0|1000|61|72
SE|25462395||ti|1|entity|C0521116|Current|tmco|||current|||0|1000|78|85
SE|25462395||ti|1|entity|C1444637|Past|tmco|||past|||0|916|90|94
SE|25462395||ti|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|916|95|120

SE|25462395|BACKGROUND|ab|1|text|128|247|BACKGROUND: Brain abnormalities in fronto-temporal structures have been implicated in major depressive disorder (MDD).
SE|25462395|BACKGROUND|ab|1|entity|C0006104|Brain|bpoc|||Brain|||0|888|140|145
SE|25462395|BACKGROUND|ab|1|entity|C0442043|temporal|spco|||temporal|||0|773|170|178
SE|25462395|BACKGROUND|ab|1|entity|C0678594|Structure|spco|||structures|||0|773|179|189
SE|25462395|BACKGROUND|ab|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|1000|214|239

SE|25462395|BACKGROUND|ab|2|text|247|359|This study aims to identify their anatomical distribution and their relation to the time course of the disease.
SE|25462395|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|252|257
SE|25462395|BACKGROUND|ab|2|entity|C0220784|anatomic|ftcn|||anatomical|||0|888|281|291
SE|25462395|BACKGROUND|ab|2|entity|C0520511|Distributing|idcn|||distribution|||0|888|292|304
SE|25462395|BACKGROUND|ab|2|entity|C0869014|Relations|socb|||relation|||0|966|315|323
SE|25462395|BACKGROUND|ab|2|entity|C0449247|Time course|tmco|||time course|||0|1000|331|342
SE|25462395|BACKGROUND|ab|2|entity|C0012634|Disease|dsyn|||disease|||0|1000|350|357

SE|25462395|METHODS|ab|3|text|359|629|METHODS: A whole-brain voxel based morphometry analysis was conducted to assess gray and white matter alterations in 56 participants with a lifetime history of MDD, including currently depressed (cMDD) and remitted patients (rMDD), and 33 matched healthy controls (HC).
SE|25462395|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|359|366
SE|25462395|METHODS|ab|3|entity|C0444667|Whole|qnco|||whole|||0|748|370|375
SE|25462395|METHODS|ab|3|entity|C0006104|Brain|bpoc|||brain|||0|748|376|381
SE|25462395|METHODS|ab|3|entity|C0200760|Morphometric analysis|lbpr|||morphometry analysis|||0|748|394|414
SE|25462395|METHODS|ab|3|entity|C0332577|Greyish color|qlco|||gray|||0|1000|439|443
SE|25462395|METHODS|ab|3|entity|C0682708|White Matter|tisu|||white matter|||0|884|448|460
SE|25462395|METHODS|ab|3|entity|C1515926|Alteration|idcn|||alterations|||0|884|461|472
SE|25462395|METHODS|ab|3|entity|C0679646|Participant|popg|||participants|||0|827|479|491
SE|25462395|METHODS|ab|3|entity|C0019664|Recording of previous events|ocdi|||history|||0|861|508|515
SE|25462395|METHODS|ab|3|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|519|522
SE|25462395|METHODS|ab|3|entity|C0521116|Current|tmco|||currently|||0|861|534|543
SE|25462395|METHODS|ab|3|entity|C0439600|Remitting|tmco|||remitted|||0|872|565|573
SE|25462395|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|872|574|582
SE|25462395|METHODS|ab|3|entity|C0150103|MATCHING|resa|||matched|||0|729|598|605
SE|25462395|METHODS|ab|3|entity|C0018684|Health|idcn|||healthy|||0|729|606|613
SE|25462395|METHODS|ab|3|entity|C0243148|control|ftcn|||controls|||0|729|614|622

SE|25462395|RESULTS|ab|4|text|629|833|RESULTS: Compared to HC, MDD participants showed increased white matter volume (WMV) in the uncinate fasciculus (UF) and decreased gray matter density (GMD) on the ventromedial prefrontal cortex (vmPFC).
SE|25462395|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|629|636
SE|25462395|RESULTS|ab|4|entity|C0018684|Health|idcn|||HC|||0|836|650|652
SE|25462395|RESULTS|ab|4|entity|C0243148|control|ftcn|||HC|||0|836|650|652
SE|25462395|RESULTS|ab|4|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|900|654|657
SE|25462395|RESULTS|ab|4|entity|C0679646|Participant|popg|||participants|||0|900|658|670
SE|25462395|RESULTS|ab|4|entity|C0205217|Increased|qnco|||increased|||0|861|678|687
SE|25462395|RESULTS|ab|4|entity|C0682708|White Matter|tisu|||white matter|||0|861|688|700
SE|25462395|RESULTS|ab|4|entity|C0449468|Volume|qnco|||volume|||0|861|701|707
SE|25462395|RESULTS|ab|4|entity|C1289510|Entire uncinate fasciculus|bpoc|||uncinate fasciculus|||0|1000|721|740
SE|25462395|RESULTS|ab|4|entity|C0018220|Gray matter|tisu|||gray matter|||0|888|760|771
SE|25462395|RESULTS|ab|4|entity|C1265608|Decreased density|fndg|||decreased gray matter density|||0|888|750|779
SE|25462395|RESULTS|ab|4|entity|C0162783|Prefrontal Cortex|bpoc|||prefrontal cortex|||0|901|806|823
SE|25462395|RESULTS|ab|4|relation|0|0|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|900|654|657|MOD/HEAD|PROCESS_OF||654|670|0|0|C0679646|Participant|popg,humn|humn|||participants|||0|900|658|670
SE|25462395|RESULTS|ab|4|relation|1|1|C0162783|Prefrontal Cortex|bpoc|bpoc|||prefrontal cortex|||0|901|806|823|PREP|LOCATION_OF||786|788|6|1|C1265608|Decreased density|fndg|fndg|||decreased gray matter density|||0|888|750|779

SE|25462395|RESULTS|ab|5|text|833|947|The increased WMV in UF was driven by both cMDD and rMDD groups and positively correlated with depression scores.
SE|25462395|RESULTS|ab|5|entity|C0205217|Increased|qnco|||increased|||0|861|837|846
SE|25462395|RESULTS|ab|5|entity|C0682708|White Matter|tisu|||WMV|||0|861|847|850
SE|25462395|RESULTS|ab|5|entity|C0449468|Volume|qnco|||WMV|||0|861|847|850
SE|25462395|RESULTS|ab|5|entity|C1289510|Entire uncinate fasciculus|bpoc|||UF|||0|1000|854|856
SE|25462395|RESULTS|ab|5|entity|C0521116|Current|tmco|||cMDD|||0|861|876|880
SE|25462395|RESULTS|ab|5|entity|C0441833|Groups|inpr|||groups|||0|861|890|896
SE|25462395|RESULTS|ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|928|938
SE|25462395|RESULTS|ab|5|entity|C0449820|Score|qnco|||scores|||0|888|939|945

SE|25462395|RESULTS|ab|6|text|947|1067|The GMD decrease in the vmPFC resulted mainly from abnormalities in rMDD and was not correlated with depression scores.
SE|25462395|RESULTS|ab|6|entity|C0018220|Gray matter|tisu|||GMD|||0|861|951|954
SE|25462395|RESULTS|ab|6|entity|C0178587|density|npop|||GMD|||0|861|951|954
SE|25462395|RESULTS|ab|6|entity|C0547047|Decrease|qnco|||decrease|||0|861|955|963
SE|25462395|RESULTS|ab|6|entity|C0162783|Prefrontal Cortex|bpoc|||vmPFC|||0|901|971|976
SE|25462395|RESULTS|ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1028|1031
SE|25462395|RESULTS|ab|6|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1048|1058
SE|25462395|RESULTS|ab|6|entity|C0449820|Score|qnco|||scores|||0|888|1059|1065

SE|25462395|RESULTS|ab|7|text|1067|1215|Finally, temporal UF and vmPFC white matter showed strong structural covariance suggesting functional interactions between these two brain regions.
SE|25462395|RESULTS|ab|7|entity|C0442043|temporal|spco|||temporal|||0|901|1076|1084
SE|25462395|RESULTS|ab|7|entity|C1289510|Entire uncinate fasciculus|bpoc|||UF|||0|901|1085|1087
SE|25462395|RESULTS|ab|7|entity|C0162783|Prefrontal Cortex|bpoc|||vmPFC|||0|826|1092|1097
SE|25462395|RESULTS|ab|7|entity|C0682708|White Matter|tisu|||white matter|||0|826|1098|1110
SE|25462395|RESULTS|ab|7|entity|C0442821|Strong|qlco|||strong|||0|660|1118|1124
SE|25462395|RESULTS|ab|7|entity|C0205245|Functional|ftcn|||functional|||0|694|1158|1168
SE|25462395|RESULTS|ab|7|entity|C0205448|Two|qnco|||two|||0|890|1196|1199
SE|25462395|RESULTS|ab|7|entity|C1273723|Brain region|blor|||brain regions|||0|890|1200|1213
SE|25462395|RESULTS|ab|7|relation|0|0|C0682708|White Matter|tisu|tisu|||white matter|||0|826|1098|1110|MOD/HEAD|PART_OF||1092|1110|0|0|C0162783|Prefrontal Cortex|bpoc|bpoc|||vmPFC|||0|826|1092|1097

SE|25462395|LIMITATIONS|ab|8|text|1215|1330|LIMITATIONS: The retrospective and cross-sectional design of the study limits the generalizability of the results.
SE|25462395|LIMITATIONS|ab|8|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1215|1226
SE|25462395|LIMITATIONS|ab|8|entity|C1514923|Retrospective|qlco|||retrospective|||0|1000|1232|1245
SE|25462395|LIMITATIONS|ab|8|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|663|1250|1265
SE|25462395|LIMITATIONS|ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1280|1285
SE|25462395|LIMITATIONS|ab|8|entity|C1274040|result|ftcn|||results|||0|966|1321|1328

SE|25462395|LIMITATIONS|ab|9|text|1330|1464|Information concerning ongoing treatment did not allow the exploration of interactions between medication and observed abnormalities.
SE|25462395|LIMITATIONS|ab|9|entity|C1533716|Information|idcn|||Information|||0|791|1330|1341
SE|25462395|LIMITATIONS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1375|1378
SE|25462395|LIMITATIONS|ab|9|entity|C1280903|Exploration procedure|topp|||exploration|||0|1000|1389|1400
SE|25462395|LIMITATIONS|ab|9|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|1425|1435

SE|25462395|LIMITATIONS|ab|10|text|1464|1575|The duration of the remission period could have influenced abnormalities in the subgroup of remitted patients.
SE|25462395|LIMITATIONS|ab|10|entity|C0449238|Duration|tmco|||duration|||0|1000|1468|1476
SE|25462395|LIMITATIONS|ab|10|entity|C0439531|/period|tmco|||period|||0|861|1494|1500
SE|25462395|LIMITATIONS|ab|10|entity|C1515021|Subgroup|clas|||subgroup|||0|1000|1544|1552
SE|25462395|LIMITATIONS|ab|10|entity|C0439600|Remitting|tmco|||remitted|||0|872|1556|1564
SE|25462395|LIMITATIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|872|1565|1573

SE|25462395|CONCLUSIONS|ab|11|text|1575|1753|CONCLUSIONS: Fronto-temporal alterations in MDD consist of alterations in a cortico-limbic network involving the ventromedial prefrontal cortex and temporal white matter tracts.
SE|25462395|CONCLUSIONS|ab|11|entity|C0442043|temporal|spco|||temporal|||0|773|1595|1603
SE|25462395|CONCLUSIONS|ab|11|entity|C1515926|Alteration|idcn|||alterations|||0|773|1604|1615
SE|25462395|CONCLUSIONS|ab|11|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|1619|1622
SE|25462395|CONCLUSIONS|ab|11|entity|C1515926|Alteration|idcn|||alterations|||0|966|1634|1645
SE|25462395|CONCLUSIONS|ab|11|entity|C0679670|network|popg|||network|||0|827|1666|1673
SE|25462395|CONCLUSIONS|ab|11|entity|C0162783|Prefrontal Cortex|bpoc|||prefrontal cortex|||0|901|1701|1718
SE|25462395|CONCLUSIONS|ab|11|entity|C0442043|temporal|spco|||temporal|||0|850|1723|1731
SE|25462395|CONCLUSIONS|ab|11|entity|C0682708|White Matter|tisu|||white matter|||0|850|1732|1744
SE|25462395|CONCLUSIONS|ab|11|entity|C1185740|Tract|bpoc|||tracts|||0|850|1745|1751
SE|25462395|CONCLUSIONS|ab|11|relation|3|1|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|1000|1619|1622|NOM|AFFECTS||1634|1645|3|1|C0679670|network|popg,humn|humn|||network|||0|827|1666|1673

SE|25462395|CONCLUSIONS|ab|12|text|1753|1884|State-like abnormalities in the UF survive remission and persist as trait-like abnormalities together with alteration in the vmPFC.
SE|25462395|CONCLUSIONS|ab|12|entity|C1442792|State|ftcn|||State|||0|1000|1753|1758
SE|25462395|CONCLUSIONS|ab|12|entity|C1289510|Entire uncinate fasciculus|bpoc|||UF|||0|1000|1785|1787
SE|25462395|CONCLUSIONS|ab|12|entity|C0599883|trait|orga|||trait|||0|1000|1821|1826
SE|25462395|CONCLUSIONS|ab|12|entity|C1515926|Alteration|idcn|||alteration|||0|1000|1860|1870
SE|25462395|CONCLUSIONS|ab|12|entity|C0162783|Prefrontal Cortex|bpoc|||vmPFC|||0|901|1878|1883


SE|25462396||ti|1|text|21|130|Contrasting and convergent patterns of amygdala connectivity in mania and depression: a resting-state study.
SE|25462396||ti|1|entity|C0443193|Convergence|spco|||convergent|||0|853|37|47
SE|25462396||ti|1|entity|C0449774|Patterns|spco|||patterns|||0|853|48|56
SE|25462396||ti|1|entity|C0002708|Amygdaloid structure|bpoc|||amygdala|||0|694|60|68
SE|25462396||ti|1|entity|C0338831|Manic|mobd|||mania|||0|1000|85|90
SE|25462396||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|95|105
SE|25462396||ti|1|entity|C0679218|Resting state|fndg|||resting-state|||0|901|109|122
SE|25462396||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|901|123|128

SE|25462396|BACKGROUND|ab|1|text|136|354|BACKGROUND: wMania and depression in bipolar disorder (BP) manifest two extremes of aberrant emotional, physiologic and behavioral arousal states despite similarities in treatment response and neurocognitive deficits.
SE|25462396|BACKGROUND|ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|159|169
SE|25462396|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|173|189
SE|25462396|BACKGROUND|ab|1|entity|C0205448|Two|qnco|||two|||0|872|204|207
SE|25462396|BACKGROUND|ab|1|entity|C0205403|Extreme|qlco|||extremes|||0|872|208|216
SE|25462396|BACKGROUND|ab|1|entity|C0443127|Aberrant|qlco|||aberrant|||0|851|220|228
SE|25462396|BACKGROUND|ab|1|entity|C0849912|Emotional|fndg|||emotional|||0|851|229|238
SE|25462396|BACKGROUND|ab|1|entity|C0205463|Physiological|ftcn|||physiologic|||0|851|240|251
SE|25462396|BACKGROUND|ab|1|entity|C0003808|Arousal|menp|||arousal|||0|861|267|274
SE|25462396|BACKGROUND|ab|1|entity|C0871364|Simile|inpr|||similarities|||0|893|290|302
SE|25462396|BACKGROUND|ab|1|entity|C0871261|response|clna|||response|||0|888|316|324
SE|25462396|BACKGROUND|ab|1|entity|C0518895|Neurocognitive|inpr|||neurocognitive|||0|872|329|343
SE|25462396|BACKGROUND|ab|1|entity|C0011155|Deficiency|ftcn|||deficits|||0|872|344|352
SE|25462396|BACKGROUND|ab|1|relation|3|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|159|169|PREP|COEXISTS_WITH||170|172|8|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|173|189

SE|25462396|BACKGROUND|ab|2|text|354|538|We used resting-state functional magnetic resonance imaging (rsfMRI) to explore the common and unique abnormal functional connectivity underlying acute manic or depressed state in BP.
SE|25462396|BACKGROUND|ab|2|entity|C0679218|Resting state|fndg|||resting-state|||0|901|362|375
SE|25462396|BACKGROUND|ab|2|entity|C0376335|fMRI|diap|||functional magnetic resonance imaging|||0|901|376|413
SE|25462396|BACKGROUND|ab|2|entity|C0205214|Common|qnco|||common|||0|1000|438|444
SE|25462396|BACKGROUND|ab|2|entity|C0205161|Abnormal|ftcn|||abnormal|||0|583|456|464
SE|25462396|BACKGROUND|ab|2|entity|C0205245|Functional|ftcn|||functional|||0|583|465|475
SE|25462396|BACKGROUND|ab|2|entity|C0205178|acute|tmco|||acute|||0|888|500|505
SE|25462396|BACKGROUND|ab|2|entity|C0338831|Manic|mobd|||manic|||0|888|506|511
SE|25462396|BACKGROUND|ab|2|entity|C0011570|Mental Depression|mobd|||depressed state|||0|1000|515|530

SE|25462396|METHODS|ab|3|text|538|721|METHODS: 18 Patients with bipolar mania (BM), 10 patients with bipolar depression (BD) and 28 healthy controls underwent resting-state functional magnetic resonance imaging scanning.
SE|25462396|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|538|545
SE|25462396|METHODS|ab|3|entity|C0030705|Patients|podg|||Patients|||0|861|550|558
SE|25462396|METHODS|ab|3|entity|C0443156|Bipolar|spco|||bipolar|||0|888|564|571
SE|25462396|METHODS|ab|3|entity|C0338831|Manic|mobd|||mania|||0|888|572|577
SE|25462396|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|861|587|595
SE|25462396|METHODS|ab|3|entity|C0005587|Depression, Bipolar|mobd|||bipolar depression|||0|1000|601|619
SE|25462396|METHODS|ab|3|entity|C0018684|Health|idcn|||healthy|||0|737|632|639
SE|25462396|METHODS|ab|3|entity|C0243148|control|ftcn|||controls|||0|737|640|648
SE|25462396|METHODS|ab|3|entity|C0679218|Resting state|fndg|||resting-state|||0|873|659|672
SE|25462396|METHODS|ab|3|entity|C0376335|fMRI|diap|||functional magnetic resonance imaging|||0|873|673|710
SE|25462396|METHODS|ab|3|entity|C0441633|Scanning|diap|||scanning|||0|873|711|719
SE|25462396|METHODS|ab|3|relation|0|0|C0376335|fMRI|diap|diap|||functional magnetic resonance imaging|||0|873|673|710|INFER|ADMINISTERED_TO(SPEC)||673|719|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|861|587|595
SE|25462396|METHODS|ab|3|relation|0|0|C0376335|fMRI|diap|diap|||functional magnetic resonance imaging|||0|873|673|710|MOD/HEAD|ISA||673|719|0|0|C0441633|Scanning|diap|diap|||scanning|||0|873|711|719
SE|25462396|METHODS|ab|3|relation|1|1|C0441633|Scanning|diap|diap|||scanning|||0|873|711|719|VERB|ADMINISTERED_TO||649|658|6|3|C0030705|Patients|podg,humn|humn|||patients|||0|861|587|595
SE|25462396|METHODS|ab|3|relation|3|1|C0005587|Depression, Bipolar|mobd|mobd|||bipolar depression|||0|1000|601|619|PREP|PROCESS_OF||596|600|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|587|595
SE|25462396|METHODS|ab|3|relation|5|1|C0338831|Manic|mobd|mobd|||mania|||0|888|572|577|PREP|PROCESS_OF||559|563|2|1|C0030705|Patients|podg,humn|humn|||Patients|||0|861|550|558

SE|25462396|METHODS|ab|4|text|721|840|Left and right amygdala seed-to-voxel based functional connectivity were assessed and compared among the three groups.
SE|25462396|METHODS|ab|4|entity|C0205091|Left|spco|||Left|||0|1000|721|725
SE|25462396|METHODS|ab|4|entity|C0205090|Right|spco|||right|||0|569|730|735
SE|25462396|METHODS|ab|4|entity|C0002708|Amygdaloid structure|bpoc|||amygdala|||0|569|736|744
SE|25462396|METHODS|ab|4|entity|C0036563|Seeds|plnt|||seed|||0|569|745|749
SE|25462396|METHODS|ab|4|entity|C0205245|Functional|ftcn|||functional|||0|694|765|775
SE|25462396|METHODS|ab|4|entity|C0205449|Three|qnco|||three|||0|888|826|831
SE|25462396|METHODS|ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|832|838

SE|25462396|METHODS|ab|5|text|840|994|The relationships between aberrant functional connectivity and the severity of clinical symptoms, number of episodes, illness duration were investigated.
SE|25462396|METHODS|ab|5|entity|C0439849|Relationships|qlco|||relationships|||0|1000|844|857
SE|25462396|METHODS|ab|5|entity|C0443127|Aberrant|qlco|||aberrant|||0|623|866|874
SE|25462396|METHODS|ab|5|entity|C0205245|Functional|ftcn|||functional|||0|623|875|885
SE|25462396|METHODS|ab|5|entity|C0439793|Severities|qlco|||severity|||0|1000|907|915
SE|25462396|METHODS|ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|888|919|927
SE|25462396|METHODS|ab|5|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|928|936
SE|25462396|METHODS|ab|5|entity|C0237753|Numbers|qnco|||number|||0|1000|938|944
SE|25462396|METHODS|ab|5|entity|C0332189|Episode of|tmco|||episodes|||0|1000|948|956
SE|25462396|METHODS|ab|5|entity|C0221423|Finding / disorder|ftcn|||illness|||0|888|958|965
SE|25462396|METHODS|ab|5|entity|C0449238|Duration|tmco|||duration|||0|888|966|974

SE|25462396|RESULTS|ab|6|text|994|1220|RESULTS: Compared to healthy controls, both BM and BD groups showed reduced functional connectivity between bilateral amygdala and inferior frontal gyrus (orbital), striatum, right lingual gyrus and posterior cerebellar lobe.
SE|25462396|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|994|1001
SE|25462396|RESULTS|ab|6|entity|C0018684|Health|idcn|||healthy|||0|836|1015|1022
SE|25462396|RESULTS|ab|6|entity|C0243148|control|ftcn|||controls|||0|836|1023|1031
SE|25462396|RESULTS|ab|6|entity|C0443156|Bipolar|spco|||BM|||0|888|1038|1040
SE|25462396|RESULTS|ab|6|entity|C0338831|Manic|mobd|||BM|||0|888|1038|1040
SE|25462396|RESULTS|ab|6|entity|C0005587|Depression, Bipolar|mobd|||BD|||0|901|1045|1047
SE|25462396|RESULTS|ab|6|entity|C0441833|Groups|inpr|||groups|||0|901|1048|1054
SE|25462396|RESULTS|ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|623|1062|1069
SE|25462396|RESULTS|ab|6|entity|C0205245|Functional|ftcn|||functional|||0|623|1070|1080
SE|25462396|RESULTS|ab|6|entity|C0238767|Bilateral|spco|||bilateral|||0|888|1102|1111
SE|25462396|RESULTS|ab|6|entity|C0002708|Amygdaloid structure|bpoc|||amygdala|||0|888|1112|1120
SE|25462396|RESULTS|ab|6|entity|C0152298|Inferior frontal gyrus|bpoc|||inferior frontal gyrus|||0|1000|1125|1147
SE|25462396|RESULTS|ab|6|entity|C0699036|Orbital|spco|||orbital|||0|1000|1149|1156
SE|25462396|RESULTS|ab|6|entity|C0162512|Neostriatum|bpoc|||striatum|||0|1000|1159|1167
SE|25462396|RESULTS|ab|6|entity|C0205090|Right|spco|||right|||0|901|1169|1174
SE|25462396|RESULTS|ab|6|entity|C0152308|Lingual gyrus|bpoc|||lingual gyrus|||0|901|1175|1188
SE|25462396|RESULTS|ab|6|entity|C0228491|Posterior lobe of cerebellum|bpoc|||posterior cerebellar lobe|||0|1000|1193|1218

SE|25462396|RESULTS|ab|7|text|1220|1313|Furthermore right amygdala-hippocampal connectivity was decreased in BD but increased in BM.
SE|25462396|RESULTS|ab|7|entity|C0205090|Right|spco|||right|||0|562|1232|1237
SE|25462396|RESULTS|ab|7|entity|C0002708|Amygdaloid structure|bpoc|||amygdala|||0|562|1238|1246
SE|25462396|RESULTS|ab|7|entity|C0005587|Depression, Bipolar|mobd|||BD|||0|1000|1289|1291
SE|25462396|RESULTS|ab|7|entity|C0443156|Bipolar|spco|||BM|||0|888|1309|1311
SE|25462396|RESULTS|ab|7|entity|C0338831|Manic|mobd|||BM|||0|888|1309|1311
SE|25462396|RESULTS|ab|7|relation|2|1|C0005587|Depression, Bipolar|mobd|mobd|||BD|||0|1000|1289|1291|PREP|COEXISTS_WITH||1306|1308|1|1|C0338831|Manic|mobd|mobd|||BM|||0|888|1309|1311

SE|25462396|RESULTS|ab|8|text|1313|1446|No significant correlations were found between strength of abnormal functional connectivity and clinical characteristic in BD or BM.
SE|25462396|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|694|1316|1327
SE|25462396|RESULTS|ab|8|entity|C0808080|STRENGTH|idcn|||strength|||0|1000|1360|1368
SE|25462396|RESULTS|ab|8|entity|C0205161|Abnormal|ftcn|||abnormal|||0|623|1372|1380
SE|25462396|RESULTS|ab|8|entity|C0205245|Functional|ftcn|||functional|||0|623|1381|1391
SE|25462396|RESULTS|ab|8|entity|C0683325|clinical aspects|clna|||clinical characteristic|||0|983|1409|1432
SE|25462396|RESULTS|ab|8|entity|C0005587|Depression, Bipolar|mobd|||BD|||0|1000|1436|1438
SE|25462396|RESULTS|ab|8|entity|C0443156|Bipolar|spco|||BM|||0|888|1442|1444
SE|25462396|RESULTS|ab|8|entity|C0338831|Manic|mobd|||BM|||0|888|1442|1444

SE|25462396|LIMITATIONS|ab|9|text|1446|1554|LIMITATIONS: No euthymic subjects were recruited, and the patients in current study were all on medication.
SE|25462396|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1446|1457
SE|25462396|LIMITATIONS|ab|9|entity|C0948853|Euthymia|mobd|||euthymic|||0|836|1462|1470
SE|25462396|LIMITATIONS|ab|9|entity|C1550501|subject|idcn|||subjects|||0|836|1471|1479
SE|25462396|LIMITATIONS|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1504|1512
SE|25462396|LIMITATIONS|ab|9|entity|C0521116|Current|tmco|||current|||0|888|1516|1523
SE|25462396|LIMITATIONS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|888|1524|1529
SE|25462396|LIMITATIONS|ab|9|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|1542|1552

SE|25462396|CONCLUSIONS|ab|10|text|1554|1764|CONCLUSIONS: The presence of substantial overlap in the pattern of disturbed connectivity between amygdala and frontal, striatal, lingual and cerebellar regions suggests mood state-independent dysconnectivity.
SE|25462396|CONCLUSIONS|ab|10|entity|C0449774|Patterns|spco|||pattern|||0|1000|1610|1617
SE|25462396|CONCLUSIONS|ab|10|entity|C0002708|Amygdaloid structure|bpoc|||amygdala|||0|1000|1652|1660
SE|25462396|CONCLUSIONS|ab|10|entity|C0205123|Coronal|spco|||frontal|||0|828|1665|1672
SE|25462396|CONCLUSIONS|ab|10|entity|C0162512|Neostriatum|bpoc|||striatal|||0|828|1674|1682
SE|25462396|CONCLUSIONS|ab|10|entity|C0040408|Tongue|bpoc|||lingual|||0|828|1684|1691
SE|25462396|CONCLUSIONS|ab|10|entity|C0007765|Cerebellum|bpoc|||cerebellar|||0|872|1696|1706
SE|25462396|CONCLUSIONS|ab|10|entity|C0205147|Region|spco|||regions|||0|872|1707|1714
SE|25462396|CONCLUSIONS|ab|10|entity|C0026516|Mood|menp|||mood|||0|608|1724|1728
SE|25462396|CONCLUSIONS|ab|10|entity|C1442792|State|ftcn|||state|||0|608|1729|1734

SE|25462396|CONCLUSIONS|ab|11|text|1764|1966|The contrasting pattern of functional connectivity between right amygdala and hippocampus in BD and BM provides a novel lead to the probable mechanistic differences in these two extremes of mood states.
SE|25462396|CONCLUSIONS|ab|11|entity|C0449774|Patterns|spco|||pattern|||0|861|1780|1787
SE|25462396|CONCLUSIONS|ab|11|entity|C0205245|Functional|ftcn|||functional|||0|694|1791|1801
SE|25462396|CONCLUSIONS|ab|11|entity|C0205090|Right|spco|||right|||0|888|1823|1828
SE|25462396|CONCLUSIONS|ab|11|entity|C0002708|Amygdaloid structure|bpoc|||amygdala|||0|888|1829|1837
SE|25462396|CONCLUSIONS|ab|11|entity|C1284077|Entire hippocampus|bpoc|||hippocampus|||0|1000|1842|1853
SE|25462396|CONCLUSIONS|ab|11|entity|C0005587|Depression, Bipolar|mobd|||BD|||0|1000|1857|1859
SE|25462396|CONCLUSIONS|ab|11|entity|C0443156|Bipolar|spco|||BM|||0|888|1864|1866
SE|25462396|CONCLUSIONS|ab|11|entity|C0338831|Manic|mobd|||BM|||0|888|1864|1866
SE|25462396|CONCLUSIONS|ab|11|entity|C0679622|novel|inpr|||novel|||0|888|1878|1883
SE|25462396|CONCLUSIONS|ab|11|entity|C0441712|Mechanisms|ftcn|||mechanistic|||0|737|1905|1916
SE|25462396|CONCLUSIONS|ab|11|entity|C1547020|*Difference|qnco|||differences|||0|737|1917|1928
SE|25462396|CONCLUSIONS|ab|11|entity|C0205448|Two|qnco|||two|||0|872|1938|1941
SE|25462396|CONCLUSIONS|ab|11|entity|C0205403|Extreme|qlco|||extremes|||0|872|1942|1950
SE|25462396|CONCLUSIONS|ab|11|entity|C0026516|Mood|menp|||mood|||0|872|1954|1958
SE|25462396|CONCLUSIONS|ab|11|entity|C1442792|State|ftcn|||states|||0|872|1959|1965


SE|25462397||ti|1|text|21|173|When hope and grief intersect: rates and risks of prolonged grief disorder among bereaved individuals and relatives of disappeared persons in Colombia.
SE|25462397||ti|1|entity|C0392347|hope|menp|||hope|||0|1000|26|30
SE|25462397||ti|1|entity|C1521828|Rate|qnco|||rates|||0|966|52|57
SE|25462397||ti|1|entity|C0439590|Prolonged|tmco|||prolonged|||0|802|71|80
SE|25462397||ti|1|entity|C0012634|Disease|dsyn|||disorder|||0|802|87|95
SE|25462397||ti|1|entity|C0237401|Individual|humn|||individuals|||0|861|111|122
SE|25462397||ti|1|entity|C0080103|Relative (related person)|famg|||relatives|||0|1000|127|136
SE|25462397||ti|1|entity|C0027361|Persons|popg|||persons|||0|861|152|159
SE|25462397||ti|1|entity|C0009367|Colombia|geoa|||Colombia|||0|1000|163|171
SE|25462397||ti|1|relation|4|1|C0012634|Disease|dsyn|dsyn|||disorder|||0|802|87|95|PREP|PROCESS_OF||96|101|4|1|C0080103|Relative (related person)|famg,humn|humn|||relatives|||0|1000|127|136
SE|25462397||ti|1|relation|4|1|C0012634|Disease|dsyn|dsyn|||disorder|||0|802|87|95|PREP|PROCESS_OF||96|101|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|861|111|122

SE|25462397|BACKGROUND|ab|1|text|179|383|BACKGROUND: Forced disappearance is a frequent phenomenon in violent conflicts and regimes, yet little is known about unresolved grief processes as a possible outcome of the disappearance of a loved one.
SE|25462397|BACKGROUND|ab|1|entity|C0443221|Forced|ftcn|||Forced|||0|694|191|197
SE|25462397|BACKGROUND|ab|1|entity|C0332183|Frequent|tmco|||frequent|||0|694|217|225
SE|25462397|BACKGROUND|ab|1|entity|C0242151|Violent|mobd|||violent|||0|888|240|247
SE|25462397|BACKGROUND|ab|1|entity|C0009671|Conflict (Psychology)|inbe|||conflicts|||0|888|248|257
SE|25462397|BACKGROUND|ab|1|entity|C0023882|Little's Disease|dsyn|||little|||0|861|275|281
SE|25462397|BACKGROUND|ab|1|entity|C0443342|Unresolved|qlco|||unresolved|||0|747|297|307
SE|25462397|BACKGROUND|ab|1|entity|C1522240|Process|phpr|||processes|||0|747|314|323
SE|25462397|BACKGROUND|ab|1|entity|C0332149|Possible|qlco|||possible|||0|888|329|337
SE|25462397|BACKGROUND|ab|1|entity|C1274040|result|ftcn|||outcome|||0|888|338|345
SE|25462397|BACKGROUND|ab|1|entity|C0024028|Love|menp|||loved|||0|872|372|377
SE|25462397|BACKGROUND|ab|1|entity|C0205447|One|qnco|||one|||0|872|378|381

SE|25462397|BACKGROUND|ab|2|text|383|662|This study investigates prolonged grief disorder (PGD) and its risk factors in a sample of persons who lost a significant other to disappearance as compared with a sample of bereaved individuals, both groups having experienced displacement due to the armed conflict in Colombia.
SE|25462397|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|388|393
SE|25462397|BACKGROUND|ab|2|entity|C0439590|Prolonged|tmco|||prolonged|||0|802|407|416
SE|25462397|BACKGROUND|ab|2|entity|C0012634|Disease|dsyn|||disorder|||0|802|423|431
SE|25462397|BACKGROUND|ab|2|entity|C0035648|risk factors|qnco|||risk factors|||0|1000|446|458
SE|25462397|BACKGROUND|ab|2|entity|C0027361|Persons|popg|||persons|||0|1000|474|481
SE|25462397|BACKGROUND|ab|2|entity|C0337610|significant other|popg|||significant other|||0|1000|493|510
SE|25462397|BACKGROUND|ab|2|entity|C0237401|Individual|humn|||individuals|||0|861|566|577
SE|25462397|BACKGROUND|ab|2|entity|C0596545|experience|menp|||experienced|||0|623|598|609
SE|25462397|BACKGROUND|ab|2|entity|C0009367|Colombia|geoa|||Colombia|||0|1000|652|660

SE|25462397|METHOD|ab|3|text|662|925|METHOD: In a cross-sectional study conducted in four Colombian provinces, 73 persons who lost a significant other to disappearance and 222 bereaved individuals completed measures of PGD (PG-13), depression (HSCL-25), and PTSD (PCL-C) via face-to-face interviews.
SE|25462397|METHOD|ab|3|entity|C0025663|Methods|inpr|||METHOD|||0|1000|662|668
SE|25462397|METHOD|ab|3|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional study|||0|1000|675|696
SE|25462397|METHOD|ab|3|entity|C0205450|Four|qnco|||four|||0|840|710|714
SE|25462397|METHOD|ab|3|entity|C1553372|Colombian|popg|||Colombian|||0|840|715|724
SE|25462397|METHOD|ab|3|entity|C1514578|Province|geoa|||provinces|||0|840|725|734
SE|25462397|METHOD|ab|3|entity|C0027361|Persons|popg|||persons|||0|861|739|746
SE|25462397|METHOD|ab|3|entity|C0337610|significant other|popg|||significant other|||0|1000|758|775
SE|25462397|METHOD|ab|3|entity|C0237401|Individual|humn|||individuals|||0|827|810|821
SE|25462397|METHOD|ab|3|entity|C0079809|Measures|qnco|||measures|||0|1000|832|840
SE|25462397|METHOD|ab|3|entity|C0439590|Prolonged|tmco|||PGD|||0|802|844|847
SE|25462397|METHOD|ab|3|entity|C0012634|Disease|dsyn|||PGD|||0|802|844|847
SE|25462397|METHOD|ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|857|867
SE|25462397|METHOD|ab|3|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|883|887
SE|25462397|METHOD|ab|3|entity|C1333569|FLT4 gene|gngm|2324|FLT4|PCL-C|||0|872|889|894
SE|25462397|METHOD|ab|3|entity|C1550513|via|idcn|||via|||0|917|896|899
SE|25462397|METHOD|ab|3|entity|C0681912|face-to-face interview|resa|||face-to-face interviews|||0|917|900|923

SE|25462397|METHOD|ab|4|text|925|1092|Trauma- and loss-related variables, including the extent to which significant others of disappeared persons hoped that their loved one was still alive, were assessed.
SE|25462397|METHOD|ab|4|entity|C0043251|Wounds and Injuries|inpo|||Trauma|||0|1000|925|931
SE|25462397|METHOD|ab|4|entity|C1517945|Loss|qnco|||loss|||0|840|937|941
SE|25462397|METHOD|ab|4|entity|C1522149|Related|ftcn|||related|||0|840|942|949
SE|25462397|METHOD|ab|4|entity|C0439828|Variable|qlco|||variables|||0|840|950|959
SE|25462397|METHOD|ab|4|entity|C0439792|Extent|spco|||extent|||0|1000|975|981
SE|25462397|METHOD|ab|4|entity|C0337610|significant other|popg|||significant others|||0|1000|991|1009
SE|25462397|METHOD|ab|4|entity|C0027361|Persons|popg|||persons|||0|861|1025|1032
SE|25462397|METHOD|ab|4|entity|C0024028|Love|menp|||loved|||0|872|1050|1055
SE|25462397|METHOD|ab|4|entity|C0205447|One|qnco|||one|||0|872|1056|1059

SE|25462397|RESULTS|ab|5|text|1092|1258|RESULTS: Results indicated that 23% of participants who lost a significant other to disappearance met criteria for PGD as compared to 31.5% in bereaved participants.
SE|25462397|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1092|1099
SE|25462397|RESULTS|ab|5|entity|C1274040|result|ftcn|||Results|||0|966|1101|1108
SE|25462397|RESULTS|ab|5|entity|C0679646|Participant|popg|||participants|||0|966|1131|1143
SE|25462397|RESULTS|ab|5|entity|C0337610|significant other|popg|||significant other|||0|1000|1155|1172
SE|25462397|RESULTS|ab|5|entity|C0243161|criteria|inpr|||criteria|||0|790|1194|1202
SE|25462397|RESULTS|ab|5|entity|C0439590|Prolonged|tmco|||PGD|||0|802|1207|1210
SE|25462397|RESULTS|ab|5|entity|C0012634|Disease|dsyn|||PGD|||0|802|1207|1210
SE|25462397|RESULTS|ab|5|entity|C0679646|Participant|popg|||participants|||0|827|1244|1256
SE|25462397|RESULTS|ab|5|relation|6|1|C0012634|Disease|dsyn|dsyn|||PGD|||0|802|1207|1210|PREP|PROCESS_OF||1232|1234|1|1|C0679646|Participant|popg,humn|humn|||participants|||0|827|1244|1256

SE|25462397|RESULTS|ab|6|text|1258|1410|No differences were found between the two groups in terms of symptom severity of PGD, depression, posttraumatic stress disorder, or traumatic exposure.
SE|25462397|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||differences|||0|966|1261|1272
SE|25462397|RESULTS|ab|6|entity|C0205448|Two|qnco|||two|||0|888|1296|1299
SE|25462397|RESULTS|ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|1300|1306
SE|25462397|RESULTS|ab|6|entity|C1457887|Symptoms|sosy|||symptom|||0|888|1319|1326
SE|25462397|RESULTS|ab|6|entity|C0439793|Severities|qlco|||severity|||0|888|1327|1335
SE|25462397|RESULTS|ab|6|entity|C0439590|Prolonged|tmco|||PGD|||0|802|1339|1342
SE|25462397|RESULTS|ab|6|entity|C0012634|Disease|dsyn|||PGD|||0|802|1339|1342
SE|25462397|RESULTS|ab|6|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1344|1354
SE|25462397|RESULTS|ab|6|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||posttraumatic stress disorder|||0|1000|1356|1385
SE|25462397|RESULTS|ab|6|entity|C0332663|Traumatic|ftcn|||traumatic|||0|694|1390|1399
SE|25462397|RESULTS|ab|6|relation|0|0|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|1344|1354|SPEC|ISA||1339|1354|0|0|C0012634|Disease|dsyn|dsyn|||PGD|||0|802|1339|1342

SE|25462397|RESULTS|ab|7|text|1410|1718|Regression analysis indicated that, among relatives and friends of disappeared persons, the extent of hope predicted PGD above and beyond depression severity whereas among bereaved persons, PGD was predicted by time since the loss, the number of traumatic events and symptom severity of PTSD and depression.
SE|25462397|RESULTS|ab|7|entity|C0034980|Regression Analysis|qnco|||Regression analysis|||0|1000|1410|1429
SE|25462397|RESULTS|ab|7|entity|C0080103|Relative (related person)|famg|||relatives|||0|1000|1452|1461
SE|25462397|RESULTS|ab|7|entity|C0079382|friend|popg|||friends|||0|1000|1466|1473
SE|25462397|RESULTS|ab|7|entity|C0027361|Persons|popg|||persons|||0|861|1489|1496
SE|25462397|RESULTS|ab|7|entity|C0439792|Extent|spco|||extent|||0|1000|1502|1508
SE|25462397|RESULTS|ab|7|entity|C0392347|hope|menp|||hope|||0|1000|1512|1516
SE|25462397|RESULTS|ab|7|entity|C0439590|Prolonged|tmco|||PGD|||0|802|1527|1530
SE|25462397|RESULTS|ab|7|entity|C0012634|Disease|dsyn|||PGD|||0|802|1527|1530
SE|25462397|RESULTS|ab|7|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1548|1558
SE|25462397|RESULTS|ab|7|entity|C0439793|Severities|qlco|||severity|||0|888|1559|1567
SE|25462397|RESULTS|ab|7|entity|C0027361|Persons|popg|||persons|||0|861|1591|1598
SE|25462397|RESULTS|ab|7|entity|C0439590|Prolonged|tmco|||PGD|||0|802|1600|1603
SE|25462397|RESULTS|ab|7|entity|C0012634|Disease|dsyn|||PGD|||0|802|1600|1603
SE|25462397|RESULTS|ab|7|entity|C0040223|Time|tmco|||time|||0|1000|1621|1625
SE|25462397|RESULTS|ab|7|entity|C1517945|Loss|qnco|||loss|||0|1000|1636|1640
SE|25462397|RESULTS|ab|7|entity|C0237753|Numbers|qnco|||number|||0|1000|1646|1652
SE|25462397|RESULTS|ab|7|entity|C0332663|Traumatic|ftcn|||traumatic|||0|888|1656|1665
SE|25462397|RESULTS|ab|7|entity|C0441471|Events|evnt|||events|||0|888|1666|1672
SE|25462397|RESULTS|ab|7|entity|C1457887|Symptoms|sosy|||symptom|||0|888|1677|1684
SE|25462397|RESULTS|ab|7|entity|C0439793|Severities|qlco|||severity|||0|888|1685|1693
SE|25462397|RESULTS|ab|7|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|1697|1701
SE|25462397|RESULTS|ab|7|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1706|1716
SE|25462397|RESULTS|ab|7|relation|8|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|1548|1558|PREP|PROCESS_OF||1576|1581|9|1|C0027361|Persons|popg,humn|humn|||persons|||0|861|1591|1598

SE|25462397|LIMITATIONS|ab|8|text|1718|1828|LIMITATIONS: The instruments were not validated for use in Colombia; generalizability of findings is limited.
SE|25462397|LIMITATIONS|ab|8|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1718|1729
SE|25462397|LIMITATIONS|ab|8|entity|C0243113|instruments|mnob|||instruments|||0|1000|1735|1746
SE|25462397|LIMITATIONS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1752|1755
SE|25462397|LIMITATIONS|ab|8|entity|C0009367|Colombia|geoa|||Colombia|||0|1000|1777|1785
SE|25462397|LIMITATIONS|ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1807|1815

SE|25462397|CONCLUSION|ab|9|text|1828|1995|CONCLUSION: Forced disappearance is related to prolonged grief reactions, particularly when those left behind maintain hope that the disappeared person is still alive.
SE|25462397|CONCLUSION|ab|9|entity|C0443221|Forced|ftcn|||Forced|||0|694|1840|1846
SE|25462397|CONCLUSION|ab|9|entity|C0439590|Prolonged|tmco|||prolonged|||0|890|1875|1884
SE|25462397|CONCLUSION|ab|9|entity|C0018235|Grief reaction|menp|||grief reactions|||0|890|1885|1900
SE|25462397|CONCLUSION|ab|9|entity|C0205091|Left|spco|||left|||0|1000|1926|1930
SE|25462397|CONCLUSION|ab|9|entity|C0205095|Dorsal|spco|||behind|||0|1000|1931|1937
SE|25462397|CONCLUSION|ab|9|entity|C0027361|Persons|popg|||person|||0|861|1973|1979


SE|25462399||ti|1|text|21|164|Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up--results from the Finnish Health 2011 Survey.
SE|25462399||ti|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|1000|50|75
SE|25462399||ti|1|entity|C0013415|Dysthymic Disorder|mobd|||dysthymia|||0|1000|80|89
SE|25462399||ti|1|entity|C0439234|year|tmco|||year|||0|861|103|107
SE|25462399||ti|1|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|108|117
SE|25462399||ti|1|entity|C1274040|result|ftcn|||results|||0|966|119|126
SE|25462399||ti|1|entity|C0018762|Health Surveys|resa|||Health 2011 Survey|||0|875|144|162

SE|25462399|BACKGROUND|ab|1|text|170|320|BACKGROUND: Up-to-date epidemiological data on depressive disorders is needed to understand changes in population health and health care utilization.
SE|25462399|BACKGROUND|ab|1|entity|C0014507|Epidemiology|bmod|||epidemiological|||0|693|193|208
SE|25462399|BACKGROUND|ab|1|entity|C1511726|Data|idcn|||data|||0|693|209|213
SE|25462399|BACKGROUND|ab|1|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|217|237
SE|25462399|BACKGROUND|ab|1|entity|C1257890|Population Group|popg|||population|||0|888|273|283
SE|25462399|BACKGROUND|ab|1|entity|C0018684|Health|idcn|||health|||0|888|284|290
SE|25462399|BACKGROUND|ab|1|entity|C0237939|health care utilization|hlca|||health care utilization|||0|1000|295|318

SE|25462399|BACKGROUND|ab|2|text|320|483|This study aims to assess the prevalence of major depressive disorder (MDD) and dysthymia in the Finnish population and possible changes during the past 11 years.
SE|25462399|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|325|330
SE|25462399|BACKGROUND|ab|2|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|1000|364|389
SE|25462399|BACKGROUND|ab|2|entity|C0013415|Dysthymic Disorder|mobd|||dysthymia|||0|1000|400|409
SE|25462399|BACKGROUND|ab|2|entity|C1257890|Population Group|popg|||population|||0|861|425|435
SE|25462399|BACKGROUND|ab|2|entity|C0332149|Possible|qlco|||possible|||0|872|440|448
SE|25462399|BACKGROUND|ab|2|entity|C1444637|Past|tmco|||past|||0|802|468|472
SE|25462399|BACKGROUND|ab|2|entity|C0439234|year|tmco|||years|||0|802|476|481
SE|25462399|BACKGROUND|ab|2|relation|4|1|C0013415|Dysthymic Disorder|mobd|mobd|||dysthymia|||0|1000|400|409|PREP|PROCESS_OF||410|412|3|1|C1257890|Population Group|popg,humn|humn|||population|||0|861|425|435
SE|25462399|BACKGROUND|ab|2|relation|4|1|C1269683|Major Depressive Disorder|mobd|mobd|||major depressive disorder|||0|1000|364|389|PREP|PROCESS_OF||410|412|3|1|C1257890|Population Group|popg,humn|humn|||population|||0|861|425|435

SE|25462399|METHODS|ab|3|text|483|686|METHODS: In a nationally representative sample of Finns aged 30 and above (BRIF8901), depressive disorders were diagnosed with the Composite International Diagnostic Interview (M-CIDI) in 2000 and 2011.
SE|25462399|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|483|490
SE|25462399|METHODS|ab|3|entity|C0337803|Finns|popg|||Finns|||0|1000|533|538
SE|25462399|METHODS|ab|3|entity|C1282910|Upper|spco|||above|||0|1000|551|556
SE|25462399|METHODS|ab|3|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|569|589
SE|25462399|METHODS|ab|3|entity|C0451085|Composite international diagnostic interview|inpr|||Composite International Diagnostic Interview|||0|1000|614|658
SE|25462399|METHODS|ab|3|entity|C0441923|M+|inpr|||M-CIDI|||0|888|660|666
SE|25462399|METHODS|ab|3|entity|C0451085|Composite international diagnostic interview|inpr|||M-CIDI|||0|888|660|666

SE|25462399|METHODS|ab|4|text|686|876|To account for nonresponse, two methods were compared: multiple imputation (MI) utilizing data from the hospital discharge register and from the interview in 2000 and statistical weighting.
SE|25462399|METHODS|ab|4|entity|C0205448|Two|qnco|||two|||0|888|714|717
SE|25462399|METHODS|ab|4|entity|C0025663|Methods|inpr|||methods|||0|888|718|725
SE|25462399|METHODS|ab|4|entity|C0439064|Numerous|qnco|||multiple|||0|791|741|749
SE|25462399|METHODS|ab|4|entity|C1511726|Data|idcn|||data|||0|791|776|780
SE|25462399|METHODS|ab|4|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|840|790|798
SE|25462399|METHODS|ab|4|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|840|799|808
SE|25462399|METHODS|ab|4|entity|C0600375|Registers|inpr|||register|||0|840|809|817
SE|25462399|METHODS|ab|4|entity|C0021822|Interview|inpr,resa|||interview|||0|1000|831|840
SE|25462399|METHODS|ab|4|entity|C0871431|Statistical Weighting|qnco,resa|||statistical weighting|||0|1000|853|874

SE|25462399|RESULTS|ab|5|text|876|1123|RESULTS: The MI-corrected 12-month prevalence of MDD was 7.4% (95% CI 5.7-9.0) and of dysthymia was 4.5% (95% CI 3.1-5.9), whereas the corresponding figures using weights were 5.4% (95% CI 4.7-6.1) for MDD and 2.0% (95% CI 1.6-2.4) for dysthymia.
SE|25462399|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|876|883
SE|25462399|RESULTS|ab|5|entity|C0439064|Numerous|qnco|||MI|||0|694|889|891
SE|25462399|RESULTS|ab|5|entity|C0439231|month|tmco|||month|||0|660|905|910
SE|25462399|RESULTS|ab|5|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|925|928
SE|25462399|RESULTS|ab|5|entity|C0013415|Dysthymic Disorder|mobd|||dysthymia|||0|1000|962|971
SE|25462399|RESULTS|ab|5|entity|C0450367|4/5|qnco|||4.5|||0|1000|976|979
SE|25462399|RESULTS|ab|5|entity|C0043100|Weight|qnco|||weights|||0|1000|1039|1046
SE|25462399|RESULTS|ab|5|entity|C0439084|>5|qnco|||5|||0|861|1052|1053
SE|25462399|RESULTS|ab|5|entity|C0387382|CI 4|aapp,phsu|||CI 4|||0|827|1062|1066
SE|25462399|RESULTS|ab|5|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|1078|1081
SE|25462399|RESULTS|ab|5|entity|C0387382|CI 4|aapp,phsu|||CI 1.6-2.4|||0|876|1096|1106
SE|25462399|RESULTS|ab|5|entity|C0013415|Dysthymic Disorder|mobd|||dysthymia|||0|1000|1112|1121

SE|25462399|RESULTS|ab|6|text|1123|1245|Women (OR 2.33, 95% CI 1.6-3.4) and unmarried people (OR 1.54, 95% CI 1.2-2.0) had a higher risk of depressive disorders.
SE|25462399|RESULTS|ab|6|entity|C0043210|Woman|popg|||Women|||0|1000|1123|1128
SE|25462399|RESULTS|ab|6|entity|C0387382|CI 4|aapp,phsu|||CI 1.6-3.4|||0|876|1143|1153
SE|25462399|RESULTS|ab|6|entity|C0087136|Unmarried|popg|||unmarried|||0|888|1159|1168
SE|25462399|RESULTS|ab|6|entity|C0027361|Persons|popg|||people|||0|888|1169|1175
SE|25462399|RESULTS|ab|6|entity|C0067503|N-(3-N-(benzyloxycarbonyl)amino-1-carboxypropyl)leucyl-O-methyltyrosine N-methylamide|aapp,phsu|||CI 1.2|||0|839|1190|1196
SE|25462399|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|872|1208|1214
SE|25462399|RESULTS|ab|6|entity|C0035647|Risk|qlco|||risk|||0|872|1215|1219
SE|25462399|RESULTS|ab|6|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|1223|1243
SE|25462399|RESULTS|ab|6|relation|0|0|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|1223|1243|INFER|PROCESS_OF(SPEC)||1159|1175|0|0|C0087136|Unmarried|popg,humn|popg|||unmarried|||0|888|1159|1168
SE|25462399|RESULTS|ab|6|relation|0|0|C0087136|Unmarried|popg,humn|popg|||unmarried|||0|888|1159|1168|MOD/HEAD|ISA||1159|1175|0|0|C0027361|Persons|popg,humn|popg|||people|||0|888|1169|1175
SE|25462399|RESULTS|ab|6|relation|2|2|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|1223|1243|AUX|PROCESS_OF||1202|1205|2|1|C0027361|Persons|popg,humn|humn|||people|||0|888|1169|1175

SE|25462399|RESULTS|ab|7|text|1245|1383|There was a significant increase in the prevalence of depressive disorders during the follow-up period from 7.3% in 2000 to 9.6% in 2011.
SE|25462399|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significant|||0|888|1257|1268
SE|25462399|RESULTS|ab|7|entity|C0442805|Increase|ftcn|||increase|||0|888|1269|1277
SE|25462399|RESULTS|ab|7|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|1299|1319
SE|25462399|RESULTS|ab|7|entity|C1522577|follow-up|hlca|||follow-up|||0|901|1331|1340
SE|25462399|RESULTS|ab|7|entity|C0439531|/period|tmco|||period|||0|901|1341|1347

SE|25462399|RESULTS|ab|8|text|1383|1479|Prevalences were two percentage points higher, on average, when using MI compared to weighting.
SE|25462399|RESULTS|ab|8|entity|C0033105|Statistical Prevalence|qnco|||Prevalences|||0|1000|1383|1394
SE|25462399|RESULTS|ab|8|entity|C0205448|Two|qnco|||two|||0|888|1400|1403
SE|25462399|RESULTS|ab|8|entity|C0439165|Percent (qualifier value)|qnco|||percentage|||0|888|1404|1414
SE|25462399|RESULTS|ab|8|entity|C0205250|High|qlco|||higher|||0|966|1422|1428
SE|25462399|RESULTS|ab|8|entity|C1510992|Average|qnco|||average|||0|1000|1433|1440
SE|25462399|RESULTS|ab|8|entity|C0439064|Numerous|qnco|||MI|||0|694|1453|1455

SE|25462399|RESULTS|ab|9|text|1479|1599|Hospital treatments for depressive disorders and other mental disorders were strongly associated with nonparticipation.
SE|25462399|RESULTS|ab|9|entity|C0019994|Hospitals|hcro,mnob|||Hospital|||0|888|1479|1487
SE|25462399|RESULTS|ab|9|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|888|1488|1498
SE|25462399|RESULTS|ab|9|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|1503|1523
SE|25462399|RESULTS|ab|9|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|1534|1550
SE|25462399|RESULTS|ab|9|relation|0|0|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|1503|1523|SPEC|ISA||1503|1550|0|0|C0004936|Mental disorders|mobd|mobd|||mental disorders|||0|1000|1534|1550
SE|25462399|RESULTS|ab|9|relation|0|0|C0087111|Therapeutic procedure|topp|topp|||treatments|||0|888|1488|1498|INFER|TREATS(SPEC)||1503|1550|0|0|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|1503|1523
SE|25462399|RESULTS|ab|9|relation|1|1|C0087111|Therapeutic procedure|topp|topp|||treatments|||0|888|1488|1498|PREP|TREATS||1499|1502|3|1|C0004936|Mental disorders|mobd|mobd|||mental disorders|||0|1000|1534|1550
SE|25462399|RESULTS|ab|9|relation|1|1|C0087111|Therapeutic procedure|topp|topp|||treatments|||0|888|1488|1498|PREP|TREATS||1499|1502|3|1|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|1503|1523

SE|25462399|LIMITATIONS|ab|10|text|1599|1724|LIMITATIONS: The CIDI response rate dropped from 75% in 2000 to 57% in 2011, but this was accounted for by MI and weighting.
SE|25462399|LIMITATIONS|ab|10|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1599|1610
SE|25462399|LIMITATIONS|ab|10|entity|C0451085|Composite international diagnostic interview|inpr|||CIDI|||0|901|1616|1620
SE|25462399|LIMITATIONS|ab|10|entity|C0237629|Frequency of Responses|tmco|||response rate|||0|901|1621|1634
SE|25462399|LIMITATIONS|ab|10|entity|C0439064|Numerous|qnco|||MI|||0|694|1706|1708

SE|25462399|CONCLUSIONS|ab|11|text|1724|1806|CONCLUSIONS: Depressive disorders are a growing public health concern in Finland.
SE|25462399|CONCLUSIONS|ab|11|entity|C0011581|Depressive disorder|mobd|||Depressive disorders|||0|1000|1737|1757
SE|25462399|CONCLUSIONS|ab|11|entity|C0018684|Health|idcn|||health|||0|645|1779|1785
SE|25462399|CONCLUSIONS|ab|11|entity|C0016132|Finland|geoa|||Finland|||0|1000|1797|1804

SE|25462399|CONCLUSIONS|ab|12|text|1806|1946|Non-participation of persons with severe mental disorders may bias the prevalence estimates of mental disorders in population-based studies.
SE|25462399|CONCLUSIONS|ab|12|entity|C0679823|participation|inbe|||participation|||0|861|1810|1823
SE|25462399|CONCLUSIONS|ab|12|entity|C0027361|Persons|popg|||persons|||0|1000|1827|1834
SE|25462399|CONCLUSIONS|ab|12|entity|C0205082|Severe|qlco|||severe|||0|901|1840|1846
SE|25462399|CONCLUSIONS|ab|12|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|901|1847|1863
SE|25462399|CONCLUSIONS|ab|12|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|1901|1917
SE|25462399|CONCLUSIONS|ab|12|entity|C0681876|Population Study|resa|||population-based studies|||0|879|1921|1945
SE|25462399|CONCLUSIONS|ab|12|relation|4|1|C0004936|Mental disorders|mobd|mobd|||mental disorders|||0|901|1847|1863|PREP|PROCESS_OF||1835|1839|2|1|C0027361|Persons|popg,humn|humn|||persons|||0|1000|1827|1834


SE|25462398||ti|1|text|21|125|Perinatal oxytocin increases the risk of offspring bipolar disorder and childhood cognitive impairment.
SE|25462398||ti|1|entity|C0178795|Perinatal|tmco|||Perinatal|||0|888|21|30
SE|25462398||ti|1|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin|||0|888|31|39
SE|25462398||ti|1|entity|C0035647|Risk|qlco|||risk|||0|1000|54|58
SE|25462398||ti|1|entity|C0680063|Offspring|famg|||offspring|||0|901|62|71
SE|25462398||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|901|72|88
SE|25462398||ti|1|entity|C0231335|Childhood|tmco|||childhood|||0|901|93|102
SE|25462398||ti|1|entity|C0338656|Impaired cognition|fndg|||cognitive impairment|||0|901|103|123
SE|25462398||ti|1|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|901|72|88|MOD/HEAD|PROCESS_OF||62|88|0|0|C0680063|Offspring|famg,humn|humn|||offspring|||0|901|62|71
SE|25462398||ti|1|relation|1|1|C0030095|Oxytocin|aapp,gngm,horm,phsu|aapp|||oxytocin|||0|888|31|39|COMPLEX|PREDISPOSES||40|58|2|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|901|72|88

SE|25462398|BACKGROUND|ab|1|text|131|339|BACKGROUND: We tested the hypothesis that perinatal oxytocin, given to pregnant women to induce labor, is related to offspring bipolar disorder (BP) and worse childhood cognitive performance among offspring.
SE|25462398|BACKGROUND|ab|1|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|157|167
SE|25462398|BACKGROUND|ab|1|entity|C0178795|Perinatal|tmco|||perinatal|||0|888|173|182
SE|25462398|BACKGROUND|ab|1|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin|||0|888|183|191
SE|25462398|BACKGROUND|ab|1|entity|C0033011|Pregnant Women|popg|||pregnant women|||0|1000|202|216
SE|25462398|BACKGROUND|ab|1|entity|C0022864|Labor (Childbirth)|orgf|||labor|||0|1000|227|232
SE|25462398|BACKGROUND|ab|1|entity|C0680063|Offspring|famg|||offspring|||0|901|248|257
SE|25462398|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|901|258|274
SE|25462398|BACKGROUND|ab|1|entity|C1279889|Deterioration of status|qlco|||worse|||0|833|284|289
SE|25462398|BACKGROUND|ab|1|entity|C0231335|Childhood|tmco|||childhood|||0|833|290|299
SE|25462398|BACKGROUND|ab|1|entity|C1516691|Cognitive|ftcn|||cognitive|||0|833|300|309
SE|25462398|BACKGROUND|ab|1|entity|C0597198|Performance|inbe|||performance|||0|833|310|321
SE|25462398|BACKGROUND|ab|1|entity|C0680063|Offspring|famg|||offspring|||0|1000|328|337
SE|25462398|BACKGROUND|ab|1|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|901|258|274|MOD/HEAD|PROCESS_OF||248|274|0|0|C0680063|Offspring|famg,humn|humn|||offspring|||0|901|248|257
SE|25462398|BACKGROUND|ab|1|relation|3|1|C0030095|Oxytocin|aapp,gngm,horm,phsu|horm|||oxytocin|||0|888|183|191|VERB|ADMINISTERED_TO||193|198|6|1|C0033011|Pregnant Women|popg,humn|humn|||pregnant women|||0|1000|202|216
SE|25462398|BACKGROUND|ab|1|relation|5|1|C0022864|Labor (Childbirth)|orgf|orgf|||labor|||0|1000|227|232|VERB|AFFECTS||237|244|4|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|901|258|274
SE|25462398|BACKGROUND|ab|1|relation|8|1|C0597198|Performance|inbe|inbe|||performance|||0|833|310|321|PREP|PROCESS_OF||322|327|1|1|C0680063|Offspring|famg,humn|humn|||offspring|||0|1000|328|337

SE|25462398|BACKGROUND|ab|2|text|339|412|We also tested the association between childhood cognition and later BP.
SE|25462398|BACKGROUND|ab|2|entity|C0231335|Childhood|tmco|||childhood|||0|888|378|387
SE|25462398|BACKGROUND|ab|2|entity|C0009240|Cognition|menp|||cognition|||0|888|388|397
SE|25462398|BACKGROUND|ab|2|entity|C0205087|Late|tmco|||later|||0|661|402|407

SE|25462398|METHODS|ab|3|text|412|681|METHODS: A population-based birth cohort derived from the Child Health and Development Study (CHDS) which included nearly all pregnant women receiving obstetric care from the Kaiser Permanente Medical Care Plan, Northern California Region (KPNC) between 1959 and 1966.
SE|25462398|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|412|419
SE|25462398|METHODS|ab|3|entity|C1257890|Population Group|popg|||population|||0|825|423|433
SE|25462398|METHODS|ab|3|entity|C0005615|Birth|orgf|||birth|||0|825|440|445
SE|25462398|METHODS|ab|3|entity|C0599755|cohort|popg|||cohort|||0|825|446|452
SE|25462398|METHODS|ab|3|entity|C0018684|Health|idcn|||Health|||0|736|476|482
SE|25462398|METHODS|ab|3|entity|C0008071|Child Development|orgf|||Child Health and Development|||0|736|470|498
SE|25462398|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||Study|||0|736|499|504
SE|25462398|METHODS|ab|3|entity|C0033011|Pregnant Women|popg|||pregnant women|||0|1000|538|552
SE|25462398|METHODS|ab|3|entity|C0496675|Medical care, unspecified|fndg|||Medical Care|||0|785|605|617
SE|25462398|METHODS|ab|3|entity|C0032074|Cognitive function: planning|menp|||Plan|||0|785|618|622
SE|25462398|METHODS|ab|3|entity|C0006754|California|geoa|||California|||0|790|633|643
SE|25462398|METHODS|ab|3|entity|C0205147|Region|spco|||Region|||0|790|644|650

SE|25462398|METHODS|ab|4|text|681|759|Prospectively obtained medical and offspring cognitive performance were used.
SE|25462398|METHODS|ab|4|entity|C0205476|Medical|ftcn|||medical|||0|1000|704|711
SE|25462398|METHODS|ab|4|entity|C0680063|Offspring|famg|||offspring|||0|851|716|725
SE|25462398|METHODS|ab|4|entity|C1516691|Cognitive|ftcn|||cognitive|||0|851|726|735
SE|25462398|METHODS|ab|4|entity|C0597198|Performance|inbe|||performance|||0|851|736|747

SE|25462398|METHODS|ab|5|text|759|837|Potential cases with BP from the cohort were identified by database linkages.
SE|25462398|METHODS|ab|5|entity|C0237399|Potential|qlco|||Potential|||0|888|759|768
SE|25462398|METHODS|ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|769|774
SE|25462398|METHODS|ab|5|entity|C0599755|cohort|popg|||cohort|||0|1000|792|798
SE|25462398|METHODS|ab|5|entity|C0242356|Databases|inpr|||database|||0|694|818|826

SE|25462398|METHODS|ab|6|text|837|905|This protocol identified 94 cases who were matched 1:8 to controls.
SE|25462398|METHODS|ab|6|entity|C0442711|Protocols documentation|inpr|||protocol|||0|1000|842|850
SE|25462398|METHODS|ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|865|870
SE|25462398|METHODS|ab|6|entity|C0243148|control|ftcn|||controls|||0|966|895|903

SE|25462398|RESULTS|ab|7|text|905|993|RESULTS: Perinatal oxytocin was associated with a 2.4 times increased odds of later BP.
SE|25462398|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|905|912
SE|25462398|RESULTS|ab|7|entity|C0178795|Perinatal|tmco|||Perinatal|||0|888|914|923
SE|25462398|RESULTS|ab|7|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin|||0|888|924|932
SE|25462398|RESULTS|ab|7|entity|C0040223|Time|tmco|||times|||0|545|959|964
SE|25462398|RESULTS|ab|7|entity|C0205217|Increased|qnco|||increased|||0|545|965|974
SE|25462398|RESULTS|ab|7|entity|C0205087|Late|tmco|||later|||0|661|983|988

SE|25462398|RESULTS|ab|8|text|993|1127|Oxytocin was also associated with decreased performance on the Raven Matrices, but not on the Peabody Picture Vocabulary Test (PPVT).
SE|25462398|RESULTS|ab|8|entity|C0030095|Oxytocin|aapp,horm,phsu|||Oxytocin|||0|1000|993|1001
SE|25462398|RESULTS|ab|8|entity|C0205216|Decreased|qnco|||decreased|||0|888|1027|1036
SE|25462398|RESULTS|ab|8|entity|C0597198|Performance|inbe|||performance|||0|888|1037|1048
SE|25462398|RESULTS|ab|8|entity|C1449597|Ravens|bird|||Raven|||0|872|1056|1061
SE|25462398|RESULTS|ab|8|entity|C0331858|Matrix|hcro|||Matrices|||0|872|1062|1070
SE|25462398|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1076|1079
SE|25462398|RESULTS|ab|8|entity|C0451373|Peabody picture vocabulary test|inpr|||Peabody Picture Vocabulary Test|||0|1000|1087|1118

SE|25462398|RESULTS|ab|9|text|1127|1181|Childhood cognition was not associated with later BP.
SE|25462398|RESULTS|ab|9|entity|C0231335|Childhood|tmco|||Childhood|||0|888|1127|1136
SE|25462398|RESULTS|ab|9|entity|C0009240|Cognition|menp|||cognition|||0|888|1137|1146
SE|25462398|RESULTS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1151|1154
SE|25462398|RESULTS|ab|9|entity|C0205087|Late|tmco|||later|||0|661|1171|1176

SE|25462398|LIMITATIONS|ab|10|text|1181|1260|LIMITATIONS: Loss to follow-up must be considered in all birth cohort studies.
SE|25462398|LIMITATIONS|ab|10|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1181|1192
SE|25462398|LIMITATIONS|ab|10|entity|C1517945|Loss|qnco|||Loss|||0|1000|1194|1198
SE|25462398|LIMITATIONS|ab|10|entity|C1522577|follow-up|hlca|||follow-up|||0|901|1202|1211
SE|25462398|LIMITATIONS|ab|10|entity|C0005615|Birth|orgf|||birth|||0|901|1238|1243
SE|25462398|LIMITATIONS|ab|10|entity|C0009247|Cohort Studies|qnco|||cohort studies|||0|901|1244|1258

SE|25462398|LIMITATIONS|ab|11|text|1260|1410|In addition, the childhood cognitive battery did not include tests related to multiple domains of cognition which have been associated with later BP.
SE|25462398|LIMITATIONS|ab|11|entity|C0231335|Childhood|tmco|||childhood|||0|623|1277|1286
SE|25462398|LIMITATIONS|ab|11|entity|C1516691|Cognitive|ftcn|||cognitive|||0|623|1287|1296
SE|25462398|LIMITATIONS|ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|1309|1312
SE|25462398|LIMITATIONS|ab|11|entity|C0392366|Tests|inpr|||tests|||0|1000|1321|1326
SE|25462398|LIMITATIONS|ab|11|entity|C0439064|Numerous|qnco|||multiple|||0|694|1338|1346
SE|25462398|LIMITATIONS|ab|11|entity|C0009240|Cognition|menp|||cognition|||0|1000|1358|1367
SE|25462398|LIMITATIONS|ab|11|entity|C0205087|Late|tmco|||later|||0|661|1400|1405

SE|25462398|LIMITATIONS|ab|12|text|1410|1485|A third limitation is the modest sample size of those exposed to oxytocin.
SE|25462398|LIMITATIONS|ab|12|entity|C0205437|Third|qnco|||third|||0|888|1412|1417
SE|25462398|LIMITATIONS|ab|12|entity|C0449295|Limitation|ftcn|||limitation|||0|888|1418|1428
SE|25462398|LIMITATIONS|ab|12|entity|C0242618|Sample Size|qnco|||sample size|||0|901|1443|1454
SE|25462398|LIMITATIONS|ab|12|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin|||0|1000|1475|1483

SE|25462398|CONCLUSIONS|ab|13|text|1485|1623|CONCLUSIONS: This study provides evidence for a potentially important perinatal risk factor for BP and cognitive impairment in childhood.
SE|25462398|CONCLUSIONS|ab|13|entity|C0008972|Clinical Research|resa|||study|||0|1000|1503|1508
SE|25462398|CONCLUSIONS|ab|13|entity|C1171167|Perinatal risk|fndg|||perinatal risk|||0|785|1555|1569
SE|25462398|CONCLUSIONS|ab|13|entity|C1521761|Factor|ftcn|||factor|||0|785|1570|1576
SE|25462398|CONCLUSIONS|ab|13|entity|C0338656|Impaired cognition|fndg|||cognitive impairment|||0|1000|1588|1608
SE|25462398|CONCLUSIONS|ab|13|entity|C0231335|Childhood|tmco|||childhood|||0|1000|1612|1621

SE|25462398|CONCLUSIONS|ab|14|text|1623|1860|While the association between perinatal oxytocin and offspring BP must be viewed cautiously until further studies can attempt to replicate the result, it lends support to the broader view that neurodevelopmental factors contribute to BP.
SE|25462398|CONCLUSIONS|ab|14|entity|C0178795|Perinatal|tmco|||perinatal|||0|888|1653|1662
SE|25462398|CONCLUSIONS|ab|14|entity|C0030095|Oxytocin|aapp,horm,phsu|||oxytocin|||0|888|1663|1671
SE|25462398|CONCLUSIONS|ab|14|entity|C0680063|Offspring|famg|||offspring|||0|694|1676|1685
SE|25462398|CONCLUSIONS|ab|14|entity|C1517331|Further|spco|||further|||0|872|1721|1728
SE|25462398|CONCLUSIONS|ab|14|entity|C0008972|Clinical Research|resa|||studies|||0|872|1729|1736
SE|25462398|CONCLUSIONS|ab|14|entity|C1274040|result|ftcn|||result|||0|1000|1766|1772
SE|25462398|CONCLUSIONS|ab|14|entity|C0332464|Widening|spco|||broader|||0|966|1798|1805
SE|25462398|CONCLUSIONS|ab|14|entity|C0599855|neurodevelopment|ortf|||neurodevelopmental|||0|836|1816|1834
SE|25462398|CONCLUSIONS|ab|14|entity|C1521761|Factor|ftcn|||factors|||0|836|1835|1842
SE|25462398|CONCLUSIONS|ab|14|relation|7|6|C0030095|Oxytocin|aapp,gngm,horm,phsu|aapp|||oxytocin|||0|888|1663|1671|NOM|AFFECTS||1835|1842|7|0|C0599855|neurodevelopment|ortf|ortf|||neurodevelopmental|||0|836|1816|1834


SE|25462400||ti|1|text|21|131|Validity of Gotland Male Depression Scale for male depression in a community study: the Sudurnesjamenn study.
SE|25462400||ti|1|entity|C0679604|depression scale|diap,inpr|||Depression Scale|||0|861|46|62
SE|25462400||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|861|72|82
SE|25462400||ti|1|entity|C0009462|Community|geoa|||community|||0|888|88|97
SE|25462400||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|888|98|103
SE|25462400||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|861|124|129

SE|25462400|BACKGROUND|ab|1|text|137|365|BACKGROUND: Several studies suggest a "male depressive syndrome", where not only the standard symptoms of major depressive disorder (MDD) but also symptoms of anxiety, anger, irritability and antisocial behaviour are prominent.
SE|25462400|BACKGROUND|ab|1|entity|C0443302|Several|qnco|||Several|||0|872|149|156
SE|25462400|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|157|164
SE|25462400|BACKGROUND|ab|1|entity|C0086133|Depressive Syndrome|mobd|||depressive syndrome|||0|901|181|200
SE|25462400|BACKGROUND|ab|1|entity|C1518422|Not|ftcn|||not|||0|861|209|212
SE|25462400|BACKGROUND|ab|1|entity|C1442989|STANDARD|ftcn|||standard|||0|888|222|230
SE|25462400|BACKGROUND|ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|888|231|239
SE|25462400|BACKGROUND|ab|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|1000|243|268
SE|25462400|BACKGROUND|ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|861|284|292
SE|25462400|BACKGROUND|ab|1|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|296|303
SE|25462400|BACKGROUND|ab|1|entity|C0002957|Anger|menp|||anger|||0|1000|305|310
SE|25462400|BACKGROUND|ab|1|entity|C0022107|Irritable Mood|fndg|||irritability|||0|1000|312|324
SE|25462400|BACKGROUND|ab|1|entity|C0233523|Antisocial behavior|mobd|||antisocial behaviour|||0|1000|329|349
SE|25462400|BACKGROUND|ab|1|entity|C0205402|Prominent|qlco|||prominent|||0|1000|354|363

SE|25462400|METHOD|ab|2|text|365|526|METHOD: In a community study, 534 males were screened for possible depression by the Gotland Male Depression Scale (GMDS) and Beck's Depression Inventory (BDI).
SE|25462400|METHOD|ab|2|entity|C0025663|Methods|inpr|||METHOD|||0|1000|365|371
SE|25462400|METHOD|ab|2|entity|C0009462|Community|geoa|||community|||0|888|378|387
SE|25462400|METHOD|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|388|393
SE|25462400|METHOD|ab|2|entity|C0024554|Male gender|orga|||males|||0|861|399|404
SE|25462400|METHOD|ab|2|entity|C0332149|Possible|qlco|||possible|||0|888|423|431
SE|25462400|METHOD|ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|432|442
SE|25462400|METHOD|ab|2|entity|C0679604|depression scale|diap,inpr|||Depression Scale|||0|861|463|479
SE|25462400|METHOD|ab|2|entity|C0451022|Beck depression inventory|diap|||Beck's Depression Inventory|||0|1000|491|518

SE|25462400|METHOD|ab|3|text|526|618|For comparison psychiatrists examined a sub-sample of healthy and depressive males (n=137).
SE|25462400|METHOD|ab|3|entity|C0033872|Psychiatrist|prog|||psychiatrists|||0|861|541|554
SE|25462400|METHOD|ab|3|entity|C0542339|Inferior|spco|||sub|||0|872|566|569
SE|25462400|METHOD|ab|3|entity|C0870078|Sampling|idcn|||sample|||0|872|570|576
SE|25462400|METHOD|ab|3|entity|C0018684|Health|idcn|||healthy|||0|928|580|587
SE|25462400|METHOD|ab|3|entity|C0024554|Male gender|orga|||males|||0|861|603|608

SE|25462400|METHOD|ab|4|text|618|713|The validity of the GMDS was compared both with the BDI and MDD diagnosis according to DSM-IV.
SE|25462400|METHOD|ab|4|entity|C0679604|depression scale|diap,inpr|||GMDS|||0|861|638|642
SE|25462400|METHOD|ab|4|entity|C0451022|Beck depression inventory|diap|||BDI|||0|1000|670|673
SE|25462400|METHOD|ab|4|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|916|678|681
SE|25462400|METHOD|ab|4|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|916|682|691
SE|25462400|METHOD|ab|4|entity|C0220952|DSM-IV|inpr|||DSM-IV|||0|1000|705|711
SE|25462400|METHOD|ab|4|relation|3|2|C0679604|depression scale|diap,inpr|diap|||GMDS|||0|861|638|642|NOM|DIAGNOSES||682|691|3|0|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|916|678|681

SE|25462400|RESULTS|ab|5|text|713|767|RESULTS: GMDS was as good as BDI for screening males.
SE|25462400|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|713|720
SE|25462400|RESULTS|ab|5|entity|C0679604|depression scale|diap,inpr|||GMDS|||0|861|722|726
SE|25462400|RESULTS|ab|5|entity|C0205170|Good|qlco|||good|||0|1000|734|738
SE|25462400|RESULTS|ab|5|entity|C0451022|Beck depression inventory|diap|||BDI|||0|1000|742|745
SE|25462400|RESULTS|ab|5|entity|C0220908|Screening procedure|hlca|||screening|||0|888|750|759
SE|25462400|RESULTS|ab|5|entity|C0024554|Male gender|orga|||males|||0|888|760|765

SE|25462400|RESULTS|ab|6|text|767|856|ROC-curve analysis gave AUC 0.945 (95% CI 0.923-0.968) for GMDS when tested against BDI.
SE|25462400|RESULTS|ab|6|entity|C0035787|ROC Curve|qnco|||ROC-curve|||0|901|767|776
SE|25462400|RESULTS|ab|6|entity|C0936012|Analysis|resa|||analysis|||0|901|777|785
SE|25462400|RESULTS|ab|6|entity|C0376690|Area Under Curve|qnco|||AUC|||0|827|791|794
SE|25462400|RESULTS|ab|6|entity|C0626183|CI 923|orch,phsu|||CI 0.923|||0|839|806|814
SE|25462400|RESULTS|ab|6|entity|C0679604|depression scale|diap,inpr|||GMDS|||0|861|826|830
SE|25462400|RESULTS|ab|6|entity|C0451022|Beck depression inventory|diap|||BDI|||0|1000|851|854

SE|25462400|RESULTS|ab|7|text|856|1011|Second, when both scales were tested by ROC-curves against DSM-IV, the GMDS had AUC=0.861 (95% CI 0.800-0.921) and BDI had AUC=0.822 (95% CI 0.751-0.893).
SE|25462400|RESULTS|ab|7|entity|C0457385|seconds|tmco|||Second|||0|1000|856|862
SE|25462400|RESULTS|ab|7|entity|C0035787|ROC Curve|qnco|||ROC-curves|||0|983|896|906
SE|25462400|RESULTS|ab|7|entity|C0220952|DSM-IV|inpr|||DSM-IV|||0|1000|915|921
SE|25462400|RESULTS|ab|7|entity|C0679604|depression scale|diap,inpr|||GMDS|||0|861|927|931
SE|25462400|RESULTS|ab|7|entity|C0376690|Area Under Curve|qnco|||AUC|||0|1000|936|939
SE|25462400|RESULTS|ab|7|entity|C0055687|CI 921|orch,phsu|||CI 0.800-0.921|||0|876|951|965
SE|25462400|RESULTS|ab|7|entity|C0451022|Beck depression inventory|diap|||BDI|||0|1000|971|974
SE|25462400|RESULTS|ab|7|entity|C0376690|Area Under Curve|qnco|||AUC|||0|1000|979|982

SE|25462400|RESULTS|ab|8|text|1011|1048|The estimated prevalence was 14-15%.
SE|25462400|RESULTS|ab|8|entity|C0750572|Estimated|qnco|||estimated|||0|694|1015|1024

SE|25462400|LIMITATIONS|ab|9|text|1048|1114|LIMITATIONS: Low participation rate (25%) in the screening phase.
SE|25462400|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1048|1059
SE|25462400|LIMITATIONS|ab|9|entity|C0205251|low|qlco|||Low|||0|851|1061|1064
SE|25462400|LIMITATIONS|ab|9|entity|C0679823|participation|inbe|||participation|||0|851|1065|1078
SE|25462400|LIMITATIONS|ab|9|entity|C1521828|Rate|qnco|||rate|||0|851|1079|1083
SE|25462400|LIMITATIONS|ab|9|entity|C0220908|Screening procedure|hlca|||screening|||0|888|1097|1106
SE|25462400|LIMITATIONS|ab|9|entity|C0205390|Phase|tmco|||phase|||0|888|1107|1112

SE|25462400|CONCLUSION|ab|10|text|1114|1194|CONCLUSION: GMDS is a valid screening tool for detecting male depression (MDD).
SE|25462400|CONCLUSION|ab|10|entity|C0679604|depression scale|diap,inpr|||GMDS|||0|861|1126|1130
SE|25462400|CONCLUSION|ab|10|entity|C0220908|Screening procedure|hlca|||screening|||0|790|1142|1151
SE|25462400|CONCLUSION|ab|10|entity|C0336791|Tool|mnob|||tool|||0|790|1152|1156
SE|25462400|CONCLUSION|ab|10|entity|C0011581|Depressive disorder|mobd|||depression|||0|785|1176|1186
SE|25462400|CONCLUSION|ab|10|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|1188|1191
SE|25462400|CONCLUSION|ab|10|relation|0|0|C0679604|depression scale|diap,inpr|diap|||GMDS|||0|861|1126|1130|INFER|DIAGNOSES(SPEC)||1176|1191|0|0|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|1000|1188|1191
SE|25462400|CONCLUSION|ab|10|relation|0|0|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|1000|1188|1191|SPEC|ISA||1176|1191|0|0|C0011581|Depressive disorder|mobd|mobd|||depression|||0|785|1176|1186
SE|25462400|CONCLUSION|ab|10|relation|3|2|C0679604|depression scale|diap,inpr|diap|||GMDS|||0|861|1126|1130|ADJ|DIAGNOSES||1161|1170|3|0|C0011581|Depressive disorder|mobd|mobd|||depression|||0|785|1176|1186

SE|25462400|CONCLUSION|ab|11|text|1194|1295|Furthermore it is a short self-rating scale, easy to use in daily practice to screen for depression.
SE|25462400|CONCLUSION|ab|11|entity|C0036588|Self|idcn|||self|||0|861|1220|1224
SE|25462400|CONCLUSION|ab|11|entity|C0681889|rating scale|inpr,qnco|||rating scale|||0|861|1225|1237
SE|25462400|CONCLUSION|ab|11|entity|C0332219|Easy|qlco|||easy|||0|1000|1239|1243
SE|25462400|CONCLUSION|ab|11|entity|C0332173|Daily|tmco|||daily|||0|1000|1254|1259
SE|25462400|CONCLUSION|ab|11|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1283|1293

SE|25462400|CONCLUSION|ab|12|text|1295|1443|Our results support recent reports of high prevalence of depressions in the community which supports active screening of males in clinical practice.
SE|25462400|CONCLUSION|ab|12|entity|C1274040|result|ftcn|||results|||0|966|1299|1306
SE|25462400|CONCLUSION|ab|12|entity|C0332185|Recent|tmco|||recent|||0|888|1315|1321
SE|25462400|CONCLUSION|ab|12|entity|C0684224|Report (document)|inpr|||reports|||0|888|1322|1329
SE|25462400|CONCLUSION|ab|12|entity|C1512456|High Prevalence|qnco|||high prevalence|||0|1000|1333|1348
SE|25462400|CONCLUSION|ab|12|entity|C0011570|Mental Depression|mobd|||depressions|||0|1000|1352|1363
SE|25462400|CONCLUSION|ab|12|entity|C0009462|Community|geoa|||community|||0|1000|1371|1380
SE|25462400|CONCLUSION|ab|12|entity|C0205177|Active|ftcn|||active|||0|888|1396|1402
SE|25462400|CONCLUSION|ab|12|entity|C0220908|Screening procedure|hlca|||screening|||0|888|1403|1412
SE|25462400|CONCLUSION|ab|12|entity|C0024554|Male gender|orga|||males|||0|1000|1416|1421
SE|25462400|CONCLUSION|ab|12|entity|C0205210|Clinical|qlco|||clinical|||0|888|1425|1433
SE|25462400|CONCLUSION|ab|12|entity|C0237607|experience (practice)|menp|||practice|||0|888|1434|1442


SE|25462401||ti|1|text|21|119|The prevalence and correlates of depression, anxiety, and stress in a sample of college students.
SE|25462401||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|54|64
SE|25462401||ti|1|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|66|73
SE|25462401||ti|1|entity|C0038435|Stress|fndg|||stress|||0|1000|79|85
SE|25462401||ti|1|entity|C0682177|college student|popg|||college students|||0|1000|101|117

SE|25462401|BACKGROUND|ab|1|text|125|306|BACKGROUND: Over the past four years, the Franciscan University Counseling Center has reported a 231% increase in yearly visits, as well as a 173% increase in total yearly clients.
SE|25462401|BACKGROUND|ab|1|entity|C0205136|Over|spco|||Over|||0|1000|137|141
SE|25462401|BACKGROUND|ab|1|entity|C1444637|Past|tmco|||past|||0|851|146|150
SE|25462401|BACKGROUND|ab|1|entity|C0205450|Four|qnco|||four|||0|851|151|155
SE|25462401|BACKGROUND|ab|1|entity|C0439234|year|tmco|||years|||0|851|156|161
SE|25462401|BACKGROUND|ab|1|entity|C0041740|Universities|mnob,orgt|||University|||0|775|178|188
SE|25462401|BACKGROUND|ab|1|entity|C0010210|Counseling|hlca|||Counseling|||0|775|189|199
SE|25462401|BACKGROUND|ab|1|entity|C0205099|Central|spco|||Center|||0|775|200|206
SE|25462401|BACKGROUND|ab|1|entity|C0442805|Increase|ftcn|||increase|||0|861|227|235
SE|25462401|BACKGROUND|ab|1|entity|C0332181|Annual|tmco|||yearly|||0|888|239|245
SE|25462401|BACKGROUND|ab|1|entity|C0545082|Visit|ftcn|||visits|||0|888|246|252
SE|25462401|BACKGROUND|ab|1|entity|C0442805|Increase|ftcn|||increase|||0|861|272|280
SE|25462401|BACKGROUND|ab|1|entity|C0439175|% of total|qnco|||total|||0|851|284|289
SE|25462401|BACKGROUND|ab|1|entity|C0332181|Annual|tmco|||yearly|||0|851|290|296
SE|25462401|BACKGROUND|ab|1|entity|C0008942|Clients|popg|||clients|||0|851|297|304

SE|25462401|BACKGROUND|ab|2|text|306|433|This trend has been observed at many universities as mental health issues pose significant problems for many college students.
SE|25462401|BACKGROUND|ab|2|entity|C1521798|trend|tmco|||trend|||0|1000|311|316
SE|25462401|BACKGROUND|ab|2|entity|C0041740|Universities|mnob,orgt|||universities|||0|1000|343|355
SE|25462401|BACKGROUND|ab|2|entity|C0025353|mental health|idcn|||mental health|||0|734|359|372
SE|25462401|BACKGROUND|ab|2|entity|C0750502|Significant|idcn|||significant|||0|888|385|396
SE|25462401|BACKGROUND|ab|2|entity|C1546466|Problems|idcn|||problems|||0|888|397|405
SE|25462401|BACKGROUND|ab|2|entity|C0682177|college student|popg|||college students|||0|1000|415|431

SE|25462401|BACKGROUND|ab|3|text|433|569|The objective of this study was to investigate potential correlates of depression, anxiety, and stress in a sample of college students.
SE|25462401|BACKGROUND|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|455|460
SE|25462401|BACKGROUND|ab|3|entity|C0237399|Potential|qlco|||potential|||0|694|480|489
SE|25462401|BACKGROUND|ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|504|514
SE|25462401|BACKGROUND|ab|3|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|516|523
SE|25462401|BACKGROUND|ab|3|entity|C0038435|Stress|fndg|||stress|||0|1000|529|535
SE|25462401|BACKGROUND|ab|3|entity|C0682177|college student|popg|||college students|||0|1000|551|567

SE|25462401|METHODS|ab|4|text|569|727|METHODS: The final analyzed sample consisted of 374 undergraduate students between the ages of 18 and 24 attending Franciscan University, Steubenville, Ohio.
SE|25462401|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|569|576
SE|25462401|METHODS|ab|4|entity|C0205088|End-stage|tmco|||final|||0|623|582|587
SE|25462401|METHODS|ab|4|entity|C1515960|Analyzed|qlco|||analyzed|||0|623|588|596
SE|25462401|METHODS|ab|4|entity|C0814964|undergraduate student|popg|||undergraduate students|||0|884|621|643
SE|25462401|METHODS|ab|4|entity|C0001779|Age|orga|||ages|||0|966|656|660
SE|25462401|METHODS|ab|4|entity|C0557300|Attending university|fndg|||attending Franciscan University|||0|875|674|705
SE|25462401|METHODS|ab|4|entity|C0028905|Ohio|geoa|||Ohio|||0|1000|721|725

SE|25462401|METHODS|ab|5|text|727|1017|Subjects completed a survey consisting of demographic questions, a section instructing participants to rate the level of concern associated with challenges pertinent to daily life (e.g. academics, family, sleep), and the 21 question version of the Depression Anxiety Stress Scale (DASS21).
SE|25462401|METHODS|ab|5|entity|C1550501|subject|idcn|||Subjects|||0|966|727|735
SE|25462401|METHODS|ab|5|entity|C0038951|Surveys|resa|||survey|||0|1000|748|754
SE|25462401|METHODS|ab|5|entity|C0011298|Demography|ocdi|||demographic|||0|623|769|780
SE|25462401|METHODS|ab|5|entity|C0679646|Participant|popg|||participants|||0|785|814|826
SE|25462401|METHODS|ab|5|entity|C1521828|Rate|qnco|||rate|||0|1000|830|834
SE|25462401|METHODS|ab|5|entity|C0332173|Daily|tmco|||daily|||0|888|896|901
SE|25462401|METHODS|ab|5|entity|C0376558|Life|idcn|||life|||0|888|902|906
SE|25462401|METHODS|ab|5|entity|C1550724|academic|idcn|||academics|||0|966|913|922
SE|25462401|METHODS|ab|5|entity|C0015576|Family|famg|||family|||0|1000|924|930
SE|25462401|METHODS|ab|5|entity|C0037313|Sleep|orgf|||sleep|||0|1000|932|937
SE|25462401|METHODS|ab|5|entity|C0333052|Version|ftcn|||version|||0|827|960|967
SE|25462401|METHODS|ab|5|entity|C0038435|Stress|fndg|||Stress|||0|916|994|1000
SE|25462401|METHODS|ab|5|entity|C0451107|Depression anxiety scale|inpr|||Depression Anxiety Stress Scale|||0|916|975|1006

SE|25462401|RESULTS|ab|6|text|1017|1151|RESULTS: The results indicated that the top three concerns were academic performance, pressure to succeed, and post-graduation plans.
SE|25462401|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1017|1024
SE|25462401|RESULTS|ab|6|entity|C1274040|result|ftcn|||results|||0|966|1030|1037
SE|25462401|RESULTS|ab|6|entity|C0205449|Three|qnco|||three|||0|623|1061|1066
SE|25462401|RESULTS|ab|6|entity|C0036373|academic performance|qlco|||academic performance|||0|1000|1081|1101
SE|25462401|RESULTS|ab|6|entity|C0205095|Dorsal|spco|||post|||0|785|1128|1132
SE|25462401|RESULTS|ab|6|entity|C0032074|Cognitive function: planning|menp|||plans|||0|785|1144|1149

SE|25462401|RESULTS|ab|7|text|1151|1279|Demographically, the most stressed, anxious, and depressed students were transfers, upperclassmen, and those living off-campus.
SE|25462401|RESULTS|ab|7|entity|C0205393|Most|qnco|||most|||0|1000|1172|1176
SE|25462401|RESULTS|ab|7|entity|C0003467|Anxiety|menp|||anxious|||0|1000|1187|1194
SE|25462401|RESULTS|ab|7|entity|C0038492|student|prog|||students|||0|861|1210|1218
SE|25462401|RESULTS|ab|7|entity|C0728827|Does transfer|fndg|||transfers|||0|1000|1224|1233
SE|25462401|RESULTS|ab|7|entity|C0870243|Campuses|mnob|||campus|||0|966|1271|1277

SE|25462401|CONCLUSIONS|ab|8|text|1279|1528|CONCLUSIONS: With the propensity for mental health issues to hinder the success of college students, it is vital that colleges continually evaluate the mental health of their students and tailor treatment programs to specifically target their needs.
SE|25462401|CONCLUSIONS|ab|8|entity|C0025353|mental health|idcn|||mental health|||0|734|1316|1329
SE|25462401|CONCLUSIONS|ab|8|entity|C0597535|Success|socb|||success|||0|1000|1351|1358
SE|25462401|CONCLUSIONS|ab|8|entity|C0682177|college student|popg|||college students|||0|1000|1362|1378
SE|25462401|CONCLUSIONS|ab|8|entity|C0442732|Vital|qlco|||vital|||0|1000|1386|1391
SE|25462401|CONCLUSIONS|ab|8|entity|C0557806|College|eehu|||colleges|||0|1000|1397|1405
SE|25462401|CONCLUSIONS|ab|8|entity|C0025353|mental health|idcn|||mental health|||0|1000|1431|1444
SE|25462401|CONCLUSIONS|ab|8|entity|C0038492|student|prog|||students|||0|1000|1454|1462
SE|25462401|CONCLUSIONS|ab|8|entity|C0027552|Needs|qlco|||needs|||0|1000|1522|1527


SE|25462402||ti|1|text|21|105|Personality and cognitive vulnerability in remitted recurrently depressed patients.
SE|25462402||ti|1|entity|C0031208|Personality|menp|||Personality|||0|1000|21|32
SE|25462402||ti|1|entity|C1516691|Cognitive|ftcn|||cognitive|||0|694|37|46
SE|25462402||ti|1|entity|C0439600|Remitting|tmco|||remitted|||0|775|64|72
SE|25462402||ti|1|entity|C0030705|Patients|podg|||patients|||0|775|95|103
SE|25462402||ti|1|relation|2|2|C0031208|Personality|menp|menp|||Personality|||0|1000|21|32|PREP|PROCESS_OF||61|63|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|775|95|103

SE|25462402|INTRODUCTION|ab|1|text|111|232|INTRODUCTION: Personality disorders (PDs) have been associated with a poor prognosis of Major Depressive Disorder (MDD).
SE|25462402|INTRODUCTION|ab|1|entity|C1293116|Introduction procedure|hlca|||INTRODUCTION|||0|1000|111|123
SE|25462402|INTRODUCTION|ab|1|entity|C0031212|Personality Disorders|mobd|||Personality disorders|||0|1000|125|146
SE|25462402|INTRODUCTION|ab|1|entity|C0025344|Menstruation|orgf|||PDs|||0|966|148|151
SE|25462402|INTRODUCTION|ab|1|entity|C0278252|Prognosis bad|fndg|||poor prognosis|||0|1000|181|195
SE|25462402|INTRODUCTION|ab|1|entity|C1269683|Major Depressive Disorder|mobd|||Major Depressive Disorder|||0|1000|199|224

SE|25462402|INTRODUCTION|ab|2|text|232|468|The aim of the current study was to examine cognitive vulnerability (i.e., dysfunctional beliefs, extremity of beliefs, cognitive reactivity, and rumination) that might contribute to this poor prognosis of patients with PD comorbidity.
SE|25462402|INTRODUCTION|ab|2|entity|C0521116|Current|tmco|||current|||0|888|247|254
SE|25462402|INTRODUCTION|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|255|260
SE|25462402|INTRODUCTION|ab|2|entity|C1516691|Cognitive|ftcn|||cognitive|||0|694|276|285
SE|25462402|INTRODUCTION|ab|2|entity|C0031847|physiopathological|ftcn|||dysfunctional|||0|714|307|320
SE|25462402|INTRODUCTION|ab|2|entity|C0004951|Beliefs|idcn|||beliefs|||0|714|321|328
SE|25462402|INTRODUCTION|ab|2|entity|C0015385|Limb structure|bpoc|||extremity|||0|1000|330|339
SE|25462402|INTRODUCTION|ab|2|entity|C0004951|Beliefs|idcn|||beliefs|||0|1000|343|350
SE|25462402|INTRODUCTION|ab|2|entity|C1516691|Cognitive|ftcn|||cognitive|||0|853|352|361
SE|25462402|INTRODUCTION|ab|2|entity|C0205332|Reactive|qlco|||reactivity|||0|853|362|372
SE|25462402|INTRODUCTION|ab|2|entity|C0232604|Rumination|mobd|||rumination|||0|1000|378|388
SE|25462402|INTRODUCTION|ab|2|entity|C0278252|Prognosis bad|fndg|||poor prognosis|||0|1000|420|434
SE|25462402|INTRODUCTION|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|438|446
SE|25462402|INTRODUCTION|ab|2|entity|C0009488|Comorbidity|idcn|||comorbidity|||0|888|455|466

SE|25462402|METHODS|ab|3|text|468|889|METHODS: 309 outpatients with remitted recurrent MDD (SCID-I; HAM-D17 <= 10) were included within two comparable RCTs and were assessed at baseline with the Personality Diagnostic Questionnaire-4(+) (PDQ-4(+)), the Dysfunctional Attitude Scale Version-A (DAS-A), the Leiden Index of Depression Sensitivity (LEIDS), the Ruminative Response Scale (RRS), and the Inventory of Depressive Symptomatology-Self Report (IDS-SR).
SE|25462402|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|468|475
SE|25462402|METHODS|ab|3|entity|C0029921|Outpatients|podg|||outpatients|||0|861|481|492
SE|25462402|METHODS|ab|3|entity|C0439600|Remitting|tmco|||remitted|||0|917|498|506
SE|25462402|METHODS|ab|3|entity|C0154409|Major Depressive Disorder, Recurrent, Unspecified|mobd|||recurrent MDD|||0|917|507|520
SE|25462402|METHODS|ab|3|entity|C0085110|Severe Combined Immunodeficiency|dsyn|||SCID|||0|1000|522|526
SE|25462402|METHODS|ab|3|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM-D17|||0|694|530|537
SE|25462402|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|660|566|569
SE|25462402|METHODS|ab|3|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|607|615
SE|25462402|METHODS|ab|3|entity|C0031208|Personality|menp|||Personality|||0|775|625|636
SE|25462402|METHODS|ab|3|entity|C0348026|Diagnostic|ftcn|||Diagnostic|||0|775|637|647
SE|25462402|METHODS|ab|3|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|775|648|661
SE|25462402|METHODS|ab|3|entity|C0031847|physiopathological|ftcn|||Dysfunctional|||0|716|683|696
SE|25462402|METHODS|ab|3|entity|C0004271|Attitude|menp|||Attitude|||0|716|697|705
SE|25462402|METHODS|ab|3|entity|C0333052|Version|ftcn|||Version|||0|716|712|719
SE|25462402|METHODS|ab|3|entity|C0918012|Index|inpr|||Index|||0|719|742|747
SE|25462402|METHODS|ab|3|entity|C0011581|Depressive disorder|mobd|||Depression|||0|719|751|761
SE|25462402|METHODS|ab|3|entity|C0232604|Rumination|mobd|||Ruminative|||0|828|787|797
SE|25462402|METHODS|ab|3|entity|C0871261|response|clna|||Response|||0|828|798|806
SE|25462402|METHODS|ab|3|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|736|828|837
SE|25462402|METHODS|ab|3|entity|C0036588|Self|idcn|||Self|||0|736|867|871
SE|25462402|METHODS|ab|3|relation|6|1|C0154409|Major Depressive Disorder, Recurrent, Unspecified|mobd|mobd|||recurrent MDD|||0|917|507|520|PREP|PROCESS_OF||493|497|2|1|C0029921|Outpatients|podg,humn|humn|||outpatients|||0|861|481|492
SE|25462402|METHODS|ab|3|relation|7|0|C0011581|Depressive disorder|mobd|mobd|||Depression|||0|719|751|761|NOM|AFFECTS||762|773|7|6|C0029921|Outpatients|podg,humn|humn|||outpatients|||0|861|481|492

SE|25462402|RESULTS|ab|4|text|889|1001|RESULTS: We found an indication that the PD prevalence was 49.5% in this remitted recurrently depressed sample.
SE|25462402|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|889|896
SE|25462402|RESULTS|ab|4|entity|C0392360|Reason for|idcn|||indication|||0|1000|910|920
SE|25462402|RESULTS|ab|4|entity|C0439600|Remitting|tmco|||remitted|||0|612|962|970

SE|25462402|RESULTS|ab|5|text|1001|1139|Having a PD (and higher levels of personality pathology) was associated with dysfunctional beliefs, cognitive reactivity, and rumination.
SE|25462402|RESULTS|ab|5|entity|C0205250|High|qlco|||higher|||0|872|1018|1024
SE|25462402|RESULTS|ab|5|entity|C0441889|Levels|inpr|||levels|||0|872|1025|1031
SE|25462402|RESULTS|ab|5|entity|C0031208|Personality|menp|||personality|||0|888|1035|1046
SE|25462402|RESULTS|ab|5|entity|C0030664|Pathology|bmod|||pathology|||0|888|1047|1056
SE|25462402|RESULTS|ab|5|entity|C0031847|physiopathological|ftcn|||dysfunctional|||0|853|1078|1091
SE|25462402|RESULTS|ab|5|entity|C0004951|Beliefs|idcn|||beliefs|||0|853|1092|1099
SE|25462402|RESULTS|ab|5|entity|C1516691|Cognitive|ftcn|||cognitive|||0|853|1101|1110
SE|25462402|RESULTS|ab|5|entity|C0205332|Reactive|qlco|||reactivity|||0|853|1111|1121
SE|25462402|RESULTS|ab|5|entity|C0232604|Rumination|mobd|||rumination|||0|1000|1127|1137

SE|25462402|RESULTS|ab|6|text|1139|1232|Extreme 'black and white thinking' on the DAS was not associated with personality pathology.
SE|25462402|RESULTS|ab|6|entity|C0205403|Extreme|qlco|||Extreme|||0|928|1139|1146
SE|25462402|RESULTS|ab|6|entity|C0563152|Black and white thinking|fndg|||black and white thinking|||0|928|1148|1172
SE|25462402|RESULTS|ab|6|entity|C0051767|amsonic acid|orch,phsu|||DAS|||0|1000|1181|1184
SE|25462402|RESULTS|ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1189|1192
SE|25462402|RESULTS|ab|6|entity|C0031208|Personality|menp|||personality|||0|888|1209|1220
SE|25462402|RESULTS|ab|6|entity|C0030664|Pathology|bmod|||pathology|||0|888|1221|1230

SE|25462402|RESULTS|ab|7|text|1232|1433|Brooding was only associated with a Cluster C classification (t(308) = 4.03, p < .001) and with avoidant PD specifically (t(308) = 4.82, p < .001), while surprisingly not with obsessive-compulsive PD.
SE|25462402|RESULTS|ab|7|entity|C0008902|Classification|clas|||classification|||0|773|1278|1292
SE|25462402|RESULTS|ab|7|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1309|1310
SE|25462402|RESULTS|ab|7|entity|C0870186|Avoidance|menp|||avoidant|||0|754|1328|1336
SE|25462402|RESULTS|ab|7|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1369|1370
SE|25462402|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1399|1402

SE|25462402|LIMITATIONS|ab|8|text|1433|1530|LIMITATIONS: PDs were assessed by questionnaire and the analyses were cross-sectional in nature.
SE|25462402|LIMITATIONS|ab|8|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1433|1444
SE|25462402|LIMITATIONS|ab|8|entity|C0025344|Menstruation|orgf|||PDs|||0|966|1446|1449
SE|25462402|LIMITATIONS|ab|8|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|1000|1467|1480
SE|25462402|LIMITATIONS|ab|8|entity|C0936012|Analysis|resa|||analyses|||0|966|1489|1497
SE|25462402|LIMITATIONS|ab|8|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|928|1503|1518
SE|25462402|LIMITATIONS|ab|8|entity|C0349590|Nature|idcn|||nature|||0|1000|1522|1528

SE|25462402|CONCLUSION|ab|9|text|1530|1828|CONCLUSION: Being the first study to examine cognitive reactivity and rumination in patients with PD and remitted MDD, we demonstrated that even after controlling for depressive symptomatology, dysfunctional beliefs, cognitive reactivity, and rumination were associated with personality pathology.
SE|25462402|CONCLUSION|ab|9|entity|C1279901|Firstly|qlco|||first|||0|1000|1552|1557
SE|25462402|CONCLUSION|ab|9|entity|C1516691|Cognitive|ftcn|||cognitive|||0|853|1575|1584
SE|25462402|CONCLUSION|ab|9|entity|C0205332|Reactive|qlco|||reactivity|||0|853|1585|1595
SE|25462402|CONCLUSION|ab|9|entity|C0232604|Rumination|mobd|||rumination|||0|1000|1600|1610
SE|25462402|CONCLUSION|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1614|1622
SE|25462402|CONCLUSION|ab|9|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|1644|1647
SE|25462402|CONCLUSION|ab|9|entity|C0243148|control|ftcn|||controlling|||0|966|1681|1692
SE|25462402|CONCLUSION|ab|9|entity|C0031847|physiopathological|ftcn|||dysfunctional|||0|853|1724|1737
SE|25462402|CONCLUSION|ab|9|entity|C0004951|Beliefs|idcn|||beliefs|||0|853|1738|1745
SE|25462402|CONCLUSION|ab|9|entity|C1516691|Cognitive|ftcn|||cognitive|||0|853|1747|1756
SE|25462402|CONCLUSION|ab|9|entity|C0205332|Reactive|qlco|||reactivity|||0|853|1757|1767
SE|25462402|CONCLUSION|ab|9|entity|C0232604|Rumination|mobd|||rumination|||0|1000|1773|1783
SE|25462402|CONCLUSION|ab|9|entity|C0031208|Personality|menp|||personality|||0|888|1805|1816
SE|25462402|CONCLUSION|ab|9|entity|C0030664|Pathology|bmod|||pathology|||0|888|1817|1826
SE|25462402|CONCLUSION|ab|9|relation|4|1|C0232604|Rumination|mobd|mobd|||rumination|||0|1000|1600|1610|PREP|PROCESS_OF||1611|1613|9|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1614|1622

SE|25462402|CONCLUSION|ab|10|text|1828|1900|Rumination might be a pathway to relapse for patients with avoidant PD.
SE|25462402|CONCLUSION|ab|10|entity|C0232604|Rumination|mobd|||Rumination|||0|1000|1828|1838
SE|25462402|CONCLUSION|ab|10|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|1000|1850|1857
SE|25462402|CONCLUSION|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1873|1881
SE|25462402|CONCLUSION|ab|10|entity|C0870186|Avoidance|menp|||avoidant|||0|853|1887|1895

SE|25462402|CONCLUSION|ab|11|text|1900|1993|Replication of our findings concerning cognitive vulnerability and specific PDs is necessary.
SE|25462402|CONCLUSION|ab|11|entity|C0243095|Finding|ftcn|||findings|||0|1000|1919|1927
SE|25462402|CONCLUSION|ab|11|entity|C1516691|Cognitive|ftcn|||cognitive|||0|694|1939|1948
SE|25462402|CONCLUSION|ab|11|entity|C0025344|Menstruation|orgf|||PDs|||0|827|1976|1979


SE|25462403||ti|1|text|21|103|Reasons and determinants of help-seeking in people with a subclinical depression.
SE|25462403||ti|1|entity|C0392360|Reason for|idcn|||Reasons|||0|1000|21|28
SE|25462403||ti|1|entity|C0027361|Persons|popg|||people|||0|1000|65|71
SE|25462403||ti|1|entity|C0205211|Subclinical|qlco|||subclinical|||0|888|79|90
SE|25462403||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|91|101
SE|25462403||ti|1|relation|1|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|91|101|PREP|PROCESS_OF||72|76|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|65|71

SE|25462403|BACKGROUND|ab|1|text|109|155|BACKGROUND: Subclinical depression is common.
SE|25462403|BACKGROUND|ab|1|entity|C0205211|Subclinical|qlco|||Subclinical|||0|888|121|132
SE|25462403|BACKGROUND|ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|133|143
SE|25462403|BACKGROUND|ab|1|entity|C0205214|Common|qnco|||common|||0|1000|147|153

SE|25462403|BACKGROUND|ab|2|text|155|236|Although interventions have proven to be effective, participation rates are low.
SE|25462403|BACKGROUND|ab|2|entity|C1273869|Intervention regimes|hlca|||interventions|||0|1000|164|177
SE|25462403|BACKGROUND|ab|2|entity|C0679823|participation|inbe|||participation|||0|840|207|220
SE|25462403|BACKGROUND|ab|2|entity|C1521828|Rate|qnco|||rates|||0|840|221|226
SE|25462403|BACKGROUND|ab|2|entity|C0205251|low|qlco|||low|||0|1000|231|234

SE|25462403|BACKGROUND|ab|3|text|236|331|This study first aimed to get more insight in help-seeking and reasons for (not) seeking care.
SE|25462403|BACKGROUND|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|241|246
SE|25462403|BACKGROUND|ab|3|entity|C1279901|Firstly|qlco|||first|||0|1000|247|252
SE|25462403|BACKGROUND|ab|3|entity|C0205172|More|ftcn|||more|||0|888|266|270
SE|25462403|BACKGROUND|ab|3|entity|C0233820|Insight|menp|||insight|||0|888|271|278
SE|25462403|BACKGROUND|ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|312|315

SE|25462403|BACKGROUND|ab|4|text|331|477|The second aim was to identify characteristics that distinguish people who receive help, those with an unmet need, or no perceived need for care.
SE|25462403|BACKGROUND|ab|4|entity|C0457385|seconds|tmco|||second|||0|694|335|341
SE|25462403|BACKGROUND|ab|4|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|362|377
SE|25462403|BACKGROUND|ab|4|entity|C0027361|Persons|popg|||people|||0|1000|395|401
SE|25462403|BACKGROUND|ab|4|entity|C0027552|Needs|qlco|||need|||0|861|440|444
SE|25462403|BACKGROUND|ab|4|entity|C0027552|Needs|qlco|||need|||0|861|462|466

SE|25462403|METHODS|ab|5|text|477|580|METHODS: Respondents with a subclinical depression (n=162) were recruited from the general population.
SE|25462403|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|477|484
SE|25462403|METHODS|ab|5|entity|C0282122|Respondents|popg|||Respondents|||0|1000|486|497
SE|25462403|METHODS|ab|5|entity|C0205211|Subclinical|qlco|||subclinical|||0|888|505|516
SE|25462403|METHODS|ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|517|527
SE|25462403|METHODS|ab|5|entity|C0683971|General Population|popg|||general population|||0|1000|560|578
SE|25462403|METHODS|ab|5|relation|3|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|517|527|PREP|PROCESS_OF||498|502|2|1|C0282122|Respondents|popg,humn|humn|||Respondents|||0|1000|486|497

SE|25462403|METHODS|ab|6|text|580|774|They were eligible for participation if they were aged 18 years or older, scored 20 or higher on the K10 screening instrument for depression, and did not meet the criteria for major depression.
SE|25462403|METHODS|ab|6|entity|C1548635|Eligible|idcn|||eligible|||0|1000|590|598
SE|25462403|METHODS|ab|6|entity|C0679823|participation|inbe|||participation|||0|1000|603|616
SE|25462403|METHODS|ab|6|entity|C0439234|year|tmco|||years|||0|861|638|643
SE|25462403|METHODS|ab|6|entity|C0580836|Old|tmco|||older|||0|966|647|652
SE|25462403|METHODS|ab|6|entity|C0205250|High|qlco|||higher|||0|966|667|673
SE|25462403|METHODS|ab|6|entity|||gngm|3858|KRT10|K10|||0|790|681|684
SE|25462403|METHODS|ab|6|entity|C0220908|Screening procedure|hlca|||screening|||0|790|685|694
SE|25462403|METHODS|ab|6|entity|C0348000|Instrument|mnob|||instrument|||0|790|695|705
SE|25462403|METHODS|ab|6|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|710|720
SE|25462403|METHODS|ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|730|733
SE|25462403|METHODS|ab|6|entity|C0243161|criteria|inpr|||criteria|||0|1000|743|751
SE|25462403|METHODS|ab|6|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|756|772

SE|25462403|RESULTS|ab|7|text|774|886|RESULTS: Of all participants, 27% received help, 33% had an unmet need, and 40% had no perceived need for care.
SE|25462403|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|774|781
SE|25462403|RESULTS|ab|7|entity|C0679646|Participant|popg|||participants|||0|966|790|802
SE|25462403|RESULTS|ab|7|entity|C1514756|Received|qlco|||received|||0|861|808|816
SE|25462403|RESULTS|ab|7|entity|C0027552|Needs|qlco|||need|||0|861|840|844
SE|25462403|RESULTS|ab|7|entity|C0439509|/40|tmco|||40|||0|1000|850|852
SE|25462403|RESULTS|ab|7|entity|C0027552|Needs|qlco|||need|||0|861|871|875

SE|25462403|RESULTS|ab|8|text|886|1039|Participants with no perceived need reported not to experience symptoms, were able to solve problems on their own, and could mobilize their own support.
SE|25462403|RESULTS|ab|8|entity|C0679646|Participant|popg|||Participants|||0|966|886|898
SE|25462403|RESULTS|ab|8|entity|C0027552|Needs|qlco|||need|||0|861|917|921
SE|25462403|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|931|934
SE|25462403|RESULTS|ab|8|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|949|957
SE|25462403|RESULTS|ab|8|entity|C1546466|Problems|idcn|||problems|||0|1000|978|986
SE|25462403|RESULTS|ab|8|entity|C1546511|Owner|idcn|||own|||0|928|996|999
SE|25462403|RESULTS|ab|8|entity|C1546511|Owner|idcn|||own|||0|853|1026|1029
SE|25462403|RESULTS|ab|8|relation|5|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|1000|949|957|VERB|PROCESS_OF|negation|938|948|2|2|C0679646|Participant|popg,humn|humn|||Participants|||0|966|886|898

SE|25462403|RESULTS|ab|9|text|1039|1141|They were characterized by lower scores on neuroticism and an older age than those who received care.
SE|25462403|RESULTS|ab|9|entity|C0441994|Lower|ftcn|||lower|||0|888|1066|1071
SE|25462403|RESULTS|ab|9|entity|C0449820|Score|qnco|||scores|||0|888|1072|1078
SE|25462403|RESULTS|ab|9|entity|C0027932|Neurotic Disorders|mobd|||neuroticism|||0|1000|1082|1093
SE|25462403|RESULTS|ab|9|entity|C0001792|Elderly|aggp|||older age|||0|983|1101|1110

SE|25462403|LIMITATIONS|ab|10|text|1141|1245|LIMITATIONS: The response rate in this study was relatively low which may have caused a selection bias.
SE|25462403|LIMITATIONS|ab|10|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1141|1152
SE|25462403|LIMITATIONS|ab|10|entity|C0237629|Frequency of Responses|tmco|||response rate|||0|1000|1158|1171
SE|25462403|LIMITATIONS|ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1180|1185
SE|25462403|LIMITATIONS|ab|10|entity|C0205251|low|qlco|||low|||0|861|1201|1204
SE|25462403|LIMITATIONS|ab|10|entity|C0036577|Selection Bias|qnco|||selection bias|||0|1000|1229|1243

SE|25462403|CONCLUSION|ab|11|text|1245|1384|CONCLUSION: Not all people with subclinical depression may need help for their symptoms, some are able to deal with problems on their own.
SE|25462403|CONCLUSION|ab|11|entity|C1518422|Not|ftcn|||Not|||0|1000|1257|1260
SE|25462403|CONCLUSION|ab|11|entity|C0027361|Persons|popg|||people|||0|1000|1265|1271
SE|25462403|CONCLUSION|ab|11|entity|C0205211|Subclinical|qlco|||subclinical|||0|888|1277|1288
SE|25462403|CONCLUSION|ab|11|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1289|1299
SE|25462403|CONCLUSION|ab|11|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|1324|1332
SE|25462403|CONCLUSION|ab|11|entity|C1546466|Problems|idcn|||problems|||0|1000|1361|1369
SE|25462403|CONCLUSION|ab|11|entity|C1546511|Owner|idcn|||own|||0|928|1379|1382
SE|25462403|CONCLUSION|ab|11|relation|5|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|1289|1299|PREP|PROCESS_OF||1272|1276|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1265|1271

SE|25462403|CONCLUSION|ab|12|text|1384|1451|However, others experience a need for care but do not receive any.
SE|25462403|CONCLUSION|ab|12|entity|C0205394|Other|qlco|||others|||0|966|1393|1399
SE|25462403|CONCLUSION|ab|12|entity|C0027552|Needs|qlco|||need|||0|1000|1413|1417
SE|25462403|CONCLUSION|ab|12|entity|C1518422|Not|ftcn|||not|||0|1000|1434|1437

SE|25462403|CONCLUSION|ab|13|text|1451|1659|Gaining insight into potential barriers for help seeking and receiving in people with an unmet need is important so appropriate measures can be taken to ensure that those who need care get the help they want.
SE|25462403|CONCLUSION|ab|13|entity|C1517378|Gain|qnco|||Gaining|||0|872|1451|1458
SE|25462403|CONCLUSION|ab|13|entity|C0233820|Insight|menp|||insight|||0|872|1459|1466
SE|25462403|CONCLUSION|ab|13|entity|C0237399|Potential|qlco|||potential|||0|694|1472|1481
SE|25462403|CONCLUSION|ab|13|entity|C0027361|Persons|popg|||people|||0|1000|1525|1531
SE|25462403|CONCLUSION|ab|13|entity|C0027552|Needs|qlco|||need|||0|861|1546|1550
SE|25462403|CONCLUSION|ab|13|entity|C1548787|Appropriate|qlco|||appropriate|||0|888|1567|1578
SE|25462403|CONCLUSION|ab|13|entity|C0079809|Measures|qnco|||measures|||0|888|1579|1587
SE|25462403|CONCLUSION|ab|13|relation|3|3|C0233820|Insight|menp|menp|||insight|||0|872|1459|1466|PREP|PROCESS_OF||1522|1524|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1525|1531


SE|25462404||ti|1|text|21|99|Self-harm in bipolar disorder: findings from a prospective clinical database.
SE|25462404||ti|1|entity|C0036588|Self|idcn|||Self|||0|694|21|25
SE|25462404||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|34|50
SE|25462404||ti|1|entity|C0243095|Finding|ftcn|||findings|||0|1000|52|60
SE|25462404||ti|1|entity|C0205210|Clinical|qlco|||clinical|||0|851|80|88
SE|25462404||ti|1|entity|C0242356|Databases|inpr|||database|||0|851|89|97

SE|25462404|BACKGROUND|ab|1|text|105|259|BACKGROUND: People with bipolar disorder may be at increased risk of suicidal behaviour but there are few prospective studies of self-harm in this group.
SE|25462404|BACKGROUND|ab|1|entity|C0027361|Persons|popg|||People|||0|1000|117|123
SE|25462404|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|129|145
SE|25462404|BACKGROUND|ab|1|entity|C0205217|Increased|qnco|||increased|||0|888|156|165
SE|25462404|BACKGROUND|ab|1|entity|C0035647|Risk|qlco|||risk|||0|888|166|170
SE|25462404|BACKGROUND|ab|1|entity|C0563664|At risk for suicide|mobd|||suicidal behaviour|||0|1000|174|192
SE|25462404|BACKGROUND|ab|1|entity|C0205388|Few|qnco|||few|||0|901|207|210
SE|25462404|BACKGROUND|ab|1|entity|C0033522|Prospective Studies|qnco,resa|||prospective studies|||0|901|211|230
SE|25462404|BACKGROUND|ab|1|entity|C0036588|Self|idcn|||self|||0|694|234|238
SE|25462404|BACKGROUND|ab|1|entity|C0441833|Groups|inpr|||group|||0|1000|252|257
SE|25462404|BACKGROUND|ab|1|relation|6|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|129|145|PREP|PROCESS_OF||124|128|2|1|C0027361|Persons|popg,humn|humn|||People|||0|1000|117|123

SE|25462404|BACKGROUND|ab|2|text|259|425|Our aim was to describe the characteristics and outcome (in terms of repetition) for individuals with bipolar disorder who presented to hospital following self-harm.
SE|25462404|BACKGROUND|ab|2|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|287|302
SE|25462404|BACKGROUND|ab|2|entity|C1274040|result|ftcn|||outcome|||0|1000|307|314
SE|25462404|BACKGROUND|ab|2|entity|C0237401|Individual|humn|||individuals|||0|1000|344|355
SE|25462404|BACKGROUND|ab|2|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|361|377
SE|25462404|BACKGROUND|ab|2|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|1000|395|403
SE|25462404|BACKGROUND|ab|2|entity|C0036588|Self|idcn|||self|||0|694|414|418
SE|25462404|BACKGROUND|ab|2|relation|3|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|361|377|PREP|PROCESS_OF||356|360|6|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|344|355

SE|25462404|METHOD|ab|3|text|425|553|METHOD: A nested case-control study was carried out using a large prospective self-harm database (1997-2010) in Manchester, UK.
SE|25462404|METHOD|ab|3|entity|C0025663|Methods|inpr|||METHOD|||0|1000|425|431
SE|25462404|METHOD|ab|3|entity|C0027775|Nested Case-Control Studies|resa|||nested case-control study|||0|1000|435|460
SE|25462404|METHOD|ab|3|entity|C0439787|Out|spco|||out|||0|1000|473|476
SE|25462404|METHOD|ab|3|entity|C0549177|Large|qnco|||large|||0|766|485|490
SE|25462404|METHOD|ab|3|entity|C0036588|Self|idcn|||self|||0|766|503|507
SE|25462404|METHOD|ab|3|entity|C0242356|Databases|inpr|||database|||0|766|513|521

SE|25462404|METHOD|ab|4|text|553|714|Characteristics of bipolar cases and non-bipolar controls were compared using conditional logistic regression, and outcomes were assessed via survival analyses.
SE|25462404|METHOD|ab|4|entity|C1521970|Characteristics|grpa|||Characteristics|||0|1000|553|568
SE|25462404|METHOD|ab|4|entity|C0443156|Bipolar|spco|||bipolar|||0|888|572|579
SE|25462404|METHOD|ab|4|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|580|585
SE|25462404|METHOD|ab|4|entity|C0443156|Bipolar|spco|||bipolar|||0|773|594|601
SE|25462404|METHOD|ab|4|entity|C0243148|control|ftcn|||controls|||0|773|602|610
SE|25462404|METHOD|ab|4|entity|C0206031|Logistic Regression|resa|||logistic regression|||0|901|643|662
SE|25462404|METHOD|ab|4|entity|C1274040|result|ftcn|||outcomes|||0|966|668|676
SE|25462404|METHOD|ab|4|entity|C1550513|via|idcn|||via|||0|901|691|694
SE|25462404|METHOD|ab|4|entity|C0038953|Survival Analysis|qnco|||survival analyses|||0|901|695|712

SE|25462404|RESULTS|ab|5|text|714|857|RESULTS: Bipolar cases (n=103) were more likely to repeat self-harm than controls (n=515): proportion with at least one repeat episode 58% vs.
SE|25462404|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|714|721
SE|25462404|RESULTS|ab|5|entity|C0443156|Bipolar|spco|||Bipolar|||0|888|723|730
SE|25462404|RESULTS|ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|731|736
SE|25462404|RESULTS|ab|5|entity|C0205172|More|ftcn|||more|||0|888|750|754
SE|25462404|RESULTS|ab|5|entity|C0036588|Self|idcn|||self|||0|694|772|776
SE|25462404|RESULTS|ab|5|entity|C0243148|control|ftcn|||controls|||0|966|787|795
SE|25462404|RESULTS|ab|5|entity|C0205351|Proportional|qlco|||proportion|||0|928|805|815
SE|25462404|RESULTS|ab|5|entity|C0205447|One|qnco|||one|||0|728|830|833
SE|25462404|RESULTS|ab|5|entity|C0205341|Repeat|ftcn|||repeat|||0|728|834|840

SE|25462404|RESULTS|ab|6|text|857|890|25%, HR 3.08 (95% CI; 2.2-4.18).

SE|25462404|RESULTS|ab|7|text|890|1025|Previous self-harm, unemployment, contact with psychiatric services and sleep disturbance were all more common in cases than controls.
SE|25462404|RESULTS|ab|7|entity|C0205156|Previous|tmco|||Previous|||0|623|890|898
SE|25462404|RESULTS|ab|7|entity|C0036588|Self|idcn|||self|||0|623|899|903
SE|25462404|RESULTS|ab|7|entity|C0041674|Unemployment|fndg|||unemployment|||0|1000|910|922
SE|25462404|RESULTS|ab|7|entity|C0740183|Psychiatry service|hcro|||psychiatric services|||0|947|937|957
SE|25462404|RESULTS|ab|7|entity|C0037317|Sleep disturbances|dsyn|||sleep disturbance|||0|1000|962|979
SE|25462404|RESULTS|ab|7|entity|C0205172|More|ftcn|||more|||0|888|989|993
SE|25462404|RESULTS|ab|7|entity|C0205214|Common|qnco|||common|||0|888|994|1000
SE|25462404|RESULTS|ab|7|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|1004|1009
SE|25462404|RESULTS|ab|7|entity|C0243148|control|ftcn|||controls|||0|966|1015|1023

SE|25462404|RESULTS|ab|8|text|1025|1170|Even after adjustment for known risk factors, the risk of repetition remained higher in the bipolar group (adjusted HR 1.68; 95% CI; 1.10-2.56).
SE|25462404|RESULTS|ab|8|entity|C0205309|Known|qlco|||known|||0|901|1051|1056
SE|25462404|RESULTS|ab|8|entity|C0035648|risk factors|qnco|||risk factors|||0|901|1057|1069
SE|25462404|RESULTS|ab|8|entity|C0035647|Risk|qlco|||risk|||0|1000|1075|1079
SE|25462404|RESULTS|ab|8|entity|C0205250|High|qlco|||higher|||0|966|1103|1109
SE|25462404|RESULTS|ab|8|entity|C0443156|Bipolar|spco|||bipolar|||0|888|1117|1124
SE|25462404|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|888|1125|1130
SE|25462404|RESULTS|ab|8|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|733|1132|1140
SE|25462404|RESULTS|ab|8|entity|C0580272|1/2|inpr|||1.10-2|||0|875|1158|1164

SE|25462404|LIMITATIONS|ab|9|text|1170|1353|LIMITATIONS: The study covers cases from hospital sites in Manchester, UK, and therefore only includes self-harm that was serious enough to present at hospital emergency departments.
SE|25462404|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1170|1181
SE|25462404|LIMITATIONS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|1000|1187|1192
SE|25462404|LIMITATIONS|ab|9|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|1200|1205
SE|25462404|LIMITATIONS|ab|9|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|888|1211|1219
SE|25462404|LIMITATIONS|ab|9|entity|C0205145|Site|spco|||sites|||0|888|1220|1225
SE|25462404|LIMITATIONS|ab|9|entity|C0036588|Self|idcn|||self|||0|1000|1273|1277
SE|25462404|LIMITATIONS|ab|9|entity|C0205404|Serious|qlco|||serious|||0|1000|1292|1299
SE|25462404|LIMITATIONS|ab|9|entity|C0019961|Hospital Departments|hcro,mnob|||hospital emergency departments|||0|901|1321|1351
SE|25462404|LIMITATIONS|ab|9|relation|1|1|C0019961|Hospital Departments|hcro,mnob|hcro|||hospital emergency departments|||0|901|1321|1351|PREP|LOCATION_OF||1318|1320|8|7|C0008972|Clinical Research|resa|resa|||study|||0|1000|1187|1192

SE|25462404|CONCLUSION|ab|10|text|1353|1483|CONCLUSION: People with bipolar disorder who self-harm have a higher risk of repetition than people who self-harm more generally.
SE|25462404|CONCLUSION|ab|10|entity|C0027361|Persons|popg|||People|||0|1000|1365|1371
SE|25462404|CONCLUSION|ab|10|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|1377|1393
SE|25462404|CONCLUSION|ab|10|entity|C0036588|Self|idcn|||self|||0|694|1398|1402
SE|25462404|CONCLUSION|ab|10|entity|C0205250|High|qlco|||higher|||0|872|1415|1421
SE|25462404|CONCLUSION|ab|10|entity|C0035647|Risk|qlco|||risk|||0|872|1422|1426
SE|25462404|CONCLUSION|ab|10|entity|C0027361|Persons|popg|||people|||0|1000|1446|1452
SE|25462404|CONCLUSION|ab|10|entity|C0036588|Self|idcn|||self|||0|812|1457|1461
SE|25462404|CONCLUSION|ab|10|relation|5|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|1377|1393|PREP|PROCESS_OF||1372|1376|2|1|C0027361|Persons|popg,humn|humn|||People|||0|1000|1365|1371

SE|25462404|CONCLUSION|ab|11|text|1483|1567|Adjusting for some known risk factors moderated, but did not abolish, this finding.
SE|25462404|CONCLUSION|ab|11|entity|C1439356|ADJUSTED|qlco|||Adjusting|||0|966|1483|1492
SE|25462404|CONCLUSION|ab|11|entity|C0205309|Known|qlco|||known|||0|901|1502|1507
SE|25462404|CONCLUSION|ab|11|entity|C0035648|risk factors|qnco|||risk factors|||0|901|1508|1520
SE|25462404|CONCLUSION|ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|1540|1543
SE|25462404|CONCLUSION|ab|11|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|1000|1558|1565

SE|25462404|CONCLUSION|ab|12|text|1567|1625|Other factors, such as impulsivity, may also be important.
SE|25462404|CONCLUSION|ab|12|entity|C1521761|Factor|ftcn|||factors|||0|966|1573|1580
SE|25462404|CONCLUSION|ab|12|entity|C0815111|impulsivity|inbe|||impulsivity|||0|1000|1590|1601


SE|25462405||ti|1|text|21|127|Prevalence rates and clinical implications of bipolar disorder "with mixed features" as defined by DSM-5.
SE|25462405||ti|1|entity|C1521828|Rate|qnco|||rates|||0|827|32|37
SE|25462405||ti|1|entity|C0205210|Clinical|qlco|||clinical|||0|694|42|50
SE|25462405||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|67|83
SE|25462405||ti|1|entity|C0205430|Mixed|ftcn|||mixed|||0|694|90|95

SE|25462405|BACKGROUND|ab|1|text|133|301|BACKGROUND: We investigated the increase in the prevalence of bipolar disorder with mixed features following the replacement of DSM-IV-TR criteria with DSM-5 criteria.
SE|25462405|BACKGROUND|ab|1|entity|C0442805|Increase|ftcn|||increase|||0|1000|165|173
SE|25462405|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|195|211
SE|25462405|BACKGROUND|ab|1|entity|C0205430|Mixed|ftcn|||mixed|||0|694|217|222
SE|25462405|BACKGROUND|ab|1|entity|C0035139|Surgical Replantation|topp|||replacement|||0|1000|246|257
SE|25462405|BACKGROUND|ab|1|entity|C0220952|DSM-IV|inpr|||DSM-IV-TR|||0|824|261|270
SE|25462405|BACKGROUND|ab|1|entity|C0243161|criteria|inpr|||criteria|||0|824|271|279
SE|25462405|BACKGROUND|ab|1|entity|C0243161|criteria|inpr|||criteria|||0|827|291|299

SE|25462405|BACKGROUND|ab|2|text|301|427|Additionally, we examined the clinical implications of the use of "with mixed features" as a specifier with bipolar disorder.
SE|25462405|BACKGROUND|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|694|331|339
SE|25462405|BACKGROUND|ab|2|entity|C0205430|Mixed|ftcn|||mixed|||0|694|373|378
SE|25462405|BACKGROUND|ab|2|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|409|425

SE|25462405|METHOD|ab|3|text|427|497|METHOD: We retrospectively reviewed medical charts from 2003 to 2013.
SE|25462405|METHOD|ab|3|entity|C0025663|Methods|inpr|||METHOD|||0|1000|427|433
SE|25462405|METHOD|ab|3|entity|C0205476|Medical|ftcn|||medical|||0|888|463|470
SE|25462405|METHOD|ab|3|entity|C0007963|Charts|medd|||charts|||0|888|471|477

SE|25462405|METHOD|ab|4|text|497|767|A total of 331 patients diagnosed with bipolar disorder using the DSM-IV TR were enrolled and categorized into four groups: manic/hypomanic with mixed features, manic/hypomanic without mixed features, depressed with mixed features, and depressed without mixed features.
SE|25462405|METHOD|ab|4|entity|C0439175|% of total|qnco|||total|||0|1000|499|504
SE|25462405|METHOD|ab|4|entity|C0030705|Patients|podg|||patients|||0|861|512|520
SE|25462405|METHOD|ab|4|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|536|552
SE|25462405|METHOD|ab|4|entity|C0220952|DSM-IV|inpr|||DSM-IV|||0|734|563|569
SE|25462405|METHOD|ab|4|entity|C0205450|Four|qnco|||four|||0|888|608|612
SE|25462405|METHOD|ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|613|619
SE|25462405|METHOD|ab|4|entity|C0338831|Manic|mobd|||manic|||0|853|621|626
SE|25462405|METHOD|ab|4|entity|C0241934|Hypomania|mobd|||hypomanic|||0|853|627|636
SE|25462405|METHOD|ab|4|entity|C0205430|Mixed|ftcn|||mixed|||0|694|642|647
SE|25462405|METHOD|ab|4|entity|C0338831|Manic|mobd|||manic|||0|853|658|663
SE|25462405|METHOD|ab|4|entity|C0241934|Hypomania|mobd|||hypomanic|||0|853|664|673
SE|25462405|METHOD|ab|4|entity|C0205430|Mixed|ftcn|||mixed|||0|694|682|687
SE|25462405|METHOD|ab|4|entity|C0205430|Mixed|ftcn|||mixed|||0|694|713|718
SE|25462405|METHOD|ab|4|entity|C0205430|Mixed|ftcn|||mixed|||0|694|751|756
SE|25462405|METHOD|ab|4|relation|9|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|536|552|VERB|PROCESS_OF||521|530|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|512|520

SE|25462405|METHOD|ab|5|text|767|882|These classifications were made in accordance with the DSM-5 definition of bipolar disorder "with mixed features."
SE|25462405|METHOD|ab|5|entity|C0008902|Classification|clas|||classifications|||0|1000|773|788
SE|25462405|METHOD|ab|5|entity|C1550452|definition|idcn|||definition|||0|827|828|838
SE|25462405|METHOD|ab|5|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|842|858
SE|25462405|METHOD|ab|5|entity|C0205430|Mixed|ftcn|||mixed|||0|694|865|870

SE|25462405|METHOD|ab|6|text|882|982|Changes in the prevalence, demographic and clinical characteristics were compared among the groups.
SE|25462405|METHOD|ab|6|entity|C0011298|Demography|ocdi|||demographic|||0|928|909|920
SE|25462405|METHOD|ab|6|entity|C0683325|clinical aspects|clna|||clinical characteristics|||0|1000|925|949
SE|25462405|METHOD|ab|6|entity|C0441833|Groups|inpr|||groups|||0|1000|974|980

SE|25462405|RESULTS|ab|7|text|982|1117|RESULTS: The prevalence rates of mixed features were significantly different when using the DSM-5 criteria vs. the DSM-IV-TR criteria.
SE|25462405|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|982|989
SE|25462405|RESULTS|ab|7|entity|C1521828|Rate|qnco|||rates|||0|827|1006|1011
SE|25462405|RESULTS|ab|7|entity|C0205430|Mixed|ftcn|||mixed|||0|694|1015|1020
SE|25462405|RESULTS|ab|7|entity|C1547020|*Difference|qnco|||different|||0|789|1049|1058
SE|25462405|RESULTS|ab|7|entity|C0243161|criteria|inpr|||criteria|||0|827|1080|1088
SE|25462405|RESULTS|ab|7|entity|C0220952|DSM-IV|inpr|||DSM-IV-TR|||0|824|1097|1106
SE|25462405|RESULTS|ab|7|entity|C0243161|criteria|inpr|||criteria|||0|824|1107|1115

SE|25462405|RESULTS|ab|8|text|1117|1329|Patients with mixed features had a younger age of onset, younger age at hospitalization, more frequent hospitalizations for mixed episodes, and greater suicide risk compared with patients without mixed features.
SE|25462405|RESULTS|ab|8|entity|C0030705|Patients|podg|||Patients|||0|1000|1117|1125
SE|25462405|RESULTS|ab|8|entity|C0205430|Mixed|ftcn|||mixed|||0|694|1131|1136
SE|25462405|RESULTS|ab|8|entity|C0332239|Young|tmco|||younger|||0|872|1152|1159
SE|25462405|RESULTS|ab|8|entity|C0001779|Age|orga|||age|||0|872|1160|1163
SE|25462405|RESULTS|ab|8|entity|C0332162|Onset|qlco|||onset|||0|1000|1167|1172
SE|25462405|RESULTS|ab|8|entity|C0332239|Young|tmco|||younger|||0|872|1174|1181
SE|25462405|RESULTS|ab|8|entity|C0001779|Age|orga|||age|||0|872|1182|1185
SE|25462405|RESULTS|ab|8|entity|C0019993|Hospitalization|hlca|||hospitalization|||0|1000|1189|1204
SE|25462405|RESULTS|ab|8|entity|C0205172|More|ftcn|||more|||0|851|1206|1210
SE|25462405|RESULTS|ab|8|entity|C0332183|Frequent|tmco|||frequent|||0|851|1211|1219
SE|25462405|RESULTS|ab|8|entity|C0019993|Hospitalization|hlca|||hospitalizations|||0|851|1220|1236
SE|25462405|RESULTS|ab|8|entity|C0205430|Mixed|ftcn|||mixed|||0|888|1241|1246
SE|25462405|RESULTS|ab|8|entity|C0332189|Episode of|tmco|||episodes|||0|888|1247|1255
SE|25462405|RESULTS|ab|8|entity|C0443228|Largest|qnco|||greater|||0|851|1261|1268
SE|25462405|RESULTS|ab|8|entity|C0038661|Suicide|inpo|||suicide|||0|851|1269|1276
SE|25462405|RESULTS|ab|8|entity|C0035647|Risk|qlco|||risk|||0|851|1277|1281
SE|25462405|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1296|1304
SE|25462405|RESULTS|ab|8|entity|C0205430|Mixed|ftcn|||mixed|||0|694|1313|1318

SE|25462405|LIMITATIONS|ab|9|text|1329|1416|LIMITATIONS: Retrospective study may have resulted in under diagnosis of mixed states.
SE|25462405|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1329|1340
SE|25462405|LIMITATIONS|ab|9|entity|C0035363|Retrospective Studies|qnco|||Retrospective study|||0|1000|1342|1361
SE|25462405|LIMITATIONS|ab|9|entity|C0542339|Inferior|spco|||under|||0|888|1383|1388
SE|25462405|LIMITATIONS|ab|9|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|888|1389|1398
SE|25462405|LIMITATIONS|ab|9|entity|C0680584|mixed state|rnlw|||mixed states|||0|983|1402|1414

SE|25462405|CONCLUSIONS|ab|10|text|1416|1606|CONCLUSIONS: An approximately three-fold greater risk for mixed features was observed in patients with bipolar disorder when using the DSM-5 criteria than when using the DSM-IV-TR criteria.
SE|25462405|CONCLUSIONS|ab|10|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|822|1432|1445
SE|25462405|CONCLUSIONS|ab|10|entity|C0205449|Three|qnco|||three|||0|822|1446|1451
SE|25462405|CONCLUSIONS|ab|10|entity|C0332462|Fold|spco|||fold|||0|822|1452|1456
SE|25462405|CONCLUSIONS|ab|10|entity|C0443228|Largest|qnco|||greater|||0|822|1457|1464
SE|25462405|CONCLUSIONS|ab|10|entity|C0035647|Risk|qlco|||risk|||0|822|1465|1469
SE|25462405|CONCLUSIONS|ab|10|entity|C0205430|Mixed|ftcn|||mixed|||0|694|1474|1479
SE|25462405|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1505|1513
SE|25462405|CONCLUSIONS|ab|10|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|1519|1535
SE|25462405|CONCLUSIONS|ab|10|entity|C0243161|criteria|inpr|||criteria|||0|827|1557|1565
SE|25462405|CONCLUSIONS|ab|10|entity|C0220952|DSM-IV|inpr|||DSM-IV-TR|||0|824|1586|1595
SE|25462405|CONCLUSIONS|ab|10|entity|C0243161|criteria|inpr|||criteria|||0|824|1596|1604
SE|25462405|CONCLUSIONS|ab|10|relation|3|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|1519|1535|PREP|PROCESS_OF||1514|1518|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1505|1513

SE|25462405|CONCLUSIONS|ab|11|text|1606|1759|The additional patients may represent patients with sub-syndromal mixed features and could indicate that patients with mixed features are underdiagnosed.
SE|25462405|CONCLUSIONS|ab|11|entity|C1524062|Additional|ftcn|||additional|||0|888|1610|1620
SE|25462405|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|888|1621|1629
SE|25462405|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1644|1652
SE|25462405|CONCLUSIONS|ab|11|entity|C0542339|Inferior|spco|||sub|||0|584|1658|1661
SE|25462405|CONCLUSIONS|ab|11|entity|C0039082|Syndrome|dsyn|||syndromal|||0|584|1662|1671
SE|25462405|CONCLUSIONS|ab|11|entity|C0205430|Mixed|ftcn|||mixed|||0|584|1672|1677
SE|25462405|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1711|1719
SE|25462405|CONCLUSIONS|ab|11|entity|C0205430|Mixed|ftcn|||mixed|||0|694|1725|1730


SE|25462406||ti|1|text|21|142|Characteristics and differences in treatment outcome of inpatients with chronic vs. episodic major depressive disorders.
SE|25462406||ti|1|entity|C1521970|Characteristics|grpa|||Characteristics|||0|1000|21|36
SE|25462406||ti|1|entity|C1547020|*Difference|qnco|||differences|||0|966|41|52
SE|25462406||ti|1|entity|C0085415|Treatment outcome|qlco|||treatment outcome|||0|1000|56|73
SE|25462406||ti|1|entity|C0021562|inpatient|podg|||inpatients|||0|1000|77|87
SE|25462406||ti|1|entity|C0205191|chronic|tmco|||chronic|||0|1000|93|100
SE|25462406||ti|1|entity|C1455761|Episodic|qlco|||episodic|||0|916|105|113
SE|25462406||ti|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorders|||0|916|114|140

SE|25462406|BACKGROUND|ab|1|text|148|273|BACKGROUND: Approximately 20-30% of patients with Major depressive disorder (MDD) develop a chronic course of their disease.
SE|25462406|BACKGROUND|ab|1|entity|C0332232|Approximate|ftcn,qlco|||Approximately|||0|827|160|173
SE|25462406|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|184|192
SE|25462406|BACKGROUND|ab|1|entity|C1269683|Major Depressive Disorder|mobd|||Major depressive disorder|||0|1000|198|223
SE|25462406|BACKGROUND|ab|1|entity|C0205191|chronic|tmco|||chronic|||0|888|240|247
SE|25462406|BACKGROUND|ab|1|entity|C0750729|Course|tmco|||course|||0|888|248|254
SE|25462406|BACKGROUND|ab|1|entity|C0012634|Disease|dsyn|||disease|||0|1000|264|271
SE|25462406|BACKGROUND|ab|1|relation|3|1|C1269683|Major Depressive Disorder|mobd|mobd|||Major depressive disorder|||0|1000|198|223|PREP|PROCESS_OF||193|197|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|184|192

SE|25462406|BACKGROUND|ab|2|text|273|391|Chronic depression is associated with increased health care utilisation, hospitalisation and a higher disease burden.
SE|25462406|BACKGROUND|ab|2|entity|C0581391|Chronic depression|mobd|||Chronic depression|||0|1000|273|291
SE|25462406|BACKGROUND|ab|2|entity|C0205217|Increased|qnco|||increased|||0|916|311|320
SE|25462406|BACKGROUND|ab|2|entity|C0237939|health care utilization|hlca|||health care utilisation|||0|916|321|344
SE|25462406|BACKGROUND|ab|2|entity|C0019993|Hospitalization|hlca|||hospitalisation|||0|1000|346|361
SE|25462406|BACKGROUND|ab|2|entity|C0205250|High|qlco|||higher|||0|606|368|374
SE|25462406|BACKGROUND|ab|2|entity|C0012634|Disease|dsyn|||disease|||0|606|375|382

SE|25462406|BACKGROUND|ab|3|text|391|583|We identified clinical correlates and differences in treatment response of chronic MDD (cMDD) patients compared with non-chronic episodic depression in a huge sample of depressive inpatients.
SE|25462406|BACKGROUND|ab|3|entity|C0205210|Clinical|qlco|||clinical|||0|694|405|413
SE|25462406|BACKGROUND|ab|3|entity|C1547020|*Difference|qnco|||differences|||0|966|429|440
SE|25462406|BACKGROUND|ab|3|entity|C0871261|response|clna|||response|||0|888|454|462
SE|25462406|BACKGROUND|ab|3|entity|C0205164|Major|qlco|||MDD|||0|916|474|477
SE|25462406|BACKGROUND|ab|3|entity|C0581391|Chronic depression|mobd|||chronic MDD|||0|916|466|477
SE|25462406|BACKGROUND|ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|485|493
SE|25462406|BACKGROUND|ab|3|entity|C1455761|Episodic|qlco|||episodic|||0|824|520|528
SE|25462406|BACKGROUND|ab|3|entity|C0581391|Chronic depression|mobd|||chronic episodic depression|||0|824|512|539
SE|25462406|BACKGROUND|ab|3|entity|C0021562|inpatient|podg|||inpatients|||0|861|571|581

SE|25462406|METHODS|ab|4|text|583|797|METHODS: Data were collected from 412 inpatients who had been diagnosed with a major depressive episode (MDE; according to ICD-10) and scored 15 or higher on the 21-item Hamilton Depression Rating Scale (HRSD-21).
SE|25462406|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|583|590
SE|25462406|METHODS|ab|4|entity|C1511726|Data|idcn|||Data|||0|1000|592|596
SE|25462406|METHODS|ab|4|entity|C0021562|inpatient|podg|||inpatients|||0|861|621|631
SE|25462406|METHODS|ab|4|entity|C0024517|Major Depressive Disorder, Single Episode, Unspecified|mobd|||major depressive episode|||0|1000|662|686
SE|25462406|METHODS|ab|4|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ICD-10|||0|1000|706|712
SE|25462406|METHODS|ab|4|entity|C0205250|High|qlco|||higher|||0|966|731|737
SE|25462406|METHODS|ab|4|entity|C0871208|Rating|resa|||Rating|||0|762|773|779
SE|25462406|METHODS|ab|4|entity|C0679604|depression scale|diap,inpr|||Depression Rating Scale|||0|762|762|785
SE|25462406|METHODS|ab|4|relation|5|1|C0024517|Major Depressive Disorder, Single Episode, Unspecified|mobd|mobd|||major depressive episode|||0|1000|662|686|VERB|PROCESS_OF||645|654|3|1|C0021562|inpatient|podg,humn|humn|||inpatients|||0|861|621|631

SE|25462406|METHODS|ab|5|text|797|877|All subjects were participants in the German Algorithm Project, phase 3 (GAP3).
SE|25462406|METHODS|ab|5|entity|C1550501|subject|idcn|||subjects|||0|966|801|809
SE|25462406|METHODS|ab|5|entity|C0679646|Participant|popg|||participants|||0|966|815|827
SE|25462406|METHODS|ab|5|entity|C0002045|algorithm|inpr|||Algorithm|||0|660|842|851
SE|25462406|METHODS|ab|5|entity|C0439561|Phase 3|tmco|||phase 3|||0|1000|861|868

SE|25462406|METHODS|ab|6|text|877|1062|Patients who were diagnosed with a MDE within the last two years or longer (herein referred to as CD) were compared with non-chronic depressive patients (herein referred to as non-CD).
SE|25462406|METHODS|ab|6|entity|C0030705|Patients|podg|||Patients|||0|1000|877|885
SE|25462406|METHODS|ab|6|entity|C1517741|Last|qlco|||last|||0|851|927|931
SE|25462406|METHODS|ab|6|entity|C0205448|Two|qnco|||two|||0|851|932|935
SE|25462406|METHODS|ab|6|entity|C0439234|year|tmco|||years|||0|851|936|941
SE|25462406|METHODS|ab|6|entity|C0205166|Long|qlco|||longer|||0|966|945|951
SE|25462406|METHODS|ab|6|entity|C0205191|chronic|tmco|||chronic|||0|763|1002|1009
SE|25462406|METHODS|ab|6|entity|C0030705|Patients|podg|||patients|||0|763|1021|1029

SE|25462406|METHODS|ab|7|text|1062|1323|CD and non-CD patients were assessed for the following: psychosocial characteristics, symptom reduction from hospital admission to discharge, symptom severity at discharge, remission and response rates, and pharmacological treatment during inpatient treatment.
SE|25462406|METHODS|ab|7|entity|C0030705|Patients|podg|||patients|||0|827|1076|1084
SE|25462406|METHODS|ab|7|entity|C0332282|Following|tmco|||following|||0|1000|1107|1116
SE|25462406|METHODS|ab|7|entity|C0542298|Psychosocial|ftcn|||psychosocial|||0|888|1118|1130
SE|25462406|METHODS|ab|7|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|1131|1146
SE|25462406|METHODS|ab|7|entity|C1457887|Symptoms|sosy|||symptom|||0|694|1148|1155
SE|25462406|METHODS|ab|7|entity|C0184666|Hospital admission|hlca|||hospital admission|||0|1000|1171|1189
SE|25462406|METHODS|ab|7|entity|C1457887|Symptoms|sosy|||symptom|||0|888|1204|1211
SE|25462406|METHODS|ab|7|entity|C0439793|Severities|qlco|||severity|||0|888|1212|1220
SE|25462406|METHODS|ab|7|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|1000|1224|1233
SE|25462406|METHODS|ab|7|entity|C0237629|Frequency of Responses|tmco|||response rates|||0|983|1249|1263
SE|25462406|METHODS|ab|7|entity|C1519033|Pharmacological Treatment|topp|||pharmacological treatment|||0|1000|1269|1294
SE|25462406|METHODS|ab|7|entity|C0019993|Hospitalization|hlca|||inpatient treatment|||0|1000|1302|1321
SE|25462406|METHODS|ab|7|relation|7|6|C1519033|Pharmacological Treatment|topp|topp|||pharmacological treatment|||0|1000|1269|1294|NOM|PREVENTS||1156|1165|4|0|C1457887|Symptoms|sosy|sosy|||symptom|||0|694|1148|1155
SE|25462406|METHODS|ab|7|relation|11|1|C1519033|Pharmacological Treatment|topp|topp|||pharmacological treatment|||0|1000|1269|1294|PREP|COEXISTS_WITH||1295|1301|1|1|C0019993|Hospitalization|hlca|hlca|||inpatient treatment|||0|1000|1302|1321

SE|25462406|METHODS|ab|8|text|1323|1368|The primary outcome measure was the HRSD-21.
SE|25462406|METHODS|ab|8|entity|C0086749|Outcome Measures|qnco|||outcome measure|||0|901|1335|1350

SE|25462406|RESULTS|ab|9|text|1368|1443|RESULTS: 13.6% (n=56) of patients met the criteria for chronic depression.
SE|25462406|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1368|1375
SE|25462406|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1393|1401
SE|25462406|RESULTS|ab|9|entity|C0243161|criteria|inpr|||criteria|||0|1000|1410|1418
SE|25462406|RESULTS|ab|9|entity|C0581391|Chronic depression|mobd|||chronic depression|||0|1000|1423|1441

SE|25462406|RESULTS|ab|10|text|1443|1747|Compared with non-CD patients, patients with CD showed increased axis I comorbidities (74% vs. 52%, chi(2) (1)=7.31, p=.02), a higher level of depressive symptoms at baseline and discharge, increased duration of inpatient treatment (64.8 vs. 53.3 days; t=2.86, p=.03) and lower response (HRSD: 60.0% vs.
SE|25462406|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|827|1464|1472
SE|25462406|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1474|1482
SE|25462406|RESULTS|ab|10|entity|C0205217|Increased|qnco|||increased|||0|888|1498|1507
SE|25462406|RESULTS|ab|10|entity|C1522496|Axis|spco|||axis|||0|888|1508|1512
SE|25462406|RESULTS|ab|10|entity|C0009488|Comorbidity|idcn|||comorbidities|||0|1000|1515|1528
SE|25462406|RESULTS|ab|10|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1560|1561
SE|25462406|RESULTS|ab|10|entity|C0205250|High|qlco|||higher|||0|661|1570|1576
SE|25462406|RESULTS|ab|10|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|1586|1605
SE|25462406|RESULTS|ab|10|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1609|1617
SE|25462406|RESULTS|ab|10|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|1000|1622|1631
SE|25462406|RESULTS|ab|10|entity|C0205217|Increased|qnco|||increased|||0|888|1633|1642
SE|25462406|RESULTS|ab|10|entity|C0449238|Duration|tmco|||duration|||0|888|1643|1651
SE|25462406|RESULTS|ab|10|entity|C0019993|Hospitalization|hlca|||inpatient treatment|||0|1000|1655|1674
SE|25462406|RESULTS|ab|10|entity|C0439228|day|tmco|||days|||0|827|1690|1694
SE|25462406|RESULTS|ab|10|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1704|1705
SE|25462406|RESULTS|ab|10|entity|C0441994|Lower|ftcn|||lower|||0|888|1715|1720
SE|25462406|RESULTS|ab|10|entity|C0871261|response|clna|||response|||0|888|1721|1729

SE|25462406|RESULTS|ab|11|text|1747|1793|72.0%; chi(2) (1)=3.61, p<.04; BDI: 40.5% vs.
SE|25462406|RESULTS|ab|11|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1771|1772
SE|25462406|RESULTS|ab|11|entity|C0451022|Beck depression inventory|diap|||BDI|||0|1000|1778|1781
SE|25462406|RESULTS|ab|11|entity|C0439509|/40|tmco|||40|||0|861|1783|1785

SE|25462406|RESULTS|ab|12|text|1793|1860|54.2%; chi(2) (1)=3.56, p=.04) and remission rates (BDI 17.9.% vs.
SE|25462406|RESULTS|ab|12|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1817|1818
SE|25462406|RESULTS|ab|12|entity|C1521828|Rate|qnco|||rates|||0|827|1838|1843
SE|25462406|RESULTS|ab|12|entity|C0451022|Beck depression inventory|diap|||BDI|||0|827|1845|1848

SE|25462406|RESULTS|ab|13|text|1860|1891|29.7%; chi(2) (1)=3.42, p=.05.
SE|25462406|RESULTS|ab|13|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1884|1885

SE|25462406|RESULTS|ab|14|text|1891|1980|However, both groups achieved a comparable symptom reduction during inpatient treatment.
SE|25462406|RESULTS|ab|14|entity|C0441833|Groups|inpr|||groups|||0|1000|1905|1911
SE|25462406|RESULTS|ab|14|entity|C1457887|Symptoms|sosy|||symptom|||0|660|1934|1941
SE|25462406|RESULTS|ab|14|entity|C0019993|Hospitalization|hlca|||inpatient treatment|||0|1000|1959|1978

SE|25462406|RESULTS|ab|15|text|1980|2091|The prescribed pharmacological strategy had no significant influence on treatment outcome in patients with CD.
SE|25462406|RESULTS|ab|15|entity|C0278329|Prescribed|ftcn|||prescribed|||0|851|1984|1994
SE|25462406|RESULTS|ab|15|entity|C0205464|pharmacological|ftcn|||pharmacological|||0|851|1995|2010
SE|25462406|RESULTS|ab|15|entity|C0750502|Significant|idcn|||significant|||0|694|2027|2038
SE|25462406|RESULTS|ab|15|entity|C0085415|Treatment outcome|qlco|||treatment outcome|||0|1000|2052|2069
SE|25462406|RESULTS|ab|15|entity|C0030705|Patients|podg|||patients|||0|1000|2073|2081

SE|25462406|CONCLUSION|ab|16|text|2091|2302|CONCLUSION: Inpatients with CD show higher symptom severity, lower response and remission rates and a longer duration of inpatient treatment, although they achieve comparable symptom reduction during treatment.
SE|25462406|CONCLUSION|ab|16|entity|C0021562|inpatient|podg|||Inpatients|||0|1000|2103|2113
SE|25462406|CONCLUSION|ab|16|entity|C0205250|High|qlco|||higher|||0|840|2127|2133
SE|25462406|CONCLUSION|ab|16|entity|C1457887|Symptoms|sosy|||symptom|||0|840|2134|2141
SE|25462406|CONCLUSION|ab|16|entity|C0439793|Severities|qlco|||severity|||0|840|2142|2150
SE|25462406|CONCLUSION|ab|16|entity|C0871261|response|clna|||response|||0|1000|2158|2166
SE|25462406|CONCLUSION|ab|16|entity|C1521828|Rate|qnco|||rates|||0|827|2181|2186
SE|25462406|CONCLUSION|ab|16|entity|C0439591|Long duration|qlco|||longer duration|||0|983|2193|2208
SE|25462406|CONCLUSION|ab|16|entity|C0019993|Hospitalization|hlca|||inpatient treatment|||0|1000|2212|2231
SE|25462406|CONCLUSION|ab|16|entity|C1457887|Symptoms|sosy|||symptom|||0|660|2266|2273
SE|25462406|CONCLUSION|ab|16|relation|8|1|C0019993|Hospitalization|hlca|hlca|||inpatient treatment|||0|1000|2212|2231|NOM|PREVENTS||2274|2283|8|0|C1457887|Symptoms|sosy|sosy|||symptom|||0|660|2266|2273

SE|25462406|CONCLUSION|ab|17|text|2302|2420|These findings support the need to recognise CD and its defining characteristics as a distinct subclass of depression.
SE|25462406|CONCLUSION|ab|17|entity|C0243095|Finding|ftcn|||findings|||0|1000|2308|2316
SE|25462406|CONCLUSION|ab|17|entity|C0027552|Needs|qlco|||need|||0|1000|2329|2333
SE|25462406|CONCLUSION|ab|17|entity|C1521970|Characteristics|grpa|||characteristics|||0|861|2367|2382
SE|25462406|CONCLUSION|ab|17|entity|C0445604|Subclass|inpr|||subclass|||0|861|2397|2405
SE|25462406|CONCLUSION|ab|17|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|2409|2419


SE|25462407||ti|1|text|21|96|Features preceding diagnosis of bipolar versus major depressive disorders.
SE|25462407||ti|1|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|40|49
SE|25462407||ti|1|entity|C0443156|Bipolar|spco|||bipolar|||0|1000|53|60
SE|25462407||ti|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorders|||0|1000|68|94

SE|25462407|BACKGROUND|ab|1|text|102|274|BACKGROUND: Better and earlier predictive differentiation of bipolar (BD) vs. unipolar major depressive disorder (UD) diagnoses should improve long-term clinical planning.
SE|25462407|BACKGROUND|ab|1|entity|C0332272|Better|qlco|||Better|||0|1000|114|120
SE|25462407|BACKGROUND|ab|1|entity|C1279919|Early|tmco|||earlier|||0|606|125|132
SE|25462407|BACKGROUND|ab|1|entity|C0681890|predictive|qlco|||predictive|||0|606|133|143
SE|25462407|BACKGROUND|ab|1|entity|C0443156|Bipolar|spco|||bipolar|||0|1000|163|170
SE|25462407|BACKGROUND|ab|1|entity|C0443340|Unipolar|spco|||unipolar|||0|916|180|188
SE|25462407|BACKGROUND|ab|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|916|189|214
SE|25462407|BACKGROUND|ab|1|entity|C0011900|Diagnosis|hlca|||diagnoses|||0|1000|220|229
SE|25462407|BACKGROUND|ab|1|entity|C0443252|Long-term|tmco|||long-term|||0|658|245|254
SE|25462407|BACKGROUND|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|658|255|263

SE|25462407|METHODS|ab|2|text|274|537|METHODS: We reviewed randomly selected clinical records of 334 adults diagnosed with DSM-IV-TR BD-I (n=109), BD-II (n=106), and UD (n=119) and compared features preceding major affective episodes or diagnoses, using bivariate, multivariate, and Bayesian methods.
SE|25462407|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|274|281
SE|25462407|METHODS|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|888|313|321
SE|25462407|METHODS|ab|2|entity|C0034869|Records|inpr|||records|||0|888|322|329
SE|25462407|METHODS|ab|2|entity|C0001675|Adult|aggp|||adults|||0|861|337|343
SE|25462407|METHODS|ab|2|entity|C0220952|DSM-IV|inpr|||DSM-IV-TR|||0|824|359|368
SE|25462407|METHODS|ab|2|entity|C0421451|Date of birth|fndg|||BD-II|||0|694|383|388
SE|25462407|METHODS|ab|2|entity|C0205164|Major|qlco|||major|||0|802|445|450
SE|25462407|METHODS|ab|2|entity|C0332189|Episode of|tmco|||episodes|||0|802|461|469
SE|25462407|METHODS|ab|2|entity|C0011900|Diagnosis|hlca|||diagnoses|||0|1000|473|482
SE|25462407|METHODS|ab|2|entity|C0242198|Bayesian Method|qnco|||Bayesian methods|||0|983|519|535

SE|25462407|RESULTS|ab|3|text|537|613|RESULTS: We identified antecedents selectively associated with later BD vs.
SE|25462407|RESULTS|ab|3|entity|C1274040|result|ftcn|||RESULTS|||0|966|537|544
SE|25462407|RESULTS|ab|3|entity|C0205087|Late|tmco|||later|||0|872|600|605

SE|25462407|RESULTS|ab|4|text|613|629|UD in 52.6% vs.

SE|25462407|RESULTS|ab|5|text|629|702|31.1% of subjects in childhood, starting at age 7.4 years, and 60.0% vs.
SE|25462407|RESULTS|ab|5|entity|C1550501|subject|idcn|||subjects|||0|966|638|646
SE|25462407|RESULTS|ab|5|entity|C0231335|Childhood|tmco|||childhood|||0|1000|650|659
SE|25462407|RESULTS|ab|5|entity|C1510829|Age-Years|tmco|||age 7.4 years|||0|902|673|686

SE|25462407|RESULTS|ab|6|text|702|810|32.8% in adolescence, with far more features in BD than UD cases (10.3 vs. 4.64/100 person-years; p<0.001).
SE|25462407|RESULTS|ab|6|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|711|722
SE|25462407|RESULTS|ab|6|entity|C1517331|Further|spco|||far|||0|966|729|732
SE|25462407|RESULTS|ab|6|entity|C0205172|More|ftcn|||more|||0|1000|733|737
SE|25462407|RESULTS|ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|861|761|766
SE|25462407|RESULTS|ab|6|entity|C0027361|Persons|popg|||person|||0|728|786|792
SE|25462407|RESULTS|ab|6|entity|C0439234|year|tmco|||years|||0|728|793|798

SE|25462407|RESULTS|ab|7|text|810|994|In multivariate modeling, BD-selective factors were: younger at first clinical event > male sex > family BD-history > cyclothymic or hyperthymic temperament > antecedents/person-year.
SE|25462407|RESULTS|ab|7|entity|C0870071|Modeling|inpr,resa|||modeling|||0|861|826|834
SE|25462407|RESULTS|ab|7|entity|C1521761|Factor|ftcn|||factors|||0|785|849|856
SE|25462407|RESULTS|ab|7|entity|C0332239|Young|tmco|||younger|||0|966|863|870
SE|25462407|RESULTS|ab|7|entity|C1279901|Firstly|qlco|||first|||0|851|874|879
SE|25462407|RESULTS|ab|7|entity|C0205210|Clinical|qlco|||clinical|||0|851|880|888
SE|25462407|RESULTS|ab|7|entity|C0441471|Events|evnt|||event|||0|851|889|894
SE|25462407|RESULTS|ab|7|entity|C0024554|Male gender|orga|||male sex|||0|1000|897|905
SE|25462407|RESULTS|ab|7|entity|C0015576|Family|famg|||family|||0|851|908|914
SE|25462407|RESULTS|ab|7|entity|C0019664|Recording of previous events|ocdi|||history|||0|851|918|925
SE|25462407|RESULTS|ab|7|entity|C0039474|Temperament|menp|||temperament|||0|861|955|966
SE|25462407|RESULTS|ab|7|entity|C0027361|Persons|popg|||person|||0|790|981|987
SE|25462407|RESULTS|ab|7|entity|C0439234|year|tmco|||year|||0|790|988|992

SE|25462407|RESULTS|ab|8|text|994|1069|Nonaffective (anxiety, eating, or substance-use) disorders preceded BD vs.
SE|25462407|RESULTS|ab|8|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|1008|1015
SE|25462407|RESULTS|ab|8|entity|C0038586|Substance Use Disorders|mobd|||substance-use) disorders|||0|1000|1028|1052

SE|25462407|RESULTS|ab|9|text|1069|1085|UD in 41.4% vs.

SE|25462407|RESULTS|ab|10|text|1085|1113|28.6% of subjects (p=0.02).
SE|25462407|RESULTS|ab|10|entity|C1550501|subject|idcn|||subjects|||0|966|1094|1102

SE|25462407|RESULTS|ab|11|text|1113|1164|By ROC analysis, differential prediction of BD vs.
SE|25462407|RESULTS|ab|11|entity|C0035787|ROC Curve|qnco|||ROC analysis|||0|1000|1116|1128
SE|25462407|RESULTS|ab|11|entity|C0681842|prediction|inpr|||prediction|||0|861|1143|1153

SE|25462407|RESULTS|ab|12|text|1164|1209|UD was optimal with any >= 3 factors/person.
SE|25462407|RESULTS|ab|12|entity|C1521761|Factor|ftcn|||factors|||0|840|1193|1200
SE|25462407|RESULTS|ab|12|entity|C0027361|Persons|popg|||person|||0|840|1201|1207

SE|25462407|LIMITATIONS|ab|13|text|1209|1523|LIMITATIONS: The validity and timing of antecedent events and factors identified retrospectively from clinical records could not be verified independently, but information was recorded systematically and consistently by a single mood-disorder expert prior to diagnosis, and extracted by two independent observers.
SE|25462407|LIMITATIONS|ab|13|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1209|1220
SE|25462407|LIMITATIONS|ab|13|entity|C0449243|Timing|tmco|||timing|||0|1000|1239|1245
SE|25462407|LIMITATIONS|ab|13|entity|C0441471|Events|evnt|||events|||0|861|1260|1266
SE|25462407|LIMITATIONS|ab|13|entity|C1521761|Factor|ftcn|||factors|||0|966|1271|1278
SE|25462407|LIMITATIONS|ab|13|entity|C0205210|Clinical|qlco|||clinical|||0|888|1311|1319
SE|25462407|LIMITATIONS|ab|13|entity|C0034869|Records|inpr|||records|||0|888|1320|1327
SE|25462407|LIMITATIONS|ab|13|entity|C1518422|Not|ftcn|||not|||0|1000|1334|1337
SE|25462407|LIMITATIONS|ab|13|entity|C1533716|Information|idcn|||information|||0|1000|1369|1380
SE|25462407|LIMITATIONS|ab|13|entity|C0037179|Unmarried person|popg|||single|||0|658|1431|1437
SE|25462407|LIMITATIONS|ab|13|entity|C0525045|Mood Disorders|mobd|||mood-disorder|||0|658|1438|1451
SE|25462407|LIMITATIONS|ab|13|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|1468|1477
SE|25462407|LIMITATIONS|ab|13|entity|C0205448|Two|qnco|||two|||0|851|1496|1499
SE|25462407|LIMITATIONS|ab|13|entity|C0870992|Observers|prog|||observers|||0|851|1512|1521

SE|25462407|COMMENT|ab|14|text|1523|1604|COMMENT: Early clinical features distinguished later BD from UD, often by years.
SE|25462407|COMMENT|ab|14|entity|C0947611|Comment|inpr|||COMMENT|||0|1000|1523|1530
SE|25462407|COMMENT|ab|14|entity|C1279919|Early|tmco|||Early|||0|623|1532|1537
SE|25462407|COMMENT|ab|14|entity|C0205210|Clinical|qlco|||clinical|||0|623|1538|1546
SE|25462407|COMMENT|ab|14|entity|C0205087|Late|tmco|||later|||0|872|1570|1575
SE|25462407|COMMENT|ab|14|entity|C0332183|Frequent|tmco|||often|||0|1000|1588|1593
SE|25462407|COMMENT|ab|14|entity|C0439234|year|tmco|||years|||0|1000|1597|1602

SE|25462407|COMMENT|ab|15|text|1604|1687|Such prediction should improve treatment-planning and limit risk of mood-switching.
SE|25462407|COMMENT|ab|15|entity|C0681842|prediction|inpr|||prediction|||0|1000|1609|1619
SE|25462407|COMMENT|ab|15|entity|C0599880|TREATMENT PLAN|inpr|||treatment-planning|||0|1000|1635|1653
SE|25462407|COMMENT|ab|15|entity|C1549649|Limit|idcn|||limit|||0|888|1658|1663
SE|25462407|COMMENT|ab|15|entity|C0035647|Risk|qlco|||risk|||0|888|1664|1668
SE|25462407|COMMENT|ab|15|entity|C0026516|Mood|menp|||mood|||0|1000|1672|1676


SE|25462408||ti|1|text|21|120|How does the ICD-10 symptom rating (ISR) with four items assess depression compared to the BDI-II?
SE|25462408||ti|1|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ICD-10|||0|880|34|40
SE|25462408||ti|1|entity|C0429688|Symptom ratings|inpr|||symptom rating|||0|880|41|55
SE|25462408||ti|1|entity|C0205450|Four|qnco|||four|||0|694|67|71
SE|25462408||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|85|95
SE|25462408||ti|1|entity|C0451022|Beck depression inventory|diap|||BDI-II|||0|756|112|118

SE|25462408||ti|2|text|120|140|A validation study.
SE|25462408||ti|2|entity|C0681836|validation study|resa|||validation study|||0|1000|122|138

SE|25462408|OBJECTIVE|ab|1|text|146|352|OBJECTIVE: The "ICD-10 Symptom-Rating" (ISR) is a novel 29-item self-rating questionnaire with scales for the assessment of depression, anxiety, OCD, somatisation and eating disorders and additional items.
SE|25462408|OBJECTIVE|ab|1|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ICD-10|||0|880|162|168
SE|25462408|OBJECTIVE|ab|1|entity|C0429688|Symptom ratings|inpr|||Symptom-Rating|||0|880|169|183
SE|25462408|OBJECTIVE|ab|1|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ISR|||0|880|186|189
SE|25462408|OBJECTIVE|ab|1|entity|C0429688|Symptom ratings|inpr|||ISR|||0|880|186|189
SE|25462408|OBJECTIVE|ab|1|entity|C0679622|novel|inpr|||novel|||0|753|196|201
SE|25462408|OBJECTIVE|ab|1|entity|C0036588|Self|idcn|||self|||0|753|210|214
SE|25462408|OBJECTIVE|ab|1|entity|C0871208|Rating|resa|||rating|||0|753|215|221
SE|25462408|OBJECTIVE|ab|1|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|753|222|235
SE|25462408|OBJECTIVE|ab|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|256|266
SE|25462408|OBJECTIVE|ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|270|280
SE|25462408|OBJECTIVE|ab|1|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|282|289
SE|25462408|OBJECTIVE|ab|1|entity|C0149779|SOMATIZATION|mobd|||somatisation|||0|1000|296|308
SE|25462408|OBJECTIVE|ab|1|entity|C0013473|Eating Disorders|mobd|||eating disorders|||0|1000|313|329
SE|25462408|OBJECTIVE|ab|1|entity|C1524062|Additional|ftcn|||additional|||0|694|334|344

SE|25462408|OBJECTIVE|ab|2|text|352|414|This study aims at the validation of the depression subscale.
SE|25462408|OBJECTIVE|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|357|362
SE|25462408|OBJECTIVE|ab|2|entity|C1519941|Validation|resa|||validation|||0|1000|375|385
SE|25462408|OBJECTIVE|ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|694|393|403

SE|25462408|METHODS|ab|3|text|414|542|METHODS: Based on a sample of 1844 depressed inpatients, the ISR was correlated with the Beck-Depression-Inventory-II (BDI-II).
SE|25462408|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|414|421
SE|25462408|METHODS|ab|3|entity|C0021562|inpatient|podg|||inpatients|||0|827|459|469
SE|25462408|METHODS|ab|3|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ISR|||0|880|475|478
SE|25462408|METHODS|ab|3|entity|C0429688|Symptom ratings|inpr|||ISR|||0|880|475|478
SE|25462408|METHODS|ab|3|entity|C0451022|Beck depression inventory|diap|||Beck-Depression-Inventory|||0|756|503|528

SE|25462408|METHODS|ab|4|text|542|620|To estimate the sensitivity to change, the effect sizes were also calculated.
SE|25462408|METHODS|ab|4|entity|C0814843|effect size|qnco|||effect sizes|||0|983|585|597

SE|25462408|RESULTS|ab|5|text|620|680|RESULTS: The correlation between ISR and BDI-II was r=0.79.
SE|25462408|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|620|627
SE|25462408|RESULTS|ab|5|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ISR|||0|880|653|656
SE|25462408|RESULTS|ab|5|entity|C0429688|Symptom ratings|inpr|||ISR|||0|880|653|656
SE|25462408|RESULTS|ab|5|entity|C0451022|Beck depression inventory|diap|||BDI-II|||0|756|661|667

SE|25462408|RESULTS|ab|6|text|680|770|The sensitivity to change for the BDI-II was d=1.44, for the ISR-depression scale d=1.64.
SE|25462408|RESULTS|ab|6|entity|C0451022|Beck depression inventory|diap|||BDI-II|||0|756|714|720
SE|25462408|RESULTS|ab|6|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ISR|||0|846|741|744
SE|25462408|RESULTS|ab|6|entity|C0429688|Symptom ratings|inpr|||ISR|||0|846|741|744
SE|25462408|RESULTS|ab|6|entity|C0679604|depression scale|diap,inpr|||depression scale|||0|846|745|761

SE|25462408|LIMITATIONS|ab|7|text|770|976|LIMITATIONS: The studied sample shows a higher psychiatric and somatic comorbidity, a lower mean age and a higher level of education than comparable samples from other psychiatric or psychosomatic studies.
SE|25462408|LIMITATIONS|ab|7|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|770|781
SE|25462408|LIMITATIONS|ab|7|entity|C0205250|High|qlco|||higher|||0|872|810|816
SE|25462408|LIMITATIONS|ab|7|entity|C0205487|Psychiatric|ftcn|||psychiatric|||0|872|817|828
SE|25462408|LIMITATIONS|ab|7|entity|C0599444|cell body (neuron)|celc|||somatic|||0|853|833|840
SE|25462408|LIMITATIONS|ab|7|entity|C0009488|Comorbidity|idcn|||comorbidity|||0|853|841|852
SE|25462408|LIMITATIONS|ab|7|entity|C0441994|Lower|ftcn|||lower|||0|802|856|861
SE|25462408|LIMITATIONS|ab|7|entity|C0001779|Age|orga|||age|||0|802|867|870
SE|25462408|LIMITATIONS|ab|7|entity|C0205250|High|qlco|||higher|||0|661|877|883
SE|25462408|LIMITATIONS|ab|7|entity|C0013621|Knowledge acquisition|edac|||education|||0|1000|893|902
SE|25462408|LIMITATIONS|ab|7|entity|C0205487|Psychiatric|ftcn|||psychiatric|||0|1000|938|949
SE|25462408|LIMITATIONS|ab|7|entity|C1537048|psychosomatic|qlco|||psychosomatic|||0|872|953|966
SE|25462408|LIMITATIONS|ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|872|967|974

SE|25462408|LIMITATIONS|ab|8|text|976|1103|Although we cannot find any effects of these differences on our results, they cannot be fully dismissed without further study.
SE|25462408|LIMITATIONS|ab|8|entity|C1280500|Effect|qlco|||effects|||0|966|1004|1011
SE|25462408|LIMITATIONS|ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1021|1032
SE|25462408|LIMITATIONS|ab|8|entity|C1274040|result|ftcn|||results|||0|966|1040|1047
SE|25462408|LIMITATIONS|ab|8|entity|C1517331|Further|spco|||further|||0|888|1088|1095
SE|25462408|LIMITATIONS|ab|8|entity|C0008972|Clinical Research|resa|||study|||0|888|1096|1101

SE|25462408|CONCLUSION|ab|9|text|1103|1175|CONCLUSION: The ISR-depression scale correlates highly with the BDI-II.
SE|25462408|CONCLUSION|ab|9|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ISR|||0|846|1119|1122
SE|25462408|CONCLUSION|ab|9|entity|C0429688|Symptom ratings|inpr|||ISR|||0|846|1119|1122
SE|25462408|CONCLUSION|ab|9|entity|C0679604|depression scale|diap,inpr|||depression scale|||0|846|1123|1139
SE|25462408|CONCLUSION|ab|9|entity|C0451022|Beck depression inventory|diap|||BDI-II|||0|756|1167|1173

SE|25462408|CONCLUSION|ab|10|text|1175|1310|Being more sensitive to change than the BDI-II, the ISR is a useful tool to diagnose and measure the severity and course of depression.
SE|25462408|CONCLUSION|ab|10|entity|C0205172|More|ftcn|||more|||0|888|1181|1185
SE|25462408|CONCLUSION|ab|10|entity|C0332324|Sensitive|ftcn|||sensitive|||0|888|1186|1195
SE|25462408|CONCLUSION|ab|10|entity|C0451022|Beck depression inventory|diap|||BDI-II|||0|756|1215|1221
SE|25462408|CONCLUSION|ab|10|entity|C1137110|International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)|inpr|||ISR|||0|880|1227|1230
SE|25462408|CONCLUSION|ab|10|entity|C0429688|Symptom ratings|inpr|||ISR|||0|880|1227|1230
SE|25462408|CONCLUSION|ab|10|entity|C0336791|Tool|mnob|||tool|||0|861|1243|1247
SE|25462408|CONCLUSION|ab|10|entity|C0439793|Severities|qlco|||severity|||0|1000|1276|1284
SE|25462408|CONCLUSION|ab|10|entity|C0750729|Course|tmco|||course|||0|1000|1289|1295
SE|25462408|CONCLUSION|ab|10|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1299|1309


SE|25462409||ti|1|text|21|105|An individual task meta-analysis of social cognition in euthymic bipolar disorders.
SE|25462409||ti|1|entity|C0237401|Individual|humn|||individual|||0|861|24|34
SE|25462409||ti|1|entity|C1042496|Meta|invt|||meta|||0|861|40|44
SE|25462409||ti|1|entity|C0556033|Task analysis|topp|||task meta-analysis|||0|861|35|53
SE|25462409||ti|1|entity|C0871381|Social Cognition|socb|||social cognition|||0|1000|57|73
SE|25462409||ti|1|entity|C0948853|Euthymia|mobd|||euthymic|||0|865|77|85
SE|25462409||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorders|||0|865|86|103
SE|25462409||ti|1|relation|2|2|C0556033|Task analysis|topp|topp|||task meta-analysis|||0|861|35|53|PREP|TREATS||74|76|1|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorders|||0|865|86|103

SE|25462409|OBJECTIVE|ab|1|text|111|213|OBJECTIVE: Social cognition has been shown to be affected in bipolar disorders, even during euthymia.
SE|25462409|OBJECTIVE|ab|1|entity|C0871381|Social Cognition|socb|||Social cognition|||0|1000|122|138
SE|25462409|OBJECTIVE|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorders|||0|1000|172|189
SE|25462409|OBJECTIVE|ab|1|entity|C0948853|Euthymia|mobd|||euthymia|||0|1000|203|211
SE|25462409|OBJECTIVE|ab|1|relation|3|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorders|||0|1000|172|189|PREP|COEXISTS_WITH||196|202|1|1|C0948853|Euthymia|mobd|mobd|||euthymia|||0|1000|203|211

SE|25462409|OBJECTIVE|ab|2|text|213|439|However, the social cognitive profile of this group of disorders remains to be ascertained, given that such a broad neuropsychological construct has not been systematically examined in bipolar subjects across different tasks.
SE|25462409|OBJECTIVE|ab|2|entity|C0871381|Social Cognition|socb|||social cognitive|||0|698|226|242
SE|25462409|OBJECTIVE|ab|2|entity|C0441833|Groups|inpr|||group|||0|1000|259|264
SE|25462409|OBJECTIVE|ab|2|entity|C0012634|Disease|dsyn|||disorders|||0|1000|268|277
SE|25462409|OBJECTIVE|ab|2|entity|C0332464|Widening|spco|||broad|||0|587|323|328
SE|25462409|OBJECTIVE|ab|2|entity|C0027903|Neuropsychology|bmod|||neuropsychological|||0|587|329|347
SE|25462409|OBJECTIVE|ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|362|365
SE|25462409|OBJECTIVE|ab|2|entity|C0443156|Bipolar|spco|||bipolar|||0|872|398|405
SE|25462409|OBJECTIVE|ab|2|entity|C1550501|subject|idcn|||subjects|||0|872|406|414
SE|25462409|OBJECTIVE|ab|2|entity|C1547020|*Difference|qnco|||different|||0|836|422|431

SE|25462409|OBJECTIVE|ab|3|text|439|718|The aim of this study was to quantify the magnitude of patient-control differences for distinct social cognition assessment instruments: the Hinting Task, the Eyes Test, Faux Pas, the Mayer-Salovey-Caruso Emotional Intelligence Test, and emotional labeling using visual stimuli.
SE|25462409|OBJECTIVE|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|455|460
SE|25462409|OBJECTIVE|ab|3|entity|C0449286|Degree or extent|qnco|||magnitude|||0|966|481|490
SE|25462409|OBJECTIVE|ab|3|entity|C0030705|Patients|podg|||patient|||0|840|494|501
SE|25462409|OBJECTIVE|ab|3|entity|C0243148|control|ftcn|||control|||0|840|502|509
SE|25462409|OBJECTIVE|ab|3|entity|C1547020|*Difference|qnco|||differences|||0|840|510|521
SE|25462409|OBJECTIVE|ab|3|entity|C0009240|Cognition|menp|||cognition|||0|798|542|551
SE|25462409|OBJECTIVE|ab|3|entity|C1320310|Social assessment|hlca|||social cognition assessment|||0|798|535|562
SE|25462409|OBJECTIVE|ab|3|entity|C0243113|instruments|mnob|||instruments|||0|798|563|574
SE|25462409|OBJECTIVE|ab|3|entity|C1512348|Health Information National Trends Survey|inpr|||Hinting|||0|872|580|587
SE|25462409|OBJECTIVE|ab|3|entity|C0015392|Eye|bpoc|||Eyes|||0|1000|598|602
SE|25462409|OBJECTIVE|ab|3|entity|C0030125|p-Aminosalicylic Acid|orch,phsu|||Pas|||0|861|614|617
SE|25462409|OBJECTIVE|ab|3|entity|C1510539|Emotional Intelligence|menp|||Emotional Intelligence|||0|762|644|666
SE|25462409|OBJECTIVE|ab|3|entity|C0039593|Testing|resa|||Test|||0|762|667|671
SE|25462409|OBJECTIVE|ab|3|entity|C0849912|Emotional|fndg|||emotional|||0|694|677|686
SE|25462409|OBJECTIVE|ab|3|entity|C0597664|visual stimulus|ortf|||visual stimuli|||0|983|702|716

SE|25462409|METHOD|ab|4|text|718|918|METHOD: Effect sizes were extracted from studies chosen according to more stringent criteria than previously used in systematic reviews on the topic and pooled by means of meta-analytical procedures.
SE|25462409|METHOD|ab|4|entity|C0025663|Methods|inpr|||METHOD|||0|1000|718|724
SE|25462409|METHOD|ab|4|entity|C0814843|effect size|qnco|||Effect sizes|||0|983|726|738
SE|25462409|METHOD|ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|966|759|766
SE|25462409|METHOD|ab|4|entity|C0205172|More|ftcn|||more|||0|802|787|791
SE|25462409|METHOD|ab|4|entity|C0243161|criteria|inpr|||criteria|||0|802|802|810
SE|25462409|METHOD|ab|4|entity|C0220922|systematic|ftcn|||systematic|||0|694|835|845
SE|25462409|METHOD|ab|4|entity|C1555712|topic|idcn|||topic|||0|1000|861|866
SE|25462409|METHOD|ab|4|entity|C1042496|Meta|invt|||meta|||0|802|890|894
SE|25462409|METHOD|ab|4|entity|C0025664|Methodology|inpr|||procedures|||0|802|906|916

SE|25462409|RESULTS|ab|5|text|918|1058|RESULTS: No significant patient-control differences were found for the recognition of three basic emotions (happiness, sadness, and anger).
SE|25462409|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|918|925
SE|25462409|RESULTS|ab|5|entity|C0750502|Significant|idcn|||significant|||0|825|930|941
SE|25462409|RESULTS|ab|5|entity|C0030705|Patients|podg|||patient|||0|825|942|949
SE|25462409|RESULTS|ab|5|entity|C0243148|control|ftcn|||control|||0|825|950|957
SE|25462409|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||differences|||0|825|958|969
SE|25462409|RESULTS|ab|5|entity|C0205449|Three|qnco|||three|||0|828|1004|1009
SE|25462409|RESULTS|ab|5|entity|C0013987|Emotions|menp|||emotions|||0|828|1016|1024
SE|25462409|RESULTS|ab|5|entity|C0018592|Happiness|menp|||happiness|||0|1000|1026|1035
SE|25462409|RESULTS|ab|5|entity|C0344315|Depressed mood|fndg|||sadness|||0|1000|1037|1044
SE|25462409|RESULTS|ab|5|entity|C0002957|Anger|menp|||anger|||0|1000|1050|1055
SE|25462409|RESULTS|ab|5|relation|0|0|C0018592|Happiness|menp|menp|||happiness|||0|1000|1026|1035|SPEC|ISA||1016|1035|0|0|C0013987|Emotions|menp|menp|||emotions|||0|828|1016|1024

SE|25462409|RESULTS|ab|6|text|1058|1259|Small but significant effect sizes favoring healthy controls (Hedges' g<0.5) were noted for emotional intelligence, the Hinting Task, the Eyes Test, and the recognition of fear, disgust, and surprise.
SE|25462409|RESULTS|ab|6|entity|C0700321|Small|qnco|||Small|||0|1000|1058|1063
SE|25462409|RESULTS|ab|6|entity|C0750502|Significant|idcn|||significant|||0|890|1068|1079
SE|25462409|RESULTS|ab|6|entity|C0814843|effect size|qnco|||effect sizes|||0|890|1080|1092
SE|25462409|RESULTS|ab|6|entity|C0018684|Health|idcn|||healthy|||0|836|1102|1109
SE|25462409|RESULTS|ab|6|entity|C0243148|control|ftcn|||controls|||0|836|1110|1118
SE|25462409|RESULTS|ab|6|entity|C0444499|0/5|qnco|||0.5|||0|1000|1130|1133
SE|25462409|RESULTS|ab|6|entity|C1510539|Emotional Intelligence|menp|||emotional intelligence|||0|1000|1150|1172
SE|25462409|RESULTS|ab|6|entity|C1512348|Health Information National Trends Survey|inpr|||Hinting|||0|872|1178|1185
SE|25462409|RESULTS|ab|6|entity|C0015392|Eye|bpoc|||Eyes|||0|1000|1196|1200
SE|25462409|RESULTS|ab|6|entity|C0015726|Fright|menp|||fear|||0|1000|1230|1234
SE|25462409|RESULTS|ab|6|entity|C0683283|repulsion|menp|||disgust|||0|1000|1236|1243

SE|25462409|RESULTS|ab|7|text|1259|1330|A medium effect size (Hedges' g=0.58) was noted for the Faux Pas Test.
SE|25462409|RESULTS|ab|7|entity|C0439536|Medium|qlco|||medium|||0|901|1261|1267
SE|25462409|RESULTS|ab|7|entity|C0814843|effect size|qnco|||effect size|||0|901|1268|1279
SE|25462409|RESULTS|ab|7|entity|C0030125|p-Aminosalicylic Acid|orch,phsu|||Pas|||0|790|1320|1323
SE|25462409|RESULTS|ab|7|entity|C0039593|Testing|resa|||Test|||0|790|1324|1328

SE|25462409|LIMITATIONS|ab|8|text|1330|1455|LIMITATIONS: The possible effects of other neurocognitive impairments on social cognitive performance could not be explored.
SE|25462409|LIMITATIONS|ab|8|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1330|1341
SE|25462409|LIMITATIONS|ab|8|entity|C0332149|Possible|qlco|||possible|||0|872|1347|1355
SE|25462409|LIMITATIONS|ab|8|entity|C1280500|Effect|qlco|||effects|||0|872|1356|1363
SE|25462409|LIMITATIONS|ab|8|entity|C0518895|Neurocognitive|inpr|||neurocognitive|||0|872|1373|1387
SE|25462409|LIMITATIONS|ab|8|entity|C0871381|Social Cognition|socb|||social cognitive|||0|877|1403|1419
SE|25462409|LIMITATIONS|ab|8|entity|C0597198|Performance|inbe|||performance|||0|877|1420|1431
SE|25462409|LIMITATIONS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1438|1441

SE|25462409|CONCLUSION|ab|9|text|1455|1700|CONCLUSION: On average, small-to-moderate differences may exist between euthymic bipolar disorder subjects and healthy controls regarding social cognitive performance, with mental state decoding being more preserved than mental state reasoning.
SE|25462409|CONCLUSION|ab|9|entity|C1510992|Average|qnco|||average|||0|1000|1470|1477
SE|25462409|CONCLUSION|ab|9|entity|C0700321|Small|qnco|||small|||0|775|1479|1484
SE|25462409|CONCLUSION|ab|9|entity|C1547020|*Difference|qnco|||differences|||0|775|1497|1508
SE|25462409|CONCLUSION|ab|9|entity|C0948853|Euthymia|mobd|||euthymic|||0|826|1527|1535
SE|25462409|CONCLUSION|ab|9|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|826|1536|1552
SE|25462409|CONCLUSION|ab|9|entity|C1550501|subject|idcn|||subjects|||0|826|1553|1561
SE|25462409|CONCLUSION|ab|9|entity|C0018684|Health|idcn|||healthy|||0|836|1566|1573
SE|25462409|CONCLUSION|ab|9|entity|C0243148|control|ftcn|||controls|||0|836|1574|1582
SE|25462409|CONCLUSION|ab|9|entity|C0871381|Social Cognition|socb|||social cognitive|||0|877|1593|1609
SE|25462409|CONCLUSION|ab|9|entity|C0597198|Performance|inbe|||performance|||0|877|1610|1621
SE|25462409|CONCLUSION|ab|9|entity|C1442792|State|ftcn|||state|||0|851|1635|1640
SE|25462409|CONCLUSION|ab|9|entity|C0870395|Decoding|menp|||decoding|||0|851|1641|1649
SE|25462409|CONCLUSION|ab|9|entity|C0205172|More|ftcn|||more|||0|1000|1656|1660
SE|25462409|CONCLUSION|ab|9|entity|C1442792|State|ftcn|||state|||0|851|1683|1688
SE|25462409|CONCLUSION|ab|9|entity|C0684328|Reasoning|menp|||reasoning|||0|851|1689|1698

SE|25462409|CONCLUSION|ab|10|text|1700|1872|The influence of clinical and neurocognitive variables, which may play an important role in the social cognitive outcomes of these patients, deserves further clarification.
SE|25462409|CONCLUSION|ab|10|entity|C0205210|Clinical|qlco|||clinical|||0|1000|1717|1725
SE|25462409|CONCLUSION|ab|10|entity|C0518895|Neurocognitive|inpr|||neurocognitive|||0|872|1730|1744
SE|25462409|CONCLUSION|ab|10|entity|C0439828|Variable|qlco|||variables|||0|872|1745|1754
SE|25462409|CONCLUSION|ab|10|entity|C0035820|Role|socb|||role|||0|861|1784|1788
SE|25462409|CONCLUSION|ab|10|entity|C0871381|Social Cognition|socb|||social cognitive|||0|866|1796|1812
SE|25462409|CONCLUSION|ab|10|entity|C1274040|result|ftcn|||outcomes|||0|866|1813|1821
SE|25462409|CONCLUSION|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1831|1839
SE|25462409|CONCLUSION|ab|10|entity|C1517331|Further|spco|||further|||0|694|1850|1857


SE|25462410||ti|1|text|21|151|Manic tendencies are not related to being an entrepreneur, intending to become an entrepreneur, or succeeding as an entrepreneur.
SE|25462410||ti|1|entity|C0338831|Manic|mobd|||Manic|||0|694|21|26
SE|25462410||ti|1|entity|C1518422|Not|ftcn|||not|||0|1000|42|45
SE|25462410||ti|1|entity|C0682250|entrepreneur|prog|||entrepreneur|||0|1000|66|78
SE|25462410||ti|1|entity|C0682250|entrepreneur|prog|||entrepreneur|||0|1000|103|115
SE|25462410||ti|1|entity|C1554211|succeeds|idcn|||succeeding|||0|966|120|130
SE|25462410||ti|1|entity|C0682250|entrepreneur|prog|||entrepreneur|||0|1000|137|149

SE|25462410|BACKGROUND|ab|1|text|157|438|BACKGROUND: Popular literature suggests a relationship between entrepreneurship and manic tendencies, yet little scientific research has evaluated whether manic tendencies foster entrance into entrepreneurial roles, intent to become an entrepreneur, or success as an entrepreneur.
SE|25462410|BACKGROUND|ab|1|entity|C0679970|popularity|socb|||Popular|||0|853|169|176
SE|25462410|BACKGROUND|ab|1|entity|C0023866|Literature|inpr|||literature|||0|853|177|187
SE|25462410|BACKGROUND|ab|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|199|211
SE|25462410|BACKGROUND|ab|1|entity|C0085116|Entrepreneurship|inbe|||entrepreneurship|||0|1000|220|236
SE|25462410|BACKGROUND|ab|1|entity|C0338831|Manic|mobd|||manic|||0|694|241|246
SE|25462410|BACKGROUND|ab|1|entity|C0023882|Little's Disease|dsyn|||little|||0|824|263|269
SE|25462410|BACKGROUND|ab|1|entity|C0683933|research in general|resa|||scientific research|||0|824|270|289
SE|25462410|BACKGROUND|ab|1|entity|C0338831|Manic|mobd|||manic|||0|791|312|317
SE|25462410|BACKGROUND|ab|1|entity|C0337095|Entrance|spco|||entrance|||0|791|336|344
SE|25462410|BACKGROUND|ab|1|entity|C0035820|Role|socb|||roles|||0|861|366|371
SE|25462410|BACKGROUND|ab|1|entity|C1283828|intent|menp|||intent|||0|1000|373|379
SE|25462410|BACKGROUND|ab|1|entity|C0682250|entrepreneur|prog|||entrepreneur|||0|1000|393|405
SE|25462410|BACKGROUND|ab|1|entity|C0597535|Success|socb|||success|||0|1000|410|417
SE|25462410|BACKGROUND|ab|1|entity|C0682250|entrepreneur|prog|||entrepreneur|||0|1000|424|436

SE|25462410|METHODS|ab|2|text|438|806|METHODS: In study 1, 225 undergraduates and business school students/affiliates took an online survey to assess engagement and intent as entrepreneurs, as well as manic tendencies, including family diagnoses as reported on the Family Index of Risk for Mania, subsyndromal manic tendencies as assessed with the Hypomanic Personality Scale, and self-reported diagnoses.
SE|25462410|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|438|445
SE|25462410|METHODS|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|861|450|455
SE|25462410|METHODS|ab|2|entity|C0682177|college student|popg|||undergraduates|||0|861|463|477
SE|25462410|METHODS|ab|2|entity|C0870236|Business Students|prog|||business school students|||0|813|482|506
SE|25462410|METHODS|ab|2|entity|C1510825|Affiliate|cnce|||affiliates|||0|813|507|517
SE|25462410|METHODS|ab|2|entity|C0038951|Surveys|resa|||survey|||0|861|533|539
SE|25462410|METHODS|ab|2|entity|C0425152|Engaged to be married|socb|||engagement|||0|1000|550|560
SE|25462410|METHODS|ab|2|entity|C1283828|intent|menp|||intent|||0|1000|565|571
SE|25462410|METHODS|ab|2|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|966|575|588
SE|25462410|METHODS|ab|2|entity|C0338831|Manic|mobd|||manic|||0|694|601|606
SE|25462410|METHODS|ab|2|entity|C0015576|Family|famg|||family|||0|888|629|635
SE|25462410|METHODS|ab|2|entity|C0011900|Diagnosis|hlca|||diagnoses|||0|888|636|645
SE|25462410|METHODS|ab|2|entity|C0015576|Family|famg|||Family|||0|888|665|671
SE|25462410|METHODS|ab|2|entity|C0918012|Index|inpr|||Index|||0|888|672|677
SE|25462410|METHODS|ab|2|entity|C0035647|Risk|qlco|||Risk|||0|1000|681|685
SE|25462410|METHODS|ab|2|entity|C0338831|Manic|mobd|||Mania|||0|1000|690|695
SE|25462410|METHODS|ab|2|entity|C0338831|Manic|mobd|||manic|||0|660|710|715
SE|25462410|METHODS|ab|2|entity|C0544669|Hypomanic personality|mobd|||Hypomanic Personality|||0|901|748|769
SE|25462410|METHODS|ab|2|entity|C0599922|self diagnosis|inbe|||self-reported diagnoses|||0|890|781|804
SE|25462410|METHODS|ab|2|relation|4|4|C0599922|self diagnosis|inbe|inbe|||self-reported diagnoses|||0|890|781|804|NOM|PREDISPOSES||681|685|4|1|C0338831|Manic|mobd|mobd|||Mania|||0|1000|690|695

SE|25462410|METHODS|ab|3|text|806|959|In study 2, the sample of entrepreneurs identified in study 1 was enriched by recruiting a larger group of established entrepreneurs from the community.
SE|25462410|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|861|809|814
SE|25462410|METHODS|ab|3|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|966|832|845
SE|25462410|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|861|860|865
SE|25462410|METHODS|ab|3|entity|C0679991|large group|grpa|||larger group|||0|983|897|909
SE|25462410|METHODS|ab|3|entity|C0443211|Established|qlco|||established|||0|872|913|924
SE|25462410|METHODS|ab|3|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|872|925|938
SE|25462410|METHODS|ab|3|entity|C0009462|Community|geoa|||community|||0|1000|948|957

SE|25462410|METHODS|ab|4|text|959|1131|Entrepreneurs (n=210) completed items concerning their success in entrepreneurship, and we examined whether the three measures of manic tendencies were related to success.
SE|25462410|METHODS|ab|4|entity|C0682250|entrepreneur|prog|||Entrepreneurs|||0|966|959|972
SE|25462410|METHODS|ab|4|entity|C0597535|Success|socb|||success|||0|1000|1014|1021
SE|25462410|METHODS|ab|4|entity|C0085116|Entrepreneurship|inbe|||entrepreneurship|||0|1000|1025|1041
SE|25462410|METHODS|ab|4|entity|C0205449|Three|qnco|||three|||0|888|1071|1076
SE|25462410|METHODS|ab|4|entity|C0079809|Measures|qnco|||measures|||0|888|1077|1085
SE|25462410|METHODS|ab|4|entity|C0338831|Manic|mobd|||manic|||0|694|1089|1094
SE|25462410|METHODS|ab|4|entity|C0597535|Success|socb|||success|||0|1000|1122|1129

SE|25462410|RESULTS|ab|5|text|1131|1325|RESULTS: There was no evidence that those vulnerable to mania, regardless of definition, were more likely to be entrepreneurs, to intend to become entrepreneurs, or to succeed as entrepreneurs.
SE|25462410|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1131|1138
SE|25462410|RESULTS|ab|5|entity|C0338831|Manic|mobd|||mania|||0|1000|1187|1192
SE|25462410|RESULTS|ab|5|entity|C1550452|definition|idcn|||definition|||0|1000|1208|1218
SE|25462410|RESULTS|ab|5|entity|C0205172|More|ftcn|||more|||0|888|1225|1229
SE|25462410|RESULTS|ab|5|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|966|1243|1256
SE|25462410|RESULTS|ab|5|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|966|1278|1291
SE|25462410|RESULTS|ab|5|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|966|1310|1323

SE|25462410|LIMITATIONS|ab|6|text|1325|1417|LIMITATIONS: The studies were limited by self-report measures and relatively small samples.
SE|25462410|LIMITATIONS|ab|6|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1325|1336
SE|25462410|LIMITATIONS|ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|1342|1349
SE|25462410|LIMITATIONS|ab|6|entity|C0036588|Self|idcn|||self|||0|851|1366|1370
SE|25462410|LIMITATIONS|ab|6|entity|C0079809|Measures|qnco|||measures|||0|851|1378|1386
SE|25462410|LIMITATIONS|ab|6|entity|C0700321|Small|qnco|||small|||0|660|1402|1407

SE|25462410|CONCLUSIONS|ab|7|text|1417|1533|CONCLUSIONS: More nuanced models may explain the frequent clinical observations of manic traits among entrepreneurs.
SE|25462410|CONCLUSIONS|ab|7|entity|C0205172|More|ftcn|||More|||0|660|1430|1434
SE|25462410|CONCLUSIONS|ab|7|entity|C0332183|Frequent|tmco|||frequent|||0|623|1466|1474
SE|25462410|CONCLUSIONS|ab|7|entity|C0205210|Clinical|qlco|||clinical|||0|623|1475|1483
SE|25462410|CONCLUSIONS|ab|7|entity|C0338831|Manic|mobd|||manic|||0|872|1500|1505
SE|25462410|CONCLUSIONS|ab|7|entity|C0599883|trait|orga|||traits|||0|872|1506|1512
SE|25462410|CONCLUSIONS|ab|7|entity|C0682250|entrepreneur|prog|||entrepreneurs|||0|966|1519|1532


SE|25462411||ti|1|text|21|177|Immediate cerebral metabolic changes induced by discontinuation of deep brain stimulation of subcallosal cingulate gyrus in treatment-resistant depression.
SE|25462411||ti|1|entity|C0205253|Immediate|tmco|||Immediate|||0|825|21|30
SE|25462411||ti|1|entity|C0006104|Brain|bpoc|||cerebral|||0|825|31|39
SE|25462411||ti|1|entity|C0311400|Metabolic|ftcn|||metabolic|||0|825|40|49
SE|25462411||ti|1|entity|C0394162|Deep Brain Stimulation|topp|||deep brain stimulation|||0|1000|88|110
SE|25462411||ti|1|entity|C0175231|Paraterminal gyrus|bpoc|||subcallosal cingulate gyrus|||0|913|114|141
SE|25462411||ti|1|entity|C0871546|Treatment Resistant Depression|mobd|||treatment-resistant depression|||0|1000|145|175
SE|25462411||ti|1|relation|4|2|C0394162|Deep Brain Stimulation|topp|topp|||deep brain stimulation|||0|1000|88|110|PREP|TREATS||142|144|1|1|C0871546|Treatment Resistant Depression|mobd|mobd|||treatment-resistant depression|||0|1000|145|175

SE|25462411|BACKGROUND|ab|1|text|183|459|BACKGROUND: Positron emission tomography (PET) studies have shown that the antidepressant effect of chronic deep brain stimulation (DBS) of the subcallosal cingulate gyrus (SCG) may be consequence of modifications of brain metabolism at key structures involved in depression.
SE|25462411|BACKGROUND|ab|1|entity|C0032743|Positron-Emission Tomography|diap|||Positron emission tomography|||0|900|195|223
SE|25462411|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|900|230|237
SE|25462411|BACKGROUND|ab|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressant|||0|888|258|272
SE|25462411|BACKGROUND|ab|1|entity|C1280500|Effect|qlco|||effect|||0|888|273|279
SE|25462411|BACKGROUND|ab|1|entity|C0205191|chronic|tmco|||chronic|||0|916|283|290
SE|25462411|BACKGROUND|ab|1|entity|C0394162|Deep Brain Stimulation|topp|||deep brain stimulation|||0|916|291|313
SE|25462411|BACKGROUND|ab|1|entity|C0175231|Paraterminal gyrus|bpoc|||subcallosal cingulate gyrus|||0|913|327|354
SE|25462411|BACKGROUND|ab|1|entity|C1522413|Modification|ftcn|||modifications|||0|966|383|396
SE|25462411|BACKGROUND|ab|1|entity|C0596215|Brain Metabolism|ortf|||brain metabolism|||0|1000|400|416
SE|25462411|BACKGROUND|ab|1|entity|C1554080|Key|idcn|||key|||0|872|420|423
SE|25462411|BACKGROUND|ab|1|entity|C0678594|Structure|spco|||structures|||0|872|424|434
SE|25462411|BACKGROUND|ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|447|457
SE|25462411|BACKGROUND|ab|1|relation|9|2|C0596215|Brain Metabolism|ortf|ortf|||brain metabolism|||0|1000|400|416|VERB|AFFECTS||435|443|1|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|447|457

SE|25462411|BACKGROUND|ab|2|text|459|592|Like clinical benefits, these metabolic changes may reverse when the stimulation is discontinued, even preceding clinical worsening.
SE|25462411|BACKGROUND|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|888|464|472
SE|25462411|BACKGROUND|ab|2|entity|C0814225|Benefits|qnco|||benefits|||0|888|473|481
SE|25462411|BACKGROUND|ab|2|entity|C0311400|Metabolic|ftcn|||metabolic|||0|872|489|498
SE|25462411|BACKGROUND|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|694|572|580

SE|25462411|BACKGROUND|ab|3|text|592|667|However no data on immediate effects of DBS discontinuation are available.
SE|25462411|BACKGROUND|ab|3|entity|C1511726|Data|idcn|||data|||0|1000|603|607
SE|25462411|BACKGROUND|ab|3|entity|C0205253|Immediate|tmco|||immediate|||0|872|611|620
SE|25462411|BACKGROUND|ab|3|entity|C1280500|Effect|qlco|||effects|||0|872|621|628
SE|25462411|BACKGROUND|ab|3|entity|C0394162|Deep Brain Stimulation|topp|||DBS|||0|916|632|635

SE|25462411|BACKGROUND|ab|4|text|667|929|The aim of this study was to determine immediate cerebral metabolism changes during a short switch-off of electrical stimulation in implanted patients with treatment-resistant depression (TRD) who had achieved clinical improvement after a period of chronic DBS.
SE|25462411|BACKGROUND|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|683|688
SE|25462411|BACKGROUND|ab|4|entity|C0205253|Immediate|tmco|||immediate|||0|851|706|715
SE|25462411|BACKGROUND|ab|4|entity|C0006104|Brain|bpoc|||cerebral|||0|851|716|724
SE|25462411|BACKGROUND|ab|4|entity|C0025519|Metabolism|orgf|||metabolism|||0|851|725|735
SE|25462411|BACKGROUND|ab|4|entity|C0013786|Electric Stimulation|lbpr|||electrical stimulation|||0|1000|773|795
SE|25462411|BACKGROUND|ab|4|entity|C0021102|Implants|medd|||implanted|||0|888|799|808
SE|25462411|BACKGROUND|ab|4|entity|C0030705|Patients|podg|||patients|||0|888|809|817
SE|25462411|BACKGROUND|ab|4|entity|C0871546|Treatment Resistant Depression|mobd|||treatment-resistant depression|||0|1000|823|853
SE|25462411|BACKGROUND|ab|4|entity|C0205210|Clinical|qlco|||clinical|||0|660|877|885
SE|25462411|BACKGROUND|ab|4|entity|C0439531|/period|tmco|||period|||0|1000|906|912
SE|25462411|BACKGROUND|ab|4|entity|C0205191|chronic|tmco|||chronic|||0|916|916|923
SE|25462411|BACKGROUND|ab|4|entity|C0394162|Deep Brain Stimulation|topp|||DBS|||0|916|924|927
SE|25462411|BACKGROUND|ab|4|relation|0|0|C0030705|Patients|podg,humn|podg|||patients|||0|888|809|817|MOD/HEAD|USES||799|817|0|0|C0021102|Implants|medd|medd|||implanted|||0|888|799|808
SE|25462411|BACKGROUND|ab|4|relation|4|1|C0871546|Treatment Resistant Depression|mobd|mobd|||treatment-resistant depression|||0|1000|823|853|PREP|PROCESS_OF||818|822|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|809|817

SE|25462411|METHODS|ab|5|text|929|1026|METHODS: Seven patients with TRD who had been previously implanted for DBS in SCG were included.
SE|25462411|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|929|936
SE|25462411|METHODS|ab|5|entity|C0205453|Seven|qnco|||Seven|||0|888|938|943
SE|25462411|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|888|944|952
SE|25462411|METHODS|ab|5|entity|C0871546|Treatment Resistant Depression|mobd|||TRD|||0|1000|958|961
SE|25462411|METHODS|ab|5|entity|C0394162|Deep Brain Stimulation|topp|||DBS|||0|1000|1000|1003
SE|25462411|METHODS|ab|5|entity|C0175231|Paraterminal gyrus|bpoc|||SCG|||0|913|1007|1010
SE|25462411|METHODS|ab|5|relation|3|1|C0871546|Treatment Resistant Depression|mobd|mobd|||TRD|||0|1000|958|961|PREP|PROCESS_OF||953|957|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|944|952

SE|25462411|METHODS|ab|6|text|1026|1191|After a period of clinical stabilization two consecutive FDG-PET were acquired, the first with active stimulation and the second after 48 h of inactive stimulation.
SE|25462411|METHODS|ab|6|entity|C0439531|/period|tmco|||period|||0|1000|1034|1040
SE|25462411|METHODS|ab|6|entity|C0205210|Clinical|qlco|||clinical|||0|771|1044|1052
SE|25462411|METHODS|ab|6|entity|C1293130|Stabilization|topp|||stabilization|||0|771|1053|1066
SE|25462411|METHODS|ab|6|entity|C0205448|Two|qnco|||two|||0|771|1067|1070
SE|25462411|METHODS|ab|6|entity|||gngm|23583|SMUG1|FDG|||0|771|1083|1086
SE|25462411|METHODS|ab|6|entity|C0032743|Positron-Emission Tomography|diap|||PET|||0|771|1087|1090
SE|25462411|METHODS|ab|6|entity|C1279901|Firstly|qlco|||first|||0|1000|1110|1115
SE|25462411|METHODS|ab|6|entity|C0205177|Active|ftcn|||active|||0|888|1121|1127
SE|25462411|METHODS|ab|6|entity|C0457385|seconds|tmco|||second|||0|1000|1148|1154
SE|25462411|METHODS|ab|6|entity|C0205254|Sedentary|fndg|||inactive|||0|888|1169|1177

SE|25462411|METHODS|ab|7|text|1191|1264|A HAMD-17 to assess depressive symptoms was performed before both scans.
SE|25462411|METHODS|ab|7|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|1211|1230
SE|25462411|METHODS|ab|7|entity|C0441633|Scanning|diap|||scans|||0|1000|1257|1262

SE|25462411|METHODS|ab|8|text|1264|1300|Analyses were performed with SnPM8.
SE|25462411|METHODS|ab|8|entity|C0936012|Analysis|resa|||Analyses|||0|966|1264|1272

SE|25462411|RESULTS|ab|9|text|1300|1495|RESULTS: Inactive stimulation was characterized by metabolism decreases in dorsal anterior cingulate (Broadmann Area, BA24), premotor region (BA6) and putamen with respect to active stimulation.
SE|25462411|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1300|1307
SE|25462411|RESULTS|ab|9|entity|C0205254|Sedentary|fndg|||Inactive|||0|888|1309|1317
SE|25462411|RESULTS|ab|9|entity|C0025519|Metabolism|orgf|||metabolism|||0|1000|1351|1361
SE|25462411|RESULTS|ab|9|entity|C0205095|Dorsal|spco|||dorsal|||0|623|1375|1381
SE|25462411|RESULTS|ab|9|entity|C0205094|Anterior|spco|||anterior|||0|623|1382|1390
SE|25462411|RESULTS|ab|9|entity|C0205146|Area|spco|||Area|||0|861|1412|1416
SE|25462411|RESULTS|ab|9|entity|C0205147|Region|spco|||region|||0|861|1434|1440
SE|25462411|RESULTS|ab|9|entity|C1281335|Entire putamen|bpoc|||putamen|||0|1000|1451|1458
SE|25462411|RESULTS|ab|9|entity|C0205177|Active|ftcn|||active|||0|888|1475|1481

SE|25462411|RESULTS|ab|10|text|1495|1551|No clinical changes according to HAMD-17 were detected.
SE|25462411|RESULTS|ab|10|entity|C0205210|Clinical|qlco|||clinical|||0|872|1498|1506

SE|25462411|LIMITATIONS|ab|11|text|1551|1624|LIMITATIONS: The main limitation of this study is the small sample size.
SE|25462411|LIMITATIONS|ab|11|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1551|1562
SE|25462411|LIMITATIONS|ab|11|entity|C0205225|Primary|qlco|||main|||0|888|1568|1572
SE|25462411|LIMITATIONS|ab|11|entity|C0449295|Limitation|ftcn|||limitation|||0|888|1573|1583
SE|25462411|LIMITATIONS|ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|1592|1597

SE|25462411|CONCLUSION|ab|12|text|1624|1836|CONCLUSION: Our results point to immediate effects of DBS discontinuation on metabolism of brain depressive network which precede clinical changes, helping to disentangle the rationale behind DBS efficacy in TRD.
SE|25462411|CONCLUSION|ab|12|entity|C1274040|result|ftcn|||results|||0|966|1640|1647
SE|25462411|CONCLUSION|ab|12|entity|C0205253|Immediate|tmco|||immediate|||0|872|1657|1666
SE|25462411|CONCLUSION|ab|12|entity|C1280500|Effect|qlco|||effects|||0|872|1667|1674
SE|25462411|CONCLUSION|ab|12|entity|C0394162|Deep Brain Stimulation|topp|||DBS|||0|916|1678|1681
SE|25462411|CONCLUSION|ab|12|entity|C0025519|Metabolism|orgf|||metabolism|||0|1000|1701|1711
SE|25462411|CONCLUSION|ab|12|entity|C0006104|Brain|bpoc|||brain|||0|802|1715|1720
SE|25462411|CONCLUSION|ab|12|entity|C0679670|network|popg|||network|||0|802|1732|1739
SE|25462411|CONCLUSION|ab|12|entity|C0205210|Clinical|qlco|||clinical|||0|872|1754|1762
SE|25462411|CONCLUSION|ab|12|entity|C0394162|Deep Brain Stimulation|topp|||DBS|||0|694|1816|1819
SE|25462411|CONCLUSION|ab|12|entity|C0871546|Treatment Resistant Depression|mobd|||TRD|||0|1000|1832|1835
SE|25462411|CONCLUSION|ab|12|relation|6|5|C0394162|Deep Brain Stimulation|topp|topp|||DBS|||0|694|1816|1819|NOM|AFFECTS||1667|1674|6|6|C0871546|Treatment Resistant Depression|mobd|mobd|||TRD|||0|1000|1832|1835


SE|25462412||ti|1|text|21|167|Self-reported school experience as a predictor of self-harm during adolescence: a prospective cohort study in the South West of England (ALSPAC).
SE|25462412||ti|1|entity|C0036588|Self|idcn|||Self|||0|775|21|25
SE|25462412||ti|1|entity|C0596545|experience|menp|||experience|||0|775|42|52
SE|25462412||ti|1|entity|C0036588|Self|idcn|||self|||0|694|71|75
SE|25462412||ti|1|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|88|99
SE|25462412||ti|1|entity|C0599755|cohort|popg|||cohort|||0|901|115|121
SE|25462412||ti|1|entity|C0033522|Prospective Studies|qnco,resa|||prospective cohort study|||0|901|103|127
SE|25462412||ti|1|entity|C0014282|England|geoa|||England|||0|1000|149|156

SE|25462412|BACKGROUND|ab|1|text|173|358|BACKGROUND: Several aspects of school life are thought to be associated with increased risk of self-harm in adolescence, but these have rarely been investigated in prospective studies.
SE|25462412|BACKGROUND|ab|1|entity|C0443302|Several|qnco|||Several|||0|872|185|192
SE|25462412|BACKGROUND|ab|1|entity|C1547011|Aspect|qnco|||aspects|||0|872|193|200
SE|25462412|BACKGROUND|ab|1|entity|C0376558|Life|idcn|||life|||0|861|211|215
SE|25462412|BACKGROUND|ab|1|entity|C0205217|Increased|qnco|||increased|||0|888|250|259
SE|25462412|BACKGROUND|ab|1|entity|C0035647|Risk|qlco|||risk|||0|888|260|264
SE|25462412|BACKGROUND|ab|1|entity|C0036588|Self|idcn|||self|||0|694|268|272
SE|25462412|BACKGROUND|ab|1|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|281|292
SE|25462412|BACKGROUND|ab|1|entity|C0522498|Rare|qlco|||rarely|||0|1000|309|315
SE|25462412|BACKGROUND|ab|1|entity|C0033522|Prospective Studies|qnco,resa|||prospective studies|||0|1000|337|356

SE|25462412|METHODS|ab|2|text|358|550|METHODS: Members of the Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort completed postal surveys of school experiences aged 14, and self-harm behaviour aged 16 (n=3939).
SE|25462412|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|358|365
SE|25462412|METHODS|ab|2|entity|C0680022|member|popg|||Members|||0|966|367|374
SE|25462412|METHODS|ab|2|entity|C0454839|Avon|geoa|||Avon|||0|901|382|386
SE|25462412|METHODS|ab|2|entity|C0023981|Longitudinal Studies|qnco,resa|||Longitudinal Study|||0|901|387|405
SE|25462412|METHODS|ab|2|entity|C0030551|parent|famg|||Parents|||0|1000|409|416
SE|25462412|METHODS|ab|2|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|421|429
SE|25462412|METHODS|ab|2|entity|C0005615|Birth|orgf|||birth|||0|888|439|444
SE|25462412|METHODS|ab|2|entity|C0599755|cohort|popg|||cohort|||0|888|445|451
SE|25462412|METHODS|ab|2|entity|C1514253|Postal|ftcn|||postal|||0|888|462|468
SE|25462412|METHODS|ab|2|entity|C0038951|Surveys|resa|||surveys|||0|888|469|476
SE|25462412|METHODS|ab|2|entity|C0596545|experience|menp|||experiences|||0|827|487|498
SE|25462412|METHODS|ab|2|entity|C0036588|Self|idcn|||self|||0|802|512|516
SE|25462412|METHODS|ab|2|entity|C0004927|Behavior|inbe|||behaviour|||0|802|522|531
SE|25462412|METHODS|ab|2|relation|0|0|C0005615|Birth|orgf|orgf|||birth|||0|888|439|444|MOD/HEAD|PROCESS_OF||439|451|0|0|C0599755|cohort|popg,humn|humn|||cohort|||0|888|445|451

SE|25462412|METHODS|ab|3|text|550|763|Associations between school experiences (feeling connected to school, enjoyment of school and perception of teachers as fair) and subsequent self-harm were examined using multivariable logistic regression models.
SE|25462412|METHODS|ab|3|entity|C0596545|experience|menp|||experiences|||0|827|578|589
SE|25462412|METHODS|ab|3|entity|C1527305|Feelings|menp|||feeling|||0|1000|591|598
SE|25462412|METHODS|ab|3|entity|C0679105|pleasurable emotion|menp|||enjoyment|||0|1000|620|629
SE|25462412|METHODS|ab|3|entity|C0030971|Perception|menp|||perception|||0|1000|644|654
SE|25462412|METHODS|ab|3|entity|C0221457|Teacher|prog|||teachers|||0|1000|658|666
SE|25462412|METHODS|ab|3|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|623|680|690
SE|25462412|METHODS|ab|3|entity|C0036588|Self|idcn|||self|||0|623|691|695
SE|25462412|METHODS|ab|3|entity|C0023965|Logistic Models|inpr,qnco|||logistic regression models|||0|875|735|761

SE|25462412|RESULTS|ab|4|text|763|1210|RESULTS: Self-harm aged 16 was associated with earlier perceptions of school, specifically not getting on well with or feeling accepted by others (OR=2.43 [1.76, 3.35] and OR=2.69 [2.16, 3.35] respectively), not liking school or the work done in class (OR=1.40 [1.17, 1.69] and OR=1.36 [1.10, 1.67]), and feeling that teachers are not clear about behaviour or fail to address misbehaviour consistently (OR=1.59 [1.20, 2.12] OR=1.89 [1.51, 2.37]).
SE|25462412|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|763|770
SE|25462412|RESULTS|ab|4|entity|C0036588|Self|idcn|||Self|||0|694|772|776
SE|25462412|RESULTS|ab|4|entity|C1279919|Early|tmco|||earlier|||0|872|810|817
SE|25462412|RESULTS|ab|4|entity|C0030971|Perception|menp|||perceptions|||0|872|818|829
SE|25462412|RESULTS|ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|854|857
SE|25462412|RESULTS|ab|4|entity|C0205170|Good|qlco|||well|||0|1000|869|873
SE|25462412|RESULTS|ab|4|entity|C1527305|Feelings|menp|||feeling|||0|1000|882|889
SE|25462412|RESULTS|ab|4|entity|C0205394|Other|qlco|||others|||0|966|902|908
SE|25462412|RESULTS|ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|971|974
SE|25462412|RESULTS|ab|4|entity|C0043227|Work|ocac|||work|||0|1000|996|1000
SE|25462412|RESULTS|ab|4|entity|C0008902|Classification|clas|||class|||0|1000|1009|1014
SE|25462412|RESULTS|ab|4|entity|C0442767|1/36|fndg|||1.36|||0|1000|1044|1048
SE|25462412|RESULTS|ab|4|entity|C0221457|Teacher|prog|||teachers|||0|1000|1081|1089
SE|25462412|RESULTS|ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|1094|1097
SE|25462412|RESULTS|ab|4|entity|C0004927|Behavior|inbe|||behaviour|||0|1000|1110|1119
SE|25462412|RESULTS|ab|4|entity|C0683308|misbehavior|inbe|||misbehaviour|||0|861|1139|1151

SE|25462412|RESULTS|ab|5|text|1210|1324|These associations were partially attenuated in models controlling for mental health concurrent with the outcome.
SE|25462412|RESULTS|ab|5|entity|C0025353|mental health|idcn|||mental health|||0|1000|1281|1294
SE|25462412|RESULTS|ab|5|entity|C0205420|Concurrent|tmco|||concurrent|||0|1000|1295|1305
SE|25462412|RESULTS|ab|5|entity|C1274040|result|ftcn|||outcome|||0|1000|1315|1322

SE|25462412|RESULTS|ab|6|text|1324|1466|Poor school experiences were related to both suicidal and non-suicidal self-harm, with slightly stronger associations visible for the former.
SE|25462412|RESULTS|ab|6|entity|C0032854|Poverty|grpa|||Poor|||0|785|1324|1328
SE|25462412|RESULTS|ab|6|entity|C0596545|experience|menp|||experiences|||0|785|1336|1347
SE|25462412|RESULTS|ab|6|entity|C0438696|Suicidal|fndg|||suicidal|||0|1000|1369|1377
SE|25462412|RESULTS|ab|6|entity|C0438696|Suicidal|fndg|||suicidal|||0|583|1386|1394
SE|25462412|RESULTS|ab|6|entity|C0036588|Self|idcn|||self|||0|583|1395|1399
SE|25462412|RESULTS|ab|6|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|840|1411|1419
SE|25462412|RESULTS|ab|6|entity|C0442821|Strong|qlco|||stronger|||0|840|1420|1428
SE|25462412|RESULTS|ab|6|entity|C0205379|Visible|qlco|||visible|||0|1000|1442|1449
SE|25462412|RESULTS|ab|6|entity|C0750523|FORMER|idcn|||former|||0|1000|1458|1464

SE|25462412|LIMITATIONS|ab|7|text|1466|1621|LIMITATIONS: (i) There was some loss to follow up, (ii) experience of bullying was not measured, and (iii) exposure and outcome measures were self-report.
SE|25462412|LIMITATIONS|ab|7|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1466|1477
SE|25462412|LIMITATIONS|ab|7|entity|C1517945|Loss|qnco|||loss|||0|1000|1498|1502
SE|25462412|LIMITATIONS|ab|7|entity|C1522577|follow-up|hlca|||follow up|||0|901|1506|1515
SE|25462412|LIMITATIONS|ab|7|entity|C0424318|Bullying|mobd|||bullying|||0|1000|1536|1544
SE|25462412|LIMITATIONS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1549|1552
SE|25462412|LIMITATIONS|ab|7|entity|C0439070|III|inpr|||iii|||0|1000|1568|1571
SE|25462412|LIMITATIONS|ab|7|entity|C0086749|Outcome Measures|qnco|||outcome measures|||0|1000|1586|1602
SE|25462412|LIMITATIONS|ab|7|entity|C0036588|Self|idcn|||self|||0|888|1608|1612

SE|25462412|CONCLUSIONS|ab|8|text|1621|1771|CONCLUSIONS: Students who feel unconnected to school, unhappy at school, or feel that teachers are unfair are more likely to self-harm in the future.
SE|25462412|CONCLUSIONS|ab|8|entity|C0038492|student|prog|||Students|||0|1000|1634|1642
SE|25462412|CONCLUSIONS|ab|8|entity|C0680208|unrelatedness|socb|||unconnected|||0|1000|1652|1663
SE|25462412|CONCLUSIONS|ab|8|entity|C0847488|Unhappy|sosy|||unhappy|||0|1000|1675|1682
SE|25462412|CONCLUSIONS|ab|8|entity|C0221457|Teacher|prog|||teachers|||0|1000|1707|1715
SE|25462412|CONCLUSIONS|ab|8|entity|C0205172|More|ftcn|||more|||0|888|1731|1735
SE|25462412|CONCLUSIONS|ab|8|entity|C0036588|Self|idcn|||self|||0|694|1746|1750
SE|25462412|CONCLUSIONS|ab|8|entity|C0016884|Future|tmco|||future|||0|1000|1763|1769

SE|25462412|CONCLUSIONS|ab|9|text|1771|1912|Assessing students' perceptions of school may serve to identify those at risk of self-harm who would benefit from preventative interventions.
SE|25462412|CONCLUSIONS|ab|9|entity|C0220825|Evaluation|ftcn|||Assessing|||0|840|1771|1780
SE|25462412|CONCLUSIONS|ab|9|entity|C0038492|student|prog|||students|||0|840|1781|1789
SE|25462412|CONCLUSIONS|ab|9|entity|C0030971|Perception|menp|||perceptions|||0|840|1791|1802
SE|25462412|CONCLUSIONS|ab|9|entity|C1444641|At risk|qlco|||at risk|||0|1000|1841|1848
SE|25462412|CONCLUSIONS|ab|9|entity|C0036588|Self|idcn|||self|||0|694|1852|1856
SE|25462412|CONCLUSIONS|ab|9|entity|C1273869|Intervention regimes|hlca|||interventions|||0|861|1898|1911


SE|25462413||ti|1|text|21|113|Increased uric acid levels in bipolar disorder subjects during different phases of illness.
SE|25462413||ti|1|entity|C0041981|Increased uric acid level|fndg|||Increased uric acid levels|||0|988|21|47
SE|25462413||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|51|67
SE|25462413||ti|1|entity|C1547020|*Difference|qnco|||different|||0|853|84|93
SE|25462413||ti|1|entity|C0205390|Phase|tmco|||phases|||0|853|94|100
SE|25462413||ti|1|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|104|111

SE|25462413|BACKGROUND|ab|1|text|119|270|BACKGROUND: Recent evidence indicates the possible involvement of adenosine and the purinergic system in the pathophysiology of bipolar disorder (BD).
SE|25462413|BACKGROUND|ab|1|entity|C0332185|Recent|tmco|||Recent|||0|694|131|137
SE|25462413|BACKGROUND|ab|1|entity|C0332149|Possible|qlco|||possible|||0|694|161|169
SE|25462413|BACKGROUND|ab|1|entity|C0001443|Adenosine|bacs,nnon,phsu|||adenosine|||0|1000|185|194
SE|25462413|BACKGROUND|ab|1|entity|C0449913|System|ftcn|||system|||0|861|214|220
SE|25462413|BACKGROUND|ab|1|entity|C0031847|physiopathological|ftcn|||pathophysiology|||0|1000|228|243
SE|25462413|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|247|263

SE|25462413|BACKGROUND|ab|2|text|270|472|The aim of this study is to compare serum uric acid (UA) levels in a large group of BD patients (in mania, depression and euthymia) vs. a control group of patients with different psychiatric disorders.
SE|25462413|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|286|291
SE|25462413|BACKGROUND|ab|2|entity|C1318242|Serum urate level result|lbtr|||serum uric acid (UA) levels|||0|988|306|333
SE|25462413|BACKGROUND|ab|2|entity|C0679991|large group|grpa|||large group|||0|1000|339|350
SE|25462413|BACKGROUND|ab|2|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|901|354|356
SE|25462413|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|901|357|365
SE|25462413|BACKGROUND|ab|2|entity|C0338831|Manic|mobd|||mania|||0|1000|370|375
SE|25462413|BACKGROUND|ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|377|387
SE|25462413|BACKGROUND|ab|2|entity|C0948853|Euthymia|mobd|||euthymia|||0|1000|392|400
SE|25462413|BACKGROUND|ab|2|entity|C0009932|Control Groups|grup|||control group|||0|1000|408|421
SE|25462413|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|425|433
SE|25462413|BACKGROUND|ab|2|entity|C1547020|*Difference|qnco|||different|||0|877|439|448
SE|25462413|BACKGROUND|ab|2|entity|C0004936|Mental disorders|mobd|||psychiatric disorders|||0|877|449|470
SE|25462413|BACKGROUND|ab|2|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||BD|||0|901|354|356|MOD/HEAD|PROCESS_OF||354|365|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|357|365
SE|25462413|BACKGROUND|ab|2|relation|1|1|C0004936|Mental disorders|mobd|mobd|||psychiatric disorders|||0|877|449|470|PREP|PROCESS_OF||434|438|10|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|425|433

SE|25462413|METHODS|ab|3|text|472|601|METHODS: 150 BD (SCID-I; DSM-IV) patients were compared to 150 age- and gender-matched subjects with MDD, OCD, or Schizophrenia.
SE|25462413|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|472|479
SE|25462413|METHODS|ab|3|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|901|485|487
SE|25462413|METHODS|ab|3|entity|C0085110|Severe Combined Immunodeficiency|dsyn|||SCID|||0|1000|489|493
SE|25462413|METHODS|ab|3|entity|C0220952|DSM-IV|inpr|||DSM-IV|||0|1000|497|503
SE|25462413|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|505|513
SE|25462413|METHODS|ab|3|entity|C0001779|Age|orga|||age|||0|861|535|538
SE|25462413|METHODS|ab|3|entity|C0079399|Gender|orga|||gender|||0|829|544|550
SE|25462413|METHODS|ab|3|entity|C0150103|MATCHING|resa|||matched|||0|829|551|558
SE|25462413|METHODS|ab|3|entity|C1550501|subject|idcn|||subjects|||0|829|559|567
SE|25462413|METHODS|ab|3|entity|C0036341|Schizophrenia|mobd|||Schizophrenia|||0|1000|586|599

SE|25462413|METHODS|ab|4|text|601|686|Mean serum UA values were compared with the ANOVA, with Bonferroni's post-hoc tests.
SE|25462413|METHODS|ab|4|entity|C0455272|Serum urate measurement|lbpr|||serum UA|||0|854|606|614
SE|25462413|METHODS|ab|4|entity|C0042295|Values|qlco|||values|||0|854|615|621
SE|25462413|METHODS|ab|4|entity|C0002780|Analysis of Variance|qnco|||ANOVA|||0|1000|645|650
SE|25462413|METHODS|ab|4|entity|C0392366|Tests|inpr|||tests|||0|763|679|684

SE|25462413|RESULTS|ab|5|text|686|869|RESULTS: Mean serum UA levels (5.06 +/- 1.45 vs. 4.17 +/- 1.05 mg/dL) and rates of hyperuricaemia (30.7% vs. 6.7%) were significantly higher in the bipolar than in the control group.
SE|25462413|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|686|693
SE|25462413|RESULTS|ab|5|entity|C1318242|Serum urate level result|lbtr|||serum UA levels|||0|926|700|715
SE|25462413|RESULTS|ab|5|entity|C1521828|Rate|qnco|||rates|||0|966|760|765
SE|25462413|RESULTS|ab|5|entity|C0740394|Hyperuricemia|dsyn|||hyperuricaemia|||0|1000|769|783
SE|25462413|RESULTS|ab|5|entity|C0205250|High|qlco|||higher|||0|827|820|826
SE|25462413|RESULTS|ab|5|entity|C0443156|Bipolar|spco|||bipolar|||0|1000|834|841
SE|25462413|RESULTS|ab|5|entity|C0009932|Control Groups|grup|||control group|||0|1000|854|867
SE|25462413|RESULTS|ab|5|relation|7|3|C0740394|Hyperuricemia|dsyn|dsyn|||hyperuricaemia|||0|1000|769|783|PREP|PROCESS_OF||847|849|1|1|C0009932|Control Groups|grup,humn|humn|||control group|||0|1000|854|867

SE|25462413|RESULTS|ab|6|text|869|1075|No differences were detected between bipolars in different phases of illness, with all three groups (manic, depressive and euthymic bipolars) showing significantly higher UA levels as compared to controls.
SE|25462413|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||differences|||0|966|872|883
SE|25462413|RESULTS|ab|6|entity|C0443156|Bipolar|spco|||bipolars|||0|966|906|914
SE|25462413|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||different|||0|853|918|927
SE|25462413|RESULTS|ab|6|entity|C0205390|Phase|tmco|||phases|||0|853|928|934
SE|25462413|RESULTS|ab|6|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|938|945
SE|25462413|RESULTS|ab|6|entity|C0205449|Three|qnco|||three|||0|888|956|961
SE|25462413|RESULTS|ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|962|968
SE|25462413|RESULTS|ab|6|entity|C0338831|Manic|mobd|||manic|||0|1000|970|975
SE|25462413|RESULTS|ab|6|entity|C0948853|Euthymia|mobd|||euthymic|||0|836|992|1000
SE|25462413|RESULTS|ab|6|entity|C0443156|Bipolar|spco|||bipolars|||0|836|1001|1009
SE|25462413|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|787|1033|1039
SE|25462413|RESULTS|ab|6|entity|C0041980|Uric Acid|bacs,orch|||UA|||0|787|1040|1042
SE|25462413|RESULTS|ab|6|entity|C0441889|Levels|inpr|||levels|||0|787|1043|1049
SE|25462413|RESULTS|ab|6|entity|C0243148|control|ftcn|||controls|||0|966|1065|1073

SE|25462413|RESULTS|ab|7|text|1075|1146|No correlations were found between UA levels and YMRS or HAM-D scores.
SE|25462413|RESULTS|ab|7|entity|C0041980|Uric Acid|bacs,orch|||UA|||0|901|1110|1112
SE|25462413|RESULTS|ab|7|entity|C0441889|Levels|inpr|||levels|||0|901|1113|1119
SE|25462413|RESULTS|ab|7|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM-D|||0|840|1132|1137
SE|25462413|RESULTS|ab|7|entity|C1367701|DHPS gene|gngm|1725|DHPS|HAM-D|||0|840|1132|1137
SE|25462413|RESULTS|ab|7|entity|C0449820|Score|qnco|||scores|||0|840|1138|1144

SE|25462413|RESULTS|ab|8|text|1146|1326|Mean UA levels were also higher in bipolars never exposed to mood stabilizers vs. controls (5.08 +/- 1.43 vs. 4.17 +/- 1.05 mg/dL), with no differences compared to other bipolars.
SE|25462413|RESULTS|ab|8|entity|C0041980|Uric Acid|bacs,orch|||UA|||0|824|1151|1153
SE|25462413|RESULTS|ab|8|entity|C0441889|Levels|inpr|||levels|||0|824|1154|1160
SE|25462413|RESULTS|ab|8|entity|C0205250|High|qlco|||higher|||0|827|1171|1177
SE|25462413|RESULTS|ab|8|entity|C0443156|Bipolar|spco|||bipolars|||0|966|1181|1189
SE|25462413|RESULTS|ab|8|entity|C1549495|Never|idcn|||never|||0|1000|1190|1195
SE|25462413|RESULTS|ab|8|entity|C0026516|Mood|menp|||mood|||0|694|1207|1211
SE|25462413|RESULTS|ab|8|entity|C0243148|control|ftcn|||controls|||0|966|1228|1236
SE|25462413|RESULTS|ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1286|1297
SE|25462413|RESULTS|ab|8|entity|C0443156|Bipolar|spco|||bipolars|||0|966|1316|1324

SE|25462413|LIMITATIONS|ab|9|text|1326|1443|LIMITATIONS: Our study suffers from the lack of a healthy comparison group; moreover, longitudinal data are missing.
SE|25462413|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1326|1337
SE|25462413|LIMITATIONS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|1000|1343|1348
SE|25462413|LIMITATIONS|ab|9|entity|C0332268|Lacking|qlco|||lack|||0|1000|1366|1370
SE|25462413|LIMITATIONS|ab|9|entity|C0018684|Health|idcn|||healthy|||0|766|1376|1383
SE|25462413|LIMITATIONS|ab|9|entity|C0441833|Groups|inpr|||group|||0|766|1395|1400
SE|25462413|LIMITATIONS|ab|9|entity|C0205127|Longitudinal|spco|||longitudinal|||0|888|1412|1424
SE|25462413|LIMITATIONS|ab|9|entity|C1511726|Data|idcn|||data|||0|888|1425|1429
SE|25462413|LIMITATIONS|ab|9|entity|C1551393|Missing|idcn|||missing|||0|1000|1434|1441

SE|25462413|CONCLUSIONS|ab|10|text|1443|1570|CONCLUSIONS: Our study provides further evidence of a purinergic dysfunction associated with BD, in all phases of the illness.
SE|25462413|CONCLUSIONS|ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1460|1465
SE|25462413|CONCLUSIONS|ab|10|entity|C1517331|Further|spco|||further|||0|694|1475|1482
SE|25462413|CONCLUSIONS|ab|10|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|1000|1536|1538
SE|25462413|CONCLUSIONS|ab|10|entity|C0205390|Phase|tmco|||phases|||0|1000|1547|1553
SE|25462413|CONCLUSIONS|ab|10|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|1561|1568

SE|25462413|CONCLUSIONS|ab|11|text|1570|1774|It is possible that increased UA levels are a trait marker of higher vulnerability to bipolar disorder, and are even more increased during mania (mostly in the first manic episode of drug-naive patients).
SE|25462413|CONCLUSIONS|ab|11|entity|C0332149|Possible|qlco|||possible|||0|1000|1576|1584
SE|25462413|CONCLUSIONS|ab|11|entity|C0041981|Increased uric acid level|fndg|||increased UA levels|||0|988|1590|1609
SE|25462413|CONCLUSIONS|ab|11|entity|C0599883|trait|orga|||trait|||0|888|1616|1621
SE|25462413|CONCLUSIONS|ab|11|entity|C0005516|Biological Markers|qlco|||marker|||0|888|1622|1628
SE|25462413|CONCLUSIONS|ab|11|entity|C0205250|High|qlco|||higher|||0|661|1632|1638
SE|25462413|CONCLUSIONS|ab|11|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|1656|1672
SE|25462413|CONCLUSIONS|ab|11|entity|C0205172|More|ftcn|||more|||0|1000|1687|1691
SE|25462413|CONCLUSIONS|ab|11|entity|C0338831|Manic|mobd|||mania|||0|1000|1709|1714
SE|25462413|CONCLUSIONS|ab|11|entity|C0750554|MOSTLY|idcn|||mostly|||0|1000|1716|1722
SE|25462413|CONCLUSIONS|ab|11|entity|C0338831|Manic|mobd|||manic|||0|901|1736|1741
SE|25462413|CONCLUSIONS|ab|11|entity|C0439615|First episode|tmco|||first manic episode|||0|901|1730|1749
SE|25462413|CONCLUSIONS|ab|11|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|802|1753|1757
SE|25462413|CONCLUSIONS|ab|11|entity|C0030705|Patients|podg|||patients|||0|802|1764|1772
SE|25462413|CONCLUSIONS|ab|11|relation|5|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|1656|1672|PREP|COEXISTS_WITH||1702|1708|3|1|C0338831|Manic|mobd|mobd|||mania|||0|1000|1709|1714


SE|25462414||ti|1|text|21|110|Depression in advanced cancer--assessment challenges and associations with disease load.
SE|25462414||ti|1|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|21|31
SE|25462414||ti|1|entity|C0877373|Advanced cancer|neop|||advanced cancer|||0|1000|35|50
SE|25462414||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|872|52|62
SE|25462414||ti|1|entity|C0012634|Disease|dsyn|||disease|||0|888|96|103
SE|25462414||ti|1|entity|C1550025|Load|idcn|||load|||0|888|104|108
SE|25462414||ti|1|relation|1|1|C0011581|Depressive disorder|mobd|mobd|||Depression|||0|1000|21|31|PREP|COEXISTS_WITH||32|34|4|1|C0877373|Advanced cancer|neop|neop|||advanced cancer|||0|1000|35|50

SE|25462414|BACKGROUND|ab|1|text|116|231|BACKGROUND: Patients with advanced cancer commonly experience multiple somatic symptoms and declining functioning.
SE|25462414|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||Patients|||0|1000|128|136
SE|25462414|BACKGROUND|ab|1|entity|C0877373|Advanced cancer|neop|||advanced cancer|||0|1000|142|157
SE|25462414|BACKGROUND|ab|1|entity|C0599444|cell body (neuron)|celc|||somatic|||0|877|187|194
SE|25462414|BACKGROUND|ab|1|entity|C0231217|Multiple symptoms|sosy|||multiple somatic symptoms|||0|877|178|203
SE|25462414|BACKGROUND|ab|1|entity|C1511741|Declining|qlco|||declining|||0|872|208|217
SE|25462414|BACKGROUND|ab|1|entity|C0031843|physiological aspects|phsf|||functioning|||0|872|218|229
SE|25462414|BACKGROUND|ab|1|relation|2|1|C0231217|Multiple symptoms|sosy|sosy|||multiple somatic symptoms|||0|877|178|203|VERB|PROCESS_OF||167|177|3|2|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|128|136
SE|25462414|BACKGROUND|ab|1|relation|3|1|C0877373|Advanced cancer|neop|neop|||advanced cancer|||0|1000|142|157|PREP|PROCESS_OF||137|141|2|1|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|128|136

SE|25462414|BACKGROUND|ab|2|text|231|323|Some highly prevalent symptoms also overlap with diagnostic symptom-criteria of depression.
SE|25462414|BACKGROUND|ab|2|entity|C0033105|Statistical Prevalence|qnco|||prevalent|||0|754|243|252
SE|25462414|BACKGROUND|ab|2|entity|C1457887|Symptoms|sosy|||symptoms|||0|754|253|261
SE|25462414|BACKGROUND|ab|2|entity|C1457887|Symptoms|sosy|||symptom|||0|901|291|298
SE|25462414|BACKGROUND|ab|2|entity|C0679228|diagnostic criteria|inpr|||diagnostic symptom-criteria|||0|901|280|307
SE|25462414|BACKGROUND|ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|311|321

SE|25462414|BACKGROUND|ab|3|text|323|388|Thus, assessing depression in these patients can be challenging.
SE|25462414|BACKGROUND|ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|339|349
SE|25462414|BACKGROUND|ab|3|entity|C0030705|Patients|podg|||patients|||0|1000|359|367
SE|25462414|BACKGROUND|ab|3|entity|C0805586|CHALLENGE|idcn|||challenging|||0|966|375|386
SE|25462414|BACKGROUND|ab|3|relation|1|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|339|349|PREP|PROCESS_OF||350|352|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|359|367

SE|25462414|BACKGROUND|ab|4|text|388|604|We therefore investigated 1) the effect of different scoring-methods of depressive symptoms on detecting depression, and 2) the relationship between disease load and depression amongst patients with advanced cancer.
SE|25462414|BACKGROUND|ab|4|entity|C1280500|Effect|qlco|||effect|||0|1000|421|427
SE|25462414|BACKGROUND|ab|4|entity|C1547020|*Difference|qnco|||different|||0|877|431|440
SE|25462414|BACKGROUND|ab|4|entity|C0036449|Scoring Methods|resa|||scoring-methods|||0|877|441|456
SE|25462414|BACKGROUND|ab|4|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|460|479
SE|25462414|BACKGROUND|ab|4|entity|C0011581|Depressive disorder|mobd|||depression|||0|872|493|503
SE|25462414|BACKGROUND|ab|4|entity|C0439849|Relationships|qlco|||relationship|||0|1000|516|528
SE|25462414|BACKGROUND|ab|4|entity|C0012634|Disease|dsyn|||disease|||0|888|537|544
SE|25462414|BACKGROUND|ab|4|entity|C1550025|Load|idcn|||load|||0|888|545|549
SE|25462414|BACKGROUND|ab|4|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|554|564
SE|25462414|BACKGROUND|ab|4|entity|C0030705|Patients|podg|||patients|||0|1000|573|581
SE|25462414|BACKGROUND|ab|4|entity|C0877373|Advanced cancer|neop|||advanced cancer|||0|1000|587|602
SE|25462414|BACKGROUND|ab|4|relation|1|1|C0877373|Advanced cancer|neop|neop|||advanced cancer|||0|1000|587|602|PREP|PROCESS_OF||582|586|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|573|581
SE|25462414|BACKGROUND|ab|4|relation|7|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|554|564|PREP|PROCESS_OF||565|572|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|573|581

SE|25462414|METHODS|ab|5|text|604|748|METHODS: The sample included 969 patients in the European Palliative Care Research Collaborative-Computer Symptom Assessment Study (EPCRC-CSA).
SE|25462414|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|604|611
SE|25462414|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|861|637|645
SE|25462414|METHODS|ab|5|entity|C0030231|Palliative Care|hlca|||Palliative Care|||0|901|662|677
SE|25462414|METHODS|ab|5|entity|C0009622|Computers|mnob|||Computer|||0|840|701|709
SE|25462414|METHODS|ab|5|entity|C1457887|Symptoms|sosy|||Symptom|||0|840|710|717
SE|25462414|METHODS|ab|5|entity|C0220825|Evaluation|ftcn|||Assessment|||0|840|718|728
SE|25462414|METHODS|ab|5|entity|C0681804|collaborative study|resa|||Collaborative-Computer Symptom Assessment Study|||0|840|687|734

SE|25462414|METHODS|ab|6|text|748|835|Inclusion criteria were: incurable metastatic/locally advanced cancer and >= 18 years.
SE|25462414|METHODS|ab|6|entity|C1516637|Clinical Trial Eligibility Criteria|qlco|||Inclusion criteria|||0|1000|748|766
SE|25462414|METHODS|ab|6|entity|C0677984|Locally Advanced Malignant Neoplasm|neop|||locally advanced cancer|||0|884|794|817
SE|25462414|METHODS|ab|6|entity|C0439234|year|tmco|||years|||0|861|828|833

SE|25462414|METHODS|ab|7|text|835|907|Biomarkers and length of survival were registered from patient-records.
SE|25462414|METHODS|ab|7|entity|C0005516|Biological Markers|qlco|||Biomarkers|||0|1000|835|845
SE|25462414|METHODS|ab|7|entity|C1444754|Length|qnco|||length|||0|1000|850|856
SE|25462414|METHODS|ab|7|entity|C0038952|Continuance of life|acty|||survival|||0|1000|860|868
SE|25462414|METHODS|ab|7|entity|C0030705|Patients|podg|||patient|||0|888|890|897
SE|25462414|METHODS|ab|7|entity|C0034869|Records|inpr|||records|||0|888|898|905

SE|25462414|METHODS|ab|8|text|907|1210|Depression was assessed using the Patient Health Questionnaire (PHQ-9) and applying three scoring-methods: inclusive (algorithm scoring including the somatic symptom-criteria), exclusive (algorithm scoring excluding the somatic symptom-criteria) and sum-score (sum of all symptoms with a cut-off >= 8).
SE|25462414|METHODS|ab|8|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|907|917
SE|25462414|METHODS|ab|8|entity|C0030705|Patients|podg|||Patient|||0|851|941|948
SE|25462414|METHODS|ab|8|entity|C0018684|Health|idcn|||Health|||0|851|949|955
SE|25462414|METHODS|ab|8|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|851|956|969
SE|25462414|METHODS|ab|8|entity|C0205449|Three|qnco|||three|||0|824|991|996
SE|25462414|METHODS|ab|8|entity|C0036449|Scoring Methods|resa|||scoring-methods|||0|824|997|1012
SE|25462414|METHODS|ab|8|entity|C0332257|Including|ftcn|||inclusive|||0|1000|1014|1023
SE|25462414|METHODS|ab|8|entity|C0002045|algorithm|inpr|||algorithm|||0|888|1025|1034
SE|25462414|METHODS|ab|8|entity|C1552081|scoring|idcn|||scoring|||0|888|1035|1042
SE|25462414|METHODS|ab|8|entity|C0599444|cell body (neuron)|celc|||somatic|||0|828|1057|1064
SE|25462414|METHODS|ab|8|entity|C1457887|Symptoms|sosy|||symptom|||0|828|1065|1072
SE|25462414|METHODS|ab|8|entity|C0243161|criteria|inpr|||criteria|||0|828|1073|1081
SE|25462414|METHODS|ab|8|entity|C1548966|Exclusive|idcn|||exclusive|||0|1000|1084|1093
SE|25462414|METHODS|ab|8|entity|C0002045|algorithm|inpr|||algorithm|||0|888|1095|1104
SE|25462414|METHODS|ab|8|entity|C1552081|scoring|idcn|||scoring|||0|888|1105|1112
SE|25462414|METHODS|ab|8|entity|C0599444|cell body (neuron)|celc|||somatic|||0|828|1127|1134
SE|25462414|METHODS|ab|8|entity|C1457887|Symptoms|sosy|||symptom|||0|828|1135|1142
SE|25462414|METHODS|ab|8|entity|C0243161|criteria|inpr|||criteria|||0|828|1143|1151
SE|25462414|METHODS|ab|8|entity|C1515051|Sum|qnco|||sum|||0|888|1157|1160
SE|25462414|METHODS|ab|8|entity|C0449820|Score|qnco|||score|||0|888|1161|1166
SE|25462414|METHODS|ab|8|entity|C1515051|Sum|qnco|||sum|||0|1000|1168|1171
SE|25462414|METHODS|ab|8|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|1179|1187
SE|25462414|METHODS|ab|8|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|1000|1195|1202

SE|25462414|RESULTS|ab|9|text|1210|1337|RESULTS: Depression prevalence rates varied according to scoring-method: inclusive 13.7%, exclusive 14.9% and sum-score 45.3%.
SE|25462414|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1210|1217
SE|25462414|RESULTS|ab|9|entity|C0011581|Depressive disorder|mobd|||Depression|||0|785|1219|1229
SE|25462414|RESULTS|ab|9|entity|C1521828|Rate|qnco|||rates|||0|785|1241|1246
SE|25462414|RESULTS|ab|9|entity|C0036449|Scoring Methods|resa|||scoring-method|||0|1000|1267|1281
SE|25462414|RESULTS|ab|9|entity|C0332257|Including|ftcn|||inclusive|||0|827|1283|1292
SE|25462414|RESULTS|ab|9|entity|C1548966|Exclusive|idcn|||exclusive|||0|827|1300|1309
SE|25462414|RESULTS|ab|9|entity|C1515051|Sum|qnco|||sum|||0|750|1320|1323
SE|25462414|RESULTS|ab|9|entity|C0449820|Score|qnco|||score|||0|750|1324|1329

SE|25462414|RESULTS|ab|10|text|1337|1485|Agreement between the algorithm scoring-methods was excellent (Kappa = 0.81), but low between the inclusive and sum scoring-methods (Kappa = 0.32).
SE|25462414|RESULTS|ab|10|entity|C0680240|Agreement|socb|||Agreement|||0|1000|1337|1346
SE|25462414|RESULTS|ab|10|entity|C0002045|algorithm|inpr|||algorithm|||0|901|1359|1368
SE|25462414|RESULTS|ab|10|entity|C0036449|Scoring Methods|resa|||scoring-methods|||0|901|1369|1384
SE|25462414|RESULTS|ab|10|entity|C0439099|Kappa|inpr|||Kappa|||0|1000|1400|1405
SE|25462414|RESULTS|ab|10|entity|C0205251|low|qlco|||low|||0|1000|1419|1422
SE|25462414|RESULTS|ab|10|entity|C0332257|Including|ftcn|||inclusive|||0|1000|1435|1444
SE|25462414|RESULTS|ab|10|entity|C1515051|Sum|qnco|||sum|||0|901|1449|1452
SE|25462414|RESULTS|ab|10|entity|C0036449|Scoring Methods|resa|||scoring-methods|||0|901|1453|1468
SE|25462414|RESULTS|ab|10|entity|C0439099|Kappa|inpr|||Kappa|||0|1000|1470|1475

SE|25462414|RESULTS|ab|11|text|1485|1684|Depression was significantly associated with more pain (OR-range: 1.09-1.19, p < 0.001-0.04) and lower performance status (KPS-score, OR-range = 0.68-0.72, p < 0.001) irrespective of scoring-method.
SE|25462414|RESULTS|ab|11|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|1485|1495
SE|25462414|RESULTS|ab|11|entity|C0205172|More|ftcn|||more|||0|888|1530|1534
SE|25462414|RESULTS|ab|11|entity|C0030193|Pain|sosy|||pain|||0|888|1535|1539
SE|25462414|RESULTS|ab|11|entity|C1514721|Range|qnco|||range|||0|1000|1544|1549
SE|25462414|RESULTS|ab|11|entity|C0441994|Lower|ftcn|||lower|||0|901|1582|1587
SE|25462414|RESULTS|ab|11|entity|C1518965|Performance Status|clna|||performance status|||0|901|1588|1606
SE|25462414|RESULTS|ab|11|entity|C0206065|Karnofsky Performance Status|diap|||KPS|||0|888|1608|1611
SE|25462414|RESULTS|ab|11|entity|C0449820|Score|qnco|||score|||0|888|1612|1617
SE|25462414|RESULTS|ab|11|entity|C1514721|Range|qnco|||range|||0|1000|1622|1627
SE|25462414|RESULTS|ab|11|entity|C0036449|Scoring Methods|resa|||scoring-method|||0|1000|1668|1682

SE|25462414|LIMITATIONS|ab|12|text|1684|1765|LIMITATIONS: Depression was assessed using self-report, not clinical interviews.
SE|25462414|LIMITATIONS|ab|12|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1684|1695
SE|25462414|LIMITATIONS|ab|12|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|1697|1707
SE|25462414|LIMITATIONS|ab|12|entity|C0036588|Self|idcn|||self|||0|888|1727|1731
SE|25462414|LIMITATIONS|ab|12|entity|C1518422|Not|ftcn|||not|||0|890|1740|1743
SE|25462414|LIMITATIONS|ab|12|entity|C0199182|History taking|hlca|||clinical interviews|||0|890|1744|1763

SE|25462414|CONCLUSIONS|ab|13|text|1765|1878|CONCLUSIONS: The scoring-method, not excluding somatic symptoms, had the greatest effect on assessment outcomes.
SE|25462414|CONCLUSIONS|ab|13|entity|C0036449|Scoring Methods|resa|||scoring-method|||0|1000|1782|1796
SE|25462414|CONCLUSIONS|ab|13|entity|C1518422|Not|ftcn|||not|||0|1000|1798|1801
SE|25462414|CONCLUSIONS|ab|13|entity|C0599444|cell body (neuron)|celc|||somatic|||0|853|1812|1819
SE|25462414|CONCLUSIONS|ab|13|entity|C1457887|Symptoms|sosy|||symptoms|||0|853|1820|1828
SE|25462414|CONCLUSIONS|ab|13|entity|C0443228|Largest|qnco|||greatest|||0|872|1838|1846
SE|25462414|CONCLUSIONS|ab|13|entity|C1280500|Effect|qlco|||effect|||0|872|1847|1853
SE|25462414|CONCLUSIONS|ab|13|entity|C0220825|Evaluation|ftcn|||assessment|||0|872|1857|1867
SE|25462414|CONCLUSIONS|ab|13|entity|C1274040|result|ftcn|||outcomes|||0|872|1868|1876

SE|25462414|CONCLUSIONS|ab|14|text|1878|1996|Increasing pain and poorer than expected physical condition should alert clinicians to possible co-morbid depression.
SE|25462414|CONCLUSIONS|ab|14|entity|C0442808|Increasing|ftcn|||Increasing|||0|888|1878|1888
SE|25462414|CONCLUSIONS|ab|14|entity|C0030193|Pain|sosy|||pain|||0|888|1889|1893
SE|25462414|CONCLUSIONS|ab|14|entity|C0032854|Poverty|grpa|||poorer|||0|966|1898|1904
SE|25462414|CONCLUSIONS|ab|14|entity|C1517001|Expected|idcn|||expected|||0|901|1910|1918
SE|25462414|CONCLUSIONS|ab|14|entity|C0516977|physical health|fndg|||physical condition|||0|901|1919|1937
SE|25462414|CONCLUSIONS|ab|14|entity|C0871685|Clinicians|prog|||clinicians|||0|1000|1951|1961
SE|25462414|CONCLUSIONS|ab|14|entity|C0332149|Possible|qlco|||possible|||0|843|1965|1973
SE|25462414|CONCLUSIONS|ab|14|entity|C0009488|Comorbidity|idcn|||co-morbid|||0|843|1974|1983
SE|25462414|CONCLUSIONS|ab|14|entity|C0011581|Depressive disorder|mobd|||depression|||0|843|1984|1994

SE|25462414|CONCLUSIONS|ab|15|text|1996|2190|The large discrepancy in prevalence rates between scoring-methods reinforces the need for consensus and validation of depression definitions and assessment in populations with high disease load.
SE|25462414|CONCLUSIONS|ab|15|entity|C0549177|Large|qnco|||large|||0|888|2000|2005
SE|25462414|CONCLUSIONS|ab|15|entity|C1290905|Discrepancy|fndg|||discrepancy|||0|888|2006|2017
SE|25462414|CONCLUSIONS|ab|15|entity|C1521828|Rate|qnco|||rates|||0|827|2032|2037
SE|25462414|CONCLUSIONS|ab|15|entity|C0036449|Scoring Methods|resa|||scoring-methods|||0|1000|2046|2061
SE|25462414|CONCLUSIONS|ab|15|entity|C0027552|Needs|qlco|||need|||0|1000|2077|2081
SE|25462414|CONCLUSIONS|ab|15|entity|C0376298|Consensus|socb|||consensus|||0|1000|2086|2095
SE|25462414|CONCLUSIONS|ab|15|entity|C1519941|Validation|resa|||validation|||0|1000|2100|2110
SE|25462414|CONCLUSIONS|ab|15|entity|C0011581|Depressive disorder|mobd|||depression|||0|872|2114|2124
SE|25462414|CONCLUSIONS|ab|15|entity|C1550452|definition|idcn|||definitions|||0|872|2125|2136
SE|25462414|CONCLUSIONS|ab|15|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|2141|2151
SE|25462414|CONCLUSIONS|ab|15|entity|C0032659|geographic population|qnco|||populations|||0|1000|2155|2166
SE|25462414|CONCLUSIONS|ab|15|entity|C0205250|High|qlco|||high|||0|851|2172|2176
SE|25462414|CONCLUSIONS|ab|15|entity|C0012634|Disease|dsyn|||disease|||0|851|2177|2184
SE|25462414|CONCLUSIONS|ab|15|entity|C1550025|Load|idcn|||load|||0|851|2185|2189


SE|25462415||ti|1|text|21|181|Emotion dysregulation mediates the relationship between trauma exposure, post-migration living difficulties and psychological outcomes in traumatized refugees.
SE|25462415||ti|1|entity|C0013987|Emotions|menp|||Emotion|||0|694|21|28
SE|25462415||ti|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|56|68
SE|25462415||ti|1|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|694|77|83
SE|25462415||ti|1|entity|C0205095|Dorsal|spco|||post|||0|775|94|98
SE|25462415||ti|1|entity|C0205486|Psychologic|ftcn|||psychological|||0|872|133|146
SE|25462415||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|872|147|155
SE|25462415||ti|1|entity|C0034961|Refugees|popg|||refugees|||0|861|171|179
SE|25462415||ti|1|relation|5|3|C0043251|Wounds and Injuries|inpo|inpo|||trauma|||0|694|77|83|PREP|PROCESS_OF||156|158|1|1|C0034961|Refugees|popg,humn|humn|||refugees|||0|861|171|179

SE|25462415|BACKGROUND|ab|1|text|187|360|BACKGROUND: While emotion dysregulation represents an important mechanism underpinning psychological responses to trauma, little research has investigated this in refugees.
SE|25462415|BACKGROUND|ab|1|entity|C0013987|Emotions|menp|||emotion|||0|694|205|212
SE|25462415|BACKGROUND|ab|1|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|740|251|260
SE|25462415|BACKGROUND|ab|1|entity|C0205486|Psychologic|ftcn|||psychological|||0|740|274|287
SE|25462415|BACKGROUND|ab|1|entity|C0871261|response|clna|||responses|||0|740|288|297
SE|25462415|BACKGROUND|ab|1|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|1000|301|307
SE|25462415|BACKGROUND|ab|1|entity|C0023882|Little's Disease|dsyn|||little|||0|888|309|315
SE|25462415|BACKGROUND|ab|1|entity|C0035168|research|resa|||research|||0|888|316|324
SE|25462415|BACKGROUND|ab|1|entity|C0034961|Refugees|popg|||refugees|||0|1000|350|358
SE|25462415|BACKGROUND|ab|1|relation|5|2|C0043251|Wounds and Injuries|inpo|inpo|||trauma|||0|1000|301|307|PREP|PROCESS_OF||347|349|1|1|C0034961|Refugees|popg,humn|humn|||refugees|||0|1000|350|358

SE|25462415|BACKGROUND|ab|2|text|360|547|In the current study, we examined the mediating role of emotion dysregulation in the relationship between refugee experiences (trauma and living difficulties) and psychological outcomes.
SE|25462415|BACKGROUND|ab|2|entity|C0521116|Current|tmco|||current|||0|888|367|374
SE|25462415|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|375|380
SE|25462415|BACKGROUND|ab|2|entity|C0035820|Role|socb|||role|||0|1000|408|412
SE|25462415|BACKGROUND|ab|2|entity|C0013987|Emotions|menp|||emotion|||0|694|416|423
SE|25462415|BACKGROUND|ab|2|entity|C0439849|Relationships|qlco|||relationship|||0|1000|445|457
SE|25462415|BACKGROUND|ab|2|entity|C0034961|Refugees|popg|||refugee|||0|872|466|473
SE|25462415|BACKGROUND|ab|2|entity|C0596545|experience|menp|||experiences|||0|872|474|485
SE|25462415|BACKGROUND|ab|2|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|1000|487|493
SE|25462415|BACKGROUND|ab|2|entity|C0205486|Psychologic|ftcn|||psychological|||0|872|523|536
SE|25462415|BACKGROUND|ab|2|entity|C1274040|result|ftcn|||outcomes|||0|872|537|545
SE|25462415|BACKGROUND|ab|2|relation|0|0|C0596545|experience|menp|menp|||experiences|||0|872|474|485|MOD/HEAD|PROCESS_OF||466|485|0|0|C0034961|Refugees|popg,humn|humn|||refugee|||0|872|466|473

SE|25462415|METHODS|ab|3|text|547|802|METHODS: Participants were 134 traumatized treatment-seeking refugees who completed measures indexing trauma exposure, post-migration living difficulties, difficulties in emotion regulation, posttraumatic stress disorder, depression, and explosive anger.
SE|25462415|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|547|554
SE|25462415|METHODS|ab|3|entity|C0679646|Participant|popg|||Participants|||0|966|556|568
SE|25462415|METHODS|ab|3|entity|C0034961|Refugees|popg|||refugees|||0|742|608|616
SE|25462415|METHODS|ab|3|entity|C0079809|Measures|qnco|||measures|||0|1000|631|639
SE|25462415|METHODS|ab|3|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|694|649|655
SE|25462415|METHODS|ab|3|entity|C0205095|Dorsal|spco|||post|||0|775|666|670
SE|25462415|METHODS|ab|3|entity|C0013987|Emotions|menp|||emotion|||0|888|718|725
SE|25462415|METHODS|ab|3|entity|C0851285|Regulation|gora|||regulation|||0|888|726|736
SE|25462415|METHODS|ab|3|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||posttraumatic stress disorder|||0|1000|738|767
SE|25462415|METHODS|ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|769|779
SE|25462415|METHODS|ab|3|entity|C0002957|Anger|menp|||anger|||0|861|795|800

SE|25462415|RESULTS|ab|4|text|802|930|RESULTS: Findings revealed distinctive patterns of emotion dysregulation associated with each of these psychological disorders.
SE|25462415|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|802|809
SE|25462415|RESULTS|ab|4|entity|C0243095|Finding|ftcn|||Findings|||0|1000|811|819
SE|25462415|RESULTS|ab|4|entity|C0449774|Patterns|spco|||patterns|||0|861|841|849
SE|25462415|RESULTS|ab|4|entity|C0013987|Emotions|menp|||emotion|||0|694|853|860
SE|25462415|RESULTS|ab|4|entity|C0004936|Mental disorders|mobd|||psychological disorders|||0|983|905|928

SE|25462415|RESULTS|ab|5|text|930|1115|Results also indicated that emotion regulation difficulties mediated the association between both trauma and psychological symptoms, and living difficulties and psychological symptoms.
SE|25462415|RESULTS|ab|5|entity|C0013987|Emotions|menp|||emotion|||0|840|958|965
SE|25462415|RESULTS|ab|5|entity|C0851285|Regulation|gora|||regulation|||0|840|966|976
SE|25462415|RESULTS|ab|5|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|1000|1028|1034
SE|25462415|RESULTS|ab|5|entity|C0233397|Psychological symptom|sosy|||psychological symptoms|||0|983|1039|1061
SE|25462415|RESULTS|ab|5|entity|C0233397|Psychological symptom|sosy|||psychological symptoms|||0|983|1091|1113

SE|25462415|LIMITATIONS|ab|6|text|1115|1267|LIMITATIONS: Limitations include a cross-sectional design and the use of measures that had not been validated across all cultural groups in this study.
SE|25462415|LIMITATIONS|ab|6|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1115|1126
SE|25462415|LIMITATIONS|ab|6|entity|C0449295|Limitation|ftcn|||Limitations|||0|966|1128|1139
SE|25462415|LIMITATIONS|ab|6|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|663|1150|1165
SE|25462415|LIMITATIONS|ab|6|entity|C0079809|Measures|qnco|||measures|||0|1000|1188|1196
SE|25462415|LIMITATIONS|ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1206|1209
SE|25462415|LIMITATIONS|ab|6|entity|C0220814|Cultural|ftcn|||cultural|||0|888|1236|1244
SE|25462415|LIMITATIONS|ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|1245|1251
SE|25462415|LIMITATIONS|ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1260|1265

SE|25462415|CONCLUSIONS|ab|7|text|1267|1472|CONCLUSIONS: These findings underscore the key role of emotion dysregulation in psychological responses of refugees, and highlight potential directions for treatment interventions for traumatized refugees.
SE|25462415|CONCLUSIONS|ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|1286|1294
SE|25462415|CONCLUSIONS|ab|7|entity|C1554080|Key|idcn|||key|||0|888|1310|1313
SE|25462415|CONCLUSIONS|ab|7|entity|C0035820|Role|socb|||role|||0|888|1314|1318
SE|25462415|CONCLUSIONS|ab|7|entity|C0013987|Emotions|menp|||emotion|||0|694|1322|1329
SE|25462415|CONCLUSIONS|ab|7|entity|C0205486|Psychologic|ftcn|||psychological|||0|888|1347|1360
SE|25462415|CONCLUSIONS|ab|7|entity|C0871261|response|clna|||responses|||0|888|1361|1370
SE|25462415|CONCLUSIONS|ab|7|entity|C0034961|Refugees|popg|||refugees|||0|1000|1374|1382
SE|25462415|CONCLUSIONS|ab|7|entity|C0237399|Potential|qlco|||potential|||0|888|1398|1407
SE|25462415|CONCLUSIONS|ab|7|entity|C0439755|Directions|spco|||directions|||0|888|1408|1418
SE|25462415|CONCLUSIONS|ab|7|entity|C1273869|Intervention regimes|hlca|||interventions|||0|888|1433|1446
SE|25462415|CONCLUSIONS|ab|7|entity|C0034961|Refugees|popg|||refugees|||0|861|1463|1471
SE|25462415|CONCLUSIONS|ab|7|relation|8|1|C1273869|Intervention regimes|hlca|hlca|||interventions|||0|888|1433|1446|PREP|TREATS||1447|1450|1|1|C0034961|Refugees|popg,humn|humn|||refugees|||0|861|1463|1471


SE|25462416||ti|1|text|21|195|Left temporal activation associated with depression severity during a verbal fluency task in patients with bipolar disorder: a multichannel near-infrared spectroscopy study.
SE|25462416||ti|1|entity|C0205091|Left|spco|||Left|||0|623|21|25
SE|25462416||ti|1|entity|C0442043|temporal|spco|||temporal|||0|623|26|34
SE|25462416||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|62|72
SE|25462416||ti|1|entity|C0439793|Severities|qlco|||severity|||0|888|73|81
SE|25462416||ti|1|entity|C0871945|Verbal Fluency|qlco|||verbal fluency|||0|901|91|105
SE|25462416||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|114|122
SE|25462416||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|128|144
SE|25462416||ti|1|entity|C0376519|Spectroscopy, Near-Infrared|lbpr|||near-infrared spectroscopy|||0|854|161|187
SE|25462416||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|854|188|193
SE|25462416||ti|1|relation|2|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|128|144|PREP|PROCESS_OF||123|127|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|114|122
SE|25462416||ti|1|relation|3|2|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|62|72|PREP|PROCESS_OF||111|113|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|114|122

SE|25462416|BACKGROUND|ab|1|text|201|414|BACKGROUND: Neuroimaging studies using multichannel near-infrared spectroscopy (NIRS) have provided compelling evidence about the dysfunction of the frontotemporal cortices in patients with bipolar disorder (BD).
SE|25462416|BACKGROUND|ab|1|entity|C0679575|neuroimaging|diap|||Neuroimaging|||0|872|213|225
SE|25462416|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|226|233
SE|25462416|BACKGROUND|ab|1|entity|C0376519|Spectroscopy, Near-Infrared|lbpr|||near-infrared spectroscopy|||0|923|253|279
SE|25462416|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|377|385
SE|25462416|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|391|407
SE|25462416|BACKGROUND|ab|1|relation|1|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|391|407|PREP|PROCESS_OF||386|390|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|377|385

SE|25462416|BACKGROUND|ab|2|text|414|517|However, it remains unclear whether the dysfunction is associated with mood state or symptom severity.
SE|25462416|BACKGROUND|ab|2|entity|C0026516|Mood|menp|||mood|||0|888|485|489
SE|25462416|BACKGROUND|ab|2|entity|C1442792|State|ftcn|||state|||0|888|490|495
SE|25462416|BACKGROUND|ab|2|entity|C1457887|Symptoms|sosy|||symptom|||0|888|499|506
SE|25462416|BACKGROUND|ab|2|entity|C0439793|Severities|qlco|||severity|||0|888|507|515

SE|25462416|BACKGROUND|ab|3|text|517|722|Using NIRS, we aimed to clarify differences in oxygenated hemoglobin (oxy-Hb) activation between depressive and euthymic states as well as regional brain dysfunction in relation to symptom severity in BD.
SE|25462416|BACKGROUND|ab|3|entity|C1547020|*Difference|qnco|||differences|||0|966|549|560
SE|25462416|BACKGROUND|ab|3|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|660|575|585
SE|25462416|BACKGROUND|ab|3|entity|C0948853|Euthymia|mobd|||euthymic|||0|836|629|637
SE|25462416|BACKGROUND|ab|3|entity|C1442792|State|ftcn|||states|||0|836|638|644
SE|25462416|BACKGROUND|ab|3|entity|C0205147|Region|spco|||regional|||0|901|656|664
SE|25462416|BACKGROUND|ab|3|entity|C0262405|Cerebral dysfunction syndrome|dsyn|||brain dysfunction|||0|901|665|682
SE|25462416|BACKGROUND|ab|3|entity|C1457887|Symptoms|sosy|||symptom|||0|888|698|705
SE|25462416|BACKGROUND|ab|3|entity|C0439793|Severities|qlco|||severity|||0|888|706|714
SE|25462416|BACKGROUND|ab|3|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|1000|718|720
SE|25462416|BACKGROUND|ab|3|relation|7|2|C0262405|Cerebral dysfunction syndrome|dsyn|dsyn|||brain dysfunction|||0|901|665|682|PREP|COEXISTS_WITH||715|717|1|1|C0005586|Bipolar Disorder|mobd|mobd|||BD|||0|1000|718|720

SE|25462416|METHODS|ab|4|text|722|905|METHODS: Fifty-five patients with BD, including 30 with bipolar depression (BPD) and 25 with euthymic bipolar disorder (BPE), and 28 healthy controls (HCs) participated in the study.
SE|25462416|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|722|729
SE|25462416|METHODS|ab|4|entity|C0205451|Five|qnco|||five|||0|790|737|741
SE|25462416|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|790|742|750
SE|25462416|METHODS|ab|4|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|1000|756|758
SE|25462416|METHODS|ab|4|entity|C0005587|Depression, Bipolar|mobd|||bipolar depression|||0|1000|778|796
SE|25462416|METHODS|ab|4|entity|C0948853|Euthymia|mobd|||euthymic|||0|865|815|823
SE|25462416|METHODS|ab|4|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|865|824|840
SE|25462416|METHODS|ab|4|entity|C0018684|Health|idcn|||healthy|||0|737|855|862
SE|25462416|METHODS|ab|4|entity|C0243148|control|ftcn|||controls|||0|737|863|871
SE|25462416|METHODS|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|898|903
SE|25462416|METHODS|ab|4|relation|6|1|C0005586|Bipolar Disorder|mobd|mobd|||BD|||0|1000|756|758|PREP|PROCESS_OF||751|755|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|790|742|750

SE|25462416|METHODS|ab|5|text|905|1019|Regional hemodynamic changes during a verbal fluency task (VFT) were monitored using a 52-channel NIRS apparatus.
SE|25462416|METHODS|ab|5|entity|C0205147|Region|spco|||Regional|||0|785|905|913
SE|25462416|METHODS|ab|5|entity|C0871945|Verbal Fluency|qlco|||verbal fluency|||0|901|943|957
SE|25462416|METHODS|ab|5|entity|C0439799|Channel|spco|||channel|||0|763|995|1002
SE|25462416|METHODS|ab|5|entity|C0243111|apparatus|mnob|||apparatus|||0|763|1008|1017

SE|25462416|RESULTS|ab|6|text|1019|1220|RESULTS: The mean oxy-Hb changes induced by VFT were significantly smaller in the BD patients than in the HCs in 18 channels in the frontotemporal regions (false-discovery rate p<0.05, p=0.000-0.011).
SE|25462416|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1019|1026
SE|25462416|RESULTS|ab|6|entity|C0019046|Hemoglobin|aapp,bacs|||oxy-Hb|||0|733|1037|1043
SE|25462416|RESULTS|ab|6|entity|C0871945|Verbal Fluency|qlco|||VFT|||0|901|1063|1066
SE|25462416|RESULTS|ab|6|entity|C0547044|Smaller|qlco|||smaller|||0|861|1086|1093
SE|25462416|RESULTS|ab|6|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|901|1101|1103
SE|25462416|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|901|1104|1112
SE|25462416|RESULTS|ab|6|entity|C0018684|Health|idcn|||HCs|||0|836|1125|1128
SE|25462416|RESULTS|ab|6|entity|C0243148|control|ftcn|||HCs|||0|836|1125|1128
SE|25462416|RESULTS|ab|6|entity|C0439799|Channel|spco|||channels|||0|827|1135|1143
SE|25462416|RESULTS|ab|6|entity|C0205147|Region|spco|||regions|||0|827|1166|1173
SE|25462416|RESULTS|ab|6|entity|C0205237|False|qlco|||false|||0|719|1175|1180
SE|25462416|RESULTS|ab|6|entity|C1521828|Rate|qnco|||rate|||0|719|1191|1195
SE|25462416|RESULTS|ab|6|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||BD|||0|901|1101|1103|MOD/HEAD|PROCESS_OF||1101|1112|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|1104|1112
SE|25462416|RESULTS|ab|6|relation|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|901|1104|1112|PREP|LOCATION_OF||1094|1096|4|3|C0019046|Hemoglobin|aapp,gngm,bacs|aapp|||oxy-Hb|||0|733|1037|1043

SE|25462416|RESULTS|ab|7|text|1220|1380|The BPD group exhibited significantly smaller changes in mean oxy-Hb compared with the BPE group in three channels of the left temporal region (p=0.005-0.014).
SE|25462416|RESULTS|ab|7|entity|C0005587|Depression, Bipolar|mobd|||BPD|||0|901|1224|1227
SE|25462416|RESULTS|ab|7|entity|C0441833|Groups|inpr|||group|||0|901|1228|1233
SE|25462416|RESULTS|ab|7|entity|C0547044|Smaller|qlco|||smaller|||0|773|1258|1265
SE|25462416|RESULTS|ab|7|entity|C0019046|Hemoglobin|aapp,bacs|||oxy-Hb|||0|827|1282|1288
SE|25462416|RESULTS|ab|7|entity|C0441833|Groups|inpr|||group|||0|861|1311|1316
SE|25462416|RESULTS|ab|7|entity|C0205449|Three|qnco|||three|||0|872|1320|1325
SE|25462416|RESULTS|ab|7|entity|C0439799|Channel|spco|||channels|||0|872|1326|1334
SE|25462416|RESULTS|ab|7|entity|C1184321|Left temporal part of head|blor|||left temporal region|||0|1000|1342|1362

SE|25462416|RESULTS|ab|8|text|1380|1537|In the BD patients, significant negative correlations were observed between mean oxy-Hb changes in the left temporal regions and the severity of depression.
SE|25462416|RESULTS|ab|8|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|901|1387|1389
SE|25462416|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|901|1390|1398
SE|25462416|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|623|1400|1411
SE|25462416|RESULTS|ab|8|entity|C0205160|Negative|qlco|||negative|||0|623|1412|1420
SE|25462416|RESULTS|ab|8|entity|C0019046|Hemoglobin|aapp,bacs|||oxy-Hb|||0|827|1461|1467
SE|25462416|RESULTS|ab|8|entity|C1184321|Left temporal part of head|blor|||left temporal regions|||0|988|1483|1504
SE|25462416|RESULTS|ab|8|entity|C0439793|Severities|qlco|||severity|||0|1000|1513|1521
SE|25462416|RESULTS|ab|8|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1525|1535
SE|25462416|RESULTS|ab|8|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||BD|||0|901|1387|1389|MOD/HEAD|PROCESS_OF||1387|1398|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|1390|1398

SE|25462416|LIMITATIONS|ab|9|text|1537|1627|LIMITATIONS: Our sample size was small, making the results susceptible to type II errors.
SE|25462416|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1537|1548
SE|25462416|LIMITATIONS|ab|9|entity|C0242618|Sample Size|qnco|||sample size|||0|1000|1554|1565
SE|25462416|LIMITATIONS|ab|9|entity|C0700321|Small|qnco|||small|||0|1000|1570|1575
SE|25462416|LIMITATIONS|ab|9|entity|C1274040|result|ftcn|||results|||0|966|1588|1595
SE|25462416|LIMITATIONS|ab|9|entity|C0231204|Susceptible|ftcn|||susceptible|||0|1000|1596|1607
SE|25462416|LIMITATIONS|ab|9|entity|C0871556|Type II Errors|fndg|||type II errors|||0|1000|1611|1625

SE|25462416|CONCLUSIONS|ab|10|text|1627|1721|CONCLUSIONS: BD patients have persistent hypofunction of the frontotemporal cortical regions.
SE|25462416|CONCLUSIONS|ab|10|entity|C0005586|Bipolar Disorder|mobd|||BD|||0|901|1640|1642
SE|25462416|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|901|1643|1651
SE|25462416|CONCLUSIONS|ab|10|entity|C0205322|Persistent|tmco|||persistent|||0|888|1657|1667
SE|25462416|CONCLUSIONS|ab|10|entity|C0679221|hypofunction|patf|||hypofunction|||0|888|1668|1680
SE|25462416|CONCLUSIONS|ab|10|entity|C1366490|ADRBK1 gene|gngm|156|GRK2|cortical|||0|745|1703|1711
SE|25462416|CONCLUSIONS|ab|10|entity|C0205147|Region|spco|||regions|||0|745|1712|1719
SE|25462416|CONCLUSIONS|ab|10|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||BD|||0|901|1640|1642|MOD/HEAD|PROCESS_OF||1640|1651|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|1643|1651
SE|25462416|CONCLUSIONS|ab|10|relation|2|1|C0679221|hypofunction|patf|patf|||hypofunction|||0|888|1668|1680|AUX|PROCESS_OF||1652|1656|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|901|1643|1651

SE|25462416|CONCLUSIONS|ab|11|text|1721|1821|Moreover, the hemodynamic response in the left temporal regions is associated with symptom severity.
SE|25462416|CONCLUSIONS|ab|11|entity|C0871261|response|clna|||response|||0|861|1747|1755
SE|25462416|CONCLUSIONS|ab|11|entity|C1184321|Left temporal part of head|blor|||left temporal regions|||0|988|1763|1784
SE|25462416|CONCLUSIONS|ab|11|entity|C1457887|Symptoms|sosy|||symptom|||0|888|1804|1811
SE|25462416|CONCLUSIONS|ab|11|entity|C0439793|Severities|qlco|||severity|||0|888|1812|1820
SE|25462416|CONCLUSIONS|ab|11|relation|2|2|C0871261|response|clna|clna|||response|||0|861|1747|1755|VERB|ASSOCIATED_WITH||1788|1798|1|1|C1457887|Symptoms|sosy|sosy|||symptom|||0|888|1804|1811


SE|25462417||ti|1|text|21|213|Sick-leave measures, socio-demographic factors and health care as risk indicators for suicidal behavior in patients with depressive disorders--a nationwide prospective cohort study in Sweden.
SE|25462417||ti|1|entity|C0242807|Sick Leave|idcn|||Sick-leave|||0|901|21|31
SE|25462417||ti|1|entity|C0079809|Measures|qnco|||measures|||0|901|32|40
SE|25462417||ti|1|entity|C0011292|Demographic Factors|idcn|||demographic factors|||0|901|48|67
SE|25462417||ti|1|entity|C0086388|Health Care|hlca|||health care|||0|1000|72|83
SE|25462417||ti|1|entity|C0035648|risk factors|qnco|||risk indicators|||0|1000|87|102
SE|25462417||ti|1|entity|C0563664|At risk for suicide|mobd|||suicidal behavior|||0|1000|107|124
SE|25462417||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|128|136
SE|25462417||ti|1|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|142|162
SE|25462417||ti|1|entity|C0599755|cohort|popg|||cohort|||0|824|189|195
SE|25462417||ti|1|entity|C0033522|Prospective Studies|qnco,resa|||prospective cohort study|||0|824|177|201
SE|25462417||ti|1|entity|C0038995|Sweden|geoa|||Sweden|||0|1000|205|211
SE|25462417||ti|1|relation|3|1|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|142|162|PREP|PROCESS_OF||137|141|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|128|136
SE|25462417||ti|1|relation|5|1|C0563664|At risk for suicide|mobd|mobd|||suicidal behavior|||0|1000|107|124|PREP|PROCESS_OF||125|127|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|128|136

SE|25462417|BACKGROUND|ab|1|text|219|381|BACKGROUND: Studies based on large data sets investigating a wide range of risk indicators on suicidal behavior in patients with depressive disorders are sparse.
SE|25462417|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||Studies|||0|966|231|238
SE|25462417|BACKGROUND|ab|1|entity|C0549177|Large|qnco|||large|||0|890|248|253
SE|25462417|BACKGROUND|ab|1|entity|C0150098|data set|inpr|||data sets|||0|890|254|263
SE|25462417|BACKGROUND|ab|1|entity|C0332464|Widening|spco|||wide|||0|888|280|284
SE|25462417|BACKGROUND|ab|1|entity|C1514721|Range|qnco|||range|||0|888|285|290
SE|25462417|BACKGROUND|ab|1|entity|C0035648|risk factors|qnco|||risk indicators|||0|1000|294|309
SE|25462417|BACKGROUND|ab|1|entity|C0563664|At risk for suicide|mobd|||suicidal behavior|||0|1000|313|330
SE|25462417|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|334|342
SE|25462417|BACKGROUND|ab|1|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|348|368
SE|25462417|BACKGROUND|ab|1|relation|2|1|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|348|368|PREP|PROCESS_OF||343|347|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|334|342
SE|25462417|BACKGROUND|ab|1|relation|6|1|C0563664|At risk for suicide|mobd|mobd|||suicidal behavior|||0|1000|313|330|PREP|PROCESS_OF||331|333|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|334|342

SE|25462417|BACKGROUND|ab|2|text|381|623|This study aimed to examine the association of sick-leave measured in different ways on one hand and socio-demographics, medication, and health care on the other hand with suicide attempt and suicide among patients with depressive disorders.
SE|25462417|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|386|391
SE|25462417|BACKGROUND|ab|2|entity|C0242807|Sick Leave|idcn|||sick-leave|||0|1000|428|438
SE|25462417|BACKGROUND|ab|2|entity|C1547020|*Difference|qnco|||different|||0|623|451|460
SE|25462417|BACKGROUND|ab|2|entity|C0205447|One|qnco|||one|||0|888|469|472
SE|25462417|BACKGROUND|ab|2|entity|C0018563|Hand|bpoc|||hand|||0|888|473|477
SE|25462417|BACKGROUND|ab|2|entity|C0011298|Demography|ocdi|||demographics|||0|861|488|500
SE|25462417|BACKGROUND|ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|502|512
SE|25462417|BACKGROUND|ab|2|entity|C0086388|Health Care|hlca|||health care|||0|1000|518|529
SE|25462417|BACKGROUND|ab|2|entity|C0038663|Suicide attempt|mobd|||suicide attempt|||0|1000|553|568
SE|25462417|BACKGROUND|ab|2|entity|C0038661|Suicide|inpo|||suicide|||0|1000|573|580
SE|25462417|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|587|595
SE|25462417|BACKGROUND|ab|2|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|601|621
SE|25462417|BACKGROUND|ab|2|relation|1|1|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|601|621|PREP|PROCESS_OF||596|600|12|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|587|595
SE|25462417|BACKGROUND|ab|2|relation|11|1|C0038661|Suicide|inpo|inpo|||suicide|||0|1000|573|580|PREP|PROCESS_OF||581|586|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|587|595
SE|25462417|BACKGROUND|ab|2|relation|11|1|C0038663|Suicide attempt|mobd|mobd|||suicide attempt|||0|1000|553|568|PREP|PROCESS_OF||581|586|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|587|595

SE|25462417|METHODS|ab|3|text|623|716|METHODS: This is a population-based prospective cohort study using nationwide register data.
SE|25462417|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|623|630
SE|25462417|METHODS|ab|3|entity|C0599755|cohort|popg|||cohort|||0|833|671|677
SE|25462417|METHODS|ab|3|entity|C0681876|Population Study|resa|||population-based prospective cohort study|||0|833|642|683
SE|25462417|METHODS|ab|3|entity|C0600375|Registers|inpr|||register|||0|773|701|709
SE|25462417|METHODS|ab|3|entity|C1511726|Data|idcn|||data|||0|773|710|714

SE|25462417|METHODS|ab|4|text|716|895|All individuals who lived in Sweden 31.12.2004, then aged 16-64 years, and had psychiatric in- or out-patient care due to depressive disorders in 2005 were included (N = 21,096).
SE|25462417|METHODS|ab|4|entity|C0237401|Individual|humn|||individuals|||0|1000|720|731
SE|25462417|METHODS|ab|4|entity|C0038995|Sweden|geoa|||Sweden|||0|812|745|751
SE|25462417|METHODS|ab|4|entity|C0439234|year|tmco|||years|||0|827|780|785
SE|25462417|METHODS|ab|4|entity|C0205487|Psychiatric|ftcn|||psychiatric|||0|1000|795|806
SE|25462417|METHODS|ab|4|entity|C0439787|Out|spco|||out|||0|901|814|817
SE|25462417|METHODS|ab|4|entity|C0017313|patient care|hlca|||patient care|||0|901|818|830
SE|25462417|METHODS|ab|4|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|838|858

SE|25462417|METHODS|ab|5|text|895|1070|Univariate and multivariate hazard ratios (HR) and 95% Confidence Intervals (CI) with regard to suicide attempt and suicide during 2006-2010 were estimated by Cox regression.
SE|25462417|METHODS|ab|5|entity|C0598697|hazard|qlco|||hazard|||0|790|923|929
SE|25462417|METHODS|ab|5|entity|C0456603|Ratio|inpr|||ratios|||0|790|930|936
SE|25462417|METHODS|ab|5|entity|C0009667|Confidence Intervals|qnco|||Confidence Intervals|||0|901|950|970
SE|25462417|METHODS|ab|5|entity|C0038663|Suicide attempt|mobd|||suicide attempt|||0|1000|991|1006
SE|25462417|METHODS|ab|5|entity|C0038661|Suicide|inpo|||suicide|||0|1000|1011|1018
SE|25462417|METHODS|ab|5|entity|C0033551|Prostaglandin-Endoperoxide Synthase|aapp,enzy|||Cox|||0|694|1054|1057

SE|25462417|RESULTS|ab|6|text|1070|1263|RESULTS: Those with new sick-leave spells, full-time spells, spells due to mental diagnoses and exceeding one year and those having >= 1 sick-leave spells had a higher risk of suicide attempt.
SE|25462417|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|1070|1077
SE|25462417|RESULTS|ab|6|entity|C0205314|New|tmco|||new|||0|861|1090|1093
SE|25462417|RESULTS|ab|6|entity|C0242807|Sick Leave|idcn|||sick-leave|||0|861|1094|1104
SE|25462417|RESULTS|ab|6|entity|C0302539|SPELL|fndg|||spells|||0|861|1105|1111
SE|25462417|RESULTS|ab|6|entity|C1553424|full-time|idcn|||full-time|||0|901|1113|1122
SE|25462417|RESULTS|ab|6|entity|C0302539|SPELL|fndg|||spells|||0|901|1123|1129
SE|25462417|RESULTS|ab|6|entity|C0302539|SPELL|fndg|||spells|||0|1000|1131|1137
SE|25462417|RESULTS|ab|6|entity|C0011900|Diagnosis|hlca|||diagnoses|||0|888|1152|1161
SE|25462417|RESULTS|ab|6|entity|C0205447|One|qnco|||one|||0|790|1176|1179
SE|25462417|RESULTS|ab|6|entity|C0439234|year|tmco|||year|||0|790|1180|1184
SE|25462417|RESULTS|ab|6|entity|C0242807|Sick Leave|idcn|||sick-leave|||0|824|1207|1217
SE|25462417|RESULTS|ab|6|entity|C0302539|SPELL|fndg|||spells|||0|824|1218|1224
SE|25462417|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|872|1231|1237
SE|25462417|RESULTS|ab|6|entity|C0035647|Risk|qlco|||risk|||0|872|1238|1242
SE|25462417|RESULTS|ab|6|entity|C0038663|Suicide attempt|mobd|||suicide attempt|||0|1000|1246|1261

SE|25462417|RESULTS|ab|7|text|1263|1507|Female sex, young age, lower education, living alone, prescription of antidepressants and anxiolytics, inpatient health care, and suicide attempts resulted in higher HRs of suicide attempt in the multivariate analyses (range of HRs 1.17-3.28).
SE|25462417|RESULTS|ab|7|entity|C0015780|Female|orga|||Female sex|||0|1000|1263|1273
SE|25462417|RESULTS|ab|7|entity|C0332239|Young|tmco|||young|||0|888|1275|1280
SE|25462417|RESULTS|ab|7|entity|C0001779|Age|orga|||age|||0|888|1281|1284
SE|25462417|RESULTS|ab|7|entity|C0013621|Knowledge acquisition|edac|||education|||0|1000|1292|1301
SE|25462417|RESULTS|ab|7|entity|C0033080|prescription procedure|hlca|||prescription|||0|861|1317|1329
SE|25462417|RESULTS|ab|7|entity|C0003289|Antidepressive Agents|phsu|||antidepressants|||0|1000|1333|1348
SE|25462417|RESULTS|ab|7|entity|C0040616|Anti-Anxiety Agents|phsu|||anxiolytics|||0|1000|1353|1364
SE|25462417|RESULTS|ab|7|entity|C0018684|Health|idcn|||health|||0|901|1376|1382
SE|25462417|RESULTS|ab|7|entity|C0019993|Hospitalization|hlca|||inpatient health care|||0|901|1366|1387
SE|25462417|RESULTS|ab|7|entity|C0038663|Suicide attempt|mobd|||suicide attempts|||0|983|1393|1409
SE|25462417|RESULTS|ab|7|entity|C0205250|High|qlco|||higher|||0|872|1422|1428
SE|25462417|RESULTS|ab|7|entity|C1366514|HGS gene|gngm|9146|HGS|HRs|||0|872|1429|1432
SE|25462417|RESULTS|ab|7|entity|C0038663|Suicide attempt|mobd|||suicide attempt|||0|1000|1436|1451
SE|25462417|RESULTS|ab|7|entity|C0026777|Multivariate Analysis|qnco|||multivariate analyses|||0|1000|1459|1480
SE|25462417|RESULTS|ab|7|entity|C1514721|Range|qnco|||range|||0|1000|1482|1487
SE|25462417|RESULTS|ab|7|entity|C1366514|HGS gene|gngm|9146|HGS|HRs|||0|804|1491|1494

SE|25462417|RESULTS|ab|8|text|1507|1676|Male sex, combined antidepressant and anxiolytic prescription, mental inpatient health care, and suicide attempts predicted subsequent suicide (range of HRs 1.84-3.33).
SE|25462417|RESULTS|ab|8|entity|C0024554|Male gender|orga|||Male sex|||0|1000|1507|1515
SE|25462417|RESULTS|ab|8|entity|C0205195|Combined|qlco|||combined|||0|888|1517|1525
SE|25462417|RESULTS|ab|8|entity|C0003289|Antidepressive Agents|phsu|||antidepressant|||0|888|1526|1540
SE|25462417|RESULTS|ab|8|entity|C0040616|Anti-Anxiety Agents|phsu|||anxiolytic|||0|888|1545|1555
SE|25462417|RESULTS|ab|8|entity|C0033080|prescription procedure|hlca|||prescription|||0|888|1556|1568
SE|25462417|RESULTS|ab|8|entity|C0021562|inpatient|podg|||inpatient|||0|916|1577|1586
SE|25462417|RESULTS|ab|8|entity|C0184643|Mental health care|topp|||mental inpatient health care|||0|916|1570|1598
SE|25462417|RESULTS|ab|8|entity|C0038661|Suicide|inpo|||suicide|||0|1000|1604|1611
SE|25462417|RESULTS|ab|8|entity|C1508497|PREDICTED|clna|||predicted|||0|851|1621|1630
SE|25462417|RESULTS|ab|8|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|851|1631|1641
SE|25462417|RESULTS|ab|8|entity|C0038661|Suicide|inpo|||suicide|||0|851|1642|1649
SE|25462417|RESULTS|ab|8|entity|C1514721|Range|qnco|||range|||0|1000|1651|1656
SE|25462417|RESULTS|ab|8|entity|C1366514|HGS gene|gngm|9146|HGS|HRs|||0|804|1660|1663

SE|25462417|LIMITATIONS|ab|9|text|1676|1746|LIMITATIONS: Focus on specialized health care limited generalization.
SE|25462417|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1676|1687
SE|25462417|LIMITATIONS|ab|9|entity|C0205234|Focal|spco|||Focus|||0|1000|1689|1694
SE|25462417|LIMITATIONS|ab|9|entity|C0205555|Special (qualifier)|qlco|||specialized|||0|622|1698|1709
SE|25462417|LIMITATIONS|ab|9|entity|C0086388|Health Care|hlca|||health care|||0|622|1710|1721
SE|25462417|LIMITATIONS|ab|9|entity|C0439801|Limited|ftcn|||limited|||0|622|1722|1729

SE|25462417|CONCLUSIONS|ab|10|text|1746|1863|CONCLUSIONS: Sickness absence, social-demographics, and medical determinants were associated with suicidal behavior.
SE|25462417|CONCLUSIONS|ab|10|entity|C0221423|Finding / disorder|ftcn|||Sickness|||0|694|1759|1767
SE|25462417|CONCLUSIONS|ab|10|entity|C0728831|SOCIAL|ftcn|||social|||0|888|1777|1783
SE|25462417|CONCLUSIONS|ab|10|entity|C0011298|Demography|ocdi|||demographics|||0|888|1784|1796
SE|25462417|CONCLUSIONS|ab|10|entity|C0205476|Medical|ftcn|||medical|||0|694|1802|1809
SE|25462417|CONCLUSIONS|ab|10|entity|C0563664|At risk for suicide|mobd|||suicidal behavior|||0|1000|1844|1861

SE|25462417|CONCLUSIONS|ab|11|text|1863|1987|These risk indicators should be considered when monitoring individuals with depressive disorders and assessing suicide risk.
SE|25462417|CONCLUSIONS|ab|11|entity|C0035648|risk factors|qnco|||risk indicators|||0|1000|1869|1884
SE|25462417|CONCLUSIONS|ab|11|entity|C0237401|Individual|humn|||individuals|||0|861|1922|1933
SE|25462417|CONCLUSIONS|ab|11|entity|C0011581|Depressive disorder|mobd|||depressive disorders|||0|1000|1939|1959
SE|25462417|CONCLUSIONS|ab|11|entity|C0220825|Evaluation|ftcn|||assessing|||0|840|1964|1973
SE|25462417|CONCLUSIONS|ab|11|entity|C0038661|Suicide|inpo|||suicide|||0|840|1974|1981
SE|25462417|CONCLUSIONS|ab|11|entity|C0035647|Risk|qlco|||risk|||0|840|1982|1986
SE|25462417|CONCLUSIONS|ab|11|relation|2|1|C0011581|Depressive disorder|mobd|mobd|||depressive disorders|||0|1000|1939|1959|PREP|PROCESS_OF||1934|1938|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|861|1922|1933
SE|25462417|CONCLUSIONS|ab|11|relation|2|1|C0038661|Suicide|inpo|inpo|||suicide|||0|840|1974|1981|PREP|PROCESS_OF||1934|1938|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|861|1922|1933


SE|25462418||ti|1|text|21|154|Cognitive tolerability following successful long term treatment of major depression and anxiety disorders with SSRi antidepressants.
SE|25462418||ti|1|entity|C1516691|Cognitive|ftcn|||Cognitive|||0|694|21|30
SE|25462418||ti|1|entity|C1272703|Successful|qlco|||successful|||0|916|54|64
SE|25462418||ti|1|entity|C0023977|long-term care|hlca|||long term treatment|||0|916|65|84
SE|25462418||ti|1|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|88|104
SE|25462418||ti|1|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|109|126
SE|25462418||ti|1|entity|C0003289|Antidepressive Agents|phsu|||antidepressants|||0|861|137|152

SE|25462418|BACKGROUND|ab|1|text|160|271|BACKGROUND: The present study aims to evaluate cognitive tolerability profile of SSRIs in long-term treatment.
SE|25462418|BACKGROUND|ab|1|entity|C0150312|Present|qnco|||present|||0|888|176|183
SE|25462418|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|184|189
SE|25462418|BACKGROUND|ab|1|entity|C1516691|Cognitive|ftcn|||cognitive|||0|660|207|216
SE|25462418|BACKGROUND|ab|1|entity|C0023977|long-term care|hlca|||long-term treatment|||0|1000|250|269

SE|25462418|BACKGROUND|ab|2|text|271|411|The secondary aim is to explore differences of side effects profile between patients with major depression (MD) and anxiety disorders (AD).
SE|25462418|BACKGROUND|ab|2|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|694|275|284
SE|25462418|BACKGROUND|ab|2|entity|C1547020|*Difference|qnco|||differences|||0|966|303|314
SE|25462418|BACKGROUND|ab|2|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|1000|318|330
SE|25462418|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|347|355
SE|25462418|BACKGROUND|ab|2|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|361|377
SE|25462418|BACKGROUND|ab|2|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|387|404
SE|25462418|BACKGROUND|ab|2|relation|2|1|C0003469|Anxiety Disorders|mobd|mobd|||anxiety disorders|||0|1000|387|404|PREP|PROCESS_OF||356|360|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|347|355
SE|25462418|BACKGROUND|ab|2|relation|2|1|C1269683|Major Depressive Disorder|mobd|mobd|||major depression|||0|1000|361|377|PREP|PROCESS_OF||356|360|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|347|355

SE|25462418|METHODS|ab|3|text|411|606|METHODS: Sixty-seven consecutive patients, successfully treated with SSRIs in monotherapy for at least six months for MD or AD, were assessed for side effects, with a special focus on cognition.
SE|25462418|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|411|418
SE|25462418|METHODS|ab|3|entity|C0205453|Seven|qnco|||seven|||0|763|426|431
SE|25462418|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|763|444|452
SE|25462418|METHODS|ab|3|entity|C0205452|Six|qnco|||six|||0|790|514|517
SE|25462418|METHODS|ab|3|entity|C0439231|month|tmco|||months|||0|790|518|524
SE|25462418|METHODS|ab|3|entity|C1269683|Major Depressive Disorder|mobd|||MD|||0|1000|529|531
SE|25462418|METHODS|ab|3|entity|C0003469|Anxiety Disorders|mobd|||AD|||0|1000|535|537
SE|25462418|METHODS|ab|3|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|1000|557|569
SE|25462418|METHODS|ab|3|entity|C0205234|Focal|spco|||focus|||0|861|586|591
SE|25462418|METHODS|ab|3|entity|C0009240|Cognition|menp|||cognition|||0|1000|595|604

SE|25462418|RESULTS|ab|4|text|606|797|RESULTS: Over 20% of MD and AD patients in long term treatment with SSRIs reported cognitive symptoms including fatigue, inattentiveness, lack of concentration, memory impairment and apathy.
SE|25462418|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|606|613
SE|25462418|RESULTS|ab|4|entity|C0205136|Over|spco|||Over|||0|861|615|619
SE|25462418|RESULTS|ab|4|entity|C1269683|Major Depressive Disorder|mobd|||MD|||0|1000|627|629
SE|25462418|RESULTS|ab|4|entity|C0003469|Anxiety Disorders|mobd|||AD|||0|901|634|636
SE|25462418|RESULTS|ab|4|entity|C0030705|Patients|podg|||patients|||0|901|637|645
SE|25462418|RESULTS|ab|4|entity|C0023977|long-term care|hlca|||long term treatment|||0|1000|649|668
SE|25462418|RESULTS|ab|4|entity|C0525041|Neurobehavioral Manifestations|sosy|||cognitive symptoms|||0|1000|689|707
SE|25462418|RESULTS|ab|4|entity|C0015672|Fatigue|sosy|||fatigue|||0|1000|718|725
SE|25462418|RESULTS|ab|4|entity|C0233415|Cognitive function: distractibility|menp|||inattentiveness|||0|1000|727|742
SE|25462418|RESULTS|ab|4|entity|C0332268|Lacking|qlco|||lack|||0|1000|744|748
SE|25462418|RESULTS|ab|4|entity|C0233794|Memory impairment|mobd|||memory impairment|||0|1000|767|784
SE|25462418|RESULTS|ab|4|entity|C0085632|Indifferent mood|sosy|||apathy|||0|1000|789|795
SE|25462418|RESULTS|ab|4|relation|0|0|C0003469|Anxiety Disorders|mobd|mobd|||AD|||0|901|634|636|MOD/HEAD|PROCESS_OF||634|645|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|637|645

SE|25462418|RESULTS|ab|5|text|797|906|Recall memory impairment, attention deficit and somnolence were most frequently rated as moderate or severe.
SE|25462418|RESULTS|ab|5|entity|C0233794|Memory impairment|mobd|||memory impairment|||0|901|804|821
SE|25462418|RESULTS|ab|5|entity|C0004268|Attention|menp|||attention|||0|888|823|832
SE|25462418|RESULTS|ab|5|entity|C0011155|Deficiency|ftcn|||deficit|||0|888|833|840
SE|25462418|RESULTS|ab|5|entity|C0013144|Drowsiness|sosy|||somnolence|||0|1000|845|855
SE|25462418|RESULTS|ab|5|entity|C0205393|Most|qnco|||most|||0|1000|861|865
SE|25462418|RESULTS|ab|5|entity|C0332183|Frequent|tmco|||frequently|||0|1000|866|876
SE|25462418|RESULTS|ab|5|entity|C0205082|Severe|qlco|||severe|||0|1000|898|904

SE|25462418|RESULTS|ab|6|text|906|1011|There were no significant differences in SSRI cognitive side effects profile between MD and AD patients.
SE|25462418|RESULTS|ab|6|entity|C0750502|Significant|idcn|||significant|||0|872|920|931
SE|25462418|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||differences|||0|872|932|943
SE|25462418|RESULTS|ab|6|entity|C1516691|Cognitive|ftcn|||cognitive|||0|824|952|961
SE|25462418|RESULTS|ab|6|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|824|962|974
SE|25462418|RESULTS|ab|6|entity|C1269683|Major Depressive Disorder|mobd|||MD|||0|1000|991|993
SE|25462418|RESULTS|ab|6|entity|C0003469|Anxiety Disorders|mobd|||AD|||0|901|998|1000
SE|25462418|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|901|1001|1009
SE|25462418|RESULTS|ab|6|relation|0|0|C0003469|Anxiety Disorders|mobd|mobd|||AD|||0|901|998|1000|MOD/HEAD|PROCESS_OF||998|1009|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|901|1001|1009

SE|25462418|LIMITATIONS|ab|7|text|1011|1115|LIMITATIONS: Subjective measure of cognitive functioning, limited sample size, lack of a control group.
SE|25462418|LIMITATIONS|ab|7|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1011|1022
SE|25462418|LIMITATIONS|ab|7|entity|C0439655|Subjective|qlco|||Subjective|||0|888|1024|1034
SE|25462418|LIMITATIONS|ab|7|entity|C0079809|Measures|qnco|||measure|||0|888|1035|1042
SE|25462418|LIMITATIONS|ab|7|entity|C0392334|Ability to perform cognitive activity|menp|||cognitive functioning|||0|1000|1046|1067
SE|25462418|LIMITATIONS|ab|7|entity|C0439801|Limited|ftcn|||limited|||0|901|1069|1076
SE|25462418|LIMITATIONS|ab|7|entity|C0242618|Sample Size|qnco|||sample size|||0|901|1077|1088
SE|25462418|LIMITATIONS|ab|7|entity|C0332268|Lacking|qlco|||lack|||0|1000|1090|1094
SE|25462418|LIMITATIONS|ab|7|entity|C0009932|Control Groups|grup|||control group|||0|1000|1100|1113

SE|25462418|CONCLUSIONS|ab|8|text|1115|1287|CONCLUSIONS: A large proportion of depressed and anxious patients treated successfully with SSRIs for over six months reported cognitive, affective, motivational symptoms.
SE|25462418|CONCLUSIONS|ab|8|entity|C0549177|Large|qnco|||large|||0|853|1130|1135
SE|25462418|CONCLUSIONS|ab|8|entity|C0205351|Proportional|qlco|||proportion|||0|853|1136|1146
SE|25462418|CONCLUSIONS|ab|8|entity|C0003467|Anxiety|menp|||anxious|||0|888|1164|1171
SE|25462418|CONCLUSIONS|ab|8|entity|C0030705|Patients|podg|||patients|||0|888|1172|1180
SE|25462418|CONCLUSIONS|ab|8|entity|C0205136|Over|spco|||over|||0|851|1217|1221
SE|25462418|CONCLUSIONS|ab|8|entity|C0205452|Six|qnco|||six|||0|851|1222|1225
SE|25462418|CONCLUSIONS|ab|8|entity|C0439231|month|tmco|||months|||0|851|1226|1232
SE|25462418|CONCLUSIONS|ab|8|entity|C1516691|Cognitive|ftcn|||cognitive|||0|843|1242|1251
SE|25462418|CONCLUSIONS|ab|8|entity|C0026605|Motivation|menp|||motivational|||0|843|1264|1276
SE|25462418|CONCLUSIONS|ab|8|entity|C0001726|Affective Symptoms|sosy|||affective, motivational symptoms|||0|843|1253|1285
SE|25462418|CONCLUSIONS|ab|8|relation|0|0|C0003467|Anxiety|menp|menp|||anxious|||0|888|1164|1171|MOD/HEAD|PROCESS_OF||1164|1180|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|888|1172|1180

SE|25462418|CONCLUSIONS|ab|9|text|1287|1391|These symptoms are likely to represent SSRI side effects rather than residual depressive symptomatology.
SE|25462418|CONCLUSIONS|ab|9|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|1293|1301
SE|25462418|CONCLUSIONS|ab|9|entity|C0001688|aspects of adverse effects|ftcn|||side effects|||0|901|1331|1343
SE|25462418|CONCLUSIONS|ab|9|entity|C1609982|Residual|qlco|||residual|||0|660|1356|1364


SE|25462419||ti|1|text|21|192|Effectiveness and acceptability of accelerated repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant major depressive disorder: an open label trial.
SE|25462419||ti|1|entity|C1280519|Effectiveness|qlco|||Effectiveness|||0|1000|21|34
SE|25462419||ti|1|entity|C0814633|acceptability|qlco|||acceptability|||0|1000|39|52
SE|25462419||ti|1|entity|C0521110|Accelerated|ftcn|||accelerated|||0|928|56|67
SE|25462419||ti|1|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|928|68|112
SE|25462419||ti|1|entity|C0332325|Resistant|ftcn|||resistant|||0|875|134|143
SE|25462419||ti|1|entity|C1269683|Major Depressive Disorder|mobd|||major depressive disorder|||0|875|144|169
SE|25462419||ti|1|entity|C0175566|Open|spco|||open|||0|851|174|178
SE|25462419||ti|1|entity|C0181496|Labels|mnob|||label|||0|851|179|184
SE|25462419||ti|1|entity|C0008976|Clinical Trials|resa|||trial|||0|851|185|190
SE|25462419||ti|1|relation|3|1|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||repetitive transcranial magnetic stimulation|||0|928|68|112|PREP|TREATS||120|123|2|1|C1269683|Major Depressive Disorder|mobd|mobd|||major depressive disorder|||0|875|144|169

SE|25462419|BACKGROUND|ab|1|text|198|325|BACKGROUND: Major depressive disorder (MDD) is a significant cause of worldwide disability and treatment resistance is common.
SE|25462419|BACKGROUND|ab|1|entity|C1269683|Major Depressive Disorder|mobd|||Major depressive disorder|||0|1000|210|235
SE|25462419|BACKGROUND|ab|1|entity|C0750502|Significant|idcn|||significant|||0|872|247|258
SE|25462419|BACKGROUND|ab|1|entity|C0015127|Etiology aspects|ftcn|||cause|||0|872|259|264
SE|25462419|BACKGROUND|ab|1|entity|C0231170|Disability NOS|patf|||disability|||0|861|278|288
SE|25462419|BACKGROUND|ab|1|entity|C0205214|Common|qnco|||common|||0|1000|317|323
SE|25462419|BACKGROUND|ab|1|relation|3|1|C0231170|Disability NOS|patf|patf|||disability|||0|861|278|288|NOM|MANIFESTATION_OF||259|264|2|1|C1269683|Major Depressive Disorder|mobd|mobd|||Major depressive disorder|||0|1000|210|235

SE|25462419|BACKGROUND|ab|2|text|325|541|High-frequency repetitive transcranial magnetic stimulation (HF-rTMS) has emerged as a treatment for MDD, and while efficacious, the daily commitment for typical 4-6 weeks of treatment poses a significant challenge.
SE|25462419|BACKGROUND|ab|2|entity|C0205212|High frequency|tmco|||High-frequency|||0|901|325|339
SE|25462419|BACKGROUND|ab|2|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||repetitive transcranial magnetic stimulation|||0|901|340|384
SE|25462419|BACKGROUND|ab|2|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|426|429
SE|25462419|BACKGROUND|ab|2|entity|C0332173|Daily|tmco|||daily|||0|888|458|463
SE|25462419|BACKGROUND|ab|2|entity|C0870312|Commitment|menp|||commitment|||0|888|464|474
SE|25462419|BACKGROUND|ab|2|entity|C0439230|week|tmco|||weeks|||0|812|491|496
SE|25462419|BACKGROUND|ab|2|entity|C0750502|Significant|idcn|||significant|||0|888|518|529
SE|25462419|BACKGROUND|ab|2|relation|1|1|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||repetitive transcranial magnetic stimulation|||0|901|340|384|NOM|TREATS||412|421|6|1|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|1000|426|429

SE|25462419|BACKGROUND|ab|3|text|541|640|We aimed to determine the effectiveness and acceptability of an accelerated rTMS protocol for MDD.
SE|25462419|BACKGROUND|ab|3|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|567|580
SE|25462419|BACKGROUND|ab|3|entity|C0814633|acceptability|qlco|||acceptability|||0|1000|585|598
SE|25462419|BACKGROUND|ab|3|entity|C0521110|Accelerated|ftcn|||accelerated|||0|888|605|616
SE|25462419|BACKGROUND|ab|3|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|888|617|621
SE|25462419|BACKGROUND|ab|3|entity|C0442711|Protocols documentation|inpr|||protocol|||0|888|622|630
SE|25462419|BACKGROUND|ab|3|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|1000|635|638

SE|25462419|METHODS|ab|4|text|640|889|METHODS: In this naturalistic trial, 27 patients with moderate to severe chronic and treatment-resistant MDD were treated with twice-daily HF-rTMS (10 Hz) applied over the left dorsolateral prefrontal cortex for 2 consecutive weeks (60,000 pulses).
SE|25462419|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|640|647
SE|25462419|METHODS|ab|4|entity|C0008976|Clinical Trials|resa|||trial|||0|861|670|675
SE|25462419|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|861|680|688
SE|25462419|METHODS|ab|4|entity|C0205082|Severe|qlco|||severe|||0|888|706|712
SE|25462419|METHODS|ab|4|entity|C0205191|chronic|tmco|||chronic|||0|888|713|720
SE|25462419|METHODS|ab|4|entity|C0332325|Resistant|ftcn|||resistant|||0|875|735|744
SE|25462419|METHODS|ab|4|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|875|745|748
SE|25462419|METHODS|ab|4|entity|C0585361|Twice a day|tmco|||twice-daily|||0|861|767|778
SE|25462419|METHODS|ab|4|entity|C0205212|High frequency|tmco|||HF-rTMS|||0|861|779|786
SE|25462419|METHODS|ab|4|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||HF-rTMS|||0|861|779|786
SE|25462419|METHODS|ab|4|entity|C0205136|Over|spco|||over|||0|1000|803|807
SE|25462419|METHODS|ab|4|entity|C0205091|Left|spco|||left|||0|824|812|816
SE|25462419|METHODS|ab|4|entity|C0162783|Prefrontal Cortex|bpoc|||prefrontal cortex|||0|824|830|847
SE|25462419|METHODS|ab|4|entity|C1442457|2 Weeks|tmco|||2 consecutive weeks|||0|913|852|871
SE|25462419|METHODS|ab|4|entity|C0034107|Pulse taking|diap|||pulses|||0|827|880|886
SE|25462419|METHODS|ab|4|relation|6|1|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||HF-rTMS|||0|861|779|786|VERB|TREATS||754|761|6|1|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|875|745|748

SE|25462419|METHODS|ab|5|text|889|1074|The primary outcomes were rates of clinical remission and response (16-item Quick Inventory of Depressive Symptomatology post-treatment score <= 6, and >= 50% reduction, respectively).
SE|25462419|METHODS|ab|5|entity|C1274040|result|ftcn|||outcomes|||0|872|901|909
SE|25462419|METHODS|ab|5|entity|C1521828|Rate|qnco|||rates|||0|966|915|920
SE|25462419|METHODS|ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|861|924|932
SE|25462419|METHODS|ab|5|entity|C0871261|response|clna|||response|||0|1000|947|955
SE|25462419|METHODS|ab|5|entity|C0439831|Rapid|qlco|||Quick|||0|750|965|970
SE|25462419|METHODS|ab|5|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|750|971|980
SE|25462419|METHODS|ab|5|entity|C0449820|Score|qnco|||score|||0|736|1025|1030

SE|25462419|METHODS|ab|6|text|1074|1219|Secondary outcomes were self-reported anxious symptoms, depressive symptoms and quality of life, and dropout rates as a proxy for acceptability.
SE|25462419|METHODS|ab|6|entity|C1522484|metastatic qualifier|qnco|||Secondary|||0|872|1074|1083
SE|25462419|METHODS|ab|6|entity|C1274040|result|ftcn|||outcomes|||0|872|1084|1092
SE|25462419|METHODS|ab|6|entity|C0036588|Self|idcn|||self|||0|843|1098|1102
SE|25462419|METHODS|ab|6|entity|C0860603|Anxiety symptoms|fndg|||anxious symptoms|||0|843|1112|1128
SE|25462419|METHODS|ab|6|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|1130|1149
SE|25462419|METHODS|ab|6|entity|C0332306|Quality|qlco|||quality|||0|1000|1154|1161
SE|25462419|METHODS|ab|6|entity|C0376558|Life|idcn|||life|||0|1000|1165|1169
SE|25462419|METHODS|ab|6|entity|C0013135|Dropouts|popg|||dropout|||0|872|1175|1182
SE|25462419|METHODS|ab|6|entity|C1521828|Rate|qnco|||rates|||0|872|1183|1188
SE|25462419|METHODS|ab|6|entity|C0600420|Proxy|grup|||proxy|||0|1000|1194|1199
SE|25462419|METHODS|ab|6|entity|C0814633|acceptability|qlco|||acceptability|||0|1000|1204|1217

SE|25462419|RESULTS|ab|7|text|1219|1390|RESULTS: Ten (37.0%) patients met criteria for clinical remission and 15 (55.6%) were classified as responders, with comparable outcomes for both moderate and severe MDD.
SE|25462419|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1219|1226
SE|25462419|RESULTS|ab|7|entity|C0205456|Ten|qnco|||Ten|||0|1000|1228|1231
SE|25462419|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|1000|1240|1248
SE|25462419|RESULTS|ab|7|entity|C0243161|criteria|inpr|||criteria|||0|1000|1253|1261
SE|25462419|RESULTS|ab|7|entity|C0205210|Clinical|qlco|||clinical|||0|861|1266|1274
SE|25462419|RESULTS|ab|7|entity|C1274040|result|ftcn|||outcomes|||0|827|1347|1355
SE|25462419|RESULTS|ab|7|entity|C0205082|Severe|qlco|||severe|||0|916|1378|1384
SE|25462419|RESULTS|ab|7|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|916|1385|1388

SE|25462419|RESULTS|ab|8|text|1390|1536|Clinician-rated improvements in depressive symptoms were paralleled in self-reported depressive and anxious symptoms, as well as quality of life.
SE|25462419|RESULTS|ab|8|entity|C1550470|clinician|idcn|||Clinician|||0|606|1390|1399
SE|25462419|RESULTS|ab|8|entity|C0871208|Rating|resa|||rated|||0|606|1400|1405
SE|25462419|RESULTS|ab|8|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|1422|1441
SE|25462419|RESULTS|ab|8|entity|C0036588|Self|idcn|||self|||0|623|1461|1465
SE|25462419|RESULTS|ab|8|entity|C0860603|Anxiety symptoms|fndg|||anxious symptoms|||0|964|1490|1506
SE|25462419|RESULTS|ab|8|entity|C0332306|Quality|qlco|||quality|||0|1000|1519|1526
SE|25462419|RESULTS|ab|8|entity|C0376558|Life|idcn|||life|||0|1000|1530|1534

SE|25462419|RESULTS|ab|9|text|1536|1571|No patient discontinued treatment.
SE|25462419|RESULTS|ab|9|entity|C0030705|Patients|podg|||patient|||0|1000|1539|1546

SE|25462419|LIMITATIONS|ab|10|text|1571|1829|LIMITATIONS: This study is limited by short treatment duration that might be lengthened with corresponding improvements in effectiveness, limited duration of follow-up, small sample size, and an open-label design requiring randomized controlled replication.
SE|25462419|LIMITATIONS|ab|10|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1571|1582
SE|25462419|LIMITATIONS|ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1589|1594
SE|25462419|LIMITATIONS|ab|10|entity|C0439593|Short duration|qlco|||short treatment duration|||0|901|1609|1633
SE|25462419|LIMITATIONS|ab|10|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|1694|1707
SE|25462419|LIMITATIONS|ab|10|entity|C0439801|Limited|ftcn|||limited|||0|888|1709|1716
SE|25462419|LIMITATIONS|ab|10|entity|C0449238|Duration|tmco|||duration|||0|888|1717|1725
SE|25462419|LIMITATIONS|ab|10|entity|C1522577|follow-up|hlca|||follow-up|||0|857|1729|1738
SE|25462419|LIMITATIONS|ab|10|entity|C0700321|Small|qnco|||small|||0|857|1740|1745
SE|25462419|LIMITATIONS|ab|10|entity|C0242618|Sample Size|qnco|||sample size|||0|857|1746|1757
SE|25462419|LIMITATIONS|ab|10|entity|C0175566|Open|spco|||open|||0|764|1766|1770
SE|25462419|LIMITATIONS|ab|10|entity|C0181496|Labels|mnob|||label|||0|764|1771|1776
SE|25462419|LIMITATIONS|ab|10|entity|C1514872|Required|ftcn|||requiring|||0|764|1784|1793
SE|25462419|LIMITATIONS|ab|10|entity|C0702113|Controlled|ftcn|||controlled|||0|888|1805|1815

SE|25462419|CONCLUSION|ab|11|text|1829|2014|CONCLUSION: An accelerated protocol involving twice-daily sessions of HF-rTMS over the left DLPFC for 2 weeks was effective in treatment-resistant MDD, and had excellent acceptability.
SE|25462419|CONCLUSION|ab|11|entity|C0521110|Accelerated|ftcn|||accelerated|||0|888|1844|1855
SE|25462419|CONCLUSION|ab|11|entity|C0442711|Protocols documentation|inpr|||protocol|||0|888|1856|1864
SE|25462419|CONCLUSION|ab|11|entity|C0585361|Twice a day|tmco|||twice-daily|||0|734|1875|1886
SE|25462419|CONCLUSION|ab|11|entity|C0205212|High frequency|tmco|||HF-rTMS|||0|901|1899|1906
SE|25462419|CONCLUSION|ab|11|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||HF-rTMS|||0|901|1899|1906
SE|25462419|CONCLUSION|ab|11|entity|C0205136|Over|spco|||over|||0|1000|1907|1911
SE|25462419|CONCLUSION|ab|11|entity|C0205091|Left|spco|||left|||0|694|1916|1920
SE|25462419|CONCLUSION|ab|11|entity|C1442457|2 Weeks|tmco|||2 weeks|||0|1000|1931|1938
SE|25462419|CONCLUSION|ab|11|entity|C0332325|Resistant|ftcn|||resistant|||0|875|1966|1975
SE|25462419|CONCLUSION|ab|11|entity|C1269683|Major Depressive Disorder|mobd|||MDD|||0|875|1976|1979
SE|25462419|CONCLUSION|ab|11|entity|C0814633|acceptability|qlco|||acceptability|||0|861|1999|2012
SE|25462419|CONCLUSION|ab|11|relation|8|5|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||HF-rTMS|||0|901|1899|1906|PREP|TREATS||1953|1955|2|1|C1269683|Major Depressive Disorder|mobd|mobd|||MDD|||0|875|1976|1979

SE|25462419|CONCLUSION|ab|12|text|2014|2147|Additional research is required to optimize accelerated rTMS treatment protocols and determine efficacy using sham-controlled trials.
SE|25462419|CONCLUSION|ab|12|entity|C1524062|Additional|ftcn|||Additional|||0|888|2014|2024
SE|25462419|CONCLUSION|ab|12|entity|C0035168|research|resa|||research|||0|888|2025|2033
SE|25462419|CONCLUSION|ab|12|entity|C0521110|Accelerated|ftcn|||accelerated|||0|873|2058|2069
SE|25462419|CONCLUSION|ab|12|entity|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|||rTMS|||0|873|2070|2074
SE|25462419|CONCLUSION|ab|12|entity|C0040808|Treatment Protocols|resa,topp|||treatment protocols|||0|873|2075|2094
SE|25462419|CONCLUSION|ab|12|entity|C0702113|Controlled|ftcn|||controlled|||0|840|2129|2139
SE|25462419|CONCLUSION|ab|12|entity|C0008976|Clinical Trials|resa|||trials|||0|840|2140|2146
SE|25462419|CONCLUSION|ab|12|relation|0|0|C0040808|Treatment Protocols|resa,topp|resa|||treatment protocols|||0|873|2075|2094|MOD/HEAD|USES||2070|2094|0|0|C0872259|Transcranial Magnetic Stimulation, Repetitive|topp|topp|||rTMS|||0|873|2070|2074


SE|25462420||ti|1|text|21|50|Hopelessness in adolescents.
SE|25462420||ti|1|entity|C0150041|Feeling hopeless|sosy|||Hopelessness|||0|1000|21|33
SE|25462420||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|37|48
SE|25462420||ti|1|relation|1|1|C0150041|Feeling hopeless|sosy|sosy|||Hopelessness|||0|1000|21|33|PREP|PROCESS_OF||34|36|1|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|37|48

SE|25462420|BACKGROUND|ab|1|text|56|203|BACKGROUND: The hopelessness scales devised by Beck and by Kazdin have been used in hundreds of studies of both non-clinical and clinical samples.
SE|25462420|BACKGROUND|ab|1|entity|C0451217|Hopelessness scale|inpr|||hopelessness scales|||0|983|72|91
SE|25462420|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|152|159
SE|25462420|BACKGROUND|ab|1|entity|C0746927|NON CLINIC|fndg|||non-clinical|||0|964|168|180
SE|25462420|BACKGROUND|ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|694|185|193

SE|25462420|BACKGROUND|ab|2|text|203|358|The present study identified non-clinical adolescent samples to see if the mean scores differed by age, sex, year of publication of the study, and nation.
SE|25462420|BACKGROUND|ab|2|entity|C0150312|Present|qnco|||present|||0|888|207|214
SE|25462420|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|215|220
SE|25462420|BACKGROUND|ab|2|entity|C0746927|NON CLINIC|fndg|||non-clinical|||0|634|232|244
SE|25462420|BACKGROUND|ab|2|entity|C0205653|Adolescent|aggp|||adolescent|||0|634|245|255
SE|25462420|BACKGROUND|ab|2|entity|C0449820|Score|qnco|||scores|||0|861|283|289
SE|25462420|BACKGROUND|ab|2|entity|C0001779|Age|orga|||age|||0|1000|302|305
SE|25462420|BACKGROUND|ab|2|entity|C0439234|year|tmco|||year|||0|1000|312|316
SE|25462420|BACKGROUND|ab|2|entity|C0034036|Publications|inpr,mnob|||publication|||0|1000|320|331
SE|25462420|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|339|344
SE|25462420|BACKGROUND|ab|2|entity|C1555720|Nation|orgt|||nation|||0|1000|350|356
SE|25462420|BACKGROUND|ab|2|relation|0|0|C0746927|NON CLINIC|fndg|fndg|||non-clinical|||0|634|232|244|MOD/HEAD|PROCESS_OF|negation|232|255|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|634|245|255

SE|25462420|METHODS|ab|3|text|358|594|METHODS: Studies of school students administered the Beck Hopelessness Scale or the Kazdin Hopelessness Scale for Children were identified from a literature search using PsycINFO and the search term "hopelessness" anywhere in the text.
SE|25462420|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|358|365
SE|25462420|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||Studies|||0|966|367|374
SE|25462420|METHODS|ab|3|entity|C0038492|student|prog|||students|||0|861|385|393
SE|25462420|METHODS|ab|3|entity|C0582612|Beck hopelessness scale|inpr|||Beck Hopelessness Scale|||0|1000|411|434
SE|25462420|METHODS|ab|3|entity|C0451217|Hopelessness scale|inpr|||Hopelessness Scale|||0|901|449|467
SE|25462420|METHODS|ab|3|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|472|480
SE|25462420|METHODS|ab|3|entity|C0023866|Literature|inpr|||literature|||0|888|504|514
SE|25462420|METHODS|ab|3|entity|C1552603|search|idcn|||search|||0|888|515|521
SE|25462420|METHODS|ab|3|entity|C1552603|search|idcn|||search|||0|775|545|551
SE|25462420|METHODS|ab|3|entity|C1515273|Term|tmco|||term|||0|775|552|556
SE|25462420|METHODS|ab|3|entity|C0150041|Feeling hopeless|sosy|||hopelessness|||0|775|558|570
SE|25462420|METHODS|ab|3|entity|C1527021|Text|inpr|||text|||0|1000|588|592

SE|25462420|METHODS|ab|4|text|594|715|Seventy-eight studies were found reporting mean scores, 44 for American students and 34 for students in other countries.
SE|25462420|METHODS|ab|4|entity|C0205454|Eight|qnco|||eight|||0|773|602|607
SE|25462420|METHODS|ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|773|608|615
SE|25462420|METHODS|ab|4|entity|C0449820|Score|qnco|||scores|||0|861|642|648
SE|25462420|METHODS|ab|4|entity|C0596070|American|popg|||American|||0|888|657|665
SE|25462420|METHODS|ab|4|entity|C0038492|student|prog|||students|||0|888|666|674
SE|25462420|METHODS|ab|4|entity|C0038492|student|prog|||students|||0|1000|686|694
SE|25462420|METHODS|ab|4|entity|C0454664|Country|geoa|||countries|||0|1000|704|713

SE|25462420|RESULTS|ab|5|text|715|952|RESULTS: The scores of American students were significantly lower than those of students in other countries, and there was a tendency for boys to have higher scores than girls (in 18 of the 27 studies which reported differences by sex).
SE|25462420|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|715|722
SE|25462420|RESULTS|ab|5|entity|C0449820|Score|qnco|||scores|||0|1000|728|734
SE|25462420|RESULTS|ab|5|entity|C0596070|American|popg|||American|||0|888|738|746
SE|25462420|RESULTS|ab|5|entity|C0038492|student|prog|||students|||0|888|747|755
SE|25462420|RESULTS|ab|5|entity|C0441994|Lower|ftcn|||lower|||0|861|775|780
SE|25462420|RESULTS|ab|5|entity|C0038492|student|prog|||students|||0|1000|795|803
SE|25462420|RESULTS|ab|5|entity|C0454664|Country|geoa|||countries|||0|1000|813|822
SE|25462420|RESULTS|ab|5|entity|C0870221|Boys|popg|||boys|||0|1000|853|857
SE|25462420|RESULTS|ab|5|entity|C0205250|High|qlco|||higher|||0|872|866|872
SE|25462420|RESULTS|ab|5|entity|C0449820|Score|qnco|||scores|||0|872|873|879
SE|25462420|RESULTS|ab|5|entity|C0870604|Girls|popg|||girls|||0|1000|885|890
SE|25462420|RESULTS|ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|827|908|915
SE|25462420|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||differences|||0|966|931|942

SE|25462420|RESULTS|ab|6|text|952|1058|There was no tendency for the hopelessness scores of American students to have increased in recent years.
SE|25462420|RESULTS|ab|6|entity|C0150041|Feeling hopeless|sosy|||hopelessness|||0|888|982|994
SE|25462420|RESULTS|ab|6|entity|C0449820|Score|qnco|||scores|||0|888|995|1001
SE|25462420|RESULTS|ab|6|entity|C0596070|American|popg|||American|||0|888|1005|1013
SE|25462420|RESULTS|ab|6|entity|C0038492|student|prog|||students|||0|888|1014|1022
SE|25462420|RESULTS|ab|6|entity|C0332185|Recent|tmco|||recent|||0|888|1044|1050
SE|25462420|RESULTS|ab|6|entity|C0439234|year|tmco|||years|||0|888|1051|1056

SE|25462420|CONCLUSIONS|ab|7|text|1058|1257|CONCLUSIONS: American adolescents appear to be less hopeless than adolescent in other nations, and the scores of American adolescents do not seem to have changed significantly over the last 30 years.
SE|25462420|CONCLUSIONS|ab|7|entity|C0596070|American|popg|||American|||0|888|1071|1079
SE|25462420|CONCLUSIONS|ab|7|entity|C0205653|Adolescent|aggp|||adolescents|||0|888|1080|1091
SE|25462420|CONCLUSIONS|ab|7|entity|C0150041|Feeling hopeless|sosy|||hopeless|||0|789|1110|1118
SE|25462420|CONCLUSIONS|ab|7|entity|C0205653|Adolescent|aggp|||adolescent|||0|1000|1124|1134
SE|25462420|CONCLUSIONS|ab|7|entity|C1555720|Nation|orgt|||nations|||0|966|1144|1151
SE|25462420|CONCLUSIONS|ab|7|entity|C0449820|Score|qnco|||scores|||0|1000|1161|1167
SE|25462420|CONCLUSIONS|ab|7|entity|C0596070|American|popg|||American|||0|888|1171|1179
SE|25462420|CONCLUSIONS|ab|7|entity|C0205653|Adolescent|aggp|||adolescents|||0|888|1180|1191
SE|25462420|CONCLUSIONS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1195|1198
SE|25462420|CONCLUSIONS|ab|7|entity|C1517741|Last|qlco|||last|||0|802|1243|1247
SE|25462420|CONCLUSIONS|ab|7|entity|C0439234|year|tmco|||years|||0|802|1251|1256


SE|25462421||ti|1|text|21|152|Adaptation and validation of the "cognitive complaints in bipolar disorder rating assessment" (COBRA) in Chinese bipolar patients.
SE|25462421||ti|1|entity|C0000934|Acclimatization|orgf|||Adaptation|||0|1000|21|31
SE|25462421||ti|1|entity|C1519941|Validation|resa|||validation|||0|1000|36|46
SE|25462421||ti|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|745|79|95
SE|25462421||ti|1|entity|C0871208|Rating|resa|||rating|||0|745|96|102
SE|25462421||ti|1|entity|C0870300|Assessment: Cognition|diap|||cognitive complaints in bipolar disorder rating assessment|||0|745|55|113
SE|25462421||ti|1|entity|C0443156|Bipolar|spco|||bipolar|||0|790|134|141
SE|25462421||ti|1|entity|C0030705|Patients|podg|||patients|||0|790|142|150
SE|25462421||ti|1|relation|2|2|C0000934|Acclimatization|orgf|orgf|||Adaptation|||0|1000|21|31|PREP|PROCESS_OF||123|125|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|790|142|150

SE|25462421|BACKGROUND|ab|1|text|158|284|BACKGROUND: There is no specific instrument available to measure cognitive deficits as reported by bipolar patients in China.
SE|25462421|BACKGROUND|ab|1|entity|C0348000|Instrument|mnob|||instrument|||0|861|191|201
SE|25462421|BACKGROUND|ab|1|entity|C0679466|COGNITIVE DEFICIT|mobd|||cognitive deficits|||0|1000|223|241
SE|25462421|BACKGROUND|ab|1|entity|C0443156|Bipolar|spco|||bipolar|||0|888|257|264
SE|25462421|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|888|265|273
SE|25462421|BACKGROUND|ab|1|entity|C0008115|China|geoa|||China|||0|1000|277|282

SE|25462421|BACKGROUND|ab|2|text|284|513|Therefore, if discrepancies between bipolar patients' reports and the results of neuropsychological tests which have been described in other countries existing or not in Chinese bipolar disorder patients have not been known yet.
SE|25462421|BACKGROUND|ab|2|entity|C1290905|Discrepancy|fndg|||discrepancies|||0|966|298|311
SE|25462421|BACKGROUND|ab|2|entity|C0443156|Bipolar|spco|||bipolar|||0|879|320|327
SE|25462421|BACKGROUND|ab|2|entity|C0747307|PATIENT REPORT|inpr|||patients' reports|||0|879|328|345
SE|25462421|BACKGROUND|ab|2|entity|C1274040|result|ftcn|||results|||0|966|354|361
SE|25462421|BACKGROUND|ab|2|entity|C0027902|Neuropsychological Tests|diap|||neuropsychological tests|||0|1000|365|389
SE|25462421|BACKGROUND|ab|2|entity|C0454664|Country|geoa|||countries|||0|1000|425|434
SE|25462421|BACKGROUND|ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|447|450
SE|25462421|BACKGROUND|ab|2|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|824|462|478
SE|25462421|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|824|479|487
SE|25462421|BACKGROUND|ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|493|496
SE|25462421|BACKGROUND|ab|2|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|824|462|478|MOD/HEAD|PROCESS_OF||462|487|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|824|479|487
SE|25462421|BACKGROUND|ab|2|relation|5|5|C1290905|Discrepancy|fndg|fndg|||discrepancies|||0|966|298|311|PREP|PROCESS_OF|negation|451|453|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|824|479|487

SE|25462421|BACKGROUND|ab|3|text|513|606|And it is completely blank about the subjective cognition of these Chinese bipolar patients.
SE|25462421|BACKGROUND|ab|3|entity|C0439655|Subjective|qlco|||subjective|||0|888|550|560
SE|25462421|BACKGROUND|ab|3|entity|C0009240|Cognition|menp|||cognition|||0|888|561|570
SE|25462421|BACKGROUND|ab|3|entity|C0443156|Bipolar|spco|||bipolar|||0|790|588|595
SE|25462421|BACKGROUND|ab|3|entity|C0030705|Patients|podg|||patients|||0|790|596|604

SE|25462421|OBJECTIVES|ab|4|text|606|810|OBJECTIVES: The aim of the study is to revise and validate a specific, user-friendly, brief instrument named the "cognitive complaints in bipolar disorder rating assessment" (COBRA) into Chinese version.
SE|25462421|OBJECTIVES|ab|4|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|606|616
SE|25462421|OBJECTIVES|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|633|638
SE|25462421|OBJECTIVES|ab|4|entity|C1548600|User|idcn|||user|||0|740|677|681
SE|25462421|OBJECTIVES|ab|4|entity|C1282927|Shortened|tmco|||brief|||0|740|692|697
SE|25462421|OBJECTIVES|ab|4|entity|C0348000|Instrument|mnob|||instrument|||0|740|698|708
SE|25462421|OBJECTIVES|ab|4|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|762|744|760
SE|25462421|OBJECTIVES|ab|4|entity|C0871208|Rating|resa|||rating|||0|762|761|767
SE|25462421|OBJECTIVES|ab|4|entity|C0870300|Assessment: Cognition|diap|||cognitive complaints in bipolar disorder rating assessment|||0|762|720|778
SE|25462421|OBJECTIVES|ab|4|entity|C0005586|Bipolar Disorder|mobd|||COBRA|||0|762|781|786
SE|25462421|OBJECTIVES|ab|4|entity|C0871208|Rating|resa|||COBRA|||0|762|781|786
SE|25462421|OBJECTIVES|ab|4|entity|C0220825|Evaluation|ftcn|||COBRA|||0|762|781|786
SE|25462421|OBJECTIVES|ab|4|entity|C0333052|Version|ftcn|||version|||0|861|801|808

SE|25462421|METHODS|ab|5|text|810|909|METHODS: The total sample (N=255) included 125 bipolar disorder patients and 130 healthy controls.
SE|25462421|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|810|817
SE|25462421|METHODS|ab|5|entity|C0439175|% of total|qnco|||total|||0|694|823|828
SE|25462421|METHODS|ab|5|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|824|857|873
SE|25462421|METHODS|ab|5|entity|C0030705|Patients|podg|||patients|||0|824|874|882
SE|25462421|METHODS|ab|5|entity|C0018684|Health|idcn|||healthy|||0|737|891|898
SE|25462421|METHODS|ab|5|entity|C0243148|control|ftcn|||controls|||0|737|899|907
SE|25462421|METHODS|ab|5|relation|0|0|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|824|857|873|MOD/HEAD|PROCESS_OF||857|882|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|824|874|882

SE|25462421|METHODS|ab|6|text|909|1149|The psychometric properties of the COBRA (e.g. internal consistency, retest reliability, discriminative validity, concurrent validity, content validity, item analysis, confirmatory factor analysis, ROC curve and feasibility) were analyzed.
SE|25462421|METHODS|ab|6|entity|C0033920|Psychometrics|diap|||psychometric|||0|872|913|925
SE|25462421|METHODS|ab|6|entity|C0871161|Property|qlco|||properties|||0|872|926|936
SE|25462421|METHODS|ab|6|entity|C0005586|Bipolar Disorder|mobd|||COBRA|||0|722|944|949
SE|25462421|METHODS|ab|6|entity|C0871208|Rating|resa|||COBRA|||0|722|944|949
SE|25462421|METHODS|ab|6|entity|C0220825|Evaluation|ftcn|||COBRA|||0|722|944|949
SE|25462421|METHODS|ab|6|entity|C0870731|Internal Consistency|qnco|||internal consistency|||0|1000|956|976
SE|25462421|METHODS|ab|6|entity|C0871697|Concurrent Validity|qlco,resa|||concurrent validity|||0|1000|1023|1042
SE|25462421|METHODS|ab|6|entity|C1510592|Content Validity|qlco|||content validity|||0|1000|1044|1060
SE|25462421|METHODS|ab|6|entity|C0936012|Analysis|resa|||analysis|||0|861|1067|1075
SE|25462421|METHODS|ab|6|entity|C0870334|Confirmatory Factor Analysis|qlco|||confirmatory factor analysis|||0|1000|1077|1105
SE|25462421|METHODS|ab|6|entity|C0035787|ROC Curve|qnco|||ROC curve|||0|1000|1107|1116

SE|25462421|RESULTS|ab|7|text|1149|1287|RESULTS: The Chinese version of the COBRA had very high internal consistency (Cronbach's alpha=0.905) and retest reliability (ICC=0.902).
SE|25462421|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1149|1156
SE|25462421|RESULTS|ab|7|entity|C0333052|Version|ftcn|||version|||0|861|1170|1177
SE|25462421|RESULTS|ab|7|entity|C0005586|Bipolar Disorder|mobd|||COBRA|||0|722|1185|1190
SE|25462421|RESULTS|ab|7|entity|C0871208|Rating|resa|||COBRA|||0|722|1185|1190
SE|25462421|RESULTS|ab|7|entity|C0220825|Evaluation|ftcn|||COBRA|||0|722|1185|1190
SE|25462421|RESULTS|ab|7|entity|C0442804|Very high|fndg|||very high|||0|888|1195|1204
SE|25462421|RESULTS|ab|7|entity|C0870731|Internal Consistency|qnco|||internal consistency|||0|888|1205|1225
SE|25462421|RESULTS|ab|7|entity|C0439095|Alpha|inpr|||alpha|||0|861|1238|1243

SE|25462421|RESULTS|ab|8|text|1287|1418|Confirmatory factor analysis validated the one-factor model and the cut-off value to discriminate the patients and controls was 11.
SE|25462421|RESULTS|ab|8|entity|C0870334|Confirmatory Factor Analysis|qlco|||Confirmatory factor analysis|||0|1000|1287|1315
SE|25462421|RESULTS|ab|8|entity|C0205447|One|qnco|||one|||0|851|1330|1333
SE|25462421|RESULTS|ab|8|entity|C1521761|Factor|ftcn|||factor|||0|851|1334|1340
SE|25462421|RESULTS|ab|8|entity|C0026336|Study models|inpr,resd|||model|||0|851|1341|1346
SE|25462421|RESULTS|ab|8|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|734|1355|1362
SE|25462421|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1389|1397
SE|25462421|RESULTS|ab|8|entity|C0243148|control|ftcn|||controls|||0|966|1402|1410

SE|25462421|RESULTS|ab|9|text|1418|1558|Bipolar patients experienced greater cognitive complaints compared to control group suggesting a discriminative validity of the instrument.
SE|25462421|RESULTS|ab|9|entity|C0443156|Bipolar|spco|||Bipolar|||0|888|1418|1425
SE|25462421|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|888|1426|1434
SE|25462421|RESULTS|ab|9|entity|C0443228|Largest|qnco|||greater|||0|623|1447|1454
SE|25462421|RESULTS|ab|9|entity|C1516691|Cognitive|ftcn|||cognitive|||0|623|1455|1464
SE|25462421|RESULTS|ab|9|entity|C0009932|Control Groups|grup|||control group|||0|901|1488|1501
SE|25462421|RESULTS|ab|9|entity|C0348000|Instrument|mnob|||instrument|||0|1000|1546|1556

SE|25462421|RESULTS|ab|10|text|1558|1798|No significant correlation was found between the COBRA and the total Montreal Cognitive Assessment Scale (MoCA), except for single measures related to executive function (phonemic fluency, p=0.045), verbal memory (delayed recall, p=0.004).
SE|25462421|RESULTS|ab|10|entity|C0750502|Significant|idcn|||significant|||0|694|1561|1572
SE|25462421|RESULTS|ab|10|entity|C0005586|Bipolar Disorder|mobd|||COBRA|||0|722|1607|1612
SE|25462421|RESULTS|ab|10|entity|C0871208|Rating|resa|||COBRA|||0|722|1607|1612
SE|25462421|RESULTS|ab|10|entity|C0220825|Evaluation|ftcn|||COBRA|||0|722|1607|1612
SE|25462421|RESULTS|ab|10|entity|C0439175|% of total|qnco|||total|||0|794|1621|1626
SE|25462421|RESULTS|ab|10|entity|C0870300|Assessment: Cognition|diap|||Cognitive Assessment|||0|794|1636|1656
SE|25462421|RESULTS|ab|10|entity|C0037179|Unmarried person|popg|||single|||0|888|1682|1688
SE|25462421|RESULTS|ab|10|entity|C0079809|Measures|qnco|||measures|||0|888|1689|1697
SE|25462421|RESULTS|ab|10|entity|C0935584|Executive Functioning|menp|||executive function|||0|1000|1709|1727
SE|25462421|RESULTS|ab|10|entity|C0871073|Phonemes|inpr|||phonemic|||0|853|1729|1737
SE|25462421|RESULTS|ab|10|entity|C0870569|Fluency|qlco|||fluency|||0|853|1738|1745
SE|25462421|RESULTS|ab|10|entity|C0439824|Verbal|orgf|||verbal|||0|888|1757|1763
SE|25462421|RESULTS|ab|10|entity|C0025260|Memory|menp|||memory|||0|888|1764|1770
SE|25462421|RESULTS|ab|10|entity|C0205421|Deferred|tmco|||delayed|||0|694|1772|1779

SE|25462421|LIMITATIONS|ab|11|text|1798|2016|LIMITATIONS: Cross-sectional design, no specific or unspecific but reliable instrument in Chinese to assess subjective cognitive difficulties in mental disorders for criterion validity or convergent validity analysis.
SE|25462421|LIMITATIONS|ab|11|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1798|1809
SE|25462421|LIMITATIONS|ab|11|entity|C0552389|CROSS SECTION|orga|||Cross-sectional|||0|663|1811|1826
SE|25462421|LIMITATIONS|ab|11|entity|C0348000|Instrument|mnob|||instrument|||0|861|1874|1884
SE|25462421|LIMITATIONS|ab|11|entity|C0439655|Subjective|qlco|||subjective|||0|840|1906|1916
SE|25462421|LIMITATIONS|ab|11|entity|C1516691|Cognitive|ftcn|||cognitive|||0|840|1917|1926
SE|25462421|LIMITATIONS|ab|11|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|1943|1959
SE|25462421|LIMITATIONS|ab|11|entity|C0243161|criteria|inpr|||criterion|||0|694|1964|1973
SE|25462421|LIMITATIONS|ab|11|entity|C1510594|Convergent Validity|qlco|||convergent validity|||0|901|1986|2005
SE|25462421|LIMITATIONS|ab|11|entity|C0936012|Analysis|resa|||analysis|||0|901|2006|2014

SE|25462421|CONCLUSIONS|ab|12|text|2016|2178|CONCLUSIONS: The Chinese version of the COBRA showed to be a simple and reliable instrument to assess subjective cognitive complaints in Chinese bipolar patients.
SE|25462421|CONCLUSIONS|ab|12|entity|C0333052|Version|ftcn|||version|||0|861|2041|2048
SE|25462421|CONCLUSIONS|ab|12|entity|C0005586|Bipolar Disorder|mobd|||COBRA|||0|722|2056|2061
SE|25462421|CONCLUSIONS|ab|12|entity|C0871208|Rating|resa|||COBRA|||0|722|2056|2061
SE|25462421|CONCLUSIONS|ab|12|entity|C0220825|Evaluation|ftcn|||COBRA|||0|722|2056|2061
SE|25462421|CONCLUSIONS|ab|12|entity|C0205352|Simple|qlco|||simple|||0|1000|2077|2083
SE|25462421|CONCLUSIONS|ab|12|entity|C0348000|Instrument|mnob|||instrument|||0|861|2097|2107
SE|25462421|CONCLUSIONS|ab|12|entity|C0439655|Subjective|qlco|||subjective|||0|623|2118|2128
SE|25462421|CONCLUSIONS|ab|12|entity|C1516691|Cognitive|ftcn|||cognitive|||0|623|2129|2138
SE|25462421|CONCLUSIONS|ab|12|entity|C0443156|Bipolar|spco|||bipolar|||0|790|2161|2168
SE|25462421|CONCLUSIONS|ab|12|entity|C0030705|Patients|podg|||patients|||0|790|2169|2177


SE|25462422||ti|1|text|21|113|Symptoms of PTSD in a sample of female victims of sexual violence in post-earthquake Haiti.
SE|25462422||ti|1|entity|C1457887|Symptoms|sosy|||Symptoms|||0|1000|21|29
SE|25462422||ti|1|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|33|37
SE|25462422||ti|1|entity|C0015780|Female|orga|||female|||0|872|53|59
SE|25462422||ti|1|entity|C0680681|VICTIM|popg|||victims|||0|872|60|67
SE|25462422||ti|1|entity|C0042693|Violence|mobd,socb|||violence|||0|861|78|86
SE|25462422||ti|1|entity|C0205095|Dorsal|spco|||post|||0|851|90|94
SE|25462422||ti|1|entity|C0013463|Earthquakes|npop|||earthquake|||0|851|95|105
SE|25462422||ti|1|entity|C0018510|Haiti|geoa|||Haiti|||0|851|106|111

SE|25462422|BACKGROUND|ab|1|text|119|261|BACKGROUND: Globally, sexual violence (SV) impacts 25-33% of women, is often perpetrated by intimate partners and occurs even post-disasters.
SE|25462422|BACKGROUND|ab|1|entity|C0042693|Violence|mobd,socb|||violence|||0|861|148|156
SE|25462422|BACKGROUND|ab|1|entity|C0043210|Woman|popg|||women|||0|1000|180|185
SE|25462422|BACKGROUND|ab|1|entity|C0332183|Frequent|tmco|||often|||0|1000|190|195
SE|25462422|BACKGROUND|ab|1|entity|C0205095|Dorsal|spco|||post|||0|790|245|249
SE|25462422|BACKGROUND|ab|1|entity|C0012618|Disasters|phpr|||disasters|||0|790|250|259

SE|25462422|BACKGROUND|ab|2|text|261|427|The 2010 Haiti earthquake occasioned a SV epidemic in Cite Soleil, where over 50% of females are reportedly victims of SV via non-intimate partners/strangers (NPSV).
SE|25462422|BACKGROUND|ab|2|entity|C0018510|Haiti|geoa|||Haiti|||0|790|270|275
SE|25462422|BACKGROUND|ab|2|entity|C0013463|Earthquakes|npop|||earthquake|||0|790|276|286
SE|25462422|BACKGROUND|ab|2|entity|C0042693|Violence|mobd,socb|||SV|||0|861|300|302
SE|25462422|BACKGROUND|ab|2|entity|C0014499|Epidemic|phpr|||epidemic|||0|1000|303|311
SE|25462422|BACKGROUND|ab|2|entity|C0015780|Female|orga|||females|||0|1000|346|353
SE|25462422|BACKGROUND|ab|2|entity|C0680681|VICTIM|popg|||victims|||0|827|369|376
SE|25462422|BACKGROUND|ab|2|entity|C0042693|Violence|mobd,socb|||SV|||0|618|380|382
SE|25462422|BACKGROUND|ab|2|entity|C0036911|Sexual Partners|popg|||SV via non-intimate partners|||0|618|380|408

SE|25462422|BACKGROUND|ab|3|text|427|587|Little is known about the psychological effects of SV perpetrated by NPSV; even less in known about the biopsychosocial consequences of NPSV on women in Haiti.
SE|25462422|BACKGROUND|ab|3|entity|C0023882|Little's Disease|dsyn|||Little|||0|1000|427|433
SE|25462422|BACKGROUND|ab|3|entity|C0205486|Psychologic|ftcn|||psychological|||0|872|453|466
SE|25462422|BACKGROUND|ab|3|entity|C1280500|Effect|qlco|||effects|||0|872|467|474
SE|25462422|BACKGROUND|ab|3|entity|C0042693|Violence|mobd,socb|||SV|||0|861|478|480
SE|25462422|BACKGROUND|ab|3|entity|C0043210|Woman|popg|||women|||0|1000|571|576
SE|25462422|BACKGROUND|ab|3|entity|C0018510|Haiti|geoa|||Haiti|||0|1000|580|585
SE|25462422|BACKGROUND|ab|3|relation|1|1|C0023882|Little's Disease|dsyn|dsyn|||Little|||0|1000|427|433|NOM|AFFECTS||467|474|6|1|C0042693|Violence|mobd,socb|mobd|||SV|||0|861|478|480

SE|25462422|BACKGROUND|ab|4|text|587|714|Yet, the World Health Organization recently called for research on NPSV, particularly in poor and disaster-affected countries.
SE|25462422|BACKGROUND|ab|4|entity|C0043237|World Health Organization|hcro|||World Health Organization|||0|1000|596|621
SE|25462422|BACKGROUND|ab|4|entity|C0332185|Recent|tmco|||recently|||0|1000|622|630
SE|25462422|BACKGROUND|ab|4|entity|C0035168|research|resa|||research|||0|1000|642|650
SE|25462422|BACKGROUND|ab|4|entity|C0032854|Poverty|grpa|||poor|||0|1000|676|680
SE|25462422|BACKGROUND|ab|4|entity|C0012618|Disasters|phpr|||disaster|||0|851|685|693
SE|25462422|BACKGROUND|ab|4|entity|C0392760|Affecting|ftcn|||affected|||0|851|694|702
SE|25462422|BACKGROUND|ab|4|entity|C0454664|Country|geoa|||countries|||0|851|703|712

SE|25462422|METHODS|ab|5|text|714|966|METHODS: As a first step in categorizing the consequences of NPSV on female victims in Haiti, we conducted 2 focus groups of 16 female residents of Cite Soleil who survived the earthquake and its aftershocks, along with ensuing hurricanes and cholera.
SE|25462422|METHODS|ab|5|entity|C0025663|Methods|inpr|||METHODS|||0|1000|714|721
SE|25462422|METHODS|ab|5|entity|C1279901|Firstly|qlco|||first|||0|888|728|733
SE|25462422|METHODS|ab|5|entity|C1261552|Step|ftcn|||step|||0|888|734|738
SE|25462422|METHODS|ab|5|entity|C0871968|Categorizing|ocac|||categorizing|||0|1000|742|754
SE|25462422|METHODS|ab|5|entity|C0015780|Female|orga|||female|||0|872|783|789
SE|25462422|METHODS|ab|5|entity|C0680681|VICTIM|popg|||victims|||0|872|790|797
SE|25462422|METHODS|ab|5|entity|C0018510|Haiti|geoa|||Haiti|||0|1000|801|806
SE|25462422|METHODS|ab|5|entity|C0016400|Focus Groups|grup|||focus groups|||0|901|823|835
SE|25462422|METHODS|ab|5|entity|C0015780|Female|orga|||female|||0|773|842|848
SE|25462422|METHODS|ab|5|entity|C1549439|Resident|inpr|||residents|||0|773|849|858
SE|25462422|METHODS|ab|5|entity|C0013463|Earthquakes|npop|||earthquake|||0|1000|891|901
SE|25462422|METHODS|ab|5|entity|C0020183|Hurricanes|npop|||hurricanes|||0|861|942|952
SE|25462422|METHODS|ab|5|entity|C0008354|Cholera|dsyn|||cholera|||0|1000|957|964

SE|25462422|RESULTS|ab|6|text|966|1054|RESULTS: Participants reported rapes by strangers who intentionally "crush the uterus."
SE|25462422|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|966|973
SE|25462422|RESULTS|ab|6|entity|C0679646|Participant|popg|||Participants|||0|966|975|987
SE|25462422|RESULTS|ab|6|entity|C0034668|Forcible intercourse|socb|||rapes|||0|1000|997|1002
SE|25462422|RESULTS|ab|6|entity|C0042149|Uterus|bpoc|||uterus|||0|1000|1045|1051

SE|25462422|RESULTS|ab|7|text|1054|1358|All endorsed criteria for PTSD, including enduring physiological, neurological and psychological symptoms: significant intrusive, avoidance, arousal, cognitive, mood changes, as well as significant distress/impairment in various areas of functioning; and all but one became pregnant from the experience.
SE|25462422|RESULTS|ab|7|entity|C0243161|criteria|inpr|||criteria|||0|861|1067|1075
SE|25462422|RESULTS|ab|7|entity|C0038436|Stress Disorders, Post-Traumatic|mobd|||PTSD|||0|1000|1080|1084
SE|25462422|RESULTS|ab|7|entity|C0205463|Physiological|ftcn|||physiological|||0|888|1105|1118
SE|25462422|RESULTS|ab|7|entity|C0205494|Neurologic|ftcn|||neurological|||0|888|1120|1132
SE|25462422|RESULTS|ab|7|entity|C0233397|Psychological symptom|sosy|||psychological symptoms|||0|983|1137|1159
SE|25462422|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significant|||0|802|1161|1172
SE|25462422|RESULTS|ab|7|entity|C0870186|Avoidance|menp|||avoidance|||0|802|1184|1193
SE|25462422|RESULTS|ab|7|entity|C0003808|Arousal|menp|||arousal|||0|1000|1195|1202
SE|25462422|RESULTS|ab|7|entity|C1516691|Cognitive|ftcn|||cognitive|||0|1000|1204|1213
SE|25462422|RESULTS|ab|7|entity|C0085633|Mood swings|mobd|||mood changes|||0|983|1215|1227
SE|25462422|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significant|||0|851|1240|1251
SE|25462422|RESULTS|ab|7|entity|C0231303|Distress|menp|||distress|||0|851|1252|1260
SE|25462422|RESULTS|ab|7|entity|C0031843|physiological aspects|phsf|||functioning|||0|966|1292|1303
SE|25462422|RESULTS|ab|7|entity|C0205447|One|qnco|||one|||0|1000|1317|1320
SE|25462422|RESULTS|ab|7|entity|C0596545|experience|menp|||experience|||0|1000|1346|1356

SE|25462422|RESULTS|ab|8|text|1358|1450|All denied substance use and other illness that is not associated with the sexual violence.
SE|25462422|RESULTS|ab|8|entity|C0237123|AOD use|inbe,mobd|||substance use|||0|1000|1369|1382
SE|25462422|RESULTS|ab|8|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|1393|1400
SE|25462422|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1409|1412
SE|25462422|RESULTS|ab|8|entity|C0042693|Violence|mobd,socb|||violence|||0|861|1440|1448
SE|25462422|RESULTS|ab|8|relation|1|1|C0042693|Violence|mobd,socb|mobd|||violence|||0|861|1440|1448|VERB|COEXISTS_WITH|negation|1413|1423|2|2|C0237123|AOD use|inbe,mobd|mobd|||substance use|||0|1000|1369|1382

SE|25462422|LIMITATIONS|ab|9|text|1450|1607|LIMITATIONS: Our study was exploratory, targeting a small sample of women in one specific neighborhood and cannot be generalized to all SV victims in Haiti.
SE|25462422|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1450|1461
SE|25462422|LIMITATIONS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|1000|1467|1472
SE|25462422|LIMITATIONS|ab|9|entity|C0700321|Small|qnco|||small|||0|694|1502|1507
SE|25462422|LIMITATIONS|ab|9|entity|C0043210|Woman|popg|||women|||0|1000|1518|1523
SE|25462422|LIMITATIONS|ab|9|entity|C0205447|One|qnco|||one|||0|802|1527|1530
SE|25462422|LIMITATIONS|ab|9|entity|C0027569|Neighborhood|geoa|||neighborhood|||0|802|1540|1552
SE|25462422|LIMITATIONS|ab|9|entity|C0042693|Violence|mobd,socb|||SV|||0|773|1586|1588
SE|25462422|LIMITATIONS|ab|9|entity|C0680681|VICTIM|popg|||victims|||0|773|1589|1596
SE|25462422|LIMITATIONS|ab|9|entity|C0018510|Haiti|geoa|||Haiti|||0|1000|1600|1605
SE|25462422|LIMITATIONS|ab|9|relation|0|0|C0042693|Violence|mobd,socb|mobd|||SV|||0|773|1586|1588|MOD/HEAD|PROCESS_OF||1586|1596|0|0|C0680681|VICTIM|popg,humn|humn|||victims|||0|773|1589|1596

SE|25462422|CONCLUSIONS|ab|10|text|1607|1749|CONCLUSIONS: Following earthquakes, there should be vigilance by public health officials and rescue teams for prevention of SV against women.
SE|25462422|CONCLUSIONS|ab|10|entity|C0013463|Earthquakes|npop|||earthquakes|||0|1000|1630|1641
SE|25462422|CONCLUSIONS|ab|10|entity|C0699864|Watchfulness|menp|||vigilance|||0|1000|1659|1668
SE|25462422|CONCLUSIONS|ab|10|entity|C0018684|Health|idcn|||health|||0|660|1679|1685
SE|25462422|CONCLUSIONS|ab|10|entity|C0871489|Teams|grup|||teams|||0|861|1707|1712
SE|25462422|CONCLUSIONS|ab|10|entity|C0199176|Prophylactic treatment|topp|||prevention|||0|1000|1717|1727
SE|25462422|CONCLUSIONS|ab|10|entity|C0042693|Violence|mobd,socb|||SV|||0|861|1731|1733
SE|25462422|CONCLUSIONS|ab|10|entity|C0043210|Woman|popg|||women|||0|1000|1742|1747

SE|25462422|CONCLUSIONS|ab|11|text|1749|1942|Women who survive SV in Haiti should be provided access to trauma-informed care that addresses biological consequences of the SV, as well as biological, neurological and psychological sequelae.
SE|25462422|CONCLUSIONS|ab|11|entity|C0043210|Woman|popg|||Women|||0|1000|1749|1754
SE|25462422|CONCLUSIONS|ab|11|entity|C0042693|Violence|mobd,socb|||SV|||0|861|1767|1769
SE|25462422|CONCLUSIONS|ab|11|entity|C0018510|Haiti|geoa|||Haiti|||0|1000|1773|1778
SE|25462422|CONCLUSIONS|ab|11|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|888|1808|1814
SE|25462422|CONCLUSIONS|ab|11|entity|C1522154|Informed|qlco|||informed|||0|888|1815|1823
SE|25462422|CONCLUSIONS|ab|11|entity|C0205460|biological|ftcn|||biological|||0|694|1844|1854
SE|25462422|CONCLUSIONS|ab|11|entity|C0042693|Violence|mobd,socb|||SV|||0|861|1875|1877
SE|25462422|CONCLUSIONS|ab|11|entity|C0205460|biological|ftcn|||biological|||0|888|1890|1900
SE|25462422|CONCLUSIONS|ab|11|entity|C0205494|Neurologic|ftcn|||neurological|||0|888|1902|1914
SE|25462422|CONCLUSIONS|ab|11|entity|C0205486|Psychologic|ftcn|||psychological|||0|888|1919|1932
SE|25462422|CONCLUSIONS|ab|11|entity|C0543419|Sequela of disorder|fndg|||sequelae|||0|888|1933|1941


SE|25462423||ti|1|text|21|111|Predictors of post-natal depression are shaped distinctly by the measure of 'depression'.
SE|25462423||ti|1|entity|C0221074|Depression, Postpartum|mobd|||post-natal depression|||0|1000|35|56
SE|25462423||ti|1|entity|C0079809|Measures|qnco|||measure|||0|1000|86|93
SE|25462423||ti|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|98|108

SE|25462423|BACKGROUND|ab|1|text|117|209|BACKGROUND: Many variables have been proposed as predictive of post-natal depression (PND).
SE|25462423|BACKGROUND|ab|1|entity|C0439828|Variable|qlco|||variables|||0|966|134|143
SE|25462423|BACKGROUND|ab|1|entity|C0681890|predictive|qlco|||predictive|||0|817|166|176
SE|25462423|BACKGROUND|ab|1|entity|C0221074|Depression, Postpartum|mobd|||post-natal depression|||0|817|180|201

SE|25462423|AIMS|ab|2|text|209|261|AIMS: To investigate and refine PND risk variables.
SE|25462423|AIMS|ab|2|entity|C0221074|Depression, Postpartum|mobd|||PND|||0|806|241|244
SE|25462423|AIMS|ab|2|entity|C0035647|Risk|qlco|||risk|||0|806|245|249
SE|25462423|AIMS|ab|2|entity|C0683956|Predictive Factor|inpr|||PND risk variables|||0|806|241|259

SE|25462423|METHOD|ab|3|text|261|428|METHOD: We recruited a large sample and employed two measures of PND (the dimensional Edinburgh Postnatal Depression Scale or EPDS, and DSM-defined major depression).
SE|25462423|METHOD|ab|3|entity|C0025663|Methods|inpr|||METHOD|||0|1000|261|267
SE|25462423|METHOD|ab|3|entity|C0549177|Large|qnco|||large|||0|694|284|289
SE|25462423|METHOD|ab|3|entity|C0557351|Employed|fndg|||employed|||0|851|301|309
SE|25462423|METHOD|ab|3|entity|C0205448|Two|qnco|||two|||0|851|310|313
SE|25462423|METHOD|ab|3|entity|C0079809|Measures|qnco|||measures|||0|851|314|322
SE|25462423|METHOD|ab|3|entity|C0681890|predictive|qlco|||PND|||0|817|326|329
SE|25462423|METHOD|ab|3|entity|C0221074|Depression, Postpartum|mobd|||PND|||0|817|326|329
SE|25462423|METHOD|ab|3|entity|C0439534|Dimensions|qnco|||dimensional|||0|914|335|346
SE|25462423|METHOD|ab|3|entity|C0451144|Edinburgh postnatal depression scale|inpr|||Edinburgh Postnatal Depression Scale|||0|914|347|383
SE|25462423|METHOD|ab|3|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|861|409|425

SE|25462423|RESULTS|ab|4|text|428|604|RESULTS: High levels of stress in the post-natal period, previous depression and higher depression scores during pregnancy were the only consistent predictors across measures.
SE|25462423|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|428|435
SE|25462423|RESULTS|ab|4|entity|C0205250|High|qlco|||High|||0|888|437|441
SE|25462423|RESULTS|ab|4|entity|C0441889|Levels|inpr|||levels|||0|888|442|448
SE|25462423|RESULTS|ab|4|entity|C0038435|Stress|fndg|||stress|||0|1000|452|458
SE|25462423|RESULTS|ab|4|entity|C0454729|Natal|geoa|||natal|||0|851|471|476
SE|25462423|RESULTS|ab|4|entity|C0439531|/period|tmco|||period|||0|851|477|483
SE|25462423|RESULTS|ab|4|entity|C0205156|Previous|tmco|||previous|||0|888|485|493
SE|25462423|RESULTS|ab|4|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|494|504
SE|25462423|RESULTS|ab|4|entity|C0205250|High|qlco|||higher|||0|872|509|515
SE|25462423|RESULTS|ab|4|entity|C0011581|Depressive disorder|mobd|||depression|||0|872|516|526
SE|25462423|RESULTS|ab|4|entity|C0032961|Pregnancy|orgf|||pregnancy|||0|1000|541|550
SE|25462423|RESULTS|ab|4|entity|C0079809|Measures|qnco|||measures|||0|1000|594|602

SE|25462423|RESULTS|ab|5|text|604|837|Those exceeding the EPDS cut-off had additional psychosocial risk factors while those meeting criteria for major depression were strongly predicted by a past history of depression as well as higher pre-natal state depression scores.
SE|25462423|RESULTS|ab|5|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|901|629|636
SE|25462423|RESULTS|ab|5|entity|C1524062|Additional|ftcn|||additional|||0|861|641|651
SE|25462423|RESULTS|ab|5|entity|C0035647|Risk|qlco|||risk|||0|861|665|669
SE|25462423|RESULTS|ab|5|entity|C0033963|Psychosocial Factors|qlco|||psychosocial risk factors|||0|861|652|677
SE|25462423|RESULTS|ab|5|entity|C0556656|Meetings|hlca|||meeting|||0|872|690|697
SE|25462423|RESULTS|ab|5|entity|C0243161|criteria|inpr|||criteria|||0|872|698|706
SE|25462423|RESULTS|ab|5|entity|C1269683|Major Depressive Disorder|mobd|||major depression|||0|1000|711|727
SE|25462423|RESULTS|ab|5|entity|C1444637|Past|tmco|||past|||0|888|757|761
SE|25462423|RESULTS|ab|5|entity|C0019664|Recording of previous events|ocdi|||history|||0|888|762|769
SE|25462423|RESULTS|ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|773|783
SE|25462423|RESULTS|ab|5|entity|C0205250|High|qlco|||higher|||0|809|795|801
SE|25462423|RESULTS|ab|5|entity|C0740175|Before values|tmco|||pre|||0|809|802|805
SE|25462423|RESULTS|ab|5|entity|C0454729|Natal|geoa|||natal|||0|809|806|811
SE|25462423|RESULTS|ab|5|entity|C1442792|State|ftcn|||state|||0|809|812|817
SE|25462423|RESULTS|ab|5|entity|C0011581|Depressive disorder|mobd|||depression|||0|809|818|828
SE|25462423|RESULTS|ab|5|entity|C0449820|Score|qnco|||scores|||0|809|829|835
SE|25462423|RESULTS|ab|5|relation|0|0|C1269683|Major Depressive Disorder|mobd|mobd|||major depression|||0|1000|711|727|SPEC|ISA||711|783|0|0|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|773|783

SE|25462423|LIMITATIONS|ab|6|text|837|927|LIMITATIONS: The EPDS has been used with variable cut off scores across multiple studies.
SE|25462423|LIMITATIONS|ab|6|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|837|848
SE|25462423|LIMITATIONS|ab|6|entity|C0439828|Variable|qlco|||variable|||0|851|878|886
SE|25462423|LIMITATIONS|ab|6|entity|C1442160|CUTOFF|ftcn|||cut off|||0|851|887|894
SE|25462423|LIMITATIONS|ab|6|entity|C0449820|Score|qnco|||scores|||0|851|895|901
SE|25462423|LIMITATIONS|ab|6|entity|C0439064|Numerous|qnco|||multiple|||0|872|909|917
SE|25462423|LIMITATIONS|ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|872|918|925

SE|25462423|LIMITATIONS|ab|7|text|927|1116|We used only nine of the 10 EPDS items, electing to exclude the self-harm related question, but preserving the recommended EPDS cut-off score, and which might have impacted on predictions.
SE|25462423|LIMITATIONS|ab|7|entity|C0205455|Nine|qnco|||nine|||0|861|940|944
SE|25462423|LIMITATIONS|ab|7|entity|C0036588|Self|idcn|||self|||0|597|991|995
SE|25462423|LIMITATIONS|ab|7|entity|C1522149|Related|ftcn|||related|||0|597|1001|1008
SE|25462423|LIMITATIONS|ab|7|entity|C0728887|Preserving|ftcn|||preserving|||0|1000|1023|1033
SE|25462423|LIMITATIONS|ab|7|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|773|1055|1062
SE|25462423|LIMITATIONS|ab|7|entity|C0449820|Score|qnco|||score|||0|773|1063|1068
SE|25462423|LIMITATIONS|ab|7|entity|C0681842|prediction|inpr|||predictions|||0|966|1103|1114

SE|25462423|CONCLUSIONS|ab|8|text|1116|1301|CONCLUSIONS: Study results generated a refined set of predictors of PND but, more importantly, identified that predictors of PND status are distinctly influenced by the measure of PND.
SE|25462423|CONCLUSIONS|ab|8|entity|C0683954|research outcome|fndg|||Study results|||0|1000|1129|1142
SE|25462423|CONCLUSIONS|ab|8|entity|C0681890|predictive|qlco|||PND|||0|817|1184|1187
SE|25462423|CONCLUSIONS|ab|8|entity|C0221074|Depression, Postpartum|mobd|||PND|||0|817|1184|1187
SE|25462423|CONCLUSIONS|ab|8|entity|C0205172|More|ftcn|||more|||0|861|1193|1197
SE|25462423|CONCLUSIONS|ab|8|entity|C0681890|predictive|qlco|||PND|||0|787|1241|1244
SE|25462423|CONCLUSIONS|ab|8|entity|C0221074|Depression, Postpartum|mobd|||PND|||0|787|1241|1244
SE|25462423|CONCLUSIONS|ab|8|entity|C0449438|Status|qlco|||status|||0|787|1245|1251
SE|25462423|CONCLUSIONS|ab|8|entity|C0079809|Measures|qnco|||measure|||0|1000|1285|1292
SE|25462423|CONCLUSIONS|ab|8|entity|C0681890|predictive|qlco|||PND|||0|817|1296|1299
SE|25462423|CONCLUSIONS|ab|8|entity|C0221074|Depression, Postpartum|mobd|||PND|||0|817|1296|1299
SE|25462423|CONCLUSIONS|ab|8|relation|3|2|C0683954|research outcome|fndg|fndg|||Study results|||0|1000|1129|1142|NOM|PREDISPOSES||1170|1180|2|1|C0221074|Depression, Postpartum|mobd|mobd|||PND|||0|817|1184|1187

SE|25462423|CONCLUSIONS|ab|9|text|1301|1418|Such inconsistencies are intrinsically noteworthy and of potential key importance in shaping intervention strategies.
SE|25462423|CONCLUSIONS|ab|9|entity|C0442809|Inconsistent|qlco|||inconsistencies|||0|916|1306|1321
SE|25462423|CONCLUSIONS|ab|9|entity|C0237399|Potential|qlco|||potential|||0|623|1358|1367
SE|25462423|CONCLUSIONS|ab|9|entity|C1554080|Key|idcn|||key|||0|623|1368|1371
SE|25462423|CONCLUSIONS|ab|9|entity|C0332479|Shapes|spco|||shaping|||0|890|1386|1393
SE|25462423|CONCLUSIONS|ab|9|entity|C1273869|Intervention regimes|hlca|||intervention strategies|||0|890|1394|1417


SE|25462424||ti|1|text|21|148|Gender differences in mental disorders and suicidality in Europe: results from a large cross-sectional population-based study.
SE|25462424||ti|1|entity|C0036866|Sex Characteristics|orga|||Gender differences|||0|1000|21|39
SE|25462424||ti|1|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|43|59
SE|25462424||ti|1|entity|C0438696|Suicidal|fndg|||suicidality|||0|928|64|75
SE|25462424||ti|1|entity|C0015176|Europe|geoa|||Europe|||0|1000|79|85
SE|25462424||ti|1|entity|C1274040|result|ftcn|||results|||0|966|87|94
SE|25462424||ti|1|entity|C0549177|Large|qnco|||large|||0|845|102|107
SE|25462424||ti|1|entity|C1257890|Population Group|popg|||population|||0|845|124|134
SE|25462424||ti|1|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional population-based study|||0|845|108|146

SE|25462424|INTRODUCTION|ab|1|text|154|421|INTRODUCTION: When evaluating gender differences in mental disorders and suicidality, specifically between European countries, studies are sparse and frequently hindered by methodological issues, such as the limited items evaluated and inconsistent sampling designs.
SE|25462424|INTRODUCTION|ab|1|entity|C1293116|Introduction procedure|hlca|||INTRODUCTION|||0|1000|154|166
SE|25462424|INTRODUCTION|ab|1|entity|C0036866|Sex Characteristics|orga|||gender differences|||0|901|184|202
SE|25462424|INTRODUCTION|ab|1|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|206|222
SE|25462424|INTRODUCTION|ab|1|entity|C0438696|Suicidal|fndg|||suicidality|||0|928|227|238
SE|25462424|INTRODUCTION|ab|1|entity|C0454713|European country|geoa|||European countries|||0|983|261|279
SE|25462424|INTRODUCTION|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|281|288
SE|25462424|INTRODUCTION|ab|1|entity|C0332183|Frequent|tmco|||frequently|||0|1000|304|314
SE|25462424|INTRODUCTION|ab|1|entity|C0025664|Methodology|inpr|||methodological|||0|623|327|341
SE|25462424|INTRODUCTION|ab|1|entity|C0439801|Limited|ftcn|||limited|||0|694|362|369
SE|25462424|INTRODUCTION|ab|1|entity|C0442809|Inconsistent|qlco|||inconsistent|||0|890|390|402
SE|25462424|INTRODUCTION|ab|1|entity|C0815259|sampling design|inpr|||sampling designs|||0|890|403|419

SE|25462424|METHODS|ab|2|text|421|623|METHODS: In ten European countries participating in the World Mental Health Survey Initiative, lifetime internalizing and externalizing disorders and suicidality were assessed among 37,289 respondents.
SE|25462424|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|421|428
SE|25462424|METHODS|ab|2|entity|C0205456|Ten|qnco|||ten|||0|890|433|436
SE|25462424|METHODS|ab|2|entity|C0454713|European country|geoa|||European countries|||0|890|437|455
SE|25462424|METHODS|ab|2|entity|C0043236|World Health|idcn|||World Mental Health|||0|840|477|496
SE|25462424|METHODS|ab|2|entity|C0038951|Surveys|resa|||Survey|||0|840|497|503
SE|25462424|METHODS|ab|2|entity|C0424093|Initiative|menp|||Initiative|||0|840|504|514
SE|25462424|METHODS|ab|2|entity|C0012634|Disease|dsyn|||disorders|||0|861|557|566
SE|25462424|METHODS|ab|2|entity|C0438696|Suicidal|fndg|||suicidality|||0|928|571|582
SE|25462424|METHODS|ab|2|entity|C0282122|Respondents|popg|||respondents|||0|827|610|621
SE|25462424|METHODS|ab|2|relation|7|1|C0012634|Disease|dsyn|dsyn|||disorders|||0|861|557|566|PREP|PROCESS_OF||597|602|1|1|C0282122|Respondents|popg,humn|humn|||respondents|||0|827|610|621
SE|25462424|METHODS|ab|2|relation|7|1|C0438696|Suicidal|fndg|fndg|||suicidality|||0|928|571|582|PREP|PROCESS_OF||597|602|1|1|C0282122|Respondents|popg,humn|humn|||respondents|||0|827|610|621

SE|25462424|METHODS|ab|3|text|623|672|Disorders were classified using DMS-IV criteria.
SE|25462424|METHODS|ab|3|entity|C0012634|Disease|dsyn|||Disorders|||0|1000|623|632
SE|25462424|METHODS|ab|3|entity|C1522726|Intravenous Route of Drug Administration|ftcn|||DMS-IV|||0|790|655|661
SE|25462424|METHODS|ab|3|entity|C0243161|criteria|inpr|||criteria|||0|790|662|670

SE|25462424|METHODS|ab|4|text|672|828|Odds ratios (OR) for gender differences were calculated using logistic regression, while trends across age-groups were tested via gender * age interaction.
SE|25462424|METHODS|ab|4|entity|C0028873|Odds Ratio|qnco|||Odds ratios|||0|1000|672|683
SE|25462424|METHODS|ab|4|entity|C0036866|Sex Characteristics|orga|||gender differences|||0|1000|693|711
SE|25462424|METHODS|ab|4|entity|C0206031|Logistic Regression|resa|||logistic regression|||0|1000|734|753
SE|25462424|METHODS|ab|4|entity|C1521798|trend|tmco|||trends|||0|1000|761|767
SE|25462424|METHODS|ab|4|entity|C0027362|Human Age Group|aggp|||age-groups|||0|1000|775|785
SE|25462424|METHODS|ab|4|entity|C1550513|via|idcn|||via|||0|888|798|801
SE|25462424|METHODS|ab|4|entity|C0079399|Gender|orga|||gender|||0|888|802|808
SE|25462424|METHODS|ab|4|entity|C0001779|Age|orga|||age|||0|888|811|814

SE|25462424|RESULTS|ab|5|text|828|1048|RESULTS: Within countries, prevalence of any lifetime internalizing disorder ranged from 10.8% to 44.5% among women and 5.9% to 26.5% among men, with women having consistently higher odds than men (OR range: 1.52-2.73).
SE|25462424|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|828|835
SE|25462424|RESULTS|ab|5|entity|C0454664|Country|geoa|||countries|||0|1000|844|853
SE|25462424|RESULTS|ab|5|entity|C0012634|Disease|dsyn|||disorder|||0|827|896|904
SE|25462424|RESULTS|ab|5|entity|C0043210|Woman|popg|||women|||0|1000|938|943
SE|25462424|RESULTS|ab|5|entity|C0439084|>5|qnco|||5|||0|861|948|949
SE|25462424|RESULTS|ab|5|entity|C0025266|Male population group|popg|||men|||0|1000|968|971
SE|25462424|RESULTS|ab|5|entity|C0043210|Woman|popg|||women|||0|1000|978|983
SE|25462424|RESULTS|ab|5|entity|C0205250|High|qlco|||higher|||0|627|1004|1010
SE|25462424|RESULTS|ab|5|entity|C0025266|Male population group|popg|||men|||0|1000|1021|1024
SE|25462424|RESULTS|ab|5|entity|C0028873|Odds Ratio|qnco|||OR|||0|901|1026|1028
SE|25462424|RESULTS|ab|5|entity|C1514721|Range|qnco|||range|||0|901|1029|1034
SE|25462424|RESULTS|ab|5|entity|C0580272|1/2|inpr|||1.52-2|||0|875|1036|1042
SE|25462424|RESULTS|ab|5|relation|4|1|C0012634|Disease|dsyn|dsyn|||disorder|||0|827|896|904|PREP|PROCESS_OF||932|937|6|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|938|943

SE|25462424|RESULTS|ab|6|text|1048|1239|Prevalence of any lifetime externalizing disorders ranged from 0.2% to 6.6% among women and 2.2% to 22.4% among men, with women having consistently lower odds than men (OR range: 0.05-0.35).
SE|25462424|RESULTS|ab|6|entity|C0012634|Disease|dsyn|||disorders|||0|827|1089|1098
SE|25462424|RESULTS|ab|6|entity|C0442750|6/6|fndg|||6.6|||0|1000|1119|1122
SE|25462424|RESULTS|ab|6|entity|C0043210|Woman|popg|||women|||0|1000|1130|1135
SE|25462424|RESULTS|ab|6|entity|C0025266|Male population group|popg|||men|||0|1000|1160|1163
SE|25462424|RESULTS|ab|6|entity|C0043210|Woman|popg|||women|||0|1000|1170|1175
SE|25462424|RESULTS|ab|6|entity|C0441994|Lower|ftcn|||lower|||0|660|1196|1201
SE|25462424|RESULTS|ab|6|entity|C0025266|Male population group|popg|||men|||0|1000|1212|1215
SE|25462424|RESULTS|ab|6|entity|C0028873|Odds Ratio|qnco|||OR|||0|901|1217|1219
SE|25462424|RESULTS|ab|6|entity|C1514721|Range|qnco|||range|||0|901|1220|1225
SE|25462424|RESULTS|ab|6|relation|2|0|C0442750|6/6|fndg|fndg|||6.6|||0|1000|1119|1122|PREP|PROCESS_OF||1124|1129|6|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1130|1135
SE|25462424|RESULTS|ab|6|relation|3|1|C0442750|6/6|fndg|fndg|||6.6|||0|1000|1119|1122|PREP|PROCESS_OF||1154|1159|5|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1160|1163

SE|25462424|RESULTS|ab|7|text|1239|1409|Any lifetime suicide attempt was found in 0.8-5.4% of women and 0.3-2.4% of men, showing inconsistent relative gender-differences across countries (OR range: 0.77-4.72).
SE|25462424|RESULTS|ab|7|entity|C0038663|Suicide attempt|mobd|||suicide attempt|||0|901|1252|1267
SE|25462424|RESULTS|ab|7|entity|C0444499|0/5|qnco|||0.8-5|||0|875|1281|1286
SE|25462424|RESULTS|ab|7|entity|C0043210|Woman|popg|||women|||0|1000|1293|1298
SE|25462424|RESULTS|ab|7|entity|C0025266|Male population group|popg|||men|||0|1000|1315|1318
SE|25462424|RESULTS|ab|7|entity|C0442809|Inconsistent|qlco|||inconsistent|||0|861|1328|1340
SE|25462424|RESULTS|ab|7|entity|C0205345|Relative|qlco|||relative|||0|861|1341|1349
SE|25462424|RESULTS|ab|7|entity|C0036866|Sex Characteristics|orga|||gender-differences|||0|861|1350|1368
SE|25462424|RESULTS|ab|7|entity|C0454664|Country|geoa|||countries|||0|1000|1376|1385
SE|25462424|RESULTS|ab|7|entity|C0028873|Odds Ratio|qnco|||OR|||0|901|1387|1389
SE|25462424|RESULTS|ab|7|entity|C1514721|Range|qnco|||range|||0|901|1390|1395

SE|25462424|RESULTS|ab|8|text|1409|1649|Significant effects in gender OR across age-groups were not observed for any internalizing disorder or suicide attempt, yet were present for any externalizing disorder in France (p = 0.01), the Netherlands (p = 0.05), and Spain (p = 0.02).
SE|25462424|RESULTS|ab|8|entity|C0750502|Significant|idcn|||Significant|||0|872|1409|1420
SE|25462424|RESULTS|ab|8|entity|C1280500|Effect|qlco|||effects|||0|872|1421|1428
SE|25462424|RESULTS|ab|8|entity|C0079399|Gender|orga|||gender|||0|901|1432|1438
SE|25462424|RESULTS|ab|8|entity|C0028873|Odds Ratio|qnco|||OR|||0|901|1439|1441
SE|25462424|RESULTS|ab|8|entity|C0027362|Human Age Group|aggp|||age-groups|||0|1000|1449|1459
SE|25462424|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1465|1468
SE|25462424|RESULTS|ab|8|entity|C0012634|Disease|dsyn|||disorder|||0|861|1500|1508
SE|25462424|RESULTS|ab|8|entity|C0038663|Suicide attempt|mobd|||suicide attempt|||0|1000|1512|1527
SE|25462424|RESULTS|ab|8|entity|C0150312|Present|qnco|||present|||0|1000|1538|1545
SE|25462424|RESULTS|ab|8|entity|C0012634|Disease|dsyn|||disorder|||0|861|1568|1576
SE|25462424|RESULTS|ab|8|entity|C0016674|France|geoa|||France|||0|1000|1580|1586
SE|25462424|RESULTS|ab|8|entity|C0027778|Netherlands|geoa|||Netherlands|||0|861|1603|1614
SE|25462424|RESULTS|ab|8|entity|C0037747|Spain|geoa|||Spain|||0|1000|1631|1636
SE|25462424|RESULTS|ab|8|relation|0|0|C0038663|Suicide attempt|mobd|mobd|||suicide attempt|||0|1000|1512|1527|SPEC|ISA||1512|1576|0|0|C0012634|Disease|dsyn|dsyn|||disorder|||0|861|1568|1576

SE|25462424|LIMITATIONS|ab|9|text|1649|1744|LIMITATIONS: Mental disorders were assessed with the CIDI 3.0 and not psychiatric evaluations.
SE|25462424|LIMITATIONS|ab|9|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1649|1660
SE|25462424|LIMITATIONS|ab|9|entity|C0004936|Mental disorders|mobd|||Mental disorders|||0|1000|1662|1678
SE|25462424|LIMITATIONS|ab|9|entity|C0451085|Composite international diagnostic interview|inpr|||CIDI|||0|827|1702|1706
SE|25462424|LIMITATIONS|ab|9|entity|C1518422|Not|ftcn|||not|||0|890|1715|1718
SE|25462424|LIMITATIONS|ab|9|entity|C0846574|Psychiatric evaluation|diap|||psychiatric evaluations|||0|890|1719|1742

SE|25462424|LIMITATIONS|ab|10|text|1744|1840|Suicidality does not fully represent more important clinical events, such as suicide mortality.
SE|25462424|LIMITATIONS|ab|10|entity|C0438696|Suicidal|fndg|||Suicidality|||0|928|1744|1755
SE|25462424|LIMITATIONS|ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1761|1764
SE|25462424|LIMITATIONS|ab|10|entity|C0205172|More|ftcn|||more|||0|775|1781|1785
SE|25462424|LIMITATIONS|ab|10|entity|C0205210|Clinical|qlco|||clinical|||0|775|1796|1804
SE|25462424|LIMITATIONS|ab|10|entity|C0441471|Events|evnt|||events|||0|775|1805|1811
SE|25462424|LIMITATIONS|ab|10|entity|C0683917|suicide mortality|qnco|||suicide mortality|||0|1000|1821|1838

SE|25462424|CONCLUSIONS|ab|11|text|1840|2031|CONCLUSIONS: Consistent across European countries, internalizing disorders are more common among women and externalizing disorders among men, whereas gender differences in suicidality varied.
SE|25462424|CONCLUSIONS|ab|11|entity|C0454713|European country|geoa|||European countries|||0|983|1871|1889
SE|25462424|CONCLUSIONS|ab|11|entity|C0012634|Disease|dsyn|||disorders|||0|861|1905|1914
SE|25462424|CONCLUSIONS|ab|11|entity|C0205172|More|ftcn|||more|||0|888|1919|1923
SE|25462424|CONCLUSIONS|ab|11|entity|C0205214|Common|qnco|||common|||0|888|1924|1930
SE|25462424|CONCLUSIONS|ab|11|entity|C0043210|Woman|popg|||women|||0|1000|1937|1942
SE|25462424|CONCLUSIONS|ab|11|entity|C0012634|Disease|dsyn|||disorders|||0|861|1961|1970
SE|25462424|CONCLUSIONS|ab|11|entity|C0025266|Male population group|popg|||men|||0|1000|1977|1980
SE|25462424|CONCLUSIONS|ab|11|entity|C0036866|Sex Characteristics|orga|||gender differences|||0|1000|1990|2008
SE|25462424|CONCLUSIONS|ab|11|entity|C0438696|Suicidal|fndg|||suicidality|||0|928|2012|2023
SE|25462424|CONCLUSIONS|ab|11|relation|5|2|C0012634|Disease|dsyn|dsyn|||disorders|||0|861|1905|1914|PREP|PROCESS_OF||1931|1936|5|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1937|1942
SE|25462424|CONCLUSIONS|ab|11|relation|7|1|C0012634|Disease|dsyn|dsyn|||disorders|||0|861|1961|1970|PREP|PROCESS_OF||1971|1976|3|1|C0025266|Male population group|popg,humn|humn|||men|||0|1000|1977|1980
SE|25462424|CONCLUSIONS|ab|11|relation|9|3|C0012634|Disease|dsyn|dsyn|||disorders|||0|861|1961|1970|PREP|COEXISTS_WITH||2009|2011|1|1|C0438696|Suicidal|fndg|fndg|||suicidality|||0|928|2012|2023


SE|25462425||ti|1|text|21|109|Long term course of bipolar I disorder in India: using retrospective life chart method.
SE|25462425||ti|1|entity|C0443252|Long-term|tmco|||Long term|||0|901|21|30
SE|25462425||ti|1|entity|C0750729|Course|tmco|||course|||0|901|31|37
SE|25462425||ti|1|entity|C0853193|Bipolar I disorder|mobd|||bipolar I disorder|||0|1000|41|59
SE|25462425||ti|1|entity|C0021201|India|geoa|||India|||0|1000|63|68
SE|25462425||ti|1|entity|C1514923|Retrospective|qlco|||retrospective|||0|833|76|89
SE|25462425||ti|1|entity|C0376558|Life|idcn|||life|||0|833|90|94
SE|25462425||ti|1|entity|C0684240|chart|inpr|||chart|||0|833|95|100
SE|25462425||ti|1|entity|C0025663|Methods|inpr|||method|||0|833|101|107

SE|25462425|BACKGROUND|ab|1|text|115|281|BACKGROUND: There are grounds to believe that the course of bipolar disorder may be different in tropical countries such as India when compared to temperate nations.
SE|25462425|BACKGROUND|ab|1|entity|C0750729|Course|tmco|||course|||0|1000|165|171
SE|25462425|BACKGROUND|ab|1|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|175|191
SE|25462425|BACKGROUND|ab|1|entity|C1547020|*Difference|qnco|||different|||0|928|199|208
SE|25462425|BACKGROUND|ab|1|entity|C0454664|Country|geoa|||countries|||0|861|221|230
SE|25462425|BACKGROUND|ab|1|entity|C0021201|India|geoa|||India|||0|1000|239|244
SE|25462425|BACKGROUND|ab|1|entity|C0039475|Temperance|inbe|||temperate|||0|737|262|271
SE|25462425|BACKGROUND|ab|1|entity|C1555720|Nation|orgt|||nations|||0|737|272|279
SE|25462425|BACKGROUND|ab|1|relation|0|0|C0021201|India|geoa|geoa|||India|||0|1000|239|244|SPEC|ISA||221|244|0|0|C0454664|Country|geoa|geoa|||countries|||0|861|221|230

SE|25462425|BACKGROUND|ab|2|text|281|364|There is a dearth of literature about the course of bipolar I disorder from India.
SE|25462425|BACKGROUND|ab|2|entity|C0023866|Literature|inpr|||literature|||0|1000|302|312
SE|25462425|BACKGROUND|ab|2|entity|C0750729|Course|tmco|||course|||0|1000|323|329
SE|25462425|BACKGROUND|ab|2|entity|C0853193|Bipolar I disorder|mobd|||bipolar I disorder|||0|1000|333|351
SE|25462425|BACKGROUND|ab|2|entity|C0021201|India|geoa|||India|||0|1000|357|362

SE|25462425|METHODS|ab|3|text|364|455|METHODS: This study was conducted in a multispecialty teaching hospital in southern India.
SE|25462425|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|364|371
SE|25462425|METHODS|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|378|383
SE|25462425|METHODS|ab|3|entity|C0000872|Academic Medical Centers|hcro,mnob|||teaching hospital|||0|901|418|435
SE|25462425|METHODS|ab|3|entity|C0021201|India|geoa|||India|||0|861|448|453
SE|25462425|METHODS|ab|3|relation|2|1|C0000872|Academic Medical Centers|hcro,mnob|hcro|||teaching hospital|||0|901|418|435|PREP|LOCATION_OF||398|400|2|1|C0008972|Clinical Research|resa|resa|||study|||0|1000|378|383

SE|25462425|METHODS|ab|4|text|455|599|Patients with a DSM-IV TR diagnosis of bipolar I disorder, confirmed using SCID-I, with a minimum duration of illness of 3 years were assessed.
SE|25462425|METHODS|ab|4|entity|C0030705|Patients|podg|||Patients|||0|1000|455|463
SE|25462425|METHODS|ab|4|entity|C0220952|DSM-IV|inpr|||DSM-IV|||0|824|471|477
SE|25462425|METHODS|ab|4|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|824|481|490
SE|25462425|METHODS|ab|4|entity|C0853193|Bipolar I disorder|mobd|||bipolar I disorder|||0|1000|494|512
SE|25462425|METHODS|ab|4|entity|C0085110|Severe Combined Immunodeficiency|dsyn|||SCID|||0|1000|530|534
SE|25462425|METHODS|ab|4|entity|C1524031|Minimum|qlco|||minimum|||0|888|545|552
SE|25462425|METHODS|ab|4|entity|C0449238|Duration|tmco|||duration|||0|888|553|561
SE|25462425|METHODS|ab|4|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|565|572
SE|25462425|METHODS|ab|4|entity|C0439234|year|tmco|||years|||0|888|578|583

SE|25462425|METHODS|ab|5|text|599|824|Information was gathered on demographic and clinical variables, and the life course of episodes was charted using the National Institute of Mental Health - Life Chart Methodology Clinician Retrospective Chart (NIMH-LCM-CRC).
SE|25462425|METHODS|ab|5|entity|C1533716|Information|idcn|||Information|||0|1000|599|610
SE|25462425|METHODS|ab|5|entity|C0011298|Demography|ocdi|||demographic|||0|928|627|638
SE|25462425|METHODS|ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|872|643|651
SE|25462425|METHODS|ab|5|entity|C0439828|Variable|qlco|||variables|||0|872|652|661
SE|25462425|METHODS|ab|5|entity|C1510618|Life Course|tmco|||life course|||0|1000|671|682
SE|25462425|METHODS|ab|5|entity|C0332189|Episode of|tmco|||episodes|||0|1000|686|694
SE|25462425|METHODS|ab|5|entity|C0021622|Institutes|orgt|||Institute|||0|565|726|735
SE|25462425|METHODS|ab|5|entity|C0376558|Life|idcn|||Life|||0|565|755|759
SE|25462425|METHODS|ab|5|entity|C1554212|health chart|idcn|||Health - Life Chart|||0|565|746|765
SE|25462425|METHODS|ab|5|entity|C0025664|Methodology|inpr|||Methodology|||0|565|766|777
SE|25462425|METHODS|ab|5|entity|C1550470|clinician|idcn|||Clinician|||0|565|778|787
SE|25462425|METHODS|ab|5|entity|C1514923|Retrospective|qlco|||Retrospective|||0|565|788|801
SE|25462425|METHODS|ab|5|entity|C0024266|Lymphocytic Choriomeningitis|dsyn|||NIMH-LCM|||0|660|809|817

SE|25462425|RESULTS|ab|6|text|824|894|RESULTS: A total of 150 patients with bipolar disorder were included.
SE|25462425|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|824|831
SE|25462425|RESULTS|ab|6|entity|C0439175|% of total|qnco|||total|||0|1000|835|840
SE|25462425|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|848|856
SE|25462425|RESULTS|ab|6|entity|C0005586|Bipolar Disorder|mobd|||bipolar disorder|||0|1000|862|878
SE|25462425|RESULTS|ab|6|relation|1|1|C0005586|Bipolar Disorder|mobd|mobd|||bipolar disorder|||0|1000|862|878|PREP|PROCESS_OF||857|861|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|848|856

SE|25462425|RESULTS|ab|7|text|894|953|The mean age at onset of illness was 24.8 (+/- 8.2) years.
SE|25462425|RESULTS|ab|7|entity|C0001779|Age|orga|||age|||0|861|903|906
SE|25462425|RESULTS|ab|7|entity|C0332162|Onset|qlco|||onset|||0|1000|910|915
SE|25462425|RESULTS|ab|7|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|919|926
SE|25462425|RESULTS|ab|7|entity|C0439234|year|tmco|||years|||0|1000|946|951

SE|25462425|RESULTS|ab|8|text|953|1103|Mania was the first episode in a majority (85%) of the cases, and was the most frequent episode in the course of the illness, followed by depression.
SE|25462425|RESULTS|ab|8|entity|C0338831|Manic|mobd|||Mania|||0|1000|953|958
SE|25462425|RESULTS|ab|8|entity|C0439615|First episode|tmco|||first episode|||0|1000|967|980
SE|25462425|RESULTS|ab|8|entity|C0680220|majority|socb|||majority|||0|1000|986|994
SE|25462425|RESULTS|ab|8|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|1008|1013
SE|25462425|RESULTS|ab|8|entity|C0205393|Most|qnco|||most|||0|623|1027|1031
SE|25462425|RESULTS|ab|8|entity|C0332183|Frequent|tmco|||frequent|||0|623|1032|1040
SE|25462425|RESULTS|ab|8|entity|C0750729|Course|tmco|||course|||0|1000|1056|1062
SE|25462425|RESULTS|ab|8|entity|C0221423|Finding / disorder|ftcn|||illness|||0|1000|1070|1077
SE|25462425|RESULTS|ab|8|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1091|1101
SE|25462425|RESULTS|ab|8|relation|7|7|C0338831|Manic|mobd|mobd|||Mania|||0|1000|953|958|VERB|PRECEDES||1079|1087|1|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|1091|1101

SE|25462425|RESULTS|ab|9|text|1103|1212|Patients spent an average of 11.1% of the illness duration in a mood episode, most commonly a manic episode.
SE|25462425|RESULTS|ab|9|entity|C0030705|Patients|podg|||Patients|||0|1000|1103|1111
SE|25462425|RESULTS|ab|9|entity|C1510992|Average|qnco|||average|||0|1000|1121|1128
SE|25462425|RESULTS|ab|9|entity|C0221423|Finding / disorder|ftcn|||illness|||0|888|1145|1152
SE|25462425|RESULTS|ab|9|entity|C0449238|Duration|tmco|||duration|||0|888|1153|1161
SE|25462425|RESULTS|ab|9|entity|C0026516|Mood|menp|||mood|||0|694|1167|1171
SE|25462425|RESULTS|ab|9|entity|C0205393|Most|qnco|||most|||0|861|1181|1185
SE|25462425|RESULTS|ab|9|entity|C0349208|[X]Manic episode, unspecified|mobd|||manic episode|||0|1000|1197|1210

SE|25462425|RESULTS|ab|10|text|1212|1277|The median duration of manic or depressive episode was 2 months.
SE|25462425|RESULTS|ab|10|entity|C0449238|Duration|tmco|||duration|||0|861|1223|1231
SE|25462425|RESULTS|ab|10|entity|C0338831|Manic|mobd|||manic|||0|1000|1235|1240
SE|25462425|RESULTS|ab|10|entity|C0349217|Depressive episode, unspecified|mobd|||depressive episode|||0|1000|1244|1262
SE|25462425|RESULTS|ab|10|entity|C1442456|2 Months|tmco|||2 months|||0|1000|1267|1275

SE|25462425|RESULTS|ab|11|text|1277|1417|Median time to recurrence after the first episode was 21 months (inter-quartile range of 10-60 months), and was shorter for women than men.
SE|25462425|RESULTS|ab|11|entity|C0040223|Time|tmco|||time|||0|861|1284|1288
SE|25462425|RESULTS|ab|11|entity|C0034897|Recurrence|phpr|||recurrence|||0|1000|1292|1302
SE|25462425|RESULTS|ab|11|entity|C0439615|First episode|tmco|||first episode|||0|1000|1313|1326
SE|25462425|RESULTS|ab|11|entity|C0439231|month|tmco|||months|||0|861|1334|1340
SE|25462425|RESULTS|ab|11|entity|C0205103|Intermediate|spco|||inter|||0|802|1342|1347
SE|25462425|RESULTS|ab|11|entity|C1514721|Range|qnco|||range|||0|802|1357|1362
SE|25462425|RESULTS|ab|11|entity|C0439231|month|tmco|||months|||0|827|1372|1378
SE|25462425|RESULTS|ab|11|entity|C0043210|Woman|popg|||women|||0|1000|1401|1406
SE|25462425|RESULTS|ab|11|entity|C0025266|Male population group|popg|||men|||0|1000|1412|1415

SE|25462425|LIMITATIONS|ab|12|text|1417|1506|LIMITATIONS: The hospital based sample from a particular region limits generalizability.
SE|25462425|LIMITATIONS|ab|12|entity|C0449295|Limitation|ftcn|||LIMITATIONS|||0|966|1417|1428
SE|25462425|LIMITATIONS|ab|12|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|1000|1434|1442
SE|25462425|LIMITATIONS|ab|12|entity|C0205147|Region|spco|||region|||0|861|1474|1480

SE|25462425|LIMITATIONS|ab|13|text|1506|1580|Recall bias may be present in this retrospective information based study.
SE|25462425|LIMITATIONS|ab|13|entity|C0242568|Biases|idcn|||bias|||0|861|1513|1517
SE|25462425|LIMITATIONS|ab|13|entity|C0150312|Present|qnco|||present|||0|1000|1525|1532
SE|25462425|LIMITATIONS|ab|13|entity|C1514923|Retrospective|qlco|||retrospective|||0|888|1541|1554
SE|25462425|LIMITATIONS|ab|13|entity|C1533716|Information|idcn|||information|||0|888|1555|1566
SE|25462425|LIMITATIONS|ab|13|entity|C0008972|Clinical Research|resa|||study|||0|1000|1573|1578

SE|25462425|LIMITATIONS|ab|14|text|1580|1795|Medical illness, personality disorders, other Axis I psychiatric disorders (apart from substance use disorder) and influence of adherence to treatment on the course of the disorder were not assessed systematically.
SE|25462425|LIMITATIONS|ab|14|entity|C0205476|Medical|ftcn|||Medical|||0|888|1580|1587
SE|25462425|LIMITATIONS|ab|14|entity|C0221423|Finding / disorder|ftcn|||illness|||0|888|1588|1595
SE|25462425|LIMITATIONS|ab|14|entity|C0031212|Personality Disorders|mobd|||personality disorders|||0|1000|1597|1618
SE|25462425|LIMITATIONS|ab|14|entity|C1522496|Axis|spco|||Axis|||0|1000|1626|1630
SE|25462425|LIMITATIONS|ab|14|entity|C0004936|Mental disorders|mobd|||psychiatric disorders|||0|1000|1633|1654
SE|25462425|LIMITATIONS|ab|14|entity|C0038586|Substance Use Disorders|mobd|||substance use disorder|||0|1000|1667|1689
SE|25462425|LIMITATIONS|ab|14|entity|C0750729|Course|tmco|||course|||0|1000|1738|1744
SE|25462425|LIMITATIONS|ab|14|entity|C0012634|Disease|dsyn|||disorder|||0|1000|1752|1760
SE|25462425|LIMITATIONS|ab|14|entity|C1518422|Not|ftcn|||not|||0|1000|1766|1769

SE|25462425|CONCLUSIONS|ab|15|text|1795|2031|CONCLUSIONS: Bipolar I disorder among Indian patients has a course characterized by predominantly manic episodes, which is in line with previous reports from tropical countries and substantially different from that of temperate regions.
SE|25462425|CONCLUSIONS|ab|15|entity|C0853193|Bipolar I disorder|mobd|||Bipolar I disorder|||0|1000|1808|1826
SE|25462425|CONCLUSIONS|ab|15|entity|C0422792|Indian ethnic group|popg|||Indian|||0|888|1833|1839
SE|25462425|CONCLUSIONS|ab|15|entity|C0030705|Patients|podg|||patients|||0|888|1840|1848
SE|25462425|CONCLUSIONS|ab|15|entity|C0750729|Course|tmco|||course|||0|1000|1855|1861
SE|25462425|CONCLUSIONS|ab|15|entity|C0349208|[X]Manic episode, unspecified|mobd|||manic episodes|||0|884|1893|1907
SE|25462425|CONCLUSIONS|ab|15|entity|C0205132|Linear|spco|||line|||0|1000|1921|1925
SE|25462425|CONCLUSIONS|ab|15|entity|C0205156|Previous|tmco|||previous|||0|888|1931|1939
SE|25462425|CONCLUSIONS|ab|15|entity|C0684224|Report (document)|inpr|||reports|||0|888|1940|1947
SE|25462425|CONCLUSIONS|ab|15|entity|C0454664|Country|geoa|||countries|||0|861|1962|1971
SE|25462425|CONCLUSIONS|ab|15|entity|C1547020|*Difference|qnco|||different|||0|789|1990|1999
SE|25462425|CONCLUSIONS|ab|15|entity|C0039475|Temperance|inbe|||temperate|||0|836|2013|2022
SE|25462425|CONCLUSIONS|ab|15|entity|C0205147|Region|spco|||regions|||0|836|2023|2030
SE|25462425|CONCLUSIONS|ab|15|relation|2|1|C0853193|Bipolar I disorder|mobd|mobd|||Bipolar I disorder|||0|1000|1808|1826|PREP|PROCESS_OF||1827|1832|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|1840|1848
SE|25462425|CONCLUSIONS|ab|15|relation|6|1|C0349208|[X]Manic episode, unspecified|mobd|mobd|||manic episodes|||0|884|1893|1907|VERB|COEXISTS_WITH||1862|1875|4|3|C0853193|Bipolar I disorder|mobd|mobd|||Bipolar I disorder|||0|1000|1808|1826


SE|25462426||ti|1|text|21|104|Clinical and psychometric validation of the psychotic depression assessment scale.
SE|25462426||ti|1|entity|C0205210|Clinical|qlco|||Clinical|||0|1000|21|29
SE|25462426||ti|1|entity|C0033920|Psychometrics|diap|||psychometric|||0|888|34|46
SE|25462426||ti|1|entity|C1519941|Validation|resa|||validation|||0|888|47|57
SE|25462426||ti|1|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|861|65|74
SE|25462426||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|861|86|96
SE|25462426||ti|1|entity|C0679604|depression scale|diap,inpr|||depression assessment scale|||0|861|75|102

SE|25462426|BACKGROUND|ab|1|text|110|441|BACKGROUND: Recent studies have indicated that the 11-item Psychotic Depression Assessment Scale (PDAS), consisting of the 6-item melancholia subscale (HAM-D6) of the Hamilton Depression Rating Scale and 5 psychosis items from the Brief Psychiatric Rating Scale (BPRS), is a valid measure for the severity of psychotic depression.
SE|25462426|BACKGROUND|ab|1|entity|C0332185|Recent|tmco|||Recent|||0|872|122|128
SE|25462426|BACKGROUND|ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|129|136
SE|25462426|BACKGROUND|ab|1|entity|C0033975|Psychotic Disorders|mobd|||Psychotic|||0|762|169|178
SE|25462426|BACKGROUND|ab|1|entity|C0220825|Evaluation|ftcn|||Assessment|||0|762|190|200
SE|25462426|BACKGROUND|ab|1|entity|C0679604|depression scale|diap,inpr|||Depression Assessment Scale|||0|762|179|206
SE|25462426|BACKGROUND|ab|1|entity|C0025193|Melancholia|mobd|||melancholia|||0|645|240|251
SE|25462426|BACKGROUND|ab|1|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM-D6|||0|888|262|268
SE|25462426|BACKGROUND|ab|1|entity|C1332648|Chemokine (C-C Motif) Receptor 9|aapp,rcpt|||HAM-D6|||0|888|262|268
SE|25462426|BACKGROUND|ab|1|entity|C0871208|Rating|resa|||Rating|||0|824|297|303
SE|25462426|BACKGROUND|ab|1|entity|C0679604|depression scale|diap,inpr|||Depression Rating Scale|||0|824|286|309
SE|25462426|BACKGROUND|ab|1|entity|C0033975|Psychotic Disorders|mobd|||psychosis|||0|623|316|325
SE|25462426|BACKGROUND|ab|1|entity|C0029941|Brief Psychiatric Rating Scale|diap,inpr|||Brief Psychiatric Rating Scale|||0|1000|341|371
SE|25462426|BACKGROUND|ab|1|entity|C0079809|Measures|qnco|||measure|||0|861|391|398
SE|25462426|BACKGROUND|ab|1|entity|C0439793|Severities|qlco|||severity|||0|1000|407|415
SE|25462426|BACKGROUND|ab|1|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|888|419|428
SE|25462426|BACKGROUND|ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|429|439

SE|25462426|BACKGROUND|ab|2|text|441|571|The aim of this study was to subject the PDAS, and its depression (HAM-D6) and psychosis (BPRS5) subscales to further validation.
SE|25462426|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|457|462
SE|25462426|BACKGROUND|ab|2|entity|C0033975|Psychotic Disorders|mobd|||PDAS|||0|861|482|486
SE|25462426|BACKGROUND|ab|2|entity|C0220825|Evaluation|ftcn|||PDAS|||0|861|482|486
SE|25462426|BACKGROUND|ab|2|entity|C0679604|depression scale|diap,inpr|||PDAS|||0|861|482|486
SE|25462426|BACKGROUND|ab|2|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|496|506
SE|25462426|BACKGROUND|ab|2|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM-D6|||0|888|508|514
SE|25462426|BACKGROUND|ab|2|entity|C1332648|Chemokine (C-C Motif) Receptor 9|aapp,rcpt|||HAM-D6|||0|888|508|514
SE|25462426|BACKGROUND|ab|2|entity|C0033975|Psychotic Disorders|mobd|||psychosis|||0|1000|520|529
SE|25462426|BACKGROUND|ab|2|entity|C1517331|Further|spco|||further|||0|888|551|558
SE|25462426|BACKGROUND|ab|2|entity|C1519941|Validation|resa|||validation|||0|888|559|569

SE|25462426|METHODS|ab|3|text|571|701|METHODS: Patients diagnosed with psychotic depression at Danish psychiatric hospitals participated in semi-structured interviews.
SE|25462426|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|571|578
SE|25462426|METHODS|ab|3|entity|C0030705|Patients|podg|||Patients|||0|1000|580|588
SE|25462426|METHODS|ab|3|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|888|604|613
SE|25462426|METHODS|ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|614|624
SE|25462426|METHODS|ab|3|entity|C0020021|Psychiatric hospital|hcro,mnob|||psychiatric hospitals|||0|901|635|656
SE|25462426|METHODS|ab|3|entity|C0681913|structured interview|resa|||structured interviews|||0|884|678|699
SE|25462426|METHODS|ab|3|relation|3|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|614|624|VERB|PROCESS_OF||589|598|2|1|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|580|588

SE|25462426|METHODS|ab|4|text|701|965|Video recordings of these interviews were assessed by two experienced psychiatrists (global severity rating of psychotic depression, depressive symptoms and psychotic symptoms) and by two young physicians (rating on 27 symptom items, including the 11 PDAS items).
SE|25462426|METHODS|ab|4|entity|C0042650|Video Recording|hcpp,mnob|||Video recordings|||0|1000|701|717
SE|25462426|METHODS|ab|4|entity|C0021822|Interview|inpr,resa|||interviews|||0|1000|727|737
SE|25462426|METHODS|ab|4|entity|C0205448|Two|qnco|||two|||0|828|755|758
SE|25462426|METHODS|ab|4|entity|C0596545|experience|menp|||experienced|||0|828|759|770
SE|25462426|METHODS|ab|4|entity|C0033872|Psychiatrist|prog|||psychiatrists|||0|828|771|784
SE|25462426|METHODS|ab|4|entity|C0205246|Generalized|spco|||global|||0|851|786|792
SE|25462426|METHODS|ab|4|entity|C0439793|Severities|qlco|||severity|||0|851|793|801
SE|25462426|METHODS|ab|4|entity|C0871208|Rating|resa|||rating|||0|851|802|808
SE|25462426|METHODS|ab|4|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|888|812|821
SE|25462426|METHODS|ab|4|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|822|832
SE|25462426|METHODS|ab|4|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|834|853
SE|25462426|METHODS|ab|4|entity|C0871189|Psychotic symptom|sosy|||psychotic symptoms|||0|1000|858|876
SE|25462426|METHODS|ab|4|entity|C0205448|Two|qnco|||two|||0|851|885|888
SE|25462426|METHODS|ab|4|entity|C0332239|Young|tmco|||young|||0|851|889|894
SE|25462426|METHODS|ab|4|entity|C0031831|Physicians|prog|||physicians|||0|851|895|905
SE|25462426|METHODS|ab|4|entity|C0871208|Rating|resa|||rating|||0|1000|907|913
SE|25462426|METHODS|ab|4|entity|C1457887|Symptoms|sosy|||symptom|||0|660|920|927
SE|25462426|METHODS|ab|4|entity|C0033975|Psychotic Disorders|mobd|||PDAS|||0|595|952|956
SE|25462426|METHODS|ab|4|entity|C0220825|Evaluation|ftcn|||PDAS|||0|595|952|956
SE|25462426|METHODS|ab|4|entity|C0679604|depression scale|diap,inpr|||PDAS|||0|595|952|956
SE|25462426|METHODS|ab|4|relation|0|0|C0596545|experience|menp|menp|||experienced|||0|828|759|770|MOD/HEAD|PROCESS_OF||759|784|0|0|C0033872|Psychiatrist|prog,humn|humn|||psychiatrists|||0|828|771|784

SE|25462426|METHODS|ab|5|text|965|1163|The clinical validity and responsiveness of the PDAS and its subscales was investigated by Spearman correlation analysis of the global severity ratings and the PDAS, HAM-D6, and BPRS5 total scores.
SE|25462426|METHODS|ab|5|entity|C0205210|Clinical|qlco|||clinical|||0|694|969|977
SE|25462426|METHODS|ab|5|entity|C0205342|Responsive|ftcn|||responsiveness|||0|928|991|1005
SE|25462426|METHODS|ab|5|entity|C0033975|Psychotic Disorders|mobd|||PDAS|||0|861|1013|1017
SE|25462426|METHODS|ab|5|entity|C0220825|Evaluation|ftcn|||PDAS|||0|861|1013|1017
SE|25462426|METHODS|ab|5|entity|C0679604|depression scale|diap,inpr|||PDAS|||0|861|1013|1017
SE|25462426|METHODS|ab|5|entity|C0010101|Correlation Study|inpr,resa|||correlation analysis|||0|901|1065|1085
SE|25462426|METHODS|ab|5|entity|C0205246|Generalized|spco|||global|||0|840|1093|1099
SE|25462426|METHODS|ab|5|entity|C0439793|Severities|qlco|||severity|||0|840|1100|1108
SE|25462426|METHODS|ab|5|entity|C0871208|Rating|resa|||ratings|||0|840|1109|1116
SE|25462426|METHODS|ab|5|entity|C0033975|Psychotic Disorders|mobd|||PDAS|||0|861|1125|1129
SE|25462426|METHODS|ab|5|entity|C0220825|Evaluation|ftcn|||PDAS|||0|861|1125|1129
SE|25462426|METHODS|ab|5|entity|C0679604|depression scale|diap,inpr|||PDAS|||0|861|1125|1129
SE|25462426|METHODS|ab|5|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM-D6|||0|888|1131|1137
SE|25462426|METHODS|ab|5|entity|C1332648|Chemokine (C-C Motif) Receptor 9|aapp,rcpt|||HAM-D6|||0|888|1131|1137
SE|25462426|METHODS|ab|5|entity|C0439175|% of total|qnco|||total|||0|790|1149|1154
SE|25462426|METHODS|ab|5|entity|C0449820|Score|qnco|||scores|||0|790|1155|1161

SE|25462426|METHODS|ab|6|text|1163|1253|The unidimensionality of the scales was tested by item response theory analysis (Mokken).
SE|25462426|METHODS|ab|6|entity|C0870753|Item Response Theory|inpr,resa|||item response theory|||0|916|1213|1233
SE|25462426|METHODS|ab|6|entity|C0936012|Analysis|resa|||analysis|||0|916|1234|1242

SE|25462426|RESULTS|ab|7|text|1253|1413|RESULTS: Ratings from 39 participants with unipolar psychotic depression and nine participants with bipolar psychotic depression were included in the analysis.
SE|25462426|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1253|1260
SE|25462426|RESULTS|ab|7|entity|C0871208|Rating|resa|||Ratings|||0|966|1262|1269
SE|25462426|RESULTS|ab|7|entity|C0679646|Participant|popg|||participants|||0|827|1278|1290
SE|25462426|RESULTS|ab|7|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|901|1305|1314
SE|25462426|RESULTS|ab|7|entity|C0041696|Unipolar Depression|mobd|||unipolar psychotic depression|||0|901|1296|1325
SE|25462426|RESULTS|ab|7|entity|C0205455|Nine|qnco|||nine|||0|872|1330|1334
SE|25462426|RESULTS|ab|7|entity|C0679646|Participant|popg|||participants|||0|872|1335|1347
SE|25462426|RESULTS|ab|7|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|901|1361|1370
SE|25462426|RESULTS|ab|7|entity|C0005587|Depression, Bipolar|mobd|||bipolar psychotic depression|||0|901|1353|1381
SE|25462426|RESULTS|ab|7|entity|C0936012|Analysis|resa|||analysis|||0|1000|1403|1411
SE|25462426|RESULTS|ab|7|relation|0|0|C0005587|Depression, Bipolar|mobd|mobd|||bipolar psychotic depression|||0|901|1353|1381|MOD/HEAD|ISA||1361|1381|0|0|C0033975|Psychotic Disorders|mobd|mobd|||psychotic|||0|901|1361|1370
SE|25462426|RESULTS|ab|7|relation|0|0|C0041696|Unipolar Depression|mobd|mobd|||unipolar psychotic depression|||0|901|1296|1325|MOD/HEAD|ISA||1305|1325|0|0|C0033975|Psychotic Disorders|mobd|mobd|||psychotic|||0|901|1305|1314
SE|25462426|RESULTS|ab|7|relation|2|1|C0005587|Depression, Bipolar|mobd|mobd|||bipolar psychotic depression|||0|901|1353|1381|PREP|PROCESS_OF||1348|1352|5|1|C0679646|Participant|popg,humn|humn|||participants|||0|872|1335|1347
SE|25462426|RESULTS|ab|7|relation|4|1|C0041696|Unipolar Depression|mobd|mobd|||unipolar psychotic depression|||0|901|1296|1325|PREP|PROCESS_OF||1291|1295|3|1|C0679646|Participant|popg,humn|humn|||participants|||0|827|1278|1290

SE|25462426|RESULTS|ab|8|text|1413|1668|The Spearman correlation analysis indicated that the PDAS, HAM-D6 and BPRS5 were clinically valid (correlation coefficients from 0.78 to 0.85, p<0.001) and responsive (correlation coefficients from 0.72 to 0.86, p<0.001) measures of psychotic depression.
SE|25462426|RESULTS|ab|8|entity|C0010101|Correlation Study|inpr,resa|||correlation analysis|||0|901|1426|1446
SE|25462426|RESULTS|ab|8|entity|C0033975|Psychotic Disorders|mobd|||PDAS|||0|861|1466|1470
SE|25462426|RESULTS|ab|8|entity|C0220825|Evaluation|ftcn|||PDAS|||0|861|1466|1470
SE|25462426|RESULTS|ab|8|entity|C0679604|depression scale|diap,inpr|||PDAS|||0|861|1466|1470
SE|25462426|RESULTS|ab|8|entity|C0030481|Tropical Spastic Paraparesis|dsyn|||HAM-D6|||0|888|1472|1478
SE|25462426|RESULTS|ab|8|entity|C1332648|Chemokine (C-C Motif) Receptor 9|aapp,rcpt|||HAM-D6|||0|888|1472|1478
SE|25462426|RESULTS|ab|8|entity|C1547015|*Coefficient|qnco|||coefficients|||0|827|1524|1536
SE|25462426|RESULTS|ab|8|entity|C0205342|Responsive|ftcn|||responsive|||0|1000|1569|1579
SE|25462426|RESULTS|ab|8|entity|C1547015|*Coefficient|qnco|||coefficients|||0|827|1593|1605
SE|25462426|RESULTS|ab|8|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|888|1646|1655
SE|25462426|RESULTS|ab|8|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1656|1666
SE|25462426|RESULTS|ab|8|relation|6|4|C0030481|Tropical Spastic Paraparesis|dsyn|dsyn|||HAM-D6|||0|888|1472|1478|ADJ|AFFECTS||1569|1579|2|2|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|1656|1666

SE|25462426|RESULTS|ab|9|text|1668|1740|According to the Mokken analysis, all three scales were unidimensional.
SE|25462426|RESULTS|ab|9|entity|C0936012|Analysis|resa|||analysis|||0|861|1692|1700
SE|25462426|RESULTS|ab|9|entity|C0205449|Three|qnco|||three|||0|888|1706|1711

SE|25462426|CONCLUSIONS|ab|10|text|1740|1921|CONCLUSIONS: The clinical validity, responsiveness and unidimensionality of the PDAS and its subscales were confirmed in an independent sample of patients with psychotic depression.
SE|25462426|CONCLUSIONS|ab|10|entity|C0205210|Clinical|qlco|||clinical|||0|694|1757|1765
SE|25462426|CONCLUSIONS|ab|10|entity|C0205342|Responsive|ftcn|||responsiveness|||0|928|1776|1790
SE|25462426|CONCLUSIONS|ab|10|entity|C0033975|Psychotic Disorders|mobd|||PDAS|||0|861|1820|1824
SE|25462426|CONCLUSIONS|ab|10|entity|C0220825|Evaluation|ftcn|||PDAS|||0|861|1820|1824
SE|25462426|CONCLUSIONS|ab|10|entity|C0679604|depression scale|diap,inpr|||PDAS|||0|861|1820|1824
SE|25462426|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1886|1894
SE|25462426|CONCLUSIONS|ab|10|entity|C0033975|Psychotic Disorders|mobd|||psychotic|||0|888|1900|1909
SE|25462426|CONCLUSIONS|ab|10|entity|C0011581|Depressive disorder|mobd|||depression|||0|888|1910|1920
SE|25462426|CONCLUSIONS|ab|10|relation|1|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|888|1910|1920|PREP|PROCESS_OF||1895|1899|8|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1886|1894


SE|25462427||ti|1|text|21|138|Do community health workers perceive mechanisms associated with the success of community case management of malaria?
SE|25462427||ti|1|entity|C0018684|Health|idcn|||health|||0|901|34|40
SE|25462427||ti|1|entity|C0009484|Community Workers|prog|||community health workers|||0|901|24|48
SE|25462427||ti|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|58|68
SE|25462427||ti|1|entity|C0597535|Success|socb|||success|||0|1000|89|96
SE|25462427||ti|1|entity|C0009462|Community|geoa|||community|||0|802|100|109
SE|25462427||ti|1|entity|C0024530|Malaria|dsyn|||malaria|||0|1000|129|136

SE|25462427||ti|2|text|138|177|A qualitative study from Burkina Faso.
SE|25462427||ti|2|entity|C0949415|Qualitative Research|resa|||qualitative study|||0|1000|140|157
SE|25462427||ti|2|entity|C0006409|Burkina Faso|geoa|||Burkina Faso|||0|1000|163|175

SE|25462427||ab|1|text|183|312|The use of community health workers to administer prompt treatments is gaining popularity in most sub-Saharan African countries.
SE|25462427||ab|1|entity|C0018684|Health|idcn|||health|||0|901|204|210
SE|25462427||ab|1|entity|C0009484|Community Workers|prog|||community health workers|||0|901|194|218
SE|25462427||ab|1|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|888|240|250
SE|25462427||ab|1|entity|C0679970|popularity|socb|||popularity|||0|1000|262|272
SE|25462427||ab|1|entity|C0542339|Inferior|spco|||sub|||0|834|281|284
SE|25462427||ab|1|entity|C0205654|Sahara|geoa|||Saharan|||0|834|285|292
SE|25462427||ab|1|entity|C0454695|African country|geoa|||African countries|||0|834|293|310
SE|25462427||ab|1|relation|3|1|C0087111|Therapeutic procedure|topp|topp|||treatments|||0|888|240|250|VERB|ADMINISTERED_TO||222|232|2|1|C0009484|Community Workers|prog,humn|humn|||community health workers|||0|901|194|218

SE|25462427||ab|2|text|312|492|Their performance is a key challenge because it varies considerably, depending on the context, while being closely associated with the effectiveness of case management strategies.
SE|25462427||ab|2|entity|C0597198|Performance|inbe|||performance|||0|1000|318|329
SE|25462427||ab|2|entity|C1554080|Key|idcn|||key|||0|888|335|338
SE|25462427||ab|2|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|447|460

SE|25462427||ab|3|text|492|569|What determines community health workers' performance is still under debate.
SE|25462427||ab|3|entity|C0018684|Health|idcn|||health|||0|861|518|524
SE|25462427||ab|3|entity|C0009484|Community Workers|prog|||community health workers|||0|861|508|532
SE|25462427||ab|3|entity|C0597198|Performance|inbe|||performance|||0|861|534|545
SE|25462427||ab|3|entity|C0870392|Debates|acty|||debate|||0|966|561|567

SE|25462427||ab|4|text|569|744|Based on a realist perspective, a systematic review recently hypothesized that several mechanisms are associated with good performance and successful community interventions.
SE|25462427||ab|4|entity|C0237815|Realism|idcn|||realist|||0|594|580|587
SE|25462427||ab|4|entity|C0220922|systematic|ftcn|||systematic|||0|694|603|613
SE|25462427||ab|4|entity|C0332185|Recent|tmco|||recently|||0|1000|621|629
SE|25462427||ab|4|entity|C0443302|Several|qnco|||several|||0|888|648|655
SE|25462427||ab|4|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|656|666
SE|25462427||ab|4|entity|C0205170|Good|qlco|||good|||0|888|687|691
SE|25462427||ab|4|entity|C0597198|Performance|inbe|||performance|||0|888|692|703
SE|25462427||ab|4|entity|C1272703|Successful|qlco|||successful|||0|851|708|718
SE|25462427||ab|4|entity|C0009462|Community|geoa|||community|||0|851|719|728
SE|25462427||ab|4|entity|C1273869|Intervention regimes|hlca|||interventions|||0|851|729|742

SE|25462427||ab|5|text|744|987|In order to empirically investigate this hypothesis and confront it with the reality, we conducted a study in Burkina Faso, where in 2010 health authorities have implemented a national program introducing community case management of malaria.
SE|25462427||ab|5|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|785|795
SE|25462427||ab|5|entity|C0871222|Reality|idcn|||reality|||0|1000|821|828
SE|25462427||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|845|850
SE|25462427||ab|5|entity|C0006409|Burkina Faso|geoa|||Burkina Faso|||0|1000|854|866
SE|25462427||ab|5|entity|C1273803|Health Authority|hcro|||health authorities|||0|884|882|900
SE|25462427||ab|5|entity|C1292748|Introduces|ftcn|||introducing|||0|774|937|948
SE|25462427||ab|5|entity|C0009462|Community|geoa|||community|||0|774|949|958
SE|25462427||ab|5|entity|C0683739|program management|ocac|||program introducing community case management|||0|774|929|974
SE|25462427||ab|5|entity|C0024530|Malaria|dsyn|||malaria|||0|1000|978|985
SE|25462427||ab|5|relation|3|1|C1273803|Health Authority|hcro|hcro|||health authorities|||0|884|882|900|PREP|LOCATION_OF||874|876|5|2|C0008972|Clinical Research|resa|resa|||study|||0|1000|845|850

SE|25462427||ab|6|text|987|1124|The objective was to assess the presence of the mechanisms in community health workers, and explore the influence of contextual factors.
SE|25462427||ab|6|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|1035|1045
SE|25462427||ab|6|entity|C0018684|Health|idcn|||health|||0|901|1059|1065
SE|25462427||ab|6|entity|C0009484|Community Workers|prog|||community health workers|||0|901|1049|1073
SE|25462427||ab|6|entity|C0542559|contextual factors|ftcn|||contextual factors|||0|1000|1104|1122

SE|25462427||ab|7|text|1124|1287|In 2012, we conducted semi-structured interviews with 35 community health workers from a study area established in two similar health districts (Kaya and Zorgho).
SE|25462427||ab|7|entity|C0681913|structured interview|resa|||structured interviews|||0|884|1151|1172
SE|25462427||ab|7|entity|C0018684|Health|idcn|||health|||0|824|1191|1197
SE|25462427||ab|7|entity|C0009484|Community Workers|prog|||community health workers|||0|824|1181|1205
SE|25462427||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|888|1213|1218
SE|25462427||ab|7|entity|C0205146|Area|spco|||area|||0|888|1219|1223
SE|25462427||ab|7|entity|C0205448|Two|qnco|||two|||0|584|1239|1242
SE|25462427||ab|7|entity|C0018684|Health|idcn|||health|||0|584|1251|1257

SE|25462427||ab|8|text|1287|1439|Results suggest that they perceive most of the mechanisms, except the sense of being valued by the health system and accountability to village members.
SE|25462427||ab|8|entity|C1274040|result|ftcn|||Results|||0|966|1287|1294
SE|25462427||ab|8|entity|C0205393|Most|qnco|||most|||0|1000|1322|1326
SE|25462427||ab|8|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|1334|1344
SE|25462427||ab|8|entity|C1456613|Health System|hcro|||health system|||0|1000|1386|1399
SE|25462427||ab|8|entity|C0078889|Accountability|idcn|||accountability|||0|1000|1404|1418
SE|25462427||ab|8|entity|C0562518|Village|geoa|||village|||0|872|1422|1429
SE|25462427||ab|8|entity|C0680022|member|popg|||members|||0|872|1430|1437

SE|25462427||ab|9|text|1439|1585|Analysis shows that drug stock-outs and past experiences of community health workers simultaneously influence the presence of several mechanisms.
SE|25462427||ab|9|entity|C0936012|Analysis|resa|||Analysis|||0|1000|1439|1447
SE|25462427||ab|9|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|785|1459|1463
SE|25462427||ab|9|entity|C0439787|Out|spco|||outs|||0|785|1470|1474
SE|25462427||ab|9|entity|C1444637|Past|tmco|||past|||0|872|1479|1483
SE|25462427||ab|9|entity|C0596545|experience|menp|||experiences|||0|872|1484|1495
SE|25462427||ab|9|entity|C0018684|Health|idcn|||health|||0|901|1509|1515
SE|25462427||ab|9|entity|C0009484|Community Workers|prog|||community health workers|||0|901|1499|1523
SE|25462427||ab|9|entity|C0443302|Several|qnco|||several|||0|888|1565|1572
SE|25462427||ab|9|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|1573|1583

SE|25462427||ab|10|text|1585|1771|The lack of integration between governmental and non-governmental interventions and the overall socio-economic deprivation, were also identified as influencing the mechanisms' presence.
SE|25462427||ab|10|entity|C0332268|Lacking|qlco|||lack|||0|1000|1589|1593
SE|25462427||ab|10|entity|C0018104|Government|orgt|||governmental|||0|928|1617|1629
SE|25462427||ab|10|entity|C0018104|Government|orgt|||governmental|||0|754|1638|1650
SE|25462427||ab|10|entity|C1273869|Intervention regimes|hlca|||interventions|||0|754|1651|1664
SE|25462427||ab|10|entity|C1561607|Overall|qlco|||overall|||0|824|1673|1680
SE|25462427||ab|10|entity|C0032854|Poverty|grpa|||economic deprivation|||0|824|1687|1707
SE|25462427||ab|10|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|888|1749|1759

SE|25462427||ab|11|text|1771|2000|By focusing on community health workers' agency, this study puts the influence of the context back at the core of the performance debate and raises the question of their ability to perform well in scaled-up anti-malaria programs.
SE|25462427||ab|11|entity|C0000936|Visual Accommodation|clna|||focusing|||0|1000|1774|1782
SE|25462427||ab|11|entity|C0018684|Health|idcn|||health|||0|852|1796|1802
SE|25462427||ab|11|entity|C0009484|Community Workers|prog|||community health workers|||0|852|1786|1810
SE|25462427||ab|11|entity|C0237463|Agencies|orgt|||agency|||0|852|1812|1818
SE|25462427||ab|11|entity|C0008972|Clinical Research|resa|||study|||0|1000|1825|1830
SE|25462427||ab|11|entity|C0004600|Back|blor|||back|||0|1000|1865|1869
SE|25462427||ab|11|entity|C0444669|Core|spco|||core|||0|1000|1877|1881
SE|25462427||ab|11|entity|C0597198|Performance|inbe|||performance|||0|872|1889|1900
SE|25462427||ab|11|entity|C0870392|Debates|acty|||debate|||0|872|1901|1907
SE|25462427||ab|11|entity|C0085732|Ability|orga|||ability|||0|1000|1941|1948
SE|25462427||ab|11|entity|C0205170|Good|qlco|||well|||0|1000|1960|1964
SE|25462427||ab|11|entity|C0222045|Integumentary scale|bpoc|||scaled|||0|581|1968|1974
SE|25462427||ab|11|entity|C0024530|Malaria|dsyn|||malaria|||0|581|1983|1990


SE|25462428||ti|1|text|21|183|Implementation of effective cigarette health warning labels among low and middle income countries: state capacity, path-dependency and tobacco industry activity.
SE|25462428||ti|1|entity|C0677453|Cigarette|mnob|||cigarette|||0|787|49|58
SE|25462428||ti|1|entity|C0018684|Health|idcn|||health|||0|787|59|65
SE|25462428||ti|1|entity|C0444598|Middle|spco|||middle|||0|762|95|101
SE|25462428||ti|1|entity|C1331016|Low income|qlco|||low and middle income|||0|762|87|108
SE|25462428||ti|1|entity|C0454664|Country|geoa|||countries|||0|762|109|118
SE|25462428||ti|1|entity|C1442792|State|ftcn|||state|||0|888|120|125
SE|25462428||ti|1|entity|C1516240|Capacity|qnco|||capacity|||0|888|126|134
SE|25462428||ti|1|entity|C0030664|Pathology|bmod|||path|||0|694|136|140
SE|25462428||ti|1|entity|C0376630|Tobacco Industry|orgt|||tobacco industry|||0|901|156|172

SE|25462428||ab|1|text|189|476|We investigates the effects of ratifying the WHO Framework Convention of Tobacco Control (FTCT), state capacity, path-dependency and tobacco industry activity on the implementation of effective health warning labels (HWL) on cigarette packs among low and middle income countries (LMIC).
SE|25462428||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|209|216
SE|25462428||ab|1|entity|C0086047|Conferences|hcpp|||Convention|||0|704|248|258
SE|25462428||ab|1|entity|C0040329|Tobacco|hops,orch,phsu|||Tobacco|||0|704|262|269
SE|25462428||ab|1|entity|C0243148|control|ftcn|||Control|||0|704|270|277
SE|25462428||ab|1|entity|C1442792|State|ftcn|||state|||0|888|286|291
SE|25462428||ab|1|entity|C1516240|Capacity|qnco|||capacity|||0|888|292|300
SE|25462428||ab|1|entity|C0030664|Pathology|bmod|||path|||0|694|302|306
SE|25462428||ab|1|entity|C0376630|Tobacco Industry|orgt|||tobacco industry|||0|901|322|338
SE|25462428||ab|1|entity|C0018684|Health|idcn|||health|||0|798|383|389
SE|25462428||ab|1|entity|C0677453|Cigarette|mnob|||cigarette|||0|888|414|423
SE|25462428||ab|1|entity|C0441122|Pack|medd|||packs|||0|888|424|429
SE|25462428||ab|1|entity|C0444598|Middle|spco|||middle|||0|762|444|450
SE|25462428||ab|1|entity|C1331016|Low income|qlco|||low and middle income|||0|762|436|457
SE|25462428||ab|1|entity|C0454664|Country|geoa|||countries|||0|762|458|467
SE|25462428||ab|1|relation|0|0|C0441122|Pack|medd|medd|||packs|||0|888|424|429|MOD/HEAD|USES||414|429|0|0|C0677453|Cigarette|mnob|mnob|||cigarette|||0|888|414|423

SE|25462428||ab|2|text|476|726|Using logistic regression in separate analyses for FCTC Article 11 compliant HWLs and graphic HWLs (GHWL), we found that the odds of FCTC compliance increased by a factor of 1.31 for each year after FCTC entered into force in the country (p < 0.01).
SE|25462428||ab|2|entity|C0206031|Logistic Regression|resa|||logistic regression|||0|1000|482|501
SE|25462428||ab|2|entity|C0443299|Separate|spco|||separate|||0|872|505|513
SE|25462428||ab|2|entity|C0936012|Analysis|resa|||analyses|||0|872|514|522
SE|25462428||ab|2|entity|C0566588|Compliant|ftcn|||compliant|||0|637|543|552
SE|25462428||ab|2|entity|C1521761|Factor|ftcn|||factor|||0|1000|640|646
SE|25462428||ab|2|entity|C0439234|year|tmco|||year|||0|1000|664|668
SE|25462428||ab|2|entity|C0441722|Force|phpr|||force|||0|1000|693|698
SE|25462428||ab|2|entity|C0454664|Country|geoa|||country|||0|1000|706|713

SE|25462428||ab|3|text|726|833|The odds of passing GHWLs increased by a factor of 1.46 (p < 0.05) per year after FCTC entered into force.
SE|25462428||ab|3|entity|C1521761|Factor|ftcn|||factor|||0|1000|767|773
SE|25462428||ab|3|entity|C0439234|year|tmco|||year|||0|1000|797|801
SE|25462428||ab|3|entity|C0441722|Force|phpr|||force|||0|1000|826|831

SE|25462428||ab|4|text|833|955|The weaker the capacity of the states were, the less likely they were to have implemented FCTC compliant HWLs (p < 0.05).
SE|25462428||ab|4|entity|C0004093|Asthenia|sosy|||weaker|||0|966|837|843
SE|25462428||ab|4|entity|C1516240|Capacity|qnco|||capacity|||0|1000|848|856
SE|25462428||ab|4|entity|C1442792|State|ftcn|||states|||0|966|864|870
SE|25462428||ab|4|entity|C0566588|Compliant|ftcn|||compliant|||0|645|928|937

SE|25462428||ab|5|text|955|1082|The countries with voluntary HWLs in 1992 were less likely (OR = 0.19, p < 0.01) to comply with FCTC 21 years later (in 2013).
SE|25462428||ab|5|entity|C0454664|Country|geoa|||countries|||0|1000|959|968
SE|25462428||ab|5|entity|C0439656|Voluntary|inbe|||voluntary|||0|694|974|983
SE|25462428||ab|5|entity|C0439234|year|tmco|||years|||0|827|1059|1064
SE|25462428||ab|5|entity|C0205087|Late|tmco|||later|||0|966|1065|1070

SE|25462428||ab|6|text|1082|1130|The FCTC has promoted HWL policies among LMICs.
SE|25462428||ab|6|entity|C0018684|Health|idcn|||HWL|||0|824|1104|1107
SE|25462428||ab|6|entity|C0242456|Policy|inpr|||policies|||0|1000|1108|1116

SE|25462428||ab|7|text|1130|1203|Public health regulations require investments in broader state capacity.
SE|25462428||ab|7|entity|C0018684|Health|idcn|||health|||0|790|1137|1143
SE|25462428||ab|7|entity|C0220905|regulatory|rnlw|||regulations|||0|790|1144|1155
SE|25462428||ab|7|entity|C0021953|Investments|mnob|||investments|||0|1000|1164|1175
SE|25462428||ab|7|entity|C0332464|Widening|spco|||broader|||0|840|1179|1186
SE|25462428||ab|7|entity|C1442792|State|ftcn|||state|||0|840|1187|1192
SE|25462428||ab|7|entity|C1516240|Capacity|qnco|||capacity|||0|840|1193|1201

SE|25462428||ab|8|text|1203|1344|As the theory of path-dependency predicts voluntary agreements have long lasting influence on the direction of tobacco control in a country.
SE|25462428||ab|8|entity|C0871935|Theories|idcn|||theory|||0|966|1210|1216
SE|25462428||ab|8|entity|C0030664|Pathology|bmod|||path|||0|694|1220|1224
SE|25462428||ab|8|entity|C0439656|Voluntary|inbe|||voluntary|||0|872|1245|1254
SE|25462428||ab|8|entity|C0680240|Agreement|socb|||agreements|||0|872|1255|1265
SE|25462428||ab|8|entity|C0205166|Long|qlco|||long|||0|660|1271|1275
SE|25462428||ab|8|entity|C0449738|Direction|spco|||direction|||0|1000|1301|1310
SE|25462428||ab|8|entity|C0040329|Tobacco|hops,orch,phsu|||tobacco|||0|888|1314|1321
SE|25462428||ab|8|entity|C0243148|control|ftcn|||control|||0|888|1322|1329
SE|25462428||ab|8|entity|C0454664|Country|geoa|||country|||0|1000|1335|1342

SE|25462428||ab|9|text|1344|1440|Adopting voluntary HWL policies reduced likelihood of having FCTC compliant HWLs decades later.
SE|25462428||ab|9|entity|C0439656|Voluntary|inbe|||voluntary|||0|861|1353|1362
SE|25462428||ab|9|entity|C0018684|Health|idcn|||HWL|||0|861|1363|1366
SE|25462428||ab|9|entity|C0242456|Policy|inpr|||policies|||0|1000|1367|1375
SE|25462428||ab|9|entity|C0566588|Compliant|ftcn|||compliant|||0|637|1410|1419

SE|25462428||ab|10|text|1440|1682|The fact that voluntary agreements delayed effective tobacco regulations suggests that policymakers must be careful of accepting industry efforts for voluntary agreements in other areas of public health as well, such as alcohol and junk food.
SE|25462428||ab|10|entity|C0439656|Voluntary|inbe|||voluntary|||0|872|1454|1463
SE|25462428||ab|10|entity|C0680240|Agreement|socb|||agreements|||0|872|1464|1474
SE|25462428||ab|10|entity|C0040329|Tobacco|hops,orch,phsu|||tobacco|||0|851|1493|1500
SE|25462428||ab|10|entity|C0220905|regulatory|rnlw|||regulations|||0|851|1501|1512
SE|25462428||ab|10|entity|C1272684|Accepted|qlco|||accepting|||0|840|1559|1568
SE|25462428||ab|10|entity|C0021267|Industry|ocac|||industry|||0|840|1569|1577
SE|25462428||ab|10|entity|C0439656|Voluntary|inbe|||voluntary|||0|872|1590|1599
SE|25462428||ab|10|entity|C0680240|Agreement|socb|||agreements|||0|872|1600|1610
SE|25462428||ab|10|entity|C0018684|Health|idcn|||health|||0|861|1636|1642
SE|25462428||ab|10|entity|C0205170|Good|qlco|||well|||0|1000|1646|1650
SE|25462428||ab|10|entity|C0001962|Ethanol|orch,phsu|||alcohol|||0|1000|1660|1667
SE|25462428||ab|10|entity|C0681578|junk food|food|||junk food|||0|1000|1672|1681


SE|25462429||ti|1|text|21|161|The impact of interventions to promote physical activity in urban green space: a systematic review and recommendations for future research.
SE|25462429||ti|1|entity|C1273869|Intervention regimes|hlca|||interventions|||0|1000|35|48
SE|25462429||ti|1|entity|C0026606|Physical activity|dora|||physical activity|||0|1000|60|77
SE|25462429||ti|1|entity|C0442529|Urban|geoa|||urban|||0|660|81|86
SE|25462429||ti|1|entity|C0220922|systematic|ftcn|||systematic|||0|694|102|112
SE|25462429||ti|1|entity|C0034866|Recommendation|idcn|||recommendations|||0|1000|124|139
SE|25462429||ti|1|entity|C0016884|Future|tmco|||future|||0|888|144|150
SE|25462429||ti|1|entity|C0035168|research|resa|||research|||0|888|151|159

SE|25462429||ab|1|text|167|303|Evidence is mounting on the association between the built environment and physical activity (PA) with a call for intervention research.
SE|25462429||ab|1|entity|C0014406|Environment|spco|||environment|||0|861|225|236
SE|25462429||ab|1|entity|C0026606|Physical activity|dora|||physical activity|||0|1000|241|258
SE|25462429||ab|1|entity|C0376154|Skin callus|acab|||call|||0|900|271|275
SE|25462429||ab|1|entity|C1273869|Intervention regimes|hlca|||intervention|||0|888|280|292
SE|25462429||ab|1|entity|C0035168|research|resa|||research|||0|888|293|301

SE|25462429||ab|2|text|303|425|A broader approach which recognizes the role of supportive environments that can make healthy choices easier is required.
SE|25462429||ab|2|entity|C0332464|Widening|spco|||broader|||0|872|305|312
SE|25462429||ab|2|entity|C0449445|Approach|spco|||approach|||0|872|313|321
SE|25462429||ab|2|entity|C0035820|Role|socb|||role|||0|1000|343|347
SE|25462429||ab|2|entity|C0014406|Environment|spco|||environments|||0|861|362|374
SE|25462429||ab|2|entity|C0018684|Health|idcn|||healthy|||0|623|389|396
SE|25462429||ab|2|entity|C0332219|Easy|qlco|||easier|||0|966|405|411

SE|25462429||ab|3|text|425|543|A systematic review was undertaken to assess the effectiveness of interventions to encourage PA in urban green space.
SE|25462429||ab|3|entity|C0220922|systematic|ftcn|||systematic|||0|694|427|437
SE|25462429||ab|3|entity|C1280519|Effectiveness|qlco|||effectiveness|||0|1000|474|487
SE|25462429||ab|3|entity|C1273869|Intervention regimes|hlca|||interventions|||0|1000|491|504
SE|25462429||ab|3|entity|C0026606|Physical activity|dora|||PA|||0|1000|518|520
SE|25462429||ab|3|entity|C0442529|Urban|geoa|||urban|||0|660|524|529

SE|25462429||ab|4|text|543|708|Five databases were searched independently by two reviewers using search terms relating to 'physical activity', 'urban green space' and 'intervention' in July 2014.
SE|25462429||ab|4|entity|C0205451|Five|qnco|||Five|||0|888|543|547
SE|25462429||ab|4|entity|C0242356|Databases|inpr|||databases|||0|888|548|557
SE|25462429||ab|4|entity|C0205448|Two|qnco|||two|||0|694|589|592
SE|25462429||ab|4|entity|C1552603|search|idcn|||search|||0|872|609|615
SE|25462429||ab|4|entity|C1515273|Term|tmco|||terms|||0|872|616|621
SE|25462429||ab|4|entity|C0026606|Physical activity|dora|||physical activity|||0|1000|635|652
SE|25462429||ab|4|entity|C0442529|Urban|geoa|||urban|||0|660|656|661
SE|25462429||ab|4|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|680|692

SE|25462429||ab|5|text|708|973|Eligibility criteria included: (i) intervention to encourage PA in urban green space which involved either a physical change to the urban green space or a PA intervention to promote use of urban green space or a combination of both; and (ii) primary outcome of PA.
SE|25462429||ab|5|entity|C0243161|criteria|inpr|||criteria|||0|861|720|728
SE|25462429||ab|5|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|743|755
SE|25462429||ab|5|entity|C0026606|Physical activity|dora|||PA|||0|1000|769|771
SE|25462429||ab|5|entity|C0442529|Urban|geoa|||urban|||0|660|775|780
SE|25462429||ab|5|entity|C0205485|Physical|ftcn|||physical|||0|888|817|825
SE|25462429||ab|5|entity|C0442529|Urban|geoa|||urban|||0|660|840|845
SE|25462429||ab|5|entity|C0026606|Physical activity|dora|||PA|||0|901|863|865
SE|25462429||ab|5|entity|C1273869|Intervention regimes|hlca|||intervention|||0|901|866|878
SE|25462429||ab|5|entity|C0442529|Urban|geoa|||urban|||0|660|897|902
SE|25462429||ab|5|entity|C0205195|Combined|qlco|||combination|||0|1000|920|931
SE|25462429||ab|5|entity|C1274040|result|ftcn|||outcome|||0|888|958|965
SE|25462429||ab|5|entity|C0026606|Physical activity|dora|||PA|||0|1000|969|971

SE|25462429||ab|6|text|973|1023|Of the 2405 studies identified, 12 were included.
SE|25462429||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|827|985|992

SE|25462429||ab|7|text|1023|1192|There was some evidence (4/9 studies showed positive effect) to support built environment only interventions for encouraging use and increasing PA in urban green space.
SE|25462429||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|793|1052|1059
SE|25462429||ab|7|entity|C1446409|Positive|qlco|||positive|||0|888|1067|1075
SE|25462429||ab|7|entity|C1280500|Effect|qlco|||effect|||0|888|1076|1082
SE|25462429||ab|7|entity|C0026118|Milieu Therapy|topp|||environment only interventions|||0|822|1101|1131
SE|25462429||ab|7|entity|C0442808|Increasing|ftcn|||increasing|||0|901|1156|1166
SE|25462429||ab|7|entity|C0026606|Physical activity|dora|||PA|||0|901|1167|1169
SE|25462429||ab|7|entity|C0442529|Urban|geoa|||urban|||0|660|1173|1178

SE|25462429||ab|8|text|1192|1412|There was more promising evidence (3/3 studies showed positive effect) to support PAprograms or PA programs combined with a physical change to the built environment, for increasing urban green space use and PA of users.
SE|25462429||ab|8|entity|C0205172|More|ftcn|||more|||0|1000|1202|1206
SE|25462429||ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|785|1231|1238
SE|25462429||ab|8|entity|C1446409|Positive|qlco|||positive|||0|888|1246|1254
SE|25462429||ab|8|entity|C1280500|Effect|qlco|||effect|||0|888|1255|1261
SE|25462429||ab|8|entity|C0026606|Physical activity|dora|||PA|||0|734|1288|1290
SE|25462429||ab|8|entity|C0205485|Physical|ftcn|||physical|||0|888|1316|1324
SE|25462429||ab|8|entity|C0014406|Environment|spco|||environment|||0|861|1345|1356
SE|25462429||ab|8|entity|C0442808|Increasing|ftcn|||increasing|||0|762|1362|1372
SE|25462429||ab|8|entity|C0442529|Urban|geoa|||urban|||0|762|1373|1378
SE|25462429||ab|8|entity|C0026606|Physical activity|dora|||PA|||0|1000|1399|1401
SE|25462429||ab|8|entity|C1548600|User|idcn|||users|||0|966|1405|1410

SE|25462429||ab|9|text|1412|1688|Recommendations for future research include the need for longer term follow-up post-intervention, adequate control groups, sufficiently powered studies, and consideration of the social environment, which was identified as a significantly under-utilized resource in this area.
SE|25462429||ab|9|entity|C0034866|Recommendation|idcn|||Recommendations|||0|1000|1412|1427
SE|25462429||ab|9|entity|C0016884|Future|tmco|||future|||0|888|1432|1438
SE|25462429||ab|9|entity|C0035168|research|resa|||research|||0|888|1439|1447
SE|25462429||ab|9|entity|C0027552|Needs|qlco|||need|||0|1000|1460|1464
SE|25462429||ab|9|entity|C1517942|Longterm Follow-up|hlca|||longer term follow-up|||0|828|1469|1490
SE|25462429||ab|9|entity|C1273869|Intervention regimes|hlca|||intervention|||0|828|1496|1508
SE|25462429||ab|9|entity|C0205411|Adequate|qlco|||adequate|||0|828|1510|1518
SE|25462429||ab|9|entity|C0009932|Control Groups|grup|||control groups|||0|828|1519|1533
SE|25462429||ab|9|entity|C0008972|Clinical Research|resa|||studies|||0|793|1556|1563
SE|25462429||ab|9|entity|C0037414|Social Environment|idcn|||social environment|||0|1000|1590|1608
SE|25462429||ab|9|entity|C0035201|Resources|idcn|||resource|||0|1000|1665|1673
SE|25462429||ab|9|entity|C0205146|Area|spco|||area|||0|1000|1682|1686

SE|25462429||ab|10|text|1688|1839|Interventions that involve the use of PA programs combined with a physical change to the built environment are likely to have a positive effect on PA.
SE|25462429||ab|10|entity|C1273869|Intervention regimes|hlca|||Interventions|||0|1000|1688|1701
SE|25462429||ab|10|entity|C0026606|Physical activity|dora|||PA|||0|734|1726|1728
SE|25462429||ab|10|entity|C0205485|Physical|ftcn|||physical|||0|888|1754|1762
SE|25462429||ab|10|entity|C0014406|Environment|spco|||environment|||0|861|1783|1794
SE|25462429||ab|10|entity|C1446409|Positive|qlco|||positive|||0|888|1816|1824
SE|25462429||ab|10|entity|C1280500|Effect|qlco|||effect|||0|888|1825|1831
SE|25462429||ab|10|entity|C0026606|Physical activity|dora|||PA|||0|1000|1835|1837

SE|25462429||ab|11|text|1839|1903|Robust evaluations of such interventions are urgently required.
SE|25462429||ab|11|entity|C0220825|Evaluation|ftcn|||evaluations|||0|861|1846|1857
SE|25462429||ab|11|entity|C1273869|Intervention regimes|hlca|||interventions|||0|1000|1866|1879

SE|25462429||ab|12|text|1903|2043|The findings provide a platform to inform the design, implementation and evaluation of future urban green space and PAintervention research.
SE|25462429||ab|12|entity|C0243095|Finding|ftcn|||findings|||0|1000|1907|1915
SE|25462429||ab|12|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|1976|1986
SE|25462429||ab|12|entity|C0016884|Future|tmco|||future|||0|583|1990|1996
SE|25462429||ab|12|entity|C0442529|Urban|geoa|||urban|||0|583|1997|2002
SE|25462429||ab|12|entity|C0035168|research|resa|||research|||0|861|2034|2042


SE|25462431||ti|1|text|21|87|Delineating monoclonal antibody specificity by mass spectrometry.
SE|25462431||ti|1|entity|C0003250|Monoclonal Antibodies|aapp,imft|||monoclonal antibody|||0|901|33|52
SE|25462431||ti|1|entity|C0037791|Specificity|qnco|||specificity|||0|901|53|64
SE|25462431||ti|1|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|1000|68|85

SE|25462431||ab|1|text|93|230|UNLABELLED: Generation of monoclonal antibody (mAb) libraries against antigens in complex matrices can prove a valuable analytical tool.
SE|25462431||ab|1|entity|C0079411|Generations|tmco|||Generation|||0|966|105|115
SE|25462431||ab|1|entity|C0003250|Monoclonal Antibodies|aapp,imft|||monoclonal antibody|||0|901|119|138
SE|25462431||ab|1|entity|C0023621|Libraries|mnob,orgt|||libraries|||0|901|145|154
SE|25462431||ab|1|entity|C0003320|Antigens|bacs,imft|||antigens|||0|1000|163|171
SE|25462431||ab|1|entity|C0439855|Complex|qlco|||complex|||0|872|175|182
SE|25462431||ab|1|entity|C0331858|Matrix|hcro|||matrices|||0|872|183|191
SE|25462431||ab|1|entity|C0336791|Tool|mnob|||tool|||0|827|224|228

SE|25462431||ab|2|text|230|336|However, delineating the specificity of newly generated antibodies is the limiting step of the procedure.
SE|25462431||ab|2|entity|C0037791|Specificity|qnco|||specificity|||0|1000|255|266
SE|25462431||ab|2|entity|C0750546|NEWLY|idcn|||newly|||0|802|270|275
SE|25462431||ab|2|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|802|286|296
SE|25462431||ab|2|entity|C0439801|Limited|ftcn|||limiting|||0|872|304|312
SE|25462431||ab|2|entity|C1261552|Step|ftcn|||step|||0|872|313|317
SE|25462431||ab|2|entity|C0184661|Procedures|hlca|||procedure|||0|1000|325|334

SE|25462431||ab|3|text|336|530|Here, we propose a strategy for mAb production by injecting mice with complex biological fluid and mAb characterization by coupling immunoaffinity techniques with Mass spectrometry (immuno-MS).
SE|25462431||ab|3|entity|C1328929|monoclonal antibody production|resa|||mAb production|||0|1000|368|382
SE|25462431||ab|3|entity|C0026809|Mus|mamm|||mice|||0|861|396|400
SE|25462431||ab|3|entity|C0439855|Complex|qlco|||complex|||0|851|406|413
SE|25462431||ab|3|entity|C0205460|biological|ftcn|||biological|||0|851|414|424
SE|25462431||ab|3|entity|C0302908|Liquid substance|sbst|||fluid|||0|851|425|430
SE|25462431||ab|3|entity|C0003250|Monoclonal Antibodies|aapp,imft|||mAb|||0|734|435|438
SE|25462431||ab|3|entity|C0010222|Couples|famg|||coupling|||0|785|459|467
SE|25462431||ab|3|entity|C0025664|Methodology|inpr|||techniques|||0|785|483|493
SE|25462431||ab|3|entity|C0037813|Spectrum Analysis, Mass|lbpr|||Mass spectrometry|||0|1000|499|516

SE|25462431||ab|4|text|530|610|Mice were immunized against fractionated seminal plasma and mAbs were produced.
SE|25462431||ab|4|entity|C0026809|Mus|mamm|||Mice|||0|1000|530|534
SE|25462431||ab|4|entity|C1519232|Seminal|clna|||seminal|||0|790|571|578
SE|25462431||ab|4|entity|C0032105|Plasma|bdsu|||plasma|||0|790|579|585
SE|25462431||ab|4|entity|C0003250|Monoclonal Antibodies|aapp,imft|||mAbs|||0|966|590|594

SE|25462431||ab|5|text|610|817|Different immuno-MS protocols based on four types of solid support (i.e. polystyrene microtiter plates, NHS-activated agarose beads, tosyl-activated magnetic beads and MSIATM pipette tips) were established.
SE|25462431||ab|5|entity|C1547020|*Difference|qnco|||Different|||0|574|610|619
SE|25462431||ab|5|entity|C0205450|Four|qnco|||four|||0|888|649|653
SE|25462431||ab|5|entity|C0332307|Type - attribute|qlco|||types|||0|888|654|659
SE|25462431||ab|5|entity|C0205208|Solid|qlco|||solid|||0|888|663|668
SE|25462431||ab|5|entity|C0032604|Polystyrenes|bodm,orch|||polystyrene|||0|742|683|694
SE|25462431||ab|5|entity|C1139930|Plates|medd|||plates|||0|742|706|712
SE|25462431||ab|5|entity|||gngm|4810|NHS|NHS|||0|764|714|717
SE|25462431||ab|5|entity|C1515877|Activate|ftcn|||activated|||0|764|718|727
SE|25462431||ab|5|entity|C0036681|Sepharose|bodm,carb|||agarose|||0|764|728|735
SE|25462431||ab|5|entity|C0991566|Beads|bodm|||beads|||0|764|736|741
SE|25462431||ab|5|entity|C1515877|Activate|ftcn|||activated|||0|813|749|758
SE|25462431||ab|5|entity|C1328924|magnetic beads|npop|||magnetic beads|||0|813|759|773
SE|25462431||ab|5|entity|C0182299|Pipette Tips|medd|||pipette tips|||0|901|785|797
SE|25462431||ab|5|relation|4|0|||gngm,aapp|gngm|4810|NHS|NHS|||0|764|714|717|ADJ|STIMULATES||718|727|4|0|C0036681|Sepharose|bodm,carb|carb|||agarose|||0|764|728|735

SE|25462431||ab|6|text|817|1055|A well-characterized mouse monoclonal anti-KLK3 (PSA) Ab was used as a model to evaluate each protocol's robustness and reproducibility and to establish a set of criteria which would allow antigen characterization of newly developed Abs.
SE|25462431||ab|6|entity|C0205170|Good|qlco|||well|||0|740|819|823
SE|25462431||ab|6|entity|C0025914|House mice|mamm|||mouse|||0|740|838|843
SE|25462431||ab|6|entity|C0746619|MONOCLONAL|fndg|||monoclonal|||0|740|844|854
SE|25462431||ab|6|entity|C0138741|Prostate-Specific Antigen|aapp,enzy,imft|354|KLK3|KLK3|||0|740|860|864
SE|25462431||ab|6|entity|C1366489|KLK3 gene|gngm|354|KLK3|PSA|||0|1000|866|869
SE|25462431||ab|6|entity|C0026336|Study models|inpr,resd|||model|||0|1000|888|893
SE|25462431||ab|6|entity|C0442711|Protocols documentation|inpr|||protocol's|||0|694|911|921
SE|25462431||ab|6|entity|C1514863|Reproducibility|qlco|||reproducibility|||0|1000|937|952
SE|25462431||ab|6|entity|C0243161|criteria|inpr|||criteria|||0|1000|979|987
SE|25462431||ab|6|entity|C0003320|Antigens|bacs,imft|||antigen|||0|694|1006|1013
SE|25462431||ab|6|entity|C0750546|NEWLY|idcn|||newly|||0|802|1034|1039
SE|25462431||ab|6|entity|C0000833|Abscess|patf|||Abs|||0|802|1050|1053

SE|25462431||ab|7|text|1055|1133|Three of the newly generated Abs were analyzed using our optimized protocols.
SE|25462431||ab|7|entity|C0205449|Three|qnco|||Three|||0|1000|1055|1060
SE|25462431||ab|7|entity|C0750546|NEWLY|idcn|||newly|||0|802|1068|1073
SE|25462431||ab|7|entity|C0000833|Abscess|patf|||Abs|||0|802|1084|1087

SE|25462431||ab|8|text|1133|1229|Analysis revealed that all assay configurations used were capable of antibody characterization.
SE|25462431||ab|8|entity|C0936012|Analysis|resa|||Analysis|||0|1000|1133|1141
SE|25462431||ab|8|entity|C1510438|Assay|lbpr|||assay|||0|694|1160|1165
SE|25462431||ab|8|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|694|1202|1210

SE|25462431||ab|9|text|1229|1351|Furthermore, low-abundance antigens (e.g. ribonuclease T2) could be identified as efficiently as the high-abundance ones.
SE|25462431||ab|9|entity|C0205251|low|qlco|||low|||0|802|1242|1245
SE|25462431||ab|9|entity|C0003320|Antigens|bacs,imft|||antigens|||0|802|1256|1264
SE|25462431||ab|9|entity|C0073249|ribonuclease T2|aapp,enzy|8635|RNASET2|ribonuclease T2|||0|1000|1271|1286
SE|25462431||ab|9|entity|C0205250|High|qlco|||high|||0|785|1330|1334
SE|25462431||ab|9|entity|C0205447|One|qnco|||ones|||0|785|1345|1349

SE|25462431||ab|10|text|1351|1578|Our data suggest that complex biological samples can be used for the production of mAbs, which will facilitate the analysis of their proteome, while the established immuno-MS protocols can offer efficient mAb characterization.
SE|25462431||ab|10|entity|C1511726|Data|idcn|||data|||0|1000|1355|1359
SE|25462431||ab|10|entity|C0439855|Complex|qlco|||complex|||0|623|1373|1380
SE|25462431||ab|10|entity|C0205460|biological|ftcn|||biological|||0|623|1381|1391
SE|25462431||ab|10|entity|C0033268|production|ocac|||production|||0|1000|1420|1430
SE|25462431||ab|10|entity|C0003250|Monoclonal Antibodies|aapp,imft|||mAbs|||0|966|1434|1438
SE|25462431||ab|10|entity|C0936012|Analysis|resa|||analysis|||0|1000|1466|1474
SE|25462431||ab|10|entity|C0751973|Proteome|aapp,bacs|||proteome|||0|1000|1484|1492
SE|25462431||ab|10|entity|C0443211|Established|qlco|||established|||0|645|1504|1515
SE|25462431||ab|10|entity|C0442799|Efficient|qlco|||efficient|||0|658|1546|1555
SE|25462431||ab|10|entity|C0003250|Monoclonal Antibodies|aapp,imft|||mAb|||0|658|1556|1559

SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|text|1578|1882|BIOLOGICAL SIGNIFICANCE: The inoculation of animals with complex biological samples is aiming at the discovery of novel disease biomarkers, present in the biological specimens, as well as the production of rare reagents that will facilitate the ultra-sensitive analysis of the biomolecules' native form.
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0205460|biological|ftcn|||BIOLOGICAL|||0|853|1578|1588
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0750502|Significant|idcn|||SIGNIFICANCE|||0|853|1589|1601
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0042196|Vaccination|topp|||inoculation|||0|1000|1607|1618
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0003062|Animals|anim|||animals|||0|1000|1622|1629
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0439855|Complex|qlco|||complex|||0|623|1635|1642
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0205460|biological|ftcn|||biological|||0|623|1643|1653
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0679622|novel|inpr|||novel|||0|851|1692|1697
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0012634|Disease|dsyn|||disease|||0|851|1698|1705
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0005516|Biological Markers|qlco|||biomarkers|||0|851|1706|1716
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0150312|Present|qnco|||present|||0|1000|1718|1725
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0370003|Specimen|sbst|||biological specimens|||0|1000|1733|1753
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0033268|production|ocac|||production|||0|1000|1770|1780
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0522498|Rare|qlco|||rare|||0|888|1784|1788
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0034760|Reagents|irda|||reagents|||0|888|1789|1797
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0728475|Ultra|medd|||ultra|||0|851|1823|1828
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0332324|Sensitive|ftcn|||sensitive|||0|851|1829|1838
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0936012|Analysis|resa|||analysis|||0|851|1839|1847
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C0302891|Native|ftcn|||native|||0|790|1869|1875
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|entity|C1522492|Formation|ftcn|||form|||0|790|1876|1880
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|11|relation|5|4|C0042196|Vaccination|topp|topp|||inoculation|||0|1000|1607|1618|NOM|PREDISPOSES||1706|1716|5|0|C0012634|Disease|dsyn|dsyn|||disease|||0|851|1698|1705

SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|text|1882|2038|In the present study, we initially propose a general workflow concerning the handling of biological samples, as well as the monoclonal antibody production.
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|entity|C0150312|Present|qnco|||present|||0|888|1889|1896
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|entity|C0008972|Clinical Research|resa|||study|||0|888|1897|1902
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|entity|C0205265|Initially|tmco|||initially|||0|1000|1907|1916
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|entity|C0205246|Generalized|spco|||general|||0|660|1927|1934
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|entity|C0205460|biological|ftcn|||biological|||0|694|1971|1981
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|12|entity|C1328929|monoclonal antibody production|resa|||monoclonal antibody production|||0|1000|2006|2036

SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|13|text|2038|2233|Furthermore, we established protocols for the reliable and reproducible identification of antibody specificity using various immuno-affinity purification techniques coupled to mass spectrometry.
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|13|entity|C1514863|Reproducibility|qlco|||reproducible|||0|611|2097|2109
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|13|entity|C0003264|Antibody Specificity|moft|||antibody specificity|||0|1000|2128|2148
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|13|entity|C0008551|Chromatography, Affinity|lbpr|||affinity purification|||0|785|2170|2191
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|13|entity|C0025664|Methodology|inpr|||techniques|||0|785|2192|2202
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|13|entity|C0037813|Spectrum Analysis, Mass|lbpr|||mass spectrometry|||0|1000|2214|2231

SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|text|2233|2468|Our data suggest that processed biological fluids can be used for the production of mAbs targeting proteins of varying abundance, and that various immuno-MS protocols can offer great capabilities for the mAb characterization procedure.
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C1511726|Data|idcn|||data|||0|1000|2237|2241
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C1522240|Process|phpr|||processed|||0|606|2255|2264
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0205460|biological|ftcn|||biological|||0|606|2265|2275
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0033268|production|ocac|||production|||0|1000|2303|2313
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0003250|Monoclonal Antibodies|aapp,imft|||mAbs|||0|966|2317|2321
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|2332|2340
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C1548673|Varies|inpr|||varying|||0|661|2344|2351
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0549177|Large|qnco|||great|||0|694|2410|2415
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0003250|Monoclonal Antibodies|aapp,imft|||mAb|||0|824|2437|2440
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|entity|C0184661|Procedures|hlca|||procedure|||0|824|2458|2467
SE|25462431|BIOLOGICAL SIGNIFICANCE|ab|14|relation|4|1|C0003250|Monoclonal Antibodies|aapp,gngm,imft|aapp|||mAbs|||0|966|2317|2321|VERB|INTERACTS_WITH||2322|2331|5|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|1000|2332|2340


SE|25462430||ti|1|text|21|159|Venomics and antivenomics of Bothrops erythromelas from five geographic populations within the Caatinga ecoregion of northeastern Brazil.
SE|25462430||ti|1|entity|C1011610|Bothrops erythromelas|rept|||Bothrops erythromelas|||0|1000|50|71
SE|25462430||ti|1|entity|C0205451|Five|qnco|||five|||0|890|77|81
SE|25462430||ti|1|entity|C0032659|geographic population|qnco|||geographic populations|||0|890|82|104
SE|25462430||ti|1|entity|C0006137|Brazil|geoa|||Brazil|||0|861|151|157

SE|25462430||ab|1|text|165|357|The Caatinga lancehead, Bothrops erythromelas, is a medically relevant species, responsible for most of the snakebite accidents in most parts of its distribution range in northeastern Brazil.
SE|25462430||ab|1|entity|C1011610|Bothrops erythromelas|rept|||Bothrops erythromelas|||0|1000|189|210
SE|25462430||ab|1|entity|C1548151|Species|idcn|||species|||0|827|236|243
SE|25462430||ab|1|entity|C0205393|Most|qnco|||most|||0|1000|261|265
SE|25462430||ab|1|entity|C0037379|Snake Bites|inpo|||snakebite|||0|901|273|282
SE|25462430||ab|1|entity|C0000924|Accidents|phpr|||accidents|||0|901|283|292
SE|25462430||ab|1|entity|C0449719|Part|spco|||parts|||0|966|301|306
SE|25462430||ab|1|entity|C0520511|Distributing|idcn|||distribution|||0|888|314|326
SE|25462430||ab|1|entity|C1514721|Range|qnco|||range|||0|888|327|332
SE|25462430||ab|1|entity|C0006137|Brazil|geoa|||Brazil|||0|861|349|355

SE|25462430||ab|2|text|357|537|The spectrum and geographic variability of its venom toxins were investigated applying a venomics approach to venom pools from five geographic areas within the Caatinga ecoregion.
SE|25462430||ab|2|entity|C1517526|Geographic|spco|||geographic|||0|853|374|384
SE|25462430||ab|2|entity|C0439828|Variable|qlco|||variability|||0|853|385|396
SE|25462430||ab|2|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|888|404|409
SE|25462430||ab|2|entity|C0040549|Toxin|bacs,hops|||toxins|||0|888|410|416
SE|25462430||ab|2|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|1000|467|472
SE|25462430||ab|2|entity|C0205451|Five|qnco|||five|||0|890|484|488
SE|25462430||ab|2|entity|C0017446|Geographic Locations|geoa|||geographic areas|||0|890|489|505
SE|25462430||ab|2|relation|0|0|C0042479|Venoms|bacs,hops,orch|bacs|||venom|||0|888|404|409|MOD/HEAD|ISA||404|416|0|0|C0040549|Toxin|bacs,hops|bacs|||toxins|||0|888|410|416

SE|25462430||ab|3|text|537|701|Despite its wide habitat, populations of B. erythromelas from Ceara, Pernambuco, Juazeiro, Paraiba, and Ilha de Itaparica exhibit highly conserved venom proteomes.
SE|25462430||ab|3|entity|C0332464|Widening|spco|||wide|||0|888|549|553
SE|25462430||ab|3|entity|C0871648|Habitat|spco|||habitat|||0|888|554|561
SE|25462430||ab|3|entity|C0032659|geographic population|qnco|||populations|||0|1000|563|574
SE|25462430||ab|3|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|750|684|689
SE|25462430||ab|3|entity|C0751973|Proteome|aapp,bacs|||proteomes|||0|750|690|699

SE|25462430||ab|4|text|701|996|Mirroring their compositional conservation, the five geographic venom pools also showed qualitatively and quantitatively overlapping antivenomic profiles against antivenoms generated in Vital Brazil (BR) and Clodomiro Picado (CR) Institutes, using different venoms in the immunization mixtures.
SE|25462430||ab|4|entity|C1168555|Mirroring|menp|||Mirroring|||0|1000|701|710
SE|25462430||ab|4|entity|C0486616|Composition|clna|||compositional|||0|623|717|730
SE|25462430||ab|4|entity|C0205451|Five|qnco|||five|||0|851|749|753
SE|25462430||ab|4|entity|C1517526|Geographic|spco|||geographic|||0|851|754|764
SE|25462430||ab|4|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|851|765|770
SE|25462430||ab|4|entity|C0003450|Antivenins|aapp,imft,phsu|||antivenoms|||0|1000|863|873
SE|25462430||ab|4|entity|C0442732|Vital|qlco|||Vital|||0|888|887|892
SE|25462430||ab|4|entity|C0006137|Brazil|geoa|||Brazil|||0|888|893|899
SE|25462430||ab|4|entity|C0021622|Institutes|orgt|||Institutes|||0|1000|931|941
SE|25462430||ab|4|entity|C1547020|*Difference|qnco|||different|||0|853|949|958
SE|25462430||ab|4|entity|C0042479|Venoms|bacs,hops,orch|||venoms|||0|853|959|965
SE|25462430||ab|4|entity|C0020971|Immunization|topp|||immunization|||0|872|973|985
SE|25462430||ab|4|entity|C0439962|Mixture|sbst|||mixtures|||0|872|986|994

SE|25462430||ab|5|text|996|1327|The paraspecificity exhibited by the Brazilian SAB and the Costa Rican BCL antivenoms against venom toxins from B. erythromelas indicates large immunoreactive epitope conservation across genus Bothrops during the last ~14 million years, thus offering promise for the possibility of generating a broad-spectrum bothropic antivenom.
SE|25462430||ab|5|entity|C0238815|BRAZILIAN|fndg|||Brazilian|||0|694|1033|1042
SE|25462430||ab|5|entity|||gngm|9467|SH3BP5|SAB|||0|694|1043|1046
SE|25462430||ab|5|entity|C0239127|Costa Rican|popg|||Costa Rican|||0|861|1055|1066
SE|25462430||ab|5|entity|C0919443|BCL1 Oncogene|gngm|||BCL|||0|861|1067|1070
SE|25462430||ab|5|entity|C0003450|Antivenins|aapp,imft,phsu|||antivenoms|||0|861|1071|1081
SE|25462430||ab|5|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|888|1090|1095
SE|25462430||ab|5|entity|C0040549|Toxin|bacs,hops|||toxins|||0|888|1096|1102
SE|25462430||ab|5|entity|C0549177|Large|qnco|||large|||0|597|1134|1139
SE|25462430||ab|5|entity|C0003316|Epitopes|imft|||epitope|||0|597|1155|1162
SE|25462430||ab|5|entity|C0206315|Bothrops|rept|||Bothrops|||0|861|1189|1197
SE|25462430||ab|5|entity|C1517741|Last|qlco|||last|||0|791|1209|1213
SE|25462430||ab|5|entity|C0439234|year|tmco|||years|||0|791|1226|1231
SE|25462430||ab|5|entity|C1555307|promise|idcn|||promise|||0|1000|1247|1254
SE|25462430||ab|5|entity|C0332464|Widening|spco|||broad|||0|791|1291|1296
SE|25462430||ab|5|entity|C0003450|Antivenins|aapp,imft,phsu|||antivenom|||0|791|1316|1325
SE|25462430||ab|5|relation|0|0|C0042479|Venoms|bacs,hops,orch|bacs|||venom|||0|888|1090|1095|MOD/HEAD|ISA||1090|1102|0|0|C0040549|Toxin|bacs,hops|bacs|||toxins|||0|888|1096|1102

SE|25462430||ab|6|text|1327|1439|Biological Significance Accidental snakebite envenomings represent an important public health hazard in Brazil.
SE|25462430||ab|6|entity|C0205460|biological|ftcn|||Biological|||0|593|1327|1337
SE|25462430||ab|6|entity|C0750502|Significant|idcn|||Significance|||0|593|1338|1350
SE|25462430||ab|6|entity|C0521129|Accidental|ftcn|||Accidental|||0|593|1351|1361
SE|25462430||ab|6|entity|C0037379|Snake Bites|inpo|||snakebite|||0|593|1362|1371
SE|25462430||ab|6|entity|C0079483|Health Hazards|hops|||health hazard|||0|861|1414|1427
SE|25462430||ab|6|entity|C0006137|Brazil|geoa|||Brazil|||0|1000|1431|1437

SE|25462430||ab|7|text|1439|1554|Ninety per cent of the yearly estimated 20-30,000 snakebite accidents are caused by species of the Bothrops genus.
SE|25462430||ab|7|entity|C0562018|cent|qnco|||cent|||0|827|1450|1454
SE|25462430||ab|7|entity|C0332181|Annual|tmco|||yearly|||0|1000|1462|1468
SE|25462430||ab|7|entity|C0037379|Snake Bites|inpo|||snakebite|||0|741|1489|1498
SE|25462430||ab|7|entity|C0000924|Accidents|phpr|||accidents|||0|741|1499|1508
SE|25462430||ab|7|entity|C1548151|Species|idcn|||species|||0|1000|1523|1530
SE|25462430||ab|7|entity|C0206315|Bothrops|rept|||Bothrops|||0|694|1538|1546

SE|25462430||ab|8|text|1554|1774|Bothrops erythromelas, a small, moderately stocky terrestrial venomous snake, is responsible for most of the snakebite accidents in its broad distribution range in the Caatinga, a large ecoregion in northeastern Brazil.
SE|25462430||ab|8|entity|C1011610|Bothrops erythromelas|rept|||Bothrops erythromelas|||0|1000|1554|1575
SE|25462430||ab|8|entity|C0700321|Small|qnco|||small|||0|805|1579|1584
SE|25462430||ab|8|entity|C0037381|Venomous snake|rept|||venomous snake|||0|805|1616|1630
SE|25462430||ab|8|entity|C0205393|Most|qnco|||most|||0|1000|1651|1655
SE|25462430||ab|8|entity|C0037379|Snake Bites|inpo|||snakebite|||0|901|1663|1672
SE|25462430||ab|8|entity|C0000924|Accidents|phpr|||accidents|||0|901|1673|1682
SE|25462430||ab|8|entity|C0332464|Widening|spco|||broad|||0|851|1690|1695
SE|25462430||ab|8|entity|C0520511|Distributing|idcn|||distribution|||0|851|1696|1708
SE|25462430||ab|8|entity|C1514721|Range|qnco|||range|||0|851|1709|1714
SE|25462430||ab|8|entity|C0549177|Large|qnco|||large|||0|694|1734|1739
SE|25462430||ab|8|entity|C0006137|Brazil|geoa|||Brazil|||0|861|1766|1772

SE|25462430||ab|9|text|1774|2038|To gain a deeper insight into the spectrum of medically important toxins present in the venom of the Caatinga lancehead, we applied a venomics approach to define the proteome and geographic variability of adult B. erythromelas venoms from five geographic regions.
SE|25462430||ab|9|entity|C0205125|Depth|spco|||deeper|||0|872|1784|1790
SE|25462430||ab|9|entity|C0233820|Insight|menp|||insight|||0|872|1791|1798
SE|25462430||ab|9|entity|C0040549|Toxin|bacs,hops|||toxins|||0|827|1840|1846
SE|25462430||ab|9|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|1000|1862|1867
SE|25462430||ab|9|entity|C0751973|Proteome|aapp,bacs|||proteome|||0|1000|1940|1948
SE|25462430||ab|9|entity|C1517526|Geographic|spco|||geographic|||0|853|1953|1963
SE|25462430||ab|9|entity|C0439828|Variable|qlco|||variability|||0|853|1964|1975
SE|25462430||ab|9|entity|C0001675|Adult|aggp|||adult|||0|764|1979|1984
SE|25462430||ab|9|entity|C0042479|Venoms|bacs,hops,orch|||venoms|||0|764|2001|2007
SE|25462430||ab|9|entity|C0205451|Five|qnco|||five|||0|901|2013|2017
SE|25462430||ab|9|entity|C0017446|Geographic Locations|geoa|||geographic regions|||0|901|2018|2036
SE|25462430||ab|9|relation|3|1|C0040549|Toxin|bacs,hops|bacs|||toxins|||0|827|1840|1846|PREP|COEXISTS_WITH||1855|1857|7|1|C0042479|Venoms|bacs,hops,orch|bacs|||venom|||0|1000|1862|1867

SE|25462430||ab|10|text|2038|2383|Although intraspecific compositional variation between venoms among specimens from different geographic regions has long been appreciated by herpetologists and toxinologists as a general feature of highly adaptable and widely distributed snake species, the five B. erythromelas populations investigated exhibit highly conserved venom proteomes.
SE|25462430||ab|10|entity|C0486616|Composition|clna|||compositional|||0|754|2061|2074
SE|25462430||ab|10|entity|C0205419|Variant|qlco|||variation|||0|754|2075|2084
SE|25462430||ab|10|entity|C0042479|Venoms|bacs,hops,orch|||venoms|||0|1000|2093|2099
SE|25462430||ab|10|entity|C0370003|Specimen|sbst|||specimens|||0|966|2106|2115
SE|25462430||ab|10|entity|C1547020|*Difference|qnco|||different|||0|877|2121|2130
SE|25462430||ab|10|entity|C0017446|Geographic Locations|geoa|||geographic regions|||0|877|2131|2149
SE|25462430||ab|10|entity|C0205166|Long|qlco|||long|||0|1000|2154|2158
SE|25462430||ab|10|entity|C0260241|Herpetologists|prog|||herpetologists|||0|1000|2179|2193
SE|25462430||ab|10|entity|C0205246|Generalized|spco|||general|||0|694|2217|2224
SE|25462430||ab|10|entity|C0520511|Distributing|idcn|||distributed|||0|764|2264|2275
SE|25462430||ab|10|entity|C0037382|Snakes|rept|||snake|||0|764|2276|2281
SE|25462430||ab|10|entity|C1548151|Species|idcn|||species|||0|764|2282|2289
SE|25462430||ab|10|entity|C0205451|Five|qnco|||five|||0|791|2295|2299
SE|25462430||ab|10|entity|C0032659|geographic population|qnco|||populations|||0|791|2316|2327
SE|25462430||ab|10|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|750|2366|2371
SE|25462430||ab|10|entity|C0751973|Proteome|aapp,bacs|||proteomes|||0|750|2372|2381

SE|25462430||ab|11|text|2383|2529|The overall toxin profile of the Caatinga lancehead's venom explains the local and systemic effects observed in envenomations by B. erythromelas.
SE|25462430||ab|11|entity|C1561607|Overall|qlco|||overall|||0|623|2387|2394
SE|25462430||ab|11|entity|C0040549|Toxin|bacs,hops|||toxin|||0|623|2395|2400
SE|25462430||ab|11|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|827|2437|2442
SE|25462430||ab|11|entity|C0205276|Local|spco|||local|||0|1000|2456|2461
SE|25462430||ab|11|entity|C0205373|Systemic|ftcn|||systemic|||0|872|2466|2474
SE|25462430||ab|11|entity|C1280500|Effect|qlco|||effects|||0|872|2475|2482

SE|25462430||ab|12|text|2529|2739|The five geographic venom pools sampled also showed qualitatively and quantitatively overlapping antivenomic profiles against antivenoms generated using different bothropic venoms in the immunization mixtures.
SE|25462430||ab|12|entity|C0205451|Five|qnco|||five|||0|608|2533|2537
SE|25462430||ab|12|entity|C1517526|Geographic|spco|||geographic|||0|608|2538|2548
SE|25462430||ab|12|entity|C0042479|Venoms|bacs,hops,orch|||venom|||0|608|2549|2554
SE|25462430||ab|12|entity|C0003450|Antivenins|aapp,imft,phsu|||antivenoms|||0|1000|2655|2665
SE|25462430||ab|12|entity|C1547020|*Difference|qnco|||different|||0|766|2682|2691
SE|25462430||ab|12|entity|C0042479|Venoms|bacs,hops,orch|||venoms|||0|766|2702|2708
SE|25462430||ab|12|entity|C0020971|Immunization|topp|||immunization|||0|872|2716|2728
SE|25462430||ab|12|entity|C0439962|Mixture|sbst|||mixtures|||0|872|2729|2737

SE|25462430||ab|13|text|2739|2881|The large immunoreactive epitope conservation across genus Bothrops offers promise for the generation of a broad-spectrum bothropic antivenom.
SE|25462430||ab|13|entity|C0549177|Large|qnco|||large|||0|597|2743|2748
SE|25462430||ab|13|entity|C0003316|Epitopes|imft|||epitope|||0|597|2764|2771
SE|25462430||ab|13|entity|C0206315|Bothrops|rept|||Bothrops|||0|861|2798|2806
SE|25462430||ab|13|entity|C0079411|Generations|tmco|||generation|||0|966|2830|2840
SE|25462430||ab|13|entity|C0332464|Widening|spco|||broad|||0|791|2846|2851
SE|25462430||ab|13|entity|C0003450|Antivenins|aapp,imft,phsu|||antivenom|||0|791|2871|2880


[290]: *** ERROR *** ERROR *** ERROR ***
SE|25462433||ti|1|text|21|118|Visual outcomes of pars plana vitrectomy with epiretinal membrane peel in patients with uveitis.
SE|25462433||ti|1|entity|C0234621|Visual|ftcn|||Visual|||0|872|21|27
SE|25462433||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|872|28|36
SE|25462433||ti|1|entity|C0032405|Poly(ADP-ribose) Polymerases|aapp,enzy|||pars|||0|840|40|44
SE|25462433||ti|1|entity|C0205324|Flat shape|spco|||plana|||0|840|45|50
SE|25462433||ti|1|entity|C0042903|Vitrectomy|topp|||vitrectomy|||0|840|51|61
SE|25462433||ti|1|entity|C0339543|Epiretinal Membrane|acab|||epiretinal membrane|||0|734|67|86
SE|25462433||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|95|103
SE|25462433||ti|1|entity|C0042164|Uveitis|dsyn|||uveitis|||0|1000|109|116
SE|25462433||ti|1|relation|0|0|C0042903|Vitrectomy|topp|topp|||vitrectomy|||0|840|51|61|INFER|TREATS(INFER)||92|94|0|0|C0042164|Uveitis|dsyn|dsyn|||uveitis|||0|1000|109|116
SE|25462433||ti|1|relation|1|1|C0042164|Uveitis|dsyn|dsyn|||uveitis|||0|1000|109|116|PREP|PROCESS_OF||104|108|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|95|103
SE|25462433||ti|1|relation|3|2|C0042903|Vitrectomy|topp|topp|||vitrectomy|||0|840|51|61|PREP|TREATS||92|94|2|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|95|103

SE|25462433|PURPOSE|ab|1|text|124|293|PURPOSE: To report the outcomes of pars plana vitrectomy with epiretinal membrane (ERM) peel, with or without internal limiting membrane peel, in patients with uveitis.
SE|25462433|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|124|131
SE|25462433|PURPOSE|ab|1|entity|C1274040|result|ftcn|||outcomes|||0|966|147|155
SE|25462433|PURPOSE|ab|1|entity|C0032405|Poly(ADP-ribose) Polymerases|aapp,enzy|||pars|||0|840|159|163
SE|25462433|PURPOSE|ab|1|entity|C0205324|Flat shape|spco|||plana|||0|840|164|169
SE|25462433|PURPOSE|ab|1|entity|C0042903|Vitrectomy|topp|||vitrectomy|||0|840|170|180
SE|25462433|PURPOSE|ab|1|entity|C0339543|Epiretinal Membrane|acab|||epiretinal membrane|||0|734|186|205
SE|25462433|PURPOSE|ab|1|entity|C0205102|Intrinsic|spco|||internal|||0|597|234|242
SE|25462433|PURPOSE|ab|1|entity|C0439801|Limited|ftcn|||limiting|||0|597|243|251
SE|25462433|PURPOSE|ab|1|entity|C0596901|Membrane|celc|||membrane|||0|597|252|260
SE|25462433|PURPOSE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|270|278
SE|25462433|PURPOSE|ab|1|entity|C0042164|Uveitis|dsyn|||uveitis|||0|1000|284|291
SE|25462433|PURPOSE|ab|1|relation|0|0|C0042903|Vitrectomy|topp|topp|||vitrectomy|||0|840|170|180|INFER|TREATS(INFER)||267|269|0|0|C0042164|Uveitis|dsyn|dsyn|||uveitis|||0|1000|284|291
SE|25462433|PURPOSE|ab|1|relation|1|1|C0042164|Uveitis|dsyn|dsyn|||uveitis|||0|1000|284|291|PREP|PROCESS_OF||279|283|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|270|278
SE|25462433|PURPOSE|ab|1|relation|5|3|C0042903|Vitrectomy|topp|topp|||vitrectomy|||0|840|170|180|PREP|TREATS||267|269|2|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|270|278

SE|25462433|METHODS|ab|2|text|293|439|METHODS: Retrospective interventional case series of patients undergoing pars plana vitrectomy with ERM peel between January 2005 and March 2012.
SE|25462433|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|293|300
SE|25462433|METHODS|ab|2|entity|C1514923|Retrospective|qlco|||Retrospective|||0|843|302|315
SE|25462433|METHODS|ab|2|entity|C1273869|Intervention regimes|hlca|||interventional|||0|843|316|330
SE|25462433|METHODS|ab|2|entity|C0150093|Case Series|resa|||case series|||0|843|331|342
SE|25462433|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|1000|346|354
SE|25462433|METHODS|ab|2|entity|C0032405|Poly(ADP-ribose) Polymerases|aapp,enzy|||pars|||0|840|366|370
SE|25462433|METHODS|ab|2|entity|C0205324|Flat shape|spco|||plana|||0|840|371|376
SE|25462433|METHODS|ab|2|entity|C0042903|Vitrectomy|topp|||vitrectomy|||0|840|377|387
SE|25462433|METHODS|ab|2|entity|C0339543|Epiretinal Membrane|acab|||ERM|||0|734|393|396
SE|25462433|METHODS|ab|2|relation|2|1|C0042903|Vitrectomy|topp|topp|||vitrectomy|||0|840|377|387|VERB|TREATS||355|365|3|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|346|354

SE|25462433|METHODS|ab|3|text|439|547|Sixteen consecutive patients (16 eyes) were identified, with a minimum postoperative follow-up of 6 months.
SE|25462433|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|827|459|467
SE|25462433|METHODS|ab|3|entity|C0015392|Eye|bpoc|||eyes|||0|861|472|476
SE|25462433|METHODS|ab|3|entity|C1524031|Minimum|qlco|||minimum|||0|824|502|509
SE|25462433|METHODS|ab|3|entity|C1522577|follow-up|hlca|||follow-up|||0|824|524|533
SE|25462433|METHODS|ab|3|entity|C0439231|month|tmco|||months|||0|861|539|545

SE|25462433|METHODS|ab|4|text|547|655|Visual acuity, anatomical outcomes, perioperative control of inflammation, and complications were assessed.
SE|25462433|METHODS|ab|4|entity|C0042812|Visual Acuity|clna|||Visual acuity|||0|1000|547|560
SE|25462433|METHODS|ab|4|entity|C0220784|anatomic|ftcn|||anatomical|||0|872|562|572
SE|25462433|METHODS|ab|4|entity|C1274040|result|ftcn|||outcomes|||0|872|573|581
SE|25462433|METHODS|ab|4|entity|C1518988|perioperative|tmco|||perioperative|||0|888|583|596
SE|25462433|METHODS|ab|4|entity|C0243148|control|ftcn|||control|||0|888|597|604
SE|25462433|METHODS|ab|4|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|608|620
SE|25462433|METHODS|ab|4|entity|C0009566|Complication|patf|||complications|||0|1000|626|639

SE|25462433|RESULTS|ab|5|text|655|794|RESULTS: The mean age at surgery was 47.3 years (range, 14-68 years), with a mean duration of ERM at surgery of 21.3 months (3-84 months).
SE|25462433|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|655|662
SE|25462433|RESULTS|ab|5|entity|C0001779|Age|orga|||age|||0|861|673|676
SE|25462433|RESULTS|ab|5|entity|C0439234|year|tmco|||years|||0|827|697|702
SE|25462433|RESULTS|ab|5|entity|C1514721|Range|qnco|||range|||0|1000|704|709
SE|25462433|RESULTS|ab|5|entity|C0439234|year|tmco|||years|||0|827|717|722
SE|25462433|RESULTS|ab|5|entity|C0449238|Duration|tmco|||duration|||0|861|737|745
SE|25462433|RESULTS|ab|5|entity|C0339543|Epiretinal Membrane|acab|||ERM|||0|1000|749|752
SE|25462433|RESULTS|ab|5|entity|C0439231|month|tmco|||months|||0|827|772|778
SE|25462433|RESULTS|ab|5|entity|C1442461|3 Months|tmco|||3-84 months|||0|913|780|791

SE|25462433|RESULTS|ab|6|text|794|895|At 6 months, visual acuity improved in 31.25% of eyes, stabilized in 31.25%, and was worse in 37.5%.
SE|25462433|RESULTS|ab|6|entity|C0439231|month|tmco|||months|||0|861|799|805
SE|25462433|RESULTS|ab|6|entity|C0042812|Visual Acuity|clna|||visual acuity|||0|1000|807|820
SE|25462433|RESULTS|ab|6|entity|C0015392|Eye|bpoc|||eyes|||0|1000|843|847
SE|25462433|RESULTS|ab|6|entity|C1279889|Deterioration of status|qlco|||worse|||0|1000|879|884

SE|25462433|RESULTS|ab|7|text|895|1018|The causes of reduced visual acuity postoperatively included severe preexisting macular pathology and unoperated cataract.
SE|25462433|RESULTS|ab|7|entity|C0015127|Etiology aspects|ftcn|||causes|||0|1000|899|905
SE|25462433|RESULTS|ab|7|entity|C0234632|Reduced visual acuity|fndg|||reduced visual acuity|||0|1000|909|930
SE|25462433|RESULTS|ab|7|entity|C0205082|Severe|qlco|||severe|||0|775|956|962
SE|25462433|RESULTS|ab|7|entity|C0332574|Macular|spco|||macular|||0|775|975|982
SE|25462433|RESULTS|ab|7|entity|C0030664|Pathology|bmod|||pathology|||0|775|983|992
SE|25462433|RESULTS|ab|7|entity|C0086543|Cataract|anab,dsyn|||cataract|||0|861|1008|1016

SE|25462433|CONCLUSION|ab|8|text|1018|1242|CONCLUSION: Pars plana vitrectomy with ERM peel in eyes with uveitis may improve or stabilize visual acuity, especially in eyes with macular traction, but in the absence of traction, outcomes are variable and unpredictable.
SE|25462433|CONCLUSION|ab|8|entity|C0032405|Poly(ADP-ribose) Polymerases|aapp,enzy|||Pars|||0|840|1030|1034
SE|25462433|CONCLUSION|ab|8|entity|C0205324|Flat shape|spco|||plana|||0|840|1035|1040
SE|25462433|CONCLUSION|ab|8|entity|C0042903|Vitrectomy|topp|||vitrectomy|||0|840|1041|1051
SE|25462433|CONCLUSION|ab|8|entity|C0339543|Epiretinal Membrane|acab|||ERM|||0|734|1057|1060
SE|25462433|CONCLUSION|ab|8|entity|C0015392|Eye|bpoc|||eyes|||0|1000|1069|1073
SE|25462433|CONCLUSION|ab|8|entity|C0042164|Uveitis|dsyn|||uveitis|||0|1000|1079|1086
SE|25462433|CONCLUSION|ab|8|entity|C0042812|Visual Acuity|clna|||visual acuity|||0|1000|1112|1125
SE|25462433|CONCLUSION|ab|8|entity|C0015392|Eye|bpoc|||eyes|||0|1000|1141|1145
SE|25462433|CONCLUSION|ab|8|entity|C0332574|Macular|spco|||macular|||0|888|1151|1158
SE|25462433|CONCLUSION|ab|8|entity|C0040597|Traction|topp|||traction|||0|888|1159|1167
SE|25462433|CONCLUSION|ab|8|entity|C0040597|Traction|topp|||traction|||0|1000|1191|1199
SE|25462433|CONCLUSION|ab|8|entity|C1274040|result|ftcn|||outcomes|||0|966|1201|1209
SE|25462433|CONCLUSION|ab|8|entity|C0439828|Variable|qlco|||variable|||0|1000|1214|1222
SE|25462433|CONCLUSION|ab|8|relation|7|1|C0015392|Eye|bpoc|bpoc|||eyes|||0|1000|1141|1145|PREP|LOCATION_OF||1138|1140|6|2|C0042164|Uveitis|dsyn|dsyn|||uveitis|||0|1000|1079|1086

SE|25462433|CONCLUSION|ab|9|text|1242|1321|Prevention of ERM formation by aggressive control of inflammation is important.
SE|25462433|CONCLUSION|ab|9|entity|C0199176|Prophylactic treatment|topp|||Prevention|||0|1000|1242|1252
SE|25462433|CONCLUSION|ab|9|entity|C0339543|Epiretinal Membrane|acab|||ERM|||0|901|1256|1259
SE|25462433|CONCLUSION|ab|9|entity|C1522492|Formation|ftcn|||formation|||0|901|1260|1269
SE|25462433|CONCLUSION|ab|9|entity|C0243148|control|ftcn|||control|||0|861|1284|1291
SE|25462433|CONCLUSION|ab|9|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|1295|1307
SE|25462433|CONCLUSION|ab|9|relation|2|2|C0199176|Prophylactic treatment|topp|topp|||Prevention|||0|1000|1242|1252|NOM|TREATS||1284|1291|2|1|C0021368|Inflammation|patf|patf|||inflammation|||0|1000|1295|1307


SE|25462434||ti|1|text|21|153|Endoresection technique with/without brachytherapy for management of high posterior choroidal melanoma: extended follow-up results.
SE|25462434||ti|1|entity|C0449851|Techniques|ftcn|||technique|||0|861|35|44
SE|25462434||ti|1|entity|C0006098|Brachytherapy|topp|||brachytherapy|||0|1000|58|71
SE|25462434||ti|1|entity|C0205250|High|qlco|||high|||0|843|90|94
SE|25462434||ti|1|entity|C0446884|Posterior choroid|blor|||posterior choroidal|||0|843|95|114
SE|25462434||ti|1|entity|C0025202|melanoma|neop|||melanoma|||0|843|115|123
SE|25462434||ti|1|entity|C1522577|follow-up|hlca|||follow-up|||0|890|134|143
SE|25462434||ti|1|entity|C1274040|result|ftcn|||results|||0|890|144|151
SE|25462434||ti|1|relation|0|0|C0446884|Posterior choroid|blor|blor|||posterior choroidal|||0|843|95|114|MOD/HEAD|LOCATION_OF||95|123|0|0|C0025202|melanoma|neop|neop|||melanoma|||0|843|115|123
SE|25462434||ti|1|relation|2|1|C0006098|Brachytherapy|topp|topp|||brachytherapy|||0|1000|58|71|NOM|TREATS|negation|76|86|2|1|C0025202|melanoma|neop|neop|||melanoma|||0|843|115|123

SE|25462434|PURPOSE|ab|1|text|159|270|PURPOSE: To evaluate the long-term efficacy and safety of endoresection for high posterior choroidal melanoma.
SE|25462434|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|159|166
SE|25462434|PURPOSE|ab|1|entity|C0443252|Long-term|tmco|||long-term|||0|734|184|193
SE|25462434|PURPOSE|ab|1|entity|C0036043|Safety|hcpp|||safety|||0|1000|207|213
SE|25462434|PURPOSE|ab|1|entity|C0205250|High|qlco|||high|||0|843|235|239
SE|25462434|PURPOSE|ab|1|entity|C0446884|Posterior choroid|blor|||posterior choroidal|||0|843|240|259
SE|25462434|PURPOSE|ab|1|entity|C0025202|melanoma|neop|||melanoma|||0|843|260|268
SE|25462434|PURPOSE|ab|1|relation|0|0|C0446884|Posterior choroid|blor|blor|||posterior choroidal|||0|843|240|259|MOD/HEAD|LOCATION_OF||240|268|0|0|C0025202|melanoma|neop|neop|||melanoma|||0|843|260|268

SE|25462434|METHODS|ab|2|text|270|335|METHODS: Retrospective nonrandomized interventional case series.
SE|25462434|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|270|277
SE|25462434|METHODS|ab|2|entity|C1514923|Retrospective|qlco|||Retrospective|||0|776|279|292
SE|25462434|METHODS|ab|2|entity|C1273869|Intervention regimes|hlca|||interventional|||0|776|307|321
SE|25462434|METHODS|ab|2|entity|C0150093|Case Series|resa|||case series|||0|776|322|333

SE|25462434|METHODS|ab|3|text|335|427|Forty-one patients had endoresection as primary treatment for posterior choroidal melanoma.
SE|25462434|METHODS|ab|3|entity|C0205447|One|qnco|||one|||0|790|341|344
SE|25462434|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|790|345|353
SE|25462434|METHODS|ab|3|entity|C0446884|Posterior choroid|blor|||posterior choroidal|||0|877|397|416
SE|25462434|METHODS|ab|3|entity|C0025202|melanoma|neop|||melanoma|||0|877|417|425
SE|25462434|METHODS|ab|3|relation|0|0|C0446884|Posterior choroid|blor|blor|||posterior choroidal|||0|877|397|416|MOD/HEAD|LOCATION_OF||397|425|0|0|C0025202|melanoma|neop|neop|||melanoma|||0|877|417|425

SE|25462434|METHODS|ab|4|text|427|477|Of these, 21 patients had adjuvant brachytherapy.
SE|25462434|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|861|440|448
SE|25462434|METHODS|ab|4|entity|C0001551|Immunologic Adjuvants|imft,phsu|||adjuvant|||0|888|453|461
SE|25462434|METHODS|ab|4|entity|C0006098|Brachytherapy|topp|||brachytherapy|||0|888|462|475
SE|25462434|METHODS|ab|4|relation|0|0|C0006098|Brachytherapy|topp|topp|||brachytherapy|||0|888|462|475|MOD/HEAD|USES||453|475|0|0|C0001551|Immunologic Adjuvants|imft,phsu|phsu|||adjuvant|||0|888|453|461

SE|25462434|METHODS|ab|5|text|477|611|The inclusion criteria were tumor thickness >=8 mm, base diameter <15 mm, and posterior tumors not extending anterior to the equator.
SE|25462434|METHODS|ab|5|entity|C1516637|Clinical Trial Eligibility Criteria|qlco|||inclusion criteria|||0|1000|481|499
SE|25462434|METHODS|ab|5|entity|C0027651|Neoplasm|neop|||tumor|||0|888|505|510
SE|25462434|METHODS|ab|5|entity|C1280412|Thick|qlco|||thickness|||0|888|511|520
SE|25462434|METHODS|ab|5|entity|C1301886|Caliber|qnco|||diameter|||0|888|534|542
SE|25462434|METHODS|ab|5|entity|C0205095|Dorsal|spco|||posterior|||0|888|555|564
SE|25462434|METHODS|ab|5|entity|C0027651|Neoplasm|neop|||tumors|||0|888|565|571
SE|25462434|METHODS|ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|572|575
SE|25462434|METHODS|ab|5|entity|C0205094|Anterior|spco|||anterior|||0|1000|586|594

SE|25462434|METHODS|ab|6|text|611|742|Main outcomes measures were enucleation rate, visual outcome, surgical complications, local recurrence, metastasis, and mortality.
SE|25462434|METHODS|ab|6|entity|C0205225|Primary|qlco|||Main|||0|872|611|615
SE|25462434|METHODS|ab|6|entity|C1274040|result|ftcn|||outcomes|||0|872|616|624
SE|25462434|METHODS|ab|6|entity|C0014392|Enucleation procedure|topp|||enucleation|||0|888|639|650
SE|25462434|METHODS|ab|6|entity|C1521828|Rate|qnco|||rate|||0|888|651|655
SE|25462434|METHODS|ab|6|entity|C0234621|Visual|ftcn|||visual|||0|888|657|663
SE|25462434|METHODS|ab|6|entity|C1274040|result|ftcn|||outcome|||0|888|664|671
SE|25462434|METHODS|ab|6|entity|C0221082|Etiology, operative procedure, as cause of|fndg|||surgical complications|||0|1000|673|695
SE|25462434|METHODS|ab|6|entity|C0205276|Local|spco|||local|||0|888|697|702
SE|25462434|METHODS|ab|6|entity|C0034897|Recurrence|phpr|||recurrence|||0|888|703|713

SE|25462434|RESULTS|ab|7|text|742|789|RESULTS: Mean follow-up time was 102.5 months.
SE|25462434|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|742|749
SE|25462434|RESULTS|ab|7|entity|C1522577|follow-up|hlca|||follow-up|||0|824|756|765
SE|25462434|RESULTS|ab|7|entity|C0040223|Time|tmco|||time|||0|824|766|770
SE|25462434|RESULTS|ab|7|entity|C0439231|month|tmco|||months|||0|827|781|787

SE|25462434|RESULTS|ab|8|text|789|848|Mean preoperative best-corrected visual acuity was 20/100.
SE|25462434|RESULTS|ab|8|entity|C0445204|Preoperative|tmco|||preoperative|||0|823|794|806
SE|25462434|RESULTS|ab|8|entity|C1275680|Corrected visual field|clna|||corrected visual acuity|||0|823|812|835

SE|25462434|RESULTS|ab|9|text|848|1006|Mean tumor thickness was 9.8 mm (range, 7.7-13.5 mm; standard deviation, 1.7 mm), mean base diameter was 9.9 mm (range, 5-15 mm; standard deviation, 2.8 mm).
SE|25462434|RESULTS|ab|9|entity|C0027651|Neoplasm|neop|||tumor|||0|790|853|858
SE|25462434|RESULTS|ab|9|entity|C1280412|Thick|qlco|||thickness|||0|790|859|868
SE|25462434|RESULTS|ab|9|entity|C1514721|Range|qnco|||range|||0|1000|881|886
SE|25462434|RESULTS|ab|9|entity|C0470355|7+7|qnco|||7.7|||0|812|888|891
SE|25462434|RESULTS|ab|9|entity|C0871420|Standard deviation|qnco|||standard deviation|||0|1000|901|919
SE|25462434|RESULTS|ab|9|entity|C1301886|Caliber|qnco|||diameter|||0|790|940|948
SE|25462434|RESULTS|ab|9|entity|C1514721|Range|qnco|||range|||0|1000|961|966
SE|25462434|RESULTS|ab|9|entity|C0439084|>5|qnco|||5-15|||0|802|968|972
SE|25462434|RESULTS|ab|9|entity|C0871420|Standard deviation|qnco|||standard deviation|||0|1000|977|995

SE|25462434|RESULTS|ab|10|text|1006|1071|At the latest visit, 36 patients (87.8%) still retained the eye.
SE|25462434|RESULTS|ab|10|entity|C0205087|Late|tmco|||latest|||0|872|1013|1019
SE|25462434|RESULTS|ab|10|entity|C0545082|Visit|ftcn|||visit|||0|872|1020|1025
SE|25462434|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|861|1030|1038
SE|25462434|RESULTS|ab|10|entity|C0015392|Eye|bpoc|||eye|||0|1000|1066|1069

SE|25462434|RESULTS|ab|11|text|1071|1133|Mean postoperative best-corrected visual acuity was 20/1,625.
SE|25462434|RESULTS|ab|11|entity|C1275680|Corrected visual field|clna|||corrected visual acuity|||0|817|1095|1118

SE|25462434|RESULTS|ab|12|text|1133|1201|Retinal detachment was the main postoperative complication (28.9%).
SE|25462434|RESULTS|ab|12|entity|C0035305|Retinal Detachment|dsyn|||Retinal detachment|||0|1000|1133|1151
SE|25462434|RESULTS|ab|12|entity|C0205225|Primary|qlco|||main|||0|901|1160|1164
SE|25462434|RESULTS|ab|12|entity|C0032787|Postoperative Complications|patf|||postoperative complication|||0|901|1165|1191

SE|25462434|RESULTS|ab|13|text|1201|1299|At completion of follow-up, 12% of patients had phthisis bulbi, and 3 developed chronic hypotony.
SE|25462434|RESULTS|ab|13|entity|C1554962|completion|qlco|||completion|||0|1000|1204|1214
SE|25462434|RESULTS|ab|13|entity|C1522577|follow-up|hlca|||follow-up|||0|901|1218|1227
SE|25462434|RESULTS|ab|13|entity|C0030705|Patients|podg|||patients|||0|1000|1236|1244
SE|25462434|RESULTS|ab|13|entity|C0271007|Phthisis bulbi|fndg|||phthisis bulbi|||0|1000|1249|1263
SE|25462434|RESULTS|ab|13|entity|C0205191|chronic|tmco|||chronic|||0|751|1281|1288
SE|25462434|RESULTS|ab|13|entity|C0241938|hypotonicity|patf|||hypotony|||0|751|1289|1297
SE|25462434|RESULTS|ab|13|relation|2|1|C0241938|hypotonicity|patf|patf|||hypotony|||0|751|1289|1297|AUX|PROCESS_OF||1245|1248|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1236|1244
SE|25462434|RESULTS|ab|13|relation|2|1|C0271007|Phthisis bulbi|fndg|fndg|||phthisis bulbi|||0|1000|1249|1263|AUX|PROCESS_OF||1245|1248|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1236|1244

SE|25462434|RESULTS|ab|14|text|1299|1411|Five patients (12.2%) had local tumor recurrence; none of them had received brachytherapy as initial treatment.
SE|25462434|RESULTS|ab|14|entity|C0205451|Five|qnco|||Five|||0|888|1299|1303
SE|25462434|RESULTS|ab|14|entity|C0030705|Patients|podg|||patients|||0|888|1304|1312
SE|25462434|RESULTS|ab|14|entity|C0205276|Local|spco|||local|||0|851|1325|1330
SE|25462434|RESULTS|ab|14|entity|C0027651|Neoplasm|neop|||tumor|||0|851|1331|1336
SE|25462434|RESULTS|ab|14|entity|C0034897|Recurrence|phpr|||recurrence|||0|851|1337|1347
SE|25462434|RESULTS|ab|14|entity|C1514756|Received|qlco|||received|||0|888|1366|1374
SE|25462434|RESULTS|ab|14|entity|C0006098|Brachytherapy|topp|||brachytherapy|||0|888|1375|1388
SE|25462434|RESULTS|ab|14|entity|C0205265|Initially|tmco|||initial|||0|888|1392|1399

SE|25462434|RESULTS|ab|15|text|1411|1476|At 5 years of follow-up, 3 patients (7.3%) had liver metastasis.
SE|25462434|RESULTS|ab|15|entity|C0439234|year|tmco|||years|||0|888|1416|1421
SE|25462434|RESULTS|ab|15|entity|C1522577|follow-up|hlca|||follow-up|||0|824|1425|1434
SE|25462434|RESULTS|ab|15|entity|C0030705|Patients|podg|||patients|||0|824|1438|1446
SE|25462434|RESULTS|ab|15|entity|C0494165|Secondary malignant neoplasm of liver|neop|||liver metastasis|||0|1000|1458|1474
SE|25462434|RESULTS|ab|15|relation|1|1|C0494165|Secondary malignant neoplasm of liver|neop|neop|||liver metastasis|||0|1000|1458|1474|AUX|PROCESS_OF||1454|1457|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|824|1438|1446

SE|25462434|RESULTS|ab|16|text|1476|1596|On Kaplan-Meier analysis at 10 years, all-cause mortality was 7.3% and specific mortality because of melanoma was 2.4%.
SE|25462434|RESULTS|ab|16|entity|C0936012|Analysis|resa|||analysis|||0|827|1492|1500
SE|25462434|RESULTS|ab|16|entity|C0439234|year|tmco|||years|||0|861|1507|1512
SE|25462434|RESULTS|ab|16|entity|C0015127|Etiology aspects|ftcn|||cause|||0|661|1518|1523
SE|25462434|RESULTS|ab|16|entity|C0025202|melanoma|neop|||melanoma|||0|1000|1577|1585

SE|25462434|CONCLUSION|ab|17|text|1596|1793|CONCLUSION: Endoresection of high posterior melanomas was not associated with a higher risk of metastasis, death, or local recurrence than other reported techniques used to treat similar melanomas.
SE|25462434|CONCLUSION|ab|17|entity|C0205250|High|qlco|||high|||0|851|1625|1629
SE|25462434|CONCLUSION|ab|17|entity|C0205095|Dorsal|spco|||posterior|||0|851|1630|1639
SE|25462434|CONCLUSION|ab|17|entity|C0025202|melanoma|neop|||melanomas|||0|851|1640|1649
SE|25462434|CONCLUSION|ab|17|entity|C1518422|Not|ftcn|||not|||0|1000|1654|1657
SE|25462434|CONCLUSION|ab|17|entity|C0205250|High|qlco|||higher|||0|872|1676|1682
SE|25462434|CONCLUSION|ab|17|entity|C0035647|Risk|qlco|||risk|||0|872|1683|1687
SE|25462434|CONCLUSION|ab|17|entity|C0011065|Cessation of life|orgf|||death|||0|1000|1703|1708
SE|25462434|CONCLUSION|ab|17|entity|C0205276|Local|spco|||local|||0|888|1713|1718
SE|25462434|CONCLUSION|ab|17|entity|C0034897|Recurrence|phpr|||recurrence|||0|888|1719|1729
SE|25462434|CONCLUSION|ab|17|entity|C0025664|Methodology|inpr|||techniques|||0|888|1750|1760
SE|25462434|CONCLUSION|ab|17|entity|C0025202|melanoma|neop|||melanomas|||0|853|1783|1792


SE|25462435||ti|1|text|21|164|Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
SE|25462435||ti|1|entity|C1171892|VEGF protein, human|aapp,bacs|7422|VEGFA|vascular endothelial growth factor|||0|842|39|73
SE|25462435||ti|1|entity|C0035344|Retinopathy of Prematurity|dsyn|||retinopathy of prematurity|||0|923|88|114
SE|25462435||ti|1|entity|C1566537|Ranibizumab|aapp,imft,phsu|||Ranibizumab|||0|1000|135|146
SE|25462435||ti|1|entity|C0796392|bevacizumab|aapp,imft,phsu|||Bevacizumab|||0|1000|151|162
SE|25462435||ti|1|relation|2|1|C1566537|Ranibizumab|aapp,gngm,imft,phsu|aapp|||Ranibizumab|||0|1000|135|146|NOM|compared_with||116|126|2|2|C0796392|bevacizumab|aapp,gngm,imft,phsu|aapp|||Bevacizumab|||0|1000|151|162

SE|25462435|PURPOSE|ab|1|text|170|320|PURPOSE: To compare the effect and the treatment outcomes of bevacizumab and ranibizumab in the treatment of Type 1 retinopathy of prematurity (ROP).
SE|25462435|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|170|177
SE|25462435|PURPOSE|ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|194|200
SE|25462435|PURPOSE|ab|1|entity|C0085415|Treatment outcome|qlco|||treatment outcomes|||0|1000|209|227
SE|25462435|PURPOSE|ab|1|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|1000|231|242
SE|25462435|PURPOSE|ab|1|entity|C1566537|Ranibizumab|aapp,imft,phsu|||ranibizumab|||0|1000|247|258
SE|25462435|PURPOSE|ab|1|entity|C0441729|Type 1|clas|||Type 1|||0|762|279|285
SE|25462435|PURPOSE|ab|1|entity|C0035309|Retinal Diseases|dsyn|||retinopathy|||0|762|286|297
SE|25462435|PURPOSE|ab|1|relation|5|3|C0796392|bevacizumab|aapp,gngm,imft,phsu|aapp|||bevacizumab|||0|1000|231|242|VERB|compared_with||182|189|5|4|C1566537|Ranibizumab|aapp,gngm,imft,phsu|aapp|||ranibizumab|||0|1000|247|258

SE|25462435|METHODS|ab|2|text|320|422|METHODS: This was a bicentered retrospective case series performed at institutional referral centers.
SE|25462435|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|320|327
SE|25462435|METHODS|ab|2|entity|C1514923|Retrospective|qlco|||retrospective|||0|824|351|364
SE|25462435|METHODS|ab|2|entity|C0150093|Case Series|resa|||case series|||0|824|365|376
SE|25462435|METHODS|ab|2|entity|C0018704|Health care facility|hcro,mnob|||institutional|||0|750|390|403
SE|25462435|METHODS|ab|2|entity|C0205099|Central|spco|||centers|||0|750|413|420

SE|25462435|METHODS|ab|3|text|422|578|Seventy-two eyes of 37 patients who had intravitreal injections of either bevacizumab or ranibizumab as the primary treatment for Type 1 ROP were included.
SE|25462435|METHODS|ab|3|entity|C0205448|Two|qnco|||two|||0|790|430|433
SE|25462435|METHODS|ab|3|entity|C0015392|Eye|bpoc|||eyes|||0|790|434|438
SE|25462435|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|861|445|453
SE|25462435|METHODS|ab|3|entity|C1554888|Injection, intravitreal|ftcn|||intravitreal injections|||0|983|462|485
SE|25462435|METHODS|ab|3|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|861|496|507
SE|25462435|METHODS|ab|3|entity|C1566537|Ranibizumab|aapp,imft,phsu|||ranibizumab|||0|1000|511|522
SE|25462435|METHODS|ab|3|entity|C0441729|Type 1|clas|||Type 1|||0|840|552|558
SE|25462435|METHODS|ab|3|entity|C0035344|Retinopathy of Prematurity|dsyn|||ROP|||0|840|559|562
SE|25462435|METHODS|ab|3|relation|1|1|C0015392|Eye|bpoc|bpoc|||eyes|||0|790|434|438|PREP|PART_OF||439|441|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|445|453
SE|25462435|METHODS|ab|3|relation|5|1|C0796392|bevacizumab|aapp,gngm,imft,phsu|aapp|||bevacizumab|||0|861|496|507|NOM|TREATS||538|547|0|1|C0035344|Retinopathy of Prematurity|dsyn|dsyn|||ROP|||0|840|559|562
SE|25462435|METHODS|ab|3|relation|5|1|C1566537|Ranibizumab|aapp,gngm,imft,phsu|phsu|||ranibizumab|||0|1000|511|522|NOM|TREATS||538|547|0|1|C0035344|Retinopathy of Prematurity|dsyn|dsyn|||ROP|||0|840|559|562

SE|25462435|METHODS|ab|4|text|578|720|Outcomes' measures included regression and recurrence of ROP, the surgical complications, and refractive errors at a corrected age of 1 year.
SE|25462435|METHODS|ab|4|entity|C1274040|result|ftcn|||Outcomes|||0|966|578|586
SE|25462435|METHODS|ab|4|entity|C0034897|Recurrence|phpr|||recurrence|||0|1000|621|631
SE|25462435|METHODS|ab|4|entity|C0035309|Retinal Diseases|dsyn|||ROP|||0|812|635|638
SE|25462435|METHODS|ab|4|entity|C0221082|Etiology, operative procedure, as cause of|fndg|||surgical complications|||0|1000|644|666
SE|25462435|METHODS|ab|4|entity|C0034951|Refractive Errors|dsyn|||refractive errors|||0|1000|672|689
SE|25462435|METHODS|ab|4|entity|C0205202|Corrected|qlco|||corrected|||0|888|695|704
SE|25462435|METHODS|ab|4|entity|C0001779|Age|orga|||age|||0|888|705|708
SE|25462435|METHODS|ab|4|entity|C0439234|year|tmco|||year|||0|861|714|718

SE|25462435|RESULTS|ab|5|text|720|886|RESULTS: All but one eye in the bevacizumab group had retinal neovascularization and plus disease regression after anti-vascular endothelium growth factor treatment.
SE|25462435|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|720|727
SE|25462435|RESULTS|ab|5|entity|C0205447|One|qnco|||one|||0|888|737|740
SE|25462435|RESULTS|ab|5|entity|C0015392|Eye|bpoc|||eye|||0|888|741|744
SE|25462435|RESULTS|ab|5|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|888|752|763
SE|25462435|RESULTS|ab|5|entity|C0441833|Groups|inpr|||group|||0|888|764|769
SE|25462435|RESULTS|ab|5|entity|C0035320|Retinal Neovascularization|patf|||retinal neovascularization|||0|1000|774|800
SE|25462435|RESULTS|ab|5|entity|C0684320|Disease regression|patf|||disease regression|||0|1000|810|828
SE|25462435|RESULTS|ab|5|entity|C1171892|VEGF protein, human|aapp,bacs|7422|VEGFA|vascular endothelium growth factor|||0|858|840|874

SE|25462435|RESULTS|ab|6|text|886|1041|Neither recurrence of ROP nor major ocular complications, including cataract, retinal detachment, and endophthalmitis occurred in any of the treated eyes.
SE|25462435|RESULTS|ab|6|entity|C0034897|Recurrence|phpr|||recurrence|||0|1000|894|904
SE|25462435|RESULTS|ab|6|entity|C0035309|Retinal Diseases|dsyn|||ROP|||0|812|908|911
SE|25462435|RESULTS|ab|6|entity|C0205164|Major|qlco|||major|||0|851|916|921
SE|25462435|RESULTS|ab|6|entity|C0015392|Eye|bpoc|||ocular|||0|851|922|928
SE|25462435|RESULTS|ab|6|entity|C0009566|Complication|patf|||complications|||0|851|929|942
SE|25462435|RESULTS|ab|6|entity|C0086543|Cataract|anab,dsyn|||cataract|||0|1000|954|962
SE|25462435|RESULTS|ab|6|entity|C0035305|Retinal Detachment|dsyn|||retinal detachment|||0|1000|964|982
SE|25462435|RESULTS|ab|6|entity|C0014236|Endophthalmitis|dsyn|||endophthalmitis|||0|1000|988|1003
SE|25462435|RESULTS|ab|6|entity|C1292734|Treats|clas|||treated|||0|872|1027|1034
SE|25462435|RESULTS|ab|6|entity|C0015392|Eye|bpoc|||eyes|||0|872|1035|1039
SE|25462435|RESULTS|ab|6|relation|0|0|C0015392|Eye|bpoc|bpoc|||ocular|||0|851|922|928|MOD/HEAD|LOCATION_OF||922|942|0|0|C0009566|Complication|patf|patf|||complications|||0|851|929|942

SE|25462435|RESULTS|ab|7|text|1041|1225|There were no significant differences in mean refractive errors between the patients treated with intravitreal injections of bevacizumab or ranibizumab at the corrected age of 1 year.
SE|25462435|RESULTS|ab|7|entity|C0750502|Significant|idcn|||significant|||0|872|1055|1066
SE|25462435|RESULTS|ab|7|entity|C1547020|*Difference|qnco|||differences|||0|872|1067|1078
SE|25462435|RESULTS|ab|7|entity|C0034951|Refractive Errors|dsyn|||refractive errors|||0|901|1087|1104
SE|25462435|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|1000|1117|1125
SE|25462435|RESULTS|ab|7|entity|C1554888|Injection, intravitreal|ftcn|||intravitreal injections|||0|983|1139|1162
SE|25462435|RESULTS|ab|7|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|1000|1166|1177
SE|25462435|RESULTS|ab|7|entity|C1566537|Ranibizumab|aapp,imft,phsu|||ranibizumab|||0|1000|1181|1192
SE|25462435|RESULTS|ab|7|entity|C0205202|Corrected|qlco|||corrected|||0|888|1200|1209
SE|25462435|RESULTS|ab|7|entity|C0001779|Age|orga|||age|||0|888|1210|1213
SE|25462435|RESULTS|ab|7|entity|C0439234|year|tmco|||year|||0|861|1219|1223

SE|25462435|RESULTS|ab|8|text|1225|1317|A significantly higher chance of high myopia was noted in the bevacizumab group (P = 0.03).
SE|25462435|RESULTS|ab|8|entity|C0205250|High|qlco|||higher|||0|773|1241|1247
SE|25462435|RESULTS|ab|8|entity|C0237506|Chance|qlco|||chance|||0|773|1248|1254
SE|25462435|RESULTS|ab|8|entity|C0271183|Severe myopia|dsyn|||high myopia|||0|1000|1258|1269
SE|25462435|RESULTS|ab|8|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|888|1287|1298
SE|25462435|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|888|1299|1304

SE|25462435|CONCLUSION|ab|9|text|1317|1473|CONCLUSION: Both bevacizumab and ranibizumab showed similar efficacy in the regression of ROP with minor mean refractive errors at 1 year of corrected age.
SE|25462435|CONCLUSION|ab|9|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|1000|1334|1345
SE|25462435|CONCLUSION|ab|9|entity|C1566537|Ranibizumab|aapp,imft,phsu|||ranibizumab|||0|1000|1350|1361
SE|25462435|CONCLUSION|ab|9|entity|C0035309|Retinal Diseases|dsyn|||ROP|||0|812|1407|1410
SE|25462435|CONCLUSION|ab|9|entity|C0034951|Refractive Errors|dsyn|||refractive errors|||0|824|1427|1444
SE|25462435|CONCLUSION|ab|9|entity|C0439234|year|tmco|||year|||0|861|1450|1454
SE|25462435|CONCLUSION|ab|9|entity|C0205202|Corrected|qlco|||corrected|||0|888|1458|1467
SE|25462435|CONCLUSION|ab|9|entity|C0001779|Age|orga|||age|||0|888|1468|1471

SE|25462435|CONCLUSION|ab|10|text|1473|1545|However, high myopia was more prevalent in the bevacizumab-treated eyes.
SE|25462435|CONCLUSION|ab|10|entity|C0271183|Severe myopia|dsyn|||high myopia|||0|1000|1482|1493
SE|25462435|CONCLUSION|ab|10|entity|C0205172|More|ftcn|||more|||0|853|1498|1502
SE|25462435|CONCLUSION|ab|10|entity|C0033105|Statistical Prevalence|qnco|||prevalent|||0|853|1503|1512
SE|25462435|CONCLUSION|ab|10|entity|C0796392|bevacizumab|aapp,imft,phsu|||bevacizumab|||0|840|1520|1531
SE|25462435|CONCLUSION|ab|10|entity|C1292734|Treats|clas|||treated|||0|840|1532|1539
SE|25462435|CONCLUSION|ab|10|entity|C0015392|Eye|bpoc|||eyes|||0|840|1540|1544
SE|25462435|CONCLUSION|ab|10|relation|1|1|C0015392|Eye|bpoc|bpoc|||eyes|||0|840|1540|1544|PREP|LOCATION_OF||1513|1515|2|2|C0271183|Severe myopia|dsyn|dsyn|||high myopia|||0|1000|1482|1493


SE|25462436||ti|1|text|21|120|Changes in choroidal thickness after panretinal photocoagulation in patients with type 2 diabetes.
SE|25462436||ti|1|entity|C0008520|Choroid|bpoc|||choroidal|||0|853|32|41
SE|25462436||ti|1|entity|C1280412|Thick|qlco|||thickness|||0|853|42|51
SE|25462436||ti|1|entity|C0730064|Panretinal photocoagulation|topp|||panretinal photocoagulation|||0|1000|58|85
SE|25462436||ti|1|entity|C0030705|Patients|podg|||patients|||0|1000|89|97
SE|25462436||ti|1|entity|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|||type 2 diabetes|||0|1000|103|118
SE|25462436||ti|1|relation|0|0|C0730064|Panretinal photocoagulation|topp|topp|||panretinal photocoagulation|||0|1000|58|85|INFER|TREATS(INFER)||86|88|0|0|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|dsyn|||type 2 diabetes|||0|1000|103|118
SE|25462436||ti|1|relation|1|1|C0011860|Diabetes Mellitus, Non-Insulin-Dependent|dsyn|dsyn|||type 2 diabetes|||0|1000|103|118|PREP|PROCESS_OF||98|102|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|89|97
SE|25462436||ti|1|relation|3|1|C0730064|Panretinal photocoagulation|topp|topp|||panretinal photocoagulation|||0|1000|58|85|PREP|TREATS||86|88|2|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|89|97

SE|25462436|PURPOSE|ab|1|text|126|368|PURPOSE: To investigate the changes in choroidal thickness (CT) in the macular and photocoagulated areas of patients with diabetic retinopathy after panretinal photocoagulation (PRP) using enhanced depth imaging optical coherence tomography.
SE|25462436|PURPOSE|ab|1|entity|C1285529|Purpose|ftcn|||PURPOSE|||0|1000|126|133
SE|25462436|PURPOSE|ab|1|entity|C0008520|Choroid|bpoc|||choroidal|||0|853|165|174
SE|25462436|PURPOSE|ab|1|entity|C1280412|Thick|qlco|||thickness|||0|853|175|184
SE|25462436|PURPOSE|ab|1|entity|C0332574|Macular|spco|||macular|||0|1000|197|204
SE|25462436|PURPOSE|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|234|242
SE|25462436|PURPOSE|ab|1|entity|C0011884|Diabetic Retinopathy|dsyn|||diabetic retinopathy|||0|1000|248|268
SE|25462436|PURPOSE|ab|1|entity|C0730064|Panretinal photocoagulation|topp|||panretinal photocoagulation|||0|1000|275|302
SE|25462436|PURPOSE|ab|1|entity|C0205125|Depth|spco|||depth|||0|861|324|329
SE|25462436|PURPOSE|ab|1|entity|C0920367|Tomography, Optical Coherence|diap|||optical coherence tomography|||0|1000|338|366
SE|25462436|PURPOSE|ab|1|relation|4|1|C0011884|Diabetic Retinopathy|dsyn|dsyn|||diabetic retinopathy|||0|1000|248|268|PREP|PROCESS_OF||243|247|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|234|242

SE|25462436|METHODS|ab|2|text|368|524|METHODS: Patients with severe nonproliferative diabetic retinopathy or early proliferative diabetic retinopathy who needed PRP were included in this study.
SE|25462436|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|368|375
SE|25462436|METHODS|ab|2|entity|C0030705|Patients|podg|||Patients|||0|1000|377|385
SE|25462436|METHODS|ab|2|entity|C0730278|Severe nonproliferative diabetic retinopathy|dsyn|||severe nonproliferative diabetic retinopathy|||0|1000|391|435
SE|25462436|METHODS|ab|2|entity|C0730279|Proliferative diabetic retinopathy - non high risk|dsyn|||early proliferative diabetic retinopathy|||0|1000|439|479
SE|25462436|METHODS|ab|2|entity|C0730064|Panretinal photocoagulation|topp|||PRP|||0|1000|491|494
SE|25462436|METHODS|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|517|522
SE|25462436|METHODS|ab|2|relation|4|1|C0730278|Severe nonproliferative diabetic retinopathy|dsyn|dsyn|||severe nonproliferative diabetic retinopathy|||0|1000|391|435|PREP|PROCESS_OF||386|390|2|1|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|377|385
SE|25462436|METHODS|ab|2|relation|4|1|C0730279|Proliferative diabetic retinopathy - non high risk|dsyn|dsyn|||early proliferative diabetic retinopathy|||0|1000|439|479|PREP|PROCESS_OF||386|390|2|1|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|377|385

SE|25462436|METHODS|ab|3|text|524|703|Choroidal thickness in the macula and the photocoagulated area was measured with enhanced depth imaging optical coherence tomography at baseline, 1 month, and 3 months after PRP.
SE|25462436|METHODS|ab|3|entity|C0008520|Choroid|bpoc|||Choroidal|||0|853|524|533
SE|25462436|METHODS|ab|3|entity|C1280412|Thick|qlco|||thickness|||0|853|534|543
SE|25462436|METHODS|ab|3|entity|C0332573|Macule|sosy|||macula|||0|1000|551|557
SE|25462436|METHODS|ab|3|entity|C0205146|Area|spco|||area|||0|861|582|586
SE|25462436|METHODS|ab|3|entity|C0205125|Depth|spco|||depth|||0|861|614|619
SE|25462436|METHODS|ab|3|entity|C0920367|Tomography, Optical Coherence|diap|||optical coherence tomography|||0|1000|628|656
SE|25462436|METHODS|ab|3|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|660|668
SE|25462436|METHODS|ab|3|entity|C1442451|1 Month|tmco|||1 month|||0|1000|670|677
SE|25462436|METHODS|ab|3|entity|C1442461|3 Months|tmco|||3 months|||0|1000|683|691
SE|25462436|METHODS|ab|3|entity|C0730064|Panretinal photocoagulation|topp|||PRP|||0|1000|698|701
SE|25462436|METHODS|ab|3|relation|1|1|C0730064|Panretinal photocoagulation|topp|topp|||PRP|||0|1000|698|701|PREP|PRECEDES||692|697|8|4|C0920367|Tomography, Optical Coherence|diap|diap|||optical coherence tomography|||0|1000|628|656

SE|25462436|RESULTS|ab|4|text|703|906|RESULTS: The mean subfoveal CT increased significantly at 1 month (318.0 +/- 76.4 MUm, P < 0.001) and 3 months (317.4 +/- 75.3 MUm, P < 0.001) after PRP when compared with baseline (307.2 +/- 70.7 MUm).
SE|25462436|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|703|710
SE|25462436|RESULTS|ab|4|entity|C0442185|Subfoveal|spco|||subfoveal|||0|751|721|730
SE|25462436|RESULTS|ab|4|entity|C0008520|Choroid|bpoc|||CT|||0|751|731|733
SE|25462436|RESULTS|ab|4|entity|C1280412|Thick|qlco|||CT|||0|751|731|733
SE|25462436|RESULTS|ab|4|entity|C1442451|1 Month|tmco|||1 month|||0|1000|761|768
SE|25462436|RESULTS|ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUm|||0|804|785|788
SE|25462436|RESULTS|ab|4|entity|C1442461|3 Months|tmco|||3 months|||0|1000|805|813
SE|25462436|RESULTS|ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUm|||0|804|830|833
SE|25462436|RESULTS|ab|4|entity|C0730064|Panretinal photocoagulation|topp|||PRP|||0|1000|852|855
SE|25462436|RESULTS|ab|4|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|875|883
SE|25462436|RESULTS|ab|4|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUm|||0|804|900|903

SE|25462436|RESULTS|ab|5|text|906|1097|The mean CT in the photocoagulated area decreased significantly from 227.5 +/- 45.0 MUm to 206.9 +/- 41.1 MUm (P < 0.001) at 1 month and 206.0 +/- 41.4 MUm (P < 0.001) at 3 months after PRP.
SE|25462436|RESULTS|ab|5|entity|C0008520|Choroid|bpoc|||CT|||0|754|915|917
SE|25462436|RESULTS|ab|5|entity|C1280412|Thick|qlco|||CT|||0|754|915|917
SE|25462436|RESULTS|ab|5|entity|C0205146|Area|spco|||area|||0|861|941|945
SE|25462436|RESULTS|ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUm|||0|804|990|993
SE|25462436|RESULTS|ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUm|||0|804|1012|1015
SE|25462436|RESULTS|ab|5|entity|C1442451|1 Month|tmco|||1 month|||0|1000|1031|1038
SE|25462436|RESULTS|ab|5|entity|C1009574|Chrysanthemum x morifolium|plnt|||MUm|||0|804|1058|1061
SE|25462436|RESULTS|ab|5|entity|C1442461|3 Months|tmco|||3 months|||0|1000|1077|1085
SE|25462436|RESULTS|ab|5|entity|C0730064|Panretinal photocoagulation|topp|||PRP|||0|1000|1092|1095

SE|25462436|RESULTS|ab|6|text|1097|1207|The subgroup analysis showed similar trends of CT changes in patients with or without diabetic macular edema.
SE|25462436|RESULTS|ab|6|entity|C1515021|Subgroup|clas|||subgroup|||0|888|1101|1109
SE|25462436|RESULTS|ab|6|entity|C0936012|Analysis|resa|||analysis|||0|888|1110|1118
SE|25462436|RESULTS|ab|6|entity|C1521798|trend|tmco|||trends|||0|853|1134|1140
SE|25462436|RESULTS|ab|6|entity|C0008520|Choroid|bpoc|||CT|||0|853|1144|1146
SE|25462436|RESULTS|ab|6|entity|C1280412|Thick|qlco|||CT|||0|853|1144|1146
SE|25462436|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|1000|1158|1166
SE|25462436|RESULTS|ab|6|entity|C0730285|Diabetic macular edema|dsyn|||diabetic macular edema|||0|1000|1183|1205

SE|25462436|RESULTS|ab|7|text|1207|1340|The mean change in CT was not statistically significantly correlated with the mean change in best-corrected visual acuity after PRP.
SE|25462436|RESULTS|ab|7|entity|C0008520|Choroid|bpoc|||CT|||0|853|1226|1228
SE|25462436|RESULTS|ab|7|entity|C1280412|Thick|qlco|||CT|||0|853|1226|1228
SE|25462436|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|861|1233|1236
SE|25462436|RESULTS|ab|7|entity|C1275680|Corrected visual field|clna|||corrected visual acuity|||0|916|1305|1328
SE|25462436|RESULTS|ab|7|entity|C0730064|Panretinal photocoagulation|topp|||PRP|||0|1000|1335|1338

SE|25462436|CONCLUSION|ab|8|text|1340|1582|CONCLUSION: In patients with severe nonproliferative diabetic retinopathy or early proliferative diabetic retinopathy, the mean CT increased significantly in the macular area and decreased significantly in the photocoagulated area after PRP.
SE|25462436|CONCLUSION|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1355|1363
SE|25462436|CONCLUSION|ab|8|entity|C0730278|Severe nonproliferative diabetic retinopathy|dsyn|||severe nonproliferative diabetic retinopathy|||0|1000|1369|1413
SE|25462436|CONCLUSION|ab|8|entity|C0730279|Proliferative diabetic retinopathy - non high risk|dsyn|||early proliferative diabetic retinopathy|||0|1000|1417|1457
SE|25462436|CONCLUSION|ab|8|entity|C0008520|Choroid|bpoc|||CT|||0|754|1468|1470
SE|25462436|CONCLUSION|ab|8|entity|C1280412|Thick|qlco|||CT|||0|754|1468|1470
SE|25462436|CONCLUSION|ab|8|entity|C0332574|Macular|spco|||macular|||0|888|1502|1509
SE|25462436|CONCLUSION|ab|8|entity|C0205146|Area|spco|||area|||0|888|1510|1514
SE|25462436|CONCLUSION|ab|8|entity|C0205146|Area|spco|||area|||0|861|1566|1570
SE|25462436|CONCLUSION|ab|8|entity|C0730064|Panretinal photocoagulation|topp|||PRP|||0|1000|1577|1580
SE|25462436|CONCLUSION|ab|8|relation|6|1|C0730278|Severe nonproliferative diabetic retinopathy|dsyn|dsyn|||severe nonproliferative diabetic retinopathy|||0|1000|1369|1413|PREP|PROCESS_OF||1364|1368|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1355|1363
SE|25462436|CONCLUSION|ab|8|relation|6|1|C0730279|Proliferative diabetic retinopathy - non high risk|dsyn|dsyn|||early proliferative diabetic retinopathy|||0|1000|1417|1457|PREP|PROCESS_OF||1364|1368|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1355|1363

SE|25462436|CONCLUSION|ab|9|text|1582|1695|The results might reflect a redistribution of choroidal blood flow, which may be critical for retinal metabolism.
SE|25462436|CONCLUSION|ab|9|entity|C1274040|result|ftcn|||results|||0|966|1586|1593
SE|25462436|CONCLUSION|ab|9|entity|C0332620|Redistribution|ftcn|||redistribution|||0|1000|1610|1624
SE|25462436|CONCLUSION|ab|9|entity|C0008520|Choroid|bpoc|||choroidal|||0|865|1628|1637
SE|25462436|CONCLUSION|ab|9|entity|C0232338|Blood flow|orgf|||blood flow|||0|865|1638|1648
SE|25462436|CONCLUSION|ab|9|entity|C1511545|Critical|qlco|||critical|||0|1000|1663|1671
SE|25462436|CONCLUSION|ab|9|entity|C1327390|retinal metabolism|moft|||retinal metabolism|||0|1000|1676|1694


SE|25462437||ti|1|text|21|77|Regulation of Flavivirus RNA synthesis and replication.
SE|25462437||ti|1|entity|C0851285|Regulation|gora|||Regulation|||0|1000|21|31
SE|25462437||ti|1|entity|C0016215|Flavivirus|virs|||Flavivirus|||0|901|35|45
SE|25462437||ti|1|entity|C1328948|RNA Synthesis|moft|||RNA synthesis|||0|901|46|59

SE|25462437||ab|1|text|83|273|RNA synthesis and replication of the members of the Flavivirus genus (including dengue, West Nile and Japanese encephalitis viruses) is regulated by a wide variety of mechanisms and actors.
SE|25462437||ab|1|entity|C1328948|RNA Synthesis|moft|||RNA synthesis|||0|1000|83|96
SE|25462437||ab|1|entity|C0680022|member|popg|||members|||0|966|120|127
SE|25462437||ab|1|entity|C0016215|Flavivirus|virs|||Flavivirus|||0|694|135|145
SE|25462437||ab|1|entity|C0206749|Encephalitis Viruses, Japanese|virs|||Japanese encephalitis viruses|||0|1000|185|214
SE|25462437||ab|1|entity|C0332464|Widening|spco|||wide|||0|694|234|238
SE|25462437||ab|1|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|1000|250|260
SE|25462437||ab|1|entity|C0335083|Actor|prog|||actors|||0|1000|265|271

SE|25462437||ab|2|text|273|538|These include the sequestration of the RNA-dependent RNA polymerase (RdRp) for functions other than RNA synthesis, regulatory interactions with other viral and host proteins within the replication complex (RC), and regulatory elements within the RNA genome itself.
SE|25462437||ab|2|entity|C0443301|Sequestration|ftcn|||sequestration|||0|1000|291|304
SE|25462437||ab|2|entity|C0035685|RNA-Directed RNA Polymerase|aapp,enzy|||RNA-dependent RNA polymerase|||0|1000|312|340
SE|25462437||ab|2|entity|C0542341|Function|ftcn|||functions|||0|1000|352|361
SE|25462437||ab|2|entity|C1328948|RNA Synthesis|moft|||RNA synthesis|||0|1000|373|386
SE|25462437||ab|2|entity|C0220905|regulatory|rnlw|||regulatory|||0|694|388|398
SE|25462437||ab|2|entity|C0521026|Viral|ftcn|||viral|||0|1000|423|428
SE|25462437||ab|2|entity|C1167395|host|celc|||host|||0|888|433|437
SE|25462437||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|438|446
SE|25462437||ab|2|entity|C0439855|Complex|qlco|||complex|||0|888|470|477
SE|25462437||ab|2|entity|C1514827|Regulatory Element|nusq|||regulatory elements|||0|983|488|507
SE|25462437||ab|2|entity|C0035668|RNA|bacs,nnon|||RNA|||0|888|519|522
SE|25462437||ab|2|entity|C0017428|Genome|gngm|||genome|||0|888|523|529

SE|25462437||ab|3|text|538|659|In this review, we discuss our current knowledge of the multiple levels at which Flavivirus RNA synthesis is controlled.
SE|25462437||ab|3|entity|C0521116|Current|tmco|||current|||0|888|569|576
SE|25462437||ab|3|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|577|586
SE|25462437||ab|3|entity|C0439064|Numerous|qnco|||multiple|||0|888|594|602
SE|25462437||ab|3|entity|C0441889|Levels|inpr|||levels|||0|888|603|609
SE|25462437||ab|3|entity|C0016215|Flavivirus|virs|||Flavivirus|||0|901|619|629
SE|25462437||ab|3|entity|C1328948|RNA Synthesis|moft|||RNA synthesis|||0|901|630|643

SE|25462437||ab|4|text|659|863|We aim to bring together two active research fields: the structural and functional biology of individual proteins of the RC and the impressive wealth of knowledge acquired regarding the viral genomic RNA.
SE|25462437||ab|4|entity|C0205448|Two|qnco|||two|||0|762|684|687
SE|25462437||ab|4|entity|C0205177|Active|ftcn|||active|||0|762|688|694
SE|25462437||ab|4|entity|C0035168|research|resa|||research|||0|762|695|703
SE|25462437||ab|4|entity|C1521738|Field|cnce|||fields|||0|762|704|710
SE|25462437||ab|4|entity|C0205245|Functional|ftcn|||functional|||0|888|731|741
SE|25462437||ab|4|entity|C0005532|Biology|bmod|||biology|||0|888|742|749
SE|25462437||ab|4|entity|C0237401|Individual|humn|||individual|||0|888|753|763
SE|25462437||ab|4|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|764|772
SE|25462437||ab|4|entity|C0439855|Complex|qlco|||RC|||0|888|780|782
SE|25462437||ab|4|entity|C0699759|Wealthy|qlco|||wealth|||0|789|802|808
SE|25462437||ab|4|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|812|821
SE|25462437||ab|4|entity|C0035736|RNA, Viral|nnon|||viral genomic RNA|||0|913|845|862


SE|25462438||ti|1|text|21|105|Past, present, and future perspectives on the diagnosis of Roseolovirus infections.
SE|25462438||ti|1|entity|C1444637|Past|tmco|||Past|||0|1000|21|25
SE|25462438||ti|1|entity|C0150312|Present|qnco|||present|||0|1000|27|34
SE|25462438||ti|1|entity|C0016884|Future|tmco|||future|||0|694|40|46
SE|25462438||ti|1|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|67|76
SE|25462438||ti|1|entity|C0376549|Roseolovirus Infections|dsyn|||Roseolovirus infections|||0|1000|80|103

SE|25462438||ab|1|text|111|218|Diagnosis of Roseolovirus infections mandates careful selection of patients, samples, and testing methods.
SE|25462438||ab|1|entity|C0011900|Diagnosis|hlca|||Diagnosis|||0|1000|111|120
SE|25462438||ab|1|entity|C0376549|Roseolovirus Infections|dsyn|||Roseolovirus infections|||0|1000|124|147
SE|25462438||ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|178|186
SE|25462438||ab|1|entity|C0871511|Testing Methods|inpr|||testing methods|||0|1000|201|216

SE|25462438||ab|2|text|218|285|We review advances in the field and highlight research priorities.
SE|25462438||ab|2|entity|C0725066|Advance|medd|||advances|||0|966|228|236
SE|25462438||ab|2|entity|C1521738|Field|cnce|||field|||0|1000|244|249
SE|25462438||ab|2|entity|C0376368|Research Priorities|resa|||research priorities|||0|901|264|283

SE|25462438||ab|3|text|285|398|Quantitative (q)PCR can accurately identify and distinguish between human herpesvirus 6 (HHV-6) species A and B.
SE|25462438||ab|3|entity|C0392762|Quantitative|qnco|||Quantitative|||0|1000|285|297
SE|25462438||ab|3|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|1000|301|304
SE|25462438||ab|3|entity|C0019381|Herpesvirus 6, Human|virs|||human herpesvirus 6|||0|916|353|372
SE|25462438||ab|3|entity|C1548151|Species|idcn|||species|||0|916|381|388

SE|25462438||ab|4|text|398|468|Whether screening of high-risk patients improves outcomes is unclear.
SE|25462438||ab|4|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|406|415
SE|25462438||ab|4|entity|C0205250|High|qlco|||high|||0|851|419|423
SE|25462438||ab|4|entity|C0035647|Risk|qlco|||risk|||0|851|424|428
SE|25462438||ab|4|entity|C0030705|Patients|podg|||patients|||0|851|429|437
SE|25462438||ab|4|entity|C1274040|result|ftcn|||outcomes|||0|966|447|455

SE|25462438||ab|5|text|468|572|Chromosomally integrated (ci)HHV-6 confounds test interpretation but can be ruled out with digital PCR.
SE|25462438||ab|5|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|884|497|502
SE|25462438||ab|5|entity|C0459471|Interpretation|inpr|||interpretation|||0|1000|518|532
SE|25462438||ab|5|entity|C0439787|Out|spco|||out|||0|1000|550|553
SE|25462438||ab|5|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|861|567|570

SE|25462438||ab|6|text|572|736|Reverse transcription qPCR may be a more specific and clinically applicable test for actively replicating Roseoloviruses, particularly among patients with ciHHV-6.
SE|25462438||ab|6|entity|C0035380|Reverse Transcription|genf|||Reverse transcription|||0|734|572|593
SE|25462438||ab|6|entity|C0205172|More|ftcn|||more|||0|694|608|612
SE|25462438||ab|6|entity|C0039593|Testing|resa|||test|||0|827|648|652
SE|25462438||ab|6|entity|C0205173|Duplicate|ftcn|||replicating|||0|773|666|677
SE|25462438||ab|6|entity|C0376477|Roseolovirus|virs|||Roseoloviruses|||0|773|678|692
SE|25462438||ab|6|entity|C0030705|Patients|podg|||patients|||0|1000|713|721
SE|25462438||ab|6|relation|4|1|C0376477|Roseolovirus|virs|virs|||Roseoloviruses|||0|773|678|692|PREP|PROCESS_OF||707|712|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|713|721

SE|25462438||ab|7|text|736|803|Interpretation of Roseolovirus test results faces many challenges.
SE|25462438||ab|7|entity|C0459471|Interpretation|inpr|||Interpretation|||0|1000|736|750
SE|25462438||ab|7|entity|C0376477|Roseolovirus|virs|||Roseolovirus|||0|890|754|766
SE|25462438||ab|7|entity|C0456984|Test Result|fndg|||test results|||0|890|767|779

SE|25462438||ab|8|text|803|987|However, careful application of refined and emerging diagnostic techniques will allow for increasingly accurate diagnosis of clinically significant infections and disease associations.
SE|25462438||ab|8|entity|C0430022|diagnostic procedure|diap|||diagnostic techniques|||0|884|856|877
SE|25462438||ab|8|entity|C0443131|Accurate|qlco|||accurate|||0|790|906|914
SE|25462438||ab|8|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|790|915|924
SE|25462438||ab|8|entity|C0750502|Significant|idcn|||significant|||0|790|939|950
SE|25462438||ab|8|entity|C0021311|Infection|dsyn|||infections|||0|790|951|961
SE|25462438||ab|8|entity|C1511978|Disease Association|tmco|||disease associations|||0|983|966|986
SE|25462438||ab|8|relation|3|1|C0430022|diagnostic procedure|diap|diap|||diagnostic techniques|||0|884|856|877|NOM|DIAGNOSES||915|924|2|1|C0021311|Infection|dsyn|dsyn|||infections|||0|790|951|961


SE|25462439||ti|1|text|21|79|Clinical impact of primary infection with roseoloviruses.
SE|25462439||ti|1|entity|C0205210|Clinical|qlco|||Clinical|||0|888|21|29
SE|25462439||ti|1|entity|C0948192|Primary infection NOS|dsyn|||primary infection|||0|1000|40|57
SE|25462439||ti|1|entity|C0376477|Roseolovirus|virs|||roseoloviruses|||0|1000|63|77
SE|25462439||ti|1|relation|2|2|C0376477|Roseolovirus|virs|virs|||roseoloviruses|||0|1000|63|77|NOM|INTERACTS_WITH||30|36|2|1|C0948192|Primary infection NOS|dsyn|dsyn|||primary infection|||0|1000|40|57

SE|25462439||ab|1|text|85|296|The roseoloviruses, human herpesvirus-6A -6B and -7 (HHV-6A, HHV-6B and HHV-7) cause acute infection, establish latency, and in the case of HHV-6A and HHV-6B, whole virus can integrate into the host chromosome.
SE|25462439||ab|1|entity|C0376477|Roseolovirus|virs|||roseoloviruses|||0|1000|89|103
SE|25462439||ab|1|entity|C0887939|Herpesvirus 6B, Human|virs|||human herpesvirus-6A -6B|||0|916|105|129
SE|25462439||ab|1|entity|C0887938|Herpesvirus 6A, Human|virs|||HHV-6A|||0|1000|138|144
SE|25462439||ab|1|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|1000|146|152
SE|25462439||ab|1|entity|C0079506|Herpesvirus 7, Human|virs|||HHV-7|||0|1000|157|162
SE|25462439||ab|1|entity|C0275518|Acute infectious disease|dsyn|||acute infection|||0|1000|170|185
SE|25462439||ab|1|entity|C0205275|Latent|qlco|||latency|||0|928|197|204
SE|25462439||ab|1|entity|C0887938|Herpesvirus 6A, Human|virs|||HHV-6A|||0|1000|225|231
SE|25462439||ab|1|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|1000|236|242
SE|25462439||ab|1|entity|C0444667|Whole|qnco|||whole|||0|888|244|249
SE|25462439||ab|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|888|250|255
SE|25462439||ab|1|entity|C1167395|host|celc|||host|||0|888|279|283
SE|25462439||ab|1|entity|C0008633|Chromosomes|celc|||chromosome|||0|888|284|294
SE|25462439||ab|1|relation|5|4|C0887939|Herpesvirus 6B, Human|virs|virs|||human herpesvirus-6A -6B|||0|916|105|129|VERB|CAUSES||164|169|7|1|C0275518|Acute infectious disease|dsyn|dsyn|||acute infection|||0|1000|170|185

SE|25462439||ab|2|text|296|420|Primary infection with HHV-6B occurs in nearly all children and was first linked to the clinical syndrome roseola infantum.
SE|25462439||ab|2|entity|C0948192|Primary infection NOS|dsyn|||Primary infection|||0|1000|296|313
SE|25462439||ab|2|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|1000|319|325
SE|25462439||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|347|355
SE|25462439||ab|2|entity|C1279901|Firstly|qlco|||first|||0|1000|364|369
SE|25462439||ab|2|entity|C0221444|Clinical Syndromes|clas|||clinical syndrome|||0|877|384|401
SE|25462439||ab|2|entity|C0015231|Exanthema Subitum|dsyn|||roseola infantum|||0|877|402|418
SE|25462439||ab|2|relation|3|2|C0887939|Herpesvirus 6B, Human|virs|virs|||HHV-6B|||0|1000|319|325|VERB|COEXISTS_WITH||370|376|1|1|C0015231|Exanthema Subitum|dsyn|dsyn|||roseola infantum|||0|877|402|418

SE|25462439||ab|3|text|420|679|However, roseolovirus infection results in a spectrum of clinical disease, ranging from asymptomatic infection to acute febrile illnesses with severe neurologic complications and accounts for a significant portion of healthcare utilization by young children.
SE|25462439||ab|3|entity|C0376549|Roseolovirus Infections|dsyn|||roseolovirus infection|||0|1000|429|451
SE|25462439||ab|3|entity|C0205210|Clinical|qlco|||clinical|||0|888|477|485
SE|25462439||ab|3|entity|C0012634|Disease|dsyn|||disease|||0|888|486|493
SE|25462439||ab|3|entity|C0231221|Asymptomatic|fndg|||asymptomatic|||0|888|508|520
SE|25462439||ab|3|entity|C0205178|acute|tmco|||acute|||0|890|534|539
SE|25462439||ab|3|entity|C0743841|Disorder characterized by fever|dsyn|||febrile illnesses|||0|890|540|557
SE|25462439||ab|3|entity|C0205082|Severe|qlco|||severe|||0|890|563|569
SE|25462439||ab|3|entity|C0235029|NEUROLOGIC COMPLICATION|patf|||neurologic complications|||0|890|570|594
SE|25462439||ab|3|entity|C0750502|Significant|idcn|||significant|||0|694|614|625
SE|25462439||ab|3|entity|C0086388|Health Care|hlca|||healthcare|||0|694|637|647
SE|25462439||ab|3|entity|C0332239|Young|tmco|||young|||0|888|663|668
SE|25462439||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|888|669|677

SE|25462439||ab|4|text|679|917|Recent advances have underscored the association of HHV-6B and HHV-7 primary infection with febrile status epilepticus as well as the role of reactivation of latent infection in encephalitis following cord blood stem cell transplantation.
SE|25462439||ab|4|entity|C0332185|Recent|tmco|||Recent|||0|872|679|685
SE|25462439||ab|4|entity|C0725066|Advance|medd|||advances|||0|872|686|694
SE|25462439||ab|4|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|1000|731|737
SE|25462439||ab|4|entity|C0079506|Herpesvirus 7, Human|virs|||HHV-7|||0|888|742|747
SE|25462439||ab|4|entity|C0948192|Primary infection NOS|dsyn|||primary infection|||0|888|748|765
SE|25462439||ab|4|entity|C0015967|Fever|fndg|||febrile|||0|901|771|778
SE|25462439||ab|4|entity|C0038220|Status Epilepticus|dsyn|||status epilepticus|||0|901|779|797
SE|25462439||ab|4|entity|C0035820|Role|socb|||role|||0|1000|813|817
SE|25462439||ab|4|entity|C0872054|Latent Infection|dsyn|||latent infection|||0|1000|837|853
SE|25462439||ab|4|entity|C0014038|Encephalitis|dsyn|||encephalitis|||0|1000|857|869
SE|25462439||ab|4|entity|C1135976|Cord Blood Stem Cell Transplantation|topp|||cord blood stem cell transplantation|||0|1000|880|916
SE|25462439||ab|4|relation|4|2|C0872054|Latent Infection|dsyn|dsyn|||latent infection|||0|1000|837|853|NOM|AFFECTS||813|817|4|3|C0014038|Encephalitis|dsyn|dsyn|||encephalitis|||0|1000|857|869


SE|25462441||ti|1|text|21|99|Bromovirus-induced remodeling of host membranes during viral RNA replication.
SE|25462441||ti|1|entity|C0206267|Bromovirus|virs|||Bromovirus|||0|623|21|31
SE|25462441||ti|1|entity|C0205263|Induced|ftcn|||induced|||0|623|32|39
SE|25462441||ti|1|entity|C1167395|host|celc|||host|||0|888|54|58
SE|25462441||ti|1|entity|C0025255|Tissue membrane|tisu|||membranes|||0|888|59|68
SE|25462441||ti|1|entity|C0035736|RNA, Viral|nnon|||viral RNA|||0|901|76|85

SE|25462441||ab|1|text|105|332|With its high yield, small genome, and ability to replicate in the yeast Saccharomyces cerevisiae, Brome mosaic virus (BMV) has served as a productive model to study the general features of positive-strand RNA virus infection.
SE|25462441||ab|1|entity|C0205250|High|qlco|||high|||0|694|114|118
SE|25462441||ab|1|entity|C0700321|Small|qnco|||small|||0|888|126|131
SE|25462441||ab|1|entity|C0017428|Genome|gngm|||genome|||0|888|132|138
SE|25462441||ab|1|entity|C0085732|Ability|orga|||ability|||0|1000|144|151
SE|25462441||ab|1|entity|C0036025|Saccharomyces cerevisiae|fngs|||yeast|||0|901|172|177
SE|25462441||ab|1|entity|C0036025|Saccharomyces cerevisiae|fngs|||Saccharomyces cerevisiae|||0|901|178|202
SE|25462441||ab|1|entity|C0376417|Brome mosaic virus|virs|||Brome mosaic virus|||0|1000|204|222
SE|25462441||ab|1|entity|C0033269|Productivity|qnco|||productive|||0|853|245|255
SE|25462441||ab|1|entity|C0026336|Study models|inpr,resd|||model|||0|853|256|261
SE|25462441||ab|1|entity|C0205246|Generalized|spco|||general|||0|694|275|282
SE|25462441||ab|1|entity|C1446409|Positive|qlco|||positive|||0|850|295|303
SE|25462441||ab|1|entity|C0035690|RNA Virus Infections|dsyn|||RNA virus infection|||0|850|311|330

SE|25462441||ab|2|text|332|515|BMV RNA is replicated in spherules, vesicle-like invaginations of the outer perinuclear endoplasmic reticulum membrane that remain connected to the cytoplasm via a neck-like opening.
SE|25462441||ab|2|entity|C0376417|Brome mosaic virus|virs|||BMV|||0|916|332|335
SE|25462441||ab|2|entity|C0035668|RNA|bacs,nnon|||RNA|||0|916|336|339
SE|25462441||ab|2|entity|C0333262|Vesicle|acab|||vesicle|||0|1000|368|375
SE|25462441||ab|2|entity|C0221224|Invagination|anab|||invaginations|||0|966|381|394
SE|25462441||ab|2|entity|C0205101|Extrinsic|spco|||outer|||0|850|402|407
SE|25462441||ab|2|entity|C0230770|Endoplasmic reticulum, membrane|celc|||endoplasmic reticulum membrane|||0|850|420|450
SE|25462441||ab|2|entity|C0010834|Cytoplasm|celc|||cytoplasm|||0|694|480|489
SE|25462441||ab|2|entity|C0027530|Neck|blor|||neck|||0|1000|496|500
SE|25462441||ab|2|entity|C0175566|Open|spco|||opening|||0|1000|506|513
SE|25462441||ab|2|relation|0|0|C0035668|RNA|bacs,nnon|bacs|||RNA|||0|916|336|339|MOD/HEAD|PART_OF||332|339|0|0|C0376417|Brome mosaic virus|virs|virs|||BMV|||0|916|332|335

SE|25462441||ab|3|text|515|592|Each spherule contains the viral replicase proteins as well as genomic RNAs.
SE|25462441||ab|3|entity|C0178827|replicase|aapp,enzy|||replicase|||0|901|548|557
SE|25462441||ab|3|entity|C0042736|Viral Proteins|aapp,bacs|||viral replicase proteins|||0|901|542|566
SE|25462441||ab|3|entity|C0035668|RNA|bacs,nnon|||RNAs|||0|827|586|590
SE|25462441||ab|3|relation|0|0|C0042736|Viral Proteins|aapp,gngm,bacs|bacs|||viral replicase proteins|||0|901|542|566|MOD/HEAD|PART_OF||548|566|0|0|C0178827|replicase|aapp,gngm,enzy|aapp|||replicase|||0|901|548|557

SE|25462441||ab|4|text|592|780|Recent advances indicate that multiple interactions between the viral proteins with themselves, cellular membranes, and host factors play crucial roles in BMV-mediated spherule formation.
SE|25462441||ab|4|entity|C0332185|Recent|tmco|||Recent|||0|872|592|598
SE|25462441||ab|4|entity|C0725066|Advance|medd|||advances|||0|872|599|607
SE|25462441||ab|4|entity|C0439064|Numerous|qnco|||multiple|||0|694|622|630
SE|25462441||ab|4|entity|C0042736|Viral Proteins|aapp,bacs|||viral proteins|||0|1000|656|670
SE|25462441||ab|4|entity|C1516370|Cellular Membrane|celc|||cellular membranes|||0|983|688|706
SE|25462441||ab|4|entity|C1167395|host|celc|||host|||0|872|712|716
SE|25462441||ab|4|entity|C1521761|Factor|ftcn|||factors|||0|872|717|724
SE|25462441||ab|4|entity|C0035820|Role|socb|||roles|||0|861|738|743
SE|25462441||ab|4|entity|C0376417|Brome mosaic virus|virs|||BMV|||0|810|747|750
SE|25462441||ab|4|entity|C0086597|Mediating|socb|||mediated|||0|810|751|759
SE|25462441||ab|4|entity|C1522492|Formation|ftcn|||formation|||0|810|769|778
SE|25462441||ab|4|relation|4|2|C0042736|Viral Proteins|aapp,gngm,bacs|aapp|||viral proteins|||0|1000|656|670|NOM|AFFECTS||717|724|4|0|C1167395|host|celc|celc|||host|||0|872|712|716
SE|25462441||ab|4|relation|4|2|C0042736|Viral Proteins|aapp,gngm,bacs|aapp|||viral proteins|||0|1000|656|670|NOM|AFFECTS||717|724|4|0|C1516370|Cellular Membrane|celc|celc|||cellular membranes|||0|983|688|706

SE|25462441||ab|5|text|780|923|These findings are probably applicable to other positive-strand RNA viruses and might potentially provide new targets for antiviral treatments.
SE|25462441||ab|5|entity|C0243095|Finding|ftcn|||findings|||0|1000|786|794
SE|25462441||ab|5|entity|C0332148|Probable diagnosis|qlco|||probably|||0|694|799|807
SE|25462441||ab|5|entity|C1446409|Positive|qlco|||positive|||0|824|828|836
SE|25462441||ab|5|entity|C0035691|RNA Viruses|virs|||RNA viruses|||0|824|844|855
SE|25462441||ab|5|entity|C0205314|New|tmco|||new|||0|872|886|889
SE|25462441||ab|5|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|861|912|922


SE|25462440||ti|1|text|21|91|Recent developments in animal models for human herpesvirus 6A and 6B.
SE|25462440||ti|1|entity|C0332185|Recent|tmco|||Recent|||0|872|21|27
SE|25462440||ti|1|entity|C1527148|Development|ftcn|||developments|||0|872|28|40
SE|25462440||ti|1|entity|C0599779|Animal Model|anim|||animal models|||0|1000|44|57
SE|25462440||ti|1|entity|C0887938|Herpesvirus 6A, Human|virs|||human herpesvirus 6A|||0|1000|62|82

SE|25462440||ab|1|text|97|222|Progress in the identification of suitable animal models for human herpesvirus (HHV)-6A and HHV-6B infections has been slow.
SE|25462440||ab|1|entity|C1280477|Progressing to|ftcn|||Progress|||0|1000|97|105
SE|25462440||ab|1|entity|C0599779|Animal Model|anim|||animal models|||0|901|140|153
SE|25462440||ab|1|entity|C0887938|Herpesvirus 6A, Human|virs|||human herpesvirus (HHV)-6A|||0|1000|158|184
SE|25462440||ab|1|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|916|189|195
SE|25462440||ab|1|entity|C0021311|Infection|dsyn|||infections|||0|916|196|206
SE|25462440||ab|1|entity|C0439834|Slow|qlco|||slow|||0|1000|216|220

SE|25462440||ab|2|text|222|344|Recently, new models have been established, mainly for HHV-6A, which reproduce some pathological features seen in humans.
SE|25462440||ab|2|entity|C0332185|Recent|tmco|||Recently|||0|1000|222|230
SE|25462440||ab|2|entity|C0205314|New|tmco|||new|||0|694|232|235
SE|25462440||ab|2|entity|C0887938|Herpesvirus 6A, Human|virs|||HHV-6A|||0|1000|277|283
SE|25462440||ab|2|entity|C1521733|Pathologic|ftcn|||pathological|||0|694|306|318
SE|25462440||ab|2|entity|C0020114|Human|humn|||humans|||0|1000|336|342
SE|25462440||ab|2|relation|3|2|C0887938|Herpesvirus 6A, Human|virs|virs|||HHV-6A|||0|1000|277|283|PREP|PROCESS_OF||333|335|1|1|C0020114|Human|grup,humn|humn|||humans|||0|1000|336|342

SE|25462440||ab|3|text|344|603|Neuroinflammatory signs were observed in infected marmosets and CD46-transgenic mice; although viral replication was not prominent, persistence of viral DNA and specific immunologic responses were detected, suggesting an immune-mediated pathogenic mechanism.
SE|25462440||ab|3|entity|C0220913|Manufactured sign|mnob|||signs|||0|861|362|367
SE|25462440||ab|3|entity|C0439663|Infected|ftcn|||infected|||0|888|385|393
SE|25462440||ab|3|entity|C0006764|Callithrix|mamm|||marmosets|||0|888|394|403
SE|25462440||ab|3|entity|||gngm|4179|CD46|CD46|||0|901|408|412
SE|25462440||ab|3|entity|C0025936|Mice, Transgenic|mamm|||transgenic mice|||0|901|413|428
SE|25462440||ab|3|entity|C0521026|Viral|ftcn|||viral|||0|888|439|444
SE|25462440||ab|3|entity|C1518422|Not|ftcn|||not|||0|851|461|464
SE|25462440||ab|3|entity|C0205402|Prominent|qlco|||prominent|||0|851|465|474
SE|25462440||ab|3|entity|C0546816|Persistence|menp|||persistence|||0|851|476|487
SE|25462440||ab|3|entity|C0012939|DNA, Viral|nnon|||viral DNA|||0|1000|491|500
SE|25462440||ab|3|entity|C0205470|immunologic|ftcn|||immunologic|||0|790|514|525
SE|25462440||ab|3|entity|C0871261|response|clna|||responses|||0|790|526|535
SE|25462440||ab|3|entity|C0439662|Immune|ftcn|||immune|||0|807|565|571
SE|25462440||ab|3|entity|C0086597|Mediating|socb|||mediated|||0|807|572|580
SE|25462440||ab|3|entity|C1136169|Pathogenicity|orga,qlco|||pathogenic|||0|807|581|591
SE|25462440||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|807|592|601

SE|25462440||ab|4|text|603|767|Pig-tailed macaques showed robust viral replication concomitant with acute-phase symptoms, and provided a model to study the effects of HHV-6A on AIDS progression.
SE|25462440||ab|4|entity|C0039005|Family suidae|mamm|||Pig|||0|840|603|606
SE|25462440||ab|4|entity|C0039259|Tail|bpoc|||tailed|||0|840|607|613
SE|25462440||ab|4|entity|C0024398|Macaca|mamm|||macaques|||0|840|614|622
SE|25462440||ab|4|entity|C0521026|Viral|ftcn|||viral|||0|790|637|642
SE|25462440||ab|4|entity|C1516780|Concomitant|qlco|||concomitant|||0|1000|655|666
SE|25462440||ab|4|entity|C0439557|Acute phase|tmco|||acute-phase|||0|901|672|683
SE|25462440||ab|4|entity|C1457887|Symptoms|sosy|||symptoms|||0|901|684|692
SE|25462440||ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|1000|709|714
SE|25462440||ab|4|entity|C1280500|Effect|qlco|||effects|||0|966|728|735
SE|25462440||ab|4|entity|C0887938|Herpesvirus 6A, Human|virs|||HHV-6A|||0|1000|739|745
SE|25462440||ab|4|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||AIDS|||0|888|749|753
SE|25462440||ab|4|entity|C0449258|Progression|ftcn|||progression|||0|888|754|765
SE|25462440||ab|4|relation|2|1|C0887938|Herpesvirus 6A, Human|virs|virs|||HHV-6A|||0|1000|739|745|NOM|INTERACTS_WITH||728|735|2|2|C0001175|Acquired Immunodeficiency Syndrome|dsyn|dsyn|||AIDS|||0|888|749|753

SE|25462440||ab|5|text|767|863|In humanized mice, viral replication was less evident, but infection led to T-cell alterations.
SE|25462440||ab|5|entity|C0026809|Mus|mamm|||mice|||0|861|780|784
SE|25462440||ab|5|entity|C0521026|Viral|ftcn|||viral|||0|888|786|791
SE|25462440||ab|5|entity|C0039194|T-Lymphocyte|cell|||T-cell|||0|884|843|849
SE|25462440||ab|5|entity|C1515926|Alteration|idcn|||alterations|||0|884|850|861

SE|25462440||ab|6|text|863|983|Altogether, these recent developments have opened new perspectives for studying the pathogenic role of HHV-6A in humans.
SE|25462440||ab|6|entity|C0332185|Recent|tmco|||recent|||0|872|881|887
SE|25462440||ab|6|entity|C1527148|Development|ftcn|||developments|||0|872|888|900
SE|25462440||ab|6|entity|C0175566|Open|spco|||opened|||0|606|906|912
SE|25462440||ab|6|entity|C0205314|New|tmco|||new|||0|606|913|916
SE|25462440||ab|6|entity|C0008972|Clinical Research|resa|||studying|||0|966|934|942
SE|25462440||ab|6|entity|C1136169|Pathogenicity|orga,qlco|||pathogenic|||0|853|947|957
SE|25462440||ab|6|entity|C0035820|Role|socb|||role|||0|853|958|962
SE|25462440||ab|6|entity|C0887938|Herpesvirus 6A, Human|virs|||HHV-6A|||0|1000|966|972
SE|25462440||ab|6|entity|C0020114|Human|humn|||humans|||0|1000|976|982
SE|25462440||ab|6|relation|5|1|C0887938|Herpesvirus 6A, Human|virs|virs|||HHV-6A|||0|1000|966|972|PREP|PROCESS_OF||973|975|1|1|C0020114|Human|grup,humn|humn|||humans|||0|1000|976|982


SE|25462442||ti|1|text|21|99|Chromosomally integrated HHV-6: impact on virus, cell and organismal biology.
SE|25462442||ti|1|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|861|46|51
SE|25462442||ti|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|63|68
SE|25462442||ti|1|entity|C0007634|Cells|cell|||cell|||0|1000|70|74
SE|25462442||ti|1|entity|C0029235|Organism|orgm|||organismal|||0|853|79|89
SE|25462442||ti|1|entity|C0005532|Biology|bmod|||biology|||0|853|90|97

SE|25462442||ab|1|text|105|170|HHV-6 integrates its genome into telomeres of human chromosomes.
SE|25462442||ab|1|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|105|110
SE|25462442||ab|1|entity|C0017428|Genome|gngm|||genome|||0|1000|126|132
SE|25462442||ab|1|entity|C0085187|telomere|celc|||telomeres|||0|1000|138|147
SE|25462442||ab|1|entity|C0008643|Chromosomes, Human|celc|||human chromosomes|||0|1000|151|168
SE|25462442||ab|1|relation|3|1|C0085187|telomere|celc|celc|||telomeres|||0|1000|138|147|PREP|PART_OF||148|150|1|1|C0008643|Chromosomes, Human|celc|celc|||human chromosomes|||0|1000|151|168

SE|25462442||ab|2|text|170|297|Integration can occur in somatic cells or gametes, the latter leading to individuals harboring the HHV-6 genome in every cell.
SE|25462442||ab|2|entity|C0737240|Somatic cell|cell|||somatic cells|||0|1000|195|208
SE|25462442||ab|2|entity|C0017471|Germ Cells|cell|||gametes|||0|1000|212|219
SE|25462442||ab|2|entity|C0237401|Individual|humn|||individuals|||0|1000|243|254
SE|25462442||ab|2|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|901|269|274
SE|25462442||ab|2|entity|C0017428|Genome|gngm|||genome|||0|901|275|281
SE|25462442||ab|2|entity|C0007634|Cells|cell|||cell|||0|1000|291|295
SE|25462442||ab|2|relation|1|1|C0007634|Cells|cell|cell|||cell|||0|1000|291|295|PREP|LOCATION_OF||282|284|6|1|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|901|269|274
SE|25462442||ab|2|relation|5|3|C0017471|Germ Cells|cell|cell|||gametes|||0|1000|212|219|VERB|LOCATION_OF||255|264|2|1|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|901|269|274
SE|25462442||ab|2|relation|5|3|C0737240|Somatic cell|cell|cell|||somatic cells|||0|1000|195|208|VERB|LOCATION_OF||255|264|2|1|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|901|269|274

SE|25462442||ab|3|text|297|428|This condition is transmitted to descendants and referred to as inherited chromosomally integrated human herpesvirus 6 (iciHHV-6).
SE|25462442||ab|3|entity|C0348080|Condition|qlco|||condition|||0|1000|302|311
SE|25462442||ab|3|entity|C0019381|Herpesvirus 6, Human|virs|||human herpesvirus 6|||0|884|396|415

SE|25462442||ab|4|text|428|535|Although integration can occur in different chromosomes, it invariably takes place in the telomere region.
SE|25462442||ab|4|entity|C1547020|*Difference|qnco|||different|||0|853|462|471
SE|25462442||ab|4|entity|C0008633|Chromosomes|celc|||chromosomes|||0|853|472|483
SE|25462442||ab|4|entity|C0442504|Place|spco|||place|||0|1000|505|510
SE|25462442||ab|4|entity|C0085187|telomere|celc|||telomere|||0|888|518|526
SE|25462442||ab|4|entity|C0205147|Region|spco|||region|||0|888|527|533

SE|25462442||ab|5|text|535|676|This integration mechanism represents a way to maintain the virus genome during latency, which is so far unique amongst human herpesviruses.
SE|25462442||ab|5|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|861|552|561
SE|25462442||ab|5|entity|C0042769|Virus Diseases|dsyn|||virus|||0|888|595|600
SE|25462442||ab|5|entity|C0017428|Genome|gngm|||genome|||0|888|601|607
SE|25462442||ab|5|entity|C0205275|Latent|qlco|||latency|||0|928|615|622
SE|25462442||ab|5|entity|C0020114|Human|humn|||human|||0|888|655|660
SE|25462442||ab|5|entity|C0019369|Herpesviridae|virs|||herpesviruses|||0|888|661|674
SE|25462442||ab|5|relation|0|0|C0019369|Herpesviridae|virs|virs|||herpesviruses|||0|888|661|674|MOD/HEAD|PROCESS_OF||655|674|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|655|660

SE|25462442||ab|6|text|676|817|Recent work provides evidence that the integrated HHV-6 genome can be mobilized from the host chromosome, resulting in the onset of disease.
SE|25462442||ab|6|entity|C0332185|Recent|tmco|||Recent|||0|888|676|682
SE|25462442||ab|6|entity|C0043227|Work|ocac|||work|||0|888|683|687
SE|25462442||ab|6|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|824|726|731
SE|25462442||ab|6|entity|C0017428|Genome|gngm|||genome|||0|824|732|738
SE|25462442||ab|6|entity|C1167395|host|celc|||host|||0|888|765|769
SE|25462442||ab|6|entity|C0008633|Chromosomes|celc|||chromosome|||0|888|770|780
SE|25462442||ab|6|entity|C0332162|Onset|qlco|||onset|||0|1000|799|804
SE|25462442||ab|6|entity|C0012634|Disease|dsyn|||disease|||0|1000|808|815

SE|25462442||ab|7|text|817|960|Details on required structural determinants, putative integration mechanisms and biological and medical consequences of iciHHV-6 are discussed.
SE|25462442||ab|7|entity|C1522508|Details|qlco|||Details|||0|1000|817|824
SE|25462442||ab|7|entity|C1514872|Required|ftcn|||required|||0|660|828|836
SE|25462442||ab|7|entity|C0441712|Mechanisms|ftcn|||mechanisms|||0|827|883|893
SE|25462442||ab|7|entity|C0205460|biological|ftcn|||biological|||0|1000|898|908
SE|25462442||ab|7|entity|C0205476|Medical|ftcn|||medical|||0|694|913|920
SE|25462442||ab|7|entity|C0019381|Herpesvirus 6, Human|virs|||iciHHV-6|||0|923|937|945


SE|25462443||ti|1|text|21|124|Expanding use of multi-origin subcellular membranes by positive-strand RNA viruses during replication.
SE|25462443||ti|1|entity|C0205229|Expanding|spco|||Expanding|||0|888|21|30
SE|25462443||ti|1|entity|C1442112|MULTI|qnco|||multi|||0|852|38|43
SE|25462443||ti|1|entity|C0439659|Beginning|tmco|||origin|||0|852|44|50
SE|25462443||ti|1|entity|C0682532|subcellular membrane|celc|||subcellular membranes|||0|852|51|72
SE|25462443||ti|1|entity|C1446409|Positive|qlco|||positive|||0|824|76|84
SE|25462443||ti|1|entity|C0035691|RNA Viruses|virs|||RNA viruses|||0|824|92|103

SE|25462443||ab|1|text|130|221|Positive-strand RNA viruses utilize various subcellular membrane surfaces for replication.
SE|25462443||ab|1|entity|C1446409|Positive|qlco|||Positive|||0|824|130|138
SE|25462443||ab|1|entity|C0035691|RNA Viruses|virs|||RNA viruses|||0|824|146|157
SE|25462443||ab|1|entity|C0682532|subcellular membrane|celc|||subcellular membrane|||0|901|174|194

SE|25462443||ab|2|text|221|453|The subverted membranes facilitate the assembly of viral replication complexes by sequestering viral and co-opted host proteins to reach high local concentrations and protect viral RNAs from destruction by host antiviral responses.
SE|25462443||ab|2|entity|C0025255|Tissue membrane|tisu|||membranes|||0|861|235|244
SE|25462443||ab|2|entity|C0521026|Viral|ftcn|||viral|||0|851|272|277
SE|25462443||ab|2|entity|C0439855|Complex|qlco|||complexes|||0|851|290|299
SE|25462443||ab|2|entity|C0869026|maintenance of localization|celf|||sequestering|||0|1000|303|315
SE|25462443||ab|2|entity|C0521026|Viral|ftcn|||viral|||0|1000|316|321
SE|25462443||ab|2|entity|C1167395|host|celc|||host|||0|888|335|339
SE|25462443||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|340|348
SE|25462443||ab|2|entity|C0205250|High|qlco|||high|||0|851|358|362
SE|25462443||ab|2|entity|C0205276|Local|spco|||local|||0|851|363|368
SE|25462443||ab|2|entity|C0035736|RNA, Viral|nnon|||viral RNAs|||0|983|396|406
SE|25462443||ab|2|entity|C0301872|Immune response|orgf|||host antiviral responses|||0|896|427|451

SE|25462443||ab|3|text|453|708|In this review, we discuss that tombusviruses and nodaviruses are capable of exploiting alternative subcellular membranes in cells and in vitro in the absence of primary membranes targeted by these viruses or when the replication proteins are retargeted.
SE|25462443||ab|3|entity|C0206350|Tombusvirus|virs|||tombusviruses|||0|966|485|498
SE|25462443||ab|3|entity|C1523987|Alternative|cnce|||alternative|||0|813|541|552
SE|25462443||ab|3|entity|C0682532|subcellular membrane|celc|||subcellular membranes|||0|813|553|574
SE|25462443||ab|3|entity|C0007634|Cells|cell|||cells|||0|1000|578|583
SE|25462443||ab|3|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|588|596
SE|25462443||ab|3|entity|C0025255|Tissue membrane|tisu|||membranes|||0|888|623|632
SE|25462443||ab|3|entity|C0042776|Virus|virs|||viruses|||0|1000|651|658
SE|25462443||ab|3|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|888|683|691
SE|25462443||ab|3|relation|6|1|C0007634|Cells|cell|cell|||cells|||0|1000|578|583|PREP|LOCATION_OF||575|577|5|4|C0206350|Tombusvirus|virs|virs|||tombusviruses|||0|966|485|498

SE|25462443||ab|4|text|708|825|The roles of protein factors and lipids and membrane contact sites in replication site selection are also discussed.
SE|25462443||ab|4|entity|C0035820|Role|socb|||roles|||0|1000|712|717
SE|25462443||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|872|721|728
SE|25462443||ab|4|entity|C1521761|Factor|ftcn|||factors|||0|872|729|736
SE|25462443||ab|4|entity|C0023779|Lipids|lipd|||lipids|||0|1000|741|747
SE|25462443||ab|4|entity|C0596901|Membrane|celc|||membrane|||0|802|752|760
SE|25462443||ab|4|entity|C0205145|Site|spco|||sites|||0|802|769|774
SE|25462443||ab|4|entity|C0205145|Site|spco|||site|||0|623|790|794

SE|25462443||ab|5|text|825|959|Surprisingly, tombusviruses could also exploit expanded ER membranes, which provide enhanced subcellular environment for replication.
SE|25462443||ab|5|entity|C0206350|Tombusvirus|virs|||tombusviruses|||0|966|839|852
SE|25462443||ab|5|entity|C0205229|Expanding|spco|||expanded|||0|879|872|880
SE|25462443||ab|5|entity|C0230770|Endoplasmic reticulum, membrane|celc|||ER membranes|||0|879|881|893
SE|25462443||ab|5|entity|C0014406|Environment|spco|||environment|||0|827|930|941

SE|25462443||ab|6|text|959|1197|The expanded ER membranes are formed due to deletion of a lipin homolog, which is responsible for de novo lipid synthesis and formation of lipid droplets, suggesting that host genes connected to genetic diseases affect virus replication.
SE|25462443||ab|6|entity|C0205229|Expanding|spco|||expanded|||0|879|963|971
SE|25462443||ab|6|entity|C0230770|Endoplasmic reticulum, membrane|celc|||ER membranes|||0|879|972|984
SE|25462443||ab|6|entity|C1442161|DELETION|comd|||deletion|||0|1000|1003|1011
SE|25462443||ab|6|entity|C0256956|lipine|phsu|||lipin|||0|888|1017|1022
SE|25462443||ab|6|entity|C1334043|Homologous Gene|gngm|||homolog|||0|888|1023|1030
SE|25462443||ab|6|entity|C1515568|de novo|idcn|||de novo|||0|861|1057|1064
SE|25462443||ab|6|entity|C0023779|Lipids|lipd|||lipid|||0|861|1065|1070
SE|25462443||ab|6|entity|C0869032|Synthesis|phpr|||synthesis|||0|861|1071|1080
SE|25462443||ab|6|entity|C1522492|Formation|ftcn|||formation|||0|1000|1085|1094
SE|25462443||ab|6|entity|C0230704|Lipid droplet|celc|||lipid droplets|||0|1000|1098|1112
SE|25462443||ab|6|entity|C1167395|host|celc|||host|||0|888|1130|1134
SE|25462443||ab|6|entity|C0017337|Genes|gngm|||genes|||0|888|1135|1140
SE|25462443||ab|6|entity|C0019247|Hereditary Diseases|dsyn|||genetic diseases|||0|1000|1154|1170
SE|25462443||ab|6|entity|C0042774|Virus Replication|orgf|||virus replication|||0|1000|1178|1195
SE|25462443||ab|6|relation|4|2|C1334043|Homologous Gene|gngm,aapp|gngm|||homolog|||0|888|1023|1030|NOM|INTERACTS_WITH||1071|1080|4|0|C0023779|Lipids|lipd|lipd|||lipid|||0|861|1065|1070
SE|25462443||ab|6|relation|9|1|C0019247|Hereditary Diseases|dsyn|dsyn|||genetic diseases|||0|1000|1154|1170|VERB|AFFECTS||1171|1177|1|1|C0042774|Virus Replication|orgf|orgf|||virus replication|||0|1000|1178|1195

SE|25462443||ab|7|text|1197|1334|Overall, these viruses show remarkable flexibility in utilizing various subcellular membranes for replication under different conditions.
SE|25462443||ab|7|entity|C1561607|Overall|qlco|||Overall|||0|1000|1197|1204
SE|25462443||ab|7|entity|C0042776|Virus|virs|||viruses|||0|1000|1212|1219
SE|25462443||ab|7|entity|C1550002|Remark|idcn|||remarkable|||0|853|1225|1235
SE|25462443||ab|7|entity|C0242808|Pliability|qlco|||flexibility|||0|853|1236|1247
SE|25462443||ab|7|entity|C0682532|subcellular membrane|celc|||subcellular membranes|||0|844|1269|1290
SE|25462443||ab|7|entity|C1547020|*Difference|qnco|||different|||0|836|1313|1322
SE|25462443||ab|7|entity|C0348080|Condition|qlco|||conditions|||0|836|1323|1333


SE|25462444||ti|1|text|21|80|Evidence linking HHV-6 with multiple sclerosis: an update.
SE|25462444||ti|1|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|861|38|43
SE|25462444||ti|1|entity|C0026769|Multiple Sclerosis|dsyn|||multiple sclerosis|||0|1000|49|67
SE|25462444||ti|1|entity|C1519814|Update|tmco|||update|||0|1000|72|78

SE|25462444||ab|1|text|86|346|Following reports of elevated antiviral antibodies in MS patient sera and viral DNA detection in MS plaques nearly two decades ago, the neurovirology community has actively explored how herpesviruses such as HHV-6 might be involved in MS disease pathogenesis.
SE|25462444||ab|1|entity|C0684224|Report (document)|inpr|||reports|||0|1000|96|103
SE|25462444||ab|1|entity|C0205250|High|qlco|||elevated|||0|890|107|115
SE|25462444||ab|1|entity|C0003253|Antibodies, Viral|aapp,imft|||antiviral antibodies|||0|890|116|136
SE|25462444||ab|1|entity|C0030705|Patients|podg|||patient|||0|790|143|150
SE|25462444||ab|1|entity|C0229671|Serum|bdsu|||sera|||0|790|151|155
SE|25462444||ab|1|entity|C0012939|DNA, Viral|nnon|||viral DNA|||0|901|160|169
SE|25462444||ab|1|entity|C1511790|Detection|topp|||detection|||0|901|170|179
SE|25462444||ab|1|entity|C0333463|Senile Plaques|acab|||plaques|||0|553|186|193
SE|25462444||ab|1|entity|C0205448|Two|qnco|||two|||0|553|201|204
SE|25462444||ab|1|entity|C1333533|FBXW7 gene|gngm|||ago|||0|553|213|216
SE|25462444||ab|1|entity|C1518305|Neurovirology|bmod|||neurovirology|||0|888|222|235
SE|25462444||ab|1|entity|C0009462|Community|geoa|||community|||0|888|236|245
SE|25462444||ab|1|entity|C0019369|Herpesviridae|virs|||herpesviruses|||0|861|272|285
SE|25462444||ab|1|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|294|299
SE|25462444||ab|1|entity|C0012634|Disease|dsyn|||disease|||0|790|324|331
SE|25462444||ab|1|entity|C0543483|pathogenic aspects|ftcn|||pathogenesis|||0|790|332|344
SE|25462444||ab|1|relation|0|0|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|1000|294|299|SPEC|ISA||272|299|0|0|C0019369|Herpesviridae|virs|virs|||herpesviruses|||0|861|272|285
SE|25462444||ab|1|relation|0|0|C0229671|Serum|bdsu|bdsu|||sera|||0|790|151|155|MOD/HEAD|PART_OF||143|155|0|0|C0030705|Patients|podg,humn|humn|||patient|||0|790|143|150
SE|25462444||ab|1|relation|7|1|C0229671|Serum|bdsu|bdsu|||sera|||0|790|151|155|PREP|LOCATION_OF||137|139|2|1|C0003253|Antibodies, Viral|aapp,gngm,imft|aapp|||antiviral antibodies|||0|890|116|136
SE|25462444||ab|1|relation|8|7|C0003253|Antibodies, Viral|aapp,gngm,imft|aapp|||antiviral antibodies|||0|890|116|136|VERB|ASSOCIATED_WITH||309|317|1|1|C0012634|Disease|dsyn|dsyn|||disease|||0|790|324|331

SE|25462444||ab|2|text|346|598|Though findings across the field are non-uniform, an emerging consensus of viral correlates with disease course and evidence of HHV-6-specific immune responses in the CNS provide compelling evidence for a role, direct or indirect, of this virus in MS.
SE|25462444||ab|2|entity|C0243095|Finding|ftcn|||findings|||0|1000|353|361
SE|25462444||ab|2|entity|C1521738|Field|cnce|||field|||0|1000|373|378
SE|25462444||ab|2|entity|C0376298|Consensus|socb|||consensus|||0|861|408|417
SE|25462444||ab|2|entity|C0521026|Viral|ftcn|||viral|||0|694|421|426
SE|25462444||ab|2|entity|C0242656|Disease Progression|patf|||disease course|||0|1000|443|457
SE|25462444||ab|2|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|886|474|479
SE|25462444||ab|2|entity|C0683201|specific immunity|ortf|||specific immune responses|||0|886|480|505
SE|25462444||ab|2|entity|C0028654|Clinical Nurse Specialists|prog|||CNS|||0|1000|513|516
SE|25462444||ab|2|entity|C0035820|Role|socb|||role|||0|1000|551|555
SE|25462444||ab|2|entity|C0439852|Indirect|qlco|||indirect|||0|1000|567|575
SE|25462444||ab|2|entity|C0042769|Virus Diseases|dsyn|||virus|||0|1000|585|590
SE|25462444||ab|2|relation|8|1|C0683201|specific immunity|ortf|ortf|||specific immune responses|||0|886|480|505|PREP|PROCESS_OF||506|508|7|1|C0028654|Clinical Nurse Specialists|prog,humn|humn|||CNS|||0|1000|513|516

SE|25462444||ab|3|text|598|792|Ultimately, the only way to demonstrate the involvement, or lack thereof, of HHV-6 or other herpesviruses in this disease is through a controlled clinical trial of an efficacious antiviral drug.
SE|25462444||ab|3|entity|C0332268|Lacking|qlco|||lack|||0|861|658|662
SE|25462444||ab|3|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|675|680
SE|25462444||ab|3|entity|C0019369|Herpesviridae|virs|||herpesviruses|||0|1000|690|703
SE|25462444||ab|3|entity|C0012634|Disease|dsyn|||disease|||0|1000|712|719
SE|25462444||ab|3|entity|C0702113|Controlled|ftcn|||controlled|||0|901|733|743
SE|25462444||ab|3|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|901|744|758
SE|25462444||ab|3|entity|C0003451|Antiviral Agents|phsu|||antiviral drug|||0|901|777|791
SE|25462444||ab|3|relation|0|0|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|1000|675|680|INFER|INTERACTS_WITH(SPEC)||675|703|0|0|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|712|719
SE|25462444||ab|3|relation|0|0|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|1000|675|680|SPEC|ISA||675|703|0|0|C0019369|Herpesviridae|virs|virs|||herpesviruses|||0|1000|690|703
SE|25462444||ab|3|relation|6|3|C0019369|Herpesviridae|virs|virs|||herpesviruses|||0|1000|690|703|NOM|INTERACTS_WITH||642|653|6|4|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|712|719
SE|25462444||ab|3|relation|6|3|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|1000|675|680|NOM|INTERACTS_WITH||642|653|6|4|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|712|719


SE|25462446||ti|1|text|21|100|RNA replication errors and the evolution of virus pathogenicity and virulence.
SE|25462446||ti|1|entity|C1328949|RNA replication|moft|||RNA replication|||0|901|21|36
SE|25462446||ti|1|entity|C0743559|error|qlco|||errors|||0|901|37|43
SE|25462446||ti|1|entity|C0015219|Evolution|genf|||evolution|||0|1000|52|61
SE|25462446||ti|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|888|65|70
SE|25462446||ti|1|entity|C1136169|Pathogenicity|orga,qlco|||pathogenicity|||0|888|71|84
SE|25462446||ti|1|entity|C0042765|Virulence|biof|||virulence|||0|1000|89|98

SE|25462446||ab|1|text|106|270|RNA viruses of plants and animals have polymerases that are error-prone and produce complex populations of related, but non-identical, genomes called quasispecies.
SE|25462446||ab|1|entity|C0035691|RNA Viruses|virs|||RNA viruses|||0|1000|106|117
SE|25462446||ab|1|entity|C0032098|Plants|plnt|||plants|||0|1000|121|127
SE|25462446||ab|1|entity|C0003062|Animals|anim|||animals|||0|1000|132|139
SE|25462446||ab|1|entity|C1335439|Polymerase|aapp,enzy|||polymerases|||0|966|145|156
SE|25462446||ab|1|entity|C0743559|error|qlco|||error|||0|861|166|171
SE|25462446||ab|1|entity|C0439855|Complex|qlco|||complex|||0|888|190|197
SE|25462446||ab|1|entity|C0032659|geographic population|qnco|||populations|||0|888|198|209
SE|25462446||ab|1|entity|C1522149|Related|ftcn|||related|||0|1000|213|220
SE|25462446||ab|1|entity|C0205280|Identical|qlco|||identical|||0|790|230|239
SE|25462446||ab|1|entity|C0017428|Genome|gngm|||genomes|||0|790|241|248

SE|25462446||ab|2|text|270|537|While there are vast variations in mutation rates among these viruses, selection has optimized the exact error rate of each species to provide maximum speed of replication and amount of variation without losing the ability to replicate because of excessive mutation.
SE|25462446||ab|2|entity|C0814230|Veterans Alcoholism Screening Test|inpr|||vast|||0|872|286|290
SE|25462446||ab|2|entity|C0205419|Variant|qlco|||variations|||0|872|291|301
SE|25462446||ab|2|entity|C0026882|Mutation|genf|||mutation|||0|872|305|313
SE|25462446||ab|2|entity|C1521828|Rate|qnco|||rates|||0|872|314|319
SE|25462446||ab|2|entity|C0042776|Virus|virs|||viruses|||0|1000|332|339
SE|25462446||ab|2|entity|C0743559|error|qlco|||error|||0|790|375|380
SE|25462446||ab|2|entity|C1521828|Rate|qnco|||rate|||0|790|381|385
SE|25462446||ab|2|entity|C1548151|Species|idcn|||species|||0|1000|394|401
SE|25462446||ab|2|entity|C0806909|Maximum|fndg|||maximum|||0|888|413|420
SE|25462446||ab|2|entity|C1265611|Quantity|qnco|||amount|||0|1000|446|452
SE|25462446||ab|2|entity|C0205419|Variant|qlco|||variation|||0|1000|456|465
SE|25462446||ab|2|entity|C0085732|Ability|orga|||ability|||0|1000|485|492
SE|25462446||ab|2|entity|C0442802|Excessive|qlco|||excessive|||0|888|517|526
SE|25462446||ab|2|entity|C0026882|Mutation|genf|||mutation|||0|888|527|535

SE|25462446||ab|3|text|537|704|High mutation rates result in the selection of populations increasingly robust, which means they are increasingly resistant to show phenotypic changes after mutation.
SE|25462446||ab|3|entity|C0205250|High|qlco|||High|||0|840|537|541
SE|25462446||ab|3|entity|C0026882|Mutation|genf|||mutation|||0|840|542|550
SE|25462446||ab|3|entity|C1521828|Rate|qnco|||rates|||0|840|551|556
SE|25462446||ab|3|entity|C0032659|geographic population|qnco|||populations|||0|1000|584|595
SE|25462446||ab|3|entity|C0332325|Resistant|ftcn|||resistant|||0|861|651|660
SE|25462446||ab|3|entity|C0026882|Mutation|genf|||mutation|||0|1000|694|702

SE|25462446||ab|4|text|704|845|It is possible to manipulate the mutation rate, either by the use of mutagens or by selection (or genetic manipulation) of fidelity mutants.
SE|25462446||ab|4|entity|C0332149|Possible|qlco|||possible|||0|1000|710|718
SE|25462446||ab|4|entity|C0026882|Mutation|genf|||mutation|||0|888|737|745
SE|25462446||ab|4|entity|C1521828|Rate|qnco|||rate|||0|888|746|750
SE|25462446||ab|4|entity|C0026879|Mutagens|hops|||mutagens|||0|1000|773|781
SE|25462446||ab|4|entity|C0178659|genetic manipulation|mbrt|||genetic manipulation|||0|1000|802|822
SE|25462446||ab|4|entity|C0680011|loyalty|socb|||fidelity|||0|872|827|835
SE|25462446||ab|4|entity|C0596988|Mutant|comd|||mutants|||0|872|836|843

SE|25462446||ab|5|text|845|1005|These polymerases usually, but not always, perform as well as wild type (wt) during cell infection, but show major phenotypic changes during in vivo infection.
SE|25462446||ab|5|entity|C1335439|Polymerase|aapp,enzy|||polymerases|||0|827|851|862
SE|25462446||ab|5|entity|C1518422|Not|ftcn|||not|||0|888|876|879
SE|25462446||ab|5|entity|C1549493|Always|idcn|||always|||0|888|880|886
SE|25462446||ab|5|entity|C0445392|Wild|inpr|||wild|||0|888|907|911
SE|25462446||ab|5|entity|C1547052|*Type|qnco|||type|||0|888|912|916
SE|25462446||ab|5|entity|C0007634|Cells|cell|||cell|||0|888|929|933
SE|25462446||ab|5|entity|C0205164|Major|qlco|||major|||0|785|954|959
SE|25462446||ab|5|entity|C1515655|in vivo|spco|||in vivo|||0|901|986|993

SE|25462446||ab|6|text|1005|1099|Both high and low fidelity variants are attenuated when the wt virus is virulent in the host.
SE|25462446||ab|6|entity|C0205250|High|qlco|||high|||0|1000|1010|1014
SE|25462446||ab|6|entity|C0205251|low|qlco|||low|||0|840|1019|1022
SE|25462446||ab|6|entity|C0680011|loyalty|socb|||fidelity|||0|840|1023|1031
SE|25462446||ab|6|entity|C0205419|Variant|qlco|||variants|||0|840|1032|1040
SE|25462446||ab|6|entity|C0445392|Wild|inpr|||wt|||0|851|1065|1067
SE|25462446||ab|6|entity|C1547052|*Type|qnco|||wt|||0|851|1065|1067
SE|25462446||ab|6|entity|C0042769|Virus Diseases|dsyn|||virus|||0|851|1068|1073
SE|25462446||ab|6|entity|C1520022|Virulent|qlco|||virulent|||0|1000|1077|1085
SE|25462446||ab|6|entity|C1167395|host|celc|||host|||0|1000|1093|1097

SE|25462446||ab|7|text|1099|1217|Alternatively when wt infection is non-apparent, the variants show major restrictions to spread in the infected host.
SE|25462446||ab|7|entity|C0445392|Wild|inpr|||wt|||0|851|1118|1120
SE|25462446||ab|7|entity|C1547052|*Type|qnco|||wt|||0|851|1118|1120
SE|25462446||ab|7|entity|C0750489|APPARENT|idcn|||apparent|||0|861|1138|1146
SE|25462446||ab|7|entity|C0205419|Variant|qlco|||variants|||0|966|1152|1160
SE|25462446||ab|7|entity|C0205164|Major|qlco|||major|||0|694|1166|1171
SE|25462446||ab|7|entity|C0439663|Infected|ftcn|||infected|||0|888|1202|1210
SE|25462446||ab|7|entity|C1167395|host|celc|||host|||0|888|1211|1215

SE|25462446||ab|8|text|1217|1328|Manipulation of mutation rates may become a new strategy to develop attenuated vaccines for humans and animals.
SE|25462446||ab|8|entity|C0947647|Manipulation procedure|topp|||Manipulation|||0|1000|1217|1229
SE|25462446||ab|8|entity|C0026882|Mutation|genf|||mutation|||0|872|1233|1241
SE|25462446||ab|8|entity|C1521828|Rate|qnco|||rates|||0|872|1242|1247
SE|25462446||ab|8|entity|C0205314|New|tmco|||new|||0|888|1261|1264
SE|25462446||ab|8|entity|C0042211|Vaccines, Attenuated|imft,phsu|||attenuated vaccines|||0|1000|1285|1304
SE|25462446||ab|8|entity|C0020114|Human|humn|||humans|||0|1000|1309|1315
SE|25462446||ab|8|entity|C0003062|Animals|anim|||animals|||0|1000|1320|1327
SE|25462446||ab|8|relation|4|1|C0042211|Vaccines, Attenuated|imft,phsu|phsu|||attenuated vaccines|||0|1000|1285|1304|PREP|TREATS||1305|1308|2|1|C0020114|Human|grup,humn|humn|||humans|||0|1000|1309|1315


SE|25462445||ti|1|text|21|75|Coupling of replication and assembly in flaviviruses.
SE|25462445||ti|1|entity|C0016215|Flavivirus|virs|||flaviviruses|||0|1000|61|73

SE|25462445||ab|1|text|81|196|Flaviviruses affect hundreds of millions of people each year causing tremendous morbidity and mortality worldwide.
SE|25462445||ab|1|entity|C0016215|Flavivirus|virs|||Flaviviruses|||0|1000|81|93
SE|25462445||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|125|131
SE|25462445||ab|1|entity|C0439234|year|tmco|||year|||0|1000|137|141

SE|25462445||ab|2|text|196|360|This genus includes significant human pathogens such as dengue, West Nile, yellow fever, tick-borne encephalitis and Japanese encephalitis virus among many others.
SE|25462445||ab|2|entity|C0750502|Significant|idcn|||significant|||0|816|216|227
SE|25462445||ab|2|entity|C0020114|Human|humn|||human|||0|816|228|233
SE|25462445||ab|2|entity|C0043395|Yellow Fever|dsyn|||yellow fever|||0|1000|271|283
SE|25462445||ab|2|entity|C0014061|Tick-Borne Encephalitis|dsyn|||tick-borne encephalitis|||0|1000|285|308
SE|25462445||ab|2|entity|C0014047|Japanese encephalitis virus|virs|||Japanese encephalitis virus|||0|1000|313|340
SE|25462445||ab|2|entity|C0205394|Other|qlco|||others|||0|966|352|358

SE|25462445||ab|3|text|360|466|The disease caused by these viruses can range from febrile illness to hemorrhagic fever and encephalitis.
SE|25462445||ab|3|entity|C0012634|Disease|dsyn|||disease|||0|1000|364|371
SE|25462445||ab|3|entity|C0042776|Virus|virs|||viruses|||0|1000|388|395
SE|25462445||ab|3|entity|C1514721|Range|qnco|||range|||0|1000|400|405
SE|25462445||ab|3|entity|C0743841|Disorder characterized by fever|dsyn|||febrile illness|||0|1000|411|426
SE|25462445||ab|3|entity|C0019104|Hemorrhagic Fevers, Viral|dsyn|||hemorrhagic fever|||0|1000|430|447
SE|25462445||ab|3|entity|C0014038|Encephalitis|dsyn|||encephalitis|||0|1000|452|464
SE|25462445||ab|3|relation|5|1|C0042776|Virus|virs|virs|||viruses|||0|1000|388|395|VERB|CAUSES||372|378|1|1|C0012634|Disease|dsyn|dsyn|||disease|||0|1000|364|371

SE|25462445||ab|4|text|466|642|A deeper understanding of the virus life cycle is required to foster development of antivirals and vaccines, which are an urgent need for many flaviviruses, especially dengue.
SE|25462445||ab|4|entity|C0205125|Depth|spco|||deeper|||0|872|468|474
SE|25462445||ab|4|entity|C0042769|Virus Diseases|dsyn|||virus|||0|851|496|501
SE|25462445||ab|4|entity|C0376558|Life|idcn|||life|||0|851|502|506
SE|25462445||ab|4|entity|C0750729|Course|tmco|||cycle|||0|851|507|512
SE|25462445||ab|4|entity|C1527148|Development|ftcn|||development|||0|861|535|546
SE|25462445||ab|4|entity|C0003451|Antiviral Agents|phsu|||antivirals|||0|1000|550|560
SE|25462445||ab|4|entity|C0042210|Vaccines|imft,phsu|||vaccines|||0|1000|565|573
SE|25462445||ab|4|entity|C0439609|Urgent|tmco|||urgent|||0|888|588|594
SE|25462445||ab|4|entity|C0027552|Needs|qlco|||need|||0|888|595|599
SE|25462445||ab|4|entity|C0016215|Flavivirus|virs|||flaviviruses|||0|1000|609|621

SE|25462445||ab|5|text|642|858|The focus of this review is to summarize our current knowledge of flaviviral replication and assembly, the proteins and lipids involved therein, and how these processes are coordinated for efficient virus production.
SE|25462445||ab|5|entity|C0205234|Focal|spco|||focus|||0|1000|646|651
SE|25462445||ab|5|entity|C0521116|Current|tmco|||current|||0|888|687|694
SE|25462445||ab|5|entity|C0376554|Knowledge|inpr|||knowledge|||0|888|695|704
SE|25462445||ab|5|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|749|757
SE|25462445||ab|5|entity|C0023779|Lipids|lipd|||lipids|||0|1000|762|768
SE|25462445||ab|5|entity|C1522240|Process|phpr|||processes|||0|966|801|810
SE|25462445||ab|5|entity|C0442799|Efficient|qlco|||efficient|||0|851|831|840
SE|25462445||ab|5|entity|C0042769|Virus Diseases|dsyn|||virus|||0|851|841|846
SE|25462445||ab|5|entity|C0033268|production|ocac|||production|||0|851|847|857


SE|25462447||ti|1|text|21|79|The development of new therapies for human herpesvirus 6.
SE|25462447||ti|1|entity|C1527148|Development|ftcn|||development|||0|1000|25|36
SE|25462447||ti|1|entity|C0205314|New|tmco|||new|||0|888|40|43
SE|25462447||ti|1|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|888|44|53
SE|25462447||ti|1|entity|C0019381|Herpesvirus 6, Human|virs|||human herpesvirus 6|||0|1000|58|77
SE|25462447||ti|1|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|888|44|53|PREP|TREATS||54|57|1|1|C0019381|Herpesvirus 6, Human|virs|virs|||human herpesvirus 6|||0|1000|58|77

SE|25462447||ab|1|text|85|189|Human herpesvirus 6 (HHV-6) infections are typically mild and in rare cases can result in encephalitis.
SE|25462447||ab|1|entity|C0854530|Human herpesvirus 6 infection|dsyn|||Human herpesvirus 6 (HHV-6) infections|||0|983|85|123
SE|25462447||ab|1|entity|C0547040|Minimal|qlco|||mild|||0|861|138|142
SE|25462447||ab|1|entity|C0522498|Rare|qlco|||rare|||0|888|150|154
SE|25462447||ab|1|entity|C0868928|Case (situation)|ftcn|||cases|||0|888|155|160
SE|25462447||ab|1|entity|C0014038|Encephalitis|dsyn|||encephalitis|||0|1000|175|187
SE|25462447||ab|1|relation|3|3|C0854530|Human herpesvirus 6 infection|dsyn|dsyn|||Human herpesvirus 6 (HHV-6) infections|||0|983|85|123|VERB|CAUSES||165|171|1|1|C0014038|Encephalitis|dsyn|dsyn|||encephalitis|||0|1000|175|187

SE|25462447||ab|2|text|189|287|A common theme among all the herpesviruses, however, is the reactivation upon immune suppression.
SE|25462447||ab|2|entity|C0205214|Common|qnco|||common|||0|694|191|197
SE|25462447||ab|2|entity|C0019369|Herpesviridae|virs|||herpesviruses|||0|1000|218|231
SE|25462447||ab|2|entity|C0021079|Therapeutic immunosuppression|topp|||immune suppression|||0|1000|267|285

SE|25462447||ab|3|text|287|340|HHV-6 commonly reactivates in transplant recipients.
SE|25462447||ab|3|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|287|292
SE|25462447||ab|3|entity|C0376387|Recipient, Transplant|podg|||transplant recipients|||0|1000|317|338
SE|25462447||ab|3|relation|1|1|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|1000|287|292|PREP|PROCESS_OF||314|316|1|1|C0376387|Recipient, Transplant|podg,humn|humn|||transplant recipients|||0|1000|317|338

SE|25462447||ab|4|text|340|559|No therapies are approved currently for the treatment of these infections, although small studies and individual case reports have reported intermittent success with drugs such as cidofovir, ganciclovir, and foscarnet.
SE|25462447||ab|4|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|1000|343|352
SE|25462447||ab|4|entity|C0521116|Current|tmco|||currently|||0|1000|366|375
SE|25462447||ab|4|entity|C0021311|Infection|dsyn|||infections|||0|1000|403|413
SE|25462447||ab|4|entity|C0700321|Small|qnco|||small|||0|872|424|429
SE|25462447||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|872|430|437
SE|25462447||ab|4|entity|C0237401|Individual|humn|||individual|||0|890|442|452
SE|25462447||ab|4|entity|C0007320|Case Reports Publication Type|inpr|||case reports|||0|890|453|465
SE|25462447||ab|4|entity|C0205267|Intermittent|tmco|||intermittent|||0|851|480|492
SE|25462447||ab|4|entity|C0597535|Success|socb|||success|||0|851|493|500
SE|25462447||ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||drugs|||0|1000|506|511
SE|25462447||ab|4|entity|C0286079|Cidofovir|nnon,phsu|||cidofovir|||0|1000|520|529
SE|25462447||ab|4|entity|C0017066|Ganciclovir|nnon,phsu|||ganciclovir|||0|1000|531|542
SE|25462447||ab|4|entity|C0070895|Foscarnet|opco,phsu|||foscarnet|||0|1000|548|557
SE|25462447||ab|4|relation|0|0|C0017066|Ganciclovir|nnon,phsu|nnon|||ganciclovir|||0|1000|531|542|SPEC|ISA||506|529|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|1000|506|511
SE|25462447||ab|4|relation|0|0|C0070895|Foscarnet|opco,phsu|opco|||foscarnet|||0|1000|548|557|SPEC|ISA||506|529|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|1000|506|511
SE|25462447||ab|4|relation|0|0|C0286079|Cidofovir|nnon,phsu|nnon|||cidofovir|||0|1000|520|529|SPEC|ISA||506|529|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drugs|||0|1000|506|511
SE|25462447||ab|4|relation|8|7|C0017066|Ganciclovir|nnon,phsu|phsu|||ganciclovir|||0|1000|531|542|NOM|TREATS|negation|384|393|8|1|C0021311|Infection|dsyn|dsyn|||infections|||0|1000|403|413
SE|25462447||ab|4|relation|8|7|C0070895|Foscarnet|opco,phsu|phsu|||foscarnet|||0|1000|548|557|NOM|TREATS|negation|384|393|8|1|C0021311|Infection|dsyn|dsyn|||infections|||0|1000|403|413
SE|25462447||ab|4|relation|8|7|C0286079|Cidofovir|nnon,phsu|nnon|||cidofovir|||0|1000|520|529|NOM|TREATS|negation|384|393|8|1|C0021311|Infection|dsyn|dsyn|||infections|||0|1000|403|413

SE|25462447||ab|5|text|559|717|In addition to the current experimental therapies, many other compounds have been reported to inhibit HHV-6 in cell culture with varying degrees of efficacy.
SE|25462447||ab|5|entity|C0521116|Current|tmco|||current|||0|901|578|585
SE|25462447||ab|5|entity|C0949266|Therapies, Investigational|topp|||experimental therapies|||0|901|586|608
SE|25462447||ab|5|entity|C0205198|Compound|qlco|||compounds|||0|966|621|630
SE|25462447||ab|5|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|661|666
SE|25462447||ab|5|entity|C0007634|Cells|cell|||cell|||0|888|670|674
SE|25462447||ab|5|entity|C0220814|Cultural|ftcn|||culture|||0|888|675|682
SE|25462447||ab|5|entity|C1548673|Varies|inpr|||varying|||0|661|688|695

SE|25462447||ab|6|text|717|877|Recent advances in the development of new small molecule inhibitors of HHV-6 will be reviewed with regard to their efficacy and spectrum of antiviral activity.
SE|25462447||ab|6|entity|C0332185|Recent|tmco|||Recent|||0|872|717|723
SE|25462447||ab|6|entity|C0725066|Advance|medd|||advances|||0|872|724|732
SE|25462447||ab|6|entity|C1527148|Development|ftcn|||development|||0|1000|740|751
SE|25462447||ab|6|entity|C0205314|New|tmco|||new|||0|861|755|758
SE|25462447||ab|6|entity|C1328819|small molecule|orch|||small molecule|||0|861|759|773
SE|25462447||ab|6|entity|C0243077|inhibitors|chvf|||inhibitors|||0|861|774|784
SE|25462447||ab|6|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|788|793

SE|25462447||ab|7|text|877|1056|The potential for new therapies for HHV-6 infections will also be discussed, and they will likely arise from efforts to develop broad spectrum antiviral therapies for DNA viruses.
SE|25462447||ab|7|entity|C0237399|Potential|qlco|||potential|||0|1000|881|890
SE|25462447||ab|7|entity|C0205314|New|tmco|||new|||0|888|895|898
SE|25462447||ab|7|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|888|899|908
SE|25462447||ab|7|entity|C0854530|Human herpesvirus 6 infection|dsyn|||HHV-6 infections|||0|983|913|929
SE|25462447||ab|7|entity|C0332464|Widening|spco|||broad|||0|813|1005|1010
SE|25462447||ab|7|entity|C0280274|Antiviral Therapy|topp|||antiviral therapies|||0|813|1020|1039
SE|25462447||ab|7|entity|C0012923|DNA Viruses|virs|||DNA viruses|||0|1000|1044|1055
SE|25462447||ab|7|relation|2|1|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|888|899|908|PREP|TREATS||909|912|4|1|C0854530|Human herpesvirus 6 infection|dsyn|dsyn|||HHV-6 infections|||0|983|913|929
SE|25462447||ab|7|relation|5|1|C0280274|Antiviral Therapy|topp|topp|||antiviral therapies|||0|813|1020|1039|PREP|TREATS||1040|1043|1|1|C0012923|DNA Viruses|virs|virs|||DNA viruses|||0|1000|1044|1055


SE|25462450||ti|1|text|21|87|Roseoloviruses: unmet needs and research priorities: perspective.
SE|25462450||ti|1|entity|C0376477|Roseolovirus|virs|||Roseoloviruses|||0|1000|21|35
SE|25462450||ti|1|entity|C0376368|Research Priorities|resa|||research priorities|||0|1000|53|72

SE|25462450||ab|1|text|93|296|The human roseoloviruses, human herpesviruses 6A (HHV-6A), HHV-6B, and HHV-7, are highly prevalent viruses that typically cause fever/rash illnesses such as roseola during early life primary infections.
SE|25462450||ab|1|entity|C0020114|Human|humn|||human|||0|888|97|102
SE|25462450||ab|1|entity|C0376477|Roseolovirus|virs|||roseoloviruses|||0|888|103|117
SE|25462450||ab|1|entity|C0887938|Herpesvirus 6A, Human|virs|||human herpesviruses 6A|||0|988|119|141
SE|25462450||ab|1|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|1000|152|158
SE|25462450||ab|1|entity|C0079506|Herpesvirus 7, Human|virs|||HHV-7|||0|1000|164|169
SE|25462450||ab|1|entity|C0033105|Statistical Prevalence|qnco|||prevalent|||0|754|182|191
SE|25462450||ab|1|entity|C0042776|Virus|virs|||viruses|||0|754|192|199
SE|25462450||ab|1|entity|C0015230|Exanthema|dsyn|||rash|||0|871|227|231
SE|25462450||ab|1|entity|C0743841|Disorder characterized by fever|dsyn|||fever/rash illnesses|||0|871|221|241
SE|25462450||ab|1|entity|C0015231|Exanthema Subitum|dsyn|||roseola|||0|1000|250|257
SE|25462450||ab|1|entity|C1279919|Early|tmco|||early|||0|852|265|270
SE|25462450||ab|1|entity|C0376558|Life|idcn|||life|||0|852|271|275
SE|25462450||ab|1|entity|C0948192|Primary infection NOS|dsyn|||primary infections|||0|852|276|294
SE|25462450||ab|1|relation|0|0|C0079506|Herpesvirus 7, Human|virs|virs|||HHV-7|||0|1000|164|169|INFER|CAUSES(SPEC)||119|199|0|0|C0743841|Disorder characterized by fever|dsyn|dsyn|||fever/rash illnesses|||0|871|221|241
SE|25462450||ab|1|relation|0|0|C0079506|Herpesvirus 7, Human|virs|virs|||HHV-7|||0|1000|164|169|SPEC|ISA||119|199|0|0|C0042776|Virus|virs|virs|||viruses|||0|754|192|199
SE|25462450||ab|1|relation|0|0|C0376477|Roseolovirus|virs|virs|||roseoloviruses|||0|888|103|117|INFER|CAUSES(SPEC)||119|199|0|0|C0743841|Disorder characterized by fever|dsyn|dsyn|||fever/rash illnesses|||0|871|221|241
SE|25462450||ab|1|relation|0|0|C0376477|Roseolovirus|virs|virs|||roseoloviruses|||0|888|103|117|MOD/HEAD|PROCESS_OF||97|117|0|0|C0020114|Human|grup,humn|humn|||human|||0|888|97|102
SE|25462450||ab|1|relation|0|0|C0376477|Roseolovirus|virs|virs|||roseoloviruses|||0|888|103|117|SPEC|ISA||119|199|0|0|C0042776|Virus|virs|virs|||viruses|||0|754|192|199
SE|25462450||ab|1|relation|0|0|C0887938|Herpesvirus 6A, Human|virs|virs|||human herpesviruses 6A|||0|988|119|141|INFER|CAUSES(SPEC)||119|199|0|0|C0743841|Disorder characterized by fever|dsyn|dsyn|||fever/rash illnesses|||0|871|221|241
SE|25462450||ab|1|relation|0|0|C0887938|Herpesvirus 6A, Human|virs|virs|||human herpesviruses 6A|||0|988|119|141|SPEC|ISA||119|199|0|0|C0042776|Virus|virs|virs|||viruses|||0|754|192|199
SE|25462450||ab|1|relation|0|0|C0887939|Herpesvirus 6B, Human|virs|virs|||HHV-6B|||0|1000|152|158|INFER|CAUSES(SPEC)||119|199|0|0|C0743841|Disorder characterized by fever|dsyn|dsyn|||fever/rash illnesses|||0|871|221|241
SE|25462450||ab|1|relation|0|0|C0887939|Herpesvirus 6B, Human|virs|virs|||HHV-6B|||0|1000|152|158|SPEC|ISA||119|199|0|0|C0042776|Virus|virs|virs|||viruses|||0|754|192|199
SE|25462450||ab|1|relation|5|1|C0042776|Virus|virs|virs|||viruses|||0|754|192|199|VERB|CAUSES||215|220|3|1|C0743841|Disorder characterized by fever|dsyn|dsyn|||fever/rash illnesses|||0|871|221|241
SE|25462450||ab|1|relation|7|1|C0015231|Exanthema Subitum|dsyn|dsyn|||roseola|||0|1000|250|257|PREP|COEXISTS_WITH||258|264|1|1|C0948192|Primary infection NOS|dsyn|dsyn|||primary infections|||0|852|276|294

SE|25462450||ab|2|text|296|532|They also cause significant neurologic disease and complications following stem cell and solid organ transplantation, and have suggestive but less certain etiologic associations with other neurologic diseases and immunologic disorders.
SE|25462450||ab|2|entity|C0750502|Significant|idcn|||significant|||0|890|312|323
SE|25462450||ab|2|entity|C1456669|Neurologic Diseases|dsyn|||neurologic disease|||0|890|324|342
SE|25462450||ab|2|entity|C0009566|Complication|patf|||complications|||0|1000|347|360
SE|25462450||ab|2|entity|C0038250|Stem cells|cell|||stem cell|||0|1000|371|380
SE|25462450||ab|2|entity|C0440790|Solid organ|bpoc|||solid organ|||0|901|385|396
SE|25462450||ab|2|entity|C0040732|Transplantation|topp|||transplantation|||0|901|397|412
SE|25462450||ab|2|entity|C1314792|Etiology|ftcn|||etiologic|||0|727|451|460
SE|25462450||ab|2|entity|C1456669|Neurologic Diseases|dsyn|||neurologic diseases|||0|1000|485|504
SE|25462450||ab|2|entity|C0021053|Immune System Diseases|dsyn|||immunologic disorders|||0|1000|509|530

SE|25462450||ab|3|text|532|801|The US National Institute of Allergy and Infectious Diseases recently sponsored a workshop (Roseoloviruses: Clinical Impact, Interventions, and Research Needs) to discuss disease associations, novel biology, and the many unmet research needs related to Roseoloviruses.
SE|25462450||ab|3|entity|C0021622|Institutes|orgt|||Institute|||0|740|548|557
SE|25462450||ab|3|entity|C0020517|Hypersensitivity|patf|||Allergy|||0|740|561|568
SE|25462450||ab|3|entity|C0009450|Communicable Diseases|dsyn|||Infectious Diseases|||0|740|573|592
SE|25462450||ab|3|entity|C0332185|Recent|tmco|||recently|||0|1000|593|601
SE|25462450||ab|3|entity|C0376477|Roseolovirus|virs|||Roseoloviruses|||0|1000|624|638
SE|25462450||ab|3|entity|C0205210|Clinical|qlco|||Clinical|||0|888|640|648
SE|25462450||ab|3|entity|C1273869|Intervention regimes|hlca|||Interventions|||0|1000|657|670
SE|25462450||ab|3|entity|C0683934|research needs|resa|||Research Needs|||0|1000|676|690
SE|25462450||ab|3|entity|C1511978|Disease Association|tmco|||disease associations|||0|983|703|723
SE|25462450||ab|3|entity|C0679622|novel|inpr|||novel|||0|888|725|730
SE|25462450||ab|3|entity|C0005532|Biology|bmod|||biology|||0|888|731|738
SE|25462450||ab|3|entity|C0683934|research needs|resa|||research needs|||0|901|759|773
SE|25462450||ab|3|entity|C0376477|Roseolovirus|virs|||Roseoloviruses|||0|1000|785|799
SE|25462450||ab|3|relation|9|9|C0009450|Communicable Diseases|dsyn|dsyn|||Infectious Diseases|||0|740|573|592|VERB|COEXISTS_WITH||774|781|1|1|C0376477|Roseolovirus|virs|virs|||Roseoloviruses|||0|1000|785|799

SE|25462450||ab|4|text|801|951|This perspective is a distillation of the workshop's presentations and discussions, with a focus on the more general research priorities that emerged.
SE|25462450||ab|4|entity|C0449450|Presentation|idcn|||presentations|||0|827|854|867
SE|25462450||ab|4|entity|C0205234|Focal|spco|||focus|||0|1000|892|897
SE|25462450||ab|4|entity|C0205172|More|ftcn|||more|||0|861|905|909
SE|25462450||ab|4|entity|C0205246|Generalized|spco|||general|||0|861|910|917
SE|25462450||ab|4|entity|C0376368|Research Priorities|resa|||research priorities|||0|861|918|937


SE|25462449||ti|1|text|21|64|Roseoloviruses manipulate host cell cycle.
SE|25462449||ti|1|entity|C0376477|Roseolovirus|virs|||Roseoloviruses|||0|1000|21|35
SE|25462449||ti|1|entity|C1167395|host|celc|||host|||0|901|47|51
SE|25462449||ti|1|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|901|52|62

SE|25462449||ab|1|text|70|223|During lytic infections HHV-6A and HHV-6B disrupt E2F1-Rb complexes by Rb degradation, releasing E2F1 and driving the infected cells toward the S-phase.
SE|25462449||ab|1|entity|C1518094|Lytic Phase|moft|||lytic infections|||0|880|77|93
SE|25462449||ab|1|entity|C0887938|Herpesvirus 6A, Human|virs|||HHV-6A|||0|880|94|100
SE|25462449||ab|1|entity|C0887939|Herpesvirus 6B, Human|virs|||HHV-6B|||0|1000|105|111
SE|25462449||ab|1|entity|C0812258|E2F1 gene|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|851|120|124
SE|25462449||ab|1|entity|C0439855|Complex|qlco|||complexes|||0|851|128|137
SE|25462449||ab|1|entity|C0243125|degradation|ftcn|||degradation|||0|888|144|155
SE|25462449||ab|1|entity|C0812258|E2F1 gene|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|1000|167|171
SE|25462449||ab|1|entity|C0439663|Infected|ftcn|||infected|||0|888|188|196
SE|25462449||ab|1|entity|C0007634|Cells|cell|||cells|||0|888|197|202
SE|25462449||ab|1|entity|C0080129|S Phase|genf|||S-phase|||0|1000|214|221
SE|25462449||ab|1|relation|6|2|C0812258|E2F1 gene|gngm,aapp|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|1000|167|171|ADJ|PART_OF||188|196|6|0|C0007634|Cells|cell|cell|||cells|||0|888|197|202

SE|25462449||ab|2|text|223|371|Whereas upon infection E2F1 and its cofactor DP1 were up-regulated, additional E2F responsive genes were expressed differentially in various cells.
SE|25462449||ab|2|entity|C0812258|E2F1 gene|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|888|246|250
SE|25462449||ab|2|entity|C0178555|cofactor|bacs|||cofactor|||0|694|259|267
SE|25462449||ab|2|entity|||gngm|5729,7027,7905|PTGDR,TFDP1,REEP5|DP1|||0|694|268|271
SE|25462449||ab|2|entity|C1524062|Additional|ftcn|||additional|||0|775|291|301
SE|25462449||ab|2|entity|C0205342|Responsive|ftcn|||responsive|||0|775|306|316
SE|25462449||ab|2|entity|C0017337|Genes|gngm|||genes|||0|775|317|322
SE|25462449||ab|2|entity|C0007634|Cells|cell|||cells|||0|861|364|369
SE|25462449||ab|2|relation|2|1|||gngm,aapp|gngm|5729,7027,7905|PTGDR,TFDP1,REEP5|DP1|||0|694|268|271|ADJ|AFFECTS||306|316|1|1|C0007634|Cells|cell|cell|||cells|||0|861|364|369
SE|25462449||ab|2|relation|2|1|C0812258|E2F1 gene|gngm,aapp|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|888|246|250|ADJ|AFFECTS||306|316|1|1|C0007634|Cells|cell|cell|||cells|||0|861|364|369

SE|25462449||ab|3|text|371|602|E2F binding sites were identified in promoters of several HHV-6 genes, including the U27 and U79 associated with viral DNA replication, revealing high dependence on the binding site and the effect of the E2F1 transcription factor.
SE|25462449||ab|3|entity|C0005456|Binding Sites|rcpt|||binding sites|||0|901|375|388
SE|25462449||ab|3|entity|C0086860|Promoter (Genetics)|bacs,nnon|||promoters|||0|1000|408|417
SE|25462449||ab|3|entity|C0443302|Several|qnco|||several|||0|861|421|428
SE|25462449||ab|3|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|861|429|434
SE|25462449||ab|3|entity|C0017337|Genes|gngm|||genes|||0|861|435|440
SE|25462449||ab|3|entity|C0012939|DNA, Viral|nnon|||viral DNA|||0|901|484|493
SE|25462449||ab|3|entity|C0205250|High|qlco|||high|||0|888|517|521
SE|25462449||ab|3|entity|C0439857|Dependence|mobd|||dependence|||0|888|522|532
SE|25462449||ab|3|entity|C0005456|Binding Sites|rcpt|||binding site|||0|1000|540|552
SE|25462449||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|561|567
SE|25462449||ab|3|entity|C1384539|E2F1 Transcription Factor|aapp,bacs|||E2F1 transcription factor|||0|1000|575|600
SE|25462449||ab|3|relation|1|1|C0005456|Binding Sites|rcpt|rcpt|||binding sites|||0|901|375|388|PREP|COEXISTS_WITH||405|407|9|1|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||promoters|||0|1000|408|417
SE|25462449||ab|3|relation|2|1|C0086860|Promoter (Genetics)|bacs,nnon|bacs|||promoters|||0|1000|408|417|PREP|PART_OF||418|420|8|1|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|861|429|434

SE|25462449||ab|4|text|602|775|Viral genes regulation by E2F1 can synchronize viral replication with the optimal cell cycle phase, enabling utilization of host resources for successful viral replication.
SE|25462449||ab|4|entity|C0017376|Genes, Viral|gngm|||Viral genes|||0|901|602|613
SE|25462449||ab|4|entity|C0851285|Regulation|gora|||regulation|||0|901|614|624
SE|25462449||ab|4|entity|C0812258|E2F1 gene|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|1000|628|632
SE|25462449||ab|4|entity|C0521026|Viral|ftcn|||viral|||0|888|649|654
SE|25462449||ab|4|entity|C0007586|Cell Cycle|celf|||cell cycle|||0|824|684|694
SE|25462449||ab|4|entity|C0205390|Phase|tmco|||phase|||0|824|695|700
SE|25462449||ab|4|entity|C1167395|host|celc|||host|||0|888|726|730
SE|25462449||ab|4|entity|C0035201|Resources|idcn|||resources|||0|888|731|740
SE|25462449||ab|4|entity|C1272703|Successful|qlco|||successful|||0|851|745|755
SE|25462449||ab|4|entity|C0521026|Viral|ftcn|||viral|||0|851|756|761
SE|25462449||ab|4|relation|6|1|C0812258|E2F1 gene|gngm,aapp|gngm|1869,7332|E2F1,UBE2L3|E2F1|||0|1000|628|632|NOM|INTERACTS_WITH||614|624|0|0|C0017376|Genes, Viral|gngm,aapp|gngm|||Viral genes|||0|901|602|613

SE|25462449||ab|5|text|775|887|Furthermore, it was found that infection by roseoloviruses leads to cell cycle arrest, mostly in the G2/M-phase.
SE|25462449||ab|5|entity|C0376477|Roseolovirus|virs|||roseoloviruses|||0|1000|819|833
SE|25462449||ab|5|entity|C1155873|Cell Cycle Arrest|celf|||cell cycle arrest|||0|1000|843|860
SE|25462449||ab|5|entity|C0750554|MOSTLY|idcn|||mostly|||0|1000|862|868
SE|25462449||ab|5|entity|C0079396|G2 Phase|celf|||G2/M-phase|||0|901|876|886
SE|25462449||ab|5|relation|3|1|C1155873|Cell Cycle Arrest|celf|celf|||cell cycle arrest|||0|1000|843|860|PREP|COEXISTS_WITH||869|871|1|1|C0079396|G2 Phase|celf|celf|||G2/M-phase|||0|901|876|886


SE|25462451||ti|1|text|21|75|Roseoloviruses and their modulation of host defenses.
SE|25462451||ti|1|entity|C0376477|Roseolovirus|virs|||Roseoloviruses|||0|1000|21|35
SE|25462451||ti|1|entity|C0520990|Host defense|clna|||host defenses|||0|983|60|73

SE|25462451||ab|1|text|81|251|Human cytomegalovirus (HCMV), the prototypical human beta-herpesvirus, encodes approximately 40 known gene products that function to subvert our host defense mechanisms.
SE|25462451||ab|1|entity|C0010825|Cytomegalovirus|virs|||Human cytomegalovirus|||0|1000|81|102
SE|25462451||ab|1|entity|C0020114|Human|humn|||human|||0|812|128|133
SE|25462451||ab|1|entity|C0682454|betaherpesvirus|virs|||beta-herpesvirus|||0|812|134|150
SE|25462451||ab|1|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|833|160|173
SE|25462451||ab|1|entity|C0205309|Known|qlco|||known|||0|833|177|182
SE|25462451||ab|1|entity|C0033684|Proteins|aapp,bacs|||gene products|||0|833|183|196
SE|25462451||ab|1|entity|C1512501|Host Defense Mechanism|orgf|||host defense mechanisms|||0|988|226|249
SE|25462451||ab|1|relation|0|0|C0682454|betaherpesvirus|virs|virs|||beta-herpesvirus|||0|812|134|150|MOD/HEAD|PROCESS_OF||128|150|0|0|C0020114|Human|grup,humn|humn|||human|||0|812|128|133

SE|25462451||ab|2|text|251|525|From HCMV, we have learned about interferon signaling, cytokine function, chemokine signaling, natural killer (NK) cells' cytotoxicity toward tumors and virus-infected cells, antigen processing and presentation, and protective initiation of the apoptotic signaling cascade.
SE|25462451||ab|2|entity|C0010825|Cytomegalovirus|virs|||HCMV|||0|1000|256|260
SE|25462451||ab|2|entity|C0021747|Interferons|aapp,imft,phsu|||interferon|||0|888|284|294
SE|25462451||ab|2|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|295|304
SE|25462451||ab|2|entity|C0079189|cytokine|aapp,imft|||cytokine|||0|888|306|314
SE|25462451||ab|2|entity|C0031843|physiological aspects|phsf|||function|||0|888|315|323
SE|25462451||ab|2|entity|C0282554|chemokine|aapp,imft|||chemokine|||0|888|325|334
SE|25462451||ab|2|entity|C0037083|Signal Transduction|celf|||signaling|||0|888|335|344
SE|25462451||ab|2|entity|C0022688|Natural Killer Cells|cell|||natural killer (NK) cells|||0|916|346|371
SE|25462451||ab|2|entity|C0596402|cytotoxicity|comd|||cytotoxicity|||0|916|373|385
SE|25462451||ab|2|entity|C0027651|Neoplasm|neop|||tumors|||0|1000|393|399
SE|25462451||ab|2|entity|C0042769|Virus Diseases|dsyn|||virus|||0|851|404|409
SE|25462451||ab|2|entity|C0439663|Infected|ftcn|||infected|||0|851|410|418
SE|25462451||ab|2|entity|C0007634|Cells|cell|||cells|||0|851|419|424
SE|25462451||ab|2|entity|C0206430|Antigen Processing|celf|||antigen processing|||0|1000|426|444
SE|25462451||ab|2|entity|C0449450|Presentation|idcn|||presentation|||0|1000|449|461
SE|25462451||ab|2|entity|C1326205|Induction of Apoptosis|celf|||apoptotic signaling|||0|698|496|515
SE|25462451||ab|2|relation|0|0|C0021747|Interferons|aapp,gngm,imft,phsu|aapp|||interferon|||0|888|284|294|SPEC|ISA||284|314|0|0|C0079189|cytokine|aapp,gngm,imft|aapp|||cytokine|||0|888|306|314
SE|25462451||ab|2|relation|0|0|C0282554|chemokine|aapp,gngm,imft|aapp|||chemokine|||0|888|325|334|SPEC|ISA||306|334|0|0|C0079189|cytokine|aapp,gngm,imft|aapp|||cytokine|||0|888|306|314
SE|25462451||ab|2|relation|6|3|C0282554|chemokine|aapp,gngm,imft|aapp|||chemokine|||0|888|325|334|ADJ|PART_OF||410|418|6|0|C0007634|Cells|cell|cell|||cells|||0|851|419|424

SE|25462451||ab|3|text|525|740|With each successive discovery of novel host evasion mechanism encoded by the cytomegaloviruses, we illuminate what these herpesviruses have learned over the course of their 100 MYr-long evolution with their hosts.
SE|25462451||ab|3|entity|C0679622|novel|inpr|||novel|||0|775|559|564
SE|25462451||ab|3|entity|C1167395|host|celc|||host|||0|775|565|569
SE|25462451||ab|3|entity|C0441712|Mechanisms|ftcn|||mechanism|||0|775|578|587
SE|25462451||ab|3|entity|C0010825|Cytomegalovirus|virs|||cytomegaloviruses|||0|1000|603|620
SE|25462451||ab|3|entity|C0019369|Herpesviridae|virs|||herpesviruses|||0|1000|647|660
SE|25462451||ab|3|entity|C0205136|Over|spco|||over|||0|1000|674|678
SE|25462451||ab|3|entity|C0750729|Course|tmco|||course|||0|1000|683|689
SE|25462451||ab|3|entity|C0205166|Long|qlco|||long|||0|750|707|711
SE|25462451||ab|3|entity|C0015219|Evolution|genf|||evolution|||0|750|712|721
SE|25462451||ab|3|entity|C1167395|host|celc|||hosts|||0|966|733|738

SE|25462451||ab|4|text|740|899|As much as we have learned from HCMV, the other members of the human beta-herpesvirus family, HHV-6 and HHV-7, are closely-related and yet largely unexplored.
SE|25462451||ab|4|entity|C0010825|Cytomegalovirus|virs|||HCMV|||0|1000|772|776
SE|25462451||ab|4|entity|C0680022|member|popg|||members|||0|966|788|795
SE|25462451||ab|4|entity|C0020114|Human|humn|||human|||0|851|803|808
SE|25462451||ab|4|entity|C0682454|betaherpesvirus|virs|||beta-herpesvirus|||0|851|809|825
SE|25462451||ab|4|entity|C0015576|Family|famg|||family|||0|851|826|832
SE|25462451||ab|4|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|834|839
SE|25462451||ab|4|entity|C0079506|Herpesvirus 7, Human|virs|||HHV-7|||0|1000|844|849
SE|25462451||ab|4|entity|C1522149|Related|ftcn|||related|||0|861|863|870
SE|25462451||ab|4|relation|0|0|C0682454|betaherpesvirus|virs|virs|||beta-herpesvirus|||0|851|809|825|MOD/HEAD|PROCESS_OF||809|832|0|0|C0015576|Family|famg,humn|humn|||family|||0|851|826|832

SE|25462451||ab|5|text|899|946|These viruses likely have much yet to teach us.
SE|25462451||ab|5|entity|C0042776|Virus|virs|||viruses|||0|1000|905|912


SE|25462448||ti|1|text|21|82|Immune response to HHV-6 and implications for immunotherapy.
SE|25462448||ti|1|entity|C0301872|Immune response|orgf|||Immune response|||0|1000|21|36
SE|25462448||ti|1|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|40|45
SE|25462448||ti|1|entity|C0021083|Immunotherapy|topp|||immunotherapy|||0|1000|67|80

SE|25462448||ab|1|text|88|251|Most adults remain chronically infected with HHV-6 after resolution of a primary infection in childhood, with the latent virus held in check by the immune system.
SE|25462448||ab|1|entity|C0001675|Adult|aggp|||adults|||0|1000|93|99
SE|25462448||ab|1|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|1000|133|138
SE|25462448||ab|1|entity|C1514893|Resolution|ftcn|||resolution|||0|1000|145|155
SE|25462448||ab|1|entity|C0948192|Primary infection NOS|dsyn|||primary infection|||0|1000|161|178
SE|25462448||ab|1|entity|C0231335|Childhood|tmco|||childhood|||0|1000|182|191
SE|25462448||ab|1|entity|C1517745|Latent Virus|virs|||latent virus|||0|1000|202|214
SE|25462448||ab|1|entity|C0020962|Immune system|bdsy|||immune system|||0|1000|236|249

SE|25462448||ab|2|text|251|413|Iatrogenic immunosuppression following solid organ transplantation (SOT) or hematopoetic stem cell transplantation (HSCT) can allow latent viruses to reactivate.
SE|25462448||ab|2|entity|C0439669|Iatrogenic|qlco|||Iatrogenic|||0|694|251|261
SE|25462448||ab|2|entity|C0440790|Solid organ|bpoc|||solid organ|||0|901|290|301
SE|25462448||ab|2|entity|C0040732|Transplantation|topp|||transplantation|||0|901|302|317
SE|25462448||ab|2|entity|C1504389|Stem cell transplant|topp|||stem cell transplantation|||0|923|340|365
SE|25462448||ab|2|entity|C1517745|Latent Virus|virs|||latent viruses|||0|983|383|397

SE|25462448||ab|3|text|413|548|HHV-6 reactivation has been associated with increased morbidity, graft rejection, and neurological complications post-transplantation.
SE|25462448||ab|3|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|734|413|418
SE|25462448||ab|3|entity|C0205217|Increased|qnco|||increased|||0|694|457|466
SE|25462448||ab|3|entity|C0018129|Graft Rejection|ortf|||graft rejection|||0|1000|478|493
SE|25462448||ab|3|entity|C0235029|NEUROLOGIC COMPLICATION|patf|||neurological complications|||0|983|499|525
SE|25462448||ab|3|entity|C0040732|Transplantation|topp|||transplantation|||0|888|531|546

SE|25462448||ab|4|text|548|677|Recent work has identified HHV-6 antigens that are targeted by the CD4+ and CD8+ T cell response in chronically infected adults.
SE|25462448||ab|4|entity|C0332185|Recent|tmco|||Recent|||0|888|548|554
SE|25462448||ab|4|entity|C0043227|Work|ocac|||work|||0|888|555|559
SE|25462448||ab|4|entity|C0205396|Identified|qlco|||identified|||0|861|564|574
SE|25462448||ab|4|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|861|575|580
SE|25462448||ab|4|entity|C0003320|Antigens|bacs,imft|||antigens|||0|861|581|589
SE|25462448||ab|4|entity|C1332714|CD4 gene|gngm|920|CD4|CD4|||0|1000|615|618
SE|25462448||ab|4|entity|C0242629|CD8-Positive T-Lymphocytes|cell|||CD8+ T cell|||0|861|624|635
SE|25462448||ab|4|entity|C0871261|response|clna|||response|||0|861|636|644
SE|25462448||ab|4|entity|C0439663|Infected|ftcn|||infected|||0|790|660|668
SE|25462448||ab|4|entity|C0001675|Adult|aggp|||adults|||0|790|669|675
SE|25462448||ab|4|relation|0|0|C0003320|Antigens|bacs,imft|bacs|||antigens|||0|861|581|589|MOD/HEAD|PART_OF||575|589|0|0|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|861|575|580
SE|25462448||ab|4|relation|3|1|C1332714|CD4 gene|gngm,aapp|gngm|920|CD4|CD4|||0|1000|615|618|VERB|INTERACTS_WITH||599|607|2|1|C0003320|Antigens|bacs,imft|bacs|||antigens|||0|861|581|589
SE|25462448||ab|4|relation|4|3|C0003320|Antigens|bacs,imft|bacs|||antigens|||0|861|581|589|ADJ|PART_OF||660|668|4|0|C0001675|Adult|aggp,humn|humn|||adults|||0|790|669|675

SE|25462448||ab|5|text|677|854|T cell populations recognizing these targets can be expanded in vitro and are being developed for use in autologous immunotherapy to control post-transplantation HHV-6 reaction.
SE|25462448||ab|5|entity|C0039194|T-Lymphocyte|cell|||T cell|||0|901|677|683
SE|25462448||ab|5|entity|C0032659|geographic population|qnco|||populations|||0|901|684|695
SE|25462448||ab|5|entity|C1533691|in vitro|qlco|||in vitro|||0|1000|738|746
SE|25462448||ab|5|entity|C0439859|Autologous|qlco|||autologous|||0|888|782|792
SE|25462448||ab|5|entity|C0021083|Immunotherapy|topp|||immunotherapy|||0|888|793|806
SE|25462448||ab|5|entity|C0040732|Transplantation|topp|||transplantation|||0|840|823|838
SE|25462448||ab|5|entity|C0019381|Herpesvirus 6, Human|virs|||HHV-6|||0|840|839|844
SE|25462448||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|840|845|853
SE|25462448||ab|5|relation|5|1|C0021083|Immunotherapy|topp|topp|||immunotherapy|||0|888|793|806|VERB|TREATS||810|817|1|1|C0019381|Herpesvirus 6, Human|virs|virs|||HHV-6|||0|840|839|844


SE|25462452||ti|1|text|21|60|ABCG1 is involved in vitamin E efflux.
SE|25462452||ti|1|entity|||gngm|9619|ABCG1|ABCG1|||0|1000|21|26
SE|25462452||ti|1|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|734|42|51

SE|25462452||ab|1|text|66|175|Vitamin E membrane transport has been shown to involve the cholesterol transporters SR-BI, ABCA1 and NPC1L1.
SE|25462452||ab|1|entity|C0042874|Vitamin E|lipd,phsu,vita|||Vitamin E|||0|888|66|75
SE|25462452||ab|1|entity|C1519624|Transmembrane Transport|celf|||membrane transport|||0|888|76|94
SE|25462452||ab|1|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|597|125|136
SE|25462452||ab|1|entity|C0596902|Membrane Transport Proteins|aapp,bacs|||transporters|||0|597|137|149
SE|25462452||ab|1|entity|C1335806|SCTR gene|gngm|6344|SCTR|SR-BI|||0|597|150|155
SE|25462452||ab|1|entity|||gngm|19|ABCA1|ABCA1|||0|1000|157|162
SE|25462452||ab|1|entity|||gngm|29881|NPC1L1|NPC1L1|||0|1000|167|173

SE|25462452||ab|2|text|175|301|Our aim was to investigate the possible participation of another cholesterol transporter in cellular vitamin E efflux: ABCG1.
SE|25462452||ab|2|entity|C0332149|Possible|qlco|||possible|||0|888|206|214
SE|25462452||ab|2|entity|C0679823|participation|inbe|||participation|||0|888|215|228
SE|25462452||ab|2|entity|C0008377|Cholesterol|bacs,strd|||cholesterol|||0|888|240|251
SE|25462452||ab|2|entity|C0596902|Membrane Transport Proteins|aapp,bacs|||transporter|||0|888|252|263
SE|25462452||ab|2|entity|C0178539|Cellular|ftcn|||cellular|||0|658|267|275
SE|25462452||ab|2|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|658|276|285
SE|25462452||ab|2|entity|||gngm|9619|ABCG1|ABCG1|||0|1000|294|299

SE|25462452||ab|3|text|301|587|In Abcgl-deficient mice, vitamin E concentration was reduced in plasma lipoproteins whereas most tissues displayed a higher vitamin E content compared to wild-type mice. alpha- and gamma-tocopherol efflux was increased in CHO cells overexpressing human ABCG1 compared to control cells.
SE|25462452||ab|3|entity|C0011155|Deficiency|ftcn|||deficient|||0|790|310|319
SE|25462452||ab|3|entity|C0026809|Mus|mamm|||mice|||0|790|320|324
SE|25462452||ab|3|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|734|326|335
SE|25462452||ab|3|entity|C0032105|Plasma|bdsu|||plasma|||0|888|365|371
SE|25462452||ab|3|entity|C0023820|Lipoproteins|aapp,bacs|||lipoproteins|||0|888|372|384
SE|25462452||ab|3|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|398|405
SE|25462452||ab|3|entity|C0205250|High|qlco|||higher|||0|641|418|424
SE|25462452||ab|3|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|641|425|434
SE|25462452||ab|3|entity|C0445392|Wild|inpr|||wild|||0|833|455|459
SE|25462452||ab|3|entity|C1547052|*Type|qnco|||type|||0|833|460|464
SE|25462452||ab|3|entity|C0026809|Mus|mamm|||mice|||0|833|465|469
SE|25462452||ab|3|entity|C0439095|Alpha|inpr|||alpha|||0|833|471|476
SE|25462452||ab|3|entity|C0017054|gamma-Tocopherol|lipd,phsu,vita|||gamma-tocopherol|||0|734|482|498
SE|25462452||ab|3|entity|C0085080|Chinese Hamster Ovary Cell|cell|||CHO cells|||0|1000|523|532
SE|25462452||ab|3|entity|C0020114|Human|humn|||human|||0|694|548|553
SE|25462452||ab|3|entity|||gngm|9619|ABCG1|ABCG1|||0|694|554|559
SE|25462452||ab|3|entity|C0007634|Cells|cell|||cells|||0|1000|580|585
SE|25462452||ab|3|relation|0|0|||gngm,aapp|gngm|9619|ABCG1|ABCG1|||0|694|554|559|MOD/HEAD|PART_OF||548|559|0|0|C0020114|Human|grup,humn|humn|||human|||0|694|548|553
SE|25462452||ab|3|relation|0|0|C0032105|Plasma|bdsu|bdsu|||plasma|||0|888|365|371|MOD/HEAD|LOCATION_OF||365|384|0|0|C0023820|Lipoproteins|aapp,gngm,bacs|aapp|||lipoproteins|||0|888|372|384
SE|25462452||ab|3|relation|7|3|C0042874|Vitamin E|lipd,phsu,vita|lipd|||vitamin E|||0|641|425|434|VERB|AUGMENTS||510|519|3|1|C0085080|Chinese Hamster Ovary Cell|cell|cell|||CHO cells|||0|1000|523|532
SE|25462452||ab|3|relation|8|1|C0023820|Lipoproteins|aapp,gngm,bacs|aapp|||lipoproteins|||0|888|372|384|VERB|INHIBITS||354|361|2|1|C0042874|Vitamin E|lipd,phsu,vita|lipd|||vitamin E|||0|734|326|335
SE|25462452||ab|3|relation|8|1|C0085080|Chinese Hamster Ovary Cell|cell|cell|||CHO cells|||0|1000|523|532|VERB|PRODUCES||533|547|2|1|||gngm,aapp|aapp|9619|ABCG1|ABCG1|||0|694|554|559

SE|25462452||ab|4|text|587|725|Conversely, alpha- and gamma- tocopherol efflux was decreased in ABCG1-knockdown human cells (Hep3B hepatocytes and THP-1 macro- phages).
SE|25462452||ab|4|entity|C0439095|Alpha|inpr|||alpha|||0|1000|599|604
SE|25462452||ab|4|entity|C0017054|gamma-Tocopherol|lipd,phsu,vita|||gamma- tocopherol|||0|734|610|627
SE|25462452||ab|4|entity|||gngm|9619|ABCG1|ABCG1|||0|861|652|657
SE|25462452||ab|4|entity|C0427861|Human cells|lbtr|||human cells|||0|861|668|679
SE|25462452||ab|4|entity|C0227525|Hepatocyte|cell|||hepatocytes|||0|861|687|698
SE|25462452||ab|4|entity|||gngm|2736|GLI2|THP-1|||0|812|703|708
SE|25462452||ab|4|entity|C0004651|Bacteriophages|virs|||phages|||0|812|716|722

SE|25462452||ab|5|text|725|914|Interestingly, alpha- and gamma-tocopherol significantly downregulated ABCG1 and ABCA1 expression levels in Hep3B and THP-1, an effect confirmed in vivo in rats given vitamin E for 5 days.
SE|25462452||ab|5|entity|C0439095|Alpha|inpr|||alpha|||0|1000|740|745
SE|25462452||ab|5|entity|C0017054|gamma-Tocopherol|lipd,phsu,vita|||gamma-tocopherol|||0|673|751|767
SE|25462452||ab|5|entity|||gngm|9619|ABCG1|ABCG1|||0|673|796|801
SE|25462452||ab|5|entity|||gngm|19|ABCA1|ABCA1|||0|790|806|811
SE|25462452||ab|5|entity|C0441889|Levels|inpr|||levels|||0|790|823|829
SE|25462452||ab|5|entity|||gngm|2736|GLI2|THP-1|||0|1000|843|848
SE|25462452||ab|5|entity|C1280500|Effect|qlco|||effect|||0|1000|853|859
SE|25462452||ab|5|entity|C1515655|in vivo|spco|||in vivo|||0|1000|870|877
SE|25462452||ab|5|entity|C0034693|Rattus norvegicus|mamm|||rats|||0|1000|881|885
SE|25462452||ab|5|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|1000|892|901
SE|25462452||ab|5|entity|C1442466|5 Days|tmco|||5 days|||0|1000|906|912
SE|25462452||ab|5|relation|2|1|C0042874|Vitamin E|lipd,phsu,vita|lipd|||vitamin E|||0|1000|892|901|VERB|ADMINISTERED_TO||886|891|7|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|881|885
SE|25462452||ab|5|relation|3|1|C0034693|Rattus norvegicus|mamm|mamm|||rats|||0|1000|881|885|PREP|LOCATION_OF||878|880|6|2|||gngm,aapp|aapp|2736|GLI2|THP-1|||0|1000|843|848

SE|25462452||ab|6|text|914|1122|This was likely due to reduced LXR activation by oxysterols, as Hep3B cells and rat liver treated with vitamin E displayed a significantly reduced content in oxysterols compared to their respective controls.
SE|25462452||ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|660|937|944
SE|25462452||ab|6|entity|C0007634|Cells|cell|||cells|||0|861|984|989
SE|25462452||ab|6|entity|C0034693|Rattus norvegicus|mamm|||rat|||0|888|994|997
SE|25462452||ab|6|entity|C0023884|Liver|bpoc|||liver|||0|888|998|1003
SE|25462452||ab|6|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|1000|1017|1026
SE|25462452||ab|6|entity|C0392756|Reduced|qlco|||reduced|||0|660|1053|1060
SE|25462452||ab|6|entity|C0243148|control|ftcn|||controls|||0|827|1112|1120
SE|25462452||ab|6|relation|0|0|C0023884|Liver|bpoc|bpoc|||liver|||0|888|998|1003|MOD/HEAD|PART_OF||994|1003|0|0|C0034693|Rattus norvegicus|mamm|mamm|||rat|||0|888|994|997

SE|25462452||ab|7|text|1122|1228|Overall, the present study reveals for the first time that ABCG1 is involved in cellular vitamin E efflux.
SE|25462452||ab|7|entity|C1561607|Overall|qlco|||Overall|||0|1000|1122|1129
SE|25462452||ab|7|entity|C0150312|Present|qnco|||present|||0|888|1135|1142
SE|25462452||ab|7|entity|C0008972|Clinical Research|resa|||study|||0|888|1143|1148
SE|25462452||ab|7|entity|C1279901|Firstly|qlco|||first|||0|888|1165|1170
SE|25462452||ab|7|entity|C0040223|Time|tmco|||time|||0|888|1171|1175
SE|25462452||ab|7|entity|||gngm|9619|ABCG1|ABCG1|||0|1000|1181|1186
SE|25462452||ab|7|entity|C0178539|Cellular|ftcn|||cellular|||0|658|1202|1210
SE|25462452||ab|7|entity|C0042874|Vitamin E|lipd,phsu,vita|||vitamin E|||0|658|1211|1220


SE|25462453||ti|1|text|21|117|LECT2 improves the outcomes in ayu with Vibrio anguillarum infection via monocytes/macrophages.
SE|25462453||ti|1|entity|||gngm|3950|LECT2|LECT2|||0|1000|21|26
SE|25462453||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|966|40|48
SE|25462453||ti|1|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|1000|52|55
SE|25462453||ti|1|entity|C0042636|Vibrio Infections|dsyn|||Vibrio anguillarum infection|||0|796|61|89
SE|25462453||ti|1|entity|C1148382|MONOCYTES AND MACROPHAGES|cell|||monocytes/macrophages|||0|796|94|115
SE|25462453||ti|1|relation|1|1|C1148382|MONOCYTES AND MACROPHAGES|cell|cell|||monocytes/macrophages|||0|796|94|115|PREP|PART_OF||56|60|3|1|C1022585|Plecoglossinae altivelis|fish|fish|||ayu|||0|1000|52|55

SE|25462453||ab|1|text|123|271|Leukocyte cell-derived chemotaxin 2 (LECT2) is reported to be a cytokine involved in the immune response against pathogenic microorganisms in fish.
SE|25462453||ab|1|entity|C0007634|Cells|cell|||cell|||0|840|133|137
SE|25462453||ab|1|entity|C0008013|Chemotactic Factors|bacs,imft|||chemotaxin|||0|840|146|156
SE|25462453||ab|1|entity|C0085358|CD8 Antigens|aapp,imft|||Leukocyte cell-derived chemotaxin 2|||0|840|123|158
SE|25462453||ab|1|entity|||gngm|3950|LECT2|LECT2|||0|1000|160|165
SE|25462453||ab|1|entity|C0079189|cytokine|aapp,imft|||cytokine|||0|1000|187|195
SE|25462453||ab|1|entity|C0301872|Immune response|orgf|||immune response|||0|1000|212|227
SE|25462453||ab|1|entity|C1136169|Pathogenicity|orga,qlco|||pathogenic|||0|853|236|246
SE|25462453||ab|1|entity|C0445623|Microorganism|idcn,orgm|||microorganisms|||0|853|247|261
SE|25462453||ab|1|entity|C0016163|Fishes|fish|||fish|||0|1000|265|269
SE|25462453||ab|1|relation|2|1|C0079189|cytokine|aapp,gngm,imft|aapp|||cytokine|||0|1000|187|195|VERB|AFFECTS||196|204|3|1|C0301872|Immune response|orgf|orgf|||immune response|||0|1000|212|227
SE|25462453||ab|1|relation|4|2|C0301872|Immune response|orgf|orgf|||immune response|||0|1000|212|227|PREP|PROCESS_OF||262|264|1|1|C0016163|Fishes|fish|fish|||fish|||0|1000|265|269

SE|25462453||ab|2|text|271|333|However, its accurate function in whole fish remains unclear.
SE|25462453||ab|2|entity|C0443131|Accurate|qlco|||accurate|||0|888|284|292
SE|25462453||ab|2|entity|C0031843|physiological aspects|phsf|||function|||0|888|293|301
SE|25462453||ab|2|entity|C0444667|Whole|qnco|||whole|||0|888|305|310
SE|25462453||ab|2|entity|C0016163|Fishes|fish|||fish|||0|888|311|315

SE|25462453||ab|3|text|333|443|In this study, we provide the first report on the effect of LECT2 on fish defenses against pathogens in vivo.
SE|25462453||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|341|346
SE|25462453||ab|3|entity|C1279901|Firstly|qlco|||first|||0|888|363|368
SE|25462453||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|383|389
SE|25462453||ab|3|entity|||gngm|3950|LECT2|LECT2|||0|1000|393|398
SE|25462453||ab|3|entity|C0016163|Fishes|fish|||fish|||0|835|402|406
SE|25462453||ab|3|entity|C0679190|defensiveness|inbe|||defenses|||0|835|407|415
SE|25462453||ab|3|entity|C1515655|in vivo|spco|||in vivo|||0|1000|434|441

SE|25462453||ab|4|text|443|546|The administration of recombinant LECT2 improved the survival rate of Vibrio anguillarum infected ayu.
SE|25462453||ab|4|entity|||gngm|3950|LECT2|LECT2|||0|661|477|482
SE|25462453||ab|4|entity|C0038954|Survival Rate|qnco|||survival rate|||0|1000|496|509
SE|25462453||ab|4|entity|C0544178|Listonella anguillarum|bact|||Vibrio anguillarum|||0|861|513|531
SE|25462453||ab|4|entity|C0439663|Infected|ftcn|||infected|||0|861|532|540
SE|25462453||ab|4|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|861|541|544
SE|25462453||ab|4|relation|3|2|||gngm,aapp|gngm|3950|LECT2|LECT2|||0|661|477|482|ADJ|PART_OF||532|540|3|0|C1022585|Plecoglossinae altivelis|fish|fish|||ayu|||0|861|541|544

SE|25462453||ab|5|text|546|696|The bacterial burden of V. anguillarum infected ayu was decreased in LECT2-treated ayu blood, liver, spleen, and kidney compared with saline control.
SE|25462453||ab|5|entity|C0521009|Bacterial|ftcn|||bacterial|||0|694|550|559
SE|25462453||ab|5|entity|C0439663|Infected|ftcn|||infected|||0|750|585|593
SE|25462453||ab|5|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|750|594|597
SE|25462453||ab|5|entity|||gngm|3950|LECT2|LECT2|||0|764|615|620
SE|25462453||ab|5|entity|C1292734|Treats|clas|||treated|||0|764|621|628
SE|25462453||ab|5|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|764|629|632
SE|25462453||ab|5|entity|C0005767|Blood|tisu|||blood|||0|764|633|638
SE|25462453||ab|5|entity|C0023884|Liver|bpoc|||liver|||0|1000|640|645
SE|25462453||ab|5|entity|C0037993|Spleen|bpoc|||spleen|||0|1000|647|653
SE|25462453||ab|5|entity|C0022646|Kidney|bpoc|||kidney|||0|1000|659|665
SE|25462453||ab|5|entity|C0036082|Saline|clnd|||saline|||0|888|680|686
SE|25462453||ab|5|entity|C0243148|control|ftcn|||control|||0|888|687|694

SE|25462453||ab|6|text|696|884|In bacteria-infected ayu, LECT2 treatment altered the mRNA expression of cytokines, including TNFalpha, IL-1beta, and IL-10, which are all important for the inflammatory response in fish.
SE|25462453||ab|6|entity|C0004611|Bacteria|bact|||bacteria|||0|851|699|707
SE|25462453||ab|6|entity|C0439663|Infected|ftcn|||infected|||0|851|708|716
SE|25462453||ab|6|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|851|717|720
SE|25462453||ab|6|entity|||gngm|3950|LECT2|LECT2|||0|861|722|727
SE|25462453||ab|6|entity|C1515670|mRNA Expression|genf|||mRNA expression|||0|1000|750|765
SE|25462453||ab|6|entity|C0079189|cytokine|aapp,imft|||cytokines|||0|1000|769|778
SE|25462453||ab|6|entity|||gngm|7124|TNF|TNFalpha|||0|1000|790|798
SE|25462453||ab|6|entity|C0021753|Interleukin-1 beta|aapp,imft|||IL-1beta|||0|1000|800|808
SE|25462453||ab|6|entity|C0085295|Interleukin-10|aapp,imft|||IL-10|||0|1000|814|819
SE|25462453||ab|6|entity|C1155266|Inflammatory Response|patf|||inflammatory response|||0|1000|853|874
SE|25462453||ab|6|entity|C0016163|Fishes|fish|||fish|||0|1000|878|882
SE|25462453||ab|6|relation|6|0|||gngm,aapp|aapp|7124|TNF|TNFalpha|||0|1000|790|798|ADJ|AFFECTS||835|844|2|1|C1155266|Inflammatory Response|patf|patf|||inflammatory response|||0|1000|853|874
SE|25462453||ab|6|relation|6|0|C0021753|Interleukin-1 beta|aapp,gngm,imft|aapp|||IL-1beta|||0|1000|800|808|ADJ|AFFECTS||835|844|2|1|C1155266|Inflammatory Response|patf|patf|||inflammatory response|||0|1000|853|874
SE|25462453||ab|6|relation|6|0|C0085295|Interleukin-10|aapp,gngm,imft|aapp|||IL-10|||0|1000|814|819|ADJ|AFFECTS||835|844|2|1|C1155266|Inflammatory Response|patf|patf|||inflammatory response|||0|1000|853|874
SE|25462453||ab|6|relation|6|1|C0079189|cytokine|aapp,gngm,imft|gngm|||cytokines|||0|1000|769|778|PREP|LOCATION_OF||766|768|3|1|C1515670|mRNA Expression|genf|genf|||mRNA expression|||0|1000|750|765
SE|25462453||ab|6|relation|8|1|C1155266|Inflammatory Response|patf|patf|||inflammatory response|||0|1000|853|874|PREP|PROCESS_OF||875|877|1|1|C0016163|Fishes|fish|fish|||fish|||0|1000|878|882

SE|25462453||ab|7|text|884|1063|LECT2 treatment also reduced histological damage in bacteria-infected ayu, and increased peritoneal monocytes/macrophages in both healthy and infected ayu at 12 h post infection.
SE|25462453||ab|7|entity|||gngm|3950|LECT2|LECT2|||0|861|884|889
SE|25462453||ab|7|entity|C0205462|Histologic|ftcn|||histological|||0|694|913|925
SE|25462453||ab|7|entity|C0004611|Bacteria|bact|||bacteria|||0|851|936|944
SE|25462453||ab|7|entity|C0439663|Infected|ftcn|||infected|||0|851|945|953
SE|25462453||ab|7|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|851|954|957
SE|25462453||ab|7|entity|C0031153|Peritoneum|bpoc|||peritoneal|||0|861|973|983
SE|25462453||ab|7|entity|C0553698|Monocyte count increased|fndg|||increased peritoneal monocytes|||0|861|963|993
SE|25462453||ab|7|entity|C0024432|macrophage|cell|||macrophages|||0|861|994|1005
SE|25462453||ab|7|entity|C0018684|Health|idcn|||healthy|||0|928|1014|1021
SE|25462453||ab|7|entity|C0439663|Infected|ftcn|||infected|||0|888|1026|1034
SE|25462453||ab|7|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|888|1035|1038
SE|25462453||ab|7|entity|C0456695|/12h|tmco|||12 h|||0|1000|1042|1046
SE|25462453||ab|7|entity|C0205095|Dorsal|spco|||post|||0|888|1047|1051
SE|25462453||ab|7|relation|5|2|C0024432|macrophage|cell|cell|||macrophages|||0|861|994|1005|ADJ|PART_OF||1026|1034|5|0|C1022585|Plecoglossinae altivelis|fish|fish|||ayu|||0|888|1035|1038

SE|25462453||ab|8|text|1063|1256|When ayu monocytes/macrophages were depleted by clodronate-liposomes treatment, LECT2 treatment did not increase the survival rate of bacteria-infected fish compared with healthy control fish.
SE|25462453||ab|8|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|901|1068|1071
SE|25462453||ab|8|entity|C1148382|MONOCYTES AND MACROPHAGES|cell|||monocytes/macrophages|||0|901|1072|1093
SE|25462453||ab|8|entity|C0162357|Clodronate|opco,phsu|||clodronate|||0|851|1111|1121
SE|25462453||ab|8|entity|C0023828|Liposomes|celc,lipd|||liposomes|||0|851|1122|1131
SE|25462453||ab|8|entity|||gngm|3950|LECT2|LECT2|||0|861|1143|1148
SE|25462453||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1163|1166
SE|25462453||ab|8|entity|C0038954|Survival Rate|qnco|||survival rate|||0|1000|1180|1193
SE|25462453||ab|8|entity|C0004611|Bacteria|bact|||bacteria|||0|851|1197|1205
SE|25462453||ab|8|entity|C0439663|Infected|ftcn|||infected|||0|851|1206|1214
SE|25462453||ab|8|entity|C0016163|Fishes|fish|||fish|||0|851|1215|1219
SE|25462453||ab|8|entity|C0018684|Health|idcn|||healthy|||0|828|1234|1241
SE|25462453||ab|8|entity|C0243148|control|ftcn|||control|||0|828|1242|1249
SE|25462453||ab|8|entity|C0016163|Fishes|fish|||fish|||0|828|1250|1254

SE|25462453||ab|9|text|1256|1415|Thus our results suggest that LECT2 can modulate host defense in ayu and mediate antibacterial protection against V. anguillarum through monocytes/macrophages.
SE|25462453||ab|9|entity|C1274040|result|ftcn|||results|||0|966|1265|1272
SE|25462453||ab|9|entity|||gngm|3950|LECT2|LECT2|||0|1000|1286|1291
SE|25462453||ab|9|entity|C0520990|Host defense|clna|||host defense|||0|1000|1305|1317
SE|25462453||ab|9|entity|C1022585|Plecoglossinae altivelis|fish|||ayu|||0|1000|1321|1324
SE|25462453||ab|9|entity|C0279516|Anti-Bacterial Agents|antb|||antibacterial|||0|888|1337|1350
SE|25462453||ab|9|entity|C1148382|MONOCYTES AND MACROPHAGES|cell|||monocytes/macrophages|||0|1000|1393|1414


SE|25462454||ti|1|text|21|194|Effect of size and temperature at vaccination on immunization and protection conferred by a live attenuated Francisella noatunensis immersion vaccine in red hybrid tilapia.
SE|25462454||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462454||ti|1|entity|C0456389|size|spco|||size|||0|1000|31|35
SE|25462454||ti|1|entity|C0039476|Temperature|qnco|||temperature|||0|1000|40|51
SE|25462454||ti|1|entity|C0042196|Vaccination|topp|||vaccination|||0|1000|55|66
SE|25462454||ti|1|entity|C0020971|Immunization|topp|||immunization|||0|1000|70|82
SE|25462454||ti|1|entity|C0016676|Francisella|bact|||Francisella|||0|768|129|140
SE|25462454||ti|1|entity|C0038561|Submersion|inpo|||immersion|||0|768|153|162
SE|25462454||ti|1|entity|C0042211|Vaccines, Attenuated|imft,phsu|||live attenuated Francisella noatunensis immersion vaccine|||0|768|113|170
SE|25462454||ti|1|entity|C0332575|Redness|fndg|||red|||0|851|174|177
SE|25462454||ti|1|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|851|178|184
SE|25462454||ti|1|entity|C0162642|Tilapia|fish|||tilapia|||0|851|185|192

SE|25462454||ab|1|text|200|396|Francisella noatunensis subsp. orientalis (Fno) is a pleomorphic, facultative intracellular, Gram-negative, emerging bacterial pathogen of marine and fresh water fish with worldwide distribution.
SE|25462454||ab|1|entity|C0016676|Francisella|bact|||Francisella|||0|645|200|211
SE|25462454||ab|1|entity|C1514164|Pleomorphic|qlco|||pleomorphic|||0|766|253|264
SE|25462454||ab|1|entity|C0175996|Protoplasm|celc|||intracellular|||0|766|278|291
SE|25462454||ab|1|entity|C0200966|Bacterial stain, routine|lbpr|||Gram|||0|766|293|297
SE|25462454||ab|1|entity|C0205160|Negative|qlco|||negative|||0|766|298|306
SE|25462454||ab|1|entity|C0521009|Bacterial|ftcn|||bacterial|||0|838|317|326
SE|25462454||ab|1|entity|C0524645|Marines|prog|||marine|||0|966|339|345
SE|25462454||ab|1|entity|C0016710|Fresh Water|sbst|||fresh water|||0|888|350|361
SE|25462454||ab|1|entity|C0016163|Fishes|fish|||fish|||0|888|362|366
SE|25462454||ab|1|entity|C0520511|Distributing|idcn|||distribution|||0|861|382|394

SE|25462454||ab|2|text|396|699|In this study, the efficacy of an attenuated Fno intracellular growth locus C (iglC) mutant was evaluated for use as a live immersion vaccine, when administered to hybrid tilapia at two different stages of growth (5 g fry and 10 g fingerlings) and at two temperatures (25  degrees C and 30  degrees C).
SE|25462454||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|404|409
SE|25462454||ab|2|entity|C0016676|Francisella|bact|||Fno|||0|703|441|444
SE|25462454||ab|2|entity|C0175996|Protoplasm|celc|||intracellular|||0|703|445|458
SE|25462454||ab|2|entity|C0018270|Growth|orgf|||growth|||0|703|459|465
SE|25462454||ab|2|entity|C0596988|Mutant|comd|||mutant|||0|703|481|487
SE|25462454||ab|2|entity|C0038561|Submersion|inpo|||immersion|||0|901|520|529
SE|25462454||ab|2|entity|C0042211|Vaccines, Attenuated|imft,phsu|||live immersion vaccine|||0|901|515|537
SE|25462454||ab|2|entity|C0007597|Cell hybridization|lbpr|||hybrid|||0|888|560|566
SE|25462454||ab|2|entity|C0162642|Tilapia|fish|||tilapia|||0|888|567|574
SE|25462454||ab|2|entity|C0205448|Two|qnco|||two|||0|828|578|581
SE|25462454||ab|2|entity|C1547020|*Difference|qnco|||different|||0|828|582|591
SE|25462454||ab|2|entity|C1306673|Stage|qlco|||stages|||0|828|592|598
SE|25462454||ab|2|entity|C0018270|Growth|orgf|||growth|||0|1000|602|608
SE|25462454||ab|2|entity|||gngm|10129|FRY|fry|||0|660|614|617
SE|25462454||ab|2|entity|C0205448|Two|qnco|||two|||0|888|647|650
SE|25462454||ab|2|entity|C0039476|Temperature|qnco|||temperatures|||0|888|651|663
SE|25462454||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|669|678
SE|25462454||ab|2|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|687|696

SE|25462454||ab|3|text|699|946|To determine vaccine efficacy, mortality, days to first death, and Fno genome equivalents (GE) in the spleens of survivors, as well as serum and mucus antibody levels, were evaluated after 30 d in fish challenged with a wild type virulent strain.
SE|25462454||ab|3|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|694|712|719
SE|25462454||ab|3|entity|C0439228|day|tmco|||days|||0|1000|741|745
SE|25462454||ab|3|entity|C1279901|Firstly|qlco|||first|||0|888|749|754
SE|25462454||ab|3|entity|C0011065|Cessation of life|orgf|||death|||0|888|755|760
SE|25462454||ab|3|entity|C0016676|Francisella|bact|||Fno|||0|756|766|769
SE|25462454||ab|3|entity|C0017428|Genome|gngm|||genome|||0|756|770|776
SE|25462454||ab|3|entity|C0439185|Eq|qnco|||equivalents|||0|756|777|788
SE|25462454||ab|3|entity|C0037993|Spleen|bpoc|||spleens|||0|1000|801|808
SE|25462454||ab|3|entity|C0206194|Survivors|podg|||survivors|||0|1000|812|821
SE|25462454||ab|3|entity|C0229671|Serum|bdsu|||serum|||0|1000|834|839
SE|25462454||ab|3|entity|C0026727|Mucous body substance|bdsu|||mucus|||0|851|844|849
SE|25462454||ab|3|entity|C0003241|Antibodies|aapp,imft|||antibody|||0|851|850|858
SE|25462454||ab|3|entity|C0441889|Levels|inpr|||levels|||0|851|859|865
SE|25462454||ab|3|entity|C0016163|Fishes|fish|||fish|||0|1000|896|900
SE|25462454||ab|3|entity|C0445392|Wild|inpr|||wild|||0|833|919|923
SE|25462454||ab|3|entity|C1547052|*Type|qnco|||type|||0|833|924|928
SE|25462454||ab|3|entity|C1520022|Virulent|qlco|||virulent|||0|833|929|937
SE|25462454||ab|3|entity|C0456178|Microbiology subtype strains|inpr|||strain|||0|833|938|944
SE|25462454||ab|3|relation|0|0|C0026727|Mucous body substance|bdsu|bdsu|||mucus|||0|851|844|849|MOD/HEAD|LOCATION_OF||844|858|0|0|C0003241|Antibodies|aapp,gngm,imft|aapp|||antibody|||0|851|850|858
SE|25462454||ab|3|relation|6|1|C0037993|Spleen|bpoc|bpoc|||spleens|||0|1000|801|808|PREP|PART_OF||809|811|6|1|C0206194|Survivors|podg,humn|humn|||survivors|||0|1000|812|821
SE|25462454||ab|3|relation|10|7|C0011065|Cessation of life|orgf|orgf|||death|||0|888|755|760|PREP|PROCESS_OF||893|895|2|1|C0016163|Fishes|fish|fish|||fish|||0|1000|896|900

SE|25462454||ab|4|text|946|1044|Both size and temperature at vaccination played an important role in immunization and protection.
SE|25462454||ab|4|entity|C0456389|size|spco|||size|||0|1000|951|955
SE|25462454||ab|4|entity|C0039476|Temperature|qnco|||temperature|||0|1000|960|971
SE|25462454||ab|4|entity|C0042196|Vaccination|topp|||vaccination|||0|1000|975|986
SE|25462454||ab|4|entity|C0035820|Role|socb|||role|||0|861|1007|1011
SE|25462454||ab|4|entity|C0020971|Immunization|topp|||immunization|||0|1000|1015|1027

SE|25462454||ab|5|text|1044|1161|Fry vaccinated at 25  degrees C were not protected when compared to non-vaccinated fry at 25  degrees C (p = 0.870).
SE|25462454||ab|5|entity|||gngm|10129|FRY|Fry|||0|1000|1044|1047
SE|25462454||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1066|1075
SE|25462454||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1081|1084
SE|25462454||ab|5|entity|C1519885|Vaccinated|fndg|||vaccinated|||0|660|1116|1126
SE|25462454||ab|5|entity|||gngm|10129|FRY|fry|||0|660|1127|1130
SE|25462454||ab|5|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1138|1147
SE|25462454||ab|5|entity|C0071054|pigment 870|bacs,orch|||p = 0.870|||0|913|1149|1158
SE|25462454||ab|5|relation|2|2|||gngm,aapp|gngm|10129|FRY|Fry|||0|1000|1044|1047|VERB|compared_with||1100|1108|2|1|||gngm,aapp|gngm|10129|FRY|fry|||0|660|1127|1130

SE|25462454||ab|6|text|1161|1300|In contrast, 5 g fry vaccinated at 30  degrees C were significantly protected compared to non-vaccinated fry at 30  degrees C (p = 0.038).
SE|25462454||ab|6|entity|||gngm|10129|FRY|fry|||0|660|1178|1181
SE|25462454||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1200|1209
SE|25462454||ab|6|entity|C1519885|Vaccinated|fndg|||vaccinated|||0|660|1255|1265
SE|25462454||ab|6|entity|||gngm|10129|FRY|fry|||0|660|1266|1269
SE|25462454||ab|6|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1277|1286
SE|25462454||ab|6|relation|3|2|||gngm,aapp|gngm|10129|FRY|fry|||0|660|1178|1181|VERB|compared_with||1239|1247|2|1|||gngm,aapp|gngm|10129|FRY|fry|||0|660|1266|1269

SE|25462454||ab|7|text|1300|1622|Although lower mortalities occurred, 10 g fingerlings vaccinated at 25  degrees C were not protected, compared to non-vaccinated fingerlings at 25  degrees C (p = 0.328), while, 10 g fingerlings vaccinated at 30  degrees C were significantly protected, compared to non-vaccinated fingerlings at 30  degrees C (p = 0.038).
SE|25462454||ab|7|entity|C0441994|Lower|ftcn|||lower|||0|888|1309|1314
SE|25462454||ab|7|entity|C0026565|Mortality Vital Statistics|qnco|||mortalities|||0|888|1315|1326
SE|25462454||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1372|1381
SE|25462454||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1387|1390
SE|25462454||ab|7|entity|C1519885|Vaccinated|fndg|||vaccinated|||0|660|1418|1428
SE|25462454||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1448|1457
SE|25462454||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1513|1522
SE|25462454||ab|7|entity|C1519885|Vaccinated|fndg|||vaccinated|||0|660|1569|1579
SE|25462454||ab|7|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|901|1599|1608

SE|25462454||ab|8|text|1622|1710|Additionally, overall mortality of 5 g fish was significantly higher than in 10 g fish.
SE|25462454||ab|8|entity|C1561607|Overall|qlco|||overall|||0|694|1636|1643
SE|25462454||ab|8|entity|C0016163|Fishes|fish|||fish|||0|802|1661|1665
SE|25462454||ab|8|entity|C0205250|High|qlco|||higher|||0|827|1684|1690
SE|25462454||ab|8|entity|C0016163|Fishes|fish|||fish|||0|827|1704|1708

SE|25462454||ab|9|text|1710|1923|Mortality was also significantly higher in fish subjected to a 30 to 25  degrees C temperature change one week prior to challenge, than in fish maintained at the same temperature during vaccination and challenge.
SE|25462454||ab|9|entity|C0205250|High|qlco|||higher|||0|793|1743|1749
SE|25462454||ab|9|entity|C0016163|Fishes|fish|||fish|||0|1000|1753|1757
SE|25462454||ab|9|entity|C0439237|degrees Celsius|qnco|||degrees C|||0|794|1783|1792
SE|25462454||ab|9|entity|C0450031|Temperature change|qlco|||temperature change|||0|794|1793|1811
SE|25462454||ab|9|entity|C0205447|One|qnco|||one|||0|794|1812|1815
SE|25462454||ab|9|entity|C0439230|week|tmco|||week|||0|794|1816|1820
SE|25462454||ab|9|entity|C0016163|Fishes|fish|||fish|||0|1000|1849|1853
SE|25462454||ab|9|entity|C0445247|Same|qlco|||same|||0|888|1872|1876
SE|25462454||ab|9|entity|C0039476|Temperature|qnco|||temperature|||0|888|1877|1888
SE|25462454||ab|9|entity|C0042196|Vaccination|topp|||vaccination|||0|1000|1896|1907

SE|25462454||ab|10|text|1923|2084|This information demonstrates that both temperature and size at vaccination are important factors when implementing immunization prophylaxis in cultured tilapia.
SE|25462454||ab|10|entity|C1533716|Information|idcn|||information|||0|1000|1928|1939
SE|25462454||ab|10|entity|C0039476|Temperature|qnco|||temperature|||0|1000|1963|1974
SE|25462454||ab|10|entity|C0456389|size|spco|||size|||0|1000|1979|1983
SE|25462454||ab|10|entity|C0042196|Vaccination|topp|||vaccination|||0|1000|1987|1998
SE|25462454||ab|10|entity|C1521761|Factor|ftcn|||factors|||0|827|2013|2020
SE|25462454||ab|10|entity|C0020971|Immunization|topp|||immunization|||0|790|2039|2051
SE|25462454||ab|10|entity|C0033107|prevention & control|inpr|||prophylaxis|||0|790|2052|2063
SE|25462454||ab|10|entity|C0010453|Anthropological Culture|idcn|||cultured|||0|853|2067|2075
SE|25462454||ab|10|entity|C0162642|Tilapia|fish|||tilapia|||0|853|2076|2083


SE|25462455||ti|1|text|21|114|Molecular characterization and functional analysis of Cactin gene from Litopenaeus vannamei.
SE|25462455||ti|1|entity|C1521991|Molecular|qlco|||Molecular|||0|694|21|30
SE|25462455||ti|1|entity|C0558024|Functional behavioral assessment|hlca|||functional analysis|||0|1000|52|71
SE|25462455||ti|1|entity|||gngm|58509|CACTIN|Cactin|||0|861|75|81
SE|25462455||ti|1|entity|C0017337|Genes|gngm|||gene|||0|861|82|86
SE|25462455||ti|1|entity|C0998219|Litopenaeus vannamei|invt|||Litopenaeus vannamei|||0|1000|92|112

SE|25462455||ab|1|text|120|257|Cactin (Cactus interactor) is a conserved protein which was initially discovered as a novel interactor of Drosophila IkB protein Cactus.
SE|25462455||ab|1|entity|||gngm|58509|CACTIN|Cactin|||0|1000|120|126
SE|25462455||ab|1|entity|C0330340|Cactaceae|plnt|||Cactus|||0|694|128|134
SE|25462455||ab|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|162|169
SE|25462455||ab|1|entity|C0205265|Initially|tmco|||initially|||0|1000|180|189
SE|25462455||ab|1|entity|C0679622|novel|inpr|||novel|||0|694|206|211
SE|25462455||ab|1|entity|C0166033|I kappa B beta protein|aapp,bacs|||IkB|||0|861|237|240
SE|25462455||ab|1|entity|C0949989|Drosophila Proteins|aapp,bacs|||Drosophila IkB protein|||0|861|226|248
SE|25462455||ab|1|entity|C0330340|Cactaceae|plnt|||Cactus|||0|861|249|255

SE|25462455||ab|2|text|257|405|Cactin was always characterized as a negative regulator of many different developmental processes, but only found to play an immune role in humans.
SE|25462455||ab|2|entity|||gngm|58509|CACTIN|Cactin|||0|1000|257|263
SE|25462455||ab|2|entity|C1549493|Always|idcn|||always|||0|1000|268|274
SE|25462455||ab|2|entity|C0205160|Negative|qlco|||negative|||0|872|294|302
SE|25462455||ab|2|entity|C1547020|*Difference|qnco|||different|||0|866|321|330
SE|25462455||ab|2|entity|C1511806|Developmental Process|ortf|||developmental processes|||0|866|331|354
SE|25462455||ab|2|entity|C0439662|Immune|ftcn|||immune|||0|888|382|388
SE|25462455||ab|2|entity|C0035820|Role|socb|||role|||0|888|389|393
SE|25462455||ab|2|entity|C0020114|Human|humn|||humans|||0|1000|397|403
SE|25462455||ab|2|relation|1|1|||gngm,aapp|gngm|58509|CACTIN|Cactin|||0|1000|257|263|NOM|AFFECTS||303|312|3|1|C1511806|Developmental Process|ortf|ortf|||developmental processes|||0|866|331|354

SE|25462455||ab|3|text|405|543|To better know the immune function of Cactin gene, Litopenaeus vannamei Cactin (LvCactin) was identified and characterized in this study.
SE|25462455||ab|3|entity|C0332272|Better|qlco|||better|||0|1000|408|414
SE|25462455||ab|3|entity|C1268930|Immunologic function|ortf|||immune function|||0|1000|424|439
SE|25462455||ab|3|entity|||gngm|58509|CACTIN|Cactin|||0|861|443|449
SE|25462455||ab|3|entity|C0017337|Genes|gngm|||gene|||0|861|450|454
SE|25462455||ab|3|entity|C0998219|Litopenaeus vannamei|invt|||Litopenaeus vannamei|||0|734|456|476
SE|25462455||ab|3|entity|||gngm|58509|CACTIN|Cactin|||0|734|477|483
SE|25462455||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|536|541
SE|25462455||ab|3|relation|0|0|||gngm,aapp|gngm|58509|CACTIN|Cactin|||0|734|477|483|MOD/HEAD|PART_OF||456|483|0|0|C0998219|Litopenaeus vannamei|invt|invt|||Litopenaeus vannamei|||0|734|456|476

SE|25462455||ab|4|text|543|756|The full-length cDNA of LvCactin is 3, 150 bp long, with an open reading frame (ORF) encoding a Cactin_mid domain in the N-terminus 356-547 residues and a CactinC_cactus domain in the C-terminal 731-855 residues.
SE|25462455||ab|4|entity|C0443225|Full|qlco|||full|||0|851|547|551
SE|25462455||ab|4|entity|C1444754|Length|qnco|||length|||0|851|552|558
SE|25462455||ab|4|entity|C0006556|DNA, Complementary|irda,nnon|||cDNA|||0|851|559|563
SE|25462455||ab|4|entity|C0205166|Long|qlco|||long|||0|1000|589|593
SE|25462455||ab|4|entity|C0079941|Open Reading Frames|gngm|||open reading frame|||0|1000|603|621
SE|25462455||ab|4|entity|||gngm|58509|CACTIN|Cactin|||0|1000|639|645
SE|25462455||ab|4|entity|C0330340|Cactaceae|plnt|||cactus|||0|660|706|712

SE|25462455||ab|5|text|756|928|The LvCactin protein was located in the cytoplasm and LvCactin mRNA was constitutively expressed in healthy L. vannamei, with the highest expression level in the eyestalk.
SE|25462455||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|861|769|776
SE|25462455||ab|5|entity|C0010834|Cytoplasm|celc|||cytoplasm|||0|1000|796|805
SE|25462455||ab|5|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA|||0|861|819|823
SE|25462455||ab|5|entity|C0018684|Health|idcn|||healthy|||0|571|856|863
SE|25462455||ab|5|entity|C1522410|Highest|qlco|||highest|||0|623|886|893

SE|25462455||ab|6|text|928|1121|LvCactin could be regulated in hemocytes after lipopolysaccharide (LPS), poly I:C, CpG-ODN2006, Vibrio parahaemolyticus, Staphylococcus aureus, and white spot syndrome virus (WSSV) challenges.
SE|25462455||ab|6|entity|C0019000|Hemocytes|cell|||hemocytes|||0|1000|959|968
SE|25462455||ab|6|entity|C0023810|Lipopolysaccharides|lipd|||lipopolysaccharide|||0|1000|975|993
SE|25462455||ab|6|entity|C0032414|Poly I-C|nnon,phsu|||poly I:C|||0|717|1001|1009
SE|25462455||ab|6|entity|C0042637|Vibrio parahaemolyticus|bact|||Vibrio parahaemolyticus|||0|1000|1024|1047
SE|25462455||ab|6|entity|C0038172|Staphylococcus aureus|bact|||Staphylococcus aureus|||0|1000|1049|1070
SE|25462455||ab|6|entity|C0043154|Dental White Spot|dsyn|||white spot|||0|831|1076|1086
SE|25462455||ab|6|entity|C0039082|Syndrome|dsyn|||syndrome|||0|831|1087|1095
SE|25462455||ab|6|entity|C0042769|Virus Diseases|dsyn|||virus|||0|831|1096|1101

SE|25462455||ab|7|text|1121|1292|Dual-luciferase reporter assays in Drosophila Schneider 2 cells revealed that LvCactin inhibited the promoters of Drosophila and shrimp antimicrobial peptide (AMP) genes.
SE|25462455||ab|7|entity|C0024075|Luciferases|aapp,enzy,irda|||luciferase|||0|764|1126|1136
SE|25462455||ab|7|entity|C0335038|Reporter|prog|||reporter|||0|764|1137|1145
SE|25462455||ab|7|entity|C1510438|Assay|lbpr|||assays|||0|764|1146|1152
SE|25462455||ab|7|entity|C0007634|Cells|cell|||cells|||0|812|1179|1184
SE|25462455||ab|7|entity|C0086860|Promoter (Genetics)|bacs,nnon|||promoters|||0|1000|1222|1231
SE|25462455||ab|7|entity|C0037017|Shrimp|invt|||shrimp|||0|825|1250|1256
SE|25462455||ab|7|entity|C1136254|Microbicides|phsu|||antimicrobial|||0|825|1257|1270
SE|25462455||ab|7|entity|C0030956|Peptides|aapp|||peptide|||0|825|1271|1278
SE|25462455||ab|7|entity|C0017337|Genes|gngm|||genes|||0|825|1285|1290

SE|25462455||ab|8|text|1292|1423|Knockdown of LvCactin by RNA interference (RNAi) increased the expression of shrimp AMP genes PEN4, crustin and ALF2 but not Lyz2.
SE|25462455||ab|8|entity|C1136031|RNA Interference|genf|||RNA interference|||0|1000|1317|1333
SE|25462455||ab|8|entity|C0037017|Shrimp|invt|||shrimp|||0|596|1369|1375
SE|25462455||ab|8|entity|C1136254|Microbicides|phsu|||AMP|||0|596|1376|1379
SE|25462455||ab|8|entity|C0030956|Peptides|aapp|||AMP|||0|596|1376|1379
SE|25462455||ab|8|entity|C0017337|Genes|gngm|||genes|||0|596|1380|1385
SE|25462455||ab|8|entity|C1518422|Not|ftcn|||not|||0|694|1413|1416

SE|25462455||ab|9|text|1423|1601|However, the mortality rates of LvCactin-knockdown shrimp in response to V. parahaemolyticus or WSSV infections were not significantly different from those of the control group.
SE|25462455||ab|9|entity|C0026565|Mortality Vital Statistics|qnco|||mortality rates|||0|983|1436|1451
SE|25462455||ab|9|entity|C0037017|Shrimp|invt|||shrimp|||0|827|1474|1480
SE|25462455||ab|9|entity|C0043154|Dental White Spot|dsyn|||WSSV|||0|849|1519|1523
SE|25462455||ab|9|entity|C0039082|Syndrome|dsyn|||WSSV|||0|849|1519|1523
SE|25462455||ab|9|entity|C0042769|Virus Diseases|dsyn|||WSSV infections|||0|849|1519|1534
SE|25462455||ab|9|entity|C1518422|Not|ftcn|||not|||0|766|1540|1543
SE|25462455||ab|9|entity|C1547020|*Difference|qnco|||different|||0|766|1558|1567
SE|25462455||ab|9|entity|C0009932|Control Groups|grup|||control group|||0|1000|1586|1599

SE|25462455||ab|10|text|1601|1705|Taken together, all the results suggested that LvCactin may play a role in innate immune in L. vannamei.
SE|25462455||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1625|1632
SE|25462455||ab|10|entity|C0035820|Role|socb|||role|||0|1000|1668|1672
SE|25462455||ab|10|entity|C0439662|Immune|ftcn|||immune|||0|861|1683|1689


SE|25462456||ti|1|text|21|118|Adaptation to abiotic stress in the oyster Crassostrea angulata relays on genetic polymorphisms.
SE|25462456||ti|1|entity|C0000934|Acclimatization|orgf|||Adaptation|||0|1000|21|31
SE|25462456||ti|1|entity|C0038435|Stress|fndg|||stress|||0|861|43|49
SE|25462456||ti|1|entity|C0030104|Oysters|invt|||oyster|||0|901|57|63
SE|25462456||ti|1|entity|C1042718|Crassostrea angulata|invt|||Crassostrea angulata|||0|901|64|84
SE|25462456||ti|1|entity|C0032529|Polymorphism, Genetic|genf|||genetic polymorphisms|||0|1000|95|116
SE|25462456||ti|1|relation|0|0|C1042718|Crassostrea angulata|invt|invt|||Crassostrea angulata|||0|901|64|84|MOD/HEAD|ISA||57|84|0|0|C0030104|Oysters|invt|invt|||oyster|||0|901|57|63

SE|25462456||ab|1|text|124|338|Here we describe the whole genome re-sequencing of the Portuguese oyster Crassostrea angulata, an edible cupped oyster of major commercial importance with an important role as biosensor of coastal water pollution.
SE|25462456||ab|1|entity|C0444667|Whole|qnco|||whole|||0|852|145|150
SE|25462456||ab|1|entity|C1328887|genome sequencing|mbrt|||genome re-sequencing|||0|852|151|171
SE|25462456||ab|1|entity|C0030104|Oysters|invt|||oyster|||0|824|190|196
SE|25462456||ab|1|entity|C1042718|Crassostrea angulata|invt|||Crassostrea angulata|||0|824|197|217
SE|25462456||ab|1|entity|C0180231|Cups|medd|||cupped|||0|890|229|235
SE|25462456||ab|1|entity|C0946717|Ostrea edulis|invt|||edible cupped oyster|||0|890|222|242
SE|25462456||ab|1|entity|C0205164|Major|qlco|||major|||0|623|246|251
SE|25462456||ab|1|entity|C0680536|commercial|inpr|||commercial|||0|623|252|262
SE|25462456||ab|1|entity|C0035820|Role|socb|||role|||0|861|292|296
SE|25462456||ab|1|entity|C0600364|Biosensors|medd,resd|||biosensor|||0|1000|300|309
SE|25462456||ab|1|entity|C0043056|Water Pollution|eehu|||water pollution|||0|901|321|336
SE|25462456||ab|1|relation|0|0|C1042718|Crassostrea angulata|invt|invt|||Crassostrea angulata|||0|824|197|217|MOD/HEAD|ISA||190|217|0|0|C0030104|Oysters|invt|invt|||oyster|||0|824|190|196

SE|25462456||ab|2|text|338|427|We sequenced the genome of the C. angulata to 29.3-fold coverage using ABI SOLID system.
SE|25462456||ab|2|entity|C0017428|Genome|gngm|||genome|||0|1000|355|361
SE|25462456||ab|2|entity|C0332462|Fold|spco|||fold|||0|750|389|393
SE|25462456||ab|2|entity|C1551362|coverage|idcn|||coverage|||0|750|394|402
SE|25462456||ab|2|entity|C0205208|Solid|qlco|||SOLID|||0|790|413|418
SE|25462456||ab|2|entity|C0449913|System|ftcn|||system|||0|790|419|425

SE|25462456||ab|3|text|427|629|Comparisons of the sequences with the reference assembly of the Pacific oyster (Crassostrea gigas), yielded 129 million SNPs, 151,620 from which were located in 20,908 genes from the C. gigas database.
SE|25462456||ab|3|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|1000|446|455
SE|25462456||ab|3|entity|C1514811|Reference|idcn|||reference|||0|694|465|474
SE|25462456||ab|3|entity|C0030104|Oysters|invt|||oyster|||0|861|499|505
SE|25462456||ab|3|entity|C1002498|Crassostrea gigas|invt|||Crassostrea gigas|||0|1000|507|524
SE|25462456||ab|3|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|827|547|551
SE|25462456||ab|3|entity|C0017337|Genes|gngm|||genes|||0|827|595|600
SE|25462456||ab|3|entity|C0242356|Databases|inpr|||database|||0|827|619|627
SE|25462456||ab|3|relation|0|0|C1002498|Crassostrea gigas|invt|invt|||Crassostrea gigas|||0|1000|507|524|SPEC|ISA||499|524|0|0|C0030104|Oysters|invt|invt|||oyster|||0|861|499|505
SE|25462456||ab|3|relation|6|1|C0752046|Single Nucleotide Polymorphism|nusq|nusq|||SNPs|||0|827|547|551|PREP|COEXISTS_WITH||585|587|2|1|C0017337|Genes|gngm,aapp|gngm|||genes|||0|827|595|600

SE|25462456||ab|4|text|629|902|The analysis of Gene Ontology (GO) terms associated with gene regions containing SNPs, revealed that significant GO terms showing differences between the two oyster species, were related to activities of response to stress caused both by drying and by metal contamination.
SE|25462456||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|1000|633|641
SE|25462456||ab|4|entity|C1138831|Gene_Ontology|inpr|||Gene Ontology|||0|890|645|658
SE|25462456||ab|4|entity|C1515273|Term|tmco|||terms|||0|890|664|669
SE|25462456||ab|4|entity|C0017337|Genes|gngm|||gene|||0|872|686|690
SE|25462456||ab|4|entity|C0205147|Region|spco|||regions|||0|872|691|698
SE|25462456||ab|4|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNPs|||0|1000|710|714
SE|25462456||ab|4|entity|C0750502|Significant|idcn|||significant|||0|852|730|741
SE|25462456||ab|4|entity|C1138831|Gene_Ontology|inpr|||GO|||0|852|742|744
SE|25462456||ab|4|entity|C1515273|Term|tmco|||terms|||0|852|745|750
SE|25462456||ab|4|entity|C1547020|*Difference|qnco|||differences|||0|966|759|770
SE|25462456||ab|4|entity|C0205448|Two|qnco|||two|||0|851|783|786
SE|25462456||ab|4|entity|C0030104|Oysters|invt|||oyster|||0|851|787|793
SE|25462456||ab|4|entity|C1548151|Species|idcn|||species|||0|851|794|801
SE|25462456||ab|4|entity|C0441655|Activities|acty|||activities|||0|1000|819|829
SE|25462456||ab|4|entity|C0871261|response|clna|||response|||0|1000|833|841
SE|25462456||ab|4|entity|C0038435|Stress|fndg|||stress|||0|1000|845|851
SE|25462456||ab|4|entity|C0011682|Desiccation|npop|||drying|||0|1000|867|873
SE|25462456||ab|4|entity|C0025552|Metals|inch|||metal|||0|888|881|886
SE|25462456||ab|4|entity|C0259846|adulteration|hcpp|||contamination|||0|888|887|900

SE|25462456||ab|5|text|902|1067|In the Biological Process domain, the GO terms ion transport, phosphorylation and proteolysis processes, among others, showed many polymorphic genes in C. angulata.
SE|25462456||ab|5|entity|C0277784|Biological function, NOS|biof|||Biological Process|||0|734|909|927
SE|25462456||ab|5|entity|C1138831|Gene_Ontology|inpr|||GO|||0|851|940|942
SE|25462456||ab|5|entity|C1515273|Term|tmco|||terms|||0|851|943|948
SE|25462456||ab|5|entity|C0162585|Ion Transport|celf|||ion transport|||0|851|949|962
SE|25462456||ab|5|entity|C0031715|Phosphorylation|moft|||phosphorylation|||0|1000|964|979
SE|25462456||ab|5|entity|C0597304|Proteolysis|moft|||proteolysis|||0|872|984|995
SE|25462456||ab|5|entity|C1522240|Process|phpr|||processes|||0|872|996|1005
SE|25462456||ab|5|entity|C0205394|Other|qlco|||others|||0|966|1013|1019
SE|25462456||ab|5|entity|C0027950|neutrophil|cell|||polymorphic|||0|853|1033|1044
SE|25462456||ab|5|entity|C0017337|Genes|gngm|||genes|||0|853|1045|1050

SE|25462456||ab|6|text|1067|1157|These processes are related to combating genotoxic and hypo-osmotic stress in the oyster.
SE|25462456||ab|6|entity|C1522240|Process|phpr|||processes|||0|966|1073|1082
SE|25462456||ab|6|entity|C0598309|genotoxicity|comd|||genotoxic|||0|928|1108|1117
SE|25462456||ab|6|entity|C0858246|Hypos|dsyn|||hypo|||0|840|1122|1126
SE|25462456||ab|6|entity|C0311417|Osmotic|ftcn|||osmotic|||0|840|1127|1134
SE|25462456||ab|6|entity|C0038435|Stress|fndg|||stress|||0|840|1135|1141
SE|25462456||ab|6|entity|C0030104|Oysters|invt|||oyster|||0|1000|1149|1155

SE|25462456||ab|7|text|1157|1254|It is noteworthy that more than 200 polymorphic genes were associated with DNA repair processes.
SE|25462456||ab|7|entity|C0205172|More|ftcn|||more|||0|1000|1179|1183
SE|25462456||ab|7|entity|C0027950|neutrophil|cell|||polymorphic|||0|754|1193|1204
SE|25462456||ab|7|entity|C0017337|Genes|gngm|||genes|||0|754|1205|1210
SE|25462456||ab|7|entity|C0012899|DNA Repair|genf|||DNA repair|||0|884|1232|1242
SE|25462456||ab|7|entity|C1522240|Process|phpr|||processes|||0|884|1243|1252

SE|25462456||ab|8|text|1254|1597|These results reveal that most of the gene polymorphisms observed in C. angulata are associated with processes related to genome adaptation to abiotic stress in estuarine regions and support that genetic polymorphisms may be the base to the observed ability of C. angulata to retain the phenomenally high concentrations of toxic heavy metals.
SE|25462456||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1260|1267
SE|25462456||ab|8|entity|C0205393|Most|qnco|||most|||0|1000|1280|1284
SE|25462456||ab|8|entity|C0678951|gene polymorphism|genf|||gene polymorphisms|||0|983|1292|1310
SE|25462456||ab|8|entity|C1522240|Process|phpr|||processes|||0|966|1355|1364
SE|25462456||ab|8|entity|C0017428|Genome|gngm|||genome|||0|888|1376|1382
SE|25462456||ab|8|entity|C0000934|Acclimatization|orgf|||adaptation|||0|888|1383|1393
SE|25462456||ab|8|entity|C0038435|Stress|fndg|||stress|||0|861|1405|1411
SE|25462456||ab|8|entity|C0205147|Region|spco|||regions|||0|827|1425|1432
SE|25462456||ab|8|entity|C0032529|Polymorphism, Genetic|genf|||genetic polymorphisms|||0|1000|1450|1471
SE|25462456||ab|8|entity|C0085732|Ability|orga|||ability|||0|888|1504|1511
SE|25462456||ab|8|entity|C0205250|High|qlco|||high|||0|790|1554|1558
SE|25462456||ab|8|entity|C1407029|Toxic|qlco|||toxic|||0|901|1577|1582
SE|25462456||ab|8|entity|C0347988|Metals, Heavy|elii|||heavy metals|||0|901|1583|1595

SE|25462456||ab|9|text|1597|1812|Our results also provide the framework for future investigations to establish the molecular basis of phenotypic variation of adaptive traits and should contribute to the management of the species' genetic resources.
SE|25462456||ab|9|entity|C1274040|result|ftcn|||results|||0|966|1601|1608
SE|25462456||ab|9|entity|C0016884|Future|tmco|||future|||0|888|1640|1646
SE|25462456||ab|9|entity|C1521991|Molecular|qlco|||molecular|||0|888|1679|1688
SE|25462456||ab|9|entity|C1527178|Basis|ftcn|||basis|||0|888|1689|1694
SE|25462456||ab|9|entity|C0205419|Variant|qlco|||variation|||0|861|1709|1718
SE|25462456||ab|9|entity|C0231193|Adaptive|ftcn|||adaptive|||0|872|1722|1730
SE|25462456||ab|9|entity|C0599883|trait|orga|||traits|||0|872|1731|1737
SE|25462456||ab|9|entity|C1548151|Species|idcn|||species|||0|890|1785|1792
SE|25462456||ab|9|entity|C0920536|genetic resource|inpr,mnob|||genetic resources|||0|890|1794|1811


SE|25462457||ti|1|text|21|148|Caspase-mediated apoptosis in crustaceans: cloning and functional characterization of EsCaspase-3-like protein from Eriocheir.
SE|25462457||ti|1|entity|C0010656|caspase|aapp,enzy|||Caspase|||0|840|21|28
SE|25462457||ti|1|entity|C0086597|Mediating|socb|||mediated|||0|840|29|37
SE|25462457||ti|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|840|38|47
SE|25462457||ti|1|entity|C0010395|Crustacea|invt|||crustaceans|||0|1000|51|62
SE|25462457||ti|1|entity|C0009015|Cloning|resa|||cloning|||0|1000|64|71
SE|25462457||ti|1|entity|C0205245|Functional|ftcn|||functional|||0|694|76|86
SE|25462457||ti|1|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|124|131
SE|25462457||ti|1|entity|C1043601|Eriocheir|invt|||Eriocheir|||0|1000|137|146
SE|25462457||ti|1|relation|0|0|C0010656|caspase|aapp,gngm,enzy|aapp|||Caspase|||0|840|21|28|ADJ|AFFECTS||29|37|0|0|C0162638|Apoptosis|celf|celf|||apoptosis|||0|840|38|47

SE|25462457||ab|1|text|154|330|The caspase-3-like gene was cloned from Eriocheir sinensis, and its properties were characterized to identify the biological implications of this caspase in apoptosis in crab.
SE|25462457||ab|1|entity|C0291573|caspase-3|aapp,enzy|||caspase-3|||0|1000|158|167
SE|25462457||ab|1|entity|C0017337|Genes|gngm|||gene|||0|1000|173|177
SE|25462457||ab|1|entity|C1043602|Eriocheir sinensis|invt|||Eriocheir sinensis|||0|1000|194|212
SE|25462457||ab|1|entity|C0871161|Property|qlco|||properties|||0|966|222|232
SE|25462457||ab|1|entity|C0205460|biological|ftcn|||biological|||0|694|268|278
SE|25462457||ab|1|entity|C0010656|caspase|aapp,enzy|||caspase|||0|1000|300|307
SE|25462457||ab|1|entity|C0162638|Apoptosis|celf|||apoptosis|||0|1000|311|320
SE|25462457||ab|1|entity|C0010260|Crabs|invt|||crab|||0|1000|324|328

SE|25462457||ab|2|text|330|466|Its deduced full-length protein sequence consists of 462 amino acid residues, including the prodomain and the large and small subunits.
SE|25462457||ab|2|entity|C0443225|Full|qlco|||full|||0|798|342|346
SE|25462457||ab|2|entity|C1444754|Length|qnco|||length|||0|798|347|353
SE|25462457||ab|2|entity|C0002518|Amino Acid Sequence|amas|||protein sequence|||0|798|354|370
SE|25462457||ab|2|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|770|387|397
SE|25462457||ab|2|entity|C0549177|Large|qnco|||large|||0|1000|440|445
SE|25462457||ab|2|entity|C0700321|Small|qnco|||small|||0|694|450|455

SE|25462457||ab|3|text|466|697|Moreover, several residues known to be critical in the caspase-3 catalytic center and binding pocket, as well as the active site pentapeptide motif Q(220)ACRG(224), were identically present in the deduced EsCaspase-3-like protein.
SE|25462457||ab|3|entity|C0443302|Several|qnco|||several|||0|847|476|483
SE|25462457||ab|3|entity|C1511545|Critical|qlco|||critical|||0|1000|505|513
SE|25462457||ab|3|entity|C0291573|caspase-3|aapp,enzy|||caspase-3|||0|843|521|530
SE|25462457||ab|3|entity|C0007382|Catalysis|npop|||catalytic|||0|843|531|540
SE|25462457||ab|3|entity|C0205099|Central|spco|||center|||0|843|541|547
SE|25462457||ab|3|entity|C0205681|Active Site|ftcn,spco|||active site|||0|795|583|594
SE|25462457||ab|3|entity|||gngm|170622|COMMD6|ACRG|||0|1000|620|624
SE|25462457||ab|3|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|688|695

SE|25462457||ab|4|text|697|848|Subsequently, the recombinant EsCaspase-3-like (rEsCaspase-3-like) protein was expressed from Escherichia coli and obtained via affinity purification.
SE|25462457||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|764|771
SE|25462457||ab|4|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|1000|791|807
SE|25462457||ab|4|entity|C1550513|via|idcn|||via|||0|901|821|824
SE|25462457||ab|4|entity|C0008551|Chromatography, Affinity|lbpr|||affinity purification|||0|901|825|846
SE|25462457||ab|4|relation|1|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein|||0|1000|764|771|VERB|INTERACTS_WITH||776|785|2|1|C0014834|Escherichia coli|bact|bact|||Escherichia coli|||0|1000|791|807

SE|25462457||ab|5|text|848|1040|Results of the in vitro enzymatic activity assays indicated that the rEsCaspase-3-like protein is capable of hydrolyzing the substrate Ac-DEVD-pNA, suggesting a functional role in physiology.
SE|25462457||ab|5|entity|C1274040|result|ftcn|||Results|||0|966|848|855
SE|25462457||ab|5|entity|C1533691|in vitro|qlco|||in vitro|||0|831|863|871
SE|25462457||ab|5|entity|C0243102|enzyme activity|moft|||enzymatic activity|||0|831|872|890
SE|25462457||ab|5|entity|C1510438|Assay|lbpr|||assays|||0|831|891|897
SE|25462457||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|935|942
SE|25462457||ab|5|entity|C0967499|acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide|aapp,phsu|||Ac-DEVD-pNA|||0|923|983|994
SE|25462457||ab|5|entity|C0205245|Functional|ftcn|||functional|||0|888|1009|1019
SE|25462457||ab|5|entity|C0035820|Role|socb|||role|||0|888|1020|1024
SE|25462457||ab|5|entity|C0031842|Physiology|bmod|||physiology|||0|1000|1028|1038
SE|25462457||ab|5|relation|0|0|C0967499|acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide|aapp,gngm,phsu|aapp|||Ac-DEVD-pNA|||0|923|983|994|SPEC|ISA||935|994|0|0|C0033684|Proteins|aapp,gngm,bacs|aapp|||protein|||0|1000|935|942

SE|25462457||ab|6|text|1040|1235|EsCaspase-3-like gene transcripts were found to be widely distributed in all tissues as detected by quantitative RT-PCR, being especially abundant in hemocytes and comparatively rare in muscles.
SE|25462457||ab|6|entity|C0017337|Genes|gngm|||gene|||0|888|1057|1061
SE|25462457||ab|6|entity|C1519595|Transcript|nnon|||transcripts|||0|888|1062|1073
SE|25462457||ab|6|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|1117|1124
SE|25462457||ab|6|entity|C1514628|Quantitative Reverse Transcriptase PCR|mbrt|||quantitative RT-PCR|||0|1000|1140|1159
SE|25462457||ab|6|entity|C0019000|Hemocytes|cell|||hemocytes|||0|1000|1190|1199
SE|25462457||ab|6|entity|C0522498|Rare|qlco|||rare|||0|861|1218|1222
SE|25462457||ab|6|entity|C0026845|Muscle|tisu|||muscles|||0|1000|1226|1233

SE|25462457||ab|7|text|1235|1452|Furthermore, EsCaspase-3-like, at both the mRNA and protein levels, was demonstrated to participate in the apoptotic process after stimulation by different pathogen-associated molecular patterns (PAMPs) in hemocytes.
SE|25462457||ab|7|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA|||0|1000|1278|1282
SE|25462457||ab|7|entity|C0033684|Proteins|aapp,bacs|||protein|||0|888|1287|1294
SE|25462457||ab|7|entity|C0441889|Levels|inpr|||levels|||0|888|1295|1301
SE|25462457||ab|7|entity|C1516044|Apoptotic|qlco|||apoptotic|||0|888|1342|1351
SE|25462457||ab|7|entity|C1522240|Process|phpr|||process|||0|888|1352|1359
SE|25462457||ab|7|entity|C1547020|*Difference|qnco|||different|||0|714|1381|1390
SE|25462457||ab|7|entity|C1521991|Molecular|qlco|||molecular|||0|714|1411|1420
SE|25462457||ab|7|entity|C0449774|Patterns|spco|||patterns|||0|714|1421|1429
SE|25462457||ab|7|entity|C0173164|poly(2-acrylamido-2-methyl-1-propanesulfonic acid)|orch,phsu|||PAMPs|||0|1000|1431|1436
SE|25462457||ab|7|entity|C0019000|Hemocytes|cell|||hemocytes|||0|1000|1441|1450

SE|25462457||ab|8|text|1452|1609|In conclusion, our findings suggest that the EsCaspase-3-like protein functions as an effector caspase and contributes to immune responses against pathogens.
SE|25462457||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1471|1479
SE|25462457||ab|8|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1514|1521
SE|25462457||ab|8|entity|C0010656|caspase|aapp,enzy|||caspase|||0|861|1547|1554
SE|25462457||ab|8|entity|C0301872|Immune response|orgf|||immune responses|||0|983|1574|1590
SE|25462457||ab|8|relation|4|1|C0010656|caspase|aapp,gngm,enzy|aapp|||caspase|||0|861|1547|1554|VERB|AFFECTS||1559|1570|2|1|C0301872|Immune response|orgf|orgf|||immune responses|||0|983|1574|1590


SE|25462458||ti|1|text|21|217|Two NF-kappaB inhibitor-alpha (IkappaBalpha) genes from rock bream (Oplegnathus fasciatus): molecular characterization, genomic organization and mRNA expression analysis after immune stimulation.
SE|25462458||ti|1|entity|C0205448|Two|qnco|||Two|||0|928|21|24
SE|25462458||ti|1|entity|C0126732|I Kappa B-Alpha|aapp,bacs|||NF-kappaB inhibitor-alpha|||0|928|25|50
SE|25462458||ti|1|entity|C0126732|I Kappa B-Alpha|aapp,bacs|||IkappaBalpha|||0|1000|52|64
SE|25462458||ti|1|entity|C0017337|Genes|gngm|||genes|||0|1000|66|71
SE|25462458||ti|1|entity|C0452965|Bream|food|||bream|||0|861|82|87
SE|25462458||ti|1|entity|C1195021|Oplegnathus fasciatus|fish|||Oplegnathus fasciatus|||0|1000|89|110
SE|25462458||ti|1|entity|C1521991|Molecular|qlco|||molecular|||0|694|113|122
SE|25462458||ti|1|entity|C0220885|organizational|qlco|||organization|||0|861|149|161
SE|25462458||ti|1|entity|C1515670|mRNA Expression|genf|||mRNA expression|||0|901|166|181
SE|25462458||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|901|182|190
SE|25462458||ti|1|entity|C0439662|Immune|ftcn|||immune|||0|888|197|203

SE|25462458||ab|1|text|223|367|IkBa is a member of IkB family, which sequesters NF-kB in an inactivate form in the cytoplasm and blocks the translocation of NF-kB to nucleus.
SE|25462458||ab|1|entity|C1334877|NFKBIA gene|gngm|4792|NFKBIA|IkBa|||0|1000|223|227
SE|25462458||ab|1|entity|C0680022|member|popg|||member|||0|1000|233|239
SE|25462458||ab|1|entity|C0166033|I kappa B beta protein|aapp,bacs|||IkB|||0|888|243|246
SE|25462458||ab|1|entity|C0015576|Family|famg|||family|||0|888|247|253
SE|25462458||ab|1|entity|C0079904|NF-kappa B|aapp,imft|||NF-kB|||0|1000|272|277
SE|25462458||ab|1|entity|C1522492|Formation|ftcn|||form|||0|1000|295|299
SE|25462458||ab|1|entity|C0010834|Cytoplasm|celc|||cytoplasm|||0|1000|307|316
SE|25462458||ab|1|entity|C0079904|NF-kappa B|aapp,imft|||NF-kB|||0|1000|349|354
SE|25462458||ab|1|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|1000|358|365
SE|25462458||ab|1|relation|2|2|C0007610|Cell Nucleus|celc|celc|||nucleus|||0|1000|358|365|NOM|LOCATION_OF||332|345|2|1|C0079904|NF-kappa B|aapp,gngm,imft|aapp|||NF-kB|||0|1000|349|354
SE|25462458||ab|1|relation|4|1|C0010834|Cytoplasm|celc|celc|||cytoplasm|||0|1000|307|316|PREP|LOCATION_OF||300|302|5|2|C0079904|NF-kappa B|aapp,gngm,imft|aapp|||NF-kB|||0|1000|272|277

SE|25462458||ab|2|text|367|559|The IkBa paralogs of rock bream (OfIkBa-A and OfIkBa-B) encoded IkBa proteins with typical features including, highly conserved IkB degradation motif, six ankyrin repeats and a PEST sequence.
SE|25462458||ab|2|entity|C1334877|NFKBIA gene|gngm|4792|NFKBIA|IkBa|||0|694|371|375
SE|25462458||ab|2|entity|C0452965|Bream|food|||bream|||0|861|393|398
SE|25462458||ab|2|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|400|406
SE|25462458||ab|2|entity|||gngm|4792|NFKBIA|OfIkBa|||0|779|413|419
SE|25462458||ab|2|entity|C1334877|NFKBIA gene|gngm|4792|NFKBIA|IkBa|||0|779|431|435
SE|25462458||ab|2|entity|C1455498|TYRP1 protein, human|aapp,bacs|7306|TYRP1|B) encoded IkBa proteins|||0|779|420|444
SE|25462458||ab|2|entity|C0166033|I kappa B beta protein|aapp,bacs|||IkB|||0|562|495|498
SE|25462458||ab|2|entity|C0243125|degradation|ftcn|||degradation|||0|562|499|510
SE|25462458||ab|2|entity|C0205452|Six|qnco|||six|||0|890|518|521
SE|25462458||ab|2|entity|C0162527|Ankyrin Repeat|moft|||ankyrin repeats|||0|890|522|537
SE|25462458||ab|2|entity|C0032064|Plague|dsyn|||PEST|||0|888|544|548
SE|25462458||ab|2|entity|C1519249|Sequence|ftcn|||sequence|||0|888|549|557
SE|25462458||ab|2|relation|5|0|C0166033|I kappa B beta protein|aapp,gngm,bacs|aapp|||IkB|||0|562|495|498|NOM|INHIBITS||499|510|5|2|C1455498|TYRP1 protein, human|aapp,gngm,bacs|aapp|7306|TYRP1|B) encoded IkBa proteins|||0|779|420|444

SE|25462458||ab|3|text|559|725|However, their amino acid identity and similarity were only 55.6 and 69.7%, respectively suggesting that these two genes could be the two different isoforms of IkBa.
SE|25462458||ab|3|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acid|||0|734|574|584
SE|25462458||ab|3|entity|C0871364|Simile|inpr|||similarity|||0|900|598|608
SE|25462458||ab|3|entity|C0205448|Two|qnco|||two|||0|888|670|673
SE|25462458||ab|3|entity|C0017337|Genes|gngm|||genes|||0|888|674|679
SE|25462458||ab|3|entity|C0205448|Two|qnco|||two|||0|587|693|696
SE|25462458||ab|3|entity|C1547020|*Difference|qnco|||different|||0|587|697|706
SE|25462458||ab|3|entity|C1334877|NFKBIA gene|gngm|4792|NFKBIA|IkBa|||0|1000|719|723

SE|25462458||ab|4|text|725|903|The number and size of the exons of OfIkBa-A and OfIkBa-B were conserved well with all the compared vertebrate species, although they have significantly different genomic sizes.
SE|25462458||ab|4|entity|C0237753|Numbers|qnco|||number|||0|1000|729|735
SE|25462458||ab|4|entity|C0456389|size|spco|||size|||0|1000|740|744
SE|25462458||ab|4|entity|C0015295|Exons|bacs,nnon|||exons|||0|1000|752|757
SE|25462458||ab|4|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|761|767
SE|25462458||ab|4|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|774|780
SE|25462458||ab|4|entity|C0205170|Good|qlco|||well|||0|1000|798|802
SE|25462458||ab|4|entity|C0042567|Vertebrates|vtbt|||vertebrate|||0|790|825|835
SE|25462458||ab|4|entity|C1548151|Species|idcn|||species|||0|790|836|843
SE|25462458||ab|4|entity|C1547020|*Difference|qnco|||different|||0|728|878|887
SE|25462458||ab|4|entity|C0456389|size|spco|||sizes|||0|728|896|901
SE|25462458||ab|4|relation|3|1|C0015295|Exons|bacs,nnon|bacs|||exons|||0|1000|752|757|PREP|PART_OF||758|760|4|1|||gngm,aapp|aapp|4792|NFKBIA|OfIkBa|||0|1000|761|767

SE|25462458||ab|5|text|903|1072|Phylogenetic analysis revealed that OfIkBa-A and OfIkBa-B proteins cluster with IkBa family members; however, they were grouped with different subclades in IkBa family.
SE|25462458||ab|5|entity|C1519068|Phylogenetic Analysis|resa|||Phylogenetic analysis|||0|1000|903|924
SE|25462458||ab|5|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|939|945
SE|25462458||ab|5|entity|||gngm|4792|NFKBIA|OfIkBa|||0|884|952|958
SE|25462458||ab|5|entity|C1455498|TYRP1 protein, human|aapp,bacs|7306|TYRP1|B proteins|||0|884|959|969
SE|25462458||ab|5|entity|C1334877|NFKBIA gene|gngm|4792|NFKBIA|IkBa|||0|901|983|987
SE|25462458||ab|5|entity|C0086282|Family member|famg|||family members|||0|901|988|1002
SE|25462458||ab|5|entity|C1547020|*Difference|qnco|||different|||0|623|1036|1045
SE|25462458||ab|5|entity|C1334877|NFKBIA gene|gngm|4792|NFKBIA|IkBa|||0|888|1059|1063
SE|25462458||ab|5|entity|C0015576|Family|famg|||family|||0|888|1064|1070
SE|25462458||ab|5|relation|5|3|C1455498|TYRP1 protein, human|aapp,gngm,bacs|aapp|7306|TYRP1|B proteins|||0|884|959|969|PREP|COEXISTS_WITH||1056|1058|1|1|C1334877|NFKBIA gene|gngm,aapp|gngm|4792|NFKBIA|IkBa|||0|888|1059|1063

SE|25462458||ab|6|text|1072|1280|Tissue specific expression of OfIkBa mRNA was constitutively detected in all the tested tissues, and they showed the higher transcription level in heart, liver, gill and peripheral blood cells, respectively.
SE|25462458||ab|6|entity|||gngm|4792|NFKBIA|OfIkBa|||0|861|1102|1108
SE|25462458||ab|6|entity|C0035696|RNA, Messenger|bacs,nnon|||mRNA|||0|861|1109|1113
SE|25462458||ab|6|entity|C0039593|Testing|resa|||tested|||0|872|1153|1159
SE|25462458||ab|6|entity|C0040300|Body tissue|tisu|||tissues|||0|872|1160|1167
SE|25462458||ab|6|entity|C0205250|High|qlco|||higher|||0|606|1189|1195
SE|25462458||ab|6|entity|C0040649|Transcription, Genetic|genf|||transcription|||0|606|1196|1209
SE|25462458||ab|6|entity|C0018787|Heart|bpoc|||heart|||0|1000|1219|1224
SE|25462458||ab|6|entity|C0023884|Liver|bpoc|||liver|||0|1000|1226|1231
SE|25462458||ab|6|entity|C0005773|Blood Cells|cell|||peripheral blood cells|||0|983|1242|1264
SE|25462458||ab|6|relation|4|1|C0018787|Heart|bpoc|bpoc|||heart|||0|1000|1219|1224|PREP|LOCATION_OF||1216|1218|4|3|||gngm,aapp|aapp|4792|NFKBIA|OfIkBa|||0|861|1102|1108

SE|25462458||ab|7|text|1280|1387|The injection of flagellin stimulated the mRNA expression of OfIkBa paralogs in head kidney and intestine.
SE|25462458||ab|7|entity|C1533685|Injection procedure|topp|||injection|||0|1000|1284|1293
SE|25462458||ab|7|entity|C0016194|Flagellin|aapp,bacs|||flagellin|||0|1000|1297|1306
SE|25462458||ab|7|entity|C1515670|mRNA Expression|genf|||mRNA expression|||0|1000|1322|1337
SE|25462458||ab|7|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|1341|1347
SE|25462458||ab|7|entity|C0018670|Head|blor|||head|||0|888|1360|1364
SE|25462458||ab|7|entity|C0022646|Kidney|bpoc|||kidney|||0|888|1365|1371
SE|25462458||ab|7|entity|C0021853|Intestines|bpoc|||intestine|||0|1000|1376|1385
SE|25462458||ab|7|relation|0|0|C0018670|Head|blor|blor|||head|||0|888|1360|1364|MOD/HEAD|LOCATION_OF||1360|1371|0|0|C0022646|Kidney|bpoc|bpoc|||kidney|||0|888|1365|1371
SE|25462458||ab|7|relation|2|1|C0016194|Flagellin|aapp,gngm,bacs|aapp|||flagellin|||0|1000|1297|1306|VERB|AUGMENTS||1307|1317|4|1|C1515670|mRNA Expression|genf|genf|||mRNA expression|||0|1000|1322|1337

SE|25462458||ab|8|text|1387|1524|Moreover, the OfIkBa mRNA expression in gill and liver was significantly upregulated by LPS, poly I:C and Edwardsiella tarda challenges.
SE|25462458||ab|8|entity|||gngm|4792|NFKBIA|OfIkBa|||0|901|1401|1407
SE|25462458||ab|8|entity|C1515670|mRNA Expression|genf|||mRNA expression|||0|901|1408|1423
SE|25462458||ab|8|entity|C0023884|Liver|bpoc|||liver|||0|1000|1436|1441
SE|25462458||ab|8|entity|C0023810|Lipopolysaccharides|lipd|||LPS|||0|1000|1475|1478
SE|25462458||ab|8|entity|C0747726|POLY|cnce|||poly|||0|1000|1480|1484
SE|25462458||ab|8|entity|C0315222|Edwardsiella tarda|bact|||Edwardsiella tarda|||0|884|1493|1511
SE|25462458||ab|8|relation|4|1|C0023810|Lipopolysaccharides|lipd|lipd|||LPS|||0|1000|1475|1478|VERB|STIMULATES||1460|1471|3|3|||gngm,aapp|gngm|4792|NFKBIA|OfIkBa|||0|901|1401|1407

SE|25462458||ab|9|text|1524|1624|The transcription of OfIkBa was up-regulated in early-phase of injection and then rapidly restored.
SE|25462458||ab|9|entity|C0040649|Transcription, Genetic|genf|||transcription|||0|1000|1528|1541
SE|25462458||ab|9|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|1545|1551
SE|25462458||ab|9|entity|C1279919|Early|tmco|||early|||0|888|1572|1577
SE|25462458||ab|9|entity|C0205390|Phase|tmco|||phase|||0|888|1578|1583
SE|25462458||ab|9|entity|C1533685|Injection procedure|topp|||injection|||0|1000|1587|1596
SE|25462458||ab|9|relation|3|1|||gngm,aapp|gngm|4792|NFKBIA|OfIkBa|||0|1000|1545|1551|PREP|LOCATION_OF||1542|1544|1|1|C0040649|Transcription, Genetic|genf|genf|||transcription|||0|1000|1528|1541

SE|25462458||ab|10|text|1624|1778|These results suggest that the OfIkBa paralogs might be involved in rapid immune responsive reactions in rock bream against bacterial and viral pathogens.
SE|25462458||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1630|1637
SE|25462458||ab|10|entity|||gngm|4792|NFKBIA|OfIkBa|||0|1000|1655|1661
SE|25462458||ab|10|entity|C0439831|Rapid|qlco|||rapid|||0|825|1692|1697
SE|25462458||ab|10|entity|C0439662|Immune|ftcn|||immune|||0|825|1698|1704
SE|25462458||ab|10|entity|C0205342|Responsive|ftcn|||responsive|||0|825|1705|1715
SE|25462458||ab|10|entity|C0443286|Reaction|ftcn|||reactions|||0|825|1716|1725
SE|25462458||ab|10|entity|C0452965|Bream|food|||bream|||0|861|1734|1739
SE|25462458||ab|10|entity|C0521009|Bacterial|ftcn|||bacterial|||0|1000|1748|1757
SE|25462458||ab|10|entity|C0521026|Viral|ftcn|||viral|||0|835|1762|1767


SE|25462459||ti|1|text|21|156|Molecular cloning, characterization and expression analysis of HSP60, HSP70 and HSP90 in the golden apple snail, Pomacea canaliculata.
SE|25462459||ti|1|entity|C0009017|Cloning, Molecular|lbpr,mbrt|||Molecular cloning|||0|1000|21|38
SE|25462459||ti|1|entity|C0936012|Analysis|resa|||analysis|||0|888|72|80
SE|25462459||ti|1|entity|||gngm|3329|HSPD1|HSP60|||0|1000|84|89
SE|25462459||ti|1|entity|C0243043|Heat-Shock Proteins 70|aapp,bacs|3308|HSPA4|HSP70|||0|1000|91|96
SE|25462459||ti|1|entity|C0243044|HSP90 Heat-Shock Proteins|aapp,bacs|3320|HSP90AA1|HSP90|||0|1000|101|106
SE|25462459||ti|1|entity|C0003625|Genus Malus|plnt|||apple|||0|790|121|126
SE|25462459||ti|1|entity|C0037378|Snails|invt|||snail|||0|790|127|132
SE|25462459||ti|1|entity|C1029524|Pomacea|invt|||Pomacea|||0|861|134|141

SE|25462459||ab|1|text|162|304|The golden apple snail, Pomacea canaliculata, has strong tolerance to high temperature, facilitating its invasion in East and Southeast Asia.
SE|25462459||ab|1|entity|C0003625|Genus Malus|plnt|||apple|||0|790|173|178
SE|25462459||ab|1|entity|C0037378|Snails|invt|||snail|||0|790|179|184
SE|25462459||ab|1|entity|C1029524|Pomacea|invt|||Pomacea|||0|861|186|193
SE|25462459||ab|1|entity|C0442821|Strong|qlco|||strong|||0|694|212|218
SE|25462459||ab|1|entity|C0015967|Fever|fndg|||high temperature|||0|1000|232|248
SE|25462459||ab|1|entity|C0003983|Asia, Southeastern|geoa|||Southeast Asia|||0|1000|288|302

SE|25462459||ab|2|text|304|451|In the present study, three cDNAs encoding heat shock proteins (PocaHSP60, PocaHSP70, PocaHSP90) in P. canaliculata were cloned and characterized.
SE|25462459||ab|2|entity|C0150312|Present|qnco|||present|||0|888|311|318
SE|25462459||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|319|324
SE|25462459||ab|2|entity|C0205449|Three|qnco|||three|||0|872|326|331
SE|25462459||ab|2|entity|C0006556|DNA, Complementary|irda,nnon|||cDNAs|||0|872|332|337
SE|25462459||ab|2|entity|C0018850|Heat shock proteins|aapp,bacs|||heat shock proteins|||0|1000|347|366
SE|25462459||ab|2|entity|||gngm|3329|HSPD1|PocaHSP60|||0|1000|368|377
SE|25462459||ab|2|entity|||gngm|3308|HSPA4|PocaHSP70|||0|1000|379|388
SE|25462459||ab|2|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|1000|390|399

SE|25462459||ab|3|text|451|544|The PocaHSP60 cDNA was 2447 bp, containing an ORF encoding a polypeptide of 574 amino acids.
SE|25462459||ab|3|entity|||gngm|3329|HSPD1|PocaHSP60|||0|861|455|464
SE|25462459||ab|3|entity|C0006556|DNA, Complementary|irda,nnon|||cDNA|||0|861|465|469
SE|25462459||ab|3|entity|C0013570|Ecthyma, Contagious|dsyn|||ORF|||0|1000|497|500
SE|25462459||ab|3|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|1000|512|523
SE|25462459||ab|3|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|901|531|542

SE|25462459||ab|4|text|544|637|The PocaHSP70 cDNA was 2644 bp, containing an ORF encoding a polypeptide of 643 amino acids.
SE|25462459||ab|4|entity|||gngm|3308|HSPA4|PocaHSP70|||0|861|548|557
SE|25462459||ab|4|entity|C0006556|DNA, Complementary|irda,nnon|||cDNA|||0|861|558|562
SE|25462459||ab|4|entity|C0013570|Ecthyma, Contagious|dsyn|||ORF|||0|1000|590|593
SE|25462459||ab|4|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|1000|605|616
SE|25462459||ab|4|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|901|624|635

SE|25462459||ab|5|text|637|730|The PocaHSP90 cDNA was 2546 bp, containing an ORF encoding a polypeptide of 726 amino acids.
SE|25462459||ab|5|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|861|641|650
SE|25462459||ab|5|entity|C0006556|DNA, Complementary|irda,nnon|||cDNA|||0|861|651|655
SE|25462459||ab|5|entity|C0013570|Ecthyma, Contagious|dsyn|||ORF|||0|1000|683|686
SE|25462459||ab|5|entity|C1305923|Polypeptides|aapp|||polypeptide|||0|1000|698|709
SE|25462459||ab|5|entity|C0002520|Amino Acids|aapp,bacs,phsu|||amino acids|||0|901|717|728

SE|25462459||ab|6|text|730|863|Genomic DNA analysis showed that PocaHSP60 had 11 introns in the coding region and PocaHSP90 had 7 introns but PocaHSP70 had no one.
SE|25462459||ab|6|entity|C0200898|DNA analysis|lbpr|||DNA analysis|||0|901|738|750
SE|25462459||ab|6|entity|||gngm|3329|HSPD1|PocaHSP60|||0|1000|763|772
SE|25462459||ab|6|entity|C0021920|Introns|bacs,nnon|||introns|||0|861|780|787
SE|25462459||ab|6|entity|C0009219|Coding|ocac|||coding|||0|888|795|801
SE|25462459||ab|6|entity|C0205147|Region|spco|||region|||0|888|802|808
SE|25462459||ab|6|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|1000|813|822
SE|25462459||ab|6|entity|C0021920|Introns|bacs,nnon|||introns|||0|861|829|836
SE|25462459||ab|6|entity|||gngm|3308|HSPA4|PocaHSP70|||0|1000|841|850

SE|25462459||ab|7|text|863|1037|The expression changes of these three PocaHSPs in the gill, digestive gland, kidney and foot muscle of P. canaliculata exposed to high and low temperature were investigated.
SE|25462459||ab|7|entity|C0205449|Three|qnco|||three|||0|694|895|900
SE|25462459||ab|7|entity|C0022646|Kidney|bpoc|||kidney|||0|1000|940|946
SE|25462459||ab|7|entity|C0016504|Pes|bpoc|||foot|||0|888|951|955
SE|25462459||ab|7|entity|C0026845|Muscle|tisu|||muscle|||0|888|956|962
SE|25462459||ab|7|entity|C0205250|High|qlco|||high|||0|1000|993|997
SE|25462459||ab|7|entity|C0009264|cold temperature|npop|||low temperature|||0|1000|1002|1017
SE|25462459||ab|7|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|888|956|962|MOD/HEAD|PART_OF||951|962|0|0|C0016504|Pes|bpoc|bpoc|||foot|||0|888|951|955

SE|25462459||ab|8|text|1037|1260|The results of quantitative PCR and western blotting showed that the expression level of PocaHSP90 was much higher than PocaHSP60 and PocaHSP70 at room temperature, and PocaHSP70 expression level was the lowest among them.
SE|25462459||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1041|1048
SE|25462459||ab|8|entity|C0392762|Quantitative|qnco|||quantitative|||0|888|1052|1064
SE|25462459||ab|8|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|888|1065|1068
SE|25462459||ab|8|entity|C0005863|Blotting, Western|lbpr,mbrt|||western blotting|||0|1000|1073|1089
SE|25462459||ab|8|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|1000|1126|1135
SE|25462459||ab|8|entity|C0205250|High|qlco|||higher|||0|966|1145|1151
SE|25462459||ab|8|entity|||gngm|3329|HSPD1|PocaHSP60|||0|1000|1157|1166
SE|25462459||ab|8|entity|||gngm|3308|HSPA4|PocaHSP70|||0|1000|1171|1180
SE|25462459||ab|8|entity|C1548796|Room temperature|qlco|||room temperature|||0|1000|1184|1200
SE|25462459||ab|8|entity|||gngm|3308|HSPA4|PocaHSP70|||0|660|1206|1215
SE|25462459||ab|8|entity|C0205251|low|qlco|||lowest|||0|966|1241|1247
SE|25462459||ab|8|entity||<<height/highness>>||||higher|||||1145|1151
SE|25462459||ab|8|relation|6|2|||gngm,aapp|gngm|3320|HSP90AA1|PocaHSP90|||0|1000|1126|1135|PREP|compared_with||1152|1156|5|1|||gngm,aapp|gngm|3329|HSPD1|PocaHSP60|||0|1000|1157|1166
SE|25462459||ab|8|relation|6|2|||gngm,aapp|gngm|3320|HSP90AA1|PocaHSP90|||0|1000|1126|1135|PREP|higher_than||1152|1156|5|1|||gngm,aapp|gngm|3329|HSPD1|PocaHSP60|||0|1000|1157|1166

SE|25462459||ab|9|text|1260|1504|Afterheat shock, PocaHSP70 expression increased rapidly, much more significantly than PocaHSP90 expression, and the effect of heat shock on the expression of PocaHSP70 and PocaHSP90 in the different tissues of P. canaliculata was not the same.
SE|25462459||ab|9|entity|C0036974|Shock|patf|||shock|||0|861|1270|1275
SE|25462459||ab|9|entity|||gngm|3308|HSPA4|PocaHSP70|||0|861|1277|1286
SE|25462459||ab|9|entity|C0205172|More|ftcn|||more|||0|861|1322|1326
SE|25462459||ab|9|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|861|1346|1355
SE|25462459||ab|9|entity|C1280500|Effect|qlco|||effect|||0|1000|1376|1382
SE|25462459||ab|9|entity|C0282498|Heat-Shock Response|orgf|||heat shock|||0|1000|1386|1396
SE|25462459||ab|9|entity|||gngm|3308|HSPA4|PocaHSP70|||0|1000|1418|1427
SE|25462459||ab|9|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|1000|1432|1441
SE|25462459||ab|9|entity|C1547020|*Difference|qnco|||different|||0|853|1449|1458
SE|25462459||ab|9|entity|C0040300|Body tissue|tisu|||tissues|||0|853|1459|1466
SE|25462459||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1490|1493
SE|25462459||ab|9|entity|C0445247|Same|qlco|||same|||0|1000|1498|1502
SE|25462459||ab|9|entity||<<significantly>>||||significantly|||||1327|1340
SE|25462459||ab|9|relation|2|1|||gngm,aapp|gngm|3308|HSPA4|PocaHSP70|||0|861|1277|1286|PREP|compared_with||1341|1345|9|1|||gngm,aapp|gngm|3320|HSP90AA1|PocaHSP90|||0|861|1346|1355
SE|25462459||ab|9|relation|2|1|||gngm,aapp|gngm|3308|HSPA4|PocaHSP70|||0|861|1277|1286|PREP|higher_than||1341|1345|9|1|||gngm,aapp|gngm|3320|HSP90AA1|PocaHSP90|||0|861|1346|1355
SE|25462459||ab|9|relation|3|1|||gngm,aapp|gngm|3308|HSPA4|PocaHSP70|||0|861|1277|1286|NOM|AFFECTS||1376|1382|7|1|C0282498|Heat-Shock Response|orgf|orgf|||heat shock|||0|1000|1386|1396
SE|25462459||ab|9|relation|3|1|||gngm,aapp|gngm|3320|HSP90AA1|PocaHSP90|||0|861|1346|1355|NOM|AFFECTS||1376|1382|7|1|C0282498|Heat-Shock Response|orgf|orgf|||heat shock|||0|1000|1386|1396
SE|25462459||ab|9|relation|3|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|853|1459|1466|PREP|LOCATION_OF||1442|1444|8|1|||gngm,aapp|aapp|3320|HSP90AA1|PocaHSP90|||0|1000|1432|1441
SE|25462459||ab|9|relation|3|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|853|1459|1466|PREP|LOCATION_OF||1442|1444|8|1|||gngm,aapp|gngm|3308|HSPA4|PocaHSP70|||0|1000|1418|1427

SE|25462459||ab|10|text|1504|1669|Unlike PocaHSP70 and PocaHSP90, PocaHSP60 expression seemed not to be affected by heat shock, because its expression was moderately induced only in the foot muscle.
SE|25462459||ab|10|entity|||gngm|3308|HSPA4|PocaHSP70|||0|1000|1511|1520
SE|25462459||ab|10|entity|||gngm|3320|HSP90AA1|PocaHSP90|||0|1000|1525|1534
SE|25462459||ab|10|entity|||gngm|3329|HSPD1|PocaHSP60|||0|861|1536|1545
SE|25462459||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1564|1567
SE|25462459||ab|10|entity|C0282498|Heat-Shock Response|orgf|||heat shock|||0|1000|1586|1596
SE|25462459||ab|10|entity|C0016504|Pes|bpoc|||foot|||0|888|1656|1660
SE|25462459||ab|10|entity|C0026845|Muscle|tisu|||muscle|||0|888|1661|1667
SE|25462459||ab|10|relation|0|0|C0026845|Muscle|tisu|tisu|||muscle|||0|888|1661|1667|MOD/HEAD|PART_OF||1656|1667|0|0|C0016504|Pes|bpoc|bpoc|||foot|||0|888|1656|1660
SE|25462459||ab|10|relation|5|3|||gngm,aapp|gngm|3329|HSPD1|PocaHSP60|||0|861|1536|1545|VERB|AUGMENTS||1636|1643|1|1|C0026845|Muscle|tisu|tisu|||muscle|||0|888|1661|1667

SE|25462459||ab|11|text|1669|1757|However, cool shock had little effect on the expression change of above three PocaHSPs.
SE|25462459||ab|11|entity|C1548792|Cool|qlco|||cool|||0|888|1678|1682
SE|25462459||ab|11|entity|C0036974|Shock|patf|||shock|||0|888|1683|1688
SE|25462459||ab|11|entity|C0023882|Little's Disease|dsyn|||little|||0|888|1693|1699
SE|25462459||ab|11|entity|C1280500|Effect|qlco|||effect|||0|888|1700|1706
SE|25462459||ab|11|entity|C1282910|Upper|spco|||above|||0|623|1735|1740
SE|25462459||ab|11|entity|C0205449|Three|qnco|||three|||0|623|1741|1746
SE|25462459||ab|11|relation|1|1|C0036974|Shock|patf|patf|||shock|||0|888|1683|1688|NOM|AFFECTS||1700|1706|1|0|C0023882|Little's Disease|dsyn|dsyn|||little|||0|888|1693|1699

SE|25462459||ab|12|text|1757|1853|These results indicated that HSPs might be related to the thermal resistance of P. canaliculata.
SE|25462459||ab|12|entity|C1274040|result|ftcn|||results|||0|966|1763|1770
SE|25462459||ab|12|entity|C0018850|Heat shock proteins|aapp,bacs|||HSPs|||0|966|1786|1790


SE|25462460||ti|1|text|21|123|Effect of dietary astaxanthin against Aeromonas hydrophila infection in common carp, Cyprinus carpio.
SE|25462460||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462460||ti|1|entity|C0052565|astaxanthine|orch|||astaxanthin|||0|861|39|50
SE|25462460||ti|1|entity|C1112472|Aeromonas hydrophila infection|dsyn|||Aeromonas hydrophila infection|||0|1000|59|89
SE|25462460||ti|1|entity|C0328038|Cyprinus carpio|fish|||common carp|||0|1000|93|104
SE|25462460||ti|1|entity|C0328038|Cyprinus carpio|fish|||Cyprinus carpio|||0|1000|106|121
SE|25462460||ti|1|relation|3|1|C1112472|Aeromonas hydrophila infection|dsyn|dsyn|||Aeromonas hydrophila infection|||0|1000|59|89|PREP|PROCESS_OF||90|92|2|1|C0328038|Cyprinus carpio|fish|fish|||common carp|||0|1000|93|104

SE|25462460||ab|1|text|129|322|The effect of astaxanthin at 0, 25, 50, and 100 mg kg(-1) incorporated in basal feed on immune response and disease resistance in Cyprinus carpio against Aeromonas hydrophila was investigated.
SE|25462460||ab|1|entity|C1280500|Effect|qlco|||effect|||0|1000|133|139
SE|25462460||ab|1|entity|C0052565|astaxanthine|orch|||astaxanthin|||0|1000|143|154
SE|25462460||ab|1|entity|C0439209|Kilogram|qnco|||kg|||0|750|180|182
SE|25462460||ab|1|entity|C0205112|Basal|spco|||basal|||0|888|203|208
SE|25462460||ab|1|entity|C0204695|Feeding patient|hlca|||feed|||0|888|209|213
SE|25462460||ab|1|entity|C0301872|Immune response|orgf|||immune response|||0|1000|217|232
SE|25462460||ab|1|entity|C1136180|Disease Resistance|orgf|||disease resistance|||0|1000|237|255
SE|25462460||ab|1|entity|C0328038|Cyprinus carpio|fish|||Cyprinus carpio|||0|1000|259|274
SE|25462460||ab|1|entity|C0085491|Aeromonas hydrophila|bact|||Aeromonas hydrophila|||0|1000|283|303
SE|25462460||ab|1|relation|5|1|C0301872|Immune response|orgf|orgf|||immune response|||0|1000|217|232|PREP|PROCESS_OF||256|258|2|1|C0328038|Cyprinus carpio|fish|fish|||Cyprinus carpio|||0|1000|259|274
SE|25462460||ab|1|relation|5|1|C1136180|Disease Resistance|orgf|orgf|||disease resistance|||0|1000|237|255|PREP|PROCESS_OF||256|258|2|1|C0328038|Cyprinus carpio|fish|fish|||Cyprinus carpio|||0|1000|259|274

SE|25462460||ab|2|text|322|448|When fed with 25 mg kg(-1) diet, the cumulative mortality was 35% whereas it was 10% and 20% with 50 and 100 mg kg(-1) diets.
SE|25462460||ab|2|entity|C0439209|Kilogram|qnco|||kg|||0|750|342|344
SE|25462460||ab|2|entity|C0012155|Diet|food|||diet|||0|1000|349|353
SE|25462460||ab|2|entity|C1511559|Cumulative|qlco|||cumulative|||0|694|359|369
SE|25462460||ab|2|entity|C0439209|Kilogram|qnco|||kg|||0|750|434|436
SE|25462460||ab|2|entity|C0012155|Diet|food|||diets|||0|1000|441|446

SE|25462460||ab|3|text|448|557|With all enriched diets the growth rate increased significantly from week 1 to 4 when compared with control.
SE|25462460||ab|3|entity|C0359583|Enrich|food|||enriched|||0|872|457|465
SE|25462460||ab|3|entity|C0012155|Diet|food|||diets|||0|872|466|471
SE|25462460||ab|3|entity|C0449249|Growth rate|tmco|||growth rate|||0|1000|476|487
SE|25462460||ab|3|entity|C0439230|week|tmco|||week|||0|861|517|521
SE|25462460||ab|3|entity|C0243148|control|ftcn|||control|||0|1000|548|555

SE|25462460||ab|4|text|557|745|However, the specific growth rate (SGR), feed conversion ratio (FCR), and protein efficiency ratio (PER) did not vary significantly from that of the control except with 50 mg kg(-1) diet.
SE|25462460||ab|4|entity|C0449249|Growth rate|tmco|||growth rate|||0|901|579|590
SE|25462460||ab|4|entity|C0204695|Feeding patient|hlca|||feed|||0|840|598|602
SE|25462460||ab|4|entity|C0439836|Conversions|spco|||conversion|||0|840|603|613
SE|25462460||ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|840|614|619
SE|25462460||ab|4|entity|C0033684|Proteins|aapp,bacs|||protein|||0|851|631|638
SE|25462460||ab|4|entity|C0013682|Efficiency|qnco|||efficiency|||0|851|639|649
SE|25462460||ab|4|entity|C0456603|Ratio|inpr|||ratio|||0|851|650|655
SE|25462460||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|666|669
SE|25462460||ab|4|entity|C0243148|control|ftcn|||control|||0|1000|706|713
SE|25462460||ab|4|entity|C0439209|Kilogram|qnco|||kg|||0|750|732|734
SE|25462460||ab|4|entity|C0012155|Diet|food|||diet|||0|1000|739|743

SE|25462460||ab|5|text|745|885|When fed with 50 and 100 mg kg(-1) diets the red blood cells, white blood cells, hemoglobin, and hematocrit values significantly increased.
SE|25462460||ab|5|entity|C0439209|Kilogram|qnco|||kg|||0|750|773|775
SE|25462460||ab|5|entity|C0012155|Diet|food|||diets|||0|1000|780|785
SE|25462460||ab|5|entity|C0014792|Erythrocytes|cell|||red blood cells|||0|1000|790|805
SE|25462460||ab|5|entity|C0023516|Leukocytes|cell|||white blood cells|||0|1000|807|824
SE|25462460||ab|5|entity|C0019046|Hemoglobin|aapp,bacs|||hemoglobin|||0|1000|826|836
SE|25462460||ab|5|entity|C0018935|Hematocrit procedure|lbpr|||hematocrit|||0|888|842|852
SE|25462460||ab|5|entity|C0042295|Values|qlco|||values|||0|888|853|859

SE|25462460||ab|6|text|885|1021|However, the serum total protein, albumin, and globulin contents significantly increased only when fed with 50 and 100 mg kg(-1) diets.
SE|25462460||ab|6|entity|C0439175|% of total|qnco|||total|||0|901|904|909
SE|25462460||ab|6|entity|C0036825|Serum Proteins|aapp,bacs|||serum total protein|||0|901|898|917
SE|25462460||ab|6|entity|C0001924|Albumins|aapp,bacs|||albumin|||0|1000|919|926
SE|25462460||ab|6|entity|C0017649|Globulins|aapp,bacs|||globulin|||0|888|932|940
SE|25462460||ab|6|entity|C0456205|Contents|sbst|||contents|||0|888|941|949
SE|25462460||ab|6|entity|C0439209|Kilogram|qnco|||kg|||0|750|1007|1009
SE|25462460||ab|6|entity|C0012155|Diet|food|||diets|||0|1000|1014|1019

SE|25462460||ab|7|text|1021|1206|The phagocytic ratio also significantly raised with 50 and 100 mg kg(-1) diets on week 2 and 4 whereas the phagocytic index significantly increased with all groups only on fourth week.
SE|25462460||ab|7|entity|C0456603|Ratio|inpr|||ratio|||0|827|1036|1041
SE|25462460||ab|7|entity|C0439209|Kilogram|qnco|||kg|||0|750|1087|1089
SE|25462460||ab|7|entity|C0012155|Diet|food|||diets|||0|1000|1094|1099
SE|25462460||ab|7|entity|C0439230|week|tmco|||week|||0|861|1103|1107
SE|25462460||ab|7|entity|C1317615|PHAGOCYTIC INDEX|qnco|||phagocytic index|||0|1000|1128|1144
SE|25462460||ab|7|entity|C0205438|Fourth|qnco|||fourth|||0|888|1193|1199
SE|25462460||ab|7|entity|C0439230|week|tmco|||week|||0|888|1200|1204

SE|25462460||ab|8|text|1206|1469|The respiratory burst activity significantly increased in 25 mg kg(-1) diet group on first week whereas in 50 and 100 mg kg(-1) diet groups the activity increased on weeks 2 and 4; a similar trend was observed in the anti-protease activity only on weeks 2 and 4.
SE|25462460||ab|8|entity|C0085416|Respiratory Burst|celf|||respiratory burst|||0|901|1210|1227
SE|25462460||ab|8|entity|C0439209|Kilogram|qnco|||kg|||0|750|1270|1272
SE|25462460||ab|8|entity|C0012155|Diet|food|||diet|||0|888|1277|1281
SE|25462460||ab|8|entity|C0441833|Groups|inpr|||group|||0|888|1282|1287
SE|25462460||ab|8|entity|C1279901|Firstly|qlco|||first|||0|888|1291|1296
SE|25462460||ab|8|entity|C0439230|week|tmco|||week|||0|888|1297|1301
SE|25462460||ab|8|entity|C0439209|Kilogram|qnco|||kg|||0|750|1327|1329
SE|25462460||ab|8|entity|C0012155|Diet|food|||diet|||0|1000|1334|1338
SE|25462460||ab|8|entity|C0439230|week|tmco|||weeks|||0|861|1372|1377
SE|25462460||ab|8|entity|C1521798|trend|tmco|||trend|||0|853|1397|1402
SE|25462460||ab|8|entity|C0030946|Endopeptidases|aapp,enzy,phsu|||protease|||0|750|1428|1436
SE|25462460||ab|8|entity|C0439230|week|tmco|||weeks|||0|861|1454|1459

SE|25462460||ab|9|text|1469|1582|The serum lysozyme activity and bactericidal activity registered a significant increase with all enriched diets.
SE|25462460||ab|9|entity|C0229671|Serum|bdsu|||serum|||0|901|1473|1478
SE|25462460||ab|9|entity|C1149582|lysozyme activity|moft|||lysozyme activity|||0|901|1479|1496
SE|25462460||ab|9|entity|C0544570|Bactericidal activity|phsf|||bactericidal activity|||0|1000|1501|1522
SE|25462460||ab|9|entity|C0750502|Significant|idcn|||significant|||0|888|1536|1547
SE|25462460||ab|9|entity|C0442805|Increase|ftcn|||increase|||0|888|1548|1556
SE|25462460||ab|9|entity|C0359583|Enrich|food|||enriched|||0|872|1566|1574
SE|25462460||ab|9|entity|C0012155|Diet|food|||diets|||0|872|1575|1580

SE|25462460||ab|10|text|1582|1803|This study suggests that supplementation of astaxanthin at 50 and 100 mg kg(-1) with the basal diet significantly promotes the growth restores hematology and modulates the immune system in C. carpio against A. hydrophila.
SE|25462460||ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1587|1592
SE|25462460||ab|10|entity|C1515075|Supplementation|topp|||supplementation|||0|1000|1607|1622
SE|25462460||ab|10|entity|C0052565|astaxanthine|orch|||astaxanthin|||0|1000|1626|1637
SE|25462460||ab|10|entity|C0439209|Kilogram|qnco|||kg|||0|750|1655|1657
SE|25462460||ab|10|entity|C0205112|Basal|spco|||basal|||0|888|1671|1676
SE|25462460||ab|10|entity|C0012155|Diet|food|||diet|||0|888|1677|1681
SE|25462460||ab|10|entity|C0018270|Growth|orgf|||growth|||0|1000|1709|1715
SE|25462460||ab|10|entity|C0018943|Hematology|bmod|||hematology|||0|1000|1725|1735
SE|25462460||ab|10|entity|C0020962|Immune system|bdsy|||immune system|||0|1000|1754|1767


SE|25462461||ti|1|text|21|192|Zebrafish fed on recombinant Artemia expressing epinecidin-1 exhibit increased survival and altered expression of immunomodulatory genes upon Vibrio vulnificus infection.
SE|25462461||ti|1|entity|C0043457|Zebrafish|fish|||Zebrafish|||0|1000|21|30
SE|25462461||ti|1|entity|C0003831|Artemia|invt|||Artemia|||0|712|50|57
SE|25462461||ti|1|entity|C0205217|Increased|qnco|||increased|||0|888|90|99
SE|25462461||ti|1|entity|C0038952|Continuance of life|acty|||survival|||0|888|100|108
SE|25462461||ti|1|entity|C0205349|Altered|ftcn|||altered|||0|888|113|120
SE|25462461||ti|1|entity|C0005525|Biological Response Modifiers|phsu|||immunomodulatory|||0|853|135|151
SE|25462461||ti|1|entity|C0017337|Genes|gngm|||genes|||0|853|152|157
SE|25462461||ti|1|entity|C1274377|Vibrio vulnificus infection|dsyn|||Vibrio vulnificus infection|||0|1000|163|190

SE|25462461||ab|1|text|198|297|Artemia has been used extensively in aquaculture as fodder for larval fish, shrimp, and shellfish.
SE|25462461||ab|1|entity|C0003831|Artemia|invt|||Artemia|||0|1000|198|205
SE|25462461||ab|1|entity|C0206225|Aquaculture|ocac,ocdi|||aquaculture|||0|1000|235|246
SE|25462461||ab|1|entity|C0023047|Larva|invt|||larval|||0|853|261|267
SE|25462461||ab|1|entity|C0016163|Fishes|fish|||fish|||0|853|268|272
SE|25462461||ab|1|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|274|280
SE|25462461||ab|1|entity|C1304606|Shellfish|invt|||shellfish|||0|1000|286|295

SE|25462461||ab|2|text|297|395|Epinecidin-1, an antimicrobial peptide, was isolated from grouper (Epinephelus coioides) in 2005.
SE|25462461||ab|2|entity|C1136254|Microbicides|phsu|||antimicrobial|||0|872|314|327
SE|25462461||ab|2|entity|C0030956|Peptides|aapp|||peptide|||0|872|328|335
SE|25462461||ab|2|entity|C1042646|Epinephelus coioides|fish|||Epinephelus coioides|||0|1000|364|384

SE|25462461||ab|3|text|395|645|Epinecidin-1 has been previously reported to possess antimicrobial activity against several Gram-positive and Gram-negative bacterial species, including Staphylococcus coagulase, Pseudomonas aeruginosa, Streptococcus pyogenes, and Vibrio vulnificus.
SE|25462461||ab|3|entity|C1271650|Antimicrobial activity|lbtr|||antimicrobial activity|||0|1000|448|470
SE|25462461||ab|3|entity|C0443302|Several|qnco|||several|||0|851|479|486
SE|25462461||ab|3|entity|C0200966|Bacterial stain, routine|lbpr|||Gram|||0|851|487|491
SE|25462461||ab|3|entity|C1446409|Positive|qlco|||positive|||0|851|492|500
SE|25462461||ab|3|entity|C0018150|Gram-Negative Bacteria|bact|||Gram-negative bacterial|||0|892|505|528
SE|25462461||ab|3|entity|C1548151|Species|idcn|||species|||0|892|529|536
SE|25462461||ab|3|entity|C0009118|Coagulase|aapp,enzy|||coagulase|||0|861|563|572
SE|25462461||ab|3|entity|C0033809|Pseudomonas aeruginosa|bact|||Pseudomonas aeruginosa|||0|1000|574|596
SE|25462461||ab|3|entity|C0038411|Streptococcus pyogenes|bact|||Streptococcus pyogenes|||0|1000|598|620
SE|25462461||ab|3|entity|C0318256|Vibrio vulnificus|bact|||Vibrio vulnificus|||0|1000|626|643

SE|25462461||ab|4|text|645|870|In this study, we used electroporation to introduce plasmid DNA encoding a green fluorescent protein (EGFP)-epinecidin-1 fusion protein under the control of the cytomegalovirus (CMV) promoter into decapsulated Artemia cysts.
SE|25462461||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|653|658
SE|25462461||ab|4|entity|C0206691|Electroporation|lbpr,resa|||electroporation|||0|1000|668|683
SE|25462461||ab|4|entity|C0032136|Plasmids|bacs,nnon|||plasmid|||0|888|697|704
SE|25462461||ab|4|entity|C0012854|DNA|bacs,nnon|||DNA|||0|888|705|708
SE|25462461||ab|4|entity|C0120285|Green Fluorescent Proteins|aapp,irda|||green fluorescent protein|||0|782|720|745
SE|25462461||ab|4|entity|C0332466|Fused structure|ftcn|||fusion|||0|782|766|772
SE|25462461||ab|4|entity|C0243148|control|ftcn|||control|||0|1000|791|798
SE|25462461||ab|4|entity|C0010825|Cytomegalovirus|virs|||cytomegalovirus|||0|694|806|821
SE|25462461||ab|4|entity|C0003831|Artemia|invt|||Artemia|||0|790|855|862
SE|25462461||ab|4|entity|C0010709|Cyst|anab|||cysts|||0|790|863|868
SE|25462461||ab|4|relation|0|0|C0032136|Plasmids|bacs,nnon|bacs|||plasmid|||0|888|697|704|MOD/HEAD|ISA||697|708|0|0|C0012854|DNA|bacs,nnon|bacs|||DNA|||0|888|705|708

SE|25462461||ab|5|text|870|1158|Optimization of various properties (including cyst weight (0.2 g), plasmid concentration (50 MUg/100 MUl), and pulse voltage (150 V), length (10 ms), and number (2)) resulted in a hatching rate of 41.15%, a transfection efficiency of 49.81%, and a fluorescence intensity (A.U.) of 47.46.
SE|25462461||ab|5|entity|C0871161|Property|qlco|||properties|||0|827|894|904
SE|25462461||ab|5|entity|C0010709|Cyst|anab|||cyst|||0|888|916|920
SE|25462461||ab|5|entity|C0043100|Weight|qnco|||weight|||0|888|921|927
SE|25462461||ab|5|entity|C0032136|Plasmids|bacs,nnon|||plasmid|||0|694|937|944
SE|25462461||ab|5|entity|||gngm|4591|TRIM37|MUl|||0|1000|971|974
SE|25462461||ab|5|entity|C0598352|voltage|qnco|||voltage|||0|861|987|994
SE|25462461||ab|5|entity|C1444754|Length|qnco|||length|||0|1000|1004|1010
SE|25462461||ab|5|entity|C0237753|Numbers|qnco|||number|||0|1000|1024|1030
SE|25462461||ab|5|entity|C0598016|hatching|orgf|||hatching|||0|888|1050|1058
SE|25462461||ab|5|entity|C1521828|Rate|qnco|||rate|||0|888|1059|1063
SE|25462461||ab|5|entity|C0040669|Transfection|genf,mbrt|||transfection|||0|888|1077|1089
SE|25462461||ab|5|entity|C0013682|Efficiency|qnco|||efficiency|||0|888|1090|1100
SE|25462461||ab|5|entity|C0016315|Fluorescence|npop|||fluorescence|||0|861|1118|1130

SE|25462461||ab|6|text|1158|1328|The expression of EGFP-epinecidin-1 was first detected by quantitative RT-PCR at 120 h post-electroporation, and protein was identified by Western blot at the same time.
SE|25462461||ab|6|entity|C0120285|Green Fluorescent Proteins|aapp,irda|||EGFP|||0|835|1176|1180
SE|25462461||ab|6|entity|C1279901|Firstly|qlco|||first|||0|1000|1198|1203
SE|25462461||ab|6|entity|C1514628|Quantitative Reverse Transcriptase PCR|mbrt|||quantitative RT-PCR|||0|1000|1216|1235
SE|25462461||ab|6|entity|C0205095|Dorsal|spco|||post|||0|775|1245|1249
SE|25462461||ab|6|entity|C0206691|Electroporation|lbpr,resa|||electroporation|||0|775|1250|1265
SE|25462461||ab|6|entity|C0033684|Proteins|aapp,bacs|||protein|||0|1000|1271|1278
SE|25462461||ab|6|entity|C0949466|Western Blot|lbpr|||Western blot|||0|1000|1297|1309
SE|25462461||ab|6|relation|2|1|C0949466|Western Blot|lbpr|lbpr|||Western blot|||0|1000|1297|1309|PREP|METHOD_OF||1294|1296|4|2|C0206691|Electroporation|lbpr,resa|lbpr|||electroporation|||0|775|1250|1265

SE|25462461||ab|7|text|1328|1456|Furthermore, the EGFP-epinecidin-1 protein inhibited V. vulnificus (204) growth, as demonstrated by zone of inhibition studies.
SE|25462461||ab|7|entity|C0120285|Green Fluorescent Proteins|aapp,irda|||EGFP|||0|827|1345|1349
SE|25462461||ab|7|entity|C0018270|Growth|orgf|||growth|||0|1000|1401|1407
SE|25462461||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|872|1447|1454

SE|25462461||ab|8|text|1456|1744|Zebrafish fed on transgenic Artemia expressing CMV-gfp-epi combined with commercial fodder were more resistant to infection by V. vulnificus (204): survival rate was enhanced by over 70% at 7, 14, and 21 days post-infection, and bacterial numbers in the liver and intestine were reduced.
SE|25462461||ab|8|entity|C0043457|Zebrafish|fish|||Zebrafish|||0|1000|1456|1465
SE|25462461||ab|8|entity|C0003831|Artemia|invt|||Artemia|||0|552|1484|1491
SE|25462461||ab|8|entity|C0010825|Cytomegalovirus|virs|||CMV|||0|552|1503|1506
SE|25462461||ab|8|entity|C0120285|Green Fluorescent Proteins|aapp,irda|||gfp|||0|552|1507|1510
SE|25462461||ab|8|entity|||gngm|7035|TFPI|epi|||0|552|1511|1514
SE|25462461||ab|8|entity|C0680536|commercial|inpr|||commercial|||0|694|1529|1539
SE|25462461||ab|8|entity|C0205172|More|ftcn|||more|||0|888|1552|1556
SE|25462461||ab|8|entity|C0332325|Resistant|ftcn|||resistant|||0|888|1557|1566
SE|25462461||ab|8|entity|C0038954|Survival Rate|qnco|||survival rate|||0|1000|1604|1617
SE|25462461||ab|8|entity|C0205136|Over|spco|||over|||0|861|1634|1638
SE|25462461||ab|8|entity|C0439228|day|tmco|||days|||0|861|1660|1664
SE|25462461||ab|8|entity|C0521009|Bacterial|ftcn|||bacterial|||0|888|1685|1694
SE|25462461||ab|8|entity|C0237753|Numbers|qnco|||numbers|||0|888|1695|1702
SE|25462461||ab|8|entity|C0023884|Liver|bpoc|||liver|||0|1000|1710|1715
SE|25462461||ab|8|entity|C0021853|Intestines|bpoc|||intestine|||0|1000|1720|1729
SE|25462461||ab|8|relation|1|1|C0043457|Zebrafish|fish|fish|||Zebrafish|||0|1000|1456|1465|ADJ|INTERACTS_WITH||1492|1502|1|0|C0010825|Cytomegalovirus|virs|virs|||CMV|||0|552|1503|1506
SE|25462461||ab|8|relation|2|1|C0021853|Intestines|bpoc|bpoc|||intestine|||0|1000|1720|1729|PREP|LOCATION_OF||1703|1705|10|9|||gngm,aapp|aapp|7035|TFPI|epi|||0|552|1511|1514
SE|25462461||ab|8|relation|2|1|C0023884|Liver|bpoc|bpoc|||liver|||0|1000|1710|1715|PREP|LOCATION_OF||1703|1705|10|9|||gngm,aapp|aapp|7035|TFPI|epi|||0|552|1511|1514

SE|25462461||ab|9|text|1744|1974|In addition, feeding of transgenic Artemia to zebrafish affected the immunomodulatory response to V. vulnificus (204) infection; expression of immune-responsive genes, including hepcidin and defbl2, was altered, as shown by qPCR.
SE|25462461||ab|9|entity|C0003831|Artemia|invt|||Artemia|||0|763|1779|1786
SE|25462461||ab|9|entity|C0043457|Zebrafish|fish|||zebrafish|||0|763|1790|1799
SE|25462461||ab|9|entity|C0005525|Biological Response Modifiers|phsu|||immunomodulatory|||0|853|1813|1829
SE|25462461||ab|9|entity|C0871261|response|clna|||response|||0|853|1830|1838
SE|25462461||ab|9|entity|C0439662|Immune|ftcn|||immune|||0|851|1887|1893
SE|25462461||ab|9|entity|C0205342|Responsive|ftcn|||responsive|||0|851|1894|1904
SE|25462461||ab|9|entity|C0017337|Genes|gngm|||genes|||0|851|1905|1910
SE|25462461||ab|9|entity|C0966897|hepcidin|aapp,bacs|||hepcidin|||0|1000|1922|1930

SE|25462461||ab|10|text|1974|2183|These findings suggest that feeding transgenic Artemia expressing CMV-gfp-epi to larval fish has antimicrobial effects, without the drawbacks of introducing drug residues or inducing bacterial drug resistance.
SE|25462461||ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1980|1988
SE|25462461||ab|10|entity|C0003831|Artemia|invt|||Artemia|||0|537|2021|2028
SE|25462461||ab|10|entity|C0010825|Cytomegalovirus|virs|||CMV|||0|537|2040|2043
SE|25462461||ab|10|entity|C0120285|Green Fluorescent Proteins|aapp,irda|||gfp|||0|537|2044|2047
SE|25462461||ab|10|entity|||gngm|7035|TFPI|epi|||0|537|2048|2051
SE|25462461||ab|10|entity|C0023047|Larva|invt|||larval|||0|853|2055|2061
SE|25462461||ab|10|entity|C0016163|Fishes|fish|||fish|||0|853|2062|2066
SE|25462461||ab|10|entity|C1516022|Antimicrobial Effect|celf|||antimicrobial effects|||0|983|2071|2092
SE|25462461||ab|10|entity|C1292748|Introduces|ftcn|||introducing|||0|890|2119|2130
SE|25462461||ab|10|entity|C0013202|Drug Residues|hops|||drug residues|||0|890|2131|2144
SE|25462461||ab|10|entity|C0205263|Induced|ftcn|||inducing|||0|905|2148|2156
SE|25462461||ab|10|entity|C0949668|Drug Resistance, Bacterial|orga|||bacterial drug resistance|||0|905|2157|2182
SE|25462461||ab|10|relation|4|1|C1516022|Antimicrobial Effect|celf|celf|||antimicrobial effects|||0|983|2071|2092|AUX|PROCESS_OF||2067|2070|3|1|C0016163|Fishes|fish|fish|||fish|||0|853|2062|2066


SE|25462462||ti|1|text|21|77|Dietary administration of Gynura bicolor (Roxb. Willd.)
SE|25462462||ti|1|entity|C1051460|Gynura|plnt|||Gynura|||0|861|47|53

SE|25462462||ti|2|text|77|234|DC water extract enhances immune response and survival rate against Vibrio alginolyticus and white spot syndrome virus in white shrimp Litopeneaus vannamei.
SE|25462462||ti|2|entity|C0020311|Hydrotherapy|topp|||water|||0|851|80|85
SE|25462462||ti|2|entity|C1555707|extract|idcn|||extract|||0|851|86|93
SE|25462462||ti|2|entity|C0301872|Immune response|orgf|||immune response|||0|1000|103|118
SE|25462462||ti|2|entity|C0038954|Survival Rate|qnco|||survival rate|||0|1000|123|136
SE|25462462||ti|2|entity|C0318255|Vibrio alginolyticus|bact|||Vibrio alginolyticus|||0|1000|145|165
SE|25462462||ti|2|entity|C0043154|Dental White Spot|dsyn|||white spot|||0|861|170|180
SE|25462462||ti|2|entity|C0039082|Syndrome|dsyn|||syndrome|||0|861|181|189
SE|25462462||ti|2|entity|C0042769|Virus Diseases|dsyn|||virus|||0|861|190|195
SE|25462462||ti|2|entity|C0007457|Caucasoid Race|popg|||white|||0|583|199|204
SE|25462462||ti|2|entity|C0037017|Shrimp|invt|||shrimp|||0|583|205|211

SE|25462462||ab|1|text|240|272|Gynura bicolor (Roxb. & Willd.)
SE|25462462||ab|1|entity|C1051460|Gynura|plnt|||Gynura|||0|861|240|246

SE|25462462||ab|2|text|272|377|DC., a perennial plant belonging to the Asteraceae family, is originated from the tropical area of Asia.
SE|25462462||ab|2|entity|C0330103|Perennial plant|plnt|||perennial plant|||0|734|279|294
SE|25462462||ab|2|entity|C0446228|Asteraceae|plnt|||Asteraceae|||0|888|312|322
SE|25462462||ab|2|entity|C0015576|Family|famg|||family|||0|888|323|329
SE|25462462||ab|2|entity|C0205146|Area|spco|||area|||0|861|363|367
SE|25462462||ab|2|entity|C0003980|Asia|geoa|||Asia|||0|1000|371|375

SE|25462462||ab|3|text|377|704|The total hemocyte count (THC), phenoloxidase (PO) activity, respiratory bursts (RBs), superoxide dismutase (SOD) activity, and lysozyme activity were examined after white shrimp Litopenaeus vannamei had been fed diets containing the water extract of G. bicolor at 0 (control), 0.5, 1.0, and 2.0 g (kg diet)(-1) for 7-28 days.
SE|25462462||ab|3|entity|C0439175|% of total|qnco|||total|||0|851|381|386
SE|25462462||ab|3|entity|C0019000|Hemocytes|cell|||hemocyte|||0|851|387|395
SE|25462462||ab|3|entity|C0750480|Count|idcn|||count|||0|851|396|401
SE|25462462||ab|3|entity|C0041484|MONOPHENOL MONOOXYGENASE|aapp,enzy|||phenoloxidase|||0|888|409|422
SE|25462462||ab|3|entity|C0085416|Respiratory Burst|celf|||respiratory bursts|||0|1000|438|456
SE|25462462||ab|3|entity|C0694889|RB1 gene|gngm|5925,129831|RB1,RBM45|RBs|||0|966|458|461
SE|25462462||ab|3|entity|C1151619|superoxide dismutase activity|moft|||superoxide dismutase (SOD) activity|||0|1000|464|499
SE|25462462||ab|3|entity|C1149582|lysozyme activity|moft|||lysozyme activity|||0|1000|505|522
SE|25462462||ab|3|entity|C0007457|Caucasoid Race|popg|||white|||0|861|543|548
SE|25462462||ab|3|entity|C0037017|Shrimp|invt|||shrimp|||0|861|549|555
SE|25462462||ab|3|entity|C0998219|Litopenaeus vannamei|invt|||Litopenaeus vannamei|||0|861|556|576
SE|25462462||ab|3|entity|C0012155|Diet|food|||diets|||0|1000|590|595
SE|25462462||ab|3|entity|C0020311|Hydrotherapy|topp|||water|||0|888|611|616
SE|25462462||ab|3|entity|C1555707|extract|idcn|||extract|||0|888|617|624
SE|25462462||ab|3|entity|C0243148|control|ftcn|||control|||0|1000|645|652
SE|25462462||ab|3|entity|C0444499|0/5|qnco|||0.5|||0|1000|655|658
SE|25462462||ab|3|entity|C0012155|Diet|food|||diet|||0|888|679|683
SE|25462462||ab|3|entity|C1547085|7 days|tmco|||7-28 days|||0|913|693|702

SE|25462462||ab|4|text|704|807|The results indicated that these parameters increased accordingly with the amount of extract and time.
SE|25462462||ab|4|entity|C1274040|result|ftcn|||results|||0|966|708|715
SE|25462462||ab|4|entity|C1265611|Quantity|qnco|||amount|||0|1000|779|785
SE|25462462||ab|4|entity|C1555707|extract|idcn|||extract|||0|1000|789|796
SE|25462462||ab|4|entity|C0040223|Time|tmco|||time|||0|1000|801|805

SE|25462462||ab|5|text|807|955|THCs of the shrimp fed the G. bicolor diets at 1.0 and 2.0 g (kg diet)(-1) were significantly higher than that fed the control diet for 14-28 days.
SE|25462462||ab|5|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|819|825
SE|25462462||ab|5|entity|C0012155|Diet|food|||diets|||0|827|845|850
SE|25462462||ab|5|entity|C0012155|Diet|food|||diet|||0|888|872|876
SE|25462462||ab|5|entity|C0205250|High|qlco|||higher|||0|827|901|907
SE|25462462||ab|5|entity|C0243148|control|ftcn|||control|||0|888|926|933
SE|25462462||ab|5|entity|C0012155|Diet|food|||diet|||0|888|934|938
SE|25462462||ab|5|entity|C0439228|day|tmco|||days|||0|827|949|953

SE|25462462||ab|6|text|955|1174|For the shrimp fed the G. bicolor diets at 0.5, 1.0, and 2.0 g (kg diet)(-1), the PO, RBs, and lysozyme activities reached the highest levels after 7 days, whereas SOD activity reached the highest levels after 14 days.
SE|25462462||ab|6|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|963|969
SE|25462462||ab|6|entity|C0012155|Diet|food|||diets|||0|827|989|994
SE|25462462||ab|6|entity|C0444499|0/5|qnco|||0.5|||0|1000|998|1001
SE|25462462||ab|6|entity|C0012155|Diet|food|||diet|||0|888|1022|1026
SE|25462462||ab|6|entity|C0041484|MONOPHENOL MONOOXYGENASE|aapp,enzy|||PO|||0|1000|1037|1039
SE|25462462||ab|6|entity|C0694889|RB1 gene|gngm|5925,129831|RB1,RBM45|RBs|||0|966|1041|1044
SE|25462462||ab|6|entity|C1149582|lysozyme activity|moft|||lysozyme activities|||0|983|1050|1069
SE|25462462||ab|6|entity|C1522410|Highest|qlco|||highest|||0|888|1082|1089
SE|25462462||ab|6|entity|C0441889|Levels|inpr|||levels|||0|888|1090|1096
SE|25462462||ab|6|entity|C1547085|7 days|tmco|||7 days|||0|1000|1103|1109
SE|25462462||ab|6|entity|C1151619|superoxide dismutase activity|moft|||SOD activity|||0|1000|1119|1131
SE|25462462||ab|6|entity|C1522410|Highest|qlco|||highest|||0|888|1144|1151
SE|25462462||ab|6|entity|C0441889|Levels|inpr|||levels|||0|888|1152|1158
SE|25462462||ab|6|entity|C0439228|day|tmco|||days|||0|861|1168|1172

SE|25462462||ab|7|text|1174|1424|In a separate experiment, white shrimp L. vannamei fed the diets containing the G. bicolor extract for 28 days were challenged with Vibrio alginolyticus at 3 * 10(6) cfu shrimp(-1) and white spot syndrome virus (WSSV) at 1 * 10(3) copies shrimp(-1).
SE|25462462||ab|7|entity|C0443299|Separate|spco|||separate|||0|888|1179|1187
SE|25462462||ab|7|entity|C0681814|research study|resa|||experiment|||0|888|1188|1198
SE|25462462||ab|7|entity|C0007457|Caucasoid Race|popg|||white|||0|597|1200|1205
SE|25462462||ab|7|entity|C0037017|Shrimp|invt|||shrimp|||0|597|1206|1212
SE|25462462||ab|7|entity|C0012155|Diet|food|||diets|||0|1000|1233|1238
SE|25462462||ab|7|entity|C1555707|extract|idcn|||extract|||0|827|1265|1272
SE|25462462||ab|7|entity|C0439228|day|tmco|||days|||0|861|1280|1284
SE|25462462||ab|7|entity|C0318255|Vibrio alginolyticus|bact|||Vibrio alginolyticus|||0|1000|1306|1326
SE|25462462||ab|7|entity|C0037017|Shrimp|invt|||shrimp|||0|861|1344|1350
SE|25462462||ab|7|entity|C0043154|Dental White Spot|dsyn|||white spot|||0|861|1359|1369
SE|25462462||ab|7|entity|C0039082|Syndrome|dsyn|||syndrome|||0|861|1370|1378
SE|25462462||ab|7|entity|C0042769|Virus Diseases|dsyn|||virus|||0|861|1379|1384
SE|25462462||ab|7|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|1412|1418

SE|25462462||ab|8|text|1424|1605|The survival rate of the shrimp fed the G. bicolor diets was significantly higher than that of the shrimp fed the control diet at 48-144 h post challenge V. alginolyticus and WSSV.
SE|25462462||ab|8|entity|C0038954|Survival Rate|qnco|||survival rate|||0|1000|1428|1441
SE|25462462||ab|8|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|1449|1455
SE|25462462||ab|8|entity|C0012155|Diet|food|||diets|||0|827|1475|1480
SE|25462462||ab|8|entity|C0205250|High|qlco|||higher|||0|827|1499|1505
SE|25462462||ab|8|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|1523|1529
SE|25462462||ab|8|entity|C0243148|control|ftcn|||control|||0|888|1538|1545
SE|25462462||ab|8|entity|C0012155|Diet|food|||diet|||0|888|1546|1550
SE|25462462||ab|8|entity|C0205095|Dorsal|spco|||post|||0|530|1563|1567
SE|25462462||ab|8|entity|C0043154|Dental White Spot|dsyn|||WSSV|||0|861|1599|1603
SE|25462462||ab|8|entity|C0039082|Syndrome|dsyn|||WSSV|||0|861|1599|1603
SE|25462462||ab|8|entity|C0042769|Virus Diseases|dsyn|||WSSV|||0|861|1599|1603

SE|25462462||ab|9|text|1605|1939|For the shrimp fed the G. bicolor diets at 0.5, 1 and 2 g (kg diet)(-1) under challenges of V. alginolyticus and WSSV, their LPS- and beta-1,3-glucan-binding protein (LGBP) and peroxinectin (PE) mRNA expressions were significantly higher than those of the challenged control shrimp at 12-96 and 24-144 h post-challenge, respectively.
SE|25462462||ab|9|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|1613|1619
SE|25462462||ab|9|entity|C0012155|Diet|food|||diets|||0|827|1639|1644
SE|25462462||ab|9|entity|C0444499|0/5|qnco|||0.5|||0|1000|1648|1651
SE|25462462||ab|9|entity|C0012155|Diet|food|||diet|||0|888|1667|1671
SE|25462462||ab|9|entity|C0043154|Dental White Spot|dsyn|||WSSV|||0|861|1718|1722
SE|25462462||ab|9|entity|C0039082|Syndrome|dsyn|||WSSV|||0|861|1718|1722
SE|25462462||ab|9|entity|C0042769|Virus Diseases|dsyn|||WSSV|||0|861|1718|1722
SE|25462462||ab|9|entity|C0023810|Lipopolysaccharides|lipd|||LPS|||0|1000|1730|1733
SE|25462462||ab|9|entity|C0061365|glucan-binding protein|aapp,bacs|||glucan-binding protein|||0|916|1748|1770
SE|25462462||ab|9|entity|C1515670|mRNA Expression|genf|||mRNA expressions|||0|884|1800|1816
SE|25462462||ab|9|entity|C0205250|High|qlco|||higher|||0|827|1836|1842
SE|25462462||ab|9|entity|C0805586|CHALLENGE|idcn|||challenged|||0|840|1861|1871
SE|25462462||ab|9|entity|C0243148|control|ftcn|||control|||0|840|1872|1879
SE|25462462||ab|9|entity|C0037017|Shrimp|invt|||shrimp|||0|840|1880|1886
SE|25462462||ab|9|entity|C0456696|/24h|tmco|||24-144 h|||0|794|1900|1908
SE|25462462||ab|9|entity|C0205095|Dorsal|spco|||post|||0|794|1909|1913

SE|25462462||ab|10|text|1939|2226|We concluded that dietary administration of a G. bicolor extract could enhance the innate immunity within 28 days as evidenced by the increases in immune parameters (PO, RBs, and lysozyme) and antioxidant enzyme (SOD) activities of shrimp to against V. alginolyticus and WSSV infections.
SE|25462462||ab|10|entity|C1555707|extract|idcn|||extract|||0|827|1996|2003
SE|25462462||ab|10|entity|C0020969|Immunity, Natural|orga|||innate immunity|||0|1000|2022|2037
SE|25462462||ab|10|entity|C0439228|day|tmco|||days|||0|861|2048|2052
SE|25462462||ab|10|entity|C0442805|Increase|ftcn|||increases|||0|966|2073|2082
SE|25462462||ab|10|entity|C0439662|Immune|ftcn|||immune|||0|888|2086|2092
SE|25462462||ab|10|entity|C0041484|MONOPHENOL MONOOXYGENASE|aapp,enzy|||PO|||0|1000|2105|2107
SE|25462462||ab|10|entity|C0694889|RB1 gene|gngm|5925,129831|RB1,RBM45|RBs|||0|966|2109|2112
SE|25462462||ab|10|entity|C0026794|Muramidase|aapp,enzy,phsu|4069|LYZ|lysozyme|||0|1000|2118|2126
SE|25462462||ab|10|entity|C0003402|Antioxidants|phsu|||antioxidant|||0|888|2132|2143
SE|25462462||ab|10|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|888|2144|2150
SE|25462462||ab|10|entity|C0038838|Superoxide Dismutase|aapp,enzy,phsu|||SOD|||0|1000|2152|2155
SE|25462462||ab|10|entity|C0441655|Activities|acty|||activities|||0|1000|2157|2167
SE|25462462||ab|10|entity|C0037017|Shrimp|invt|||shrimp|||0|1000|2171|2177
SE|25462462||ab|10|entity|C0043154|Dental White Spot|dsyn|||WSSV|||0|849|2210|2214
SE|25462462||ab|10|entity|C0039082|Syndrome|dsyn|||WSSV|||0|849|2210|2214
SE|25462462||ab|10|entity|C0042769|Virus Diseases|dsyn|||WSSV infections|||0|849|2210|2225
SE|25462462||ab|10|relation|0|0|C0038838|Superoxide Dismutase|aapp,gngm,enzy,phsu|aapp|||SOD|||0|1000|2152|2155|SPEC|ISA||2132|2155|0|0|C0003402|Antioxidants|phsu|phsu|||antioxidant|||0|888|2132|2143


SE|25462463||ti|1|text|21|165|Protein encoded by ORF093 is an effective vaccine candidate for infectious spleen and kidney necrosis virus in Chinese perch Siniperca chuatsi.
SE|25462463||ti|1|entity|C0033684|Proteins|aapp,bacs|||Protein|||0|1000|21|28
SE|25462463||ti|1|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|623|63|70
SE|25462463||ti|1|entity|C1550587|infectious|idcn|||infectious|||0|888|85|95
SE|25462463||ti|1|entity|C0037993|Spleen|bpoc|||spleen|||0|888|96|102
SE|25462463||ti|1|entity|C0848084|Renal necrosis|patf|||kidney necrosis|||0|901|107|122
SE|25462463||ti|1|entity|C0042769|Virus Diseases|dsyn|||virus|||0|901|123|128
SE|25462463||ti|1|entity|C0030979|Perch|fish|||perch|||0|824|140|145
SE|25462463||ti|1|entity|C1057284|Siniperca chuatsi|fish|||Siniperca chuatsi|||0|824|146|163
SE|25462463||ti|1|relation|5|1|C0042769|Virus Diseases|dsyn|dsyn|||virus|||0|901|123|128|PREP|PROCESS_OF||129|131|1|1|C1057284|Siniperca chuatsi|fish|fish|||Siniperca chuatsi|||0|824|146|163

SE|25462463||ab|1|text|171|348|Infectious spleen and kidney necrosis virus (ISKNV) is the causative agent of a disease causing high mortality and economic losses in Chinese perch, Siniperca chuatsi in China.
SE|25462463||ab|1|entity|C1550587|infectious|idcn|||Infectious|||0|804|171|181
SE|25462463||ab|1|entity|C0022646|Kidney|bpoc|||kidney|||0|804|193|199
SE|25462463||ab|1|entity|C1000210|Spleen necrosis virus|virs|||spleen and kidney necrosis virus|||0|804|182|214
SE|25462463||ab|1|entity|C0449411|Causative_agents|fndg|||causative agent|||0|1000|230|245
SE|25462463||ab|1|entity|C0205250|High|qlco|||high|||0|861|267|271
SE|25462463||ab|1|entity|C0681679|disease mortality|qnco|||disease causing high mortality|||0|861|251|281
SE|25462463||ab|1|entity|C0681022|economic loss|qnco|||economic losses|||0|983|286|301
SE|25462463||ab|1|entity|C0030979|Perch|fish|||perch|||0|861|313|318
SE|25462463||ab|1|entity|C1057284|Siniperca chuatsi|fish|||Siniperca chuatsi|||0|1000|320|337
SE|25462463||ab|1|entity|C0008115|China|geoa|||China|||0|1000|341|346

SE|25462463||ab|2|text|348|422|Little information about the antigenicity of ISKNV proteins is available.
SE|25462463||ab|2|entity|C0023882|Little's Disease|dsyn|||Little|||0|888|348|354
SE|25462463||ab|2|entity|C1533716|Information|idcn|||information|||0|888|355|366
SE|25462463||ab|2|entity|C0003320|Antigens|bacs,imft|||antigenicity|||0|900|377|389
SE|25462463||ab|2|entity|C1550587|infectious|idcn|||ISKNV|||0|761|393|398
SE|25462463||ab|2|entity|C0022646|Kidney|bpoc|||ISKNV|||0|761|393|398
SE|25462463||ab|2|entity|C1000210|Spleen necrosis virus|virs|||ISKNV|||0|761|393|398
SE|25462463||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|761|399|407
SE|25462463||ab|2|relation|2|1|C0003320|Antigens|bacs,imft|bacs|||antigenicity|||0|900|377|389|PREP|PART_OF||390|392|2|1|C0033684|Proteins|aapp,gngm,bacs|aapp|||proteins|||0|761|399|407

SE|25462463||ab|3|text|422|622|In this study the ORF093 gene of ISKNV was cloned into the prokaryotic expression vector pET32a(+) and eukaryotic expression vector pcDNA3.1(+), and designated as pET-093 and pcDNA-093, respectively.
SE|25462463||ab|3|entity|C0017337|Genes|gngm|||gene|||0|861|447|451
SE|25462463||ab|3|entity|C1550587|infectious|idcn|||ISKNV|||0|778|455|460
SE|25462463||ab|3|entity|C0022646|Kidney|bpoc|||ISKNV|||0|778|455|460
SE|25462463||ab|3|entity|C1000210|Spleen necrosis virus|virs|||ISKNV|||0|778|455|460
SE|25462463||ab|3|entity|C0599566|expression vector|nnon,virs|||expression vector|||0|694|493|510
SE|25462463||ab|3|entity|C0684063|Eukaryota|orgm|||eukaryotic|||0|761|525|535
SE|25462463||ab|3|entity|C0599566|expression vector|nnon,virs|||expression vector|||0|761|536|553

SE|25462463||ab|4|text|622|732|A recombinant 51-kDa protein was detected in Escherichia coli BL21 (harboring pET-093) after IPTG inducement.
SE|25462463||ab|4|entity|C1532717|kDa|qnco|||kDa|||0|824|639|642
SE|25462463||ab|4|entity|C0034861|Recombinant Proteins|aapp|||recombinant 51-kDa protein|||0|824|624|650
SE|25462463||ab|4|entity|C0014834|Escherichia coli|bact|||Escherichia coli|||0|901|667|683
SE|25462463||ab|4|entity|C0450615|BL21|blor|||BL21|||0|901|684|688
SE|25462463||ab|4|entity|C0475311|Harbor|mnob|||harboring|||0|793|690|699
SE|25462463||ab|4|entity|C0022239|Isopropyl Thiogalactoside|carb|||IPTG|||0|888|715|719
SE|25462463||ab|4|entity|C0021147|Incentives|qlco|||inducement|||0|888|720|730

SE|25462463||ab|5|text|732|922|Polyclonal antibodies were raised in rabbits against the purified ORF093 protein and the reaction of the antibodies was confirmed by western blotting using the purified recombinant protein.
SE|25462463||ab|5|entity|C0312586|Polyclonal antibody|aapp,imft|||Polyclonal antibodies|||0|983|732|753
SE|25462463||ab|5|entity|C0034493|Oryctolagus cuniculus|mamm|||rabbits|||0|1000|769|776
SE|25462463||ab|5|entity|C0033684|Proteins|aapp,bacs|||protein|||0|827|805|812
SE|25462463||ab|5|entity|C0443286|Reaction|ftcn|||reaction|||0|1000|821|829
SE|25462463||ab|5|entity|C0003241|Antibodies|aapp,imft|||antibodies|||0|1000|837|847
SE|25462463||ab|5|entity|C0005863|Blotting, Western|lbpr,mbrt|||western blotting|||0|1000|865|881
SE|25462463||ab|5|entity|C0034861|Recombinant Proteins|aapp|||recombinant protein|||0|901|901|920
SE|25462463||ab|5|relation|6|1|C0005863|Blotting, Western|lbpr,mbrt|lbpr|||western blotting|||0|1000|865|881|VERB|USES||882|887|1|1|C0034861|Recombinant Proteins|aapp,gngm|aapp|||recombinant protein|||0|901|901|920
SE|25462463||ab|5|relation|6|1|C0034493|Oryctolagus cuniculus|mamm|mamm|||rabbits|||0|1000|769|776|PREP|LOCATION_OF||766|768|1|1|C0312586|Polyclonal antibody|aapp,gngm,imft|aapp|||Polyclonal antibodies|||0|983|732|753

SE|25462463||ab|6|text|922|1021|Expression of the pcDNA-093 in muscle tissue of vaccinated fish was confirmed by western blotting.
SE|25462463||ab|6|entity|C0026845|Muscle|tisu|||muscle tissue|||0|1000|953|966
SE|25462463||ab|6|entity|C1519885|Vaccinated|fndg|||vaccinated|||0|888|970|980
SE|25462463||ab|6|entity|C0016163|Fishes|fish|||fish|||0|888|981|985
SE|25462463||ab|6|entity|C0005863|Blotting, Western|lbpr,mbrt|||western blotting|||0|1000|1003|1019
SE|25462463||ab|6|relation|2|1|C0026845|Muscle|tisu|tisu|||muscle tissue|||0|1000|953|966|PREP|PART_OF||967|969|2|1|C0016163|Fishes|fish|fish|||fish|||0|888|981|985

SE|25462463||ab|7|text|1021|1322|The protection efficacy of ORF093 was investigated and results showed that cumulative mortality of Chinese perch was significant differences between immune groups and control (P<0.05) after ISKNV challenge, and the RPS value of 093 recombinant protein, pcDNA093 and pcDNA093+MCP was 47%, 50% and 57%.
SE|25462463||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1076|1083
SE|25462463||ab|7|entity|C1511559|Cumulative|qlco|||cumulative|||0|694|1096|1106
SE|25462463||ab|7|entity|C0030979|Perch|fish|||perch|||0|861|1128|1133
SE|25462463||ab|7|entity|C0750502|Significant|idcn|||significant|||0|872|1138|1149
SE|25462463||ab|7|entity|C1547020|*Difference|qnco|||differences|||0|872|1150|1161
SE|25462463||ab|7|entity|C0439662|Immune|ftcn|||immune|||0|888|1170|1176
SE|25462463||ab|7|entity|C0441833|Groups|inpr|||groups|||0|888|1177|1183
SE|25462463||ab|7|entity|C0243148|control|ftcn|||control|||0|1000|1188|1195
SE|25462463||ab|7|entity|C1550587|infectious|idcn|||ISKNV|||0|761|1211|1216
SE|25462463||ab|7|entity|C0022646|Kidney|bpoc|||ISKNV|||0|761|1211|1216
SE|25462463||ab|7|entity|C1000210|Spleen necrosis virus|virs|||ISKNV|||0|761|1211|1216
SE|25462463||ab|7|entity|C0034861|Recombinant Proteins|aapp|||recombinant protein|||0|901|1253|1272
SE|25462463||ab|7|entity|||gngm|822,4179|CAPG,CD46|MCP|||0|1000|1296|1299

SE|25462463||ab|8|text|1322|1468|The results suggested that ORF093 is an effective vaccine candidate for ISKNV and it can be used in the control of ISKNV disease in Chinese perch.
SE|25462463||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1326|1333
SE|25462463||ab|8|entity|C0042210|Vaccines|imft,phsu|||vaccine|||0|623|1372|1379
SE|25462463||ab|8|entity|C1550587|infectious|idcn|||ISKNV|||0|778|1394|1399
SE|25462463||ab|8|entity|C0022646|Kidney|bpoc|||ISKNV|||0|778|1394|1399
SE|25462463||ab|8|entity|C1000210|Spleen necrosis virus|virs|||ISKNV|||0|778|1394|1399
SE|25462463||ab|8|entity|C0243148|control|ftcn|||control|||0|1000|1426|1433
SE|25462463||ab|8|entity|C0022646|Kidney|bpoc|||ISKNV|||0|773|1437|1442
SE|25462463||ab|8|entity|C1000210|Spleen necrosis virus|virs|||ISKNV|||0|773|1437|1442
SE|25462463||ab|8|entity|C0009450|Communicable Diseases|dsyn|||ISKNV disease|||0|773|1437|1450
SE|25462463||ab|8|entity|C0030979|Perch|fish|||perch|||0|861|1462|1467
SE|25462463||ab|8|relation|3|0|C1000210|Spleen necrosis virus|virs|virs|||ISKNV|||0|778|1394|1399|NOM|INTERACTS_WITH||1426|1433|1|1|C0009450|Communicable Diseases|dsyn|dsyn|||ISKNV disease|||0|773|1437|1450
SE|25462463||ab|8|relation|4|0|C0009450|Communicable Diseases|dsyn|dsyn|||ISKNV disease|||0|773|1437|1450|PREP|PROCESS_OF||1451|1453|1|1|C0030979|Perch|fish|fish|||perch|||0|861|1462|1467


SE|25462464||ti|1|text|21|167|Post-capture immune gene expression studies in the deep-sea hydrothermal vent mussel Bathymodiolus azoricus acclimatized to atmospheric pressure.
SE|25462464||ti|1|entity|C0205095|Dorsal|spco|||Post|||0|1000|21|25
SE|25462464||ti|1|entity|C0439662|Immune|ftcn|||immune|||0|901|34|40
SE|25462464||ti|1|entity|C0017262|Gene Expression|genf|||gene expression|||0|901|41|56
SE|25462464||ti|1|entity|C0719712|Deep Sea|orch,phsu|||deep-sea|||0|773|72|80
SE|25462464||ti|1|entity|C0148297|Vent|aapp,enzy|||vent|||0|773|94|98
SE|25462464||ti|1|entity|C0026871|Mussels|invt|||mussel|||0|773|99|105
SE|25462464||ti|1|entity|C1192243|Bathymodiolus azoricus|invt|||Bathymodiolus azoricus|||0|773|106|128
SE|25462464||ti|1|entity|C0004180|Atmospheric Pressure|npop|||atmospheric pressure|||0|1000|145|165

SE|25462464||ab|1|text|173|587|Deep-sea hydrothermal vents are extreme habitats that are distributed worldwide in association with volcanic and tectonic events, resulting thus in the establishment of particular environmental conditions, in which high pressure, steep temperature gradients, and potentially toxic concentrations of sulfur, methane and heavy metals constitute driving factors for the foundation of chemosynthetic-based ecosystems.
SE|25462464||ab|1|entity|C0719712|Deep Sea|orch,phsu|||Deep-sea|||0|813|173|181
SE|25462464||ab|1|entity|C0148297|Vent|aapp,enzy|||vents|||0|813|195|200
SE|25462464||ab|1|entity|C0205403|Extreme|qlco|||extreme|||0|888|205|212
SE|25462464||ab|1|entity|C0871648|Habitat|spco|||habitats|||0|888|213|221
SE|25462464||ab|1|entity|C0445315|Tectonic|spco|||tectonic|||0|888|286|294
SE|25462464||ab|1|entity|C0441471|Events|evnt|||events|||0|888|295|301
SE|25462464||ab|1|entity|C0348080|Condition|qlco|||conditions|||0|793|367|377
SE|25462464||ab|1|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|777|393|401
SE|25462464||ab|1|entity|C0015967|Fever|fndg|||high pressure, steep temperature|||0|777|388|420
SE|25462464||ab|1|entity|C0439182|% gradient|qnco|||gradients|||0|777|421|430
SE|25462464||ab|1|entity|C1407029|Toxic|qlco|||toxic|||0|790|448|453
SE|25462464||ab|1|entity|C0038774|Sulfur|elii,phsu|||sulfur|||0|1000|472|478
SE|25462464||ab|1|entity|C0025617|Methane|orch|||methane|||0|1000|480|487
SE|25462464||ab|1|entity|C0347988|Metals, Heavy|elii|||heavy metals|||0|1000|492|504
SE|25462464||ab|1|entity|C1521761|Factor|ftcn|||factors|||0|827|524|531
SE|25462464||ab|1|entity|C0016617|Foundations|orgt|||foundation|||0|1000|540|550
SE|25462464||ab|1|entity|C0162358|Ecosystem|npop|||ecosystems|||0|773|575|585

SE|25462464||ab|2|text|587|790|Of all the different macroorganisms found at deep-sea hydrothermal vents, the mussel Bathymodiolus azoricus is the most abundant species inhabiting the vent ecosystems from the Mid-Atlantic Ridge (MAR).
SE|25462464||ab|2|entity|C1547020|*Difference|qnco|||different|||0|623|598|607
SE|25462464||ab|2|entity|C0719712|Deep Sea|orch,phsu|||deep-sea|||0|813|632|640
SE|25462464||ab|2|entity|C0148297|Vent|aapp,enzy|||vents|||0|813|654|659
SE|25462464||ab|2|entity|C0026871|Mussels|invt|||mussel|||0|901|665|671
SE|25462464||ab|2|entity|C1192243|Bathymodiolus azoricus|invt|||Bathymodiolus azoricus|||0|901|672|694
SE|25462464||ab|2|entity|C0205393|Most|qnco|||most|||0|802|702|706
SE|25462464||ab|2|entity|C1548151|Species|idcn|||species|||0|802|716|723
SE|25462464||ab|2|entity|C0148297|Vent|aapp,enzy|||vent|||0|888|739|743
SE|25462464||ab|2|entity|C0162358|Ecosystem|npop|||ecosystems|||0|888|744|754
SE|25462464||ab|2|entity|C0444598|Middle|spco|||Mid|||0|802|764|767
SE|25462464||ab|2|entity|C0332243|Ridging|ftcn|||Ridge|||0|802|777|782

SE|25462464||ab|3|text|790|1083|In the present study, the effect of long term acclimatization at atmospheric pressure on host-symbiotic associations were studied in light of the ensuing physiological adaptations from which the immune and endosymbiont gene expressions were concomitantly quantified by means of real-time PCR.
SE|25462464||ab|3|entity|C0150312|Present|qnco|||present|||0|888|797|804
SE|25462464||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|805|810
SE|25462464||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|816|822
SE|25462464||ab|3|entity|C0443252|Long-term|tmco|||long term|||0|901|826|835
SE|25462464||ab|3|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|901|836|851
SE|25462464||ab|3|entity|C0004180|Atmospheric Pressure|npop|||atmospheric pressure|||0|1000|855|875
SE|25462464||ab|3|entity|C1167395|host|celc|||host|||0|851|879|883
SE|25462464||ab|3|entity|C0231202|Symbiotic|ftcn|||symbiotic|||0|851|884|893
SE|25462464||ab|3|entity|C0001400|Adaptation, Physiological|orgf|||physiological adaptations|||0|901|944|969
SE|25462464||ab|3|entity|C0439662|Immune|ftcn|||immune|||0|1000|985|991
SE|25462464||ab|3|entity|C0017262|Gene Expression|genf|||gene expressions|||0|901|1009|1025
SE|25462464||ab|3|entity|C1550177|Real Time|idcn|||real-time|||0|901|1068|1077
SE|25462464||ab|3|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|901|1078|1081
SE|25462464||ab|3|relation|8|7|C0017262|Gene Expression|genf|genf|||gene expressions|||0|901|1009|1025|NOM|AFFECTS||816|822|8|1|C0000934|Acclimatization|orgf|orgf|||acclimatization|||0|901|836|851

SE|25462464||ab|4|text|1083|1272|The expression of immune genes at 0 h, 12 h, 24 h, 36 h, 48 h, 72 h, 1 week and 3 weeks post-capture acclimatization was investigated and their profiles compared across the samples tested.
SE|25462464||ab|4|entity|C0439662|Immune|ftcn|||immune|||0|888|1101|1107
SE|25462464||ab|4|entity|C0017337|Genes|gngm|||genes|||0|888|1108|1113
SE|25462464||ab|4|entity|C0456695|/12h|tmco|||12 h|||0|1000|1122|1126
SE|25462464||ab|4|entity|C0456696|/24h|tmco|||24 h|||0|1000|1128|1132
SE|25462464||ab|4|entity|C1442452|1 Week|tmco|||1 week|||0|1000|1152|1158
SE|25462464||ab|4|entity|C1442462|3 Weeks|tmco|||3 weeks|||0|794|1163|1170
SE|25462464||ab|4|entity|C0205095|Dorsal|spco|||post|||0|794|1171|1175
SE|25462464||ab|4|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|794|1184|1199

SE|25462464||ab|5|text|1272|1505|The gene signal distribution for host immune and bacterial genes followed phasic changes in gene expression at 24 h, 1 week and 3 weeks acclimatization when compared to other time points tested during this temporal expression study.
SE|25462464||ab|5|entity|C0017337|Genes|gngm|||gene|||0|802|1276|1280
SE|25462464||ab|5|entity|C0520511|Distributing|idcn|||distribution|||0|802|1288|1300
SE|25462464||ab|5|entity|C1167395|host|celc|||host|||0|1000|1305|1309
SE|25462464||ab|5|entity|C0439662|Immune|ftcn|||immune|||0|1000|1310|1316
SE|25462464||ab|5|entity|C0017339|Genes, Bacterial|gngm|||bacterial genes|||0|1000|1321|1336
SE|25462464||ab|5|entity|C0017262|Gene Expression|genf|||gene expression|||0|1000|1364|1379
SE|25462464||ab|5|entity|C0456696|/24h|tmco|||24 h|||0|1000|1383|1387
SE|25462464||ab|5|entity|C1442452|1 Week|tmco|||1 week|||0|1000|1389|1395
SE|25462464||ab|5|entity|C1442462|3 Weeks|tmco|||3 weeks|||0|901|1400|1407
SE|25462464||ab|5|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|901|1408|1423
SE|25462464||ab|5|entity|C0040223|Time|tmco|||time|||0|861|1447|1451
SE|25462464||ab|5|entity|C0442043|temporal|spco|||temporal|||0|851|1478|1486
SE|25462464||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|851|1498|1503

SE|25462464||ab|6|text|1505|1777|Analyses of the bacterial gene expression also suggested that both bacterial density and activity could contribute to shaping the intricate association between endosymbionts and host immune genes whose expression patterns seem to be concomitant at 1 week acclimatization.
SE|25462464||ab|6|entity|C0936012|Analysis|resa|||Analyses|||0|966|1505|1513
SE|25462464||ab|6|entity|C0017339|Genes, Bacterial|gngm|||bacterial gene|||0|901|1521|1535
SE|25462464||ab|6|entity|C0521009|Bacterial|ftcn|||bacterial|||0|888|1572|1581
SE|25462464||ab|6|entity|C0178587|density|npop|||density|||0|888|1582|1589
SE|25462464||ab|6|entity|C0439662|Immune|ftcn|||immune|||0|888|1688|1694
SE|25462464||ab|6|entity|C0017337|Genes|gngm|||genes|||0|888|1695|1700
SE|25462464||ab|6|entity|C0449774|Patterns|spco|||patterns|||0|888|1718|1726
SE|25462464||ab|6|entity|C1516780|Concomitant|qlco|||concomitant|||0|1000|1738|1749
SE|25462464||ab|6|entity|C1442452|1 Week|tmco|||1 week|||0|901|1753|1759
SE|25462464||ab|6|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|901|1760|1775

SE|25462464||ab|7|text|1777|2023|Fluorescence in situ hybridization was used to assess the distribution and prevalence of endosymbiont bacteria within gill tissues confirming the gradual loss of sulfur-oxidizing (SOX) and methane-oxidizing (MOX) bacteria during acclimatization.
SE|25462464||ab|7|entity|C0162789|Fluorescent in Situ Hybridization|lbpr,mbrt|||Fluorescence in situ hybridization|||0|1000|1777|1811
SE|25462464||ab|7|entity|C0520511|Distributing|idcn|||distribution|||0|1000|1835|1847
SE|25462464||ab|7|entity|C0004611|Bacteria|bact|||bacteria|||0|861|1879|1887
SE|25462464||ab|7|entity|C0040300|Body tissue|tisu|||tissues|||0|861|1900|1907
SE|25462464||ab|7|entity|C0439833|Gradual|qlco|||gradual|||0|888|1923|1930
SE|25462464||ab|7|entity|C1517945|Loss|qnco|||loss|||0|888|1931|1935
SE|25462464||ab|7|entity|C0038774|Sulfur|elii,phsu|||sulfur|||0|694|1939|1945
SE|25462464||ab|7|entity|C0025807|Methylococcaceae|bact|||methane-oxidizing (MOX) bacteria|||0|1000|1966|1998
SE|25462464||ab|7|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|1000|2006|2021
SE|25462464||ab|7|relation|5|1|C0040300|Body tissue|tisu|tisu|||tissues|||0|861|1900|1907|PREP|LOCATION_OF||1888|1894|4|1|C0004611|Bacteria|bact|bact|||bacteria|||0|861|1879|1887
SE|25462464||ab|7|relation|6|3|C0004611|Bacteria|bact|bact|||bacteria|||0|861|1879|1887|ADJ|INTERACTS_WITH||1946|1955|2|1|C0025807|Methylococcaceae|bact|bact|||methane-oxidizing (MOX) bacteria|||0|1000|1966|1998

SE|25462464||ab|8|text|2023|2238|The present study addresses the deep-sea vent mussel B. azoricus as a model organism to study how acclimatization in aquaria and the prevalence of symbiotic bacteria are driving the expression of host immune genes.
SE|25462464||ab|8|entity|C0150312|Present|qnco|||present|||0|888|2027|2034
SE|25462464||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|888|2035|2040
SE|25462464||ab|8|entity|C0719712|Deep Sea|orch,phsu|||deep-sea|||0|614|2055|2063
SE|25462464||ab|8|entity|C0148297|Vent|aapp,enzy|||vent|||0|614|2064|2068
SE|25462464||ab|8|entity|C0026871|Mussels|invt|||mussel|||0|614|2069|2075
SE|25462464||ab|8|entity|C0026336|Study models|inpr,resd|||model|||0|888|2093|2098
SE|25462464||ab|8|entity|C0029235|Organism|orgm|||organism|||0|888|2099|2107
SE|25462464||ab|8|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|861|2121|2136
SE|25462464||ab|8|entity|C0231202|Symbiotic|ftcn|||symbiotic|||0|888|2170|2179
SE|25462464||ab|8|entity|C0004611|Bacteria|bact|||bacteria|||0|888|2180|2188
SE|25462464||ab|8|entity|C1167395|host|celc|||host|||0|851|2219|2223
SE|25462464||ab|8|entity|C0439662|Immune|ftcn|||immune|||0|851|2224|2230
SE|25462464||ab|8|entity|C0017337|Genes|gngm|||genes|||0|851|2231|2236

SE|25462464||ab|9|text|2238|2441|Tight associations, unseen thus far, suggest that host immune and bacterial gene expression patterns reflect distinct physiological responses over the course of acclimatization under aquarium conditions.
SE|25462464||ab|9|entity|C0439816|Tightness sensation quality|qlco|||Tight|||0|888|2238|2243
SE|25462464||ab|9|entity|C1517331|Further|spco|||far|||0|793|2270|2273
SE|25462464||ab|9|entity|C1167395|host|celc|||host|||0|1000|2288|2292
SE|25462464||ab|9|entity|C0439662|Immune|ftcn|||immune|||0|1000|2293|2299
SE|25462464||ab|9|entity|C0017339|Genes, Bacterial|gngm|||bacterial gene|||0|861|2304|2318
SE|25462464||ab|9|entity|C0449774|Patterns|spco|||patterns|||0|861|2330|2338
SE|25462464||ab|9|entity|C1546213|Physiologic Responses|fndg|||physiological responses|||0|851|2356|2379
SE|25462464||ab|9|entity|C0205136|Over|spco|||over|||0|1000|2380|2384
SE|25462464||ab|9|entity|C0750729|Course|tmco|||course|||0|1000|2389|2395
SE|25462464||ab|9|entity|C0000934|Acclimatization|orgf|||acclimatization|||0|1000|2399|2414
SE|25462464||ab|9|entity|C0348080|Condition|qlco|||conditions|||0|827|2430|2440


SE|25462465||ti|1|text|21|97|Developmental lag of visuospatial attention in Duchenne muscular dystrophy.
SE|25462465||ti|1|entity|C0458003|Developmental|qlco|||Developmental|||0|888|21|34
SE|25462465||ti|1|entity|C0024219|Lymphangiography|diap|||lag|||0|888|35|38
SE|25462465||ti|1|entity|C0004268|Attention|menp|||attention|||0|861|55|64
SE|25462465||ti|1|entity|C0013264|Muscular Dystrophy, Duchenne|dsyn|||Duchenne muscular dystrophy|||0|1000|68|95
SE|25462465||ti|1|relation|2|2|C0024219|Lymphangiography|diap|diap|||lag|||0|888|35|38|PREP|DIAGNOSES||65|67|1|1|C0013264|Muscular Dystrophy, Duchenne|dsyn|dsyn|||Duchenne muscular dystrophy|||0|1000|68|95

SE|25462465||ab|1|text|103|283|Children with Duchenne muscular dystrophy (DMD) present a specific deficit of voluntary attention but to date there has been no clear characterization of their attentional skills.
SE|25462465||ab|1|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|103|111
SE|25462465||ab|1|entity|C0013264|Muscular Dystrophy, Duchenne|dsyn|||Duchenne muscular dystrophy|||0|1000|117|144
SE|25462465||ab|1|entity|||gngm|1756|DMD|DMD|||0|1000|146|149
SE|25462465||ab|1|entity|C0011155|Deficiency|ftcn|||deficit|||0|861|170|177
SE|25462465||ab|1|entity|C0439656|Voluntary|inbe|||voluntary|||0|888|181|190
SE|25462465||ab|1|entity|C0004268|Attention|menp|||attention|||0|888|191|200
SE|25462465||ab|1|entity|C0522503|Translucent|qlco|||clear|||0|694|231|236
SE|25462465||ab|1|entity|C0004268|Attention|menp|||attentional|||0|853|263|274
SE|25462465||ab|1|entity|C0678856|skills|inbe|||skills|||0|853|275|281
SE|25462465||ab|1|relation|7|1|C0013264|Muscular Dystrophy, Duchenne|dsyn|dsyn|||Duchenne muscular dystrophy|||0|1000|117|144|PREP|PROCESS_OF||112|116|1|1|C0008059|Child|aggp,humn,inpr|humn|||Children|||0|1000|103|111

SE|25462465||ab|2|text|283|508|The present study investigated the hypothesis that DMD patients present deficits of both voluntary and automatic visuospatial attention systems and that their performance could be equivalent to that of younger healthy males.
SE|25462465||ab|2|entity|C0150312|Present|qnco|||present|||0|888|287|294
SE|25462465||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|295|300
SE|25462465||ab|2|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|318|328
SE|25462465||ab|2|entity|||gngm|1756|DMD|DMD|||0|861|334|337
SE|25462465||ab|2|entity|C0030705|Patients|podg|||patients|||0|861|338|346
SE|25462465||ab|2|entity|C0011155|Deficiency|ftcn|||deficits|||0|966|355|363
SE|25462465||ab|2|entity|C0439656|Voluntary|inbe|||voluntary|||0|1000|372|381
SE|25462465||ab|2|entity|C0205554|Automated|ftcn|||automatic|||0|775|386|395
SE|25462465||ab|2|entity|C0004268|Attention|menp|||attention|||0|775|409|418
SE|25462465||ab|2|entity|C0449913|System|ftcn|||systems|||0|775|419|426
SE|25462465||ab|2|entity|C0597198|Performance|inbe|||performance|||0|1000|442|453
SE|25462465||ab|2|entity|C0439185|Eq|qnco|||equivalent|||0|1000|463|473
SE|25462465||ab|2|entity|C0332239|Young|tmco|||younger|||0|816|485|492
SE|25462465||ab|2|entity|C0018684|Health|idcn|||healthy|||0|816|493|500
SE|25462465||ab|2|entity|C0024554|Male gender|orga|||males|||0|816|501|506

SE|25462465||ab|3|text|508|745|Twenty males (mean age 10 years) with diagnosis of DMD, 20 age-matched healthy males (10 years 3 months) and 20 healthy younger males (7 years 6 months) were required to perform two visuospatial attention tasks: voluntary and automatic.
SE|25462465||ab|3|entity|C0024554|Male gender|orga|||males|||0|861|515|520
SE|25462465||ab|3|entity|C1510829|Age-Years|tmco|||age 10 years|||0|875|527|539
SE|25462465||ab|3|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|546|555
SE|25462465||ab|3|entity|||gngm|1756|DMD|DMD|||0|1000|559|562
SE|25462465||ab|3|entity|C0001779|Age|orga|||age|||0|744|567|570
SE|25462465||ab|3|entity|C0150103|MATCHING|resa|||matched|||0|744|571|578
SE|25462465||ab|3|entity|C0018684|Health|idcn|||healthy|||0|744|579|586
SE|25462465||ab|3|entity|C0024554|Male gender|orga|||males|||0|744|587|592
SE|25462465||ab|3|entity|C0439234|year|tmco|||years|||0|763|597|602
SE|25462465||ab|3|entity|C0439231|month|tmco|||months|||0|763|605|611
SE|25462465||ab|3|entity|C0018684|Health|idcn|||healthy|||0|740|620|627
SE|25462465||ab|3|entity|C0332239|Young|tmco|||younger|||0|740|628|635
SE|25462465||ab|3|entity|C0024554|Male gender|orga|||males|||0|740|636|641
SE|25462465||ab|3|entity|C0439234|year|tmco|||years|||0|763|645|650
SE|25462465||ab|3|entity|C0439231|month|tmco|||months|||0|763|653|659
SE|25462465||ab|3|entity|C0205448|Two|qnco|||two|||0|764|686|689
SE|25462465||ab|3|entity|C0004268|Attention|menp|||attention|||0|764|703|712
SE|25462465||ab|3|entity|C0439656|Voluntary|inbe|||voluntary|||0|1000|720|729
SE|25462465||ab|3|entity|C0205554|Automated|ftcn|||automatic|||0|1000|734|743

SE|25462465||ab|4|text|745|904|In the voluntary task, the performance of the DMD group was significantly worse than that of the age-matched group, and equal to that of the younger controls.
SE|25462465||ab|4|entity|C0439656|Voluntary|inbe|||voluntary|||0|888|752|761
SE|25462465||ab|4|entity|C0597198|Performance|inbe|||performance|||0|1000|772|783
SE|25462465||ab|4|entity|||gngm|1756|DMD|DMD|||0|861|791|794
SE|25462465||ab|4|entity|C0441833|Groups|inpr|||group|||0|861|795|800
SE|25462465||ab|4|entity|C1279889|Deterioration of status|qlco|||worse|||0|861|819|824
SE|25462465||ab|4|entity|C0001779|Age|orga|||age|||0|901|842|845
SE|25462465||ab|4|entity|C0024908|Matched Groups|grup|||matched group|||0|901|846|859
SE|25462465||ab|4|entity|C0205163|Equal|qlco|||equal|||0|1000|865|870
SE|25462465||ab|4|entity|C0332239|Young|tmco|||younger|||0|855|886|893
SE|25462465||ab|4|entity|C0243148|control|ftcn|||controls|||0|855|894|902

SE|25462465||ab|5|text|904|1078|In the automatic attention task also, the performance of the DMD patients was less efficient than that of the age-matched controls and equal to that of the younger children.
SE|25462465||ab|5|entity|C0205554|Automated|ftcn|||automatic|||0|775|911|920
SE|25462465||ab|5|entity|C0004268|Attention|menp|||attention|||0|775|921|930
SE|25462465||ab|5|entity|C0597198|Performance|inbe|||performance|||0|1000|946|957
SE|25462465||ab|5|entity|||gngm|1756|DMD|DMD|||0|861|965|968
SE|25462465||ab|5|entity|C0030705|Patients|podg|||patients|||0|861|969|977
SE|25462465||ab|5|entity|C0442799|Efficient|qlco|||efficient|||0|861|987|996
SE|25462465||ab|5|entity|C0001779|Age|orga|||age|||0|829|1014|1017
SE|25462465||ab|5|entity|C0150103|MATCHING|resa|||matched|||0|829|1018|1025
SE|25462465||ab|5|entity|C0243148|control|ftcn|||controls|||0|829|1026|1034
SE|25462465||ab|5|entity|C0205163|Equal|qlco|||equal|||0|1000|1039|1044
SE|25462465||ab|5|entity|C0332239|Young|tmco|||younger|||0|872|1060|1067
SE|25462465||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|872|1068|1076

SE|25462465||ab|6|text|1078|1236|This study supports the previous report of voluntary attention deficit in DMD and extends the evidence to include also an automatic attention system deficit.
SE|25462465||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|1083|1088
SE|25462465||ab|6|entity|C0205156|Previous|tmco|||previous|||0|888|1102|1110
SE|25462465||ab|6|entity|C0439656|Voluntary|inbe|||voluntary|||0|851|1121|1130
SE|25462465||ab|6|entity|C0004268|Attention|menp|||attention|||0|851|1131|1140
SE|25462465||ab|6|entity|C0011155|Deficiency|ftcn|||deficit|||0|851|1141|1148
SE|25462465||ab|6|entity|||gngm|1756|DMD|DMD|||0|1000|1152|1155
SE|25462465||ab|6|entity|C0205554|Automated|ftcn|||automatic|||0|833|1200|1209
SE|25462465||ab|6|entity|C0004268|Attention|menp|||attention|||0|833|1210|1219
SE|25462465||ab|6|entity|C0449913|System|ftcn|||system|||0|833|1220|1226
SE|25462465||ab|6|entity|C0011155|Deficiency|ftcn|||deficit|||0|833|1227|1234

SE|25462465||ab|7|text|1236|1372|The development level of attention in DMD patients is below that expected for their age and corresponds to a delay of about three years.
SE|25462465||ab|7|entity|C1527148|Development|ftcn|||development|||0|694|1240|1251
SE|25462465||ab|7|entity|C0004268|Attention|menp|||attention|||0|1000|1261|1270
SE|25462465||ab|7|entity|||gngm|1756|DMD|DMD|||0|861|1274|1277
SE|25462465||ab|7|entity|C0030705|Patients|podg|||patients|||0|861|1278|1286
SE|25462465||ab|7|entity|C0542339|Inferior|spco|||below|||0|1000|1290|1295
SE|25462465||ab|7|entity|C0001779|Age|orga|||age|||0|1000|1320|1323
SE|25462465||ab|7|entity|C0205421|Deferred|tmco|||delay|||0|1000|1345|1350
SE|25462465||ab|7|entity|C0205449|Three|qnco|||three|||0|790|1360|1365
SE|25462465||ab|7|entity|C0439234|year|tmco|||years|||0|790|1366|1371
SE|25462465||ab|7|relation|2|1|C0004268|Attention|menp|menp|||attention|||0|1000|1261|1270|PREP|PROCESS_OF||1271|1273|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|1278|1286


SE|25462467||ti|1|text|21|117|Capacity of adolescents with cerebral palsy on paediatric balance scale and Berg balance scale.
SE|25462467||ti|1|entity|C1516240|Capacity|qnco|||Capacity|||0|1000|21|29
SE|25462467||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|33|44
SE|25462467||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|50|64
SE|25462467||ti|1|entity|C0014653|Equilibrium|orgf|||balance|||0|890|79|86
SE|25462467||ti|1|entity|C0183109|Infant scale|medd|||paediatric balance scale|||0|890|68|92
SE|25462467||ti|1|entity|C0014653|Equilibrium|orgf|||balance|||0|790|102|109
SE|25462467||ti|1|relation|3|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|50|64|PREP|PROCESS_OF||45|49|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|33|44

SE|25462467||ab|1|text|123|241|The Berg balance scale (BBS) and the paediatric balance scale (PBS) are reliable tools for measuring balance ability.
SE|25462467||ab|1|entity|C0014653|Equilibrium|orgf|||balance|||0|790|132|139
SE|25462467||ab|1|entity|C0014653|Equilibrium|orgf|||balance|||0|890|171|178
SE|25462467||ab|1|entity|C0183109|Infant scale|medd|||paediatric balance scale|||0|890|160|184
SE|25462467||ab|1|entity|C0336791|Tool|mnob|||tools|||0|827|204|209
SE|25462467||ab|1|entity|C0079809|Measures|qnco|||measuring|||0|840|214|223
SE|25462467||ab|1|entity|C0014653|Equilibrium|orgf|||balance|||0|840|224|231
SE|25462467||ab|1|entity|C0085732|Ability|orga|||ability|||0|840|232|239

SE|25462467||ab|2|text|241|328|However, reports of BBS and PBS scores in adolescent cerebral palsy have been limited.
SE|25462467||ab|2|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|261|264
SE|25462467||ab|2|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|269|272
SE|25462467||ab|2|entity|C0183109|Infant scale|medd|||PBS|||0|890|269|272
SE|25462467||ab|2|entity|C0205653|Adolescent|aggp|||adolescent|||0|901|283|293
SE|25462467||ab|2|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|901|294|308
SE|25462467||ab|2|relation|0|0|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|901|294|308|MOD/HEAD|PROCESS_OF||283|308|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|901|283|293
SE|25462467||ab|2|relation|2|1|C0183109|Infant scale|medd|medd|||PBS|||0|890|269|272|PREP|TREATS||280|282|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|901|294|308

SE|25462467||ab|3|text|328|688|The objectives of this study were to investigate functional balance capacities, as tested with the BBS and PBS in adolescents with cerebral palsy, to compare the total PBS and BBS scores between Gross Motor Function Classification System-Expanded and Revised (GMFCS-E&R) levels and to compare the static balance PBS and BBS scores within each GMFCS-E&R level.
SE|25462467||ab|3|entity|C0018017|objective (goal)|inpr|||objectives|||0|1000|332|342
SE|25462467||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|351|356
SE|25462467||ab|3|entity|C0205245|Functional|ftcn|||functional|||0|840|377|387
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||balance|||0|840|388|395
SE|25462467||ab|3|entity|C1516240|Capacity|qnco|||capacities|||0|840|396|406
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|427|430
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|435|438
SE|25462467||ab|3|entity|C0183109|Infant scale|medd|||PBS|||0|890|435|438
SE|25462467||ab|3|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|442|453
SE|25462467||ab|3|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|459|473
SE|25462467||ab|3|entity|C0439175|% of total|qnco|||total|||0|852|490|495
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||PBS|||0|852|496|499
SE|25462467||ab|3|entity|C0183109|Infant scale|medd|||PBS|||0|852|496|499
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|504|507
SE|25462467||ab|3|entity|C0677549|Gross motor functions|orgf|||Gross Motor Function|||0|753|523|543
SE|25462467||ab|3|entity|C0008902|Classification|clas|||Classification System|||0|753|544|565
SE|25462467||ab|3|entity|C0205229|Expanding|spco|||Expanded|||0|753|566|574
SE|25462467||ab|3|entity|C0441889|Levels|inpr|||levels|||0|753|599|605
SE|25462467||ab|3|entity|C0441463|Static|qlco|||static|||0|786|625|631
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||balance|||0|786|632|639
SE|25462467||ab|3|entity|C0183109|Infant scale|medd|||PBS|||0|786|640|643
SE|25462467||ab|3|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|648|651
SE|25462467||ab|3|entity|C0677549|Gross motor functions|orgf|||GMFCS-E&R|||0|722|671|680
SE|25462467||ab|3|entity|C0008902|Classification|clas|||GMFCS-E&R|||0|722|671|680
SE|25462467||ab|3|entity|C0205229|Expanding|spco|||GMFCS-E&R|||0|722|671|680
SE|25462467||ab|3|relation|0|0|C0183109|Infant scale|medd|medd|||PBS|||0|890|435|438|INFER|TREATS(INFER)||439|441|0|0|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|459|473
SE|25462467||ab|3|relation|5|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|459|473|PREP|PROCESS_OF||454|458|6|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|442|453
SE|25462467||ab|3|relation|5|1|C0183109|Infant scale|medd|medd|||PBS|||0|890|435|438|PREP|TREATS||439|441|6|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|442|453

SE|25462467||ab|4|text|688|829|Fifty-eight school-aged adolescents with cerebral palsy between the ages of 12 and 18 years with GMFCS-E&R levels of I to IV were recruited.
SE|25462467||ab|4|entity|C0205454|Eight|qnco|||eight|||0|740|694|699
SE|25462467||ab|4|entity|C0205653|Adolescent|aggp|||adolescents|||0|740|712|723
SE|25462467||ab|4|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|729|743
SE|25462467||ab|4|entity|C0001779|Age|orga|||ages|||0|966|756|760
SE|25462467||ab|4|entity|C0439234|year|tmco|||years|||0|861|774|779
SE|25462467||ab|4|entity|C0677549|Gross motor functions|orgf|||GMFCS-E&R|||0|753|785|794
SE|25462467||ab|4|entity|C0008902|Classification|clas|||GMFCS-E&R|||0|753|785|794
SE|25462467||ab|4|entity|C0205229|Expanding|spco|||GMFCS-E&R|||0|753|785|794
SE|25462467||ab|4|entity|C0441889|Levels|inpr|||levels|||0|753|795|801
SE|25462467||ab|4|relation|4|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|729|743|PREP|PROCESS_OF||724|728|1|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|740|712|723

SE|25462467||ab|5|text|829|955|The Kruskal-Wallis test was utilized to compare the median scores for the PBS and BBS between the different GMFCS-E&R levels.
SE|25462467||ab|5|entity|C0039593|Testing|resa|||test|||0|827|848|852
SE|25462467||ab|5|entity|C0449820|Score|qnco|||scores|||0|861|888|894
SE|25462467||ab|5|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|903|906
SE|25462467||ab|5|entity|C0183109|Infant scale|medd|||PBS|||0|890|903|906
SE|25462467||ab|5|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|911|914
SE|25462467||ab|5|entity|C1547020|*Difference|qnco|||different|||0|722|927|936
SE|25462467||ab|5|entity|C0677549|Gross motor functions|orgf|||GMFCS-E&R|||0|722|937|946
SE|25462467||ab|5|entity|C0008902|Classification|clas|||GMFCS-E&R|||0|722|937|946
SE|25462467||ab|5|entity|C0205229|Expanding|spco|||GMFCS-E&R|||0|722|937|946
SE|25462467||ab|5|entity|C0441889|Levels|inpr|||levels|||0|722|947|953

SE|25462467||ab|6|text|955|1115|Wilcoxon signed-rank tests were performed to examine the differences in the static balance scores between the PBS and the BBS within the same GMFCS-E&R levels.
SE|25462467||ab|6|entity|C0871608|Wilcoxon Sign Rank Test|inpr,qnco|||Wilcoxon signed-rank tests|||0|983|955|981
SE|25462467||ab|6|entity|C1547020|*Difference|qnco|||differences|||0|966|1012|1023
SE|25462467||ab|6|entity|C0441463|Static|qlco|||static|||0|888|1031|1037
SE|25462467||ab|6|entity|C0014653|Equilibrium|orgf|||balance|||0|888|1038|1045
SE|25462467||ab|6|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|1065|1068
SE|25462467||ab|6|entity|C0183109|Infant scale|medd|||PBS|||0|890|1065|1068
SE|25462467||ab|6|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|1077|1080
SE|25462467||ab|6|entity|C0445247|Same|qlco|||same|||0|732|1092|1096
SE|25462467||ab|6|entity|C0677549|Gross motor functions|orgf|||GMFCS-E&R|||0|732|1097|1106
SE|25462467||ab|6|entity|C0008902|Classification|clas|||GMFCS-E&R|||0|732|1097|1106
SE|25462467||ab|6|entity|C0205229|Expanding|spco|||GMFCS-E&R|||0|732|1097|1106
SE|25462467||ab|6|entity|C0441889|Levels|inpr|||levels|||0|732|1107|1113

SE|25462467||ab|7|text|1115|1221|The results reveal that there were differences in the BBS and PBS scores among the four GMFCS-E&R levels.
SE|25462467||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1119|1126
SE|25462467||ab|7|entity|C1547020|*Difference|qnco|||differences|||0|966|1150|1161
SE|25462467||ab|7|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|1169|1172
SE|25462467||ab|7|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|1177|1180
SE|25462467||ab|7|entity|C0183109|Infant scale|medd|||PBS|||0|890|1177|1180
SE|25462467||ab|7|entity|C0205450|Four|qnco|||four|||0|732|1198|1202
SE|25462467||ab|7|entity|C0677549|Gross motor functions|orgf|||GMFCS-E&R|||0|732|1203|1212
SE|25462467||ab|7|entity|C0008902|Classification|clas|||GMFCS-E&R|||0|732|1203|1212
SE|25462467||ab|7|entity|C0205229|Expanding|spco|||GMFCS-E&R|||0|732|1203|1212
SE|25462467||ab|7|entity|C0441889|Levels|inpr|||levels|||0|732|1213|1219

SE|25462467||ab|8|text|1221|1356|A significant difference was found between the BBS and PBS scores only among the patients with cerebral palsy and level III GMFCS-E&R.
SE|25462467||ab|8|entity|C0750502|Significant|idcn|||significant|||0|888|1223|1234
SE|25462467||ab|8|entity|C1547020|*Difference|qnco|||difference|||0|888|1235|1245
SE|25462467||ab|8|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|1268|1271
SE|25462467||ab|8|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|1276|1279
SE|25462467||ab|8|entity|C0183109|Infant scale|medd|||PBS|||0|890|1276|1279
SE|25462467||ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1302|1310
SE|25462467||ab|8|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|1316|1330
SE|25462467||ab|8|entity|C0441927|Level III|inpr|||level III|||0|768|1335|1344
SE|25462467||ab|8|entity|C0677549|Gross motor functions|orgf|||GMFCS-E&R|||0|768|1345|1354
SE|25462467||ab|8|entity|C0008902|Classification|clas|||GMFCS-E&R|||0|768|1345|1354
SE|25462467||ab|8|entity|C0205229|Expanding|spco|||GMFCS-E&R|||0|768|1345|1354
SE|25462467||ab|8|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|1316|1330|PREP|PROCESS_OF||1311|1315|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1302|1310

SE|25462467||ab|9|text|1356|1521|The BBS and PBS are valid and reliable tools for clinical examination and for distinguishing between levels of functional balance in adolescents with cerebral palsy.
SE|25462467||ab|9|entity|C0014653|Equilibrium|orgf|||BBS|||0|790|1360|1363
SE|25462467||ab|9|entity|C0014653|Equilibrium|orgf|||PBS|||0|890|1368|1371
SE|25462467||ab|9|entity|C0183109|Infant scale|medd|||PBS|||0|890|1368|1371
SE|25462467||ab|9|entity|C0336791|Tool|mnob|||tools|||0|827|1395|1400
SE|25462467||ab|9|entity|C0031809|Physical Examination|hlca|||clinical examination|||0|1000|1405|1425
SE|25462467||ab|9|entity|C0441889|Levels|inpr|||levels|||0|1000|1457|1463
SE|25462467||ab|9|entity|C0205245|Functional|ftcn|||functional|||0|888|1467|1477
SE|25462467||ab|9|entity|C0014653|Equilibrium|orgf|||balance|||0|888|1478|1485
SE|25462467||ab|9|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|1489|1500
SE|25462467||ab|9|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|1506|1520
SE|25462467||ab|9|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|1506|1520|PREP|PROCESS_OF||1501|1505|9|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1489|1500
SE|25462467||ab|9|relation|8|1|C0014653|Equilibrium|orgf|orgf|||balance|||0|888|1478|1485|PREP|PROCESS_OF||1486|1488|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1489|1500


SE|25462466||ti|1|text|21|115|Developmental trajectories of attentional control in preschool males with fragile X syndrome.
SE|25462466||ti|1|entity|C0458003|Developmental|qlco|||Developmental|||0|694|21|34
SE|25462466||ti|1|entity|C0004268|Attention|menp|||attentional|||0|853|51|62
SE|25462466||ti|1|entity|C0243148|control|ftcn|||control|||0|853|63|70
SE|25462466||ti|1|entity|C0024554|Male gender|orga|||males|||0|861|84|89
SE|25462466||ti|1|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||fragile X syndrome|||0|1000|95|113

SE|25462466||ab|1|text|121|220|Attention problems are among the most impairing features associated with fragile X syndrome (FXS).
SE|25462466||ab|1|entity|C0004268|Attention|menp|||Attention|||0|888|121|130
SE|25462466||ab|1|entity|C1546466|Problems|idcn|||problems|||0|888|131|139
SE|25462466||ab|1|entity|C0205393|Most|qnco|||most|||0|606|154|158
SE|25462466||ab|1|entity|C0221099|Impaired|ftcn|||impairing|||0|606|159|168
SE|25462466||ab|1|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||fragile X syndrome|||0|1000|194|212

SE|25462466||ab|2|text|220|333|However, few studies have examined behavioral development of inhibitory control in very young children with FXS.
SE|25462466||ab|2|entity|C1527148|Development|ftcn|||development|||0|802|266|277
SE|25462466||ab|2|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|281|291
SE|25462466||ab|2|entity|C0243148|control|ftcn|||control|||0|853|292|299
SE|25462466||ab|2|entity|C0442824|Very|qlco|||very|||0|851|303|307
SE|25462466||ab|2|entity|C0332239|Young|tmco|||young|||0|851|308|313
SE|25462466||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|851|314|322
SE|25462466||ab|2|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||FXS|||0|1000|328|331
SE|25462466||ab|2|relation|1|1|C0016667|Fragile X Syndrome|cgab,dsyn|dsyn|||FXS|||0|1000|328|331|PREP|PROCESS_OF||323|327|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|851|314|322

SE|25462466||ab|3|text|333|487|We examined attentional control in 3-6 year boys with FXS using both an experimental inhibitory control paradigm and parent-report of attention problems.
SE|25462466||ab|3|entity|C0004268|Attention|menp|||attentional|||0|853|345|356
SE|25462466||ab|3|entity|C0243148|control|ftcn|||control|||0|853|357|364
SE|25462466||ab|3|entity|C0439234|year|tmco|||year|||0|861|372|376
SE|25462466||ab|3|entity|C0870221|Boys|popg|||boys|||0|861|377|381
SE|25462466||ab|3|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||FXS|||0|1000|387|390
SE|25462466||ab|3|entity|C1517004|Experimental|ftcn|||experimental|||0|815|405|417
SE|25462466||ab|3|entity|C0243077|inhibitors|chvf|||inhibitory|||0|815|418|428
SE|25462466||ab|3|entity|C0243148|control|ftcn|||control|||0|815|429|436
SE|25462466||ab|3|entity|C0681797|paradigm|resa|||paradigm|||0|815|437|445
SE|25462466||ab|3|entity|C0030551|parent|famg|||parent|||0|888|450|456
SE|25462466||ab|3|entity|C0004268|Attention|menp|||attention|||0|888|467|476
SE|25462466||ab|3|entity|C1546466|Problems|idcn|||problems|||0|888|477|485
SE|25462466||ab|3|relation|4|1|C0016667|Fragile X Syndrome|cgab,dsyn|dsyn|||FXS|||0|1000|387|390|PREP|PROCESS_OF||382|386|2|1|C0870221|Boys|popg,humn|humn|||boys|||0|861|377|381

SE|25462466||ab|4|text|487|602|Study 1 examined attentional control in FXS compared to comparison groups matched on chronological and mental age.
SE|25462466||ab|4|entity|C0008972|Clinical Research|resa|||Study|||0|748|487|492
SE|25462466||ab|4|entity|C0004268|Attention|menp|||attentional|||0|748|504|515
SE|25462466||ab|4|entity|C0243148|control|ftcn|||control|||0|748|516|523
SE|25462466||ab|4|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||FXS|||0|1000|527|530
SE|25462466||ab|4|entity|C0441833|Groups|inpr|||groups|||0|861|554|560
SE|25462466||ab|4|entity|C0008717|Chronology|tmco|||chronological|||0|928|572|585
SE|25462466||ab|4|entity|C0598705|Mental Age|menp|||mental age|||0|1000|590|600

SE|25462466||ab|5|text|602|748|To determine the stability of impairments over time in FXS, Study 2 examined patterns of developmental change in an expanded longitudinal sample.
SE|25462466||ab|5|entity|C1317741|STABILITY|qlco|||stability|||0|1000|619|628
SE|25462466||ab|5|entity|C0040223|Time|tmco|||time|||0|785|649|653
SE|25462466||ab|5|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||FXS|||0|1000|657|660
SE|25462466||ab|5|entity|C0008972|Clinical Research|resa|||Study|||0|775|662|667
SE|25462466||ab|5|entity|C0449774|Patterns|spco|||patterns|||0|775|679|687
SE|25462466||ab|5|entity|C0458003|Developmental|qlco|||developmental|||0|888|691|704
SE|25462466||ab|5|entity|C0205229|Expanding|spco|||expanded|||0|606|718|726
SE|25462466||ab|5|entity|C0205127|Longitudinal|spco|||longitudinal|||0|606|727|739

SE|25462466||ab|6|text|748|877|Across studies, males with FXS demonstrated persistent impairments in inhibitory control and parent-reported attention problems.
SE|25462466||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|755|762
SE|25462466||ab|6|entity|C0024554|Male gender|orga|||males|||0|1000|764|769
SE|25462466||ab|6|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||FXS|||0|1000|775|778
SE|25462466||ab|6|entity|C0205322|Persistent|tmco|||persistent|||0|872|792|802
SE|25462466||ab|6|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|818|828
SE|25462466||ab|6|entity|C0243148|control|ftcn|||control|||0|853|829|836
SE|25462466||ab|6|entity|C0030551|parent|famg|||parent|||0|833|841|847
SE|25462466||ab|6|entity|C0004268|Attention|menp|||attention|||0|833|857|866
SE|25462466||ab|6|entity|C1546466|Problems|idcn|||problems|||0|833|867|875

SE|25462466||ab|7|text|877|956|Inhibitory control was related to, but not solely driven by, lower mental age.
SE|25462466||ab|7|entity|C0243077|inhibitors|chvf|||Inhibitory|||0|853|877|887
SE|25462466||ab|7|entity|C0243148|control|ftcn|||control|||0|853|888|895
SE|25462466||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|916|919
SE|25462466||ab|7|entity|C0598705|Mental Age|menp|||mental age|||0|1000|944|954

SE|25462466||ab|8|text|956|1065|Although parent-rated attention problems remained stable across ages, inhibitory control improved with time.
SE|25462466||ab|8|entity|C0030551|parent|famg|||parent|||0|825|965|971
SE|25462466||ab|8|entity|C0871208|Rating|resa|||rated|||0|825|972|977
SE|25462466||ab|8|entity|C0004268|Attention|menp|||attention|||0|825|978|987
SE|25462466||ab|8|entity|C1546466|Problems|idcn|||problems|||0|825|988|996
SE|25462466||ab|8|entity|C0001779|Age|orga|||ages|||0|966|1020|1024
SE|25462466||ab|8|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|1026|1036
SE|25462466||ab|8|entity|C0243148|control|ftcn|||control|||0|853|1037|1044
SE|25462466||ab|8|entity|C0040223|Time|tmco|||time|||0|1000|1059|1063

SE|25462466||ab|9|text|1065|1163|Children with more severe attention problems often displayed initially poorer inhibitory control.
SE|25462466||ab|9|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|1065|1073
SE|25462466||ab|9|entity|C0205172|More|ftcn|||more|||0|833|1079|1083
SE|25462466||ab|9|entity|C0205082|Severe|qlco|||severe|||0|833|1084|1090
SE|25462466||ab|9|entity|C0004268|Attention|menp|||attention|||0|833|1091|1100
SE|25462466||ab|9|entity|C1546466|Problems|idcn|||problems|||0|833|1101|1109
SE|25462466||ab|9|entity|C0332183|Frequent|tmco|||often|||0|1000|1110|1115
SE|25462466||ab|9|entity|C0205265|Initially|tmco|||initially|||0|807|1126|1135
SE|25462466||ab|9|entity|C0032854|Poverty|grpa|||poorer|||0|807|1136|1142
SE|25462466||ab|9|entity|C0243077|inhibitors|chvf|||inhibitory|||0|807|1143|1153
SE|25462466||ab|9|entity|C0243148|control|ftcn|||control|||0|807|1154|1161

SE|25462466||ab|10|text|1163|1228|However, these trajectories also improved more rapidly with age.
SE|25462466||ab|10|entity|C0205172|More|ftcn|||more|||0|861|1205|1209
SE|25462466||ab|10|entity|C0001779|Age|orga|||age|||0|1000|1223|1226

SE|25462466||ab|11|text|1228|1472|Our findings indicate that despite persistent deficits in attentional control in young children with FXS, multi-method assessment can be used to capture developmental growth that should be further supported through early, targeted intervention.
SE|25462466||ab|11|entity|C0243095|Finding|ftcn|||findings|||0|1000|1232|1240
SE|25462466||ab|11|entity|C0205322|Persistent|tmco|||persistent|||0|872|1263|1273
SE|25462466||ab|11|entity|C0011155|Deficiency|ftcn|||deficits|||0|872|1274|1282
SE|25462466||ab|11|entity|C0004268|Attention|menp|||attentional|||0|853|1286|1297
SE|25462466||ab|11|entity|C0243148|control|ftcn|||control|||0|853|1298|1305
SE|25462466||ab|11|entity|C0332239|Young|tmco|||young|||0|888|1309|1314
SE|25462466||ab|11|entity|C0008059|Child|aggp,inpr|||children|||0|888|1315|1323
SE|25462466||ab|11|entity|C0016667|Fragile X Syndrome|cgab,dsyn|||FXS|||0|1000|1329|1332
SE|25462466||ab|11|entity|C1442112|MULTI|qnco|||multi|||0|851|1334|1339
SE|25462466||ab|11|entity|C0025663|Methods|inpr|||method|||0|851|1340|1346
SE|25462466||ab|11|entity|C0220825|Evaluation|ftcn|||assessment|||0|851|1347|1357
SE|25462466||ab|11|entity|C0458003|Developmental|qlco|||developmental|||0|888|1381|1394
SE|25462466||ab|11|entity|C0018270|Growth|orgf|||growth|||0|888|1395|1401
SE|25462466||ab|11|entity|C1517331|Further|spco|||further|||0|1000|1417|1424
SE|25462466||ab|11|entity|C1279919|Early|tmco|||early|||0|1000|1443|1448
SE|25462466||ab|11|entity|C0599894|targeting|celf|||targeted|||0|872|1450|1458
SE|25462466||ab|11|entity|C1273869|Intervention regimes|hlca|||intervention|||0|872|1459|1471
SE|25462466||ab|11|relation|4|1|C0016667|Fragile X Syndrome|cgab,dsyn|dsyn|||FXS|||0|1000|1329|1332|PREP|PROCESS_OF||1324|1328|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|1315|1323


SE|25462468||ti|1|text|21|159|The difference in medical utilization and associated factors between children and adolescents with and without autism spectrum disorders.
SE|25462468||ti|1|entity|C1547020|*Difference|qnco|||difference|||0|1000|25|35
SE|25462468||ti|1|entity|C0205476|Medical|ftcn|||medical|||0|694|39|46
SE|25462468||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|827|74|81
SE|25462468||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|90|98
SE|25462468||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|103|114
SE|25462468||ti|1|entity|C1510586|Autism spectrum disorder|mobd|||autism spectrum disorders|||0|1000|132|157

SE|25462468||ab|1|text|165|373|This study determined differences in health care utilization and health care expenditures between children with and without autism spectrum disorder (ASD) and examined possible reasons for these differences.
SE|25462468||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|816|170|175
SE|25462468||ab|1|entity|C0680730|Adjudication|gora|||determined|||0|816|176|186
SE|25462468||ab|1|entity|C1547020|*Difference|qnco|||differences|||0|816|187|198
SE|25462468||ab|1|entity|C0237939|health care utilization|hlca|||health care utilization|||0|1000|202|225
SE|25462468||ab|1|entity|C0015318|Health Expenditures|qnco|||health care expenditures|||0|913|230|254
SE|25462468||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|263|271
SE|25462468||ab|1|entity|C1510586|Autism spectrum disorder|mobd|||autism spectrum disorder|||0|1000|289|313
SE|25462468||ab|1|entity|C0332149|Possible|qlco|||possible|||0|851|333|341
SE|25462468||ab|1|entity|C0392360|Reason for|idcn|||reasons|||0|851|342|349
SE|25462468||ab|1|entity|C1547020|*Difference|qnco|||differences|||0|966|360|371

SE|25462468||ab|2|text|373|640|A retrospective longitudinal study of children aged younger than 18 years both with and without ASD was conducted using the 2008 database of the Ministry of the Interior registry of the disabled persons in tandem with the National Health Insurance Research Database.
SE|25462468||ab|2|entity|C0205127|Longitudinal|spco|||longitudinal|||0|901|389|401
SE|25462468||ab|2|entity|C0035363|Retrospective Studies|qnco|||retrospective longitudinal study|||0|901|375|407
SE|25462468||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|411|419
SE|25462468||ab|2|entity|C0332239|Young|tmco|||younger|||0|966|425|432
SE|25462468||ab|2|entity|C0439234|year|tmco|||years|||0|861|441|446
SE|25462468||ab|2|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|469|472
SE|25462468||ab|2|entity|C0242356|Databases|inpr|||database|||0|861|502|510
SE|25462468||ab|2|entity|C0034975|Registries|inpr,qnco|||registry|||0|861|543|551
SE|25462468||ab|2|entity|C0018576|Disabled Persons|podg|||disabled persons|||0|1000|559|575
SE|25462468||ab|2|entity|C0027452|National Health Insurance|hlca|||National Health Insurance|||0|875|595|620
SE|25462468||ab|2|entity|C0035168|research|resa|||Research|||0|875|621|629
SE|25462468||ab|2|entity|C0242356|Databases|inpr|||Database|||0|875|630|638

SE|25462468||ab|3|text|640|864|Propensity score matching for the covariates of age, sex, and parental monthly salary was used to match children at a ratio of 1:3 for observing health care utilization among children with and without ASD from 2008 to 2011.
SE|25462468||ab|3|entity|C0449820|Score|qnco|||score|||0|790|651|656
SE|25462468||ab|3|entity|C0150103|MATCHING|resa|||matching|||0|790|657|665
SE|25462468||ab|3|entity|C0001779|Age|orga|||age|||0|1000|688|691
SE|25462468||ab|3|entity|C0332177|Monthly|tmco|||monthly|||0|790|711|718
SE|25462468||ab|3|entity|C0036064|Wages|qnco|||salary|||0|790|719|725
SE|25462468||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|744|752
SE|25462468||ab|3|entity|C0456603|Ratio|inpr|||ratio|||0|1000|758|763
SE|25462468||ab|3|entity|C1441672|Observed|ftcn|||observing|||0|905|775|784
SE|25462468||ab|3|entity|C0237939|health care utilization|hlca|||health care utilization|||0|905|785|808
SE|25462468||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|815|823
SE|25462468||ab|3|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|841|844

SE|25462468||ab|4|text|864|1079|Generalized estimating equation analysis was performed to determine factors that affect health care utilization, such as physician visits, emergency room (ER) visits, hospitalizations, and health care expenditures.
SE|25462468||ab|4|entity|C0205246|Generalized|spco|||Generalized|||0|825|864|875
SE|25462468||ab|4|entity|C0750572|Estimated|qnco|||estimating|||0|825|876|886
SE|25462468||ab|4|entity|C0552449|Equation|cnce|||equation|||0|825|887|895
SE|25462468||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|825|896|904
SE|25462468||ab|4|entity|C1521761|Factor|ftcn|||factors|||0|966|932|939
SE|25462468||ab|4|entity|C0237939|health care utilization|hlca|||health care utilization|||0|1000|952|975
SE|25462468||ab|4|entity|C0031831|Physicians|prog|||physician|||0|888|985|994
SE|25462468||ab|4|entity|C0545082|Visit|ftcn|||visits|||0|888|995|1001
SE|25462468||ab|4|entity|C0562508|Accident and Emergency department|hcro,mnob|||emergency room|||0|901|1003|1017
SE|25462468||ab|4|entity|C0545082|Visit|ftcn|||visits|||0|901|1023|1029
SE|25462468||ab|4|entity|C0019993|Hospitalization|hlca|||hospitalizations|||0|1000|1031|1047
SE|25462468||ab|4|entity|C0015318|Health Expenditures|qnco|||health care expenditures|||0|913|1053|1077

SE|25462468||ab|5|text|1079|1189|After matching was completed, the sample size comprised 3280 children with ASD and 9840 children without ASD.
SE|25462468||ab|5|entity|C0150103|MATCHING|resa|||matching|||0|1000|1085|1093
SE|25462468||ab|5|entity|C0242618|Sample Size|qnco|||sample size|||0|1000|1113|1124
SE|25462468||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|861|1140|1148
SE|25462468||ab|5|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1154|1157
SE|25462468||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|861|1167|1175
SE|25462468||ab|5|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1184|1187
SE|25462468||ab|5|relation|3|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|1154|1157|PREP|PROCESS_OF||1149|1153|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|1140|1148

SE|25462468||ab|6|text|1189|1330|Among the children in the sample, most were boys (86.68%) between the ages of 6-11 years, and the average age of both samples was 9.8 years.
SE|25462468||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1199|1207
SE|25462468||ab|6|entity|C0205393|Most|qnco|||most|||0|1000|1223|1227
SE|25462468||ab|6|entity|C0870221|Boys|popg|||boys|||0|1000|1233|1237
SE|25462468||ab|6|entity|C0001779|Age|orga|||ages|||0|966|1259|1263
SE|25462468||ab|6|entity|C0439234|year|tmco|||years|||0|827|1272|1277
SE|25462468||ab|6|entity|C1510992|Average|qnco|||average|||0|888|1287|1294
SE|25462468||ab|6|entity|C0001779|Age|orga|||age|||0|888|1295|1298
SE|25462468||ab|6|entity|C0439234|year|tmco|||years|||0|827|1323|1328

SE|25462468||ab|7|text|1330|1582|After relevant factors were controlled for, the children with ASD yielded an average of 14.2 more annual physician visits and were more likely to visit the ER (OR=1.12, P<.05) or be hospitalized (OR=1.48; P<.05) compared with the children without ASD.
SE|25462468||ab|7|entity|C1521761|Factor|ftcn|||factors|||0|827|1345|1352
SE|25462468||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1378|1386
SE|25462468||ab|7|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1392|1395
SE|25462468||ab|7|entity|C1510992|Average|qnco|||average|||0|1000|1407|1414
SE|25462468||ab|7|entity|C0332181|Annual|tmco|||annual|||0|712|1428|1434
SE|25462468||ab|7|entity|C0031831|Physicians|prog|||physician|||0|712|1435|1444
SE|25462468||ab|7|entity|C0545082|Visit|ftcn|||visits|||0|712|1445|1451
SE|25462468||ab|7|entity|C0205172|More|ftcn|||more|||0|888|1461|1465
SE|25462468||ab|7|entity|C0562508|Accident and Emergency department|hcro,mnob|||ER|||0|1000|1486|1488
SE|25462468||ab|7|entity|C0202178|Phosphorus measurement|lbpr|||P|||0|861|1499|1500
SE|25462468||ab|7|entity|C0202178|Phosphorus measurement|lbpr|||P|||0|861|1535|1536
SE|25462468||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1560|1568
SE|25462468||ab|7|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1577|1580
SE|25462468||ab|7|relation|6|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|1392|1395|PREP|PROCESS_OF||1387|1391|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1378|1386

SE|25462468||ab|8|text|1582|1873|Compared with the children without ASD, the children with ASD exhibited higher annual physician visit expenditures (NT$26,580 more), higher ER visit expenditures (NT$50 more), higher hospitalization expenditures (NT$5830 more), and NT$32,460 more total health care expenditures (all P<.05).
SE|25462468||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1600|1608
SE|25462468||ab|8|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1617|1620
SE|25462468||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1626|1634
SE|25462468||ab|8|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1640|1643
SE|25462468||ab|8|entity|C0205250|High|qlco|||higher|||0|815|1654|1660
SE|25462468||ab|8|entity|C0332181|Annual|tmco|||annual|||0|815|1661|1667
SE|25462468||ab|8|entity|C0031831|Physicians|prog|||physician|||0|815|1668|1677
SE|25462468||ab|8|entity|C0545082|Visit|ftcn|||visit|||0|815|1678|1683
SE|25462468||ab|8|entity|C0015316|Expenditures|qnco|||expenditures|||0|815|1684|1696
SE|25462468||ab|8|entity|C0205250|High|qlco|||higher|||0|833|1715|1721
SE|25462468||ab|8|entity|C1547703|Room|spco|||ER|||0|833|1722|1724
SE|25462468||ab|8|entity|C0553618|Emergency visit|hlca|||ER visit|||0|833|1722|1730
SE|25462468||ab|8|entity|C0015316|Expenditures|qnco|||expenditures|||0|833|1731|1743
SE|25462468||ab|8|entity|C0205250|High|qlco|||higher|||0|840|1758|1764
SE|25462468||ab|8|entity|C0019993|Hospitalization|hlca|||hospitalization|||0|840|1765|1780
SE|25462468||ab|8|entity|C0015316|Expenditures|qnco|||expenditures|||0|840|1781|1793
SE|25462468||ab|8|entity|C0439175|% of total|qnco|||total|||0|760|1829|1834
SE|25462468||ab|8|entity|C0015318|Health Expenditures|qnco|||health care expenditures|||0|760|1835|1859
SE|25462468||ab|8|entity|C0202178|Phosphorus measurement|lbpr|||P|||0|861|1865|1866
SE|25462468||ab|8|relation|5|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|1640|1643|PREP|PROCESS_OF||1635|1639|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1626|1634

SE|25462468||ab|9|text|1873|2016|Significant predictors of health care expenditures among the children with ASD were age, parental monthly salary, and severity of comorbidity.
SE|25462468||ab|9|entity|C0750502|Significant|idcn|||Significant|||0|694|1873|1884
SE|25462468||ab|9|entity|C0015318|Health Expenditures|qnco|||health care expenditures|||0|913|1899|1923
SE|25462468||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1934|1942
SE|25462468||ab|9|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1948|1951
SE|25462468||ab|9|entity|C0001779|Age|orga|||age|||0|1000|1957|1960
SE|25462468||ab|9|entity|C0332177|Monthly|tmco|||monthly|||0|790|1971|1978
SE|25462468||ab|9|entity|C0036064|Wages|qnco|||salary|||0|790|1979|1985
SE|25462468||ab|9|entity|C0439793|Severities|qlco|||severity|||0|1000|1991|1999
SE|25462468||ab|9|entity|C0009488|Comorbidity|idcn|||comorbidity|||0|1000|2003|2014
SE|25462468||ab|9|relation|5|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|1948|1951|PREP|PROCESS_OF||1943|1947|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1934|1942

SE|25462468||ab|10|text|2016|2185|The most common reasons for physician visits or hospitalizations among the children with ASD were psychiatric illnesses, respiratory illnesses, and digestive illnesses.
SE|25462468||ab|10|entity|C0205393|Most|qnco|||most|||0|851|2020|2024
SE|25462468||ab|10|entity|C0205214|Common|qnco|||common|||0|851|2025|2031
SE|25462468||ab|10|entity|C0392360|Reason for|idcn|||reasons|||0|851|2032|2039
SE|25462468||ab|10|entity|C0031831|Physicians|prog|||physician|||0|888|2044|2053
SE|25462468||ab|10|entity|C0545082|Visit|ftcn|||visits|||0|888|2054|2060
SE|25462468||ab|10|entity|C0019993|Hospitalization|hlca|||hospitalizations|||0|1000|2064|2080
SE|25462468||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|2091|2099
SE|25462468||ab|10|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|2105|2108
SE|25462468||ab|10|entity|C0004936|Mental disorders|mobd|||psychiatric illnesses|||0|983|2114|2135
SE|25462468||ab|10|entity|C0521346|respiratory|ftcn|||respiratory|||0|872|2137|2148
SE|25462468||ab|10|entity|C0221423|Finding / disorder|ftcn|||illnesses|||0|872|2149|2158
SE|25462468||ab|10|entity|C0221423|Finding / disorder|ftcn|||illnesses|||0|827|2174|2183
SE|25462468||ab|10|relation|0|0|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|2105|2108|SPEC|ISA||2105|2135|0|0|C0004936|Mental disorders|mobd|mobd|||psychiatric illnesses|||0|983|2114|2135
SE|25462468||ab|10|relation|4|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|2105|2108|PREP|PROCESS_OF||2100|2104|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|2091|2099

SE|25462468||ab|11|text|2185|2305|The children without ASD most commonly experienced respiratory, digestive, and nervous system or sense organ illnesses.
SE|25462468||ab|11|entity|C0008059|Child|aggp,inpr|||children|||0|1000|2189|2197
SE|25462468||ab|11|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|923|2206|2209
SE|25462468||ab|11|entity|C0521346|respiratory|ftcn|||respiratory|||0|694|2236|2247
SE|25462468||ab|11|entity|C1269560|Entire nervous system|bdsy|||nervous system|||0|1000|2264|2278
SE|25462468||ab|11|entity|C0036665|Sense Organs|bpoc|||sense organ|||0|884|2282|2293
SE|25462468||ab|11|entity|C0221423|Finding / disorder|ftcn|||illnesses|||0|884|2294|2303

SE|25462468||ab|12|text|2305|2401|Health care utilization among children with ASD is higher than that among children without ASD.
SE|25462468||ab|12|entity|C0237939|health care utilization|hlca|||Health care utilization|||0|1000|2305|2328
SE|25462468||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|2335|2343
SE|25462468||ab|12|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|2349|2352
SE|25462468||ab|12|entity|C0205250|High|qlco|||higher|||0|966|2356|2362
SE|25462468||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|2379|2387
SE|25462468||ab|12|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|2396|2399
SE|25462468||ab|12|relation|4|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|2349|2352|PREP|PROCESS_OF||2344|2348|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|2335|2343

SE|25462468||ab|13|text|2401|2517|The results of this study can serve as a reference for governmental agencies enacting relevant health care policies.
SE|25462468||ab|13|entity|C1274040|result|ftcn|||results|||0|966|2405|2412
SE|25462468||ab|13|entity|C0008972|Clinical Research|resa|||study|||0|1000|2421|2426
SE|25462468||ab|13|entity|C1514811|Reference|idcn|||reference|||0|1000|2442|2451
SE|25462468||ab|13|entity|C0018105|Government Agencies|orgt|||governmental agencies|||0|964|2456|2477
SE|25462468||ab|13|entity|C0018735|Health Policy|rnlw|||health care policies|||0|906|2496|2516


SE|25462469||ti|1|text|21|110|Efficacy of upper limb strengthening in children with Cerebral Palsy: A critical review.
SE|25462469||ti|1|entity|C1140618|Upper Extremity|bpoc|||upper limb|||0|734|33|43
SE|25462469||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|61|69
SE|25462469||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||Cerebral Palsy|||0|1000|75|89
SE|25462469||ti|1|entity|C1511545|Critical|qlco|||critical|||0|694|93|101
SE|25462469||ti|1|relation|2|1|C0007789|Cerebral Palsy|dsyn|dsyn|||Cerebral Palsy|||0|1000|75|89|PREP|PROCESS_OF||70|74|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|61|69

SE|25462469|OBJECTIVE|ab|1|text|116|249|OBJECTIVE: This review focuses on the effects of strengthening interventions of the upper limb in children with Cerebral Palsy (CP).
SE|25462469|OBJECTIVE|ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|154|161
SE|25462469|OBJECTIVE|ab|1|entity|C1273869|Intervention regimes|hlca|||interventions|||0|861|179|192
SE|25462469|OBJECTIVE|ab|1|entity|C1140618|Upper Extremity|bpoc|||upper limb|||0|1000|200|210
SE|25462469|OBJECTIVE|ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|214|222
SE|25462469|OBJECTIVE|ab|1|entity|C0007789|Cerebral Palsy|dsyn|||Cerebral Palsy|||0|1000|228|242
SE|25462469|OBJECTIVE|ab|1|relation|4|4|C0007789|Cerebral Palsy|dsyn|dsyn|||Cerebral Palsy|||0|1000|228|242|NOM|AFFECTS||154|161|4|3|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|214|222

SE|25462469|OBJECTIVE|ab|2|text|249|432|The strengthening intervention studies were divided in two categories: those based on stand-alone strength training, and those on strength training combined with other interventions.
SE|25462469|OBJECTIVE|ab|2|entity|C0021810|Intervention Studies|resa|||intervention studies|||0|901|267|287
SE|25462469|OBJECTIVE|ab|2|entity|C0205448|Two|qnco|||two|||0|888|304|307
SE|25462469|OBJECTIVE|ab|2|entity|C0683312|Categories|inpr|||categories|||0|888|308|318
SE|25462469|OBJECTIVE|ab|2|entity|C0596013|Does stand|clna|||stand|||0|813|335|340
SE|25462469|OBJECTIVE|ab|2|entity|C0872279|strength training|acty|||strength training|||0|813|347|364
SE|25462469|OBJECTIVE|ab|2|entity|C0872279|strength training|acty|||strength training|||0|1000|379|396
SE|25462469|OBJECTIVE|ab|2|entity|C1273869|Intervention regimes|hlca|||interventions|||0|1000|417|430

SE|25462469|DATA SOURCES AND EXTRACTION|ab|3|text|432|511|DATA SOURCES AND EXTRACTION: A search in all relevant databases was performed.
SE|25462469|DATA SOURCES AND EXTRACTION|ab|3|entity|C0011001|Data Sources|qnco|||DATA SOURCES|||0|1000|432|444
SE|25462469|DATA SOURCES AND EXTRACTION|ab|3|entity|C0185115|Extraction|topp|||EXTRACTION|||0|1000|449|459
SE|25462469|DATA SOURCES AND EXTRACTION|ab|3|entity|C1552603|search|idcn|||search|||0|1000|463|469
SE|25462469|DATA SOURCES AND EXTRACTION|ab|3|entity|C0242356|Databases|inpr|||databases|||0|861|486|495

SE|25462469|DATA SYNTHESIS|ab|4|text|511|642|DATA SYNTHESIS: Six articles were included: three randomized controlled trials (RCTs), two clinical trial (CT) and one case study.
SE|25462469|DATA SYNTHESIS|ab|4|entity|C1511726|Data|idcn|||DATA|||0|888|511|515
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0869032|Synthesis|phpr|||SYNTHESIS|||0|888|516|525
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0205452|Six|qnco|||Six|||0|694|527|530
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0205449|Three|qnco|||three|||0|1000|555|560
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0702113|Controlled|ftcn|||controlled|||0|840|572|582
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0008976|Clinical Trials|resa|||trials|||0|840|583|589
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0205448|Two|qnco|||two|||0|901|598|601
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0008976|Clinical Trials|resa|||clinical trial|||0|901|602|616
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0205447|One|qnco|||one|||0|901|626|629
SE|25462469|DATA SYNTHESIS|ab|4|entity|C0085973|Case Study|inpr|||case study|||0|901|630|640

SE|25462469|DATA SYNTHESIS|ab|5|text|642|743|Effect sizes of strength training on muscle strength and function of the upper limb were calculated.
SE|25462469|DATA SYNTHESIS|ab|5|entity|C1280500|Effect|qlco|||Effect|||0|1000|642|648
SE|25462469|DATA SYNTHESIS|ab|5|entity|C0872279|strength training|acty|||strength training|||0|1000|658|675
SE|25462469|DATA SYNTHESIS|ab|5|entity|C0517349|Muscle strength|ortf|||muscle strength|||0|1000|679|694
SE|25462469|DATA SYNTHESIS|ab|5|entity|C0031843|physiological aspects|phsf|||function|||0|1000|699|707
SE|25462469|DATA SYNTHESIS|ab|5|entity|C1140618|Upper Extremity|bpoc|||upper limb|||0|1000|715|725

SE|25462469|CONCLUSION|ab|6|text|743|840|CONCLUSION: There are no coherent recommendations for strength training, based on these studies.
SE|25462469|CONCLUSION|ab|6|entity|C0034866|Recommendation|idcn|||recommendations|||0|861|777|792
SE|25462469|CONCLUSION|ab|6|entity|C0872279|strength training|acty|||strength training|||0|1000|797|814
SE|25462469|CONCLUSION|ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|831|838

SE|25462469|CONCLUSION|ab|7|text|840|931|The causes include too much variety of types of training, level of intensity and duration.
SE|25462469|CONCLUSION|ab|7|entity|C0015127|Etiology aspects|ftcn|||causes|||0|1000|844|850
SE|25462469|CONCLUSION|ab|7|entity|C0332307|Type - attribute|qlco|||types|||0|1000|879|884
SE|25462469|CONCLUSION|ab|7|entity|C0220931|Training|edac|||training|||0|1000|888|896
SE|25462469|CONCLUSION|ab|7|entity|C0449238|Duration|tmco|||duration|||0|1000|921|929

SE|25462469|CONCLUSION|ab|8|text|931|1026|All of the reported upper limb strength training studies found an increase in muscle strength.
SE|25462469|CONCLUSION|ab|8|entity|C0808080|STRENGTH|idcn|||strength|||0|845|962|970
SE|25462469|CONCLUSION|ab|8|entity|C0556501|Upper limb training|topp|||upper limb strength training|||0|845|951|979
SE|25462469|CONCLUSION|ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|845|980|987
SE|25462469|CONCLUSION|ab|8|entity|C0442805|Increase|ftcn|||increase|||0|1000|997|1005
SE|25462469|CONCLUSION|ab|8|entity|C0517349|Muscle strength|ortf|||muscle strength|||0|1000|1009|1024
SE|25462469|CONCLUSION|ab|8|relation|0|0|C0008972|Clinical Research|resa|resa|||studies|||0|845|980|987|MOD/HEAD|USES||951|987|0|0|C0556501|Upper limb training|topp|topp|||upper limb strength training|||0|845|951|979

SE|25462469|CONCLUSION|ab|9|text|1026|1082|In addition, the quality of these studies was not high.
SE|25462469|CONCLUSION|ab|9|entity|C0332306|Quality|qlco|||quality|||0|1000|1043|1050
SE|25462469|CONCLUSION|ab|9|entity|C0008972|Clinical Research|resa|||studies|||0|966|1060|1067
SE|25462469|CONCLUSION|ab|9|entity|C1518422|Not|ftcn|||not|||0|888|1072|1075
SE|25462469|CONCLUSION|ab|9|entity|C0205250|High|qlco|||high|||0|888|1076|1080

SE|25462469|CONCLUSION|ab|10|text|1082|1326|More RCTs on strength training according to the official strength training guidelines are necessary to assess the impact and potential of strength training of the upper limb to improve the daily activities and participation in children with CP.
SE|25462469|CONCLUSION|ab|10|entity|C0205172|More|ftcn|||More|||0|1000|1082|1086
SE|25462469|CONCLUSION|ab|10|entity|C0702113|Controlled|ftcn|||RCTs|||0|840|1087|1091
SE|25462469|CONCLUSION|ab|10|entity|C0008976|Clinical Trials|resa|||RCTs|||0|840|1087|1091
SE|25462469|CONCLUSION|ab|10|entity|C0872279|strength training|acty|||strength training|||0|1000|1095|1112
SE|25462469|CONCLUSION|ab|10|entity|C0872279|strength training|acty|||strength training|||0|824|1139|1156
SE|25462469|CONCLUSION|ab|10|entity|C0162791|Guidelines|inpr|||guidelines|||0|824|1157|1167
SE|25462469|CONCLUSION|ab|10|entity|C0237399|Potential|qlco|||potential|||0|1000|1207|1216
SE|25462469|CONCLUSION|ab|10|entity|C0872279|strength training|acty|||strength training|||0|1000|1220|1237
SE|25462469|CONCLUSION|ab|10|entity|C1140618|Upper Extremity|bpoc|||upper limb|||0|1000|1245|1255
SE|25462469|CONCLUSION|ab|10|entity|C0871707|Daily Activities|dora|||daily activities|||0|1000|1271|1287
SE|25462469|CONCLUSION|ab|10|entity|C0679823|participation|inbe|||participation|||0|1000|1292|1305
SE|25462469|CONCLUSION|ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1309|1317
SE|25462469|CONCLUSION|ab|10|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|1323|1325
SE|25462469|CONCLUSION|ab|10|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|1323|1325|PREP|PROCESS_OF||1318|1322|10|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1309|1317
SE|25462469|CONCLUSION|ab|10|relation|9|1|C0679823|participation|inbe|inbe|||participation|||0|1000|1292|1305|PREP|PROCESS_OF||1306|1308|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1309|1317


SE|25462470||ti|1|text|21|117|Motor development and sensory processing: A comparative study between preterm and term infants.
SE|25462470||ti|1|entity|C0870919|Motor Development|orgf|||Motor development|||0|1000|21|38
SE|25462470||ti|1|entity|C1327511|Sensory Process|ortf|||sensory processing|||0|1000|43|61
SE|25462470||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|861|77|82
SE|25462470||ti|1|entity|C0456128|Term infant|fndg|||term infants|||0|983|103|115

SE|25462470||ab|1|text|123|453|Infants born preterm and/or with low birth weight may present a clinical condition of organic instability and usually face a long period of hospitalization in the Neonatal Intensive Care Units, being exposed to biopsychosocial risk factors to their development due to decreased spontaneous movement and excessive sensory stimuli.
SE|25462470||ab|1|entity|C0021294|Infant, Premature|aggp|||Infants born preterm|||0|896|123|143
SE|25462470||ab|1|entity|C0024032|Low Birth Weights|fndg|||low birth weight|||0|1000|156|172
SE|25462470||ab|1|entity|C0205210|Clinical|qlco|||clinical|||0|888|187|195
SE|25462470||ab|1|entity|C0348080|Condition|qlco|||condition|||0|888|196|205
SE|25462470||ab|1|entity|C0747055|ORGANIC|qlco|||organic|||0|888|209|216
SE|25462470||ab|1|entity|C1444783|Instability|fndg|||instability|||0|888|217|228
SE|25462470||ab|1|entity|C0205166|Long|qlco|||long|||0|888|248|252
SE|25462470||ab|1|entity|C0439531|/period|tmco|||period|||0|888|253|259
SE|25462470||ab|1|entity|C0019993|Hospitalization|hlca|||hospitalization|||0|1000|263|278
SE|25462470||ab|1|entity|C0021709|Intensive Care Units, Neonatal|hcro,mnob|||Neonatal Intensive Care Units|||0|1000|286|315
SE|25462470||ab|1|entity|C0035648|risk factors|qnco|||risk factors|||0|901|350|362
SE|25462470||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|372|383
SE|25462470||ab|1|entity|C0205216|Decreased|qnco|||decreased|||0|851|391|400
SE|25462470||ab|1|entity|C0205359|Spontaneous|ftcn|||spontaneous|||0|851|401|412
SE|25462470||ab|1|entity|C0026649|Movement|orgf|||movement|||0|851|413|421
SE|25462470||ab|1|entity|C0442802|Excessive|qlco|||excessive|||0|901|426|435
SE|25462470||ab|1|entity|C0683107|sensory stimuli|npop|||sensory stimuli|||0|901|436|451

SE|25462470||ab|2|text|453|616|This study assumes that there are relationships between the integration of sensory information of preterm infants, motor development and their subsequent effects.
SE|25462470||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|458|463
SE|25462470||ab|2|entity|C0439849|Relationships|qlco|||relationships|||0|1000|487|500
SE|25462470||ab|2|entity|C0445254|Sensory|qlco|||sensory|||0|888|528|535
SE|25462470||ab|2|entity|C1533716|Information|idcn|||information|||0|888|536|547
SE|25462470||ab|2|entity|C0021294|Infant, Premature|aggp|||preterm infants|||0|983|551|566
SE|25462470||ab|2|entity|C0870919|Motor Development|orgf|||motor development|||0|1000|568|585
SE|25462470||ab|2|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|872|596|606
SE|25462470||ab|2|entity|C1280500|Effect|qlco|||effects|||0|872|607|614

SE|25462470|OBJECTIVE|ab|3|text|616|779|OBJECTIVE: To evaluate the sensory processing and motor development in preterm infants aged 4-6 months and compare performance data with their peers born at term.
SE|25462470|OBJECTIVE|ab|3|entity|C1327511|Sensory Process|ortf|||sensory processing|||0|1000|643|661
SE|25462470|OBJECTIVE|ab|3|entity|C0870919|Motor Development|orgf|||motor development|||0|1000|666|683
SE|25462470|OBJECTIVE|ab|3|entity|C0021294|Infant, Premature|aggp|||preterm infants|||0|983|687|702
SE|25462470|OBJECTIVE|ab|3|entity|C0439231|month|tmco|||months|||0|901|712|718
SE|25462470|OBJECTIVE|ab|3|entity|C0597198|Performance|inbe|||performance|||0|888|731|742
SE|25462470|OBJECTIVE|ab|3|entity|C1511726|Data|idcn|||data|||0|888|743|747
SE|25462470|OBJECTIVE|ab|3|entity|C0679739|peer|popg|||peers|||0|1000|759|764
SE|25462470|OBJECTIVE|ab|3|entity|C1515273|Term|tmco|||term|||0|1000|773|777
SE|25462470|OBJECTIVE|ab|3|relation|3|1|C0870919|Motor Development|orgf|orgf|||motor development|||0|1000|666|683|PREP|PROCESS_OF||684|686|6|1|C0021294|Infant, Premature|aggp,humn|humn|||preterm infants|||0|983|687|702
SE|25462470|OBJECTIVE|ab|3|relation|3|1|C1327511|Sensory Process|ortf|ortf|||sensory processing|||0|1000|643|661|PREP|PROCESS_OF||684|686|6|1|C0021294|Infant, Premature|aggp,humn|humn|||preterm infants|||0|983|687|702

SE|25462470|METHOD|ab|4|text|779|1026|METHOD: This was a cross-sectional and comparative study consisting of a group of preterm infants (n=15) and a group of term infants (n=15), assessed using the Test of Sensory Functions in Infants (TSFI) and the Alberta Infant Motor Scale (AIMS).
SE|25462470|METHOD|ab|4|entity|C0025663|Methods|inpr|||METHOD|||0|1000|779|785
SE|25462470|METHOD|ab|4|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|928|798|813
SE|25462470|METHOD|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|861|830|835
SE|25462470|METHOD|ab|4|entity|C0441833|Groups|inpr|||group|||0|1000|852|857
SE|25462470|METHOD|ab|4|entity|C0021294|Infant, Premature|aggp|||preterm infants|||0|983|861|876
SE|25462470|METHOD|ab|4|entity|C0441833|Groups|inpr|||group|||0|1000|890|895
SE|25462470|METHOD|ab|4|entity|C0456128|Term infant|fndg|||term infants|||0|983|899|911
SE|25462470|METHOD|ab|4|entity|C0039593|Testing|resa|||Test|||0|739|939|943
SE|25462470|METHOD|ab|4|entity|C0423552|Sensory function|ortf|||Sensory Functions|||0|739|947|964
SE|25462470|METHOD|ab|4|entity|C0021270|Infant|aggp|||Infants|||0|739|968|975
SE|25462470|METHOD|ab|4|entity|C1513492|Motor|idcn|||Motor|||0|824|1006|1011
SE|25462470|METHOD|ab|4|entity|C0183109|Infant scale|medd|||Infant Motor Scale|||0|824|999|1017
SE|25462470|METHOD|ab|4|relation|9|2|C0456128|Term infant|fndg|fndg|||term infants|||0|983|899|911|PREP|PROCESS_OF||965|967|2|1|C0021270|Infant|aggp,humn|humn|||Infants|||0|739|968|975

SE|25462470|RESULTS|ab|5|text|1026|1189|RESULTS: The results showed no significant association between motor performance on the AIMS scale (total score) and sensory processing in the TSFI (total score).
SE|25462470|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1026|1033
SE|25462470|RESULTS|ab|5|entity|C1274040|result|ftcn|||results|||0|966|1039|1046
SE|25462470|RESULTS|ab|5|entity|C0750502|Significant|idcn|||significant|||0|694|1057|1068
SE|25462470|RESULTS|ab|5|entity|C0870921|Motor Performance|orgf|||motor performance|||0|1000|1089|1106
SE|25462470|RESULTS|ab|5|entity|C1513492|Motor|idcn|||AIMS|||0|619|1114|1118
SE|25462470|RESULTS|ab|5|entity|C0183109|Infant scale|medd|||AIMS|||0|619|1114|1118
SE|25462470|RESULTS|ab|5|entity|C0439175|% of total|qnco|||total|||0|888|1126|1131
SE|25462470|RESULTS|ab|5|entity|C0449820|Score|qnco|||score|||0|888|1132|1137
SE|25462470|RESULTS|ab|5|entity|C1327511|Sensory Process|ortf|||sensory processing|||0|1000|1143|1161
SE|25462470|RESULTS|ab|5|entity|C0039593|Testing|resa|||TSFI|||0|724|1169|1173
SE|25462470|RESULTS|ab|5|entity|C0423552|Sensory function|ortf|||TSFI|||0|724|1169|1173
SE|25462470|RESULTS|ab|5|entity|C0021270|Infant|aggp|||TSFI|||0|724|1169|1173
SE|25462470|RESULTS|ab|5|entity|C0439175|% of total|qnco|||total|||0|888|1175|1180
SE|25462470|RESULTS|ab|5|entity|C0449820|Score|qnco|||score|||0|888|1181|1186
SE|25462470|RESULTS|ab|5|relation|7|1|C1327511|Sensory Process|ortf|ortf|||sensory processing|||0|1000|1143|1161|PREP|PROCESS_OF||1162|1164|2|1|C0021270|Infant|aggp,humn|humn|||TSFI|||0|724|1169|1173

SE|25462470|RESULTS|ab|6|text|1189|1362|However, all infants who scored abnormal in the total TSFI score, subdomain 1, and subdomain 5 presented motor performance at or below the 5th percentile on the AIMS scale.
SE|25462470|RESULTS|ab|6|entity|C0021270|Infant|aggp|||infants|||0|1000|1202|1209
SE|25462470|RESULTS|ab|6|entity|C0205161|Abnormal|ftcn|||abnormal|||0|1000|1221|1229
SE|25462470|RESULTS|ab|6|entity|C0439175|% of total|qnco|||total|||0|709|1237|1242
SE|25462470|RESULTS|ab|6|entity|C0039593|Testing|resa|||TSFI|||0|709|1243|1247
SE|25462470|RESULTS|ab|6|entity|C0423552|Sensory function|ortf|||TSFI|||0|709|1243|1247
SE|25462470|RESULTS|ab|6|entity|C0021270|Infant|aggp|||TSFI|||0|709|1243|1247
SE|25462470|RESULTS|ab|6|entity|C0150312|Present|qnco|||presented|||0|774|1284|1293
SE|25462470|RESULTS|ab|6|entity|C0870921|Motor Performance|orgf|||motor performance|||0|774|1294|1311
SE|25462470|RESULTS|ab|6|entity|C0542339|Inferior|spco|||below|||0|1000|1318|1323
SE|25462470|RESULTS|ab|6|entity|C0205439|Fifth|qnco|||5th|||0|888|1328|1331
SE|25462470|RESULTS|ab|6|entity|C1264641|Percentile|qnco|||percentile|||0|888|1332|1342
SE|25462470|RESULTS|ab|6|entity|C1513492|Motor|idcn|||AIMS|||0|619|1350|1354
SE|25462470|RESULTS|ab|6|entity|C0183109|Infant scale|medd|||AIMS|||0|619|1350|1354

SE|25462470|CONCLUSION|ab|7|text|1362|1684|CONCLUSION: Since all infants who presented definite alteration in tolerating tactile deep pressure and poor postural control are at risk of delayed gross motor development, there may be peculiarities not detected by the tests used that seem to establish some relationship between sensory processing and motor development.
SE|25462470|CONCLUSION|ab|7|entity|C0021270|Infant|aggp|||infants|||0|1000|1384|1391
SE|25462470|CONCLUSION|ab|7|entity|C0439544|Definite|qlco|||definite|||0|888|1406|1414
SE|25462470|CONCLUSION|ab|7|entity|C1515926|Alteration|idcn|||alteration|||0|888|1415|1425
SE|25462470|CONCLUSION|ab|7|entity|C0439815|Tactile|ftcn|||tactile|||0|775|1440|1447
SE|25462470|CONCLUSION|ab|7|entity|C0205125|Depth|spco|||deep|||0|775|1448|1452
SE|25462470|CONCLUSION|ab|7|entity|C0033095|Pressure- physical agent|phpr|||pressure|||0|775|1453|1461
SE|25462470|CONCLUSION|ab|7|entity|C0426976|Poor posture|fndg|||poor postural|||0|877|1466|1479
SE|25462470|CONCLUSION|ab|7|entity|C0243148|control|ftcn|||control|||0|877|1480|1487
SE|25462470|CONCLUSION|ab|7|entity|C1444641|At risk|qlco|||at risk|||0|1000|1492|1499
SE|25462470|CONCLUSION|ab|7|entity|C0439806|Gross|qnco|||gross|||0|861|1511|1516
SE|25462470|CONCLUSION|ab|7|entity|C1513492|Motor|idcn|||motor|||0|861|1517|1522
SE|25462470|CONCLUSION|ab|7|entity|C0424605|Developmental delay (disorder)|mobd|||delayed gross motor development|||0|861|1503|1534
SE|25462470|CONCLUSION|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1563|1566
SE|25462470|CONCLUSION|ab|7|entity|C0392366|Tests|inpr|||tests|||0|1000|1583|1588
SE|25462470|CONCLUSION|ab|7|entity|C0439849|Relationships|qlco|||relationship|||0|1000|1622|1634
SE|25462470|CONCLUSION|ab|7|entity|C1327511|Sensory Process|ortf|||sensory processing|||0|1000|1643|1661
SE|25462470|CONCLUSION|ab|7|entity|C0870919|Motor Development|orgf|||motor development|||0|1000|1666|1683


SE|25462471||ti|1|text|21|147|Risk for osteopenia and osteoporosis in institution-dwelling individuals with intellectual and/or developmental disabilities.
SE|25462471||ti|1|entity|C0035647|Risk|qlco|||Risk|||0|1000|21|25
SE|25462471||ti|1|entity|C0029453|Osteopenia|dsyn|||osteopenia|||0|1000|30|40
SE|25462471||ti|1|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|45|57
SE|25462471||ti|1|entity|C0018704|Health care facility|hcro,mnob|||institution|||0|851|61|72
SE|25462471||ti|1|entity|C0442519|Home environment|mnob|||dwelling|||0|851|73|81
SE|25462471||ti|1|entity|C0237401|Individual|humn|||individuals|||0|851|82|93
SE|25462471||ti|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|119|145
SE|25462471||ti|1|relation|3|1|C0029453|Osteopenia|dsyn|dsyn|||osteopenia|||0|1000|30|40|PREP|PROCESS_OF||58|60|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|851|82|93
SE|25462471||ti|1|relation|3|1|C0029456|Osteoporosis|dsyn|dsyn|||osteoporosis|||0|1000|45|57|PREP|PROCESS_OF||58|60|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|851|82|93

SE|25462471||ab|1|text|153|408|The purpose of this study was to investigate the prevalence of and contributing factors to osteopenia and osteoporosis among people with intellectual disabilities (ID) or/and developmental disabilities (DD) residing in a disability institution in Taiwan.
SE|25462471||ab|1|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|157|164
SE|25462471||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|173|178
SE|25462471||ab|1|entity|C1521761|Factor|ftcn|||factors|||0|827|233|240
SE|25462471||ab|1|entity|C0029453|Osteopenia|dsyn|||osteopenia|||0|1000|244|254
SE|25462471||ab|1|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|259|271
SE|25462471||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|278|284
SE|25462471||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|290|315
SE|25462471||ab|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|328|354
SE|25462471||ab|1|entity|C0231170|Disability NOS|patf|||disability|||0|888|374|384
SE|25462471||ab|1|entity|C0018704|Health care facility|hcro,mnob|||institution|||0|888|385|396
SE|25462471||ab|1|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|400|406
SE|25462471||ab|1|relation|4|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|290|315|PREP|PROCESS_OF||285|289|7|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|278|284
SE|25462471||ab|1|relation|6|1|C0029453|Osteopenia|dsyn|dsyn|||osteopenia|||0|1000|244|254|PREP|PROCESS_OF||272|277|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|278|284
SE|25462471||ab|1|relation|6|1|C0029456|Osteoporosis|dsyn|dsyn|||osteoporosis|||0|1000|259|271|PREP|PROCESS_OF||272|277|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|278|284

SE|25462471||ab|2|text|408|598|The present study was conducted at one disability institution in Taiwan and recruited 184 institutionalized residents with ID and/or DD (115 men and 69 women aged 18-72 years) for analysis.
SE|25462471||ab|2|entity|C0150312|Present|qnco|||present|||0|888|412|419
SE|25462471||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|420|425
SE|25462471||ab|2|entity|C0205447|One|qnco|||one|||0|851|443|446
SE|25462471||ab|2|entity|C0231170|Disability NOS|patf|||disability|||0|851|447|457
SE|25462471||ab|2|entity|C0018704|Health care facility|hcro,mnob|||institution|||0|851|458|469
SE|25462471||ab|2|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|473|479
SE|25462471||ab|2|entity|C0562359|Institutionalized|fndg|||institutionalized|||0|773|498|515
SE|25462471||ab|2|entity|C1549439|Resident|inpr|||residents|||0|773|516|525
SE|25462471||ab|2|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|531|533
SE|25462471||ab|2|entity|C0008073|Child Development Disorders|mobd|||DD|||0|1000|541|543
SE|25462471||ab|2|entity|C0025266|Male population group|popg|||men|||0|861|549|552
SE|25462471||ab|2|entity|C0043210|Woman|popg|||women|||0|861|560|565
SE|25462471||ab|2|entity|C0439234|year|tmco|||years|||0|827|577|582
SE|25462471||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|588|596
SE|25462471||ab|2|relation|9|1|C0018704|Health care facility|hcro,mnob|hcro|||institution|||0|851|458|469|PREP|LOCATION_OF||440|442|1|1|C0008972|Clinical Research|resa|resa|||study|||0|888|420|425

SE|25462471||ab|3|text|598|735|For all residents with ID and/or DD, information was obtained about their age, gender, level of ID, BMI, and bone mineral density (BMD).
SE|25462471||ab|3|entity|C1549439|Resident|inpr|||residents|||0|966|606|615
SE|25462471||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|621|623
SE|25462471||ab|3|entity|C0008073|Child Development Disorders|mobd|||DD|||0|1000|631|633
SE|25462471||ab|3|entity|C1533716|Information|idcn|||information|||0|1000|635|646
SE|25462471||ab|3|entity|C0001779|Age|orga|||age|||0|1000|672|675
SE|25462471||ab|3|entity|C0079399|Gender|orga|||gender|||0|1000|677|683
SE|25462471||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|694|696
SE|25462471||ab|3|entity|C1305855|Body mass index|clna|||BMI|||0|1000|698|701
SE|25462471||ab|3|entity|C0005938|Bone Density|lbtr|||bone mineral density|||0|1000|707|727

SE|25462471||ab|4|text|735|846|BMD is a measurement of calcium levels in bones that can estimate the risk of osteoporosis and bone fractures.
SE|25462471||ab|4|entity|C0005938|Bone Density|lbtr|||BMD|||0|1000|735|738
SE|25462471||ab|4|entity|C0242485|Measurement|ftcn|||measurement|||0|1000|744|755
SE|25462471||ab|4|entity|C0201925|Calcium measurement|lbpr|||calcium levels|||0|983|759|773
SE|25462471||ab|4|entity|C0262950|Skeletal bone|bpoc|||bones|||0|1000|777|782
SE|25462471||ab|4|entity|C0035647|Risk|qlco|||risk|||0|1000|805|809
SE|25462471||ab|4|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|813|825
SE|25462471||ab|4|entity|C0016658|Fracture|inpo|||bone fractures|||0|983|830|844
SE|25462471||ab|4|relation|4|4|C0005938|Bone Density|lbtr|lbtr|||BMD|||0|1000|735|738|NOM|PREDISPOSES||805|809|2|1|C0029456|Osteoporosis|dsyn|dsyn|||osteoporosis|||0|1000|813|825

SE|25462471||ab|5|text|846|1028|Bone tests were divided into three outcome categories based on their calcaneal BMD T-scores: Normal BMD, a T-score?-1; Osteopenia, -2.5?T-score<-1; and Osteoporosis, a T-score<-2.5.
SE|25462471||ab|5|entity|C1266909|Entire bony skeleton|bdsy|||Bone|||0|888|846|850
SE|25462471||ab|5|entity|C0392366|Tests|inpr|||tests|||0|888|851|856
SE|25462471||ab|5|entity|C0205449|Three|qnco|||three|||0|851|875|880
SE|25462471||ab|5|entity|C1274040|result|ftcn|||outcome|||0|851|881|888
SE|25462471||ab|5|entity|C0683312|Categories|inpr|||categories|||0|851|889|899
SE|25462471||ab|5|entity|C0006655|Bone structure of calcaneum|bpoc|||calcaneal|||0|883|915|924
SE|25462471||ab|5|entity|C0026162|Minerals|inch|||BMD|||0|883|925|928
SE|25462471||ab|5|entity|C1507318|BONE DENSITY T-SCORE|orga|||BMD T-scores|||0|883|925|937
SE|25462471||ab|5|entity|C0205307|Normal|qlco|||Normal|||0|916|939|945
SE|25462471||ab|5|entity|C0005938|Bone Density|lbtr|||BMD|||0|916|946|949
SE|25462471||ab|5|entity|C0449820|Score|qnco|||score|||0|827|955|960
SE|25462471||ab|5|entity|C0029453|Osteopenia|dsyn|||Osteopenia|||0|1000|965|975
SE|25462471||ab|5|entity|C0450346|2/5|qnco|||2.5|||0|824|978|981
SE|25462471||ab|5|entity|C0449820|Score|qnco|||score|||0|824|984|989
SE|25462471||ab|5|entity|C0029456|Osteoporosis|dsyn|||Osteoporosis|||0|1000|998|1010
SE|25462471||ab|5|entity|C0449820|Score|qnco|||score|||0|861|1016|1021
SE|25462471||ab|5|entity|C0450346|2/5|qnco|||2.5|||0|1000|1023|1026

SE|25462471||ab|6|text|1028|1162|The results revealed that 46.2% of cases were normal and that 27.7% and 26.1% of cases had osteopenia and osteoporosis, respectively.
SE|25462471||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1032|1039
SE|25462471||ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|1063|1068
SE|25462471||ab|6|entity|C0205307|Normal|qlco|||normal|||0|1000|1074|1080
SE|25462471||ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|1109|1114
SE|25462471||ab|6|entity|C0029453|Osteopenia|dsyn|||osteopenia|||0|1000|1119|1129
SE|25462471||ab|6|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|1134|1146

SE|25462471||ab|7|text|1162|1428|Multiple logistic regression analyses found that male gender (OR=2.482, 95% CI=1.04-5.93, p<0.05), age?40 years (OR=3.051, 95% CI=1.07-8.69, p<0.05) and being overweight/obese (OR=0.395, 95% CI=0.17-0.93, p<0.05) were more likely to be associated with osteoporosis.
SE|25462471||ab|7|entity|C0439064|Numerous|qnco|||Multiple|||0|905|1162|1170
SE|25462471||ab|7|entity|C0681925|logistic regression analysis|qnco,resa|||logistic regression analyses|||0|905|1171|1199
SE|25462471||ab|7|entity|C0024554|Male gender|orga|||male gender|||0|1000|1211|1222
SE|25462471||ab|7|entity|C0450316|1/5|qnco|||1.04-5|||0|875|1241|1247
SE|25462471||ab|7|entity|C1510829|Age-Years|tmco|||age?40 years|||0|901|1261|1273
SE|25462471||ab|7|entity|C0497406|Overweight|sosy|||overweight|||0|888|1321|1331
SE|25462471||ab|7|entity|C0028754|Obesity|dsyn|||obese|||0|888|1332|1337
SE|25462471||ab|7|entity|C0205172|More|ftcn|||more|||0|888|1380|1384
SE|25462471||ab|7|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|1414|1426
SE|25462471||ab|7|relation|7|6|C0024554|Male gender|orga|orga|||male gender|||0|1000|1211|1222|VERB|ASSOCIATED_WITH||1398|1408|1|1|C0029456|Osteoporosis|dsyn|dsyn|||osteoporosis|||0|1000|1414|1426

SE|25462471||ab|8|text|1428|1624|Another model indicated that males (OR=2.169, 95% CI=1.12-4.19, p<0.05) and those aged?40 years (OR=3.026, 95% CI=1.32-7, p<0.01) tended to have an increased risk for osteopenia and osteoporosis.
SE|25462471||ab|8|entity|C0026336|Study models|inpr,resd|||model|||0|1000|1436|1441
SE|25462471||ab|8|entity|C0024554|Male gender|orga|||males|||0|1000|1457|1462
SE|25462471||ab|8|entity|C1510829|Age-Years|tmco|||aged?40 years|||0|877|1510|1523
SE|25462471||ab|8|entity|C0205217|Increased|qnco|||increased|||0|888|1576|1585
SE|25462471||ab|8|entity|C0035647|Risk|qlco|||risk|||0|888|1586|1590
SE|25462471||ab|8|entity|C0029453|Osteopenia|dsyn|||osteopenia|||0|1000|1595|1605
SE|25462471||ab|8|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|1610|1622
SE|25462471||ab|8|relation|5|4|C0024554|Male gender|orga|orga|||males|||0|1000|1457|1462|NOM|PREDISPOSES||1586|1590|2|1|C0029453|Osteopenia|dsyn|dsyn|||osteopenia|||0|1000|1595|1605
SE|25462471||ab|8|relation|5|4|C0024554|Male gender|orga|orga|||males|||0|1000|1457|1462|NOM|PREDISPOSES||1586|1590|2|1|C0029456|Osteoporosis|dsyn|dsyn|||osteoporosis|||0|1000|1610|1622

SE|25462471||ab|9|text|1624|1883|To improve the bone quality of individuals with ID or/and DD and to decrease the occurrence of osteopenia and osteoporosis, this study highlights that we should pay much attention to the potential risk factors for bone quality in these vulnerable populations.
SE|25462471||ab|9|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|888|1639|1643
SE|25462471||ab|9|entity|C0332306|Quality|qlco|||quality|||0|888|1644|1651
SE|25462471||ab|9|entity|C0237401|Individual|humn|||individuals|||0|1000|1655|1666
SE|25462471||ab|9|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1672|1674
SE|25462471||ab|9|entity|C0008073|Child Development Disorders|mobd|||DD|||0|1000|1682|1684
SE|25462471||ab|9|entity|C0243132|occurrence|qnco|||occurrence|||0|1000|1705|1715
SE|25462471||ab|9|entity|C0029453|Osteopenia|dsyn|||osteopenia|||0|1000|1719|1729
SE|25462471||ab|9|entity|C0029456|Osteoporosis|dsyn|||osteoporosis|||0|1000|1734|1746
SE|25462471||ab|9|entity|C0008972|Clinical Research|resa|||study|||0|1000|1753|1758
SE|25462471||ab|9|entity|C0004268|Attention|menp|||attention|||0|1000|1794|1803
SE|25462471||ab|9|entity|C0237399|Potential|qlco|||potential|||0|901|1811|1820
SE|25462471||ab|9|entity|C0035648|risk factors|qnco|||risk factors|||0|901|1821|1833
SE|25462471||ab|9|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|888|1838|1842
SE|25462471||ab|9|entity|C0332306|Quality|qlco|||quality|||0|888|1843|1850
SE|25462471||ab|9|entity|C0949366|Vulnerable Populations|popg|||vulnerable populations|||0|1000|1860|1882
SE|25462471||ab|9|relation|4|1|C0008073|Child Development Disorders|mobd|mobd|||DD|||0|1000|1682|1684|VERB|AFFECTS||1692|1700|8|2|C0029453|Osteopenia|dsyn|dsyn|||osteopenia|||0|1000|1719|1729
SE|25462471||ab|9|relation|4|1|C0008073|Child Development Disorders|mobd|mobd|||DD|||0|1000|1682|1684|VERB|AFFECTS||1692|1700|8|2|C0029456|Osteoporosis|dsyn|dsyn|||osteoporosis|||0|1000|1734|1746
SE|25462471||ab|9|relation|10|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1672|1674|PREP|PROCESS_OF||1667|1671|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1655|1666
SE|25462471||ab|9|relation|11|3|C0004268|Attention|menp|menp|||attention|||0|1000|1794|1803|PREP|PROCESS_OF||1851|1853|1|1|C0949366|Vulnerable Populations|popg,humn|humn|||vulnerable populations|||0|1000|1860|1882


SE|25462472||ti|1|text|21|95|Predictive validity of kindergarten assessments on handwriting readiness.
SE|25462472||ti|1|entity|C0681898|predictive validity|qlco,resa|||Predictive validity|||0|1000|21|40
SE|25462472||ti|1|entity|C0681406|kindergarten|inpr|||kindergarten|||0|872|44|56
SE|25462472||ti|1|entity|C0220825|Evaluation|ftcn|||assessments|||0|872|57|68
SE|25462472||ti|1|entity|C0018582|Handwriting|acty|||handwriting|||0|888|72|83
SE|25462472||ti|1|entity|C1318963|Readiness|fndg|||readiness|||0|888|84|93

SE|25462472||ab|1|text|101|335|We investigated the predictive value of a new kindergarten assessment of handwriting readiness on handwriting performance in first grade as evaluated by the Systematic Screening for Handwriting Difficulties (Dutch abbreviation: SOS).
SE|25462472||ab|1|entity|C1514307|Predictive Value|qlco|||predictive value|||0|1000|121|137
SE|25462472||ab|1|entity|C0205314|New|tmco|||new|||0|851|143|146
SE|25462472||ab|1|entity|C0681406|kindergarten|inpr|||kindergarten|||0|851|147|159
SE|25462472||ab|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|851|160|170
SE|25462472||ab|1|entity|C0018582|Handwriting|acty|||handwriting|||0|888|174|185
SE|25462472||ab|1|entity|C1318963|Readiness|fndg|||readiness|||0|888|186|195
SE|25462472||ab|1|entity|C0018582|Handwriting|acty|||handwriting|||0|888|199|210
SE|25462472||ab|1|entity|C0597198|Performance|inbe|||performance|||0|888|211|222
SE|25462472||ab|1|entity|C1279901|Firstly|qlco|||first|||0|888|226|231
SE|25462472||ab|1|entity|C0220922|systematic|ftcn|||Systematic|||0|888|258|268
SE|25462472||ab|1|entity|C0220908|Screening procedure|hlca|||Screening|||0|888|269|278
SE|25462472||ab|1|entity|C0018582|Handwriting|acty|||Handwriting|||0|872|283|294
SE|25462472||ab|1|entity|C0000723|Abbreviations|inpr|||abbreviation|||0|861|315|327

SE|25462472||ab|2|text|335|550|The kindergarten assessment consisted of the Writing Readiness Inventory Tool In Context (WRITIC), the Beery-Buktenica Developmental Test of Visual-Motor Integration (BeeryTMVMI) and the Nine-Hole Peg Test (9-HPT).
SE|25462472||ab|2|entity|C0681406|kindergarten|inpr|||kindergarten|||0|888|339|351
SE|25462472||ab|2|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|352|362
SE|25462472||ab|2|entity|C0043266|Writing|ocdi|||Writing|||0|712|380|387
SE|25462472||ab|2|entity|C1318963|Readiness|fndg|||Readiness|||0|712|388|397
SE|25462472||ab|2|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|712|398|407
SE|25462472||ab|2|entity|C0336791|Tool|mnob|||Tool|||0|712|408|412
SE|25462472||ab|2|entity|C0004922|Beer|food|||Beery|||0|751|438|443
SE|25462472||ab|2|entity|C0458003|Developmental|qlco|||Developmental|||0|751|454|467
SE|25462472||ab|2|entity|C0039593|Testing|resa|||Test|||0|751|468|472
SE|25462472||ab|2|entity|C0234621|Visual|ftcn|||Visual|||0|623|476|482
SE|25462472||ab|2|entity|C1513492|Motor|idcn|||Motor|||0|623|483|488
SE|25462472||ab|2|entity|C0451335|Nine hole peg test|inpr|||Nine-Hole Peg Test|||0|1000|522|540

SE|25462472||ab|3|text|550|770|The WRITIC evaluates in kindergarten children (aged 5-6 years) prewriting skills, the BeeryTMVMI and 9-HPT evaluate visual motor integration and fine-motor coordination, all elements important for handwriting readiness.
SE|25462472||ab|3|entity|C0043266|Writing|ocdi|||WRITIC|||0|733|554|560
SE|25462472||ab|3|entity|C1318963|Readiness|fndg|||WRITIC|||0|733|554|560
SE|25462472||ab|3|entity|C0021941|Equipment and supply inventories|mnob|||WRITIC|||0|733|554|560
SE|25462472||ab|3|entity|C0336791|Tool|mnob|||WRITIC|||0|733|554|560
SE|25462472||ab|3|entity|C0681406|kindergarten|inpr|||kindergarten|||0|888|574|586
SE|25462472||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|888|587|595
SE|25462472||ab|3|entity|C1510829|Age-Years|tmco|||aged 5-6 years|||0|867|597|611
SE|25462472||ab|3|entity|C0678856|skills|inbe|||skills|||0|861|624|630
SE|25462472||ab|3|entity|C0234621|Visual|ftcn|||visual|||0|623|666|672
SE|25462472||ab|3|entity|C1513492|Motor|idcn|||motor|||0|623|673|678
SE|25462472||ab|3|entity|C1299705|Fine motor coordination|orgf|||fine-motor coordination|||0|1000|695|718
SE|25462472||ab|3|entity|C0013879|Elements|elii|||elements|||0|1000|724|732
SE|25462472||ab|3|entity|C0018582|Handwriting|acty|||handwriting|||0|888|747|758
SE|25462472||ab|3|entity|C1318963|Readiness|fndg|||readiness|||0|888|759|768

SE|25462472||ab|4|text|770|979|In kindergarten, 109 children (55 boys; mean age 70 months, SD 4.8 months) were tested with the WRITIC, BeeryTMVMI and 9-HPT and one year later in first grade (mean age 85 months, SD 4.5 months) with the SOS.
SE|25462472||ab|4|entity|C0681406|kindergarten|inpr|||kindergarten|||0|1000|773|785
SE|25462472||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|861|791|799
SE|25462472||ab|4|entity|C0870221|Boys|popg|||boys|||0|861|804|808
SE|25462472||ab|4|entity|C1510828|Age-Months|orga|||age 70 months|||0|875|815|828
SE|25462472||ab|4|entity|C0439231|month|tmco|||months|||0|791|837|843
SE|25462472||ab|4|entity|C0043266|Writing|ocdi|||WRITIC|||0|712|866|872
SE|25462472||ab|4|entity|C1318963|Readiness|fndg|||WRITIC|||0|712|866|872
SE|25462472||ab|4|entity|C0021941|Equipment and supply inventories|mnob|||WRITIC|||0|712|866|872
SE|25462472||ab|4|entity|C0336791|Tool|mnob|||WRITIC|||0|712|866|872
SE|25462472||ab|4|entity|C0205447|One|qnco|||one|||0|888|899|902
SE|25462472||ab|4|entity|C0439234|year|tmco|||year|||0|888|903|907
SE|25462472||ab|4|entity|C0205087|Late|tmco|||later|||0|966|908|913
SE|25462472||ab|4|entity|C1279901|Firstly|qlco|||first|||0|888|917|922
SE|25462472||ab|4|entity|C1510828|Age-Months|orga|||age 85 months|||0|875|935|948
SE|25462472||ab|4|entity|C0439231|month|tmco|||months|||0|791|957|963

SE|25462472||ab|5|text|979|1238|A multivariable linear mixed model was used to identify variables that independently predict outcomes in first grade (SOS): baseline scores on WRITIC-TP, BeeryTMVMI, 9-HPT, 'sustained attention,' 'gender,' 'age' and 'intervention' in the intermediate period.
SE|25462472||ab|5|entity|C0205430|Mixed|ftcn|||mixed|||0|824|1002|1007
SE|25462472||ab|5|entity|C0023732|Linear Models|qnco|||linear mixed model|||0|824|995|1013
SE|25462472||ab|5|entity|C0439828|Variable|qlco|||variables|||0|966|1035|1044
SE|25462472||ab|5|entity|C1274040|result|ftcn|||outcomes|||0|966|1072|1080
SE|25462472||ab|5|entity|C1279901|Firstly|qlco|||first|||0|888|1084|1089
SE|25462472||ab|5|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1103|1111
SE|25462472||ab|5|entity|C0043266|Writing|ocdi|||WRITIC|||0|724|1122|1128
SE|25462472||ab|5|entity|C1318963|Readiness|fndg|||WRITIC|||0|724|1122|1128
SE|25462472||ab|5|entity|C0021941|Equipment and supply inventories|mnob|||WRITIC|||0|724|1122|1128
SE|25462472||ab|5|entity|C0336791|Tool|mnob|||WRITIC|||0|724|1122|1128
SE|25462472||ab|5|entity|C0589099|Sustained attention|menp|||sustained attention|||0|1000|1153|1172
SE|25462472||ab|5|entity|C0079399|Gender|orga|||gender|||0|1000|1176|1182
SE|25462472||ab|5|entity|C0001779|Age|orga|||age|||0|1000|1186|1189
SE|25462472||ab|5|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|1196|1208
SE|25462472||ab|5|entity|C0205103|Intermediate|spco|||intermediate|||0|888|1217|1229
SE|25462472||ab|5|entity|C0439531|/period|tmco|||period|||0|888|1230|1236

SE|25462472||ab|6|text|1238|1400|The results showed that WRITIC-TP, BeeryTMVMI, and 9-HPT, 'sustained attention,' 'gender' and 'intervention' had all predictive value on the handwriting outcome.
SE|25462472||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1242|1249
SE|25462472||ab|6|entity|C0043266|Writing|ocdi|||WRITIC|||0|724|1262|1268
SE|25462472||ab|6|entity|C1318963|Readiness|fndg|||WRITIC|||0|724|1262|1268
SE|25462472||ab|6|entity|C0021941|Equipment and supply inventories|mnob|||WRITIC|||0|724|1262|1268
SE|25462472||ab|6|entity|C0336791|Tool|mnob|||WRITIC|||0|724|1262|1268
SE|25462472||ab|6|entity|C0589099|Sustained attention|menp|||sustained attention|||0|1000|1297|1316
SE|25462472||ab|6|entity|C0079399|Gender|orga|||gender|||0|1000|1320|1326
SE|25462472||ab|6|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|1333|1345
SE|25462472||ab|6|entity|C1514307|Predictive Value|qlco|||predictive value|||0|1000|1355|1371
SE|25462472||ab|6|entity|C0018582|Handwriting|acty|||handwriting|||0|888|1379|1390
SE|25462472||ab|6|entity|C1274040|result|ftcn|||outcome|||0|888|1391|1398

SE|25462472||ab|7|text|1400|1533|Thereby WRITIC-TP was the main predictor for outcome of SOS-Quality, and BeeryTMVMI and 9-HPT were the main predictors of SOS-Speed.
SE|25462472||ab|7|entity|C1318963|Readiness|fndg|||WRITIC|||0|749|1408|1414
SE|25462472||ab|7|entity|C0021941|Equipment and supply inventories|mnob|||WRITIC|||0|749|1408|1414
SE|25462472||ab|7|entity|C0336791|Tool|mnob|||WRITIC|||0|749|1408|1414
SE|25462472||ab|7|entity|C0205225|Primary|qlco|||main|||0|694|1426|1430
SE|25462472||ab|7|entity|C1274040|result|ftcn|||outcome|||0|1000|1445|1452
SE|25462472||ab|7|entity|C0332306|Quality|qlco|||Quality|||0|861|1460|1467
SE|25462472||ab|7|entity|C0205225|Primary|qlco|||main|||0|694|1503|1507

SE|25462472||ab|8|text|1533|1683|This kindergarten assessment of WRITIC-TP, BeeryTMVMI, and 9-HPT contributes to the detection of children at risk for developing handwriting problems.
SE|25462472||ab|8|entity|C0681406|kindergarten|inpr|||kindergarten|||0|888|1538|1550
SE|25462472||ab|8|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|1551|1561
SE|25462472||ab|8|entity|C0043266|Writing|ocdi|||WRITIC|||0|724|1565|1571
SE|25462472||ab|8|entity|C1318963|Readiness|fndg|||WRITIC|||0|724|1565|1571
SE|25462472||ab|8|entity|C0021941|Equipment and supply inventories|mnob|||WRITIC|||0|724|1565|1571
SE|25462472||ab|8|entity|C0336791|Tool|mnob|||WRITIC|||0|724|1565|1571
SE|25462472||ab|8|entity|C1511790|Detection|topp|||detection|||0|1000|1617|1626
SE|25462472||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1630|1638
SE|25462472||ab|8|entity|C1444641|At risk|qlco|||at risk|||0|1000|1639|1646
SE|25462472||ab|8|entity|C0018582|Handwriting|acty|||handwriting|||0|790|1662|1673
SE|25462472||ab|8|entity|C1546466|Problems|idcn|||problems|||0|790|1674|1682


SE|25462474||ti|1|text|21|174|Humeral external rotation handling by using the Bobath concept approach affects trunk extensor muscles electromyography in children with cerebral palsy.
SE|25462474||ti|1|entity|C0020164|Bone structure of humerus|bpoc|||Humeral|||0|658|21|28
SE|25462474||ti|1|entity|C0231462|Lateral rotation|ftcn|||external rotation|||0|658|29|46
SE|25462474||ti|1|entity|C0178566|concept|idcn|||concept|||0|790|76|83
SE|25462474||ti|1|entity|C0449445|Approach|spco|||approach|||0|790|84|92
SE|25462474||ti|1|entity|C1280632|Entire trunk|bpoc|||trunk|||0|852|101|106
SE|25462474||ti|1|entity|C0682594|Extensor muscle|tisu|||extensor muscles|||0|852|107|123
SE|25462474||ti|1|entity|C0013839|Electromyography|diap|||electromyography|||0|852|124|140
SE|25462474||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|144|152
SE|25462474||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|158|172
SE|25462474||ti|1|relation|0|0|C0682594|Extensor muscle|tisu|tisu|||extensor muscles|||0|852|107|123|MOD/HEAD|LOCATION_OF||107|140|0|0|C0013839|Electromyography|diap|diap|||electromyography|||0|852|124|140
SE|25462474||ti|1|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|158|172|PREP|PROCESS_OF||153|157|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|144|152

SE|25462474||ab|1|text|180|369|This study aimed to investigate the electromyographic activity of cervical and trunk extensors muscles in children with cerebral palsy during two handlings according to the Bobath concept.
SE|25462474||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|185|190
SE|25462474||ab|1|entity|C0205064|Cervical|spco|||cervical|||0|1000|246|254
SE|25462474||ab|1|entity|C1280632|Entire trunk|bpoc|||trunk|||0|879|259|264
SE|25462474||ab|1|entity|C0682594|Extensor muscle|tisu|||extensors muscles|||0|879|265|282
SE|25462474||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|286|294
SE|25462474||ab|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|300|314
SE|25462474||ab|1|entity|C0205448|Two|qnco|||two|||0|694|322|325
SE|25462474||ab|1|entity|C0178566|concept|idcn|||concept|||0|861|360|367
SE|25462474||ab|1|relation|0|0|C0682594|Extensor muscle|tisu|tisu|||extensors muscles|||0|879|265|282|MOD/HEAD|PART_OF||259|282|0|0|C1280632|Entire trunk|bpoc|bpoc|||trunk|||0|879|259|264
SE|25462474||ab|1|relation|3|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|300|314|PREP|PROCESS_OF||295|299|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|286|294

SE|25462474||ab|2|text|369|441|A crossover trial involving 40 spastic diplegic children was conducted.
SE|25462474||ab|2|entity|C0150097|Cross-Over Studies|resa|||crossover trial|||0|1000|371|386
SE|25462474||ab|2|entity|C0023882|Little's Disease|dsyn|||spastic diplegic|||0|843|400|416
SE|25462474||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|843|417|425
SE|25462474||ab|2|relation|0|0|C0023882|Little's Disease|dsyn|dsyn|||spastic diplegic|||0|843|400|416|MOD/HEAD|PROCESS_OF||400|425|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|843|417|425

SE|25462474||ab|3|text|441|682|Electromyography (EMG) was used to measure muscular activity at sitting position (SP), during shoulder internal rotation (IR) and shoulder external rotation (ER) handlings, which were performed using the elbow joint as key point of control.
SE|25462474||ab|3|entity|C0013839|Electromyography|diap|||Electromyography|||0|1000|441|457
SE|25462474||ab|3|entity|C0231484|Muscle function|ortf|||muscular activity|||0|1000|484|501
SE|25462474||ab|3|entity|C0277814|Sitting position|fndg|||sitting position|||0|1000|505|521
SE|25462474||ab|3|entity|C0037004|Shoulder|bpoc|||shoulder|||0|901|535|543
SE|25462474||ab|3|entity|C0231459|Medial rotation|ftcn|||internal rotation|||0|901|544|561
SE|25462474||ab|3|entity|C0037004|Shoulder|bpoc|||shoulder|||0|658|571|579
SE|25462474||ab|3|entity|C0231462|Lateral rotation|ftcn|||external rotation|||0|658|580|597
SE|25462474||ab|3|entity|C1275495|Entire elbow joint|bsoj|||elbow joint|||0|1000|645|656
SE|25462474||ab|3|entity|C1554080|Key|idcn|||key|||0|694|660|663
SE|25462474||ab|3|entity|C0243148|control|ftcn|||control|||0|1000|673|680
SE|25462474||ab|3|relation|1|1|C0013839|Electromyography|diap|diap|||Electromyography|||0|1000|441|457|VERB|MEASURES||476|483|7|1|C0231484|Muscle function|ortf|ortf|||muscular activity|||0|1000|484|501

SE|25462474||ab|4|text|682|793|Muscle recordings were performed at the fourth cervical (C4) and at the tenth thoracic (T10) vertebral levels.
SE|25462474||ab|4|entity|C0026845|Muscle|tisu|||Muscle|||0|694|682|688
SE|25462474||ab|4|entity|C0205438|Fourth|qnco|||fourth|||0|1000|722|728
SE|25462474||ab|4|entity|C0205064|Cervical|spco|||cervical|||0|1000|729|737
SE|25462474||ab|4|entity|C0205444|Tenth|qnco|||tenth|||0|888|754|759
SE|25462474||ab|4|entity|C0817096|Chest|blor|||thoracic|||0|888|760|768
SE|25462474||ab|4|entity|C1179694|T10|blor|||T10|||0|1000|770|773
SE|25462474||ab|4|entity|C0446409|Vertebral level|blor|||vertebral levels|||0|983|775|791

SE|25462474||ab|5|text|793|945|The Gross Motor Function Classification System (GMFCS) was used to assess whether muscle activity would vary according to different levels of severity.
SE|25462474||ab|5|entity|C0677549|Gross motor functions|orgf|||Gross Motor Function|||0|885|797|817
SE|25462474||ab|5|entity|C0008902|Classification|clas|||Classification System|||0|885|818|839
SE|25462474||ab|5|entity|C0231484|Muscle function|ortf|||muscle activity|||0|964|875|890
SE|25462474||ab|5|entity|C1547020|*Difference|qnco|||different|||0|853|915|924
SE|25462474||ab|5|entity|C0441889|Levels|inpr|||levels|||0|853|925|931
SE|25462474||ab|5|entity|C0439793|Severities|qlco|||severity|||0|1000|935|943

SE|25462474||ab|6|text|945|1081|Humeral ER handling induced an increase on EMG signal of trunk extensor muscles at the C4 (P=0.007) and T10 (P<0.001) vertebral levels.
SE|25462474||ab|6|entity|C0020164|Bone structure of humerus|bpoc|||Humeral|||0|658|945|952
SE|25462474||ab|6|entity|C0231462|Lateral rotation|ftcn|||ER|||0|658|953|955
SE|25462474||ab|6|entity|C0442805|Increase|ftcn|||increase|||0|1000|976|984
SE|25462474||ab|6|entity|C0013839|Electromyography|diap|||EMG|||0|694|988|991
SE|25462474||ab|6|entity|C1280632|Entire trunk|bpoc|||trunk|||0|890|1002|1007
SE|25462474||ab|6|entity|C0682594|Extensor muscle|tisu|||extensor muscles|||0|890|1008|1024
SE|25462474||ab|6|entity|C1179694|T10|blor|||T10|||0|1000|1049|1052
SE|25462474||ab|6|entity|C0446409|Vertebral level|blor|||vertebral levels|||0|983|1063|1079
SE|25462474||ab|6|relation|0|0|C0682594|Extensor muscle|tisu|tisu|||extensor muscles|||0|890|1008|1024|MOD/HEAD|PART_OF||1002|1024|0|0|C1280632|Entire trunk|bpoc|bpoc|||trunk|||0|890|1002|1007

SE|25462474||ab|7|text|1081|1254|No significant effects were observed between SP and humeral IR handling at C4 level; However at T10 region, humeral IR handling induced an increase of EMG signal (P=0.019).
SE|25462474||ab|7|entity|C0750502|Significant|idcn|||significant|||0|872|1084|1095
SE|25462474||ab|7|entity|C1280500|Effect|qlco|||effects|||0|872|1096|1103
SE|25462474||ab|7|entity|C0277814|Sitting position|fndg|||SP|||0|1000|1126|1128
SE|25462474||ab|7|entity|C0020164|Bone structure of humerus|bpoc|||humeral|||0|658|1133|1140
SE|25462474||ab|7|entity|C0231459|Medial rotation|ftcn|||IR|||0|658|1141|1143
SE|25462474||ab|7|entity|C0446414|Level of the fourth cervical vertebra|blor|||C4 level|||0|1000|1156|1164
SE|25462474||ab|7|entity|C1179694|T10|blor|||T10|||0|888|1177|1180
SE|25462474||ab|7|entity|C0205147|Region|spco|||region|||0|888|1181|1187
SE|25462474||ab|7|entity|C0020164|Bone structure of humerus|bpoc|||humeral|||0|658|1189|1196
SE|25462474||ab|7|entity|C0231459|Medial rotation|ftcn|||IR|||0|658|1197|1199
SE|25462474||ab|7|entity|C0442805|Increase|ftcn|||increase|||0|1000|1220|1228
SE|25462474||ab|7|entity|C0013839|Electromyography|diap|||EMG|||0|694|1232|1235
SE|25462474||ab|7|relation|5|1|C0446414|Level of the fourth cervical vertebra|blor|blor|||C4 level|||0|1000|1156|1164|PREP|LOCATION_OF||1153|1155|3|2|C0277814|Sitting position|fndg|fndg|||SP|||0|1000|1126|1128

SE|25462474||ab|8|text|1254|1370|Humeral ER resulted in an increase of EMG signal at both levels, suggesting increase of extensor muscle activation.
SE|25462474||ab|8|entity|C0020164|Bone structure of humerus|bpoc|||Humeral|||0|901|1254|1261
SE|25462474||ab|8|entity|C0231462|Lateral rotation|ftcn|||ER|||0|901|1262|1264
SE|25462474||ab|8|entity|C0442805|Increase|ftcn|||increase|||0|1000|1280|1288
SE|25462474||ab|8|entity|C0013839|Electromyography|diap|||EMG|||0|694|1292|1295
SE|25462474||ab|8|entity|C0441889|Levels|inpr|||levels|||0|1000|1311|1317
SE|25462474||ab|8|entity|C0442805|Increase|ftcn|||increase|||0|1000|1330|1338
SE|25462474||ab|8|entity|C0682594|Extensor muscle|tisu|||extensor muscle|||0|734|1342|1357

SE|25462474||ab|9|text|1370|1520|Furthermore, the humeral ER handling caused different responses on EMG signal at T10 vertebra level, according to the GMFCS classification (P=0.017).
SE|25462474||ab|9|entity|C0020164|Bone structure of humerus|bpoc|||humeral|||0|735|1387|1394
SE|25462474||ab|9|entity|C0231462|Lateral rotation|ftcn|||ER|||0|735|1395|1397
SE|25462474||ab|9|entity|C0015127|Etiology aspects|ftcn|||caused|||0|735|1407|1413
SE|25462474||ab|9|entity|C1547020|*Difference|qnco|||different|||0|735|1414|1423
SE|25462474||ab|9|entity|C0871261|response|clna|||responses|||0|735|1424|1433
SE|25462474||ab|9|entity|C0013839|Electromyography|diap|||EMG|||0|694|1437|1440
SE|25462474||ab|9|entity|C0549207|Bone structure of spine|bpoc|||vertebra|||0|901|1455|1463
SE|25462474||ab|9|entity|C0446428|Level of the tenth thoracic vertebra|blor|||T10 vertebra level|||0|901|1451|1469
SE|25462474||ab|9|entity|C0677549|Gross motor functions|orgf|||GMFCS|||0|665|1488|1493
SE|25462474||ab|9|entity|C0008902|Classification|clas|||GMFCS|||0|665|1488|1493

SE|25462474||ab|10|text|1520|1661|In summary, an increase of EMG signal was observed during ER handling in both evaluated levels, suggesting an increase of muscle activation.
SE|25462474||ab|10|entity|C0442805|Increase|ftcn|||increase|||0|1000|1535|1543
SE|25462474||ab|10|entity|C0013839|Electromyography|diap|||EMG|||0|694|1547|1550
SE|25462474||ab|10|entity|C0231462|Lateral rotation|ftcn|||ER|||0|734|1578|1580
SE|25462474||ab|10|entity|C0441889|Levels|inpr|||levels|||0|861|1608|1614
SE|25462474||ab|10|entity|C0442805|Increase|ftcn|||increase|||0|1000|1630|1638
SE|25462474||ab|10|entity|C0026845|Muscle|tisu|||muscle|||0|694|1642|1648

SE|25462474||ab|11|text|1661|1854|These results indicate that humeral ER handling can be used for diplegic CP children rehabilitation to facilitate cervical and trunk extensor muscles activity in a GMFCS level-dependent manner.
SE|25462474||ab|11|entity|C1274040|result|ftcn|||results|||0|966|1667|1674
SE|25462474||ab|11|entity|C0020164|Bone structure of humerus|bpoc|||humeral|||0|658|1689|1696
SE|25462474||ab|11|entity|C0231462|Lateral rotation|ftcn|||ER|||0|658|1697|1699
SE|25462474||ab|11|entity|C0221165|Diplegia|dsyn|||diplegic|||0|561|1725|1733
SE|25462474||ab|11|entity|C0008059|Child|aggp,inpr|||children|||0|561|1737|1745
SE|25462474||ab|11|entity|C0205064|Cervical|spco|||cervical|||0|1000|1775|1783
SE|25462474||ab|11|entity|C1280632|Entire trunk|bpoc|||trunk|||0|852|1788|1793
SE|25462474||ab|11|entity|C0682594|Extensor muscle|tisu|||extensor muscles|||0|852|1794|1810
SE|25462474||ab|11|entity|C0677549|Gross motor functions|orgf|||GMFCS|||0|611|1825|1830
SE|25462474||ab|11|entity|C0008902|Classification|clas|||GMFCS|||0|611|1825|1830
SE|25462474||ab|11|relation|0|0|C0682594|Extensor muscle|tisu|tisu|||extensor muscles|||0|852|1794|1810|MOD/HEAD|PART_OF||1788|1810|0|0|C1280632|Entire trunk|bpoc|bpoc|||trunk|||0|852|1788|1793


SE|25462473||ti|1|text|21|96|Paroxysmal phenomena in severe disabled children with refractory seizures.
SE|25462473||ti|1|entity|C0205311|Paroxysmal|tmco|||Paroxysmal|||0|694|21|31
SE|25462473||ti|1|entity|C0205082|Severe|qlco|||severe|||0|901|45|51
SE|25462473||ti|1|entity|C0259916|Disabled Children|podg|||disabled children|||0|901|52|69
SE|25462473||ti|1|entity|C0205269|Intractable|ftcn|||refractory|||0|888|75|85
SE|25462473||ti|1|entity|C0036572|Seizures|sosy|||seizures|||0|888|86|94
SE|25462473||ti|1|relation|1|1|C0036572|Seizures|sosy|sosy|||seizures|||0|888|86|94|PREP|PROCESS_OF||70|74|2|1|C0259916|Disabled Children|podg,humn|humn|||disabled children|||0|901|52|69

SE|25462473||ti|2|text|96|174|From clinical to long-video-EEG processing data to re-examine suspect events.
SE|25462473||ti|2|entity|C0205210|Clinical|qlco|||clinical|||0|1000|101|109
SE|25462473||ti|2|entity|C0205166|Long|qlco|||long|||0|833|113|117
SE|25462473||ti|2|entity|C0430801|Video EEG|diap|||video-EEG|||0|833|118|127
SE|25462473||ti|2|entity|C1522240|Process|phpr|||processing|||0|833|128|138
SE|25462473||ti|2|entity|C1511726|Data|idcn|||data|||0|833|139|143
SE|25462473||ti|2|entity|C0750491|Suspected qualifier|idcn|||suspect|||0|888|158|165
SE|25462473||ti|2|entity|C0441471|Events|evnt|||events|||0|888|166|172

SE|25462473||ab|1|text|180|338|To provide an estimate of the occurrence of misdiagnosis in paroxysmal events in institutionalized children with severe disabilities and refractory epilepsy.
SE|25462473||ab|1|entity|C0243132|occurrence|qnco|||occurrence|||0|1000|210|220
SE|25462473||ab|1|entity|C0679838|misdiagnosis|fndg|||misdiagnosis|||0|1000|224|236
SE|25462473||ab|1|entity|C0205311|Paroxysmal|tmco|||paroxysmal|||0|888|240|250
SE|25462473||ab|1|entity|C0441471|Events|evnt|||events|||0|888|251|257
SE|25462473||ab|1|entity|C0008099|Child, Institutionalized|podg|||institutionalized children|||0|1000|261|287
SE|25462473||ab|1|entity|C0205082|Severe|qlco|||severe|||0|888|293|299
SE|25462473||ab|1|entity|C0231170|Disability NOS|patf|||disabilities|||0|888|300|312
SE|25462473||ab|1|entity|C0205269|Intractable|ftcn|||refractory|||0|888|317|327
SE|25462473||ab|1|entity|C0014544|Epilepsy|dsyn|||epilepsy|||0|888|328|336
SE|25462473||ab|1|relation|2|1|C0014544|Epilepsy|dsyn|dsyn|||epilepsy|||0|888|328|336|PREP|PROCESS_OF||288|292|5|1|C0008099|Child, Institutionalized|podg,humn|humn|||institutionalized children|||0|1000|261|287
SE|25462473||ab|1|relation|2|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|888|300|312|PREP|PROCESS_OF||288|292|5|1|C0008099|Child, Institutionalized|podg,humn|humn|||institutionalized children|||0|1000|261|287
SE|25462473||ab|1|relation|4|2|C0679838|misdiagnosis|fndg|fndg|||misdiagnosis|||0|1000|224|236|PREP|PROCESS_OF||258|260|3|1|C0008099|Child, Institutionalized|podg,humn|humn|||institutionalized children|||0|1000|261|287

SE|25462473||ab|2|text|338|469|A multi-step diagnostic survey, from observational to long-term video-EEG monitoring was performed in 46 severe disabled children.
SE|25462473||ab|2|entity|C1442112|MULTI|qnco|||multi|||0|833|340|345
SE|25462473||ab|2|entity|C1261552|Step|ftcn|||step|||0|833|346|350
SE|25462473||ab|2|entity|C0348026|Diagnostic|ftcn|||diagnostic|||0|833|351|361
SE|25462473||ab|2|entity|C0038951|Surveys|resa|||survey|||0|833|362|368
SE|25462473||ab|2|entity|C0443252|Long-term|tmco|||long-term|||0|893|392|401
SE|25462473||ab|2|entity|C0430801|Video EEG|diap|||video-EEG monitoring|||0|893|402|422
SE|25462473||ab|2|entity|C0205082|Severe|qlco|||severe|||0|824|443|449
SE|25462473||ab|2|entity|C0259916|Disabled Children|podg|||disabled children|||0|824|450|467
SE|25462473||ab|2|relation|3|1|C0430801|Video EEG|diap|diap|||video-EEG monitoring|||0|893|402|422|VERB|ADMINISTERED_TO||427|436|1|1|C0259916|Disabled Children|podg,humn|humn|||disabled children|||0|824|450|467

SE|25462473||ab|3|text|469|611|Multirater Kappa statistic was used to assess agreement between investigators and to individualize children who remained with dubious events.
SE|25462473||ab|3|entity|C0439099|Kappa|inpr|||Kappa|||0|660|480|485
SE|25462473||ab|3|entity|C0680240|Agreement|socb|||agreement|||0|1000|515|524
SE|25462473||ab|3|entity|C0035173|Research Personnel|prog|||investigators|||0|1000|533|546
SE|25462473||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|568|576
SE|25462473||ab|3|entity|C0441471|Events|evnt|||events|||0|861|603|609

SE|25462473||ab|4|text|611|737|Subsequently, prolonged EEG-video monitoring analysis was performed in selected children to define phenomena due to seizures.
SE|25462473||ab|4|entity|C0439590|Prolonged|tmco|||prolonged|||0|833|625|634
SE|25462473||ab|4|entity|C0441069|Video|mnob|||video|||0|833|639|644
SE|25462473||ab|4|entity|C0180585|Electroencephaloscopes|medd|||EEG-video monitoring|||0|833|635|655
SE|25462473||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|833|656|664
SE|25462473||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|872|691|699
SE|25462473||ab|4|entity|C0036572|Seizures|sosy|||seizures|||0|1000|727|735

SE|25462473||ab|5|text|737|878|A total of 128 video records were performed, 64 routine video-EEG and 27 long-monitoring video-EEG data were screened for detailed analysis.
SE|25462473||ab|5|entity|C0439175|% of total|qnco|||total|||0|1000|739|744
SE|25462473||ab|5|entity|C0205547|Routine|qlco|||routine|||0|824|785|792
SE|25462473||ab|5|entity|C0430801|Video EEG|diap|||video-EEG|||0|824|793|802
SE|25462473||ab|5|entity|C0205166|Long|qlco|||long|||0|762|810|814
SE|25462473||ab|5|entity|C0430801|Video EEG|diap|||video-EEG|||0|762|826|835
SE|25462473||ab|5|entity|C1511726|Data|idcn|||data|||0|762|836|840
SE|25462473||ab|5|entity|C1522508|Details|qlco|||detailed|||0|872|859|867
SE|25462473||ab|5|entity|C0936012|Analysis|resa|||analysis|||0|872|868|876

SE|25462473||ab|6|text|878|997|Thirty (21 female, 9 male) children (65%) with dubious seizures were identified by video records (concordance K=0.63).
SE|25462473||ab|6|entity|C0015780|Female|orga|||female|||0|861|889|895
SE|25462473||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|905|913
SE|25462473||ab|6|entity|C0036572|Seizures|sosy|||seizures|||0|861|933|941
SE|25462473||ab|6|entity|C0680240|Agreement|socb|||concordance|||0|888|976|987

SE|25462473||ab|7|text|997|1093|Of these, in 18 children (39%) seizures were excluded by routine video-EEG monitoring (K=0.86).
SE|25462473||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|861|1013|1021
SE|25462473||ab|7|entity|C0036572|Seizures|sosy|||seizures|||0|1000|1028|1036
SE|25462473||ab|7|entity|C0205547|Routine|qlco|||routine|||0|916|1054|1061
SE|25462473||ab|7|entity|C0430801|Video EEG|diap|||video-EEG monitoring|||0|916|1062|1082

SE|25462473||ab|8|text|1093|1174|Twelve children (26%) required accurate investigations with long-term video-EEG.
SE|25462473||ab|8|entity|C0205458|Twelve|qnco|||Twelve|||0|888|1093|1099
SE|25462473||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|888|1100|1108
SE|25462473||ab|8|entity|C0443131|Accurate|qlco|||accurate|||0|888|1124|1132
SE|25462473||ab|8|entity|C0443252|Long-term|tmco|||long-term|||0|888|1153|1162
SE|25462473||ab|8|entity|C0430801|Video EEG|diap|||video-EEG|||0|888|1163|1172

SE|25462473||ab|9|text|1174|1313|In 5 children (11%), 3 symptomatic and 2 cryptogenic, very short and subtle seizures were confirmed by investigators concordance (K=0.83).
SE|25462473||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|888|1179|1187
SE|25462473||ab|9|entity|C0231220|Symptomatic|ftcn|||symptomatic|||0|888|1197|1208
SE|25462473||ab|9|entity|C0332240|Unknown (origin)|ftcn|||cryptogenic|||0|775|1215|1226
SE|25462473||ab|9|entity|C0442824|Very|qlco|||very|||0|775|1228|1232
SE|25462473||ab|9|entity|C0036572|Seizures|sosy|||seizures|||0|861|1250|1258
SE|25462473||ab|9|entity|C0035173|Research Personnel|prog|||investigators|||0|888|1277|1290
SE|25462473||ab|9|entity|C0680240|Agreement|socb|||concordance|||0|888|1291|1302

SE|25462473||ab|10|text|1313|1495|Distinguishing paroxysmal phenomena is a challenge in children with severe disabilities; its most remarkable consequence is inappropriate pharmacological treatment and social costs.
SE|25462473||ab|10|entity|C0205311|Paroxysmal|tmco|||paroxysmal|||0|694|1328|1338
SE|25462473||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1367|1375
SE|25462473||ab|10|entity|C0205082|Severe|qlco|||severe|||0|888|1381|1387
SE|25462473||ab|10|entity|C0231170|Disability NOS|patf|||disabilities|||0|888|1388|1400
SE|25462473||ab|10|entity|C0205393|Most|qnco|||most|||0|587|1406|1410
SE|25462473||ab|10|entity|C1550002|Remark|idcn|||remarkable|||0|587|1411|1421
SE|25462473||ab|10|entity|C1548788|Inappropriate|qlco|||inappropriate|||0|901|1437|1450
SE|25462473||ab|10|entity|C1519033|Pharmacological Treatment|topp|||pharmacological treatment|||0|901|1451|1476
SE|25462473||ab|10|entity|C0728831|SOCIAL|ftcn|||social|||0|1000|1481|1487
SE|25462473||ab|10|relation|4|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|888|1388|1400|PREP|PROCESS_OF||1376|1380|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1367|1375

SE|25462473||ab|11|text|1495|1579|Our data suggest that the frequency of misdiagnosis could have been underestimated.
SE|25462473||ab|11|entity|C1511726|Data|idcn|||data|||0|1000|1499|1503
SE|25462473||ab|11|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|1521|1530
SE|25462473||ab|11|entity|C0679838|misdiagnosis|fndg|||misdiagnosis|||0|1000|1534|1546

SE|25462473||ab|12|text|1579|1715|The clinicians who manage children with severe disabilities and refractory epilepsy must remain alert to risk of an incorrect treatment.
SE|25462473||ab|12|entity|C0871685|Clinicians|prog|||clinicians|||0|1000|1583|1593
SE|25462473||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1605|1613
SE|25462473||ab|12|entity|C0205082|Severe|qlco|||severe|||0|888|1619|1625
SE|25462473||ab|12|entity|C0231170|Disability NOS|patf|||disabilities|||0|888|1626|1638
SE|25462473||ab|12|entity|C0205269|Intractable|ftcn|||refractory|||0|888|1643|1653
SE|25462473||ab|12|entity|C0014544|Epilepsy|dsyn|||epilepsy|||0|888|1654|1662
SE|25462473||ab|12|relation|4|1|C0014544|Epilepsy|dsyn|dsyn|||epilepsy|||0|888|1654|1662|PREP|PROCESS_OF||1614|1618|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1605|1613
SE|25462473||ab|12|relation|4|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|888|1626|1638|PREP|PROCESS_OF||1614|1618|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1605|1613


SE|25462475||ti|1|text|21|103|Digital memory encoding in Chinese dyscalculia: An event-related potential study.
SE|25462475||ti|1|entity|C0025260|Memory|menp|||memory|||0|660|29|35
SE|25462475||ti|1|entity|C0236824|Dyscalculia|mobd|||dyscalculia|||0|861|56|67
SE|25462475||ti|1|entity|C0282171|Potentials, Event-Related|fndg|||event-related potential|||0|908|72|95
SE|25462475||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|908|96|101

SE|25462475||ab|1|text|109|266|This study reports the neurophysiological and behavioral correlates of digital memory encoding features in Chinese individuals with and without dyscalculia.
SE|25462475||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|114|119
SE|25462475||ab|1|entity|C0025260|Memory|menp|||memory|||0|645|188|194
SE|25462475||ab|1|entity|C0237401|Individual|humn|||individuals|||0|861|224|235
SE|25462475||ab|1|entity|C0236824|Dyscalculia|mobd|||dyscalculia|||0|1000|253|264

SE|25462475||ab|2|text|266|462|Eighteen children with dyscalculia (ages 11.5-13.5) and 18 matched controls were tested, and their event-related potentials (ERPs) were digitally recorded simultaneously with behavioral measures.
SE|25462475||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|861|275|283
SE|25462475||ab|2|entity|C0236824|Dyscalculia|mobd|||dyscalculia|||0|1000|289|300
SE|25462475||ab|2|entity|C0001779|Age|orga|||ages|||0|771|302|306
SE|25462475||ab|2|entity|C0150103|MATCHING|resa|||matched|||0|756|325|332
SE|25462475||ab|2|entity|C0243148|control|ftcn|||controls|||0|756|333|341
SE|25462475||ab|2|entity|C0282171|Potentials, Event-Related|fndg|||event-related potentials|||0|1000|365|389
SE|25462475||ab|2|entity|C0079809|Measures|qnco|||measures|||0|861|452|460
SE|25462475||ab|2|relation|4|1|C0236824|Dyscalculia|mobd|mobd|||dyscalculia|||0|1000|289|300|PREP|PROCESS_OF||284|288|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|275|283

SE|25462475||ab|3|text|462|577|The results showed that both groups had a significant Dm effect, and this effect was greater in the control group.
SE|25462475||ab|3|entity|C1274040|result|ftcn|||results|||0|966|466|473
SE|25462475||ab|3|entity|C0441833|Groups|inpr|||groups|||0|1000|491|497
SE|25462475||ab|3|entity|C0750502|Significant|idcn|||significant|||0|802|504|515
SE|25462475||ab|3|entity|C1280500|Effect|qlco|||effect|||0|802|519|525
SE|25462475||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|536|542
SE|25462475||ab|3|entity|C0443228|Largest|qnco|||greater|||0|1000|547|554
SE|25462475||ab|3|entity|C0009932|Control Groups|grup|||control group|||0|1000|562|575

SE|25462475||ab|4|text|577|759|In the 300-400-ms, 400-500-ms, and 600-700-ms processing stages, both groups showed significant differences of digital memory encoding in the frontal, central, and parietal regions.
SE|25462475||ab|4|entity|C1522240|Process|phpr|||processing|||0|712|623|633
SE|25462475||ab|4|entity|C1306673|Stage|qlco|||stages|||0|712|634|640
SE|25462475||ab|4|entity|C0441833|Groups|inpr|||groups|||0|1000|647|653
SE|25462475||ab|4|entity|C0750502|Significant|idcn|||significant|||0|872|661|672
SE|25462475||ab|4|entity|C1547020|*Difference|qnco|||differences|||0|872|673|684
SE|25462475||ab|4|entity|C0025260|Memory|menp|||memory|||0|660|696|702
SE|25462475||ab|4|entity|C0205123|Coronal|spco|||frontal|||0|888|719|726
SE|25462475||ab|4|entity|C0205099|Central|spco|||central|||0|888|728|735
SE|25462475||ab|4|entity|C0030560|Parietal Lobe|bpoc|||parietal regions|||0|983|741|757

SE|25462475||ab|5|text|759|910|In the 500-600-ms period, the Dm effect in the control group was significantly greater than that in the dyscalculia group only in the parietal region.
SE|25462475||ab|5|entity|C0439531|/period|tmco|||period|||0|812|777|783
SE|25462475||ab|5|entity|C1280500|Effect|qlco|||effect|||0|861|792|798
SE|25462475||ab|5|entity|C0009932|Control Groups|grup|||control group|||0|1000|806|819
SE|25462475||ab|5|entity|C0443228|Largest|qnco|||greater|||0|861|838|845
SE|25462475||ab|5|entity|C0236824|Dyscalculia|mobd|||dyscalculia|||0|790|863|874
SE|25462475||ab|5|entity|C0441833|Groups|inpr|||group|||0|790|875|880
SE|25462475||ab|5|entity|C0030560|Parietal Lobe|bpoc|||parietal region|||0|1000|893|908

SE|25462475||ab|6|text|910|1057|These results suggest that individuals with dyscalculia exhibit impaired digital memory encoding and deficits in psychological resource allocation.
SE|25462475||ab|6|entity|C1274040|result|ftcn|||results|||0|966|916|923
SE|25462475||ab|6|entity|C0237401|Individual|humn|||individuals|||0|1000|937|948
SE|25462475||ab|6|entity|C0236824|Dyscalculia|mobd|||dyscalculia|||0|595|954|965
SE|25462475||ab|6|entity|C0015272|Exhibits|mnob|||exhibit|||0|595|966|973
SE|25462475||ab|6|entity|C0233794|Memory impairment|mobd|||impaired digital memory|||0|595|974|997
SE|25462475||ab|6|entity|C0011155|Deficiency|ftcn|||deficits|||0|966|1011|1019
SE|25462475||ab|6|entity|C0205486|Psychologic|ftcn|||psychological|||0|901|1023|1036
SE|25462475||ab|6|entity|C0086914|Resource Allocation|qnco|||resource allocation|||0|901|1037|1056


SE|25462476||ti|1|text|21|116|Learning of writing letter-like sequences in children with physical and multiple disabilities.
SE|25462476||ti|1|entity|C0023185|Learning|menp|||Learning|||0|1000|21|29
SE|25462476||ti|1|entity|C0043266|Writing|ocdi|||writing|||0|694|33|40
SE|25462476||ti|1|entity|C0162326|DNA Sequence|nnon,nusq|||sequences|||0|1000|53|62
SE|25462476||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|66|74
SE|25462476||ti|1|entity|C0205485|Physical|ftcn|||physical|||0|1000|80|88
SE|25462476||ti|1|entity|C0935560|Multiple disability|dsyn|||multiple disabilities|||0|1000|93|114
SE|25462476||ti|1|relation|3|3|C0023185|Learning|menp|menp|||Learning|||0|1000|21|29|PREP|PROCESS_OF||63|65|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|66|74

SE|25462476||ab|1|text|122|203|This study compared implicit and explicit learning instructions in hand writing.
SE|25462476||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|127|132
SE|25462476||ab|1|entity|C0023185|Learning|menp|||learning|||0|773|164|172
SE|25462476||ab|1|entity|C1186996|instruction|edac|||instructions|||0|773|173|185
SE|25462476||ab|1|entity|C0018563|Hand|bpoc|||hand|||0|888|189|193
SE|25462476||ab|1|entity|C0043266|Writing|ocdi|||writing|||0|888|194|201

SE|25462476||ab|2|text|203|322|Implicit learning is the ability to acquire a new skill without a corresponding increase in knowledge about the skill.
SE|25462476||ab|2|entity|C1510548|Implicit Learning|menp|||Implicit learning|||0|1000|203|220
SE|25462476||ab|2|entity|C0085732|Ability|orga|||ability|||0|1000|228|235
SE|25462476||ab|2|entity|C0205314|New|tmco|||new|||0|872|249|252
SE|25462476||ab|2|entity|C0678856|skills|inbe|||skill|||0|872|253|258
SE|25462476||ab|2|entity|C0442805|Increase|ftcn|||increase|||0|861|283|291
SE|25462476||ab|2|entity|C0376554|Knowledge|inpr|||knowledge|||0|1000|295|304
SE|25462476||ab|2|entity|C0678856|skills|inbe|||skill|||0|966|315|320

SE|25462476||ab|3|text|322|459|In contrast, explicit learning uses declarative knowledge to build up a set of performance rules that guide motor performance or skills.
SE|25462476||ab|3|entity|C0023185|Learning|menp|||learning|||0|861|344|352
SE|25462476||ab|3|entity|C0870394|Declarative Knowledge|qlco|||declarative knowledge|||0|673|358|379
SE|25462476||ab|3|entity|C0597198|Performance|inbe|||performance|||0|1000|401|412
SE|25462476||ab|3|entity|C0870921|Motor Performance|orgf|||motor performance|||0|901|430|447
SE|25462476||ab|3|entity|C0678856|skills|inbe|||skills|||0|1000|451|457

SE|25462476||ab|4|text|459|535|Explicit learning is dependent on working memory, implicit learning is not.
SE|25462476||ab|4|entity|C0023185|Learning|menp|||learning|||0|861|468|476
SE|25462476||ab|4|entity|C0025265|Memory, Short-Term|menp|||working memory|||0|1000|493|507
SE|25462476||ab|4|entity|C1510548|Implicit Learning|menp|||implicit learning|||0|1000|509|526
SE|25462476||ab|4|entity|C1518422|Not|ftcn|||not|||0|1000|530|533
SE|25462476||ab|4|relation|0|0|C0025265|Memory, Short-Term|menp|menp|||working memory|||0|1000|493|507|SPEC|ISA||468|507|0|0|C0023185|Learning|menp|menp|||learning|||0|861|468|476

SE|25462476||ab|5|text|535|696|Therefore, implicit learning was expected to be easier than explicit learning in children in special education, given their expected compromised working memory.
SE|25462476||ab|5|entity|C1510548|Implicit Learning|menp|||implicit learning|||0|1000|546|563
SE|25462476||ab|5|entity|C0332219|Easy|qlco|||easier|||0|966|583|589
SE|25462476||ab|5|entity|C0023185|Learning|menp|||learning|||0|861|604|612
SE|25462476||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|616|624
SE|25462476||ab|5|entity|C0013649|Special Education|edac|||special education|||0|1000|628|645
SE|25462476||ab|5|entity|C1517001|Expected|idcn|||expected|||0|852|659|667
SE|25462476||ab|5|entity|C0518076|Compromised work|fndg|||compromised working|||0|852|668|687
SE|25462476||ab|5|entity|C0025260|Memory|menp|||memory|||0|852|688|694
SE|25462476||ab|5|relation|3|1|C0023185|Learning|menp|menp|||learning|||0|861|604|612|PREP|PROCESS_OF||613|615|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|616|624

SE|25462476||ab|6|text|696|878|Two groups of children (5-12 years) participated, children in special education with physical or multiple disabilities (study group, n=22), and typically developing controls (n=32).
SE|25462476||ab|6|entity|C0205448|Two|qnco|||Two|||0|888|696|699
SE|25462476||ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|700|706
SE|25462476||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|710|718
SE|25462476||ab|6|entity|C0439084|>5|qnco|||5-12|||0|802|720|724
SE|25462476||ab|6|entity|C0439234|year|tmco|||years|||0|802|725|730
SE|25462476||ab|6|entity|C1518902|Participating|ftcn|||participated|||0|872|732|744
SE|25462476||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|872|746|754
SE|25462476||ab|6|entity|C0013649|Special Education|edac|||special education|||0|1000|758|775
SE|25462476||ab|6|entity|C0205485|Physical|ftcn|||physical|||0|1000|781|789
SE|25462476||ab|6|entity|C0935560|Multiple disability|dsyn|||multiple disabilities|||0|1000|793|814
SE|25462476||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|888|816|821
SE|25462476||ab|6|entity|C0441833|Groups|inpr|||group|||0|888|822|827
SE|25462476||ab|6|entity|C0243148|control|ftcn|||controls|||0|793|861|869

SE|25462476||ab|7|text|878|1018|Children learned to write letter-like patterns on a digitizer by tracking a moving target (implicitly) and verbal instruction (explicitly).
SE|25462476||ab|7|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|878|886
SE|25462476||ab|7|entity|C0449774|Patterns|spco|||patterns|||0|1000|916|924
SE|25462476||ab|7|entity|C1322783|Digitizers|medd|||digitizer|||0|966|930|939
SE|25462476||ab|7|entity|C0560560|Moving|orgf|||moving|||0|888|954|960
SE|25462476||ab|7|entity|C0439824|Verbal|orgf|||verbal|||0|888|985|991
SE|25462476||ab|7|entity|C1186996|instruction|edac|||instruction|||0|888|992|1003

SE|25462476||ab|8|text|1018|1113|We further tested visual working memory, visual-motor integration, and gross manual dexterity.
SE|25462476||ab|8|entity|C1517331|Further|spco|||further|||0|1000|1021|1028
SE|25462476||ab|8|entity|C0043227|Work|ocac|||working|||0|901|1043|1050
SE|25462476||ab|8|entity|C0542316|Visual memory|menp|||visual working memory|||0|901|1036|1057
SE|25462476||ab|8|entity|C0234621|Visual|ftcn|||visual|||0|623|1059|1065
SE|25462476||ab|8|entity|C1513492|Motor|idcn|||motor|||0|623|1066|1071
SE|25462476||ab|8|entity|C0439806|Gross|qnco|||gross|||0|851|1089|1094
SE|25462476||ab|8|entity|C0024763|Manuals|inpr,mnob|||manual|||0|851|1095|1101
SE|25462476||ab|8|entity|C0565699|Ability to perform general manipulative activities|fndg|||dexterity|||0|851|1102|1111

SE|25462476||ab|9|text|1113|1248|Learning curves were similar for both groups in both conditions; children in the study group did learn both implicitly and explicitly.
SE|25462476||ab|9|entity|C0023185|Learning|menp|||Learning|||0|847|1113|1121
SE|25462476||ab|9|entity|C0205134|Curved|spco|||curves|||0|847|1122|1128
SE|25462476||ab|9|entity|C0348080|Condition|qlco|||conditions|||0|966|1166|1176
SE|25462476||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1178|1186
SE|25462476||ab|9|entity|C0008972|Clinical Research|resa|||study|||0|888|1194|1199
SE|25462476||ab|9|entity|C0441833|Groups|inpr|||group|||0|888|1200|1205

SE|25462476||ab|10|text|1248|1299|Motor performance was related to the writing task.
SE|25462476||ab|10|entity|C0870921|Motor Performance|orgf|||Motor performance|||0|1000|1248|1265
SE|25462476||ab|10|entity|C0043266|Writing|ocdi|||writing|||0|888|1285|1292

SE|25462476||ab|11|text|1299|1407|In contrast to our hypothesis, visual working memory was not an important factor in the explicit condition.
SE|25462476||ab|11|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|1318|1328
SE|25462476||ab|11|entity|C0043227|Work|ocac|||working|||0|901|1337|1344
SE|25462476||ab|11|entity|C0542316|Visual memory|menp|||visual working memory|||0|901|1330|1351
SE|25462476||ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|1356|1359
SE|25462476||ab|11|entity|C1521761|Factor|ftcn|||factor|||0|861|1373|1379
SE|25462476||ab|11|entity|C0348080|Condition|qlco|||condition|||0|861|1396|1405

SE|25462476||ab|12|text|1407|1544|These results shed new light on the conceptual difference between implicit and explicit learning, and the role of working memory therein.
SE|25462476||ab|12|entity|C1274040|result|ftcn|||results|||0|966|1413|1420
SE|25462476||ab|12|entity|C0205314|New|tmco|||new|||0|888|1426|1429
SE|25462476||ab|12|entity|C0178566|concept|idcn|||conceptual|||0|853|1443|1453
SE|25462476||ab|12|entity|C1547020|*Difference|qnco|||difference|||0|853|1454|1464
SE|25462476||ab|12|entity|C0023185|Learning|menp|||learning|||0|861|1495|1503
SE|25462476||ab|12|entity|C0035820|Role|socb|||role|||0|1000|1513|1517
SE|25462476||ab|12|entity|C0025265|Memory, Short-Term|menp|||working memory|||0|901|1521|1535


SE|25462477||ti|1|text|21|126|Evaluation and characterization of manual reaching in children with cerebral palsy: A systematic review.
SE|25462477||ti|1|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|21|31
SE|25462477||ti|1|entity|C0024763|Manuals|inpr,mnob|||manual|||0|872|56|62
SE|25462477||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|75|83
SE|25462477||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|89|103
SE|25462477||ti|1|entity|C0220922|systematic|ftcn|||systematic|||0|694|107|117
SE|25462477||ti|1|relation|2|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|89|103|PREP|PROCESS_OF||84|88|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|75|83

SE|25462477||ab|1|text|132|225|Manual reaching is used daily to perform manipulative tasks and activities of daily routine.
SE|25462477||ab|1|entity|C0024763|Manuals|inpr,mnob|||Manual|||0|872|132|138
SE|25462477||ab|1|entity|C0332173|Daily|tmco|||daily|||0|1000|156|161
SE|25462477||ab|1|entity|C0441655|Activities|acty|||activities|||0|1000|196|206
SE|25462477||ab|1|entity|C0332173|Daily|tmco|||daily|||0|888|210|215
SE|25462477||ab|1|entity|C0205547|Routine|qlco|||routine|||0|888|216|223

SE|25462477||ab|2|text|225|342|Children with cerebral palsy (CP) have limitations in this activity, with functional loss as a possible consequence.
SE|25462477||ab|2|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|225|233
SE|25462477||ab|2|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|239|253
SE|25462477||ab|2|entity|C0449295|Limitation|ftcn|||limitations|||0|966|264|275
SE|25462477||ab|2|entity|C0205245|Functional|ftcn|||functional|||0|888|299|309
SE|25462477||ab|2|entity|C1517945|Loss|qnco|||loss|||0|888|310|314
SE|25462477||ab|2|entity|C0332149|Possible|qlco|||possible|||0|694|320|328
SE|25462477||ab|2|relation|5|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|239|253|PREP|PROCESS_OF||234|238|1|1|C0008059|Child|aggp,humn,inpr|humn|||Children|||0|1000|225|233

SE|25462477||ab|3|text|342|622|This review aimed to gather studies that evaluated and characterized manual reaching in children with CP, with the purpose of identifying the aspects analyzed, as well as review and discuss the results in the studies and its relationship to the children's level of functionality.
SE|25462477||ab|3|entity|C0024763|Manuals|inpr,mnob|||manual|||0|773|411|417
SE|25462477||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|430|438
SE|25462477||ab|3|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|444|446
SE|25462477||ab|3|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|457|464
SE|25462477||ab|3|entity|C0205396|Identified|qlco|||identifying|||0|966|468|479
SE|25462477||ab|3|entity|C1547011|Aspect|qnco|||aspects|||0|966|484|491
SE|25462477||ab|3|entity|C1274040|result|ftcn|||results|||0|966|536|543
SE|25462477||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|966|551|558
SE|25462477||ab|3|entity|C0439849|Relationships|qlco|||relationship|||0|1000|567|579
SE|25462477||ab|3|entity|C0008059|Child|aggp,inpr|||children's|||0|694|587|597
SE|25462477||ab|3|entity|C0205245|Functional|ftcn|||functionality|||0|928|607|620
SE|25462477||ab|3|relation|10|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|444|446|PREP|PROCESS_OF||439|443|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|430|438

SE|25462477||ab|4|text|622|715|17 studies were selected for this systematic review from the search in electronic databases.
SE|25462477||ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|827|625|632
SE|25462477||ab|4|entity|C0220922|systematic|ftcn|||systematic|||0|694|656|666
SE|25462477||ab|4|entity|C1552603|search|idcn|||search|||0|1000|683|689
SE|25462477||ab|4|entity|C0242356|Databases|inpr|||electronic databases|||0|983|693|713

SE|25462477||ab|5|text|715|1061|The studies showed that children with CP show deficits in several spatio-temporal variables of reaching compared to typical children, such as longer time to perform the activity, higher peak velocity, lower index of curvature, and greater number of units of motion, which indicates lower smoothness and linearity of the movements of upper limbs.
SE|25462477||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|966|719|726
SE|25462477||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|739|747
SE|25462477||ab|5|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|753|755
SE|25462477||ab|5|entity|C0011155|Deficiency|ftcn|||deficits|||0|966|761|769
SE|25462477||ab|5|entity|C0443302|Several|qnco|||several|||0|764|773|780
SE|25462477||ab|5|entity|C0442043|temporal|spco|||temporal|||0|764|788|796
SE|25462477||ab|5|entity|C0439828|Variable|qlco|||variables|||0|764|797|806
SE|25462477||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|861|839|847
SE|25462477||ab|5|entity|C0205166|Long|qlco|||longer|||0|872|857|863
SE|25462477||ab|5|entity|C0040223|Time|tmco|||time|||0|872|864|868
SE|25462477||ab|5|entity|C0205250|High|qlco|||higher|||0|785|894|900
SE|25462477||ab|5|entity|C0439830|Velocity|ftcn|||velocity|||0|785|906|914
SE|25462477||ab|5|entity|C0918012|Index|inpr|||index|||0|1000|922|927
SE|25462477||ab|5|entity|C0443228|Largest|qnco|||greater|||0|888|946|953
SE|25462477||ab|5|entity|C0237753|Numbers|qnco|||number|||0|888|954|960
SE|25462477||ab|5|entity|C0439148|Unit|qnco|||units|||0|1000|964|969
SE|25462477||ab|5|entity|C0026597|Motion|npop|||motion|||0|1000|973|979
SE|25462477||ab|5|entity|C0441994|Lower|ftcn|||lower|||0|853|997|1002
SE|25462477||ab|5|entity|C0205357|Smooth|qlco|||smoothness|||0|853|1003|1013
SE|25462477||ab|5|entity|C0205132|Linear|spco|||linearity|||0|928|1018|1027
SE|25462477||ab|5|entity|C0026649|Movement|orgf|||movements|||0|1000|1035|1044
SE|25462477||ab|5|entity|C1140618|Upper Extremity|bpoc|||upper limbs|||0|1000|1048|1059
SE|25462477||ab|5|relation|17|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|753|755|PREP|PROCESS_OF||748|752|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|739|747

SE|25462477||ab|6|text|1061|1163|The performance is influenced by the level of motor impairment and various manipulations of the task.
SE|25462477||ab|6|entity|C0597198|Performance|inbe|||performance|||0|1000|1065|1076
SE|25462477||ab|6|entity|C1513492|Motor|idcn|||motor|||0|888|1107|1112
SE|25462477||ab|6|entity|C0185111|Surgical Manipulation|topp|||manipulations|||0|861|1136|1149

SE|25462477||ab|7|text|1163|1331|However, more studies are needed that help translating these results into treatment strategies that facilitate the performance of manual activities in children with CP.
SE|25462477||ab|7|entity|C0205172|More|ftcn|||more|||0|1000|1172|1176
SE|25462477||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1224|1231
SE|25462477||ab|7|entity|C0597198|Performance|inbe|||performance|||0|1000|1278|1289
SE|25462477||ab|7|entity|C0024763|Manuals|inpr,mnob|||manual|||0|888|1293|1299
SE|25462477||ab|7|entity|C0441655|Activities|acty|||activities|||0|888|1300|1310
SE|25462477||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1314|1322
SE|25462477||ab|7|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|1328|1330
SE|25462477||ab|7|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|1328|1330|PREP|PROCESS_OF||1323|1327|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1314|1322
SE|25462477||ab|7|relation|4|2|C0597198|Performance|inbe|inbe|||performance|||0|1000|1278|1289|PREP|PROCESS_OF||1311|1313|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1314|1322


SE|25462478||ti|1|text|21|124|Anxiety disorders in children and adolescents with intellectual disability: Prevalence and assessment.
SE|25462478||ti|1|entity|C0003469|Anxiety Disorders|mobd|||Anxiety disorders|||0|1000|21|38
SE|25462478||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|42|50
SE|25462478||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|55|66
SE|25462478||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|72|95
SE|25462478||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|112|122
SE|25462478||ti|1|relation|1|1|C0003469|Anxiety Disorders|mobd|mobd|||Anxiety disorders|||0|1000|21|38|PREP|PROCESS_OF||39|41|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|42|50
SE|25462478||ti|1|relation|1|1|C0003469|Anxiety Disorders|mobd|mobd|||Anxiety disorders|||0|1000|21|38|PREP|PROCESS_OF||39|41|5|1|C0205653|Adolescent|aggp,humn|aggp|||adolescents|||0|1000|55|66
SE|25462478||ti|1|relation|3|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|72|95|PREP|PROCESS_OF||67|71|3|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|42|50
SE|25462478||ti|1|relation|3|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|72|95|PREP|PROCESS_OF||67|71|3|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|55|66

SE|25462478||ab|1|text|130|317|Children and adolescents with intellectual disability are known to experience mental health disorders, but anxiety disorders in this population have received relatively little attention.
SE|25462478||ab|1|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|130|138
SE|25462478||ab|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|143|154
SE|25462478||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|160|183
SE|25462478||ab|1|entity|C0004936|Mental disorders|mobd|||mental health disorders|||0|983|208|231
SE|25462478||ab|1|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|237|254
SE|25462478||ab|1|entity|C1257890|Population Group|popg|||population|||0|1000|263|273
SE|25462478||ab|1|entity|C0023882|Little's Disease|dsyn|||little|||0|790|299|305
SE|25462478||ab|1|entity|C0004268|Attention|menp|||attention|||0|790|306|315
SE|25462478||ab|1|relation|4|1|C0004936|Mental disorders|mobd|mobd|||mental health disorders|||0|983|208|231|VERB|PROCESS_OF||197|207|3|2|C0008059|Child|aggp,humn,inpr|aggp|||Children|||0|1000|130|138
SE|25462478||ab|1|relation|4|1|C0004936|Mental disorders|mobd|mobd|||mental health disorders|||0|983|208|231|VERB|PROCESS_OF||197|207|3|2|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|143|154
SE|25462478||ab|1|relation|5|1|C0003469|Anxiety Disorders|mobd|mobd|||anxiety disorders|||0|1000|237|254|PREP|PROCESS_OF||255|257|2|1|C1257890|Population Group|popg,humn|humn|||population|||0|1000|263|273
SE|25462478||ab|1|relation|5|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|160|183|PREP|PROCESS_OF||155|159|2|1|C0008059|Child|aggp,humn,inpr|aggp|||Children|||0|1000|130|138
SE|25462478||ab|1|relation|5|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|160|183|PREP|PROCESS_OF||155|159|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|143|154

SE|25462478||ab|2|text|317|482|Firstly, this paper provides a review of published studies reporting prevalence rates of anxiety disorders in children and adolescents with intellectual disability.
SE|25462478||ab|2|entity|C1279901|Firstly|qlco|||Firstly|||0|1000|317|324
SE|25462478||ab|2|entity|C0030351|Paper|mnob|||paper|||0|1000|331|336
SE|25462478||ab|2|entity|C0034037|Publishing|ocac|||published|||0|855|358|367
SE|25462478||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|855|368|375
SE|25462478||ab|2|entity|C1521828|Rate|qnco|||rates|||0|827|397|402
SE|25462478||ab|2|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|406|423
SE|25462478||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|427|435
SE|25462478||ab|2|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|440|451
SE|25462478||ab|2|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|457|480
SE|25462478||ab|2|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|457|480|PREP|PROCESS_OF||452|456|7|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|427|435
SE|25462478||ab|2|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|457|480|PREP|PROCESS_OF||452|456|7|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|440|451
SE|25462478||ab|2|relation|4|1|C0003469|Anxiety Disorders|mobd|mobd|||anxiety disorders|||0|1000|406|423|NOM|OCCURS_IN||386|396|4|2|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|427|435
SE|25462478||ab|2|relation|4|1|C0003469|Anxiety Disorders|mobd|mobd|||anxiety disorders|||0|1000|406|423|NOM|OCCURS_IN||386|396|4|2|C0205653|Adolescent|aggp,humn|aggp|||adolescents|||0|1000|440|451

SE|25462478||ab|3|text|482|661|Secondly, the paper reviews measures of anxiety that have been evaluated in children/adolescents with intellectual disability, and details the associated psychometric properties.
SE|25462478||ab|3|entity|C0205436|second (number)|qnco|||Secondly|||0|1000|482|490
SE|25462478||ab|3|entity|C0030351|Paper|mnob|||paper|||0|694|496|501
SE|25462478||ab|3|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|522|529
SE|25462478||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|888|558|566
SE|25462478||ab|3|entity|C0205653|Adolescent|aggp|||adolescents|||0|888|567|578
SE|25462478||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|584|607
SE|25462478||ab|3|entity|C0033920|Psychometrics|diap|||psychometric|||0|773|636|648
SE|25462478||ab|3|entity|C0871161|Property|qlco|||properties|||0|773|649|659
SE|25462478||ab|3|relation|2|1|C0003467|Anxiety|menp|menp|||anxiety|||0|1000|522|529|PREP|PROCESS_OF||555|557|3|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|888|567|578
SE|25462478||ab|3|relation|2|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|584|607|PREP|PROCESS_OF||579|583|3|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|888|567|578

SE|25462478||ab|4|text|661|803|Seven studies reporting prevalence rates of anxiety disorders in this population were identified, with reported rates varying from 3% to 22%.
SE|25462478||ab|4|entity|C0205453|Seven|qnco|||Seven|||0|1000|661|666
SE|25462478||ab|4|entity|C0700287|Reporting|hlca|||reporting|||0|785|675|684
SE|25462478||ab|4|entity|C1521828|Rate|qnco|||rates|||0|785|696|701
SE|25462478||ab|4|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|705|722
SE|25462478||ab|4|entity|C1257890|Population Group|popg|||population|||0|1000|731|741
SE|25462478||ab|4|entity|C1521828|Rate|qnco|||rates|||0|872|773|778
SE|25462478||ab|4|relation|3|1|C0003469|Anxiety Disorders|mobd|mobd|||anxiety disorders|||0|1000|705|722|NOM|OCCURS_IN||685|695|3|2|C1257890|Population Group|popg,humn|popg|||population|||0|1000|731|741

SE|25462478||ab|5|text|803|933|Two-one studies evaluating a measure of anxiety in a sample of children/adolescents with intellectual disability were identified.
SE|25462478||ab|5|entity|C0205448|Two|qnco|||Two|||0|840|803|806
SE|25462478||ab|5|entity|C0205447|One|qnco|||one|||0|840|807|810
SE|25462478||ab|5|entity|C0008972|Clinical Research|resa|||studies|||0|840|811|818
SE|25462478||ab|5|entity|C0079809|Measures|qnco|||measure|||0|1000|832|839
SE|25462478||ab|5|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|843|850
SE|25462478||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|888|866|874
SE|25462478||ab|5|entity|C0205653|Adolescent|aggp|||adolescents|||0|888|875|886
SE|25462478||ab|5|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|892|915
SE|25462478||ab|5|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|892|915|PREP|PROCESS_OF||887|891|5|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|888|875|886

SE|25462478||ab|6|text|933|1154|While these studies indicate that several measures show promise, further evaluation studies are needed; particularly those that evaluate the capacity of measures to screen for anxiety disorders, not only measure symptoms.
SE|25462478||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|966|945|952
SE|25462478||ab|6|entity|C0443302|Several|qnco|||several|||0|888|967|974
SE|25462478||ab|6|entity|C0079809|Measures|qnco|||measures|||0|888|975|983
SE|25462478||ab|6|entity|C1555307|promise|idcn|||promise|||0|1000|989|996
SE|25462478||ab|6|entity|C1517331|Further|spco|||further|||0|901|998|1005
SE|25462478||ab|6|entity|C0015196|Evaluation Studies|resa|||evaluation studies|||0|901|1006|1024
SE|25462478||ab|6|entity|C1516240|Capacity|qnco|||capacity|||0|1000|1074|1082
SE|25462478||ab|6|entity|C0079809|Measures|qnco|||measures|||0|1000|1086|1094
SE|25462478||ab|6|entity|C0003469|Anxiety Disorders|mobd|||anxiety disorders|||0|1000|1109|1126
SE|25462478||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1128|1131
SE|25462478||ab|6|entity|C1457887|Symptoms|sosy|||symptoms|||0|1000|1145|1153


SE|25462479||ti|1|text|21|131|(The null) Importance of police experience on intuitive credibility of people with intellectual disabilities.
SE|25462479||ti|1|entity|C0456148|Null|qnco|||null|||0|1000|26|30
SE|25462479||ti|1|entity|C0085098|Police|prog|||police|||0|888|46|52
SE|25462479||ti|1|entity|C0596545|experience|menp|||experience|||0|888|53|63
SE|25462479||ti|1|entity|C0233828|Intuition|menp|||intuitive|||0|853|67|76
SE|25462479||ti|1|entity|C0870373|Credibility|qlco|||credibility|||0|853|77|88
SE|25462479||ti|1|entity|C0027361|Persons|popg|||people|||0|1000|92|98
SE|25462479||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|104|129
SE|25462479||ti|1|relation|0|0|C0596545|experience|menp|menp|||experience|||0|888|53|63|MOD/HEAD|PROCESS_OF||46|63|0|0|C0085098|Police|prog,humn|humn|||police|||0|888|46|52
SE|25462479||ti|1|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|104|129|PREP|PROCESS_OF||99|103|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|92|98

SE|25462479||ab|1|text|137|350|In the present study, the intuitive ability of police to discriminate between real and false statements of people with mild and moderate (IQ range=50-80, average=60.0) intellectual disabilities (ID) was analyzed.
SE|25462479||ab|1|entity|C0150312|Present|qnco|||present|||0|888|144|151
SE|25462479||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|152|157
SE|25462479||ab|1|entity|C0233828|Intuition|menp|||intuitive|||0|853|163|172
SE|25462479||ab|1|entity|C0085732|Ability|orga|||ability|||0|853|173|180
SE|25462479||ab|1|entity|C0085098|Police|prog|||police|||0|1000|184|190
SE|25462479||ab|1|entity|C0871222|Reality|idcn|||real|||0|928|215|219
SE|25462479||ab|1|entity|C0205237|False|qlco|||false|||0|694|224|229
SE|25462479||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|244|250
SE|25462479||ab|1|entity|C0547040|Minimal|qlco|||mild|||0|1000|256|260
SE|25462479||ab|1|entity|C1514721|Range|qnco|||range|||0|888|278|283
SE|25462479||ab|1|entity|C1510992|Average|qnco|||average|||0|1000|291|298
SE|25462479||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|305|330
SE|25462479||ab|1|relation|0|0|C0233828|Intuition|menp|menp|||intuitive|||0|853|163|172|MOD/HEAD|ISA||163|180|0|0|C0085732|Ability|orga|orga|||ability|||0|853|173|180

SE|25462479||ab|2|text|350|498|The assessments issued by groups with different levels of experience in police techniques (psychology students, and police officers) were compared.
SE|25462479||ab|2|entity|C0220825|Evaluation|ftcn|||assessments|||0|966|354|365
SE|25462479||ab|2|entity|C0441833|Groups|inpr|||groups|||0|1000|376|382
SE|25462479||ab|2|entity|C1547020|*Difference|qnco|||different|||0|853|388|397
SE|25462479||ab|2|entity|C0441889|Levels|inpr|||levels|||0|853|398|404
SE|25462479||ab|2|entity|C0596545|experience|menp|||experience|||0|1000|408|418
SE|25462479||ab|2|entity|C0085098|Police|prog|||police|||0|888|422|428
SE|25462479||ab|2|entity|C0025664|Methodology|inpr|||techniques|||0|888|429|439
SE|25462479||ab|2|entity|C0033909|Psychology|bmod|||psychology|||0|888|441|451
SE|25462479||ab|2|entity|C0038492|student|prog|||students|||0|888|452|460
SE|25462479||ab|2|entity|C0086825|Police officer|prog|||police officers|||0|1000|466|481

SE|25462479||ab|3|text|498|627|The results showed no differences between the two groups in their ability to discriminate (d'=0.785 and d'=0.644, respectively).
SE|25462479||ab|3|entity|C1274040|result|ftcn|||results|||0|966|502|509
SE|25462479||ab|3|entity|C1547020|*Difference|qnco|||differences|||0|966|520|531
SE|25462479||ab|3|entity|C0205448|Two|qnco|||two|||0|888|544|547
SE|25462479||ab|3|entity|C0441833|Groups|inpr|||groups|||0|888|548|554
SE|25462479||ab|3|entity|C0085732|Ability|orga|||ability|||0|1000|564|571

SE|25462479||ab|4|text|627|807|When the experience of the police was taken into consideration, no differences were found between "experienced" and "novice" police officers (d'=0.721 and d'=0.582, respectively).
SE|25462479||ab|4|entity|C0596545|experience|menp|||experience|||0|1000|636|646
SE|25462479||ab|4|entity|C0085098|Police|prog|||police|||0|1000|654|660
SE|25462479||ab|4|entity|C1547020|*Difference|qnco|||differences|||0|966|694|705
SE|25462479||ab|4|entity|C0086825|Police officer|prog|||police officers|||0|901|752|767

SE|25462479||ab|5|text|807|888|No differences were found in response criteria, which were neutral in all cases.
SE|25462479||ab|5|entity|C1547020|*Difference|qnco|||differences|||0|966|810|821
SE|25462479||ab|5|entity|C0871261|response|clna|||response|||0|888|836|844
SE|25462479||ab|5|entity|C0243161|criteria|inpr|||criteria|||0|888|845|853
SE|25462479||ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|881|886

SE|25462479||ab|6|text|888|1052|Moreover, 34.73% of cases evaluated by the inexperienced group were incorrectly discriminated, in comparison to the 37.75% of incorrect assessments made by police.
SE|25462479||ab|6|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|908|913
SE|25462479||ab|6|entity|C0441833|Groups|inpr|||group|||0|861|945|950
SE|25462479||ab|6|entity|C0220825|Evaluation|ftcn|||assessments|||0|827|1024|1035
SE|25462479||ab|6|entity|C0085098|Police|prog|||police|||0|1000|1044|1050

SE|25462479||ab|7|text|1052|1311|The implications of the limited ability of intuition to discriminate between real and simulated victims with ID, which did not yield significant differences between experienced and inexperienced assessors in obtaining and assessing statements, are discussed.
SE|25462479||ab|7|entity|C0439801|Limited|ftcn|||limited|||0|888|1076|1083
SE|25462479||ab|7|entity|C0085732|Ability|orga|||ability|||0|888|1084|1091
SE|25462479||ab|7|entity|C0233828|Intuition|menp|||intuition|||0|1000|1095|1104
SE|25462479||ab|7|entity|C0871222|Reality|idcn|||real|||0|928|1129|1133
SE|25462479||ab|7|entity|C0680681|VICTIM|popg|||victims|||0|827|1148|1155
SE|25462479||ab|7|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1161|1163
SE|25462479||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1175|1178
SE|25462479||ab|7|entity|C0750502|Significant|idcn|||significant|||0|872|1185|1196
SE|25462479||ab|7|entity|C1547020|*Difference|qnco|||differences|||0|872|1197|1208
SE|25462479||ab|7|entity|C0596545|experience|menp|||experienced|||0|928|1217|1228
SE|25462479||ab|7|entity|C1301820|Obtained|ftcn|||obtaining|||0|966|1260|1269
SE|25462479||ab|7|entity|C0220825|Evaluation|ftcn|||assessing|||0|661|1274|1283
SE|25462479||ab|7|relation|6|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1161|1163|PREP|PROCESS_OF||1156|1160|5|1|C0680681|VICTIM|popg,humn|humn|||victims|||0|827|1148|1155

SE|25462479||ab|8|text|1311|1537|In light of the results of this study, it is concluded that adequate resources and standardized procedures to properly address people with ID who come into contact with the police and judicial institutions need to be provided.
SE|25462479||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1327|1334
SE|25462479||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1343|1348
SE|25462479||ab|8|entity|C0205411|Adequate|qlco|||adequate|||0|888|1371|1379
SE|25462479||ab|8|entity|C0035201|Resources|idcn|||resources|||0|888|1380|1389
SE|25462479||ab|8|entity|C0025664|Methodology|inpr|||procedures|||0|861|1407|1417
SE|25462479||ab|8|entity|C0027361|Persons|popg|||people|||0|1000|1438|1444
SE|25462479||ab|8|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1450|1452
SE|25462479||ab|8|entity|C0085098|Police|prog|||police|||0|1000|1484|1490
SE|25462479||ab|8|entity|C0018704|Health care facility|hcro,mnob|||institutions|||0|827|1504|1516
SE|25462479||ab|8|relation|4|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1450|1452|PREP|PROCESS_OF||1445|1449|6|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1438|1444


SE|25462480||ti|1|text|21|118|Impact of obesity and Down syndrome on peak heart rate and aerobic capacity in youth and adults.
SE|25462480||ti|1|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|31|38
SE|25462480||ti|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|43|56
SE|25462480||ti|1|entity|C0018810|heart rate|orga|||heart rate|||0|901|65|75
SE|25462480||ti|1|entity|C1510824|Aerobic|qlco|||aerobic|||0|888|80|87
SE|25462480||ti|1|entity|C1516240|Capacity|qnco|||capacity|||0|888|88|96
SE|25462480||ti|1|entity|C0087178|Youth|aggp|||youth|||0|1000|100|105
SE|25462480||ti|1|entity|C0001675|Adult|aggp|||adults|||0|1000|110|116
SE|25462480||ti|1|relation|5|3|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|43|56|PREP|PROCESS_OF||97|99|2|1|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|110|116
SE|25462480||ti|1|relation|5|3|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|43|56|PREP|PROCESS_OF||97|99|2|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|100|105
SE|25462480||ti|1|relation|5|3|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|31|38|PREP|PROCESS_OF||97|99|2|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|100|105
SE|25462480||ti|1|relation|5|4|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|31|38|PREP|PROCESS_OF||97|99|2|2|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|110|116

SE|25462480||ab|1|text|124|232|Individuals with Down syndrome (DS) exhibit reduced aerobic capacity with reduced peak heart rate (HRpeak).
SE|25462480||ab|1|entity|C0237401|Individual|humn|||Individuals|||0|1000|124|135
SE|25462480||ab|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|901|141|154
SE|25462480||ab|1|entity|C0015272|Exhibits|mnob|||exhibit|||0|901|160|167
SE|25462480||ab|1|entity|C1510824|Aerobic|qlco|||aerobic|||0|888|176|183
SE|25462480||ab|1|entity|C1516240|Capacity|qnco|||capacity|||0|888|184|192
SE|25462480||ab|1|entity|C0392756|Reduced|qlco|||reduced|||0|824|198|205
SE|25462480||ab|1|entity|C0018810|heart rate|orga|||heart rate|||0|824|211|221

SE|25462480||ab|2|text|232|332|This condition is often coexistent with higher level of obesity compared to individuals without DS.
SE|25462480||ab|2|entity|C0348080|Condition|qlco|||condition|||0|1000|237|246
SE|25462480||ab|2|entity|C0332183|Frequent|tmco|||often|||0|694|250|255
SE|25462480||ab|2|entity|C0205250|High|qlco|||higher|||0|661|272|278
SE|25462480||ab|2|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|288|295
SE|25462480||ab|2|entity|C0237401|Individual|humn|||individuals|||0|1000|308|319
SE|25462480||ab|2|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|328|330

SE|25462480||ab|3|text|332|566|The purpose of this study is to investigate the effects of obesity and Down syndrome (DS) on peak heart rate (HRpeak) and peak oxygen consumption (VO2peak) in children and adults both with and without intellectual disabilities (ID)s.
SE|25462480||ab|3|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|336|343
SE|25462480||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|352|357
SE|25462480||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|380|387
SE|25462480||ab|3|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|391|398
SE|25462480||ab|3|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|403|416
SE|25462480||ab|3|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|418|420
SE|25462480||ab|3|entity|C0018810|heart rate|orga|||heart rate|||0|901|430|440
SE|25462480||ab|3|entity|C0030055|Oxygen Consumption|clna|||oxygen consumption|||0|901|459|477
SE|25462480||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|491|499
SE|25462480||ab|3|entity|C0001675|Adult|aggp|||adults|||0|1000|504|510
SE|25462480||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|879|533|558
SE|25462480||ab|3|relation|10|6|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|403|416|PREP|PROCESS_OF||488|490|3|1|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|504|510
SE|25462480||ab|3|relation|10|6|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|403|416|PREP|PROCESS_OF||488|490|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|491|499
SE|25462480||ab|3|relation|10|6|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|391|398|PREP|PROCESS_OF||488|490|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|491|499
SE|25462480||ab|3|relation|10|7|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|391|398|PREP|PROCESS_OF||488|490|3|2|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|504|510

SE|25462480||ab|4|text|566|655|VO2peak and HRpeak from individualized treadmill tests on 654 individuals were analyzed.
SE|25462480||ab|4|entity|C0087110|Treadmill Test|diap|||treadmill tests|||0|901|605|620
SE|25462480||ab|4|entity|C0237401|Individual|humn|||individuals|||0|861|628|639

SE|25462480||ab|5|text|655|746|Body mass index was used to categorize individuals' weight status using standard cut-offs.
SE|25462480||ab|5|entity|C0005893|Body mass index procedure|diap|||Body mass index|||0|1000|655|670
SE|25462480||ab|5|entity|C0237401|Individual|humn|||individuals|||0|851|694|705
SE|25462480||ab|5|entity|C0043100|Weight|qnco|||weight|||0|851|707|713
SE|25462480||ab|5|entity|C0449438|Status|qlco|||status|||0|851|714|720
SE|25462480||ab|5|entity|C1442989|STANDARD|ftcn|||standard|||0|872|727|735
SE|25462480||ab|5|entity|C1442160|CUTOFF|ftcn|||cut-offs|||0|872|736|744

SE|25462480||ab|6|text|746|869|DS groups had the lowest HRpeak (167bpm+/-14, p<0.05) compared to individuals with (183bpm+/-12) without ID (187bpm+/-12).
SE|25462480||ab|6|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|901|746|748
SE|25462480||ab|6|entity|C0441833|Groups|inpr|||groups|||0|901|749|755
SE|25462480||ab|6|entity|C0205251|low|qlco|||lowest|||0|661|764|770
SE|25462480||ab|6|entity|C0237401|Individual|humn|||individuals|||0|1000|812|823
SE|25462480||ab|6|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|851|853

SE|25462480||ab|7|text|869|934|Obesity did not affect HRpeak among adults and children with DS.
SE|25462480||ab|7|entity|C0028754|Obesity|dsyn|||Obesity|||0|1000|869|876
SE|25462480||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|881|884
SE|25462480||ab|7|entity|C0001675|Adult|aggp|||adults|||0|1000|905|911
SE|25462480||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|916|924
SE|25462480||ab|7|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|930|932
SE|25462480||ab|7|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|930|932|PREP|PROCESS_OF||925|929|4|1|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|905|911
SE|25462480||ab|7|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|930|932|PREP|PROCESS_OF||925|929|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|916|924
SE|25462480||ab|7|relation|2|2|C0028754|Obesity|dsyn|dsyn|||Obesity|||0|1000|869|876|PREP|PROCESS_OF|negation|899|904|3|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|905|911
SE|25462480||ab|7|relation|2|2|C0028754|Obesity|dsyn|dsyn|||Obesity|||0|1000|869|876|PREP|PROCESS_OF|negation|899|904|3|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|916|924

SE|25462480||ab|8|text|934|1101|VO2peak was lower among individuals with DS (25.2mL/kg/min+/-6.3, p<0.05) when compared individuals with (37.0mL/kg/min+/-10.5) and without ID (36.1mL/kg/min+/-10.4).
SE|25462480||ab|8|entity|C0441994|Lower|ftcn|||lower|||0|1000|946|951
SE|25462480||ab|8|entity|C0237401|Individual|humn|||individuals|||0|1000|958|969
SE|25462480||ab|8|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|975|977
SE|25462480||ab|8|entity|C0470388|2mL|qnco|||2mL|||0|762|982|985
SE|25462480||ab|8|entity|C1532757|kg/min|cnce|||kg/min|||0|762|986|992
SE|25462480||ab|8|entity|C0237401|Individual|humn|||individuals|||0|861|1022|1033
SE|25462480||ab|8|entity|C1532757|kg/min|cnce|||kg/min|||0|827|1047|1053
SE|25462480||ab|8|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1074|1076
SE|25462480||ab|8|entity|C0470386|1mL|qnco|||1mL|||0|762|1081|1084
SE|25462480||ab|8|entity|C1532757|kg/min|cnce|||kg/min|||0|762|1085|1091
SE|25462480||ab|8|relation|3|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|975|977|PREP|PROCESS_OF||970|974|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|958|969

SE|25462480||ab|9|text|1101|1276|Obese adults with DS had lower VO2peak (24.3mL/kg/min+/-6.9, p=0.001) compared to the normal weight (26.7+/-7.1mL/kg/min) and overweight groups (27.0mL/kg/min+/-6.1) with DS.
SE|25462480||ab|9|entity|C0028754|Obesity|dsyn|||Obese|||0|888|1101|1106
SE|25462480||ab|9|entity|C0001675|Adult|aggp|||adults|||0|888|1107|1113
SE|25462480||ab|9|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1119|1121
SE|25462480||ab|9|entity|C0441994|Lower|ftcn|||lower|||0|694|1126|1131
SE|25462480||ab|9|entity|C0470391|3mL|qnco|||3mL|||0|762|1144|1147
SE|25462480||ab|9|entity|C1532757|kg/min|cnce|||kg/min|||0|762|1148|1154
SE|25462480||ab|9|entity|C0332541|Normal weight|qlco|||normal weight|||0|1000|1187|1200
SE|25462480||ab|9|entity|C0470386|1mL|qnco|||1mL|||0|805|1211|1214
SE|25462480||ab|9|entity|C1532757|kg/min|cnce|||kg/min|||0|805|1215|1221
SE|25462480||ab|9|entity|C0497406|Overweight|sosy|||overweight|||0|888|1227|1237
SE|25462480||ab|9|entity|C0441833|Groups|inpr|||groups|||0|888|1238|1244
SE|25462480||ab|9|entity|C1532757|kg/min|cnce|||kg/min|||0|827|1253|1259
SE|25462480||ab|9|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1272|1274
SE|25462480||ab|9|relation|0|0|C0028754|Obesity|dsyn|dsyn|||Obese|||0|888|1101|1106|MOD/HEAD|PROCESS_OF||1101|1113|0|0|C0001675|Adult|aggp,humn|humn|||adults|||0|888|1107|1113
SE|25462480||ab|9|relation|6|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|1119|1121|PREP|PROCESS_OF||1114|1118|1|1|C0001675|Adult|aggp,humn|humn|||adults|||0|888|1107|1113

SE|25462480||ab|10|text|1276|1362|Conversely, in children, obesity level did not impact VO2peak in individuals with DS.
SE|25462480||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1291|1299
SE|25462480||ab|10|entity|C0028754|Obesity|dsyn|||obesity|||0|694|1301|1308
SE|25462480||ab|10|entity|C1518422|Not|ftcn|||not|||0|623|1319|1322
SE|25462480||ab|10|entity|C0237401|Individual|humn|||individuals|||0|1000|1341|1352
SE|25462480||ab|10|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1358|1360
SE|25462480||ab|10|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|1358|1360|PREP|PROCESS_OF||1353|1357|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1341|1352
SE|25462480||ab|10|relation|3|2|C0028754|Obesity|dsyn|dsyn|||obesity|||0|694|1301|1308|PREP|PROCESS_OF|negation|1338|1340|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1341|1352

SE|25462480||ab|11|text|1362|1470|Our results suggest that DS attenuates both VO2peak and HRpeak, regardless of obesity status and age group.
SE|25462480||ab|11|entity|C1274040|result|ftcn|||results|||0|966|1366|1373
SE|25462480||ab|11|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1387|1389
SE|25462480||ab|11|entity|C0028754|Obesity|dsyn|||obesity|||0|888|1440|1447
SE|25462480||ab|11|entity|C0449438|Status|qlco|||status|||0|888|1448|1454
SE|25462480||ab|11|entity|C0027362|Human Age Group|aggp|||age group|||0|1000|1459|1468

SE|25462480||ab|12|text|1470|1564|However, obesity was associated with lower VO2peak in all adults, but not in children with DS.
SE|25462480||ab|12|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|1479|1486
SE|25462480||ab|12|entity|C0441994|Lower|ftcn|||lower|||0|694|1507|1512
SE|25462480||ab|12|entity|C0001675|Adult|aggp|||adults|||0|1000|1528|1534
SE|25462480||ab|12|entity|C1518422|Not|ftcn|||not|||0|1000|1540|1543
SE|25462480||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1547|1555
SE|25462480||ab|12|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1561|1563
SE|25462480||ab|12|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|1561|1563|PREP|PROCESS_OF||1556|1560|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1547|1555
SE|25462480||ab|12|relation|2|2|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|1479|1486|PREP|PROCESS_OF||1521|1523|3|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|1528|1534


SE|25462481||ti|1|text|21|120|Estimating the prevalence of cerebral palsy in Taiwan: A comparison of different case definitions.
SE|25462481||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|50|64
SE|25462481||ti|1|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|68|74
SE|25462481||ti|1|entity|C1547020|*Difference|qnco|||different|||0|750|92|101
SE|25462481||ti|1|entity|C1550452|definition|idcn|||definitions|||0|750|107|118

SE|25462481||ab|1|text|126|331|The estimated prevalence of cerebral palsy (CP) worldwide ranged from 0.74 to 3.6 per 1000 live births according to different studies, which may be due to different data sources and case definitions used.
SE|25462481||ab|1|entity|C0750572|Estimated|qnco|||estimated|||0|694|130|139
SE|25462481||ab|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|154|168
SE|25462481||ab|1|entity|C0442759|3/6|fndg|||3.6|||0|1000|204|207
SE|25462481||ab|1|entity|C0481667|Live Birth|qlco|||live births|||0|901|217|228
SE|25462481||ab|1|entity|C1547020|*Difference|qnco|||different|||0|836|242|251
SE|25462481||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|836|252|259
SE|25462481||ab|1|entity|C1547020|*Difference|qnco|||different|||0|865|281|290
SE|25462481||ab|1|entity|C0011001|Data Sources|qnco|||data sources|||0|865|291|303
SE|25462481||ab|1|entity|C1550452|definition|idcn|||definitions|||0|827|313|324

SE|25462481||ab|2|text|331|533|We used a representative sample of one million patients (about 1/23 of total population) covered by Taiwan's National Health Insurance (NHI) to estimate the prevalence using different case definitions.
SE|25462481||ab|2|entity|C0205447|One|qnco|||one|||0|802|366|369
SE|25462481||ab|2|entity|C0030705|Patients|podg|||patients|||0|802|378|386
SE|25462481||ab|2|entity|C0439175|% of total|qnco|||total|||0|888|402|407
SE|25462481||ab|2|entity|C1257890|Population Group|popg|||population|||0|888|408|418
SE|25462481||ab|2|entity|C0039260|Taiwan|geoa|||Taiwan's|||0|916|431|439
SE|25462481||ab|2|entity|C0027452|National Health Insurance|hlca|||National Health Insurance|||0|916|440|465
SE|25462481||ab|2|entity|C1547020|*Difference|qnco|||different|||0|750|505|514
SE|25462481||ab|2|entity|C1550452|definition|idcn|||definitions|||0|750|520|531

SE|25462481||ab|3|text|533|658|Eight years of NHI Research Database claims data for all children born between 1996 and 2000 were reviewed for CP diagnoses.
SE|25462481||ab|3|entity|C0205454|Eight|qnco|||Eight|||0|888|533|538
SE|25462481||ab|3|entity|C0439234|year|tmco|||years|||0|888|539|544
SE|25462481||ab|3|entity|C0027452|National Health Insurance|hlca|||NHI|||0|875|548|551
SE|25462481||ab|3|entity|C0035168|research|resa|||Research|||0|875|552|560
SE|25462481||ab|3|entity|C0242356|Databases|inpr|||Database|||0|875|561|569
SE|25462481||ab|3|entity|C1511726|Data|idcn|||data|||0|1000|577|581
SE|25462481||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|590|598
SE|25462481||ab|3|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|644|646
SE|25462481||ab|3|entity|C0011900|Diagnosis|hlca|||diagnoses|||0|901|647|656

SE|25462481||ab|4|text|658|773|The estimated prevalence of CP (cases per 1000 live births) varied from 4.1 to 1.3 for different case definitions.
SE|25462481||ab|4|entity|C0750572|Estimated|qnco|||estimated|||0|694|662|671
SE|25462481||ab|4|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|686|688
SE|25462481||ab|4|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|690|695
SE|25462481||ab|4|entity|C0481667|Live Birth|qlco|||live births|||0|901|705|716
SE|25462481||ab|4|entity|C1547020|*Difference|qnco|||different|||0|750|745|754
SE|25462481||ab|4|entity|C1550452|definition|idcn|||definitions|||0|750|760|771

SE|25462481||ab|5|text|773|1058|For a minimum age of 4 years old at diagnosis, a diagnosis made by specialists (pediatricians and physicians of physical medicine and rehabilitation), and the CP diagnosis was mentioned at least three times in claims data, the mean estimated prevalence of CP was 3.2 (95% CI 2.8-3.7).
SE|25462481||ab|5|entity|C1524031|Minimum|qlco|||minimum|||0|888|779|786
SE|25462481||ab|5|entity|C0001779|Age|orga|||age|||0|888|787|790
SE|25462481||ab|5|entity|C0439234|year|tmco|||years|||0|790|796|801
SE|25462481||ab|5|entity|C0580836|Old|tmco|||old|||0|790|802|805
SE|25462481||ab|5|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|809|818
SE|25462481||ab|5|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|822|831
SE|25462481||ab|5|entity|C0087009|Hospital specialist|prog|||specialists|||0|1000|840|851
SE|25462481||ab|5|entity|C0237433|Pediatrician|prog|||pediatricians|||0|1000|853|866
SE|25462481||ab|5|entity|C0031831|Physicians|prog|||physicians|||0|1000|871|881
SE|25462481||ab|5|entity|C0031813|Physical Medicine|bmod|||physical medicine|||0|1000|885|902
SE|25462481||ab|5|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|932|934
SE|25462481||ab|5|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|901|935|944
SE|25462481||ab|5|entity|C0205449|Three|qnco|||three|||0|773|968|973
SE|25462481||ab|5|entity|C0040223|Time|tmco|||times|||0|773|974|979
SE|25462481||ab|5|entity|C1511726|Data|idcn|||data|||0|861|990|994
SE|25462481||ab|5|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|1029|1031
SE|25462481||ab|5|entity|C0067503|N-(3-N-(benzyloxycarbonyl)amino-1-carboxypropyl)leucyl-O-methyltyrosine N-methylamide|aapp,phsu|||CI 2|||0|827|1045|1049
SE|25462481||ab|5|relation|9|5|C0031831|Physicians|prog,humn|prog|||physicians|||0|1000|871|881|NOM|DIAGNOSES||935|944|9|0|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|932|934
SE|25462481||ab|5|relation|9|5|C0087009|Hospital specialist|prog,humn|prog|||specialists|||0|1000|840|851|NOM|DIAGNOSES||935|944|9|0|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|932|934
SE|25462481||ab|5|relation|9|5|C0237433|Pediatrician|prog,humn|prog|||pediatricians|||0|1000|853|866|NOM|DIAGNOSES||935|944|9|0|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|932|934

SE|25462481||ab|6|text|1058|1292|According to this definition, which is most compatible with previous studies, the estimated prevalence in Taiwan was 3.4 (95% CI 2.8-4.0) for boys and 3.1 (95% CI 2.5-3.7) for girls, significantly higher than that in other countries.
SE|25462481||ab|6|entity|C1550452|definition|idcn|||definition|||0|1000|1076|1086
SE|25462481||ab|6|entity|C0205393|Most|qnco|||most|||0|888|1097|1101
SE|25462481||ab|6|entity|C1524057|Compatible|qlco|||compatible|||0|888|1102|1112
SE|25462481||ab|6|entity|C0205156|Previous|tmco|||previous|||0|872|1118|1126
SE|25462481||ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|872|1127|1134
SE|25462481||ab|6|entity|C0750572|Estimated|qnco|||estimated|||0|694|1140|1149
SE|25462481||ab|6|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|1164|1170
SE|25462481||ab|6|entity|C0442757|3/4|fndg|||3.4|||0|1000|1175|1178
SE|25462481||ab|6|entity|C0387382|CI 4|aapp,phsu|||CI 2.8-4|||0|858|1184|1192
SE|25462481||ab|6|entity|C0870221|Boys|popg|||boys|||0|1000|1200|1204
SE|25462481||ab|6|entity|C0067503|N-(3-N-(benzyloxycarbonyl)amino-1-carboxypropyl)leucyl-O-methyltyrosine N-methylamide|aapp,phsu|||CI 2|||0|827|1218|1222
SE|25462481||ab|6|entity|C0870604|Girls|popg|||girls|||0|1000|1234|1239
SE|25462481||ab|6|entity|C0205250|High|qlco|||higher|||0|827|1255|1261
SE|25462481||ab|6|entity|C0454664|Country|geoa|||countries|||0|1000|1281|1290

SE|25462481||ab|7|text|1292|1378|Additional studies are needed to determine the reasons of higher prevalence in Taiwan.
SE|25462481||ab|7|entity|C1524062|Additional|ftcn|||Additional|||0|872|1292|1302
SE|25462481||ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|872|1303|1310
SE|25462481||ab|7|entity|C0392360|Reason for|idcn|||reasons|||0|1000|1339|1346
SE|25462481||ab|7|entity|C1512456|High Prevalence|qnco|||higher prevalence|||0|983|1350|1367
SE|25462481||ab|7|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|1371|1377


SE|25462482||ti|1|text|21|91|Activity and participation in children with neurofibromatosis type 1.
SE|25462482||ti|1|entity|C0679823|participation|inbe|||participation|||0|1000|34|47
SE|25462482||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|51|59
SE|25462482||ti|1|entity|C0027831|Neurofibromatosis 1|neop|||neurofibromatosis type 1|||0|1000|65|89
SE|25462482||ti|1|relation|1|1|C0027831|Neurofibromatosis 1|neop|neop|||neurofibromatosis type 1|||0|1000|65|89|PREP|PROCESS_OF||60|64|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|51|59
SE|25462482||ti|1|relation|2|1|C0679823|participation|inbe|inbe|||participation|||0|1000|34|47|PREP|PROCESS_OF||48|50|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|51|59

SE|25462482||ab|1|text|97|405|We describe activity and participation in children and youth with neurofibromatosis type 1 (NF1), and compared an intervention and control group after a strengthening program using the Pediatric Outcomes Data Collection Instrument (PODCI) and the Children's Assessment of Participation and Enjoyment (CAPE).
SE|25462482||ab|1|entity|C0679823|participation|inbe|||participation|||0|1000|122|135
SE|25462482||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|139|147
SE|25462482||ab|1|entity|C0087178|Youth|aggp|||youth|||0|1000|152|157
SE|25462482||ab|1|entity|C0027831|Neurofibromatosis 1|neop|||neurofibromatosis type 1|||0|1000|163|187
SE|25462482||ab|1|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|211|223
SE|25462482||ab|1|entity|C0009932|Control Groups|grup|||control group|||0|1000|228|241
SE|25462482||ab|1|entity|C1521725|Pediatric|qlco|||Pediatric|||0|831|282|291
SE|25462482||ab|1|entity|C1274040|result|ftcn|||Outcomes|||0|831|292|300
SE|25462482||ab|1|entity|C0010995|Data Collection|resa|||Data Collection|||0|831|301|316
SE|25462482||ab|1|entity|C0348000|Instrument|mnob|||Instrument|||0|831|317|327
SE|25462482||ab|1|entity|C0008059|Child|aggp,inpr|||Children's|||0|719|344|354
SE|25462482||ab|1|entity|C0220825|Evaluation|ftcn|||Assessment|||0|719|355|365
SE|25462482||ab|1|entity|C0679823|participation|inbe|||Participation|||0|719|369|382
SE|25462482||ab|1|entity|C0679105|pleasurable emotion|menp|||Enjoyment|||0|719|387|396
SE|25462482||ab|1|relation|2|1|C0679823|participation|inbe|inbe|||participation|||0|1000|122|135|PREP|PROCESS_OF||136|138|6|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|139|147
SE|25462482||ab|1|relation|2|1|C0679823|participation|inbe|inbe|||participation|||0|1000|122|135|PREP|PROCESS_OF||136|138|6|1|C0087178|Youth|aggp,humn|aggp|||youth|||0|1000|152|157
SE|25462482||ab|1|relation|5|1|C0027831|Neurofibromatosis 1|neop|neop|||neurofibromatosis type 1|||0|1000|163|187|PREP|PROCESS_OF||158|162|4|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|139|147
SE|25462482||ab|1|relation|5|1|C0027831|Neurofibromatosis 1|neop|neop|||neurofibromatosis type 1|||0|1000|163|187|PREP|PROCESS_OF||158|162|4|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|152|157

SE|25462482||ab|2|text|405|482|Questionnaires were filled out by parents at baseline, 12-weeks, and 1-year.
SE|25462482||ab|2|entity|C0034394|Questionnaires|inpr|||Questionnaires|||0|1000|405|419
SE|25462482||ab|2|entity|C0439787|Out|spco|||out|||0|1000|432|435
SE|25462482||ab|2|entity|C0030551|parent|famg|||parents|||0|1000|439|446
SE|25462482||ab|2|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|450|458
SE|25462482||ab|2|entity|C0439230|week|tmco|||weeks|||0|861|463|468
SE|25462482||ab|2|entity|C0439234|year|tmco|||year|||0|861|476|480

SE|25462482||ab|3|text|482|610|The intervention group performed a strengthening program twice a week for ten weeks, followed by a 9-month independent program.
SE|25462482||ab|3|entity|C1273869|Intervention regimes|hlca|||intervention|||0|888|486|498
SE|25462482||ab|3|entity|C0441833|Groups|inpr|||group|||0|888|499|504
SE|25462482||ab|3|entity|C0439230|week|tmco|||week|||0|1000|547|551
SE|25462482||ab|3|entity|C0205456|Ten|qnco|||ten|||0|888|556|559
SE|25462482||ab|3|entity|C0439230|week|tmco|||weeks|||0|888|560|565
SE|25462482||ab|3|entity|C0439231|month|tmco|||month|||0|583|583|588

SE|25462482||ab|4|text|610|787|Thirty-six participants (18 control, 18 intervention) between the ages of 5- and 18-years (mean 10.6 years, SD 4.6 years) were enrolled, and 34 completed the 1-year assessment.
SE|25462482||ab|4|entity|C0205452|Six|qnco|||six|||0|773|617|620
SE|25462482||ab|4|entity|C0679646|Participant|popg|||participants|||0|773|621|633
SE|25462482||ab|4|entity|C0243148|control|ftcn|||control|||0|861|638|645
SE|25462482||ab|4|entity|C1273869|Intervention regimes|hlca|||intervention|||0|861|650|662
SE|25462482||ab|4|entity|C0001779|Age|orga|||ages|||0|966|676|680
SE|25462482||ab|4|entity|C0439234|year|tmco|||years|||0|861|694|699
SE|25462482||ab|4|entity|C0439234|year|tmco|||years|||0|812|711|716
SE|25462482||ab|4|entity|C0439234|year|tmco|||years|||0|791|725|730
SE|25462482||ab|4|entity|C0439234|year|tmco|||year|||0|790|770|774
SE|25462482||ab|4|entity|C0220825|Evaluation|ftcn|||assessment|||0|790|775|785

SE|25462482||ab|5|text|787|922|There were significant differences between formal and informal participation (p<0.0001) in baseline CAPE scores for the entire cohort.
SE|25462482||ab|5|entity|C0750502|Significant|idcn|||significant|||0|872|798|809
SE|25462482||ab|5|entity|C1547020|*Difference|qnco|||differences|||0|872|810|821
SE|25462482||ab|5|entity|C0376315|Manufactured form|mnob|||formal|||0|928|830|836
SE|25462482||ab|5|entity|C0679823|participation|inbe|||participation|||0|861|850|863
SE|25462482||ab|5|entity|C1442488|BASELINE|qnco|||baseline|||0|716|878|886
SE|25462482||ab|5|entity|C0008059|Child|aggp,inpr|||CAPE|||0|716|887|891
SE|25462482||ab|5|entity|C0220825|Evaluation|ftcn|||CAPE|||0|716|887|891
SE|25462482||ab|5|entity|C0679823|participation|inbe|||CAPE|||0|716|887|891
SE|25462482||ab|5|entity|C0679105|pleasurable emotion|menp|||CAPE|||0|716|887|891
SE|25462482||ab|5|entity|C0439751|Entire|qnco|||entire|||0|888|907|913
SE|25462482||ab|5|entity|C0599755|cohort|popg|||cohort|||0|888|914|920

SE|25462482||ab|6|text|922|1105|At 12 weeks, PODCI upper extremity function improved in intervention and decreased in controls (p=0.040), while happiness declined in intervention and increased in control (p=0.003).
SE|25462482||ab|6|entity|C0439230|week|tmco|||weeks|||0|861|928|933
SE|25462482||ab|6|entity|C1521725|Pediatric|qlco|||PODCI|||0|813|935|940
SE|25462482||ab|6|entity|C1274040|result|ftcn|||PODCI|||0|813|935|940
SE|25462482||ab|6|entity|C0010995|Data Collection|resa|||PODCI|||0|813|935|940
SE|25462482||ab|6|entity|C0348000|Instrument|mnob|||PODCI|||0|813|935|940
SE|25462482||ab|6|entity|C1140618|Upper Extremity|bpoc|||upper extremity|||0|813|941|956
SE|25462482||ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|813|957|965
SE|25462482||ab|6|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|978|990
SE|25462482||ab|6|entity|C0243148|control|ftcn|||controls|||0|966|1008|1016
SE|25462482||ab|6|entity|C0018592|Happiness|menp|||happiness|||0|1000|1034|1043
SE|25462482||ab|6|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|1056|1068
SE|25462482||ab|6|entity|C0243148|control|ftcn|||control|||0|1000|1086|1093

SE|25462482||ab|7|text|1105|1250|There were no significant differences between control and intervention groups in any of the CAPE or PODCI change scores from baseline to 1-year.
SE|25462482||ab|7|entity|C0750502|Significant|idcn|||significant|||0|872|1119|1130
SE|25462482||ab|7|entity|C1547020|*Difference|qnco|||differences|||0|872|1131|1142
SE|25462482||ab|7|entity|C0243148|control|ftcn|||control|||0|1000|1151|1158
SE|25462482||ab|7|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|1163|1175
SE|25462482||ab|7|entity|C0008059|Child|aggp,inpr|||CAPE|||0|704|1197|1201
SE|25462482||ab|7|entity|C0220825|Evaluation|ftcn|||CAPE|||0|704|1197|1201
SE|25462482||ab|7|entity|C0679823|participation|inbe|||CAPE|||0|704|1197|1201
SE|25462482||ab|7|entity|C0679105|pleasurable emotion|menp|||CAPE|||0|704|1197|1201
SE|25462482||ab|7|entity|C1521725|Pediatric|qlco|||PODCI|||0|813|1205|1210
SE|25462482||ab|7|entity|C1274040|result|ftcn|||PODCI|||0|813|1205|1210
SE|25462482||ab|7|entity|C0010995|Data Collection|resa|||PODCI|||0|813|1205|1210
SE|25462482||ab|7|entity|C0348000|Instrument|mnob|||PODCI|||0|813|1205|1210
SE|25462482||ab|7|entity|C0449820|Score|qnco|||scores|||0|813|1218|1224
SE|25462482||ab|7|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|1230|1238
SE|25462482||ab|7|entity|C0439234|year|tmco|||year|||0|861|1244|1248

SE|25462482||ab|8|text|1250|1379|Upper extremity function, sport and physical function, comfort/pain and happiness PODCI scores were lower than normative values.
SE|25462482||ab|8|entity|C1140618|Upper Extremity|bpoc|||Upper extremity|||0|901|1250|1265
SE|25462482||ab|8|entity|C0031843|physiological aspects|phsf|||function|||0|901|1266|1274
SE|25462482||ab|8|entity|C0038039|Sports|dora|||sport|||0|1000|1276|1281
SE|25462482||ab|8|entity|C0516981|Physical function|fndg|||physical function|||0|1000|1286|1303
SE|25462482||ab|8|entity|C1331418|Comfort|menp|||comfort|||0|888|1305|1312
SE|25462482||ab|8|entity|C0030193|Pain|sosy|||pain|||0|888|1313|1317
SE|25462482||ab|8|entity|C0018592|Happiness|menp|||happiness|||0|813|1322|1331
SE|25462482||ab|8|entity|C1521725|Pediatric|qlco|||PODCI|||0|813|1332|1337
SE|25462482||ab|8|entity|C1274040|result|ftcn|||PODCI|||0|813|1332|1337
SE|25462482||ab|8|entity|C0010995|Data Collection|resa|||PODCI|||0|813|1332|1337
SE|25462482||ab|8|entity|C0348000|Instrument|mnob|||PODCI|||0|813|1332|1337
SE|25462482||ab|8|entity|C0449820|Score|qnco|||scores|||0|813|1338|1344
SE|25462482||ab|8|entity|C0441994|Lower|ftcn|||lower|||0|1000|1350|1355
SE|25462482||ab|8|entity|C0042295|Values|qlco|||values|||0|861|1371|1377

SE|25462482||ab|9|text|1379|1470|The NF1 cohort had low participation in formal active physical and skill-based activities.
SE|25462482||ab|9|entity|C0027831|Neurofibromatosis 1|neop|||NF1|||0|916|1383|1386
SE|25462482||ab|9|entity|C0599755|cohort|popg|||cohort|||0|916|1387|1393
SE|25462482||ab|9|entity|C0205251|low|qlco|||low|||0|888|1398|1401
SE|25462482||ab|9|entity|C0679823|participation|inbe|||participation|||0|888|1402|1415
SE|25462482||ab|9|entity|C0376315|Manufactured form|mnob|||formal|||0|828|1419|1425
SE|25462482||ab|9|entity|C0205177|Active|ftcn|||active|||0|828|1426|1432
SE|25462482||ab|9|entity|C0205485|Physical|ftcn|||physical|||0|828|1433|1441
SE|25462482||ab|9|entity|C0678856|skills|inbe|||skill|||0|829|1446|1451
SE|25462482||ab|9|entity|C0441655|Activities|acty|||activities|||0|829|1458|1468
SE|25462482||ab|9|relation|3|1|C0679823|participation|inbe|inbe|||participation|||0|888|1402|1415|AUX|PROCESS_OF||1394|1397|1|1|C0599755|cohort|popg,humn|humn|||cohort|||0|916|1387|1393

SE|25462482||ab|10|text|1470|1660|The companionship and location dimensions suggest participation occurs with family and other relatives in the home or a relative's home and reflects a pattern of social isolation from peers.
SE|25462482||ab|10|entity|C0699797|Companionship|socb|||companionship|||0|1000|1474|1487
SE|25462482||ab|10|entity|C0450429|Location|spco|||location|||0|888|1492|1500
SE|25462482||ab|10|entity|C0439534|Dimensions|qnco|||dimensions|||0|888|1501|1511
SE|25462482||ab|10|entity|C0679823|participation|inbe|||participation|||0|1000|1520|1533
SE|25462482||ab|10|entity|C0015576|Family|famg|||family|||0|1000|1546|1552
SE|25462482||ab|10|entity|C0080103|Relative (related person)|famg|||relatives|||0|1000|1563|1572
SE|25462482||ab|10|entity|C0205345|Relative|qlco|||relative's|||0|694|1590|1600
SE|25462482||ab|10|entity|C0449774|Patterns|spco|||pattern|||0|1000|1621|1628
SE|25462482||ab|10|entity|C0037421|Social isolation|socb|||social isolation|||0|1000|1632|1648
SE|25462482||ab|10|entity|C0679739|peer|popg|||peers|||0|1000|1654|1659


SE|25462483||ti|1|text|21|77|Numerical estimation in individuals with Down syndrome.
SE|25462483||ti|1|entity|C0680844|estimation|menp|||estimation|||0|861|31|41
SE|25462483||ti|1|entity|C0237401|Individual|humn|||individuals|||0|1000|45|56
SE|25462483||ti|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|62|75
SE|25462483||ti|1|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|62|75|PREP|PROCESS_OF||57|61|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|45|56
SE|25462483||ti|1|relation|1|1|C0680844|estimation|menp|menp|||estimation|||0|861|31|41|PREP|PROCESS_OF||42|44|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|45|56

SE|25462483||ab|1|text|83|292|We investigated numerical estimation in children with Down syndrome (DS) in order to assess whether their pattern of performance is tied to experience (age), overall cognitive level, or specifically impaired.
SE|25462483||ab|1|entity|C0680844|estimation|menp|||estimation|||0|861|109|119
SE|25462483||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|123|131
SE|25462483||ab|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|137|150
SE|25462483||ab|1|entity|C0449774|Patterns|spco|||pattern|||0|1000|189|196
SE|25462483||ab|1|entity|C0597198|Performance|inbe|||performance|||0|1000|200|211
SE|25462483||ab|1|entity|C0001779|Age|orga|||age|||0|1000|235|238
SE|25462483||ab|1|entity|C1561607|Overall|qlco|||overall|||0|623|241|248
SE|25462483||ab|1|entity|C1516691|Cognitive|ftcn|||cognitive|||0|623|249|258
SE|25462483||ab|1|relation|1|1|C0680844|estimation|menp|menp|||estimation|||0|861|109|119|PREP|PROCESS_OF||120|122|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|123|131
SE|25462483||ab|1|relation|6|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|137|150|PREP|PROCESS_OF||132|136|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|123|131

SE|25462483||ab|2|text|292|580|Siegler and Opfer's (2003) number to position task, which requires translating a number into a spatial position on a number line, was administered to a group of 21 children with DS and to two control groups of typically developing children (TD), matched for mental and chronological age.
SE|25462483||ab|2|entity|C0237753|Numbers|qnco|||number|||0|1000|319|325
SE|25462483||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|888|329|337
SE|25462483||ab|2|entity|C0040710|Translating|ocac,ocdi|||translating|||0|1000|359|370
SE|25462483||ab|2|entity|C0237753|Numbers|qnco|||number|||0|1000|373|379
SE|25462483||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|861|395|403
SE|25462483||ab|2|entity|C0237753|Numbers|qnco|||number|||0|888|409|415
SE|25462483||ab|2|entity|C0205132|Linear|spco|||line|||0|888|416|420
SE|25462483||ab|2|entity|C0441833|Groups|inpr|||group|||0|1000|444|449
SE|25462483||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|861|456|464
SE|25462483||ab|2|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|470|472
SE|25462483||ab|2|entity|C0205448|Two|qnco|||two|||0|901|480|483
SE|25462483||ab|2|entity|C0009932|Control Groups|grup|||control groups|||0|901|484|498
SE|25462483||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|827|523|531
SE|25462483||ab|2|entity|C0008717|Chronology|tmco|||chronological|||0|853|561|574
SE|25462483||ab|2|entity|C0001779|Age|orga|||age|||0|853|575|578
SE|25462483||ab|2|relation|5|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|470|472|PREP|PROCESS_OF||465|469|10|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|456|464

SE|25462483||ab|3|text|580|837|Results suggest that numerical estimation and the developmental transition between logarithm and linear patterns of estimates in children with DS is more similar to that of children with the same mental age than to children with the same chronological age.
SE|25462483||ab|3|entity|C1274040|result|ftcn|||Results|||0|966|580|587
SE|25462483||ab|3|entity|C0680844|estimation|menp|||estimation|||0|861|611|621
SE|25462483||ab|3|entity|C0458003|Developmental|qlco|||developmental|||0|694|630|643
SE|25462483||ab|3|entity|C0205132|Linear|spco|||linear|||0|888|677|683
SE|25462483||ab|3|entity|C0449774|Patterns|spco|||patterns|||0|888|684|692
SE|25462483||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|709|717
SE|25462483||ab|3|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|723|725
SE|25462483||ab|3|entity|C0205172|More|ftcn|||more|||0|853|729|733
SE|25462483||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|753|761
SE|25462483||ab|3|entity|C0445247|Same|qlco|||same|||0|901|771|775
SE|25462483||ab|3|entity|C0598705|Mental Age|menp|||mental age|||0|901|776|786
SE|25462483||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|795|803
SE|25462483||ab|3|entity|C0445247|Same|qlco|||same|||0|828|813|817
SE|25462483||ab|3|entity|C0008717|Chronology|tmco|||chronological|||0|828|818|831
SE|25462483||ab|3|entity|C0001779|Age|orga|||age|||0|828|832|835
SE|25462483||ab|3|relation|3|1|C0598705|Mental Age|menp|menp|||mental age|||0|901|776|786|PREP|PROCESS_OF||762|766|10|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|753|761
SE|25462483||ab|3|relation|6|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|723|725|PREP|PROCESS_OF||718|722|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|709|717
SE|25462483||ab|3|relation|6|5|C0680844|estimation|menp|menp|||estimation|||0|861|611|621|PREP|PROCESS_OF||706|708|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|709|717

SE|25462483||ab|4|text|837|957|Moreover linearity was related to the cognitive level in DS while in TD children it was related to the experience level.
SE|25462483||ab|4|entity|C0205132|Linear|spco|||linearity|||0|789|846|855
SE|25462483||ab|4|entity|C1516691|Cognitive|ftcn|||cognitive|||0|694|875|884
SE|25462483||ab|4|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|894|896
SE|25462483||ab|4|entity|C0008059|Child|aggp,inpr|||TD|||0|645|906|908
SE|25462483||ab|4|entity|C0870520|Experience Level|qlco|||experience level|||0|1000|940|956


SE|25462484||ti|1|text|21|64|Low verbal assessment with the Bayley-III.
SE|25462484||ti|1|entity|C0205251|low|qlco|||Low|||0|851|21|24
SE|25462484||ti|1|entity|C0439824|Verbal|orgf|||verbal|||0|851|25|31
SE|25462484||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|851|32|42
SE|25462484||ti|1|entity|C0439070|III|inpr|||III|||0|861|59|62

SE|25462484||ab|1|text|70|203|Recently, the authors have developed the Bayley-III-NL Low Verbal for developmental assessment of children with language impairment.
SE|25462484||ab|1|entity|C0332185|Recent|tmco|||Recently|||0|1000|70|78
SE|25462484||ab|1|entity|C0221192|Author|idcn,prog|||authors|||0|1000|84|91
SE|25462484||ab|1|entity|C0439070|III|inpr|||III-NL|||0|771|118|124
SE|25462484||ab|1|entity|C0205307|Normal|qlco|||III-NL|||0|771|118|124
SE|25462484||ab|1|entity|C0205251|low|qlco|||Low|||0|771|125|128
SE|25462484||ab|1|entity|C0439824|Verbal|orgf|||Verbal|||0|771|129|135
SE|25462484||ab|1|entity|C0458003|Developmental|qlco|||developmental|||0|888|140|153
SE|25462484||ab|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|154|164
SE|25462484||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|168|176
SE|25462484||ab|1|entity|C0023015|Language Disorders|mobd|||language impairment|||0|1000|182|201
SE|25462484||ab|1|relation|1|1|C0023015|Language Disorders|mobd|mobd|||language impairment|||0|1000|182|201|PREP|PROCESS_OF||177|181|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|168|176
SE|25462484||ab|1|relation|4|1|C0439824|Verbal|orgf|orgf|||Verbal|||0|771|129|135|VERB|PROCESS_OF||97|106|1|1|C0221192|Author|idcn,prog,humn|humn|||authors|||0|1000|84|91

SE|25462484||ab|2|text|203|324|The Low Verbal version consists of an accommodated cognition scale, and non-accommodated communication and motor scales.
SE|25462484||ab|2|entity|C0205251|low|qlco|||Low|||0|851|207|210
SE|25462484||ab|2|entity|C0439824|Verbal|orgf|||Verbal|||0|851|211|217
SE|25462484||ab|2|entity|C0333052|Version|ftcn|||version|||0|851|218|225
SE|25462484||ab|2|entity|C0009240|Cognition|menp|||cognition|||0|790|254|263
SE|25462484||ab|2|entity|C0009452|Communication|socb|||communication|||0|827|292|305
SE|25462484||ab|2|entity|C1513492|Motor|idcn|||motor|||0|888|310|315

SE|25462484||ab|3|text|324|542|The purpose of the study was to evaluate the validity and added value of the Bayley-III-NL Low Verbal for children with a language impairment, in relation to the standard Bayley-III-NL for children without impairment.
SE|25462484||ab|3|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|328|335
SE|25462484||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|343|348
SE|25462484||ab|3|entity|C1524062|Additional|ftcn|||added|||0|661|382|387
SE|25462484||ab|3|entity|C0439070|III|inpr|||III-NL|||0|771|408|414
SE|25462484||ab|3|entity|C0205307|Normal|qlco|||III-NL|||0|771|408|414
SE|25462484||ab|3|entity|C0205251|low|qlco|||Low|||0|771|415|418
SE|25462484||ab|3|entity|C0439824|Verbal|orgf|||Verbal|||0|771|419|425
SE|25462484||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|430|438
SE|25462484||ab|3|entity|C0023015|Language Disorders|mobd|||language impairment|||0|1000|446|465
SE|25462484||ab|3|entity|C1442989|STANDARD|ftcn|||standard|||0|775|486|494
SE|25462484||ab|3|entity|C0439070|III|inpr|||III-NL|||0|775|502|508
SE|25462484||ab|3|entity|C0205307|Normal|qlco|||III-NL|||0|775|502|508
SE|25462484||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|513|521
SE|25462484||ab|3|relation|4|1|C0023015|Language Disorders|mobd|mobd|||language impairment|||0|1000|446|465|PREP|PROCESS_OF||439|443|6|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|430|438

SE|25462484||ab|4|text|542|694|We administered the Bayley-III Low Verbal to 69 children with language impairment, and the standard Bayley-III-NL to 1132 children without impairments.
SE|25462484||ab|4|entity|C0439070|III|inpr|||III|||0|775|569|572
SE|25462484||ab|4|entity|C0205251|low|qlco|||Low|||0|775|573|576
SE|25462484||ab|4|entity|C0439824|Verbal|orgf|||Verbal|||0|775|577|583
SE|25462484||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|861|590|598
SE|25462484||ab|4|entity|C0023015|Language Disorders|mobd|||language impairment|||0|1000|604|623
SE|25462484||ab|4|entity|C1442989|STANDARD|ftcn|||standard|||0|775|633|641
SE|25462484||ab|4|entity|C0439070|III|inpr|||III-NL|||0|775|649|655
SE|25462484||ab|4|entity|C0205307|Normal|qlco|||III-NL|||0|775|649|655
SE|25462484||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|861|664|672
SE|25462484||ab|4|relation|4|1|C0023015|Language Disorders|mobd|mobd|||language impairment|||0|1000|604|623|PREP|PROCESS_OF||599|603|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|590|598

SE|25462484||ab|5|text|694|869|We used an evaluation form for test administrators and interviews with developmental psychologists to evaluate the suitability of the Low Verbal version for the target group.
SE|25462484||ab|5|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|705|715
SE|25462484||ab|5|entity|C1522492|Formation|ftcn|||form|||0|888|716|720
SE|25462484||ab|5|entity|C0039593|Testing|resa|||test|||0|888|725|729
SE|25462484||ab|5|entity|C0085751|Administrators|prog|||administrators|||0|888|730|744
SE|25462484||ab|5|entity|C0458003|Developmental|qlco|||developmental|||0|888|765|778
SE|25462484||ab|5|entity|C0033908|Psychologist|prog|||psychologists|||0|888|779|792
SE|25462484||ab|5|entity|C0205251|low|qlco|||Low|||0|851|828|831
SE|25462484||ab|5|entity|C0439824|Verbal|orgf|||Verbal|||0|851|832|838
SE|25462484||ab|5|entity|C0333052|Version|ftcn|||version|||0|851|839|846
SE|25462484||ab|5|entity|C0680888|target group|popg|||target group|||0|1000|855|867

SE|25462484||ab|6|text|869|1031|We analyzed the test results using nonparametric item response theory (IRT) to investigate whether test results can be reasonably compared across the two groups.
SE|25462484||ab|6|entity|C0456984|Test Result|fndg|||test results|||0|983|885|897
SE|25462484||ab|6|entity|C0870753|Item Response Theory|inpr,resa|||item response theory|||0|923|918|938
SE|25462484||ab|6|entity|C0456984|Test Result|fndg|||test results|||0|983|968|980
SE|25462484||ab|6|entity|C0205448|Two|qnco|||two|||0|888|1019|1022
SE|25462484||ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|1023|1029

SE|25462484||ab|7|text|1031|1275|The results of the IRT analyses support the validity of the Bayley-III-NL Low Verbal: the test items do not suffer from differential item functioning (DIF) across the two groups, and thus measure the ability levels of interest in the same way.
SE|25462484||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1035|1042
SE|25462484||ab|7|entity|C0870753|Item Response Theory|inpr,resa|||IRT|||0|908|1050|1053
SE|25462484||ab|7|entity|C0936012|Analysis|resa|||analyses|||0|908|1054|1062
SE|25462484||ab|7|entity|C0439070|III|inpr|||III-NL|||0|771|1098|1104
SE|25462484||ab|7|entity|C0205307|Normal|qlco|||III-NL|||0|771|1098|1104
SE|25462484||ab|7|entity|C0205251|low|qlco|||Low|||0|771|1105|1108
SE|25462484||ab|7|entity|C0439824|Verbal|orgf|||Verbal|||0|771|1109|1115
SE|25462484||ab|7|entity|C0871509|Test Items|inpr,resa|||test items|||0|1000|1121|1131
SE|25462484||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1135|1138
SE|25462484||ab|7|entity|C0031843|physiological aspects|phsf|||functioning|||0|793|1169|1180
SE|25462484||ab|7|entity|C0205448|Two|qnco|||two|||0|888|1198|1201
SE|25462484||ab|7|entity|C0441833|Groups|inpr|||groups|||0|888|1202|1208
SE|25462484||ab|7|entity|C0870086|Ability Level|qlco|||ability levels|||0|983|1231|1245
SE|25462484||ab|7|entity|C0543488|Interested|menp|||interest|||0|1000|1249|1257
SE|25462484||ab|7|entity|C0445247|Same|qlco|||same|||0|694|1265|1269
SE|25462484||ab|7|relation|5|1|C0031843|physiological aspects|phsf|phsf|||functioning|||0|793|1169|1180|VERB|AFFECTS|negation|1139|1145|5|2|C0439824|Verbal|orgf|orgf|||Verbal|||0|771|1109|1115

SE|25462484||ab|8|text|1275|1477|The results of the evaluation form and interviews confirm that the Bayley-III-NL Low Verbal has added value for testing children with a language impairment, especially for children up to 36 months old.
SE|25462484||ab|8|entity|C1274040|result|ftcn|||results|||0|966|1279|1286
SE|25462484||ab|8|entity|C0220825|Evaluation|ftcn|||evaluation|||0|888|1294|1304
SE|25462484||ab|8|entity|C1522492|Formation|ftcn|||form|||0|888|1305|1309
SE|25462484||ab|8|entity|C0021822|Interview|inpr,resa|||interviews|||0|1000|1314|1324
SE|25462484||ab|8|entity|C0439070|III|inpr|||III-NL|||0|771|1349|1355
SE|25462484||ab|8|entity|C0205307|Normal|qlco|||III-NL|||0|771|1349|1355
SE|25462484||ab|8|entity|C0205251|low|qlco|||Low|||0|771|1356|1359
SE|25462484||ab|8|entity|C0439824|Verbal|orgf|||Verbal|||0|771|1360|1366
SE|25462484||ab|8|entity|C1524062|Additional|ftcn|||added|||0|661|1371|1376
SE|25462484||ab|8|entity|C0039593|Testing|resa|||testing|||0|888|1387|1394
SE|25462484||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|888|1395|1403
SE|25462484||ab|8|entity|C0023015|Language Disorders|mobd|||language impairment|||0|1000|1411|1430
SE|25462484||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1447|1455
SE|25462484||ab|8|entity|C0439231|month|tmco|||months|||0|790|1465|1471
SE|25462484||ab|8|entity|C0580836|Old|tmco|||old|||0|790|1472|1475
SE|25462484||ab|8|relation|3|1|C0023015|Language Disorders|mobd|mobd|||language impairment|||0|1000|1411|1430|PREP|PROCESS_OF||1404|1408|6|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|1395|1403

SE|25462484||ab|9|text|1477|1544|It is also suitable for children with general developmental delay.
SE|25462484||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1501|1509
SE|25462484||ab|9|entity|C0424601|General development|fndg|||general developmental|||0|877|1515|1536
SE|25462484||ab|9|entity|C0205421|Deferred|tmco|||delay|||0|877|1537|1542

SE|25462484||ab|10|text|1544|1755|We conclude that the Bayley-III-NL Low Verbal can validly assess the cognitive, language, and motor development of young children with a language impairment and is the preferred instrument for this target group.
SE|25462484||ab|10|entity|C0439070|III|inpr|||III-NL|||0|771|1572|1578
SE|25462484||ab|10|entity|C0205307|Normal|qlco|||III-NL|||0|771|1572|1578
SE|25462484||ab|10|entity|C0205251|low|qlco|||Low|||0|771|1579|1582
SE|25462484||ab|10|entity|C0439824|Verbal|orgf|||Verbal|||0|771|1583|1589
SE|25462484||ab|10|entity|C1516691|Cognitive|ftcn|||cognitive|||0|888|1613|1622
SE|25462484||ab|10|entity|C0023008|Language|lang|||language|||0|888|1624|1632
SE|25462484||ab|10|entity|C0870919|Motor Development|orgf|||motor development|||0|1000|1638|1655
SE|25462484||ab|10|entity|C0332239|Young|tmco|||young|||0|888|1659|1664
SE|25462484||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|888|1665|1673
SE|25462484||ab|10|entity|C0023015|Language Disorders|mobd|||language impairment|||0|1000|1681|1700
SE|25462484||ab|10|entity|C1548789|Preferred|qlco|||preferred|||0|888|1712|1721
SE|25462484||ab|10|entity|C0348000|Instrument|mnob|||instrument|||0|888|1722|1732
SE|25462484||ab|10|entity|C0680888|target group|popg|||target group|||0|1000|1742|1754
SE|25462484||ab|10|relation|3|1|C0023015|Language Disorders|mobd|mobd|||language impairment|||0|1000|1681|1700|PREP|PROCESS_OF||1674|1678|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|1665|1673


SE|25462485||ti|1|text|21|146|Coupling online control and inhibitory systems in children with Developmental Coordination Disorder: Goal-directed reaching.
SE|25462485||ti|1|entity|C0010222|Couples|famg|||Coupling|||0|785|21|29
SE|25462485||ti|1|entity|C0243148|control|ftcn|||control|||0|785|37|44
SE|25462485||ti|1|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|49|59
SE|25462485||ti|1|entity|C0449913|System|ftcn|||systems|||0|853|60|67
SE|25462485||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|71|79
SE|25462485||ti|1|entity|C0011757|Developmental Coordination Disorder|dsyn|||Developmental Coordination Disorder|||0|1000|85|120
SE|25462485||ti|1|entity|C0018017|objective (goal)|inpr|||Goal|||0|785|122|126
SE|25462485||ti|1|relation|2|1|C0011757|Developmental Coordination Disorder|dsyn|dsyn|||Developmental Coordination Disorder|||0|1000|85|120|PREP|PROCESS_OF||80|84|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|71|79

SE|25462485||ab|1|text|152|360|For children with Developmental Coordination Disorder (DCD), the real-time coupling between frontal executive function and online motor control has not been explored despite reported deficits in each domain.
SE|25462485||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|156|164
SE|25462485||ab|1|entity|C0011757|Developmental Coordination Disorder|dsyn|||Developmental Coordination Disorder|||0|1000|170|205
SE|25462485||ab|1|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|1000|207|210
SE|25462485||ab|1|entity|C1550177|Real Time|idcn|||real-time|||0|734|217|226
SE|25462485||ab|1|entity|C0205123|Coronal|spco|||frontal|||0|901|244|251
SE|25462485||ab|1|entity|C0935584|Executive Functioning|menp|||executive function|||0|901|252|270
SE|25462485||ab|1|entity|C1513492|Motor|idcn|||motor|||0|790|282|287
SE|25462485||ab|1|entity|C0243148|control|ftcn|||control|||0|790|288|295
SE|25462485||ab|1|entity|C1518422|Not|ftcn|||not|||0|1000|300|303
SE|25462485||ab|1|entity|C0011155|Deficiency|ftcn|||deficits|||0|872|335|343
SE|25462485||ab|1|relation|7|1|C0011757|Developmental Coordination Disorder|dsyn|dsyn|||Developmental Coordination Disorder|||0|1000|170|205|PREP|PROCESS_OF||165|169|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|156|164

SE|25462485||ab|2|text|360|520|The aim of the present study was to investigate how children with DCD enlist online control under task constraints that compel the need for inhibitory control.
SE|25462485||ab|2|entity|C0150312|Present|qnco|||present|||0|888|375|382
SE|25462485||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|383|388
SE|25462485||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|861|412|420
SE|25462485||ab|2|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|1000|426|429
SE|25462485||ab|2|entity|C0243148|control|ftcn|||control|||0|861|444|451
SE|25462485||ab|2|entity|C0027552|Needs|qlco|||need|||0|1000|491|495
SE|25462485||ab|2|entity|C0243077|inhibitors|chvf|||inhibitory|||0|853|500|510
SE|25462485||ab|2|entity|C0243148|control|ftcn|||control|||0|853|511|518

SE|25462485||ab|3|text|520|597|A total of 129 school children were sampled from mainstream primary schools.
SE|25462485||ab|3|entity|C0439175|% of total|qnco|||total|||0|1000|522|527
SE|25462485||ab|3|entity|C0260267|School child|aggp|||school children|||0|901|535|550
SE|25462485||ab|3|entity|C0033145|Primary Schools|mnob,orgt|||primary schools|||0|901|580|595

SE|25462485||ab|4|text|597|743|Forty-two children who met research criteria for DCD were compared with 87 typically developing controls on a modified double-jump reaching task.
SE|25462485||ab|4|entity|C0205448|Two|qnco|||two|||0|790|603|606
SE|25462485||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|790|607|615
SE|25462485||ab|4|entity|C0035168|research|resa|||research|||0|888|624|632
SE|25462485||ab|4|entity|C0243161|criteria|inpr|||criteria|||0|888|633|641
SE|25462485||ab|4|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|1000|646|649
SE|25462485||ab|4|entity|C0243148|control|ftcn|||controls|||0|779|693|701
SE|25462485||ab|4|entity|C0205349|Altered|ftcn|||modified|||0|808|707|715
SE|25462485||ab|4|entity|C0205173|Duplicate|ftcn|||double|||0|808|716|722
SE|25462485||ab|4|entity|C0560453|Does jump|fndg|||jump|||0|808|723|727

SE|25462485||ab|5|text|743|867|Children within each skill group were divided into three age bands: younger (6-7 years), mid-aged (8-9), and older (10-12).
SE|25462485||ab|5|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|743|751
SE|25462485||ab|5|entity|C0678856|skills|inbe|||skill|||0|872|764|769
SE|25462485||ab|5|entity|C0441833|Groups|inpr|||group|||0|872|770|775
SE|25462485||ab|5|entity|C0205449|Three|qnco|||three|||0|851|794|799
SE|25462485||ab|5|entity|C0001779|Age|orga|||age|||0|851|800|803
SE|25462485||ab|5|entity|C0175723|Bands|medd|||bands|||0|851|804|809
SE|25462485||ab|5|entity|C0332239|Young|tmco|||younger|||0|966|811|818
SE|25462485||ab|5|entity|C0439234|year|tmco|||years|||0|827|824|829
SE|25462485||ab|5|entity|C0444598|Middle|spco|||mid|||0|888|832|835
SE|25462485||ab|5|entity|C0580836|Old|tmco|||older|||0|966|852|857

SE|25462485||ab|6|text|867|967|Online control was compared between groups as a function of trial type (non-jump, jump, anti-jump).
SE|25462485||ab|6|entity|C0243148|control|ftcn|||control|||0|861|874|881
SE|25462485||ab|6|entity|C0441833|Groups|inpr|||groups|||0|1000|903|909
SE|25462485||ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|1000|915|923
SE|25462485||ab|6|entity|C0008976|Clinical Trials|resa|||trial|||0|888|927|932
SE|25462485||ab|6|entity|C1547052|*Type|qnco|||type|||0|888|933|937
SE|25462485||ab|6|entity|C0560453|Does jump|fndg|||jump|||0|827|943|947
SE|25462485||ab|6|entity|C0560453|Does jump|fndg|||jump|||0|966|949|953
SE|25462485||ab|6|entity|C0560453|Does jump|fndg|||jump|||0|827|960|964

SE|25462485||ab|7|text|967|1214|Overall, results showed that while movement times were similar between skill groups under simple task constraints (non-jump), on perturbation (or jump) trials the DCD group were significantly slower than controls and corrected trajectories later.
SE|25462485||ab|7|entity|C1561607|Overall|qlco|||Overall|||0|1000|967|974
SE|25462485||ab|7|entity|C1274040|result|ftcn|||results|||0|966|976|983
SE|25462485||ab|7|entity|C0026649|Movement|orgf|||movement|||0|872|1002|1010
SE|25462485||ab|7|entity|C0040223|Time|tmco|||times|||0|872|1011|1016
SE|25462485||ab|7|entity|C0678856|skills|inbe|||skill|||0|966|1038|1043
SE|25462485||ab|7|entity|C0205352|Simple|qlco|||simple|||0|623|1057|1063
SE|25462485||ab|7|entity|C0560453|Does jump|fndg|||jump|||0|827|1086|1090
SE|25462485||ab|7|entity|C0560453|Does jump|fndg|||jump|||0|966|1113|1117
SE|25462485||ab|7|entity|C0008976|Clinical Trials|resa|||trials|||0|966|1119|1125
SE|25462485||ab|7|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|888|1130|1133
SE|25462485||ab|7|entity|C0441833|Groups|inpr|||group|||0|888|1134|1139
SE|25462485||ab|7|entity|C0439834|Slow|qlco|||slower|||0|827|1159|1165
SE|25462485||ab|7|entity|C0243148|control|ftcn|||controls|||0|966|1171|1179
SE|25462485||ab|7|entity|C0205202|Corrected|qlco|||corrected|||0|660|1184|1193

SE|25462485||ab|8|text|1214|1364|Critically, the DCD group was further disadvantaged by anti-jump trials where inhibitory control was required; however, this effect reduced with age.
SE|25462485||ab|8|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|888|1230|1233
SE|25462485||ab|8|entity|C0441833|Groups|inpr|||group|||0|888|1234|1239
SE|25462485||ab|8|entity|C1517331|Further|spco|||further|||0|1000|1244|1251
SE|25462485||ab|8|entity|C0560453|Does jump|fndg|||jump|||0|693|1274|1278
SE|25462485||ab|8|entity|C0008976|Clinical Trials|resa|||trials|||0|693|1279|1285
SE|25462485||ab|8|entity|C0243077|inhibitors|chvf|||inhibitory|||0|693|1292|1302
SE|25462485||ab|8|entity|C0243148|control|ftcn|||control|||0|693|1303|1310
SE|25462485||ab|8|entity|C1280500|Effect|qlco|||effect|||0|1000|1339|1345
SE|25462485||ab|8|entity|C0001779|Age|orga|||age|||0|1000|1359|1362

SE|25462485||ab|9|text|1364|1537|While coupling online control and executive systems is not well developed in younger and mid-aged children, there is evidence of age-appropriate coupling in older children.
SE|25462485||ab|9|entity|C0010222|Couples|famg|||coupling|||0|785|1370|1378
SE|25462485||ab|9|entity|C0243148|control|ftcn|||control|||0|785|1386|1393
SE|25462485||ab|9|entity|C0449913|System|ftcn|||systems|||0|872|1408|1415
SE|25462485||ab|9|entity|C1518422|Not|ftcn|||not|||0|790|1419|1422
SE|25462485||ab|9|entity|C0205170|Good|qlco|||well|||0|790|1423|1427
SE|25462485||ab|9|entity|C0332239|Young|tmco|||younger|||0|966|1441|1448
SE|25462485||ab|9|entity|C0444598|Middle|spco|||mid|||0|851|1453|1456
SE|25462485||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|851|1462|1470
SE|25462485||ab|9|entity|C0001779|Age|orga|||age|||0|623|1493|1496
SE|25462485||ab|9|entity|C1548787|Appropriate|qlco|||appropriate|||0|623|1497|1508
SE|25462485||ab|9|entity|C0580836|Old|tmco|||older|||0|872|1521|1526
SE|25462485||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|872|1527|1535

SE|25462485||ab|10|text|1537|1602|Longitudinal data are needed to clarify this intriguing finding.
SE|25462485||ab|10|entity|C0205127|Longitudinal|spco|||Longitudinal|||0|888|1537|1549
SE|25462485||ab|10|entity|C1511726|Data|idcn|||data|||0|888|1550|1554
SE|25462485||ab|10|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|861|1593|1600

SE|25462485||ab|11|text|1602|1674|The theoretical and applied implications of these results are discussed.
SE|25462485||ab|11|entity|C1274040|result|ftcn|||results|||0|966|1652|1659


SE|25462486||ti|1|text|21|166|Psychometric properties of the Chinese Behavior Problems Inventory-01 in children and adolescents with or at risk for intellectual disabilities.
SE|25462486||ti|1|entity|C0033920|Psychometrics|diap|||Psychometric|||0|872|21|33
SE|25462486||ti|1|entity|C0871161|Property|qlco|||properties|||0|872|34|44
SE|25462486||ti|1|entity|C0260653|Problem behavior|mobd|||Behavior Problems|||0|785|60|77
SE|25462486||ti|1|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|785|78|87
SE|25462486||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|94|102
SE|25462486||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|107|118
SE|25462486||ti|1|entity|C1444641|At risk|qlco|||at risk|||0|1000|127|134
SE|25462486||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|139|164

SE|25462486||ab|1|text|172|313|As the world's most populous country, China is likely to have the highest number of people with intellectual disabilities (ID) in the world.
SE|25462486||ab|1|entity|C0454664|Country|geoa|||country|||0|812|201|208
SE|25462486||ab|1|entity|C0008115|China|geoa|||China|||0|1000|210|215
SE|25462486||ab|1|entity|C1522410|Highest|qlco|||highest|||0|888|238|245
SE|25462486||ab|1|entity|C0237753|Numbers|qnco|||number|||0|888|246|252
SE|25462486||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|256|262
SE|25462486||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|268|293
SE|25462486||ab|1|relation|2|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|268|293|PREP|PROCESS_OF||263|267|4|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|256|262

SE|25462486||ab|2|text|313|467|As many people with ID are susceptible to serious and persistent behavior problems, research by Chinese scientists on this public health issue is needed.
SE|25462486||ab|2|entity|C0027361|Persons|popg|||people|||0|1000|321|327
SE|25462486||ab|2|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|333|335
SE|25462486||ab|2|entity|C0231204|Susceptible|ftcn|||susceptible|||0|1000|340|351
SE|25462486||ab|2|entity|C0205404|Serious|qlco|||serious|||0|1000|355|362
SE|25462486||ab|2|entity|C0205322|Persistent|tmco|||persistent|||0|901|367|377
SE|25462486||ab|2|entity|C0260653|Problem behavior|mobd|||behavior problems|||0|901|378|395
SE|25462486||ab|2|entity|C0035168|research|resa|||research|||0|1000|397|405
SE|25462486||ab|2|entity|C0402112|Scientist|prog|||scientists|||0|861|417|427
SE|25462486||ab|2|entity|C0018684|Health|idcn|||health|||0|660|443|449
SE|25462486||ab|2|relation|7|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|333|335|PREP|PROCESS_OF||328|332|1|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|321|327

SE|25462486||ab|3|text|467|581|However, there are only very few reliable Chinese-language behavior assessment instruments for problem behaviors.
SE|25462486||ab|3|entity|C0442824|Very|qlco|||very|||0|751|491|495
SE|25462486||ab|3|entity|C0008120|Chinese Language|lang|||Chinese-language|||0|751|509|525
SE|25462486||ab|3|entity|C1160858|Behavior assessment|hlca|||behavior assessment|||0|751|526|545
SE|25462486||ab|3|entity|C0243113|instruments|mnob|||instruments|||0|751|546|557
SE|25462486||ab|3|entity|C0260653|Problem behavior|mobd|||problem behaviors|||0|983|562|579

SE|25462486||ab|4|text|581|718|To fill this gap we translated the Behavior Problems Inventory-01 (BPI-01; Rojahn, Matson, Lott, Esbensen, & Smalls, 2001) into Chinese.
SE|25462486||ab|4|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||gap|||0|1000|594|597
SE|25462486||ab|4|entity|C0260653|Problem behavior|mobd|||Behavior Problems|||0|824|616|633
SE|25462486||ab|4|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|824|634|643

SE|25462486||ab|5|text|718|919|The BPI-01 is an informant-based behavior rating instrument that was designed to assess self-injurious behavior (SIB), stereotyped behavior, and aggressive/destructive behavior in individuals with ID.
SE|25462486||ab|5|entity|C1550484|informant|idcn|||informant|||0|815|735|744
SE|25462486||ab|5|entity|C0004927|Behavior|inbe|||behavior|||0|815|751|759
SE|25462486||ab|5|entity|C0871208|Rating|resa|||rating|||0|815|760|766
SE|25462486||ab|5|entity|C0348000|Instrument|mnob|||instrument|||0|815|767|777
SE|25462486||ab|5|entity|C0085271|Self-Injurious Behavior|mobd|||self-injurious behavior|||0|1000|806|829
SE|25462486||ab|5|entity|C0004927|Behavior|inbe|||behavior|||0|1000|849|857
SE|25462486||ab|5|entity|C0233520|Destructive|inbe|||destructive|||0|901|874|885
SE|25462486||ab|5|entity|C0001807|Aggressive behavior|mobd|||aggressive/destructive behavior|||0|901|863|894
SE|25462486||ab|5|entity|C0237401|Individual|humn|||individuals|||0|1000|898|909
SE|25462486||ab|5|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|915|917
SE|25462486||ab|5|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|915|917|PREP|PROCESS_OF||910|914|5|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|898|909
SE|25462486||ab|5|relation|4|1|C0001807|Aggressive behavior|mobd|mobd|||aggressive/destructive behavior|||0|901|863|894|PREP|PROCESS_OF||895|897|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|898|909

SE|25462486||ab|6|text|919|1093|We then assessed the behavior of 222 children and young adults (age range 1.5-21.5 years) with or at risk for ID from three special needs service programs in mainland China.
SE|25462486||ab|6|entity|C0004927|Behavior|inbe|||behavior|||0|1000|940|948
SE|25462486||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|861|956|964
SE|25462486||ab|6|entity|C0238598|Young adult|aggp|||young adults|||0|983|969|981
SE|25462486||ab|6|entity|C1514721|Range|qnco|||range|||0|801|987|992
SE|25462486||ab|6|entity|C1510829|Age-Years|tmco|||age range 1.5-21.5 years|||0|801|983|1007
SE|25462486||ab|6|entity|C1444641|At risk|qlco|||at risk|||0|1000|1017|1024
SE|25462486||ab|6|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1029|1031
SE|25462486||ab|6|entity|C0205449|Three|qnco|||three|||0|861|1037|1042
SE|25462486||ab|6|entity|C0871403|Special Needs|ftcn|||special needs|||0|861|1043|1056
SE|25462486||ab|6|entity|C0557854|Services|ftcn|||service|||0|861|1057|1064
SE|25462486||ab|6|entity|C0008115|China|geoa|||mainland China|||0|1000|1077|1091

SE|25462486||ab|7|text|1093|1157|Teachers or staff members, respectively, served as respondents.
SE|25462486||ab|7|entity|C0221457|Teacher|prog|||Teachers|||0|1000|1093|1101
SE|25462486||ab|7|entity|C1552089|Staff Member|idcn|||staff members|||0|983|1105|1118
SE|25462486||ab|7|entity|C0282122|Respondents|popg|||respondents|||0|1000|1144|1155

SE|25462486||ab|8|text|1157|1306|The Chinese version of the BPI-01 showed good reliability (internal consistency) and good factor validity tested by confirmatory factorial analysis.
SE|25462486||ab|8|entity|C0333052|Version|ftcn|||version|||0|861|1169|1176
SE|25462486||ab|8|entity|C0205170|Good|qlco|||good|||0|694|1198|1202
SE|25462486||ab|8|entity|C0870731|Internal Consistency|qnco|||internal consistency|||0|1000|1216|1236
SE|25462486||ab|8|entity|C0205170|Good|qlco|||good|||0|623|1242|1246
SE|25462486||ab|8|entity|C1521761|Factor|ftcn|||factor|||0|623|1247|1253
SE|25462486||ab|8|entity|C0750568|CONFIRMATORY|idcn|||confirmatory|||0|802|1273|1285
SE|25462486||ab|8|entity|C0936012|Analysis|resa|||analysis|||0|802|1296|1304

SE|25462486||ab|9|text|1306|1450|We conclude that the Chinese version of the BPI-01 can be used for research and clinical evaluation of Chinese children and adolescents with ID.
SE|25462486||ab|9|entity|C0333052|Version|ftcn|||version|||0|861|1335|1342
SE|25462486||ab|9|entity|C0035168|research|resa|||research|||0|1000|1373|1381
SE|25462486||ab|9|entity|C1261322|Assessment procedure|hlca|||clinical evaluation|||0|1000|1386|1405
SE|25462486||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|861|1417|1425
SE|25462486||ab|9|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|1430|1441
SE|25462486||ab|9|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1447|1449
SE|25462486||ab|9|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1447|1449|PREP|PROCESS_OF||1442|1446|5|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|861|1417|1425
SE|25462486||ab|9|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1447|1449|PREP|PROCESS_OF||1442|1446|5|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1430|1441


SE|25462488||ti|1|text|21|123|Spelling in oral deaf and hearing dyslexic children: A comparison of phonologically plausible errors.
SE|25462488||ti|1|entity|C0541736|Spelling|lang|||Spelling|||0|1000|21|29
SE|25462488||ti|1|entity|C0442027|Oral|spco|||oral|||0|888|33|37
SE|25462488||ti|1|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|888|38|42
SE|25462488||ti|1|entity|C0018767|Hearing|phsf|||hearing|||0|851|47|54
SE|25462488||ti|1|entity|C0476254|Dyslexia|mobd|||dyslexic|||0|851|55|63
SE|25462488||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|851|64|72
SE|25462488||ti|1|entity|C0743559|error|qlco|||errors|||0|827|115|121
SE|25462488||ti|1|relation|0|0|C0476254|Dyslexia|mobd|mobd|||dyslexic|||0|851|55|63|MOD/HEAD|PROCESS_OF||55|72|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|851|64|72

SE|25462488||ab|1|text|129|332|A written single word spelling to dictation test and a single word reading test were given to 68 severe-profoundly oral deaf 10-11-year-old children and 20 hearing children with a diagnosis of dyslexia.
SE|25462488||ab|1|entity|C0037179|Unmarried person|popg|||single|||0|756|139|145
SE|25462488||ab|1|entity|C0439824|Verbal|orgf|||word|||0|756|146|150
SE|25462488||ab|1|entity|C0541736|Spelling|lang|||spelling|||0|756|151|159
SE|25462488||ab|1|entity|C0039593|Testing|resa|||test|||0|861|173|177
SE|25462488||ab|1|entity|C0037179|Unmarried person|popg|||single|||0|838|184|190
SE|25462488||ab|1|entity|C0034754|Reading|dora|||reading|||0|838|196|203
SE|25462488||ab|1|entity|C0871573|Verbal Tests|edac,resa|||word reading test|||0|838|191|208
SE|25462488||ab|1|entity|C0205082|Severe|qlco|||severe|||0|708|226|232
SE|25462488||ab|1|entity|C0442027|Oral|spco|||oral|||0|708|244|248
SE|25462488||ab|1|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|708|249|253
SE|25462488||ab|1|entity|C0439234|year|tmco|||year|||0|708|260|264
SE|25462488||ab|1|entity|C0580836|Old|tmco|||old|||0|708|265|268
SE|25462488||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|708|269|277
SE|25462488||ab|1|entity|C0018767|Hearing|phsf|||hearing|||0|790|285|292
SE|25462488||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|790|293|301
SE|25462488||ab|1|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|309|318
SE|25462488||ab|1|entity|C0476254|Dyslexia|mobd|||dyslexia|||0|1000|322|330
SE|25462488||ab|1|relation|0|0|C0018767|Hearing|phsf|phsf|||hearing|||0|790|285|292|MOD/HEAD|PROCESS_OF||285|301|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|790|293|301

SE|25462488||ab|2|text|332|499|The literacy scores of the deaf children and the hearing children with dyslexia were lower than expected for children of their age and did not differ from each other.
SE|25462488||ab|2|entity|C0023864|Literacy|qlco|||literacy|||0|1000|336|344
SE|25462488||ab|2|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|888|359|363
SE|25462488||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|888|364|372
SE|25462488||ab|2|entity|C0018767|Hearing|phsf|||hearing|||0|888|381|388
SE|25462488||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|888|389|397
SE|25462488||ab|2|entity|C0476254|Dyslexia|mobd|||dyslexia|||0|1000|403|411
SE|25462488||ab|2|entity|C0441994|Lower|ftcn|||lower|||0|1000|417|422
SE|25462488||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|441|449
SE|25462488||ab|2|entity|C0001779|Age|orga|||age|||0|1000|459|462
SE|25462488||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|471|474
SE|25462488||ab|2|relation|0|0|C0018767|Hearing|phsf|phsf|||hearing|||0|888|381|388|MOD/HEAD|PROCESS_OF||381|397|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|389|397
SE|25462488||ab|2|relation|4|1|C0476254|Dyslexia|mobd|mobd|||dyslexia|||0|1000|403|411|PREP|PROCESS_OF||398|402|3|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|888|364|372
SE|25462488||ab|2|relation|4|1|C0476254|Dyslexia|mobd|mobd|||dyslexia|||0|1000|403|411|PREP|PROCESS_OF||398|402|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|389|397

SE|25462488||ab|3|text|499|665|Three quarters of the spelling errors of hearing children with dyslexia compared with just over half the errors of the oral deaf group were phonologically plausible.
SE|25462488||ab|3|entity|C0205449|Three|qnco|||Three|||0|694|499|504
SE|25462488||ab|3|entity|C0331515|Triticum spelta|plnt|||spelling|||0|888|521|529
SE|25462488||ab|3|entity|C0743559|error|qlco|||errors|||0|888|530|536
SE|25462488||ab|3|entity|C0018767|Hearing|phsf|||hearing|||0|888|540|547
SE|25462488||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|888|548|556
SE|25462488||ab|3|entity|C0476254|Dyslexia|mobd|||dyslexia|||0|1000|562|570
SE|25462488||ab|3|entity|C0743559|error|qlco|||errors|||0|1000|604|610
SE|25462488||ab|3|entity|C0442027|Oral|spco|||oral|||0|851|618|622
SE|25462488||ab|3|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|851|623|627
SE|25462488||ab|3|entity|C0441833|Groups|inpr|||group|||0|851|628|633
SE|25462488||ab|3|relation|0|0|C0018767|Hearing|phsf|phsf|||hearing|||0|888|540|547|MOD/HEAD|PROCESS_OF||540|556|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|548|556
SE|25462488||ab|3|relation|5|1|C0476254|Dyslexia|mobd|mobd|||dyslexia|||0|1000|562|570|PREP|PROCESS_OF||557|561|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|548|556

SE|25462488||ab|4|text|665|798|Expressive vocabulary and speech intelligibility predicted the percentage of phonologically plausible errors in the deaf group only.
SE|25462488||ab|4|entity|C0042926|Vocabulary|inpr|||vocabulary|||0|861|676|686
SE|25462488||ab|4|entity|C0037824|Speech Intelligibility|qlco|||speech intelligibility|||0|1000|691|713
SE|25462488||ab|4|entity|C0439165|Percent (qualifier value)|qnco|||percentage|||0|1000|728|738
SE|25462488||ab|4|entity|C0743559|error|qlco|||errors|||0|827|767|773
SE|25462488||ab|4|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|790|781|785
SE|25462488||ab|4|entity|C0441833|Groups|inpr|||group|||0|790|786|791

SE|25462488||ab|5|text|798|927|Implications of findings for the phonological decoding self-teaching model and for supporting literacy development are discussed.
SE|25462488||ab|5|entity|C0243095|Finding|ftcn|||findings|||0|1000|814|822
SE|25462488||ab|5|entity|C0597725|Phonology|ocdi|||phonological|||0|807|831|843
SE|25462488||ab|5|entity|C0870395|Decoding|menp|||decoding|||0|807|844|852
SE|25462488||ab|5|entity|C0036588|Self|idcn|||self|||0|807|853|857
SE|25462488||ab|5|entity|C0039401|Educational process of instructing|edac|||teaching|||0|807|858|866
SE|25462488||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|807|867|872
SE|25462488||ab|5|entity|C0023864|Literacy|qlco|||literacy|||0|840|892|900
SE|25462488||ab|5|entity|C1527148|Development|ftcn|||development|||0|840|901|912


SE|25462487||ti|1|text|21|168|Parenting stress and child behavior problems within families of children with developmental disabilities: Transactional relations across 15 years.
SE|25462487||ti|1|entity|C0038435|Stress|fndg|||stress|||0|861|31|37
SE|25462487||ti|1|entity|C0474413|Problematic behavior in children|fndg|||child behavior problems|||0|988|42|65
SE|25462487||ti|1|entity|C0015576|Family|famg|||families|||0|1000|73|81
SE|25462487||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|85|93
SE|25462487||ti|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|99|125
SE|25462487||ti|1|entity|C0869014|Relations|socb|||relations|||0|861|141|150
SE|25462487||ti|1|entity|C0439234|year|tmco|||years|||0|861|161|166
SE|25462487||ti|1|relation|3|1|C0008073|Child Development Disorders|mobd|mobd|||developmental disabilities|||0|1000|99|125|PREP|PROCESS_OF||94|98|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|85|93

SE|25462487||ab|1|text|174|317|Parents of children with developmental disabilities (DD) are at increased risk of experiencing psychological stress compared to other parents.
SE|25462487||ab|1|entity|C0030551|parent|famg|||Parents|||0|1000|174|181
SE|25462487||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|185|193
SE|25462487||ab|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|199|225
SE|25462487||ab|1|entity|C0205217|Increased|qnco|||increased|||0|888|238|247
SE|25462487||ab|1|entity|C0035647|Risk|qlco|||risk|||0|888|248|252
SE|25462487||ab|1|entity|C0596545|experience|menp|||experiencing|||0|890|256|268
SE|25462487||ab|1|entity|C0038443|Stress, Psychological|mobd|||psychological stress|||0|890|269|289
SE|25462487||ab|1|entity|C0030551|parent|famg|||parents|||0|1000|308|315
SE|25462487||ab|1|relation|4|1|C0008073|Child Development Disorders|mobd|mobd|||developmental disabilities|||0|1000|199|225|PREP|PROCESS_OF||194|198|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|185|193

SE|25462487||ab|2|text|317|448|Children's high levels of internalizing and externalizing problems have been found to contribute to this elevated level of stress.
SE|25462487||ab|2|entity|C0008059|Child|aggp,inpr|||Children's|||0|851|317|327
SE|25462487||ab|2|entity|C0205250|High|qlco|||high|||0|851|328|332
SE|25462487||ab|2|entity|C0441889|Levels|inpr|||levels|||0|851|333|339
SE|25462487||ab|2|entity|C1546466|Problems|idcn|||problems|||0|861|375|383
SE|25462487||ab|2|entity|C0205250|High|qlco|||elevated|||0|694|422|430
SE|25462487||ab|2|entity|C0038435|Stress|fndg|||stress|||0|1000|440|446

SE|25462487||ab|3|text|448|555|Few studies have considered the reverse direction of effects, however, in families where a child has a DD.
SE|25462487||ab|3|entity|C0205388|Few|qnco|||Few|||0|872|448|451
SE|25462487||ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|872|452|459
SE|25462487||ab|3|entity|C1555029|reverses|idcn|||reverse|||0|872|480|487
SE|25462487||ab|3|entity|C0449738|Direction|spco|||direction|||0|872|488|497
SE|25462487||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|501|508
SE|25462487||ab|3|entity|C0015576|Family|famg|||families|||0|861|522|530
SE|25462487||ab|3|entity|C0008059|Child|aggp,inpr|||child|||0|1000|539|544
SE|25462487||ab|3|entity|C0008073|Child Development Disorders|mobd|||DD|||0|1000|551|553
SE|25462487||ab|3|relation|1|1|C0008073|Child Development Disorders|mobd|mobd|||DD|||0|1000|551|553|AUX|PROCESS_OF||545|548|5|1|C0008059|Child|aggp,humn,inpr|humn|||child|||0|1000|539|544

SE|25462487||ab|4|text|555|723|The present study investigated transactional relations between child behavior problems and maternal stress within 176 families raising a child with early diagnosed DD.
SE|25462487||ab|4|entity|C0150312|Present|qnco|||present|||0|888|559|566
SE|25462487||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|888|567|572
SE|25462487||ab|4|entity|C0869014|Relations|socb|||relations|||0|861|600|609
SE|25462487||ab|4|entity|C0474413|Problematic behavior in children|fndg|||child behavior problems|||0|988|618|641
SE|25462487||ab|4|entity|C0746432|MATERNAL STRESS|menp|||maternal stress|||0|1000|646|661
SE|25462487||ab|4|entity|C0015576|Family|famg|||families|||0|861|673|681
SE|25462487||ab|4|entity|C0008059|Child|aggp,inpr|||child|||0|1000|692|697
SE|25462487||ab|4|entity|C0596473|Early Diagnosis|diap|||early diagnosed|||0|877|703|718
SE|25462487||ab|4|entity|C0008073|Child Development Disorders|mobd|||DD|||0|877|719|721
SE|25462487||ab|4|relation|1|1|C0008073|Child Development Disorders|mobd|mobd|||DD|||0|877|719|721|PREP|PROCESS_OF||698|702|6|1|C0008059|Child|aggp,humn,inpr|humn|||child|||0|1000|692|697

SE|25462487||ab|5|text|723|936|There was evidence of both child-driven and parent-driven effects over the 15-year study period, spanning from early childhood (age 3) to adolescence (age 18), consistent with transactional models of development.
SE|25462487||ab|5|entity|C0008059|Child|aggp,inpr|||child|||0|1000|750|755
SE|25462487||ab|5|entity|C0030551|parent|famg|||parent|||0|1000|767|773
SE|25462487||ab|5|entity|C1280500|Effect|qlco|||effects|||0|966|781|788
SE|25462487||ab|5|entity|C0205136|Over|spco|||over|||0|1000|789|793
SE|25462487||ab|5|entity|C0439234|year|tmco|||year|||0|775|801|805
SE|25462487||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|775|806|811
SE|25462487||ab|5|entity|C0439531|/period|tmco|||period|||0|775|812|818
SE|25462487||ab|5|entity|C0599196|early childhood|tmco|||early childhood|||0|1000|834|849
SE|25462487||ab|5|entity|C0001779|Age|orga|||age|||0|861|851|854
SE|25462487||ab|5|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|861|872
SE|25462487||ab|5|entity|C0001779|Age|orga|||age|||0|861|874|877
SE|25462487||ab|5|entity|C1527148|Development|ftcn|||development|||0|1000|923|934

SE|25462487||ab|6|text|936|1058|Parent-child transactions were found to vary across different life phases and with different domains of behavior problems.
SE|25462487||ab|6|entity|C0030551|parent|famg|||Parent|||0|623|936|942
SE|25462487||ab|6|entity|C0008059|Child|aggp,inpr|||child|||0|623|943|948
SE|25462487||ab|6|entity|C1547020|*Difference|qnco|||different|||0|828|988|997
SE|25462487||ab|6|entity|C0376558|Life|idcn|||life|||0|828|998|1002
SE|25462487||ab|6|entity|C0205390|Phase|tmco|||phases|||0|828|1003|1009
SE|25462487||ab|6|entity|C1547020|*Difference|qnco|||different|||0|623|1019|1028
SE|25462487||ab|6|entity|C0260653|Problem behavior|mobd|||behavior problems|||0|1000|1040|1057


SE|25462489||ti|1|text|21|180|Examining the psychometrics of the Psychopathology Inventory for Mentally Retarded Adults-II for individuals with mild and moderate intellectual disabilities.
SE|25462489||ti|1|entity|C0033920|Psychometrics|diap|||psychometrics|||0|1000|35|48
SE|25462489||ti|1|entity|C0033927|Psychopathology|bmod|||Psychopathology|||0|888|56|71
SE|25462489||ti|1|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|888|72|81
SE|25462489||ti|1|entity|C0079822|Mentally Disabled Persons|podg|||Mentally Retarded|||0|658|86|103
SE|25462489||ti|1|entity|C0001675|Adult|aggp|||Adults|||0|658|104|110
SE|25462489||ti|1|entity|C0237401|Individual|humn|||individuals|||0|1000|118|129
SE|25462489||ti|1|entity|C0547040|Minimal|qlco|||mild|||0|1000|135|139
SE|25462489||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|884|153|178

SE|25462489||ab|1|text|186|435|With growing recognition of the occurrence of psychological disorders in individuals with intellectual disability (ID), researchers and clinicians alike have placed emphasis on developing measures to assess for psychopathologies in this population.
SE|25462489||ab|1|entity|C0243132|occurrence|qnco|||occurrence|||0|1000|218|228
SE|25462489||ab|1|entity|C0004936|Mental disorders|mobd|||psychological disorders|||0|983|232|255
SE|25462489||ab|1|entity|C0237401|Individual|humn|||individuals|||0|1000|259|270
SE|25462489||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|276|299
SE|25462489||ab|1|entity|C0035173|Research Personnel|prog|||researchers|||0|1000|306|317
SE|25462489||ab|1|entity|C0871685|Clinicians|prog|||clinicians|||0|1000|322|332
SE|25462489||ab|1|entity|C0442504|Place|spco|||placed|||0|623|344|350
SE|25462489||ab|1|entity|C0079809|Measures|qnco|||measures|||0|861|374|382
SE|25462489||ab|1|entity|C0033927|Psychopathology|bmod|||psychopathologies|||0|966|397|414
SE|25462489||ab|1|entity|C1257890|Population Group|popg|||population|||0|1000|423|433
SE|25462489||ab|1|relation|8|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|276|299|PREP|PROCESS_OF||271|275|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|259|270
SE|25462489||ab|1|relation|10|1|C0004936|Mental disorders|mobd|mobd|||psychological disorders|||0|983|232|255|NOM|OCCURS_IN||218|228|10|2|C0237401|Individual|grup,humn|grup|||individuals|||0|1000|259|270

SE|25462489||ab|2|text|435|616|Despite an increased interest in the topic, there is still a dearth of psychometrically robust measures available to assess for psychopathology in adults with mild and moderate ID.
SE|25462489||ab|2|entity|C0205217|Increased|qnco|||increased|||0|888|446|455
SE|25462489||ab|2|entity|C0543488|Interested|menp|||interest|||0|888|456|464
SE|25462489||ab|2|entity|C1555712|topic|idcn|||topic|||0|1000|472|477
SE|25462489||ab|2|entity|C0079809|Measures|qnco|||measures|||0|827|530|538
SE|25462489||ab|2|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|1000|563|578
SE|25462489||ab|2|entity|C0001675|Adult|aggp|||adults|||0|1000|582|588
SE|25462489||ab|2|entity|C0547040|Minimal|qlco|||mild|||0|1000|594|598
SE|25462489||ab|2|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|901|612|614
SE|25462489||ab|2|relation|6|6|C0543488|Interested|menp|menp|||interest|||0|888|456|464|PREP|PROCESS_OF||579|581|3|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|582|588

SE|25462489||ab|3|text|616|856|The purpose of this study was to examine the psychometric properties of a revised measure for psychopathology in individuals with mild and moderate ID, the Psychopathology Inventory for Mentally Retarded Adults - second edition (PIMRA-II).
SE|25462489||ab|3|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|620|627
SE|25462489||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|636|641
SE|25462489||ab|3|entity|C0033920|Psychometrics|diap|||psychometric|||0|872|661|673
SE|25462489||ab|3|entity|C0871161|Property|qlco|||properties|||0|872|674|684
SE|25462489||ab|3|entity|C0079809|Measures|qnco|||measure|||0|861|698|705
SE|25462489||ab|3|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|1000|710|725
SE|25462489||ab|3|entity|C0237401|Individual|humn|||individuals|||0|1000|729|740
SE|25462489||ab|3|entity|C0547040|Minimal|qlco|||mild|||0|1000|746|750
SE|25462489||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|901|764|766
SE|25462489||ab|3|entity|C0033927|Psychopathology|bmod|||Psychopathology|||0|743|772|787
SE|25462489||ab|3|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|743|788|797
SE|25462489||ab|3|entity|C0079822|Mentally Disabled Persons|podg|||Mentally Retarded|||0|743|802|819
SE|25462489||ab|3|entity|C0001675|Adult|aggp|||Adults|||0|743|820|826
SE|25462489||ab|3|entity|C0441795|Second edition|inpr|||second edition|||0|743|829|843

SE|25462489||ab|4|text|856|950|Internal consistency, inter-rater reliability, and test-retest reliability were investigated.
SE|25462489||ab|4|entity|C0870731|Internal Consistency|qnco|||Internal consistency|||0|1000|856|876
SE|25462489||ab|4|entity|C0205103|Intermediate|spco|||inter|||0|660|878|883
SE|25462489||ab|4|entity|C0039593|Testing|resa|||test|||0|1000|907|911

SE|25462489||ab|5|text|950|1186|Validity was studied via convergent validity by comparing the PIMRA-II to the Assessment of Dual Diagnosis (ADD) and via discriminate validity by comparing the PIMRA-II to the Social Performance Survey Schedule (SPSS) prosocial scores.
SE|25462489||ab|5|entity|C1550513|via|idcn|||via|||0|901|971|974
SE|25462489||ab|5|entity|C1510594|Convergent Validity|qlco|||convergent validity|||0|901|975|994
SE|25462489||ab|5|entity|C0033927|Psychopathology|bmod|||PIMRA-II|||0|743|1012|1020
SE|25462489||ab|5|entity|C0021941|Equipment and supply inventories|mnob|||PIMRA-II|||0|743|1012|1020
SE|25462489||ab|5|entity|C0079822|Mentally Disabled Persons|podg|||PIMRA-II|||0|743|1012|1020
SE|25462489||ab|5|entity|C0001675|Adult|aggp|||PIMRA-II|||0|743|1012|1020
SE|25462489||ab|5|entity|C0441795|Second edition|inpr|||PIMRA-II|||0|743|1012|1020
SE|25462489||ab|5|entity|C0220825|Evaluation|ftcn|||Assessment|||0|768|1028|1038
SE|25462489||ab|5|entity|C0700319|Mentally ill chemical abuse|mobd|||Dual Diagnosis|||0|768|1042|1056
SE|25462489||ab|5|entity|C1550513|via|idcn|||via|||0|1000|1067|1070
SE|25462489||ab|5|entity|C0033927|Psychopathology|bmod|||PIMRA-II|||0|743|1110|1118
SE|25462489||ab|5|entity|C0021941|Equipment and supply inventories|mnob|||PIMRA-II|||0|743|1110|1118
SE|25462489||ab|5|entity|C0079822|Mentally Disabled Persons|podg|||PIMRA-II|||0|743|1110|1118
SE|25462489||ab|5|entity|C0001675|Adult|aggp|||PIMRA-II|||0|743|1110|1118
SE|25462489||ab|5|entity|C0441795|Second edition|inpr|||PIMRA-II|||0|743|1110|1118
SE|25462489||ab|5|entity|C0597198|Performance|inbe|||Performance|||0|658|1133|1144
SE|25462489||ab|5|entity|C0681818|Social survey|resa|||Social Performance Survey|||0|658|1126|1151
SE|25462489||ab|5|entity|C0449820|Score|qnco|||scores|||0|861|1178|1184

SE|25462489||ab|6|text|1186|1286|Lastly, an exploratory factor analysis was conducted to determine the factor structure of the scale.
SE|25462489||ab|6|entity|C0085801|Analysis, Factor|qlco,qnco|||factor analysis|||0|901|1209|1224
SE|25462489||ab|6|entity|C0870541|Factor Structure|qnco|||factor structure|||0|1000|1256|1272


SE|25462490||ti|1|text|21|121|Persistence of visuo-constructional and executive deficits in adolescents after open-heart surgery.
SE|25462490||ti|1|entity|C0546816|Persistence|menp|||Persistence|||0|1000|21|32
SE|25462490||ti|1|entity|C0011155|Deficiency|ftcn|||deficits|||0|855|71|79
SE|25462490||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|83|94
SE|25462490||ti|1|entity|C0189745|Open heart surgery|topp|||open-heart surgery|||0|1000|101|119
SE|25462490||ti|1|relation|3|3|C0546816|Persistence|menp|menp|||Persistence|||0|1000|21|32|PREP|PROCESS_OF||80|82|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|83|94

SE|25462490|AIM|ab|1|text|127|392|AIM: This study assesses whether previously reported performance deficiencies in visuo-constructional and executive functions, using the Rey-Osterrieth Complex Figure Test (ROCFT) in pediatric patients with congenital heart disease (CHD), persist into adolescence.
SE|25462490|AIM|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|137|142
SE|25462490|AIM|ab|1|entity|C0597198|Performance|inbe|||performance|||0|764|180|191
SE|25462490|AIM|ab|1|entity|C0011155|Deficiency|ftcn|||deficiencies|||0|764|192|204
SE|25462490|AIM|ab|1|entity|C0935584|Executive Functioning|menp|||executive functions|||0|983|233|252
SE|25462490|AIM|ab|1|entity|C0589103|Rey complex figure test|inpr|||Rey-Osterrieth Complex Figure Test|||0|933|264|298
SE|25462490|AIM|ab|1|entity|C1521725|Pediatric|qlco|||pediatric|||0|888|310|319
SE|25462490|AIM|ab|1|entity|C0030705|Patients|podg|||patients|||0|888|320|328
SE|25462490|AIM|ab|1|entity|C0152021|Congenital heart disease|dsyn|||congenital heart disease|||0|1000|334|358
SE|25462490|AIM|ab|1|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|379|390
SE|25462490|AIM|ab|1|relation|2|1|C0152021|Congenital heart disease|dsyn|dsyn|||congenital heart disease|||0|1000|334|358|PREP|PROCESS_OF||329|333|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|320|328
SE|25462490|AIM|ab|1|relation|6|2|C0935584|Executive Functioning|menp|menp|||executive functions|||0|983|233|252|PREP|PROCESS_OF||307|309|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|320|328

SE|25462490|METHODS|ab|2|text|392|498|METHODS: 53 adolescent CHD patients (mean age 13.7) and 39 healthy controls (mean age 14.1) participated.
SE|25462490|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|392|399
SE|25462490|METHODS|ab|2|entity|C0205653|Adolescent|aggp|||adolescent|||0|823|404|414
SE|25462490|METHODS|ab|2|entity|C0152021|Congenital heart disease|dsyn|||CHD|||0|823|415|418
SE|25462490|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|823|419|427
SE|25462490|METHODS|ab|2|entity|C0001779|Age|orga|||age|||0|812|434|437
SE|25462490|METHODS|ab|2|entity|C0018684|Health|idcn|||healthy|||0|737|451|458
SE|25462490|METHODS|ab|2|entity|C0243148|control|ftcn|||controls|||0|737|459|467
SE|25462490|METHODS|ab|2|entity|C0001779|Age|orga|||age|||0|812|474|477
SE|25462490|METHODS|ab|2|relation|0|0|C0152021|Congenital heart disease|dsyn|dsyn|||CHD|||0|823|415|418|MOD/HEAD|PROCESS_OF||415|427|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|823|419|427

SE|25462490|METHODS|ab|3|text|498|714|ROCFT performance was measured by three different scoring methods, focusing either on quantitative (Meyers & Meyers, 1995), qualitative (Wallon & Mesmin, 2009), or both performance aspects (Bernstein & Waber, 1996).
SE|25462490|METHODS|ab|3|entity|C0589103|Rey complex figure test|inpr|||ROCFT|||0|870|498|503
SE|25462490|METHODS|ab|3|entity|C0597198|Performance|inbe|||performance|||0|870|504|515
SE|25462490|METHODS|ab|3|entity|C0205449|Three|qnco|||three|||0|843|532|537
SE|25462490|METHODS|ab|3|entity|C1547020|*Difference|qnco|||different|||0|843|538|547
SE|25462490|METHODS|ab|3|entity|C0036449|Scoring Methods|resa|||scoring methods|||0|843|548|563
SE|25462490|METHODS|ab|3|entity|C0392762|Quantitative|qnco|||quantitative|||0|1000|584|596
SE|25462490|METHODS|ab|3|entity|C0205556|Qualitative|qlco|||qualitative|||0|1000|622|633
SE|25462490|METHODS|ab|3|entity|C0597198|Performance|inbe|||performance|||0|872|667|678
SE|25462490|METHODS|ab|3|entity|C1547011|Aspect|qnco|||aspects|||0|872|679|686

SE|25462490|METHODS|ab|4|text|714|853|Potential confounders (i.e., intelligence and visuomotor integration) and surgery-related risk factors were included in the data analysis.
SE|25462490|METHODS|ab|4|entity|C0237399|Potential|qlco|||Potential|||0|694|714|723
SE|25462490|METHODS|ab|4|entity|C0021704|Intelligence|menp|||intelligence|||0|827|743|755
SE|25462490|METHODS|ab|4|entity|C1522149|Related|ftcn|||related|||0|861|796|803
SE|25462490|METHODS|ab|4|entity|C0035648|risk factors|qnco|||risk factors|||0|861|804|816
SE|25462490|METHODS|ab|4|entity|C0010992|Data Analysis|ocac|||data analysis|||0|1000|838|851

SE|25462490|RESULTS|ab|5|text|853|1005|RESULTS: Adolescents with CHD demonstrated immature copy and recall approaches on the ROCFT using the qualitative system by Wallon and Mesmin (p<.001).
SE|25462490|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|853|860
SE|25462490|RESULTS|ab|5|entity|C0205653|Adolescent|aggp|||Adolescents|||0|1000|862|873
SE|25462490|RESULTS|ab|5|entity|C0152021|Congenital heart disease|dsyn|||CHD|||0|1000|879|882
SE|25462490|RESULTS|ab|5|entity|C0205252|Immature|tmco|||immature|||0|694|896|904
SE|25462490|RESULTS|ab|5|entity|C0449445|Approach|spco|||approaches|||0|861|921|931
SE|25462490|RESULTS|ab|5|entity|C0589103|Rey complex figure test|inpr|||ROCFT|||0|933|939|944
SE|25462490|RESULTS|ab|5|entity|C0205556|Qualitative|qlco|||qualitative|||0|888|955|966
SE|25462490|RESULTS|ab|5|entity|C0449913|System|ftcn|||system|||0|888|967|973
SE|25462490|RESULTS|ab|5|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|996|997
SE|25462490|RESULTS|ab|5|relation|7|1|C0152021|Congenital heart disease|dsyn|dsyn|||CHD|||0|1000|879|882|PREP|PROCESS_OF||874|878|2|1|C0205653|Adolescent|aggp,humn|humn|||Adolescents|||0|1000|862|873

SE|25462490|RESULTS|ab|6|text|1005|1169|Memory performance was also predicted by Bernstein and Waber scores (p<.03), whereas group differences were not significant according to the other scoring methods.
SE|25462490|RESULTS|ab|6|entity|C1285654|Memory performance|menp|||Memory performance|||0|1000|1005|1023
SE|25462490|RESULTS|ab|6|entity|C0449820|Score|qnco|||scores|||0|861|1066|1072
SE|25462490|RESULTS|ab|6|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1074|1075
SE|25462490|RESULTS|ab|6|entity|C0441833|Groups|inpr|||group|||0|872|1090|1095
SE|25462490|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||differences|||0|872|1096|1107
SE|25462490|RESULTS|ab|6|entity|C1273937|Not significant|fndg|||not significant|||0|1000|1113|1128
SE|25462490|RESULTS|ab|6|entity|C0036449|Scoring Methods|resa|||scoring methods|||0|1000|1152|1167

SE|25462490|RESULTS|ab|7|text|1169|1307|Intelligence and visuomotor skills, but not surgery-related risk factors, were positively correlated with ROCFT performance (each p<.02).
SE|25462490|RESULTS|ab|7|entity|C0021704|Intelligence|menp|||Intelligence|||0|1000|1169|1181
SE|25462490|RESULTS|ab|7|entity|C0678856|skills|inbe|||skills|||0|861|1197|1203
SE|25462490|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|840|1209|1212
SE|25462490|RESULTS|ab|7|entity|C1522149|Related|ftcn|||related|||0|840|1221|1228
SE|25462490|RESULTS|ab|7|entity|C0035648|risk factors|qnco|||risk factors|||0|840|1229|1241
SE|25462490|RESULTS|ab|7|entity|C0589103|Rey complex figure test|inpr|||ROCFT|||0|870|1275|1280
SE|25462490|RESULTS|ab|7|entity|C0597198|Performance|inbe|||performance|||0|870|1281|1292
SE|25462490|RESULTS|ab|7|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1299|1300
SE|25462490|RESULTS|ab|7|relation|3|2|C0678856|skills|inbe|inbe|||skills|||0|861|1197|1203|VERB|AFFECTS|negation|1259|1269|1|1|C0597198|Performance|inbe|inbe|||performance|||0|870|1281|1292

SE|25462490|RESULTS|ab|8|text|1307|1418|Interpretation: Visuoconstructional and executive deficiencies could be found in adolescent patients with CHD.
SE|25462490|RESULTS|ab|8|entity|C0459471|Interpretation|inpr|||Interpretation|||0|1000|1307|1321
SE|25462490|RESULTS|ab|8|entity|C0011155|Deficiency|ftcn|||deficiencies|||0|855|1357|1369
SE|25462490|RESULTS|ab|8|entity|C0205653|Adolescent|aggp|||adolescent|||0|888|1388|1398
SE|25462490|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|888|1399|1407
SE|25462490|RESULTS|ab|8|entity|C0152021|Congenital heart disease|dsyn|||CHD|||0|1000|1413|1416
SE|25462490|RESULTS|ab|8|relation|1|1|C0152021|Congenital heart disease|dsyn|dsyn|||CHD|||0|1000|1413|1416|PREP|PROCESS_OF||1408|1412|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|1399|1407

SE|25462490|RESULTS|ab|9|text|1418|1692|However, not all ROCFT scoring methods were equally apt to detect group differences: especially the qualitative scoring method developed by Wallon and Mesmin seems sufficiently sensitive to detect long-lasting visuo-constructional and executive deficiencies in CHD patients.
SE|25462490|RESULTS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1427|1430
SE|25462490|RESULTS|ab|9|entity|C0589103|Rey complex figure test|inpr|||ROCFT|||0|849|1435|1440
SE|25462490|RESULTS|ab|9|entity|C0036449|Scoring Methods|resa|||scoring methods|||0|849|1441|1456
SE|25462490|RESULTS|ab|9|entity|C0003618|Desire for food|orgf|||apt|||0|861|1470|1473
SE|25462490|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|872|1484|1489
SE|25462490|RESULTS|ab|9|entity|C1547020|*Difference|qnco|||differences|||0|872|1490|1501
SE|25462490|RESULTS|ab|9|entity|C0205556|Qualitative|qlco|||qualitative|||0|901|1518|1529
SE|25462490|RESULTS|ab|9|entity|C0036449|Scoring Methods|resa|||scoring method|||0|901|1530|1544
SE|25462490|RESULTS|ab|9|entity|C0332324|Sensitive|ftcn|||sensitive|||0|861|1595|1604
SE|25462490|RESULTS|ab|9|entity|C0205166|Long|qlco|||long|||0|645|1615|1619
SE|25462490|RESULTS|ab|9|entity|C0011155|Deficiency|ftcn|||deficiencies|||0|855|1663|1675
SE|25462490|RESULTS|ab|9|entity|C0152021|Congenital heart disease|dsyn|||CHD|||0|916|1679|1682
SE|25462490|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|916|1683|1691
SE|25462490|RESULTS|ab|9|relation|0|0|C0152021|Congenital heart disease|dsyn|dsyn|||CHD|||0|916|1679|1682|MOD/HEAD|PROCESS_OF||1679|1691|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|916|1683|1691
SE|25462490|RESULTS|ab|9|relation|9|8|C0003618|Desire for food|orgf|orgf|||apt|||0|861|1470|1473|PREP|PROCESS_OF||1676|1678|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|916|1683|1691


SE|25462491||ti|1|text|21|148|The role of physiological arousal in the management of challenging behaviours in individuals with autistic spectrum disorders.
SE|25462491||ti|1|entity|C0035820|Role|socb|||role|||0|1000|25|29
SE|25462491||ti|1|entity|C0237476|Physiological Arousal|phsf|||physiological arousal|||0|1000|33|54
SE|25462491||ti|1|entity|C0474414|Challenging behavior|fndg|||challenging behaviours|||0|983|76|98
SE|25462491||ti|1|entity|C0237401|Individual|humn|||individuals|||0|1000|102|113
SE|25462491||ti|1|entity|C0524528|Pervasive Development Disorders|mobd|||autistic spectrum disorders|||0|988|119|146
SE|25462491||ti|1|relation|1|1|C0524528|Pervasive Development Disorders|mobd|mobd|||autistic spectrum disorders|||0|988|119|146|PREP|PROCESS_OF||114|118|5|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|102|113
SE|25462491||ti|1|relation|4|1|C0474414|Challenging behavior|fndg|fndg|||challenging behaviours|||0|983|76|98|PREP|PROCESS_OF||99|101|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|102|113

SE|25462491||ab|1|text|154|333|Challenging behaviours restrict opportunities and choices for people with autistic spectrum disorders (ASD) and frequently lead to inappropriate and costly service interventions.
SE|25462491||ab|1|entity|C0474414|Challenging behavior|fndg|||Challenging behaviours|||0|983|154|176
SE|25462491||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|216|222
SE|25462491||ab|1|entity|C0524528|Pervasive Development Disorders|mobd|||autistic spectrum disorders|||0|988|228|255
SE|25462491||ab|1|entity|C0332183|Frequent|tmco|||frequently|||0|1000|266|276
SE|25462491||ab|1|entity|C1548788|Inappropriate|qlco|||inappropriate|||0|1000|285|298
SE|25462491||ab|1|entity|C0557854|Services|ftcn|||service|||0|790|310|317
SE|25462491||ab|1|entity|C1273869|Intervention regimes|hlca|||interventions|||0|790|318|331
SE|25462491||ab|1|relation|3|1|C0524528|Pervasive Development Disorders|mobd|mobd|||autistic spectrum disorders|||0|988|228|255|PREP|PROCESS_OF||223|227|4|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|216|222

SE|25462491||ab|2|text|333|421|Managing challenging behaviours of people with autism is an important area of research.
SE|25462491||ab|2|entity|C0474414|Challenging behavior|fndg|||challenging behaviours|||0|884|342|364
SE|25462491||ab|2|entity|C0027361|Persons|popg|||people|||0|1000|368|374
SE|25462491||ab|2|entity|C0004352|Autistic Disorder|mobd|||autism|||0|1000|380|386
SE|25462491||ab|2|entity|C0205146|Area|spco|||area|||0|861|403|407
SE|25462491||ab|2|entity|C0035168|research|resa|||research|||0|1000|411|419
SE|25462491||ab|2|relation|3|1|C0004352|Autistic Disorder|mobd|mobd|||autism|||0|1000|380|386|PREP|PROCESS_OF||375|379|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|368|374

SE|25462491||ab|3|text|421|530|This paper examines some of the evidence for the role of physiological arousal influencing these behaviours.
SE|25462491||ab|3|entity|C0030351|Paper|mnob|||paper|||0|1000|426|431
SE|25462491||ab|3|entity|C0035820|Role|socb|||role|||0|1000|470|474
SE|25462491||ab|3|entity|C0237476|Physiological Arousal|phsf|||physiological arousal|||0|1000|478|499
SE|25462491||ab|3|entity|C0004927|Behavior|inbe|||behaviours|||0|1000|518|528

SE|25462491||ab|4|text|530|607|Evidence from the emerging literature about sensory differences is examined.
SE|25462491||ab|4|entity|C0023866|Literature|inpr|||literature|||0|861|557|567
SE|25462491||ab|4|entity|C0445254|Sensory|qlco|||sensory|||0|872|574|581
SE|25462491||ab|4|entity|C1547020|*Difference|qnco|||differences|||0|872|582|593

SE|25462491||ab|5|text|607|765|It is proposed that sensory reactivity is associated with hyperarousal; catatonic type behaviours are associated with low levels of reactivity (hypoarousal).
SE|25462491||ab|5|entity|C0445254|Sensory|qlco|||sensory|||0|853|627|634
SE|25462491||ab|5|entity|C0205332|Reactive|qlco|||reactivity|||0|853|635|645
SE|25462491||ab|5|entity|C0007398|Catatonia|sosy|||catatonic|||0|851|679|688
SE|25462491||ab|5|entity|C1547052|*Type|qnco|||type|||0|851|689|693
SE|25462491||ab|5|entity|C0004927|Behavior|inbe|||behaviours|||0|851|694|704
SE|25462491||ab|5|entity|C0205251|low|qlco|||low|||0|888|725|728
SE|25462491||ab|5|entity|C0441889|Levels|inpr|||levels|||0|888|729|735
SE|25462491||ab|5|entity|C0205332|Reactive|qlco|||reactivity|||0|928|739|749

SE|25462491||ab|6|text|765|871|A low arousal approach is proposed as a generalised strategy to managing challenging behaviours with ASD.
SE|25462491||ab|6|entity|C0003808|Arousal|menp|||arousal|||0|901|771|778
SE|25462491||ab|6|entity|C0442415|Low approach|spco|||low arousal approach|||0|901|767|787
SE|25462491||ab|6|entity|C0205246|Generalized|spco|||generalised|||0|888|805|816
SE|25462491||ab|6|entity|C0474414|Challenging behavior|fndg|||challenging behaviours|||0|884|838|860
SE|25462491||ab|6|entity|C0524528|Pervasive Development Disorders|mobd|||ASD|||0|988|866|869

SE|25462491||ab|7|text|871|1029|The use of non-contingent reinforcement and antecedent control strategies are recommended for use with challenging behaviours which have a sensory component.
SE|25462491||ab|7|entity|C0243148|control|ftcn|||control|||0|790|926|933
SE|25462491||ab|7|entity|C0474414|Challenging behavior|fndg|||challenging behaviours|||0|983|974|996
SE|25462491||ab|7|entity|C0445254|Sensory|qlco|||sensory|||0|888|1010|1017
SE|25462491||ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|888|1018|1027

SE|25462491||ab|8|text|1029|1079|Examples are provided to illustrate the approach.
SE|25462491||ab|8|entity|C0449445|Approach|spco|||approach|||0|1000|1069|1077

SE|25462491||ab|9|text|1079|1160|The implications of arousal and the use of physical interventions are discussed.
SE|25462491||ab|9|entity|C0003808|Arousal|menp|||arousal|||0|1000|1099|1106
SE|25462491||ab|9|entity|C0205485|Physical|ftcn|||physical|||0|888|1122|1130
SE|25462491||ab|9|entity|C1273869|Intervention regimes|hlca|||interventions|||0|888|1131|1144

SE|25462491||ab|10|text|1160|1275|It is proposed that arousal is a construct which has significant heuristic value for researchers and practitioners.
SE|25462491||ab|10|entity|C0003808|Arousal|menp|||arousal|||0|1000|1180|1187
SE|25462491||ab|10|entity|C0597916|heuristics|inpr|||heuristic|||0|855|1225|1234
SE|25462491||ab|10|entity|C1273936|Significance values|qlco|||significant heuristic value|||0|855|1213|1240
SE|25462491||ab|10|entity|C0035173|Research Personnel|prog|||researchers|||0|1000|1245|1256


SE|25462492||ti|1|text|21|79|Essential components of written behavior treatment plans.
SE|25462492||ti|1|entity|C0205224|Essential|qlco|||Essential|||0|872|21|30
SE|25462492||ti|1|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|872|31|41
SE|25462492||ti|1|entity|C0004927|Behavior|inbe|||behavior|||0|813|53|61
SE|25462492||ti|1|entity|C0599880|TREATMENT PLAN|inpr|||treatment plans|||0|813|62|77

SE|25462492||ab|1|text|85|238|For the last 25 years, the only empirically determined system to evaluate the content of written behavior analysis plans was developed by Vollmer et al.
SE|25462492||ab|1|entity|C1517741|Last|qlco|||last|||0|802|93|97
SE|25462492||ab|1|entity|C0439234|year|tmco|||years|||0|802|101|106
SE|25462492||ab|1|entity|C0680730|Adjudication|gora|||determined|||0|714|129|139
SE|25462492||ab|1|entity|C0449913|System|ftcn|||system|||0|714|140|146
SE|25462492||ab|1|entity|C0935545|Behavior Analysis|resa|||behavior analysis|||0|813|182|199
SE|25462492||ab|1|entity|C0032074|Cognitive function: planning|menp|||plans|||0|813|200|205

SE|25462492||ab|2|text|238|246|(1992).

SE|25462492||ab|3|text|246|568|For the current study, the content of that earlier system was revised by the first author and submitted to 48 members of the editorial board of the Journal of Applied Behavior Analysis and seven (7) other acknowledged experts on the editorial boards of Behavioral Interventions and Research in Developmental Disabilities.
SE|25462492||ab|3|entity|C0521116|Current|tmco|||current|||0|888|254|261
SE|25462492||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|888|262|267
SE|25462492||ab|3|entity|C1279919|Early|tmco|||earlier|||0|872|289|296
SE|25462492||ab|3|entity|C0449913|System|ftcn|||system|||0|872|297|303
SE|25462492||ab|3|entity|C1279901|Firstly|qlco|||first|||0|888|323|328
SE|25462492||ab|3|entity|C0221192|Author|idcn,prog|||author|||0|888|329|335
SE|25462492||ab|3|entity|C0680022|member|popg|||members|||0|827|356|363
SE|25462492||ab|3|entity|C0972401|Boards|medd|||board|||0|827|381|386
SE|25462492||ab|3|entity|C0162443|Magazines|inpr,mnob|||Journal|||0|1000|394|401
SE|25462492||ab|3|entity|C0935545|Behavior Analysis|resa|||Behavior Analysis|||0|901|413|430
SE|25462492||ab|3|entity|C0205453|Seven|qnco|||seven|||0|1000|435|440
SE|25462492||ab|3|entity|C0972401|Boards|medd|||boards|||0|861|489|495
SE|25462492||ab|3|entity|C0004933|Behavior Therapy|topp|||Behavioral Interventions|||0|1000|499|523
SE|25462492||ab|3|entity|C0035168|research|resa|||Research|||0|1000|528|536
SE|25462492||ab|3|entity|C0008073|Child Development Disorders|mobd|||Developmental Disabilities|||0|1000|540|566
SE|25462492||ab|3|relation|13|2|C0004933|Behavior Therapy|topp|topp|||Behavioral Interventions|||0|1000|499|523|PREP|TREATS||537|539|1|1|C0008073|Child Development Disorders|mobd|mobd|||Developmental Disabilities|||0|1000|540|566

SE|25462492||ab|4|text|568|600|Of 55 recipients, 36 responded.

SE|25462492||ab|5|text|600|720|The thirty-six (36) respondents rated each of 28 items from essential to non-essential using a five-point Likert scale.
SE|25462492||ab|5|entity|C0205452|Six|qnco|||six|||0|861|611|614
SE|25462492||ab|5|entity|C0282122|Respondents|popg|||respondents|||0|1000|620|631
SE|25462492||ab|5|entity|C0205224|Essential|qlco|||essential|||0|1000|660|669
SE|25462492||ab|5|entity|C0205224|Essential|qlco|||essential|||0|861|677|686
SE|25462492||ab|5|entity|C0205451|Five|qnco|||five|||0|824|695|699
SE|25462492||ab|5|entity|C0451267|Likert scale|inpr,qnco|||Likert scale|||0|824|706|718

SE|25462492||ab|6|text|720|863|After reviewing the expert panel members' evaluations, we reduced the 28 items to 20 essential components of written behavior treatment plans.
SE|25462492||ab|6|entity|C0680022|member|popg|||members|||0|733|753|760
SE|25462492||ab|6|entity|C0220825|Evaluation|ftcn|||evaluations|||0|733|762|773
SE|25462492||ab|6|entity|C0205224|Essential|qlco|||essential|||0|773|805|814
SE|25462492||ab|6|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|773|815|825
SE|25462492||ab|6|entity|C0004927|Behavior|inbe|||behavior|||0|813|837|845
SE|25462492||ab|6|entity|C0599880|TREATMENT PLAN|inpr|||treatment plans|||0|813|846|861

SE|25462492||ab|7|text|863|910|The implications of the results were discussed.
SE|25462492||ab|7|entity|C1274040|result|ftcn|||results|||0|966|887|894


SE|25462493||ti|1|text|21|166|Long-term outcomes on spatial hearing, speech recognition and receptive vocabulary after sequential bilateral cochlear implantation in children.
SE|25462493||ti|1|entity|C0443252|Long-term|tmco|||Long-term|||0|884|21|30
SE|25462493||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|884|31|39
SE|25462493||ti|1|entity|C0018767|Hearing|phsf|||hearing|||0|861|51|58
SE|25462493||ti|1|entity|C0597498|speech recognition|menp|||speech recognition|||0|1000|60|78
SE|25462493||ti|1|entity|C0518606|Receptiveness|fndg|||receptive|||0|853|83|92
SE|25462493||ti|1|entity|C0042926|Vocabulary|inpr|||vocabulary|||0|853|93|103
SE|25462493||ti|1|entity|C1548958|Sequential|idcn|||sequential|||0|861|110|120
SE|25462493||ti|1|entity|C0238767|Bilateral|spco|||bilateral|||0|861|121|130
SE|25462493||ti|1|entity|C0302559|Cochlear implant procedure|topp|||cochlear implantation|||0|861|131|152
SE|25462493||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|156|164
SE|25462493||ti|1|relation|5|3|C0597498|speech recognition|menp|menp|||speech recognition|||0|1000|60|78|PREP|PROCESS_OF||153|155|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|156|164

SE|25462493||ab|1|text|172|320|Sequential bilateral cochlear implantation in profoundly deaf children often leads to primary advantages in spatial hearing and speech recognition.
SE|25462493||ab|1|entity|C1548958|Sequential|idcn|||Sequential|||0|861|172|182
SE|25462493||ab|1|entity|C0238767|Bilateral|spco|||bilateral|||0|861|183|192
SE|25462493||ab|1|entity|C0302559|Cochlear implant procedure|topp|||cochlear implantation|||0|861|193|214
SE|25462493||ab|1|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|790|229|233
SE|25462493||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|790|234|242
SE|25462493||ab|1|entity|C0332183|Frequent|tmco|||often|||0|1000|243|248
SE|25462493||ab|1|entity|C0018767|Hearing|phsf|||hearing|||0|861|288|295
SE|25462493||ab|1|entity|C0597498|speech recognition|menp|||speech recognition|||0|1000|300|318

SE|25462493||ab|2|text|320|488|It is not yet known how these children develop in the long-term and if these primary advantages will also lead to secondary advantages, e.g. in better language skills.
SE|25462493||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|326|329
SE|25462493||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|350|358
SE|25462493||ab|2|entity|C0443252|Long-term|tmco|||long-term|||0|1000|374|383
SE|25462493||ab|2|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|694|434|443
SE|25462493||ab|2|entity|C0332272|Better|qlco|||better|||0|890|464|470
SE|25462493||ab|2|entity|C1145677|language ability|menp|||language skills|||0|890|471|486

SE|25462493||ab|3|text|488|718|The aim of the present longitudinal cohort study was to assess the long-term effects of sequential bilateral cochlear implantation in children on spatial hearing, speech recognition in quiet and in noise and receptive vocabulary.
SE|25462493||ab|3|entity|C0150312|Present|qnco|||present|||0|861|503|510
SE|25462493||ab|3|entity|C0599755|cohort|popg|||cohort|||0|861|524|530
SE|25462493||ab|3|entity|C0023981|Longitudinal Studies|qnco,resa|||longitudinal cohort study|||0|861|511|536
SE|25462493||ab|3|entity|C0023983|Longterm Effects|phpr|||long-term effects|||0|1000|555|572
SE|25462493||ab|3|entity|C1548958|Sequential|idcn|||sequential|||0|861|576|586
SE|25462493||ab|3|entity|C0238767|Bilateral|spco|||bilateral|||0|861|587|596
SE|25462493||ab|3|entity|C0302559|Cochlear implant procedure|topp|||cochlear implantation|||0|861|597|618
SE|25462493||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|622|630
SE|25462493||ab|3|entity|C0018767|Hearing|phsf|||hearing|||0|861|642|649
SE|25462493||ab|3|entity|C0597498|speech recognition|menp|||speech recognition|||0|1000|651|669
SE|25462493||ab|3|entity|C0439654|Quiet|qlco|||quiet|||0|1000|673|678
SE|25462493||ab|3|entity|C0028263|Noise|phpr|||noise|||0|1000|686|691
SE|25462493||ab|3|entity|C0518606|Receptiveness|fndg|||receptive|||0|853|696|705
SE|25462493||ab|3|entity|C0042926|Vocabulary|inpr|||vocabulary|||0|853|706|716

SE|25462493||ab|4|text|718|852|Twenty-four children with bilateral cochlear implants (BiCIs) were tested 5-6 years after sequential bilateral cochlear implantation.
SE|25462493||ab|4|entity|C0205450|Four|qnco|||four|||0|790|725|729
SE|25462493||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|790|730|738
SE|25462493||ab|4|entity|C0238767|Bilateral|spco|||bilateral|||0|901|744|753
SE|25462493||ab|4|entity|C0009199|Cochlear Implants|medd|||cochlear implants|||0|901|754|771
SE|25462493||ab|4|entity|C0439084|>5|qnco|||5-6|||0|802|792|795
SE|25462493||ab|4|entity|C0439234|year|tmco|||years|||0|802|796|801
SE|25462493||ab|4|entity|C1548958|Sequential|idcn|||sequential|||0|861|808|818
SE|25462493||ab|4|entity|C0238767|Bilateral|spco|||bilateral|||0|861|819|828
SE|25462493||ab|4|entity|C0302559|Cochlear implant procedure|topp|||cochlear implantation|||0|861|829|850

SE|25462493||ab|5|text|852|931|These children received their second implant between 2.4 and 8.5 years of age.
SE|25462493||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|858|866
SE|25462493||ab|5|entity|C0457385|seconds|tmco|||second|||0|888|882|888
SE|25462493||ab|5|entity|C0021102|Implants|medd|||implant|||0|888|889|896
SE|25462493||ab|5|entity|C0439234|year|tmco|||years|||0|827|917|922
SE|25462493||ab|5|entity|C0001779|Age|orga|||age|||0|1000|926|929

SE|25462493||ab|6|text|931|1061|Speech and language data were also gathered in a matched reference group of 26 children with a unilateral cochlear implant (UCI).
SE|25462493||ab|6|entity|C0037817|Speech|orgf|||Speech|||0|1000|931|937
SE|25462493||ab|6|entity|C0023008|Language|lang|||language|||0|888|942|950
SE|25462493||ab|6|entity|C1511726|Data|idcn|||data|||0|888|951|955
SE|25462493||ab|6|entity|C1514811|Reference|idcn|||reference|||0|901|988|997
SE|25462493||ab|6|entity|C0024908|Matched Groups|grup|||matched reference group|||0|901|980|1003
SE|25462493||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|861|1010|1018
SE|25462493||ab|6|entity|C0205092|Unilateral|spco|||unilateral|||0|901|1026|1036
SE|25462493||ab|6|entity|C0009199|Cochlear Implants|medd|||cochlear implant|||0|901|1037|1053
SE|25462493||ab|6|relation|2|2|C0037817|Speech|orgf|orgf|||Speech|||0|1000|931|937|PREP|PROCESS_OF||975|977|3|1|C0024908|Matched Groups|grup,humn|humn|||matched reference group|||0|901|980|1003
SE|25462493||ab|6|relation|4|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|861|1010|1018|PREP|USES||1019|1023|1|1|C0009199|Cochlear Implants|medd|medd|||cochlear implant|||0|901|1037|1053

SE|25462493||ab|7|text|1061|1288|Spatial hearing was assessed with a minimum audible angle (MAA) task with different stimulus types to gain global insight into the effective use of interaural level difference (ILD) and interaural timing difference (ITD) cues.
SE|25462493||ab|7|entity|C0018767|Hearing|phsf|||hearing|||0|861|1069|1076
SE|25462493||ab|7|entity|C1524031|Minimum|qlco|||minimum|||0|775|1097|1104
SE|25462493||ab|7|entity|C0205143|Angular|spco|||angle|||0|775|1113|1118
SE|25462493||ab|7|entity|C1547020|*Difference|qnco|||different|||0|828|1135|1144
SE|25462493||ab|7|entity|C0234402|Stimulus|phpr|||stimulus|||0|828|1145|1153
SE|25462493||ab|7|entity|C0332307|Type - attribute|qlco|||types|||0|828|1154|1159
SE|25462493||ab|7|entity|C0205246|Generalized|spco|||global|||0|888|1168|1174
SE|25462493||ab|7|entity|C0233820|Insight|menp|||insight|||0|888|1175|1182
SE|25462493||ab|7|entity|C1547020|*Difference|qnco|||difference|||0|827|1226|1236
SE|25462493||ab|7|entity|C0449243|Timing|tmco|||timing|||0|775|1258|1264
SE|25462493||ab|7|entity|C1547020|*Difference|qnco|||difference|||0|775|1265|1275
SE|25462493||ab|7|entity|C0010439|Cues|idcn|||cues|||0|775|1282|1286

SE|25462493||ab|8|text|1288|1360|In the long-term, children still showed improvements in spatial acuity.
SE|25462493||ab|8|entity|C0443252|Long-term|tmco|||long-term|||0|901|1295|1304
SE|25462493||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|901|1306|1314
SE|25462493||ab|8|entity|C0750509|ACUITY|idcn|||acuity|||0|861|1352|1358

SE|25462493||ab|9|text|1360|1422|Spatial acuity was highest for ILD cues compared to ITD cues.
SE|25462493||ab|9|entity|C0750509|ACUITY|idcn|||acuity|||0|861|1368|1374
SE|25462493||ab|9|entity|C1522410|Highest|qlco|||highest|||0|1000|1379|1386
SE|25462493||ab|9|entity|C1547020|*Difference|qnco|||ILD|||0|750|1391|1394
SE|25462493||ab|9|entity|C0010439|Cues|idcn|||cues|||0|750|1395|1399
SE|25462493||ab|9|entity|C0449243|Timing|tmco|||ITD|||0|775|1412|1415
SE|25462493||ab|9|entity|C1547020|*Difference|qnco|||ITD|||0|775|1412|1415
SE|25462493||ab|9|entity|C0010439|Cues|idcn|||cues|||0|775|1416|1420

SE|25462493||ab|10|text|1422|1567|For speech recognition in quiet and noise, and receptive vocabulary, children with BiCIs had significant higher scores than children with a UCI.
SE|25462493||ab|10|entity|C0597498|speech recognition|menp|||speech recognition|||0|1000|1426|1444
SE|25462493||ab|10|entity|C0439654|Quiet|qlco|||quiet|||0|1000|1448|1453
SE|25462493||ab|10|entity|C0028263|Noise|phpr|||noise|||0|1000|1458|1463
SE|25462493||ab|10|entity|C0518606|Receptiveness|fndg|||receptive|||0|853|1469|1478
SE|25462493||ab|10|entity|C0042926|Vocabulary|inpr|||vocabulary|||0|853|1479|1489
SE|25462493||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1491|1499
SE|25462493||ab|10|entity|C0238767|Bilateral|spco|||BiCIs|||0|901|1505|1510
SE|25462493||ab|10|entity|C0009199|Cochlear Implants|medd|||BiCIs|||0|901|1505|1510
SE|25462493||ab|10|entity|C0750502|Significant|idcn|||significant|||0|840|1515|1526
SE|25462493||ab|10|entity|C0205250|High|qlco|||higher|||0|840|1527|1533
SE|25462493||ab|10|entity|C0449820|Score|qnco|||scores|||0|840|1534|1540
SE|25462493||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1546|1554
SE|25462493||ab|10|entity|C0205092|Unilateral|spco|||UCI|||0|901|1562|1565
SE|25462493||ab|10|entity|C0009199|Cochlear Implants|medd|||UCI|||0|901|1562|1565
SE|25462493||ab|10|relation|8|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|1546|1554|PREP|USES||1555|1559|1|1|C0009199|Cochlear Implants|medd|medd|||UCI|||0|901|1562|1565

SE|25462493||ab|11|text|1567|1750|Results also indicate that attending a mainstream school has a significant positive effect on speech recognition and receptive vocabulary compared to attending a school for the deaf.
SE|25462493||ab|11|entity|C1547429|Attending|prog|||attending|||0|1000|1594|1603
SE|25462493||ab|11|entity|C0589339|Mainstream school|mnob,orgt|||mainstream school|||0|1000|1606|1623
SE|25462493||ab|11|entity|C0750502|Significant|idcn|||significant|||0|851|1630|1641
SE|25462493||ab|11|entity|C1446409|Positive|qlco|||positive|||0|851|1642|1650
SE|25462493||ab|11|entity|C1280500|Effect|qlco|||effect|||0|851|1651|1657
SE|25462493||ab|11|entity|C0597498|speech recognition|menp|||speech recognition|||0|1000|1661|1679
SE|25462493||ab|11|entity|C0518606|Receptiveness|fndg|||receptive|||0|853|1684|1693
SE|25462493||ab|11|entity|C0042926|Vocabulary|inpr|||vocabulary|||0|853|1694|1704
SE|25462493||ab|11|entity|C1547429|Attending|prog|||attending|||0|1000|1717|1726
SE|25462493||ab|11|entity|C0525064|Hearing Impaired Persons|podg|||deaf|||0|1000|1744|1748

SE|25462493||ab|12|text|1750|1894|Despite of a period of unilateral deafness, children with BiCIs, participating in mainstream education obtained age-appropriate language scores.
SE|25462493||ab|12|entity|C0439531|/period|tmco|||period|||0|1000|1763|1769
SE|25462493||ab|12|entity|C0521785|Hearing Loss, Unilateral|dsyn|||unilateral deafness|||0|1000|1773|1792
SE|25462493||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1794|1802
SE|25462493||ab|12|entity|C0238767|Bilateral|spco|||BiCIs|||0|901|1808|1813
SE|25462493||ab|12|entity|C0009199|Cochlear Implants|medd|||BiCIs|||0|901|1808|1813
SE|25462493||ab|12|entity|C0013621|Knowledge acquisition|edac|||education|||0|861|1843|1852
SE|25462493||ab|12|entity|C0001779|Age|orga|||age|||0|833|1862|1865
SE|25462493||ab|12|entity|C1548787|Appropriate|qlco|||appropriate|||0|833|1866|1877
SE|25462493||ab|12|entity|C0023008|Language|lang|||language|||0|833|1878|1886
SE|25462493||ab|12|entity|C0449820|Score|qnco|||scores|||0|833|1887|1893


SE|25462494||ti|1|text|21|154|What is the evidence of impaired motor skills and motor control among children with attention deficit hyperactivity disorder (ADHD)?
SE|25462494||ti|1|entity|C0221099|Impaired|ftcn|||impaired|||0|901|45|53
SE|25462494||ti|1|entity|C0026612|Motor Skills|orgf|||motor skills|||0|901|54|66
SE|25462494||ti|1|entity|C1513492|Motor|idcn|||motor|||0|888|71|76
SE|25462494||ti|1|entity|C0243148|control|ftcn|||control|||0|888|77|84
SE|25462494||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|91|99
SE|25462494||ti|1|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||attention deficit hyperactivity disorder|||0|1000|105|145
SE|25462494||ti|1|relation|1|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||attention deficit hyperactivity disorder|||0|1000|105|145|PREP|PROCESS_OF||100|104|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|91|99
SE|25462494||ti|1|relation|3|2|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|901|54|66|PREP|PROCESS_OF||85|90|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|91|99

SE|25462494||ti|2|text|154|191|Systematic review of the literature.
SE|25462494||ti|2|entity|C0220922|systematic|ftcn|||Systematic|||0|694|154|164
SE|25462494||ti|2|entity|C0023866|Literature|inpr|||literature|||0|1000|179|189

SE|25462494||ab|1|text|197|370|This article presents a review of the studies that have analysed the motor skills of ADHD children without medication and the influence of medication on their motor skills.
SE|25462494||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|235|242
SE|25462494||ab|1|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|266|278
SE|25462494||ab|1|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|928|282|286
SE|25462494||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|928|287|295
SE|25462494||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|304|314
SE|25462494||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|336|346
SE|25462494||ab|1|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|356|368
SE|25462494||ab|1|relation|0|0|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|928|282|286|MOD/HEAD|PROCESS_OF||282|295|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|928|287|295
SE|25462494||ab|1|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication|||0|1000|336|346|NOM|AFFECTS||323|332|2|2|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|1000|356|368

SE|25462494||ab|2|text|370|550|The following two questions guided the study: What is the evidence of impairment of motor skills and aspects of motor control among children with ADHD aged between 6 and 16 years?
SE|25462494||ab|2|entity|C0332282|Following|tmco|||following|||0|623|374|383
SE|25462494||ab|2|entity|C0205448|Two|qnco|||two|||0|623|384|387
SE|25462494||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|409|414
SE|25462494||ab|2|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|454|466
SE|25462494||ab|2|entity|C1547011|Aspect|qnco|||aspects|||0|966|471|478
SE|25462494||ab|2|entity|C1513492|Motor|idcn|||motor|||0|888|482|487
SE|25462494||ab|2|entity|C0243148|control|ftcn|||control|||0|888|488|495
SE|25462494||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|502|510
SE|25462494||ab|2|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|516|520
SE|25462494||ab|2|entity|C0439234|year|tmco|||years|||0|861|543|548
SE|25462494||ab|2|relation|2|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|516|520|PREP|PROCESS_OF||511|515|8|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|502|510
SE|25462494||ab|2|relation|7|3|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|1000|454|466|PREP|PROCESS_OF||496|501|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|502|510

SE|25462494||ab|3|text|550|625|What are the effects of ADHD medication on motor skills and motor control?
SE|25462494||ab|3|entity|C1280500|Effect|qlco|||effects|||0|966|563|570
SE|25462494||ab|3|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|928|574|578
SE|25462494||ab|3|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|928|579|589
SE|25462494||ab|3|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|593|605
SE|25462494||ab|3|entity|C1513492|Motor|idcn|||motor|||0|888|610|615
SE|25462494||ab|3|entity|C0243148|control|ftcn|||control|||0|888|616|623
SE|25462494||ab|3|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication|||0|928|579|589|NOM|AFFECTS||563|570|3|2|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|1000|593|605

SE|25462494||ab|4|text|625|774|The following keywords were introduced in the main databases: attention disorder and/or ADHD, motor skills and/or handwriting, children, medication.
SE|25462494||ab|4|entity|C0332282|Following|tmco|||following|||0|694|629|638
SE|25462494||ab|4|entity|C0205225|Primary|qlco|||main|||0|888|671|675
SE|25462494||ab|4|entity|C0242356|Databases|inpr|||databases|||0|888|676|685
SE|25462494||ab|4|entity|C0679466|COGNITIVE DEFICIT|mobd|||attention disorder|||0|983|687|705
SE|25462494||ab|4|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|713|717
SE|25462494||ab|4|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|719|731
SE|25462494||ab|4|entity|C0018582|Handwriting|acty|||handwriting|||0|1000|739|750
SE|25462494||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|1000|752|760
SE|25462494||ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|762|772

SE|25462494||ab|5|text|774|945|Of the 45 articles retrieved, 30 described motor skills of children with ADHD and 15 articles analysed the influence of ADHD medication on motor skills and motor control.
SE|25462494||ab|5|entity|C1552738|described|idcn|||described|||0|824|807|816
SE|25462494||ab|5|entity|C0026612|Motor Skills|orgf|||motor skills|||0|824|817|829
SE|25462494||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|833|841
SE|25462494||ab|5|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|847|851
SE|25462494||ab|5|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|928|894|898
SE|25462494||ab|5|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|928|899|909
SE|25462494||ab|5|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|913|925
SE|25462494||ab|5|entity|C1513492|Motor|idcn|||motor|||0|888|930|935
SE|25462494||ab|5|entity|C0243148|control|ftcn|||control|||0|888|936|943
SE|25462494||ab|5|relation|3|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication|||0|928|899|909|NOM|AFFECTS||881|890|3|2|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|1000|913|925
SE|25462494||ab|5|relation|6|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|847|851|PREP|PROCESS_OF||842|846|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|833|841

SE|25462494||ab|6|text|945|1038|More than half of the children with ADHD have difficulties with gross and fine motor skills.
SE|25462494||ab|6|entity|C0205172|More|ftcn|||More|||0|1000|945|949
SE|25462494||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|967|975
SE|25462494||ab|6|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|981|985
SE|25462494||ab|6|entity|C0439806|Gross|qnco|||gross|||0|1000|1009|1014
SE|25462494||ab|6|entity|C0678857|fine motor skills|ortf|||fine motor skills|||0|1000|1019|1036
SE|25462494||ab|6|relation|4|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|981|985|PREP|PROCESS_OF||976|980|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|967|975

SE|25462494||ab|7|text|1038|1202|The children with ADHD inattentive subtype seem to present more impairment of fine motor skills, slow reaction time, and online motor control during complex tasks.
SE|25462494||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1042|1050
SE|25462494||ab|7|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|865|1056|1060
SE|25462494||ab|7|entity|C0233415|Cognitive function: distractibility|menp|||inattentive|||0|865|1061|1072
SE|25462494||ab|7|entity|C0449560|Subtype|clas|||subtype|||0|865|1073|1080
SE|25462494||ab|7|entity|C0205172|More|ftcn|||more|||0|888|1097|1101
SE|25462494||ab|7|entity|C0678857|fine motor skills|ortf|||fine motor skills|||0|1000|1116|1133
SE|25462494||ab|7|entity|C0439834|Slow|qlco|||slow|||0|901|1135|1139
SE|25462494||ab|7|entity|C0034746|Reaction Time|tmco|||reaction time|||0|901|1140|1153
SE|25462494||ab|7|entity|C1513492|Motor|idcn|||motor|||0|790|1166|1171
SE|25462494||ab|7|entity|C0243148|control|ftcn|||control|||0|790|1172|1179
SE|25462494||ab|7|entity|C0439855|Complex|qlco|||complex|||0|872|1187|1194
SE|25462494||ab|7|relation|1|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|1042|1050|PREP|USES||1051|1055|6|1|C0449560|Subtype|clas|clas|||subtype|||0|865|1073|1080

SE|25462494||ab|8|text|1202|1351|The proportion of children with ADHD who improved their motor skills to the normal range by using medication varied from 28% to 67% between studies.
SE|25462494||ab|8|entity|C0205351|Proportional|qlco|||proportion|||0|928|1206|1216
SE|25462494||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1220|1228
SE|25462494||ab|8|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|1234|1238
SE|25462494||ab|8|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|1258|1270
SE|25462494||ab|8|entity|C0086715|Normal Range|qnco|||normal range|||0|1000|1278|1290
SE|25462494||ab|8|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|1300|1310
SE|25462494||ab|8|entity|C0008972|Clinical Research|resa|||studies|||0|966|1342|1349
SE|25462494||ab|8|relation|2|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||medication|||0|1000|1300|1310|VERB|ADMINISTERED_TO||1294|1299|5|4|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1220|1228
SE|25462494||ab|8|relation|3|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|1234|1238|VERB|AFFECTS||1243|1251|4|1|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|1000|1258|1270
SE|25462494||ab|8|relation|5|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|1234|1238|PREP|PROCESS_OF||1229|1233|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1220|1228

SE|25462494||ab|9|text|1351|1494|The children who still show motor deficit while on medication might meet the diagnostic criteria of developmental coordination disorder (DCD).
SE|25462494||ab|9|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1355|1363
SE|25462494||ab|9|entity|C0746626|MOTOR DEFICIT|patf|||motor deficit|||0|1000|1379|1392
SE|25462494||ab|9|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|1402|1412
SE|25462494||ab|9|entity|C0679228|diagnostic criteria|inpr|||diagnostic criteria|||0|1000|1428|1447
SE|25462494||ab|9|entity|C0011757|Developmental Coordination Disorder|dsyn|||developmental coordination disorder|||0|1000|1451|1486
SE|25462494||ab|9|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|1000|1488|1491

SE|25462494||ab|10|text|1494|1679|It is important to assess motor skills among children with ADHD because of the risk of reduced participation in activities of daily living that require motor coordination and attention.
SE|25462494||ab|10|entity|C0026612|Motor Skills|orgf|||motor skills|||0|1000|1520|1532
SE|25462494||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1539|1547
SE|25462494||ab|10|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|1553|1557
SE|25462494||ab|10|entity|C0035647|Risk|qlco|||risk|||0|1000|1573|1577
SE|25462494||ab|10|entity|C0392756|Reduced|qlco|||reduced|||0|888|1581|1588
SE|25462494||ab|10|entity|C0679823|participation|inbe|||participation|||0|888|1589|1602
SE|25462494||ab|10|entity|C0441655|Activities|acty|||activities|||0|1000|1606|1616
SE|25462494||ab|10|entity|C0332173|Daily|tmco|||daily|||0|1000|1620|1625
SE|25462494||ab|10|entity|C0237543|motor coordination|ortf|||motor coordination|||0|1000|1646|1664
SE|25462494||ab|10|entity|C0004268|Attention|menp|||attention|||0|1000|1669|1678
SE|25462494||ab|10|relation|2|1|C0026612|Motor Skills|orgf|orgf|||motor skills|||0|1000|1520|1532|PREP|PROCESS_OF||1533|1538|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1539|1547
SE|25462494||ab|10|relation|6|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|1553|1557|PREP|PROCESS_OF||1548|1552|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1539|1547


SE|25462495||ti|1|text|21|138|Child problem behaviours are associated with obesity in parents caring for children with developmental disabilities.
SE|25462495||ti|1|entity|C0008065|Child Behavior|inbe|||Child problem behaviours|||0|890|21|45
SE|25462495||ti|1|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|66|73
SE|25462495||ti|1|entity|C0030551|parent|famg|||parents|||0|1000|77|84
SE|25462495||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|96|104
SE|25462495||ti|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|110|136
SE|25462495||ti|1|relation|1|1|C0008073|Child Development Disorders|mobd|mobd|||developmental disabilities|||0|1000|110|136|PREP|PROCESS_OF||105|109|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|96|104
SE|25462495||ti|1|relation|2|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|66|73|PREP|PROCESS_OF||74|76|3|1|C0030551|parent|famg,humn|humn|||parents|||0|1000|77|84

SE|25462495||ab|1|text|144|228|Epidemiological evidence suggests that obesity and depression are highly co-morbid.
SE|25462495||ab|1|entity|C0014507|Epidemiology|bmod|||Epidemiological|||0|623|144|159
SE|25462495||ab|1|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|183|190
SE|25462495||ab|1|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|195|205
SE|25462495||ab|1|entity|C0009488|Comorbidity|idcn|||co-morbid|||0|865|217|226

SE|25462495||ab|2|text|228|509|In a national cohort study, we examined whether parents caring for children with disabilities were more likely to be classified as obese compared to parents of children without disabilities and if obesity was associated with depressive symptoms or child behaviour characteristics.
SE|25462495||ab|2|entity|C0009247|Cohort Studies|qnco|||cohort study|||0|901|242|254
SE|25462495||ab|2|entity|C0030551|parent|famg|||parents|||0|1000|276|283
SE|25462495||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|295|303
SE|25462495||ab|2|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|309|321
SE|25462495||ab|2|entity|C0205172|More|ftcn|||more|||0|888|327|331
SE|25462495||ab|2|entity|C0028754|Obesity|dsyn|||obese|||0|1000|359|364
SE|25462495||ab|2|entity|C0030551|parent|famg|||parents|||0|1000|377|384
SE|25462495||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|388|396
SE|25462495||ab|2|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|405|417
SE|25462495||ab|2|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|425|432
SE|25462495||ab|2|entity|C0086132|Depressive Symptoms|sosy|||depressive symptoms|||0|1000|453|472
SE|25462495||ab|2|entity|C0008065|Child Behavior|inbe|||child behaviour|||0|901|476|491
SE|25462495||ab|2|entity|C1521970|Characteristics|grpa|||characteristics|||0|901|492|507
SE|25462495||ab|2|relation|2|1|C0086132|Depressive Symptoms|sosy|sosy|||depressive symptoms|||0|1000|453|472|VERB|ASSOCIATED_WITH||437|447|9|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|425|432
SE|25462495||ab|2|relation|8|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|309|321|PREP|PROCESS_OF||304|308|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|295|303

SE|25462495||ab|3|text|509|914|Using data from the Growing Up in Ireland National Longitudinal Study of Children (2006 to date), 627 parents of children with developmental disabilities were compared with 7941 parents of typically developing children on objectively measured levels of obesity (body mass index >=30kg/m2), depression, health behaviours, chronic health conditions, socio-demographic and child behavioural characteristics.
SE|25462495||ab|3|entity|C1511726|Data|idcn|||data|||0|1000|515|519
SE|25462495||ab|3|entity|C0022067|Ireland|geoa|||Ireland|||0|861|543|550
SE|25462495||ab|3|entity|C0023981|Longitudinal Studies|qnco,resa|||Longitudinal Study|||0|861|560|578
SE|25462495||ab|3|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|582|590
SE|25462495||ab|3|entity|C0030551|parent|famg|||parents|||0|861|611|618
SE|25462495||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|622|630
SE|25462495||ab|3|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|636|662
SE|25462495||ab|3|entity|C0030551|parent|famg|||parents|||0|861|687|694
SE|25462495||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|827|719|727
SE|25462495||ab|3|entity|C0444706|Measured|qlco|||measured|||0|790|743|751
SE|25462495||ab|3|entity|C0441889|Levels|inpr|||levels|||0|790|752|758
SE|25462495||ab|3|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|762|769
SE|25462495||ab|3|entity|C0005893|Body mass index procedure|diap|||body mass index|||0|1000|771|786
SE|25462495||ab|3|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|799|809
SE|25462495||ab|3|entity|C0018687|Health behavior|inbe|||health behaviours|||0|1000|811|828
SE|25462495||ab|3|entity|C0205191|chronic|tmco|||chronic|||0|840|830|837
SE|25462495||ab|3|entity|C0018684|Health|idcn|||health|||0|840|838|844
SE|25462495||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|840|845|855
SE|25462495||ab|3|entity|C0011298|Demography|ocdi|||demographic|||0|789|863|874
SE|25462495||ab|3|entity|C0008065|Child Behavior|inbe|||child behavioural|||0|877|879|896
SE|25462495||ab|3|entity|C1521970|Characteristics|grpa|||characteristics|||0|877|897|912
SE|25462495||ab|3|relation|12|1|C0008073|Child Development Disorders|mobd|mobd|||developmental disabilities|||0|1000|636|662|PREP|PROCESS_OF||631|635|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|622|630

SE|25462495||ab|4|text|914|1067|Parents of children with disabilities were more likely to be classified as obese compared to control parents (24.5% vs. 19.6%, p=0.005, Cramer's V<0.1).
SE|25462495||ab|4|entity|C0030551|parent|famg|||Parents|||0|1000|914|921
SE|25462495||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|1000|925|933
SE|25462495||ab|4|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|939|951
SE|25462495||ab|4|entity|C0205172|More|ftcn|||more|||0|888|957|961
SE|25462495||ab|4|entity|C0028754|Obesity|dsyn|||obese|||0|1000|989|994
SE|25462495||ab|4|entity|C0030551|parent|famg|||parents|||0|1000|1015|1022
SE|25462495||ab|4|relation|3|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|939|951|PREP|PROCESS_OF||934|938|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|925|933
SE|25462495||ab|4|relation|4|1|C0028754|Obesity|dsyn|dsyn|||obese|||0|1000|989|994|VERB|AFFECTS||1007|1014|1|1|C0030551|parent|famg,humn|humn|||parents|||0|1000|1015|1022

SE|25462495||ab|5|text|1067|1111|Depression was not associated with obesity.
SE|25462495||ab|5|entity|C0011581|Depressive disorder|mobd|||Depression|||0|1000|1067|1077
SE|25462495||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1082|1085
SE|25462495||ab|5|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|1102|1109
SE|25462495||ab|5|relation|1|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|1102|1109|VERB|COEXISTS_WITH|negation|1086|1096|1|1|C0011581|Depressive disorder|mobd|mobd|||Depression|||0|1000|1067|1077

SE|25462495||ab|6|text|1111|1219|However, the odds of obesity increased with increasing child problem behaviour (OR 1.05, 95% CI 1.03-1.06).
SE|25462495||ab|6|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|1132|1139
SE|25462495||ab|6|entity|C0442808|Increasing|ftcn|||increasing|||0|861|1155|1165
SE|25462495||ab|6|entity|C0008065|Child Behavior|inbe|||child problem behaviour|||0|861|1166|1189

SE|25462495||ab|7|text|1219|1342|Over half (57%) of obese parents caring for children with disabilities reported trying to lose weight often or very often.
SE|25462495||ab|7|entity|C0205136|Over|spco|||Over|||0|694|1219|1223
SE|25462495||ab|7|entity|C0028754|Obesity|dsyn|||obese|||0|888|1238|1243
SE|25462495||ab|7|entity|C0030551|parent|famg|||parents|||0|888|1244|1251
SE|25462495||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1263|1271
SE|25462495||ab|7|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|1277|1289
SE|25462495||ab|7|entity|C0043100|Weight|qnco|||weight|||0|888|1314|1320
SE|25462495||ab|7|entity|C0332183|Frequent|tmco|||often|||0|888|1321|1326
SE|25462495||ab|7|entity|C0442824|Very|qlco|||very|||0|888|1330|1334
SE|25462495||ab|7|entity|C0332183|Frequent|tmco|||often|||0|888|1335|1340
SE|25462495||ab|7|relation|0|0|C0028754|Obesity|dsyn|dsyn|||obese|||0|888|1238|1243|MOD/HEAD|PROCESS_OF||1238|1251|0|0|C0030551|parent|famg,humn|humn|||parents|||0|888|1244|1251
SE|25462495||ab|7|relation|2|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|1277|1289|PREP|PROCESS_OF||1272|1276|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1263|1271

SE|25462495||ab|8|text|1342|1612|This study has confirmed, in a population-based sample, the high risk of obesity in parents caring for children with disabilities after adjusting for the presence of depression and other health behaviours; increasing child problem behaviours were predictive of obesity.
SE|25462495||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1347|1352
SE|25462495||ab|8|entity|C1257890|Population Group|popg|||population|||0|606|1373|1383
SE|25462495||ab|8|entity|C0205250|High|qlco|||high|||0|888|1402|1406
SE|25462495||ab|8|entity|C0035647|Risk|qlco|||risk|||0|888|1407|1411
SE|25462495||ab|8|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|1415|1422
SE|25462495||ab|8|entity|C0030551|parent|famg|||parents|||0|1000|1426|1433
SE|25462495||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1445|1453
SE|25462495||ab|8|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|1459|1471
SE|25462495||ab|8|entity|C1439356|ADJUSTED|qlco|||adjusting|||0|966|1478|1487
SE|25462495||ab|8|entity|C0011581|Depressive disorder|mobd|||depression|||0|1000|1508|1518
SE|25462495||ab|8|entity|C0018687|Health behavior|inbe|||health behaviours|||0|1000|1529|1546
SE|25462495||ab|8|entity|C0008065|Child Behavior|inbe|||child problem behaviours|||0|890|1559|1583
SE|25462495||ab|8|entity|C0681890|predictive|qlco|||predictive|||0|1000|1589|1599
SE|25462495||ab|8|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|1603|1610
SE|25462495||ab|8|relation|4|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|1415|1422|PREP|PROCESS_OF||1423|1425|10|1|C0030551|parent|famg,humn|humn|||parents|||0|1000|1426|1433
SE|25462495||ab|8|relation|8|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|1459|1471|PREP|PROCESS_OF||1454|1458|6|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1445|1453
SE|25462495||ab|8|relation|8|2|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|1459|1471|NOM|COEXISTS_WITH||1496|1504|5|1|C0011581|Depressive disorder|mobd|mobd|||depression|||0|1000|1508|1518
SE|25462495||ab|8|relation|12|1|C0008065|Child Behavior|inbe|inbe|||child problem behaviours|||0|890|1559|1583|ADJ|PREDISPOSES||1589|1599|1|1|C0028754|Obesity|dsyn|dsyn|||obesity|||0|1000|1603|1610

SE|25462495||ab|9|text|1612|1816|Importantly, given the negative health correlates of obesity, it is imperative that health professionals pay attention to weight issues in these parents and support their efforts in managing these issues.
SE|25462495||ab|9|entity|C0205160|Negative|qlco|||negative|||0|888|1635|1643
SE|25462495||ab|9|entity|C0018684|Health|idcn|||health|||0|888|1644|1650
SE|25462495||ab|9|entity|C0028754|Obesity|dsyn|||obesity|||0|1000|1665|1672
SE|25462495||ab|9|entity|C0018724|Health Personnel|prog|||health professionals|||0|983|1696|1716
SE|25462495||ab|9|entity|C0004268|Attention|menp|||attention|||0|1000|1721|1730
SE|25462495||ab|9|entity|C0043100|Weight|qnco|||weight|||0|694|1734|1740
SE|25462495||ab|9|entity|C0030551|parent|famg|||parents|||0|1000|1757|1764
SE|25462495||ab|9|relation|6|2|C0004268|Attention|menp|menp|||attention|||0|1000|1721|1730|PREP|PROCESS_OF||1748|1750|4|1|C0030551|parent|famg,humn|humn|||parents|||0|1000|1757|1764


SE|25462497||ti|1|text|21|138|Effects of pubertal timing on alcohol and tobacco use in the early adulthood: A longitudinal cohort study in Taiwan.
SE|25462497||ti|1|entity|C1280500|Effect|qlco|||Effects|||0|966|21|28
SE|25462497||ti|1|entity|C0034011|Puberty|orgf|||pubertal|||0|853|32|40
SE|25462497||ti|1|entity|C0449243|Timing|tmco|||timing|||0|853|41|47
SE|25462497||ti|1|entity|C0001962|Ethanol|orch,phsu|||alcohol|||0|1000|51|58
SE|25462497||ti|1|entity|C0040335|Encounter due to tobacco use|fndg|||tobacco use|||0|1000|63|74
SE|25462497||ti|1|entity|C0680085|young adulthood|aggp|||early adulthood|||0|1000|82|97
SE|25462497||ti|1|entity|C0599755|cohort|popg|||cohort|||0|901|114|120
SE|25462497||ti|1|entity|C0023981|Longitudinal Studies|qnco,resa|||longitudinal cohort study|||0|901|101|126
SE|25462497||ti|1|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|130|136
SE|25462497||ti|1|relation|4|1|C0040335|Encounter due to tobacco use|fndg|fndg|||tobacco use|||0|1000|63|74|PREP|PROCESS_OF||75|77|3|1|C0680085|young adulthood|aggp,humn|humn|||early adulthood|||0|1000|82|97

SE|25462497||ab|1|text|144|277|We aimed to examine the effects of pubertal timing on adolescents' alcohol and tobacco use from late adolescence to young adulthood.
SE|25462497||ab|1|entity|C1280500|Effect|qlco|||effects|||0|966|168|175
SE|25462497||ab|1|entity|C0034011|Puberty|orgf|||pubertal|||0|853|179|187
SE|25462497||ab|1|entity|C0449243|Timing|tmco|||timing|||0|853|188|194
SE|25462497||ab|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|888|198|209
SE|25462497||ab|1|entity|C0001962|Ethanol|orch,phsu|||alcohol|||0|888|211|218
SE|25462497||ab|1|entity|C0040335|Encounter due to tobacco use|fndg|||tobacco use|||0|1000|223|234
SE|25462497||ab|1|entity|C0205087|Late|tmco|||late|||0|888|240|244
SE|25462497||ab|1|entity|C0001578|Adolescence|tmco|||adolescence|||0|888|245|256
SE|25462497||ab|1|entity|C0680085|young adulthood|aggp|||young adulthood|||0|1000|260|275

SE|25462497||ab|2|text|277|396|In addition, we separately explored associative factors of the use of these substances stratified by pubertal timings.
SE|25462497||ab|2|entity|C1521761|Factor|ftcn|||factors|||0|827|325|332
SE|25462497||ab|2|entity|C0439861|Substance|sbst|||substances|||0|1000|353|363
SE|25462497||ab|2|entity|C0034011|Puberty|orgf|||pubertal|||0|836|378|386
SE|25462497||ab|2|entity|C0449243|Timing|tmco|||timings|||0|836|387|394

SE|25462497||ab|3|text|396|474|A longitudinal cohort of 7th- and 9th-grade students was recruited in Taiwan.
SE|25462497||ab|3|entity|C0205127|Longitudinal|spco|||longitudinal|||0|888|398|410
SE|25462497||ab|3|entity|C0599755|cohort|popg|||cohort|||0|888|411|417
SE|25462497||ab|3|entity|C0038492|student|prog|||students|||0|790|440|448
SE|25462497||ab|3|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|466|472

SE|25462497||ab|4|text|474|552|Pubertal timing was classified according to the Pubertal Developmental Scale.
SE|25462497||ab|4|entity|C0034011|Puberty|orgf|||Pubertal|||0|853|474|482
SE|25462497||ab|4|entity|C0449243|Timing|tmco|||timing|||0|853|483|489
SE|25462497||ab|4|entity|C0034011|Puberty|orgf|||Pubertal|||0|828|522|530
SE|25462497||ab|4|entity|C0458003|Developmental|qlco|||Developmental|||0|828|531|544

SE|25462497||ab|5|text|552|690|Effects of pubertal timing on self-reported drinking and smoking at age 20 were evaluated using generalized estimating equation analysis.
SE|25462497||ab|5|entity|C1280500|Effect|qlco|||Effects|||0|966|552|559
SE|25462497||ab|5|entity|C0034011|Puberty|orgf|||pubertal|||0|853|563|571
SE|25462497||ab|5|entity|C0449243|Timing|tmco|||timing|||0|853|572|578
SE|25462497||ab|5|entity|C0036588|Self|idcn|||self|||0|851|582|586
SE|25462497||ab|5|entity|C0001948|Alcohol consumption|inbe|||drinking|||0|851|596|604
SE|25462497||ab|5|entity|C0037369|Smoking|inbe|||smoking|||0|1000|609|616
SE|25462497||ab|5|entity|C0001779|Age|orga|||age|||0|861|620|623
SE|25462497||ab|5|entity|C0205246|Generalized|spco|||generalized|||0|825|648|659
SE|25462497||ab|5|entity|C0750572|Estimated|qnco|||estimating|||0|825|660|670
SE|25462497||ab|5|entity|C0552449|Equation|cnce|||equation|||0|825|671|679
SE|25462497||ab|5|entity|C0936012|Analysis|resa|||analysis|||0|825|680|688

SE|25462497||ab|6|text|690|919|Furthermore, we assessed the predictive roles of parental monitoring, parent-child relationships, peer influence, and school adhesion among participants, stratified by pubertal timing using multiple logistic regression analysis.
SE|25462497||ab|6|entity|C0681890|predictive|qlco|||predictive|||0|888|719|729
SE|25462497||ab|6|entity|C0035820|Role|socb|||roles|||0|888|730|735
SE|25462497||ab|6|entity|C0814580|parental monitoring|socb|||parental monitoring|||0|1000|739|758
SE|25462497||ab|6|entity|C0030542|Parent-Child Relations|socb|||parent-child relationships|||0|1000|760|786
SE|25462497||ab|6|entity|C0683549|peer influence|socb|||peer influence|||0|1000|788|802
SE|25462497||ab|6|entity|C0001511|Adhesions|acab,dsyn|||adhesion|||0|861|815|823
SE|25462497||ab|6|entity|C0679646|Participant|popg|||participants|||0|966|830|842
SE|25462497||ab|6|entity|C0034011|Puberty|orgf|||pubertal|||0|853|858|866
SE|25462497||ab|6|entity|C0449243|Timing|tmco|||timing|||0|853|867|873
SE|25462497||ab|6|entity|C0439064|Numerous|qnco|||multiple|||0|916|880|888
SE|25462497||ab|6|entity|C0681925|logistic regression analysis|qnco,resa|||logistic regression analysis|||0|916|889|917
SE|25462497||ab|6|relation|5|1|C0001511|Adhesions|acab,dsyn|dsyn|||adhesion|||0|861|815|823|PREP|PROCESS_OF||824|829|3|1|C0679646|Participant|popg,humn|humn|||participants|||0|966|830|842

SE|25462497||ab|7|text|919|988|A survey of 2290 participants was analyzed, with 51.2% being female.
SE|25462497||ab|7|entity|C0038951|Surveys|resa|||survey|||0|1000|921|927
SE|25462497||ab|7|entity|C0679646|Participant|popg|||participants|||0|827|936|948
SE|25462497||ab|7|entity|C0015780|Female|orga|||female|||0|1000|980|986

SE|25462497||ab|8|text|988|1256|The smoking rate is 19.2% (adjusted odds ratio [OR] 1.43, 95% confidence interval [CI] 1.03-2.00) and the alcohol drinking rate is 41.6% (adjusted OR 1.34, 95% CI 1.07-1.69) for early maturing adolescents as compared to 12.3% and 41.6% respectively for on-time peers.
SE|25462497||ab|8|entity|C0037369|Smoking|inbe|||smoking|||0|888|992|999
SE|25462497||ab|8|entity|C1521828|Rate|qnco|||rate|||0|888|1000|1004
SE|25462497||ab|8|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|785|1015|1023
SE|25462497||ab|8|entity|C0028873|Odds Ratio|qnco|||odds ratio|||0|785|1024|1034
SE|25462497||ab|8|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|818|1050|1069
SE|25462497||ab|8|entity|C0001948|Alcohol consumption|inbe|||alcohol drinking|||0|901|1094|1110
SE|25462497||ab|8|entity|C1521828|Rate|qnco|||rate|||0|901|1111|1115
SE|25462497||ab|8|entity|C1439356|ADJUSTED|qlco|||adjusted|||0|785|1126|1134
SE|25462497||ab|8|entity|C0028873|Odds Ratio|qnco|||OR|||0|785|1135|1137
SE|25462497||ab|8|entity|C0009667|Confidence Intervals|qnco|||CI|||0|818|1148|1150
SE|25462497||ab|8|entity|C1279919|Early|tmco|||early|||0|840|1166|1171
SE|25462497||ab|8|entity|C0205286|Mature|tmco|||maturing|||0|840|1172|1180
SE|25462497||ab|8|entity|C0205653|Adolescent|aggp|||adolescents|||0|840|1181|1192
SE|25462497||ab|8|entity|C0040223|Time|tmco|||time|||0|790|1244|1248
SE|25462497||ab|8|entity|C0679739|peer|popg|||peers|||0|790|1249|1254

SE|25462497||ab|9|text|1256|1436|A satisfactory parent-child relationship is a protective factor and strict parental monitoring is a risk factor for future tobacco and alcohol use in logistic regression analyses.
SE|25462497||ab|9|entity|C1547307|Satisfactory|inpr|||satisfactory|||0|916|1258|1270
SE|25462497||ab|9|entity|C0030542|Parent-Child Relations|socb|||parent-child relationship|||0|916|1271|1296
SE|25462497||ab|9|entity|C0679688|protective factors|biof|||protective factor|||0|983|1302|1319
SE|25462497||ab|9|entity|C0814580|parental monitoring|socb|||parental monitoring|||0|901|1331|1350
SE|25462497||ab|9|entity|C0035648|risk factors|qnco|||risk factor|||0|1000|1356|1367
SE|25462497||ab|9|entity|C0016884|Future|tmco|||future|||0|888|1372|1378
SE|25462497||ab|9|entity|C0040329|Tobacco|hops,orch,phsu|||tobacco|||0|888|1379|1386
SE|25462497||ab|9|entity|C0001948|Alcohol consumption|inbe|||alcohol use|||0|1000|1391|1402
SE|25462497||ab|9|entity|C0681925|logistic regression analysis|qnco,resa|||logistic regression analyses|||0|983|1406|1434

SE|25462497||ab|10|text|1436|1532|Early maturation confers risk for cigarette smoking and alcohol consumption in young adulthood.
SE|25462497||ab|10|entity|C1279919|Early|tmco|||Early|||0|694|1436|1441
SE|25462497||ab|10|entity|C0035647|Risk|qlco|||risk|||0|1000|1461|1465
SE|25462497||ab|10|entity|C0700219|Cigarette Smoking|dora|||cigarette smoking|||0|1000|1470|1487
SE|25462497||ab|10|entity|C0001948|Alcohol consumption|inbe|||alcohol consumption|||0|1000|1492|1511
SE|25462497||ab|10|entity|C0680085|young adulthood|aggp|||young adulthood|||0|1000|1515|1530
SE|25462497||ab|10|relation|4|1|C0001948|Alcohol consumption|inbe|inbe|||alcohol consumption|||0|1000|1492|1511|PREP|PROCESS_OF||1512|1514|1|1|C0680085|young adulthood|aggp,humn|humn|||young adulthood|||0|1000|1515|1530

SE|25462497||ab|11|text|1532|1697|Health professionals and parents should be advised of the potential associative factors with future substance use among adolescents with different maturation tempo.
SE|25462497||ab|11|entity|C0018724|Health Personnel|prog|||Health professionals|||0|983|1532|1552
SE|25462497||ab|11|entity|C0030551|parent|famg|||parents|||0|1000|1557|1564
SE|25462497||ab|11|entity|C0237399|Potential|qlco|||potential|||0|785|1590|1599
SE|25462497||ab|11|entity|C1521761|Factor|ftcn|||factors|||0|785|1612|1619
SE|25462497||ab|11|entity|C0016884|Future|tmco|||future|||0|901|1625|1631
SE|25462497||ab|11|entity|C0237123|AOD use|inbe,mobd|||substance use|||0|901|1632|1645
SE|25462497||ab|11|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|1652|1663
SE|25462497||ab|11|entity|C1547020|*Difference|qnco|||different|||0|589|1669|1678
SE|25462497||ab|11|relation|4|1|C0237123|AOD use|inbe,mobd|inbe|||substance use|||0|901|1632|1645|PREP|PROCESS_OF||1646|1651|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1652|1663

SE|25462497||ab|12|text|1697|1797|Emphasis could be placed on promoting positive parenting strategies and intra-familial interactions.
SE|25462497||ab|12|entity|C1446409|Positive|qlco|||positive|||0|763|1735|1743
SE|25462497||ab|12|entity|C0347985|During values|tmco|||intra|||0|623|1769|1774
SE|25462497||ab|12|entity|C0241888|Familial|ftcn|||familial|||0|623|1775|1783


SE|25462496||ti|1|text|21|156|Related factors and incidence risk of acute myocardial infarction among the people with disability: A national population-based study.
SE|25462496||ti|1|entity|C1522149|Related|ftcn|||Related|||0|872|21|28
SE|25462496||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|872|29|36
SE|25462496||ti|1|entity|C0021149|Incidence|qnco|||incidence|||0|888|41|50
SE|25462496||ti|1|entity|C0035647|Risk|qlco|||risk|||0|888|51|55
SE|25462496||ti|1|entity|C0155626|Acute myocardial infarction|dsyn|||acute myocardial infarction|||0|1000|59|86
SE|25462496||ti|1|entity|C0027361|Persons|popg|||people|||0|1000|97|103
SE|25462496||ti|1|entity|C0231170|Disability NOS|patf|||disability|||0|1000|109|119
SE|25462496||ti|1|entity|C0681876|Population Study|resa|||population-based study|||0|852|132|154
SE|25462496||ti|1|relation|3|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||acute myocardial infarction|||0|1000|59|86|PREP|PROCESS_OF||87|92|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|97|103
SE|25462496||ti|1|relation|4|3|C0231170|Disability NOS|patf|patf|||disability|||0|1000|109|119|NOM|PREDISPOSES||51|55|4|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||acute myocardial infarction|||0|1000|59|86

SE|25462496||ab|1|text|162|237|Cardiovascular disease has always been a leading cause of death worldwide.
SE|25462496||ab|1|entity|C0007222|Cardiovascular Diseases|dsyn|||Cardiovascular disease|||0|1000|162|184
SE|25462496||ab|1|entity|C1549493|Always|idcn|||always|||0|1000|189|195
SE|25462496||ab|1|entity|C0015127|Etiology aspects|ftcn|||cause|||0|827|211|216
SE|25462496||ab|1|entity|C0011065|Cessation of life|orgf|||death|||0|861|220|225
SE|25462496||ab|1|relation|1|1|C0007222|Cardiovascular Diseases|dsyn|dsyn|||Cardiovascular disease|||0|1000|162|184|NOM|CAUSES||211|216|1|1|C0011065|Cessation of life|orgf|orgf|||death|||0|861|220|225

SE|25462496||ab|2|text|237|360|Because the mobility of people with disability is relatively decreased, their risk of cardiovascular disease is increased.
SE|25462496||ab|2|entity|C0027361|Persons|popg|||people|||0|1000|261|267
SE|25462496||ab|2|entity|C0231170|Disability NOS|patf|||disability|||0|1000|273|283
SE|25462496||ab|2|entity|C0035647|Risk|qlco|||risk|||0|1000|315|319
SE|25462496||ab|2|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular disease|||0|1000|323|345
SE|25462496||ab|2|relation|4|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|273|283|PREP|PROCESS_OF||268|272|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|261|267

SE|25462496||ab|3|text|360|482|This study investigated the risks and relevant factors of acute myocardial infarction (AMI) among people with disability.
SE|25462496||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|365|370
SE|25462496||ab|3|entity|C1521761|Factor|ftcn|||factors|||0|827|407|414
SE|25462496||ab|3|entity|C0155626|Acute myocardial infarction|dsyn|||acute myocardial infarction|||0|1000|418|445
SE|25462496||ab|3|entity|C0027361|Persons|popg|||people|||0|1000|458|464
SE|25462496||ab|3|entity|C0231170|Disability NOS|patf|||disability|||0|1000|470|480
SE|25462496||ab|3|relation|1|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|470|480|PREP|PROCESS_OF||465|469|4|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|458|464
SE|25462496||ab|3|relation|3|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||acute myocardial infarction|||0|1000|418|445|PREP|PROCESS_OF||452|457|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|458|464

SE|25462496||ab|4|text|482|553|This is a retrospective cohort study based on secondary data analysis.
SE|25462496||ab|4|entity|C0599755|cohort|popg|||cohort|||0|901|506|512
SE|25462496||ab|4|entity|C0035363|Retrospective Studies|qnco|||retrospective cohort study|||0|901|492|518
SE|25462496||ab|4|entity|C0683944|secondary data analysis|resa|||secondary data analysis|||0|1000|528|551

SE|25462496||ab|5|text|553|832|This study focused on 798,328 people with disability who were aged 35 and above during 2002-2008 and were registered in the National Disability Registration Database; the relevant medical data from 2000 to 2011 were acquired from the National Health Insurance Research Database.
SE|25462496||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|558|563
SE|25462496||ab|5|entity|C0027361|Persons|popg|||people|||0|827|583|589
SE|25462496||ab|5|entity|C0231170|Disability NOS|patf|||disability|||0|1000|595|605
SE|25462496||ab|5|entity|C1282910|Upper|spco|||above|||0|1000|627|632
SE|25462496||ab|5|entity|C0231170|Disability NOS|patf|||Disability|||0|833|686|696
SE|25462496||ab|5|entity|C1514821|Registration|hlca|||Registration|||0|833|697|709
SE|25462496||ab|5|entity|C0242356|Databases|inpr|||Database|||0|833|710|718
SE|25462496||ab|5|entity|C0205476|Medical|ftcn|||medical|||0|790|733|740
SE|25462496||ab|5|entity|C1511726|Data|idcn|||data|||0|790|741|745
SE|25462496||ab|5|entity|C0027452|National Health Insurance|hlca|||National Health Insurance|||0|875|787|812
SE|25462496||ab|5|entity|C0035168|research|resa|||Research|||0|875|813|821
SE|25462496||ab|5|entity|C0242356|Databases|inpr|||Database|||0|875|822|830
SE|25462496||ab|5|relation|5|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|595|605|PREP|PROCESS_OF||590|594|2|1|C0027361|Persons|popg,humn|humn|||people|||0|827|583|589

SE|25462496||ab|6|text|832|980|A Cox proportional hazards model was adopted for analyzing the relative AMI risks among different disability types and finding latent risk factors.
SE|25462496||ab|6|entity|C0010235|Cox Proportional Hazards Models|inpr,qnco|||Cox proportional hazards model|||0|966|834|864
SE|25462496||ab|6|entity|C1515960|Analyzed|qlco|||analyzing|||0|966|881|890
SE|25462496||ab|6|entity|C0205345|Relative|qlco|||relative|||0|916|895|903
SE|25462496||ab|6|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|916|904|907
SE|25462496||ab|6|entity|C1547020|*Difference|qnco|||different|||0|828|920|929
SE|25462496||ab|6|entity|C0231170|Disability NOS|patf|||disability|||0|828|930|940
SE|25462496||ab|6|entity|C0332307|Type - attribute|qlco|||types|||0|828|941|946
SE|25462496||ab|6|entity|C0037088|Signs and Symptoms|sosy|||finding|||0|861|951|958
SE|25462496||ab|6|entity|C0205275|Latent|qlco|||latent|||0|861|959|965
SE|25462496||ab|6|entity|C0035648|risk factors|qnco|||risk factors|||0|861|966|978

SE|25462496||ab|7|text|980|1094|The results indicated that the AMI incidence rate (per 1000 patient-years) among people with disability was 2.48.
SE|25462496||ab|7|entity|C1274040|result|ftcn|||results|||0|966|984|991
SE|25462496||ab|7|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|875|1011|1014
SE|25462496||ab|7|entity|C0021149|Incidence|qnco|||incidence|||0|875|1015|1024
SE|25462496||ab|7|entity|C1521828|Rate|qnco|||rate|||0|875|1025|1029
SE|25462496||ab|7|entity|C0030705|Patients|podg|||patient|||0|790|1040|1047
SE|25462496||ab|7|entity|C0439234|year|tmco|||years|||0|790|1048|1053
SE|25462496||ab|7|entity|C0027361|Persons|popg|||people|||0|1000|1061|1067
SE|25462496||ab|7|entity|C0231170|Disability NOS|patf|||disability|||0|1000|1073|1083
SE|25462496||ab|7|relation|1|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|1073|1083|PREP|PROCESS_OF||1068|1072|4|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1061|1067
SE|25462496||ab|7|relation|3|2|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|875|1011|1014|PREP|PROCESS_OF||1055|1060|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1061|1067

SE|25462496||ab|8|text|1094|1221|Men had an AMI incidence rate of 2.68 per 1000 patient-years, which was significantly higher than that of women (2.21; p<.05).
SE|25462496||ab|8|entity|C0025266|Male population group|popg|||Men|||0|1000|1094|1097
SE|25462496||ab|8|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|875|1105|1108
SE|25462496||ab|8|entity|C0021149|Incidence|qnco|||incidence|||0|875|1109|1118
SE|25462496||ab|8|entity|C1521828|Rate|qnco|||rate|||0|875|1119|1123
SE|25462496||ab|8|entity|C0030705|Patients|podg|||patient|||0|790|1141|1148
SE|25462496||ab|8|entity|C0439234|year|tmco|||years|||0|790|1149|1154
SE|25462496||ab|8|entity|C0205250|High|qlco|||higher|||0|827|1180|1186
SE|25462496||ab|8|entity|C0043210|Woman|popg|||women|||0|1000|1200|1205
SE|25462496||ab|8|entity|C0202178|Phosphorus measurement|lbpr|||p|||0|861|1213|1214
SE|25462496||ab|8|relation|4|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|875|1105|1108|AUX|PROCESS_OF||1098|1101|1|1|C0025266|Male population group|popg,humn|humn|||Men|||0|1000|1094|1097

SE|25462496||ab|9|text|1221|1374|The AMI risk for people with mental disabilities was 0.76 times the risk for people with physical disabilities (95% confidence interval [CI]=0.71-0.82).
SE|25462496||ab|9|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|916|1225|1228
SE|25462496||ab|9|entity|C0035647|Risk|qlco|||risk|||0|916|1229|1233
SE|25462496||ab|9|entity|C0027361|Persons|popg|||people|||0|1000|1238|1244
SE|25462496||ab|9|entity|C1306341|Mental handicap|mobd|||mental disabilities|||0|983|1250|1269
SE|25462496||ab|9|entity|C0040223|Time|tmco|||times|||0|793|1279|1284
SE|25462496||ab|9|entity|C0035647|Risk|qlco|||risk|||0|1000|1289|1293
SE|25462496||ab|9|entity|C0027361|Persons|popg|||people|||0|1000|1298|1304
SE|25462496||ab|9|entity|C0520817|Physical disability|patf|||physical disabilities|||0|983|1310|1331
SE|25462496||ab|9|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|901|1337|1356
SE|25462496||ab|9|relation|2|1|C0520817|Physical disability|patf|patf|||physical disabilities|||0|983|1310|1331|PREP|PROCESS_OF||1305|1309|6|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1298|1304
SE|25462496||ab|9|relation|6|1|C1306341|Mental handicap|mobd|mobd|||mental disabilities|||0|983|1250|1269|PREP|PROCESS_OF||1245|1249|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1238|1244

SE|25462496||ab|10|text|1374|1503|The AMI risk for people with profound disabilities was 2.04 times (95% CI=1.93-2.16) the risk for people with mild disabilities.
SE|25462496||ab|10|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|916|1378|1381
SE|25462496||ab|10|entity|C0035647|Risk|qlco|||risk|||0|916|1382|1386
SE|25462496||ab|10|entity|C0027361|Persons|popg|||people|||0|1000|1391|1397
SE|25462496||ab|10|entity|C0439808|Profound|qlco|||profound|||0|888|1403|1411
SE|25462496||ab|10|entity|C0231170|Disability NOS|patf|||disabilities|||0|888|1412|1424
SE|25462496||ab|10|entity|C0040223|Time|tmco|||times|||0|793|1434|1439
SE|25462496||ab|10|entity|C0009667|Confidence Intervals|qnco|||CI|||0|901|1445|1447
SE|25462496||ab|10|entity|C0580272|1/2|inpr|||1.93-2|||0|875|1448|1454
SE|25462496||ab|10|entity|C0035647|Risk|qlco|||risk|||0|1000|1463|1467
SE|25462496||ab|10|entity|C0027361|Persons|popg|||people|||0|1000|1472|1478
SE|25462496||ab|10|entity|C0547040|Minimal|qlco|||mild|||0|888|1484|1488
SE|25462496||ab|10|entity|C0231170|Disability NOS|patf|||disabilities|||0|888|1489|1501
SE|25462496||ab|10|relation|1|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|888|1489|1501|PREP|PROCESS_OF||1479|1483|7|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1472|1478
SE|25462496||ab|10|relation|7|2|C0231170|Disability NOS|patf|patf|||disabilities|||0|888|1412|1424|NOM|PREDISPOSES||1382|1386|0|0|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|916|1378|1381

SE|25462496||ab|11|text|1503|1532|AMI risk increased with age.
SE|25462496||ab|11|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|916|1503|1506
SE|25462496||ab|11|entity|C0035647|Risk|qlco|||risk|||0|916|1507|1511
SE|25462496||ab|11|entity|C0001779|Age|orga|||age|||0|1000|1527|1530

SE|25462496||ab|12|text|1532|1665|People with disability aged 65 and above had an AMI risk that was 5.01-6.03 times the risk for people with disability aged below 45.
SE|25462496||ab|12|entity|C0027361|Persons|popg|||People|||0|1000|1532|1538
SE|25462496||ab|12|entity|C0231170|Disability NOS|patf|||disability|||0|1000|1544|1554
SE|25462496||ab|12|entity|C1282910|Upper|spco|||above|||0|1000|1567|1572
SE|25462496||ab|12|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|1000|1580|1583
SE|25462496||ab|12|entity|C0040223|Time|tmco|||times|||0|770|1608|1613
SE|25462496||ab|12|entity|C0035647|Risk|qlco|||risk|||0|1000|1618|1622
SE|25462496||ab|12|entity|C0027361|Persons|popg|||people|||0|1000|1627|1633
SE|25462496||ab|12|entity|C0231170|Disability NOS|patf|||disability|||0|1000|1639|1649
SE|25462496||ab|12|entity|C0542339|Inferior|spco|||below|||0|861|1655|1660
SE|25462496||ab|12|relation|1|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|1639|1649|PREP|PROCESS_OF||1634|1638|7|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1627|1633
SE|25462496||ab|12|relation|5|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|1000|1580|1583|AUX|PROCESS_OF||1573|1576|3|3|C0027361|Persons|popg,humn|humn|||People|||0|1000|1532|1538
SE|25462496||ab|12|relation|7|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|1544|1554|PREP|PROCESS_OF||1539|1543|1|1|C0027361|Persons|popg,humn|humn|||People|||0|1000|1532|1538

SE|25462496||ab|13|text|1665|1754|Disabled indigenous people had a relatively higher AMI risk (HR=1.35, 95% CI=1.19-1.52).
SE|25462496||ab|13|entity|C0079891|Natives|popg|||indigenous people|||0|901|1674|1691
SE|25462496||ab|13|entity|C0205250|High|qlco|||higher|||0|811|1709|1715
SE|25462496||ab|13|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|811|1716|1719
SE|25462496||ab|13|entity|C0035647|Risk|qlco|||risk|||0|811|1720|1724
SE|25462496||ab|13|entity|C0009667|Confidence Intervals|qnco|||CI|||0|901|1739|1741
SE|25462496||ab|13|relation|3|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|811|1716|1719|AUX|PROCESS_OF||1692|1695|1|1|C0079891|Natives|popg,humn|humn|||indigenous people|||0|901|1674|1691

SE|25462496||ab|14|text|1754|1919|The AMI risk for people with disability with a Charlson comorbidity index (CCI) of 4 and above was 5.89 times (95% CI=5.56-6.25) the risk for those with a CCI of 0.
SE|25462496||ab|14|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|916|1758|1761
SE|25462496||ab|14|entity|C0035647|Risk|qlco|||risk|||0|916|1762|1766
SE|25462496||ab|14|entity|C0027361|Persons|popg|||people|||0|1000|1771|1777
SE|25462496||ab|14|entity|C0231170|Disability NOS|patf|||disability|||0|1000|1783|1793
SE|25462496||ab|14|entity|C1516737|Comorbidity Index|qnco|||comorbidity index|||0|901|1810|1827
SE|25462496||ab|14|entity|C1282910|Upper|spco|||above|||0|1000|1843|1848
SE|25462496||ab|14|entity|C0040223|Time|tmco|||times|||0|785|1858|1863
SE|25462496||ab|14|entity|C0009667|Confidence Intervals|qnco|||CI|||0|901|1869|1871
SE|25462496||ab|14|entity|C0035647|Risk|qlco|||risk|||0|1000|1887|1891
SE|25462496||ab|14|entity|C1516737|Comorbidity Index|qnco|||CCI|||0|861|1909|1912
SE|25462496||ab|14|relation|8|2|C0231170|Disability NOS|patf|patf|||disability|||0|1000|1783|1793|NOM|PREDISPOSES||1762|1766|0|0|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|916|1758|1761

SE|25462496||ab|15|text|1919|2098|Compared with people with physical disabilities, people with visual impairment and people with dysfunctional primary organs had significantly higher AMI risks (HR=1.15; HR=1.66).
SE|25462496||ab|15|entity|C0027361|Persons|popg|||people|||0|1000|1933|1939
SE|25462496||ab|15|entity|C0520817|Physical disability|patf|||physical disabilities|||0|983|1945|1966
SE|25462496||ab|15|entity|C0027361|Persons|popg|||people|||0|1000|1968|1974
SE|25462496||ab|15|entity|C0042798|Visual impairment|fndg|||visual impairment|||0|1000|1980|1997
SE|25462496||ab|15|entity|C0027361|Persons|popg|||people|||0|1000|2002|2008
SE|25462496||ab|15|entity|C0031847|physiopathological|ftcn|||dysfunctional|||0|816|2014|2027
SE|25462496||ab|15|entity|C0178784|Organ|bpoc|||organs|||0|816|2036|2042
SE|25462496||ab|15|entity|C0205250|High|qlco|||higher|||0|837|2061|2067
SE|25462496||ab|15|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|837|2068|2071
SE|25462496||ab|15|relation|3|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|837|2068|2071|AUX|PROCESS_OF||2043|2046|6|2|C0027361|Persons|popg,humn|humn|||people|||0|1000|2002|2008
SE|25462496||ab|15|relation|4|1|C0178784|Organ|bpoc|bpoc|||organs|||0|816|2036|2042|PREP|PART_OF||2009|2013|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|2002|2008
SE|25462496||ab|15|relation|6|1|C0042798|Visual impairment|fndg|fndg|||visual impairment|||0|1000|1980|1997|PREP|PROCESS_OF||1975|1979|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1968|1974
SE|25462496||ab|15|relation|8|1|C0520817|Physical disability|patf|patf|||physical disabilities|||0|983|1945|1966|PREP|PROCESS_OF||1940|1944|1|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1933|1939

SE|25462496||ab|16|text|2098|2347|This study found that people with disability who were male, aged 65 and above, married, indigenous, with physical disabilities, with high comorbidity, or with high disability levels had relatively higher AMI risks than other people with disability.
SE|25462496||ab|16|entity|C0008972|Clinical Research|resa|||study|||0|1000|2103|2108
SE|25462496||ab|16|entity|C0027361|Persons|popg|||people|||0|1000|2120|2126
SE|25462496||ab|16|entity|C0231170|Disability NOS|patf|||disability|||0|1000|2132|2142
SE|25462496||ab|16|entity|C1282910|Upper|spco|||above|||0|1000|2170|2175
SE|25462496||ab|16|entity|C1512704|Indigenous|grpa|||indigenous|||0|1000|2186|2196
SE|25462496||ab|16|entity|C0520817|Physical disability|patf|||physical disabilities|||0|983|2203|2224
SE|25462496||ab|16|entity|C0205250|High|qlco|||high|||0|888|2231|2235
SE|25462496||ab|16|entity|C0009488|Comorbidity|idcn|||comorbidity|||0|888|2236|2247
SE|25462496||ab|16|entity|C0205250|High|qlco|||high|||0|851|2257|2261
SE|25462496||ab|16|entity|C0231170|Disability NOS|patf|||disability|||0|851|2262|2272
SE|25462496||ab|16|entity|C0441889|Levels|inpr|||levels|||0|851|2273|2279
SE|25462496||ab|16|entity|C0205250|High|qlco|||higher|||0|837|2295|2301
SE|25462496||ab|16|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|837|2302|2305
SE|25462496||ab|16|entity|C0027361|Persons|popg|||people|||0|1000|2323|2329
SE|25462496||ab|16|entity|C0231170|Disability NOS|patf|||disability|||0|1000|2335|2345
SE|25462496||ab|16|relation|1|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|2335|2345|PREP|PROCESS_OF||2330|2334|11|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|2323|2329
SE|25462496||ab|16|relation|3|1|C0155626|Acute myocardial infarction|dsyn|dsyn|||AMI|||0|837|2302|2305|AUX|PROCESS_OF||2280|2283|9|8|C0027361|Persons|popg,humn|humn|||people|||0|1000|2120|2126
SE|25462496||ab|16|relation|10|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|2132|2142|PREP|PROCESS_OF||2127|2131|2|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|2120|2126

SE|25462496||ab|17|text|2347|2510|The research outcomes can be used as references by public health authorities to improve the engagement of people with disability in AMI-prevention health services.
SE|25462496||ab|17|entity|C0683954|research outcome|fndg|||research outcomes|||0|983|2351|2368
SE|25462496||ab|17|entity|C1514811|Reference|idcn|||references|||0|966|2384|2394
SE|25462496||ab|17|entity|C1273803|Health Authority|hcro|||health authorities|||0|884|2405|2423
SE|25462496||ab|17|entity|C0425152|Engaged to be married|socb|||engagement|||0|1000|2439|2449
SE|25462496||ab|17|entity|C0027361|Persons|popg|||people|||0|1000|2453|2459
SE|25462496||ab|17|entity|C0231170|Disability NOS|patf|||disability|||0|1000|2465|2475
SE|25462496||ab|17|entity|C0155626|Acute myocardial infarction|dsyn|||AMI|||0|864|2479|2482
SE|25462496||ab|17|entity|C0199176|Prophylactic treatment|topp|||prevention|||0|864|2483|2493
SE|25462496||ab|17|entity|C0018747|Health Services|hlca|||health services|||0|864|2494|2509
SE|25462496||ab|17|relation|2|1|C0231170|Disability NOS|patf|patf|||disability|||0|1000|2465|2475|PREP|PROCESS_OF||2460|2464|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|2453|2459


SE|25462498||ti|1|text|21|172|Is the impairment in temporal allocation of visual attention in children with ADHD related to a developmental delay or a structural cognitive deficit?
SE|25462498||ti|1|entity|C0442043|temporal|spco|||temporal|||0|694|42|50
SE|25462498||ti|1|entity|C0589102|Visual attention|menp|||visual attention|||0|1000|65|81
SE|25462498||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|85|93
SE|25462498||ti|1|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|99|103
SE|25462498||ti|1|entity|C0458003|Developmental|qlco|||developmental|||0|888|117|130
SE|25462498||ti|1|entity|C0205421|Deferred|tmco|||delay|||0|888|131|136
SE|25462498||ti|1|entity|C0679466|COGNITIVE DEFICIT|mobd|||cognitive deficit|||0|901|153|170
SE|25462498||ti|1|relation|3|1|C0589102|Visual attention|menp|menp|||visual attention|||0|1000|65|81|PREP|PROCESS_OF||82|84|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|85|93
SE|25462498||ti|1|relation|3|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|99|103|PREP|PROCESS_OF||94|98|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|85|93

SE|25462498||ab|1|text|178|522|We investigated the temporal allocation of visual attention in 11-year-old children with attention-deficit/hyperactivity disorder (ADHD) by comparing their attentional blink (AB) parameters (duration, amplitude and minimum performance) with those observed in three groups of healthy control participants (8-year-olds, 11-year-olds and adults).
SE|25462498||ab|1|entity|C0442043|temporal|spco|||temporal|||0|694|198|206
SE|25462498||ab|1|entity|C0589102|Visual attention|menp|||visual attention|||0|1000|221|237
SE|25462498||ab|1|entity|C0439234|year|tmco|||year|||0|775|244|248
SE|25462498||ab|1|entity|C0580836|Old|tmco|||old|||0|775|249|252
SE|25462498||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|775|253|261
SE|25462498||ab|1|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||attention-deficit/hyperactivity disorder|||0|1000|267|307
SE|25462498||ab|1|entity|C0004268|Attention|menp|||attentional|||0|766|334|345
SE|25462498||ab|1|entity|C0449238|Duration|tmco|||duration|||0|1000|369|377
SE|25462498||ab|1|entity|C1524031|Minimum|qlco|||minimum|||0|888|393|400
SE|25462498||ab|1|entity|C0597198|Performance|inbe|||performance|||0|888|401|412
SE|25462498||ab|1|entity|C0205449|Three|qnco|||three|||0|888|437|442
SE|25462498||ab|1|entity|C0441833|Groups|inpr|||groups|||0|888|443|449
SE|25462498||ab|1|entity|C0018684|Health|idcn|||healthy|||0|816|453|460
SE|25462498||ab|1|entity|C0243148|control|ftcn|||control|||0|816|461|468
SE|25462498||ab|1|entity|C0679646|Participant|popg|||participants|||0|816|469|481
SE|25462498||ab|1|entity|C0439234|year|tmco|||year|||0|773|485|489
SE|25462498||ab|1|entity|C0580836|Old|tmco|||olds|||0|773|490|494
SE|25462498||ab|1|entity|C0439234|year|tmco|||year|||0|773|499|503
SE|25462498||ab|1|entity|C0580836|Old|tmco|||olds|||0|773|504|508
SE|25462498||ab|1|entity|C0001675|Adult|aggp|||adults|||0|1000|513|519
SE|25462498||ab|1|relation|2|1|C0589102|Visual attention|menp|menp|||visual attention|||0|1000|221|237|PREP|PROCESS_OF||238|240|12|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|775|253|261
SE|25462498||ab|1|relation|11|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||attention-deficit/hyperactivity disorder|||0|1000|267|307|PREP|PROCESS_OF||262|266|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|775|253|261

SE|25462498||ab|2|text|522|705|The AB is a marker of impaired ability to detect a second target following the identification of a first target when both appear randomly within a rapid sequence of distractor items.
SE|25462498||ab|2|entity|C0004268|Attention|menp|||AB|||0|623|526|528
SE|25462498||ab|2|entity|C0005516|Biological Markers|qlco|||marker|||0|1000|534|540
SE|25462498||ab|2|entity|C0221099|Impaired|ftcn|||impaired|||0|888|544|552
SE|25462498||ab|2|entity|C0085732|Ability|orga|||ability|||0|888|553|560
SE|25462498||ab|2|entity|C0457385|seconds|tmco|||second|||0|888|573|579
SE|25462498||ab|2|entity|C1279901|Firstly|qlco|||first|||0|888|621|626
SE|25462498||ab|2|entity|C0439831|Rapid|qlco|||rapid|||0|888|669|674
SE|25462498||ab|2|entity|C1519249|Sequence|ftcn|||sequence|||0|888|675|683
SE|25462498||ab|2|entity|C0180482|Distractors|medd|||distractor|||0|661|687|697

SE|25462498||ab|3|text|705|830|Our results showed developmental effects; with age, the AB duration decreased and the AB minimum moved to shorter lag times.
SE|25462498||ab|3|entity|C1274040|result|ftcn|||results|||0|966|709|716
SE|25462498||ab|3|entity|C0458003|Developmental|qlco|||developmental|||0|872|724|737
SE|25462498||ab|3|entity|C1280500|Effect|qlco|||effects|||0|872|738|745
SE|25462498||ab|3|entity|C0001779|Age|orga|||age|||0|1000|752|755
SE|25462498||ab|3|entity|C0004268|Attention|menp|||AB|||0|766|761|763
SE|25462498||ab|3|entity|C0449238|Duration|tmco|||duration|||0|766|764|772
SE|25462498||ab|3|entity|C0004268|Attention|menp|||AB|||0|766|791|793
SE|25462498||ab|3|entity|C1524031|Minimum|qlco|||minimum|||0|766|794|801
SE|25462498||ab|3|entity|C0024219|Lymphangiography|diap|||lag|||0|829|819|822
SE|25462498||ab|3|entity|C0040223|Time|tmco|||times|||0|829|823|828

SE|25462498||ab|4|text|830|998|Importantly, 11-year old children with ADHD presented much the same similar AB patterns (in terms of duration and minimum position) as the healthy 8-year-old controls.
SE|25462498||ab|4|entity|C0439234|year|tmco|||year|||0|775|846|850
SE|25462498||ab|4|entity|C0580836|Old|tmco|||old|||0|775|851|854
SE|25462498||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|775|855|863
SE|25462498||ab|4|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|869|873
SE|25462498||ab|4|entity|C0445247|Same|qlco|||same|||0|730|893|897
SE|25462498||ab|4|entity|C0004268|Attention|menp|||AB|||0|730|906|908
SE|25462498||ab|4|entity|C0449774|Patterns|spco|||patterns|||0|730|909|917
SE|25462498||ab|4|entity|C0449238|Duration|tmco|||duration|||0|1000|931|939
SE|25462498||ab|4|entity|C1524031|Minimum|qlco|||minimum|||0|888|944|951
SE|25462498||ab|4|entity|C0733755|Positioning Attribute|spco|||position|||0|888|952|960
SE|25462498||ab|4|entity|C0018684|Health|idcn|||healthy|||0|740|969|976
SE|25462498||ab|4|entity|C0439234|year|tmco|||year|||0|740|979|983
SE|25462498||ab|4|entity|C0580836|Old|tmco|||old|||0|740|984|987
SE|25462498||ab|4|entity|C0243148|control|ftcn|||controls|||0|740|988|996
SE|25462498||ab|4|relation|6|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|869|873|PREP|PROCESS_OF||864|868|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|775|855|863

SE|25462498||ab|5|text|998|1184|Our results support the hypothesis whereby impaired allocation of temporal selective attention in children with ADHD is due to a developmental delay and not a specific cognitive deficit.
SE|25462498||ab|5|entity|C1274040|result|ftcn|||results|||0|966|1002|1009
SE|25462498||ab|5|entity|C1512571|Hypothesis|idcn|||hypothesis|||0|1000|1022|1032
SE|25462498||ab|5|entity|C0442043|temporal|spco|||temporal|||0|901|1064|1072
SE|25462498||ab|5|entity|C0233421|Selective inattention|menp|||selective attention|||0|901|1073|1092
SE|25462498||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1096|1104
SE|25462498||ab|5|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||ADHD|||0|1000|1110|1114
SE|25462498||ab|5|entity|C0458003|Developmental|qlco|||developmental|||0|888|1127|1140
SE|25462498||ab|5|entity|C0205421|Deferred|tmco|||delay|||0|888|1141|1146
SE|25462498||ab|5|entity|C1518422|Not|ftcn|||not|||0|1000|1151|1154
SE|25462498||ab|5|entity|C0679466|COGNITIVE DEFICIT|mobd|||cognitive deficit|||0|901|1166|1183
SE|25462498||ab|5|relation|3|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||ADHD|||0|1000|1110|1114|PREP|PROCESS_OF||1105|1109|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1096|1104
SE|25462498||ab|5|relation|4|1|C0233421|Selective inattention|menp|menp|||selective attention|||0|901|1073|1092|PREP|PROCESS_OF||1093|1095|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1096|1104


SE|25462499||ti|1|text|21|167|Augmented reality-based self-facial modeling to promote the emotional expression and social skills of adolescents with autism spectrum disorders.
SE|25462499||ti|1|entity|C0205217|Increased|qnco|||Augmented|||0|809|21|30
SE|25462499||ti|1|entity|C0871222|Reality|idcn|||reality|||0|809|31|38
SE|25462499||ti|1|entity|C0036588|Self|idcn|||self|||0|809|45|49
SE|25462499||ti|1|entity|C0524465|Facial|spco|||facial|||0|809|50|56
SE|25462499||ti|1|entity|C0870071|Modeling|inpr,resa|||modeling|||0|809|57|65
SE|25462499||ti|1|entity|C0849912|Emotional|fndg|||emotional|||0|888|81|90
SE|25462499||ti|1|entity|C0683256|social skills|socb|||social skills|||0|1000|106|119
SE|25462499||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|123|134
SE|25462499||ti|1|entity|C1510586|Autism spectrum disorder|mobd|||autism spectrum disorders|||0|1000|140|165
SE|25462499||ti|1|relation|1|1|C1510586|Autism spectrum disorder|mobd|mobd|||autism spectrum disorders|||0|1000|140|165|PREP|PROCESS_OF||135|139|4|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|123|134

SE|25462499||ab|1|text|173|342|Autism spectrum disorders (ASD) are characterized by a reduced ability to understand the emotions of other people; this ability involves recognizing facial expressions.
SE|25462499||ab|1|entity|C1510586|Autism spectrum disorder|mobd|||Autism spectrum disorders|||0|1000|173|198
SE|25462499||ab|1|entity|C0392756|Reduced|qlco|||reduced|||0|888|228|235
SE|25462499||ab|1|entity|C0085732|Ability|orga|||ability|||0|888|236|243
SE|25462499||ab|1|entity|C0013987|Emotions|menp|||emotions|||0|1000|262|270
SE|25462499||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|280|286
SE|25462499||ab|1|entity|C0085732|Ability|orga|||ability|||0|1000|293|300
SE|25462499||ab|1|entity|C0015457|Facial Expression|fndg|||facial expressions|||0|901|322|340

SE|25462499||ab|2|text|342|549|This study assessed the possibility of enabling three adolescents with ASD to become aware of facial expressions observed in situations in a school setting simulated using augmented reality (AR) technology.
SE|25462499||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|347|352
SE|25462499||ab|2|entity|C1171285|Enabling|menp|||enabling|||0|851|381|389
SE|25462499||ab|2|entity|C0205449|Three|qnco|||three|||0|851|390|395
SE|25462499||ab|2|entity|C0205653|Adolescent|aggp|||adolescents|||0|851|396|407
SE|25462499||ab|2|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|413|416
SE|25462499||ab|2|entity|C0004448|Awareness|menp|||aware|||0|928|427|432
SE|25462499||ab|2|entity|C0015457|Facial Expression|fndg|||facial expressions|||0|1000|436|454
SE|25462499||ab|2|entity|C0542559|contextual factors|ftcn|||setting|||0|861|490|497
SE|25462499||ab|2|entity|C0205217|Increased|qnco|||augmented|||0|851|514|523
SE|25462499||ab|2|entity|C0871222|Reality|idcn|||reality|||0|851|524|531
SE|25462499||ab|2|entity|C0039421|Technology|ocdi|||technology|||0|851|537|547
SE|25462499||ab|2|relation|6|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|413|416|PREP|PROCESS_OF||408|412|3|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|851|396|407

SE|25462499||ab|3|text|549|733|The AR system provided three-dimensional (3-D) animations of six basic facial expressions overlaid on participant faces to facilitate practicing emotional judgments and social skills.
SE|25462499||ab|3|entity|C0205217|Increased|qnco|||AR|||0|851|553|555
SE|25462499||ab|3|entity|C0871222|Reality|idcn|||AR|||0|851|553|555
SE|25462499||ab|3|entity|C0449913|System|ftcn|||system|||0|851|556|562
SE|25462499||ab|3|entity|C0450363|Three-dimensional|spco|||three-dimensional|||0|1000|572|589
SE|25462499||ab|3|entity|C0205452|Six|qnco|||six|||0|843|610|613
SE|25462499||ab|3|entity|C0015457|Facial Expression|fndg|||facial expressions|||0|843|620|638
SE|25462499||ab|3|entity|C0679646|Participant|popg|||participant|||0|1000|651|662
SE|25462499||ab|3|entity|C0237607|experience (practice)|menp|||practicing|||0|840|683|693
SE|25462499||ab|3|entity|C0849912|Emotional|fndg|||emotional|||0|840|694|703
SE|25462499||ab|3|entity|C0022423|Judgment|menp|||judgments|||0|840|704|713
SE|25462499||ab|3|entity|C0683256|social skills|socb|||social skills|||0|1000|718|731

SE|25462499||ab|4|text|733|942|Based on the multiple baseline design across subjects, the data indicated that AR intervention can improve the appropriate recognition and response to facial emotional expressions seen in the situational task.
SE|25462499||ab|4|entity|C0439064|Numerous|qnco|||multiple|||0|623|746|754
SE|25462499||ab|4|entity|C1442488|BASELINE|qnco|||baseline|||0|623|755|763
SE|25462499||ab|4|entity|C1550501|subject|idcn|||subjects|||0|966|778|786
SE|25462499||ab|4|entity|C1511726|Data|idcn|||data|||0|1000|792|796
SE|25462499||ab|4|entity|C0205217|Increased|qnco|||AR|||0|851|812|814
SE|25462499||ab|4|entity|C0871222|Reality|idcn|||AR|||0|851|812|814
SE|25462499||ab|4|entity|C1273869|Intervention regimes|hlca|||intervention|||0|851|815|827
SE|25462499||ab|4|entity|C1548787|Appropriate|qlco|||appropriate|||0|694|844|855
SE|25462499||ab|4|entity|C0871261|response|clna|||response|||0|1000|872|880
SE|25462499||ab|4|entity|C0849912|Emotional|fndg|||emotional|||0|901|891|900
SE|25462499||ab|4|entity|C0015457|Facial Expression|fndg|||facial emotional expressions|||0|901|884|912


SE|25462500||ti|1|text|21|130|Exposure to aggressive behaviour and burnout in direct support providers: The role of positive work factors.
SE|25462500||ti|1|entity|C0001807|Aggressive behavior|mobd|||aggressive behaviour|||0|1000|33|53
SE|25462500||ti|1|entity|C0476644|Physical and emotional exhaustion state|fndg|||burnout|||0|1000|58|65
SE|25462500||ti|1|entity|C1138603|Provider|prog|||providers|||0|773|84|93
SE|25462500||ti|1|entity|C0035820|Role|socb|||role|||0|1000|99|103
SE|25462500||ti|1|entity|C1446409|Positive|qlco|||positive|||0|840|107|115
SE|25462500||ti|1|entity|C0043227|Work|ocac|||work|||0|840|116|120
SE|25462500||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|840|121|128
SE|25462500||ti|1|relation|3|1|C0001807|Aggressive behavior|mobd|mobd|||aggressive behaviour|||0|1000|33|53|PREP|PROCESS_OF||66|68|3|1|C1138603|Provider|prog,humn|humn|||providers|||0|773|84|93
SE|25462500||ti|1|relation|3|1|C0476644|Physical and emotional exhaustion state|fndg|fndg|||burnout|||0|1000|58|65|PREP|PROCESS_OF||66|68|3|1|C1138603|Provider|prog,humn|humn|||providers|||0|773|84|93

SE|25462500||ab|1|text|136|293|Many direct support providers (DSPs) are exposed to aggressive behaviour in their work supporting adults with developmental disabilities service recipients.
SE|25462500||ab|1|entity|C1138603|Provider|prog|||providers|||0|773|156|165
SE|25462500||ab|1|entity|C0001807|Aggressive behavior|mobd|||aggressive behaviour|||0|1000|188|208
SE|25462500||ab|1|entity|C0043227|Work|ocac|||work|||0|840|218|222
SE|25462500||ab|1|entity|C0001675|Adult|aggp|||adults|||0|840|234|240
SE|25462500||ab|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|658|246|272
SE|25462500||ab|1|entity|C0557854|Services|ftcn|||service|||0|658|273|280
SE|25462500||ab|1|relation|2|1|C0001807|Aggressive behavior|mobd|mobd|||aggressive behaviour|||0|1000|188|208|PREP|PROCESS_OF||209|211|2|1|C0001675|Adult|aggp,humn|humn|||adults|||0|840|234|240

SE|25462500||ab|2|text|293|364|This is a work environment factor that has been linked to job burnout.
SE|25462500||ab|2|entity|C0162579|Workplace|spco|||work environment|||0|901|303|319
SE|25462500||ab|2|entity|C1521761|Factor|ftcn|||factor|||0|901|320|326
SE|25462500||ab|2|entity|C0028811|Occupations|ocdi|||job|||0|888|351|354
SE|25462500||ab|2|entity|C0476644|Physical and emotional exhaustion state|fndg|||burnout|||0|888|355|362

SE|25462500||ab|3|text|364|524|The objective of this study was to examine the impact of positive work factors on emotional exhaustion (EE) among DSPs who are exposed to aggressive behaviour.
SE|25462500||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|386|391
SE|25462500||ab|3|entity|C1446409|Positive|qlco|||positive|||0|840|421|429
SE|25462500||ab|3|entity|C0043227|Work|ocac|||work|||0|840|430|434
SE|25462500||ab|3|entity|C1521761|Factor|ftcn|||factors|||0|840|435|442
SE|25462500||ab|3|entity|C0849912|Emotional|fndg|||emotional|||0|888|446|455
SE|25462500||ab|3|entity|C0392674|Exhaustion|sosy|||exhaustion|||0|888|456|466
SE|25462500||ab|3|entity|C1138603|Provider|prog|||DSPs|||0|773|478|482
SE|25462500||ab|3|entity|C0001807|Aggressive behavior|mobd|||aggressive behaviour|||0|1000|502|522
SE|25462500||ab|3|relation|5|1|C0392674|Exhaustion|sosy|sosy|||exhaustion|||0|888|456|466|PREP|PROCESS_OF||472|477|2|1|C1138603|Provider|prog,humn|humn|||DSPs|||0|773|478|482

SE|25462500||ab|4|text|524|719|Survey responses from 671 DSPs who were working in community service settings for adults with developmental disabilities, and were exposed to aggressive behaviour at least monthly were examined.
SE|25462500||ab|4|entity|C0038951|Surveys|resa|||Survey|||0|888|524|530
SE|25462500||ab|4|entity|C0871261|response|clna|||responses|||0|888|531|540
SE|25462500||ab|4|entity|C1138603|Provider|prog|||DSPs|||0|733|550|554
SE|25462500||ab|4|entity|C0043227|Work|ocac|||working|||0|1000|564|571
SE|25462500||ab|4|entity|C0009482|Services, Community|shro|||community service|||0|890|575|592
SE|25462500||ab|4|entity|C0542559|contextual factors|ftcn|||settings|||0|890|593|601
SE|25462500||ab|4|entity|C0001675|Adult|aggp|||adults|||0|1000|606|612
SE|25462500||ab|4|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|618|644
SE|25462500||ab|4|entity|C0001807|Aggressive behavior|mobd|||aggressive behaviour|||0|1000|666|686
SE|25462500||ab|4|entity|C0332177|Monthly|tmco|||monthly|||0|1000|696|703
SE|25462500||ab|4|relation|2|1|C0008073|Child Development Disorders|mobd|mobd|||developmental disabilities|||0|1000|618|644|PREP|PROCESS_OF||613|617|5|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|606|612

SE|25462500||ab|5|text|719|1099|Hierarchical linear regression examined the direct contribution and moderating role of positive work factors (self-efficacy for dealing with aggression and work contributions) on EE measured with the Maslach Burnout Inventory-Human Services Survey, after controlling for demographics, occupational variables, exposure to aggression and negative emotional reactions to aggression.
SE|25462500||ab|5|entity|C0699032|Hierarchy|ftcn|||Hierarchical|||0|865|719|731
SE|25462500||ab|5|entity|C0023733|Linear Regression|qnco|||linear regression|||0|865|732|749
SE|25462500||ab|5|entity|C0035820|Role|socb|||role|||0|861|798|802
SE|25462500||ab|5|entity|C1446409|Positive|qlco|||positive|||0|840|806|814
SE|25462500||ab|5|entity|C0043227|Work|ocac|||work|||0|840|815|819
SE|25462500||ab|5|entity|C1521761|Factor|ftcn|||factors|||0|840|820|827
SE|25462500||ab|5|entity|C0600564|Self Efficacy|menp|||self-efficacy|||0|1000|829|842
SE|25462500||ab|5|entity|C0001807|Aggressive behavior|mobd|||aggression|||0|1000|860|870
SE|25462500||ab|5|entity|C0043227|Work|ocac|||work|||0|694|875|879
SE|25462500||ab|5|entity|C0849912|Emotional|fndg|||EE|||0|888|898|900
SE|25462500||ab|5|entity|C0392674|Exhaustion|sosy|||EE|||0|888|898|900
SE|25462500||ab|5|entity|C0476644|Physical and emotional exhaustion state|fndg|||Burnout|||0|787|927|934
SE|25462500||ab|5|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|787|935|944
SE|25462500||ab|5|entity|C0037440|Social Welfare|shro|||Human Services|||0|787|945|959
SE|25462500||ab|5|entity|C0038951|Surveys|resa|||Survey|||0|787|960|966
SE|25462500||ab|5|entity|C0243148|control|ftcn|||controlling|||0|966|974|985
SE|25462500||ab|5|entity|C0011298|Demography|ocdi|||demographics|||0|1000|990|1002
SE|25462500||ab|5|entity|C0521127|Occupational|ftcn|||occupational|||0|872|1004|1016
SE|25462500||ab|5|entity|C0439828|Variable|qlco|||variables|||0|872|1017|1026
SE|25462500||ab|5|entity|C0001807|Aggressive behavior|mobd|||aggression|||0|1000|1040|1050
SE|25462500||ab|5|entity|C0205160|Negative|qlco|||negative|||0|890|1055|1063
SE|25462500||ab|5|entity|C0221736|Reaction emotional|fndg|||emotional reactions|||0|890|1064|1083
SE|25462500||ab|5|entity|C0001807|Aggressive behavior|mobd|||aggression|||0|1000|1087|1097

SE|25462500||ab|6|text|1099|1302|Results showed that younger age, more experience, more depression/anger emotions in response to aggression, lower self-efficacy and low positive work contributions were significantly associated with EE.
SE|25462500||ab|6|entity|C1274040|result|ftcn|||Results|||0|966|1099|1106
SE|25462500||ab|6|entity|C0332239|Young|tmco|||younger|||0|872|1119|1126
SE|25462500||ab|6|entity|C0001779|Age|orga|||age|||0|872|1127|1130
SE|25462500||ab|6|entity|C0205172|More|ftcn|||more|||0|1000|1132|1136
SE|25462500||ab|6|entity|C0205172|More|ftcn|||more|||0|833|1149|1153
SE|25462500||ab|6|entity|C0011581|Depressive disorder|mobd|||depression|||0|833|1154|1164
SE|25462500||ab|6|entity|C0002957|Anger|menp|||anger|||0|833|1165|1170
SE|25462500||ab|6|entity|C0013987|Emotions|menp|||emotions|||0|833|1171|1179
SE|25462500||ab|6|entity|C0001807|Aggressive behavior|mobd|||aggression|||0|1000|1195|1205
SE|25462500||ab|6|entity|C0600564|Self Efficacy|menp|||self-efficacy|||0|1000|1213|1226
SE|25462500||ab|6|entity|C0205251|low|qlco|||low|||0|608|1231|1234
SE|25462500||ab|6|entity|C1446409|Positive|qlco|||positive|||0|608|1235|1243
SE|25462500||ab|6|entity|C0043227|Work|ocac|||work|||0|608|1244|1248
SE|25462500||ab|6|entity|C0849912|Emotional|fndg|||EE|||0|888|1298|1300
SE|25462500||ab|6|entity|C0392674|Exhaustion|sosy|||EE|||0|888|1298|1300
SE|25462500||ab|6|relation|0|0|C0002957|Anger|menp|menp|||anger|||0|833|1165|1170|MOD/HEAD|ISA||1165|1179|0|0|C0013987|Emotions|menp|menp|||emotions|||0|833|1171|1179

SE|25462500||ab|7|text|1302|1377|Positive work motivation was a moderator of exposure to aggression and EE.
SE|25462500||ab|7|entity|C1446409|Positive|qlco|||Positive|||0|851|1302|1310
SE|25462500||ab|7|entity|C0043227|Work|ocac|||work|||0|851|1311|1315
SE|25462500||ab|7|entity|C0026605|Motivation|menp|||motivation|||0|851|1316|1326
SE|25462500||ab|7|entity|C0001807|Aggressive behavior|mobd|||aggression|||0|1000|1358|1368
SE|25462500||ab|7|entity|C0849912|Emotional|fndg|||EE|||0|888|1373|1375
SE|25462500||ab|7|entity|C0392674|Exhaustion|sosy|||EE|||0|888|1373|1375

SE|25462500||ab|8|text|1377|1478|When work motivations were low, DSPs were more negatively affected by higher exposure to aggression.
SE|25462500||ab|8|entity|C0043227|Work|ocac|||work|||0|872|1382|1386
SE|25462500||ab|8|entity|C0026605|Motivation|menp|||motivations|||0|872|1387|1398
SE|25462500||ab|8|entity|C0205251|low|qlco|||low|||0|764|1404|1407
SE|25462500||ab|8|entity|C1138603|Provider|prog|||DSPs|||0|764|1409|1413
SE|25462500||ab|8|entity|C0205172|More|ftcn|||more|||0|1000|1419|1423
SE|25462500||ab|8|entity|C0205250|High|qlco|||higher|||0|661|1447|1453
SE|25462500||ab|8|entity|C0001807|Aggressive behavior|mobd|||aggression|||0|1000|1466|1476

SE|25462500||ab|9|text|1478|1702|These findings suggest that in addition to addressing the negative emotional reactions to the aggressive behaviour encountered at work, it is also important to foster positive work factors which may be protective against EE.
SE|25462500||ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1484|1492
SE|25462500||ab|9|entity|C1442065|Address|spco|||addressing|||0|966|1521|1531
SE|25462500||ab|9|entity|C0205160|Negative|qlco|||negative|||0|890|1536|1544
SE|25462500||ab|9|entity|C0221736|Reaction emotional|fndg|||emotional reactions|||0|890|1545|1564
SE|25462500||ab|9|entity|C0001807|Aggressive behavior|mobd|||aggressive behaviour|||0|1000|1572|1592
SE|25462500||ab|9|entity|C0043227|Work|ocac|||work|||0|1000|1608|1612
SE|25462500||ab|9|entity|C1446409|Positive|qlco|||positive|||0|840|1645|1653
SE|25462500||ab|9|entity|C0043227|Work|ocac|||work|||0|840|1654|1658
SE|25462500||ab|9|entity|C1521761|Factor|ftcn|||factors|||0|840|1659|1666
SE|25462500||ab|9|entity|C0849912|Emotional|fndg|||EE|||0|888|1699|1701
SE|25462500||ab|9|entity|C0392674|Exhaustion|sosy|||EE|||0|888|1699|1701


SE|25462501||ti|1|text|21|126|Effect of the angle of shoulder flexion on the reach trajectory of children with spastic cerebral palsy.
SE|25462501||ti|1|entity|C1280500|Effect|qlco|||Effect|||0|1000|21|27
SE|25462501||ti|1|entity|C0205143|Angular|spco|||angle|||0|1000|35|40
SE|25462501||ti|1|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|44|52
SE|25462501||ti|1|entity|C0231452|Flexion|orgf|||flexion|||0|888|53|60
SE|25462501||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|88|96
SE|25462501||ti|1|entity|C0338596|Cerebral Palsy, Spastic|dsyn|||spastic cerebral palsy|||0|1000|102|124
SE|25462501||ti|1|relation|1|1|C0338596|Cerebral Palsy, Spastic|dsyn|dsyn|||spastic cerebral palsy|||0|1000|102|124|PREP|PROCESS_OF||97|101|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|88|96

SE|25462501||ab|1|text|132|325|Many children with cerebral palsy (CP) use a wheelchair during activities of daily living and often extend their hand upward and downward to reach objects in a seated position in a wheelchair.
SE|25462501||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|137|145
SE|25462501||ab|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|151|165
SE|25462501||ab|1|entity|C0043143|wheelchair|medd|||wheelchair|||0|1000|177|187
SE|25462501||ab|1|entity|C0441655|Activities|acty|||activities|||0|1000|195|205
SE|25462501||ab|1|entity|C0332173|Daily|tmco|||daily|||0|694|209|214
SE|25462501||ab|1|entity|C0332183|Frequent|tmco|||often|||0|1000|226|231
SE|25462501||ab|1|entity|C0018563|Hand|bpoc|||hand|||0|1000|245|249
SE|25462501||ab|1|entity|C1282911|Upward|spco|||upward|||0|1000|250|256
SE|25462501||ab|1|entity|C0205104|Downward|spco|||downward|||0|1000|261|269
SE|25462501||ab|1|entity|C0347997|Physical object|mnob|||objects|||0|1000|279|286
SE|25462501||ab|1|entity|C1283233|Seating|mnob|||seated|||0|872|292|298
SE|25462501||ab|1|entity|C0733755|Positioning Attribute|spco|||position|||0|872|299|307
SE|25462501||ab|1|entity|C0043143|wheelchair|medd|||wheelchair|||0|1000|313|323
SE|25462501||ab|1|relation|2|2|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|137|145|VERB|USES||171|174|9|1|C0043143|wheelchair|medd|medd|||wheelchair|||0|1000|177|187
SE|25462501||ab|1|relation|10|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|151|165|PREP|PROCESS_OF||146|150|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|137|145

SE|25462501||ab|2|text|325|428|However, the effect of shoulder position on reaching movements of children with CP is not established.
SE|25462501||ab|2|entity|C1280500|Effect|qlco|||effect|||0|1000|338|344
SE|25462501||ab|2|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|348|356
SE|25462501||ab|2|entity|C0733755|Positioning Attribute|spco|||position|||0|888|357|365
SE|25462501||ab|2|entity|C0026649|Movement|orgf|||movements|||0|872|378|387
SE|25462501||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|391|399
SE|25462501||ab|2|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|405|407
SE|25462501||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|411|414
SE|25462501||ab|2|relation|4|4|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|405|407|NOM|AFFECTS||338|344|4|2|C0026649|Movement|orgf|orgf|||movements|||0|872|378|387

SE|25462501||ab|3|text|428|568|The purpose of this study was to determine the effect of the angle of shoulder flexion on the reach trajectory of children with spastic CP.
SE|25462501||ab|3|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|432|439
SE|25462501||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|448|453
SE|25462501||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|475|481
SE|25462501||ab|3|entity|C0205143|Angular|spco|||angle|||0|1000|489|494
SE|25462501||ab|3|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|498|506
SE|25462501||ab|3|entity|C0231452|Flexion|orgf|||flexion|||0|888|507|514
SE|25462501||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|542|550
SE|25462501||ab|3|entity|C0338596|Cerebral Palsy, Spastic|dsyn|||spastic CP|||0|1000|556|566
SE|25462501||ab|3|relation|1|1|C0338596|Cerebral Palsy, Spastic|dsyn|dsyn|||spastic CP|||0|1000|556|566|PREP|PROCESS_OF||551|555|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|542|550

SE|25462501||ab|4|text|568|761|Seven children with mild CP [Manual Ability Classification System (MACS) levels I-II], five children with severe CP (MACS levels III-V) and six typically developing (TD) children participated.
SE|25462501||ab|4|entity|C0205453|Seven|qnco|||Seven|||0|888|568|573
SE|25462501||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|888|574|582
SE|25462501||ab|4|entity|C0547040|Minimal|qlco|||mild|||0|901|588|592
SE|25462501||ab|4|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|593|595
SE|25462501||ab|4|entity|C0024763|Manuals|inpr,mnob|||Manual|||0|851|597|603
SE|25462501||ab|4|entity|C0008902|Classification|clas|||Classification System|||0|851|612|633
SE|25462501||ab|4|entity|C0870086|Ability Level|qlco|||Ability Classification System (MACS) levels|||0|851|604|647
SE|25462501||ab|4|entity|C0205451|Five|qnco|||five|||0|888|655|659
SE|25462501||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|888|660|668
SE|25462501||ab|4|entity|C0205082|Severe|qlco|||severe|||0|901|674|680
SE|25462501||ab|4|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|681|683
SE|25462501||ab|4|entity|C0024763|Manuals|inpr,mnob|||MACS|||0|621|685|689
SE|25462501||ab|4|entity|C0008902|Classification|clas|||MACS|||0|621|685|689
SE|25462501||ab|4|entity|C0870086|Ability Level|qlco|||MACS levels|||0|621|685|696
SE|25462501||ab|4|entity|C0439070|III|inpr|||III|||0|621|697|700
SE|25462501||ab|4|entity|C0205452|Six|qnco|||six|||0|791|708|711
SE|25462501||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|791|738|746
SE|25462501||ab|4|relation|3|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|681|683|PREP|PROCESS_OF||669|673|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|660|668
SE|25462501||ab|4|relation|7|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|593|595|PREP|PROCESS_OF||583|587|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|888|574|582

SE|25462501||ab|5|text|761|905|We prepared the device to have a top board with variable tilting angle in order to reduce the effect of gravity imposing on reaching movements.
SE|25462501||ab|5|entity|C0699733|Devices|mnob|||device|||0|1000|777|783
SE|25462501||ab|5|entity|C0972401|Boards|medd|||board|||0|872|798|803
SE|25462501||ab|5|entity|C0439828|Variable|qlco|||variable|||0|890|809|817
SE|25462501||ab|5|entity|C0454235|Tilt angle|spco|||tilting angle|||0|890|818|831
SE|25462501||ab|5|entity|C1280500|Effect|qlco|||effect|||0|1000|855|861
SE|25462501||ab|5|entity|C0026649|Movement|orgf|||movements|||0|872|894|903

SE|25462501||ab|6|text|905|1015|By using this device, the subjects could extend their arm by sliding it on the board to push a target button.
SE|25462501||ab|6|entity|C0699733|Devices|mnob|||device|||0|1000|919|925
SE|25462501||ab|6|entity|C1550501|subject|idcn|||subjects|||0|966|931|939
SE|25462501||ab|6|entity|C1140618|Upper Extremity|bpoc|||arm|||0|1000|959|962
SE|25462501||ab|6|entity|C0332246|Sliding|ftcn|||sliding|||0|1000|966|973
SE|25462501||ab|6|entity|C0972401|Boards|medd|||board|||0|966|984|989
SE|25462501||ab|6|entity|C0453985|Button|mnob|||button|||0|888|1007|1013

SE|25462501||ab|7|text|1015|1213|The reaching movements were performed with the more affected hand at three angles (60 degrees , 90 degrees  and 120 degrees ) of shoulder flexion and captured using a camera motion analysis system.
SE|25462501||ab|7|entity|C0026649|Movement|orgf|||movements|||0|872|1028|1037
SE|25462501||ab|7|entity|C0205172|More|ftcn|||more|||0|851|1062|1066
SE|25462501||ab|7|entity|C0392760|Affecting|ftcn|||affected|||0|851|1067|1075
SE|25462501||ab|7|entity|C0018563|Hand|bpoc|||hand|||0|851|1076|1080
SE|25462501||ab|7|entity|C0205449|Three|qnco|||three|||0|872|1084|1089
SE|25462501||ab|7|entity|C0205143|Angular|spco|||angles|||0|872|1090|1096
SE|25462501||ab|7|entity|C0441983|<90 degrees|qnco|||90 degrees|||0|1000|1111|1121
SE|25462501||ab|7|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1144|1152
SE|25462501||ab|7|entity|C0231452|Flexion|orgf|||flexion|||0|888|1153|1160
SE|25462501||ab|7|entity|C0179533|Camera|medd|||camera|||0|908|1182|1188
SE|25462501||ab|7|entity|C0181906|Analyzers, Physiologic, Neuromuscular Function, Body Motion|medd|||motion analysis system|||0|908|1189|1211
SE|25462501||ab|7|relation|0|0|C0181906|Analyzers, Physiologic, Neuromuscular Function, Body Motion|medd|medd|||motion analysis system|||0|908|1189|1211|MOD/HEAD|USES||1182|1211|0|0|C0179533|Camera|medd|medd|||camera|||0|908|1182|1188

SE|25462501||ab|8|text|1213|1336|Subjects in the TD and mild CP groups reached the target at 60 degrees , 90 degrees  and 120 degrees  of shoulder flexion.
SE|25462501||ab|8|entity|C1550501|subject|idcn|||Subjects|||0|966|1213|1221
SE|25462501||ab|8|entity|C0547040|Minimal|qlco|||mild|||0|861|1236|1240
SE|25462501||ab|8|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|861|1241|1243
SE|25462501||ab|8|entity|C0441833|Groups|inpr|||groups|||0|861|1244|1250
SE|25462501||ab|8|entity|C0441983|<90 degrees|qnco|||90 degrees|||0|1000|1286|1296
SE|25462501||ab|8|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1318|1326
SE|25462501||ab|8|entity|C0231452|Flexion|orgf|||flexion|||0|888|1327|1334

SE|25462501||ab|9|text|1336|1527|Subjects of the severe CP group reached the target at 60 degrees  and 90 degrees  of shoulder flexion, but two of the subjects could not reach the target at 120 degrees  of shoulder flexion.
SE|25462501||ab|9|entity|C1550501|subject|idcn|||Subjects|||0|966|1336|1344
SE|25462501||ab|9|entity|C0205082|Severe|qlco|||severe|||0|861|1352|1358
SE|25462501||ab|9|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|861|1359|1361
SE|25462501||ab|9|entity|C0441833|Groups|inpr|||group|||0|861|1362|1367
SE|25462501||ab|9|entity|C0441983|<90 degrees|qnco|||90 degrees|||0|1000|1406|1416
SE|25462501||ab|9|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1421|1429
SE|25462501||ab|9|entity|C0231452|Flexion|orgf|||flexion|||0|888|1430|1437
SE|25462501||ab|9|entity|C0205448|Two|qnco|||two|||0|1000|1443|1446
SE|25462501||ab|9|entity|C1550501|subject|idcn|||subjects|||0|966|1454|1462
SE|25462501||ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1469|1472
SE|25462501||ab|9|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1509|1517
SE|25462501||ab|9|entity|C0231452|Flexion|orgf|||flexion|||0|888|1518|1525

SE|25462501||ab|10|text|1527|1746|The TD and mild CP groups showed smooth and almost straight trajectories at all three angles of shoulder flexion; however, the reach trajectory in the subjects with severe CP changed with the angle of shoulder flexion.
SE|25462501||ab|10|entity|C0547040|Minimal|qlco|||mild|||0|861|1538|1542
SE|25462501||ab|10|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|861|1543|1545
SE|25462501||ab|10|entity|C0441833|Groups|inpr|||groups|||0|861|1546|1552
SE|25462501||ab|10|entity|C0205357|Smooth|qlco|||smooth|||0|1000|1560|1566
SE|25462501||ab|10|entity|C0445291|Straight|spco|||straight|||0|660|1578|1586
SE|25462501||ab|10|entity|C0205449|Three|qnco|||three|||0|872|1607|1612
SE|25462501||ab|10|entity|C0205143|Angular|spco|||angles|||0|872|1613|1619
SE|25462501||ab|10|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1623|1631
SE|25462501||ab|10|entity|C0231452|Flexion|orgf|||flexion|||0|888|1632|1639
SE|25462501||ab|10|entity|C1550501|subject|idcn|||subjects|||0|966|1678|1686
SE|25462501||ab|10|entity|C0205082|Severe|qlco|||severe|||0|901|1692|1698
SE|25462501||ab|10|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|1699|1701
SE|25462501||ab|10|entity|C0205143|Angular|spco|||angle|||0|1000|1719|1724
SE|25462501||ab|10|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1728|1736
SE|25462501||ab|10|entity|C0231452|Flexion|orgf|||flexion|||0|888|1737|1744

SE|25462501||ab|11|text|1746|1831|A large angle of shoulder flexion induced great outward deviation in the trajectory.
SE|25462501||ab|11|entity|C0549177|Large|qnco|||large|||0|888|1748|1753
SE|25462501||ab|11|entity|C0205143|Angular|spco|||angle|||0|888|1754|1759
SE|25462501||ab|11|entity|C0037004|Shoulder|bpoc|||shoulder|||0|888|1763|1771
SE|25462501||ab|11|entity|C0231452|Flexion|orgf|||flexion|||0|888|1772|1779
SE|25462501||ab|11|entity|C0549177|Large|qnco|||great|||0|851|1788|1793
SE|25462501||ab|11|entity|C0439788|Outward|spco|||outward|||0|851|1794|1801
SE|25462501||ab|11|entity|C0012727|Spatial Displacement|spco|||deviation|||0|851|1802|1811

SE|25462501||ab|12|text|1831|2106|These findings suggest that the difficulty of the reaching task is changed depending on the shoulder joint angle in children with severe CP and that therapeutic interventions for children with severe CP should be provided in a manner appropriate for the shoulder joint angle.
SE|25462501||ab|12|entity|C0243095|Finding|ftcn|||findings|||0|1000|1837|1845
SE|25462501||ab|12|entity|C0459456|Glenohumeral joint structure|bsoj|||shoulder joint|||0|901|1923|1937
SE|25462501||ab|12|entity|C0205143|Angular|spco|||angle|||0|901|1938|1943
SE|25462501||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1947|1955
SE|25462501||ab|12|entity|C0205082|Severe|qlco|||severe|||0|901|1961|1967
SE|25462501||ab|12|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|1968|1970
SE|25462501||ab|12|entity|C0087111|Therapeutic procedure|topp|||therapeutic interventions|||0|1000|1980|2005
SE|25462501||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|1000|2010|2018
SE|25462501||ab|12|entity|C0205082|Severe|qlco|||severe|||0|901|2024|2030
SE|25462501||ab|12|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|901|2031|2033
SE|25462501||ab|12|entity|C1548787|Appropriate|qlco|||appropriate|||0|1000|2065|2076
SE|25462501||ab|12|entity|C0459456|Glenohumeral joint structure|bsoj|||shoulder joint|||0|901|2085|2099
SE|25462501||ab|12|entity|C0205143|Angular|spco|||angle|||0|901|2100|2105
SE|25462501||ab|12|relation|0|0|C0087111|Therapeutic procedure|topp|topp|||therapeutic interventions|||0|1000|1980|2005|INFER|TREATS(INFER)||2006|2009|0|0|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|2031|2033
SE|25462501||ab|12|relation|4|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|2031|2033|PREP|PROCESS_OF||2019|2023|8|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|2010|2018
SE|25462501||ab|12|relation|7|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|901|1968|1970|PREP|PROCESS_OF||1956|1960|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1947|1955
SE|25462501||ab|12|relation|7|1|C0087111|Therapeutic procedure|topp|topp|||therapeutic interventions|||0|1000|1980|2005|PREP|TREATS||2006|2009|5|1|C0008059|Child|aggp,humn,inpr|aggp|||children|||0|1000|2010|2018


SE|25462502||ti|1|text|21|125|Stereotyped behaviors predicting self-injurious behavior in individuals with intellectual disabilities.
SE|25462502||ti|1|entity|C0038271|Stereotyped Behavior|mobd|||Stereotyped behaviors|||0|1000|21|42
SE|25462502||ti|1|entity|C0085271|Self-Injurious Behavior|mobd|||self-injurious behavior|||0|1000|54|77
SE|25462502||ti|1|entity|C0237401|Individual|humn|||individuals|||0|1000|81|92
SE|25462502||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|98|123
SE|25462502||ti|1|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|98|123|PREP|PROCESS_OF||93|97|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|81|92
SE|25462502||ti|1|relation|2|1|C0085271|Self-Injurious Behavior|mobd|mobd|||self-injurious behavior|||0|1000|54|77|PREP|PROCESS_OF||78|80|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|81|92

SE|25462502||ab|1|text|131|358|We examined the relation between stereotyped behavior and self-injurious behavior (SIB) for 1871 individuals with intellectual disabilities who had a score of >0 on the Behavior Problem Inventory (BPI-01; Rojahn et al., 2001).
SE|25462502||ab|1|entity|C0869014|Relations|socb|||relation|||0|966|147|155
SE|25462502||ab|1|entity|C0038271|Stereotyped Behavior|mobd|||stereotyped behavior|||0|1000|164|184
SE|25462502||ab|1|entity|C0085271|Self-Injurious Behavior|mobd|||self-injurious behavior|||0|1000|189|212
SE|25462502||ab|1|entity|C0237401|Individual|humn|||individuals|||0|861|228|239
SE|25462502||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|245|270
SE|25462502||ab|1|entity|C0449820|Score|qnco|||score|||0|1000|281|286
SE|25462502||ab|1|entity|C0260653|Problem behavior|mobd|||Behavior Problem|||0|901|300|316
SE|25462502||ab|1|entity|C0021941|Equipment and supply inventories|mnob|||Inventory|||0|901|317|326
SE|25462502||ab|1|relation|4|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|245|270|PREP|PROCESS_OF||240|244|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|861|228|239

SE|25462502||ab|2|text|358|541|We report three main findings: First, structural equation modeling techniques (SEM) revealed that the BPI-01stereotyped behavior subscale scores predicted BPI-01 SIB subscale scores.
SE|25462502||ab|2|entity|C0205449|Three|qnco|||three|||0|851|368|373
SE|25462502||ab|2|entity|C0205225|Primary|qlco|||main|||0|851|374|378
SE|25462502||ab|2|entity|C0243095|Finding|ftcn|||findings|||0|851|379|387
SE|25462502||ab|2|entity|C1279901|Firstly|qlco|||First|||0|1000|389|394
SE|25462502||ab|2|entity|C0681947|structural equation model|resa|||structural equation modeling|||0|916|396|424
SE|25462502||ab|2|entity|C0025664|Methodology|inpr|||techniques|||0|916|425|435
SE|25462502||ab|2|entity|||gngm|671|BPI|BPI|||0|645|460|463
SE|25462502||ab|2|entity|C0004927|Behavior|inbe|||behavior|||0|645|478|486
SE|25462502||ab|2|entity|C1508497|PREDICTED|clna|||predicted|||0|792|503|512
SE|25462502||ab|2|entity|C0085271|Self-Injurious Behavior|mobd|||SIB|||0|792|520|523
SE|25462502||ab|2|entity|C0459443|Subscale score|qnco|||subscale scores|||0|792|524|539

SE|25462502||ab|3|text|541|866|Second, when stereotyped behavior was modeled as a predictor of SIB, mixture-modeling techniques revealed two groups of individuals: one in which stereotyped behavior was a strong, statistically significant predictor of SIB (69% of the sample), and another one in which stereotyped behavior was not a predictor of SIB (31%).
SE|25462502||ab|3|entity|C0457385|seconds|tmco|||Second|||0|1000|541|547
SE|25462502||ab|3|entity|C0038271|Stereotyped Behavior|mobd|||stereotyped behavior|||0|1000|554|574
SE|25462502||ab|3|entity|C0085271|Self-Injurious Behavior|mobd|||SIB|||0|1000|605|608
SE|25462502||ab|3|entity|C0439962|Mixture|sbst|||mixture|||0|851|610|617
SE|25462502||ab|3|entity|C0870071|Modeling|inpr,resa|||modeling|||0|851|618|626
SE|25462502||ab|3|entity|C0025664|Methodology|inpr|||techniques|||0|851|627|637
SE|25462502||ab|3|entity|C0205448|Two|qnco|||two|||0|888|647|650
SE|25462502||ab|3|entity|C0441833|Groups|inpr|||groups|||0|888|651|657
SE|25462502||ab|3|entity|C0237401|Individual|humn|||individuals|||0|1000|661|672
SE|25462502||ab|3|entity|C0205447|One|qnco|||one|||0|1000|674|677
SE|25462502||ab|3|entity|C0004927|Behavior|inbe|||behavior|||0|1000|699|707
SE|25462502||ab|3|entity|C0442821|Strong|qlco|||strong|||0|658|714|720
SE|25462502||ab|3|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|658|722|747
SE|25462502||ab|3|entity|C0085271|Self-Injurious Behavior|mobd|||SIB|||0|1000|761|764
SE|25462502||ab|3|entity|C0205447|One|qnco|||one|||0|1000|798|801
SE|25462502||ab|3|entity|C0004927|Behavior|inbe|||behavior|||0|1000|823|831
SE|25462502||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|836|839
SE|25462502||ab|3|entity|C0085271|Self-Injurious Behavior|mobd|||SIB|||0|1000|855|858
SE|25462502||ab|3|relation|9|1|C0004927|Behavior|inbe|inbe|||behavior|||0|1000|699|707|NOM|PREDISPOSES||748|757|6|1|C0085271|Self-Injurious Behavior|mobd|mobd|||SIB|||0|1000|761|764
SE|25462502||ab|3|relation|14|1|C0004927|Behavior|inbe|inbe|||behavior|||0|1000|823|831|NOM|PREDISPOSES|negation|842|851|1|1|C0085271|Self-Injurious Behavior|mobd|mobd|||SIB|||0|1000|855|858

SE|25462502||ab|4|text|866|1114|Finally, two specific stereotyped behavior topographies (i.e., body rocking and yelling) were identified that significantly predicted five different SIB topographies (i.e., self-biting, head hitting, body hitting, self-pinching, and hair pulling).
SE|25462502||ab|4|entity|C0205448|Two|qnco|||two|||0|786|875|878
SE|25462502||ab|4|entity|C0038271|Stereotyped Behavior|mobd|||stereotyped behavior|||0|786|888|908
SE|25462502||ab|4|entity|C0870781|Landscapes|spco|||topographies|||0|786|909|921
SE|25462502||ab|4|entity|C0005899|Body Rocking|inbe|||body rocking|||0|861|929|941
SE|25462502||ab|4|entity|C0205451|Five|qnco|||five|||0|834|1000|1004
SE|25462502||ab|4|entity|C1547020|*Difference|qnco|||different|||0|834|1005|1014
SE|25462502||ab|4|entity|C0085271|Self-Injurious Behavior|mobd|||SIB|||0|834|1015|1018
SE|25462502||ab|4|entity|C0870781|Landscapes|spco|||topographies|||0|834|1019|1031
SE|25462502||ab|4|entity|C0036588|Self|idcn|||self|||0|645|1039|1043
SE|25462502||ab|4|entity|C0424373|Head-hitting|fndg|||head hitting|||0|1000|1052|1064
SE|25462502||ab|4|entity|C0036588|Self|idcn|||self|||0|872|1080|1084
SE|25462502||ab|4|entity|C0418416|Pinched|inpo|||pinching|||0|872|1085|1093
SE|25462502||ab|4|entity|C0040953|Trichotillomania|mobd|||hair pulling|||0|1000|1099|1111

SE|25462502||ab|5|text|1114|1312|Results are discussed in terms of future research needed to identify bio-behavioral variables correlated with cases of SIB that can, and cannot, be predicted by the presence of stereotyped behavior.
SE|25462502||ab|5|entity|C1274040|result|ftcn|||Results|||0|966|1114|1121
SE|25462502||ab|5|entity|C0016884|Future|tmco|||future|||0|888|1148|1154
SE|25462502||ab|5|entity|C0035168|research|resa|||research|||0|888|1155|1163
SE|25462502||ab|5|entity|C0205460|biological|ftcn|||bio|||0|785|1183|1186
SE|25462502||ab|5|entity|C0439828|Variable|qlco|||variables|||0|785|1198|1207
SE|25462502||ab|5|entity|C0868928|Case (situation)|ftcn|||cases|||0|1000|1224|1229
SE|25462502||ab|5|entity|C0085271|Self-Injurious Behavior|mobd|||SIB|||0|1000|1233|1236
SE|25462502||ab|5|entity|C0038271|Stereotyped Behavior|mobd|||stereotyped behavior|||0|1000|1291|1311
SE|25462502||ab|5|relation|6|1|C0085271|Self-Injurious Behavior|mobd|mobd|||SIB|||0|1000|1233|1236|NOM|COEXISTS_WITH||1279|1287|1|1|C0038271|Stereotyped Behavior|mobd|mobd|||stereotyped behavior|||0|1000|1291|1311


SE|25462503||ti|1|text|21|134|Associations of physical activity with fatness and fitness in adolescents with Down syndrome: The UP&DOWN study.
SE|25462503||ti|1|entity|C0026606|Physical activity|dora|||physical activity|||0|1000|37|54
SE|25462503||ti|1|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|1000|60|67
SE|25462503||ti|1|entity|C1456706|Fitness|dora|||fitness|||0|1000|72|79
SE|25462503||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|83|94
SE|25462503||ti|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|100|113
SE|25462503||ti|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|127|132
SE|25462503||ti|1|relation|3|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|100|113|PREP|PROCESS_OF||95|99|5|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|83|94
SE|25462503||ti|1|relation|4|2|C0235433|Fat tissue increased|fndg|fndg|||fatness|||0|1000|60|67|PREP|PROCESS_OF||80|82|4|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|83|94

SE|25462503||ab|1|text|140|361|The aim of the present study was to examine the associations of objectively measured physical activity (PA) with several markers of fatness and fitness in a relatively large sample of adolescents with Down syndrome (DS).
SE|25462503||ab|1|entity|C0150312|Present|qnco|||present|||0|888|155|162
SE|25462503||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|163|168
SE|25462503||ab|1|entity|C0026606|Physical activity|dora|||physical activity|||0|1000|225|242
SE|25462503||ab|1|entity|C0443302|Several|qnco|||several|||0|694|253|260
SE|25462503||ab|1|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|1000|272|279
SE|25462503||ab|1|entity|C1456706|Fitness|dora|||fitness|||0|1000|284|291
SE|25462503||ab|1|entity|C0549177|Large|qnco|||large|||0|660|308|313
SE|25462503||ab|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|324|335
SE|25462503||ab|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|341|354
SE|25462503||ab|1|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|341|354|PREP|PROCESS_OF||336|340|9|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|324|335

SE|25462503||ab|2|text|361|554|This study comprised a total of 100 adolescents with DS (37 females) aged 11-20 years-old, and a sex-matched sample of 100 adolescents without disabilities, participating in the UP&DOWN study.
SE|25462503||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|366|371
SE|25462503||ab|2|entity|C0439175|% of total|qnco|||total|||0|1000|384|389
SE|25462503||ab|2|entity|C0205653|Adolescent|aggp|||adolescents|||0|861|397|408
SE|25462503||ab|2|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|414|416
SE|25462503||ab|2|entity|C0015780|Female|orga|||females|||0|861|421|428
SE|25462503||ab|2|entity|C0439234|year|tmco|||years|||0|750|441|446
SE|25462503||ab|2|entity|C0580836|Old|tmco|||old|||0|750|447|450
SE|25462503||ab|2|entity|C1314687|Sexual intercourse - finding|fndg|||sex|||0|606|458|461
SE|25462503||ab|2|entity|C0150103|MATCHING|resa|||matched|||0|606|462|469
SE|25462503||ab|2|entity|C0205653|Adolescent|aggp|||adolescents|||0|861|484|495
SE|25462503||ab|2|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|504|516
SE|25462503||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|547|552
SE|25462503||ab|2|relation|8|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|414|416|PREP|PROCESS_OF||409|413|3|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|861|397|408

SE|25462503||ab|3|text|554|656|The ALPHA health-related fitness test battery for adolescents was used to assess fatness and fitness.
SE|25462503||ab|3|entity|C0439095|Alpha|inpr|||ALPHA|||0|603|558|563
SE|25462503||ab|3|entity|C0018684|Health|idcn|||health|||0|603|564|570
SE|25462503||ab|3|entity|C1522149|Related|ftcn|||related|||0|603|571|578
SE|25462503||ab|3|entity|C1456706|Fitness|dora|||fitness|||0|603|579|586
SE|25462503||ab|3|entity|C0039593|Testing|resa|||test|||0|603|587|591
SE|25462503||ab|3|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|604|615
SE|25462503||ab|3|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|1000|635|642
SE|25462503||ab|3|entity|C1456706|Fitness|dora|||fitness|||0|1000|647|654

SE|25462503||ab|4|text|656|690|PA was measured by accelerometry.
SE|25462503||ab|4|entity|C0026606|Physical activity|dora|||PA|||0|1000|656|658
SE|25462503||ab|4|entity|C0441677|Accelerometry|lbpr|||accelerometry|||0|1000|675|688

SE|25462503||ab|5|text|690|836|Adolescents with DS had higher fatness and significantly lower fitness levels in all variables measured than adolescents without DS (all p<0.05).
SE|25462503||ab|5|entity|C0205653|Adolescent|aggp|||Adolescents|||0|1000|690|701
SE|25462503||ab|5|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|707|709
SE|25462503||ab|5|entity|C0205250|High|qlco|||higher|||0|872|714|720
SE|25462503||ab|5|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|872|721|728
SE|25462503||ab|5|entity|C0441994|Lower|ftcn|||lower|||0|775|747|752
SE|25462503||ab|5|entity|C1456706|Fitness|dora|||fitness|||0|775|753|760
SE|25462503||ab|5|entity|C0441889|Levels|inpr|||levels|||0|775|761|767
SE|25462503||ab|5|entity|C0439828|Variable|qlco|||variables|||0|966|775|784
SE|25462503||ab|5|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|799|810
SE|25462503||ab|5|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|819|821
SE|25462503||ab|5|relation|5|1|C0235433|Fat tissue increased|fndg|fndg|||fatness|||0|872|721|728|AUX|PROCESS_OF||710|713|2|2|C0205653|Adolescent|aggp,humn|humn|||Adolescents|||0|1000|690|701
SE|25462503||ab|5|relation|6|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|707|709|PREP|PROCESS_OF||702|706|1|1|C0205653|Adolescent|aggp,humn|humn|||Adolescents|||0|1000|690|701

SE|25462503||ab|6|text|836|989|Moderate-to-large effects were observed in fatness variables (d=0.65-1.42), but particularly large values were found in fitness variables (d=2.05-2.43).
SE|25462503||ab|6|entity|C0549177|Large|qnco|||large|||0|773|848|853
SE|25462503||ab|6|entity|C1280500|Effect|qlco|||effects|||0|773|854|861
SE|25462503||ab|6|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|872|879|886
SE|25462503||ab|6|entity|C0439828|Variable|qlco|||variables|||0|872|887|896
SE|25462503||ab|6|entity|C0549177|Large|qnco|||large|||0|790|929|934
SE|25462503||ab|6|entity|C0042295|Values|qlco|||values|||0|790|935|941
SE|25462503||ab|6|entity|C1456706|Fitness|dora|||fitness|||0|872|956|963
SE|25462503||ab|6|entity|C0439828|Variable|qlco|||variables|||0|872|964|973

SE|25462503||ab|7|text|989|1263|In addition, PA levels was not associated with fatness variables, whereas total PA and vigorous PA were associated with all fitness variables (p<0.05), and moderate-vigorous PA (MVPA) was associated with muscular fitness (p<0.05), after adjusting for potential confounders.
SE|25462503||ab|7|entity|C0026606|Physical activity|dora|||PA|||0|901|1002|1004
SE|25462503||ab|7|entity|C0441889|Levels|inpr|||levels|||0|901|1005|1011
SE|25462503||ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1016|1019
SE|25462503||ab|7|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|872|1036|1043
SE|25462503||ab|7|entity|C0439828|Variable|qlco|||variables|||0|872|1044|1053
SE|25462503||ab|7|entity|C0439175|% of total|qnco|||total|||0|901|1063|1068
SE|25462503||ab|7|entity|C0026606|Physical activity|dora|||PA|||0|901|1069|1071
SE|25462503||ab|7|entity|C0026606|Physical activity|dora|||PA|||0|901|1085|1087
SE|25462503||ab|7|entity|C1456706|Fitness|dora|||fitness|||0|872|1113|1120
SE|25462503||ab|7|entity|C0439828|Variable|qlco|||variables|||0|872|1121|1130
SE|25462503||ab|7|entity|C0026606|Physical activity|dora|||PA|||0|901|1163|1165
SE|25462503||ab|7|entity|C0442025|Muscular|spco|||muscular|||0|888|1193|1201
SE|25462503||ab|7|entity|C1456706|Fitness|dora|||fitness|||0|888|1202|1209
SE|25462503||ab|7|entity|C1439356|ADJUSTED|qlco|||adjusting|||0|966|1226|1235
SE|25462503||ab|7|entity|C0237399|Potential|qlco|||potential|||0|694|1240|1249

SE|25462503||ab|8|text|1263|1436|Further analysis revealed that there were differences in fitness by tertiles of vigorous PA between the lowest and the highest groups in all fitness variables (all p<0.05).
SE|25462503||ab|8|entity|C1517331|Further|spco|||Further|||0|888|1263|1270
SE|25462503||ab|8|entity|C0936012|Analysis|resa|||analysis|||0|888|1271|1279
SE|25462503||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1305|1316
SE|25462503||ab|8|entity|C1456706|Fitness|dora|||fitness|||0|1000|1320|1327
SE|25462503||ab|8|entity|C0026606|Physical activity|dora|||PA|||0|901|1352|1354
SE|25462503||ab|8|entity|C0205251|low|qlco|||lowest|||0|966|1367|1373
SE|25462503||ab|8|entity|C1522410|Highest|qlco|||highest|||0|888|1382|1389
SE|25462503||ab|8|entity|C0441833|Groups|inpr|||groups|||0|888|1390|1396
SE|25462503||ab|8|entity|C1456706|Fitness|dora|||fitness|||0|872|1404|1411
SE|25462503||ab|8|entity|C0439828|Variable|qlco|||variables|||0|872|1412|1421

SE|25462503||ab|9|text|1436|1562|However, no significant differences were found in fitness by tertiles of MVPA according with PA guidelines (>=60min in MVPA).
SE|25462503||ab|9|entity|C0750502|Significant|idcn|||significant|||0|872|1448|1459
SE|25462503||ab|9|entity|C1547020|*Difference|qnco|||differences|||0|872|1460|1471
SE|25462503||ab|9|entity|C1456706|Fitness|dora|||fitness|||0|1000|1486|1493
SE|25462503||ab|9|entity|C0026606|Physical activity|dora|||PA|||0|901|1529|1531
SE|25462503||ab|9|entity|C0162791|Guidelines|inpr|||guidelines|||0|901|1532|1542

SE|25462503||ab|10|text|1562|1760|Our findings indicate that PA levels are not associated with fatness variables, whereas high PA levels, in particular vigorous PA, are positively associated with high fitness in adolescents with DS.
SE|25462503||ab|10|entity|C0243095|Finding|ftcn|||findings|||0|1000|1566|1574
SE|25462503||ab|10|entity|C0026606|Physical activity|dora|||PA|||0|901|1589|1591
SE|25462503||ab|10|entity|C0441889|Levels|inpr|||levels|||0|901|1592|1598
SE|25462503||ab|10|entity|C1518422|Not|ftcn|||not|||0|1000|1603|1606
SE|25462503||ab|10|entity|C0235433|Fat tissue increased|fndg|||fatness|||0|872|1623|1630
SE|25462503||ab|10|entity|C0439828|Variable|qlco|||variables|||0|872|1631|1640
SE|25462503||ab|10|entity|C0205250|High|qlco|||high|||0|861|1650|1654
SE|25462503||ab|10|entity|C0026606|Physical activity|dora|||PA|||0|861|1655|1657
SE|25462503||ab|10|entity|C0441889|Levels|inpr|||levels|||0|861|1658|1664
SE|25462503||ab|10|entity|C0026606|Physical activity|dora|||PA|||0|861|1689|1691
SE|25462503||ab|10|entity|C0205250|High|qlco|||high|||0|888|1724|1728
SE|25462503||ab|10|entity|C1456706|Fitness|dora|||fitness|||0|888|1729|1736
SE|25462503||ab|10|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|1740|1751
SE|25462503||ab|10|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1757|1759
SE|25462503||ab|10|relation|0|0|C1456706|Fitness|dora|dora|||fitness|||0|888|1729|1736|INFER|TREATS(INFER)||1737|1739|0|0|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|1757|1759
SE|25462503||ab|10|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|1757|1759|PREP|PROCESS_OF||1752|1756|7|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1740|1751
SE|25462503||ab|10|relation|6|1|C1456706|Fitness|dora|dora|||fitness|||0|888|1729|1736|PREP|TREATS||1737|1739|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1740|1751


SE|25462504||ti|1|text|21|184|The mediating effect of affective stigma between face concern and general mental health - The case of Chinese caregivers of children with intellectual disability.
SE|25462504||ti|1|entity|C1280500|Effect|qlco|||effect|||0|1000|35|41
SE|25462504||ti|1|entity|C0277787|Social stigmata|sosy|||stigma|||0|861|55|61
SE|25462504||ti|1|entity|C0015450|Face|blor|||face|||0|694|70|74
SE|25462504||ti|1|entity|C0424575|General body state finding|fndg|||general mental health|||0|901|87|108
SE|25462504||ti|1|entity|C0085537|Caregiver|prog|||caregivers|||0|861|131|141
SE|25462504||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|145|153
SE|25462504||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|159|182
SE|25462504||ti|1|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|159|182|PREP|PROCESS_OF||154|158|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|145|153

SE|25462504||ab|1|text|190|386|An earlier study revealed that the mental health of caregivers of children with intellectual disability is related to the affective dimension of affiliated stigma, loss of face and anxiety level.
SE|25462504||ab|1|entity|C1279919|Early|tmco|||earlier|||0|872|193|200
SE|25462504||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|872|201|206
SE|25462504||ab|1|entity|C0025353|mental health|idcn|||mental health|||0|1000|225|238
SE|25462504||ab|1|entity|C0085537|Caregiver|prog|||caregivers|||0|1000|242|252
SE|25462504||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|256|264
SE|25462504||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|270|293
SE|25462504||ab|1|entity|C0439534|Dimensions|qnco|||dimension|||0|861|322|331
SE|25462504||ab|1|entity|C1510826|Affiliated|qlco|||affiliated|||0|888|335|345
SE|25462504||ab|1|entity|C0277787|Social stigmata|sosy|||stigma|||0|888|346|352
SE|25462504||ab|1|entity|C1517945|Loss|qnco|||loss|||0|1000|354|358
SE|25462504||ab|1|entity|C0015450|Face|blor|||face|||0|1000|362|366
SE|25462504||ab|1|entity|C0003467|Anxiety|menp|||anxiety|||0|694|371|378
SE|25462504||ab|1|relation|6|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|270|293|PREP|PROCESS_OF||265|269|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|256|264

SE|25462504||ab|2|text|386|483|However, how cultural values such as face concern interplay with stigma remains largely unknown.
SE|25462504||ab|2|entity|C0683623|cultural values|idcn|||cultural values|||0|901|399|414
SE|25462504||ab|2|entity|C0015450|Face|blor|||face|||0|660|423|427
SE|25462504||ab|2|entity|C0277787|Social stigmata|sosy|||stigma|||0|1000|451|457
SE|25462504||ab|2|entity|C0439673|Unknown|idcn|||unknown|||0|861|474|481

SE|25462504||ab|3|text|483|766|This extended study goes further to test the mediating role of affective stigma on two slightly different pathway models between the face concern and the mental health outcome of 211 caregivers in two Chinese cities, against the required standards and procedure of being a mediator.
SE|25462504||ab|3|entity|C0231449|Extended|spco|||extended|||0|608|488|496
SE|25462504||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|608|497|502
SE|25462504||ab|3|entity|C1517331|Further|spco|||further|||0|608|508|515
SE|25462504||ab|3|entity|C0035820|Role|socb|||role|||0|1000|538|542
SE|25462504||ab|3|entity|C0277787|Social stigmata|sosy|||stigma|||0|861|556|562
SE|25462504||ab|3|entity|C0205448|Two|qnco|||two|||0|815|566|569
SE|25462504||ab|3|entity|C0750482|SLIGHTLY|idcn|||slightly|||0|815|570|578
SE|25462504||ab|3|entity|C1547020|*Difference|qnco|||different|||0|815|579|588
SE|25462504||ab|3|entity|C0243123|biochemical pathways|ftcn|||pathway|||0|815|589|596
SE|25462504||ab|3|entity|C0015450|Face|blor|||face|||0|694|616|620
SE|25462504||ab|3|entity|C0025353|mental health|idcn|||mental health|||0|901|637|650
SE|25462504||ab|3|entity|C1274040|result|ftcn|||outcome|||0|901|651|658
SE|25462504||ab|3|entity|C0085537|Caregiver|prog|||caregivers|||0|861|666|676
SE|25462504||ab|3|entity|C0205448|Two|qnco|||two|||0|802|680|683
SE|25462504||ab|3|entity|C0008848|Cities|geoa|||cities|||0|802|692|698
SE|25462504||ab|3|entity|C1514872|Required|ftcn|||required|||0|694|712|720
SE|25462504||ab|3|entity|C0184661|Procedures|hlca|||procedure|||0|1000|735|744

SE|25462504||ab|4|text|766|869|The mediating effect of affective stigma is confirmed by meeting Baron and Kenny's required standards.
SE|25462504||ab|4|entity|C1280500|Effect|qlco|||effect|||0|1000|780|786
SE|25462504||ab|4|entity|C0277787|Social stigmata|sosy|||stigma|||0|861|800|806
SE|25462504||ab|4|entity|C0556656|Meetings|hlca|||meeting|||0|872|823|830
SE|25462504||ab|4|entity|C0331778|Baron|hcro|||Baron|||0|872|831|836
SE|25462504||ab|4|entity|C1514872|Required|ftcn|||required|||0|660|849|857

SE|25462504||ab|5|text|869|1103|Two viable path models are worked out: one model with anxiety as a co-mediating variable successfully accounts for 17% more of the variance on the outcome than another model without anxiety, explaining a total of 56% of the variance.
SE|25462504||ab|5|entity|C0205448|Two|qnco|||Two|||0|608|869|872
SE|25462504||ab|5|entity|C0443348|Viable|qlco|||viable|||0|608|873|879
SE|25462504||ab|5|entity|C0030664|Pathology|bmod|||path|||0|608|880|884
SE|25462504||ab|5|entity|C0439787|Out|spco|||out|||0|1000|903|906
SE|25462504||ab|5|entity|C0205447|One|qnco|||one|||0|888|908|911
SE|25462504||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|888|912|917
SE|25462504||ab|5|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|923|930
SE|25462504||ab|5|entity|C0439828|Variable|qlco|||variable|||0|1000|949|957
SE|25462504||ab|5|entity|C0205419|Variant|qlco|||variance|||0|928|1000|1008
SE|25462504||ab|5|entity|C1274040|result|ftcn|||outcome|||0|1000|1016|1023
SE|25462504||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|1000|1037|1042
SE|25462504||ab|5|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|1051|1058
SE|25462504||ab|5|entity|C0439175|% of total|qnco|||total|||0|1000|1073|1078
SE|25462504||ab|5|entity|C0205419|Variant|qlco|||variance|||0|928|1093|1101

SE|25462504||ab|6|text|1103|1368|This provides empirical evidence for the first time that cultural values such as face value do not influence directly one's mental health; but works through the experience of real stigma or anticipated stigma situations, to induce anxiety and worsen mental health.
SE|25462504||ab|6|entity|C1279901|Firstly|qlco|||first|||0|888|1144|1149
SE|25462504||ab|6|entity|C0040223|Time|tmco|||time|||0|888|1150|1154
SE|25462504||ab|6|entity|C0683623|cultural values|idcn|||cultural values|||0|1000|1160|1175
SE|25462504||ab|6|entity|C0015450|Face|blor|||face|||0|694|1184|1188
SE|25462504||ab|6|entity|C1518422|Not|ftcn|||not|||0|1000|1198|1201
SE|25462504||ab|6|entity|C0205447|One|qnco|||one's|||0|824|1221|1226
SE|25462504||ab|6|entity|C0025353|mental health|idcn|||mental health|||0|824|1227|1240
SE|25462504||ab|6|entity|C0596545|experience|menp|||experience|||0|1000|1264|1274
SE|25462504||ab|6|entity|C0871222|Reality|idcn|||real|||0|853|1278|1282
SE|25462504||ab|6|entity|C0277787|Social stigmata|sosy|||stigma|||0|853|1283|1289
SE|25462504||ab|6|entity|C0277787|Social stigmata|sosy|||stigma|||0|660|1305|1311
SE|25462504||ab|6|entity|C0003467|Anxiety|menp|||anxiety|||0|1000|1334|1341
SE|25462504||ab|6|entity|C0025353|mental health|idcn|||mental health|||0|1000|1353|1366

SE|25462504||ab|7|text|1368|1551|Practitioners may need to employ anti-stigma and anxiety reduction strategy in promoting better mental health and to explore cultural elements that can be tapped on for better coping.
SE|25462504||ab|7|entity|C0277787|Social stigmata|sosy|||stigma|||0|861|1406|1412
SE|25462504||ab|7|entity|C0150135|Alleviating anxiety|topp|||anxiety reduction|||0|901|1417|1434
SE|25462504||ab|7|entity|C0332272|Better|qlco|||better|||0|824|1457|1463
SE|25462504||ab|7|entity|C0025353|mental health|idcn|||mental health|||0|824|1464|1477
SE|25462504||ab|7|entity|C0220814|Cultural|ftcn|||cultural|||0|888|1493|1501
SE|25462504||ab|7|entity|C0013879|Elements|elii|||elements|||0|888|1502|1510
SE|25462504||ab|7|entity|C0332272|Better|qlco|||better|||0|694|1537|1543


SE|25462505||ti|1|text|21|240|The development and discussion of computerized visual perception assessment tool for Chinese characters structures - Concurrent estimation of the overall ability and the domain ability in item response theory approach.
SE|25462505||ti|1|entity|C1527148|Development|ftcn|||development|||0|1000|25|36
SE|25462505||ti|1|entity|C0042789|Vision|orgf|||visual perception|||0|798|68|85
SE|25462505||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|798|86|96
SE|25462505||ti|1|entity|C0336791|Tool|mnob|||tool|||0|798|97|101
SE|25462505||ti|1|entity|C0007952|Personality Character|menp|||characters|||0|861|114|124
SE|25462505||ti|1|entity|C0205420|Concurrent|tmco|||Concurrent|||0|888|138|148
SE|25462505||ti|1|entity|C0680844|estimation|menp|||estimation|||0|888|149|159
SE|25462505||ti|1|entity|C1561607|Overall|qlco|||overall|||0|888|167|174
SE|25462505||ti|1|entity|C0085732|Ability|orga|||ability|||0|888|175|182
SE|25462505||ti|1|entity|C0085732|Ability|orga|||ability|||0|861|198|205
SE|25462505||ti|1|entity|C0870753|Item Response Theory|inpr,resa|||item response theory|||0|916|209|229
SE|25462505||ti|1|entity|C0449445|Approach|spco|||approach|||0|916|230|238

SE|25462505||ab|1|text|246|353|Visual perception is the fundamental skill required for a child to recognize words, and to read and write.
SE|25462505||ab|1|entity|C0042789|Vision|orgf|||Visual perception|||0|1000|246|263
SE|25462505||ab|1|entity|C0678856|skills|inbe|||skill|||0|827|283|288
SE|25462505||ab|1|entity|C0008059|Child|aggp,inpr|||child|||0|1000|304|309
SE|25462505||ab|1|entity|C0439824|Verbal|orgf|||words|||0|928|323|328

SE|25462505||ab|2|text|353|472|There was no visual perception assessment tool developed for preschool children based on Chinese characters in Taiwan.
SE|25462505||ab|2|entity|C0042789|Vision|orgf|||visual perception|||0|861|366|383
SE|25462505||ab|2|entity|C0220825|Evaluation|ftcn|||assessment|||0|861|384|394
SE|25462505||ab|2|entity|C0336791|Tool|mnob|||tool|||0|861|395|399
SE|25462505||ab|2|entity|C0008100|Child, Preschool|aggp|||preschool children|||0|1000|414|432
SE|25462505||ab|2|entity|C0007952|Personality Character|menp|||characters|||0|861|450|460
SE|25462505||ab|2|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|464|470

SE|25462505||ab|3|text|472|655|The purposes were to develop the computerized visual perception assessment tool for Chinese Characters Structures and to explore the psychometrical characteristic of assessment tool.
SE|25462505||ab|3|entity|C1285529|Purpose|ftcn|||purposes|||0|966|476|484
SE|25462505||ab|3|entity|C0042789|Vision|orgf|||visual perception|||0|798|518|535
SE|25462505||ab|3|entity|C0220825|Evaluation|ftcn|||assessment|||0|798|536|546
SE|25462505||ab|3|entity|C0336791|Tool|mnob|||tool|||0|798|547|551
SE|25462505||ab|3|entity|C0007952|Personality Character|menp|||Characters|||0|861|564|574
SE|25462505||ab|3|entity|C0033920|Psychometrics|diap|||psychometrical|||0|822|605|619
SE|25462505||ab|3|entity|C1521970|Characteristics|grpa|||characteristic|||0|822|620|634
SE|25462505||ab|3|entity|C0220825|Evaluation|ftcn|||assessment|||0|888|638|648
SE|25462505||ab|3|entity|C0336791|Tool|mnob|||tool|||0|888|649|653

SE|25462505||ab|4|text|655|694|This study adopted purposive sampling.
SE|25462505||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|660|665
SE|25462505||ab|4|entity|C0870078|Sampling|idcn|||sampling|||0|861|684|692

SE|25462505||ab|5|text|694|803|The study evaluated 551 kindergarten-age children (293 boys, 258 girls) ranging from 46 to 81 months of age.
SE|25462505||ab|5|entity|C0008972|Clinical Research|resa|||study|||0|1000|698|703
SE|25462505||ab|5|entity|C0681406|kindergarten|inpr|||kindergarten|||0|775|718|730
SE|25462505||ab|5|entity|C0001779|Age|orga|||age|||0|775|731|734
SE|25462505||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|775|735|743
SE|25462505||ab|5|entity|C0870221|Boys|popg|||boys|||0|861|749|753
SE|25462505||ab|5|entity|C0870604|Girls|popg|||girls|||0|861|759|764
SE|25462505||ab|5|entity|C1514721|Range|qnco|||ranging|||0|966|766|773
SE|25462505||ab|5|entity|C0439231|month|tmco|||months|||0|861|788|794
SE|25462505||ab|5|entity|C0001779|Age|orga|||age|||0|1000|798|801

SE|25462505||ab|6|text|803|972|The test instrument used in this study consisted of three subtests and 58 items, including tests of basic strokes, single-component characters, and compound characters.
SE|25462505||ab|6|entity|C0039593|Testing|resa|||test|||0|888|807|811
SE|25462505||ab|6|entity|C0348000|Instrument|mnob|||instrument|||0|888|812|822
SE|25462505||ab|6|entity|C0008972|Clinical Research|resa|||study|||0|1000|836|841
SE|25462505||ab|6|entity|C0205449|Three|qnco|||three|||0|888|855|860
SE|25462505||ab|6|entity|C0871459|Subtests|inpr,resa|||subtests|||0|888|861|869
SE|25462505||ab|6|entity|C0392366|Tests|inpr|||tests|||0|1000|894|899
SE|25462505||ab|6|entity|C0038454|Cerebrovascular accident|dsyn|||strokes|||0|853|909|916
SE|25462505||ab|6|entity|C0037179|Unmarried person|popg|||single|||0|851|918|924
SE|25462505||ab|6|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|925|934
SE|25462505||ab|6|entity|C0007952|Personality Character|menp|||characters|||0|851|935|945
SE|25462505||ab|6|entity|C0205198|Compound|qlco|||compound|||0|888|951|959
SE|25462505||ab|6|entity|C0007952|Personality Character|menp|||characters|||0|888|960|970

SE|25462505||ab|7|text|972|1197|Based on the results of model fit analysis, the higher-order item response theory was used to estimate the performance in visual perception, basic strokes, single-component characters, and compound characters simultaneously.
SE|25462505||ab|7|entity|C1274040|result|ftcn|||results|||0|966|985|992
SE|25462505||ab|7|entity|C0026336|Study models|inpr,resd|||model|||0|851|996|1001
SE|25462505||ab|7|entity|C0036572|Seizures|sosy|||fit|||0|851|1002|1005
SE|25462505||ab|7|entity|C0936012|Analysis|resa|||analysis|||0|851|1006|1014
SE|25462505||ab|7|entity|C0205250|High|qlco|||higher|||0|841|1020|1026
SE|25462505||ab|7|entity|C0870753|Item Response Theory|inpr,resa|||item response theory|||0|841|1033|1053
SE|25462505||ab|7|entity|C0597198|Performance|inbe|||performance|||0|1000|1079|1090
SE|25462505||ab|7|entity|C0042789|Vision|orgf|||visual perception|||0|1000|1094|1111
SE|25462505||ab|7|entity|C0038454|Cerebrovascular accident|dsyn|||strokes|||0|853|1119|1126
SE|25462505||ab|7|entity|C0037179|Unmarried person|popg|||single|||0|851|1128|1134
SE|25462505||ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|1135|1144
SE|25462505||ab|7|entity|C0007952|Personality Character|menp|||characters|||0|851|1145|1155
SE|25462505||ab|7|entity|C0205198|Compound|qlco|||compound|||0|790|1161|1169
SE|25462505||ab|7|entity|C0007952|Personality Character|menp|||characters|||0|790|1170|1180

SE|25462505||ab|8|text|1197|1294|Analyses of variance were used to detect significant difference in age groups and gender groups.
SE|25462505||ab|8|entity|C0936012|Analysis|resa|||Analyses|||0|966|1197|1205
SE|25462505||ab|8|entity|C0205419|Variant|qlco|||variance|||0|928|1209|1217
SE|25462505||ab|8|entity|C0750502|Significant|idcn|||significant|||0|888|1238|1249
SE|25462505||ab|8|entity|C1547020|*Difference|qnco|||difference|||0|888|1250|1260
SE|25462505||ab|8|entity|C0027362|Human Age Group|aggp|||age groups|||0|1000|1264|1274
SE|25462505||ab|8|entity|C0079399|Gender|orga|||gender|||0|888|1279|1285
SE|25462505||ab|8|entity|C0441833|Groups|inpr|||groups|||0|888|1286|1292

SE|25462505||ab|9|text|1294|1379|The difficulty of identifying items in a visual perception test ranged from -2 to 1.
SE|25462505||ab|9|entity|C0205396|Identified|qlco|||identifying|||0|661|1312|1323
SE|25462505||ab|9|entity|C0042789|Vision|orgf|||visual perception|||0|901|1335|1352
SE|25462505||ab|9|entity|C0039593|Testing|resa|||test|||0|901|1353|1357

SE|25462505||ab|10|text|1379|1465|The visual perception ability of 4- to 6-year-old children ranged from -1.66 to 2.19.
SE|25462505||ab|10|entity|C0042789|Vision|orgf|||visual perception|||0|901|1383|1400
SE|25462505||ab|10|entity|C0085732|Ability|orga|||ability|||0|901|1401|1408
SE|25462505||ab|10|entity|C0439234|year|tmco|||year|||0|775|1420|1424
SE|25462505||ab|10|entity|C0580836|Old|tmco|||old|||0|775|1425|1428
SE|25462505||ab|10|entity|C0008059|Child|aggp,inpr|||children|||0|775|1429|1437

SE|25462505||ab|11|text|1465|1521|Gender did not have significant effects on performance.
SE|25462505||ab|11|entity|C0079399|Gender|orga|||Gender|||0|1000|1465|1471
SE|25462505||ab|11|entity|C1518422|Not|ftcn|||not|||0|1000|1476|1479
SE|25462505||ab|11|entity|C0750502|Significant|idcn|||significant|||0|872|1485|1496
SE|25462505||ab|11|entity|C1280500|Effect|qlco|||effects|||0|872|1497|1504
SE|25462505||ab|11|entity|C0597198|Performance|inbe|||performance|||0|1000|1508|1519

SE|25462505||ab|12|text|1521|1597|However, there were significant differences among the different age groups.
SE|25462505||ab|12|entity|C0750502|Significant|idcn|||significant|||0|872|1541|1552
SE|25462505||ab|12|entity|C1547020|*Difference|qnco|||differences|||0|872|1553|1564
SE|25462505||ab|12|entity|C1547020|*Difference|qnco|||different|||0|877|1575|1584
SE|25462505||ab|12|entity|C0027362|Human Age Group|aggp|||age groups|||0|877|1585|1595

SE|25462505||ab|13|text|1597|1708|The performance of 6-year-olds was better than that of 5-year-olds, which was better than that of 4-year-olds.
SE|25462505||ab|13|entity|C0597198|Performance|inbe|||performance|||0|1000|1601|1612
SE|25462505||ab|13|entity|C0439234|year|tmco|||year|||0|773|1618|1622
SE|25462505||ab|13|entity|C0580836|Old|tmco|||olds|||0|773|1623|1627
SE|25462505||ab|13|entity|C0332272|Better|qlco|||better|||0|1000|1632|1638
SE|25462505||ab|13|entity|C0439234|year|tmco|||year|||0|840|1654|1658
SE|25462505||ab|13|entity|C0580836|Old|tmco|||olds|||0|840|1659|1663
SE|25462505||ab|13|entity|C0332272|Better|qlco|||better|||0|1000|1675|1681
SE|25462505||ab|13|entity|C0439234|year|tmco|||year|||0|773|1697|1701
SE|25462505||ab|13|entity|C0580836|Old|tmco|||olds|||0|773|1702|1706

SE|25462505||ab|14|text|1708|1914|This study obtained detailed diagnostic scores by using a higher-order item response theory model to understand the visual perception of basic strokes, single-component characters, and compound characters.
SE|25462505||ab|14|entity|C0008972|Clinical Research|resa|||study|||0|1000|1713|1718
SE|25462505||ab|14|entity|C1522508|Details|qlco|||detailed|||0|840|1728|1736
SE|25462505||ab|14|entity|C0348026|Diagnostic|ftcn|||diagnostic|||0|840|1737|1747
SE|25462505||ab|14|entity|C0449820|Score|qnco|||scores|||0|840|1748|1754
SE|25462505||ab|14|entity|C0205250|High|qlco|||higher|||0|810|1766|1772
SE|25462505||ab|14|entity|C0870753|Item Response Theory|inpr,resa|||item response theory|||0|810|1779|1799
SE|25462505||ab|14|entity|C0026336|Study models|inpr,resd|||model|||0|810|1800|1805
SE|25462505||ab|14|entity|C0042789|Vision|orgf|||visual perception|||0|1000|1824|1841
SE|25462505||ab|14|entity|C0038454|Cerebrovascular accident|dsyn|||strokes|||0|853|1851|1858
SE|25462505||ab|14|entity|C0037179|Unmarried person|popg|||single|||0|851|1860|1866
SE|25462505||ab|14|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|1867|1876
SE|25462505||ab|14|entity|C0007952|Personality Character|menp|||characters|||0|851|1877|1887
SE|25462505||ab|14|entity|C0205198|Compound|qlco|||compound|||0|888|1893|1901
SE|25462505||ab|14|entity|C0007952|Personality Character|menp|||characters|||0|888|1902|1912
SE|25462505||ab|14|relation|2|2|C0008972|Clinical Research|resa|resa|||study|||0|1000|1713|1718|VERB|USES||1758|1763|5|1|C0026336|Study models|inpr,resd|resd|||model|||0|810|1800|1805

SE|25462505||ab|15|text|1914|2088|Further statistical analysis showed that, for basic strokes and compound characters, girls performed better than did boys; there also were differences within each age group.
SE|25462505||ab|15|entity|C1517331|Further|spco|||Further|||0|901|1914|1921
SE|25462505||ab|15|entity|C0871424|Statistical Analysis|resa|||statistical analysis|||0|901|1922|1942
SE|25462505||ab|15|entity|C0038454|Cerebrovascular accident|dsyn|||strokes|||0|853|1966|1973
SE|25462505||ab|15|entity|C0205198|Compound|qlco|||compound|||0|888|1978|1986
SE|25462505||ab|15|entity|C0007952|Personality Character|menp|||characters|||0|888|1987|1997
SE|25462505||ab|15|entity|C0870604|Girls|popg|||girls|||0|1000|1999|2004
SE|25462505||ab|15|entity|C0332272|Better|qlco|||better|||0|1000|2015|2021
SE|25462505||ab|15|entity|C0870221|Boys|popg|||boys|||0|1000|2031|2035
SE|25462505||ab|15|entity|C1547020|*Difference|qnco|||differences|||0|966|2053|2064
SE|25462505||ab|15|entity|C0027362|Human Age Group|aggp|||age group|||0|1000|2077|2086

SE|25462505||ab|16|text|2088|2184|For single-component characters, there was no difference in performance between boys and girls.
SE|25462505||ab|16|entity|C0037179|Unmarried person|popg|||single|||0|851|2092|2098
SE|25462505||ab|16|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|2099|2108
SE|25462505||ab|16|entity|C0007952|Personality Character|menp|||characters|||0|851|2109|2119
SE|25462505||ab|16|entity|C1547020|*Difference|qnco|||difference|||0|1000|2134|2144
SE|25462505||ab|16|entity|C0597198|Performance|inbe|||performance|||0|1000|2148|2159
SE|25462505||ab|16|entity|C0870221|Boys|popg|||boys|||0|1000|2168|2172
SE|25462505||ab|16|entity|C0870604|Girls|popg|||girls|||0|1000|2177|2182

SE|25462505||ab|17|text|2184|2365|However, again the performance of 6-year-olds was better than that of 4-year-olds, but there were no statistical differences between the performance of 5-year-olds and 6-year-olds.
SE|25462505||ab|17|entity|C0597198|Performance|inbe|||performance|||0|1000|2203|2214
SE|25462505||ab|17|entity|C0439234|year|tmco|||year|||0|773|2220|2224
SE|25462505||ab|17|entity|C0580836|Old|tmco|||olds|||0|773|2225|2229
SE|25462505||ab|17|entity|C0332272|Better|qlco|||better|||0|1000|2234|2240
SE|25462505||ab|17|entity|C0439234|year|tmco|||year|||0|773|2256|2260
SE|25462505||ab|17|entity|C0580836|Old|tmco|||olds|||0|773|2261|2265
SE|25462505||ab|17|entity|C0220917|statistical|inpr|||statistical|||0|872|2285|2296
SE|25462505||ab|17|entity|C1547020|*Difference|qnco|||differences|||0|872|2297|2308
SE|25462505||ab|17|entity|C0597198|Performance|inbe|||performance|||0|1000|2321|2332
SE|25462505||ab|17|entity|C0439234|year|tmco|||year|||0|840|2338|2342
SE|25462505||ab|17|entity|C0580836|Old|tmco|||olds|||0|840|2343|2347
SE|25462505||ab|17|entity|C0439234|year|tmco|||year|||0|773|2354|2358
SE|25462505||ab|17|entity|C0580836|Old|tmco|||olds|||0|773|2359|2363

SE|25462505||ab|18|text|2365|2495|Results of tests with basic strokes, single-component characters and compound characters tests had good reliability and validity.
SE|25462505||ab|18|entity|C1274040|result|ftcn|||Results|||0|966|2365|2372
SE|25462505||ab|18|entity|C0392366|Tests|inpr|||tests|||0|1000|2376|2381
SE|25462505||ab|18|entity|C0038454|Cerebrovascular accident|dsyn|||strokes|||0|853|2393|2400
SE|25462505||ab|18|entity|C0037179|Unmarried person|popg|||single|||0|851|2402|2408
SE|25462505||ab|18|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|851|2409|2418
SE|25462505||ab|18|entity|C0007952|Personality Character|menp|||characters|||0|851|2419|2429
SE|25462505||ab|18|entity|C0205198|Compound|qlco|||compound|||0|888|2434|2442
SE|25462505||ab|18|entity|C0007952|Personality Character|menp|||characters|||0|888|2443|2453
SE|25462505||ab|18|entity|C0205170|Good|qlco|||good|||0|694|2464|2468

SE|25462505||ab|19|text|2495|2580|Therefore, it can be apply to diagnose the problem of visual perception at preschool.
SE|25462505||ab|19|entity|C0042789|Vision|orgf|||visual perception|||0|1000|2549|2566


SE|25462506||ti|1|text|21|210|Emotional and behavioural difficulties in children referred for learning disabilities from two Arab countries: A cross-cultural examination of the Strengths and Difficulties Questionnaire.
SE|25462506||ti|1|entity|C0849912|Emotional|fndg|||Emotional|||0|1000|21|30
SE|25462506||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|63|71
SE|25462506||ti|1|entity|C0751265|Learning Disabilities|mobd|||learning disabilities|||0|1000|85|106
SE|25462506||ti|1|entity|C0205448|Two|qnco|||two|||0|901|112|115
SE|25462506||ti|1|entity|C0242398|Arab Countries|geoa|||Arab countries|||0|901|116|130
SE|25462506||ti|1|entity|C0220814|Cultural|ftcn|||cultural|||0|660|140|148
SE|25462506||ti|1|entity|C0808080|STRENGTH|idcn|||Strengths|||0|696|168|177
SE|25462506||ti|1|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|696|195|208
SE|25462506||ti|1|relation|2|2|C0849912|Emotional|fndg|fndg|||Emotional|||0|1000|21|30|PREP|PROCESS_OF||60|62|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|63|71

SE|25462506||ab|1|text|216|352|The Strengths and Difficulties Questionnaire (SDQ) is a widely used child mental health questionnaire with five hypothesized subscales.
SE|25462506||ab|1|entity|C0808080|STRENGTH|idcn|||Strengths|||0|718|220|229
SE|25462506||ab|1|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|718|247|260
SE|25462506||ab|1|entity|C0042153|utilization qualifier|ftcn|||used|||0|805|279|283
SE|25462506||ab|1|entity|C1456644|Child Mental Health|grpa|||child mental health|||0|805|284|303
SE|25462506||ab|1|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|805|304|317
SE|25462506||ab|1|entity|C0205451|Five|qnco|||five|||0|660|323|327

SE|25462506||ab|2|text|352|642|There is theoretical and preliminary empirical support for combining the SDQ's hypothesized emotional and peer subscales into an 'internalizing' subscale and the hypothesized behavioural and hyperactivity subscales into an 'externalizing' subscale (alongside the fifth prosocial subscale).
SE|25462506||ab|2|entity|C0439611|Preliminary|tmco|||preliminary|||0|802|377|388
SE|25462506||ab|2|entity|C0205195|Combined|qlco|||combining|||0|966|411|420
SE|25462506||ab|2|entity|C0849912|Emotional|fndg|||emotional|||0|827|444|453
SE|25462506||ab|2|entity|C0679739|peer|popg|||peer|||0|694|458|462
SE|25462506||ab|2|entity|C0424295|Hyperactive behavior|fndg|||hyperactivity|||0|694|543|556
SE|25462506||ab|2|entity|C0205439|Fifth|qnco|||fifth|||0|660|615|620

SE|25462506||ab|3|text|642|778|We examined both structures using the teacher informant version data from two Arab countries, namely Saudi Arabia (323) and Oman (439).
SE|25462506||ab|3|entity|C0678594|Structure|spco|||structures|||0|966|659|669
SE|25462506||ab|3|entity|C0221457|Teacher|prog|||teacher|||0|833|680|687
SE|25462506||ab|3|entity|C1550484|informant|idcn|||informant|||0|833|688|697
SE|25462506||ab|3|entity|C0333052|Version|ftcn|||version|||0|833|698|705
SE|25462506||ab|3|entity|C1511726|Data|idcn|||data|||0|833|706|710
SE|25462506||ab|3|entity|C0205448|Two|qnco|||two|||0|901|716|719
SE|25462506||ab|3|entity|C0242398|Arab Countries|geoa|||Arab countries|||0|901|720|734
SE|25462506||ab|3|entity|C0036243|Saudi Arabia|geoa|||Saudi Arabia|||0|901|743|755
SE|25462506||ab|3|entity|C0028971|Oman|geoa|||Oman|||0|1000|766|770

SE|25462506||ab|4|text|778|874|Multigroup CFAs based on structural equation modelling revealed culture invariance for the SDQ.
SE|25462506||ab|4|entity|C1003714|Cell fusing agent virus|virs|||CFAs|||0|827|789|793
SE|25462506||ab|4|entity|C0681947|structural equation model|resa|||structural equation modelling|||0|656|803|832
SE|25462506||ab|4|entity|C0443289|Revealed|qlco|||revealed|||0|656|833|841
SE|25462506||ab|4|entity|C0220814|Cultural|ftcn|||culture|||0|656|842|849
SE|25462506||ab|4|entity|C0808080|STRENGTH|idcn|||SDQ|||0|696|869|872
SE|25462506||ab|4|entity|C0034394|Questionnaires|inpr|||SDQ|||0|696|869|872

SE|25462506||ab|5|text|874|947|The three-factor model showed a better description of the SDQ structure.
SE|25462506||ab|5|entity|C0205449|Three|qnco|||three|||0|851|878|883
SE|25462506||ab|5|entity|C1521761|Factor|ftcn|||factor|||0|851|884|890
SE|25462506||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|851|891|896
SE|25462506||ab|5|entity|C0332272|Better|qlco|||better|||0|888|906|912
SE|25462506||ab|5|entity|C0678257|Description|idcn|||description|||0|888|913|924
SE|25462506||ab|5|entity|C0808080|STRENGTH|idcn|||SDQ|||0|696|932|935
SE|25462506||ab|5|entity|C0034394|Questionnaires|inpr|||SDQ|||0|696|932|935
SE|25462506||ab|5|entity|C0678594|Structure|spco|||structure|||0|696|936|945

SE|25462506||ab|6|text|947|1070|The analysis also revealed gender invariance for the SDQ three and five factor models in both the Omani and Saudi samples.
SE|25462506||ab|6|entity|C0936012|Analysis|resa|||analysis|||0|574|951|959
SE|25462506||ab|6|entity|C0443289|Revealed|qlco|||revealed|||0|574|965|973
SE|25462506||ab|6|entity|C0079399|Gender|orga|||gender|||0|574|974|980
SE|25462506||ab|6|entity|C0808080|STRENGTH|idcn|||SDQ|||0|696|1000|1003
SE|25462506||ab|6|entity|C0034394|Questionnaires|inpr|||SDQ|||0|696|1000|1003
SE|25462506||ab|6|entity|C0205449|Three|qnco|||three|||0|696|1004|1009
SE|25462506||ab|6|entity|C0205451|Five|qnco|||five|||0|888|1014|1018
SE|25462506||ab|6|entity|C1521761|Factor|ftcn|||factor|||0|888|1019|1025

SE|25462506||ab|7|text|1070|1170|There were gender differences in all the three and five factors between the Saudi and Omani samples.
SE|25462506||ab|7|entity|C0036866|Sex Characteristics|orga|||gender differences|||0|1000|1081|1099
SE|25462506||ab|7|entity|C0205449|Three|qnco|||three|||0|1000|1111|1116
SE|25462506||ab|7|entity|C0205451|Five|qnco|||five|||0|872|1121|1125
SE|25462506||ab|7|entity|C1521761|Factor|ftcn|||factors|||0|872|1126|1133


SE|25462507||ti|1|text|21|72|A quantitative examination of punishment research.
SE|25462507||ti|1|entity|C0392762|Quantitative|qnco|||quantitative|||0|694|23|35
SE|25462507||ti|1|entity|C0034119|Punishment|idcn|||punishment|||0|888|51|61
SE|25462507||ti|1|entity|C0035168|research|resa|||research|||0|888|62|70

SE|25462507||ab|1|text|78|744|The current review examined 368 articles, published between 1967 and 2013, which evaluated punishment-based procedures for the treatment of challenging behavior among persons with developmental disabilities and quantitatively analyzed: (a) the amount of research that has assessed different types of punishment procedures; (b) the characteristics of the participants, behaviors, and treatments included in these studies, and (c) the relative efficacy of the various punishment procedures in general and with regard to the inclusion of reinforcement-based components, method of treatment selection and development, and function of the targeted challenging behaviors.
SE|25462507||ab|1|entity|C0521116|Current|tmco|||current|||0|694|82|89
SE|25462507||ab|1|entity|C0034119|Punishment|idcn|||punishment|||0|840|169|179
SE|25462507||ab|1|entity|C0025664|Methodology|inpr|||procedures|||0|840|186|196
SE|25462507||ab|1|entity|C0474414|Challenging behavior|fndg|||challenging behavior|||0|1000|218|238
SE|25462507||ab|1|entity|C0027361|Persons|popg|||persons|||0|1000|245|252
SE|25462507||ab|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|258|284
SE|25462507||ab|1|entity|C1265611|Quantity|qnco|||amount|||0|1000|322|328
SE|25462507||ab|1|entity|C0035168|research|resa|||research|||0|1000|332|340
SE|25462507||ab|1|entity|C1516048|Assessed|qlco|||assessed|||0|828|350|358
SE|25462507||ab|1|entity|C1547020|*Difference|qnco|||different|||0|828|359|368
SE|25462507||ab|1|entity|C0332307|Type - attribute|qlco|||types|||0|828|369|374
SE|25462507||ab|1|entity|C0034119|Punishment|idcn|||punishment|||0|888|378|388
SE|25462507||ab|1|entity|C0025664|Methodology|inpr|||procedures|||0|888|389|399
SE|25462507||ab|1|entity|C1521970|Characteristics|grpa|||characteristics|||0|1000|409|424
SE|25462507||ab|1|entity|C0679646|Participant|popg|||participants|||0|966|432|444
SE|25462507||ab|1|entity|C0004927|Behavior|inbe|||behaviors|||0|1000|446|455
SE|25462507||ab|1|entity|C0087111|Therapeutic procedure|topp|||treatments|||0|1000|461|471
SE|25462507||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|966|490|497
SE|25462507||ab|1|entity|C0205345|Relative|qlco|||relative|||0|694|511|519
SE|25462507||ab|1|entity|C0034119|Punishment|idcn|||punishment|||0|790|544|554
SE|25462507||ab|1|entity|C0025664|Methodology|inpr|||procedures|||0|790|555|565
SE|25462507||ab|1|entity|C0205246|Generalized|spco|||general|||0|1000|569|576
SE|25462507||ab|1|entity|C1512693|Inclusion|qlco|||inclusion|||0|1000|600|609
SE|25462507||ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|756|633|643
SE|25462507||ab|1|entity|C0025663|Methods|inpr|||method|||0|1000|645|651
SE|25462507||ab|1|entity|C1527148|Development|ftcn|||development|||0|1000|679|690
SE|25462507||ab|1|entity|C0031843|physiological aspects|phsf|||function|||0|1000|696|704
SE|25462507||ab|1|entity|C0599894|targeting|celf|||targeted|||0|879|712|720
SE|25462507||ab|1|entity|C0474414|Challenging behavior|fndg|||challenging behaviors|||0|879|721|742
SE|25462507||ab|1|relation|5|1|C0474414|Challenging behavior|fndg|fndg|||challenging behavior|||0|1000|218|238|PREP|PROCESS_OF||239|244|24|1|C0027361|Persons|popg,humn|humn|||persons|||0|1000|245|252
SE|25462507||ab|1|relation|23|1|C0008073|Child Development Disorders|mobd|mobd|||developmental disabilities|||0|1000|258|284|PREP|PROCESS_OF||253|257|6|1|C0027361|Persons|popg,humn|humn|||persons|||0|1000|245|252

SE|25462507||ab|2|text|744|844|Further, the study evaluated the included studies for the presence of important quality indicators.
SE|25462507||ab|2|entity|C1517331|Further|spco|||Further|||0|1000|744|751
SE|25462507||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|757|762
SE|25462507||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|827|786|793
SE|25462507||ab|2|entity|C0525060|Quality Indicators|qlco,qnco|||quality indicators|||0|901|824|842

SE|25462507||ab|3|text|844|997|It was intended that such an analysis would provide a useful overview of the extant research on punishment procedures as a behavior reduction technique.
SE|25462507||ab|3|entity|C0936012|Analysis|resa|||analysis|||0|1000|873|881
SE|25462507||ab|3|entity|C0814812|overview|inpr|||overview|||0|861|905|913
SE|25462507||ab|3|entity|C0035168|research|resa|||research|||0|861|928|936
SE|25462507||ab|3|entity|C0034119|Punishment|idcn|||punishment|||0|888|940|950
SE|25462507||ab|3|entity|C0025664|Methodology|inpr|||procedures|||0|888|951|961
SE|25462507||ab|3|entity|C0004927|Behavior|inbe|||behavior|||0|802|967|975
SE|25462507||ab|3|entity|C0449851|Techniques|ftcn|||technique|||0|802|986|995

SE|25462507||ab|4|text|997|1147|Suggestions regarding research methodology and areas for further investigation are made for future research evaluating punishment-based interventions.
SE|25462507||ab|4|entity|C0086912|Research Methodology|resa|||research methodology|||0|1000|1019|1039
SE|25462507||ab|4|entity|C1517331|Further|spco|||further|||0|888|1054|1061
SE|25462507||ab|4|entity|C0016884|Future|tmco|||future|||0|821|1089|1095
SE|25462507||ab|4|entity|C0035168|research|resa|||research|||0|821|1096|1104
SE|25462507||ab|4|entity|C0034119|Punishment|idcn|||punishment|||0|821|1116|1126
SE|25462507||ab|4|entity|C0557980|Evaluating interventions|hlca|||evaluating punishment-based interventions|||0|821|1105|1146


SE|25462508||ti|1|text|21|148|Association of 5-HT2A receptor gene polymorphisms with gastrointestinal disorders in Egyptian children with autistic disorder.
SE|25462508||ti|1|entity|C0289174|Receptor, Serotonin, 5-HT2A|aapp,rcpt|22954|TRIM32|5-HT2A receptor|||0|886|36|51
SE|25462508||ti|1|entity|C0678951|gene polymorphism|genf|||gene polymorphisms|||0|886|52|70
SE|25462508||ti|1|entity|C0017178|Gastrointestinal Diseases|dsyn|||gastrointestinal disorders|||0|1000|76|102
SE|25462508||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|861|115|123
SE|25462508||ti|1|entity|C0004352|Autistic Disorder|mobd|||autistic disorder|||0|1000|129|146
SE|25462508||ti|1|relation|0|0|C0678951|gene polymorphism|genf|genf|||gene polymorphisms|||0|886|52|70|MOD/HEAD|PROCESS_OF||36|70|0|0|C0289174|Receptor, Serotonin, 5-HT2A|aapp,gngm,rcpt|gngm|22954|TRIM32|5-HT2A receptor|||0|886|36|51
SE|25462508||ti|1|relation|1|1|C0004352|Autistic Disorder|mobd|mobd|||autistic disorder|||0|1000|129|146|PREP|PROCESS_OF||124|128|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|115|123
SE|25462508||ti|1|relation|3|1|C0017178|Gastrointestinal Diseases|dsyn|dsyn|||gastrointestinal disorders|||0|1000|76|102|PREP|PROCESS_OF||103|105|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|115|123
SE|25462508||ti|1|relation|4|2|C0017178|Gastrointestinal Diseases|dsyn|dsyn|||gastrointestinal disorders|||0|1000|76|102|NOM|ASSOCIATED_WITH||21|32|4|1|C0678951|gene polymorphism|genf|genf|||gene polymorphisms|||0|886|52|70

SE|25462508||ab|1|text|154|264|Gastrointestinal disturbances (GID) are frequently reported in children with autism spectrum disorders (ASD).
SE|25462508||ab|1|entity|C0232459|Abnormal digestive tract function|fndg|||Gastrointestinal disturbances|||0|983|154|183
SE|25462508||ab|1|entity|C0332183|Frequent|tmco|||frequently|||0|1000|194|204
SE|25462508||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|217|225
SE|25462508||ab|1|entity|C1510586|Autism spectrum disorder|mobd|||autism spectrum disorders|||0|1000|231|256
SE|25462508||ab|1|relation|1|1|C0232459|Abnormal digestive tract function|fndg|fndg|||Gastrointestinal disturbances|||0|983|154|183|PREP|PROCESS_OF||214|216|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|217|225
SE|25462508||ab|1|relation|1|1|C1510586|Autism spectrum disorder|mobd|mobd|||autism spectrum disorders|||0|1000|231|256|PREP|PROCESS_OF||226|230|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|217|225

SE|25462508||ab|2|text|264|381|Recently, mounting evidence suggests that there may be a genetic link for autism with gastrointestinal disturbances.
SE|25462508||ab|2|entity|C0332185|Recent|tmco|||Recently|||0|1000|264|272
SE|25462508||ab|2|entity|C0314603|Genetic|ftcn|||genetic|||0|694|321|328
SE|25462508||ab|2|entity|C0004352|Autistic Disorder|mobd|||autism|||0|1000|338|344
SE|25462508||ab|2|entity|C0232459|Abnormal digestive tract function|fndg|||gastrointestinal disturbances|||0|983|350|379

SE|25462508||ab|3|text|381|579|We aimed to investigate whether there were any association between the -1438A/G, 102T/C and His452Tyr polymorphisms of the serotonin 2A receptor gene (5-HT2A) in Egyptian children with ASD and GID.
SE|25462508||ab|3|entity|C0032529|Polymorphism, Genetic|genf|||polymorphisms|||0|827|483|496
SE|25462508||ab|3|entity|C0289174|Receptor, Serotonin, 5-HT2A|aapp,rcpt|||serotonin 2A receptor|||0|916|504|525
SE|25462508||ab|3|entity|C0017337|Genes|gngm|||gene|||0|916|526|530
SE|25462508||ab|3|entity|C1415809|HTR2A gene|gngm|3356|HTR2A|5-HT2A|||0|1000|532|538
SE|25462508||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|861|552|560
SE|25462508||ab|3|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|566|569
SE|25462508||ab|3|entity|C0232459|Abnormal digestive tract function|fndg|||GID|||0|983|574|577
SE|25462508||ab|3|relation|2|1|C0232459|Abnormal digestive tract function|fndg|fndg|||GID|||0|983|574|577|PREP|PROCESS_OF||561|565|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|552|560
SE|25462508||ab|3|relation|2|1|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|1000|566|569|PREP|PROCESS_OF||561|565|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|552|560
SE|25462508||ab|3|relation|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|552|560|PREP|LOCATION_OF||540|542|6|2|C0289174|Receptor, Serotonin, 5-HT2A|aapp,gngm,rcpt|aapp|||serotonin 2A receptor|||0|916|504|525

SE|25462508||ab|4|text|579|666|Eighty children with autistic disorder and 100 healthy control children were examined.
SE|25462508||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|861|586|594
SE|25462508||ab|4|entity|C0004352|Autistic Disorder|mobd|||autistic disorder|||0|1000|600|617
SE|25462508||ab|4|entity|C0018684|Health|idcn|||healthy|||0|751|626|633
SE|25462508||ab|4|entity|C0243148|control|ftcn|||control|||0|751|634|641
SE|25462508||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|751|642|650
SE|25462508||ab|4|relation|2|1|C0004352|Autistic Disorder|mobd|mobd|||autistic disorder|||0|1000|600|617|PREP|PROCESS_OF||595|599|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|586|594

SE|25462508||ab|5|text|666|825|-1438A/G, 102T/C and His452Tyr polymorphisms of 5-HT2A were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method.
SE|25462508||ab|5|entity|C0032529|Polymorphism, Genetic|genf|||polymorphisms|||0|827|697|710
SE|25462508||ab|5|entity|C1415809|HTR2A gene|gngm|3356|HTR2A|5-HT2A|||0|1000|714|720
SE|25462508||ab|5|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||polymerase chain reaction|||0|891|739|764
SE|25462508||ab|5|entity|C0035268|Restriction fragment length polymorphism|clna|||restriction fragment length polymorphism|||0|891|765|805
SE|25462508||ab|5|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR-RFLP|||0|888|807|815
SE|25462508||ab|5|entity|C0035268|Restriction fragment length polymorphism|clna|||PCR-RFLP|||0|888|807|815
SE|25462508||ab|5|entity|C0025663|Methods|inpr|||method|||0|1000|817|823

SE|25462508||ab|6|text|825|1099|Significant increase of the G allele and the GG genotype of the -1438A/G polymorphism was observed in children with autism than control, but there were no significant differences in the frequencies either of the 102T/C genotype or His452Tyr genotype between the two groups.
SE|25462508||ab|6|entity|C0750502|Significant|idcn|||Significant|||0|888|825|836
SE|25462508||ab|6|entity|C0442805|Increase|ftcn|||increase|||0|888|837|845
SE|25462508||ab|6|entity|C0002085|Alleles|gngm|||allele|||0|861|855|861
SE|25462508||ab|6|entity|C0017431|Genotype|orga|||genotype|||0|861|873|881
SE|25462508||ab|6|entity|C0032529|Polymorphism, Genetic|genf|||polymorphism|||0|827|898|910
SE|25462508||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|927|935
SE|25462508||ab|6|entity|C0004352|Autistic Disorder|mobd|||autism|||0|1000|941|947
SE|25462508||ab|6|entity|C0243148|control|ftcn|||control|||0|1000|953|960
SE|25462508||ab|6|entity|C0750502|Significant|idcn|||significant|||0|872|980|991
SE|25462508||ab|6|entity|C1547020|*Difference|qnco|||differences|||0|872|992|1003
SE|25462508||ab|6|entity|C0017431|Genotype|orga|||genotype|||0|827|1044|1052
SE|25462508||ab|6|entity|C0017431|Genotype|orga|||genotype|||0|861|1066|1074
SE|25462508||ab|6|entity|C0205448|Two|qnco|||two|||0|888|1087|1090
SE|25462508||ab|6|entity|C0441833|Groups|inpr|||groups|||0|888|1091|1097
SE|25462508||ab|6|relation|7|1|C0004352|Autistic Disorder|mobd|mobd|||autism|||0|1000|941|947|PREP|PROCESS_OF||936|940|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|927|935

SE|25462508||ab|7|text|1099|1240|There was a significant increase of homozygote A allele of the -1438A/G and CC genotype of the 102T/C polymorphism in ASD children with GID.
SE|25462508||ab|7|entity|C0750502|Significant|idcn|||significant|||0|888|1111|1122
SE|25462508||ab|7|entity|C0442805|Increase|ftcn|||increase|||0|888|1123|1131
SE|25462508||ab|7|entity|C0019904|Homozygote|orgm|||homozygote|||0|1000|1135|1145
SE|25462508||ab|7|entity|C0002085|Alleles|gngm|||allele|||0|1000|1148|1154
SE|25462508||ab|7|entity|C0017431|Genotype|orga|||genotype|||0|888|1178|1186
SE|25462508||ab|7|entity|C0032529|Polymorphism, Genetic|genf|||polymorphism|||0|827|1201|1213
SE|25462508||ab|7|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|916|1217|1220
SE|25462508||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|916|1221|1229
SE|25462508||ab|7|entity|C0232459|Abnormal digestive tract function|fndg|||GID|||0|983|1235|1238
SE|25462508||ab|7|relation|0|0|C1510586|Autism spectrum disorder|mobd|mobd|||ASD|||0|916|1217|1220|MOD/HEAD|PROCESS_OF||1217|1229|0|0|C0008059|Child|aggp,humn,inpr|humn|||children|||0|916|1221|1229
SE|25462508||ab|7|relation|1|1|C0232459|Abnormal digestive tract function|fndg|fndg|||GID|||0|983|1235|1238|PREP|PROCESS_OF||1230|1234|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|916|1221|1229
SE|25462508||ab|7|relation|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|916|1221|1229|PREP|LOCATION_OF||1214|1216|6|4|C0002085|Alleles|gngm,aapp|aapp|||allele|||0|1000|1148|1154

SE|25462508||ab|8|text|1240|1353|This study supports the possible involvement of the 5-HT2A receptor in the development of ASD and associated GID.
SE|25462508||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1245|1250
SE|25462508||ab|8|entity|C0332149|Possible|qlco|||possible|||0|694|1264|1272
SE|25462508||ab|8|entity|C0289174|Receptor, Serotonin, 5-HT2A|aapp,rcpt|22954|TRIM32|5-HT2A receptor|||0|1000|1292|1307
SE|25462508||ab|8|entity|C1527148|Development|ftcn|||development|||0|1000|1315|1326
SE|25462508||ab|8|entity|C1510586|Autism spectrum disorder|mobd|||ASD|||0|1000|1330|1333
SE|25462508||ab|8|entity|C0232459|Abnormal digestive tract function|fndg|||GID|||0|884|1349|1352


SE|25462509||ti|1|text|21|170|Sociodemographic characteristics and health-related factors affecting the use of Pap smear screening among women with mental disabilities in Taiwan.
SE|25462509||ti|1|entity|C1521970|Characteristics|grpa|||characteristics|||0|861|38|53
SE|25462509||ti|1|entity|C0018684|Health|idcn|||health|||0|840|58|64
SE|25462509||ti|1|entity|C1522149|Related|ftcn|||related|||0|840|65|72
SE|25462509||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|840|73|80
SE|25462509||ti|1|entity|C0747226|PAP SMEAR SCREENING|diap|||Pap smear screening|||0|1000|102|121
SE|25462509||ti|1|entity|C0043210|Woman|popg|||women|||0|1000|128|133
SE|25462509||ti|1|entity|C1306341|Mental handicap|mobd|||mental disabilities|||0|983|139|158
SE|25462509||ti|1|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|162|168
SE|25462509||ti|1|relation|2|1|C1306341|Mental handicap|mobd|mobd|||mental disabilities|||0|983|139|158|PREP|PROCESS_OF||134|138|5|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|128|133

SE|25462509||ab|1|text|176|331|This study examined the use of the Pap cervical cancer screening test among women with mental disabilities in Taiwan and analyzed factors related thereto.
SE|25462509||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|181|186
SE|25462509||ab|1|entity|C0281187|early detection of cervical cancer|topp|||cervical cancer screening|||0|893|215|240
SE|25462509||ab|1|entity|C0079104|Pap smear|diap|||Pap cervical cancer screening test|||0|893|211|245
SE|25462509||ab|1|entity|C0043210|Woman|popg|||women|||0|1000|252|257
SE|25462509||ab|1|entity|C1306341|Mental handicap|mobd|||mental disabilities|||0|983|263|282
SE|25462509||ab|1|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|286|292
SE|25462509||ab|1|entity|C1515960|Analyzed|qlco|||analyzed|||0|872|297|305
SE|25462509||ab|1|entity|C1521761|Factor|ftcn|||factors|||0|872|306|313
SE|25462509||ab|1|relation|3|1|C1306341|Mental handicap|mobd|mobd|||mental disabilities|||0|983|263|282|PREP|PROCESS_OF||258|262|4|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|252|257

SE|25462509||ab|2|text|331|630|Data were obtained from three national databases in Taiwan: the 2008 database of physically and mentally disabled persons from the Ministry of the Interior, 2007-2008 Pap smear test data from the Health Promotion Administration, and claims data from the National Health Insurance Research Database.
SE|25462509||ab|2|entity|C1511726|Data|idcn|||Data|||0|1000|331|335
SE|25462509||ab|2|entity|C0205449|Three|qnco|||three|||0|851|355|360
SE|25462509||ab|2|entity|C0242356|Databases|inpr|||databases|||0|851|370|379
SE|25462509||ab|2|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|383|389
SE|25462509||ab|2|entity|C0242356|Databases|inpr|||database|||0|861|400|408
SE|25462509||ab|2|entity|C0079822|Mentally Disabled Persons|podg|||mentally disabled persons|||0|1000|427|452
SE|25462509||ab|2|entity|C0079104|Pap smear|diap|||Pap smear test|||0|753|498|512
SE|25462509||ab|2|entity|C1511726|Data|idcn|||data|||0|753|513|517
SE|25462509||ab|2|entity|C0033414|Promotion|ocac|||Promotion|||0|901|534|543
SE|25462509||ab|2|entity|C0178672|Health administration|ocac|||Health Promotion Administration|||0|901|527|558
SE|25462509||ab|2|entity|C1511726|Data|idcn|||data|||0|1000|571|575
SE|25462509||ab|2|entity|C0027452|National Health Insurance|hlca|||National Health Insurance|||0|875|585|610
SE|25462509||ab|2|entity|C0035168|research|resa|||Research|||0|875|611|619
SE|25462509||ab|2|entity|C0242356|Databases|inpr|||Database|||0|875|620|628
SE|25462509||ab|2|relation|0|0|C0033414|Promotion|ocac|ocac|||Promotion|||0|901|534|543|MOD/HEAD|ISA||534|558|0|0|C0178672|Health administration|ocac|ocac|||Health Promotion Administration|||0|901|527|558

SE|25462509||ab|3|text|630|723|The study subjects included 49,642 Taiwanese women aged >=30 years with mental disabilities.
SE|25462509||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|872|634|639
SE|25462509||ab|3|entity|C1550501|subject|idcn|||subjects|||0|872|640|648
SE|25462509||ab|3|entity|C0043210|Woman|popg|||women|||0|812|675|680
SE|25462509||ab|3|entity|C0439234|year|tmco|||years|||0|861|691|696
SE|25462509||ab|3|entity|C1306341|Mental handicap|mobd|||mental disabilities|||0|983|702|721

SE|25462509||ab|4|text|723|859|Besides descriptive and bivariate analyses, logistic regression analysis was also performed to examine factors affecting Pap smear use.
SE|25462509||ab|4|entity|C0681927|bivariate analysis|qnco,resa|||bivariate analyses|||0|983|747|765
SE|25462509||ab|4|entity|C0681925|logistic regression analysis|qnco,resa|||logistic regression analysis|||0|1000|767|795
SE|25462509||ab|4|entity|C1521761|Factor|ftcn|||factors|||0|966|826|833
SE|25462509||ab|4|entity|C0079104|Pap smear|diap|||Pap smear|||0|901|844|853

SE|25462509||ab|5|text|859|950|In 2007-2008, Taiwanese women with mental disabilities had a Pap screening rate of 11.05%.
SE|25462509||ab|5|entity|C0043210|Woman|popg|||women|||0|861|883|888
SE|25462509||ab|5|entity|C1306341|Mental handicap|mobd|||mental disabilities|||0|983|894|913
SE|25462509||ab|5|entity|C0220908|Screening procedure|hlca|||screening|||0|790|924|933
SE|25462509||ab|5|entity|C1521828|Rate|qnco|||rate|||0|790|934|938
SE|25462509||ab|5|relation|2|1|C1306341|Mental handicap|mobd|mobd|||mental disabilities|||0|983|894|913|PREP|PROCESS_OF||889|893|1|1|C0043210|Woman|popg,humn|humn|||women|||0|861|883|888

SE|25462509||ab|6|text|950|1132|Age, income, education, marital status, catastrophic illness/injury, relevant chronic illnesses, and severity of disability were identified as factors affecting their Pap smear use.
SE|25462509||ab|6|entity|C0001779|Age|orga|||Age|||0|1000|950|953
SE|25462509||ab|6|entity|C0021162|Income|qnco|||income|||0|1000|955|961
SE|25462509||ab|6|entity|C0013621|Knowledge acquisition|edac|||education|||0|1000|963|972
SE|25462509||ab|6|entity|C0024819|Marital Status|grpa|||marital status|||0|1000|974|988
SE|25462509||ab|6|entity|C0007397|Catastrophic Illness|dsyn|||catastrophic illness|||0|901|990|1010
SE|25462509||ab|6|entity|C0175677|Injury|inpo|||injury|||0|901|1011|1017
SE|25462509||ab|6|entity|C0008679|Chronic Disease|dsyn|||chronic illnesses|||0|901|1028|1045
SE|25462509||ab|6|entity|C0439793|Severities|qlco|||severity|||0|1000|1051|1059
SE|25462509||ab|6|entity|C0231170|Disability NOS|patf|||disability|||0|1000|1063|1073
SE|25462509||ab|6|entity|C1521761|Factor|ftcn|||factors|||0|966|1093|1100
SE|25462509||ab|6|entity|C0079104|Pap smear|diap|||Pap smear|||0|901|1117|1126

SE|25462509||ab|7|text|1132|1376|Age and severity of disability were negatively correlated with Pap screening, with the odds of screening being 0.37 times as high in >=70-year-olds as in 30-39-year-olds and 0.49 times as high for very severe disability as for mild disability.
SE|25462509||ab|7|entity|C0001779|Age|orga|||Age|||0|1000|1132|1135
SE|25462509||ab|7|entity|C0439793|Severities|qlco|||severity|||0|1000|1140|1148
SE|25462509||ab|7|entity|C0231170|Disability NOS|patf|||disability|||0|1000|1152|1162
SE|25462509||ab|7|entity|C0220908|Screening procedure|hlca|||screening|||0|861|1199|1208
SE|25462509||ab|7|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|1227|1236
SE|25462509||ab|7|entity|C0040223|Time|tmco|||times|||0|793|1248|1253
SE|25462509||ab|7|entity|C0205250|High|qlco|||high|||0|861|1257|1261
SE|25462509||ab|7|entity|C0439234|year|tmco|||year|||0|773|1270|1274
SE|25462509||ab|7|entity|C0580836|Old|tmco|||olds|||0|773|1275|1279
SE|25462509||ab|7|entity|C0439234|year|tmco|||year|||0|733|1292|1296
SE|25462509||ab|7|entity|C0580836|Old|tmco|||olds|||0|733|1297|1301
SE|25462509||ab|7|entity|C0040223|Time|tmco|||times|||0|793|1311|1316
SE|25462509||ab|7|entity|C0205250|High|qlco|||high|||0|1000|1320|1324
SE|25462509||ab|7|entity|C0442824|Very|qlco|||very|||0|851|1329|1333
SE|25462509||ab|7|entity|C0205082|Severe|qlco|||severe|||0|851|1334|1340
SE|25462509||ab|7|entity|C0231170|Disability NOS|patf|||disability|||0|851|1341|1351
SE|25462509||ab|7|entity|C0547040|Minimal|qlco|||mild|||0|888|1359|1363
SE|25462509||ab|7|entity|C0231170|Disability NOS|patf|||disability|||0|888|1364|1374

SE|25462509||ab|8|text|1376|1429|Income was positively correlated with Pap screening.
SE|25462509||ab|8|entity|C0021162|Income|qnco|||Income|||0|1000|1376|1382
SE|25462509||ab|8|entity|C0220908|Screening procedure|hlca|||screening|||0|861|1418|1427

SE|25462509||ab|9|text|1429|1656|Being married (OR=2.55) or divorced or widowed (OR=2.40) relative to being unmarried, and having a catastrophic illness/injury (OR=1.13), cancer (OR=1.47), or diabetes (OR=1.25), were associated with greater odds of screening.
SE|25462509||ab|9|entity|C0206275|Widowhood|fndg|||widowed|||0|1000|1468|1475
SE|25462509||ab|9|entity|C0205345|Relative|qlco|||relative|||0|1000|1486|1494
SE|25462509||ab|9|entity|C0087136|Unmarried|popg|||unmarried|||0|1000|1504|1513
SE|25462509||ab|9|entity|C0007397|Catastrophic Illness|dsyn|||catastrophic illness|||0|901|1528|1548
SE|25462509||ab|9|entity|C0175677|Injury|inpo|||injury|||0|901|1549|1555
SE|25462509||ab|9|entity|C0006826|Malignant Neoplasms|neop|||cancer|||0|1000|1567|1573
SE|25462509||ab|9|entity|C0011847|Diabetes|dsyn|||diabetes|||0|1000|1588|1596
SE|25462509||ab|9|entity|C0443228|Largest|qnco|||greater|||0|694|1629|1636
SE|25462509||ab|9|entity|C0220908|Screening procedure|hlca|||screening|||0|1000|1645|1654
SE|25462509||ab|9|relation|5|1|C0175677|Injury|inpo|inpo|||injury|||0|901|1549|1555|AUX|PROCESS_OF||1519|1525|3|1|C0087136|Unmarried|popg,humn|humn|||unmarried|||0|1000|1504|1513

SE|25462509||ab|10|text|1656|1759|In Taiwan, women with mental disabilities receive Pap smears at a far lower rate than women in general.
SE|25462509||ab|10|entity|C0039260|Taiwan|geoa|||Taiwan|||0|1000|1659|1665
SE|25462509||ab|10|entity|C0043210|Woman|popg|||women|||0|1000|1667|1672
SE|25462509||ab|10|entity|C1306341|Mental handicap|mobd|||mental disabilities|||0|983|1678|1697
SE|25462509||ab|10|entity|C0079104|Pap smear|diap|||Pap smears|||0|983|1706|1716
SE|25462509||ab|10|entity|C1517331|Further|spco|||far|||0|840|1722|1725
SE|25462509||ab|10|entity|C0441994|Lower|ftcn|||lower|||0|840|1726|1731
SE|25462509||ab|10|entity|C1521828|Rate|qnco|||rate|||0|840|1732|1736
SE|25462509||ab|10|entity|C0043210|Woman|popg|||women|||0|1000|1742|1747
SE|25462509||ab|10|entity|C0205246|Generalized|spco|||general|||0|1000|1751|1758
SE|25462509||ab|10|relation|4|1|C0079104|Pap smear|diap|diap|||Pap smears|||0|983|1706|1716|VERB|ADMINISTERED_TO||1698|1705|3|2|C0043210|Woman|popg,humn|humn|||women|||0|1000|1667|1672
SE|25462509||ab|10|relation|5|1|C1306341|Mental handicap|mobd|mobd|||mental disabilities|||0|983|1678|1697|PREP|PROCESS_OF||1673|1677|2|1|C0043210|Woman|popg,humn|humn|||women|||0|1000|1667|1672


SE|25462510||ti|1|text|21|190|Screening for intellectual disability in persons with a substance abuse problem: Exploring the validity of the Hayes Ability Screening Index in a Dutch-speaking sample.
SE|25462510||ti|1|entity|C0220908|Screening procedure|hlca|||Screening|||0|1000|21|30
SE|25462510||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|35|58
SE|25462510||ti|1|entity|C0027361|Persons|popg|||persons|||0|1000|62|69
SE|25462510||ti|1|entity|C0740858|Substance abuse problem|mobd|||substance abuse problem|||0|1000|77|100
SE|25462510||ti|1|entity|C0085732|Ability|orga|||Ability|||0|775|138|145
SE|25462510||ti|1|entity|C0220908|Screening procedure|hlca|||Screening|||0|775|146|155
SE|25462510||ti|1|entity|C0918012|Index|inpr|||Index|||0|775|156|161
SE|25462510||ti|1|entity|C0234856|Speaking|dora|||speaking|||0|660|173|181
SE|25462510||ti|1|relation|1|1|C0220908|Screening procedure|hlca|hlca|||Screening|||0|1000|21|30|PREP|TREATS||31|34|6|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|35|58
SE|25462510||ti|1|relation|2|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|35|58|PREP|PROCESS_OF||59|61|5|1|C0027361|Persons|popg,humn|humn|||persons|||0|1000|62|69
SE|25462510||ti|1|relation|4|1|C0740858|Substance abuse problem|mobd|mobd|||substance abuse problem|||0|1000|77|100|PREP|PROCESS_OF||70|74|3|1|C0027361|Persons|popg,humn|humn|||persons|||0|1000|62|69

SE|25462510||ab|1|text|196|475|There is an increasing interest in screening instruments to detect intellectual disability (ID) in a quick and accurate way in mental health services as well as in the criminal justice system in order to provide appropriate support for people with undetected needs caused by ID.
SE|25462510||ab|1|entity|C0442808|Increasing|ftcn|||increasing|||0|888|208|218
SE|25462510||ab|1|entity|C0543488|Interested|menp|||interest|||0|888|219|227
SE|25462510||ab|1|entity|C0220908|Screening procedure|hlca|||screening|||0|888|231|240
SE|25462510||ab|1|entity|C0243113|instruments|mnob|||instruments|||0|888|241|252
SE|25462510||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|263|286
SE|25462510||ab|1|entity|C0439831|Rapid|qlco|||quick|||0|1000|297|302
SE|25462510||ab|1|entity|C0443131|Accurate|qlco|||accurate|||0|694|307|315
SE|25462510||ab|1|entity|C0025355|Mental Health Services|hlca|||mental health services|||0|1000|323|345
SE|25462510||ab|1|entity|C0680641|criminal justice system|gora|||criminal justice system|||0|1000|364|387
SE|25462510||ab|1|entity|C1548787|Appropriate|qlco|||appropriate|||0|888|408|419
SE|25462510||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|432|438
SE|25462510||ab|1|entity|C0027552|Needs|qlco|||needs|||0|861|455|460
SE|25462510||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|1000|471|473

SE|25462510||ab|2|text|475|585|An instrument that has been proven to be useful in both settings is the Hayes Ability Screening Index (HASI).
SE|25462510||ab|2|entity|C0348000|Instrument|mnob|||instrument|||0|1000|478|488
SE|25462510||ab|2|entity|C0542559|contextual factors|ftcn|||settings|||0|966|531|539
SE|25462510||ab|2|entity|C0085732|Ability|orga|||Ability|||0|775|553|560
SE|25462510||ab|2|entity|C0220908|Screening procedure|hlca|||Screening|||0|775|561|570
SE|25462510||ab|2|entity|C0918012|Index|inpr|||Index|||0|775|571|576

SE|25462510||ab|3|text|585|782|This study assessed the validity of the Dutch version of the HASI in persons with a substance abuse problem residing in mental health services, whether or not mandated to treatment by court order.
SE|25462510||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|590|595
SE|25462510||ab|3|entity|C0333052|Version|ftcn|||version|||0|861|631|638
SE|25462510||ab|3|entity|C0085732|Ability|orga|||HASI|||0|775|646|650
SE|25462510||ab|3|entity|C0220908|Screening procedure|hlca|||HASI|||0|775|646|650
SE|25462510||ab|3|entity|C0918012|Index|inpr|||HASI|||0|775|646|650
SE|25462510||ab|3|entity|C0027361|Persons|popg|||persons|||0|1000|654|661
SE|25462510||ab|3|entity|C0740858|Substance abuse problem|mobd|||substance abuse problem|||0|756|669|692
SE|25462510||ab|3|entity|C0025355|Mental Health Services|hlca|||mental health services|||0|1000|705|727
SE|25462510||ab|3|entity|C1518422|Not|ftcn|||not|||0|1000|740|743
SE|25462510||ab|3|entity|C0178572|Courts|orgt|||court|||0|694|769|774

SE|25462510||ab|4|text|782|908|The HASI was conducted along with the Wechsler Adult Intelligence Scale III as the criterion for validity to 90 participants.
SE|25462510||ab|4|entity|C0085732|Ability|orga|||HASI|||0|775|786|790
SE|25462510||ab|4|entity|C0220908|Screening procedure|hlca|||HASI|||0|775|786|790
SE|25462510||ab|4|entity|C0918012|Index|inpr|||HASI|||0|775|786|790
SE|25462510||ab|4|entity|C0204456|Wechsler adult intelligence scale|diap|||Wechsler Adult Intelligence Scale|||0|928|820|853
SE|25462510||ab|4|entity|C0439070|III|inpr|||III|||0|928|854|857
SE|25462510||ab|4|entity|C0243161|criteria|inpr|||criterion|||0|1000|865|874
SE|25462510||ab|4|entity|C0679646|Participant|popg|||participants|||0|872|894|906

SE|25462510||ab|5|text|908|1012|Additionally, the influence of psychiatric disorder and medication use on the HASI result was examined.
SE|25462510||ab|5|entity|C0004936|Mental disorders|mobd|||psychiatric disorder|||0|1000|939|959
SE|25462510||ab|5|entity|C0240320|Medication use|fndg|||medication use|||0|1000|964|978
SE|25462510||ab|5|entity|C0085732|Ability|orga|||HASI|||0|798|986|990
SE|25462510||ab|5|entity|C0918012|Index|inpr|||HASI|||0|798|986|990
SE|25462510||ab|5|entity|C1519205|Screening Result|cnce|||HASI result|||0|798|986|997

SE|25462510||ab|6|text|1012|1122|A significant positive relationship was found between the two instruments, demonstrating convergent validity.
SE|25462510||ab|6|entity|C0750502|Significant|idcn|||significant|||0|851|1014|1025
SE|25462510||ab|6|entity|C1446409|Positive|qlco|||positive|||0|851|1026|1034
SE|25462510||ab|6|entity|C0439849|Relationships|qlco|||relationship|||0|851|1035|1047
SE|25462510||ab|6|entity|C0205448|Two|qnco|||two|||0|888|1070|1073
SE|25462510||ab|6|entity|C0243113|instruments|mnob|||instruments|||0|888|1074|1085
SE|25462510||ab|6|entity|C1510594|Convergent Validity|qlco|||convergent validity|||0|1000|1101|1120

SE|25462510||ab|7|text|1122|1342|Using a Receiver Operating Characteristic (ROC) curve analysis, the discriminative ability of the HASI with a cut-off score of 85 was found to be adequate, yielding in a good balance between sensitivity and specificity.
SE|25462510||ab|7|entity|C0034772|Receiver Operating Characteristic|qnco|||Receiver Operating Characteristic|||0|851|1130|1163
SE|25462510||ab|7|entity|C0205134|Curved|spco|||curve|||0|851|1170|1175
SE|25462510||ab|7|entity|C0936012|Analysis|resa|||analysis|||0|851|1176|1184
SE|25462510||ab|7|entity|C0085732|Ability|orga|||ability|||0|861|1205|1212
SE|25462510||ab|7|entity|C0085732|Ability|orga|||HASI|||0|775|1220|1224
SE|25462510||ab|7|entity|C0220908|Screening procedure|hlca|||HASI|||0|775|1220|1224
SE|25462510||ab|7|entity|C0918012|Index|inpr|||HASI|||0|775|1220|1224
SE|25462510||ab|7|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|888|1232|1239
SE|25462510||ab|7|entity|C0449820|Score|qnco|||score|||0|888|1240|1245
SE|25462510||ab|7|entity|C0205411|Adequate|qlco|||adequate|||0|1000|1268|1276
SE|25462510||ab|7|entity|C0205170|Good|qlco|||good|||0|888|1292|1296
SE|25462510||ab|7|entity|C0014653|Equilibrium|orgf|||balance|||0|888|1297|1304
SE|25462510||ab|7|entity|C0036668|Sensitivity and Specificity|qnco|||sensitivity and specificity|||0|1000|1313|1340

SE|25462510||ab|8|text|1342|1511|The HASI was not distorted by the presence of the substance abuse problem or other psychiatric illnesses and medication did not influence the HASI scores in this study.
SE|25462510||ab|8|entity|C0085732|Ability|orga|||HASI|||0|775|1346|1350
SE|25462510||ab|8|entity|C0220908|Screening procedure|hlca|||HASI|||0|775|1346|1350
SE|25462510||ab|8|entity|C0918012|Index|inpr|||HASI|||0|775|1346|1350
SE|25462510||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1355|1358
SE|25462510||ab|8|entity|C0740858|Substance abuse problem|mobd|||substance abuse problem|||0|1000|1392|1415
SE|25462510||ab|8|entity|C0004936|Mental disorders|mobd|||psychiatric illnesses|||0|983|1425|1446
SE|25462510||ab|8|entity|C0013227|Pharmaceutical Preparations|phsu|||medication|||0|1000|1451|1461
SE|25462510||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1466|1469
SE|25462510||ab|8|entity|C0085732|Ability|orga|||HASI|||0|775|1484|1488
SE|25462510||ab|8|entity|C0220908|Screening procedure|hlca|||HASI|||0|775|1484|1488
SE|25462510||ab|8|entity|C0918012|Index|inpr|||HASI|||0|775|1484|1488
SE|25462510||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1504|1509
SE|25462510||ab|8|relation|0|0|C0740858|Substance abuse problem|mobd|mobd|||substance abuse problem|||0|1000|1392|1415|SPEC|ISA||1392|1446|0|0|C0004936|Mental disorders|mobd|mobd|||psychiatric illnesses|||0|983|1425|1446

SE|25462510||ab|9|text|1511|1710|These findings indicate that the HASI provides a time-efficient and resource-conscious way to detect ID in persons with a substance problem, thus addressing a critical need in mental health settings.
SE|25462510||ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1517|1525
SE|25462510||ab|9|entity|C0085732|Ability|orga|||HASI|||0|775|1544|1548
SE|25462510||ab|9|entity|C0220908|Screening procedure|hlca|||HASI|||0|775|1544|1548
SE|25462510||ab|9|entity|C0918012|Index|inpr|||HASI|||0|775|1544|1548
SE|25462510||ab|9|entity|C0040223|Time|tmco|||time|||0|888|1560|1564
SE|25462510||ab|9|entity|C0442799|Efficient|qlco|||efficient|||0|888|1565|1574
SE|25462510||ab|9|entity|C0035201|Resources|idcn|||resource|||0|623|1579|1587
SE|25462510||ab|9|entity|C0234421|Conscious|menp|||conscious|||0|623|1588|1597
SE|25462510||ab|9|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|1000|1612|1614
SE|25462510||ab|9|entity|C0027361|Persons|popg|||persons|||0|1000|1618|1625
SE|25462510||ab|9|entity|C0439861|Substance|sbst|||substance|||0|888|1633|1642
SE|25462510||ab|9|entity|C1511545|Critical|qlco|||critical|||0|888|1670|1678
SE|25462510||ab|9|entity|C0027552|Needs|qlco|||need|||0|888|1679|1683
SE|25462510||ab|9|entity|C0025353|mental health|idcn|||mental health|||0|884|1687|1700
SE|25462510||ab|9|entity|C0542559|contextual factors|ftcn|||settings|||0|884|1701|1709
SE|25462510||ab|9|relation|5|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|1000|1612|1614|PREP|PROCESS_OF||1615|1617|4|1|C0027361|Persons|popg,humn|humn|||persons|||0|1000|1618|1625


SE|25462511||ti|1|text|21|155|Evaluation of the implementation and impact of an integrated prevention model on the academic progress of students with disabilities.
SE|25462511||ti|1|entity|C0220825|Evaluation|ftcn|||Evaluation|||0|1000|21|31
SE|25462511||ti|1|entity|C0679710|prevention model|inpr|||prevention model|||0|901|82|98
SE|25462511||ti|1|entity|C1299701|Academic progress|fndg|||academic progress|||0|1000|106|123
SE|25462511||ti|1|entity|C0038492|student|prog|||students|||0|1000|127|135
SE|25462511||ti|1|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|141|153
SE|25462511||ti|1|relation|1|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|141|153|PREP|PROCESS_OF||136|140|6|1|C0038492|student|prog,humn|humn|||students|||0|1000|127|135

SE|25462511||ab|1|text|161|363|In this paper we report on the implementation and impact of an integrated prevention model (Achievement for All - AfA) to improve the educational experiences and outcomes of students with disabilities.
SE|25462511||ab|1|entity|C0030351|Paper|mnob|||paper|||0|1000|169|174
SE|25462511||ab|1|entity|C0679710|prevention model|inpr|||prevention model|||0|901|235|251
SE|25462511||ab|1|entity|C0001072|Achievement|inbe|||Achievement|||0|1000|253|264
SE|25462511||ab|1|entity|C0280580|doxorubicin/fluorouracil protocol|topp|||AfA|||0|1000|275|278
SE|25462511||ab|1|entity|C0596545|experience|menp|||experiences|||0|827|307|318
SE|25462511||ab|1|entity|C1274040|result|ftcn|||outcomes|||0|966|323|331
SE|25462511||ab|1|entity|C0038492|student|prog|||students|||0|1000|335|343
SE|25462511||ab|1|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|349|361
SE|25462511||ab|1|relation|1|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|349|361|PREP|PROCESS_OF||344|348|9|1|C0038492|student|prog,humn|humn|||students|||0|1000|335|343

SE|25462511||ab|2|text|363|529|It comprises three inter-related strands: assessment, tracking and intervention; structured conversations with parents; and, developing provision for wider outcomes.
SE|25462511||ab|2|entity|C0205449|Three|qnco|||three|||0|608|376|381
SE|25462511||ab|2|entity|C0205103|Intermediate|spco|||inter|||0|608|382|387
SE|25462511||ab|2|entity|C1522149|Related|ftcn|||related|||0|608|388|395
SE|25462511||ab|2|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|405|415
SE|25462511||ab|2|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|430|442
SE|25462511||ab|2|entity|C0871703|Conversation|socb|||conversations|||0|827|455|468
SE|25462511||ab|2|entity|C0030551|parent|famg|||parents|||0|1000|474|481
SE|25462511||ab|2|entity|C1549071|Provisional|idcn|||provision|||0|928|499|508
SE|25462511||ab|2|entity|C0332464|Widening|spco|||wider|||0|855|513|518
SE|25462511||ab|2|entity|C1274040|result|ftcn|||outcomes|||0|855|519|527

SE|25462511||ab|3|text|529|706|Participants were 12,038 students with disabilities from 431 mainstream primary and secondary schools across 10 Local Authorities in England involved in the two-year AfA pilot.
SE|25462511||ab|3|entity|C0679646|Participant|popg|||Participants|||0|966|529|541
SE|25462511||ab|3|entity|C0038492|student|prog|||students|||0|827|554|562
SE|25462511||ab|3|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|568|580
SE|25462511||ab|3|entity|C0036530|Schools, Secondary|mnob,orgt|||secondary schools|||0|1000|613|630
SE|25462511||ab|3|entity|C0205276|Local|spco|||Local|||0|773|641|646
SE|25462511||ab|3|entity|C0599437|Authority|socb|||Authorities|||0|773|647|658
SE|25462511||ab|3|entity|C0014282|England|geoa|||England|||0|1000|662|669
SE|25462511||ab|3|entity|C0205448|Two|qnco|||two|||0|833|686|689
SE|25462511||ab|3|entity|C0439234|year|tmco|||year|||0|833|690|694
SE|25462511||ab|3|entity|C0280580|doxorubicin/fluorouracil protocol|topp|||AfA|||0|833|695|698
SE|25462511||ab|3|entity|C0473169|Pilot|prog|||pilot|||0|833|699|704
SE|25462511||ab|3|relation|6|1|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|568|580|PREP|PROCESS_OF||563|567|2|1|C0038492|student|prog,humn|humn|||students|||0|827|554|562
SE|25462511||ab|3|relation|7|5|C0231170|Disability NOS|patf|patf|||disabilities|||0|1000|568|580|VERB|AFFECTS||670|678|1|1|C0473169|Pilot|prog,humn|humn|||pilot|||0|833|699|704

SE|25462511||ab|4|text|706|906|Pre- and post-test data on academic attainment in English and Maths were compared with national data on academic progress for students with and without disabilities over an equivalent period of time.
SE|25462511||ab|4|entity|C0039593|Testing|resa|||test|||0|851|720|724
SE|25462511||ab|4|entity|C1511726|Data|idcn|||data|||0|851|725|729
SE|25462511||ab|4|entity|C1550724|academic|idcn|||academic|||0|694|733|741
SE|25462511||ab|4|entity|C1511726|Data|idcn|||data|||0|888|802|806
SE|25462511||ab|4|entity|C1299701|Academic progress|fndg|||academic progress|||0|1000|810|827
SE|25462511||ab|4|entity|C0038492|student|prog|||students|||0|1000|832|840
SE|25462511||ab|4|entity|C0231170|Disability NOS|patf|||disabilities|||0|1000|858|870
SE|25462511||ab|4|entity|C0205136|Over|spco|||over|||0|1000|871|875
SE|25462511||ab|4|entity|C0439185|Eq|qnco|||equivalent|||0|888|879|889
SE|25462511||ab|4|entity|C0439531|/period|tmco|||period|||0|888|890|896
SE|25462511||ab|4|entity|C0040223|Time|tmco|||time|||0|1000|900|904

SE|25462511||ab|5|text|906|1033|School-level contextual and implementation data and student-level socio-demographic and psychosocial data were also collected.
SE|25462511||ab|5|entity|C1511726|Data|idcn|||data|||0|861|949|953
SE|25462511||ab|5|entity|C0038492|student|prog|||student|||0|694|958|965
SE|25462511||ab|5|entity|C0011298|Demography|ocdi|||demographic|||0|789|978|989
SE|25462511||ab|5|entity|C0542298|Psychosocial|ftcn|||psychosocial|||0|888|994|1006
SE|25462511||ab|5|entity|C1511726|Data|idcn|||data|||0|888|1007|1011

SE|25462511||ab|6|text|1033|1269|Four hypotheses were tested regarding the impact of AfA on academic attainment in English (H1) and Maths (H2); the influence of aspects of the implementation context and processes (H3); and individual differences between students (H4).
SE|25462511||ab|6|entity|C0205450|Four|qnco|||Four|||0|872|1033|1037
SE|25462511||ab|6|entity|C1512571|Hypothesis|idcn|||hypotheses|||0|872|1038|1048
SE|25462511||ab|6|entity|C0280580|doxorubicin/fluorouracil protocol|topp|||AfA|||0|1000|1085|1088
SE|25462511||ab|6|entity|C1550724|academic|idcn|||academic|||0|694|1092|1100
SE|25462511||ab|6|entity|C1547011|Aspect|qnco|||aspects|||0|966|1161|1168
SE|25462511||ab|6|entity|C1522240|Process|phpr|||processes|||0|966|1203|1212
SE|25462511||ab|6|entity|C0021228|Individuality|menp|||individual differences|||0|1000|1223|1245
SE|25462511||ab|6|entity|C0038492|student|prog|||students|||0|1000|1254|1262

SE|25462511||ab|7|text|1269|1481|Our findings are discussed in relation to the identification and validation of critical intervention components and standards for assessing the practical significance of attempts to improve outcomes for students.
SE|25462511||ab|7|entity|C0243095|Finding|ftcn|||findings|||0|1000|1273|1281
SE|25462511||ab|7|entity|C1519941|Validation|resa|||validation|||0|1000|1334|1344
SE|25462511||ab|7|entity|C0010332|Crisis Intervention|topp|||critical intervention|||0|866|1348|1369
SE|25462511||ab|7|entity|C1524073|Component, LOINC Axis 1|clas|||components|||0|866|1370|1380
SE|25462511||ab|7|entity|C0220825|Evaluation|ftcn|||assessing|||0|966|1399|1408
SE|25462511||ab|7|entity|C0237607|experience (practice)|menp|||practical|||0|817|1413|1422
SE|25462511||ab|7|entity|C0750502|Significant|idcn|||significance|||0|817|1423|1435
SE|25462511||ab|7|entity|C1516084|Attempt|evnt|||attempts|||0|966|1439|1447
SE|25462511||ab|7|entity|C1274040|result|ftcn|||outcomes|||0|966|1459|1467
SE|25462511||ab|7|entity|C0038492|student|prog|||students|||0|1000|1472|1480


SE|25462512||ti|1|text|21|121|The prevalence of peripheral arterial disease in middle-aged people with intellectual disabilities.
SE|25462512||ti|1|entity|C0085096|Peripheral Vascular Diseases|dsyn|||peripheral arterial disease|||0|1000|39|66
SE|25462512||ti|1|entity|C0205847|Middle Aged|aggp|||middle-aged|||0|901|70|81
SE|25462512||ti|1|entity|C0027361|Persons|popg|||people|||0|901|82|88
SE|25462512||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|94|119
SE|25462512||ti|1|relation|0|0|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||peripheral arterial disease|||0|1000|39|66|INFER|OCCURS_IN(SPEC)||70|88|0|0|C0205847|Middle Aged|aggp,humn|aggp|||middle-aged|||0|901|70|81
SE|25462512||ti|1|relation|0|0|C0205847|Middle Aged|aggp,humn|aggp|||middle-aged|||0|901|70|81|MOD/HEAD|ISA||70|88|0|0|C0027361|Persons|popg,humn|popg|||people|||0|901|82|88
SE|25462512||ti|1|relation|0|0|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|94|119|INFER|PROCESS_OF(SPEC)||70|88|0|0|C0205847|Middle Aged|aggp,humn|aggp|||middle-aged|||0|901|70|81
SE|25462512||ti|1|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|94|119|PREP|PROCESS_OF||89|93|3|1|C0027361|Persons|popg,humn|humn|||people|||0|901|82|88
SE|25462512||ti|1|relation|3|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||peripheral arterial disease|||0|1000|39|66|NOM|OCCURS_IN||25|35|3|2|C0027361|Persons|popg,humn|popg|||people|||0|901|82|88

SE|25462512||ab|1|text|127|245|Peripheral arterial disease (PAD) is a manifestation of atherosclerosis below the bifurcation of the abdominal aorta.
SE|25462512||ab|1|entity|C0085096|Peripheral Vascular Diseases|dsyn|||Peripheral arterial disease|||0|1000|127|154
SE|25462512||ab|1|entity|C0004153|Atherosclerosis|dsyn|||atherosclerosis|||0|861|183|198
SE|25462512||ab|1|entity|C0184906|Bifurcation|topp|||bifurcation|||0|1000|209|220
SE|25462512||ab|1|entity|C0003484|Abdominal aorta structure|bpoc|||abdominal aorta|||0|1000|228|243

SE|25462512||ab|2|text|245|320|PAD increases the risk of cardiovascular disease and associated mortality.
SE|25462512||ab|2|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|245|248
SE|25462512||ab|2|entity|C0035647|Risk|qlco|||risk|||0|1000|263|267
SE|25462512||ab|2|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular disease|||0|1000|271|293
SE|25462512||ab|2|relation|1|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|245|248|COMPLEX|PREDISPOSES||249|267|2|1|C0007222|Cardiovascular Diseases|dsyn|dsyn|||cardiovascular disease|||0|1000|271|293

SE|25462512||ab|3|text|320|424|Little is known about the prevalence of PAD in middle-aged persons with intellectual disabilities (ID).
SE|25462512||ab|3|entity|C0023882|Little's Disease|dsyn|||Little|||0|1000|320|326
SE|25462512||ab|3|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|360|363
SE|25462512||ab|3|entity|C0205847|Middle Aged|aggp|||middle-aged|||0|901|367|378
SE|25462512||ab|3|entity|C0027361|Persons|popg|||persons|||0|901|379|386
SE|25462512||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|392|417
SE|25462512||ab|3|relation|0|0|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|360|363|INFER|OCCURS_IN(SPEC)||367|386|0|0|C0205847|Middle Aged|aggp,humn|aggp|||middle-aged|||0|901|367|378
SE|25462512||ab|3|relation|0|0|C0205847|Middle Aged|aggp,humn|aggp|||middle-aged|||0|901|367|378|MOD/HEAD|ISA||367|386|0|0|C0027361|Persons|popg,humn|popg|||persons|||0|901|379|386
SE|25462512||ab|3|relation|0|0|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|392|417|INFER|PROCESS_OF(SPEC)||367|386|0|0|C0205847|Middle Aged|aggp,humn|aggp|||middle-aged|||0|901|367|378
SE|25462512||ab|3|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|392|417|PREP|PROCESS_OF||387|391|4|1|C0027361|Persons|popg,humn|humn|||persons|||0|901|379|386
SE|25462512||ab|3|relation|3|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|360|363|NOM|OCCURS_IN||346|356|3|2|C0027361|Persons|popg,humn|popg|||persons|||0|901|379|386

SE|25462512||ab|4|text|424|499|We determined the prevalence of PAD among people with ID aged 40-59 years.
SE|25462512||ab|4|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|456|459
SE|25462512||ab|4|entity|C0027361|Persons|popg|||people|||0|1000|466|472
SE|25462512||ab|4|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|478|480
SE|25462512||ab|4|entity|C0439509|/40|tmco|||40-59|||0|802|486|491
SE|25462512||ab|4|entity|C0439234|year|tmco|||years|||0|802|492|497
SE|25462512||ab|4|relation|2|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|478|480|PREP|PROCESS_OF||473|477|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|466|472
SE|25462512||ab|4|relation|4|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|456|459|NOM|OCCURS_IN||442|452|4|2|C0027361|Persons|popg,humn|popg|||people|||0|1000|466|472

SE|25462512||ab|5|text|499|588|Independent associations between PAD and patient and care characteristics were explored.
SE|25462512||ab|5|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|532|535
SE|25462512||ab|5|entity|C0030705|Patients|podg|||patient|||0|1000|540|547
SE|25462512||ab|5|entity|C1521970|Characteristics|grpa|||characteristics|||0|861|557|572

SE|25462512||ab|6|text|588|724|A multi-center cross-sectional observational study was conducted in four care providing agencies for people with ID in the Netherlands.
SE|25462512||ab|6|entity|C1442112|MULTI|qnco|||multi|||0|825|590|595
SE|25462512||ab|6|entity|C0205099|Central|spco|||center|||0|825|596|602
SE|25462512||ab|6|entity|C0552389|CROSS SECTION|orga|||cross-sectional|||0|825|603|618
SE|25462512||ab|6|entity|C1518527|Observational Study|resa|||observational study|||0|825|619|638
SE|25462512||ab|6|entity|C0205450|Four|qnco|||four|||0|764|656|660
SE|25462512||ab|6|entity|C0237463|Agencies|orgt|||agencies|||0|764|676|684
SE|25462512||ab|6|entity|C0027361|Persons|popg|||people|||0|1000|689|695
SE|25462512||ab|6|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|701|703
SE|25462512||ab|6|entity|C0027778|Netherlands|geoa|||Netherlands|||0|861|711|722
SE|25462512||ab|6|relation|2|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|701|703|PREP|PROCESS_OF||696|700|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|689|695

SE|25462512||ab|7|text|724|851|We included 407 participants with mild to profound ID aged 40-59 years, receiving medical care from specialized ID physicians.
SE|25462512||ab|7|entity|C0679646|Participant|popg|||participants|||0|827|740|752
SE|25462512||ab|7|entity|C0547040|Minimal|qlco|||mild|||0|1000|758|762
SE|25462512||ab|7|entity|C0439808|Profound|qlco|||profound|||0|890|766|774
SE|25462512||ab|7|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|890|775|777
SE|25462512||ab|7|entity|C0439509|/40|tmco|||40-59|||0|802|783|788
SE|25462512||ab|7|entity|C0439234|year|tmco|||years|||0|802|789|794
SE|25462512||ab|7|entity|C0496675|Medical care, unspecified|fndg|||medical care|||0|1000|806|818
SE|25462512||ab|7|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|872|836|838
SE|25462512||ab|7|entity|C0334886|Specialized physician|prog|||specialized ID physicians|||0|872|824|849
SE|25462512||ab|7|relation|0|0|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|872|836|838|MOD/HEAD|PROCESS_OF||836|849|0|0|C0334886|Specialized physician|prog,humn|humn|||specialized ID physicians|||0|872|824|849

SE|25462512||ab|8|text|851|902|The ankle-brachial index was used to diagnose PAD.
SE|25462512||ab|8|entity|C1328319|Ankle brachial index|diap|||ankle-brachial index|||0|1000|855|875
SE|25462512||ab|8|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|897|900
SE|25462512||ab|8|relation|1|1|C1328319|Ankle brachial index|diap|diap|||ankle-brachial index|||0|1000|855|875|VERB|DIAGNOSES||888|896|1|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|897|900

SE|25462512||ab|9|text|902|1055|The overall prevalence of PAD was 8.4% (95% CI=6.0-11.4%), with no significant differences between age groups 40-49 years (8.2%) and 50-59 years (8.5%).
SE|25462512||ab|9|entity|C1561607|Overall|qlco|||overall|||0|694|906|913
SE|25462512||ab|9|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|928|931
SE|25462512||ab|9|entity|C0470358|8+4|qnco|||8.4|||0|1000|936|939
SE|25462512||ab|9|entity|C0442748|6/4|fndg|||6|||0|902|949|950
SE|25462512||ab|9|entity|C0750502|Significant|idcn|||significant|||0|872|969|980
SE|25462512||ab|9|entity|C1547020|*Difference|qnco|||differences|||0|872|981|992
SE|25462512||ab|9|entity|C0441833|Groups|inpr|||groups|||0|794|1005|1011
SE|25462512||ab|9|entity|C0439509|/40|tmco|||40-49|||0|794|1012|1017
SE|25462512||ab|9|entity|C1510829|Age-Years|tmco|||age groups 40-49 years|||0|794|1001|1023
SE|25462512||ab|9|entity|C0439234|year|tmco|||years|||0|827|1041|1046

SE|25462512||ab|10|text|1055|1195|None of the participants had been diagnosed with PAD prior to this study and only one participant with PAD had PAD-related symptoms (1/34).
SE|25462512||ab|10|entity|C0679646|Participant|popg|||participants|||0|966|1067|1079
SE|25462512||ab|10|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|1104|1107
SE|25462512||ab|10|entity|C0008972|Clinical Research|resa|||study|||0|1000|1122|1127
SE|25462512||ab|10|entity|C0205447|One|qnco|||one|||0|790|1137|1140
SE|25462512||ab|10|entity|C0679646|Participant|popg|||participant|||0|790|1141|1152
SE|25462512||ab|10|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|1158|1161
SE|25462512||ab|10|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|875|1166|1169
SE|25462512||ab|10|entity|C1522149|Related|ftcn|||related|||0|875|1170|1177
SE|25462512||ab|10|entity|C1457887|Symptoms|sosy|||symptoms|||0|875|1178|1186
SE|25462512||ab|10|relation|1|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|875|1178|1186|AUX|PROCESS_OF||1162|1165|5|2|C0679646|Participant|popg,humn|humn|||participant|||0|790|1141|1152
SE|25462512||ab|10|relation|2|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|1158|1161|PREP|PROCESS_OF||1153|1157|4|1|C0679646|Participant|popg,humn|humn|||participant|||0|790|1141|1152
SE|25462512||ab|10|relation|5|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|1104|1107|VERB|PROCESS_OF||1089|1098|1|1|C0679646|Participant|popg,humn|humn|||participants|||0|966|1067|1079

SE|25462512||ab|11|text|1195|1266|Wheelchair dependence was independently associated with PAD (OR=5.43).
SE|25462512||ab|11|entity|C0043143|wheelchair|medd|||Wheelchair|||0|888|1195|1205
SE|25462512||ab|11|entity|C0439857|Dependence|mobd|||dependence|||0|888|1206|1216
SE|25462512||ab|11|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|1251|1254
SE|25462512||ab|11|relation|1|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|1251|1254|VERB|COEXISTS_WITH||1235|1245|1|1|C0439857|Dependence|mobd|mobd|||dependence|||0|888|1206|1216

SE|25462512||ab|12|text|1266|1371|Prevalence of PAD among people with ID is high, which is especially remarkable in age group 40-49 years.
SE|25462512||ab|12|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|1280|1283
SE|25462512||ab|12|entity|C0027361|Persons|popg|||people|||0|1000|1290|1296
SE|25462512||ab|12|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1302|1304
SE|25462512||ab|12|entity|C0205250|High|qlco|||high|||0|1000|1308|1312
SE|25462512||ab|12|entity|C1550002|Remark|idcn|||remarkable|||0|789|1334|1344
SE|25462512||ab|12|entity|C0441833|Groups|inpr|||group|||0|794|1352|1357
SE|25462512||ab|12|entity|C0439509|/40|tmco|||40-49|||0|794|1358|1363
SE|25462512||ab|12|entity|C1510829|Age-Years|tmco|||age group 40-49 years|||0|794|1348|1369
SE|25462512||ab|12|relation|4|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1302|1304|PREP|PROCESS_OF||1297|1301|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1290|1296
SE|25462512||ab|12|relation|6|1|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||PAD|||0|1000|1280|1283|NOM|OCCURS_IN||1266|1276|6|2|C0027361|Persons|popg,humn|popg|||people|||0|1000|1290|1296

SE|25462512||ab|13|text|1371|1505|Physicians need to be aware of this high prevalence of PAD and the increased risk of cardiovascular disease in (young) people with ID.
SE|25462512||ab|13|entity|C0031831|Physicians|prog|||Physicians|||0|1000|1371|1381
SE|25462512||ab|13|entity|C0004448|Awareness|menp|||aware|||0|928|1393|1398
SE|25462512||ab|13|entity|C1512456|High Prevalence|qnco|||high prevalence|||0|1000|1407|1422
SE|25462512||ab|13|entity|C0085096|Peripheral Vascular Diseases|dsyn|||PAD|||0|1000|1426|1429
SE|25462512||ab|13|entity|C0205217|Increased|qnco|||increased|||0|888|1438|1447
SE|25462512||ab|13|entity|C0035647|Risk|qlco|||risk|||0|888|1448|1452
SE|25462512||ab|13|entity|C0007222|Cardiovascular Diseases|dsyn|||cardiovascular disease|||0|1000|1456|1478
SE|25462512||ab|13|entity|C0332239|Young|tmco|||young|||0|1000|1483|1488
SE|25462512||ab|13|entity|C0027361|Persons|popg|||people|||0|1000|1490|1496
SE|25462512||ab|13|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|983|1502|1504
SE|25462512||ab|13|relation|4|4|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|983|1502|1504|NOM|PREDISPOSES||1448|1452|4|1|C0007222|Cardiovascular Diseases|dsyn|dsyn|||cardiovascular disease|||0|1000|1456|1478


SE|25462513||ti|1|text|21|133|Are early onset aging conditions correlated to daily activity functions in youth and adults with Down syndrome?
SE|25462513||ti|1|entity|C1279919|Early|tmco|||early|||0|825|25|30
SE|25462513||ti|1|entity|C0332162|Onset|qlco|||onset|||0|825|31|36
SE|25462513||ti|1|entity|C0001811|Aging|orgf|||aging|||0|825|37|42
SE|25462513||ti|1|entity|C0348080|Condition|qlco|||conditions|||0|825|43|53
SE|25462513||ti|1|entity|C0871707|Daily Activities|dora|||daily activity|||0|983|68|82
SE|25462513||ti|1|entity|C0087178|Youth|aggp|||youth|||0|1000|96|101
SE|25462513||ti|1|entity|C0001675|Adult|aggp|||adults|||0|1000|106|112
SE|25462513||ti|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|118|131
SE|25462513||ti|1|relation|0|0|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|68|82|INFER|TREATS(INFER)||93|95|0|0|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|118|131
SE|25462513||ti|1|relation|0|0|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|68|82|INFER|TREATS(INFER)||93|95|0|0|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|118|131
SE|25462513||ti|1|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|118|131|PREP|PROCESS_OF||113|117|4|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|106|112
SE|25462513||ti|1|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|118|131|PREP|PROCESS_OF||113|117|4|1|C0087178|Youth|aggp,humn|aggp|||youth|||0|1000|96|101
SE|25462513||ti|1|relation|2|1|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|68|82|PREP|TREATS||93|95|3|1|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|106|112
SE|25462513||ti|1|relation|2|1|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|68|82|PREP|TREATS||93|95|3|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|96|101

SE|25462513||ab|1|text|139|309|This study aims to answer the research question of "Are early onset aging conditions correlated to daily activity functions in youth and adults with Down syndrome (DS)?"
SE|25462513||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|144|149
SE|25462513||ab|1|entity|C0681799|research issue|idcn|||research question|||0|1000|169|186
SE|25462513||ab|1|entity|C1279919|Early|tmco|||early|||0|825|195|200
SE|25462513||ab|1|entity|C0332162|Onset|qlco|||onset|||0|825|201|206
SE|25462513||ab|1|entity|C0001811|Aging|orgf|||aging|||0|825|207|212
SE|25462513||ab|1|entity|C0348080|Condition|qlco|||conditions|||0|825|213|223
SE|25462513||ab|1|entity|C0871707|Daily Activities|dora|||daily activity|||0|983|238|252
SE|25462513||ab|1|entity|C0087178|Youth|aggp|||youth|||0|1000|266|271
SE|25462513||ab|1|entity|C0001675|Adult|aggp|||adults|||0|1000|276|282
SE|25462513||ab|1|entity|C0013080|Down Syndrome|cgab,dsyn|||Down syndrome|||0|1000|288|301
SE|25462513||ab|1|relation|0|0|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|238|252|INFER|TREATS(INFER)||263|265|0|0|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|288|301
SE|25462513||ab|1|relation|0|0|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|238|252|INFER|TREATS(INFER)||263|265|0|0|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|288|301
SE|25462513||ab|1|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|288|301|PREP|PROCESS_OF||283|287|6|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|276|282
SE|25462513||ab|1|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||Down syndrome|||0|1000|288|301|PREP|PROCESS_OF||283|287|6|1|C0087178|Youth|aggp,humn|aggp|||youth|||0|1000|266|271
SE|25462513||ab|1|relation|4|1|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|238|252|PREP|TREATS||263|265|3|1|C0001675|Adult|aggp,humn|aggp|||adults|||0|1000|276|282
SE|25462513||ab|1|relation|4|1|C0871707|Daily Activities|dora|dora|||daily activity|||0|983|238|252|PREP|TREATS||263|265|3|1|C0087178|Youth|aggp,humn|humn|||youth|||0|1000|266|271

SE|25462513||ab|2|text|309|420|A cross-sectional survey was employed to recruit 216 individuals with DS over 15 years of age in the analyses.
SE|25462513||ab|2|entity|C0010362|Cross-Sectional Studies|resa|||cross-sectional survey|||0|1000|311|333
SE|25462513||ab|2|entity|C0237401|Individual|humn|||individuals|||0|861|362|373
SE|25462513||ab|2|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|812|379|381
SE|25462513||ab|2|entity|C0439234|year|tmco|||years|||0|812|390|395
SE|25462513||ab|2|entity|C0001779|Age|orga|||age|||0|1000|399|402
SE|25462513||ab|2|entity|C0936012|Analysis|resa|||analyses|||0|966|410|418

SE|25462513||ab|3|text|420|784|A structured questionnaire included demographic data, brief self-reported aging conditions, Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID) and activity of daily living (ADL) scales were completed by the primary caregivers who were well-suited for providing information on the functioning conditions of the DS individuals.
SE|25462513||ab|3|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|861|433|446
SE|25462513||ab|3|entity|C0011298|Demography|ocdi|||demographic|||0|853|456|467
SE|25462513||ab|3|entity|C1511726|Data|idcn|||data|||0|853|468|472
SE|25462513||ab|3|entity|C1282927|Shortened|tmco|||brief|||0|815|474|479
SE|25462513||ab|3|entity|C0036588|Self|idcn|||self|||0|815|480|484
SE|25462513||ab|3|entity|C0001811|Aging|orgf|||aging|||0|815|494|499
SE|25462513||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|815|500|510
SE|25462513||ab|3|entity|C0497327|Dementia|mobd|||Dementia|||0|901|512|520
SE|25462513||ab|3|entity|C1134635|screening questionnaire|resa|||Screening Questionnaire|||0|901|521|544
SE|25462513||ab|3|entity|C0237401|Individual|humn|||Individuals|||0|1000|549|560
SE|25462513||ab|3|entity|C0453879|Intellectual functioning disability|fndg|||Intellectual Disabilities|||0|983|566|591
SE|25462513||ab|3|entity|C0001288|Activities of Daily Living|dora|||activity of daily living|||0|928|605|629
SE|25462513||ab|3|entity|C0085537|Caregiver|prog|||caregivers|||0|888|673|683
SE|25462513||ab|3|entity|C0205170|Good|qlco|||well|||0|1000|693|697
SE|25462513||ab|3|entity|C1533716|Information|idcn|||information|||0|872|719|730
SE|25462513||ab|3|entity|C0031843|physiological aspects|phsf|||functioning|||0|855|738|749
SE|25462513||ab|3|entity|C0348080|Condition|qlco|||conditions|||0|855|750|760
SE|25462513||ab|3|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|901|768|770
SE|25462513||ab|3|entity|C0237401|Individual|humn|||individuals|||0|901|771|782
SE|25462513||ab|3|relation|0|0|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|901|768|770|MOD/HEAD|PROCESS_OF||768|782|0|0|C0237401|Individual|grup,humn|humn|||individuals|||0|901|771|782
SE|25462513||ab|3|relation|6|1|C0453879|Intellectual functioning disability|fndg|fndg|||Intellectual Disabilities|||0|983|566|591|PREP|PROCESS_OF||561|565|5|1|C0237401|Individual|grup,humn|humn|||Individuals|||0|1000|549|560

SE|25462513||ab|4|text|784|1013|Results showed that the most five frequent aging conditions (sometimes, usually and always) included frailty (20.2%), vision problem (15.8%), loss of language ability (15.3%), sleep problem (14.9%) and memory impairment (14.5%).
SE|25462513||ab|4|entity|C1274040|result|ftcn|||Results|||0|966|784|791
SE|25462513||ab|4|entity|C0205393|Most|qnco|||most|||0|815|808|812
SE|25462513||ab|4|entity|C0205451|Five|qnco|||five|||0|815|813|817
SE|25462513||ab|4|entity|C0332183|Frequent|tmco|||frequent|||0|815|818|826
SE|25462513||ab|4|entity|C0001811|Aging|orgf|||aging|||0|815|827|832
SE|25462513||ab|4|entity|C0348080|Condition|qlco|||conditions|||0|815|833|843
SE|25462513||ab|4|entity|C1549493|Always|idcn|||always|||0|1000|868|874
SE|25462513||ab|4|entity|C0424594|Frailty|fndg|||frailty|||0|861|885|892
SE|25462513||ab|4|entity|C0042798|Visual impairment|fndg|||vision problem|||0|1000|902|916
SE|25462513||ab|4|entity|C1517945|Loss|qnco|||loss|||0|1000|926|930
SE|25462513||ab|4|entity|C1145677|language ability|menp|||language ability|||0|1000|934|950
SE|25462513||ab|4|entity|C0700201|Dyssomnias|dsyn|||sleep problem|||0|1000|960|973
SE|25462513||ab|4|entity|C0233794|Memory impairment|mobd|||memory impairment|||0|1000|986|1003

SE|25462513||ab|5|text|1013|1256|Other onset aging conditions included more chronic diseases (13.9%), hearing loss (13%), chewing ability and tooth loss (12.5%), incontinence (11.1%), depressive syndrome (7.7%), falls and gait disorder (7.2%), loss of taste and smell (7.2%).
SE|25462513||ab|5|entity|C0332162|Onset|qlco|||onset|||0|840|1019|1024
SE|25462513||ab|5|entity|C0001811|Aging|orgf|||aging|||0|840|1025|1030
SE|25462513||ab|5|entity|C0348080|Condition|qlco|||conditions|||0|840|1031|1041
SE|25462513||ab|5|entity|C0205172|More|ftcn|||more|||0|901|1051|1055
SE|25462513||ab|5|entity|C0008679|Chronic Disease|dsyn|||chronic diseases|||0|901|1056|1072
SE|25462513||ab|5|entity|C1384666|hearing impairment|sosy|||hearing loss|||0|1000|1082|1094
SE|25462513||ab|5|entity|C0085732|Ability|orga|||ability|||0|1000|1110|1117
SE|25462513||ab|5|entity|C0080233|Tooth Loss|acab,dsyn|||tooth loss|||0|1000|1122|1132
SE|25462513||ab|5|entity|C0021167|Incontinence|dsyn|||incontinence|||0|1000|1142|1154
SE|25462513||ab|5|entity|C0086133|Depressive Syndrome|mobd|||depressive syndrome|||0|1000|1164|1183
SE|25462513||ab|5|entity|C0470355|7+7|qnco|||7.7|||0|1000|1185|1188
SE|25462513||ab|5|entity|C0085639|Falls|fndg|||falls|||0|1000|1192|1197
SE|25462513||ab|5|entity|C0575081|Gait abnormality|sosy|||gait disorder|||0|1000|1202|1215
SE|25462513||ab|5|entity|C1517945|Loss|qnco|||loss|||0|1000|1224|1228

SE|25462513||ab|6|text|1256|1399|The data also showed scores of DSQIID, onset aging conditions and ADL has significant relationships each other in Pearson's correlation tests.
SE|25462513||ab|6|entity|C1511726|Data|idcn|||data|||0|1000|1260|1264
SE|25462513||ab|6|entity|C0449820|Score|qnco|||scores|||0|1000|1277|1283
SE|25462513||ab|6|entity|C0332162|Onset|qlco|||onset|||0|840|1295|1300
SE|25462513||ab|6|entity|C0001811|Aging|orgf|||aging|||0|840|1301|1306
SE|25462513||ab|6|entity|C0348080|Condition|qlco|||conditions|||0|840|1307|1317
SE|25462513||ab|6|entity|C0001288|Activities of Daily Living|dora|||ADL|||0|1000|1322|1325
SE|25462513||ab|6|entity|C0750502|Significant|idcn|||significant|||0|888|1330|1341
SE|25462513||ab|6|entity|C0439849|Relationships|qlco|||relationships|||0|888|1342|1355
SE|25462513||ab|6|entity|C0392366|Tests|inpr|||tests|||0|827|1392|1397

SE|25462513||ab|7|text|1399|1598|Finally, multiple linear regression analyses indicated onset aging conditions (beta=-0.735, p<0.001) can significantly predicted the variation in ADL scores after adjusting other factors (R2=0.381).
SE|25462513||ab|7|entity|C0439064|Numerous|qnco|||multiple|||0|861|1408|1416
SE|25462513||ab|7|entity|C0205132|Linear|spco|||linear|||0|861|1417|1423
SE|25462513||ab|7|entity|C0034980|Regression Analysis|qnco|||regression analyses|||0|861|1424|1443
SE|25462513||ab|7|entity|C0332162|Onset|qlco|||onset|||0|840|1454|1459
SE|25462513||ab|7|entity|C0001811|Aging|orgf|||aging|||0|840|1460|1465
SE|25462513||ab|7|entity|C0348080|Condition|qlco|||conditions|||0|840|1466|1476
SE|25462513||ab|7|entity|C0205419|Variant|qlco|||variation|||0|1000|1532|1541
SE|25462513||ab|7|entity|C0001288|Activities of Daily Living|dora|||ADL|||0|876|1545|1548
SE|25462513||ab|7|entity|C0449820|Score|qnco|||scores|||0|876|1549|1555
SE|25462513||ab|7|entity|C1439356|ADJUSTED|qlco|||adjusting|||0|966|1562|1571
SE|25462513||ab|7|entity|C1521761|Factor|ftcn|||factors|||0|966|1578|1585

SE|25462513||ab|8|text|1598|1747|This study suggests that the authority should initiate early intervention programs aim to improve healthy aging and ADL functions for people with DS.
SE|25462513||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1603|1608
SE|25462513||ab|8|entity|C0599437|Authority|socb|||authority|||0|1000|1627|1636
SE|25462513||ab|8|entity|C1279919|Early|tmco|||early|||0|890|1653|1658
SE|25462513||ab|8|entity|C0599917|intervention program|topp|||intervention programs|||0|890|1659|1680
SE|25462513||ab|8|entity|C0018684|Health|idcn|||healthy|||0|853|1696|1703
SE|25462513||ab|8|entity|C0001811|Aging|orgf|||aging|||0|853|1704|1709
SE|25462513||ab|8|entity|C0001288|Activities of Daily Living|dora|||ADL|||0|928|1714|1717
SE|25462513||ab|8|entity|C0542341|Function|ftcn|||functions|||0|928|1718|1727
SE|25462513||ab|8|entity|C0027361|Persons|popg|||people|||0|1000|1732|1738
SE|25462513||ab|8|entity|C0013080|Down Syndrome|cgab,dsyn|||DS|||0|1000|1744|1746
SE|25462513||ab|8|relation|1|1|C0013080|Down Syndrome|cgab,dsyn|dsyn|||DS|||0|1000|1744|1746|PREP|PROCESS_OF||1739|1743|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1732|1738


SE|25462514||ti|1|text|21|138|Validity and reliability of the Spanish version of the diagnostic assessment for the severely handicapped (DASH-II).
SE|25462514||ti|1|entity|C0086409|Hispanics|popg|||Spanish|||0|888|53|60
SE|25462514||ti|1|entity|C0333052|Version|ftcn|||version|||0|888|61|68
SE|25462514||ti|1|entity|C0431080|Diagnostic assessment|diap|||diagnostic assessment|||0|1000|76|97
SE|25462514||ti|1|entity|C0205082|Severe|qlco|||severely|||0|1000|106|114

SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|text|144|321|BACKGROUND AND OBJECTIVES: The DASH-II scale is a specific instrument for measuring psychopathological symptoms in people with severe and profound intellectual disability (ID).
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0018017|objective (goal)|inpr|||OBJECTIVES|||0|1000|159|169
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0348000|Instrument|mnob|||instrument|||0|861|203|213
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0079809|Measures|qnco|||measuring|||0|816|218|227
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0033927|Psychopathology|bmod|||psychopathological|||0|816|228|246
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C1457887|Symptoms|sosy|||symptoms|||0|816|247|255
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0027361|Persons|popg|||people|||0|1000|259|265
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0205082|Severe|qlco|||severe|||0|1000|271|277
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0439808|Profound|qlco|||profound|||0|901|282|290
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|901|291|314
SE|25462514|BACKGROUND AND OBJECTIVES|ab|1|relation|5|1|C1457887|Symptoms|sosy|sosy|||symptoms|||0|816|247|255|PREP|PROCESS_OF||256|258|3|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|259|265

SE|25462514|BACKGROUND AND OBJECTIVES|ab|2|text|321|425|The aim of the study is the validation of the Spanish version, evaluating its reliability and validity.
SE|25462514|BACKGROUND AND OBJECTIVES|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|336|341
SE|25462514|BACKGROUND AND OBJECTIVES|ab|2|entity|C1519941|Validation|resa|||validation|||0|1000|349|359
SE|25462514|BACKGROUND AND OBJECTIVES|ab|2|entity|C0086409|Hispanics|popg|||Spanish|||0|888|367|374
SE|25462514|BACKGROUND AND OBJECTIVES|ab|2|entity|C0333052|Version|ftcn|||version|||0|888|375|382

SE|25462514|BACKGROUND AND OBJECTIVES|ab|3|text|425|503|At the same time we examine the prevalence of mental disorders in our sample.
SE|25462514|BACKGROUND AND OBJECTIVES|ab|3|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|471|487

SE|25462514|MATERIAL AND METHODS|ab|4|text|503|657|MATERIAL AND METHODS: Two reviewers independently passed the Spanish version of the DASH-II (DASH-II-S) to 83 users to establish inter-rater reliability.
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C0520510|Materials|sbst|||MATERIAL|||0|1000|503|511
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|516|523
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C0205448|Two|qnco|||Two|||0|694|525|528
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C0086409|Hispanics|popg|||Spanish|||0|888|564|571
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C0333052|Version|ftcn|||version|||0|888|572|579
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C1548600|User|idcn|||users|||0|827|613|618
SE|25462514|MATERIAL AND METHODS|ab|4|entity|C0205103|Intermediate|spco|||inter|||0|660|632|637

SE|25462514|MATERIAL AND METHODS|ab|5|text|657|787|To assess inter-rater reliability or test-retest reliability, fifty participants were reassessed by the same rater within 7 days.
SE|25462514|MATERIAL AND METHODS|ab|5|entity|C0205103|Intermediate|spco|||inter|||0|660|667|672
SE|25462514|MATERIAL AND METHODS|ab|5|entity|C0039593|Testing|resa|||test|||0|1000|694|698
SE|25462514|MATERIAL AND METHODS|ab|5|entity|C0679646|Participant|popg|||participants|||0|827|725|737
SE|25462514|MATERIAL AND METHODS|ab|5|entity|C0445247|Same|qlco|||same|||0|694|761|765
SE|25462514|MATERIAL AND METHODS|ab|5|entity|C1547085|7 days|tmco|||7 days|||0|1000|779|785

SE|25462514|RESULTS|ab|6|text|787|926|RESULTS: DASH-II-S showed good internal consistency (Cronbach's alpha=0.879) and good reliability, both intra and inter-rater reliability.
SE|25462514|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|787|794
SE|25462514|RESULTS|ab|6|entity|C0205170|Good|qlco|||good|||0|901|813|817
SE|25462514|RESULTS|ab|6|entity|C0870731|Internal Consistency|qnco|||internal consistency|||0|901|818|838
SE|25462514|RESULTS|ab|6|entity|C0439095|Alpha|inpr|||alpha|||0|861|851|856
SE|25462514|RESULTS|ab|6|entity|C0205170|Good|qlco|||good|||0|694|868|872
SE|25462514|RESULTS|ab|6|entity|C0347985|During values|tmco|||intra|||0|1000|891|896
SE|25462514|RESULTS|ab|6|entity|C0205103|Intermediate|spco|||inter|||0|660|901|906

SE|25462514|RESULTS|ab|7|text|926|1079|The prevalence of psychopathology in the sample is 94%, and the use of psychotropic drugs is also high, with 61.4% receiving one or more antipsychotics.
SE|25462514|RESULTS|ab|7|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|1000|944|959
SE|25462514|RESULTS|ab|7|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic drugs|||0|1000|997|1015
SE|25462514|RESULTS|ab|7|entity|C0205250|High|qlco|||high|||0|861|1024|1028
SE|25462514|RESULTS|ab|7|entity|C1514756|Received|qlco|||receiving|||0|733|1041|1050
SE|25462514|RESULTS|ab|7|entity|C0205447|One|qnco|||one|||0|733|1051|1054
SE|25462514|RESULTS|ab|7|entity|C0205172|More|ftcn|||more|||0|888|1058|1062
SE|25462514|RESULTS|ab|7|entity|C0040615|Antipsychotic Agents|phsu|||antipsychotics|||0|888|1063|1077
SE|25462514|RESULTS|ab|7|relation|0|0|C0040615|Antipsychotic Agents|phsu|phsu|||antipsychotics|||0|888|1063|1077|SPEC|ISA||997|1077|0|0|C0033978|Psychotropic Drugs|phsu|phsu|||psychotropic drugs|||0|1000|997|1015

SE|25462514|CONCLUSIONS|ab|8|text|1079|1211|CONCLUSIONS: DASH-II-S is a valid and reliable instrument that can be used for the assessment of psychopathology in people with ID.
SE|25462514|CONCLUSIONS|ab|8|entity|C0348000|Instrument|mnob|||instrument|||0|861|1126|1136
SE|25462514|CONCLUSIONS|ab|8|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|1162|1172
SE|25462514|CONCLUSIONS|ab|8|entity|C0033927|Psychopathology|bmod|||psychopathology|||0|1000|1176|1191
SE|25462514|CONCLUSIONS|ab|8|entity|C0027361|Persons|popg|||people|||0|1000|1195|1201
SE|25462514|CONCLUSIONS|ab|8|entity|C0453879|Intellectual functioning disability|fndg|||ID|||0|1000|1207|1209
SE|25462514|CONCLUSIONS|ab|8|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||ID|||0|1000|1207|1209|PREP|PROCESS_OF||1202|1206|7|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|1195|1201

SE|25462514|CONCLUSIONS|ab|9|text|1211|1303|The translated version retains the psychometric properties of the original English version.
SE|25462514|CONCLUSIONS|ab|9|entity|C0040710|Translating|ocac,ocdi|||translated|||0|872|1215|1225
SE|25462514|CONCLUSIONS|ab|9|entity|C0333052|Version|ftcn|||version|||0|872|1226|1233
SE|25462514|CONCLUSIONS|ab|9|entity|C0033920|Psychometrics|diap|||psychometric|||0|872|1246|1258
SE|25462514|CONCLUSIONS|ab|9|entity|C0871161|Property|qlco|||properties|||0|872|1259|1269
SE|25462514|CONCLUSIONS|ab|9|entity|C0205313|Original|idcn|||original|||0|802|1277|1285
SE|25462514|CONCLUSIONS|ab|9|entity|C0333052|Version|ftcn|||version|||0|802|1294|1301

SE|25462514|CONCLUSIONS|ab|10|text|1303|1488|Moreover, the high prevalence of mental disorders in this population may explain the widespread use of psychotropic drugs, but it forces us to continuous reassessment and justification.
SE|25462514|CONCLUSIONS|ab|10|entity|C1512456|High Prevalence|qnco|||high prevalence|||0|1000|1317|1332
SE|25462514|CONCLUSIONS|ab|10|entity|C0004936|Mental disorders|mobd|||mental disorders|||0|1000|1336|1352
SE|25462514|CONCLUSIONS|ab|10|entity|C1257890|Population Group|popg|||population|||0|1000|1361|1371
SE|25462514|CONCLUSIONS|ab|10|entity|C0205391|Widespread|spco|||widespread|||0|888|1388|1398
SE|25462514|CONCLUSIONS|ab|10|entity|C0033978|Psychotropic Drugs|phsu|||psychotropic drugs|||0|1000|1406|1424
SE|25462514|CONCLUSIONS|ab|10|entity|C0549178|Continuous|tmco|||continuous|||0|694|1446|1456
SE|25462514|CONCLUSIONS|ab|10|entity|C0392360|Reason for|idcn|||justification|||0|1000|1474|1487
SE|25462514|CONCLUSIONS|ab|10|relation|2|1|C0004936|Mental disorders|mobd|mobd|||mental disorders|||0|1000|1336|1352|PREP|PROCESS_OF||1353|1355|5|1|C1257890|Population Group|popg,humn|humn|||population|||0|1000|1361|1371


SE|25462515||ti|1|text|21|141|Psychometric properties of the Italian version of the Developmental Coordination Disorder Questionnaire (DCDQ-Italian).
SE|25462515||ti|1|entity|C0033920|Psychometrics|diap|||Psychometric|||0|872|21|33
SE|25462515||ti|1|entity|C0871161|Property|qlco|||properties|||0|872|34|44
SE|25462515||ti|1|entity|C0337810|Italians|popg|||Italian|||0|888|52|59
SE|25462515||ti|1|entity|C0333052|Version|ftcn|||version|||0|888|60|67
SE|25462515||ti|1|entity|C0011757|Developmental Coordination Disorder|dsyn|||Developmental Coordination Disorder|||0|916|75|110
SE|25462515||ti|1|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|916|111|124
SE|25462515||ti|1|entity|C0337810|Italians|popg|||Italian|||0|861|131|138

SE|25462515||ab|1|text|147|327|A valid tool that contributes to the diagnosis of Developmental Coordination Disorder (DCD) is represented by the Developmental Coordination Disorder Questionnaire 2007 (DCDQ'07).
SE|25462515||ab|1|entity|C0336791|Tool|mnob|||tool|||0|861|155|159
SE|25462515||ab|1|entity|C0011900|Diagnosis|hlca|||diagnosis|||0|1000|184|193
SE|25462515||ab|1|entity|C0011757|Developmental Coordination Disorder|dsyn|||Developmental Coordination Disorder|||0|1000|197|232
SE|25462515||ab|1|entity|C0608070|dicarboxydine|hops,orch|||DCD|||0|1000|234|237
SE|25462515||ab|1|entity|C0011757|Developmental Coordination Disorder|dsyn|||Developmental Coordination Disorder|||0|854|261|296
SE|25462515||ab|1|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|854|297|310

SE|25462515||ab|2|text|327|393|Recently we developed the Italian version of DCDQ (DCDQ-Italian).
SE|25462515||ab|2|entity|C0332185|Recent|tmco|||Recently|||0|1000|327|335
SE|25462515||ab|2|entity|C0337810|Italians|popg|||Italian|||0|888|353|360
SE|25462515||ab|2|entity|C0333052|Version|ftcn|||version|||0|888|361|368
SE|25462515||ab|2|entity|C0337810|Italians|popg|||Italian|||0|861|383|390

SE|25462515||ab|3|text|393|581|The aim of this study was to further analyze the psychometric properties in a sample of Italian school children aged 5-12 years and to establish cut-off scores with respect to age groups.
SE|25462515||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|409|414
SE|25462515||ab|3|entity|C1517331|Further|spco|||further|||0|1000|422|429
SE|25462515||ab|3|entity|C0033920|Psychometrics|diap|||psychometric|||0|872|442|454
SE|25462515||ab|3|entity|C0871161|Property|qlco|||properties|||0|872|455|465
SE|25462515||ab|3|entity|C0337810|Italians|popg|||Italian|||0|901|481|488
SE|25462515||ab|3|entity|C0260267|School child|aggp|||school children|||0|901|489|504
SE|25462515||ab|3|entity|C0439084|>5|qnco|||5-12|||0|802|510|514
SE|25462515||ab|3|entity|C0439234|year|tmco|||years|||0|802|515|520
SE|25462515||ab|3|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|888|538|545
SE|25462515||ab|3|entity|C0449820|Score|qnco|||scores|||0|888|546|552
SE|25462515||ab|3|entity|C0027362|Human Age Group|aggp|||age groups|||0|1000|569|579

SE|25462515||ab|4|text|581|701|A total of 698 parents completed the DCDQ-Italian and 45 of them repeated it after 2 weeks for test-retest reliability.
SE|25462515||ab|4|entity|C0439175|% of total|qnco|||total|||0|1000|583|588
SE|25462515||ab|4|entity|C0030551|parent|famg|||parents|||0|861|596|603
SE|25462515||ab|4|entity|C0337810|Italians|popg|||Italian|||0|861|623|630
SE|25462515||ab|4|entity|C1442457|2 Weeks|tmco|||2 weeks|||0|1000|664|671
SE|25462515||ab|4|entity|C0039593|Testing|resa|||test|||0|1000|676|680

SE|25462515||ab|5|text|701|800|One hundred and seventeen children were tested using the Movement Assessment Battery for Children.
SE|25462515||ab|5|entity|C0205447|One|qnco|||One|||0|1000|701|704
SE|25462515||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|861|727|735
SE|25462515||ab|5|entity|C0026649|Movement|orgf|||Movement|||0|623|758|766
SE|25462515||ab|5|entity|C0220825|Evaluation|ftcn|||Assessment|||0|623|767|777
SE|25462515||ab|5|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|790|798

SE|25462515||ab|6|text|800|888|Confirmatory factor analysis supported this version to be consistent with the original.
SE|25462515||ab|6|entity|C0870334|Confirmatory Factor Analysis|qlco|||Confirmatory factor analysis|||0|1000|800|828
SE|25462515||ab|6|entity|C0333052|Version|ftcn|||version|||0|1000|844|851
SE|25462515||ab|6|entity|C0205313|Original|idcn|||original|||0|1000|878|886

SE|25462515||ab|7|text|888|972|Cronbach's alpha for the total score was 0.89 and test-retest reliability was 0.88.
SE|25462515||ab|7|entity|C0439095|Alpha|inpr|||alpha|||0|861|899|904
SE|25462515||ab|7|entity|C0439175|% of total|qnco|||total|||0|888|913|918
SE|25462515||ab|7|entity|C0449820|Score|qnco|||score|||0|888|919|924
SE|25462515||ab|7|entity|C0039593|Testing|resa|||test|||0|1000|938|942

SE|25462515||ab|8|text|972|1090|Two-ways ANOVA for total and single subscales showed a significant main effect for age group only and not for gender.
SE|25462515||ab|8|entity|C0205448|Two|qnco|||Two|||0|802|972|975
SE|25462515||ab|8|entity|C0002780|Analysis of Variance|qnco|||ANOVA|||0|802|981|986
SE|25462515||ab|8|entity|C0439175|% of total|qnco|||total|||0|1000|991|996
SE|25462515||ab|8|entity|C0037179|Unmarried person|popg|||single|||0|694|1001|1007
SE|25462515||ab|8|entity|C0750502|Significant|idcn|||significant|||0|851|1027|1038
SE|25462515||ab|8|entity|C0205225|Primary|qlco|||main|||0|851|1039|1043
SE|25462515||ab|8|entity|C1280500|Effect|qlco|||effect|||0|851|1044|1050
SE|25462515||ab|8|entity|C0027362|Human Age Group|aggp|||age group|||0|901|1055|1064
SE|25462515||ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1074|1077
SE|25462515||ab|8|entity|C0079399|Gender|orga|||gender|||0|1000|1082|1088

SE|25462515||ab|9|text|1090|1317|Sensitivity and specificity for our community based sample were 59% and 65% respectively, considering the cut-off scores for the 15th percentile of M-ABC and increasing when age groups were taken into account (ROC curve=0.62).
SE|25462515||ab|9|entity|C0036668|Sensitivity and Specificity|qnco|||Sensitivity and specificity|||0|1000|1090|1117
SE|25462515||ab|9|entity|C0009462|Community|geoa|||community|||0|606|1126|1135
SE|25462515||ab|9|entity|C1442160|CUTOFF|ftcn|||cut-off|||0|888|1196|1203
SE|25462515||ab|9|entity|C0449820|Score|qnco|||scores|||0|888|1204|1210
SE|25462515||ab|9|entity|C1264641|Percentile|qnco|||percentile|||0|861|1224|1234
SE|25462515||ab|9|entity|C0441923|M+|inpr|||M-ABC|||0|888|1238|1243
SE|25462515||ab|9|entity|C0683712|alcoholic beverage control board|orgt|||M-ABC|||0|888|1238|1243
SE|25462515||ab|9|entity|C0442808|Increasing|ftcn|||increasing|||0|1000|1248|1258
SE|25462515||ab|9|entity|C0027362|Human Age Group|aggp|||age groups|||0|1000|1264|1274
SE|25462515||ab|9|entity|C1551359|account|idcn|||account|||0|1000|1291|1298
SE|25462515||ab|9|entity|C0035787|ROC Curve|qnco|||ROC curve|||0|1000|1300|1309

SE|25462515||ab|10|text|1317|1381|The agreement with the original was good if 15th is considered.
SE|25462515||ab|10|entity|C0680240|Agreement|socb|||agreement|||0|1000|1321|1330
SE|25462515||ab|10|entity|C0205313|Original|idcn|||original|||0|1000|1340|1348
SE|25462515||ab|10|entity|C0205170|Good|qlco|||good|||0|1000|1353|1357

SE|25462515||ab|11|text|1381|1485|This is the first study on the psychometric property of DCDQ in a community sample of Italian children.
SE|25462515||ab|11|entity|C1279901|Firstly|qlco|||first|||0|888|1393|1398
SE|25462515||ab|11|entity|C0008972|Clinical Research|resa|||study|||0|888|1399|1404
SE|25462515||ab|11|entity|C0033920|Psychometrics|diap|||psychometric|||0|888|1412|1424
SE|25462515||ab|11|entity|C0871161|Property|qlco|||property|||0|888|1425|1433
SE|25462515||ab|11|entity|C0009462|Community|geoa|||community|||0|694|1447|1456
SE|25462515||ab|11|entity|C0337810|Italians|popg|||Italian|||0|888|1467|1474
SE|25462515||ab|11|entity|C0008059|Child|aggp,inpr|||children|||0|888|1475|1483

SE|25462515||ab|12|text|1485|1593|The DCDQ-Italian could be used as a screening tool for motor coordination difficulties in Italian children.
SE|25462515||ab|12|entity|C0337810|Italians|popg|||Italian|||0|861|1494|1501
SE|25462515||ab|12|entity|C0220908|Screening procedure|hlca|||screening|||0|888|1521|1530
SE|25462515||ab|12|entity|C0336791|Tool|mnob|||tool|||0|888|1531|1535
SE|25462515||ab|12|entity|C0237543|motor coordination|ortf|||motor coordination|||0|890|1540|1558
SE|25462515||ab|12|entity|C0337810|Italians|popg|||Italian|||0|888|1575|1582
SE|25462515||ab|12|entity|C0008059|Child|aggp,inpr|||children|||0|888|1583|1591

SE|25462515||ab|13|text|1593|1669|Slight differences in cut-offs should be considered when using this version.
SE|25462515||ab|13|entity|C0547040|Minimal|qlco|||Slight|||0|872|1593|1599
SE|25462515||ab|13|entity|C1547020|*Difference|qnco|||differences|||0|872|1600|1611
SE|25462515||ab|13|entity|C1442160|CUTOFF|ftcn|||cut-offs|||0|966|1615|1623
SE|25462515||ab|13|entity|C0333052|Version|ftcn|||version|||0|1000|1661|1668


SE|25462517||ti|1|text|21|118|Music lessons are associated with increased verbal memory in individuals with Williams syndrome.
SE|25462517||ti|1|entity|C0026867|Music|inpr|||Music|||0|694|21|26
SE|25462517||ti|1|entity|C0205217|Increased|qnco|||increased|||0|851|55|64
SE|25462517||ti|1|entity|C0439824|Verbal|orgf|||verbal|||0|851|65|71
SE|25462517||ti|1|entity|C0025260|Memory|menp|||memory|||0|851|72|78
SE|25462517||ti|1|entity|C0237401|Individual|humn|||individuals|||0|1000|82|93
SE|25462517||ti|1|entity|C0175702|Williams Syndrome|dsyn|||Williams syndrome|||0|1000|99|116
SE|25462517||ti|1|relation|1|1|C0175702|Williams Syndrome|dsyn|dsyn|||Williams syndrome|||0|1000|99|116|PREP|PROCESS_OF||94|98|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|82|93
SE|25462517||ti|1|relation|2|1|C0025260|Memory|menp|menp|||memory|||0|851|72|78|PREP|PROCESS_OF||79|81|2|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|82|93

SE|25462517||ab|1|text|124|232|Williams syndrome (WS) is a genetic disorder characterized by intellectual delay and an affinity for music.
SE|25462517||ab|1|entity|C0175702|Williams Syndrome|dsyn|||Williams syndrome|||0|1000|124|141
SE|25462517||ab|1|entity|C0019247|Hereditary Diseases|dsyn|||genetic disorder|||0|1000|152|168
SE|25462517||ab|1|entity|C0205421|Deferred|tmco|||delay|||0|861|199|204
SE|25462517||ab|1|entity|C0026867|Music|inpr|||music|||0|1000|225|230
SE|25462517||ab|1|relation|0|0|C0175702|Williams Syndrome|dsyn|dsyn|||Williams syndrome|||0|1000|124|141|SPEC|ISA||124|168|0|0|C0019247|Hereditary Diseases|dsyn|dsyn|||genetic disorder|||0|1000|152|168

SE|25462517||ab|2|text|232|359|It has been previously shown that familiar music can enhance verbal memory in individuals with WS who have had music training.
SE|25462517||ab|2|entity|C0026867|Music|inpr|||music|||0|861|275|280
SE|25462517||ab|2|entity|C0439824|Verbal|orgf|||verbal|||0|888|293|299
SE|25462517||ab|2|entity|C0025260|Memory|menp|||memory|||0|888|300|306
SE|25462517||ab|2|entity|C0237401|Individual|humn|||individuals|||0|1000|310|321
SE|25462517||ab|2|entity|C0175702|Williams Syndrome|dsyn|||WS|||0|1000|327|329
SE|25462517||ab|2|entity|C0026867|Music|inpr|||music|||0|888|343|348
SE|25462517||ab|2|entity|C0220931|Training|edac|||training|||0|888|349|357
SE|25462517||ab|2|relation|2|1|C0025260|Memory|menp|menp|||memory|||0|888|300|306|PREP|PROCESS_OF||307|309|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|310|321
SE|25462517||ab|2|relation|2|1|C0175702|Williams Syndrome|dsyn|dsyn|||WS|||0|1000|327|329|PREP|PROCESS_OF||322|326|3|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|310|321

SE|25462517||ab|3|text|359|450|There is also evidence that unfamiliar, or novel, music may also improve cognitive recall.
SE|25462517||ab|3|entity|C0679622|novel|inpr|||novel|||0|888|402|407
SE|25462517||ab|3|entity|C0026867|Music|inpr|||music|||0|888|409|414
SE|25462517||ab|3|entity|C1516691|Cognitive|ftcn|||cognitive|||0|694|432|441

SE|25462517||ab|4|text|450|626|This study was designed to examine if a novel melody could also enhance verbal memory in individuals with WS, and to more fully characterize music training in this population.
SE|25462517||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|455|460
SE|25462517||ab|4|entity|C0679622|novel|inpr|||novel|||0|694|490|495
SE|25462517||ab|4|entity|C0439824|Verbal|orgf|||verbal|||0|888|522|528
SE|25462517||ab|4|entity|C0025260|Memory|menp|||memory|||0|888|529|535
SE|25462517||ab|4|entity|C0237401|Individual|humn|||individuals|||0|1000|539|550
SE|25462517||ab|4|entity|C0175702|Williams Syndrome|dsyn|||WS|||0|1000|556|558
SE|25462517||ab|4|entity|C0026867|Music|inpr|||music|||0|888|591|596
SE|25462517||ab|4|entity|C0220931|Training|edac|||training|||0|888|597|605
SE|25462517||ab|4|entity|C1257890|Population Group|popg|||population|||0|1000|614|624
SE|25462517||ab|4|relation|3|1|C0025260|Memory|menp|menp|||memory|||0|888|529|535|PREP|PROCESS_OF||536|538|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|539|550
SE|25462517||ab|4|relation|3|1|C0175702|Williams Syndrome|dsyn|dsyn|||WS|||0|1000|556|558|PREP|PROCESS_OF||551|555|4|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|539|550
SE|25462517||ab|4|relation|6|4|C0025260|Memory|menp|menp|||memory|||0|888|529|535|PREP|PROCESS_OF||606|608|1|1|C1257890|Population Group|popg,humn|humn|||population|||0|1000|614|624

SE|25462517||ab|5|text|626|833|We presented spoken or sung sentences that described an animal and its group name to 44 individuals with WS, and then tested their immediate and delayed memory using both recall and multiple choice formats.
SE|25462517||ab|5|entity|C0234856|Speaking|dora|||spoken|||0|966|639|645
SE|25462517||ab|5|entity|C0234857|Singing|inbe|||sung|||0|872|649|653
SE|25462517||ab|5|entity|C0876929|Sentences|inpr|||sentences|||0|872|654|663
SE|25462517||ab|5|entity|C0003043|Animalia|anim|||animal|||0|1000|682|688
SE|25462517||ab|5|entity|C0441833|Groups|inpr|||group|||0|888|697|702
SE|25462517||ab|5|entity|C0027365|Name|inpr|||name|||0|888|703|707
SE|25462517||ab|5|entity|C0237401|Individual|humn|||individuals|||0|861|714|725
SE|25462517||ab|5|entity|C0175702|Williams Syndrome|dsyn|||WS|||0|1000|731|733
SE|25462517||ab|5|entity|C0205253|Immediate|tmco|||immediate|||0|1000|757|766
SE|25462517||ab|5|entity|C0376364|Delayed Memory|menp|||delayed memory|||0|1000|771|785
SE|25462517||ab|5|entity|C0439064|Numerous|qnco|||multiple|||0|785|808|816
SE|25462517||ab|5|entity|C1301627|Format|inpr|||formats|||0|785|824|831
SE|25462517||ab|5|relation|5|1|C0175702|Williams Syndrome|dsyn|dsyn|||WS|||0|1000|731|733|PREP|PROCESS_OF||726|730|5|1|C0237401|Individual|grup,humn|humn|||individuals|||0|861|714|725

SE|25462517||ab|6|text|833|1061|Those with formal music training (average duration of training 41/2 years) scored significantly higher on both the spoken and sung recall items, as well as on the spoken multiple choice items, than those with no music training.
SE|25462517||ab|6|entity|C0376315|Manufactured form|mnob|||formal|||0|751|844|850
SE|25462517||ab|6|entity|C0026867|Music|inpr|||music|||0|751|851|856
SE|25462517||ab|6|entity|C0220931|Training|edac|||training|||0|751|857|865
SE|25462517||ab|6|entity|C1510992|Average|qnco|||average|||0|888|867|874
SE|25462517||ab|6|entity|C0449238|Duration|tmco|||duration|||0|888|875|883
SE|25462517||ab|6|entity|C0220931|Training|edac|||training|||0|791|887|895
SE|25462517||ab|6|entity|C0439234|year|tmco|||years|||0|791|901|906
SE|25462517||ab|6|entity|C0205250|High|qlco|||higher|||0|827|929|935
SE|25462517||ab|6|entity|C0234856|Speaking|dora|||spoken|||0|966|948|954
SE|25462517||ab|6|entity|C0234857|Singing|inbe|||sung|||0|627|959|963
SE|25462517||ab|6|entity|C0234856|Speaking|dora|||spoken|||0|566|996|1002
SE|25462517||ab|6|entity|C0439064|Numerous|qnco|||multiple|||0|566|1003|1011
SE|25462517||ab|6|entity|C0026867|Music|inpr|||music|||0|888|1045|1050
SE|25462517||ab|6|entity|C0220931|Training|edac|||training|||0|888|1051|1059

SE|25462517||ab|7|text|1061|1160|Music therapy, music enjoyment, age, and Verbal IQ did not impact performance on the memory tasks.
SE|25462517||ab|7|entity|C0026868|Music Therapy|topp|||Music therapy|||0|1000|1061|1074
SE|25462517||ab|7|entity|C0026867|Music|inpr|||music|||0|888|1076|1081
SE|25462517||ab|7|entity|C0679105|pleasurable emotion|menp|||enjoyment|||0|888|1082|1091
SE|25462517||ab|7|entity|C0001779|Age|orga|||age|||0|1000|1093|1096
SE|25462517||ab|7|entity|C0439824|Verbal|orgf|||Verbal|||0|888|1102|1108
SE|25462517||ab|7|entity|C1518422|Not|ftcn|||not|||0|851|1116|1119
SE|25462517||ab|7|entity|C0597198|Performance|inbe|||performance|||0|851|1127|1138
SE|25462517||ab|7|entity|C0025260|Memory|menp|||memory|||0|872|1146|1152

SE|25462517||ab|8|text|1160|1378|These findings provide further evidence that formal music lessons may impact the neurological pathways associated with verbal memory in individuals with WS, consistent with findings in typically developing individuals.
SE|25462517||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1166|1174
SE|25462517||ab|8|entity|C1517331|Further|spco|||further|||0|694|1183|1190
SE|25462517||ab|8|entity|C0376315|Manufactured form|mnob|||formal|||0|587|1205|1211
SE|25462517||ab|8|entity|C0026867|Music|inpr|||music|||0|587|1212|1217
SE|25462517||ab|8|entity|C0205494|Neurologic|ftcn|||neurological|||0|694|1241|1253
SE|25462517||ab|8|entity|C0439824|Verbal|orgf|||verbal|||0|888|1279|1285
SE|25462517||ab|8|entity|C0025260|Memory|menp|||memory|||0|888|1286|1292
SE|25462517||ab|8|entity|C0237401|Individual|humn|||individuals|||0|1000|1296|1307
SE|25462517||ab|8|entity|C0175702|Williams Syndrome|dsyn|||WS|||0|1000|1313|1315
SE|25462517||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1333|1341
SE|25462517||ab|8|entity|C0237401|Individual|humn|||individuals|||0|827|1366|1377
SE|25462517||ab|8|relation|4|1|C0175702|Williams Syndrome|dsyn|dsyn|||WS|||0|1000|1313|1315|PREP|PROCESS_OF||1308|1312|7|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1296|1307
SE|25462517||ab|8|relation|6|1|C0025260|Memory|menp|menp|||memory|||0|888|1286|1292|PREP|PROCESS_OF||1293|1295|5|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1296|1307
SE|25462517||ab|8|relation|10|5|C0025260|Memory|menp|menp|||memory|||0|888|1286|1292|PREP|PROCESS_OF||1342|1344|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|827|1366|1377


SE|25462516||ti|1|text|21|129|Predictors of participation of adolescents with cerebral palsy: A European multi-centre longitudinal study.
SE|25462516||ti|1|entity|C0679823|participation|inbe|||participation|||0|1000|35|48
SE|25462516||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|52|63
SE|25462516||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|69|83
SE|25462516||ti|1|entity|C1442112|MULTI|qnco|||multi|||0|798|96|101
SE|25462516||ti|1|entity|C0205099|Central|spco|||centre|||0|798|102|108
SE|25462516||ti|1|entity|C0023981|Longitudinal Studies|qnco,resa|||longitudinal study|||0|798|109|127
SE|25462516||ti|1|relation|2|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|69|83|PREP|PROCESS_OF||64|68|3|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|52|63

SE|25462516||ab|1|text|135|371|We investigated whether childhood factors that are amenable to intervention (parenting stress, child psychological problems and pain) predicted participation in daily activities and social roles of adolescents with cerebral palsy (CP).
SE|25462516||ab|1|entity|C0231335|Childhood|tmco|||childhood|||0|872|159|168
SE|25462516||ab|1|entity|C1521761|Factor|ftcn|||factors|||0|872|169|176
SE|25462516||ab|1|entity|C1273869|Intervention regimes|hlca|||intervention|||0|1000|198|210
SE|25462516||ab|1|entity|C0038435|Stress|fndg|||stress|||0|861|222|228
SE|25462516||ab|1|entity|C0008059|Child|aggp,inpr|||child|||0|901|230|235
SE|25462516||ab|1|entity|C0848067|Mental problem|fndg|||psychological problems|||0|901|236|258
SE|25462516||ab|1|entity|C0030193|Pain|sosy|||pain|||0|1000|263|267
SE|25462516||ab|1|entity|C1508497|PREDICTED|clna|||predicted|||0|888|269|278
SE|25462516||ab|1|entity|C0679823|participation|inbe|||participation|||0|888|279|292
SE|25462516||ab|1|entity|C0871707|Daily Activities|dora|||daily activities|||0|1000|296|312
SE|25462516||ab|1|entity|C0035820|Role|socb|||social roles|||0|983|317|329
SE|25462516||ab|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|333|344
SE|25462516||ab|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|350|364
SE|25462516||ab|1|relation|0|0|C0848067|Mental problem|fndg|fndg|||psychological problems|||0|901|236|258|MOD/HEAD|PROCESS_OF||230|258|0|0|C0008059|Child|aggp,humn,inpr|humn|||child|||0|901|230|235
SE|25462516||ab|1|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|350|364|PREP|PROCESS_OF||345|349|10|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|333|344

SE|25462516||ab|2|text|371|540|We randomly selected 1174 children aged 8-12 years from eight population-based registers of children with CP in six European countries; 743 (63%) agreed to participate.
SE|25462516||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|861|397|405
SE|25462516||ab|2|entity|C0470359|8+12|qnco|||8-12|||0|901|411|415
SE|25462516||ab|2|entity|C0439234|year|tmco|||years|||0|901|416|421
SE|25462516||ab|2|entity|C0205454|Eight|qnco|||eight|||0|852|427|432
SE|25462516||ab|2|entity|C0032681|Population Register|inpr,qnco|||population-based registers|||0|852|433|459
SE|25462516||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|463|471
SE|25462516||ab|2|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|477|479
SE|25462516||ab|2|entity|C0205452|Six|qnco|||six|||0|890|483|486
SE|25462516||ab|2|entity|C0454713|European country|geoa|||European countries|||0|890|487|505
SE|25462516||ab|2|relation|2|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|477|479|PREP|PROCESS_OF||472|476|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|463|471

SE|25462516||ab|3|text|540|604|One further region recruited 75 children from multiple sources.
SE|25462516||ab|3|entity|C0205447|One|qnco|||One|||0|851|540|543
SE|25462516||ab|3|entity|C1517331|Further|spco|||further|||0|851|544|551
SE|25462516||ab|3|entity|C0205147|Region|spco|||region|||0|851|552|558
SE|25462516||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|861|572|580
SE|25462516||ab|3|entity|C0439064|Numerous|qnco|||multiple|||0|872|586|594

SE|25462516||ab|4|text|604|713|These 818 children were visited at home at age 8-12 years, 594 (73%) agreed to follow-up at age 13-17 years.
SE|25462516||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|861|614|622
SE|25462516||ab|4|entity|C0470359|8+12|qnco|||8-12|||0|888|651|655
SE|25462516||ab|4|entity|C1510829|Age-Years|tmco|||age 8-12 years|||0|888|647|661
SE|25462516||ab|4|entity|C1522577|follow-up|hlca|||follow-up|||0|901|683|692
SE|25462516||ab|4|entity|C1510829|Age-Years|tmco|||age 13-17 years|||0|902|696|711

SE|25462516||ab|5|text|713|1011|We used the following measures: parent reported stress (Parenting Stress Index Short Form), their child's psychological difficulties (Strength and Difficulties Questionnaire) and frequency and severity of pain; either child or parent reported the child's participation (LIFE Habits questionnaire).
SE|25462516||ab|5|entity|C0332282|Following|tmco|||following|||0|888|725|734
SE|25462516||ab|5|entity|C0079809|Measures|qnco|||measures|||0|888|735|743
SE|25462516||ab|5|entity|C0030551|parent|famg|||parent|||0|851|745|751
SE|25462516||ab|5|entity|C0038435|Stress|fndg|||stress|||0|851|761|767
SE|25462516||ab|5|entity|C0038435|Stress|fndg|||Stress|||0|771|779|785
SE|25462516||ab|5|entity|C0918012|Index|inpr|||Index|||0|771|786|791
SE|25462516||ab|5|entity|C1522492|Formation|ftcn|||Form|||0|771|798|802
SE|25462516||ab|5|entity|C0008089|Child Psychology|bmod|||child's psychological|||0|866|811|832
SE|25462516||ab|5|entity|C0808080|STRENGTH|idcn|||Strength|||0|1000|847|855
SE|25462516||ab|5|entity|C0034394|Questionnaires|inpr|||Questionnaire|||0|872|873|886
SE|25462516||ab|5|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|892|901
SE|25462516||ab|5|entity|C0439793|Severities|qlco|||severity|||0|1000|906|914
SE|25462516||ab|5|entity|C0030193|Pain|sosy|||pain|||0|1000|918|922
SE|25462516||ab|5|entity|C0008059|Child|aggp,inpr|||child|||0|861|931|936
SE|25462516||ab|5|entity|C0030551|parent|famg|||parent|||0|1000|940|946
SE|25462516||ab|5|entity|C0008059|Child|aggp,inpr|||child's|||0|888|960|967
SE|25462516||ab|5|entity|C0679823|participation|inbe|||participation|||0|888|968|981
SE|25462516||ab|5|entity|C0376558|Life|idcn|||LIFE|||0|851|983|987
SE|25462516||ab|5|entity|C0018464|Habits|inbe|||Habits|||0|851|988|994
SE|25462516||ab|5|entity|C0034394|Questionnaires|inpr|||questionnaire|||0|851|995|1008
SE|25462516||ab|5|relation|0|0|C0679823|participation|inbe|inbe|||participation|||0|888|968|981|MOD/HEAD|PROCESS_OF||960|981|0|0|C0008059|Child|aggp,humn,inpr|humn|||child's|||0|888|960|967

SE|25462516||ab|6|text|1011|1336|We fitted a structural equation model to each of the participation domains, regressing participation in childhood and adolescence on parenting stress, child psychological problems and pain, and regressing adolescent factors on the corresponding childhood factors; models were adjusted for impairment, region, age and gender.
SE|25462516||ab|6|entity|C0681947|structural equation model|resa|||structural equation model|||0|1000|1023|1048
SE|25462516||ab|6|entity|C0679823|participation|inbe|||participation|||0|694|1064|1077
SE|25462516||ab|6|entity|C0679823|participation|inbe|||participation|||0|1000|1098|1111
SE|25462516||ab|6|entity|C0231335|Childhood|tmco|||childhood|||0|1000|1115|1124
SE|25462516||ab|6|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|1129|1140
SE|25462516||ab|6|entity|C0038435|Stress|fndg|||stress|||0|861|1154|1160
SE|25462516||ab|6|entity|C0008059|Child|aggp,inpr|||child|||0|901|1162|1167
SE|25462516||ab|6|entity|C0848067|Mental problem|fndg|||psychological problems|||0|901|1168|1190
SE|25462516||ab|6|entity|C0030193|Pain|sosy|||pain|||0|1000|1195|1199
SE|25462516||ab|6|entity|C0700186|Involuted|qlco|||regressing|||0|816|1205|1215
SE|25462516||ab|6|entity|C0205653|Adolescent|aggp|||adolescent|||0|816|1216|1226
SE|25462516||ab|6|entity|C1521761|Factor|ftcn|||factors|||0|816|1227|1234
SE|25462516||ab|6|entity|C0231335|Childhood|tmco|||childhood|||0|773|1256|1265
SE|25462516||ab|6|entity|C1521761|Factor|ftcn|||factors|||0|773|1266|1273
SE|25462516||ab|6|entity|C0205147|Region|spco|||region|||0|1000|1312|1318
SE|25462516||ab|6|entity|C0001779|Age|orga|||age|||0|1000|1320|1323
SE|25462516||ab|6|entity|C0079399|Gender|orga|||gender|||0|1000|1328|1334
SE|25462516||ab|6|relation|0|0|C0848067|Mental problem|fndg|fndg|||psychological problems|||0|901|1168|1190|MOD/HEAD|PROCESS_OF||1162|1190|0|0|C0008059|Child|aggp,humn,inpr|humn|||child|||0|901|1162|1167

SE|25462516||ab|7|text|1336|1554|Pain in childhood predicted restricted adolescent participation in all domains except Mealtimes and Communication (standardized total indirect effects beta -0.05 to -0.18, 0.01<p<0.05 to p<0.001, depending on domain).
SE|25462516||ab|7|entity|C0030193|Pain|sosy|||Pain|||0|1000|1336|1340
SE|25462516||ab|7|entity|C0231335|Childhood|tmco|||childhood|||0|1000|1344|1353
SE|25462516||ab|7|entity|C0443288|Restricted|ftcn|||restricted|||0|851|1364|1374
SE|25462516||ab|7|entity|C0205653|Adolescent|aggp|||adolescent|||0|851|1375|1385
SE|25462516||ab|7|entity|C0679823|participation|inbe|||participation|||0|851|1386|1399
SE|25462516||ab|7|entity|C0587119|Mealtimes|tmco|||Mealtimes|||0|1000|1422|1431
SE|25462516||ab|7|entity|C0009452|Communication|socb|||Communication|||0|1000|1436|1449
SE|25462516||ab|7|entity|C0439175|% of total|qnco|||total|||0|686|1464|1469
SE|25462516||ab|7|entity|C0439852|Indirect|qlco|||indirect|||0|686|1470|1478
SE|25462516||ab|7|entity|C1280500|Effect|qlco|||effects|||0|686|1479|1486
SE|25462516||ab|7|relation|0|0|C0679823|participation|inbe|inbe|||participation|||0|851|1386|1399|MOD/HEAD|PROCESS_OF||1375|1399|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|851|1375|1385

SE|25462516||ab|8|text|1554|1755|Psychological problems in childhood predicted restricted adolescent participation in all domains of social roles, and in Personal Care and Communication (beta -0.07 to -0.17, 0.001<p<0.01 to p<0.001).
SE|25462516||ab|8|entity|C0848067|Mental problem|fndg|||Psychological problems|||0|1000|1554|1576
SE|25462516||ab|8|entity|C0231335|Childhood|tmco|||childhood|||0|1000|1580|1589
SE|25462516||ab|8|entity|C0443288|Restricted|ftcn|||restricted|||0|851|1600|1610
SE|25462516||ab|8|entity|C0205653|Adolescent|aggp|||adolescent|||0|851|1611|1621
SE|25462516||ab|8|entity|C0679823|participation|inbe|||participation|||0|851|1622|1635
SE|25462516||ab|8|entity|C0035820|Role|socb|||social roles|||0|983|1654|1666
SE|25462516||ab|8|entity|C0036592|Self Care|hlca|||Personal Care|||0|1000|1675|1688
SE|25462516||ab|8|entity|C0009452|Communication|socb|||Communication|||0|1000|1693|1706
SE|25462516||ab|8|relation|0|0|C0679823|participation|inbe|inbe|||participation|||0|851|1622|1635|MOD/HEAD|PROCESS_OF||1611|1635|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|851|1611|1621

SE|25462516||ab|9|text|1755|1925|Parenting stress in childhood predicted restricted adolescent participation in Health Hygiene, Mobility and Relationships (beta -0.07 to -0.18, 0.001<p<0.01 to p<0.001).
SE|25462516||ab|9|entity|C0038435|Stress|fndg|||stress|||0|861|1765|1771
SE|25462516||ab|9|entity|C0231335|Childhood|tmco|||childhood|||0|1000|1775|1784
SE|25462516||ab|9|entity|C0443288|Restricted|ftcn|||restricted|||0|851|1795|1805
SE|25462516||ab|9|entity|C0205653|Adolescent|aggp|||adolescent|||0|851|1806|1816
SE|25462516||ab|9|entity|C0679823|participation|inbe|||participation|||0|851|1817|1830
SE|25462516||ab|9|entity|C0018684|Health|idcn|||Health|||0|888|1834|1840
SE|25462516||ab|9|entity|C0020405|Hygiene|bmod|||Hygiene|||0|888|1841|1848
SE|25462516||ab|9|entity|C0439849|Relationships|qlco|||Relationships|||0|1000|1863|1876
SE|25462516||ab|9|relation|0|0|C0679823|participation|inbe|inbe|||participation|||0|851|1817|1830|MOD/HEAD|PROCESS_OF||1806|1830|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|851|1806|1816

SE|25462516||ab|10|text|1925|2211|These childhood factors predicted adolescent participation largely via their effects on childhood participation; though in some domains early psychological problems and parenting stress in childhood predicted adolescent participation largely through their persistence into adolescence.
SE|25462516||ab|10|entity|C0231335|Childhood|tmco|||childhood|||0|872|1931|1940
SE|25462516||ab|10|entity|C1521761|Factor|ftcn|||factors|||0|872|1941|1948
SE|25462516||ab|10|entity|C0205653|Adolescent|aggp|||adolescent|||0|583|1959|1969
SE|25462516||ab|10|entity|C0679823|participation|inbe|||participation|||0|583|1970|1983
SE|25462516||ab|10|entity|C1280500|Effect|qlco|||effects|||0|966|2002|2009
SE|25462516||ab|10|entity|C0231335|Childhood|tmco|||childhood|||0|888|2013|2022
SE|25462516||ab|10|entity|C0679823|participation|inbe|||participation|||0|888|2023|2036
SE|25462516||ab|10|entity|C1279919|Early|tmco|||early|||0|824|2061|2066
SE|25462516||ab|10|entity|C0848067|Mental problem|fndg|||psychological problems|||0|824|2067|2089
SE|25462516||ab|10|entity|C0038435|Stress|fndg|||stress|||0|861|2104|2110
SE|25462516||ab|10|entity|C0231335|Childhood|tmco|||childhood|||0|1000|2114|2123
SE|25462516||ab|10|entity|C0205653|Adolescent|aggp|||adolescent|||0|790|2134|2144
SE|25462516||ab|10|entity|C0679823|participation|inbe|||participation|||0|790|2145|2158
SE|25462516||ab|10|entity|C0546816|Persistence|menp|||persistence|||0|1000|2181|2192
SE|25462516||ab|10|entity|C0001578|Adolescence|tmco|||adolescence|||0|1000|2198|2209
SE|25462516||ab|10|relation|0|0|C0679823|participation|inbe|inbe|||participation|||0|790|2145|2158|MOD/HEAD|PROCESS_OF||2134|2158|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|790|2134|2144

SE|25462516||ab|11|text|2211|2340|We conclude that participation of adolescents with CP was predicted by early modifiable factors related to the child and family.
SE|25462516||ab|11|entity|C0679823|participation|inbe|||participation|||0|1000|2228|2241
SE|25462516||ab|11|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|2245|2256
SE|25462516||ab|11|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|2262|2264
SE|25462516||ab|11|entity|C1279919|Early|tmco|||early|||0|785|2282|2287
SE|25462516||ab|11|entity|C1521761|Factor|ftcn|||factors|||0|785|2299|2306
SE|25462516||ab|11|entity|C0008059|Child|aggp,inpr|||child|||0|1000|2322|2327
SE|25462516||ab|11|entity|C0015576|Family|famg|||family|||0|1000|2332|2338
SE|25462516||ab|11|relation|4|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|2262|2264|PREP|PROCESS_OF||2257|2261|2|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|2245|2256

SE|25462516||ab|12|text|2340|2561|Interventions for reduction of pain, psychological difficulties and parenting stress in childhood are justified not only for their intrinsic value, but also for probable benefits to childhood and adolescent participation.
SE|25462516||ab|12|entity|C1273869|Intervention regimes|hlca|||Interventions|||0|1000|2340|2353
SE|25462516||ab|12|entity|C0030193|Pain|sosy|||pain|||0|1000|2371|2375
SE|25462516||ab|12|entity|C0205486|Psychologic|ftcn|||psychological|||0|872|2377|2390
SE|25462516||ab|12|entity|C0038435|Stress|fndg|||stress|||0|861|2418|2424
SE|25462516||ab|12|entity|C0231335|Childhood|tmco|||childhood|||0|1000|2428|2437
SE|25462516||ab|12|entity|C1518422|Not|ftcn|||not|||0|861|2452|2455
SE|25462516||ab|12|entity|C0205102|Intrinsic|spco|||intrinsic|||0|694|2471|2480
SE|25462516||ab|12|entity|C0814225|Benefits|qnco|||benefits|||0|861|2510|2518
SE|25462516||ab|12|entity|C0231335|Childhood|tmco|||childhood|||0|1000|2522|2531
SE|25462516||ab|12|entity|C0205653|Adolescent|aggp|||adolescent|||0|888|2536|2546
SE|25462516||ab|12|entity|C0679823|participation|inbe|||participation|||0|888|2547|2560
SE|25462516||ab|12|relation|0|0|C0679823|participation|inbe|inbe|||participation|||0|888|2547|2560|MOD/HEAD|PROCESS_OF||2536|2560|0|0|C0205653|Adolescent|aggp,humn|humn|||adolescent|||0|888|2536|2546
SE|25462516||ab|12|relation|1|1|C1273869|Intervention regimes|hlca|hlca|||Interventions|||0|1000|2340|2353|NOM|PREVENTS||2358|2367|8|1|C0030193|Pain|sosy|sosy|||pain|||0|1000|2371|2375


SE|25462518||ti|1|text|21|142|Physical activity levels of adolescents with and without intellectual disabilities during physical education and recess.
SE|25462518||ti|1|entity|C0026606|Physical activity|dora|||Physical activity|||0|901|21|38
SE|25462518||ti|1|entity|C0441889|Levels|inpr|||levels|||0|901|39|45
SE|25462518||ti|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|49|60
SE|25462518||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|78|103
SE|25462518||ti|1|entity|C0031805|Physical Education|edac,ocdi|||physical education|||0|1000|111|129

SE|25462518||ab|1|text|148|280|To compare physical activity levels in adolescents with and without intellectual disabilities during physical education and recess.
SE|25462518||ab|1|entity|C0026606|Physical activity|dora|||physical activity|||0|901|159|176
SE|25462518||ab|1|entity|C0441889|Levels|inpr|||levels|||0|901|177|183
SE|25462518||ab|1|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|187|198
SE|25462518||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|216|241
SE|25462518||ab|1|entity|C0031805|Physical Education|edac,ocdi|||physical education|||0|1000|249|267
SE|25462518||ab|1|relation|1|1|C0026606|Physical activity|dora|dora|||physical activity|||0|901|159|176|PREP|TREATS||184|186|4|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|187|198

SE|25462518||ab|2|text|280|482|Forty adolescents diagnosed with intellectual disabilities (inclusive classrooms, n=20; self-contained classrooms, n=20) and 40 age-matched typically developing peers (general classrooms) participated.
SE|25462518||ab|2|entity|C0205653|Adolescent|aggp|||adolescents|||0|861|286|297
SE|25462518||ab|2|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|313|338
SE|25462518||ab|2|entity|C0332257|Including|ftcn|||inclusive|||0|888|340|349
SE|25462518||ab|2|entity|C0870287|Classrooms|mnob|||classrooms|||0|888|350|360
SE|25462518||ab|2|entity|C0036588|Self|idcn|||self|||0|840|368|372
SE|25462518||ab|2|entity|C0332256|Containing|ftcn|||contained|||0|840|373|382
SE|25462518||ab|2|entity|C0870287|Classrooms|mnob|||classrooms|||0|840|383|393
SE|25462518||ab|2|entity|C0001779|Age|orga|||age|||0|744|408|411
SE|25462518||ab|2|entity|C0150103|MATCHING|resa|||matched|||0|744|412|419
SE|25462518||ab|2|entity|C0679739|peer|popg|||peers|||0|744|441|446
SE|25462518||ab|2|entity|C0205246|Generalized|spco|||general|||0|888|448|455
SE|25462518||ab|2|entity|C0870287|Classrooms|mnob|||classrooms|||0|888|456|466
SE|25462518||ab|2|relation|7|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|313|338|VERB|PROCESS_OF||298|307|1|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|861|286|297

SE|25462518||ab|3|text|482|584|All participants wore an Actigraph GT1M accelerometer for 5 consecutive weekdays during school hours.
SE|25462518||ab|3|entity|C0679646|Participant|popg|||participants|||0|966|486|498
SE|25462518||ab|3|entity|C1139952|Recorders, Electronic Storage, Data, Physical Activity|medd|||Actigraph|||0|769|507|516
SE|25462518||ab|3|entity|C0178951|Accelerometers|medd|||accelerometer|||0|769|522|535
SE|25462518||ab|3|entity|C0680189|weekday|tmco|||weekdays|||0|785|554|562
SE|25462518||ab|3|entity|C0439227|Hour|tmco|||hours|||0|861|577|582

SE|25462518||ab|4|text|584|804|Three groups of adolescents were similarly active during physical education; however, adolescents with intellectual disabilities in self-contained classrooms were less active during recess than did the other two groups.
SE|25462518||ab|4|entity|C0205449|Three|qnco|||Three|||0|888|584|589
SE|25462518||ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|590|596
SE|25462518||ab|4|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|600|611
SE|25462518||ab|4|entity|C0205177|Active|ftcn|||active|||0|861|627|633
SE|25462518||ab|4|entity|C0031805|Physical Education|edac,ocdi|||physical education|||0|1000|641|659
SE|25462518||ab|4|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|670|681
SE|25462518||ab|4|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|687|712
SE|25462518||ab|4|entity|C0036588|Self|idcn|||self|||0|840|716|720
SE|25462518||ab|4|entity|C0332256|Containing|ftcn|||contained|||0|840|721|730
SE|25462518||ab|4|entity|C0870287|Classrooms|mnob|||classrooms|||0|840|731|741
SE|25462518||ab|4|entity|C0205177|Active|ftcn|||active|||0|861|752|758
SE|25462518||ab|4|entity|C0205448|Two|qnco|||two|||0|888|792|795
SE|25462518||ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|796|802
SE|25462518||ab|4|relation|5|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|687|712|PREP|PROCESS_OF||682|686|5|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|670|681

SE|25462518||ab|5|text|804|955|In addition, they spent less percentage of time in moderate-to-vigorous physical activity during recess than did the typically developing adolescents.
SE|25462518||ab|5|entity|C0439165|Percent (qualifier value)|qnco|||percentage|||0|861|833|843
SE|25462518||ab|5|entity|C0040223|Time|tmco|||time|||0|1000|847|851
SE|25462518||ab|5|entity|C0026606|Physical activity|dora|||physical activity|||0|840|876|893
SE|25462518||ab|5|entity|C0205653|Adolescent|aggp|||adolescents|||0|827|942|953

SE|25462518||ab|6|text|955|1092|An inclusive, structured, and supportive environment promotes physical activity engagement in adolescents with intellectual disabilities.
SE|25462518||ab|6|entity|C0332257|Including|ftcn|||inclusive|||0|1000|958|967
SE|25462518||ab|6|entity|C0014406|Environment|spco|||environment|||0|861|996|1007
SE|25462518||ab|6|entity|C0026606|Physical activity|dora|||physical activity|||0|901|1017|1034
SE|25462518||ab|6|entity|C0425152|Engaged to be married|socb|||engagement|||0|901|1035|1045
SE|25462518||ab|6|entity|C0205653|Adolescent|aggp|||adolescents|||0|1000|1049|1060
SE|25462518||ab|6|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disabilities|||0|983|1066|1091
SE|25462518||ab|6|relation|1|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disabilities|||0|983|1066|1091|PREP|PROCESS_OF||1061|1065|4|1|C0205653|Adolescent|aggp,humn|humn|||adolescents|||0|1000|1049|1060


SE|25462519||ti|1|text|21|154|Assessing effortful control in typical and atypical development: Are questionnaires and neuropsychological measures interchangeable?
SE|25462519||ti|1|entity|C0243148|control|ftcn|||control|||0|861|41|48
SE|25462519||ti|1|entity|C0205182|Atypical|qlco|||atypical|||0|888|64|72
SE|25462519||ti|1|entity|C1527148|Development|ftcn|||development|||0|888|73|84
SE|25462519||ti|1|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|1000|90|104
SE|25462519||ti|1|entity|C0027903|Neuropsychology|bmod|||neuropsychological|||0|853|109|127
SE|25462519||ti|1|entity|C0079809|Measures|qnco|||measures|||0|853|128|136

SE|25462519||ti|2|text|154|182|A latent-variable analysis.
SE|25462519||ti|2|entity|C0814889|latent variable|qlco|||latent-variable|||0|901|156|171
SE|25462519||ti|2|entity|C0936012|Analysis|resa|||analysis|||0|901|172|180

SE|25462519|OBJECTIVE|ab|1|text|188|317|OBJECTIVE: Effortful control (EC), the self-regulation component of temperament, is traditionally measured using questionnaires.
SE|25462519|OBJECTIVE|ab|1|entity|C0243148|control|ftcn|||control|||0|861|209|216
SE|25462519|OBJECTIVE|ab|1|entity|C0037407|Social Control, Informal|hcpp|||self-regulation|||0|901|227|242
SE|25462519|OBJECTIVE|ab|1|entity|C1524073|Component, LOINC Axis 1|clas|||component|||0|901|243|252
SE|25462519|OBJECTIVE|ab|1|entity|C0039474|Temperament|menp|||temperament|||0|1000|256|267
SE|25462519|OBJECTIVE|ab|1|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|1000|301|315

SE|25462519|OBJECTIVE|ab|2|text|317|527|Through the years, several neuropsychological measures originating from the cognitive psychology and the executive function (EF) literature have been introduced in the domain of temperament research to tap EC.
SE|25462519|OBJECTIVE|ab|2|entity|C0439234|year|tmco|||years|||0|1000|329|334
SE|25462519|OBJECTIVE|ab|2|entity|C0443302|Several|qnco|||several|||0|828|336|343
SE|25462519|OBJECTIVE|ab|2|entity|C0027903|Neuropsychology|bmod|||neuropsychological|||0|828|344|362
SE|25462519|OBJECTIVE|ab|2|entity|C0079809|Measures|qnco|||measures|||0|828|363|371
SE|25462519|OBJECTIVE|ab|2|entity|C0678963|cognitive psychology|bmod|||cognitive psychology|||0|1000|393|413
SE|25462519|OBJECTIVE|ab|2|entity|C0935584|Executive Functioning|menp|||executive function|||0|901|422|440
SE|25462519|OBJECTIVE|ab|2|entity|C0023866|Literature|inpr|||literature|||0|901|446|456
SE|25462519|OBJECTIVE|ab|2|entity|C0039474|Temperament|menp|||temperament|||0|1000|495|506
SE|25462519|OBJECTIVE|ab|2|entity|C0243148|control|ftcn|||EC|||0|861|523|525

SE|25462519|OBJECTIVE|ab|3|text|527|752|Although this is not particularly surprising, given the conceptual overlap between EC and EF, it remains unclear whether EC questionnaires and neuropsychological EF tasks can really be used interchangeably when measuring EC.
SE|25462519|OBJECTIVE|ab|3|entity|C1518422|Not|ftcn|||not|||0|660|544|547
SE|25462519|OBJECTIVE|ab|3|entity|C0178566|concept|idcn|||conceptual|||0|623|583|593
SE|25462519|OBJECTIVE|ab|3|entity|C0243148|control|ftcn|||EC|||0|861|610|612
SE|25462519|OBJECTIVE|ab|3|entity|C0935584|Executive Functioning|menp|||EF|||0|1000|617|619
SE|25462519|OBJECTIVE|ab|3|entity|C0243148|control|ftcn|||EC|||0|790|648|650
SE|25462519|OBJECTIVE|ab|3|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|790|651|665
SE|25462519|OBJECTIVE|ab|3|entity|C0027903|Neuropsychology|bmod|||neuropsychological|||0|826|670|688
SE|25462519|OBJECTIVE|ab|3|entity|C0935584|Executive Functioning|menp|||EF|||0|826|689|691
SE|25462519|OBJECTIVE|ab|3|entity|C0079809|Measures|qnco|||measuring|||0|785|738|747
SE|25462519|OBJECTIVE|ab|3|entity|C0243148|control|ftcn|||EC|||0|785|748|750

SE|25462519|OBJECTIVE|ab|4|text|752|990|The current study addressed two important aspects in evaluating the interchangeability of both types of measures, that is: (a) do they measure the same construct? and (b) do they give the same results when comparing clinical populations?
SE|25462519|OBJECTIVE|ab|4|entity|C0521116|Current|tmco|||current|||0|888|756|763
SE|25462519|OBJECTIVE|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|888|764|769
SE|25462519|OBJECTIVE|ab|4|entity|C0205448|Two|qnco|||two|||0|785|780|783
SE|25462519|OBJECTIVE|ab|4|entity|C1547011|Aspect|qnco|||aspects|||0|785|794|801
SE|25462519|OBJECTIVE|ab|4|entity|C0332307|Type - attribute|qlco|||types|||0|1000|847|852
SE|25462519|OBJECTIVE|ab|4|entity|C0079809|Measures|qnco|||measures|||0|1000|856|864
SE|25462519|OBJECTIVE|ab|4|entity|C0445247|Same|qlco|||same|||0|694|899|903
SE|25462519|OBJECTIVE|ab|4|entity|C0445247|Same|qlco|||same|||0|872|940|944
SE|25462519|OBJECTIVE|ab|4|entity|C1274040|result|ftcn|||results|||0|872|945|952
SE|25462519|OBJECTIVE|ab|4|entity|C0205210|Clinical|qlco|||clinical|||0|888|968|976
SE|25462519|OBJECTIVE|ab|4|entity|C0032659|geographic population|qnco|||populations|||0|888|977|988

SE|25462519|METHOD|ab|5|text|990|1262|METHOD: Three EC questionnaires, two inhibitory control tasks, and two attentional control tasks were administered in 148 typically developing children, 30 children with attention-deficit/hyperactivity disorder (ADHD), and 31 children with autism spectrum disorder (ASD).
SE|25462519|METHOD|ab|5|entity|C0025663|Methods|inpr|||METHOD|||0|1000|990|996
SE|25462519|METHOD|ab|5|entity|C0205449|Three|qnco|||Three|||0|775|998|1003
SE|25462519|METHOD|ab|5|entity|C0243148|control|ftcn|||EC|||0|775|1004|1006
SE|25462519|METHOD|ab|5|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|775|1007|1021
SE|25462519|METHOD|ab|5|entity|C0205448|Two|qnco|||two|||0|807|1023|1026
SE|25462519|METHOD|ab|5|entity|C0243077|inhibitors|chvf|||inhibitory|||0|807|1027|1037
SE|25462519|METHOD|ab|5|entity|C0243148|control|ftcn|||control|||0|807|1038|1045
SE|25462519|METHOD|ab|5|entity|C0205448|Two|qnco|||two|||0|807|1057|1060
SE|25462519|METHOD|ab|5|entity|C0004268|Attention|menp|||attentional|||0|807|1061|1072
SE|25462519|METHOD|ab|5|entity|C0243148|control|ftcn|||control|||0|807|1073|1080
SE|25462519|METHOD|ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|812|1133|1141
SE|25462519|METHOD|ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|861|1146|1154
SE|25462519|METHOD|ab|5|entity|C1263846|Attention deficit hyperactivity disorder|mobd|||attention-deficit/hyperactivity disorder|||0|1000|1160|1200
SE|25462519|METHOD|ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|861|1216|1224
SE|25462519|METHOD|ab|5|entity|C1510586|Autism spectrum disorder|mobd|||autism spectrum disorder|||0|1000|1230|1254
SE|25462519|METHOD|ab|5|relation|1|1|C1510586|Autism spectrum disorder|mobd|mobd|||autism spectrum disorder|||0|1000|1230|1254|PREP|PROCESS_OF||1225|1229|8|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|1216|1224
SE|25462519|METHOD|ab|5|relation|3|1|C1263846|Attention deficit hyperactivity disorder|mobd|mobd|||attention-deficit/hyperactivity disorder|||0|1000|1160|1200|PREP|PROCESS_OF||1155|1159|6|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|1146|1154

SE|25462519|METHOD|ab|6|text|1262|1352|All children were between 10 and 15 years of age and had a full scale IQ of 80 or higher.
SE|25462519|METHOD|ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1266|1274
SE|25462519|METHOD|ab|6|entity|C0439234|year|tmco|||years|||0|861|1298|1303
SE|25462519|METHOD|ab|6|entity|C0001779|Age|orga|||age|||0|1000|1307|1310
SE|25462519|METHOD|ab|6|entity|C0443225|Full|qlco|||full|||0|851|1321|1325
SE|25462519|METHOD|ab|6|entity|C0205250|High|qlco|||higher|||0|966|1344|1350

SE|25462519|RESULTS|ab|7|text|1352|1491|RESULTS: Confirmatory factor analyses revealed that the questionnaires and EF tasks do not capture the same underlying latent variable(s).
SE|25462519|RESULTS|ab|7|entity|C1274040|result|ftcn|||RESULTS|||0|966|1352|1359
SE|25462519|RESULTS|ab|7|entity|C0870334|Confirmatory Factor Analysis|qlco|||Confirmatory factor analyses|||0|988|1361|1389
SE|25462519|RESULTS|ab|7|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|1000|1408|1422
SE|25462519|RESULTS|ab|7|entity|C0935584|Executive Functioning|menp|||EF|||0|884|1427|1429
SE|25462519|RESULTS|ab|7|entity|C1518422|Not|ftcn|||not|||0|1000|1439|1442
SE|25462519|RESULTS|ab|7|entity|C0445247|Same|qlco|||same|||0|824|1455|1459
SE|25462519|RESULTS|ab|7|entity|C0814889|latent variable|qlco|||latent variable|||0|824|1471|1486

SE|25462519|RESULTS|ab|8|text|1491|1651|Groups could not be differentiated from each other based on their performance on EF tasks, whereas significant group differences were found for all EC-reports.
SE|25462519|RESULTS|ab|8|entity|C0441833|Groups|inpr|||Groups|||0|1000|1491|1497
SE|25462519|RESULTS|ab|8|entity|C1518422|Not|ftcn|||not|||0|1000|1504|1507
SE|25462519|RESULTS|ab|8|entity|C0597198|Performance|inbe|||performance|||0|1000|1557|1568
SE|25462519|RESULTS|ab|8|entity|C0935584|Executive Functioning|menp|||EF|||0|884|1572|1574
SE|25462519|RESULTS|ab|8|entity|C0750502|Significant|idcn|||significant|||0|840|1590|1601
SE|25462519|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|840|1602|1607
SE|25462519|RESULTS|ab|8|entity|C1547020|*Difference|qnco|||differences|||0|840|1608|1619
SE|25462519|RESULTS|ab|8|entity|C0243148|control|ftcn|||EC|||0|790|1639|1641
SE|25462519|RESULTS|ab|8|entity|C0684224|Report (document)|inpr|||reports|||0|790|1642|1649

SE|25462519|CONCLUSIONS|ab|9|text|1651|1860|CONCLUSIONS: Overall, our findings show more differences than commonalities between the EC questionnaires and EF tasks and, consequently, suggest that both types of measures should not be used interchangeably.
SE|25462519|CONCLUSIONS|ab|9|entity|C1561607|Overall|qlco|||Overall|||0|1000|1664|1671
SE|25462519|CONCLUSIONS|ab|9|entity|C0243095|Finding|ftcn|||findings|||0|1000|1677|1685
SE|25462519|CONCLUSIONS|ab|9|entity|C0205172|More|ftcn|||more|||0|872|1691|1695
SE|25462519|CONCLUSIONS|ab|9|entity|C1547020|*Difference|qnco|||differences|||0|872|1696|1707
SE|25462519|CONCLUSIONS|ab|9|entity|C0243148|control|ftcn|||EC|||0|790|1739|1741
SE|25462519|CONCLUSIONS|ab|9|entity|C0034394|Questionnaires|inpr|||questionnaires|||0|790|1742|1756
SE|25462519|CONCLUSIONS|ab|9|entity|C0935584|Executive Functioning|menp|||EF|||0|884|1761|1763
SE|25462519|CONCLUSIONS|ab|9|entity|C0332307|Type - attribute|qlco|||types|||0|1000|1807|1812
SE|25462519|CONCLUSIONS|ab|9|entity|C0079809|Measures|qnco|||measures|||0|1000|1816|1824
SE|25462519|CONCLUSIONS|ab|9|entity|C1518422|Not|ftcn|||not|||0|1000|1832|1835


SE|25462520||ti|1|text|21|166|Validity and reliability of the INICO-FEAPS Scale: An assessment of quality of life for people with intellectual and developmental disabilities.
SE|25462520||ti|1|entity|C0220825|Evaluation|ftcn|||assessment|||0|1000|75|85
SE|25462520||ti|1|entity|C0332306|Quality|qlco|||quality|||0|1000|89|96
SE|25462520||ti|1|entity|C0376558|Life|idcn|||life|||0|1000|100|104
SE|25462520||ti|1|entity|C0027361|Persons|popg|||people|||0|1000|109|115
SE|25462520||ti|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|138|164

SE|25462520||ab|1|text|172|399|This paper documents the validation of a comprehensive scale designed to assess quality-of-life related personal outcomes for people with intellectual and developmental disabilities who receive support in social organizations.
SE|25462520||ab|1|entity|C0030351|Paper|mnob|||paper|||0|1000|177|182
SE|25462520||ab|1|entity|C1519941|Validation|resa|||validation|||0|1000|197|207
SE|25462520||ab|1|entity|C0332306|Quality|qlco|||quality|||0|1000|252|259
SE|25462520||ab|1|entity|C0376558|Life|idcn|||life|||0|1000|263|267
SE|25462520||ab|1|entity|C1274040|result|ftcn|||outcomes|||0|827|285|293
SE|25462520||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|298|304
SE|25462520||ab|1|entity|C0008073|Child Development Disorders|mobd|||developmental disabilities|||0|1000|327|353
SE|25462520||ab|1|entity|C0597480|social organization|orgt|||social organizations|||0|983|377|397
SE|25462520||ab|1|relation|1|1|C0597480|social organization|orgt|orgt|||social organizations|||0|983|377|397|PREP|LOCATION_OF||374|376|10|9|C1519941|Validation|resa|resa|||validation|||0|1000|197|207

SE|25462520||ab|2|text|399|500|The INICO-FEAPS Scale was administered to 1627 people whose ages ranged between 16 and 72 years old.
SE|25462520||ab|2|entity|C0027361|Persons|popg|||people|||0|861|446|452
SE|25462520||ab|2|entity|C0439234|year|tmco|||years|||0|790|489|494
SE|25462520||ab|2|entity|C0580836|Old|tmco|||old|||0|790|495|498

SE|25462520||ab|3|text|500|654|The instrument comprises 72 parallel items organized around eight quality-of-life domains in each of the two forms: a self-report and a report by others.
SE|25462520||ab|3|entity|C0348000|Instrument|mnob|||instrument|||0|1000|504|514
SE|25462520||ab|3|entity|C0205454|Eight|qnco|||eight|||0|888|560|565
SE|25462520||ab|3|entity|C0332306|Quality|qlco|||quality|||0|888|566|573
SE|25462520||ab|3|entity|C0376558|Life|idcn|||life|||0|694|577|581
SE|25462520||ab|3|entity|C0205448|Two|qnco|||two|||0|888|605|608
SE|25462520||ab|3|entity|C0036588|Self|idcn|||self|||0|888|618|622
SE|25462520||ab|3|entity|C0205394|Other|qlco|||others|||0|966|646|652

SE|25462520||ab|4|text|654|731|Several internal consistence indexes showed a good reliability of the scale.
SE|25462520||ab|4|entity|C0443302|Several|qnco|||Several|||0|836|654|661
SE|25462520||ab|4|entity|C0870731|Internal Consistency|qnco|||internal consistence|||0|836|662|682
SE|25462520||ab|4|entity|C0918012|Index|inpr|||indexes|||0|836|683|690
SE|25462520||ab|4|entity|C0205170|Good|qlco|||good|||0|694|700|704

SE|25462520||ab|5|text|731|810|CFA was used to compare the goodness-of-fit to the data of alternative models.
SE|25462520||ab|5|entity|C1003714|Cell fusing agent virus|virs|||CFA|||0|1000|731|734
SE|25462520||ab|5|entity|C0205170|Good|qlco|||goodness|||0|928|759|767
SE|25462520||ab|5|entity|C0036572|Seizures|sosy|||fit|||0|1000|771|774
SE|25462520||ab|5|entity|C1511726|Data|idcn|||data|||0|1000|782|786
SE|25462520||ab|5|entity|C1523987|Alternative|cnce|||alternative|||0|694|790|801

SE|25462520||ab|6|text|810|953|The eight-correlated first-order factors showed the best fit to the data in comparison to the unidimensional solution and hierarchical models.
SE|25462520||ab|6|entity|C0205454|Eight|qnco|||eight|||0|742|814|819
SE|25462520||ab|6|entity|C1279901|Firstly|qlco|||first|||0|742|831|836
SE|25462520||ab|6|entity|C1521761|Factor|ftcn|||factors|||0|742|843|850
SE|25462520||ab|6|entity|C0036572|Seizures|sosy|||fit|||0|888|867|870
SE|25462520||ab|6|entity|C1511726|Data|idcn|||data|||0|1000|878|882
SE|25462520||ab|6|entity|C0037633|Solutions|sbst|||solution|||0|861|919|927
SE|25462520||ab|6|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|623|932|944

SE|25462520||ab|7|text|953|1175|The instrument serves as a helpful tool for organizations to operate as bridges to the community, develop person-centered planning and individualized support, and implement evidence-based practices for quality improvement.
SE|25462520||ab|7|entity|C0348000|Instrument|mnob|||instrument|||0|1000|957|967
SE|25462520||ab|7|entity|C1552861|help|idcn|||helpful|||0|853|980|987
SE|25462520||ab|7|entity|C0336791|Tool|mnob|||tool|||0|853|988|992
SE|25462520||ab|7|entity|C0029246|Organization administrative structures|orgt|||organizations|||0|1000|997|1010
SE|25462520||ab|7|entity|C0009462|Community|geoa|||community|||0|1000|1040|1049
SE|25462520||ab|7|entity|C0027361|Persons|popg|||person|||0|587|1059|1065
SE|25462520||ab|7|entity|C0205099|Central|spco|||centered|||0|587|1066|1074
SE|25462520||ab|7|entity|C0332306|Quality|qlco|||quality|||0|694|1155|1162


SE|25462521||ti|1|text|21|215|Assessing the bullying and victimisation experiences of children with special educational needs in mainstream schools: Development and validation of the Bullying Behaviour and Experience Scale.
SE|25462521||ti|1|entity|C0424318|Bullying|mobd|||bullying|||0|1000|35|43
SE|25462521||ti|1|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|48|61
SE|25462521||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|77|85
SE|25462521||ti|1|entity|C0556278|Special educational needs|fndg|||special educational needs|||0|1000|91|116
SE|25462521||ti|1|entity|C0589339|Mainstream school|mnob,orgt|||mainstream schools|||0|983|120|138
SE|25462521||ti|1|entity|C1527148|Development|ftcn|||Development|||0|1000|140|151
SE|25462521||ti|1|entity|C1519941|Validation|resa|||validation|||0|1000|156|166
SE|25462521||ti|1|entity|C0424318|Bullying|mobd|||Bullying|||0|888|174|182
SE|25462521||ti|1|entity|C0004927|Behavior|inbe|||Behaviour|||0|888|183|192
SE|25462521||ti|1|entity|C0596545|experience|menp|||Experience|||0|888|197|207
SE|25462521||ti|1|relation|6|1|C0556278|Special educational needs|fndg|fndg|||special educational needs|||0|1000|91|116|PREP|PROCESS_OF||86|90|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|77|85

SE|25462521||ab|1|text|221|538|Children with special educational needs (SEN) are more likely to experience victimisation at school and there is some evidence to suggest that these children are also more likely to engage in bullying behaviours; however, no measure of bullying experiences has been designed specifically for use with these children.
SE|25462521||ab|1|entity|C0008059|Child|aggp,inpr|||Children|||0|1000|221|229
SE|25462521||ab|1|entity|C0556278|Special educational needs|fndg|||special educational needs|||0|1000|235|260
SE|25462521||ab|1|entity|C0205172|More|ftcn|||more|||0|888|271|275
SE|25462521||ab|1|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|297|310
SE|25462521||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|370|378
SE|25462521||ab|1|entity|C0424318|Bullying|mobd|||bullying|||0|888|413|421
SE|25462521||ab|1|entity|C0004927|Behavior|inbe|||behaviours|||0|888|422|432
SE|25462521||ab|1|entity|C0079809|Measures|qnco|||measure|||0|1000|446|453
SE|25462521||ab|1|entity|C0424318|Bullying|mobd|||bullying|||0|872|457|465
SE|25462521||ab|1|entity|C0596545|experience|menp|||experiences|||0|872|466|477
SE|25462521||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|528|536
SE|25462521||ab|1|relation|10|1|C0556278|Special educational needs|fndg|fndg|||special educational needs|||0|1000|235|260|PREP|PROCESS_OF||230|234|1|1|C0008059|Child|aggp,humn,inpr|humn|||Children|||0|1000|221|229

SE|25462521||ab|2|text|538|705|The Bullying Behaviour and Experiences Scale (BBES) was specifically developed as a self-report measure of victimisation and bullying behaviour for children with SEN.
SE|25462521||ab|2|entity|C0424318|Bullying|mobd|||Bullying|||0|720|542|550
SE|25462521||ab|2|entity|C0004927|Behavior|inbe|||Behaviour|||0|720|551|560
SE|25462521||ab|2|entity|C0036588|Self|idcn|||self|||0|851|622|626
SE|25462521||ab|2|entity|C0079809|Measures|qnco|||measure|||0|851|634|641
SE|25462521||ab|2|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|645|658
SE|25462521||ab|2|entity|C0424318|Bullying|mobd|||bullying|||0|888|663|671
SE|25462521||ab|2|entity|C0004927|Behavior|inbe|||behaviour|||0|888|672|681
SE|25462521||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|686|694
SE|25462521||ab|2|entity|C0556278|Special educational needs|fndg|||SEN|||0|1000|700|703
SE|25462521||ab|2|relation|1|1|C0556278|Special educational needs|fndg|fndg|||SEN|||0|1000|700|703|PREP|PROCESS_OF||695|699|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|686|694

SE|25462521||ab|3|text|705|1001|This study examines the initial psychometric properties of the BBES using a sample of 348 children (67 of which had SEN, mean age=10 years), and compares the incidence of both victimisation and bullying in children with SEN to their peers, controlling for behavioural and emotional difficulties.
SE|25462521||ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|710|715
SE|25462521||ab|3|entity|C0205265|Initially|tmco|||initial|||0|840|729|736
SE|25462521||ab|3|entity|C0033920|Psychometrics|diap|||psychometric|||0|840|737|749
SE|25462521||ab|3|entity|C0871161|Property|qlco|||properties|||0|840|750|760
SE|25462521||ab|3|entity|C0424318|Bullying|mobd|||BBES|||0|700|768|772
SE|25462521||ab|3|entity|C0004927|Behavior|inbe|||BBES|||0|700|768|772
SE|25462521||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|861|795|803
SE|25462521||ab|3|entity|C0556278|Special educational needs|fndg|||SEN|||0|1000|821|824
SE|25462521||ab|3|entity|C0001779|Age|orga|||age|||0|861|831|834
SE|25462521||ab|3|entity|C0439234|year|tmco|||years|||0|861|838|843
SE|25462521||ab|3|entity|C0021149|Incidence|qnco|||incidence|||0|1000|863|872
SE|25462521||ab|3|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|881|894
SE|25462521||ab|3|entity|C0424318|Bullying|mobd|||bullying|||0|1000|899|907
SE|25462521||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|1000|911|919
SE|25462521||ab|3|entity|C0556278|Special educational needs|fndg|||SEN|||0|1000|925|928
SE|25462521||ab|3|entity|C0679739|peer|popg|||peers|||0|1000|938|943
SE|25462521||ab|3|entity|C0849912|Emotional|fndg|||emotional|||0|872|977|986
SE|25462521||ab|3|relation|4|1|C0556278|Special educational needs|fndg|fndg|||SEN|||0|1000|925|928|PREP|PROCESS_OF||920|924|11|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|911|919
SE|25462521||ab|3|relation|10|1|C0424318|Bullying|mobd|mobd|||bullying|||0|1000|899|907|PREP|PROCESS_OF||908|910|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|911|919

SE|25462521||ab|4|text|1001|1143|Overall, the BBES showed favourable psychometric properties using multi-group confirmatory factor analyses and differential item functioning.
SE|25462521||ab|4|entity|C1561607|Overall|qlco|||Overall|||0|1000|1001|1008
SE|25462521||ab|4|entity|C0424318|Bullying|mobd|||BBES|||0|720|1014|1018
SE|25462521||ab|4|entity|C0004927|Behavior|inbe|||BBES|||0|720|1014|1018
SE|25462521||ab|4|entity|C0033920|Psychometrics|diap|||psychometric|||0|816|1037|1049
SE|25462521||ab|4|entity|C0871161|Property|qlco|||properties|||0|816|1050|1060
SE|25462521||ab|4|entity|C1442112|MULTI|qnco|||multi|||0|868|1067|1072
SE|25462521||ab|4|entity|C0441833|Groups|inpr|||group|||0|868|1073|1078
SE|25462521||ab|4|entity|C0870334|Confirmatory Factor Analysis|qlco|||confirmatory factor analyses|||0|868|1079|1107
SE|25462521||ab|4|entity|C0031843|physiological aspects|phsf|||functioning|||0|793|1130|1141

SE|25462521||ab|5|text|1143|1456|Comparing the frequency of victimisation and bullying using the BBES showed that children with SEN were not more likely to experience victimisation compared to their peers but when extant behavioural and emotional difficulties were controlled for then they were significantly more likely to report victimisation.
SE|25462521||ab|5|entity|C0439603|Frequencies (time pattern)|tmco|||frequency|||0|1000|1157|1166
SE|25462521||ab|5|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|1170|1183
SE|25462521||ab|5|entity|C0424318|Bullying|mobd|||bullying|||0|1000|1188|1196
SE|25462521||ab|5|entity|C0424318|Bullying|mobd|||BBES|||0|720|1207|1211
SE|25462521||ab|5|entity|C0004927|Behavior|inbe|||BBES|||0|720|1207|1211
SE|25462521||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1224|1232
SE|25462521||ab|5|entity|C0556278|Special educational needs|fndg|||SEN|||0|1000|1238|1241
SE|25462521||ab|5|entity|C1518422|Not|ftcn|||not|||0|802|1247|1250
SE|25462521||ab|5|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|1277|1290
SE|25462521||ab|5|entity|C0679739|peer|popg|||peers|||0|1000|1309|1314
SE|25462521||ab|5|entity|C0849912|Emotional|fndg|||emotional|||0|872|1347|1356
SE|25462521||ab|5|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|1441|1454
SE|25462521||ab|5|relation|6|1|C0556278|Special educational needs|fndg|fndg|||SEN|||0|1000|1238|1241|PREP|PROCESS_OF||1233|1237|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1224|1232

SE|25462521||ab|6|text|1456|1643|Conversely, children with SEN were more likely to report bullying compared to their peers, but this effect disappeared when extant behavioural and emotional difficulties were controlled.
SE|25462521||ab|6|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1468|1476
SE|25462521||ab|6|entity|C0556278|Special educational needs|fndg|||SEN|||0|1000|1482|1485
SE|25462521||ab|6|entity|C0205172|More|ftcn|||more|||0|888|1491|1495
SE|25462521||ab|6|entity|C0424318|Bullying|mobd|||bullying|||0|1000|1513|1521
SE|25462521||ab|6|entity|C0679739|peer|popg|||peers|||0|1000|1540|1545
SE|25462521||ab|6|entity|C1280500|Effect|qlco|||effect|||0|1000|1556|1562
SE|25462521||ab|6|entity|C0849912|Emotional|fndg|||emotional|||0|872|1603|1612
SE|25462521||ab|6|relation|6|1|C0556278|Special educational needs|fndg|fndg|||SEN|||0|1000|1482|1485|PREP|PROCESS_OF||1477|1481|1|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1468|1476

SE|25462521||ab|7|text|1643|1748|Overall, the BBES appears to be a promising measure of victimisation and bullying for children with SEN.
SE|25462521||ab|7|entity|C1561607|Overall|qlco|||Overall|||0|1000|1643|1650
SE|25462521||ab|7|entity|C0424318|Bullying|mobd|||BBES|||0|720|1656|1660
SE|25462521||ab|7|entity|C0004927|Behavior|inbe|||BBES|||0|720|1656|1660
SE|25462521||ab|7|entity|C1555307|promise|idcn|||promising|||0|872|1677|1686
SE|25462521||ab|7|entity|C0079809|Measures|qnco|||measure|||0|872|1687|1694
SE|25462521||ab|7|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|1698|1711
SE|25462521||ab|7|entity|C0424318|Bullying|mobd|||bullying|||0|1000|1716|1724
SE|25462521||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1729|1737
SE|25462521||ab|7|entity|C0556278|Special educational needs|fndg|||SEN|||0|1000|1743|1746
SE|25462521||ab|7|relation|1|1|C0556278|Special educational needs|fndg|fndg|||SEN|||0|1000|1743|1746|PREP|PROCESS_OF||1738|1742|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1729|1737

SE|25462521||ab|8|text|1748|1971|This study also highlights the need to consider SEN status independently of behavioural and emotional problems to help understand the nature and extent of bullying and victimisation in this important population of children.
SE|25462521||ab|8|entity|C0008972|Clinical Research|resa|||study|||0|1000|1753|1758
SE|25462521||ab|8|entity|C0027552|Needs|qlco|||need|||0|1000|1779|1783
SE|25462521||ab|8|entity|C0556278|Special educational needs|fndg|||SEN|||0|916|1796|1799
SE|25462521||ab|8|entity|C0449438|Status|qlco|||status|||0|916|1800|1806
SE|25462521||ab|8|entity|C0677660|Emotional problems|fndg|||emotional problems|||0|1000|1840|1858
SE|25462521||ab|8|entity|C0349590|Nature|idcn|||nature|||0|1000|1882|1888
SE|25462521||ab|8|entity|C0439792|Extent|spco|||extent|||0|1000|1893|1899
SE|25462521||ab|8|entity|C0424318|Bullying|mobd|||bullying|||0|1000|1903|1911
SE|25462521||ab|8|entity|C0376695|Victimization|hcpp|||victimisation|||0|1000|1916|1929
SE|25462521||ab|8|entity|C1257890|Population Group|popg|||population|||0|861|1948|1958
SE|25462521||ab|8|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1962|1970
SE|25462521||ab|8|relation|9|2|C0424318|Bullying|mobd|mobd|||bullying|||0|1000|1903|1911|PREP|PROCESS_OF||1930|1932|2|1|C1257890|Population Group|popg,humn|humn|||population|||0|861|1948|1958


SE|25462523||ti|1|text|21|101|Spontaneous improvement in oculomotor function of children with cerebral palsy.
SE|25462523||ti|1|entity|C0205359|Spontaneous|ftcn|||Spontaneous|||0|694|21|32
SE|25462523||ti|1|entity|C0683208|oculomotor function|ortf|||oculomotor function|||0|1000|48|67
SE|25462523||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|71|79
SE|25462523||ti|1|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|85|99
SE|25462523||ti|1|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|85|99|PREP|PROCESS_OF||80|84|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|71|79

SE|25462523||ab|1|text|107|176|Eye movements are essential to get a clear vision of moving objects.
SE|25462523||ab|1|entity|C0015413|Eye Movements|ortf|||Eye movements|||0|1000|107|120
SE|25462523||ab|1|entity|C0205224|Essential|qlco|||essential|||0|1000|125|134
SE|25462523||ab|1|entity|C0522503|Translucent|qlco|||clear|||0|888|144|149
SE|25462523||ab|1|entity|C0042789|Vision|orgf|||vision|||0|888|150|156
SE|25462523||ab|1|entity|C0560560|Moving|orgf|||moving|||0|888|160|166
SE|25462523||ab|1|entity|C0347997|Physical object|mnob|||objects|||0|888|167|174
SE|25462523||ab|1|relation|0|0|C0015413|Eye Movements|ortf|ortf|||Eye movements|||0|1000|107|120|SPEC|ISA||107|156|0|0|C0042789|Vision|orgf|orgf|||vision|||0|888|150|156

SE|25462523||ab|2|text|176|287|In the present study, we assessed quantitatively the oculomotor deficits of children with cerebral palsy (CP).
SE|25462523||ab|2|entity|C0150312|Present|qnco|||present|||0|888|183|190
SE|25462523||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|888|191|196
SE|25462523||ab|2|entity|C0872237|oculomotor|ortf|||oculomotor|||0|872|229|239
SE|25462523||ab|2|entity|C0011155|Deficiency|ftcn|||deficits|||0|872|240|248
SE|25462523||ab|2|entity|C0008059|Child|aggp,inpr|||children|||0|1000|252|260
SE|25462523||ab|2|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|266|280
SE|25462523||ab|2|relation|1|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|266|280|PREP|PROCESS_OF||261|265|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|252|260

SE|25462523||ab|3|text|287|484|We recorded eye movements of 51 children with cerebral palsy (aged 5-16 years) with relatively mild motor impairment and compared their performance with age-matched control and premature children.
SE|25462523||ab|3|entity|C0015413|Eye Movements|ortf|||eye movements|||0|1000|299|312
SE|25462523||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|861|319|327
SE|25462523||ab|3|entity|C0007789|Cerebral Palsy|dsyn|||cerebral palsy|||0|1000|333|347
SE|25462523||ab|3|entity|C1510829|Age-Years|tmco|||aged 5-16 years|||0|867|349|364
SE|25462523||ab|3|entity|C0547040|Minimal|qlco|||mild|||0|775|382|386
SE|25462523||ab|3|entity|C1513492|Motor|idcn|||motor|||0|775|387|392
SE|25462523||ab|3|entity|C0597198|Performance|inbe|||performance|||0|1000|423|434
SE|25462523||ab|3|entity|C0001779|Age|orga|||age|||0|840|440|443
SE|25462523||ab|3|entity|C0150103|MATCHING|resa|||matched|||0|840|444|451
SE|25462523||ab|3|entity|C0243148|control|ftcn|||control|||0|840|452|459
SE|25462523||ab|3|entity|C0205252|Immature|tmco|||premature|||0|888|464|473
SE|25462523||ab|3|entity|C0008059|Child|aggp,inpr|||children|||0|888|474|482
SE|25462523||ab|3|relation|6|1|C0007789|Cerebral Palsy|dsyn|dsyn|||cerebral palsy|||0|1000|333|347|PREP|PROCESS_OF||328|332|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|861|319|327

SE|25462523||ab|4|text|484|647|Overall eye movements of children with CP are unexpectedly close to those of controls even though some oculomotor parameters are biased by the side of hemiplegia.
SE|25462523||ab|4|entity|C1561607|Overall|qlco|||Overall|||0|901|484|491
SE|25462523||ab|4|entity|C0015413|Eye Movements|ortf|||eye movements|||0|901|492|505
SE|25462523||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|1000|509|517
SE|25462523||ab|4|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|523|525
SE|25462523||ab|4|entity|C0243148|control|ftcn|||controls|||0|827|561|569
SE|25462523||ab|4|entity|C0872237|oculomotor|ortf|||oculomotor|||0|888|587|597
SE|25462523||ab|4|entity|C0441987|Side|spco|||side|||0|1000|627|631
SE|25462523||ab|4|entity|C0018991|Hemiplegia|sosy|||hemiplegia|||0|1000|635|645
SE|25462523||ab|4|relation|5|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|523|525|PREP|PROCESS_OF||518|522|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|509|517

SE|25462523||ab|5|text|647|897|Importantly, the difference in performance between children with CP and controls decreases with age, demonstrating that the oculomotor function of children with CP develops as fast as or even faster than controls for some visual tracking parameters.
SE|25462523||ab|5|entity|C1547020|*Difference|qnco|||difference|||0|1000|664|674
SE|25462523||ab|5|entity|C0597198|Performance|inbe|||performance|||0|1000|678|689
SE|25462523||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|698|706
SE|25462523||ab|5|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|712|714
SE|25462523||ab|5|entity|C0001779|Age|orga|||age|||0|1000|743|746
SE|25462523||ab|5|entity|C0683208|oculomotor function|ortf|||oculomotor function|||0|1000|771|790
SE|25462523||ab|5|entity|C0008059|Child|aggp,inpr|||children|||0|1000|794|802
SE|25462523||ab|5|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|808|810
SE|25462523||ab|5|entity|C0456962|Fast|qlco|||fast|||0|1000|823|827
SE|25462523||ab|5|entity|C0456962|Fast|qlco|||faster|||0|827|839|845
SE|25462523||ab|5|entity|C0597666|visual tracking|phsf|||visual tracking|||0|901|869|884
SE|25462523||ab|5|relation|4|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|808|810|PREP|PROCESS_OF||803|807|7|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|794|802
SE|25462523||ab|5|relation|8|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|712|714|PREP|PROCESS_OF||707|711|3|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|698|706

SE|25462523||ab|6|text|897|979|That is, oculomotor function spontaneously improves over the course of childhood.
SE|25462523||ab|6|entity|C0872237|oculomotor|ortf|||oculomotor|||0|1000|906|916
SE|25462523||ab|6|entity|C0205136|Over|spco|||over|||0|1000|949|953
SE|25462523||ab|6|entity|C0750729|Course|tmco|||course|||0|1000|958|964
SE|25462523||ab|6|entity|C0231335|Childhood|tmco|||childhood|||0|1000|968|977

SE|25462523||ab|7|text|979|1160|This evolution highlights the ability of lesioned brain of children with CP to compensate for impaired motor function beyond what would be achieved by normal development on its own.
SE|25462523||ab|7|entity|C0015219|Evolution|genf|||evolution|||0|1000|984|993
SE|25462523||ab|7|entity|C0085732|Ability|orga|||ability|||0|1000|1009|1016
SE|25462523||ab|7|entity|C0221198|Lesion|fndg|||lesioned|||0|853|1020|1028
SE|25462523||ab|7|entity|C0006104|Brain|bpoc|||brain|||0|853|1029|1034
SE|25462523||ab|7|entity|C0008059|Child|aggp,inpr|||children|||0|1000|1038|1046
SE|25462523||ab|7|entity|C0007789|Cerebral Palsy|dsyn|||CP|||0|1000|1052|1054
SE|25462523||ab|7|entity|C0221099|Impaired|ftcn|||impaired|||0|901|1073|1081
SE|25462523||ab|7|entity|C0234130|Motor function|ftcn|||motor function|||0|901|1082|1096
SE|25462523||ab|7|entity|C0205307|Normal|qlco|||normal|||0|888|1130|1136
SE|25462523||ab|7|entity|C1527148|Development|ftcn|||development|||0|888|1137|1148
SE|25462523||ab|7|entity|C1546511|Owner|idcn|||own|||0|928|1156|1159
SE|25462523||ab|7|relation|3|1|C0006104|Brain|bpoc|bpoc|||brain|||0|853|1029|1034|PREP|PART_OF||1035|1037|5|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1038|1046
SE|25462523||ab|7|relation|4|1|C0007789|Cerebral Palsy|dsyn|dsyn|||CP|||0|1000|1052|1054|PREP|PROCESS_OF||1047|1051|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|1038|1046


SE|25462522||ti|1|text|21|167|For fathers raising children with autism, do coping strategies mediate or moderate the relationship between parenting stress and quality of life?
SE|25462522||ti|1|entity|C0015671|father|famg|||fathers|||0|1000|25|32
SE|25462522||ti|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|41|49
SE|25462522||ti|1|entity|C0004352|Autistic Disorder|mobd|||autism|||0|1000|55|61
SE|25462522||ti|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|108|120
SE|25462522||ti|1|entity|C0038435|Stress|fndg|||stress|||0|861|139|145
SE|25462522||ti|1|entity|C0034380|Quality of life|qlco|||quality of life|||0|1000|150|165
SE|25462522||ti|1|relation|4|1|C0004352|Autistic Disorder|mobd|mobd|||autism|||0|1000|55|61|PREP|PROCESS_OF||50|54|2|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|41|49

SE|25462522||ab|1|text|173|513|In response to the dramatic change in the perception of fatherhood and the significant expansion in fatherhood research, this study came to fill the gap in literature and examine the possible mediation and moderation effects of coping in the relationship between fathers' of children with autism parenting stress and quality of life (QoL).
SE|25462522||ab|1|entity|C0013109|Drama|inpr|||dramatic|||0|853|192|200
SE|25462522||ab|1|entity|C0030971|Perception|menp|||perception|||0|1000|215|225
SE|25462522||ab|1|entity|C0337499|Fatherhood|socb|||fatherhood|||0|1000|229|239
SE|25462522||ab|1|entity|C0750502|Significant|idcn|||significant|||0|694|248|259
SE|25462522||ab|1|entity|C0337499|Fatherhood|socb|||fatherhood|||0|888|273|283
SE|25462522||ab|1|entity|C0035168|research|resa|||research|||0|888|284|292
SE|25462522||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|299|304
SE|25462522||ab|1|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||gap|||0|1000|322|325
SE|25462522||ab|1|entity|C0023866|Literature|inpr|||literature|||0|1000|329|339
SE|25462522||ab|1|entity|C0332149|Possible|qlco|||possible|||0|888|356|364
SE|25462522||ab|1|entity|C0680727|Mediation|socb|||mediation|||0|888|365|374
SE|25462522||ab|1|entity|C1280500|Effect|qlco|||effects|||0|827|390|397
SE|25462522||ab|1|entity|C0439849|Relationships|qlco|||relationship|||0|1000|415|427
SE|25462522||ab|1|entity|C0015671|father|famg|||fathers|||0|1000|436|443
SE|25462522||ab|1|entity|C0008059|Child|aggp,inpr|||children|||0|1000|448|456
SE|25462522||ab|1|entity|C0004352|Autistic Disorder|mobd|||autism|||0|802|462|468
SE|25462522||ab|1|entity|C0038435|Stress|fndg|||stress|||0|802|479|485
SE|25462522||ab|1|entity|C0034380|Quality of life|qlco|||quality of life|||0|1000|490|505
SE|25462522||ab|1|relation|1|1|C0038435|Stress|fndg|fndg|||stress|||0|802|479|485|PREP|PROCESS_OF||457|461|15|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|448|456

SE|25462522||ab|2|text|513|741|Mediation and moderation effects were examined using multiple programs and software which included hierarchical regression, structural equation modeling and special Macros added to the analysis programs to confirm the findings.
SE|25462522||ab|2|entity|C0680727|Mediation|socb|||Mediation|||0|1000|513|522
SE|25462522||ab|2|entity|C1280500|Effect|qlco|||effects|||0|827|538|545
SE|25462522||ab|2|entity|C0439064|Numerous|qnco|||multiple|||0|694|566|574
SE|25462522||ab|2|entity|C0699032|Hierarchy|ftcn|||hierarchical|||0|623|612|624
SE|25462522||ab|2|entity|C0681947|structural equation model|resa|||structural equation modeling|||0|1000|637|665
SE|25462522||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|1000|698|706
SE|25462522||ab|2|entity|C0243095|Finding|ftcn|||findings|||0|1000|731|739

SE|25462522||ab|3|text|741|875|None of the investigated coping strategies could mediate or moderate the stress-QoL relationship among the 101 participating fathers.
SE|25462522||ab|3|entity|C1292732|Investigates|ftcn|||investigated|||0|785|753|765
SE|25462522||ab|3|entity|C0038435|Stress|fndg|||stress|||0|823|814|820
SE|25462522||ab|3|entity|C0034380|Quality of life|qlco|||QoL|||0|823|821|824
SE|25462522||ab|3|entity|C0439849|Relationships|qlco|||relationship|||0|823|825|837
SE|25462522||ab|3|entity|C1518902|Participating|ftcn|||participating|||0|790|852|865
SE|25462522||ab|3|entity|C0015671|father|famg|||fathers|||0|790|866|873

SE|25462522||ab|4|text|875|1209|This study provides interesting information on how the stress-coping-QoL relationship among fathers of children with autism can be affected by the nature of their stress provoking situation, their individual characteristics, the environment and its demands and resources, and the way fathers perceive and apply their coping responses.
SE|25462522||ab|4|entity|C0008972|Clinical Research|resa|||study|||0|1000|880|885
SE|25462522||ab|4|entity|C1533716|Information|idcn|||information|||0|861|907|918
SE|25462522||ab|4|entity|C0038435|Stress|fndg|||stress|||0|787|930|936
SE|25462522||ab|4|entity|C0034380|Quality of life|qlco|||QoL|||0|787|944|947
SE|25462522||ab|4|entity|C0439849|Relationships|qlco|||relationship|||0|787|948|960
SE|25462522||ab|4|entity|C0015671|father|famg|||fathers|||0|1000|967|974
SE|25462522||ab|4|entity|C0008059|Child|aggp,inpr|||children|||0|1000|978|986
SE|25462522||ab|4|entity|C0004352|Autistic Disorder|mobd|||autism|||0|1000|992|998
SE|25462522||ab|4|entity|C0349590|Nature|idcn|||nature|||0|1000|1022|1028
SE|25462522||ab|4|entity|C0038435|Stress|fndg|||stress|||0|606|1038|1044
SE|25462522||ab|4|entity|C1444748|Triggered by|qlco|||provoking|||0|606|1045|1054
SE|25462522||ab|4|entity|C0237401|Individual|humn|||individual|||0|888|1072|1082
SE|25462522||ab|4|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|1083|1098
SE|25462522||ab|4|entity|C0014406|Environment|spco|||environment|||0|1000|1104|1115
SE|25462522||ab|4|entity|C0035201|Resources|idcn|||resources|||0|1000|1136|1145
SE|25462522||ab|4|entity|C0015671|father|famg|||fathers|||0|861|1159|1166
SE|25462522||ab|4|entity|C1328744|Coping Responses|menp|||coping responses|||0|1000|1192|1208
SE|25462522||ab|4|relation|9|1|C0004352|Autistic Disorder|mobd|mobd|||autism|||0|1000|992|998|PREP|PROCESS_OF||987|991|4|1|C0008059|Child|aggp,humn,inpr|humn|||children|||0|1000|978|986


SE|25462524||ti|1|text|21|114|Teaching individuals with intellectual disability to email across multiple device platforms.
SE|25462524||ti|1|entity|C0039401|Educational process of instructing|edac|||Teaching|||0|888|21|29
SE|25462524||ti|1|entity|C0237401|Individual|humn|||individuals|||0|888|30|41
SE|25462524||ti|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|47|70
SE|25462524||ti|1|entity|C0013849|email|inpr|||email|||0|1000|74|79
SE|25462524||ti|1|entity|C0439064|Numerous|qnco|||multiple|||0|623|87|95
SE|25462524||ti|1|entity|C0699733|Devices|mnob|||device|||0|623|96|102
SE|25462524||ti|1|relation|3|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|47|70|PREP|PROCESS_OF||42|46|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|888|30|41

SE|25462524||ab|1|text|120|269|The purpose of this study was to examine the use of email by people with intellectual disability across multiple technological devices or platforms.
SE|25462524||ab|1|entity|C1285529|Purpose|ftcn|||purpose|||0|1000|124|131
SE|25462524||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|140|145
SE|25462524||ab|1|entity|C0013849|email|inpr|||email|||0|1000|172|177
SE|25462524||ab|1|entity|C0027361|Persons|popg|||people|||0|1000|181|187
SE|25462524||ab|1|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|193|216
SE|25462524||ab|1|entity|C0439064|Numerous|qnco|||multiple|||0|828|224|232
SE|25462524||ab|1|entity|C0039421|Technology|ocdi|||technological|||0|828|233|246
SE|25462524||ab|1|entity|C0220819|device aspects|mnob|||devices|||0|828|247|254
SE|25462524||ab|1|relation|3|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|193|216|PREP|PROCESS_OF||188|192|5|1|C0027361|Persons|popg,humn|humn|||people|||0|1000|181|187

SE|25462524||ab|2|text|269|343|Four individuals with intellectual disability participated in this study.
SE|25462524||ab|2|entity|C0205450|Four|qnco|||Four|||0|888|269|273
SE|25462524||ab|2|entity|C0237401|Individual|humn|||individuals|||0|888|274|285
SE|25462524||ab|2|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|291|314
SE|25462524||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|336|341
SE|25462524||ab|2|relation|2|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|291|314|PREP|PROCESS_OF||286|290|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|888|274|285

SE|25462524||ab|3|text|343|466|Participants were taught how to access and send an email on a Windows desktop computer, laptop, and an iPad tablet device.
SE|25462524||ab|3|entity|C0679646|Participant|popg|||Participants|||0|966|343|355
SE|25462524||ab|3|entity|C0013849|email|inpr|||email|||0|1000|394|399
SE|25462524||ab|3|entity|C0557702|Window|mnob|||Windows|||0|785|405|412
SE|25462524||ab|3|entity|C0009622|Computers|mnob|||computer|||0|785|421|429
SE|25462524||ab|3|entity|C0599108|laptop|mnob|||laptop|||0|1000|431|437
SE|25462524||ab|3|entity|C0039225|Tablets|bodm|||tablet|||0|790|451|457
SE|25462524||ab|3|entity|C0699733|Devices|mnob|||device|||0|790|458|464

SE|25462524||ab|4|text|466|507|Results indicated a functional relation.
SE|25462524||ab|4|entity|C1274040|result|ftcn|||Results|||0|966|466|473
SE|25462524||ab|4|entity|C0205245|Functional|ftcn|||functional|||0|872|486|496
SE|25462524||ab|4|entity|C0869014|Relations|socb|||relation|||0|872|497|505

SE|25462524||ab|5|text|507|605|All participants acquired and generalized sending and receiving an email from multiple platforms.
SE|25462524||ab|5|entity|C0679646|Participant|popg|||participants|||0|966|511|523
SE|25462524||ab|5|entity|C0205246|Generalized|spco|||generalized|||0|694|537|548
SE|25462524||ab|5|entity|C0013849|email|inpr|||email|||0|1000|574|579
SE|25462524||ab|5|entity|C0439064|Numerous|qnco|||multiple|||0|694|585|593

SE|25462524||ab|6|text|605|821|Conclusions are discussed about the importance of empowering people with intellectual disability by providing multiple means of expression, including the ability to communicate effectively using a variety of devices.
SE|25462524||ab|6|entity|C0562342|Empowered|menp|||empowering|||0|872|655|665
SE|25462524||ab|6|entity|C0027361|Persons|popg|||people|||0|872|666|672
SE|25462524||ab|6|entity|C0453879|Intellectual functioning disability|fndg|||intellectual disability|||0|1000|678|701
SE|25462524||ab|6|entity|C0439064|Numerous|qnco|||multiple|||0|606|715|723
SE|25462524||ab|6|entity|C0085732|Ability|orga|||ability|||0|1000|759|766
SE|25462524||ab|6|entity|C0220819|device aspects|mnob|||devices|||0|1000|813|820
SE|25462524||ab|6|relation|0|0|C0562342|Empowered|menp|menp|||empowering|||0|872|655|665|MOD/HEAD|PROCESS_OF||655|672|0|0|C0027361|Persons|popg,humn|humn|||people|||0|872|666|672
SE|25462524||ab|6|relation|6|1|C0453879|Intellectual functioning disability|fndg|fndg|||intellectual disability|||0|1000|678|701|PREP|PROCESS_OF||673|677|3|1|C0027361|Persons|popg,humn|humn|||people|||0|872|666|672


SE|25462525||ti|1|text|21|86|Directing collagen fibers using counter-rotating cone extrusion.
SE|25462525||ti|1|entity|C0225325|Collagen fiber|tisu|||collagen fibers|||0|884|31|46
SE|25462525||ti|1|entity|C0443213|Extrusion|qlco|||extrusion|||0|861|75|84

SE|25462525||ab|1|text|92|250|The bio-inspired engineering of tissue equivalents should take into account anisotropic morphology and the mechanical properties of the extracellular matrix.
SE|25462525||ab|1|entity|C0205460|biological|ftcn|||bio|||0|851|96|99
SE|25462525||ab|1|entity|C0004048|Inspiration function|ortf|||inspired|||0|851|100|108
SE|25462525||ab|1|entity|C0014279|Engineering|ocdi|||engineering|||0|851|109|120
SE|25462525||ab|1|entity|C0439185|Eq|qnco|||equivalents|||0|861|131|142
SE|25462525||ab|1|entity|C1551359|account|idcn|||account|||0|828|160|167
SE|25462525||ab|1|entity|C0085406|Anisotropy|npop|||anisotropic|||0|828|168|179
SE|25462525||ab|1|entity|C0332437|Morphology|qlco|||morphology|||0|828|180|190
SE|25462525||ab|1|entity|C0871161|Property|qlco|||properties|||0|827|210|220
SE|25462525||ab|1|entity|C0015350|Extracellular Matrix|tisu|||extracellular matrix|||0|1000|228|248

SE|25462525||ab|2|text|250|379|This especially applies to collagen fibrils, which have various, but highly defined, orientations throughout tissues and organs.
SE|25462525||ab|2|entity|C1179626|Collagen fibril|tisu|||collagen fibrils|||0|983|277|293
SE|25462525||ab|2|entity|C0029266|psychological orientation|menp|||orientations|||0|1000|335|347
SE|25462525||ab|2|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|359|366
SE|25462525||ab|2|entity|C0178784|Organ|bpoc|||organs|||0|966|371|377

SE|25462525||ab|3|text|379|542|There are several methods available to control the alignment of soluble collagen monomers, but the options to direct native insoluble collagen fibers are limited.
SE|25462525||ab|3|entity|C0443302|Several|qnco|||several|||0|888|389|396
SE|25462525||ab|3|entity|C0025663|Methods|inpr|||methods|||0|888|397|404
SE|25462525||ab|3|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|773|451|459
SE|25462525||ab|3|entity|C0596973|monomer|chvs|||monomers|||0|773|460|468
SE|25462525||ab|3|entity|C1518601|Options|ftcn|||options|||0|1000|478|485
SE|25462525||ab|3|entity|C0302891|Native|ftcn|||native|||0|813|496|502
SE|25462525||ab|3|entity|C0225325|Collagen fiber|tisu|||collagen fibers|||0|813|513|528

SE|25462525||ab|4|text|542|677|Here we apply a controlled counter-rotating cone extrusion technology to engineer tubular collagen constructs with defined anisotropy.
SE|25462525||ab|4|entity|C0702113|Controlled|ftcn|||controlled|||0|1000|558|568
SE|25462525||ab|4|entity|C0443213|Extrusion|qlco|||extrusion|||0|790|591|600
SE|25462525||ab|4|entity|C0039421|Technology|ocdi|||technology|||0|790|601|611
SE|25462525||ab|4|entity|C0878517|Engineer|prog|||engineer|||0|851|615|623
SE|25462525||ab|4|entity|C0151747|Renal tubular disorder|dsyn|||tubular|||0|851|624|631
SE|25462525||ab|4|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|851|632|640
SE|25462525||ab|4|entity|C0085406|Anisotropy|npop|||anisotropy|||0|861|665|675

SE|25462525||ab|5|text|677|943|Driven by diverging inner and outer cone rotation speeds, collagen fibrils from bovine skin were extruded and precipitated onto mandrels as tubes with oriented fibers and bundles, as examined by second harmonic generation microscopy and quantitative image analysis.
SE|25462525||ab|5|entity|C0205102|Intrinsic|spco|||inner|||0|1000|697|702
SE|25462525||ab|5|entity|C0205101|Extrinsic|spco|||outer|||0|764|707|712
SE|25462525||ab|5|entity|C0035868|Rotation|ftcn|||rotation|||0|764|718|726
SE|25462525||ab|5|entity|C1179626|Collagen fibril|tisu|||collagen fibrils|||0|983|735|751
SE|25462525||ab|5|entity|C0007452|Cattle|mamm|||bovine|||0|888|757|763
SE|25462525||ab|5|entity|C0037267|Integumentary system|bdsy|||skin|||0|888|764|768
SE|25462525||ab|5|entity|C0181721|Mandrels|medd|||mandrels|||0|1000|805|813
SE|25462525||ab|5|entity|C0175730|biomedical tube device|medd|||tubes|||0|1000|817|822
SE|25462525||ab|5|entity|C1304649|Tissue fiber|tisu|||fibers|||0|861|837|843
SE|25462525||ab|5|entity|C0457385|seconds|tmco|||second|||0|764|872|878
SE|25462525||ab|5|entity|C0079411|Generations|tmco|||generation|||0|764|888|898
SE|25462525||ab|5|entity|C0026018|Microscopy|lbpr|||microscopy|||0|764|899|909
SE|25462525||ab|5|entity|C0200767|Image analysis, quantitative|lbpr|||quantitative image analysis|||0|1000|914|941

SE|25462525||ab|6|text|943|1152|A clear correlation was found whereby the direction and extent of collagen fiber alignment during extrusion were a function of the shear forces caused by a combination of the cone rotation and flow direction.
SE|25462525||ab|6|entity|C0522503|Translucent|qlco|||clear|||0|694|945|950
SE|25462525||ab|6|entity|C0449738|Direction|spco|||direction|||0|1000|985|994
SE|25462525||ab|6|entity|C0439792|Extent|spco|||extent|||0|1000|999|1005
SE|25462525||ab|6|entity|C0225325|Collagen fiber|tisu|||collagen fiber|||0|734|1009|1023
SE|25462525||ab|6|entity|C0443213|Extrusion|qlco|||extrusion|||0|1000|1041|1050
SE|25462525||ab|6|entity|C0031843|physiological aspects|phsf|||function|||0|1000|1058|1066
SE|25462525||ab|6|entity|C0441722|Force|phpr|||forces|||0|966|1080|1086
SE|25462525||ab|6|entity|C0205195|Combined|qlco|||combination|||0|1000|1099|1110
SE|25462525||ab|6|entity|C0035868|Rotation|ftcn|||rotation|||0|861|1123|1131
SE|25462525||ab|6|entity|C0806140|Flow|orga|||flow|||0|888|1136|1140
SE|25462525||ab|6|entity|C0449738|Direction|spco|||direction|||0|888|1141|1150

SE|25462525||ab|7|text|1152|1346|A gradual change in the fiber direction, spanning +50 to -40 degrees , was observed throughout the sections of the sample, with an average decrease ranging from 2.3 to 2.6 degrees  every 10MUm.
SE|25462525||ab|7|entity|C0439833|Gradual|qlco|||gradual|||0|888|1154|1161
SE|25462525||ab|7|entity|C0225326|Fiber|phsu|||fiber|||0|888|1176|1181
SE|25462525||ab|7|entity|C0449738|Direction|spco|||direction|||0|888|1182|1191
SE|25462525||ab|7|entity|C1510992|Average|qnco|||average|||0|840|1283|1290
SE|25462525||ab|7|entity|C0547047|Decrease|qnco|||decrease|||0|840|1291|1299
SE|25462525||ab|7|entity|C1514721|Range|qnco|||ranging|||0|840|1300|1307

SE|25462525||ab|8|text|1346|1494|By varying the cone speeds, the collagen constructs showed differences in elasticity and toughness, spanning 900-2000kPa and 19-35mJ, respectively.
SE|25462525||ab|8|entity|C1548673|Varies|inpr|||varying|||0|966|1349|1356
SE|25462525||ab|8|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|694|1378|1386
SE|25462525||ab|8|entity|C1547020|*Difference|qnco|||differences|||0|966|1405|1416
SE|25462525||ab|8|entity|C0013764|elasticity|npop|||elasticity|||0|1000|1420|1430

SE|25462525||ab|9|text|1494|1687|Rotational extrusion presents an enabling technology to create and control the (an)isotropic architecture of collagen constructs for application in tissue engineering and regenerative medicine.
SE|25462525||ab|9|entity|C0445237|Rotational|spco|||Rotational|||0|888|1494|1504
SE|25462525||ab|9|entity|C0443213|Extrusion|qlco|||extrusion|||0|888|1505|1514
SE|25462525||ab|9|entity|C1171285|Enabling|menp|||enabling|||0|888|1527|1535
SE|25462525||ab|9|entity|C0039421|Technology|ocdi|||technology|||0|888|1536|1546
SE|25462525||ab|9|entity|C0745428|Isotropy|fndg|||isotropic|||0|754|1577|1586
SE|25462525||ab|9|entity|C0003737|Architecture|ocdi|||architecture|||0|754|1587|1599
SE|25462525||ab|9|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|1000|1603|1611
SE|25462525||ab|9|entity|C0596171|Tissue Engineering|topp|||tissue engineering|||0|1000|1642|1660
SE|25462525||ab|9|entity|C1257974|Regenerative Medicine|bmod|||regenerative medicine|||0|1000|1665|1686


SE|25462526||ti|1|text|21|155|Visible-light-initiated hydrogels preserving cartilage extracellular signaling for inducing chondrogenesis of mesenchymal stem cells.
SE|25462526||ti|1|entity|C0242377|Light, Visible|npop|||Visible-light|||0|850|21|34
SE|25462526||ti|1|entity|C1548602|Initiate|idcn|||initiated|||0|850|35|44
SE|25462526||ti|1|entity|C0600484|Hydrogels|bodm|||hydrogels|||0|850|45|54
SE|25462526||ti|1|entity|C0007301|Cartilage|tisu|||cartilage|||0|851|66|75
SE|25462526||ti|1|entity|C0521119|Extracellular|celc|||extracellular|||0|851|76|89
SE|25462526||ti|1|entity|C0037083|Signal Transduction|celf|||signaling|||0|851|90|99
SE|25462526||ti|1|entity|C0205263|Induced|ftcn|||inducing|||0|872|104|112
SE|25462526||ti|1|entity|C0598067|Chondrogenesis|ortf|||chondrogenesis|||0|872|113|127
SE|25462526||ti|1|entity|C1257975|Mesenchymal Stem Cells|cell|||mesenchymal stem cells|||0|1000|131|153
SE|25462526||ti|1|relation|0|0|C0521119|Extracellular|celc|celc|||extracellular|||0|851|76|89|MOD/HEAD|PART_OF||66|89|0|0|C0007301|Cartilage|tisu|tisu|||cartilage|||0|851|66|75

SE|25462526||ab|1|text|161|346|Hydrogels have a unique opportunity to regenerate damaged cartilage tissues by introducing mesenchymal stem cells (MSCs) in a highly swollen environment similar to articular cartilage.
SE|25462526||ab|1|entity|C0600484|Hydrogels|bodm|||Hydrogels|||0|1000|161|170
SE|25462526||ab|1|entity|C0007301|Cartilage|tisu|||cartilage tissues|||0|884|219|236
SE|25462526||ab|1|entity|C1292748|Introduces|ftcn|||introducing|||0|905|240|251
SE|25462526||ab|1|entity|C1257975|Mesenchymal Stem Cells|cell|||mesenchymal stem cells|||0|905|252|274
SE|25462526||ab|1|entity|C0038999|Swelling|fndg|||swollen|||0|790|294|301
SE|25462526||ab|1|entity|C0014406|Environment|spco|||environment|||0|790|302|313
SE|25462526||ab|1|entity|C0007303|Structure of articular cartilage|tisu|||articular cartilage|||0|1000|325|344
SE|25462526||ab|1|relation|3|1|C0014406|Environment|spco|spco|||environment|||0|790|302|313|PREP|LOCATION_OF||282|284|4|1|C1257975|Mesenchymal Stem Cells|cell|cell|||mesenchymal stem cells|||0|905|252|274

SE|25462526||ab|2|text|346|552|During cartilage development, collagen-cell interactions play an important role in mediating early mesenchymal condensation and chondrogenesis with transforming growth factor-beta1 (TGF-beta1) stimulation.
SE|25462526||ab|2|entity|C1268862|Cartilage formation|orgf,ortf|||cartilage development|||0|1000|353|374
SE|25462526||ab|2|entity|C0009325|Collagen|aapp,bacs,bodm|||collagen|||0|901|376|384
SE|25462526||ab|2|entity|C0007582|Cell Communication|celf|||cell interactions|||0|901|385|402
SE|25462526||ab|2|entity|C0035820|Role|socb|||role|||0|861|421|425
SE|25462526||ab|2|entity|C1279919|Early|tmco|||early|||0|623|439|444
SE|25462526||ab|2|entity|C1513143|Mesenchymal|qlco|||mesenchymal|||0|623|445|456
SE|25462526||ab|2|entity|C0598067|Chondrogenesis|ortf|||chondrogenesis|||0|1000|474|488
SE|25462526||ab|2|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|transforming growth factor-beta1|||0|928|494|526

SE|25462526||ab|3|text|552|814|Here, a hydrogel environment that can enhance cell-matrix interactions and chondrogenesis by stabilizing type-II collagen (Col II) and TGF-beta1 into photopolymerizable (methacrylated) chitosan (MeGC) with simple entrapment and affinity binding is demonstrated.
SE|25462526||ab|3|entity|C0063083|Hydrogel|bodm|||hydrogel|||0|888|560|568
SE|25462526||ab|3|entity|C0014406|Environment|spco|||environment|||0|888|569|580
SE|25462526||ab|3|entity|C0331858|Matrix|hcro|||matrix|||0|901|603|609
SE|25462526||ab|3|entity|C0007582|Cell Communication|celf|||cell-matrix interactions|||0|901|598|622
SE|25462526||ab|3|entity|C0598067|Chondrogenesis|ortf|||chondrogenesis|||0|1000|627|641
SE|25462526||ab|3|entity|C0184512|Stabilized|qlco|||stabilizing|||0|900|645|656
SE|25462526||ab|3|entity|C0009331|Collagen Type II|aapp,bacs|||type-II collagen|||0|900|657|673
SE|25462526||ab|3|entity|C0009413|Colostrum|bdsu|||Col|||0|861|675|678
SE|25462526||ab|3|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|TGF-beta1|||0|1000|687|696
SE|25462526||ab|3|entity|C0162969|Chitosan|carb,phsu|||chitosan|||0|1000|737|745
SE|25462526||ab|3|entity|C0205352|Simple|qlco|||simple|||0|888|758|764
SE|25462526||ab|3|entity|C1285497|Entrapment|anab|||entrapment|||0|888|765|775

SE|25462526||ab|4|text|814|976|The MeGC hydrogel was designed to gel upon initiation by exposure to visible blue light in the presence of riboflavin, an aqueous initiator from natural vitamin.
SE|25462526||ab|4|entity|C0063083|Hydrogel|bodm|||hydrogel|||0|861|823|831
SE|25462526||ab|4|entity|C0017243|Gel|bodm|||gel|||0|1000|848|851
SE|25462526||ab|4|entity|C0242377|Light, Visible|npop|||visible blue light|||0|913|883|901
SE|25462526||ab|4|entity|C0035527|Riboflavin|orch,phsu,vita|||riboflavin|||0|1000|921|931
SE|25462526||ab|4|entity|C0599956|Aqueous|qlco|||aqueous|||0|694|936|943
SE|25462526||ab|4|entity|C0205296|Natural|ftcn|||natural|||0|888|959|966
SE|25462526||ab|4|entity|C0042890|Vitamins|orch,phsu,vita|||vitamin|||0|888|967|974

SE|25462526||ab|5|text|976|1139|The incorporation of Col II into MeGC hydrogels increased cellular condensation and deposition of cartilaginous extracellular matrix by encapsulated chondrocytes.
SE|25462526||ab|5|entity|C0243126|incorporation|ftcn|||incorporation|||0|1000|980|993
SE|25462526||ab|5|entity|C0009413|Colostrum|bdsu|||Col|||0|861|997|1000
SE|25462526||ab|5|entity|C0600484|Hydrogels|bodm|||hydrogels|||0|861|1014|1023
SE|25462526||ab|5|entity|C0178539|Cellular|ftcn|||cellular|||0|694|1034|1042
SE|25462526||ab|5|entity|C0333562|Deposition|ftcn|||deposition|||0|1000|1060|1070
SE|25462526||ab|5|entity|C0007301|Cartilage|tisu|||cartilaginous|||0|901|1074|1087
SE|25462526||ab|5|entity|C0015350|Extracellular Matrix|tisu|||extracellular matrix|||0|901|1088|1108
SE|25462526||ab|5|entity|C0205223|Encapsulated|qlco|||encapsulated|||0|888|1112|1124
SE|25462526||ab|5|entity|C0225369|Chondrocytes|cell|||chondrocytes|||0|888|1125|1137
SE|25462526||ab|5|relation|0|0|C0015350|Extracellular Matrix|tisu|tisu|||extracellular matrix|||0|901|1088|1108|MOD/HEAD|PART_OF||1074|1108|0|0|C0007301|Cartilage|tisu|tisu|||cartilaginous|||0|901|1074|1087

SE|25462526||ab|6|text|1139|1391|MeGC hydrogels containing Col II supported the release of TGF-beta1 in a controlled manner over time in chondrogenic medium and the incorporated TGF-beta1 further enhanced chondrogenesis of encapsulated chondrocytes and MSCs, especially synovial MSCs.
SE|25462526||ab|6|entity|C0600484|Hydrogels|bodm|||hydrogels|||0|861|1144|1153
SE|25462526||ab|6|entity|C0009413|Colostrum|bdsu|||Col|||0|861|1165|1168
SE|25462526||ab|6|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|TGF-beta1|||0|1000|1197|1206
SE|25462526||ab|6|entity|C0702113|Controlled|ftcn|||controlled|||0|791|1212|1222
SE|25462526||ab|6|entity|C0040223|Time|tmco|||time|||0|791|1235|1239
SE|25462526||ab|6|entity|C0439536|Medium|qlco|||medium|||0|861|1256|1262
SE|25462526||ab|6|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|TGF-beta1|||0|809|1284|1293
SE|25462526||ab|6|entity|C1517331|Further|spco|||further|||0|809|1294|1301
SE|25462526||ab|6|entity|C0598067|Chondrogenesis|ortf|||chondrogenesis|||0|809|1311|1325
SE|25462526||ab|6|entity|C0205223|Encapsulated|qlco|||encapsulated|||0|888|1329|1341
SE|25462526||ab|6|entity|C0225369|Chondrocytes|cell|||chondrocytes|||0|888|1342|1354
SE|25462526||ab|6|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|1000|1359|1363
SE|25462526||ab|6|entity|C1550315|Synovial|bpoc|||synovial|||0|854|1376|1384
SE|25462526||ab|6|entity|C1257975|Mesenchymal Stem Cells|cell|||MSCs|||0|854|1385|1389
SE|25462526||ab|6|relation|0|0|C1257975|Mesenchymal Stem Cells|cell|cell|||MSCs|||0|854|1385|1389|MOD/HEAD|PART_OF||1376|1389|0|0|C1550315|Synovial|bpoc|bpoc|||synovial|||0|854|1376|1384

SE|25462526||ab|7|text|1391|1545|Subcutaneous implantation of hydrogel cultures showed greatly improved neocartilage formation in constructs loaded with TGF-beta1 compared with controls.
SE|25462526||ab|7|entity|C0443315|subcutaneous|spco|||Subcutaneous|||0|888|1391|1403
SE|25462526||ab|7|entity|C0021107|Implantation procedure|topp|||implantation|||0|888|1404|1416
SE|25462526||ab|7|entity|C0063083|Hydrogel|bodm|||hydrogel|||0|888|1420|1428
SE|25462526||ab|7|entity|C0010453|Anthropological Culture|idcn|||cultures|||0|888|1429|1437
SE|25462526||ab|7|entity|C0184511|Improved|qlco|||improved|||0|763|1453|1461
SE|25462526||ab|7|entity|C1522492|Formation|ftcn|||formation|||0|763|1475|1484
SE|25462526||ab|7|entity|C0080222|TGFB1 protein, human|aapp,bacs|7040|TGFB1|TGF-beta1|||0|1000|1511|1520
SE|25462526||ab|7|entity|C0243148|control|ftcn|||controls|||0|966|1535|1543

SE|25462526||ab|8|text|1545|1644|These findings suggest that cartilage mimetic hydrogels have a high potential for cartilage repair.
SE|25462526||ab|8|entity|C0243095|Finding|ftcn|||findings|||0|1000|1551|1559
SE|25462526||ab|8|entity|C0007301|Cartilage|tisu|||cartilage|||0|840|1573|1582
SE|25462526||ab|8|entity|C0920591|mimetics|bmod|||mimetic|||0|840|1583|1590
SE|25462526||ab|8|entity|C0600484|Hydrogels|bodm|||hydrogels|||0|840|1591|1600
SE|25462526||ab|8|entity|C0205250|High|qlco|||high|||0|888|1608|1612
SE|25462526||ab|8|entity|C0237399|Potential|qlco|||potential|||0|888|1613|1622
SE|25462526||ab|8|entity|C1112785|Cartilage repair|topp|||cartilage repair|||0|1000|1627|1643


SE|25462527||ti|1|text|21|150|To what extent can cortical bone millimeter-scale elasticity be predicted by a two-phase composite model with variable porosity?
SE|25462527||ti|1|entity|C0439792|Extent|spco|||extent|||0|1000|29|35
SE|25462527||ti|1|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|840|40|53
SE|25462527||ti|1|entity|C0439200|millimeter|qnco|||millimeter|||0|840|54|64
SE|25462527||ti|1|entity|C0013764|elasticity|npop|||elasticity|||0|840|71|81
SE|25462527||ti|1|entity|C0205448|Two|qnco|||two|||0|833|100|103
SE|25462527||ti|1|entity|C0205390|Phase|tmco|||phase|||0|833|104|109
SE|25462527||ti|1|entity|C0205199|Composite|qlco|||composite|||0|833|110|119
SE|25462527||ti|1|entity|C0026336|Study models|inpr,resd|||model|||0|833|120|125
SE|25462527||ti|1|entity|C0439828|Variable|qlco|||variable|||0|888|131|139
SE|25462527||ti|1|entity|C0080037|Porosity|qlco|||porosity|||0|888|140|148

SE|25462527||ab|1|text|156|327|An evidence gap exists in fully understanding and reliably modeling the variations in elastic anisotropy that are observed at the millimeter scale in human cortical bone.
SE|25462527||ab|1|entity|C0061928|GTPase-Activating Proteins|aapp,bacs|||gap|||0|861|168|171
SE|25462527||ab|1|entity|C0205419|Variant|qlco|||variations|||0|966|228|238
SE|25462527||ab|1|entity|C0681018|elastic|ftcn|||elastic|||0|888|242|249
SE|25462527||ab|1|entity|C0085406|Anisotropy|npop|||anisotropy|||0|888|250|260
SE|25462527||ab|1|entity|C0439200|millimeter|qnco|||millimeter|||0|888|286|296
SE|25462527||ab|1|entity|C0020114|Human|humn|||human|||0|901|306|311
SE|25462527||ab|1|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|901|312|325
SE|25462527||ab|1|relation|0|0|C0222652|Cortex of bone|bpoc|bpoc|||cortical bone|||0|901|312|325|MOD/HEAD|PART_OF||306|325|0|0|C0020114|Human|grup,humn|humn|||human|||0|901|306|311
SE|25462527||ab|1|relation|1|1|C0222652|Cortex of bone|bpoc|bpoc|||cortical bone|||0|901|312|325|PREP|LOCATION_OF||303|305|5|5|C0061928|GTPase-Activating Proteins|aapp,gngm,bacs|aapp|||gap|||0|861|168|171

SE|25462527||ab|2|text|327|444|The porosity (pore volume fraction) is known to account for a large part, but not all, of the elasticity variations.
SE|25462527||ab|2|entity|C0080037|Porosity|qlco|||porosity|||0|1000|331|339
SE|25462527||ab|2|entity|C1264666|Volume fraction|qnco|||volume fraction|||0|901|346|361
SE|25462527||ab|2|entity|C0549177|Large|qnco|||large|||0|888|389|394
SE|25462527||ab|2|entity|C0449719|Part|spco|||part|||0|888|395|399
SE|25462527||ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|405|408
SE|25462527||ab|2|entity|C0013764|elasticity|npop|||elasticity|||0|872|421|431
SE|25462527||ab|2|entity|C0205419|Variant|qlco|||variations|||0|872|432|442

SE|25462527||ab|3|text|444|574|This effect may be modeled by a two-phase micromechanical model consisting of a homogeneous matrix pervaded by cylindrical pores.
SE|25462527||ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|449|455
SE|25462527||ab|3|entity|C0205448|Two|qnco|||two|||0|775|476|479
SE|25462527||ab|3|entity|C0205390|Phase|tmco|||phase|||0|775|480|485
SE|25462527||ab|3|entity|C0026336|Study models|inpr,resd|||model|||0|775|502|507
SE|25462527||ab|3|entity|C0331858|Matrix|hcro|||matrix|||0|861|536|542
SE|25462527||ab|3|entity|C0205114|Cylindrical|spco|||cylindrical|||0|694|555|566

SE|25462527||ab|4|text|574|650|Although this model has been widely used, it lacks experimental validation.
SE|25462527||ab|4|entity|C0026336|Study models|inpr,resd|||model|||0|1000|588|593
SE|25462527||ab|4|entity|C1517004|Experimental|ftcn|||experimental|||0|888|625|637
SE|25462527||ab|4|entity|C1519941|Validation|resa|||validation|||0|888|638|648

SE|25462527||ab|5|text|650|928|The aim of the present work is to revisit experimental data (elastic coefficients, porosity) previously obtained from 21 cortical bone specimens from the femoral mid-diaphysis of 10 donors and test the validity of the model by proposing a detailed discussion of its hypotheses.
SE|25462527||ab|5|entity|C0150312|Present|qnco|||present|||0|888|665|672
SE|25462527||ab|5|entity|C0043227|Work|ocac|||work|||0|888|673|677
SE|25462527||ab|5|entity|C1517004|Experimental|ftcn|||experimental|||0|888|692|704
SE|25462527||ab|5|entity|C1511726|Data|idcn|||data|||0|888|705|709
SE|25462527||ab|5|entity|C0681018|elastic|ftcn|||elastic|||0|872|711|718
SE|25462527||ab|5|entity|C1547015|*Coefficient|qnco|||coefficients|||0|872|719|731
SE|25462527||ab|5|entity|C0080037|Porosity|qlco|||porosity|||0|1000|733|741
SE|25462527||ab|5|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|808|771|784
SE|25462527||ab|5|entity|C0370003|Specimen|sbst|||specimens|||0|808|785|794
SE|25462527||ab|5|entity|C0588193|Bone structure of shaft of femur|bpoc|||femoral mid-diaphysis|||0|877|804|825
SE|25462527||ab|5|entity|C0013018|Donor person|humn|||donors|||0|861|832|838
SE|25462527||ab|5|entity|C0026336|Study models|inpr,resd|||model|||0|1000|868|873
SE|25462527||ab|5|entity|C1441414|PROPOSED|idcn|||proposing|||0|966|877|886
SE|25462527||ab|5|entity|C1522508|Details|qlco|||detailed|||0|872|889|897
SE|25462527||ab|5|entity|C1512571|Hypothesis|idcn|||hypotheses|||0|966|916|926
SE|25462527||ab|5|relation|7|1|C0588193|Bone structure of shaft of femur|bpoc|bpoc|||femoral mid-diaphysis|||0|877|804|825|PREP|PART_OF||826|828|6|1|C0013018|Donor person|grup,humn|humn|||donors|||0|861|832|838

SE|25462527||ab|6|text|928|1091|This includes investigating to what extent the experimental uncertainties, pore network modeling, and matrix elastic properties influence the model's predictions.
SE|25462527||ab|6|entity|C1292732|Investigates|ftcn|||investigating|||0|966|942|955
SE|25462527||ab|6|entity|C0439792|Extent|spco|||extent|||0|1000|964|970
SE|25462527||ab|6|entity|C1517004|Experimental|ftcn|||experimental|||0|872|975|987
SE|25462527||ab|6|entity|C0087130|Uncertainty|idcn|||uncertainties|||0|872|988|1001
SE|25462527||ab|6|entity|C0679670|network|popg|||network|||0|790|1008|1015
SE|25462527||ab|6|entity|C0870071|Modeling|inpr,resa|||modeling|||0|790|1016|1024
SE|25462527||ab|6|entity|C0331858|Matrix|hcro|||matrix|||0|840|1030|1036
SE|25462527||ab|6|entity|C0681018|elastic|ftcn|||elastic|||0|840|1037|1044
SE|25462527||ab|6|entity|C0871161|Property|qlco|||properties|||0|840|1045|1055
SE|25462527||ab|6|entity|C0026336|Study models|inpr,resd|||model's|||0|872|1070|1077
SE|25462527||ab|6|entity|C0681842|prediction|inpr|||predictions|||0|872|1078|1089

SE|25462527||ab|7|text|1091|1309|The results support the validity of the two-phase model of cortical bone which assumes that the essential source of variations of elastic properties at the millimeter-scale is the volume fraction of vascular porosity.
SE|25462527||ab|7|entity|C1274040|result|ftcn|||results|||0|966|1095|1102
SE|25462527||ab|7|entity|C0205448|Two|qnco|||two|||0|851|1131|1134
SE|25462527||ab|7|entity|C0205390|Phase|tmco|||phase|||0|851|1135|1140
SE|25462527||ab|7|entity|C0026336|Study models|inpr,resd|||model|||0|851|1141|1146
SE|25462527||ab|7|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|1000|1150|1163
SE|25462527||ab|7|entity|C0205224|Essential|qlco|||essential|||0|888|1187|1196
SE|25462527||ab|7|entity|C0205419|Variant|qlco|||variations|||0|966|1207|1217
SE|25462527||ab|7|entity|C0681018|elastic|ftcn|||elastic|||0|872|1221|1228
SE|25462527||ab|7|entity|C0871161|Property|qlco|||properties|||0|872|1229|1239
SE|25462527||ab|7|entity|C0439200|millimeter|qnco|||millimeter|||0|888|1247|1257
SE|25462527||ab|7|entity|C1264666|Volume fraction|qnco|||volume fraction|||0|1000|1271|1286
SE|25462527||ab|7|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|888|1290|1298
SE|25462527||ab|7|entity|C0080037|Porosity|qlco|||porosity|||0|888|1299|1307

SE|25462527||ab|8|text|1309|1564|We propose that the bulk of the remaining discrepancies between predicted stiffness coefficients and experimental data (RMSE between 6% and 9%) is in part due to experimental errors and part due to small variations of the extravascular matrix properties.
SE|25462527||ab|8|entity|C1527428|Remaining|qlco|||remaining|||0|872|1341|1350
SE|25462527||ab|8|entity|C1290905|Discrepancy|fndg|||discrepancies|||0|872|1351|1364
SE|25462527||ab|8|entity|C1508497|PREDICTED|clna|||predicted|||0|840|1373|1382
SE|25462527||ab|8|entity|C0427008|Stiffness|sosy|||stiffness|||0|840|1383|1392
SE|25462527||ab|8|entity|C1547015|*Coefficient|qnco|||coefficients|||0|840|1393|1405
SE|25462527||ab|8|entity|C1517004|Experimental|ftcn|||experimental|||0|888|1410|1422
SE|25462527||ab|8|entity|C1511726|Data|idcn|||data|||0|888|1423|1427
SE|25462527||ab|8|entity|C0449719|Part|spco|||part|||0|1000|1459|1463
SE|25462527||ab|8|entity|C1517004|Experimental|ftcn|||experimental|||0|888|1471|1483
SE|25462527||ab|8|entity|C0743559|error|qlco|||errors|||0|888|1484|1490
SE|25462527||ab|8|entity|C0449719|Part|spco|||part|||0|1000|1495|1499
SE|25462527||ab|8|entity|C0700321|Small|qnco|||small|||0|872|1507|1512
SE|25462527||ab|8|entity|C0205419|Variant|qlco|||variations|||0|872|1513|1523
SE|25462527||ab|8|entity|C0331858|Matrix|hcro|||matrix|||0|773|1545|1551
SE|25462527||ab|8|entity|C0871161|Property|qlco|||properties|||0|773|1552|1562

SE|25462527||ab|9|text|1564|1883|More significantly, although most of the models that have been proposed for cortical bone were based on several homogenization steps and a large number of variable parameters, we show that a model with a single parameter, namely the volume fraction of vascular porosity, is a suitable representation for cortical bone.
SE|25462527||ab|9|entity|C0205172|More|ftcn|||More|||0|861|1564|1568
SE|25462527||ab|9|entity|C0205393|Most|qnco|||most|||0|1000|1593|1597
SE|25462527||ab|9|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|1000|1640|1653
SE|25462527||ab|9|entity|C0443302|Several|qnco|||several|||0|785|1668|1675
SE|25462527||ab|9|entity|C1261552|Step|ftcn|||steps|||0|785|1691|1696
SE|25462527||ab|9|entity|C0549177|Large|qnco|||large|||0|888|1703|1708
SE|25462527||ab|9|entity|C0237753|Numbers|qnco|||number|||0|888|1709|1715
SE|25462527||ab|9|entity|C0439828|Variable|qlco|||variable|||0|888|1719|1727
SE|25462527||ab|9|entity|C0026336|Study models|inpr,resd|||model|||0|1000|1755|1760
SE|25462527||ab|9|entity|C0037179|Unmarried person|popg|||single|||0|888|1768|1774
SE|25462527||ab|9|entity|C0549193|Parameter|spco|||parameter|||0|888|1775|1784
SE|25462527||ab|9|entity|C1264666|Volume fraction|qnco|||volume fraction|||0|1000|1797|1812
SE|25462527||ab|9|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|888|1816|1824
SE|25462527||ab|9|entity|C0080037|Porosity|qlco|||porosity|||0|888|1825|1833
SE|25462527||ab|9|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|1000|1868|1881

SE|25462527||ab|10|text|1883|1966|The results could provide a guide to build specimen-specific cortical bone models.
SE|25462527||ab|10|entity|C1274040|result|ftcn|||results|||0|966|1887|1894
SE|25462527||ab|10|entity|C0370003|Specimen|sbst|||specimen|||0|623|1926|1934
SE|25462527||ab|10|entity|C0222652|Cortex of bone|bpoc|||cortical bone|||0|623|1944|1957

SE|25462527||ab|11|text|1966|2085|This will be of interest to analyze the structure-function relationship in bone and to design bone-mimicking materials.
SE|25462527||ab|11|entity|C0543488|Interested|menp|||interest|||0|1000|1982|1990
SE|25462527||ab|11|entity|C0031843|physiological aspects|phsf|||function|||0|877|2016|2024
SE|25462527||ab|11|entity|C0923800|Structural relationship|cnce|||structure-function relationship|||0|877|2006|2037
SE|25462527||ab|11|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|1000|2041|2045
SE|25462527||ab|11|entity|C1266909|Entire bony skeleton|bdsy|||bone|||0|802|2060|2064
SE|25462527||ab|11|entity|C0520510|Materials|sbst|||materials|||0|802|2075|2084


SE|25462528||ti|1|text|21|127|Photoactivated miR-148b-nanoparticle conjugates improve closure of critical size mouse calvarial defects.
SE|25462528||ti|1|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|575|36|39
SE|25462528||ti|1|entity|C1450054|Artificial nanoparticles|mnob|||nanoparticle|||0|575|45|57
SE|25462528||ti|1|entity|C1511545|Critical|qlco|||critical|||0|586|88|96
SE|25462528||ti|1|entity|C0456389|size|spco|||size|||0|586|97|101
SE|25462528||ti|1|entity|C0025914|House mice|mamm|||mouse|||0|586|102|107
SE|25462528||ti|1|entity|C0205950|Calvaria|bpoc|||calvarial|||0|586|108|117

SE|25462528||ab|1|text|133|357|Inducible systems providing temporal control of differentiation have the potential to improve outcomes in surgical reconstruction and regenerative medicine by precise modulation of wound healing and tissue repair processes.
SE|25462528||ab|1|entity|C0449913|System|ftcn|||systems|||0|861|143|150
SE|25462528||ab|1|entity|C0442043|temporal|spco|||temporal|||0|888|161|169
SE|25462528||ab|1|entity|C0243148|control|ftcn|||control|||0|888|170|177
SE|25462528||ab|1|entity|C0237399|Potential|qlco|||potential|||0|1000|206|215
SE|25462528||ab|1|entity|C1274040|result|ftcn|||outcomes|||0|966|227|235
SE|25462528||ab|1|entity|C0524865|Reconstructive Surgical Procedures|topp|||surgical reconstruction|||0|1000|239|262
SE|25462528||ab|1|entity|C1257974|Regenerative Medicine|bmod|||regenerative medicine|||0|1000|267|288
SE|25462528||ab|1|entity|C0043240|Wound Healing|orgf|||wound healing|||0|1000|314|327
SE|25462528||ab|1|entity|C0043240|Wound Healing|orgf|||tissue repair|||0|890|332|345
SE|25462528||ab|1|entity|C1522240|Process|phpr|||processes|||0|890|346|355
SE|25462528||ab|1|relation|7|2|C0524865|Reconstructive Surgical Procedures|topp|topp|||surgical reconstruction|||0|1000|239|262|NOM|AFFECTS||300|310|2|1|C0043240|Wound Healing|orgf|orgf|||tissue repair|||0|890|332|345
SE|25462528||ab|1|relation|7|2|C0524865|Reconstructive Surgical Procedures|topp|topp|||surgical reconstruction|||0|1000|239|262|NOM|AFFECTS||300|310|2|1|C0043240|Wound Healing|orgf|orgf|||wound healing|||0|1000|314|327

SE|25462528||ab|2|text|357|587|The aim of this study was to demonstrate that nanoformulated microRNA (miRNA) conjugates activated via photo exposure can lead to the induced osteogenic differentiation of human adipose-derived stromal/stem cells (hASCs) in vivo.
SE|25462528||ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|373|378
SE|25462528||ab|2|entity|C1101610|MicroRNAs|bacs,nnon|||microRNA|||0|660|418|426
SE|25462528||ab|2|entity|C1550513|via|idcn|||via|||0|660|456|459
SE|25462528||ab|2|entity|C0205263|Induced|ftcn|||induced|||0|587|491|498
SE|25462528||ab|2|entity|C0699612|Osteogen|bodm,inch,phsu|||osteogenic|||0|587|499|509
SE|25462528||ab|2|entity|C0020114|Human|humn|||human|||0|768|529|534
SE|25462528||ab|2|entity|C0162597|Stromal Cells|cell|||stromal/stem cells|||0|768|551|569
SE|25462528||ab|2|entity|C1515655|in vivo|spco|||in vivo|||0|1000|578|585
SE|25462528||ab|2|relation|4|2|C1101610|MicroRNAs|bacs,nnon|bacs|||microRNA|||0|660|418|426|ADJ|STIMULATES||491|498|4|0|C0699612|Osteogen|bodm,inch,phsu|inch|||osteogenic|||0|587|499|509

SE|25462528||ab|3|text|587|860|The conjugate PC-miR-148b-SNP, a mimic of miRNA-148b tethered to silver nanoparticles (SNPs) via a photolabile linker, was used to modulate gene expression for improved closure of a critical size defect drilled on the right parietal bone of male CD-1 nude homozygous mice.
SE|25462528||ab|3|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|740|604|607
SE|25462528||ab|3|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNP|||0|740|613|616
SE|25462528||ab|3|entity|C1537803|MIRN148B gene|gngm|442892|MIR148B|miRNA-148b|||0|1000|629|639
SE|25462528||ab|3|entity|C0037125|Silver|bacs,bodm,elii,hops|||silver|||0|660|652|658
SE|25462528||ab|3|entity|C0017262|Gene Expression|genf|||gene expression|||0|1000|727|742
SE|25462528||ab|3|entity|C0184511|Improved|qlco|||improved|||0|888|747|755
SE|25462528||ab|3|entity|C1511545|Critical|qlco|||critical|||0|851|769|777
SE|25462528||ab|3|entity|C0456389|size|spco|||size|||0|851|778|782
SE|25462528||ab|3|entity|C1457869|Defect|ftcn|||defect|||0|851|783|789
SE|25462528||ab|3|entity|C0925353|Right parietal bone|bpoc|||right parietal bone|||0|1000|805|824
SE|25462528||ab|3|entity|||gngm|909,910,911|CD1A,CD1B,CD1C|CD-1|||0|839|833|837
SE|25462528||ab|3|entity|C0025932|Mice, Nude|mamm|||nude homozygous mice|||0|839|838|858
SE|25462528||ab|3|relation|4|3|C1537803|MIRN148B gene|gngm,aapp|gngm|442892|MIR148B|miRNA-148b|||0|1000|629|639|VERB|AFFECTS||718|726|5|1|C0017262|Gene Expression|genf|genf|||gene expression|||0|1000|727|742
SE|25462528||ab|3|relation|8|1|C0925353|Right parietal bone|bpoc|bpoc|||right parietal bone|||0|1000|805|824|PREP|PART_OF||825|827|1|1|C0025932|Mice, Nude|mamm|mamm|||nude homozygous mice|||0|839|838|858

SE|25462528||ab|4|text|860|1027|The PC-miR-148b-SNP conjugates added to hASCs and loaded to either Matrigel or polycaprolactone (PCL) scaffolds resulted in different levels of healing of the defect.
SE|25462528||ab|4|entity|C1101610|MicroRNAs|bacs,nnon|||miR|||0|574|867|870
SE|25462528||ab|4|entity|C0752046|Single Nucleotide Polymorphism|nusq|||SNP|||0|574|876|879
SE|25462528||ab|4|entity|C0020114|Human|humn|||hASCs|||0|768|900|905
SE|25462528||ab|4|entity|C0162597|Stromal Cells|cell|||hASCs|||0|768|900|905
SE|25462528||ab|4|entity|C0065749|matrigel|aapp,irda|||Matrigel|||0|861|927|935
SE|25462528||ab|4|entity|C0137734|polycaprolactone|orch|||polycaprolactone|||0|1000|939|955
SE|25462528||ab|4|entity|C1333569|FLT4 gene|gngm|2324|FLT4|PCL|||0|1000|957|960
SE|25462528||ab|4|entity|C0337143|Scaffold|mnob|||scaffolds|||0|966|962|971
SE|25462528||ab|4|entity|C1547020|*Difference|qnco|||different|||0|853|984|993
SE|25462528||ab|4|entity|C0441889|Levels|inpr|||levels|||0|853|994|1000
SE|25462528||ab|4|entity|C0205249|Healed|ftcn|||healing|||0|1000|1004|1011
SE|25462528||ab|4|entity|C1457869|Defect|ftcn|||defect|||0|1000|1019|1025

SE|25462528||ab|5|text|1027|1306|After 4 and 12weeks, 3-D micro-computed tomography reconstructed images indicate statistically significant defect closure from 3.83+/-1.19% to 5.46+/-2.01% and 6.54+/-4.28% to 32.53+/-8.3% for non-photoactivated and photoactivated conjugates, respectively, in the PCL scaffolds.
SE|25462528||ab|5|entity|C1441526|COMPUTED|lbpr|||computed|||0|784|1058|1066
SE|25462528||ab|5|entity|C0040395|tomography|diap|||tomography|||0|784|1067|1077
SE|25462528||ab|5|entity|C1253948|3-D Image|mnob|||3-D micro-computed tomography reconstructed images|||0|784|1048|1098
SE|25462528||ab|5|entity|C1514961|Statistically Significant|qnco|||statistically significant|||0|861|1108|1133
SE|25462528||ab|5|entity|C1457869|Defect|ftcn|||defect|||0|861|1134|1140
SE|25462528||ab|5|entity|C1333569|FLT4 gene|gngm|2324|FLT4|PCL|||0|872|1291|1294
SE|25462528||ab|5|entity|C0337143|Scaffold|mnob|||scaffolds|||0|872|1295|1304

SE|25462528||ab|6|text|1306|1429|The results were confirmed with H&E and Masson's Trichrome stains in the transverse sections of photoactivated conjugates.
SE|25462528||ab|6|entity|C1274040|result|ftcn|||results|||0|966|1310|1317
SE|25462528||ab|6|entity|C1317796|TRANSVERSE SECTION|spco|||transverse sections|||0|983|1379|1398

SE|25462528||ab|7|text|1429|1563|Collagen fiber staining was greatest at 12weeks when it reached approximately the same density and thickness as the native calvarium.
SE|25462528||ab|7|entity|C0225325|Collagen fiber|tisu|||Collagen fiber|||0|734|1429|1443
SE|25462528||ab|7|entity|C0443228|Largest|qnco|||greatest|||0|966|1457|1465
SE|25462528||ab|7|entity|C0332232|Approximate|ftcn,qlco|||approximately|||0|1000|1493|1506
SE|25462528||ab|7|entity|C0445247|Same|qlco|||same|||0|888|1511|1515
SE|25462528||ab|7|entity|C0178587|density|npop|||density|||0|888|1516|1523
SE|25462528||ab|7|entity|C1280412|Thick|qlco|||thickness|||0|1000|1528|1537
SE|25462528||ab|7|entity|C0302891|Native|ftcn|||native|||0|888|1545|1551
SE|25462528||ab|7|entity|C0205950|Calvaria|bpoc|||calvarium|||0|888|1552|1561

SE|25462528||ab|8|text|1563|1725|This technology provides a platform that can be used with other miRNAs that actively govern the pathways responsible for regenerative and wound healing processes.
SE|25462528||ab|8|entity|C0039421|Technology|ocdi|||technology|||0|1000|1568|1578
SE|25462528||ab|8|entity|C1101610|MicroRNAs|bacs,nnon|||miRNAs|||0|1000|1627|1633
SE|25462528||ab|8|entity|C0043240|Wound Healing|orgf|||wound healing|||0|884|1701|1714
SE|25462528||ab|8|entity|C1522240|Process|phpr|||processes|||0|884|1715|1724


SE|25462530||ti|1|text|21|106|COSMID: A Web-based Tool for Identifying and Validating CRISPR/Cas Off-target Sites.
SE|25462530||ti|1|entity|C0010167|Cosmids|bacs,nnon|||COSMID|||0|1000|21|27
SE|25462530||ti|1|entity|C0332875|Congenital webbing|cgab|||Web|||0|840|31|34
SE|25462530||ti|1|entity|C0336791|Tool|mnob|||Tool|||0|840|41|45
SE|25462530||ti|1|entity|C0205396|Identified|qlco|||Identifying|||0|966|50|61
SE|25462530||ti|1|entity|C0205341|Repeat|ftcn|||CRISPR|||0|719|77|83
SE|25462530||ti|1|entity|C1366459|BCAR1 gene|gngm|9564|BCAR1|Cas|||0|719|84|87
SE|25462530||ti|1|entity|C0205145|Site|spco|||Sites|||0|888|99|104

SE|25462530||ab|1|text|112|233|Precise genome editing using engineered nucleases can significantly facilitate biological studies and disease treatment.
SE|25462530||ab|1|entity|C0017428|Genome|gngm|||genome|||0|790|120|126
SE|25462530||ab|1|entity|C0868955|Editing|ocac|||editing|||0|790|127|134
SE|25462530||ab|1|entity|C0014279|Engineering|ocdi|||engineered|||0|855|141|151
SE|25462530||ab|1|entity|C0597094|nuclease|aapp,enzy|||nucleases|||0|855|152|161
SE|25462530||ab|1|entity|C0205460|biological|ftcn|||biological|||0|872|191|201
SE|25462530||ab|1|entity|C0008972|Clinical Research|resa|||studies|||0|872|202|209
SE|25462530||ab|1|entity|C0012634|Disease|dsyn|||disease|||0|888|214|221

SE|25462530||ab|2|text|233|491|In particular, clustered regularly interspaced short palindromic repeats (CRISPR) with CRISPR-associated (Cas) proteins are a potentially powerful tool for modifying a genome by targeted cleavage of DNA sequences complementary to designed guide strand RNAs.
SE|25462530||ab|2|entity|C0205341|Repeat|ftcn|||repeats|||0|727|298|305
SE|25462530||ab|2|entity|C0009085|statistical cluster|qnco|||CRISPR|||0|542|320|326
SE|25462530||ab|2|entity|C0205341|Repeat|ftcn|||CRISPR|||0|542|320|326
SE|25462530||ab|2|entity|C1366459|BCAR1 gene|gngm|9564|BCAR1|Cas|||0|1000|339|342
SE|25462530||ab|2|entity|C0033684|Proteins|aapp,bacs|||proteins|||0|1000|344|352
SE|25462530||ab|2|entity|C0336794|Power tool|mnob|||powerful tool|||0|865|371|384
SE|25462530||ab|2|entity|C0205349|Altered|ftcn|||modifying|||0|966|389|398
SE|25462530||ab|2|entity|C0017428|Genome|gngm|||genome|||0|1000|401|407
SE|25462530||ab|2|entity|C0599894|targeting|celf|||targeted|||0|872|411|419
SE|25462530||ab|2|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|872|420|428
SE|25462530||ab|2|entity|C0012854|DNA|bacs,nnon|||DNA|||0|1000|432|435
SE|25462530||ab|2|entity|C0082774|RNA, Guide|bacs,irda,nnon|||guide strand RNAs|||0|858|472|489

SE|25462530||ab|3|text|491|771|Although CRISPR/Cas systems can have on-target cleavage rates close to the transfection rates, they may also have relatively high off-target cleavage at similar genomic sites that contain one or more base pair mismatches, and insertions or deletions relative to the guide strand.
SE|25462530||ab|3|entity|C0205341|Repeat|ftcn|||CRISPR|||0|716|500|506
SE|25462530||ab|3|entity|C1366459|BCAR1 gene|gngm|9564|BCAR1|Cas|||0|716|507|510
SE|25462530||ab|3|entity|C0449913|System|ftcn|||systems|||0|716|511|518
SE|25462530||ab|3|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|764|538|546
SE|25462530||ab|3|entity|C1521828|Rate|qnco|||rates|||0|764|547|552
SE|25462530||ab|3|entity|C0040669|Transfection|genf,mbrt|||transfection|||0|872|566|578
SE|25462530||ab|3|entity|C1521828|Rate|qnco|||rates|||0|872|579|584
SE|25462530||ab|3|entity|C0205250|High|qlco|||high|||0|861|616|620
SE|25462530||ab|3|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|888|632|640
SE|25462530||ab|3|entity|C0205145|Site|spco|||sites|||0|766|660|665
SE|25462530||ab|3|entity|C0205447|One|qnco|||one|||0|1000|679|682
SE|25462530||ab|3|entity|C0205172|More|ftcn|||more|||0|916|686|690
SE|25462530||ab|3|entity|C0600501|Base Pair Mismatch|comd|||base pair mismatches|||0|916|691|711
SE|25462530||ab|3|entity|C0021107|Implantation procedure|topp|||insertions|||0|966|717|727
SE|25462530||ab|3|entity|C1442161|DELETION|comd|||deletions|||0|966|731|740
SE|25462530||ab|3|entity|C0205345|Relative|qlco|||relative|||0|1000|741|749

SE|25462530||ab|4|text|771|979|We have developed a bioinformatics-based tool, COSMID (CRISPR Off-target Sites with Mismatches, Insertions, and Deletions) that searches genomes for potential off-target sites (http://crispr.bme.gatech.edu).
SE|25462530||ab|4|entity|C1140694|Bio-Informatics|bmod|||bioinformatics|||0|840|791|805
SE|25462530||ab|4|entity|C0336791|Tool|mnob|||tool|||0|840|812|816
SE|25462530||ab|4|entity|C0010167|Cosmids|bacs,nnon|||COSMID|||0|1000|818|824
SE|25462530||ab|4|entity|C0205341|Repeat|ftcn|||CRISPR|||0|727|826|832
SE|25462530||ab|4|entity|C0205145|Site|spco|||Sites|||0|888|844|849
SE|25462530||ab|4|entity|C0021107|Implantation procedure|topp|||Insertions|||0|966|867|877
SE|25462530||ab|4|entity|C1442161|DELETION|comd|||Deletions|||0|966|883|892
SE|25462530||ab|4|entity|C0017428|Genome|gngm|||genomes|||0|1000|908|915
SE|25462530||ab|4|entity|C0237399|Potential|qlco|||potential|||0|1000|920|929
SE|25462530||ab|4|entity|C0205145|Site|spco|||sites|||0|888|941|946
SE|25462530||ab|4|entity|C1555015|HTTP|idcn|||http|||0|1000|948|952
SE|25462530||ab|4|entity|C0059804|ethylene diurea|orch,phsu|||edu|||0|812|973|976

SE|25462530||ab|5|text|979|1197|Based on the user-supplied guide strand and input parameters, COSMID identifies potential off-target sites with the specified number of mismatched bases and insertions or deletions when compared with the guide strand.
SE|25462530||ab|5|entity|C1548600|User|idcn|||user|||0|645|992|996
SE|25462530||ab|5|entity|C0010167|Cosmids|bacs,nnon|||COSMID|||0|1000|1041|1047
SE|25462530||ab|5|entity|C0237399|Potential|qlco|||potential|||0|1000|1059|1068
SE|25462530||ab|5|entity|C0205145|Site|spco|||sites|||0|888|1080|1085
SE|25462530||ab|5|entity|C0205369|Specific qualifier value|qlco|||specified|||0|888|1095|1104
SE|25462530||ab|5|entity|C0237753|Numbers|qnco|||number|||0|888|1105|1111
SE|25462530||ab|5|entity|C0021107|Implantation procedure|topp|||insertions|||0|966|1136|1146
SE|25462530||ab|5|entity|C1442161|DELETION|comd|||deletions|||0|966|1150|1159

SE|25462530||ab|6|text|1197|1295|For each site, amplification primers optimal for the chosen application are also given as output.
SE|25462530||ab|6|entity|C0205145|Site|spco|||site|||0|1000|1206|1210
SE|25462530||ab|6|entity|C1521871|Amplification|phpr|||amplification|||0|694|1212|1225

SE|25462530||ab|7|text|1295|1581|This ranked-list of potential off-target sites assists the choice and evaluation of intended target sites, thus helping the design of CRISPR/Cas systems with minimal off-target effects, as well as the identification and quantification of CRISPR/Cas induced off-target cleavage in cells.
SE|25462530||ab|7|entity|C0699794|Rank|inpr|||ranked|||0|872|1300|1306
SE|25462530||ab|7|entity|C0745732|LIST|cnce|||list|||0|872|1307|1311
SE|25462530||ab|7|entity|C0237399|Potential|qlco|||potential|||0|1000|1315|1324
SE|25462530||ab|7|entity|C0205145|Site|spco|||sites|||0|888|1336|1341
SE|25462530||ab|7|entity|C0220825|Evaluation|ftcn|||evaluation|||0|1000|1365|1375
SE|25462530||ab|7|entity|C1551357|intended|idcn|||intended|||0|851|1379|1387
SE|25462530||ab|7|entity|C0205145|Site|spco|||sites|||0|851|1395|1400
SE|25462530||ab|7|entity|C0009085|statistical cluster|qnco|||CRISPR|||0|716|1429|1435
SE|25462530||ab|7|entity|C0205341|Repeat|ftcn|||CRISPR|||0|716|1429|1435
SE|25462530||ab|7|entity|C1366459|BCAR1 gene|gngm|9564|BCAR1|Cas|||0|716|1436|1439
SE|25462530||ab|7|entity|C0449913|System|ftcn|||systems|||0|716|1440|1447
SE|25462530||ab|7|entity|C0547040|Minimal|qlco|||minimal|||0|1000|1453|1460
SE|25462530||ab|7|entity|C1280500|Effect|qlco|||effects|||0|872|1472|1479
SE|25462530||ab|7|entity|C0009085|statistical cluster|qnco|||CRISPR|||0|719|1533|1539
SE|25462530||ab|7|entity|C0205341|Repeat|ftcn|||CRISPR|||0|719|1533|1539
SE|25462530||ab|7|entity|C1366459|BCAR1 gene|gngm|9564|BCAR1|Cas|||0|719|1540|1543
SE|25462530||ab|7|entity|C1330957|Cytokinesis of the fertilized ovum|celf|||cleavage|||0|888|1563|1571
SE|25462530||ab|7|entity|C0007634|Cells|cell|||cells|||0|1000|1575|1580
SE|25462530||ab|7|relation|1|1|C0007634|Cells|cell|cell|||cells|||0|1000|1575|1580|PREP|LOCATION_OF||1572|1574|14|1|C1330957|Cytokinesis of the fertilized ovum|celf|celf|||cleavage|||0|888|1563|1571
SE|25462530||ab|7|relation|13|1|C1366459|BCAR1 gene|gngm,aapp|gngm|9564|BCAR1|Cas|||0|719|1540|1543|VERB|CAUSES||1544|1551|2|1|C1330957|Cytokinesis of the fertilized ovum|celf|celf|||cleavage|||0|888|1563|1571


SE|25462531||ti|1|text|21|236|Validation of three automatic devices for the self-measurement of blood pressure according to the European Society of Hypertension International Protocol revision 2010: the Omron HEM-7130, HEM-7320F, and HEM-7500F.
SE|25462531||ti|1|entity|C1519941|Validation|resa|||Validation|||0|1000|21|31
SE|25462531||ti|1|entity|C0205449|Three|qnco|||three|||0|851|35|40
SE|25462531||ti|1|entity|C0205554|Automated|ftcn|||automatic|||0|851|41|50
SE|25462531||ti|1|entity|C0220819|device aspects|mnob|||devices|||0|851|51|58
SE|25462531||ti|1|entity|C0036588|Self|idcn|||self|||0|888|67|71
SE|25462531||ti|1|entity|C0242485|Measurement|ftcn|||measurement|||0|888|72|83
SE|25462531||ti|1|entity|C0005823|Blood Pressure|orgf|||blood pressure|||0|1000|87|101
SE|25462531||ti|1|entity|C0037455|Societies|orgt|||Society|||0|861|128|135
SE|25462531||ti|1|entity|C0020538|Hypertensive disease|dsyn|||Hypertension|||0|815|139|151
SE|25462531||ti|1|entity|C1512888|International|idcn|||International|||0|815|152|165
SE|25462531||ti|1|entity|C0442711|Protocols documentation|inpr|||Protocol|||0|815|166|174
SE|25462531||ti|1|entity|C0439617|Revision|tmco|||revision|||0|815|175|183
SE|25462531||ti|1|entity|C0681761|2010s|tmco|||2010|||0|815|184|188
SE|25462531||ti|1|entity|C0019080|Hemorrhage|fndg|||HEM-7130|||0|827|200|208
SE|25462531||ti|1|entity|C0019080|Hemorrhage|fndg|||HEM-7320F|||0|694|210|219
SE|25462531||ti|1|entity|C0019080|Hemorrhage|fndg|||HEM-7500F|||0|694|225|234

SE|25462531|OBJECTIVE|ab|1|text|242|499|OBJECTIVE: The aim of the present study was to validate the Omron HEM-7130, HEM-7320F, and HEM-7500F for monitoring upper arm blood pressure (BP) according to the European Society of Hypertension International Protocol revision 2010 (ESH-IP revision 2010).
SE|25462531|OBJECTIVE|ab|1|entity|C0150312|Present|qnco|||present|||0|888|268|275
SE|25462531|OBJECTIVE|ab|1|entity|C0008972|Clinical Research|resa|||study|||0|888|276|281
SE|25462531|OBJECTIVE|ab|1|entity|C0019080|Hemorrhage|fndg|||HEM-7130|||0|827|308|316
SE|25462531|OBJECTIVE|ab|1|entity|C0019080|Hemorrhage|fndg|||HEM-7320F|||0|694|318|327
SE|25462531|OBJECTIVE|ab|1|entity|C0019080|Hemorrhage|fndg|||HEM-7500F|||0|694|333|342
SE|25462531|OBJECTIVE|ab|1|entity|C0446516|Upper arm|blor|||upper arm|||0|893|358|367
SE|25462531|OBJECTIVE|ab|1|entity|C0026426|Blood pressure monitoring|diap|||monitoring upper arm blood pressure|||0|893|347|382
SE|25462531|OBJECTIVE|ab|1|entity|C0037455|Societies|orgt|||Society|||0|861|414|421
SE|25462531|OBJECTIVE|ab|1|entity|C0020538|Hypertensive disease|dsyn|||Hypertension|||0|815|425|437
SE|25462531|OBJECTIVE|ab|1|entity|C1512888|International|idcn|||International|||0|815|438|451
SE|25462531|OBJECTIVE|ab|1|entity|C0442711|Protocols documentation|inpr|||Protocol|||0|815|452|460
SE|25462531|OBJECTIVE|ab|1|entity|C0439617|Revision|tmco|||revision|||0|815|461|469
SE|25462531|OBJECTIVE|ab|1|entity|C0681761|2010s|tmco|||2010|||0|815|470|474
SE|25462531|OBJECTIVE|ab|1|entity|C0021069|Immunoprecipitation|lbpr|||ESH-IP|||0|764|476|482
SE|25462531|OBJECTIVE|ab|1|entity|C0439617|Revision|tmco|||revision|||0|764|483|491
SE|25462531|OBJECTIVE|ab|1|entity|C0681761|2010s|tmco|||2010|||0|764|492|496
SE|25462531|OBJECTIVE|ab|1|relation|0|0|C0446516|Upper arm|blor|blor|||upper arm|||0|893|358|367|MOD/HEAD|LOCATION_OF||358|382|0|0|C0026426|Blood pressure monitoring|diap|diap|||monitoring upper arm blood pressure|||0|893|347|382

SE|25462531|METHODS|ab|2|text|499|680|METHODS: Three trained medical doctors validated the performance of these devices by comparing the data obtained from the devices with those of a standard mercury sphygmomanometer.
SE|25462531|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|499|506
SE|25462531|METHODS|ab|2|entity|C0205449|Three|qnco|||Three|||0|1000|508|513
SE|25462531|METHODS|ab|2|entity|C0031831|Physicians|prog|||medical doctors|||0|1000|522|537
SE|25462531|METHODS|ab|2|entity|C0597198|Performance|inbe|||performance|||0|1000|552|563
SE|25462531|METHODS|ab|2|entity|C0220819|device aspects|mnob|||devices|||0|1000|573|580
SE|25462531|METHODS|ab|2|entity|C1511726|Data|idcn|||data|||0|1000|598|602
SE|25462531|METHODS|ab|2|entity|C0220819|device aspects|mnob|||devices|||0|1000|621|628
SE|25462531|METHODS|ab|2|entity|C1442989|STANDARD|ftcn|||standard|||0|901|645|653
SE|25462531|METHODS|ab|2|entity|C0183432|Mercury sphygmomanometer|medd|||mercury sphygmomanometer|||0|901|654|678

SE|25462531|METHODS|ab|3|text|680|863|We included 33 participants (20 men and 13 women for the HEM-7130 experiment; 18 men and 15 women for the HEM-7320F experiment; and 21 men and 12 women for the HEM-7500F experiment).
SE|25462531|METHODS|ab|3|entity|C0679646|Participant|popg|||participants|||0|827|695|707
SE|25462531|METHODS|ab|3|entity|C0025266|Male population group|popg|||men|||0|861|712|715
SE|25462531|METHODS|ab|3|entity|C0043210|Woman|popg|||women|||0|861|723|728
SE|25462531|METHODS|ab|3|entity|C0019080|Hemorrhage|fndg|||HEM-7130|||0|802|737|745
SE|25462531|METHODS|ab|3|entity|C0681814|research study|resa|||experiment|||0|802|746|756
SE|25462531|METHODS|ab|3|entity|C0025266|Male population group|popg|||men|||0|861|761|764
SE|25462531|METHODS|ab|3|entity|C0043210|Woman|popg|||women|||0|861|772|777
SE|25462531|METHODS|ab|3|entity|C0019080|Hemorrhage|fndg|||HEM-7320F|||0|802|786|795
SE|25462531|METHODS|ab|3|entity|C0681814|research study|resa|||experiment|||0|802|796|806
SE|25462531|METHODS|ab|3|entity|C0025266|Male population group|popg|||men|||0|861|815|818
SE|25462531|METHODS|ab|3|entity|C0043210|Woman|popg|||women|||0|861|826|831
SE|25462531|METHODS|ab|3|entity|C0019080|Hemorrhage|fndg|||HEM-7500F|||0|802|840|849
SE|25462531|METHODS|ab|3|entity|C0681814|research study|resa|||experiment|||0|802|850|860

SE|25462531|METHODS|ab|4|text|863|963|The mean age of the participants was 49+/-15, 50+/-11, and 50+/-11 years in the respective studies.
SE|25462531|METHODS|ab|4|entity|C0001779|Age|orga|||age|||0|861|872|875
SE|25462531|METHODS|ab|4|entity|C0679646|Participant|popg|||participants|||0|966|883|895
SE|25462531|METHODS|ab|4|entity|C0439234|year|tmco|||years|||0|827|930|935
SE|25462531|METHODS|ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|827|954|961

SE|25462531|RESULTS|ab|5|text|963|1258|RESULTS: The mean differences between the device and the mercury readings for systolic and diastolic BP were as follows: HEM-7130, -1.8+/-5.3 and -0.1+/-4.0 mmHg, respectively; HEM-7320F, -0.9+/-4.7 and -1.9+/-4.4 mmHg, respectively; and HEM-7500F, -1.0+/-4.6 and -1.1+/-4.0 mmHg, respectively.
SE|25462531|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|963|970
SE|25462531|RESULTS|ab|5|entity|C1547020|*Difference|qnco|||differences|||0|827|981|992
SE|25462531|RESULTS|ab|5|entity|C0699733|Devices|mnob|||device|||0|1000|1005|1011
SE|25462531|RESULTS|ab|5|entity|C0025424|Mercury|elii,hops|||mercury|||0|888|1020|1027
SE|25462531|RESULTS|ab|5|entity|C0034754|Reading|dora|||readings|||0|888|1028|1036
SE|25462531|RESULTS|ab|5|entity|C0039155|Systole|tmco|||systolic|||0|1000|1041|1049
SE|25462531|RESULTS|ab|5|entity|C0428883|Diastolic blood pressure|clna|||diastolic BP|||0|1000|1054|1066
SE|25462531|RESULTS|ab|5|entity|C0019080|Hemorrhage|fndg|||HEM-7130|||0|861|1084|1092
SE|25462531|RESULTS|ab|5|entity|C0450316|1/5|qnco|||1.8+/-5|||0|875|1095|1102
SE|25462531|RESULTS|ab|5|entity|C0439475|mmHg|qnco|||mmHg|||0|804|1120|1124
SE|25462531|RESULTS|ab|5|entity|C0019080|Hemorrhage|fndg|||HEM-7320F|||0|694|1140|1149
SE|25462531|RESULTS|ab|5|entity|C0439475|mmHg|qnco|||mmHg|||0|804|1177|1181
SE|25462531|RESULTS|ab|5|entity|C0019080|Hemorrhage|fndg|||HEM-7500F|||0|694|1201|1210
SE|25462531|RESULTS|ab|5|entity|C0439475|mmHg|qnco|||mmHg|||0|804|1238|1242

SE|25462531|RESULTS|ab|6|text|1258|1335|These findings indicated that the device was reading lower than the mercury.
SE|25462531|RESULTS|ab|6|entity|C0243095|Finding|ftcn|||findings|||0|1000|1264|1272
SE|25462531|RESULTS|ab|6|entity|C0699733|Devices|mnob|||device|||0|1000|1292|1298
SE|25462531|RESULTS|ab|6|entity|C0034754|Reading|dora|||reading|||0|1000|1303|1310
SE|25462531|RESULTS|ab|6|entity|C0441994|Lower|ftcn|||lower|||0|1000|1311|1316
SE|25462531|RESULTS|ab|6|entity|C0025424|Mercury|elii,hops|||mercury|||0|1000|1326|1333

SE|25462531|RESULTS|ab|7|text|1335|1468|However, the number of absolute differences between the devices and observers fulfilled the requirement of the ESH-IP revision 2010.
SE|25462531|RESULTS|ab|7|entity|C0237753|Numbers|qnco|||number|||0|1000|1348|1354
SE|25462531|RESULTS|ab|7|entity|C0205344|Absolute|qlco|||absolute|||0|872|1358|1366
SE|25462531|RESULTS|ab|7|entity|C1547020|*Difference|qnco|||differences|||0|872|1367|1378
SE|25462531|RESULTS|ab|7|entity|C0220819|device aspects|mnob|||devices|||0|1000|1391|1398
SE|25462531|RESULTS|ab|7|entity|C0870992|Observers|prog|||observers|||0|1000|1403|1412
SE|25462531|RESULTS|ab|7|entity|C1514873|Requirement|idcn|||requirement|||0|1000|1427|1438
SE|25462531|RESULTS|ab|7|entity|C0021069|Immunoprecipitation|lbpr|||ESH-IP|||0|764|1446|1452
SE|25462531|RESULTS|ab|7|entity|C0439617|Revision|tmco|||revision|||0|764|1453|1461
SE|25462531|RESULTS|ab|7|entity|C0681761|2010s|tmco|||2010|||0|764|1462|1466

SE|25462531|CONCLUSION|ab|8|text|1468|1582|CONCLUSION: The Omron HEM-7130, HEM-7320F, and HEM-7500F passed all the requirements of the ESH-IP 2010 revision.
SE|25462531|CONCLUSION|ab|8|entity|C0019080|Hemorrhage|fndg|||HEM-7130|||0|827|1490|1498
SE|25462531|CONCLUSION|ab|8|entity|C0019080|Hemorrhage|fndg|||HEM-7320F|||0|694|1500|1509
SE|25462531|CONCLUSION|ab|8|entity|C0019080|Hemorrhage|fndg|||HEM-7500F|||0|694|1515|1524
SE|25462531|CONCLUSION|ab|8|entity|C1514873|Requirement|idcn|||requirements|||0|966|1540|1552
SE|25462531|CONCLUSION|ab|8|entity|C0021069|Immunoprecipitation|lbpr|||ESH-IP|||0|763|1560|1566
SE|25462531|CONCLUSION|ab|8|entity|C0439617|Revision|tmco|||revision|||0|763|1572|1580

SE|25462531|CONCLUSION|ab|9|text|1582|1661|Therefore, we recommend these devices for the home measurement of BP in adults.
SE|25462531|CONCLUSION|ab|9|entity|C0220819|device aspects|mnob|||devices|||0|1000|1612|1619
SE|25462531|CONCLUSION|ab|9|entity|C0242485|Measurement|ftcn|||measurement|||0|861|1633|1644
SE|25462531|CONCLUSION|ab|9|entity|C0005823|Blood Pressure|orgf|||BP|||0|1000|1648|1650
SE|25462531|CONCLUSION|ab|9|entity|C0001675|Adult|aggp|||adults|||0|1000|1654|1660
SE|25462531|CONCLUSION|ab|9|relation|3|1|C0005823|Blood Pressure|orgf|orgf|||BP|||0|1000|1648|1650|PREP|PROCESS_OF||1651|1653|1|1|C0001675|Adult|aggp,humn|humn|||adults|||0|1000|1654|1660


SE|25462529||ti|1|text|21|158|Comparison Between Several Integrase-defective Lentiviral Vectors Reveals Increased Integration of an HIV Vector Bearing a D167H Mutant.
SE|25462529||ti|1|entity|C0443302|Several|qnco|||Several|||0|766|40|47
SE|25462529||ti|1|entity|C0063690|Integrase|aapp,enzy|||Integrase|||0|766|48|57
SE|25462529||ti|1|entity|C0332452|Defective|ftcn|||defective|||0|766|58|67
SE|25462529||ti|1|entity|C0442335|Vectors|spco|||Vectors|||0|766|79|86
SE|25462529||ti|1|entity|C0205217|Increased|qnco|||Increased|||0|694|95|104
SE|25462529||ti|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|888|123|126
SE|25462529||ti|1|entity|C0442335|Vectors|spco|||Vector|||0|888|127|133
SE|25462529||ti|1|entity|C0596988|Mutant|comd|||Mutant|||0|861|150|156

SE|25462529||ab|1|text|164|259|HIV-1 derived vectors are among the most efficient for gene transduction in mammalian tissues.
SE|25462529||ab|1|entity|C0019704|HIV-1|virs|||HIV-1|||0|861|164|169
SE|25462529||ab|1|entity|C0442335|Vectors|spco|||vectors|||0|861|178|185
SE|25462529||ab|1|entity|C0205393|Most|qnco|||most|||0|888|200|204
SE|25462529||ab|1|entity|C0442799|Efficient|qlco|||efficient|||0|888|205|214
SE|25462529||ab|1|entity|C0017337|Genes|gngm|||gene|||0|888|219|223
SE|25462529||ab|1|entity|C1160185|transduction|orgf|||transduction|||0|888|224|236
SE|25462529||ab|1|entity|C0040300|Body tissue|tisu|||tissues|||0|861|250|257

SE|25462529||ab|2|text|259|349|As the parent virus, they carry out vector genome insertion into the host cell chromatin.
SE|25462529||ab|2|entity|C0030551|parent|famg|||parent|||0|888|266|272
SE|25462529||ab|2|entity|C0042769|Virus Diseases|dsyn|||virus|||0|888|273|278
SE|25462529||ab|2|entity|C0439787|Out|spco|||out|||0|833|291|294
SE|25462529||ab|2|entity|C0442335|Vectors|spco|||vector|||0|833|295|301
SE|25462529||ab|2|entity|C0017428|Genome|gngm|||genome|||0|833|302|308
SE|25462529||ab|2|entity|C0021107|Implantation procedure|topp|||insertion|||0|833|309|318
SE|25462529||ab|2|entity|C1167395|host|celc|||host|||0|851|328|332
SE|25462529||ab|2|entity|C0007634|Cells|cell|||cell|||0|851|333|337
SE|25462529||ab|2|entity|C0008546|Chromatin|aapp|||chromatin|||0|851|338|347
SE|25462529||ab|2|relation|0|0|C0008546|Chromatin|aapp,gngm|aapp|||chromatin|||0|851|338|347|MOD/HEAD|PART_OF||333|347|0|0|C0007634|Cells|cell|cell|||cell|||0|851|333|337
SE|25462529||ab|2|relation|0|0|C0042769|Virus Diseases|dsyn|dsyn|||virus|||0|888|273|278|MOD/HEAD|PROCESS_OF||266|278|0|0|C0030551|parent|famg,humn|humn|||parent|||0|888|266|272

SE|25462529||ab|3|text|349|460|Consequently, their preferential integration in transcribed genes raises several conceptual and safety issues.
SE|25462529||ab|3|entity|C0558295|preference|clna|||preferential|||0|623|369|381
SE|25462529||ab|3|entity|C0017337|Genes|gngm|||genes|||0|861|409|414
SE|25462529||ab|3|entity|C0443302|Several|qnco|||several|||0|853|422|429
SE|25462529||ab|3|entity|C0178566|concept|idcn|||conceptual|||0|853|430|440
SE|25462529||ab|3|entity|C1456697|Safety Issues|hcpp|||safety issues|||0|1000|445|458

SE|25462529||ab|4|text|460|559|To address part of these questions, HIV-derived vectors have been engineered to be nonintegrating.
SE|25462529||ab|4|entity|C0449719|Part|spco|||part|||0|1000|471|475
SE|25462529||ab|4|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|851|496|499
SE|25462529||ab|4|entity|C0442335|Vectors|spco|||vectors|||0|851|508|515

SE|25462529||ab|5|text|559|746|This was mainly achieved by mutating HIV-1 integrase at functional hotspots of the enzyme enabling the development of streamlined nuclear DNA circles functional for transgene expression.
SE|25462529||ab|5|entity|C1513776|Mutate|genf|||mutating|||0|908|587|595
SE|25462529||ab|5|entity|C0917728|HIV-1 Integrase|aapp,enzy|||HIV-1 integrase|||0|908|596|611
SE|25462529||ab|5|entity|C0205245|Functional|ftcn|||functional|||0|694|615|625
SE|25462529||ab|5|entity|C0014442|Enzymes|enzy,orch|||enzyme|||0|1000|642|648
SE|25462529||ab|5|entity|C1527148|Development|ftcn|||development|||0|1000|662|673
SE|25462529||ab|5|entity|C1179920|Nuclear deoxyribonucleic acid|bacs,nnon|||nuclear DNA|||0|694|689|700
SE|25462529||ab|5|entity|C0205245|Functional|ftcn|||functional|||0|1000|709|719
SE|25462529||ab|5|entity|C0282641|Transgenes|gngm|||transgene|||0|888|724|733

SE|25462529||ab|6|text|746|831|Few integrase mutant vectors have been successfully tested so far for gene transfer.
SE|25462529||ab|6|entity|C0205388|Few|qnco|||Few|||0|833|746|749
SE|25462529||ab|6|entity|C0063690|Integrase|aapp,enzy|||integrase|||0|833|750|759
SE|25462529||ab|6|entity|C0596988|Mutant|comd|||mutant|||0|833|760|766
SE|25462529||ab|6|entity|C0442335|Vectors|spco|||vectors|||0|833|767|774
SE|25462529||ab|6|entity|C1517499|Gene Transfer|mbrt|||gene transfer|||0|1000|816|829

SE|25462529||ab|7|text|831|931|They are cleared with time in mitotic cells, but stable within nondividing retina cells or neurons.
SE|25462529||ab|7|entity|C0040223|Time|tmco|||time|||0|1000|853|857
SE|25462529||ab|7|entity|C0230518|Mitotic cell|cell|||mitotic cells|||0|983|861|874
SE|25462529||ab|7|entity|C0035298|Retina|bpoc|||retina|||0|905|906|912
SE|25462529||ab|7|entity|C1512899|Interphase Cell|cell|||nondividing retina cells|||0|905|894|918
SE|25462529||ab|7|entity|C0027882|Neurons|cell|||neurons|||0|1000|922|929
SE|25462529||ab|7|relation|0|0|C1512899|Interphase Cell|cell|cell|||nondividing retina cells|||0|905|894|918|MOD/HEAD|PART_OF||906|918|0|0|C0035298|Retina|bpoc|bpoc|||retina|||0|905|906|912

SE|25462529||ab|8|text|931|1251|Here, we compared six HIV vectors carrying different integrases, either wild type or with different mutations (D64V, D167H, Q168A, K186Q+Q214L+Q216L, and RRK262-264AAH) shown to modify integrase enzymatic activity, oligomerization, or interaction with key cellular cofactor of HIV DNA integration as LEDGF/p75 or TNPO3.
SE|25462529||ab|8|entity|C0205452|Six|qnco|||six|||0|851|949|952
SE|25462529||ab|8|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|851|953|956
SE|25462529||ab|8|entity|C0442335|Vectors|spco|||vectors|||0|851|957|964
SE|25462529||ab|8|entity|C1547020|*Difference|qnco|||different|||0|853|974|983
SE|25462529||ab|8|entity|C0063690|Integrase|aapp,enzy|||integrases|||0|853|984|994
SE|25462529||ab|8|entity|C0445392|Wild|inpr|||wild|||0|790|1003|1007
SE|25462529||ab|8|entity|C1547052|*Type|qnco|||type|||0|790|1008|1012
SE|25462529||ab|8|entity|C1547020|*Difference|qnco|||different|||0|853|1021|1030
SE|25462529||ab|8|entity|C0026882|Mutation|genf|||mutations|||0|853|1031|1040
SE|25462529||ab|8|entity|C0014442|Enzymes|enzy,orch|||enzymatic|||0|877|1126|1135
SE|25462529||ab|8|entity|C1150296|integrase activity|moft|||integrase enzymatic activity|||0|877|1116|1144
SE|25462529||ab|8|entity|C1554080|Key|idcn|||key|||0|851|1183|1186
SE|25462529||ab|8|entity|C0178539|Cellular|ftcn|||cellular|||0|851|1187|1195
SE|25462529||ab|8|entity|C0178555|cofactor|bacs|||cofactor|||0|851|1196|1204
SE|25462529||ab|8|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|901|1208|1211
SE|25462529||ab|8|entity|C1158478|DNA Integration|genf|||DNA integration|||0|901|1212|1227
SE|25462529||ab|8|entity|C0767950|lens epithelium-derived growth factor|aapp,bacs|11168|PSIP1|LEDGF|||0|694|1231|1236
SE|25462529||ab|8|entity|||gngm|1523,3059,7133,11168,27036|CUX1,HCLS1,TNFRSF1B,PSIP1,SIGLEC7|p75|||0|694|1237|1240
SE|25462529||ab|8|entity|||gngm|23534|TNPO3|TNPO3|||0|1000|1244|1249
SE|25462529||ab|8|relation|9|8|C0063690|Integrase|aapp,gngm,enzy|aapp|||integrases|||0|853|984|994|VERB|AFFECTS||1109|1115|7|1|C1150296|integrase activity|moft|moft|||integrase enzymatic activity|||0|877|1116|1144
SE|25462529||ab|8|relation|9|8|C0178555|cofactor|bacs|bacs|||cofactor|||0|851|1196|1204|VERB|AFFECTS||1109|1115|7|1|C1150296|integrase activity|moft|moft|||integrase enzymatic activity|||0|877|1116|1144
SE|25462529||ab|8|relation|16|2|C0063690|Integrase|aapp,gngm,enzy|aapp|||integrases|||0|853|984|994|VERB|compared_with||940|948|16|13|C0178555|cofactor|bacs|bacs|||cofactor|||0|851|1196|1204

SE|25462529||ab|9|text|1251|1449|We show that these mutations differently affect the transduction efficiency as well as rates and patterns of integration of HIV-derived vectors suggesting their different processing in the nucleus.
SE|25462529||ab|9|entity|C0026882|Mutation|genf|||mutations|||0|1000|1270|1279
SE|25462529||ab|9|entity|C1160185|transduction|orgf|||transduction|||0|888|1303|1315
SE|25462529||ab|9|entity|C0013682|Efficiency|qnco|||efficiency|||0|888|1316|1326
SE|25462529||ab|9|entity|C1521828|Rate|qnco|||rates|||0|966|1338|1343
SE|25462529||ab|9|entity|C0449774|Patterns|spco|||patterns|||0|1000|1348|1356
SE|25462529||ab|9|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|851|1375|1378
SE|25462529||ab|9|entity|C0442335|Vectors|spco|||vectors|||0|851|1387|1394
SE|25462529||ab|9|entity|C1547020|*Difference|qnco|||different|||0|836|1412|1421
SE|25462529||ab|9|entity|C1522240|Process|phpr|||processing|||0|836|1422|1432
SE|25462529||ab|9|entity|C0007610|Cell Nucleus|celc|||nucleus|||0|1000|1440|1447

SE|25462529||ab|10|text|1449|1643|Surprisingly and most interestingly, we report that an integrase carrying the D167H substitution improves vector transduction efficiency and integration in both HEK-293T and primary CD34+ cells.
SE|25462529||ab|10|entity|C0205393|Most|qnco|||most|||0|861|1466|1470
SE|25462529||ab|10|entity|C0063690|Integrase|aapp,enzy|||integrase|||0|1000|1504|1513
SE|25462529||ab|10|entity|C1555721|Substitution|idcn|||substitution|||0|861|1533|1545
SE|25462529||ab|10|entity|C0442335|Vectors|spco|||vector|||0|851|1555|1561
SE|25462529||ab|10|entity|C1160185|transduction|orgf|||transduction|||0|851|1562|1574
SE|25462529||ab|10|entity|C0013682|Efficiency|qnco|||efficiency|||0|851|1575|1585
SE|25462529||ab|10|entity|C0121258|EphA3 Receptor|aapp,enzy,rcpt|||HEK-293T|||0|694|1610|1618
SE|25462529||ab|10|entity|C0882849|CD34+ cell|cell|||CD34+ cells|||0|890|1631|1642
SE|25462529||ab|10|relation|4|4|C0063690|Integrase|aapp,gngm,enzy|aapp|||integrase|||0|1000|1504|1513|PREP|COEXISTS_WITH||1602|1604|2|1|C0121258|EphA3 Receptor|aapp,gngm,enzy,rcpt|gngm|||HEK-293T|||0|694|1610|1618


SE|25462532||ti|1|text|21|66|Target selection for FDA-approved medicines.
SE|25462532||ti|1|entity|C0205540|Approved|qlco|||approved|||0|790|46|54
SE|25462532||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicines|||0|790|55|64

SE|25462532||ab|1|text|72|171|The biopharmaceutical industry translates fundamental understanding of disease into new medicines.
SE|25462532||ab|1|entity|C0005522|Biological Products|bacs,phsu|||biopharmaceutical|||0|888|76|93
SE|25462532||ab|1|entity|C0021267|Industry|ocac|||industry|||0|888|94|102
SE|25462532||ab|1|entity|C0012634|Disease|dsyn|||disease|||0|1000|143|150
SE|25462532||ab|1|entity|C0205314|New|tmco|||new|||0|888|156|159
SE|25462532||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medicines|||0|888|160|169

SE|25462532||ab|2|text|171|341|As part of a comprehensive analysis of FDA-approved new molecular entities (NMEs), we assessed the mechanistic basis of drug efficacy, with emphasis on target selection.
SE|25462532||ab|2|entity|C0449719|Part|spco|||part|||0|1000|174|178
SE|25462532||ab|2|entity|C0936012|Analysis|resa|||analysis|||0|861|198|206
SE|25462532||ab|2|entity|C0205540|Approved|qlco|||approved|||0|762|214|222
SE|25462532||ab|2|entity|C0205314|New|tmco|||new|||0|762|223|226
SE|25462532||ab|2|entity|C1521991|Molecular|qlco|||molecular|||0|762|227|236
SE|25462532||ab|2|entity|C1551338|entity|idcn|||entities|||0|762|237|245
SE|25462532||ab|2|entity|C0441712|Mechanisms|ftcn|||mechanistic|||0|853|270|281
SE|25462532||ab|2|entity|C1527178|Basis|ftcn|||basis|||0|853|282|287
SE|25462532||ab|2|entity|C0598333|drug efficacy|qlco|||drug efficacy|||0|1000|291|304

SE|25462532||ab|3|text|341|475|Three target families capture almost half of all NMEs and the leading ten families capture more than three-quarters of NME approvals.
SE|25462532||ab|3|entity|C0205449|Three|qnco|||Three|||0|851|341|346
SE|25462532||ab|3|entity|C0015576|Family|famg|||families|||0|851|354|362
SE|25462532||ab|3|entity|C0205314|New|tmco|||NMEs|||0|840|390|394
SE|25462532||ab|3|entity|C1521991|Molecular|qlco|||NMEs|||0|840|390|394
SE|25462532||ab|3|entity|C1551338|entity|idcn|||NMEs|||0|840|390|394
SE|25462532||ab|3|entity|C0205456|Ten|qnco|||ten|||0|790|411|414
SE|25462532||ab|3|entity|C0015576|Family|famg|||families|||0|790|415|423
SE|25462532||ab|3|entity|C0205172|More|ftcn|||more|||0|1000|432|436
SE|25462532||ab|3|entity|C0205449|Three|qnco|||three|||0|694|442|447

SE|25462532||ab|4|text|475|586|Target families were related to their clinical application and identify dynamic trends in targeting over time.
SE|25462532||ab|4|entity|C0015576|Family|famg|||families|||0|888|482|490
SE|25462532||ab|4|entity|C0205210|Clinical|qlco|||clinical|||0|888|513|521
SE|25462532||ab|4|entity|C0729333|Dynamic|ftcn|||dynamic|||0|888|547|554
SE|25462532||ab|4|entity|C1521798|trend|tmco|||trends|||0|888|555|561
SE|25462532||ab|4|entity|C0040223|Time|tmco|||time|||0|802|580|584

SE|25462532||ab|5|text|586|727|These data suggest increasing attention toward novel target families, which presumably reflects increased understanding of disease etiology.
SE|25462532||ab|5|entity|C1511726|Data|idcn|||data|||0|1000|592|596
SE|25462532||ab|5|entity|C0442808|Increasing|ftcn|||increasing|||0|888|605|615
SE|25462532||ab|5|entity|C0004268|Attention|menp|||attention|||0|888|616|625
SE|25462532||ab|5|entity|C0679622|novel|inpr|||novel|||0|851|633|638
SE|25462532||ab|5|entity|C0015576|Family|famg|||families|||0|851|646|654
SE|25462532||ab|5|entity|C0205217|Increased|qnco|||increased|||0|888|682|691
SE|25462532||ab|5|entity|C1314792|Etiology|ftcn|||disease etiology|||0|1000|709|725

SE|25462532||ab|6|text|727|860|We also suggest the need to balance the ongoing emphasis on target-based drug discovery with phenotypic approaches to drug discovery.
SE|25462532||ab|6|entity|C0027552|Needs|qlco|||need|||0|1000|747|751
SE|25462532||ab|6|entity|C0014653|Equilibrium|orgf|||balance|||0|1000|755|762
SE|25462532||ab|6|entity|C0920472|Drug Discovery|resa|||drug discovery|||0|852|800|814
SE|25462532||ab|6|entity|C0449445|Approach|spco|||approaches|||0|861|831|841
SE|25462532||ab|6|entity|C0920472|Drug Discovery|resa|||drug discovery|||0|1000|845|859


SE|25462533||ti|1|text|21|116|Splice variants in the proteome: a promising and challenging field to targeted drug discovery.
SE|25462533||ti|1|entity|C0205419|Variant|qlco|||variants|||0|827|28|36
SE|25462533||ti|1|entity|C0751973|Proteome|aapp,bacs|||proteome|||0|1000|44|52
SE|25462533||ti|1|entity|C1555307|promise|idcn|||promising|||0|966|56|65
SE|25462533||ti|1|entity|C0805586|CHALLENGE|idcn|||challenging|||0|872|70|81
SE|25462533||ti|1|entity|C1521738|Field|cnce|||field|||0|872|82|87
SE|25462533||ti|1|entity|C0599894|targeting|celf|||targeted|||0|890|91|99
SE|25462533||ti|1|entity|C0920472|Drug Discovery|resa|||drug discovery|||0|890|100|114

SE|25462533||ab|1|text|122|295|The advent and improvement of high-throughput sequencing over the past decade leveraged the study of whole genomes and transcriptomes of different organisms at lower costs.
SE|25462533||ab|1|entity|C0205250|High|qlco|||high|||0|802|152|156
SE|25462533||ab|1|entity|C1561491|Sequencing|ftcn|||sequencing|||0|802|168|178
SE|25462533||ab|1|entity|C0205136|Over|spco|||over|||0|1000|179|183
SE|25462533||ab|1|entity|C1444637|Past|tmco|||past|||0|694|188|192
SE|25462533||ab|1|entity|C0008972|Clinical Research|resa|||study|||0|1000|214|219
SE|25462533||ab|1|entity|C0444667|Whole|qnco|||whole|||0|888|223|228
SE|25462533||ab|1|entity|C0017428|Genome|gngm|||genomes|||0|888|229|236
SE|25462533||ab|1|entity|C1547020|*Difference|qnco|||different|||0|853|259|268
SE|25462533||ab|1|entity|C0029235|Organism|orgm|||organisms|||0|853|269|278
SE|25462533||ab|1|entity|C0441994|Lower|ftcn|||lower|||0|1000|282|287

SE|25462533||ab|2|text|295|482|In transcriptomics, RNA-Seq expands our capacity to understand gene expression in different tissues and pathologies, and how alternative splicing might affect the final protein sequence.
SE|25462533||ab|2|entity|C0035668|RNA|bacs,nnon|||RNA|||0|888|315|318
SE|25462533||ab|2|entity|C1519249|Sequence|ftcn|||Seq|||0|888|319|322
SE|25462533||ab|2|entity|C1516240|Capacity|qnco|||capacity|||0|1000|335|343
SE|25462533||ab|2|entity|C0017262|Gene Expression|genf|||gene expression|||0|1000|358|373
SE|25462533||ab|2|entity|C1547020|*Difference|qnco|||different|||0|853|377|386
SE|25462533||ab|2|entity|C0040300|Body tissue|tisu|||tissues|||0|853|387|394
SE|25462533||ab|2|entity|C0030664|Pathology|bmod|||pathologies|||0|1000|399|410
SE|25462533||ab|2|entity|C0002345|Alternative Splicing|genf|||alternative splicing|||0|901|420|440
SE|25462533||ab|2|entity|C0205088|End-stage|tmco|||final|||0|901|458|463
SE|25462533||ab|2|entity|C0002518|Amino Acid Sequence|amas|||protein sequence|||0|901|464|480

SE|25462533||ab|3|text|482|598|Here, we discuss the association of using transcriptome and proteome high-throughput data to foster drug discovery.
SE|25462533||ab|3|entity|C0751973|Proteome|aapp,bacs|||proteome|||0|775|542|550
SE|25462533||ab|3|entity|C0205250|High|qlco|||high|||0|775|551|555
SE|25462533||ab|3|entity|C1511726|Data|idcn|||data|||0|775|567|571
SE|25462533||ab|3|entity|C0920472|Drug Discovery|resa|||drug discovery|||0|901|582|596

SE|25462533||ab|4|text|598|791|Using this innovative strategy, some research groups have already identified computationally predicted novel peptides derived from putative splice variants in experimental human proteome data.
SE|25462533||ab|4|entity|C0683243|innovativeness|menp|||innovative|||0|853|609|619
SE|25462533||ab|4|entity|C0035168|research|resa|||research|||0|888|635|643
SE|25462533||ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|644|650
SE|25462533||ab|4|entity|C0679622|novel|inpr|||novel|||0|888|701|706
SE|25462533||ab|4|entity|C0030956|Peptides|aapp|||peptides|||0|888|707|715
SE|25462533||ab|4|entity|C0205419|Variant|qlco|||variants|||0|793|745|753
SE|25462533||ab|4|entity|C1517004|Experimental|ftcn|||experimental|||0|861|757|769
SE|25462533||ab|4|entity|C0751973|Proteome|aapp,bacs|||proteome|||0|861|776|784
SE|25462533||ab|4|entity|C0596723|human data|inpr,resa|||human proteome data|||0|861|770|789

SE|25462533||ab|5|text|791|865|These discoveries provide new opportunities for targeted drug development.
SE|25462533||ab|5|entity|C0205314|New|tmco|||new|||0|694|817|820
SE|25462533||ab|5|entity|C0599894|targeting|celf|||targeted|||0|890|839|847
SE|25462533||ab|5|entity|C0872152|Drug Development|bmod|||drug development|||0|890|848|864


SE|25462534||ti|1|text|21|62|Emerging therapeutic strategies in COPD.
SE|25462534||ti|1|entity|C0024117|Chronic Obstructive Airway Disease|dsyn|||COPD|||0|1000|56|60

SE|25462534||ab|1|text|68|431|Chronic obstructive pulmonary disease (COPD) management is changing with the advent of newer inhaled medications and devices that belong to the current group of therapies [i.e. inhaled corticosteroid (ICS), long-acting beta2 agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)], providing patients as well as physicians with a wider range of options.
SE|25462534||ab|1|entity|C0024117|Chronic Obstructive Airway Disease|dsyn|||Chronic obstructive pulmonary disease|||0|928|68|105
SE|25462534||ab|1|entity|C0205314|New|tmco|||newer|||0|840|155|160
SE|25462534||ab|1|entity|C0004048|Inspiration function|ortf|||inhaled|||0|840|161|168
SE|25462534||ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||medications|||0|840|169|180
SE|25462534||ab|1|entity|C0220819|device aspects|mnob|||devices|||0|1000|185|192
SE|25462534||ab|1|entity|C0521116|Current|tmco|||current|||0|888|212|219
SE|25462534||ab|1|entity|C0441833|Groups|inpr|||group|||0|888|220|225
SE|25462534||ab|1|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|1000|229|238
SE|25462534||ab|1|entity|C0004048|Inspiration function|ortf|||inhaled|||0|750|245|252
SE|25462534||ab|1|entity|C0001617|Adrenal Cortex Hormones|horm,phsu,strd|||corticosteroid|||0|750|253|267
SE|25462534||ab|1|entity|C0205166|Long|qlco|||long|||0|764|275|279
SE|25462534||ab|1|entity|C0427611|Activated clotting time measurement|lbpr|||acting|||0|764|280|286
SE|25462534||ab|1|entity|||gngm|4760,10383|NEUROD1,TUBB4B|beta2|||0|764|287|292
SE|25462534||ab|1|entity|C0243192|agonists|phsu|||agonists|||0|764|293|301
SE|25462534||ab|1|entity|C0205166|Long|qlco|||long|||0|852|314|318
SE|25462534||ab|1|entity|C0427611|Activated clotting time measurement|lbpr|||acting|||0|852|319|325
SE|25462534||ab|1|entity|C0003385|Muscarinic Antagonists|phsu|||muscarinic antagonists|||0|852|326|348
SE|25462534||ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|369|377
SE|25462534||ab|1|entity|C0031831|Physicians|prog|||physicians|||0|1000|389|399
SE|25462534||ab|1|entity|C0332464|Widening|spco|||wider|||0|872|407|412
SE|25462534||ab|1|entity|C1514721|Range|qnco|||range|||0|872|413|418
SE|25462534||ab|1|entity|C1518601|Options|ftcn|||options|||0|1000|422|429

SE|25462534||ab|2|text|431|512|In this review, we examine Phase II studies currently underway in COPD patients.
SE|25462534||ab|2|entity|C0205390|Phase|tmco|||Phase|||0|694|458|463
SE|25462534||ab|2|entity|C0521116|Current|tmco|||currently|||0|694|475|484
SE|25462534||ab|2|entity|C0024117|Chronic Obstructive Airway Disease|dsyn|||COPD|||0|928|497|501
SE|25462534||ab|2|entity|C0030705|Patients|podg|||patients|||0|928|502|510
SE|25462534||ab|2|relation|0|0|C0024117|Chronic Obstructive Airway Disease|dsyn|dsyn|||COPD|||0|928|497|501|MOD/HEAD|PROCESS_OF||497|510|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|928|502|510

SE|25462534||ab|3|text|512|709|With improved understanding of the condition, the role for biological and immunomodulatory therapies in COPD patients is also an interesting and important aspect looked upon with great enthusiasm.
SE|25462534||ab|3|entity|C0184511|Improved|qlco|||improved|||0|888|517|525
SE|25462534||ab|3|entity|C0348080|Condition|qlco|||condition|||0|1000|547|556
SE|25462534||ab|3|entity|C0035820|Role|socb|||role|||0|1000|562|566
SE|25462534||ab|3|entity|C0205460|biological|ftcn|||biological|||0|1000|571|581
SE|25462534||ab|3|entity|C0005525|Biological Response Modifiers|phsu|||immunomodulatory|||0|853|586|602
SE|25462534||ab|3|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|853|603|612
SE|25462534||ab|3|entity|C0024117|Chronic Obstructive Airway Disease|dsyn|||COPD|||0|928|616|620
SE|25462534||ab|3|entity|C0030705|Patients|podg|||patients|||0|928|621|629
SE|25462534||ab|3|entity|C1547011|Aspect|qnco|||aspect|||0|861|667|673
SE|25462534||ab|3|entity|C0549177|Large|qnco|||great|||0|888|691|696
SE|25462534||ab|3|entity|C0424090|Level of interest|menp|||enthusiasm|||0|888|697|707
SE|25462534||ab|3|relation|0|0|C0005525|Biological Response Modifiers|phsu|phsu|||immunomodulatory|||0|853|586|602|INFER|TREATS(SPEC)||586|612|0|0|C0030705|Patients|podg,humn|podg|||patients|||0|928|621|629
SE|25462534||ab|3|relation|0|0|C0005525|Biological Response Modifiers|phsu|phsu|||immunomodulatory|||0|853|586|602|MOD/HEAD|ISA||586|612|0|0|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|853|603|612
SE|25462534||ab|3|relation|0|0|C0024117|Chronic Obstructive Airway Disease|dsyn|dsyn|||COPD|||0|928|616|620|MOD/HEAD|PROCESS_OF||616|629|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|928|621|629
SE|25462534||ab|3|relation|0|0|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|853|603|612|INFER|TREATS(INFER)||613|615|0|0|C0024117|Chronic Obstructive Airway Disease|dsyn|dsyn|||COPD|||0|928|616|620
SE|25462534||ab|3|relation|0|0|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|853|603|612|MOD/HEAD|USES||586|612|0|0|C0005525|Biological Response Modifiers|phsu|phsu|||immunomodulatory|||0|853|586|602
SE|25462534||ab|3|relation|5|1|C0087111|Therapeutic procedure|topp|topp|||therapies|||0|853|603|612|PREP|TREATS||613|615|4|1|C0030705|Patients|podg,humn|podg|||patients|||0|928|621|629

SE|25462534||ab|4|text|709|951|It is indeed interesting to note that the future COPD treatment options could include novel interventional strategies in addition to innovative inhaled therapies, which have been the backbone of COPD management for the past couple of decades.
SE|25462534||ab|4|entity|C0016884|Future|tmco|||future|||0|873|751|757
SE|25462534||ab|4|entity|C0024117|Chronic Obstructive Airway Disease|dsyn|||COPD|||0|873|758|762
SE|25462534||ab|4|entity|C0683525|treatment options|inpr|||treatment options|||0|873|763|780
SE|25462534||ab|4|entity|C0679622|novel|inpr|||novel|||0|877|795|800
SE|25462534||ab|4|entity|C1273869|Intervention regimes|hlca|||interventional strategies|||0|877|801|826
SE|25462534||ab|4|entity|C0004048|Inspiration function|ortf|||inhaled|||0|901|853|860
SE|25462534||ab|4|entity|C1136080|Innovative Therapies|topp|||innovative inhaled therapies|||0|901|842|870
SE|25462534||ab|4|entity|C0037949|Vertebral column|bpoc|||backbone|||0|1000|892|900
SE|25462534||ab|4|entity|C0024117|Chronic Obstructive Airway Disease|dsyn|||COPD|||0|928|904|908
SE|25462534||ab|4|entity|C1444637|Past|tmco|||past|||0|872|928|932
SE|25462534||ab|4|entity|C0010222|Couples|famg|||couple|||0|872|933|939
SE|25462534||ab|4|relation|5|2|C1136080|Innovative Therapies|topp|topp|||innovative inhaled therapies|||0|901|842|870|NOM|TREATS||909|919|5|0|C0024117|Chronic Obstructive Airway Disease|dsyn|dsyn|||COPD|||0|928|904|908


SE|25462536||ti|1|text|21|123|Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
SE|25462536||ti|1|entity|C1511790|Detection|topp|||Detection|||0|1000|21|30
SE|25462536||ti|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|794|34|38
SE|25462536||ti|1|entity|C0175630|Circulating|ftcn|||circulating|||0|794|48|59
SE|25462536||ti|1|entity|C0003313|Antigen-Antibody Complex|aapp,imft|||immune complexes|||0|794|60|76
SE|25462536||ti|1|entity|C1515655|in vivo|spco|||in vivo|||0|843|82|89
SE|25462536||ti|1|entity|C0024399|Macaca fascicularis|mamm|||cynomolgus monkey|||0|843|90|107
SE|25462536||ti|1|entity|C0444266|Serum specimen|bdsu|||serum samples|||0|843|108|121
SE|25462536||ti|1|relation|1|1|C0444266|Serum specimen|bdsu|bdsu|||serum samples|||0|843|108|121|PREP|LOCATION_OF||77|81|2|1|C0003313|Antigen-Antibody Complex|aapp,gngm,imft|aapp|||immune complexes|||0|794|60|76

SE|25462536|BACKGROUND|ab|1|text|129|236|BACKGROUND: Administration of a biotherapeutic can result in the formation of anti-drug antibodies (ADAs).
SE|25462536|BACKGROUND|ab|1|entity|C1522492|Formation|ftcn|||formation|||0|1000|194|203
SE|25462536|BACKGROUND|ab|1|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|901|212|216
SE|25462536|BACKGROUND|ab|1|entity|C0003242|Antibodies, Anti-Idiotypic|aapp,imft|||anti-drug antibodies|||0|901|207|227
SE|25462536|BACKGROUND|ab|1|relation|0|0|C0003242|Antibodies, Anti-Idiotypic|aapp,gngm,imft|aapp|||anti-drug antibodies|||0|901|207|227|MOD/HEAD|ISA||212|227|0|0|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|901|212|216

SE|25462536|BACKGROUND|ab|2|text|236|384|The resulting ADA can potentially form immune complexes (ICs) with the drug leading to altered pharmacokinetic (PK) profiles and/or adverse events.
SE|25462536|BACKGROUND|ab|2|entity|C1274040|result|ftcn|||resulting|||0|661|240|249
SE|25462536|BACKGROUND|ab|2|entity|||gngm|100|ADA|ADA|||0|661|250|253
SE|25462536|BACKGROUND|ab|2|entity|C0003313|Antigen-Antibody Complex|aapp,imft|||immune complexes|||0|1000|275|291
SE|25462536|BACKGROUND|ab|2|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|1000|307|311
SE|25462536|BACKGROUND|ab|2|entity|C0205349|Altered|ftcn|||altered|||0|623|323|330
SE|25462536|BACKGROUND|ab|2|entity|C0031328|Pharmacokinetic|ftcn|||pharmacokinetic|||0|623|331|346
SE|25462536|BACKGROUND|ab|2|entity|C0877248|Adverse event|fndg|||adverse events|||0|983|368|382

SE|25462536|BACKGROUND|ab|3|text|384|520|Furthermore the presence of such complexes may interfere with accurate PK assessment, and/or detection of ADA in immunogenicity assays.
SE|25462536|BACKGROUND|ab|3|entity|C0439855|Complex|qlco|||complexes|||0|1000|417|426
SE|25462536|BACKGROUND|ab|3|entity|C0443131|Accurate|qlco|||accurate|||0|851|446|454
SE|25462536|BACKGROUND|ab|3|entity|C0031328|Pharmacokinetic|ftcn|||PK|||0|851|455|457
SE|25462536|BACKGROUND|ab|3|entity|C0220825|Evaluation|ftcn|||assessment|||0|851|458|468
SE|25462536|BACKGROUND|ab|3|entity|C1511790|Detection|topp|||detection|||0|1000|477|486
SE|25462536|BACKGROUND|ab|3|entity|||gngm|100|ADA|ADA|||0|1000|490|493
SE|25462536|BACKGROUND|ab|3|entity|C0872192|immunogenic|ftcn|||immunogenicity|||0|836|497|511
SE|25462536|BACKGROUND|ab|3|entity|C1510438|Assay|lbpr|||assays|||0|836|512|518

SE|25462536|BACKGROUND|ab|4|text|520|623|Here, we present two assays to detect the presence of drug-ADA immune complexes in cynomolgus monkeys.
SE|25462536|BACKGROUND|ab|4|entity|C0205448|Two|qnco|||two|||0|872|537|540
SE|25462536|BACKGROUND|ab|4|entity|C1510438|Assay|lbpr|||assays|||0|872|541|547
SE|25462536|BACKGROUND|ab|4|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|824|574|578
SE|25462536|BACKGROUND|ab|4|entity|||gngm|100|ADA|ADA|||0|824|579|582
SE|25462536|BACKGROUND|ab|4|entity|C0003313|Antigen-Antibody Complex|aapp,imft|||immune complexes|||0|824|583|599
SE|25462536|BACKGROUND|ab|4|entity|C0024399|Macaca fascicularis|mamm|||cynomolgus monkeys|||0|1000|603|621
SE|25462536|BACKGROUND|ab|4|relation|1|1|C0024399|Macaca fascicularis|mamm|mamm|||cynomolgus monkeys|||0|1000|603|621|PREP|LOCATION_OF||600|602|3|1|C0003313|Antigen-Antibody Complex|aapp,gngm,imft|aapp|||immune complexes|||0|824|583|599

SE|25462536|RESULTS|ab|5|text|623|686|RESULTS: Serum samples were analyzed for IC formation in vivo.
SE|25462536|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|623|630
SE|25462536|RESULTS|ab|5|entity|C0444266|Serum specimen|bdsu|||Serum samples|||0|983|632|645
SE|25462536|RESULTS|ab|5|entity|C1522492|Formation|ftcn|||formation|||0|888|667|676
SE|25462536|RESULTS|ab|5|entity|C1515655|in vivo|spco|||in vivo|||0|1000|677|684

SE|25462536|RESULTS|ab|6|text|686|741|8/8 tested animals were positive for drug specific IC.
SE|25462536|RESULTS|ab|6|entity|C0039593|Testing|resa|||tested|||0|733|690|696
SE|25462536|RESULTS|ab|6|entity|C0003062|Animals|anim|||animals|||0|733|697|704
SE|25462536|RESULTS|ab|6|entity|C1446409|Positive|qlco|||positive|||0|1000|710|718
SE|25462536|RESULTS|ab|6|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|802|723|727

SE|25462536|RESULTS|ab|7|text|741|839|Depending on the time point tested 4/8 or 7/8 animals tested positive for ADA during drug dosing.
SE|25462536|RESULTS|ab|7|entity|C0040223|Time|tmco|||time|||0|861|758|762
SE|25462536|RESULTS|ab|7|entity|C0003062|Animals|anim|||animals|||0|827|787|794
SE|25462536|RESULTS|ab|7|entity|C1446409|Positive|qlco|||positive|||0|1000|802|810
SE|25462536|RESULTS|ab|7|entity|||gngm|100|ADA|ADA|||0|1000|815|818
SE|25462536|RESULTS|ab|7|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|694|826|830
SE|25462536|RESULTS|ab|7|relation|4|1|||gngm,aapp|gngm|100|ADA|ADA|||0|1000|815|818|PREP|COEXISTS_WITH||819|825|1|1|C0013227|Pharmaceutical Preparations|phsu|phsu|||drug|||0|694|826|830

SE|25462536|RESULTS|ab|8|text|839|963|All 8 animals were confirmed positive for ADA during the washout phase, indicating drug interference in the bridging assay.
SE|25462536|RESULTS|ab|8|entity|C0003062|Animals|anim|||animals|||0|861|845|852
SE|25462536|RESULTS|ab|8|entity|C1446409|Positive|qlco|||positive|||0|1000|868|876
SE|25462536|RESULTS|ab|8|entity|||gngm|100|ADA|ADA|||0|1000|881|884
SE|25462536|RESULTS|ab|8|entity|C0205390|Phase|tmco|||phase|||0|861|904|909
SE|25462536|RESULTS|ab|8|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|694|922|926
SE|25462536|RESULTS|ab|8|entity|C1510438|Assay|lbpr|||assay|||0|861|956|961

SE|25462536|RESULTS|ab|9|text|963|1065|Relative amount of IC over time was determined and its correlation with PK and ADA was then assessed.
SE|25462536|RESULTS|ab|9|entity|C0205345|Relative|qlco|||Relative|||0|888|963|971
SE|25462536|RESULTS|ab|9|entity|C1265611|Quantity|qnco|||amount|||0|888|972|978
SE|25462536|RESULTS|ab|9|entity|C0040223|Time|tmco|||time|||0|802|990|994
SE|25462536|RESULTS|ab|9|entity|C0031328|Pharmacokinetic|ftcn|||PK|||0|1000|1035|1037
SE|25462536|RESULTS|ab|9|entity|||gngm|100|ADA|ADA|||0|1000|1042|1045

SE|25462536|RESULTS|ab|10|text|1065|1320|Multivariate data analysis demonstrates good correlation between signals obtained from the anti-drug and FcgammaRIIIa based capture assays, although due to its biological characteristic FcgammaRIIIa based assay captured only a subset of drug specific IC.
SE|25462536|RESULTS|ab|10|entity|C1511726|Data|idcn|||data|||0|901|1078|1082
SE|25462536|RESULTS|ab|10|entity|C0026777|Multivariate Analysis|qnco|||Multivariate data analysis|||0|901|1065|1091
SE|25462536|RESULTS|ab|10|entity|C0205170|Good|qlco|||good|||0|694|1105|1109
SE|25462536|RESULTS|ab|10|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|861|1161|1165
SE|25462536|RESULTS|ab|10|entity|C1510438|Assay|lbpr|||assays|||0|827|1197|1203
SE|25462536|RESULTS|ab|10|entity|C0005510|Characteristics, Biological|grpa|||biological characteristic|||0|734|1225|1250
SE|25462536|RESULTS|ab|10|entity|C1510438|Assay|lbpr|||assay|||0|1000|1270|1275
SE|25462536|RESULTS|ab|10|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|802|1302|1306

SE|25462536|RESULTS|ab|11|text|1320|1420|In one animal IC remained in circulation even when the drug levels decreased below detection limit.
SE|25462536|RESULTS|ab|11|entity|C0205447|One|qnco|||one|||0|851|1323|1326
SE|25462536|RESULTS|ab|11|entity|C0003043|Animalia|anim|||animal|||0|851|1327|1333
SE|25462536|RESULTS|ab|11|entity|C1261153|Drug measurement|lbpr|||drug levels|||0|983|1375|1386
SE|25462536|RESULTS|ab|11|entity|C0542339|Inferior|spco|||below|||0|851|1397|1402
SE|25462536|RESULTS|ab|11|entity|C1511790|Detection|topp|||detection|||0|851|1403|1412
SE|25462536|RESULTS|ab|11|entity|C1549649|Limit|idcn|||limit|||0|851|1413|1418

SE|25462536|CONCLUSION|ab|12|text|1420|1540|CONCLUSION: Results from this study indicate the presence of IC during administration of an immunogenic biotherapeutic.
SE|25462536|CONCLUSION|ab|12|entity|C1274040|result|ftcn|||Results|||0|966|1432|1439
SE|25462536|CONCLUSION|ab|12|entity|C0008972|Clinical Research|resa|||study|||0|1000|1450|1455
SE|25462536|CONCLUSION|ab|12|entity|C0872192|immunogenic|ftcn|||immunogenic|||0|694|1512|1523

SE|25462536|CONCLUSION|ab|13|text|1540|1638|Potential application of these assays includes detection of ADA in an IC during high drug levels.
SE|25462536|CONCLUSION|ab|13|entity|C0237399|Potential|qlco|||Potential|||0|888|1540|1549
SE|25462536|CONCLUSION|ab|13|entity|C1510438|Assay|lbpr|||assays|||0|966|1571|1577
SE|25462536|CONCLUSION|ab|13|entity|C1511790|Detection|topp|||detection|||0|1000|1587|1596
SE|25462536|CONCLUSION|ab|13|entity|||gngm|100|ADA|ADA|||0|1000|1600|1603
SE|25462536|CONCLUSION|ab|13|entity|C0205250|High|qlco|||high|||0|890|1620|1624
SE|25462536|CONCLUSION|ab|13|entity|C1261153|Drug measurement|lbpr|||drug levels|||0|890|1625|1636

SE|25462536|CONCLUSION|ab|14|text|1638|1759|The results on the kinetics of IC formation during ADA response can complement the understanding of PK and ADA profiles.
SE|25462536|CONCLUSION|ab|14|entity|C1274040|result|ftcn|||results|||0|966|1642|1649
SE|25462536|CONCLUSION|ab|14|entity|C0022702|Kinetics|idcn|||kinetics|||0|1000|1657|1665
SE|25462536|CONCLUSION|ab|14|entity|C1522492|Formation|ftcn|||formation|||0|888|1672|1681
SE|25462536|CONCLUSION|ab|14|entity|||gngm|100|ADA|ADA|||0|861|1689|1692
SE|25462536|CONCLUSION|ab|14|entity|C0871261|response|clna|||response|||0|861|1693|1701
SE|25462536|CONCLUSION|ab|14|entity|C0031328|Pharmacokinetic|ftcn|||PK|||0|1000|1738|1740
SE|25462536|CONCLUSION|ab|14|entity|||gngm|100|ADA|ADA|||0|1000|1745|1748

SE|25462536|CONCLUSION|ab|15|text|1759|1922|Moreover, the presence of IC indicates possible ADA interference in standard PK assays and potential underestimation of total drug exposure in toxicology studies.
SE|25462536|CONCLUSION|ab|15|entity|C0332149|Possible|qlco|||possible|||0|660|1798|1806
SE|25462536|CONCLUSION|ab|15|entity|||gngm|100|ADA|ADA|||0|660|1807|1810
SE|25462536|CONCLUSION|ab|15|entity|C1442989|STANDARD|ftcn|||standard|||0|840|1827|1835
SE|25462536|CONCLUSION|ab|15|entity|C0031328|Pharmacokinetic|ftcn|||PK|||0|840|1836|1838
SE|25462536|CONCLUSION|ab|15|entity|C1510438|Assay|lbpr|||assays|||0|840|1839|1845
SE|25462536|CONCLUSION|ab|15|entity|C0237399|Potential|qlco|||potential|||0|694|1850|1859
SE|25462536|CONCLUSION|ab|15|entity|C0439175|% of total|qnco|||total|||0|901|1879|1884
SE|25462536|CONCLUSION|ab|15|entity|C0743284|Drug Exposure|fndg|||drug exposure|||0|901|1885|1898
SE|25462536|CONCLUSION|ab|15|entity|C0040541|Toxicology|bmod|||toxicology|||0|872|1902|1912
SE|25462536|CONCLUSION|ab|15|entity|C0008972|Clinical Research|resa|||studies|||0|872|1913|1920

SE|25462536|CONCLUSION|ab|16|text|1922|2090|In addition this study also highlights the need to understand downstream in vivo consequences of drug-ADA IC as no animals under investigation developed adverse events.
SE|25462536|CONCLUSION|ab|16|entity|C0008972|Clinical Research|resa|||study|||0|1000|1939|1944
SE|25462536|CONCLUSION|ab|16|entity|C0027552|Needs|qlco|||need|||0|1000|1965|1969
SE|25462536|CONCLUSION|ab|16|entity|C0522506|Downstream|spco|||downstream|||0|658|1984|1994
SE|25462536|CONCLUSION|ab|16|entity|C1515655|in vivo|spco|||in vivo|||0|658|1995|2002
SE|25462536|CONCLUSION|ab|16|entity|C0013227|Pharmaceutical Preparations|phsu|||drug|||0|802|2019|2023
SE|25462536|CONCLUSION|ab|16|entity|||gngm|100|ADA|ADA|||0|802|2024|2027
SE|25462536|CONCLUSION|ab|16|entity|C0003062|Animals|anim|||animals|||0|1000|2037|2044
SE|25462536|CONCLUSION|ab|16|entity|C0877248|Adverse event|fndg|||adverse events|||0|983|2075|2089


SE|25462535||ti|1|text|21|173|Different plasma markers of inflammation are influenced by immune recovery and cART composition or intensification in treated HIV infected individuals.
SE|25462535||ti|1|entity|C1547020|*Difference|qnco|||Different|||0|587|21|30
SE|25462535||ti|1|entity|C0032105|Plasma|bdsu|||plasma|||0|587|31|37
SE|25462535||ti|1|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|49|61
SE|25462535||ti|1|entity|C0439662|Immune|ftcn|||immune|||0|888|80|86
SE|25462535||ti|1|entity|C0237820|Recovery|orgf|||recovery|||0|888|87|95
SE|25462535||ti|1|entity|C0009429|Combined Modality Therapy|topp|||cART|||0|824|100|104
SE|25462535||ti|1|entity|C0486616|Composition|clna|||composition|||0|824|105|116
SE|25462535||ti|1|entity|C1292734|Treats|clas|||treated|||0|825|139|146
SE|25462535||ti|1|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|825|147|150
SE|25462535||ti|1|entity|C0439663|Infected|ftcn|||infected|||0|825|151|159
SE|25462535||ti|1|entity|C0237401|Individual|humn|||individuals|||0|825|160|171
SE|25462535||ti|1|relation|5|4|C0021368|Inflammation|patf|patf|||inflammation|||0|1000|49|61|PREP|PROCESS_OF||136|138|1|1|C0237401|Individual|grup,humn|humn|||individuals|||0|825|160|171

SE|25462535|BACKGROUND|ab|1|text|179|256|BACKGROUND: HIV-1 infection increases plasma levels of inflammatory markers.
SE|25462535|BACKGROUND|ab|1|entity|C0019693|HIV Infections|dsyn|||HIV-1 infection|||0|913|191|206
SE|25462535|BACKGROUND|ab|1|entity|C0032105|Plasma|bdsu|||plasma|||0|888|217|223
SE|25462535|BACKGROUND|ab|1|entity|C0441889|Levels|inpr|||levels|||0|888|224|230
SE|25462535|BACKGROUND|ab|1|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|694|234|246

SE|25462535|BACKGROUND|ab|2|text|256|354|Combination antiretroviral therapy (cART) does not restore inflammatory markers to normal levels.
SE|25462535|BACKGROUND|ab|2|entity|C0009429|Combined Modality Therapy|topp|||Combination antiretroviral therapy|||0|913|256|290
SE|25462535|BACKGROUND|ab|2|entity|C1518422|Not|ftcn|||not|||0|1000|303|306
SE|25462535|BACKGROUND|ab|2|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|694|315|327
SE|25462535|BACKGROUND|ab|2|entity|C0205307|Normal|qlco|||normal|||0|888|339|345
SE|25462535|BACKGROUND|ab|2|entity|C0441889|Levels|inpr|||levels|||0|888|346|352

SE|25462535|BACKGROUND|ab|3|text|354|589|Since intensification of cART with raltegravir reduced CD8 T-cell activation in the Discor-Ral and IntegRal studies, we have evaluated the effect of raltegravir intensification on several soluble inflammation markers in these studies.
SE|25462535|BACKGROUND|ab|3|entity|C0009429|Combined Modality Therapy|topp|||cART|||0|913|379|383
SE|25462535|BACKGROUND|ab|3|entity|C0392756|Reduced|qlco|||reduced|||0|823|401|408
SE|25462535|BACKGROUND|ab|3|entity|C1367471|CD8B1 gene|gngm|926|CD8B|CD8|||0|823|409|412
SE|25462535|BACKGROUND|ab|3|entity|C1155065|T-Cell Activation|celf|||T-cell activation|||0|823|413|430
SE|25462535|BACKGROUND|ab|3|entity|C0812284|RALA gene|gngm|5898|RALA|Ral|||0|861|445|448
SE|25462535|BACKGROUND|ab|3|entity|C0443238|Integral|qnco|||IntegRal|||0|872|453|461
SE|25462535|BACKGROUND|ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|872|462|469
SE|25462535|BACKGROUND|ab|3|entity|C1280500|Effect|qlco|||effect|||0|1000|493|499
SE|25462535|BACKGROUND|ab|3|entity|C0443302|Several|qnco|||several|||0|597|534|541
SE|25462535|BACKGROUND|ab|3|entity|C0021368|Inflammation|patf|||inflammation|||0|597|550|562
SE|25462535|BACKGROUND|ab|3|entity|C0008972|Clinical Research|resa|||studies|||0|966|580|587
SE|25462535|BACKGROUND|ab|3|relation|7|4|C0812284|RALA gene|gngm,aapp|gngm|5898|RALA|Ral|||0|861|445|448|NOM|PREDISPOSES||563|570|7|0|C0021368|Inflammation|patf|patf|||inflammation|||0|597|550|562

SE|25462535|METHODS|ab|4|text|589|849|METHODS: Longitudinal plasma samples (0-48 weeks) from the IntegRal (n = 67, 22 control and 45 intensified individuals) and the Discor-Ral studies (44 individuals with CD4 T-cell counts<350 cells/ul, 14 control and 30 intensified) were assayed for 25 markers.
SE|25462535|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|589|596
SE|25462535|METHODS|ab|4|entity|C0205127|Longitudinal|spco|||Longitudinal|||0|890|598|610
SE|25462535|METHODS|ab|4|entity|C0444263|Plasma specimen|bdsu|||plasma samples|||0|890|611|625
SE|25462535|METHODS|ab|4|entity|C0439230|week|tmco|||weeks|||0|827|632|637
SE|25462535|METHODS|ab|4|entity|C0443238|Integral|qnco|||IntegRal|||0|1000|648|656
SE|25462535|METHODS|ab|4|entity|C0243148|control|ftcn|||control|||0|861|669|676
SE|25462535|METHODS|ab|4|entity|C0237401|Individual|humn|||individuals|||0|827|696|707
SE|25462535|METHODS|ab|4|entity|C0812284|RALA gene|gngm|5898|RALA|Ral|||0|773|724|727
SE|25462535|METHODS|ab|4|entity|C0008972|Clinical Research|resa|||studies|||0|773|728|735
SE|25462535|METHODS|ab|4|entity|C0237401|Individual|humn|||individuals|||0|861|740|751
SE|25462535|METHODS|ab|4|entity|C0039215|CD4 Positive T Lymphocytes|cell|||CD4 T-cell|||0|901|757|767
SE|25462535|METHODS|ab|4|entity|C0007634|Cells|cell|||cells|||0|790|779|784
SE|25462535|METHODS|ab|4|entity|C0243148|control|ftcn|||control|||0|861|792|799
SE|25462535|METHODS|ab|4|relation|5|1|C0039215|CD4 Positive T Lymphocytes|cell|cell|||CD4 T-cell|||0|901|757|767|PREP|PART_OF||752|756|9|1|C0237401|Individual|grup,humn|humn|||individuals|||0|861|740|751

SE|25462535|METHODS|ab|5|text|849|935|Mann-Whitney, Wilcoxon, Spearman test and linear mixed models were used for analysis.
SE|25462535|METHODS|ab|5|entity|C0039593|Testing|resa|||test|||0|861|882|886
SE|25462535|METHODS|ab|5|entity|C0205430|Mixed|ftcn|||mixed|||0|901|898|903
SE|25462535|METHODS|ab|5|entity|C0023732|Linear Models|qnco|||linear mixed models|||0|901|891|910
SE|25462535|METHODS|ab|5|entity|C0936012|Analysis|resa|||analysis|||0|1000|925|933

SE|25462535|RESULTS|ab|6|text|935|1197|RESULTS: At baseline, different inflammatory markers were strongly associated with HCV co-infection, lower CD4 counts and with cART regimens (being higher in PI-treated individuals), but poorly correlated with detection of markers of residual viral replication.
SE|25462535|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|935|942
SE|25462535|RESULTS|ab|6|entity|C1442488|BASELINE|qnco|||baseline|||0|1000|947|955
SE|25462535|RESULTS|ab|6|entity|C1547020|*Difference|qnco|||different|||0|587|957|966
SE|25462535|RESULTS|ab|6|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|587|967|979
SE|25462535|RESULTS|ab|6|entity|C0220847|Hepatitis C virus|virs|||HCV|||0|840|1018|1021
SE|25462535|RESULTS|ab|6|entity|C0243009|CD4 Count determination procedure|lbpr|||CD4 counts|||0|1000|1042|1052
SE|25462535|RESULTS|ab|6|entity|C0009429|Combined Modality Therapy|topp|||cART|||0|813|1062|1066
SE|25462535|RESULTS|ab|6|entity|C0040808|Treatment Protocols|resa,topp|||regimens|||0|813|1067|1075
SE|25462535|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|966|1083|1089
SE|25462535|RESULTS|ab|6|entity|C0033607|Protease Inhibitor|bacs,phsu|||PI|||0|850|1093|1095
SE|25462535|RESULTS|ab|6|entity|C1292734|Treats|clas|||treated|||0|850|1096|1103
SE|25462535|RESULTS|ab|6|entity|C0237401|Individual|humn|||individuals|||0|850|1104|1115
SE|25462535|RESULTS|ab|6|entity|C0205169|Bad|qlco|||poorly|||0|1000|1122|1128
SE|25462535|RESULTS|ab|6|entity|C1511790|Detection|topp|||detection|||0|1000|1145|1154
SE|25462535|RESULTS|ab|6|entity|C1609982|Residual|qlco|||residual|||0|851|1169|1177
SE|25462535|RESULTS|ab|6|entity|C0521026|Viral|ftcn|||viral|||0|851|1178|1183
SE|25462535|RESULTS|ab|6|relation|0|0|C0040808|Treatment Protocols|resa,topp|resa|||regimens|||0|813|1067|1075|MOD/HEAD|USES||1062|1075|0|0|C0009429|Combined Modality Therapy|topp|topp|||cART|||0|813|1062|1066

SE|25462535|RESULTS|ab|7|text|1197|1398|Although raltegravir intensification reduced inflammation in individuals with lower CD4 T-cell counts, no effect of intensification was observed on plasma markers of inflammation in a global analysis.
SE|25462535|RESULTS|ab|7|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|1242|1254
SE|25462535|RESULTS|ab|7|entity|C0237401|Individual|humn|||individuals|||0|1000|1258|1269
SE|25462535|RESULTS|ab|7|entity|C0441994|Lower|ftcn|||lower|||0|875|1275|1280
SE|25462535|RESULTS|ab|7|entity|C0243009|CD4 Count determination procedure|lbpr|||CD4 T-cell counts|||0|875|1281|1298
SE|25462535|RESULTS|ab|7|entity|C1280500|Effect|qlco|||effect|||0|1000|1303|1309
SE|25462535|RESULTS|ab|7|entity|C0032105|Plasma|bdsu|||plasma|||0|694|1345|1351
SE|25462535|RESULTS|ab|7|entity|C0021368|Inflammation|patf|||inflammation|||0|1000|1363|1375
SE|25462535|RESULTS|ab|7|entity|C0205246|Generalized|spco|||global|||0|888|1381|1387
SE|25462535|RESULTS|ab|7|entity|C0936012|Analysis|resa|||analysis|||0|888|1388|1396
SE|25462535|RESULTS|ab|7|relation|2|1|C0021368|Inflammation|patf|patf|||inflammation|||0|1000|1242|1254|PREP|PROCESS_OF||1255|1257|7|1|C0237401|Individual|grup,humn|humn|||individuals|||0|1000|1258|1269

SE|25462535|RESULTS|ab|8|text|1398|1638|An association was found, however, between reductions in immune activation and plasma levels of the coagulation marker D-dimer, which exclusively decreased in intensified patients on protease inhibitor (PI)-based cART regimens (P = 0.040).
SE|25462535|RESULTS|ab|8|entity|C0439662|Immune|ftcn|||immune|||0|694|1455|1461
SE|25462535|RESULTS|ab|8|entity|C0032105|Plasma|bdsu|||plasma|||0|888|1477|1483
SE|25462535|RESULTS|ab|8|entity|C0441889|Levels|inpr|||levels|||0|888|1484|1490
SE|25462535|RESULTS|ab|8|entity|C0441509|Coagulation procedure|topp|||coagulation|||0|888|1498|1509
SE|25462535|RESULTS|ab|8|entity|C0005516|Biological Markers|qlco|||marker|||0|888|1510|1516
SE|25462535|RESULTS|ab|8|entity|C0596448|dimer|chvs|||dimer|||0|1000|1519|1524
SE|25462535|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|861|1569|1577
SE|25462535|RESULTS|ab|8|entity|C0033607|Protease Inhibitor|bacs,phsu|||protease inhibitor|||0|760|1581|1599
SE|25462535|RESULTS|ab|8|entity|C0009429|Combined Modality Therapy|topp|||cART|||0|760|1611|1615
SE|25462535|RESULTS|ab|8|entity|C0040808|Treatment Protocols|resa,topp|||regimens|||0|760|1616|1624
SE|25462535|RESULTS|ab|8|relation|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|1569|1577|PREP|LOCATION_OF||1554|1556|6|3|C0032105|Plasma|bdsu|bdsu|||plasma|||0|888|1477|1483
SE|25462535|RESULTS|ab|8|relation|7|0|C0040808|Treatment Protocols|resa,topp|topp|||regimens|||0|760|1616|1624|ADJ|USES||1605|1610|7|0|C0033607|Protease Inhibitor|bacs,phsu|phsu|||protease inhibitor|||0|760|1581|1599

SE|25462535|CONCLUSIONS|ab|9|text|1638|1812|CONCLUSIONS: The inflammatory profile in treated HIV-infected individuals showed a complex association with HCV co-infection, the levels of CD4 T cells and the cART regimen.
SE|25462535|CONCLUSIONS|ab|9|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|694|1655|1667
SE|25462535|CONCLUSIONS|ab|9|entity|C1292734|Treats|clas|||treated|||0|825|1679|1686
SE|25462535|CONCLUSIONS|ab|9|entity|C0001175|Acquired Immunodeficiency Syndrome|dsyn|||HIV|||0|825|1687|1690
SE|25462535|CONCLUSIONS|ab|9|entity|C0439663|Infected|ftcn|||infected|||0|825|1691|1699
SE|25462535|CONCLUSIONS|ab|9|entity|C0237401|Individual|humn|||individuals|||0|825|1700|1711
SE|25462535|CONCLUSIONS|ab|9|entity|C0439855|Complex|qlco|||complex|||0|694|1721|1728
SE|25462535|CONCLUSIONS|ab|9|entity|C0220847|Hepatitis C virus|virs|||HCV|||0|840|1746|1749
SE|25462535|CONCLUSIONS|ab|9|entity|C0441889|Levels|inpr|||levels|||0|1000|1768|1774
SE|25462535|CONCLUSIONS|ab|9|entity|C1332714|CD4 gene|gngm|920|CD4|CD4|||0|901|1778|1781
SE|25462535|CONCLUSIONS|ab|9|entity|C0039194|T-Lymphocyte|cell|||T cells|||0|901|1782|1789
SE|25462535|CONCLUSIONS|ab|9|entity|C0009429|Combined Modality Therapy|topp|||cART|||0|824|1798|1802
SE|25462535|CONCLUSIONS|ab|9|entity|C0040808|Treatment Protocols|resa,topp|||regimen|||0|824|1803|1810
SE|25462535|CONCLUSIONS|ab|9|relation|0|0|C0040808|Treatment Protocols|resa,topp|resa|||regimen|||0|824|1803|1810|MOD/HEAD|USES||1798|1810|0|0|C0009429|Combined Modality Therapy|topp|topp|||cART|||0|824|1798|1802

SE|25462535|CONCLUSIONS|ab|10|text|1812|2048|Raltegravir intensification specifically reduced D-dimer levels in PI-treated patients, highlighting the link between cART composition and residual viral replication; however, raltegravir had little effect on other inflammatory markers.
SE|25462535|CONCLUSIONS|ab|10|entity|C0392756|Reduced|qlco|||reduced|||0|861|1853|1860
SE|25462535|CONCLUSIONS|ab|10|entity|C0596448|dimer|chvs|||dimer|||0|888|1863|1868
SE|25462535|CONCLUSIONS|ab|10|entity|C0441889|Levels|inpr|||levels|||0|888|1869|1875
SE|25462535|CONCLUSIONS|ab|10|entity|C0033607|Protease Inhibitor|bacs,phsu|||PI|||0|850|1879|1881
SE|25462535|CONCLUSIONS|ab|10|entity|C1292734|Treats|clas|||treated|||0|850|1882|1889
SE|25462535|CONCLUSIONS|ab|10|entity|C0030705|Patients|podg|||patients|||0|850|1890|1898
SE|25462535|CONCLUSIONS|ab|10|entity|C0009429|Combined Modality Therapy|topp|||cART|||0|824|1930|1934
SE|25462535|CONCLUSIONS|ab|10|entity|C0486616|Composition|clna|||composition|||0|824|1935|1946
SE|25462535|CONCLUSIONS|ab|10|entity|C1609982|Residual|qlco|||residual|||0|851|1951|1959
SE|25462535|CONCLUSIONS|ab|10|entity|C0521026|Viral|ftcn|||viral|||0|851|1960|1965
SE|25462535|CONCLUSIONS|ab|10|entity|C0023882|Little's Disease|dsyn|||little|||0|888|2004|2010
SE|25462535|CONCLUSIONS|ab|10|entity|C1280500|Effect|qlco|||effect|||0|888|2011|2017
SE|25462535|CONCLUSIONS|ab|10|entity|C0333348|Inflammatory|ftcn|||inflammatory|||0|694|2027|2039


SE|25462537||ti|1|text|21|149|Fetal gut laser microdissection in combination with RNA preamplification enables epithelial-specific transcriptional profiling.
SE|25462537||ti|1|entity|C0521457|Foeto-|ftcn|||Fetal|||0|833|21|26
SE|25462537||ti|1|entity|C0699819|Gut|bpoc|||gut|||0|833|27|30
SE|25462537||ti|1|entity|C0023089|Lasers|mnob|||laser|||0|833|31|36
SE|25462537||ti|1|entity|C0598304|Microdissection|diap,resa|||microdissection|||0|833|37|52
SE|25462537||ti|1|entity|C0205195|Combined|qlco|||combination|||0|1000|56|67
SE|25462537||ti|1|entity|C0035668|RNA|bacs,nnon|||RNA|||0|694|73|76
SE|25462537||ti|1|entity|C0221908|Epithelial|ftcn|||epithelial|||0|561|102|112
SE|25462537||ti|1|entity|C0040649|Transcription, Genetic|genf|||transcriptional|||0|561|122|137

SE|25462537||ab|1|text|155|318|Laser microdissection (LMD) technology enables highly specific gene expression analyses of biologically relevant questions at cell- or tissue-specific resolution.
SE|25462537||ab|1|entity|C0023089|Lasers|mnob|||Laser|||0|851|155|160
SE|25462537||ab|1|entity|C0598304|Microdissection|diap,resa|||microdissection|||0|851|161|176
SE|25462537||ab|1|entity|C0039421|Technology|ocdi|||technology|||0|851|183|193
SE|25462537||ab|1|entity|C0017262|Gene Expression|genf|||gene expression|||0|769|218|233
SE|25462537||ab|1|entity|C0936012|Analysis|resa|||analyses|||0|769|234|242
SE|25462537||ab|1|entity|C0007634|Cells|cell|||cell|||0|1000|281|285
SE|25462537||ab|1|entity|C1514893|Resolution|ftcn|||resolution|||0|827|306|316

SE|25462537||ab|2|text|318|554|Nevertheless, specific cell types are often limited in quantity (i.e. fetal tissue), making high quality RNA extraction and subsequent gene expression approaches via common reverse transcriptase-quantitative PCR (RT-q-PCR) challenging.
SE|25462537||ab|2|entity|C0007634|Cells|cell|||cell types|||0|901|341|351
SE|25462537||ab|2|entity|C0332183|Frequent|tmco|||often|||0|1000|356|361
SE|25462537||ab|2|entity|C1265611|Quantity|qnco|||quantity|||0|1000|373|381
SE|25462537||ab|2|entity|C0242291|Fetal Tissue|tisu|||fetal tissue|||0|861|388|400
SE|25462537||ab|2|entity|C0205250|High|qlco|||high|||0|833|410|414
SE|25462537||ab|2|entity|C0332306|Quality|qlco|||quality|||0|833|415|422
SE|25462537||ab|2|entity|C0035668|RNA|bacs,nnon|||RNA|||0|833|423|426
SE|25462537||ab|2|entity|C0185115|Extraction|topp|||extraction|||0|833|427|437
SE|25462537||ab|2|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|901|442|452
SE|25462537||ab|2|entity|C0017262|Gene Expression|genf|||gene expression|||0|901|453|468
SE|25462537||ab|2|entity|C1550513|via|idcn|||via|||0|831|480|483
SE|25462537||ab|2|entity|C0205214|Common|qnco|||common|||0|831|484|490
SE|25462537||ab|2|entity|C0392762|Quantitative|qnco|||quantitative|||0|831|513|525
SE|25462537||ab|2|entity|C0599161|Reverse Transcriptase Polymerase Chain Reaction|mbrt|||reverse transcriptase-quantitative PCR|||0|831|491|529
SE|25462537||ab|2|entity|C0805586|CHALLENGE|idcn|||challenging|||0|831|541|552

SE|25462537||ab|3|text|554|711|In the case of fetal gut epithelia representing immune modulatory interphases gene expression analysis with common RT-q-PCR is limited to a few genes (<10).
SE|25462537||ab|3|entity|C0521457|Foeto-|ftcn|||fetal|||0|890|569|574
SE|25462537||ab|3|entity|C0836205|Gut Epithelium|bpoc,tisu|||gut epithelia|||0|890|575|588
SE|25462537||ab|3|entity|C0005525|Biological Response Modifiers|phsu|||immune modulatory|||0|825|602|619
SE|25462537||ab|3|entity|C0021798|Interphase|tmco|||interphases|||0|825|620|631
SE|25462537||ab|3|entity|C0017262|Gene Expression|genf|||gene expression|||0|825|632|647
SE|25462537||ab|3|entity|C0936012|Analysis|resa|||analysis|||0|825|648|656
SE|25462537||ab|3|entity|C0205214|Common|qnco|||common|||0|875|662|668
SE|25462537||ab|3|entity|C0392762|Quantitative|qnco|||RT-q-PCR|||0|875|669|677
SE|25462537||ab|3|entity|C0599161|Reverse Transcriptase Polymerase Chain Reaction|mbrt|||RT-q-PCR|||0|875|669|677
SE|25462537||ab|3|entity|C0205388|Few|qnco|||few|||0|888|694|697
SE|25462537||ab|3|entity|C0017337|Genes|gngm|||genes|||0|888|698|703

SE|25462537||ab|4|text|711|1047|To circumvent these limitations we provide a workflow using laser microdissection of 1.5MioMUm(2) dissected area of murine fetal intestinal epithelial cells (IEC) from fetal ileum and colon with subsequent RNA isolation, whole transcriptome preamplification (WTA) and gene expression analysis by microarray and quantitative PCR (qPCR).
SE|25462537||ab|4|entity|C0449295|Limitation|ftcn|||limitations|||0|966|731|742
SE|25462537||ab|4|entity|C0023089|Lasers|mnob|||laser|||0|888|771|776
SE|25462537||ab|4|entity|C0598304|Microdissection|diap,resa|||microdissection|||0|888|777|792
SE|25462537||ab|4|entity|C0205239|Dissecting|ftcn|||dissected|||0|872|809|818
SE|25462537||ab|4|entity|C0205146|Area|spco|||area|||0|872|819|823
SE|25462537||ab|4|entity|C0026809|Mus|mamm|||murine|||0|840|827|833
SE|25462537||ab|4|entity|C0021853|Intestines|bpoc|||intestinal|||0|840|840|850
SE|25462537||ab|4|entity|C0221908|Epithelial|ftcn|||epithelial|||0|840|851|861
SE|25462537||ab|4|entity|C0439170|% fetal cells|qnco|||fetal intestinal epithelial cells|||0|840|834|867
SE|25462537||ab|4|entity|C0521457|Foeto-|ftcn|||fetal|||0|888|879|884
SE|25462537||ab|4|entity|C0020885|ileum|bpoc|||ileum|||0|888|885|890
SE|25462537||ab|4|entity|C0009368|Colon|bpoc|||colon|||0|1000|895|900
SE|25462537||ab|4|entity|C0750530|SUBSEQUENT|idcn|||subsequent|||0|851|906|916
SE|25462537||ab|4|entity|C0035668|RNA|bacs,nnon|||RNA|||0|851|917|920
SE|25462537||ab|4|entity|C0204727|Isolation procedure|topp|||isolation|||0|851|921|930
SE|25462537||ab|4|entity|C0444667|Whole|qnco|||whole|||0|660|932|937
SE|25462537||ab|4|entity|C0017262|Gene Expression|genf|||gene expression|||0|901|979|994
SE|25462537||ab|4|entity|C0936012|Analysis|resa|||analysis|||0|901|995|1003
SE|25462537||ab|4|entity|C0392762|Quantitative|qnco|||quantitative|||0|888|1022|1034
SE|25462537||ab|4|entity|C0032520|Polymerase Chain Reaction|lbpr,mbrt|||PCR|||0|888|1035|1038

SE|25462537||ab|5|text|1047|1231|This workflow allows simultaneous analyses of global (microarrays) and targeted gene expression (qPCR) and consequently increases the number of measurable genes up to 25-fold by qPCR.
SE|25462537||ab|5|entity|C0521115|Simultaneous|tmco|||simultaneous|||0|872|1068|1080
SE|25462537||ab|5|entity|C0936012|Analysis|resa|||analyses|||0|872|1081|1089
SE|25462537||ab|5|entity|C0205246|Generalized|spco|||global|||0|1000|1093|1099
SE|25462537||ab|5|entity|C0599894|targeting|celf|||targeted|||0|884|1118|1126
SE|25462537||ab|5|entity|C0017262|Gene Expression|genf|||gene expression|||0|884|1127|1142
SE|25462537||ab|5|entity|C0237753|Numbers|qnco|||number|||0|1000|1181|1187
SE|25462537||ab|5|entity|C1513040|Measurable|ftcn|||measurable|||0|888|1191|1201
SE|25462537||ab|5|entity|C0017337|Genes|gngm|||genes|||0|888|1202|1207
SE|25462537||ab|5|entity|C0332462|Fold|spco|||fold|||0|861|1217|1221

SE|25462537||ab|6|text|1231|1369|It is suitable for cryosections from many tissues and species in order to evaluate in utero biological effects on specific effector sites.
SE|25462537||ab|6|entity|C0040300|Body tissue|tisu|||tissues|||0|1000|1273|1280
SE|25462537||ab|6|entity|C1548151|Species|idcn|||species|||0|1000|1285|1292
SE|25462537||ab|6|entity|C0042149|Uterus|bpoc|||utero|||0|764|1317|1322
SE|25462537||ab|6|entity|C0205460|biological|ftcn|||biological|||0|764|1323|1333
SE|25462537||ab|6|entity|C1280500|Effect|qlco|||effects|||0|764|1334|1341
SE|25462537||ab|6|entity|C0449604|Specific site|spco|||specific effector sites|||0|896|1345|1368


SE|25462538||ti|1|text|21|178|International trends in patient selection for elective endovascular aneurysm repair: sicker patients with safer anatomy leading to improved 1-year survival.
SE|25462538||ti|1|entity|C1512888|International|idcn|||International|||0|888|21|34
SE|25462538||ti|1|entity|C1521798|trend|tmco|||trends|||0|888|35|41
SE|25462538||ti|1|entity|C0242802|Patient Selection|hlca,resa|||patient selection|||0|1000|45|62
SE|25462538||ti|1|entity|C0439608|elective|tmco|||elective|||0|833|67|75
SE|25462538||ti|1|entity|C0524425|Endovascular|blor|||endovascular|||0|833|76|88
SE|25462538||ti|1|entity|C0002940|Aneurysm|anab|||aneurysm|||0|833|89|97
SE|25462538||ti|1|entity|C0043240|Wound Healing|orgf|||repair|||0|833|98|104
SE|25462538||ti|1|entity|C0221423|Finding / disorder|ftcn|||sicker|||0|847|106|112
SE|25462538||ti|1|entity|C0030705|Patients|podg|||patients|||0|847|113|121
SE|25462538||ti|1|entity|C0036043|Safety|hcpp|||safer|||0|847|127|132
SE|25462538||ti|1|entity|C0700276|Anatomic structures|anst|||anatomy|||0|847|133|140
SE|25462538||ti|1|entity|C0184511|Improved|qlco|||improved|||0|775|152|160
SE|25462538||ti|1|entity|C0439234|year|tmco|||year|||0|775|163|167
SE|25462538||ti|1|entity|C0038952|Continuance of life|acty|||survival|||0|775|168|176
SE|25462538||ti|1|relation|2|1|C0700276|Anatomic structures|anst|anst|||anatomy|||0|847|133|140|PREP|PART_OF||122|126|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|847|113|121

SE|25462538|BACKGROUND|ab|1|text|184|376|BACKGROUND: To review the trends in patient selection and early death rate for patients undergoing elective endovascular repair of infrarenal abdominal aortic aneurysms (EVAR) in 3 countries.
SE|25462538|BACKGROUND|ab|1|entity|C1521798|trend|tmco|||trends|||0|1000|210|216
SE|25462538|BACKGROUND|ab|1|entity|C0242802|Patient Selection|hlca,resa|||patient selection|||0|1000|220|237
SE|25462538|BACKGROUND|ab|1|entity|C1279919|Early|tmco|||early|||0|901|242|247
SE|25462538|BACKGROUND|ab|1|entity|C0205848|Death Rate|qnco|||death rate|||0|901|248|258
SE|25462538|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|263|271
SE|25462538|BACKGROUND|ab|1|entity|C0439608|elective|tmco|||elective|||0|851|283|291
SE|25462538|BACKGROUND|ab|1|entity|C0524425|Endovascular|blor|||endovascular|||0|851|292|304
SE|25462538|BACKGROUND|ab|1|entity|C0043240|Wound Healing|orgf|||repair|||0|851|305|311
SE|25462538|BACKGROUND|ab|1|entity|C0162871|Aortic Aneurysm, Abdominal|dsyn|||abdominal aortic aneurysms|||0|923|326|352
SE|25462538|BACKGROUND|ab|1|entity|C0454664|Country|geoa|||countries|||0|888|365|374

SE|25462538|BACKGROUND|ab|2|text|376|484|For this study, audit data from 4,163 patients who had undergone elective infrarenal EVAR were amalgamated.
SE|25462538|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|385|390
SE|25462538|BACKGROUND|ab|2|entity|C0450985|Alcohol use disorders identification test|inpr|||audit|||0|888|392|397
SE|25462538|BACKGROUND|ab|2|entity|C1511726|Data|idcn|||data|||0|888|398|402
SE|25462538|BACKGROUND|ab|2|entity|C0030705|Patients|podg|||patients|||0|827|414|422
SE|25462538|BACKGROUND|ab|2|entity|C0439608|elective|tmco|||elective|||0|645|441|449

SE|25462538|BACKGROUND|ab|3|text|484|586|The data originated from Australia, Canada (Ontario), and England (London, Cambridge, and Leicester).
SE|25462538|BACKGROUND|ab|3|entity|C1511726|Data|idcn|||data|||0|1000|488|492
SE|25462538|BACKGROUND|ab|3|entity|C0004340|Australia|geoa|||Australia|||0|1000|509|518
SE|25462538|BACKGROUND|ab|3|entity|C0006823|Canada|geoa|||Canada|||0|1000|520|526
SE|25462538|BACKGROUND|ab|3|entity|C0029040|Ontario|geoa|||Ontario|||0|1000|528|535
SE|25462538|BACKGROUND|ab|3|entity|C0014282|England|geoa|||England|||0|1000|542|549
SE|25462538|BACKGROUND|ab|3|entity|C0023973|London|geoa|||London|||0|1000|551|557

SE|25462538|METHODS|ab|4|text|586|752|METHODS: Statistical analyses were undertaken to determine whether patient characteristics and early death rate varied between and within study groups and over time.
SE|25462538|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|586|593
SE|25462538|METHODS|ab|4|entity|C0871424|Statistical Analysis|resa|||Statistical analyses|||0|983|595|615
SE|25462538|METHODS|ab|4|entity|C0815172|patient characteristics|clna|||patient characteristics|||0|1000|653|676
SE|25462538|METHODS|ab|4|entity|C1279919|Early|tmco|||early|||0|901|681|686
SE|25462538|METHODS|ab|4|entity|C0205848|Death Rate|qnco|||death rate|||0|901|687|697
SE|25462538|METHODS|ab|4|entity|C0008972|Clinical Research|resa|||study|||0|888|724|729
SE|25462538|METHODS|ab|4|entity|C0441833|Groups|inpr|||groups|||0|888|730|736
SE|25462538|METHODS|ab|4|entity|C0205136|Over|spco|||over|||0|888|741|745
SE|25462538|METHODS|ab|4|entity|C0040223|Time|tmco|||time|||0|888|746|750

SE|25462538|METHODS|ab|5|text|752|851|The study design was retrospective analysis of data collected prospectively between 1999 and 2012.
SE|25462538|METHODS|ab|5|entity|C0035171|Research Design|resa|||study design|||0|1000|756|768
SE|25462538|METHODS|ab|5|entity|C1514923|Retrospective|qlco|||retrospective|||0|888|773|786
SE|25462538|METHODS|ab|5|entity|C0936012|Analysis|resa|||analysis|||0|888|787|795
SE|25462538|METHODS|ab|5|entity|C1511726|Data|idcn|||data|||0|1000|799|803

SE|25462538|RESULTS|ab|6|text|851|911|RESULTS: One-year survival improved over time (P = 0.0013).
SE|25462538|RESULTS|ab|6|entity|C1274040|result|ftcn|||RESULTS|||0|966|851|858
SE|25462538|RESULTS|ab|6|entity|C0205447|One|qnco|||One|||0|851|860|863
SE|25462538|RESULTS|ab|6|entity|C0439234|year|tmco|||year|||0|851|864|868
SE|25462538|RESULTS|ab|6|entity|C0038952|Continuance of life|acty|||survival|||0|851|869|877
SE|25462538|RESULTS|ab|6|entity|C0205136|Over|spco|||over|||0|888|887|891
SE|25462538|RESULTS|ab|6|entity|C0040223|Time|tmco|||time|||0|888|892|896

SE|25462538|RESULTS|ab|7|text|911|989|Canadian patients were sicker than those in Australia or England (P < 0.001).
SE|25462538|RESULTS|ab|7|entity|C0238884|CANADIAN|fndg|||Canadian|||0|888|911|919
SE|25462538|RESULTS|ab|7|entity|C0030705|Patients|podg|||patients|||0|888|920|928
SE|25462538|RESULTS|ab|7|entity|C0221423|Finding / disorder|ftcn|||sicker|||0|916|934|940
SE|25462538|RESULTS|ab|7|entity|C0004340|Australia|geoa|||Australia|||0|1000|955|964
SE|25462538|RESULTS|ab|7|entity|C0014282|England|geoa|||England|||0|1000|968|975
SE|25462538|RESULTS|ab|7|relation|0|0|C0238884|CANADIAN|fndg|fndg|||Canadian|||0|888|911|919|MOD/HEAD|PROCESS_OF||911|928|0|0|C0030705|Patients|podg,humn|humn|||patients|||0|888|920|928

SE|25462538|RESULTS|ab|8|text|989|1128|American Society of Anesthesiologists classification (ASA) increased over time across all countries although more significantly in Canada.
SE|25462538|RESULTS|ab|8|entity|C0596070|American|popg|||American|||0|749|989|997
SE|25462538|RESULTS|ab|8|entity|C0037455|Societies|orgt|||Society|||0|749|998|1005
SE|25462538|RESULTS|ab|8|entity|C0334910|Anesthesiologist|prog|||Anesthesiologists|||0|749|1009|1026
SE|25462538|RESULTS|ab|8|entity|C0008902|Classification|clas|||classification|||0|749|1027|1041
SE|25462538|RESULTS|ab|8|entity|C0205136|Over|spco|||over|||0|888|1058|1062
SE|25462538|RESULTS|ab|8|entity|C0040223|Time|tmco|||time|||0|888|1063|1067
SE|25462538|RESULTS|ab|8|entity|C0454664|Country|geoa|||countries|||0|1000|1079|1088
SE|25462538|RESULTS|ab|8|entity|C0205172|More|ftcn|||more|||0|861|1098|1102
SE|25462538|RESULTS|ab|8|entity|C0006823|Canada|geoa|||Canada|||0|1000|1120|1126

SE|25462538|RESULTS|ab|9|text|1128|1238|Age at operation remained constant, although older patients were treated more recently in London (P < 0.001).
SE|25462538|RESULTS|ab|9|entity|C0001779|Age|orga|||Age|||0|1000|1128|1131
SE|25462538|RESULTS|ab|9|entity|C0543467|Operative Surgical Procedures|topp|||operation|||0|1000|1135|1144
SE|25462538|RESULTS|ab|9|entity|C1547014|*Constant|qnco|||constant|||0|1000|1154|1162
SE|25462538|RESULTS|ab|9|entity|C0580836|Old|tmco|||older|||0|872|1173|1178
SE|25462538|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|872|1179|1187
SE|25462538|RESULTS|ab|9|entity|C0205172|More|ftcn|||more|||0|888|1201|1205
SE|25462538|RESULTS|ab|9|entity|C0332185|Recent|tmco|||recently|||0|888|1206|1214
SE|25462538|RESULTS|ab|9|entity|C0023973|London|geoa|||London|||0|1000|1218|1224

SE|25462538|RESULTS|ab|10|text|1238|1327|English centers treated larger aneurysms compared with Australia and Canada (P < 0.001).
SE|25462538|RESULTS|ab|10|entity|C0205099|Central|spco|||centers|||0|827|1246|1253
SE|25462538|RESULTS|ab|10|entity|C0443228|Largest|qnco|||larger|||0|888|1262|1268
SE|25462538|RESULTS|ab|10|entity|C0002940|Aneurysm|anab|||aneurysms|||0|888|1269|1278
SE|25462538|RESULTS|ab|10|entity|C0004340|Australia|geoa|||Australia|||0|1000|1293|1302
SE|25462538|RESULTS|ab|10|entity|C0006823|Canada|geoa|||Canada|||0|1000|1307|1313

SE|25462538|RESULTS|ab|11|text|1327|1431|Australian centers treated a much larger proportion of aneurysms that were <55 mm than other countries.
SE|25462538|RESULTS|ab|11|entity|C0238711|AUSTRALIAN|fndg|||Australian|||0|872|1327|1337
SE|25462538|RESULTS|ab|11|entity|C0205099|Central|spco|||centers|||0|872|1338|1345
SE|25462538|RESULTS|ab|11|entity|C0443228|Largest|qnco|||larger|||0|853|1361|1367
SE|25462538|RESULTS|ab|11|entity|C0205351|Proportional|qlco|||proportion|||0|853|1368|1378
SE|25462538|RESULTS|ab|11|entity|C0002940|Aneurysm|anab|||aneurysms|||0|1000|1382|1391
SE|25462538|RESULTS|ab|11|entity|C0454664|Country|geoa|||countries|||0|1000|1420|1429

SE|25462538|RESULTS|ab|12|text|1431|1525|Preoperative creatinine levels decreased over time for all countries and centers (P < 0.001).
SE|25462538|RESULTS|ab|12|entity|C0445204|Preoperative|tmco|||Preoperative|||0|851|1431|1443
SE|25462538|RESULTS|ab|12|entity|C0010294|Creatinine|bacs,orch|||creatinine|||0|851|1444|1454
SE|25462538|RESULTS|ab|12|entity|C0441889|Levels|inpr|||levels|||0|851|1455|1461
SE|25462538|RESULTS|ab|12|entity|C0205136|Over|spco|||over|||0|888|1472|1476
SE|25462538|RESULTS|ab|12|entity|C0040223|Time|tmco|||time|||0|888|1477|1481
SE|25462538|RESULTS|ab|12|entity|C0454664|Country|geoa|||countries|||0|1000|1490|1499
SE|25462538|RESULTS|ab|12|entity|C0205099|Central|spco|||centers|||0|966|1504|1511

SE|25462538|RESULTS|ab|13|text|1525|1600|Infrarenal neck angles have significantly decreased over time (P < 0.001).
SE|25462538|RESULTS|ab|13|entity|C0027530|Neck|blor|||neck|||0|773|1536|1540
SE|25462538|RESULTS|ab|13|entity|C0205143|Angular|spco|||angles|||0|773|1541|1547
SE|25462538|RESULTS|ab|13|entity|C0205136|Over|spco|||over|||0|888|1577|1581
SE|25462538|RESULTS|ab|13|entity|C0040223|Time|tmco|||time|||0|888|1582|1586

SE|25462538|RESULTS|ab|14|text|1600|1744|Recent data from London (UK) showed that operations were performed on longer (P < 0.001) and wider (P < 0.001) infrarenal necks than elsewhere.
SE|25462538|RESULTS|ab|14|entity|C0332185|Recent|tmco|||Recent|||0|888|1600|1606
SE|25462538|RESULTS|ab|14|entity|C1511726|Data|idcn|||data|||0|888|1607|1611
SE|25462538|RESULTS|ab|14|entity|C0023973|London|geoa|||London|||0|1000|1617|1623
SE|25462538|RESULTS|ab|14|entity|C0038895|Surgical aspects|ftcn|||operations|||0|1000|1641|1651
SE|25462538|RESULTS|ab|14|entity|C0205166|Long|qlco|||longer|||0|966|1670|1676
SE|25462538|RESULTS|ab|14|entity|C0332464|Widening|spco|||wider|||0|966|1693|1698
SE|25462538|RESULTS|ab|14|entity|C0027530|Neck|blor|||necks|||0|861|1722|1727

SE|25462538|CONCLUSIONS|ab|15|text|1744|1925|CONCLUSIONS: In this international comparison, several trends were noted including improved 1-year survival despite declining patient health (as measured by increasing ASA status).
SE|25462538|CONCLUSIONS|ab|15|entity|C1512888|International|idcn|||international|||0|694|1765|1778
SE|25462538|CONCLUSIONS|ab|15|entity|C0443302|Several|qnco|||several|||0|888|1791|1798
SE|25462538|CONCLUSIONS|ab|15|entity|C1521798|trend|tmco|||trends|||0|888|1799|1805
SE|25462538|CONCLUSIONS|ab|15|entity|C0439234|year|tmco|||year|||0|790|1838|1842
SE|25462538|CONCLUSIONS|ab|15|entity|C0038952|Continuance of life|acty|||survival|||0|790|1843|1851
SE|25462538|CONCLUSIONS|ab|15|entity|C1511741|Declining|qlco|||declining|||0|851|1860|1869
SE|25462538|CONCLUSIONS|ab|15|entity|C0030705|Patients|podg|||patient|||0|851|1870|1877
SE|25462538|CONCLUSIONS|ab|15|entity|C0018684|Health|idcn|||health|||0|851|1878|1884
SE|25462538|CONCLUSIONS|ab|15|entity|C0442808|Increasing|ftcn|||increasing|||0|802|1901|1911
SE|25462538|CONCLUSIONS|ab|15|entity|C0449438|Status|qlco|||status|||0|802|1916|1922

SE|25462538|CONCLUSIONS|ab|16|text|1925|2114|This may reflect greater knowledge regarding EVAR that centers from different countries have gained over the last decade and improved medical management of patients with aneurysmal disease.
SE|25462538|CONCLUSIONS|ab|16|entity|C0443228|Largest|qnco|||greater|||0|583|1942|1949
SE|25462538|CONCLUSIONS|ab|16|entity|C0376554|Knowledge|inpr|||knowledge|||0|583|1950|1959
SE|25462538|CONCLUSIONS|ab|16|entity|C0205099|Central|spco|||centers|||0|966|1980|1987
SE|25462538|CONCLUSIONS|ab|16|entity|C1547020|*Difference|qnco|||different|||0|853|1993|2002
SE|25462538|CONCLUSIONS|ab|16|entity|C0454664|Country|geoa|||countries|||0|853|2003|2012
SE|25462538|CONCLUSIONS|ab|16|entity|C0205136|Over|spco|||over|||0|1000|2025|2029
SE|25462538|CONCLUSIONS|ab|16|entity|C1517741|Last|qlco|||last|||0|694|2034|2038
SE|25462538|CONCLUSIONS|ab|16|entity|C0184511|Improved|qlco|||improved|||0|851|2050|2058
SE|25462538|CONCLUSIONS|ab|16|entity|C0205476|Medical|ftcn|||medical|||0|851|2059|2066
SE|25462538|CONCLUSIONS|ab|16|entity|C0030705|Patients|podg|||patients|||0|1000|2081|2089
SE|25462538|CONCLUSIONS|ab|16|entity|C0439651|Aneurysmal|spco|||aneurysmal|||0|888|2095|2105
SE|25462538|CONCLUSIONS|ab|16|entity|C0012634|Disease|dsyn|||disease|||0|888|2106|2113
SE|25462538|CONCLUSIONS|ab|16|relation|1|1|C0012634|Disease|dsyn|dsyn|||disease|||0|888|2106|2113|PREP|PROCESS_OF||2090|2094|7|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|2081|2089


SE|25462539||ti|1|text|21|137|Clinical predictors of major adverse cardiovascular events during long-term follow-up after carotid endarterectomy.
SE|25462539||ti|1|entity|C0205210|Clinical|qlco|||Clinical|||0|694|21|29
SE|25462539||ti|1|entity|C0205164|Major|qlco|||major|||0|813|44|49
SE|25462539||ti|1|entity|C0877248|Adverse event|fndg|||adverse cardiovascular events|||0|813|50|79
SE|25462539||ti|1|entity|C0443252|Long-term|tmco|||long-term|||0|888|87|96
SE|25462539||ti|1|entity|C1522577|follow-up|hlca|||follow-up|||0|888|97|106
SE|25462539||ti|1|entity|C0014099|Endarterectomy, Carotid|topp|||carotid endarterectomy|||0|1000|113|135

SE|25462539|BACKGROUND|ab|1|text|143|301|BACKGROUND: Those patients who undergo a carotid endarterectomy (CEA) will present a higher cardiovascular risk during follow-up than the general population.
SE|25462539|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|161|169
SE|25462539|BACKGROUND|ab|1|entity|C0014099|Endarterectomy, Carotid|topp|||carotid endarterectomy|||0|1000|184|206
SE|25462539|BACKGROUND|ab|1|entity|C0007082|Carcinoembryonic Antigen|aapp,imft|1048,1084,5670|CEACAM5,CEACAM3,PSG2|CEA|||0|1000|208|211
SE|25462539|BACKGROUND|ab|1|entity|C0205250|High|qlco|||higher|||0|785|228|234
SE|25462539|BACKGROUND|ab|1|entity|C0035647|Risk|qlco|||risk|||0|785|250|254
SE|25462539|BACKGROUND|ab|1|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|262|271
SE|25462539|BACKGROUND|ab|1|entity|C0683971|General Population|popg|||general population|||0|1000|281|299
SE|25462539|BACKGROUND|ab|1|relation|5|1|C0014099|Endarterectomy, Carotid|topp|topp|||carotid endarterectomy|||0|1000|184|206|VERB|TREATS||174|181|2|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|161|169

SE|25462539|BACKGROUND|ab|2|text|301|526|The objective of this study was to determine the prognostic factors and validate the accuracy of 3 cardiovascular risk scores as predictors of major adverse cardiovascular events (MACEs) during long-term follow-up after CEA.
SE|25462539|BACKGROUND|ab|2|entity|C0008972|Clinical Research|resa|||study|||0|1000|323|328
SE|25462539|BACKGROUND|ab|2|entity|C1514474|Prognostic Factor|clna|||prognostic factors|||0|983|350|368
SE|25462539|BACKGROUND|ab|2|entity|C0443131|Accurate|qlco|||accuracy|||0|928|386|394
SE|25462539|BACKGROUND|ab|2|entity|C0035647|Risk|qlco|||risk|||0|775|415|419
SE|25462539|BACKGROUND|ab|2|entity|C0449820|Score|qnco|||scores|||0|775|420|426
SE|25462539|BACKGROUND|ab|2|entity|C0205164|Major|qlco|||major|||0|813|444|449
SE|25462539|BACKGROUND|ab|2|entity|C0877248|Adverse event|fndg|||adverse cardiovascular events|||0|813|450|479
SE|25462539|BACKGROUND|ab|2|entity|C0443252|Long-term|tmco|||long-term|||0|888|495|504
SE|25462539|BACKGROUND|ab|2|entity|C1522577|follow-up|hlca|||follow-up|||0|888|505|514
SE|25462539|BACKGROUND|ab|2|entity|C0007082|Carcinoembryonic Antigen|aapp,imft|1048,1084,5670|CEACAM5,CEACAM3,PSG2|CEA|||0|1000|521|524

SE|25462539|METHODS|ab|3|text|526|652|METHODS: Observational retrospective follow-up study with 416 CEAs conducted consecutively in 385 patients from 1994 to 2011.
SE|25462539|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|526|533
SE|25462539|METHODS|ab|3|entity|C1514923|Retrospective|qlco|||retrospective|||0|857|549|562
SE|25462539|METHODS|ab|3|entity|C1522577|follow-up|hlca|||follow-up|||0|857|563|572
SE|25462539|METHODS|ab|3|entity|C1518527|Observational Study|resa|||Observational retrospective follow-up study|||0|857|535|578
SE|25462539|METHODS|ab|3|entity|C0007082|Carcinoembryonic Antigen|aapp,imft|||CEAs|||0|827|588|592
SE|25462539|METHODS|ab|3|entity|C0030705|Patients|podg|||patients|||0|861|624|632
SE|25462539|METHODS|ab|3|relation|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|624|632|PREP|LOCATION_OF||617|619|3|1|C0007082|Carcinoembryonic Antigen|aapp,gngm,imft|aapp|||CEAs|||0|827|588|592

SE|25462539|METHODS|ab|4|text|652|764|The primary end point was MACE, single event including myocardial infarction, stroke, and cardiovascular death.
SE|25462539|METHODS|ab|4|entity|C0150100|End Point|resa|||end point|||0|901|664|673
SE|25462539|METHODS|ab|4|entity|C0949745|Myristica fragrans|plnt|||MACE|||0|1000|678|682
SE|25462539|METHODS|ab|4|entity|C0585347|Single event|tmco|||single event|||0|1000|684|696
SE|25462539|METHODS|ab|4|entity|C0027051|Myocardial Infarction|dsyn|||myocardial infarction|||0|1000|707|728
SE|25462539|METHODS|ab|4|entity|C0038454|Cerebrovascular accident|dsyn|||stroke|||0|1000|730|736
SE|25462539|METHODS|ab|4|entity|C0011065|Cessation of life|orgf|||death|||0|861|757|762

SE|25462539|METHODS|ab|5|text|764|841|Preoperative risk factors and medical treatment at discharge were collected.
SE|25462539|METHODS|ab|5|entity|C0445204|Preoperative|tmco|||Preoperative|||0|901|764|776
SE|25462539|METHODS|ab|5|entity|C0035648|risk factors|qnco|||risk factors|||0|901|777|789
SE|25462539|METHODS|ab|5|entity|C0205476|Medical|ftcn|||medical|||0|888|794|801
SE|25462539|METHODS|ab|5|entity|C0012621|Discharge, Body Substance|bdsu|||discharge|||0|1000|815|824

SE|25462539|METHODS|ab|6|text|841|972|A general cardiovascular risk score, the Revised Cardiac Risk Index (RCRI), was used, and 2 scores specific for CEA (Halm and Tu).
SE|25462539|METHODS|ab|6|entity|C0205246|Generalized|spco|||general|||0|775|843|850
SE|25462539|METHODS|ab|6|entity|C0035647|Risk|qlco|||risk|||0|775|866|870
SE|25462539|METHODS|ab|6|entity|C0449820|Score|qnco|||score|||0|775|871|876
SE|25462539|METHODS|ab|6|entity|C0035647|Risk|qlco|||Risk|||0|824|898|902
SE|25462539|METHODS|ab|6|entity|C0428776|Cardiac index|fndg|||Cardiac Risk Index|||0|824|890|908
SE|25462539|METHODS|ab|6|entity|C0007082|Carcinoembryonic Antigen|aapp,imft|1048,1084,5670|CEACAM5,CEACAM3,PSG2|CEA|||0|1000|953|956

SE|25462539|METHODS|ab|7|text|972|1028|Descriptive analysis and Cox regression were conducted.
SE|25462539|METHODS|ab|7|entity|C0678257|Description|idcn|||Descriptive analysis|||0|1000|972|992
SE|25462539|METHODS|ab|7|entity|C0033551|Prostaglandin-Endoperoxide Synthase|aapp,enzy|||Cox|||0|694|997|1000

SE|25462539|METHODS|ab|8|text|1028|1110|Informed consent from patients was obtained and approval by the ethics committee.
SE|25462539|METHODS|ab|8|entity|C0021430|Informed Consent|rnlw|||Informed consent|||0|1000|1028|1044
SE|25462539|METHODS|ab|8|entity|C0030705|Patients|podg|||patients|||0|1000|1050|1058
SE|25462539|METHODS|ab|8|entity|C0085546|Ethics Committees|prog|||ethics committee|||0|1000|1092|1108

SE|25462539|RESULTS|ab|9|text|1110|1156|RESULTS: The median follow-up was 4.94 years.
SE|25462539|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1110|1117
SE|25462539|RESULTS|ab|9|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1130|1139
SE|25462539|RESULTS|ab|9|entity|C0439234|year|tmco|||years|||0|827|1149|1154

SE|25462539|RESULTS|ab|10|text|1156|1255|MACEs appeared in 22.1% (95% confidence interval [CI], 18.0-26.2%) of the series during follow-up.
SE|25462539|RESULTS|ab|10|entity|C0205164|Major|qlco|||MACEs|||0|813|1156|1161
SE|25462539|RESULTS|ab|10|entity|C0877248|Adverse event|fndg|||MACEs|||0|813|1156|1161
SE|25462539|RESULTS|ab|10|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|901|1185|1204
SE|25462539|RESULTS|ab|10|entity|C0205549|Series|qnco|||series|||0|1000|1230|1236
SE|25462539|RESULTS|ab|10|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1244|1253

SE|25462539|RESULTS|ab|11|text|1255|1344|The MACEs rate at 1 year, 3 years, and 5 years, was 3.1%, 9.3%, and 15.8%, respectively.
SE|25462539|RESULTS|ab|11|entity|C0205164|Major|qlco|||MACEs|||0|786|1259|1264
SE|25462539|RESULTS|ab|11|entity|C1320716|Cardiovascular event|fndg|||MACEs|||0|786|1259|1264
SE|25462539|RESULTS|ab|11|entity|C1521828|Rate|qnco|||rate|||0|786|1265|1269
SE|25462539|RESULTS|ab|11|entity|C0439234|year|tmco|||year|||0|861|1275|1279
SE|25462539|RESULTS|ab|11|entity|C0439234|year|tmco|||years|||0|888|1283|1288
SE|25462539|RESULTS|ab|11|entity|C0439234|year|tmco|||years|||0|888|1296|1301
SE|25462539|RESULTS|ab|11|entity|C0439086|<3|qnco|||3|||0|861|1307|1308

SE|25462539|RESULTS|ab|12|text|1344|1534|In the Cox regression model, the MACE predictor variables were: the presence of peripheral artery disease (hazard ratio [HR], 1.69; 95% CI, 1.06-2.70) and RCRI (HR,1.61; 95% CI, 1.04-2.50).
SE|25462539|RESULTS|ab|12|entity|C0010234|Cox Models|inpr,qnco|||Cox regression model|||0|896|1351|1371
SE|25462539|RESULTS|ab|12|entity|C0949745|Myristica fragrans|plnt|||MACE|||0|890|1377|1381
SE|25462539|RESULTS|ab|12|entity|C0683956|Predictive Factor|inpr|||predictor variables|||0|890|1382|1401
SE|25462539|RESULTS|ab|12|entity|C0085096|Peripheral Vascular Diseases|dsyn|||peripheral artery disease|||0|976|1424|1449
SE|25462539|RESULTS|ab|12|entity|C0598697|hazard|qlco|||hazard|||0|888|1451|1457
SE|25462539|RESULTS|ab|12|entity|C0456603|Ratio|inpr|||ratio|||0|888|1458|1463
SE|25462539|RESULTS|ab|12|entity|C0009667|Confidence Intervals|qnco|||CI|||0|901|1480|1482
SE|25462539|RESULTS|ab|12|entity|C0580272|1/2|inpr|||1.06-2|||0|875|1484|1490
SE|25462539|RESULTS|ab|12|entity|C0598697|hazard|qlco|||HR|||0|888|1505|1507
SE|25462539|RESULTS|ab|12|entity|C0456603|Ratio|inpr|||HR|||0|888|1505|1507
SE|25462539|RESULTS|ab|12|entity|C0009667|Confidence Intervals|qnco|||CI|||0|901|1518|1520
SE|25462539|RESULTS|ab|12|entity|C0580272|1/2|inpr|||1.04-2|||0|875|1522|1528

SE|25462539|RESULTS|ab|13|text|1534|1686|The RCRI area under the curve for predicting events, with a 2.5 cutoff point, was 0.59 with 85.9% sensitivity and a positive predictive value of 25.2%.
SE|25462539|RESULTS|ab|13|entity|C0205146|Area|spco|||area|||0|861|1543|1547
SE|25462539|RESULTS|ab|13|entity|C0205134|Curved|spco|||curve|||0|928|1558|1563
SE|25462539|RESULTS|ab|13|entity|C1508497|PREDICTED|clna|||predicting|||0|872|1568|1578
SE|25462539|RESULTS|ab|13|entity|C0441471|Events|evnt|||events|||0|872|1579|1585
SE|25462539|RESULTS|ab|13|entity|C0450346|2/5|qnco|||2.5|||0|658|1594|1597
SE|25462539|RESULTS|ab|13|entity|C1442160|CUTOFF|ftcn|||cutoff|||0|658|1598|1604
SE|25462539|RESULTS|ab|13|entity|C1446409|Positive|qlco|||positive|||0|901|1650|1658
SE|25462539|RESULTS|ab|13|entity|C1514307|Predictive Value|qlco|||predictive value|||0|901|1659|1675
SE|25462539|RESULTS|ab|13|entity|C0470369|25+2|qnco|||25.2|||0|1000|1679|1683

SE|25462539|CONCLUSIONS|ab|14|text|1686|1787|CONCLUSIONS: Peripheral artery disease and high RCRI have an independent effect on predicting MACEs.
SE|25462539|CONCLUSIONS|ab|14|entity|C0085096|Peripheral Vascular Diseases|dsyn|||Peripheral artery disease|||0|976|1699|1724
SE|25462539|CONCLUSIONS|ab|14|entity|C0205250|High|qlco|||high|||0|694|1729|1733
SE|25462539|CONCLUSIONS|ab|14|entity|C1280500|Effect|qlco|||effect|||0|888|1759|1765
SE|25462539|CONCLUSIONS|ab|14|entity|C1508497|PREDICTED|clna|||predicting|||0|777|1769|1779
SE|25462539|CONCLUSIONS|ab|14|entity|C0205164|Major|qlco|||MACEs|||0|777|1780|1785
SE|25462539|CONCLUSIONS|ab|14|entity|C0877248|Adverse event|fndg|||MACEs|||0|777|1780|1785
SE|25462539|CONCLUSIONS|ab|14|relation|3|2|C0085096|Peripheral Vascular Diseases|dsyn|dsyn|||Peripheral artery disease|||0|976|1699|1724|NOM|AFFECTS||1759|1765|1|1|C0877248|Adverse event|fndg|fndg|||MACEs|||0|777|1780|1785

SE|25462539|CONCLUSIONS|ab|15|text|1787|1877|The 3 different scores have a low ability for predicting MACEs during long-term follow-up.
SE|25462539|CONCLUSIONS|ab|15|entity|C1547020|*Difference|qnco|||different|||0|828|1793|1802
SE|25462539|CONCLUSIONS|ab|15|entity|C0449820|Score|qnco|||scores|||0|828|1803|1809
SE|25462539|CONCLUSIONS|ab|15|entity|C0205251|low|qlco|||low|||0|888|1817|1820
SE|25462539|CONCLUSIONS|ab|15|entity|C0085732|Ability|orga|||ability|||0|888|1821|1828
SE|25462539|CONCLUSIONS|ab|15|entity|C1508497|PREDICTED|clna|||predicting|||0|777|1833|1843
SE|25462539|CONCLUSIONS|ab|15|entity|C0205164|Major|qlco|||MACEs|||0|777|1844|1849
SE|25462539|CONCLUSIONS|ab|15|entity|C0877248|Adverse event|fndg|||MACEs|||0|777|1844|1849
SE|25462539|CONCLUSIONS|ab|15|entity|C0443252|Long-term|tmco|||long-term|||0|888|1857|1866
SE|25462539|CONCLUSIONS|ab|15|entity|C1522577|follow-up|hlca|||follow-up|||0|888|1867|1876


SE|25462540||ti|1|text|21|58|Do not bite the hand that feeds you.
SE|25462540||ti|1|entity|C1518422|Not|ftcn|||not|||0|1000|24|27
SE|25462540||ti|1|entity|C0018563|Hand|bpoc|||hand|||0|1000|37|41
SE|25462540||ti|1|entity|C1510670|Feeds|ftcn|||feeds|||0|1000|47|52

SE|25462540||ab|1|text|64|235|Radial artery pseudoaneurysms occur infrequently and are most commonly associated with medical interventions such as arterial lines or cardiac catheterization procedures.
SE|25462540||ab|1|entity|C0748224|RADIAL ARTERY PSEUDOANEURYSM|dsyn|||Radial artery pseudoaneurysms|||0|983|64|93
SE|25462540||ab|1|entity|C0521114|Infrequent|tmco|||infrequently|||0|1000|100|112
SE|25462540||ab|1|entity|C0205393|Most|qnco|||most|||0|1000|121|125
SE|25462540||ab|1|entity|C0205476|Medical|ftcn|||medical|||0|888|151|158
SE|25462540||ab|1|entity|C1273869|Intervention regimes|hlca|||interventions|||0|888|159|172
SE|25462540||ab|1|entity|C0003835|Arterial Lines|medd|||arterial lines|||0|1000|181|195
SE|25462540||ab|1|entity|C0018795|Cardiac Catheterization Procedures|diap|||cardiac catheterization procedures|||0|1000|199|233

SE|25462540||ab|2|text|235|393|Animal bites, particularly cat bites, as a cause for radial artery pseudoaneurysms are extremely rare with only 1 previously reported case in the literature.
SE|25462540||ab|2|entity|C0003044|Animal bites NOS|inpo|||Animal bites|||0|1000|235|247
SE|25462540||ab|2|entity|C0417713|Cat bite|inpo|||cat bites|||0|884|262|271
SE|25462540||ab|2|entity|C0015127|Etiology aspects|ftcn|||cause|||0|966|278|283
SE|25462540||ab|2|entity|C0748224|RADIAL ARTERY PSEUDOANEURYSM|dsyn|||radial artery pseudoaneurysms|||0|983|288|317
SE|25462540||ab|2|entity|C0522498|Rare|qlco|||rare|||0|861|332|336
SE|25462540||ab|2|entity|C0023866|Literature|inpr|||literature|||0|1000|381|391
SE|25462540||ab|2|relation|0|0|C0417713|Cat bite|inpo|inpo|||cat bites|||0|884|262|271|SPEC|ISA||235|271|0|0|C0003044|Animal bites NOS|inpo|inpo|||Animal bites|||0|1000|235|247
SE|25462540||ab|2|relation|2|1|C0417713|Cat bite|inpo|inpo|||cat bites|||0|884|262|271|NOM|CAUSES||278|283|4|1|C0748224|RADIAL ARTERY PSEUDOANEURYSM|dsyn|dsyn|||radial artery pseudoaneurysms|||0|983|288|317

SE|25462540||ab|3|text|393|514|A unique case of digital micro emboli from a radial artery pseudoaneurysm caused by a cat bite to the wrist is presented.
SE|25462540||ab|3|entity|C0333227|Microembolus|acab|||micro emboli|||0|901|418|430
SE|25462540||ab|3|entity|C0748224|RADIAL ARTERY PSEUDOANEURYSM|dsyn|||radial artery pseudoaneurysm|||0|1000|438|466
SE|25462540||ab|3|entity|C0417713|Cat bite|inpo|||cat bite|||0|1000|479|487
SE|25462540||ab|3|entity|C0043262|Wrist|blor|||wrist|||0|1000|495|500
SE|25462540||ab|3|relation|2|1|C0417713|Cat bite|inpo|inpo|||cat bite|||0|1000|479|487|VERB|CAUSES||467|473|3|1|C0748224|RADIAL ARTERY PSEUDOANEURYSM|dsyn|dsyn|||radial artery pseudoaneurysm|||0|1000|438|466


SE|25462541||ti|1|text|21|130|Bibliometric analysis of factors predicting increased citations in the vascular and endovascular literature.
SE|25462541||ti|1|entity|C0005364|Bibliometrics|resa|||Bibliometric analysis|||0|1000|21|42
SE|25462541||ti|1|entity|C1521761|Factor|ftcn|||factors|||0|966|46|53
SE|25462541||ti|1|entity|C0205217|Increased|qnco|||increased|||0|872|65|74
SE|25462541||ti|1|entity|C0552371|Citation|inpr|||citations|||0|872|75|84
SE|25462541||ti|1|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|1000|92|100
SE|25462541||ti|1|entity|C0524425|Endovascular|blor|||endovascular|||0|888|105|117
SE|25462541||ti|1|entity|C0023866|Literature|inpr|||literature|||0|888|118|128

SE|25462541|BACKGROUND|ab|1|text|136|247|BACKGROUND: Dissemination of research findings in the scientific community is reflected by the citation count.
SE|25462541|BACKGROUND|ab|1|entity|C0035168|research|resa|||research|||0|888|165|173
SE|25462541|BACKGROUND|ab|1|entity|C0243095|Finding|ftcn|||findings|||0|888|174|182
SE|25462541|BACKGROUND|ab|1|entity|C0036397|Science|ocdi|||scientific|||0|853|190|200
SE|25462541|BACKGROUND|ab|1|entity|C0009462|Community|geoa|||community|||0|853|201|210
SE|25462541|BACKGROUND|ab|1|entity|C0552371|Citation|inpr|||citation|||0|888|231|239
SE|25462541|BACKGROUND|ab|1|entity|C0750480|Count|idcn|||count|||0|888|240|245

SE|25462541|BACKGROUND|ab|2|text|247|401|Our objective was to investigate the relative citation impact of vascular research studies and identify potential predictors of increased citation rates.
SE|25462541|BACKGROUND|ab|2|entity|C0205345|Relative|qlco|||relative|||0|851|284|292
SE|25462541|BACKGROUND|ab|2|entity|C0552371|Citation|inpr|||citation|||0|851|293|301
SE|25462541|BACKGROUND|ab|2|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|890|312|320
SE|25462541|BACKGROUND|ab|2|entity|C0681814|research study|resa|||research studies|||0|890|321|337
SE|25462541|BACKGROUND|ab|2|entity|C0237399|Potential|qlco|||potential|||0|694|351|360
SE|25462541|BACKGROUND|ab|2|entity|C0205217|Increased|qnco|||increased|||0|840|375|384
SE|25462541|BACKGROUND|ab|2|entity|C0552371|Citation|inpr|||citation|||0|840|385|393
SE|25462541|BACKGROUND|ab|2|entity|C1521828|Rate|qnco|||rates|||0|840|394|399

SE|25462541|METHODS|ab|3|text|401|810|METHODS: Articles published in leading journals of vascular and general surgery (Journal of Vascular Surgery, European Journal of Vascular and Endovascular Surgery, Journal of Endovascular Therapy, Annals of Vascular Surgery and Annals of Surgery, British Journal of Surgery, Journal of the American College of Surgeons, and JAMA Surgery) during a 4-month period were identified through electronic databases.
SE|25462541|METHODS|ab|3|entity|C0025663|Methods|inpr|||METHODS|||0|1000|401|408
SE|25462541|METHODS|ab|3|entity|C0162443|Magazines|inpr,mnob|||journals|||0|861|440|448
SE|25462541|METHODS|ab|3|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|1000|452|460
SE|25462541|METHODS|ab|3|entity|C1274039|General surgery|bmod|||general surgery|||0|1000|465|480
SE|25462541|METHODS|ab|3|entity|C0162443|Magazines|inpr,mnob|||Journal|||0|1000|482|489
SE|25462541|METHODS|ab|3|entity|C0042381|Vascular Surgical Procedures|topp|||Vascular Surgery|||0|1000|493|509
SE|25462541|METHODS|ab|3|entity|C0162443|Magazines|inpr,mnob|||Journal|||0|861|520|527
SE|25462541|METHODS|ab|3|entity|C0005847|Blood Vessels|bpoc|||Vascular|||0|1000|531|539
SE|25462541|METHODS|ab|3|entity|C0524425|Endovascular|blor|||Endovascular|||0|888|544|556
SE|25462541|METHODS|ab|3|entity|C0162443|Magazines|inpr,mnob|||Journal|||0|1000|566|573
SE|25462541|METHODS|ab|3|entity|C0524425|Endovascular|blor|||Endovascular|||0|888|577|589
SE|25462541|METHODS|ab|3|entity|C0042381|Vascular Surgical Procedures|topp|||Vascular Surgery|||0|1000|609|625
SE|25462541|METHODS|ab|3|entity|C0596227|British|popg|||British|||0|888|649|656
SE|25462541|METHODS|ab|3|entity|C0162443|Magazines|inpr,mnob|||Journal|||0|888|657|664
SE|25462541|METHODS|ab|3|entity|C0162443|Magazines|inpr,mnob|||Journal|||0|1000|677|684
SE|25462541|METHODS|ab|3|entity|C0596070|American|popg|||American|||0|888|692|700
SE|25462541|METHODS|ab|3|entity|C0557806|College|eehu|||College|||0|888|701|708
SE|25462541|METHODS|ab|3|entity|C0582175|Surgeon|prog|||Surgeons|||0|1000|712|720
SE|25462541|METHODS|ab|3|entity|||gngm|50848|F11R|JAMA|||0|861|726|730
SE|25462541|METHODS|ab|3|entity|C0439231|month|tmco|||month|||0|790|751|756
SE|25462541|METHODS|ab|3|entity|C0439531|/period|tmco|||period|||0|790|757|763
SE|25462541|METHODS|ab|3|entity|C0242356|Databases|inpr|||electronic databases|||0|983|788|808

SE|25462541|METHODS|ab|4|text|810|1154|Variables potentially associated with increased citation rates, including subject, design, title characteristics, article length, bibliographic references, authorship, geographic distribution, interdisciplinary collaboration, article access, and funding, were assessed in univariate and multiple linear regression models through December 2012.
SE|25462541|METHODS|ab|4|entity|C0439828|Variable|qlco|||Variables|||0|966|810|819
SE|25462541|METHODS|ab|4|entity|C0205217|Increased|qnco|||increased|||0|840|848|857
SE|25462541|METHODS|ab|4|entity|C0552371|Citation|inpr|||citation|||0|840|858|866
SE|25462541|METHODS|ab|4|entity|C1521828|Rate|qnco|||rates|||0|840|867|872
SE|25462541|METHODS|ab|4|entity|C1550501|subject|idcn|||subject|||0|1000|884|891
SE|25462541|METHODS|ab|4|entity|C1519530|Title|idcn|||title|||0|888|901|906
SE|25462541|METHODS|ab|4|entity|C1521970|Characteristics|grpa|||characteristics|||0|888|907|922
SE|25462541|METHODS|ab|4|entity|C1444754|Length|qnco|||length|||0|861|932|938
SE|25462541|METHODS|ab|4|entity|C0005358|Bibliography|inpr,mnob|||bibliographic|||0|836|940|953
SE|25462541|METHODS|ab|4|entity|C1514811|Reference|idcn|||references|||0|836|954|964
SE|25462541|METHODS|ab|4|entity|C0004351|Authorship|ocac|||authorship|||0|1000|966|976
SE|25462541|METHODS|ab|4|entity|C0681686|Geographic Distribution|tmco|||geographic distribution|||0|1000|978|1001
SE|25462541|METHODS|ab|4|entity|C0597720|interdisciplinary treatment method|hlca|||interdisciplinary collaboration|||0|1000|1003|1034
SE|25462541|METHODS|ab|4|entity|C0444454|Access|spco|||access|||0|861|1044|1050
SE|25462541|METHODS|ab|4|entity|C0243098|Funding|qnco|||funding|||0|1000|1056|1063
SE|25462541|METHODS|ab|4|entity|C0205132|Linear|spco|||linear|||0|901|1106|1112
SE|25462541|METHODS|ab|4|entity|C0681923|multiple regression|qlco|||multiple linear regression|||0|901|1097|1123

SE|25462541|RESULTS|ab|5|text|1154|1243|RESULTS: A total of 226 articles with a total number of 4,605 citations were identified.
SE|25462541|RESULTS|ab|5|entity|C1274040|result|ftcn|||RESULTS|||0|966|1154|1161
SE|25462541|RESULTS|ab|5|entity|C0439175|% of total|qnco|||total|||0|1000|1165|1170
SE|25462541|RESULTS|ab|5|entity|C0439175|% of total|qnco|||total|||0|888|1194|1199
SE|25462541|RESULTS|ab|5|entity|C0237753|Numbers|qnco|||number|||0|888|1200|1206
SE|25462541|RESULTS|ab|5|entity|C0552371|Citation|inpr|||citations|||0|793|1216|1225

SE|25462541|RESULTS|ab|6|text|1243|1462|Univariate analysis revealed that endovascular-related studies, study design, studies reporting design in the title, long articles, and studies with high number of references were associated with higher citation rates.
SE|25462541|RESULTS|ab|6|entity|C0683962|univariate analysis|resa|||Univariate analysis|||0|1000|1243|1262
SE|25462541|RESULTS|ab|6|entity|C0524425|Endovascular|blor|||endovascular|||0|840|1277|1289
SE|25462541|RESULTS|ab|6|entity|C1522149|Related|ftcn|||related|||0|840|1290|1297
SE|25462541|RESULTS|ab|6|entity|C0008972|Clinical Research|resa|||studies|||0|840|1298|1305
SE|25462541|RESULTS|ab|6|entity|C0035171|Research Design|resa|||study design|||0|1000|1307|1319
SE|25462541|RESULTS|ab|6|entity|C0700287|Reporting|hlca|||reporting|||0|694|1329|1338
SE|25462541|RESULTS|ab|6|entity|C1519530|Title|idcn|||title|||0|1000|1353|1358
SE|25462541|RESULTS|ab|6|entity|C0205166|Long|qlco|||long|||0|694|1360|1364
SE|25462541|RESULTS|ab|6|entity|C0205250|High|qlco|||high|||0|888|1392|1396
SE|25462541|RESULTS|ab|6|entity|C0237753|Numbers|qnco|||number|||0|888|1397|1403
SE|25462541|RESULTS|ab|6|entity|C1514811|Reference|idcn|||references|||0|966|1407|1417
SE|25462541|RESULTS|ab|6|entity|C0205250|High|qlco|||higher|||0|829|1439|1445
SE|25462541|RESULTS|ab|6|entity|C0552371|Citation|inpr|||citation|||0|829|1446|1454
SE|25462541|RESULTS|ab|6|entity|C1521828|Rate|qnco|||rates|||0|829|1455|1460

SE|25462541|RESULTS|ab|7|text|1462|1935|On multivariate analysis, 3 variables were found to independently predict the number of citations: study subject (endovascular-related studies; regression coefficient [95% confidence interval], 0.474 [0.240-0.708]; P < 0.001); study design (randomized controlled trial; regression coefficient [95% confidence interval], 0.575 [0.145-1.005]; P = 0.009); and article length (number of pages; regression coefficient [95% confidence interval], 0.069 [0.016-0.123]; P = 0.011).
SE|25462541|RESULTS|ab|7|entity|C0026777|Multivariate Analysis|qnco|||multivariate analysis|||0|1000|1465|1486
SE|25462541|RESULTS|ab|7|entity|C0439828|Variable|qlco|||variables|||0|872|1490|1499
SE|25462541|RESULTS|ab|7|entity|C0237753|Numbers|qnco|||number|||0|1000|1540|1546
SE|25462541|RESULTS|ab|7|entity|C0552371|Citation|inpr|||citations|||0|966|1550|1559
SE|25462541|RESULTS|ab|7|entity|C0008972|Clinical Research|resa|||study|||0|888|1561|1566
SE|25462541|RESULTS|ab|7|entity|C1550501|subject|idcn|||subject|||0|888|1567|1574
SE|25462541|RESULTS|ab|7|entity|C0524425|Endovascular|blor|||endovascular|||0|840|1576|1588
SE|25462541|RESULTS|ab|7|entity|C1522149|Related|ftcn|||related|||0|840|1589|1596
SE|25462541|RESULTS|ab|7|entity|C0008972|Clinical Research|resa|||studies|||0|840|1597|1604
SE|25462541|RESULTS|ab|7|entity|C1547015|*Coefficient|qnco|||coefficient|||0|861|1617|1628
SE|25462541|RESULTS|ab|7|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|901|1634|1653
SE|25462541|RESULTS|ab|7|entity|C0035171|Research Design|resa|||study design|||0|1000|1689|1701
SE|25462541|RESULTS|ab|7|entity|C1514720|Randomized|ftcn|||randomized|||0|851|1703|1713
SE|25462541|RESULTS|ab|7|entity|C0702113|Controlled|ftcn|||controlled|||0|851|1714|1724
SE|25462541|RESULTS|ab|7|entity|C0008976|Clinical Trials|resa|||trial|||0|851|1725|1730
SE|25462541|RESULTS|ab|7|entity|C1547015|*Coefficient|qnco|||coefficient|||0|861|1743|1754
SE|25462541|RESULTS|ab|7|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|901|1760|1779
SE|25462541|RESULTS|ab|7|entity|C1444754|Length|qnco|||length|||0|861|1827|1833
SE|25462541|RESULTS|ab|7|entity|C0237753|Numbers|qnco|||number|||0|1000|1835|1841
SE|25462541|RESULTS|ab|7|entity|C1548329|Pages|idcn|||pages|||0|1000|1845|1850
SE|25462541|RESULTS|ab|7|entity|C1547015|*Coefficient|qnco|||coefficient|||0|861|1863|1874
SE|25462541|RESULTS|ab|7|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|901|1880|1899
SE|25462541|RESULTS|ab|7|entity|C0450303|0.016"|qnco|||0.016|||0|861|1909|1914

SE|25462541|CONCLUSIONS|ab|8|text|1935|2172|CONCLUSIONS: Authors involved in vascular research may enhance the impact of their work by embarking on research strategies of high methodologic quality and pursuing work related with new technologies and evolving endovascular therapies.
SE|25462541|CONCLUSIONS|ab|8|entity|C0221192|Author|idcn,prog|||Authors|||0|1000|1948|1955
SE|25462541|CONCLUSIONS|ab|8|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|888|1968|1976
SE|25462541|CONCLUSIONS|ab|8|entity|C0035168|research|resa|||research|||0|888|1977|1985
SE|25462541|CONCLUSIONS|ab|8|entity|C0043227|Work|ocac|||work|||0|1000|2018|2022
SE|25462541|CONCLUSIONS|ab|8|entity|C0035168|research|resa|||research|||0|888|2039|2047
SE|25462541|CONCLUSIONS|ab|8|entity|C0205250|High|qlco|||high|||0|867|2062|2066
SE|25462541|CONCLUSIONS|ab|8|entity|C0815254|methodological quality|resa|||methodologic quality|||0|867|2067|2087
SE|25462541|CONCLUSIONS|ab|8|entity|C0043227|Work|ocac|||work|||0|790|2101|2105
SE|25462541|CONCLUSIONS|ab|8|entity|C1522149|Related|ftcn|||related|||0|790|2106|2113
SE|25462541|CONCLUSIONS|ab|8|entity|C0683887|new technology|inpr|||new technologies|||0|983|2119|2135
SE|25462541|CONCLUSIONS|ab|8|entity|C0332253|Evolving|ftcn|||evolving|||0|851|2140|2148
SE|25462541|CONCLUSIONS|ab|8|entity|C0524425|Endovascular|blor|||endovascular|||0|851|2149|2161
SE|25462541|CONCLUSIONS|ab|8|entity|C0087111|Therapeutic procedure|topp|||therapies|||0|851|2162|2171


SE|25462542||ti|1|text|21|97|Carotid artery pseudoaneurysm as a complication of carotid artery stenting.
SE|25462542||ti|1|entity|C0003842|Arteries|bpoc|||artery|||0|901|29|35
SE|25462542||ti|1|entity|C0751816|Carotid Pseudoaneurysm|dsyn|||Carotid artery pseudoaneurysm|||0|901|21|50
SE|25462542||ti|1|entity|C0009566|Complication|patf|||complication|||0|1000|56|68
SE|25462542||ti|1|entity|C0007272|Carotid Arteries|bpoc|||carotid artery|||0|734|72|86
SE|25462542||ti|1|relation|0|0|C0003842|Arteries|bpoc|bpoc|||artery|||0|901|29|35|MOD/HEAD|LOCATION_OF||29|50|0|0|C0751816|Carotid Pseudoaneurysm|dsyn|dsyn|||Carotid artery pseudoaneurysm|||0|901|21|50

SE|25462542||ab|1|text|103|209|Carotid artery stenting (CAS) has been adopted more in the treatment of carotid artery stenosis recently.
SE|25462542||ab|1|entity|C0007272|Carotid Arteries|bpoc|||Carotid artery|||0|734|103|117
SE|25462542||ab|1|entity|C0205172|More|ftcn|||more|||0|1000|150|154
SE|25462542||ab|1|entity|C0007282|Carotid Stenosis|dsyn|||carotid artery stenosis|||0|916|175|198
SE|25462542||ab|1|entity|C0332185|Recent|tmco|||recently|||0|916|199|207

SE|25462542||ab|2|text|209|392|The vast majority of studies about this procedure have concentrated mainly on the short- and long-term clinical complications, that is, stroke, myocardial infarction, and restenosis.
SE|25462542||ab|2|entity|C0814230|Veterans Alcoholism Screening Test|inpr|||vast|||0|888|213|217
SE|25462542||ab|2|entity|C0680220|majority|socb|||majority|||0|888|218|226
SE|25462542||ab|2|entity|C0008972|Clinical Research|resa|||studies|||0|966|230|237
SE|25462542||ab|2|entity|C0184661|Procedures|hlca|||procedure|||0|1000|249|258
SE|25462542||ab|2|entity|C0443252|Long-term|tmco|||long-term|||0|861|302|311
SE|25462542||ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|861|312|320
SE|25462542||ab|2|entity|C0009566|Complication|patf|||complications|||0|861|321|334
SE|25462542||ab|2|entity|C0038454|Cerebrovascular accident|dsyn|||stroke|||0|1000|345|351
SE|25462542||ab|2|entity|C0027051|Myocardial Infarction|dsyn|||myocardial infarction|||0|1000|353|374
SE|25462542||ab|2|entity|C0333186|Restenosis|acab|||restenosis|||0|1000|380|390

SE|25462542||ab|3|text|392|503|However, mechanical complications including both stent fracture and carotid pseudoaneurysm are under-reported.
SE|25462542||ab|3|entity|C0009566|Complication|patf|||complications|||0|861|412|425
SE|25462542||ab|3|entity|C1562726|Stent fracture|fndg|||stent fracture|||0|1000|441|455
SE|25462542||ab|3|entity|C0751816|Carotid Pseudoaneurysm|dsyn|||carotid pseudoaneurysm|||0|1000|460|482

SE|25462542||ab|4|text|503|616|In the present report, we present a patient with a common carotid artery psuedoaneurysm as a complication of CAS.
SE|25462542||ab|4|entity|C0150312|Present|qnco|||present|||0|888|510|517
SE|25462542||ab|4|entity|C0030705|Patients|podg|||patient|||0|1000|539|546
SE|25462542||ab|4|entity|C0162859|Common carotid artery|bpoc|||common carotid artery|||0|756|554|575
SE|25462542||ab|4|entity|C0009566|Complication|patf|||complication|||0|1000|596|608
SE|25462542||ab|4|entity|C0007272|Carotid Arteries|bpoc|||CAS|||0|734|612|615


SE|25462543||ti|1|text|21|79|Thoracic aorta stent grafting through transapical access.
SE|25462543||ti|1|entity|C1281571|Entire thoracic aorta|bpoc|||Thoracic aorta|||0|861|21|35
SE|25462543||ti|1|entity|C0038257|Stents|medd|||stent|||0|861|36|41
SE|25462543||ti|1|entity|C0040732|Transplantation|topp|||grafting|||0|861|42|50
SE|25462543||ti|1|entity|C0444454|Access|spco|||access|||0|861|71|77
SE|25462543||ti|1|relation|0|0|C0040732|Transplantation|topp|topp|||grafting|||0|861|42|50|MOD/HEAD|USES||36|50|0|0|C0038257|Stents|medd|medd|||stent|||0|861|36|41

SE|25462543|BACKGROUND|ab|1|text|85|183|BACKGROUND: To describe the transapical approach for thoracic endovascular aortic repair (TEVAR).
SE|25462543|BACKGROUND|ab|1|entity|C0449445|Approach|spco|||approach|||0|861|125|133
SE|25462543|BACKGROUND|ab|1|entity|C0524425|Endovascular|blor|||endovascular|||0|843|147|159
SE|25462543|BACKGROUND|ab|1|entity|C1281571|Entire thoracic aorta|bpoc|||thoracic endovascular aortic|||0|843|138|166
SE|25462543|BACKGROUND|ab|1|entity|C0043240|Wound Healing|orgf|||repair|||0|843|167|173

SE|25462543|METHODS|ab|2|text|183|378|METHODS: Three patients, 2 elective and 1 emergent, with thoracic aorta aneurysm are described with vascular or direct aortic inaccessible access, who underwent TEVAR through transapical access.
SE|25462543|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|183|190
SE|25462543|METHODS|ab|2|entity|C0205449|Three|qnco|||Three|||0|888|192|197
SE|25462543|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|888|198|206
SE|25462543|METHODS|ab|2|entity|C0439608|elective|tmco|||elective|||0|861|210|218
SE|25462543|METHODS|ab|2|entity|C0750573|EMERGENT|idcn|||emergent|||0|861|225|233
SE|25462543|METHODS|ab|2|entity|C0162872|Aortic Aneurysm, Thoracic|dsyn|||thoracic aorta aneurysm|||0|1000|240|263
SE|25462543|METHODS|ab|2|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|1000|283|291
SE|25462543|METHODS|ab|2|entity|C0003483|Aorta|bpoc|||aortic|||0|763|302|308
SE|25462543|METHODS|ab|2|entity|C0444454|Access|spco|||access|||0|763|322|328
SE|25462543|METHODS|ab|2|entity|C0524425|Endovascular|blor|||TEVAR|||0|843|344|349
SE|25462543|METHODS|ab|2|entity|C1281571|Entire thoracic aorta|bpoc|||TEVAR|||0|843|344|349
SE|25462543|METHODS|ab|2|entity|C0043240|Wound Healing|orgf|||TEVAR|||0|843|344|349
SE|25462543|METHODS|ab|2|entity|C0444454|Access|spco|||access|||0|861|370|376

SE|25462543|METHODS|ab|3|text|378|541|The technique is described in detail emphasizing the usefulness of the through-and-through guidewire, rapid pacing, and transesophageal echocardiography guidance.
SE|25462543|METHODS|ab|3|entity|C0449851|Techniques|ftcn|||technique|||0|1000|382|391
SE|25462543|METHODS|ab|3|entity|C0332273|Through|ftcn|||through|||0|645|449|456
SE|25462543|METHODS|ab|3|entity|C0439831|Rapid|qlco|||rapid|||0|694|480|485
SE|25462543|METHODS|ab|3|entity|C0206054|Echocardiography, Transesophageal|diap|||transesophageal echocardiography|||0|901|498|530

SE|25462543|RESULTS|ab|4|text|541|638|RESULTS: All patients were technical successfully treated with TEVAR through transapical access.
SE|25462543|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|541|548
SE|25462543|RESULTS|ab|4|entity|C0030705|Patients|podg|||patients|||0|1000|554|562
SE|25462543|RESULTS|ab|4|entity|C0025664|Methodology|inpr|||technical|||0|928|568|577
SE|25462543|RESULTS|ab|4|entity|C0524425|Endovascular|blor|||TEVAR|||0|843|604|609
SE|25462543|RESULTS|ab|4|entity|C1281571|Entire thoracic aorta|bpoc|||TEVAR|||0|843|604|609
SE|25462543|RESULTS|ab|4|entity|C0043240|Wound Healing|orgf|||TEVAR|||0|843|604|609
SE|25462543|RESULTS|ab|4|entity|C0444454|Access|spco|||access|||0|861|630|636

SE|25462543|RESULTS|ab|5|text|638|701|The emergent patient, however, died due to multiorgan failure.
SE|25462543|RESULTS|ab|5|entity|C0750573|EMERGENT|idcn|||emergent|||0|888|642|650
SE|25462543|RESULTS|ab|5|entity|C0030705|Patients|podg|||patient|||0|888|651|658
SE|25462543|RESULTS|ab|5|entity|C0026766|Multiple Organ Failure|patf|||multiorgan failure|||0|1000|681|699

SE|25462543|CONCLUSIONS|ab|6|text|701|826|CONCLUSIONS: Our early experience shows that the transapical approach for TEVAR procedures is feasible in experienced hands.
SE|25462543|CONCLUSIONS|ab|6|entity|C1279919|Early|tmco|||early|||0|888|718|723
SE|25462543|CONCLUSIONS|ab|6|entity|C0596545|experience|menp|||experience|||0|888|724|734
SE|25462543|CONCLUSIONS|ab|6|entity|C0449445|Approach|spco|||approach|||0|861|762|770
SE|25462543|CONCLUSIONS|ab|6|entity|C0524425|Endovascular|blor|||TEVAR|||0|825|775|780
SE|25462543|CONCLUSIONS|ab|6|entity|C1281571|Entire thoracic aorta|bpoc|||TEVAR|||0|825|775|780
SE|25462543|CONCLUSIONS|ab|6|entity|C0043240|Wound Healing|orgf|||TEVAR|||0|825|775|780
SE|25462543|CONCLUSIONS|ab|6|entity|C0025664|Methodology|inpr|||procedures|||0|825|781|791
SE|25462543|CONCLUSIONS|ab|6|entity|C0596545|experience|menp|||experienced|||0|853|807|818
SE|25462543|CONCLUSIONS|ab|6|entity|C0018563|Hand|bpoc|||hands|||0|853|819|824

SE|25462543|CONCLUSIONS|ab|7|text|826|1017|The selection of the patient and careful planning based on imaging are of paramount importance and should lead to the most suitable access site tailored to the need of the individual patient.
SE|25462543|CONCLUSIONS|ab|7|entity|C0030705|Patients|podg|||patient|||0|1000|847|854
SE|25462543|CONCLUSIONS|ab|7|entity|C0205393|Most|qnco|||most|||0|775|944|948
SE|25462543|CONCLUSIONS|ab|7|entity|C0444454|Access|spco|||access|||0|775|958|964
SE|25462543|CONCLUSIONS|ab|7|entity|C0205145|Site|spco|||site|||0|775|965|969
SE|25462543|CONCLUSIONS|ab|7|entity|C0027552|Needs|qlco|||need|||0|1000|986|990
SE|25462543|CONCLUSIONS|ab|7|entity|C0237401|Individual|humn|||individual|||0|888|998|1008
SE|25462543|CONCLUSIONS|ab|7|entity|C0030705|Patients|podg|||patient|||0|888|1009|1016


SE|25462544||ti|1|text|21|110|Three-year delayed presentation of femoral pseudoaneurysm after penetrating limb trauma.
SE|25462544||ti|1|entity|C0205449|Three|qnco|||Three|||0|888|21|26
SE|25462544||ti|1|entity|C0439234|year|tmco|||year|||0|888|27|31
SE|25462544||ti|1|entity|C0449450|Presentation|idcn|||presentation|||0|1000|40|52
SE|25462544||ti|1|entity|C0015811|Femur|bpoc|||femoral|||0|888|56|63
SE|25462544||ti|1|entity|C1510412|Pseudoaneurysm|anab|||pseudoaneurysm|||0|888|64|78
SE|25462544||ti|1|entity|C0205321|Penetration|ftcn|||penetrating|||0|851|85|96
SE|25462544||ti|1|entity|C1280090|Entire limb|bpoc|||limb|||0|851|97|101
SE|25462544||ti|1|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|851|102|108
SE|25462544||ti|1|relation|0|0|C0015811|Femur|bpoc|bpoc|||femoral|||0|888|56|63|MOD/HEAD|LOCATION_OF||56|78|0|0|C1510412|Pseudoaneurysm|anab|anab|||pseudoaneurysm|||0|888|64|78
SE|25462544||ti|1|relation|0|0|C1280090|Entire limb|bpoc|bpoc|||limb|||0|851|97|101|MOD/HEAD|LOCATION_OF||97|108|0|0|C0043251|Wounds and Injuries|inpo|inpo|||trauma|||0|851|102|108

SE|25462544|BACKGROUND|ab|1|text|116|235|BACKGROUND: Delayed presentations of lower limb pseudoaneurysms secondary to penetrating trauma are particularly rare.
SE|25462544|BACKGROUND|ab|1|entity|C0205421|Deferred|tmco|||Delayed|||0|872|128|135
SE|25462544|BACKGROUND|ab|1|entity|C0449450|Presentation|idcn|||presentations|||0|872|136|149
SE|25462544|BACKGROUND|ab|1|entity|C0023216|Lower Extremity|blor|||lower limb|||0|901|153|163
SE|25462544|BACKGROUND|ab|1|entity|C1510412|Pseudoaneurysm|anab|||pseudoaneurysms|||0|901|164|179
SE|25462544|BACKGROUND|ab|1|entity|C1522484|metastatic qualifier|qnco|||secondary|||0|1000|180|189
SE|25462544|BACKGROUND|ab|1|entity|C0205321|Penetration|ftcn|||penetrating|||0|888|193|204
SE|25462544|BACKGROUND|ab|1|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|888|205|211
SE|25462544|BACKGROUND|ab|1|entity|C0522498|Rare|qlco|||rare|||0|861|229|233
SE|25462544|BACKGROUND|ab|1|relation|2|1|C0043251|Wounds and Injuries|inpo|inpo|||trauma|||0|888|205|211|ADJ|CAUSES||180|189|3|1|C1510412|Pseudoaneurysm|anab|anab|||pseudoaneurysms|||0|901|164|179

SE|25462544|METHODS|ab|2|text|235|330|METHODS: After presentation of this rare case report, we review relevant published literature.
SE|25462544|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|235|242
SE|25462544|METHODS|ab|2|entity|C0449450|Presentation|idcn|||presentation|||0|1000|250|262
SE|25462544|METHODS|ab|2|entity|C0522498|Rare|qlco|||rare|||0|901|271|275
SE|25462544|METHODS|ab|2|entity|C0007320|Case Reports Publication Type|inpr|||case report|||0|901|276|287
SE|25462544|METHODS|ab|2|entity|C0034037|Publishing|ocac|||published|||0|773|308|317
SE|25462544|METHODS|ab|2|entity|C0023866|Literature|inpr|||literature|||0|773|318|328

SE|25462544|RESULTS|ab|3|text|330|509|RESULTS: We report a rare case of a 55-year-old man with a progressively enlarging mass measuring 15 cm by 15 cm on his right anteromedial thigh 3 years after penetrating trauma.
SE|25462544|RESULTS|ab|3|entity|C1274040|result|ftcn|||RESULTS|||0|966|330|337
SE|25462544|RESULTS|ab|3|entity|C0522498|Rare|qlco|||rare|||0|694|351|355
SE|25462544|RESULTS|ab|3|entity|C0439234|year|tmco|||year|||0|775|369|373
SE|25462544|RESULTS|ab|3|entity|C0580836|Old|tmco|||old|||0|775|374|377
SE|25462544|RESULTS|ab|3|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|1000|413|417
SE|25462544|RESULTS|ab|3|entity|C1179847|Anteromedial|spco|||anteromedial|||0|794|456|468
SE|25462544|RESULTS|ab|3|entity|C1279548|Entire right thigh|bpoc|||right anteromedial thigh|||0|794|450|474
SE|25462544|RESULTS|ab|3|entity|C0439234|year|tmco|||years|||0|794|477|482
SE|25462544|RESULTS|ab|3|entity|C0205321|Penetration|ftcn|||penetrating|||0|888|489|500
SE|25462544|RESULTS|ab|3|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|888|501|507

SE|25462544|RESULTS|ab|4|text|509|658|Computer tomography angiogram revealed this to be a large pseudoaneurysm supplied by a side branch artery from the right superficial femoral artery.
SE|25462544|RESULTS|ab|4|entity|C0009622|Computers|mnob|||Computer|||0|851|509|517
SE|25462544|RESULTS|ab|4|entity|C0040395|tomography|diap|||tomography|||0|851|518|528
SE|25462544|RESULTS|ab|4|entity|C0002978|angiogram|diap|||angiogram|||0|851|529|538
SE|25462544|RESULTS|ab|4|entity|C0549177|Large|qnco|||large|||0|888|561|566
SE|25462544|RESULTS|ab|4|entity|C1510412|Pseudoaneurysm|anab|||pseudoaneurysm|||0|888|567|581
SE|25462544|RESULTS|ab|4|entity|C0441987|Side|spco|||side|||0|802|596|600
SE|25462544|RESULTS|ab|4|entity|C0003842|Arteries|bpoc|||artery|||0|802|608|614
SE|25462544|RESULTS|ab|4|entity|C0205124|Superficial|spco|||superficial|||0|916|630|641
SE|25462544|RESULTS|ab|4|entity|C1281566|Entire right femoral artery|bpoc|||right superficial femoral artery|||0|916|624|656

SE|25462544|RESULTS|ab|5|text|658|839|Using an open approach, the pseudoanerysm was successfully repaired with the side branch oversewn, and the patient made a good recovery being discharged from hospital 4 days later.
SE|25462544|RESULTS|ab|5|entity|C0348025|Open approach|topp|||open approach|||0|1000|667|680
SE|25462544|RESULTS|ab|5|entity|C0441987|Side|spco|||side|||0|785|735|739
SE|25462544|RESULTS|ab|5|entity|C0521212|Oversewing|topp|||oversewn|||0|785|747|755
SE|25462544|RESULTS|ab|5|entity|C0030705|Patients|podg|||patient|||0|1000|765|772
SE|25462544|RESULTS|ab|5|entity|C0205170|Good|qlco|||good|||0|888|780|784
SE|25462544|RESULTS|ab|5|entity|C0237820|Recovery|orgf|||recovery|||0|888|785|793
SE|25462544|RESULTS|ab|5|entity|C0019994|Hospitals|hcro,mnob|||hospital|||0|763|816|824
SE|25462544|RESULTS|ab|5|entity|C0439228|day|tmco|||days|||0|763|827|831

SE|25462544|CONCLUSIONS|ab|6|text|839|1094|CONCLUSIONS: Surgeons must retain pseudoaneurysm as a prominent differential for a patient presenting with a progressively enlarging, expansile mass of an extremity after penetrating trauma to ensure urgent investigation and prompt vascular intervention.
SE|25462544|CONCLUSIONS|ab|6|entity|C0582175|Surgeon|prog|||Surgeons|||0|1000|852|860
SE|25462544|CONCLUSIONS|ab|6|entity|C1510412|Pseudoaneurysm|anab|||pseudoaneurysm|||0|1000|873|887
SE|25462544|CONCLUSIONS|ab|6|entity|C0205402|Prominent|qlco|||prominent|||0|694|893|902
SE|25462544|CONCLUSIONS|ab|6|entity|C0030705|Patients|podg|||patient|||0|872|922|929
SE|25462544|CONCLUSIONS|ab|6|entity|C0150312|Present|qnco|||presenting|||0|872|930|940
SE|25462544|CONCLUSIONS|ab|6|entity|C0442800|Enlarged|qlco|||enlarging|||0|827|962|971
SE|25462544|CONCLUSIONS|ab|6|entity|C1306372|Mass, a measure of quantity of matter|qnco|||mass|||0|861|983|987
SE|25462544|CONCLUSIONS|ab|6|entity|C0015385|Limb structure|bpoc|||extremity|||0|1000|994|1003
SE|25462544|CONCLUSIONS|ab|6|entity|C0205321|Penetration|ftcn|||penetrating|||0|888|1010|1021
SE|25462544|CONCLUSIONS|ab|6|entity|C0043251|Wounds and Injuries|inpo|||trauma|||0|888|1022|1028
SE|25462544|CONCLUSIONS|ab|6|entity|C0439609|Urgent|tmco|||urgent|||0|888|1039|1045
SE|25462544|CONCLUSIONS|ab|6|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|888|1071|1079
SE|25462544|CONCLUSIONS|ab|6|entity|C1273869|Intervention regimes|hlca|||intervention|||0|888|1080|1092

SE|25462544|CONCLUSIONS|ab|7|text|1094|1294|Both open surgical ablation and endovascular embolization of pseudoaneurysms of the extremities are effective techniques with low rates of complications and morbidity reported in published literature.
SE|25462544|CONCLUSIONS|ab|7|entity|C0175566|Open|spco|||open|||0|851|1099|1103
SE|25462544|CONCLUSIONS|ab|7|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|851|1104|1112
SE|25462544|CONCLUSIONS|ab|7|entity|C0547070|Ablation|topp|||ablation|||0|851|1113|1121
SE|25462544|CONCLUSIONS|ab|7|entity|C0524425|Endovascular|blor|||endovascular|||0|888|1126|1138
SE|25462544|CONCLUSIONS|ab|7|entity|C0013931|Embolization, Therapeutic|topp|||embolization|||0|888|1139|1151
SE|25462544|CONCLUSIONS|ab|7|entity|C1510412|Pseudoaneurysm|anab|||pseudoaneurysms|||0|1000|1155|1170
SE|25462544|CONCLUSIONS|ab|7|entity|C0015385|Limb structure|bpoc|||extremities|||0|1000|1178|1189
SE|25462544|CONCLUSIONS|ab|7|entity|C0025664|Methodology|inpr|||techniques|||0|888|1204|1214
SE|25462544|CONCLUSIONS|ab|7|entity|C0205251|low|qlco|||low|||0|872|1220|1223
SE|25462544|CONCLUSIONS|ab|7|entity|C1521828|Rate|qnco|||rates|||0|872|1224|1229
SE|25462544|CONCLUSIONS|ab|7|entity|C0009566|Complication|patf|||complications|||0|1000|1233|1246
SE|25462544|CONCLUSIONS|ab|7|entity|C0034037|Publishing|ocac|||published|||0|872|1273|1282
SE|25462544|CONCLUSIONS|ab|7|entity|C0023866|Literature|inpr|||literature|||0|872|1283|1293
SE|25462544|CONCLUSIONS|ab|7|relation|0|0|C0547070|Ablation|topp|topp|||ablation|||0|851|1113|1121|MOD/HEAD|ISA||1104|1121|0|0|C0543467|Operative Surgical Procedures|topp|topp|||surgical|||0|851|1104|1112
SE|25462544|CONCLUSIONS|ab|7|relation|6|1|C0015385|Limb structure|bpoc|bpoc|||extremities|||0|1000|1178|1189|PREP|LOCATION_OF||1171|1173|3|1|C1510412|Pseudoaneurysm|anab|anab|||pseudoaneurysms|||0|1000|1155|1170


SE|25462546||ti|1|text|21|142|Therapeutic outcomes and thromboembolic events after treatment of acute arterial thromboembolism of the upper extremity.
SE|25462546||ti|1|entity|C0085415|Treatment outcome|qlco|||Therapeutic outcomes|||0|1000|21|41
SE|25462546||ti|1|entity|C0857496|Thromboembolic event|patf|||thromboembolic events|||0|983|46|67
SE|25462546||ti|1|entity|C0205178|acute|tmco|||acute|||0|851|87|92
SE|25462546||ti|1|entity|C0221464|Arterial|spco|||arterial|||0|851|93|101
SE|25462546||ti|1|entity|C0040038|Thromboembolism|patf|||thromboembolism|||0|851|102|117
SE|25462546||ti|1|entity|C1140618|Upper Extremity|bpoc|||upper extremity|||0|1000|125|140
SE|25462546||ti|1|relation|1|1|C1140618|Upper Extremity|bpoc|bpoc|||upper extremity|||0|1000|125|140|PREP|LOCATION_OF||118|120|4|1|C0040038|Thromboembolism|patf|patf|||thromboembolism|||0|851|102|117

SE|25462546|BACKGROUND|ab|1|text|148|334|BACKGROUND: To investigate short- and long-term outcomes of patients with acute arterial thromboembolism of upper extremity, focusing on postoperative thromboembolic events by etiology.
SE|25462546|BACKGROUND|ab|1|entity|C0443252|Long-term|tmco|||long-term|||0|884|186|195
SE|25462546|BACKGROUND|ab|1|entity|C1274040|result|ftcn|||outcomes|||0|884|196|204
SE|25462546|BACKGROUND|ab|1|entity|C0030705|Patients|podg|||patients|||0|1000|208|216
SE|25462546|BACKGROUND|ab|1|entity|C0205178|acute|tmco|||acute|||0|851|222|227
SE|25462546|BACKGROUND|ab|1|entity|C0221464|Arterial|spco|||arterial|||0|851|228|236
SE|25462546|BACKGROUND|ab|1|entity|C0040038|Thromboembolism|patf|||thromboembolism|||0|851|237|252
SE|25462546|BACKGROUND|ab|1|entity|C1140618|Upper Extremity|bpoc|||upper extremity|||0|1000|256|271
SE|25462546|BACKGROUND|ab|1|entity|C0857496|Thromboembolic event|patf|||thromboembolic events|||0|884|299|320
SE|25462546|BACKGROUND|ab|1|entity|C1314792|Etiology|ftcn|||etiology|||0|1000|324|332
SE|25462546|BACKGROUND|ab|1|relation|3|1|C1140618|Upper Extremity|bpoc|bpoc|||upper extremity|||0|1000|256|271|PREP|LOCATION_OF||253|255|5|1|C0040038|Thromboembolism|patf|patf|||thromboembolism|||0|851|237|252
SE|25462546|BACKGROUND|ab|1|relation|4|1|C0040038|Thromboembolism|patf|patf|||thromboembolism|||0|851|237|252|PREP|PROCESS_OF||217|221|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|208|216

SE|25462546|METHODS|ab|2|text|334|623|METHODS: Hospital records of 53 patients (average age 70 years; males 49%) with acute arterial thromboembolism of upper extremity treated between June 1993 and December 2013 were retrospectively reviewed, evaluating patient characteristics and clinical outcomes, both short and long term.
SE|25462546|METHODS|ab|2|entity|C0025663|Methods|inpr|||METHODS|||0|1000|334|341
SE|25462546|METHODS|ab|2|entity|C0019994|Hospitals|hcro,mnob|||Hospital|||0|1000|343|351
SE|25462546|METHODS|ab|2|entity|C0030705|Patients|podg|||patients|||0|861|366|374
SE|25462546|METHODS|ab|2|entity|C1510992|Average|qnco|||average|||0|824|376|383
SE|25462546|METHODS|ab|2|entity|C1510829|Age-Years|tmco|||age 70 years|||0|824|384|396
SE|25462546|METHODS|ab|2|entity|C0024554|Male gender|orga|||males|||0|861|398|403
SE|25462546|METHODS|ab|2|entity|C0205178|acute|tmco|||acute|||0|851|414|419
SE|25462546|METHODS|ab|2|entity|C0221464|Arterial|spco|||arterial|||0|851|420|428
SE|25462546|METHODS|ab|2|entity|C0040038|Thromboembolism|patf|||thromboembolism|||0|851|429|444
SE|25462546|METHODS|ab|2|entity|C1140618|Upper Extremity|bpoc|||upper extremity|||0|1000|448|463
SE|25462546|METHODS|ab|2|entity|C0815172|patient characteristics|clna|||patient characteristics|||0|1000|550|573
SE|25462546|METHODS|ab|2|entity|C0205210|Clinical|qlco|||clinical|||0|872|578|586
SE|25462546|METHODS|ab|2|entity|C1274040|result|ftcn|||outcomes|||0|872|587|595
SE|25462546|METHODS|ab|2|entity|C0443252|Long-term|tmco|||long term|||0|1000|612|621
SE|25462546|METHODS|ab|2|relation|5|1|C1140618|Upper Extremity|bpoc|bpoc|||upper extremity|||0|1000|448|463|PREP|LOCATION_OF||445|447|5|1|C0040038|Thromboembolism|patf|patf|||thromboembolism|||0|851|429|444

SE|25462546|METHODS|ab|3|text|623|744|Subjects were stratified as those with (group I, 34) and without (group II, 19) atrial fibrillation as underlying cause.
SE|25462546|METHODS|ab|3|entity|C1550501|subject|idcn|||Subjects|||0|966|623|631
SE|25462546|METHODS|ab|3|entity|C0441833|Groups|inpr|||group|||0|1000|663|668
SE|25462546|METHODS|ab|3|entity|C0441833|Groups|inpr|||group|||0|694|689|694
SE|25462546|METHODS|ab|3|entity|C0004238|Atrial Fibrillation|patf|||atrial fibrillation|||0|1000|703|722
SE|25462546|METHODS|ab|3|entity|C0015127|Etiology aspects|ftcn|||cause|||0|827|737|742

SE|25462546|RESULTS|ab|4|text|744|824|RESULTS: Two patients received anticoagulation alone as conservative treatment.
SE|25462546|RESULTS|ab|4|entity|C1274040|result|ftcn|||RESULTS|||0|966|744|751
SE|25462546|RESULTS|ab|4|entity|C0205448|Two|qnco|||Two|||0|888|753|756
SE|25462546|RESULTS|ab|4|entity|C0030705|Patients|podg|||patients|||0|888|757|765
SE|25462546|RESULTS|ab|4|entity|C0003281|anticoagulation|topp|||anticoagulation|||0|1000|775|790
SE|25462546|RESULTS|ab|4|relation|3|1|C0003281|anticoagulation|topp|topp|||anticoagulation|||0|1000|775|790|VERB|ADMINISTERED_TO||766|774|2|1|C0030705|Patients|podg,humn|humn|||patients|||0|888|757|765

SE|25462546|RESULTS|ab|5|text|824|885|The remainder (n = 51) underwent surgical revascularization.
SE|25462546|RESULTS|ab|5|entity|C0543467|Operative Surgical Procedures|topp|||surgical|||0|694|857|865

SE|25462546|RESULTS|ab|6|text|885|1027|Symptoms resolved in 51 patients (96%) except 2 patients with postoperative reocclusion, and there was no need of amputation in all patients.
SE|25462546|RESULTS|ab|6|entity|C1457887|Symptoms|sosy|||Symptoms|||0|1000|885|893
SE|25462546|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|909|917
SE|25462546|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|861|933|941
SE|25462546|RESULTS|ab|6|entity|C0854571|Reocclusion|inpo|||reocclusion|||0|861|961|972
SE|25462546|RESULTS|ab|6|entity|C0027552|Needs|qlco|||need|||0|1000|991|995
SE|25462546|RESULTS|ab|6|entity|C0002688|Amputation|topp|||amputation|||0|1000|999|1009
SE|25462546|RESULTS|ab|6|entity|C0030705|Patients|podg|||patients|||0|1000|1017|1025
SE|25462546|RESULTS|ab|6|relation|1|1|C1457887|Symptoms|sosy|sosy|||Symptoms|||0|1000|885|893|PREP|PROCESS_OF||903|905|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|909|917
SE|25462546|RESULTS|ab|6|relation|4|1|C0854571|Reocclusion|inpo|inpo|||reocclusion|||0|861|961|972|PREP|PROCESS_OF||942|946|3|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|933|941
SE|25462546|RESULTS|ab|6|relation|6|1|C0002688|Amputation|topp|topp|||amputation|||0|1000|999|1009|PREP|TREATS||1010|1012|1|1|C0030705|Patients|podg,humn|podg|||patients|||0|1000|1017|1025

SE|25462546|RESULTS|ab|7|text|1027|1072|Overall inpatient mortality was 5.6% (3/53).
SE|25462546|RESULTS|ab|7|entity|C1561607|Overall|qlco|||Overall|||0|623|1027|1034
SE|25462546|RESULTS|ab|7|entity|C0021562|inpatient|podg|||inpatient|||0|623|1035|1044
SE|25462546|RESULTS|ab|7|entity|C0439084|>5|qnco|||5|||0|861|1059|1060

SE|25462546|RESULTS|ab|8|text|1072|1275|Patients of group I suffered most of the recurrent thromboembolic events (group I: 17 events, 14 patients; group II: 2 events, 2 patients) recorded during follow-up (mean duration 56.8 +/- 62.2 months).
SE|25462546|RESULTS|ab|8|entity|C0030705|Patients|podg|||Patients|||0|1000|1072|1080
SE|25462546|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|1000|1084|1089
SE|25462546|RESULTS|ab|8|entity|C0205393|Most|qnco|||most|||0|1000|1101|1105
SE|25462546|RESULTS|ab|8|entity|C0034897|Recurrence|phpr|||recurrent|||0|890|1113|1122
SE|25462546|RESULTS|ab|8|entity|C0857496|Thromboembolic event|patf|||thromboembolic events|||0|890|1123|1144
SE|25462546|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|1000|1146|1151
SE|25462546|RESULTS|ab|8|entity|C0441471|Events|evnt|||events|||0|861|1158|1164
SE|25462546|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|861|1169|1177
SE|25462546|RESULTS|ab|8|entity|C0441833|Groups|inpr|||group|||0|694|1179|1184
SE|25462546|RESULTS|ab|8|entity|C0441471|Events|evnt|||events|||0|861|1191|1197
SE|25462546|RESULTS|ab|8|entity|C0030705|Patients|podg|||patients|||0|861|1201|1209
SE|25462546|RESULTS|ab|8|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1227|1236
SE|25462546|RESULTS|ab|8|entity|C0449238|Duration|tmco|||duration|||0|766|1243|1251
SE|25462546|RESULTS|ab|8|entity|C0439231|month|tmco|||months|||0|766|1266|1272
SE|25462546|RESULTS|ab|8|relation|9|1|C0857496|Thromboembolic event|patf|patf|||thromboembolic events|||0|890|1123|1144|VERB|PROCESS_OF||1092|1100|2|2|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|1072|1080

SE|25462546|RESULTS|ab|9|text|1275|1443|Respective event-free survival rates at 1, 3, and 5 years differed significantly by group: 77%, 44%, and 44% for group I; 100%, 100%, and 83% for group II (P = 0.004).
SE|25462546|RESULTS|ab|9|entity|C0242793|Disease-Free Survival|qnco|||event-free survival|||0|846|1286|1305
SE|25462546|RESULTS|ab|9|entity|C0871208|Rating|resa|||rates|||0|846|1306|1311
SE|25462546|RESULTS|ab|9|entity|C0439234|year|tmco|||years|||0|888|1327|1332
SE|25462546|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|1000|1359|1364
SE|25462546|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|1000|1388|1393
SE|25462546|RESULTS|ab|9|entity|C0441833|Groups|inpr|||group|||0|694|1421|1426

SE|25462546|RESULTS|ab|10|text|1443|1617|Among 14 patients with recurrent embolic events in group I, half of the patients were not receiving anticoagulants; however, anticoagulant cessation was generally arbitrary.
SE|25462546|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|861|1452|1460
SE|25462546|RESULTS|ab|10|entity|C0034897|Recurrence|phpr|||recurrent|||0|851|1466|1475
SE|25462546|RESULTS|ab|10|entity|C0013922|Embolism|patf|||embolic|||0|851|1476|1483
SE|25462546|RESULTS|ab|10|entity|C0441471|Events|evnt|||events|||0|851|1484|1490
SE|25462546|RESULTS|ab|10|entity|C0441833|Groups|inpr|||group|||0|1000|1494|1499
SE|25462546|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1515|1523
SE|25462546|RESULTS|ab|10|entity|C1518422|Not|ftcn|||not|||0|840|1529|1532
SE|25462546|RESULTS|ab|10|entity|C1514756|Received|qlco|||receiving|||0|840|1533|1542
SE|25462546|RESULTS|ab|10|entity|C0003280|Anticoagulants|phsu|||anticoagulants|||0|840|1543|1557
SE|25462546|RESULTS|ab|10|entity|C0003280|Anticoagulants|phsu|||anticoagulant|||0|694|1568|1581
SE|25462546|RESULTS|ab|10|entity|C1264693|Arbitrary|qnco|||arbitrary|||0|861|1606|1615
SE|25462546|RESULTS|ab|10|relation|5|0|C0003280|Anticoagulants|phsu|phsu|||anticoagulants|||0|840|1543|1557|ADJ|ADMINISTERED_TO|negation|1533|1542|5|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1515|1523

SE|25462546|RESULTS|ab|11|text|1617|1743|Overall survival rates at 1, 3, and 5 years were 82%, 69%, and 52% for group I and 84%, 78%, and 70% for group II (P = 0.21).
SE|25462546|RESULTS|ab|11|entity|C1561607|Overall|qlco|||Overall|||0|901|1617|1624
SE|25462546|RESULTS|ab|11|entity|C0038954|Survival Rate|qnco|||survival rates|||0|901|1625|1639
SE|25462546|RESULTS|ab|11|entity|C0439234|year|tmco|||years|||0|888|1655|1660
SE|25462546|RESULTS|ab|11|entity|C0441833|Groups|inpr|||group|||0|1000|1688|1693
SE|25462546|RESULTS|ab|11|entity|C0441833|Groups|inpr|||group|||0|694|1722|1727

SE|25462546|CONCLUSIONS|ab|12|text|1743|1867|CONCLUSIONS: In this study, surgical treatment of acute arterial thromboembolism of upper extremity was largely successful.
SE|25462546|CONCLUSIONS|ab|12|entity|C0008972|Clinical Research|resa|||study|||0|1000|1764|1769
SE|25462546|CONCLUSIONS|ab|12|entity|C0543467|Operative Surgical Procedures|topp|||surgical treatment|||0|1000|1771|1789
SE|25462546|CONCLUSIONS|ab|12|entity|C0205178|acute|tmco|||acute|||0|851|1793|1798
SE|25462546|CONCLUSIONS|ab|12|entity|C0221464|Arterial|spco|||arterial|||0|851|1799|1807
SE|25462546|CONCLUSIONS|ab|12|entity|C0040038|Thromboembolism|patf|||thromboembolism|||0|851|1808|1823
SE|25462546|CONCLUSIONS|ab|12|entity|C1140618|Upper Extremity|bpoc|||upper extremity|||0|1000|1827|1842
SE|25462546|CONCLUSIONS|ab|12|entity|C1272703|Successful|qlco|||successful|||0|861|1855|1865
SE|25462546|CONCLUSIONS|ab|12|relation|2|1|C1140618|Upper Extremity|bpoc|bpoc|||upper extremity|||0|1000|1827|1842|PREP|LOCATION_OF||1824|1826|4|1|C0040038|Thromboembolism|patf|patf|||thromboembolism|||0|851|1808|1823

SE|25462546|CONCLUSIONS|ab|13|text|1867|2036|Especially in patients with atrial fibrillation, adequate long-term anticoagulation is indicated as prophylaxis, given the high rates of recurrent thromboembolic events.
SE|25462546|CONCLUSIONS|ab|13|entity|C0030705|Patients|podg|||patients|||0|1000|1881|1889
SE|25462546|CONCLUSIONS|ab|13|entity|C0004238|Atrial Fibrillation|patf|||atrial fibrillation|||0|1000|1895|1914
SE|25462546|CONCLUSIONS|ab|13|entity|C0205411|Adequate|qlco|||adequate|||0|861|1916|1924
SE|25462546|CONCLUSIONS|ab|13|entity|C0443252|Long-term|tmco|||long-term|||0|861|1925|1934
SE|25462546|CONCLUSIONS|ab|13|entity|C0003281|anticoagulation|topp|||anticoagulation|||0|861|1935|1950
SE|25462546|CONCLUSIONS|ab|13|entity|C0033107|prevention & control|inpr|||prophylaxis|||0|1000|1967|1978
SE|25462546|CONCLUSIONS|ab|13|entity|C0205250|High|qlco|||high|||0|872|1990|1994
SE|25462546|CONCLUSIONS|ab|13|entity|C1521828|Rate|qnco|||rates|||0|872|1995|2000
SE|25462546|CONCLUSIONS|ab|13|entity|C0034897|Recurrence|phpr|||recurrent|||0|890|2004|2013
SE|25462546|CONCLUSIONS|ab|13|entity|C0857496|Thromboembolic event|patf|||thromboembolic events|||0|890|2014|2035
SE|25462546|CONCLUSIONS|ab|13|relation|5|1|C0004238|Atrial Fibrillation|patf|patf|||atrial fibrillation|||0|1000|1895|1914|PREP|PROCESS_OF||1890|1894|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1881|1889


SE|25462545||ti|1|text|21|133|The impact of perioperative red blood cell transfusions on postoperative outcomes in vascular surgery patients.
SE|25462545||ti|1|entity|C1518988|perioperative|tmco|||perioperative|||0|928|35|48
SE|25462545||ti|1|entity|C0086252|Erythrocyte Transfusion|topp|||red blood cell transfusions|||0|928|49|76
SE|25462545||ti|1|entity|C1274040|result|ftcn|||outcomes|||0|827|94|102
SE|25462545||ti|1|entity|C0042381|Vascular Surgical Procedures|topp|||vascular surgery|||0|901|106|122
SE|25462545||ti|1|entity|C0030705|Patients|podg|||patients|||0|901|123|131
SE|25462545||ti|1|relation|3|2|C0086252|Erythrocyte Transfusion|topp|topp|||red blood cell transfusions|||0|928|49|76|PREP|TREATS||103|105|1|1|C0030705|Patients|podg,humn|podg|||patients|||0|901|123|131

SE|25462545|BACKGROUND|ab|1|text|139|251|BACKGROUND: Red blood cell (RBC) transfusions are common in vascular surgery and aim to reduce tissue ischemia.
SE|25462545|BACKGROUND|ab|1|entity|C0086252|Erythrocyte Transfusion|topp|||Red blood cell (RBC) transfusions|||0|1000|151|184
SE|25462545|BACKGROUND|ab|1|entity|C0205214|Common|qnco|||common|||0|1000|189|195
SE|25462545|BACKGROUND|ab|1|entity|C0042381|Vascular Surgical Procedures|topp|||vascular surgery|||0|1000|199|215
SE|25462545|BACKGROUND|ab|1|entity|C0022116|Ischemia|dsyn|||ischemia|||0|861|241|249
SE|25462545|BACKGROUND|ab|1|relation|0|0|C0086252|Erythrocyte Transfusion|topp|topp|||Red blood cell (RBC) transfusions|||0|1000|151|184|INFER|PREVENTS(SPEC)||151|215|0|0|C0022116|Ischemia|dsyn|dsyn|||ischemia|||0|861|241|249
SE|25462545|BACKGROUND|ab|1|relation|0|0|C0086252|Erythrocyte Transfusion|topp|topp|||Red blood cell (RBC) transfusions|||0|1000|151|184|SPEC|ISA||151|215|0|0|C0042381|Vascular Surgical Procedures|topp|topp|||vascular surgery|||0|1000|199|215
SE|25462545|BACKGROUND|ab|1|relation|4|1|C0042381|Vascular Surgical Procedures|topp|topp|||vascular surgery|||0|1000|199|215|VERB|PREVENTS||227|233|1|1|C0022116|Ischemia|dsyn|dsyn|||ischemia|||0|861|241|249

SE|25462545|BACKGROUND|ab|2|text|251|324|However, the evidence that transfusions are beneficial is contradictory.
SE|25462545|BACKGROUND|ab|2|entity|C0199960|Transfusion - action|topp|||transfusions|||0|1000|278|290

SE|25462545|BACKGROUND|ab|3|text|324|496|This study evaluates the impact of perioperative transfusion (transfusion within 3 days of surgery) on 30-day postoperative outcomes in elective vascular surgery patients.
SE|25462545|BACKGROUND|ab|3|entity|C0008972|Clinical Research|resa|||study|||0|1000|329|334
SE|25462545|BACKGROUND|ab|3|entity|C1518988|perioperative|tmco|||perioperative|||0|694|359|372
SE|25462545|BACKGROUND|ab|3|entity|C1442459|3 Days|tmco|||3 days|||0|1000|405|411
SE|25462545|BACKGROUND|ab|3|entity|C0439228|day|tmco|||day|||0|747|430|433
SE|25462545|BACKGROUND|ab|3|entity|C1274040|result|ftcn|||outcomes|||0|747|448|456
SE|25462545|BACKGROUND|ab|3|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|861|469|477
SE|25462545|BACKGROUND|ab|3|entity|C0206058|Surgical Procedures, Elective|topp|||elective vascular surgery|||0|861|460|485
SE|25462545|BACKGROUND|ab|3|entity|C0030705|Patients|podg|||patients|||0|861|486|494

SE|25462545|METHODS|ab|4|text|496|683|METHODS: This observational cohort included 1,041 vascular surgery patients between 2002 and 2011 in a tertiary referral center for whom hemoglobin levels were retrospectively available.
SE|25462545|METHODS|ab|4|entity|C0025663|Methods|inpr|||METHODS|||0|1000|496|503
SE|25462545|METHODS|ab|4|entity|C0599755|cohort|popg|||cohort|||0|861|524|530
SE|25462545|METHODS|ab|4|entity|C0042381|Vascular Surgical Procedures|topp|||vascular surgery|||0|785|546|562
SE|25462545|METHODS|ab|4|entity|C0030705|Patients|podg|||patients|||0|785|563|571
SE|25462545|METHODS|ab|4|entity|C0587437|Tertiary referral hospital|hcro,mnob|||tertiary referral center|||0|1000|599|623
SE|25462545|METHODS|ab|4|entity|C0019029|Hemoglobin concentration result|lbtr|||hemoglobin levels|||0|983|633|650

SE|25462545|METHODS|ab|5|text|683|762|Patients who received transfusions after 3 days postoperatively were excluded.
SE|25462545|METHODS|ab|5|entity|C0030705|Patients|podg|||Patients|||0|1000|683|691
SE|25462545|METHODS|ab|5|entity|C0199960|Transfusion - action|topp|||transfusions|||0|1000|705|717
SE|25462545|METHODS|ab|5|entity|C1442459|3 Days|tmco|||3 days|||0|1000|724|730
SE|25462545|METHODS|ab|5|relation|2|1|C0199960|Transfusion - action|topp|topp|||transfusions|||0|1000|705|717|VERB|ADMINISTERED_TO||696|704|1|1|C0030705|Patients|podg,humn|humn|||Patients|||0|1000|683|691

SE|25462545|METHODS|ab|6|text|762|854|A propensity score was developed for the likelihood of receiving perioperative transfusion.
SE|25462545|METHODS|ab|6|entity|C0449820|Score|qnco|||score|||0|861|775|780
SE|25462545|METHODS|ab|6|entity|C1514756|Received|qlco|||receiving|||0|606|817|826
SE|25462545|METHODS|ab|6|entity|C1518988|perioperative|tmco|||perioperative|||0|606|827|840

SE|25462545|METHODS|ab|7|text|854|1046|The study end points were 30-day cardiovascular (CV) events (myocardial infarction, heart failure, arrhythmias, stroke, asymptomatic troponin-T release, and CV death) and all-cause mortality.
SE|25462545|METHODS|ab|7|entity|C0008972|Clinical Research|resa|||study|||0|888|858|863
SE|25462545|METHODS|ab|7|entity|C0150100|End Point|resa|||end points|||0|888|864|874
SE|25462545|METHODS|ab|7|entity|C0439228|day|tmco|||day|||0|813|883|886
SE|25462545|METHODS|ab|7|entity|C1320716|Cardiovascular event|fndg|||cardiovascular (CV) events|||0|813|887|913
SE|25462545|METHODS|ab|7|entity|C0027051|Myocardial Infarction|dsyn|||myocardial infarction|||0|1000|915|936
SE|25462545|METHODS|ab|7|entity|C0018801|Heart failure|dsyn|||heart failure|||0|1000|938|951
SE|25462545|METHODS|ab|7|entity|C0003811|cardiac arrhythmia|patf|||arrhythmias|||0|1000|953|964
SE|25462545|METHODS|ab|7|entity|C0038454|Cerebrovascular accident|dsyn|||stroke|||0|1000|966|972
SE|25462545|METHODS|ab|7|entity|C0231221|Asymptomatic|fndg|||asymptomatic|||0|861|974|986
SE|25462545|METHODS|ab|7|entity|C0077404|Troponin T|aapp,bacs|||troponin-T|||0|861|987|997
SE|25462545|METHODS|ab|7|entity|C0011065|Cessation of life|orgf|||death|||0|861|1014|1019
SE|25462545|METHODS|ab|7|entity|C0015127|Etiology aspects|ftcn|||cause|||0|661|1029|1034

SE|25462545|METHODS|ab|8|text|1046|1253|Multivariable logistic regression analyses, adjusting for relevant confounders and transfusion propensity, were used to determine the associations between perioperative transfusion and the study end points.
SE|25462545|METHODS|ab|8|entity|C0681925|logistic regression analysis|qnco,resa|||logistic regression analyses|||0|906|1060|1088
SE|25462545|METHODS|ab|8|entity|C1518988|perioperative|tmco|||perioperative|||0|694|1201|1214
SE|25462545|METHODS|ab|8|entity|C0008972|Clinical Research|resa|||study|||0|888|1235|1240
SE|25462545|METHODS|ab|8|entity|C0150100|End Point|resa|||end points|||0|888|1241|1251

SE|25462545|RESULTS|ab|9|text|1253|1365|RESULTS: The final study sample comprised 992 patients; 265 (27%) patients received perioperative transfusions.
SE|25462545|RESULTS|ab|9|entity|C1274040|result|ftcn|||RESULTS|||0|966|1253|1260
SE|25462545|RESULTS|ab|9|entity|C0205088|End-stage|tmco|||final|||0|623|1266|1271
SE|25462545|RESULTS|ab|9|entity|C0008972|Clinical Research|resa|||study|||0|623|1272|1277
SE|25462545|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|861|1299|1307
SE|25462545|RESULTS|ab|9|entity|C0030705|Patients|podg|||patients|||0|1000|1319|1327
SE|25462545|RESULTS|ab|9|entity|C1518988|perioperative|tmco|||perioperative|||0|888|1337|1350
SE|25462545|RESULTS|ab|9|entity|C0199960|Transfusion - action|topp|||transfusions|||0|888|1351|1363
SE|25462545|RESULTS|ab|9|relation|1|1|C0199960|Transfusion - action|topp|topp|||transfusions|||0|888|1351|1363|VERB|ADMINISTERED_TO||1328|1336|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1319|1327

SE|25462545|RESULTS|ab|10|text|1365|1620|During the 30-day follow-up, a total of 190 (19%) patients suffered from a 30-day postoperative CV event, of which 116 (44%) occurred in patients who received perioperative RBC transfusions compared with 74 (10%) patients without transfusions (P < 0.01).
SE|25462545|RESULTS|ab|10|entity|C0439228|day|tmco|||day|||0|861|1379|1382
SE|25462545|RESULTS|ab|10|entity|C1522577|follow-up|hlca|||follow-up|||0|1000|1383|1392
SE|25462545|RESULTS|ab|10|entity|C0439175|% of total|qnco|||total|||0|1000|1396|1401
SE|25462545|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1415|1423
SE|25462545|RESULTS|ab|10|entity|C0439228|day|tmco|||day|||0|790|1443|1446
SE|25462545|RESULTS|ab|10|entity|C1320716|Cardiovascular event|fndg|||CV event|||0|790|1461|1469
SE|25462545|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1502|1510
SE|25462545|RESULTS|ab|10|entity|C1518988|perioperative|tmco|||perioperative|||0|928|1524|1537
SE|25462545|RESULTS|ab|10|entity|C0086252|Erythrocyte Transfusion|topp|||RBC transfusions|||0|928|1538|1554
SE|25462545|RESULTS|ab|10|entity|C0030705|Patients|podg|||patients|||0|1000|1578|1586
SE|25462545|RESULTS|ab|10|entity|C0199960|Transfusion - action|topp|||transfusions|||0|1000|1595|1607
SE|25462545|RESULTS|ab|10|relation|3|1|C0086252|Erythrocyte Transfusion|topp|topp|||RBC transfusions|||0|928|1538|1554|VERB|ADMINISTERED_TO||1515|1523|6|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1502|1510
SE|25462545|RESULTS|ab|10|relation|5|1|C1320716|Cardiovascular event|fndg|fndg|||CV event|||0|790|1461|1469|VERB|PROCESS_OF||1424|1432|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1415|1423
SE|25462545|RESULTS|ab|10|relation|5|4|C1522577|follow-up|hlca|hlca|||follow-up|||0|1000|1383|1392|PREP|TREATS||1499|1501|4|1|C0030705|Patients|podg,humn|humn|||patients|||0|1000|1502|1510

SE|25462545|RESULTS|ab|11|text|1620|1802|The end point all-cause mortality was reached in 36 (4%) patients-26 (10%) patients with perioperative RBC transfusion compared with 10 (1%) patients without transfusion (P < 0.01).
SE|25462545|RESULTS|ab|11|entity|C0150100|End Point|resa|||end point|||0|1000|1624|1633
SE|25462545|RESULTS|ab|11|entity|C0015127|Etiology aspects|ftcn|||cause|||0|661|1638|1643
SE|25462545|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|861|1677|1685
SE|25462545|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1695|1703
SE|25462545|RESULTS|ab|11|entity|C1518988|perioperative|tmco|||perioperative|||0|928|1709|1722
SE|25462545|RESULTS|ab|11|entity|C0086252|Erythrocyte Transfusion|topp|||RBC transfusion|||0|928|1723|1738
SE|25462545|RESULTS|ab|11|entity|C0030705|Patients|podg|||patients|||0|1000|1761|1769

SE|25462545|RESULTS|ab|12|text|1802|2026|Perioperative transfusion was associated with an independently increased risk of 30-day CV events (odds ratio 5.0; 95% confidence interval 3.1-8.2) and all-cause mortality (odds ratio 4.4; 95% confidence interval 1.6-12.1).
SE|25462545|RESULTS|ab|12|entity|C1518988|perioperative|tmco|||Perioperative|||0|694|1802|1815
SE|25462545|RESULTS|ab|12|entity|C0205217|Increased|qnco|||increased|||0|790|1865|1874
SE|25462545|RESULTS|ab|12|entity|C0035647|Risk|qlco|||risk|||0|790|1875|1879
SE|25462545|RESULTS|ab|12|entity|C0439228|day|tmco|||day|||0|813|1886|1889
SE|25462545|RESULTS|ab|12|entity|C1320716|Cardiovascular event|fndg|||CV events|||0|813|1890|1899
SE|25462545|RESULTS|ab|12|entity|C0028873|Odds Ratio|qnco|||odds ratio|||0|861|1901|1911
SE|25462545|RESULTS|ab|12|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|818|1921|1940
SE|25462545|RESULTS|ab|12|entity|C0015127|Etiology aspects|ftcn|||cause|||0|661|1958|1963
SE|25462545|RESULTS|ab|12|entity|C0028873|Odds Ratio|qnco|||odds ratio|||0|861|1975|1985
SE|25462545|RESULTS|ab|12|entity|C0009667|Confidence Intervals|qnco|||confidence interval|||0|818|1995|2014

SE|25462545|CONCLUSION|ab|13|text|2026|2186|CONCLUSION: Perioperative transfusion is associated with a strongly increased risk of both 30-day CV events and mortality in elective vascular surgery patients.
SE|25462545|CONCLUSION|ab|13|entity|C1518988|perioperative|tmco|||Perioperative|||0|694|2038|2051
SE|25462545|CONCLUSION|ab|13|entity|C0205217|Increased|qnco|||increased|||0|790|2094|2103
SE|25462545|CONCLUSION|ab|13|entity|C0035647|Risk|qlco|||risk|||0|790|2104|2108
SE|25462545|CONCLUSION|ab|13|entity|C0439228|day|tmco|||day|||0|813|2120|2123
SE|25462545|CONCLUSION|ab|13|entity|C1320716|Cardiovascular event|fndg|||CV events|||0|813|2124|2133
SE|25462545|CONCLUSION|ab|13|entity|C0005847|Blood Vessels|bpoc|||vascular|||0|861|2160|2168
SE|25462545|CONCLUSION|ab|13|entity|C0206058|Surgical Procedures, Elective|topp|||elective vascular surgery|||0|861|2151|2176
SE|25462545|CONCLUSION|ab|13|entity|C0030705|Patients|podg|||patients|||0|861|2177|2185
SE|25462545|CONCLUSION|ab|13|relation|5|2|C1320716|Cardiovascular event|fndg|fndg|||CV events|||0|813|2124|2133|PREP|PROCESS_OF||2148|2150|1|1|C0030705|Patients|podg,humn|humn|||patients|||0|861|2177|2185


